DDI-DrugBank.d436.s0|a|No drug, nutritional supplement, food or herb interactions have yet been reported.
DDI-DrugBank.d519.s0|a|No formal drug/drug interaction studies with Plenaxis were performed.
DDI-DrugBank.d519.s0	45	52	Plenaxis	brand	DDI-DrugBank.d519.s0.e0
DDI-DrugBank.d519.s1|a|Cytochrome P-450 is not known to be involved in the metabolism of Plenaxis.
DDI-DrugBank.d519.s1	66	73	Plenaxis	brand	DDI-DrugBank.d519.s1.e0
DDI-DrugBank.d519.s2|a|Plenaxis is highly bound to plasma proteins (96 to 99%).
DDI-DrugBank.d519.s2	0	7	Plenaxis	brand	DDI-DrugBank.d519.s2.e0
DDI-DrugBank.d519.s3|a|Laboratory Tests Response to Plenaxis should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.
DDI-DrugBank.d519.s3	29	36	Plenaxis	brand	DDI-DrugBank.d519.s3.e0
DDI-DrugBank.d519.s3	83	94	testosterone	drug	DDI-DrugBank.d519.s3.e1
DDI-DrugBank.d519.s3	false	DDI-DrugBank.d519.s3.e0	DDI-DrugBank.d519.s3.e1
DDI-DrugBank.d519.s4|a|Serum transaminase levels should be obtained before starting treatment with Plenaxis and periodically during treatment.
DDI-DrugBank.d519.s4	76	83	Plenaxis	brand	DDI-DrugBank.d519.s4.e0
DDI-DrugBank.d519.s5|a|Periodic measurement of serum PSA levels may also be considered.
DDI-DrugBank.d297.s0|a|Formal drug interaction studies have not been conducted with ORENCIA.
DDI-DrugBank.d297.s0	61	67	ORENCIA	brand	DDI-DrugBank.d297.s0.e0
DDI-DrugBank.d297.s1|a|Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.
DDI-DrugBank.d297.s1	50	52	MTX	drug	DDI-DrugBank.d297.s1.e0
DDI-DrugBank.d297.s1	55	60	NSAIDs	group	DDI-DrugBank.d297.s1.e1
DDI-DrugBank.d297.s1	63	77	corticosteroids	group	DDI-DrugBank.d297.s1.e2
DDI-DrugBank.d297.s1	84	102	TNF blocking agents	group	DDI-DrugBank.d297.s1.e3
DDI-DrugBank.d297.s1	122	130	abatacept	drug	DDI-DrugBank.d297.s1.e4
DDI-DrugBank.d297.s1	false	DDI-DrugBank.d297.s1.e0	DDI-DrugBank.d297.s1.e1
DDI-DrugBank.d297.s1	false	DDI-DrugBank.d297.s1.e0	DDI-DrugBank.d297.s1.e2
DDI-DrugBank.d297.s1	false	DDI-DrugBank.d297.s1.e0	DDI-DrugBank.d297.s1.e3
DDI-DrugBank.d297.s1	false	DDI-DrugBank.d297.s1.e0	DDI-DrugBank.d297.s1.e4
DDI-DrugBank.d297.s1	false	DDI-DrugBank.d297.s1.e1	DDI-DrugBank.d297.s1.e2
DDI-DrugBank.d297.s1	false	DDI-DrugBank.d297.s1.e1	DDI-DrugBank.d297.s1.e3
DDI-DrugBank.d297.s1	false	DDI-DrugBank.d297.s1.e1	DDI-DrugBank.d297.s1.e4
DDI-DrugBank.d297.s1	false	DDI-DrugBank.d297.s1.e2	DDI-DrugBank.d297.s1.e3
DDI-DrugBank.d297.s1	false	DDI-DrugBank.d297.s1.e2	DDI-DrugBank.d297.s1.e4
DDI-DrugBank.d297.s1	false	DDI-DrugBank.d297.s1.e3	DDI-DrugBank.d297.s1.e4
DDI-DrugBank.d297.s2|a|The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
DDI-DrugBank.d297.s2	115	121	ORENCIA	brand	DDI-DrugBank.d297.s2.e0
DDI-DrugBank.d297.s2	124	126	MTX	drug	DDI-DrugBank.d297.s2.e1
DDI-DrugBank.d297.s2	129	134	NSAIDs	group	DDI-DrugBank.d297.s2.e2
DDI-DrugBank.d297.s2	137	151	corticosteroids	group	DDI-DrugBank.d297.s2.e3
DDI-DrugBank.d297.s2	154	172	TNF blocking agents	group	DDI-DrugBank.d297.s2.e4
DDI-DrugBank.d297.s2	175	186	azathioprine	drug	DDI-DrugBank.d297.s2.e5
DDI-DrugBank.d297.s2	189	199	chloroquine	drug	DDI-DrugBank.d297.s2.e6
DDI-DrugBank.d297.s2	202	205	gold	drug	DDI-DrugBank.d297.s2.e7
DDI-DrugBank.d297.s2	208	225	hydroxychloroquine	drug	DDI-DrugBank.d297.s2.e8
DDI-DrugBank.d297.s2	228	238	leflunomide	drug	DDI-DrugBank.d297.s2.e9
DDI-DrugBank.d297.s2	false	DDI-DrugBank.d297.s2.e0	DDI-DrugBank.d297.s2.e1
DDI-DrugBank.d297.s2	false	DDI-DrugBank.d297.s2.e0	DDI-DrugBank.d297.s2.e2
DDI-DrugBank.d297.s2	false	DDI-DrugBank.d297.s2.e0	DDI-DrugBank.d297.s2.e3
DDI-DrugBank.d297.s2	false	DDI-DrugBank.d297.s2.e0	DDI-DrugBank.d297.s2.e4
DDI-DrugBank.d297.s2	false	DDI-DrugBank.d297.s2.e0	DDI-DrugBank.d297.s2.e5
DDI-DrugBank.d297.s2	false	DDI-DrugBank.d297.s2.e0	DDI-DrugBank.d297.s2.e6
DDI-DrugBank.d297.s2	false	DDI-DrugBank.d297.s2.e0	DDI-DrugBank.d297.s2.e7
DDI-DrugBank.d297.s2	false	DDI-DrugBank.d297.s2.e0	DDI-DrugBank.d297.s2.e8
DDI-DrugBank.d297.s2	false	DDI-DrugBank.d297.s2.e0	DDI-DrugBank.d297.s2.e9
DDI-DrugBank.d297.s2	false	DDI-DrugBank.d297.s2.e0	DDI-DrugBank.d297.s2.e10
DDI-DrugBank.d297.s3|a|Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.
DDI-DrugBank.d297.s3	31	44	TNF antagonist	group	DDI-DrugBank.d297.s3.e0
DDI-DrugBank.d297.s3	51	57	ORENCIA	brand	DDI-DrugBank.d297.s3.e1
DDI-DrugBank.d297.s3	179	193	TNF antagonists	group	DDI-DrugBank.d297.s3.e2
DDI-DrugBank.d297.s3	true	DDI-DrugBank.d297.s3.e0	DDI-DrugBank.d297.s3.e1
DDI-DrugBank.d297.s3	false	DDI-DrugBank.d297.s3.e0	DDI-DrugBank.d297.s3.e2
DDI-DrugBank.d297.s3	false	DDI-DrugBank.d297.s3.e1	DDI-DrugBank.d297.s3.e2
DDI-DrugBank.d297.s4|a|Concurrent therapy with ORENCIA and TNF antagonists is not recommended.
DDI-DrugBank.d297.s4	24	30	ORENCIA	brand	DDI-DrugBank.d297.s4.e0
DDI-DrugBank.d297.s4	36	50	TNF antagonists	group	DDI-DrugBank.d297.s4.e1
DDI-DrugBank.d297.s4	true	DDI-DrugBank.d297.s4.e0	DDI-DrugBank.d297.s4.e1
DDI-DrugBank.d297.s5|a|There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.
DDI-DrugBank.d297.s5	70	76	ORENCIA	brand	DDI-DrugBank.d297.s5.e0
DDI-DrugBank.d297.s5	109	116	anakinra	drug	DDI-DrugBank.d297.s5.e1
DDI-DrugBank.d297.s5	true	DDI-DrugBank.d297.s5.e0	DDI-DrugBank.d297.s5.e1
DDI-DrugBank.d532.s0|a|Formal drug interaction studies with Abciximab have not been conducted.
DDI-DrugBank.d532.s0	37	45	Abciximab	drug	DDI-DrugBank.d532.s0.e0
DDI-DrugBank.d532.s1|a|Abciximab has been administered to patients with ischemic heart disease treated concomitantly with a broad range of medications used in the treatment of angina myocardial infarction and hypertension.
DDI-DrugBank.d532.s1	0	8	Abciximab	drug	DDI-DrugBank.d532.s1.e0
DDI-DrugBank.d532.s2|a|These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
DDI-DrugBank.d532.s2	32	38	heparin	drug	DDI-DrugBank.d532.s2.e0
DDI-DrugBank.d532.s2	41	48	warfarin	drug	DDI-DrugBank.d532.s2.e1
DDI-DrugBank.d532.s2	51	83	beta-adrenergic receptor blockers	group	DDI-DrugBank.d532.s2.e2
DDI-DrugBank.d532.s2	86	112	calcium channel antagonists	group	DDI-DrugBank.d532.s2.e3
DDI-DrugBank.d532.s2	115	154	angiotensin converting enzyme inhibitors	group	DDI-DrugBank.d532.s2.e4
DDI-DrugBank.d532.s2	178	185	nitrates	group	DDI-DrugBank.d532.s2.e5
DDI-DrugBank.d532.s2	188	198	ticlopidine	drug	DDI-DrugBank.d532.s2.e6
DDI-DrugBank.d532.s2	205	211	aspirin	brand	DDI-DrugBank.d532.s2.e7
DDI-DrugBank.d532.s2	false	DDI-DrugBank.d532.s2.e0	DDI-DrugBank.d532.s2.e1
DDI-DrugBank.d532.s2	false	DDI-DrugBank.d532.s2.e0	DDI-DrugBank.d532.s2.e2
DDI-DrugBank.d532.s2	false	DDI-DrugBank.d532.s2.e0	DDI-DrugBank.d532.s2.e3
DDI-DrugBank.d532.s2	false	DDI-DrugBank.d532.s2.e0	DDI-DrugBank.d532.s2.e4
DDI-DrugBank.d532.s2	false	DDI-DrugBank.d532.s2.e0	DDI-DrugBank.d532.s2.e5
DDI-DrugBank.d532.s2	false	DDI-DrugBank.d532.s2.e0	DDI-DrugBank.d532.s2.e6
DDI-DrugBank.d532.s2	false	DDI-DrugBank.d532.s2.e0	DDI-DrugBank.d532.s2.e7
DDI-DrugBank.d532.s2	false	DDI-DrugBank.d532.s2.e1	DDI-DrugBank.d532.s2.e2
DDI-DrugBank.d532.s2	false	DDI-DrugBank.d532.s2.e1	DDI-DrugBank.d532.s2.e3
DDI-DrugBank.d532.s2	false	DDI-DrugBank.d532.s2.e1	DDI-DrugBank.d532.s2.e4
DDI-DrugBank.d532.s3|a|Heparin, other anticoagulants, thrombolytics, and anti platelet agents are associated with an increase in bleeding.
DDI-DrugBank.d532.s3	0	6	Heparin	drug	DDI-DrugBank.d532.s3.e0
DDI-DrugBank.d532.s3	15	28	anticoagulants	group	DDI-DrugBank.d532.s3.e1
DDI-DrugBank.d532.s3	31	43	thrombolytics	group	DDI-DrugBank.d532.s3.e2
DDI-DrugBank.d532.s3	50	69	anti platelet agents	group	DDI-DrugBank.d532.s3.e3
DDI-DrugBank.d532.s3	false	DDI-DrugBank.d532.s3.e0	DDI-DrugBank.d532.s3.e1
DDI-DrugBank.d532.s3	false	DDI-DrugBank.d532.s3.e0	DDI-DrugBank.d532.s3.e2
DDI-DrugBank.d532.s3	false	DDI-DrugBank.d532.s3.e0	DDI-DrugBank.d532.s3.e3
DDI-DrugBank.d532.s3	false	DDI-DrugBank.d532.s3.e1	DDI-DrugBank.d532.s3.e2
DDI-DrugBank.d532.s3	false	DDI-DrugBank.d532.s3.e1	DDI-DrugBank.d532.s3.e3
DDI-DrugBank.d532.s3	false	DDI-DrugBank.d532.s3.e2	DDI-DrugBank.d532.s3.e3
DDI-DrugBank.d532.s4|a|Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
DDI-DrugBank.d532.s4	98	107	diagnostic monoclonal antibodies	group	DDI-DrugBank.d532.s4.e0
DDI-DrugBank.d532.s4	124	144	diagnostic monoclonal antibodies	group	DDI-DrugBank.d532.s4.e0
DDI-DrugBank.d532.s4	112	144	therapeutic monoclonal antibodies	group	DDI-DrugBank.d532.s4.e1
DDI-DrugBank.d532.s4	false	DDI-DrugBank.d532.s4.e0	DDI-DrugBank.d532.s4.e1
DDI-DrugBank.d0.s0|a|The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.
DDI-DrugBank.d0.s0	26	32	alcohol	drug	DDI-DrugBank.d0.s0.e0
DDI-DrugBank.d0.s0	38	48	Acamprosate	drug	DDI-DrugBank.d0.s0.e1
DDI-DrugBank.d0.s0	97	103	alcohol	drug	DDI-DrugBank.d0.s0.e2
DDI-DrugBank.d0.s0	108	118	acamprosate	drug	DDI-DrugBank.d0.s0.e3
DDI-DrugBank.d0.s0	false	DDI-DrugBank.d0.s0.e0	DDI-DrugBank.d0.s0.e1
DDI-DrugBank.d0.s0	false	DDI-DrugBank.d0.s0.e0	DDI-DrugBank.d0.s0.e2
DDI-DrugBank.d0.s0	false	DDI-DrugBank.d0.s0.e0	DDI-DrugBank.d0.s0.e3
DDI-DrugBank.d0.s0	false	DDI-DrugBank.d0.s0.e1	DDI-DrugBank.d0.s0.e2
DDI-DrugBank.d0.s0	false	DDI-DrugBank.d0.s0.e1	DDI-DrugBank.d0.s0.e3
DDI-DrugBank.d0.s0	false	DDI-DrugBank.d0.s0.e2	DDI-DrugBank.d0.s0.e3
DDI-DrugBank.d0.s1|a|Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate.
DDI-DrugBank.d0.s1	56	65	disulfiram	drug	DDI-DrugBank.d0.s1.e0
DDI-DrugBank.d0.s1	70	77	diazepam	drug	DDI-DrugBank.d0.s1.e1
DDI-DrugBank.d0.s1	119	129	acamprosate	drug	DDI-DrugBank.d0.s1.e2
DDI-DrugBank.d0.s1	false	DDI-DrugBank.d0.s1.e0	DDI-DrugBank.d0.s1.e1
DDI-DrugBank.d0.s1	false	DDI-DrugBank.d0.s1.e0	DDI-DrugBank.d0.s1.e2
DDI-DrugBank.d0.s1	false	DDI-DrugBank.d0.s1.e1	DDI-DrugBank.d0.s1.e2
DDI-DrugBank.d0.s2|a|Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.
DDI-DrugBank.d0.s2	21	30	naltrexone	drug	DDI-DrugBank.d0.s2.e0
DDI-DrugBank.d0.s2	37	47	Acamprosate	drug	DDI-DrugBank.d0.s2.e1
DDI-DrugBank.d0.s2	114	124	acamprosate	drug	DDI-DrugBank.d0.s2.e2
DDI-DrugBank.d0.s2	true	DDI-DrugBank.d0.s2.e0	DDI-DrugBank.d0.s2.e1
DDI-DrugBank.d0.s2	false	DDI-DrugBank.d0.s2.e0	DDI-DrugBank.d0.s2.e2
DDI-DrugBank.d0.s2	false	DDI-DrugBank.d0.s2.e1	DDI-DrugBank.d0.s2.e2
DDI-DrugBank.d0.s3|a|No adjustment of dosage is recommended in such patients.
DDI-DrugBank.d0.s4|a|The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate.
DDI-DrugBank.d0.s4	24	33	naltrexone	drug	DDI-DrugBank.d0.s4.e0
DDI-DrugBank.d0.s4	60	75	6-beta-naltrexol	drug_n	DDI-DrugBank.d0.s4.e1
DDI-DrugBank.d0.s4	126	136	Acamprosate	drug	DDI-DrugBank.d0.s4.e2
DDI-DrugBank.d0.s4	false	DDI-DrugBank.d0.s4.e0	DDI-DrugBank.d0.s4.e1
DDI-DrugBank.d0.s4	false	DDI-DrugBank.d0.s4.e0	DDI-DrugBank.d0.s4.e2
DDI-DrugBank.d0.s4	false	DDI-DrugBank.d0.s4.e1	DDI-DrugBank.d0.s4.e2
DDI-DrugBank.d0.s5|a|Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.
DDI-DrugBank.d0.s5	93	103	Acamprosate	drug	DDI-DrugBank.d0.s5.e0
DDI-DrugBank.d0.s5	124	134	anxiolytics	group	DDI-DrugBank.d0.s5.e1
DDI-DrugBank.d0.s5	137	145	hypnotics	group	DDI-DrugBank.d0.s5.e2
DDI-DrugBank.d0.s5	151	159	sedatives	group	DDI-DrugBank.d0.s5.e3
DDI-DrugBank.d0.s5	172	186	benzodiazepines	group	DDI-DrugBank.d0.s5.e4
DDI-DrugBank.d0.s5	193	213	non-opioid analgesics	group	DDI-DrugBank.d0.s5.e5
DDI-DrugBank.d0.s5	false	DDI-DrugBank.d0.s5.e0	DDI-DrugBank.d0.s5.e1
DDI-DrugBank.d0.s5	false	DDI-DrugBank.d0.s5.e0	DDI-DrugBank.d0.s5.e2
DDI-DrugBank.d0.s5	false	DDI-DrugBank.d0.s5.e0	DDI-DrugBank.d0.s5.e3
DDI-DrugBank.d0.s5	false	DDI-DrugBank.d0.s5.e0	DDI-DrugBank.d0.s5.e4
DDI-DrugBank.d0.s5	false	DDI-DrugBank.d0.s5.e0	DDI-DrugBank.d0.s5.e5
DDI-DrugBank.d0.s5	false	DDI-DrugBank.d0.s5.e1	DDI-DrugBank.d0.s5.e2
DDI-DrugBank.d0.s5	false	DDI-DrugBank.d0.s5.e1	DDI-DrugBank.d0.s5.e3
DDI-DrugBank.d0.s5	false	DDI-DrugBank.d0.s5.e1	DDI-DrugBank.d0.s5.e4
DDI-DrugBank.d0.s5	false	DDI-DrugBank.d0.s5.e1	DDI-DrugBank.d0.s5.e5
DDI-DrugBank.d0.s5	false	DDI-DrugBank.d0.s5.e2	DDI-DrugBank.d0.s5.e3
DDI-DrugBank.d0.s6|a|Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
DDI-DrugBank.d0.s6	16	26	Acamprosate	drug	DDI-DrugBank.d0.s6.e0
DDI-DrugBank.d0.s6	47	61	antidepressants	group	DDI-DrugBank.d0.s6.e1
DDI-DrugBank.d0.s6	true	DDI-DrugBank.d0.s6.e0	DDI-DrugBank.d0.s6.e1
DDI-DrugBank.d536.s0|a|Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control.
DDI-DrugBank.d536.s1|a|These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
DDI-DrugBank.d536.s1	24	32	thiazides	group	DDI-DrugBank.d536.s1.e0
DDI-DrugBank.d536.s1	44	52	diuretics	group	DDI-DrugBank.d536.s1.e1
DDI-DrugBank.d536.s1	55	69	corticosteroids	group	DDI-DrugBank.d536.s1.e2
DDI-DrugBank.d536.s1	72	85	phenothiazines	group	DDI-DrugBank.d536.s1.e3
DDI-DrugBank.d536.s1	88	103	thyroid products	group	DDI-DrugBank.d536.s1.e4
DDI-DrugBank.d536.s1	106	114	estrogens	group	DDI-DrugBank.d536.s1.e5
DDI-DrugBank.d536.s1	122	135	contraceptives	group	DDI-DrugBank.d536.s1.e6
DDI-DrugBank.d536.s1	138	146	phenytoin	drug	DDI-DrugBank.d536.s1.e7
DDI-DrugBank.d536.s1	149	162	nicotinic acid	drug	DDI-DrugBank.d536.s1.e8
DDI-DrugBank.d536.s1	165	180	sympathomimetics	group	DDI-DrugBank.d536.s1.e9
DDI-DrugBank.d536.s1	false	DDI-DrugBank.d536.s1.e0	DDI-DrugBank.d536.s1.e1
DDI-DrugBank.d536.s1	false	DDI-DrugBank.d536.s1.e0	DDI-DrugBank.d536.s1.e2
DDI-DrugBank.d536.s1	false	DDI-DrugBank.d536.s1.e0	DDI-DrugBank.d536.s1.e3
DDI-DrugBank.d536.s1	false	DDI-DrugBank.d536.s1.e0	DDI-DrugBank.d536.s1.e4
DDI-DrugBank.d536.s1	false	DDI-DrugBank.d536.s1.e0	DDI-DrugBank.d536.s1.e5
DDI-DrugBank.d536.s1	false	DDI-DrugBank.d536.s1.e0	DDI-DrugBank.d536.s1.e6
DDI-DrugBank.d536.s1	false	DDI-DrugBank.d536.s1.e0	DDI-DrugBank.d536.s1.e7
DDI-DrugBank.d536.s1	false	DDI-DrugBank.d536.s1.e0	DDI-DrugBank.d536.s1.e8
DDI-DrugBank.d536.s1	false	DDI-DrugBank.d536.s1.e0	DDI-DrugBank.d536.s1.e9
DDI-DrugBank.d536.s1	false	DDI-DrugBank.d536.s1.e0	DDI-DrugBank.d536.s1.e10
DDI-DrugBank.d536.s2|a|When such drugs are administered to a patient receiving Acarbose, the patient should be closely observed for loss of blood glucose control.
DDI-DrugBank.d536.s2	56	63	Acarbose	drug	DDI-DrugBank.d536.s2.e0
DDI-DrugBank.d536.s3|a|When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.
DDI-DrugBank.d536.s3	54	61	Acarbose	drug	DDI-DrugBank.d536.s3.e0
DDI-DrugBank.d536.s3	83	95	sulfonylureas	group	DDI-DrugBank.d536.s3.e1
DDI-DrugBank.d536.s3	100	106	insulin	drug	DDI-DrugBank.d536.s3.e2
DDI-DrugBank.d536.s3	false	DDI-DrugBank.d536.s3.e0	DDI-DrugBank.d536.s3.e1
DDI-DrugBank.d536.s3	false	DDI-DrugBank.d536.s3.e0	DDI-DrugBank.d536.s3.e2
DDI-DrugBank.d536.s3	false	DDI-DrugBank.d536.s3.e1	DDI-DrugBank.d536.s3.e2
DDI-DrugBank.d536.s4|a|Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
DDI-DrugBank.d536.s4	0	20	Intestinal adsorbents	group	DDI-DrugBank.d536.s4.e0
DDI-DrugBank.d536.s4	30	37	charcoal	drug	DDI-DrugBank.d536.s4.e1
DDI-DrugBank.d536.s4	44	72	digestive enzyme preparations	group	DDI-DrugBank.d536.s4.e2
DDI-DrugBank.d536.s4	124	130	amylase	drug	DDI-DrugBank.d536.s4.e3
DDI-DrugBank.d536.s4	133	142	pancreatin	drug	DDI-DrugBank.d536.s4.e4
DDI-DrugBank.d536.s4	170	177	Acarbose	drug	DDI-DrugBank.d536.s4.e5
DDI-DrugBank.d536.s4	false	DDI-DrugBank.d536.s4.e0	DDI-DrugBank.d536.s4.e1
DDI-DrugBank.d536.s4	false	DDI-DrugBank.d536.s4.e0	DDI-DrugBank.d536.s4.e2
DDI-DrugBank.d536.s4	false	DDI-DrugBank.d536.s4.e0	DDI-DrugBank.d536.s4.e3
DDI-DrugBank.d536.s4	false	DDI-DrugBank.d536.s4.e0	DDI-DrugBank.d536.s4.e4
DDI-DrugBank.d536.s4	true	DDI-DrugBank.d536.s4.e0	DDI-DrugBank.d536.s4.e5
DDI-DrugBank.d536.s4	false	DDI-DrugBank.d536.s4.e1	DDI-DrugBank.d536.s4.e2
DDI-DrugBank.d536.s4	false	DDI-DrugBank.d536.s4.e1	DDI-DrugBank.d536.s4.e3
DDI-DrugBank.d536.s4	false	DDI-DrugBank.d536.s4.e1	DDI-DrugBank.d536.s4.e4
DDI-DrugBank.d536.s4	true	DDI-DrugBank.d536.s4.e1	DDI-DrugBank.d536.s4.e5
DDI-DrugBank.d536.s4	false	DDI-DrugBank.d536.s4.e2	DDI-DrugBank.d536.s4.e3
DDI-DrugBank.d536.s5|a|Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.
DDI-DrugBank.d536.s5	0	7	Acarbose	drug	DDI-DrugBank.d536.s5.e0
DDI-DrugBank.d536.s5	54	60	digoxin	drug	DDI-DrugBank.d536.s5.e1
DDI-DrugBank.d536.s5	111	117	digoxin	drug	DDI-DrugBank.d536.s5.e2
DDI-DrugBank.d536.s5	true	DDI-DrugBank.d536.s5.e0	DDI-DrugBank.d536.s5.e1
DDI-DrugBank.d536.s5	false	DDI-DrugBank.d536.s5.e0	DDI-DrugBank.d536.s5.e2
DDI-DrugBank.d536.s5	false	DDI-DrugBank.d536.s5.e1	DDI-DrugBank.d536.s5.e2
DDI-DrugBank.d536.s6|a|Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.
DDI-DrugBank.d536.s6	46	53	Acarbose	drug	DDI-DrugBank.d536.s6.e0
DDI-DrugBank.d536.s6	123	129	digoxin	drug	DDI-DrugBank.d536.s6.e1
DDI-DrugBank.d536.s6	132	141	nifedipine	drug	DDI-DrugBank.d536.s6.e2
DDI-DrugBank.d536.s6	144	154	propranolol	drug	DDI-DrugBank.d536.s6.e3
DDI-DrugBank.d536.s6	160	169	ranitidine	drug	DDI-DrugBank.d536.s6.e4
DDI-DrugBank.d536.s6	false	DDI-DrugBank.d536.s6.e0	DDI-DrugBank.d536.s6.e1
DDI-DrugBank.d536.s6	false	DDI-DrugBank.d536.s6.e0	DDI-DrugBank.d536.s6.e2
DDI-DrugBank.d536.s6	false	DDI-DrugBank.d536.s6.e0	DDI-DrugBank.d536.s6.e3
DDI-DrugBank.d536.s6	false	DDI-DrugBank.d536.s6.e0	DDI-DrugBank.d536.s6.e4
DDI-DrugBank.d536.s6	false	DDI-DrugBank.d536.s6.e1	DDI-DrugBank.d536.s6.e2
DDI-DrugBank.d536.s6	false	DDI-DrugBank.d536.s6.e1	DDI-DrugBank.d536.s6.e3
DDI-DrugBank.d536.s6	false	DDI-DrugBank.d536.s6.e1	DDI-DrugBank.d536.s6.e4
DDI-DrugBank.d536.s6	false	DDI-DrugBank.d536.s6.e2	DDI-DrugBank.d536.s6.e3
DDI-DrugBank.d536.s6	false	DDI-DrugBank.d536.s6.e2	DDI-DrugBank.d536.s6.e4
DDI-DrugBank.d536.s6	false	DDI-DrugBank.d536.s6.e3	DDI-DrugBank.d536.s6.e4
DDI-DrugBank.d536.s7|a|Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.
DDI-DrugBank.d536.s7	0	7	Acarbose	drug	DDI-DrugBank.d536.s7.e0
DDI-DrugBank.d536.s7	69	80	sulfonylurea	drug	DDI-DrugBank.d536.s7.e1
DDI-DrugBank.d536.s7	82	90	glyburide	drug	DDI-DrugBank.d536.s7.e2
DDI-DrugBank.d536.s7	false	DDI-DrugBank.d536.s7.e0	DDI-DrugBank.d536.s7.e1
DDI-DrugBank.d536.s7	false	DDI-DrugBank.d536.s7.e0	DDI-DrugBank.d536.s7.e2
DDI-DrugBank.d536.s7	false	DDI-DrugBank.d536.s7.e1	DDI-DrugBank.d536.s7.e2
DDI-DrugBank.d536.s8|a|Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
DDI-DrugBank.d536.s8	0	7	Acarbose	drug	DDI-DrugBank.d536.s8.e0
DDI-DrugBank.d536.s8	20	26	digoxin	drug	DDI-DrugBank.d536.s8.e1
DDI-DrugBank.d536.s8	79	85	digoxin	drug	DDI-DrugBank.d536.s8.e2
DDI-DrugBank.d536.s8	148	154	digoxin	drug	DDI-DrugBank.d536.s8.e3
DDI-DrugBank.d536.s8	240	246	digoxin	drug	DDI-DrugBank.d536.s8.e4
DDI-DrugBank.d536.s8	false	DDI-DrugBank.d536.s8.e0	DDI-DrugBank.d536.s8.e1
DDI-DrugBank.d536.s8	false	DDI-DrugBank.d536.s8.e0	DDI-DrugBank.d536.s8.e2
DDI-DrugBank.d536.s8	false	DDI-DrugBank.d536.s8.e0	DDI-DrugBank.d536.s8.e3
DDI-DrugBank.d536.s8	false	DDI-DrugBank.d536.s8.e0	DDI-DrugBank.d536.s8.e4
DDI-DrugBank.d536.s8	false	DDI-DrugBank.d536.s8.e1	DDI-DrugBank.d536.s8.e2
DDI-DrugBank.d536.s8	false	DDI-DrugBank.d536.s8.e1	DDI-DrugBank.d536.s8.e3
DDI-DrugBank.d536.s8	false	DDI-DrugBank.d536.s8.e1	DDI-DrugBank.d536.s8.e4
DDI-DrugBank.d536.s8	false	DDI-DrugBank.d536.s8.e2	DDI-DrugBank.d536.s8.e3
DDI-DrugBank.d536.s8	false	DDI-DrugBank.d536.s8.e2	DDI-DrugBank.d536.s8.e4
DDI-DrugBank.d536.s8	false	DDI-DrugBank.d536.s8.e3	DDI-DrugBank.d536.s8.e4
DDI-DrugBank.d536.s9|a|The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.
DDI-DrugBank.d536.s9	14	22	metformin	drug	DDI-DrugBank.d536.s9.e0
DDI-DrugBank.d536.s9	46	53	Acarbose	drug	DDI-DrugBank.d536.s9.e1
DDI-DrugBank.d536.s9	false	DDI-DrugBank.d536.s9.e0	DDI-DrugBank.d536.s9.e1
DDI-DrugBank.d536.s10|a|However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.
DDI-DrugBank.d536.s10	34	42	metformin	drug	DDI-DrugBank.d536.s10.e0
DDI-DrugBank.d536.s10	89	96	Acarbose	drug	DDI-DrugBank.d536.s10.e1
DDI-DrugBank.d536.s10	141	149	metformin	drug	DDI-DrugBank.d536.s10.e2
DDI-DrugBank.d536.s10	true	DDI-DrugBank.d536.s10.e0	DDI-DrugBank.d536.s10.e1
DDI-DrugBank.d536.s10	false	DDI-DrugBank.d536.s10.e0	DDI-DrugBank.d536.s10.e2
DDI-DrugBank.d536.s10	true	DDI-DrugBank.d536.s10.e1	DDI-DrugBank.d536.s10.e2
DDI-DrugBank.d536.s11|a|There is little if any clinically significant interaction between Acarbose and metformin.
DDI-DrugBank.d536.s11	66	73	Acarbose	drug	DDI-DrugBank.d536.s11.e0
DDI-DrugBank.d536.s11	79	87	metformin	drug	DDI-DrugBank.d536.s11.e1
DDI-DrugBank.d536.s11	false	DDI-DrugBank.d536.s11.e0	DDI-DrugBank.d536.s11.e1
DDI-DrugBank.d388.s0|a|Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.
DDI-DrugBank.d388.s0	0	28	Catecholamine-depleting drugs	group	DDI-DrugBank.d388.s0.e0
DDI-DrugBank.d388.s0	39	47	reserpine	drug	DDI-DrugBank.d388.s0.e1
DDI-DrugBank.d388.s0	94	113	beta-blocking agents	group	DDI-DrugBank.d388.s0.e2
DDI-DrugBank.d388.s0	false	DDI-DrugBank.d388.s0.e0	DDI-DrugBank.d388.s0.e1
DDI-DrugBank.d388.s0	true	DDI-DrugBank.d388.s0.e0	DDI-DrugBank.d388.s0.e2
DDI-DrugBank.d388.s0	true	DDI-DrugBank.d388.s0.e1	DDI-DrugBank.d388.s0.e2
DDI-DrugBank.d388.s1|a|Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.
DDI-DrugBank.d388.s1	22	31	acebutolol	drug	DDI-DrugBank.d388.s1.e0
DDI-DrugBank.d388.s1	38	60	catecholamine depletors	group	DDI-DrugBank.d388.s1.e1
DDI-DrugBank.d388.s1	true	DDI-DrugBank.d388.s1.e0	DDI-DrugBank.d388.s1.e1
DDI-DrugBank.d388.s2|a|Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.
DDI-DrugBank.d388.s2	79	105	beta-adrenergic antagonists	group	DDI-DrugBank.d388.s2.e0
DDI-DrugBank.d388.s2	111	137	alpha-adrenergic stimulants	group	DDI-DrugBank.d388.s2.e1
DDI-DrugBank.d388.s2	true	DDI-DrugBank.d388.s2.e0	DDI-DrugBank.d388.s2.e1
DDI-DrugBank.d388.s3|a|Patients receiving beta-blockers should be warned of this potential hazard.
DDI-DrugBank.d388.s3	19	31	beta-blockers	group	DDI-DrugBank.d388.s3.e0
DDI-DrugBank.d388.s4|a|Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.
DDI-DrugBank.d388.s4	43	75	beta-adrenoceptor blocking agents	group	DDI-DrugBank.d388.s4.e0
DDI-DrugBank.d388.s4	80	115	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d388.s4.e1
DDI-DrugBank.d388.s4	true	DDI-DrugBank.d388.s4.e0	DDI-DrugBank.d388.s4.e1
DDI-DrugBank.d388.s5|a|No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.
DDI-DrugBank.d388.s5	33	39	digoxin	drug	DDI-DrugBank.d388.s5.e0
DDI-DrugBank.d388.s5	42	60	hydrochlorothiazide	drug	DDI-DrugBank.d388.s5.e1
DDI-DrugBank.d388.s5	63	73	hydralazine	drug	DDI-DrugBank.d388.s5.e2
DDI-DrugBank.d388.s5	76	89	sulfinpyrazone	drug	DDI-DrugBank.d388.s5.e3
DDI-DrugBank.d388.s5	97	110	contraceptives	group	DDI-DrugBank.d388.s5.e4
DDI-DrugBank.d388.s5	113	123	tolbutamide	drug	DDI-DrugBank.d388.s5.e5
DDI-DrugBank.d388.s5	129	136	warfarin	drug	DDI-DrugBank.d388.s5.e6
DDI-DrugBank.d388.s5	false	DDI-DrugBank.d388.s5.e0	DDI-DrugBank.d388.s5.e1
DDI-DrugBank.d388.s5	false	DDI-DrugBank.d388.s5.e0	DDI-DrugBank.d388.s5.e2
DDI-DrugBank.d388.s5	false	DDI-DrugBank.d388.s5.e0	DDI-DrugBank.d388.s5.e3
DDI-DrugBank.d388.s5	false	DDI-DrugBank.d388.s5.e0	DDI-DrugBank.d388.s5.e4
DDI-DrugBank.d388.s5	false	DDI-DrugBank.d388.s5.e0	DDI-DrugBank.d388.s5.e5
DDI-DrugBank.d388.s5	false	DDI-DrugBank.d388.s5.e0	DDI-DrugBank.d388.s5.e6
DDI-DrugBank.d388.s5	false	DDI-DrugBank.d388.s5.e1	DDI-DrugBank.d388.s5.e2
DDI-DrugBank.d388.s5	false	DDI-DrugBank.d388.s5.e1	DDI-DrugBank.d388.s5.e3
DDI-DrugBank.d388.s5	false	DDI-DrugBank.d388.s5.e1	DDI-DrugBank.d388.s5.e4
DDI-DrugBank.d388.s5	false	DDI-DrugBank.d388.s5.e1	DDI-DrugBank.d388.s5.e5
DDI-DrugBank.d368.s0|a|DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.
DDI-DrugBank.d368.s0	0	5	DIAMOX	brand	DDI-DrugBank.d368.s0.e0
DDI-DrugBank.d368.s0	16	24	phenytoin	drug	DDI-DrugBank.d368.s0.e1
DDI-DrugBank.d368.s0	68	76	phenytoin	drug	DDI-DrugBank.d368.s0.e2
DDI-DrugBank.d368.s0	true	DDI-DrugBank.d368.s0.e0	DDI-DrugBank.d368.s0.e1
DDI-DrugBank.d368.s0	true	DDI-DrugBank.d368.s0.e0	DDI-DrugBank.d368.s0.e2
DDI-DrugBank.d368.s0	false	DDI-DrugBank.d368.s0.e1	DDI-DrugBank.d368.s0.e2
DDI-DrugBank.d368.s1|a|This may increase or enhance the occurrence of osteomalacia in some patients receiving chronic phenytoin therapy.
DDI-DrugBank.d368.s1	95	103	phenytoin	drug	DDI-DrugBank.d368.s1.e0
DDI-DrugBank.d368.s2|a|Caution is advised in patients receiving chronic concomitant therapy.
DDI-DrugBank.d368.s3|a|By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.
DDI-DrugBank.d368.s3	49	57	primidone	drug	DDI-DrugBank.d368.s3.e0
DDI-DrugBank.d368.s3	60	65	DIAMOX	brand	DDI-DrugBank.d368.s3.e1
DDI-DrugBank.d368.s3	104	112	primidone	drug	DDI-DrugBank.d368.s3.e2
DDI-DrugBank.d368.s3	false	DDI-DrugBank.d368.s3.e0	DDI-DrugBank.d368.s3.e1
DDI-DrugBank.d368.s3	false	DDI-DrugBank.d368.s3.e0	DDI-DrugBank.d368.s3.e2
DDI-DrugBank.d368.s3	true	DDI-DrugBank.d368.s3.e1	DDI-DrugBank.d368.s3.e2
DDI-DrugBank.d368.s4|a|Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.
DDI-DrugBank.d368.s4	74	79	DIAMOX	brand	DDI-DrugBank.d368.s4.e0
DDI-DrugBank.d368.s4	103	111	primidone	drug	DDI-DrugBank.d368.s4.e1
DDI-DrugBank.d368.s4	true	DDI-DrugBank.d368.s4.e0	DDI-DrugBank.d368.s4.e1
DDI-DrugBank.d368.s5|a|Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable.
DDI-DrugBank.d368.s5	48	76	carbonic anhydrase inhibitors	group	DDI-DrugBank.d368.s5.e0
DDI-DrugBank.d368.s6|a|Acetazolamide may increase the effects of other folic acid antagonists.
DDI-DrugBank.d368.s6	0	12	Acetazolamide	drug	DDI-DrugBank.d368.s6.e0
DDI-DrugBank.d368.s6	48	69	folic acid antagonists	group	DDI-DrugBank.d368.s6.e1
DDI-DrugBank.d368.s6	true	DDI-DrugBank.d368.s6.e0	DDI-DrugBank.d368.s6.e1
DDI-DrugBank.d368.s7|a|Acetazolamide may increase or decrease blood glucose levels.
DDI-DrugBank.d368.s7	0	12	Acetazolamide	drug	DDI-DrugBank.d368.s7.e0
DDI-DrugBank.d368.s8|a|Consideration should be taken in patients being treated with antidiabetic agents.
DDI-DrugBank.d368.s8	61	72	antidiabetic	drug	DDI-DrugBank.d368.s8.e0
DDI-DrugBank.d368.s9|a|Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.
DDI-DrugBank.d368.s9	0	12	Acetazolamide	drug	DDI-DrugBank.d368.s9.e0
DDI-DrugBank.d368.s9	45	55	amphetamine	drug	DDI-DrugBank.d368.s9.e1
DDI-DrugBank.d368.s9	true	DDI-DrugBank.d368.s9.e0	DDI-DrugBank.d368.s9.e1
DDI-DrugBank.d368.s10|a|Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
DDI-DrugBank.d368.s10	0	12	Acetazolamide	drug	DDI-DrugBank.d368.s10.e0
DDI-DrugBank.d368.s10	43	51	quinidine	drug	DDI-DrugBank.d368.s10.e1
DDI-DrugBank.d368.s10	true	DDI-DrugBank.d368.s10.e0	DDI-DrugBank.d368.s10.e1
DDI-DrugBank.d368.s11|a|Acetazolamide may prevent the urinary antiseptic effect of methenamine.
DDI-DrugBank.d368.s11	0	12	Acetazolamide	drug	DDI-DrugBank.d368.s11.e0
DDI-DrugBank.d368.s11	59	69	methenamine	drug	DDI-DrugBank.d368.s11.e1
DDI-DrugBank.d368.s11	true	DDI-DrugBank.d368.s11.e0	DDI-DrugBank.d368.s11.e1
DDI-DrugBank.d368.s12|a|Acetazolamide increases lithium excretion and the lithium may be decreased.
DDI-DrugBank.d368.s12	0	12	Acetazolamide	drug	DDI-DrugBank.d368.s12.e0
DDI-DrugBank.d368.s12	24	30	lithium	drug	DDI-DrugBank.d368.s12.e1
DDI-DrugBank.d368.s12	50	56	lithium	drug	DDI-DrugBank.d368.s12.e2
DDI-DrugBank.d368.s12	true	DDI-DrugBank.d368.s12.e0	DDI-DrugBank.d368.s12.e1
DDI-DrugBank.d368.s12	false	DDI-DrugBank.d368.s12.e0	DDI-DrugBank.d368.s12.e2
DDI-DrugBank.d368.s12	false	DDI-DrugBank.d368.s12.e1	DDI-DrugBank.d368.s12.e2
DDI-DrugBank.d368.s13|a|Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.
DDI-DrugBank.d368.s13	0	12	Acetazolamide	drug	DDI-DrugBank.d368.s13.e0
DDI-DrugBank.d368.s13	18	35	sodium bicarbonate	drug	DDI-DrugBank.d368.s13.e1
DDI-DrugBank.d368.s13	true	DDI-DrugBank.d368.s13.e0	DDI-DrugBank.d368.s13.e1
DDI-DrugBank.d368.s14|a|Acetazolamide may elevate cyclosporine levels.
DDI-DrugBank.d368.s14	0	12	Acetazolamide	drug	DDI-DrugBank.d368.s14.e0
DDI-DrugBank.d368.s14	26	37	cyclosporine	drug	DDI-DrugBank.d368.s14.e1
DDI-DrugBank.d368.s14	true	DDI-DrugBank.d368.s14.e0	DDI-DrugBank.d368.s14.e1
DDI-DrugBank.d117.s0|a|Concomitant use with iron supplements may result in the reduced absorption of iron.
DDI-DrugBank.d117.s0	21	35	iron supplement	group	DDI-DrugBank.d117.s0.e0
DDI-DrugBank.d117.s0	78	81	iron	drug	DDI-DrugBank.d117.s0.e1
DDI-DrugBank.d117.s0	false	DDI-DrugBank.d117.s0.e0	DDI-DrugBank.d117.s0.e1
DDI-DrugBank.d200.s0|a|Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.
DDI-DrugBank.d200.s0	21	30	probenecid	drug	DDI-DrugBank.d200.s0.e0
DDI-DrugBank.d200.s0	37	45	acyclovir	drug	DDI-DrugBank.d200.s0.e1
DDI-DrugBank.d200.s0	true	DDI-DrugBank.d200.s0.e0	DDI-DrugBank.d200.s0.e1
DDI-DrugBank.d200.s1|a|Urinary excretion and renal clearance were correspondingly reduced.
DDI-DrugBank.d200.s2|a|The clinical effects of this combination have not been studied.
DDI-DrugBank.d353.s0|a|Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.
DDI-DrugBank.d353.s0	0	6	Ethanol	drug	DDI-DrugBank.d353.s0.e0
DDI-DrugBank.d353.s0	41	50	etretinate	drug	DDI-DrugBank.d353.s0.e1
DDI-DrugBank.d353.s0	95	103	acitretin	drug	DDI-DrugBank.d353.s0.e2
DDI-DrugBank.d353.s0	109	115	ethanol	drug	DDI-DrugBank.d353.s0.e3
DDI-DrugBank.d353.s0	false	DDI-DrugBank.d353.s0.e0	DDI-DrugBank.d353.s0.e1
DDI-DrugBank.d353.s0	false	DDI-DrugBank.d353.s0.e0	DDI-DrugBank.d353.s0.e2
DDI-DrugBank.d353.s0	false	DDI-DrugBank.d353.s0.e0	DDI-DrugBank.d353.s0.e3
DDI-DrugBank.d353.s0	false	DDI-DrugBank.d353.s0.e1	DDI-DrugBank.d353.s0.e2
DDI-DrugBank.d353.s0	false	DDI-DrugBank.d353.s0.e1	DDI-DrugBank.d353.s0.e3
DDI-DrugBank.d353.s0	true	DDI-DrugBank.d353.s0.e2	DDI-DrugBank.d353.s0.e3
DDI-DrugBank.d353.s1|a|Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
DDI-DrugBank.d353.s1	0	12	Glibenclamide	drug	DDI-DrugBank.d353.s1.e0
DDI-DrugBank.d353.s1	56	64	acitretin	drug	DDI-DrugBank.d353.s1.e1
DDI-DrugBank.d353.s1	125	137	glibenclamide	drug	DDI-DrugBank.d353.s1.e2
DDI-DrugBank.d353.s1	142	153	sulfonylurea	group	DDI-DrugBank.d353.s1.e3
DDI-DrugBank.d353.s1	166	179	chlorpropamide	drug	DDI-DrugBank.d353.s1.e4
DDI-DrugBank.d353.s1	false	DDI-DrugBank.d353.s1.e0	DDI-DrugBank.d353.s1.e1
DDI-DrugBank.d353.s1	false	DDI-DrugBank.d353.s1.e0	DDI-DrugBank.d353.s1.e2
DDI-DrugBank.d353.s1	false	DDI-DrugBank.d353.s1.e0	DDI-DrugBank.d353.s1.e3
DDI-DrugBank.d353.s1	false	DDI-DrugBank.d353.s1.e0	DDI-DrugBank.d353.s1.e4
DDI-DrugBank.d353.s1	true	DDI-DrugBank.d353.s1.e1	DDI-DrugBank.d353.s1.e2
DDI-DrugBank.d353.s1	false	DDI-DrugBank.d353.s1.e1	DDI-DrugBank.d353.s1.e3
DDI-DrugBank.d353.s1	false	DDI-DrugBank.d353.s1.e1	DDI-DrugBank.d353.s1.e4
DDI-DrugBank.d353.s1	false	DDI-DrugBank.d353.s1.e2	DDI-DrugBank.d353.s1.e3
DDI-DrugBank.d353.s1	false	DDI-DrugBank.d353.s1.e2	DDI-DrugBank.d353.s1.e4
DDI-DrugBank.d353.s1	false	DDI-DrugBank.d353.s1.e3	DDI-DrugBank.d353.s1.e4
DDI-DrugBank.d353.s2|a|Repeating the study with 6 healthy male volunteers in the absence of glibenclamide did not detect an effect of acitretin on glucose tolerance.
DDI-DrugBank.d353.s2	69	81	glibenclamide	drug	DDI-DrugBank.d353.s2.e0
DDI-DrugBank.d353.s2	111	119	acitretin	drug	DDI-DrugBank.d353.s2.e1
DDI-DrugBank.d353.s2	false	DDI-DrugBank.d353.s2.e0	DDI-DrugBank.d353.s2.e1
DDI-DrugBank.d353.s3|a|Careful supervision of diabetic patients under treatment with Soriatane is recommended.
DDI-DrugBank.d353.s3	62	70	Soriatane	brand	DDI-DrugBank.d353.s3.e0
DDI-DrugBank.d353.s4|a|Hormonal Contraceptives: It has not been established if there is a pharmacokinetic interaction between acitretin and combined oral contraceptives.
DDI-DrugBank.d353.s4	0	22	Hormonal Contraceptives	group	DDI-DrugBank.d353.s4.e0
DDI-DrugBank.d353.s4	103	111	acitretin	drug	DDI-DrugBank.d353.s4.e1
DDI-DrugBank.d353.s4	117	144	combined oral contraceptives	group	DDI-DrugBank.d353.s4.e2
DDI-DrugBank.d353.s4	false	DDI-DrugBank.d353.s4.e0	DDI-DrugBank.d353.s4.e1
DDI-DrugBank.d353.s4	false	DDI-DrugBank.d353.s4.e0	DDI-DrugBank.d353.s4.e2
DDI-DrugBank.d353.s4	false	DDI-DrugBank.d353.s4.e1	DDI-DrugBank.d353.s4.e2
DDI-DrugBank.d353.s5|a|However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.
DDI-DrugBank.d353.s5	38	46	acitretin	drug	DDI-DrugBank.d353.s5.e0
DDI-DrugBank.d353.s5	103	111	progestin	drug	DDI-DrugBank.d353.s5.e1
DDI-DrugBank.d353.s5	true	DDI-DrugBank.d353.s5.e0	DDI-DrugBank.d353.s5.e1
DDI-DrugBank.d353.s6|a|Microdosed minipill progestin preparations are not recommended for use with Soriatane.
DDI-DrugBank.d353.s6	20	28	progestin	drug	DDI-DrugBank.d353.s6.e0
DDI-DrugBank.d353.s6	76	84	Soriatane	drug	DDI-DrugBank.d353.s6.e1
DDI-DrugBank.d353.s6	true	DDI-DrugBank.d353.s6.e0	DDI-DrugBank.d353.s6.e1
DDI-DrugBank.d353.s7|a|It is not known whether other progestational contraceptives, such as implants and injectables, are adequate methods of contraception during acitretin therapy.
DDI-DrugBank.d353.s7	30	58	progestational contraceptives	group	DDI-DrugBank.d353.s7.e0
DDI-DrugBank.d353.s7	140	148	acitretin	drug	DDI-DrugBank.d353.s7.e1
DDI-DrugBank.d353.s7	false	DDI-DrugBank.d353.s7.e0	DDI-DrugBank.d353.s7.e1
DDI-DrugBank.d353.s8|a|Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.
DDI-DrugBank.d353.s8	0	11	Methotrexate	drug	DDI-DrugBank.d353.s8.e0
DDI-DrugBank.d353.s8	94	105	methotrexate	drug	DDI-DrugBank.d353.s8.e1
DDI-DrugBank.d353.s8	111	120	etretinate	drug	DDI-DrugBank.d353.s8.e2
DDI-DrugBank.d353.s8	false	DDI-DrugBank.d353.s8.e0	DDI-DrugBank.d353.s8.e1
DDI-DrugBank.d353.s8	false	DDI-DrugBank.d353.s8.e0	DDI-DrugBank.d353.s8.e2
DDI-DrugBank.d353.s8	true	DDI-DrugBank.d353.s8.e1	DDI-DrugBank.d353.s8.e2
DDI-DrugBank.d353.s9|a|Consequently, the combination of methotrexate with acitretin is also contraindicated.
DDI-DrugBank.d353.s9	33	44	methotrexate	drug	DDI-DrugBank.d353.s9.e0
DDI-DrugBank.d353.s9	51	59	acitretin	drug	DDI-DrugBank.d353.s9.e1
DDI-DrugBank.d353.s9	true	DDI-DrugBank.d353.s9.e0	DDI-DrugBank.d353.s9.e1
DDI-DrugBank.d353.s10|a|Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
DDI-DrugBank.d353.s10	0	8	Phenytoin	drug	DDI-DrugBank.d353.s10.e0
DDI-DrugBank.d353.s10	14	22	acitretin	drug	DDI-DrugBank.d353.s10.e1
DDI-DrugBank.d353.s10	51	59	phenytoin	drug	DDI-DrugBank.d353.s10.e2
DDI-DrugBank.d353.s10	85	93	phenytoin	drug	DDI-DrugBank.d353.s10.e3
DDI-DrugBank.d353.s10	false	DDI-DrugBank.d353.s10.e0	DDI-DrugBank.d353.s10.e1
DDI-DrugBank.d353.s10	false	DDI-DrugBank.d353.s10.e0	DDI-DrugBank.d353.s10.e2
DDI-DrugBank.d353.s10	false	DDI-DrugBank.d353.s10.e0	DDI-DrugBank.d353.s10.e3
DDI-DrugBank.d353.s10	true	DDI-DrugBank.d353.s10.e1	DDI-DrugBank.d353.s10.e2
DDI-DrugBank.d353.s10	false	DDI-DrugBank.d353.s10.e1	DDI-DrugBank.d353.s10.e3
DDI-DrugBank.d353.s10	false	DDI-DrugBank.d353.s10.e2	DDI-DrugBank.d353.s10.e3
DDI-DrugBank.d353.s11|a|Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.
DDI-DrugBank.d353.s11	0	12	Tetracyclines	group	DDI-DrugBank.d353.s11.e0
DDI-DrugBank.d353.s11	26	34	acitretin	drug	DDI-DrugBank.d353.s11.e1
DDI-DrugBank.d353.s11	40	52	tetracyclines	group	DDI-DrugBank.d353.s11.e2
DDI-DrugBank.d353.s11	false	DDI-DrugBank.d353.s11.e0	DDI-DrugBank.d353.s11.e1
DDI-DrugBank.d353.s11	false	DDI-DrugBank.d353.s11.e0	DDI-DrugBank.d353.s11.e2
DDI-DrugBank.d353.s11	true	DDI-DrugBank.d353.s11.e1	DDI-DrugBank.d353.s11.e2
DDI-DrugBank.d353.s12|a|Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
DDI-DrugBank.d353.s12	0	8	Vitamin A	group	DDI-DrugBank.d353.s12.e0
DDI-DrugBank.d353.s12	19	27	retinoids	group	DDI-DrugBank.d353.s12.e1
DDI-DrugBank.d353.s12	60	68	vitamin A	group	DDI-DrugBank.d353.s12.e2
DDI-DrugBank.d353.s12	88	96	retinoids	group	DDI-DrugBank.d353.s12.e3
DDI-DrugBank.d353.s12	103	111	acitretin	drug	DDI-DrugBank.d353.s12.e4
DDI-DrugBank.d353.s12	false	DDI-DrugBank.d353.s12.e0	DDI-DrugBank.d353.s12.e1
DDI-DrugBank.d353.s12	false	DDI-DrugBank.d353.s12.e0	DDI-DrugBank.d353.s12.e2
DDI-DrugBank.d353.s12	false	DDI-DrugBank.d353.s12.e0	DDI-DrugBank.d353.s12.e3
DDI-DrugBank.d353.s12	false	DDI-DrugBank.d353.s12.e0	DDI-DrugBank.d353.s12.e4
DDI-DrugBank.d353.s12	false	DDI-DrugBank.d353.s12.e1	DDI-DrugBank.d353.s12.e2
DDI-DrugBank.d353.s12	false	DDI-DrugBank.d353.s12.e1	DDI-DrugBank.d353.s12.e3
DDI-DrugBank.d353.s12	false	DDI-DrugBank.d353.s12.e1	DDI-DrugBank.d353.s12.e4
DDI-DrugBank.d353.s12	false	DDI-DrugBank.d353.s12.e2	DDI-DrugBank.d353.s12.e3
DDI-DrugBank.d353.s12	true	DDI-DrugBank.d353.s12.e2	DDI-DrugBank.d353.s12.e4
DDI-DrugBank.d353.s12	true	DDI-DrugBank.d353.s12.e3	DDI-DrugBank.d353.s12.e4
DDI-DrugBank.d353.s13|a|Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide.
DDI-DrugBank.d353.s13	66	74	acitretin	drug	DDI-DrugBank.d353.s13.e0
DDI-DrugBank.d353.s13	80	89	cimetidine	drug	DDI-DrugBank.d353.s13.e1
DDI-DrugBank.d353.s13	92	98	digoxin	drug	DDI-DrugBank.d353.s13.e2
DDI-DrugBank.d353.s13	104	112	glyburide	drug	DDI-DrugBank.d353.s13.e3
DDI-DrugBank.d353.s13	false	DDI-DrugBank.d353.s13.e0	DDI-DrugBank.d353.s13.e1
DDI-DrugBank.d353.s13	false	DDI-DrugBank.d353.s13.e0	DDI-DrugBank.d353.s13.e2
DDI-DrugBank.d353.s13	false	DDI-DrugBank.d353.s13.e0	DDI-DrugBank.d353.s13.e3
DDI-DrugBank.d353.s13	false	DDI-DrugBank.d353.s13.e1	DDI-DrugBank.d353.s13.e2
DDI-DrugBank.d353.s13	false	DDI-DrugBank.d353.s13.e1	DDI-DrugBank.d353.s13.e3
DDI-DrugBank.d353.s13	false	DDI-DrugBank.d353.s13.e2	DDI-DrugBank.d353.s13.e3
DDI-DrugBank.d353.s14|a|Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.
DDI-DrugBank.d353.s14	34	42	acitretin	drug	DDI-DrugBank.d353.s14.e0
DDI-DrugBank.d353.s14	70	104	anticoagulants of the coumarin type	group	DDI-DrugBank.d353.s14.e1
DDI-DrugBank.d353.s14	107	114	warfarin	drug	DDI-DrugBank.d353.s14.e2
DDI-DrugBank.d353.s14	false	DDI-DrugBank.d353.s14.e0	DDI-DrugBank.d353.s14.e1
DDI-DrugBank.d353.s14	false	DDI-DrugBank.d353.s14.e0	DDI-DrugBank.d353.s14.e2
DDI-DrugBank.d353.s14	false	DDI-DrugBank.d353.s14.e1	DDI-DrugBank.d353.s14.e2
DDI-DrugBank.d353.s15|a|Laboratory Tests If significant abnormal laboratory results are obtained, either dosage reduction with careful monitoring or treatment discontinuation is recommended, depending on clinical judgement.
DDI-DrugBank.d353.s16|a|Blood Sugar: Some patients receiving retinoids have experienced problems with blood sugar control.
DDI-DrugBank.d353.s16	37	45	retinoids	group	DDI-DrugBank.d353.s16.e0
DDI-DrugBank.d353.s17|a|In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.
DDI-DrugBank.d353.s17	62	69	retinoid	group	DDI-DrugBank.d353.s17.e0
DDI-DrugBank.d353.s18|a|In diabetics, blood-sugar levels should be monitored very carefully.
DDI-DrugBank.d353.s19|a|Lipids: In clinical studies, the incidence of hypertriglyceridemia was 66%, hypercholesterolemia was 33% and that of decreased HDL was 40%.
DDI-DrugBank.d353.s20|a|Pretreatment and follow-up measurements should be obtained under fasting conditions.
DDI-DrugBank.d353.s21|a|It is recommended that these tests be performed weekly or every other week until the lipid response to Soriatane has stabilized.
DDI-DrugBank.d353.s21	103	111	Soriatane	brand	DDI-DrugBank.d353.s21.e0
DDI-DrugBank.d353.s22|a|Liver Function Tests: Elevations of AST (SGOT), ALT (SGPT) or LDH were experienced by approximately 1 in 3 patients treated with Soriatane.
DDI-DrugBank.d353.s22	129	137	Soriatane	brand	DDI-DrugBank.d353.s22.e0
DDI-DrugBank.d353.s23|a|It is recommended that these tests be performed prior to initiation of Soriatane therapy, at 1- to 2-week intervals until stable and thereafter at intervals as clinically indicated.
DDI-DrugBank.d353.s23	71	79	Soriatane	brand	DDI-DrugBank.d353.s23.e0
DDI-DrugBank.d493.s0|a|Methotrexate: HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX.
DDI-DrugBank.d493.s0	0	11	Methotrexate	drug	DDI-DrugBank.d493.s0.e0
DDI-DrugBank.d493.s0	14	19	HUMIRA	brand	DDI-DrugBank.d493.s0.e1
DDI-DrugBank.d493.s0	90	92	MTX	drug	DDI-DrugBank.d493.s0.e2
DDI-DrugBank.d493.s0	false	DDI-DrugBank.d493.s0.e0	DDI-DrugBank.d493.s0.e1
DDI-DrugBank.d493.s0	false	DDI-DrugBank.d493.s0.e0	DDI-DrugBank.d493.s0.e2
DDI-DrugBank.d493.s0	false	DDI-DrugBank.d493.s0.e1	DDI-DrugBank.d493.s0.e2
DDI-DrugBank.d493.s1|a|The data do not suggest the need for dose adjustment of either HUMIRA or MTX.
DDI-DrugBank.d493.s1	63	68	HUMIRA	brand	DDI-DrugBank.d493.s1.e0
DDI-DrugBank.d493.s1	73	75	MTX	drug	DDI-DrugBank.d493.s1.e1
DDI-DrugBank.d493.s1	false	DDI-DrugBank.d493.s1.e0	DDI-DrugBank.d493.s1.e1
DDI-DrugBank.d493.s2|a|Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
DDI-DrugBank.d493.s2	0	7	Anakinra	drug	DDI-DrugBank.d493.s2.e0
DDI-DrugBank.d493.s2	39	46	anakinra	drug	DDI-DrugBank.d493.s2.e1
DDI-DrugBank.d493.s2	52	75	interleukin-1 antagonist	group	DDI-DrugBank.d493.s2.e2
DDI-DrugBank.d493.s2	90	107	TNF-blocking agent	group	DDI-DrugBank.d493.s2.e3
DDI-DrugBank.d493.s2	false	DDI-DrugBank.d493.s2.e0	DDI-DrugBank.d493.s2.e1
DDI-DrugBank.d493.s2	false	DDI-DrugBank.d493.s2.e0	DDI-DrugBank.d493.s2.e2
DDI-DrugBank.d493.s2	false	DDI-DrugBank.d493.s2.e0	DDI-DrugBank.d493.s2.e3
DDI-DrugBank.d493.s2	false	DDI-DrugBank.d493.s2.e1	DDI-DrugBank.d493.s2.e2
DDI-DrugBank.d493.s2	true	DDI-DrugBank.d493.s2.e1	DDI-DrugBank.d493.s2.e3
DDI-DrugBank.d493.s2	true	DDI-DrugBank.d493.s2.e2	DDI-DrugBank.d493.s2.e3
DDI-DrugBank.d493.s3|a|The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.
DDI-DrugBank.d493.s3	27	34	anakinra	drug	DDI-DrugBank.d493.s3.e0
DDI-DrugBank.d493.s3	61	66	HUMIRA	brand	DDI-DrugBank.d493.s3.e1
DDI-DrugBank.d493.s3	false	DDI-DrugBank.d493.s3.e0	DDI-DrugBank.d493.s3.e1
DDI-DrugBank.d493.s4|a|Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
DDI-DrugBank.d493.s4	30	37	anakinra	drug	DDI-DrugBank.d493.s4.e0
DDI-DrugBank.d493.s4	50	68	TNF-blocking agents	group	DDI-DrugBank.d493.s4.e1
DDI-DrugBank.d493.s4	81	86	HUMIRA	brand	DDI-DrugBank.d493.s4.e2
DDI-DrugBank.d493.s4	true	DDI-DrugBank.d493.s4.e0	DDI-DrugBank.d493.s4.e1
DDI-DrugBank.d493.s4	true	DDI-DrugBank.d493.s4.e0	DDI-DrugBank.d493.s4.e2
DDI-DrugBank.d493.s4	false	DDI-DrugBank.d493.s4.e1	DDI-DrugBank.d493.s4.e2
DDI-DrugBank.d370.s0|a|As DIFFERIN Gel has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime) should be approached with caution.
DDI-DrugBank.d370.s0	3	10	DIFFERIN	brand	DDI-DrugBank.d370.s0.e0
DDI-DrugBank.d370.s1|a|Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.
DDI-DrugBank.d370.s1	72	77	sulfur	drug	DDI-DrugBank.d370.s1.e0
DDI-DrugBank.d370.s1	80	89	resorcinol	drug	DDI-DrugBank.d370.s1.e1
DDI-DrugBank.d370.s1	95	108	salicylic acid	drug	DDI-DrugBank.d370.s1.e2
DDI-DrugBank.d370.s1	130	137	DIFFERIN	brand	DDI-DrugBank.d370.s1.e3
DDI-DrugBank.d370.s1	false	DDI-DrugBank.d370.s1.e0	DDI-DrugBank.d370.s1.e1
DDI-DrugBank.d370.s1	false	DDI-DrugBank.d370.s1.e0	DDI-DrugBank.d370.s1.e2
DDI-DrugBank.d370.s1	false	DDI-DrugBank.d370.s1.e0	DDI-DrugBank.d370.s1.e3
DDI-DrugBank.d370.s1	false	DDI-DrugBank.d370.s1.e1	DDI-DrugBank.d370.s1.e2
DDI-DrugBank.d370.s1	false	DDI-DrugBank.d370.s1.e1	DDI-DrugBank.d370.s1.e3
DDI-DrugBank.d370.s1	false	DDI-DrugBank.d370.s1.e2	DDI-DrugBank.d370.s1.e3
DDI-DrugBank.d370.s2|a|If these preparations have been used it is advisable not to start therapy with DIFFERIN Gel until the effects of such preparations in the skin have subsided.
DDI-DrugBank.d370.s2	79	86	DIFFERIN	brand	DDI-DrugBank.d370.s2.e0
DDI-DrugBank.d244.s0|a|Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
DDI-DrugBank.d244.s0	138	152	aminoglycosides	group	DDI-DrugBank.d244.s0.e0
DDI-DrugBank.d244.s0	161	170	gentamicin	drug	DDI-DrugBank.d244.s0.e1
DDI-DrugBank.d244.s0	173	180	amikacin	drug	DDI-DrugBank.d244.s0.e2
DDI-DrugBank.d244.s0	184	197	amphotericin B	drug	DDI-DrugBank.d244.s0.e3
DDI-DrugBank.d244.s0	200	211	cyclosporine	drug	DDI-DrugBank.d244.s0.e4
DDI-DrugBank.d244.s0	214	244	non-steroidal anti-inflammatory	group	DDI-DrugBank.d244.s0.e5
DDI-DrugBank.d244.s0	259	267	ibuprofen	drug	DDI-DrugBank.d244.s0.e6
DDI-DrugBank.d244.s0	271	280	tacrolimus	drug	DDI-DrugBank.d244.s0.e7
DDI-DrugBank.d244.s0	283	292	vancomycin	drug	DDI-DrugBank.d244.s0.e8
DDI-DrugBank.d244.s0	false	DDI-DrugBank.d244.s0.e0	DDI-DrugBank.d244.s0.e1
DDI-DrugBank.d244.s0	false	DDI-DrugBank.d244.s0.e0	DDI-DrugBank.d244.s0.e2
DDI-DrugBank.d244.s0	false	DDI-DrugBank.d244.s0.e0	DDI-DrugBank.d244.s0.e3
DDI-DrugBank.d244.s0	false	DDI-DrugBank.d244.s0.e0	DDI-DrugBank.d244.s0.e4
DDI-DrugBank.d244.s0	false	DDI-DrugBank.d244.s0.e0	DDI-DrugBank.d244.s0.e5
DDI-DrugBank.d244.s0	false	DDI-DrugBank.d244.s0.e0	DDI-DrugBank.d244.s0.e6
DDI-DrugBank.d244.s0	false	DDI-DrugBank.d244.s0.e0	DDI-DrugBank.d244.s0.e7
DDI-DrugBank.d244.s0	false	DDI-DrugBank.d244.s0.e0	DDI-DrugBank.d244.s0.e8
DDI-DrugBank.d244.s0	false	DDI-DrugBank.d244.s0.e1	DDI-DrugBank.d244.s0.e2
DDI-DrugBank.d244.s0	false	DDI-DrugBank.d244.s0.e1	DDI-DrugBank.d244.s0.e3
DDI-DrugBank.d244.s1|a|Do not start or stop any medicine without doctor or pharmacist approval.
DDI-DrugBank.d226.s0|a|Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
DDI-DrugBank.d226.s0	12	20	Adenocard	brand	DDI-DrugBank.d226.s0.e0
DDI-DrugBank.d226.s0	23	31	adenosine	drug	DDI-DrugBank.d226.s0.e1
DDI-DrugBank.d226.s0	121	129	quinidine	drug	DDI-DrugBank.d226.s0.e2
DDI-DrugBank.d226.s0	132	162	beta-adrenergic blocking agents	group	DDI-DrugBank.d226.s0.e3
DDI-DrugBank.d226.s0	165	195	calcium channel blocking agents	group	DDI-DrugBank.d226.s0.e4
DDI-DrugBank.d226.s0	202	241	angiotensin converting enzyme inhibitors	group	DDI-DrugBank.d226.s0.e5
DDI-DrugBank.d226.s0	false	DDI-DrugBank.d226.s0.e0	DDI-DrugBank.d226.s0.e1
DDI-DrugBank.d226.s0	false	DDI-DrugBank.d226.s0.e0	DDI-DrugBank.d226.s0.e2
DDI-DrugBank.d226.s0	false	DDI-DrugBank.d226.s0.e0	DDI-DrugBank.d226.s0.e3
DDI-DrugBank.d226.s0	false	DDI-DrugBank.d226.s0.e0	DDI-DrugBank.d226.s0.e4
DDI-DrugBank.d226.s0	false	DDI-DrugBank.d226.s0.e0	DDI-DrugBank.d226.s0.e5
DDI-DrugBank.d226.s0	false	DDI-DrugBank.d226.s0.e1	DDI-DrugBank.d226.s0.e2
DDI-DrugBank.d226.s0	false	DDI-DrugBank.d226.s0.e1	DDI-DrugBank.d226.s0.e3
DDI-DrugBank.d226.s0	false	DDI-DrugBank.d226.s0.e1	DDI-DrugBank.d226.s0.e4
DDI-DrugBank.d226.s0	false	DDI-DrugBank.d226.s0.e1	DDI-DrugBank.d226.s0.e5
DDI-DrugBank.d226.s0	false	DDI-DrugBank.d226.s0.e2	DDI-DrugBank.d226.s0.e3
DDI-DrugBank.d226.s1|a|Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
DDI-DrugBank.d226.s1	0	6	Digoxin	drug	DDI-DrugBank.d226.s1.e0
DDI-DrugBank.d226.s1	12	20	verapamil	drug	DDI-DrugBank.d226.s1.e1
DDI-DrugBank.d226.s1	100	108	Adenocard	brand	DDI-DrugBank.d226.s1.e2
DDI-DrugBank.d226.s1	false	DDI-DrugBank.d226.s1.e0	DDI-DrugBank.d226.s1.e1
DDI-DrugBank.d226.s1	true	DDI-DrugBank.d226.s1.e0	DDI-DrugBank.d226.s1.e2
DDI-DrugBank.d226.s1	true	DDI-DrugBank.d226.s1.e1	DDI-DrugBank.d226.s1.e2
DDI-DrugBank.d226.s2|a|Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenocard should be used with caution in the presence of these agents.
DDI-DrugBank.d226.s2	105	113	Adenocard	brand	DDI-DrugBank.d226.s2.e0
DDI-DrugBank.d226.s3|a|The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.
DDI-DrugBank.d226.s3	11	19	Adenocard	brand	DDI-DrugBank.d226.s3.e0
DDI-DrugBank.d226.s3	43	51	digitalis	group	DDI-DrugBank.d226.s3.e1
DDI-DrugBank.d226.s3	true	DDI-DrugBank.d226.s3.e0	DDI-DrugBank.d226.s3.e1
DDI-DrugBank.d226.s4|a|The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
DDI-DrugBank.d226.s4	15	23	adenosine	drug	DDI-DrugBank.d226.s4.e0
DDI-DrugBank.d226.s4	44	58	methylxanthines	group	DDI-DrugBank.d226.s4.e1
DDI-DrugBank.d226.s4	68	75	caffeine	drug	DDI-DrugBank.d226.s4.e2
DDI-DrugBank.d226.s4	81	92	theophylline	drug	DDI-DrugBank.d226.s4.e3
DDI-DrugBank.d226.s4	true	DDI-DrugBank.d226.s4.e0	DDI-DrugBank.d226.s4.e1
DDI-DrugBank.d226.s4	true	DDI-DrugBank.d226.s4.e0	DDI-DrugBank.d226.s4.e2
DDI-DrugBank.d226.s4	true	DDI-DrugBank.d226.s4.e0	DDI-DrugBank.d226.s4.e3
DDI-DrugBank.d226.s4	false	DDI-DrugBank.d226.s4.e1	DDI-DrugBank.d226.s4.e2
DDI-DrugBank.d226.s4	false	DDI-DrugBank.d226.s4.e1	DDI-DrugBank.d226.s4.e3
DDI-DrugBank.d226.s4	false	DDI-DrugBank.d226.s4.e2	DDI-DrugBank.d226.s4.e3
DDI-DrugBank.d226.s5|a|In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.
DDI-DrugBank.d226.s5	25	39	methylxanthines	group	DDI-DrugBank.d226.s5.e0
DDI-DrugBank.d226.s5	58	66	adenosine	drug	DDI-DrugBank.d226.s5.e1
DDI-DrugBank.d226.s5	87	95	adenosine	drug	DDI-DrugBank.d226.s5.e2
DDI-DrugBank.d226.s5	true	DDI-DrugBank.d226.s5.e0	DDI-DrugBank.d226.s5.e1
DDI-DrugBank.d226.s5	true	DDI-DrugBank.d226.s5.e0	DDI-DrugBank.d226.s5.e2
DDI-DrugBank.d226.s5	false	DDI-DrugBank.d226.s5.e1	DDI-DrugBank.d226.s5.e2
DDI-DrugBank.d226.s6|a|Adenosine effects are potentiated by dipyridamole.
DDI-DrugBank.d226.s6	0	8	Adenosine	drug	DDI-DrugBank.d226.s6.e0
DDI-DrugBank.d226.s6	37	48	dipyridamole	drug	DDI-DrugBank.d226.s6.e1
DDI-DrugBank.d226.s6	true	DDI-DrugBank.d226.s6.e0	DDI-DrugBank.d226.s6.e1
DDI-DrugBank.d226.s7|a|Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.
DDI-DrugBank.d226.s7	23	31	adenosine	drug	DDI-DrugBank.d226.s7.e0
DDI-DrugBank.d226.s7	69	80	dipyridamole	drug	DDI-DrugBank.d226.s7.e1
DDI-DrugBank.d226.s7	true	DDI-DrugBank.d226.s7.e0	DDI-DrugBank.d226.s7.e1
DDI-DrugBank.d226.s8|a|Carbamazepine has been reported to increase the degree of heart block produced by other agents.
DDI-DrugBank.d226.s8	0	12	Carbamazepine	drug	DDI-DrugBank.d226.s8.e0
DDI-DrugBank.d226.s9|a|As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.
DDI-DrugBank.d226.s9	25	33	adenosine	drug	DDI-DrugBank.d226.s9.e0
DDI-DrugBank.d226.s9	148	160	carbamazepine	drug	DDI-DrugBank.d226.s9.e1
DDI-DrugBank.d226.s9	true	DDI-DrugBank.d226.s9.e0	DDI-DrugBank.d226.s9.e1
DDI-DrugBank.d449.s0|a|Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended.
DDI-DrugBank.d449.s0	23	39	antifungal agents	group	DDI-DrugBank.d449.s0.e0
DDI-DrugBank.d449.s0	49	60	ketoconazole	drug	DDI-DrugBank.d449.s0.e1
DDI-DrugBank.d449.s0	65	76	itraconazole	drug	DDI-DrugBank.d449.s0.e2
DDI-DrugBank.d449.s0	false	DDI-DrugBank.d449.s0.e0	DDI-DrugBank.d449.s0.e1
DDI-DrugBank.d449.s0	false	DDI-DrugBank.d449.s0.e0	DDI-DrugBank.d449.s0.e2
DDI-DrugBank.d449.s0	false	DDI-DrugBank.d449.s0.e1	DDI-DrugBank.d449.s0.e2
DDI-DrugBank.d449.s1|a|Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
DDI-DrugBank.d449.s1	0	9	Nafazodone	drug	DDI-DrugBank.d449.s1.e0
DDI-DrugBank.d449.s1	12	22	fluvoxamine	drug	DDI-DrugBank.d449.s1.e1
DDI-DrugBank.d449.s1	25	34	cimetidine	drug	DDI-DrugBank.d449.s1.e2
DDI-DrugBank.d449.s1	46	50	Xanax	brand	DDI-DrugBank.d449.s1.e3
DDI-DrugBank.d449.s1	false	DDI-DrugBank.d449.s1.e0	DDI-DrugBank.d449.s1.e1
DDI-DrugBank.d449.s1	false	DDI-DrugBank.d449.s1.e0	DDI-DrugBank.d449.s1.e2
DDI-DrugBank.d449.s1	true	DDI-DrugBank.d449.s1.e0	DDI-DrugBank.d449.s1.e3
DDI-DrugBank.d449.s1	false	DDI-DrugBank.d449.s1.e1	DDI-DrugBank.d449.s1.e2
DDI-DrugBank.d449.s1	true	DDI-DrugBank.d449.s1.e1	DDI-DrugBank.d449.s1.e3
DDI-DrugBank.d449.s1	true	DDI-DrugBank.d449.s1.e2	DDI-DrugBank.d449.s1.e3
DDI-DrugBank.d449.s2|a|Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).
DDI-DrugBank.d449.s2	0	9	Fluoxetine	drug	DDI-DrugBank.d449.s2.e0
DDI-DrugBank.d449.s2	12	14	OCs	group	DDI-DrugBank.d449.s2.e1
DDI-DrugBank.d449.s2	17	26	sertraline	drug	DDI-DrugBank.d449.s2.e2
DDI-DrugBank.d449.s2	29	37	diltiazem	drug	DDI-DrugBank.d449.s2.e3
DDI-DrugBank.d449.s2	40	60	macrolide antibiotics	group	DDI-DrugBank.d449.s2.e4
DDI-DrugBank.d449.s2	false	DDI-DrugBank.d449.s2.e0	DDI-DrugBank.d449.s2.e1
DDI-DrugBank.d449.s2	false	DDI-DrugBank.d449.s2.e0	DDI-DrugBank.d449.s2.e2
DDI-DrugBank.d449.s2	false	DDI-DrugBank.d449.s2.e0	DDI-DrugBank.d449.s2.e3
DDI-DrugBank.d449.s2	false	DDI-DrugBank.d449.s2.e0	DDI-DrugBank.d449.s2.e4
DDI-DrugBank.d449.s2	false	DDI-DrugBank.d449.s2.e1	DDI-DrugBank.d449.s2.e2
DDI-DrugBank.d449.s2	false	DDI-DrugBank.d449.s2.e1	DDI-DrugBank.d449.s2.e3
DDI-DrugBank.d449.s2	false	DDI-DrugBank.d449.s2.e1	DDI-DrugBank.d449.s2.e4
DDI-DrugBank.d449.s2	false	DDI-DrugBank.d449.s2.e2	DDI-DrugBank.d449.s2.e3
DDI-DrugBank.d449.s2	false	DDI-DrugBank.d449.s2.e2	DDI-DrugBank.d449.s2.e4
DDI-DrugBank.d449.s2	false	DDI-DrugBank.d449.s2.e3	DDI-DrugBank.d449.s2.e4
DDI-DrugBank.d164.s0|a|No drug interaction studies were performed.
DDI-DrugBank.d164.s1|a|No in vitro metabolism studies were performed.
DDI-DrugBank.d321.s0|a|Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
DDI-DrugBank.d321.s0	0	12	Dexamethasone	drug	DDI-DrugBank.d321.s0.e0
DDI-DrugBank.d321.s0	53	73	albendazole sulfoxide	drug	DDI-DrugBank.d321.s0.e1
DDI-DrugBank.d321.s0	107	119	dexamethasone	drug	DDI-DrugBank.d321.s0.e2
DDI-DrugBank.d321.s0	158	168	albendazole	drug	DDI-DrugBank.d321.s0.e3
DDI-DrugBank.d321.s0	false	DDI-DrugBank.d321.s0.e0	DDI-DrugBank.d321.s0.e1
DDI-DrugBank.d321.s0	false	DDI-DrugBank.d321.s0.e0	DDI-DrugBank.d321.s0.e2
DDI-DrugBank.d321.s0	false	DDI-DrugBank.d321.s0.e0	DDI-DrugBank.d321.s0.e3
DDI-DrugBank.d321.s0	false	DDI-DrugBank.d321.s0.e1	DDI-DrugBank.d321.s0.e2
DDI-DrugBank.d321.s0	false	DDI-DrugBank.d321.s0.e1	DDI-DrugBank.d321.s0.e3
DDI-DrugBank.d321.s0	true	DDI-DrugBank.d321.s0.e2	DDI-DrugBank.d321.s0.e3
DDI-DrugBank.d321.s1|a|Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
DDI-DrugBank.d321.s1	0	11	Praziquantel	drug	DDI-DrugBank.d321.s1.e0
DDI-DrugBank.d321.s1	32	43	praziquantel	drug	DDI-DrugBank.d321.s1.e1
DDI-DrugBank.d321.s1	128	148	albendazole sulfoxide	drug	DDI-DrugBank.d321.s1.e2
DDI-DrugBank.d321.s1	245	255	albendazole	drug	DDI-DrugBank.d321.s1.e3
DDI-DrugBank.d321.s1	false	DDI-DrugBank.d321.s1.e0	DDI-DrugBank.d321.s1.e1
DDI-DrugBank.d321.s1	false	DDI-DrugBank.d321.s1.e0	DDI-DrugBank.d321.s1.e2
DDI-DrugBank.d321.s1	false	DDI-DrugBank.d321.s1.e0	DDI-DrugBank.d321.s1.e3
DDI-DrugBank.d321.s1	true	DDI-DrugBank.d321.s1.e1	DDI-DrugBank.d321.s1.e2
DDI-DrugBank.d321.s1	false	DDI-DrugBank.d321.s1.e1	DDI-DrugBank.d321.s1.e3
DDI-DrugBank.d321.s1	false	DDI-DrugBank.d321.s1.e2	DDI-DrugBank.d321.s1.e3
DDI-DrugBank.d321.s2|a|Mean T max and mean plasma elimination half-life of albendazole sulfoxide were unchanged.
DDI-DrugBank.d321.s2	52	72	albendazole sulfoxide	drug	DDI-DrugBank.d321.s2.e0
DDI-DrugBank.d321.s3|a|The pharmacokinetics of praziquantel were unchanged following coadministration with albendazole (400 mg).
DDI-DrugBank.d321.s3	24	35	praziquantel	drug	DDI-DrugBank.d321.s3.e0
DDI-DrugBank.d321.s3	84	94	albendazole	drug	DDI-DrugBank.d321.s3.e1
DDI-DrugBank.d321.s3	false	DDI-DrugBank.d321.s3.e0	DDI-DrugBank.d321.s3.e1
DDI-DrugBank.d321.s4|a|Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
DDI-DrugBank.d321.s4	0	9	Cimetidine	drug	DDI-DrugBank.d321.s4.e0
DDI-DrugBank.d321.s4	12	32	Albendazole sulfoxide	drug	DDI-DrugBank.d321.s4.e1
DDI-DrugBank.d321.s4	142	151	cimetidine	drug	DDI-DrugBank.d321.s4.e2
DDI-DrugBank.d321.s4	188	198	albendazole	drug	DDI-DrugBank.d321.s4.e3
DDI-DrugBank.d321.s4	false	DDI-DrugBank.d321.s4.e0	DDI-DrugBank.d321.s4.e1
DDI-DrugBank.d321.s4	false	DDI-DrugBank.d321.s4.e0	DDI-DrugBank.d321.s4.e2
DDI-DrugBank.d321.s4	false	DDI-DrugBank.d321.s4.e0	DDI-DrugBank.d321.s4.e3
DDI-DrugBank.d321.s4	true	DDI-DrugBank.d321.s4.e1	DDI-DrugBank.d321.s4.e2
DDI-DrugBank.d321.s4	false	DDI-DrugBank.d321.s4.e1	DDI-DrugBank.d321.s4.e3
DDI-DrugBank.d321.s4	false	DDI-DrugBank.d321.s4.e2	DDI-DrugBank.d321.s4.e3
DDI-DrugBank.d321.s5|a|Albendazole sulfoxide plasma concentrations were unchanged 4 hours after dosing.
DDI-DrugBank.d321.s5	0	20	Albendazole sulfoxide	drug	DDI-DrugBank.d321.s5.e0
DDI-DrugBank.d321.s6|a|Theophylline: The pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.
DDI-DrugBank.d321.s6	0	11	Theophylline	drug	DDI-DrugBank.d321.s6.e0
DDI-DrugBank.d321.s6	38	49	theophylline	drug	DDI-DrugBank.d321.s6.e1
DDI-DrugBank.d321.s6	52	64	aminophylline	drug	DDI-DrugBank.d321.s6.e2
DDI-DrugBank.d321.s6	148	158	albendazole	drug	DDI-DrugBank.d321.s6.e3
DDI-DrugBank.d321.s6	false	DDI-DrugBank.d321.s6.e0	DDI-DrugBank.d321.s6.e1
DDI-DrugBank.d321.s6	false	DDI-DrugBank.d321.s6.e0	DDI-DrugBank.d321.s6.e2
DDI-DrugBank.d321.s6	false	DDI-DrugBank.d321.s6.e0	DDI-DrugBank.d321.s6.e3
DDI-DrugBank.d321.s6	false	DDI-DrugBank.d321.s6.e1	DDI-DrugBank.d321.s6.e2
DDI-DrugBank.d321.s6	false	DDI-DrugBank.d321.s6.e1	DDI-DrugBank.d321.s6.e3
DDI-DrugBank.d321.s6	false	DDI-DrugBank.d321.s6.e2	DDI-DrugBank.d321.s6.e3
DDI-DrugBank.d102.s0|a|No information provided
DDI-DrugBank.d114.s0|a|PROLEUKIN may affect central nervous function.
DDI-DrugBank.d114.s0	0	8	PROLEUKIN	brand	DDI-DrugBank.d114.s0.e0
DDI-DrugBank.d114.s1|a|Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, sedatives, tranquilizers).
DDI-DrugBank.d114.s1	76	93	psychotropic drugs	group	DDI-DrugBank.d114.s1.e0
DDI-DrugBank.d114.s1	102	110	narcotics	group	DDI-DrugBank.d114.s1.e1
DDI-DrugBank.d114.s1	113	122	analgesics	group	DDI-DrugBank.d114.s1.e2
DDI-DrugBank.d114.s1	125	135	antiemetics	group	DDI-DrugBank.d114.s1.e3
DDI-DrugBank.d114.s1	138	146	sedatives	group	DDI-DrugBank.d114.s1.e4
DDI-DrugBank.d114.s1	149	161	tranquilizers	group	DDI-DrugBank.d114.s1.e5
DDI-DrugBank.d114.s1	false	DDI-DrugBank.d114.s1.e0	DDI-DrugBank.d114.s1.e1
DDI-DrugBank.d114.s1	false	DDI-DrugBank.d114.s1.e0	DDI-DrugBank.d114.s1.e2
DDI-DrugBank.d114.s1	false	DDI-DrugBank.d114.s1.e0	DDI-DrugBank.d114.s1.e3
DDI-DrugBank.d114.s1	false	DDI-DrugBank.d114.s1.e0	DDI-DrugBank.d114.s1.e4
DDI-DrugBank.d114.s1	false	DDI-DrugBank.d114.s1.e0	DDI-DrugBank.d114.s1.e5
DDI-DrugBank.d114.s1	false	DDI-DrugBank.d114.s1.e1	DDI-DrugBank.d114.s1.e2
DDI-DrugBank.d114.s1	false	DDI-DrugBank.d114.s1.e1	DDI-DrugBank.d114.s1.e3
DDI-DrugBank.d114.s1	false	DDI-DrugBank.d114.s1.e1	DDI-DrugBank.d114.s1.e4
DDI-DrugBank.d114.s1	false	DDI-DrugBank.d114.s1.e1	DDI-DrugBank.d114.s1.e5
DDI-DrugBank.d114.s1	false	DDI-DrugBank.d114.s1.e2	DDI-DrugBank.d114.s1.e3
DDI-DrugBank.d114.s2|a|Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
DDI-DrugBank.d114.s2	65	79	aminoglycosides	group	DDI-DrugBank.d114.s2.e0
DDI-DrugBank.d114.s2	82	93	indomethacin	drug	DDI-DrugBank.d114.s2.e1
DDI-DrugBank.d114.s2	115	123	cytotoxic	group	DDI-DrugBank.d114.s2.e2
DDI-DrugBank.d114.s2	159	169	doxorubicin	drug	DDI-DrugBank.d114.s2.e3
DDI-DrugBank.d114.s2	194	205	methotrexate	drug	DDI-DrugBank.d114.s2.e4
DDI-DrugBank.d114.s2	208	219	asparaginase	drug	DDI-DrugBank.d114.s2.e5
DDI-DrugBank.d114.s2	235	243	PROLEUKIN	brand	DDI-DrugBank.d114.s2.e6
DDI-DrugBank.d114.s2	false	DDI-DrugBank.d114.s2.e0	DDI-DrugBank.d114.s2.e1
DDI-DrugBank.d114.s2	false	DDI-DrugBank.d114.s2.e0	DDI-DrugBank.d114.s2.e2
DDI-DrugBank.d114.s2	false	DDI-DrugBank.d114.s2.e0	DDI-DrugBank.d114.s2.e3
DDI-DrugBank.d114.s2	false	DDI-DrugBank.d114.s2.e0	DDI-DrugBank.d114.s2.e4
DDI-DrugBank.d114.s2	false	DDI-DrugBank.d114.s2.e0	DDI-DrugBank.d114.s2.e5
DDI-DrugBank.d114.s2	true	DDI-DrugBank.d114.s2.e0	DDI-DrugBank.d114.s2.e6
DDI-DrugBank.d114.s2	false	DDI-DrugBank.d114.s2.e1	DDI-DrugBank.d114.s2.e2
DDI-DrugBank.d114.s2	false	DDI-DrugBank.d114.s2.e1	DDI-DrugBank.d114.s2.e3
DDI-DrugBank.d114.s2	false	DDI-DrugBank.d114.s2.e1	DDI-DrugBank.d114.s2.e4
DDI-DrugBank.d114.s2	false	DDI-DrugBank.d114.s2.e1	DDI-DrugBank.d114.s2.e5
DDI-DrugBank.d114.s3|a|The safety and efficacy of PROLEUKIN in combination with any antineoplastic agents have not been established.
DDI-DrugBank.d114.s3	27	35	PROLEUKIN	brand	DDI-DrugBank.d114.s3.e0
DDI-DrugBank.d114.s3	61	81	antineoplastic agents	group	DDI-DrugBank.d114.s3.e1
DDI-DrugBank.d114.s3	false	DDI-DrugBank.d114.s3.e0	DDI-DrugBank.d114.s3.e1
DDI-DrugBank.d114.s4|a|In addition, reduced kidney and liver function secondary to PROLEUKIN treatment may delay elimination of concomitant medications and increase the risk of adverse events from those drugs.
DDI-DrugBank.d114.s4	60	68	PROLEUKIN	brand	DDI-DrugBank.d114.s4.e0
DDI-DrugBank.d114.s5|a|Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
DDI-DrugBank.d114.s5	121	129	PROLEUKIN	brand	DDI-DrugBank.d114.s5.e0
DDI-DrugBank.d114.s5	135	155	antineoplastic agents	group	DDI-DrugBank.d114.s5.e1
DDI-DrugBank.d114.s5	172	182	dacarbazine	drug	DDI-DrugBank.d114.s5.e2
DDI-DrugBank.d114.s5	185	196	cis-platinum	drug	DDI-DrugBank.d114.s5.e3
DDI-DrugBank.d114.s5	199	207	tamoxifen	drug	DDI-DrugBank.d114.s5.e4
DDI-DrugBank.d114.s5	213	227	interferon-alfa	drug	DDI-DrugBank.d114.s5.e5
DDI-DrugBank.d114.s5	true	DDI-DrugBank.d114.s5.e0	DDI-DrugBank.d114.s5.e1
DDI-DrugBank.d114.s5	true	DDI-DrugBank.d114.s5.e0	DDI-DrugBank.d114.s5.e2
DDI-DrugBank.d114.s5	true	DDI-DrugBank.d114.s5.e0	DDI-DrugBank.d114.s5.e3
DDI-DrugBank.d114.s5	true	DDI-DrugBank.d114.s5.e0	DDI-DrugBank.d114.s5.e4
DDI-DrugBank.d114.s5	true	DDI-DrugBank.d114.s5.e0	DDI-DrugBank.d114.s5.e5
DDI-DrugBank.d114.s5	false	DDI-DrugBank.d114.s5.e1	DDI-DrugBank.d114.s5.e2
DDI-DrugBank.d114.s5	false	DDI-DrugBank.d114.s5.e1	DDI-DrugBank.d114.s5.e3
DDI-DrugBank.d114.s5	false	DDI-DrugBank.d114.s5.e1	DDI-DrugBank.d114.s5.e4
DDI-DrugBank.d114.s5	false	DDI-DrugBank.d114.s5.e1	DDI-DrugBank.d114.s5.e5
DDI-DrugBank.d114.s5	false	DDI-DrugBank.d114.s5.e2	DDI-DrugBank.d114.s5.e3
DDI-DrugBank.d114.s6|a|These reactions consisted of erythema, pruritus, and hypotension and occurred within hours of administration of chemotherapy.
DDI-DrugBank.d114.s7|a|These events required medical intervention in some patients.
DDI-DrugBank.d114.s8|a|Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.
DDI-DrugBank.d114.s8	161	169	PROLEUKIN	brand	DDI-DrugBank.d114.s8.e0
DDI-DrugBank.d114.s8	175	189	interferon-alfa	drug	DDI-DrugBank.d114.s8.e1
DDI-DrugBank.d114.s8	true	DDI-DrugBank.d114.s8.e0	DDI-DrugBank.d114.s8.e1
DDI-DrugBank.d114.s9|a|Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
DDI-DrugBank.d114.s9	140	154	interferon-alfa	drug	DDI-DrugBank.d114.s9.e0
DDI-DrugBank.d114.s9	160	168	PROLEUKIN	brand	DDI-DrugBank.d114.s9.e1
DDI-DrugBank.d114.s9	true	DDI-DrugBank.d114.s9.e0	DDI-DrugBank.d114.s9.e1
DDI-DrugBank.d114.s10|a|Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
DDI-DrugBank.d114.s10	9	23	glucocorticoids	group	DDI-DrugBank.d114.s10.e0
DDI-DrugBank.d114.s10	51	59	PROLEUKIN	brand	DDI-DrugBank.d114.s10.e1
DDI-DrugBank.d114.s10	212	220	PROLEUKIN	brand	DDI-DrugBank.d114.s10.e2
DDI-DrugBank.d114.s10	264	272	PROLEUKIN	brand	DDI-DrugBank.d114.s10.e3
DDI-DrugBank.d114.s10	305	317	Beta-blockers	group	DDI-DrugBank.d114.s10.e4
DDI-DrugBank.d114.s10	329	345	antihypertensives	group	DDI-DrugBank.d114.s10.e5
DDI-DrugBank.d114.s10	388	396	PROLEUKIN	brand	DDI-DrugBank.d114.s10.e6
DDI-DrugBank.d114.s10	true	DDI-DrugBank.d114.s10.e0	DDI-DrugBank.d114.s10.e1
DDI-DrugBank.d114.s10	false	DDI-DrugBank.d114.s10.e0	DDI-DrugBank.d114.s10.e2
DDI-DrugBank.d114.s10	false	DDI-DrugBank.d114.s10.e0	DDI-DrugBank.d114.s10.e3
DDI-DrugBank.d114.s10	false	DDI-DrugBank.d114.s10.e0	DDI-DrugBank.d114.s10.e4
DDI-DrugBank.d114.s10	false	DDI-DrugBank.d114.s10.e0	DDI-DrugBank.d114.s10.e5
DDI-DrugBank.d114.s10	false	DDI-DrugBank.d114.s10.e0	DDI-DrugBank.d114.s10.e6
DDI-DrugBank.d114.s10	false	DDI-DrugBank.d114.s10.e1	DDI-DrugBank.d114.s10.e2
DDI-DrugBank.d114.s10	false	DDI-DrugBank.d114.s10.e1	DDI-DrugBank.d114.s10.e3
DDI-DrugBank.d114.s10	false	DDI-DrugBank.d114.s10.e1	DDI-DrugBank.d114.s10.e4
DDI-DrugBank.d114.s10	false	DDI-DrugBank.d114.s10.e1	DDI-DrugBank.d114.s10.e5
DDI-DrugBank.d114.s11|a|Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
DDI-DrugBank.d114.s11	29	52	Iodinated Contrast Media	group	DDI-DrugBank.d114.s11.e0
DDI-DrugBank.d114.s11	154	166	interleukin-2	drug	DDI-DrugBank.d114.s11.e1
DDI-DrugBank.d114.s11	223	259	radiographic iodinated contrast media	group	DDI-DrugBank.d114.s11.e2
DDI-DrugBank.d114.s11	false	DDI-DrugBank.d114.s11.e0	DDI-DrugBank.d114.s11.e1
DDI-DrugBank.d114.s11	false	DDI-DrugBank.d114.s11.e0	DDI-DrugBank.d114.s11.e2
DDI-DrugBank.d114.s11	true	DDI-DrugBank.d114.s11.e1	DDI-DrugBank.d114.s11.e2
DDI-DrugBank.d114.s12|a|The onset of symptoms usually occurred within hours (most commonly 1 to 4 hours) following the administration of contrast media.
DDI-DrugBank.d114.s13|a|These reactions include fever, chills, nausea, vomiting, pruritus, rash, diarrhea, hypotension, edema, and oliguria.
DDI-DrugBank.d114.s14|a|Some clinicians have noted that these reactions resemble the immediate side effects caused by interleukin-2 administration, however the cause of contrast reactions after interleukin-2 therapy is unknown.
DDI-DrugBank.d114.s14	94	106	interleukin-2	drug	DDI-DrugBank.d114.s14.e0
DDI-DrugBank.d114.s15|a|Most events were reported to occur when contrast media was given within 4 weeks after the last dose of interleukin-2.
DDI-DrugBank.d114.s15	103	115	interleukin-2	drug	DDI-DrugBank.d114.s15.e0
DDI-DrugBank.d114.s16|a|These events were also reported to occur when contrast media was given several months after interleukin-2 treatment.
DDI-DrugBank.d114.s16	92	104	interleukin-2	drug	DDI-DrugBank.d114.s16.e0
DDI-DrugBank.d491.s0|a|No formal interaction studies have been performed.
DDI-DrugBank.d491.s1|a|The duration of the period following treatment with AMEVIVE  before one should consider starting other immunosuppressive therapy has not been evaluated.
DDI-DrugBank.d491.s1	52	58	AMEVIVE	brand	DDI-DrugBank.d491.s1.e0
DDI-DrugBank.d491.s1	103	119	immunosuppressive	group	DDI-DrugBank.d491.s1.e1
DDI-DrugBank.d491.s1	false	DDI-DrugBank.d491.s1.e0	DDI-DrugBank.d491.s1.e1
DDI-DrugBank.d491.s2|a|Carcinogenesis, Mutagenesis, and Fertility
DDI-DrugBank.d491.s3|a|In a chronic toxicity study, cynomolgus monkeys were dosed weekly for 52 weeks with intravenous alefacept at 1 mg/kg/dose or 20 mg/kg/dose.
DDI-DrugBank.d491.s3	96	104	alefacept	drug	DDI-DrugBank.d491.s3.e0
DDI-DrugBank.d491.s4|a|One animal in the high dose group developed a B-cell lymphoma that was detected after 28 weeks of dosing.
DDI-DrugBank.d491.s5|a|Additional animals in both dose groups developed B-cell hyperplasia of the spleen and lymph nodes.
DDI-DrugBank.d491.s6|a|All animals in the study were positive for an endemic primate gammaherpes virus also known as lymphocryptovirus (LCV).
DDI-DrugBank.d491.s7|a|Latent LCV infection is generally asymptomatic, but can lead to B-cell lymphomas when animals are immune suppressed.
DDI-DrugBank.d491.s8|a|In a separate study, baboons given 3 doses of alefacept at 1 mg/kg every 8 weeks were found to have centroblast proliferation in B-cell dependent areas in the germinal centers of the spleen following a 116-day washout period.
DDI-DrugBank.d491.s8	46	54	alefacept	drug	DDI-DrugBank.d491.s8.e0
DDI-DrugBank.d491.s9|a|The role of AMEVIVE in the development of the lymphoid malignancy and the hyperplasia observed in non-human primates and the relevance to humans is unknown.
DDI-DrugBank.d491.s9	12	18	AMEVIVE	brand	DDI-DrugBank.d491.s9.e0
DDI-DrugBank.d491.s10|a|Immunodeficiency-associated lymphocyte disorders (plasmacytic hyperplasia, polymorphic proliferation, and B-cell lymphomas) occur in patients who have congenital or acquired immunodeficiencies including those resulting from immunosuppressive therapy.
DDI-DrugBank.d491.s10	224	240	immunosuppressive	group	DDI-DrugBank.d491.s10.e0
DDI-DrugBank.d491.s11|a|No carcinogenicity or fertility studies were conducted.
DDI-DrugBank.d491.s12|a|Mutagenicity studies were conducted in vitro and in vivo;
DDI-DrugBank.d491.s13|a|no evidence of mutagenicity was observed.
DDI-DrugBank.d491.s14|a|Pregnancy (Category B)
DDI-DrugBank.d491.s15|a|Women of childbearing potential make up a considerable segment of the patient population affected by psoriasis.
DDI-DrugBank.d491.s16|a|Since the effect of AMEVIVE on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking AMEVIVE who become pregnant into the Biogen Pregnancy Registry by calling 1-866-AMEVIVE (1-866-263-8483).
DDI-DrugBank.d491.s16	20	26	AMEVIVE	brand	DDI-DrugBank.d491.s16.e0
DDI-DrugBank.d491.s16	188	194	AMEVIVE	brand	DDI-DrugBank.d491.s16.e1
DDI-DrugBank.d491.s16	268	274	AMEVIVE	brand	DDI-DrugBank.d491.s16.e2
DDI-DrugBank.d491.s16	false	DDI-DrugBank.d491.s16.e0	DDI-DrugBank.d491.s16.e1
DDI-DrugBank.d491.s16	false	DDI-DrugBank.d491.s16.e0	DDI-DrugBank.d491.s16.e2
DDI-DrugBank.d491.s16	false	DDI-DrugBank.d491.s16.e1	DDI-DrugBank.d491.s16.e2
DDI-DrugBank.d491.s17|a|Reproductive toxicology studies have been performed in cynomolgus monkeys at doses up to 5 mg/kg/week (about 62 times the human dose based on body weight) and have revealed no evidence of impaired fertility or harm to the fetus due to AMEVIVE.
DDI-DrugBank.d491.s17	235	241	AMEVIVE	brand	DDI-DrugBank.d491.s17.e0
DDI-DrugBank.d491.s18|a|No abortifacient or teratogenic effects were observed in cynomolgus monkeys following intravenous bolus injections of AMEVIVE administered weekly during the period of organogenesis to gestation.
DDI-DrugBank.d491.s18	118	124	AMEVIVE	brand	DDI-DrugBank.d491.s18.e0
DDI-DrugBank.d491.s19|a|AMEVIVE underwent trans-placental passage and produced in utero exposure in the developing monkeys.
DDI-DrugBank.d491.s19	0	6	AMEVIVE	brand	DDI-DrugBank.d491.s19.e0
DDI-DrugBank.d491.s20|a|In utero, serum levels of exposure in these monkeys were 23% of maternal serum levels.
DDI-DrugBank.d491.s21|a|No evidence of fetal toxicity including adverse effects on immune system development was observed in any of these animals.
DDI-DrugBank.d491.s22|a|Animal reproduction studies, however, are not always predictive of human response and there are no adequate and well-controlled studies in pregnant women.
DDI-DrugBank.d491.s23|a|Because the risk to the development of the fetal immune system and postnatal immune function in humans is unknown, AMEVIVE  should be used during pregnancy only if clearly needed.
DDI-DrugBank.d491.s23	115	121	AMEVIVE	brand	DDI-DrugBank.d491.s23.e0
DDI-DrugBank.d491.s24|a|If pregnancy occurs while taking AMEVIVE, continued use of the drug should be assessed.
DDI-DrugBank.d491.s24	33	39	AMEVIVE	brand	DDI-DrugBank.d491.s24.e0
DDI-DrugBank.d491.s25|a|Nursing Mothers
DDI-DrugBank.d491.s26|a|It is not known whether AMEVIVE is excreted in human milk.
DDI-DrugBank.d491.s26	24	30	AMEVIVE	brand	DDI-DrugBank.d491.s26.e0
DDI-DrugBank.d491.s27|a|Because many drugs are excreted in human milk, and because there exists the potential for serious adverse reactions in nursing infants from AMEVIVE, a decision should be made whether to discontinue nursing while taking the drug or to discontinue the use of the drug, taking into account the importance of the drug to the mother.
DDI-DrugBank.d491.s27	140	146	AMEVIVE	brand	DDI-DrugBank.d491.s27.e0
DDI-DrugBank.d491.s28|a|Geriatric Use
DDI-DrugBank.d491.s29|a|Of the 1357 patients who received AMEVIVE in clinical trials, a total of 100 patients were
DDI-DrugBank.d491.s29	34	40	AMEVIVE	brand	DDI-DrugBank.d491.s29.e0
DDI-DrugBank.d491.s30|a|65 years of age and 13 patients were
DDI-DrugBank.d491.s31|a|75 years of age.
DDI-DrugBank.d491.s32|a|No differences in safety or efficacy were observed between older and younger patients, but there were not sufficient data to exclude important differences.
DDI-DrugBank.d491.s33|a|Because the incidence of infections and certain malignancies is higher in the elderly population, in general, caution should be used in treating the elderly.
DDI-DrugBank.d491.s34|a|Pediatric Use
DDI-DrugBank.d491.s35|a|The safety and efficacy of AMEVIVE in pediatric patients have not been studied.
DDI-DrugBank.d491.s35	27	33	AMEVIVE	brand	DDI-DrugBank.d491.s35.e0
DDI-DrugBank.d491.s36|a|AMEVIVE is not indicated for pediatric patients.
DDI-DrugBank.d491.s36	0	6	AMEVIVE	brand	DDI-DrugBank.d491.s36.e0
DDI-DrugBank.d407.s0|a|Drug/Laboratory Interactions No formal drug interaction studies have been performed with Campath.
DDI-DrugBank.d407.s0	89	95	Campath	brand	DDI-DrugBank.d407.s0.e0
DDI-DrugBank.d407.s1|a|An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies
DDI-DrugBank.d407.s1	22	28	Campath	brand	DDI-DrugBank.d407.s1.e0
DDI-DrugBank.d407.s1	96	105	antibodies	group	DDI-DrugBank.d407.s1.e1
DDI-DrugBank.d407.s1	false	DDI-DrugBank.d407.s1.e0	DDI-DrugBank.d407.s1.e1
DDI-DrugBank.d407.s2|a|.
DDI-DrugBank.d407.s3|a|
DDI-DrugBank.d430.s0|a|Intravenous ranitidine was shown to double the bioavailability of oral alendronate.
DDI-DrugBank.d430.s0	12	21	ranitidine	drug	DDI-DrugBank.d430.s0.e0
DDI-DrugBank.d430.s0	71	81	alendronate	drug	DDI-DrugBank.d430.s0.e1
DDI-DrugBank.d430.s0	true	DDI-DrugBank.d430.s0.e0	DDI-DrugBank.d430.s0.e1
DDI-DrugBank.d430.s1|a|The clinical significance of this increased bioavailability and whether similar increases will occur in patients given oral H2-antagonists is unknown;
DDI-DrugBank.d430.s1	124	137	H2-antagonists	group	DDI-DrugBank.d430.s1.e0
DDI-DrugBank.d430.s2|a|no other specific drug interaction studies were performed.
DDI-DrugBank.d430.s3|a|Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
DDI-DrugBank.d430.s3	20	26	calcium	drug	DDI-DrugBank.d430.s3.e0
DDI-DrugBank.d430.s3	38	56	multivalent cations	drug	DDI-DrugBank.d430.s3.e1
DDI-DrugBank.d430.s3	99	109	alendronate	drug	DDI-DrugBank.d430.s3.e2
DDI-DrugBank.d430.s3	false	DDI-DrugBank.d430.s3.e0	DDI-DrugBank.d430.s3.e1
DDI-DrugBank.d430.s3	true	DDI-DrugBank.d430.s3.e0	DDI-DrugBank.d430.s3.e2
DDI-DrugBank.d430.s3	true	DDI-DrugBank.d430.s3.e1	DDI-DrugBank.d430.s3.e2
DDI-DrugBank.d8.s0|a|Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
DDI-DrugBank.d8.s0	106	112	ALFENTA	brand	DDI-DrugBank.d8.s0.e0
DDI-DrugBank.d8.s0	156	170	CNS depressants	group	DDI-DrugBank.d8.s0.e1
DDI-DrugBank.d8.s0	180	191	barbiturates	group	DDI-DrugBank.d8.s0.e2
DDI-DrugBank.d8.s0	194	206	tranquilizers	group	DDI-DrugBank.d8.s0.e3
DDI-DrugBank.d8.s0	209	215	opioids	group	DDI-DrugBank.d8.s0.e4
DDI-DrugBank.d8.s0	240	250	anesthetics	group	DDI-DrugBank.d8.s0.e5
DDI-DrugBank.d8.s0	true	DDI-DrugBank.d8.s0.e0	DDI-DrugBank.d8.s0.e1
DDI-DrugBank.d8.s0	true	DDI-DrugBank.d8.s0.e0	DDI-DrugBank.d8.s0.e2
DDI-DrugBank.d8.s0	true	DDI-DrugBank.d8.s0.e0	DDI-DrugBank.d8.s0.e3
DDI-DrugBank.d8.s0	true	DDI-DrugBank.d8.s0.e0	DDI-DrugBank.d8.s0.e4
DDI-DrugBank.d8.s0	true	DDI-DrugBank.d8.s0.e0	DDI-DrugBank.d8.s0.e5
DDI-DrugBank.d8.s0	false	DDI-DrugBank.d8.s0.e1	DDI-DrugBank.d8.s0.e2
DDI-DrugBank.d8.s0	false	DDI-DrugBank.d8.s0.e1	DDI-DrugBank.d8.s0.e3
DDI-DrugBank.d8.s0	false	DDI-DrugBank.d8.s0.e1	DDI-DrugBank.d8.s0.e4
DDI-DrugBank.d8.s0	false	DDI-DrugBank.d8.s0.e1	DDI-DrugBank.d8.s0.e5
DDI-DrugBank.d8.s0	false	DDI-DrugBank.d8.s0.e2	DDI-DrugBank.d8.s0.e3
DDI-DrugBank.d8.s1|a|Postoperative respiratory depression may be enhanced or prolonged by these agents.
DDI-DrugBank.d8.s2|a|In such cases of combined treatment, the dose of one or both agents should be reduced.
DDI-DrugBank.d8.s3|a|Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
DDI-DrugBank.d8.s3	60	90	volatile inhalation anesthetics	group	DDI-DrugBank.d8.s3.e0
DDI-DrugBank.d8.s3	160	166	ALFENTA	brand	DDI-DrugBank.d8.s3.e1
DDI-DrugBank.d8.s3	201	212	erythromycin	drug	DDI-DrugBank.d8.s3.e2
DDI-DrugBank.d8.s3	219	225	ALFENTA	brand	DDI-DrugBank.d8.s3.e3
DDI-DrugBank.d8.s3	253	259	ALFENTA	brand	DDI-DrugBank.d8.s3.e4
DDI-DrugBank.d8.s3	true	DDI-DrugBank.d8.s3.e0	DDI-DrugBank.d8.s3.e1
DDI-DrugBank.d8.s3	false	DDI-DrugBank.d8.s3.e0	DDI-DrugBank.d8.s3.e2
DDI-DrugBank.d8.s3	false	DDI-DrugBank.d8.s3.e0	DDI-DrugBank.d8.s3.e3
DDI-DrugBank.d8.s3	false	DDI-DrugBank.d8.s3.e0	DDI-DrugBank.d8.s3.e4
DDI-DrugBank.d8.s3	false	DDI-DrugBank.d8.s3.e1	DDI-DrugBank.d8.s3.e2
DDI-DrugBank.d8.s3	false	DDI-DrugBank.d8.s3.e1	DDI-DrugBank.d8.s3.e3
DDI-DrugBank.d8.s3	false	DDI-DrugBank.d8.s3.e1	DDI-DrugBank.d8.s3.e4
DDI-DrugBank.d8.s3	true	DDI-DrugBank.d8.s3.e2	DDI-DrugBank.d8.s3.e3
DDI-DrugBank.d8.s3	false	DDI-DrugBank.d8.s3.e2	DDI-DrugBank.d8.s3.e4
DDI-DrugBank.d8.s3	false	DDI-DrugBank.d8.s3.e3	DDI-DrugBank.d8.s3.e4
DDI-DrugBank.d8.s4|a|Cimetidine reduces the clearance of ALFENTA.
DDI-DrugBank.d8.s4	0	9	Cimetidine	drug	DDI-DrugBank.d8.s4.e0
DDI-DrugBank.d8.s4	36	42	ALFENTA	brand	DDI-DrugBank.d8.s4.e1
DDI-DrugBank.d8.s4	true	DDI-DrugBank.d8.s4.e0	DDI-DrugBank.d8.s4.e1
DDI-DrugBank.d8.s5|a|Therefore smaller ALFENTA doses will be required with prolonged administration and the duration of action of ALFENTA my be extended.
DDI-DrugBank.d8.s5	18	24	ALFENTA	brand	DDI-DrugBank.d8.s5.e0
DDI-DrugBank.d8.s5	109	115	ALFENTA	brand	DDI-DrugBank.d8.s5.e1
DDI-DrugBank.d8.s5	false	DDI-DrugBank.d8.s5.e0	DDI-DrugBank.d8.s5.e1
DDI-DrugBank.d8.s6|a|Perioperative administration of drugs affecting hepatic blood flow or enzyme function may reduce plasma clearance and prolong recovery.
DDI-DrugBank.d273.s0|a|Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between UROXATRAL and other alpha-blockers have not been determined.
DDI-DrugBank.d273.s0	85	93	UROXATRAL	brand	DDI-DrugBank.d273.s0.e0
DDI-DrugBank.d273.s0	105	118	alpha-blockers	group	DDI-DrugBank.d273.s0.e1
DDI-DrugBank.d273.s0	false	DDI-DrugBank.d273.s0.e0	DDI-DrugBank.d273.s0.e1
DDI-DrugBank.d273.s1|a|However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.
DDI-DrugBank.d273.s1	43	51	UROXATRAL	brand	DDI-DrugBank.d273.s1.e0
DDI-DrugBank.d273.s1	98	111	alpha-blockers	group	DDI-DrugBank.d273.s1.e1
DDI-DrugBank.d273.s1	true	DDI-DrugBank.d273.s1.e0	DDI-DrugBank.d273.s1.e1
DDI-DrugBank.d90.s0|a|No drug interaction studies have been performed.
DDI-DrugBank.d533.s0|a|Effects of Other Drugs on Aliskiren Based on in-vitro studies, aliskiren is metabolized by CYP 3A4.
DDI-DrugBank.d533.s0	26	34	Aliskiren	drug	DDI-DrugBank.d533.s0.e0
DDI-DrugBank.d533.s0	63	71	aliskiren	drug	DDI-DrugBank.d533.s0.e1
DDI-DrugBank.d533.s0	false	DDI-DrugBank.d533.s0.e0	DDI-DrugBank.d533.s0.e1
DDI-DrugBank.d533.s1|a|Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
DDI-DrugBank.d533.s1	21	30	lovastatin	drug	DDI-DrugBank.d533.s1.e0
DDI-DrugBank.d533.s1	33	40	atenolol	drug	DDI-DrugBank.d533.s1.e1
DDI-DrugBank.d533.s1	43	50	warfarin	drug	DDI-DrugBank.d533.s1.e2
DDI-DrugBank.d533.s1	53	62	furosemide	drug	DDI-DrugBank.d533.s1.e3
DDI-DrugBank.d533.s1	65	71	digoxin	drug	DDI-DrugBank.d533.s1.e4
DDI-DrugBank.d533.s1	74	82	celecoxib	drug	DDI-DrugBank.d533.s1.e5
DDI-DrugBank.d533.s1	85	103	hydrochlorothiazide	drug	DDI-DrugBank.d533.s1.e6
DDI-DrugBank.d533.s1	106	113	ramipril	drug	DDI-DrugBank.d533.s1.e7
DDI-DrugBank.d533.s1	116	124	valsartan	drug	DDI-DrugBank.d533.s1.e8
DDI-DrugBank.d533.s1	127	135	metformin	drug	DDI-DrugBank.d533.s1.e9
DDI-DrugBank.d533.s1	false	DDI-DrugBank.d533.s1.e0	DDI-DrugBank.d533.s1.e1
DDI-DrugBank.d533.s1	false	DDI-DrugBank.d533.s1.e0	DDI-DrugBank.d533.s1.e2
DDI-DrugBank.d533.s1	false	DDI-DrugBank.d533.s1.e0	DDI-DrugBank.d533.s1.e3
DDI-DrugBank.d533.s1	false	DDI-DrugBank.d533.s1.e0	DDI-DrugBank.d533.s1.e4
DDI-DrugBank.d533.s1	false	DDI-DrugBank.d533.s1.e0	DDI-DrugBank.d533.s1.e5
DDI-DrugBank.d533.s1	false	DDI-DrugBank.d533.s1.e0	DDI-DrugBank.d533.s1.e6
DDI-DrugBank.d533.s1	false	DDI-DrugBank.d533.s1.e0	DDI-DrugBank.d533.s1.e7
DDI-DrugBank.d533.s1	false	DDI-DrugBank.d533.s1.e0	DDI-DrugBank.d533.s1.e8
DDI-DrugBank.d533.s1	false	DDI-DrugBank.d533.s1.e0	DDI-DrugBank.d533.s1.e9
DDI-DrugBank.d533.s1	false	DDI-DrugBank.d533.s1.e0	DDI-DrugBank.d533.s1.e10
DDI-DrugBank.d533.s2|a|Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.
DDI-DrugBank.d533.s2	21	30	irbesartan	drug	DDI-DrugBank.d533.s2.e0
DDI-DrugBank.d533.s2	40	48	aliskiren	drug	DDI-DrugBank.d533.s2.e1
DDI-DrugBank.d533.s2	true	DDI-DrugBank.d533.s2.e0	DDI-DrugBank.d533.s2.e1
DDI-DrugBank.d533.s3|a|Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.
DDI-DrugBank.d533.s3	21	32	atorvastatin	drug	DDI-DrugBank.d533.s3.e0
DDI-DrugBank.d533.s3	70	78	aliskiren	drug	DDI-DrugBank.d533.s3.e1
DDI-DrugBank.d533.s3	true	DDI-DrugBank.d533.s3.e0	DDI-DrugBank.d533.s3.e1
DDI-DrugBank.d533.s4|a|Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
DDI-DrugBank.d533.s4	0	11	Ketoconazole	drug	DDI-DrugBank.d533.s4.e0
DDI-DrugBank.d533.s4	54	65	ketoconazole	drug	DDI-DrugBank.d533.s4.e1
DDI-DrugBank.d533.s4	72	80	aliskiren	drug	DDI-DrugBank.d533.s4.e2
DDI-DrugBank.d533.s4	142	150	aliskiren	drug	DDI-DrugBank.d533.s4.e3
DDI-DrugBank.d533.s4	false	DDI-DrugBank.d533.s4.e0	DDI-DrugBank.d533.s4.e1
DDI-DrugBank.d533.s4	false	DDI-DrugBank.d533.s4.e0	DDI-DrugBank.d533.s4.e2
DDI-DrugBank.d533.s4	false	DDI-DrugBank.d533.s4.e0	DDI-DrugBank.d533.s4.e3
DDI-DrugBank.d533.s4	true	DDI-DrugBank.d533.s4.e1	DDI-DrugBank.d533.s4.e2
DDI-DrugBank.d533.s4	false	DDI-DrugBank.d533.s4.e1	DDI-DrugBank.d533.s4.e3
DDI-DrugBank.d533.s4	false	DDI-DrugBank.d533.s4.e2	DDI-DrugBank.d533.s4.e3
DDI-DrugBank.d533.s5|a|A 400 mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.
DDI-DrugBank.d533.s5	75	83	aliskiren	drug	DDI-DrugBank.d533.s5.e0
DDI-DrugBank.d533.s6|a|Effects of Aliskiren on Other Drugs Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.
DDI-DrugBank.d533.s6	11	19	Aliskiren	drug	DDI-DrugBank.d533.s6.e0
DDI-DrugBank.d533.s6	36	44	Aliskiren	drug	DDI-DrugBank.d533.s6.e1
DDI-DrugBank.d533.s6	false	DDI-DrugBank.d533.s6.e0	DDI-DrugBank.d533.s6.e1
DDI-DrugBank.d533.s7|a|Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
DDI-DrugBank.d533.s7	21	29	aliskiren	drug	DDI-DrugBank.d533.s7.e0
DDI-DrugBank.d533.s7	84	93	lovastatin	drug	DDI-DrugBank.d533.s7.e1
DDI-DrugBank.d533.s7	96	102	digoxin	drug	DDI-DrugBank.d533.s7.e2
DDI-DrugBank.d533.s7	105	113	valsartan	drug	DDI-DrugBank.d533.s7.e3
DDI-DrugBank.d533.s7	116	125	amlodipine	drug	DDI-DrugBank.d533.s7.e4
DDI-DrugBank.d533.s7	128	136	metformin	drug	DDI-DrugBank.d533.s7.e5
DDI-DrugBank.d533.s7	139	147	celecoxib	drug	DDI-DrugBank.d533.s7.e6
DDI-DrugBank.d533.s7	150	157	atenolol	drug	DDI-DrugBank.d533.s7.e7
DDI-DrugBank.d533.s7	160	171	atorvastatin	drug	DDI-DrugBank.d533.s7.e8
DDI-DrugBank.d533.s7	174	181	ramipril	drug	DDI-DrugBank.d533.s7.e9
DDI-DrugBank.d533.s7	false	DDI-DrugBank.d533.s7.e0	DDI-DrugBank.d533.s7.e1
DDI-DrugBank.d533.s7	false	DDI-DrugBank.d533.s7.e0	DDI-DrugBank.d533.s7.e2
DDI-DrugBank.d533.s7	false	DDI-DrugBank.d533.s7.e0	DDI-DrugBank.d533.s7.e3
DDI-DrugBank.d533.s7	false	DDI-DrugBank.d533.s7.e0	DDI-DrugBank.d533.s7.e4
DDI-DrugBank.d533.s7	false	DDI-DrugBank.d533.s7.e0	DDI-DrugBank.d533.s7.e5
DDI-DrugBank.d533.s7	false	DDI-DrugBank.d533.s7.e0	DDI-DrugBank.d533.s7.e6
DDI-DrugBank.d533.s7	false	DDI-DrugBank.d533.s7.e0	DDI-DrugBank.d533.s7.e7
DDI-DrugBank.d533.s7	false	DDI-DrugBank.d533.s7.e0	DDI-DrugBank.d533.s7.e8
DDI-DrugBank.d533.s7	false	DDI-DrugBank.d533.s7.e0	DDI-DrugBank.d533.s7.e9
DDI-DrugBank.d533.s7	false	DDI-DrugBank.d533.s7.e0	DDI-DrugBank.d533.s7.e10
DDI-DrugBank.d533.s8|a|Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated in a well-controlled clinical trial.
DDI-DrugBank.d533.s8	0	7	Warfarin	drug	DDI-DrugBank.d533.s8.e0
DDI-DrugBank.d533.s8	25	33	aliskiren	drug	DDI-DrugBank.d533.s8.e1
DDI-DrugBank.d533.s8	38	45	warfarin	drug	DDI-DrugBank.d533.s8.e2
DDI-DrugBank.d533.s8	false	DDI-DrugBank.d533.s8.e0	DDI-DrugBank.d533.s8.e1
DDI-DrugBank.d533.s8	false	DDI-DrugBank.d533.s8.e0	DDI-DrugBank.d533.s8.e2
DDI-DrugBank.d533.s8	false	DDI-DrugBank.d533.s8.e1	DDI-DrugBank.d533.s8.e2
DDI-DrugBank.d533.s9|a|Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
DDI-DrugBank.d533.s9	0	9	Furosemide	drug	DDI-DrugBank.d533.s9.e0
DDI-DrugBank.d533.s9	17	25	aliskiren	drug	DDI-DrugBank.d533.s9.e1
DDI-DrugBank.d533.s9	52	61	furosemide	drug	DDI-DrugBank.d533.s9.e2
DDI-DrugBank.d533.s9	84	93	furosemide	drug	DDI-DrugBank.d533.s9.e3
DDI-DrugBank.d533.s9	false	DDI-DrugBank.d533.s9.e0	DDI-DrugBank.d533.s9.e1
DDI-DrugBank.d533.s9	false	DDI-DrugBank.d533.s9.e0	DDI-DrugBank.d533.s9.e2
DDI-DrugBank.d533.s9	false	DDI-DrugBank.d533.s9.e0	DDI-DrugBank.d533.s9.e3
DDI-DrugBank.d533.s9	true	DDI-DrugBank.d533.s9.e1	DDI-DrugBank.d533.s9.e2
DDI-DrugBank.d533.s9	false	DDI-DrugBank.d533.s9.e1	DDI-DrugBank.d533.s9.e3
DDI-DrugBank.d533.s9	false	DDI-DrugBank.d533.s9.e2	DDI-DrugBank.d533.s9.e3
DDI-DrugBank.d392.s0|a|Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
DDI-DrugBank.d392.s0	26	33	Panretin	brand	DDI-DrugBank.d392.s0.e0
DDI-DrugBank.d392.s0	89	92	DEET	drug	DDI-DrugBank.d392.s0.e1
DDI-DrugBank.d392.s0	98	118	N-diethyl-m-toluamide	drug	DDI-DrugBank.d392.s0.e2
DDI-DrugBank.d392.s0	true	DDI-DrugBank.d392.s0.e0	DDI-DrugBank.d392.s0.e1
DDI-DrugBank.d392.s0	true	DDI-DrugBank.d392.s0.e0	DDI-DrugBank.d392.s0.e2
DDI-DrugBank.d392.s0	false	DDI-DrugBank.d392.s0.e1	DDI-DrugBank.d392.s0.e2
DDI-DrugBank.d392.s1|a|Animal toxicology studies showed increased DEET toxicity when DEET was included as proof of the formulation.
DDI-DrugBank.d392.s1	43	46	DEET	drug	DDI-DrugBank.d392.s1.e0
DDI-DrugBank.d392.s1	62	65	DEET	drug	DDI-DrugBank.d392.s1.e1
DDI-DrugBank.d392.s1	false	DDI-DrugBank.d392.s1.e0	DDI-DrugBank.d392.s1.e1
DDI-DrugBank.d392.s2|a|Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.
DDI-DrugBank.d392.s2	109	129	antiretroviral agents	group	DDI-DrugBank.d392.s2.e0
DDI-DrugBank.d392.s2	142	160	protease inhibitors	group	DDI-DrugBank.d392.s2.e1
DDI-DrugBank.d392.s2	163	183	macrolide antibiotics	group	DDI-DrugBank.d392.s2.e2
DDI-DrugBank.d392.s2	190	206	azole antifungals	group	DDI-DrugBank.d392.s2.e3
DDI-DrugBank.d392.s2	223	230	Panretin	brand	DDI-DrugBank.d392.s2.e4
DDI-DrugBank.d392.s2	false	DDI-DrugBank.d392.s2.e0	DDI-DrugBank.d392.s2.e1
DDI-DrugBank.d392.s2	false	DDI-DrugBank.d392.s2.e0	DDI-DrugBank.d392.s2.e2
DDI-DrugBank.d392.s2	false	DDI-DrugBank.d392.s2.e0	DDI-DrugBank.d392.s2.e3
DDI-DrugBank.d392.s2	false	DDI-DrugBank.d392.s2.e0	DDI-DrugBank.d392.s2.e4
DDI-DrugBank.d392.s2	false	DDI-DrugBank.d392.s2.e1	DDI-DrugBank.d392.s2.e2
DDI-DrugBank.d392.s2	false	DDI-DrugBank.d392.s2.e1	DDI-DrugBank.d392.s2.e3
DDI-DrugBank.d392.s2	false	DDI-DrugBank.d392.s2.e1	DDI-DrugBank.d392.s2.e4
DDI-DrugBank.d392.s2	false	DDI-DrugBank.d392.s2.e2	DDI-DrugBank.d392.s2.e3
DDI-DrugBank.d392.s2	false	DDI-DrugBank.d392.s2.e2	DDI-DrugBank.d392.s2.e4
DDI-DrugBank.d392.s2	false	DDI-DrugBank.d392.s2.e3	DDI-DrugBank.d392.s2.e4
DDI-DrugBank.d392.s3|a|No drug interaction data are available on concomitant administration of Panretin gel and systemic anti-KS agents.
DDI-DrugBank.d392.s3	72	79	Panretin	brand	DDI-DrugBank.d392.s3.e0
DDI-DrugBank.d413.s0|a|The following drug interactions were observed in some patients undergoing treatment with oral allopurinol.
DDI-DrugBank.d413.s0	94	104	allopurinol	drug	DDI-DrugBank.d413.s0.e0
DDI-DrugBank.d413.s1|a|Although the pattern of use for oral allopurinol includes longer term therapy, particularly for gout and renal calculi, the experience gained may be relevant.
DDI-DrugBank.d413.s1	37	47	allopurinol	drug	DDI-DrugBank.d413.s1.e0
DDI-DrugBank.d413.s2|a|Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
DDI-DrugBank.d413.s2	0	13	Mercaptopurine	drug	DDI-DrugBank.d413.s2.e0
DDI-DrugBank.d413.s2	15	26	Azathioprine	drug	DDI-DrugBank.d413.s2.e1
DDI-DrugBank.d413.s2	29	39	Allopurinol	drug	DDI-DrugBank.d413.s2.e2
DDI-DrugBank.d413.s2	77	90	mercaptopurine	drug	DDI-DrugBank.d413.s2.e3
DDI-DrugBank.d413.s2	96	107	azathioprine	drug	DDI-DrugBank.d413.s2.e4
DDI-DrugBank.d413.s2	112	126	6-thiouric acid	drug	DDI-DrugBank.d413.s2.e5
DDI-DrugBank.d413.s2	false	DDI-DrugBank.d413.s2.e0	DDI-DrugBank.d413.s2.e1
DDI-DrugBank.d413.s2	false	DDI-DrugBank.d413.s2.e0	DDI-DrugBank.d413.s2.e2
DDI-DrugBank.d413.s2	false	DDI-DrugBank.d413.s2.e0	DDI-DrugBank.d413.s2.e3
DDI-DrugBank.d413.s2	false	DDI-DrugBank.d413.s2.e0	DDI-DrugBank.d413.s2.e4
DDI-DrugBank.d413.s2	false	DDI-DrugBank.d413.s2.e0	DDI-DrugBank.d413.s2.e5
DDI-DrugBank.d413.s2	false	DDI-DrugBank.d413.s2.e1	DDI-DrugBank.d413.s2.e2
DDI-DrugBank.d413.s2	false	DDI-DrugBank.d413.s2.e1	DDI-DrugBank.d413.s2.e3
DDI-DrugBank.d413.s2	false	DDI-DrugBank.d413.s2.e1	DDI-DrugBank.d413.s2.e4
DDI-DrugBank.d413.s2	false	DDI-DrugBank.d413.s2.e1	DDI-DrugBank.d413.s2.e5
DDI-DrugBank.d413.s2	true	DDI-DrugBank.d413.s2.e2	DDI-DrugBank.d413.s2.e3
DDI-DrugBank.d413.s3|a|This oxidation, which is catalyzed by xanthine oxidase, inactivates mercaptopurine.
DDI-DrugBank.d413.s3	68	81	mercaptopurine	drug	DDI-DrugBank.d413.s3.e0
DDI-DrugBank.d413.s4|a|In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
DDI-DrugBank.d413.s4	22	35	mercaptopurine	drug	DDI-DrugBank.d413.s4.e0
DDI-DrugBank.d413.s4	38	47	Purinethol	brand	DDI-DrugBank.d413.s4.e1
DDI-DrugBank.d413.s4	53	64	azathioprine	drug	DDI-DrugBank.d413.s4.e2
DDI-DrugBank.d413.s4	67	72	Imuran	brand	DDI-DrugBank.d413.s4.e3
DDI-DrugBank.d413.s4	124	134	allopurinol	drug	DDI-DrugBank.d413.s4.e4
DDI-DrugBank.d413.s4	239	252	mercaptopurine	drug	DDI-DrugBank.d413.s4.e5
DDI-DrugBank.d413.s4	257	268	azathioprine	drug	DDI-DrugBank.d413.s4.e6
DDI-DrugBank.d413.s4	false	DDI-DrugBank.d413.s4.e0	DDI-DrugBank.d413.s4.e1
DDI-DrugBank.d413.s4	false	DDI-DrugBank.d413.s4.e0	DDI-DrugBank.d413.s4.e2
DDI-DrugBank.d413.s4	false	DDI-DrugBank.d413.s4.e0	DDI-DrugBank.d413.s4.e3
DDI-DrugBank.d413.s4	false	DDI-DrugBank.d413.s4.e0	DDI-DrugBank.d413.s4.e4
DDI-DrugBank.d413.s4	false	DDI-DrugBank.d413.s4.e0	DDI-DrugBank.d413.s4.e5
DDI-DrugBank.d413.s4	false	DDI-DrugBank.d413.s4.e0	DDI-DrugBank.d413.s4.e6
DDI-DrugBank.d413.s4	false	DDI-DrugBank.d413.s4.e1	DDI-DrugBank.d413.s4.e2
DDI-DrugBank.d413.s4	false	DDI-DrugBank.d413.s4.e1	DDI-DrugBank.d413.s4.e3
DDI-DrugBank.d413.s4	false	DDI-DrugBank.d413.s4.e1	DDI-DrugBank.d413.s4.e4
DDI-DrugBank.d413.s4	false	DDI-DrugBank.d413.s4.e1	DDI-DrugBank.d413.s4.e5
DDI-DrugBank.d413.s5|a|Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.
DDI-DrugBank.d413.s5	34	47	mercaptopurine	drug	DDI-DrugBank.d413.s5.e0
DDI-DrugBank.d413.s5	52	63	azathioprine	drug	DDI-DrugBank.d413.s5.e1
DDI-DrugBank.d413.s5	false	DDI-DrugBank.d413.s5.e0	DDI-DrugBank.d413.s5.e1
DDI-DrugBank.d413.s6|a|Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.
DDI-DrugBank.d413.s6	0	8	Dicumarol	drug	DDI-DrugBank.d413.s6.e0
DDI-DrugBank.d413.s6	37	47	allopurinol	drug	DDI-DrugBank.d413.s6.e1
DDI-DrugBank.d413.s6	79	91	anticoagulant	group	DDI-DrugBank.d413.s6.e2
DDI-DrugBank.d413.s6	94	102	dicumarol	drug	DDI-DrugBank.d413.s6.e3
DDI-DrugBank.d413.s6	false	DDI-DrugBank.d413.s6.e0	DDI-DrugBank.d413.s6.e1
DDI-DrugBank.d413.s6	false	DDI-DrugBank.d413.s6.e0	DDI-DrugBank.d413.s6.e2
DDI-DrugBank.d413.s6	false	DDI-DrugBank.d413.s6.e0	DDI-DrugBank.d413.s6.e3
DDI-DrugBank.d413.s6	false	DDI-DrugBank.d413.s6.e1	DDI-DrugBank.d413.s6.e2
DDI-DrugBank.d413.s6	true	DDI-DrugBank.d413.s6.e1	DDI-DrugBank.d413.s6.e3
DDI-DrugBank.d413.s6	false	DDI-DrugBank.d413.s6.e2	DDI-DrugBank.d413.s6.e3
DDI-DrugBank.d413.s7|a|The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.
DDI-DrugBank.d413.s7	94	104	allopurinol	drug	DDI-DrugBank.d413.s7.e0
DDI-DrugBank.d413.s7	138	146	dicumarol	drug	DDI-DrugBank.d413.s7.e1
DDI-DrugBank.d413.s7	false	DDI-DrugBank.d413.s7.e0	DDI-DrugBank.d413.s7.e1
DDI-DrugBank.d413.s8|a|Consequently, prothrombin time should be reassessed periodically in patients receiving both drugs.
DDI-DrugBank.d413.s9|a|Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
DDI-DrugBank.d413.s9	0	16	Uricosuric Agents	group	DDI-DrugBank.d413.s9.e0
DDI-DrugBank.d413.s9	42	51	oxipurinol	drug	DDI-DrugBank.d413.s9.e1
DDI-DrugBank.d413.s9	82	98	uricosuric agents	group	DDI-DrugBank.d413.s9.e2
DDI-DrugBank.d413.s9	185	194	oxipurinol	drug	DDI-DrugBank.d413.s9.e3
DDI-DrugBank.d413.s9	false	DDI-DrugBank.d413.s9.e0	DDI-DrugBank.d413.s9.e1
DDI-DrugBank.d413.s9	false	DDI-DrugBank.d413.s9.e0	DDI-DrugBank.d413.s9.e2
DDI-DrugBank.d413.s9	false	DDI-DrugBank.d413.s9.e0	DDI-DrugBank.d413.s9.e3
DDI-DrugBank.d413.s9	false	DDI-DrugBank.d413.s9.e1	DDI-DrugBank.d413.s9.e2
DDI-DrugBank.d413.s9	false	DDI-DrugBank.d413.s9.e1	DDI-DrugBank.d413.s9.e3
DDI-DrugBank.d413.s9	true	DDI-DrugBank.d413.s9.e2	DDI-DrugBank.d413.s9.e3
DDI-DrugBank.d413.s10|a|The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
DDI-DrugBank.d413.s10	34	50	uricosuric agents	group	DDI-DrugBank.d413.s10.e0
DDI-DrugBank.d413.s10	56	66	allopurinol	drug	DDI-DrugBank.d413.s10.e1
DDI-DrugBank.d413.s10	243	253	allopurinol	drug	DDI-DrugBank.d413.s10.e2
DDI-DrugBank.d413.s10	true	DDI-DrugBank.d413.s10.e0	DDI-DrugBank.d413.s10.e1
DDI-DrugBank.d413.s10	false	DDI-DrugBank.d413.s10.e0	DDI-DrugBank.d413.s10.e2
DDI-DrugBank.d413.s10	false	DDI-DrugBank.d413.s10.e1	DDI-DrugBank.d413.s10.e2
DDI-DrugBank.d413.s11|a|Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric agents, the possibility should be kept in mind.
DDI-DrugBank.d413.s11	112	122	allopurinol	drug	DDI-DrugBank.d413.s11.e0
DDI-DrugBank.d413.s11	153	169	uricosuric agents	group	DDI-DrugBank.d413.s11.e1
DDI-DrugBank.d413.s11	false	DDI-DrugBank.d413.s11.e0	DDI-DrugBank.d413.s11.e1
DDI-DrugBank.d413.s12|a|Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
DDI-DrugBank.d413.s12	0	17	Thiazide Diuretics	group	DDI-DrugBank.d413.s12.e0
DDI-DrugBank.d413.s12	60	70	allopurinol	drug	DDI-DrugBank.d413.s12.e1
DDI-DrugBank.d413.s12	76	93	thiazide diuretics	group	DDI-DrugBank.d413.s12.e2
DDI-DrugBank.d413.s12	132	142	allopurinol	drug	DDI-DrugBank.d413.s12.e3
DDI-DrugBank.d413.s12	false	DDI-DrugBank.d413.s12.e0	DDI-DrugBank.d413.s12.e1
DDI-DrugBank.d413.s12	false	DDI-DrugBank.d413.s12.e0	DDI-DrugBank.d413.s12.e2
DDI-DrugBank.d413.s12	false	DDI-DrugBank.d413.s12.e0	DDI-DrugBank.d413.s12.e3
DDI-DrugBank.d413.s12	true	DDI-DrugBank.d413.s12.e1	DDI-DrugBank.d413.s12.e2
DDI-DrugBank.d413.s12	false	DDI-DrugBank.d413.s12.e1	DDI-DrugBank.d413.s12.e3
DDI-DrugBank.d413.s12	false	DDI-DrugBank.d413.s12.e2	DDI-DrugBank.d413.s12.e3
DDI-DrugBank.d413.s13|a|Review of these case reports indicates that the patients were mainly receiving thiazide diuretics for hypertension and that tests to rule out decreased renal function secondary to hypertensive nephropathy were not often performed.
DDI-DrugBank.d413.s13	79	96	thiazide diuretics	group	DDI-DrugBank.d413.s13.e0
DDI-DrugBank.d413.s14|a|In those patients in whom renal insufficiency was documented, however, the recommendation to lower the dose of allopurinol was not followed.
DDI-DrugBank.d413.s14	111	121	allopurinol	drug	DDI-DrugBank.d413.s14.e0
DDI-DrugBank.d413.s15|a|Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..
DDI-DrugBank.d413.s15	172	189	thiazide diuretics	group	DDI-DrugBank.d413.s15.e0
DDI-DrugBank.d413.s15	195	205	allopurinol	drug	DDI-DrugBank.d413.s15.e1
DDI-DrugBank.d413.s15	true	DDI-DrugBank.d413.s15.e0	DDI-DrugBank.d413.s15.e1
DDI-DrugBank.d413.s16|a|Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
DDI-DrugBank.d413.s16	0	9	Ampicillin	drug	DDI-DrugBank.d413.s16.e0
DDI-DrugBank.d413.s16	11	21	Amoxicillin	drug	DDI-DrugBank.d413.s16.e1
DDI-DrugBank.d413.s16	109	118	ampicillin	drug	DDI-DrugBank.d413.s16.e2
DDI-DrugBank.d413.s16	123	133	amoxicillin	drug	DDI-DrugBank.d413.s16.e3
DDI-DrugBank.d413.s16	153	163	allopurinol	drug	DDI-DrugBank.d413.s16.e4
DDI-DrugBank.d413.s16	false	DDI-DrugBank.d413.s16.e0	DDI-DrugBank.d413.s16.e1
DDI-DrugBank.d413.s16	false	DDI-DrugBank.d413.s16.e0	DDI-DrugBank.d413.s16.e2
DDI-DrugBank.d413.s16	false	DDI-DrugBank.d413.s16.e0	DDI-DrugBank.d413.s16.e3
DDI-DrugBank.d413.s16	false	DDI-DrugBank.d413.s16.e0	DDI-DrugBank.d413.s16.e4
DDI-DrugBank.d413.s16	false	DDI-DrugBank.d413.s16.e1	DDI-DrugBank.d413.s16.e2
DDI-DrugBank.d413.s16	false	DDI-DrugBank.d413.s16.e1	DDI-DrugBank.d413.s16.e3
DDI-DrugBank.d413.s16	false	DDI-DrugBank.d413.s16.e1	DDI-DrugBank.d413.s16.e4
DDI-DrugBank.d413.s16	false	DDI-DrugBank.d413.s16.e2	DDI-DrugBank.d413.s16.e3
DDI-DrugBank.d413.s16	true	DDI-DrugBank.d413.s16.e2	DDI-DrugBank.d413.s16.e4
DDI-DrugBank.d413.s16	true	DDI-DrugBank.d413.s16.e3	DDI-DrugBank.d413.s16.e4
DDI-DrugBank.d413.s17|a|The cause of the reported association has not been established.
DDI-DrugBank.d413.s18|a|Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
DDI-DrugBank.d413.s18	0	15	Cytotoxic Agents	group	DDI-DrugBank.d413.s18.e0
DDI-DrugBank.d413.s18	54	69	cyclophosphamide	drug	DDI-DrugBank.d413.s18.e1
DDI-DrugBank.d413.s18	81	96	cytotoxic agents	group	DDI-DrugBank.d413.s18.e2
DDI-DrugBank.d413.s18	192	202	allopurinol	drug	DDI-DrugBank.d413.s18.e3
DDI-DrugBank.d413.s18	false	DDI-DrugBank.d413.s18.e0	DDI-DrugBank.d413.s18.e1
DDI-DrugBank.d413.s18	false	DDI-DrugBank.d413.s18.e0	DDI-DrugBank.d413.s18.e2
DDI-DrugBank.d413.s18	false	DDI-DrugBank.d413.s18.e0	DDI-DrugBank.d413.s18.e3
DDI-DrugBank.d413.s18	false	DDI-DrugBank.d413.s18.e1	DDI-DrugBank.d413.s18.e2
DDI-DrugBank.d413.s18	true	DDI-DrugBank.d413.s18.e1	DDI-DrugBank.d413.s18.e3
DDI-DrugBank.d413.s18	true	DDI-DrugBank.d413.s18.e2	DDI-DrugBank.d413.s18.e3
DDI-DrugBank.d413.s19|a|However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechlorethamine.
DDI-DrugBank.d413.s19	86	96	allopurinol	drug	DDI-DrugBank.d413.s19.e0
DDI-DrugBank.d413.s19	160	175	cyclophosphamide	drug	DDI-DrugBank.d413.s19.e1
DDI-DrugBank.d413.s19	178	188	doxorubicin	drug	DDI-DrugBank.d413.s19.e2
DDI-DrugBank.d413.s19	191	199	bleomycin	drug	DDI-DrugBank.d413.s19.e3
DDI-DrugBank.d413.s19	202	213	procarbazine	drug	DDI-DrugBank.d413.s19.e4
DDI-DrugBank.d413.s19	222	236	mechlorethamine	drug	DDI-DrugBank.d413.s19.e5
DDI-DrugBank.d413.s19	false	DDI-DrugBank.d413.s19.e0	DDI-DrugBank.d413.s19.e1
DDI-DrugBank.d413.s19	false	DDI-DrugBank.d413.s19.e0	DDI-DrugBank.d413.s19.e2
DDI-DrugBank.d413.s19	false	DDI-DrugBank.d413.s19.e0	DDI-DrugBank.d413.s19.e3
DDI-DrugBank.d413.s19	false	DDI-DrugBank.d413.s19.e0	DDI-DrugBank.d413.s19.e4
DDI-DrugBank.d413.s19	false	DDI-DrugBank.d413.s19.e0	DDI-DrugBank.d413.s19.e5
DDI-DrugBank.d413.s19	false	DDI-DrugBank.d413.s19.e1	DDI-DrugBank.d413.s19.e2
DDI-DrugBank.d413.s19	false	DDI-DrugBank.d413.s19.e1	DDI-DrugBank.d413.s19.e3
DDI-DrugBank.d413.s19	false	DDI-DrugBank.d413.s19.e1	DDI-DrugBank.d413.s19.e4
DDI-DrugBank.d413.s19	false	DDI-DrugBank.d413.s19.e1	DDI-DrugBank.d413.s19.e5
DDI-DrugBank.d413.s19	false	DDI-DrugBank.d413.s19.e2	DDI-DrugBank.d413.s19.e3
DDI-DrugBank.d413.s20|a|Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
DDI-DrugBank.d413.s20	0	13	Chlorpropamide	drug	DDI-DrugBank.d413.s20.e0
DDI-DrugBank.d413.s20	16	29	Chlorpropamide	drug	DDI-DrugBank.d413.s20.e1
DDI-DrugBank.d413.s20	69	79	allopurinol	drug	DDI-DrugBank.d413.s20.e2
DDI-DrugBank.d413.s20	88	98	allopurinol	drug	DDI-DrugBank.d413.s20.e3
DDI-DrugBank.d413.s20	104	117	chlorpropamide	drug	DDI-DrugBank.d413.s20.e4
DDI-DrugBank.d413.s20	false	DDI-DrugBank.d413.s20.e0	DDI-DrugBank.d413.s20.e1
DDI-DrugBank.d413.s20	false	DDI-DrugBank.d413.s20.e0	DDI-DrugBank.d413.s20.e2
DDI-DrugBank.d413.s20	false	DDI-DrugBank.d413.s20.e0	DDI-DrugBank.d413.s20.e3
DDI-DrugBank.d413.s20	false	DDI-DrugBank.d413.s20.e0	DDI-DrugBank.d413.s20.e4
DDI-DrugBank.d413.s20	true	DDI-DrugBank.d413.s20.e1	DDI-DrugBank.d413.s20.e2
DDI-DrugBank.d413.s20	false	DDI-DrugBank.d413.s20.e1	DDI-DrugBank.d413.s20.e3
DDI-DrugBank.d413.s20	false	DDI-DrugBank.d413.s20.e1	DDI-DrugBank.d413.s20.e4
DDI-DrugBank.d413.s20	false	DDI-DrugBank.d413.s20.e2	DDI-DrugBank.d413.s20.e3
DDI-DrugBank.d413.s20	false	DDI-DrugBank.d413.s20.e2	DDI-DrugBank.d413.s20.e4
DDI-DrugBank.d413.s20	true	DDI-DrugBank.d413.s20.e3	DDI-DrugBank.d413.s20.e4
DDI-DrugBank.d413.s21|a|The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
DDI-DrugBank.d413.s21	73	83	allopurinol	drug	DDI-DrugBank.d413.s21.e0
DDI-DrugBank.d413.s21	89	102	chlorpropamide	drug	DDI-DrugBank.d413.s21.e1
DDI-DrugBank.d413.s21	true	DDI-DrugBank.d413.s21.e0	DDI-DrugBank.d413.s21.e1
DDI-DrugBank.d413.s22|a|Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.
DDI-DrugBank.d413.s22	0	10	Cyclosporin	drug	DDI-DrugBank.d413.s22.e0
DDI-DrugBank.d413.s22	35	46	cyclosporine	drug	DDI-DrugBank.d413.s22.e1
DDI-DrugBank.d413.s22	106	123	allopurinol sodium	drug	DDI-DrugBank.d413.s22.e2
DDI-DrugBank.d413.s22	false	DDI-DrugBank.d413.s22.e0	DDI-DrugBank.d413.s22.e1
DDI-DrugBank.d413.s22	false	DDI-DrugBank.d413.s22.e0	DDI-DrugBank.d413.s22.e2
DDI-DrugBank.d413.s22	true	DDI-DrugBank.d413.s22.e1	DDI-DrugBank.d413.s22.e2
DDI-DrugBank.d413.s23|a|Monitoring of cyclosporine levels and possible adjustment of cyclosporine dosage should be considered when these drugs are co-administered.
DDI-DrugBank.d413.s23	14	25	cyclosporine	drug	DDI-DrugBank.d413.s23.e0
DDI-DrugBank.d413.s23	61	72	cyclosporine	drug	DDI-DrugBank.d413.s23.e1
DDI-DrugBank.d413.s23	false	DDI-DrugBank.d413.s23.e0	DDI-DrugBank.d413.s23.e1
DDI-DrugBank.d413.s24|a|Tolbutamides conversion to inactive metabolites has been shown to be catalyzed by xanthine oxidase from rat liver.
DDI-DrugBank.d413.s24	0	10	Tolbutamide	drug	DDI-DrugBank.d413.s24.e0
DDI-DrugBank.d413.s25|a|The clinical significance, if any, of these observations is unknown.
DDI-DrugBank.d299.s0|a|Ergot-Containing Drugs: These drugs have been reported to cause prolonged vasospastic reactions.
DDI-DrugBank.d299.s0	0	21	Ergot-Containing Drugs	group	DDI-DrugBank.d299.s0.e0
DDI-DrugBank.d299.s1|a|Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
DDI-DrugBank.d299.s1	80	89	ergotamine	drug	DDI-DrugBank.d299.s1.e0
DDI-DrugBank.d299.s1	105	126	ergot-type medications	group	DDI-DrugBank.d299.s1.e1
DDI-DrugBank.d299.s1	134	150	dihydroergotamine	drug	DDI-DrugBank.d299.s1.e2
DDI-DrugBank.d299.s1	155	166	methysergide	drug	DDI-DrugBank.d299.s1.e3
DDI-DrugBank.d299.s1	173	177	AXERT	brand	DDI-DrugBank.d299.s1.e4
DDI-DrugBank.d299.s1	false	DDI-DrugBank.d299.s1.e0	DDI-DrugBank.d299.s1.e1
DDI-DrugBank.d299.s1	false	DDI-DrugBank.d299.s1.e0	DDI-DrugBank.d299.s1.e2
DDI-DrugBank.d299.s1	false	DDI-DrugBank.d299.s1.e0	DDI-DrugBank.d299.s1.e3
DDI-DrugBank.d299.s1	true	DDI-DrugBank.d299.s1.e0	DDI-DrugBank.d299.s1.e4
DDI-DrugBank.d299.s1	false	DDI-DrugBank.d299.s1.e1	DDI-DrugBank.d299.s1.e2
DDI-DrugBank.d299.s1	false	DDI-DrugBank.d299.s1.e1	DDI-DrugBank.d299.s1.e3
DDI-DrugBank.d299.s1	true	DDI-DrugBank.d299.s1.e1	DDI-DrugBank.d299.s1.e4
DDI-DrugBank.d299.s1	false	DDI-DrugBank.d299.s1.e2	DDI-DrugBank.d299.s1.e3
DDI-DrugBank.d299.s1	true	DDI-DrugBank.d299.s1.e2	DDI-DrugBank.d299.s1.e4
DDI-DrugBank.d299.s1	true	DDI-DrugBank.d299.s1.e3	DDI-DrugBank.d299.s1.e4
DDI-DrugBank.d299.s2|a|Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
DDI-DrugBank.d299.s2	0	27	Monoamine Oxidase Inhibitors	group	DDI-DrugBank.d299.s2.e0
DDI-DrugBank.d299.s2	50	60	moclobemide	drug	DDI-DrugBank.d299.s2.e1
DDI-DrugBank.d299.s2	92	102	almotriptan	drug	DDI-DrugBank.d299.s2.e2
DDI-DrugBank.d299.s2	false	DDI-DrugBank.d299.s2.e0	DDI-DrugBank.d299.s2.e1
DDI-DrugBank.d299.s2	false	DDI-DrugBank.d299.s2.e0	DDI-DrugBank.d299.s2.e2
DDI-DrugBank.d299.s2	true	DDI-DrugBank.d299.s2.e1	DDI-DrugBank.d299.s2.e2
DDI-DrugBank.d299.s3|a|No dose adjustment is necessary.
DDI-DrugBank.d299.s4|a|Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.
DDI-DrugBank.d299.s4	6	23	5-HT1B/1D Agonists	group	DDI-DrugBank.d299.s4.e0
DDI-DrugBank.d299.s4	50	67	5-HT1B/1D agonists	group	DDI-DrugBank.d299.s4.e1
DDI-DrugBank.d299.s4	103	107	AXERT	brand	DDI-DrugBank.d299.s4.e2
DDI-DrugBank.d299.s4	false	DDI-DrugBank.d299.s4.e0	DDI-DrugBank.d299.s4.e1
DDI-DrugBank.d299.s4	false	DDI-DrugBank.d299.s4.e0	DDI-DrugBank.d299.s4.e2
DDI-DrugBank.d299.s4	true	DDI-DrugBank.d299.s4.e1	DDI-DrugBank.d299.s4.e2
DDI-DrugBank.d299.s5|a|Propanolol: The pharmacokinetics of almotriptan were not affected by coadministration of propranolol.
DDI-DrugBank.d299.s5	0	9	Propanolol	drug	DDI-DrugBank.d299.s5.e0
DDI-DrugBank.d299.s5	36	46	almotriptan	drug	DDI-DrugBank.d299.s5.e1
DDI-DrugBank.d299.s5	89	99	propranolol	drug	DDI-DrugBank.d299.s5.e2
DDI-DrugBank.d299.s5	false	DDI-DrugBank.d299.s5.e0	DDI-DrugBank.d299.s5.e1
DDI-DrugBank.d299.s5	false	DDI-DrugBank.d299.s5.e0	DDI-DrugBank.d299.s5.e2
DDI-DrugBank.d299.s5	false	DDI-DrugBank.d299.s5.e1	DDI-DrugBank.d299.s5.e2
DDI-DrugBank.d299.s6|a|Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d299.s6	0	38	Selective Serotonin Reuptake Inhibitors	group	DDI-DrugBank.d299.s6.e0
DDI-DrugBank.d299.s6	41	45	SSRIs	group	DDI-DrugBank.d299.s6.e1
DDI-DrugBank.d299.s6	49	53	SSRIs	group	DDI-DrugBank.d299.s6.e2
DDI-DrugBank.d299.s6	62	71	fluoxetine	drug	DDI-DrugBank.d299.s6.e3
DDI-DrugBank.d299.s6	74	84	fluvoxamine	drug	DDI-DrugBank.d299.s6.e4
DDI-DrugBank.d299.s6	87	96	paroxetine	drug	DDI-DrugBank.d299.s6.e5
DDI-DrugBank.d299.s6	99	108	sertraline	drug	DDI-DrugBank.d299.s6.e6
DDI-DrugBank.d299.s6	215	228	5-HT1 agonists	group	DDI-DrugBank.d299.s6.e7
DDI-DrugBank.d299.s6	false	DDI-DrugBank.d299.s6.e0	DDI-DrugBank.d299.s6.e1
DDI-DrugBank.d299.s6	false	DDI-DrugBank.d299.s6.e0	DDI-DrugBank.d299.s6.e2
DDI-DrugBank.d299.s6	false	DDI-DrugBank.d299.s6.e0	DDI-DrugBank.d299.s6.e3
DDI-DrugBank.d299.s6	false	DDI-DrugBank.d299.s6.e0	DDI-DrugBank.d299.s6.e4
DDI-DrugBank.d299.s6	false	DDI-DrugBank.d299.s6.e0	DDI-DrugBank.d299.s6.e5
DDI-DrugBank.d299.s6	false	DDI-DrugBank.d299.s6.e0	DDI-DrugBank.d299.s6.e6
DDI-DrugBank.d299.s6	false	DDI-DrugBank.d299.s6.e0	DDI-DrugBank.d299.s6.e7
DDI-DrugBank.d299.s6	false	DDI-DrugBank.d299.s6.e1	DDI-DrugBank.d299.s6.e2
DDI-DrugBank.d299.s6	false	DDI-DrugBank.d299.s6.e1	DDI-DrugBank.d299.s6.e3
DDI-DrugBank.d299.s6	false	DDI-DrugBank.d299.s6.e1	DDI-DrugBank.d299.s6.e4
DDI-DrugBank.d299.s7|a|If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d299.s7	30	34	AXERT	brand	DDI-DrugBank.d299.s7.e0
DDI-DrugBank.d299.s7	43	46	SSRI	group	DDI-DrugBank.d299.s7.e1
DDI-DrugBank.d299.s7	true	DDI-DrugBank.d299.s7.e0	DDI-DrugBank.d299.s7.e1
DDI-DrugBank.d299.s8|a|Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
DDI-DrugBank.d299.s8	0	8	Verapamil	drug	DDI-DrugBank.d299.s8.e0
DDI-DrugBank.d299.s8	31	41	almotriptan	drug	DDI-DrugBank.d299.s8.e1
DDI-DrugBank.d299.s8	47	55	verapamil	drug	DDI-DrugBank.d299.s8.e2
DDI-DrugBank.d299.s8	112	122	almotriptan	drug	DDI-DrugBank.d299.s8.e3
DDI-DrugBank.d299.s8	false	DDI-DrugBank.d299.s8.e0	DDI-DrugBank.d299.s8.e1
DDI-DrugBank.d299.s8	false	DDI-DrugBank.d299.s8.e0	DDI-DrugBank.d299.s8.e2
DDI-DrugBank.d299.s8	false	DDI-DrugBank.d299.s8.e0	DDI-DrugBank.d299.s8.e3
DDI-DrugBank.d299.s8	true	DDI-DrugBank.d299.s8.e1	DDI-DrugBank.d299.s8.e2
DDI-DrugBank.d299.s8	false	DDI-DrugBank.d299.s8.e1	DDI-DrugBank.d299.s8.e3
DDI-DrugBank.d299.s8	false	DDI-DrugBank.d299.s8.e2	DDI-DrugBank.d299.s8.e3
DDI-DrugBank.d299.s9|a|No dose adjustment is necessary.
DDI-DrugBank.d299.s10|a|Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.
DDI-DrugBank.d299.s10	20	30	almotriptan	drug	DDI-DrugBank.d299.s10.e0
DDI-DrugBank.d299.s10	64	75	ketoconazole	drug	DDI-DrugBank.d299.s10.e1
DDI-DrugBank.d299.s10	235	245	almotriptan	drug	DDI-DrugBank.d299.s10.e2
DDI-DrugBank.d299.s10	true	DDI-DrugBank.d299.s10.e0	DDI-DrugBank.d299.s10.e1
DDI-DrugBank.d299.s10	false	DDI-DrugBank.d299.s10.e0	DDI-DrugBank.d299.s10.e2
DDI-DrugBank.d299.s10	false	DDI-DrugBank.d299.s10.e1	DDI-DrugBank.d299.s10.e2
DDI-DrugBank.d299.s11|a|Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
DDI-DrugBank.d299.s11	33	43	almotriptan	drug	DDI-DrugBank.d299.s11.e0
DDI-DrugBank.d299.s11	87	98	itraconazole	drug	DDI-DrugBank.d299.s11.e1
DDI-DrugBank.d299.s11	101	109	ritonavir	drug	DDI-DrugBank.d299.s11.e2
DDI-DrugBank.d299.s11	116	127	erythromycin	drug	DDI-DrugBank.d299.s11.e3
DDI-DrugBank.d299.s11	175	185	almotriptan	drug	DDI-DrugBank.d299.s11.e4
DDI-DrugBank.d299.s11	208	218	almotriptan	drug	DDI-DrugBank.d299.s11.e5
DDI-DrugBank.d299.s11	false	DDI-DrugBank.d299.s11.e0	DDI-DrugBank.d299.s11.e1
DDI-DrugBank.d299.s11	false	DDI-DrugBank.d299.s11.e0	DDI-DrugBank.d299.s11.e2
DDI-DrugBank.d299.s11	false	DDI-DrugBank.d299.s11.e0	DDI-DrugBank.d299.s11.e3
DDI-DrugBank.d299.s11	false	DDI-DrugBank.d299.s11.e0	DDI-DrugBank.d299.s11.e4
DDI-DrugBank.d299.s11	false	DDI-DrugBank.d299.s11.e0	DDI-DrugBank.d299.s11.e5
DDI-DrugBank.d299.s11	false	DDI-DrugBank.d299.s11.e1	DDI-DrugBank.d299.s11.e2
DDI-DrugBank.d299.s11	false	DDI-DrugBank.d299.s11.e1	DDI-DrugBank.d299.s11.e3
DDI-DrugBank.d299.s11	false	DDI-DrugBank.d299.s11.e1	DDI-DrugBank.d299.s11.e4
DDI-DrugBank.d299.s11	true	DDI-DrugBank.d299.s11.e1	DDI-DrugBank.d299.s11.e5
DDI-DrugBank.d299.s11	false	DDI-DrugBank.d299.s11.e2	DDI-DrugBank.d299.s11.e3
DDI-DrugBank.d299.s12|a|AXERT is not known to interfere with commonly employed clinical laboratory tests.
DDI-DrugBank.d299.s12	0	4	AXERT	brand	DDI-DrugBank.d299.s12.e0
DDI-DrugBank.d364.s0|a|Because alosetron is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron.
DDI-DrugBank.d364.s0	8	16	alosetron	drug	DDI-DrugBank.d364.s0.e0
DDI-DrugBank.d364.s0	156	164	alosetron	drug	DDI-DrugBank.d364.s0.e1
DDI-DrugBank.d364.s0	false	DDI-DrugBank.d364.s0.e0	DDI-DrugBank.d364.s0.e1
DDI-DrugBank.d364.s1|a|Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9, and CYP2C19.
DDI-DrugBank.d364.s1	0	10	Fluvoxamine	drug	DDI-DrugBank.d364.s1.e0
DDI-DrugBank.d364.s2|a|In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of alosetron 1 mg on the last day.
DDI-DrugBank.d364.s2	64	74	fluvoxamine	drug	DDI-DrugBank.d364.s2.e0
DDI-DrugBank.d364.s2	160	168	alosetron	drug	DDI-DrugBank.d364.s2.e1
DDI-DrugBank.d364.s2	false	DDI-DrugBank.d364.s2.e0	DDI-DrugBank.d364.s2.e1
DDI-DrugBank.d364.s3|a|Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
DDI-DrugBank.d364.s3	0	10	Fluvoxamine	drug	DDI-DrugBank.d364.s3.e0
DDI-DrugBank.d364.s3	27	35	alosetron	drug	DDI-DrugBank.d364.s3.e1
DDI-DrugBank.d364.s3	true	DDI-DrugBank.d364.s3.e0	DDI-DrugBank.d364.s3.e1
DDI-DrugBank.d364.s4|a|Concomitant administration of alosetron and fluvoxamine is contraindicated.
DDI-DrugBank.d364.s4	30	38	alosetron	drug	DDI-DrugBank.d364.s4.e0
DDI-DrugBank.d364.s4	44	54	fluvoxamine	drug	DDI-DrugBank.d364.s4.e1
DDI-DrugBank.d364.s4	true	DDI-DrugBank.d364.s4.e0	DDI-DrugBank.d364.s4.e1
DDI-DrugBank.d364.s5|a|Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
DDI-DrugBank.d364.s5	30	38	alosetron	drug	DDI-DrugBank.d364.s5.e0
DDI-DrugBank.d364.s5	82	102	quinolone antibiotics	group	DDI-DrugBank.d364.s5.e1
DDI-DrugBank.d364.s5	108	117	cimetidine	drug	DDI-DrugBank.d364.s5.e2
DDI-DrugBank.d364.s5	true	DDI-DrugBank.d364.s5.e0	DDI-DrugBank.d364.s5.e1
DDI-DrugBank.d364.s5	true	DDI-DrugBank.d364.s5.e0	DDI-DrugBank.d364.s5.e2
DDI-DrugBank.d364.s5	false	DDI-DrugBank.d364.s5.e1	DDI-DrugBank.d364.s5.e2
DDI-DrugBank.d364.s6|a|Ketoconazole is a known strong inhibitor of CYP3A4.
DDI-DrugBank.d364.s6	0	11	Ketoconazole	drug	DDI-DrugBank.d364.s6.e0
DDI-DrugBank.d364.s7|a|In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day.
DDI-DrugBank.d364.s7	64	75	ketoconazole	drug	DDI-DrugBank.d364.s7.e0
DDI-DrugBank.d364.s7	133	141	alosetron	drug	DDI-DrugBank.d364.s7.e1
DDI-DrugBank.d364.s7	false	DDI-DrugBank.d364.s7.e0	DDI-DrugBank.d364.s7.e1
DDI-DrugBank.d364.s8|a|Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.
DDI-DrugBank.d364.s8	0	11	Ketoconazole	drug	DDI-DrugBank.d364.s8.e0
DDI-DrugBank.d364.s8	28	36	alosetron	drug	DDI-DrugBank.d364.s8.e1
DDI-DrugBank.d364.s8	true	DDI-DrugBank.d364.s8.e0	DDI-DrugBank.d364.s8.e1
DDI-DrugBank.d364.s9|a|Caution should be used when alosetron and ketoconazole are administered concomitantly.
DDI-DrugBank.d364.s9	28	36	alosetron	drug	DDI-DrugBank.d364.s9.e0
DDI-DrugBank.d364.s9	42	53	ketoconazole	drug	DDI-DrugBank.d364.s9.e1
DDI-DrugBank.d364.s9	true	DDI-DrugBank.d364.s9.e0	DDI-DrugBank.d364.s9.e1
DDI-DrugBank.d364.s10|a|Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
DDI-DrugBank.d364.s10	20	28	alosetron	drug	DDI-DrugBank.d364.s10.e0
DDI-DrugBank.d364.s10	68	81	clarithromycin	drug	DDI-DrugBank.d364.s10.e1
DDI-DrugBank.d364.s10	84	96	telithromycin	drug	DDI-DrugBank.d364.s10.e2
DDI-DrugBank.d364.s10	99	117	protease inhibitors	group	DDI-DrugBank.d364.s10.e3
DDI-DrugBank.d364.s10	120	131	voriconazole	drug	DDI-DrugBank.d364.s10.e4
DDI-DrugBank.d364.s10	138	149	itraconazole	drug	DDI-DrugBank.d364.s10.e5
DDI-DrugBank.d364.s10	true	DDI-DrugBank.d364.s10.e0	DDI-DrugBank.d364.s10.e1
DDI-DrugBank.d364.s10	true	DDI-DrugBank.d364.s10.e0	DDI-DrugBank.d364.s10.e2
DDI-DrugBank.d364.s10	true	DDI-DrugBank.d364.s10.e0	DDI-DrugBank.d364.s10.e3
DDI-DrugBank.d364.s10	true	DDI-DrugBank.d364.s10.e0	DDI-DrugBank.d364.s10.e4
DDI-DrugBank.d364.s10	true	DDI-DrugBank.d364.s10.e0	DDI-DrugBank.d364.s10.e5
DDI-DrugBank.d364.s10	false	DDI-DrugBank.d364.s10.e1	DDI-DrugBank.d364.s10.e2
DDI-DrugBank.d364.s10	false	DDI-DrugBank.d364.s10.e1	DDI-DrugBank.d364.s10.e3
DDI-DrugBank.d364.s10	false	DDI-DrugBank.d364.s10.e1	DDI-DrugBank.d364.s10.e4
DDI-DrugBank.d364.s10	false	DDI-DrugBank.d364.s10.e1	DDI-DrugBank.d364.s10.e5
DDI-DrugBank.d364.s10	false	DDI-DrugBank.d364.s10.e2	DDI-DrugBank.d364.s10.e3
DDI-DrugBank.d364.s11|a|The effect of induction or inhibition of other pathways on exposure to alosetron and its metabolites is not known.
DDI-DrugBank.d364.s11	71	79	alosetron	drug	DDI-DrugBank.d364.s11.e0
DDI-DrugBank.d364.s12|a|In vitro human liver microsome studies and an in vivo metabolic probe study demonstrated that alosetron did not inhibit CYP enzymes 2D6, 3A4, 2C9, or 2C19.
DDI-DrugBank.d364.s12	94	102	alosetron	drug	DDI-DrugBank.d364.s12.e0
DDI-DrugBank.d364.s13|a|In vitro, at total drug concentrations 27-fold higher than peak plasma concentrations observed with the 1-mg dosage, alosetron inhibited CYP enzymes 1A2 (60%) and 2E1 (50%).
DDI-DrugBank.d364.s13	117	125	alosetron	drug	DDI-DrugBank.d364.s13.e0
DDI-DrugBank.d364.s14|a|In an in vivo metabolic probe study, alosetron did not inhibit CYP2E1 but did produce 30% inhibition of both CYP1A2 and N-acetyltransferase.
DDI-DrugBank.d364.s14	37	45	alosetron	drug	DDI-DrugBank.d364.s14.e0
DDI-DrugBank.d364.s15|a|Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
DDI-DrugBank.d364.s15	26	34	alosetron	drug	DDI-DrugBank.d364.s15.e0
DDI-DrugBank.d364.s15	131	139	isoniazid	drug	DDI-DrugBank.d364.s15.e1
DDI-DrugBank.d364.s15	142	153	procainamide	drug	DDI-DrugBank.d364.s15.e2
DDI-DrugBank.d364.s15	160	170	hydralazine	drug	DDI-DrugBank.d364.s15.e3
DDI-DrugBank.d364.s15	true	DDI-DrugBank.d364.s15.e0	DDI-DrugBank.d364.s15.e1
DDI-DrugBank.d364.s15	true	DDI-DrugBank.d364.s15.e0	DDI-DrugBank.d364.s15.e2
DDI-DrugBank.d364.s15	true	DDI-DrugBank.d364.s15.e0	DDI-DrugBank.d364.s15.e3
DDI-DrugBank.d364.s15	false	DDI-DrugBank.d364.s15.e1	DDI-DrugBank.d364.s15.e2
DDI-DrugBank.d364.s15	false	DDI-DrugBank.d364.s15.e1	DDI-DrugBank.d364.s15.e3
DDI-DrugBank.d364.s15	false	DDI-DrugBank.d364.s15.e2	DDI-DrugBank.d364.s15.e3
DDI-DrugBank.d364.s16|a|The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed.
DDI-DrugBank.d364.s16	79	90	theophylline	drug	DDI-DrugBank.d364.s16.e0
DDI-DrugBank.d364.s17|a|Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates).
DDI-DrugBank.d364.s17	26	34	alosetron	drug	DDI-DrugBank.d364.s17.e0
DDI-DrugBank.d364.s17	110	129	contraceptive agents	group	DDI-DrugBank.d364.s17.e1
DDI-DrugBank.d364.s17	131	147	ethinyl estradiol	drug	DDI-DrugBank.d364.s17.e2
DDI-DrugBank.d364.s17	153	166	levonorgestrel	drug	DDI-DrugBank.d364.s17.e3
DDI-DrugBank.d364.s17	false	DDI-DrugBank.d364.s17.e0	DDI-DrugBank.d364.s17.e1
DDI-DrugBank.d364.s17	false	DDI-DrugBank.d364.s17.e0	DDI-DrugBank.d364.s17.e2
DDI-DrugBank.d364.s17	false	DDI-DrugBank.d364.s17.e0	DDI-DrugBank.d364.s17.e3
DDI-DrugBank.d364.s17	false	DDI-DrugBank.d364.s17.e1	DDI-DrugBank.d364.s17.e2
DDI-DrugBank.d364.s17	false	DDI-DrugBank.d364.s17.e1	DDI-DrugBank.d364.s17.e3
DDI-DrugBank.d364.s17	false	DDI-DrugBank.d364.s17.e2	DDI-DrugBank.d364.s17.e3
DDI-DrugBank.d364.s18|a|A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride.
DDI-DrugBank.d364.s18	53	61	alosetron	drug	DDI-DrugBank.d364.s18.e0
DDI-DrugBank.d364.s18	88	96	cisapride	drug	DDI-DrugBank.d364.s18.e1
DDI-DrugBank.d364.s18	false	DDI-DrugBank.d364.s18.e0	DDI-DrugBank.d364.s18.e1
DDI-DrugBank.d364.s19|a|No significant effects on cisapride metabolism or QT interval were noted.
DDI-DrugBank.d364.s19	26	34	cisapride	drug	DDI-DrugBank.d364.s19.e0
DDI-DrugBank.d364.s20|a|The effect of alosetron on monoamine oxidases and on intestinal first pass secondary to high intraluminal concentrations have not been examined.
DDI-DrugBank.d364.s20	14	22	alosetron	drug	DDI-DrugBank.d364.s20.e0
DDI-DrugBank.d364.s21|a|Based on the above data from in vitro and in vivo studies, it is unlikely that alosetron will inhibit the hepatic metabolic clearance of drugs metabolized by the major CYP enzyme 3A4, as well as the CYP enzymes 2D6, 2C9, 2C19, 2E1, or 1A2.
DDI-DrugBank.d364.s21	79	87	alosetron	drug	DDI-DrugBank.d364.s21.e0
DDI-DrugBank.d364.s22|a|Alosetron does not appear to induce the major cytochrome P450 (CYP) drug metabolizing enzyme 3A.
DDI-DrugBank.d364.s22	0	8	Alosetron	drug	DDI-DrugBank.d364.s22.e0
DDI-DrugBank.d364.s23|a|Alosetron also does not appear to induce CYP enzymes 2E1 or 2C19.
DDI-DrugBank.d364.s23	0	8	Alosetron	drug	DDI-DrugBank.d364.s23.e0
DDI-DrugBank.d364.s24|a|It is not known whether alosetron might induce other enzymes.
DDI-DrugBank.d364.s24	24	32	alosetron	drug	DDI-DrugBank.d364.s24.e0
DDI-DrugBank.d131.s0|a|The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DDI-DrugBank.d131.s0	4	18	benzodiazepines	group	DDI-DrugBank.d131.s0.e0
DDI-DrugBank.d131.s0	31	40	alprazolam	drug	DDI-DrugBank.d131.s0.e1
DDI-DrugBank.d131.s0	115	138	psychotropic medications	group	DDI-DrugBank.d131.s0.e2
DDI-DrugBank.d131.s0	141	155	anticonvulsants	group	DDI-DrugBank.d131.s0.e3
DDI-DrugBank.d131.s0	158	172	antihistaminics	group	DDI-DrugBank.d131.s0.e4
DDI-DrugBank.d131.s0	175	181	ethanol	drug	DDI-DrugBank.d131.s0.e5
DDI-DrugBank.d131.s0	false	DDI-DrugBank.d131.s0.e0	DDI-DrugBank.d131.s0.e1
DDI-DrugBank.d131.s0	true	DDI-DrugBank.d131.s0.e0	DDI-DrugBank.d131.s0.e2
DDI-DrugBank.d131.s0	true	DDI-DrugBank.d131.s0.e0	DDI-DrugBank.d131.s0.e3
DDI-DrugBank.d131.s0	true	DDI-DrugBank.d131.s0.e0	DDI-DrugBank.d131.s0.e4
DDI-DrugBank.d131.s0	true	DDI-DrugBank.d131.s0.e0	DDI-DrugBank.d131.s0.e5
DDI-DrugBank.d131.s0	true	DDI-DrugBank.d131.s0.e1	DDI-DrugBank.d131.s0.e2
DDI-DrugBank.d131.s0	true	DDI-DrugBank.d131.s0.e1	DDI-DrugBank.d131.s0.e3
DDI-DrugBank.d131.s0	true	DDI-DrugBank.d131.s0.e1	DDI-DrugBank.d131.s0.e4
DDI-DrugBank.d131.s0	true	DDI-DrugBank.d131.s0.e1	DDI-DrugBank.d131.s0.e5
DDI-DrugBank.d131.s0	false	DDI-DrugBank.d131.s0.e2	DDI-DrugBank.d131.s0.e3
DDI-DrugBank.d131.s1|a|The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
DDI-DrugBank.d131.s1	42	51	imipramine	drug	DDI-DrugBank.d131.s1.e0
DDI-DrugBank.d131.s1	57	67	desipramine	drug	DDI-DrugBank.d131.s1.e1
DDI-DrugBank.d131.s1	182	191	alprazolam	drug	DDI-DrugBank.d131.s1.e2
DDI-DrugBank.d131.s1	false	DDI-DrugBank.d131.s1.e0	DDI-DrugBank.d131.s1.e1
DDI-DrugBank.d131.s1	true	DDI-DrugBank.d131.s1.e0	DDI-DrugBank.d131.s1.e2
DDI-DrugBank.d131.s1	true	DDI-DrugBank.d131.s1.e1	DDI-DrugBank.d131.s1.e2
DDI-DrugBank.d131.s2|a|The clinical significance of these changes is unknown.
DDI-DrugBank.d131.s3|a|Drugs That Inhibit Alprazolam Metabolism Via Cytochrome P450 3A: The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).
DDI-DrugBank.d131.s3	19	28	Alprazolam	drug	DDI-DrugBank.d131.s3.e0
DDI-DrugBank.d131.s3	85	94	alprazolam	drug	DDI-DrugBank.d131.s3.e1
DDI-DrugBank.d131.s3	false	DDI-DrugBank.d131.s3.e0	DDI-DrugBank.d131.s3.e1
DDI-DrugBank.d131.s4|a|Drugs which inhibit this metabolic pathway may have a profound effect on the clearance of alprazolam .
DDI-DrugBank.d131.s4	90	99	alprazolam	drug	DDI-DrugBank.d131.s4.e0
DDI-DrugBank.d131.s5|a|Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
DDI-DrugBank.d131.s5	120	129	Alprazolam	drug	DDI-DrugBank.d131.s5.e0
DDI-DrugBank.d131.s5	184	193	alprazolam	drug	DDI-DrugBank.d131.s5.e1
DDI-DrugBank.d131.s5	217	226	fluoxetine	drug	DDI-DrugBank.d131.s5.e2
DDI-DrugBank.d131.s5	233	242	alprazolam	drug	DDI-DrugBank.d131.s5.e3
DDI-DrugBank.d131.s5	290	299	alprazolam	drug	DDI-DrugBank.d131.s5.e4
DDI-DrugBank.d131.s5	false	DDI-DrugBank.d131.s5.e0	DDI-DrugBank.d131.s5.e1
DDI-DrugBank.d131.s5	false	DDI-DrugBank.d131.s5.e0	DDI-DrugBank.d131.s5.e2
DDI-DrugBank.d131.s5	false	DDI-DrugBank.d131.s5.e0	DDI-DrugBank.d131.s5.e3
DDI-DrugBank.d131.s5	false	DDI-DrugBank.d131.s5.e0	DDI-DrugBank.d131.s5.e4
DDI-DrugBank.d131.s5	false	DDI-DrugBank.d131.s5.e1	DDI-DrugBank.d131.s5.e2
DDI-DrugBank.d131.s5	false	DDI-DrugBank.d131.s5.e1	DDI-DrugBank.d131.s5.e3
DDI-DrugBank.d131.s5	false	DDI-DrugBank.d131.s5.e1	DDI-DrugBank.d131.s5.e4
DDI-DrugBank.d131.s5	true	DDI-DrugBank.d131.s5.e2	DDI-DrugBank.d131.s5.e3
DDI-DrugBank.d131.s5	false	DDI-DrugBank.d131.s5.e2	DDI-DrugBank.d131.s5.e4
DDI-DrugBank.d131.s5	false	DDI-DrugBank.d131.s5.e3	DDI-DrugBank.d131.s5.e4
DDI-DrugBank.d131.s6|a|Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.
DDI-DrugBank.d131.s6	20	31	propoxyphene	drug	DDI-DrugBank.d131.s6.e0
DDI-DrugBank.d131.s6	79	88	alprazolam	drug	DDI-DrugBank.d131.s6.e1
DDI-DrugBank.d131.s6	true	DDI-DrugBank.d131.s6.e0	DDI-DrugBank.d131.s6.e1
DDI-DrugBank.d131.s7|a|Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.
DDI-DrugBank.d131.s7	25	38	contraceptives	group	DDI-DrugBank.d131.s7.e0
DDI-DrugBank.d131.s7	86	95	alprazolam	drug	DDI-DrugBank.d131.s7.e1
DDI-DrugBank.d131.s7	true	DDI-DrugBank.d131.s7.e0	DDI-DrugBank.d131.s7.e1
DDI-DrugBank.d131.s8|a|Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
DDI-DrugBank.d131.s8	107	121	benzodiazepines	group	DDI-DrugBank.d131.s8.e0
DDI-DrugBank.d131.s8	148	157	alprazolam	drug	DDI-DrugBank.d131.s8.e1
DDI-DrugBank.d131.s8	200	209	alprazolam	drug	DDI-DrugBank.d131.s8.e2
DDI-DrugBank.d131.s8	220	234	benzodiazepines	group	DDI-DrugBank.d131.s8.e3
DDI-DrugBank.d131.s8	289	298	alprazolam	drug	DDI-DrugBank.d131.s8.e4
DDI-DrugBank.d131.s8	342	356	benzodiazepines	group	DDI-DrugBank.d131.s8.e5
DDI-DrugBank.d131.s8	369	378	alprazolam	drug	DDI-DrugBank.d131.s8.e6
DDI-DrugBank.d131.s8	421	430	alprazolam	drug	DDI-DrugBank.d131.s8.e7
DDI-DrugBank.d131.s8	451	459	diltiazem	drug	DDI-DrugBank.d131.s8.e8
DDI-DrugBank.d131.s8	462	470	isoniazid	drug	DDI-DrugBank.d131.s8.e9
DDI-DrugBank.d131.s8	false	DDI-DrugBank.d131.s8.e0	DDI-DrugBank.d131.s8.e1
DDI-DrugBank.d131.s8	false	DDI-DrugBank.d131.s8.e0	DDI-DrugBank.d131.s8.e2
DDI-DrugBank.d131.s8	false	DDI-DrugBank.d131.s8.e0	DDI-DrugBank.d131.s8.e3
DDI-DrugBank.d131.s8	false	DDI-DrugBank.d131.s8.e0	DDI-DrugBank.d131.s8.e4
DDI-DrugBank.d131.s8	false	DDI-DrugBank.d131.s8.e0	DDI-DrugBank.d131.s8.e5
DDI-DrugBank.d131.s8	false	DDI-DrugBank.d131.s8.e0	DDI-DrugBank.d131.s8.e6
DDI-DrugBank.d131.s8	false	DDI-DrugBank.d131.s8.e0	DDI-DrugBank.d131.s8.e7
DDI-DrugBank.d131.s8	false	DDI-DrugBank.d131.s8.e0	DDI-DrugBank.d131.s8.e8
DDI-DrugBank.d131.s8	false	DDI-DrugBank.d131.s8.e0	DDI-DrugBank.d131.s8.e9
DDI-DrugBank.d131.s8	false	DDI-DrugBank.d131.s8.e0	DDI-DrugBank.d131.s8.e10
DDI-DrugBank.d131.s9|a|Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
DDI-DrugBank.d131.s9	30	39	alprazolam	drug	DDI-DrugBank.d131.s9.e0
DDI-DrugBank.d131.s9	82	91	alprazolam	drug	DDI-DrugBank.d131.s9.e1
DDI-DrugBank.d131.s9	112	121	sertraline	drug	DDI-DrugBank.d131.s9.e2
DDI-DrugBank.d131.s9	127	136	paroxetine	drug	DDI-DrugBank.d131.s9.e3
DDI-DrugBank.d131.s9	false	DDI-DrugBank.d131.s9.e0	DDI-DrugBank.d131.s9.e1
DDI-DrugBank.d131.s9	false	DDI-DrugBank.d131.s9.e0	DDI-DrugBank.d131.s9.e2
DDI-DrugBank.d131.s9	false	DDI-DrugBank.d131.s9.e0	DDI-DrugBank.d131.s9.e3
DDI-DrugBank.d131.s9	true	DDI-DrugBank.d131.s9.e1	DDI-DrugBank.d131.s9.e2
DDI-DrugBank.d131.s9	true	DDI-DrugBank.d131.s9.e1	DDI-DrugBank.d131.s9.e3
DDI-DrugBank.d131.s9	false	DDI-DrugBank.d131.s9.e2	DDI-DrugBank.d131.s9.e3
DDI-DrugBank.d131.s10|a|Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s10	30	44	benzodiazepines	group	DDI-DrugBank.d131.s10.e0
DDI-DrugBank.d131.s10	57	66	alprazolam	drug	DDI-DrugBank.d131.s10.e1
DDI-DrugBank.d131.s10	123	132	ergotamine	drug	DDI-DrugBank.d131.s10.e2
DDI-DrugBank.d131.s10	135	146	cyclosporine	drug	DDI-DrugBank.d131.s10.e3
DDI-DrugBank.d131.s10	149	158	amiodarone	drug	DDI-DrugBank.d131.s10.e4
DDI-DrugBank.d131.s10	161	171	nicardipine	drug	DDI-DrugBank.d131.s10.e5
DDI-DrugBank.d131.s10	178	187	nifedipine	drug	DDI-DrugBank.d131.s10.e6
DDI-DrugBank.d131.s10	false	DDI-DrugBank.d131.s10.e0	DDI-DrugBank.d131.s10.e1
DDI-DrugBank.d131.s10	true	DDI-DrugBank.d131.s10.e0	DDI-DrugBank.d131.s10.e2
DDI-DrugBank.d131.s10	true	DDI-DrugBank.d131.s10.e0	DDI-DrugBank.d131.s10.e3
DDI-DrugBank.d131.s10	true	DDI-DrugBank.d131.s10.e0	DDI-DrugBank.d131.s10.e4
DDI-DrugBank.d131.s10	true	DDI-DrugBank.d131.s10.e0	DDI-DrugBank.d131.s10.e5
DDI-DrugBank.d131.s10	true	DDI-DrugBank.d131.s10.e0	DDI-DrugBank.d131.s10.e6
DDI-DrugBank.d131.s10	true	DDI-DrugBank.d131.s10.e1	DDI-DrugBank.d131.s10.e2
DDI-DrugBank.d131.s10	true	DDI-DrugBank.d131.s10.e1	DDI-DrugBank.d131.s10.e3
DDI-DrugBank.d131.s10	true	DDI-DrugBank.d131.s10.e1	DDI-DrugBank.d131.s10.e4
DDI-DrugBank.d131.s10	true	DDI-DrugBank.d131.s10.e1	DDI-DrugBank.d131.s10.e5
DDI-DrugBank.d131.s11|a|Caution is recommended during the coadministration of any of these with alprazolam.
DDI-DrugBank.d131.s11	72	81	alprazolam	drug	DDI-DrugBank.d131.s11.e0
DDI-DrugBank.d290.s0|a|No drug interactions have been reported between Prostin VR Pediatric and the therapy standard in neonates with restricted pulmonary or systemic blood flow.
DDI-DrugBank.d290.s0	48	67	Prostin VR Pediatric	brand	DDI-DrugBank.d290.s0.e0
DDI-DrugBank.d290.s1|a|Standard therapy includes antibiotics, such as penicillin and gentamicin;
DDI-DrugBank.d290.s1	26	36	antibiotics	group	DDI-DrugBank.d290.s1.e0
DDI-DrugBank.d290.s1	47	56	penicillin	drug	DDI-DrugBank.d290.s1.e1
DDI-DrugBank.d290.s1	62	71	gentamicin	drug	DDI-DrugBank.d290.s1.e2
DDI-DrugBank.d290.s1	false	DDI-DrugBank.d290.s1.e0	DDI-DrugBank.d290.s1.e1
DDI-DrugBank.d290.s1	false	DDI-DrugBank.d290.s1.e0	DDI-DrugBank.d290.s1.e2
DDI-DrugBank.d290.s1	false	DDI-DrugBank.d290.s1.e1	DDI-DrugBank.d290.s1.e2
DDI-DrugBank.d290.s2|a|vasopressors, such as dopamine and isoproterenol;
DDI-DrugBank.d290.s2	0	11	vasopressors	group	DDI-DrugBank.d290.s2.e0
DDI-DrugBank.d290.s2	22	29	dopamine	drug	DDI-DrugBank.d290.s2.e1
DDI-DrugBank.d290.s2	35	47	isoproterenol	drug	DDI-DrugBank.d290.s2.e2
DDI-DrugBank.d290.s2	false	DDI-DrugBank.d290.s2.e0	DDI-DrugBank.d290.s2.e1
DDI-DrugBank.d290.s2	false	DDI-DrugBank.d290.s2.e0	DDI-DrugBank.d290.s2.e2
DDI-DrugBank.d290.s2	false	DDI-DrugBank.d290.s2.e1	DDI-DrugBank.d290.s2.e2
DDI-DrugBank.d290.s3|a|cardiac glycosides;
DDI-DrugBank.d290.s3	0	17	cardiac glycosides	group	DDI-DrugBank.d290.s3.e0
DDI-DrugBank.d290.s4|a|and diuretics, such as furosemide.
DDI-DrugBank.d290.s4	4	12	diuretics	group	DDI-DrugBank.d290.s4.e0
DDI-DrugBank.d290.s4	23	32	furosemide	drug	DDI-DrugBank.d290.s4.e1
DDI-DrugBank.d290.s4	false	DDI-DrugBank.d290.s4.e0	DDI-DrugBank.d290.s4.e1
DDI-DrugBank.d290.s5|a|Caverject: The potential for pharmacokinetic drug-drug interactions between alprostadil and other agents has not been formally studied.
DDI-DrugBank.d290.s5	0	8	Caverject	brand	DDI-DrugBank.d290.s5.e0
DDI-DrugBank.d290.s5	76	86	alprostadil	drug	DDI-DrugBank.d290.s5.e1
DDI-DrugBank.d290.s5	false	DDI-DrugBank.d290.s5.e0	DDI-DrugBank.d290.s5.e1
DDI-DrugBank.d508.s0|a|The interaction of Activase with other cardioactive or cerebroactive drugs has not been studied.
DDI-DrugBank.d508.s0	19	26	Activase	brand	DDI-DrugBank.d508.s0.e0
DDI-DrugBank.d508.s1|a|In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
DDI-DrugBank.d508.s1	40	46	heparin	drug	DDI-DrugBank.d508.s1.e0
DDI-DrugBank.d508.s1	52	72	vitamin K antagonists	group	DDI-DrugBank.d508.s1.e1
DDI-DrugBank.d508.s1	119	138	acetylsalicylic acid	drug	DDI-DrugBank.d508.s1.e2
DDI-DrugBank.d508.s1	141	152	dipyridamole	drug	DDI-DrugBank.d508.s1.e3
DDI-DrugBank.d508.s1	158	166	Abciximab	drug	DDI-DrugBank.d508.s1.e4
DDI-DrugBank.d508.s1	246	253	Activase	brand	DDI-DrugBank.d508.s1.e5
DDI-DrugBank.d508.s1	false	DDI-DrugBank.d508.s1.e0	DDI-DrugBank.d508.s1.e1
DDI-DrugBank.d508.s1	false	DDI-DrugBank.d508.s1.e0	DDI-DrugBank.d508.s1.e2
DDI-DrugBank.d508.s1	false	DDI-DrugBank.d508.s1.e0	DDI-DrugBank.d508.s1.e3
DDI-DrugBank.d508.s1	false	DDI-DrugBank.d508.s1.e0	DDI-DrugBank.d508.s1.e4
DDI-DrugBank.d508.s1	true	DDI-DrugBank.d508.s1.e0	DDI-DrugBank.d508.s1.e5
DDI-DrugBank.d508.s1	false	DDI-DrugBank.d508.s1.e1	DDI-DrugBank.d508.s1.e2
DDI-DrugBank.d508.s1	false	DDI-DrugBank.d508.s1.e1	DDI-DrugBank.d508.s1.e3
DDI-DrugBank.d508.s1	false	DDI-DrugBank.d508.s1.e1	DDI-DrugBank.d508.s1.e4
DDI-DrugBank.d508.s1	true	DDI-DrugBank.d508.s1.e1	DDI-DrugBank.d508.s1.e5
DDI-DrugBank.d508.s1	false	DDI-DrugBank.d508.s1.e2	DDI-DrugBank.d508.s1.e3
DDI-DrugBank.d508.s2|a|Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
DDI-DrugBank.d508.s2	7	21	Antithrombotics	group	DDI-DrugBank.d508.s2.e0
DDI-DrugBank.d508.s2	23	29	Aspirin	brand	DDI-DrugBank.d508.s2.e1
DDI-DrugBank.d508.s2	35	41	heparin	drug	DDI-DrugBank.d508.s2.e2
DDI-DrugBank.d508.s2	112	119	Activase	brand	DDI-DrugBank.d508.s2.e3
DDI-DrugBank.d508.s2	false	DDI-DrugBank.d508.s2.e0	DDI-DrugBank.d508.s2.e1
DDI-DrugBank.d508.s2	false	DDI-DrugBank.d508.s2.e0	DDI-DrugBank.d508.s2.e2
DDI-DrugBank.d508.s2	false	DDI-DrugBank.d508.s2.e0	DDI-DrugBank.d508.s2.e3
DDI-DrugBank.d508.s2	false	DDI-DrugBank.d508.s2.e1	DDI-DrugBank.d508.s2.e2
DDI-DrugBank.d508.s2	false	DDI-DrugBank.d508.s2.e1	DDI-DrugBank.d508.s2.e3
DDI-DrugBank.d508.s2	false	DDI-DrugBank.d508.s2.e2	DDI-DrugBank.d508.s2.e3
DDI-DrugBank.d508.s3|a|Because heparin, aspirin, or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.
DDI-DrugBank.d508.s3	8	14	heparin	drug	DDI-DrugBank.d508.s3.e0
DDI-DrugBank.d508.s3	17	23	aspirin	brand	DDI-DrugBank.d508.s3.e1
DDI-DrugBank.d508.s3	29	36	Activase	brand	DDI-DrugBank.d508.s3.e2
DDI-DrugBank.d508.s3	false	DDI-DrugBank.d508.s3.e0	DDI-DrugBank.d508.s3.e1
DDI-DrugBank.d508.s3	false	DDI-DrugBank.d508.s3.e0	DDI-DrugBank.d508.s3.e2
DDI-DrugBank.d508.s3	false	DDI-DrugBank.d508.s3.e1	DDI-DrugBank.d508.s3.e2
DDI-DrugBank.d508.s4|a|The concomitant use of heparin or aspirin during the first 24 hours following symptom onset were prohibited in The NINDS t-PA Stroke Trial.
DDI-DrugBank.d508.s4	23	29	heparin	drug	DDI-DrugBank.d508.s4.e0
DDI-DrugBank.d508.s4	34	40	aspirin	brand	DDI-DrugBank.d508.s4.e1
DDI-DrugBank.d508.s4	false	DDI-DrugBank.d508.s4.e0	DDI-DrugBank.d508.s4.e1
DDI-DrugBank.d508.s5|a|The safety of such concomitant use with Activase for the management of acute ischemic stroke is unknown.
DDI-DrugBank.d508.s5	40	47	Activase	brand	DDI-DrugBank.d508.s5.e0
DDI-DrugBank.d188.s0|a|Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
DDI-DrugBank.d188.s0	29	35	HEXALEN	brand	DDI-DrugBank.d188.s0.e0
DDI-DrugBank.d188.s0	41	82	antidepressants of the MAO inhibitor class	group	DDI-DrugBank.d188.s0.e1
DDI-DrugBank.d188.s0	125	134	Cimetidine	drug	DDI-DrugBank.d188.s0.e2
DDI-DrugBank.d188.s0	191	201	altretamine	drug	DDI-DrugBank.d188.s0.e3
DDI-DrugBank.d188.s0	true	DDI-DrugBank.d188.s0.e0	DDI-DrugBank.d188.s0.e1
DDI-DrugBank.d188.s0	false	DDI-DrugBank.d188.s0.e0	DDI-DrugBank.d188.s0.e2
DDI-DrugBank.d188.s0	false	DDI-DrugBank.d188.s0.e0	DDI-DrugBank.d188.s0.e3
DDI-DrugBank.d188.s0	false	DDI-DrugBank.d188.s0.e1	DDI-DrugBank.d188.s0.e2
DDI-DrugBank.d188.s0	false	DDI-DrugBank.d188.s0.e1	DDI-DrugBank.d188.s0.e3
DDI-DrugBank.d188.s0	true	DDI-DrugBank.d188.s0.e2	DDI-DrugBank.d188.s0.e3
DDI-DrugBank.d188.s1|a|Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
DDI-DrugBank.d188.s1	32	38	HEXALEN	brand	DDI-DrugBank.d188.s1.e0
DDI-DrugBank.d188.s1	44	52	cisplatin	drug	DDI-DrugBank.d188.s1.e1
DDI-DrugBank.d188.s1	68	77	pyridoxine	drug	DDI-DrugBank.d188.s1.e2
DDI-DrugBank.d188.s1	112	121	pyridoxine	drug	DDI-DrugBank.d188.s1.e3
DDI-DrugBank.d188.s1	true	DDI-DrugBank.d188.s1.e0	DDI-DrugBank.d188.s1.e1
DDI-DrugBank.d188.s1	false	DDI-DrugBank.d188.s1.e0	DDI-DrugBank.d188.s1.e2
DDI-DrugBank.d188.s1	false	DDI-DrugBank.d188.s1.e0	DDI-DrugBank.d188.s1.e3
DDI-DrugBank.d188.s1	false	DDI-DrugBank.d188.s1.e1	DDI-DrugBank.d188.s1.e2
DDI-DrugBank.d188.s1	false	DDI-DrugBank.d188.s1.e1	DDI-DrugBank.d188.s1.e3
DDI-DrugBank.d188.s1	false	DDI-DrugBank.d188.s1.e2	DDI-DrugBank.d188.s1.e3
DDI-DrugBank.d188.s2|a|however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1
DDI-DrugBank.d188.s2	65	74	pyridoxine	drug	DDI-DrugBank.d188.s2.e0
DDI-DrugBank.d188.s2	108	114	HEXALEN	brand	DDI-DrugBank.d188.s2.e1
DDI-DrugBank.d188.s2	123	131	cisplatin	drug	DDI-DrugBank.d188.s2.e2
DDI-DrugBank.d188.s2	true	DDI-DrugBank.d188.s2.e0	DDI-DrugBank.d188.s2.e1
DDI-DrugBank.d188.s2	true	DDI-DrugBank.d188.s2.e0	DDI-DrugBank.d188.s2.e2
DDI-DrugBank.d188.s2	false	DDI-DrugBank.d188.s2.e1	DDI-DrugBank.d188.s2.e2
DDI-DrugBank.d116.s0|a|Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.
DDI-DrugBank.d116.s0	37	46	amantadine	drug	DDI-DrugBank.d116.s0.e0
DDI-DrugBank.d116.s0	82	114	central nervous system stimulants	group	DDI-DrugBank.d116.s0.e1
DDI-DrugBank.d116.s0	true	DDI-DrugBank.d116.s0.e0	DDI-DrugBank.d116.s0.e1
DDI-DrugBank.d116.s1|a|Coadministration of thioridazine has been reported to worsen the tremor in elderly patients with Parkinsons disease;
DDI-DrugBank.d116.s1	20	31	thioridazine	drug	DDI-DrugBank.d116.s1.e0
DDI-DrugBank.d116.s2|a|however, it is not known if other phenothiazines produce a similar response.
DDI-DrugBank.d116.s2	34	47	phenothiazines	group	DDI-DrugBank.d116.s2.e0
DDI-DrugBank.d563.s0|a|Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.
DDI-DrugBank.d563.s0	63	68	ETHYOL	brand	DDI-DrugBank.d563.s0.e0
DDI-DrugBank.d563.s0	92	119	antihypertensive medications	group	DDI-DrugBank.d563.s0.e1
DDI-DrugBank.d563.s0	true	DDI-DrugBank.d563.s0.e0	DDI-DrugBank.d563.s0.e1
DDI-DrugBank.d356.s0|a|When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.
DDI-DrugBank.d356.s0	5	13	amiloride	drug	DDI-DrugBank.d356.s0.e0
DDI-DrugBank.d356.s0	57	95	angiotensin-converting enzyme inhibitor	group	DDI-DrugBank.d356.s0.e1
DDI-DrugBank.d356.s0	true	DDI-DrugBank.d356.s0.e0	DDI-DrugBank.d356.s0.e1
DDI-DrugBank.d356.s1|a|Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.
DDI-DrugBank.d356.s2|a|Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
DDI-DrugBank.d356.s2	0	6	Lithium	drug	DDI-DrugBank.d356.s2.e0
DDI-DrugBank.d356.s2	43	51	diuretics	group	DDI-DrugBank.d356.s2.e1
DDI-DrugBank.d356.s2	true	DDI-DrugBank.d356.s2.e0	DDI-DrugBank.d356.s2.e1
DDI-DrugBank.d356.s3|a|Read circulars for lithium preparations before use of such concomitant therapy.
DDI-DrugBank.d356.s3	19	25	lithium	drug	DDI-DrugBank.d356.s3.e0
DDI-DrugBank.d356.s4|a|In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d356.s4	42	78	non-steroidal anti-inflammatory agent	group	DDI-DrugBank.d356.s4.e0
DDI-DrugBank.d356.s4	150	153	loop diuretics	group	DDI-DrugBank.d356.s4.e1
DDI-DrugBank.d356.s4	187	195	loop diuretics	group	DDI-DrugBank.d356.s4.e1
DDI-DrugBank.d356.s4	156	172	potassium-sparing diuretics	group	DDI-DrugBank.d356.s4.e2
DDI-DrugBank.d356.s4	187	195	potassium-sparing diuretics	group	DDI-DrugBank.d356.s4.e2
DDI-DrugBank.d356.s4	178	195	thiazide diuretics	group	DDI-DrugBank.d356.s4.e3
DDI-DrugBank.d356.s4	true	DDI-DrugBank.d356.s4.e0	DDI-DrugBank.d356.s4.e1
DDI-DrugBank.d356.s4	true	DDI-DrugBank.d356.s4.e0	DDI-DrugBank.d356.s4.e2
DDI-DrugBank.d356.s4	true	DDI-DrugBank.d356.s4.e0	DDI-DrugBank.d356.s4.e3
DDI-DrugBank.d356.s4	false	DDI-DrugBank.d356.s4.e1	DDI-DrugBank.d356.s4.e2
DDI-DrugBank.d356.s4	false	DDI-DrugBank.d356.s4.e1	DDI-DrugBank.d356.s4.e3
DDI-DrugBank.d356.s4	false	DDI-DrugBank.d356.s4.e2	DDI-DrugBank.d356.s4.e3
DDI-DrugBank.d356.s5|a|Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
DDI-DrugBank.d356.s5	16	22	MIDAMOR	brand	DDI-DrugBank.d356.s5.e0
DDI-DrugBank.d356.s5	28	65	non-steroidal anti-inflammatory agents	group	DDI-DrugBank.d356.s5.e1
DDI-DrugBank.d356.s5	172	179	diuretic	group	DDI-DrugBank.d356.s5.e2
DDI-DrugBank.d356.s5	true	DDI-DrugBank.d356.s5.e0	DDI-DrugBank.d356.s5.e1
DDI-DrugBank.d356.s5	false	DDI-DrugBank.d356.s5.e0	DDI-DrugBank.d356.s5.e2
DDI-DrugBank.d356.s5	false	DDI-DrugBank.d356.s5.e1	DDI-DrugBank.d356.s5.e2
DDI-DrugBank.d356.s6|a|Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
DDI-DrugBank.d356.s6	6	17	indomethacin	drug	DDI-DrugBank.d356.s6.e0
DDI-DrugBank.d356.s6	23	49	potassium-sparing diuretics	group	DDI-DrugBank.d356.s6.e1
DDI-DrugBank.d356.s6	62	68	MIDAMOR	brand	DDI-DrugBank.d356.s6.e2
DDI-DrugBank.d356.s6	true	DDI-DrugBank.d356.s6.e0	DDI-DrugBank.d356.s6.e1
DDI-DrugBank.d356.s6	true	DDI-DrugBank.d356.s6.e0	DDI-DrugBank.d356.s6.e2
DDI-DrugBank.d356.s6	false	DDI-DrugBank.d356.s6.e1	DDI-DrugBank.d356.s6.e2
DDI-DrugBank.d553.s0|a|Drug Laboratory Test Interactions: Prolongation of the template bleeding time has been reported during continuous intravenous infusion of AMICAR at dosages exceeding 24 g/day.
DDI-DrugBank.d553.s0	138	143	AMICAR	brand	DDI-DrugBank.d553.s0.e0
DDI-DrugBank.d553.s1|a|Platelet function studies in these patients have not demonstrated any significant platelet dysfunction.
DDI-DrugBank.d553.s2|a|However, in vitro studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) EACA inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner.
DDI-DrugBank.d553.s2	104	107	EACA	drug	DDI-DrugBank.d553.s2.e0
DDI-DrugBank.d553.s3|a|Following a 10 g bolus of AMICAR, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained.
DDI-DrugBank.d553.s3	26	31	AMICAR	brand	DDI-DrugBank.d553.s3.e0
DDI-DrugBank.d553.s4|a|The concentration of AMICAR necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL.
DDI-DrugBank.d553.s4	21	26	AMICAR	brand	DDI-DrugBank.d553.s4.e0
DDI-DrugBank.d553.s5|a|Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL.
DDI-DrugBank.d553.s6|a|Thus, concentrations which have been obtained in vivo clinically in patients with normal renal function are considerably lower than the in vitro concentrations found to induce abnormalities in platelet function tests.
DDI-DrugBank.d553.s7|a|However, higher plasma concentrations of AMICAR may occur in patients with severe renal failure.
DDI-DrugBank.d553.s7	41	46	AMICAR	brand	DDI-DrugBank.d553.s7.e0
DDI-DrugBank.d372.s0|a|Cytadren accelerates the metabolism of dexamethasone;
DDI-DrugBank.d372.s0	0	7	Cytadren	brand	DDI-DrugBank.d372.s0.e0
DDI-DrugBank.d372.s0	39	51	dexamethasone	drug	DDI-DrugBank.d372.s0.e1
DDI-DrugBank.d372.s0	true	DDI-DrugBank.d372.s0.e0	DDI-DrugBank.d372.s0.e1
DDI-DrugBank.d372.s1|a|therefore, if glucocorticoid replacement is needed, hydrocortisone should be prescribed.
DDI-DrugBank.d372.s1	14	27	glucocorticoid	group	DDI-DrugBank.d372.s1.e0
DDI-DrugBank.d372.s1	52	65	hydrocortisone	drug	DDI-DrugBank.d372.s1.e1
DDI-DrugBank.d372.s1	false	DDI-DrugBank.d372.s1.e0	DDI-DrugBank.d372.s1.e1
DDI-DrugBank.d372.s2|a|Aminoglutethimide diminishes the effect of coumarin and warfarin.
DDI-DrugBank.d372.s2	0	16	Aminoglutethimide	drug	DDI-DrugBank.d372.s2.e0
DDI-DrugBank.d372.s2	43	50	coumarin	group	DDI-DrugBank.d372.s2.e1
DDI-DrugBank.d372.s2	56	63	warfarin	drug	DDI-DrugBank.d372.s2.e2
DDI-DrugBank.d372.s2	true	DDI-DrugBank.d372.s2.e0	DDI-DrugBank.d372.s2.e1
DDI-DrugBank.d372.s2	true	DDI-DrugBank.d372.s2.e0	DDI-DrugBank.d372.s2.e2
DDI-DrugBank.d372.s2	false	DDI-DrugBank.d372.s2.e1	DDI-DrugBank.d372.s2.e2
DDI-DrugBank.d416.s0|a|Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
DDI-DrugBank.d416.s0	32	34	PAH	drug	DDI-DrugBank.d416.s0.e0
DDI-DrugBank.d416.s0	103	114	sulfonamides	group	DDI-DrugBank.d416.s0.e1
DDI-DrugBank.d416.s0	117	124	procaine	drug	DDI-DrugBank.d416.s0.e2
DDI-DrugBank.d416.s0	130	144	thiazolesulfone	drug	DDI-DrugBank.d416.s0.e3
DDI-DrugBank.d416.s0	true	DDI-DrugBank.d416.s0.e0	DDI-DrugBank.d416.s0.e1
DDI-DrugBank.d416.s0	true	DDI-DrugBank.d416.s0.e0	DDI-DrugBank.d416.s0.e2
DDI-DrugBank.d416.s0	true	DDI-DrugBank.d416.s0.e0	DDI-DrugBank.d416.s0.e3
DDI-DrugBank.d416.s0	false	DDI-DrugBank.d416.s0.e1	DDI-DrugBank.d416.s0.e2
DDI-DrugBank.d416.s0	false	DDI-DrugBank.d416.s0.e1	DDI-DrugBank.d416.s0.e3
DDI-DrugBank.d416.s0	false	DDI-DrugBank.d416.s0.e2	DDI-DrugBank.d416.s0.e3
DDI-DrugBank.d416.s1|a|These compounds interfere with chemical color development essential to the analytical procedures.
DDI-DrugBank.d416.s2|a|Probenecid depresses tubular secretion of certain weak acids such as PAH.
DDI-DrugBank.d416.s2	0	9	Probenecid	drug	DDI-DrugBank.d416.s2.e0
DDI-DrugBank.d416.s2	69	71	PAH	drug	DDI-DrugBank.d416.s2.e1
DDI-DrugBank.d416.s2	true	DDI-DrugBank.d416.s2.e0	DDI-DrugBank.d416.s2.e1
DDI-DrugBank.d416.s3|a|Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.
DDI-DrugBank.d416.s3	30	39	probenecid	drug	DDI-DrugBank.d416.s3.e0
DDI-DrugBank.d416.s3	79	81	PAH	drug	DDI-DrugBank.d416.s3.e1
DDI-DrugBank.d416.s3	true	DDI-DrugBank.d416.s3.e0	DDI-DrugBank.d416.s3.e1
DDI-DrugBank.d379.s0|a|There have been no formal studies of the interaction of LEVULAN KERASTICK for Topical Solution with any other drugs, and no drug-specific interactions were noted during any of the controlled clinical trials.
DDI-DrugBank.d379.s0	56	72	LEVULAN KERASTICK	brand	DDI-DrugBank.d379.s0.e0
DDI-DrugBank.d379.s1|a|It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
DDI-DrugBank.d379.s1	61	83	photosensitizing agents	group	DDI-DrugBank.d379.s1.e0
DDI-DrugBank.d379.s1	93	104	griseofulvin	drug	DDI-DrugBank.d379.s1.e1
DDI-DrugBank.d379.s1	107	124	thiazide diuretics	group	DDI-DrugBank.d379.s1.e2
DDI-DrugBank.d379.s1	127	139	sulfonylureas	group	DDI-DrugBank.d379.s1.e3
DDI-DrugBank.d379.s1	142	155	phenothiazines	group	DDI-DrugBank.d379.s1.e4
DDI-DrugBank.d379.s1	158	169	sulfonamides	group	DDI-DrugBank.d379.s1.e5
DDI-DrugBank.d379.s1	175	187	tetracyclines	group	DDI-DrugBank.d379.s1.e6
DDI-DrugBank.d379.s1	272	288	LEVULAN KERASTICK	brand	DDI-DrugBank.d379.s1.e7
DDI-DrugBank.d379.s1	false	DDI-DrugBank.d379.s1.e0	DDI-DrugBank.d379.s1.e1
DDI-DrugBank.d379.s1	false	DDI-DrugBank.d379.s1.e0	DDI-DrugBank.d379.s1.e2
DDI-DrugBank.d379.s1	false	DDI-DrugBank.d379.s1.e0	DDI-DrugBank.d379.s1.e3
DDI-DrugBank.d379.s1	false	DDI-DrugBank.d379.s1.e0	DDI-DrugBank.d379.s1.e4
DDI-DrugBank.d379.s1	false	DDI-DrugBank.d379.s1.e0	DDI-DrugBank.d379.s1.e5
DDI-DrugBank.d379.s1	false	DDI-DrugBank.d379.s1.e0	DDI-DrugBank.d379.s1.e6
DDI-DrugBank.d379.s1	true	DDI-DrugBank.d379.s1.e0	DDI-DrugBank.d379.s1.e7
DDI-DrugBank.d379.s1	false	DDI-DrugBank.d379.s1.e1	DDI-DrugBank.d379.s1.e2
DDI-DrugBank.d379.s1	false	DDI-DrugBank.d379.s1.e1	DDI-DrugBank.d379.s1.e3
DDI-DrugBank.d379.s1	false	DDI-DrugBank.d379.s1.e1	DDI-DrugBank.d379.s1.e4
DDI-DrugBank.d22.s0|a|Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
DDI-DrugBank.d22.s0	0	18	Aminosalicylic acid	drug	DDI-DrugBank.d22.s0.e0
DDI-DrugBank.d22.s0	47	53	digoxin	drug	DDI-DrugBank.d22.s0.e1
DDI-DrugBank.d22.s0	56	62	Lanoxin	brand	DDI-DrugBank.d22.s0.e2
DDI-DrugBank.d22.s0	65	74	Lanoxicaps	drug	DDI-DrugBank.d22.s0.e3
DDI-DrugBank.d22.s0	true	DDI-DrugBank.d22.s0.e0	DDI-DrugBank.d22.s0.e1
DDI-DrugBank.d22.s0	true	DDI-DrugBank.d22.s0.e0	DDI-DrugBank.d22.s0.e2
DDI-DrugBank.d22.s0	false	DDI-DrugBank.d22.s0.e0	DDI-DrugBank.d22.s0.e3
DDI-DrugBank.d22.s0	false	DDI-DrugBank.d22.s0.e1	DDI-DrugBank.d22.s0.e2
DDI-DrugBank.d22.s0	false	DDI-DrugBank.d22.s0.e1	DDI-DrugBank.d22.s0.e3
DDI-DrugBank.d22.s0	false	DDI-DrugBank.d22.s0.e2	DDI-DrugBank.d22.s0.e3
DDI-DrugBank.d22.s1|a|In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.
DDI-DrugBank.d22.s1	32	38	digoxin	drug	DDI-DrugBank.d22.s1.e0
DDI-DrugBank.d22.s1	53	71	aminosalicylic acid	drug	DDI-DrugBank.d22.s1.e1
DDI-DrugBank.d22.s1	90	96	digoxin	drug	DDI-DrugBank.d22.s1.e2
DDI-DrugBank.d22.s1	true	DDI-DrugBank.d22.s1.e0	DDI-DrugBank.d22.s1.e1
DDI-DrugBank.d22.s1	false	DDI-DrugBank.d22.s1.e0	DDI-DrugBank.d22.s1.e2
DDI-DrugBank.d22.s1	false	DDI-DrugBank.d22.s1.e1	DDI-DrugBank.d22.s1.e2
DDI-DrugBank.d22.s2|a|Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.
DDI-DrugBank.d22.s2	0	18	Aminosalicylic acid	drug	DDI-DrugBank.d22.s2.e0
DDI-DrugBank.d22.s2	56	66	vitamin B12	drug	DDI-DrugBank.d22.s2.e1
DDI-DrugBank.d22.s2	true	DDI-DrugBank.d22.s2.e0	DDI-DrugBank.d22.s2.e1
DDI-DrugBank.d22.s3|a|Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.
DDI-DrugBank.d22.s3	33	43	vitamin B12	drug	DDI-DrugBank.d22.s3.e0
DDI-DrugBank.d22.s3	69	87	aminosalicylic acid	drug	DDI-DrugBank.d22.s3.e1
DDI-DrugBank.d22.s3	true	DDI-DrugBank.d22.s3.e0	DDI-DrugBank.d22.s3.e1
DDI-DrugBank.d143.s0|a|Amiodarone is metabolized to desethylamiodarone by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.
DDI-DrugBank.d143.s0	0	9	Amiodarone	drug	DDI-DrugBank.d143.s0.e0
DDI-DrugBank.d143.s0	29	46	desethylamiodarone	drug	DDI-DrugBank.d143.s0.e1
DDI-DrugBank.d143.s0	false	DDI-DrugBank.d143.s0.e0	DDI-DrugBank.d143.s0.e1
DDI-DrugBank.d143.s1|a|The CYP3A4 isoenzyme is present in both the liver and intestines.
DDI-DrugBank.d143.s2|a|Amiodarone is also known to be an inhibitor of CYP3A4.
DDI-DrugBank.d143.s2	0	9	Amiodarone	drug	DDI-DrugBank.d143.s2.e0
DDI-DrugBank.d143.s3|a|Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4.
DDI-DrugBank.d143.s3	11	20	amiodarone	drug	DDI-DrugBank.d143.s3.e0
DDI-DrugBank.d143.s4|a|While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, chiefly with the oral formulation, the potential for other interactions should be anticipated.
DDI-DrugBank.d143.s4	67	76	amiodarone	drug	DDI-DrugBank.d143.s4.e0
DDI-DrugBank.d143.s5|a|This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics.
DDI-DrugBank.d143.s5	87	101	antiarrhythmics	group	DDI-DrugBank.d143.s5.e0
DDI-DrugBank.d143.s6|a|If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured.
DDI-DrugBank.d143.s7|a|In view of the long and variable half-life of amiodarone, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone.
DDI-DrugBank.d143.s7	46	55	amiodarone	drug	DDI-DrugBank.d143.s7.e0
DDI-DrugBank.d143.s7	192	201	amiodarone	drug	DDI-DrugBank.d143.s7.e1
DDI-DrugBank.d143.s7	false	DDI-DrugBank.d143.s7.e0	DDI-DrugBank.d143.s7.e1
DDI-DrugBank.d143.s8|a|Since amiodarone is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone.
DDI-DrugBank.d143.s8	6	15	amiodarone	drug	DDI-DrugBank.d143.s8.e0
DDI-DrugBank.d143.s8	166	175	amiodarone	drug	DDI-DrugBank.d143.s8.e1
DDI-DrugBank.d143.s8	false	DDI-DrugBank.d143.s8.e0	DDI-DrugBank.d143.s8.e1
DDI-DrugBank.d143.s9|a|Reported examples include the following: Protease Inhibitors: Protease inhibitors are known to inhibit CYP3A4 to varying degrees.
DDI-DrugBank.d143.s9	41	59	Protease Inhibitors	group	DDI-DrugBank.d143.s9.e0
DDI-DrugBank.d143.s9	62	80	Protease inhibitors	group	DDI-DrugBank.d143.s9.e1
DDI-DrugBank.d143.s9	false	DDI-DrugBank.d143.s9.e0	DDI-DrugBank.d143.s9.e1
DDI-DrugBank.d143.s10|a|A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
DDI-DrugBank.d143.s10	36	45	amiodarone	drug	DDI-DrugBank.d143.s10.e0
DDI-DrugBank.d143.s10	58	66	indinavir	drug	DDI-DrugBank.d143.s10.e1
DDI-DrugBank.d143.s10	118	127	amiodarone	drug	DDI-DrugBank.d143.s10.e2
DDI-DrugBank.d143.s10	true	DDI-DrugBank.d143.s10.e0	DDI-DrugBank.d143.s10.e1
DDI-DrugBank.d143.s10	false	DDI-DrugBank.d143.s10.e0	DDI-DrugBank.d143.s10.e2
DDI-DrugBank.d143.s10	false	DDI-DrugBank.d143.s10.e1	DDI-DrugBank.d143.s10.e2
DDI-DrugBank.d143.s11|a|DEA concentrations were not affected.
DDI-DrugBank.d143.s12|a|There was no evidence of toxicity.
DDI-DrugBank.d143.s13|a|Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.
DDI-DrugBank.d143.s13	15	24	amiodarone	drug	DDI-DrugBank.d143.s13.e0
DDI-DrugBank.d143.s13	61	70	amiodarone	drug	DDI-DrugBank.d143.s13.e1
DDI-DrugBank.d143.s13	111	128	protease inhibitor	group	DDI-DrugBank.d143.s13.e2
DDI-DrugBank.d143.s13	false	DDI-DrugBank.d143.s13.e0	DDI-DrugBank.d143.s13.e1
DDI-DrugBank.d143.s13	false	DDI-DrugBank.d143.s13.e0	DDI-DrugBank.d143.s13.e2
DDI-DrugBank.d143.s13	true	DDI-DrugBank.d143.s13.e1	DDI-DrugBank.d143.s13.e2
DDI-DrugBank.d143.s14|a|Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.
DDI-DrugBank.d143.s14	0	23	Histamine H2 antagonists	group	DDI-DrugBank.d143.s14.e0
DDI-DrugBank.d143.s14	26	35	Cimetidine	drug	DDI-DrugBank.d143.s14.e1
DDI-DrugBank.d143.s14	76	85	amiodarone	drug	DDI-DrugBank.d143.s14.e2
DDI-DrugBank.d143.s14	true	DDI-DrugBank.d143.s14.e0	DDI-DrugBank.d143.s14.e1
DDI-DrugBank.d143.s14	false	DDI-DrugBank.d143.s14.e0	DDI-DrugBank.d143.s14.e2
DDI-DrugBank.d143.s14	false	DDI-DrugBank.d143.s14.e1	DDI-DrugBank.d143.s14.e2
DDI-DrugBank.d143.s15|a|Other substances: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone.
DDI-DrugBank.d143.s15	73	82	amiodarone	drug	DDI-DrugBank.d143.s15.e0
DDI-DrugBank.d143.s15	152	161	amiodarone	drug	DDI-DrugBank.d143.s15.e1
DDI-DrugBank.d143.s15	false	DDI-DrugBank.d143.s15.e0	DDI-DrugBank.d143.s15.e1
DDI-DrugBank.d143.s16|a|Grapefruit juice should not be taken during treatment with oral amiodarone.
DDI-DrugBank.d143.s17|a|This information should be considered when changing from intravenous amiodarone to oral amiodarone .
DDI-DrugBank.d143.s17	69	78	amiodarone	drug	DDI-DrugBank.d143.s17.e0
DDI-DrugBank.d143.s17	88	97	amiodarone	drug	DDI-DrugBank.d143.s17.e1
DDI-DrugBank.d143.s17	false	DDI-DrugBank.d143.s17.e0	DDI-DrugBank.d143.s17.e1
DDI-DrugBank.d143.s18|a|Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4.
DDI-DrugBank.d143.s18	0	9	Amiodarone	drug	DDI-DrugBank.d143.s18.e0
DDI-DrugBank.d143.s18	58	63	CYP1A2	drug	DDI-DrugBank.d143.s18.e1
DDI-DrugBank.d143.s18	66	71	CYP2C9	drug	DDI-DrugBank.d143.s18.e2
DDI-DrugBank.d143.s18	74	79	CYP2D6	drug	DDI-DrugBank.d143.s18.e3
DDI-DrugBank.d143.s18	86	91	CYP3A4	drug	DDI-DrugBank.d143.s18.e4
DDI-DrugBank.d143.s18	false	DDI-DrugBank.d143.s18.e0	DDI-DrugBank.d143.s18.e1
DDI-DrugBank.d143.s18	false	DDI-DrugBank.d143.s18.e0	DDI-DrugBank.d143.s18.e2
DDI-DrugBank.d143.s18	false	DDI-DrugBank.d143.s18.e0	DDI-DrugBank.d143.s18.e3
DDI-DrugBank.d143.s18	false	DDI-DrugBank.d143.s18.e0	DDI-DrugBank.d143.s18.e4
DDI-DrugBank.d143.s18	false	DDI-DrugBank.d143.s18.e1	DDI-DrugBank.d143.s18.e2
DDI-DrugBank.d143.s18	false	DDI-DrugBank.d143.s18.e1	DDI-DrugBank.d143.s18.e3
DDI-DrugBank.d143.s18	false	DDI-DrugBank.d143.s18.e1	DDI-DrugBank.d143.s18.e4
DDI-DrugBank.d143.s18	false	DDI-DrugBank.d143.s18.e2	DDI-DrugBank.d143.s18.e3
DDI-DrugBank.d143.s18	false	DDI-DrugBank.d143.s18.e2	DDI-DrugBank.d143.s18.e4
DDI-DrugBank.d143.s18	false	DDI-DrugBank.d143.s18.e3	DDI-DrugBank.d143.s18.e4
DDI-DrugBank.d143.s19|a|This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes.
DDI-DrugBank.d143.s19	71	75	drugs	drug	DDI-DrugBank.d143.s19.e0
DDI-DrugBank.d143.s20|a|Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.
DDI-DrugBank.d143.s20	61	77	Immunosuppressive	drug	DDI-DrugBank.d143.s20.e0
DDI-DrugBank.d143.s20	81	92	Cyclosporine	drug	DDI-DrugBank.d143.s20.e1
DDI-DrugBank.d143.s20	95	100	CYP3A4	drug	DDI-DrugBank.d143.s20.e2
DDI-DrugBank.d143.s20	151	160	amiodarone	drug	DDI-DrugBank.d143.s20.e3
DDI-DrugBank.d143.s20	238	249	cyclosporine	drug	DDI-DrugBank.d143.s20.e4
DDI-DrugBank.d143.s20	314	325	cyclosporine	drug	DDI-DrugBank.d143.s20.e5
DDI-DrugBank.d143.s20	false	DDI-DrugBank.d143.s20.e0	DDI-DrugBank.d143.s20.e1
DDI-DrugBank.d143.s20	false	DDI-DrugBank.d143.s20.e0	DDI-DrugBank.d143.s20.e2
DDI-DrugBank.d143.s20	false	DDI-DrugBank.d143.s20.e0	DDI-DrugBank.d143.s20.e3
DDI-DrugBank.d143.s20	false	DDI-DrugBank.d143.s20.e0	DDI-DrugBank.d143.s20.e4
DDI-DrugBank.d143.s20	false	DDI-DrugBank.d143.s20.e0	DDI-DrugBank.d143.s20.e5
DDI-DrugBank.d143.s20	false	DDI-DrugBank.d143.s20.e1	DDI-DrugBank.d143.s20.e2
DDI-DrugBank.d143.s20	false	DDI-DrugBank.d143.s20.e1	DDI-DrugBank.d143.s20.e3
DDI-DrugBank.d143.s20	false	DDI-DrugBank.d143.s20.e1	DDI-DrugBank.d143.s20.e4
DDI-DrugBank.d143.s20	false	DDI-DrugBank.d143.s20.e1	DDI-DrugBank.d143.s20.e5
DDI-DrugBank.d143.s20	false	DDI-DrugBank.d143.s20.e2	DDI-DrugBank.d143.s20.e3
DDI-DrugBank.d143.s21|a|HMG-CoA Reductase Inhibitors: Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.
DDI-DrugBank.d143.s21	0	27	HMG-CoA Reductase Inhibitors	drug	DDI-DrugBank.d143.s21.e0
DDI-DrugBank.d143.s21	30	40	Simvastatin	drug	DDI-DrugBank.d143.s21.e1
DDI-DrugBank.d143.s21	43	48	CYP3A4	drug	DDI-DrugBank.d143.s21.e2
DDI-DrugBank.d143.s21	81	90	amiodarone	drug	DDI-DrugBank.d143.s21.e3
DDI-DrugBank.d143.s21	false	DDI-DrugBank.d143.s21.e0	DDI-DrugBank.d143.s21.e1
DDI-DrugBank.d143.s21	false	DDI-DrugBank.d143.s21.e0	DDI-DrugBank.d143.s21.e2
DDI-DrugBank.d143.s21	false	DDI-DrugBank.d143.s21.e0	DDI-DrugBank.d143.s21.e3
DDI-DrugBank.d143.s21	false	DDI-DrugBank.d143.s21.e1	DDI-DrugBank.d143.s21.e2
DDI-DrugBank.d143.s21	false	DDI-DrugBank.d143.s21.e1	DDI-DrugBank.d143.s21.e3
DDI-DrugBank.d143.s21	false	DDI-DrugBank.d143.s21.e2	DDI-DrugBank.d143.s21.e3
DDI-DrugBank.d143.s22|a|Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.
DDI-DrugBank.d143.s22	17	34	Cardiac glycosides	drug	DDI-DrugBank.d143.s22.e0
DDI-DrugBank.d143.s22	59	65	digoxin	drug	DDI-DrugBank.d143.s22.e1
DDI-DrugBank.d143.s22	99	108	amiodarone	drug	DDI-DrugBank.d143.s22.e2
DDI-DrugBank.d143.s22	152	158	digoxin	drug	DDI-DrugBank.d143.s22.e3
DDI-DrugBank.d143.s22	false	DDI-DrugBank.d143.s22.e0	DDI-DrugBank.d143.s22.e1
DDI-DrugBank.d143.s22	false	DDI-DrugBank.d143.s22.e0	DDI-DrugBank.d143.s22.e2
DDI-DrugBank.d143.s22	false	DDI-DrugBank.d143.s22.e0	DDI-DrugBank.d143.s22.e3
DDI-DrugBank.d143.s22	false	DDI-DrugBank.d143.s22.e1	DDI-DrugBank.d143.s22.e2
DDI-DrugBank.d143.s22	false	DDI-DrugBank.d143.s22.e1	DDI-DrugBank.d143.s22.e3
DDI-DrugBank.d143.s22	false	DDI-DrugBank.d143.s22.e2	DDI-DrugBank.d143.s22.e3
DDI-DrugBank.d143.s23|a|Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day.
DDI-DrugBank.d143.s23	0	9	Amiodarone	drug	DDI-DrugBank.d143.s23.e0
DDI-DrugBank.d143.s23	36	42	digoxin	drug	DDI-DrugBank.d143.s23.e1
DDI-DrugBank.d143.s23	64	70	digoxin	drug	DDI-DrugBank.d143.s23.e2
DDI-DrugBank.d143.s23	false	DDI-DrugBank.d143.s23.e0	DDI-DrugBank.d143.s23.e1
DDI-DrugBank.d143.s23	false	DDI-DrugBank.d143.s23.e0	DDI-DrugBank.d143.s23.e2
DDI-DrugBank.d143.s23	false	DDI-DrugBank.d143.s23.e1	DDI-DrugBank.d143.s23.e2
DDI-DrugBank.d143.s24|a|On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.
DDI-DrugBank.d143.s24	26	35	amiodarone	drug	DDI-DrugBank.d143.s24.e0
DDI-DrugBank.d143.s24	51	59	digitalis	group	DDI-DrugBank.d143.s24.e1
DDI-DrugBank.d143.s24	true	DDI-DrugBank.d143.s24.e0	DDI-DrugBank.d143.s24.e1
DDI-DrugBank.d143.s25|a|If digitalis treatment is continued, serum levels should be closely monitored and patients observed for clinical evidence of toxicity.
DDI-DrugBank.d143.s25	3	11	digitalis	drug	DDI-DrugBank.d143.s25.e0
DDI-DrugBank.d143.s26|a|These precautions probably should apply to digitoxin administration as well.
DDI-DrugBank.d143.s26	43	51	digitoxin	drug	DDI-DrugBank.d143.s26.e0
DDI-DrugBank.d143.s27|a|Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.
DDI-DrugBank.d143.s27	0	14	Antiarrhythmics	drug	DDI-DrugBank.d143.s27.e0
DDI-DrugBank.d143.s27	23	36	antiarrhythmic	drug	DDI-DrugBank.d143.s27.e1
DDI-DrugBank.d143.s27	53	61	quinidine	drug	DDI-DrugBank.d143.s27.e2
DDI-DrugBank.d143.s27	64	75	procainamide	drug	DDI-DrugBank.d143.s27.e3
DDI-DrugBank.d143.s27	78	89	disopyramide	drug	DDI-DrugBank.d143.s27.e4
DDI-DrugBank.d143.s27	96	104	phenytoin	drug	DDI-DrugBank.d143.s27.e5
DDI-DrugBank.d143.s27	140	149	amiodarone	drug	DDI-DrugBank.d143.s27.e6
DDI-DrugBank.d143.s27	false	DDI-DrugBank.d143.s27.e0	DDI-DrugBank.d143.s27.e1
DDI-DrugBank.d143.s27	false	DDI-DrugBank.d143.s27.e0	DDI-DrugBank.d143.s27.e2
DDI-DrugBank.d143.s27	false	DDI-DrugBank.d143.s27.e0	DDI-DrugBank.d143.s27.e3
DDI-DrugBank.d143.s27	false	DDI-DrugBank.d143.s27.e0	DDI-DrugBank.d143.s27.e4
DDI-DrugBank.d143.s27	false	DDI-DrugBank.d143.s27.e0	DDI-DrugBank.d143.s27.e5
DDI-DrugBank.d143.s27	false	DDI-DrugBank.d143.s27.e0	DDI-DrugBank.d143.s27.e6
DDI-DrugBank.d143.s27	false	DDI-DrugBank.d143.s27.e1	DDI-DrugBank.d143.s27.e2
DDI-DrugBank.d143.s27	false	DDI-DrugBank.d143.s27.e1	DDI-DrugBank.d143.s27.e3
DDI-DrugBank.d143.s27	false	DDI-DrugBank.d143.s27.e1	DDI-DrugBank.d143.s27.e4
DDI-DrugBank.d143.s27	false	DDI-DrugBank.d143.s27.e1	DDI-DrugBank.d143.s27.e5
DDI-DrugBank.d143.s28|a|There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone.
DDI-DrugBank.d143.s28	65	73	quinidine	drug	DDI-DrugBank.d143.s28.e0
DDI-DrugBank.d143.s28	76	87	procainamide	drug	DDI-DrugBank.d143.s28.e1
DDI-DrugBank.d143.s28	94	102	phenytoin	drug	DDI-DrugBank.d143.s28.e2
DDI-DrugBank.d143.s28	136	145	amiodarone	drug	DDI-DrugBank.d143.s28.e3
DDI-DrugBank.d143.s28	false	DDI-DrugBank.d143.s28.e0	DDI-DrugBank.d143.s28.e1
DDI-DrugBank.d143.s28	false	DDI-DrugBank.d143.s28.e0	DDI-DrugBank.d143.s28.e2
DDI-DrugBank.d143.s28	false	DDI-DrugBank.d143.s28.e0	DDI-DrugBank.d143.s28.e3
DDI-DrugBank.d143.s28	false	DDI-DrugBank.d143.s28.e1	DDI-DrugBank.d143.s28.e2
DDI-DrugBank.d143.s28	false	DDI-DrugBank.d143.s28.e1	DDI-DrugBank.d143.s28.e3
DDI-DrugBank.d143.s28	false	DDI-DrugBank.d143.s28.e2	DDI-DrugBank.d143.s28.e3
DDI-DrugBank.d143.s29|a|Phenytoin decreases serum amiodarone levels.
DDI-DrugBank.d143.s29	0	8	Phenytoin	drug	DDI-DrugBank.d143.s29.e0
DDI-DrugBank.d143.s30|a|Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days.
DDI-DrugBank.d143.s30	0	9	Amiodarone	drug	DDI-DrugBank.d143.s30.e0
DDI-DrugBank.d143.s30	36	44	quinidine	drug	DDI-DrugBank.d143.s30.e1
DDI-DrugBank.d143.s30	56	64	quinidine	drug	DDI-DrugBank.d143.s30.e2
DDI-DrugBank.d143.s30	false	DDI-DrugBank.d143.s30.e0	DDI-DrugBank.d143.s30.e1
DDI-DrugBank.d143.s30	false	DDI-DrugBank.d143.s30.e0	DDI-DrugBank.d143.s30.e2
DDI-DrugBank.d143.s30	false	DDI-DrugBank.d143.s30.e1	DDI-DrugBank.d143.s30.e2
DDI-DrugBank.d143.s31|a|Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.
DDI-DrugBank.d143.s31	0	9	Amiodarone	drug	DDI-DrugBank.d143.s31.e0
DDI-DrugBank.d143.s31	36	47	procainamide	drug	DDI-DrugBank.d143.s31.e1
DDI-DrugBank.d143.s31	109	120	procainamide	drug	DDI-DrugBank.d143.s31.e2
DDI-DrugBank.d143.s31	135	146	procainamide	drug	DDI-DrugBank.d143.s31.e3
DDI-DrugBank.d143.s31	false	DDI-DrugBank.d143.s31.e0	DDI-DrugBank.d143.s31.e1
DDI-DrugBank.d143.s31	false	DDI-DrugBank.d143.s31.e0	DDI-DrugBank.d143.s31.e2
DDI-DrugBank.d143.s31	false	DDI-DrugBank.d143.s31.e0	DDI-DrugBank.d143.s31.e3
DDI-DrugBank.d143.s31	false	DDI-DrugBank.d143.s31.e1	DDI-DrugBank.d143.s31.e2
DDI-DrugBank.d143.s31	false	DDI-DrugBank.d143.s31.e1	DDI-DrugBank.d143.s31.e3
DDI-DrugBank.d143.s31	false	DDI-DrugBank.d143.s31.e2	DDI-DrugBank.d143.s31.e3
DDI-DrugBank.d143.s32|a|Quinidine and procainamide doses should be reduced by one-third when either is administered with amiodarone.
DDI-DrugBank.d143.s32	0	8	Quinidine	drug	DDI-DrugBank.d143.s32.e0
DDI-DrugBank.d143.s32	97	106	amiodarone	drug	DDI-DrugBank.d143.s32.e1
DDI-DrugBank.d143.s32	false	DDI-DrugBank.d143.s32.e0	DDI-DrugBank.d143.s32.e1
DDI-DrugBank.d143.s33|a|Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone;
DDI-DrugBank.d143.s33	17	26	flecainide	drug	DDI-DrugBank.d143.s33.e0
DDI-DrugBank.d143.s33	83	92	amiodarone	drug	DDI-DrugBank.d143.s33.e1
DDI-DrugBank.d143.s33	false	DDI-DrugBank.d143.s33.e0	DDI-DrugBank.d143.s33.e1
DDI-DrugBank.d143.s34|a|because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly.
DDI-DrugBank.d143.s34	31	40	flecainide	drug	DDI-DrugBank.d143.s34.e0
DDI-DrugBank.d143.s34	72	76	drugs	drug	DDI-DrugBank.d143.s34.e1
DDI-DrugBank.d143.s34	false	DDI-DrugBank.d143.s34.e0	DDI-DrugBank.d143.s34.e1
DDI-DrugBank.d143.s35|a|In general, any added antiarrhythmic drug should be initiated at a lower than usual dose with careful monitoring.
DDI-DrugBank.d143.s35	22	40	antiarrhythmic drug	drug	DDI-DrugBank.d143.s35.e0
DDI-DrugBank.d143.s36|a|Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.
DDI-DrugBank.d143.s36	15	24	amiodarone	drug	DDI-DrugBank.d143.s36.e0
DDI-DrugBank.d143.s36	37	50	antiarrhythmic	drug	DDI-DrugBank.d143.s36.e1
DDI-DrugBank.d143.s36	218	227	amiodarone	drug	DDI-DrugBank.d143.s36.e2
DDI-DrugBank.d143.s36	false	DDI-DrugBank.d143.s36.e0	DDI-DrugBank.d143.s36.e1
DDI-DrugBank.d143.s36	false	DDI-DrugBank.d143.s36.e0	DDI-DrugBank.d143.s36.e2
DDI-DrugBank.d143.s36	false	DDI-DrugBank.d143.s36.e1	DDI-DrugBank.d143.s36.e2
DDI-DrugBank.d143.s37|a|During transfer to oral amiodarone, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral amiodarone.
DDI-DrugBank.d143.s37	24	33	amiodarone	drug	DDI-DrugBank.d143.s37.e0
DDI-DrugBank.d143.s37	157	166	amiodarone	drug	DDI-DrugBank.d143.s37.e1
DDI-DrugBank.d143.s37	false	DDI-DrugBank.d143.s37.e0	DDI-DrugBank.d143.s37.e1
DDI-DrugBank.d143.s38|a|The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted.
DDI-DrugBank.d143.s38	33	46	antiarrhythmic	drug	DDI-DrugBank.d143.s38.e0
DDI-DrugBank.d143.s38	94	103	amiodarone	drug	DDI-DrugBank.d143.s38.e1
DDI-DrugBank.d143.s38	false	DDI-DrugBank.d143.s38.e0	DDI-DrugBank.d143.s38.e1
DDI-DrugBank.d143.s39|a|If the treatment is continued, these patients should be particularly carefully monitored for adverse effects, especially conduction disturbances and exacerbation of tachyarrhythmias, as amiodarone is continued.
DDI-DrugBank.d143.s39	186	195	amiodarone	drug	DDI-DrugBank.d143.s39.e0
DDI-DrugBank.d143.s40|a|In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.
DDI-DrugBank.d143.s40	3	12	amiodarone	drug	DDI-DrugBank.d143.s40.e0
DDI-DrugBank.d143.s40	54	67	antiarrhythmic	drug	DDI-DrugBank.d143.s40.e1
DDI-DrugBank.d143.s40	false	DDI-DrugBank.d143.s40.e0	DDI-DrugBank.d143.s40.e1
DDI-DrugBank.d143.s41|a|Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
DDI-DrugBank.d143.s41	0	16	Antihypertensives	drug	DDI-DrugBank.d143.s41.e0
DDI-DrugBank.d143.s41	19	28	Amiodarone	drug	DDI-DrugBank.d143.s41.e1
DDI-DrugBank.d143.s41	82	89	receptor	drug	DDI-DrugBank.d143.s41.e2
DDI-DrugBank.d143.s41	114	124	propranolol	drug	DDI-DrugBank.d143.s41.e3
DDI-DrugBank.d143.s41	129	134	CYP3A4	drug	DDI-DrugBank.d143.s41.e4
DDI-DrugBank.d143.s41	150	164	calcium channel	drug	DDI-DrugBank.d143.s41.e5
DDI-DrugBank.d143.s41	185	193	verapamil	drug	DDI-DrugBank.d143.s41.e6
DDI-DrugBank.d143.s41	198	203	CYP3A4	drug	DDI-DrugBank.d143.s41.e7
DDI-DrugBank.d143.s41	220	228	diltiazem	drug	DDI-DrugBank.d143.s41.e8
DDI-DrugBank.d143.s41	233	238	CYP3A4	drug	DDI-DrugBank.d143.s41.e9
DDI-DrugBank.d143.s41	false	DDI-DrugBank.d143.s41.e0	DDI-DrugBank.d143.s41.e1
DDI-DrugBank.d143.s41	false	DDI-DrugBank.d143.s41.e0	DDI-DrugBank.d143.s41.e2
DDI-DrugBank.d143.s41	false	DDI-DrugBank.d143.s41.e0	DDI-DrugBank.d143.s41.e3
DDI-DrugBank.d143.s41	false	DDI-DrugBank.d143.s41.e0	DDI-DrugBank.d143.s41.e4
DDI-DrugBank.d143.s41	false	DDI-DrugBank.d143.s41.e0	DDI-DrugBank.d143.s41.e5
DDI-DrugBank.d143.s41	false	DDI-DrugBank.d143.s41.e0	DDI-DrugBank.d143.s41.e6
DDI-DrugBank.d143.s41	false	DDI-DrugBank.d143.s41.e0	DDI-DrugBank.d143.s41.e7
DDI-DrugBank.d143.s41	false	DDI-DrugBank.d143.s41.e0	DDI-DrugBank.d143.s41.e8
DDI-DrugBank.d143.s41	false	DDI-DrugBank.d143.s41.e0	DDI-DrugBank.d143.s41.e9
DDI-DrugBank.d143.s41	false	DDI-DrugBank.d143.s41.e1	DDI-DrugBank.d143.s41.e2
DDI-DrugBank.d143.s42|a|if necessary, amiodarone can continue to be used after insertion of a pacemaker in patients with severe bradycardia or sinus arrest.
DDI-DrugBank.d143.s42	14	23	amiodarone	drug	DDI-DrugBank.d143.s42.e0
DDI-DrugBank.d143.s43|a|Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
DDI-DrugBank.d143.s43	0	13	Anticoagulants	drug	DDI-DrugBank.d143.s43.e0
DDI-DrugBank.d143.s43	32	39	warfarin	drug	DDI-DrugBank.d143.s43.e1
DDI-DrugBank.d143.s43	47	52	CYP2C9	drug	DDI-DrugBank.d143.s43.e2
DDI-DrugBank.d143.s43	58	63	CYP3A4	drug	DDI-DrugBank.d143.s43.e3
DDI-DrugBank.d143.s43	76	88	anticoagulant	drug	DDI-DrugBank.d143.s43.e4
DDI-DrugBank.d143.s43	143	152	amiodarone	drug	DDI-DrugBank.d143.s43.e5
DDI-DrugBank.d143.s43	false	DDI-DrugBank.d143.s43.e0	DDI-DrugBank.d143.s43.e1
DDI-DrugBank.d143.s43	false	DDI-DrugBank.d143.s43.e0	DDI-DrugBank.d143.s43.e2
DDI-DrugBank.d143.s43	false	DDI-DrugBank.d143.s43.e0	DDI-DrugBank.d143.s43.e3
DDI-DrugBank.d143.s43	false	DDI-DrugBank.d143.s43.e0	DDI-DrugBank.d143.s43.e4
DDI-DrugBank.d143.s43	false	DDI-DrugBank.d143.s43.e0	DDI-DrugBank.d143.s43.e5
DDI-DrugBank.d143.s43	false	DDI-DrugBank.d143.s43.e1	DDI-DrugBank.d143.s43.e2
DDI-DrugBank.d143.s43	false	DDI-DrugBank.d143.s43.e1	DDI-DrugBank.d143.s43.e3
DDI-DrugBank.d143.s43	false	DDI-DrugBank.d143.s43.e1	DDI-DrugBank.d143.s43.e4
DDI-DrugBank.d143.s43	false	DDI-DrugBank.d143.s43.e1	DDI-DrugBank.d143.s43.e5
DDI-DrugBank.d143.s43	false	DDI-DrugBank.d143.s43.e2	DDI-DrugBank.d143.s43.e3
DDI-DrugBank.d143.s44|a|Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.
DDI-DrugBank.d143.s44	40	47	warfarin	drug	DDI-DrugBank.d143.s44.e0
DDI-DrugBank.d143.s44	54	63	amiodarone	drug	DDI-DrugBank.d143.s44.e1
DDI-DrugBank.d143.s44	139	151	anticoagulant	drug	DDI-DrugBank.d143.s44.e2
DDI-DrugBank.d143.s44	false	DDI-DrugBank.d143.s44.e0	DDI-DrugBank.d143.s44.e1
DDI-DrugBank.d143.s44	false	DDI-DrugBank.d143.s44.e0	DDI-DrugBank.d143.s44.e2
DDI-DrugBank.d143.s44	false	DDI-DrugBank.d143.s44.e1	DDI-DrugBank.d143.s44.e2
DDI-DrugBank.d143.s45|a|Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).
DDI-DrugBank.d143.s45	5	9	drugs	drug	DDI-DrugBank.d143.s45.e0
DDI-DrugBank.d143.s45	64	73	amiodarone	drug	DDI-DrugBank.d143.s45.e1
DDI-DrugBank.d143.s45	107	112	CYP3A4	drug	DDI-DrugBank.d143.s45.e2
DDI-DrugBank.d143.s45	false	DDI-DrugBank.d143.s45.e0	DDI-DrugBank.d143.s45.e1
DDI-DrugBank.d143.s45	false	DDI-DrugBank.d143.s45.e0	DDI-DrugBank.d143.s45.e2
DDI-DrugBank.d143.s45	false	DDI-DrugBank.d143.s45.e1	DDI-DrugBank.d143.s45.e2
DDI-DrugBank.d143.s46|a|This may lead to low amiodarone serum levels and potential decrease in efficacy.
DDI-DrugBank.d143.s46	21	30	amiodarone	drug	DDI-DrugBank.d143.s46.e0
DDI-DrugBank.d143.s47|a|Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.
DDI-DrugBank.d143.s47	61	71	Antibiotics	drug	DDI-DrugBank.d143.s47.e0
DDI-DrugBank.d143.s47	74	81	Rifampin	drug	DDI-DrugBank.d143.s47.e1
DDI-DrugBank.d143.s47	106	111	CYP3A4	drug	DDI-DrugBank.d143.s47.e2
DDI-DrugBank.d143.s47	false	DDI-DrugBank.d143.s47.e0	DDI-DrugBank.d143.s47.e1
DDI-DrugBank.d143.s47	false	DDI-DrugBank.d143.s47.e0	DDI-DrugBank.d143.s47.e2
DDI-DrugBank.d143.s47	false	DDI-DrugBank.d143.s47.e1	DDI-DrugBank.d143.s47.e2
DDI-DrugBank.d143.s48|a|Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.
DDI-DrugBank.d143.s48	18	25	rifampin	drug	DDI-DrugBank.d143.s48.e0
DDI-DrugBank.d143.s48	51	60	amiodarone	drug	DDI-DrugBank.d143.s48.e1
DDI-DrugBank.d143.s48	127	136	amiodarone	drug	DDI-DrugBank.d143.s48.e2
DDI-DrugBank.d143.s48	142	159	desethylamiodarone	drug	DDI-DrugBank.d143.s48.e3
DDI-DrugBank.d143.s48	false	DDI-DrugBank.d143.s48.e0	DDI-DrugBank.d143.s48.e1
DDI-DrugBank.d143.s48	false	DDI-DrugBank.d143.s48.e0	DDI-DrugBank.d143.s48.e2
DDI-DrugBank.d143.s48	false	DDI-DrugBank.d143.s48.e0	DDI-DrugBank.d143.s48.e3
DDI-DrugBank.d143.s48	false	DDI-DrugBank.d143.s48.e1	DDI-DrugBank.d143.s48.e2
DDI-DrugBank.d143.s48	false	DDI-DrugBank.d143.s48.e1	DDI-DrugBank.d143.s48.e3
DDI-DrugBank.d143.s48	false	DDI-DrugBank.d143.s48.e2	DDI-DrugBank.d143.s48.e3
DDI-DrugBank.d143.s49|a|Other substances, including herbal preparations: St. John s Wort (Hypericum perforatum) induces CYP3A4.
DDI-DrugBank.d143.s50|a|Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.
DDI-DrugBank.d143.s50	6	15	amiodarone	drug	DDI-DrugBank.d143.s50.e0
DDI-DrugBank.d143.s50	36	41	CYP3A4	drug	DDI-DrugBank.d143.s50.e1
DDI-DrugBank.d143.s50	121	130	amiodarone	drug	DDI-DrugBank.d143.s50.e2
DDI-DrugBank.d143.s50	156	165	amiodarone	drug	DDI-DrugBank.d143.s50.e3
DDI-DrugBank.d143.s50	false	DDI-DrugBank.d143.s50.e0	DDI-DrugBank.d143.s50.e1
DDI-DrugBank.d143.s50	false	DDI-DrugBank.d143.s50.e0	DDI-DrugBank.d143.s50.e2
DDI-DrugBank.d143.s50	false	DDI-DrugBank.d143.s50.e0	DDI-DrugBank.d143.s50.e3
DDI-DrugBank.d143.s50	false	DDI-DrugBank.d143.s50.e1	DDI-DrugBank.d143.s50.e2
DDI-DrugBank.d143.s50	false	DDI-DrugBank.d143.s50.e1	DDI-DrugBank.d143.s50.e3
DDI-DrugBank.d143.s50	false	DDI-DrugBank.d143.s50.e2	DDI-DrugBank.d143.s50.e3
DDI-DrugBank.d143.s51|a|Other reported interactions with amiodarone: Fentanyl (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.
DDI-DrugBank.d143.s51	33	42	amiodarone	drug	DDI-DrugBank.d143.s51.e0
DDI-DrugBank.d143.s51	45	52	Fentanyl	drug	DDI-DrugBank.d143.s51.e1
DDI-DrugBank.d143.s51	55	60	CYP3A4	drug	DDI-DrugBank.d143.s51.e2
DDI-DrugBank.d143.s51	93	102	amiodarone	drug	DDI-DrugBank.d143.s51.e3
DDI-DrugBank.d143.s51	false	DDI-DrugBank.d143.s51.e0	DDI-DrugBank.d143.s51.e1
DDI-DrugBank.d143.s51	false	DDI-DrugBank.d143.s51.e0	DDI-DrugBank.d143.s51.e2
DDI-DrugBank.d143.s51	false	DDI-DrugBank.d143.s51.e0	DDI-DrugBank.d143.s51.e3
DDI-DrugBank.d143.s51	false	DDI-DrugBank.d143.s51.e1	DDI-DrugBank.d143.s51.e2
DDI-DrugBank.d143.s51	false	DDI-DrugBank.d143.s51.e1	DDI-DrugBank.d143.s51.e3
DDI-DrugBank.d143.s51	false	DDI-DrugBank.d143.s51.e2	DDI-DrugBank.d143.s51.e3
DDI-DrugBank.d143.s52|a|Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (CYP3A4 substrate) given for local anesthesia.
DDI-DrugBank.d143.s52	46	55	amiodarone	drug	DDI-DrugBank.d143.s52.e0
DDI-DrugBank.d143.s52	77	85	lidocaine	drug	DDI-DrugBank.d143.s52.e1
DDI-DrugBank.d143.s52	88	93	CYP3A4	drug	DDI-DrugBank.d143.s52.e2
DDI-DrugBank.d143.s52	122	131	anesthesia	drug	DDI-DrugBank.d143.s52.e3
DDI-DrugBank.d143.s52	false	DDI-DrugBank.d143.s52.e0	DDI-DrugBank.d143.s52.e1
DDI-DrugBank.d143.s52	false	DDI-DrugBank.d143.s52.e0	DDI-DrugBank.d143.s52.e2
DDI-DrugBank.d143.s52	false	DDI-DrugBank.d143.s52.e0	DDI-DrugBank.d143.s52.e3
DDI-DrugBank.d143.s52	false	DDI-DrugBank.d143.s52.e1	DDI-DrugBank.d143.s52.e2
DDI-DrugBank.d143.s52	false	DDI-DrugBank.d143.s52.e1	DDI-DrugBank.d143.s52.e3
DDI-DrugBank.d143.s52	false	DDI-DrugBank.d143.s52.e2	DDI-DrugBank.d143.s52.e3
DDI-DrugBank.d143.s53|a|Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone.
DDI-DrugBank.d143.s53	35	43	lidocaine	drug	DDI-DrugBank.d143.s53.e0
DDI-DrugBank.d143.s53	126	135	amiodarone	drug	DDI-DrugBank.d143.s53.e1
DDI-DrugBank.d143.s53	false	DDI-DrugBank.d143.s53.e0	DDI-DrugBank.d143.s53.e1
DDI-DrugBank.d143.s54|a|Dextromethorphan is a substrate for both CYP2D6 and CYP3A4.
DDI-DrugBank.d143.s54	0	15	Dextromethorphan	drug	DDI-DrugBank.d143.s54.e0
DDI-DrugBank.d143.s54	41	46	CYP2D6	drug	DDI-DrugBank.d143.s54.e1
DDI-DrugBank.d143.s54	52	57	CYP3A4	drug	DDI-DrugBank.d143.s54.e2
DDI-DrugBank.d143.s54	false	DDI-DrugBank.d143.s54.e0	DDI-DrugBank.d143.s54.e1
DDI-DrugBank.d143.s54	false	DDI-DrugBank.d143.s54.e0	DDI-DrugBank.d143.s54.e2
DDI-DrugBank.d143.s54	false	DDI-DrugBank.d143.s54.e1	DDI-DrugBank.d143.s54.e2
DDI-DrugBank.d143.s55|a|Amiodarone inhibits CYP2D6.
DDI-DrugBank.d143.s55	0	9	Amiodarone	drug	DDI-DrugBank.d143.s55.e0
DDI-DrugBank.d143.s55	20	25	CYP2D6	drug	DDI-DrugBank.d143.s55.e1
DDI-DrugBank.d143.s55	false	DDI-DrugBank.d143.s55.e0	DDI-DrugBank.d143.s55.e1
DDI-DrugBank.d143.s56|a|Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1/2.
DDI-DrugBank.d143.s56	0	13	Cholestyramine	drug	DDI-DrugBank.d143.s56.e0
DDI-DrugBank.d143.s56	54	63	amiodarone	drug	DDI-DrugBank.d143.s56.e1
DDI-DrugBank.d143.s56	101	102	t1	drug	DDI-DrugBank.d143.s56.e2
DDI-DrugBank.d143.s56	false	DDI-DrugBank.d143.s56.e0	DDI-DrugBank.d143.s56.e1
DDI-DrugBank.d143.s56	false	DDI-DrugBank.d143.s56.e0	DDI-DrugBank.d143.s56.e2
DDI-DrugBank.d143.s56	false	DDI-DrugBank.d143.s56.e1	DDI-DrugBank.d143.s56.e2
DDI-DrugBank.d143.s57|a|Disopyramide increases QT prolongation which could cause arrhythmia.
DDI-DrugBank.d143.s57	0	11	Disopyramide	drug	DDI-DrugBank.d143.s57.e0
DDI-DrugBank.d143.s58|a|Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation.
DDI-DrugBank.d143.s58	0	15	Fluoroquinolones	drug	DDI-DrugBank.d143.s58.e0
DDI-DrugBank.d143.s58	18	38	macrolide antibiotics	drug	DDI-DrugBank.d143.s58.e1
DDI-DrugBank.d143.s58	false	DDI-DrugBank.d143.s58.e0	DDI-DrugBank.d143.s58.e1
DDI-DrugBank.d143.s59|a|There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.
DDI-DrugBank.d143.s59	85	94	amiodarone	drug	DDI-DrugBank.d143.s59.e0
DDI-DrugBank.d143.s59	101	116	fluoroquinolones	drug	DDI-DrugBank.d143.s59.e1
DDI-DrugBank.d143.s59	119	139	macrolide antibiotics	drug	DDI-DrugBank.d143.s59.e2
DDI-DrugBank.d143.s59	false	DDI-DrugBank.d143.s59.e0	DDI-DrugBank.d143.s59.e1
DDI-DrugBank.d143.s59	false	DDI-DrugBank.d143.s59.e0	DDI-DrugBank.d143.s59.e2
DDI-DrugBank.d143.s59	false	DDI-DrugBank.d143.s59.e1	DDI-DrugBank.d143.s59.e2
DDI-DrugBank.d143.s60|a|Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, diltiazem, and verapamil.
DDI-DrugBank.d143.s60	110	120	propranolol	drug	DDI-DrugBank.d143.s60.e0
DDI-DrugBank.d143.s60	123	131	diltiazem	drug	DDI-DrugBank.d143.s60.e1
DDI-DrugBank.d143.s60	138	146	verapamil	drug	DDI-DrugBank.d143.s60.e2
DDI-DrugBank.d143.s60	false	DDI-DrugBank.d143.s60.e0	DDI-DrugBank.d143.s60.e1
DDI-DrugBank.d143.s60	false	DDI-DrugBank.d143.s60.e0	DDI-DrugBank.d143.s60.e2
DDI-DrugBank.d143.s60	false	DDI-DrugBank.d143.s60.e1	DDI-DrugBank.d143.s60.e2
DDI-DrugBank.d143.s61|a|Volatile Anesthetic Agents:.
DDI-DrugBank.d143.s61	9	18	Anesthetic	drug	DDI-DrugBank.d143.s61.e0
DDI-DrugBank.d143.s62|a|In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, dextromethorphan, and methotrexate.
DDI-DrugBank.d143.s62	70	78	Cordarone	drug	DDI-DrugBank.d143.s62.e0
DDI-DrugBank.d143.s62	117	125	phenytoin	drug	DDI-DrugBank.d143.s62.e1
DDI-DrugBank.d143.s62	128	143	dextromethorphan	drug	DDI-DrugBank.d143.s62.e2
DDI-DrugBank.d143.s62	150	161	methotrexate	drug	DDI-DrugBank.d143.s62.e3
DDI-DrugBank.d143.s62	false	DDI-DrugBank.d143.s62.e0	DDI-DrugBank.d143.s62.e1
DDI-DrugBank.d143.s62	false	DDI-DrugBank.d143.s62.e0	DDI-DrugBank.d143.s62.e2
DDI-DrugBank.d143.s62	false	DDI-DrugBank.d143.s62.e0	DDI-DrugBank.d143.s62.e3
DDI-DrugBank.d143.s62	false	DDI-DrugBank.d143.s62.e1	DDI-DrugBank.d143.s62.e2
DDI-DrugBank.d143.s62	false	DDI-DrugBank.d143.s62.e1	DDI-DrugBank.d143.s62.e3
DDI-DrugBank.d143.s62	false	DDI-DrugBank.d143.s62.e2	DDI-DrugBank.d143.s62.e3
DDI-DrugBank.d143.s63|a|Electrolyte Disturbances Patients with hypokalemia or hypomagnesemia should have the condition corrected whenever possible before being treated with Cordarone I.V., as these disorders can exaggerate the degree of QTc prolongation and increase the potential for TdP.
DDI-DrugBank.d143.s63	149	162	Cordarone I.V.	drug	DDI-DrugBank.d143.s63.e0
DDI-DrugBank.d143.s64|a|Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics.
DDI-DrugBank.d143.s64	162	170	diuretics	drug	DDI-DrugBank.d143.s64.e0
DDI-DrugBank.d99.s0|a|Drugs Metabolized by P450 2D6 - The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called poor metabolizers);
DDI-DrugBank.d99.s1|a|reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
DDI-DrugBank.d99.s2|a|Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
DDI-DrugBank.d99.s2	69	93	tricyclic antidepressants	group	DDI-DrugBank.d99.s2.e0
DDI-DrugBank.d99.s2	96	99	TCAs	group	DDI-DrugBank.d99.s2.e1
DDI-DrugBank.d99.s2	false	DDI-DrugBank.d99.s2.e0	DDI-DrugBank.d99.s2.e1
DDI-DrugBank.d99.s3|a|Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).
DDI-DrugBank.d99.s3	163	165	TCA	group	DDI-DrugBank.d99.s3.e0
DDI-DrugBank.d99.s4|a|In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
DDI-DrugBank.d99.s5|a|An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
DDI-DrugBank.d99.s5	47	49	TCA	group	DDI-DrugBank.d99.s5.e0
DDI-DrugBank.d99.s6|a|The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;
DDI-DrugBank.d99.s6	96	104	quinidine	drug	DDI-DrugBank.d99.s6.e0
DDI-DrugBank.d99.s7|a|cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
DDI-DrugBank.d99.s7	0	9	cimetidine	drug	DDI-DrugBank.d99.s7.e0
DDI-DrugBank.d99.s7	66	80	antidepressants	group	DDI-DrugBank.d99.s7.e1
DDI-DrugBank.d99.s7	83	96	phenothiazines	group	DDI-DrugBank.d99.s7.e2
DDI-DrugBank.d99.s7	107	129	Type 1C antiarrhythmics	group	DDI-DrugBank.d99.s7.e3
DDI-DrugBank.d99.s7	131	141	propafenone	drug	DDI-DrugBank.d99.s7.e4
DDI-DrugBank.d99.s7	147	156	flecainide	drug	DDI-DrugBank.d99.s7.e5
DDI-DrugBank.d99.s7	false	DDI-DrugBank.d99.s7.e0	DDI-DrugBank.d99.s7.e1
DDI-DrugBank.d99.s7	false	DDI-DrugBank.d99.s7.e0	DDI-DrugBank.d99.s7.e2
DDI-DrugBank.d99.s7	false	DDI-DrugBank.d99.s7.e0	DDI-DrugBank.d99.s7.e3
DDI-DrugBank.d99.s7	false	DDI-DrugBank.d99.s7.e0	DDI-DrugBank.d99.s7.e4
DDI-DrugBank.d99.s7	false	DDI-DrugBank.d99.s7.e0	DDI-DrugBank.d99.s7.e5
DDI-DrugBank.d99.s7	false	DDI-DrugBank.d99.s7.e1	DDI-DrugBank.d99.s7.e2
DDI-DrugBank.d99.s7	false	DDI-DrugBank.d99.s7.e1	DDI-DrugBank.d99.s7.e3
DDI-DrugBank.d99.s7	false	DDI-DrugBank.d99.s7.e1	DDI-DrugBank.d99.s7.e4
DDI-DrugBank.d99.s7	false	DDI-DrugBank.d99.s7.e1	DDI-DrugBank.d99.s7.e5
DDI-DrugBank.d99.s7	false	DDI-DrugBank.d99.s7.e2	DDI-DrugBank.d99.s7.e3
DDI-DrugBank.d99.s8|a|While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
DDI-DrugBank.d99.s8	24	52	serotonin reuptake inhibitors	group	DDI-DrugBank.d99.s8.e0
DDI-DrugBank.d99.s8	55	59	SSRIs	group	DDI-DrugBank.d99.s8.e1
DDI-DrugBank.d99.s8	69	78	fluoxetine	drug	DDI-DrugBank.d99.s8.e2
DDI-DrugBank.d99.s8	81	90	sertraline	drug	DDI-DrugBank.d99.s8.e3
DDI-DrugBank.d99.s8	97	106	paroxetine	drug	DDI-DrugBank.d99.s8.e4
DDI-DrugBank.d99.s8	false	DDI-DrugBank.d99.s8.e0	DDI-DrugBank.d99.s8.e1
DDI-DrugBank.d99.s8	false	DDI-DrugBank.d99.s8.e0	DDI-DrugBank.d99.s8.e2
DDI-DrugBank.d99.s8	false	DDI-DrugBank.d99.s8.e0	DDI-DrugBank.d99.s8.e3
DDI-DrugBank.d99.s8	false	DDI-DrugBank.d99.s8.e0	DDI-DrugBank.d99.s8.e4
DDI-DrugBank.d99.s8	false	DDI-DrugBank.d99.s8.e1	DDI-DrugBank.d99.s8.e2
DDI-DrugBank.d99.s8	false	DDI-DrugBank.d99.s8.e1	DDI-DrugBank.d99.s8.e3
DDI-DrugBank.d99.s8	false	DDI-DrugBank.d99.s8.e1	DDI-DrugBank.d99.s8.e4
DDI-DrugBank.d99.s8	false	DDI-DrugBank.d99.s8.e2	DDI-DrugBank.d99.s8.e3
DDI-DrugBank.d99.s8	false	DDI-DrugBank.d99.s8.e2	DDI-DrugBank.d99.s8.e4
DDI-DrugBank.d99.s8	false	DDI-DrugBank.d99.s8.e3	DDI-DrugBank.d99.s8.e4
DDI-DrugBank.d99.s9|a|The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
DDI-DrugBank.d99.s9	20	23	SSRI	group	DDI-DrugBank.d99.s9.e0
DDI-DrugBank.d99.s9	25	27	TCA	group	DDI-DrugBank.d99.s9.e1
DDI-DrugBank.d99.s9	141	144	SSRI	group	DDI-DrugBank.d99.s9.e2
DDI-DrugBank.d99.s9	true	DDI-DrugBank.d99.s9.e0	DDI-DrugBank.d99.s9.e1
DDI-DrugBank.d99.s9	false	DDI-DrugBank.d99.s9.e0	DDI-DrugBank.d99.s9.e2
DDI-DrugBank.d99.s9	false	DDI-DrugBank.d99.s9.e1	DDI-DrugBank.d99.s9.e2
DDI-DrugBank.d99.s10|a|Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.
DDI-DrugBank.d99.s10	62	65	TCAs	group	DDI-DrugBank.d99.s10.e0
DDI-DrugBank.d99.s10	83	87	SSRIs	group	DDI-DrugBank.d99.s10.e1
DDI-DrugBank.d99.s10	true	DDI-DrugBank.d99.s10.e0	DDI-DrugBank.d99.s10.e1
DDI-DrugBank.d99.s11|a|Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
DDI-DrugBank.d99.s11	120	129	fluoxetine	drug	DDI-DrugBank.d99.s11.e0
DDI-DrugBank.d99.s12|a|Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
DDI-DrugBank.d99.s12	19	43	tricyclic antidepressants	group	DDI-DrugBank.d99.s12.e0
DDI-DrugBank.d99.s12	156	179	tricyclic antidepressant	group	DDI-DrugBank.d99.s12.e1
DDI-DrugBank.d99.s12	false	DDI-DrugBank.d99.s12.e0	DDI-DrugBank.d99.s12.e1
DDI-DrugBank.d99.s13|a|Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.
DDI-DrugBank.d99.s13	98	121	tricyclic antidepressant	drug	DDI-DrugBank.d99.s13.e0
DDI-DrugBank.d99.s14|a|It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.
DDI-DrugBank.d99.s14	27	29	TCA	group	DDI-DrugBank.d99.s14.e0
DDI-DrugBank.d99.s14	56	58	TCA	group	DDI-DrugBank.d99.s14.e1
DDI-DrugBank.d99.s14	false	DDI-DrugBank.d99.s14.e0	DDI-DrugBank.d99.s14.e1
DDI-DrugBank.d99.s15|a|Monoamine Oxidase Inhibitors: Guanethidine or similarly acting compounds;
DDI-DrugBank.d99.s15	0	27	Monoamine Oxidase Inhibitors	drug	DDI-DrugBank.d99.s15.e0
DDI-DrugBank.d99.s15	30	41	Guanethidine	drug	DDI-DrugBank.d99.s15.e1
DDI-DrugBank.d99.s15	false	DDI-DrugBank.d99.s15.e0	DDI-DrugBank.d99.s15.e1
DDI-DrugBank.d99.s16|a|thyroid medication;
DDI-DrugBank.d99.s16	0	6	thyroid	drug	DDI-DrugBank.d99.s16.e0
DDI-DrugBank.d99.s17|a|alcohol, barbiturates and other CNS depressants;
DDI-DrugBank.d99.s17	0	6	alcohol	drug	DDI-DrugBank.d99.s17.e0
DDI-DrugBank.d99.s17	9	20	barbiturates	drug	DDI-DrugBank.d99.s17.e1
DDI-DrugBank.d99.s17	32	46	CNS depressants	drug	DDI-DrugBank.d99.s17.e2
DDI-DrugBank.d99.s17	false	DDI-DrugBank.d99.s17.e0	DDI-DrugBank.d99.s17.e1
DDI-DrugBank.d99.s17	false	DDI-DrugBank.d99.s17.e0	DDI-DrugBank.d99.s17.e2
DDI-DrugBank.d99.s17	false	DDI-DrugBank.d99.s17.e1	DDI-DrugBank.d99.s17.e2
DDI-DrugBank.d99.s18|a|and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
DDI-DrugBank.d99.s18	4	13	disulfiram	drug	DDI-DrugBank.d99.s18.e0
DDI-DrugBank.d99.s18	20	36	amitriptyline HCl	drug	DDI-DrugBank.d99.s18.e1
DDI-DrugBank.d99.s18	52	66	anticholinergic	drug	DDI-DrugBank.d99.s18.e2
DDI-DrugBank.d99.s18	78	92	sympathomimetic	drug	DDI-DrugBank.d99.s18.e3
DDI-DrugBank.d99.s18	111	121	epinephrine	drug	DDI-DrugBank.d99.s18.e4
DDI-DrugBank.d99.s18	143	153	anesthetics	drug	DDI-DrugBank.d99.s18.e5
DDI-DrugBank.d99.s18	false	DDI-DrugBank.d99.s18.e0	DDI-DrugBank.d99.s18.e1
DDI-DrugBank.d99.s18	false	DDI-DrugBank.d99.s18.e0	DDI-DrugBank.d99.s18.e2
DDI-DrugBank.d99.s18	false	DDI-DrugBank.d99.s18.e0	DDI-DrugBank.d99.s18.e3
DDI-DrugBank.d99.s18	false	DDI-DrugBank.d99.s18.e0	DDI-DrugBank.d99.s18.e4
DDI-DrugBank.d99.s18	false	DDI-DrugBank.d99.s18.e0	DDI-DrugBank.d99.s18.e5
DDI-DrugBank.d99.s18	false	DDI-DrugBank.d99.s18.e1	DDI-DrugBank.d99.s18.e2
DDI-DrugBank.d99.s18	false	DDI-DrugBank.d99.s18.e1	DDI-DrugBank.d99.s18.e3
DDI-DrugBank.d99.s18	false	DDI-DrugBank.d99.s18.e1	DDI-DrugBank.d99.s18.e4
DDI-DrugBank.d99.s18	false	DDI-DrugBank.d99.s18.e1	DDI-DrugBank.d99.s18.e5
DDI-DrugBank.d99.s18	false	DDI-DrugBank.d99.s18.e2	DDI-DrugBank.d99.s18.e3
DDI-DrugBank.d99.s19|a|Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.
DDI-DrugBank.d99.s19	36	52	amitriptyline HCl	drug	DDI-DrugBank.d99.s19.e0
DDI-DrugBank.d99.s19	75	89	anticholinergic	drug	DDI-DrugBank.d99.s19.e1
DDI-DrugBank.d99.s19	106	116	neuroleptic	drug	DDI-DrugBank.d99.s19.e2
DDI-DrugBank.d99.s19	true	DDI-DrugBank.d99.s19.e0	DDI-DrugBank.d99.s19.e1
DDI-DrugBank.d99.s19	false	DDI-DrugBank.d99.s19.e0	DDI-DrugBank.d99.s19.e2
DDI-DrugBank.d99.s19	false	DDI-DrugBank.d99.s19.e1	DDI-DrugBank.d99.s19.e2
DDI-DrugBank.d99.s20|a|Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.
DDI-DrugBank.d99.s20	45	69	tricyclic antidepressants	drug	DDI-DrugBank.d99.s20.e0
DDI-DrugBank.d99.s20	91	105	anticholinergic	drug	DDI-DrugBank.d99.s20.e1
DDI-DrugBank.d99.s20	true	DDI-DrugBank.d99.s20.e0	DDI-DrugBank.d99.s20.e1
DDI-DrugBank.d99.s21|a|Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.
DDI-DrugBank.d99.s21	0	9	Cimetidine	drug	DDI-DrugBank.d99.s21.e0
DDI-DrugBank.d99.s21	63	87	tricyclic antidepressants	drug	DDI-DrugBank.d99.s21.e1
DDI-DrugBank.d99.s21	171	175	drugs	drug	DDI-DrugBank.d99.s21.e2
DDI-DrugBank.d99.s21	true	DDI-DrugBank.d99.s21.e0	DDI-DrugBank.d99.s21.e1
DDI-DrugBank.d99.s21	false	DDI-DrugBank.d99.s21.e0	DDI-DrugBank.d99.s21.e2
DDI-DrugBank.d99.s21	false	DDI-DrugBank.d99.s21.e1	DDI-DrugBank.d99.s21.e2
DDI-DrugBank.d99.s22|a|Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.
DDI-DrugBank.d99.s22	59	83	tricyclic antidepressants	drug	DDI-DrugBank.d99.s22.e0
DDI-DrugBank.d99.s22	114	123	cimetidine	drug	DDI-DrugBank.d99.s22.e1
DDI-DrugBank.d99.s22	true	DDI-DrugBank.d99.s22.e0	DDI-DrugBank.d99.s22.e1
DDI-DrugBank.d99.s23|a|Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.
DDI-DrugBank.d99.s23	30	54	tricyclic antidepressants	drug	DDI-DrugBank.d99.s23.e0
DDI-DrugBank.d99.s23	121	135	anticholinergic	drug	DDI-DrugBank.d99.s23.e1
DDI-DrugBank.d99.s23	162	171	cimetidine	drug	DDI-DrugBank.d99.s23.e2
DDI-DrugBank.d99.s23	190	193	drug	drug	DDI-DrugBank.d99.s23.e3
DDI-DrugBank.d99.s23	false	DDI-DrugBank.d99.s23.e0	DDI-DrugBank.d99.s23.e1
DDI-DrugBank.d99.s23	true	DDI-DrugBank.d99.s23.e0	DDI-DrugBank.d99.s23.e2
DDI-DrugBank.d99.s23	false	DDI-DrugBank.d99.s23.e0	DDI-DrugBank.d99.s23.e3
DDI-DrugBank.d99.s23	false	DDI-DrugBank.d99.s23.e1	DDI-DrugBank.d99.s23.e2
DDI-DrugBank.d99.s23	false	DDI-DrugBank.d99.s23.e1	DDI-DrugBank.d99.s23.e3
DDI-DrugBank.d99.s23	false	DDI-DrugBank.d99.s23.e2	DDI-DrugBank.d99.s23.e3
DDI-DrugBank.d99.s24|a|Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
DDI-DrugBank.d99.s24	19	28	cimetidine	drug	DDI-DrugBank.d99.s24.e0
DDI-DrugBank.d99.s24	68	92	tricyclic antidepressants	drug	DDI-DrugBank.d99.s24.e1
DDI-DrugBank.d99.s24	98	107	cimetidine	drug	DDI-DrugBank.d99.s24.e2
DDI-DrugBank.d99.s24	160	174	antidepressants	drug	DDI-DrugBank.d99.s24.e3
DDI-DrugBank.d99.s24	false	DDI-DrugBank.d99.s24.e0	DDI-DrugBank.d99.s24.e1
DDI-DrugBank.d99.s24	false	DDI-DrugBank.d99.s24.e0	DDI-DrugBank.d99.s24.e2
DDI-DrugBank.d99.s24	false	DDI-DrugBank.d99.s24.e0	DDI-DrugBank.d99.s24.e3
DDI-DrugBank.d99.s24	true	DDI-DrugBank.d99.s24.e1	DDI-DrugBank.d99.s24.e2
DDI-DrugBank.d99.s24	false	DDI-DrugBank.d99.s24.e1	DDI-DrugBank.d99.s24.e3
DDI-DrugBank.d99.s24	false	DDI-DrugBank.d99.s24.e2	DDI-DrugBank.d99.s24.e3
DDI-DrugBank.d99.s25|a|Caution is advised if patients receive large doses of ethchlorvynol concurrently.
DDI-DrugBank.d99.s25	54	66	ethchlorvynol	drug	DDI-DrugBank.d99.s25.e0
DDI-DrugBank.d99.s26|a|Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.
DDI-DrugBank.d99.s26	83	95	ethchlorvynol	drug	DDI-DrugBank.d99.s26.e0
DDI-DrugBank.d99.s26	116	132	amitriptyline HCl	drug	DDI-DrugBank.d99.s26.e1
DDI-DrugBank.d99.s26	true	DDI-DrugBank.d99.s26.e0	DDI-DrugBank.d99.s26.e1
DDI-DrugBank.d318.s0|a|When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.
DDI-DrugBank.d318.s0	70	83	amphotericin B	drug	DDI-DrugBank.d318.s0.e0
DDI-DrugBank.d318.s0	86	106	Antineoplastic agents	group	DDI-DrugBank.d318.s0.e1
DDI-DrugBank.d318.s0	true	DDI-DrugBank.d318.s0.e0	DDI-DrugBank.d318.s0.e1
DDI-DrugBank.d318.s1|a|Antineoplastic agents (e. g., nitrogen mustard, etc.) should be given concomitantly only with great caution.
DDI-DrugBank.d318.s1	0	20	Antineoplastic agents	group	DDI-DrugBank.d318.s1.e0
DDI-DrugBank.d318.s1	30	45	nitrogen mustard	drug	DDI-DrugBank.d318.s1.e1
DDI-DrugBank.d318.s1	false	DDI-DrugBank.d318.s1.e0	DDI-DrugBank.d318.s1.e1
DDI-DrugBank.d318.s2|a|Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
DDI-DrugBank.d318.s2	0	14	Corticosteroids	group	DDI-DrugBank.d318.s2.e0
DDI-DrugBank.d318.s2	20	32	Corticotropin	drug	DDI-DrugBank.d318.s2.e1
DDI-DrugBank.d318.s2	35	38	ACTH	group	DDI-DrugBank.d318.s2.e2
DDI-DrugBank.d318.s2	57	70	amphotericin B	drug	DDI-DrugBank.d318.s2.e3
DDI-DrugBank.d318.s2	false	DDI-DrugBank.d318.s2.e0	DDI-DrugBank.d318.s2.e1
DDI-DrugBank.d318.s2	false	DDI-DrugBank.d318.s2.e0	DDI-DrugBank.d318.s2.e2
DDI-DrugBank.d318.s2	true	DDI-DrugBank.d318.s2.e0	DDI-DrugBank.d318.s2.e3
DDI-DrugBank.d318.s2	false	DDI-DrugBank.d318.s2.e1	DDI-DrugBank.d318.s2.e2
DDI-DrugBank.d318.s2	true	DDI-DrugBank.d318.s2.e1	DDI-DrugBank.d318.s2.e3
DDI-DrugBank.d318.s2	true	DDI-DrugBank.d318.s2.e2	DDI-DrugBank.d318.s2.e3
DDI-DrugBank.d318.s3|a|Avoid concomitant use unless necessary to control side effects of amphotericin B.
DDI-DrugBank.d318.s3	66	79	amphotericin B	drug	DDI-DrugBank.d318.s3.e0
DDI-DrugBank.d318.s4|a|If used concomitantly, closely monitor serum electrolytes and cardiac function.
DDI-DrugBank.d318.s5|a|Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.
DDI-DrugBank.d318.s5	0	19	Digitalis glycosides	group	DDI-DrugBank.d318.s5.e0
DDI-DrugBank.d318.s5	22	35	amphotericin B	drug	DDI-DrugBank.d318.s5.e1
DDI-DrugBank.d318.s5	72	80	digitalis	group	DDI-DrugBank.d318.s5.e2
DDI-DrugBank.d318.s5	false	DDI-DrugBank.d318.s5.e0	DDI-DrugBank.d318.s5.e1
DDI-DrugBank.d318.s5	false	DDI-DrugBank.d318.s5.e0	DDI-DrugBank.d318.s5.e2
DDI-DrugBank.d318.s5	true	DDI-DrugBank.d318.s5.e1	DDI-DrugBank.d318.s5.e2
DDI-DrugBank.d318.s6|a|Serum potassium levels and cardiac function should be closely monitored and any deficit promptly corrected.
DDI-DrugBank.d318.s7|a|Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.
DDI-DrugBank.d318.s7	0	10	Flucytosine	drug	DDI-DrugBank.d318.s7.e0
DDI-DrugBank.d318.s7	51	64	amphotericin B	drug	DDI-DrugBank.d318.s7.e1
DDI-DrugBank.d318.s7	130	140	flucytosine	drug	DDI-DrugBank.d318.s7.e2
DDI-DrugBank.d318.s7	false	DDI-DrugBank.d318.s7.e0	DDI-DrugBank.d318.s7.e1
DDI-DrugBank.d318.s7	false	DDI-DrugBank.d318.s7.e0	DDI-DrugBank.d318.s7.e2
DDI-DrugBank.d318.s7	true	DDI-DrugBank.d318.s7.e1	DDI-DrugBank.d318.s7.e2
DDI-DrugBank.d318.s8|a|Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
DDI-DrugBank.d318.s8	0	9	Imidazoles	group	DDI-DrugBank.d318.s8.e0
DDI-DrugBank.d318.s8	19	30	ketoconazole	drug	DDI-DrugBank.d318.s8.e1
DDI-DrugBank.d318.s8	33	42	miconazole	drug	DDI-DrugBank.d318.s8.e2
DDI-DrugBank.d318.s8	45	56	clotrimazole	drug	DDI-DrugBank.d318.s8.e3
DDI-DrugBank.d318.s8	59	69	fluconazole	drug	DDI-DrugBank.d318.s8.e4
DDI-DrugBank.d318.s8	131	144	amphotericin B	drug	DDI-DrugBank.d318.s8.e5
DDI-DrugBank.d318.s8	150	159	imidazoles	group	DDI-DrugBank.d318.s8.e6
DDI-DrugBank.d318.s8	174	183	imidazoles	group	DDI-DrugBank.d318.s8.e7
DDI-DrugBank.d318.s8	217	230	amphotericin B	drug	DDI-DrugBank.d318.s8.e8
DDI-DrugBank.d318.s8	false	DDI-DrugBank.d318.s8.e0	DDI-DrugBank.d318.s8.e1
DDI-DrugBank.d318.s8	false	DDI-DrugBank.d318.s8.e0	DDI-DrugBank.d318.s8.e2
DDI-DrugBank.d318.s8	false	DDI-DrugBank.d318.s8.e0	DDI-DrugBank.d318.s8.e3
DDI-DrugBank.d318.s8	false	DDI-DrugBank.d318.s8.e0	DDI-DrugBank.d318.s8.e4
DDI-DrugBank.d318.s8	false	DDI-DrugBank.d318.s8.e0	DDI-DrugBank.d318.s8.e5
DDI-DrugBank.d318.s8	false	DDI-DrugBank.d318.s8.e0	DDI-DrugBank.d318.s8.e6
DDI-DrugBank.d318.s8	false	DDI-DrugBank.d318.s8.e0	DDI-DrugBank.d318.s8.e7
DDI-DrugBank.d318.s8	false	DDI-DrugBank.d318.s8.e0	DDI-DrugBank.d318.s8.e8
DDI-DrugBank.d318.s8	false	DDI-DrugBank.d318.s8.e1	DDI-DrugBank.d318.s8.e2
DDI-DrugBank.d318.s8	false	DDI-DrugBank.d318.s8.e1	DDI-DrugBank.d318.s8.e3
DDI-DrugBank.d318.s9|a|Combination therapy should be administered with caution, especially in immunocompromised patients.
DDI-DrugBank.d318.s10|a|Other nephrotoxic medications: agents such as aminoglycosides, cyclosporine, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
DDI-DrugBank.d318.s10	46	60	aminoglycosides	group	DDI-DrugBank.d318.s10.e0
DDI-DrugBank.d318.s10	63	74	cyclosporine	drug	DDI-DrugBank.d318.s10.e1
DDI-DrugBank.d318.s10	81	91	pentamidine	drug	DDI-DrugBank.d318.s10.e2
DDI-DrugBank.d318.s10	false	DDI-DrugBank.d318.s10.e0	DDI-DrugBank.d318.s10.e1
DDI-DrugBank.d318.s10	false	DDI-DrugBank.d318.s10.e0	DDI-DrugBank.d318.s10.e2
DDI-DrugBank.d318.s10	false	DDI-DrugBank.d318.s10.e1	DDI-DrugBank.d318.s10.e2
DDI-DrugBank.d318.s11|a|Intensive monitoring of renal function is recommended in patients requiring any combination of nephrotoxic medications .
DDI-DrugBank.d318.s12|a|Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
DDI-DrugBank.d318.s12	0	24	Skeletal muscle relaxants	group	DDI-DrugBank.d318.s12.e0
DDI-DrugBank.d318.s12	27	40	amphotericin B	drug	DDI-DrugBank.d318.s12.e1
DDI-DrugBank.d318.s12	99	123	skeletal muscle relaxants	group	DDI-DrugBank.d318.s12.e2
DDI-DrugBank.d318.s12	132	143	tubocurarine	drug	DDI-DrugBank.d318.s12.e3
DDI-DrugBank.d318.s12	false	DDI-DrugBank.d318.s12.e0	DDI-DrugBank.d318.s12.e1
DDI-DrugBank.d318.s12	false	DDI-DrugBank.d318.s12.e0	DDI-DrugBank.d318.s12.e2
DDI-DrugBank.d318.s12	false	DDI-DrugBank.d318.s12.e0	DDI-DrugBank.d318.s12.e3
DDI-DrugBank.d318.s12	true	DDI-DrugBank.d318.s12.e1	DDI-DrugBank.d318.s12.e2
DDI-DrugBank.d318.s12	true	DDI-DrugBank.d318.s12.e1	DDI-DrugBank.d318.s12.e3
DDI-DrugBank.d318.s12	false	DDI-DrugBank.d318.s12.e2	DDI-DrugBank.d318.s12.e3
DDI-DrugBank.d318.s13|a|Serum potassium levels should be monitored and deficiencies corrected.
DDI-DrugBank.d318.s14|a|Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.
DDI-DrugBank.d318.s14	0	21	Leukocyte transfusions	drug_n	DDI-DrugBank.d318.s14.e0
DDI-DrugBank.d318.s14	101	114	amphotericin B	drug	DDI-DrugBank.d318.s14.e1
DDI-DrugBank.d318.s14	120	141	leukocyte transfusions	drug_n	DDI-DrugBank.d318.s14.e2
DDI-DrugBank.d318.s14	false	DDI-DrugBank.d318.s14.e0	DDI-DrugBank.d318.s14.e1
DDI-DrugBank.d318.s14	false	DDI-DrugBank.d318.s14.e0	DDI-DrugBank.d318.s14.e2
DDI-DrugBank.d318.s14	true	DDI-DrugBank.d318.s14.e1	DDI-DrugBank.d318.s14.e2
DDI-DrugBank.d211.s0|a|When administered concurrently, the following drugs may interact with ampicillin.
DDI-DrugBank.d211.s0	70	79	ampicillin	drug	DDI-DrugBank.d211.s0.e0
DDI-DrugBank.d211.s1|a|Allopurinol: Increased possibility of skin rash, particularly in hyperuricemic patients may occur.
DDI-DrugBank.d211.s1	0	10	Allopurinol	drug	DDI-DrugBank.d211.s1.e0
DDI-DrugBank.d211.s2|a|Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
DDI-DrugBank.d211.s2	0	25	Bacteriostatic Antibiotics	group	DDI-DrugBank.d211.s2.e0
DDI-DrugBank.d211.s2	28	42	Chloramphenicol	drug	DDI-DrugBank.d211.s2.e1
DDI-DrugBank.d211.s2	45	57	erythromycins	drug	DDI-DrugBank.d211.s2.e2
DDI-DrugBank.d211.s2	60	71	sulfonamides	group	DDI-DrugBank.d211.s2.e3
DDI-DrugBank.d211.s2	77	89	tetracyclines	group	DDI-DrugBank.d211.s2.e4
DDI-DrugBank.d211.s2	137	147	penicillins	group	DDI-DrugBank.d211.s2.e5
DDI-DrugBank.d211.s2	false	DDI-DrugBank.d211.s2.e0	DDI-DrugBank.d211.s2.e1
DDI-DrugBank.d211.s2	false	DDI-DrugBank.d211.s2.e0	DDI-DrugBank.d211.s2.e2
DDI-DrugBank.d211.s2	false	DDI-DrugBank.d211.s2.e0	DDI-DrugBank.d211.s2.e3
DDI-DrugBank.d211.s2	false	DDI-DrugBank.d211.s2.e0	DDI-DrugBank.d211.s2.e4
DDI-DrugBank.d211.s2	false	DDI-DrugBank.d211.s2.e0	DDI-DrugBank.d211.s2.e5
DDI-DrugBank.d211.s2	false	DDI-DrugBank.d211.s2.e1	DDI-DrugBank.d211.s2.e2
DDI-DrugBank.d211.s2	false	DDI-DrugBank.d211.s2.e1	DDI-DrugBank.d211.s2.e3
DDI-DrugBank.d211.s2	false	DDI-DrugBank.d211.s2.e1	DDI-DrugBank.d211.s2.e4
DDI-DrugBank.d211.s2	true	DDI-DrugBank.d211.s2.e1	DDI-DrugBank.d211.s2.e5
DDI-DrugBank.d211.s2	false	DDI-DrugBank.d211.s2.e2	DDI-DrugBank.d211.s2.e3
DDI-DrugBank.d211.s3|a|This has been demonstrated in view, however, the clinical significance of this interaction is not well documented.
DDI-DrugBank.d211.s4|a|Oral Contraceptives: May be less effective and increased breakthrough bleeding may occur.
DDI-DrugBank.d211.s4	5	18	Contraceptives	group	DDI-DrugBank.d211.s4.e0
DDI-DrugBank.d211.s5|a|Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
DDI-DrugBank.d211.s5	0	9	Probenecid	drug	DDI-DrugBank.d211.s5.e0
DDI-DrugBank.d211.s5	52	61	ampicillin	drug	DDI-DrugBank.d211.s5.e1
DDI-DrugBank.d211.s5	106	115	ampicillin	drug	DDI-DrugBank.d211.s5.e2
DDI-DrugBank.d211.s5	true	DDI-DrugBank.d211.s5.e0	DDI-DrugBank.d211.s5.e1
DDI-DrugBank.d211.s5	false	DDI-DrugBank.d211.s5.e0	DDI-DrugBank.d211.s5.e2
DDI-DrugBank.d211.s5	false	DDI-DrugBank.d211.s5.e1	DDI-DrugBank.d211.s5.e2
DDI-DrugBank.d211.s6|a|Drug/Laboratory Test Interaction After treatment with ampicillin, a false-positive reaction for glucose in the urine may occur with copper sulfate tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP.
DDI-DrugBank.d211.s6	54	63	ampicillin	drug	DDI-DrugBank.d211.s6.e0
DDI-DrugBank.d211.s6	132	145	copper sulfate	drug_n	DDI-DrugBank.d211.s6.e1
DDI-DrugBank.d211.s6	false	DDI-DrugBank.d211.s6.e0	DDI-DrugBank.d211.s6.e1
DDI-DrugBank.d437.s0|a|Amprenavir is metabolized in the liver by the cytochrome P450 enzyme system.
DDI-DrugBank.d437.s0	0	9	Amprenavir	drug	DDI-DrugBank.d437.s0.e0
DDI-DrugBank.d437.s1|a|Amprenavir inhibits CYP3A4.
DDI-DrugBank.d437.s1	0	9	Amprenavir	drug	DDI-DrugBank.d437.s1.e0
DDI-DrugBank.d437.s2|a|Caution should be used when coadministering medications that are substrates, inhibitors, or inducers of CYP3A4, or potentially toxic medications that are metabolized by CYP3A4.
DDI-DrugBank.d437.s3|a|Amprenavir does not inhibit CYP2D6, CYP1A2, CYP2C9, CYP2C19, CYP2E1, or uridine glucuronosyltransferase (UDPGT).
DDI-DrugBank.d437.s3	0	9	Amprenavir	drug	DDI-DrugBank.d437.s3.e0
DDI-DrugBank.d437.s4|a|HIV Protease Inhibitors: The effect of amprenavir on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data.
DDI-DrugBank.d437.s4	0	22	HIV Protease Inhibitors	group	DDI-DrugBank.d437.s4.e0
DDI-DrugBank.d437.s4	39	48	amprenavir	drug	DDI-DrugBank.d437.s4.e1
DDI-DrugBank.d437.s4	88	110	HIV protease inhibitors	group	DDI-DrugBank.d437.s4.e2
DDI-DrugBank.d437.s4	false	DDI-DrugBank.d437.s4.e0	DDI-DrugBank.d437.s4.e1
DDI-DrugBank.d437.s4	false	DDI-DrugBank.d437.s4.e0	DDI-DrugBank.d437.s4.e2
DDI-DrugBank.d437.s4	false	DDI-DrugBank.d437.s4.e1	DDI-DrugBank.d437.s4.e2
DDI-DrugBank.d437.s5|a|Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.
DDI-DrugBank.d437.s5	0	8	Indinavir	drug	DDI-DrugBank.d437.s5.e0
DDI-DrugBank.d437.s5	109	118	amprenavir	drug	DDI-DrugBank.d437.s5.e1
DDI-DrugBank.d437.s5	true	DDI-DrugBank.d437.s5.e0	DDI-DrugBank.d437.s5.e1
DDI-DrugBank.d437.s6|a|Similar decreases in Cmax and AUC were seen after the first dose.
DDI-DrugBank.d437.s7|a|Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.
DDI-DrugBank.d437.s7	0	9	Saquinavir	drug	DDI-DrugBank.d437.s7.e0
DDI-DrugBank.d437.s7	127	136	amprenavir	drug	DDI-DrugBank.d437.s7.e1
DDI-DrugBank.d437.s7	true	DDI-DrugBank.d437.s7.e0	DDI-DrugBank.d437.s7.e1
DDI-DrugBank.d437.s8|a|Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.
DDI-DrugBank.d437.s8	0	9	Nelfinavir	drug	DDI-DrugBank.d437.s8.e0
DDI-DrugBank.d437.s8	110	119	amprenavir	drug	DDI-DrugBank.d437.s8.e1
DDI-DrugBank.d437.s8	true	DDI-DrugBank.d437.s8.e0	DDI-DrugBank.d437.s8.e1
DDI-DrugBank.d437.s9|a|Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.
DDI-DrugBank.d437.s9	0	8	Methadone	drug	DDI-DrugBank.d437.s9.e0
DDI-DrugBank.d437.s9	31	40	amprenavir	drug	DDI-DrugBank.d437.s9.e1
DDI-DrugBank.d437.s9	46	54	methadone	drug	DDI-DrugBank.d437.s9.e2
DDI-DrugBank.d437.s9	86	94	methadone	drug	DDI-DrugBank.d437.s9.e3
DDI-DrugBank.d437.s9	false	DDI-DrugBank.d437.s9.e0	DDI-DrugBank.d437.s9.e1
DDI-DrugBank.d437.s9	false	DDI-DrugBank.d437.s9.e0	DDI-DrugBank.d437.s9.e2
DDI-DrugBank.d437.s9	false	DDI-DrugBank.d437.s9.e0	DDI-DrugBank.d437.s9.e3
DDI-DrugBank.d437.s9	true	DDI-DrugBank.d437.s9.e1	DDI-DrugBank.d437.s9.e2
DDI-DrugBank.d437.s9	false	DDI-DrugBank.d437.s9.e1	DDI-DrugBank.d437.s9.e3
DDI-DrugBank.d437.s9	false	DDI-DrugBank.d437.s9.e2	DDI-DrugBank.d437.s9.e3
DDI-DrugBank.d437.s10|a|Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
DDI-DrugBank.d437.s10	20	29	amprenavir	drug	DDI-DrugBank.d437.s10.e0
DDI-DrugBank.d437.s10	35	43	methadone	drug	DDI-DrugBank.d437.s10.e1
DDI-DrugBank.d437.s10	148	157	amprenavir	drug	DDI-DrugBank.d437.s10.e2
DDI-DrugBank.d437.s10	true	DDI-DrugBank.d437.s10.e0	DDI-DrugBank.d437.s10.e1
DDI-DrugBank.d437.s10	false	DDI-DrugBank.d437.s10.e0	DDI-DrugBank.d437.s10.e2
DDI-DrugBank.d437.s10	false	DDI-DrugBank.d437.s10.e1	DDI-DrugBank.d437.s10.e2
DDI-DrugBank.d437.s11|a|Amprenavir is an inhibitor of cytochrome P450 C.P.A. metabolism and therefore should not be administered concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4.
DDI-DrugBank.d437.s11	0	9	Amprenavir	drug	DDI-DrugBank.d437.s11.e0
DDI-DrugBank.d437.s12|a|There are other agents that may result in serious and/or life-threatening drug interactions.
DDI-DrugBank.d437.s13|a|Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
DDI-DrugBank.d437.s13	37	46	Amprenavir	drug	DDI-DrugBank.d437.s13.e0
DDI-DrugBank.d437.s13	61	69	ritonavir	drug	DDI-DrugBank.d437.s13.e1
DDI-DrugBank.d437.s13	true	DDI-DrugBank.d437.s13.e0	DDI-DrugBank.d437.s13.e1
DDI-DrugBank.d437.s14|a|Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
DDI-DrugBank.d437.s14	97	106	Amprenavir	drug	DDI-DrugBank.d437.s14.e0
DDI-DrugBank.d437.s14	112	120	ritonavir	drug	DDI-DrugBank.d437.s14.e1
DDI-DrugBank.d437.s14	true	DDI-DrugBank.d437.s14.e0	DDI-DrugBank.d437.s14.e1
DDI-DrugBank.d437.s15|a|For comprehensive information concerning laboratory test alterations associated with ritonavir, physicians should refer to the complete prescribing information for NORVIR (ritonavir).
DDI-DrugBank.d437.s15	85	93	ritonavir	drug	DDI-DrugBank.d437.s15.e0
DDI-DrugBank.d437.s15	164	169	NORVIR	brand	DDI-DrugBank.d437.s15.e1
DDI-DrugBank.d437.s15	172	180	ritonavir	drug	DDI-DrugBank.d437.s15.e2
DDI-DrugBank.d437.s15	false	DDI-DrugBank.d437.s15.e0	DDI-DrugBank.d437.s15.e1
DDI-DrugBank.d437.s15	false	DDI-DrugBank.d437.s15.e0	DDI-DrugBank.d437.s15.e2
DDI-DrugBank.d437.s15	false	DDI-DrugBank.d437.s15.e1	DDI-DrugBank.d437.s15.e2
DDI-DrugBank.d56.s0|a|Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.
DDI-DrugBank.d56.s0	7	18	amyl nitrite	drug	DDI-DrugBank.d56.s0.e0
DDI-DrugBank.d56.s0	35	41	alcohol	drug	DDI-DrugBank.d56.s0.e1
DDI-DrugBank.d56.s0	true	DDI-DrugBank.d56.s0.e0	DDI-DrugBank.d56.s0.e1
DDI-DrugBank.d75.s0|a|Limited PK and/or PD studies investigating possible interactions between anagrelide and other medicinal products have been conducted.
DDI-DrugBank.d75.s0	73	82	anagrelide	drug	DDI-DrugBank.d75.s0.e0
DDI-DrugBank.d75.s1|a|In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin.
DDI-DrugBank.d75.s1	61	67	digoxin	drug	DDI-DrugBank.d75.s1.e0
DDI-DrugBank.d75.s1	73	80	warfarin	drug	DDI-DrugBank.d75.s1.e1
DDI-DrugBank.d75.s1	117	126	anagrelide	drug	DDI-DrugBank.d75.s1.e2
DDI-DrugBank.d75.s1	138	147	anagrelide	drug	DDI-DrugBank.d75.s1.e3
DDI-DrugBank.d75.s1	177	183	digoxin	drug	DDI-DrugBank.d75.s1.e4
DDI-DrugBank.d75.s1	188	195	warfarin	drug	DDI-DrugBank.d75.s1.e5
DDI-DrugBank.d75.s1	false	DDI-DrugBank.d75.s1.e0	DDI-DrugBank.d75.s1.e1
DDI-DrugBank.d75.s1	false	DDI-DrugBank.d75.s1.e0	DDI-DrugBank.d75.s1.e2
DDI-DrugBank.d75.s1	false	DDI-DrugBank.d75.s1.e0	DDI-DrugBank.d75.s1.e3
DDI-DrugBank.d75.s1	false	DDI-DrugBank.d75.s1.e0	DDI-DrugBank.d75.s1.e4
DDI-DrugBank.d75.s1	false	DDI-DrugBank.d75.s1.e0	DDI-DrugBank.d75.s1.e5
DDI-DrugBank.d75.s1	false	DDI-DrugBank.d75.s1.e1	DDI-DrugBank.d75.s1.e2
DDI-DrugBank.d75.s1	false	DDI-DrugBank.d75.s1.e1	DDI-DrugBank.d75.s1.e3
DDI-DrugBank.d75.s1	false	DDI-DrugBank.d75.s1.e1	DDI-DrugBank.d75.s1.e4
DDI-DrugBank.d75.s1	false	DDI-DrugBank.d75.s1.e1	DDI-DrugBank.d75.s1.e5
DDI-DrugBank.d75.s1	false	DDI-DrugBank.d75.s1.e2	DDI-DrugBank.d75.s1.e3
DDI-DrugBank.d75.s2|a|Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
DDI-DrugBank.d75.s2	122	131	anagrelide	drug	DDI-DrugBank.d75.s2.e0
DDI-DrugBank.d75.s2	157	163	aspirin	brand	DDI-DrugBank.d75.s2.e1
DDI-DrugBank.d75.s2	166	178	acetaminophen	drug	DDI-DrugBank.d75.s2.e2
DDI-DrugBank.d75.s2	181	190	furosemide	drug	DDI-DrugBank.d75.s2.e3
DDI-DrugBank.d75.s2	193	196	iron	drug	DDI-DrugBank.d75.s2.e4
DDI-DrugBank.d75.s2	199	208	ranitidine	drug	DDI-DrugBank.d75.s2.e5
DDI-DrugBank.d75.s2	211	221	hydroxyurea	drug	DDI-DrugBank.d75.s2.e6
DDI-DrugBank.d75.s2	228	238	allopurinol	drug	DDI-DrugBank.d75.s2.e7
DDI-DrugBank.d75.s2	false	DDI-DrugBank.d75.s2.e0	DDI-DrugBank.d75.s2.e1
DDI-DrugBank.d75.s2	false	DDI-DrugBank.d75.s2.e0	DDI-DrugBank.d75.s2.e2
DDI-DrugBank.d75.s2	false	DDI-DrugBank.d75.s2.e0	DDI-DrugBank.d75.s2.e3
DDI-DrugBank.d75.s2	false	DDI-DrugBank.d75.s2.e0	DDI-DrugBank.d75.s2.e4
DDI-DrugBank.d75.s2	false	DDI-DrugBank.d75.s2.e0	DDI-DrugBank.d75.s2.e5
DDI-DrugBank.d75.s2	false	DDI-DrugBank.d75.s2.e0	DDI-DrugBank.d75.s2.e6
DDI-DrugBank.d75.s2	false	DDI-DrugBank.d75.s2.e0	DDI-DrugBank.d75.s2.e7
DDI-DrugBank.d75.s2	false	DDI-DrugBank.d75.s2.e1	DDI-DrugBank.d75.s2.e2
DDI-DrugBank.d75.s2	false	DDI-DrugBank.d75.s2.e1	DDI-DrugBank.d75.s2.e3
DDI-DrugBank.d75.s2	false	DDI-DrugBank.d75.s2.e1	DDI-DrugBank.d75.s2.e4
DDI-DrugBank.d75.s3|a|There is no clinical evidence to suggest that anagrelide interacts with any of these compounds.
DDI-DrugBank.d75.s3	46	55	anagrelide	drug	DDI-DrugBank.d75.s3.e0
DDI-DrugBank.d75.s4|a|An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated.
DDI-DrugBank.d75.s4	78	87	anagrelide	drug	DDI-DrugBank.d75.s4.e0
DDI-DrugBank.d75.s4	145	151	aspirin	brand	DDI-DrugBank.d75.s4.e1
DDI-DrugBank.d75.s4	false	DDI-DrugBank.d75.s4.e0	DDI-DrugBank.d75.s4.e1
DDI-DrugBank.d75.s5|a|There was no effect on bleeding time, PT or aPTT.
DDI-DrugBank.d75.s6|a|No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed.
DDI-DrugBank.d75.s6	60	69	anagrelide	drug	DDI-DrugBank.d75.s6.e0
DDI-DrugBank.d75.s6	75	94	acetylsalicylic acid	drug	DDI-DrugBank.d75.s6.e1
DDI-DrugBank.d75.s6	false	DDI-DrugBank.d75.s6.e0	DDI-DrugBank.d75.s6.e1
DDI-DrugBank.d75.s7|a|In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo.
DDI-DrugBank.d75.s7	20	26	aspirin	brand	DDI-DrugBank.d75.s7.e0
DDI-DrugBank.d75.s8|a|Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.
DDI-DrugBank.d75.s8	0	9	Anagrelide	drug	DDI-DrugBank.d75.s8.e0
DDI-DrugBank.d75.s8	123	129	aspirin	brand	DDI-DrugBank.d75.s8.e1
DDI-DrugBank.d75.s8	true	DDI-DrugBank.d75.s8.e0	DDI-DrugBank.d75.s8.e1
DDI-DrugBank.d75.s9|a|Anagrelide is metabolized at least in part by CYP1A2.
DDI-DrugBank.d75.s9	0	9	Anagrelide	drug	DDI-DrugBank.d75.s9.e0
DDI-DrugBank.d75.s10|a|It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.
DDI-DrugBank.d75.s10	78	88	fluvoxamine	drug	DDI-DrugBank.d75.s10.e0
DDI-DrugBank.d75.s10	176	185	anagrelide	drug	DDI-DrugBank.d75.s10.e1
DDI-DrugBank.d75.s10	true	DDI-DrugBank.d75.s10.e0	DDI-DrugBank.d75.s10.e1
DDI-DrugBank.d75.s11|a|Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g.
DDI-DrugBank.d75.s11	0	9	Anagrelide	drug	DDI-DrugBank.d75.s11.e0
DDI-DrugBank.d75.s12|a|Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.
DDI-DrugBank.d75.s12	0	9	Anagrelide	drug	DDI-DrugBank.d75.s12.e0
DDI-DrugBank.d75.s12	213	224	theophylline	drug	DDI-DrugBank.d75.s12.e1
DDI-DrugBank.d75.s12	true	DDI-DrugBank.d75.s12.e0	DDI-DrugBank.d75.s12.e1
DDI-DrugBank.d75.s13|a|Anagrelide is an inhibitor of cyclic AMP PDE III.
DDI-DrugBank.d75.s13	0	9	Anagrelide	drug	DDI-DrugBank.d75.s13.e0
DDI-DrugBank.d75.s14|a|The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
DDI-DrugBank.d75.s14	76	84	milrinone	drug	DDI-DrugBank.d75.s14.e0
DDI-DrugBank.d75.s14	87	95	enoximone	drug	DDI-DrugBank.d75.s14.e1
DDI-DrugBank.d75.s14	98	105	amrinone	drug	DDI-DrugBank.d75.s14.e2
DDI-DrugBank.d75.s14	108	116	olprinone	drug_n	DDI-DrugBank.d75.s14.e3
DDI-DrugBank.d75.s14	122	131	cilostazol	drug	DDI-DrugBank.d75.s14.e4
DDI-DrugBank.d75.s14	155	164	anagrelide	drug	DDI-DrugBank.d75.s14.e5
DDI-DrugBank.d75.s14	false	DDI-DrugBank.d75.s14.e0	DDI-DrugBank.d75.s14.e1
DDI-DrugBank.d75.s14	false	DDI-DrugBank.d75.s14.e0	DDI-DrugBank.d75.s14.e2
DDI-DrugBank.d75.s14	false	DDI-DrugBank.d75.s14.e0	DDI-DrugBank.d75.s14.e3
DDI-DrugBank.d75.s14	false	DDI-DrugBank.d75.s14.e0	DDI-DrugBank.d75.s14.e4
DDI-DrugBank.d75.s14	true	DDI-DrugBank.d75.s14.e0	DDI-DrugBank.d75.s14.e5
DDI-DrugBank.d75.s14	false	DDI-DrugBank.d75.s14.e1	DDI-DrugBank.d75.s14.e2
DDI-DrugBank.d75.s14	false	DDI-DrugBank.d75.s14.e1	DDI-DrugBank.d75.s14.e3
DDI-DrugBank.d75.s14	false	DDI-DrugBank.d75.s14.e1	DDI-DrugBank.d75.s14.e4
DDI-DrugBank.d75.s14	true	DDI-DrugBank.d75.s14.e1	DDI-DrugBank.d75.s14.e5
DDI-DrugBank.d75.s14	false	DDI-DrugBank.d75.s14.e2	DDI-DrugBank.d75.s14.e3
DDI-DrugBank.d75.s15|a|There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.
DDI-DrugBank.d75.s15	51	60	sucralfate	drug	DDI-DrugBank.d75.s15.e0
DDI-DrugBank.d75.s15	81	90	anagrelide	drug	DDI-DrugBank.d75.s15.e1
DDI-DrugBank.d75.s15	true	DDI-DrugBank.d75.s15.e0	DDI-DrugBank.d75.s15.e1
DDI-DrugBank.d75.s16|a|Food has no clinically significant effect on the bioavailability of anagrelide.
DDI-DrugBank.d75.s16	68	77	anagrelide	drug	DDI-DrugBank.d75.s16.e0
DDI-DrugBank.d275.s0|a|No drug-drug interaction studies in human subjects have been conducted.
DDI-DrugBank.d275.s1|a|Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.
DDI-DrugBank.d275.s1	132	143	methotrexate	drug	DDI-DrugBank.d275.s1.e0
DDI-DrugBank.d275.s1	148	154	Kineret	brand	DDI-DrugBank.d275.s1.e1
DDI-DrugBank.d275.s1	false	DDI-DrugBank.d275.s1.e0	DDI-DrugBank.d275.s1.e1
DDI-DrugBank.d275.s2|a|In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).
DDI-DrugBank.d275.s2	92	98	Kineret	brand	DDI-DrugBank.d275.s2.e0
DDI-DrugBank.d275.s2	104	113	etanercept	drug	DDI-DrugBank.d275.s2.e1
DDI-DrugBank.d275.s2	211	220	etanercept	drug	DDI-DrugBank.d275.s2.e2
DDI-DrugBank.d275.s2	true	DDI-DrugBank.d275.s2.e0	DDI-DrugBank.d275.s2.e1
DDI-DrugBank.d275.s2	false	DDI-DrugBank.d275.s2.e0	DDI-DrugBank.d275.s2.e2
DDI-DrugBank.d275.s2	false	DDI-DrugBank.d275.s2.e1	DDI-DrugBank.d275.s2.e2
DDI-DrugBank.d275.s3|a|Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).
DDI-DrugBank.d275.s3	50	56	Kineret	brand	DDI-DrugBank.d275.s3.e0
DDI-DrugBank.d275.s3	62	71	etanercept	drug	DDI-DrugBank.d275.s3.e1
DDI-DrugBank.d275.s3	true	DDI-DrugBank.d275.s3.e0	DDI-DrugBank.d275.s3.e1
DDI-DrugBank.d195.s0|a|Anastrozole inhibited in vitro metabolic reactions catalyzed by cytochromes P450 1A2, 2C8/9, and 3A4 but only at relatively high concentrations.
DDI-DrugBank.d195.s0	0	10	Anastrozole	drug	DDI-DrugBank.d195.s0.e0
DDI-DrugBank.d195.s1|a|Anastrozole did not inhibit P450 2A6 or the polymorphic P450 2D6 in human liver microsomes.
DDI-DrugBank.d195.s1	0	10	Anastrozole	drug	DDI-DrugBank.d195.s1.e0
DDI-DrugBank.d195.s2|a|Anastrozole did not alter the pharmacokinetics of antipyrine.
DDI-DrugBank.d195.s2	0	10	Anastrozole	drug	DDI-DrugBank.d195.s2.e0
DDI-DrugBank.d195.s2	50	59	antipyrine	drug	DDI-DrugBank.d195.s2.e1
DDI-DrugBank.d195.s2	false	DDI-DrugBank.d195.s2.e0	DDI-DrugBank.d195.s2.e1
DDI-DrugBank.d195.s3|a|Although there have been no formal interaction studies other than with antipyrine, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of ARIMIDEX with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.
DDI-DrugBank.d195.s3	71	80	antipyrine	drug	DDI-DrugBank.d195.s3.e0
DDI-DrugBank.d195.s3	184	191	ARIMIDEX	brand	DDI-DrugBank.d195.s3.e1
DDI-DrugBank.d195.s3	false	DDI-DrugBank.d195.s3.e0	DDI-DrugBank.d195.s3.e1
DDI-DrugBank.d195.s4|a|An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.
DDI-DrugBank.d195.s4	26	33	warfarin	drug	DDI-DrugBank.d195.s4.e0
DDI-DrugBank.d195.s4	78	88	anastrozole	drug	DDI-DrugBank.d195.s4.e1
DDI-DrugBank.d195.s4	93	100	warfarin	drug	DDI-DrugBank.d195.s4.e2
DDI-DrugBank.d195.s4	false	DDI-DrugBank.d195.s4.e0	DDI-DrugBank.d195.s4.e1
DDI-DrugBank.d195.s4	false	DDI-DrugBank.d195.s4.e0	DDI-DrugBank.d195.s4.e2
DDI-DrugBank.d195.s4	false	DDI-DrugBank.d195.s4.e1	DDI-DrugBank.d195.s4.e2
DDI-DrugBank.d195.s5|a|At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.
DDI-DrugBank.d195.s5	55	62	ARIMIDEX	brand	DDI-DrugBank.d195.s5.e0
DDI-DrugBank.d195.s5	68	76	tamoxifen	drug	DDI-DrugBank.d195.s5.e1
DDI-DrugBank.d195.s5	138	146	tamoxifen	drug	DDI-DrugBank.d195.s5.e2
DDI-DrugBank.d195.s5	false	DDI-DrugBank.d195.s5.e0	DDI-DrugBank.d195.s5.e1
DDI-DrugBank.d195.s5	false	DDI-DrugBank.d195.s5.e0	DDI-DrugBank.d195.s5.e2
DDI-DrugBank.d195.s5	false	DDI-DrugBank.d195.s5.e1	DDI-DrugBank.d195.s5.e2
DDI-DrugBank.d195.s6|a|This treatment arm was discontinued from the trial.
DDI-DrugBank.d195.s7|a|Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
DDI-DrugBank.d195.s7	67	75	tamoxifen	drug	DDI-DrugBank.d195.s7.e0
DDI-DrugBank.d195.s7	109	119	anastrozole	drug	DDI-DrugBank.d195.s7.e1
DDI-DrugBank.d195.s7	true	DDI-DrugBank.d195.s7.e0	DDI-DrugBank.d195.s7.e1
DDI-DrugBank.d195.s8|a|Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.
DDI-DrugBank.d195.s8	21	31	anastrozole	drug	DDI-DrugBank.d195.s8.e0
DDI-DrugBank.d195.s8	37	45	tamoxifen	drug	DDI-DrugBank.d195.s8.e1
DDI-DrugBank.d195.s8	74	84	anastrozole	drug	DDI-DrugBank.d195.s8.e2
DDI-DrugBank.d195.s8	141	151	anastrozole	drug	DDI-DrugBank.d195.s8.e3
DDI-DrugBank.d195.s8	true	DDI-DrugBank.d195.s8.e0	DDI-DrugBank.d195.s8.e1
DDI-DrugBank.d195.s8	false	DDI-DrugBank.d195.s8.e0	DDI-DrugBank.d195.s8.e2
DDI-DrugBank.d195.s8	false	DDI-DrugBank.d195.s8.e0	DDI-DrugBank.d195.s8.e3
DDI-DrugBank.d195.s8	false	DDI-DrugBank.d195.s8.e1	DDI-DrugBank.d195.s8.e2
DDI-DrugBank.d195.s8	false	DDI-DrugBank.d195.s8.e1	DDI-DrugBank.d195.s8.e3
DDI-DrugBank.d195.s8	false	DDI-DrugBank.d195.s8.e2	DDI-DrugBank.d195.s8.e3
DDI-DrugBank.d195.s9|a|Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.
DDI-DrugBank.d195.s9	0	7	Estrogen	group	DDI-DrugBank.d195.s9.e0
DDI-DrugBank.d195.s9	54	61	ARIMIDEX	brand	DDI-DrugBank.d195.s9.e1
DDI-DrugBank.d195.s9	true	DDI-DrugBank.d195.s9.e0	DDI-DrugBank.d195.s9.e1
DDI-DrugBank.d195.s10|a|Drug/Laboratory Test Interactions No clinically significant changes in the results of clinical laboratory tests have been observed
DDI-DrugBank.d195.s11|a|.
DDI-DrugBank.d195.s12|a|
DDI-DrugBank.d445.s0|a|No clinically relevant drug-drug interactions have been observed with drugs likely to be co-administered with anidulafungin.
DDI-DrugBank.d445.s0	110	122	anidulafungin	drug	DDI-DrugBank.d445.s0.e0
DDI-DrugBank.d215.s0|a|Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
DDI-DrugBank.d215.s0	32	42	anileridine	drug	DDI-DrugBank.d215.s0.e0
DDI-DrugBank.d215.s0	73	79	opioids	group	DDI-DrugBank.d215.s0.e1
DDI-DrugBank.d215.s0	82	90	sedatives	group	DDI-DrugBank.d215.s0.e2
DDI-DrugBank.d215.s0	93	106	phenothiazines	group	DDI-DrugBank.d215.s0.e3
DDI-DrugBank.d215.s0	112	122	anesthetics	group	DDI-DrugBank.d215.s0.e4
DDI-DrugBank.d215.s0	true	DDI-DrugBank.d215.s0.e0	DDI-DrugBank.d215.s0.e1
DDI-DrugBank.d215.s0	true	DDI-DrugBank.d215.s0.e0	DDI-DrugBank.d215.s0.e2
DDI-DrugBank.d215.s0	true	DDI-DrugBank.d215.s0.e0	DDI-DrugBank.d215.s0.e3
DDI-DrugBank.d215.s0	true	DDI-DrugBank.d215.s0.e0	DDI-DrugBank.d215.s0.e4
DDI-DrugBank.d215.s0	false	DDI-DrugBank.d215.s0.e1	DDI-DrugBank.d215.s0.e2
DDI-DrugBank.d215.s0	false	DDI-DrugBank.d215.s0.e1	DDI-DrugBank.d215.s0.e3
DDI-DrugBank.d215.s0	false	DDI-DrugBank.d215.s0.e1	DDI-DrugBank.d215.s0.e4
DDI-DrugBank.d215.s0	false	DDI-DrugBank.d215.s0.e2	DDI-DrugBank.d215.s0.e3
DDI-DrugBank.d215.s0	false	DDI-DrugBank.d215.s0.e2	DDI-DrugBank.d215.s0.e4
DDI-DrugBank.d215.s0	false	DDI-DrugBank.d215.s0.e3	DDI-DrugBank.d215.s0.e4
DDI-DrugBank.d64.s0|a|Addition or deletion of any drug from the therapeutic regimen of patients receiving oral anticoagulants may affect patient response to the anticoagulant.
DDI-DrugBank.d64.s0	89	102	anticoagulants	group	DDI-DrugBank.d64.s0.e0
DDI-DrugBank.d64.s0	139	151	anticoagulant	group	DDI-DrugBank.d64.s0.e1
DDI-DrugBank.d64.s0	false	DDI-DrugBank.d64.s0.e0	DDI-DrugBank.d64.s0.e1
DDI-DrugBank.d64.s1|a|Frequent determination of prothrombin time and close monitoring of the patient is essential to ascertain when adjustment of dosage of anticoagulant may be needed.
DDI-DrugBank.d64.s1	134	146	anticoagulant	group	DDI-DrugBank.d64.s1.e0
DDI-DrugBank.d64.s2|a|Because of the variability of individual patient response, multiple interacting mechanisms with some drugs, the dependency of the extent of the interaction on the dosage and duration of therapy, and the possible administration of several interacting drugs simultaneously, it is difficult to predict the direction and degree of the ultimate effect of concomitant medications on anticoagulant response.
DDI-DrugBank.d64.s2	377	389	anticoagulant	group	DDI-DrugBank.d64.s2.e0
DDI-DrugBank.d64.s3|a|For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
DDI-DrugBank.d64.s3	19	32	cholestyramine	drug	DDI-DrugBank.d64.s3.e0
DDI-DrugBank.d64.s3	94	107	anticoagulants	group	DDI-DrugBank.d64.s3.e1
DDI-DrugBank.d64.s3	113	121	vitamin K	group	DDI-DrugBank.d64.s3.e2
DDI-DrugBank.d64.s3	true	DDI-DrugBank.d64.s3.e0	DDI-DrugBank.d64.s3.e1
DDI-DrugBank.d64.s3	true	DDI-DrugBank.d64.s3.e0	DDI-DrugBank.d64.s3.e2
DDI-DrugBank.d64.s3	false	DDI-DrugBank.d64.s3.e1	DDI-DrugBank.d64.s3.e2
DDI-DrugBank.d64.s4|a|Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.
DDI-DrugBank.d64.s4	0	14	Chloral hydrate	drug	DDI-DrugBank.d64.s4.e0
DDI-DrugBank.d64.s4	78	90	anticoagulant	group	DDI-DrugBank.d64.s4.e1
DDI-DrugBank.d64.s4	true	DDI-DrugBank.d64.s4.e0	DDI-DrugBank.d64.s4.e1
DDI-DrugBank.d64.s5|a|An interacting drug which leads to a decrease in prothrombin time necessitating an increased dose of oral anticoagulant to maintain an adequate degree of anticoagulation may, if abruptly discontinued, increase the risk of subsequent bleeding.
DDI-DrugBank.d64.s5	106	118	anticoagulant	group	DDI-DrugBank.d64.s5.e0
DDI-DrugBank.d64.s6|a|Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;
DDI-DrugBank.d64.s6	47	59	anticoagulant	group	DDI-DrugBank.d64.s6.e0
DDI-DrugBank.d64.s6	143	165	adrenocortical steroids	group	DDI-DrugBank.d64.s6.e1
DDI-DrugBank.d64.s6	true	DDI-DrugBank.d64.s6.e0	DDI-DrugBank.d64.s6.e1
DDI-DrugBank.d64.s7|a|alcohol*;
DDI-DrugBank.d64.s7	0	6	alcohol	drug	DDI-DrugBank.d64.s7.e0
DDI-DrugBank.d64.s8|a|antacids;
DDI-DrugBank.d64.s8	0	7	antacids	group	DDI-DrugBank.d64.s8.e0
DDI-DrugBank.d64.s9|a|antihistamines;
DDI-DrugBank.d64.s9	0	13	antihistamines	group	DDI-DrugBank.d64.s9.e0
DDI-DrugBank.d64.s10|a|barbiturates;
DDI-DrugBank.d64.s10	0	11	barbiturates	group	DDI-DrugBank.d64.s10.e0
DDI-DrugBank.d64.s11|a|carbamazepine;
DDI-DrugBank.d64.s11	0	12	carbamazepine	drug	DDI-DrugBank.d64.s11.e0
DDI-DrugBank.d64.s12|a|chloral hydrate*;
DDI-DrugBank.d64.s12	0	14	chloral hydrate	drug	DDI-DrugBank.d64.s12.e0
DDI-DrugBank.d64.s13|a|chlordiazepoxide;
DDI-DrugBank.d64.s13	0	15	chlordiazepoxide	drug	DDI-DrugBank.d64.s13.e0
DDI-DrugBank.d64.s14|a|cholestyramine;
DDI-DrugBank.d64.s14	0	13	cholestyramine	drug	DDI-DrugBank.d64.s14.e0
DDI-DrugBank.d64.s15|a|diet high in vitamin K;
DDI-DrugBank.d64.s15	13	21	vitamin K	group	DDI-DrugBank.d64.s15.e0
DDI-DrugBank.d64.s16|a|diuretics*;
DDI-DrugBank.d64.s16	0	8	diuretics	group	DDI-DrugBank.d64.s16.e0
DDI-DrugBank.d64.s17|a|ethchlorvynol;
DDI-DrugBank.d64.s17	0	12	ethchlorvynol	drug	DDI-DrugBank.d64.s17.e0
DDI-DrugBank.d64.s18|a|glutethimide;
DDI-DrugBank.d64.s18	0	11	glutethimide	drug	DDI-DrugBank.d64.s18.e0
DDI-DrugBank.d64.s19|a|griseofulvin;
DDI-DrugBank.d64.s19	0	11	griseofulvin	drug	DDI-DrugBank.d64.s19.e0
DDI-DrugBank.d64.s20|a|haloperidol;
DDI-DrugBank.d64.s20	0	10	haloperidol	drug	DDI-DrugBank.d64.s20.e0
DDI-DrugBank.d64.s21|a|meprobamate;
DDI-DrugBank.d64.s21	0	10	meprobamate	drug	DDI-DrugBank.d64.s21.e0
DDI-DrugBank.d64.s22|a|oral contraceptives;
DDI-DrugBank.d64.s22	5	18	contraceptives	group	DDI-DrugBank.d64.s22.e0
DDI-DrugBank.d64.s23|a|paraldehyde;
DDI-DrugBank.d64.s23	0	10	paraldehyde	drug	DDI-DrugBank.d64.s23.e0
DDI-DrugBank.d64.s24|a|primidone;
DDI-DrugBank.d64.s24	0	8	primidone	drug	DDI-DrugBank.d64.s24.e0
DDI-DrugBank.d64.s25|a|ranitidine*;
DDI-DrugBank.d64.s25	0	9	ranitidine	drug	DDI-DrugBank.d64.s25.e0
DDI-DrugBank.d64.s26|a|rifampin;
DDI-DrugBank.d64.s26	0	7	rifampin	drug	DDI-DrugBank.d64.s26.e0
DDI-DrugBank.d64.s27|a|unreliable prothrombin time determinations;
DDI-DrugBank.d64.s28|a|vitamin C;
DDI-DrugBank.d64.s28	0	8	vitamin C	drug	DDI-DrugBank.d64.s28.e0
DDI-DrugBank.d64.s29|a|Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29	47	59	anticoagulant	group	DDI-DrugBank.d64.s29.e0
DDI-DrugBank.d64.s29	143	165	adrenocortical steroids	group	DDI-DrugBank.d64.s29.e1
DDI-DrugBank.d64.s29	167	173	alcohol	drug	DDI-DrugBank.d64.s29.e2
DDI-DrugBank.d64.s29	176	183	antacids	group	DDI-DrugBank.d64.s29.e3
DDI-DrugBank.d64.s29	185	198	antihistamines	group	DDI-DrugBank.d64.s29.e4
DDI-DrugBank.d64.s29	200	211	barbiturates	group	DDI-DrugBank.d64.s29.e5
DDI-DrugBank.d64.s29	213	225	carbamazepine	drug	DDI-DrugBank.d64.s29.e6
DDI-DrugBank.d64.s29	227	241	chloral hydrate	drug	DDI-DrugBank.d64.s29.e7
DDI-DrugBank.d64.s29	244	259	chlordiazepoxide	drug	DDI-DrugBank.d64.s29.e8
DDI-DrugBank.d64.s29	261	274	cholestyramine	drug	DDI-DrugBank.d64.s29.e9
DDI-DrugBank.d64.s29	true	DDI-DrugBank.d64.s29.e0	DDI-DrugBank.d64.s29.e1
DDI-DrugBank.d64.s29	true	DDI-DrugBank.d64.s29.e0	DDI-DrugBank.d64.s29.e2
DDI-DrugBank.d64.s29	true	DDI-DrugBank.d64.s29.e0	DDI-DrugBank.d64.s29.e3
DDI-DrugBank.d64.s29	true	DDI-DrugBank.d64.s29.e0	DDI-DrugBank.d64.s29.e4
DDI-DrugBank.d64.s29	true	DDI-DrugBank.d64.s29.e0	DDI-DrugBank.d64.s29.e5
DDI-DrugBank.d64.s29	true	DDI-DrugBank.d64.s29.e0	DDI-DrugBank.d64.s29.e6
DDI-DrugBank.d64.s29	true	DDI-DrugBank.d64.s29.e0	DDI-DrugBank.d64.s29.e7
DDI-DrugBank.d64.s29	true	DDI-DrugBank.d64.s29.e0	DDI-DrugBank.d64.s29.e8
DDI-DrugBank.d64.s29	true	DDI-DrugBank.d64.s29.e0	DDI-DrugBank.d64.s29.e9
DDI-DrugBank.d64.s29	true	DDI-DrugBank.d64.s29.e0	DDI-DrugBank.d64.s29.e10
DDI-DrugBank.d64.s30|a|Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;
DDI-DrugBank.d64.s30	40	52	anticoagulant	group	DDI-DrugBank.d64.s30.e0
DDI-DrugBank.d64.s30	115	121	alcohol	drug	DDI-DrugBank.d64.s30.e1
DDI-DrugBank.d64.s30	true	DDI-DrugBank.d64.s30.e0	DDI-DrugBank.d64.s30.e1
DDI-DrugBank.d64.s31|a|allopurinol;
DDI-DrugBank.d64.s31	0	10	allopurinol	drug	DDI-DrugBank.d64.s31.e0
DDI-DrugBank.d64.s32|a|aminosalicylic acid;
DDI-DrugBank.d64.s32	0	18	aminosalicylic acid	drug	DDI-DrugBank.d64.s32.e0
DDI-DrugBank.d64.s33|a|amiodarone;
DDI-DrugBank.d64.s33	0	9	amiodarone	drug	DDI-DrugBank.d64.s33.e0
DDI-DrugBank.d64.s34|a|anabolic steroids;
DDI-DrugBank.d64.s34	0	16	anabolic steroids	group	DDI-DrugBank.d64.s34.e0
DDI-DrugBank.d64.s35|a|antibiotics;
DDI-DrugBank.d64.s35	0	10	antibiotics	group	DDI-DrugBank.d64.s35.e0
DDI-DrugBank.d64.s36|a|bromelains;
DDI-DrugBank.d64.s36	0	9	bromelains	drug	DDI-DrugBank.d64.s36.e0
DDI-DrugBank.d64.s37|a|chloral hydrate*;
DDI-DrugBank.d64.s37	0	14	chloral hydrate	drug	DDI-DrugBank.d64.s37.e0
DDI-DrugBank.d64.s38|a|chlorpropamide;
DDI-DrugBank.d64.s38	0	13	chlorpropamide	drug	DDI-DrugBank.d64.s38.e0
DDI-DrugBank.d64.s39|a|chymotrypsin;
DDI-DrugBank.d64.s39	0	11	chymotrypsin	drug	DDI-DrugBank.d64.s39.e0
DDI-DrugBank.d64.s40|a|cimetidine;
DDI-DrugBank.d64.s40	0	9	cimetidine	drug	DDI-DrugBank.d64.s40.e0
DDI-DrugBank.d64.s41|a|cinchophen;
DDI-DrugBank.d64.s41	0	9	cinchophen	drug	DDI-DrugBank.d64.s41.e0
DDI-DrugBank.d64.s42|a|clofibrate;
DDI-DrugBank.d64.s42	0	9	clofibrate	drug	DDI-DrugBank.d64.s42.e0
DDI-DrugBank.d64.s43|a|dextran;
DDI-DrugBank.d64.s43	0	6	dextran	drug	DDI-DrugBank.d64.s43.e0
DDI-DrugBank.d64.s44|a|dextrothyroxine;
DDI-DrugBank.d64.s44	0	14	dextrothyroxine	drug	DDI-DrugBank.d64.s44.e0
DDI-DrugBank.d64.s45|a|diazoxide;
DDI-DrugBank.d64.s45	0	8	diazoxide	drug	DDI-DrugBank.d64.s45.e0
DDI-DrugBank.d64.s46|a|dietary deficiencies;
DDI-DrugBank.d64.s47|a|diflunisal;
DDI-DrugBank.d64.s47	0	9	diflunisal	drug	DDI-DrugBank.d64.s47.e0
DDI-DrugBank.d64.s48|a|diuretics*;
DDI-DrugBank.d64.s48	0	8	diuretics	group	DDI-DrugBank.d64.s48.e0
DDI-DrugBank.d64.s49|a|disulfiram;
DDI-DrugBank.d64.s49	0	9	disulfiram	drug	DDI-DrugBank.d64.s49.e0
DDI-DrugBank.d64.s50|a|drugs affecting blood elements;
DDI-DrugBank.d64.s51|a|ethacrynic acid;
DDI-DrugBank.d64.s51	0	14	ethacrynic acid	drug	DDI-DrugBank.d64.s51.e0
DDI-DrugBank.d64.s52|a|fenoprofen;
DDI-DrugBank.d64.s52	0	9	fenoprofen	drug	DDI-DrugBank.d64.s52.e0
DDI-DrugBank.d64.s53|a|glucagon;
DDI-DrugBank.d64.s53	0	7	glucagon	drug	DDI-DrugBank.d64.s53.e0
DDI-DrugBank.d64.s54|a|hepatotoxic drugs;
DDI-DrugBank.d64.s55|a|ibuprofen;
DDI-DrugBank.d64.s55	0	8	ibuprofen	drug	DDI-DrugBank.d64.s55.e0
DDI-DrugBank.d64.s56|a|indomethacin;
DDI-DrugBank.d64.s56	0	11	indomethacin	drug	DDI-DrugBank.d64.s56.e0
DDI-DrugBank.d64.s57|a|influenza virus vaccine;
DDI-DrugBank.d64.s57	0	22	influenza virus vaccine	group	DDI-DrugBank.d64.s57.e0
DDI-DrugBank.d64.s58|a|inhalation anesthetics;
DDI-DrugBank.d64.s58	11	21	anesthetics	group	DDI-DrugBank.d64.s58.e0
DDI-DrugBank.d64.s59|a|mefenamic acid;
DDI-DrugBank.d64.s59	0	13	mefenamic acid	drug	DDI-DrugBank.d64.s59.e0
DDI-DrugBank.d64.s60|a|methyldopa;
DDI-DrugBank.d64.s60	0	9	methyldopa	drug	DDI-DrugBank.d64.s60.e0
DDI-DrugBank.d64.s61|a|methylphenidate;
DDI-DrugBank.d64.s61	0	14	methylphenidate	drug	DDI-DrugBank.d64.s61.e0
DDI-DrugBank.d64.s62|a|metronidazole;
DDI-DrugBank.d64.s62	0	12	metronidazole	drug	DDI-DrugBank.d64.s62.e0
DDI-DrugBank.d64.s63|a|miconazole;
DDI-DrugBank.d64.s63	0	9	miconazole	drug	DDI-DrugBank.d64.s63.e0
DDI-DrugBank.d64.s64|a|monoamine oxidase inhibitors;
DDI-DrugBank.d64.s64	0	27	monoamine oxidase inhibitors	group	DDI-DrugBank.d64.s64.e0
DDI-DrugBank.d64.s65|a|nalidixic acid;
DDI-DrugBank.d64.s65	0	13	nalidixic acid	drug	DDI-DrugBank.d64.s65.e0
DDI-DrugBank.d64.s66|a|naproxen;
DDI-DrugBank.d64.s66	0	7	naproxen	drug	DDI-DrugBank.d64.s66.e0
DDI-DrugBank.d64.s67|a|oxolinic acid;
DDI-DrugBank.d64.s67	0	12	oxolinic acid	drug	DDI-DrugBank.d64.s67.e0
DDI-DrugBank.d64.s68|a|oxyphenbutazone;
DDI-DrugBank.d64.s68	0	14	oxyphenbutazone	drug	DDI-DrugBank.d64.s68.e0
DDI-DrugBank.d64.s69|a|pentoxifylline;
DDI-DrugBank.d64.s69	0	13	pentoxifylline	drug	DDI-DrugBank.d64.s69.e0
DDI-DrugBank.d64.s70|a|phenylbutazone;
DDI-DrugBank.d64.s70	0	13	phenylbutazone	drug	DDI-DrugBank.d64.s70.e0
DDI-DrugBank.d64.s71|a|phenyramidol;
DDI-DrugBank.d64.s71	0	11	phenyramidol	drug_n	DDI-DrugBank.d64.s71.e0
DDI-DrugBank.d64.s72|a|phenytoin;
DDI-DrugBank.d64.s72	0	8	phenytoin	drug	DDI-DrugBank.d64.s72.e0
DDI-DrugBank.d64.s73|a|prolonged hot weather;
DDI-DrugBank.d64.s74|a|prolonged narcotics;
DDI-DrugBank.d64.s74	0	18	prolonged narcotics	group	DDI-DrugBank.d64.s74.e0
DDI-DrugBank.d64.s75|a|pyrazolones;
DDI-DrugBank.d64.s75	0	10	pyrazolones	group	DDI-DrugBank.d64.s75.e0
DDI-DrugBank.d64.s76|a|quinidine;
DDI-DrugBank.d64.s76	0	8	quinidine	drug	DDI-DrugBank.d64.s76.e0
DDI-DrugBank.d64.s77|a|quinine;
DDI-DrugBank.d64.s77	0	6	quinine	drug	DDI-DrugBank.d64.s77.e0
DDI-DrugBank.d64.s78|a|ranitidine*;
DDI-DrugBank.d64.s78	0	9	ranitidine	drug	DDI-DrugBank.d64.s78.e0
DDI-DrugBank.d64.s79|a|salicylates;sulfinpyrazone;
DDI-DrugBank.d64.s79	0	10	salicylates	group	DDI-DrugBank.d64.s79.e0
DDI-DrugBank.d64.s79	12	25	sulfinpyrazone	drug	DDI-DrugBank.d64.s79.e1
DDI-DrugBank.d64.s79	false	DDI-DrugBank.d64.s79.e0	DDI-DrugBank.d64.s79.e1
DDI-DrugBank.d64.s80|a|sulfonamides, long acting;
DDI-DrugBank.d64.s80	0	11	sulfonamides	group	DDI-DrugBank.d64.s80.e0
DDI-DrugBank.d64.s81|a|sulindac;
DDI-DrugBank.d64.s81	0	7	sulindac	drug	DDI-DrugBank.d64.s81.e0
DDI-DrugBank.d64.s82|a|thyroid drugs;
DDI-DrugBank.d64.s82	0	12	thyroid drugs	group	DDI-DrugBank.d64.s82.e0
DDI-DrugBank.d64.s83|a|tolbutamide;
DDI-DrugBank.d64.s83	0	10	tolbutamide	drug	DDI-DrugBank.d64.s83.e0
DDI-DrugBank.d64.s84|a|triclofos sodium;
DDI-DrugBank.d64.s84	0	15	triclofos sodium	drug	DDI-DrugBank.d64.s84.e0
DDI-DrugBank.d64.s85|a|trimethoprim/sulfamethoxazole;
DDI-DrugBank.d64.s85	0	11	trimethoprim	drug	DDI-DrugBank.d64.s85.e0
DDI-DrugBank.d64.s85	13	28	sulfamethoxazole	drug	DDI-DrugBank.d64.s85.e1
DDI-DrugBank.d64.s85	false	DDI-DrugBank.d64.s85.e0	DDI-DrugBank.d64.s85.e1
DDI-DrugBank.d64.s86|a|unreliable prothrombin time determinations;
DDI-DrugBank.d64.s87|a|Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
DDI-DrugBank.d64.s87	40	52	anticoagulant	group	DDI-DrugBank.d64.s87.e0
DDI-DrugBank.d64.s87	115	121	alcohol	drug	DDI-DrugBank.d64.s87.e1
DDI-DrugBank.d64.s87	124	134	allopurinol	drug	DDI-DrugBank.d64.s87.e2
DDI-DrugBank.d64.s87	136	154	aminosalicylic acid	drug	DDI-DrugBank.d64.s87.e3
DDI-DrugBank.d64.s87	156	165	amiodarone	drug	DDI-DrugBank.d64.s87.e4
DDI-DrugBank.d64.s87	167	183	anabolic steroids	group	DDI-DrugBank.d64.s87.e5
DDI-DrugBank.d64.s87	185	195	antibiotics	group	DDI-DrugBank.d64.s87.e6
DDI-DrugBank.d64.s87	197	206	bromelains	drug	DDI-DrugBank.d64.s87.e7
DDI-DrugBank.d64.s87	208	222	chloral hydrate	drug	DDI-DrugBank.d64.s87.e8
DDI-DrugBank.d64.s87	225	238	chlorpropamide	drug	DDI-DrugBank.d64.s87.e9
DDI-DrugBank.d64.s87	true	DDI-DrugBank.d64.s87.e0	DDI-DrugBank.d64.s87.e1
DDI-DrugBank.d64.s87	true	DDI-DrugBank.d64.s87.e0	DDI-DrugBank.d64.s87.e2
DDI-DrugBank.d64.s87	true	DDI-DrugBank.d64.s87.e0	DDI-DrugBank.d64.s87.e3
DDI-DrugBank.d64.s87	true	DDI-DrugBank.d64.s87.e0	DDI-DrugBank.d64.s87.e4
DDI-DrugBank.d64.s87	true	DDI-DrugBank.d64.s87.e0	DDI-DrugBank.d64.s87.e5
DDI-DrugBank.d64.s87	true	DDI-DrugBank.d64.s87.e0	DDI-DrugBank.d64.s87.e6
DDI-DrugBank.d64.s87	true	DDI-DrugBank.d64.s87.e0	DDI-DrugBank.d64.s87.e7
DDI-DrugBank.d64.s87	true	DDI-DrugBank.d64.s87.e0	DDI-DrugBank.d64.s87.e8
DDI-DrugBank.d64.s87	true	DDI-DrugBank.d64.s87.e0	DDI-DrugBank.d64.s87.e9
DDI-DrugBank.d64.s87	true	DDI-DrugBank.d64.s87.e0	DDI-DrugBank.d64.s87.e10
DDI-DrugBank.d64.s88|a|Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
DDI-DrugBank.d64.s88	5	18	anticoagulants	group	DDI-DrugBank.d64.s88.e0
DDI-DrugBank.d64.s88	62	80	hypoglycemic agents	group	DDI-DrugBank.d64.s88.e1
DDI-DrugBank.d64.s88	87	97	tolbutamide	drug	DDI-DrugBank.d64.s88.e2
DDI-DrugBank.d64.s88	103	116	chlorpropamide	drug	DDI-DrugBank.d64.s88.e3
DDI-DrugBank.d64.s88	true	DDI-DrugBank.d64.s88.e0	DDI-DrugBank.d64.s88.e1
DDI-DrugBank.d64.s88	true	DDI-DrugBank.d64.s88.e0	DDI-DrugBank.d64.s88.e2
DDI-DrugBank.d64.s88	true	DDI-DrugBank.d64.s88.e0	DDI-DrugBank.d64.s88.e3
DDI-DrugBank.d64.s88	false	DDI-DrugBank.d64.s88.e1	DDI-DrugBank.d64.s88.e2
DDI-DrugBank.d64.s88	false	DDI-DrugBank.d64.s88.e1	DDI-DrugBank.d64.s88.e3
DDI-DrugBank.d64.s88	false	DDI-DrugBank.d64.s88.e2	DDI-DrugBank.d64.s88.e3
DDI-DrugBank.d64.s89|a|Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.
DDI-DrugBank.d64.s89	13	26	anticoagulants	group	DDI-DrugBank.d64.s89.e0
DDI-DrugBank.d64.s89	73	81	phenytoin	drug	DDI-DrugBank.d64.s89.e1
DDI-DrugBank.d64.s89	104	117	anticonvulsant	group	DDI-DrugBank.d64.s89.e2
DDI-DrugBank.d64.s89	142	154	anticoagulant	group	DDI-DrugBank.d64.s89.e3
DDI-DrugBank.d64.s89	160	168	phenytoin	drug	DDI-DrugBank.d64.s89.e4
DDI-DrugBank.d64.s89	true	DDI-DrugBank.d64.s89.e0	DDI-DrugBank.d64.s89.e1
DDI-DrugBank.d64.s89	false	DDI-DrugBank.d64.s89.e0	DDI-DrugBank.d64.s89.e2
DDI-DrugBank.d64.s89	false	DDI-DrugBank.d64.s89.e0	DDI-DrugBank.d64.s89.e3
DDI-DrugBank.d64.s89	false	DDI-DrugBank.d64.s89.e0	DDI-DrugBank.d64.s89.e4
DDI-DrugBank.d64.s89	false	DDI-DrugBank.d64.s89.e1	DDI-DrugBank.d64.s89.e2
DDI-DrugBank.d64.s89	false	DDI-DrugBank.d64.s89.e1	DDI-DrugBank.d64.s89.e3
DDI-DrugBank.d64.s89	false	DDI-DrugBank.d64.s89.e1	DDI-DrugBank.d64.s89.e4
DDI-DrugBank.d64.s89	false	DDI-DrugBank.d64.s89.e2	DDI-DrugBank.d64.s89.e3
DDI-DrugBank.d64.s89	false	DDI-DrugBank.d64.s89.e2	DDI-DrugBank.d64.s89.e4
DDI-DrugBank.d64.s89	true	DDI-DrugBank.d64.s89.e3	DDI-DrugBank.d64.s89.e4
DDI-DrugBank.d64.s90|a|Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
DDI-DrugBank.d64.s90	91	111	antineoplastic agents	group	DDI-DrugBank.d64.s90.e0
DDI-DrugBank.d64.s90	160	166	aspirin	brand	DDI-DrugBank.d64.s90.e1
DDI-DrugBank.d64.s90	178	214	non-steroidal anti-inflammatory drugs	group	DDI-DrugBank.d64.s90.e2
DDI-DrugBank.d64.s90	217	228	dipyridamole	drug	DDI-DrugBank.d64.s90.e3
DDI-DrugBank.d64.s90	231	246	hydrochloroquine	drug	DDI-DrugBank.d64.s90.e4
DDI-DrugBank.d64.s90	249	258	clofibrate	drug	DDI-DrugBank.d64.s90.e5
DDI-DrugBank.d64.s90	261	267	dextran	drug	DDI-DrugBank.d64.s90.e6
DDI-DrugBank.d64.s90	317	330	anticoagulants	group	DDI-DrugBank.d64.s90.e7
DDI-DrugBank.d64.s90	false	DDI-DrugBank.d64.s90.e0	DDI-DrugBank.d64.s90.e1
DDI-DrugBank.d64.s90	false	DDI-DrugBank.d64.s90.e0	DDI-DrugBank.d64.s90.e2
DDI-DrugBank.d64.s90	false	DDI-DrugBank.d64.s90.e0	DDI-DrugBank.d64.s90.e3
DDI-DrugBank.d64.s90	false	DDI-DrugBank.d64.s90.e0	DDI-DrugBank.d64.s90.e4
DDI-DrugBank.d64.s90	false	DDI-DrugBank.d64.s90.e0	DDI-DrugBank.d64.s90.e5
DDI-DrugBank.d64.s90	false	DDI-DrugBank.d64.s90.e0	DDI-DrugBank.d64.s90.e6
DDI-DrugBank.d64.s90	true	DDI-DrugBank.d64.s90.e0	DDI-DrugBank.d64.s90.e7
DDI-DrugBank.d64.s90	false	DDI-DrugBank.d64.s90.e1	DDI-DrugBank.d64.s90.e2
DDI-DrugBank.d64.s90	false	DDI-DrugBank.d64.s90.e1	DDI-DrugBank.d64.s90.e3
DDI-DrugBank.d64.s90	false	DDI-DrugBank.d64.s90.e1	DDI-DrugBank.d64.s90.e4
DDI-DrugBank.d64.s91|a|The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.
DDI-DrugBank.d64.s91	81	92	antiplatelet medication	group	DDI-DrugBank.d64.s91.e0
DDI-DrugBank.d64.s91	112	121	antiplatelet medication	group	DDI-DrugBank.d64.s91.e0
DDI-DrugBank.d64.s91	98	121	anticoagulant medication	group	DDI-DrugBank.d64.s91.e1
DDI-DrugBank.d64.s91	true	DDI-DrugBank.d64.s91.e0	DDI-DrugBank.d64.s91.e1
DDI-DrugBank.d64.s92|a|*Increased and decreased prothrombin time responses have been reported.
DDI-DrugBank.d64.s93|a|Drug/Laboratory Test Interferences: Dicumarol and indanedione anticoagulants, including anisindione, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.
DDI-DrugBank.d64.s93	36	44	Dicumarol	drug	DDI-DrugBank.d64.s93.e0
DDI-DrugBank.d64.s93	50	75	indanedione anticoagulants	group	DDI-DrugBank.d64.s93.e1
DDI-DrugBank.d64.s93	88	98	anisindione	drug	DDI-DrugBank.d64.s93.e2
DDI-DrugBank.d64.s93	false	DDI-DrugBank.d64.s93.e0	DDI-DrugBank.d64.s93.e1
DDI-DrugBank.d64.s93	false	DDI-DrugBank.d64.s93.e0	DDI-DrugBank.d64.s93.e2
DDI-DrugBank.d64.s93	false	DDI-DrugBank.d64.s93.e1	DDI-DrugBank.d64.s93.e2
DDI-DrugBank.d64.s94|a|The color reverses when the test sample is acidified in vitro to a pH below 4.
DDI-DrugBank.d357.s0|a|5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d357.s0	0	15	5HT3 Antagonists	group	DDI-DrugBank.d357.s0.e0
DDI-DrugBank.d357.s0	90	100	apomorphine	drug	DDI-DrugBank.d357.s0.e1
DDI-DrugBank.d357.s0	124	134	ondansetron	drug	DDI-DrugBank.d357.s0.e2
DDI-DrugBank.d357.s0	160	170	apomorphine	drug	DDI-DrugBank.d357.s0.e3
DDI-DrugBank.d357.s0	190	210	5HT3 antagonist class	group	DDI-DrugBank.d357.s0.e4
DDI-DrugBank.d357.s0	237	247	ondansetron	drug	DDI-DrugBank.d357.s0.e5
DDI-DrugBank.d357.s0	250	260	granisetron	drug	DDI-DrugBank.d357.s0.e6
DDI-DrugBank.d357.s0	263	272	dolasetron	drug	DDI-DrugBank.d357.s0.e7
DDI-DrugBank.d357.s0	275	286	palonosetron	drug	DDI-DrugBank.d357.s0.e8
DDI-DrugBank.d357.s0	293	301	alosetron	drug	DDI-DrugBank.d357.s0.e9
DDI-DrugBank.d357.s0	false	DDI-DrugBank.d357.s0.e0	DDI-DrugBank.d357.s0.e1
DDI-DrugBank.d357.s0	false	DDI-DrugBank.d357.s0.e0	DDI-DrugBank.d357.s0.e2
DDI-DrugBank.d357.s0	false	DDI-DrugBank.d357.s0.e0	DDI-DrugBank.d357.s0.e3
DDI-DrugBank.d357.s0	false	DDI-DrugBank.d357.s0.e0	DDI-DrugBank.d357.s0.e4
DDI-DrugBank.d357.s0	false	DDI-DrugBank.d357.s0.e0	DDI-DrugBank.d357.s0.e5
DDI-DrugBank.d357.s0	false	DDI-DrugBank.d357.s0.e0	DDI-DrugBank.d357.s0.e6
DDI-DrugBank.d357.s0	false	DDI-DrugBank.d357.s0.e0	DDI-DrugBank.d357.s0.e7
DDI-DrugBank.d357.s0	false	DDI-DrugBank.d357.s0.e0	DDI-DrugBank.d357.s0.e8
DDI-DrugBank.d357.s0	false	DDI-DrugBank.d357.s0.e0	DDI-DrugBank.d357.s0.e9
DDI-DrugBank.d357.s0	true	DDI-DrugBank.d357.s0.e1	DDI-DrugBank.d357.s0.e2
DDI-DrugBank.d357.s1|a|Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
DDI-DrugBank.d357.s1	0	26	Antihypertensive Medication	group	DDI-DrugBank.d357.s1.e0
DDI-DrugBank.d357.s1	33	44	Vasodilators	group	DDI-DrugBank.d357.s1.e1
DDI-DrugBank.d357.s1	141	168	antihypertensive medications	group	DDI-DrugBank.d357.s1.e2
DDI-DrugBank.d357.s1	173	184	vasodilators	group	DDI-DrugBank.d357.s1.e3
DDI-DrugBank.d357.s1	false	DDI-DrugBank.d357.s1.e0	DDI-DrugBank.d357.s1.e1
DDI-DrugBank.d357.s1	false	DDI-DrugBank.d357.s1.e0	DDI-DrugBank.d357.s1.e2
DDI-DrugBank.d357.s1	false	DDI-DrugBank.d357.s1.e0	DDI-DrugBank.d357.s1.e3
DDI-DrugBank.d357.s1	false	DDI-DrugBank.d357.s1.e1	DDI-DrugBank.d357.s1.e2
DDI-DrugBank.d357.s1	false	DDI-DrugBank.d357.s1.e1	DDI-DrugBank.d357.s1.e3
DDI-DrugBank.d357.s1	true	DDI-DrugBank.d357.s1.e2	DDI-DrugBank.d357.s1.e3
DDI-DrugBank.d357.s2|a|The mechanism underlying many of these events is unknown, but may represent increased hypotension .
DDI-DrugBank.d357.s3|a|Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
DDI-DrugBank.d357.s3	0	19	Dopamine Antagonists	group	DDI-DrugBank.d357.s3.e0
DDI-DrugBank.d357.s3	28	38	apomorphine	drug	DDI-DrugBank.d357.s3.e1
DDI-DrugBank.d357.s3	45	60	dopamine agonist	group	DDI-DrugBank.d357.s3.e2
DDI-DrugBank.d357.s3	83	102	dopamine antagonists	group	DDI-DrugBank.d357.s3.e3
DDI-DrugBank.d357.s3	117	128	neuroleptics	group	DDI-DrugBank.d357.s3.e4
DDI-DrugBank.d357.s3	131	144	phenothiazines	group	DDI-DrugBank.d357.s3.e5
DDI-DrugBank.d357.s3	147	160	butyrophenones	group	DDI-DrugBank.d357.s3.e6
DDI-DrugBank.d357.s3	163	175	thioxanthenes	group	DDI-DrugBank.d357.s3.e7
DDI-DrugBank.d357.s3	181	194	metoclopramide	drug	DDI-DrugBank.d357.s3.e8
DDI-DrugBank.d357.s3	231	236	APOKYN	brand	DDI-DrugBank.d357.s3.e9
DDI-DrugBank.d357.s3	false	DDI-DrugBank.d357.s3.e0	DDI-DrugBank.d357.s3.e1
DDI-DrugBank.d357.s3	false	DDI-DrugBank.d357.s3.e0	DDI-DrugBank.d357.s3.e2
DDI-DrugBank.d357.s3	false	DDI-DrugBank.d357.s3.e0	DDI-DrugBank.d357.s3.e3
DDI-DrugBank.d357.s3	false	DDI-DrugBank.d357.s3.e0	DDI-DrugBank.d357.s3.e4
DDI-DrugBank.d357.s3	false	DDI-DrugBank.d357.s3.e0	DDI-DrugBank.d357.s3.e5
DDI-DrugBank.d357.s3	false	DDI-DrugBank.d357.s3.e0	DDI-DrugBank.d357.s3.e6
DDI-DrugBank.d357.s3	false	DDI-DrugBank.d357.s3.e0	DDI-DrugBank.d357.s3.e7
DDI-DrugBank.d357.s3	false	DDI-DrugBank.d357.s3.e0	DDI-DrugBank.d357.s3.e8
DDI-DrugBank.d357.s3	false	DDI-DrugBank.d357.s3.e0	DDI-DrugBank.d357.s3.e9
DDI-DrugBank.d357.s3	false	DDI-DrugBank.d357.s3.e1	DDI-DrugBank.d357.s3.e2
DDI-DrugBank.d357.s4|a|Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.
DDI-DrugBank.d357.s4	54	65	neuroleptics	group	DDI-DrugBank.d357.s4.e0
DDI-DrugBank.d357.s4	91	107	dopamine agonists	group	DDI-DrugBank.d357.s4.e1
DDI-DrugBank.d357.s4	true	DDI-DrugBank.d357.s4.e0	DDI-DrugBank.d357.s4.e1
DDI-DrugBank.d357.s5|a|Drugs Prolonging the QT/QTc Interval Caution should be exercised when prescribing apomorphine concomitantly with drugs that prolong the QT/QTc interval.
DDI-DrugBank.d357.s5	82	92	apomorphine	drug	DDI-DrugBank.d357.s5.e0
DDI-DrugBank.d357.s6|a|Drug/Laboratory Test Interactions There are no known interactions between APOKYN and laboratory tests.
DDI-DrugBank.d357.s6	74	79	APOKYN	brand	DDI-DrugBank.d357.s6.e0
DDI-DrugBank.d224.s0|a|Apraclonidine should not be used in patients receiving MAO inhibitors..
DDI-DrugBank.d224.s0	0	12	Apraclonidine	drug	DDI-DrugBank.d224.s0.e0
DDI-DrugBank.d224.s0	55	68	MAO inhibitors	group	DDI-DrugBank.d224.s0.e1
DDI-DrugBank.d224.s0	true	DDI-DrugBank.d224.s0.e0	DDI-DrugBank.d224.s0.e1
DDI-DrugBank.d224.s1|a|Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
DDI-DrugBank.d224.s1	130	137	IOPIDINE	brand	DDI-DrugBank.d224.s1.e0
DDI-DrugBank.d224.s1	224	238	CNS depressants	group	DDI-DrugBank.d224.s1.e1
DDI-DrugBank.d224.s1	241	247	alcohol	drug	DDI-DrugBank.d224.s1.e2
DDI-DrugBank.d224.s1	250	261	barbiturates	group	DDI-DrugBank.d224.s1.e3
DDI-DrugBank.d224.s1	264	270	opiates	group	DDI-DrugBank.d224.s1.e4
DDI-DrugBank.d224.s1	273	281	sedatives	group	DDI-DrugBank.d224.s1.e5
DDI-DrugBank.d224.s1	284	294	anesthetics	group	DDI-DrugBank.d224.s1.e6
DDI-DrugBank.d224.s1	true	DDI-DrugBank.d224.s1.e0	DDI-DrugBank.d224.s1.e1
DDI-DrugBank.d224.s1	true	DDI-DrugBank.d224.s1.e0	DDI-DrugBank.d224.s1.e2
DDI-DrugBank.d224.s1	true	DDI-DrugBank.d224.s1.e0	DDI-DrugBank.d224.s1.e3
DDI-DrugBank.d224.s1	true	DDI-DrugBank.d224.s1.e0	DDI-DrugBank.d224.s1.e4
DDI-DrugBank.d224.s1	true	DDI-DrugBank.d224.s1.e0	DDI-DrugBank.d224.s1.e5
DDI-DrugBank.d224.s1	true	DDI-DrugBank.d224.s1.e0	DDI-DrugBank.d224.s1.e6
DDI-DrugBank.d224.s1	false	DDI-DrugBank.d224.s1.e1	DDI-DrugBank.d224.s1.e2
DDI-DrugBank.d224.s1	false	DDI-DrugBank.d224.s1.e1	DDI-DrugBank.d224.s1.e3
DDI-DrugBank.d224.s1	false	DDI-DrugBank.d224.s1.e1	DDI-DrugBank.d224.s1.e4
DDI-DrugBank.d224.s1	false	DDI-DrugBank.d224.s1.e1	DDI-DrugBank.d224.s1.e5
DDI-DrugBank.d224.s2|a|Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.
DDI-DrugBank.d224.s2	0	24	Tricyclic antidepressants	group	DDI-DrugBank.d224.s2.e0
DDI-DrugBank.d224.s2	89	97	clonidine	drug	DDI-DrugBank.d224.s2.e1
DDI-DrugBank.d224.s2	true	DDI-DrugBank.d224.s2.e0	DDI-DrugBank.d224.s2.e1
DDI-DrugBank.d224.s3|a|It is not known whether the concurrent use of these agents with apraclonidine can lead to a reduction in IOP lowering effect.
DDI-DrugBank.d224.s3	64	76	apraclonidine	drug	DDI-DrugBank.d224.s3.e0
DDI-DrugBank.d224.s4|a|No data on the level of circulating catecholamines after apraclonidine withdrawal are available.
DDI-DrugBank.d224.s4	57	69	apraclonidine	drug	DDI-DrugBank.d224.s4.e0
DDI-DrugBank.d224.s5|a|Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.
DDI-DrugBank.d224.s5	48	72	tricyclic antidepressants	group	DDI-DrugBank.d224.s5.e0
DDI-DrugBank.d224.s6|a|An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.
DDI-DrugBank.d224.s6	82	90	clonidine	drug	DDI-DrugBank.d224.s6.e0
DDI-DrugBank.d224.s6	96	106	neuroleptic	group	DDI-DrugBank.d224.s6.e1
DDI-DrugBank.d224.s6	true	DDI-DrugBank.d224.s6.e0	DDI-DrugBank.d224.s6.e1
DDI-DrugBank.d224.s7|a|Systemic clonidine may inhibit the production of catecholamines in response to insulin-induced hypoglycemia and mask the signs and symptoms of hypoglycemia.
DDI-DrugBank.d224.s7	9	17	clonidine	drug	DDI-DrugBank.d224.s7.e0
DDI-DrugBank.d224.s8|a|Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
DDI-DrugBank.d224.s8	6	18	apraclonidine	drug	DDI-DrugBank.d224.s8.e0
DDI-DrugBank.d224.s8	88	100	beta-blockers	group	DDI-DrugBank.d224.s8.e1
DDI-DrugBank.d224.s8	129	145	antihypertensives	group	DDI-DrugBank.d224.s8.e2
DDI-DrugBank.d224.s8	152	169	cardiac glycosides	group	DDI-DrugBank.d224.s8.e3
DDI-DrugBank.d224.s8	true	DDI-DrugBank.d224.s8.e0	DDI-DrugBank.d224.s8.e1
DDI-DrugBank.d224.s8	true	DDI-DrugBank.d224.s8.e0	DDI-DrugBank.d224.s8.e2
DDI-DrugBank.d224.s8	true	DDI-DrugBank.d224.s8.e0	DDI-DrugBank.d224.s8.e3
DDI-DrugBank.d224.s8	false	DDI-DrugBank.d224.s8.e1	DDI-DrugBank.d224.s8.e2
DDI-DrugBank.d224.s8	false	DDI-DrugBank.d224.s8.e1	DDI-DrugBank.d224.s8.e3
DDI-DrugBank.d224.s8	false	DDI-DrugBank.d224.s8.e2	DDI-DrugBank.d224.s8.e3
DDI-DrugBank.d224.s9|a|Patients using cardiovascular drugs concurrently with IOPIDINE 0.5% Ophthalmic Solution should have pulse and blood pressures frequently monitored.
DDI-DrugBank.d224.s9	54	61	IOPIDINE	brand	DDI-DrugBank.d224.s9.e0
DDI-DrugBank.d224.s10|a|Caution should be exercised with simultaneous use of clonidine and other similar pharmacologic agents
DDI-DrugBank.d224.s10	53	61	clonidine	drug	DDI-DrugBank.d224.s10.e0
DDI-DrugBank.d224.s11|a|.
DDI-DrugBank.d224.s12|a|
DDI-DrugBank.d382.s0|a|Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4.
DDI-DrugBank.d382.s0	0	9	Aprepitant	drug	DDI-DrugBank.d382.s0.e0
DDI-DrugBank.d382.s1|a|Aprepitant is also an inducer of CYP2C9.
DDI-DrugBank.d382.s1	0	9	Aprepitant	drug	DDI-DrugBank.d382.s1.e0
DDI-DrugBank.d382.s2|a|Effect of aprepitant on the pharmacokinetics of other agents
DDI-DrugBank.d382.s2	10	19	aprepitant	drug	DDI-DrugBank.d382.s2.e0
DDI-DrugBank.d382.s3|a|As a moderate inhibitor of CYP3A4, aprepitant can increase plasma concentrations of coadministered medicinal products that are metabolized through CYP3A4.
DDI-DrugBank.d382.s3	35	44	aprepitant	drug	DDI-DrugBank.d382.s3.e0
DDI-DrugBank.d382.s4|a|Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
DDI-DrugBank.d382.s4	0	9	Aprepitant	drug	DDI-DrugBank.d382.s4.e0
DDI-DrugBank.d382.s4	54	66	S(-) warfarin	drug	DDI-DrugBank.d382.s4.e1
DDI-DrugBank.d382.s4	72	82	tolbutamide	drug	DDI-DrugBank.d382.s4.e2
DDI-DrugBank.d382.s4	true	DDI-DrugBank.d382.s4.e0	DDI-DrugBank.d382.s4.e1
DDI-DrugBank.d382.s4	true	DDI-DrugBank.d382.s4.e0	DDI-DrugBank.d382.s4.e2
DDI-DrugBank.d382.s4	false	DDI-DrugBank.d382.s4.e1	DDI-DrugBank.d382.s4.e2
DDI-DrugBank.d382.s5|a|Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.
DDI-DrugBank.d382.s5	20	29	Aprepitant	drug	DDI-DrugBank.d382.s5.e0
DDI-DrugBank.d382.s5	115	123	phenytoin	drug	DDI-DrugBank.d382.s5.e1
DDI-DrugBank.d382.s5	true	DDI-DrugBank.d382.s5.e0	DDI-DrugBank.d382.s5.e1
DDI-DrugBank.d382.s6|a|Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study.
DDI-DrugBank.d382.s6	0	9	Aprepitant	drug	DDI-DrugBank.d382.s6.e0
DDI-DrugBank.d382.s6	148	157	Aprepitant	drug	DDI-DrugBank.d382.s6.e1
DDI-DrugBank.d382.s6	164	170	digoxin	drug	DDI-DrugBank.d382.s6.e2
DDI-DrugBank.d382.s6	false	DDI-DrugBank.d382.s6.e0	DDI-DrugBank.d382.s6.e1
DDI-DrugBank.d382.s6	false	DDI-DrugBank.d382.s6.e0	DDI-DrugBank.d382.s6.e2
DDI-DrugBank.d382.s6	false	DDI-DrugBank.d382.s6.e1	DDI-DrugBank.d382.s6.e2
DDI-DrugBank.d382.s7|a|5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron.
DDI-DrugBank.d382.s7	0	16	5-HT3 antagonists	group	DDI-DrugBank.d382.s7.e0
DDI-DrugBank.d382.s7	57	66	aprepitant	drug	DDI-DrugBank.d382.s7.e1
DDI-DrugBank.d382.s7	137	147	ondansetron	drug	DDI-DrugBank.d382.s7.e2
DDI-DrugBank.d382.s7	152	162	granisetron	drug	DDI-DrugBank.d382.s7.e3
DDI-DrugBank.d382.s7	false	DDI-DrugBank.d382.s7.e0	DDI-DrugBank.d382.s7.e1
DDI-DrugBank.d382.s7	false	DDI-DrugBank.d382.s7.e0	DDI-DrugBank.d382.s7.e2
DDI-DrugBank.d382.s7	false	DDI-DrugBank.d382.s7.e0	DDI-DrugBank.d382.s7.e3
DDI-DrugBank.d382.s7	false	DDI-DrugBank.d382.s7.e1	DDI-DrugBank.d382.s7.e2
DDI-DrugBank.d382.s7	false	DDI-DrugBank.d382.s7.e1	DDI-DrugBank.d382.s7.e3
DDI-DrugBank.d382.s7	false	DDI-DrugBank.d382.s7.e2	DDI-DrugBank.d382.s7.e3
DDI-DrugBank.d382.s8|a|No clinical or drug interaction study was conducted with dolasetron.
DDI-DrugBank.d382.s8	57	66	dolasetron	drug	DDI-DrugBank.d382.s8.e0
DDI-DrugBank.d382.s9|a|Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
DDI-DrugBank.d382.s9	0	14	Corticosteroids	group	DDI-DrugBank.d382.s9.e0
DDI-DrugBank.d382.s9	17	29	Dexamethasone	drug	DDI-DrugBank.d382.s9.e1
DDI-DrugBank.d382.s9	32	41	Aprepitant	drug	DDI-DrugBank.d382.s9.e2
DDI-DrugBank.d382.s9	82	94	dexamethasone	drug	DDI-DrugBank.d382.s9.e3
DDI-DrugBank.d382.s9	141	150	Aprepitant	drug	DDI-DrugBank.d382.s9.e4
DDI-DrugBank.d382.s9	181	193	dexamethasone	drug	DDI-DrugBank.d382.s9.e5
DDI-DrugBank.d382.s9	267	279	dexamethasone	drug	DDI-DrugBank.d382.s9.e6
DDI-DrugBank.d382.s9	false	DDI-DrugBank.d382.s9.e0	DDI-DrugBank.d382.s9.e1
DDI-DrugBank.d382.s9	false	DDI-DrugBank.d382.s9.e0	DDI-DrugBank.d382.s9.e2
DDI-DrugBank.d382.s9	false	DDI-DrugBank.d382.s9.e0	DDI-DrugBank.d382.s9.e3
DDI-DrugBank.d382.s9	false	DDI-DrugBank.d382.s9.e0	DDI-DrugBank.d382.s9.e4
DDI-DrugBank.d382.s9	false	DDI-DrugBank.d382.s9.e0	DDI-DrugBank.d382.s9.e5
DDI-DrugBank.d382.s9	false	DDI-DrugBank.d382.s9.e0	DDI-DrugBank.d382.s9.e6
DDI-DrugBank.d382.s9	false	DDI-DrugBank.d382.s9.e1	DDI-DrugBank.d382.s9.e2
DDI-DrugBank.d382.s9	false	DDI-DrugBank.d382.s9.e1	DDI-DrugBank.d382.s9.e3
DDI-DrugBank.d382.s9	false	DDI-DrugBank.d382.s9.e1	DDI-DrugBank.d382.s9.e4
DDI-DrugBank.d382.s9	false	DDI-DrugBank.d382.s9.e1	DDI-DrugBank.d382.s9.e5
DDI-DrugBank.d382.s10|a|The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.
DDI-DrugBank.d382.s10	9	21	dexamethasone	drug	DDI-DrugBank.d382.s10.e0
DDI-DrugBank.d382.s10	93	102	Aprepitant	drug	DDI-DrugBank.d382.s10.e1
DDI-DrugBank.d382.s10	129	141	dexamethasone	drug	DDI-DrugBank.d382.s10.e2
DDI-DrugBank.d382.s10	194	203	Aprepitant	drug	DDI-DrugBank.d382.s10.e3
DDI-DrugBank.d382.s10	true	DDI-DrugBank.d382.s10.e0	DDI-DrugBank.d382.s10.e1
DDI-DrugBank.d382.s10	false	DDI-DrugBank.d382.s10.e0	DDI-DrugBank.d382.s10.e2
DDI-DrugBank.d382.s10	false	DDI-DrugBank.d382.s10.e0	DDI-DrugBank.d382.s10.e3
DDI-DrugBank.d382.s10	false	DDI-DrugBank.d382.s10.e1	DDI-DrugBank.d382.s10.e2
DDI-DrugBank.d382.s10	false	DDI-DrugBank.d382.s10.e1	DDI-DrugBank.d382.s10.e3
DDI-DrugBank.d382.s10	false	DDI-DrugBank.d382.s10.e2	DDI-DrugBank.d382.s10.e3
DDI-DrugBank.d382.s11|a|The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.
DDI-DrugBank.d382.s11	18	30	dexamethasone	drug	DDI-DrugBank.d382.s11.e0
DDI-DrugBank.d382.s11	70	79	Aprepitant	drug	DDI-DrugBank.d382.s11.e1
DDI-DrugBank.d382.s11	134	146	dexamethasone	drug	DDI-DrugBank.d382.s11.e2
DDI-DrugBank.d382.s11	true	DDI-DrugBank.d382.s11.e0	DDI-DrugBank.d382.s11.e1
DDI-DrugBank.d382.s11	false	DDI-DrugBank.d382.s11.e0	DDI-DrugBank.d382.s11.e2
DDI-DrugBank.d382.s11	false	DDI-DrugBank.d382.s11.e1	DDI-DrugBank.d382.s11.e2
DDI-DrugBank.d382.s12|a|Methylprednisolone
DDI-DrugBank.d382.s12	0	17	Methylprednisolone	drug	DDI-DrugBank.d382.s12.e0
DDI-DrugBank.d382.s13|a|Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
DDI-DrugBank.d382.s13	0	9	Aprepitant	drug	DDI-DrugBank.d382.s13.e0
DDI-DrugBank.d382.s13	107	124	methylprednisolone	drug	DDI-DrugBank.d382.s13.e1
DDI-DrugBank.d382.s13	200	217	methylprednisolone	drug	DDI-DrugBank.d382.s13.e2
DDI-DrugBank.d382.s13	true	DDI-DrugBank.d382.s13.e0	DDI-DrugBank.d382.s13.e1
DDI-DrugBank.d382.s13	false	DDI-DrugBank.d382.s13.e0	DDI-DrugBank.d382.s13.e2
DDI-DrugBank.d382.s13	false	DDI-DrugBank.d382.s13.e1	DDI-DrugBank.d382.s13.e2
DDI-DrugBank.d382.s14|a|The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
DDI-DrugBank.d382.s14	7	24	methylprednisolone	drug	DDI-DrugBank.d382.s14.e0
DDI-DrugBank.d382.s14	84	101	methylprednisolone	drug	DDI-DrugBank.d382.s14.e1
DDI-DrugBank.d382.s14	172	181	Aprepitant	drug	DDI-DrugBank.d382.s14.e2
DDI-DrugBank.d382.s14	207	224	methylprednisolone	drug	DDI-DrugBank.d382.s14.e3
DDI-DrugBank.d382.s14	277	286	Aprepitant	drug	DDI-DrugBank.d382.s14.e4
DDI-DrugBank.d382.s14	false	DDI-DrugBank.d382.s14.e0	DDI-DrugBank.d382.s14.e1
DDI-DrugBank.d382.s14	true	DDI-DrugBank.d382.s14.e0	DDI-DrugBank.d382.s14.e2
DDI-DrugBank.d382.s14	false	DDI-DrugBank.d382.s14.e0	DDI-DrugBank.d382.s14.e3
DDI-DrugBank.d382.s14	false	DDI-DrugBank.d382.s14.e0	DDI-DrugBank.d382.s14.e4
DDI-DrugBank.d382.s14	true	DDI-DrugBank.d382.s14.e1	DDI-DrugBank.d382.s14.e2
DDI-DrugBank.d382.s14	false	DDI-DrugBank.d382.s14.e1	DDI-DrugBank.d382.s14.e3
DDI-DrugBank.d382.s14	false	DDI-DrugBank.d382.s14.e1	DDI-DrugBank.d382.s14.e4
DDI-DrugBank.d382.s14	false	DDI-DrugBank.d382.s14.e2	DDI-DrugBank.d382.s14.e3
DDI-DrugBank.d382.s14	false	DDI-DrugBank.d382.s14.e2	DDI-DrugBank.d382.s14.e4
DDI-DrugBank.d382.s14	false	DDI-DrugBank.d382.s14.e3	DDI-DrugBank.d382.s14.e4
DDI-DrugBank.d382.s15|a|Warfarin: A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy.
DDI-DrugBank.d382.s15	0	7	Warfarin	drug	DDI-DrugBank.d382.s15.e0
DDI-DrugBank.d382.s15	34	43	Aprepitant	drug	DDI-DrugBank.d382.s15.e1
DDI-DrugBank.d382.s15	152	159	warfarin	drug	DDI-DrugBank.d382.s15.e2
DDI-DrugBank.d382.s15	false	DDI-DrugBank.d382.s15.e0	DDI-DrugBank.d382.s15.e1
DDI-DrugBank.d382.s15	false	DDI-DrugBank.d382.s15.e0	DDI-DrugBank.d382.s15.e2
DDI-DrugBank.d382.s15	false	DDI-DrugBank.d382.s15.e1	DDI-DrugBank.d382.s15.e2
DDI-DrugBank.d382.s16|a|Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.
DDI-DrugBank.d382.s16	32	41	Aprepitant	drug	DDI-DrugBank.d382.s16.e0
DDI-DrugBank.d382.s16	64	67	R(+) warfarin	drug	DDI-DrugBank.d382.s16.e1
DDI-DrugBank.d382.s16	77	84	R(+) warfarin	drug	DDI-DrugBank.d382.s16.e1
DDI-DrugBank.d382.s16	72	84	S(-) warfarin	drug	DDI-DrugBank.d382.s16.e2
DDI-DrugBank.d382.s16	135	146	S(-)warfarin	drug	DDI-DrugBank.d382.s16.e3
DDI-DrugBank.d382.s16	335	344	Aprepitant	drug	DDI-DrugBank.d382.s16.e4
DDI-DrugBank.d382.s16	false	DDI-DrugBank.d382.s16.e0	DDI-DrugBank.d382.s16.e1
DDI-DrugBank.d382.s16	false	DDI-DrugBank.d382.s16.e0	DDI-DrugBank.d382.s16.e2
DDI-DrugBank.d382.s16	false	DDI-DrugBank.d382.s16.e0	DDI-DrugBank.d382.s16.e3
DDI-DrugBank.d382.s16	false	DDI-DrugBank.d382.s16.e0	DDI-DrugBank.d382.s16.e4
DDI-DrugBank.d382.s16	false	DDI-DrugBank.d382.s16.e1	DDI-DrugBank.d382.s16.e2
DDI-DrugBank.d382.s16	false	DDI-DrugBank.d382.s16.e1	DDI-DrugBank.d382.s16.e3
DDI-DrugBank.d382.s16	false	DDI-DrugBank.d382.s16.e1	DDI-DrugBank.d382.s16.e4
DDI-DrugBank.d382.s16	false	DDI-DrugBank.d382.s16.e2	DDI-DrugBank.d382.s16.e3
DDI-DrugBank.d382.s16	false	DDI-DrugBank.d382.s16.e2	DDI-DrugBank.d382.s16.e4
DDI-DrugBank.d382.s16	true	DDI-DrugBank.d382.s16.e3	DDI-DrugBank.d382.s16.e4
DDI-DrugBank.d382.s17|a|In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.
DDI-DrugBank.d382.s17	23	30	warfarin	drug	DDI-DrugBank.d382.s17.e0
DDI-DrugBank.d382.s17	193	202	Aprepitant	drug	DDI-DrugBank.d382.s17.e1
DDI-DrugBank.d382.s17	true	DDI-DrugBank.d382.s17.e0	DDI-DrugBank.d382.s17.e1
DDI-DrugBank.d382.s18|a|Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
DDI-DrugBank.d382.s18	0	10	Tolbutamide	drug	DDI-DrugBank.d382.s18.e0
DDI-DrugBank.d382.s18	13	22	Aprepitant	drug	DDI-DrugBank.d382.s18.e1
DDI-DrugBank.d382.s18	107	117	tolbutamide	drug	DDI-DrugBank.d382.s18.e2
DDI-DrugBank.d382.s18	212	222	tolbutamide	drug	DDI-DrugBank.d382.s18.e3
DDI-DrugBank.d382.s18	308	317	Aprepitant	drug	DDI-DrugBank.d382.s18.e4
DDI-DrugBank.d382.s18	false	DDI-DrugBank.d382.s18.e0	DDI-DrugBank.d382.s18.e1
DDI-DrugBank.d382.s18	false	DDI-DrugBank.d382.s18.e0	DDI-DrugBank.d382.s18.e2
DDI-DrugBank.d382.s18	false	DDI-DrugBank.d382.s18.e0	DDI-DrugBank.d382.s18.e3
DDI-DrugBank.d382.s18	false	DDI-DrugBank.d382.s18.e0	DDI-DrugBank.d382.s18.e4
DDI-DrugBank.d382.s18	false	DDI-DrugBank.d382.s18.e1	DDI-DrugBank.d382.s18.e2
DDI-DrugBank.d382.s18	false	DDI-DrugBank.d382.s18.e1	DDI-DrugBank.d382.s18.e3
DDI-DrugBank.d382.s18	false	DDI-DrugBank.d382.s18.e1	DDI-DrugBank.d382.s18.e4
DDI-DrugBank.d382.s18	false	DDI-DrugBank.d382.s18.e2	DDI-DrugBank.d382.s18.e3
DDI-DrugBank.d382.s18	false	DDI-DrugBank.d382.s18.e2	DDI-DrugBank.d382.s18.e4
DDI-DrugBank.d382.s18	true	DDI-DrugBank.d382.s18.e3	DDI-DrugBank.d382.s18.e4
DDI-DrugBank.d382.s19|a|Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
DDI-DrugBank.d382.s19	5	18	contraceptives	group	DDI-DrugBank.d382.s19.e0
DDI-DrugBank.d382.s19	21	30	Aprepitant	drug	DDI-DrugBank.d382.s19.e1
DDI-DrugBank.d382.s19	100	112	contraceptive	group	DDI-DrugBank.d382.s19.e2
DDI-DrugBank.d382.s19	135	151	ethinyl estradiol	drug	DDI-DrugBank.d382.s19.e3
DDI-DrugBank.d382.s19	165	177	norethindrone	drug	DDI-DrugBank.d382.s19.e4
DDI-DrugBank.d382.s19	201	217	ethinyl estradiol	drug	DDI-DrugBank.d382.s19.e5
DDI-DrugBank.d382.s19	252	264	norethindrone	drug	DDI-DrugBank.d382.s19.e6
DDI-DrugBank.d382.s19	false	DDI-DrugBank.d382.s19.e0	DDI-DrugBank.d382.s19.e1
DDI-DrugBank.d382.s19	false	DDI-DrugBank.d382.s19.e0	DDI-DrugBank.d382.s19.e2
DDI-DrugBank.d382.s19	false	DDI-DrugBank.d382.s19.e0	DDI-DrugBank.d382.s19.e3
DDI-DrugBank.d382.s19	false	DDI-DrugBank.d382.s19.e0	DDI-DrugBank.d382.s19.e4
DDI-DrugBank.d382.s19	false	DDI-DrugBank.d382.s19.e0	DDI-DrugBank.d382.s19.e5
DDI-DrugBank.d382.s19	false	DDI-DrugBank.d382.s19.e0	DDI-DrugBank.d382.s19.e6
DDI-DrugBank.d382.s19	false	DDI-DrugBank.d382.s19.e1	DDI-DrugBank.d382.s19.e2
DDI-DrugBank.d382.s19	true	DDI-DrugBank.d382.s19.e1	DDI-DrugBank.d382.s19.e3
DDI-DrugBank.d382.s19	true	DDI-DrugBank.d382.s19.e1	DDI-DrugBank.d382.s19.e4
DDI-DrugBank.d382.s19	false	DDI-DrugBank.d382.s19.e1	DDI-DrugBank.d382.s19.e5
DDI-DrugBank.d382.s20|a|therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.
DDI-DrugBank.d382.s20	32	45	contraceptives	group	DDI-DrugBank.d382.s20.e0
DDI-DrugBank.d382.s20	72	81	Aprepitant	drug	DDI-DrugBank.d382.s20.e1
DDI-DrugBank.d382.s20	true	DDI-DrugBank.d382.s20.e0	DDI-DrugBank.d382.s20.e1
DDI-DrugBank.d382.s21|a|Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.
DDI-DrugBank.d382.s21	28	37	Aprepitant	drug	DDI-DrugBank.d382.s21.e0
DDI-DrugBank.d382.s21	69	82	contraceptives	group	DDI-DrugBank.d382.s21.e1
DDI-DrugBank.d382.s21	true	DDI-DrugBank.d382.s21.e0	DDI-DrugBank.d382.s21.e1
DDI-DrugBank.d382.s22|a|Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
DDI-DrugBank.d382.s22	0	8	Midazolam	drug	DDI-DrugBank.d382.s22.e0
DDI-DrugBank.d382.s22	11	20	Aprepitant	drug	DDI-DrugBank.d382.s22.e1
DDI-DrugBank.d382.s22	43	51	midazolam	drug	DDI-DrugBank.d382.s22.e2
DDI-DrugBank.d382.s22	155	163	midazolam	drug	DDI-DrugBank.d382.s22.e3
DDI-DrugBank.d382.s22	224	233	Aprepitant	drug	DDI-DrugBank.d382.s22.e4
DDI-DrugBank.d382.s22	false	DDI-DrugBank.d382.s22.e0	DDI-DrugBank.d382.s22.e1
DDI-DrugBank.d382.s22	false	DDI-DrugBank.d382.s22.e0	DDI-DrugBank.d382.s22.e2
DDI-DrugBank.d382.s22	false	DDI-DrugBank.d382.s22.e0	DDI-DrugBank.d382.s22.e3
DDI-DrugBank.d382.s22	false	DDI-DrugBank.d382.s22.e0	DDI-DrugBank.d382.s22.e4
DDI-DrugBank.d382.s22	true	DDI-DrugBank.d382.s22.e1	DDI-DrugBank.d382.s22.e2
DDI-DrugBank.d382.s22	false	DDI-DrugBank.d382.s22.e1	DDI-DrugBank.d382.s22.e3
DDI-DrugBank.d382.s22	false	DDI-DrugBank.d382.s22.e1	DDI-DrugBank.d382.s22.e4
DDI-DrugBank.d382.s22	false	DDI-DrugBank.d382.s22.e2	DDI-DrugBank.d382.s22.e3
DDI-DrugBank.d382.s22	false	DDI-DrugBank.d382.s22.e2	DDI-DrugBank.d382.s22.e4
DDI-DrugBank.d382.s22	false	DDI-DrugBank.d382.s22.e3	DDI-DrugBank.d382.s22.e4
DDI-DrugBank.d382.s23|a|The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
DDI-DrugBank.d382.s23	60	68	midazolam	drug	DDI-DrugBank.d382.s23.e0
DDI-DrugBank.d382.s23	79	93	benzodiazepines	group	DDI-DrugBank.d382.s23.e1
DDI-DrugBank.d382.s23	119	128	alprazolam	drug	DDI-DrugBank.d382.s23.e2
DDI-DrugBank.d382.s23	131	139	triazolam	drug	DDI-DrugBank.d382.s23.e3
DDI-DrugBank.d382.s23	202	211	Aprepitant	drug	DDI-DrugBank.d382.s23.e4
DDI-DrugBank.d382.s23	false	DDI-DrugBank.d382.s23.e0	DDI-DrugBank.d382.s23.e1
DDI-DrugBank.d382.s23	false	DDI-DrugBank.d382.s23.e0	DDI-DrugBank.d382.s23.e2
DDI-DrugBank.d382.s23	false	DDI-DrugBank.d382.s23.e0	DDI-DrugBank.d382.s23.e3
DDI-DrugBank.d382.s23	true	DDI-DrugBank.d382.s23.e0	DDI-DrugBank.d382.s23.e4
DDI-DrugBank.d382.s23	false	DDI-DrugBank.d382.s23.e1	DDI-DrugBank.d382.s23.e2
DDI-DrugBank.d382.s23	false	DDI-DrugBank.d382.s23.e1	DDI-DrugBank.d382.s23.e3
DDI-DrugBank.d382.s23	true	DDI-DrugBank.d382.s23.e1	DDI-DrugBank.d382.s23.e4
DDI-DrugBank.d382.s23	false	DDI-DrugBank.d382.s23.e2	DDI-DrugBank.d382.s23.e3
DDI-DrugBank.d382.s23	true	DDI-DrugBank.d382.s23.e2	DDI-DrugBank.d382.s23.e4
DDI-DrugBank.d382.s23	true	DDI-DrugBank.d382.s23.e3	DDI-DrugBank.d382.s23.e4
DDI-DrugBank.d382.s24|a|In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.
DDI-DrugBank.d382.s24	52	60	midazolam	drug	DDI-DrugBank.d382.s24.e0
DDI-DrugBank.d382.s24	63	72	Aprepitant	drug	DDI-DrugBank.d382.s24.e1
DDI-DrugBank.d382.s24	138	146	midazolam	drug	DDI-DrugBank.d382.s24.e2
DDI-DrugBank.d382.s24	218	227	Aprepitant	drug	DDI-DrugBank.d382.s24.e3
DDI-DrugBank.d382.s24	false	DDI-DrugBank.d382.s24.e0	DDI-DrugBank.d382.s24.e1
DDI-DrugBank.d382.s24	false	DDI-DrugBank.d382.s24.e0	DDI-DrugBank.d382.s24.e2
DDI-DrugBank.d382.s24	false	DDI-DrugBank.d382.s24.e0	DDI-DrugBank.d382.s24.e3
DDI-DrugBank.d382.s24	false	DDI-DrugBank.d382.s24.e1	DDI-DrugBank.d382.s24.e2
DDI-DrugBank.d382.s24	false	DDI-DrugBank.d382.s24.e1	DDI-DrugBank.d382.s24.e3
DDI-DrugBank.d382.s24	false	DDI-DrugBank.d382.s24.e2	DDI-DrugBank.d382.s24.e3
DDI-DrugBank.d382.s25|a|Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
DDI-DrugBank.d382.s25	0	9	Aprepitant	drug	DDI-DrugBank.d382.s25.e0
DDI-DrugBank.d382.s25	32	40	midazolam	drug	DDI-DrugBank.d382.s25.e1
DDI-DrugBank.d382.s25	83	91	midazolam	drug	DDI-DrugBank.d382.s25.e2
DDI-DrugBank.d382.s25	135	144	Aprepitant	drug	DDI-DrugBank.d382.s25.e3
DDI-DrugBank.d382.s25	true	DDI-DrugBank.d382.s25.e0	DDI-DrugBank.d382.s25.e1
DDI-DrugBank.d382.s25	true	DDI-DrugBank.d382.s25.e0	DDI-DrugBank.d382.s25.e2
DDI-DrugBank.d382.s25	false	DDI-DrugBank.d382.s25.e0	DDI-DrugBank.d382.s25.e3
DDI-DrugBank.d382.s25	false	DDI-DrugBank.d382.s25.e1	DDI-DrugBank.d382.s25.e2
DDI-DrugBank.d382.s25	false	DDI-DrugBank.d382.s25.e1	DDI-DrugBank.d382.s25.e3
DDI-DrugBank.d382.s25	false	DDI-DrugBank.d382.s25.e2	DDI-DrugBank.d382.s25.e3
DDI-DrugBank.d382.s26|a|These effects were not considered clinically important.
DDI-DrugBank.d382.s27|a|The AUC of midazolam on Day 15 was similar to that observed at baseline.
DDI-DrugBank.d382.s27	11	19	midazolam	drug	DDI-DrugBank.d382.s27.e0
DDI-DrugBank.d382.s28|a|Effect of other agents on the pharmacokinefics of aprepitant
DDI-DrugBank.d382.s28	50	59	aprepitant	drug	DDI-DrugBank.d382.s28.e0
DDI-DrugBank.d382.s29|a|Aprepitant is a substrate for CYP3A4;
DDI-DrugBank.d382.s29	0	9	Aprepitant	drug	DDI-DrugBank.d382.s29.e0
DDI-DrugBank.d382.s30|a|therefore, coadministration of Aprepitant with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant.
DDI-DrugBank.d382.s30	31	40	Aprepitant	drug	DDI-DrugBank.d382.s30.e0
DDI-DrugBank.d382.s30	131	140	aprepitant	drug	DDI-DrugBank.d382.s30.e1
DDI-DrugBank.d382.s30	false	DDI-DrugBank.d382.s30.e0	DDI-DrugBank.d382.s30.e1
DDI-DrugBank.d382.s31|a|Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s31	44	53	Aprepitant	drug	DDI-DrugBank.d382.s31.e0
DDI-DrugBank.d382.s31	92	103	ketoconazole	drug	DDI-DrugBank.d382.s31.e1
DDI-DrugBank.d382.s31	106	117	itraconazole	drug	DDI-DrugBank.d382.s31.e2
DDI-DrugBank.d382.s31	120	129	nefazodone	drug	DDI-DrugBank.d382.s31.e3
DDI-DrugBank.d382.s31	132	145	troleandomycin	drug	DDI-DrugBank.d382.s31.e4
DDI-DrugBank.d382.s31	148	161	clarithromycin	drug	DDI-DrugBank.d382.s31.e5
DDI-DrugBank.d382.s31	164	172	ritonavir	drug	DDI-DrugBank.d382.s31.e6
DDI-DrugBank.d382.s31	175	184	nelfinavir	drug	DDI-DrugBank.d382.s31.e7
DDI-DrugBank.d382.s31	true	DDI-DrugBank.d382.s31.e0	DDI-DrugBank.d382.s31.e1
DDI-DrugBank.d382.s31	true	DDI-DrugBank.d382.s31.e0	DDI-DrugBank.d382.s31.e2
DDI-DrugBank.d382.s31	true	DDI-DrugBank.d382.s31.e0	DDI-DrugBank.d382.s31.e3
DDI-DrugBank.d382.s31	true	DDI-DrugBank.d382.s31.e0	DDI-DrugBank.d382.s31.e4
DDI-DrugBank.d382.s31	true	DDI-DrugBank.d382.s31.e0	DDI-DrugBank.d382.s31.e5
DDI-DrugBank.d382.s31	true	DDI-DrugBank.d382.s31.e0	DDI-DrugBank.d382.s31.e6
DDI-DrugBank.d382.s31	true	DDI-DrugBank.d382.s31.e0	DDI-DrugBank.d382.s31.e7
DDI-DrugBank.d382.s31	false	DDI-DrugBank.d382.s31.e1	DDI-DrugBank.d382.s31.e2
DDI-DrugBank.d382.s31	false	DDI-DrugBank.d382.s31.e1	DDI-DrugBank.d382.s31.e3
DDI-DrugBank.d382.s31	false	DDI-DrugBank.d382.s31.e1	DDI-DrugBank.d382.s31.e4
DDI-DrugBank.d382.s32|a|Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.
DDI-DrugBank.d382.s32	42	50	diltiazem	drug	DDI-DrugBank.d382.s32.e0
DDI-DrugBank.d382.s32	107	116	aprepitant	drug	DDI-DrugBank.d382.s32.e1
DDI-DrugBank.d382.s32	true	DDI-DrugBank.d382.s32.e0	DDI-DrugBank.d382.s32.e1
DDI-DrugBank.d382.s33|a|Aprepitant is a substrate for CYP3A4;
DDI-DrugBank.d382.s33	0	9	Aprepitant	drug	DDI-DrugBank.d382.s33.e0
DDI-DrugBank.d382.s34|a|therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
DDI-DrugBank.d382.s34	31	40	Aprepitant	drug	DDI-DrugBank.d382.s34.e0
DDI-DrugBank.d382.s34	97	104	rifampin	drug	DDI-DrugBank.d382.s34.e1
DDI-DrugBank.d382.s34	107	119	carbamazepine	drug	DDI-DrugBank.d382.s34.e2
DDI-DrugBank.d382.s34	122	130	phenytoin	drug	DDI-DrugBank.d382.s34.e3
DDI-DrugBank.d382.s34	180	189	aprepitant	drug	DDI-DrugBank.d382.s34.e4
DDI-DrugBank.d382.s34	232	241	Aprepitant	drug	DDI-DrugBank.d382.s34.e5
DDI-DrugBank.d382.s34	true	DDI-DrugBank.d382.s34.e0	DDI-DrugBank.d382.s34.e1
DDI-DrugBank.d382.s34	false	DDI-DrugBank.d382.s34.e0	DDI-DrugBank.d382.s34.e2
DDI-DrugBank.d382.s34	true	DDI-DrugBank.d382.s34.e0	DDI-DrugBank.d382.s34.e3
DDI-DrugBank.d382.s34	true	DDI-DrugBank.d382.s34.e0	DDI-DrugBank.d382.s34.e4
DDI-DrugBank.d382.s34	false	DDI-DrugBank.d382.s34.e0	DDI-DrugBank.d382.s34.e5
DDI-DrugBank.d382.s34	false	DDI-DrugBank.d382.s34.e1	DDI-DrugBank.d382.s34.e2
DDI-DrugBank.d382.s34	false	DDI-DrugBank.d382.s34.e1	DDI-DrugBank.d382.s34.e3
DDI-DrugBank.d382.s34	false	DDI-DrugBank.d382.s34.e1	DDI-DrugBank.d382.s34.e4
DDI-DrugBank.d382.s34	false	DDI-DrugBank.d382.s34.e1	DDI-DrugBank.d382.s34.e5
DDI-DrugBank.d382.s34	false	DDI-DrugBank.d382.s34.e2	DDI-DrugBank.d382.s34.e3
DDI-DrugBank.d382.s35|a|Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a
DDI-DrugBank.d382.s35	0	11	Ketoconazole	drug	DDI-DrugBank.d382.s35.e0
DDI-DrugBank.d382.s35	43	52	Aprepitant	drug	DDI-DrugBank.d382.s35.e1
DDI-DrugBank.d382.s35	false	DDI-DrugBank.d382.s35.e0	DDI-DrugBank.d382.s35.e1
DDI-DrugBank.d382.s36|a|Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
DDI-DrugBank.d382.s36	0	11	Ketoconazole	drug	DDI-DrugBank.d382.s36.e0
DDI-DrugBank.d382.s36	43	52	Aprepitant	drug	DDI-DrugBank.d382.s36.e1
DDI-DrugBank.d382.s36	116	127	ketoconazole	drug	DDI-DrugBank.d382.s36.e2
DDI-DrugBank.d382.s36	168	177	aprepitant	drug	DDI-DrugBank.d382.s36.e3
DDI-DrugBank.d382.s36	245	254	aprepitant	drug	DDI-DrugBank.d382.s36.e4
DDI-DrugBank.d382.s36	false	DDI-DrugBank.d382.s36.e0	DDI-DrugBank.d382.s36.e1
DDI-DrugBank.d382.s36	false	DDI-DrugBank.d382.s36.e0	DDI-DrugBank.d382.s36.e2
DDI-DrugBank.d382.s36	false	DDI-DrugBank.d382.s36.e0	DDI-DrugBank.d382.s36.e3
DDI-DrugBank.d382.s36	false	DDI-DrugBank.d382.s36.e0	DDI-DrugBank.d382.s36.e4
DDI-DrugBank.d382.s36	true	DDI-DrugBank.d382.s36.e1	DDI-DrugBank.d382.s36.e2
DDI-DrugBank.d382.s36	false	DDI-DrugBank.d382.s36.e1	DDI-DrugBank.d382.s36.e3
DDI-DrugBank.d382.s36	false	DDI-DrugBank.d382.s36.e1	DDI-DrugBank.d382.s36.e4
DDI-DrugBank.d382.s36	false	DDI-DrugBank.d382.s36.e2	DDI-DrugBank.d382.s36.e3
DDI-DrugBank.d382.s36	false	DDI-DrugBank.d382.s36.e2	DDI-DrugBank.d382.s36.e4
DDI-DrugBank.d382.s36	false	DDI-DrugBank.d382.s36.e3	DDI-DrugBank.d382.s36.e4
DDI-DrugBank.d382.s37|a|Concomitant administration of Aprepitant with strong CYP3A4 inhibitors should be approached cautiously.
DDI-DrugBank.d382.s37	30	39	Aprepitant	drug	DDI-DrugBank.d382.s37.e0
DDI-DrugBank.d382.s38|a|Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.
DDI-DrugBank.d382.s38	0	7	Rifampin	drug	DDI-DrugBank.d382.s38.e0
DDI-DrugBank.d382.s38	39	48	Aprepitant	drug	DDI-DrugBank.d382.s38.e1
DDI-DrugBank.d382.s38	112	119	rifampin	drug	DDI-DrugBank.d382.s38.e2
DDI-DrugBank.d382.s38	158	167	aprepitant	drug	DDI-DrugBank.d382.s38.e3
DDI-DrugBank.d382.s38	false	DDI-DrugBank.d382.s38.e0	DDI-DrugBank.d382.s38.e1
DDI-DrugBank.d382.s38	false	DDI-DrugBank.d382.s38.e0	DDI-DrugBank.d382.s38.e2
DDI-DrugBank.d382.s38	false	DDI-DrugBank.d382.s38.e0	DDI-DrugBank.d382.s38.e3
DDI-DrugBank.d382.s38	true	DDI-DrugBank.d382.s38.e1	DDI-DrugBank.d382.s38.e2
DDI-DrugBank.d382.s38	false	DDI-DrugBank.d382.s38.e1	DDI-DrugBank.d382.s38.e3
DDI-DrugBank.d382.s38	false	DDI-DrugBank.d382.s38.e2	DDI-DrugBank.d382.s38.e3
DDI-DrugBank.d382.s39|a|Coadministration of Aprepitant with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of Aprepitant.
DDI-DrugBank.d382.s39	20	29	Aprepitant	drug	DDI-DrugBank.d382.s39.e0
DDI-DrugBank.d382.s39	140	149	Aprepitant	drug	DDI-DrugBank.d382.s39.e1
DDI-DrugBank.d382.s39	false	DDI-DrugBank.d382.s39.e0	DDI-DrugBank.d382.s39.e1
DDI-DrugBank.d382.s40|a|Additional interactions
DDI-DrugBank.d382.s41|a|Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.
DDI-DrugBank.d382.s41	0	8	Diltiazem	drug	DDI-DrugBank.d382.s41.e0
DDI-DrugBank.d382.s41	77	86	aprepitant	drug	DDI-DrugBank.d382.s41.e1
DDI-DrugBank.d382.s41	178	186	diltiazem	drug	DDI-DrugBank.d382.s41.e2
DDI-DrugBank.d382.s41	254	263	aprepitant	drug	DDI-DrugBank.d382.s41.e3
DDI-DrugBank.d382.s41	309	317	diltiazem	drug	DDI-DrugBank.d382.s41.e4
DDI-DrugBank.d382.s41	false	DDI-DrugBank.d382.s41.e0	DDI-DrugBank.d382.s41.e1
DDI-DrugBank.d382.s41	false	DDI-DrugBank.d382.s41.e0	DDI-DrugBank.d382.s41.e2
DDI-DrugBank.d382.s41	false	DDI-DrugBank.d382.s41.e0	DDI-DrugBank.d382.s41.e3
DDI-DrugBank.d382.s41	false	DDI-DrugBank.d382.s41.e0	DDI-DrugBank.d382.s41.e4
DDI-DrugBank.d382.s41	true	DDI-DrugBank.d382.s41.e1	DDI-DrugBank.d382.s41.e2
DDI-DrugBank.d382.s41	false	DDI-DrugBank.d382.s41.e1	DDI-DrugBank.d382.s41.e3
DDI-DrugBank.d382.s41	false	DDI-DrugBank.d382.s41.e1	DDI-DrugBank.d382.s41.e4
DDI-DrugBank.d382.s41	false	DDI-DrugBank.d382.s41.e2	DDI-DrugBank.d382.s41.e3
DDI-DrugBank.d382.s41	false	DDI-DrugBank.d382.s41.e2	DDI-DrugBank.d382.s41.e4
DDI-DrugBank.d382.s41	false	DDI-DrugBank.d382.s41.e3	DDI-DrugBank.d382.s41.e4
DDI-DrugBank.d382.s42|a|These pharmacokinetic effects did not result in clinically meaningful changes in ECG, heart rate or blood pressure beyond those changes induced by diltiazem alone.
DDI-DrugBank.d382.s42	147	155	diltiazem	drug	DDI-DrugBank.d382.s42.e0
DDI-DrugBank.d382.s43|a|Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.
DDI-DrugBank.d382.s43	0	9	Paroxetine	drug	DDI-DrugBank.d382.s43.e0
DDI-DrugBank.d382.s43	52	61	aprepitant	drug	DDI-DrugBank.d382.s43.e1
DDI-DrugBank.d382.s43	151	160	paroxetine	drug	DDI-DrugBank.d382.s43.e2
DDI-DrugBank.d382.s43	270	279	aprepitant	drug	DDI-DrugBank.d382.s43.e3
DDI-DrugBank.d382.s43	285	294	paroxetine	drug	DDI-DrugBank.d382.s43.e4
DDI-DrugBank.d382.s43	false	DDI-DrugBank.d382.s43.e0	DDI-DrugBank.d382.s43.e1
DDI-DrugBank.d382.s43	false	DDI-DrugBank.d382.s43.e0	DDI-DrugBank.d382.s43.e2
DDI-DrugBank.d382.s43	false	DDI-DrugBank.d382.s43.e0	DDI-DrugBank.d382.s43.e3
DDI-DrugBank.d382.s43	false	DDI-DrugBank.d382.s43.e0	DDI-DrugBank.d382.s43.e4
DDI-DrugBank.d382.s43	true	DDI-DrugBank.d382.s43.e1	DDI-DrugBank.d382.s43.e2
DDI-DrugBank.d382.s43	false	DDI-DrugBank.d382.s43.e1	DDI-DrugBank.d382.s43.e3
DDI-DrugBank.d382.s43	false	DDI-DrugBank.d382.s43.e1	DDI-DrugBank.d382.s43.e4
DDI-DrugBank.d382.s43	false	DDI-DrugBank.d382.s43.e2	DDI-DrugBank.d382.s43.e3
DDI-DrugBank.d382.s43	false	DDI-DrugBank.d382.s43.e2	DDI-DrugBank.d382.s43.e4
DDI-DrugBank.d382.s43	false	DDI-DrugBank.d382.s43.e3	DDI-DrugBank.d382.s43.e4
DDI-DrugBank.d253.s0|a|Beta-adrenergic blocking agents: concurrent use may blunt the response to arbutamine.
DDI-DrugBank.d253.s0	0	30	Beta-adrenergic blocking agents	group	DDI-DrugBank.d253.s0.e0
DDI-DrugBank.d253.s0	74	83	arbutamine	drug	DDI-DrugBank.d253.s0.e1
DDI-DrugBank.d253.s0	false	DDI-DrugBank.d253.s0.e0	DDI-DrugBank.d253.s0.e1
DDI-DrugBank.d253.s1|a|Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine-mediated stress test.
DDI-DrugBank.d253.s1	0	30	Beta-adrenergic blocking agents	group	DDI-DrugBank.d253.s1.e0
DDI-DrugBank.d253.s1	91	100	arbutamine	drug	DDI-DrugBank.d253.s1.e1
DDI-DrugBank.d253.s1	true	DDI-DrugBank.d253.s1.e0	DDI-DrugBank.d253.s1.e1
DDI-DrugBank.d253.s2|a|Antiarrhythmic agents, class I (such as flecainide, lidocaine, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.
DDI-DrugBank.d253.s2	0	29	Antiarrhythmic agents, class I	drug	DDI-DrugBank.d253.s2.e0
DDI-DrugBank.d253.s2	40	49	flecainide	drug	DDI-DrugBank.d253.s2.e1
DDI-DrugBank.d253.s2	52	60	lidocaine	drug	DDI-DrugBank.d253.s2.e2
DDI-DrugBank.d253.s2	66	74	quinidine	drug	DDI-DrugBank.d253.s2.e3
DDI-DrugBank.d253.s2	98	107	arbutamine	drug	DDI-DrugBank.d253.s2.e4
DDI-DrugBank.d253.s2	false	DDI-DrugBank.d253.s2.e0	DDI-DrugBank.d253.s2.e1
DDI-DrugBank.d253.s2	false	DDI-DrugBank.d253.s2.e0	DDI-DrugBank.d253.s2.e2
DDI-DrugBank.d253.s2	false	DDI-DrugBank.d253.s2.e0	DDI-DrugBank.d253.s2.e3
DDI-DrugBank.d253.s2	false	DDI-DrugBank.d253.s2.e0	DDI-DrugBank.d253.s2.e4
DDI-DrugBank.d253.s2	false	DDI-DrugBank.d253.s2.e1	DDI-DrugBank.d253.s2.e2
DDI-DrugBank.d253.s2	false	DDI-DrugBank.d253.s2.e1	DDI-DrugBank.d253.s2.e3
DDI-DrugBank.d253.s2	false	DDI-DrugBank.d253.s2.e1	DDI-DrugBank.d253.s2.e4
DDI-DrugBank.d253.s2	false	DDI-DrugBank.d253.s2.e2	DDI-DrugBank.d253.s2.e3
DDI-DrugBank.d253.s2	false	DDI-DrugBank.d253.s2.e2	DDI-DrugBank.d253.s2.e4
DDI-DrugBank.d253.s2	false	DDI-DrugBank.d253.s2.e3	DDI-DrugBank.d253.s2.e4
DDI-DrugBank.d253.s3|a|Antidepressants (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
DDI-DrugBank.d253.s3	0	14	Antidepressants	group	DDI-DrugBank.d253.s3.e0
DDI-DrugBank.d253.s3	17	25	tricyclic	group	DDI-DrugBank.d253.s3.e1
DDI-DrugBank.d253.s3	29	36	atropine	drug	DDI-DrugBank.d253.s3.e2
DDI-DrugBank.d253.s3	47	68	anticholinergic agents	group	DDI-DrugBank.d253.s3.e3
DDI-DrugBank.d253.s3	74	93	digitalis glycosides	group	DDI-DrugBank.d253.s3.e4
DDI-DrugBank.d253.s3	116	125	arbutamine	drug	DDI-DrugBank.d253.s3.e5
DDI-DrugBank.d253.s3	false	DDI-DrugBank.d253.s3.e0	DDI-DrugBank.d253.s3.e1
DDI-DrugBank.d253.s3	false	DDI-DrugBank.d253.s3.e0	DDI-DrugBank.d253.s3.e2
DDI-DrugBank.d253.s3	false	DDI-DrugBank.d253.s3.e0	DDI-DrugBank.d253.s3.e3
DDI-DrugBank.d253.s3	false	DDI-DrugBank.d253.s3.e0	DDI-DrugBank.d253.s3.e4
DDI-DrugBank.d253.s3	false	DDI-DrugBank.d253.s3.e0	DDI-DrugBank.d253.s3.e5
DDI-DrugBank.d253.s3	false	DDI-DrugBank.d253.s3.e1	DDI-DrugBank.d253.s3.e2
DDI-DrugBank.d253.s3	false	DDI-DrugBank.d253.s3.e1	DDI-DrugBank.d253.s3.e3
DDI-DrugBank.d253.s3	false	DDI-DrugBank.d253.s3.e1	DDI-DrugBank.d253.s3.e4
DDI-DrugBank.d253.s3	false	DDI-DrugBank.d253.s3.e1	DDI-DrugBank.d253.s3.e5
DDI-DrugBank.d253.s3	false	DDI-DrugBank.d253.s3.e2	DDI-DrugBank.d253.s3.e3
DDI-DrugBank.d105.s0|a|Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
DDI-DrugBank.d105.s0	0	13	Anticoagulants	group	DDI-DrugBank.d105.s0.e0
DDI-DrugBank.d105.s0	75	105	platelet aggregation inhibitors	group	DDI-DrugBank.d105.s0.e1
DDI-DrugBank.d105.s0	115	150	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d105.s0.e2
DDI-DrugBank.d105.s0	153	158	NSAIDs	group	DDI-DrugBank.d105.s0.e3
DDI-DrugBank.d105.s0	166	172	aspirin	brand	DDI-DrugBank.d105.s0.e4
DDI-DrugBank.d105.s0	245	253	ardeparin	drug	DDI-DrugBank.d105.s0.e5
DDI-DrugBank.d105.s0	false	DDI-DrugBank.d105.s0.e0	DDI-DrugBank.d105.s0.e1
DDI-DrugBank.d105.s0	false	DDI-DrugBank.d105.s0.e0	DDI-DrugBank.d105.s0.e2
DDI-DrugBank.d105.s0	false	DDI-DrugBank.d105.s0.e0	DDI-DrugBank.d105.s0.e3
DDI-DrugBank.d105.s0	false	DDI-DrugBank.d105.s0.e0	DDI-DrugBank.d105.s0.e4
DDI-DrugBank.d105.s0	true	DDI-DrugBank.d105.s0.e0	DDI-DrugBank.d105.s0.e5
DDI-DrugBank.d105.s0	false	DDI-DrugBank.d105.s0.e1	DDI-DrugBank.d105.s0.e2
DDI-DrugBank.d105.s0	false	DDI-DrugBank.d105.s0.e1	DDI-DrugBank.d105.s0.e3
DDI-DrugBank.d105.s0	false	DDI-DrugBank.d105.s0.e1	DDI-DrugBank.d105.s0.e4
DDI-DrugBank.d105.s0	true	DDI-DrugBank.d105.s0.e1	DDI-DrugBank.d105.s0.e5
DDI-DrugBank.d105.s0	false	DDI-DrugBank.d105.s0.e2	DDI-DrugBank.d105.s0.e3
DDI-DrugBank.d284.s0|a|If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.
DDI-DrugBank.d284.s0	14	29	adrenergic drugs	group	DDI-DrugBank.d284.s0.e0
DDI-DrugBank.d284.s0	166	172	BROVANA	brand	DDI-DrugBank.d284.s0.e1
DDI-DrugBank.d284.s0	true	DDI-DrugBank.d284.s0.e0	DDI-DrugBank.d284.s0.e1
DDI-DrugBank.d284.s1|a|When paroxetine, a potent inhibitor of CYP2D6, was co-administered with BROVANA at steady-state, exposure to either drug was not altered.
DDI-DrugBank.d284.s1	5	14	paroxetine	drug	DDI-DrugBank.d284.s1.e0
DDI-DrugBank.d284.s1	72	78	BROVANA	brand	DDI-DrugBank.d284.s1.e1
DDI-DrugBank.d284.s1	false	DDI-DrugBank.d284.s1.e0	DDI-DrugBank.d284.s1.e1
DDI-DrugBank.d284.s2|a|Dosage adjustments of BROVANA are not necessary when the drug is given concomitantly with potent CYP2D6 inhibitors.
DDI-DrugBank.d284.s2	22	28	BROVANA	brand	DDI-DrugBank.d284.s2.e0
DDI-DrugBank.d284.s3|a|Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
DDI-DrugBank.d284.s3	27	41	methylxanthines	group	DDI-DrugBank.d284.s3.e0
DDI-DrugBank.d284.s3	44	56	aminophylline	drug	DDI-DrugBank.d284.s3.e1
DDI-DrugBank.d284.s3	59	70	theophylline	drug	DDI-DrugBank.d284.s3.e2
DDI-DrugBank.d284.s3	74	81	steroids	group	DDI-DrugBank.d284.s3.e3
DDI-DrugBank.d284.s3	87	95	diuretics	group	DDI-DrugBank.d284.s3.e4
DDI-DrugBank.d284.s3	138	156	adrenergic agonists	group	DDI-DrugBank.d284.s3.e5
DDI-DrugBank.d284.s3	false	DDI-DrugBank.d284.s3.e0	DDI-DrugBank.d284.s3.e1
DDI-DrugBank.d284.s3	false	DDI-DrugBank.d284.s3.e0	DDI-DrugBank.d284.s3.e2
DDI-DrugBank.d284.s3	false	DDI-DrugBank.d284.s3.e0	DDI-DrugBank.d284.s3.e3
DDI-DrugBank.d284.s3	false	DDI-DrugBank.d284.s3.e0	DDI-DrugBank.d284.s3.e4
DDI-DrugBank.d284.s3	true	DDI-DrugBank.d284.s3.e0	DDI-DrugBank.d284.s3.e5
DDI-DrugBank.d284.s3	false	DDI-DrugBank.d284.s3.e1	DDI-DrugBank.d284.s3.e2
DDI-DrugBank.d284.s3	false	DDI-DrugBank.d284.s3.e1	DDI-DrugBank.d284.s3.e3
DDI-DrugBank.d284.s3	false	DDI-DrugBank.d284.s3.e1	DDI-DrugBank.d284.s3.e4
DDI-DrugBank.d284.s3	true	DDI-DrugBank.d284.s3.e1	DDI-DrugBank.d284.s3.e5
DDI-DrugBank.d284.s3	false	DDI-DrugBank.d284.s3.e2	DDI-DrugBank.d284.s3.e3
DDI-DrugBank.d284.s4|a|The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
DDI-DrugBank.d284.s4	78	108	non-potassium sparing diuretics	group	DDI-DrugBank.d284.s4.e0
DDI-DrugBank.d284.s4	119	122	loop diuretics	group	DDI-DrugBank.d284.s4.e1
DDI-DrugBank.d284.s4	136	144	loop diuretics	group	DDI-DrugBank.d284.s4.e1
DDI-DrugBank.d284.s4	127	144	thiazide diuretics	group	DDI-DrugBank.d284.s4.e2
DDI-DrugBank.d284.s4	174	186	beta-agonists	group	DDI-DrugBank.d284.s4.e3
DDI-DrugBank.d284.s4	233	244	beta-agonist	group	DDI-DrugBank.d284.s4.e4
DDI-DrugBank.d284.s4	false	DDI-DrugBank.d284.s4.e0	DDI-DrugBank.d284.s4.e1
DDI-DrugBank.d284.s4	false	DDI-DrugBank.d284.s4.e0	DDI-DrugBank.d284.s4.e2
DDI-DrugBank.d284.s4	true	DDI-DrugBank.d284.s4.e0	DDI-DrugBank.d284.s4.e3
DDI-DrugBank.d284.s4	false	DDI-DrugBank.d284.s4.e0	DDI-DrugBank.d284.s4.e4
DDI-DrugBank.d284.s4	false	DDI-DrugBank.d284.s4.e1	DDI-DrugBank.d284.s4.e2
DDI-DrugBank.d284.s4	true	DDI-DrugBank.d284.s4.e1	DDI-DrugBank.d284.s4.e3
DDI-DrugBank.d284.s4	false	DDI-DrugBank.d284.s4.e1	DDI-DrugBank.d284.s4.e4
DDI-DrugBank.d284.s4	true	DDI-DrugBank.d284.s4.e2	DDI-DrugBank.d284.s4.e3
DDI-DrugBank.d284.s4	false	DDI-DrugBank.d284.s4.e2	DDI-DrugBank.d284.s4.e4
DDI-DrugBank.d284.s4	false	DDI-DrugBank.d284.s4.e3	DDI-DrugBank.d284.s4.e4
DDI-DrugBank.d284.s5|a|Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.
DDI-DrugBank.d284.s5	113	125	beta-agonists	group	DDI-DrugBank.d284.s5.e0
DDI-DrugBank.d284.s5	132	162	non-potassium sparing diuretics	group	DDI-DrugBank.d284.s5.e1
DDI-DrugBank.d284.s5	true	DDI-DrugBank.d284.s5.e0	DDI-DrugBank.d284.s5.e1
DDI-DrugBank.d284.s6|a|BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
DDI-DrugBank.d284.s6	0	6	BROVANA	brand	DDI-DrugBank.d284.s6.e0
DDI-DrugBank.d284.s6	23	36	beta2-agonists	group	DDI-DrugBank.d284.s6.e1
DDI-DrugBank.d284.s6	114	141	monoamine oxidase inhibitors	group	DDI-DrugBank.d284.s6.e2
DDI-DrugBank.d284.s6	144	168	tricyclic antidepressants	group	DDI-DrugBank.d284.s6.e3
DDI-DrugBank.d284.s6	236	254	adrenergic agonists	group	DDI-DrugBank.d284.s6.e4
DDI-DrugBank.d284.s6	false	DDI-DrugBank.d284.s6.e0	DDI-DrugBank.d284.s6.e1
DDI-DrugBank.d284.s6	true	DDI-DrugBank.d284.s6.e0	DDI-DrugBank.d284.s6.e2
DDI-DrugBank.d284.s6	true	DDI-DrugBank.d284.s6.e0	DDI-DrugBank.d284.s6.e3
DDI-DrugBank.d284.s6	false	DDI-DrugBank.d284.s6.e0	DDI-DrugBank.d284.s6.e4
DDI-DrugBank.d284.s6	true	DDI-DrugBank.d284.s6.e1	DDI-DrugBank.d284.s6.e2
DDI-DrugBank.d284.s6	true	DDI-DrugBank.d284.s6.e1	DDI-DrugBank.d284.s6.e3
DDI-DrugBank.d284.s6	false	DDI-DrugBank.d284.s6.e1	DDI-DrugBank.d284.s6.e4
DDI-DrugBank.d284.s6	false	DDI-DrugBank.d284.s6.e2	DDI-DrugBank.d284.s6.e3
DDI-DrugBank.d284.s6	true	DDI-DrugBank.d284.s6.e2	DDI-DrugBank.d284.s6.e4
DDI-DrugBank.d284.s6	true	DDI-DrugBank.d284.s6.e3	DDI-DrugBank.d284.s6.e4
DDI-DrugBank.d284.s7|a|Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.
DDI-DrugBank.d284.s8|a|The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by patients receiving BROVANA has not been completely evaluated.
DDI-DrugBank.d284.s8	59	73	methylxanthines	group	DDI-DrugBank.d284.s8.e0
DDI-DrugBank.d284.s8	82	94	aminophylline	drug	DDI-DrugBank.d284.s8.e1
DDI-DrugBank.d284.s8	97	108	theophylline	drug	DDI-DrugBank.d284.s8.e2
DDI-DrugBank.d284.s8	133	139	BROVANA	brand	DDI-DrugBank.d284.s8.e3
DDI-DrugBank.d284.s8	false	DDI-DrugBank.d284.s8.e0	DDI-DrugBank.d284.s8.e1
DDI-DrugBank.d284.s8	false	DDI-DrugBank.d284.s8.e0	DDI-DrugBank.d284.s8.e2
DDI-DrugBank.d284.s8	false	DDI-DrugBank.d284.s8.e0	DDI-DrugBank.d284.s8.e3
DDI-DrugBank.d284.s8	false	DDI-DrugBank.d284.s8.e1	DDI-DrugBank.d284.s8.e2
DDI-DrugBank.d284.s8	false	DDI-DrugBank.d284.s8.e1	DDI-DrugBank.d284.s8.e3
DDI-DrugBank.d284.s8	false	DDI-DrugBank.d284.s8.e2	DDI-DrugBank.d284.s8.e3
DDI-DrugBank.d284.s9|a|In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant theophylline at study entry.
DDI-DrugBank.d284.s9	64	70	BROVANA	brand	DDI-DrugBank.d284.s9.e0
DDI-DrugBank.d284.s9	154	160	BROVANA	brand	DDI-DrugBank.d284.s9.e1
DDI-DrugBank.d284.s9	201	212	theophylline	drug	DDI-DrugBank.d284.s9.e2
DDI-DrugBank.d284.s9	false	DDI-DrugBank.d284.s9.e0	DDI-DrugBank.d284.s9.e1
DDI-DrugBank.d284.s9	false	DDI-DrugBank.d284.s9.e0	DDI-DrugBank.d284.s9.e2
DDI-DrugBank.d284.s9	false	DDI-DrugBank.d284.s9.e1	DDI-DrugBank.d284.s9.e2
DDI-DrugBank.d284.s10|a|In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 BROVANA -treated subjects received concomitant theophylline at study entry.
DDI-DrugBank.d284.s10	65	71	BROVANA	brand	DDI-DrugBank.d284.s10.e0
DDI-DrugBank.d284.s10	93	99	BROVANA	brand	DDI-DrugBank.d284.s10.e1
DDI-DrugBank.d284.s10	140	151	theophylline	drug	DDI-DrugBank.d284.s10.e2
DDI-DrugBank.d284.s10	false	DDI-DrugBank.d284.s10.e0	DDI-DrugBank.d284.s10.e1
DDI-DrugBank.d284.s10	false	DDI-DrugBank.d284.s10.e0	DDI-DrugBank.d284.s10.e2
DDI-DrugBank.d284.s10	false	DDI-DrugBank.d284.s10.e1	DDI-DrugBank.d284.s10.e2
DDI-DrugBank.d284.s11|a|In these trials, heart rate and systolic blood pressure were approximately 2-3 bpm and 6-8 mm Hg higher, respectively, in subjects on concomitant theophylline compared with the overall population.
DDI-DrugBank.d284.s11	146	157	theophylline	drug	DDI-DrugBank.d284.s11.e0
DDI-DrugBank.d284.s12|a|Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.
DDI-DrugBank.d284.s12	0	35	Beta-adrenergic receptor antagonists	group	DDI-DrugBank.d284.s12.e0
DDI-DrugBank.d284.s12	38	50	beta-blockers	group	DDI-DrugBank.d284.s12.e1
DDI-DrugBank.d284.s12	57	63	BROVANA	brand	DDI-DrugBank.d284.s12.e2
DDI-DrugBank.d284.s12	false	DDI-DrugBank.d284.s12.e0	DDI-DrugBank.d284.s12.e1
DDI-DrugBank.d284.s12	true	DDI-DrugBank.d284.s12.e0	DDI-DrugBank.d284.s12.e2
DDI-DrugBank.d284.s12	true	DDI-DrugBank.d284.s12.e1	DDI-DrugBank.d284.s12.e2
DDI-DrugBank.d284.s13|a|Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients.
DDI-DrugBank.d284.s13	0	12	Beta-blockers	group	DDI-DrugBank.d284.s13.e0
DDI-DrugBank.d284.s13	56	68	beta-agonists	group	DDI-DrugBank.d284.s13.e1
DDI-DrugBank.d284.s13	true	DDI-DrugBank.d284.s13.e0	DDI-DrugBank.d284.s13.e1
DDI-DrugBank.d284.s14|a|Therefore, patients with COPD should not normally be treated with beta-blockers.
DDI-DrugBank.d284.s14	66	78	beta-blockers	group	DDI-DrugBank.d284.s14.e0
DDI-DrugBank.d284.s15|a|However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD.
DDI-DrugBank.d284.s15	142	154	beta-blockers	group	DDI-DrugBank.d284.s15.e0
DDI-DrugBank.d284.s16|a|In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.
DDI-DrugBank.d284.s16	17	45	cardioselective beta-blockers	group	DDI-DrugBank.d284.s16.e0
DDI-DrugBank.d148.s0|a|Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.
DDI-DrugBank.d148.s0	0	6	Heparin	drug	DDI-DrugBank.d148.s0.e0
DDI-DrugBank.d148.s0	15	21	heparin	drug	DDI-DrugBank.d148.s0.e1
DDI-DrugBank.d148.s0	59	65	heparin	drug	DDI-DrugBank.d148.s0.e2
DDI-DrugBank.d148.s0	118	127	Argatroban	drug	DDI-DrugBank.d148.s0.e3
DDI-DrugBank.d148.s0	133	139	heparin	drug	DDI-DrugBank.d148.s0.e4
DDI-DrugBank.d148.s0	false	DDI-DrugBank.d148.s0.e0	DDI-DrugBank.d148.s0.e1
DDI-DrugBank.d148.s0	false	DDI-DrugBank.d148.s0.e0	DDI-DrugBank.d148.s0.e2
DDI-DrugBank.d148.s0	false	DDI-DrugBank.d148.s0.e0	DDI-DrugBank.d148.s0.e3
DDI-DrugBank.d148.s0	false	DDI-DrugBank.d148.s0.e0	DDI-DrugBank.d148.s0.e4
DDI-DrugBank.d148.s0	false	DDI-DrugBank.d148.s0.e1	DDI-DrugBank.d148.s0.e2
DDI-DrugBank.d148.s0	false	DDI-DrugBank.d148.s0.e1	DDI-DrugBank.d148.s0.e3
DDI-DrugBank.d148.s0	false	DDI-DrugBank.d148.s0.e1	DDI-DrugBank.d148.s0.e4
DDI-DrugBank.d148.s0	false	DDI-DrugBank.d148.s0.e2	DDI-DrugBank.d148.s0.e3
DDI-DrugBank.d148.s0	false	DDI-DrugBank.d148.s0.e2	DDI-DrugBank.d148.s0.e4
DDI-DrugBank.d148.s0	false	DDI-DrugBank.d148.s0.e3	DDI-DrugBank.d148.s0.e4
DDI-DrugBank.d148.s1|a|However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.
DDI-DrugBank.d148.s1	12	21	Argatroban	drug	DDI-DrugBank.d148.s1.e0
DDI-DrugBank.d148.s1	61	67	heparin	drug	DDI-DrugBank.d148.s1.e1
DDI-DrugBank.d148.s1	167	176	Argatroban	drug	DDI-DrugBank.d148.s1.e2
DDI-DrugBank.d148.s1	false	DDI-DrugBank.d148.s1.e0	DDI-DrugBank.d148.s1.e1
DDI-DrugBank.d148.s1	false	DDI-DrugBank.d148.s1.e0	DDI-DrugBank.d148.s1.e2
DDI-DrugBank.d148.s1	false	DDI-DrugBank.d148.s1.e1	DDI-DrugBank.d148.s1.e2
DDI-DrugBank.d148.s2|a|Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
DDI-DrugBank.d148.s2	0	6	Aspirin	brand	DDI-DrugBank.d148.s2.e0
DDI-DrugBank.d148.s2	8	20	Acetaminophen	drug	DDI-DrugBank.d148.s2.e1
DDI-DrugBank.d148.s2	116	125	Argatroban	drug	DDI-DrugBank.d148.s2.e2
DDI-DrugBank.d148.s2	158	164	aspirin	brand	DDI-DrugBank.d148.s2.e3
DDI-DrugBank.d148.s2	227	236	Argatroban	drug	DDI-DrugBank.d148.s2.e4
DDI-DrugBank.d148.s2	268	280	acetaminophen	drug	DDI-DrugBank.d148.s2.e5
DDI-DrugBank.d148.s2	380	389	Argatroban	drug	DDI-DrugBank.d148.s2.e6
DDI-DrugBank.d148.s2	false	DDI-DrugBank.d148.s2.e0	DDI-DrugBank.d148.s2.e1
DDI-DrugBank.d148.s2	false	DDI-DrugBank.d148.s2.e0	DDI-DrugBank.d148.s2.e2
DDI-DrugBank.d148.s2	false	DDI-DrugBank.d148.s2.e0	DDI-DrugBank.d148.s2.e3
DDI-DrugBank.d148.s2	false	DDI-DrugBank.d148.s2.e0	DDI-DrugBank.d148.s2.e4
DDI-DrugBank.d148.s2	false	DDI-DrugBank.d148.s2.e0	DDI-DrugBank.d148.s2.e5
DDI-DrugBank.d148.s2	false	DDI-DrugBank.d148.s2.e0	DDI-DrugBank.d148.s2.e6
DDI-DrugBank.d148.s2	false	DDI-DrugBank.d148.s2.e1	DDI-DrugBank.d148.s2.e2
DDI-DrugBank.d148.s2	false	DDI-DrugBank.d148.s2.e1	DDI-DrugBank.d148.s2.e3
DDI-DrugBank.d148.s2	false	DDI-DrugBank.d148.s2.e1	DDI-DrugBank.d148.s2.e4
DDI-DrugBank.d148.s2	false	DDI-DrugBank.d148.s2.e1	DDI-DrugBank.d148.s2.e5
DDI-DrugBank.d148.s3|a|Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between Argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated.
DDI-DrugBank.d148.s3	5	24	anticoagulant agents	group	DDI-DrugBank.d148.s3.e0
DDI-DrugBank.d148.s3	74	83	Argatroban	drug	DDI-DrugBank.d148.s3.e1
DDI-DrugBank.d148.s3	89	96	warfarin	drug	DDI-DrugBank.d148.s3.e2
DDI-DrugBank.d148.s3	false	DDI-DrugBank.d148.s3.e0	DDI-DrugBank.d148.s3.e1
DDI-DrugBank.d148.s3	false	DDI-DrugBank.d148.s3.e0	DDI-DrugBank.d148.s3.e2
DDI-DrugBank.d148.s3	false	DDI-DrugBank.d148.s3.e1	DDI-DrugBank.d148.s3.e2
DDI-DrugBank.d148.s4|a|However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
DDI-DrugBank.d148.s4	32	41	Argatroban	drug	DDI-DrugBank.d148.s4.e0
DDI-DrugBank.d148.s4	47	54	warfarin	drug	DDI-DrugBank.d148.s4.e1
DDI-DrugBank.d148.s4	true	DDI-DrugBank.d148.s4.e0	DDI-DrugBank.d148.s4.e1
DDI-DrugBank.d148.s5|a|Thrombolytic agents: The safety and effectiveness of Argatroban with thrombolytic agents have not been established.
DDI-DrugBank.d148.s5	0	18	Thrombolytic agents	group	DDI-DrugBank.d148.s5.e0
DDI-DrugBank.d148.s5	53	62	Argatroban	drug	DDI-DrugBank.d148.s5.e1
DDI-DrugBank.d148.s5	69	87	thrombolytic agents	group	DDI-DrugBank.d148.s5.e2
DDI-DrugBank.d148.s5	false	DDI-DrugBank.d148.s5.e0	DDI-DrugBank.d148.s5.e1
DDI-DrugBank.d148.s5	false	DDI-DrugBank.d148.s5.e0	DDI-DrugBank.d148.s5.e2
DDI-DrugBank.d148.s5	false	DDI-DrugBank.d148.s5.e1	DDI-DrugBank.d148.s5.e2
DDI-DrugBank.d148.s6|a|Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
DDI-DrugBank.d148.s6	38	47	Argatroban	drug	DDI-DrugBank.d148.s6.e0
DDI-DrugBank.d148.s6	54	72	antiplatelet agents	group	DDI-DrugBank.d148.s6.e1
DDI-DrugBank.d148.s6	75	87	thrombolytics	group	DDI-DrugBank.d148.s6.e2
DDI-DrugBank.d148.s6	100	113	anticoagulants	group	DDI-DrugBank.d148.s6.e3
DDI-DrugBank.d148.s6	true	DDI-DrugBank.d148.s6.e0	DDI-DrugBank.d148.s6.e1
DDI-DrugBank.d148.s6	true	DDI-DrugBank.d148.s6.e0	DDI-DrugBank.d148.s6.e2
DDI-DrugBank.d148.s6	true	DDI-DrugBank.d148.s6.e0	DDI-DrugBank.d148.s6.e3
DDI-DrugBank.d148.s6	false	DDI-DrugBank.d148.s6.e1	DDI-DrugBank.d148.s6.e2
DDI-DrugBank.d148.s6	false	DDI-DrugBank.d148.s6.e1	DDI-DrugBank.d148.s6.e3
DDI-DrugBank.d148.s6	false	DDI-DrugBank.d148.s6.e2	DDI-DrugBank.d148.s6.e3
DDI-DrugBank.d148.s7|a|Drug-drug interactions have not been observed between Argatroban and digoxin or erythromycin.
DDI-DrugBank.d148.s7	54	63	Argatroban	drug	DDI-DrugBank.d148.s7.e0
DDI-DrugBank.d148.s7	69	75	digoxin	drug	DDI-DrugBank.d148.s7.e1
DDI-DrugBank.d148.s7	80	91	erythromycin	drug	DDI-DrugBank.d148.s7.e2
DDI-DrugBank.d148.s7	false	DDI-DrugBank.d148.s7.e0	DDI-DrugBank.d148.s7.e1
DDI-DrugBank.d148.s7	false	DDI-DrugBank.d148.s7.e0	DDI-DrugBank.d148.s7.e2
DDI-DrugBank.d148.s7	false	DDI-DrugBank.d148.s7.e1	DDI-DrugBank.d148.s7.e2
DDI-DrugBank.d509.s0|a|Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.
DDI-DrugBank.d509.s0	56	67	aripiprazole	drug	DDI-DrugBank.d509.s0.e0
DDI-DrugBank.d509.s0	98	104	ABILIFY	brand	DDI-DrugBank.d509.s0.e1
DDI-DrugBank.d509.s0	141	162	centrally acting drugs	group	DDI-DrugBank.d509.s0.e2
DDI-DrugBank.d509.s0	168	174	alcohol	drug	DDI-DrugBank.d509.s0.e3
DDI-DrugBank.d509.s0	false	DDI-DrugBank.d509.s0.e0	DDI-DrugBank.d509.s0.e1
DDI-DrugBank.d509.s0	false	DDI-DrugBank.d509.s0.e0	DDI-DrugBank.d509.s0.e2
DDI-DrugBank.d509.s0	false	DDI-DrugBank.d509.s0.e0	DDI-DrugBank.d509.s0.e3
DDI-DrugBank.d509.s0	true	DDI-DrugBank.d509.s0.e1	DDI-DrugBank.d509.s0.e2
DDI-DrugBank.d509.s0	true	DDI-DrugBank.d509.s0.e1	DDI-DrugBank.d509.s0.e3
DDI-DrugBank.d509.s0	false	DDI-DrugBank.d509.s0.e2	DDI-DrugBank.d509.s0.e3
DDI-DrugBank.d509.s1|a|Due to its
DDI-DrugBank.d509.s2|a|1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.
DDI-DrugBank.d509.s2	35	46	aripiprazole	drug	DDI-DrugBank.d509.s2.e0
DDI-DrugBank.d509.s2	99	121	antihypertensive agents	group	DDI-DrugBank.d509.s2.e1
DDI-DrugBank.d509.s2	true	DDI-DrugBank.d509.s2.e0	DDI-DrugBank.d509.s2.e1
DDI-DrugBank.d509.s3|a|Potential for Other Drugs to Affect ABILIFY Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.
DDI-DrugBank.d509.s3	36	42	ABILIFY	brand	DDI-DrugBank.d509.s3.e0
DDI-DrugBank.d509.s3	44	55	Aripiprazole	brand	DDI-DrugBank.d509.s3.e1
DDI-DrugBank.d509.s3	false	DDI-DrugBank.d509.s3.e0	DDI-DrugBank.d509.s3.e1
DDI-DrugBank.d509.s4|a|Aripiprazole also does not undergo direct glucuronidation.
DDI-DrugBank.d509.s4	0	11	Aripiprazole	drug	DDI-DrugBank.d509.s4.e0
DDI-DrugBank.d509.s5|a|This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
DDI-DrugBank.d509.s5	37	48	aripiprazole	drug	DDI-DrugBank.d509.s5.e0
DDI-DrugBank.d509.s6|a|Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism.
DDI-DrugBank.d509.s6	43	54	aripiprazole	drug	DDI-DrugBank.d509.s6.e0
DDI-DrugBank.d509.s7|a|Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.
DDI-DrugBank.d509.s7	31	43	carbamazepine	drug	DDI-DrugBank.d509.s7.e0
DDI-DrugBank.d509.s7	73	84	aripiprazole	drug	DDI-DrugBank.d509.s7.e1
DDI-DrugBank.d509.s7	true	DDI-DrugBank.d509.s7.e0	DDI-DrugBank.d509.s7.e1
DDI-DrugBank.d509.s8|a|Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
DDI-DrugBank.d509.s8	26	37	ketoconazole	drug	DDI-DrugBank.d509.s8.e0
DDI-DrugBank.d509.s8	55	63	quinidine	drug	DDI-DrugBank.d509.s8.e1
DDI-DrugBank.d509.s8	66	75	fluoxetine	drug	DDI-DrugBank.d509.s8.e2
DDI-DrugBank.d509.s8	81	90	paroxetine	drug	DDI-DrugBank.d509.s8.e3
DDI-DrugBank.d509.s8	105	116	aripiprazole	drug	DDI-DrugBank.d509.s8.e4
DDI-DrugBank.d509.s8	false	DDI-DrugBank.d509.s8.e0	DDI-DrugBank.d509.s8.e1
DDI-DrugBank.d509.s8	false	DDI-DrugBank.d509.s8.e0	DDI-DrugBank.d509.s8.e2
DDI-DrugBank.d509.s8	false	DDI-DrugBank.d509.s8.e0	DDI-DrugBank.d509.s8.e3
DDI-DrugBank.d509.s8	true	DDI-DrugBank.d509.s8.e0	DDI-DrugBank.d509.s8.e4
DDI-DrugBank.d509.s8	false	DDI-DrugBank.d509.s8.e1	DDI-DrugBank.d509.s8.e2
DDI-DrugBank.d509.s8	false	DDI-DrugBank.d509.s8.e1	DDI-DrugBank.d509.s8.e3
DDI-DrugBank.d509.s8	true	DDI-DrugBank.d509.s8.e1	DDI-DrugBank.d509.s8.e4
DDI-DrugBank.d509.s8	false	DDI-DrugBank.d509.s8.e2	DDI-DrugBank.d509.s8.e3
DDI-DrugBank.d509.s8	true	DDI-DrugBank.d509.s8.e2	DDI-DrugBank.d509.s8.e4
DDI-DrugBank.d509.s8	true	DDI-DrugBank.d509.s8.e3	DDI-DrugBank.d509.s8.e4
DDI-DrugBank.d509.s9|a|Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.
DDI-DrugBank.d509.s9	0	11	Ketoconazole	drug	DDI-DrugBank.d509.s9.e0
DDI-DrugBank.d509.s9	34	45	ketoconazole	drug	DDI-DrugBank.d509.s9.e1
DDI-DrugBank.d509.s9	100	111	aripiprazole	drug	DDI-DrugBank.d509.s9.e2
DDI-DrugBank.d509.s9	134	145	aripiprazole	drug	DDI-DrugBank.d509.s9.e3
DDI-DrugBank.d509.s9	false	DDI-DrugBank.d509.s9.e0	DDI-DrugBank.d509.s9.e1
DDI-DrugBank.d509.s9	false	DDI-DrugBank.d509.s9.e0	DDI-DrugBank.d509.s9.e2
DDI-DrugBank.d509.s9	false	DDI-DrugBank.d509.s9.e0	DDI-DrugBank.d509.s9.e3
DDI-DrugBank.d509.s9	true	DDI-DrugBank.d509.s9.e1	DDI-DrugBank.d509.s9.e2
DDI-DrugBank.d509.s9	false	DDI-DrugBank.d509.s9.e1	DDI-DrugBank.d509.s9.e3
DDI-DrugBank.d509.s9	false	DDI-DrugBank.d509.s9.e2	DDI-DrugBank.d509.s9.e3
DDI-DrugBank.d509.s10|a|The effect of a higher ketoconazole dose (400 mg/day) has not been studied.
DDI-DrugBank.d509.s10	23	34	ketoconazole	drug	DDI-DrugBank.d509.s10.e0
DDI-DrugBank.d509.s11|a|When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.
DDI-DrugBank.d509.s11	35	46	ketoconazole	drug	DDI-DrugBank.d509.s11.e0
DDI-DrugBank.d509.s11	53	64	aripiprazole	drug	DDI-DrugBank.d509.s11.e1
DDI-DrugBank.d509.s11	74	85	aripiprazole	drug	DDI-DrugBank.d509.s11.e2
DDI-DrugBank.d509.s11	true	DDI-DrugBank.d509.s11.e0	DDI-DrugBank.d509.s11.e1
DDI-DrugBank.d509.s11	false	DDI-DrugBank.d509.s11.e0	DDI-DrugBank.d509.s11.e2
DDI-DrugBank.d509.s11	false	DDI-DrugBank.d509.s11.e1	DDI-DrugBank.d509.s11.e2
DDI-DrugBank.d509.s12|a|Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions;
DDI-DrugBank.d509.s12	35	46	itraconazole	drug	DDI-DrugBank.d509.s12.e0
DDI-DrugBank.d509.s13|a|weaker inhibitors (erythromycin, grapefruit juice) have not been studied.
DDI-DrugBank.d509.s13	19	30	erythromycin	drug	DDI-DrugBank.d509.s13.e0
DDI-DrugBank.d509.s14|a|When the CYP3A4 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased.
DDI-DrugBank.d509.s14	69	80	aripiprazole	drug	DDI-DrugBank.d509.s14.e0
DDI-DrugBank.d509.s15|a|Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.
DDI-DrugBank.d509.s15	0	8	Quinidine	drug	DDI-DrugBank.d509.s15.e0
DDI-DrugBank.d509.s15	54	65	aripiprazole	drug	DDI-DrugBank.d509.s15.e1
DDI-DrugBank.d509.s15	72	80	quinidine	drug	DDI-DrugBank.d509.s15.e2
DDI-DrugBank.d509.s15	159	170	aripiprazole	drug	DDI-DrugBank.d509.s15.e3
DDI-DrugBank.d509.s15	228	246	dehydroaripiprazole	drug_n	DDI-DrugBank.d509.s15.e4
DDI-DrugBank.d509.s15	false	DDI-DrugBank.d509.s15.e0	DDI-DrugBank.d509.s15.e1
DDI-DrugBank.d509.s15	false	DDI-DrugBank.d509.s15.e0	DDI-DrugBank.d509.s15.e2
DDI-DrugBank.d509.s15	false	DDI-DrugBank.d509.s15.e0	DDI-DrugBank.d509.s15.e3
DDI-DrugBank.d509.s15	false	DDI-DrugBank.d509.s15.e0	DDI-DrugBank.d509.s15.e4
DDI-DrugBank.d509.s15	true	DDI-DrugBank.d509.s15.e1	DDI-DrugBank.d509.s15.e2
DDI-DrugBank.d509.s15	false	DDI-DrugBank.d509.s15.e1	DDI-DrugBank.d509.s15.e3
DDI-DrugBank.d509.s15	false	DDI-DrugBank.d509.s15.e1	DDI-DrugBank.d509.s15.e4
DDI-DrugBank.d509.s15	false	DDI-DrugBank.d509.s15.e2	DDI-DrugBank.d509.s15.e3
DDI-DrugBank.d509.s15	false	DDI-DrugBank.d509.s15.e2	DDI-DrugBank.d509.s15.e4
DDI-DrugBank.d509.s15	false	DDI-DrugBank.d509.s15.e3	DDI-DrugBank.d509.s15.e4
DDI-DrugBank.d509.s16|a|Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
DDI-DrugBank.d509.s16	0	11	Aripiprazole	drug	DDI-DrugBank.d509.s16.e0
DDI-DrugBank.d509.s16	102	110	quinidine	drug	DDI-DrugBank.d509.s16.e1
DDI-DrugBank.d509.s16	117	128	aripiprazole	drug	DDI-DrugBank.d509.s16.e2
DDI-DrugBank.d509.s16	false	DDI-DrugBank.d509.s16.e0	DDI-DrugBank.d509.s16.e1
DDI-DrugBank.d509.s16	false	DDI-DrugBank.d509.s16.e0	DDI-DrugBank.d509.s16.e2
DDI-DrugBank.d509.s16	true	DDI-DrugBank.d509.s16.e1	DDI-DrugBank.d509.s16.e2
DDI-DrugBank.d509.s17|a|Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions.
DDI-DrugBank.d509.s17	48	57	fluoxetine	drug	DDI-DrugBank.d509.s17.e0
DDI-DrugBank.d509.s17	62	71	paroxetine	drug	DDI-DrugBank.d509.s17.e1
DDI-DrugBank.d509.s17	false	DDI-DrugBank.d509.s17.e0	DDI-DrugBank.d509.s17.e1
DDI-DrugBank.d509.s18|a|When the CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased.
DDI-DrugBank.d509.s18	69	80	aripiprazole	drug	DDI-DrugBank.d509.s18.e0
DDI-DrugBank.d509.s19|a|Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.
DDI-DrugBank.d509.s19	0	12	Carbamazepine	drug	DDI-DrugBank.d509.s19.e0
DDI-DrugBank.d509.s19	35	47	carbamazepine	drug	DDI-DrugBank.d509.s19.e1
DDI-DrugBank.d509.s19	93	104	aripiprazole	drug	DDI-DrugBank.d509.s19.e2
DDI-DrugBank.d509.s19	188	199	aripiprazole	drug	DDI-DrugBank.d509.s19.e3
DDI-DrugBank.d509.s19	228	247	dehydro-aripiprazole	drug_n	DDI-DrugBank.d509.s19.e4
DDI-DrugBank.d509.s19	false	DDI-DrugBank.d509.s19.e0	DDI-DrugBank.d509.s19.e1
DDI-DrugBank.d509.s19	false	DDI-DrugBank.d509.s19.e0	DDI-DrugBank.d509.s19.e2
DDI-DrugBank.d509.s19	false	DDI-DrugBank.d509.s19.e0	DDI-DrugBank.d509.s19.e3
DDI-DrugBank.d509.s19	false	DDI-DrugBank.d509.s19.e0	DDI-DrugBank.d509.s19.e4
DDI-DrugBank.d509.s19	true	DDI-DrugBank.d509.s19.e1	DDI-DrugBank.d509.s19.e2
DDI-DrugBank.d509.s19	false	DDI-DrugBank.d509.s19.e1	DDI-DrugBank.d509.s19.e3
DDI-DrugBank.d509.s19	false	DDI-DrugBank.d509.s19.e1	DDI-DrugBank.d509.s19.e4
DDI-DrugBank.d509.s19	false	DDI-DrugBank.d509.s19.e2	DDI-DrugBank.d509.s19.e3
DDI-DrugBank.d509.s19	false	DDI-DrugBank.d509.s19.e2	DDI-DrugBank.d509.s19.e4
DDI-DrugBank.d509.s19	false	DDI-DrugBank.d509.s19.e3	DDI-DrugBank.d509.s19.e4
DDI-DrugBank.d509.s20|a|When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.
DDI-DrugBank.d509.s20	5	17	carbamazepine	drug	DDI-DrugBank.d509.s20.e0
DDI-DrugBank.d509.s20	31	42	aripiprazole	drug	DDI-DrugBank.d509.s20.e1
DDI-DrugBank.d509.s20	53	64	aripiprazole	drug	DDI-DrugBank.d509.s20.e2
DDI-DrugBank.d509.s20	true	DDI-DrugBank.d509.s20.e0	DDI-DrugBank.d509.s20.e1
DDI-DrugBank.d509.s20	false	DDI-DrugBank.d509.s20.e0	DDI-DrugBank.d509.s20.e2
DDI-DrugBank.d509.s20	false	DDI-DrugBank.d509.s20.e1	DDI-DrugBank.d509.s20.e2
DDI-DrugBank.d509.s21|a|Additional dose increases should be based on clinical evaluation.
DDI-DrugBank.d509.s22|a|When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.
DDI-DrugBank.d509.s22	5	17	carbamazepine	drug	DDI-DrugBank.d509.s22.e0
DDI-DrugBank.d509.s22	62	73	aripiprazole	drug	DDI-DrugBank.d509.s22.e1
DDI-DrugBank.d509.s22	true	DDI-DrugBank.d509.s22.e0	DDI-DrugBank.d509.s22.e1
DDI-DrugBank.d509.s23|a|No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).
DDI-DrugBank.d509.s23	36	45	famotidine	drug	DDI-DrugBank.d509.s23.e0
DDI-DrugBank.d509.s23	48	56	valproate	drug	DDI-DrugBank.d509.s23.e1
DDI-DrugBank.d509.s23	62	68	lithium	drug	DDI-DrugBank.d509.s23.e2
DDI-DrugBank.d509.s23	106	117	aripiprazole	drug	DDI-DrugBank.d509.s23.e3
DDI-DrugBank.d509.s23	false	DDI-DrugBank.d509.s23.e0	DDI-DrugBank.d509.s23.e1
DDI-DrugBank.d509.s23	false	DDI-DrugBank.d509.s23.e0	DDI-DrugBank.d509.s23.e2
DDI-DrugBank.d509.s23	false	DDI-DrugBank.d509.s23.e0	DDI-DrugBank.d509.s23.e3
DDI-DrugBank.d509.s23	false	DDI-DrugBank.d509.s23.e1	DDI-DrugBank.d509.s23.e2
DDI-DrugBank.d509.s23	false	DDI-DrugBank.d509.s23.e1	DDI-DrugBank.d509.s23.e3
DDI-DrugBank.d509.s23	false	DDI-DrugBank.d509.s23.e2	DDI-DrugBank.d509.s23.e3
DDI-DrugBank.d509.s24|a|Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.
DDI-DrugBank.d509.s24	14	20	ABILIFY	brand	DDI-DrugBank.d509.s24.e0
DDI-DrugBank.d509.s24	44	55	Aripiprazole	drug	DDI-DrugBank.d509.s24.e1
DDI-DrugBank.d509.s24	false	DDI-DrugBank.d509.s24.e0	DDI-DrugBank.d509.s24.e1
DDI-DrugBank.d509.s25|a|In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.
DDI-DrugBank.d509.s25	46	57	aripiprazole	drug	DDI-DrugBank.d509.s25.e0
DDI-DrugBank.d509.s25	110	125	dextromethorphan	drug	DDI-DrugBank.d509.s25.e1
DDI-DrugBank.d509.s25	137	144	warfarin	drug	DDI-DrugBank.d509.s25.e2
DDI-DrugBank.d509.s25	157	166	omeprazole	drug	DDI-DrugBank.d509.s25.e3
DDI-DrugBank.d509.s25	169	176	warfarin	drug	DDI-DrugBank.d509.s25.e4
DDI-DrugBank.d509.s25	192	207	dextromethorphan	drug	DDI-DrugBank.d509.s25.e5
DDI-DrugBank.d509.s25	false	DDI-DrugBank.d509.s25.e0	DDI-DrugBank.d509.s25.e1
DDI-DrugBank.d509.s25	false	DDI-DrugBank.d509.s25.e0	DDI-DrugBank.d509.s25.e2
DDI-DrugBank.d509.s25	false	DDI-DrugBank.d509.s25.e0	DDI-DrugBank.d509.s25.e3
DDI-DrugBank.d509.s25	false	DDI-DrugBank.d509.s25.e0	DDI-DrugBank.d509.s25.e4
DDI-DrugBank.d509.s25	false	DDI-DrugBank.d509.s25.e0	DDI-DrugBank.d509.s25.e5
DDI-DrugBank.d509.s25	false	DDI-DrugBank.d509.s25.e1	DDI-DrugBank.d509.s25.e2
DDI-DrugBank.d509.s25	false	DDI-DrugBank.d509.s25.e1	DDI-DrugBank.d509.s25.e3
DDI-DrugBank.d509.s25	false	DDI-DrugBank.d509.s25.e1	DDI-DrugBank.d509.s25.e4
DDI-DrugBank.d509.s25	false	DDI-DrugBank.d509.s25.e1	DDI-DrugBank.d509.s25.e5
DDI-DrugBank.d509.s25	false	DDI-DrugBank.d509.s25.e2	DDI-DrugBank.d509.s25.e3
DDI-DrugBank.d509.s26|a|Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
DDI-DrugBank.d509.s26	14	25	aripiprazole	drug	DDI-DrugBank.d509.s26.e0
DDI-DrugBank.d509.s26	31	49	dehydroaripiprazole	drug_n	DDI-DrugBank.d509.s26.e1
DDI-DrugBank.d509.s26	false	DDI-DrugBank.d509.s26.e0	DDI-DrugBank.d509.s26.e1
DDI-DrugBank.d509.s27|a|Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.
DDI-DrugBank.d509.s27	0	6	Alcohol	drug	DDI-DrugBank.d509.s27.e0
DDI-DrugBank.d509.s27	53	64	aripiprazole	drug	DDI-DrugBank.d509.s27.e1
DDI-DrugBank.d509.s27	86	92	ethanol	drug	DDI-DrugBank.d509.s27.e2
DDI-DrugBank.d509.s27	126	132	ethanol	drug	DDI-DrugBank.d509.s27.e3
DDI-DrugBank.d509.s27	false	DDI-DrugBank.d509.s27.e0	DDI-DrugBank.d509.s27.e1
DDI-DrugBank.d509.s27	false	DDI-DrugBank.d509.s27.e0	DDI-DrugBank.d509.s27.e2
DDI-DrugBank.d509.s27	false	DDI-DrugBank.d509.s27.e0	DDI-DrugBank.d509.s27.e3
DDI-DrugBank.d509.s27	false	DDI-DrugBank.d509.s27.e1	DDI-DrugBank.d509.s27.e2
DDI-DrugBank.d509.s27	false	DDI-DrugBank.d509.s27.e1	DDI-DrugBank.d509.s27.e3
DDI-DrugBank.d509.s27	false	DDI-DrugBank.d509.s27.e2	DDI-DrugBank.d509.s27.e3
DDI-DrugBank.d509.s28|a|As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY
DDI-DrugBank.d509.s28	75	81	alcohol	drug	DDI-DrugBank.d509.s28.e0
DDI-DrugBank.d509.s28	96	102	ABILIFY	brand	DDI-DrugBank.d509.s28.e1
DDI-DrugBank.d509.s28	true	DDI-DrugBank.d509.s28.e0	DDI-DrugBank.d509.s28.e1
DDI-DrugBank.d509.s29|a|.
DDI-DrugBank.d509.s30|a|
DDI-DrugBank.d470.s0|a|No formal assessments of pharmacokinetic drug-drug interactions between TRISENOX and other agents have been conducted.
DDI-DrugBank.d470.s0	72	79	TRISENOX	brand	DDI-DrugBank.d470.s0.e0
DDI-DrugBank.d470.s1|a|Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
DDI-DrugBank.d470.s1	24	31	TRISENOX	brand	DDI-DrugBank.d470.s1.e0
DDI-DrugBank.d470.s1	121	135	antiarrhythmics	group	DDI-DrugBank.d470.s1.e1
DDI-DrugBank.d470.s1	140	151	thioridazine	drug	DDI-DrugBank.d470.s1.e2
DDI-DrugBank.d470.s1	200	208	diuretics	group	DDI-DrugBank.d470.s1.e3
DDI-DrugBank.d470.s1	213	226	amphotericin B	drug	DDI-DrugBank.d470.s1.e4
DDI-DrugBank.d470.s1	true	DDI-DrugBank.d470.s1.e0	DDI-DrugBank.d470.s1.e1
DDI-DrugBank.d470.s1	true	DDI-DrugBank.d470.s1.e0	DDI-DrugBank.d470.s1.e2
DDI-DrugBank.d470.s1	true	DDI-DrugBank.d470.s1.e0	DDI-DrugBank.d470.s1.e3
DDI-DrugBank.d470.s1	true	DDI-DrugBank.d470.s1.e0	DDI-DrugBank.d470.s1.e4
DDI-DrugBank.d470.s1	false	DDI-DrugBank.d470.s1.e1	DDI-DrugBank.d470.s1.e2
DDI-DrugBank.d470.s1	false	DDI-DrugBank.d470.s1.e1	DDI-DrugBank.d470.s1.e3
DDI-DrugBank.d470.s1	false	DDI-DrugBank.d470.s1.e1	DDI-DrugBank.d470.s1.e4
DDI-DrugBank.d470.s1	false	DDI-DrugBank.d470.s1.e2	DDI-DrugBank.d470.s1.e3
DDI-DrugBank.d470.s1	false	DDI-DrugBank.d470.s1.e2	DDI-DrugBank.d470.s1.e4
DDI-DrugBank.d470.s1	false	DDI-DrugBank.d470.s1.e3	DDI-DrugBank.d470.s1.e4
DDI-DrugBank.d21.s0|a|Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
DDI-DrugBank.d21.s0	48	53	ELSPAR	brand	DDI-DrugBank.d21.s0.e0
DDI-DrugBank.d21.s0	93	104	methotrexate	drug	DDI-DrugBank.d21.s0.e1
DDI-DrugBank.d21.s0	143	154	methotrexate	drug	DDI-DrugBank.d21.s0.e2
DDI-DrugBank.d21.s0	true	DDI-DrugBank.d21.s0.e0	DDI-DrugBank.d21.s0.e1
DDI-DrugBank.d21.s0	false	DDI-DrugBank.d21.s0.e0	DDI-DrugBank.d21.s0.e2
DDI-DrugBank.d21.s0	false	DDI-DrugBank.d21.s0.e1	DDI-DrugBank.d21.s0.e2
DDI-DrugBank.d21.s1|a|These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.
DDI-DrugBank.d21.s1	64	75	methotrexate	drug	DDI-DrugBank.d21.s1.e0
DDI-DrugBank.d21.s1	82	87	ELSPAR	brand	DDI-DrugBank.d21.s1.e1
DDI-DrugBank.d21.s1	121	126	ELSPAR	brand	DDI-DrugBank.d21.s1.e2
DDI-DrugBank.d21.s1	true	DDI-DrugBank.d21.s1.e0	DDI-DrugBank.d21.s1.e1
DDI-DrugBank.d21.s1	false	DDI-DrugBank.d21.s1.e0	DDI-DrugBank.d21.s1.e2
DDI-DrugBank.d21.s1	false	DDI-DrugBank.d21.s1.e1	DDI-DrugBank.d21.s1.e2
DDI-DrugBank.d443.s0|a|Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
DDI-DrugBank.d443.s0	0	16	Uricosuric Agents	group	DDI-DrugBank.d443.s0.e0
DDI-DrugBank.d443.s0	19	25	Aspirin	brand	DDI-DrugBank.d443.s0.e1
DDI-DrugBank.d443.s0	55	64	probenecid	drug	DDI-DrugBank.d443.s0.e2
DDI-DrugBank.d443.s0	67	80	sulfinpyrazone	drug	DDI-DrugBank.d443.s0.e3
DDI-DrugBank.d443.s0	87	100	phenylbutazone	drug	DDI-DrugBank.d443.s0.e4
DDI-DrugBank.d443.s0	false	DDI-DrugBank.d443.s0.e0	DDI-DrugBank.d443.s0.e1
DDI-DrugBank.d443.s0	false	DDI-DrugBank.d443.s0.e0	DDI-DrugBank.d443.s0.e2
DDI-DrugBank.d443.s0	false	DDI-DrugBank.d443.s0.e0	DDI-DrugBank.d443.s0.e3
DDI-DrugBank.d443.s0	false	DDI-DrugBank.d443.s0.e0	DDI-DrugBank.d443.s0.e4
DDI-DrugBank.d443.s0	true	DDI-DrugBank.d443.s0.e1	DDI-DrugBank.d443.s0.e2
DDI-DrugBank.d443.s0	true	DDI-DrugBank.d443.s0.e1	DDI-DrugBank.d443.s0.e3
DDI-DrugBank.d443.s0	true	DDI-DrugBank.d443.s0.e1	DDI-DrugBank.d443.s0.e4
DDI-DrugBank.d443.s0	false	DDI-DrugBank.d443.s0.e2	DDI-DrugBank.d443.s0.e3
DDI-DrugBank.d443.s0	false	DDI-DrugBank.d443.s0.e2	DDI-DrugBank.d443.s0.e4
DDI-DrugBank.d443.s0	false	DDI-DrugBank.d443.s0.e3	DDI-DrugBank.d443.s0.e4
DDI-DrugBank.d443.s1|a|Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.
DDI-DrugBank.d443.s1	0	6	Alcohol	drug	DDI-DrugBank.d443.s1.e0
DDI-DrugBank.d443.s1	39	45	aspirin	brand	DDI-DrugBank.d443.s1.e1
DDI-DrugBank.d443.s1	true	DDI-DrugBank.d443.s1.e0	DDI-DrugBank.d443.s1.e1
DDI-DrugBank.d443.s2|a|Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
DDI-DrugBank.d443.s2	0	14	Corticosteroids	group	DDI-DrugBank.d443.s2.e0
DDI-DrugBank.d443.s2	49	55	aspirin	brand	DDI-DrugBank.d443.s2.e1
DDI-DrugBank.d443.s2	true	DDI-DrugBank.d443.s2.e0	DDI-DrugBank.d443.s2.e1
DDI-DrugBank.d443.s3|a|Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
DDI-DrugBank.d443.s3	0	21	Pyrazolone Derivatives	group	DDI-DrugBank.d443.s3.e0
DDI-DrugBank.d443.s3	24	37	phenylbutazone	drug	DDI-DrugBank.d443.s3.e1
DDI-DrugBank.d443.s3	40	54	oxyphenbutazone	drug	DDI-DrugBank.d443.s3.e2
DDI-DrugBank.d443.s3	70	77	dipyrone	drug	DDI-DrugBank.d443.s3.e3
DDI-DrugBank.d443.s3	113	119	aspirin	drug	DDI-DrugBank.d443.s3.e4
DDI-DrugBank.d443.s3	false	DDI-DrugBank.d443.s3.e0	DDI-DrugBank.d443.s3.e1
DDI-DrugBank.d443.s3	false	DDI-DrugBank.d443.s3.e0	DDI-DrugBank.d443.s3.e2
DDI-DrugBank.d443.s3	false	DDI-DrugBank.d443.s3.e0	DDI-DrugBank.d443.s3.e3
DDI-DrugBank.d443.s3	true	DDI-DrugBank.d443.s3.e0	DDI-DrugBank.d443.s3.e4
DDI-DrugBank.d443.s3	false	DDI-DrugBank.d443.s3.e1	DDI-DrugBank.d443.s3.e2
DDI-DrugBank.d443.s3	false	DDI-DrugBank.d443.s3.e1	DDI-DrugBank.d443.s3.e3
DDI-DrugBank.d443.s3	true	DDI-DrugBank.d443.s3.e1	DDI-DrugBank.d443.s3.e4
DDI-DrugBank.d443.s3	false	DDI-DrugBank.d443.s3.e2	DDI-DrugBank.d443.s3.e3
DDI-DrugBank.d443.s3	true	DDI-DrugBank.d443.s3.e2	DDI-DrugBank.d443.s3.e4
DDI-DrugBank.d443.s3	true	DDI-DrugBank.d443.s3.e3	DDI-DrugBank.d443.s3.e4
DDI-DrugBank.d443.s4|a|Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
DDI-DrugBank.d443.s4	0	28	Nonsteroidal Antiinflammatory	drug	DDI-DrugBank.d443.s4.e0
DDI-DrugBank.d443.s4	38	44	Aspirin	drug	DDI-DrugBank.d443.s4.e1
DDI-DrugBank.d443.s4	103	132	nonsteroidal anti-inflammatory	drug	DDI-DrugBank.d443.s4.e2
DDI-DrugBank.d443.s4	false	DDI-DrugBank.d443.s4.e0	DDI-DrugBank.d443.s4.e1
DDI-DrugBank.d443.s4	false	DDI-DrugBank.d443.s4.e0	DDI-DrugBank.d443.s4.e2
DDI-DrugBank.d443.s4	true	DDI-DrugBank.d443.s4.e1	DDI-DrugBank.d443.s4.e2
DDI-DrugBank.d443.s5|a|Urinary Alkalinizers: Decrease aspirin effectiveness by increasing the rate of salicylate renal excretion.
DDI-DrugBank.d443.s5	31	37	aspirin	brand	DDI-DrugBank.d443.s5.e0
DDI-DrugBank.d443.s5	79	88	salicylate	group	DDI-DrugBank.d443.s5.e1
DDI-DrugBank.d443.s5	false	DDI-DrugBank.d443.s5.e0	DDI-DrugBank.d443.s5.e1
DDI-DrugBank.d443.s6|a|Phenobarbital: Decreases aspirin effectiveness by enzyme induction.
DDI-DrugBank.d443.s6	0	12	Phenobarbital	drug	DDI-DrugBank.d443.s6.e0
DDI-DrugBank.d443.s6	25	31	aspirin	brand	DDI-DrugBank.d443.s6.e1
DDI-DrugBank.d443.s6	true	DDI-DrugBank.d443.s6.e0	DDI-DrugBank.d443.s6.e1
DDI-DrugBank.d443.s7|a|Phenytoin: Serum phenytoin levels may be increased by aspirin.
DDI-DrugBank.d443.s7	0	8	Phenytoin	drug	DDI-DrugBank.d443.s7.e0
DDI-DrugBank.d443.s7	17	25	phenytoin	drug	DDI-DrugBank.d443.s7.e1
DDI-DrugBank.d443.s7	54	60	aspirin	brand	DDI-DrugBank.d443.s7.e2
DDI-DrugBank.d443.s7	false	DDI-DrugBank.d443.s7.e0	DDI-DrugBank.d443.s7.e1
DDI-DrugBank.d443.s7	false	DDI-DrugBank.d443.s7.e0	DDI-DrugBank.d443.s7.e2
DDI-DrugBank.d443.s7	true	DDI-DrugBank.d443.s7.e1	DDI-DrugBank.d443.s7.e2
DDI-DrugBank.d443.s8|a|Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.
DDI-DrugBank.d443.s8	0	10	Propranolol	drug	DDI-DrugBank.d443.s8.e0
DDI-DrugBank.d443.s8	26	33	aspirins	brand	DDI-DrugBank.d443.s8.e1
DDI-DrugBank.d443.s8	true	DDI-DrugBank.d443.s8.e0	DDI-DrugBank.d443.s8.e1
DDI-DrugBank.d443.s9|a|Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.
DDI-DrugBank.d443.s9	0	7	Antacids	group	DDI-DrugBank.d443.s9.e0
DDI-DrugBank.d443.s9	25	31	Aspirin	brand	DDI-DrugBank.d443.s9.e1
DDI-DrugBank.d443.s9	71	78	antacids	group	DDI-DrugBank.d443.s9.e2
DDI-DrugBank.d443.s9	false	DDI-DrugBank.d443.s9.e0	DDI-DrugBank.d443.s9.e1
DDI-DrugBank.d443.s9	false	DDI-DrugBank.d443.s9.e0	DDI-DrugBank.d443.s9.e2
DDI-DrugBank.d443.s9	true	DDI-DrugBank.d443.s9.e1	DDI-DrugBank.d443.s9.e2
DDI-DrugBank.d109.s0|a|Ketoconazole/Itraconazole, Macrolides, Including Erythromycin
DDI-DrugBank.d109.s0	0	11	Ketoconazole	drug	DDI-DrugBank.d109.s0.e0
DDI-DrugBank.d109.s0	13	24	Itraconazole	drug	DDI-DrugBank.d109.s0.e1
DDI-DrugBank.d109.s0	27	36	Macrolides	group	DDI-DrugBank.d109.s0.e2
DDI-DrugBank.d109.s0	49	60	Erythromycin	drug	DDI-DrugBank.d109.s0.e3
DDI-DrugBank.d109.s0	false	DDI-DrugBank.d109.s0.e0	DDI-DrugBank.d109.s0.e1
DDI-DrugBank.d109.s0	false	DDI-DrugBank.d109.s0.e0	DDI-DrugBank.d109.s0.e2
DDI-DrugBank.d109.s0	false	DDI-DrugBank.d109.s0.e0	DDI-DrugBank.d109.s0.e3
DDI-DrugBank.d109.s0	false	DDI-DrugBank.d109.s0.e1	DDI-DrugBank.d109.s0.e2
DDI-DrugBank.d109.s0	false	DDI-DrugBank.d109.s0.e1	DDI-DrugBank.d109.s0.e3
DDI-DrugBank.d109.s0	false	DDI-DrugBank.d109.s0.e2	DDI-DrugBank.d109.s0.e3
DDI-DrugBank.d73.s0|a|Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.
DDI-DrugBank.d73.s0	35	43	reserpine	drug	DDI-DrugBank.d73.s0.e0
DDI-DrugBank.d73.s0	90	108	beta-blocking agent	group	DDI-DrugBank.d73.s0.e1
DDI-DrugBank.d73.s0	true	DDI-DrugBank.d73.s0.e0	DDI-DrugBank.d73.s0.e1
DDI-DrugBank.d73.s1|a|Patients treated with TENORMIN plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.
DDI-DrugBank.d73.s1	22	29	TENORMIN	brand	DDI-DrugBank.d73.s1.e0
DDI-DrugBank.d73.s2|a|Calcium channel blockers may also have an additive effect when given with TENORMIN .
DDI-DrugBank.d73.s2	0	23	Calcium channel blockers	group	DDI-DrugBank.d73.s2.e0
DDI-DrugBank.d73.s2	74	81	TENORMIN	brand	DDI-DrugBank.d73.s2.e1
DDI-DrugBank.d73.s2	true	DDI-DrugBank.d73.s2.e0	DDI-DrugBank.d73.s2.e1
DDI-DrugBank.d73.s3|a|Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.
DDI-DrugBank.d73.s3	0	12	Beta blockers	group	DDI-DrugBank.d73.s3.e0
DDI-DrugBank.d73.s3	89	97	clonidine	drug	DDI-DrugBank.d73.s3.e1
DDI-DrugBank.d73.s3	true	DDI-DrugBank.d73.s3.e0	DDI-DrugBank.d73.s3.e1
DDI-DrugBank.d73.s4|a|If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.
DDI-DrugBank.d73.s4	41	52	beta blocker	group	DDI-DrugBank.d73.s4.e0
DDI-DrugBank.d73.s4	120	128	clonidine	drug	DDI-DrugBank.d73.s4.e1
DDI-DrugBank.d73.s4	true	DDI-DrugBank.d73.s4.e0	DDI-DrugBank.d73.s4.e1
DDI-DrugBank.d73.s5|a|If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
DDI-DrugBank.d73.s5	13	21	clonidine	drug	DDI-DrugBank.d73.s5.e0
DDI-DrugBank.d73.s5	26	37	beta-blocker	group	DDI-DrugBank.d73.s5.e1
DDI-DrugBank.d73.s5	68	80	beta blockers	group	DDI-DrugBank.d73.s5.e2
DDI-DrugBank.d73.s5	123	131	clonidine	drug	DDI-DrugBank.d73.s5.e3
DDI-DrugBank.d73.s5	false	DDI-DrugBank.d73.s5.e0	DDI-DrugBank.d73.s5.e1
DDI-DrugBank.d73.s5	false	DDI-DrugBank.d73.s5.e0	DDI-DrugBank.d73.s5.e2
DDI-DrugBank.d73.s5	false	DDI-DrugBank.d73.s5.e0	DDI-DrugBank.d73.s5.e3
DDI-DrugBank.d73.s5	false	DDI-DrugBank.d73.s5.e1	DDI-DrugBank.d73.s5.e2
DDI-DrugBank.d73.s5	false	DDI-DrugBank.d73.s5.e1	DDI-DrugBank.d73.s5.e3
DDI-DrugBank.d73.s5	true	DDI-DrugBank.d73.s5.e2	DDI-DrugBank.d73.s5.e3
DDI-DrugBank.d73.s6|a|Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.
DDI-DrugBank.d73.s6	64	75	indomethacin	drug	DDI-DrugBank.d73.s6.e0
DDI-DrugBank.d73.s6	118	130	beta blockers	group	DDI-DrugBank.d73.s6.e1
DDI-DrugBank.d73.s6	true	DDI-DrugBank.d73.s6.e0	DDI-DrugBank.d73.s6.e1
DDI-DrugBank.d73.s7|a|Information on concurrent usage of atenolol and aspirin is limited.
DDI-DrugBank.d73.s7	35	42	atenolol	drug	DDI-DrugBank.d73.s7.e0
DDI-DrugBank.d73.s7	48	54	aspirin	brand	DDI-DrugBank.d73.s7.e1
DDI-DrugBank.d73.s7	false	DDI-DrugBank.d73.s7.e0	DDI-DrugBank.d73.s7.e1
DDI-DrugBank.d73.s8|a|Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting.
DDI-DrugBank.d73.s8	106	112	aspirin	brand	DDI-DrugBank.d73.s8.e0
DDI-DrugBank.d73.s8	118	130	beta blockers	group	DDI-DrugBank.d73.s8.e1
DDI-DrugBank.d73.s8	false	DDI-DrugBank.d73.s8.e0	DDI-DrugBank.d73.s8.e1
DDI-DrugBank.d73.s9|a|While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic.
DDI-DrugBank.d73.s9	13	25	beta blockers	group	DDI-DrugBank.d73.s9.e0
DDI-DrugBank.d73.s10|a|Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.
DDI-DrugBank.d73.s10	56	66	epinephrine	drug	DDI-DrugBank.d73.s10.e0
DDI-DrugBank.d11.s0|a|Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
DDI-DrugBank.d11.s0	23	31	Albuterol	drug	DDI-DrugBank.d11.s0.e0
DDI-DrugBank.d11.s0	35	43	STRATTERA	brand	DDI-DrugBank.d11.s0.e1
DDI-DrugBank.d11.s0	160	168	albuterol	drug	DDI-DrugBank.d11.s0.e2
DDI-DrugBank.d11.s0	180	193	beta2 agonists	group	DDI-DrugBank.d11.s0.e3
DDI-DrugBank.d11.s0	218	226	albuterol	drug	DDI-DrugBank.d11.s0.e4
DDI-DrugBank.d11.s0	false	DDI-DrugBank.d11.s0.e0	DDI-DrugBank.d11.s0.e1
DDI-DrugBank.d11.s0	false	DDI-DrugBank.d11.s0.e0	DDI-DrugBank.d11.s0.e2
DDI-DrugBank.d11.s0	false	DDI-DrugBank.d11.s0.e0	DDI-DrugBank.d11.s0.e3
DDI-DrugBank.d11.s0	false	DDI-DrugBank.d11.s0.e0	DDI-DrugBank.d11.s0.e4
DDI-DrugBank.d11.s0	true	DDI-DrugBank.d11.s0.e1	DDI-DrugBank.d11.s0.e2
DDI-DrugBank.d11.s0	false	DDI-DrugBank.d11.s0.e1	DDI-DrugBank.d11.s0.e3
DDI-DrugBank.d11.s0	false	DDI-DrugBank.d11.s0.e1	DDI-DrugBank.d11.s0.e4
DDI-DrugBank.d11.s0	false	DDI-DrugBank.d11.s0.e2	DDI-DrugBank.d11.s0.e3
DDI-DrugBank.d11.s0	false	DDI-DrugBank.d11.s0.e2	DDI-DrugBank.d11.s0.e4
DDI-DrugBank.d11.s0	false	DDI-DrugBank.d11.s0.e3	DDI-DrugBank.d11.s0.e4
DDI-DrugBank.d11.s1|a|CYP2D6 inhibitors - Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine.
DDI-DrugBank.d11.s1	20	30	Atomoxetine	drug	DDI-DrugBank.d11.s1.e0
DDI-DrugBank.d11.s1	82	101	4-hydroxyatomoxetine	drug_n	DDI-DrugBank.d11.s1.e1
DDI-DrugBank.d11.s1	false	DDI-DrugBank.d11.s1.e0	DDI-DrugBank.d11.s1.e1
DDI-DrugBank.d11.s2|a|In EMs, selective inhibitors of CYP2D6 increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in PMs.
DDI-DrugBank.d11.s2	48	58	atomoxetine	drug	DDI-DrugBank.d11.s2.e0
DDI-DrugBank.d11.s3|a|Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
DDI-DrugBank.d11.s3	21	29	STRATTERA	brand	DDI-DrugBank.d11.s3.e0
DDI-DrugBank.d11.s3	98	107	paroxetine	drug	DDI-DrugBank.d11.s3.e1
DDI-DrugBank.d11.s3	110	119	fluoxetine	drug	DDI-DrugBank.d11.s3.e2
DDI-DrugBank.d11.s3	126	134	quinidine	drug	DDI-DrugBank.d11.s3.e3
DDI-DrugBank.d11.s3	true	DDI-DrugBank.d11.s3.e0	DDI-DrugBank.d11.s3.e1
DDI-DrugBank.d11.s3	true	DDI-DrugBank.d11.s3.e0	DDI-DrugBank.d11.s3.e2
DDI-DrugBank.d11.s3	true	DDI-DrugBank.d11.s3.e0	DDI-DrugBank.d11.s3.e3
DDI-DrugBank.d11.s3	false	DDI-DrugBank.d11.s3.e1	DDI-DrugBank.d11.s3.e2
DDI-DrugBank.d11.s3	false	DDI-DrugBank.d11.s3.e1	DDI-DrugBank.d11.s3.e3
DDI-DrugBank.d11.s3	false	DDI-DrugBank.d11.s3.e2	DDI-DrugBank.d11.s3.e3
DDI-DrugBank.d11.s4|a|In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
DDI-DrugBank.d11.s4	31	40	paroxetine	drug	DDI-DrugBank.d11.s4.e0
DDI-DrugBank.d11.s4	45	54	fluoxetine	drug	DDI-DrugBank.d11.s4.e1
DDI-DrugBank.d11.s4	68	78	atomoxetine	drug	DDI-DrugBank.d11.s4.e2
DDI-DrugBank.d11.s4	157	167	atomoxetine	drug	DDI-DrugBank.d11.s4.e3
DDI-DrugBank.d11.s4	false	DDI-DrugBank.d11.s4.e0	DDI-DrugBank.d11.s4.e1
DDI-DrugBank.d11.s4	true	DDI-DrugBank.d11.s4.e0	DDI-DrugBank.d11.s4.e2
DDI-DrugBank.d11.s4	false	DDI-DrugBank.d11.s4.e0	DDI-DrugBank.d11.s4.e3
DDI-DrugBank.d11.s4	true	DDI-DrugBank.d11.s4.e1	DDI-DrugBank.d11.s4.e2
DDI-DrugBank.d11.s4	false	DDI-DrugBank.d11.s4.e1	DDI-DrugBank.d11.s4.e3
DDI-DrugBank.d11.s4	false	DDI-DrugBank.d11.s4.e2	DDI-DrugBank.d11.s4.e3
DDI-DrugBank.d11.s5|a|In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.
DDI-DrugBank.d11.s5	131	141	atomoxetine	drug	DDI-DrugBank.d11.s5.e0
DDI-DrugBank.d11.s6|a|Pressor agents - Because of possible effects on blood pressure, STRATTERA should be used cautiously with pressor agents.
DDI-DrugBank.d11.s6	64	72	STRATTERA	brand	DDI-DrugBank.d11.s6.e0
DDI-DrugBank.d140.s0|a|The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), erythromycin, azole antifungals.
DDI-DrugBank.d140.s0	110	121	cyclosporine	drug	DDI-DrugBank.d140.s0.e0
DDI-DrugBank.d140.s0	124	146	fibric acid derivatives	group	DDI-DrugBank.d140.s0.e1
DDI-DrugBank.d140.s0	149	154	niacin	drug	DDI-DrugBank.d140.s0.e2
DDI-DrugBank.d140.s0	157	170	nicotinic acid	drug	DDI-DrugBank.d140.s0.e3
DDI-DrugBank.d140.s0	174	185	erythromycin	drug	DDI-DrugBank.d140.s0.e4
DDI-DrugBank.d140.s0	188	204	azole antifungals	group	DDI-DrugBank.d140.s0.e5
DDI-DrugBank.d140.s0	false	DDI-DrugBank.d140.s0.e0	DDI-DrugBank.d140.s0.e1
DDI-DrugBank.d140.s0	false	DDI-DrugBank.d140.s0.e0	DDI-DrugBank.d140.s0.e2
DDI-DrugBank.d140.s0	false	DDI-DrugBank.d140.s0.e0	DDI-DrugBank.d140.s0.e3
DDI-DrugBank.d140.s0	false	DDI-DrugBank.d140.s0.e0	DDI-DrugBank.d140.s0.e4
DDI-DrugBank.d140.s0	false	DDI-DrugBank.d140.s0.e0	DDI-DrugBank.d140.s0.e5
DDI-DrugBank.d140.s0	false	DDI-DrugBank.d140.s0.e1	DDI-DrugBank.d140.s0.e2
DDI-DrugBank.d140.s0	false	DDI-DrugBank.d140.s0.e1	DDI-DrugBank.d140.s0.e3
DDI-DrugBank.d140.s0	false	DDI-DrugBank.d140.s0.e1	DDI-DrugBank.d140.s0.e4
DDI-DrugBank.d140.s0	false	DDI-DrugBank.d140.s0.e1	DDI-DrugBank.d140.s0.e5
DDI-DrugBank.d140.s0	false	DDI-DrugBank.d140.s0.e2	DDI-DrugBank.d140.s0.e3
DDI-DrugBank.d140.s1|a|Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
DDI-DrugBank.d140.s1	0	6	Antacid	group	DDI-DrugBank.d140.s1.e0
DDI-DrugBank.d140.s1	14	25	atorvastatin	drug	DDI-DrugBank.d140.s1.e1
DDI-DrugBank.d140.s1	31	39	Maalox TC	brand	DDI-DrugBank.d140.s1.e2
DDI-DrugBank.d140.s1	98	109	atorvastatin	drug	DDI-DrugBank.d140.s1.e3
DDI-DrugBank.d140.s1	false	DDI-DrugBank.d140.s1.e0	DDI-DrugBank.d140.s1.e1
DDI-DrugBank.d140.s1	false	DDI-DrugBank.d140.s1.e0	DDI-DrugBank.d140.s1.e2
DDI-DrugBank.d140.s1	false	DDI-DrugBank.d140.s1.e0	DDI-DrugBank.d140.s1.e3
DDI-DrugBank.d140.s1	true	DDI-DrugBank.d140.s1.e1	DDI-DrugBank.d140.s1.e2
DDI-DrugBank.d140.s1	false	DDI-DrugBank.d140.s1.e1	DDI-DrugBank.d140.s1.e3
DDI-DrugBank.d140.s1	false	DDI-DrugBank.d140.s1.e2	DDI-DrugBank.d140.s1.e3
DDI-DrugBank.d140.s2|a|However, LDL-C reduction was not altered.
DDI-DrugBank.d140.s3|a|Antipyrine: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.
DDI-DrugBank.d140.s3	0	9	Antipyrine	drug	DDI-DrugBank.d140.s3.e0
DDI-DrugBank.d140.s3	20	31	atorvastatin	drug	DDI-DrugBank.d140.s3.e1
DDI-DrugBank.d140.s3	73	82	antipyrine	drug	DDI-DrugBank.d140.s3.e2
DDI-DrugBank.d140.s3	109	113	drugs	drug	DDI-DrugBank.d140.s3.e3
DDI-DrugBank.d140.s3	false	DDI-DrugBank.d140.s3.e0	DDI-DrugBank.d140.s3.e1
DDI-DrugBank.d140.s3	false	DDI-DrugBank.d140.s3.e0	DDI-DrugBank.d140.s3.e2
DDI-DrugBank.d140.s3	false	DDI-DrugBank.d140.s3.e0	DDI-DrugBank.d140.s3.e3
DDI-DrugBank.d140.s3	false	DDI-DrugBank.d140.s3.e1	DDI-DrugBank.d140.s3.e2
DDI-DrugBank.d140.s3	false	DDI-DrugBank.d140.s3.e1	DDI-DrugBank.d140.s3.e3
DDI-DrugBank.d140.s3	false	DDI-DrugBank.d140.s3.e2	DDI-DrugBank.d140.s3.e3
DDI-DrugBank.d140.s4|a|Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.
DDI-DrugBank.d140.s4	0	9	Colestipol	drug	DDI-DrugBank.d140.s4.e0
DDI-DrugBank.d140.s4	37	48	atorvastatin	drug	DDI-DrugBank.d140.s4.e1
DDI-DrugBank.d140.s4	83	92	colestipol	drug	DDI-DrugBank.d140.s4.e2
DDI-DrugBank.d140.s4	98	109	atorvastatin	drug	DDI-DrugBank.d140.s4.e3
DDI-DrugBank.d140.s4	false	DDI-DrugBank.d140.s4.e0	DDI-DrugBank.d140.s4.e1
DDI-DrugBank.d140.s4	false	DDI-DrugBank.d140.s4.e0	DDI-DrugBank.d140.s4.e2
DDI-DrugBank.d140.s4	false	DDI-DrugBank.d140.s4.e0	DDI-DrugBank.d140.s4.e3
DDI-DrugBank.d140.s4	false	DDI-DrugBank.d140.s4.e1	DDI-DrugBank.d140.s4.e2
DDI-DrugBank.d140.s4	false	DDI-DrugBank.d140.s4.e1	DDI-DrugBank.d140.s4.e3
DDI-DrugBank.d140.s4	true	DDI-DrugBank.d140.s4.e2	DDI-DrugBank.d140.s4.e3
DDI-DrugBank.d140.s5|a|However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
DDI-DrugBank.d140.s5	42	53	atorvastatin	drug	DDI-DrugBank.d140.s5.e0
DDI-DrugBank.d140.s5	59	68	colestipol	drug	DDI-DrugBank.d140.s5.e1
DDI-DrugBank.d140.s5	true	DDI-DrugBank.d140.s5.e0	DDI-DrugBank.d140.s5.e1
DDI-DrugBank.d140.s6|a|Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.
DDI-DrugBank.d140.s6	0	9	Cimetidine	drug	DDI-DrugBank.d140.s6.e0
DDI-DrugBank.d140.s6	12	23	Atorvastatin	drug	DDI-DrugBank.d140.s6.e1
DDI-DrugBank.d140.s6	107	116	cimetidine	drug	DDI-DrugBank.d140.s6.e2
DDI-DrugBank.d140.s6	false	DDI-DrugBank.d140.s6.e0	DDI-DrugBank.d140.s6.e1
DDI-DrugBank.d140.s6	false	DDI-DrugBank.d140.s6.e0	DDI-DrugBank.d140.s6.e2
DDI-DrugBank.d140.s6	false	DDI-DrugBank.d140.s6.e1	DDI-DrugBank.d140.s6.e2
DDI-DrugBank.d140.s7|a|Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
DDI-DrugBank.d140.s7	0	6	Digoxin	drug	DDI-DrugBank.d140.s7.e0
DDI-DrugBank.d140.s7	32	43	atorvastatin	drug	DDI-DrugBank.d140.s7.e1
DDI-DrugBank.d140.s7	49	55	digoxin	drug	DDI-DrugBank.d140.s7.e2
DDI-DrugBank.d140.s7	98	104	digoxin	drug	DDI-DrugBank.d140.s7.e3
DDI-DrugBank.d140.s7	false	DDI-DrugBank.d140.s7.e0	DDI-DrugBank.d140.s7.e1
DDI-DrugBank.d140.s7	false	DDI-DrugBank.d140.s7.e0	DDI-DrugBank.d140.s7.e2
DDI-DrugBank.d140.s7	false	DDI-DrugBank.d140.s7.e0	DDI-DrugBank.d140.s7.e3
DDI-DrugBank.d140.s7	true	DDI-DrugBank.d140.s7.e1	DDI-DrugBank.d140.s7.e2
DDI-DrugBank.d140.s7	false	DDI-DrugBank.d140.s7.e1	DDI-DrugBank.d140.s7.e3
DDI-DrugBank.d140.s7	false	DDI-DrugBank.d140.s7.e2	DDI-DrugBank.d140.s7.e3
DDI-DrugBank.d140.s8|a|Patients taking digoxin should be monitored appropriately.
DDI-DrugBank.d140.s8	16	22	digoxin	drug	DDI-DrugBank.d140.s8.e0
DDI-DrugBank.d140.s9|a|Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
DDI-DrugBank.d140.s9	0	11	Erythromycin	drug	DDI-DrugBank.d140.s9.e0
DDI-DrugBank.d140.s9	63	74	atorvastatin	drug	DDI-DrugBank.d140.s9.e1
DDI-DrugBank.d140.s9	129	140	atorvastatin	drug	DDI-DrugBank.d140.s9.e2
DDI-DrugBank.d140.s9	146	157	erythromycin	drug	DDI-DrugBank.d140.s9.e3
DDI-DrugBank.d140.s9	false	DDI-DrugBank.d140.s9.e0	DDI-DrugBank.d140.s9.e1
DDI-DrugBank.d140.s9	false	DDI-DrugBank.d140.s9.e0	DDI-DrugBank.d140.s9.e2
DDI-DrugBank.d140.s9	false	DDI-DrugBank.d140.s9.e0	DDI-DrugBank.d140.s9.e3
DDI-DrugBank.d140.s9	false	DDI-DrugBank.d140.s9.e1	DDI-DrugBank.d140.s9.e2
DDI-DrugBank.d140.s9	false	DDI-DrugBank.d140.s9.e1	DDI-DrugBank.d140.s9.e3
DDI-DrugBank.d140.s9	true	DDI-DrugBank.d140.s9.e2	DDI-DrugBank.d140.s9.e3
DDI-DrugBank.d140.s10|a|Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
DDI-DrugBank.d140.s10	5	18	Contraceptives	group	DDI-DrugBank.d140.s10.e0
DDI-DrugBank.d140.s10	41	52	atorvastatin	drug	DDI-DrugBank.d140.s10.e1
DDI-DrugBank.d140.s10	66	78	contraceptive	group	DDI-DrugBank.d140.s10.e2
DDI-DrugBank.d140.s10	105	117	norethindrone	drug	DDI-DrugBank.d140.s10.e3
DDI-DrugBank.d140.s10	123	139	ethinyl estradiol	drug	DDI-DrugBank.d140.s10.e4
DDI-DrugBank.d140.s10	false	DDI-DrugBank.d140.s10.e0	DDI-DrugBank.d140.s10.e1
DDI-DrugBank.d140.s10	false	DDI-DrugBank.d140.s10.e0	DDI-DrugBank.d140.s10.e2
DDI-DrugBank.d140.s10	false	DDI-DrugBank.d140.s10.e0	DDI-DrugBank.d140.s10.e3
DDI-DrugBank.d140.s10	false	DDI-DrugBank.d140.s10.e0	DDI-DrugBank.d140.s10.e4
DDI-DrugBank.d140.s10	true	DDI-DrugBank.d140.s10.e1	DDI-DrugBank.d140.s10.e2
DDI-DrugBank.d140.s10	true	DDI-DrugBank.d140.s10.e1	DDI-DrugBank.d140.s10.e3
DDI-DrugBank.d140.s10	true	DDI-DrugBank.d140.s10.e1	DDI-DrugBank.d140.s10.e4
DDI-DrugBank.d140.s10	false	DDI-DrugBank.d140.s10.e2	DDI-DrugBank.d140.s10.e3
DDI-DrugBank.d140.s10	false	DDI-DrugBank.d140.s10.e2	DDI-DrugBank.d140.s10.e4
DDI-DrugBank.d140.s10	false	DDI-DrugBank.d140.s10.e3	DDI-DrugBank.d140.s10.e4
DDI-DrugBank.d140.s11|a|These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.
DDI-DrugBank.d140.s11	60	72	contraceptive	group	DDI-DrugBank.d140.s11.e0
DDI-DrugBank.d140.s11	93	104	atorvastatin	drug	DDI-DrugBank.d140.s11.e1
DDI-DrugBank.d140.s11	true	DDI-DrugBank.d140.s11.e0	DDI-DrugBank.d140.s11.e1
DDI-DrugBank.d140.s12|a|Warfarin: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.
DDI-DrugBank.d140.s12	0	7	Warfarin	drug	DDI-DrugBank.d140.s12.e0
DDI-DrugBank.d140.s12	10	21	Atorvastatin	drug	DDI-DrugBank.d140.s12.e1
DDI-DrugBank.d140.s12	128	135	warfarin	drug	DDI-DrugBank.d140.s12.e2
DDI-DrugBank.d140.s12	false	DDI-DrugBank.d140.s12.e0	DDI-DrugBank.d140.s12.e1
DDI-DrugBank.d140.s12	false	DDI-DrugBank.d140.s12.e0	DDI-DrugBank.d140.s12.e2
DDI-DrugBank.d140.s12	false	DDI-DrugBank.d140.s12.e1	DDI-DrugBank.d140.s12.e2
DDI-DrugBank.d140.s13|a|Endocrine Function HMG-CoA reductase inhibitors interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production.
DDI-DrugBank.d140.s13	19	46	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d140.s13.e0
DDI-DrugBank.d140.s14|a|Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve.
DDI-DrugBank.d140.s14	33	44	atorvastatin	drug	DDI-DrugBank.d140.s14.e0
DDI-DrugBank.d140.s15|a|The effects of HMG-CoA reductase inhibitors on male fertility have not been studied in adequate numbers of patients.
DDI-DrugBank.d140.s15	15	42	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d140.s15.e0
DDI-DrugBank.d140.s16|a|The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown.
DDI-DrugBank.d140.s17|a|Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
DDI-DrugBank.d140.s17	34	60	HMG-CoA reductase inhibitor	group	DDI-DrugBank.d140.s17.e0
DDI-DrugBank.d140.s17	184	195	ketoconazole	drug	DDI-DrugBank.d140.s17.e1
DDI-DrugBank.d140.s17	198	211	spironolactone	drug	DDI-DrugBank.d140.s17.e2
DDI-DrugBank.d140.s17	218	227	cimetidine	drug	DDI-DrugBank.d140.s17.e3
DDI-DrugBank.d140.s17	true	DDI-DrugBank.d140.s17.e0	DDI-DrugBank.d140.s17.e1
DDI-DrugBank.d140.s17	true	DDI-DrugBank.d140.s17.e0	DDI-DrugBank.d140.s17.e2
DDI-DrugBank.d140.s17	true	DDI-DrugBank.d140.s17.e0	DDI-DrugBank.d140.s17.e3
DDI-DrugBank.d140.s17	false	DDI-DrugBank.d140.s17.e1	DDI-DrugBank.d140.s17.e2
DDI-DrugBank.d140.s17	false	DDI-DrugBank.d140.s17.e1	DDI-DrugBank.d140.s17.e3
DDI-DrugBank.d140.s17	false	DDI-DrugBank.d140.s17.e2	DDI-DrugBank.d140.s17.e3
DDI-DrugBank.d140.s18|a|CNS Toxicity Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day.
DDI-DrugBank.d140.s19|a|Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day.
DDI-DrugBank.d140.s20|a|The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day.
DDI-DrugBank.d140.s21|a|A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study.
DDI-DrugBank.d140.s22|a|No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day.
DDI-DrugBank.d140.s23|a|These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0-24) based on the maximum recommended human dose of 80 mg/day.
DDI-DrugBank.d140.s24|a|CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class.
DDI-DrugBank.d140.s25|a|A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.
DDI-DrugBank.d424.s0|a|Atovaquone is highly bound to plasma protein (99.9%).
DDI-DrugBank.d424.s0	0	9	Atovaquone	drug	DDI-DrugBank.d424.s0.e0
DDI-DrugBank.d424.s1|a|Therefore, caution should be used when administering MEPRON concurrently with other highly plasma protein- bound drugs with narrow therapeutic indices, as competition for binding sites may occur.
DDI-DrugBank.d424.s1	53	58	MEPRON	brand	DDI-DrugBank.d424.s1.e0
DDI-DrugBank.d424.s2|a|The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone.
DDI-DrugBank.d424.s2	40	49	atovaquone	drug	DDI-DrugBank.d424.s2.e0
DDI-DrugBank.d424.s2	132	140	phenytoin	drug	DDI-DrugBank.d424.s2.e1
DDI-DrugBank.d424.s2	178	186	phenytoin	drug	DDI-DrugBank.d424.s2.e2
DDI-DrugBank.d424.s2	216	225	atovaquone	drug	DDI-DrugBank.d424.s2.e3
DDI-DrugBank.d424.s2	false	DDI-DrugBank.d424.s2.e0	DDI-DrugBank.d424.s2.e1
DDI-DrugBank.d424.s2	false	DDI-DrugBank.d424.s2.e0	DDI-DrugBank.d424.s2.e2
DDI-DrugBank.d424.s2	false	DDI-DrugBank.d424.s2.e0	DDI-DrugBank.d424.s2.e3
DDI-DrugBank.d424.s2	false	DDI-DrugBank.d424.s2.e1	DDI-DrugBank.d424.s2.e2
DDI-DrugBank.d424.s2	false	DDI-DrugBank.d424.s2.e1	DDI-DrugBank.d424.s2.e3
DDI-DrugBank.d424.s2	false	DDI-DrugBank.d424.s2.e2	DDI-DrugBank.d424.s2.e3
DDI-DrugBank.d424.s3|a|Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
DDI-DrugBank.d424.s3	0	7	Rifampin	drug	DDI-DrugBank.d424.s3.e0
DDI-DrugBank.d424.s3	30	37	rifampin	drug	DDI-DrugBank.d424.s3.e1
DDI-DrugBank.d424.s3	43	48	MEPRON	brand	DDI-DrugBank.d424.s3.e2
DDI-DrugBank.d424.s3	127	136	atovaquone	drug	DDI-DrugBank.d424.s3.e3
DDI-DrugBank.d424.s3	false	DDI-DrugBank.d424.s3.e0	DDI-DrugBank.d424.s3.e1
DDI-DrugBank.d424.s3	false	DDI-DrugBank.d424.s3.e0	DDI-DrugBank.d424.s3.e2
DDI-DrugBank.d424.s3	false	DDI-DrugBank.d424.s3.e0	DDI-DrugBank.d424.s3.e3
DDI-DrugBank.d424.s3	true	DDI-DrugBank.d424.s3.e1	DDI-DrugBank.d424.s3.e2
DDI-DrugBank.d424.s3	false	DDI-DrugBank.d424.s3.e1	DDI-DrugBank.d424.s3.e3
DDI-DrugBank.d424.s3	false	DDI-DrugBank.d424.s3.e2	DDI-DrugBank.d424.s3.e3
DDI-DrugBank.d424.s4|a|Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.
DDI-DrugBank.d424.s4	16	23	rifampin	drug	DDI-DrugBank.d424.s4.e0
DDI-DrugBank.d424.s4	86	91	MEPRON	brand	DDI-DrugBank.d424.s4.e1
DDI-DrugBank.d424.s4	true	DDI-DrugBank.d424.s4.e0	DDI-DrugBank.d424.s4.e1
DDI-DrugBank.d424.s5|a|Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.
DDI-DrugBank.d424.s5	0	8	Rifabutin	drug	DDI-DrugBank.d424.s5.e0
DDI-DrugBank.d424.s5	19	27	rifamycin	drug	DDI-DrugBank.d424.s5.e1
DDI-DrugBank.d424.s5	57	64	rifampin	drug	DDI-DrugBank.d424.s5.e2
DDI-DrugBank.d424.s5	126	133	rifampin	drug	DDI-DrugBank.d424.s5.e3
DDI-DrugBank.d424.s5	false	DDI-DrugBank.d424.s5.e0	DDI-DrugBank.d424.s5.e1
DDI-DrugBank.d424.s5	false	DDI-DrugBank.d424.s5.e0	DDI-DrugBank.d424.s5.e2
DDI-DrugBank.d424.s5	false	DDI-DrugBank.d424.s5.e0	DDI-DrugBank.d424.s5.e3
DDI-DrugBank.d424.s5	false	DDI-DrugBank.d424.s5.e1	DDI-DrugBank.d424.s5.e2
DDI-DrugBank.d424.s5	false	DDI-DrugBank.d424.s5.e1	DDI-DrugBank.d424.s5.e3
DDI-DrugBank.d424.s5	false	DDI-DrugBank.d424.s5.e2	DDI-DrugBank.d424.s5.e3
DDI-DrugBank.d424.s6|a|No interaction trials have been conducted with MEPRON and rifabutin.
DDI-DrugBank.d424.s6	47	52	MEPRON	brand	DDI-DrugBank.d424.s6.e0
DDI-DrugBank.d424.s6	58	66	rifabutin	drug	DDI-DrugBank.d424.s6.e1
DDI-DrugBank.d424.s6	false	DDI-DrugBank.d424.s6.e0	DDI-DrugBank.d424.s6.e1
DDI-DrugBank.d424.s7|a|Drug/ Laboratory Test Interactions: It is not known if MEPRON interferes with clinical laboratory test or assay results.
DDI-DrugBank.d424.s7	55	60	MEPRON	brand	DDI-DrugBank.d424.s7.e0
DDI-DrugBank.d469.s0|a|Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;
DDI-DrugBank.d469.s0	61	68	TRACRIUM	brand	DDI-DrugBank.d469.s0.e0
DDI-DrugBank.d469.s0	79	87	enflurane	drug	DDI-DrugBank.d469.s0.e1
DDI-DrugBank.d469.s0	true	DDI-DrugBank.d469.s0.e0	DDI-DrugBank.d469.s0.e1
DDI-DrugBank.d469.s1|a|isoflurane;
DDI-DrugBank.d469.s1	0	9	isoflurane	drug	DDI-DrugBank.d469.s1.e0
DDI-DrugBank.d469.s2|a|halothane;
DDI-DrugBank.d469.s2	0	8	halothane	drug	DDI-DrugBank.d469.s2.e0
DDI-DrugBank.d469.s3|a|certain antibiotics, especially the aminoglycosides and polymyxins;
DDI-DrugBank.d469.s3	8	18	antibiotics	group	DDI-DrugBank.d469.s3.e0
DDI-DrugBank.d469.s3	36	50	aminoglycosides	group	DDI-DrugBank.d469.s3.e1
DDI-DrugBank.d469.s3	56	65	polymyxins	group	DDI-DrugBank.d469.s3.e2
DDI-DrugBank.d469.s3	false	DDI-DrugBank.d469.s3.e0	DDI-DrugBank.d469.s3.e1
DDI-DrugBank.d469.s3	false	DDI-DrugBank.d469.s3.e0	DDI-DrugBank.d469.s3.e2
DDI-DrugBank.d469.s3	false	DDI-DrugBank.d469.s3.e1	DDI-DrugBank.d469.s3.e2
DDI-DrugBank.d469.s4|a|lithium;
DDI-DrugBank.d469.s4	0	6	lithium	drug	DDI-DrugBank.d469.s4.e0
DDI-DrugBank.d469.s5|a|magnesium salts;
DDI-DrugBank.d469.s5	0	8	magnesium	drug	DDI-DrugBank.d469.s5.e0
DDI-DrugBank.d469.s6|a|procainamide;
DDI-DrugBank.d469.s6	0	11	procainamide	drug	DDI-DrugBank.d469.s6.e0
DDI-DrugBank.d469.s7|a|Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d469.s7	61	68	TRACRIUM	brand	DDI-DrugBank.d469.s7.e0
DDI-DrugBank.d469.s7	79	87	enflurane	drug	DDI-DrugBank.d469.s7.e1
DDI-DrugBank.d469.s7	89	98	isoflurane	drug	DDI-DrugBank.d469.s7.e2
DDI-DrugBank.d469.s7	100	108	halothane	drug	DDI-DrugBank.d469.s7.e3
DDI-DrugBank.d469.s7	118	128	antibiotics	group	DDI-DrugBank.d469.s7.e4
DDI-DrugBank.d469.s7	146	160	aminoglycosides	group	DDI-DrugBank.d469.s7.e5
DDI-DrugBank.d469.s7	166	175	polymyxins	group	DDI-DrugBank.d469.s7.e6
DDI-DrugBank.d469.s7	177	183	lithium	drug	DDI-DrugBank.d469.s7.e7
DDI-DrugBank.d469.s7	185	193	magnesium	drug	DDI-DrugBank.d469.s7.e8
DDI-DrugBank.d469.s7	201	212	procainamide	drug	DDI-DrugBank.d469.s7.e9
DDI-DrugBank.d469.s7	true	DDI-DrugBank.d469.s7.e0	DDI-DrugBank.d469.s7.e1
DDI-DrugBank.d469.s7	true	DDI-DrugBank.d469.s7.e0	DDI-DrugBank.d469.s7.e2
DDI-DrugBank.d469.s7	true	DDI-DrugBank.d469.s7.e0	DDI-DrugBank.d469.s7.e3
DDI-DrugBank.d469.s7	true	DDI-DrugBank.d469.s7.e0	DDI-DrugBank.d469.s7.e4
DDI-DrugBank.d469.s7	true	DDI-DrugBank.d469.s7.e0	DDI-DrugBank.d469.s7.e5
DDI-DrugBank.d469.s7	true	DDI-DrugBank.d469.s7.e0	DDI-DrugBank.d469.s7.e6
DDI-DrugBank.d469.s7	true	DDI-DrugBank.d469.s7.e0	DDI-DrugBank.d469.s7.e7
DDI-DrugBank.d469.s7	true	DDI-DrugBank.d469.s7.e0	DDI-DrugBank.d469.s7.e8
DDI-DrugBank.d469.s7	true	DDI-DrugBank.d469.s7.e0	DDI-DrugBank.d469.s7.e9
DDI-DrugBank.d469.s7	true	DDI-DrugBank.d469.s7.e0	DDI-DrugBank.d469.s7.e10
DDI-DrugBank.d469.s8|a|If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.
DDI-DrugBank.d469.s8	9	24	muscle relaxants	group	DDI-DrugBank.d469.s8.e0
DDI-DrugBank.d469.s9|a|The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM.
DDI-DrugBank.d469.s9	28	42	succinylcholine	drug	DDI-DrugBank.d469.s9.e0
DDI-DrugBank.d469.s9	160	167	TRACRIUM	brand	DDI-DrugBank.d469.s9.e1
DDI-DrugBank.d469.s9	true	DDI-DrugBank.d469.s9.e0	DDI-DrugBank.d469.s9.e1
DDI-DrugBank.d469.s10|a|TRACRIUM should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.
DDI-DrugBank.d469.s10	0	7	TRACRIUM	brand	DDI-DrugBank.d469.s10.e0
DDI-DrugBank.d469.s10	71	85	succinylcholine	drug	DDI-DrugBank.d469.s10.e1
DDI-DrugBank.d469.s10	true	DDI-DrugBank.d469.s10.e0	DDI-DrugBank.d469.s10.e1
DDI-DrugBank.d222.s0|a|When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
DDI-DrugBank.d222.s0	5	12	atropine	drug	DDI-DrugBank.d222.s0.e0
DDI-DrugBank.d222.s0	18	28	pralidoxime	drug	DDI-DrugBank.d222.s0.e1
DDI-DrugBank.d222.s0	194	201	atropine	drug	DDI-DrugBank.d222.s0.e2
DDI-DrugBank.d222.s0	225	235	pralidoxime	drug	DDI-DrugBank.d222.s0.e3
DDI-DrugBank.d222.s0	266	273	atropine	drug	DDI-DrugBank.d222.s0.e4
DDI-DrugBank.d222.s0	true	DDI-DrugBank.d222.s0.e0	DDI-DrugBank.d222.s0.e1
DDI-DrugBank.d222.s0	false	DDI-DrugBank.d222.s0.e0	DDI-DrugBank.d222.s0.e2
DDI-DrugBank.d222.s0	false	DDI-DrugBank.d222.s0.e0	DDI-DrugBank.d222.s0.e3
DDI-DrugBank.d222.s0	false	DDI-DrugBank.d222.s0.e0	DDI-DrugBank.d222.s0.e4
DDI-DrugBank.d222.s0	false	DDI-DrugBank.d222.s0.e1	DDI-DrugBank.d222.s0.e2
DDI-DrugBank.d222.s0	false	DDI-DrugBank.d222.s0.e1	DDI-DrugBank.d222.s0.e3
DDI-DrugBank.d222.s0	false	DDI-DrugBank.d222.s0.e1	DDI-DrugBank.d222.s0.e4
DDI-DrugBank.d222.s0	false	DDI-DrugBank.d222.s0.e2	DDI-DrugBank.d222.s0.e3
DDI-DrugBank.d222.s0	false	DDI-DrugBank.d222.s0.e2	DDI-DrugBank.d222.s0.e4
DDI-DrugBank.d222.s0	true	DDI-DrugBank.d222.s0.e3	DDI-DrugBank.d222.s0.e4
DDI-DrugBank.d222.s1|a|The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.
DDI-DrugBank.d222.s1	147	154	atropine	drug	DDI-DrugBank.d222.s1.e0
DDI-DrugBank.d222.s1	160	170	pralidoxime	drug	DDI-DrugBank.d222.s1.e1
DDI-DrugBank.d222.s1	true	DDI-DrugBank.d222.s1.e0	DDI-DrugBank.d222.s1.e1
DDI-DrugBank.d222.s2|a|Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.
DDI-DrugBank.d222.s2	6	17	barbiturates	group	DDI-DrugBank.d222.s2.e0
DDI-DrugBank.d222.s2	42	60	anticholinesterases	group	DDI-DrugBank.d222.s2.e1
DDI-DrugBank.d222.s2	true	DDI-DrugBank.d222.s2.e0	DDI-DrugBank.d222.s2.e1
DDI-DrugBank.d374.s0|a|Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
DDI-DrugBank.d374.s0	0	8	Auranofin	drug	DDI-DrugBank.d374.s0.e0
DDI-DrugBank.d374.s0	82	96	gold medication	group	DDI-DrugBank.d374.s0.e1
DDI-DrugBank.d374.s0	109	116	Solganal	brand	DDI-DrugBank.d374.s0.e2
DDI-DrugBank.d374.s0	122	132	Myochrysine	brand	DDI-DrugBank.d374.s0.e3
DDI-DrugBank.d374.s0	true	DDI-DrugBank.d374.s0.e0	DDI-DrugBank.d374.s0.e1
DDI-DrugBank.d374.s0	true	DDI-DrugBank.d374.s0.e0	DDI-DrugBank.d374.s0.e2
DDI-DrugBank.d374.s0	true	DDI-DrugBank.d374.s0.e0	DDI-DrugBank.d374.s0.e3
DDI-DrugBank.d374.s0	false	DDI-DrugBank.d374.s0.e1	DDI-DrugBank.d374.s0.e2
DDI-DrugBank.d374.s0	false	DDI-DrugBank.d374.s0.e1	DDI-DrugBank.d374.s0.e3
DDI-DrugBank.d374.s0	false	DDI-DrugBank.d374.s0.e2	DDI-DrugBank.d374.s0.e3
DDI-DrugBank.d374.s1|a|Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
DDI-DrugBank.d374.s1	0	8	Auranofin	drug	DDI-DrugBank.d374.s1.e0
DDI-DrugBank.d374.s1	43	55	penicillamine	drug	DDI-DrugBank.d374.s1.e1
DDI-DrugBank.d374.s1	58	62	Depen	brand	DDI-DrugBank.d374.s1.e2
DDI-DrugBank.d374.s1	65	73	Cuprimine	brand	DDI-DrugBank.d374.s1.e3
DDI-DrugBank.d374.s1	true	DDI-DrugBank.d374.s1.e0	DDI-DrugBank.d374.s1.e1
DDI-DrugBank.d374.s1	true	DDI-DrugBank.d374.s1.e0	DDI-DrugBank.d374.s1.e2
DDI-DrugBank.d374.s1	true	DDI-DrugBank.d374.s1.e0	DDI-DrugBank.d374.s1.e3
DDI-DrugBank.d374.s1	false	DDI-DrugBank.d374.s1.e1	DDI-DrugBank.d374.s1.e2
DDI-DrugBank.d374.s1	false	DDI-DrugBank.d374.s1.e1	DDI-DrugBank.d374.s1.e3
DDI-DrugBank.d374.s1	false	DDI-DrugBank.d374.s1.e2	DDI-DrugBank.d374.s1.e3
DDI-DrugBank.d374.s2|a|It should also be avoided in patients with blood, liver or kidney diseases, recent radiation treatment, or uncontrolled diabetes.
DDI-DrugBank.d374.s3|a|Patients should report to their practitioners any new rashes, itching, mouth sores, or unusual taste while taking auranofin.
DDI-DrugBank.d374.s3	114	122	auranofin	drug	DDI-DrugBank.d374.s3.e0
DDI-DrugBank.d374.s4|a|Gold is excreted slowly from the body.
DDI-DrugBank.d374.s4	0	3	Gold	group	DDI-DrugBank.d374.s4.e0
DDI-DrugBank.d374.s5|a|Safety and effectiveness in children has not been established.
DDI-DrugBank.d147.s0|a|No formal assessments of drug-drug interactions between Vidaza and other agents have been conducted
DDI-DrugBank.d147.s0	56	61	Vidaza	brand	DDI-DrugBank.d147.s0.e0
DDI-DrugBank.d147.s1|a|.
DDI-DrugBank.d147.s2|a|
DDI-DrugBank.d448.s0|a|MAO inhibitors prolong and intensify the effects of antihistamines.
DDI-DrugBank.d448.s0	0	13	MAO inhibitors	group	DDI-DrugBank.d448.s0.e0
DDI-DrugBank.d448.s0	52	65	antihistamines	group	DDI-DrugBank.d448.s0.e1
DDI-DrugBank.d448.s0	true	DDI-DrugBank.d448.s0.e0	DDI-DrugBank.d448.s0.e1
DDI-DrugBank.d448.s1|a|Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
DDI-DrugBank.d448.s1	19	32	antihistamines	group	DDI-DrugBank.d448.s1.e0
DDI-DrugBank.d448.s1	39	45	alcohol	drug	DDI-DrugBank.d448.s1.e1
DDI-DrugBank.d448.s1	48	72	tricyclic antidepressants	group	DDI-DrugBank.d448.s1.e2
DDI-DrugBank.d448.s1	75	86	barbiturates	group	DDI-DrugBank.d448.s1.e3
DDI-DrugBank.d448.s1	98	131	central nervous system depressants	group	DDI-DrugBank.d448.s1.e4
DDI-DrugBank.d448.s1	true	DDI-DrugBank.d448.s1.e0	DDI-DrugBank.d448.s1.e1
DDI-DrugBank.d448.s1	true	DDI-DrugBank.d448.s1.e0	DDI-DrugBank.d448.s1.e2
DDI-DrugBank.d448.s1	true	DDI-DrugBank.d448.s1.e0	DDI-DrugBank.d448.s1.e3
DDI-DrugBank.d448.s1	true	DDI-DrugBank.d448.s1.e0	DDI-DrugBank.d448.s1.e4
DDI-DrugBank.d448.s1	false	DDI-DrugBank.d448.s1.e1	DDI-DrugBank.d448.s1.e2
DDI-DrugBank.d448.s1	false	DDI-DrugBank.d448.s1.e1	DDI-DrugBank.d448.s1.e3
DDI-DrugBank.d448.s1	false	DDI-DrugBank.d448.s1.e1	DDI-DrugBank.d448.s1.e4
DDI-DrugBank.d448.s1	false	DDI-DrugBank.d448.s1.e2	DDI-DrugBank.d448.s1.e3
DDI-DrugBank.d448.s1	false	DDI-DrugBank.d448.s1.e2	DDI-DrugBank.d448.s1.e4
DDI-DrugBank.d448.s1	false	DDI-DrugBank.d448.s1.e3	DDI-DrugBank.d448.s1.e4
DDI-DrugBank.d448.s2|a|When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.
DDI-DrugBank.d448.s2	5	25	sympathomimetic drugs	group	DDI-DrugBank.d448.s2.e0
DDI-DrugBank.d448.s2	59	86	monoamine oxidase inhibitors	group	DDI-DrugBank.d448.s2.e1
DDI-DrugBank.d448.s2	true	DDI-DrugBank.d448.s2.e0	DDI-DrugBank.d448.s2.e1
DDI-DrugBank.d448.s3|a|The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
DDI-DrugBank.d448.s3	32	41	methyldopa	drug	DDI-DrugBank.d448.s3.e0
DDI-DrugBank.d448.s3	44	55	mecamylamine	drug	DDI-DrugBank.d448.s3.e1
DDI-DrugBank.d448.s3	58	66	reserpine	drug	DDI-DrugBank.d448.s3.e2
DDI-DrugBank.d448.s3	73	90	veratrum alkaloids	drug	DDI-DrugBank.d448.s3.e3
DDI-DrugBank.d448.s3	110	125	sympathomimetics	group	DDI-DrugBank.d448.s3.e4
DDI-DrugBank.d448.s3	false	DDI-DrugBank.d448.s3.e0	DDI-DrugBank.d448.s3.e1
DDI-DrugBank.d448.s3	false	DDI-DrugBank.d448.s3.e0	DDI-DrugBank.d448.s3.e2
DDI-DrugBank.d448.s3	false	DDI-DrugBank.d448.s3.e0	DDI-DrugBank.d448.s3.e3
DDI-DrugBank.d448.s3	true	DDI-DrugBank.d448.s3.e0	DDI-DrugBank.d448.s3.e4
DDI-DrugBank.d448.s3	false	DDI-DrugBank.d448.s3.e1	DDI-DrugBank.d448.s3.e2
DDI-DrugBank.d448.s3	false	DDI-DrugBank.d448.s3.e1	DDI-DrugBank.d448.s3.e3
DDI-DrugBank.d448.s3	true	DDI-DrugBank.d448.s3.e1	DDI-DrugBank.d448.s3.e4
DDI-DrugBank.d448.s3	false	DDI-DrugBank.d448.s3.e2	DDI-DrugBank.d448.s3.e3
DDI-DrugBank.d448.s3	true	DDI-DrugBank.d448.s3.e2	DDI-DrugBank.d448.s3.e4
DDI-DrugBank.d448.s3	true	DDI-DrugBank.d448.s3.e3	DDI-DrugBank.d448.s3.e4
DDI-DrugBank.d448.s4|a|Beta-adrenergic blocking agents may also interact with sympathomimetics.
DDI-DrugBank.d448.s4	0	30	Beta-adrenergic blocking agents	group	DDI-DrugBank.d448.s4.e0
DDI-DrugBank.d448.s4	55	70	sympathomimetics	group	DDI-DrugBank.d448.s4.e1
DDI-DrugBank.d448.s4	true	DDI-DrugBank.d448.s4.e0	DDI-DrugBank.d448.s4.e1
DDI-DrugBank.d448.s5|a|Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.
DDI-DrugBank.d448.s5	52	66	pseudoephedrine	drug	DDI-DrugBank.d448.s5.e0
DDI-DrugBank.d448.s5	95	103	digitalis	group	DDI-DrugBank.d448.s5.e1
DDI-DrugBank.d448.s5	true	DDI-DrugBank.d448.s5.e0	DDI-DrugBank.d448.s5.e1
DDI-DrugBank.d448.s6|a|Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
DDI-DrugBank.d448.s6	0	7	Antacids	group	DDI-DrugBank.d448.s6.e0
DDI-DrugBank.d448.s6	44	58	pseudoephedrine	drug	DDI-DrugBank.d448.s6.e1
DDI-DrugBank.d448.s6	67	72	kaolin	drug	DDI-DrugBank.d448.s6.e2
DDI-DrugBank.d448.s6	true	DDI-DrugBank.d448.s6.e0	DDI-DrugBank.d448.s6.e1
DDI-DrugBank.d448.s6	false	DDI-DrugBank.d448.s6.e0	DDI-DrugBank.d448.s6.e2
DDI-DrugBank.d448.s6	true	DDI-DrugBank.d448.s6.e1	DDI-DrugBank.d448.s6.e2
DDI-DrugBank.d233.s0|a|Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.
DDI-DrugBank.d233.s0	9	19	Allopurinol	drug	DDI-DrugBank.d233.s0.e0
DDI-DrugBank.d233.s0	66	77	azathioprine	drug	DDI-DrugBank.d233.s0.e1
DDI-DrugBank.d233.s0	95	105	allopurinol	drug	DDI-DrugBank.d233.s0.e2
DDI-DrugBank.d233.s0	false	DDI-DrugBank.d233.s0.e0	DDI-DrugBank.d233.s0.e1
DDI-DrugBank.d233.s0	false	DDI-DrugBank.d233.s0.e0	DDI-DrugBank.d233.s0.e2
DDI-DrugBank.d233.s0	true	DDI-DrugBank.d233.s0.e1	DDI-DrugBank.d233.s0.e2
DDI-DrugBank.d233.s1|a|Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.
DDI-DrugBank.d233.s1	19	30	azathioprine	drug	DDI-DrugBank.d233.s1.e0
DDI-DrugBank.d233.s1	36	46	allopurinol	drug	DDI-DrugBank.d233.s1.e1
DDI-DrugBank.d233.s1	94	105	azathioprine	drug	DDI-DrugBank.d233.s1.e2
DDI-DrugBank.d233.s1	true	DDI-DrugBank.d233.s1.e0	DDI-DrugBank.d233.s1.e1
DDI-DrugBank.d233.s1	false	DDI-DrugBank.d233.s1.e0	DDI-DrugBank.d233.s1.e2
DDI-DrugBank.d233.s1	false	DDI-DrugBank.d233.s1.e1	DDI-DrugBank.d233.s1.e2
DDI-DrugBank.d233.s2|a|Use with Other Agents Affecting Myelopoesis: Drugs which may affect leukocyte production, including co-trimoxazole, may lead to exaggerated leukopenia, especially in renal transplant recipients.
DDI-DrugBank.d233.s2	100	113	co-trimoxazole	brand	DDI-DrugBank.d233.s2.e0
DDI-DrugBank.d233.s3|a|Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
DDI-DrugBank.d233.s3	9	48	Angiotensln Converting Enzyme Inhibitors	group	DDI-DrugBank.d233.s3.e0
DDI-DrugBank.d233.s3	62	101	angiotensin converting enzyme inhibitors	group	DDI-DrugBank.d233.s3.e1
DDI-DrugBank.d233.s3	142	153	azathioprine	drug	DDI-DrugBank.d233.s3.e2
DDI-DrugBank.d233.s3	false	DDI-DrugBank.d233.s3.e0	DDI-DrugBank.d233.s3.e1
DDI-DrugBank.d233.s3	false	DDI-DrugBank.d233.s3.e0	DDI-DrugBank.d233.s3.e2
DDI-DrugBank.d233.s3	true	DDI-DrugBank.d233.s3.e1	DDI-DrugBank.d233.s3.e2
DDI-DrugBank.d383.s0|a|No information provided
DDI-DrugBank.d53.s0|a|Co-administration of nelfinavir at steady-state with a single dose of azithromycin.
DDI-DrugBank.d53.s0	21	30	nelfinavir	drug	DDI-DrugBank.d53.s0.e0
DDI-DrugBank.d53.s0	70	81	azithromycin	drug	DDI-DrugBank.d53.s0.e1
DDI-DrugBank.d53.s0	false	DDI-DrugBank.d53.s0.e0	DDI-DrugBank.d53.s0.e1
DDI-DrugBank.d53.s1|a|Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.
DDI-DrugBank.d53.s1	21	30	nelfinavir	drug	DDI-DrugBank.d53.s1.e0
DDI-DrugBank.d53.s1	70	81	azithromycin	drug	DDI-DrugBank.d53.s1.e1
DDI-DrugBank.d53.s1	125	136	azithromycin	drug	DDI-DrugBank.d53.s1.e2
DDI-DrugBank.d53.s1	true	DDI-DrugBank.d53.s1.e0	DDI-DrugBank.d53.s1.e1
DDI-DrugBank.d53.s1	false	DDI-DrugBank.d53.s1.e0	DDI-DrugBank.d53.s1.e2
DDI-DrugBank.d53.s1	false	DDI-DrugBank.d53.s1.e1	DDI-DrugBank.d53.s1.e2
DDI-DrugBank.d53.s2|a|Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.
DDI-DrugBank.d53.s2	30	41	azithromycin	drug	DDI-DrugBank.d53.s2.e0
DDI-DrugBank.d53.s2	100	109	nelfinavir	drug	DDI-DrugBank.d53.s2.e1
DDI-DrugBank.d53.s2	155	166	azithromycin	drug	DDI-DrugBank.d53.s2.e2
DDI-DrugBank.d53.s2	true	DDI-DrugBank.d53.s2.e0	DDI-DrugBank.d53.s2.e1
DDI-DrugBank.d53.s2	false	DDI-DrugBank.d53.s2.e0	DDI-DrugBank.d53.s2.e2
DDI-DrugBank.d53.s2	false	DDI-DrugBank.d53.s2.e1	DDI-DrugBank.d53.s2.e2
DDI-DrugBank.d53.s3|a|Azithromycin did not affect the prothrombin time response to a single dose of warfarin.
DDI-DrugBank.d53.s3	0	11	Azithromycin	drug	DDI-DrugBank.d53.s3.e0
DDI-DrugBank.d53.s3	78	85	warfarin	drug	DDI-DrugBank.d53.s3.e1
DDI-DrugBank.d53.s3	false	DDI-DrugBank.d53.s3.e0	DDI-DrugBank.d53.s3.e1
DDI-DrugBank.d53.s4|a|However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.
DDI-DrugBank.d53.s4	111	122	azithromycin	drug	DDI-DrugBank.d53.s4.e0
DDI-DrugBank.d53.s4	128	135	warfarin	drug	DDI-DrugBank.d53.s4.e1
DDI-DrugBank.d53.s4	true	DDI-DrugBank.d53.s4.e0	DDI-DrugBank.d53.s4.e1
DDI-DrugBank.d53.s5|a|Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.
DDI-DrugBank.d53.s5	18	27	macrolides	group	DDI-DrugBank.d53.s5.e0
DDI-DrugBank.d53.s5	33	40	warfarin	drug	DDI-DrugBank.d53.s5.e1
DDI-DrugBank.d53.s5	true	DDI-DrugBank.d53.s5.e0	DDI-DrugBank.d53.s5.e1
DDI-DrugBank.d53.s6|a|Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered.
DDI-DrugBank.d53.s6	45	56	azithromycin	drug	DDI-DrugBank.d53.s6.e0
DDI-DrugBank.d53.s7|a|When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d53.s7	32	43	azithromycin	drug	DDI-DrugBank.d53.s7.e0
DDI-DrugBank.d53.s7	92	103	atorvastatin	drug	DDI-DrugBank.d53.s7.e1
DDI-DrugBank.d53.s7	106	118	carbamazepine	drug	DDI-DrugBank.d53.s7.e2
DDI-DrugBank.d53.s7	121	130	cetirizine	drug	DDI-DrugBank.d53.s7.e3
DDI-DrugBank.d53.s7	133	142	didanosine	drug	DDI-DrugBank.d53.s7.e4
DDI-DrugBank.d53.s7	145	153	efavirenz	drug	DDI-DrugBank.d53.s7.e5
DDI-DrugBank.d53.s7	156	166	fluconazole	drug	DDI-DrugBank.d53.s7.e6
DDI-DrugBank.d53.s7	169	177	indinavir	drug	DDI-DrugBank.d53.s7.e7
DDI-DrugBank.d53.s7	180	188	midazolam	drug	DDI-DrugBank.d53.s7.e8
DDI-DrugBank.d53.s7	191	199	rifabutin	drug	DDI-DrugBank.d53.s7.e9
DDI-DrugBank.d53.s7	true	DDI-DrugBank.d53.s7.e0	DDI-DrugBank.d53.s7.e1
DDI-DrugBank.d53.s7	true	DDI-DrugBank.d53.s7.e0	DDI-DrugBank.d53.s7.e2
DDI-DrugBank.d53.s7	true	DDI-DrugBank.d53.s7.e0	DDI-DrugBank.d53.s7.e3
DDI-DrugBank.d53.s7	true	DDI-DrugBank.d53.s7.e0	DDI-DrugBank.d53.s7.e4
DDI-DrugBank.d53.s7	true	DDI-DrugBank.d53.s7.e0	DDI-DrugBank.d53.s7.e5
DDI-DrugBank.d53.s7	true	DDI-DrugBank.d53.s7.e0	DDI-DrugBank.d53.s7.e6
DDI-DrugBank.d53.s7	true	DDI-DrugBank.d53.s7.e0	DDI-DrugBank.d53.s7.e7
DDI-DrugBank.d53.s7	true	DDI-DrugBank.d53.s7.e0	DDI-DrugBank.d53.s7.e8
DDI-DrugBank.d53.s7	true	DDI-DrugBank.d53.s7.e0	DDI-DrugBank.d53.s7.e9
DDI-DrugBank.d53.s7	true	DDI-DrugBank.d53.s7.e0	DDI-DrugBank.d53.s7.e10
DDI-DrugBank.d53.s8|a|Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.
DDI-DrugBank.d53.s8	23	31	efavirenz	drug	DDI-DrugBank.d53.s8.e0
DDI-DrugBank.d53.s8	36	46	fluconazole	drug	DDI-DrugBank.d53.s8.e1
DDI-DrugBank.d53.s8	95	106	azithromycin	drug	DDI-DrugBank.d53.s8.e2
DDI-DrugBank.d53.s8	false	DDI-DrugBank.d53.s8.e0	DDI-DrugBank.d53.s8.e1
DDI-DrugBank.d53.s8	true	DDI-DrugBank.d53.s8.e0	DDI-DrugBank.d53.s8.e2
DDI-DrugBank.d53.s8	true	DDI-DrugBank.d53.s8.e1	DDI-DrugBank.d53.s8.e2
DDI-DrugBank.d53.s9|a|No dosage adjustment of either drug is recommended when azithromycin is co administered with any of the above agents.
DDI-DrugBank.d53.s9	56	67	azithromycin	drug	DDI-DrugBank.d53.s9.e0
DDI-DrugBank.d53.s10|a|Interactions with the drugs listed below have not been reported in clinical trials with azithromycin;
DDI-DrugBank.d53.s10	88	99	azithromycin	drug	DDI-DrugBank.d53.s10.e0
DDI-DrugBank.d53.s11|a|however, no specific drug interaction studies have been performed to evaluate potential drug-drug interaction.
DDI-DrugBank.d53.s12|a|Nonetheless, they have been observed with macrolide products.
DDI-DrugBank.d53.s12	42	59	macrolide products	group	DDI-DrugBank.d53.s12.e0
DDI-DrugBank.d53.s13|a|Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.
DDI-DrugBank.d53.s13	66	77	azithromycin	drug	DDI-DrugBank.d53.s13.e0
DDI-DrugBank.d53.s13	162	168	Digoxin	drug	DDI-DrugBank.d53.s13.e1
DDI-DrugBank.d53.s13	179	185	digoxin	drug	DDI-DrugBank.d53.s13.e2
DDI-DrugBank.d53.s13	false	DDI-DrugBank.d53.s13.e0	DDI-DrugBank.d53.s13.e1
DDI-DrugBank.d53.s13	false	DDI-DrugBank.d53.s13.e0	DDI-DrugBank.d53.s13.e2
DDI-DrugBank.d53.s13	false	DDI-DrugBank.d53.s13.e1	DDI-DrugBank.d53.s13.e2
DDI-DrugBank.d53.s14|a|Ergotamine or dihydroergotamine acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DDI-DrugBank.d53.s14	0	9	Ergotamine	drug	DDI-DrugBank.d53.s14.e0
DDI-DrugBank.d53.s14	14	30	dihydroergotamine	drug	DDI-DrugBank.d53.s14.e1
DDI-DrugBank.d53.s14	false	DDI-DrugBank.d53.s14.e0	DDI-DrugBank.d53.s14.e1
DDI-DrugBank.d53.s15|a|Cyclosporine, hexobarbital and phenytoin concentrations.
DDI-DrugBank.d53.s15	0	11	Cyclosporine	drug	DDI-DrugBank.d53.s15.e0
DDI-DrugBank.d53.s15	14	25	hexobarbital	drug	DDI-DrugBank.d53.s15.e1
DDI-DrugBank.d53.s15	31	39	phenytoin	drug	DDI-DrugBank.d53.s15.e2
DDI-DrugBank.d53.s15	false	DDI-DrugBank.d53.s15.e0	DDI-DrugBank.d53.s15.e1
DDI-DrugBank.d53.s15	false	DDI-DrugBank.d53.s15.e0	DDI-DrugBank.d53.s15.e2
DDI-DrugBank.d53.s15	false	DDI-DrugBank.d53.s15.e1	DDI-DrugBank.d53.s15.e2
DDI-DrugBank.d53.s16|a|Laboratory Test Interactions There are no reported laboratory test interactions.
DDI-DrugBank.d53.s17|a|Repeat Treatment Studies evaluating the use of repeated courses of Zmax have not been conducted.
DDI-DrugBank.d53.s17	67	70	Zmax	brand	DDI-DrugBank.d53.s17.e0
DDI-DrugBank.d9.s0|a|Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
DDI-DrugBank.d9.s0	0	9	Azlocillin	drug	DDI-DrugBank.d9.s0.e0
DDI-DrugBank.d9.s0	57	64	amikacin	drug	DDI-DrugBank.d9.s0.e1
DDI-DrugBank.d9.s0	67	79	ciprofloxacin	drug	DDI-DrugBank.d9.s0.e2
DDI-DrugBank.d9.s0	82	91	gentamicin	drug	DDI-DrugBank.d9.s0.e3
DDI-DrugBank.d9.s0	94	103	netilmicin	drug	DDI-DrugBank.d9.s0.e4
DDI-DrugBank.d9.s0	109	118	tobramycin	drug	DDI-DrugBank.d9.s0.e5
DDI-DrugBank.d9.s0	true	DDI-DrugBank.d9.s0.e0	DDI-DrugBank.d9.s0.e1
DDI-DrugBank.d9.s0	true	DDI-DrugBank.d9.s0.e0	DDI-DrugBank.d9.s0.e2
DDI-DrugBank.d9.s0	true	DDI-DrugBank.d9.s0.e0	DDI-DrugBank.d9.s0.e3
DDI-DrugBank.d9.s0	true	DDI-DrugBank.d9.s0.e0	DDI-DrugBank.d9.s0.e4
DDI-DrugBank.d9.s0	true	DDI-DrugBank.d9.s0.e0	DDI-DrugBank.d9.s0.e5
DDI-DrugBank.d9.s0	false	DDI-DrugBank.d9.s0.e1	DDI-DrugBank.d9.s0.e2
DDI-DrugBank.d9.s0	false	DDI-DrugBank.d9.s0.e1	DDI-DrugBank.d9.s0.e3
DDI-DrugBank.d9.s0	false	DDI-DrugBank.d9.s0.e1	DDI-DrugBank.d9.s0.e4
DDI-DrugBank.d9.s0	false	DDI-DrugBank.d9.s0.e1	DDI-DrugBank.d9.s0.e5
DDI-DrugBank.d9.s0	false	DDI-DrugBank.d9.s0.e2	DDI-DrugBank.d9.s0.e3
DDI-DrugBank.d523.s0|a|Injection There is inadequate systematic experience with the use of baclofen injection in combination with other medications to predict specific drug-drug interactions.
DDI-DrugBank.d523.s0	68	75	baclofen	drug	DDI-DrugBank.d523.s0.e0
DDI-DrugBank.d523.s1|a|Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.
DDI-DrugBank.d523.s1	47	54	baclofen	drug	DDI-DrugBank.d523.s1.e0
DDI-DrugBank.d523.s1	79	86	morphine	drug	DDI-DrugBank.d523.s1.e1
DDI-DrugBank.d523.s1	true	DDI-DrugBank.d523.s1.e0	DDI-DrugBank.d523.s1.e1
DDI-DrugBank.d523.s2|a|SIDE EFFECTS (KEMSTRO) The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63%).
DDI-DrugBank.d523.s2	14	20	KEMSTRO	brand	DDI-DrugBank.d523.s2.e0
DDI-DrugBank.d523.s2	78	85	baclofen	drug	DDI-DrugBank.d523.s2.e1
DDI-DrugBank.d523.s2	false	DDI-DrugBank.d523.s2.e0	DDI-DrugBank.d523.s2.e1
DDI-DrugBank.d523.s3|a|In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen tablets compared to 36% of those in the placebo group.
DDI-DrugBank.d523.s3	101	108	baclofen	drug	DDI-DrugBank.d523.s3.e0
DDI-DrugBank.d523.s4|a|Other common adverse reactions are dizziness (5-15%), weakness (5-15%) and fatigue (2-4%).
DDI-DrugBank.d523.s5|a|Others reported: Neuropsychiatric: Confusion (1-11%), headache (4-8%), insomnia (2-7%);
DDI-DrugBank.d523.s6|a|and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure.
DDI-DrugBank.d523.s7|a|Cardiovascular: Hypotension (0-9%).
DDI-DrugBank.d523.s8|a|Rare instances of dyspnea, palpitation, chest pain, syncope.
DDI-DrugBank.d523.s9|a|Gastrointestinal: Nausea (4-12%), constipation (2-6%);
DDI-DrugBank.d523.s10|a|and, rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool.
DDI-DrugBank.d523.s11|a|Genitourinary: Urinary frequency (2-6%);
DDI-DrugBank.d523.s12|a|and, rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria.
DDI-DrugBank.d523.s13|a|Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion.
DDI-DrugBank.d523.s14|a|Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy.
DDI-DrugBank.d523.s15|a|The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.
DDI-DrugBank.d523.s15	90	97	baclofen	drug	DDI-DrugBank.d523.s15.e0
DDI-DrugBank.d523.s16|a|The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets.
DDI-DrugBank.d523.s16	41	49	KEMSTROTM	brand	DDI-DrugBank.d523.s16.e0
DDI-DrugBank.d523.s16	81	88	baclofen	drug	DDI-DrugBank.d523.s16.e1
DDI-DrugBank.d523.s16	false	DDI-DrugBank.d523.s16.e0	DDI-DrugBank.d523.s16.e1
DDI-DrugBank.d486.s0|a|No drug interaction studies have been conducted for COLAZAL, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.
DDI-DrugBank.d486.s0	52	58	COLAZAL	brand	DDI-DrugBank.d486.s0.e0
DDI-DrugBank.d486.s0	100	110	antibiotics	group	DDI-DrugBank.d486.s0.e1
DDI-DrugBank.d486.s0	164	173	mesalamine	drug	DDI-DrugBank.d486.s0.e2
DDI-DrugBank.d486.s0	false	DDI-DrugBank.d486.s0.e0	DDI-DrugBank.d486.s0.e1
DDI-DrugBank.d486.s0	false	DDI-DrugBank.d486.s0.e0	DDI-DrugBank.d486.s0.e2
DDI-DrugBank.d486.s0	false	DDI-DrugBank.d486.s0.e1	DDI-DrugBank.d486.s0.e2
DDI-DrugBank.d544.s0|a|No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil.
DDI-DrugBank.d544.s0	37	44	Simulect	brand	DDI-DrugBank.d544.s0.e0
DDI-DrugBank.d544.s0	102	113	cyclosporine	drug	DDI-DrugBank.d544.s0.e1
DDI-DrugBank.d544.s0	116	130	corticosteroids	group	DDI-DrugBank.d544.s0.e2
DDI-DrugBank.d544.s0	144	155	azathioprine	drug	DDI-DrugBank.d544.s0.e3
DDI-DrugBank.d544.s0	160	180	mycophenolate mofetil	drug	DDI-DrugBank.d544.s0.e4
DDI-DrugBank.d544.s0	false	DDI-DrugBank.d544.s0.e0	DDI-DrugBank.d544.s0.e1
DDI-DrugBank.d544.s0	false	DDI-DrugBank.d544.s0.e0	DDI-DrugBank.d544.s0.e2
DDI-DrugBank.d544.s0	false	DDI-DrugBank.d544.s0.e0	DDI-DrugBank.d544.s0.e3
DDI-DrugBank.d544.s0	false	DDI-DrugBank.d544.s0.e0	DDI-DrugBank.d544.s0.e4
DDI-DrugBank.d544.s0	false	DDI-DrugBank.d544.s0.e1	DDI-DrugBank.d544.s0.e2
DDI-DrugBank.d544.s0	false	DDI-DrugBank.d544.s0.e1	DDI-DrugBank.d544.s0.e3
DDI-DrugBank.d544.s0	false	DDI-DrugBank.d544.s0.e1	DDI-DrugBank.d544.s0.e4
DDI-DrugBank.d544.s0	false	DDI-DrugBank.d544.s0.e2	DDI-DrugBank.d544.s0.e3
DDI-DrugBank.d544.s0	false	DDI-DrugBank.d544.s0.e2	DDI-DrugBank.d544.s0.e4
DDI-DrugBank.d544.s0	false	DDI-DrugBank.d544.s0.e3	DDI-DrugBank.d544.s0.e4
DDI-DrugBank.d544.s1|a|Three clinical trials have investigated Simulect use in combination with triple-therapy regimens.
DDI-DrugBank.d544.s1	40	47	Simulect	brand	DDI-DrugBank.d544.s1.e0
DDI-DrugBank.d544.s2|a|Pharmacokinetics were assessed in two of these trials.
DDI-DrugBank.d544.s3|a|Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
DDI-DrugBank.d544.s3	24	31	Simulect	brand	DDI-DrugBank.d544.s3.e0
DDI-DrugBank.d544.s3	76	87	azathioprine	drug	DDI-DrugBank.d544.s3.e1
DDI-DrugBank.d544.s3	93	113	mycophenolate mofetil	drug	DDI-DrugBank.d544.s3.e2
DDI-DrugBank.d544.s3	168	179	cyclosporine	drug	DDI-DrugBank.d544.s3.e3
DDI-DrugBank.d544.s3	201	215	corticosteroids	group	DDI-DrugBank.d544.s3.e4
DDI-DrugBank.d544.s3	true	DDI-DrugBank.d544.s3.e0	DDI-DrugBank.d544.s3.e1
DDI-DrugBank.d544.s3	true	DDI-DrugBank.d544.s3.e0	DDI-DrugBank.d544.s3.e2
DDI-DrugBank.d544.s3	false	DDI-DrugBank.d544.s3.e0	DDI-DrugBank.d544.s3.e3
DDI-DrugBank.d544.s3	false	DDI-DrugBank.d544.s3.e0	DDI-DrugBank.d544.s3.e4
DDI-DrugBank.d544.s3	false	DDI-DrugBank.d544.s3.e1	DDI-DrugBank.d544.s3.e2
DDI-DrugBank.d544.s3	false	DDI-DrugBank.d544.s3.e1	DDI-DrugBank.d544.s3.e3
DDI-DrugBank.d544.s3	false	DDI-DrugBank.d544.s3.e1	DDI-DrugBank.d544.s3.e4
DDI-DrugBank.d544.s3	false	DDI-DrugBank.d544.s3.e2	DDI-DrugBank.d544.s3.e3
DDI-DrugBank.d544.s3	false	DDI-DrugBank.d544.s3.e2	DDI-DrugBank.d544.s3.e4
DDI-DrugBank.d544.s3	false	DDI-DrugBank.d544.s3.e3	DDI-DrugBank.d544.s3.e4
DDI-DrugBank.d544.s4|a|Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).
DDI-DrugBank.d544.s4	37	44	Simulect	brand	DDI-DrugBank.d544.s4.e0
DDI-DrugBank.d544.s4	82	93	azathioprine	drug	DDI-DrugBank.d544.s4.e1
DDI-DrugBank.d544.s4	111	131	mycophenolate mofetil	drug	DDI-DrugBank.d544.s4.e2
DDI-DrugBank.d544.s4	false	DDI-DrugBank.d544.s4.e0	DDI-DrugBank.d544.s4.e1
DDI-DrugBank.d544.s4	false	DDI-DrugBank.d544.s4.e0	DDI-DrugBank.d544.s4.e2
DDI-DrugBank.d544.s4	false	DDI-DrugBank.d544.s4.e1	DDI-DrugBank.d544.s4.e2
DDI-DrugBank.d544.s5|a|The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.
DDI-DrugBank.d544.s5	73	80	Simulect	brand	DDI-DrugBank.d544.s5.e0
DDI-DrugBank.d544.s5	130	141	azathioprine	drug	DDI-DrugBank.d544.s5.e1
DDI-DrugBank.d544.s5	144	158	corticosteroids	group	DDI-DrugBank.d544.s5.e2
DDI-DrugBank.d544.s5	161	172	cyclosporine	drug	DDI-DrugBank.d544.s5.e3
DDI-DrugBank.d544.s5	175	195	mycophenolate mofetil	drug	DDI-DrugBank.d544.s5.e4
DDI-DrugBank.d544.s5	202	214	muromonab-CD3	drug	DDI-DrugBank.d544.s5.e5
DDI-DrugBank.d544.s5	false	DDI-DrugBank.d544.s5.e0	DDI-DrugBank.d544.s5.e1
DDI-DrugBank.d544.s5	false	DDI-DrugBank.d544.s5.e0	DDI-DrugBank.d544.s5.e2
DDI-DrugBank.d544.s5	false	DDI-DrugBank.d544.s5.e0	DDI-DrugBank.d544.s5.e3
DDI-DrugBank.d544.s5	false	DDI-DrugBank.d544.s5.e0	DDI-DrugBank.d544.s5.e4
DDI-DrugBank.d544.s5	false	DDI-DrugBank.d544.s5.e0	DDI-DrugBank.d544.s5.e5
DDI-DrugBank.d544.s5	false	DDI-DrugBank.d544.s5.e1	DDI-DrugBank.d544.s5.e2
DDI-DrugBank.d544.s5	false	DDI-DrugBank.d544.s5.e1	DDI-DrugBank.d544.s5.e3
DDI-DrugBank.d544.s5	false	DDI-DrugBank.d544.s5.e1	DDI-DrugBank.d544.s5.e4
DDI-DrugBank.d544.s5	false	DDI-DrugBank.d544.s5.e1	DDI-DrugBank.d544.s5.e5
DDI-DrugBank.d544.s5	false	DDI-DrugBank.d544.s5.e2	DDI-DrugBank.d544.s5.e3
DDI-DrugBank.d385.s0|a|It is not known if REGRANEX Gel interacts with other topical medications applied to the ulcer site.
DDI-DrugBank.d385.s0	19	26	REGRANEX	brand	DDI-DrugBank.d385.s0.e0
DDI-DrugBank.d385.s1|a|The use of REGRANEX Gel with other topical drugs has not been studied.
DDI-DrugBank.d385.s1	11	18	REGRANEX	brand	DDI-DrugBank.d385.s1.e0
DDI-DrugBank.d524.s0|a|Albuterol, Antihistamines, antidiabetic drugs, diuretics, digitalis.
DDI-DrugBank.d524.s0	0	8	Albuterol	drug	DDI-DrugBank.d524.s0.e0
DDI-DrugBank.d524.s0	11	24	Antihistamines	group	DDI-DrugBank.d524.s0.e1
DDI-DrugBank.d524.s0	27	44	antidiabetic drugs	group	DDI-DrugBank.d524.s0.e2
DDI-DrugBank.d524.s0	47	55	diuretics	group	DDI-DrugBank.d524.s0.e3
DDI-DrugBank.d524.s0	58	66	digitalis	group	DDI-DrugBank.d524.s0.e4
DDI-DrugBank.d524.s0	false	DDI-DrugBank.d524.s0.e0	DDI-DrugBank.d524.s0.e1
DDI-DrugBank.d524.s0	false	DDI-DrugBank.d524.s0.e0	DDI-DrugBank.d524.s0.e2
DDI-DrugBank.d524.s0	false	DDI-DrugBank.d524.s0.e0	DDI-DrugBank.d524.s0.e3
DDI-DrugBank.d524.s0	false	DDI-DrugBank.d524.s0.e0	DDI-DrugBank.d524.s0.e4
DDI-DrugBank.d524.s0	false	DDI-DrugBank.d524.s0.e1	DDI-DrugBank.d524.s0.e2
DDI-DrugBank.d524.s0	false	DDI-DrugBank.d524.s0.e1	DDI-DrugBank.d524.s0.e3
DDI-DrugBank.d524.s0	false	DDI-DrugBank.d524.s0.e1	DDI-DrugBank.d524.s0.e4
DDI-DrugBank.d524.s0	false	DDI-DrugBank.d524.s0.e2	DDI-DrugBank.d524.s0.e3
DDI-DrugBank.d524.s0	false	DDI-DrugBank.d524.s0.e2	DDI-DrugBank.d524.s0.e4
DDI-DrugBank.d524.s0	false	DDI-DrugBank.d524.s0.e3	DDI-DrugBank.d524.s0.e4
DDI-DrugBank.d561.s0|a|Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.
DDI-DrugBank.d561.s0	0	8	Diuretics	group	DDI-DrugBank.d561.s0.e0
DDI-DrugBank.d561.s0	23	31	diuretics	group	DDI-DrugBank.d561.s0.e1
DDI-DrugBank.d561.s0	203	210	Lotensin	brand	DDI-DrugBank.d561.s0.e2
DDI-DrugBank.d561.s0	false	DDI-DrugBank.d561.s0.e0	DDI-DrugBank.d561.s0.e1
DDI-DrugBank.d561.s0	false	DDI-DrugBank.d561.s0.e0	DDI-DrugBank.d561.s0.e2
DDI-DrugBank.d561.s0	true	DDI-DrugBank.d561.s0.e1	DDI-DrugBank.d561.s0.e2
DDI-DrugBank.d561.s1|a|The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.
DDI-DrugBank.d561.s1	44	51	Lotensin	brand	DDI-DrugBank.d561.s1.e0
DDI-DrugBank.d561.s1	98	105	diuretic	group	DDI-DrugBank.d561.s1.e1
DDI-DrugBank.d561.s1	175	182	Lotensin	brand	DDI-DrugBank.d561.s1.e2
DDI-DrugBank.d561.s1	false	DDI-DrugBank.d561.s1.e0	DDI-DrugBank.d561.s1.e1
DDI-DrugBank.d561.s1	false	DDI-DrugBank.d561.s1.e0	DDI-DrugBank.d561.s1.e2
DDI-DrugBank.d561.s1	true	DDI-DrugBank.d561.s1.e1	DDI-DrugBank.d561.s1.e2
DDI-DrugBank.d561.s2|a|If this is not possible, the starting dose should be reduced.
DDI-DrugBank.d561.s3|a|Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.
DDI-DrugBank.d561.s3	0	8	Potassium	drug	DDI-DrugBank.d561.s3.e0
DDI-DrugBank.d561.s3	26	52	Potassium-Sparing Diuretics	group	DDI-DrugBank.d561.s3.e1
DDI-DrugBank.d561.s3	102	119	thiazide diuretics	group	DDI-DrugBank.d561.s3.e2
DDI-DrugBank.d561.s3	false	DDI-DrugBank.d561.s3.e0	DDI-DrugBank.d561.s3.e1
DDI-DrugBank.d561.s3	false	DDI-DrugBank.d561.s3.e0	DDI-DrugBank.d561.s3.e2
DDI-DrugBank.d561.s3	true	DDI-DrugBank.d561.s3.e1	DDI-DrugBank.d561.s3.e2
DDI-DrugBank.d561.s4|a|Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
DDI-DrugBank.d561.s4	0	26	Potassium-sparing diuretics	group	DDI-DrugBank.d561.s4.e0
DDI-DrugBank.d561.s4	29	42	spironolactone	drug	DDI-DrugBank.d561.s4.e1
DDI-DrugBank.d561.s4	45	53	amiloride	drug	DDI-DrugBank.d561.s4.e2
DDI-DrugBank.d561.s4	56	66	triamterene	drug	DDI-DrugBank.d561.s4.e3
DDI-DrugBank.d561.s4	84	92	potassium	drug	DDI-DrugBank.d561.s4.e4
DDI-DrugBank.d561.s4	false	DDI-DrugBank.d561.s4.e0	DDI-DrugBank.d561.s4.e1
DDI-DrugBank.d561.s4	false	DDI-DrugBank.d561.s4.e0	DDI-DrugBank.d561.s4.e2
DDI-DrugBank.d561.s4	false	DDI-DrugBank.d561.s4.e0	DDI-DrugBank.d561.s4.e3
DDI-DrugBank.d561.s4	false	DDI-DrugBank.d561.s4.e0	DDI-DrugBank.d561.s4.e4
DDI-DrugBank.d561.s4	false	DDI-DrugBank.d561.s4.e1	DDI-DrugBank.d561.s4.e2
DDI-DrugBank.d561.s4	false	DDI-DrugBank.d561.s4.e1	DDI-DrugBank.d561.s4.e3
DDI-DrugBank.d561.s4	false	DDI-DrugBank.d561.s4.e1	DDI-DrugBank.d561.s4.e4
DDI-DrugBank.d561.s4	false	DDI-DrugBank.d561.s4.e2	DDI-DrugBank.d561.s4.e3
DDI-DrugBank.d561.s4	false	DDI-DrugBank.d561.s4.e2	DDI-DrugBank.d561.s4.e4
DDI-DrugBank.d561.s4	false	DDI-DrugBank.d561.s4.e3	DDI-DrugBank.d561.s4.e4
DDI-DrugBank.d561.s5|a|Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patient's serum potassium should be monitored frequently.
DDI-DrugBank.d561.s6|a|Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.
DDI-DrugBank.d561.s6	5	18	Anticoagulants	group	DDI-DrugBank.d561.s6.e0
DDI-DrugBank.d561.s6	45	52	warfarin	drug	DDI-DrugBank.d561.s6.e1
DDI-DrugBank.d561.s6	58	70	acenocoumarol	drug	DDI-DrugBank.d561.s6.e2
DDI-DrugBank.d561.s6	181	194	anticoagulants	group	DDI-DrugBank.d561.s6.e3
DDI-DrugBank.d561.s6	false	DDI-DrugBank.d561.s6.e0	DDI-DrugBank.d561.s6.e1
DDI-DrugBank.d561.s6	false	DDI-DrugBank.d561.s6.e0	DDI-DrugBank.d561.s6.e2
DDI-DrugBank.d561.s6	false	DDI-DrugBank.d561.s6.e0	DDI-DrugBank.d561.s6.e3
DDI-DrugBank.d561.s6	false	DDI-DrugBank.d561.s6.e1	DDI-DrugBank.d561.s6.e2
DDI-DrugBank.d561.s6	false	DDI-DrugBank.d561.s6.e1	DDI-DrugBank.d561.s6.e3
DDI-DrugBank.d561.s6	false	DDI-DrugBank.d561.s6.e2	DDI-DrugBank.d561.s6.e3
DDI-DrugBank.d561.s7|a|Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
DDI-DrugBank.d561.s7	0	6	Lithium	drug	DDI-DrugBank.d561.s7.e0
DDI-DrugBank.d561.s7	25	31	lithium	drug	DDI-DrugBank.d561.s7.e1
DDI-DrugBank.d561.s7	56	62	lithium	drug	DDI-DrugBank.d561.s7.e2
DDI-DrugBank.d561.s7	114	127	ACE inhibitors	group	DDI-DrugBank.d561.s7.e3
DDI-DrugBank.d561.s7	149	155	lithium	drug	DDI-DrugBank.d561.s7.e4
DDI-DrugBank.d561.s7	false	DDI-DrugBank.d561.s7.e0	DDI-DrugBank.d561.s7.e1
DDI-DrugBank.d561.s7	false	DDI-DrugBank.d561.s7.e0	DDI-DrugBank.d561.s7.e2
DDI-DrugBank.d561.s7	false	DDI-DrugBank.d561.s7.e0	DDI-DrugBank.d561.s7.e3
DDI-DrugBank.d561.s7	false	DDI-DrugBank.d561.s7.e0	DDI-DrugBank.d561.s7.e4
DDI-DrugBank.d561.s7	false	DDI-DrugBank.d561.s7.e1	DDI-DrugBank.d561.s7.e2
DDI-DrugBank.d561.s7	false	DDI-DrugBank.d561.s7.e1	DDI-DrugBank.d561.s7.e3
DDI-DrugBank.d561.s7	false	DDI-DrugBank.d561.s7.e1	DDI-DrugBank.d561.s7.e4
DDI-DrugBank.d561.s7	false	DDI-DrugBank.d561.s7.e2	DDI-DrugBank.d561.s7.e3
DDI-DrugBank.d561.s7	false	DDI-DrugBank.d561.s7.e2	DDI-DrugBank.d561.s7.e4
DDI-DrugBank.d561.s7	true	DDI-DrugBank.d561.s7.e3	DDI-DrugBank.d561.s7.e4
DDI-DrugBank.d561.s8|a|These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.
DDI-DrugBank.d561.s8	84	90	lithium	drug	DDI-DrugBank.d561.s8.e0
DDI-DrugBank.d561.s9|a|If a diuretic is also used, the risk of lithium toxicity may be increased.
DDI-DrugBank.d561.s9	5	12	diuretic	group	DDI-DrugBank.d561.s9.e0
DDI-DrugBank.d561.s9	40	46	lithium	drug	DDI-DrugBank.d561.s9.e1
DDI-DrugBank.d561.s9	true	DDI-DrugBank.d561.s9.e0	DDI-DrugBank.d561.s9.e1
DDI-DrugBank.d561.s10|a|Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin, propranolol, atenolol, naproxen, or cimetidine.
DDI-DrugBank.d561.s10	73	80	Lotensin	brand	DDI-DrugBank.d561.s10.e0
DDI-DrugBank.d561.s10	118	136	hydrochlorothiazide	drug	DDI-DrugBank.d561.s10.e1
DDI-DrugBank.d561.s10	139	152	chlorthalidone	drug	DDI-DrugBank.d561.s10.e2
DDI-DrugBank.d561.s10	155	164	furosemide	drug	DDI-DrugBank.d561.s10.e3
DDI-DrugBank.d561.s10	167	173	digoxin	drug	DDI-DrugBank.d561.s10.e4
DDI-DrugBank.d561.s10	176	186	propranolol	drug	DDI-DrugBank.d561.s10.e5
DDI-DrugBank.d561.s10	189	196	atenolol	drug	DDI-DrugBank.d561.s10.e6
DDI-DrugBank.d561.s10	199	206	naproxen	drug	DDI-DrugBank.d561.s10.e7
DDI-DrugBank.d561.s10	212	221	cimetidine	drug	DDI-DrugBank.d561.s10.e8
DDI-DrugBank.d561.s10	false	DDI-DrugBank.d561.s10.e0	DDI-DrugBank.d561.s10.e1
DDI-DrugBank.d561.s10	false	DDI-DrugBank.d561.s10.e0	DDI-DrugBank.d561.s10.e2
DDI-DrugBank.d561.s10	false	DDI-DrugBank.d561.s10.e0	DDI-DrugBank.d561.s10.e3
DDI-DrugBank.d561.s10	false	DDI-DrugBank.d561.s10.e0	DDI-DrugBank.d561.s10.e4
DDI-DrugBank.d561.s10	false	DDI-DrugBank.d561.s10.e0	DDI-DrugBank.d561.s10.e5
DDI-DrugBank.d561.s10	false	DDI-DrugBank.d561.s10.e0	DDI-DrugBank.d561.s10.e6
DDI-DrugBank.d561.s10	false	DDI-DrugBank.d561.s10.e0	DDI-DrugBank.d561.s10.e7
DDI-DrugBank.d561.s10	false	DDI-DrugBank.d561.s10.e0	DDI-DrugBank.d561.s10.e8
DDI-DrugBank.d561.s10	false	DDI-DrugBank.d561.s10.e1	DDI-DrugBank.d561.s10.e2
DDI-DrugBank.d561.s10	false	DDI-DrugBank.d561.s10.e1	DDI-DrugBank.d561.s10.e3
DDI-DrugBank.d561.s11|a|Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
DDI-DrugBank.d561.s11	0	7	Lotensin	brand	DDI-DrugBank.d561.s11.e0
DDI-DrugBank.d561.s11	42	72	beta-adrenergic-blocking agents	group	DDI-DrugBank.d561.s11.e1
DDI-DrugBank.d561.s11	75	105	calcium-channel-blocking agents	group	DDI-DrugBank.d561.s11.e2
DDI-DrugBank.d561.s11	108	116	diuretics	group	DDI-DrugBank.d561.s11.e3
DDI-DrugBank.d561.s11	119	125	digoxin	drug	DDI-DrugBank.d561.s11.e4
DDI-DrugBank.d561.s11	132	142	hydralazine	drug	DDI-DrugBank.d561.s11.e5
DDI-DrugBank.d561.s11	false	DDI-DrugBank.d561.s11.e0	DDI-DrugBank.d561.s11.e1
DDI-DrugBank.d561.s11	false	DDI-DrugBank.d561.s11.e0	DDI-DrugBank.d561.s11.e2
DDI-DrugBank.d561.s11	false	DDI-DrugBank.d561.s11.e0	DDI-DrugBank.d561.s11.e3
DDI-DrugBank.d561.s11	false	DDI-DrugBank.d561.s11.e0	DDI-DrugBank.d561.s11.e4
DDI-DrugBank.d561.s11	false	DDI-DrugBank.d561.s11.e0	DDI-DrugBank.d561.s11.e5
DDI-DrugBank.d561.s11	false	DDI-DrugBank.d561.s11.e1	DDI-DrugBank.d561.s11.e2
DDI-DrugBank.d561.s11	false	DDI-DrugBank.d561.s11.e1	DDI-DrugBank.d561.s11.e3
DDI-DrugBank.d561.s11	false	DDI-DrugBank.d561.s11.e1	DDI-DrugBank.d561.s11.e4
DDI-DrugBank.d561.s11	false	DDI-DrugBank.d561.s11.e1	DDI-DrugBank.d561.s11.e5
DDI-DrugBank.d561.s11	false	DDI-DrugBank.d561.s11.e2	DDI-DrugBank.d561.s11.e3
DDI-DrugBank.d561.s12|a|Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
DDI-DrugBank.d561.s12	0	9	Benazepril	drug	DDI-DrugBank.d561.s12.e0
DDI-DrugBank.d561.s12	23	36	ACE inhibitors	group	DDI-DrugBank.d561.s12.e1
DDI-DrugBank.d561.s12	79	102	beta-adrenergic blockers	group	DDI-DrugBank.d561.s12.e2
DDI-DrugBank.d561.s12	false	DDI-DrugBank.d561.s12.e0	DDI-DrugBank.d561.s12.e1
DDI-DrugBank.d561.s12	true	DDI-DrugBank.d561.s12.e0	DDI-DrugBank.d561.s12.e2
DDI-DrugBank.d561.s12	true	DDI-DrugBank.d561.s12.e1	DDI-DrugBank.d561.s12.e2
DDI-DrugBank.d561.s13|a|.
DDI-DrugBank.d561.s14|a|
DDI-DrugBank.d304.s0|a|May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;
DDI-DrugBank.d304.s0	33	46	cholestyramine	drug	DDI-DrugBank.d304.s0.e0
DDI-DrugBank.d304.s0	49	58	colestipol	drug	DDI-DrugBank.d304.s0.e1
DDI-DrugBank.d304.s0	70	87	thiazide diuretics	group	DDI-DrugBank.d304.s0.e2
DDI-DrugBank.d304.s0	105	112	diuretic	group	DDI-DrugBank.d304.s0.e3
DDI-DrugBank.d304.s0	false	DDI-DrugBank.d304.s0.e0	DDI-DrugBank.d304.s0.e1
DDI-DrugBank.d304.s0	true	DDI-DrugBank.d304.s0.e0	DDI-DrugBank.d304.s0.e2
DDI-DrugBank.d304.s0	false	DDI-DrugBank.d304.s0.e0	DDI-DrugBank.d304.s0.e3
DDI-DrugBank.d304.s0	true	DDI-DrugBank.d304.s0.e1	DDI-DrugBank.d304.s0.e2
DDI-DrugBank.d304.s0	false	DDI-DrugBank.d304.s0.e1	DDI-DrugBank.d304.s0.e3
DDI-DrugBank.d304.s0	false	DDI-DrugBank.d304.s0.e2	DDI-DrugBank.d304.s0.e3
DDI-DrugBank.d537.s0|a|Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d537.s0	0	10	Bentiromide	drug	DDI-DrugBank.d537.s0.e0
DDI-DrugBank.d537.s0	30	42	acetaminophen	drug	DDI-DrugBank.d537.s0.e1
DDI-DrugBank.d537.s0	51	57	Tylenol	brand	DDI-DrugBank.d537.s0.e2
DDI-DrugBank.d537.s0	61	75	chloramphenicol	drug	DDI-DrugBank.d537.s0.e3
DDI-DrugBank.d537.s0	84	96	Chloromycetin	brand	DDI-DrugBank.d537.s0.e4
DDI-DrugBank.d537.s0	106	116	anesthetics	group	DDI-DrugBank.d537.s0.e5
DDI-DrugBank.d537.s0	125	134	benzocaine	drug	DDI-DrugBank.d537.s0.e6
DDI-DrugBank.d537.s0	140	148	lidocaine	drug	DDI-DrugBank.d537.s0.e7
DDI-DrugBank.d537.s0	152	173	para-aminobenzoic acid	drug_n	DDI-DrugBank.d537.s0.e8
DDI-DrugBank.d537.s0	176	179	PABA	drug_n	DDI-DrugBank.d537.s0.e9
DDI-DrugBank.d537.s0	true	DDI-DrugBank.d537.s0.e0	DDI-DrugBank.d537.s0.e1
DDI-DrugBank.d537.s0	true	DDI-DrugBank.d537.s0.e0	DDI-DrugBank.d537.s0.e2
DDI-DrugBank.d537.s0	true	DDI-DrugBank.d537.s0.e0	DDI-DrugBank.d537.s0.e3
DDI-DrugBank.d537.s0	true	DDI-DrugBank.d537.s0.e0	DDI-DrugBank.d537.s0.e4
DDI-DrugBank.d537.s0	true	DDI-DrugBank.d537.s0.e0	DDI-DrugBank.d537.s0.e5
DDI-DrugBank.d537.s0	true	DDI-DrugBank.d537.s0.e0	DDI-DrugBank.d537.s0.e6
DDI-DrugBank.d537.s0	true	DDI-DrugBank.d537.s0.e0	DDI-DrugBank.d537.s0.e7
DDI-DrugBank.d537.s0	true	DDI-DrugBank.d537.s0.e0	DDI-DrugBank.d537.s0.e8
DDI-DrugBank.d537.s0	true	DDI-DrugBank.d537.s0.e0	DDI-DrugBank.d537.s0.e9
DDI-DrugBank.d537.s0	true	DDI-DrugBank.d537.s0.e0	DDI-DrugBank.d537.s0.e10
DDI-DrugBank.d173.s0|a|May interact with other creams, lotions, or skin medicines when placed on the same areas of your skin that you are using bentoquatam.
DDI-DrugBank.d173.s0	121	131	bentoquatam	drug_n	DDI-DrugBank.d173.s0.e0
DDI-DrugBank.d24.s0|a|No information is available.
DDI-DrugBank.d477.s0|a|Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.
DDI-DrugBank.d477.s0	39	60	sympathomimetic amines	group	DDI-DrugBank.d477.s0.e0
DDI-DrugBank.d477.s0	122	149	monoamine oxidase inhibitors	group	DDI-DrugBank.d477.s0.e1
DDI-DrugBank.d477.s0	true	DDI-DrugBank.d477.s0.e0	DDI-DrugBank.d477.s0.e1
DDI-DrugBank.d477.s1|a|DIDREX should not be used concomitantly with other CNS stimulants.
DDI-DrugBank.d477.s1	0	5	DIDREX	brand	DDI-DrugBank.d477.s1.e0
DDI-DrugBank.d477.s1	51	64	CNS stimulants	group	DDI-DrugBank.d477.s1.e1
DDI-DrugBank.d477.s1	true	DDI-DrugBank.d477.s1.e0	DDI-DrugBank.d477.s1.e1
DDI-DrugBank.d477.s2|a|Amphetamines may decrease the hypotensive effect of antihypertensives.
DDI-DrugBank.d477.s2	0	11	Amphetamines	group	DDI-DrugBank.d477.s2.e0
DDI-DrugBank.d477.s2	52	68	antihypertensives	group	DDI-DrugBank.d477.s2.e1
DDI-DrugBank.d477.s2	true	DDI-DrugBank.d477.s2.e0	DDI-DrugBank.d477.s2.e1
DDI-DrugBank.d477.s3|a|Amphetamines may enhance the effects of tricyclic antidepressants.
DDI-DrugBank.d477.s3	0	11	Amphetamines	group	DDI-DrugBank.d477.s3.e0
DDI-DrugBank.d477.s3	40	64	tricyclic antidepressants	group	DDI-DrugBank.d477.s3.e1
DDI-DrugBank.d477.s3	true	DDI-DrugBank.d477.s3.e0	DDI-DrugBank.d477.s3.e1
DDI-DrugBank.d477.s4|a|Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines.
DDI-DrugBank.d477.s4	76	87	amphetamines	group	DDI-DrugBank.d477.s4.e0
DDI-DrugBank.d477.s5|a|Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.
DDI-DrugBank.d477.s5	0	17	Urinary acidifying	drug	DDI-DrugBank.d477.s5.e0
DDI-DrugBank.d477.s5	74	85	amphetamines	group	DDI-DrugBank.d477.s5.e1
DDI-DrugBank.d477.s5	true	DDI-DrugBank.d477.s5.e0	DDI-DrugBank.d477.s5.e1
DDI-DrugBank.d208.s0|a|Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d208.s0	0	11	Benzthiazide	drug	DDI-DrugBank.d208.s0.e0
DDI-DrugBank.d208.s0	31	37	alcohol	drug	DDI-DrugBank.d208.s0.e1
DDI-DrugBank.d208.s0	40	52	blood thinner	group	DDI-DrugBank.d208.s0.e2
DDI-DrugBank.d208.s0	56	73	decongestant drugs	group	DDI-DrugBank.d208.s0.e3
DDI-DrugBank.d208.s0	129	135	lithium	drug	DDI-DrugBank.d208.s0.e4
DDI-DrugBank.d208.s0	138	151	norepinephrine	drug	DDI-DrugBank.d208.s0.e5
DDI-DrugBank.d208.s0	154	159	NSAIDs	group	DDI-DrugBank.d208.s0.e6
DDI-DrugBank.d208.s0	166	170	Aleve	brand	DDI-DrugBank.d208.s0.e7
DDI-DrugBank.d208.s0	175	183	Ibuprofen	drug	DDI-DrugBank.d208.s0.e8
DDI-DrugBank.d208.s0	true	DDI-DrugBank.d208.s0.e0	DDI-DrugBank.d208.s0.e1
DDI-DrugBank.d208.s0	true	DDI-DrugBank.d208.s0.e0	DDI-DrugBank.d208.s0.e2
DDI-DrugBank.d208.s0	true	DDI-DrugBank.d208.s0.e0	DDI-DrugBank.d208.s0.e3
DDI-DrugBank.d208.s0	true	DDI-DrugBank.d208.s0.e0	DDI-DrugBank.d208.s0.e4
DDI-DrugBank.d208.s0	true	DDI-DrugBank.d208.s0.e0	DDI-DrugBank.d208.s0.e5
DDI-DrugBank.d208.s0	true	DDI-DrugBank.d208.s0.e0	DDI-DrugBank.d208.s0.e6
DDI-DrugBank.d208.s0	true	DDI-DrugBank.d208.s0.e0	DDI-DrugBank.d208.s0.e7
DDI-DrugBank.d208.s0	true	DDI-DrugBank.d208.s0.e0	DDI-DrugBank.d208.s0.e8
DDI-DrugBank.d208.s0	false	DDI-DrugBank.d208.s0.e1	DDI-DrugBank.d208.s0.e2
DDI-DrugBank.d208.s0	false	DDI-DrugBank.d208.s0.e1	DDI-DrugBank.d208.s0.e3
DDI-DrugBank.d390.s0|a|Antipsychotic drugs such as phenothiazines or haloperidol;
DDI-DrugBank.d390.s0	0	18	Antipsychotic drugs	group	DDI-DrugBank.d390.s0.e0
DDI-DrugBank.d390.s0	28	41	phenothiazines	group	DDI-DrugBank.d390.s0.e1
DDI-DrugBank.d390.s0	46	56	haloperidol	drug	DDI-DrugBank.d390.s0.e2
DDI-DrugBank.d390.s0	false	DDI-DrugBank.d390.s0.e0	DDI-DrugBank.d390.s0.e1
DDI-DrugBank.d390.s0	false	DDI-DrugBank.d390.s0.e0	DDI-DrugBank.d390.s0.e2
DDI-DrugBank.d390.s0	false	DDI-DrugBank.d390.s0.e1	DDI-DrugBank.d390.s0.e2
DDI-DrugBank.d390.s1|a|tricyclic antidepressants.
DDI-DrugBank.d390.s1	0	24	tricyclic antidepressants	group	DDI-DrugBank.d390.s1.e0
DDI-DrugBank.d137.s0|a|Nitrates: The concomitant use of Bepridil with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.
DDI-DrugBank.d137.s0	0	7	Nitrates	group	DDI-DrugBank.d137.s0.e0
DDI-DrugBank.d137.s0	33	40	Bepridil	drug	DDI-DrugBank.d137.s0.e1
DDI-DrugBank.d137.s0	70	77	nitrates	group	DDI-DrugBank.d137.s0.e2
DDI-DrugBank.d137.s0	false	DDI-DrugBank.d137.s0.e0	DDI-DrugBank.d137.s0.e1
DDI-DrugBank.d137.s0	false	DDI-DrugBank.d137.s0.e0	DDI-DrugBank.d137.s0.e2
DDI-DrugBank.d137.s0	false	DDI-DrugBank.d137.s0.e1	DDI-DrugBank.d137.s0.e2
DDI-DrugBank.d137.s1|a|Sublingual nitroglycerin may be taken if necessary for the control of acute angina attacks during Bepridil therapy.
DDI-DrugBank.d137.s1	11	23	nitroglycerin	drug	DDI-DrugBank.d137.s1.e0
DDI-DrugBank.d137.s1	98	105	Bepridil	drug	DDI-DrugBank.d137.s1.e1
DDI-DrugBank.d137.s1	false	DDI-DrugBank.d137.s1.e0	DDI-DrugBank.d137.s1.e1
DDI-DrugBank.d137.s2|a|Beta-blocking Agents: The concomitant use of Bepridil and beta-blocking agents has been well tolerated in patients with stable angina.
DDI-DrugBank.d137.s2	0	19	Beta-blocking Agents	group	DDI-DrugBank.d137.s2.e0
DDI-DrugBank.d137.s2	45	52	Bepridil	drug	DDI-DrugBank.d137.s2.e1
DDI-DrugBank.d137.s2	58	77	beta-blocking agents	group	DDI-DrugBank.d137.s2.e2
DDI-DrugBank.d137.s2	false	DDI-DrugBank.d137.s2.e0	DDI-DrugBank.d137.s2.e1
DDI-DrugBank.d137.s2	false	DDI-DrugBank.d137.s2.e0	DDI-DrugBank.d137.s2.e2
DDI-DrugBank.d137.s2	false	DDI-DrugBank.d137.s2.e1	DDI-DrugBank.d137.s2.e2
DDI-DrugBank.d137.s3|a|Available data are not sufficient, however, to predict the effects of concomitant medication on patients with impaired ventricular function or cardiac conduction abnormalities.
DDI-DrugBank.d137.s4|a|Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.
DDI-DrugBank.d137.s4	0	6	Digoxin	drug	DDI-DrugBank.d137.s4.e0
DDI-DrugBank.d137.s4	54	75	bepridil hydrochloride	drug	DDI-DrugBank.d137.s4.e1
DDI-DrugBank.d137.s4	197	203	digoxin	drug	DDI-DrugBank.d137.s4.e2
DDI-DrugBank.d137.s4	false	DDI-DrugBank.d137.s4.e0	DDI-DrugBank.d137.s4.e1
DDI-DrugBank.d137.s4	false	DDI-DrugBank.d137.s4.e0	DDI-DrugBank.d137.s4.e2
DDI-DrugBank.d137.s4	true	DDI-DrugBank.d137.s4.e1	DDI-DrugBank.d137.s4.e2
DDI-DrugBank.d137.s5|a|Limited clinical data in angina patients receiving concomitant bepridil hydrochloride and digoxin therapy indicate no discernible changes in serum digoxin levels.
DDI-DrugBank.d137.s5	63	84	bepridil hydrochloride	drug	DDI-DrugBank.d137.s5.e0
DDI-DrugBank.d137.s5	90	96	digoxin	drug	DDI-DrugBank.d137.s5.e1
DDI-DrugBank.d137.s5	false	DDI-DrugBank.d137.s5.e0	DDI-DrugBank.d137.s5.e1
DDI-DrugBank.d137.s6|a|Available data are neither sufficient to rule out possible increases in serum digoxin with concomitant treatment in some patients, nor other possible interactions, particularly in patients with cardiac conduction abnormalities (Also see WARNINGS Congestive Heart Failure).
DDI-DrugBank.d137.s6	78	84	digoxin	drug	DDI-DrugBank.d137.s6.e0
DDI-DrugBank.d137.s7|a|Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.
DDI-DrugBank.d137.s7	5	17	Hypoglycemics	group	DDI-DrugBank.d137.s7.e0
DDI-DrugBank.d137.s7	20	27	Bepridil	drug	DDI-DrugBank.d137.s7.e1
DDI-DrugBank.d137.s7	156	162	insulin	drug	DDI-DrugBank.d137.s7.e2
DDI-DrugBank.d137.s7	172	190	hypoglycemic agents	group	DDI-DrugBank.d137.s7.e3
DDI-DrugBank.d137.s7	false	DDI-DrugBank.d137.s7.e0	DDI-DrugBank.d137.s7.e1
DDI-DrugBank.d137.s7	false	DDI-DrugBank.d137.s7.e0	DDI-DrugBank.d137.s7.e2
DDI-DrugBank.d137.s7	false	DDI-DrugBank.d137.s7.e0	DDI-DrugBank.d137.s7.e3
DDI-DrugBank.d137.s7	false	DDI-DrugBank.d137.s7.e1	DDI-DrugBank.d137.s7.e2
DDI-DrugBank.d137.s7	false	DDI-DrugBank.d137.s7.e1	DDI-DrugBank.d137.s7.e3
DDI-DrugBank.d137.s7	false	DDI-DrugBank.d137.s7.e2	DDI-DrugBank.d137.s7.e3
DDI-DrugBank.d137.s8|a|General Interactions: Certain drugs could increase the likelihood of potentially serious adverse effects with bepridil hydrochloride.
DDI-DrugBank.d137.s8	110	131	bepridil hydrochloride	drug	DDI-DrugBank.d137.s8.e0
DDI-DrugBank.d137.s9|a|In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.
DDI-DrugBank.d137.s9	86	107	bepridil hydrochloride	drug	DDI-DrugBank.d137.s9.e0
DDI-DrugBank.d137.s9	120	141	anti-arrhythmic agents	group	DDI-DrugBank.d137.s9.e1
DDI-DrugBank.d137.s9	151	159	quinidine	drug	DDI-DrugBank.d137.s9.e2
DDI-DrugBank.d137.s9	165	176	procainamide	drug	DDI-DrugBank.d137.s9.e3
DDI-DrugBank.d137.s9	179	196	cardiac glycosides	group	DDI-DrugBank.d137.s9.e4
DDI-DrugBank.d137.s9	202	227	tricyclic anti-depressants	group	DDI-DrugBank.d137.s9.e5
DDI-DrugBank.d137.s9	false	DDI-DrugBank.d137.s9.e0	DDI-DrugBank.d137.s9.e1
DDI-DrugBank.d137.s9	false	DDI-DrugBank.d137.s9.e0	DDI-DrugBank.d137.s9.e2
DDI-DrugBank.d137.s9	false	DDI-DrugBank.d137.s9.e0	DDI-DrugBank.d137.s9.e3
DDI-DrugBank.d137.s9	false	DDI-DrugBank.d137.s9.e0	DDI-DrugBank.d137.s9.e4
DDI-DrugBank.d137.s9	false	DDI-DrugBank.d137.s9.e0	DDI-DrugBank.d137.s9.e5
DDI-DrugBank.d137.s9	false	DDI-DrugBank.d137.s9.e1	DDI-DrugBank.d137.s9.e2
DDI-DrugBank.d137.s9	false	DDI-DrugBank.d137.s9.e1	DDI-DrugBank.d137.s9.e3
DDI-DrugBank.d137.s9	false	DDI-DrugBank.d137.s9.e1	DDI-DrugBank.d137.s9.e4
DDI-DrugBank.d137.s9	false	DDI-DrugBank.d137.s9.e1	DDI-DrugBank.d137.s9.e5
DDI-DrugBank.d137.s9	false	DDI-DrugBank.d137.s9.e2	DDI-DrugBank.d137.s9.e3
DDI-DrugBank.d137.s10|a|Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.
DDI-DrugBank.d137.s10	0	15	Anti-arrhythmics	group	DDI-DrugBank.d137.s10.e0
DDI-DrugBank.d137.s10	21	46	tricyclic anti-depressants	group	DDI-DrugBank.d137.s10.e1
DDI-DrugBank.d137.s10	115	136	bepridil hydrochloride	drug	DDI-DrugBank.d137.s10.e2
DDI-DrugBank.d137.s10	false	DDI-DrugBank.d137.s10.e0	DDI-DrugBank.d137.s10.e1
DDI-DrugBank.d137.s10	true	DDI-DrugBank.d137.s10.e0	DDI-DrugBank.d137.s10.e2
DDI-DrugBank.d137.s10	true	DDI-DrugBank.d137.s10.e1	DDI-DrugBank.d137.s10.e2
DDI-DrugBank.d137.s11|a|Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.
DDI-DrugBank.d137.s11	0	17	Cardiac glycosides	group	DDI-DrugBank.d137.s11.e0
DDI-DrugBank.d137.s11	88	109	bepridil hydrochloride	drug	DDI-DrugBank.d137.s11.e1
DDI-DrugBank.d137.s11	true	DDI-DrugBank.d137.s11.e0	DDI-DrugBank.d137.s11.e1
DDI-DrugBank.d432.s0|a|APRD00513_IN,txt
DDI-DrugBank.d489.s0|a|The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine, nifedipine, chlorthalidone, and hydrochlorothiazide.
DDI-DrugBank.d489.s0	50	56	Kerlone	brand	DDI-DrugBank.d489.s0.e0
DDI-DrugBank.d489.s0	101	110	cimetidine	drug	DDI-DrugBank.d489.s0.e1
DDI-DrugBank.d489.s0	113	122	nifedipine	drug	DDI-DrugBank.d489.s0.e2
DDI-DrugBank.d489.s0	125	138	chlorthalidone	drug	DDI-DrugBank.d489.s0.e3
DDI-DrugBank.d489.s0	145	163	hydrochlorothiazide	drug	DDI-DrugBank.d489.s0.e4
DDI-DrugBank.d489.s0	false	DDI-DrugBank.d489.s0.e0	DDI-DrugBank.d489.s0.e1
DDI-DrugBank.d489.s0	false	DDI-DrugBank.d489.s0.e0	DDI-DrugBank.d489.s0.e2
DDI-DrugBank.d489.s0	false	DDI-DrugBank.d489.s0.e0	DDI-DrugBank.d489.s0.e3
DDI-DrugBank.d489.s0	false	DDI-DrugBank.d489.s0.e0	DDI-DrugBank.d489.s0.e4
DDI-DrugBank.d489.s0	false	DDI-DrugBank.d489.s0.e1	DDI-DrugBank.d489.s0.e2
DDI-DrugBank.d489.s0	false	DDI-DrugBank.d489.s0.e1	DDI-DrugBank.d489.s0.e3
DDI-DrugBank.d489.s0	false	DDI-DrugBank.d489.s0.e1	DDI-DrugBank.d489.s0.e4
DDI-DrugBank.d489.s0	false	DDI-DrugBank.d489.s0.e2	DDI-DrugBank.d489.s0.e3
DDI-DrugBank.d489.s0	false	DDI-DrugBank.d489.s0.e2	DDI-DrugBank.d489.s0.e4
DDI-DrugBank.d489.s0	false	DDI-DrugBank.d489.s0.e3	DDI-DrugBank.d489.s0.e4
DDI-DrugBank.d489.s1|a|Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.
DDI-DrugBank.d489.s1	30	36	Kerlone	brand	DDI-DrugBank.d489.s1.e0
DDI-DrugBank.d489.s1	52	64	anticoagulant	group	DDI-DrugBank.d489.s1.e1
DDI-DrugBank.d489.s1	66	73	warfarin	drug	DDI-DrugBank.d489.s1.e2
DDI-DrugBank.d489.s1	136	143	warfarin	drug	DDI-DrugBank.d489.s1.e3
DDI-DrugBank.d489.s1	false	DDI-DrugBank.d489.s1.e0	DDI-DrugBank.d489.s1.e1
DDI-DrugBank.d489.s1	false	DDI-DrugBank.d489.s1.e0	DDI-DrugBank.d489.s1.e2
DDI-DrugBank.d489.s1	false	DDI-DrugBank.d489.s1.e0	DDI-DrugBank.d489.s1.e3
DDI-DrugBank.d489.s1	false	DDI-DrugBank.d489.s1.e1	DDI-DrugBank.d489.s1.e2
DDI-DrugBank.d489.s1	false	DDI-DrugBank.d489.s1.e1	DDI-DrugBank.d489.s1.e3
DDI-DrugBank.d489.s1	false	DDI-DrugBank.d489.s1.e2	DDI-DrugBank.d489.s1.e3
DDI-DrugBank.d489.s2|a|Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
DDI-DrugBank.d489.s2	37	45	reserpine	drug	DDI-DrugBank.d489.s2.e0
DDI-DrugBank.d489.s2	92	104	beta-blocking	drug	DDI-DrugBank.d489.s2.e1
DDI-DrugBank.d489.s2	true	DDI-DrugBank.d489.s2.e0	DDI-DrugBank.d489.s2.e1
DDI-DrugBank.d489.s3|a|Patients treated with a beta-adrenergic receptor blocking agent plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
DDI-DrugBank.d489.s3	24	62	beta-adrenergic receptor blocking agent	group	DDI-DrugBank.d489.s3.e0
DDI-DrugBank.d489.s4|a|Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.
DDI-DrugBank.d489.s4	66	78	beta-blockers	group	DDI-DrugBank.d489.s4.e0
DDI-DrugBank.d489.s4	84	92	clonidine	drug	DDI-DrugBank.d489.s4.e1
DDI-DrugBank.d489.s4	112	123	beta-blocker	group	DDI-DrugBank.d489.s4.e2
DDI-DrugBank.d489.s4	206	214	clonidine	drug	DDI-DrugBank.d489.s4.e3
DDI-DrugBank.d489.s4	true	DDI-DrugBank.d489.s4.e0	DDI-DrugBank.d489.s4.e1
DDI-DrugBank.d489.s4	false	DDI-DrugBank.d489.s4.e0	DDI-DrugBank.d489.s4.e2
DDI-DrugBank.d489.s4	false	DDI-DrugBank.d489.s4.e0	DDI-DrugBank.d489.s4.e3
DDI-DrugBank.d489.s4	false	DDI-DrugBank.d489.s4.e1	DDI-DrugBank.d489.s4.e2
DDI-DrugBank.d489.s4	false	DDI-DrugBank.d489.s4.e1	DDI-DrugBank.d489.s4.e3
DDI-DrugBank.d489.s4	true	DDI-DrugBank.d489.s4.e2	DDI-DrugBank.d489.s4.e3
DDI-DrugBank.d489.s5|a|Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.
DDI-DrugBank.d489.s5	37	55	calcium antagonists	group	DDI-DrugBank.d489.s5.e0
DDI-DrugBank.d489.s5	89	119	beta-adrenergic blocking agents	group	DDI-DrugBank.d489.s5.e1
DDI-DrugBank.d489.s5	true	DDI-DrugBank.d489.s5.e0	DDI-DrugBank.d489.s5.e1
DDI-DrugBank.d489.s6|a|Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.
DDI-DrugBank.d489.s6	116	146	beta-adrenergic blocking agents	group	DDI-DrugBank.d489.s6.e0
DDI-DrugBank.d489.s6	161	178	calcium antagonist	group	DDI-DrugBank.d489.s6.e1
DDI-DrugBank.d489.s6	true	DDI-DrugBank.d489.s6.e0	DDI-DrugBank.d489.s6.e1
DDI-DrugBank.d489.s7|a|Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.
DDI-DrugBank.d489.s7	44	61	calcium antagonist	group	DDI-DrugBank.d489.s7.e0
DDI-DrugBank.d489.s7	70	95	dihydropyridine derivative	group	DDI-DrugBank.d489.s7.e1
DDI-DrugBank.d489.s7	104	113	nifedipine	drug	DDI-DrugBank.d489.s7.e2
DDI-DrugBank.d489.s7	249	257	verapamil	drug	DDI-DrugBank.d489.s7.e3
DDI-DrugBank.d489.s7	262	270	diltiazem	drug	DDI-DrugBank.d489.s7.e4
DDI-DrugBank.d489.s7	false	DDI-DrugBank.d489.s7.e0	DDI-DrugBank.d489.s7.e1
DDI-DrugBank.d489.s7	false	DDI-DrugBank.d489.s7.e0	DDI-DrugBank.d489.s7.e2
DDI-DrugBank.d489.s7	false	DDI-DrugBank.d489.s7.e0	DDI-DrugBank.d489.s7.e3
DDI-DrugBank.d489.s7	false	DDI-DrugBank.d489.s7.e0	DDI-DrugBank.d489.s7.e4
DDI-DrugBank.d489.s7	false	DDI-DrugBank.d489.s7.e1	DDI-DrugBank.d489.s7.e2
DDI-DrugBank.d489.s7	false	DDI-DrugBank.d489.s7.e1	DDI-DrugBank.d489.s7.e3
DDI-DrugBank.d489.s7	false	DDI-DrugBank.d489.s7.e1	DDI-DrugBank.d489.s7.e4
DDI-DrugBank.d489.s7	false	DDI-DrugBank.d489.s7.e2	DDI-DrugBank.d489.s7.e3
DDI-DrugBank.d489.s7	false	DDI-DrugBank.d489.s7.e2	DDI-DrugBank.d489.s7.e4
DDI-DrugBank.d489.s7	false	DDI-DrugBank.d489.s7.e3	DDI-DrugBank.d489.s7.e4
DDI-DrugBank.d489.s8|a|Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
DDI-DrugBank.d489.s8	69	81	beta-blockers	group	DDI-DrugBank.d489.s8.e0
DDI-DrugBank.d489.s8	104	114	epinephrine	drug	DDI-DrugBank.d489.s8.e1
DDI-DrugBank.d489.s8	156	168	beta-blockers	group	DDI-DrugBank.d489.s8.e2
DDI-DrugBank.d489.s8	true	DDI-DrugBank.d489.s8.e0	DDI-DrugBank.d489.s8.e1
DDI-DrugBank.d489.s8	false	DDI-DrugBank.d489.s8.e0	DDI-DrugBank.d489.s8.e2
DDI-DrugBank.d489.s8	false	DDI-DrugBank.d489.s8.e1	DDI-DrugBank.d489.s8.e2
DDI-DrugBank.d489.s9|a|Severe allergic reactions including anaphylaxis have been reported in patients exposed to a variety of allergens either by repeated challenge, or accidental contact, and with diagnostic or therapeutic agents while receiving beta-blockers.
DDI-DrugBank.d489.s9	224	236	beta-blockers	group	DDI-DrugBank.d489.s9.e0
DDI-DrugBank.d489.s10|a|Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
DDI-DrugBank.d489.s10	56	66	epinephrine	drug	DDI-DrugBank.d489.s10.e0
DDI-DrugBank.d513.s0|a|Special care is required if this drug is given to patients receiving ganglion blocking compounds because a critical fall in blood pressure may occur.
DDI-DrugBank.d513.s0	69	95	ganglion blocking compounds	group	DDI-DrugBank.d513.s0.e0
DDI-DrugBank.d513.s1|a|Usually, severe abdominal symptoms appear before there is such a fall in the blood pressure.
DDI-DrugBank.d312.s0|a|No formal drug interaction studies with anti-neoplastic agents have been conducted.
DDI-DrugBank.d312.s0	40	61	anti-neoplastic agents	group	DDI-DrugBank.d312.s0.e0
DDI-DrugBank.d312.s1|a|In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN.
DDI-DrugBank.d312.s1	55	64	irinotecan	drug	DDI-DrugBank.d312.s1.e0
DDI-DrugBank.d312.s1	66	69	5-FU	drug	DDI-DrugBank.d312.s1.e1
DDI-DrugBank.d312.s1	71	80	leucovorin	drug	DDI-DrugBank.d312.s1.e2
DDI-DrugBank.d312.s1	110	116	AVASTIN	brand	DDI-DrugBank.d312.s1.e3
DDI-DrugBank.d312.s1	false	DDI-DrugBank.d312.s1.e0	DDI-DrugBank.d312.s1.e1
DDI-DrugBank.d312.s1	false	DDI-DrugBank.d312.s1.e0	DDI-DrugBank.d312.s1.e2
DDI-DrugBank.d312.s1	false	DDI-DrugBank.d312.s1.e0	DDI-DrugBank.d312.s1.e3
DDI-DrugBank.d312.s1	false	DDI-DrugBank.d312.s1.e1	DDI-DrugBank.d312.s1.e2
DDI-DrugBank.d312.s1	false	DDI-DrugBank.d312.s1.e1	DDI-DrugBank.d312.s1.e3
DDI-DrugBank.d312.s1	false	DDI-DrugBank.d312.s1.e2	DDI-DrugBank.d312.s1.e3
DDI-DrugBank.d312.s2|a|Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN.
DDI-DrugBank.d312.s2	0	9	Irinotecan	drug	DDI-DrugBank.d312.s2.e0
DDI-DrugBank.d312.s2	101	107	AVASTIN	brand	DDI-DrugBank.d312.s2.e1
DDI-DrugBank.d312.s2	false	DDI-DrugBank.d312.s2.e0	DDI-DrugBank.d312.s2.e1
DDI-DrugBank.d312.s3|a|The concentrations of SN38, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.
DDI-DrugBank.d312.s3	22	25	SN38	drug_n	DDI-DrugBank.d312.s3.e0
DDI-DrugBank.d312.s3	53	62	irinotecan	drug	DDI-DrugBank.d312.s3.e1
DDI-DrugBank.d312.s3	144	150	AVASTIN	brand	DDI-DrugBank.d312.s3.e2
DDI-DrugBank.d312.s3	false	DDI-DrugBank.d312.s3.e0	DDI-DrugBank.d312.s3.e1
DDI-DrugBank.d312.s3	false	DDI-DrugBank.d312.s3.e0	DDI-DrugBank.d312.s3.e2
DDI-DrugBank.d312.s3	false	DDI-DrugBank.d312.s3.e1	DDI-DrugBank.d312.s3.e2
DDI-DrugBank.d312.s4|a|In Study 1, patients receiving bolus-IFL plus AVASTIN had a higher incidence of Grade 3-4 diarrhea and neutropenia.
DDI-DrugBank.d312.s4	46	52	AVASTIN	brand	DDI-DrugBank.d312.s4.e0
DDI-DrugBank.d312.s5|a|Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.
DDI-DrugBank.d312.s5	90	93	SN38	drug_n	DDI-DrugBank.d312.s5.e0
DDI-DrugBank.d312.s5	135	144	irinotecan	drug	DDI-DrugBank.d312.s5.e1
DDI-DrugBank.d312.s5	150	156	AVASTIN	brand	DDI-DrugBank.d312.s5.e2
DDI-DrugBank.d312.s5	false	DDI-DrugBank.d312.s5.e0	DDI-DrugBank.d312.s5.e1
DDI-DrugBank.d312.s5	false	DDI-DrugBank.d312.s5.e0	DDI-DrugBank.d312.s5.e2
DDI-DrugBank.d312.s5	false	DDI-DrugBank.d312.s5.e1	DDI-DrugBank.d312.s5.e2
DDI-DrugBank.d467.s0|a|No formal studies to evaluate drug interactions with bexarotene have been conducted.
DDI-DrugBank.d467.s0	53	62	bexarotene	drug	DDI-DrugBank.d467.s0.e0
DDI-DrugBank.d467.s1|a|Bexarotene oxidative metabolites appear to be formed by cytochrome P450 3A4.
DDI-DrugBank.d467.s1	0	9	Bexarotene	drug	DDI-DrugBank.d467.s1.e0
DDI-DrugBank.d467.s2|a|On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
DDI-DrugBank.d467.s2	34	43	bexarotene	drug	DDI-DrugBank.d467.s2.e0
DDI-DrugBank.d467.s2	69	80	ketoconazole	drug	DDI-DrugBank.d467.s2.e1
DDI-DrugBank.d467.s2	83	94	itraconazole	drug	DDI-DrugBank.d467.s2.e2
DDI-DrugBank.d467.s2	97	108	erythromycin	drug	DDI-DrugBank.d467.s2.e3
DDI-DrugBank.d467.s2	111	121	gemfibrozil	drug	DDI-DrugBank.d467.s2.e4
DDI-DrugBank.d467.s2	237	246	bexarotene	drug	DDI-DrugBank.d467.s2.e5
DDI-DrugBank.d467.s2	false	DDI-DrugBank.d467.s2.e0	DDI-DrugBank.d467.s2.e1
DDI-DrugBank.d467.s2	false	DDI-DrugBank.d467.s2.e0	DDI-DrugBank.d467.s2.e2
DDI-DrugBank.d467.s2	false	DDI-DrugBank.d467.s2.e0	DDI-DrugBank.d467.s2.e3
DDI-DrugBank.d467.s2	false	DDI-DrugBank.d467.s2.e0	DDI-DrugBank.d467.s2.e4
DDI-DrugBank.d467.s2	false	DDI-DrugBank.d467.s2.e0	DDI-DrugBank.d467.s2.e5
DDI-DrugBank.d467.s2	false	DDI-DrugBank.d467.s2.e1	DDI-DrugBank.d467.s2.e2
DDI-DrugBank.d467.s2	false	DDI-DrugBank.d467.s2.e1	DDI-DrugBank.d467.s2.e3
DDI-DrugBank.d467.s2	false	DDI-DrugBank.d467.s2.e1	DDI-DrugBank.d467.s2.e4
DDI-DrugBank.d467.s2	true	DDI-DrugBank.d467.s2.e1	DDI-DrugBank.d467.s2.e5
DDI-DrugBank.d467.s2	false	DDI-DrugBank.d467.s2.e2	DDI-DrugBank.d467.s2.e3
DDI-DrugBank.d467.s3|a|Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
DDI-DrugBank.d467.s3	13	20	rifampin	drug	DDI-DrugBank.d467.s3.e0
DDI-DrugBank.d467.s3	23	31	phenytoin	drug	DDI-DrugBank.d467.s3.e1
DDI-DrugBank.d467.s3	34	46	phenobarbital	drug	DDI-DrugBank.d467.s3.e2
DDI-DrugBank.d467.s3	123	132	bexarotene	drug	DDI-DrugBank.d467.s3.e3
DDI-DrugBank.d467.s3	false	DDI-DrugBank.d467.s3.e0	DDI-DrugBank.d467.s3.e1
DDI-DrugBank.d467.s3	false	DDI-DrugBank.d467.s3.e0	DDI-DrugBank.d467.s3.e2
DDI-DrugBank.d467.s3	true	DDI-DrugBank.d467.s3.e0	DDI-DrugBank.d467.s3.e3
DDI-DrugBank.d467.s3	false	DDI-DrugBank.d467.s3.e1	DDI-DrugBank.d467.s3.e2
DDI-DrugBank.d467.s3	true	DDI-DrugBank.d467.s3.e1	DDI-DrugBank.d467.s3.e3
DDI-DrugBank.d467.s3	true	DDI-DrugBank.d467.s3.e2	DDI-DrugBank.d467.s3.e3
DDI-DrugBank.d467.s4|a|Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
DDI-DrugBank.d467.s4	30	38	Targretin	brand	DDI-DrugBank.d467.s4.e0
DDI-DrugBank.d467.s4	53	63	gemfibrozil	drug	DDI-DrugBank.d467.s4.e1
DDI-DrugBank.d467.s4	127	136	bexarotene	drug	DDI-DrugBank.d467.s4.e2
DDI-DrugBank.d467.s4	212	222	gemfibrozil	drug	DDI-DrugBank.d467.s4.e3
DDI-DrugBank.d467.s4	true	DDI-DrugBank.d467.s4.e0	DDI-DrugBank.d467.s4.e1
DDI-DrugBank.d467.s4	false	DDI-DrugBank.d467.s4.e0	DDI-DrugBank.d467.s4.e2
DDI-DrugBank.d467.s4	false	DDI-DrugBank.d467.s4.e0	DDI-DrugBank.d467.s4.e3
DDI-DrugBank.d467.s4	false	DDI-DrugBank.d467.s4.e1	DDI-DrugBank.d467.s4.e2
DDI-DrugBank.d467.s4	false	DDI-DrugBank.d467.s4.e1	DDI-DrugBank.d467.s4.e3
DDI-DrugBank.d467.s4	false	DDI-DrugBank.d467.s4.e2	DDI-DrugBank.d467.s4.e3
DDI-DrugBank.d467.s5|a|Under similar conditions, bexarotene concentrations were not affected by concomitant atorvastatin administration.
DDI-DrugBank.d467.s5	26	35	bexarotene	drug	DDI-DrugBank.d467.s5.e0
DDI-DrugBank.d467.s5	85	96	atorvastatin	drug	DDI-DrugBank.d467.s5.e1
DDI-DrugBank.d467.s5	false	DDI-DrugBank.d467.s5.e0	DDI-DrugBank.d467.s5.e1
DDI-DrugBank.d467.s6|a|Concomitant administration of gemfibrozil with Targretin capsules is not recommended.
DDI-DrugBank.d467.s6	30	40	gemfibrozil	drug	DDI-DrugBank.d467.s6.e0
DDI-DrugBank.d467.s6	47	55	Targretin	brand	DDI-DrugBank.d467.s6.e1
DDI-DrugBank.d467.s6	true	DDI-DrugBank.d467.s6.e0	DDI-DrugBank.d467.s6.e1
DDI-DrugBank.d291.s0|a|When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
DDI-DrugBank.d291.s0	5	11	Bezalip	brand	DDI-DrugBank.d291.s0.e0
DDI-DrugBank.d291.s0	16	29	Bezalip retard	brand	DDI-DrugBank.d291.s0.e1
DDI-DrugBank.d291.s0	146	152	Bezalip	brand	DDI-DrugBank.d291.s0.e2
DDI-DrugBank.d291.s0	158	171	Bezalip retard	brand	DDI-DrugBank.d291.s0.e3
DDI-DrugBank.d291.s0	199	233	anticoagulants of the coumarin type	group	DDI-DrugBank.d291.s0.e4
DDI-DrugBank.d291.s0	false	DDI-DrugBank.d291.s0.e0	DDI-DrugBank.d291.s0.e1
DDI-DrugBank.d291.s0	false	DDI-DrugBank.d291.s0.e0	DDI-DrugBank.d291.s0.e2
DDI-DrugBank.d291.s0	false	DDI-DrugBank.d291.s0.e0	DDI-DrugBank.d291.s0.e3
DDI-DrugBank.d291.s0	false	DDI-DrugBank.d291.s0.e0	DDI-DrugBank.d291.s0.e4
DDI-DrugBank.d291.s0	false	DDI-DrugBank.d291.s0.e1	DDI-DrugBank.d291.s0.e2
DDI-DrugBank.d291.s0	false	DDI-DrugBank.d291.s0.e1	DDI-DrugBank.d291.s0.e3
DDI-DrugBank.d291.s0	false	DDI-DrugBank.d291.s0.e1	DDI-DrugBank.d291.s0.e4
DDI-DrugBank.d291.s0	false	DDI-DrugBank.d291.s0.e2	DDI-DrugBank.d291.s0.e3
DDI-DrugBank.d291.s0	true	DDI-DrugBank.d291.s0.e2	DDI-DrugBank.d291.s0.e4
DDI-DrugBank.d291.s0	true	DDI-DrugBank.d291.s0.e3	DDI-DrugBank.d291.s0.e4
DDI-DrugBank.d291.s1|a|For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters
DDI-DrugBank.d291.s1	33	45	anticoagulant	drug	DDI-DrugBank.d291.s1.e0
DDI-DrugBank.d291.s1	108	114	Bezalip	brand	DDI-DrugBank.d291.s1.e1
DDI-DrugBank.d291.s1	119	125	Bezalip	brand	DDI-DrugBank.d291.s1.e2
DDI-DrugBank.d291.s1	true	DDI-DrugBank.d291.s1.e0	DDI-DrugBank.d291.s1.e1
DDI-DrugBank.d291.s1	true	DDI-DrugBank.d291.s1.e0	DDI-DrugBank.d291.s1.e2
DDI-DrugBank.d291.s1	false	DDI-DrugBank.d291.s1.e1	DDI-DrugBank.d291.s1.e2
DDI-DrugBank.d291.s2|a|.
DDI-DrugBank.d291.s3|a|- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
DDI-DrugBank.d291.s3	16	29	sulphonylureas	group	DDI-DrugBank.d291.s3.e0
DDI-DrugBank.d291.s3	35	41	insulin	drug	DDI-DrugBank.d291.s3.e1
DDI-DrugBank.d291.s3	62	68	Bezalip	brand	DDI-DrugBank.d291.s3.e2
DDI-DrugBank.d291.s3	73	86	Bezalip retard	brand	DDI-DrugBank.d291.s3.e3
DDI-DrugBank.d291.s3	false	DDI-DrugBank.d291.s3.e0	DDI-DrugBank.d291.s3.e1
DDI-DrugBank.d291.s3	true	DDI-DrugBank.d291.s3.e0	DDI-DrugBank.d291.s3.e2
DDI-DrugBank.d291.s3	true	DDI-DrugBank.d291.s3.e0	DDI-DrugBank.d291.s3.e3
DDI-DrugBank.d291.s3	true	DDI-DrugBank.d291.s3.e1	DDI-DrugBank.d291.s3.e2
DDI-DrugBank.d291.s3	true	DDI-DrugBank.d291.s3.e1	DDI-DrugBank.d291.s3.e3
DDI-DrugBank.d291.s3	false	DDI-DrugBank.d291.s3.e2	DDI-DrugBank.d291.s3.e3
DDI-DrugBank.d291.s4|a|This may be due to an improved glucose utilization with simultaneous reduction in insulin requirement
DDI-DrugBank.d291.s4	82	88	insulin	drug	DDI-DrugBank.d291.s4.e0
DDI-DrugBank.d291.s5|a|.
DDI-DrugBank.d291.s6|a|- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.
DDI-DrugBank.d291.s6	211	228	immuno-suppressant	group	DDI-DrugBank.d291.s6.e0
DDI-DrugBank.d291.s6	254	264	bezafibrate	drug	DDI-DrugBank.d291.s6.e1
DDI-DrugBank.d291.s6	true	DDI-DrugBank.d291.s6.e0	DDI-DrugBank.d291.s6.e1
DDI-DrugBank.d291.s7|a|Accordingly, renal function should be closely monitored in these patients and, in the event of relevant significant changes in laboratory parameters, bezafibrate should, if necessary, be discontinued
DDI-DrugBank.d291.s7	150	160	bezafibrate	drug	DDI-DrugBank.d291.s7.e0
DDI-DrugBank.d291.s8|a|.
DDI-DrugBank.d291.s9|a|- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
DDI-DrugBank.d291.s9	7	13	Bezalip	brand	DDI-DrugBank.d291.s9.e0
DDI-DrugBank.d291.s9	18	31	Bezalip retard	brand	DDI-DrugBank.d291.s9.e1
DDI-DrugBank.d291.s9	59	79	anion-exchange resins	group	DDI-DrugBank.d291.s9.e2
DDI-DrugBank.d291.s9	87	101	cholestryramine	drug	DDI-DrugBank.d291.s9.e3
DDI-DrugBank.d291.s9	209	215	Bezalip	brand	DDI-DrugBank.d291.s9.e4
DDI-DrugBank.d291.s9	220	233	Bezalip retard	brand	DDI-DrugBank.d291.s9.e5
DDI-DrugBank.d291.s9	false	DDI-DrugBank.d291.s9.e0	DDI-DrugBank.d291.s9.e1
DDI-DrugBank.d291.s9	true	DDI-DrugBank.d291.s9.e0	DDI-DrugBank.d291.s9.e2
DDI-DrugBank.d291.s9	true	DDI-DrugBank.d291.s9.e0	DDI-DrugBank.d291.s9.e3
DDI-DrugBank.d291.s9	false	DDI-DrugBank.d291.s9.e0	DDI-DrugBank.d291.s9.e4
DDI-DrugBank.d291.s9	false	DDI-DrugBank.d291.s9.e0	DDI-DrugBank.d291.s9.e5
DDI-DrugBank.d291.s9	true	DDI-DrugBank.d291.s9.e1	DDI-DrugBank.d291.s9.e2
DDI-DrugBank.d291.s9	true	DDI-DrugBank.d291.s9.e1	DDI-DrugBank.d291.s9.e3
DDI-DrugBank.d291.s9	false	DDI-DrugBank.d291.s9.e1	DDI-DrugBank.d291.s9.e4
DDI-DrugBank.d291.s9	false	DDI-DrugBank.d291.s9.e1	DDI-DrugBank.d291.s9.e5
DDI-DrugBank.d291.s9	false	DDI-DrugBank.d291.s9.e2	DDI-DrugBank.d291.s9.e3
DDI-DrugBank.d291.s10|a|.
DDI-DrugBank.d291.s11|a|- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
DDI-DrugBank.d291.s11	2	29	Perhexiline hydrogen maleate	drug	DDI-DrugBank.d291.s11.e0
DDI-DrugBank.d291.s11	34	47	MAO-inhibitors	group	DDI-DrugBank.d291.s11.e1
DDI-DrugBank.d291.s11	117	123	Bezalip	brand	DDI-DrugBank.d291.s11.e2
DDI-DrugBank.d291.s11	128	141	Bezalip retard	brand	DDI-DrugBank.d291.s11.e3
DDI-DrugBank.d291.s11	false	DDI-DrugBank.d291.s11.e0	DDI-DrugBank.d291.s11.e1
DDI-DrugBank.d291.s11	true	DDI-DrugBank.d291.s11.e0	DDI-DrugBank.d291.s11.e2
DDI-DrugBank.d291.s11	true	DDI-DrugBank.d291.s11.e0	DDI-DrugBank.d291.s11.e3
DDI-DrugBank.d291.s11	true	DDI-DrugBank.d291.s11.e1	DDI-DrugBank.d291.s11.e2
DDI-DrugBank.d291.s11	true	DDI-DrugBank.d291.s11.e1	DDI-DrugBank.d291.s11.e3
DDI-DrugBank.d291.s11	false	DDI-DrugBank.d291.s11.e2	DDI-DrugBank.d291.s11.e3
DDI-DrugBank.d266.s0|a|In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.
DDI-DrugBank.d266.s0	28	34	CASODEX	brand	DDI-DrugBank.d266.s0.e0
DDI-DrugBank.d266.s0	49	70	coumarin anticoagulant	group	DDI-DrugBank.d266.s0.e1
DDI-DrugBank.d266.s0	82	89	warfarin	drug	DDI-DrugBank.d266.s0.e2
DDI-DrugBank.d266.s0	true	DDI-DrugBank.d266.s0.e0	DDI-DrugBank.d266.s0.e1
DDI-DrugBank.d266.s0	true	DDI-DrugBank.d266.s0.e0	DDI-DrugBank.d266.s0.e2
DDI-DrugBank.d266.s0	false	DDI-DrugBank.d266.s0.e1	DDI-DrugBank.d266.s0.e2
DDI-DrugBank.d266.s1|a|It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
DDI-DrugBank.d266.s1	26	32	CASODEX	brand	DDI-DrugBank.d266.s1.e0
DDI-DrugBank.d266.s1	75	97	coumarin anticoagulants	group	DDI-DrugBank.d266.s1.e1
DDI-DrugBank.d266.s1	168	180	anticoagulant	group	DDI-DrugBank.d266.s1.e2
DDI-DrugBank.d266.s1	true	DDI-DrugBank.d266.s1.e0	DDI-DrugBank.d266.s1.e1
DDI-DrugBank.d266.s1	true	DDI-DrugBank.d266.s1.e0	DDI-DrugBank.d266.s1.e2
DDI-DrugBank.d266.s1	false	DDI-DrugBank.d266.s1.e1	DDI-DrugBank.d266.s1.e2
DDI-DrugBank.d264.s0|a|No Information Provided
DDI-DrugBank.d401.s0|a|Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0	31	45	anticholinergic	group	DDI-DrugBank.d401.s0.e0
DDI-DrugBank.d401.s0	102	109	AKINETON	brand	DDI-DrugBank.d401.s0.e1
DDI-DrugBank.d401.s0	212	230	narcotic analgesics	group	DDI-DrugBank.d401.s0.e2
DDI-DrugBank.d401.s0	240	249	meperidine	drug	DDI-DrugBank.d401.s0.e3
DDI-DrugBank.d401.s0	256	269	phenothiazines	group	DDI-DrugBank.d401.s0.e4
DDI-DrugBank.d401.s0	281	294	antipsychotics	group	DDI-DrugBank.d401.s0.e5
DDI-DrugBank.d401.s0	297	321	tricyclic antidepressants	group	DDI-DrugBank.d401.s0.e6
DDI-DrugBank.d401.s0	332	346	antiarrhythmics	group	DDI-DrugBank.d401.s0.e7
DDI-DrugBank.d401.s0	360	368	quinidine	drug	DDI-DrugBank.d401.s0.e8
DDI-DrugBank.d401.s0	381	394	antihistamines	group	DDI-DrugBank.d401.s0.e9
DDI-DrugBank.d401.s0	false	DDI-DrugBank.d401.s0.e0	DDI-DrugBank.d401.s0.e1
DDI-DrugBank.d401.s0	true	DDI-DrugBank.d401.s0.e0	DDI-DrugBank.d401.s0.e2
DDI-DrugBank.d401.s0	true	DDI-DrugBank.d401.s0.e0	DDI-DrugBank.d401.s0.e3
DDI-DrugBank.d401.s0	true	DDI-DrugBank.d401.s0.e0	DDI-DrugBank.d401.s0.e4
DDI-DrugBank.d401.s0	true	DDI-DrugBank.d401.s0.e0	DDI-DrugBank.d401.s0.e5
DDI-DrugBank.d401.s0	true	DDI-DrugBank.d401.s0.e0	DDI-DrugBank.d401.s0.e6
DDI-DrugBank.d401.s0	true	DDI-DrugBank.d401.s0.e0	DDI-DrugBank.d401.s0.e7
DDI-DrugBank.d401.s0	true	DDI-DrugBank.d401.s0.e0	DDI-DrugBank.d401.s0.e8
DDI-DrugBank.d401.s0	true	DDI-DrugBank.d401.s0.e0	DDI-DrugBank.d401.s0.e9
DDI-DrugBank.d401.s0	true	DDI-DrugBank.d401.s0.e1	DDI-DrugBank.d401.s0.e2
DDI-DrugBank.d476.s0|a|ZEBETA should not be combined with other beta-blocking agents.
DDI-DrugBank.d476.s0	0	5	ZEBETA	brand	DDI-DrugBank.d476.s0.e0
DDI-DrugBank.d476.s0	41	60	beta-blocking agents	group	DDI-DrugBank.d476.s0.e1
DDI-DrugBank.d476.s0	true	DDI-DrugBank.d476.s0.e0	DDI-DrugBank.d476.s0.e1
DDI-DrugBank.d476.s1|a|Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
DDI-DrugBank.d476.s1	58	66	reserpine	drug	DDI-DrugBank.d476.s1.e0
DDI-DrugBank.d476.s1	71	82	guanethidine	drug	DDI-DrugBank.d476.s1.e1
DDI-DrugBank.d476.s1	167	172	ZEBETA	brand	DDI-DrugBank.d476.s1.e2
DDI-DrugBank.d476.s1	false	DDI-DrugBank.d476.s1.e0	DDI-DrugBank.d476.s1.e1
DDI-DrugBank.d476.s1	true	DDI-DrugBank.d476.s1.e0	DDI-DrugBank.d476.s1.e2
DDI-DrugBank.d476.s1	true	DDI-DrugBank.d476.s1.e1	DDI-DrugBank.d476.s1.e2
DDI-DrugBank.d476.s2|a|In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.
DDI-DrugBank.d476.s2	46	54	clonidine	drug	DDI-DrugBank.d476.s2.e0
DDI-DrugBank.d476.s2	112	117	ZEBETA	brand	DDI-DrugBank.d476.s2.e1
DDI-DrugBank.d476.s2	177	185	clonidine	drug	DDI-DrugBank.d476.s2.e2
DDI-DrugBank.d476.s2	false	DDI-DrugBank.d476.s2.e0	DDI-DrugBank.d476.s2.e1
DDI-DrugBank.d476.s2	false	DDI-DrugBank.d476.s2.e0	DDI-DrugBank.d476.s2.e2
DDI-DrugBank.d476.s2	true	DDI-DrugBank.d476.s2.e1	DDI-DrugBank.d476.s2.e2
DDI-DrugBank.d476.s3|a|ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
DDI-DrugBank.d476.s3	0	5	ZEBETA	brand	DDI-DrugBank.d476.s3.e0
DDI-DrugBank.d476.s3	37	58	myocardial depressants	group	DDI-DrugBank.d476.s3.e1
DDI-DrugBank.d476.s3	108	126	calcium antagonists	group	DDI-DrugBank.d476.s3.e2
DDI-DrugBank.d476.s3	149	164	phenylalkylamine	group	DDI-DrugBank.d476.s3.e3
DDI-DrugBank.d476.s3	167	175	verapamil	drug	DDI-DrugBank.d476.s3.e4
DDI-DrugBank.d476.s3	182	196	benzothiazepine	group	DDI-DrugBank.d476.s3.e5
DDI-DrugBank.d476.s3	199	207	diltiazem	drug	DDI-DrugBank.d476.s3.e6
DDI-DrugBank.d476.s3	223	243	antiarrhythmic agents	group	DDI-DrugBank.d476.s3.e7
DDI-DrugBank.d476.s3	254	265	disopyramide	drug	DDI-DrugBank.d476.s3.e8
DDI-DrugBank.d476.s3	true	DDI-DrugBank.d476.s3.e0	DDI-DrugBank.d476.s3.e1
DDI-DrugBank.d476.s3	true	DDI-DrugBank.d476.s3.e0	DDI-DrugBank.d476.s3.e2
DDI-DrugBank.d476.s3	true	DDI-DrugBank.d476.s3.e0	DDI-DrugBank.d476.s3.e3
DDI-DrugBank.d476.s3	true	DDI-DrugBank.d476.s3.e0	DDI-DrugBank.d476.s3.e4
DDI-DrugBank.d476.s3	true	DDI-DrugBank.d476.s3.e0	DDI-DrugBank.d476.s3.e5
DDI-DrugBank.d476.s3	true	DDI-DrugBank.d476.s3.e0	DDI-DrugBank.d476.s3.e6
DDI-DrugBank.d476.s3	true	DDI-DrugBank.d476.s3.e0	DDI-DrugBank.d476.s3.e7
DDI-DrugBank.d476.s3	true	DDI-DrugBank.d476.s3.e0	DDI-DrugBank.d476.s3.e8
DDI-DrugBank.d476.s3	false	DDI-DrugBank.d476.s3.e1	DDI-DrugBank.d476.s3.e2
DDI-DrugBank.d476.s3	false	DDI-DrugBank.d476.s3.e1	DDI-DrugBank.d476.s3.e3
DDI-DrugBank.d476.s4|a|Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.
DDI-DrugBank.d476.s4	18	25	rifampin	drug	DDI-DrugBank.d476.s4.e0
DDI-DrugBank.d476.s4	64	69	ZEBETA	brand	DDI-DrugBank.d476.s4.e1
DDI-DrugBank.d476.s4	122	127	ZEBETA	brand	DDI-DrugBank.d476.s4.e2
DDI-DrugBank.d476.s4	true	DDI-DrugBank.d476.s4.e0	DDI-DrugBank.d476.s4.e1
DDI-DrugBank.d476.s4	false	DDI-DrugBank.d476.s4.e0	DDI-DrugBank.d476.s4.e2
DDI-DrugBank.d476.s4	false	DDI-DrugBank.d476.s4.e1	DDI-DrugBank.d476.s4.e2
DDI-DrugBank.d476.s5|a|However, initial dose modification is generally not necessary.
DDI-DrugBank.d476.s6|a|Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, digoxin, and cimetidine.
DDI-DrugBank.d476.s6	118	135	thiazide diuretics	group	DDI-DrugBank.d476.s6.e0
DDI-DrugBank.d476.s6	138	144	digoxin	drug	DDI-DrugBank.d476.s6.e1
DDI-DrugBank.d476.s6	151	160	cimetidine	drug	DDI-DrugBank.d476.s6.e2
DDI-DrugBank.d476.s6	false	DDI-DrugBank.d476.s6.e0	DDI-DrugBank.d476.s6.e1
DDI-DrugBank.d476.s6	false	DDI-DrugBank.d476.s6.e0	DDI-DrugBank.d476.s6.e2
DDI-DrugBank.d476.s6	false	DDI-DrugBank.d476.s6.e1	DDI-DrugBank.d476.s6.e2
DDI-DrugBank.d476.s7|a|There was no effect of ZEBETA on prothrombin time in patients on stable doses of warfarin.
DDI-DrugBank.d476.s7	23	28	ZEBETA	brand	DDI-DrugBank.d476.s7.e0
DDI-DrugBank.d476.s7	81	88	warfarin	drug	DDI-DrugBank.d476.s7.e1
DDI-DrugBank.d476.s7	false	DDI-DrugBank.d476.s7.e0	DDI-DrugBank.d476.s7.e1
DDI-DrugBank.d476.s8|a|Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.
DDI-DrugBank.d476.s8	44	56	beta-blockers	group	DDI-DrugBank.d476.s8.e0
DDI-DrugBank.d476.s9|a|Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.
DDI-DrugBank.d476.s9	56	66	epinephrine	drug	DDI-DrugBank.d476.s9.e0
DDI-DrugBank.d560.s0|a|Use of MAO inhibitors may cause an excessive increase in blood pressure and heart stimulation.
DDI-DrugBank.d560.s0	7	20	MAO inhibitors	group	DDI-DrugBank.d560.s0.e0
DDI-DrugBank.d560.s1|a|If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.
DDI-DrugBank.d560.s1	24	30	steroid	group	DDI-DrugBank.d560.s1.e0
DDI-DrugBank.d560.s1	46	55	bitolterol	drug	DDI-DrugBank.d560.s1.e1
DDI-DrugBank.d560.s1	111	117	steroid	group	DDI-DrugBank.d560.s1.e2
DDI-DrugBank.d560.s1	true	DDI-DrugBank.d560.s1.e0	DDI-DrugBank.d560.s1.e1
DDI-DrugBank.d560.s1	false	DDI-DrugBank.d560.s1.e0	DDI-DrugBank.d560.s1.e2
DDI-DrugBank.d560.s1	true	DDI-DrugBank.d560.s1.e1	DDI-DrugBank.d560.s1.e2
DDI-DrugBank.d560.s2|a|This allows bitolterol to open air passages, increasing the effectiveness of the steroid.
DDI-DrugBank.d560.s2	12	21	bitolterol	drug	DDI-DrugBank.d560.s2.e0
DDI-DrugBank.d560.s2	81	87	steroid	group	DDI-DrugBank.d560.s2.e1
DDI-DrugBank.d560.s2	true	DDI-DrugBank.d560.s2.e0	DDI-DrugBank.d560.s2.e1
DDI-DrugBank.d569.s0|a|Angiomax does not exhibit binding to plasma proteins (other than thrombin) or red blood cells.
DDI-DrugBank.d569.s0	0	7	Angiomax	brand	DDI-DrugBank.d569.s0.e0
DDI-DrugBank.d569.s1|a|In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
DDI-DrugBank.d569.s1	73	80	Angiomax	brand	DDI-DrugBank.d569.s1.e0
DDI-DrugBank.d569.s1	87	93	heparin	drug	DDI-DrugBank.d569.s1.e1
DDI-DrugBank.d569.s1	96	103	warfarin	drug	DDI-DrugBank.d569.s1.e2
DDI-DrugBank.d569.s1	106	118	thrombolytics	group	DDI-DrugBank.d569.s1.e3
DDI-DrugBank.d569.s1	true	DDI-DrugBank.d569.s1.e0	DDI-DrugBank.d569.s1.e1
DDI-DrugBank.d569.s1	true	DDI-DrugBank.d569.s1.e0	DDI-DrugBank.d569.s1.e2
DDI-DrugBank.d569.s1	true	DDI-DrugBank.d569.s1.e0	DDI-DrugBank.d569.s1.e3
DDI-DrugBank.d569.s1	false	DDI-DrugBank.d569.s1.e1	DDI-DrugBank.d569.s1.e2
DDI-DrugBank.d569.s1	false	DDI-DrugBank.d569.s1.e1	DDI-DrugBank.d569.s1.e3
DDI-DrugBank.d569.s1	false	DDI-DrugBank.d569.s1.e2	DDI-DrugBank.d569.s1.e3
DDI-DrugBank.d569.s2|a|There is no experience with co-administration of Angiomax and plasma expanders such as dextran.
DDI-DrugBank.d569.s2	49	56	Angiomax	brand	DDI-DrugBank.d569.s2.e0
DDI-DrugBank.d569.s2	87	93	dextran	drug	DDI-DrugBank.d569.s2.e1
DDI-DrugBank.d569.s2	false	DDI-DrugBank.d569.s2.e0	DDI-DrugBank.d569.s2.e1
DDI-DrugBank.d569.s3|a|Angiomax should be used with caution in patients with disease states associated with an increased risk of bleeding.
DDI-DrugBank.d569.s3	0	7	Angiomax	brand	DDI-DrugBank.d569.s3.e0
DDI-DrugBank.d569.s4|a|Immunogenicity/Re-exposure: In in vitro studies, Angiomax exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.
DDI-DrugBank.d569.s4	49	56	Angiomax	brand	DDI-DrugBank.d569.s4.e0
DDI-DrugBank.d569.s5|a|Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests.
DDI-DrugBank.d569.s5	32	39	Angiomax	brand	DDI-DrugBank.d569.s5.e0
DDI-DrugBank.d569.s5	135	145	bivalirudin	drug	DDI-DrugBank.d569.s5.e1
DDI-DrugBank.d569.s5	false	DDI-DrugBank.d569.s5.e0	DDI-DrugBank.d569.s5.e1
DDI-DrugBank.d569.s6|a|Neither subject demonstrated clinical evidence of allergic or anaphylactic reactions and repeat testing was not performed.
DDI-DrugBank.d569.s7|a|Nine additional patients who had initial positive tests were negative on repeat testing.
DDI-DrugBank.d554.s0|a|Certain antibiotic, cisplatin, cyclosporine, diuretic, foscarnet, and vaccines.
DDI-DrugBank.d554.s0	8	17	antibiotic	group	DDI-DrugBank.d554.s0.e0
DDI-DrugBank.d554.s0	20	28	cisplatin	drug	DDI-DrugBank.d554.s0.e1
DDI-DrugBank.d554.s0	31	42	cyclosporine	drug	DDI-DrugBank.d554.s0.e2
DDI-DrugBank.d554.s0	45	52	diuretic	group	DDI-DrugBank.d554.s0.e3
DDI-DrugBank.d554.s0	55	63	foscarnet	drug	DDI-DrugBank.d554.s0.e4
DDI-DrugBank.d554.s0	70	77	vaccines	group	DDI-DrugBank.d554.s0.e5
DDI-DrugBank.d554.s0	false	DDI-DrugBank.d554.s0.e0	DDI-DrugBank.d554.s0.e1
DDI-DrugBank.d554.s0	false	DDI-DrugBank.d554.s0.e0	DDI-DrugBank.d554.s0.e2
DDI-DrugBank.d554.s0	false	DDI-DrugBank.d554.s0.e0	DDI-DrugBank.d554.s0.e3
DDI-DrugBank.d554.s0	false	DDI-DrugBank.d554.s0.e0	DDI-DrugBank.d554.s0.e4
DDI-DrugBank.d554.s0	false	DDI-DrugBank.d554.s0.e0	DDI-DrugBank.d554.s0.e5
DDI-DrugBank.d554.s0	false	DDI-DrugBank.d554.s0.e1	DDI-DrugBank.d554.s0.e2
DDI-DrugBank.d554.s0	false	DDI-DrugBank.d554.s0.e1	DDI-DrugBank.d554.s0.e3
DDI-DrugBank.d554.s0	false	DDI-DrugBank.d554.s0.e1	DDI-DrugBank.d554.s0.e4
DDI-DrugBank.d554.s0	false	DDI-DrugBank.d554.s0.e1	DDI-DrugBank.d554.s0.e5
DDI-DrugBank.d554.s0	false	DDI-DrugBank.d554.s0.e2	DDI-DrugBank.d554.s0.e3
DDI-DrugBank.d571.s0|a|No formal drug interaction studies have been conducted with VELCADE.
DDI-DrugBank.d571.s0	60	66	VELCADE	brand	DDI-DrugBank.d571.s0.e0
DDI-DrugBank.d571.s1|a|In vitro studies with human liver microsomes indicate that bortezomib is primarily a substrate for cytochrome P450 3A4, 2C19, and 1A2.
DDI-DrugBank.d571.s1	59	68	bortezomib	drug	DDI-DrugBank.d571.s1.e0
DDI-DrugBank.d571.s2|a|Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy .
DDI-DrugBank.d571.s2	41	47	VELCADE	brand	DDI-DrugBank.d571.s2.e0
DDI-DrugBank.d571.s3|a|During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics.
DDI-DrugBank.d571.s3	105	117	hypoglycemics	group	DDI-DrugBank.d571.s3.e0
DDI-DrugBank.d571.s4|a|Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.
DDI-DrugBank.d571.s4	17	35	antidiabetic agents	group	DDI-DrugBank.d571.s4.e0
DDI-DrugBank.d571.s4	47	53	VELCADE	brand	DDI-DrugBank.d571.s4.e1
DDI-DrugBank.d571.s4	160	182	antidiabetic medication	group	DDI-DrugBank.d571.s4.e2
DDI-DrugBank.d571.s4	true	DDI-DrugBank.d571.s4.e0	DDI-DrugBank.d571.s4.e1
DDI-DrugBank.d571.s4	false	DDI-DrugBank.d571.s4.e0	DDI-DrugBank.d571.s4.e2
DDI-DrugBank.d571.s4	false	DDI-DrugBank.d571.s4.e1	DDI-DrugBank.d571.s4.e2
DDI-DrugBank.d571.s5|a|Drug Laboratory Test Interactions None known.
DDI-DrugBank.d289.s0|a|Bosentan is metabolized by CYP2C9 and CYP3A4.
DDI-DrugBank.d289.s0	0	7	Bosentan	drug	DDI-DrugBank.d289.s0.e0
DDI-DrugBank.d289.s1|a|Inhibition of these isoenzymes may increase the plasma concentration of bosentan.
DDI-DrugBank.d289.s1	72	79	bosentan	drug	DDI-DrugBank.d289.s1.e0
DDI-DrugBank.d289.s2|a|Bosentan is an inducer of CYP3A4 and CYP2C9.
DDI-DrugBank.d289.s2	0	7	Bosentan	drug	DDI-DrugBank.d289.s2.e0
DDI-DrugBank.d289.s3|a|Consequently, plasma concentrations of drugs metabolized by these two isoenzymes will be decreased when TRACLEER is co-administered.
DDI-DrugBank.d289.s3	104	111	TRACLEER	brand	DDI-DrugBank.d289.s3.e0
DDI-DrugBank.d289.s4|a|Bosentan had no relevant inhibitory effect on any CYP isoenzymes tested (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4).
DDI-DrugBank.d289.s4	0	7	Bosentan	drug	DDI-DrugBank.d289.s4.e0
DDI-DrugBank.d289.s5|a|Consequently, TRACLEER is not expected to increase the plasma concentrations of drugs metabolized by these enzymes.
DDI-DrugBank.d289.s5	14	21	TRACLEER	brand	DDI-DrugBank.d289.s5.e0
DDI-DrugBank.d289.s6|a|Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
DDI-DrugBank.d289.s6	0	22	Hormonal Contraceptives	group	DDI-DrugBank.d289.s6.e0
DDI-DrugBank.d289.s6	82	95	Contraceptives	group	DDI-DrugBank.d289.s6.e1
DDI-DrugBank.d289.s6	158	165	bosentan	drug	DDI-DrugBank.d289.s6.e2
DDI-DrugBank.d289.s6	180	201	hormonal contraceptive	group	DDI-DrugBank.d289.s6.e3
DDI-DrugBank.d289.s6	203	213	Ortho-Novum	brand	DDI-DrugBank.d289.s6.e4
DDI-DrugBank.d289.s6	245	257	norethindrone	drug	DDI-DrugBank.d289.s6.e5
DDI-DrugBank.d289.s6	263	279	ethinyl estradiol	drug	DDI-DrugBank.d289.s6.e6
DDI-DrugBank.d289.s6	false	DDI-DrugBank.d289.s6.e0	DDI-DrugBank.d289.s6.e1
DDI-DrugBank.d289.s6	false	DDI-DrugBank.d289.s6.e0	DDI-DrugBank.d289.s6.e2
DDI-DrugBank.d289.s6	false	DDI-DrugBank.d289.s6.e0	DDI-DrugBank.d289.s6.e3
DDI-DrugBank.d289.s6	false	DDI-DrugBank.d289.s6.e0	DDI-DrugBank.d289.s6.e4
DDI-DrugBank.d289.s6	false	DDI-DrugBank.d289.s6.e0	DDI-DrugBank.d289.s6.e5
DDI-DrugBank.d289.s6	false	DDI-DrugBank.d289.s6.e0	DDI-DrugBank.d289.s6.e6
DDI-DrugBank.d289.s6	false	DDI-DrugBank.d289.s6.e1	DDI-DrugBank.d289.s6.e2
DDI-DrugBank.d289.s6	false	DDI-DrugBank.d289.s6.e1	DDI-DrugBank.d289.s6.e3
DDI-DrugBank.d289.s6	false	DDI-DrugBank.d289.s6.e1	DDI-DrugBank.d289.s6.e4
DDI-DrugBank.d289.s6	false	DDI-DrugBank.d289.s6.e1	DDI-DrugBank.d289.s6.e5
DDI-DrugBank.d289.s7|a|However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects.
DDI-DrugBank.d289.s8|a|Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.
DDI-DrugBank.d289.s8	11	33	hormonal contraceptives	group	DDI-DrugBank.d289.s8.e0
DDI-DrugBank.d289.s8	125	132	TRACLEER	brand	DDI-DrugBank.d289.s8.e1
DDI-DrugBank.d289.s8	true	DDI-DrugBank.d289.s8.e0	DDI-DrugBank.d289.s8.e1
DDI-DrugBank.d289.s9|a|Women should practice additional methods of contraception and not rely on hormonal contraception alone when taking TRACLEER.
DDI-DrugBank.d289.s9	115	122	TRACLEER	brand	DDI-DrugBank.d289.s9.e0
DDI-DrugBank.d289.s10|a|Specific interaction studies have demonstrated the following: Cyclosporine A: During the first day of concomitant administration, trough concentrations of bosentan were increased by about 30-fold.
DDI-DrugBank.d289.s10	62	75	Cyclosporine A	drug	DDI-DrugBank.d289.s10.e0
DDI-DrugBank.d289.s10	155	162	bosentan	drug	DDI-DrugBank.d289.s10.e1
DDI-DrugBank.d289.s10	false	DDI-DrugBank.d289.s10.e0	DDI-DrugBank.d289.s10.e1
DDI-DrugBank.d289.s11|a|Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.
DDI-DrugBank.d289.s11	13	20	bosentan	drug	DDI-DrugBank.d289.s11.e0
DDI-DrugBank.d289.s11	92	105	cyclosporine A	drug	DDI-DrugBank.d289.s11.e1
DDI-DrugBank.d289.s11	true	DDI-DrugBank.d289.s11.e0	DDI-DrugBank.d289.s11.e1
DDI-DrugBank.d289.s12|a|The concomitant administration of bosentan and cyclosporine A is contraindicated.
DDI-DrugBank.d289.s12	34	41	bosentan	drug	DDI-DrugBank.d289.s12.e0
DDI-DrugBank.d289.s12	47	60	cyclosporine A	drug	DDI-DrugBank.d289.s12.e1
DDI-DrugBank.d289.s12	true	DDI-DrugBank.d289.s12.e0	DDI-DrugBank.d289.s12.e1
DDI-DrugBank.d289.s13|a|Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.
DDI-DrugBank.d289.s13	21	28	bosentan	drug	DDI-DrugBank.d289.s13.e0
DDI-DrugBank.d289.s13	69	82	cyclosporine A	drug	DDI-DrugBank.d289.s13.e1
DDI-DrugBank.d289.s13	true	DDI-DrugBank.d289.s13.e0	DDI-DrugBank.d289.s13.e1
DDI-DrugBank.d289.s14|a|Tacrolimus: Co-administration of tacrolimus and bosentan has not been studied in man.
DDI-DrugBank.d289.s14	0	9	Tacrolimus	drug	DDI-DrugBank.d289.s14.e0
DDI-DrugBank.d289.s14	33	42	tacrolimus	drug	DDI-DrugBank.d289.s14.e1
DDI-DrugBank.d289.s14	48	55	bosentan	drug	DDI-DrugBank.d289.s14.e2
DDI-DrugBank.d289.s14	false	DDI-DrugBank.d289.s14.e0	DDI-DrugBank.d289.s14.e1
DDI-DrugBank.d289.s14	false	DDI-DrugBank.d289.s14.e0	DDI-DrugBank.d289.s14.e2
DDI-DrugBank.d289.s14	false	DDI-DrugBank.d289.s14.e1	DDI-DrugBank.d289.s14.e2
DDI-DrugBank.d289.s15|a|Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.
DDI-DrugBank.d289.s15	21	30	tacrolimus	drug	DDI-DrugBank.d289.s15.e0
DDI-DrugBank.d289.s15	36	43	bosentan	drug	DDI-DrugBank.d289.s15.e1
DDI-DrugBank.d289.s15	101	108	bosentan	drug	DDI-DrugBank.d289.s15.e2
DDI-DrugBank.d289.s15	true	DDI-DrugBank.d289.s15.e0	DDI-DrugBank.d289.s15.e1
DDI-DrugBank.d289.s15	false	DDI-DrugBank.d289.s15.e0	DDI-DrugBank.d289.s15.e2
DDI-DrugBank.d289.s15	false	DDI-DrugBank.d289.s15.e1	DDI-DrugBank.d289.s15.e2
DDI-DrugBank.d289.s16|a|Caution should be exercised if tacrolimus and bosentan are used together.
DDI-DrugBank.d289.s16	31	40	tacrolimus	drug	DDI-DrugBank.d289.s16.e0
DDI-DrugBank.d289.s16	46	53	bosentan	drug	DDI-DrugBank.d289.s16.e1
DDI-DrugBank.d289.s16	true	DDI-DrugBank.d289.s16.e0	DDI-DrugBank.d289.s16.e1
DDI-DrugBank.d289.s17|a|Glyburide: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide.
DDI-DrugBank.d289.s17	0	8	Glyburide	drug	DDI-DrugBank.d289.s17.e0
DDI-DrugBank.d289.s17	125	133	glyburide	drug	DDI-DrugBank.d289.s17.e1
DDI-DrugBank.d289.s17	false	DDI-DrugBank.d289.s17.e0	DDI-DrugBank.d289.s17.e1
DDI-DrugBank.d289.s18|a|Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.
DDI-DrugBank.d289.s18	45	52	TRACLEER	brand	DDI-DrugBank.d289.s18.e0
DDI-DrugBank.d289.s18	58	66	glyburide	drug	DDI-DrugBank.d289.s18.e1
DDI-DrugBank.d289.s18	104	122	hypoglycemic agents	group	DDI-DrugBank.d289.s18.e2
DDI-DrugBank.d289.s18	true	DDI-DrugBank.d289.s18.e0	DDI-DrugBank.d289.s18.e1
DDI-DrugBank.d289.s18	false	DDI-DrugBank.d289.s18.e0	DDI-DrugBank.d289.s18.e2
DDI-DrugBank.d289.s18	false	DDI-DrugBank.d289.s18.e1	DDI-DrugBank.d289.s18.e2
DDI-DrugBank.d289.s19|a|Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.
DDI-DrugBank.d289.s19	21	28	bosentan	drug	DDI-DrugBank.d289.s19.e0
DDI-DrugBank.d289.s19	69	77	glyburide	drug	DDI-DrugBank.d289.s19.e1
DDI-DrugBank.d289.s19	true	DDI-DrugBank.d289.s19.e0	DDI-DrugBank.d289.s19.e1
DDI-DrugBank.d289.s20|a|The plasma concentrations of bosentan were also decreased by approximately 30%.
DDI-DrugBank.d289.s20	29	36	bosentan	drug	DDI-DrugBank.d289.s20.e0
DDI-DrugBank.d289.s21|a|Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.
DDI-DrugBank.d289.s21	0	7	Bosentan	drug	DDI-DrugBank.d289.s21.e0
DDI-DrugBank.d289.s21	72	90	hypoglycemic agents	group	DDI-DrugBank.d289.s21.e1
DDI-DrugBank.d289.s21	true	DDI-DrugBank.d289.s21.e0	DDI-DrugBank.d289.s21.e1
DDI-DrugBank.d289.s22|a|The possibility of worsened glucose control in patients using these agents should be considered.
DDI-DrugBank.d289.s23|a|Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.
DDI-DrugBank.d289.s23	0	11	Ketoconazole	drug	DDI-DrugBank.d289.s23.e0
DDI-DrugBank.d289.s23	35	42	bosentan	drug	DDI-DrugBank.d289.s23.e1
DDI-DrugBank.d289.s23	62	73	ketoconazole	drug	DDI-DrugBank.d289.s23.e2
DDI-DrugBank.d289.s23	142	149	bosentan	drug	DDI-DrugBank.d289.s23.e3
DDI-DrugBank.d289.s23	false	DDI-DrugBank.d289.s23.e0	DDI-DrugBank.d289.s23.e1
DDI-DrugBank.d289.s23	false	DDI-DrugBank.d289.s23.e0	DDI-DrugBank.d289.s23.e2
DDI-DrugBank.d289.s23	false	DDI-DrugBank.d289.s23.e0	DDI-DrugBank.d289.s23.e3
DDI-DrugBank.d289.s23	true	DDI-DrugBank.d289.s23.e1	DDI-DrugBank.d289.s23.e2
DDI-DrugBank.d289.s23	false	DDI-DrugBank.d289.s23.e1	DDI-DrugBank.d289.s23.e3
DDI-DrugBank.d289.s23	false	DDI-DrugBank.d289.s23.e2	DDI-DrugBank.d289.s23.e3
DDI-DrugBank.d289.s24|a|No dose adjustment of bosentan is necessary, but increased effects of bosentan should be considered.
DDI-DrugBank.d289.s24	22	29	bosentan	drug	DDI-DrugBank.d289.s24.e0
DDI-DrugBank.d289.s24	70	77	bosentan	drug	DDI-DrugBank.d289.s24.e1
DDI-DrugBank.d289.s24	false	DDI-DrugBank.d289.s24.e0	DDI-DrugBank.d289.s24.e1
DDI-DrugBank.d289.s25|a|Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.
DDI-DrugBank.d289.s25	0	10	Simvastatin	drug	DDI-DrugBank.d289.s25.e0
DDI-DrugBank.d289.s25	22	28	Statins	group	DDI-DrugBank.d289.s25.e1
DDI-DrugBank.d289.s25	52	59	bosentan	drug	DDI-DrugBank.d289.s25.e2
DDI-DrugBank.d289.s25	100	110	simvastatin	drug	DDI-DrugBank.d289.s25.e3
DDI-DrugBank.d289.s25	false	DDI-DrugBank.d289.s25.e0	DDI-DrugBank.d289.s25.e1
DDI-DrugBank.d289.s25	false	DDI-DrugBank.d289.s25.e0	DDI-DrugBank.d289.s25.e2
DDI-DrugBank.d289.s25	false	DDI-DrugBank.d289.s25.e0	DDI-DrugBank.d289.s25.e3
DDI-DrugBank.d289.s25	false	DDI-DrugBank.d289.s25.e1	DDI-DrugBank.d289.s25.e2
DDI-DrugBank.d289.s25	false	DDI-DrugBank.d289.s25.e1	DDI-DrugBank.d289.s25.e3
DDI-DrugBank.d289.s25	true	DDI-DrugBank.d289.s25.e2	DDI-DrugBank.d289.s25.e3
DDI-DrugBank.d289.s26|a|The plasma concentrations of bosentan were not affected.
DDI-DrugBank.d289.s26	29	36	bosentan	drug	DDI-DrugBank.d289.s26.e0
DDI-DrugBank.d289.s27|a|Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
DDI-DrugBank.d289.s27	0	7	Bosentan	drug	DDI-DrugBank.d289.s27.e0
DDI-DrugBank.d289.s27	67	73	statins	group	DDI-DrugBank.d289.s27.e1
DDI-DrugBank.d289.s27	127	136	lovastatin	drug	DDI-DrugBank.d289.s27.e2
DDI-DrugBank.d289.s27	142	153	atorvastatin	drug	DDI-DrugBank.d289.s27.e3
DDI-DrugBank.d289.s27	true	DDI-DrugBank.d289.s27.e0	DDI-DrugBank.d289.s27.e1
DDI-DrugBank.d289.s27	true	DDI-DrugBank.d289.s27.e0	DDI-DrugBank.d289.s27.e2
DDI-DrugBank.d289.s27	true	DDI-DrugBank.d289.s27.e0	DDI-DrugBank.d289.s27.e3
DDI-DrugBank.d289.s27	false	DDI-DrugBank.d289.s27.e1	DDI-DrugBank.d289.s27.e2
DDI-DrugBank.d289.s27	false	DDI-DrugBank.d289.s27.e1	DDI-DrugBank.d289.s27.e3
DDI-DrugBank.d289.s27	false	DDI-DrugBank.d289.s27.e2	DDI-DrugBank.d289.s27.e3
DDI-DrugBank.d289.s28|a|The possibility of reduced statin efficacy should be considered.
DDI-DrugBank.d289.s28	27	32	statin	group	DDI-DrugBank.d289.s28.e0
DDI-DrugBank.d289.s29|a|Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.
DDI-DrugBank.d289.s29	34	40	statins	group	DDI-DrugBank.d289.s29.e0
DDI-DrugBank.d289.s29	89	96	TRACLEER	brand	DDI-DrugBank.d289.s29.e1
DDI-DrugBank.d289.s29	130	135	statin	group	DDI-DrugBank.d289.s29.e2
DDI-DrugBank.d289.s29	true	DDI-DrugBank.d289.s29.e0	DDI-DrugBank.d289.s29.e1
DDI-DrugBank.d289.s29	false	DDI-DrugBank.d289.s29.e0	DDI-DrugBank.d289.s29.e2
DDI-DrugBank.d289.s29	false	DDI-DrugBank.d289.s29.e1	DDI-DrugBank.d289.s29.e2
DDI-DrugBank.d289.s30|a|Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
DDI-DrugBank.d289.s30	0	7	Warfarin	drug	DDI-DrugBank.d289.s30.e0
DDI-DrugBank.d289.s30	31	38	bosentan	drug	DDI-DrugBank.d289.s30.e1
DDI-DrugBank.d289.s30	109	118	S-warfarin	drug	DDI-DrugBank.d289.s30.e2
DDI-DrugBank.d289.s30	145	154	R-warfarin	drug	DDI-DrugBank.d289.s30.e3
DDI-DrugBank.d289.s30	false	DDI-DrugBank.d289.s30.e0	DDI-DrugBank.d289.s30.e1
DDI-DrugBank.d289.s30	false	DDI-DrugBank.d289.s30.e0	DDI-DrugBank.d289.s30.e2
DDI-DrugBank.d289.s30	false	DDI-DrugBank.d289.s30.e0	DDI-DrugBank.d289.s30.e3
DDI-DrugBank.d289.s30	true	DDI-DrugBank.d289.s30.e1	DDI-DrugBank.d289.s30.e2
DDI-DrugBank.d289.s30	true	DDI-DrugBank.d289.s30.e1	DDI-DrugBank.d289.s30.e3
DDI-DrugBank.d289.s30	false	DDI-DrugBank.d289.s30.e2	DDI-DrugBank.d289.s30.e3
DDI-DrugBank.d289.s31|a|Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.
DDI-DrugBank.d289.s31	55	62	bosentan	drug	DDI-DrugBank.d289.s31.e0
DDI-DrugBank.d289.s31	68	75	warfarin	drug	DDI-DrugBank.d289.s31.e1
DDI-DrugBank.d289.s31	177	184	warfarin	drug	DDI-DrugBank.d289.s31.e2
DDI-DrugBank.d289.s31	262	269	warfarin	drug	DDI-DrugBank.d289.s31.e3
DDI-DrugBank.d289.s31	359	366	bosentan	drug	DDI-DrugBank.d289.s31.e4
DDI-DrugBank.d289.s31	false	DDI-DrugBank.d289.s31.e0	DDI-DrugBank.d289.s31.e1
DDI-DrugBank.d289.s31	false	DDI-DrugBank.d289.s31.e0	DDI-DrugBank.d289.s31.e2
DDI-DrugBank.d289.s31	false	DDI-DrugBank.d289.s31.e0	DDI-DrugBank.d289.s31.e3
DDI-DrugBank.d289.s31	false	DDI-DrugBank.d289.s31.e0	DDI-DrugBank.d289.s31.e4
DDI-DrugBank.d289.s31	false	DDI-DrugBank.d289.s31.e1	DDI-DrugBank.d289.s31.e2
DDI-DrugBank.d289.s31	false	DDI-DrugBank.d289.s31.e1	DDI-DrugBank.d289.s31.e3
DDI-DrugBank.d289.s31	false	DDI-DrugBank.d289.s31.e1	DDI-DrugBank.d289.s31.e4
DDI-DrugBank.d289.s31	false	DDI-DrugBank.d289.s31.e2	DDI-DrugBank.d289.s31.e3
DDI-DrugBank.d289.s31	false	DDI-DrugBank.d289.s31.e2	DDI-DrugBank.d289.s31.e4
DDI-DrugBank.d289.s31	false	DDI-DrugBank.d289.s31.e3	DDI-DrugBank.d289.s31.e4
DDI-DrugBank.d289.s32|a|Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.
DDI-DrugBank.d289.s32	0	6	Digoxin	drug	DDI-DrugBank.d289.s32.e0
DDI-DrugBank.d289.s32	9	18	Nimodipine	drug	DDI-DrugBank.d289.s32.e1
DDI-DrugBank.d289.s32	24	31	Losartan	drug	DDI-DrugBank.d289.s32.e2
DDI-DrugBank.d289.s32	34	41	Bosentan	drug	DDI-DrugBank.d289.s32.e3
DDI-DrugBank.d289.s32	96	102	digoxin	drug	DDI-DrugBank.d289.s32.e4
DDI-DrugBank.d289.s32	108	117	nimodipine	drug	DDI-DrugBank.d289.s32.e5
DDI-DrugBank.d289.s32	124	131	losartan	drug	DDI-DrugBank.d289.s32.e6
DDI-DrugBank.d289.s32	179	186	bosentan	drug	DDI-DrugBank.d289.s32.e7
DDI-DrugBank.d289.s32	false	DDI-DrugBank.d289.s32.e0	DDI-DrugBank.d289.s32.e1
DDI-DrugBank.d289.s32	false	DDI-DrugBank.d289.s32.e0	DDI-DrugBank.d289.s32.e2
DDI-DrugBank.d289.s32	false	DDI-DrugBank.d289.s32.e0	DDI-DrugBank.d289.s32.e3
DDI-DrugBank.d289.s32	false	DDI-DrugBank.d289.s32.e0	DDI-DrugBank.d289.s32.e4
DDI-DrugBank.d289.s32	false	DDI-DrugBank.d289.s32.e0	DDI-DrugBank.d289.s32.e5
DDI-DrugBank.d289.s32	false	DDI-DrugBank.d289.s32.e0	DDI-DrugBank.d289.s32.e6
DDI-DrugBank.d289.s32	false	DDI-DrugBank.d289.s32.e0	DDI-DrugBank.d289.s32.e7
DDI-DrugBank.d289.s32	false	DDI-DrugBank.d289.s32.e1	DDI-DrugBank.d289.s32.e2
DDI-DrugBank.d289.s32	false	DDI-DrugBank.d289.s32.e1	DDI-DrugBank.d289.s32.e3
DDI-DrugBank.d289.s32	false	DDI-DrugBank.d289.s32.e1	DDI-DrugBank.d289.s32.e4
DDI-DrugBank.d133.s0|a|Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
DDI-DrugBank.d133.s0	21	25	BOTOX	brand	DDI-DrugBank.d133.s0.e0
DDI-DrugBank.d133.s0	31	45	aminoglycosides	group	DDI-DrugBank.d133.s0.e1
DDI-DrugBank.d133.s0	114	134	curare-like compounds	group	DDI-DrugBank.d133.s0.e2
DDI-DrugBank.d133.s0	196	200	toxin	drug	DDI-DrugBank.d133.s0.e3
DDI-DrugBank.d133.s0	true	DDI-DrugBank.d133.s0.e0	DDI-DrugBank.d133.s0.e1
DDI-DrugBank.d133.s0	true	DDI-DrugBank.d133.s0.e0	DDI-DrugBank.d133.s0.e2
DDI-DrugBank.d133.s0	false	DDI-DrugBank.d133.s0.e0	DDI-DrugBank.d133.s0.e3
DDI-DrugBank.d133.s0	false	DDI-DrugBank.d133.s0.e1	DDI-DrugBank.d133.s0.e2
DDI-DrugBank.d133.s0	false	DDI-DrugBank.d133.s0.e1	DDI-DrugBank.d133.s0.e3
DDI-DrugBank.d133.s0	false	DDI-DrugBank.d133.s0.e2	DDI-DrugBank.d133.s0.e3
DDI-DrugBank.d133.s1|a|The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown.
DDI-DrugBank.d133.s1	38	57	botulinum neurotoxin	group	DDI-DrugBank.d133.s1.e0
DDI-DrugBank.d133.s2|a|Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
DDI-DrugBank.d133.s2	81	95	botulinum toxin	group	DDI-DrugBank.d133.s2.e0
DDI-DrugBank.d133.s2	165	179	botulinum toxin	group	DDI-DrugBank.d133.s2.e1
DDI-DrugBank.d133.s2	true	DDI-DrugBank.d133.s2.e0	DDI-DrugBank.d133.s2.e1
DDI-DrugBank.d323.s0|a|Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
DDI-DrugBank.d323.s0	21	27	MYOBLOC	brand	DDI-DrugBank.d323.s0.e0
DDI-DrugBank.d323.s0	33	47	aminoglycosides	group	DDI-DrugBank.d323.s0.e1
DDI-DrugBank.d323.s0	116	136	curare-like compounds	group	DDI-DrugBank.d323.s0.e2
DDI-DrugBank.d323.s0	198	202	toxin	drug	DDI-DrugBank.d323.s0.e3
DDI-DrugBank.d323.s0	true	DDI-DrugBank.d323.s0.e0	DDI-DrugBank.d323.s0.e1
DDI-DrugBank.d323.s0	true	DDI-DrugBank.d323.s0.e0	DDI-DrugBank.d323.s0.e2
DDI-DrugBank.d323.s0	false	DDI-DrugBank.d323.s0.e0	DDI-DrugBank.d323.s0.e3
DDI-DrugBank.d323.s0	false	DDI-DrugBank.d323.s0.e1	DDI-DrugBank.d323.s0.e2
DDI-DrugBank.d323.s0	false	DDI-DrugBank.d323.s0.e1	DDI-DrugBank.d323.s0.e3
DDI-DrugBank.d323.s0	false	DDI-DrugBank.d323.s0.e2	DDI-DrugBank.d323.s0.e3
DDI-DrugBank.d323.s1|a|The effect of administering different botulinum neurotoxin serotypes at the same time or within less than 4 months of each other is unknown.
DDI-DrugBank.d323.s1	38	57	botulinum neurotoxin	group	DDI-DrugBank.d323.s1.e0
DDI-DrugBank.d323.s2|a|However, neuromuscular paralysis may be potentiated by co-administration or overlapping administration of different botulinum toxin serotypes.
DDI-DrugBank.d323.s2	116	130	botulinum toxin	group	DDI-DrugBank.d323.s2.e0
DDI-DrugBank.d180.s0|a|Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.
DDI-DrugBank.d180.s0	0	8	Digitalis	group	DDI-DrugBank.d180.s0.e0
DDI-DrugBank.d180.s0	88	105	Bretylium Tosylate	drug	DDI-DrugBank.d180.s0.e1
DDI-DrugBank.d180.s0	true	DDI-DrugBank.d180.s0.e0	DDI-DrugBank.d180.s0.e1
DDI-DrugBank.d180.s1|a|The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
DDI-DrugBank.d180.s1	23	36	catecholamines	group	DDI-DrugBank.d180.s1.e0
DDI-DrugBank.d180.s1	46	53	dopamine	drug	DDI-DrugBank.d180.s1.e1
DDI-DrugBank.d180.s1	58	71	norepinephrine	drug	DDI-DrugBank.d180.s1.e2
DDI-DrugBank.d180.s1	89	106	Bretylium Tosylate	drug	DDI-DrugBank.d180.s1.e3
DDI-DrugBank.d180.s1	false	DDI-DrugBank.d180.s1.e0	DDI-DrugBank.d180.s1.e1
DDI-DrugBank.d180.s1	false	DDI-DrugBank.d180.s1.e0	DDI-DrugBank.d180.s1.e2
DDI-DrugBank.d180.s1	true	DDI-DrugBank.d180.s1.e0	DDI-DrugBank.d180.s1.e3
DDI-DrugBank.d180.s1	false	DDI-DrugBank.d180.s1.e1	DDI-DrugBank.d180.s1.e2
DDI-DrugBank.d180.s1	true	DDI-DrugBank.d180.s1.e1	DDI-DrugBank.d180.s1.e3
DDI-DrugBank.d180.s1	true	DDI-DrugBank.d180.s1.e2	DDI-DrugBank.d180.s1.e3
DDI-DrugBank.d180.s2|a|When catecholamines are administered, dilute solutions should be used and blood pressure should be monitored closely.
DDI-DrugBank.d180.s2	5	18	catecholamines	group	DDI-DrugBank.d180.s2.e0
DDI-DrugBank.d180.s3|a|Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.
DDI-DrugBank.d180.s3	80	88	lidocaine	drug	DDI-DrugBank.d180.s3.e0
DDI-DrugBank.d180.s3	94	111	Bretylium Tosylate	drug	DDI-DrugBank.d180.s3.e1
DDI-DrugBank.d180.s3	false	DDI-DrugBank.d180.s3.e0	DDI-DrugBank.d180.s3.e1
DDI-DrugBank.d138.s0|a|Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
DDI-DrugBank.d138.s0	72	81	ALPHAGAN P	brand	DDI-DrugBank.d138.s0.e0
DDI-DrugBank.d138.s0	143	157	CNS depressants	group	DDI-DrugBank.d138.s0.e1
DDI-DrugBank.d138.s0	160	166	alcohol	drug	DDI-DrugBank.d138.s0.e2
DDI-DrugBank.d138.s0	169	180	barbiturates	group	DDI-DrugBank.d138.s0.e3
DDI-DrugBank.d138.s0	183	189	opiates	group	DDI-DrugBank.d138.s0.e4
DDI-DrugBank.d138.s0	192	200	sedatives	group	DDI-DrugBank.d138.s0.e5
DDI-DrugBank.d138.s0	206	216	anesthetics	group	DDI-DrugBank.d138.s0.e6
DDI-DrugBank.d138.s0	true	DDI-DrugBank.d138.s0.e0	DDI-DrugBank.d138.s0.e1
DDI-DrugBank.d138.s0	true	DDI-DrugBank.d138.s0.e0	DDI-DrugBank.d138.s0.e2
DDI-DrugBank.d138.s0	true	DDI-DrugBank.d138.s0.e0	DDI-DrugBank.d138.s0.e3
DDI-DrugBank.d138.s0	true	DDI-DrugBank.d138.s0.e0	DDI-DrugBank.d138.s0.e4
DDI-DrugBank.d138.s0	true	DDI-DrugBank.d138.s0.e0	DDI-DrugBank.d138.s0.e5
DDI-DrugBank.d138.s0	true	DDI-DrugBank.d138.s0.e0	DDI-DrugBank.d138.s0.e6
DDI-DrugBank.d138.s0	false	DDI-DrugBank.d138.s0.e1	DDI-DrugBank.d138.s0.e2
DDI-DrugBank.d138.s0	false	DDI-DrugBank.d138.s0.e1	DDI-DrugBank.d138.s0.e3
DDI-DrugBank.d138.s0	false	DDI-DrugBank.d138.s0.e1	DDI-DrugBank.d138.s0.e4
DDI-DrugBank.d138.s0	false	DDI-DrugBank.d138.s0.e1	DDI-DrugBank.d138.s0.e5
DDI-DrugBank.d138.s1|a|Alpha-agonists, as a class, may reduce pulse and blood pressure.
DDI-DrugBank.d138.s1	0	13	Alpha-agonists	group	DDI-DrugBank.d138.s1.e0
DDI-DrugBank.d138.s2|a|Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.
DDI-DrugBank.d138.s2	43	55	beta-blockers	group	DDI-DrugBank.d138.s2.e0
DDI-DrugBank.d138.s2	84	101	anti-hypertensives	group	DDI-DrugBank.d138.s2.e1
DDI-DrugBank.d138.s2	110	127	cardiac glycosides	group	DDI-DrugBank.d138.s2.e2
DDI-DrugBank.d138.s2	false	DDI-DrugBank.d138.s2.e0	DDI-DrugBank.d138.s2.e1
DDI-DrugBank.d138.s2	false	DDI-DrugBank.d138.s2.e0	DDI-DrugBank.d138.s2.e2
DDI-DrugBank.d138.s2	false	DDI-DrugBank.d138.s2.e1	DDI-DrugBank.d138.s2.e2
DDI-DrugBank.d138.s3|a|Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.
DDI-DrugBank.d138.s3	0	24	Tricyclic antidepressants	group	DDI-DrugBank.d138.s3.e0
DDI-DrugBank.d138.s3	89	97	clonidine	drug	DDI-DrugBank.d138.s3.e1
DDI-DrugBank.d138.s3	163	172	ALPHAGAN P	brand	DDI-DrugBank.d138.s3.e2
DDI-DrugBank.d138.s3	true	DDI-DrugBank.d138.s3.e0	DDI-DrugBank.d138.s3.e1
DDI-DrugBank.d138.s3	false	DDI-DrugBank.d138.s3.e0	DDI-DrugBank.d138.s3.e2
DDI-DrugBank.d138.s3	false	DDI-DrugBank.d138.s3.e1	DDI-DrugBank.d138.s3.e2
DDI-DrugBank.d138.s4|a|No data on the level of circulating catecholamines after ALPHAGAN P administration are available.
DDI-DrugBank.d138.s4	57	66	ALPHAGAN P	brand	DDI-DrugBank.d138.s4.e0
DDI-DrugBank.d138.s5|a|Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.
DDI-DrugBank.d138.s5	48	72	tricyclic antidepressants	group	DDI-DrugBank.d138.s5.e0
DDI-DrugBank.d497.s0|a|AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.
DDI-DrugBank.d497.s0	0	4	AZOPT	brand	DDI-DrugBank.d497.s0.e0
DDI-DrugBank.d497.s0	7	18	brinzolamide	drug	DDI-DrugBank.d497.s0.e1
DDI-DrugBank.d497.s0	57	84	carbonic anhydrase inhibitor	group	DDI-DrugBank.d497.s0.e2
DDI-DrugBank.d497.s0	false	DDI-DrugBank.d497.s0.e0	DDI-DrugBank.d497.s0.e1
DDI-DrugBank.d497.s0	false	DDI-DrugBank.d497.s0.e0	DDI-DrugBank.d497.s0.e2
DDI-DrugBank.d497.s0	false	DDI-DrugBank.d497.s0.e1	DDI-DrugBank.d497.s0.e2
DDI-DrugBank.d497.s1|a|Acid-base and electrolyte alterations were not reported in the clinical trials with brinzolamide.
DDI-DrugBank.d497.s1	84	95	brinzolamide	drug	DDI-DrugBank.d497.s1.e0
DDI-DrugBank.d497.s2|a|However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.
DDI-DrugBank.d497.s2	39	67	carbonic anhydrase inhibitors	group	DDI-DrugBank.d497.s2.e0
DDI-DrugBank.d497.s2	135	144	salicylate	drug	DDI-DrugBank.d497.s2.e1
DDI-DrugBank.d497.s2	true	DDI-DrugBank.d497.s2.e0	DDI-DrugBank.d497.s2.e1
DDI-DrugBank.d497.s3|a|Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT (brinzolamide ophthalmic suspension) 1%.
DDI-DrugBank.d497.s3	94	98	AZOPT	brand	DDI-DrugBank.d497.s3.e0
DDI-DrugBank.d497.s3	101	112	brinzolamide	drug	DDI-DrugBank.d497.s3.e1
DDI-DrugBank.d497.s3	false	DDI-DrugBank.d497.s3.e0	DDI-DrugBank.d497.s3.e1
DDI-DrugBank.d272.s0|a|The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.
DDI-DrugBank.d272.s0	18	39	bromocriptine mesylate	drug	DDI-DrugBank.d272.s0.e0
DDI-DrugBank.d272.s0	116	122	alcohol	drug	DDI-DrugBank.d272.s0.e1
DDI-DrugBank.d272.s0	159	180	bromocriptine mesylate	drug	DDI-DrugBank.d272.s0.e2
DDI-DrugBank.d272.s0	false	DDI-DrugBank.d272.s0.e0	DDI-DrugBank.d272.s0.e1
DDI-DrugBank.d272.s0	false	DDI-DrugBank.d272.s0.e0	DDI-DrugBank.d272.s0.e2
DDI-DrugBank.d272.s0	true	DDI-DrugBank.d272.s0.e1	DDI-DrugBank.d272.s0.e2
DDI-DrugBank.d272.s1|a|Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.
DDI-DrugBank.d272.s1	0	21	Bromocriptine mesylate	drug	DDI-DrugBank.d272.s1.e0
DDI-DrugBank.d272.s1	41	60	dopamine antagonists	group	DDI-DrugBank.d272.s1.e1
DDI-DrugBank.d272.s1	63	76	butyrophenones	group	DDI-DrugBank.d272.s1.e2
DDI-DrugBank.d272.s1	true	DDI-DrugBank.d272.s1.e0	DDI-DrugBank.d272.s1.e1
DDI-DrugBank.d272.s1	true	DDI-DrugBank.d272.s1.e0	DDI-DrugBank.d272.s1.e2
DDI-DrugBank.d272.s1	false	DDI-DrugBank.d272.s1.e1	DDI-DrugBank.d272.s1.e2
DDI-DrugBank.d272.s2|a|Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
DDI-DrugBank.d272.s2	64	85	bromocriptine mesylate	drug	DDI-DrugBank.d272.s2.e0
DDI-DrugBank.d272.s2	88	101	phenothiazines	group	DDI-DrugBank.d272.s2.e1
DDI-DrugBank.d272.s2	104	114	haloperidol	drug	DDI-DrugBank.d272.s2.e2
DDI-DrugBank.d272.s2	117	130	metoclopramide	drug	DDI-DrugBank.d272.s2.e3
DDI-DrugBank.d272.s2	133	140	pimozide	drug	DDI-DrugBank.d272.s2.e4
DDI-DrugBank.d272.s2	true	DDI-DrugBank.d272.s2.e0	DDI-DrugBank.d272.s2.e1
DDI-DrugBank.d272.s2	true	DDI-DrugBank.d272.s2.e0	DDI-DrugBank.d272.s2.e2
DDI-DrugBank.d272.s2	true	DDI-DrugBank.d272.s2.e0	DDI-DrugBank.d272.s2.e3
DDI-DrugBank.d272.s2	true	DDI-DrugBank.d272.s2.e0	DDI-DrugBank.d272.s2.e4
DDI-DrugBank.d272.s2	false	DDI-DrugBank.d272.s2.e1	DDI-DrugBank.d272.s2.e2
DDI-DrugBank.d272.s2	false	DDI-DrugBank.d272.s2.e1	DDI-DrugBank.d272.s2.e3
DDI-DrugBank.d272.s2	false	DDI-DrugBank.d272.s2.e1	DDI-DrugBank.d272.s2.e4
DDI-DrugBank.d272.s2	false	DDI-DrugBank.d272.s2.e2	DDI-DrugBank.d272.s2.e3
DDI-DrugBank.d272.s2	false	DDI-DrugBank.d272.s2.e2	DDI-DrugBank.d272.s2.e4
DDI-DrugBank.d272.s2	false	DDI-DrugBank.d272.s2.e3	DDI-DrugBank.d272.s2.e4
DDI-DrugBank.d272.s3|a|Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.
DDI-DrugBank.d272.s3	19	40	bromocriptine mesylate	drug	DDI-DrugBank.d272.s3.e0
DDI-DrugBank.d272.s3	53	67	ergot alkaloids	group	DDI-DrugBank.d272.s3.e1
DDI-DrugBank.d272.s3	true	DDI-DrugBank.d272.s3.e0	DDI-DrugBank.d272.s3.e1
DDI-DrugBank.d192.s0|a|Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d192.s0	0	17	Dexbrompheniramine	drug	DDI-DrugBank.d192.s0.e0
DDI-DrugBank.d192.s0	37	43	alcohol	drug	DDI-DrugBank.d192.s0.e1
DDI-DrugBank.d192.s0	54	68	CNS depressants	group	DDI-DrugBank.d192.s0.e2
DDI-DrugBank.d192.s0	144	157	antihistamines	group	DDI-DrugBank.d192.s0.e3
DDI-DrugBank.d192.s0	161	176	anticholinergics	group	DDI-DrugBank.d192.s0.e4
DDI-DrugBank.d192.s0	323	336	antihistamines	group	DDI-DrugBank.d192.s0.e5
DDI-DrugBank.d192.s0	344	377	monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d192.s0.e6
DDI-DrugBank.d192.s0	400	413	antihistamines	group	DDI-DrugBank.d192.s0.e7
DDI-DrugBank.d192.s0	491	504	antihistamines	group	DDI-DrugBank.d192.s0.e8
DDI-DrugBank.d192.s0	true	DDI-DrugBank.d192.s0.e0	DDI-DrugBank.d192.s0.e1
DDI-DrugBank.d192.s0	true	DDI-DrugBank.d192.s0.e0	DDI-DrugBank.d192.s0.e2
DDI-DrugBank.d192.s0	false	DDI-DrugBank.d192.s0.e0	DDI-DrugBank.d192.s0.e3
DDI-DrugBank.d192.s0	true	DDI-DrugBank.d192.s0.e0	DDI-DrugBank.d192.s0.e4
DDI-DrugBank.d192.s0	false	DDI-DrugBank.d192.s0.e0	DDI-DrugBank.d192.s0.e5
DDI-DrugBank.d192.s0	true	DDI-DrugBank.d192.s0.e0	DDI-DrugBank.d192.s0.e6
DDI-DrugBank.d192.s0	false	DDI-DrugBank.d192.s0.e0	DDI-DrugBank.d192.s0.e7
DDI-DrugBank.d192.s0	false	DDI-DrugBank.d192.s0.e0	DDI-DrugBank.d192.s0.e8
DDI-DrugBank.d192.s0	false	DDI-DrugBank.d192.s0.e1	DDI-DrugBank.d192.s0.e2
DDI-DrugBank.d192.s0	false	DDI-DrugBank.d192.s0.e1	DDI-DrugBank.d192.s0.e3
DDI-DrugBank.d342.s0|a|This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d342.s0	28	34	alcohol	drug	DDI-DrugBank.d342.s0.e0
DDI-DrugBank.d342.s0	45	59	CNS depressants	group	DDI-DrugBank.d342.s0.e1
DDI-DrugBank.d342.s0	135	148	antihistamines	group	DDI-DrugBank.d342.s0.e2
DDI-DrugBank.d342.s0	152	167	anticholinergics	group	DDI-DrugBank.d342.s0.e3
DDI-DrugBank.d342.s0	314	327	antihistamines	group	DDI-DrugBank.d342.s0.e4
DDI-DrugBank.d342.s0	335	368	monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d342.s0.e5
DDI-DrugBank.d342.s0	391	404	antihistamines	group	DDI-DrugBank.d342.s0.e6
DDI-DrugBank.d342.s0	482	495	antihistamines	group	DDI-DrugBank.d342.s0.e7
DDI-DrugBank.d342.s0	false	DDI-DrugBank.d342.s0.e0	DDI-DrugBank.d342.s0.e1
DDI-DrugBank.d342.s0	false	DDI-DrugBank.d342.s0.e0	DDI-DrugBank.d342.s0.e2
DDI-DrugBank.d342.s0	false	DDI-DrugBank.d342.s0.e0	DDI-DrugBank.d342.s0.e3
DDI-DrugBank.d342.s0	false	DDI-DrugBank.d342.s0.e0	DDI-DrugBank.d342.s0.e4
DDI-DrugBank.d342.s0	false	DDI-DrugBank.d342.s0.e0	DDI-DrugBank.d342.s0.e5
DDI-DrugBank.d342.s0	false	DDI-DrugBank.d342.s0.e0	DDI-DrugBank.d342.s0.e6
DDI-DrugBank.d342.s0	false	DDI-DrugBank.d342.s0.e0	DDI-DrugBank.d342.s0.e7
DDI-DrugBank.d342.s0	false	DDI-DrugBank.d342.s0.e1	DDI-DrugBank.d342.s0.e2
DDI-DrugBank.d342.s0	false	DDI-DrugBank.d342.s0.e1	DDI-DrugBank.d342.s0.e3
DDI-DrugBank.d342.s0	false	DDI-DrugBank.d342.s0.e1	DDI-DrugBank.d342.s0.e4
DDI-DrugBank.d144.s0|a|Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.
DDI-DrugBank.d144.s0	35	46	ketoconazole	drug	DDI-DrugBank.d144.s0.e0
DDI-DrugBank.d144.s0	192	201	budesonide	drug	DDI-DrugBank.d144.s0.e1
DDI-DrugBank.d144.s0	true	DDI-DrugBank.d144.s0.e0	DDI-DrugBank.d144.s0.e1
DDI-DrugBank.d144.s1|a|If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d144.s1	57	68	ketoconazole	drug	DDI-DrugBank.d144.s1.e0
DDI-DrugBank.d144.s1	71	83	intraconazole	drug	DDI-DrugBank.d144.s1.e1
DDI-DrugBank.d144.s1	86	94	ritonavir	drug	DDI-DrugBank.d144.s1.e2
DDI-DrugBank.d144.s1	97	105	indinavir	drug	DDI-DrugBank.d144.s1.e3
DDI-DrugBank.d144.s1	108	117	saquinavir	drug	DDI-DrugBank.d144.s1.e4
DDI-DrugBank.d144.s1	120	131	erythromycin	drug	DDI-DrugBank.d144.s1.e5
DDI-DrugBank.d144.s1	171	180	budesonide	drug	DDI-DrugBank.d144.s1.e6
DDI-DrugBank.d144.s1	false	DDI-DrugBank.d144.s1.e0	DDI-DrugBank.d144.s1.e1
DDI-DrugBank.d144.s1	false	DDI-DrugBank.d144.s1.e0	DDI-DrugBank.d144.s1.e2
DDI-DrugBank.d144.s1	false	DDI-DrugBank.d144.s1.e0	DDI-DrugBank.d144.s1.e3
DDI-DrugBank.d144.s1	false	DDI-DrugBank.d144.s1.e0	DDI-DrugBank.d144.s1.e4
DDI-DrugBank.d144.s1	false	DDI-DrugBank.d144.s1.e0	DDI-DrugBank.d144.s1.e5
DDI-DrugBank.d144.s1	true	DDI-DrugBank.d144.s1.e0	DDI-DrugBank.d144.s1.e6
DDI-DrugBank.d144.s1	false	DDI-DrugBank.d144.s1.e1	DDI-DrugBank.d144.s1.e2
DDI-DrugBank.d144.s1	false	DDI-DrugBank.d144.s1.e1	DDI-DrugBank.d144.s1.e3
DDI-DrugBank.d144.s1	false	DDI-DrugBank.d144.s1.e1	DDI-DrugBank.d144.s1.e4
DDI-DrugBank.d144.s1	false	DDI-DrugBank.d144.s1.e1	DDI-DrugBank.d144.s1.e5
DDI-DrugBank.d144.s2|a|After extensive intake of grapefruit juice (which inhibits CYP3A4 activity predominantly in the intestinal mucosa), the systemic exposure for oral budesonide increased about two times.
DDI-DrugBank.d144.s2	147	156	budesonide	drug	DDI-DrugBank.d144.s2.e0
DDI-DrugBank.d144.s3|a|As with other drugs primarily being metabolized through CYP3A4, ingestion of grapefruit or grapefruit juice should be avoided in connection with budesonide administration.
DDI-DrugBank.d144.s3	145	154	budesonide	drug	DDI-DrugBank.d144.s3.e0
DDI-DrugBank.d331.s0|a|- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.
DDI-DrugBank.d331.s0	125	134	bumetanide	drug	DDI-DrugBank.d331.s0.e0
DDI-DrugBank.d331.s0	156	181	aminoglycoside antibiotics	group	DDI-DrugBank.d331.s0.e1
DDI-DrugBank.d331.s0	true	DDI-DrugBank.d331.s0.e0	DDI-DrugBank.d331.s0.e1
DDI-DrugBank.d331.s1|a|- Drugs with nephrotoxic potential: There has been no experience on the concurrent use of bumetanide with drugs known to have a nephrotoxic potential.
DDI-DrugBank.d331.s1	90	99	bumetanide	drug	DDI-DrugBank.d331.s1.e0
DDI-DrugBank.d331.s2|a|Therefore, the simultaneous administration of these drugs should be avoided.
DDI-DrugBank.d331.s3|a|- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.
DDI-DrugBank.d331.s3	2	8	Lithium	drug	DDI-DrugBank.d331.s3.e0
DDI-DrugBank.d331.s3	11	17	Lithium	drug	DDI-DrugBank.d331.s3.e1
DDI-DrugBank.d331.s3	54	62	diuretics	group	DDI-DrugBank.d331.s3.e2
DDI-DrugBank.d331.s3	73	82	bumetanide	drug	DDI-DrugBank.d331.s3.e3
DDI-DrugBank.d331.s3	148	154	lithium	drug	DDI-DrugBank.d331.s3.e4
DDI-DrugBank.d331.s3	false	DDI-DrugBank.d331.s3.e0	DDI-DrugBank.d331.s3.e1
DDI-DrugBank.d331.s3	false	DDI-DrugBank.d331.s3.e0	DDI-DrugBank.d331.s3.e2
DDI-DrugBank.d331.s3	false	DDI-DrugBank.d331.s3.e0	DDI-DrugBank.d331.s3.e3
DDI-DrugBank.d331.s3	false	DDI-DrugBank.d331.s3.e0	DDI-DrugBank.d331.s3.e4
DDI-DrugBank.d331.s3	true	DDI-DrugBank.d331.s3.e1	DDI-DrugBank.d331.s3.e2
DDI-DrugBank.d331.s3	true	DDI-DrugBank.d331.s3.e1	DDI-DrugBank.d331.s3.e3
DDI-DrugBank.d331.s3	false	DDI-DrugBank.d331.s3.e1	DDI-DrugBank.d331.s3.e4
DDI-DrugBank.d331.s3	false	DDI-DrugBank.d331.s3.e2	DDI-DrugBank.d331.s3.e3
DDI-DrugBank.d331.s3	false	DDI-DrugBank.d331.s3.e2	DDI-DrugBank.d331.s3.e4
DDI-DrugBank.d331.s3	false	DDI-DrugBank.d331.s3.e3	DDI-DrugBank.d331.s3.e4
DDI-DrugBank.d331.s4|a|- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.
DDI-DrugBank.d331.s4	2	11	Probenecid	drug	DDI-DrugBank.d331.s4.e0
DDI-DrugBank.d331.s4	32	41	probenecid	drug	DDI-DrugBank.d331.s4.e1
DDI-DrugBank.d331.s4	103	112	bumetanide	drug	DDI-DrugBank.d331.s4.e2
DDI-DrugBank.d331.s4	false	DDI-DrugBank.d331.s4.e0	DDI-DrugBank.d331.s4.e1
DDI-DrugBank.d331.s4	false	DDI-DrugBank.d331.s4.e0	DDI-DrugBank.d331.s4.e2
DDI-DrugBank.d331.s4	true	DDI-DrugBank.d331.s4.e1	DDI-DrugBank.d331.s4.e2
DDI-DrugBank.d331.s5|a|This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
DDI-DrugBank.d331.s5	28	37	probenecid	drug	DDI-DrugBank.d331.s5.e0
DDI-DrugBank.d331.s5	42	51	bumetanide	drug	DDI-DrugBank.d331.s5.e1
DDI-DrugBank.d331.s5	196	205	bumetanide	drug	DDI-DrugBank.d331.s5.e2
DDI-DrugBank.d331.s5	true	DDI-DrugBank.d331.s5.e0	DDI-DrugBank.d331.s5.e1
DDI-DrugBank.d331.s5	false	DDI-DrugBank.d331.s5.e0	DDI-DrugBank.d331.s5.e2
DDI-DrugBank.d331.s5	false	DDI-DrugBank.d331.s5.e1	DDI-DrugBank.d331.s5.e2
DDI-DrugBank.d331.s6|a|Thus, probenecid should not be administered concurrently with bumetanide.
DDI-DrugBank.d331.s6	6	15	probenecid	drug	DDI-DrugBank.d331.s6.e0
DDI-DrugBank.d331.s6	62	71	bumetanide	drug	DDI-DrugBank.d331.s6.e1
DDI-DrugBank.d331.s6	true	DDI-DrugBank.d331.s6.e0	DDI-DrugBank.d331.s6.e1
DDI-DrugBank.d331.s7|a|- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.
DDI-DrugBank.d331.s7	2	13	Indomethacin	drug	DDI-DrugBank.d331.s7.e0
DDI-DrugBank.d331.s7	16	27	Indomethacin	drug	DDI-DrugBank.d331.s7.e1
DDI-DrugBank.d331.s7	99	108	bumetanide	drug	DDI-DrugBank.d331.s7.e2
DDI-DrugBank.d331.s7	137	146	bumetanide	drug	DDI-DrugBank.d331.s7.e3
DDI-DrugBank.d331.s7	false	DDI-DrugBank.d331.s7.e0	DDI-DrugBank.d331.s7.e1
DDI-DrugBank.d331.s7	false	DDI-DrugBank.d331.s7.e0	DDI-DrugBank.d331.s7.e2
DDI-DrugBank.d331.s7	false	DDI-DrugBank.d331.s7.e0	DDI-DrugBank.d331.s7.e3
DDI-DrugBank.d331.s7	true	DDI-DrugBank.d331.s7.e1	DDI-DrugBank.d331.s7.e2
DDI-DrugBank.d331.s7	true	DDI-DrugBank.d331.s7.e1	DDI-DrugBank.d331.s7.e3
DDI-DrugBank.d331.s7	false	DDI-DrugBank.d331.s7.e2	DDI-DrugBank.d331.s7.e3
DDI-DrugBank.d331.s8|a|Concurrent therapy with bumetanide is thus not recommended.
DDI-DrugBank.d331.s8	24	33	bumetanide	drug	DDI-DrugBank.d331.s8.e0
DDI-DrugBank.d331.s9|a|- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.
DDI-DrugBank.d331.s9	2	18	Antihypertensives	group	DDI-DrugBank.d331.s9.e0
DDI-DrugBank.d331.s9	21	30	Bumetanide	drug	DDI-DrugBank.d331.s9.e1
DDI-DrugBank.d331.s9	69	90	antihypertensive drugs	group	DDI-DrugBank.d331.s9.e2
DDI-DrugBank.d331.s9	false	DDI-DrugBank.d331.s9.e0	DDI-DrugBank.d331.s9.e1
DDI-DrugBank.d331.s9	false	DDI-DrugBank.d331.s9.e0	DDI-DrugBank.d331.s9.e2
DDI-DrugBank.d331.s9	true	DDI-DrugBank.d331.s9.e1	DDI-DrugBank.d331.s9.e2
DDI-DrugBank.d331.s10|a|- Digoxin: Interaction studies in humans have shown no effect on digoxin blood levels.
DDI-DrugBank.d331.s10	2	8	Digoxin	drug	DDI-DrugBank.d331.s10.e0
DDI-DrugBank.d331.s10	65	71	digoxin	drug	DDI-DrugBank.d331.s10.e1
DDI-DrugBank.d331.s10	false	DDI-DrugBank.d331.s10.e0	DDI-DrugBank.d331.s10.e1
DDI-DrugBank.d331.s11|a|- Anticoagulants: Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.
DDI-DrugBank.d331.s11	2	15	Anticoagulants	group	DDI-DrugBank.d331.s11.e0
DDI-DrugBank.d331.s11	59	68	bumetanide	drug	DDI-DrugBank.d331.s11.e1
DDI-DrugBank.d331.s11	91	98	warfarin	drug	DDI-DrugBank.d331.s11.e2
DDI-DrugBank.d331.s11	false	DDI-DrugBank.d331.s11.e0	DDI-DrugBank.d331.s11.e1
DDI-DrugBank.d331.s11	false	DDI-DrugBank.d331.s11.e0	DDI-DrugBank.d331.s11.e2
DDI-DrugBank.d331.s11	false	DDI-DrugBank.d331.s11.e1	DDI-DrugBank.d331.s11.e2
DDI-DrugBank.d153.s0|a|The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
DDI-DrugBank.d153.s0	28	47	anesthetic solutions	group	DDI-DrugBank.d153.s0.e0
DDI-DrugBank.d153.s0	60	70	epinephrine	drug	DDI-DrugBank.d153.s0.e1
DDI-DrugBank.d153.s0	75	88	norepinephrine	drug	DDI-DrugBank.d153.s0.e2
DDI-DrugBank.d153.s0	112	139	monoamine oxidase inhibitors	group	DDI-DrugBank.d153.s0.e3
DDI-DrugBank.d153.s0	144	168	tricyclic antidepressants	group	DDI-DrugBank.d153.s0.e4
DDI-DrugBank.d153.s0	false	DDI-DrugBank.d153.s0.e0	DDI-DrugBank.d153.s0.e1
DDI-DrugBank.d153.s0	false	DDI-DrugBank.d153.s0.e0	DDI-DrugBank.d153.s0.e2
DDI-DrugBank.d153.s0	false	DDI-DrugBank.d153.s0.e0	DDI-DrugBank.d153.s0.e3
DDI-DrugBank.d153.s0	false	DDI-DrugBank.d153.s0.e0	DDI-DrugBank.d153.s0.e4
DDI-DrugBank.d153.s0	false	DDI-DrugBank.d153.s0.e1	DDI-DrugBank.d153.s0.e2
DDI-DrugBank.d153.s0	true	DDI-DrugBank.d153.s0.e1	DDI-DrugBank.d153.s0.e3
DDI-DrugBank.d153.s0	true	DDI-DrugBank.d153.s0.e1	DDI-DrugBank.d153.s0.e4
DDI-DrugBank.d153.s0	true	DDI-DrugBank.d153.s0.e2	DDI-DrugBank.d153.s0.e3
DDI-DrugBank.d153.s0	true	DDI-DrugBank.d153.s0.e2	DDI-DrugBank.d153.s0.e4
DDI-DrugBank.d153.s0	false	DDI-DrugBank.d153.s0.e3	DDI-DrugBank.d153.s0.e4
DDI-DrugBank.d153.s1|a|Concurrent use of these agents should generally be avoided.
DDI-DrugBank.d153.s2|a|In situations in which concurrent therapy is necessary, careful patient monitoring is essential.
DDI-DrugBank.d153.s3|a|Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
DDI-DrugBank.d153.s3	29	45	vasopressor drugs	group	DDI-DrugBank.d153.s3.e0
DDI-DrugBank.d153.s3	54	78	ergot-type oxytocic drugs	group	DDI-DrugBank.d153.s3.e1
DDI-DrugBank.d153.s3	false	DDI-DrugBank.d153.s3.e0	DDI-DrugBank.d153.s3.e1
DDI-DrugBank.d153.s4|a|Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
DDI-DrugBank.d153.s4	0	13	Phenothiazines	group	DDI-DrugBank.d153.s4.e0
DDI-DrugBank.d153.s4	19	32	butyrophenones	group	DDI-DrugBank.d153.s4.e1
DDI-DrugBank.d153.s4	78	88	epinephrine	drug	DDI-DrugBank.d153.s4.e2
DDI-DrugBank.d153.s4	false	DDI-DrugBank.d153.s4.e0	DDI-DrugBank.d153.s4.e1
DDI-DrugBank.d153.s4	true	DDI-DrugBank.d153.s4.e0	DDI-DrugBank.d153.s4.e2
DDI-DrugBank.d153.s4	true	DDI-DrugBank.d153.s4.e1	DDI-DrugBank.d153.s4.e2
DDI-DrugBank.d380.s0|a|Buprenorphine is metabolized to norbuprenorphine by cytochrome CYP 3A4.
DDI-DrugBank.d380.s0	0	12	Buprenorphine	drug	DDI-DrugBank.d380.s0.e0
DDI-DrugBank.d380.s0	32	47	norbuprenorphine	drug_n	DDI-DrugBank.d380.s0.e1
DDI-DrugBank.d380.s0	false	DDI-DrugBank.d380.s0.e0	DDI-DrugBank.d380.s0.e1
DDI-DrugBank.d380.s1|a|Because CYP 3A4 inhibitors may increase plasma concentrations of buprenorphine, patients already on CYP 3A4 inhibitors such as azole antifungals (e.g.
DDI-DrugBank.d380.s1	65	77	buprenorphine	drug	DDI-DrugBank.d380.s1.e0
DDI-DrugBank.d380.s1	127	143	azole antifungals	group	DDI-DrugBank.d380.s1.e1
DDI-DrugBank.d380.s1	false	DDI-DrugBank.d380.s1.e0	DDI-DrugBank.d380.s1.e1
DDI-DrugBank.d380.s2|a|ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
DDI-DrugBank.d380.s2	0	11	ketoconazole	drug	DDI-DrugBank.d380.s2.e0
DDI-DrugBank.d380.s2	15	35	macrolide antibiotics	group	DDI-DrugBank.d380.s2.e1
DDI-DrugBank.d380.s2	43	54	erythromycin	drug	DDI-DrugBank.d380.s2.e2
DDI-DrugBank.d380.s2	62	84	HIV protease inhibitors	group	DDI-DrugBank.d380.s2.e3
DDI-DrugBank.d380.s2	92	100	ritonavir	drug	DDI-DrugBank.d380.s2.e4
DDI-DrugBank.d380.s2	103	111	indinavir	drug	DDI-DrugBank.d380.s2.e5
DDI-DrugBank.d380.s2	117	126	saquinavir	drug	DDI-DrugBank.d380.s2.e6
DDI-DrugBank.d380.s2	155	161	SUBUTEX	brand	DDI-DrugBank.d380.s2.e7
DDI-DrugBank.d380.s2	166	173	SUBOXONE	brand	DDI-DrugBank.d380.s2.e8
DDI-DrugBank.d380.s2	false	DDI-DrugBank.d380.s2.e0	DDI-DrugBank.d380.s2.e1
DDI-DrugBank.d380.s2	false	DDI-DrugBank.d380.s2.e0	DDI-DrugBank.d380.s2.e2
DDI-DrugBank.d380.s2	false	DDI-DrugBank.d380.s2.e0	DDI-DrugBank.d380.s2.e3
DDI-DrugBank.d380.s2	false	DDI-DrugBank.d380.s2.e0	DDI-DrugBank.d380.s2.e4
DDI-DrugBank.d380.s2	false	DDI-DrugBank.d380.s2.e0	DDI-DrugBank.d380.s2.e5
DDI-DrugBank.d380.s2	false	DDI-DrugBank.d380.s2.e0	DDI-DrugBank.d380.s2.e6
DDI-DrugBank.d380.s2	false	DDI-DrugBank.d380.s2.e0	DDI-DrugBank.d380.s2.e7
DDI-DrugBank.d380.s2	false	DDI-DrugBank.d380.s2.e0	DDI-DrugBank.d380.s2.e8
DDI-DrugBank.d380.s2	false	DDI-DrugBank.d380.s2.e1	DDI-DrugBank.d380.s2.e2
DDI-DrugBank.d380.s2	false	DDI-DrugBank.d380.s2.e1	DDI-DrugBank.d380.s2.e3
DDI-DrugBank.d380.s3|a|Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.
DDI-DrugBank.d380.s3	64	76	buprenorphine	drug	DDI-DrugBank.d380.s3.e0
DDI-DrugBank.d380.s3	82	96	benzodiazepines	group	DDI-DrugBank.d380.s3.e1
DDI-DrugBank.d380.s3	true	DDI-DrugBank.d380.s3.e0	DDI-DrugBank.d380.s3.e1
DDI-DrugBank.d380.s4|a|There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.
DDI-DrugBank.d380.s4	141	153	buprenorphine	drug	DDI-DrugBank.d380.s4.e0
DDI-DrugBank.d380.s4	159	173	benzodiazepines	drug	DDI-DrugBank.d380.s4.e1
DDI-DrugBank.d380.s4	true	DDI-DrugBank.d380.s4.e0	DDI-DrugBank.d380.s4.e1
DDI-DrugBank.d380.s5|a|In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.
DDI-DrugBank.d380.s5	24	36	buprenorphine	drug	DDI-DrugBank.d380.s5.e0
DDI-DrugBank.d380.s5	79	85	SUBUTEX	brand	DDI-DrugBank.d380.s5.e1
DDI-DrugBank.d380.s5	false	DDI-DrugBank.d380.s5.e0	DDI-DrugBank.d380.s5.e1
DDI-DrugBank.d380.s6|a|SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
DDI-DrugBank.d380.s6	0	6	SUBUTEX	brand	DDI-DrugBank.d380.s6.e0
DDI-DrugBank.d380.s6	12	19	SUBOXONE	brand	DDI-DrugBank.d380.s6.e1
DDI-DrugBank.d380.s6	70	84	benzodiazepines	group	DDI-DrugBank.d380.s6.e2
DDI-DrugBank.d380.s6	false	DDI-DrugBank.d380.s6.e0	DDI-DrugBank.d380.s6.e1
DDI-DrugBank.d380.s6	true	DDI-DrugBank.d380.s6.e0	DDI-DrugBank.d380.s6.e2
DDI-DrugBank.d380.s6	true	DDI-DrugBank.d380.s6.e1	DDI-DrugBank.d380.s6.e2
DDI-DrugBank.d380.s7|a|Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
DDI-DrugBank.d380.s7	92	106	benzodiazepines	group	DDI-DrugBank.d380.s7.e0
DDI-DrugBank.d380.s7	135	142	SUBOXONE	brand	DDI-DrugBank.d380.s7.e1
DDI-DrugBank.d380.s7	147	153	SUBUTEX	brand	DDI-DrugBank.d380.s7.e2
DDI-DrugBank.d380.s7	true	DDI-DrugBank.d380.s7.e0	DDI-DrugBank.d380.s7.e1
DDI-DrugBank.d380.s7	true	DDI-DrugBank.d380.s7.e0	DDI-DrugBank.d380.s7.e2
DDI-DrugBank.d380.s7	false	DDI-DrugBank.d380.s7.e1	DDI-DrugBank.d380.s7.e2
DDI-DrugBank.d5.s0|a|Few systemic data have been collected on the metabolism of WELLBUTRIN following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of WELLBUTRIN on the metabolism of other drugs.
DDI-DrugBank.d5.s0	59	68	WELLBUTRIN	brand	DDI-DrugBank.d5.s0.e0
DDI-DrugBank.d5.s0	187	196	WELLBUTRIN	brand	DDI-DrugBank.d5.s0.e1
DDI-DrugBank.d5.s0	false	DDI-DrugBank.d5.s0.e0	DDI-DrugBank.d5.s0.e1
DDI-DrugBank.d5.s1|a|Because bupropion is extensively metabolized, the coadministration of other drugs may affect its clinical activity.
DDI-DrugBank.d5.s1	8	16	bupropion	drug	DDI-DrugBank.d5.s1.e0
DDI-DrugBank.d5.s2|a|In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme.
DDI-DrugBank.d5.s2	31	39	bupropion	drug	DDI-DrugBank.d5.s2.e0
DDI-DrugBank.d5.s2	69	84	hydroxybupropion	drug_n	DDI-DrugBank.d5.s2.e1
DDI-DrugBank.d5.s2	false	DDI-DrugBank.d5.s2.e0	DDI-DrugBank.d5.s2.e1
DDI-DrugBank.d5.s3|a|Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
DDI-DrugBank.d5.s3	63	72	WELLBUTRIN	brand	DDI-DrugBank.d5.s3.e0
DDI-DrugBank.d5.s3	124	135	orphenadrine	drug	DDI-DrugBank.d5.s3.e1
DDI-DrugBank.d5.s3	141	156	cyclophosphamide	drug	DDI-DrugBank.d5.s3.e2
DDI-DrugBank.d5.s3	true	DDI-DrugBank.d5.s3.e0	DDI-DrugBank.d5.s3.e1
DDI-DrugBank.d5.s3	true	DDI-DrugBank.d5.s3.e0	DDI-DrugBank.d5.s3.e2
DDI-DrugBank.d5.s3	false	DDI-DrugBank.d5.s3.e1	DDI-DrugBank.d5.s3.e2
DDI-DrugBank.d5.s4|a|The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes.
DDI-DrugBank.d5.s4	4	22	threohydrobupropion	drug_n	DDI-DrugBank.d5.s4.e0
DDI-DrugBank.d5.s4	38	46	bupropion	drug	DDI-DrugBank.d5.s4.e1
DDI-DrugBank.d5.s4	false	DDI-DrugBank.d5.s4.e0	DDI-DrugBank.d5.s4.e1
DDI-DrugBank.d5.s5|a|The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers.
DDI-DrugBank.d5.s5	45	54	cimetidine	drug	DDI-DrugBank.d5.s5.e0
DDI-DrugBank.d5.s5	83	91	bupropion	drug	DDI-DrugBank.d5.s5.e1
DDI-DrugBank.d5.s5	false	DDI-DrugBank.d5.s5.e0	DDI-DrugBank.d5.s5.e1
DDI-DrugBank.d5.s6|a|Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.
DDI-DrugBank.d5.s6	97	106	cimetidine	drug	DDI-DrugBank.d5.s6.e0
DDI-DrugBank.d5.s6	133	141	bupropion	drug	DDI-DrugBank.d5.s6.e1
DDI-DrugBank.d5.s6	147	162	hydroxybupropion	drug_n	DDI-DrugBank.d5.s6.e2
DDI-DrugBank.d5.s6	false	DDI-DrugBank.d5.s6.e0	DDI-DrugBank.d5.s6.e1
DDI-DrugBank.d5.s6	false	DDI-DrugBank.d5.s6.e0	DDI-DrugBank.d5.s6.e2
DDI-DrugBank.d5.s6	false	DDI-DrugBank.d5.s6.e1	DDI-DrugBank.d5.s6.e2
DDI-DrugBank.d5.s7|a|However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.
DDI-DrugBank.d5.s7	105	123	threohydrobupropion	drug_n	DDI-DrugBank.d5.s7.e0
DDI-DrugBank.d5.s7	129	149	erythrohydrobupropion	drug_n	DDI-DrugBank.d5.s7.e1
DDI-DrugBank.d5.s7	false	DDI-DrugBank.d5.s7.e0	DDI-DrugBank.d5.s7.e1
DDI-DrugBank.d5.s8|a|While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
DDI-DrugBank.d5.s8	77	85	bupropion	drug	DDI-DrugBank.d5.s8.e0
DDI-DrugBank.d5.s8	94	106	carbamazepine	drug	DDI-DrugBank.d5.s8.e1
DDI-DrugBank.d5.s8	109	121	phenobarbital	drug	DDI-DrugBank.d5.s8.e2
DDI-DrugBank.d5.s8	124	132	phenytoin	drug	DDI-DrugBank.d5.s8.e3
DDI-DrugBank.d5.s8	true	DDI-DrugBank.d5.s8.e0	DDI-DrugBank.d5.s8.e1
DDI-DrugBank.d5.s8	true	DDI-DrugBank.d5.s8.e0	DDI-DrugBank.d5.s8.e2
DDI-DrugBank.d5.s8	true	DDI-DrugBank.d5.s8.e0	DDI-DrugBank.d5.s8.e3
DDI-DrugBank.d5.s8	false	DDI-DrugBank.d5.s8.e1	DDI-DrugBank.d5.s8.e2
DDI-DrugBank.d5.s8	false	DDI-DrugBank.d5.s8.e1	DDI-DrugBank.d5.s8.e3
DDI-DrugBank.d5.s8	false	DDI-DrugBank.d5.s8.e2	DDI-DrugBank.d5.s8.e3
DDI-DrugBank.d5.s9|a|Animal data indicated that bupropion may be an inducer of drug-metabolizing enzymes in humans.
DDI-DrugBank.d5.s9	27	35	bupropion	drug	DDI-DrugBank.d5.s9.e0
DDI-DrugBank.d5.s10|a|In one study, following chronic administration of bupropion, 100 mg 3 times daily to 8 healthy male volunteers for 14 days, there was no evidence of induction of its own metabolism.
DDI-DrugBank.d5.s10	50	58	bupropion	drug	DDI-DrugBank.d5.s10.e0
DDI-DrugBank.d5.s11|a|Nevertheless, there may be the potential for clinically important alterations of blood levels of coadministered drugs.
DDI-DrugBank.d5.s12|a|Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.
DDI-DrugBank.d5.s12	78	92	antidepressants	group	DDI-DrugBank.d5.s12.e0
DDI-DrugBank.d5.s12	107	116	tricyclics	group	DDI-DrugBank.d5.s12.e1
DDI-DrugBank.d5.s12	120	132	beta-blockers	group	DDI-DrugBank.d5.s12.e2
DDI-DrugBank.d5.s12	135	149	antiarrhythmics	drug	DDI-DrugBank.d5.s12.e3
DDI-DrugBank.d5.s12	156	169	antipsychotics	group	DDI-DrugBank.d5.s12.e4
DDI-DrugBank.d5.s12	false	DDI-DrugBank.d5.s12.e0	DDI-DrugBank.d5.s12.e1
DDI-DrugBank.d5.s12	false	DDI-DrugBank.d5.s12.e0	DDI-DrugBank.d5.s12.e2
DDI-DrugBank.d5.s12	false	DDI-DrugBank.d5.s12.e0	DDI-DrugBank.d5.s12.e3
DDI-DrugBank.d5.s12	false	DDI-DrugBank.d5.s12.e0	DDI-DrugBank.d5.s12.e4
DDI-DrugBank.d5.s12	false	DDI-DrugBank.d5.s12.e1	DDI-DrugBank.d5.s12.e2
DDI-DrugBank.d5.s12	false	DDI-DrugBank.d5.s12.e1	DDI-DrugBank.d5.s12.e3
DDI-DrugBank.d5.s12	false	DDI-DrugBank.d5.s12.e1	DDI-DrugBank.d5.s12.e4
DDI-DrugBank.d5.s12	false	DDI-DrugBank.d5.s12.e2	DDI-DrugBank.d5.s12.e3
DDI-DrugBank.d5.s12	false	DDI-DrugBank.d5.s12.e2	DDI-DrugBank.d5.s12.e4
DDI-DrugBank.d5.s12	false	DDI-DrugBank.d5.s12.e3	DDI-DrugBank.d5.s12.e4
DDI-DrugBank.d5.s13|a|Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.
DDI-DrugBank.d5.s13	9	17	bupropion	drug	DDI-DrugBank.d5.s13.e0
DDI-DrugBank.d5.s13	57	65	bupropion	drug	DDI-DrugBank.d5.s13.e1
DDI-DrugBank.d5.s13	71	86	hydroxybupropion	drug_n	DDI-DrugBank.d5.s13.e2
DDI-DrugBank.d5.s13	false	DDI-DrugBank.d5.s13.e0	DDI-DrugBank.d5.s13.e1
DDI-DrugBank.d5.s13	false	DDI-DrugBank.d5.s13.e0	DDI-DrugBank.d5.s13.e2
DDI-DrugBank.d5.s13	false	DDI-DrugBank.d5.s13.e1	DDI-DrugBank.d5.s13.e2
DDI-DrugBank.d5.s14|a|In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.
DDI-DrugBank.d5.s14	125	133	bupropion	drug	DDI-DrugBank.d5.s14.e0
DDI-DrugBank.d5.s14	198	208	desipramine	drug	DDI-DrugBank.d5.s14.e1
DDI-DrugBank.d5.s14	247	257	desipramine	drug	DDI-DrugBank.d5.s14.e2
DDI-DrugBank.d5.s14	true	DDI-DrugBank.d5.s14.e0	DDI-DrugBank.d5.s14.e1
DDI-DrugBank.d5.s14	false	DDI-DrugBank.d5.s14.e0	DDI-DrugBank.d5.s14.e2
DDI-DrugBank.d5.s14	false	DDI-DrugBank.d5.s14.e1	DDI-DrugBank.d5.s14.e2
DDI-DrugBank.d5.s15|a|The effect was present for at least 7 days after the last dose of bupropion.
DDI-DrugBank.d5.s15	66	74	bupropion	drug	DDI-DrugBank.d5.s15.e0
DDI-DrugBank.d5.s16|a|Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.
DDI-DrugBank.d5.s16	19	27	bupropion	drug	DDI-DrugBank.d5.s16.e0
DDI-DrugBank.d5.s17|a|Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s17	32	40	bupropion	drug	DDI-DrugBank.d5.s17.e0
DDI-DrugBank.d5.s17	112	126	antidepressants	group	DDI-DrugBank.d5.s17.e1
DDI-DrugBank.d5.s17	135	147	nortriptyline	drug	DDI-DrugBank.d5.s17.e2
DDI-DrugBank.d5.s17	150	159	imipramine	drug	DDI-DrugBank.d5.s17.e3
DDI-DrugBank.d5.s17	162	172	desipramine	drug	DDI-DrugBank.d5.s17.e4
DDI-DrugBank.d5.s17	175	184	paroxetine	drug	DDI-DrugBank.d5.s17.e5
DDI-DrugBank.d5.s17	187	196	fluoxetine	drug	DDI-DrugBank.d5.s17.e6
DDI-DrugBank.d5.s17	199	208	sertraline	drug	DDI-DrugBank.d5.s17.e7
DDI-DrugBank.d5.s17	212	225	antipsychotics	group	DDI-DrugBank.d5.s17.e8
DDI-DrugBank.d5.s17	234	244	haloperidol	drug	DDI-DrugBank.d5.s17.e9
DDI-DrugBank.d5.s17	true	DDI-DrugBank.d5.s17.e0	DDI-DrugBank.d5.s17.e1
DDI-DrugBank.d5.s17	true	DDI-DrugBank.d5.s17.e0	DDI-DrugBank.d5.s17.e2
DDI-DrugBank.d5.s17	true	DDI-DrugBank.d5.s17.e0	DDI-DrugBank.d5.s17.e3
DDI-DrugBank.d5.s17	true	DDI-DrugBank.d5.s17.e0	DDI-DrugBank.d5.s17.e4
DDI-DrugBank.d5.s17	true	DDI-DrugBank.d5.s17.e0	DDI-DrugBank.d5.s17.e5
DDI-DrugBank.d5.s17	true	DDI-DrugBank.d5.s17.e0	DDI-DrugBank.d5.s17.e6
DDI-DrugBank.d5.s17	true	DDI-DrugBank.d5.s17.e0	DDI-DrugBank.d5.s17.e7
DDI-DrugBank.d5.s17	true	DDI-DrugBank.d5.s17.e0	DDI-DrugBank.d5.s17.e8
DDI-DrugBank.d5.s17	true	DDI-DrugBank.d5.s17.e0	DDI-DrugBank.d5.s17.e9
DDI-DrugBank.d5.s17	true	DDI-DrugBank.d5.s17.e0	DDI-DrugBank.d5.s17.e10
DDI-DrugBank.d5.s18|a|If bupropion is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index.
DDI-DrugBank.d5.s18	3	11	bupropion	drug	DDI-DrugBank.d5.s18.e0
DDI-DrugBank.d5.s19|a|MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .
DDI-DrugBank.d5.s19	0	13	MAO Inhibitors	group	DDI-DrugBank.d5.s19.e0
DDI-DrugBank.d5.s19	74	82	bupropion	drug	DDI-DrugBank.d5.s19.e1
DDI-DrugBank.d5.s19	103	115	MAO inhibitor	group	DDI-DrugBank.d5.s19.e2
DDI-DrugBank.d5.s19	117	126	phenelzine	drug	DDI-DrugBank.d5.s19.e3
DDI-DrugBank.d5.s19	false	DDI-DrugBank.d5.s19.e0	DDI-DrugBank.d5.s19.e1
DDI-DrugBank.d5.s19	false	DDI-DrugBank.d5.s19.e0	DDI-DrugBank.d5.s19.e2
DDI-DrugBank.d5.s19	false	DDI-DrugBank.d5.s19.e0	DDI-DrugBank.d5.s19.e3
DDI-DrugBank.d5.s19	false	DDI-DrugBank.d5.s19.e1	DDI-DrugBank.d5.s19.e2
DDI-DrugBank.d5.s19	true	DDI-DrugBank.d5.s19.e1	DDI-DrugBank.d5.s19.e3
DDI-DrugBank.d5.s19	false	DDI-DrugBank.d5.s19.e2	DDI-DrugBank.d5.s19.e3
DDI-DrugBank.d5.s20|a|Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
DDI-DrugBank.d5.s20	0	7	Levodopa	drug	DDI-DrugBank.d5.s20.e0
DDI-DrugBank.d5.s20	13	22	Amantadine	drug	DDI-DrugBank.d5.s20.e1
DDI-DrugBank.d5.s20	119	127	bupropion	drug	DDI-DrugBank.d5.s20.e2
DDI-DrugBank.d5.s20	154	161	levodopa	drug	DDI-DrugBank.d5.s20.e3
DDI-DrugBank.d5.s20	166	175	amantadine	drug	DDI-DrugBank.d5.s20.e4
DDI-DrugBank.d5.s20	false	DDI-DrugBank.d5.s20.e0	DDI-DrugBank.d5.s20.e1
DDI-DrugBank.d5.s20	false	DDI-DrugBank.d5.s20.e0	DDI-DrugBank.d5.s20.e2
DDI-DrugBank.d5.s20	false	DDI-DrugBank.d5.s20.e0	DDI-DrugBank.d5.s20.e3
DDI-DrugBank.d5.s20	false	DDI-DrugBank.d5.s20.e0	DDI-DrugBank.d5.s20.e4
DDI-DrugBank.d5.s20	false	DDI-DrugBank.d5.s20.e1	DDI-DrugBank.d5.s20.e2
DDI-DrugBank.d5.s20	false	DDI-DrugBank.d5.s20.e1	DDI-DrugBank.d5.s20.e3
DDI-DrugBank.d5.s20	false	DDI-DrugBank.d5.s20.e1	DDI-DrugBank.d5.s20.e4
DDI-DrugBank.d5.s20	true	DDI-DrugBank.d5.s20.e2	DDI-DrugBank.d5.s20.e3
DDI-DrugBank.d5.s20	true	DDI-DrugBank.d5.s20.e2	DDI-DrugBank.d5.s20.e4
DDI-DrugBank.d5.s20	false	DDI-DrugBank.d5.s20.e3	DDI-DrugBank.d5.s20.e4
DDI-DrugBank.d5.s21|a|Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
DDI-DrugBank.d5.s21	18	27	WELLBUTRIN	brand	DDI-DrugBank.d5.s21.e0
DDI-DrugBank.d5.s21	66	73	levodopa	drug	DDI-DrugBank.d5.s21.e1
DDI-DrugBank.d5.s21	78	87	amantadine	drug	DDI-DrugBank.d5.s21.e2
DDI-DrugBank.d5.s21	true	DDI-DrugBank.d5.s21.e0	DDI-DrugBank.d5.s21.e1
DDI-DrugBank.d5.s21	true	DDI-DrugBank.d5.s21.e0	DDI-DrugBank.d5.s21.e2
DDI-DrugBank.d5.s21	false	DDI-DrugBank.d5.s21.e1	DDI-DrugBank.d5.s21.e2
DDI-DrugBank.d5.s22|a|Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
DDI-DrugBank.d5.s22	65	74	WELLBUTRIN	brand	DDI-DrugBank.d5.s22.e0
DDI-DrugBank.d5.s22	94	107	antipsychotics	group	DDI-DrugBank.d5.s22.e1
DDI-DrugBank.d5.s22	116	130	antidepressants	group	DDI-DrugBank.d5.s22.e2
DDI-DrugBank.d5.s22	133	144	theophylline	drug	DDI-DrugBank.d5.s22.e3
DDI-DrugBank.d5.s22	156	163	steroids	group	DDI-DrugBank.d5.s22.e4
DDI-DrugBank.d5.s22	true	DDI-DrugBank.d5.s22.e0	DDI-DrugBank.d5.s22.e1
DDI-DrugBank.d5.s22	true	DDI-DrugBank.d5.s22.e0	DDI-DrugBank.d5.s22.e2
DDI-DrugBank.d5.s22	true	DDI-DrugBank.d5.s22.e0	DDI-DrugBank.d5.s22.e3
DDI-DrugBank.d5.s22	true	DDI-DrugBank.d5.s22.e0	DDI-DrugBank.d5.s22.e4
DDI-DrugBank.d5.s22	false	DDI-DrugBank.d5.s22.e1	DDI-DrugBank.d5.s22.e2
DDI-DrugBank.d5.s22	false	DDI-DrugBank.d5.s22.e1	DDI-DrugBank.d5.s22.e3
DDI-DrugBank.d5.s22	false	DDI-DrugBank.d5.s22.e1	DDI-DrugBank.d5.s22.e4
DDI-DrugBank.d5.s22	false	DDI-DrugBank.d5.s22.e2	DDI-DrugBank.d5.s22.e3
DDI-DrugBank.d5.s22	false	DDI-DrugBank.d5.s22.e2	DDI-DrugBank.d5.s22.e4
DDI-DrugBank.d5.s22	false	DDI-DrugBank.d5.s22.e3	DDI-DrugBank.d5.s22.e4
DDI-DrugBank.d5.s23|a|Low initial dosing and small gradual dose increases should be employed.
DDI-DrugBank.d5.s24|a|Nicotine Transdermal System: .
DDI-DrugBank.d5.s24	0	7	Nicotine	drug	DDI-DrugBank.d5.s24.e0
DDI-DrugBank.d5.s25|a|Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.
DDI-DrugBank.d5.s25	0	6	Alcohol	drug	DDI-DrugBank.d5.s25.e0
DDI-DrugBank.d5.s25	114	120	alcohol	drug	DDI-DrugBank.d5.s25.e1
DDI-DrugBank.d5.s25	162	168	alcohol	drug	DDI-DrugBank.d5.s25.e2
DDI-DrugBank.d5.s25	192	201	WELLBUTRIN	brand	DDI-DrugBank.d5.s25.e3
DDI-DrugBank.d5.s25	false	DDI-DrugBank.d5.s25.e0	DDI-DrugBank.d5.s25.e1
DDI-DrugBank.d5.s25	false	DDI-DrugBank.d5.s25.e0	DDI-DrugBank.d5.s25.e2
DDI-DrugBank.d5.s25	false	DDI-DrugBank.d5.s25.e0	DDI-DrugBank.d5.s25.e3
DDI-DrugBank.d5.s25	false	DDI-DrugBank.d5.s25.e1	DDI-DrugBank.d5.s25.e2
DDI-DrugBank.d5.s25	false	DDI-DrugBank.d5.s25.e1	DDI-DrugBank.d5.s25.e3
DDI-DrugBank.d5.s25	true	DDI-DrugBank.d5.s25.e2	DDI-DrugBank.d5.s25.e3
DDI-DrugBank.d5.s26|a|The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)
DDI-DrugBank.d5.s26	19	25	alcohol	drug	DDI-DrugBank.d5.s26.e0
DDI-DrugBank.d5.s26	49	58	WELLBUTRIN	brand	DDI-DrugBank.d5.s26.e1
DDI-DrugBank.d5.s26	true	DDI-DrugBank.d5.s26.e0	DDI-DrugBank.d5.s26.e1
DDI-DrugBank.d5.s27|a|.
DDI-DrugBank.d5.s28|a|
DDI-DrugBank.d463.s0|a|It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
DDI-DrugBank.d463.s0	23	45	buspirone hydrochloride	drug	DDI-DrugBank.d463.s0.e0
DDI-DrugBank.d463.s0	78	91	MAO inhibitors	group	DDI-DrugBank.d463.s0.e1
DDI-DrugBank.d463.s0	146	158	buspirone HCl	drug	DDI-DrugBank.d463.s0.e2
DDI-DrugBank.d463.s0	176	193	psychotropic drugs	group	DDI-DrugBank.d463.s0.e3
DDI-DrugBank.d463.s0	241	253	buspirone HCl	drug	DDI-DrugBank.d463.s0.e4
DDI-DrugBank.d463.s0	true	DDI-DrugBank.d463.s0.e0	DDI-DrugBank.d463.s0.e1
DDI-DrugBank.d463.s0	false	DDI-DrugBank.d463.s0.e0	DDI-DrugBank.d463.s0.e2
DDI-DrugBank.d463.s0	false	DDI-DrugBank.d463.s0.e0	DDI-DrugBank.d463.s0.e3
DDI-DrugBank.d463.s0	false	DDI-DrugBank.d463.s0.e0	DDI-DrugBank.d463.s0.e4
DDI-DrugBank.d463.s0	false	DDI-DrugBank.d463.s0.e1	DDI-DrugBank.d463.s0.e2
DDI-DrugBank.d463.s0	false	DDI-DrugBank.d463.s0.e1	DDI-DrugBank.d463.s0.e3
DDI-DrugBank.d463.s0	false	DDI-DrugBank.d463.s0.e1	DDI-DrugBank.d463.s0.e4
DDI-DrugBank.d463.s0	false	DDI-DrugBank.d463.s0.e2	DDI-DrugBank.d463.s0.e3
DDI-DrugBank.d463.s0	false	DDI-DrugBank.d463.s0.e2	DDI-DrugBank.d463.s0.e4
DDI-DrugBank.d463.s0	false	DDI-DrugBank.d463.s0.e3	DDI-DrugBank.d463.s0.e4
DDI-DrugBank.d463.s1|a|There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
DDI-DrugBank.d463.s1	59	81	trazodone hydrochloride	drug	DDI-DrugBank.d463.s1.e0
DDI-DrugBank.d463.s1	84	90	Desyrel	brand	DDI-DrugBank.d463.s1.e1
DDI-DrugBank.d463.s1	97	109	buspirone HCl	drug	DDI-DrugBank.d463.s1.e2
DDI-DrugBank.d463.s1	false	DDI-DrugBank.d463.s1.e0	DDI-DrugBank.d463.s1.e1
DDI-DrugBank.d463.s1	true	DDI-DrugBank.d463.s1.e0	DDI-DrugBank.d463.s1.e2
DDI-DrugBank.d463.s1	true	DDI-DrugBank.d463.s1.e1	DDI-DrugBank.d463.s1.e2
DDI-DrugBank.d463.s2|a|In a similar study, attempting to replicate this finding, no interactive effect on hepatic transaminases was identified.
DDI-DrugBank.d463.s3|a|In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.
DDI-DrugBank.d463.s3	63	75	buspirone HCl	drug	DDI-DrugBank.d463.s3.e0
DDI-DrugBank.d463.s3	81	91	haloperidol	drug	DDI-DrugBank.d463.s3.e1
DDI-DrugBank.d463.s3	121	131	haloperidol	drug	DDI-DrugBank.d463.s3.e2
DDI-DrugBank.d463.s3	true	DDI-DrugBank.d463.s3.e0	DDI-DrugBank.d463.s3.e1
DDI-DrugBank.d463.s3	false	DDI-DrugBank.d463.s3.e0	DDI-DrugBank.d463.s3.e2
DDI-DrugBank.d463.s3	false	DDI-DrugBank.d463.s3.e1	DDI-DrugBank.d463.s3.e2
DDI-DrugBank.d463.s4|a|The clinical significance of this finding is not clear.
DDI-DrugBank.d463.s5|a|In vitro, buspirone does not displace tightly bound drugs like phenytoin, propranolol, and warfarin from serum proteins.
DDI-DrugBank.d463.s5	10	18	buspirone	drug	DDI-DrugBank.d463.s5.e0
DDI-DrugBank.d463.s5	63	71	phenytoin	drug	DDI-DrugBank.d463.s5.e1
DDI-DrugBank.d463.s5	74	84	propranolol	drug	DDI-DrugBank.d463.s5.e2
DDI-DrugBank.d463.s5	91	98	warfarin	drug	DDI-DrugBank.d463.s5.e3
DDI-DrugBank.d463.s5	false	DDI-DrugBank.d463.s5.e0	DDI-DrugBank.d463.s5.e1
DDI-DrugBank.d463.s5	false	DDI-DrugBank.d463.s5.e0	DDI-DrugBank.d463.s5.e2
DDI-DrugBank.d463.s5	false	DDI-DrugBank.d463.s5.e0	DDI-DrugBank.d463.s5.e3
DDI-DrugBank.d463.s5	false	DDI-DrugBank.d463.s5.e1	DDI-DrugBank.d463.s5.e2
DDI-DrugBank.d463.s5	false	DDI-DrugBank.d463.s5.e1	DDI-DrugBank.d463.s5.e3
DDI-DrugBank.d463.s5	false	DDI-DrugBank.d463.s5.e2	DDI-DrugBank.d463.s5.e3
DDI-DrugBank.d463.s6|a|However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.
DDI-DrugBank.d463.s6	70	78	buspirone	drug	DDI-DrugBank.d463.s6.e0
DDI-DrugBank.d463.s6	131	138	warfarin	drug	DDI-DrugBank.d463.s6.e1
DDI-DrugBank.d463.s6	true	DDI-DrugBank.d463.s6.e0	DDI-DrugBank.d463.s6.e1
DDI-DrugBank.d463.s7|a|The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and levothyroxine sodium.
DDI-DrugBank.d463.s7	43	51	phenytoin	drug	DDI-DrugBank.d463.s7.e0
DDI-DrugBank.d463.s7	54	66	phenobarbital	drug	DDI-DrugBank.d463.s7.e1
DDI-DrugBank.d463.s7	69	75	digoxin	drug	DDI-DrugBank.d463.s7.e2
DDI-DrugBank.d463.s7	82	101	levothyroxine sodium	drug	DDI-DrugBank.d463.s7.e3
DDI-DrugBank.d463.s7	false	DDI-DrugBank.d463.s7.e0	DDI-DrugBank.d463.s7.e1
DDI-DrugBank.d463.s7	false	DDI-DrugBank.d463.s7.e0	DDI-DrugBank.d463.s7.e2
DDI-DrugBank.d463.s7	false	DDI-DrugBank.d463.s7.e0	DDI-DrugBank.d463.s7.e3
DDI-DrugBank.d463.s7	false	DDI-DrugBank.d463.s7.e1	DDI-DrugBank.d463.s7.e2
DDI-DrugBank.d463.s7	false	DDI-DrugBank.d463.s7.e1	DDI-DrugBank.d463.s7.e3
DDI-DrugBank.d463.s7	false	DDI-DrugBank.d463.s7.e2	DDI-DrugBank.d463.s7.e3
DDI-DrugBank.d463.s8|a|In vitro, buspirone may displace less firmly bound drugs like digoxin.
DDI-DrugBank.d463.s8	10	18	buspirone	drug	DDI-DrugBank.d463.s8.e0
DDI-DrugBank.d463.s8	62	68	digoxin	drug	DDI-DrugBank.d463.s8.e1
DDI-DrugBank.d463.s8	true	DDI-DrugBank.d463.s8.e0	DDI-DrugBank.d463.s8.e1
DDI-DrugBank.d463.s9|a|The clinical significance of this property is unknown.
DDI-DrugBank.d72.s0|a|Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.
DDI-DrugBank.d72.s0	0	11	Itraconazole	drug	DDI-DrugBank.d72.s0.e0
DDI-DrugBank.d72.s0	23	30	busulfan	drug	DDI-DrugBank.d72.s0.e1
DDI-DrugBank.d72.s0	true	DDI-DrugBank.d72.s0.e0	DDI-DrugBank.d72.s0.e1
DDI-DrugBank.d72.s1|a|Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.
DDI-DrugBank.d72.s1	0	10	Fluconazole	drug	DDI-DrugBank.d72.s1.e0
DDI-DrugBank.d72.s1	21	37	5-HT3 antiemetics	group	DDI-DrugBank.d72.s1.e1
DDI-DrugBank.d72.s1	39	49	ondansetron	drug	DDI-DrugBank.d72.s1.e2
DDI-DrugBank.d72.s1	52	57	Zofran	brand	DDI-DrugBank.d72.s1.e3
DDI-DrugBank.d72.s1	64	74	granisetron	drug	DDI-DrugBank.d72.s1.e4
DDI-DrugBank.d72.s1	77	82	Kytril	brand	DDI-DrugBank.d72.s1.e5
DDI-DrugBank.d72.s1	109	116	BUSULFEX	brand	DDI-DrugBank.d72.s1.e6
DDI-DrugBank.d72.s1	false	DDI-DrugBank.d72.s1.e0	DDI-DrugBank.d72.s1.e1
DDI-DrugBank.d72.s1	false	DDI-DrugBank.d72.s1.e0	DDI-DrugBank.d72.s1.e2
DDI-DrugBank.d72.s1	false	DDI-DrugBank.d72.s1.e0	DDI-DrugBank.d72.s1.e3
DDI-DrugBank.d72.s1	false	DDI-DrugBank.d72.s1.e0	DDI-DrugBank.d72.s1.e4
DDI-DrugBank.d72.s1	false	DDI-DrugBank.d72.s1.e0	DDI-DrugBank.d72.s1.e5
DDI-DrugBank.d72.s1	false	DDI-DrugBank.d72.s1.e0	DDI-DrugBank.d72.s1.e6
DDI-DrugBank.d72.s1	false	DDI-DrugBank.d72.s1.e1	DDI-DrugBank.d72.s1.e2
DDI-DrugBank.d72.s1	false	DDI-DrugBank.d72.s1.e1	DDI-DrugBank.d72.s1.e3
DDI-DrugBank.d72.s1	false	DDI-DrugBank.d72.s1.e1	DDI-DrugBank.d72.s1.e4
DDI-DrugBank.d72.s1	false	DDI-DrugBank.d72.s1.e1	DDI-DrugBank.d72.s1.e5
DDI-DrugBank.d72.s2|a|Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.
DDI-DrugBank.d72.s2	0	8	Phenytoin	drug	DDI-DrugBank.d72.s2.e0
DDI-DrugBank.d72.s2	37	44	busulfan	drug	DDI-DrugBank.d72.s2.e1
DDI-DrugBank.d72.s2	true	DDI-DrugBank.d72.s2.e0	DDI-DrugBank.d72.s2.e1
DDI-DrugBank.d72.s3|a|Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
DDI-DrugBank.d72.s3	30	37	BUSULFEX	brand	DDI-DrugBank.d72.s3.e0
DDI-DrugBank.d72.s3	77	85	phenytoin	drug	DDI-DrugBank.d72.s3.e1
DDI-DrugBank.d72.s3	105	112	BUSULFEX	brand	DDI-DrugBank.d72.s3.e2
DDI-DrugBank.d72.s3	206	214	phenytoin	drug	DDI-DrugBank.d72.s3.e3
DDI-DrugBank.d72.s3	true	DDI-DrugBank.d72.s3.e0	DDI-DrugBank.d72.s3.e1
DDI-DrugBank.d72.s3	false	DDI-DrugBank.d72.s3.e0	DDI-DrugBank.d72.s3.e2
DDI-DrugBank.d72.s3	false	DDI-DrugBank.d72.s3.e0	DDI-DrugBank.d72.s3.e3
DDI-DrugBank.d72.s3	false	DDI-DrugBank.d72.s3.e1	DDI-DrugBank.d72.s3.e2
DDI-DrugBank.d72.s3	false	DDI-DrugBank.d72.s3.e1	DDI-DrugBank.d72.s3.e3
DDI-DrugBank.d72.s3	false	DDI-DrugBank.d72.s3.e2	DDI-DrugBank.d72.s3.e3
DDI-DrugBank.d72.s4|a|Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
DDI-DrugBank.d72.s4	8	15	busulfan	drug	DDI-DrugBank.d72.s4.e0
DDI-DrugBank.d72.s4	86	98	acetaminophen	drug	DDI-DrugBank.d72.s4.e1
DDI-DrugBank.d72.s4	140	147	BUSULFEX	brand	DDI-DrugBank.d72.s4.e2
DDI-DrugBank.d72.s4	171	178	busulfan	drug	DDI-DrugBank.d72.s4.e3
DDI-DrugBank.d72.s4	223	235	acetaminophen	drug	DDI-DrugBank.d72.s4.e4
DDI-DrugBank.d72.s4	false	DDI-DrugBank.d72.s4.e0	DDI-DrugBank.d72.s4.e1
DDI-DrugBank.d72.s4	false	DDI-DrugBank.d72.s4.e0	DDI-DrugBank.d72.s4.e2
DDI-DrugBank.d72.s4	false	DDI-DrugBank.d72.s4.e0	DDI-DrugBank.d72.s4.e3
DDI-DrugBank.d72.s4	false	DDI-DrugBank.d72.s4.e0	DDI-DrugBank.d72.s4.e4
DDI-DrugBank.d72.s4	true	DDI-DrugBank.d72.s4.e1	DDI-DrugBank.d72.s4.e2
DDI-DrugBank.d72.s4	false	DDI-DrugBank.d72.s4.e1	DDI-DrugBank.d72.s4.e3
DDI-DrugBank.d72.s4	false	DDI-DrugBank.d72.s4.e1	DDI-DrugBank.d72.s4.e4
DDI-DrugBank.d72.s4	false	DDI-DrugBank.d72.s4.e2	DDI-DrugBank.d72.s4.e3
DDI-DrugBank.d72.s4	false	DDI-DrugBank.d72.s4.e2	DDI-DrugBank.d72.s4.e4
DDI-DrugBank.d72.s4	false	DDI-DrugBank.d72.s4.e3	DDI-DrugBank.d72.s4.e4
DDI-DrugBank.d184.s0|a|Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
DDI-DrugBank.d184.s0	87	100	anticoagulants	group	DDI-DrugBank.d184.s0.e0
DDI-DrugBank.d184.s0	103	115	blood thinner	group	DDI-DrugBank.d184.s0.e1
DDI-DrugBank.d184.s0	120	132	carbamazepine	drug	DDI-DrugBank.d184.s0.e2
DDI-DrugBank.d184.s0	135	147	corticotropin	drug	DDI-DrugBank.d184.s0.e3
DDI-DrugBank.d184.s0	150	161	barbiturates	group	DDI-DrugBank.d184.s0.e4
DDI-DrugBank.d184.s0	209	248	central nervous system (CNS) depressants	group	DDI-DrugBank.d184.s0.e5
DDI-DrugBank.d184.s0	278	289	barbiturates	group	DDI-DrugBank.d184.s0.e6
DDI-DrugBank.d184.s0	340	356	divalproex sodium	drug	DDI-DrugBank.d184.s0.e7
DDI-DrugBank.d184.s0	359	371	valproic acid	drug	DDI-DrugBank.d184.s0.e8
DDI-DrugBank.d184.s0	401	412	barbiturates	group	DDI-DrugBank.d184.s0.e9
DDI-DrugBank.d184.s0	false	DDI-DrugBank.d184.s0.e0	DDI-DrugBank.d184.s0.e1
DDI-DrugBank.d184.s0	false	DDI-DrugBank.d184.s0.e0	DDI-DrugBank.d184.s0.e2
DDI-DrugBank.d184.s0	false	DDI-DrugBank.d184.s0.e0	DDI-DrugBank.d184.s0.e3
DDI-DrugBank.d184.s0	false	DDI-DrugBank.d184.s0.e0	DDI-DrugBank.d184.s0.e4
DDI-DrugBank.d184.s0	false	DDI-DrugBank.d184.s0.e0	DDI-DrugBank.d184.s0.e5
DDI-DrugBank.d184.s0	false	DDI-DrugBank.d184.s0.e0	DDI-DrugBank.d184.s0.e6
DDI-DrugBank.d184.s0	false	DDI-DrugBank.d184.s0.e0	DDI-DrugBank.d184.s0.e7
DDI-DrugBank.d184.s0	false	DDI-DrugBank.d184.s0.e0	DDI-DrugBank.d184.s0.e8
DDI-DrugBank.d184.s0	false	DDI-DrugBank.d184.s0.e0	DDI-DrugBank.d184.s0.e9
DDI-DrugBank.d184.s0	false	DDI-DrugBank.d184.s0.e0	DDI-DrugBank.d184.s0.e10
DDI-DrugBank.d559.s0|a|The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.
DDI-DrugBank.d559.s0	19	28	butalbital	drug	DDI-DrugBank.d559.s0.e0
DDI-DrugBank.d559.s0	49	82	monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d559.s0.e1
DDI-DrugBank.d559.s0	true	DDI-DrugBank.d559.s0.e0	DDI-DrugBank.d559.s0.e1
DDI-DrugBank.d559.s1|a|Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1	0	9	Butalbital	drug	DDI-DrugBank.d559.s1.e0
DDI-DrugBank.d559.s1	12	24	acetaminophen	drug	DDI-DrugBank.d559.s1.e1
DDI-DrugBank.d559.s1	30	37	caffeine	drug	DDI-DrugBank.d559.s1.e2
DDI-DrugBank.d559.s1	73	90	narcotic analgesic	group	DDI-DrugBank.d559.s1.e3
DDI-DrugBank.d559.s1	94	100	alcohol	drug	DDI-DrugBank.d559.s1.e4
DDI-DrugBank.d559.s1	111	121	anesthetics	group	DDI-DrugBank.d559.s1.e5
DDI-DrugBank.d559.s1	124	136	tranquilizers	group	DDI-DrugBank.d559.s1.e6
DDI-DrugBank.d559.s1	146	161	chlordiazepoxide	drug	DDI-DrugBank.d559.s1.e7
DDI-DrugBank.d559.s1	164	181	sedative-hypnotics	group	DDI-DrugBank.d559.s1.e8
DDI-DrugBank.d559.s1	193	207	CNS depressants	group	DDI-DrugBank.d559.s1.e9
DDI-DrugBank.d559.s1	false	DDI-DrugBank.d559.s1.e0	DDI-DrugBank.d559.s1.e1
DDI-DrugBank.d559.s1	false	DDI-DrugBank.d559.s1.e0	DDI-DrugBank.d559.s1.e2
DDI-DrugBank.d559.s1	true	DDI-DrugBank.d559.s1.e0	DDI-DrugBank.d559.s1.e3
DDI-DrugBank.d559.s1	true	DDI-DrugBank.d559.s1.e0	DDI-DrugBank.d559.s1.e4
DDI-DrugBank.d559.s1	true	DDI-DrugBank.d559.s1.e0	DDI-DrugBank.d559.s1.e5
DDI-DrugBank.d559.s1	true	DDI-DrugBank.d559.s1.e0	DDI-DrugBank.d559.s1.e6
DDI-DrugBank.d559.s1	true	DDI-DrugBank.d559.s1.e0	DDI-DrugBank.d559.s1.e7
DDI-DrugBank.d559.s1	true	DDI-DrugBank.d559.s1.e0	DDI-DrugBank.d559.s1.e8
DDI-DrugBank.d559.s1	true	DDI-DrugBank.d559.s1.e0	DDI-DrugBank.d559.s1.e9
DDI-DrugBank.d559.s1	false	DDI-DrugBank.d559.s1.e1	DDI-DrugBank.d559.s1.e2
DDI-DrugBank.d559.s2|a|Drug/Laboratory Test Interactions Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.
DDI-DrugBank.d559.s2	34	46	Acetaminophen	drug	DDI-DrugBank.d559.s2.e0
DDI-DrugBank.d80.s0|a|Potential drug interactions between Mentax (butenafine HCl cream) Cream, 1%, and other drugs have not been systematically evaluated.
DDI-DrugBank.d80.s0	36	41	Mentax	brand	DDI-DrugBank.d80.s0.e0
DDI-DrugBank.d80.s0	44	57	butenafine HCl	drug	DDI-DrugBank.d80.s0.e1
DDI-DrugBank.d80.s0	false	DDI-DrugBank.d80.s0.e0	DDI-DrugBank.d80.s0.e1
DDI-DrugBank.d246.s0|a|Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
DDI-DrugBank.d246.s0	18	28	butorphanol	drug	DDI-DrugBank.d246.s0.e0
DDI-DrugBank.d246.s0	35	68	central nervous system depressants	group	DDI-DrugBank.d246.s0.e1
DDI-DrugBank.d246.s0	77	83	alcohol	drug	DDI-DrugBank.d246.s0.e2
DDI-DrugBank.d246.s0	86	97	barbiturates	group	DDI-DrugBank.d246.s0.e3
DDI-DrugBank.d246.s0	100	112	tranquilizers	group	DDI-DrugBank.d246.s0.e4
DDI-DrugBank.d246.s0	119	132	antihistamines	group	DDI-DrugBank.d246.s0.e5
DDI-DrugBank.d246.s0	159	191	central nervous system depressant	group	DDI-DrugBank.d246.s0.e6
DDI-DrugBank.d246.s0	true	DDI-DrugBank.d246.s0.e0	DDI-DrugBank.d246.s0.e1
DDI-DrugBank.d246.s0	true	DDI-DrugBank.d246.s0.e0	DDI-DrugBank.d246.s0.e2
DDI-DrugBank.d246.s0	true	DDI-DrugBank.d246.s0.e0	DDI-DrugBank.d246.s0.e3
DDI-DrugBank.d246.s0	true	DDI-DrugBank.d246.s0.e0	DDI-DrugBank.d246.s0.e4
DDI-DrugBank.d246.s0	true	DDI-DrugBank.d246.s0.e0	DDI-DrugBank.d246.s0.e5
DDI-DrugBank.d246.s0	false	DDI-DrugBank.d246.s0.e0	DDI-DrugBank.d246.s0.e6
DDI-DrugBank.d246.s0	false	DDI-DrugBank.d246.s0.e1	DDI-DrugBank.d246.s0.e2
DDI-DrugBank.d246.s0	false	DDI-DrugBank.d246.s0.e1	DDI-DrugBank.d246.s0.e3
DDI-DrugBank.d246.s0	false	DDI-DrugBank.d246.s0.e1	DDI-DrugBank.d246.s0.e4
DDI-DrugBank.d246.s0	false	DDI-DrugBank.d246.s0.e1	DDI-DrugBank.d246.s0.e5
DDI-DrugBank.d246.s1|a|When used concurrently with such drugs, the dose of butorphanol should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of opioids.
DDI-DrugBank.d246.s1	52	62	butorphanol	drug	DDI-DrugBank.d246.s1.e0
DDI-DrugBank.d246.s1	231	237	opioids	group	DDI-DrugBank.d246.s1.e1
DDI-DrugBank.d246.s1	false	DDI-DrugBank.d246.s1.e0	DDI-DrugBank.d246.s1.e1
DDI-DrugBank.d246.s2|a|In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan.
DDI-DrugBank.d246.s2	62	72	butorphanol	drug	DDI-DrugBank.d246.s2.e0
DDI-DrugBank.d246.s2	90	98	STADOL NS	brand	DDI-DrugBank.d246.s2.e1
DDI-DrugBank.d246.s2	180	190	sumatriptan	drug	DDI-DrugBank.d246.s2.e2
DDI-DrugBank.d246.s2	false	DDI-DrugBank.d246.s2.e0	DDI-DrugBank.d246.s2.e1
DDI-DrugBank.d246.s2	false	DDI-DrugBank.d246.s2.e0	DDI-DrugBank.d246.s2.e2
DDI-DrugBank.d246.s2	false	DDI-DrugBank.d246.s2.e1	DDI-DrugBank.d246.s2.e2
DDI-DrugBank.d246.s3|a|However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.
DDI-DrugBank.d246.s3	73	83	butorphanol	drug	DDI-DrugBank.d246.s3.e0
DDI-DrugBank.d246.s3	179	187	STADOL NS	brand	DDI-DrugBank.d246.s3.e1
DDI-DrugBank.d246.s3	237	247	sumatriptan	drug	DDI-DrugBank.d246.s3.e2
DDI-DrugBank.d246.s3	false	DDI-DrugBank.d246.s3.e0	DDI-DrugBank.d246.s3.e1
DDI-DrugBank.d246.s3	false	DDI-DrugBank.d246.s3.e0	DDI-DrugBank.d246.s3.e2
DDI-DrugBank.d246.s3	true	DDI-DrugBank.d246.s3.e1	DDI-DrugBank.d246.s3.e2
DDI-DrugBank.d246.s4|a|(The two drugs were administered in opposite nostrils.)
DDI-DrugBank.d246.s5|a|When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.
DDI-DrugBank.d246.s5	9	17	STADOL NS	brand	DDI-DrugBank.d246.s5.e0
DDI-DrugBank.d246.s5	57	67	sumatriptan	drug	DDI-DrugBank.d246.s5.e1
DDI-DrugBank.d246.s5	93	103	butorphanol	drug	DDI-DrugBank.d246.s5.e2
DDI-DrugBank.d246.s5	true	DDI-DrugBank.d246.s5.e0	DDI-DrugBank.d246.s5.e1
DDI-DrugBank.d246.s5	false	DDI-DrugBank.d246.s5.e0	DDI-DrugBank.d246.s5.e2
DDI-DrugBank.d246.s5	false	DDI-DrugBank.d246.s5.e1	DDI-DrugBank.d246.s5.e2
DDI-DrugBank.d246.s6|a|In neither case were the pharmacokinetics of sumatriptan affected by coadministration with STADOL NS.
DDI-DrugBank.d246.s6	45	55	sumatriptan	drug	DDI-DrugBank.d246.s6.e0
DDI-DrugBank.d246.s6	91	99	STADOL NS	brand	DDI-DrugBank.d246.s6.e1
DDI-DrugBank.d246.s6	false	DDI-DrugBank.d246.s6.e0	DDI-DrugBank.d246.s6.e1
DDI-DrugBank.d246.s7|a|These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.
DDI-DrugBank.d246.s7	51	59	STADOL NS	brand	DDI-DrugBank.d246.s7.e0
DDI-DrugBank.d246.s7	117	127	sumatriptan	drug	DDI-DrugBank.d246.s7.e1
DDI-DrugBank.d246.s7	true	DDI-DrugBank.d246.s7.e0	DDI-DrugBank.d246.s7.e1
DDI-DrugBank.d246.s8|a|The safety of using STADOL NS and IMITREX (sumatriptan) Nasal Spray during the same episode of migraine has not been established.
DDI-DrugBank.d246.s8	20	28	STADOL NS	brand	DDI-DrugBank.d246.s8.e0
DDI-DrugBank.d246.s8	34	40	IMITREX	brand	DDI-DrugBank.d246.s8.e1
DDI-DrugBank.d246.s8	43	53	sumatriptan	drug	DDI-DrugBank.d246.s8.e2
DDI-DrugBank.d246.s8	false	DDI-DrugBank.d246.s8.e0	DDI-DrugBank.d246.s8.e1
DDI-DrugBank.d246.s8	false	DDI-DrugBank.d246.s8.e0	DDI-DrugBank.d246.s8.e2
DDI-DrugBank.d246.s8	false	DDI-DrugBank.d246.s8.e1	DDI-DrugBank.d246.s8.e2
DDI-DrugBank.d246.s9|a|However, it should be noted that both products are capable of producing transient increases in blood pressure.
DDI-DrugBank.d246.s10|a|The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of cimetidine (300 mg QID).
DDI-DrugBank.d246.s10	39	49	butorphanol	drug	DDI-DrugBank.d246.s10.e0
DDI-DrugBank.d246.s10	67	75	STADOL NS	brand	DDI-DrugBank.d246.s10.e1
DDI-DrugBank.d246.s10	122	131	cimetidine	drug	DDI-DrugBank.d246.s10.e2
DDI-DrugBank.d246.s10	false	DDI-DrugBank.d246.s10.e0	DDI-DrugBank.d246.s10.e1
DDI-DrugBank.d246.s10	false	DDI-DrugBank.d246.s10.e0	DDI-DrugBank.d246.s10.e2
DDI-DrugBank.d246.s10	false	DDI-DrugBank.d246.s10.e1	DDI-DrugBank.d246.s10.e2
DDI-DrugBank.d246.s11|a|Conversely, the administration of STADOL NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.
DDI-DrugBank.d246.s11	34	42	STADOL NS	brand	DDI-DrugBank.d246.s11.e0
DDI-DrugBank.d246.s11	50	60	butorphanol	drug	DDI-DrugBank.d246.s11.e1
DDI-DrugBank.d246.s11	122	131	cimetidine	drug	DDI-DrugBank.d246.s11.e2
DDI-DrugBank.d246.s11	false	DDI-DrugBank.d246.s11.e0	DDI-DrugBank.d246.s11.e1
DDI-DrugBank.d246.s11	false	DDI-DrugBank.d246.s11.e0	DDI-DrugBank.d246.s11.e2
DDI-DrugBank.d246.s11	false	DDI-DrugBank.d246.s11.e1	DDI-DrugBank.d246.s11.e2
DDI-DrugBank.d246.s12|a|It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.
DDI-DrugBank.d246.s12	34	44	butorphanol	drug	DDI-DrugBank.d246.s12.e0
DDI-DrugBank.d246.s12	126	137	erythromycin	drug	DDI-DrugBank.d246.s12.e1
DDI-DrugBank.d246.s12	true	DDI-DrugBank.d246.s12.e0	DDI-DrugBank.d246.s12.e1
DDI-DrugBank.d246.s13|a|The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (oxymetazoline), but the rate of absorption is decreased.
DDI-DrugBank.d246.s13	16	24	STADOL NS	brand	DDI-DrugBank.d246.s13.e0
DDI-DrugBank.d246.s13	88	108	nasal vasoconstrictor	group	DDI-DrugBank.d246.s13.e1
DDI-DrugBank.d246.s13	111	123	oxymetazoline	drug	DDI-DrugBank.d246.s13.e2
DDI-DrugBank.d246.s13	false	DDI-DrugBank.d246.s13.e0	DDI-DrugBank.d246.s13.e1
DDI-DrugBank.d246.s13	false	DDI-DrugBank.d246.s13.e0	DDI-DrugBank.d246.s13.e2
DDI-DrugBank.d246.s13	false	DDI-DrugBank.d246.s13.e1	DDI-DrugBank.d246.s13.e2
DDI-DrugBank.d246.s14|a|Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.
DDI-DrugBank.d246.s14	48	56	STADOL NS	brand	DDI-DrugBank.d246.s14.e0
DDI-DrugBank.d246.s14	122	142	nasal vasoconstrictor	group	DDI-DrugBank.d246.s14.e1
DDI-DrugBank.d246.s14	true	DDI-DrugBank.d246.s14.e0	DDI-DrugBank.d246.s14.e1
DDI-DrugBank.d246.s15|a|No information is available about the use of butorphanol concurrently with MAO inhibitors.
DDI-DrugBank.d246.s15	45	55	butorphanol	drug	DDI-DrugBank.d246.s15.e0
DDI-DrugBank.d246.s15	75	88	MAO inhibitors	group	DDI-DrugBank.d246.s15.e1
DDI-DrugBank.d246.s15	false	DDI-DrugBank.d246.s15.e0	DDI-DrugBank.d246.s15.e1
DDI-DrugBank.d282.s0|a|DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
DDI-DrugBank.d282.s0	0	7	DOSTINEX	brand	DDI-DrugBank.d282.s0.e0
DDI-DrugBank.d282.s0	78	91	phenothiazines	group	DDI-DrugBank.d282.s0.e1
DDI-DrugBank.d282.s0	94	107	butyrophenones	group	DDI-DrugBank.d282.s0.e2
DDI-DrugBank.d282.s0	110	122	thioxanthines	group	DDI-DrugBank.d282.s0.e3
DDI-DrugBank.d282.s0	128	141	metoclopramide	drug	DDI-DrugBank.d282.s0.e4
DDI-DrugBank.d282.s0	true	DDI-DrugBank.d282.s0.e0	DDI-DrugBank.d282.s0.e1
DDI-DrugBank.d282.s0	true	DDI-DrugBank.d282.s0.e0	DDI-DrugBank.d282.s0.e2
DDI-DrugBank.d282.s0	true	DDI-DrugBank.d282.s0.e0	DDI-DrugBank.d282.s0.e3
DDI-DrugBank.d282.s0	true	DDI-DrugBank.d282.s0.e0	DDI-DrugBank.d282.s0.e4
DDI-DrugBank.d282.s0	false	DDI-DrugBank.d282.s0.e1	DDI-DrugBank.d282.s0.e2
DDI-DrugBank.d282.s0	false	DDI-DrugBank.d282.s0.e1	DDI-DrugBank.d282.s0.e3
DDI-DrugBank.d282.s0	false	DDI-DrugBank.d282.s0.e1	DDI-DrugBank.d282.s0.e4
DDI-DrugBank.d282.s0	false	DDI-DrugBank.d282.s0.e2	DDI-DrugBank.d282.s0.e3
DDI-DrugBank.d282.s0	false	DDI-DrugBank.d282.s0.e2	DDI-DrugBank.d282.s0.e4
DDI-DrugBank.d282.s0	false	DDI-DrugBank.d282.s0.e3	DDI-DrugBank.d282.s0.e4
DDI-DrugBank.d89.s0|a|Cytochrome P450 1A2 (CYP1A2) is known to be the major enzyme involved in the metabolism of caffeine.
DDI-DrugBank.d89.s0	91	98	caffeine	drug	DDI-DrugBank.d89.s0.e0
DDI-DrugBank.d89.s1|a|Therefore, caffeine has the potential to interact with drugs that are substrates for CYP1A2, inhibit CYP1A2, or induce CYP1A2.
DDI-DrugBank.d89.s1	11	18	caffeine	drug	DDI-DrugBank.d89.s1.e0
DDI-DrugBank.d89.s2|a|Few data exist on drug interactions with caffeine in preterm neonates.
DDI-DrugBank.d89.s2	41	48	caffeine	drug	DDI-DrugBank.d89.s2.e0
DDI-DrugBank.d89.s3|a|Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
DDI-DrugBank.d89.s3	36	43	caffeine	drug	DDI-DrugBank.d89.s3.e0
DDI-DrugBank.d89.s3	126	133	caffeine	drug	DDI-DrugBank.d89.s3.e1
DDI-DrugBank.d89.s3	154	163	cimetidine	drug	DDI-DrugBank.d89.s3.e2
DDI-DrugBank.d89.s3	169	180	ketoconazole	drug	DDI-DrugBank.d89.s3.e3
DDI-DrugBank.d89.s3	194	201	caffeine	drug	DDI-DrugBank.d89.s3.e4
DDI-DrugBank.d89.s3	273	280	caffeine	drug	DDI-DrugBank.d89.s3.e5
DDI-DrugBank.d89.s3	301	313	phenobarbital	drug	DDI-DrugBank.d89.s3.e6
DDI-DrugBank.d89.s3	319	327	phenytoin	drug	DDI-DrugBank.d89.s3.e7
DDI-DrugBank.d89.s3	false	DDI-DrugBank.d89.s3.e0	DDI-DrugBank.d89.s3.e1
DDI-DrugBank.d89.s3	true	DDI-DrugBank.d89.s3.e0	DDI-DrugBank.d89.s3.e2
DDI-DrugBank.d89.s3	true	DDI-DrugBank.d89.s3.e0	DDI-DrugBank.d89.s3.e3
DDI-DrugBank.d89.s3	false	DDI-DrugBank.d89.s3.e0	DDI-DrugBank.d89.s3.e4
DDI-DrugBank.d89.s3	false	DDI-DrugBank.d89.s3.e0	DDI-DrugBank.d89.s3.e5
DDI-DrugBank.d89.s3	false	DDI-DrugBank.d89.s3.e0	DDI-DrugBank.d89.s3.e6
DDI-DrugBank.d89.s3	false	DDI-DrugBank.d89.s3.e0	DDI-DrugBank.d89.s3.e7
DDI-DrugBank.d89.s3	false	DDI-DrugBank.d89.s3.e1	DDI-DrugBank.d89.s3.e2
DDI-DrugBank.d89.s3	false	DDI-DrugBank.d89.s3.e1	DDI-DrugBank.d89.s3.e3
DDI-DrugBank.d89.s3	false	DDI-DrugBank.d89.s3.e1	DDI-DrugBank.d89.s3.e4
DDI-DrugBank.d89.s4|a|Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.
DDI-DrugBank.d89.s4	0	7	Caffeine	drug	DDI-DrugBank.d89.s4.e0
DDI-DrugBank.d89.s4	40	49	ketoprofen	drug	DDI-DrugBank.d89.s4.e1
DDI-DrugBank.d89.s4	true	DDI-DrugBank.d89.s4.e0	DDI-DrugBank.d89.s4.e1
DDI-DrugBank.d89.s5|a|The clinical significance of this interaction in preterm neonates is not known.
DDI-DrugBank.d89.s6|a|Interconversion between caffeine and theophylline has been reported in preterm neonates.
DDI-DrugBank.d89.s6	24	31	caffeine	drug	DDI-DrugBank.d89.s6.e0
DDI-DrugBank.d89.s6	37	48	theophylline	drug	DDI-DrugBank.d89.s6.e1
DDI-DrugBank.d89.s6	false	DDI-DrugBank.d89.s6.e0	DDI-DrugBank.d89.s6.e1
DDI-DrugBank.d89.s7|a|The concurrent use of these drugs is not recommended.
DDI-DrugBank.d98.s0|a|Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
DDI-DrugBank.d98.s0	17	35	vitamin D analogues	group	DDI-DrugBank.d98.s0.e0
DDI-DrugBank.d98.s0	38	47	Vitamin D2	drug	DDI-DrugBank.d98.s0.e1
DDI-DrugBank.d98.s0	50	59	Vitamin D3	drug	DDI-DrugBank.d98.s0.e2
DDI-DrugBank.d98.s0	62	71	Calcitriol	drug	DDI-DrugBank.d98.s0.e3
DDI-DrugBank.d98.s0	78	86	Calcidiol	drug	DDI-DrugBank.d98.s0.e4
DDI-DrugBank.d98.s0	90	103	Cholestyramine	drug	DDI-DrugBank.d98.s0.e5
DDI-DrugBank.d98.s0	106	119	Cholestyramine	drug	DDI-DrugBank.d98.s0.e6
DDI-DrugBank.d98.s0	174	193	fat soluble vitamins	group	DDI-DrugBank.d98.s0.e7
DDI-DrugBank.d98.s0	false	DDI-DrugBank.d98.s0.e0	DDI-DrugBank.d98.s0.e1
DDI-DrugBank.d98.s0	false	DDI-DrugBank.d98.s0.e0	DDI-DrugBank.d98.s0.e2
DDI-DrugBank.d98.s0	false	DDI-DrugBank.d98.s0.e0	DDI-DrugBank.d98.s0.e3
DDI-DrugBank.d98.s0	false	DDI-DrugBank.d98.s0.e0	DDI-DrugBank.d98.s0.e4
DDI-DrugBank.d98.s0	false	DDI-DrugBank.d98.s0.e0	DDI-DrugBank.d98.s0.e5
DDI-DrugBank.d98.s0	false	DDI-DrugBank.d98.s0.e0	DDI-DrugBank.d98.s0.e6
DDI-DrugBank.d98.s0	false	DDI-DrugBank.d98.s0.e0	DDI-DrugBank.d98.s0.e7
DDI-DrugBank.d98.s0	false	DDI-DrugBank.d98.s0.e1	DDI-DrugBank.d98.s0.e2
DDI-DrugBank.d98.s0	false	DDI-DrugBank.d98.s0.e1	DDI-DrugBank.d98.s0.e3
DDI-DrugBank.d98.s0	false	DDI-DrugBank.d98.s0.e1	DDI-DrugBank.d98.s0.e4
DDI-DrugBank.d98.s1|a|as such it may impair intestinal absorption of any of vitamin D.
DDI-DrugBank.d98.s1	54	62	vitamin D	group	DDI-DrugBank.d98.s1.e0
DDI-DrugBank.d98.s2|a|Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DDI-DrugBank.d98.s2	0	8	Phenytoin	drug	DDI-DrugBank.d98.s2.e0
DDI-DrugBank.d98.s2	10	22	Phenobarbital	drug	DDI-DrugBank.d98.s2.e1
DDI-DrugBank.d98.s2	49	57	phenytoin	drug	DDI-DrugBank.d98.s2.e2
DDI-DrugBank.d98.s2	62	74	phenobarbital	drug	DDI-DrugBank.d98.s2.e3
DDI-DrugBank.d98.s2	117	125	vitamin D	group	DDI-DrugBank.d98.s2.e4
DDI-DrugBank.d98.s2	171	180	calcitriol	drug	DDI-DrugBank.d98.s2.e5
DDI-DrugBank.d98.s2	false	DDI-DrugBank.d98.s2.e0	DDI-DrugBank.d98.s2.e1
DDI-DrugBank.d98.s2	false	DDI-DrugBank.d98.s2.e0	DDI-DrugBank.d98.s2.e2
DDI-DrugBank.d98.s2	false	DDI-DrugBank.d98.s2.e0	DDI-DrugBank.d98.s2.e3
DDI-DrugBank.d98.s2	false	DDI-DrugBank.d98.s2.e0	DDI-DrugBank.d98.s2.e4
DDI-DrugBank.d98.s2	false	DDI-DrugBank.d98.s2.e0	DDI-DrugBank.d98.s2.e5
DDI-DrugBank.d98.s2	false	DDI-DrugBank.d98.s2.e1	DDI-DrugBank.d98.s2.e2
DDI-DrugBank.d98.s2	false	DDI-DrugBank.d98.s2.e1	DDI-DrugBank.d98.s2.e3
DDI-DrugBank.d98.s2	false	DDI-DrugBank.d98.s2.e1	DDI-DrugBank.d98.s2.e4
DDI-DrugBank.d98.s2	false	DDI-DrugBank.d98.s2.e1	DDI-DrugBank.d98.s2.e5
DDI-DrugBank.d98.s2	false	DDI-DrugBank.d98.s2.e2	DDI-DrugBank.d98.s2.e3
DDI-DrugBank.d98.s3|a|Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
DDI-DrugBank.d98.s3	21	30	calcitriol	drug	DDI-DrugBank.d98.s3.e0
DDI-DrugBank.d98.s3	80	88	Rocaltrol	brand	DDI-DrugBank.d98.s3.e1
DDI-DrugBank.d98.s3	false	DDI-DrugBank.d98.s3.e0	DDI-DrugBank.d98.s3.e1
DDI-DrugBank.d98.s4|a|Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
DDI-DrugBank.d98.s4	0	8	Thiazides	group	DDI-DrugBank.d98.s4.e0
DDI-DrugBank.d98.s4	11	19	Thiazides	group	DDI-DrugBank.d98.s4.e1
DDI-DrugBank.d98.s4	false	DDI-DrugBank.d98.s4.e0	DDI-DrugBank.d98.s4.e1
DDI-DrugBank.d98.s5|a|Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
DDI-DrugBank.d98.s5	63	71	thiazides	group	DDI-DrugBank.d98.s5.e0
DDI-DrugBank.d98.s5	78	86	vitamin D	group	DDI-DrugBank.d98.s5.e1
DDI-DrugBank.d98.s5	true	DDI-DrugBank.d98.s5.e0	DDI-DrugBank.d98.s5.e1
DDI-DrugBank.d98.s6|a|Therefore, precaution should be taken when coadministration is necessary.
DDI-DrugBank.d98.s7|a|Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
DDI-DrugBank.d98.s7	0	8	Digitalis	group	DDI-DrugBank.d98.s7.e0
DDI-DrugBank.d98.s7	11	19	Vitamin D	group	DDI-DrugBank.d98.s7.e1
DDI-DrugBank.d98.s7	95	103	digitalis	group	DDI-DrugBank.d98.s7.e2
DDI-DrugBank.d98.s7	false	DDI-DrugBank.d98.s7.e0	DDI-DrugBank.d98.s7.e1
DDI-DrugBank.d98.s7	false	DDI-DrugBank.d98.s7.e0	DDI-DrugBank.d98.s7.e2
DDI-DrugBank.d98.s7	true	DDI-DrugBank.d98.s7.e1	DDI-DrugBank.d98.s7.e2
DDI-DrugBank.d98.s8|a|Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
DDI-DrugBank.d98.s8	0	11	Ketoconazole	drug	DDI-DrugBank.d98.s8.e0
DDI-DrugBank.d98.s8	14	25	Ketoconazole	drug	DDI-DrugBank.d98.s8.e1
DDI-DrugBank.d98.s8	79	87	vitamin D	group	DDI-DrugBank.d98.s8.e2
DDI-DrugBank.d98.s8	false	DDI-DrugBank.d98.s8.e0	DDI-DrugBank.d98.s8.e1
DDI-DrugBank.d98.s8	false	DDI-DrugBank.d98.s8.e0	DDI-DrugBank.d98.s8.e2
DDI-DrugBank.d98.s8	true	DDI-DrugBank.d98.s8.e1	DDI-DrugBank.d98.s8.e2
DDI-DrugBank.d98.s9|a|Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.
DDI-DrugBank.d98.s9	133	144	ketoconazole	drug	DDI-DrugBank.d98.s9.e0
DDI-DrugBank.d98.s10|a|However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
DDI-DrugBank.d98.s10	45	56	ketoconazole	drug	DDI-DrugBank.d98.s10.e0
DDI-DrugBank.d98.s10	63	71	vitamin D	group	DDI-DrugBank.d98.s10.e1
DDI-DrugBank.d98.s10	false	DDI-DrugBank.d98.s10.e0	DDI-DrugBank.d98.s10.e1
DDI-DrugBank.d98.s11|a|Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
DDI-DrugBank.d98.s11	0	14	Corticosteroids	group	DDI-DrugBank.d98.s11.e0
DDI-DrugBank.d98.s11	72	90	vitamin D analogues	group	DDI-DrugBank.d98.s11.e1
DDI-DrugBank.d98.s11	131	145	corticosteroids	group	DDI-DrugBank.d98.s11.e2
DDI-DrugBank.d98.s11	false	DDI-DrugBank.d98.s11.e0	DDI-DrugBank.d98.s11.e1
DDI-DrugBank.d98.s11	false	DDI-DrugBank.d98.s11.e0	DDI-DrugBank.d98.s11.e2
DDI-DrugBank.d98.s11	true	DDI-DrugBank.d98.s11.e1	DDI-DrugBank.d98.s11.e2
DDI-DrugBank.d98.s12|a|Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.
DDI-DrugBank.d98.s12	32	40	vitamin D	group	DDI-DrugBank.d98.s12.e0
DDI-DrugBank.d98.s13|a|Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
DDI-DrugBank.d98.s13	0	8	Vitamin D	group	DDI-DrugBank.d98.s13.e0
DDI-DrugBank.d98.s13	46	64	vitamin D analogues	group	DDI-DrugBank.d98.s13.e1
DDI-DrugBank.d98.s13	false	DDI-DrugBank.d98.s13.e0	DDI-DrugBank.d98.s13.e1
DDI-DrugBank.d98.s14|a|Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
DDI-DrugBank.d98.s14	0	6	Calcium	drug	DDI-DrugBank.d98.s14.e0
DDI-DrugBank.d98.s14	55	61	calcium	drug	DDI-DrugBank.d98.s14.e1
DDI-DrugBank.d98.s14	false	DDI-DrugBank.d98.s14.e0	DDI-DrugBank.d98.s14.e1
DDI-DrugBank.d98.s15|a|Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
DDI-DrugBank.d98.s15	0	8	Magnesium	drug	DDI-DrugBank.d98.s15.e0
DDI-DrugBank.d98.s15	11	19	Magnesium	drug	DDI-DrugBank.d98.s15.e1
DDI-DrugBank.d98.s15	50	57	antacids	group	DDI-DrugBank.d98.s15.e2
DDI-DrugBank.d98.s15	140	148	vitamin D	group	DDI-DrugBank.d98.s15.e3
DDI-DrugBank.d98.s15	false	DDI-DrugBank.d98.s15.e0	DDI-DrugBank.d98.s15.e1
DDI-DrugBank.d98.s15	false	DDI-DrugBank.d98.s15.e0	DDI-DrugBank.d98.s15.e2
DDI-DrugBank.d98.s15	false	DDI-DrugBank.d98.s15.e0	DDI-DrugBank.d98.s15.e3
DDI-DrugBank.d98.s15	false	DDI-DrugBank.d98.s15.e1	DDI-DrugBank.d98.s15.e2
DDI-DrugBank.d98.s15	true	DDI-DrugBank.d98.s15.e1	DDI-DrugBank.d98.s15.e3
DDI-DrugBank.d98.s15	true	DDI-DrugBank.d98.s15.e2	DDI-DrugBank.d98.s15.e3
DDI-DrugBank.d384.s0|a|Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
DDI-DrugBank.d384.s0	17	35	vitamin D analogues	group	DDI-DrugBank.d384.s0.e0
DDI-DrugBank.d384.s0	38	47	Vitamin D2	drug	DDI-DrugBank.d384.s0.e1
DDI-DrugBank.d384.s0	50	59	Vitamin D3	drug	DDI-DrugBank.d384.s0.e2
DDI-DrugBank.d384.s0	62	71	Calcitriol	drug	DDI-DrugBank.d384.s0.e3
DDI-DrugBank.d384.s0	78	86	Calcidiol	drug	DDI-DrugBank.d384.s0.e4
DDI-DrugBank.d384.s0	90	103	Cholestyramine	drug	DDI-DrugBank.d384.s0.e5
DDI-DrugBank.d384.s0	106	119	Cholestyramine	drug	DDI-DrugBank.d384.s0.e6
DDI-DrugBank.d384.s0	174	193	fat soluble vitamins	group	DDI-DrugBank.d384.s0.e7
DDI-DrugBank.d384.s0	false	DDI-DrugBank.d384.s0.e0	DDI-DrugBank.d384.s0.e1
DDI-DrugBank.d384.s0	false	DDI-DrugBank.d384.s0.e0	DDI-DrugBank.d384.s0.e2
DDI-DrugBank.d384.s0	false	DDI-DrugBank.d384.s0.e0	DDI-DrugBank.d384.s0.e3
DDI-DrugBank.d384.s0	false	DDI-DrugBank.d384.s0.e0	DDI-DrugBank.d384.s0.e4
DDI-DrugBank.d384.s0	false	DDI-DrugBank.d384.s0.e0	DDI-DrugBank.d384.s0.e5
DDI-DrugBank.d384.s0	false	DDI-DrugBank.d384.s0.e0	DDI-DrugBank.d384.s0.e6
DDI-DrugBank.d384.s0	false	DDI-DrugBank.d384.s0.e0	DDI-DrugBank.d384.s0.e7
DDI-DrugBank.d384.s0	false	DDI-DrugBank.d384.s0.e1	DDI-DrugBank.d384.s0.e2
DDI-DrugBank.d384.s0	false	DDI-DrugBank.d384.s0.e1	DDI-DrugBank.d384.s0.e3
DDI-DrugBank.d384.s0	false	DDI-DrugBank.d384.s0.e1	DDI-DrugBank.d384.s0.e4
DDI-DrugBank.d384.s1|a|as such it may impair intestinal absorption of any of vitamin D.
DDI-DrugBank.d384.s1	54	62	vitamin D	group	DDI-DrugBank.d384.s1.e0
DDI-DrugBank.d384.s2|a|Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DDI-DrugBank.d384.s2	0	8	Phenytoin	drug	DDI-DrugBank.d384.s2.e0
DDI-DrugBank.d384.s2	10	22	Phenobarbital	drug	DDI-DrugBank.d384.s2.e1
DDI-DrugBank.d384.s2	49	57	phenytoin	drug	DDI-DrugBank.d384.s2.e2
DDI-DrugBank.d384.s2	62	74	phenobarbital	drug	DDI-DrugBank.d384.s2.e3
DDI-DrugBank.d384.s2	117	125	vitamin D	group	DDI-DrugBank.d384.s2.e4
DDI-DrugBank.d384.s2	171	180	calcitriol	drug	DDI-DrugBank.d384.s2.e5
DDI-DrugBank.d384.s2	false	DDI-DrugBank.d384.s2.e0	DDI-DrugBank.d384.s2.e1
DDI-DrugBank.d384.s2	false	DDI-DrugBank.d384.s2.e0	DDI-DrugBank.d384.s2.e2
DDI-DrugBank.d384.s2	false	DDI-DrugBank.d384.s2.e0	DDI-DrugBank.d384.s2.e3
DDI-DrugBank.d384.s2	false	DDI-DrugBank.d384.s2.e0	DDI-DrugBank.d384.s2.e4
DDI-DrugBank.d384.s2	false	DDI-DrugBank.d384.s2.e0	DDI-DrugBank.d384.s2.e5
DDI-DrugBank.d384.s2	false	DDI-DrugBank.d384.s2.e1	DDI-DrugBank.d384.s2.e2
DDI-DrugBank.d384.s2	false	DDI-DrugBank.d384.s2.e1	DDI-DrugBank.d384.s2.e3
DDI-DrugBank.d384.s2	false	DDI-DrugBank.d384.s2.e1	DDI-DrugBank.d384.s2.e4
DDI-DrugBank.d384.s2	false	DDI-DrugBank.d384.s2.e1	DDI-DrugBank.d384.s2.e5
DDI-DrugBank.d384.s2	false	DDI-DrugBank.d384.s2.e2	DDI-DrugBank.d384.s2.e3
DDI-DrugBank.d384.s3|a|Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
DDI-DrugBank.d384.s3	21	30	calcitriol	drug	DDI-DrugBank.d384.s3.e0
DDI-DrugBank.d384.s3	80	88	Rocaltrol	brand	DDI-DrugBank.d384.s3.e1
DDI-DrugBank.d384.s3	false	DDI-DrugBank.d384.s3.e0	DDI-DrugBank.d384.s3.e1
DDI-DrugBank.d384.s4|a|Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
DDI-DrugBank.d384.s4	0	8	Thiazides	group	DDI-DrugBank.d384.s4.e0
DDI-DrugBank.d384.s4	11	19	Thiazides	group	DDI-DrugBank.d384.s4.e1
DDI-DrugBank.d384.s4	75	81	calcium	drug	DDI-DrugBank.d384.s4.e2
DDI-DrugBank.d384.s4	false	DDI-DrugBank.d384.s4.e0	DDI-DrugBank.d384.s4.e1
DDI-DrugBank.d384.s4	false	DDI-DrugBank.d384.s4.e0	DDI-DrugBank.d384.s4.e2
DDI-DrugBank.d384.s4	false	DDI-DrugBank.d384.s4.e1	DDI-DrugBank.d384.s4.e2
DDI-DrugBank.d384.s5|a|Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
DDI-DrugBank.d384.s5	63	71	thiazides	group	DDI-DrugBank.d384.s5.e0
DDI-DrugBank.d384.s5	78	86	vitamin D	group	DDI-DrugBank.d384.s5.e1
DDI-DrugBank.d384.s5	true	DDI-DrugBank.d384.s5.e0	DDI-DrugBank.d384.s5.e1
DDI-DrugBank.d384.s6|a|Therefore, precaution should be taken when coadministration is necessary.
DDI-DrugBank.d384.s7|a|Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
DDI-DrugBank.d384.s7	0	8	Digitalis	group	DDI-DrugBank.d384.s7.e0
DDI-DrugBank.d384.s7	11	19	Vitamin D	group	DDI-DrugBank.d384.s7.e1
DDI-DrugBank.d384.s7	95	103	digitalis	group	DDI-DrugBank.d384.s7.e2
DDI-DrugBank.d384.s7	false	DDI-DrugBank.d384.s7.e0	DDI-DrugBank.d384.s7.e1
DDI-DrugBank.d384.s7	false	DDI-DrugBank.d384.s7.e0	DDI-DrugBank.d384.s7.e2
DDI-DrugBank.d384.s7	true	DDI-DrugBank.d384.s7.e1	DDI-DrugBank.d384.s7.e2
DDI-DrugBank.d384.s8|a|Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
DDI-DrugBank.d384.s8	0	11	Ketoconazole	drug	DDI-DrugBank.d384.s8.e0
DDI-DrugBank.d384.s8	14	25	Ketoconazole	drug	DDI-DrugBank.d384.s8.e1
DDI-DrugBank.d384.s8	79	87	vitamin D	group	DDI-DrugBank.d384.s8.e2
DDI-DrugBank.d384.s8	false	DDI-DrugBank.d384.s8.e0	DDI-DrugBank.d384.s8.e1
DDI-DrugBank.d384.s8	false	DDI-DrugBank.d384.s8.e0	DDI-DrugBank.d384.s8.e2
DDI-DrugBank.d384.s8	true	DDI-DrugBank.d384.s8.e1	DDI-DrugBank.d384.s8.e2
DDI-DrugBank.d384.s9|a|Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.
DDI-DrugBank.d384.s9	133	144	ketoconazole	drug	DDI-DrugBank.d384.s9.e0
DDI-DrugBank.d384.s10|a|However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
DDI-DrugBank.d384.s10	45	56	ketoconazole	drug	DDI-DrugBank.d384.s10.e0
DDI-DrugBank.d384.s10	63	71	vitamin D	group	DDI-DrugBank.d384.s10.e1
DDI-DrugBank.d384.s10	false	DDI-DrugBank.d384.s10.e0	DDI-DrugBank.d384.s10.e1
DDI-DrugBank.d384.s11|a|Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
DDI-DrugBank.d384.s11	0	14	Corticosteroids	group	DDI-DrugBank.d384.s11.e0
DDI-DrugBank.d384.s11	72	90	vitamin D analogues	group	DDI-DrugBank.d384.s11.e1
DDI-DrugBank.d384.s11	131	145	corticosteroids	group	DDI-DrugBank.d384.s11.e2
DDI-DrugBank.d384.s11	false	DDI-DrugBank.d384.s11.e0	DDI-DrugBank.d384.s11.e1
DDI-DrugBank.d384.s11	false	DDI-DrugBank.d384.s11.e0	DDI-DrugBank.d384.s11.e2
DDI-DrugBank.d384.s11	true	DDI-DrugBank.d384.s11.e1	DDI-DrugBank.d384.s11.e2
DDI-DrugBank.d384.s12|a|Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.
DDI-DrugBank.d384.s12	32	40	vitamin D	group	DDI-DrugBank.d384.s12.e0
DDI-DrugBank.d384.s13|a|Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
DDI-DrugBank.d384.s13	0	8	Vitamin D	group	DDI-DrugBank.d384.s13.e0
DDI-DrugBank.d384.s13	46	64	vitamin D analogues	group	DDI-DrugBank.d384.s13.e1
DDI-DrugBank.d384.s13	false	DDI-DrugBank.d384.s13.e0	DDI-DrugBank.d384.s13.e1
DDI-DrugBank.d384.s14|a|Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
DDI-DrugBank.d384.s14	0	6	Calcium	drug	DDI-DrugBank.d384.s14.e0
DDI-DrugBank.d384.s14	55	61	calcium	drug	DDI-DrugBank.d384.s14.e1
DDI-DrugBank.d384.s14	false	DDI-DrugBank.d384.s14.e0	DDI-DrugBank.d384.s14.e1
DDI-DrugBank.d384.s15|a|Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
DDI-DrugBank.d384.s15	0	8	Magnesium	drug	DDI-DrugBank.d384.s15.e0
DDI-DrugBank.d384.s15	11	19	Magnesium	drug	DDI-DrugBank.d384.s15.e1
DDI-DrugBank.d384.s15	50	57	antacids	group	DDI-DrugBank.d384.s15.e2
DDI-DrugBank.d384.s15	140	148	vitamin D	group	DDI-DrugBank.d384.s15.e3
DDI-DrugBank.d384.s15	false	DDI-DrugBank.d384.s15.e0	DDI-DrugBank.d384.s15.e1
DDI-DrugBank.d384.s15	false	DDI-DrugBank.d384.s15.e0	DDI-DrugBank.d384.s15.e2
DDI-DrugBank.d384.s15	false	DDI-DrugBank.d384.s15.e0	DDI-DrugBank.d384.s15.e3
DDI-DrugBank.d384.s15	false	DDI-DrugBank.d384.s15.e1	DDI-DrugBank.d384.s15.e2
DDI-DrugBank.d384.s15	true	DDI-DrugBank.d384.s15.e1	DDI-DrugBank.d384.s15.e3
DDI-DrugBank.d384.s15	true	DDI-DrugBank.d384.s15.e2	DDI-DrugBank.d384.s15.e3
DDI-DrugBank.d494.s0|a|Concomitant use with other calcium-containing medicines (including antacids) may cause too much calcium in the blood or urine, which may increase the chance of side effects.
DDI-DrugBank.d494.s0	27	33	calcium	drug	DDI-DrugBank.d494.s0.e0
DDI-DrugBank.d494.s0	67	74	antacids	group	DDI-DrugBank.d494.s0.e1
DDI-DrugBank.d494.s0	96	102	calcium	drug	DDI-DrugBank.d494.s0.e2
DDI-DrugBank.d494.s0	false	DDI-DrugBank.d494.s0.e0	DDI-DrugBank.d494.s0.e1
DDI-DrugBank.d494.s0	false	DDI-DrugBank.d494.s0.e0	DDI-DrugBank.d494.s0.e2
DDI-DrugBank.d494.s0	false	DDI-DrugBank.d494.s0.e1	DDI-DrugBank.d494.s0.e2
DDI-DrugBank.d494.s1|a|Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.
DDI-DrugBank.d494.s1	6	20	calcium acetate	drug	DDI-DrugBank.d494.s1.e0
DDI-DrugBank.d494.s1	27	46	digitalis glycosides	group	DDI-DrugBank.d494.s1.e1
DDI-DrugBank.d494.s1	99	105	calcium	drug	DDI-DrugBank.d494.s1.e2
DDI-DrugBank.d494.s1	true	DDI-DrugBank.d494.s1.e0	DDI-DrugBank.d494.s1.e1
DDI-DrugBank.d494.s1	false	DDI-DrugBank.d494.s1.e0	DDI-DrugBank.d494.s1.e2
DDI-DrugBank.d494.s1	false	DDI-DrugBank.d494.s1.e1	DDI-DrugBank.d494.s1.e2
DDI-DrugBank.d406.s0|a|May interact with cefamandole naftate, cephalothin sodium, magnesium sulfate, prednisolone sodium succinate, and prochlorperazine edisylate.
DDI-DrugBank.d406.s0	18	36	cefamandole naftate	drug	DDI-DrugBank.d406.s0.e0
DDI-DrugBank.d406.s0	39	56	cephalothin sodium	drug	DDI-DrugBank.d406.s0.e1
DDI-DrugBank.d406.s0	59	75	magnesium sulfate	drug	DDI-DrugBank.d406.s0.e2
DDI-DrugBank.d406.s0	78	106	prednisolone sodium succinate	drug	DDI-DrugBank.d406.s0.e3
DDI-DrugBank.d406.s0	113	138	prochlorperazine edisylate	drug	DDI-DrugBank.d406.s0.e4
DDI-DrugBank.d406.s0	false	DDI-DrugBank.d406.s0.e0	DDI-DrugBank.d406.s0.e1
DDI-DrugBank.d406.s0	false	DDI-DrugBank.d406.s0.e0	DDI-DrugBank.d406.s0.e2
DDI-DrugBank.d406.s0	false	DDI-DrugBank.d406.s0.e0	DDI-DrugBank.d406.s0.e3
DDI-DrugBank.d406.s0	false	DDI-DrugBank.d406.s0.e0	DDI-DrugBank.d406.s0.e4
DDI-DrugBank.d406.s0	false	DDI-DrugBank.d406.s0.e1	DDI-DrugBank.d406.s0.e2
DDI-DrugBank.d406.s0	false	DDI-DrugBank.d406.s0.e1	DDI-DrugBank.d406.s0.e3
DDI-DrugBank.d406.s0	false	DDI-DrugBank.d406.s0.e1	DDI-DrugBank.d406.s0.e4
DDI-DrugBank.d406.s0	false	DDI-DrugBank.d406.s0.e2	DDI-DrugBank.d406.s0.e3
DDI-DrugBank.d406.s0	false	DDI-DrugBank.d406.s0.e2	DDI-DrugBank.d406.s0.e4
DDI-DrugBank.d406.s0	false	DDI-DrugBank.d406.s0.e3	DDI-DrugBank.d406.s0.e4
DDI-DrugBank.d547.s0|a|No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
DDI-DrugBank.d547.s0	66	86	candesartan cilexetil	drug	DDI-DrugBank.d547.s0.e0
DDI-DrugBank.d547.s0	119	127	glyburide	drug	DDI-DrugBank.d547.s0.e1
DDI-DrugBank.d547.s0	130	139	nifedipine	drug	DDI-DrugBank.d547.s0.e2
DDI-DrugBank.d547.s0	142	148	digoxin	drug	DDI-DrugBank.d547.s0.e3
DDI-DrugBank.d547.s0	151	158	warfarin	drug	DDI-DrugBank.d547.s0.e4
DDI-DrugBank.d547.s0	161	179	hydrochlorothiazide	drug	DDI-DrugBank.d547.s0.e5
DDI-DrugBank.d547.s0	191	204	contraceptives	group	DDI-DrugBank.d547.s0.e6
DDI-DrugBank.d547.s0	243	251	enalapril	drug	DDI-DrugBank.d547.s0.e7
DDI-DrugBank.d547.s0	false	DDI-DrugBank.d547.s0.e0	DDI-DrugBank.d547.s0.e1
DDI-DrugBank.d547.s0	false	DDI-DrugBank.d547.s0.e0	DDI-DrugBank.d547.s0.e2
DDI-DrugBank.d547.s0	false	DDI-DrugBank.d547.s0.e0	DDI-DrugBank.d547.s0.e3
DDI-DrugBank.d547.s0	false	DDI-DrugBank.d547.s0.e0	DDI-DrugBank.d547.s0.e4
DDI-DrugBank.d547.s0	false	DDI-DrugBank.d547.s0.e0	DDI-DrugBank.d547.s0.e5
DDI-DrugBank.d547.s0	false	DDI-DrugBank.d547.s0.e0	DDI-DrugBank.d547.s0.e6
DDI-DrugBank.d547.s0	false	DDI-DrugBank.d547.s0.e0	DDI-DrugBank.d547.s0.e7
DDI-DrugBank.d547.s0	false	DDI-DrugBank.d547.s0.e1	DDI-DrugBank.d547.s0.e2
DDI-DrugBank.d547.s0	false	DDI-DrugBank.d547.s0.e1	DDI-DrugBank.d547.s0.e3
DDI-DrugBank.d547.s0	false	DDI-DrugBank.d547.s0.e1	DDI-DrugBank.d547.s0.e4
DDI-DrugBank.d547.s1|a|Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.
DDI-DrugBank.d547.s1	8	18	candesartan	drug	DDI-DrugBank.d547.s1.e0
DDI-DrugBank.d547.s2|a|Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
DDI-DrugBank.d547.s2	0	6	Lithium	drug	DDI-DrugBank.d547.s2.e0
DDI-DrugBank.d547.s2	38	44	lithium	drug	DDI-DrugBank.d547.s2.e1
DDI-DrugBank.d547.s2	130	136	lithium	drug	DDI-DrugBank.d547.s2.e2
DDI-DrugBank.d547.s2	143	156	ACE inhibitors	group	DDI-DrugBank.d547.s2.e3
DDI-DrugBank.d547.s2	173	207	angiotensin II receptor antagonists	group	DDI-DrugBank.d547.s2.e4
DDI-DrugBank.d547.s2	false	DDI-DrugBank.d547.s2.e0	DDI-DrugBank.d547.s2.e1
DDI-DrugBank.d547.s2	false	DDI-DrugBank.d547.s2.e0	DDI-DrugBank.d547.s2.e2
DDI-DrugBank.d547.s2	false	DDI-DrugBank.d547.s2.e0	DDI-DrugBank.d547.s2.e3
DDI-DrugBank.d547.s2	false	DDI-DrugBank.d547.s2.e0	DDI-DrugBank.d547.s2.e4
DDI-DrugBank.d547.s2	false	DDI-DrugBank.d547.s2.e1	DDI-DrugBank.d547.s2.e2
DDI-DrugBank.d547.s2	false	DDI-DrugBank.d547.s2.e1	DDI-DrugBank.d547.s2.e3
DDI-DrugBank.d547.s2	false	DDI-DrugBank.d547.s2.e1	DDI-DrugBank.d547.s2.e4
DDI-DrugBank.d547.s2	true	DDI-DrugBank.d547.s2.e2	DDI-DrugBank.d547.s2.e3
DDI-DrugBank.d547.s2	true	DDI-DrugBank.d547.s2.e2	DDI-DrugBank.d547.s2.e4
DDI-DrugBank.d547.s2	false	DDI-DrugBank.d547.s2.e3	DDI-DrugBank.d547.s2.e4
DDI-DrugBank.d547.s3|a|An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.
DDI-DrugBank.d547.s3	21	27	lithium	drug	DDI-DrugBank.d547.s3.e0
DDI-DrugBank.d547.s3	98	104	lithium	drug	DDI-DrugBank.d547.s3.e1
DDI-DrugBank.d547.s3	111	117	ATACAND	brand	DDI-DrugBank.d547.s3.e2
DDI-DrugBank.d547.s3	151	157	lithium	drug	DDI-DrugBank.d547.s3.e3
DDI-DrugBank.d547.s3	false	DDI-DrugBank.d547.s3.e0	DDI-DrugBank.d547.s3.e1
DDI-DrugBank.d547.s3	false	DDI-DrugBank.d547.s3.e0	DDI-DrugBank.d547.s3.e2
DDI-DrugBank.d547.s3	false	DDI-DrugBank.d547.s3.e0	DDI-DrugBank.d547.s3.e3
DDI-DrugBank.d547.s3	true	DDI-DrugBank.d547.s3.e1	DDI-DrugBank.d547.s3.e2
DDI-DrugBank.d547.s3	false	DDI-DrugBank.d547.s3.e1	DDI-DrugBank.d547.s3.e3
DDI-DrugBank.d547.s3	false	DDI-DrugBank.d547.s3.e2	DDI-DrugBank.d547.s3.e3
DDI-DrugBank.d88.s0|a|Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
DDI-DrugBank.d88.s0	0	6	Antacid	group	DDI-DrugBank.d88.s0.e0
DDI-DrugBank.d88.s0	26	43	aluminum hydroxide	drug	DDI-DrugBank.d88.s0.e1
DDI-DrugBank.d88.s0	50	68	magnesium hydroxide	drug	DDI-DrugBank.d88.s0.e2
DDI-DrugBank.d88.s0	81	87	antacid	group	DDI-DrugBank.d88.s0.e3
DDI-DrugBank.d88.s0	90	95	Maalox	brand	DDI-DrugBank.d88.s0.e4
DDI-DrugBank.d88.s0	126	137	capecitabine	drug	DDI-DrugBank.d88.s0.e5
DDI-DrugBank.d88.s0	false	DDI-DrugBank.d88.s0.e0	DDI-DrugBank.d88.s0.e1
DDI-DrugBank.d88.s0	false	DDI-DrugBank.d88.s0.e0	DDI-DrugBank.d88.s0.e2
DDI-DrugBank.d88.s0	false	DDI-DrugBank.d88.s0.e0	DDI-DrugBank.d88.s0.e3
DDI-DrugBank.d88.s0	false	DDI-DrugBank.d88.s0.e0	DDI-DrugBank.d88.s0.e4
DDI-DrugBank.d88.s0	false	DDI-DrugBank.d88.s0.e0	DDI-DrugBank.d88.s0.e5
DDI-DrugBank.d88.s0	false	DDI-DrugBank.d88.s0.e1	DDI-DrugBank.d88.s0.e2
DDI-DrugBank.d88.s0	false	DDI-DrugBank.d88.s0.e1	DDI-DrugBank.d88.s0.e3
DDI-DrugBank.d88.s0	false	DDI-DrugBank.d88.s0.e1	DDI-DrugBank.d88.s0.e4
DDI-DrugBank.d88.s0	false	DDI-DrugBank.d88.s0.e1	DDI-DrugBank.d88.s0.e5
DDI-DrugBank.d88.s0	false	DDI-DrugBank.d88.s0.e2	DDI-DrugBank.d88.s0.e3
DDI-DrugBank.d88.s1|a|There was a small increase in plasma concentrations of capecitabine and one metabolite (5-DFCR);
DDI-DrugBank.d88.s1	55	66	capecitabine	drug	DDI-DrugBank.d88.s1.e0
DDI-DrugBank.d88.s1	88	93	5-DFCR	drug_n	DDI-DrugBank.d88.s1.e1
DDI-DrugBank.d88.s1	false	DDI-DrugBank.d88.s1.e0	DDI-DrugBank.d88.s1.e1
DDI-DrugBank.d88.s2|a|there was no effect on the 3 major metabolites (5-DFUR, 5-FU and FBAL).
DDI-DrugBank.d88.s2	48	53	5-DFUR	drug_n	DDI-DrugBank.d88.s2.e0
DDI-DrugBank.d88.s2	56	59	5-FU	drug_n	DDI-DrugBank.d88.s2.e1
DDI-DrugBank.d88.s2	65	68	FBAL	drug_n	DDI-DrugBank.d88.s2.e2
DDI-DrugBank.d88.s2	false	DDI-DrugBank.d88.s2.e0	DDI-DrugBank.d88.s2.e1
DDI-DrugBank.d88.s2	false	DDI-DrugBank.d88.s2.e0	DDI-DrugBank.d88.s2.e2
DDI-DrugBank.d88.s2	false	DDI-DrugBank.d88.s2.e1	DDI-DrugBank.d88.s2.e2
DDI-DrugBank.d88.s3|a|Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
DDI-DrugBank.d88.s3	0	22	Coumarin Anticoagulants	group	DDI-DrugBank.d88.s3.e0
DDI-DrugBank.d88.s3	109	120	capecitabine	drug	DDI-DrugBank.d88.s3.e1
DDI-DrugBank.d88.s3	141	174	coumarin-derivative anticoagulants	group	DDI-DrugBank.d88.s3.e2
DDI-DrugBank.d88.s3	184	191	warfarin	drug	DDI-DrugBank.d88.s3.e3
DDI-DrugBank.d88.s3	197	209	phenprocoumon	drug	DDI-DrugBank.d88.s3.e4
DDI-DrugBank.d88.s3	false	DDI-DrugBank.d88.s3.e0	DDI-DrugBank.d88.s3.e1
DDI-DrugBank.d88.s3	false	DDI-DrugBank.d88.s3.e0	DDI-DrugBank.d88.s3.e2
DDI-DrugBank.d88.s3	false	DDI-DrugBank.d88.s3.e0	DDI-DrugBank.d88.s3.e3
DDI-DrugBank.d88.s3	false	DDI-DrugBank.d88.s3.e0	DDI-DrugBank.d88.s3.e4
DDI-DrugBank.d88.s3	true	DDI-DrugBank.d88.s3.e1	DDI-DrugBank.d88.s3.e2
DDI-DrugBank.d88.s3	false	DDI-DrugBank.d88.s3.e1	DDI-DrugBank.d88.s3.e3
DDI-DrugBank.d88.s3	true	DDI-DrugBank.d88.s3.e1	DDI-DrugBank.d88.s3.e4
DDI-DrugBank.d88.s3	false	DDI-DrugBank.d88.s3.e2	DDI-DrugBank.d88.s3.e3
DDI-DrugBank.d88.s3	false	DDI-DrugBank.d88.s3.e2	DDI-DrugBank.d88.s3.e4
DDI-DrugBank.d88.s3	false	DDI-DrugBank.d88.s3.e3	DDI-DrugBank.d88.s3.e4
DDI-DrugBank.d88.s4|a|Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).
DDI-DrugBank.d88.s4	16	49	coumarin-derivative anticoagulants	group	DDI-DrugBank.d88.s4.e0
DDI-DrugBank.d88.s4	70	81	capecitabine	drug	DDI-DrugBank.d88.s4.e1
DDI-DrugBank.d88.s4	true	DDI-DrugBank.d88.s4.e0	DDI-DrugBank.d88.s4.e1
DDI-DrugBank.d88.s5|a|Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
DDI-DrugBank.d88.s5	0	9	Leucovorin	drug	DDI-DrugBank.d88.s5.e0
DDI-DrugBank.d88.s5	33	46	5-fluorouracil	drug	DDI-DrugBank.d88.s5.e1
DDI-DrugBank.d88.s5	97	106	leucovorin	drug	DDI-DrugBank.d88.s5.e2
DDI-DrugBank.d88.s5	false	DDI-DrugBank.d88.s5.e0	DDI-DrugBank.d88.s5.e1
DDI-DrugBank.d88.s5	false	DDI-DrugBank.d88.s5.e0	DDI-DrugBank.d88.s5.e2
DDI-DrugBank.d88.s5	true	DDI-DrugBank.d88.s5.e1	DDI-DrugBank.d88.s5.e2
DDI-DrugBank.d88.s6|a|Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.
DDI-DrugBank.d88.s6	116	125	leucovorin	drug	DDI-DrugBank.d88.s6.e0
DDI-DrugBank.d88.s6	131	142	fluorouracil	drug	DDI-DrugBank.d88.s6.e1
DDI-DrugBank.d88.s6	true	DDI-DrugBank.d88.s6.e0	DDI-DrugBank.d88.s6.e1
DDI-DrugBank.d175.s0|a|Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.
DDI-DrugBank.d175.s0	26	33	Diuretic	group	DDI-DrugBank.d175.s0.e0
DDI-DrugBank.d175.s0	56	64	diuretics	group	DDI-DrugBank.d175.s0.e1
DDI-DrugBank.d175.s0	95	102	diuretic	group	DDI-DrugBank.d175.s0.e2
DDI-DrugBank.d175.s0	338	346	captopril	drug	DDI-DrugBank.d175.s0.e3
DDI-DrugBank.d175.s0	false	DDI-DrugBank.d175.s0.e0	DDI-DrugBank.d175.s0.e1
DDI-DrugBank.d175.s0	false	DDI-DrugBank.d175.s0.e0	DDI-DrugBank.d175.s0.e2
DDI-DrugBank.d175.s0	false	DDI-DrugBank.d175.s0.e0	DDI-DrugBank.d175.s0.e3
DDI-DrugBank.d175.s0	false	DDI-DrugBank.d175.s0.e1	DDI-DrugBank.d175.s0.e2
DDI-DrugBank.d175.s0	true	DDI-DrugBank.d175.s0.e1	DDI-DrugBank.d175.s0.e3
DDI-DrugBank.d175.s0	false	DDI-DrugBank.d175.s0.e2	DDI-DrugBank.d175.s0.e3
DDI-DrugBank.d175.s1|a|The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).
DDI-DrugBank.d175.s1	44	52	captopril	drug	DDI-DrugBank.d175.s1.e0
DDI-DrugBank.d175.s1	99	106	diuretic	group	DDI-DrugBank.d175.s1.e1
DDI-DrugBank.d175.s1	199	207	captopril	drug	DDI-DrugBank.d175.s1.e2
DDI-DrugBank.d175.s1	210	218	captopril	drug	DDI-DrugBank.d175.s1.e3
DDI-DrugBank.d175.s1	true	DDI-DrugBank.d175.s1.e0	DDI-DrugBank.d175.s1.e1
DDI-DrugBank.d175.s1	false	DDI-DrugBank.d175.s1.e0	DDI-DrugBank.d175.s1.e2
DDI-DrugBank.d175.s1	false	DDI-DrugBank.d175.s1.e0	DDI-DrugBank.d175.s1.e3
DDI-DrugBank.d175.s1	false	DDI-DrugBank.d175.s1.e1	DDI-DrugBank.d175.s1.e2
DDI-DrugBank.d175.s1	false	DDI-DrugBank.d175.s1.e1	DDI-DrugBank.d175.s1.e3
DDI-DrugBank.d175.s1	false	DDI-DrugBank.d175.s1.e2	DDI-DrugBank.d175.s1.e3
DDI-DrugBank.d175.s2|a|Alternatively, provide medical supervision for at least one hour after the initial dose.
DDI-DrugBank.d175.s3|a|If hypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline.
DDI-DrugBank.d175.s4|a|This transient hypotensive response is not a contraindication to further doses which can be given without difficulty once the blood pressure has increased after volume expansion.
DDI-DrugBank.d175.s5|a|Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available;
DDI-DrugBank.d175.s5	83	94	vasodilators	group	DDI-DrugBank.d175.s5.e0
DDI-DrugBank.d175.s5	118	126	captopril	drug	DDI-DrugBank.d175.s5.e1
DDI-DrugBank.d175.s5	false	DDI-DrugBank.d175.s5.e0	DDI-DrugBank.d175.s5.e1
DDI-DrugBank.d175.s6|a|therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
DDI-DrugBank.d175.s6	11	23	nitroglycerin	drug	DDI-DrugBank.d175.s6.e0
DDI-DrugBank.d175.s6	34	41	nitrates	group	DDI-DrugBank.d175.s6.e1
DDI-DrugBank.d175.s6	174	182	captopril	drug	DDI-DrugBank.d175.s6.e2
DDI-DrugBank.d175.s6	false	DDI-DrugBank.d175.s6.e0	DDI-DrugBank.d175.s6.e1
DDI-DrugBank.d175.s6	true	DDI-DrugBank.d175.s6.e0	DDI-DrugBank.d175.s6.e2
DDI-DrugBank.d175.s6	true	DDI-DrugBank.d175.s6.e1	DDI-DrugBank.d175.s6.e2
DDI-DrugBank.d175.s7|a|If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower dosage.
DDI-DrugBank.d175.s7	18	26	captopril	drug	DDI-DrugBank.d175.s7.e0
DDI-DrugBank.d175.s8|a|Agents Causing Renin Release Captopril's effect will be augmented by antihypertensive agents that cause renin release.
DDI-DrugBank.d175.s8	29	37	Captopril	drug	DDI-DrugBank.d175.s8.e0
DDI-DrugBank.d175.s8	69	91	antihypertensive agents	group	DDI-DrugBank.d175.s8.e1
DDI-DrugBank.d175.s8	true	DDI-DrugBank.d175.s8.e0	DDI-DrugBank.d175.s8.e1
DDI-DrugBank.d175.s9|a|For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system.
DDI-DrugBank.d175.s9	13	21	diuretics	group	DDI-DrugBank.d175.s9.e0
DDI-DrugBank.d175.s9	30	38	thiazides	group	DDI-DrugBank.d175.s9.e1
DDI-DrugBank.d175.s9	false	DDI-DrugBank.d175.s9.e0	DDI-DrugBank.d175.s9.e1
DDI-DrugBank.d175.s10|a|Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics.
DDI-DrugBank.d175.s10	148	156	captopril	drug	DDI-DrugBank.d175.s10.e0
DDI-DrugBank.d175.s10	172	180	diuretics	group	DDI-DrugBank.d175.s10.e1
DDI-DrugBank.d175.s10	false	DDI-DrugBank.d175.s10.e0	DDI-DrugBank.d175.s10.e1
DDI-DrugBank.d175.s11|a|Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution.
DDI-DrugBank.d175.s11	56	81	ganglionic blocking agents	group	DDI-DrugBank.d175.s11.e0
DDI-DrugBank.d175.s11	86	118	adrenergic neuron blocking agents	group	DDI-DrugBank.d175.s11.e1
DDI-DrugBank.d175.s11	false	DDI-DrugBank.d175.s11.e0	DDI-DrugBank.d175.s11.e1
DDI-DrugBank.d175.s12|a|Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.
DDI-DrugBank.d175.s12	0	29	Beta-adrenergic blocking drugs	group	DDI-DrugBank.d175.s12.e0
DDI-DrugBank.d175.s12	75	83	captopril	drug	DDI-DrugBank.d175.s12.e1
DDI-DrugBank.d175.s12	true	DDI-DrugBank.d175.s12.e0	DDI-DrugBank.d175.s12.e1
DDI-DrugBank.d175.s13|a|Agents Increasing Serum Potassium Since captopril decreases aldosterone production, elevation of serum potassium may occur.
DDI-DrugBank.d175.s13	40	48	captopril	drug	DDI-DrugBank.d175.s13.e0
DDI-DrugBank.d175.s14|a|Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
DDI-DrugBank.d175.s14	0	26	Potassium-sparing diuretics	group	DDI-DrugBank.d175.s14.e0
DDI-DrugBank.d175.s14	36	49	spironolactone	drug	DDI-DrugBank.d175.s14.e1
DDI-DrugBank.d175.s14	52	62	triamterene	drug	DDI-DrugBank.d175.s14.e2
DDI-DrugBank.d175.s14	68	76	amiloride	drug	DDI-DrugBank.d175.s14.e3
DDI-DrugBank.d175.s14	82	90	potassium	drug	DDI-DrugBank.d175.s14.e4
DDI-DrugBank.d175.s14	false	DDI-DrugBank.d175.s14.e0	DDI-DrugBank.d175.s14.e1
DDI-DrugBank.d175.s14	false	DDI-DrugBank.d175.s14.e0	DDI-DrugBank.d175.s14.e2
DDI-DrugBank.d175.s14	false	DDI-DrugBank.d175.s14.e0	DDI-DrugBank.d175.s14.e3
DDI-DrugBank.d175.s14	false	DDI-DrugBank.d175.s14.e0	DDI-DrugBank.d175.s14.e4
DDI-DrugBank.d175.s14	false	DDI-DrugBank.d175.s14.e1	DDI-DrugBank.d175.s14.e2
DDI-DrugBank.d175.s14	false	DDI-DrugBank.d175.s14.e1	DDI-DrugBank.d175.s14.e3
DDI-DrugBank.d175.s14	false	DDI-DrugBank.d175.s14.e1	DDI-DrugBank.d175.s14.e4
DDI-DrugBank.d175.s14	false	DDI-DrugBank.d175.s14.e2	DDI-DrugBank.d175.s14.e3
DDI-DrugBank.d175.s14	false	DDI-DrugBank.d175.s14.e2	DDI-DrugBank.d175.s14.e4
DDI-DrugBank.d175.s14	false	DDI-DrugBank.d175.s14.e3	DDI-DrugBank.d175.s14.e4
DDI-DrugBank.d175.s15|a|Salt substitutes containing potassium should also be used with caution.
DDI-DrugBank.d175.s15	28	36	potassium	drug	DDI-DrugBank.d175.s15.e0
DDI-DrugBank.d175.s16|a|Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.
DDI-DrugBank.d175.s16	75	86	indomethacin	drug	DDI-DrugBank.d175.s16.e0
DDI-DrugBank.d175.s16	130	138	captopril	drug	DDI-DrugBank.d175.s16.e1
DDI-DrugBank.d175.s16	true	DDI-DrugBank.d175.s16.e0	DDI-DrugBank.d175.s16.e1
DDI-DrugBank.d175.s17|a|Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect.
DDI-DrugBank.d175.s17	6	42	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d175.s17.e0
DDI-DrugBank.d175.s17	51	57	aspirin	brand	DDI-DrugBank.d175.s17.e1
DDI-DrugBank.d175.s17	false	DDI-DrugBank.d175.s17.e0	DDI-DrugBank.d175.s17.e1
DDI-DrugBank.d175.s18|a|Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
DDI-DrugBank.d175.s18	0	6	Lithium	drug	DDI-DrugBank.d175.s18.e0
DDI-DrugBank.d175.s18	25	31	lithium	drug	DDI-DrugBank.d175.s18.e1
DDI-DrugBank.d175.s18	56	62	lithium	drug	DDI-DrugBank.d175.s18.e2
DDI-DrugBank.d175.s18	126	132	lithium	drug	DDI-DrugBank.d175.s18.e3
DDI-DrugBank.d175.s18	138	150	ACE inhibitor	group	DDI-DrugBank.d175.s18.e4
DDI-DrugBank.d175.s18	false	DDI-DrugBank.d175.s18.e0	DDI-DrugBank.d175.s18.e1
DDI-DrugBank.d175.s18	false	DDI-DrugBank.d175.s18.e0	DDI-DrugBank.d175.s18.e2
DDI-DrugBank.d175.s18	false	DDI-DrugBank.d175.s18.e0	DDI-DrugBank.d175.s18.e3
DDI-DrugBank.d175.s18	false	DDI-DrugBank.d175.s18.e0	DDI-DrugBank.d175.s18.e4
DDI-DrugBank.d175.s18	false	DDI-DrugBank.d175.s18.e1	DDI-DrugBank.d175.s18.e2
DDI-DrugBank.d175.s18	false	DDI-DrugBank.d175.s18.e1	DDI-DrugBank.d175.s18.e3
DDI-DrugBank.d175.s18	false	DDI-DrugBank.d175.s18.e1	DDI-DrugBank.d175.s18.e4
DDI-DrugBank.d175.s18	false	DDI-DrugBank.d175.s18.e2	DDI-DrugBank.d175.s18.e3
DDI-DrugBank.d175.s18	false	DDI-DrugBank.d175.s18.e2	DDI-DrugBank.d175.s18.e4
DDI-DrugBank.d175.s18	true	DDI-DrugBank.d175.s18.e3	DDI-DrugBank.d175.s18.e4
DDI-DrugBank.d175.s19|a|These drugs should be coad-ministered with caution and frequent monitoring of serum lithium levels is recommended.
DDI-DrugBank.d175.s19	84	90	lithium	drug	DDI-DrugBank.d175.s19.e0
DDI-DrugBank.d175.s20|a|If a diuretic is also used, it may increase the risk of lithium toxicity.
DDI-DrugBank.d175.s20	5	12	diuretic	group	DDI-DrugBank.d175.s20.e0
DDI-DrugBank.d175.s20	56	62	lithium	drug	DDI-DrugBank.d175.s20.e1
DDI-DrugBank.d175.s20	true	DDI-DrugBank.d175.s20.e0	DDI-DrugBank.d175.s20.e1
DDI-DrugBank.d175.s21|a|Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found.
DDI-DrugBank.d175.s21	0	17	Cardiac Glycosides	group	DDI-DrugBank.d175.s21.e0
DDI-DrugBank.d175.s21	102	110	captopril	drug	DDI-DrugBank.d175.s21.e1
DDI-DrugBank.d175.s21	112	118	digoxin	drug	DDI-DrugBank.d175.s21.e2
DDI-DrugBank.d175.s21	false	DDI-DrugBank.d175.s21.e0	DDI-DrugBank.d175.s21.e1
DDI-DrugBank.d175.s21	false	DDI-DrugBank.d175.s21.e0	DDI-DrugBank.d175.s21.e2
DDI-DrugBank.d175.s21	false	DDI-DrugBank.d175.s21.e1	DDI-DrugBank.d175.s21.e2
DDI-DrugBank.d175.s22|a|Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.
DDI-DrugBank.d175.s22	0	13	Loop Diuretics	group	DDI-DrugBank.d175.s22.e0
DDI-DrugBank.d175.s22	16	25	Furosemide	drug	DDI-DrugBank.d175.s22.e1
DDI-DrugBank.d175.s22	58	66	captopril	drug	DDI-DrugBank.d175.s22.e2
DDI-DrugBank.d175.s22	107	115	captopril	drug	DDI-DrugBank.d175.s22.e3
DDI-DrugBank.d175.s22	false	DDI-DrugBank.d175.s22.e0	DDI-DrugBank.d175.s22.e1
DDI-DrugBank.d175.s22	false	DDI-DrugBank.d175.s22.e0	DDI-DrugBank.d175.s22.e2
DDI-DrugBank.d175.s22	false	DDI-DrugBank.d175.s22.e0	DDI-DrugBank.d175.s22.e3
DDI-DrugBank.d175.s22	false	DDI-DrugBank.d175.s22.e1	DDI-DrugBank.d175.s22.e2
DDI-DrugBank.d175.s22	false	DDI-DrugBank.d175.s22.e1	DDI-DrugBank.d175.s22.e3
DDI-DrugBank.d175.s22	false	DDI-DrugBank.d175.s22.e2	DDI-DrugBank.d175.s22.e3
DDI-DrugBank.d175.s23|a|Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allopurinol were administered concomitantly for 6 days.
DDI-DrugBank.d175.s23	0	10	Allopurinol	drug	DDI-DrugBank.d175.s23.e0
DDI-DrugBank.d175.s23	108	116	captopril	drug	DDI-DrugBank.d175.s23.e1
DDI-DrugBank.d175.s23	122	132	allopurinol	drug	DDI-DrugBank.d175.s23.e2
DDI-DrugBank.d175.s23	false	DDI-DrugBank.d175.s23.e0	DDI-DrugBank.d175.s23.e1
DDI-DrugBank.d175.s23	false	DDI-DrugBank.d175.s23.e0	DDI-DrugBank.d175.s23.e2
DDI-DrugBank.d175.s23	false	DDI-DrugBank.d175.s23.e1	DDI-DrugBank.d175.s23.e2
DDI-DrugBank.d175.s24|a|Drug/Laboratory Test Interaction Captopril may cause a false-positive urine test for acetone.
DDI-DrugBank.d175.s24	33	41	Captopril	drug	DDI-DrugBank.d175.s24.e0
DDI-DrugBank.d94.s0|a|Clinically meaningful drug interactions have occurred with concomitant medications and include, but are not limited to the following: Agents Highly Bound to Plasma Protein Carbamazepine is not highly bound to plasma proteins;
DDI-DrugBank.d94.s0	172	184	Carbamazepine	drug	DDI-DrugBank.d94.s0.e0
DDI-DrugBank.d94.s1|a|therefore, administration of EQUETROTM to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.
DDI-DrugBank.d94.s1	29	37	EQUETROTM	brand	DDI-DrugBank.d94.s1.e0
DDI-DrugBank.d94.s2|a|Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase Carbamazepine is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active carbamazepine 10,11-epoxide, which is further metabolized to the trans-diol by epoxide hydrolase.
DDI-DrugBank.d94.s2	72	84	Carbamazepine	drug	DDI-DrugBank.d94.s2.e0
DDI-DrugBank.d94.s2	151	177	carbamazepine 10,11-epoxide	drug	DDI-DrugBank.d94.s2.e1
DDI-DrugBank.d94.s2	false	DDI-DrugBank.d94.s2.e0	DDI-DrugBank.d94.s2.e1
DDI-DrugBank.d94.s3|a|Therefore, the potential exists for interaction between carbamazepine and any agent that inhibits CYP3A4 and/or epoxide hydrolase.
DDI-DrugBank.d94.s3	56	68	carbamazepine	drug	DDI-DrugBank.d94.s3.e0
DDI-DrugBank.d94.s4|a|Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4	102	110	EQUETROTM	brand	DDI-DrugBank.d94.s4.e0
DDI-DrugBank.d94.s4	131	143	Acetazolamide	drug	DDI-DrugBank.d94.s4.e1
DDI-DrugBank.d94.s4	146	162	azole antifungals	group	DDI-DrugBank.d94.s4.e2
DDI-DrugBank.d94.s4	165	174	cimetidine	drug	DDI-DrugBank.d94.s4.e3
DDI-DrugBank.d94.s4	177	190	clarithromycin	drug	DDI-DrugBank.d94.s4.e4
DDI-DrugBank.d94.s4	196	207	dalfopristin	drug	DDI-DrugBank.d94.s4.e5
DDI-DrugBank.d94.s4	210	216	danazol	drug	DDI-DrugBank.d94.s4.e6
DDI-DrugBank.d94.s4	219	229	delavirdine	drug	DDI-DrugBank.d94.s4.e7
DDI-DrugBank.d94.s4	232	240	diltiazem	drug	DDI-DrugBank.d94.s4.e8
DDI-DrugBank.d94.s4	243	254	erythromycin	drug	DDI-DrugBank.d94.s4.e9
DDI-DrugBank.d94.s4	true	DDI-DrugBank.d94.s4.e0	DDI-DrugBank.d94.s4.e1
DDI-DrugBank.d94.s4	true	DDI-DrugBank.d94.s4.e0	DDI-DrugBank.d94.s4.e2
DDI-DrugBank.d94.s4	true	DDI-DrugBank.d94.s4.e0	DDI-DrugBank.d94.s4.e3
DDI-DrugBank.d94.s4	true	DDI-DrugBank.d94.s4.e0	DDI-DrugBank.d94.s4.e4
DDI-DrugBank.d94.s4	true	DDI-DrugBank.d94.s4.e0	DDI-DrugBank.d94.s4.e5
DDI-DrugBank.d94.s4	true	DDI-DrugBank.d94.s4.e0	DDI-DrugBank.d94.s4.e6
DDI-DrugBank.d94.s4	true	DDI-DrugBank.d94.s4.e0	DDI-DrugBank.d94.s4.e7
DDI-DrugBank.d94.s4	true	DDI-DrugBank.d94.s4.e0	DDI-DrugBank.d94.s4.e8
DDI-DrugBank.d94.s4	true	DDI-DrugBank.d94.s4.e0	DDI-DrugBank.d94.s4.e9
DDI-DrugBank.d94.s4	true	DDI-DrugBank.d94.s4.e0	DDI-DrugBank.d94.s4.e10
DDI-DrugBank.d94.s5|a|Thus, if a patient has been titrated to a stable dosage of EQUETROTM, and then begins a course of treatment with one of these CYP3A4 or epoxide hydrolase inhibitors, it is reasonable to expect that a dose reduction for EQUETROTM may be necessary.
DDI-DrugBank.d94.s5	59	67	EQUETROTM	brand	DDI-DrugBank.d94.s5.e0
DDI-DrugBank.d94.s5	219	227	EQUETROTM	brand	DDI-DrugBank.d94.s5.e1
DDI-DrugBank.d94.s5	false	DDI-DrugBank.d94.s5.e0	DDI-DrugBank.d94.s5.e1
DDI-DrugBank.d94.s6|a|Agents that Induce Cytochrome P450 Isoenzymes Carbamazepine is metabolized by CYP3A4.
DDI-DrugBank.d94.s6	46	58	Carbamazepine	drug	DDI-DrugBank.d94.s6.e0
DDI-DrugBank.d94.s7|a|Therefore, the potential exists for interaction between carbamazepine and any agent that induces CYP3A4.
DDI-DrugBank.d94.s7	56	68	carbamazepine	drug	DDI-DrugBank.d94.s7.e0
DDI-DrugBank.d94.s8|a|Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
DDI-DrugBank.d94.s8	97	105	EQUETROTM	brand	DDI-DrugBank.d94.s8.e0
DDI-DrugBank.d94.s8	126	134	Cisplatin	drug	DDI-DrugBank.d94.s8.e1
DDI-DrugBank.d94.s8	137	151	doxorubicin HCL	drug	DDI-DrugBank.d94.s8.e2
DDI-DrugBank.d94.s8	154	162	felbamate	drug	DDI-DrugBank.d94.s8.e3
DDI-DrugBank.d94.s8	165	172	rifampin	drug	DDI-DrugBank.d94.s8.e4
DDI-DrugBank.d94.s8	175	187	phenobarbital	drug	DDI-DrugBank.d94.s8.e5
DDI-DrugBank.d94.s8	190	198	Phenytoin	drug	DDI-DrugBank.d94.s8.e6
DDI-DrugBank.d94.s8	204	212	primidone	drug	DDI-DrugBank.d94.s8.e7
DDI-DrugBank.d94.s8	215	226	methsuximide	drug	DDI-DrugBank.d94.s8.e8
DDI-DrugBank.d94.s8	233	244	theophylline	drug	DDI-DrugBank.d94.s8.e9
DDI-DrugBank.d94.s8	true	DDI-DrugBank.d94.s8.e0	DDI-DrugBank.d94.s8.e1
DDI-DrugBank.d94.s8	true	DDI-DrugBank.d94.s8.e0	DDI-DrugBank.d94.s8.e2
DDI-DrugBank.d94.s8	true	DDI-DrugBank.d94.s8.e0	DDI-DrugBank.d94.s8.e3
DDI-DrugBank.d94.s8	true	DDI-DrugBank.d94.s8.e0	DDI-DrugBank.d94.s8.e4
DDI-DrugBank.d94.s8	true	DDI-DrugBank.d94.s8.e0	DDI-DrugBank.d94.s8.e5
DDI-DrugBank.d94.s8	true	DDI-DrugBank.d94.s8.e0	DDI-DrugBank.d94.s8.e6
DDI-DrugBank.d94.s8	true	DDI-DrugBank.d94.s8.e0	DDI-DrugBank.d94.s8.e7
DDI-DrugBank.d94.s8	true	DDI-DrugBank.d94.s8.e0	DDI-DrugBank.d94.s8.e8
DDI-DrugBank.d94.s8	true	DDI-DrugBank.d94.s8.e0	DDI-DrugBank.d94.s8.e9
DDI-DrugBank.d94.s8	false	DDI-DrugBank.d94.s8.e0	DDI-DrugBank.d94.s8.e10
DDI-DrugBank.d94.s9|a|Agents with Decreased Levels in the Presence of Carbamazepine due to Induction of Cytochrome P450 Enzymes Carbamazepine is known to induce CYP1A2 and CYP3A4.
DDI-DrugBank.d94.s9	48	60	Carbamazepine	drug	DDI-DrugBank.d94.s9.e0
DDI-DrugBank.d94.s9	106	118	Carbamazepine	drug	DDI-DrugBank.d94.s9.e1
DDI-DrugBank.d94.s9	false	DDI-DrugBank.d94.s9.e0	DDI-DrugBank.d94.s9.e1
DDI-DrugBank.d94.s10|a|Therefore, the potential exists for interaction between carbamazepine and any agent metabolized by one (or more) of these enzymes.
DDI-DrugBank.d94.s10	56	68	carbamazepine	drug	DDI-DrugBank.d94.s10.e0
DDI-DrugBank.d94.s11|a|Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11	96	104	EQUETROTM	brand	DDI-DrugBank.d94.s11.e0
DDI-DrugBank.d94.s11	157	169	Acetaminophen	drug	DDI-DrugBank.d94.s11.e1
DDI-DrugBank.d94.s11	172	181	alprazolam	drug	DDI-DrugBank.d94.s11.e2
DDI-DrugBank.d94.s11	184	196	amitriptyline	drug	DDI-DrugBank.d94.s11.e3
DDI-DrugBank.d94.s11	199	207	bupropion	drug	DDI-DrugBank.d94.s11.e4
DDI-DrugBank.d94.s11	210	218	buspirone	drug	DDI-DrugBank.d94.s11.e5
DDI-DrugBank.d94.s11	221	230	citalopram	drug	DDI-DrugBank.d94.s11.e6
DDI-DrugBank.d94.s11	233	240	clobazam	drug	DDI-DrugBank.d94.s11.e7
DDI-DrugBank.d94.s11	243	252	clonazepam	drug	DDI-DrugBank.d94.s11.e8
DDI-DrugBank.d94.s11	255	263	clozapine	drug	DDI-DrugBank.d94.s11.e9
DDI-DrugBank.d94.s11	true	DDI-DrugBank.d94.s11.e0	DDI-DrugBank.d94.s11.e1
DDI-DrugBank.d94.s11	true	DDI-DrugBank.d94.s11.e0	DDI-DrugBank.d94.s11.e2
DDI-DrugBank.d94.s11	true	DDI-DrugBank.d94.s11.e0	DDI-DrugBank.d94.s11.e3
DDI-DrugBank.d94.s11	true	DDI-DrugBank.d94.s11.e0	DDI-DrugBank.d94.s11.e4
DDI-DrugBank.d94.s11	true	DDI-DrugBank.d94.s11.e0	DDI-DrugBank.d94.s11.e5
DDI-DrugBank.d94.s11	true	DDI-DrugBank.d94.s11.e0	DDI-DrugBank.d94.s11.e6
DDI-DrugBank.d94.s11	true	DDI-DrugBank.d94.s11.e0	DDI-DrugBank.d94.s11.e7
DDI-DrugBank.d94.s11	true	DDI-DrugBank.d94.s11.e0	DDI-DrugBank.d94.s11.e8
DDI-DrugBank.d94.s11	true	DDI-DrugBank.d94.s11.e0	DDI-DrugBank.d94.s11.e9
DDI-DrugBank.d94.s11	true	DDI-DrugBank.d94.s11.e0	DDI-DrugBank.d94.s11.e10
DDI-DrugBank.d94.s12|a|Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with EQUETROTM, it is reasonable to expect that a dose increase for the concomitant agent may be necessary.
DDI-DrugBank.d94.s12	138	146	EQUETROTM	brand	DDI-DrugBank.d94.s12.e0
DDI-DrugBank.d94.s13|a|Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
DDI-DrugBank.d94.s13	48	60	Carbamazepine	drug	DDI-DrugBank.d94.s13.e0
DDI-DrugBank.d94.s13	63	71	EQUETROTM	brand	DDI-DrugBank.d94.s13.e1
DDI-DrugBank.d94.s13	126	141	Clomipramine HCl	drug	DDI-DrugBank.d94.s13.e2
DDI-DrugBank.d94.s13	144	152	Phenytoin	drug	DDI-DrugBank.d94.s13.e3
DDI-DrugBank.d94.s13	162	170	primidone	drug	DDI-DrugBank.d94.s13.e4
DDI-DrugBank.d94.s13	314	322	EQUETROTM	brand	DDI-DrugBank.d94.s13.e5
DDI-DrugBank.d94.s13	false	DDI-DrugBank.d94.s13.e0	DDI-DrugBank.d94.s13.e1
DDI-DrugBank.d94.s13	false	DDI-DrugBank.d94.s13.e0	DDI-DrugBank.d94.s13.e2
DDI-DrugBank.d94.s13	false	DDI-DrugBank.d94.s13.e0	DDI-DrugBank.d94.s13.e3
DDI-DrugBank.d94.s13	false	DDI-DrugBank.d94.s13.e0	DDI-DrugBank.d94.s13.e4
DDI-DrugBank.d94.s13	false	DDI-DrugBank.d94.s13.e0	DDI-DrugBank.d94.s13.e5
DDI-DrugBank.d94.s13	true	DDI-DrugBank.d94.s13.e1	DDI-DrugBank.d94.s13.e2
DDI-DrugBank.d94.s13	true	DDI-DrugBank.d94.s13.e1	DDI-DrugBank.d94.s13.e3
DDI-DrugBank.d94.s13	true	DDI-DrugBank.d94.s13.e1	DDI-DrugBank.d94.s13.e4
DDI-DrugBank.d94.s13	false	DDI-DrugBank.d94.s13.e1	DDI-DrugBank.d94.s13.e5
DDI-DrugBank.d94.s13	false	DDI-DrugBank.d94.s13.e2	DDI-DrugBank.d94.s13.e3
DDI-DrugBank.d94.s14|a|Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.
DDI-DrugBank.d94.s14	50	62	Carbamazepine	drug	DDI-DrugBank.d94.s14.e0
DDI-DrugBank.d94.s14	94	106	carbamazepine	drug	DDI-DrugBank.d94.s14.e1
DDI-DrugBank.d94.s14	112	118	lithium	drug	DDI-DrugBank.d94.s14.e2
DDI-DrugBank.d94.s14	false	DDI-DrugBank.d94.s14.e0	DDI-DrugBank.d94.s14.e1
DDI-DrugBank.d94.s14	false	DDI-DrugBank.d94.s14.e0	DDI-DrugBank.d94.s14.e2
DDI-DrugBank.d94.s14	true	DDI-DrugBank.d94.s14.e1	DDI-DrugBank.d94.s14.e2
DDI-DrugBank.d94.s15|a|Given the anticonvulsant properties of carbamazepine, EQUETROTM may reduce the thyroid function as has been reported with other anticonvulsants.
DDI-DrugBank.d94.s15	39	51	carbamazepine	drug	DDI-DrugBank.d94.s15.e0
DDI-DrugBank.d94.s15	54	62	EQUETROTM	brand	DDI-DrugBank.d94.s15.e1
DDI-DrugBank.d94.s15	128	142	anticonvulsants	group	DDI-DrugBank.d94.s15.e2
DDI-DrugBank.d94.s15	false	DDI-DrugBank.d94.s15.e0	DDI-DrugBank.d94.s15.e1
DDI-DrugBank.d94.s15	false	DDI-DrugBank.d94.s15.e0	DDI-DrugBank.d94.s15.e2
DDI-DrugBank.d94.s15	false	DDI-DrugBank.d94.s15.e1	DDI-DrugBank.d94.s15.e2
DDI-DrugBank.d94.s16|a|Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
DDI-DrugBank.d94.s16	14	32	anti-malarial drugs	group	DDI-DrugBank.d94.s16.e0
DDI-DrugBank.d94.s16	43	53	chloroquine	drug	DDI-DrugBank.d94.s16.e1
DDI-DrugBank.d94.s16	59	68	mefloquine	drug	DDI-DrugBank.d94.s16.e2
DDI-DrugBank.d94.s16	102	114	carbamazepine	drug	DDI-DrugBank.d94.s16.e3
DDI-DrugBank.d94.s16	false	DDI-DrugBank.d94.s16.e0	DDI-DrugBank.d94.s16.e1
DDI-DrugBank.d94.s16	false	DDI-DrugBank.d94.s16.e0	DDI-DrugBank.d94.s16.e2
DDI-DrugBank.d94.s16	true	DDI-DrugBank.d94.s16.e0	DDI-DrugBank.d94.s16.e3
DDI-DrugBank.d94.s16	false	DDI-DrugBank.d94.s16.e1	DDI-DrugBank.d94.s16.e2
DDI-DrugBank.d94.s16	true	DDI-DrugBank.d94.s16.e1	DDI-DrugBank.d94.s16.e3
DDI-DrugBank.d94.s16	true	DDI-DrugBank.d94.s16.e2	DDI-DrugBank.d94.s16.e3
DDI-DrugBank.d94.s17|a|Thus if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with EQUETROTM, it is reasonable to expect that a dose adjustment may be necessary.
DDI-DrugBank.d94.s17	137	145	EQUETROTM	brand	DDI-DrugBank.d94.s17.e0
DDI-DrugBank.d94.s18|a|Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.
DDI-DrugBank.d94.s18	63	71	EQUETROTM	brand	DDI-DrugBank.d94.s18.e0
DDI-DrugBank.d94.s18	93	114	centrally acting drugs	group	DDI-DrugBank.d94.s18.e1
DDI-DrugBank.d94.s18	120	126	alcohol	drug	DDI-DrugBank.d94.s18.e2
DDI-DrugBank.d94.s18	true	DDI-DrugBank.d94.s18.e0	DDI-DrugBank.d94.s18.e1
DDI-DrugBank.d94.s18	true	DDI-DrugBank.d94.s18.e0	DDI-DrugBank.d94.s18.e2
DDI-DrugBank.d94.s18	false	DDI-DrugBank.d94.s18.e1	DDI-DrugBank.d94.s18.e2
DDI-DrugBank.d545.s0|a|Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.
DDI-DrugBank.d545.s0	0	8	Geocillin	brand	DDI-DrugBank.d545.s0.e0
DDI-DrugBank.d545.s0	11	38	carbenicillin indanyl sodium	drug	DDI-DrugBank.d545.s0.e1
DDI-DrugBank.d545.s0	117	126	probenecid	drug	DDI-DrugBank.d545.s0.e2
DDI-DrugBank.d545.s0	false	DDI-DrugBank.d545.s0.e0	DDI-DrugBank.d545.s0.e1
DDI-DrugBank.d545.s0	true	DDI-DrugBank.d545.s0.e0	DDI-DrugBank.d545.s0.e2
DDI-DrugBank.d545.s0	true	DDI-DrugBank.d545.s0.e1	DDI-DrugBank.d545.s0.e2
DDI-DrugBank.d47.s0|a|Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.
DDI-DrugBank.d47.s0	89	95	LODOSYN	brand	DDI-DrugBank.d47.s0.e0
DDI-DrugBank.d47.s0	98	106	Carbidopa	drug	DDI-DrugBank.d47.s0.e1
DDI-DrugBank.d47.s0	120	127	levodopa	drug	DDI-DrugBank.d47.s0.e2
DDI-DrugBank.d47.s0	132	140	carbidopa	drug	DDI-DrugBank.d47.s0.e3
DDI-DrugBank.d47.s0	142	149	levodopa	drug	DDI-DrugBank.d47.s0.e4
DDI-DrugBank.d47.s0	false	DDI-DrugBank.d47.s0.e0	DDI-DrugBank.d47.s0.e1
DDI-DrugBank.d47.s0	false	DDI-DrugBank.d47.s0.e0	DDI-DrugBank.d47.s0.e2
DDI-DrugBank.d47.s0	false	DDI-DrugBank.d47.s0.e0	DDI-DrugBank.d47.s0.e3
DDI-DrugBank.d47.s0	false	DDI-DrugBank.d47.s0.e0	DDI-DrugBank.d47.s0.e4
DDI-DrugBank.d47.s0	false	DDI-DrugBank.d47.s0.e1	DDI-DrugBank.d47.s0.e2
DDI-DrugBank.d47.s0	false	DDI-DrugBank.d47.s0.e1	DDI-DrugBank.d47.s0.e3
DDI-DrugBank.d47.s0	false	DDI-DrugBank.d47.s0.e1	DDI-DrugBank.d47.s0.e4
DDI-DrugBank.d47.s0	false	DDI-DrugBank.d47.s0.e2	DDI-DrugBank.d47.s0.e3
DDI-DrugBank.d47.s0	false	DDI-DrugBank.d47.s0.e2	DDI-DrugBank.d47.s0.e4
DDI-DrugBank.d47.s0	false	DDI-DrugBank.d47.s0.e3	DDI-DrugBank.d47.s0.e4
DDI-DrugBank.d47.s1|a|For patients receiving monoamine oxidase inhibitors, see CONTRAINDICATIONS.
DDI-DrugBank.d47.s1	23	50	monoamine oxidase inhibitors	group	DDI-DrugBank.d47.s1.e0
DDI-DrugBank.d47.s2|a|Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
DDI-DrugBank.d47.s2	0	31	Dopamine D2 receptor antagonists	group	DDI-DrugBank.d47.s2.e0
DDI-DrugBank.d47.s2	40	53	phenothiazines	group	DDI-DrugBank.d47.s2.e1
DDI-DrugBank.d47.s2	56	69	butyrophenones	group	DDI-DrugBank.d47.s2.e2
DDI-DrugBank.d47.s2	72	82	risperidone	drug	DDI-DrugBank.d47.s2.e3
DDI-DrugBank.d47.s2	89	97	isoniazid	drug	DDI-DrugBank.d47.s2.e4
DDI-DrugBank.d47.s2	137	144	levodopa	drug	DDI-DrugBank.d47.s2.e5
DDI-DrugBank.d47.s2	false	DDI-DrugBank.d47.s2.e0	DDI-DrugBank.d47.s2.e1
DDI-DrugBank.d47.s2	false	DDI-DrugBank.d47.s2.e0	DDI-DrugBank.d47.s2.e2
DDI-DrugBank.d47.s2	false	DDI-DrugBank.d47.s2.e0	DDI-DrugBank.d47.s2.e3
DDI-DrugBank.d47.s2	false	DDI-DrugBank.d47.s2.e0	DDI-DrugBank.d47.s2.e4
DDI-DrugBank.d47.s2	true	DDI-DrugBank.d47.s2.e0	DDI-DrugBank.d47.s2.e5
DDI-DrugBank.d47.s2	false	DDI-DrugBank.d47.s2.e1	DDI-DrugBank.d47.s2.e2
DDI-DrugBank.d47.s2	false	DDI-DrugBank.d47.s2.e1	DDI-DrugBank.d47.s2.e3
DDI-DrugBank.d47.s2	false	DDI-DrugBank.d47.s2.e1	DDI-DrugBank.d47.s2.e4
DDI-DrugBank.d47.s2	true	DDI-DrugBank.d47.s2.e1	DDI-DrugBank.d47.s2.e5
DDI-DrugBank.d47.s2	false	DDI-DrugBank.d47.s2.e2	DDI-DrugBank.d47.s2.e3
DDI-DrugBank.d47.s3|a|In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
DDI-DrugBank.d47.s3	39	46	levodopa	drug	DDI-DrugBank.d47.s3.e0
DDI-DrugBank.d47.s3	107	115	phenytoin	drug	DDI-DrugBank.d47.s3.e1
DDI-DrugBank.d47.s3	121	130	papaverine	drug	DDI-DrugBank.d47.s3.e2
DDI-DrugBank.d47.s3	true	DDI-DrugBank.d47.s3.e0	DDI-DrugBank.d47.s3.e1
DDI-DrugBank.d47.s3	true	DDI-DrugBank.d47.s3.e0	DDI-DrugBank.d47.s3.e2
DDI-DrugBank.d47.s3	false	DDI-DrugBank.d47.s3.e1	DDI-DrugBank.d47.s3.e2
DDI-DrugBank.d47.s4|a|Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.
DDI-DrugBank.d47.s4	33	39	LODOSYN	brand	DDI-DrugBank.d47.s4.e0
DDI-DrugBank.d47.s4	45	52	levodopa	drug	DDI-DrugBank.d47.s4.e1
DDI-DrugBank.d47.s4	57	65	carbidopa	drug	DDI-DrugBank.d47.s4.e2
DDI-DrugBank.d47.s4	67	74	levodopa	drug	DDI-DrugBank.d47.s4.e3
DDI-DrugBank.d47.s4	false	DDI-DrugBank.d47.s4.e0	DDI-DrugBank.d47.s4.e1
DDI-DrugBank.d47.s4	false	DDI-DrugBank.d47.s4.e0	DDI-DrugBank.d47.s4.e2
DDI-DrugBank.d47.s4	false	DDI-DrugBank.d47.s4.e0	DDI-DrugBank.d47.s4.e3
DDI-DrugBank.d47.s4	false	DDI-DrugBank.d47.s4.e1	DDI-DrugBank.d47.s4.e2
DDI-DrugBank.d47.s4	false	DDI-DrugBank.d47.s4.e1	DDI-DrugBank.d47.s4.e3
DDI-DrugBank.d47.s4	false	DDI-DrugBank.d47.s4.e2	DDI-DrugBank.d47.s4.e3
DDI-DrugBank.d47.s5|a|Iron salts may reduce the bioavailability of carbidopa and levodopa.
DDI-DrugBank.d47.s5	0	3	Iron	drug	DDI-DrugBank.d47.s5.e0
DDI-DrugBank.d47.s5	45	53	carbidopa	drug	DDI-DrugBank.d47.s5.e1
DDI-DrugBank.d47.s5	59	66	levodopa	drug	DDI-DrugBank.d47.s5.e2
DDI-DrugBank.d47.s5	true	DDI-DrugBank.d47.s5.e0	DDI-DrugBank.d47.s5.e1
DDI-DrugBank.d47.s5	true	DDI-DrugBank.d47.s5.e0	DDI-DrugBank.d47.s5.e2
DDI-DrugBank.d47.s5	false	DDI-DrugBank.d47.s5.e1	DDI-DrugBank.d47.s5.e2
DDI-DrugBank.d47.s6|a|The clinical relevance is unclear.
DDI-DrugBank.d47.s7|a|Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
DDI-DrugBank.d47.s7	9	22	metoclopramide	drug	DDI-DrugBank.d47.s7.e0
DDI-DrugBank.d47.s7	60	67	levodopa	drug	DDI-DrugBank.d47.s7.e1
DDI-DrugBank.d47.s7	101	114	metoclopramide	drug	DDI-DrugBank.d47.s7.e2
DDI-DrugBank.d47.s7	true	DDI-DrugBank.d47.s7.e0	DDI-DrugBank.d47.s7.e1
DDI-DrugBank.d47.s7	false	DDI-DrugBank.d47.s7.e0	DDI-DrugBank.d47.s7.e2
DDI-DrugBank.d47.s7	false	DDI-DrugBank.d47.s7.e1	DDI-DrugBank.d47.s7.e2
DDI-DrugBank.d213.s0|a|Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
DDI-DrugBank.d213.s0	0	5	Iodine	drug	DDI-DrugBank.d213.s0.e0
DDI-DrugBank.d213.s0	10	15	iodine	drug	DDI-DrugBank.d213.s0.e1
DDI-DrugBank.d213.s0	51	61	Carbimazole	drug	DDI-DrugBank.d213.s0.e2
DDI-DrugBank.d213.s0	71	76	iodine	drug	DDI-DrugBank.d213.s0.e3
DDI-DrugBank.d213.s0	116	126	Carbimazole	drug	DDI-DrugBank.d213.s0.e4
DDI-DrugBank.d213.s0	false	DDI-DrugBank.d213.s0.e0	DDI-DrugBank.d213.s0.e1
DDI-DrugBank.d213.s0	true	DDI-DrugBank.d213.s0.e0	DDI-DrugBank.d213.s0.e2
DDI-DrugBank.d213.s0	false	DDI-DrugBank.d213.s0.e0	DDI-DrugBank.d213.s0.e3
DDI-DrugBank.d213.s0	false	DDI-DrugBank.d213.s0.e0	DDI-DrugBank.d213.s0.e4
DDI-DrugBank.d213.s0	false	DDI-DrugBank.d213.s0.e1	DDI-DrugBank.d213.s0.e2
DDI-DrugBank.d213.s0	false	DDI-DrugBank.d213.s0.e1	DDI-DrugBank.d213.s0.e3
DDI-DrugBank.d213.s0	false	DDI-DrugBank.d213.s0.e1	DDI-DrugBank.d213.s0.e4
DDI-DrugBank.d213.s0	false	DDI-DrugBank.d213.s0.e2	DDI-DrugBank.d213.s0.e3
DDI-DrugBank.d213.s0	false	DDI-DrugBank.d213.s0.e2	DDI-DrugBank.d213.s0.e4
DDI-DrugBank.d213.s0	true	DDI-DrugBank.d213.s0.e3	DDI-DrugBank.d213.s0.e4
DDI-DrugBank.d213.s1|a|Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.
DDI-DrugBank.d213.s1	23	29	digoxin	drug	DDI-DrugBank.d213.s1.e0
DDI-DrugBank.d213.s1	35	43	digitoxin	drug	DDI-DrugBank.d213.s1.e1
DDI-DrugBank.d213.s1	77	94	antithyroid agents	group	DDI-DrugBank.d213.s1.e2
DDI-DrugBank.d213.s1	false	DDI-DrugBank.d213.s1.e0	DDI-DrugBank.d213.s1.e1
DDI-DrugBank.d213.s1	true	DDI-DrugBank.d213.s1.e0	DDI-DrugBank.d213.s1.e2
DDI-DrugBank.d213.s1	true	DDI-DrugBank.d213.s1.e1	DDI-DrugBank.d213.s1.e2
DDI-DrugBank.d213.s2|a|A decrease of the dosage may be necessary when patient becomes euthyroid.
DDI-DrugBank.d213.s3|a|Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.
DDI-DrugBank.d213.s3	0	17	Antithyroid agents	group	DDI-DrugBank.d213.s3.e0
DDI-DrugBank.d213.s3	52	69	sodium iodide I131	drug	DDI-DrugBank.d213.s3.e1
DDI-DrugBank.d213.s3	142	152	Carbimazole	drug	DDI-DrugBank.d213.s3.e2
DDI-DrugBank.d213.s3	true	DDI-DrugBank.d213.s3.e0	DDI-DrugBank.d213.s3.e1
DDI-DrugBank.d213.s3	false	DDI-DrugBank.d213.s3.e0	DDI-DrugBank.d213.s3.e2
DDI-DrugBank.d213.s3	false	DDI-DrugBank.d213.s3.e1	DDI-DrugBank.d213.s3.e2
DDI-DrugBank.d213.s4|a|Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status.
DDI-DrugBank.d213.s4	26	39	anticoagulants	group	DDI-DrugBank.d213.s4.e0
DDI-DrugBank.d213.s5|a|An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended
DDI-DrugBank.d213.s5	55	67	anticoagulant	group	DDI-DrugBank.d213.s5.e0
DDI-DrugBank.d389.s0|a|Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
DDI-DrugBank.d389.s0	0	13	Antihistamines	group	DDI-DrugBank.d389.s0.e0
DDI-DrugBank.d389.s0	42	66	tricyclic antidepressants	group	DDI-DrugBank.d389.s0.e1
DDI-DrugBank.d389.s0	69	80	barbiturates	group	DDI-DrugBank.d389.s0.e2
DDI-DrugBank.d389.s0	83	89	alcohol	drug	DDI-DrugBank.d389.s0.e3
DDI-DrugBank.d389.s0	102	116	CNS depressants	group	DDI-DrugBank.d389.s0.e4
DDI-DrugBank.d389.s0	true	DDI-DrugBank.d389.s0.e0	DDI-DrugBank.d389.s0.e1
DDI-DrugBank.d389.s0	true	DDI-DrugBank.d389.s0.e0	DDI-DrugBank.d389.s0.e2
DDI-DrugBank.d389.s0	true	DDI-DrugBank.d389.s0.e0	DDI-DrugBank.d389.s0.e3
DDI-DrugBank.d389.s0	true	DDI-DrugBank.d389.s0.e0	DDI-DrugBank.d389.s0.e4
DDI-DrugBank.d389.s0	false	DDI-DrugBank.d389.s0.e1	DDI-DrugBank.d389.s0.e2
DDI-DrugBank.d389.s0	false	DDI-DrugBank.d389.s0.e1	DDI-DrugBank.d389.s0.e3
DDI-DrugBank.d389.s0	false	DDI-DrugBank.d389.s0.e1	DDI-DrugBank.d389.s0.e4
DDI-DrugBank.d389.s0	false	DDI-DrugBank.d389.s0.e2	DDI-DrugBank.d389.s0.e3
DDI-DrugBank.d389.s0	false	DDI-DrugBank.d389.s0.e2	DDI-DrugBank.d389.s0.e4
DDI-DrugBank.d389.s0	false	DDI-DrugBank.d389.s0.e3	DDI-DrugBank.d389.s0.e4
DDI-DrugBank.d389.s1|a|MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
DDI-DrugBank.d389.s1	0	13	MAO inhibitors	group	DDI-DrugBank.d389.s1.e0
DDI-DrugBank.d389.s1	68	81	antihistamines	group	DDI-DrugBank.d389.s1.e1
DDI-DrugBank.d389.s1	true	DDI-DrugBank.d389.s1.e0	DDI-DrugBank.d389.s1.e1
DDI-DrugBank.d389.s2|a|Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
DDI-DrugBank.d389.s2	0	21	Sympathomimetic amines	group	DDI-DrugBank.d389.s2.e0
DDI-DrugBank.d389.s2	66	74	reserpine	drug	DDI-DrugBank.d389.s2.e1
DDI-DrugBank.d389.s2	77	94	veratrum alkaloids	group	DDI-DrugBank.d389.s2.e2
DDI-DrugBank.d389.s2	97	106	methyldopa	drug	DDI-DrugBank.d389.s2.e3
DDI-DrugBank.d389.s2	112	123	mecamylamine	drug	DDI-DrugBank.d389.s2.e4
DDI-DrugBank.d389.s2	true	DDI-DrugBank.d389.s2.e0	DDI-DrugBank.d389.s2.e1
DDI-DrugBank.d389.s2	true	DDI-DrugBank.d389.s2.e0	DDI-DrugBank.d389.s2.e2
DDI-DrugBank.d389.s2	true	DDI-DrugBank.d389.s2.e0	DDI-DrugBank.d389.s2.e3
DDI-DrugBank.d389.s2	true	DDI-DrugBank.d389.s2.e0	DDI-DrugBank.d389.s2.e4
DDI-DrugBank.d389.s2	false	DDI-DrugBank.d389.s2.e1	DDI-DrugBank.d389.s2.e2
DDI-DrugBank.d389.s2	false	DDI-DrugBank.d389.s2.e1	DDI-DrugBank.d389.s2.e3
DDI-DrugBank.d389.s2	false	DDI-DrugBank.d389.s2.e1	DDI-DrugBank.d389.s2.e4
DDI-DrugBank.d389.s2	false	DDI-DrugBank.d389.s2.e2	DDI-DrugBank.d389.s2.e3
DDI-DrugBank.d389.s2	false	DDI-DrugBank.d389.s2.e2	DDI-DrugBank.d389.s2.e4
DDI-DrugBank.d389.s2	false	DDI-DrugBank.d389.s2.e3	DDI-DrugBank.d389.s2.e4
DDI-DrugBank.d389.s3|a|Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.
DDI-DrugBank.d389.s3	11	26	sympathomimetics	group	DDI-DrugBank.d389.s3.e0
DDI-DrugBank.d389.s3	47	60	MAO inhibitors	group	DDI-DrugBank.d389.s3.e1
DDI-DrugBank.d389.s3	66	89	beta adrenergic blockers	group	DDI-DrugBank.d389.s3.e2
DDI-DrugBank.d389.s3	true	DDI-DrugBank.d389.s3.e0	DDI-DrugBank.d389.s3.e1
DDI-DrugBank.d389.s3	true	DDI-DrugBank.d389.s3.e0	DDI-DrugBank.d389.s3.e2
DDI-DrugBank.d389.s3	false	DDI-DrugBank.d389.s3.e1	DDI-DrugBank.d389.s3.e2
DDI-DrugBank.d520.s0|a|The renal effects of nephrotoxic compounds may be potentiated by Carboplatin.
DDI-DrugBank.d520.s0	65	75	Carboplatin	drug	DDI-DrugBank.d520.s0.e0
DDI-DrugBank.d23.s0|a|HEMABATE may augment the activity of other oxytocic agents.
DDI-DrugBank.d23.s0	0	7	HEMABATE	brand	DDI-DrugBank.d23.s0.e0
DDI-DrugBank.d23.s0	43	57	oxytocic agents	group	DDI-DrugBank.d23.s0.e1
DDI-DrugBank.d23.s0	true	DDI-DrugBank.d23.s0.e0	DDI-DrugBank.d23.s0.e1
DDI-DrugBank.d23.s1|a|Concomitant use with other oxytocic agents is not recommended
DDI-DrugBank.d23.s1	27	41	oxytocic agents	group	DDI-DrugBank.d23.s1.e0
DDI-DrugBank.d23.s2|a|.
DDI-DrugBank.d23.s3|a|
DDI-DrugBank.d502.s0|a|Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.
DDI-DrugBank.d502.s0	0	7	Ocupress	brand	DDI-DrugBank.d502.s0.e0
DDI-DrugBank.d502.s0	69	98	beta-adrenergic blocking agent	group	DDI-DrugBank.d502.s0.e1
DDI-DrugBank.d502.s0	true	DDI-DrugBank.d502.s0.e0	DDI-DrugBank.d502.s0.e1
DDI-DrugBank.d502.s1|a|Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
DDI-DrugBank.d502.s1	55	66	beta-blocker	group	DDI-DrugBank.d502.s1.e0
DDI-DrugBank.d502.s1	144	152	reserpine	drug	DDI-DrugBank.d502.s1.e1
DDI-DrugBank.d502.s1	true	DDI-DrugBank.d502.s1.e0	DDI-DrugBank.d502.s1.e1
DDI-DrugBank.d269.s0|a|Inhibitors of CYP2D6;
DDI-DrugBank.d269.s1|a|poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
DDI-DrugBank.d269.s1	21	31	debrisoquin	drug	DDI-DrugBank.d269.s1.e0
DDI-DrugBank.d269.s1	50	59	carvedilol	drug	DDI-DrugBank.d269.s1.e1
DDI-DrugBank.d269.s1	103	111	quinidine	drug	DDI-DrugBank.d269.s1.e2
DDI-DrugBank.d269.s1	114	123	fluoxetine	drug	DDI-DrugBank.d269.s1.e3
DDI-DrugBank.d269.s1	126	135	paroxetine	drug	DDI-DrugBank.d269.s1.e4
DDI-DrugBank.d269.s1	142	152	propafenone	drug	DDI-DrugBank.d269.s1.e5
DDI-DrugBank.d269.s1	263	272	carvedilol	drug	DDI-DrugBank.d269.s1.e6
DDI-DrugBank.d269.s1	false	DDI-DrugBank.d269.s1.e0	DDI-DrugBank.d269.s1.e1
DDI-DrugBank.d269.s1	false	DDI-DrugBank.d269.s1.e0	DDI-DrugBank.d269.s1.e2
DDI-DrugBank.d269.s1	false	DDI-DrugBank.d269.s1.e0	DDI-DrugBank.d269.s1.e3
DDI-DrugBank.d269.s1	false	DDI-DrugBank.d269.s1.e0	DDI-DrugBank.d269.s1.e4
DDI-DrugBank.d269.s1	false	DDI-DrugBank.d269.s1.e0	DDI-DrugBank.d269.s1.e5
DDI-DrugBank.d269.s1	false	DDI-DrugBank.d269.s1.e0	DDI-DrugBank.d269.s1.e6
DDI-DrugBank.d269.s1	false	DDI-DrugBank.d269.s1.e1	DDI-DrugBank.d269.s1.e2
DDI-DrugBank.d269.s1	false	DDI-DrugBank.d269.s1.e1	DDI-DrugBank.d269.s1.e3
DDI-DrugBank.d269.s1	false	DDI-DrugBank.d269.s1.e1	DDI-DrugBank.d269.s1.e4
DDI-DrugBank.d269.s1	false	DDI-DrugBank.d269.s1.e1	DDI-DrugBank.d269.s1.e5
DDI-DrugBank.d269.s2|a|Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the a-blocking R(+) enantiomer.
DDI-DrugBank.d269.s3|a|Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.
DDI-DrugBank.d269.s3	53	85	agents with b-blocking properties	group	DDI-DrugBank.d269.s3.e0
DDI-DrugBank.d269.s3	137	145	reserpine	drug	DDI-DrugBank.d269.s3.e1
DDI-DrugBank.d269.s3	151	178	monoamine oxidase inhibitors	group	DDI-DrugBank.d269.s3.e2
DDI-DrugBank.d269.s3	true	DDI-DrugBank.d269.s3.e0	DDI-DrugBank.d269.s3.e1
DDI-DrugBank.d269.s3	true	DDI-DrugBank.d269.s3.e0	DDI-DrugBank.d269.s3.e2
DDI-DrugBank.d269.s3	false	DDI-DrugBank.d269.s3.e1	DDI-DrugBank.d269.s3.e2
DDI-DrugBank.d269.s4|a|Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.
DDI-DrugBank.d269.s4	0	8	Clonidine	drug	DDI-DrugBank.d269.s4.e0
DDI-DrugBank.d269.s4	41	49	clonidine	drug	DDI-DrugBank.d269.s4.e1
DDI-DrugBank.d269.s4	56	88	agents with b-blocking properties	group	DDI-DrugBank.d269.s4.e2
DDI-DrugBank.d269.s4	false	DDI-DrugBank.d269.s4.e0	DDI-DrugBank.d269.s4.e1
DDI-DrugBank.d269.s4	false	DDI-DrugBank.d269.s4.e0	DDI-DrugBank.d269.s4.e2
DDI-DrugBank.d269.s4	true	DDI-DrugBank.d269.s4.e1	DDI-DrugBank.d269.s4.e2
DDI-DrugBank.d269.s5|a|When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.
DDI-DrugBank.d269.s5	32	64	agents with b-blocking properties	group	DDI-DrugBank.d269.s5.e0
DDI-DrugBank.d269.s5	70	78	clonidine	drug	DDI-DrugBank.d269.s5.e1
DDI-DrugBank.d269.s5	105	120	b-blocking agent	group	DDI-DrugBank.d269.s5.e2
DDI-DrugBank.d269.s5	true	DDI-DrugBank.d269.s5.e0	DDI-DrugBank.d269.s5.e1
DDI-DrugBank.d269.s5	false	DDI-DrugBank.d269.s5.e0	DDI-DrugBank.d269.s5.e2
DDI-DrugBank.d269.s5	false	DDI-DrugBank.d269.s5.e1	DDI-DrugBank.d269.s5.e2
DDI-DrugBank.d269.s6|a|Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.
DDI-DrugBank.d269.s6	0	8	Clonidine	drug	DDI-DrugBank.d269.s6.e0
DDI-DrugBank.d269.s7|a|Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.
DDI-DrugBank.d269.s7	0	11	Cyclosporine	drug	DDI-DrugBank.d269.s7.e0
DDI-DrugBank.d269.s7	46	57	cyclosporine	drug	DDI-DrugBank.d269.s7.e1
DDI-DrugBank.d269.s7	112	121	carvedilol	drug	DDI-DrugBank.d269.s7.e2
DDI-DrugBank.d269.s7	false	DDI-DrugBank.d269.s7.e0	DDI-DrugBank.d269.s7.e1
DDI-DrugBank.d269.s7	false	DDI-DrugBank.d269.s7.e0	DDI-DrugBank.d269.s7.e2
DDI-DrugBank.d269.s7	true	DDI-DrugBank.d269.s7.e1	DDI-DrugBank.d269.s7.e2
DDI-DrugBank.d269.s8|a|In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.
DDI-DrugBank.d269.s8	38	49	cyclosporine	drug	DDI-DrugBank.d269.s8.e0
DDI-DrugBank.d269.s8	90	101	cyclosporine	drug	DDI-DrugBank.d269.s8.e1
DDI-DrugBank.d269.s8	false	DDI-DrugBank.d269.s8.e0	DDI-DrugBank.d269.s8.e1
DDI-DrugBank.d269.s9|a|On the average for the group, the dose of cyclosporine was reduced about 20% in these patients.
DDI-DrugBank.d269.s9	42	53	cyclosporine	drug	DDI-DrugBank.d269.s9.e0
DDI-DrugBank.d269.s10|a|Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
DDI-DrugBank.d269.s10	96	107	cyclosporine	drug	DDI-DrugBank.d269.s10.e0
DDI-DrugBank.d269.s10	165	174	carvedilol	drug	DDI-DrugBank.d269.s10.e1
DDI-DrugBank.d269.s10	205	216	cyclosporine	drug	DDI-DrugBank.d269.s10.e2
DDI-DrugBank.d269.s10	true	DDI-DrugBank.d269.s10.e0	DDI-DrugBank.d269.s10.e1
DDI-DrugBank.d269.s10	false	DDI-DrugBank.d269.s10.e0	DDI-DrugBank.d269.s10.e2
DDI-DrugBank.d269.s10	true	DDI-DrugBank.d269.s10.e1	DDI-DrugBank.d269.s10.e2
DDI-DrugBank.d269.s11|a|Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.
DDI-DrugBank.d269.s11	0	6	Digoxin	drug	DDI-DrugBank.d269.s11.e0
DDI-DrugBank.d269.s11	9	15	Digoxin	drug	DDI-DrugBank.d269.s11.e1
DDI-DrugBank.d269.s11	64	70	digoxin	drug	DDI-DrugBank.d269.s11.e2
DDI-DrugBank.d269.s11	76	85	carvedilol	drug	DDI-DrugBank.d269.s11.e3
DDI-DrugBank.d269.s11	false	DDI-DrugBank.d269.s11.e0	DDI-DrugBank.d269.s11.e1
DDI-DrugBank.d269.s11	false	DDI-DrugBank.d269.s11.e0	DDI-DrugBank.d269.s11.e2
DDI-DrugBank.d269.s11	false	DDI-DrugBank.d269.s11.e0	DDI-DrugBank.d269.s11.e3
DDI-DrugBank.d269.s11	false	DDI-DrugBank.d269.s11.e1	DDI-DrugBank.d269.s11.e2
DDI-DrugBank.d269.s11	false	DDI-DrugBank.d269.s11.e1	DDI-DrugBank.d269.s11.e3
DDI-DrugBank.d269.s11	true	DDI-DrugBank.d269.s11.e2	DDI-DrugBank.d269.s11.e3
DDI-DrugBank.d269.s12|a|Both digoxin and COREG slow AV conduction.
DDI-DrugBank.d269.s12	5	11	digoxin	drug	DDI-DrugBank.d269.s12.e0
DDI-DrugBank.d269.s12	17	21	COREG	brand	DDI-DrugBank.d269.s12.e1
DDI-DrugBank.d269.s12	true	DDI-DrugBank.d269.s12.e0	DDI-DrugBank.d269.s12.e1
DDI-DrugBank.d269.s13|a|Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.
DDI-DrugBank.d269.s13	35	41	digoxin	drug	DDI-DrugBank.d269.s13.e0
DDI-DrugBank.d269.s13	103	107	COREG	brand	DDI-DrugBank.d269.s13.e1
DDI-DrugBank.d269.s13	true	DDI-DrugBank.d269.s13.e0	DDI-DrugBank.d269.s13.e1
DDI-DrugBank.d269.s14|a|Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.
DDI-DrugBank.d269.s14	47	54	Rifampin	drug	DDI-DrugBank.d269.s14.e0
DDI-DrugBank.d269.s14	89	98	carvedilol	drug	DDI-DrugBank.d269.s14.e1
DDI-DrugBank.d269.s14	true	DDI-DrugBank.d269.s14.e0	DDI-DrugBank.d269.s14.e1
DDI-DrugBank.d269.s15|a|Cimetidine increased AUC by about 30% but caused no change in Cmax.
DDI-DrugBank.d269.s15	0	9	Cimetidine	drug	DDI-DrugBank.d269.s15.e0
DDI-DrugBank.d269.s16|a|Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.
DDI-DrugBank.d269.s16	0	23	Calcium Channel Blockers	group	DDI-DrugBank.d269.s16.e0
DDI-DrugBank.d269.s16	128	132	COREG	brand	DDI-DrugBank.d269.s16.e1
DDI-DrugBank.d269.s16	158	166	diltiazem	drug	DDI-DrugBank.d269.s16.e2
DDI-DrugBank.d269.s16	false	DDI-DrugBank.d269.s16.e0	DDI-DrugBank.d269.s16.e1
DDI-DrugBank.d269.s16	false	DDI-DrugBank.d269.s16.e0	DDI-DrugBank.d269.s16.e2
DDI-DrugBank.d269.s16	true	DDI-DrugBank.d269.s16.e1	DDI-DrugBank.d269.s16.e2
DDI-DrugBank.d269.s17|a|As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
DDI-DrugBank.d269.s17	14	46	agents with b-blocking properties	group	DDI-DrugBank.d269.s17.e0
DDI-DrugBank.d269.s17	52	56	COREG	brand	DDI-DrugBank.d269.s17.e1
DDI-DrugBank.d269.s17	92	115	calcium channel blockers	group	DDI-DrugBank.d269.s17.e2
DDI-DrugBank.d269.s17	124	132	verapamil	drug	DDI-DrugBank.d269.s17.e3
DDI-DrugBank.d269.s17	137	145	diltiazem	drug	DDI-DrugBank.d269.s17.e4
DDI-DrugBank.d269.s17	false	DDI-DrugBank.d269.s17.e0	DDI-DrugBank.d269.s17.e1
DDI-DrugBank.d269.s17	false	DDI-DrugBank.d269.s17.e0	DDI-DrugBank.d269.s17.e2
DDI-DrugBank.d269.s17	false	DDI-DrugBank.d269.s17.e0	DDI-DrugBank.d269.s17.e3
DDI-DrugBank.d269.s17	false	DDI-DrugBank.d269.s17.e0	DDI-DrugBank.d269.s17.e4
DDI-DrugBank.d269.s17	false	DDI-DrugBank.d269.s17.e1	DDI-DrugBank.d269.s17.e2
DDI-DrugBank.d269.s17	true	DDI-DrugBank.d269.s17.e1	DDI-DrugBank.d269.s17.e3
DDI-DrugBank.d269.s17	true	DDI-DrugBank.d269.s17.e1	DDI-DrugBank.d269.s17.e4
DDI-DrugBank.d269.s17	false	DDI-DrugBank.d269.s17.e2	DDI-DrugBank.d269.s17.e3
DDI-DrugBank.d269.s17	false	DDI-DrugBank.d269.s17.e2	DDI-DrugBank.d269.s17.e4
DDI-DrugBank.d269.s17	false	DDI-DrugBank.d269.s17.e3	DDI-DrugBank.d269.s17.e4
DDI-DrugBank.d269.s18|a|Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.
DDI-DrugBank.d269.s18	0	6	Insulin	drug	DDI-DrugBank.d269.s18.e0
DDI-DrugBank.d269.s18	16	28	Hypoglycemics	group	DDI-DrugBank.d269.s18.e1
DDI-DrugBank.d269.s18	31	63	Agents with b-blocking properties	group	DDI-DrugBank.d269.s18.e2
DDI-DrugBank.d269.s18	112	118	insulin	drug	DDI-DrugBank.d269.s18.e3
DDI-DrugBank.d269.s18	129	141	hypoglycemics	group	DDI-DrugBank.d269.s18.e4
DDI-DrugBank.d269.s18	false	DDI-DrugBank.d269.s18.e0	DDI-DrugBank.d269.s18.e1
DDI-DrugBank.d269.s18	false	DDI-DrugBank.d269.s18.e0	DDI-DrugBank.d269.s18.e2
DDI-DrugBank.d269.s18	false	DDI-DrugBank.d269.s18.e0	DDI-DrugBank.d269.s18.e3
DDI-DrugBank.d269.s18	false	DDI-DrugBank.d269.s18.e0	DDI-DrugBank.d269.s18.e4
DDI-DrugBank.d269.s18	false	DDI-DrugBank.d269.s18.e1	DDI-DrugBank.d269.s18.e2
DDI-DrugBank.d269.s18	false	DDI-DrugBank.d269.s18.e1	DDI-DrugBank.d269.s18.e3
DDI-DrugBank.d269.s18	false	DDI-DrugBank.d269.s18.e1	DDI-DrugBank.d269.s18.e4
DDI-DrugBank.d269.s18	true	DDI-DrugBank.d269.s18.e2	DDI-DrugBank.d269.s18.e3
DDI-DrugBank.d269.s18	true	DDI-DrugBank.d269.s18.e2	DDI-DrugBank.d269.s18.e4
DDI-DrugBank.d269.s18	false	DDI-DrugBank.d269.s18.e3	DDI-DrugBank.d269.s18.e4
DDI-DrugBank.d269.s19|a|Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended.
DDI-DrugBank.d269.s19	30	36	insulin	drug	DDI-DrugBank.d269.s19.e0
DDI-DrugBank.d269.s19	46	58	hypoglycemics	group	DDI-DrugBank.d269.s19.e1
DDI-DrugBank.d269.s19	false	DDI-DrugBank.d269.s19.e0	DDI-DrugBank.d269.s19.e1
DDI-DrugBank.d350.s0|a|Studies in vitro show that caspofungin acetate is not an inhibitor of any enzyme in the cytochrome P450 (CYP) system.
DDI-DrugBank.d350.s0	27	45	caspofungin acetate	drug	DDI-DrugBank.d350.s0.e0
DDI-DrugBank.d350.s1|a|In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other drugs.
DDI-DrugBank.d350.s1	21	31	caspofungin	drug	DDI-DrugBank.d350.s1.e0
DDI-DrugBank.d350.s2|a|Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.
DDI-DrugBank.d350.s2	0	10	Caspofungin	drug	DDI-DrugBank.d350.s2.e0
DDI-DrugBank.d350.s3|a|Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.
DDI-DrugBank.d350.s3	73	80	CANCIDAS	brand	DDI-DrugBank.d350.s3.e0
DDI-DrugBank.d350.s3	101	112	itraconazole	drug	DDI-DrugBank.d350.s3.e1
DDI-DrugBank.d350.s3	115	128	amphotericin B	drug	DDI-DrugBank.d350.s3.e2
DDI-DrugBank.d350.s3	131	143	mycophenolate	drug	DDI-DrugBank.d350.s3.e3
DDI-DrugBank.d350.s3	146	155	nelfinavir	drug	DDI-DrugBank.d350.s3.e4
DDI-DrugBank.d350.s3	161	170	tacrolimus	drug	DDI-DrugBank.d350.s3.e5
DDI-DrugBank.d350.s3	false	DDI-DrugBank.d350.s3.e0	DDI-DrugBank.d350.s3.e1
DDI-DrugBank.d350.s3	false	DDI-DrugBank.d350.s3.e0	DDI-DrugBank.d350.s3.e2
DDI-DrugBank.d350.s3	false	DDI-DrugBank.d350.s3.e0	DDI-DrugBank.d350.s3.e3
DDI-DrugBank.d350.s3	false	DDI-DrugBank.d350.s3.e0	DDI-DrugBank.d350.s3.e4
DDI-DrugBank.d350.s3	false	DDI-DrugBank.d350.s3.e0	DDI-DrugBank.d350.s3.e5
DDI-DrugBank.d350.s3	false	DDI-DrugBank.d350.s3.e1	DDI-DrugBank.d350.s3.e2
DDI-DrugBank.d350.s3	false	DDI-DrugBank.d350.s3.e1	DDI-DrugBank.d350.s3.e3
DDI-DrugBank.d350.s3	false	DDI-DrugBank.d350.s3.e1	DDI-DrugBank.d350.s3.e4
DDI-DrugBank.d350.s3	false	DDI-DrugBank.d350.s3.e1	DDI-DrugBank.d350.s3.e5
DDI-DrugBank.d350.s3	false	DDI-DrugBank.d350.s3.e2	DDI-DrugBank.d350.s3.e3
DDI-DrugBank.d350.s4|a|CANCIDAS has no effect on the pharmacokinetics of itraconazole, amphotericin B, or the active metabolite of mycophenolate.
DDI-DrugBank.d350.s4	0	7	CANCIDAS	brand	DDI-DrugBank.d350.s4.e0
DDI-DrugBank.d350.s4	50	61	itraconazole	drug	DDI-DrugBank.d350.s4.e1
DDI-DrugBank.d350.s4	64	77	amphotericin B	drug	DDI-DrugBank.d350.s4.e2
DDI-DrugBank.d350.s4	false	DDI-DrugBank.d350.s4.e0	DDI-DrugBank.d350.s4.e1
DDI-DrugBank.d350.s4	false	DDI-DrugBank.d350.s4.e0	DDI-DrugBank.d350.s4.e2
DDI-DrugBank.d350.s4	false	DDI-DrugBank.d350.s4.e1	DDI-DrugBank.d350.s4.e2
DDI-DrugBank.d350.s5|a|CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
DDI-DrugBank.d350.s5	0	7	CANCIDAS	brand	DDI-DrugBank.d350.s5.e0
DDI-DrugBank.d350.s5	38	47	tacrolimus	drug	DDI-DrugBank.d350.s5.e1
DDI-DrugBank.d350.s5	183	192	tacrolimus	drug	DDI-DrugBank.d350.s5.e2
DDI-DrugBank.d350.s5	268	275	CANCIDAS	brand	DDI-DrugBank.d350.s5.e3
DDI-DrugBank.d350.s5	344	353	tacrolimus	drug	DDI-DrugBank.d350.s5.e4
DDI-DrugBank.d350.s5	true	DDI-DrugBank.d350.s5.e0	DDI-DrugBank.d350.s5.e1
DDI-DrugBank.d350.s5	false	DDI-DrugBank.d350.s5.e0	DDI-DrugBank.d350.s5.e2
DDI-DrugBank.d350.s5	false	DDI-DrugBank.d350.s5.e0	DDI-DrugBank.d350.s5.e3
DDI-DrugBank.d350.s5	false	DDI-DrugBank.d350.s5.e0	DDI-DrugBank.d350.s5.e4
DDI-DrugBank.d350.s5	false	DDI-DrugBank.d350.s5.e1	DDI-DrugBank.d350.s5.e2
DDI-DrugBank.d350.s5	false	DDI-DrugBank.d350.s5.e1	DDI-DrugBank.d350.s5.e3
DDI-DrugBank.d350.s5	false	DDI-DrugBank.d350.s5.e1	DDI-DrugBank.d350.s5.e4
DDI-DrugBank.d350.s5	false	DDI-DrugBank.d350.s5.e2	DDI-DrugBank.d350.s5.e3
DDI-DrugBank.d350.s5	false	DDI-DrugBank.d350.s5.e2	DDI-DrugBank.d350.s5.e4
DDI-DrugBank.d350.s5	false	DDI-DrugBank.d350.s5.e3	DDI-DrugBank.d350.s5.e4
DDI-DrugBank.d350.s6|a|For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
DDI-DrugBank.d350.s6	62	71	tacrolimus	drug	DDI-DrugBank.d350.s6.e0
DDI-DrugBank.d350.s6	110	119	tacrolimus	drug	DDI-DrugBank.d350.s6.e1
DDI-DrugBank.d350.s6	false	DDI-DrugBank.d350.s6.e0	DDI-DrugBank.d350.s6.e1
DDI-DrugBank.d350.s7|a|In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.
DDI-DrugBank.d350.s7	25	36	cyclosporine	drug	DDI-DrugBank.d350.s7.e0
DDI-DrugBank.d350.s7	99	109	caspofungin	drug	DDI-DrugBank.d350.s7.e1
DDI-DrugBank.d350.s7	true	DDI-DrugBank.d350.s7.e0	DDI-DrugBank.d350.s7.e1
DDI-DrugBank.d350.s8|a|CANCIDAS did not increase the plasma levels of cyclosporine.
DDI-DrugBank.d350.s8	0	7	CANCIDAS	brand	DDI-DrugBank.d350.s8.e0
DDI-DrugBank.d350.s8	47	58	cyclosporine	drug	DDI-DrugBank.d350.s8.e1
DDI-DrugBank.d350.s8	false	DDI-DrugBank.d350.s8.e0	DDI-DrugBank.d350.s8.e1
DDI-DrugBank.d350.s9|a|There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.
DDI-DrugBank.d350.s9	57	64	CANCIDAS	brand	DDI-DrugBank.d350.s9.e0
DDI-DrugBank.d350.s9	70	81	cyclosporine	drug	DDI-DrugBank.d350.s9.e1
DDI-DrugBank.d350.s9	true	DDI-DrugBank.d350.s9.e0	DDI-DrugBank.d350.s9.e1
DDI-DrugBank.d350.s10|a|A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.
DDI-DrugBank.d350.s10	35	42	rifampin	drug	DDI-DrugBank.d350.s10.e0
DDI-DrugBank.d350.s10	94	104	caspofungin	drug	DDI-DrugBank.d350.s10.e1
DDI-DrugBank.d350.s10	true	DDI-DrugBank.d350.s10.e0	DDI-DrugBank.d350.s10.e1
DDI-DrugBank.d350.s11|a|Patients on rifampin should receive 70 mg of CANCIDAS daily.
DDI-DrugBank.d350.s11	12	19	rifampin	drug	DDI-DrugBank.d350.s11.e0
DDI-DrugBank.d350.s11	45	52	CANCIDAS	brand	DDI-DrugBank.d350.s11.e1
DDI-DrugBank.d350.s11	true	DDI-DrugBank.d350.s11.e0	DDI-DrugBank.d350.s11.e1
DDI-DrugBank.d350.s12|a|In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
DDI-DrugBank.d350.s12	146	154	efavirenz	drug	DDI-DrugBank.d350.s12.e0
DDI-DrugBank.d350.s12	157	166	nevirapine	drug	DDI-DrugBank.d350.s12.e1
DDI-DrugBank.d350.s12	169	177	phenytoin	drug	DDI-DrugBank.d350.s12.e2
DDI-DrugBank.d350.s12	180	192	dexamethasone	drug	DDI-DrugBank.d350.s12.e3
DDI-DrugBank.d350.s12	198	210	carbamazepine	drug	DDI-DrugBank.d350.s12.e4
DDI-DrugBank.d350.s12	218	225	CANCIDAS	brand	DDI-DrugBank.d350.s12.e5
DDI-DrugBank.d350.s12	277	287	caspofungin	drug	DDI-DrugBank.d350.s12.e6
DDI-DrugBank.d350.s12	false	DDI-DrugBank.d350.s12.e0	DDI-DrugBank.d350.s12.e1
DDI-DrugBank.d350.s12	false	DDI-DrugBank.d350.s12.e0	DDI-DrugBank.d350.s12.e2
DDI-DrugBank.d350.s12	false	DDI-DrugBank.d350.s12.e0	DDI-DrugBank.d350.s12.e3
DDI-DrugBank.d350.s12	false	DDI-DrugBank.d350.s12.e0	DDI-DrugBank.d350.s12.e4
DDI-DrugBank.d350.s12	true	DDI-DrugBank.d350.s12.e0	DDI-DrugBank.d350.s12.e5
DDI-DrugBank.d350.s12	false	DDI-DrugBank.d350.s12.e0	DDI-DrugBank.d350.s12.e6
DDI-DrugBank.d350.s12	false	DDI-DrugBank.d350.s12.e1	DDI-DrugBank.d350.s12.e2
DDI-DrugBank.d350.s12	false	DDI-DrugBank.d350.s12.e1	DDI-DrugBank.d350.s12.e3
DDI-DrugBank.d350.s12	false	DDI-DrugBank.d350.s12.e1	DDI-DrugBank.d350.s12.e4
DDI-DrugBank.d350.s12	true	DDI-DrugBank.d350.s12.e1	DDI-DrugBank.d350.s12.e5
DDI-DrugBank.d350.s13|a|It is not known which drug clearance mechanism involved in caspofungin disposition may be inducible.
DDI-DrugBank.d350.s13	59	69	caspofungin	drug	DDI-DrugBank.d350.s13.e0
DDI-DrugBank.d350.s14|a|When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
DDI-DrugBank.d350.s14	5	12	CANCIDAS	brand	DDI-DrugBank.d350.s14.e0
DDI-DrugBank.d350.s14	74	82	efavirenz	drug	DDI-DrugBank.d350.s14.e1
DDI-DrugBank.d350.s14	85	94	nevirapine	drug	DDI-DrugBank.d350.s14.e2
DDI-DrugBank.d350.s14	97	105	phenytoin	drug	DDI-DrugBank.d350.s14.e3
DDI-DrugBank.d350.s14	108	120	dexamethasone	drug	DDI-DrugBank.d350.s14.e4
DDI-DrugBank.d350.s14	126	138	carbamazepine	drug	DDI-DrugBank.d350.s14.e5
DDI-DrugBank.d350.s14	173	180	CANCIDAS	brand	DDI-DrugBank.d350.s14.e6
DDI-DrugBank.d350.s14	true	DDI-DrugBank.d350.s14.e0	DDI-DrugBank.d350.s14.e1
DDI-DrugBank.d350.s14	true	DDI-DrugBank.d350.s14.e0	DDI-DrugBank.d350.s14.e2
DDI-DrugBank.d350.s14	true	DDI-DrugBank.d350.s14.e0	DDI-DrugBank.d350.s14.e3
DDI-DrugBank.d350.s14	true	DDI-DrugBank.d350.s14.e0	DDI-DrugBank.d350.s14.e4
DDI-DrugBank.d350.s14	true	DDI-DrugBank.d350.s14.e0	DDI-DrugBank.d350.s14.e5
DDI-DrugBank.d350.s14	false	DDI-DrugBank.d350.s14.e0	DDI-DrugBank.d350.s14.e6
DDI-DrugBank.d350.s14	false	DDI-DrugBank.d350.s14.e1	DDI-DrugBank.d350.s14.e2
DDI-DrugBank.d350.s14	false	DDI-DrugBank.d350.s14.e1	DDI-DrugBank.d350.s14.e3
DDI-DrugBank.d350.s14	false	DDI-DrugBank.d350.s14.e1	DDI-DrugBank.d350.s14.e4
DDI-DrugBank.d350.s14	false	DDI-DrugBank.d350.s14.e1	DDI-DrugBank.d350.s14.e5
DDI-DrugBank.d350.s15|a|.
DDI-DrugBank.d350.s16|a|
DDI-DrugBank.d557.s0|a|Drug/Laboratory Test Interactions Positive direct Coombs  tests have been reported during treatment with the cephalosporin antibiotics.
DDI-DrugBank.d557.s0	109	133	cephalosporin antibiotics	group	DDI-DrugBank.d557.s0.e0
DDI-DrugBank.d557.s1|a|In hematologic studies or in transfusion cross-matching procedures when anti-globulin tests are performed on the minor side or in Coombs  testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs  test may be due to the drug.
DDI-DrugBank.d557.s1	186	210	cephalosporin antibiotics	group	DDI-DrugBank.d557.s1.e0
DDI-DrugBank.d281.s0|a|Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.
DDI-DrugBank.d281.s0	0	9	Probenecid	drug	DDI-DrugBank.d281.s0.e0
DDI-DrugBank.d281.s0	51	64	cephalosporins	group	DDI-DrugBank.d281.s0.e1
DDI-DrugBank.d281.s0	132	144	cephalosporin	group	DDI-DrugBank.d281.s0.e2
DDI-DrugBank.d281.s0	true	DDI-DrugBank.d281.s0.e0	DDI-DrugBank.d281.s0.e1
DDI-DrugBank.d281.s0	false	DDI-DrugBank.d281.s0.e0	DDI-DrugBank.d281.s0.e2
DDI-DrugBank.d281.s0	false	DDI-DrugBank.d281.s0.e1	DDI-DrugBank.d281.s0.e2
DDI-DrugBank.d281.s1|a|Drug/Laboratory Test Interactions A false positive reaction for glucose in the urine may occur with Benedicts solution, Fehlings solution or with CLINITEST  tablets, but not with enzyme-based tests such as CLINISTIX .
DDI-DrugBank.d281.s2|a|Positive direct and indirect antiglobulin (Coombs) tests have occurred;
DDI-DrugBank.d281.s3|a|these may also occur in neonates whose mothers received cephalosporins before delivery.
DDI-DrugBank.d281.s3	56	69	cephalosporins	group	DDI-DrugBank.d281.s3.e0
DDI-DrugBank.d420.s0|a|Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
DDI-DrugBank.d420.s0	0	7	Antacids	group	DDI-DrugBank.d420.s0.e0
DDI-DrugBank.d420.s0	10	17	aluminum	drug	DDI-DrugBank.d420.s0.e1
DDI-DrugBank.d420.s0	23	31	magnesium	drug	DDI-DrugBank.d420.s0.e2
DDI-DrugBank.d420.s0	83	90	cefdinir	drug	DDI-DrugBank.d420.s0.e3
DDI-DrugBank.d420.s0	112	120	Maalox TC	brand	DDI-DrugBank.d420.s0.e4
DDI-DrugBank.d420.s0	false	DDI-DrugBank.d420.s0.e0	DDI-DrugBank.d420.s0.e1
DDI-DrugBank.d420.s0	false	DDI-DrugBank.d420.s0.e0	DDI-DrugBank.d420.s0.e2
DDI-DrugBank.d420.s0	false	DDI-DrugBank.d420.s0.e0	DDI-DrugBank.d420.s0.e3
DDI-DrugBank.d420.s0	false	DDI-DrugBank.d420.s0.e0	DDI-DrugBank.d420.s0.e4
DDI-DrugBank.d420.s0	false	DDI-DrugBank.d420.s0.e1	DDI-DrugBank.d420.s0.e2
DDI-DrugBank.d420.s0	false	DDI-DrugBank.d420.s0.e1	DDI-DrugBank.d420.s0.e3
DDI-DrugBank.d420.s0	false	DDI-DrugBank.d420.s0.e1	DDI-DrugBank.d420.s0.e4
DDI-DrugBank.d420.s0	false	DDI-DrugBank.d420.s0.e2	DDI-DrugBank.d420.s0.e3
DDI-DrugBank.d420.s0	false	DDI-DrugBank.d420.s0.e2	DDI-DrugBank.d420.s0.e4
DDI-DrugBank.d420.s0	true	DDI-DrugBank.d420.s0.e3	DDI-DrugBank.d420.s0.e4
DDI-DrugBank.d420.s1|a|Time to reach Cmax is also prolonged by 1 hour.
DDI-DrugBank.d420.s2|a|There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.
DDI-DrugBank.d420.s2	36	43	cefdinir	drug	DDI-DrugBank.d420.s2.e0
DDI-DrugBank.d420.s2	69	75	antacid	group	DDI-DrugBank.d420.s2.e1
DDI-DrugBank.d420.s2	125	132	cefdinir	drug	DDI-DrugBank.d420.s2.e2
DDI-DrugBank.d420.s2	false	DDI-DrugBank.d420.s2.e0	DDI-DrugBank.d420.s2.e1
DDI-DrugBank.d420.s2	false	DDI-DrugBank.d420.s2.e0	DDI-DrugBank.d420.s2.e2
DDI-DrugBank.d420.s2	false	DDI-DrugBank.d420.s2.e1	DDI-DrugBank.d420.s2.e2
DDI-DrugBank.d420.s3|a|If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.
DDI-DrugBank.d420.s3	3	10	antacids	group	DDI-DrugBank.d420.s3.e0
DDI-DrugBank.d420.s3	32	38	OMNICEF	brand	DDI-DrugBank.d420.s3.e1
DDI-DrugBank.d420.s3	49	55	OMNICEF	brand	DDI-DrugBank.d420.s3.e2
DDI-DrugBank.d420.s3	110	116	antacid	group	DDI-DrugBank.d420.s3.e3
DDI-DrugBank.d420.s3	false	DDI-DrugBank.d420.s3.e0	DDI-DrugBank.d420.s3.e1
DDI-DrugBank.d420.s3	false	DDI-DrugBank.d420.s3.e0	DDI-DrugBank.d420.s3.e2
DDI-DrugBank.d420.s3	false	DDI-DrugBank.d420.s3.e0	DDI-DrugBank.d420.s3.e3
DDI-DrugBank.d420.s3	false	DDI-DrugBank.d420.s3.e1	DDI-DrugBank.d420.s3.e2
DDI-DrugBank.d420.s3	false	DDI-DrugBank.d420.s3.e1	DDI-DrugBank.d420.s3.e3
DDI-DrugBank.d420.s3	true	DDI-DrugBank.d420.s3.e2	DDI-DrugBank.d420.s3.e3
DDI-DrugBank.d420.s4|a|Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
DDI-DrugBank.d420.s4	0	9	Probenecid	drug	DDI-DrugBank.d420.s4.e0
DDI-DrugBank.d420.s4	26	45	b-lactam antibiotics	group	DDI-DrugBank.d420.s4.e1
DDI-DrugBank.d420.s4	48	57	probenecid	drug	DDI-DrugBank.d420.s4.e2
DDI-DrugBank.d420.s4	91	98	cefdinir	drug	DDI-DrugBank.d420.s4.e3
DDI-DrugBank.d420.s4	169	176	cefdinir	drug	DDI-DrugBank.d420.s4.e4
DDI-DrugBank.d420.s4	false	DDI-DrugBank.d420.s4.e0	DDI-DrugBank.d420.s4.e1
DDI-DrugBank.d420.s4	false	DDI-DrugBank.d420.s4.e0	DDI-DrugBank.d420.s4.e2
DDI-DrugBank.d420.s4	false	DDI-DrugBank.d420.s4.e0	DDI-DrugBank.d420.s4.e3
DDI-DrugBank.d420.s4	false	DDI-DrugBank.d420.s4.e0	DDI-DrugBank.d420.s4.e4
DDI-DrugBank.d420.s4	false	DDI-DrugBank.d420.s4.e1	DDI-DrugBank.d420.s4.e2
DDI-DrugBank.d420.s4	true	DDI-DrugBank.d420.s4.e1	DDI-DrugBank.d420.s4.e3
DDI-DrugBank.d420.s4	false	DDI-DrugBank.d420.s4.e1	DDI-DrugBank.d420.s4.e4
DDI-DrugBank.d420.s4	true	DDI-DrugBank.d420.s4.e2	DDI-DrugBank.d420.s4.e3
DDI-DrugBank.d420.s4	false	DDI-DrugBank.d420.s4.e2	DDI-DrugBank.d420.s4.e4
DDI-DrugBank.d420.s4	false	DDI-DrugBank.d420.s4.e3	DDI-DrugBank.d420.s4.e4
DDI-DrugBank.d420.s5|a|Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
DDI-DrugBank.d420.s5	0	15	Iron Supplements	group	DDI-DrugBank.d420.s5.e0
DDI-DrugBank.d420.s5	42	45	Iron	drug	DDI-DrugBank.d420.s5.e1
DDI-DrugBank.d420.s5	77	84	cefdinir	drug	DDI-DrugBank.d420.s5.e2
DDI-DrugBank.d420.s5	105	119	iron supplement	group	DDI-DrugBank.d420.s5.e3
DDI-DrugBank.d420.s5	151	154	iron	drug	DDI-DrugBank.d420.s5.e4
DDI-DrugBank.d420.s5	170	177	vitamins	group	DDI-DrugBank.d420.s5.e5
DDI-DrugBank.d420.s5	216	219	iron	drug	DDI-DrugBank.d420.s5.e6
DDI-DrugBank.d420.s5	false	DDI-DrugBank.d420.s5.e0	DDI-DrugBank.d420.s5.e1
DDI-DrugBank.d420.s5	false	DDI-DrugBank.d420.s5.e0	DDI-DrugBank.d420.s5.e2
DDI-DrugBank.d420.s5	false	DDI-DrugBank.d420.s5.e0	DDI-DrugBank.d420.s5.e3
DDI-DrugBank.d420.s5	false	DDI-DrugBank.d420.s5.e0	DDI-DrugBank.d420.s5.e4
DDI-DrugBank.d420.s5	false	DDI-DrugBank.d420.s5.e0	DDI-DrugBank.d420.s5.e5
DDI-DrugBank.d420.s5	false	DDI-DrugBank.d420.s5.e0	DDI-DrugBank.d420.s5.e6
DDI-DrugBank.d420.s5	false	DDI-DrugBank.d420.s5.e1	DDI-DrugBank.d420.s5.e2
DDI-DrugBank.d420.s5	false	DDI-DrugBank.d420.s5.e1	DDI-DrugBank.d420.s5.e3
DDI-DrugBank.d420.s5	false	DDI-DrugBank.d420.s5.e1	DDI-DrugBank.d420.s5.e4
DDI-DrugBank.d420.s5	false	DDI-DrugBank.d420.s5.e1	DDI-DrugBank.d420.s5.e5
DDI-DrugBank.d420.s6|a|If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.
DDI-DrugBank.d420.s6	3	18	iron supplements	group	DDI-DrugBank.d420.s6.e0
DDI-DrugBank.d420.s6	40	46	OMNICEF	brand	DDI-DrugBank.d420.s6.e1
DDI-DrugBank.d420.s6	57	63	OMNICEF	brand	DDI-DrugBank.d420.s6.e2
DDI-DrugBank.d420.s6	false	DDI-DrugBank.d420.s6.e0	DDI-DrugBank.d420.s6.e1
DDI-DrugBank.d420.s6	true	DDI-DrugBank.d420.s6.e0	DDI-DrugBank.d420.s6.e2
DDI-DrugBank.d420.s6	false	DDI-DrugBank.d420.s6.e1	DDI-DrugBank.d420.s6.e2
DDI-DrugBank.d420.s7|a|The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.
DDI-DrugBank.d420.s7	52	55	iron	drug_n	DDI-DrugBank.d420.s7.e0
DDI-DrugBank.d420.s7	68	71	iron	drug_n	DDI-DrugBank.d420.s7.e1
DDI-DrugBank.d420.s7	105	112	cefdinir	drug	DDI-DrugBank.d420.s7.e2
DDI-DrugBank.d420.s7	false	DDI-DrugBank.d420.s7.e0	DDI-DrugBank.d420.s7.e1
DDI-DrugBank.d420.s7	false	DDI-DrugBank.d420.s7.e0	DDI-DrugBank.d420.s7.e2
DDI-DrugBank.d420.s7	false	DDI-DrugBank.d420.s7.e1	DDI-DrugBank.d420.s7.e2
DDI-DrugBank.d420.s8|a|Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.
DDI-DrugBank.d420.s8	27	30	iron	drug_n	DDI-DrugBank.d420.s8.e0
DDI-DrugBank.d420.s8	75	78	iron	drug_n	DDI-DrugBank.d420.s8.e1
DDI-DrugBank.d420.s8	115	122	cefdinir	drug	DDI-DrugBank.d420.s8.e2
DDI-DrugBank.d420.s8	false	DDI-DrugBank.d420.s8.e0	DDI-DrugBank.d420.s8.e1
DDI-DrugBank.d420.s8	false	DDI-DrugBank.d420.s8.e0	DDI-DrugBank.d420.s8.e2
DDI-DrugBank.d420.s8	false	DDI-DrugBank.d420.s8.e1	DDI-DrugBank.d420.s8.e2
DDI-DrugBank.d420.s9|a|Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.
DDI-DrugBank.d420.s9	11	17	OMNICEF	brand	DDI-DrugBank.d420.s9.e0
DDI-DrugBank.d420.s9	64	67	iron	drug_n	DDI-DrugBank.d420.s9.e1
DDI-DrugBank.d420.s9	false	DDI-DrugBank.d420.s9.e0	DDI-DrugBank.d420.s9.e1
DDI-DrugBank.d420.s10|a|There have been rare reports of reddish stools in patients who have received cefdinir in Japan.
DDI-DrugBank.d420.s10	77	84	cefdinir	drug	DDI-DrugBank.d420.s10.e0
DDI-DrugBank.d420.s11|a|The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.
DDI-DrugBank.d420.s11	77	84	cefdinir	drug	DDI-DrugBank.d420.s11.e0
DDI-DrugBank.d420.s11	116	119	iron	drug	DDI-DrugBank.d420.s11.e1
DDI-DrugBank.d420.s11	true	DDI-DrugBank.d420.s11.e0	DDI-DrugBank.d420.s11.e1
DDI-DrugBank.d420.s12|a|Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide.
DDI-DrugBank.d420.s12	112	124	nitroprusside	drug	DDI-DrugBank.d420.s12.e0
DDI-DrugBank.d420.s12	152	168	nitroferricyanide	drug	DDI-DrugBank.d420.s12.e1
DDI-DrugBank.d420.s12	false	DDI-DrugBank.d420.s12.e0	DDI-DrugBank.d420.s12.e1
DDI-DrugBank.d420.s13|a|The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest , Benedict s solution, or Fehlings solution.
DDI-DrugBank.d420.s13	22	29	cefdinir	drug	DDI-DrugBank.d420.s13.e0
DDI-DrugBank.d420.s14|a|It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix  or Tes-Tape ) be used.
DDI-DrugBank.d420.s15|a|Cephalosporins are known to occasionally induce a positive direct Coombs  test.
DDI-DrugBank.d420.s15	0	13	Cephalosporins	group	DDI-DrugBank.d420.s15.e0
DDI-DrugBank.d550.s0|a|Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
DDI-DrugBank.d550.s0	5	18	Contraceptives	group	DDI-DrugBank.d550.s0.e0
DDI-DrugBank.d550.s0	38	55	cefditoren pivoxil	drug	DDI-DrugBank.d550.s0.e1
DDI-DrugBank.d550.s0	98	114	ethinyl estradiol	drug	DDI-DrugBank.d550.s0.e2
DDI-DrugBank.d550.s0	155	168	contraceptives	group	DDI-DrugBank.d550.s0.e3
DDI-DrugBank.d550.s0	false	DDI-DrugBank.d550.s0.e0	DDI-DrugBank.d550.s0.e1
DDI-DrugBank.d550.s0	false	DDI-DrugBank.d550.s0.e0	DDI-DrugBank.d550.s0.e2
DDI-DrugBank.d550.s0	false	DDI-DrugBank.d550.s0.e0	DDI-DrugBank.d550.s0.e3
DDI-DrugBank.d550.s0	false	DDI-DrugBank.d550.s0.e1	DDI-DrugBank.d550.s0.e2
DDI-DrugBank.d550.s0	false	DDI-DrugBank.d550.s0.e1	DDI-DrugBank.d550.s0.e3
DDI-DrugBank.d550.s0	false	DDI-DrugBank.d550.s0.e2	DDI-DrugBank.d550.s0.e3
DDI-DrugBank.d550.s1|a|Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.
DDI-DrugBank.d550.s1	76	93	cefditoren pivoxil	drug	DDI-DrugBank.d550.s1.e0
DDI-DrugBank.d550.s1	123	130	antacids	group	DDI-DrugBank.d550.s1.e1
DDI-DrugBank.d550.s1	true	DDI-DrugBank.d550.s1.e0	DDI-DrugBank.d550.s1.e1
DDI-DrugBank.d550.s2|a|H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
DDI-DrugBank.d550.s2	0	22	H2-Receptor Antagonists	group	DDI-DrugBank.d550.s2.e0
DDI-DrugBank.d550.s2	90	99	famotidine	drug	DDI-DrugBank.d550.s2.e1
DDI-DrugBank.d550.s2	164	181	cefditoren pivoxil	drug	DDI-DrugBank.d550.s2.e2
DDI-DrugBank.d550.s2	false	DDI-DrugBank.d550.s2.e0	DDI-DrugBank.d550.s2.e1
DDI-DrugBank.d550.s2	false	DDI-DrugBank.d550.s2.e0	DDI-DrugBank.d550.s2.e2
DDI-DrugBank.d550.s2	true	DDI-DrugBank.d550.s2.e1	DDI-DrugBank.d550.s2.e2
DDI-DrugBank.d550.s3|a|Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with H2 receptor antagonists.
DDI-DrugBank.d550.s3	76	93	cefditoren pivoxil	drug	DDI-DrugBank.d550.s3.e0
DDI-DrugBank.d550.s3	123	145	H2 receptor antagonists	group	DDI-DrugBank.d550.s3.e1
DDI-DrugBank.d550.s3	false	DDI-DrugBank.d550.s3.e0	DDI-DrugBank.d550.s3.e1
DDI-DrugBank.d550.s4|a|Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
DDI-DrugBank.d550.s4	0	9	Probenecid	drug	DDI-DrugBank.d550.s4.e0
DDI-DrugBank.d550.s4	26	45	b-lactam antibiotics	group	DDI-DrugBank.d550.s4.e1
DDI-DrugBank.d550.s4	69	78	probenecid	drug	DDI-DrugBank.d550.s4.e2
DDI-DrugBank.d550.s4	85	102	cefditoren pivoxil	drug	DDI-DrugBank.d550.s4.e3
DDI-DrugBank.d550.s4	154	163	cefditoren	drug	DDI-DrugBank.d550.s4.e4
DDI-DrugBank.d550.s4	false	DDI-DrugBank.d550.s4.e0	DDI-DrugBank.d550.s4.e1
DDI-DrugBank.d550.s4	false	DDI-DrugBank.d550.s4.e0	DDI-DrugBank.d550.s4.e2
DDI-DrugBank.d550.s4	false	DDI-DrugBank.d550.s4.e0	DDI-DrugBank.d550.s4.e3
DDI-DrugBank.d550.s4	false	DDI-DrugBank.d550.s4.e0	DDI-DrugBank.d550.s4.e4
DDI-DrugBank.d550.s4	false	DDI-DrugBank.d550.s4.e1	DDI-DrugBank.d550.s4.e2
DDI-DrugBank.d550.s4	true	DDI-DrugBank.d550.s4.e1	DDI-DrugBank.d550.s4.e3
DDI-DrugBank.d550.s4	false	DDI-DrugBank.d550.s4.e1	DDI-DrugBank.d550.s4.e4
DDI-DrugBank.d550.s4	true	DDI-DrugBank.d550.s4.e2	DDI-DrugBank.d550.s4.e3
DDI-DrugBank.d550.s4	false	DDI-DrugBank.d550.s4.e2	DDI-DrugBank.d550.s4.e4
DDI-DrugBank.d550.s4	false	DDI-DrugBank.d550.s4.e3	DDI-DrugBank.d550.s4.e4
DDI-DrugBank.d550.s5|a|Drug/Laboratory Test Interactions Cephalosporins are known to occasionally induce a positive direct Coombs test.
DDI-DrugBank.d550.s5	34	47	Cephalosporins	group	DDI-DrugBank.d550.s5.e0
DDI-DrugBank.d550.s6|a|A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedicts or Fehlings solution or with CLINITEST tablets), but not with enzyme-based tests for glycosuria (e.g., CLINISTIX, TES-TAPE).
DDI-DrugBank.d550.s7|a|As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood/plasma glucose levels in patients receiving cefditoren pivoxil.
DDI-DrugBank.d550.s7	205	222	cefditoren pivoxil	drug	DDI-DrugBank.d550.s7.e0
DDI-DrugBank.d378.s0|a|Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.
DDI-DrugBank.d378.s0	62	76	aminoglycosides	group	DDI-DrugBank.d378.s0.e0
DDI-DrugBank.d378.s0	106	113	MAXIPIME	brand	DDI-DrugBank.d378.s0.e1
DDI-DrugBank.d378.s0	187	212	aminoglycoside antibiotics	group	DDI-DrugBank.d378.s0.e2
DDI-DrugBank.d378.s0	true	DDI-DrugBank.d378.s0.e0	DDI-DrugBank.d378.s0.e1
DDI-DrugBank.d378.s0	false	DDI-DrugBank.d378.s0.e0	DDI-DrugBank.d378.s0.e2
DDI-DrugBank.d378.s0	false	DDI-DrugBank.d378.s0.e1	DDI-DrugBank.d378.s0.e2
DDI-DrugBank.d378.s1|a|Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
DDI-DrugBank.d378.s1	79	92	cephalosporins	group	DDI-DrugBank.d378.s1.e0
DDI-DrugBank.d378.s1	106	114	diuretics	group	DDI-DrugBank.d378.s1.e1
DDI-DrugBank.d378.s1	124	133	furosemide	drug	DDI-DrugBank.d378.s1.e2
DDI-DrugBank.d378.s1	true	DDI-DrugBank.d378.s1.e0	DDI-DrugBank.d378.s1.e1
DDI-DrugBank.d378.s1	true	DDI-DrugBank.d378.s1.e0	DDI-DrugBank.d378.s1.e2
DDI-DrugBank.d378.s1	false	DDI-DrugBank.d378.s1.e1	DDI-DrugBank.d378.s1.e2
DDI-DrugBank.d378.s2|a|Drug/Laboratory Test Interactions The administration of cefepime may result in a false-positive reaction for glucose in the urine when using Clinitest  tablets.
DDI-DrugBank.d378.s2	56	63	cefepime	drug	DDI-DrugBank.d378.s2.e0
DDI-DrugBank.d378.s3|a|It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix  or Tes-Tape  ) be used.
DDI-DrugBank.d339.s0|a|Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.
DDI-DrugBank.d339.s0	0	12	Carbamazepine	drug	DDI-DrugBank.d339.s0.e0
DDI-DrugBank.d339.s0	24	36	carbamazepine	drug	DDI-DrugBank.d339.s0.e1
DDI-DrugBank.d339.s0	97	102	SUPRAX	brand	DDI-DrugBank.d339.s0.e2
DDI-DrugBank.d339.s0	false	DDI-DrugBank.d339.s0.e0	DDI-DrugBank.d339.s0.e1
DDI-DrugBank.d339.s0	false	DDI-DrugBank.d339.s0.e0	DDI-DrugBank.d339.s0.e2
DDI-DrugBank.d339.s0	true	DDI-DrugBank.d339.s0.e1	DDI-DrugBank.d339.s0.e2
DDI-DrugBank.d339.s1|a|Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations.
DDI-DrugBank.d339.s1	65	77	carbamazepine	drug	DDI-DrugBank.d339.s1.e0
DDI-DrugBank.d339.s2|a|Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
DDI-DrugBank.d339.s2	0	7	Warfarin	drug	DDI-DrugBank.d339.s2.e0
DDI-DrugBank.d339.s2	13	26	Anticoagulants	group	DDI-DrugBank.d339.s2.e1
DDI-DrugBank.d339.s2	115	122	cefixime	drug	DDI-DrugBank.d339.s2.e2
DDI-DrugBank.d339.s2	false	DDI-DrugBank.d339.s2.e0	DDI-DrugBank.d339.s2.e1
DDI-DrugBank.d339.s2	true	DDI-DrugBank.d339.s2.e0	DDI-DrugBank.d339.s2.e2
DDI-DrugBank.d339.s2	true	DDI-DrugBank.d339.s2.e1	DDI-DrugBank.d339.s2.e2
DDI-DrugBank.d339.s3|a|Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide.
DDI-DrugBank.d339.s3	112	124	nitroprusside	drug	DDI-DrugBank.d339.s3.e0
DDI-DrugBank.d339.s3	151	167	nitroferricyanide	drug	DDI-DrugBank.d339.s3.e1
DDI-DrugBank.d339.s3	false	DDI-DrugBank.d339.s3.e0	DDI-DrugBank.d339.s3.e1
DDI-DrugBank.d339.s4|a|The administration of SUPRAX may result in a false-positive reaction for glucose in the urine using Clinitest **, Benedict s solution, or Fehling s solution.
DDI-DrugBank.d339.s4	22	27	SUPRAX	brand	DDI-DrugBank.d339.s4.e0
DDI-DrugBank.d339.s5|a|It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix ** or Tes-Tape **) be used.
DDI-DrugBank.d339.s6|a|A false-positive direct Coombs test has been reported during treatment with other cephalosporin antibiotics;
DDI-DrugBank.d339.s6	82	106	cephalosporin antibiotics	group	DDI-DrugBank.d339.s6.e0
DDI-DrugBank.d339.s7|a|therefore, it should be recognized that a positive Coombs test may be due to the drug.
DDI-DrugBank.d100.s0|a|Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
DDI-DrugBank.d100.s0	83	96	cephalosporins	group	DDI-DrugBank.d100.s0.e0
DDI-DrugBank.d100.s0	102	127	aminoglycoside antibiotics	group	DDI-DrugBank.d100.s0.e1
DDI-DrugBank.d100.s0	true	DDI-DrugBank.d100.s0.e0	DDI-DrugBank.d100.s0.e1
DDI-DrugBank.d100.s1|a|Drug/Laboratory Test Interactions Cephalosporins, including cefotaxime sodium, are known to occasionally induce a positive direct Coombs test.
DDI-DrugBank.d100.s1	34	47	Cephalosporins	group	DDI-DrugBank.d100.s1.e0
DDI-DrugBank.d100.s1	60	76	cefotaxime sodium	drug	DDI-DrugBank.d100.s1.e1
DDI-DrugBank.d100.s1	false	DDI-DrugBank.d100.s1.e0	DDI-DrugBank.d100.s1.e1
DDI-DrugBank.d483.s0|a|Increases in serum creatinine have occurred when CEFOTAN was given alone.
DDI-DrugBank.d483.s0	49	55	CEFOTAN	brand	DDI-DrugBank.d483.s0.e0
DDI-DrugBank.d483.s1|a|If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.
DDI-DrugBank.d483.s1	3	9	CEFOTAN	brand	DDI-DrugBank.d483.s1.e0
DDI-DrugBank.d483.s1	18	31	aminoglycoside	group	DDI-DrugBank.d483.s1.e1
DDI-DrugBank.d483.s1	true	DDI-DrugBank.d483.s1.e0	DDI-DrugBank.d483.s1.e1
DDI-DrugBank.d483.s2|a|Drug/Laboratory Test Interactions: The administration of CEFOTAN may result in a false positive reaction for glucose in the urine using Clinitest  , Benedicts solution, or Fehlings solution.
DDI-DrugBank.d483.s2	57	63	CEFOTAN	brand	DDI-DrugBank.d483.s2.e0
DDI-DrugBank.d483.s3|a|It is recommended that glucose tests based on enzymatic glucose oxidase be used.
DDI-DrugBank.d483.s4|a|As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffe  reaction and produce false increases in the levels of creatinine reported.
DDI-DrugBank.d483.s4	14	27	cephalosporins	group	DDI-DrugBank.d483.s4.e0
DDI-DrugBank.d483.s4	53	61	cefotetan	drug	DDI-DrugBank.d483.s4.e1
DDI-DrugBank.d483.s4	false	DDI-DrugBank.d483.s4.e0	DDI-DrugBank.d483.s4.e1
DDI-DrugBank.d556.s0|a|Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
DDI-DrugBank.d556.s0	83	96	cephalosporins	group	DDI-DrugBank.d556.s0.e0
DDI-DrugBank.d556.s0	102	127	aminoglycoside antibiotics	group	DDI-DrugBank.d556.s0.e1
DDI-DrugBank.d556.s0	true	DDI-DrugBank.d556.s0.e0	DDI-DrugBank.d556.s0.e1
DDI-DrugBank.d556.s1|a|Drug/Laboratory Test Interactions As with cephalothin, high concentrations of cefoxitin ( 100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaff  reaction, and produce false increases of modest degree in the levels of creatinine reported.
DDI-DrugBank.d556.s1	42	52	cephalothin	drug	DDI-DrugBank.d556.s1.e0
DDI-DrugBank.d556.s1	78	86	cefoxitin	drug	DDI-DrugBank.d556.s1.e1
DDI-DrugBank.d556.s1	false	DDI-DrugBank.d556.s1.e0	DDI-DrugBank.d556.s1.e1
DDI-DrugBank.d556.s2|a|Serum samples from patients treated with cefoxitin should not be analyzed for creatinine if withdrawn within 2 hours of drug administration.
DDI-DrugBank.d556.s2	41	49	cefoxitin	drug	DDI-DrugBank.d556.s2.e0
DDI-DrugBank.d556.s3|a|High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported.
DDI-DrugBank.d556.s3	23	31	cefoxitin	drug	DDI-DrugBank.d556.s3.e0
DDI-DrugBank.d556.s4|a|A false-positive reaction for glucose in the urine may occur.
DDI-DrugBank.d556.s5|a|This has been observed with CLINITEST  reagent tablets
DDI-DrugBank.d556.s6|a|.
DDI-DrugBank.d556.s7|a|Registered trademark of Ames Company, Division of Miles Laboratories, Inc.
DDI-DrugBank.d121.s0|a|Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.
DDI-DrugBank.d121.s0	73	98	aminoglycoside antibiotics	group	DDI-DrugBank.d121.s0.e0
DDI-DrugBank.d121.s0	104	128	cephalosporin antibiotics	group	DDI-DrugBank.d121.s0.e1
DDI-DrugBank.d121.s0	true	DDI-DrugBank.d121.s0.e0	DDI-DrugBank.d121.s0.e1
DDI-DrugBank.d121.s1|a|Concomitant administration of probenecid doubled the AUC for cefprozil.
DDI-DrugBank.d121.s1	30	39	probenecid	drug	DDI-DrugBank.d121.s1.e0
DDI-DrugBank.d121.s1	61	69	cefprozil	drug	DDI-DrugBank.d121.s1.e1
DDI-DrugBank.d121.s1	true	DDI-DrugBank.d121.s1.e0	DDI-DrugBank.d121.s1.e1
DDI-DrugBank.d121.s2|a|The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.
DDI-DrugBank.d121.s2	50	58	cefprozil	drug	DDI-DrugBank.d121.s2.e0
DDI-DrugBank.d121.s2	118	124	antacid	group	DDI-DrugBank.d121.s2.e1
DDI-DrugBank.d121.s2	false	DDI-DrugBank.d121.s2.e0	DDI-DrugBank.d121.s2.e1
DDI-DrugBank.d122.s0|a|Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
DDI-DrugBank.d122.s0	73	86	cephalosporins	group	DDI-DrugBank.d122.s0.e0
DDI-DrugBank.d122.s0	93	118	aminoglycoside antibiotics	group	DDI-DrugBank.d122.s0.e1
DDI-DrugBank.d122.s0	130	138	diuretics	group	DDI-DrugBank.d122.s0.e2
DDI-DrugBank.d122.s0	148	157	furosemide	drug	DDI-DrugBank.d122.s0.e3
DDI-DrugBank.d122.s0	true	DDI-DrugBank.d122.s0.e0	DDI-DrugBank.d122.s0.e1
DDI-DrugBank.d122.s0	true	DDI-DrugBank.d122.s0.e0	DDI-DrugBank.d122.s0.e2
DDI-DrugBank.d122.s0	true	DDI-DrugBank.d122.s0.e0	DDI-DrugBank.d122.s0.e3
DDI-DrugBank.d122.s0	false	DDI-DrugBank.d122.s0.e1	DDI-DrugBank.d122.s0.e2
DDI-DrugBank.d122.s0	false	DDI-DrugBank.d122.s0.e1	DDI-DrugBank.d122.s0.e3
DDI-DrugBank.d122.s0	false	DDI-DrugBank.d122.s0.e2	DDI-DrugBank.d122.s0.e3
DDI-DrugBank.d122.s1|a|Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics.
DDI-DrugBank.d122.s1	82	96	aminoglycosides	group	DDI-DrugBank.d122.s1.e0
DDI-DrugBank.d122.s1	208	234	aminoglycosidic antibiotics	group	DDI-DrugBank.d122.s1.e1
DDI-DrugBank.d122.s1	false	DDI-DrugBank.d122.s1.e0	DDI-DrugBank.d122.s1.e1
DDI-DrugBank.d122.s2|a|Nephrotoxicity and ototoxicity were not noted when ceftazidime was given alone in clinical trials.
DDI-DrugBank.d122.s2	51	61	ceftazidime	drug	DDI-DrugBank.d122.s2.e0
DDI-DrugBank.d122.s3|a|Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
DDI-DrugBank.d122.s3	0	14	Chloramphenicol	drug	DDI-DrugBank.d122.s3.e0
DDI-DrugBank.d122.s3	53	75	beta-lactam antibiotics	group	DDI-DrugBank.d122.s3.e1
DDI-DrugBank.d122.s3	88	98	ceftazidime	drug	DDI-DrugBank.d122.s3.e2
DDI-DrugBank.d122.s3	true	DDI-DrugBank.d122.s3.e0	DDI-DrugBank.d122.s3.e1
DDI-DrugBank.d122.s3	true	DDI-DrugBank.d122.s3.e0	DDI-DrugBank.d122.s3.e2
DDI-DrugBank.d122.s3	false	DDI-DrugBank.d122.s3.e1	DDI-DrugBank.d122.s3.e2
DDI-DrugBank.d122.s4|a|Due to the possibility of antagonism in vivo, particularly when bactericidal activity is desired, this drug combination should be avoided.
DDI-DrugBank.d122.s5|a|Drug/Laboratory Test Interactions The administration of ceftazidime may result in a false-positive reaction for glucose in the urine when using CLINITEST  tablets, Benedicts solution, or Fehlings solution.
DDI-DrugBank.d122.s5	56	66	ceftazidime	drug	DDI-DrugBank.d122.s5.e0
DDI-DrugBank.d122.s6|a|It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX  or TES-TAPE ) be used.
DDI-DrugBank.d32.s0|a|Theophylline: Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days.
DDI-DrugBank.d32.s0	0	11	Theophylline	drug	DDI-DrugBank.d32.s0.e0
DDI-DrugBank.d32.s0	74	83	ceftibuten	drug	DDI-DrugBank.d32.s0.e1
DDI-DrugBank.d32.s0	false	DDI-DrugBank.d32.s0.e0	DDI-DrugBank.d32.s0.e1
DDI-DrugBank.d32.s1|a|With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg).
DDI-DrugBank.d32.s1	25	34	ceftibuten	drug	DDI-DrugBank.d32.s1.e0
DDI-DrugBank.d32.s1	103	114	theophylline	drug	DDI-DrugBank.d32.s1.e1
DDI-DrugBank.d32.s1	false	DDI-DrugBank.d32.s1.e0	DDI-DrugBank.d32.s1.e1
DDI-DrugBank.d32.s2|a|The pharmacokinetics of theophylline were not altered.
DDI-DrugBank.d32.s2	24	35	theophylline	drug	DDI-DrugBank.d32.s2.e0
DDI-DrugBank.d32.s3|a|The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.
DDI-DrugBank.d32.s3	14	23	ceftibuten	drug	DDI-DrugBank.d32.s3.e0
DDI-DrugBank.d32.s3	52	63	theophylline	drug	DDI-DrugBank.d32.s3.e1
DDI-DrugBank.d32.s3	false	DDI-DrugBank.d32.s3.e0	DDI-DrugBank.d32.s3.e1
DDI-DrugBank.d32.s4|a|Antacids or H 2 -receptor antagonists: The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers.
DDI-DrugBank.d32.s4	0	7	Antacids	group	DDI-DrugBank.d32.s4.e0
DDI-DrugBank.d32.s4	12	36	H 2 -receptor antagonists	group	DDI-DrugBank.d32.s4.e1
DDI-DrugBank.d32.s4	100	109	ceftibuten	drug	DDI-DrugBank.d32.s4.e2
DDI-DrugBank.d32.s4	false	DDI-DrugBank.d32.s4.e0	DDI-DrugBank.d32.s4.e1
DDI-DrugBank.d32.s4	false	DDI-DrugBank.d32.s4.e0	DDI-DrugBank.d32.s4.e2
DDI-DrugBank.d32.s4	false	DDI-DrugBank.d32.s4.e1	DDI-DrugBank.d32.s4.e2
DDI-DrugBank.d32.s5|a|Each volunteer was administered one 400-mg ceftibuten capsule.
DDI-DrugBank.d32.s5	43	52	ceftibuten	drug	DDI-DrugBank.d32.s5.e0
DDI-DrugBank.d32.s6|a|A single dose of liquid antacid did not affect the C max or AUC of ceftibuten;
DDI-DrugBank.d32.s6	24	30	antacid	group	DDI-DrugBank.d32.s6.e0
DDI-DrugBank.d32.s6	67	76	ceftibuten	drug	DDI-DrugBank.d32.s6.e1
DDI-DrugBank.d32.s6	false	DDI-DrugBank.d32.s6.e0	DDI-DrugBank.d32.s6.e1
DDI-DrugBank.d32.s7|a|however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
DDI-DrugBank.d32.s7	19	28	ranitidine	drug	DDI-DrugBank.d32.s7.e0
DDI-DrugBank.d32.s7	60	69	ceftibuten	drug	DDI-DrugBank.d32.s7.e1
DDI-DrugBank.d32.s7	88	97	ceftibuten	drug	DDI-DrugBank.d32.s7.e2
DDI-DrugBank.d32.s7	true	DDI-DrugBank.d32.s7.e0	DDI-DrugBank.d32.s7.e1
DDI-DrugBank.d32.s7	true	DDI-DrugBank.d32.s7.e0	DDI-DrugBank.d32.s7.e2
DDI-DrugBank.d32.s7	false	DDI-DrugBank.d32.s7.e1	DDI-DrugBank.d32.s7.e2
DDI-DrugBank.d32.s8|a|The clinical relevance of these increases is not known.
DDI-DrugBank.d32.s9|a|Drug/Laboratory Test Interactions: There have been no chemical or laboratory test interactions with ceftibuten noted to date.
DDI-DrugBank.d32.s9	100	109	ceftibuten	drug	DDI-DrugBank.d32.s9.e0
DDI-DrugBank.d32.s10|a|False-positive direct Coombs tests have been reported during treatment with other cephalosporins.
DDI-DrugBank.d32.s10	82	95	cephalosporins	group	DDI-DrugBank.d32.s10.e0
DDI-DrugBank.d32.s11|a|Therefore, it should be recognized that a positive Coombs test could be due to the drug.
DDI-DrugBank.d32.s12|a|The results of assays using red cells from healthy subjects to determine whether ceftibuten would cause direct Coombs reactions in vitro showed no positive reaction at ceftibuten concentrations as high as 40  g/mL.
DDI-DrugBank.d32.s12	81	90	ceftibuten	drug	DDI-DrugBank.d32.s12.e0
DDI-DrugBank.d32.s12	168	177	ceftibuten	drug	DDI-DrugBank.d32.s12.e1
DDI-DrugBank.d32.s12	false	DDI-DrugBank.d32.s12.e0	DDI-DrugBank.d32.s12.e1
DDI-DrugBank.d33.s0|a|Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.
DDI-DrugBank.d33.s0	51	57	Cefizox	brand	DDI-DrugBank.d33.s0.e0
DDI-DrugBank.d33.s0	139	152	cephalosporins	group	DDI-DrugBank.d33.s0.e1
DDI-DrugBank.d33.s0	158	172	aminoglycosides	group	DDI-DrugBank.d33.s0.e2
DDI-DrugBank.d33.s0	false	DDI-DrugBank.d33.s0.e0	DDI-DrugBank.d33.s0.e1
DDI-DrugBank.d33.s0	false	DDI-DrugBank.d33.s0.e0	DDI-DrugBank.d33.s0.e2
DDI-DrugBank.d33.s0	true	DDI-DrugBank.d33.s0.e1	DDI-DrugBank.d33.s0.e2
DDI-DrugBank.d447.s0|a|Drug/Laboratory Test Interactions: A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict s or Fehling s solution or with Clinitest  tablets) but not with enzyme-based tests for glycosuria.
DDI-DrugBank.d447.s1|a|As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving cefuroxime.
DDI-DrugBank.d447.s1	205	214	cefuroxime	drug	DDI-DrugBank.d447.s1.e0
DDI-DrugBank.d447.s2|a|Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.
DDI-DrugBank.d447.s2	0	9	Cefuroxime	drug	DDI-DrugBank.d447.s2.e0
DDI-DrugBank.d172.s0|a|General: Significant interactions may occur when celecoxib is administered together with drugs that inhibit P450 2C9.
DDI-DrugBank.d172.s0	49	57	celecoxib	drug	DDI-DrugBank.d172.s0.e0
DDI-DrugBank.d172.s1|a|Celecoxib metabolism is predominantly mediated via cytochrome P450 2C9 in the liver.
DDI-DrugBank.d172.s1	0	8	Celecoxib	drug	DDI-DrugBank.d172.s1.e0
DDI-DrugBank.d172.s2|a|Co-administration of celecoxib with drugs that are known to inhibit 2C9 should be done with caution.
DDI-DrugBank.d172.s2	21	29	celecoxib	drug	DDI-DrugBank.d172.s2.e0
DDI-DrugBank.d172.s3|a|In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.
DDI-DrugBank.d172.s3	31	39	celecoxib	drug	DDI-DrugBank.d172.s3.e0
DDI-DrugBank.d172.s4|a|In vitro studies also indicate that celecoxib, although not a substrate, is an inhibitor of cytochrome P450 2D6.
DDI-DrugBank.d172.s4	36	44	celecoxib	drug	DDI-DrugBank.d172.s4.e0
DDI-DrugBank.d172.s5|a|Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by P450 2D6.
DDI-DrugBank.d172.s6|a|Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
DDI-DrugBank.d172.s6	22	30	celecoxib	drug	DDI-DrugBank.d172.s6.e0
DDI-DrugBank.d172.s6	90	100	fluconazole	drug	DDI-DrugBank.d172.s6.e1
DDI-DrugBank.d172.s6	106	112	lithium	drug	DDI-DrugBank.d172.s6.e2
DDI-DrugBank.d172.s6	true	DDI-DrugBank.d172.s6.e0	DDI-DrugBank.d172.s6.e1
DDI-DrugBank.d172.s6	true	DDI-DrugBank.d172.s6.e0	DDI-DrugBank.d172.s6.e2
DDI-DrugBank.d172.s6	false	DDI-DrugBank.d172.s6.e1	DDI-DrugBank.d172.s6.e2
DDI-DrugBank.d172.s7|a|Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
DDI-DrugBank.d172.s7	16	51	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d172.s7.e0
DDI-DrugBank.d172.s7	54	59	NSAIDs	group	DDI-DrugBank.d172.s7.e1
DDI-DrugBank.d172.s7	107	116	furosemide	drug	DDI-DrugBank.d172.s7.e2
DDI-DrugBank.d172.s7	122	135	ACE inhibitors	group	DDI-DrugBank.d172.s7.e3
DDI-DrugBank.d172.s7	false	DDI-DrugBank.d172.s7.e0	DDI-DrugBank.d172.s7.e1
DDI-DrugBank.d172.s7	true	DDI-DrugBank.d172.s7.e0	DDI-DrugBank.d172.s7.e2
DDI-DrugBank.d172.s7	true	DDI-DrugBank.d172.s7.e0	DDI-DrugBank.d172.s7.e3
DDI-DrugBank.d172.s7	true	DDI-DrugBank.d172.s7.e1	DDI-DrugBank.d172.s7.e2
DDI-DrugBank.d172.s7	true	DDI-DrugBank.d172.s7.e1	DDI-DrugBank.d172.s7.e3
DDI-DrugBank.d172.s7	false	DDI-DrugBank.d172.s7.e2	DDI-DrugBank.d172.s7.e3
DDI-DrugBank.d172.s8|a|The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
DDI-DrugBank.d172.s8	12	20	celecoxib	drug	DDI-DrugBank.d172.s8.e0
DDI-DrugBank.d172.s8	73	81	glyburide	drug	DDI-DrugBank.d172.s8.e1
DDI-DrugBank.d172.s8	84	95	ketoconazole	drug	DDI-DrugBank.d172.s8.e2
DDI-DrugBank.d172.s8	98	109	methotrexate	drug	DDI-DrugBank.d172.s8.e3
DDI-DrugBank.d172.s8	112	120	phenytoin	drug	DDI-DrugBank.d172.s8.e4
DDI-DrugBank.d172.s8	123	133	tolbutamide	drug	DDI-DrugBank.d172.s8.e5
DDI-DrugBank.d172.s8	140	147	warfarin	drug	DDI-DrugBank.d172.s8.e6
DDI-DrugBank.d172.s8	false	DDI-DrugBank.d172.s8.e0	DDI-DrugBank.d172.s8.e1
DDI-DrugBank.d172.s8	false	DDI-DrugBank.d172.s8.e0	DDI-DrugBank.d172.s8.e2
DDI-DrugBank.d172.s8	false	DDI-DrugBank.d172.s8.e0	DDI-DrugBank.d172.s8.e3
DDI-DrugBank.d172.s8	false	DDI-DrugBank.d172.s8.e0	DDI-DrugBank.d172.s8.e4
DDI-DrugBank.d172.s8	false	DDI-DrugBank.d172.s8.e0	DDI-DrugBank.d172.s8.e5
DDI-DrugBank.d172.s8	false	DDI-DrugBank.d172.s8.e0	DDI-DrugBank.d172.s8.e6
DDI-DrugBank.d172.s8	false	DDI-DrugBank.d172.s8.e1	DDI-DrugBank.d172.s8.e2
DDI-DrugBank.d172.s8	false	DDI-DrugBank.d172.s8.e1	DDI-DrugBank.d172.s8.e3
DDI-DrugBank.d172.s8	false	DDI-DrugBank.d172.s8.e1	DDI-DrugBank.d172.s8.e4
DDI-DrugBank.d172.s8	false	DDI-DrugBank.d172.s8.e1	DDI-DrugBank.d172.s8.e5
DDI-DrugBank.d172.s9|a|ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
DDI-DrugBank.d172.s9	0	13	ACE inhibitors	group	DDI-DrugBank.d172.s9.e0
DDI-DrugBank.d172.s9	37	42	NSAIDs	group	DDI-DrugBank.d172.s9.e1
DDI-DrugBank.d172.s9	88	133	Angiotensin Converting Enzyme (ACE) inhibitors	group	DDI-DrugBank.d172.s9.e2
DDI-DrugBank.d172.s9	false	DDI-DrugBank.d172.s9.e0	DDI-DrugBank.d172.s9.e1
DDI-DrugBank.d172.s9	false	DDI-DrugBank.d172.s9.e0	DDI-DrugBank.d172.s9.e2
DDI-DrugBank.d172.s9	true	DDI-DrugBank.d172.s9.e1	DDI-DrugBank.d172.s9.e2
DDI-DrugBank.d172.s10|a|This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.
DDI-DrugBank.d172.s10	66	73	CELEBREX	brand	DDI-DrugBank.d172.s10.e0
DDI-DrugBank.d172.s10	94	107	ACE-inhibitors	group	DDI-DrugBank.d172.s10.e1
DDI-DrugBank.d172.s10	true	DDI-DrugBank.d172.s10.e0	DDI-DrugBank.d172.s10.e1
DDI-DrugBank.d172.s11|a|Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d172.s11	0	9	Furosemide	drug	DDI-DrugBank.d172.s11.e0
DDI-DrugBank.d172.s11	86	91	NSAIDs	group	DDI-DrugBank.d172.s11.e1
DDI-DrugBank.d172.s11	130	139	furosemide	drug	DDI-DrugBank.d172.s11.e2
DDI-DrugBank.d172.s11	145	153	thiazides	group	DDI-DrugBank.d172.s11.e3
DDI-DrugBank.d172.s11	false	DDI-DrugBank.d172.s11.e0	DDI-DrugBank.d172.s11.e1
DDI-DrugBank.d172.s11	false	DDI-DrugBank.d172.s11.e0	DDI-DrugBank.d172.s11.e2
DDI-DrugBank.d172.s11	false	DDI-DrugBank.d172.s11.e0	DDI-DrugBank.d172.s11.e3
DDI-DrugBank.d172.s11	true	DDI-DrugBank.d172.s11.e1	DDI-DrugBank.d172.s11.e2
DDI-DrugBank.d172.s11	true	DDI-DrugBank.d172.s11.e1	DDI-DrugBank.d172.s11.e3
DDI-DrugBank.d172.s11	false	DDI-DrugBank.d172.s11.e2	DDI-DrugBank.d172.s11.e3
DDI-DrugBank.d172.s12|a|This response has been attributed to inhibition of renal prostaglandin synthesis.
DDI-DrugBank.d172.s13|a|Aspirin: CELEBREX can be used with low dose aspirin.
DDI-DrugBank.d172.s13	0	6	Aspirin	brand	DDI-DrugBank.d172.s13.e0
DDI-DrugBank.d172.s13	9	16	CELEBREX	brand	DDI-DrugBank.d172.s13.e1
DDI-DrugBank.d172.s13	44	50	aspirin	brand	DDI-DrugBank.d172.s13.e2
DDI-DrugBank.d172.s13	false	DDI-DrugBank.d172.s13.e0	DDI-DrugBank.d172.s13.e1
DDI-DrugBank.d172.s13	false	DDI-DrugBank.d172.s13.e0	DDI-DrugBank.d172.s13.e2
DDI-DrugBank.d172.s13	true	DDI-DrugBank.d172.s13.e1	DDI-DrugBank.d172.s13.e2
DDI-DrugBank.d172.s14|a|However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
DDI-DrugBank.d172.s14	39	45	aspirin	brand	DDI-DrugBank.d172.s14.e0
DDI-DrugBank.d172.s14	52	59	CELEBREX	brand	DDI-DrugBank.d172.s14.e1
DDI-DrugBank.d172.s14	153	160	CELEBREX	brand	DDI-DrugBank.d172.s14.e2
DDI-DrugBank.d172.s14	true	DDI-DrugBank.d172.s14.e0	DDI-DrugBank.d172.s14.e1
DDI-DrugBank.d172.s14	false	DDI-DrugBank.d172.s14.e0	DDI-DrugBank.d172.s14.e2
DDI-DrugBank.d172.s14	false	DDI-DrugBank.d172.s14.e1	DDI-DrugBank.d172.s14.e2
DDI-DrugBank.d172.s15|a|Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis.
DDI-DrugBank.d172.s15	41	48	CELEBREX	brand	DDI-DrugBank.d172.s15.e0
DDI-DrugBank.d172.s15	74	80	aspirin	brand	DDI-DrugBank.d172.s15.e1
DDI-DrugBank.d172.s15	false	DDI-DrugBank.d172.s15.e0	DDI-DrugBank.d172.s15.e1
DDI-DrugBank.d172.s16|a|Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
DDI-DrugBank.d172.s16	0	10	Fluconazole	drug	DDI-DrugBank.d172.s16.e0
DDI-DrugBank.d172.s16	43	53	fluconazole	drug	DDI-DrugBank.d172.s16.e1
DDI-DrugBank.d172.s16	103	111	celecoxib	drug	DDI-DrugBank.d172.s16.e2
DDI-DrugBank.d172.s16	false	DDI-DrugBank.d172.s16.e0	DDI-DrugBank.d172.s16.e1
DDI-DrugBank.d172.s16	false	DDI-DrugBank.d172.s16.e0	DDI-DrugBank.d172.s16.e2
DDI-DrugBank.d172.s16	true	DDI-DrugBank.d172.s16.e1	DDI-DrugBank.d172.s16.e2
DDI-DrugBank.d172.s17|a|This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
DDI-DrugBank.d172.s17	42	50	celecoxib	drug	DDI-DrugBank.d172.s17.e0
DDI-DrugBank.d172.s17	79	89	fluconazole	drug	DDI-DrugBank.d172.s17.e1
DDI-DrugBank.d172.s17	true	DDI-DrugBank.d172.s17.e0	DDI-DrugBank.d172.s17.e1
DDI-DrugBank.d172.s18|a|CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.
DDI-DrugBank.d172.s18	0	7	CELEBREX	brand	DDI-DrugBank.d172.s18.e0
DDI-DrugBank.d172.s18	83	93	fluconazole	drug	DDI-DrugBank.d172.s18.e1
DDI-DrugBank.d172.s18	true	DDI-DrugBank.d172.s18.e0	DDI-DrugBank.d172.s18.e1
DDI-DrugBank.d172.s19|a|Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.
DDI-DrugBank.d172.s19	0	6	Lithium	drug	DDI-DrugBank.d172.s19.e0
DDI-DrugBank.d172.s19	69	75	lithium	drug	DDI-DrugBank.d172.s19.e1
DDI-DrugBank.d172.s19	141	147	lithium	drug	DDI-DrugBank.d172.s19.e2
DDI-DrugBank.d172.s19	165	172	CELEBREX	brand	DDI-DrugBank.d172.s19.e3
DDI-DrugBank.d172.s19	219	225	lithium	drug	DDI-DrugBank.d172.s19.e4
DDI-DrugBank.d172.s19	false	DDI-DrugBank.d172.s19.e0	DDI-DrugBank.d172.s19.e1
DDI-DrugBank.d172.s19	false	DDI-DrugBank.d172.s19.e0	DDI-DrugBank.d172.s19.e2
DDI-DrugBank.d172.s19	false	DDI-DrugBank.d172.s19.e0	DDI-DrugBank.d172.s19.e3
DDI-DrugBank.d172.s19	false	DDI-DrugBank.d172.s19.e0	DDI-DrugBank.d172.s19.e4
DDI-DrugBank.d172.s19	false	DDI-DrugBank.d172.s19.e1	DDI-DrugBank.d172.s19.e2
DDI-DrugBank.d172.s19	false	DDI-DrugBank.d172.s19.e1	DDI-DrugBank.d172.s19.e3
DDI-DrugBank.d172.s19	false	DDI-DrugBank.d172.s19.e1	DDI-DrugBank.d172.s19.e4
DDI-DrugBank.d172.s19	true	DDI-DrugBank.d172.s19.e2	DDI-DrugBank.d172.s19.e3
DDI-DrugBank.d172.s19	false	DDI-DrugBank.d172.s19.e2	DDI-DrugBank.d172.s19.e4
DDI-DrugBank.d172.s19	false	DDI-DrugBank.d172.s19.e3	DDI-DrugBank.d172.s19.e4
DDI-DrugBank.d172.s20|a|Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.
DDI-DrugBank.d172.s20	12	18	lithium	drug	DDI-DrugBank.d172.s20.e0
DDI-DrugBank.d172.s20	63	70	CELEBREX	brand	DDI-DrugBank.d172.s20.e1
DDI-DrugBank.d172.s20	true	DDI-DrugBank.d172.s20.e0	DDI-DrugBank.d172.s20.e1
DDI-DrugBank.d172.s21|a|Methotrexate: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate.
DDI-DrugBank.d172.s21	0	11	Methotrexate	drug	DDI-DrugBank.d172.s21.e0
DDI-DrugBank.d172.s21	78	89	methotrexate	drug	DDI-DrugBank.d172.s21.e1
DDI-DrugBank.d172.s21	92	99	CELEBREX	brand	DDI-DrugBank.d172.s21.e2
DDI-DrugBank.d172.s21	162	173	methotrexate	drug	DDI-DrugBank.d172.s21.e3
DDI-DrugBank.d172.s21	false	DDI-DrugBank.d172.s21.e0	DDI-DrugBank.d172.s21.e1
DDI-DrugBank.d172.s21	false	DDI-DrugBank.d172.s21.e0	DDI-DrugBank.d172.s21.e2
DDI-DrugBank.d172.s21	false	DDI-DrugBank.d172.s21.e0	DDI-DrugBank.d172.s21.e3
DDI-DrugBank.d172.s21	false	DDI-DrugBank.d172.s21.e1	DDI-DrugBank.d172.s21.e2
DDI-DrugBank.d172.s21	false	DDI-DrugBank.d172.s21.e1	DDI-DrugBank.d172.s21.e3
DDI-DrugBank.d172.s21	false	DDI-DrugBank.d172.s21.e2	DDI-DrugBank.d172.s21.e3
DDI-DrugBank.d172.s22|a|Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.
DDI-DrugBank.d172.s22	0	7	Warfarin	drug	DDI-DrugBank.d172.s22.e0
DDI-DrugBank.d172.s22	24	32	celecoxib	drug	DDI-DrugBank.d172.s22.e1
DDI-DrugBank.d172.s22	66	73	warfarin	drug	DDI-DrugBank.d172.s22.e2
DDI-DrugBank.d172.s22	153	160	warfarin	drug	DDI-DrugBank.d172.s22.e3
DDI-DrugBank.d172.s22	false	DDI-DrugBank.d172.s22.e0	DDI-DrugBank.d172.s22.e1
DDI-DrugBank.d172.s22	false	DDI-DrugBank.d172.s22.e0	DDI-DrugBank.d172.s22.e2
DDI-DrugBank.d172.s22	false	DDI-DrugBank.d172.s22.e0	DDI-DrugBank.d172.s22.e3
DDI-DrugBank.d172.s22	false	DDI-DrugBank.d172.s22.e1	DDI-DrugBank.d172.s22.e2
DDI-DrugBank.d172.s22	false	DDI-DrugBank.d172.s22.e1	DDI-DrugBank.d172.s22.e3
DDI-DrugBank.d172.s22	false	DDI-DrugBank.d172.s22.e2	DDI-DrugBank.d172.s22.e3
DDI-DrugBank.d172.s23|a|In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time.
DDI-DrugBank.d172.s23	19	27	celecoxib	drug	DDI-DrugBank.d172.s23.e0
DDI-DrugBank.d172.s23	71	78	warfarin	drug	DDI-DrugBank.d172.s23.e1
DDI-DrugBank.d172.s23	false	DDI-DrugBank.d172.s23.e0	DDI-DrugBank.d172.s23.e1
DDI-DrugBank.d172.s24|a|However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.
DDI-DrugBank.d172.s24	51	58	CELEBREX	brand	DDI-DrugBank.d172.s24.e0
DDI-DrugBank.d172.s24	65	72	warfarin	drug	DDI-DrugBank.d172.s24.e1
DDI-DrugBank.d172.s24	true	DDI-DrugBank.d172.s24.e0	DDI-DrugBank.d172.s24.e1
DDI-DrugBank.d303.s0|a|Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
DDI-DrugBank.d303.s0	0	8	Metformin	drug	DDI-DrugBank.d303.s0.e0
DDI-DrugBank.d303.s0	60	69	cephalexin	drug	DDI-DrugBank.d303.s0.e1
DDI-DrugBank.d303.s0	75	83	metformin	drug	DDI-DrugBank.d303.s0.e2
DDI-DrugBank.d303.s0	93	101	metformin	drug	DDI-DrugBank.d303.s0.e3
DDI-DrugBank.d303.s0	179	187	metformin	drug	DDI-DrugBank.d303.s0.e4
DDI-DrugBank.d303.s0	false	DDI-DrugBank.d303.s0.e0	DDI-DrugBank.d303.s0.e1
DDI-DrugBank.d303.s0	false	DDI-DrugBank.d303.s0.e0	DDI-DrugBank.d303.s0.e2
DDI-DrugBank.d303.s0	false	DDI-DrugBank.d303.s0.e0	DDI-DrugBank.d303.s0.e3
DDI-DrugBank.d303.s0	false	DDI-DrugBank.d303.s0.e0	DDI-DrugBank.d303.s0.e4
DDI-DrugBank.d303.s0	true	DDI-DrugBank.d303.s0.e1	DDI-DrugBank.d303.s0.e2
DDI-DrugBank.d303.s0	false	DDI-DrugBank.d303.s0.e1	DDI-DrugBank.d303.s0.e3
DDI-DrugBank.d303.s0	false	DDI-DrugBank.d303.s0.e1	DDI-DrugBank.d303.s0.e4
DDI-DrugBank.d303.s0	false	DDI-DrugBank.d303.s0.e2	DDI-DrugBank.d303.s0.e3
DDI-DrugBank.d303.s0	false	DDI-DrugBank.d303.s0.e2	DDI-DrugBank.d303.s0.e4
DDI-DrugBank.d303.s0	false	DDI-DrugBank.d303.s0.e3	DDI-DrugBank.d303.s0.e4
DDI-DrugBank.d303.s1|a|No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.
DDI-DrugBank.d303.s1	53	62	cephalexin	drug	DDI-DrugBank.d303.s1.e0
DDI-DrugBank.d303.s1	68	76	metformin	drug	DDI-DrugBank.d303.s1.e1
DDI-DrugBank.d303.s1	false	DDI-DrugBank.d303.s1.e0	DDI-DrugBank.d303.s1.e1
DDI-DrugBank.d303.s2|a|Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.
DDI-DrugBank.d303.s2	103	112	cephalexin	drug	DDI-DrugBank.d303.s2.e0
DDI-DrugBank.d303.s2	118	126	metformin	drug	DDI-DrugBank.d303.s2.e1
DDI-DrugBank.d303.s2	true	DDI-DrugBank.d303.s2.e0	DDI-DrugBank.d303.s2.e1
DDI-DrugBank.d303.s3|a|Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.
DDI-DrugBank.d303.s3	63	71	metformin	drug	DDI-DrugBank.d303.s3.e0
DDI-DrugBank.d303.s3	121	130	cephalexin	drug	DDI-DrugBank.d303.s3.e1
DDI-DrugBank.d303.s3	136	144	metformin	drug	DDI-DrugBank.d303.s3.e2
DDI-DrugBank.d303.s3	false	DDI-DrugBank.d303.s3.e0	DDI-DrugBank.d303.s3.e1
DDI-DrugBank.d303.s3	false	DDI-DrugBank.d303.s3.e0	DDI-DrugBank.d303.s3.e2
DDI-DrugBank.d303.s3	true	DDI-DrugBank.d303.s3.e1	DDI-DrugBank.d303.s3.e2
DDI-DrugBank.d303.s4|a|Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.
DDI-DrugBank.d303.s4	0	9	Probenecid	drug	DDI-DrugBank.d303.s4.e0
DDI-DrugBank.d303.s4	26	34	b-lactams	group	DDI-DrugBank.d303.s4.e1
DDI-DrugBank.d303.s4	60	69	cephalexin	drug	DDI-DrugBank.d303.s4.e2
DDI-DrugBank.d303.s4	87	96	probenecid	drug	DDI-DrugBank.d303.s4.e3
DDI-DrugBank.d303.s4	false	DDI-DrugBank.d303.s4.e0	DDI-DrugBank.d303.s4.e1
DDI-DrugBank.d303.s4	false	DDI-DrugBank.d303.s4.e0	DDI-DrugBank.d303.s4.e2
DDI-DrugBank.d303.s4	false	DDI-DrugBank.d303.s4.e0	DDI-DrugBank.d303.s4.e3
DDI-DrugBank.d303.s4	false	DDI-DrugBank.d303.s4.e1	DDI-DrugBank.d303.s4.e2
DDI-DrugBank.d303.s4	false	DDI-DrugBank.d303.s4.e1	DDI-DrugBank.d303.s4.e3
DDI-DrugBank.d303.s4	true	DDI-DrugBank.d303.s4.e2	DDI-DrugBank.d303.s4.e3
DDI-DrugBank.d303.s5|a|Drug / Laboratory Test Interactions As a result of administration of Keflex, a false-positive reaction for glucose in the urine may occur.
DDI-DrugBank.d303.s5	69	74	Keflex	brand	DDI-DrugBank.d303.s5.e0
DDI-DrugBank.d303.s6|a|This has been observed with Benedict s and Fehling s solutions and also with Clinitest  tablets.
DDI-DrugBank.d141.s0|a|Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.
DDI-DrugBank.d141.s0	0	22	Immunosuppressive Drugs	group	DDI-DrugBank.d141.s0.e0
DDI-DrugBank.d141.s0	25	47	Fibric Acid Derivatives	group	DDI-DrugBank.d141.s0.e1
DDI-DrugBank.d141.s0	50	55	Niacin	drug	DDI-DrugBank.d141.s0.e2
DDI-DrugBank.d141.s0	58	71	Nicotinic Acid	drug	DDI-DrugBank.d141.s0.e3
DDI-DrugBank.d141.s0	74	85	Erythromycin	drug	DDI-DrugBank.d141.s0.e4
DDI-DrugBank.d141.s0	88	104	Azole Antifungals	group	DDI-DrugBank.d141.s0.e5
DDI-DrugBank.d141.s0	false	DDI-DrugBank.d141.s0.e0	DDI-DrugBank.d141.s0.e1
DDI-DrugBank.d141.s0	false	DDI-DrugBank.d141.s0.e0	DDI-DrugBank.d141.s0.e2
DDI-DrugBank.d141.s0	false	DDI-DrugBank.d141.s0.e0	DDI-DrugBank.d141.s0.e3
DDI-DrugBank.d141.s0	false	DDI-DrugBank.d141.s0.e0	DDI-DrugBank.d141.s0.e4
DDI-DrugBank.d141.s0	false	DDI-DrugBank.d141.s0.e0	DDI-DrugBank.d141.s0.e5
DDI-DrugBank.d141.s0	false	DDI-DrugBank.d141.s0.e1	DDI-DrugBank.d141.s0.e2
DDI-DrugBank.d141.s0	false	DDI-DrugBank.d141.s0.e1	DDI-DrugBank.d141.s0.e3
DDI-DrugBank.d141.s0	false	DDI-DrugBank.d141.s0.e1	DDI-DrugBank.d141.s0.e4
DDI-DrugBank.d141.s0	false	DDI-DrugBank.d141.s0.e1	DDI-DrugBank.d141.s0.e5
DDI-DrugBank.d141.s0	false	DDI-DrugBank.d141.s0.e2	DDI-DrugBank.d141.s0.e3
DDI-DrugBank.d141.s1|a|ANTACID (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of antacid.
DDI-DrugBank.d141.s1	0	6	ANTACID	group	DDI-DrugBank.d141.s1.e0
DDI-DrugBank.d141.s1	9	36	Magnesium-Aluminum Hydroxide	drug	DDI-DrugBank.d141.s1.e1
DDI-DrugBank.d141.s1	40	51	Cerivastatin	drug	DDI-DrugBank.d141.s1.e2
DDI-DrugBank.d141.s1	117	123	antacid	group	DDI-DrugBank.d141.s1.e3
DDI-DrugBank.d141.s1	false	DDI-DrugBank.d141.s1.e0	DDI-DrugBank.d141.s1.e1
DDI-DrugBank.d141.s1	false	DDI-DrugBank.d141.s1.e0	DDI-DrugBank.d141.s1.e2
DDI-DrugBank.d141.s1	false	DDI-DrugBank.d141.s1.e0	DDI-DrugBank.d141.s1.e3
DDI-DrugBank.d141.s1	false	DDI-DrugBank.d141.s1.e1	DDI-DrugBank.d141.s1.e2
DDI-DrugBank.d141.s1	false	DDI-DrugBank.d141.s1.e1	DDI-DrugBank.d141.s1.e3
DDI-DrugBank.d141.s1	false	DDI-DrugBank.d141.s1.e2	DDI-DrugBank.d141.s1.e3
DDI-DrugBank.d141.s2|a|CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine.
DDI-DrugBank.d141.s2	0	9	CIMETlDINE	drug	DDI-DrugBank.d141.s2.e0
DDI-DrugBank.d141.s2	12	23	Cerivastatin	drug	DDI-DrugBank.d141.s2.e1
DDI-DrugBank.d141.s2	89	98	cimetidine	drug	DDI-DrugBank.d141.s2.e2
DDI-DrugBank.d141.s2	false	DDI-DrugBank.d141.s2.e0	DDI-DrugBank.d141.s2.e1
DDI-DrugBank.d141.s2	false	DDI-DrugBank.d141.s2.e0	DDI-DrugBank.d141.s2.e2
DDI-DrugBank.d141.s2	false	DDI-DrugBank.d141.s2.e1	DDI-DrugBank.d141.s2.e2
DDI-DrugBank.d141.s3|a|CHOLESTYRAMINE: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.
DDI-DrugBank.d141.s3	0	13	CHOLESTYRAMINE	drug	DDI-DrugBank.d141.s3.e0
DDI-DrugBank.d141.s3	65	78	cholestyramine	drug	DDI-DrugBank.d141.s3.e1
DDI-DrugBank.d141.s3	107	125	cerivastatin sodium	drug	DDI-DrugBank.d141.s3.e2
DDI-DrugBank.d141.s3	false	DDI-DrugBank.d141.s3.e0	DDI-DrugBank.d141.s3.e1
DDI-DrugBank.d141.s3	false	DDI-DrugBank.d141.s3.e0	DDI-DrugBank.d141.s3.e2
DDI-DrugBank.d141.s3	false	DDI-DrugBank.d141.s3.e1	DDI-DrugBank.d141.s3.e2
DDI-DrugBank.d141.s4|a|In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.
DDI-DrugBank.d141.s4	57	75	cerivastatin sodium	drug	DDI-DrugBank.d141.s4.e0
DDI-DrugBank.d141.s4	86	99	cholestyramine	drug	DDI-DrugBank.d141.s4.e1
DDI-DrugBank.d141.s4	189	207	cerivastatin sodium	drug	DDI-DrugBank.d141.s4.e2
DDI-DrugBank.d141.s4	true	DDI-DrugBank.d141.s4.e0	DDI-DrugBank.d141.s4.e1
DDI-DrugBank.d141.s4	false	DDI-DrugBank.d141.s4.e0	DDI-DrugBank.d141.s4.e2
DDI-DrugBank.d141.s4	false	DDI-DrugBank.d141.s4.e1	DDI-DrugBank.d141.s4.e2
DDI-DrugBank.d141.s5|a|However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.
DDI-DrugBank.d141.s5	53	66	cholestyramine	drug	DDI-DrugBank.d141.s5.e0
DDI-DrugBank.d141.s5	110	128	cerivastatin sodium	drug	DDI-DrugBank.d141.s5.e1
DDI-DrugBank.d141.s5	210	221	cerivastatin	drug	DDI-DrugBank.d141.s5.e2
DDI-DrugBank.d141.s5	304	322	cerivastatin sodium	drug	DDI-DrugBank.d141.s5.e3
DDI-DrugBank.d141.s5	true	DDI-DrugBank.d141.s5.e0	DDI-DrugBank.d141.s5.e1
DDI-DrugBank.d141.s5	false	DDI-DrugBank.d141.s5.e0	DDI-DrugBank.d141.s5.e2
DDI-DrugBank.d141.s5	false	DDI-DrugBank.d141.s5.e0	DDI-DrugBank.d141.s5.e3
DDI-DrugBank.d141.s5	false	DDI-DrugBank.d141.s5.e1	DDI-DrugBank.d141.s5.e2
DDI-DrugBank.d141.s5	false	DDI-DrugBank.d141.s5.e1	DDI-DrugBank.d141.s5.e3
DDI-DrugBank.d141.s5	false	DDI-DrugBank.d141.s5.e2	DDI-DrugBank.d141.s5.e3
DDI-DrugBank.d141.s6|a|Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.
DDI-DrugBank.d141.s6	58	76	cerivastatin sodium	drug	DDI-DrugBank.d141.s6.e0
DDI-DrugBank.d141.s6	99	112	cholestyramine	drug	DDI-DrugBank.d141.s6.e1
DDI-DrugBank.d141.s6	213	231	cerivastatin sodium	drug	DDI-DrugBank.d141.s6.e2
DDI-DrugBank.d141.s6	false	DDI-DrugBank.d141.s6.e0	DDI-DrugBank.d141.s6.e1
DDI-DrugBank.d141.s6	false	DDI-DrugBank.d141.s6.e0	DDI-DrugBank.d141.s6.e2
DDI-DrugBank.d141.s6	false	DDI-DrugBank.d141.s6.e1	DDI-DrugBank.d141.s6.e2
DDI-DrugBank.d141.s7|a|DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.
DDI-DrugBank.d141.s7	0	6	DIGOXIN	drug	DDI-DrugBank.d141.s7.e0
DDI-DrugBank.d141.s7	16	22	digoxin	drug	DDI-DrugBank.d141.s7.e1
DDI-DrugBank.d141.s7	35	41	digoxin	drug	DDI-DrugBank.d141.s7.e2
DDI-DrugBank.d141.s7	118	136	cerivastatin sodium	drug	DDI-DrugBank.d141.s7.e3
DDI-DrugBank.d141.s7	false	DDI-DrugBank.d141.s7.e0	DDI-DrugBank.d141.s7.e1
DDI-DrugBank.d141.s7	false	DDI-DrugBank.d141.s7.e0	DDI-DrugBank.d141.s7.e2
DDI-DrugBank.d141.s7	false	DDI-DrugBank.d141.s7.e0	DDI-DrugBank.d141.s7.e3
DDI-DrugBank.d141.s7	false	DDI-DrugBank.d141.s7.e1	DDI-DrugBank.d141.s7.e2
DDI-DrugBank.d141.s7	false	DDI-DrugBank.d141.s7.e1	DDI-DrugBank.d141.s7.e3
DDI-DrugBank.d141.s7	false	DDI-DrugBank.d141.s7.e2	DDI-DrugBank.d141.s7.e3
DDI-DrugBank.d141.s8|a|Cerivastatin plasma concentrations were also not affected by co-administration of digoxin.
DDI-DrugBank.d141.s8	0	11	Cerivastatin	drug	DDI-DrugBank.d141.s8.e0
DDI-DrugBank.d141.s8	82	88	digoxin	drug	DDI-DrugBank.d141.s8.e1
DDI-DrugBank.d141.s8	false	DDI-DrugBank.d141.s8.e0	DDI-DrugBank.d141.s8.e1
DDI-DrugBank.d141.s9|a|WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.
DDI-DrugBank.d141.s9	0	7	WARFARIN	drug	DDI-DrugBank.d141.s9.e0
DDI-DrugBank.d141.s9	32	39	warfarin	drug	DDI-DrugBank.d141.s9.e1
DDI-DrugBank.d141.s9	45	56	cerivastatin	drug	DDI-DrugBank.d141.s9.e2
DDI-DrugBank.d141.s9	191	198	warfarin	drug	DDI-DrugBank.d141.s9.e3
DDI-DrugBank.d141.s9	false	DDI-DrugBank.d141.s9.e0	DDI-DrugBank.d141.s9.e1
DDI-DrugBank.d141.s9	false	DDI-DrugBank.d141.s9.e0	DDI-DrugBank.d141.s9.e2
DDI-DrugBank.d141.s9	false	DDI-DrugBank.d141.s9.e0	DDI-DrugBank.d141.s9.e3
DDI-DrugBank.d141.s9	false	DDI-DrugBank.d141.s9.e1	DDI-DrugBank.d141.s9.e2
DDI-DrugBank.d141.s9	false	DDI-DrugBank.d141.s9.e1	DDI-DrugBank.d141.s9.e3
DDI-DrugBank.d141.s9	false	DDI-DrugBank.d141.s9.e2	DDI-DrugBank.d141.s9.e3
DDI-DrugBank.d141.s10|a|The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium.
DDI-DrugBank.d141.s10	52	59	warfarin	drug	DDI-DrugBank.d141.s10.e0
DDI-DrugBank.d141.s10	108	126	cerivastatin sodium	drug	DDI-DrugBank.d141.s10.e1
DDI-DrugBank.d141.s10	false	DDI-DrugBank.d141.s10.e0	DDI-DrugBank.d141.s10.e1
DDI-DrugBank.d141.s11|a|Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium.
DDI-DrugBank.d141.s11	21	28	warfarin	drug	DDI-DrugBank.d141.s11.e0
DDI-DrugBank.d141.s11	34	45	cerivastatin	drug	DDI-DrugBank.d141.s11.e1
DDI-DrugBank.d141.s11	85	103	cerivastatin sodium	drug	DDI-DrugBank.d141.s11.e2
DDI-DrugBank.d141.s11	false	DDI-DrugBank.d141.s11.e0	DDI-DrugBank.d141.s11.e1
DDI-DrugBank.d141.s11	false	DDI-DrugBank.d141.s11.e0	DDI-DrugBank.d141.s11.e2
DDI-DrugBank.d141.s11	false	DDI-DrugBank.d141.s11.e1	DDI-DrugBank.d141.s11.e2
DDI-DrugBank.d141.s12|a|ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.
DDI-DrugBank.d141.s12	0	11	ERYTHROMYCIN	drug	DDI-DrugBank.d141.s12.e0
DDI-DrugBank.d141.s12	61	72	cerivastatin	drug	DDI-DrugBank.d141.s12.e1
DDI-DrugBank.d141.s12	176	187	erythromycin	drug	DDI-DrugBank.d141.s12.e2
DDI-DrugBank.d141.s12	false	DDI-DrugBank.d141.s12.e0	DDI-DrugBank.d141.s12.e1
DDI-DrugBank.d141.s12	false	DDI-DrugBank.d141.s12.e0	DDI-DrugBank.d141.s12.e2
DDI-DrugBank.d141.s12	true	DDI-DrugBank.d141.s12.e1	DDI-DrugBank.d141.s12.e2
DDI-DrugBank.d141.s13|a|OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.
DDI-DrugBank.d141.s13	106	124	cerivastatin sodium	drug	DDI-DrugBank.d141.s13.e0
DDI-DrugBank.d141.s13	154	200	angiotensin- converting enzyme (ACE) inhibitors	group	DDI-DrugBank.d141.s13.e1
DDI-DrugBank.d141.s13	203	214	betablockers	group	DDI-DrugBank.d141.s13.e2
DDI-DrugBank.d141.s13	217	240	calcium-channel blockers	group	DDI-DrugBank.d141.s13.e3
DDI-DrugBank.d141.s13	243	251	diuretics	group	DDI-DrugBank.d141.s13.e4
DDI-DrugBank.d141.s13	258	293	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d141.s13.e5
DDI-DrugBank.d141.s13	296	301	NSAIDs	group	DDI-DrugBank.d141.s13.e6
DDI-DrugBank.d141.s13	false	DDI-DrugBank.d141.s13.e0	DDI-DrugBank.d141.s13.e1
DDI-DrugBank.d141.s13	false	DDI-DrugBank.d141.s13.e0	DDI-DrugBank.d141.s13.e2
DDI-DrugBank.d141.s13	false	DDI-DrugBank.d141.s13.e0	DDI-DrugBank.d141.s13.e3
DDI-DrugBank.d141.s13	false	DDI-DrugBank.d141.s13.e0	DDI-DrugBank.d141.s13.e4
DDI-DrugBank.d141.s13	false	DDI-DrugBank.d141.s13.e0	DDI-DrugBank.d141.s13.e5
DDI-DrugBank.d141.s13	false	DDI-DrugBank.d141.s13.e0	DDI-DrugBank.d141.s13.e6
DDI-DrugBank.d141.s13	false	DDI-DrugBank.d141.s13.e1	DDI-DrugBank.d141.s13.e2
DDI-DrugBank.d141.s13	false	DDI-DrugBank.d141.s13.e1	DDI-DrugBank.d141.s13.e3
DDI-DrugBank.d141.s13	false	DDI-DrugBank.d141.s13.e1	DDI-DrugBank.d141.s13.e4
DDI-DrugBank.d141.s13	false	DDI-DrugBank.d141.s13.e1	DDI-DrugBank.d141.s13.e5
DDI-DrugBank.d393.s0|a|Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin.
DDI-DrugBank.d393.s0	41	50	cetirizine	drug	DDI-DrugBank.d393.s0.e0
DDI-DrugBank.d393.s0	82	96	pseudoephedrine	drug	DDI-DrugBank.d393.s0.e1
DDI-DrugBank.d393.s0	99	108	antipyrine	drug	DDI-DrugBank.d393.s0.e2
DDI-DrugBank.d393.s0	111	122	ketoconazole	drug	DDI-DrugBank.d393.s0.e3
DDI-DrugBank.d393.s0	125	136	erythromycin	drug	DDI-DrugBank.d393.s0.e4
DDI-DrugBank.d393.s0	142	153	azithromycin	drug	DDI-DrugBank.d393.s0.e5
DDI-DrugBank.d393.s0	false	DDI-DrugBank.d393.s0.e0	DDI-DrugBank.d393.s0.e1
DDI-DrugBank.d393.s0	false	DDI-DrugBank.d393.s0.e0	DDI-DrugBank.d393.s0.e2
DDI-DrugBank.d393.s0	false	DDI-DrugBank.d393.s0.e0	DDI-DrugBank.d393.s0.e3
DDI-DrugBank.d393.s0	false	DDI-DrugBank.d393.s0.e0	DDI-DrugBank.d393.s0.e4
DDI-DrugBank.d393.s0	false	DDI-DrugBank.d393.s0.e0	DDI-DrugBank.d393.s0.e5
DDI-DrugBank.d393.s0	false	DDI-DrugBank.d393.s0.e1	DDI-DrugBank.d393.s0.e2
DDI-DrugBank.d393.s0	false	DDI-DrugBank.d393.s0.e1	DDI-DrugBank.d393.s0.e3
DDI-DrugBank.d393.s0	false	DDI-DrugBank.d393.s0.e1	DDI-DrugBank.d393.s0.e4
DDI-DrugBank.d393.s0	false	DDI-DrugBank.d393.s0.e1	DDI-DrugBank.d393.s0.e5
DDI-DrugBank.d393.s0	false	DDI-DrugBank.d393.s0.e2	DDI-DrugBank.d393.s0.e3
DDI-DrugBank.d393.s1|a|No interactions were observed.
DDI-DrugBank.d393.s2|a|In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.
DDI-DrugBank.d393.s2	28	39	theophylline	drug	DDI-DrugBank.d393.s2.e0
DDI-DrugBank.d393.s2	76	85	cetirizine	drug	DDI-DrugBank.d393.s2.e1
DDI-DrugBank.d393.s2	153	162	cetirizine	drug	DDI-DrugBank.d393.s2.e2
DDI-DrugBank.d393.s2	true	DDI-DrugBank.d393.s2.e0	DDI-DrugBank.d393.s2.e1
DDI-DrugBank.d393.s2	false	DDI-DrugBank.d393.s2.e0	DDI-DrugBank.d393.s2.e2
DDI-DrugBank.d393.s2	false	DDI-DrugBank.d393.s2.e1	DDI-DrugBank.d393.s2.e2
DDI-DrugBank.d393.s3|a|The disposition of theophylline was not altered by concomitant cetirizine administration.
DDI-DrugBank.d393.s3	19	30	theophylline	drug	DDI-DrugBank.d393.s3.e0
DDI-DrugBank.d393.s3	63	72	cetirizine	drug	DDI-DrugBank.d393.s3.e1
DDI-DrugBank.d393.s3	false	DDI-DrugBank.d393.s3.e0	DDI-DrugBank.d393.s3.e1
DDI-DrugBank.d393.s4|a|Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.
DDI-DrugBank.d393.s4	89	100	theophylline	drug	DDI-DrugBank.d393.s4.e0
DDI-DrugBank.d393.s4	117	128	azithromycin	drug	DDI-DrugBank.d393.s4.e1
DDI-DrugBank.d393.s4	131	145	pseudoephedrine	drug	DDI-DrugBank.d393.s4.e2
DDI-DrugBank.d393.s4	148	159	ketoconazole	drug	DDI-DrugBank.d393.s4.e3
DDI-DrugBank.d393.s4	165	176	erythromycin	drug	DDI-DrugBank.d393.s4.e4
DDI-DrugBank.d393.s4	false	DDI-DrugBank.d393.s4.e0	DDI-DrugBank.d393.s4.e1
DDI-DrugBank.d393.s4	false	DDI-DrugBank.d393.s4.e0	DDI-DrugBank.d393.s4.e2
DDI-DrugBank.d393.s4	false	DDI-DrugBank.d393.s4.e0	DDI-DrugBank.d393.s4.e3
DDI-DrugBank.d393.s4	false	DDI-DrugBank.d393.s4.e0	DDI-DrugBank.d393.s4.e4
DDI-DrugBank.d393.s4	false	DDI-DrugBank.d393.s4.e1	DDI-DrugBank.d393.s4.e2
DDI-DrugBank.d393.s4	false	DDI-DrugBank.d393.s4.e1	DDI-DrugBank.d393.s4.e3
DDI-DrugBank.d393.s4	false	DDI-DrugBank.d393.s4.e1	DDI-DrugBank.d393.s4.e4
DDI-DrugBank.d393.s4	false	DDI-DrugBank.d393.s4.e2	DDI-DrugBank.d393.s4.e3
DDI-DrugBank.d393.s4	false	DDI-DrugBank.d393.s4.e2	DDI-DrugBank.d393.s4.e4
DDI-DrugBank.d393.s4	false	DDI-DrugBank.d393.s4.e3	DDI-DrugBank.d393.s4.e4
DDI-DrugBank.d393.s5|a|There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;
DDI-DrugBank.d393.s5	47	56	cetirizine	drug	DDI-DrugBank.d393.s5.e0
DDI-DrugBank.d393.s5	85	96	theophylline	drug	DDI-DrugBank.d393.s5.e1
DDI-DrugBank.d393.s5	true	DDI-DrugBank.d393.s5.e0	DDI-DrugBank.d393.s5.e1
DDI-DrugBank.d393.s6|a|it is possible that larger theophylline doses could have a greater effect.
DDI-DrugBank.d393.s6	27	38	theophylline	drug	DDI-DrugBank.d393.s6.e0
DDI-DrugBank.d540.s0|a|No formal drug interaction studies have been performed with Cetrotide .
DDI-DrugBank.d540.s0	60	68	Cetrotide	brand	DDI-DrugBank.d540.s0.e0
DDI-DrugBank.d193.s0|a|A drug interaction study was performed in which ERBITUX was administered in combination with irinotecan.
DDI-DrugBank.d193.s0	48	54	ERBITUX	brand	DDI-DrugBank.d193.s0.e0
DDI-DrugBank.d193.s0	93	102	irinotecan	drug	DDI-DrugBank.d193.s0.e1
DDI-DrugBank.d193.s0	false	DDI-DrugBank.d193.s0.e0	DDI-DrugBank.d193.s0.e1
DDI-DrugBank.d193.s1|a|There was no evidence of any pharmacokinetic interactions between ERBITUX and irinotecan.
DDI-DrugBank.d193.s1	66	72	ERBITUX	brand	DDI-DrugBank.d193.s1.e0
DDI-DrugBank.d193.s1	78	87	irinotecan	drug	DDI-DrugBank.d193.s1.e1
DDI-DrugBank.d193.s1	false	DDI-DrugBank.d193.s1.e0	DDI-DrugBank.d193.s1.e1
DDI-DrugBank.d287.s0|a|Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.
DDI-DrugBank.d287.s0	0	9	Cevimeline	drug	DDI-DrugBank.d287.s0.e0
DDI-DrugBank.d287.s0	66	92	beta adrenergic antagonists	group	DDI-DrugBank.d287.s0.e1
DDI-DrugBank.d287.s0	true	DDI-DrugBank.d287.s0.e0	DDI-DrugBank.d287.s0.e1
DDI-DrugBank.d287.s1|a|Drugs with parasympathomimetic effects administered concurrently with cevimeline can be expected to have additive effects.
DDI-DrugBank.d287.s1	70	79	cevimeline	drug	DDI-DrugBank.d287.s1.e0
DDI-DrugBank.d287.s2|a|Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly.
DDI-DrugBank.d287.s2	0	9	Cevimeline	drug	DDI-DrugBank.d287.s2.e0
DDI-DrugBank.d287.s3|a|Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline.
DDI-DrugBank.d287.s3	71	80	cevimeline	drug	DDI-DrugBank.d287.s3.e0
DDI-DrugBank.d287.s4|a|Cevimeline should be used with caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they may be at a higher risk of adverse events.
DDI-DrugBank.d287.s4	0	9	Cevimeline	drug	DDI-DrugBank.d287.s4.e0
DDI-DrugBank.d287.s5|a|In an in vitro study, cytochrome P450 isozymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 were not inhibited by exposure to cevimeline.
DDI-DrugBank.d287.s5	120	129	cevimeline	drug	DDI-DrugBank.d287.s5.e0
DDI-DrugBank.d255.s0|a|There are no known drug/drug interactions with chlorambucil.
DDI-DrugBank.d255.s0	47	58	chlorambucil	drug	DDI-DrugBank.d255.s0.e0
DDI-DrugBank.d336.s0|a|Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.
DDI-DrugBank.d336.s0	208	221	anticoagulants	group	DDI-DrugBank.d336.s0.e0
DDI-DrugBank.d336.s0	227	242	chlordiazepoxide	drug	DDI-DrugBank.d336.s0.e1
DDI-DrugBank.d336.s0	true	DDI-DrugBank.d336.s0.e0	DDI-DrugBank.d336.s0.e1
DDI-DrugBank.d336.s1|a|The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
DDI-DrugBank.d336.s1	23	29	alcohol	drug	DDI-DrugBank.d336.s1.e0
DDI-DrugBank.d336.s1	40	73	central nervous system depressants	group	DDI-DrugBank.d336.s1.e1
DDI-DrugBank.d336.s1	false	DDI-DrugBank.d336.s1.e0	DDI-DrugBank.d336.s1.e1
DDI-DrugBank.d110.s0|a|The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
DDI-DrugBank.d110.s0	28	47	anesthetic solutions	group	DDI-DrugBank.d110.s0.e0
DDI-DrugBank.d110.s0	60	70	epinephrine	drug	DDI-DrugBank.d110.s0.e1
DDI-DrugBank.d110.s0	75	88	norepinephrine	drug	DDI-DrugBank.d110.s0.e2
DDI-DrugBank.d110.s0	112	139	monoamine oxidase inhibitors	group	DDI-DrugBank.d110.s0.e3
DDI-DrugBank.d110.s0	142	166	tricyclic antidepressants	group	DDI-DrugBank.d110.s0.e4
DDI-DrugBank.d110.s0	171	184	phenothiazines	group	DDI-DrugBank.d110.s0.e5
DDI-DrugBank.d110.s0	false	DDI-DrugBank.d110.s0.e0	DDI-DrugBank.d110.s0.e1
DDI-DrugBank.d110.s0	false	DDI-DrugBank.d110.s0.e0	DDI-DrugBank.d110.s0.e2
DDI-DrugBank.d110.s0	false	DDI-DrugBank.d110.s0.e0	DDI-DrugBank.d110.s0.e3
DDI-DrugBank.d110.s0	true	DDI-DrugBank.d110.s0.e0	DDI-DrugBank.d110.s0.e4
DDI-DrugBank.d110.s0	true	DDI-DrugBank.d110.s0.e0	DDI-DrugBank.d110.s0.e5
DDI-DrugBank.d110.s0	false	DDI-DrugBank.d110.s0.e1	DDI-DrugBank.d110.s0.e2
DDI-DrugBank.d110.s0	true	DDI-DrugBank.d110.s0.e1	DDI-DrugBank.d110.s0.e3
DDI-DrugBank.d110.s0	true	DDI-DrugBank.d110.s0.e1	DDI-DrugBank.d110.s0.e4
DDI-DrugBank.d110.s0	true	DDI-DrugBank.d110.s0.e1	DDI-DrugBank.d110.s0.e5
DDI-DrugBank.d110.s0	true	DDI-DrugBank.d110.s0.e2	DDI-DrugBank.d110.s0.e3
DDI-DrugBank.d110.s1|a|Concurrent use of these agents should generally be avoided.
DDI-DrugBank.d110.s2|a|In situations when concurrent therapy is necessary, careful patient monitoring is essential.
DDI-DrugBank.d110.s3|a|Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
DDI-DrugBank.d110.s3	29	45	vasopressor drugs	group	DDI-DrugBank.d110.s3.e0
DDI-DrugBank.d110.s3	114	138	ergot-type oxytocic drugs	group	DDI-DrugBank.d110.s3.e1
DDI-DrugBank.d110.s3	true	DDI-DrugBank.d110.s3.e0	DDI-DrugBank.d110.s3.e1
DDI-DrugBank.d110.s4|a|The para-aminobenzoic acid metabolite of chloroprocaine inhibits the action of sulfonamides.
DDI-DrugBank.d110.s4	79	90	sulfonamides	group	DDI-DrugBank.d110.s4.e0
DDI-DrugBank.d110.s5|a|Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.
DDI-DrugBank.d110.s5	11	24	chloroprocaine	drug	DDI-DrugBank.d110.s5.e0
DDI-DrugBank.d110.s5	73	88	sulfonamide drug	group	DDI-DrugBank.d110.s5.e1
DDI-DrugBank.d110.s5	true	DDI-DrugBank.d110.s5.e0	DDI-DrugBank.d110.s5.e1
DDI-DrugBank.d429.s0|a|Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
DDI-DrugBank.d429.s0	0	7	Antacids	group	DDI-DrugBank.d429.s0.e0
DDI-DrugBank.d429.s0	13	18	kaolin	drug	DDI-DrugBank.d429.s0.e1
DDI-DrugBank.d429.s0	21	28	Antacids	group	DDI-DrugBank.d429.s0.e2
DDI-DrugBank.d429.s0	34	39	kaolin	drug	DDI-DrugBank.d429.s0.e3
DDI-DrugBank.d429.s0	66	76	chloroquine	drug	DDI-DrugBank.d429.s0.e4
DDI-DrugBank.d429.s0	false	DDI-DrugBank.d429.s0.e0	DDI-DrugBank.d429.s0.e1
DDI-DrugBank.d429.s0	false	DDI-DrugBank.d429.s0.e0	DDI-DrugBank.d429.s0.e2
DDI-DrugBank.d429.s0	false	DDI-DrugBank.d429.s0.e0	DDI-DrugBank.d429.s0.e3
DDI-DrugBank.d429.s0	false	DDI-DrugBank.d429.s0.e0	DDI-DrugBank.d429.s0.e4
DDI-DrugBank.d429.s0	false	DDI-DrugBank.d429.s0.e1	DDI-DrugBank.d429.s0.e2
DDI-DrugBank.d429.s0	false	DDI-DrugBank.d429.s0.e1	DDI-DrugBank.d429.s0.e3
DDI-DrugBank.d429.s0	false	DDI-DrugBank.d429.s0.e1	DDI-DrugBank.d429.s0.e4
DDI-DrugBank.d429.s0	false	DDI-DrugBank.d429.s0.e2	DDI-DrugBank.d429.s0.e3
DDI-DrugBank.d429.s0	true	DDI-DrugBank.d429.s0.e2	DDI-DrugBank.d429.s0.e4
DDI-DrugBank.d429.s0	true	DDI-DrugBank.d429.s0.e3	DDI-DrugBank.d429.s0.e4
DDI-DrugBank.d429.s1|a|an interval of at least 4 hours between intake of these agents and chloroquine should be observed.
DDI-DrugBank.d429.s1	67	77	chloroquine	drug	DDI-DrugBank.d429.s1.e0
DDI-DrugBank.d429.s2|a|Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.
DDI-DrugBank.d429.s2	0	9	Cimetidine	drug	DDI-DrugBank.d429.s2.e0
DDI-DrugBank.d429.s2	12	21	Cimetidine	drug	DDI-DrugBank.d429.s2.e1
DDI-DrugBank.d429.s2	53	63	chloroquine	drug	DDI-DrugBank.d429.s2.e2
DDI-DrugBank.d429.s2	false	DDI-DrugBank.d429.s2.e0	DDI-DrugBank.d429.s2.e1
DDI-DrugBank.d429.s2	false	DDI-DrugBank.d429.s2.e0	DDI-DrugBank.d429.s2.e2
DDI-DrugBank.d429.s2	true	DDI-DrugBank.d429.s2.e1	DDI-DrugBank.d429.s2.e2
DDI-DrugBank.d429.s3|a|Concomitant use of cimetidine should be avoided.
DDI-DrugBank.d429.s3	19	28	cimetidine	drug	DDI-DrugBank.d429.s3.e0
DDI-DrugBank.d429.s4|a|Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.
DDI-DrugBank.d429.s4	0	9	Ampicillin	drug	DDI-DrugBank.d429.s4.e0
DDI-DrugBank.d429.s4	46	56	chloroquine	drug	DDI-DrugBank.d429.s4.e1
DDI-DrugBank.d429.s4	103	112	ampicillin	drug	DDI-DrugBank.d429.s4.e2
DDI-DrugBank.d429.s4	false	DDI-DrugBank.d429.s4.e0	DDI-DrugBank.d429.s4.e1
DDI-DrugBank.d429.s4	false	DDI-DrugBank.d429.s4.e0	DDI-DrugBank.d429.s4.e2
DDI-DrugBank.d429.s4	true	DDI-DrugBank.d429.s4.e1	DDI-DrugBank.d429.s4.e2
DDI-DrugBank.d429.s5|a|An interval of at least two hours between intake of this agent and chloroquine should be observed.
DDI-DrugBank.d429.s5	67	77	chloroquine	drug	DDI-DrugBank.d429.s5.e0
DDI-DrugBank.d429.s6|a|Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.
DDI-DrugBank.d429.s6	0	10	Cyclosporin	drug	DDI-DrugBank.d429.s6.e0
DDI-DrugBank.d429.s6	35	45	chloroquine	drug	DDI-DrugBank.d429.s6.e1
DDI-DrugBank.d429.s6	87	97	cyclosporin	drug	DDI-DrugBank.d429.s6.e2
DDI-DrugBank.d429.s6	false	DDI-DrugBank.d429.s6.e0	DDI-DrugBank.d429.s6.e1
DDI-DrugBank.d429.s6	false	DDI-DrugBank.d429.s6.e0	DDI-DrugBank.d429.s6.e2
DDI-DrugBank.d429.s6	true	DDI-DrugBank.d429.s6.e1	DDI-DrugBank.d429.s6.e2
DDI-DrugBank.d429.s7|a|Therefore, close monitoring of serum cyclosporin level is recommended and, if necessary, chloroquine should be discontinued.
DDI-DrugBank.d429.s7	37	47	cyclosporin	drug	DDI-DrugBank.d429.s7.e0
DDI-DrugBank.d429.s7	89	99	chloroquine	drug	DDI-DrugBank.d429.s7.e1
DDI-DrugBank.d429.s7	false	DDI-DrugBank.d429.s7.e0	DDI-DrugBank.d429.s7.e1
DDI-DrugBank.d46.s0|a|When given concurrently the following drugs may interact with thiazide diuretics.
DDI-DrugBank.d46.s0	62	79	thiazide diuretics	group	DDI-DrugBank.d46.s0.e0
DDI-DrugBank.d46.s1|a|- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur
DDI-DrugBank.d46.s1	2	8	Alcohol	drug	DDI-DrugBank.d46.s1.e0
DDI-DrugBank.d46.s1	11	22	barbiturates	group	DDI-DrugBank.d46.s1.e1
DDI-DrugBank.d46.s1	28	36	narcotics	group	DDI-DrugBank.d46.s1.e2
DDI-DrugBank.d46.s1	false	DDI-DrugBank.d46.s1.e0	DDI-DrugBank.d46.s1.e1
DDI-DrugBank.d46.s1	false	DDI-DrugBank.d46.s1.e0	DDI-DrugBank.d46.s1.e2
DDI-DrugBank.d46.s1	false	DDI-DrugBank.d46.s1.e1	DDI-DrugBank.d46.s1.e2
DDI-DrugBank.d46.s2|a|.
DDI-DrugBank.d46.s3|a|- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required
DDI-DrugBank.d46.s3	2	19	Antidiabetic drugs	group	DDI-DrugBank.d46.s3.e0
DDI-DrugBank.d46.s3	39	45	insulin	drug	DDI-DrugBank.d46.s3.e1
DDI-DrugBank.d46.s3	73	89	antidiabetic drug	group	DDI-DrugBank.d46.s3.e2
DDI-DrugBank.d46.s3	false	DDI-DrugBank.d46.s3.e0	DDI-DrugBank.d46.s3.e1
DDI-DrugBank.d46.s3	false	DDI-DrugBank.d46.s3.e0	DDI-DrugBank.d46.s3.e2
DDI-DrugBank.d46.s3	false	DDI-DrugBank.d46.s3.e1	DDI-DrugBank.d46.s3.e2
DDI-DrugBank.d46.s4|a|.
DDI-DrugBank.d46.s5|a|- Other antihypertensive drugs: Additive effect or potentiation
DDI-DrugBank.d46.s5	8	29	antihypertensive drugs	group	DDI-DrugBank.d46.s5.e0
DDI-DrugBank.d46.s6|a|.
DDI-DrugBank.d46.s7|a|- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7	2	15	Cholestyramine	drug	DDI-DrugBank.d46.s7.e0
DDI-DrugBank.d46.s7	21	30	colestipol	drug	DDI-DrugBank.d46.s7.e1
DDI-DrugBank.d46.s7	32	37	resins	group	DDI-DrugBank.d46.s7.e2
DDI-DrugBank.d46.s7	40	53	Cholestytamine	drug	DDI-DrugBank.d46.s7.e3
DDI-DrugBank.d46.s7	59	68	colestipol	drug	DDI-DrugBank.d46.s7.e4
DDI-DrugBank.d46.s7	70	75	resins	group	DDI-DrugBank.d46.s7.e5
DDI-DrugBank.d46.s7	107	124	thiazide diuretics	group	DDI-DrugBank.d46.s7.e6
DDI-DrugBank.d46.s7	139	146	diuretic	group	DDI-DrugBank.d46.s7.e7
DDI-DrugBank.d46.s7	false	DDI-DrugBank.d46.s7.e0	DDI-DrugBank.d46.s7.e1
DDI-DrugBank.d46.s7	false	DDI-DrugBank.d46.s7.e0	DDI-DrugBank.d46.s7.e2
DDI-DrugBank.d46.s7	false	DDI-DrugBank.d46.s7.e0	DDI-DrugBank.d46.s7.e3
DDI-DrugBank.d46.s7	false	DDI-DrugBank.d46.s7.e0	DDI-DrugBank.d46.s7.e4
DDI-DrugBank.d46.s7	false	DDI-DrugBank.d46.s7.e0	DDI-DrugBank.d46.s7.e5
DDI-DrugBank.d46.s7	false	DDI-DrugBank.d46.s7.e0	DDI-DrugBank.d46.s7.e6
DDI-DrugBank.d46.s7	false	DDI-DrugBank.d46.s7.e0	DDI-DrugBank.d46.s7.e7
DDI-DrugBank.d46.s7	false	DDI-DrugBank.d46.s7.e1	DDI-DrugBank.d46.s7.e2
DDI-DrugBank.d46.s7	false	DDI-DrugBank.d46.s7.e1	DDI-DrugBank.d46.s7.e3
DDI-DrugBank.d46.s7	false	DDI-DrugBank.d46.s7.e1	DDI-DrugBank.d46.s7.e4
DDI-DrugBank.d46.s8|a|.
DDI-DrugBank.d46.s9|a|- Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia
DDI-DrugBank.d46.s9	2	16	Corticosteroids	group	DDI-DrugBank.d46.s9.e0
DDI-DrugBank.d46.s9	19	22	ACTH	drug	DDI-DrugBank.d46.s9.e1
DDI-DrugBank.d46.s9	false	DDI-DrugBank.d46.s9.e0	DDI-DrugBank.d46.s9.e1
DDI-DrugBank.d46.s10|a|.
DDI-DrugBank.d46.s11|a|- Pressor amines (e.g., norepinephrine): Possible decreased response to pressor amines but not sufficient to preclude their use
DDI-DrugBank.d46.s11	24	37	norepinephrine	drug	DDI-DrugBank.d46.s11.e0
DDI-DrugBank.d46.s12|a|.
DDI-DrugBank.d46.s13|a|- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant
DDI-DrugBank.d46.s13	2	26	Skeletal muscle relaxants	group	DDI-DrugBank.d46.s13.e0
DDI-DrugBank.d46.s13	52	63	tubocurarine	drug	DDI-DrugBank.d46.s13.e1
DDI-DrugBank.d46.s13	108	122	muscle relaxant	group	DDI-DrugBank.d46.s13.e2
DDI-DrugBank.d46.s13	false	DDI-DrugBank.d46.s13.e0	DDI-DrugBank.d46.s13.e1
DDI-DrugBank.d46.s13	false	DDI-DrugBank.d46.s13.e0	DDI-DrugBank.d46.s13.e2
DDI-DrugBank.d46.s13	false	DDI-DrugBank.d46.s13.e1	DDI-DrugBank.d46.s13.e2
DDI-DrugBank.d46.s14|a|.
DDI-DrugBank.d46.s15|a|- Lithium: Generally should not be given with diuretics.
DDI-DrugBank.d46.s15	2	8	Lithium	drug	DDI-DrugBank.d46.s15.e0
DDI-DrugBank.d46.s15	46	54	diuretics	group	DDI-DrugBank.d46.s15.e1
DDI-DrugBank.d46.s15	true	DDI-DrugBank.d46.s15.e0	DDI-DrugBank.d46.s15.e1
DDI-DrugBank.d46.s16|a|Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
DDI-DrugBank.d46.s16	0	14	Diuretic agents	group	DDI-DrugBank.d46.s16.e0
DDI-DrugBank.d46.s16	46	52	lithium	drug	DDI-DrugBank.d46.s16.e1
DDI-DrugBank.d46.s16	77	83	lithium	drug	DDI-DrugBank.d46.s16.e2
DDI-DrugBank.d46.s16	true	DDI-DrugBank.d46.s16.e0	DDI-DrugBank.d46.s16.e1
DDI-DrugBank.d46.s16	true	DDI-DrugBank.d46.s16.e0	DDI-DrugBank.d46.s16.e2
DDI-DrugBank.d46.s16	false	DDI-DrugBank.d46.s16.e1	DDI-DrugBank.d46.s16.e2
DDI-DrugBank.d46.s17|a|Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide
DDI-DrugBank.d46.s17	32	38	lithium	drug	DDI-DrugBank.d46.s17.e0
DDI-DrugBank.d46.s17	90	103	chlorothiazide	drug	DDI-DrugBank.d46.s17.e1
DDI-DrugBank.d46.s17	true	DDI-DrugBank.d46.s17.e0	DDI-DrugBank.d46.s17.e1
DDI-DrugBank.d46.s18|a|.
DDI-DrugBank.d46.s19|a|- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d46.s19	2	38	Non-steroidal Anti-inflammatory Drugs	group	DDI-DrugBank.d46.s19.e0
DDI-DrugBank.d46.s19	83	119	non-steroidal anti-inflammatory agent	group	DDI-DrugBank.d46.s19.e1
DDI-DrugBank.d46.s19	191	194	loop diuretics	group	DDI-DrugBank.d46.s19.e2
DDI-DrugBank.d46.s19	228	236	loop diuretics	group	DDI-DrugBank.d46.s19.e2
DDI-DrugBank.d46.s19	197	213	potassium-sparing diuretics	group	DDI-DrugBank.d46.s19.e3
DDI-DrugBank.d46.s19	228	236	potassium-sparing diuretics	group	DDI-DrugBank.d46.s19.e3
DDI-DrugBank.d46.s19	219	236	thiazide diuretics	drug	DDI-DrugBank.d46.s19.e4
DDI-DrugBank.d46.s19	false	DDI-DrugBank.d46.s19.e0	DDI-DrugBank.d46.s19.e1
DDI-DrugBank.d46.s19	false	DDI-DrugBank.d46.s19.e0	DDI-DrugBank.d46.s19.e2
DDI-DrugBank.d46.s19	false	DDI-DrugBank.d46.s19.e0	DDI-DrugBank.d46.s19.e3
DDI-DrugBank.d46.s19	false	DDI-DrugBank.d46.s19.e0	DDI-DrugBank.d46.s19.e4
DDI-DrugBank.d46.s19	true	DDI-DrugBank.d46.s19.e1	DDI-DrugBank.d46.s19.e2
DDI-DrugBank.d46.s19	true	DDI-DrugBank.d46.s19.e1	DDI-DrugBank.d46.s19.e3
DDI-DrugBank.d46.s19	true	DDI-DrugBank.d46.s19.e1	DDI-DrugBank.d46.s19.e4
DDI-DrugBank.d46.s19	false	DDI-DrugBank.d46.s19.e2	DDI-DrugBank.d46.s19.e3
DDI-DrugBank.d46.s19	false	DDI-DrugBank.d46.s19.e2	DDI-DrugBank.d46.s19.e4
DDI-DrugBank.d46.s19	false	DDI-DrugBank.d46.s19.e3	DDI-DrugBank.d46.s19.e4
DDI-DrugBank.d46.s20|a|Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained
DDI-DrugBank.d46.s20	16	29	chlorothiazide	drug	DDI-DrugBank.d46.s20.e0
DDI-DrugBank.d46.s20	35	72	non-steroidal anti-inflammatory agents	group	DDI-DrugBank.d46.s20.e1
DDI-DrugBank.d46.s20	179	186	diuretic	group	DDI-DrugBank.d46.s20.e2
DDI-DrugBank.d46.s20	true	DDI-DrugBank.d46.s20.e0	DDI-DrugBank.d46.s20.e1
DDI-DrugBank.d46.s20	false	DDI-DrugBank.d46.s20.e0	DDI-DrugBank.d46.s20.e2
DDI-DrugBank.d46.s20	false	DDI-DrugBank.d46.s20.e1	DDI-DrugBank.d46.s20.e2
DDI-DrugBank.d46.s21|a|.
DDI-DrugBank.d46.s22|a|- Drug/Laboratory Test Interactions: Thiazides should be discontinued before carrying out tests for parathyroid function.
DDI-DrugBank.d46.s22	37	45	Thiazides	group	DDI-DrugBank.d46.s22.e0
DDI-DrugBank.d446.s0|a|Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d446.s0	0	15	Chlorotrianisene	drug	DDI-DrugBank.d446.s0.e0
DDI-DrugBank.d446.s0	35	49	antidepressants	group	DDI-DrugBank.d446.s0.e1
DDI-DrugBank.d446.s0	52	58	aspirin	brand	DDI-DrugBank.d446.s0.e2
DDI-DrugBank.d446.s0	61	72	barbiturates	group	DDI-DrugBank.d446.s0.e3
DDI-DrugBank.d446.s0	75	87	bromocriptine	drug	DDI-DrugBank.d446.s0.e4
DDI-DrugBank.d446.s0	90	96	calcium	drug	DDI-DrugBank.d446.s0.e5
DDI-DrugBank.d446.s0	111	125	corticosteroids	group	DDI-DrugBank.d446.s0.e6
DDI-DrugBank.d446.s0	128	140	corticotropin	drug	DDI-DrugBank.d446.s0.e7
DDI-DrugBank.d446.s0	143	154	cyclosporine	drug	DDI-DrugBank.d446.s0.e8
DDI-DrugBank.d446.s0	157	166	dantrolene	drug	DDI-DrugBank.d446.s0.e9
DDI-DrugBank.d446.s0	true	DDI-DrugBank.d446.s0.e0	DDI-DrugBank.d446.s0.e1
DDI-DrugBank.d446.s0	true	DDI-DrugBank.d446.s0.e0	DDI-DrugBank.d446.s0.e2
DDI-DrugBank.d446.s0	true	DDI-DrugBank.d446.s0.e0	DDI-DrugBank.d446.s0.e3
DDI-DrugBank.d446.s0	true	DDI-DrugBank.d446.s0.e0	DDI-DrugBank.d446.s0.e4
DDI-DrugBank.d446.s0	true	DDI-DrugBank.d446.s0.e0	DDI-DrugBank.d446.s0.e5
DDI-DrugBank.d446.s0	true	DDI-DrugBank.d446.s0.e0	DDI-DrugBank.d446.s0.e6
DDI-DrugBank.d446.s0	true	DDI-DrugBank.d446.s0.e0	DDI-DrugBank.d446.s0.e7
DDI-DrugBank.d446.s0	true	DDI-DrugBank.d446.s0.e0	DDI-DrugBank.d446.s0.e8
DDI-DrugBank.d446.s0	true	DDI-DrugBank.d446.s0.e0	DDI-DrugBank.d446.s0.e9
DDI-DrugBank.d446.s0	true	DDI-DrugBank.d446.s0.e0	DDI-DrugBank.d446.s0.e10
DDI-DrugBank.d366.s0|a|May interact with skin products or shampoos for dandruff or psoriasis.
DDI-DrugBank.d235.s0|a|Substrate of CYP2D6 (minor), 3A4 (major);
DDI-DrugBank.d235.s1|a|Inhibits CYP2D6 (weak).
DDI-DrugBank.d235.s2|a|Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, tricyclic antidepressants, phenothiazines.
DDI-DrugBank.d235.s2	37	51	CNS depressants	group	DDI-DrugBank.d235.s2.e0
DDI-DrugBank.d235.s2	54	67	MAO inhibitors	group	DDI-DrugBank.d235.s2.e1
DDI-DrugBank.d235.s2	70	94	tricyclic antidepressants	group	DDI-DrugBank.d235.s2.e2
DDI-DrugBank.d235.s2	97	110	phenothiazines	group	DDI-DrugBank.d235.s2.e3
DDI-DrugBank.d235.s2	false	DDI-DrugBank.d235.s2.e0	DDI-DrugBank.d235.s2.e1
DDI-DrugBank.d235.s2	false	DDI-DrugBank.d235.s2.e0	DDI-DrugBank.d235.s2.e2
DDI-DrugBank.d235.s2	false	DDI-DrugBank.d235.s2.e0	DDI-DrugBank.d235.s2.e3
DDI-DrugBank.d235.s2	false	DDI-DrugBank.d235.s2.e1	DDI-DrugBank.d235.s2.e2
DDI-DrugBank.d235.s2	false	DDI-DrugBank.d235.s2.e1	DDI-DrugBank.d235.s2.e3
DDI-DrugBank.d235.s2	false	DDI-DrugBank.d235.s2.e2	DDI-DrugBank.d235.s2.e3
DDI-DrugBank.d235.s3|a|CYP3A4 inhibitors: May increase the levels/effects of chlorpheniramine.
DDI-DrugBank.d235.s3	54	69	chlorpheniramine	drug	DDI-DrugBank.d235.s3.e0
DDI-DrugBank.d235.s4|a|Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
DDI-DrugBank.d235.s4	27	43	azole antifungals	group	DDI-DrugBank.d235.s4.e0
DDI-DrugBank.d235.s4	46	58	ciprofloxacin	drug	DDI-DrugBank.d235.s4.e1
DDI-DrugBank.d235.s4	61	74	clarithromycin	drug	DDI-DrugBank.d235.s4.e2
DDI-DrugBank.d235.s4	77	86	diclofenac	drug	DDI-DrugBank.d235.s4.e3
DDI-DrugBank.d235.s4	89	99	doxycycline	drug	DDI-DrugBank.d235.s4.e4
DDI-DrugBank.d235.s4	102	113	erythromycin	drug	DDI-DrugBank.d235.s4.e5
DDI-DrugBank.d235.s4	116	123	imatinib	drug	DDI-DrugBank.d235.s4.e6
DDI-DrugBank.d235.s4	126	134	isoniazid	drug	DDI-DrugBank.d235.s4.e7
DDI-DrugBank.d235.s4	137	146	nefazodone	drug	DDI-DrugBank.d235.s4.e8
DDI-DrugBank.d235.s4	149	159	nicardipine	drug	DDI-DrugBank.d235.s4.e9
DDI-DrugBank.d235.s4	false	DDI-DrugBank.d235.s4.e0	DDI-DrugBank.d235.s4.e1
DDI-DrugBank.d235.s4	false	DDI-DrugBank.d235.s4.e0	DDI-DrugBank.d235.s4.e2
DDI-DrugBank.d235.s4	false	DDI-DrugBank.d235.s4.e0	DDI-DrugBank.d235.s4.e3
DDI-DrugBank.d235.s4	false	DDI-DrugBank.d235.s4.e0	DDI-DrugBank.d235.s4.e4
DDI-DrugBank.d235.s4	false	DDI-DrugBank.d235.s4.e0	DDI-DrugBank.d235.s4.e5
DDI-DrugBank.d235.s4	false	DDI-DrugBank.d235.s4.e0	DDI-DrugBank.d235.s4.e6
DDI-DrugBank.d235.s4	false	DDI-DrugBank.d235.s4.e0	DDI-DrugBank.d235.s4.e7
DDI-DrugBank.d235.s4	false	DDI-DrugBank.d235.s4.e0	DDI-DrugBank.d235.s4.e8
DDI-DrugBank.d235.s4	false	DDI-DrugBank.d235.s4.e0	DDI-DrugBank.d235.s4.e9
DDI-DrugBank.d235.s4	false	DDI-DrugBank.d235.s4.e0	DDI-DrugBank.d235.s4.e10
DDI-DrugBank.d86.s0|a|The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d86.s0	82	99	antipsychotic drug	group	DDI-DrugBank.d86.s0.e0
DDI-DrugBank.d86.s0	106	119	chlorpromazine	drug	DDI-DrugBank.d86.s0.e1
DDI-DrugBank.d86.s0	126	146	antiparkinsonian drug	group	DDI-DrugBank.d86.s0.e2
DDI-DrugBank.d86.s0	153	167	trihexyphenidyl	drug	DDI-DrugBank.d86.s0.e3
DDI-DrugBank.d86.s0	180	203	tricyclic antidepressant	group	DDI-DrugBank.d86.s0.e4
DDI-DrugBank.d86.s0	210	222	amitriptyline	drug	DDI-DrugBank.d86.s0.e5
DDI-DrugBank.d86.s0	false	DDI-DrugBank.d86.s0.e0	DDI-DrugBank.d86.s0.e1
DDI-DrugBank.d86.s0	true	DDI-DrugBank.d86.s0.e0	DDI-DrugBank.d86.s0.e2
DDI-DrugBank.d86.s0	true	DDI-DrugBank.d86.s0.e0	DDI-DrugBank.d86.s0.e3
DDI-DrugBank.d86.s0	true	DDI-DrugBank.d86.s0.e0	DDI-DrugBank.d86.s0.e4
DDI-DrugBank.d86.s0	true	DDI-DrugBank.d86.s0.e0	DDI-DrugBank.d86.s0.e5
DDI-DrugBank.d86.s0	true	DDI-DrugBank.d86.s0.e1	DDI-DrugBank.d86.s0.e2
DDI-DrugBank.d86.s0	true	DDI-DrugBank.d86.s0.e1	DDI-DrugBank.d86.s0.e3
DDI-DrugBank.d86.s0	true	DDI-DrugBank.d86.s0.e1	DDI-DrugBank.d86.s0.e4
DDI-DrugBank.d86.s0	true	DDI-DrugBank.d86.s0.e1	DDI-DrugBank.d86.s0.e5
DDI-DrugBank.d86.s0	false	DDI-DrugBank.d86.s0.e2	DDI-DrugBank.d86.s0.e3
DDI-DrugBank.d86.s1|a|Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
DDI-DrugBank.d86.s1	48	63	anti-depressants	group	DDI-DrugBank.d86.s1.e0
DDI-DrugBank.d86.s1	65	82	anti-anxiety drugs	group	DDI-DrugBank.d86.s1.e1
DDI-DrugBank.d86.s1	128	140	beta-blockers	group	DDI-DrugBank.d86.s1.e2
DDI-DrugBank.d86.s1	149	159	propranolol	drug	DDI-DrugBank.d86.s1.e3
DDI-DrugBank.d86.s1	163	174	sparfloxacin	drug	DDI-DrugBank.d86.s1.e4
DDI-DrugBank.d86.s1	177	189	grepafloxacin	drug	DDI-DrugBank.d86.s1.e5
DDI-DrugBank.d86.s1	192	203	guanethidine	drug	DDI-DrugBank.d86.s1.e6
DDI-DrugBank.d86.s1	206	214	guanadrel	drug	DDI-DrugBank.d86.s1.e7
DDI-DrugBank.d86.s1	217	227	metrizamide	drug	DDI-DrugBank.d86.s1.e8
DDI-DrugBank.d86.s1	230	240	cabergoline	drug	DDI-DrugBank.d86.s1.e9
DDI-DrugBank.d86.s1	false	DDI-DrugBank.d86.s1.e0	DDI-DrugBank.d86.s1.e1
DDI-DrugBank.d86.s1	false	DDI-DrugBank.d86.s1.e0	DDI-DrugBank.d86.s1.e2
DDI-DrugBank.d86.s1	false	DDI-DrugBank.d86.s1.e0	DDI-DrugBank.d86.s1.e3
DDI-DrugBank.d86.s1	false	DDI-DrugBank.d86.s1.e0	DDI-DrugBank.d86.s1.e4
DDI-DrugBank.d86.s1	false	DDI-DrugBank.d86.s1.e0	DDI-DrugBank.d86.s1.e5
DDI-DrugBank.d86.s1	false	DDI-DrugBank.d86.s1.e0	DDI-DrugBank.d86.s1.e6
DDI-DrugBank.d86.s1	false	DDI-DrugBank.d86.s1.e0	DDI-DrugBank.d86.s1.e7
DDI-DrugBank.d86.s1	false	DDI-DrugBank.d86.s1.e0	DDI-DrugBank.d86.s1.e8
DDI-DrugBank.d86.s1	false	DDI-DrugBank.d86.s1.e0	DDI-DrugBank.d86.s1.e9
DDI-DrugBank.d86.s1	false	DDI-DrugBank.d86.s1.e0	DDI-DrugBank.d86.s1.e10
DDI-DrugBank.d245.s0|a|The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d245.s0	27	38	sulfonylurea	group	DDI-DrugBank.d245.s0.e0
DDI-DrugBank.d245.s0	86	122	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d245.s0.e1
DDI-DrugBank.d245.s0	171	181	salicylates	group	DDI-DrugBank.d245.s0.e2
DDI-DrugBank.d245.s0	184	195	sulfonamides	group	DDI-DrugBank.d245.s0.e3
DDI-DrugBank.d245.s0	198	212	chloramphenicol	drug	DDI-DrugBank.d245.s0.e4
DDI-DrugBank.d245.s0	215	224	probenecid	drug	DDI-DrugBank.d245.s0.e5
DDI-DrugBank.d245.s0	227	235	coumarins	group	DDI-DrugBank.d245.s0.e6
DDI-DrugBank.d245.s0	238	265	monoamine oxidase inhibitors	group	DDI-DrugBank.d245.s0.e7
DDI-DrugBank.d245.s0	272	302	beta adrenergic blocking agents	group	DDI-DrugBank.d245.s0.e8
DDI-DrugBank.d245.s0	true	DDI-DrugBank.d245.s0.e0	DDI-DrugBank.d245.s0.e1
DDI-DrugBank.d245.s0	true	DDI-DrugBank.d245.s0.e0	DDI-DrugBank.d245.s0.e2
DDI-DrugBank.d245.s0	true	DDI-DrugBank.d245.s0.e0	DDI-DrugBank.d245.s0.e3
DDI-DrugBank.d245.s0	true	DDI-DrugBank.d245.s0.e0	DDI-DrugBank.d245.s0.e4
DDI-DrugBank.d245.s0	true	DDI-DrugBank.d245.s0.e0	DDI-DrugBank.d245.s0.e5
DDI-DrugBank.d245.s0	true	DDI-DrugBank.d245.s0.e0	DDI-DrugBank.d245.s0.e6
DDI-DrugBank.d245.s0	true	DDI-DrugBank.d245.s0.e0	DDI-DrugBank.d245.s0.e7
DDI-DrugBank.d245.s0	true	DDI-DrugBank.d245.s0.e0	DDI-DrugBank.d245.s0.e8
DDI-DrugBank.d245.s0	false	DDI-DrugBank.d245.s0.e1	DDI-DrugBank.d245.s0.e2
DDI-DrugBank.d245.s0	false	DDI-DrugBank.d245.s0.e1	DDI-DrugBank.d245.s0.e3
DDI-DrugBank.d245.s1|a|When such drugs are administered to a patient receiving DIABINESE, the patient should be observed closely for hypoglycemia.
DDI-DrugBank.d245.s1	56	64	DIABINESE	brand	DDI-DrugBank.d245.s1.e0
DDI-DrugBank.d245.s2|a|When such drugs are withdrawn from a patient receiving DIABINESE, the patient should be observed closely for loss of control.
DDI-DrugBank.d245.s2	55	63	DIABINESE	brand	DDI-DrugBank.d245.s2.e0
DDI-DrugBank.d245.s3|a|Certain drugs tend to produce hyperglycemia and may lead to loss of control.
DDI-DrugBank.d245.s4|a|These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
DDI-DrugBank.d245.s4	24	32	thiazides	group	DDI-DrugBank.d245.s4.e0
DDI-DrugBank.d245.s4	44	52	diuretics	group	DDI-DrugBank.d245.s4.e1
DDI-DrugBank.d245.s4	55	69	corticosteroids	group	DDI-DrugBank.d245.s4.e2
DDI-DrugBank.d245.s4	72	85	phenothiazines	group	DDI-DrugBank.d245.s4.e3
DDI-DrugBank.d245.s4	106	114	estrogens	group	DDI-DrugBank.d245.s4.e4
DDI-DrugBank.d245.s4	122	135	contraceptives	group	DDI-DrugBank.d245.s4.e5
DDI-DrugBank.d245.s4	138	146	phenytoin	drug	DDI-DrugBank.d245.s4.e6
DDI-DrugBank.d245.s4	149	162	nicotinic acid	drug	DDI-DrugBank.d245.s4.e7
DDI-DrugBank.d245.s4	165	180	sympathomimetics	group	DDI-DrugBank.d245.s4.e8
DDI-DrugBank.d245.s4	183	212	calcium channel blocking drugs	group	DDI-DrugBank.d245.s4.e9
DDI-DrugBank.d245.s4	false	DDI-DrugBank.d245.s4.e0	DDI-DrugBank.d245.s4.e1
DDI-DrugBank.d245.s4	false	DDI-DrugBank.d245.s4.e0	DDI-DrugBank.d245.s4.e2
DDI-DrugBank.d245.s4	false	DDI-DrugBank.d245.s4.e0	DDI-DrugBank.d245.s4.e3
DDI-DrugBank.d245.s4	false	DDI-DrugBank.d245.s4.e0	DDI-DrugBank.d245.s4.e4
DDI-DrugBank.d245.s4	false	DDI-DrugBank.d245.s4.e0	DDI-DrugBank.d245.s4.e5
DDI-DrugBank.d245.s4	false	DDI-DrugBank.d245.s4.e0	DDI-DrugBank.d245.s4.e6
DDI-DrugBank.d245.s4	false	DDI-DrugBank.d245.s4.e0	DDI-DrugBank.d245.s4.e7
DDI-DrugBank.d245.s4	false	DDI-DrugBank.d245.s4.e0	DDI-DrugBank.d245.s4.e8
DDI-DrugBank.d245.s4	false	DDI-DrugBank.d245.s4.e0	DDI-DrugBank.d245.s4.e9
DDI-DrugBank.d245.s4	false	DDI-DrugBank.d245.s4.e0	DDI-DrugBank.d245.s4.e10
DDI-DrugBank.d245.s5|a|When such drugs are administered to a patient receiving DIABINESE, the patient should be closely observed for loss of control.
DDI-DrugBank.d245.s5	56	64	DIABINESE	brand	DDI-DrugBank.d245.s5.e0
DDI-DrugBank.d245.s6|a|When such drugs are withdrawn from a patient receiving DIABINESE, the patient should be observed closely for hypoglycemia.
DDI-DrugBank.d245.s6	55	63	DIABINESE	brand	DDI-DrugBank.d245.s6.e0
DDI-DrugBank.d245.s7|a|Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.
DDI-DrugBank.d245.s7	48	59	barbiturates	group	DDI-DrugBank.d245.s7.e0
DDI-DrugBank.d245.s7	94	107	chlorpropamide	drug	DDI-DrugBank.d245.s7.e1
DDI-DrugBank.d245.s7	110	121	barbiturates	group	DDI-DrugBank.d245.s7.e2
DDI-DrugBank.d245.s7	true	DDI-DrugBank.d245.s7.e0	DDI-DrugBank.d245.s7.e1
DDI-DrugBank.d245.s7	false	DDI-DrugBank.d245.s7.e0	DDI-DrugBank.d245.s7.e2
DDI-DrugBank.d245.s7	false	DDI-DrugBank.d245.s7.e1	DDI-DrugBank.d245.s7.e2
DDI-DrugBank.d245.s8|a|In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.
DDI-DrugBank.d245.s8	20	29	disulfiram	drug	DDI-DrugBank.d245.s8.e0
DDI-DrugBank.d245.s8	81	87	alcohol	drug	DDI-DrugBank.d245.s8.e1
DDI-DrugBank.d245.s8	false	DDI-DrugBank.d245.s8.e0	DDI-DrugBank.d245.s8.e1
DDI-DrugBank.d245.s9|a|A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
DDI-DrugBank.d245.s9	37	46	miconazole	drug	DDI-DrugBank.d245.s9.e0
DDI-DrugBank.d245.s9	57	75	hypoglycemic agents	group	DDI-DrugBank.d245.s9.e1
DDI-DrugBank.d245.s9	true	DDI-DrugBank.d245.s9.e0	DDI-DrugBank.d245.s9.e1
DDI-DrugBank.d245.s10|a|Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.
DDI-DrugBank.d245.s10	95	104	miconazole	drug	DDI-DrugBank.d245.s10.e0
DDI-DrugBank.d503.s0|a|Chlorprothixene may increase the plasma-level of concomitantly given lithium.
DDI-DrugBank.d503.s0	0	14	Chlorprothixene	drug	DDI-DrugBank.d503.s0.e0
DDI-DrugBank.d503.s0	69	75	lithium	drug	DDI-DrugBank.d503.s0.e1
DDI-DrugBank.d503.s0	true	DDI-DrugBank.d503.s0.e0	DDI-DrugBank.d503.s0.e1
DDI-DrugBank.d503.s1|a|In order to avoid lithium intoxication, lithium plasma levels should be monitored closely.
DDI-DrugBank.d503.s1	18	24	lithium	drug	DDI-DrugBank.d503.s1.e0
DDI-DrugBank.d503.s1	40	46	lithium	drug	DDI-DrugBank.d503.s1.e1
DDI-DrugBank.d503.s1	false	DDI-DrugBank.d503.s1.e0	DDI-DrugBank.d503.s1.e1
DDI-DrugBank.d503.s2|a|If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
DDI-DrugBank.d503.s2	3	17	chlorprothixene	drug	DDI-DrugBank.d503.s2.e0
DDI-DrugBank.d503.s2	47	53	opioids	group	DDI-DrugBank.d503.s2.e1
DDI-DrugBank.d503.s2	60	65	opioid	group	DDI-DrugBank.d503.s2.e2
DDI-DrugBank.d503.s2	116	130	chlorprothixene	drug	DDI-DrugBank.d503.s2.e3
DDI-DrugBank.d503.s2	186	192	opioids	group	DDI-DrugBank.d503.s2.e4
DDI-DrugBank.d503.s2	true	DDI-DrugBank.d503.s2.e0	DDI-DrugBank.d503.s2.e1
DDI-DrugBank.d503.s2	false	DDI-DrugBank.d503.s2.e0	DDI-DrugBank.d503.s2.e2
DDI-DrugBank.d503.s2	false	DDI-DrugBank.d503.s2.e0	DDI-DrugBank.d503.s2.e3
DDI-DrugBank.d503.s2	false	DDI-DrugBank.d503.s2.e0	DDI-DrugBank.d503.s2.e4
DDI-DrugBank.d503.s2	false	DDI-DrugBank.d503.s2.e1	DDI-DrugBank.d503.s2.e2
DDI-DrugBank.d503.s2	false	DDI-DrugBank.d503.s2.e1	DDI-DrugBank.d503.s2.e3
DDI-DrugBank.d503.s2	false	DDI-DrugBank.d503.s2.e1	DDI-DrugBank.d503.s2.e4
DDI-DrugBank.d503.s2	false	DDI-DrugBank.d503.s2.e2	DDI-DrugBank.d503.s2.e3
DDI-DrugBank.d503.s2	false	DDI-DrugBank.d503.s2.e2	DDI-DrugBank.d503.s2.e4
DDI-DrugBank.d503.s2	true	DDI-DrugBank.d503.s2.e3	DDI-DrugBank.d503.s2.e4
DDI-DrugBank.d503.s3|a|Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
DDI-DrugBank.d503.s3	29	43	chlorprothixene	drug	DDI-DrugBank.d503.s3.e0
DDI-DrugBank.d503.s3	49	56	tramadol	drug	DDI-DrugBank.d503.s3.e1
DDI-DrugBank.d503.s3	59	64	Ultram	brand	DDI-DrugBank.d503.s3.e2
DDI-DrugBank.d503.s3	true	DDI-DrugBank.d503.s3.e0	DDI-DrugBank.d503.s3.e1
DDI-DrugBank.d503.s3	true	DDI-DrugBank.d503.s3.e0	DDI-DrugBank.d503.s3.e2
DDI-DrugBank.d503.s3	false	DDI-DrugBank.d503.s3.e1	DDI-DrugBank.d503.s3.e2
DDI-DrugBank.d503.s4|a|Massive seizures may be encountered with this combination.
DDI-DrugBank.d503.s5|a|Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.
DDI-DrugBank.d503.s5	72	86	chlorprothixene	drug	DDI-DrugBank.d503.s5.e0
DDI-DrugBank.d503.s5	102	116	benzodiazepines	group	DDI-DrugBank.d503.s5.e1
DDI-DrugBank.d503.s5	121	131	barbituates	group	DDI-DrugBank.d503.s5.e2
DDI-DrugBank.d503.s5	true	DDI-DrugBank.d503.s5.e0	DDI-DrugBank.d503.s5.e1
DDI-DrugBank.d503.s5	true	DDI-DrugBank.d503.s5.e0	DDI-DrugBank.d503.s5.e2
DDI-DrugBank.d503.s5	false	DDI-DrugBank.d503.s5.e1	DDI-DrugBank.d503.s5.e2
DDI-DrugBank.d503.s6|a|Choose particular low doses of these drugs.
DDI-DrugBank.d503.s7|a|Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
DDI-DrugBank.d503.s7	38	52	chlorprothixene	drug	DDI-DrugBank.d503.s7.e0
DDI-DrugBank.d503.s7	65	85	anticholinergic drugs	group	DDI-DrugBank.d503.s7.e1
DDI-DrugBank.d503.s7	88	112	tricyclic antidepressants	group	DDI-DrugBank.d503.s7.e2
DDI-DrugBank.d503.s7	118	140	antiparkinsonian agents	group	DDI-DrugBank.d503.s7.e3
DDI-DrugBank.d503.s7	true	DDI-DrugBank.d503.s7.e0	DDI-DrugBank.d503.s7.e1
DDI-DrugBank.d503.s7	true	DDI-DrugBank.d503.s7.e0	DDI-DrugBank.d503.s7.e2
DDI-DrugBank.d503.s7	true	DDI-DrugBank.d503.s7.e0	DDI-DrugBank.d503.s7.e3
DDI-DrugBank.d503.s7	false	DDI-DrugBank.d503.s7.e1	DDI-DrugBank.d503.s7.e2
DDI-DrugBank.d503.s7	false	DDI-DrugBank.d503.s7.e1	DDI-DrugBank.d503.s7.e3
DDI-DrugBank.d503.s7	false	DDI-DrugBank.d503.s7.e2	DDI-DrugBank.d503.s7.e3
DDI-DrugBank.d265.s0|a|Chlorthalidone may add to or potentiate the action of other antihypertensive drugs.
DDI-DrugBank.d265.s0	0	13	Chlorthalidone	drug	DDI-DrugBank.d265.s0.e0
DDI-DrugBank.d265.s0	60	81	antihypertensive drugs	group	DDI-DrugBank.d265.s0.e1
DDI-DrugBank.d265.s0	true	DDI-DrugBank.d265.s0.e0	DDI-DrugBank.d265.s0.e1
DDI-DrugBank.d265.s1|a|Potentiation occurs with ganglionic peripheral adrenergic blocking drugs.
DDI-DrugBank.d265.s1	25	71	ganglionic peripheral adrenergic blocking drugs	group	DDI-DrugBank.d265.s1.e0
DDI-DrugBank.d265.s2|a|Medication such as digitalis may also influence serum electrolytes.
DDI-DrugBank.d265.s2	19	27	digitalis	group	DDI-DrugBank.d265.s2.e0
DDI-DrugBank.d265.s3|a|Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.
DDI-DrugBank.d265.s4|a|Insulin requirements in diabetic patients may be increased, decreased, or unchanged.
DDI-DrugBank.d265.s4	0	6	Insulin	drug	DDI-DrugBank.d265.s4.e0
DDI-DrugBank.d265.s5|a|Higher dosage of oral hypoglycemic agents may be required.
DDI-DrugBank.d265.s5	22	40	hypoglycemic agents	group	DDI-DrugBank.d265.s5.e0
DDI-DrugBank.d265.s6|a|Latent diabetes mellitus may become manifest during chlorthalidone administration.
DDI-DrugBank.d265.s6	52	65	chlorthalidone	drug	DDI-DrugBank.d265.s6.e0
DDI-DrugBank.d265.s7|a|Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.
DDI-DrugBank.d265.s7	0	13	Chlorthalidone	drug	DDI-DrugBank.d265.s7.e0
DDI-DrugBank.d265.s7	68	79	tubocurarine	drug	DDI-DrugBank.d265.s7.e1
DDI-DrugBank.d265.s7	true	DDI-DrugBank.d265.s7.e0	DDI-DrugBank.d265.s7.e1
DDI-DrugBank.d265.s8|a|Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.
DDI-DrugBank.d265.s8	0	13	Chlorthalidone	drug	DDI-DrugBank.d265.s8.e0
DDI-DrugBank.d265.s8	73	86	norepinephrine	drug	DDI-DrugBank.d265.s8.e1
DDI-DrugBank.d265.s8	true	DDI-DrugBank.d265.s8.e0	DDI-DrugBank.d265.s8.e1
DDI-DrugBank.d265.s9|a|This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
DDI-DrugBank.d262.s0|a|The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
DDI-DrugBank.d262.s0	23	29	alcohol	drug	DDI-DrugBank.d262.s0.e0
DDI-DrugBank.d262.s0	40	73	central nervous system depressants	group	DDI-DrugBank.d262.s0.e1
DDI-DrugBank.d262.s0	false	DDI-DrugBank.d262.s0.e0	DDI-DrugBank.d262.s0.e1
DDI-DrugBank.d404.s0|a|Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
DDI-DrugBank.d404.s0	17	25	vitamin D	group	DDI-DrugBank.d404.s0.e0
DDI-DrugBank.d404.s0	38	47	Vitamin D2	drug	DDI-DrugBank.d404.s0.e1
DDI-DrugBank.d404.s0	50	59	Vitamin D3	drug	DDI-DrugBank.d404.s0.e2
DDI-DrugBank.d404.s0	62	71	Calcitriol	drug	DDI-DrugBank.d404.s0.e3
DDI-DrugBank.d404.s0	78	86	Calcidiol	drug	DDI-DrugBank.d404.s0.e4
DDI-DrugBank.d404.s0	90	103	Cholestyramine	drug	DDI-DrugBank.d404.s0.e5
DDI-DrugBank.d404.s0	106	119	Cholestyramine	drug	DDI-DrugBank.d404.s0.e6
DDI-DrugBank.d404.s0	174	193	fat soluble vitamins	group	DDI-DrugBank.d404.s0.e7
DDI-DrugBank.d404.s0	false	DDI-DrugBank.d404.s0.e0	DDI-DrugBank.d404.s0.e1
DDI-DrugBank.d404.s0	false	DDI-DrugBank.d404.s0.e0	DDI-DrugBank.d404.s0.e2
DDI-DrugBank.d404.s0	false	DDI-DrugBank.d404.s0.e0	DDI-DrugBank.d404.s0.e3
DDI-DrugBank.d404.s0	false	DDI-DrugBank.d404.s0.e0	DDI-DrugBank.d404.s0.e4
DDI-DrugBank.d404.s0	false	DDI-DrugBank.d404.s0.e0	DDI-DrugBank.d404.s0.e5
DDI-DrugBank.d404.s0	false	DDI-DrugBank.d404.s0.e0	DDI-DrugBank.d404.s0.e6
DDI-DrugBank.d404.s0	false	DDI-DrugBank.d404.s0.e0	DDI-DrugBank.d404.s0.e7
DDI-DrugBank.d404.s0	false	DDI-DrugBank.d404.s0.e1	DDI-DrugBank.d404.s0.e2
DDI-DrugBank.d404.s0	false	DDI-DrugBank.d404.s0.e1	DDI-DrugBank.d404.s0.e3
DDI-DrugBank.d404.s0	false	DDI-DrugBank.d404.s0.e1	DDI-DrugBank.d404.s0.e4
DDI-DrugBank.d404.s1|a|as such it may impair intestinal absorption of any of vitamin D.
DDI-DrugBank.d404.s1	54	62	vitamin D	group	DDI-DrugBank.d404.s1.e0
DDI-DrugBank.d404.s2|a|Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DDI-DrugBank.d404.s2	0	8	Phenytoin	drug	DDI-DrugBank.d404.s2.e0
DDI-DrugBank.d404.s2	10	22	Phenobarbital	drug	DDI-DrugBank.d404.s2.e1
DDI-DrugBank.d404.s2	49	57	phenytoin	drug	DDI-DrugBank.d404.s2.e2
DDI-DrugBank.d404.s2	62	74	phenobarbital	drug	DDI-DrugBank.d404.s2.e3
DDI-DrugBank.d404.s2	117	125	vitamin D	group	DDI-DrugBank.d404.s2.e4
DDI-DrugBank.d404.s2	171	180	calcitriol	drug	DDI-DrugBank.d404.s2.e5
DDI-DrugBank.d404.s2	false	DDI-DrugBank.d404.s2.e0	DDI-DrugBank.d404.s2.e1
DDI-DrugBank.d404.s2	false	DDI-DrugBank.d404.s2.e0	DDI-DrugBank.d404.s2.e2
DDI-DrugBank.d404.s2	false	DDI-DrugBank.d404.s2.e0	DDI-DrugBank.d404.s2.e3
DDI-DrugBank.d404.s2	false	DDI-DrugBank.d404.s2.e0	DDI-DrugBank.d404.s2.e4
DDI-DrugBank.d404.s2	false	DDI-DrugBank.d404.s2.e0	DDI-DrugBank.d404.s2.e5
DDI-DrugBank.d404.s2	false	DDI-DrugBank.d404.s2.e1	DDI-DrugBank.d404.s2.e2
DDI-DrugBank.d404.s2	false	DDI-DrugBank.d404.s2.e1	DDI-DrugBank.d404.s2.e3
DDI-DrugBank.d404.s2	false	DDI-DrugBank.d404.s2.e1	DDI-DrugBank.d404.s2.e4
DDI-DrugBank.d404.s2	false	DDI-DrugBank.d404.s2.e1	DDI-DrugBank.d404.s2.e5
DDI-DrugBank.d404.s2	false	DDI-DrugBank.d404.s2.e2	DDI-DrugBank.d404.s2.e3
DDI-DrugBank.d404.s3|a|Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
DDI-DrugBank.d404.s3	21	30	calcitriol	drug	DDI-DrugBank.d404.s3.e0
DDI-DrugBank.d404.s3	80	88	Rocaltrol	brand	DDI-DrugBank.d404.s3.e1
DDI-DrugBank.d404.s3	false	DDI-DrugBank.d404.s3.e0	DDI-DrugBank.d404.s3.e1
DDI-DrugBank.d404.s4|a|Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
DDI-DrugBank.d404.s4	0	8	Thiazides	group	DDI-DrugBank.d404.s4.e0
DDI-DrugBank.d404.s4	11	19	Thiazides	group	DDI-DrugBank.d404.s4.e1
DDI-DrugBank.d404.s4	false	DDI-DrugBank.d404.s4.e0	DDI-DrugBank.d404.s4.e1
DDI-DrugBank.d404.s5|a|Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
DDI-DrugBank.d404.s5	63	71	thiazides	group	DDI-DrugBank.d404.s5.e0
DDI-DrugBank.d404.s5	78	86	vitamin D	group	DDI-DrugBank.d404.s5.e1
DDI-DrugBank.d404.s5	true	DDI-DrugBank.d404.s5.e0	DDI-DrugBank.d404.s5.e1
DDI-DrugBank.d404.s6|a|Therefore, precaution should be taken when coadministration is necessary.
DDI-DrugBank.d404.s7|a|Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
DDI-DrugBank.d404.s7	0	8	Digitalis	group	DDI-DrugBank.d404.s7.e0
DDI-DrugBank.d404.s7	11	19	Vitamin D	group	DDI-DrugBank.d404.s7.e1
DDI-DrugBank.d404.s7	95	103	digitalis	group	DDI-DrugBank.d404.s7.e2
DDI-DrugBank.d404.s7	false	DDI-DrugBank.d404.s7.e0	DDI-DrugBank.d404.s7.e1
DDI-DrugBank.d404.s7	false	DDI-DrugBank.d404.s7.e0	DDI-DrugBank.d404.s7.e2
DDI-DrugBank.d404.s7	true	DDI-DrugBank.d404.s7.e1	DDI-DrugBank.d404.s7.e2
DDI-DrugBank.d404.s8|a|Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
DDI-DrugBank.d404.s8	0	11	Ketoconazole	drug	DDI-DrugBank.d404.s8.e0
DDI-DrugBank.d404.s8	14	25	Ketoconazole	drug	DDI-DrugBank.d404.s8.e1
DDI-DrugBank.d404.s8	79	87	vitamin D	group	DDI-DrugBank.d404.s8.e2
DDI-DrugBank.d404.s8	false	DDI-DrugBank.d404.s8.e0	DDI-DrugBank.d404.s8.e1
DDI-DrugBank.d404.s8	false	DDI-DrugBank.d404.s8.e0	DDI-DrugBank.d404.s8.e2
DDI-DrugBank.d404.s8	true	DDI-DrugBank.d404.s8.e1	DDI-DrugBank.d404.s8.e2
DDI-DrugBank.d404.s9|a|Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.
DDI-DrugBank.d404.s9	133	144	ketoconazole	drug	DDI-DrugBank.d404.s9.e0
DDI-DrugBank.d404.s10|a|However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
DDI-DrugBank.d404.s10	45	56	ketoconazole	drug	DDI-DrugBank.d404.s10.e0
DDI-DrugBank.d404.s10	63	71	vitamin D	group	DDI-DrugBank.d404.s10.e1
DDI-DrugBank.d404.s10	false	DDI-DrugBank.d404.s10.e0	DDI-DrugBank.d404.s10.e1
DDI-DrugBank.d404.s11|a|Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
DDI-DrugBank.d404.s11	0	14	Corticosteroids	group	DDI-DrugBank.d404.s11.e0
DDI-DrugBank.d404.s11	72	80	vitamin D	group	DDI-DrugBank.d404.s11.e1
DDI-DrugBank.d404.s11	131	145	corticosteroids	group	DDI-DrugBank.d404.s11.e2
DDI-DrugBank.d404.s11	false	DDI-DrugBank.d404.s11.e0	DDI-DrugBank.d404.s11.e1
DDI-DrugBank.d404.s11	false	DDI-DrugBank.d404.s11.e0	DDI-DrugBank.d404.s11.e2
DDI-DrugBank.d404.s11	true	DDI-DrugBank.d404.s11.e1	DDI-DrugBank.d404.s11.e2
DDI-DrugBank.d404.s12|a|Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.
DDI-DrugBank.d404.s12	32	40	vitamin D	group	DDI-DrugBank.d404.s12.e0
DDI-DrugBank.d404.s13|a|Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
DDI-DrugBank.d404.s13	0	8	Vitamin D	group	DDI-DrugBank.d404.s13.e0
DDI-DrugBank.d404.s13	46	54	vitamin D	group	DDI-DrugBank.d404.s13.e1
DDI-DrugBank.d404.s13	false	DDI-DrugBank.d404.s13.e0	DDI-DrugBank.d404.s13.e1
DDI-DrugBank.d404.s14|a|Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
DDI-DrugBank.d404.s14	0	6	Calcium	drug	DDI-DrugBank.d404.s14.e0
DDI-DrugBank.d404.s14	55	61	calcium	drug	DDI-DrugBank.d404.s14.e1
DDI-DrugBank.d404.s14	false	DDI-DrugBank.d404.s14.e0	DDI-DrugBank.d404.s14.e1
DDI-DrugBank.d404.s15|a|Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
DDI-DrugBank.d404.s15	0	8	Magnesium	drug	DDI-DrugBank.d404.s15.e0
DDI-DrugBank.d404.s15	11	19	Magnesium	drug	DDI-DrugBank.d404.s15.e1
DDI-DrugBank.d404.s15	50	57	antacids	group	DDI-DrugBank.d404.s15.e2
DDI-DrugBank.d404.s15	140	148	vitamin D	group	DDI-DrugBank.d404.s15.e3
DDI-DrugBank.d404.s15	false	DDI-DrugBank.d404.s15.e0	DDI-DrugBank.d404.s15.e1
DDI-DrugBank.d404.s15	false	DDI-DrugBank.d404.s15.e0	DDI-DrugBank.d404.s15.e2
DDI-DrugBank.d404.s15	false	DDI-DrugBank.d404.s15.e0	DDI-DrugBank.d404.s15.e3
DDI-DrugBank.d404.s15	false	DDI-DrugBank.d404.s15.e1	DDI-DrugBank.d404.s15.e2
DDI-DrugBank.d404.s15	true	DDI-DrugBank.d404.s15.e1	DDI-DrugBank.d404.s15.e3
DDI-DrugBank.d404.s15	true	DDI-DrugBank.d404.s15.e2	DDI-DrugBank.d404.s15.e3
DDI-DrugBank.d566.s0|a|Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d566.s0	0	13	Cholestyramine	drug	DDI-DrugBank.d566.s0.e0
DDI-DrugBank.d566.s0	15	19	resin	group	DDI-DrugBank.d566.s0.e1
DDI-DrugBank.d566.s0	95	108	phenylbutazone	group	DDI-DrugBank.d566.s0.e2
DDI-DrugBank.d566.s0	111	118	warfarin	drug	DDI-DrugBank.d566.s0.e3
DDI-DrugBank.d566.s0	121	138	thiazide diuretics	group	DDI-DrugBank.d566.s0.e4
DDI-DrugBank.d566.s0	152	162	propranolol	drug	DDI-DrugBank.d566.s0.e5
DDI-DrugBank.d566.s0	184	195	tetracycline	drug	DDI-DrugBank.d566.s0.e6
DDI-DrugBank.d566.s0	197	208	penicillin G	drug	DDI-DrugBank.d566.s0.e7
DDI-DrugBank.d566.s0	211	223	phenobarbital	drug	DDI-DrugBank.d566.s0.e8
DDI-DrugBank.d566.s0	238	246	thyroxine	drug	DDI-DrugBank.d566.s0.e9
DDI-DrugBank.d566.s0	false	DDI-DrugBank.d566.s0.e0	DDI-DrugBank.d566.s0.e1
DDI-DrugBank.d566.s0	true	DDI-DrugBank.d566.s0.e0	DDI-DrugBank.d566.s0.e2
DDI-DrugBank.d566.s0	true	DDI-DrugBank.d566.s0.e0	DDI-DrugBank.d566.s0.e3
DDI-DrugBank.d566.s0	true	DDI-DrugBank.d566.s0.e0	DDI-DrugBank.d566.s0.e4
DDI-DrugBank.d566.s0	true	DDI-DrugBank.d566.s0.e0	DDI-DrugBank.d566.s0.e5
DDI-DrugBank.d566.s0	true	DDI-DrugBank.d566.s0.e0	DDI-DrugBank.d566.s0.e6
DDI-DrugBank.d566.s0	true	DDI-DrugBank.d566.s0.e0	DDI-DrugBank.d566.s0.e7
DDI-DrugBank.d566.s0	true	DDI-DrugBank.d566.s0.e0	DDI-DrugBank.d566.s0.e8
DDI-DrugBank.d566.s0	true	DDI-DrugBank.d566.s0.e0	DDI-DrugBank.d566.s0.e9
DDI-DrugBank.d566.s0	true	DDI-DrugBank.d566.s0.e0	DDI-DrugBank.d566.s0.e10
DDI-DrugBank.d566.s1|a|Interference with the absorption of oral phosphate supplements has been observed with another positively-charged bile acid sequestrant.
DDI-DrugBank.d566.s1	41	49	phosphate	drug_n	DDI-DrugBank.d566.s1.e0
DDI-DrugBank.d566.s2|a|Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
DDI-DrugBank.d566.s2	0	13	Cholestyramine	drug	DDI-DrugBank.d566.s2.e0
DDI-DrugBank.d566.s2	15	19	resin	group	DDI-DrugBank.d566.s2.e1
DDI-DrugBank.d566.s2	132	145	cholestyramine	drug	DDI-DrugBank.d566.s2.e2
DDI-DrugBank.d566.s2	147	151	resin	group	DDI-DrugBank.d566.s2.e3
DDI-DrugBank.d566.s2	219	227	digitalis	group	DDI-DrugBank.d566.s2.e4
DDI-DrugBank.d566.s2	300	313	cholestyramine	drug	DDI-DrugBank.d566.s2.e5
DDI-DrugBank.d566.s2	315	319	resin	group	DDI-DrugBank.d566.s2.e6
DDI-DrugBank.d566.s2	false	DDI-DrugBank.d566.s2.e0	DDI-DrugBank.d566.s2.e1
DDI-DrugBank.d566.s2	false	DDI-DrugBank.d566.s2.e0	DDI-DrugBank.d566.s2.e2
DDI-DrugBank.d566.s2	false	DDI-DrugBank.d566.s2.e0	DDI-DrugBank.d566.s2.e3
DDI-DrugBank.d566.s2	false	DDI-DrugBank.d566.s2.e0	DDI-DrugBank.d566.s2.e4
DDI-DrugBank.d566.s2	false	DDI-DrugBank.d566.s2.e0	DDI-DrugBank.d566.s2.e5
DDI-DrugBank.d566.s2	false	DDI-DrugBank.d566.s2.e0	DDI-DrugBank.d566.s2.e6
DDI-DrugBank.d566.s2	false	DDI-DrugBank.d566.s2.e1	DDI-DrugBank.d566.s2.e2
DDI-DrugBank.d566.s2	false	DDI-DrugBank.d566.s2.e1	DDI-DrugBank.d566.s2.e3
DDI-DrugBank.d566.s2	false	DDI-DrugBank.d566.s2.e1	DDI-DrugBank.d566.s2.e4
DDI-DrugBank.d566.s2	false	DDI-DrugBank.d566.s2.e1	DDI-DrugBank.d566.s2.e5
DDI-DrugBank.d566.s3|a|Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.
DDI-DrugBank.d566.s3	8	21	cholestyramine	drug	DDI-DrugBank.d566.s3.e0
DDI-DrugBank.d566.s3	41	54	cholestyramine	drug	DDI-DrugBank.d566.s3.e1
DDI-DrugBank.d566.s3	56	60	resin	group	DDI-DrugBank.d566.s3.e2
DDI-DrugBank.d566.s3	152	171	fat soluble vitamins	group	DDI-DrugBank.d566.s3.e3
DDI-DrugBank.d566.s3	false	DDI-DrugBank.d566.s3.e0	DDI-DrugBank.d566.s3.e1
DDI-DrugBank.d566.s3	false	DDI-DrugBank.d566.s3.e0	DDI-DrugBank.d566.s3.e2
DDI-DrugBank.d566.s3	false	DDI-DrugBank.d566.s3.e0	DDI-DrugBank.d566.s3.e3
DDI-DrugBank.d566.s3	false	DDI-DrugBank.d566.s3.e1	DDI-DrugBank.d566.s3.e2
DDI-DrugBank.d566.s3	false	DDI-DrugBank.d566.s3.e1	DDI-DrugBank.d566.s3.e3
DDI-DrugBank.d566.s3	false	DDI-DrugBank.d566.s3.e2	DDI-DrugBank.d566.s3.e3
DDI-DrugBank.d566.s4|a|When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.
DDI-DrugBank.d566.s4	5	18	cholestyramine	drug	DDI-DrugBank.d566.s4.e0
DDI-DrugBank.d566.s4	20	24	resin	group	DDI-DrugBank.d566.s4.e1
DDI-DrugBank.d566.s4	134	153	fat-soluble vitamins	group	DDI-DrugBank.d566.s4.e2
DDI-DrugBank.d566.s4	false	DDI-DrugBank.d566.s4.e0	DDI-DrugBank.d566.s4.e1
DDI-DrugBank.d566.s4	false	DDI-DrugBank.d566.s4.e0	DDI-DrugBank.d566.s4.e2
DDI-DrugBank.d566.s4	false	DDI-DrugBank.d566.s4.e1	DDI-DrugBank.d566.s4.e2
DDI-DrugBank.d566.s5|a|SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
DDI-DrugBank.d566.s5	6	19	CHOLESTYRAMINE	drug	DDI-DrugBank.d566.s5.e0
DDI-DrugBank.d566.s5	21	25	RESIN	group	DDI-DrugBank.d566.s5.e1
DDI-DrugBank.d566.s5	162	175	CHOLESTYRAMINE	drug	DDI-DrugBank.d566.s5.e2
DDI-DrugBank.d566.s5	177	181	RESIN	group	DDI-DrugBank.d566.s5.e3
DDI-DrugBank.d566.s5	false	DDI-DrugBank.d566.s5.e0	DDI-DrugBank.d566.s5.e1
DDI-DrugBank.d566.s5	false	DDI-DrugBank.d566.s5.e0	DDI-DrugBank.d566.s5.e2
DDI-DrugBank.d566.s5	false	DDI-DrugBank.d566.s5.e0	DDI-DrugBank.d566.s5.e3
DDI-DrugBank.d566.s5	false	DDI-DrugBank.d566.s5.e1	DDI-DrugBank.d566.s5.e2
DDI-DrugBank.d566.s5	false	DDI-DrugBank.d566.s5.e1	DDI-DrugBank.d566.s5.e3
DDI-DrugBank.d566.s5	false	DDI-DrugBank.d566.s5.e2	DDI-DrugBank.d566.s5.e3
DDI-DrugBank.d362.s0|a|Based on in vitro studies in human liver microsomes, des-ciclesonide appears to have no inhibitory or induction potential on the metabolism of other drugs metabolized by CYP 450 enzymes.
DDI-DrugBank.d362.s0	53	67	des-ciclesonide	drug	DDI-DrugBank.d362.s0.e0
DDI-DrugBank.d362.s1|a|The inhibitory potential of ciclesonide on CYP450 isoenzymes has not been studied.
DDI-DrugBank.d362.s1	28	38	ciclesonide	drug	DDI-DrugBank.d362.s1.e0
DDI-DrugBank.d362.s2|a|In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by warfarin or salicylic acid, indicating no potential for protein binding-based drug interactions.
DDI-DrugBank.d362.s2	65	79	des-ciclesonide	drug	DDI-DrugBank.d362.s2.e0
DDI-DrugBank.d362.s2	101	108	warfarin	drug	DDI-DrugBank.d362.s2.e1
DDI-DrugBank.d362.s2	113	126	salicylic acid	drug	DDI-DrugBank.d362.s2.e2
DDI-DrugBank.d362.s2	false	DDI-DrugBank.d362.s2.e0	DDI-DrugBank.d362.s2.e1
DDI-DrugBank.d362.s2	false	DDI-DrugBank.d362.s2.e0	DDI-DrugBank.d362.s2.e2
DDI-DrugBank.d362.s2	false	DDI-DrugBank.d362.s2.e1	DDI-DrugBank.d362.s2.e2
DDI-DrugBank.d362.s3|a|In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin.
DDI-DrugBank.d362.s3	65	75	ciclesonide	drug	DDI-DrugBank.d362.s3.e0
DDI-DrugBank.d362.s3	86	97	erythromycin	drug	DDI-DrugBank.d362.s3.e1
DDI-DrugBank.d362.s3	185	199	des-ciclesonide	drug	DDI-DrugBank.d362.s3.e2
DDI-DrugBank.d362.s3	204	215	erythromycin	drug	DDI-DrugBank.d362.s3.e3
DDI-DrugBank.d362.s3	false	DDI-DrugBank.d362.s3.e0	DDI-DrugBank.d362.s3.e1
DDI-DrugBank.d362.s3	false	DDI-DrugBank.d362.s3.e0	DDI-DrugBank.d362.s3.e2
DDI-DrugBank.d362.s3	false	DDI-DrugBank.d362.s3.e0	DDI-DrugBank.d362.s3.e3
DDI-DrugBank.d362.s3	false	DDI-DrugBank.d362.s3.e1	DDI-DrugBank.d362.s3.e2
DDI-DrugBank.d362.s3	false	DDI-DrugBank.d362.s3.e1	DDI-DrugBank.d362.s3.e3
DDI-DrugBank.d362.s3	false	DDI-DrugBank.d362.s3.e2	DDI-DrugBank.d362.s3.e3
DDI-DrugBank.d362.s4|a|In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
DDI-DrugBank.d362.s4	71	81	ciclesonide	drug	DDI-DrugBank.d362.s4.e0
DDI-DrugBank.d362.s4	92	103	ketoconazole	drug	DDI-DrugBank.d362.s4.e1
DDI-DrugBank.d362.s4	181	195	des-ciclesonide	drug	DDI-DrugBank.d362.s4.e2
DDI-DrugBank.d362.s4	256	266	ciclesonide	drug	DDI-DrugBank.d362.s4.e3
DDI-DrugBank.d362.s4	true	DDI-DrugBank.d362.s4.e0	DDI-DrugBank.d362.s4.e1
DDI-DrugBank.d362.s4	false	DDI-DrugBank.d362.s4.e0	DDI-DrugBank.d362.s4.e2
DDI-DrugBank.d362.s4	false	DDI-DrugBank.d362.s4.e0	DDI-DrugBank.d362.s4.e3
DDI-DrugBank.d362.s4	false	DDI-DrugBank.d362.s4.e1	DDI-DrugBank.d362.s4.e2
DDI-DrugBank.d362.s4	false	DDI-DrugBank.d362.s4.e1	DDI-DrugBank.d362.s4.e3
DDI-DrugBank.d362.s4	false	DDI-DrugBank.d362.s4.e2	DDI-DrugBank.d362.s4.e3
DDI-DrugBank.d362.s5|a|Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.
DDI-DrugBank.d362.s5	11	22	ketoconazole	drug	DDI-DrugBank.d362.s5.e0
DDI-DrugBank.d362.s5	76	86	ciclesonide	drug	DDI-DrugBank.d362.s5.e1
DDI-DrugBank.d362.s5	true	DDI-DrugBank.d362.s5.e0	DDI-DrugBank.d362.s5.e1
DDI-DrugBank.d260.s0|a|Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0	0	9	Probenecid	drug	DDI-DrugBank.d260.s0.e0
DDI-DrugBank.d260.s0	13	22	Probenecid	drug	DDI-DrugBank.d260.s0.e1
DDI-DrugBank.d260.s0	113	125	acetaminophen	drug	DDI-DrugBank.d260.s0.e2
DDI-DrugBank.d260.s0	128	136	acyclovir	drug	DDI-DrugBank.d260.s0.e3
DDI-DrugBank.d260.s0	139	178	angiotensin-converting enzyme inhibitors	group	DDI-DrugBank.d260.s0.e4
DDI-DrugBank.d260.s0	181	199	aminosalicylic acid	drug	DDI-DrugBank.d260.s0.e5
DDI-DrugBank.d260.s0	202	213	barbiturates	group	DDI-DrugBank.d260.s0.e6
DDI-DrugBank.d260.s0	216	230	benzodiazepines	group	DDI-DrugBank.d260.s0.e7
DDI-DrugBank.d260.s0	233	242	bumetanide	drug	DDI-DrugBank.d260.s0.e8
DDI-DrugBank.d260.s0	245	254	clofibrate	drug	DDI-DrugBank.d260.s0.e9
DDI-DrugBank.d260.s0	false	DDI-DrugBank.d260.s0.e0	DDI-DrugBank.d260.s0.e1
DDI-DrugBank.d260.s0	false	DDI-DrugBank.d260.s0.e0	DDI-DrugBank.d260.s0.e2
DDI-DrugBank.d260.s0	false	DDI-DrugBank.d260.s0.e0	DDI-DrugBank.d260.s0.e3
DDI-DrugBank.d260.s0	false	DDI-DrugBank.d260.s0.e0	DDI-DrugBank.d260.s0.e4
DDI-DrugBank.d260.s0	false	DDI-DrugBank.d260.s0.e0	DDI-DrugBank.d260.s0.e5
DDI-DrugBank.d260.s0	false	DDI-DrugBank.d260.s0.e0	DDI-DrugBank.d260.s0.e6
DDI-DrugBank.d260.s0	false	DDI-DrugBank.d260.s0.e0	DDI-DrugBank.d260.s0.e7
DDI-DrugBank.d260.s0	false	DDI-DrugBank.d260.s0.e0	DDI-DrugBank.d260.s0.e8
DDI-DrugBank.d260.s0	false	DDI-DrugBank.d260.s0.e0	DDI-DrugBank.d260.s0.e9
DDI-DrugBank.d260.s0	false	DDI-DrugBank.d260.s0.e0	DDI-DrugBank.d260.s0.e10
DDI-DrugBank.d260.s1|a|Concomitant medications should be carefully assessed.
DDI-DrugBank.d260.s2|a|Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.
DDI-DrugBank.d260.s2	0	9	Zidovudine	drug	DDI-DrugBank.d260.s2.e0
DDI-DrugBank.d260.s2	98	107	probenecid	drug	DDI-DrugBank.d260.s2.e1
DDI-DrugBank.d260.s2	123	129	VISTIDE	brand	DDI-DrugBank.d260.s2.e2
DDI-DrugBank.d260.s2	true	DDI-DrugBank.d260.s2.e0	DDI-DrugBank.d260.s2.e1
DDI-DrugBank.d260.s2	false	DDI-DrugBank.d260.s2.e0	DDI-DrugBank.d260.s2.e2
DDI-DrugBank.d260.s2	false	DDI-DrugBank.d260.s2.e1	DDI-DrugBank.d260.s2.e2
DDI-DrugBank.d260.s3|a|Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DDI-DrugBank.d260.s3	51	57	VISTIDE	brand	DDI-DrugBank.d260.s3.e0
DDI-DrugBank.d260.s3	116	130	aminoglycosides	group	DDI-DrugBank.d260.s3.e1
DDI-DrugBank.d260.s3	139	148	tobramycin	drug	DDI-DrugBank.d260.s3.e2
DDI-DrugBank.d260.s3	151	160	gentamicin	drug	DDI-DrugBank.d260.s3.e3
DDI-DrugBank.d260.s3	167	174	amikacin	drug	DDI-DrugBank.d260.s3.e4
DDI-DrugBank.d260.s3	178	191	amphotericin B	drug	DDI-DrugBank.d260.s3.e5
DDI-DrugBank.d260.s3	194	202	foscarnet	drug	DDI-DrugBank.d260.s3.e6
DDI-DrugBank.d260.s3	217	227	pentamidine	drug	DDI-DrugBank.d260.s3.e7
DDI-DrugBank.d260.s3	230	239	vancomycin	drug	DDI-DrugBank.d260.s3.e8
DDI-DrugBank.d260.s3	246	283	non-steroidal anti-inflammatory agents	group	DDI-DrugBank.d260.s3.e9
DDI-DrugBank.d260.s3	true	DDI-DrugBank.d260.s3.e0	DDI-DrugBank.d260.s3.e1
DDI-DrugBank.d260.s3	true	DDI-DrugBank.d260.s3.e0	DDI-DrugBank.d260.s3.e2
DDI-DrugBank.d260.s3	true	DDI-DrugBank.d260.s3.e0	DDI-DrugBank.d260.s3.e3
DDI-DrugBank.d260.s3	true	DDI-DrugBank.d260.s3.e0	DDI-DrugBank.d260.s3.e4
DDI-DrugBank.d260.s3	true	DDI-DrugBank.d260.s3.e0	DDI-DrugBank.d260.s3.e5
DDI-DrugBank.d260.s3	true	DDI-DrugBank.d260.s3.e0	DDI-DrugBank.d260.s3.e6
DDI-DrugBank.d260.s3	true	DDI-DrugBank.d260.s3.e0	DDI-DrugBank.d260.s3.e7
DDI-DrugBank.d260.s3	true	DDI-DrugBank.d260.s3.e0	DDI-DrugBank.d260.s3.e8
DDI-DrugBank.d260.s3	true	DDI-DrugBank.d260.s3.e0	DDI-DrugBank.d260.s3.e9
DDI-DrugBank.d260.s3	false	DDI-DrugBank.d260.s3.e1	DDI-DrugBank.d260.s3.e2
DDI-DrugBank.d260.s4|a|Such agents must be discontinued at least seven days prior to starting therapy with VISTIDE.
DDI-DrugBank.d260.s4	84	90	VISTIDE	brand	DDI-DrugBank.d260.s4.e0
DDI-DrugBank.d358.s0|a|Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
DDI-DrugBank.d358.s0	6	11	PLETAL	brand	DDI-DrugBank.d358.s0.e0
DDI-DrugBank.d358.s0	105	110	PLETAL	brand	DDI-DrugBank.d358.s0.e1
DDI-DrugBank.d358.s0	164	175	ketoconazole	drug	DDI-DrugBank.d358.s0.e2
DDI-DrugBank.d358.s0	181	192	erythromycin	drug	DDI-DrugBank.d358.s0.e3
DDI-DrugBank.d358.s0	227	236	omeprazole	drug	DDI-DrugBank.d358.s0.e4
DDI-DrugBank.d358.s0	false	DDI-DrugBank.d358.s0.e0	DDI-DrugBank.d358.s0.e1
DDI-DrugBank.d358.s0	false	DDI-DrugBank.d358.s0.e0	DDI-DrugBank.d358.s0.e2
DDI-DrugBank.d358.s0	false	DDI-DrugBank.d358.s0.e0	DDI-DrugBank.d358.s0.e3
DDI-DrugBank.d358.s0	false	DDI-DrugBank.d358.s0.e0	DDI-DrugBank.d358.s0.e4
DDI-DrugBank.d358.s0	true	DDI-DrugBank.d358.s0.e1	DDI-DrugBank.d358.s0.e2
DDI-DrugBank.d358.s0	true	DDI-DrugBank.d358.s0.e1	DDI-DrugBank.d358.s0.e3
DDI-DrugBank.d358.s0	true	DDI-DrugBank.d358.s0.e1	DDI-DrugBank.d358.s0.e4
DDI-DrugBank.d358.s0	false	DDI-DrugBank.d358.s0.e2	DDI-DrugBank.d358.s0.e3
DDI-DrugBank.d358.s0	false	DDI-DrugBank.d358.s0.e2	DDI-DrugBank.d358.s0.e4
DDI-DrugBank.d358.s0	false	DDI-DrugBank.d358.s0.e3	DDI-DrugBank.d358.s0.e4
DDI-DrugBank.d358.s1|a|Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
DDI-DrugBank.d358.s1	47	56	omeprazole	drug	DDI-DrugBank.d358.s1.e0
DDI-DrugBank.d358.s1	62	73	erythromycin	drug	DDI-DrugBank.d358.s1.e1
DDI-DrugBank.d358.s1	124	133	cilostazol	drug	DDI-DrugBank.d358.s1.e2
DDI-DrugBank.d358.s1	false	DDI-DrugBank.d358.s1.e0	DDI-DrugBank.d358.s1.e1
DDI-DrugBank.d358.s1	true	DDI-DrugBank.d358.s1.e0	DDI-DrugBank.d358.s1.e2
DDI-DrugBank.d358.s1	true	DDI-DrugBank.d358.s1.e1	DDI-DrugBank.d358.s1.e2
DDI-DrugBank.d358.s2|a|Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..
DDI-DrugBank.d358.s2	67	76	cilostazol	drug	DDI-DrugBank.d358.s2.e0
DDI-DrugBank.d358.s2	119	127	diltiazem	drug	DDI-DrugBank.d358.s2.e1
DDI-DrugBank.d358.s2	true	DDI-DrugBank.d358.s2.e0	DDI-DrugBank.d358.s2.e1
DDI-DrugBank.d358.s3|a|Pletal does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to C.P.A. inhibition.
DDI-DrugBank.d358.s3	0	5	Pletal	brand	DDI-DrugBank.d358.s3.e0
DDI-DrugBank.d358.s3	120	129	lovastatin	drug	DDI-DrugBank.d358.s3.e1
DDI-DrugBank.d358.s3	false	DDI-DrugBank.d358.s3.e0	DDI-DrugBank.d358.s3.e1
DDI-DrugBank.d171.s0|a|Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d171.s0	0	6	Tagamet	brand	DDI-DrugBank.d171.s0.e0
DDI-DrugBank.d171.s0	130	157	warfarin-type anticoagulants	group	DDI-DrugBank.d171.s0.e1
DDI-DrugBank.d171.s0	160	168	phenytoin	drug	DDI-DrugBank.d171.s0.e2
DDI-DrugBank.d171.s0	171	181	propranolol	drug	DDI-DrugBank.d171.s0.e3
DDI-DrugBank.d171.s0	184	193	nifedipine	drug	DDI-DrugBank.d171.s0.e4
DDI-DrugBank.d171.s0	196	211	chlordiazepoxide	drug	DDI-DrugBank.d171.s0.e5
DDI-DrugBank.d171.s0	214	221	diazepam	drug	DDI-DrugBank.d171.s0.e6
DDI-DrugBank.d171.s0	232	256	tricyclic antidepressants	group	DDI-DrugBank.d171.s0.e7
DDI-DrugBank.d171.s0	259	267	lidocaine	drug	DDI-DrugBank.d171.s0.e8
DDI-DrugBank.d171.s0	270	281	theophylline	drug	DDI-DrugBank.d171.s0.e9
DDI-DrugBank.d171.s0	true	DDI-DrugBank.d171.s0.e0	DDI-DrugBank.d171.s0.e1
DDI-DrugBank.d171.s0	true	DDI-DrugBank.d171.s0.e0	DDI-DrugBank.d171.s0.e2
DDI-DrugBank.d171.s0	true	DDI-DrugBank.d171.s0.e0	DDI-DrugBank.d171.s0.e3
DDI-DrugBank.d171.s0	true	DDI-DrugBank.d171.s0.e0	DDI-DrugBank.d171.s0.e4
DDI-DrugBank.d171.s0	true	DDI-DrugBank.d171.s0.e0	DDI-DrugBank.d171.s0.e5
DDI-DrugBank.d171.s0	true	DDI-DrugBank.d171.s0.e0	DDI-DrugBank.d171.s0.e6
DDI-DrugBank.d171.s0	true	DDI-DrugBank.d171.s0.e0	DDI-DrugBank.d171.s0.e7
DDI-DrugBank.d171.s0	true	DDI-DrugBank.d171.s0.e0	DDI-DrugBank.d171.s0.e8
DDI-DrugBank.d171.s0	true	DDI-DrugBank.d171.s0.e0	DDI-DrugBank.d171.s0.e9
DDI-DrugBank.d171.s0	true	DDI-DrugBank.d171.s0.e0	DDI-DrugBank.d171.s0.e10
DDI-DrugBank.d171.s1|a|Clinically significant effects have been reported with the warfarin anticoagulants;
DDI-DrugBank.d171.s1	59	81	warfarin anticoagulants	group	DDI-DrugBank.d171.s1.e0
DDI-DrugBank.d171.s2|a|therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.
DDI-DrugBank.d171.s2	86	98	anticoagulant	group	DDI-DrugBank.d171.s2.e0
DDI-DrugBank.d171.s2	127	133	Tagamet	brand	DDI-DrugBank.d171.s2.e1
DDI-DrugBank.d171.s2	true	DDI-DrugBank.d171.s2.e0	DDI-DrugBank.d171.s2.e1
DDI-DrugBank.d171.s3|a|Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects.
DDI-DrugBank.d171.s3	17	25	phenytoin	drug	DDI-DrugBank.d171.s3.e0
DDI-DrugBank.d171.s3	28	36	lidocaine	drug	DDI-DrugBank.d171.s3.e1
DDI-DrugBank.d171.s3	42	53	theophylline	drug	DDI-DrugBank.d171.s3.e2
DDI-DrugBank.d171.s3	false	DDI-DrugBank.d171.s3.e0	DDI-DrugBank.d171.s3.e1
DDI-DrugBank.d171.s3	false	DDI-DrugBank.d171.s3.e0	DDI-DrugBank.d171.s3.e2
DDI-DrugBank.d171.s3	false	DDI-DrugBank.d171.s3.e1	DDI-DrugBank.d171.s3.e2
DDI-DrugBank.d171.s4|a|However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
DDI-DrugBank.d171.s4	64	70	Tagamet	brand	DDI-DrugBank.d171.s4.e0
DDI-DrugBank.d171.s4	146	157	theophylline	drug	DDI-DrugBank.d171.s4.e1
DDI-DrugBank.d171.s4	160	167	Theo-Dur	brand	DDI-DrugBank.d171.s4.e2
DDI-DrugBank.d171.s4	243	254	theophylline	drug	DDI-DrugBank.d171.s4.e3
DDI-DrugBank.d171.s4	true	DDI-DrugBank.d171.s4.e0	DDI-DrugBank.d171.s4.e1
DDI-DrugBank.d171.s4	true	DDI-DrugBank.d171.s4.e0	DDI-DrugBank.d171.s4.e2
DDI-DrugBank.d171.s4	false	DDI-DrugBank.d171.s4.e0	DDI-DrugBank.d171.s4.e3
DDI-DrugBank.d171.s4	false	DDI-DrugBank.d171.s4.e1	DDI-DrugBank.d171.s4.e2
DDI-DrugBank.d171.s4	false	DDI-DrugBank.d171.s4.e1	DDI-DrugBank.d171.s4.e3
DDI-DrugBank.d171.s4	false	DDI-DrugBank.d171.s4.e2	DDI-DrugBank.d171.s4.e3
DDI-DrugBank.d171.s5|a|Data beyond 10 days are not available.
DDI-DrugBank.d171.s6|a|(Note: All patients receiving theophylline should be monitored appropriately, regardless of concomitant drug therapy.)
DDI-DrugBank.d171.s6	30	41	theophylline	drug	DDI-DrugBank.d171.s6.e0
DDI-DrugBank.d171.s7|a|Dosage of the drugs mentioned above and other similarly metabolized drugs, particularly those of low therapeutic ratio or in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered Tagamet to maintain optimum therapeutic blood levels.
DDI-DrugBank.d171.s7	248	254	Tagamet	brand	DDI-DrugBank.d171.s7.e0
DDI-DrugBank.d171.s8|a|Alteration of pH may affect absorption of certain drugs (e.g., ketoconazole).
DDI-DrugBank.d171.s8	63	74	ketoconazole	drug	DDI-DrugBank.d171.s8.e0
DDI-DrugBank.d171.s9|a|If these products are needed, they should be given at least 2 hours before cimetidine administration.
DDI-DrugBank.d171.s9	75	84	cimetidine	drug	DDI-DrugBank.d171.s9.e0
DDI-DrugBank.d171.s10|a|Additional clinical experience may reveal other drugs affected by the concomitant administration of Tagamet.
DDI-DrugBank.d171.s10	100	106	Tagamet	brand	DDI-DrugBank.d171.s10.e0
DDI-DrugBank.d512.s0|a|and/or Drug/Laboratory Test Interactions See CLINICAL PHARMACOLOGY, Pharmacokinetics and Drug Interactions.
DDI-DrugBank.d512.s1|a|Effect of Sensipar on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6): Sensipar  is a strong in vitro inhibitor of CYP2D6.
DDI-DrugBank.d512.s1	10	17	Sensipar	brand	DDI-DrugBank.d512.s1.e0
DDI-DrugBank.d512.s1	86	93	Sensipar	brand	DDI-DrugBank.d512.s1.e1
DDI-DrugBank.d512.s1	false	DDI-DrugBank.d512.s1.e0	DDI-DrugBank.d512.s1.e1
DDI-DrugBank.d512.s2|a|Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine and most tricyclic antidepressants) may be required.
DDI-DrugBank.d512.s2	143	152	flecainide	drug	DDI-DrugBank.d512.s2.e0
DDI-DrugBank.d512.s2	155	165	vinblastine	drug	DDI-DrugBank.d512.s2.e1
DDI-DrugBank.d512.s2	168	179	thioridazine	drug	DDI-DrugBank.d512.s2.e2
DDI-DrugBank.d512.s2	190	214	tricyclic antidepressants	group	DDI-DrugBank.d512.s2.e3
DDI-DrugBank.d512.s2	false	DDI-DrugBank.d512.s2.e0	DDI-DrugBank.d512.s2.e1
DDI-DrugBank.d512.s2	false	DDI-DrugBank.d512.s2.e0	DDI-DrugBank.d512.s2.e2
DDI-DrugBank.d512.s2	false	DDI-DrugBank.d512.s2.e0	DDI-DrugBank.d512.s2.e3
DDI-DrugBank.d512.s2	false	DDI-DrugBank.d512.s2.e1	DDI-DrugBank.d512.s2.e2
DDI-DrugBank.d512.s2	false	DDI-DrugBank.d512.s2.e1	DDI-DrugBank.d512.s2.e3
DDI-DrugBank.d512.s2	false	DDI-DrugBank.d512.s2.e2	DDI-DrugBank.d512.s2.e3
DDI-DrugBank.d512.s3|a|Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
DDI-DrugBank.d512.s3	0	12	Amitriptyline	drug	DDI-DrugBank.d512.s3.e0
DDI-DrugBank.d512.s3	60	69	cinacalcet	drug	DDI-DrugBank.d512.s3.e1
DDI-DrugBank.d512.s3	82	94	amitriptyline	drug	DDI-DrugBank.d512.s3.e2
DDI-DrugBank.d512.s3	106	118	amitriptyline	drug	DDI-DrugBank.d512.s3.e3
DDI-DrugBank.d512.s3	133	145	nortriptyline	drug_n	DDI-DrugBank.d512.s3.e4
DDI-DrugBank.d512.s3	false	DDI-DrugBank.d512.s3.e0	DDI-DrugBank.d512.s3.e1
DDI-DrugBank.d512.s3	false	DDI-DrugBank.d512.s3.e0	DDI-DrugBank.d512.s3.e2
DDI-DrugBank.d512.s3	false	DDI-DrugBank.d512.s3.e0	DDI-DrugBank.d512.s3.e3
DDI-DrugBank.d512.s3	false	DDI-DrugBank.d512.s3.e0	DDI-DrugBank.d512.s3.e4
DDI-DrugBank.d512.s3	true	DDI-DrugBank.d512.s3.e1	DDI-DrugBank.d512.s3.e2
DDI-DrugBank.d512.s3	false	DDI-DrugBank.d512.s3.e1	DDI-DrugBank.d512.s3.e3
DDI-DrugBank.d512.s3	false	DDI-DrugBank.d512.s3.e1	DDI-DrugBank.d512.s3.e4
DDI-DrugBank.d512.s3	false	DDI-DrugBank.d512.s3.e2	DDI-DrugBank.d512.s3.e3
DDI-DrugBank.d512.s3	false	DDI-DrugBank.d512.s3.e2	DDI-DrugBank.d512.s3.e4
DDI-DrugBank.d512.s3	false	DDI-DrugBank.d512.s3.e3	DDI-DrugBank.d512.s3.e4
DDI-DrugBank.d512.s4|a|Effect of other drugs on Sensipar : Sensipar  is metabolized by multiple cytochrome P450 enzymes, primarily CYP3A4, CYP2D6, and CYP1A2.
DDI-DrugBank.d512.s4	25	32	Sensipar	brand	DDI-DrugBank.d512.s4.e0
DDI-DrugBank.d512.s4	36	43	Sensipar	brand	DDI-DrugBank.d512.s4.e1
DDI-DrugBank.d512.s4	false	DDI-DrugBank.d512.s4.e0	DDI-DrugBank.d512.s4.e1
DDI-DrugBank.d512.s5|a|Ketoconazole: Sensipar is metabolized in part by CYP3A4.
DDI-DrugBank.d512.s5	0	11	Ketoconazole	drug	DDI-DrugBank.d512.s5.e0
DDI-DrugBank.d512.s5	14	21	Sensipar	brand	DDI-DrugBank.d512.s5.e1
DDI-DrugBank.d512.s5	false	DDI-DrugBank.d512.s5.e0	DDI-DrugBank.d512.s5.e1
DDI-DrugBank.d512.s6|a|Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.
DDI-DrugBank.d512.s6	21	32	ketoconazole	drug	DDI-DrugBank.d512.s6.e0
DDI-DrugBank.d512.s6	75	84	cinacalcet	drug	DDI-DrugBank.d512.s6.e1
DDI-DrugBank.d512.s6	128	135	Sensipar	brand	DDI-DrugBank.d512.s6.e2
DDI-DrugBank.d512.s6	true	DDI-DrugBank.d512.s6.e0	DDI-DrugBank.d512.s6.e1
DDI-DrugBank.d512.s6	false	DDI-DrugBank.d512.s6.e0	DDI-DrugBank.d512.s6.e2
DDI-DrugBank.d512.s6	false	DDI-DrugBank.d512.s6.e1	DDI-DrugBank.d512.s6.e2
DDI-DrugBank.d512.s7|a|Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
DDI-DrugBank.d512.s7	19	26	Sensipar	brand	DDI-DrugBank.d512.s7.e0
DDI-DrugBank.d512.s7	198	209	ketoconazole	drug	DDI-DrugBank.d512.s7.e1
DDI-DrugBank.d512.s7	212	223	erythromycin	drug	DDI-DrugBank.d512.s7.e2
DDI-DrugBank.d512.s7	226	237	itraconazole	drug	DDI-DrugBank.d512.s7.e3
DDI-DrugBank.d512.s7	true	DDI-DrugBank.d512.s7.e0	DDI-DrugBank.d512.s7.e1
DDI-DrugBank.d512.s7	true	DDI-DrugBank.d512.s7.e0	DDI-DrugBank.d512.s7.e2
DDI-DrugBank.d512.s7	true	DDI-DrugBank.d512.s7.e0	DDI-DrugBank.d512.s7.e3
DDI-DrugBank.d512.s7	false	DDI-DrugBank.d512.s7.e1	DDI-DrugBank.d512.s7.e2
DDI-DrugBank.d512.s7	false	DDI-DrugBank.d512.s7.e1	DDI-DrugBank.d512.s7.e3
DDI-DrugBank.d512.s7	false	DDI-DrugBank.d512.s7.e2	DDI-DrugBank.d512.s7.e3
DDI-DrugBank.d512.s8|a|see DOSAGE AND ADMINISTRATION).
DDI-DrugBank.d562.s0|a|Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.
DDI-DrugBank.d562.s0	26	37	theophylline	drug	DDI-DrugBank.d562.s0.e0
DDI-DrugBank.d562.s0	87	96	quinolones	group	DDI-DrugBank.d562.s0.e1
DDI-DrugBank.d562.s0	true	DDI-DrugBank.d562.s0.e0	DDI-DrugBank.d562.s0.e1
DDI-DrugBank.d562.s1|a|There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.
DDI-DrugBank.d562.s1	27	38	theophylline	drug	DDI-DrugBank.d562.s1.e0
DDI-DrugBank.d562.s1	88	99	theophylline	drug	DDI-DrugBank.d562.s1.e1
DDI-DrugBank.d562.s1	101	109	quinolone	group	DDI-DrugBank.d562.s1.e2
DDI-DrugBank.d562.s1	false	DDI-DrugBank.d562.s1.e0	DDI-DrugBank.d562.s1.e1
DDI-DrugBank.d562.s1	false	DDI-DrugBank.d562.s1.e0	DDI-DrugBank.d562.s1.e2
DDI-DrugBank.d562.s1	true	DDI-DrugBank.d562.s1.e1	DDI-DrugBank.d562.s1.e2
DDI-DrugBank.d562.s2|a|Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
DDI-DrugBank.d562.s2	25	36	theophylline	drug	DDI-DrugBank.d562.s2.e0
DDI-DrugBank.d562.s2	87	98	theophylline	drug	DDI-DrugBank.d562.s2.e1
DDI-DrugBank.d562.s2	false	DDI-DrugBank.d562.s2.e0	DDI-DrugBank.d562.s2.e1
DDI-DrugBank.d562.s3|a|Quinolones have also been shown to interfere with the metabolism of caffeine.
DDI-DrugBank.d562.s3	0	9	Quinolones	group	DDI-DrugBank.d562.s3.e0
DDI-DrugBank.d562.s3	68	75	caffeine	drug	DDI-DrugBank.d562.s3.e1
DDI-DrugBank.d562.s3	true	DDI-DrugBank.d562.s3.e0	DDI-DrugBank.d562.s3.e1
DDI-DrugBank.d562.s4|a|This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.
DDI-DrugBank.d562.s4	38	45	caffeine	drug	DDI-DrugBank.d562.s4.e0
DDI-DrugBank.d562.s5|a|Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.
DDI-DrugBank.d562.s5	53	61	cinoxacin	drug	DDI-DrugBank.d562.s5.e0
DDI-DrugBank.d562.s5	97	105	cinoxacin	drug	DDI-DrugBank.d562.s5.e1
DDI-DrugBank.d562.s5	135	142	caffeine	drug	DDI-DrugBank.d562.s5.e2
DDI-DrugBank.d562.s5	false	DDI-DrugBank.d562.s5.e0	DDI-DrugBank.d562.s5.e1
DDI-DrugBank.d562.s5	false	DDI-DrugBank.d562.s5.e0	DDI-DrugBank.d562.s5.e2
DDI-DrugBank.d562.s5	true	DDI-DrugBank.d562.s5.e1	DDI-DrugBank.d562.s5.e2
DDI-DrugBank.d562.s6|a|Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.
DDI-DrugBank.d562.s6	0	7	Antacids	group	DDI-DrugBank.d562.s6.e0
DDI-DrugBank.d562.s6	12	21	sucralfate	drug	DDI-DrugBank.d562.s6.e1
DDI-DrugBank.d562.s6	75	84	quinolones	group	DDI-DrugBank.d562.s6.e2
DDI-DrugBank.d562.s6	false	DDI-DrugBank.d562.s6.e0	DDI-DrugBank.d562.s6.e1
DDI-DrugBank.d562.s6	true	DDI-DrugBank.d562.s6.e0	DDI-DrugBank.d562.s6.e2
DDI-DrugBank.d562.s6	true	DDI-DrugBank.d562.s6.e1	DDI-DrugBank.d562.s6.e2
DDI-DrugBank.d562.s7|a|Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
DDI-DrugBank.d562.s7	36	45	quinolones	group	DDI-DrugBank.d562.s7.e0
DDI-DrugBank.d562.s7	72	75	iron	drug	DDI-DrugBank.d562.s7.e1
DDI-DrugBank.d562.s7	78	90	multivitamins	group	DDI-DrugBank.d562.s7.e2
DDI-DrugBank.d562.s7	103	106	zinc	drug	DDI-DrugBank.d562.s7.e3
DDI-DrugBank.d562.s7	112	116	Videx	brand	DDI-DrugBank.d562.s7.e4
DDI-DrugBank.d562.s7	119	128	didanosine	drug	DDI-DrugBank.d562.s7.e5
DDI-DrugBank.d562.s7	true	DDI-DrugBank.d562.s7.e0	DDI-DrugBank.d562.s7.e1
DDI-DrugBank.d562.s7	false	DDI-DrugBank.d562.s7.e0	DDI-DrugBank.d562.s7.e2
DDI-DrugBank.d562.s7	true	DDI-DrugBank.d562.s7.e0	DDI-DrugBank.d562.s7.e3
DDI-DrugBank.d562.s7	true	DDI-DrugBank.d562.s7.e0	DDI-DrugBank.d562.s7.e4
DDI-DrugBank.d562.s7	true	DDI-DrugBank.d562.s7.e0	DDI-DrugBank.d562.s7.e5
DDI-DrugBank.d562.s7	false	DDI-DrugBank.d562.s7.e1	DDI-DrugBank.d562.s7.e2
DDI-DrugBank.d562.s7	false	DDI-DrugBank.d562.s7.e1	DDI-DrugBank.d562.s7.e3
DDI-DrugBank.d562.s7	false	DDI-DrugBank.d562.s7.e1	DDI-DrugBank.d562.s7.e4
DDI-DrugBank.d562.s7	false	DDI-DrugBank.d562.s7.e1	DDI-DrugBank.d562.s7.e5
DDI-DrugBank.d562.s7	false	DDI-DrugBank.d562.s7.e2	DDI-DrugBank.d562.s7.e3
DDI-DrugBank.d562.s8|a|Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
DDI-DrugBank.d562.s8	0	9	Quinolones	group	DDI-DrugBank.d562.s8.e0
DDI-DrugBank.d562.s8	22	30	cinoxacin	drug	DDI-DrugBank.d562.s8.e1
DDI-DrugBank.d562.s8	65	78	anticoagulants	group	DDI-DrugBank.d562.s8.e2
DDI-DrugBank.d562.s8	89	96	warfarin	drug	DDI-DrugBank.d562.s8.e3
DDI-DrugBank.d562.s8	false	DDI-DrugBank.d562.s8.e0	DDI-DrugBank.d562.s8.e1
DDI-DrugBank.d562.s8	true	DDI-DrugBank.d562.s8.e0	DDI-DrugBank.d562.s8.e2
DDI-DrugBank.d562.s8	true	DDI-DrugBank.d562.s8.e0	DDI-DrugBank.d562.s8.e3
DDI-DrugBank.d562.s8	true	DDI-DrugBank.d562.s8.e1	DDI-DrugBank.d562.s8.e2
DDI-DrugBank.d562.s8	true	DDI-DrugBank.d562.s8.e1	DDI-DrugBank.d562.s8.e3
DDI-DrugBank.d562.s8	false	DDI-DrugBank.d562.s8.e2	DDI-DrugBank.d562.s8.e3
DDI-DrugBank.d562.s9|a|When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored.
DDI-DrugBank.d562.s10|a|Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.
DDI-DrugBank.d562.s10	55	83	quinolone class antimicrobial	group	DDI-DrugBank.d562.s10.e0
DDI-DrugBank.d562.s10	93	127	nonsteroidal anti-inflammatory drug	group	DDI-DrugBank.d562.s10.e1
DDI-DrugBank.d562.s10	129	136	fenbufen	drug	DDI-DrugBank.d562.s10.e2
DDI-DrugBank.d562.s10	true	DDI-DrugBank.d562.s10.e0	DDI-DrugBank.d562.s10.e1
DDI-DrugBank.d562.s10	true	DDI-DrugBank.d562.s10.e0	DDI-DrugBank.d562.s10.e2
DDI-DrugBank.d562.s10	false	DDI-DrugBank.d562.s10.e1	DDI-DrugBank.d562.s10.e2
DDI-DrugBank.d562.s11|a|Animal studies also suggest an increased potential for seizures when these 2 drugs are given concomitantly.
DDI-DrugBank.d562.s12|a|Fenbufen is not approved in the United States at this time.
DDI-DrugBank.d562.s12	0	7	Fenbufen	drug	DDI-DrugBank.d562.s12.e0
DDI-DrugBank.d562.s13|a|Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.
DDI-DrugBank.d562.s13	110	118	cinoxacin	drug	DDI-DrugBank.d562.s13.e0
DDI-DrugBank.d562.s13	132	168	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d562.s13.e1
DDI-DrugBank.d562.s13	true	DDI-DrugBank.d562.s13.e0	DDI-DrugBank.d562.s13.e1
DDI-DrugBank.d562.s14|a|Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.
DDI-DrugBank.d562.s14	9	20	cyclosporine	drug	DDI-DrugBank.d562.s14.e0
DDI-DrugBank.d562.s14	82	91	quinolones	group	DDI-DrugBank.d562.s14.e1
DDI-DrugBank.d562.s14	97	108	cyclosporine	drug	DDI-DrugBank.d562.s14.e2
DDI-DrugBank.d562.s14	false	DDI-DrugBank.d562.s14.e0	DDI-DrugBank.d562.s14.e1
DDI-DrugBank.d562.s14	false	DDI-DrugBank.d562.s14.e0	DDI-DrugBank.d562.s14.e2
DDI-DrugBank.d562.s14	true	DDI-DrugBank.d562.s14.e1	DDI-DrugBank.d562.s14.e2
DDI-DrugBank.d123.s0|a|Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
DDI-DrugBank.d123.s0	5	14	quinolones	group	DDI-DrugBank.d123.s0.e0
DDI-DrugBank.d123.s0	27	39	ciprofloxacin	drug	DDI-DrugBank.d123.s0.e1
DDI-DrugBank.d123.s0	99	106	caffeine	drug	DDI-DrugBank.d123.s0.e2
DDI-DrugBank.d123.s0	false	DDI-DrugBank.d123.s0.e0	DDI-DrugBank.d123.s0.e1
DDI-DrugBank.d123.s0	true	DDI-DrugBank.d123.s0.e0	DDI-DrugBank.d123.s0.e2
DDI-DrugBank.d123.s0	true	DDI-DrugBank.d123.s0.e1	DDI-DrugBank.d123.s0.e2
DDI-DrugBank.d123.s1|a|This may lead to reduced clearance of caffeine and a prolongation of its serum half-life.
DDI-DrugBank.d123.s1	38	45	caffeine	drug	DDI-DrugBank.d123.s1.e0
DDI-DrugBank.d123.s2|a|Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
DDI-DrugBank.d123.s2	5	14	quinolones	group	DDI-DrugBank.d123.s2.e0
DDI-DrugBank.d123.s2	27	39	ciprofloxacin	drug	DDI-DrugBank.d123.s2.e1
DDI-DrugBank.d123.s2	131	142	cyclosporine	drug	DDI-DrugBank.d123.s2.e2
DDI-DrugBank.d123.s2	false	DDI-DrugBank.d123.s2.e0	DDI-DrugBank.d123.s2.e1
DDI-DrugBank.d123.s2	true	DDI-DrugBank.d123.s2.e0	DDI-DrugBank.d123.s2.e2
DDI-DrugBank.d123.s2	true	DDI-DrugBank.d123.s2.e1	DDI-DrugBank.d123.s2.e2
DDI-DrugBank.d123.s3|a|Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
DDI-DrugBank.d123.s3	0	8	Glyburide	drug	DDI-DrugBank.d123.s3.e0
DDI-DrugBank.d123.s3	45	57	ciprofloxacin	drug	DDI-DrugBank.d123.s3.e1
DDI-DrugBank.d123.s3	68	79	sulfonylurea	group	DDI-DrugBank.d123.s3.e2
DDI-DrugBank.d123.s3	81	89	glyburide	drug	DDI-DrugBank.d123.s3.e3
DDI-DrugBank.d123.s3	false	DDI-DrugBank.d123.s3.e0	DDI-DrugBank.d123.s3.e1
DDI-DrugBank.d123.s3	false	DDI-DrugBank.d123.s3.e0	DDI-DrugBank.d123.s3.e2
DDI-DrugBank.d123.s3	false	DDI-DrugBank.d123.s3.e0	DDI-DrugBank.d123.s3.e3
DDI-DrugBank.d123.s3	true	DDI-DrugBank.d123.s3.e1	DDI-DrugBank.d123.s3.e2
DDI-DrugBank.d123.s3	true	DDI-DrugBank.d123.s3.e1	DDI-DrugBank.d123.s3.e3
DDI-DrugBank.d123.s3	false	DDI-DrugBank.d123.s3.e2	DDI-DrugBank.d123.s3.e3
DDI-DrugBank.d123.s4|a|Histamine H2-receptor antagonists: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin.
DDI-DrugBank.d123.s4	0	32	Histamine H2-receptor antagonists	group	DDI-DrugBank.d123.s4.e0
DDI-DrugBank.d123.s4	35	67	Histamine H2-receptor antagonists	group	DDI-DrugBank.d123.s4.e1
DDI-DrugBank.d123.s4	132	144	ciprofloxacin	drug	DDI-DrugBank.d123.s4.e2
DDI-DrugBank.d123.s4	false	DDI-DrugBank.d123.s4.e0	DDI-DrugBank.d123.s4.e1
DDI-DrugBank.d123.s4	false	DDI-DrugBank.d123.s4.e0	DDI-DrugBank.d123.s4.e2
DDI-DrugBank.d123.s4	false	DDI-DrugBank.d123.s4.e1	DDI-DrugBank.d123.s4.e2
DDI-DrugBank.d123.s5|a|Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
DDI-DrugBank.d123.s5	0	11	Methotrexate	drug	DDI-DrugBank.d123.s5.e0
DDI-DrugBank.d123.s5	40	51	methotrexate	drug	DDI-DrugBank.d123.s5.e1
DDI-DrugBank.d123.s5	103	115	ciprofloxacin	drug	DDI-DrugBank.d123.s5.e2
DDI-DrugBank.d123.s5	168	179	methotrexate	drug	DDI-DrugBank.d123.s5.e3
DDI-DrugBank.d123.s5	false	DDI-DrugBank.d123.s5.e0	DDI-DrugBank.d123.s5.e1
DDI-DrugBank.d123.s5	false	DDI-DrugBank.d123.s5.e0	DDI-DrugBank.d123.s5.e2
DDI-DrugBank.d123.s5	false	DDI-DrugBank.d123.s5.e0	DDI-DrugBank.d123.s5.e3
DDI-DrugBank.d123.s5	true	DDI-DrugBank.d123.s5.e1	DDI-DrugBank.d123.s5.e2
DDI-DrugBank.d123.s5	false	DDI-DrugBank.d123.s5.e1	DDI-DrugBank.d123.s5.e3
DDI-DrugBank.d123.s5	false	DDI-DrugBank.d123.s5.e2	DDI-DrugBank.d123.s5.e3
DDI-DrugBank.d123.s6|a|This might increase the risk of methotrexate toxic reactions.
DDI-DrugBank.d123.s6	32	43	methotrexate	drug	DDI-DrugBank.d123.s6.e0
DDI-DrugBank.d123.s7|a|Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
DDI-DrugBank.d123.s7	26	37	methotrexate	drug	DDI-DrugBank.d123.s7.e0
DDI-DrugBank.d123.s7	94	106	ciprofloxacin	drug	DDI-DrugBank.d123.s7.e1
DDI-DrugBank.d123.s7	true	DDI-DrugBank.d123.s7.e0	DDI-DrugBank.d123.s7.e1
DDI-DrugBank.d123.s8|a|Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8	71	79	quinolone	group	DDI-DrugBank.d123.s8.e0
DDI-DrugBank.d123.s8	92	104	ciprofloxacin	drug	DDI-DrugBank.d123.s8.e1
DDI-DrugBank.d123.s8	159	167	magnesium	drug	DDI-DrugBank.d123.s8.e2
DDI-DrugBank.d123.s8	172	179	aluminum	drug	DDI-DrugBank.d123.s8.e3
DDI-DrugBank.d123.s8	181	188	antacids	group	DDI-DrugBank.d123.s8.e4
DDI-DrugBank.d123.s8	191	200	sucralfate	drug	DDI-DrugBank.d123.s8.e5
DDI-DrugBank.d123.s8	203	207	VIDEX	brand	DDI-DrugBank.d123.s8.e6
DDI-DrugBank.d123.s8	279	285	calcium	drug	DDI-DrugBank.d123.s8.e7
DDI-DrugBank.d123.s8	288	291	iron	drug	DDI-DrugBank.d123.s8.e8
DDI-DrugBank.d123.s8	297	300	zinc	drug	DDI-DrugBank.d123.s8.e9
DDI-DrugBank.d123.s8	false	DDI-DrugBank.d123.s8.e0	DDI-DrugBank.d123.s8.e1
DDI-DrugBank.d123.s8	true	DDI-DrugBank.d123.s8.e0	DDI-DrugBank.d123.s8.e2
DDI-DrugBank.d123.s8	true	DDI-DrugBank.d123.s8.e0	DDI-DrugBank.d123.s8.e3
DDI-DrugBank.d123.s8	true	DDI-DrugBank.d123.s8.e0	DDI-DrugBank.d123.s8.e4
DDI-DrugBank.d123.s8	true	DDI-DrugBank.d123.s8.e0	DDI-DrugBank.d123.s8.e5
DDI-DrugBank.d123.s8	true	DDI-DrugBank.d123.s8.e0	DDI-DrugBank.d123.s8.e6
DDI-DrugBank.d123.s8	true	DDI-DrugBank.d123.s8.e0	DDI-DrugBank.d123.s8.e7
DDI-DrugBank.d123.s8	true	DDI-DrugBank.d123.s8.e0	DDI-DrugBank.d123.s8.e8
DDI-DrugBank.d123.s8	true	DDI-DrugBank.d123.s8.e0	DDI-DrugBank.d123.s8.e9
DDI-DrugBank.d123.s8	false	DDI-DrugBank.d123.s8.e0	DDI-DrugBank.d123.s8.e10
DDI-DrugBank.d123.s9|a|Proquin XR should be administered at least 4 hours before or 2 hours after these products.
DDI-DrugBank.d123.s9	0	9	Proquin XR	brand	DDI-DrugBank.d123.s9.e0
DDI-DrugBank.d123.s10|a|This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.
DDI-DrugBank.d123.s10	66	78	ciprofloxacin	drug	DDI-DrugBank.d123.s10.e0
DDI-DrugBank.d123.s10	144	151	antacids	group	DDI-DrugBank.d123.s10.e1
DDI-DrugBank.d123.s10	true	DDI-DrugBank.d123.s10.e0	DDI-DrugBank.d123.s10.e1
DDI-DrugBank.d123.s11|a|Non-steroidal anti-inflammatory drugs (but not aspirin): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.
DDI-DrugBank.d123.s11	0	36	Non-steroidal anti-inflammatory drugs	group	DDI-DrugBank.d123.s11.e0
DDI-DrugBank.d123.s11	47	53	aspirin	brand	DDI-DrugBank.d123.s11.e1
DDI-DrugBank.d123.s11	108	117	quinolones	group	DDI-DrugBank.d123.s11.e2
DDI-DrugBank.d123.s11	false	DDI-DrugBank.d123.s11.e0	DDI-DrugBank.d123.s11.e1
DDI-DrugBank.d123.s11	false	DDI-DrugBank.d123.s11.e0	DDI-DrugBank.d123.s11.e2
DDI-DrugBank.d123.s11	false	DDI-DrugBank.d123.s11.e1	DDI-DrugBank.d123.s11.e2
DDI-DrugBank.d123.s12|a|Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
DDI-DrugBank.d123.s12	0	9	Omeprazole	drug	DDI-DrugBank.d123.s12.e0
DDI-DrugBank.d123.s12	49	61	ciprofloxacin	drug	DDI-DrugBank.d123.s12.e1
DDI-DrugBank.d123.s12	86	95	Proquin XR	brand	DDI-DrugBank.d123.s12.e2
DDI-DrugBank.d123.s12	121	130	Proquin XR	brand	DDI-DrugBank.d123.s12.e3
DDI-DrugBank.d123.s12	156	165	omeprazole	drug	DDI-DrugBank.d123.s12.e4
DDI-DrugBank.d123.s12	false	DDI-DrugBank.d123.s12.e0	DDI-DrugBank.d123.s12.e1
DDI-DrugBank.d123.s12	false	DDI-DrugBank.d123.s12.e0	DDI-DrugBank.d123.s12.e2
DDI-DrugBank.d123.s12	false	DDI-DrugBank.d123.s12.e0	DDI-DrugBank.d123.s12.e3
DDI-DrugBank.d123.s12	false	DDI-DrugBank.d123.s12.e0	DDI-DrugBank.d123.s12.e4
DDI-DrugBank.d123.s12	false	DDI-DrugBank.d123.s12.e1	DDI-DrugBank.d123.s12.e2
DDI-DrugBank.d123.s12	false	DDI-DrugBank.d123.s12.e1	DDI-DrugBank.d123.s12.e3
DDI-DrugBank.d123.s12	false	DDI-DrugBank.d123.s12.e1	DDI-DrugBank.d123.s12.e4
DDI-DrugBank.d123.s12	false	DDI-DrugBank.d123.s12.e2	DDI-DrugBank.d123.s12.e3
DDI-DrugBank.d123.s12	false	DDI-DrugBank.d123.s12.e2	DDI-DrugBank.d123.s12.e4
DDI-DrugBank.d123.s12	false	DDI-DrugBank.d123.s12.e3	DDI-DrugBank.d123.s12.e4
DDI-DrugBank.d123.s13|a|Omeprazole should be taken as directed and Proquin XR should be taken with a main meal of the day, preferably the evening meal..
DDI-DrugBank.d123.s13	0	9	Omeprazole	drug	DDI-DrugBank.d123.s13.e0
DDI-DrugBank.d123.s13	43	52	Proquin XR	brand	DDI-DrugBank.d123.s13.e1
DDI-DrugBank.d123.s13	false	DDI-DrugBank.d123.s13.e0	DDI-DrugBank.d123.s13.e1
DDI-DrugBank.d123.s14|a|Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
DDI-DrugBank.d123.s14	0	8	Phenytoin	drug	DDI-DrugBank.d123.s14.e0
DDI-DrugBank.d123.s14	35	43	phenytoin	drug	DDI-DrugBank.d123.s14.e1
DDI-DrugBank.d123.s14	124	136	ciprofloxacin	drug	DDI-DrugBank.d123.s14.e2
DDI-DrugBank.d123.s14	false	DDI-DrugBank.d123.s14.e0	DDI-DrugBank.d123.s14.e1
DDI-DrugBank.d123.s14	false	DDI-DrugBank.d123.s14.e0	DDI-DrugBank.d123.s14.e2
DDI-DrugBank.d123.s14	true	DDI-DrugBank.d123.s14.e1	DDI-DrugBank.d123.s14.e2
DDI-DrugBank.d123.s15|a|Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
DDI-DrugBank.d123.s15	0	9	Probenecid	drug	DDI-DrugBank.d123.s15.e0
DDI-DrugBank.d123.s15	12	21	Probenecid	drug	DDI-DrugBank.d123.s15.e1
DDI-DrugBank.d123.s15	66	78	ciprofloxacin	drug	DDI-DrugBank.d123.s15.e2
DDI-DrugBank.d123.s15	121	133	ciprofloxacin	drug	DDI-DrugBank.d123.s15.e3
DDI-DrugBank.d123.s15	false	DDI-DrugBank.d123.s15.e0	DDI-DrugBank.d123.s15.e1
DDI-DrugBank.d123.s15	false	DDI-DrugBank.d123.s15.e0	DDI-DrugBank.d123.s15.e2
DDI-DrugBank.d123.s15	false	DDI-DrugBank.d123.s15.e0	DDI-DrugBank.d123.s15.e3
DDI-DrugBank.d123.s15	true	DDI-DrugBank.d123.s15.e1	DDI-DrugBank.d123.s15.e2
DDI-DrugBank.d123.s15	true	DDI-DrugBank.d123.s15.e1	DDI-DrugBank.d123.s15.e3
DDI-DrugBank.d123.s15	false	DDI-DrugBank.d123.s15.e2	DDI-DrugBank.d123.s15.e3
DDI-DrugBank.d123.s16|a|Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
DDI-DrugBank.d123.s16	0	11	Theophylline	drug	DDI-DrugBank.d123.s16.e0
DDI-DrugBank.d123.s16	33	42	quinolones	group	DDI-DrugBank.d123.s16.e1
DDI-DrugBank.d123.s16	74	86	ciprofloxacin	drug	DDI-DrugBank.d123.s16.e2
DDI-DrugBank.d123.s16	93	104	theophylline	drug	DDI-DrugBank.d123.s16.e3
DDI-DrugBank.d123.s16	151	162	theophylline	drug	DDI-DrugBank.d123.s16.e4
DDI-DrugBank.d123.s16	false	DDI-DrugBank.d123.s16.e0	DDI-DrugBank.d123.s16.e1
DDI-DrugBank.d123.s16	false	DDI-DrugBank.d123.s16.e0	DDI-DrugBank.d123.s16.e2
DDI-DrugBank.d123.s16	false	DDI-DrugBank.d123.s16.e0	DDI-DrugBank.d123.s16.e3
DDI-DrugBank.d123.s16	false	DDI-DrugBank.d123.s16.e0	DDI-DrugBank.d123.s16.e4
DDI-DrugBank.d123.s16	false	DDI-DrugBank.d123.s16.e1	DDI-DrugBank.d123.s16.e2
DDI-DrugBank.d123.s16	true	DDI-DrugBank.d123.s16.e1	DDI-DrugBank.d123.s16.e3
DDI-DrugBank.d123.s16	false	DDI-DrugBank.d123.s16.e1	DDI-DrugBank.d123.s16.e4
DDI-DrugBank.d123.s16	true	DDI-DrugBank.d123.s16.e2	DDI-DrugBank.d123.s16.e3
DDI-DrugBank.d123.s16	false	DDI-DrugBank.d123.s16.e2	DDI-DrugBank.d123.s16.e4
DDI-DrugBank.d123.s16	false	DDI-DrugBank.d123.s16.e3	DDI-DrugBank.d123.s16.e4
DDI-DrugBank.d123.s17|a|This may result in increased risk of theophylline-related adverse reactions.
DDI-DrugBank.d123.s17	37	48	theophylline	drug	DDI-DrugBank.d123.s17.e0
DDI-DrugBank.d123.s18|a|If concomitant use cannot be avoided, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.
DDI-DrugBank.d123.s18	54	65	theophylline	drug	DDI-DrugBank.d123.s18.e0
DDI-DrugBank.d123.s19|a|Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.
DDI-DrugBank.d123.s19	0	7	Warfarin	drug	DDI-DrugBank.d123.s19.e0
DDI-DrugBank.d123.s19	10	19	Quinolones	group	DDI-DrugBank.d123.s19.e1
DDI-DrugBank.d123.s19	75	87	anticoagulant	group	DDI-DrugBank.d123.s19.e2
DDI-DrugBank.d123.s19	89	96	warfarin	drug	DDI-DrugBank.d123.s19.e3
DDI-DrugBank.d123.s19	false	DDI-DrugBank.d123.s19.e0	DDI-DrugBank.d123.s19.e1
DDI-DrugBank.d123.s19	false	DDI-DrugBank.d123.s19.e0	DDI-DrugBank.d123.s19.e2
DDI-DrugBank.d123.s19	false	DDI-DrugBank.d123.s19.e0	DDI-DrugBank.d123.s19.e3
DDI-DrugBank.d123.s19	false	DDI-DrugBank.d123.s19.e1	DDI-DrugBank.d123.s19.e2
DDI-DrugBank.d123.s19	true	DDI-DrugBank.d123.s19.e1	DDI-DrugBank.d123.s19.e3
DDI-DrugBank.d123.s19	false	DDI-DrugBank.d123.s19.e2	DDI-DrugBank.d123.s19.e3
DDI-DrugBank.d123.s20|a|When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be monitored.
DDI-DrugBank.d237.s0|a|Cisapride is metabolized mainly via the cytochrome P450 3A4 enzyme.
DDI-DrugBank.d237.s0	0	8	Cisapride	drug	DDI-DrugBank.d237.s0.e0
DDI-DrugBank.d237.s1|a|In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when cisapride was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood cisapride levels were noted at the time of the QT prolongation.
DDI-DrugBank.d237.s1	113	121	cisapride	drug	DDI-DrugBank.d237.s1.e0
DDI-DrugBank.d237.s1	211	219	cisapride	drug	DDI-DrugBank.d237.s1.e1
DDI-DrugBank.d237.s1	false	DDI-DrugBank.d237.s1.e0	DDI-DrugBank.d237.s1.e1
DDI-DrugBank.d237.s2|a|Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s2	0	10	Antibiotics	group	DDI-DrugBank.d237.s2.e0
DDI-DrugBank.d237.s2	52	65	clarithromycin	drug	DDI-DrugBank.d237.s2.e1
DDI-DrugBank.d237.s2	68	79	erythromycin	drug	DDI-DrugBank.d237.s2.e2
DDI-DrugBank.d237.s2	86	99	troleandomycin	drug	DDI-DrugBank.d237.s2.e3
DDI-DrugBank.d237.s2	136	144	cisapride	drug	DDI-DrugBank.d237.s2.e4
DDI-DrugBank.d237.s2	189	197	cisapride	drug	DDI-DrugBank.d237.s2.e5
DDI-DrugBank.d237.s2	false	DDI-DrugBank.d237.s2.e0	DDI-DrugBank.d237.s2.e1
DDI-DrugBank.d237.s2	false	DDI-DrugBank.d237.s2.e0	DDI-DrugBank.d237.s2.e2
DDI-DrugBank.d237.s2	false	DDI-DrugBank.d237.s2.e0	DDI-DrugBank.d237.s2.e3
DDI-DrugBank.d237.s2	false	DDI-DrugBank.d237.s2.e0	DDI-DrugBank.d237.s2.e4
DDI-DrugBank.d237.s2	false	DDI-DrugBank.d237.s2.e0	DDI-DrugBank.d237.s2.e5
DDI-DrugBank.d237.s2	false	DDI-DrugBank.d237.s2.e1	DDI-DrugBank.d237.s2.e2
DDI-DrugBank.d237.s2	false	DDI-DrugBank.d237.s2.e1	DDI-DrugBank.d237.s2.e3
DDI-DrugBank.d237.s2	true	DDI-DrugBank.d237.s2.e1	DDI-DrugBank.d237.s2.e4
DDI-DrugBank.d237.s2	false	DDI-DrugBank.d237.s2.e1	DDI-DrugBank.d237.s2.e5
DDI-DrugBank.d237.s2	false	DDI-DrugBank.d237.s2.e2	DDI-DrugBank.d237.s2.e3
DDI-DrugBank.d237.s3|a|Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
DDI-DrugBank.d237.s3	0	15	Anticholinergics	group	DDI-DrugBank.d237.s3.e0
DDI-DrugBank.d237.s3	55	79	anticholinergic compounds	group	DDI-DrugBank.d237.s3.e1
DDI-DrugBank.d237.s3	90	109	belladonna alkaloids	group	DDI-DrugBank.d237.s3.e2
DDI-DrugBank.d237.s3	115	125	dicyclomine	drug	DDI-DrugBank.d237.s3.e3
DDI-DrugBank.d237.s3	186	194	cisapride	drug	DDI-DrugBank.d237.s3.e4
DDI-DrugBank.d237.s3	false	DDI-DrugBank.d237.s3.e0	DDI-DrugBank.d237.s3.e1
DDI-DrugBank.d237.s3	false	DDI-DrugBank.d237.s3.e0	DDI-DrugBank.d237.s3.e2
DDI-DrugBank.d237.s3	false	DDI-DrugBank.d237.s3.e0	DDI-DrugBank.d237.s3.e3
DDI-DrugBank.d237.s3	false	DDI-DrugBank.d237.s3.e0	DDI-DrugBank.d237.s3.e4
DDI-DrugBank.d237.s3	false	DDI-DrugBank.d237.s3.e1	DDI-DrugBank.d237.s3.e2
DDI-DrugBank.d237.s3	false	DDI-DrugBank.d237.s3.e1	DDI-DrugBank.d237.s3.e3
DDI-DrugBank.d237.s3	true	DDI-DrugBank.d237.s3.e1	DDI-DrugBank.d237.s3.e4
DDI-DrugBank.d237.s3	false	DDI-DrugBank.d237.s3.e2	DDI-DrugBank.d237.s3.e3
DDI-DrugBank.d237.s3	true	DDI-DrugBank.d237.s3.e2	DDI-DrugBank.d237.s3.e4
DDI-DrugBank.d237.s3	true	DDI-DrugBank.d237.s3.e3	DDI-DrugBank.d237.s3.e4
DDI-DrugBank.d237.s4|a|Anticoagulants (Oral): In patients receiving oral anticoagulants, the coagulation times were increased in some cases.
DDI-DrugBank.d237.s4	0	13	Anticoagulants	group	DDI-DrugBank.d237.s4.e0
DDI-DrugBank.d237.s4	50	63	anticoagulants	group	DDI-DrugBank.d237.s4.e1
DDI-DrugBank.d237.s4	false	DDI-DrugBank.d237.s4.e0	DDI-DrugBank.d237.s4.e1
DDI-DrugBank.d237.s5|a|It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.
DDI-DrugBank.d237.s5	107	115	cisapride	drug	DDI-DrugBank.d237.s5.e0
DDI-DrugBank.d237.s5	164	176	anticoagulant	group	DDI-DrugBank.d237.s5.e1
DDI-DrugBank.d237.s5	true	DDI-DrugBank.d237.s5.e0	DDI-DrugBank.d237.s5.e1
DDI-DrugBank.d237.s6|a|Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s6	0	14	Antidepressants	group	DDI-DrugBank.d237.s6.e0
DDI-DrugBank.d237.s6	45	54	nefazodone	drug	DDI-DrugBank.d237.s6.e1
DDI-DrugBank.d237.s6	83	91	cisapride	drug	DDI-DrugBank.d237.s6.e2
DDI-DrugBank.d237.s6	136	144	cisapride	drug	DDI-DrugBank.d237.s6.e3
DDI-DrugBank.d237.s6	false	DDI-DrugBank.d237.s6.e0	DDI-DrugBank.d237.s6.e1
DDI-DrugBank.d237.s6	false	DDI-DrugBank.d237.s6.e0	DDI-DrugBank.d237.s6.e2
DDI-DrugBank.d237.s6	false	DDI-DrugBank.d237.s6.e0	DDI-DrugBank.d237.s6.e3
DDI-DrugBank.d237.s6	true	DDI-DrugBank.d237.s6.e1	DDI-DrugBank.d237.s6.e2
DDI-DrugBank.d237.s6	false	DDI-DrugBank.d237.s6.e1	DDI-DrugBank.d237.s6.e3
DDI-DrugBank.d237.s6	false	DDI-DrugBank.d237.s6.e2	DDI-DrugBank.d237.s6.e3
DDI-DrugBank.d237.s7|a|Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s7	0	10	Antifungals	group	DDI-DrugBank.d237.s7.e0
DDI-DrugBank.d237.s7	56	66	fluconazole	drug	DDI-DrugBank.d237.s7.e1
DDI-DrugBank.d237.s7	69	80	itraconazole	drug	DDI-DrugBank.d237.s7.e2
DDI-DrugBank.d237.s7	92	103	ketoconazole	drug	DDI-DrugBank.d237.s7.e3
DDI-DrugBank.d237.s7	140	148	cisapride	drug	DDI-DrugBank.d237.s7.e4
DDI-DrugBank.d237.s7	193	201	cisapride	drug	DDI-DrugBank.d237.s7.e5
DDI-DrugBank.d237.s7	false	DDI-DrugBank.d237.s7.e0	DDI-DrugBank.d237.s7.e1
DDI-DrugBank.d237.s7	false	DDI-DrugBank.d237.s7.e0	DDI-DrugBank.d237.s7.e2
DDI-DrugBank.d237.s7	false	DDI-DrugBank.d237.s7.e0	DDI-DrugBank.d237.s7.e3
DDI-DrugBank.d237.s7	false	DDI-DrugBank.d237.s7.e0	DDI-DrugBank.d237.s7.e4
DDI-DrugBank.d237.s7	false	DDI-DrugBank.d237.s7.e0	DDI-DrugBank.d237.s7.e5
DDI-DrugBank.d237.s7	false	DDI-DrugBank.d237.s7.e1	DDI-DrugBank.d237.s7.e2
DDI-DrugBank.d237.s7	false	DDI-DrugBank.d237.s7.e1	DDI-DrugBank.d237.s7.e3
DDI-DrugBank.d237.s7	true	DDI-DrugBank.d237.s7.e1	DDI-DrugBank.d237.s7.e4
DDI-DrugBank.d237.s7	false	DDI-DrugBank.d237.s7.e1	DDI-DrugBank.d237.s7.e5
DDI-DrugBank.d237.s7	false	DDI-DrugBank.d237.s7.e2	DDI-DrugBank.d237.s7.e3
DDI-DrugBank.d237.s8|a|Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.
DDI-DrugBank.d237.s8	46	57	ketoconazole	drug	DDI-DrugBank.d237.s8.e0
DDI-DrugBank.d237.s8	95	103	cisapride	drug	DDI-DrugBank.d237.s8.e1
DDI-DrugBank.d237.s8	156	164	cisapride	drug	DDI-DrugBank.d237.s8.e2
DDI-DrugBank.d237.s8	true	DDI-DrugBank.d237.s8.e0	DDI-DrugBank.d237.s8.e1
DDI-DrugBank.d237.s8	false	DDI-DrugBank.d237.s8.e0	DDI-DrugBank.d237.s8.e2
DDI-DrugBank.d237.s8	false	DDI-DrugBank.d237.s8.e1	DDI-DrugBank.d237.s8.e2
DDI-DrugBank.d237.s9|a|A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s9	82	90	cisapride	drug	DDI-DrugBank.d237.s9.e0
DDI-DrugBank.d237.s9	96	107	ketoconazole	drug	DDI-DrugBank.d237.s9.e1
DDI-DrugBank.d237.s9	true	DDI-DrugBank.d237.s9.e0	DDI-DrugBank.d237.s9.e1
DDI-DrugBank.d237.s10|a|H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.
DDI-DrugBank.d237.s10	0	22	H2 Receptor Antagonists	group	DDI-DrugBank.d237.s10.e0
DDI-DrugBank.d237.s10	25	34	Cimetidine	drug	DDI-DrugBank.d237.s10.e1
DDI-DrugBank.d237.s10	112	120	cisapride	drug	DDI-DrugBank.d237.s10.e2
DDI-DrugBank.d237.s10	145	153	cisapride	drug	DDI-DrugBank.d237.s10.e3
DDI-DrugBank.d237.s10	197	206	ranitidine	drug	DDI-DrugBank.d237.s10.e4
DDI-DrugBank.d237.s10	false	DDI-DrugBank.d237.s10.e0	DDI-DrugBank.d237.s10.e1
DDI-DrugBank.d237.s10	false	DDI-DrugBank.d237.s10.e0	DDI-DrugBank.d237.s10.e2
DDI-DrugBank.d237.s10	false	DDI-DrugBank.d237.s10.e0	DDI-DrugBank.d237.s10.e3
DDI-DrugBank.d237.s10	false	DDI-DrugBank.d237.s10.e0	DDI-DrugBank.d237.s10.e4
DDI-DrugBank.d237.s10	true	DDI-DrugBank.d237.s10.e1	DDI-DrugBank.d237.s10.e2
DDI-DrugBank.d237.s10	false	DDI-DrugBank.d237.s10.e1	DDI-DrugBank.d237.s10.e3
DDI-DrugBank.d237.s10	false	DDI-DrugBank.d237.s10.e1	DDI-DrugBank.d237.s10.e4
DDI-DrugBank.d237.s10	false	DDI-DrugBank.d237.s10.e2	DDI-DrugBank.d237.s10.e3
DDI-DrugBank.d237.s10	false	DDI-DrugBank.d237.s10.e2	DDI-DrugBank.d237.s10.e4
DDI-DrugBank.d237.s10	false	DDI-DrugBank.d237.s10.e3	DDI-DrugBank.d237.s10.e4
DDI-DrugBank.d237.s11|a|The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
DDI-DrugBank.d237.s11	35	44	cimetidine	drug	DDI-DrugBank.d237.s11.e0
DDI-DrugBank.d237.s11	50	59	ranitidine	drug	DDI-DrugBank.d237.s11.e1
DDI-DrugBank.d237.s11	110	118	cisapride	drug	DDI-DrugBank.d237.s11.e2
DDI-DrugBank.d237.s11	false	DDI-DrugBank.d237.s11.e0	DDI-DrugBank.d237.s11.e1
DDI-DrugBank.d237.s11	true	DDI-DrugBank.d237.s11.e0	DDI-DrugBank.d237.s11.e2
DDI-DrugBank.d237.s11	true	DDI-DrugBank.d237.s11.e1	DDI-DrugBank.d237.s11.e2
DDI-DrugBank.d237.s12|a|Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s12	0	18	Protease Inhibitors	group	DDI-DrugBank.d237.s12.e0
DDI-DrugBank.d237.s12	49	57	indinavir	drug	DDI-DrugBank.d237.s12.e1
DDI-DrugBank.d237.s12	63	71	ritonavir	drug	DDI-DrugBank.d237.s12.e2
DDI-DrugBank.d237.s12	108	116	cisapride	drug	DDI-DrugBank.d237.s12.e3
DDI-DrugBank.d237.s12	160	168	cisapride	drug	DDI-DrugBank.d237.s12.e4
DDI-DrugBank.d237.s12	false	DDI-DrugBank.d237.s12.e0	DDI-DrugBank.d237.s12.e1
DDI-DrugBank.d237.s12	false	DDI-DrugBank.d237.s12.e0	DDI-DrugBank.d237.s12.e2
DDI-DrugBank.d237.s12	false	DDI-DrugBank.d237.s12.e0	DDI-DrugBank.d237.s12.e3
DDI-DrugBank.d237.s12	false	DDI-DrugBank.d237.s12.e0	DDI-DrugBank.d237.s12.e4
DDI-DrugBank.d237.s12	false	DDI-DrugBank.d237.s12.e1	DDI-DrugBank.d237.s12.e2
DDI-DrugBank.d237.s12	true	DDI-DrugBank.d237.s12.e1	DDI-DrugBank.d237.s12.e3
DDI-DrugBank.d237.s12	false	DDI-DrugBank.d237.s12.e1	DDI-DrugBank.d237.s12.e4
DDI-DrugBank.d237.s12	true	DDI-DrugBank.d237.s12.e2	DDI-DrugBank.d237.s12.e3
DDI-DrugBank.d237.s12	false	DDI-DrugBank.d237.s12.e2	DDI-DrugBank.d237.s12.e4
DDI-DrugBank.d237.s12	false	DDI-DrugBank.d237.s12.e3	DDI-DrugBank.d237.s12.e4
DDI-DrugBank.d237.s13|a|Other: Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride and concomitant use should be avoided.
DDI-DrugBank.d237.s13	49	57	cisapride	drug	DDI-DrugBank.d237.s13.e0
DDI-DrugBank.d237.s13	92	100	cisapride	drug	DDI-DrugBank.d237.s13.e1
DDI-DrugBank.d237.s13	false	DDI-DrugBank.d237.s13.e0	DDI-DrugBank.d237.s13.e1
DDI-DrugBank.d237.s14|a|Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
DDI-DrugBank.d237.s14	0	8	Cisapride	drug	DDI-DrugBank.d237.s14.e0
DDI-DrugBank.d237.s14	102	116	antiarrhythmics	group	DDI-DrugBank.d237.s14.e1
DDI-DrugBank.d237.s14	156	164	quinidine	drug	DDI-DrugBank.d237.s14.e2
DDI-DrugBank.d237.s14	170	181	procainamide	drug	DDI-DrugBank.d237.s14.e3
DDI-DrugBank.d237.s14	207	213	sotalol	drug	DDI-DrugBank.d237.s14.e4
DDI-DrugBank.d237.s14	true	DDI-DrugBank.d237.s14.e0	DDI-DrugBank.d237.s14.e1
DDI-DrugBank.d237.s14	true	DDI-DrugBank.d237.s14.e0	DDI-DrugBank.d237.s14.e2
DDI-DrugBank.d237.s14	true	DDI-DrugBank.d237.s14.e0	DDI-DrugBank.d237.s14.e3
DDI-DrugBank.d237.s14	true	DDI-DrugBank.d237.s14.e0	DDI-DrugBank.d237.s14.e4
DDI-DrugBank.d237.s14	false	DDI-DrugBank.d237.s14.e1	DDI-DrugBank.d237.s14.e2
DDI-DrugBank.d237.s14	false	DDI-DrugBank.d237.s14.e1	DDI-DrugBank.d237.s14.e3
DDI-DrugBank.d237.s14	false	DDI-DrugBank.d237.s14.e1	DDI-DrugBank.d237.s14.e4
DDI-DrugBank.d237.s14	false	DDI-DrugBank.d237.s14.e2	DDI-DrugBank.d237.s14.e3
DDI-DrugBank.d237.s14	false	DDI-DrugBank.d237.s14.e2	DDI-DrugBank.d237.s14.e4
DDI-DrugBank.d237.s14	false	DDI-DrugBank.d237.s14.e3	DDI-DrugBank.d237.s14.e4
DDI-DrugBank.d237.s15|a|tricyclic antidepressants (such as amitriptyline);
DDI-DrugBank.d237.s15	0	24	tricyclic antidepressants	group	DDI-DrugBank.d237.s15.e0
DDI-DrugBank.d237.s15	35	47	amitriptyline	drug	DDI-DrugBank.d237.s15.e1
DDI-DrugBank.d237.s15	false	DDI-DrugBank.d237.s15.e0	DDI-DrugBank.d237.s15.e1
DDI-DrugBank.d237.s16|a|certain tetracyclic antidepressants (such as maprotiline);
DDI-DrugBank.d237.s16	8	34	tetracyclic antidepressants	group	DDI-DrugBank.d237.s16.e0
DDI-DrugBank.d237.s16	45	55	maprotiline	drug	DDI-DrugBank.d237.s16.e1
DDI-DrugBank.d237.s16	false	DDI-DrugBank.d237.s16.e0	DDI-DrugBank.d237.s16.e1
DDI-DrugBank.d237.s17|a|certain antipsychotic medications (such as sertindole);
DDI-DrugBank.d237.s17	8	32	antipsychotic medications	group	DDI-DrugBank.d237.s17.e0
DDI-DrugBank.d237.s17	43	52	sertindole	drug	DDI-DrugBank.d237.s17.e1
DDI-DrugBank.d237.s17	false	DDI-DrugBank.d237.s17.e0	DDI-DrugBank.d237.s17.e1
DDI-DrugBank.d237.s18|a|astemizole, bepridil, sparfloxacin, and terodiline.
DDI-DrugBank.d237.s18	0	9	astemizole	drug	DDI-DrugBank.d237.s18.e0
DDI-DrugBank.d237.s18	12	19	bepridil	drug	DDI-DrugBank.d237.s18.e1
DDI-DrugBank.d237.s18	22	33	sparfloxacin	drug	DDI-DrugBank.d237.s18.e2
DDI-DrugBank.d237.s18	40	49	terodiline	drug	DDI-DrugBank.d237.s18.e3
DDI-DrugBank.d237.s18	false	DDI-DrugBank.d237.s18.e0	DDI-DrugBank.d237.s18.e1
DDI-DrugBank.d237.s18	false	DDI-DrugBank.d237.s18.e0	DDI-DrugBank.d237.s18.e2
DDI-DrugBank.d237.s18	false	DDI-DrugBank.d237.s18.e0	DDI-DrugBank.d237.s18.e3
DDI-DrugBank.d237.s18	false	DDI-DrugBank.d237.s18.e1	DDI-DrugBank.d237.s18.e2
DDI-DrugBank.d237.s18	false	DDI-DrugBank.d237.s18.e1	DDI-DrugBank.d237.s18.e3
DDI-DrugBank.d237.s18	false	DDI-DrugBank.d237.s18.e2	DDI-DrugBank.d237.s18.e3
DDI-DrugBank.d237.s19|a|The preceding lists of drugs are not comprehensive.
DDI-DrugBank.d237.s20|a|The acceleration of gastric emptying by cisapride could affect the rate of absorption of other drugs.
DDI-DrugBank.d237.s20	40	48	cisapride	drug	DDI-DrugBank.d237.s20.e0
DDI-DrugBank.d237.s21|a|Patients receiving narrow therapeutic ratio drugs or other drugs that require careful titration should be followed closely;
DDI-DrugBank.d237.s22|a|if plasma levels are being monitored, they should be reassessed.
DDI-DrugBank.d60.s0|a|Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.
DDI-DrugBank.d60.s0	39	44	NIMBEX	brand	DDI-DrugBank.d60.s0.e0
DDI-DrugBank.d60.s0	101	115	succinylcholine	drug	DDI-DrugBank.d60.s0.e1
DDI-DrugBank.d60.s0	true	DDI-DrugBank.d60.s0.e0	DDI-DrugBank.d60.s0.e1
DDI-DrugBank.d60.s1|a|The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.
DDI-DrugBank.d60.s1	45	50	NIMBEX	brand	DDI-DrugBank.d60.s1.e0
DDI-DrugBank.d60.s1	115	129	succinylcholine	drug	DDI-DrugBank.d60.s1.e1
DDI-DrugBank.d60.s1	true	DDI-DrugBank.d60.s1.e0	DDI-DrugBank.d60.s1.e1
DDI-DrugBank.d60.s2|a|Prior administration of succinylcholine had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of NIMBEX.
DDI-DrugBank.d60.s2	24	38	succinylcholine	drug	DDI-DrugBank.d60.s2.e0
DDI-DrugBank.d60.s2	141	146	NIMBEX	brand	DDI-DrugBank.d60.s2.e1
DDI-DrugBank.d60.s2	false	DDI-DrugBank.d60.s2.e0	DDI-DrugBank.d60.s2.e1
DDI-DrugBank.d60.s3|a|Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.
DDI-DrugBank.d60.s3	25	30	NIMBEX	brand	DDI-DrugBank.d60.s3.e0
DDI-DrugBank.d60.s3	57	71	succinylcholine	drug	DDI-DrugBank.d60.s3.e1
DDI-DrugBank.d60.s3	95	100	NIMBEX	brand	DDI-DrugBank.d60.s3.e2
DDI-DrugBank.d60.s3	151	165	succinylcholine	drug	DDI-DrugBank.d60.s3.e3
DDI-DrugBank.d60.s3	false	DDI-DrugBank.d60.s3.e0	DDI-DrugBank.d60.s3.e1
DDI-DrugBank.d60.s3	false	DDI-DrugBank.d60.s3.e0	DDI-DrugBank.d60.s3.e2
DDI-DrugBank.d60.s3	false	DDI-DrugBank.d60.s3.e0	DDI-DrugBank.d60.s3.e3
DDI-DrugBank.d60.s3	true	DDI-DrugBank.d60.s3.e1	DDI-DrugBank.d60.s3.e2
DDI-DrugBank.d60.s3	false	DDI-DrugBank.d60.s3.e1	DDI-DrugBank.d60.s3.e3
DDI-DrugBank.d60.s3	false	DDI-DrugBank.d60.s3.e2	DDI-DrugBank.d60.s3.e3
DDI-DrugBank.d60.s4|a|The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
DDI-DrugBank.d60.s4	11	16	NIMBEX	brand	DDI-DrugBank.d60.s4.e0
DDI-DrugBank.d60.s4	25	39	succinylcholine	drug	DDI-DrugBank.d60.s4.e1
DDI-DrugBank.d60.s4	82	96	succinylcholine	drug	DDI-DrugBank.d60.s4.e2
DDI-DrugBank.d60.s4	false	DDI-DrugBank.d60.s4.e0	DDI-DrugBank.d60.s4.e1
DDI-DrugBank.d60.s4	false	DDI-DrugBank.d60.s4.e0	DDI-DrugBank.d60.s4.e2
DDI-DrugBank.d60.s4	false	DDI-DrugBank.d60.s4.e1	DDI-DrugBank.d60.s4.e2
DDI-DrugBank.d60.s5|a|Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium, pancuronium, or atracurium were administered following varying degrees of recovery from single doses or infusions of NIMBEX.
DDI-DrugBank.d60.s5	96	105	vecuronium	drug	DDI-DrugBank.d60.s5.e0
DDI-DrugBank.d60.s5	108	118	pancuronium	drug	DDI-DrugBank.d60.s5.e1
DDI-DrugBank.d60.s5	124	133	atracurium	drug	DDI-DrugBank.d60.s5.e2
DDI-DrugBank.d60.s5	225	230	NIMBEX	brand	DDI-DrugBank.d60.s5.e3
DDI-DrugBank.d60.s5	false	DDI-DrugBank.d60.s5.e0	DDI-DrugBank.d60.s5.e1
DDI-DrugBank.d60.s5	false	DDI-DrugBank.d60.s5.e0	DDI-DrugBank.d60.s5.e2
DDI-DrugBank.d60.s5	false	DDI-DrugBank.d60.s5.e0	DDI-DrugBank.d60.s5.e3
DDI-DrugBank.d60.s5	false	DDI-DrugBank.d60.s5.e1	DDI-DrugBank.d60.s5.e2
DDI-DrugBank.d60.s5	false	DDI-DrugBank.d60.s5.e1	DDI-DrugBank.d60.s5.e3
DDI-DrugBank.d60.s5	false	DDI-DrugBank.d60.s5.e2	DDI-DrugBank.d60.s5.e3
DDI-DrugBank.d60.s6|a|Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
DDI-DrugBank.d60.s6	0	9	Isoflurane	drug	DDI-DrugBank.d60.s6.e0
DDI-DrugBank.d60.s6	14	22	enflurane	drug	DDI-DrugBank.d60.s6.e1
DDI-DrugBank.d60.s6	42	54	nitrous oxide	drug	DDI-DrugBank.d60.s6.e2
DDI-DrugBank.d60.s6	56	61	oxygen	drug	DDI-DrugBank.d60.s6.e3
DDI-DrugBank.d60.s6	208	213	NIMBEX	brand	DDI-DrugBank.d60.s6.e4
DDI-DrugBank.d60.s6	258	263	NIMBEX	brand	DDI-DrugBank.d60.s6.e5
DDI-DrugBank.d60.s6	false	DDI-DrugBank.d60.s6.e0	DDI-DrugBank.d60.s6.e1
DDI-DrugBank.d60.s6	false	DDI-DrugBank.d60.s6.e0	DDI-DrugBank.d60.s6.e2
DDI-DrugBank.d60.s6	false	DDI-DrugBank.d60.s6.e0	DDI-DrugBank.d60.s6.e3
DDI-DrugBank.d60.s6	true	DDI-DrugBank.d60.s6.e0	DDI-DrugBank.d60.s6.e4
DDI-DrugBank.d60.s6	true	DDI-DrugBank.d60.s6.e0	DDI-DrugBank.d60.s6.e5
DDI-DrugBank.d60.s6	false	DDI-DrugBank.d60.s6.e1	DDI-DrugBank.d60.s6.e2
DDI-DrugBank.d60.s6	false	DDI-DrugBank.d60.s6.e1	DDI-DrugBank.d60.s6.e3
DDI-DrugBank.d60.s6	true	DDI-DrugBank.d60.s6.e1	DDI-DrugBank.d60.s6.e4
DDI-DrugBank.d60.s6	true	DDI-DrugBank.d60.s6.e1	DDI-DrugBank.d60.s6.e5
DDI-DrugBank.d60.s6	false	DDI-DrugBank.d60.s6.e2	DDI-DrugBank.d60.s6.e3
DDI-DrugBank.d60.s7|a|The magnitude of these effects may depend on the duration of administration of the volatile agents.
DDI-DrugBank.d60.s8|a|Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.
DDI-DrugBank.d60.s8	46	55	isoflurane	drug	DDI-DrugBank.d60.s8.e0
DDI-DrugBank.d60.s8	60	68	enflurane	drug	DDI-DrugBank.d60.s8.e1
DDI-DrugBank.d60.s8	136	141	NIMBEX	brand	DDI-DrugBank.d60.s8.e2
DDI-DrugBank.d60.s8	217	222	NIMBEX	brand	DDI-DrugBank.d60.s8.e3
DDI-DrugBank.d60.s8	false	DDI-DrugBank.d60.s8.e0	DDI-DrugBank.d60.s8.e1
DDI-DrugBank.d60.s8	false	DDI-DrugBank.d60.s8.e0	DDI-DrugBank.d60.s8.e2
DDI-DrugBank.d60.s8	false	DDI-DrugBank.d60.s8.e0	DDI-DrugBank.d60.s8.e3
DDI-DrugBank.d60.s8	false	DDI-DrugBank.d60.s8.e1	DDI-DrugBank.d60.s8.e2
DDI-DrugBank.d60.s8	false	DDI-DrugBank.d60.s8.e1	DDI-DrugBank.d60.s8.e3
DDI-DrugBank.d60.s8	false	DDI-DrugBank.d60.s8.e2	DDI-DrugBank.d60.s8.e3
DDI-DrugBank.d60.s9|a|In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
DDI-DrugBank.d60.s9	35	43	enflurane	drug	DDI-DrugBank.d60.s9.e0
DDI-DrugBank.d60.s9	48	57	isoflurane	drug	DDI-DrugBank.d60.s9.e1
DDI-DrugBank.d60.s9	159	164	NIMBEX	brand	DDI-DrugBank.d60.s9.e2
DDI-DrugBank.d60.s9	false	DDI-DrugBank.d60.s9.e0	DDI-DrugBank.d60.s9.e1
DDI-DrugBank.d60.s9	true	DDI-DrugBank.d60.s9.e0	DDI-DrugBank.d60.s9.e2
DDI-DrugBank.d60.s9	true	DDI-DrugBank.d60.s9.e1	DDI-DrugBank.d60.s9.e2
DDI-DrugBank.d60.s10|a|The average infusion rate requirement may be decreased by as much as 30% to 40%.
DDI-DrugBank.d60.s11|a|In clinical studies propofol had no effect on the duration of action or dosing requirements for NIMBEX.
DDI-DrugBank.d60.s11	20	27	propofol	drug	DDI-DrugBank.d60.s11.e0
DDI-DrugBank.d60.s11	96	101	NIMBEX	brand	DDI-DrugBank.d60.s11.e1
DDI-DrugBank.d60.s11	false	DDI-DrugBank.d60.s11.e0	DDI-DrugBank.d60.s11.e1
DDI-DrugBank.d60.s12|a|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12	67	88	nondepolarizing agents	group	DDI-DrugBank.d60.s12.e0
DDI-DrugBank.d60.s12	98	103	NIMBEX	brand	DDI-DrugBank.d60.s12.e1
DDI-DrugBank.d60.s12	121	131	antibiotics	group	DDI-DrugBank.d60.s12.e2
DDI-DrugBank.d60.s12	141	155	aminoglycosides	group	DDI-DrugBank.d60.s12.e3
DDI-DrugBank.d60.s12	158	170	tetracyclines	group	DDI-DrugBank.d60.s12.e4
DDI-DrugBank.d60.s12	173	182	bacitracin	drug	DDI-DrugBank.d60.s12.e5
DDI-DrugBank.d60.s12	185	194	polymyxins	group	DDI-DrugBank.d60.s12.e6
DDI-DrugBank.d60.s12	197	206	lincomycin	drug	DDI-DrugBank.d60.s12.e7
DDI-DrugBank.d60.s12	209	219	clindamycin	drug	DDI-DrugBank.d60.s12.e8
DDI-DrugBank.d60.s12	222	229	colistin	drug	DDI-DrugBank.d60.s12.e9
DDI-DrugBank.d60.s12	true	DDI-DrugBank.d60.s12.e0	DDI-DrugBank.d60.s12.e1
DDI-DrugBank.d60.s12	true	DDI-DrugBank.d60.s12.e0	DDI-DrugBank.d60.s12.e2
DDI-DrugBank.d60.s12	true	DDI-DrugBank.d60.s12.e0	DDI-DrugBank.d60.s12.e3
DDI-DrugBank.d60.s12	true	DDI-DrugBank.d60.s12.e0	DDI-DrugBank.d60.s12.e4
DDI-DrugBank.d60.s12	true	DDI-DrugBank.d60.s12.e0	DDI-DrugBank.d60.s12.e5
DDI-DrugBank.d60.s12	true	DDI-DrugBank.d60.s12.e0	DDI-DrugBank.d60.s12.e6
DDI-DrugBank.d60.s12	true	DDI-DrugBank.d60.s12.e0	DDI-DrugBank.d60.s12.e7
DDI-DrugBank.d60.s12	true	DDI-DrugBank.d60.s12.e0	DDI-DrugBank.d60.s12.e8
DDI-DrugBank.d60.s12	true	DDI-DrugBank.d60.s12.e0	DDI-DrugBank.d60.s12.e9
DDI-DrugBank.d60.s12	true	DDI-DrugBank.d60.s12.e0	DDI-DrugBank.d60.s12.e10
DDI-DrugBank.d60.s13|a|Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
DDI-DrugBank.d60.s13	51	95	nondepolarizing neuromuscular blocking agents	group	DDI-DrugBank.d60.s13.e0
DDI-DrugBank.d60.s13	156	164	phenytoin	drug	DDI-DrugBank.d60.s13.e1
DDI-DrugBank.d60.s13	169	181	carbamazepine	drug	DDI-DrugBank.d60.s13.e2
DDI-DrugBank.d60.s13	true	DDI-DrugBank.d60.s13.e0	DDI-DrugBank.d60.s13.e1
DDI-DrugBank.d60.s13	true	DDI-DrugBank.d60.s13.e0	DDI-DrugBank.d60.s13.e2
DDI-DrugBank.d60.s13	false	DDI-DrugBank.d60.s13.e1	DDI-DrugBank.d60.s13.e2
DDI-DrugBank.d60.s14|a|While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
DDI-DrugBank.d60.s14	29	37	phenytoin	drug	DDI-DrugBank.d60.s14.e0
DDI-DrugBank.d60.s14	42	54	carbamazepine	drug	DDI-DrugBank.d60.s14.e1
DDI-DrugBank.d60.s14	81	86	NIMBEX	brand	DDI-DrugBank.d60.s14.e2
DDI-DrugBank.d60.s14	false	DDI-DrugBank.d60.s14.e0	DDI-DrugBank.d60.s14.e1
DDI-DrugBank.d60.s14	true	DDI-DrugBank.d60.s14.e0	DDI-DrugBank.d60.s14.e2
DDI-DrugBank.d60.s14	true	DDI-DrugBank.d60.s14.e1	DDI-DrugBank.d60.s14.e2
DDI-DrugBank.d60.s15|a|Drug/Laboratory Test Interactions None known.
DDI-DrugBank.d145.s0|a|Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.
DDI-DrugBank.d145.s0	17	37	anticonvulsant agents	group	DDI-DrugBank.d145.s0.e0
DDI-DrugBank.d145.s0	72	80	cisplatin	drug	DDI-DrugBank.d145.s0.e1
DDI-DrugBank.d145.s0	true	DDI-DrugBank.d145.s0.e0	DDI-DrugBank.d145.s0.e1
DDI-DrugBank.d472.s0|a|Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
DDI-DrugBank.d472.s0	0	32	Central nervous system depressant	group	DDI-DrugBank.d472.s0.e0
DDI-DrugBank.d472.s0	56	62	alcohol	drug	DDI-DrugBank.d472.s0.e1
DDI-DrugBank.d472.s0	65	79	antidepressants	group	DDI-DrugBank.d472.s0.e2
DDI-DrugBank.d472.s0	82	95	antihistamines	group	DDI-DrugBank.d472.s0.e3
DDI-DrugBank.d472.s0	98	111	antipsychotics	group	DDI-DrugBank.d472.s0.e4
DDI-DrugBank.d472.s0	142	150	reserpine	drug	DDI-DrugBank.d472.s0.e5
DDI-DrugBank.d472.s0	153	162	methyldopa	drug	DDI-DrugBank.d472.s0.e6
DDI-DrugBank.d472.s0	165	177	beta-blockers	group	DDI-DrugBank.d472.s0.e7
DDI-DrugBank.d472.s0	210	225	muscle relaxants	group	DDI-DrugBank.d472.s0.e8
DDI-DrugBank.d472.s0	228	236	narcotics	group	DDI-DrugBank.d472.s0.e9
DDI-DrugBank.d472.s0	false	DDI-DrugBank.d472.s0.e0	DDI-DrugBank.d472.s0.e1
DDI-DrugBank.d472.s0	false	DDI-DrugBank.d472.s0.e0	DDI-DrugBank.d472.s0.e2
DDI-DrugBank.d472.s0	false	DDI-DrugBank.d472.s0.e0	DDI-DrugBank.d472.s0.e3
DDI-DrugBank.d472.s0	false	DDI-DrugBank.d472.s0.e0	DDI-DrugBank.d472.s0.e4
DDI-DrugBank.d472.s0	false	DDI-DrugBank.d472.s0.e0	DDI-DrugBank.d472.s0.e5
DDI-DrugBank.d472.s0	false	DDI-DrugBank.d472.s0.e0	DDI-DrugBank.d472.s0.e6
DDI-DrugBank.d472.s0	false	DDI-DrugBank.d472.s0.e0	DDI-DrugBank.d472.s0.e7
DDI-DrugBank.d472.s0	false	DDI-DrugBank.d472.s0.e0	DDI-DrugBank.d472.s0.e8
DDI-DrugBank.d472.s0	false	DDI-DrugBank.d472.s0.e0	DDI-DrugBank.d472.s0.e9
DDI-DrugBank.d472.s0	false	DDI-DrugBank.d472.s0.e0	DDI-DrugBank.d472.s0.e10
DDI-DrugBank.d134.s0|a|There are no known drug interactions with LEUSTATIN Injection.
DDI-DrugBank.d134.s0	42	50	LEUSTATIN	brand	DDI-DrugBank.d134.s0.e0
DDI-DrugBank.d134.s1|a|Caution should be exercised if LEUSTATIN Injection is administered before, after, or in conjunction with other drugs known to cause immunosuppression or myelosuppression.
DDI-DrugBank.d134.s1	31	39	LEUSTATIN	brand	DDI-DrugBank.d134.s1.e0
DDI-DrugBank.d419.s0|a|The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
DDI-DrugBank.d419.s0	33	43	allopurinol	drug	DDI-DrugBank.d419.s0.e0
DDI-DrugBank.d419.s0	49	58	ampicillin	drug	DDI-DrugBank.d419.s0.e1
DDI-DrugBank.d419.s0	175	184	ampicillin	drug	DDI-DrugBank.d419.s0.e2
DDI-DrugBank.d419.s0	true	DDI-DrugBank.d419.s0.e0	DDI-DrugBank.d419.s0.e1
DDI-DrugBank.d419.s0	false	DDI-DrugBank.d419.s0.e0	DDI-DrugBank.d419.s0.e2
DDI-DrugBank.d419.s0	false	DDI-DrugBank.d419.s0.e1	DDI-DrugBank.d419.s0.e2
DDI-DrugBank.d419.s1|a|It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.
DDI-DrugBank.d419.s1	45	54	ampicillin	drug	DDI-DrugBank.d419.s1.e0
DDI-DrugBank.d419.s1	73	83	allopurinol	drug	DDI-DrugBank.d419.s1.e1
DDI-DrugBank.d419.s1	true	DDI-DrugBank.d419.s1.e0	DDI-DrugBank.d419.s1.e1
DDI-DrugBank.d419.s2|a|In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.
DDI-DrugBank.d419.s2	33	44	AUGMENTIN XR	brand	DDI-DrugBank.d419.s2.e0
DDI-DrugBank.d419.s2	80	90	allopurinol	drug	DDI-DrugBank.d419.s2.e1
DDI-DrugBank.d419.s2	96	107	AUGMENTIN XR	brand	DDI-DrugBank.d419.s2.e2
DDI-DrugBank.d419.s2	false	DDI-DrugBank.d419.s2.e0	DDI-DrugBank.d419.s2.e1
DDI-DrugBank.d419.s2	false	DDI-DrugBank.d419.s2.e0	DDI-DrugBank.d419.s2.e2
DDI-DrugBank.d419.s2	false	DDI-DrugBank.d419.s2.e1	DDI-DrugBank.d419.s2.e2
DDI-DrugBank.d419.s3|a|No rashes were reported in these patients.
DDI-DrugBank.d419.s4|a|However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.
DDI-DrugBank.d419.s4	126	137	AUGMENTIN XR	brand	DDI-DrugBank.d419.s4.e0
DDI-DrugBank.d419.s4	143	153	allopurinol	drug	DDI-DrugBank.d419.s4.e1
DDI-DrugBank.d419.s4	false	DDI-DrugBank.d419.s4.e0	DDI-DrugBank.d419.s4.e1
DDI-DrugBank.d419.s5|a|In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives
DDI-DrugBank.d419.s5	21	46	broad-spectrum antibiotics	group	DDI-DrugBank.d419.s5.e0
DDI-DrugBank.d419.s5	49	60	AUGMENTIN XR	brand	DDI-DrugBank.d419.s5.e1
DDI-DrugBank.d419.s5	94	107	contraceptives	group	DDI-DrugBank.d419.s5.e2
DDI-DrugBank.d419.s5	false	DDI-DrugBank.d419.s5.e0	DDI-DrugBank.d419.s5.e1
DDI-DrugBank.d419.s5	true	DDI-DrugBank.d419.s5.e0	DDI-DrugBank.d419.s5.e2
DDI-DrugBank.d419.s5	true	DDI-DrugBank.d419.s5.e1	DDI-DrugBank.d419.s5.e2
DDI-DrugBank.d309.s0|a|Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
DDI-DrugBank.d309.s0	39	52	antihistamines	group	DDI-DrugBank.d309.s0.e0
DDI-DrugBank.d309.s0	96	110	CNS depressants	group	DDI-DrugBank.d309.s0.e1
DDI-DrugBank.d309.s0	122	133	barbiturates	group	DDI-DrugBank.d309.s0.e2
DDI-DrugBank.d309.s0	136	148	tranquilizers	group	DDI-DrugBank.d309.s0.e3
DDI-DrugBank.d309.s0	155	161	alcohol	drug	DDI-DrugBank.d309.s0.e4
DDI-DrugBank.d309.s0	true	DDI-DrugBank.d309.s0.e0	DDI-DrugBank.d309.s0.e1
DDI-DrugBank.d309.s0	true	DDI-DrugBank.d309.s0.e0	DDI-DrugBank.d309.s0.e2
DDI-DrugBank.d309.s0	true	DDI-DrugBank.d309.s0.e0	DDI-DrugBank.d309.s0.e3
DDI-DrugBank.d309.s0	true	DDI-DrugBank.d309.s0.e0	DDI-DrugBank.d309.s0.e4
DDI-DrugBank.d309.s0	false	DDI-DrugBank.d309.s0.e1	DDI-DrugBank.d309.s0.e2
DDI-DrugBank.d309.s0	false	DDI-DrugBank.d309.s0.e1	DDI-DrugBank.d309.s0.e3
DDI-DrugBank.d309.s0	false	DDI-DrugBank.d309.s0.e1	DDI-DrugBank.d309.s0.e4
DDI-DrugBank.d309.s0	false	DDI-DrugBank.d309.s0.e2	DDI-DrugBank.d309.s0.e3
DDI-DrugBank.d309.s0	false	DDI-DrugBank.d309.s0.e2	DDI-DrugBank.d309.s0.e4
DDI-DrugBank.d309.s0	false	DDI-DrugBank.d309.s0.e3	DDI-DrugBank.d309.s0.e4
DDI-DrugBank.d309.s1|a|Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.
DDI-DrugBank.d309.s1	19	32	antihistamines	group	DDI-DrugBank.d309.s1.e0
DDI-DrugBank.d309.s1	88	107	CNS depressant drugs	group	DDI-DrugBank.d309.s1.e1
DDI-DrugBank.d309.s1	true	DDI-DrugBank.d309.s1.e0	DDI-DrugBank.d309.s1.e1
DDI-DrugBank.d309.s2|a|Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.
DDI-DrugBank.d309.s2	0	33	Monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d309.s2.e0
DDI-DrugBank.d309.s2	88	101	antihistamines	group	DDI-DrugBank.d309.s2.e1
DDI-DrugBank.d309.s2	true	DDI-DrugBank.d309.s2.e0	DDI-DrugBank.d309.s2.e1
DDI-DrugBank.d322.s0|a|Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
DDI-DrugBank.d322.s0	0	9	Amantadine	drug	DDI-DrugBank.d322.s0.e0
DDI-DrugBank.d322.s0	12	36	tricyclic antidepressants	group	DDI-DrugBank.d322.s0.e1
DDI-DrugBank.d322.s0	43	47	MAOIs	group	DDI-DrugBank.d322.s0.e2
DDI-DrugBank.d322.s0	88	96	clidinium	drug	DDI-DrugBank.d322.s0.e3
DDI-DrugBank.d322.s0	false	DDI-DrugBank.d322.s0.e0	DDI-DrugBank.d322.s0.e1
DDI-DrugBank.d322.s0	false	DDI-DrugBank.d322.s0.e0	DDI-DrugBank.d322.s0.e2
DDI-DrugBank.d322.s0	true	DDI-DrugBank.d322.s0.e0	DDI-DrugBank.d322.s0.e3
DDI-DrugBank.d322.s0	false	DDI-DrugBank.d322.s0.e1	DDI-DrugBank.d322.s0.e2
DDI-DrugBank.d322.s0	true	DDI-DrugBank.d322.s0.e1	DDI-DrugBank.d322.s0.e3
DDI-DrugBank.d322.s0	true	DDI-DrugBank.d322.s0.e2	DDI-DrugBank.d322.s0.e3
DDI-DrugBank.d322.s1|a|Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
DDI-DrugBank.d322.s1	0	8	Clidinium	drug	DDI-DrugBank.d322.s1.e0
DDI-DrugBank.d322.s1	37	50	phenothiazines	group	DDI-DrugBank.d322.s1.e1
DDI-DrugBank.d322.s1	53	60	levodopa	drug	DDI-DrugBank.d322.s1.e2
DDI-DrugBank.d322.s1	67	78	ketoconazole	drug	DDI-DrugBank.d322.s1.e3
DDI-DrugBank.d322.s1	true	DDI-DrugBank.d322.s1.e0	DDI-DrugBank.d322.s1.e1
DDI-DrugBank.d322.s1	true	DDI-DrugBank.d322.s1.e0	DDI-DrugBank.d322.s1.e2
DDI-DrugBank.d322.s1	true	DDI-DrugBank.d322.s1.e0	DDI-DrugBank.d322.s1.e3
DDI-DrugBank.d322.s1	false	DDI-DrugBank.d322.s1.e1	DDI-DrugBank.d322.s1.e2
DDI-DrugBank.d322.s1	false	DDI-DrugBank.d322.s1.e1	DDI-DrugBank.d322.s1.e3
DDI-DrugBank.d322.s1	false	DDI-DrugBank.d322.s1.e2	DDI-DrugBank.d322.s1.e3
DDI-DrugBank.d256.s0|a|Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
DDI-DrugBank.d256.s0	0	10	Clindamycin	drug	DDI-DrugBank.d256.s0.e0
DDI-DrugBank.d256.s0	106	134	neuromuscular blocking agents	group	DDI-DrugBank.d256.s0.e1
DDI-DrugBank.d256.s0	true	DDI-DrugBank.d256.s0.e0	DDI-DrugBank.d256.s0.e1
DDI-DrugBank.d256.s1|a|Therefore, it should be used with caution in patients receiving such agents.
DDI-DrugBank.d256.s2|a|Antagonism has been demonstrated between clindamycin and erythromycin in vitro.
DDI-DrugBank.d256.s2	41	51	clindamycin	drug	DDI-DrugBank.d256.s2.e0
DDI-DrugBank.d256.s2	57	68	erythromycin	drug	DDI-DrugBank.d256.s2.e1
DDI-DrugBank.d256.s2	true	DDI-DrugBank.d256.s2.e0	DDI-DrugBank.d256.s2.e1
DDI-DrugBank.d256.s3|a|Because of possible clinical significance, these two drugs should not be administered concurrently.
DDI-DrugBank.d136.s0|a|Alcohol (increases bioavailability by 50%), cimetidine, and valproates.
DDI-DrugBank.d136.s0	0	6	Alcohol	drug	DDI-DrugBank.d136.s0.e0
DDI-DrugBank.d136.s0	44	53	cimetidine	drug	DDI-DrugBank.d136.s0.e1
DDI-DrugBank.d136.s0	false	DDI-DrugBank.d136.s0.e0	DDI-DrugBank.d136.s0.e1
DDI-DrugBank.d391.s0|a|No separate information available
DDI-DrugBank.d473.s0|a|Although no clinical drug-drug interaction studies have been conducted to date, on the basis of the in vitro studies, cytochrome p450 inhibitors and inducers are unlikely to affect the metabolism of clofarabine.
DDI-DrugBank.d473.s0	199	209	clofarabine	drug	DDI-DrugBank.d473.s0.e0
DDI-DrugBank.d473.s1|a|The effect of clofarabine on the metabolism of cytochrome p450 substrates has not been studied.
DDI-DrugBank.d473.s1	14	24	clofarabine	drug	DDI-DrugBank.d473.s1.e0
DDI-DrugBank.d473.s2|a|Drug/Laboratory Tests Interactions There are no known clinically significant interactions of CLOLAR  with other medications or laboratory tests.
DDI-DrugBank.d473.s2	93	98	CLOLAR	brand	DDI-DrugBank.d473.s2.e0
DDI-DrugBank.d473.s3|a|No formal drug/laboratory test interaction studies have been conducted with CLOLAR  .
DDI-DrugBank.d473.s3	76	81	CLOLAR	brand	DDI-DrugBank.d473.s3.e0
DDI-DrugBank.d399.s0|a|Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.
DDI-DrugBank.d399.s0	36	42	dapsone	drug	DDI-DrugBank.d399.s0.e0
DDI-DrugBank.d399.s0	90	97	Lamprene	brand	DDI-DrugBank.d399.s0.e1
DDI-DrugBank.d399.s0	true	DDI-DrugBank.d399.s0.e0	DDI-DrugBank.d399.s0.e1
DDI-DrugBank.d399.s1|a|If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.
DDI-DrugBank.d399.s1	84	90	dapsone	drug	DDI-DrugBank.d399.s1.e0
DDI-DrugBank.d399.s1	96	106	clofazimine	drug	DDI-DrugBank.d399.s1.e1
DDI-DrugBank.d399.s1	true	DDI-DrugBank.d399.s1.e0	DDI-DrugBank.d399.s1.e1
DDI-DrugBank.d12.s0|a|Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.
DDI-DrugBank.d12.s0	33	46	anticoagulants	group	DDI-DrugBank.d12.s0.e0
DDI-DrugBank.d12.s0	78	86	Atromid-S	brand	DDI-DrugBank.d12.s0.e1
DDI-DrugBank.d12.s0	true	DDI-DrugBank.d12.s0.e0	DDI-DrugBank.d12.s0.e1
DDI-DrugBank.d12.s1|a|Usually, the dosage of the anticoagulant should be reduced by one-half (depending on the individual case) to maintain the prothrombin time at the desired level to prevent bleeding complications.
DDI-DrugBank.d12.s1	27	39	anticoagulant	group	DDI-DrugBank.d12.s1.e0
DDI-DrugBank.d12.s2|a|Frequent prothrombin determinations are advisable until it has been determined definitely that the prothrombin level has been stabilized.
DDI-DrugBank.d12.s3|a|Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
DDI-DrugBank.d12.s3	0	8	Atromid-S	brand	DDI-DrugBank.d12.s3.e0
DDI-DrugBank.d12.s3	44	52	phenytoin	drug	DDI-DrugBank.d12.s3.e1
DDI-DrugBank.d12.s3	57	67	tolbutamide	drug	DDI-DrugBank.d12.s3.e2
DDI-DrugBank.d12.s3	true	DDI-DrugBank.d12.s3.e0	DDI-DrugBank.d12.s3.e1
DDI-DrugBank.d12.s3	true	DDI-DrugBank.d12.s3.e0	DDI-DrugBank.d12.s3.e2
DDI-DrugBank.d12.s3	false	DDI-DrugBank.d12.s3.e1	DDI-DrugBank.d12.s3.e2
DDI-DrugBank.d12.s4|a|Caution should be exercised when treating patients with either of these drugs or other highly protein-bound drugs and Atromid-S.
DDI-DrugBank.d12.s4	118	126	Atromid-S	brand	DDI-DrugBank.d12.s4.e0
DDI-DrugBank.d12.s5|a|The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.
DDI-DrugBank.d12.s5	27	37	tolbutamide	drug	DDI-DrugBank.d12.s5.e0
DDI-DrugBank.d12.s5	74	82	Atromid-S	brand	DDI-DrugBank.d12.s5.e1
DDI-DrugBank.d12.s5	true	DDI-DrugBank.d12.s5.e0	DDI-DrugBank.d12.s5.e1
DDI-DrugBank.d12.s6|a|Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.
DDI-DrugBank.d12.s6	113	119	fibrate	group	DDI-DrugBank.d12.s6.e0
DDI-DrugBank.d12.s6	125	134	lovastatin	drug	DDI-DrugBank.d12.s6.e1
DDI-DrugBank.d12.s6	true	DDI-DrugBank.d12.s6.e0	DDI-DrugBank.d12.s6.e1
DDI-DrugBank.d12.s7|a|For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.
DDI-DrugBank.d12.s7	168	177	lovastatin	drug	DDI-DrugBank.d12.s7.e0
DDI-DrugBank.d12.s7	185	191	fibrate	group	DDI-DrugBank.d12.s7.e1
DDI-DrugBank.d12.s7	true	DDI-DrugBank.d12.s7.e0	DDI-DrugBank.d12.s7.e1
DDI-DrugBank.d12.s8|a|While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.
DDI-DrugBank.d12.s8	59	66	fibrates	group	DDI-DrugBank.d12.s8.e0
DDI-DrugBank.d12.s8	79	89	gemfibrozil	drug	DDI-DrugBank.d12.s8.e1
DDI-DrugBank.d12.s8	170	177	fibrates	group	DDI-DrugBank.d12.s8.e2
DDI-DrugBank.d12.s8	196	205	clofibrate	drug	DDI-DrugBank.d12.s8.e3
DDI-DrugBank.d12.s8	false	DDI-DrugBank.d12.s8.e0	DDI-DrugBank.d12.s8.e1
DDI-DrugBank.d12.s8	false	DDI-DrugBank.d12.s8.e0	DDI-DrugBank.d12.s8.e2
DDI-DrugBank.d12.s8	false	DDI-DrugBank.d12.s8.e0	DDI-DrugBank.d12.s8.e3
DDI-DrugBank.d12.s8	false	DDI-DrugBank.d12.s8.e1	DDI-DrugBank.d12.s8.e2
DDI-DrugBank.d12.s8	false	DDI-DrugBank.d12.s8.e1	DDI-DrugBank.d12.s8.e3
DDI-DrugBank.d12.s8	false	DDI-DrugBank.d12.s8.e2	DDI-DrugBank.d12.s8.e3
DDI-DrugBank.d12.s9|a|Therefore, the combined use of lovastatin with fibrates should generally be avoided.
DDI-DrugBank.d12.s9	31	40	lovastatin	drug	DDI-DrugBank.d12.s9.e0
DDI-DrugBank.d12.s9	47	54	fibrates	group	DDI-DrugBank.d12.s9.e1
DDI-DrugBank.d12.s9	true	DDI-DrugBank.d12.s9.e0	DDI-DrugBank.d12.s9.e1
DDI-DrugBank.d451.s0|a|Drug interactions with clomiphene citrate tablets USP have not been documented.
DDI-DrugBank.d451.s0	23	40	clomiphene citrate	drug	DDI-DrugBank.d451.s0.e0
DDI-DrugBank.d238.s0|a|The risks of using Anafranil in combination with other drugs have not been systematically evaluated.
DDI-DrugBank.d238.s0	19	27	Anafranil	brand	DDI-DrugBank.d238.s0.e0
DDI-DrugBank.d238.s1|a|Given the primary CNS effects of Anafranil, caution is advised in using it concomitantly with other CNS-active drugs.
DDI-DrugBank.d238.s1	33	41	Anafranil	brand	DDI-DrugBank.d238.s1.e0
DDI-DrugBank.d238.s2|a|Anafranil should not be used with MAO inhibitors.
DDI-DrugBank.d238.s2	0	8	Anafranil	brand	DDI-DrugBank.d238.s2.e0
DDI-DrugBank.d238.s2	34	47	MAO inhibitors	group	DDI-DrugBank.d238.s2.e1
DDI-DrugBank.d238.s2	true	DDI-DrugBank.d238.s2.e0	DDI-DrugBank.d238.s2.e1
DDI-DrugBank.d238.s3|a|Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.
DDI-DrugBank.d238.s3	69	77	Anafranil	brand	DDI-DrugBank.d238.s3.e0
DDI-DrugBank.d238.s3	100	114	anticholinergic	group	DDI-DrugBank.d238.s3.e1
DDI-DrugBank.d238.s3	119	139	sympathomimetic drugs	group	DDI-DrugBank.d238.s3.e2
DDI-DrugBank.d238.s3	true	DDI-DrugBank.d238.s3.e0	DDI-DrugBank.d238.s3.e1
DDI-DrugBank.d238.s3	true	DDI-DrugBank.d238.s3.e0	DDI-DrugBank.d238.s3.e2
DDI-DrugBank.d238.s3	false	DDI-DrugBank.d238.s3.e1	DDI-DrugBank.d238.s3.e2
DDI-DrugBank.d238.s4|a|Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
DDI-DrugBank.d238.s4	8	32	tricyclic antidepressants	group	DDI-DrugBank.d238.s4.e0
DDI-DrugBank.d238.s4	91	102	guanethidine	drug	DDI-DrugBank.d238.s4.e1
DDI-DrugBank.d238.s4	105	113	clonidine	drug	DDI-DrugBank.d238.s4.e2
DDI-DrugBank.d238.s4	178	180	CMI	drug	DDI-DrugBank.d238.s4.e3
DDI-DrugBank.d238.s4	228	252	tricyclic antidepressants	group	DDI-DrugBank.d238.s4.e4
DDI-DrugBank.d238.s4	true	DDI-DrugBank.d238.s4.e0	DDI-DrugBank.d238.s4.e1
DDI-DrugBank.d238.s4	true	DDI-DrugBank.d238.s4.e0	DDI-DrugBank.d238.s4.e2
DDI-DrugBank.d238.s4	true	DDI-DrugBank.d238.s4.e0	DDI-DrugBank.d238.s4.e3
DDI-DrugBank.d238.s4	true	DDI-DrugBank.d238.s4.e0	DDI-DrugBank.d238.s4.e4
DDI-DrugBank.d238.s4	false	DDI-DrugBank.d238.s4.e1	DDI-DrugBank.d238.s4.e2
DDI-DrugBank.d238.s4	false	DDI-DrugBank.d238.s4.e1	DDI-DrugBank.d238.s4.e3
DDI-DrugBank.d238.s4	false	DDI-DrugBank.d238.s4.e1	DDI-DrugBank.d238.s4.e4
DDI-DrugBank.d238.s4	false	DDI-DrugBank.d238.s4.e2	DDI-DrugBank.d238.s4.e3
DDI-DrugBank.d238.s4	false	DDI-DrugBank.d238.s4.e2	DDI-DrugBank.d238.s4.e4
DDI-DrugBank.d238.s4	false	DDI-DrugBank.d238.s4.e3	DDI-DrugBank.d238.s4.e4
DDI-DrugBank.d238.s5|a|The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol;
DDI-DrugBank.d238.s5	28	30	CMI	drug	DDI-DrugBank.d238.s5.e0
DDI-DrugBank.d238.s5	103	113	haloperidol	drug	DDI-DrugBank.d238.s5.e1
DDI-DrugBank.d238.s5	true	DDI-DrugBank.d238.s5.e0	DDI-DrugBank.d238.s5.e1
DDI-DrugBank.d238.s6|a|plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d238.s6	41	65	tricyclic antidepressants	group	DDI-DrugBank.d238.s6.e0
DDI-DrugBank.d238.s6	139	153	methylphenidate	drug	DDI-DrugBank.d238.s6.e1
DDI-DrugBank.d238.s6	191	200	cimetidine	drug	DDI-DrugBank.d238.s6.e2
DDI-DrugBank.d238.s6	203	212	fluoxetine	drug	DDI-DrugBank.d238.s6.e3
DDI-DrugBank.d238.s6	297	308	barbiturates	group	DDI-DrugBank.d238.s6.e4
DDI-DrugBank.d238.s6	311	319	phenytoin	drug	DDI-DrugBank.d238.s6.e5
DDI-DrugBank.d238.s6	366	368	CMI	drug	DDI-DrugBank.d238.s6.e6
DDI-DrugBank.d238.s6	true	DDI-DrugBank.d238.s6.e0	DDI-DrugBank.d238.s6.e1
DDI-DrugBank.d238.s6	true	DDI-DrugBank.d238.s6.e0	DDI-DrugBank.d238.s6.e2
DDI-DrugBank.d238.s6	true	DDI-DrugBank.d238.s6.e0	DDI-DrugBank.d238.s6.e3
DDI-DrugBank.d238.s6	true	DDI-DrugBank.d238.s6.e0	DDI-DrugBank.d238.s6.e4
DDI-DrugBank.d238.s6	true	DDI-DrugBank.d238.s6.e0	DDI-DrugBank.d238.s6.e5
DDI-DrugBank.d238.s6	false	DDI-DrugBank.d238.s6.e0	DDI-DrugBank.d238.s6.e6
DDI-DrugBank.d238.s6	false	DDI-DrugBank.d238.s6.e1	DDI-DrugBank.d238.s6.e2
DDI-DrugBank.d238.s6	false	DDI-DrugBank.d238.s6.e1	DDI-DrugBank.d238.s6.e3
DDI-DrugBank.d238.s6	false	DDI-DrugBank.d238.s6.e1	DDI-DrugBank.d238.s6.e4
DDI-DrugBank.d238.s6	false	DDI-DrugBank.d238.s6.e1	DDI-DrugBank.d238.s6.e5
DDI-DrugBank.d238.s7|a|Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.
DDI-DrugBank.d238.s7	18	20	CMI	drug	DDI-DrugBank.d238.s7.e0
DDI-DrugBank.d238.s7	73	85	phenobarbital	drug	DDI-DrugBank.d238.s7.e1
DDI-DrugBank.d238.s7	true	DDI-DrugBank.d238.s7.e0	DDI-DrugBank.d238.s7.e1
DDI-DrugBank.d238.s8|a|Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the aucasian population (about 7%-10% of Caucasians are so-called poor metabolizers);
DDI-DrugBank.d238.s9|a|reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
DDI-DrugBank.d238.s10|a|Poor metabolizers have higher than expected lasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
DDI-DrugBank.d238.s10	68	92	tricyclic antidepressants	group	DDI-DrugBank.d238.s10.e0
DDI-DrugBank.d238.s10	95	98	TCAs	group	DDI-DrugBank.d238.s10.e1
DDI-DrugBank.d238.s10	false	DDI-DrugBank.d238.s10.e0	DDI-DrugBank.d238.s10.e1
DDI-DrugBank.d238.s11|a|Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).
DDI-DrugBank.d238.s11	163	165	TCA	group	DDI-DrugBank.d238.s11.e0
DDI-DrugBank.d238.s12|a|In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
DDI-DrugBank.d238.s13|a|An individual who is stable on a given dose of TCAmay become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
DDI-DrugBank.d238.s13	47	49	TCA	group	DDI-DrugBank.d238.s13.e0
DDI-DrugBank.d238.s14|a|The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;
DDI-DrugBank.d238.s14	96	104	quinidine	drug	DDI-DrugBank.d238.s14.e0
DDI-DrugBank.d238.s15|a|cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
DDI-DrugBank.d238.s15	0	9	cimetidine	drug	DDI-DrugBank.d238.s15.e0
DDI-DrugBank.d238.s15	66	80	antidepressants	group	DDI-DrugBank.d238.s15.e1
DDI-DrugBank.d238.s15	83	96	phenothiazines	group	DDI-DrugBank.d238.s15.e2
DDI-DrugBank.d238.s15	107	129	Type 1C antiarrhythmics	group	DDI-DrugBank.d238.s15.e3
DDI-DrugBank.d238.s15	131	141	propafenone	drug	DDI-DrugBank.d238.s15.e4
DDI-DrugBank.d238.s15	147	156	flecainide	drug	DDI-DrugBank.d238.s15.e5
DDI-DrugBank.d238.s15	false	DDI-DrugBank.d238.s15.e0	DDI-DrugBank.d238.s15.e1
DDI-DrugBank.d238.s15	false	DDI-DrugBank.d238.s15.e0	DDI-DrugBank.d238.s15.e2
DDI-DrugBank.d238.s15	false	DDI-DrugBank.d238.s15.e0	DDI-DrugBank.d238.s15.e3
DDI-DrugBank.d238.s15	false	DDI-DrugBank.d238.s15.e0	DDI-DrugBank.d238.s15.e4
DDI-DrugBank.d238.s15	false	DDI-DrugBank.d238.s15.e0	DDI-DrugBank.d238.s15.e5
DDI-DrugBank.d238.s15	false	DDI-DrugBank.d238.s15.e1	DDI-DrugBank.d238.s15.e2
DDI-DrugBank.d238.s15	false	DDI-DrugBank.d238.s15.e1	DDI-DrugBank.d238.s15.e3
DDI-DrugBank.d238.s15	false	DDI-DrugBank.d238.s15.e1	DDI-DrugBank.d238.s15.e4
DDI-DrugBank.d238.s15	false	DDI-DrugBank.d238.s15.e1	DDI-DrugBank.d238.s15.e5
DDI-DrugBank.d238.s15	false	DDI-DrugBank.d238.s15.e2	DDI-DrugBank.d238.s15.e3
DDI-DrugBank.d238.s16|a|While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
DDI-DrugBank.d238.s16	14	52	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d238.s16.e0
DDI-DrugBank.d238.s16	55	59	SSRIs	group	DDI-DrugBank.d238.s16.e1
DDI-DrugBank.d238.s16	69	78	fluoxetine	drug	DDI-DrugBank.d238.s16.e2
DDI-DrugBank.d238.s16	81	90	sertraline	drug	DDI-DrugBank.d238.s16.e3
DDI-DrugBank.d238.s16	93	102	paroxetine	drug	DDI-DrugBank.d238.s16.e4
DDI-DrugBank.d238.s16	109	119	fluvoxamine	drug	DDI-DrugBank.d238.s16.e5
DDI-DrugBank.d238.s16	false	DDI-DrugBank.d238.s16.e0	DDI-DrugBank.d238.s16.e1
DDI-DrugBank.d238.s16	false	DDI-DrugBank.d238.s16.e0	DDI-DrugBank.d238.s16.e2
DDI-DrugBank.d238.s16	false	DDI-DrugBank.d238.s16.e0	DDI-DrugBank.d238.s16.e3
DDI-DrugBank.d238.s16	false	DDI-DrugBank.d238.s16.e0	DDI-DrugBank.d238.s16.e4
DDI-DrugBank.d238.s16	false	DDI-DrugBank.d238.s16.e0	DDI-DrugBank.d238.s16.e5
DDI-DrugBank.d238.s16	false	DDI-DrugBank.d238.s16.e1	DDI-DrugBank.d238.s16.e2
DDI-DrugBank.d238.s16	false	DDI-DrugBank.d238.s16.e1	DDI-DrugBank.d238.s16.e3
DDI-DrugBank.d238.s16	false	DDI-DrugBank.d238.s16.e1	DDI-DrugBank.d238.s16.e4
DDI-DrugBank.d238.s16	false	DDI-DrugBank.d238.s16.e1	DDI-DrugBank.d238.s16.e5
DDI-DrugBank.d238.s16	false	DDI-DrugBank.d238.s16.e2	DDI-DrugBank.d238.s16.e3
DDI-DrugBank.d238.s17|a|Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.
DDI-DrugBank.d238.s17	0	10	Fluvoxamine	drug	DDI-DrugBank.d238.s17.e0
DDI-DrugBank.d238.s17	81	83	TCA	group	DDI-DrugBank.d238.s17.e1
DDI-DrugBank.d238.s17	true	DDI-DrugBank.d238.s17.e0	DDI-DrugBank.d238.s17.e1
DDI-DrugBank.d238.s18|a|The extent to which SSRI-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
DDI-DrugBank.d238.s18	20	23	SSRI	group	DDI-DrugBank.d238.s18.e0
DDI-DrugBank.d238.s18	25	27	TCA	group	DDI-DrugBank.d238.s18.e1
DDI-DrugBank.d238.s18	140	143	SSRI	group	DDI-DrugBank.d238.s18.e2
DDI-DrugBank.d238.s18	true	DDI-DrugBank.d238.s18.e0	DDI-DrugBank.d238.s18.e1
DDI-DrugBank.d238.s18	false	DDI-DrugBank.d238.s18.e0	DDI-DrugBank.d238.s18.e2
DDI-DrugBank.d238.s18	false	DDI-DrugBank.d238.s18.e1	DDI-DrugBank.d238.s18.e2
DDI-DrugBank.d238.s19|a|Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
DDI-DrugBank.d238.s19	63	66	TCAs	group	DDI-DrugBank.d238.s19.e0
DDI-DrugBank.d238.s19	84	88	SSRIs	group	DDI-DrugBank.d238.s19.e1
DDI-DrugBank.d238.s19	true	DDI-DrugBank.d238.s19.e0	DDI-DrugBank.d238.s19.e1
DDI-DrugBank.d238.s20|a|Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
DDI-DrugBank.d238.s20	72	74	TCA	group	DDI-DrugBank.d238.s20.e0
DDI-DrugBank.d238.s20	119	128	fluoxetine	drug	DDI-DrugBank.d238.s20.e1
DDI-DrugBank.d238.s20	true	DDI-DrugBank.d238.s20.e0	DDI-DrugBank.d238.s20.e1
DDI-DrugBank.d238.s21|a|Concomitant use of agents in the tricyclic antidepressant class (which includes Anafranil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.
DDI-DrugBank.d238.s21	33	62	tricyclic antidepressant class	group	DDI-DrugBank.d238.s21.e0
DDI-DrugBank.d238.s21	80	88	Anafranil	brand	DDI-DrugBank.d238.s21.e1
DDI-DrugBank.d238.s21	202	231	tricyclic antidepressant agent	group	DDI-DrugBank.d238.s21.e2
DDI-DrugBank.d238.s21	false	DDI-DrugBank.d238.s21.e0	DDI-DrugBank.d238.s21.e1
DDI-DrugBank.d238.s21	false	DDI-DrugBank.d238.s21.e0	DDI-DrugBank.d238.s21.e2
DDI-DrugBank.d238.s21	false	DDI-DrugBank.d238.s21.e1	DDI-DrugBank.d238.s21.e2
DDI-DrugBank.d238.s22|a|Furthermore, whenever one of these drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant agent may be required.
DDI-DrugBank.d238.s22	92	121	tricyclic antidepressant agent	group	DDI-DrugBank.d238.s22.e0
DDI-DrugBank.d238.s23|a|It is desirable to monitor TCAplasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).
DDI-DrugBank.d238.s23	27	29	TCA	group	DDI-DrugBank.d238.s23.e0
DDI-DrugBank.d238.s23	69	98	tricyclic antidepressant class	group	DDI-DrugBank.d238.s23.e1
DDI-DrugBank.d238.s23	110	118	Anafranil	brand	DDI-DrugBank.d238.s23.e2
DDI-DrugBank.d238.s23	false	DDI-DrugBank.d238.s23.e0	DDI-DrugBank.d238.s23.e1
DDI-DrugBank.d238.s23	false	DDI-DrugBank.d238.s23.e0	DDI-DrugBank.d238.s23.e2
DDI-DrugBank.d238.s23	false	DDI-DrugBank.d238.s23.e1	DDI-DrugBank.d238.s23.e2
DDI-DrugBank.d238.s24|a|Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
DDI-DrugBank.d238.s24	8	16	Anafranil	brand	DDI-DrugBank.d238.s24.e0
DDI-DrugBank.d238.s24	74	82	Anafranil	brand	DDI-DrugBank.d238.s24.e1
DDI-DrugBank.d238.s24	155	162	warfarin	drug	DDI-DrugBank.d238.s24.e2
DDI-DrugBank.d238.s24	165	171	digoxin	drug	DDI-DrugBank.d238.s24.e3
DDI-DrugBank.d238.s24	false	DDI-DrugBank.d238.s24.e0	DDI-DrugBank.d238.s24.e1
DDI-DrugBank.d238.s24	false	DDI-DrugBank.d238.s24.e0	DDI-DrugBank.d238.s24.e2
DDI-DrugBank.d238.s24	false	DDI-DrugBank.d238.s24.e0	DDI-DrugBank.d238.s24.e3
DDI-DrugBank.d238.s24	true	DDI-DrugBank.d238.s24.e1	DDI-DrugBank.d238.s24.e2
DDI-DrugBank.d238.s24	true	DDI-DrugBank.d238.s24.e1	DDI-DrugBank.d238.s24.e3
DDI-DrugBank.d238.s24	false	DDI-DrugBank.d238.s24.e2	DDI-DrugBank.d238.s24.e3
DDI-DrugBank.d238.s25|a|Conversely, adverse effects may result from displacement of protein-bound Anafranil by other highly bound drugs.
DDI-DrugBank.d238.s25	74	82	Anafranil	brand	DDI-DrugBank.d238.s25.e0
DDI-DrugBank.d333.s0|a|Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.
DDI-DrugBank.d333.s0	10	19	Clonazepam	drug	DDI-DrugBank.d333.s0.e0
DDI-DrugBank.d333.s0	61	70	Clonazepam	drug	DDI-DrugBank.d333.s0.e1
DDI-DrugBank.d333.s0	121	129	phenytoin	drug	DDI-DrugBank.d333.s0.e2
DDI-DrugBank.d333.s0	132	144	carbamazepine	drug	DDI-DrugBank.d333.s0.e3
DDI-DrugBank.d333.s0	150	162	phenobarbital	drug	DDI-DrugBank.d333.s0.e4
DDI-DrugBank.d333.s0	false	DDI-DrugBank.d333.s0.e0	DDI-DrugBank.d333.s0.e1
DDI-DrugBank.d333.s0	false	DDI-DrugBank.d333.s0.e0	DDI-DrugBank.d333.s0.e2
DDI-DrugBank.d333.s0	false	DDI-DrugBank.d333.s0.e0	DDI-DrugBank.d333.s0.e3
DDI-DrugBank.d333.s0	false	DDI-DrugBank.d333.s0.e0	DDI-DrugBank.d333.s0.e4
DDI-DrugBank.d333.s0	false	DDI-DrugBank.d333.s0.e1	DDI-DrugBank.d333.s0.e2
DDI-DrugBank.d333.s0	false	DDI-DrugBank.d333.s0.e1	DDI-DrugBank.d333.s0.e3
DDI-DrugBank.d333.s0	false	DDI-DrugBank.d333.s0.e1	DDI-DrugBank.d333.s0.e4
DDI-DrugBank.d333.s0	false	DDI-DrugBank.d333.s0.e2	DDI-DrugBank.d333.s0.e3
DDI-DrugBank.d333.s0	false	DDI-DrugBank.d333.s0.e2	DDI-DrugBank.d333.s0.e4
DDI-DrugBank.d333.s0	false	DDI-DrugBank.d333.s0.e3	DDI-DrugBank.d333.s0.e4
DDI-DrugBank.d333.s1|a|The effect of clonazepam on the metabolism of other drugs has not been investigated.
DDI-DrugBank.d333.s1	14	23	clonazepam	drug	DDI-DrugBank.d333.s1.e0
DDI-DrugBank.d333.s2|a|Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.
DDI-DrugBank.d333.s2	49	58	Clonazepam	drug	DDI-DrugBank.d333.s2.e0
DDI-DrugBank.d333.s2	93	102	ranitidine	drug	DDI-DrugBank.d333.s2.e1
DDI-DrugBank.d333.s2	169	178	clonazepam	drug	DDI-DrugBank.d333.s2.e2
DDI-DrugBank.d333.s2	false	DDI-DrugBank.d333.s2.e0	DDI-DrugBank.d333.s2.e1
DDI-DrugBank.d333.s2	false	DDI-DrugBank.d333.s2.e0	DDI-DrugBank.d333.s2.e2
DDI-DrugBank.d333.s2	false	DDI-DrugBank.d333.s2.e1	DDI-DrugBank.d333.s2.e2
DDI-DrugBank.d333.s3|a|In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
DDI-DrugBank.d333.s3	29	38	clonazepam	drug	DDI-DrugBank.d333.s3.e0
DDI-DrugBank.d333.s3	103	115	propantheline	drug	DDI-DrugBank.d333.s3.e1
DDI-DrugBank.d333.s3	121	141	anticholinergic agent	group	DDI-DrugBank.d333.s3.e2
DDI-DrugBank.d333.s3	216	225	clonazepam	drug	DDI-DrugBank.d333.s3.e3
DDI-DrugBank.d333.s3	257	266	clonazepam	drug	DDI-DrugBank.d333.s3.e4
DDI-DrugBank.d333.s3	335	347	propantheline	drug	DDI-DrugBank.d333.s3.e5
DDI-DrugBank.d333.s3	true	DDI-DrugBank.d333.s3.e0	DDI-DrugBank.d333.s3.e1
DDI-DrugBank.d333.s3	false	DDI-DrugBank.d333.s3.e0	DDI-DrugBank.d333.s3.e2
DDI-DrugBank.d333.s3	false	DDI-DrugBank.d333.s3.e0	DDI-DrugBank.d333.s3.e3
DDI-DrugBank.d333.s3	false	DDI-DrugBank.d333.s3.e0	DDI-DrugBank.d333.s3.e4
DDI-DrugBank.d333.s3	false	DDI-DrugBank.d333.s3.e0	DDI-DrugBank.d333.s3.e5
DDI-DrugBank.d333.s3	false	DDI-DrugBank.d333.s3.e1	DDI-DrugBank.d333.s3.e2
DDI-DrugBank.d333.s3	false	DDI-DrugBank.d333.s3.e1	DDI-DrugBank.d333.s3.e3
DDI-DrugBank.d333.s3	false	DDI-DrugBank.d333.s3.e1	DDI-DrugBank.d333.s3.e4
DDI-DrugBank.d333.s3	false	DDI-DrugBank.d333.s3.e1	DDI-DrugBank.d333.s3.e5
DDI-DrugBank.d333.s3	false	DDI-DrugBank.d333.s3.e2	DDI-DrugBank.d333.s3.e3
DDI-DrugBank.d333.s4|a|Fluoxetine does not affect the pharmacokinetics of clonazepam.
DDI-DrugBank.d333.s4	0	9	Fluoxetine	drug	DDI-DrugBank.d333.s4.e0
DDI-DrugBank.d333.s4	51	60	clonazepam	drug	DDI-DrugBank.d333.s4.e1
DDI-DrugBank.d333.s4	false	DDI-DrugBank.d333.s4.e0	DDI-DrugBank.d333.s4.e1
DDI-DrugBank.d333.s5|a|Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
DDI-DrugBank.d333.s5	35	43	phenytoin	drug	DDI-DrugBank.d333.s5.e0
DDI-DrugBank.d333.s5	46	58	carbamazepine	drug	DDI-DrugBank.d333.s5.e1
DDI-DrugBank.d333.s5	64	76	phenobarbital	drug	DDI-DrugBank.d333.s5.e2
DDI-DrugBank.d333.s5	86	95	clonazepam	drug	DDI-DrugBank.d333.s5.e3
DDI-DrugBank.d333.s5	157	166	clonazepam	drug	DDI-DrugBank.d333.s5.e4
DDI-DrugBank.d333.s5	false	DDI-DrugBank.d333.s5.e0	DDI-DrugBank.d333.s5.e1
DDI-DrugBank.d333.s5	false	DDI-DrugBank.d333.s5.e0	DDI-DrugBank.d333.s5.e2
DDI-DrugBank.d333.s5	true	DDI-DrugBank.d333.s5.e0	DDI-DrugBank.d333.s5.e3
DDI-DrugBank.d333.s5	false	DDI-DrugBank.d333.s5.e0	DDI-DrugBank.d333.s5.e4
DDI-DrugBank.d333.s5	false	DDI-DrugBank.d333.s5.e1	DDI-DrugBank.d333.s5.e2
DDI-DrugBank.d333.s5	true	DDI-DrugBank.d333.s5.e1	DDI-DrugBank.d333.s5.e3
DDI-DrugBank.d333.s5	false	DDI-DrugBank.d333.s5.e1	DDI-DrugBank.d333.s5.e4
DDI-DrugBank.d333.s5	true	DDI-DrugBank.d333.s5.e2	DDI-DrugBank.d333.s5.e3
DDI-DrugBank.d333.s5	false	DDI-DrugBank.d333.s5.e2	DDI-DrugBank.d333.s5.e4
DDI-DrugBank.d333.s5	false	DDI-DrugBank.d333.s5.e3	DDI-DrugBank.d333.s5.e4
DDI-DrugBank.d333.s6|a|Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.
DDI-DrugBank.d333.s6	113	122	clonazepam	drug	DDI-DrugBank.d333.s6.e0
DDI-DrugBank.d333.s6	183	199	antifungal agents	group	DDI-DrugBank.d333.s6.e1
DDI-DrugBank.d333.s6	250	259	clonazepam	drug	DDI-DrugBank.d333.s6.e2
DDI-DrugBank.d333.s6	false	DDI-DrugBank.d333.s6.e0	DDI-DrugBank.d333.s6.e1
DDI-DrugBank.d333.s6	false	DDI-DrugBank.d333.s6.e0	DDI-DrugBank.d333.s6.e2
DDI-DrugBank.d333.s6	true	DDI-DrugBank.d333.s6.e1	DDI-DrugBank.d333.s6.e2
DDI-DrugBank.d333.s7|a|Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d333.s7	63	82	benzodiazepine class	group	DDI-DrugBank.d333.s7.e0
DDI-DrugBank.d333.s7	115	121	alcohol	drug	DDI-DrugBank.d333.s7.e1
DDI-DrugBank.d333.s7	124	132	narcotics	group	DDI-DrugBank.d333.s7.e2
DDI-DrugBank.d333.s7	135	146	barbiturates	group	DDI-DrugBank.d333.s7.e3
DDI-DrugBank.d333.s7	149	172	nonbarbiturate hypnotics	group	DDI-DrugBank.d333.s7.e4
DDI-DrugBank.d333.s7	175	192	antianxiety agents	group	DDI-DrugBank.d333.s7.e5
DDI-DrugBank.d333.s7	199	212	phenothiazines classes of antipsychotic agents	group	DDI-DrugBank.d333.s7.e6
DDI-DrugBank.d333.s7	246	276	phenothiazines classes of antipsychotic agents	group	DDI-DrugBank.d333.s7.e6
DDI-DrugBank.d333.s7	215	226	thioxanthene classes of antipsychotic agents	group	DDI-DrugBank.d333.s7.e7
DDI-DrugBank.d333.s7	246	276	thioxanthene classes of antipsychotic agents	group	DDI-DrugBank.d333.s7.e7
DDI-DrugBank.d333.s7	232	276	butyrophenone classes of antipsychotic agents	group	DDI-DrugBank.d333.s7.e8
DDI-DrugBank.d333.s7	279	306	monoamine oxidase inhibitors	group	DDI-DrugBank.d333.s7.e9
DDI-DrugBank.d333.s7	true	DDI-DrugBank.d333.s7.e0	DDI-DrugBank.d333.s7.e1
DDI-DrugBank.d333.s7	true	DDI-DrugBank.d333.s7.e0	DDI-DrugBank.d333.s7.e2
DDI-DrugBank.d333.s7	true	DDI-DrugBank.d333.s7.e0	DDI-DrugBank.d333.s7.e3
DDI-DrugBank.d333.s7	true	DDI-DrugBank.d333.s7.e0	DDI-DrugBank.d333.s7.e4
DDI-DrugBank.d333.s7	true	DDI-DrugBank.d333.s7.e0	DDI-DrugBank.d333.s7.e5
DDI-DrugBank.d333.s7	true	DDI-DrugBank.d333.s7.e0	DDI-DrugBank.d333.s7.e6
DDI-DrugBank.d333.s7	true	DDI-DrugBank.d333.s7.e0	DDI-DrugBank.d333.s7.e7
DDI-DrugBank.d333.s7	true	DDI-DrugBank.d333.s7.e0	DDI-DrugBank.d333.s7.e8
DDI-DrugBank.d333.s7	true	DDI-DrugBank.d333.s7.e0	DDI-DrugBank.d333.s7.e9
DDI-DrugBank.d333.s7	true	DDI-DrugBank.d333.s7.e0	DDI-DrugBank.d333.s7.e10
DDI-DrugBank.d495.s0|a|Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.
DDI-DrugBank.d495.s0	30	52	clonidine hydrochloride	drug	DDI-DrugBank.d495.s0.e0
DDI-DrugBank.d495.s0	69	93	tricyclic antidepressants	group	DDI-DrugBank.d495.s0.e1
DDI-DrugBank.d495.s0	110	118	clonidine	drug	DDI-DrugBank.d495.s0.e2
DDI-DrugBank.d495.s0	true	DDI-DrugBank.d495.s0.e0	DDI-DrugBank.d495.s0.e1
DDI-DrugBank.d495.s0	false	DDI-DrugBank.d495.s0.e0	DDI-DrugBank.d495.s0.e2
DDI-DrugBank.d495.s0	false	DDI-DrugBank.d495.s0.e1	DDI-DrugBank.d495.s0.e2
DDI-DrugBank.d495.s1|a|Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
DDI-DrugBank.d495.s1	0	22	Clonidine hydrochloride	drug	DDI-DrugBank.d495.s1.e0
DDI-DrugBank.d495.s1	66	72	alcohol	drug	DDI-DrugBank.d495.s1.e1
DDI-DrugBank.d495.s1	75	86	barbiturates	group	DDI-DrugBank.d495.s1.e2
DDI-DrugBank.d495.s1	97	105	sedatives	group	DDI-DrugBank.d495.s1.e3
DDI-DrugBank.d495.s1	true	DDI-DrugBank.d495.s1.e0	DDI-DrugBank.d495.s1.e1
DDI-DrugBank.d495.s1	true	DDI-DrugBank.d495.s1.e0	DDI-DrugBank.d495.s1.e2
DDI-DrugBank.d495.s1	true	DDI-DrugBank.d495.s1.e0	DDI-DrugBank.d495.s1.e3
DDI-DrugBank.d495.s1	false	DDI-DrugBank.d495.s1.e1	DDI-DrugBank.d495.s1.e2
DDI-DrugBank.d495.s1	false	DDI-DrugBank.d495.s1.e1	DDI-DrugBank.d495.s1.e3
DDI-DrugBank.d495.s1	false	DDI-DrugBank.d495.s1.e2	DDI-DrugBank.d495.s1.e3
DDI-DrugBank.d495.s2|a|Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
DDI-DrugBank.d495.s2	0	12	Amitriptyline	drug	DDI-DrugBank.d495.s2.e0
DDI-DrugBank.d495.s2	34	42	clonidine	drug	DDI-DrugBank.d495.s2.e1
DDI-DrugBank.d495.s2	117	125	Clonidine	drug	DDI-DrugBank.d495.s2.e2
DDI-DrugBank.d495.s2	171	177	alcohol	drug	DDI-DrugBank.d495.s2.e3
DDI-DrugBank.d495.s2	180	191	barbiturates	group	DDI-DrugBank.d495.s2.e4
DDI-DrugBank.d495.s2	202	215	sedating drugs	group	DDI-DrugBank.d495.s2.e5
DDI-DrugBank.d495.s2	true	DDI-DrugBank.d495.s2.e0	DDI-DrugBank.d495.s2.e1
DDI-DrugBank.d495.s2	false	DDI-DrugBank.d495.s2.e0	DDI-DrugBank.d495.s2.e2
DDI-DrugBank.d495.s2	false	DDI-DrugBank.d495.s2.e0	DDI-DrugBank.d495.s2.e3
DDI-DrugBank.d495.s2	false	DDI-DrugBank.d495.s2.e0	DDI-DrugBank.d495.s2.e4
DDI-DrugBank.d495.s2	false	DDI-DrugBank.d495.s2.e0	DDI-DrugBank.d495.s2.e5
DDI-DrugBank.d495.s2	false	DDI-DrugBank.d495.s2.e1	DDI-DrugBank.d495.s2.e2
DDI-DrugBank.d495.s2	false	DDI-DrugBank.d495.s2.e1	DDI-DrugBank.d495.s2.e3
DDI-DrugBank.d495.s2	false	DDI-DrugBank.d495.s2.e1	DDI-DrugBank.d495.s2.e4
DDI-DrugBank.d495.s2	false	DDI-DrugBank.d495.s2.e1	DDI-DrugBank.d495.s2.e5
DDI-DrugBank.d495.s2	true	DDI-DrugBank.d495.s2.e2	DDI-DrugBank.d495.s2.e3
DDI-DrugBank.d495.s3|a|Narcotic analgesics may potentiate the hypotensive effects of clonidine.
DDI-DrugBank.d495.s3	0	18	Narcotic analgesics	group	DDI-DrugBank.d495.s3.e0
DDI-DrugBank.d495.s3	62	70	clonidine	drug	DDI-DrugBank.d495.s3.e1
DDI-DrugBank.d495.s3	true	DDI-DrugBank.d495.s3.e0	DDI-DrugBank.d495.s3.e1
DDI-DrugBank.d495.s4|a|Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.
DDI-DrugBank.d495.s4	0	24	Tricyclic antidepressants	group	DDI-DrugBank.d495.s4.e0
DDI-DrugBank.d495.s4	68	76	clonidine	drug	DDI-DrugBank.d495.s4.e1
DDI-DrugBank.d495.s4	true	DDI-DrugBank.d495.s4.e0	DDI-DrugBank.d495.s4.e1
DDI-DrugBank.d495.s5|a|The effects of tricyclic antidepressants on clonidines analgesic actions are not known.
DDI-DrugBank.d495.s5	15	39	tricyclic antidepressants	group	DDI-DrugBank.d495.s5.e0
DDI-DrugBank.d495.s5	44	52	clonidine	drug	DDI-DrugBank.d495.s5.e1
DDI-DrugBank.d495.s5	false	DDI-DrugBank.d495.s5.e0	DDI-DrugBank.d495.s5.e1
DDI-DrugBank.d495.s6|a|Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.
DDI-DrugBank.d495.s6	0	12	Beta blockers	group	DDI-DrugBank.d495.s6.e0
DDI-DrugBank.d495.s6	65	73	clonidine	drug	DDI-DrugBank.d495.s6.e1
DDI-DrugBank.d495.s6	true	DDI-DrugBank.d495.s6.e0	DDI-DrugBank.d495.s6.e1
DDI-DrugBank.d495.s7|a|Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
DDI-DrugBank.d495.s7	125	133	clonidine	drug	DDI-DrugBank.d495.s7.e0
DDI-DrugBank.d495.s7	213	221	digitalis	group	DDI-DrugBank.d495.s7.e1
DDI-DrugBank.d495.s7	224	247	calcium channel blockers	group	DDI-DrugBank.d495.s7.e2
DDI-DrugBank.d495.s7	254	266	beta-blockers	group	DDI-DrugBank.d495.s7.e3
DDI-DrugBank.d495.s7	true	DDI-DrugBank.d495.s7.e0	DDI-DrugBank.d495.s7.e1
DDI-DrugBank.d495.s7	true	DDI-DrugBank.d495.s7.e0	DDI-DrugBank.d495.s7.e2
DDI-DrugBank.d495.s7	true	DDI-DrugBank.d495.s7.e0	DDI-DrugBank.d495.s7.e3
DDI-DrugBank.d495.s7	false	DDI-DrugBank.d495.s7.e1	DDI-DrugBank.d495.s7.e2
DDI-DrugBank.d495.s7	false	DDI-DrugBank.d495.s7.e1	DDI-DrugBank.d495.s7.e3
DDI-DrugBank.d495.s7	false	DDI-DrugBank.d495.s7.e2	DDI-DrugBank.d495.s7.e3
DDI-DrugBank.d495.s8|a|There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.
DDI-DrugBank.d495.s8	100	111	fluphenazine	drug	DDI-DrugBank.d495.s8.e0
DDI-DrugBank.d495.s8	122	130	clonidine	drug	DDI-DrugBank.d495.s8.e1
DDI-DrugBank.d495.s8	true	DDI-DrugBank.d495.s8.e0	DDI-DrugBank.d495.s8.e1
DDI-DrugBank.d495.s9|a|Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine.
DDI-DrugBank.d495.s9	23	31	clonidine	drug	DDI-DrugBank.d495.s9.e0
DDI-DrugBank.d495.s9	99	107	clonidine	drug	DDI-DrugBank.d495.s9.e1
DDI-DrugBank.d495.s9	false	DDI-DrugBank.d495.s9.e0	DDI-DrugBank.d495.s9.e1
DDI-DrugBank.d495.s10|a|Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.
DDI-DrugBank.d495.s10	9	17	clonidine	drug	DDI-DrugBank.d495.s10.e0
DDI-DrugBank.d495.s10	87	97	anesthetics	group	DDI-DrugBank.d495.s10.e1
DDI-DrugBank.d495.s10	true	DDI-DrugBank.d495.s10.e0	DDI-DrugBank.d495.s10.e1
DDI-DrugBank.d343.s0|a|Aspirin, warfarin, heparin, NSAIDs
DDI-DrugBank.d343.s0	0	6	Aspirin	brand	DDI-DrugBank.d343.s0.e0
DDI-DrugBank.d343.s0	9	16	warfarin	drug	DDI-DrugBank.d343.s0.e1
DDI-DrugBank.d343.s0	19	25	heparin	drug	DDI-DrugBank.d343.s0.e2
DDI-DrugBank.d343.s0	28	33	NSAIDs	group	DDI-DrugBank.d343.s0.e3
DDI-DrugBank.d343.s0	false	DDI-DrugBank.d343.s0.e0	DDI-DrugBank.d343.s0.e1
DDI-DrugBank.d343.s0	false	DDI-DrugBank.d343.s0.e0	DDI-DrugBank.d343.s0.e2
DDI-DrugBank.d343.s0	false	DDI-DrugBank.d343.s0.e0	DDI-DrugBank.d343.s0.e3
DDI-DrugBank.d343.s0	false	DDI-DrugBank.d343.s0.e1	DDI-DrugBank.d343.s0.e2
DDI-DrugBank.d343.s0	false	DDI-DrugBank.d343.s0.e1	DDI-DrugBank.d343.s0.e3
DDI-DrugBank.d343.s0	false	DDI-DrugBank.d343.s0.e2	DDI-DrugBank.d343.s0.e3
DDI-DrugBank.d335.s0|a|If TRANXENE is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed.
DDI-DrugBank.d335.s0	3	10	TRANXENE	brand	DDI-DrugBank.d335.s0.e0
DDI-DrugBank.d335.s1|a|Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
DDI-DrugBank.d335.s1	33	55	clorazepate dipotassium	drug	DDI-DrugBank.d335.s1.e0
DDI-DrugBank.d335.s1	90	101	hexobarbital	drug	DDI-DrugBank.d335.s1.e1
DDI-DrugBank.d335.s1	112	124	ethyl alcohol	drug	DDI-DrugBank.d335.s1.e2
DDI-DrugBank.d335.s1	163	176	chlorpromazine	drug	DDI-DrugBank.d335.s1.e3
DDI-DrugBank.d335.s1	true	DDI-DrugBank.d335.s1.e0	DDI-DrugBank.d335.s1.e1
DDI-DrugBank.d335.s1	true	DDI-DrugBank.d335.s1.e0	DDI-DrugBank.d335.s1.e2
DDI-DrugBank.d335.s1	true	DDI-DrugBank.d335.s1.e0	DDI-DrugBank.d335.s1.e3
DDI-DrugBank.d335.s1	false	DDI-DrugBank.d335.s1.e1	DDI-DrugBank.d335.s1.e2
DDI-DrugBank.d335.s1	false	DDI-DrugBank.d335.s1.e1	DDI-DrugBank.d335.s1.e3
DDI-DrugBank.d335.s1	false	DDI-DrugBank.d335.s1.e2	DDI-DrugBank.d335.s1.e3
DDI-DrugBank.d335.s2|a|Clinical studies have shown increased sedation with concurrent hypnotic medications.
DDI-DrugBank.d335.s2	63	82	hypnotic medications	group	DDI-DrugBank.d335.s2.e0
DDI-DrugBank.d335.s3|a|The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
DDI-DrugBank.d335.s3	19	33	benzodiazepines	group	DDI-DrugBank.d335.s3.e0
DDI-DrugBank.d335.s3	57	68	barbiturates	group	DDI-DrugBank.d335.s3.e1
DDI-DrugBank.d335.s3	71	79	narcotics	group	DDI-DrugBank.d335.s3.e2
DDI-DrugBank.d335.s3	82	95	phenothiazines	group	DDI-DrugBank.d335.s3.e3
DDI-DrugBank.d335.s3	98	125	monoamine oxidase inhibitors	group	DDI-DrugBank.d335.s3.e4
DDI-DrugBank.d335.s3	136	150	antidepressants	group	DDI-DrugBank.d335.s3.e5
DDI-DrugBank.d335.s3	true	DDI-DrugBank.d335.s3.e0	DDI-DrugBank.d335.s3.e1
DDI-DrugBank.d335.s3	true	DDI-DrugBank.d335.s3.e0	DDI-DrugBank.d335.s3.e2
DDI-DrugBank.d335.s3	true	DDI-DrugBank.d335.s3.e0	DDI-DrugBank.d335.s3.e3
DDI-DrugBank.d335.s3	true	DDI-DrugBank.d335.s3.e0	DDI-DrugBank.d335.s3.e4
DDI-DrugBank.d335.s3	true	DDI-DrugBank.d335.s3.e0	DDI-DrugBank.d335.s3.e5
DDI-DrugBank.d335.s3	false	DDI-DrugBank.d335.s3.e1	DDI-DrugBank.d335.s3.e2
DDI-DrugBank.d335.s3	false	DDI-DrugBank.d335.s3.e1	DDI-DrugBank.d335.s3.e3
DDI-DrugBank.d335.s3	false	DDI-DrugBank.d335.s3.e1	DDI-DrugBank.d335.s3.e4
DDI-DrugBank.d335.s3	false	DDI-DrugBank.d335.s3.e1	DDI-DrugBank.d335.s3.e5
DDI-DrugBank.d335.s3	false	DDI-DrugBank.d335.s3.e2	DDI-DrugBank.d335.s3.e3
DDI-DrugBank.d335.s4|a|If TRANXENE tablets are used to treat anxiety associated with somatic disease states, careful attention must be paid to possible drug interaction with concomitant medication.
DDI-DrugBank.d335.s4	3	10	TRANXENE	brand	DDI-DrugBank.d335.s4.e0
DDI-DrugBank.d335.s5|a|In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of TRANXENE tablets.
DDI-DrugBank.d335.s5	82	89	antacids	group	DDI-DrugBank.d335.s5.e0
DDI-DrugBank.d335.s5	168	175	TRANXENE	brand	DDI-DrugBank.d335.s5.e1
DDI-DrugBank.d335.s5	false	DDI-DrugBank.d335.s5.e0	DDI-DrugBank.d335.s5.e1
DDI-DrugBank.d480.s0|a|The risks of using Clozapine in combination with other drugs have not been systematically evaluated.
DDI-DrugBank.d480.s0	19	27	Clozapine	drug	DDI-DrugBank.d480.s0.e0
DDI-DrugBank.d480.s1|a|Pharmacodynamic-related Interactions: The mechanism of Clozapine induced agranulocytosis is unknown;
DDI-DrugBank.d480.s1	55	63	Clozapine	drug	DDI-DrugBank.d480.s1.e0
DDI-DrugBank.d480.s2|a|nonetheless, the possibility that causative factors may interact synergistically to increase the risk and/or severity of bone marrow suppression warrants consideration.
DDI-DrugBank.d480.s3|a|Therefore, Clozapine should not be used with other agents having a well-known potential to suppress bone marrow function.
DDI-DrugBank.d480.s3	11	19	Clozapine	drug	DDI-DrugBank.d480.s3.e0
DDI-DrugBank.d480.s4|a|Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.
DDI-DrugBank.d480.s4	33	41	Clozapine	drug	DDI-DrugBank.d480.s4.e0
DDI-DrugBank.d480.s4	120	126	alcohol	drug	DDI-DrugBank.d480.s4.e1
DDI-DrugBank.d480.s4	true	DDI-DrugBank.d480.s4.e0	DDI-DrugBank.d480.s4.e1
DDI-DrugBank.d480.s5|a|Orthostatic hypotension in patients taking clozapine can, in rare cases (approximately 1 case per 3,000 patients), be accompanied by profound collapse and respiratory and/or cardiac arrest.
DDI-DrugBank.d480.s5	43	51	clozapine	drug	DDI-DrugBank.d480.s5.e0
DDI-DrugBank.d480.s6|a|Some of the cases of collapse/respiratory arrest/cardiac arrest during initial treatment occurred in patients who were being administered benzodiazepines;
DDI-DrugBank.d480.s6	138	152	benzodiazepines	group	DDI-DrugBank.d480.s6.e0
DDI-DrugBank.d480.s7|a|similar events have been reported in patients taking other psychotropic drugs or even Clozapine by itself.
DDI-DrugBank.d480.s7	59	76	psychotropic drugs	group	DDI-DrugBank.d480.s7.e0
DDI-DrugBank.d480.s7	86	94	Clozapine	drug	DDI-DrugBank.d480.s7.e1
DDI-DrugBank.d480.s7	false	DDI-DrugBank.d480.s7.e0	DDI-DrugBank.d480.s7.e1
DDI-DrugBank.d480.s8|a|Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
DDI-DrugBank.d480.s8	74	82	Clozapine	drug	DDI-DrugBank.d480.s8.e0
DDI-DrugBank.d480.s8	88	102	benzodiazepines	group	DDI-DrugBank.d480.s8.e1
DDI-DrugBank.d480.s8	113	125	psychotropics	group	DDI-DrugBank.d480.s8.e2
DDI-DrugBank.d480.s8	152	160	clozapine	drug	DDI-DrugBank.d480.s8.e3
DDI-DrugBank.d480.s8	196	209	benzodiazepine	group	DDI-DrugBank.d480.s8.e4
DDI-DrugBank.d480.s8	224	240	psychotropic drug	group	DDI-DrugBank.d480.s8.e5
DDI-DrugBank.d480.s8	false	DDI-DrugBank.d480.s8.e0	DDI-DrugBank.d480.s8.e1
DDI-DrugBank.d480.s8	false	DDI-DrugBank.d480.s8.e0	DDI-DrugBank.d480.s8.e2
DDI-DrugBank.d480.s8	false	DDI-DrugBank.d480.s8.e0	DDI-DrugBank.d480.s8.e3
DDI-DrugBank.d480.s8	false	DDI-DrugBank.d480.s8.e0	DDI-DrugBank.d480.s8.e4
DDI-DrugBank.d480.s8	false	DDI-DrugBank.d480.s8.e0	DDI-DrugBank.d480.s8.e5
DDI-DrugBank.d480.s8	false	DDI-DrugBank.d480.s8.e1	DDI-DrugBank.d480.s8.e2
DDI-DrugBank.d480.s8	false	DDI-DrugBank.d480.s8.e1	DDI-DrugBank.d480.s8.e3
DDI-DrugBank.d480.s8	false	DDI-DrugBank.d480.s8.e1	DDI-DrugBank.d480.s8.e4
DDI-DrugBank.d480.s8	false	DDI-DrugBank.d480.s8.e1	DDI-DrugBank.d480.s8.e5
DDI-DrugBank.d480.s8	false	DDI-DrugBank.d480.s8.e2	DDI-DrugBank.d480.s8.e3
DDI-DrugBank.d480.s9|a|Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
DDI-DrugBank.d480.s9	0	8	Clozapine	drug	DDI-DrugBank.d480.s9.e0
DDI-DrugBank.d480.s9	52	73	antihypertensive drugs	group	DDI-DrugBank.d480.s9.e1
DDI-DrugBank.d480.s9	110	117	atropine	drug	DDI-DrugBank.d480.s9.e2
DDI-DrugBank.d480.s9	true	DDI-DrugBank.d480.s9.e0	DDI-DrugBank.d480.s9.e1
DDI-DrugBank.d480.s9	true	DDI-DrugBank.d480.s9.e0	DDI-DrugBank.d480.s9.e2
DDI-DrugBank.d480.s9	false	DDI-DrugBank.d480.s9.e1	DDI-DrugBank.d480.s9.e2
DDI-DrugBank.d480.s10|a|The administration of epinephrine should be avoided in the treatment of drug induced hypotension because of a possible reverse epinephrine effect.
DDI-DrugBank.d480.s10	22	32	epinephrine	drug	DDI-DrugBank.d480.s10.e0
DDI-DrugBank.d480.s10	127	137	epinephrine	drug	DDI-DrugBank.d480.s10.e1
DDI-DrugBank.d480.s10	false	DDI-DrugBank.d480.s10.e0	DDI-DrugBank.d480.s10.e1
DDI-DrugBank.d480.s11|a|Pharmacokinetic-related Interactions: Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4.
DDI-DrugBank.d480.s11	38	46	Clozapine	drug	DDI-DrugBank.d480.s11.e0
DDI-DrugBank.d480.s12|a|The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized.
DDI-DrugBank.d480.s13|a|Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes.
DDI-DrugBank.d480.s14|a|Concomitant administration of drugs known to induce cytochrome P450 enzymes may decrease the plasma levels of clozapine.
DDI-DrugBank.d480.s14	110	118	clozapine	drug	DDI-DrugBank.d480.s14.e0
DDI-DrugBank.d480.s15|a|Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
DDI-DrugBank.d480.s15	0	8	Phenytoin	drug	DDI-DrugBank.d480.s15.e0
DDI-DrugBank.d480.s15	11	18	nicotine	drug	DDI-DrugBank.d480.s15.e1
DDI-DrugBank.d480.s15	25	32	rifampin	drug	DDI-DrugBank.d480.s15.e2
DDI-DrugBank.d480.s15	47	55	Clozapine	drug	DDI-DrugBank.d480.s15.e3
DDI-DrugBank.d480.s15	139	147	Clozapine	drug	DDI-DrugBank.d480.s15.e4
DDI-DrugBank.d480.s15	false	DDI-DrugBank.d480.s15.e0	DDI-DrugBank.d480.s15.e1
DDI-DrugBank.d480.s15	false	DDI-DrugBank.d480.s15.e0	DDI-DrugBank.d480.s15.e2
DDI-DrugBank.d480.s15	true	DDI-DrugBank.d480.s15.e0	DDI-DrugBank.d480.s15.e3
DDI-DrugBank.d480.s15	false	DDI-DrugBank.d480.s15.e0	DDI-DrugBank.d480.s15.e4
DDI-DrugBank.d480.s15	false	DDI-DrugBank.d480.s15.e1	DDI-DrugBank.d480.s15.e2
DDI-DrugBank.d480.s15	true	DDI-DrugBank.d480.s15.e1	DDI-DrugBank.d480.s15.e3
DDI-DrugBank.d480.s15	false	DDI-DrugBank.d480.s15.e1	DDI-DrugBank.d480.s15.e4
DDI-DrugBank.d480.s15	true	DDI-DrugBank.d480.s15.e2	DDI-DrugBank.d480.s15.e3
DDI-DrugBank.d480.s15	false	DDI-DrugBank.d480.s15.e2	DDI-DrugBank.d480.s15.e4
DDI-DrugBank.d480.s15	false	DDI-DrugBank.d480.s15.e3	DDI-DrugBank.d480.s15.e4
DDI-DrugBank.d480.s16|a|Concomitant administration of drugs known to inhibit the activity of cytochrome P450 isozymes may increase the plasma levels of clozapine.
DDI-DrugBank.d480.s16	128	136	clozapine	drug	DDI-DrugBank.d480.s16.e0
DDI-DrugBank.d480.s17|a|Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
DDI-DrugBank.d480.s17	0	9	Cimetidine	drug	DDI-DrugBank.d480.s17.e0
DDI-DrugBank.d480.s17	12	19	caffeine	drug	DDI-DrugBank.d480.s17.e1
DDI-DrugBank.d480.s17	26	37	erythromycin	drug	DDI-DrugBank.d480.s17.e2
DDI-DrugBank.d480.s17	69	77	Clozapine	drug	DDI-DrugBank.d480.s17.e3
DDI-DrugBank.d480.s17	false	DDI-DrugBank.d480.s17.e0	DDI-DrugBank.d480.s17.e1
DDI-DrugBank.d480.s17	false	DDI-DrugBank.d480.s17.e0	DDI-DrugBank.d480.s17.e2
DDI-DrugBank.d480.s17	true	DDI-DrugBank.d480.s17.e0	DDI-DrugBank.d480.s17.e3
DDI-DrugBank.d480.s17	false	DDI-DrugBank.d480.s17.e1	DDI-DrugBank.d480.s17.e2
DDI-DrugBank.d480.s17	true	DDI-DrugBank.d480.s17.e1	DDI-DrugBank.d480.s17.e3
DDI-DrugBank.d480.s17	true	DDI-DrugBank.d480.s17.e2	DDI-DrugBank.d480.s17.e3
DDI-DrugBank.d480.s18|a|Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
DDI-DrugBank.d480.s18	28	36	Clozapine	drug	DDI-DrugBank.d480.s18.e0
DDI-DrugBank.d480.s18	42	54	carbamazepine	drug	DDI-DrugBank.d480.s18.e1
DDI-DrugBank.d480.s18	131	143	carbamazepine	drug	DDI-DrugBank.d480.s18.e2
DDI-DrugBank.d480.s18	189	197	Clozapine	drug	DDI-DrugBank.d480.s18.e3
DDI-DrugBank.d480.s18	true	DDI-DrugBank.d480.s18.e0	DDI-DrugBank.d480.s18.e1
DDI-DrugBank.d480.s18	false	DDI-DrugBank.d480.s18.e0	DDI-DrugBank.d480.s18.e2
DDI-DrugBank.d480.s18	false	DDI-DrugBank.d480.s18.e0	DDI-DrugBank.d480.s18.e3
DDI-DrugBank.d480.s18	false	DDI-DrugBank.d480.s18.e1	DDI-DrugBank.d480.s18.e2
DDI-DrugBank.d480.s18	false	DDI-DrugBank.d480.s18.e1	DDI-DrugBank.d480.s18.e3
DDI-DrugBank.d480.s18	true	DDI-DrugBank.d480.s18.e2	DDI-DrugBank.d480.s18.e3
DDI-DrugBank.d480.s19|a|In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.
DDI-DrugBank.d480.s19	50	58	clozapine	drug	DDI-DrugBank.d480.s19.e0
DDI-DrugBank.d480.s19	91	101	fluvoxamine	drug	DDI-DrugBank.d480.s19.e1
DDI-DrugBank.d480.s19	106	115	paroxetine	drug	DDI-DrugBank.d480.s19.e2
DDI-DrugBank.d480.s19	false	DDI-DrugBank.d480.s19.e0	DDI-DrugBank.d480.s19.e1
DDI-DrugBank.d480.s19	false	DDI-DrugBank.d480.s19.e0	DDI-DrugBank.d480.s19.e2
DDI-DrugBank.d480.s19	false	DDI-DrugBank.d480.s19.e1	DDI-DrugBank.d480.s19.e2
DDI-DrugBank.d480.s20|a|After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.
DDI-DrugBank.d480.s20	66	74	clozapine	drug	DDI-DrugBank.d480.s20.e0
DDI-DrugBank.d480.s20	97	116	N-desmethylclozapine	drug_n	DDI-DrugBank.d480.s20.e1
DDI-DrugBank.d480.s20	122	138	clozapine N-oxide	drug_n	DDI-DrugBank.d480.s20.e2
DDI-DrugBank.d480.s20	160	170	fluvoxamine	drug	DDI-DrugBank.d480.s20.e3
DDI-DrugBank.d480.s20	false	DDI-DrugBank.d480.s20.e0	DDI-DrugBank.d480.s20.e1
DDI-DrugBank.d480.s20	false	DDI-DrugBank.d480.s20.e0	DDI-DrugBank.d480.s20.e2
DDI-DrugBank.d480.s20	false	DDI-DrugBank.d480.s20.e0	DDI-DrugBank.d480.s20.e3
DDI-DrugBank.d480.s20	false	DDI-DrugBank.d480.s20.e1	DDI-DrugBank.d480.s20.e2
DDI-DrugBank.d480.s20	false	DDI-DrugBank.d480.s20.e1	DDI-DrugBank.d480.s20.e3
DDI-DrugBank.d480.s20	false	DDI-DrugBank.d480.s20.e2	DDI-DrugBank.d480.s20.e3
DDI-DrugBank.d480.s21|a|Paroxetine produced only minor changes in the levels of clozapine and its metabolites.
DDI-DrugBank.d480.s21	0	9	Paroxetine	drug	DDI-DrugBank.d480.s21.e0
DDI-DrugBank.d480.s21	56	64	clozapine	drug	DDI-DrugBank.d480.s21.e1
DDI-DrugBank.d480.s21	true	DDI-DrugBank.d480.s21.e0	DDI-DrugBank.d480.s21.e1
DDI-DrugBank.d480.s22|a|However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
DDI-DrugBank.d480.s22	84	92	clozapine	drug	DDI-DrugBank.d480.s22.e0
DDI-DrugBank.d480.s22	129	137	clozapine	drug	DDI-DrugBank.d480.s22.e1
DDI-DrugBank.d480.s22	154	163	paroxetine	drug	DDI-DrugBank.d480.s22.e2
DDI-DrugBank.d480.s22	166	175	fluoxetine	drug	DDI-DrugBank.d480.s22.e3
DDI-DrugBank.d480.s22	182	191	sertraline	drug	DDI-DrugBank.d480.s22.e4
DDI-DrugBank.d480.s22	false	DDI-DrugBank.d480.s22.e0	DDI-DrugBank.d480.s22.e1
DDI-DrugBank.d480.s22	false	DDI-DrugBank.d480.s22.e0	DDI-DrugBank.d480.s22.e2
DDI-DrugBank.d480.s22	false	DDI-DrugBank.d480.s22.e0	DDI-DrugBank.d480.s22.e3
DDI-DrugBank.d480.s22	false	DDI-DrugBank.d480.s22.e0	DDI-DrugBank.d480.s22.e4
DDI-DrugBank.d480.s22	true	DDI-DrugBank.d480.s22.e1	DDI-DrugBank.d480.s22.e2
DDI-DrugBank.d480.s22	true	DDI-DrugBank.d480.s22.e1	DDI-DrugBank.d480.s22.e3
DDI-DrugBank.d480.s22	true	DDI-DrugBank.d480.s22.e1	DDI-DrugBank.d480.s22.e4
DDI-DrugBank.d480.s22	false	DDI-DrugBank.d480.s22.e2	DDI-DrugBank.d480.s22.e3
DDI-DrugBank.d480.s22	false	DDI-DrugBank.d480.s22.e2	DDI-DrugBank.d480.s22.e4
DDI-DrugBank.d480.s22	false	DDI-DrugBank.d480.s22.e3	DDI-DrugBank.d480.s22.e4
DDI-DrugBank.d480.s23|a|Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.
DDI-DrugBank.d480.s23	115	123	Clozapine	drug	DDI-DrugBank.d480.s23.e0
DDI-DrugBank.d480.s23	173	183	fluvoxamine	drug	DDI-DrugBank.d480.s23.e1
DDI-DrugBank.d480.s23	true	DDI-DrugBank.d480.s23.e0	DDI-DrugBank.d480.s23.e1
DDI-DrugBank.d480.s24|a|A reduced Clozapine dose should be considered.
DDI-DrugBank.d480.s24	10	18	Clozapine	drug	DDI-DrugBank.d480.s24.e0
DDI-DrugBank.d480.s25|a|A subset (3%-10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isozyme P450 2D6.
DDI-DrugBank.d480.s26|a|Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, the tricyclic antidepressants, and clozapine.
DDI-DrugBank.d480.s26	71	81	debrisoquin	drug	DDI-DrugBank.d480.s26.e0
DDI-DrugBank.d480.s26	84	99	dextromethorphan	drug	DDI-DrugBank.d480.s26.e1
DDI-DrugBank.d480.s26	106	130	tricyclic antidepressants	group	DDI-DrugBank.d480.s26.e2
DDI-DrugBank.d480.s26	137	145	clozapine	drug	DDI-DrugBank.d480.s26.e3
DDI-DrugBank.d480.s26	false	DDI-DrugBank.d480.s26.e0	DDI-DrugBank.d480.s26.e1
DDI-DrugBank.d480.s26	false	DDI-DrugBank.d480.s26.e0	DDI-DrugBank.d480.s26.e2
DDI-DrugBank.d480.s26	false	DDI-DrugBank.d480.s26.e0	DDI-DrugBank.d480.s26.e3
DDI-DrugBank.d480.s26	false	DDI-DrugBank.d480.s26.e1	DDI-DrugBank.d480.s26.e2
DDI-DrugBank.d480.s26	false	DDI-DrugBank.d480.s26.e1	DDI-DrugBank.d480.s26.e3
DDI-DrugBank.d480.s26	false	DDI-DrugBank.d480.s26.e2	DDI-DrugBank.d480.s26.e3
DDI-DrugBank.d480.s27|a|These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.
DDI-DrugBank.d480.s27	76	84	clozapine	drug	DDI-DrugBank.d480.s27.e0
DDI-DrugBank.d480.s28|a|In addition, certain drugs that are metabolized by this isozyme, including many antidepressants (clozapine, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isozyme, and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.
DDI-DrugBank.d480.s28	80	94	antidepressants	group	DDI-DrugBank.d480.s28.e0
DDI-DrugBank.d480.s28	97	105	clozapine	drug	DDI-DrugBank.d480.s28.e1
DDI-DrugBank.d480.s28	108	146	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d480.s28.e2
DDI-DrugBank.d480.s28	false	DDI-DrugBank.d480.s28.e0	DDI-DrugBank.d480.s28.e1
DDI-DrugBank.d480.s28	false	DDI-DrugBank.d480.s28.e0	DDI-DrugBank.d480.s28.e2
DDI-DrugBank.d480.s28	false	DDI-DrugBank.d480.s28.e1	DDI-DrugBank.d480.s28.e2
DDI-DrugBank.d480.s29|a|Concomitant use of clozapine with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either clozapine or the other drug.
DDI-DrugBank.d480.s29	19	27	clozapine	drug	DDI-DrugBank.d480.s29.e0
DDI-DrugBank.d480.s29	140	148	clozapine	drug	DDI-DrugBank.d480.s29.e1
DDI-DrugBank.d480.s29	false	DDI-DrugBank.d480.s29.e0	DDI-DrugBank.d480.s29.e1
DDI-DrugBank.d480.s30|a|Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DDI-DrugBank.d480.s30	32	40	clozapine	drug	DDI-DrugBank.d480.s30.e0
DDI-DrugBank.d480.s30	107	121	antidepressants	group	DDI-DrugBank.d480.s30.e1
DDI-DrugBank.d480.s30	124	137	phenothiazines	group	DDI-DrugBank.d480.s30.e2
DDI-DrugBank.d480.s30	140	152	carbamazepine	drug	DDI-DrugBank.d480.s30.e3
DDI-DrugBank.d480.s30	159	181	Type 1C antiarrhythmics	group	DDI-DrugBank.d480.s30.e4
DDI-DrugBank.d480.s30	190	200	propafenone	drug	DDI-DrugBank.d480.s30.e5
DDI-DrugBank.d480.s30	203	212	flecainide	drug	DDI-DrugBank.d480.s30.e6
DDI-DrugBank.d480.s30	218	226	encainide	drug	DDI-DrugBank.d480.s30.e7
DDI-DrugBank.d480.s30	265	273	quinidine	drug	DDI-DrugBank.d480.s30.e8
DDI-DrugBank.d480.s30	true	DDI-DrugBank.d480.s30.e0	DDI-DrugBank.d480.s30.e1
DDI-DrugBank.d480.s30	true	DDI-DrugBank.d480.s30.e0	DDI-DrugBank.d480.s30.e2
DDI-DrugBank.d480.s30	true	DDI-DrugBank.d480.s30.e0	DDI-DrugBank.d480.s30.e3
DDI-DrugBank.d480.s30	true	DDI-DrugBank.d480.s30.e0	DDI-DrugBank.d480.s30.e4
DDI-DrugBank.d480.s30	true	DDI-DrugBank.d480.s30.e0	DDI-DrugBank.d480.s30.e5
DDI-DrugBank.d480.s30	true	DDI-DrugBank.d480.s30.e0	DDI-DrugBank.d480.s30.e6
DDI-DrugBank.d480.s30	true	DDI-DrugBank.d480.s30.e0	DDI-DrugBank.d480.s30.e7
DDI-DrugBank.d480.s30	true	DDI-DrugBank.d480.s30.e0	DDI-DrugBank.d480.s30.e8
DDI-DrugBank.d480.s30	false	DDI-DrugBank.d480.s30.e1	DDI-DrugBank.d480.s30.e2
DDI-DrugBank.d480.s30	false	DDI-DrugBank.d480.s30.e1	DDI-DrugBank.d480.s30.e3
DDI-DrugBank.d221.s0|a|The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies.
DDI-DrugBank.d221.s0	44	52	NovoSeven	brand	DDI-DrugBank.d221.s0.e0
DDI-DrugBank.d221.s0	58	75	coagulation factor	group	DDI-DrugBank.d221.s0.e1
DDI-DrugBank.d221.s0	false	DDI-DrugBank.d221.s0.e0	DDI-DrugBank.d221.s0.e1
DDI-DrugBank.d221.s1|a|Simultaneous use of activated prothrombin complex concentrates or prothrombin complex concentrates should be avoided.
DDI-DrugBank.d221.s1	20	61	activated prothrombin complex concentrates	group	DDI-DrugBank.d221.s1.e0
DDI-DrugBank.d221.s1	66	97	prothrombin complex concentrates	group	DDI-DrugBank.d221.s1.e1
DDI-DrugBank.d221.s1	false	DDI-DrugBank.d221.s1.e0	DDI-DrugBank.d221.s1.e1
DDI-DrugBank.d221.s2|a|Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.
DDI-DrugBank.d221.s2	170	184	tranexamic acid	drug	DDI-DrugBank.d221.s2.e0
DDI-DrugBank.d221.s2	187	203	aminocaproic acid	drug	DDI-DrugBank.d221.s2.e1
DDI-DrugBank.d221.s2	210	218	NovoSeven	brand	DDI-DrugBank.d221.s2.e2
DDI-DrugBank.d221.s2	false	DDI-DrugBank.d221.s2.e0	DDI-DrugBank.d221.s2.e1
DDI-DrugBank.d221.s2	false	DDI-DrugBank.d221.s2.e0	DDI-DrugBank.d221.s2.e2
DDI-DrugBank.d221.s2	false	DDI-DrugBank.d221.s2.e1	DDI-DrugBank.d221.s2.e2
DDI-DrugBank.d221.s3|a|NovoSeven should not be mixed with infusion solutions until clinical data are available to direct this use.
DDI-DrugBank.d221.s3	0	8	NovoSeven	brand	DDI-DrugBank.d221.s3.e0
DDI-DrugBank.d464.s0|a|Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
DDI-DrugBank.d464.s0	0	6	Codeine	drug	DDI-DrugBank.d464.s0.e0
DDI-DrugBank.d464.s0	34	52	narcotic analgesics	group	DDI-DrugBank.d464.s0.e1
DDI-DrugBank.d464.s0	63	73	anesthetics	group	DDI-DrugBank.d464.s0.e2
DDI-DrugBank.d464.s0	76	89	phenothiazines	group	DDI-DrugBank.d464.s0.e3
DDI-DrugBank.d464.s0	92	104	tranquilizers	group	DDI-DrugBank.d464.s0.e4
DDI-DrugBank.d464.s0	107	124	sedative-hypnotics	group	DDI-DrugBank.d464.s0.e5
DDI-DrugBank.d464.s0	136	150	CNS depressants	group	DDI-DrugBank.d464.s0.e6
DDI-DrugBank.d464.s0	163	169	alcohol	drug	DDI-DrugBank.d464.s0.e7
DDI-DrugBank.d464.s0	true	DDI-DrugBank.d464.s0.e0	DDI-DrugBank.d464.s0.e1
DDI-DrugBank.d464.s0	true	DDI-DrugBank.d464.s0.e0	DDI-DrugBank.d464.s0.e2
DDI-DrugBank.d464.s0	true	DDI-DrugBank.d464.s0.e0	DDI-DrugBank.d464.s0.e3
DDI-DrugBank.d464.s0	true	DDI-DrugBank.d464.s0.e0	DDI-DrugBank.d464.s0.e4
DDI-DrugBank.d464.s0	true	DDI-DrugBank.d464.s0.e0	DDI-DrugBank.d464.s0.e5
DDI-DrugBank.d464.s0	true	DDI-DrugBank.d464.s0.e0	DDI-DrugBank.d464.s0.e6
DDI-DrugBank.d464.s0	true	DDI-DrugBank.d464.s0.e0	DDI-DrugBank.d464.s0.e7
DDI-DrugBank.d464.s0	false	DDI-DrugBank.d464.s0.e1	DDI-DrugBank.d464.s0.e2
DDI-DrugBank.d464.s0	false	DDI-DrugBank.d464.s0.e1	DDI-DrugBank.d464.s0.e3
DDI-DrugBank.d464.s0	false	DDI-DrugBank.d464.s0.e1	DDI-DrugBank.d464.s0.e4
DDI-DrugBank.d464.s1|a|When s.c.
DDI-DrugBank.d464.s2|a|combination therapy is contemplated, the dosage of one or both agents should be reduced.
DDI-DrugBank.d146.s0|a|Colchicine is inhibited by acidifying agents.
DDI-DrugBank.d146.s0	0	9	Colchicine	drug	DDI-DrugBank.d146.s0.e0
DDI-DrugBank.d146.s0	27	43	acidifying agents	group	DDI-DrugBank.d146.s0.e1
DDI-DrugBank.d146.s0	true	DDI-DrugBank.d146.s0.e0	DDI-DrugBank.d146.s0.e1
DDI-DrugBank.d146.s1|a|The action of colchicine is potentiated by alkalinizing agents.
DDI-DrugBank.d146.s1	14	23	colchicine	drug	DDI-DrugBank.d146.s1.e0
DDI-DrugBank.d146.s1	43	61	alkalinizing agents	group	DDI-DrugBank.d146.s1.e1
DDI-DrugBank.d146.s1	true	DDI-DrugBank.d146.s1.e0	DDI-DrugBank.d146.s1.e1
DDI-DrugBank.d146.s2|a|Colchicine may increase sensitivity to the CNS depressants.
DDI-DrugBank.d146.s2	0	9	Colchicine	drug	DDI-DrugBank.d146.s2.e0
DDI-DrugBank.d146.s2	43	57	CNS depressants	group	DDI-DrugBank.d146.s2.e1
DDI-DrugBank.d146.s2	true	DDI-DrugBank.d146.s2.e0	DDI-DrugBank.d146.s2.e1
DDI-DrugBank.d146.s3|a|Response to sympathomimetic agents may be enhanced by colchicine.
DDI-DrugBank.d146.s3	12	33	sympathomimetic agents	group	DDI-DrugBank.d146.s3.e0
DDI-DrugBank.d146.s3	54	63	colchicine	drug	DDI-DrugBank.d146.s3.e1
DDI-DrugBank.d146.s3	true	DDI-DrugBank.d146.s3.e0	DDI-DrugBank.d146.s3.e1
DDI-DrugBank.d551.s0|a|WelChol  has been studied in several human drug interaction studies in which it was administered with a meal and the test drug.
DDI-DrugBank.d551.s0	0	6	WelChol	brand	DDI-DrugBank.d551.s0.e0
DDI-DrugBank.d551.s1|a|WelChol  was found to have no significant effect on the bioavailability of digoxin, lovastatin, metoprolol, quinidine, valproic acid, and warfarin.
DDI-DrugBank.d551.s1	0	6	WelChol	brand	DDI-DrugBank.d551.s1.e0
DDI-DrugBank.d551.s1	75	81	digoxin	drug	DDI-DrugBank.d551.s1.e1
DDI-DrugBank.d551.s1	84	93	lovastatin	drug	DDI-DrugBank.d551.s1.e2
DDI-DrugBank.d551.s1	96	105	metoprolol	drug	DDI-DrugBank.d551.s1.e3
DDI-DrugBank.d551.s1	108	116	quinidine	drug	DDI-DrugBank.d551.s1.e4
DDI-DrugBank.d551.s1	119	131	valproic acid	drug	DDI-DrugBank.d551.s1.e5
DDI-DrugBank.d551.s1	138	145	warfarin	drug	DDI-DrugBank.d551.s1.e6
DDI-DrugBank.d551.s1	false	DDI-DrugBank.d551.s1.e0	DDI-DrugBank.d551.s1.e1
DDI-DrugBank.d551.s1	false	DDI-DrugBank.d551.s1.e0	DDI-DrugBank.d551.s1.e2
DDI-DrugBank.d551.s1	false	DDI-DrugBank.d551.s1.e0	DDI-DrugBank.d551.s1.e3
DDI-DrugBank.d551.s1	false	DDI-DrugBank.d551.s1.e0	DDI-DrugBank.d551.s1.e4
DDI-DrugBank.d551.s1	false	DDI-DrugBank.d551.s1.e0	DDI-DrugBank.d551.s1.e5
DDI-DrugBank.d551.s1	false	DDI-DrugBank.d551.s1.e0	DDI-DrugBank.d551.s1.e6
DDI-DrugBank.d551.s1	false	DDI-DrugBank.d551.s1.e1	DDI-DrugBank.d551.s1.e2
DDI-DrugBank.d551.s1	false	DDI-DrugBank.d551.s1.e1	DDI-DrugBank.d551.s1.e3
DDI-DrugBank.d551.s1	false	DDI-DrugBank.d551.s1.e1	DDI-DrugBank.d551.s1.e4
DDI-DrugBank.d551.s1	false	DDI-DrugBank.d551.s1.e1	DDI-DrugBank.d551.s1.e5
DDI-DrugBank.d551.s2|a|WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
DDI-DrugBank.d551.s2	0	6	WelChol	brand	DDI-DrugBank.d551.s2.e0
DDI-DrugBank.d551.s2	57	65	verapamil	drug	DDI-DrugBank.d551.s2.e1
DDI-DrugBank.d551.s2	68	75	Calan SR	brand	DDI-DrugBank.d551.s2.e2
DDI-DrugBank.d551.s2	true	DDI-DrugBank.d551.s2.e0	DDI-DrugBank.d551.s2.e1
DDI-DrugBank.d551.s2	true	DDI-DrugBank.d551.s2.e0	DDI-DrugBank.d551.s2.e2
DDI-DrugBank.d551.s2	false	DDI-DrugBank.d551.s2.e1	DDI-DrugBank.d551.s2.e2
DDI-DrugBank.d551.s3|a|Since there is a high degree of variability in the bioavailability of verapamil, the clinical significance of this finding is unclear.
DDI-DrugBank.d551.s3	70	78	verapamil	drug	DDI-DrugBank.d551.s3.e0
DDI-DrugBank.d551.s4|a|In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.
DDI-DrugBank.d551.s4	41	47	WelChol	brand	DDI-DrugBank.d551.s4.e0
DDI-DrugBank.d551.s4	55	66	atorvastatin	drug	DDI-DrugBank.d551.s4.e1
DDI-DrugBank.d551.s4	69	78	lovastatin	drug	DDI-DrugBank.d551.s4.e2
DDI-DrugBank.d551.s4	84	94	simvastatin	drug	DDI-DrugBank.d551.s4.e3
DDI-DrugBank.d551.s4	154	180	HMG-CoA reductase inhibitor	group	DDI-DrugBank.d551.s4.e4
DDI-DrugBank.d551.s4	false	DDI-DrugBank.d551.s4.e0	DDI-DrugBank.d551.s4.e1
DDI-DrugBank.d551.s4	false	DDI-DrugBank.d551.s4.e0	DDI-DrugBank.d551.s4.e2
DDI-DrugBank.d551.s4	false	DDI-DrugBank.d551.s4.e0	DDI-DrugBank.d551.s4.e3
DDI-DrugBank.d551.s4	false	DDI-DrugBank.d551.s4.e0	DDI-DrugBank.d551.s4.e4
DDI-DrugBank.d551.s4	false	DDI-DrugBank.d551.s4.e1	DDI-DrugBank.d551.s4.e2
DDI-DrugBank.d551.s4	false	DDI-DrugBank.d551.s4.e1	DDI-DrugBank.d551.s4.e3
DDI-DrugBank.d551.s4	false	DDI-DrugBank.d551.s4.e1	DDI-DrugBank.d551.s4.e4
DDI-DrugBank.d551.s4	false	DDI-DrugBank.d551.s4.e2	DDI-DrugBank.d551.s4.e3
DDI-DrugBank.d551.s4	false	DDI-DrugBank.d551.s4.e2	DDI-DrugBank.d551.s4.e4
DDI-DrugBank.d551.s4	false	DDI-DrugBank.d551.s4.e3	DDI-DrugBank.d551.s4.e4
DDI-DrugBank.d551.s5|a|Other drugs have not been studied.
DDI-DrugBank.d551.s6|a|When administering other drugs for which alterations in blood levels could have a clinically significant effect on safety or efficacy, physicians should consider monitoring drug levels or effects.
DDI-DrugBank.d345.s0|a|Since colestipol hydrochloride is an anion exchange resin, it may have a strong affinity for anions other than the bile acids.
DDI-DrugBank.d345.s0	6	29	colestipol hydrochloride	drug	DDI-DrugBank.d345.s0.e0
DDI-DrugBank.d345.s0	37	56	anion exchange resin	group	DDI-DrugBank.d345.s0.e1
DDI-DrugBank.d345.s0	false	DDI-DrugBank.d345.s0.e0	DDI-DrugBank.d345.s0.e1
DDI-DrugBank.d345.s1|a|In vitro studies have indicated that colestipol hydrochloride binds a number of drugs.
DDI-DrugBank.d345.s1	37	60	colestipol hydrochloride	drug	DDI-DrugBank.d345.s1.e0
DDI-DrugBank.d345.s2|a|Therefore, COLESTlD Tablets may delay or reduce the absorption of concomitant oral medication.
DDI-DrugBank.d345.s2	11	18	COLESTlD	brand	DDI-DrugBank.d345.s2.e0
DDI-DrugBank.d345.s3|a|The interval between the administration of COLESTID Tablets and any other medication should be as long as possible.
DDI-DrugBank.d345.s3	43	50	COLESTID	brand	DDI-DrugBank.d345.s3.e0
DDI-DrugBank.d345.s4|a|Patients should take other drugs at least one hour before or four hours after COLESTID Tablets to avoid impeding their absorption.
DDI-DrugBank.d345.s4	78	85	COLESTID	brand	DDI-DrugBank.d345.s4.e0
DDI-DrugBank.d345.s5|a|Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.
DDI-DrugBank.d345.s5	18	41	colestipol hydrochloride	drug	DDI-DrugBank.d345.s5.e0
DDI-DrugBank.d345.s5	75	85	propranolol	drug	DDI-DrugBank.d345.s5.e1
DDI-DrugBank.d345.s5	134	144	propranolol	drug	DDI-DrugBank.d345.s5.e2
DDI-DrugBank.d345.s5	true	DDI-DrugBank.d345.s5.e0	DDI-DrugBank.d345.s5.e1
DDI-DrugBank.d345.s5	false	DDI-DrugBank.d345.s5.e0	DDI-DrugBank.d345.s5.e2
DDI-DrugBank.d345.s5	false	DDI-DrugBank.d345.s5.e1	DDI-DrugBank.d345.s5.e2
DDI-DrugBank.d345.s6|a|However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;
DDI-DrugBank.d345.s6	80	103	colestipol hydrochloride	drug	DDI-DrugBank.d345.s6.e0
DDI-DrugBank.d345.s6	109	119	propranolol	drug	DDI-DrugBank.d345.s6.e1
DDI-DrugBank.d345.s6	207	217	propranolol	drug	DDI-DrugBank.d345.s6.e2
DDI-DrugBank.d345.s6	false	DDI-DrugBank.d345.s6.e0	DDI-DrugBank.d345.s6.e1
DDI-DrugBank.d345.s6	false	DDI-DrugBank.d345.s6.e0	DDI-DrugBank.d345.s6.e2
DDI-DrugBank.d345.s6	false	DDI-DrugBank.d345.s6.e1	DDI-DrugBank.d345.s6.e2
DDI-DrugBank.d345.s7|a|the time to reach maximum concentration was delayed approximately 30 minutes.
DDI-DrugBank.d345.s8|a|Effects on the absorption of other beta-blockers have not been determined.
DDI-DrugBank.d345.s8	35	47	beta-blockers	group	DDI-DrugBank.d345.s8.e0
DDI-DrugBank.d345.s9|a|Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.
DDI-DrugBank.d345.s9	23	33	propranolol	drug	DDI-DrugBank.d345.s9.e0
DDI-DrugBank.d345.s9	59	66	COLESTID	brand	DDI-DrugBank.d345.s9.e1
DDI-DrugBank.d345.s9	true	DDI-DrugBank.d345.s9.e0	DDI-DrugBank.d345.s9.e1
DDI-DrugBank.d345.s10|a|Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride.
DDI-DrugBank.d345.s10	46	59	chlorothiazide	drug	DDI-DrugBank.d345.s10.e0
DDI-DrugBank.d345.s10	156	179	colestipol hydrochloride	drug	DDI-DrugBank.d345.s10.e1
DDI-DrugBank.d345.s10	true	DDI-DrugBank.d345.s10.e0	DDI-DrugBank.d345.s10.e1
DDI-DrugBank.d345.s11|a|The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
DDI-DrugBank.d345.s11	18	29	tetracycline	drug	DDI-DrugBank.d345.s11.e0
DDI-DrugBank.d345.s11	32	41	furosemide	drug	DDI-DrugBank.d345.s11.e1
DDI-DrugBank.d345.s11	44	55	penicillin G	drug	DDI-DrugBank.d345.s11.e2
DDI-DrugBank.d345.s11	58	76	hydrochlorothiazide	drug	DDI-DrugBank.d345.s11.e3
DDI-DrugBank.d345.s11	83	93	gemfibrozil	drug	DDI-DrugBank.d345.s11.e4
DDI-DrugBank.d345.s11	154	177	colestipol hydrochloride	drug	DDI-DrugBank.d345.s11.e5
DDI-DrugBank.d345.s11	false	DDI-DrugBank.d345.s11.e0	DDI-DrugBank.d345.s11.e1
DDI-DrugBank.d345.s11	false	DDI-DrugBank.d345.s11.e0	DDI-DrugBank.d345.s11.e2
DDI-DrugBank.d345.s11	false	DDI-DrugBank.d345.s11.e0	DDI-DrugBank.d345.s11.e3
DDI-DrugBank.d345.s11	false	DDI-DrugBank.d345.s11.e0	DDI-DrugBank.d345.s11.e4
DDI-DrugBank.d345.s11	true	DDI-DrugBank.d345.s11.e0	DDI-DrugBank.d345.s11.e5
DDI-DrugBank.d345.s11	false	DDI-DrugBank.d345.s11.e1	DDI-DrugBank.d345.s11.e2
DDI-DrugBank.d345.s11	false	DDI-DrugBank.d345.s11.e1	DDI-DrugBank.d345.s11.e3
DDI-DrugBank.d345.s11	false	DDI-DrugBank.d345.s11.e1	DDI-DrugBank.d345.s11.e4
DDI-DrugBank.d345.s11	true	DDI-DrugBank.d345.s11.e1	DDI-DrugBank.d345.s11.e5
DDI-DrugBank.d345.s11	false	DDI-DrugBank.d345.s11.e2	DDI-DrugBank.d345.s11.e3
DDI-DrugBank.d345.s12|a|these drugs were not tested to determine the effect of administration one hour before colestipol hydrochloride.
DDI-DrugBank.d345.s12	86	109	colestipol hydrochloride	drug	DDI-DrugBank.d345.s12.e0
DDI-DrugBank.d345.s13|a|No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.
DDI-DrugBank.d345.s13	62	85	colestipol hydrochloride	drug	DDI-DrugBank.d345.s13.e0
DDI-DrugBank.d345.s13	137	143	aspirin	brand	DDI-DrugBank.d345.s13.e1
DDI-DrugBank.d345.s13	146	156	clindamycin	brand	DDI-DrugBank.d345.s13.e2
DDI-DrugBank.d345.s13	159	168	clofibrate	drug	DDI-DrugBank.d345.s13.e3
DDI-DrugBank.d345.s13	171	180	methyldopa	drug	DDI-DrugBank.d345.s13.e4
DDI-DrugBank.d345.s13	183	196	nicotinic acid	drug	DDI-DrugBank.d345.s13.e5
DDI-DrugBank.d345.s13	199	204	niacin	drug	DDI-DrugBank.d345.s13.e6
DDI-DrugBank.d345.s13	208	218	tolbutamide	drug	DDI-DrugBank.d345.s13.e7
DDI-DrugBank.d345.s13	221	229	phenytoin	drug	DDI-DrugBank.d345.s13.e8
DDI-DrugBank.d345.s13	234	241	warfarin	drug	DDI-DrugBank.d345.s13.e9
DDI-DrugBank.d345.s13	false	DDI-DrugBank.d345.s13.e0	DDI-DrugBank.d345.s13.e1
DDI-DrugBank.d345.s13	false	DDI-DrugBank.d345.s13.e0	DDI-DrugBank.d345.s13.e2
DDI-DrugBank.d345.s13	false	DDI-DrugBank.d345.s13.e0	DDI-DrugBank.d345.s13.e3
DDI-DrugBank.d345.s13	false	DDI-DrugBank.d345.s13.e0	DDI-DrugBank.d345.s13.e4
DDI-DrugBank.d345.s13	false	DDI-DrugBank.d345.s13.e0	DDI-DrugBank.d345.s13.e5
DDI-DrugBank.d345.s13	false	DDI-DrugBank.d345.s13.e0	DDI-DrugBank.d345.s13.e6
DDI-DrugBank.d345.s13	false	DDI-DrugBank.d345.s13.e0	DDI-DrugBank.d345.s13.e7
DDI-DrugBank.d345.s13	false	DDI-DrugBank.d345.s13.e0	DDI-DrugBank.d345.s13.e8
DDI-DrugBank.d345.s13	false	DDI-DrugBank.d345.s13.e0	DDI-DrugBank.d345.s13.e9
DDI-DrugBank.d345.s13	false	DDI-DrugBank.d345.s13.e1	DDI-DrugBank.d345.s13.e2
DDI-DrugBank.d345.s14|a|Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
DDI-DrugBank.d345.s14	43	64	digitalis preparations	group	DDI-DrugBank.d345.s14.e0
DDI-DrugBank.d345.s14	120	143	colestipol hydrochloride	drug	DDI-DrugBank.d345.s14.e1
DDI-DrugBank.d345.s14	168	174	digoxin	drug	DDI-DrugBank.d345.s14.e2
DDI-DrugBank.d345.s14	180	188	digitoxin	drug	DDI-DrugBank.d345.s14.e3
DDI-DrugBank.d345.s14	true	DDI-DrugBank.d345.s14.e0	DDI-DrugBank.d345.s14.e1
DDI-DrugBank.d345.s14	false	DDI-DrugBank.d345.s14.e0	DDI-DrugBank.d345.s14.e2
DDI-DrugBank.d345.s14	false	DDI-DrugBank.d345.s14.e0	DDI-DrugBank.d345.s14.e3
DDI-DrugBank.d345.s14	true	DDI-DrugBank.d345.s14.e1	DDI-DrugBank.d345.s14.e2
DDI-DrugBank.d345.s14	true	DDI-DrugBank.d345.s14.e1	DDI-DrugBank.d345.s14.e3
DDI-DrugBank.d345.s14	false	DDI-DrugBank.d345.s14.e2	DDI-DrugBank.d345.s14.e3
DDI-DrugBank.d345.s15|a|The potential for binding of these drugs if given concomitantly is present.
DDI-DrugBank.d345.s16|a|Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.
DDI-DrugBank.d345.s16	14	37	colestipol hydrochloride	drug	DDI-DrugBank.d345.s16.e0
DDI-DrugBank.d345.s16	132	136	resin	group	DDI-DrugBank.d345.s16.e1
DDI-DrugBank.d345.s16	208	231	colestipol hydrochloride	drug	DDI-DrugBank.d345.s16.e2
DDI-DrugBank.d345.s16	false	DDI-DrugBank.d345.s16.e0	DDI-DrugBank.d345.s16.e1
DDI-DrugBank.d345.s16	false	DDI-DrugBank.d345.s16.e0	DDI-DrugBank.d345.s16.e2
DDI-DrugBank.d345.s16	false	DDI-DrugBank.d345.s16.e1	DDI-DrugBank.d345.s16.e2
DDI-DrugBank.d345.s17|a|Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.
DDI-DrugBank.d345.s17	0	23	Bile acid binding resins	group	DDI-DrugBank.d345.s17.e0
DDI-DrugBank.d345.s17	72	80	phosphate	drug	DDI-DrugBank.d345.s17.e1
DDI-DrugBank.d345.s17	98	111	hydrocortisone	drug	DDI-DrugBank.d345.s17.e2
DDI-DrugBank.d345.s17	true	DDI-DrugBank.d345.s17.e0	DDI-DrugBank.d345.s17.e1
DDI-DrugBank.d345.s17	true	DDI-DrugBank.d345.s17.e0	DDI-DrugBank.d345.s17.e2
DDI-DrugBank.d345.s17	false	DDI-DrugBank.d345.s17.e1	DDI-DrugBank.d345.s17.e2
DDI-DrugBank.d250.s0|a|Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction.
DDI-DrugBank.d250.s0	14	24	antibiotics	group	DDI-DrugBank.d250.s0.e0
DDI-DrugBank.d250.s0	27	41	aminoglycosides	group	DDI-DrugBank.d250.s0.e1
DDI-DrugBank.d250.s0	47	55	polymyxin	group	DDI-DrugBank.d250.s0.e2
DDI-DrugBank.d250.s0	false	DDI-DrugBank.d250.s0.e0	DDI-DrugBank.d250.s0.e1
DDI-DrugBank.d250.s0	false	DDI-DrugBank.d250.s0.e0	DDI-DrugBank.d250.s0.e2
DDI-DrugBank.d250.s0	false	DDI-DrugBank.d250.s0.e1	DDI-DrugBank.d250.s0.e2
DDI-DrugBank.d250.s1|a|Based on this reported activity, they should not be given concomitantly with Coly-Mycin M Parenteral except with the greatest caution.
DDI-DrugBank.d250.s1	77	88	Coly-Mycin M	brand	DDI-DrugBank.d250.s1.e0
DDI-DrugBank.d250.s2|a|Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
DDI-DrugBank.d250.s2	0	26	Curariform muscle relaxants	brand	DDI-DrugBank.d250.s2.e0
DDI-DrugBank.d250.s2	33	44	tubocurarine	drug	DDI-DrugBank.d250.s2.e1
DDI-DrugBank.d250.s2	81	95	succinylcholine	drug	DDI-DrugBank.d250.s2.e2
DDI-DrugBank.d250.s2	98	106	gallamine	drug	DDI-DrugBank.d250.s2.e3
DDI-DrugBank.d250.s2	109	121	decamethonium	drug	DDI-DrugBank.d250.s2.e4
DDI-DrugBank.d250.s2	127	140	sodium citrate	drug	DDI-DrugBank.d250.s2.e5
DDI-DrugBank.d250.s2	259	270	Coly-Mycin M	brand	DDI-DrugBank.d250.s2.e6
DDI-DrugBank.d250.s2	false	DDI-DrugBank.d250.s2.e0	DDI-DrugBank.d250.s2.e1
DDI-DrugBank.d250.s2	false	DDI-DrugBank.d250.s2.e0	DDI-DrugBank.d250.s2.e2
DDI-DrugBank.d250.s2	false	DDI-DrugBank.d250.s2.e0	DDI-DrugBank.d250.s2.e3
DDI-DrugBank.d250.s2	false	DDI-DrugBank.d250.s2.e0	DDI-DrugBank.d250.s2.e4
DDI-DrugBank.d250.s2	false	DDI-DrugBank.d250.s2.e0	DDI-DrugBank.d250.s2.e5
DDI-DrugBank.d250.s2	true	DDI-DrugBank.d250.s2.e0	DDI-DrugBank.d250.s2.e6
DDI-DrugBank.d250.s2	false	DDI-DrugBank.d250.s2.e1	DDI-DrugBank.d250.s2.e2
DDI-DrugBank.d250.s2	false	DDI-DrugBank.d250.s2.e1	DDI-DrugBank.d250.s2.e3
DDI-DrugBank.d250.s2	false	DDI-DrugBank.d250.s2.e1	DDI-DrugBank.d250.s2.e4
DDI-DrugBank.d250.s2	false	DDI-DrugBank.d250.s2.e1	DDI-DrugBank.d250.s2.e5
DDI-DrugBank.d250.s3|a|Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.
DDI-DrugBank.d250.s3	0	17	Sodium cephalothin	drug	DDI-DrugBank.d250.s3.e0
DDI-DrugBank.d250.s3	53	64	Coly-Mycin M	brand	DDI-DrugBank.d250.s3.e1
DDI-DrugBank.d250.s3	true	DDI-DrugBank.d250.s3.e0	DDI-DrugBank.d250.s3.e1
DDI-DrugBank.d250.s4|a|The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.
DDI-DrugBank.d250.s4	23	40	sodium cephalothin	drug	DDI-DrugBank.d250.s4.e0
DDI-DrugBank.d250.s4	46	57	Coly-Mycin M	brand	DDI-DrugBank.d250.s4.e1
DDI-DrugBank.d250.s4	true	DDI-DrugBank.d250.s4.e0	DDI-DrugBank.d250.s4.e1
DDI-DrugBank.d315.s0|a|Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
DDI-DrugBank.d315.s0	0	6	Digoxin	drug	DDI-DrugBank.d315.s0.e0
DDI-DrugBank.d315.s0	29	35	digoxin	drug	DDI-DrugBank.d315.s0.e1
DDI-DrugBank.d315.s0	76	85	conivaptan	drug	DDI-DrugBank.d315.s0.e2
DDI-DrugBank.d315.s0	143	149	digoxin	drug	DDI-DrugBank.d315.s0.e3
DDI-DrugBank.d315.s0	false	DDI-DrugBank.d315.s0.e0	DDI-DrugBank.d315.s0.e1
DDI-DrugBank.d315.s0	false	DDI-DrugBank.d315.s0.e0	DDI-DrugBank.d315.s0.e2
DDI-DrugBank.d315.s0	false	DDI-DrugBank.d315.s0.e0	DDI-DrugBank.d315.s0.e3
DDI-DrugBank.d315.s0	true	DDI-DrugBank.d315.s0.e1	DDI-DrugBank.d315.s0.e2
DDI-DrugBank.d315.s0	false	DDI-DrugBank.d315.s0.e1	DDI-DrugBank.d315.s0.e3
DDI-DrugBank.d315.s0	false	DDI-DrugBank.d315.s0.e2	DDI-DrugBank.d315.s0.e3
DDI-DrugBank.d315.s1|a|Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.
DDI-DrugBank.d315.s1	14	20	digoxin	drug	DDI-DrugBank.d315.s1.e0
DDI-DrugBank.d315.s1	43	50	VAPRISOL	brand	DDI-DrugBank.d315.s1.e1
DDI-DrugBank.d315.s1	118	124	digoxin	drug	DDI-DrugBank.d315.s1.e2
DDI-DrugBank.d315.s1	true	DDI-DrugBank.d315.s1.e0	DDI-DrugBank.d315.s1.e1
DDI-DrugBank.d315.s1	false	DDI-DrugBank.d315.s1.e0	DDI-DrugBank.d315.s1.e2
DDI-DrugBank.d315.s1	false	DDI-DrugBank.d315.s1.e1	DDI-DrugBank.d315.s1.e2
DDI-DrugBank.d317.s0|a|DRUG/LABORATORY TEST INTERACTIONS 1.
DDI-DrugBank.d317.s1|a|Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time;
DDI-DrugBank.d317.s2|a|increased platelet count;
DDI-DrugBank.d317.s3|a|increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin;
DDI-DrugBank.d317.s4|a|decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;
DDI-DrugBank.d317.s4	39	54	antithrombin III	drug	DDI-DrugBank.d317.s4.e0
DDI-DrugBank.d317.s4	67	82	antithrombin III	drug	DDI-DrugBank.d317.s4.e1
DDI-DrugBank.d317.s4	false	DDI-DrugBank.d317.s4.e0	DDI-DrugBank.d317.s4.e1
DDI-DrugBank.d317.s5|a|increased levels of fibrinogen and fibrinogen activity;
DDI-DrugBank.d317.s5	20	29	fibrinogen	drug	DDI-DrugBank.d317.s5.e0
DDI-DrugBank.d317.s5	35	44	fibrinogen	drug	DDI-DrugBank.d317.s5.e1
DDI-DrugBank.d317.s5	false	DDI-DrugBank.d317.s5.e0	DDI-DrugBank.d317.s5.e1
DDI-DrugBank.d317.s6|a|increased plasminogen antigen and activity.
DDI-DrugBank.d317.s7|a|2.
DDI-DrugBank.d317.s8|a|Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.
DDI-DrugBank.d317.s8	139	144	iodine	drug	DDI-DrugBank.d317.s8.e0
DDI-DrugBank.d317.s9|a|T3 resin uptake is decreased, reflecting the elevated TBG.
DDI-DrugBank.d317.s10|a|Free T4 and free T3 concentrations are unaltered.
DDI-DrugBank.d317.s11|a|Patients on thyroid replacement therapy may require higher doses of thyroid hormone.
DDI-DrugBank.d317.s11	68	82	thyroid hormone	group	DDI-DrugBank.d317.s11.e0
DDI-DrugBank.d317.s12|a|3.
DDI-DrugBank.d317.s13|a|Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively.
DDI-DrugBank.d317.s13	171	185	corticosteroids	group	DDI-DrugBank.d317.s13.e0
DDI-DrugBank.d317.s13	191	202	sex steroids	group	DDI-DrugBank.d317.s13.e1
DDI-DrugBank.d317.s13	false	DDI-DrugBank.d317.s13.e0	DDI-DrugBank.d317.s13.e1
DDI-DrugBank.d317.s14|a|Free hormone concentrations may be decreased.
DDI-DrugBank.d317.s15|a|Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
DDI-DrugBank.d317.s16|a|4.
DDI-DrugBank.d317.s17|a|Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.
DDI-DrugBank.d317.s18|a|5.
DDI-DrugBank.d317.s19|a|Impaired glucose tolerance.
DDI-DrugBank.d317.s20|a|6.
DDI-DrugBank.d317.s21|a|Reduced response to metyrapone test.
DDI-DrugBank.d25.s0|a|Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
DDI-DrugBank.d25.s0	0	12	Corticotropin	drug	DDI-DrugBank.d25.s0.e0
DDI-DrugBank.d25.s0	66	73	diuretic	drug	DDI-DrugBank.d25.s0.e1
DDI-DrugBank.d25.s0	true	DDI-DrugBank.d25.s0.e0	DDI-DrugBank.d25.s0.e1
DDI-DrugBank.d487.s0|a|The pharmacokinetic interactions listed below are potentially clinically important.
DDI-DrugBank.d487.s1|a|Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d487.s1	42	54	phenobarbital	drug	DDI-DrugBank.d487.s1.e0
DDI-DrugBank.d487.s1	57	65	phenytoin	drug	DDI-DrugBank.d487.s1.e1
DDI-DrugBank.d487.s1	71	78	rifampin	drug	DDI-DrugBank.d487.s1.e2
DDI-DrugBank.d487.s1	110	124	corticosteroids	group	DDI-DrugBank.d487.s1.e3
DDI-DrugBank.d487.s1	155	168	corticosteroid	group	DDI-DrugBank.d487.s1.e4
DDI-DrugBank.d487.s1	false	DDI-DrugBank.d487.s1.e0	DDI-DrugBank.d487.s1.e1
DDI-DrugBank.d487.s1	false	DDI-DrugBank.d487.s1.e0	DDI-DrugBank.d487.s1.e2
DDI-DrugBank.d487.s1	true	DDI-DrugBank.d487.s1.e0	DDI-DrugBank.d487.s1.e3
DDI-DrugBank.d487.s1	true	DDI-DrugBank.d487.s1.e0	DDI-DrugBank.d487.s1.e4
DDI-DrugBank.d487.s1	false	DDI-DrugBank.d487.s1.e1	DDI-DrugBank.d487.s1.e2
DDI-DrugBank.d487.s1	true	DDI-DrugBank.d487.s1.e1	DDI-DrugBank.d487.s1.e3
DDI-DrugBank.d487.s1	true	DDI-DrugBank.d487.s1.e1	DDI-DrugBank.d487.s1.e4
DDI-DrugBank.d487.s1	true	DDI-DrugBank.d487.s1.e2	DDI-DrugBank.d487.s1.e3
DDI-DrugBank.d487.s1	true	DDI-DrugBank.d487.s1.e2	DDI-DrugBank.d487.s1.e4
DDI-DrugBank.d487.s1	false	DDI-DrugBank.d487.s1.e3	DDI-DrugBank.d487.s1.e4
DDI-DrugBank.d487.s2|a|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
DDI-DrugBank.d487.s2	14	27	troleandomycin	drug	DDI-DrugBank.d487.s2.e0
DDI-DrugBank.d487.s2	33	44	ketoconazole	drug	DDI-DrugBank.d487.s2.e1
DDI-DrugBank.d487.s2	76	90	corticosteroids	group	DDI-DrugBank.d487.s2.e2
DDI-DrugBank.d487.s2	false	DDI-DrugBank.d487.s2.e0	DDI-DrugBank.d487.s2.e1
DDI-DrugBank.d487.s2	true	DDI-DrugBank.d487.s2.e0	DDI-DrugBank.d487.s2.e2
DDI-DrugBank.d487.s2	true	DDI-DrugBank.d487.s2.e1	DDI-DrugBank.d487.s2.e2
DDI-DrugBank.d487.s3|a|Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity.
DDI-DrugBank.d487.s3	23	36	corticosteroid	group	DDI-DrugBank.d487.s3.e0
DDI-DrugBank.d487.s4|a|Corticosteroids may increase the clearance of chronic high dose aspirin.
DDI-DrugBank.d487.s4	0	14	Corticosteroids	group	DDI-DrugBank.d487.s4.e0
DDI-DrugBank.d487.s4	64	70	aspirin	brand	DDI-DrugBank.d487.s4.e1
DDI-DrugBank.d487.s4	true	DDI-DrugBank.d487.s4.e0	DDI-DrugBank.d487.s4.e1
DDI-DrugBank.d487.s5|a|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
DDI-DrugBank.d487.s5	29	38	salicylate	group	DDI-DrugBank.d487.s5.e0
DDI-DrugBank.d487.s5	77	86	salicylate	group	DDI-DrugBank.d487.s5.e1
DDI-DrugBank.d487.s5	102	115	corticosteroid	drug	DDI-DrugBank.d487.s5.e2
DDI-DrugBank.d487.s5	false	DDI-DrugBank.d487.s5.e0	DDI-DrugBank.d487.s5.e1
DDI-DrugBank.d487.s5	false	DDI-DrugBank.d487.s5.e0	DDI-DrugBank.d487.s5.e2
DDI-DrugBank.d487.s5	true	DDI-DrugBank.d487.s5.e1	DDI-DrugBank.d487.s5.e2
DDI-DrugBank.d487.s6|a|Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.
DDI-DrugBank.d487.s6	0	6	Aspirin	brand	DDI-DrugBank.d487.s6.e0
DDI-DrugBank.d487.s6	54	69	cortico-steroids	group	DDI-DrugBank.d487.s6.e1
DDI-DrugBank.d487.s6	true	DDI-DrugBank.d487.s6.e0	DDI-DrugBank.d487.s6.e1
DDI-DrugBank.d487.s7|a|The effect of corticosteroids on oral anticoagulants is variable.
DDI-DrugBank.d487.s7	14	28	corticosteroids	group	DDI-DrugBank.d487.s7.e0
DDI-DrugBank.d487.s7	38	51	anticoagulants	group	DDI-DrugBank.d487.s7.e1
DDI-DrugBank.d487.s7	true	DDI-DrugBank.d487.s7.e0	DDI-DrugBank.d487.s7.e1
DDI-DrugBank.d487.s8|a|There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
DDI-DrugBank.d487.s8	63	76	anticoagulants	group	DDI-DrugBank.d487.s8.e0
DDI-DrugBank.d487.s8	107	121	corticosteroids	group	DDI-DrugBank.d487.s8.e1
DDI-DrugBank.d487.s8	true	DDI-DrugBank.d487.s8.e0	DDI-DrugBank.d487.s8.e1
DDI-DrugBank.d487.s9|a|Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.
DDI-DrugBank.d439.s0|a|Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
DDI-DrugBank.d439.s0	0	12	Corticotropin	drug	DDI-DrugBank.d439.s0.e0
DDI-DrugBank.d439.s0	66	73	diuretic	group	DDI-DrugBank.d439.s0.e1
DDI-DrugBank.d439.s0	true	DDI-DrugBank.d439.s0.e0	DDI-DrugBank.d439.s0.e1
DDI-DrugBank.d229.s0|a|Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.
DDI-DrugBank.d229.s0	35	49	Cromolyn sodium	drug	DDI-DrugBank.d229.s0.e0
DDI-DrugBank.d229.s0	55	67	isoproterenol	drug	DDI-DrugBank.d229.s0.e1
DDI-DrugBank.d229.s0	false	DDI-DrugBank.d229.s0.e0	DDI-DrugBank.d229.s0.e1
DDI-DrugBank.d229.s1|a|Cromolyn sodium alone in doses up to 540 mg/kg/day (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) did not cause significant increases in resorptions or major malformations.
DDI-DrugBank.d229.s1	0	14	Cromolyn sodium	drug	DDI-DrugBank.d229.s1.e0
DDI-DrugBank.d229.s2|a|Isoproterenol alone at a dose of 2.7 mg/kg/day (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) increased both resorptions and malformations.
DDI-DrugBank.d229.s2	0	12	Isoproterenol	drug	DDI-DrugBank.d229.s2.e0
DDI-DrugBank.d229.s3|a|The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.
DDI-DrugBank.d229.s3	33	47	cromolyn sodium	drug	DDI-DrugBank.d229.s3.e0
DDI-DrugBank.d229.s3	168	180	isoproterenol	drug	DDI-DrugBank.d229.s3.e1
DDI-DrugBank.d229.s3	true	DDI-DrugBank.d229.s3.e0	DDI-DrugBank.d229.s3.e1
DDI-DrugBank.d349.s0|a|None known.
DDI-DrugBank.d39.s0|a|Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.
DDI-DrugBank.d39.s0	20	30	antibiotics	group	DDI-DrugBank.d39.s0.e0
DDI-DrugBank.d39.s0	33	44	methotrexate	drug	DDI-DrugBank.d39.s0.e1
DDI-DrugBank.d39.s0	50	62	pyrimethamine	drug	DDI-DrugBank.d39.s0.e2
DDI-DrugBank.d39.s0	75	84	folic acid	drug	DDI-DrugBank.d39.s0.e3
DDI-DrugBank.d39.s0	90	100	vitamin B12	drug	DDI-DrugBank.d39.s0.e4
DDI-DrugBank.d39.s0	false	DDI-DrugBank.d39.s0.e0	DDI-DrugBank.d39.s0.e1
DDI-DrugBank.d39.s0	false	DDI-DrugBank.d39.s0.e0	DDI-DrugBank.d39.s0.e2
DDI-DrugBank.d39.s0	false	DDI-DrugBank.d39.s0.e0	DDI-DrugBank.d39.s0.e3
DDI-DrugBank.d39.s0	false	DDI-DrugBank.d39.s0.e0	DDI-DrugBank.d39.s0.e4
DDI-DrugBank.d39.s0	false	DDI-DrugBank.d39.s0.e1	DDI-DrugBank.d39.s0.e2
DDI-DrugBank.d39.s0	false	DDI-DrugBank.d39.s0.e1	DDI-DrugBank.d39.s0.e3
DDI-DrugBank.d39.s0	false	DDI-DrugBank.d39.s0.e1	DDI-DrugBank.d39.s0.e4
DDI-DrugBank.d39.s0	false	DDI-DrugBank.d39.s0.e2	DDI-DrugBank.d39.s0.e3
DDI-DrugBank.d39.s0	false	DDI-DrugBank.d39.s0.e2	DDI-DrugBank.d39.s0.e4
DDI-DrugBank.d39.s0	false	DDI-DrugBank.d39.s0.e3	DDI-DrugBank.d39.s0.e4
DDI-DrugBank.d39.s1|a|Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
DDI-DrugBank.d39.s1	0	9	Colchicine	drug	DDI-DrugBank.d39.s1.e0
DDI-DrugBank.d39.s1	11	34	para-aminosalicylic acid	drug	DDI-DrugBank.d39.s1.e1
DDI-DrugBank.d39.s1	46	52	alcohol	drug	DDI-DrugBank.d39.s1.e2
DDI-DrugBank.d39.s1	114	124	vitamin B12	drug	DDI-DrugBank.d39.s1.e3
DDI-DrugBank.d39.s1	false	DDI-DrugBank.d39.s1.e0	DDI-DrugBank.d39.s1.e1
DDI-DrugBank.d39.s1	false	DDI-DrugBank.d39.s1.e0	DDI-DrugBank.d39.s1.e2
DDI-DrugBank.d39.s1	true	DDI-DrugBank.d39.s1.e0	DDI-DrugBank.d39.s1.e3
DDI-DrugBank.d39.s1	false	DDI-DrugBank.d39.s1.e1	DDI-DrugBank.d39.s1.e2
DDI-DrugBank.d39.s1	true	DDI-DrugBank.d39.s1.e1	DDI-DrugBank.d39.s1.e3
DDI-DrugBank.d39.s1	true	DDI-DrugBank.d39.s1.e2	DDI-DrugBank.d39.s1.e3
DDI-DrugBank.d150.s0|a|FLEXERIL may have life-threatening interactions with MAO inhibitors.
DDI-DrugBank.d150.s0	0	7	FLEXERIL	brand	DDI-DrugBank.d150.s0.e0
DDI-DrugBank.d150.s0	53	66	MAO inhibitors	group	DDI-DrugBank.d150.s0.e1
DDI-DrugBank.d150.s0	true	DDI-DrugBank.d150.s0.e0	DDI-DrugBank.d150.s0.e1
DDI-DrugBank.d150.s1|a|FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
DDI-DrugBank.d150.s1	0	7	FLEXERIL	brand	DDI-DrugBank.d150.s1.e0
DDI-DrugBank.d150.s1	36	42	alcohol	drug	DDI-DrugBank.d150.s1.e1
DDI-DrugBank.d150.s1	45	56	barbiturates	group	DDI-DrugBank.d150.s1.e2
DDI-DrugBank.d150.s1	69	83	CNS depressants	group	DDI-DrugBank.d150.s1.e3
DDI-DrugBank.d150.s1	true	DDI-DrugBank.d150.s1.e0	DDI-DrugBank.d150.s1.e1
DDI-DrugBank.d150.s1	true	DDI-DrugBank.d150.s1.e0	DDI-DrugBank.d150.s1.e2
DDI-DrugBank.d150.s1	true	DDI-DrugBank.d150.s1.e0	DDI-DrugBank.d150.s1.e3
DDI-DrugBank.d150.s1	false	DDI-DrugBank.d150.s1.e1	DDI-DrugBank.d150.s1.e2
DDI-DrugBank.d150.s1	false	DDI-DrugBank.d150.s1.e1	DDI-DrugBank.d150.s1.e3
DDI-DrugBank.d150.s1	false	DDI-DrugBank.d150.s1.e2	DDI-DrugBank.d150.s1.e3
DDI-DrugBank.d150.s2|a|Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.
DDI-DrugBank.d150.s2	0	24	Tricyclic antidepressants	group	DDI-DrugBank.d150.s2.e0
DDI-DrugBank.d150.s2	67	78	guanethidine	drug	DDI-DrugBank.d150.s2.e1
DDI-DrugBank.d150.s2	true	DDI-DrugBank.d150.s2.e0	DDI-DrugBank.d150.s2.e1
DDI-DrugBank.d150.s3|a|Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol
DDI-DrugBank.d150.s3	0	24	Tricyclic antidepressants	group	DDI-DrugBank.d150.s3.e0
DDI-DrugBank.d150.s3	74	81	tramadol	drug	DDI-DrugBank.d150.s3.e1
DDI-DrugBank.d150.s3	true	DDI-DrugBank.d150.s3.e0	DDI-DrugBank.d150.s3.e1
DDI-DrugBank.d150.s4|a|.
DDI-DrugBank.d150.s5|a|
DDI-DrugBank.d298.s0|a|Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
DDI-DrugBank.d298.s0	0	13	Cyclopentolate	drug	DDI-DrugBank.d298.s0.e0
DDI-DrugBank.d298.s0	62	70	carbachol	drug	DDI-DrugBank.d298.s0.e1
DDI-DrugBank.d298.s0	75	85	pilocarpine	drug	DDI-DrugBank.d298.s0.e2
DDI-DrugBank.d298.s0	true	DDI-DrugBank.d298.s0.e0	DDI-DrugBank.d298.s0.e1
DDI-DrugBank.d298.s0	true	DDI-DrugBank.d298.s0.e0	DDI-DrugBank.d298.s0.e2
DDI-DrugBank.d298.s0	false	DDI-DrugBank.d298.s0.e1	DDI-DrugBank.d298.s0.e2
DDI-DrugBank.d298.s1|a|also, concurrent use of this medication may antagonise the anti-glaucoma and miotic actions of ophthalmic cholinesterase inhibitors.
DDI-DrugBank.d298.s1	106	130	cholinesterase inhibitors	group	DDI-DrugBank.d298.s1.e0
DDI-DrugBank.d7.s0|a|The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.
DDI-DrugBank.d7.s0	54	69	cyclophosphamide	drug	DDI-DrugBank.d7.s0.e0
DDI-DrugBank.d7.s0	139	151	phenobarbital	drug	DDI-DrugBank.d7.s0.e1
DDI-DrugBank.d7.s0	true	DDI-DrugBank.d7.s0.e0	DDI-DrugBank.d7.s0.e1
DDI-DrugBank.d7.s1|a|The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.
DDI-DrugBank.d7.s1	102	117	cyclophosphamide	drug	DDI-DrugBank.d7.s1.e0
DDI-DrugBank.d7.s1	131	146	cyclophosphamide	drug	DDI-DrugBank.d7.s1.e1
DDI-DrugBank.d7.s1	false	DDI-DrugBank.d7.s1.e0	DDI-DrugBank.d7.s1.e1
DDI-DrugBank.d7.s2|a|Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.
DDI-DrugBank.d7.s2	0	15	Cyclophosphamide	drug	DDI-DrugBank.d7.s2.e0
DDI-DrugBank.d7.s2	130	153	succinylcholine chloride	drug	DDI-DrugBank.d7.s2.e1
DDI-DrugBank.d7.s2	true	DDI-DrugBank.d7.s2.e0	DDI-DrugBank.d7.s2.e1
DDI-DrugBank.d7.s3|a|If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.
DDI-DrugBank.d7.s3	35	50	cyclophosphamide	drug	DDI-DrugBank.d7.s3.e0
DDI-DrugBank.d128.s0|a|May interact with wthionamide (Trecator-SC) and isoniazid (Nydrazid).
DDI-DrugBank.d128.s0	31	41	Trecator-SC	brand	DDI-DrugBank.d128.s0.e0
DDI-DrugBank.d128.s0	48	56	isoniazid	drug	DDI-DrugBank.d128.s0.e1
DDI-DrugBank.d128.s0	59	66	Nydrazid	brand	DDI-DrugBank.d128.s0.e2
DDI-DrugBank.d128.s0	false	DDI-DrugBank.d128.s0.e0	DDI-DrugBank.d128.s0.e1
DDI-DrugBank.d128.s0	false	DDI-DrugBank.d128.s0.e0	DDI-DrugBank.d128.s0.e2
DDI-DrugBank.d128.s0	false	DDI-DrugBank.d128.s0.e1	DDI-DrugBank.d128.s0.e2
DDI-DrugBank.d492.s0|a|MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
DDI-DrugBank.d492.s0	0	13	MAO inhibitors	group	DDI-DrugBank.d492.s0.e0
DDI-DrugBank.d492.s0	68	81	antihistamines	group	DDI-DrugBank.d492.s0.e1
DDI-DrugBank.d492.s0	true	DDI-DrugBank.d492.s0.e0	DDI-DrugBank.d492.s0.e1
DDI-DrugBank.d492.s1|a|Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
DDI-DrugBank.d492.s1	0	13	Antihistamines	group	DDI-DrugBank.d492.s1.e0
DDI-DrugBank.d492.s1	46	52	alcohol	drug	DDI-DrugBank.d492.s1.e1
DDI-DrugBank.d492.s1	64	78	CNS depressants	group	DDI-DrugBank.d492.s1.e2
DDI-DrugBank.d492.s1	87	95	hypnotics	group	DDI-DrugBank.d492.s1.e3
DDI-DrugBank.d492.s1	98	106	sedatives	group	DDI-DrugBank.d492.s1.e4
DDI-DrugBank.d492.s1	109	121	tranquilizers	group	DDI-DrugBank.d492.s1.e5
DDI-DrugBank.d492.s1	124	141	antianxiety agents	group	DDI-DrugBank.d492.s1.e6
DDI-DrugBank.d492.s1	true	DDI-DrugBank.d492.s1.e0	DDI-DrugBank.d492.s1.e1
DDI-DrugBank.d492.s1	true	DDI-DrugBank.d492.s1.e0	DDI-DrugBank.d492.s1.e2
DDI-DrugBank.d492.s1	true	DDI-DrugBank.d492.s1.e0	DDI-DrugBank.d492.s1.e3
DDI-DrugBank.d492.s1	true	DDI-DrugBank.d492.s1.e0	DDI-DrugBank.d492.s1.e4
DDI-DrugBank.d492.s1	true	DDI-DrugBank.d492.s1.e0	DDI-DrugBank.d492.s1.e5
DDI-DrugBank.d492.s1	true	DDI-DrugBank.d492.s1.e0	DDI-DrugBank.d492.s1.e6
DDI-DrugBank.d492.s1	false	DDI-DrugBank.d492.s1.e1	DDI-DrugBank.d492.s1.e2
DDI-DrugBank.d492.s1	false	DDI-DrugBank.d492.s1.e1	DDI-DrugBank.d492.s1.e3
DDI-DrugBank.d492.s1	false	DDI-DrugBank.d492.s1.e1	DDI-DrugBank.d492.s1.e4
DDI-DrugBank.d492.s1	false	DDI-DrugBank.d492.s1.e1	DDI-DrugBank.d492.s1.e5
DDI-DrugBank.d259.s0|a|No drug interactions have been reported.
DDI-DrugBank.d101.s0|a|Steady state plasma digitoxin concentrations did not appear to change.
DDI-DrugBank.d101.s0	20	28	digitoxin	drug	DDI-DrugBank.d101.s0.e0
DDI-DrugBank.d101.s1|a|Therefore, monitoring of plasma digoxin levels may be indicated in patients receiving similar combination chemotherapy regimens.
DDI-DrugBank.d101.s1	32	38	digoxin	drug	DDI-DrugBank.d101.s1.e0
DDI-DrugBank.d101.s2|a|The utilization of digitoxin for such patients may be considered as an alternative.
DDI-DrugBank.d101.s2	19	27	digitoxin	drug	DDI-DrugBank.d101.s2.e0
DDI-DrugBank.d101.s3|a|Also flucytosine.
DDI-DrugBank.d101.s3	5	15	flucytosine	drug	DDI-DrugBank.d101.s3.e0
DDI-DrugBank.d294.s0|a|Drug/LaboratoryTest Interactions Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels.
DDI-DrugBank.d294.s0	33	44	Dactinomycin	drug	DDI-DrugBank.d294.s0.e0
DDI-DrugBank.d294.s0	110	127	antibacterial drug	group	DDI-DrugBank.d294.s0.e1
DDI-DrugBank.d294.s0	false	DDI-DrugBank.d294.s0.e0	DDI-DrugBank.d294.s0.e1
DDI-DrugBank.d305.s0|a|Dantrium is metabolized by the liver, and it is theoretically possible that its metabolism may be enhanced by drugs known to induce hepatic microsomal enzymes.
DDI-DrugBank.d305.s0	0	7	Dantrium	brand	DDI-DrugBank.d305.s0.e0
DDI-DrugBank.d305.s1|a|However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism.
DDI-DrugBank.d305.s1	17	29	phenobarbital	drug	DDI-DrugBank.d305.s1.e0
DDI-DrugBank.d305.s1	35	42	diazepam	drug	DDI-DrugBank.d305.s1.e1
DDI-DrugBank.d305.s1	62	69	Dantrium	brand	DDI-DrugBank.d305.s1.e2
DDI-DrugBank.d305.s1	false	DDI-DrugBank.d305.s1.e0	DDI-DrugBank.d305.s1.e1
DDI-DrugBank.d305.s1	false	DDI-DrugBank.d305.s1.e0	DDI-DrugBank.d305.s1.e2
DDI-DrugBank.d305.s1	false	DDI-DrugBank.d305.s1.e1	DDI-DrugBank.d305.s1.e2
DDI-DrugBank.d305.s2|a|Binding to plasma protein is not significantly altered by diazepam, diphenylhydantoin, or phenylbutazone.
DDI-DrugBank.d305.s2	58	65	diazepam	drug	DDI-DrugBank.d305.s2.e0
DDI-DrugBank.d305.s2	68	84	diphenylhydantoin	drug	DDI-DrugBank.d305.s2.e1
DDI-DrugBank.d305.s2	90	103	phenylbutazone	drug	DDI-DrugBank.d305.s2.e2
DDI-DrugBank.d305.s2	false	DDI-DrugBank.d305.s2.e0	DDI-DrugBank.d305.s2.e1
DDI-DrugBank.d305.s2	false	DDI-DrugBank.d305.s2.e0	DDI-DrugBank.d305.s2.e2
DDI-DrugBank.d305.s2	false	DDI-DrugBank.d305.s2.e1	DDI-DrugBank.d305.s2.e2
DDI-DrugBank.d305.s3|a|Binding to plasma proteins is reduced by warfarin and clotibrate and increased by tolbutamide.
DDI-DrugBank.d305.s3	41	48	warfarin	drug	DDI-DrugBank.d305.s3.e0
DDI-DrugBank.d305.s3	82	92	tolbutamide	drug	DDI-DrugBank.d305.s3.e1
DDI-DrugBank.d305.s3	false	DDI-DrugBank.d305.s3.e0	DDI-DrugBank.d305.s3.e1
DDI-DrugBank.d305.s4|a|Cardiovascular collapse in patients treated simultaneously with varapamil and dantrolene sodium is rare.
DDI-DrugBank.d305.s4	78	94	dantrolene sodium	drug	DDI-DrugBank.d305.s4.e0
DDI-DrugBank.d305.s5|a|The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.
DDI-DrugBank.d305.s5	52	68	dantrolene sodium	drug	DDI-DrugBank.d305.s5.e0
DDI-DrugBank.d305.s5	74	82	verapamil	drug	DDI-DrugBank.d305.s5.e1
DDI-DrugBank.d305.s5	87	95	halothane	drug	DDI-DrugBank.d305.s5.e2
DDI-DrugBank.d305.s5	false	DDI-DrugBank.d305.s5.e0	DDI-DrugBank.d305.s5.e1
DDI-DrugBank.d305.s5	false	DDI-DrugBank.d305.s5.e0	DDI-DrugBank.d305.s5.e2
DDI-DrugBank.d305.s5	false	DDI-DrugBank.d305.s5.e1	DDI-DrugBank.d305.s5.e2
DDI-DrugBank.d305.s6|a|It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
DDI-DrugBank.d305.s6	54	70	dantrolene sodium	drug	DDI-DrugBank.d305.s6.e0
DDI-DrugBank.d305.s6	76	99	calcium channel blockers	group	DDI-DrugBank.d305.s6.e1
DDI-DrugBank.d305.s6	110	118	verapamil	drug	DDI-DrugBank.d305.s6.e2
DDI-DrugBank.d305.s6	true	DDI-DrugBank.d305.s6.e0	DDI-DrugBank.d305.s6.e1
DDI-DrugBank.d305.s6	true	DDI-DrugBank.d305.s6.e0	DDI-DrugBank.d305.s6.e2
DDI-DrugBank.d305.s6	false	DDI-DrugBank.d305.s6.e1	DDI-DrugBank.d305.s6.e2
DDI-DrugBank.d305.s7|a|Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
DDI-DrugBank.d305.s7	18	27	dantrolene	drug	DDI-DrugBank.d305.s7.e0
DDI-DrugBank.d305.s7	44	53	vecuronium	drug	DDI-DrugBank.d305.s7.e1
DDI-DrugBank.d305.s7	true	DDI-DrugBank.d305.s7.e0	DDI-DrugBank.d305.s7.e1
DDI-DrugBank.d185.s0|a|A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/SMX).
DDI-DrugBank.d185.s0	65	70	ACZONE	brand	DDI-DrugBank.d185.s0.e0
DDI-DrugBank.d185.s0	133	144	trimethoprim	drug	DDI-DrugBank.d185.s0.e1
DDI-DrugBank.d185.s0	146	161	sulfamethoxazole	drug	DDI-DrugBank.d185.s0.e2
DDI-DrugBank.d185.s0	164	166	TMP	drug	DDI-DrugBank.d185.s0.e3
DDI-DrugBank.d185.s0	168	170	SMX	drug	DDI-DrugBank.d185.s0.e4
DDI-DrugBank.d185.s0	false	DDI-DrugBank.d185.s0.e0	DDI-DrugBank.d185.s0.e1
DDI-DrugBank.d185.s0	false	DDI-DrugBank.d185.s0.e0	DDI-DrugBank.d185.s0.e2
DDI-DrugBank.d185.s0	false	DDI-DrugBank.d185.s0.e0	DDI-DrugBank.d185.s0.e3
DDI-DrugBank.d185.s0	false	DDI-DrugBank.d185.s0.e0	DDI-DrugBank.d185.s0.e4
DDI-DrugBank.d185.s0	false	DDI-DrugBank.d185.s0.e1	DDI-DrugBank.d185.s0.e2
DDI-DrugBank.d185.s0	false	DDI-DrugBank.d185.s0.e1	DDI-DrugBank.d185.s0.e3
DDI-DrugBank.d185.s0	false	DDI-DrugBank.d185.s0.e1	DDI-DrugBank.d185.s0.e4
DDI-DrugBank.d185.s0	false	DDI-DrugBank.d185.s0.e2	DDI-DrugBank.d185.s0.e3
DDI-DrugBank.d185.s0	false	DDI-DrugBank.d185.s0.e2	DDI-DrugBank.d185.s0.e4
DDI-DrugBank.d185.s0	false	DDI-DrugBank.d185.s0.e3	DDI-DrugBank.d185.s0.e4
DDI-DrugBank.d185.s1|a|During co-administration, systemic levels of TMP and SMX were essentially unchanged.
DDI-DrugBank.d185.s1	45	47	TMP	drug	DDI-DrugBank.d185.s1.e0
DDI-DrugBank.d185.s1	53	55	SMX	drug	DDI-DrugBank.d185.s1.e1
DDI-DrugBank.d185.s1	false	DDI-DrugBank.d185.s1.e0	DDI-DrugBank.d185.s1.e1
DDI-DrugBank.d185.s2|a|Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of TMP/SMX.
DDI-DrugBank.d185.s2	40	60	dapsone hydroxylamine	drug_n	DDI-DrugBank.d185.s2.e0
DDI-DrugBank.d185.s2	63	65	DHA	drug_n	DDI-DrugBank.d185.s2.e1
DDI-DrugBank.d185.s2	109	111	TMP	drug	DDI-DrugBank.d185.s2.e2
DDI-DrugBank.d185.s2	113	115	SMX	drug	DDI-DrugBank.d185.s2.e3
DDI-DrugBank.d185.s2	false	DDI-DrugBank.d185.s2.e0	DDI-DrugBank.d185.s2.e1
DDI-DrugBank.d185.s2	false	DDI-DrugBank.d185.s2.e0	DDI-DrugBank.d185.s2.e2
DDI-DrugBank.d185.s2	false	DDI-DrugBank.d185.s2.e0	DDI-DrugBank.d185.s2.e3
DDI-DrugBank.d185.s2	false	DDI-DrugBank.d185.s2.e1	DDI-DrugBank.d185.s2.e2
DDI-DrugBank.d185.s2	false	DDI-DrugBank.d185.s2.e1	DDI-DrugBank.d185.s2.e3
DDI-DrugBank.d185.s2	false	DDI-DrugBank.d185.s2.e2	DDI-DrugBank.d185.s2.e3
DDI-DrugBank.d185.s3|a|Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX.
DDI-DrugBank.d185.s3	118	120	TMP	drug	DDI-DrugBank.d185.s3.e0
DDI-DrugBank.d185.s3	122	124	SMX	drug	DDI-DrugBank.d185.s3.e1
DDI-DrugBank.d185.s3	false	DDI-DrugBank.d185.s3.e0	DDI-DrugBank.d185.s3.e1
DDI-DrugBank.d185.s4|a|Certain concomitant medications (such as rifampin, anticonvulsants, St.
DDI-DrugBank.d185.s4	41	48	rifampin	drug	DDI-DrugBank.d185.s4.e0
DDI-DrugBank.d185.s4	51	65	anticonvulsants	group	DDI-DrugBank.d185.s4.e1
DDI-DrugBank.d185.s4	false	DDI-DrugBank.d185.s4.e0	DDI-DrugBank.d185.s4.e1
DDI-DrugBank.d185.s5|a|John s wort) may increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis.
DDI-DrugBank.d185.s5	43	63	dapsone hydroxylamine	drug_n	DDI-DrugBank.d185.s5.e0
DDI-DrugBank.d185.s5	82	88	dapsone	drug	DDI-DrugBank.d185.s5.e1
DDI-DrugBank.d185.s5	false	DDI-DrugBank.d185.s5.e0	DDI-DrugBank.d185.s5.e1
DDI-DrugBank.d185.s6|a|With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
DDI-DrugBank.d185.s6	10	16	dapsone	drug	DDI-DrugBank.d185.s6.e0
DDI-DrugBank.d185.s6	29	50	folic acid antagonists	group	DDI-DrugBank.d185.s6.e1
DDI-DrugBank.d185.s6	60	72	pyrimethamine	drug	DDI-DrugBank.d185.s6.e2
DDI-DrugBank.d185.s6	true	DDI-DrugBank.d185.s6.e0	DDI-DrugBank.d185.s6.e1
DDI-DrugBank.d185.s6	true	DDI-DrugBank.d185.s6.e0	DDI-DrugBank.d185.s6.e2
DDI-DrugBank.d185.s6	false	DDI-DrugBank.d185.s6.e1	DDI-DrugBank.d185.s6.e2
DDI-DrugBank.d185.s7|a|.
DDI-DrugBank.d185.s8|a|
DDI-DrugBank.d337.s0|a|Warfarin: Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.
DDI-DrugBank.d337.s0	0	7	Warfarin	drug	DDI-DrugBank.d337.s0.e0
DDI-DrugBank.d337.s0	40	49	daptomycin	drug	DDI-DrugBank.d337.s0.e1
DDI-DrugBank.d337.s0	96	103	warfarin	drug	DDI-DrugBank.d337.s0.e2
DDI-DrugBank.d337.s0	false	DDI-DrugBank.d337.s0.e0	DDI-DrugBank.d337.s0.e1
DDI-DrugBank.d337.s0	false	DDI-DrugBank.d337.s0.e0	DDI-DrugBank.d337.s0.e2
DDI-DrugBank.d337.s0	false	DDI-DrugBank.d337.s0.e1	DDI-DrugBank.d337.s0.e2
DDI-DrugBank.d337.s1|a|HMG-CoA Reductase Inhibitors: Inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.
DDI-DrugBank.d337.s1	0	27	HMG-CoA Reductase Inhibitors	group	DDI-DrugBank.d337.s1.e0
DDI-DrugBank.d337.s1	30	60	Inhibitors of HMG-CoA reductase	group	DDI-DrugBank.d337.s1.e1
DDI-DrugBank.d337.s1	false	DDI-DrugBank.d337.s1.e0	DDI-DrugBank.d337.s1.e1
DDI-DrugBank.d337.s2|a|There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days.
DDI-DrugBank.d337.s2	120	130	simvastatin	drug	DDI-DrugBank.d337.s2.e0
DDI-DrugBank.d337.s2	171	180	daptomycin	drug	DDI-DrugBank.d337.s2.e1
DDI-DrugBank.d337.s2	false	DDI-DrugBank.d337.s2.e0	DDI-DrugBank.d337.s2.e1
DDI-DrugBank.d337.s3|a|Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.
DDI-DrugBank.d337.s3	37	64	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d337.s3.e0
DDI-DrugBank.d337.s3	70	77	Fentanyl	drug	DDI-DrugBank.d337.s3.e1
DDI-DrugBank.d337.s3	175	202	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d337.s3.e2
DDI-DrugBank.d337.s3	226	233	Fentanyl	drug	DDI-DrugBank.d337.s3.e3
DDI-DrugBank.d337.s3	false	DDI-DrugBank.d337.s3.e0	DDI-DrugBank.d337.s3.e1
DDI-DrugBank.d337.s3	false	DDI-DrugBank.d337.s3.e0	DDI-DrugBank.d337.s3.e2
DDI-DrugBank.d337.s3	false	DDI-DrugBank.d337.s3.e0	DDI-DrugBank.d337.s3.e3
DDI-DrugBank.d337.s3	false	DDI-DrugBank.d337.s3.e1	DDI-DrugBank.d337.s3.e2
DDI-DrugBank.d337.s3	false	DDI-DrugBank.d337.s3.e1	DDI-DrugBank.d337.s3.e3
DDI-DrugBank.d337.s3	true	DDI-DrugBank.d337.s3.e2	DDI-DrugBank.d337.s3.e3
DDI-DrugBank.d337.s4|a|Drug-Laboratory Test Interactions: There are no reported drug-laboratory test interactions.
DDI-DrugBank.d534.s0|a|No formal drug interaction studies of Aranesp  have been performed.
DDI-DrugBank.d534.s0	38	44	Aranesp	brand	DDI-DrugBank.d534.s0.e0
DDI-DrugBank.d459.s0|a|The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DDI-DrugBank.d459.s0	18	24	ENABLEX	brand	DDI-DrugBank.d459.s0.e0
DDI-DrugBank.d459.s0	108	119	ketoconazole	drug	DDI-DrugBank.d459.s0.e1
DDI-DrugBank.d459.s0	122	133	itraconazole	drug	DDI-DrugBank.d459.s0.e2
DDI-DrugBank.d459.s0	136	144	ritonavir	drug	DDI-DrugBank.d459.s0.e3
DDI-DrugBank.d459.s0	147	156	nelfinavir	drug	DDI-DrugBank.d459.s0.e4
DDI-DrugBank.d459.s0	159	172	clarithromycin	drug	DDI-DrugBank.d459.s0.e5
DDI-DrugBank.d459.s0	true	DDI-DrugBank.d459.s0.e0	DDI-DrugBank.d459.s0.e1
DDI-DrugBank.d459.s0	true	DDI-DrugBank.d459.s0.e0	DDI-DrugBank.d459.s0.e2
DDI-DrugBank.d459.s0	true	DDI-DrugBank.d459.s0.e0	DDI-DrugBank.d459.s0.e3
DDI-DrugBank.d459.s0	true	DDI-DrugBank.d459.s0.e0	DDI-DrugBank.d459.s0.e4
DDI-DrugBank.d459.s0	true	DDI-DrugBank.d459.s0.e0	DDI-DrugBank.d459.s0.e5
DDI-DrugBank.d459.s0	false	DDI-DrugBank.d459.s0.e1	DDI-DrugBank.d459.s0.e2
DDI-DrugBank.d459.s0	false	DDI-DrugBank.d459.s0.e1	DDI-DrugBank.d459.s0.e3
DDI-DrugBank.d459.s0	false	DDI-DrugBank.d459.s0.e1	DDI-DrugBank.d459.s0.e4
DDI-DrugBank.d459.s0	false	DDI-DrugBank.d459.s0.e1	DDI-DrugBank.d459.s0.e5
DDI-DrugBank.d459.s0	false	DDI-DrugBank.d459.s0.e2	DDI-DrugBank.d459.s0.e3
DDI-DrugBank.d459.s1|a|Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
DDI-DrugBank.d459.s1	29	35	ENABLEX	brand	DDI-DrugBank.d459.s1.e0
DDI-DrugBank.d459.s1	173	182	flecainide	drug	DDI-DrugBank.d459.s1.e1
DDI-DrugBank.d459.s1	185	196	thioridazine	drug	DDI-DrugBank.d459.s1.e2
DDI-DrugBank.d459.s1	202	226	tricyclic antidepressants	group	DDI-DrugBank.d459.s1.e3
DDI-DrugBank.d459.s1	true	DDI-DrugBank.d459.s1.e0	DDI-DrugBank.d459.s1.e1
DDI-DrugBank.d459.s1	true	DDI-DrugBank.d459.s1.e0	DDI-DrugBank.d459.s1.e2
DDI-DrugBank.d459.s1	true	DDI-DrugBank.d459.s1.e0	DDI-DrugBank.d459.s1.e3
DDI-DrugBank.d459.s1	false	DDI-DrugBank.d459.s1.e1	DDI-DrugBank.d459.s1.e2
DDI-DrugBank.d459.s1	false	DDI-DrugBank.d459.s1.e1	DDI-DrugBank.d459.s1.e3
DDI-DrugBank.d459.s1	false	DDI-DrugBank.d459.s1.e2	DDI-DrugBank.d459.s1.e3
DDI-DrugBank.d459.s2|a|The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.
DDI-DrugBank.d459.s2	23	29	ENABLEX	brand	DDI-DrugBank.d459.s2.e0
DDI-DrugBank.d459.s2	42	63	anticholinergic agents	group	DDI-DrugBank.d459.s2.e1
DDI-DrugBank.d459.s2	true	DDI-DrugBank.d459.s2.e0	DDI-DrugBank.d459.s2.e1
DDI-DrugBank.d459.s3|a|Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to effects on gastrointestinal motility.
DDI-DrugBank.d459.s3	0	21	Anticholinergic agents	group	DDI-DrugBank.d459.s3.e0
DDI-DrugBank.d459.s4|a|Drug Laboratory Test Interactions Interactions between darifenacin and laboratory tests have not been studied.
DDI-DrugBank.d459.s4	55	65	darifenacin	drug	DDI-DrugBank.d459.s4.e0
DDI-DrugBank.d48.s0|a|Drugs that may increase dasatinib plasma concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate.
DDI-DrugBank.d48.s0	24	32	dasatinib	drug	DDI-DrugBank.d48.s0.e0
DDI-DrugBank.d48.s0	75	83	Dasatinib	drug	DDI-DrugBank.d48.s0.e1
DDI-DrugBank.d48.s0	false	DDI-DrugBank.d48.s0.e0	DDI-DrugBank.d48.s0.e1
DDI-DrugBank.d48.s1|a|Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s1	19	25	SPRYCEL	brand	DDI-DrugBank.d48.s1.e0
DDI-DrugBank.d48.s1	62	73	ketoconazole	drug	DDI-DrugBank.d48.s1.e1
DDI-DrugBank.d48.s1	76	87	itraconazole	drug	DDI-DrugBank.d48.s1.e2
DDI-DrugBank.d48.s1	90	101	erythromycin	drug	DDI-DrugBank.d48.s1.e3
DDI-DrugBank.d48.s1	104	117	clarithromycin	drug	DDI-DrugBank.d48.s1.e4
DDI-DrugBank.d48.s1	120	128	ritonavir	drug	DDI-DrugBank.d48.s1.e5
DDI-DrugBank.d48.s1	131	140	atazanavir	drug	DDI-DrugBank.d48.s1.e6
DDI-DrugBank.d48.s1	143	151	indinavir	drug	DDI-DrugBank.d48.s1.e7
DDI-DrugBank.d48.s1	154	163	nefazodone	drug	DDI-DrugBank.d48.s1.e8
DDI-DrugBank.d48.s1	166	175	nelfinavir	drug	DDI-DrugBank.d48.s1.e9
DDI-DrugBank.d48.s1	true	DDI-DrugBank.d48.s1.e0	DDI-DrugBank.d48.s1.e1
DDI-DrugBank.d48.s1	true	DDI-DrugBank.d48.s1.e0	DDI-DrugBank.d48.s1.e2
DDI-DrugBank.d48.s1	true	DDI-DrugBank.d48.s1.e0	DDI-DrugBank.d48.s1.e3
DDI-DrugBank.d48.s1	true	DDI-DrugBank.d48.s1.e0	DDI-DrugBank.d48.s1.e4
DDI-DrugBank.d48.s1	true	DDI-DrugBank.d48.s1.e0	DDI-DrugBank.d48.s1.e5
DDI-DrugBank.d48.s1	true	DDI-DrugBank.d48.s1.e0	DDI-DrugBank.d48.s1.e6
DDI-DrugBank.d48.s1	true	DDI-DrugBank.d48.s1.e0	DDI-DrugBank.d48.s1.e7
DDI-DrugBank.d48.s1	true	DDI-DrugBank.d48.s1.e0	DDI-DrugBank.d48.s1.e8
DDI-DrugBank.d48.s1	true	DDI-DrugBank.d48.s1.e0	DDI-DrugBank.d48.s1.e9
DDI-DrugBank.d48.s1	true	DDI-DrugBank.d48.s1.e0	DDI-DrugBank.d48.s1.e10
DDI-DrugBank.d48.s2|a|In patients receiving treatment with SPRYCEL, close monitoring for toxicity and a SPRYCEL dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.
DDI-DrugBank.d48.s2	37	43	SPRYCEL	brand	DDI-DrugBank.d48.s2.e0
DDI-DrugBank.d48.s2	82	88	SPRYCEL	brand	DDI-DrugBank.d48.s2.e1
DDI-DrugBank.d48.s2	false	DDI-DrugBank.d48.s2.e0	DDI-DrugBank.d48.s2.e1
DDI-DrugBank.d48.s3|a|Drugs that may decrease dasatinib plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease dasatinib plasma concentrations.
DDI-DrugBank.d48.s3	24	32	dasatinib	drug	DDI-DrugBank.d48.s3.e0
DDI-DrugBank.d48.s3	120	128	dasatinib	drug	DDI-DrugBank.d48.s3.e1
DDI-DrugBank.d48.s3	false	DDI-DrugBank.d48.s3.e0	DDI-DrugBank.d48.s3.e1
DDI-DrugBank.d48.s4|a|In patients in whom CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital) are indicated, alternative agents with less enzyme induction potential should be used.
DDI-DrugBank.d48.s4	41	53	dexamethasone	drug	DDI-DrugBank.d48.s4.e0
DDI-DrugBank.d48.s4	56	64	phenytoin	drug	DDI-DrugBank.d48.s4.e1
DDI-DrugBank.d48.s4	67	79	carbamazepine	drug	DDI-DrugBank.d48.s4.e2
DDI-DrugBank.d48.s4	82	91	rifampicin	drug	DDI-DrugBank.d48.s4.e3
DDI-DrugBank.d48.s4	94	106	phenobarbital	drug	DDI-DrugBank.d48.s4.e4
DDI-DrugBank.d48.s4	false	DDI-DrugBank.d48.s4.e0	DDI-DrugBank.d48.s4.e1
DDI-DrugBank.d48.s4	false	DDI-DrugBank.d48.s4.e0	DDI-DrugBank.d48.s4.e2
DDI-DrugBank.d48.s4	false	DDI-DrugBank.d48.s4.e0	DDI-DrugBank.d48.s4.e3
DDI-DrugBank.d48.s4	false	DDI-DrugBank.d48.s4.e0	DDI-DrugBank.d48.s4.e4
DDI-DrugBank.d48.s4	false	DDI-DrugBank.d48.s4.e1	DDI-DrugBank.d48.s4.e2
DDI-DrugBank.d48.s4	false	DDI-DrugBank.d48.s4.e1	DDI-DrugBank.d48.s4.e3
DDI-DrugBank.d48.s4	false	DDI-DrugBank.d48.s4.e1	DDI-DrugBank.d48.s4.e4
DDI-DrugBank.d48.s4	false	DDI-DrugBank.d48.s4.e2	DDI-DrugBank.d48.s4.e3
DDI-DrugBank.d48.s4	false	DDI-DrugBank.d48.s4.e2	DDI-DrugBank.d48.s4.e4
DDI-DrugBank.d48.s4	false	DDI-DrugBank.d48.s4.e3	DDI-DrugBank.d48.s4.e4
DDI-DrugBank.d48.s5|a|If SPRYCEL must be administered with a CYP3A4 inducer, a dose increase in SPRYCEL should be considered.
DDI-DrugBank.d48.s5	3	9	SPRYCEL	brand	DDI-DrugBank.d48.s5.e0
DDI-DrugBank.d48.s5	74	80	SPRYCEL	brand	DDI-DrugBank.d48.s5.e1
DDI-DrugBank.d48.s5	false	DDI-DrugBank.d48.s5.e0	DDI-DrugBank.d48.s5.e1
DDI-DrugBank.d48.s6|a|St. Johns wort (Hypericum perforatum) may decrease SPRYCEL plasma concentrations unpredictably.
DDI-DrugBank.d48.s6	51	57	SPRYCEL	brand	DDI-DrugBank.d48.s6.e0
DDI-DrugBank.d48.s7|a|Patients receiving SPRYCEL should not take St. Johns wort.
DDI-DrugBank.d48.s7	19	25	SPRYCEL	brand	DDI-DrugBank.d48.s7.e0
DDI-DrugBank.d48.s8|a|Antacids: Nonclinical data demonstrate that the solubility of dasatinib is pH dependent.
DDI-DrugBank.d48.s8	0	7	Antacids	group	DDI-DrugBank.d48.s8.e0
DDI-DrugBank.d48.s8	62	70	dasatinib	drug	DDI-DrugBank.d48.s8.e1
DDI-DrugBank.d48.s8	false	DDI-DrugBank.d48.s8.e0	DDI-DrugBank.d48.s8.e1
DDI-DrugBank.d48.s9|a|Simultaneous administration of SPRYCEL with antacids should be avoided.
DDI-DrugBank.d48.s9	31	37	SPRYCEL	brand	DDI-DrugBank.d48.s9.e0
DDI-DrugBank.d48.s9	44	51	antacids	group	DDI-DrugBank.d48.s9.e1
DDI-DrugBank.d48.s9	true	DDI-DrugBank.d48.s9.e0	DDI-DrugBank.d48.s9.e1
DDI-DrugBank.d48.s10|a|If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.
DDI-DrugBank.d48.s10	3	9	antacid	group	DDI-DrugBank.d48.s10.e0
DDI-DrugBank.d48.s10	125	131	SPRYCEL	brand	DDI-DrugBank.d48.s10.e1
DDI-DrugBank.d48.s10	true	DDI-DrugBank.d48.s10.e0	DDI-DrugBank.d48.s10.e1
DDI-DrugBank.d48.s11|a|H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
DDI-DrugBank.d48.s11	0	10	H2 Blockers	group	DDI-DrugBank.d48.s11.e0
DDI-DrugBank.d48.s11	12	33	Proton Pump Inhibitors	group	DDI-DrugBank.d48.s11.e1
DDI-DrugBank.d48.s11	87	97	H2 blockers	group	DDI-DrugBank.d48.s11.e2
DDI-DrugBank.d48.s11	102	123	proton pump inhibitors	group	DDI-DrugBank.d48.s11.e3
DDI-DrugBank.d48.s11	130	139	famotidine	drug	DDI-DrugBank.d48.s11.e4
DDI-DrugBank.d48.s11	145	154	omeprazole	drug	DDI-DrugBank.d48.s11.e5
DDI-DrugBank.d48.s11	177	185	dasatinib	drug	DDI-DrugBank.d48.s11.e6
DDI-DrugBank.d48.s11	false	DDI-DrugBank.d48.s11.e0	DDI-DrugBank.d48.s11.e1
DDI-DrugBank.d48.s11	false	DDI-DrugBank.d48.s11.e0	DDI-DrugBank.d48.s11.e2
DDI-DrugBank.d48.s11	false	DDI-DrugBank.d48.s11.e0	DDI-DrugBank.d48.s11.e3
DDI-DrugBank.d48.s11	false	DDI-DrugBank.d48.s11.e0	DDI-DrugBank.d48.s11.e4
DDI-DrugBank.d48.s11	false	DDI-DrugBank.d48.s11.e0	DDI-DrugBank.d48.s11.e5
DDI-DrugBank.d48.s11	false	DDI-DrugBank.d48.s11.e0	DDI-DrugBank.d48.s11.e6
DDI-DrugBank.d48.s11	false	DDI-DrugBank.d48.s11.e1	DDI-DrugBank.d48.s11.e2
DDI-DrugBank.d48.s11	false	DDI-DrugBank.d48.s11.e1	DDI-DrugBank.d48.s11.e3
DDI-DrugBank.d48.s11	false	DDI-DrugBank.d48.s11.e1	DDI-DrugBank.d48.s11.e4
DDI-DrugBank.d48.s11	false	DDI-DrugBank.d48.s11.e1	DDI-DrugBank.d48.s11.e5
DDI-DrugBank.d48.s12|a|The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.
DDI-DrugBank.d48.s12	23	33	H2 blockers	group	DDI-DrugBank.d48.s12.e0
DDI-DrugBank.d48.s12	38	59	proton pump inhibitors	group	DDI-DrugBank.d48.s12.e1
DDI-DrugBank.d48.s12	66	72	SPRYCEL	brand	DDI-DrugBank.d48.s12.e2
DDI-DrugBank.d48.s12	false	DDI-DrugBank.d48.s12.e0	DDI-DrugBank.d48.s12.e1
DDI-DrugBank.d48.s12	true	DDI-DrugBank.d48.s12.e0	DDI-DrugBank.d48.s12.e2
DDI-DrugBank.d48.s12	true	DDI-DrugBank.d48.s12.e1	DDI-DrugBank.d48.s12.e2
DDI-DrugBank.d48.s13|a|The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.
DDI-DrugBank.d48.s13	11	18	antacids	group	DDI-DrugBank.d48.s13.e0
DDI-DrugBank.d48.s13	53	63	H2 blockers	group	DDI-DrugBank.d48.s13.e1
DDI-DrugBank.d48.s13	68	89	proton pump inhibitors	group	DDI-DrugBank.d48.s13.e2
DDI-DrugBank.d48.s13	113	119	SPRYCEL	brand	DDI-DrugBank.d48.s13.e3
DDI-DrugBank.d48.s13	false	DDI-DrugBank.d48.s13.e0	DDI-DrugBank.d48.s13.e1
DDI-DrugBank.d48.s13	false	DDI-DrugBank.d48.s13.e0	DDI-DrugBank.d48.s13.e2
DDI-DrugBank.d48.s13	false	DDI-DrugBank.d48.s13.e0	DDI-DrugBank.d48.s13.e3
DDI-DrugBank.d48.s13	false	DDI-DrugBank.d48.s13.e1	DDI-DrugBank.d48.s13.e2
DDI-DrugBank.d48.s13	true	DDI-DrugBank.d48.s13.e1	DDI-DrugBank.d48.s13.e3
DDI-DrugBank.d48.s13	true	DDI-DrugBank.d48.s13.e2	DDI-DrugBank.d48.s13.e3
DDI-DrugBank.d48.s14|a|Drugs that may have their plasma concentration altered by dasatinib CYP3A4 Substrates: Dasatinib is a time-dependent inhibitor of CYP3A4.
DDI-DrugBank.d48.s14	58	66	dasatinib	drug	DDI-DrugBank.d48.s14.e0
DDI-DrugBank.d48.s14	87	95	Dasatinib	drug	DDI-DrugBank.d48.s14.e1
DDI-DrugBank.d48.s14	false	DDI-DrugBank.d48.s14.e0	DDI-DrugBank.d48.s14.e1
DDI-DrugBank.d48.s15|a|Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d48.s15	78	87	alfentanil	drug	DDI-DrugBank.d48.s15.e0
DDI-DrugBank.d48.s15	90	99	astemizole	drug	DDI-DrugBank.d48.s15.e1
DDI-DrugBank.d48.s15	102	112	terfenadine	drug	DDI-DrugBank.d48.s15.e2
DDI-DrugBank.d48.s15	115	123	cisapride	drug	DDI-DrugBank.d48.s15.e3
DDI-DrugBank.d48.s15	126	137	cyclosporine	drug	DDI-DrugBank.d48.s15.e4
DDI-DrugBank.d48.s15	140	147	fentanyl	drug	DDI-DrugBank.d48.s15.e5
DDI-DrugBank.d48.s15	150	157	pimozide	drug	DDI-DrugBank.d48.s15.e6
DDI-DrugBank.d48.s15	160	168	quinidine	drug	DDI-DrugBank.d48.s15.e7
DDI-DrugBank.d48.s15	171	179	sirolimus	drug	DDI-DrugBank.d48.s15.e8
DDI-DrugBank.d48.s15	182	191	tacrolimus	drug	DDI-DrugBank.d48.s15.e9
DDI-DrugBank.d48.s15	false	DDI-DrugBank.d48.s15.e0	DDI-DrugBank.d48.s15.e1
DDI-DrugBank.d48.s15	false	DDI-DrugBank.d48.s15.e0	DDI-DrugBank.d48.s15.e2
DDI-DrugBank.d48.s15	false	DDI-DrugBank.d48.s15.e0	DDI-DrugBank.d48.s15.e3
DDI-DrugBank.d48.s15	false	DDI-DrugBank.d48.s15.e0	DDI-DrugBank.d48.s15.e4
DDI-DrugBank.d48.s15	false	DDI-DrugBank.d48.s15.e0	DDI-DrugBank.d48.s15.e5
DDI-DrugBank.d48.s15	false	DDI-DrugBank.d48.s15.e0	DDI-DrugBank.d48.s15.e6
DDI-DrugBank.d48.s15	false	DDI-DrugBank.d48.s15.e0	DDI-DrugBank.d48.s15.e7
DDI-DrugBank.d48.s15	false	DDI-DrugBank.d48.s15.e0	DDI-DrugBank.d48.s15.e8
DDI-DrugBank.d48.s15	false	DDI-DrugBank.d48.s15.e0	DDI-DrugBank.d48.s15.e9
DDI-DrugBank.d48.s15	false	DDI-DrugBank.d48.s15.e0	DDI-DrugBank.d48.s15.e10
DDI-DrugBank.d48.s16|a|Hepatic Impairment There are currently no clinical studies with SPRYCEL in patients with impaired liver function (clinical studies have excluded patients with ALT and/or AST  2.5 times the upper limit of the normal range and/or total bilirubin  2 times the upper limit of the normal range).
DDI-DrugBank.d48.s16	64	70	SPRYCEL	brand	DDI-DrugBank.d48.s16.e0
DDI-DrugBank.d48.s17|a|Metabolism of dasatinib is mainly hepatic.
DDI-DrugBank.d48.s17	14	22	dasatinib	drug	DDI-DrugBank.d48.s17.e0
DDI-DrugBank.d48.s18|a|Caution is recommended in patients with hepatic impairment.
DDI-DrugBank.d48.s19|a|Renal Impairment There are currently no clinical studies with SPRYCEL in patients with impaired renal function (clinical studies have excluded patients with serum creatinine concentration  1.5 times the upper limit of the normal range).
DDI-DrugBank.d48.s19	62	68	SPRYCEL	brand	DDI-DrugBank.d48.s19.e0
DDI-DrugBank.d48.s20|a|Dasatinib and its metabolites are minimally excreted via the kidney.
DDI-DrugBank.d48.s20	0	8	Dasatinib	drug	DDI-DrugBank.d48.s20.e0
DDI-DrugBank.d48.s21|a|Since the renal excretion of unchanged dasatinib and its metabolites is  4%, a decrease in total body clearance is not expected in patients with renal insufficiency.
DDI-DrugBank.d48.s21	39	47	dasatinib	drug	DDI-DrugBank.d48.s21.e0
DDI-DrugBank.d69.s0|a|Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.
DDI-DrugBank.d69.s0	7	16	Cerubidine	brand	DDI-DrugBank.d69.s0.e0
DDI-DrugBank.d69.s0	59	69	doxorubicin	drug	DDI-DrugBank.d69.s0.e1
DDI-DrugBank.d69.s0	true	DDI-DrugBank.d69.s0.e0	DDI-DrugBank.d69.s0.e1
DDI-DrugBank.d69.s1|a|Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.
DDI-DrugBank.d69.s1	0	9	Cerubidine	brand	DDI-DrugBank.d69.s1.e0
DDI-DrugBank.d69.s1	115	125	doxorubicin	drug	DDI-DrugBank.d69.s1.e1
DDI-DrugBank.d69.s1	130	139	Cerubidine	brand	DDI-DrugBank.d69.s1.e2
DDI-DrugBank.d69.s1	true	DDI-DrugBank.d69.s1.e0	DDI-DrugBank.d69.s1.e1
DDI-DrugBank.d69.s1	false	DDI-DrugBank.d69.s1.e0	DDI-DrugBank.d69.s1.e2
DDI-DrugBank.d69.s1	false	DDI-DrugBank.d69.s1.e1	DDI-DrugBank.d69.s1.e2
DDI-DrugBank.d69.s2|a|Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.
DDI-DrugBank.d69.s2	0	15	Cyclophosphamide	drug	DDI-DrugBank.d69.s2.e0
DDI-DrugBank.d69.s2	40	49	Cerubidine	brand	DDI-DrugBank.d69.s2.e1
DDI-DrugBank.d69.s2	true	DDI-DrugBank.d69.s2.e0	DDI-DrugBank.d69.s2.e1
DDI-DrugBank.d69.s3|a|Dosage reduction of Cerubidine may be required when used concurrently with other myelosuppressive agents.
DDI-DrugBank.d69.s3	20	29	Cerubidine	brand	DDI-DrugBank.d69.s3.e0
DDI-DrugBank.d69.s4|a|Hepatotoxic medications, such as high-dose methotrexate, may impair liver function and increase the risk of toxicity.
DDI-DrugBank.d69.s4	43	54	methotrexate	drug	DDI-DrugBank.d69.s4.e0
DDI-DrugBank.d167.s0|a|Potentially fatal drug interactions may occur when coadministered with digoxin, as this may enhance cardiovascular depression and bradyarrhythmias may occur.
DDI-DrugBank.d167.s0	71	77	digoxin	drug	DDI-DrugBank.d167.s0.e0
DDI-DrugBank.d167.s1|a|Anticholinesterases (neostgmine, physostigmine), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.
DDI-DrugBank.d167.s1	0	18	Anticholinesterases	group	DDI-DrugBank.d167.s1.e0
DDI-DrugBank.d167.s1	33	45	physostigmine	drug	DDI-DrugBank.d167.s1.e1
DDI-DrugBank.d167.s1	49	58	lignocaine	drug	DDI-DrugBank.d167.s1.e2
DDI-DrugBank.d167.s1	61	67	quinine	drug	DDI-DrugBank.d167.s1.e3
DDI-DrugBank.d167.s1	70	81	procainamide	drug	DDI-DrugBank.d167.s1.e4
DDI-DrugBank.d167.s1	false	DDI-DrugBank.d167.s1.e0	DDI-DrugBank.d167.s1.e1
DDI-DrugBank.d167.s1	false	DDI-DrugBank.d167.s1.e0	DDI-DrugBank.d167.s1.e2
DDI-DrugBank.d167.s1	false	DDI-DrugBank.d167.s1.e0	DDI-DrugBank.d167.s1.e3
DDI-DrugBank.d167.s1	false	DDI-DrugBank.d167.s1.e0	DDI-DrugBank.d167.s1.e4
DDI-DrugBank.d167.s1	false	DDI-DrugBank.d167.s1.e1	DDI-DrugBank.d167.s1.e2
DDI-DrugBank.d167.s1	false	DDI-DrugBank.d167.s1.e1	DDI-DrugBank.d167.s1.e3
DDI-DrugBank.d167.s1	false	DDI-DrugBank.d167.s1.e1	DDI-DrugBank.d167.s1.e4
DDI-DrugBank.d167.s1	false	DDI-DrugBank.d167.s1.e2	DDI-DrugBank.d167.s1.e3
DDI-DrugBank.d167.s1	false	DDI-DrugBank.d167.s1.e2	DDI-DrugBank.d167.s1.e4
DDI-DrugBank.d167.s1	false	DDI-DrugBank.d167.s1.e3	DDI-DrugBank.d167.s1.e4
DDI-DrugBank.d167.s2|a|In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.
DDI-DrugBank.d167.s2	66	76	anesthetics	group	DDI-DrugBank.d167.s2.e0
DDI-DrugBank.d167.s2	85	95	anesthetics	group	DDI-DrugBank.d167.s2.e1
DDI-DrugBank.d167.s2	102	110	lidocaine	drug	DDI-DrugBank.d167.s2.e2
DDI-DrugBank.d167.s2	113	120	procaine	drug	DDI-DrugBank.d167.s2.e3
DDI-DrugBank.d167.s2	123	135	beta-blockers	group	DDI-DrugBank.d167.s2.e4
DDI-DrugBank.d167.s2	138	151	metaclopramide	drug	DDI-DrugBank.d167.s2.e5
DDI-DrugBank.d167.s2	154	170	lithium carbonate	drug	DDI-DrugBank.d167.s2.e6
DDI-DrugBank.d167.s2	177	187	terbutaline	drug	DDI-DrugBank.d167.s2.e7
DDI-DrugBank.d167.s2	false	DDI-DrugBank.d167.s2.e0	DDI-DrugBank.d167.s2.e1
DDI-DrugBank.d167.s2	false	DDI-DrugBank.d167.s2.e0	DDI-DrugBank.d167.s2.e2
DDI-DrugBank.d167.s2	false	DDI-DrugBank.d167.s2.e0	DDI-DrugBank.d167.s2.e3
DDI-DrugBank.d167.s2	false	DDI-DrugBank.d167.s2.e0	DDI-DrugBank.d167.s2.e4
DDI-DrugBank.d167.s2	false	DDI-DrugBank.d167.s2.e0	DDI-DrugBank.d167.s2.e5
DDI-DrugBank.d167.s2	false	DDI-DrugBank.d167.s2.e0	DDI-DrugBank.d167.s2.e6
DDI-DrugBank.d167.s2	false	DDI-DrugBank.d167.s2.e0	DDI-DrugBank.d167.s2.e7
DDI-DrugBank.d167.s2	false	DDI-DrugBank.d167.s2.e1	DDI-DrugBank.d167.s2.e2
DDI-DrugBank.d167.s2	false	DDI-DrugBank.d167.s2.e1	DDI-DrugBank.d167.s2.e3
DDI-DrugBank.d167.s2	false	DDI-DrugBank.d167.s2.e1	DDI-DrugBank.d167.s2.e4
DDI-DrugBank.d126.s0|a|Drug interaction studies with decitabine have not been conducted.
DDI-DrugBank.d126.s0	30	39	decitabine	drug	DDI-DrugBank.d126.s0.e0
DDI-DrugBank.d126.s1|a|In vitro studies in human liver microsomes suggest that decitabine is unlikely to inhibit or induce cytochrome P450 enzymes.
DDI-DrugBank.d126.s1	56	65	decitabine	drug	DDI-DrugBank.d126.s1.e0
DDI-DrugBank.d126.s2|a|In vitro metabolism studies have suggested that decitabine is not a substrate for the human liver cytochrome P450 enzymes.
DDI-DrugBank.d126.s2	48	57	decitabine	drug	DDI-DrugBank.d126.s2.e0
DDI-DrugBank.d126.s3|a|As plasma protein binding of decitabine is negligible ( 1%), interactions due to displacement of more highly protein bound drugs from plasma proteins are not expected.
DDI-DrugBank.d126.s3	29	38	decitabine	drug	DDI-DrugBank.d126.s3.e0
DDI-DrugBank.d84.s0|a|The concomitant administration of Exjade and aluminum-containing antacid preparations has not been formally studied.
DDI-DrugBank.d84.s0	34	39	Exjade	brand	DDI-DrugBank.d84.s0.e0
DDI-DrugBank.d84.s0	45	52	aluminum	drug	DDI-DrugBank.d84.s0.e1
DDI-DrugBank.d84.s0	65	84	antacid preparations	group	DDI-DrugBank.d84.s0.e2
DDI-DrugBank.d84.s0	false	DDI-DrugBank.d84.s0.e0	DDI-DrugBank.d84.s0.e1
DDI-DrugBank.d84.s0	false	DDI-DrugBank.d84.s0.e0	DDI-DrugBank.d84.s0.e2
DDI-DrugBank.d84.s0	false	DDI-DrugBank.d84.s0.e1	DDI-DrugBank.d84.s0.e2
DDI-DrugBank.d84.s1|a|Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.
DDI-DrugBank.d84.s1	9	19	deferasirox	drug	DDI-DrugBank.d84.s1.e0
DDI-DrugBank.d84.s1	46	53	aluminum	drug	DDI-DrugBank.d84.s1.e1
DDI-DrugBank.d84.s1	64	67	iron	drug	DDI-DrugBank.d84.s1.e2
DDI-DrugBank.d84.s1	70	75	Exjade	brand	DDI-DrugBank.d84.s1.e3
DDI-DrugBank.d84.s1	102	109	aluminum	drug	DDI-DrugBank.d84.s1.e4
DDI-DrugBank.d84.s1	122	141	antacid preparations	group	DDI-DrugBank.d84.s1.e5
DDI-DrugBank.d84.s1	false	DDI-DrugBank.d84.s1.e0	DDI-DrugBank.d84.s1.e1
DDI-DrugBank.d84.s1	false	DDI-DrugBank.d84.s1.e0	DDI-DrugBank.d84.s1.e2
DDI-DrugBank.d84.s1	false	DDI-DrugBank.d84.s1.e0	DDI-DrugBank.d84.s1.e3
DDI-DrugBank.d84.s1	false	DDI-DrugBank.d84.s1.e0	DDI-DrugBank.d84.s1.e4
DDI-DrugBank.d84.s1	false	DDI-DrugBank.d84.s1.e0	DDI-DrugBank.d84.s1.e5
DDI-DrugBank.d84.s1	false	DDI-DrugBank.d84.s1.e1	DDI-DrugBank.d84.s1.e2
DDI-DrugBank.d84.s1	false	DDI-DrugBank.d84.s1.e1	DDI-DrugBank.d84.s1.e3
DDI-DrugBank.d84.s1	false	DDI-DrugBank.d84.s1.e1	DDI-DrugBank.d84.s1.e4
DDI-DrugBank.d84.s1	false	DDI-DrugBank.d84.s1.e1	DDI-DrugBank.d84.s1.e5
DDI-DrugBank.d84.s1	false	DDI-DrugBank.d84.s1.e2	DDI-DrugBank.d84.s1.e3
DDI-DrugBank.d84.s2|a|In healthy volunteers, Exjade had no effect on the pharmacokinetics of digoxin.
DDI-DrugBank.d84.s2	23	28	Exjade	brand	DDI-DrugBank.d84.s2.e0
DDI-DrugBank.d84.s2	71	77	digoxin	drug	DDI-DrugBank.d84.s2.e1
DDI-DrugBank.d84.s2	false	DDI-DrugBank.d84.s2.e0	DDI-DrugBank.d84.s2.e1
DDI-DrugBank.d84.s3|a|The effect of digoxin on Exjade pharmacokinetics has not been studied.
DDI-DrugBank.d84.s3	14	20	digoxin	drug	DDI-DrugBank.d84.s3.e0
DDI-DrugBank.d84.s3	25	30	Exjade	brand	DDI-DrugBank.d84.s3.e1
DDI-DrugBank.d84.s3	false	DDI-DrugBank.d84.s3.e0	DDI-DrugBank.d84.s3.e1
DDI-DrugBank.d84.s4|a|The concomitant administration of Exjade and vitamin C has not been formally studied.
DDI-DrugBank.d84.s4	34	39	Exjade	brand	DDI-DrugBank.d84.s4.e0
DDI-DrugBank.d84.s4	45	53	vitamin C	drug	DDI-DrugBank.d84.s4.e1
DDI-DrugBank.d84.s4	false	DDI-DrugBank.d84.s4.e0	DDI-DrugBank.d84.s4.e1
DDI-DrugBank.d84.s5|a|Doses of vitamin C up to 200 mg were allowed in clinical studies without negative consequences.
DDI-DrugBank.d84.s5	9	17	vitamin C	drug	DDI-DrugBank.d84.s5.e0
DDI-DrugBank.d84.s6|a|The interaction of Exjade with hydroxyurea has not been formally studied.
DDI-DrugBank.d84.s6	19	24	Exjade	brand	DDI-DrugBank.d84.s6.e0
DDI-DrugBank.d84.s6	31	41	hydroxyurea	drug	DDI-DrugBank.d84.s6.e1
DDI-DrugBank.d84.s6	false	DDI-DrugBank.d84.s6.e0	DDI-DrugBank.d84.s6.e1
DDI-DrugBank.d84.s7|a|No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.
DDI-DrugBank.d84.s7	17	27	deferasirox	drug	DDI-DrugBank.d84.s7.e0
DDI-DrugBank.d84.s7	43	53	hydroxyurea	drug	DDI-DrugBank.d84.s7.e1
DDI-DrugBank.d84.s7	false	DDI-DrugBank.d84.s7.e0	DDI-DrugBank.d84.s7.e1
DDI-DrugBank.d84.s8|a|Exjade should not be combined with other iron chelator therapies, as safety of such combinations has not been established.
DDI-DrugBank.d84.s8	0	5	Exjade	brand	DDI-DrugBank.d84.s8.e0
DDI-DrugBank.d84.s9|a|Drug/Food Interactions The bioavailability (AUC) of deferasirox was variably increased when taken with a meal.
DDI-DrugBank.d84.s9	52	62	deferasirox	drug	DDI-DrugBank.d84.s9.e0
DDI-DrugBank.d84.s10|a|Deferasirox should be taken on an empty stomach 30 minutes before eating.
DDI-DrugBank.d84.s10	0	10	Deferasirox	drug	DDI-DrugBank.d84.s10.e0
DDI-DrugBank.d84.s11|a|Exjade tablets for oral suspension can be dispersed in water, orange juice, or apple juice.
DDI-DrugBank.d84.s11	0	5	Exjade	brand	DDI-DrugBank.d84.s11.e0
DDI-DrugBank.d251.s0|a|Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
DDI-DrugBank.d251.s0	10	23	clarithromycin	drug	DDI-DrugBank.d251.s0.e0
DDI-DrugBank.d251.s0	26	35	Didanosine	drug	DDI-DrugBank.d251.s0.e1
DDI-DrugBank.d251.s0	38	48	Fluconazole	drug	DDI-DrugBank.d251.s0.e2
DDI-DrugBank.d251.s0	51	60	Fluoxetine	drug	DDI-DrugBank.d251.s0.e3
DDI-DrugBank.d251.s0	74	85	Ketoconazole	drug	DDI-DrugBank.d251.s0.e4
DDI-DrugBank.d251.s0	88	96	Phenytoin	drug	DDI-DrugBank.d251.s0.e5
DDI-DrugBank.d251.s0	114	126	carbamazepine	drug	DDI-DrugBank.d251.s0.e6
DDI-DrugBank.d251.s0	129	137	Rifabutin	drug	DDI-DrugBank.d251.s0.e7
DDI-DrugBank.d251.s0	140	147	Rifampin	drug	DDI-DrugBank.d251.s0.e8
DDI-DrugBank.d251.s0	161	170	Saquinavir	drug	DDI-DrugBank.d251.s0.e9
DDI-DrugBank.d251.s0	false	DDI-DrugBank.d251.s0.e0	DDI-DrugBank.d251.s0.e1
DDI-DrugBank.d251.s0	false	DDI-DrugBank.d251.s0.e0	DDI-DrugBank.d251.s0.e2
DDI-DrugBank.d251.s0	false	DDI-DrugBank.d251.s0.e0	DDI-DrugBank.d251.s0.e3
DDI-DrugBank.d251.s0	false	DDI-DrugBank.d251.s0.e0	DDI-DrugBank.d251.s0.e4
DDI-DrugBank.d251.s0	false	DDI-DrugBank.d251.s0.e0	DDI-DrugBank.d251.s0.e5
DDI-DrugBank.d251.s0	false	DDI-DrugBank.d251.s0.e0	DDI-DrugBank.d251.s0.e6
DDI-DrugBank.d251.s0	false	DDI-DrugBank.d251.s0.e0	DDI-DrugBank.d251.s0.e7
DDI-DrugBank.d251.s0	false	DDI-DrugBank.d251.s0.e0	DDI-DrugBank.d251.s0.e8
DDI-DrugBank.d251.s0	false	DDI-DrugBank.d251.s0.e0	DDI-DrugBank.d251.s0.e9
DDI-DrugBank.d251.s0	false	DDI-DrugBank.d251.s0.e1	DDI-DrugBank.d251.s0.e2
DDI-DrugBank.d149.s0|a|Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.
DDI-DrugBank.d149.s0	30	37	HUMORSOL	brand	DDI-DrugBank.d149.s0.e0
DDI-DrugBank.d149.s0	44	58	succinylcholine	drug	DDI-DrugBank.d149.s0.e1
DDI-DrugBank.d149.s0	74	98	anticholinesterase agents	group	DDI-DrugBank.d149.s0.e2
DDI-DrugBank.d149.s0	true	DDI-DrugBank.d149.s0.e0	DDI-DrugBank.d149.s0.e1
DDI-DrugBank.d149.s0	true	DDI-DrugBank.d149.s0.e0	DDI-DrugBank.d149.s0.e2
DDI-DrugBank.d149.s0	false	DDI-DrugBank.d149.s0.e1	DDI-DrugBank.d149.s0.e2
DDI-DrugBank.d409.s0|a|Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
DDI-DrugBank.d409.s0	12	24	tetracyclines	group	DDI-DrugBank.d409.s0.e0
DDI-DrugBank.d409.s0	102	114	anticoagulant	group	DDI-DrugBank.d409.s0.e1
DDI-DrugBank.d409.s0	165	177	anticoagulant	group	DDI-DrugBank.d409.s0.e2
DDI-DrugBank.d409.s0	true	DDI-DrugBank.d409.s0.e0	DDI-DrugBank.d409.s0.e1
DDI-DrugBank.d409.s0	false	DDI-DrugBank.d409.s0.e0	DDI-DrugBank.d409.s0.e2
DDI-DrugBank.d409.s0	false	DDI-DrugBank.d409.s0.e1	DDI-DrugBank.d409.s0.e2
DDI-DrugBank.d409.s1|a|Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.
DDI-DrugBank.d409.s1	40	57	tetracycline class	group	DDI-DrugBank.d409.s1.e0
DDI-DrugBank.d409.s1	62	72	antibiotics	group	DDI-DrugBank.d409.s1.e1
DDI-DrugBank.d409.s1	121	131	penicillins	group	DDI-DrugBank.d409.s1.e2
DDI-DrugBank.d409.s1	false	DDI-DrugBank.d409.s1.e0	DDI-DrugBank.d409.s1.e1
DDI-DrugBank.d409.s1	true	DDI-DrugBank.d409.s1.e0	DDI-DrugBank.d409.s1.e2
DDI-DrugBank.d409.s1	false	DDI-DrugBank.d409.s1.e1	DDI-DrugBank.d409.s1.e2
DDI-DrugBank.d409.s2|a|Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
DDI-DrugBank.d409.s2	18	30	tetracyclines	group	DDI-DrugBank.d409.s2.e0
DDI-DrugBank.d409.s2	42	55	contraceptives	group	DDI-DrugBank.d409.s2.e1
DDI-DrugBank.d409.s2	73	86	contraceptives	group	DDI-DrugBank.d409.s2.e2
DDI-DrugBank.d409.s2	true	DDI-DrugBank.d409.s2.e0	DDI-DrugBank.d409.s2.e1
DDI-DrugBank.d409.s2	false	DDI-DrugBank.d409.s2.e0	DDI-DrugBank.d409.s2.e2
DDI-DrugBank.d409.s2	false	DDI-DrugBank.d409.s2.e1	DDI-DrugBank.d409.s2.e2
DDI-DrugBank.d409.s3|a|Breakthrough bleeding has been reported
DDI-DrugBank.d182.s0|a|No clinical drug interaction studies have been conducted.
DDI-DrugBank.d182.s1|a|However, in a single in vivo rodent study denileukin diftitox had no effect on P450 levels.
DDI-DrugBank.d182.s1	42	60	denileukin diftitox	drug	DDI-DrugBank.d182.s1.e0
DDI-DrugBank.d311.s0|a|Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.
DDI-DrugBank.d311.s0	9	26	rauwolfia alkaloid	group	DDI-DrugBank.d311.s0.e0
DDI-DrugBank.d311.s0	77	90	MAO inhibitors	group	DDI-DrugBank.d311.s0.e1
DDI-DrugBank.d311.s0	true	DDI-DrugBank.d311.s0.e0	DDI-DrugBank.d311.s0.e1
DDI-DrugBank.d363.s0|a|No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials.
DDI-DrugBank.d363.s0	120	135	muscle relaxants	group	DDI-DrugBank.d363.s0.e0
DDI-DrugBank.d363.s0	168	184	anesthetic agents	group	DDI-DrugBank.d363.s0.e1
DDI-DrugBank.d363.s0	false	DDI-DrugBank.d363.s0.e0	DDI-DrugBank.d363.s0.e1
DDI-DrugBank.d363.s1|a|The effect of desflurane on the disposition of other drugs has not been determined.
DDI-DrugBank.d363.s1	14	23	desflurane	drug	DDI-DrugBank.d363.s1.e0
DDI-DrugBank.d363.s2|a|Like isoflurane, desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.
DDI-DrugBank.d363.s2	5	14	isoflurane	drug	DDI-DrugBank.d363.s2.e0
DDI-DrugBank.d363.s2	17	26	desflurane	drug	DDI-DrugBank.d363.s2.e1
DDI-DrugBank.d363.s2	124	134	epinephrine	drug	DDI-DrugBank.d363.s2.e2
DDI-DrugBank.d363.s2	false	DDI-DrugBank.d363.s2.e0	DDI-DrugBank.d363.s2.e1
DDI-DrugBank.d363.s2	false	DDI-DrugBank.d363.s2.e0	DDI-DrugBank.d363.s2.e2
DDI-DrugBank.d363.s2	false	DDI-DrugBank.d363.s2.e1	DDI-DrugBank.d363.s2.e2
DDI-DrugBank.d386.s0|a|1.
DDI-DrugBank.d386.s1|a|Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers);
DDI-DrugBank.d386.s2|a|reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
DDI-DrugBank.d386.s3|a|Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
DDI-DrugBank.d386.s3	69	93	tricyclic antidepressants	group	DDI-DrugBank.d386.s3.e0
DDI-DrugBank.d386.s3	96	99	TCAs	group	DDI-DrugBank.d386.s3.e1
DDI-DrugBank.d386.s3	false	DDI-DrugBank.d386.s3.e0	DDI-DrugBank.d386.s3.e1
DDI-DrugBank.d386.s4|a|Depending on the traction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).
DDI-DrugBank.d386.s4	163	165	TCA	group	DDI-DrugBank.d386.s4.e0
DDI-DrugBank.d386.s5|a|In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o.
DDI-DrugBank.d386.s6|a|metabolizers.
DDI-DrugBank.d386.s7|a|An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
DDI-DrugBank.d386.s7	47	49	TCA	group	DDI-DrugBank.d386.s7.e0
DDI-DrugBank.d386.s8|a|The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;
DDI-DrugBank.d386.s8	96	104	quinidine	drug	DDI-DrugBank.d386.s8.e0
DDI-DrugBank.d386.s9|a|cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).
DDI-DrugBank.d386.s9	0	9	cimetidine	drug	DDI-DrugBank.d386.s9.e0
DDI-DrugBank.d386.s9	66	80	antidepressants	group	DDI-DrugBank.d386.s9.e1
DDI-DrugBank.d386.s9	83	96	phenothiazines	group	DDI-DrugBank.d386.s9.e2
DDI-DrugBank.d386.s9	148	157	flecainide	drug	DDI-DrugBank.d386.s9.e3
DDI-DrugBank.d386.s9	false	DDI-DrugBank.d386.s9.e0	DDI-DrugBank.d386.s9.e1
DDI-DrugBank.d386.s9	false	DDI-DrugBank.d386.s9.e0	DDI-DrugBank.d386.s9.e2
DDI-DrugBank.d386.s9	false	DDI-DrugBank.d386.s9.e0	DDI-DrugBank.d386.s9.e3
DDI-DrugBank.d386.s9	false	DDI-DrugBank.d386.s9.e1	DDI-DrugBank.d386.s9.e2
DDI-DrugBank.d386.s9	false	DDI-DrugBank.d386.s9.e1	DDI-DrugBank.d386.s9.e3
DDI-DrugBank.d386.s9	false	DDI-DrugBank.d386.s9.e2	DDI-DrugBank.d386.s9.e3
DDI-DrugBank.d386.s10|a|While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
DDI-DrugBank.d386.s10	14	52	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d386.s10.e0
DDI-DrugBank.d386.s10	55	59	SSRIs	group	DDI-DrugBank.d386.s10.e1
DDI-DrugBank.d386.s10	69	78	fluoxetine	drug	DDI-DrugBank.d386.s10.e2
DDI-DrugBank.d386.s10	97	106	paroxetine	drug	DDI-DrugBank.d386.s10.e3
DDI-DrugBank.d386.s10	false	DDI-DrugBank.d386.s10.e0	DDI-DrugBank.d386.s10.e1
DDI-DrugBank.d386.s10	false	DDI-DrugBank.d386.s10.e0	DDI-DrugBank.d386.s10.e2
DDI-DrugBank.d386.s10	false	DDI-DrugBank.d386.s10.e0	DDI-DrugBank.d386.s10.e3
DDI-DrugBank.d386.s10	false	DDI-DrugBank.d386.s10.e1	DDI-DrugBank.d386.s10.e2
DDI-DrugBank.d386.s10	false	DDI-DrugBank.d386.s10.e1	DDI-DrugBank.d386.s10.e3
DDI-DrugBank.d386.s10	false	DDI-DrugBank.d386.s10.e2	DDI-DrugBank.d386.s10.e3
DDI-DrugBank.d386.s11|a|The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
DDI-DrugBank.d386.s11	20	23	SSRI	group	DDI-DrugBank.d386.s11.e0
DDI-DrugBank.d386.s11	25	27	TCA	group	DDI-DrugBank.d386.s11.e1
DDI-DrugBank.d386.s11	141	144	SSRI	group	DDI-DrugBank.d386.s11.e2
DDI-DrugBank.d386.s11	true	DDI-DrugBank.d386.s11.e0	DDI-DrugBank.d386.s11.e1
DDI-DrugBank.d386.s11	false	DDI-DrugBank.d386.s11.e0	DDI-DrugBank.d386.s11.e2
DDI-DrugBank.d386.s11	false	DDI-DrugBank.d386.s11.e1	DDI-DrugBank.d386.s11.e2
DDI-DrugBank.d386.s12|a|Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.
DDI-DrugBank.d386.s12	63	66	T.A.	group	DDI-DrugBank.d386.s12.e0
DDI-DrugBank.d386.s12	84	88	SSRIs	group	DDI-DrugBank.d386.s12.e1
DDI-DrugBank.d386.s12	true	DDI-DrugBank.d386.s12.e0	DDI-DrugBank.d386.s12.e1
DDI-DrugBank.d386.s13|a|Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
DDI-DrugBank.d386.s13	120	129	fluoxetine	drug	DDI-DrugBank.d386.s13.e0
DDI-DrugBank.d386.s14|a|Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
DDI-DrugBank.d386.s14	19	43	tricyclic antidepressants	group	DDI-DrugBank.d386.s14.e0
DDI-DrugBank.d386.s14	156	179	tricyclic antidepressant	group	DDI-DrugBank.d386.s14.e1
DDI-DrugBank.d386.s14	false	DDI-DrugBank.d386.s14.e0	DDI-DrugBank.d386.s14.e1
DDI-DrugBank.d386.s15|a|Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.
DDI-DrugBank.d386.s15	98	121	tricyclic antidepressant	group	DDI-DrugBank.d386.s15.e0
DDI-DrugBank.d386.s16|a|It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
DDI-DrugBank.d386.s16	27	29	TCA	group	DDI-DrugBank.d386.s16.e0
DDI-DrugBank.d386.s16	56	58	TCA	group	DDI-DrugBank.d386.s16.e1
DDI-DrugBank.d386.s16	false	DDI-DrugBank.d386.s16.e0	DDI-DrugBank.d386.s16.e1
DDI-DrugBank.d386.s17|a|2.
DDI-DrugBank.d386.s18|a|Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs.
DDI-DrugBank.d386.s18	107	121	anticholinergic	group	DDI-DrugBank.d386.s18.e0
DDI-DrugBank.d386.s18	126	146	sympathomimetic drugs	group	DDI-DrugBank.d386.s18.e1
DDI-DrugBank.d386.s18	false	DDI-DrugBank.d386.s18.e0	DDI-DrugBank.d386.s18.e1
DDI-DrugBank.d386.s19|a|3.
DDI-DrugBank.d386.s20|a|Clinical experience in the concurrent administration of ECT and antidepressant drugs is limited.
DDI-DrugBank.d386.s20	64	83	antidepressant drugs	group	DDI-DrugBank.d386.s20.e0
DDI-DrugBank.d386.s21|a|Thus, if such treatment is essential, the possibility of increased risk relative to benefits should be considered.
DDI-DrugBank.d386.s22|a|4.
DDI-DrugBank.d386.s23|a|If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
DDI-DrugBank.d386.s23	3	27	desipramine hydrochloride	drug	DDI-DrugBank.d386.s23.e0
DDI-DrugBank.d386.s23	58	76	psychotropic agents	group	DDI-DrugBank.d386.s23.e1
DDI-DrugBank.d386.s23	86	98	tranquilizers	group	DDI-DrugBank.d386.s23.e2
DDI-DrugBank.d386.s23	103	110	sedative	group	DDI-DrugBank.d386.s23.e3
DDI-DrugBank.d386.s23	112	120	hypnotics	group	DDI-DrugBank.d386.s23.e4
DDI-DrugBank.d386.s23	234	244	desipramine	drug	DDI-DrugBank.d386.s23.e5
DDI-DrugBank.d386.s23	250	264	benzodiazepines	group	DDI-DrugBank.d386.s23.e6
DDI-DrugBank.d386.s23	273	288	chlordiazepoxide	drug	DDI-DrugBank.d386.s23.e7
DDI-DrugBank.d386.s23	293	300	diazepam	drug	DDI-DrugBank.d386.s23.e8
DDI-DrugBank.d386.s23	true	DDI-DrugBank.d386.s23.e0	DDI-DrugBank.d386.s23.e1
DDI-DrugBank.d386.s23	true	DDI-DrugBank.d386.s23.e0	DDI-DrugBank.d386.s23.e2
DDI-DrugBank.d386.s23	true	DDI-DrugBank.d386.s23.e0	DDI-DrugBank.d386.s23.e3
DDI-DrugBank.d386.s23	true	DDI-DrugBank.d386.s23.e0	DDI-DrugBank.d386.s23.e4
DDI-DrugBank.d386.s23	false	DDI-DrugBank.d386.s23.e0	DDI-DrugBank.d386.s23.e5
DDI-DrugBank.d386.s23	false	DDI-DrugBank.d386.s23.e0	DDI-DrugBank.d386.s23.e6
DDI-DrugBank.d386.s23	false	DDI-DrugBank.d386.s23.e0	DDI-DrugBank.d386.s23.e7
DDI-DrugBank.d386.s23	false	DDI-DrugBank.d386.s23.e0	DDI-DrugBank.d386.s23.e8
DDI-DrugBank.d386.s23	false	DDI-DrugBank.d386.s23.e1	DDI-DrugBank.d386.s23.e2
DDI-DrugBank.d386.s23	false	DDI-DrugBank.d386.s23.e1	DDI-DrugBank.d386.s23.e3
DDI-DrugBank.d386.s24|a|Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.
DDI-DrugBank.d386.s24	53	71	major tranquilizers	group	DDI-DrugBank.d386.s24.e0
DDI-DrugBank.d386.s24	103	113	desipramine	drug	DDI-DrugBank.d386.s24.e1
DDI-DrugBank.d386.s24	true	DDI-DrugBank.d386.s24.e0	DDI-DrugBank.d386.s24.e1
DDI-DrugBank.d386.s25|a|5.
DDI-DrugBank.d386.s26|a|Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.
DDI-DrugBank.d386.s26	29	38	cimetidine	drug	DDI-DrugBank.d386.s26.e0
DDI-DrugBank.d386.s26	44	68	tricyclic antidepressants	group	DDI-DrugBank.d386.s26.e1
DDI-DrugBank.d386.s26	143	167	tricyclic antidepressants	group	DDI-DrugBank.d386.s26.e2
DDI-DrugBank.d386.s26	true	DDI-DrugBank.d386.s26.e0	DDI-DrugBank.d386.s26.e1
DDI-DrugBank.d386.s26	false	DDI-DrugBank.d386.s26.e0	DDI-DrugBank.d386.s26.e2
DDI-DrugBank.d386.s26	false	DDI-DrugBank.d386.s26.e1	DDI-DrugBank.d386.s26.e2
DDI-DrugBank.d386.s27|a|Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.
DDI-DrugBank.d386.s27	46	70	tricyclic antidepressants	group	DDI-DrugBank.d386.s27.e0
DDI-DrugBank.d386.s27	115	124	cimetidine	drug	DDI-DrugBank.d386.s27.e1
DDI-DrugBank.d386.s27	190	213	tricyclic antidepressant	group	DDI-DrugBank.d386.s27.e2
DDI-DrugBank.d386.s27	true	DDI-DrugBank.d386.s27.e0	DDI-DrugBank.d386.s27.e1
DDI-DrugBank.d386.s27	false	DDI-DrugBank.d386.s27.e0	DDI-DrugBank.d386.s27.e2
DDI-DrugBank.d386.s27	false	DDI-DrugBank.d386.s27.e1	DDI-DrugBank.d386.s27.e2
DDI-DrugBank.d386.s28|a|There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.
DDI-DrugBank.d386.s28	86	110	tricyclic antidepressants	group	DDI-DrugBank.d386.s28.e0
DDI-DrugBank.d386.s28	117	126	fluoxetine	drug	DDI-DrugBank.d386.s28.e1
DDI-DrugBank.d386.s28	true	DDI-DrugBank.d386.s28.e0	DDI-DrugBank.d386.s28.e1
DDI-DrugBank.d67.s0|a|In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.
DDI-DrugBank.d67.s0	140	152	desloratadine	drug	DDI-DrugBank.d67.s0.e0
DDI-DrugBank.d67.s0	223	234	erythromycin	drug	DDI-DrugBank.d67.s0.e1
DDI-DrugBank.d67.s0	260	271	ketoconazole	drug	DDI-DrugBank.d67.s0.e2
DDI-DrugBank.d67.s0	false	DDI-DrugBank.d67.s0.e0	DDI-DrugBank.d67.s0.e1
DDI-DrugBank.d67.s0	false	DDI-DrugBank.d67.s0.e0	DDI-DrugBank.d67.s0.e2
DDI-DrugBank.d67.s0	false	DDI-DrugBank.d67.s0.e1	DDI-DrugBank.d67.s0.e2
DDI-DrugBank.d67.s1|a|In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
DDI-DrugBank.d67.s1	76	88	desloratadine	drug	DDI-DrugBank.d67.s1.e0
DDI-DrugBank.d67.s1	148	159	azithromycin	drug	DDI-DrugBank.d67.s1.e1
DDI-DrugBank.d67.s1	224	233	fluoxetine	drug	DDI-DrugBank.d67.s1.e2
DDI-DrugBank.d67.s1	303	312	fluoxetine	drug	DDI-DrugBank.d67.s1.e3
DDI-DrugBank.d67.s1	329	338	cimetidine	drug	DDI-DrugBank.d67.s1.e4
DDI-DrugBank.d67.s1	false	DDI-DrugBank.d67.s1.e0	DDI-DrugBank.d67.s1.e1
DDI-DrugBank.d67.s1	false	DDI-DrugBank.d67.s1.e0	DDI-DrugBank.d67.s1.e2
DDI-DrugBank.d67.s1	false	DDI-DrugBank.d67.s1.e0	DDI-DrugBank.d67.s1.e3
DDI-DrugBank.d67.s1	false	DDI-DrugBank.d67.s1.e0	DDI-DrugBank.d67.s1.e4
DDI-DrugBank.d67.s1	false	DDI-DrugBank.d67.s1.e1	DDI-DrugBank.d67.s1.e2
DDI-DrugBank.d67.s1	false	DDI-DrugBank.d67.s1.e1	DDI-DrugBank.d67.s1.e3
DDI-DrugBank.d67.s1	false	DDI-DrugBank.d67.s1.e1	DDI-DrugBank.d67.s1.e4
DDI-DrugBank.d67.s1	false	DDI-DrugBank.d67.s1.e2	DDI-DrugBank.d67.s1.e3
DDI-DrugBank.d67.s1	false	DDI-DrugBank.d67.s1.e2	DDI-DrugBank.d67.s1.e4
DDI-DrugBank.d67.s1	false	DDI-DrugBank.d67.s1.e3	DDI-DrugBank.d67.s1.e4
DDI-DrugBank.d67.s2|a|Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.
DDI-DrugBank.d67.s2	69	81	desloratadine	drug	DDI-DrugBank.d67.s2.e0
DDI-DrugBank.d67.s2	87	108	3-hydroxydesloratadine	drug_n	DDI-DrugBank.d67.s2.e1
DDI-DrugBank.d67.s2	193	205	desloratadine	drug	DDI-DrugBank.d67.s2.e2
DDI-DrugBank.d67.s2	false	DDI-DrugBank.d67.s2.e0	DDI-DrugBank.d67.s2.e1
DDI-DrugBank.d67.s2	false	DDI-DrugBank.d67.s2.e0	DDI-DrugBank.d67.s2.e2
DDI-DrugBank.d67.s2	false	DDI-DrugBank.d67.s2.e1	DDI-DrugBank.d67.s2.e2
DDI-DrugBank.d67.s3|a|Table 1 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers
DDI-DrugBank.d67.s3	19	31	Desloratadine	drug	DDI-DrugBank.d67.s3.e0
DDI-DrugBank.d67.s3	37	58	3-Hydroxydesloratadine	drug_n	DDI-DrugBank.d67.s3.e1
DDI-DrugBank.d67.s3	false	DDI-DrugBank.d67.s3.e0	DDI-DrugBank.d67.s3.e1
DDI-DrugBank.d67.s4|a|
DDI-DrugBank.d67.s5|a|Desloratadine 3-Hydroxydesloratadine
DDI-DrugBank.d67.s5	0	12	Desloratadine	drug	DDI-DrugBank.d67.s5.e0
DDI-DrugBank.d67.s5	14	35	3-Hydroxydesloratadine	drug_n	DDI-DrugBank.d67.s5.e1
DDI-DrugBank.d67.s5	false	DDI-DrugBank.d67.s5.e0	DDI-DrugBank.d67.s5.e1
DDI-DrugBank.d67.s6|a|
DDI-DrugBank.d67.s7|a|C max AUC 0-24 hrs C max AUC 0-24 hrs
DDI-DrugBank.d67.s8|a|Erythromycin
DDI-DrugBank.d67.s8	0	11	Erythromycin	drug	DDI-DrugBank.d67.s8.e0
DDI-DrugBank.d67.s9|a|(500 mg Q8h)
DDI-DrugBank.d67.s10|a|+24% +14% +43% +40%
DDI-DrugBank.d67.s11|a|Ketoconazole
DDI-DrugBank.d67.s11	0	11	Ketoconazole	drug	DDI-DrugBank.d67.s11.e0
DDI-DrugBank.d67.s12|a|(200 mg Q12h)
DDI-DrugBank.d67.s13|a|+45% +39% +43% +72%
DDI-DrugBank.d67.s14|a|Azithromycin
DDI-DrugBank.d67.s14	0	11	Azithromycin	drug	DDI-DrugBank.d67.s14.e0
DDI-DrugBank.d67.s15|a|(500 mg day 1, 250 mg QD   4 days)
DDI-DrugBank.d67.s16|a|+15% +5% +15% +4%
DDI-DrugBank.d67.s17|a|Fluoxetine
DDI-DrugBank.d67.s17	0	9	Fluoxetine	drug	DDI-DrugBank.d67.s17.e0
DDI-DrugBank.d67.s18|a|(20 mg QD)
DDI-DrugBank.d67.s19|a|+15% +0% +17% +13%
DDI-DrugBank.d67.s20|a|Cimetidine
DDI-DrugBank.d67.s20	0	9	Cimetidine	drug	DDI-DrugBank.d67.s20.e0
DDI-DrugBank.d67.s21|a|(600 mg Q12h)
DDI-DrugBank.d67.s22|a|+12% +19% -11%  -3%
DDI-DrugBank.d348.s0|a|Although the pressor activity of Desmopressin is very low compared to its antidiuretic activity, large doses of Desmopressin Tablets should be used with other pressor agents only with careful patient monitoring.
DDI-DrugBank.d348.s0	33	44	Desmopressin	drug	DDI-DrugBank.d348.s0.e0
DDI-DrugBank.d348.s0	112	123	Desmopressin	drug	DDI-DrugBank.d348.s0.e1
DDI-DrugBank.d348.s0	false	DDI-DrugBank.d348.s0.e0	DDI-DrugBank.d348.s0.e1
DDI-DrugBank.d285.s0|a|Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin.
DDI-DrugBank.d285.s0	140	147	rifampin	drug	DDI-DrugBank.d285.s0.e0
DDI-DrugBank.d285.s1|a|A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)
DDI-DrugBank.d285.s1	67	78	barbiturates	group	DDI-DrugBank.d285.s1.e0
DDI-DrugBank.d285.s1	98	113	phenytoin sodium	drug	DDI-DrugBank.d285.s1.e1
DDI-DrugBank.d285.s1	116	128	carbamazepine	drug	DDI-DrugBank.d285.s1.e2
DDI-DrugBank.d285.s1	148	159	griseofulvin	drug	DDI-DrugBank.d285.s1.e3
DDI-DrugBank.d285.s1	162	171	ampicillin	drug	DDI-DrugBank.d285.s1.e4
DDI-DrugBank.d285.s1	178	190	tetracyclines	group	DDI-DrugBank.d285.s1.e5
DDI-DrugBank.d285.s1	false	DDI-DrugBank.d285.s1.e0	DDI-DrugBank.d285.s1.e1
DDI-DrugBank.d285.s1	false	DDI-DrugBank.d285.s1.e0	DDI-DrugBank.d285.s1.e2
DDI-DrugBank.d285.s1	false	DDI-DrugBank.d285.s1.e0	DDI-DrugBank.d285.s1.e3
DDI-DrugBank.d285.s1	false	DDI-DrugBank.d285.s1.e0	DDI-DrugBank.d285.s1.e4
DDI-DrugBank.d285.s1	false	DDI-DrugBank.d285.s1.e0	DDI-DrugBank.d285.s1.e5
DDI-DrugBank.d285.s1	false	DDI-DrugBank.d285.s1.e1	DDI-DrugBank.d285.s1.e2
DDI-DrugBank.d285.s1	false	DDI-DrugBank.d285.s1.e1	DDI-DrugBank.d285.s1.e3
DDI-DrugBank.d285.s1	false	DDI-DrugBank.d285.s1.e1	DDI-DrugBank.d285.s1.e4
DDI-DrugBank.d285.s1	false	DDI-DrugBank.d285.s1.e1	DDI-DrugBank.d285.s1.e5
DDI-DrugBank.d285.s1	false	DDI-DrugBank.d285.s1.e2	DDI-DrugBank.d285.s1.e3
DDI-DrugBank.d285.s2|a|.
DDI-DrugBank.d285.s3|a|
DDI-DrugBank.d285.s4|a|
DDI-DrugBank.d280.s0|a|No specific information available
DDI-DrugBank.d280.s1|a|.
DDI-DrugBank.d280.s2|a|
DDI-DrugBank.d314.s0|a|Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.
DDI-DrugBank.d314.s0	0	16	Aminoglutethimide	drug	DDI-DrugBank.d314.s0.e0
DDI-DrugBank.d314.s0	19	35	Aminoglutethimide	drug	DDI-DrugBank.d314.s0.e1
DDI-DrugBank.d314.s0	73	87	corticosteroids	group	DDI-DrugBank.d314.s0.e2
DDI-DrugBank.d314.s0	false	DDI-DrugBank.d314.s0.e0	DDI-DrugBank.d314.s0.e1
DDI-DrugBank.d314.s0	false	DDI-DrugBank.d314.s0.e0	DDI-DrugBank.d314.s0.e2
DDI-DrugBank.d314.s0	true	DDI-DrugBank.d314.s0.e1	DDI-DrugBank.d314.s0.e2
DDI-DrugBank.d314.s1|a|Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.
DDI-DrugBank.d314.s1	0	13	Amphotericin B	drug	DDI-DrugBank.d314.s1.e0
DDI-DrugBank.d314.s1	62	76	corticosteroids	group	DDI-DrugBank.d314.s1.e1
DDI-DrugBank.d314.s1	148	161	amphotericin B	drug	DDI-DrugBank.d314.s1.e2
DDI-DrugBank.d314.s1	164	172	diuretics	group	DDI-DrugBank.d314.s1.e3
DDI-DrugBank.d314.s1	false	DDI-DrugBank.d314.s1.e0	DDI-DrugBank.d314.s1.e1
DDI-DrugBank.d314.s1	false	DDI-DrugBank.d314.s1.e0	DDI-DrugBank.d314.s1.e2
DDI-DrugBank.d314.s1	false	DDI-DrugBank.d314.s1.e0	DDI-DrugBank.d314.s1.e3
DDI-DrugBank.d314.s1	true	DDI-DrugBank.d314.s1.e1	DDI-DrugBank.d314.s1.e2
DDI-DrugBank.d314.s1	true	DDI-DrugBank.d314.s1.e1	DDI-DrugBank.d314.s1.e3
DDI-DrugBank.d314.s1	false	DDI-DrugBank.d314.s1.e2	DDI-DrugBank.d314.s1.e3
DDI-DrugBank.d314.s2|a|In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
DDI-DrugBank.d314.s2	72	85	amphotericin B	drug	DDI-DrugBank.d314.s2.e0
DDI-DrugBank.d314.s2	91	104	hydrocortisone	drug	DDI-DrugBank.d314.s2.e1
DDI-DrugBank.d314.s2	true	DDI-DrugBank.d314.s2.e0	DDI-DrugBank.d314.s2.e1
DDI-DrugBank.d314.s3|a|Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.
DDI-DrugBank.d314.s3	0	10	Antibiotics	group	DDI-DrugBank.d314.s3.e0
DDI-DrugBank.d314.s3	13	33	Macrolide antibiotics	group	DDI-DrugBank.d314.s3.e1
DDI-DrugBank.d314.s3	89	102	corticosteroid	group	DDI-DrugBank.d314.s3.e2
DDI-DrugBank.d314.s3	false	DDI-DrugBank.d314.s3.e0	DDI-DrugBank.d314.s3.e1
DDI-DrugBank.d314.s3	false	DDI-DrugBank.d314.s3.e0	DDI-DrugBank.d314.s3.e2
DDI-DrugBank.d314.s3	true	DDI-DrugBank.d314.s3.e1	DDI-DrugBank.d314.s3.e2
DDI-DrugBank.d314.s4|a|Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.
DDI-DrugBank.d314.s4	0	18	Anticholinesterases	group	DDI-DrugBank.d314.s4.e0
DDI-DrugBank.d314.s4	40	64	anticholinesterase agents	group	DDI-DrugBank.d314.s4.e1
DDI-DrugBank.d314.s4	70	84	corticosteroids	group	DDI-DrugBank.d314.s4.e2
DDI-DrugBank.d314.s4	false	DDI-DrugBank.d314.s4.e0	DDI-DrugBank.d314.s4.e1
DDI-DrugBank.d314.s4	false	DDI-DrugBank.d314.s4.e0	DDI-DrugBank.d314.s4.e2
DDI-DrugBank.d314.s4	true	DDI-DrugBank.d314.s4.e1	DDI-DrugBank.d314.s4.e2
DDI-DrugBank.d314.s5|a|If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.
DDI-DrugBank.d314.s5	13	37	anticholinesterase agents	group	DDI-DrugBank.d314.s5.e0
DDI-DrugBank.d314.s5	95	108	corticosteroid	group	DDI-DrugBank.d314.s5.e1
DDI-DrugBank.d314.s5	true	DDI-DrugBank.d314.s5.e0	DDI-DrugBank.d314.s5.e1
DDI-DrugBank.d314.s6|a|Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.
DDI-DrugBank.d314.s6	0	13	Anticoagulants	group	DDI-DrugBank.d314.s6.e0
DDI-DrugBank.d314.s6	43	57	corticosteroids	group	DDI-DrugBank.d314.s6.e1
DDI-DrugBank.d314.s6	63	70	warfarin	drug	DDI-DrugBank.d314.s6.e2
DDI-DrugBank.d314.s6	117	124	warfarin	drug	DDI-DrugBank.d314.s6.e3
DDI-DrugBank.d314.s6	false	DDI-DrugBank.d314.s6.e0	DDI-DrugBank.d314.s6.e1
DDI-DrugBank.d314.s6	false	DDI-DrugBank.d314.s6.e0	DDI-DrugBank.d314.s6.e2
DDI-DrugBank.d314.s6	false	DDI-DrugBank.d314.s6.e0	DDI-DrugBank.d314.s6.e3
DDI-DrugBank.d314.s6	true	DDI-DrugBank.d314.s6.e1	DDI-DrugBank.d314.s6.e2
DDI-DrugBank.d314.s6	false	DDI-DrugBank.d314.s6.e1	DDI-DrugBank.d314.s6.e3
DDI-DrugBank.d314.s6	false	DDI-DrugBank.d314.s6.e2	DDI-DrugBank.d314.s6.e3
DDI-DrugBank.d314.s7|a|Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.
DDI-DrugBank.d314.s8|a|Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.
DDI-DrugBank.d314.s8	0	12	Antidiabetics	group	DDI-DrugBank.d314.s8.e0
DDI-DrugBank.d314.s8	23	37	corticosteroids	group	DDI-DrugBank.d314.s8.e1
DDI-DrugBank.d314.s8	104	122	antidiabetic agents	group	DDI-DrugBank.d314.s8.e2
DDI-DrugBank.d314.s8	false	DDI-DrugBank.d314.s8.e0	DDI-DrugBank.d314.s8.e1
DDI-DrugBank.d314.s8	false	DDI-DrugBank.d314.s8.e0	DDI-DrugBank.d314.s8.e2
DDI-DrugBank.d314.s8	true	DDI-DrugBank.d314.s8.e1	DDI-DrugBank.d314.s8.e2
DDI-DrugBank.d314.s9|a|Antitubercular drugs: Serum concentrations of isoniazid may be decreased.
DDI-DrugBank.d314.s9	46	54	isoniazid	drug	DDI-DrugBank.d314.s9.e0
DDI-DrugBank.d314.s10|a|Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.
DDI-DrugBank.d314.s10	0	13	Cholestyramine	drug	DDI-DrugBank.d314.s10.e0
DDI-DrugBank.d314.s10	16	29	Cholestyramine	drug	DDI-DrugBank.d314.s10.e1
DDI-DrugBank.d314.s10	61	75	corticosteroids	group	DDI-DrugBank.d314.s10.e2
DDI-DrugBank.d314.s10	false	DDI-DrugBank.d314.s10.e0	DDI-DrugBank.d314.s10.e1
DDI-DrugBank.d314.s10	false	DDI-DrugBank.d314.s10.e0	DDI-DrugBank.d314.s10.e2
DDI-DrugBank.d314.s10	true	DDI-DrugBank.d314.s10.e1	DDI-DrugBank.d314.s10.e2
DDI-DrugBank.d314.s11|a|Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.
DDI-DrugBank.d314.s11	0	11	Cyclosporine	drug	DDI-DrugBank.d314.s11.e0
DDI-DrugBank.d314.s11	41	52	cyclosporine	drug	DDI-DrugBank.d314.s11.e1
DDI-DrugBank.d314.s11	58	72	corticosteroids	group	DDI-DrugBank.d314.s11.e2
DDI-DrugBank.d314.s11	false	DDI-DrugBank.d314.s11.e0	DDI-DrugBank.d314.s11.e1
DDI-DrugBank.d314.s11	false	DDI-DrugBank.d314.s11.e0	DDI-DrugBank.d314.s11.e2
DDI-DrugBank.d314.s11	true	DDI-DrugBank.d314.s11.e1	DDI-DrugBank.d314.s11.e2
DDI-DrugBank.d314.s12|a|Convulsions have been reported with this concurrent use.
DDI-DrugBank.d314.s13|a|Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported.
DDI-DrugBank.d314.s13	136	147	indomethacin	drug	DDI-DrugBank.d314.s13.e0
DDI-DrugBank.d314.s14|a|Thus, results of the DST should be interpreted with caution in these patients.
DDI-DrugBank.d314.s15|a|Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.
DDI-DrugBank.d314.s15	0	19	Digitalis glycosides	group	DDI-DrugBank.d314.s15.e0
DDI-DrugBank.d314.s15	34	53	digitalis glycosides	group	DDI-DrugBank.d314.s15.e1
DDI-DrugBank.d314.s15	false	DDI-DrugBank.d314.s15.e0	DDI-DrugBank.d314.s15.e1
DDI-DrugBank.d314.s16|a|Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
DDI-DrugBank.d314.s16	0	8	Ephedrine	drug	DDI-DrugBank.d314.s16.e0
DDI-DrugBank.d314.s16	11	19	Ephedrine	drug	DDI-DrugBank.d314.s16.e1
DDI-DrugBank.d314.s16	60	74	corticosteroids	group	DDI-DrugBank.d314.s16.e2
DDI-DrugBank.d314.s16	178	191	corticosteroid	group	DDI-DrugBank.d314.s16.e3
DDI-DrugBank.d314.s16	false	DDI-DrugBank.d314.s16.e0	DDI-DrugBank.d314.s16.e1
DDI-DrugBank.d314.s16	false	DDI-DrugBank.d314.s16.e0	DDI-DrugBank.d314.s16.e2
DDI-DrugBank.d314.s16	false	DDI-DrugBank.d314.s16.e0	DDI-DrugBank.d314.s16.e3
DDI-DrugBank.d314.s16	true	DDI-DrugBank.d314.s16.e1	DDI-DrugBank.d314.s16.e2
DDI-DrugBank.d314.s16	false	DDI-DrugBank.d314.s16.e1	DDI-DrugBank.d314.s16.e3
DDI-DrugBank.d314.s16	false	DDI-DrugBank.d314.s16.e2	DDI-DrugBank.d314.s16.e3
DDI-DrugBank.d314.s17|a|Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
DDI-DrugBank.d314.s17	0	8	Estrogens	group	DDI-DrugBank.d314.s17.e0
DDI-DrugBank.d314.s17	26	39	contraceptives	group	DDI-DrugBank.d314.s17.e1
DDI-DrugBank.d314.s17	42	50	Estrogens	group	DDI-DrugBank.d314.s17.e2
DDI-DrugBank.d314.s17	99	113	corticosteroids	group	DDI-DrugBank.d314.s17.e3
DDI-DrugBank.d314.s17	false	DDI-DrugBank.d314.s17.e0	DDI-DrugBank.d314.s17.e1
DDI-DrugBank.d314.s17	false	DDI-DrugBank.d314.s17.e0	DDI-DrugBank.d314.s17.e2
DDI-DrugBank.d314.s17	false	DDI-DrugBank.d314.s17.e0	DDI-DrugBank.d314.s17.e3
DDI-DrugBank.d314.s17	false	DDI-DrugBank.d314.s17.e1	DDI-DrugBank.d314.s17.e2
DDI-DrugBank.d314.s17	false	DDI-DrugBank.d314.s17.e1	DDI-DrugBank.d314.s17.e3
DDI-DrugBank.d314.s17	true	DDI-DrugBank.d314.s17.e2	DDI-DrugBank.d314.s17.e3
DDI-DrugBank.d314.s18|a|Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
DDI-DrugBank.d314.s18	124	135	barbiturates	group	DDI-DrugBank.d314.s18.e0
DDI-DrugBank.d314.s18	138	146	phenytoin	drug	DDI-DrugBank.d314.s18.e1
DDI-DrugBank.d314.s18	149	161	carbamazepine	drug	DDI-DrugBank.d314.s18.e2
DDI-DrugBank.d314.s18	164	171	rifampin	drug	DDI-DrugBank.d314.s18.e3
DDI-DrugBank.d314.s18	204	218	corticosteroids	group	DDI-DrugBank.d314.s18.e4
DDI-DrugBank.d314.s18	255	268	corticosteroid	group	DDI-DrugBank.d314.s18.e5
DDI-DrugBank.d314.s18	false	DDI-DrugBank.d314.s18.e0	DDI-DrugBank.d314.s18.e1
DDI-DrugBank.d314.s18	false	DDI-DrugBank.d314.s18.e0	DDI-DrugBank.d314.s18.e2
DDI-DrugBank.d314.s18	false	DDI-DrugBank.d314.s18.e0	DDI-DrugBank.d314.s18.e3
DDI-DrugBank.d314.s18	true	DDI-DrugBank.d314.s18.e0	DDI-DrugBank.d314.s18.e4
DDI-DrugBank.d314.s18	false	DDI-DrugBank.d314.s18.e0	DDI-DrugBank.d314.s18.e5
DDI-DrugBank.d314.s18	false	DDI-DrugBank.d314.s18.e1	DDI-DrugBank.d314.s18.e2
DDI-DrugBank.d314.s18	false	DDI-DrugBank.d314.s18.e1	DDI-DrugBank.d314.s18.e3
DDI-DrugBank.d314.s18	true	DDI-DrugBank.d314.s18.e1	DDI-DrugBank.d314.s18.e4
DDI-DrugBank.d314.s18	false	DDI-DrugBank.d314.s18.e1	DDI-DrugBank.d314.s18.e5
DDI-DrugBank.d314.s18	false	DDI-DrugBank.d314.s18.e2	DDI-DrugBank.d314.s18.e3
DDI-DrugBank.d314.s19|a|Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
DDI-DrugBank.d314.s19	35	46	ketoconazole	drug	DDI-DrugBank.d314.s19.e0
DDI-DrugBank.d314.s19	49	69	macrolide antibiotics	group	DDI-DrugBank.d314.s19.e1
DDI-DrugBank.d314.s19	79	90	erythromycin	drug	DDI-DrugBank.d314.s19.e2
DDI-DrugBank.d314.s19	160	174	corticosteroids	group	DDI-DrugBank.d314.s19.e3
DDI-DrugBank.d314.s19	false	DDI-DrugBank.d314.s19.e0	DDI-DrugBank.d314.s19.e1
DDI-DrugBank.d314.s19	false	DDI-DrugBank.d314.s19.e0	DDI-DrugBank.d314.s19.e2
DDI-DrugBank.d314.s19	true	DDI-DrugBank.d314.s19.e0	DDI-DrugBank.d314.s19.e3
DDI-DrugBank.d314.s19	false	DDI-DrugBank.d314.s19.e1	DDI-DrugBank.d314.s19.e2
DDI-DrugBank.d314.s19	true	DDI-DrugBank.d314.s19.e1	DDI-DrugBank.d314.s19.e3
DDI-DrugBank.d314.s19	true	DDI-DrugBank.d314.s19.e2	DDI-DrugBank.d314.s19.e3
DDI-DrugBank.d314.s20|a|Dexamethasone is a moderate inducer of CYP 3A4.
DDI-DrugBank.d314.s20	0	12	Dexamethasone	drug	DDI-DrugBank.d314.s20.e0
DDI-DrugBank.d314.s21|a|Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration.
DDI-DrugBank.d314.s21	74	82	indinavir	drug	DDI-DrugBank.d314.s21.e0
DDI-DrugBank.d314.s21	85	96	erythromycin	drug	DDI-DrugBank.d314.s21.e1
DDI-DrugBank.d314.s21	false	DDI-DrugBank.d314.s21.e0	DDI-DrugBank.d314.s21.e1
DDI-DrugBank.d314.s22|a|Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.
DDI-DrugBank.d314.s22	0	11	Ketoconazole	drug	DDI-DrugBank.d314.s22.e0
DDI-DrugBank.d314.s22	14	25	Ketoconazole	drug	DDI-DrugBank.d314.s22.e1
DDI-DrugBank.d314.s22	83	97	corticosteroids	group	DDI-DrugBank.d314.s22.e2
DDI-DrugBank.d314.s22	142	155	corticosteroid	group	DDI-DrugBank.d314.s22.e3
DDI-DrugBank.d314.s22	false	DDI-DrugBank.d314.s22.e0	DDI-DrugBank.d314.s22.e1
DDI-DrugBank.d314.s22	false	DDI-DrugBank.d314.s22.e0	DDI-DrugBank.d314.s22.e2
DDI-DrugBank.d314.s22	false	DDI-DrugBank.d314.s22.e0	DDI-DrugBank.d314.s22.e3
DDI-DrugBank.d314.s22	true	DDI-DrugBank.d314.s22.e1	DDI-DrugBank.d314.s22.e2
DDI-DrugBank.d314.s22	false	DDI-DrugBank.d314.s22.e1	DDI-DrugBank.d314.s22.e3
DDI-DrugBank.d314.s22	false	DDI-DrugBank.d314.s22.e2	DDI-DrugBank.d314.s22.e3
DDI-DrugBank.d314.s23|a|In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.
DDI-DrugBank.d314.s23	13	24	ketoconazole	drug	DDI-DrugBank.d314.s23.e0
DDI-DrugBank.d314.s23	52	65	corticosteroid	drug	DDI-DrugBank.d314.s23.e1
DDI-DrugBank.d314.s23	true	DDI-DrugBank.d314.s23.e0	DDI-DrugBank.d314.s23.e1
DDI-DrugBank.d314.s24|a|Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
DDI-DrugBank.d314.s24	0	36	Nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d314.s24.e0
DDI-DrugBank.d314.s24	39	44	NSAIDS	group	DDI-DrugBank.d314.s24.e1
DDI-DrugBank.d314.s24	67	73	aspirin	brand	DDI-DrugBank.d314.s24.e2
DDI-DrugBank.d314.s24	85	120	nonsteroidal antiinflammatory agents	group	DDI-DrugBank.d314.s24.e3
DDI-DrugBank.d314.s24	127	141	corticosteroids	group	DDI-DrugBank.d314.s24.e4
DDI-DrugBank.d314.s24	false	DDI-DrugBank.d314.s24.e0	DDI-DrugBank.d314.s24.e1
DDI-DrugBank.d314.s24	false	DDI-DrugBank.d314.s24.e0	DDI-DrugBank.d314.s24.e2
DDI-DrugBank.d314.s24	false	DDI-DrugBank.d314.s24.e0	DDI-DrugBank.d314.s24.e3
DDI-DrugBank.d314.s24	false	DDI-DrugBank.d314.s24.e0	DDI-DrugBank.d314.s24.e4
DDI-DrugBank.d314.s24	false	DDI-DrugBank.d314.s24.e1	DDI-DrugBank.d314.s24.e2
DDI-DrugBank.d314.s24	false	DDI-DrugBank.d314.s24.e1	DDI-DrugBank.d314.s24.e3
DDI-DrugBank.d314.s24	false	DDI-DrugBank.d314.s24.e1	DDI-DrugBank.d314.s24.e4
DDI-DrugBank.d314.s24	false	DDI-DrugBank.d314.s24.e2	DDI-DrugBank.d314.s24.e3
DDI-DrugBank.d314.s24	true	DDI-DrugBank.d314.s24.e2	DDI-DrugBank.d314.s24.e4
DDI-DrugBank.d314.s24	true	DDI-DrugBank.d314.s24.e3	DDI-DrugBank.d314.s24.e4
DDI-DrugBank.d314.s25|a|Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
DDI-DrugBank.d314.s25	0	6	Aspirin	brand	DDI-DrugBank.d314.s25.e0
DDI-DrugBank.d314.s25	54	68	corticosteroids	group	DDI-DrugBank.d314.s25.e1
DDI-DrugBank.d314.s25	true	DDI-DrugBank.d314.s25.e0	DDI-DrugBank.d314.s25.e1
DDI-DrugBank.d314.s26|a|The clearance of salicylates may be increased with concurrent use of corticosteroids.
DDI-DrugBank.d314.s26	17	27	salicylates	group	DDI-DrugBank.d314.s26.e0
DDI-DrugBank.d314.s26	69	83	corticosteroids	group	DDI-DrugBank.d314.s26.e1
DDI-DrugBank.d314.s26	true	DDI-DrugBank.d314.s26.e0	DDI-DrugBank.d314.s26.e1
DDI-DrugBank.d314.s27|a|Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.
DDI-DrugBank.d314.s27	0	8	Phenytoin	drug	DDI-DrugBank.d314.s27.e0
DDI-DrugBank.d314.s27	100	108	phenytoin	drug	DDI-DrugBank.d314.s27.e1
DDI-DrugBank.d314.s27	122	134	dexamethasone	drug	DDI-DrugBank.d314.s27.e2
DDI-DrugBank.d314.s27	false	DDI-DrugBank.d314.s27.e0	DDI-DrugBank.d314.s27.e1
DDI-DrugBank.d314.s27	false	DDI-DrugBank.d314.s27.e0	DDI-DrugBank.d314.s27.e2
DDI-DrugBank.d314.s27	true	DDI-DrugBank.d314.s27.e1	DDI-DrugBank.d314.s27.e2
DDI-DrugBank.d314.s28|a|Skin tests: Corticosteroids may suppress reactions to skin tests.
DDI-DrugBank.d314.s28	12	26	Corticosteroids	group	DDI-DrugBank.d314.s28.e0
DDI-DrugBank.d314.s29|a|Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.
DDI-DrugBank.d314.s29	0	10	Thalidomide	drug	DDI-DrugBank.d314.s29.e0
DDI-DrugBank.d314.s29	36	46	thalidomide	drug	DDI-DrugBank.d314.s29.e1
DDI-DrugBank.d314.s29	false	DDI-DrugBank.d314.s29.e0	DDI-DrugBank.d314.s29.e1
DDI-DrugBank.d314.s30|a|Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
DDI-DrugBank.d314.s30	0	7	Vaccines	group	DDI-DrugBank.d314.s30.e0
DDI-DrugBank.d314.s30	22	35	corticosteroid	group	DDI-DrugBank.d314.s30.e1
DDI-DrugBank.d314.s30	94	97	live vaccines	group	DDI-DrugBank.d314.s30.e2
DDI-DrugBank.d314.s30	114	121	live vaccines	group	DDI-DrugBank.d314.s30.e2
DDI-DrugBank.d314.s30	102	121	inactivated vaccines	group	DDI-DrugBank.d314.s30.e3
DDI-DrugBank.d314.s30	false	DDI-DrugBank.d314.s30.e0	DDI-DrugBank.d314.s30.e1
DDI-DrugBank.d314.s30	false	DDI-DrugBank.d314.s30.e0	DDI-DrugBank.d314.s30.e2
DDI-DrugBank.d314.s30	false	DDI-DrugBank.d314.s30.e0	DDI-DrugBank.d314.s30.e3
DDI-DrugBank.d314.s30	true	DDI-DrugBank.d314.s30.e1	DDI-DrugBank.d314.s30.e2
DDI-DrugBank.d314.s30	true	DDI-DrugBank.d314.s30.e1	DDI-DrugBank.d314.s30.e3
DDI-DrugBank.d314.s30	false	DDI-DrugBank.d314.s30.e2	DDI-DrugBank.d314.s30.e3
DDI-DrugBank.d314.s31|a|Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.
DDI-DrugBank.d314.s31	0	14	Corticosteroids	group	DDI-DrugBank.d314.s31.e0
DDI-DrugBank.d314.s31	83	106	live attenuated vaccines	group	DDI-DrugBank.d314.s31.e1
DDI-DrugBank.d314.s31	true	DDI-DrugBank.d314.s31.e0	DDI-DrugBank.d314.s31.e1
DDI-DrugBank.d314.s32|a|Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.
DDI-DrugBank.d314.s32	26	33	vaccines	group	DDI-DrugBank.d314.s32.e0
DDI-DrugBank.d314.s32	71	84	corticosteroid	group	DDI-DrugBank.d314.s32.e1
DDI-DrugBank.d314.s32	true	DDI-DrugBank.d314.s32.e0	DDI-DrugBank.d314.s32.e1
DDI-DrugBank.d62.s0|a|Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d62.s0	0	17	Dexbrompheniramine	drug	DDI-DrugBank.d62.s0.e0
DDI-DrugBank.d62.s0	37	43	alcohol	drug	DDI-DrugBank.d62.s0.e1
DDI-DrugBank.d62.s0	54	68	CNS depressants	group	DDI-DrugBank.d62.s0.e2
DDI-DrugBank.d62.s0	144	157	antihistamines	group	DDI-DrugBank.d62.s0.e3
DDI-DrugBank.d62.s0	161	176	anticholinergics	group	DDI-DrugBank.d62.s0.e4
DDI-DrugBank.d62.s0	323	336	antihistamines	group	DDI-DrugBank.d62.s0.e5
DDI-DrugBank.d62.s0	344	377	monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d62.s0.e6
DDI-DrugBank.d62.s0	400	413	antihistamines	group	DDI-DrugBank.d62.s0.e7
DDI-DrugBank.d62.s0	491	504	antihistamines	group	DDI-DrugBank.d62.s0.e8
DDI-DrugBank.d62.s0	true	DDI-DrugBank.d62.s0.e0	DDI-DrugBank.d62.s0.e1
DDI-DrugBank.d62.s0	true	DDI-DrugBank.d62.s0.e0	DDI-DrugBank.d62.s0.e2
DDI-DrugBank.d62.s0	false	DDI-DrugBank.d62.s0.e0	DDI-DrugBank.d62.s0.e3
DDI-DrugBank.d62.s0	true	DDI-DrugBank.d62.s0.e0	DDI-DrugBank.d62.s0.e4
DDI-DrugBank.d62.s0	false	DDI-DrugBank.d62.s0.e0	DDI-DrugBank.d62.s0.e5
DDI-DrugBank.d62.s0	true	DDI-DrugBank.d62.s0.e0	DDI-DrugBank.d62.s0.e6
DDI-DrugBank.d62.s0	false	DDI-DrugBank.d62.s0.e0	DDI-DrugBank.d62.s0.e7
DDI-DrugBank.d62.s0	false	DDI-DrugBank.d62.s0.e0	DDI-DrugBank.d62.s0.e8
DDI-DrugBank.d62.s0	false	DDI-DrugBank.d62.s0.e1	DDI-DrugBank.d62.s0.e2
DDI-DrugBank.d62.s0	false	DDI-DrugBank.d62.s0.e1	DDI-DrugBank.d62.s0.e3
DDI-DrugBank.d423.s0|a|In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0	35	62	monoamine oxidase inhibitors	group	DDI-DrugBank.d423.s0.e0
DDI-DrugBank.d423.s0	65	69	MAOIs	group	DDI-DrugBank.d423.s0.e1
DDI-DrugBank.d423.s0	79	102	selegiline hydrochloride	drug	DDI-DrugBank.d423.s0.e2
DDI-DrugBank.d423.s0	125	145	serotoninergic agents	group	DDI-DrugBank.d423.s0.e3
DDI-DrugBank.d423.s0	154	163	fluoxetine	drug	DDI-DrugBank.d423.s0.e4
DDI-DrugBank.d423.s0	166	176	fluvoxamine	drug	DDI-DrugBank.d423.s0.e5
DDI-DrugBank.d423.s0	179	188	paroxetine	drug	DDI-DrugBank.d423.s0.e6
DDI-DrugBank.d423.s0	191	200	sertraline	drug	DDI-DrugBank.d423.s0.e7
DDI-DrugBank.d423.s0	203	213	venlafaxine	drug	DDI-DrugBank.d423.s0.e8
DDI-DrugBank.d423.s0	false	DDI-DrugBank.d423.s0.e0	DDI-DrugBank.d423.s0.e1
DDI-DrugBank.d423.s0	false	DDI-DrugBank.d423.s0.e0	DDI-DrugBank.d423.s0.e2
DDI-DrugBank.d423.s0	true	DDI-DrugBank.d423.s0.e0	DDI-DrugBank.d423.s0.e3
DDI-DrugBank.d423.s0	true	DDI-DrugBank.d423.s0.e0	DDI-DrugBank.d423.s0.e4
DDI-DrugBank.d423.s0	true	DDI-DrugBank.d423.s0.e0	DDI-DrugBank.d423.s0.e5
DDI-DrugBank.d423.s0	true	DDI-DrugBank.d423.s0.e0	DDI-DrugBank.d423.s0.e6
DDI-DrugBank.d423.s0	true	DDI-DrugBank.d423.s0.e0	DDI-DrugBank.d423.s0.e7
DDI-DrugBank.d423.s0	true	DDI-DrugBank.d423.s0.e0	DDI-DrugBank.d423.s0.e8
DDI-DrugBank.d423.s0	false	DDI-DrugBank.d423.s0.e1	DDI-DrugBank.d423.s0.e2
DDI-DrugBank.d423.s0	true	DDI-DrugBank.d423.s0.e1	DDI-DrugBank.d423.s0.e3
DDI-DrugBank.d423.s1|a|Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.
DDI-DrugBank.d423.s1	8	22	dexfenfluramine	drug	DDI-DrugBank.d423.s1.e0
DDI-DrugBank.d423.s1	72	86	dexfenfluramine	drug	DDI-DrugBank.d423.s1.e1
DDI-DrugBank.d423.s1	128	140	MAO inhibitor	group	DDI-DrugBank.d423.s1.e2
DDI-DrugBank.d423.s1	false	DDI-DrugBank.d423.s1.e0	DDI-DrugBank.d423.s1.e1
DDI-DrugBank.d423.s1	false	DDI-DrugBank.d423.s1.e0	DDI-DrugBank.d423.s1.e2
DDI-DrugBank.d423.s1	true	DDI-DrugBank.d423.s1.e1	DDI-DrugBank.d423.s1.e2
DDI-DrugBank.d423.s2|a|At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.
DDI-DrugBank.d423.s2	60	72	MAO inhibitor	group	DDI-DrugBank.d423.s2.e0
DDI-DrugBank.d423.s2	107	121	dexfenfluramine	drug	DDI-DrugBank.d423.s2.e1
DDI-DrugBank.d423.s2	true	DDI-DrugBank.d423.s2.e0	DDI-DrugBank.d423.s2.e1
DDI-DrugBank.d423.s3|a|At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.
DDI-DrugBank.d423.s3	58	72	dexfenfluramine	drug	DDI-DrugBank.d423.s3.e0
DDI-DrugBank.d423.s3	109	121	MAO inhibitor	group	DDI-DrugBank.d423.s3.e1
DDI-DrugBank.d423.s3	true	DDI-DrugBank.d423.s3.e0	DDI-DrugBank.d423.s3.e1
DDI-DrugBank.d423.s4|a|A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
DDI-DrugBank.d423.s4	121	159	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d423.s4.e0
DDI-DrugBank.d423.s4	162	166	SSRIs	group	DDI-DrugBank.d423.s4.e1
DDI-DrugBank.d423.s4	210	216	Imitrex	brand	DDI-DrugBank.d423.s4.e2
DDI-DrugBank.d423.s4	219	239	sumatriptan succinate	drug	DDI-DrugBank.d423.s4.e3
DDI-DrugBank.d423.s4	246	262	dihydroergotamine	drug	DDI-DrugBank.d423.s4.e4
DDI-DrugBank.d423.s4	false	DDI-DrugBank.d423.s4.e0	DDI-DrugBank.d423.s4.e1
DDI-DrugBank.d423.s4	true	DDI-DrugBank.d423.s4.e0	DDI-DrugBank.d423.s4.e2
DDI-DrugBank.d423.s4	true	DDI-DrugBank.d423.s4.e0	DDI-DrugBank.d423.s4.e3
DDI-DrugBank.d423.s4	true	DDI-DrugBank.d423.s4.e0	DDI-DrugBank.d423.s4.e4
DDI-DrugBank.d423.s4	true	DDI-DrugBank.d423.s4.e1	DDI-DrugBank.d423.s4.e2
DDI-DrugBank.d423.s4	true	DDI-DrugBank.d423.s4.e1	DDI-DrugBank.d423.s4.e3
DDI-DrugBank.d423.s4	true	DDI-DrugBank.d423.s4.e1	DDI-DrugBank.d423.s4.e4
DDI-DrugBank.d423.s4	false	DDI-DrugBank.d423.s4.e2	DDI-DrugBank.d423.s4.e3
DDI-DrugBank.d423.s4	false	DDI-DrugBank.d423.s4.e2	DDI-DrugBank.d423.s4.e4
DDI-DrugBank.d423.s4	false	DDI-DrugBank.d423.s4.e3	DDI-DrugBank.d423.s4.e4
DDI-DrugBank.d423.s5|a|The syndrome requires immediate medical attention and may include one or more of the following symptoms: excitement, hypomania, restlessness, loss of consciousness, confusion, disorientation, anxiety, agitation, motor weakness, myoclonus, tremor, hemiballismus, hyperreflexia, ataxia, dysarthria, incoordination, hyperthermia, shivering, pupillary dilation, diaphoresis, emesis, and tachycardia.
DDI-DrugBank.d423.s6|a|Dexfenfluramine should not be administered with other serotoninergic agents.
DDI-DrugBank.d423.s6	0	14	Dexfenfluramine	drug	DDI-DrugBank.d423.s6.e0
DDI-DrugBank.d423.s6	54	74	serotoninergic agents	group	DDI-DrugBank.d423.s6.e1
DDI-DrugBank.d423.s6	true	DDI-DrugBank.d423.s6.e0	DDI-DrugBank.d423.s6.e1
DDI-DrugBank.d423.s7|a|The appropriate interval between administration of these agents and dexfenfluramine has not been established.
DDI-DrugBank.d423.s7	68	82	dexfenfluramine	drug	DDI-DrugBank.d423.s7.e0
DDI-DrugBank.d423.s8|a|The use of dexfenfluramine with other CNS-active drugs has not been systematically evaluated;
DDI-DrugBank.d423.s8	11	25	dexfenfluramine	drug	DDI-DrugBank.d423.s8.e0
DDI-DrugBank.d423.s9|a|consequently, caution is advised if dexfenfluramine and such drugs are prescribed concurrently.
DDI-DrugBank.d423.s9	36	50	dexfenfluramine	drug	DDI-DrugBank.d423.s9.e0
DDI-DrugBank.d197.s0|a|General In vitro studies in human liver microsomes demonstrated no evidence of cytochrome P450-mediated drug interactions that are likely to be of clinical relevance.
DDI-DrugBank.d197.s1|a|Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
DDI-DrugBank.d197.s1	0	10	Anesthetics	group	DDI-DrugBank.d197.s1.e0
DDI-DrugBank.d197.s1	12	20	Sedatives	group	DDI-DrugBank.d197.s1.e1
DDI-DrugBank.d197.s1	22	30	Hypnotics	group	DDI-DrugBank.d197.s1.e2
DDI-DrugBank.d197.s1	32	38	Opioids	group	DDI-DrugBank.d197.s1.e3
DDI-DrugBank.d197.s1	62	69	PRECEDEX	brand	DDI-DrugBank.d197.s1.e4
DDI-DrugBank.d197.s1	76	86	anesthetics	group	DDI-DrugBank.d197.s1.e5
DDI-DrugBank.d197.s1	89	97	sedatives	group	DDI-DrugBank.d197.s1.e6
DDI-DrugBank.d197.s1	100	108	hypnotics	group	DDI-DrugBank.d197.s1.e7
DDI-DrugBank.d197.s1	115	121	opioids	group	DDI-DrugBank.d197.s1.e8
DDI-DrugBank.d197.s1	false	DDI-DrugBank.d197.s1.e0	DDI-DrugBank.d197.s1.e1
DDI-DrugBank.d197.s1	false	DDI-DrugBank.d197.s1.e0	DDI-DrugBank.d197.s1.e2
DDI-DrugBank.d197.s1	false	DDI-DrugBank.d197.s1.e0	DDI-DrugBank.d197.s1.e3
DDI-DrugBank.d197.s1	false	DDI-DrugBank.d197.s1.e0	DDI-DrugBank.d197.s1.e4
DDI-DrugBank.d197.s1	false	DDI-DrugBank.d197.s1.e0	DDI-DrugBank.d197.s1.e5
DDI-DrugBank.d197.s1	false	DDI-DrugBank.d197.s1.e0	DDI-DrugBank.d197.s1.e6
DDI-DrugBank.d197.s1	false	DDI-DrugBank.d197.s1.e0	DDI-DrugBank.d197.s1.e7
DDI-DrugBank.d197.s1	false	DDI-DrugBank.d197.s1.e0	DDI-DrugBank.d197.s1.e8
DDI-DrugBank.d197.s1	false	DDI-DrugBank.d197.s1.e1	DDI-DrugBank.d197.s1.e2
DDI-DrugBank.d197.s1	false	DDI-DrugBank.d197.s1.e1	DDI-DrugBank.d197.s1.e3
DDI-DrugBank.d197.s2|a|Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.
DDI-DrugBank.d197.s2	51	61	sevoflurane	drug	DDI-DrugBank.d197.s2.e0
DDI-DrugBank.d197.s2	64	73	isoflurane	drug	DDI-DrugBank.d197.s2.e1
DDI-DrugBank.d197.s2	76	83	propofol	drug	DDI-DrugBank.d197.s2.e2
DDI-DrugBank.d197.s2	86	95	alfentanil	drug	DDI-DrugBank.d197.s2.e3
DDI-DrugBank.d197.s2	102	110	midazolam	drug	DDI-DrugBank.d197.s2.e4
DDI-DrugBank.d197.s2	false	DDI-DrugBank.d197.s2.e0	DDI-DrugBank.d197.s2.e1
DDI-DrugBank.d197.s2	false	DDI-DrugBank.d197.s2.e0	DDI-DrugBank.d197.s2.e2
DDI-DrugBank.d197.s2	false	DDI-DrugBank.d197.s2.e0	DDI-DrugBank.d197.s2.e3
DDI-DrugBank.d197.s2	false	DDI-DrugBank.d197.s2.e0	DDI-DrugBank.d197.s2.e4
DDI-DrugBank.d197.s2	false	DDI-DrugBank.d197.s2.e1	DDI-DrugBank.d197.s2.e2
DDI-DrugBank.d197.s2	false	DDI-DrugBank.d197.s2.e1	DDI-DrugBank.d197.s2.e3
DDI-DrugBank.d197.s2	false	DDI-DrugBank.d197.s2.e1	DDI-DrugBank.d197.s2.e4
DDI-DrugBank.d197.s2	false	DDI-DrugBank.d197.s2.e2	DDI-DrugBank.d197.s2.e3
DDI-DrugBank.d197.s2	false	DDI-DrugBank.d197.s2.e2	DDI-DrugBank.d197.s2.e4
DDI-DrugBank.d197.s2	false	DDI-DrugBank.d197.s2.e3	DDI-DrugBank.d197.s2.e4
DDI-DrugBank.d197.s3|a|No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.
DDI-DrugBank.d197.s3	40	54	dexmedetomidine	drug	DDI-DrugBank.d197.s3.e0
DDI-DrugBank.d197.s3	60	69	isoflurane	drug	DDI-DrugBank.d197.s3.e1
DDI-DrugBank.d197.s3	72	79	propofol	drug	DDI-DrugBank.d197.s3.e2
DDI-DrugBank.d197.s3	82	91	alfentanil	drug	DDI-DrugBank.d197.s3.e3
DDI-DrugBank.d197.s3	98	106	midazolam	drug	DDI-DrugBank.d197.s3.e4
DDI-DrugBank.d197.s3	false	DDI-DrugBank.d197.s3.e0	DDI-DrugBank.d197.s3.e1
DDI-DrugBank.d197.s3	false	DDI-DrugBank.d197.s3.e0	DDI-DrugBank.d197.s3.e2
DDI-DrugBank.d197.s3	false	DDI-DrugBank.d197.s3.e0	DDI-DrugBank.d197.s3.e3
DDI-DrugBank.d197.s3	false	DDI-DrugBank.d197.s3.e0	DDI-DrugBank.d197.s3.e4
DDI-DrugBank.d197.s3	false	DDI-DrugBank.d197.s3.e1	DDI-DrugBank.d197.s3.e2
DDI-DrugBank.d197.s3	false	DDI-DrugBank.d197.s3.e1	DDI-DrugBank.d197.s3.e3
DDI-DrugBank.d197.s3	false	DDI-DrugBank.d197.s3.e1	DDI-DrugBank.d197.s3.e4
DDI-DrugBank.d197.s3	false	DDI-DrugBank.d197.s3.e2	DDI-DrugBank.d197.s3.e3
DDI-DrugBank.d197.s3	false	DDI-DrugBank.d197.s3.e2	DDI-DrugBank.d197.s3.e4
DDI-DrugBank.d197.s3	false	DDI-DrugBank.d197.s3.e3	DDI-DrugBank.d197.s3.e4
DDI-DrugBank.d197.s4|a|However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
DDI-DrugBank.d197.s4	81	88	PRECEDEX	brand	DDI-DrugBank.d197.s4.e0
DDI-DrugBank.d197.s4	116	123	PRECEDEX	brand	DDI-DrugBank.d197.s4.e1
DDI-DrugBank.d197.s4	144	153	anesthetic	group	DDI-DrugBank.d197.s4.e2
DDI-DrugBank.d197.s4	156	163	sedative	group	DDI-DrugBank.d197.s4.e3
DDI-DrugBank.d197.s4	166	173	hypnotic	group	DDI-DrugBank.d197.s4.e4
DDI-DrugBank.d197.s4	178	183	opioid	group	DDI-DrugBank.d197.s4.e5
DDI-DrugBank.d197.s4	false	DDI-DrugBank.d197.s4.e0	DDI-DrugBank.d197.s4.e1
DDI-DrugBank.d197.s4	false	DDI-DrugBank.d197.s4.e0	DDI-DrugBank.d197.s4.e2
DDI-DrugBank.d197.s4	false	DDI-DrugBank.d197.s4.e0	DDI-DrugBank.d197.s4.e3
DDI-DrugBank.d197.s4	false	DDI-DrugBank.d197.s4.e0	DDI-DrugBank.d197.s4.e4
DDI-DrugBank.d197.s4	false	DDI-DrugBank.d197.s4.e0	DDI-DrugBank.d197.s4.e5
DDI-DrugBank.d197.s4	true	DDI-DrugBank.d197.s4.e1	DDI-DrugBank.d197.s4.e2
DDI-DrugBank.d197.s4	true	DDI-DrugBank.d197.s4.e1	DDI-DrugBank.d197.s4.e3
DDI-DrugBank.d197.s4	true	DDI-DrugBank.d197.s4.e1	DDI-DrugBank.d197.s4.e4
DDI-DrugBank.d197.s4	true	DDI-DrugBank.d197.s4.e1	DDI-DrugBank.d197.s4.e5
DDI-DrugBank.d197.s4	false	DDI-DrugBank.d197.s4.e2	DDI-DrugBank.d197.s4.e3
DDI-DrugBank.d197.s5|a|Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.
DDI-DrugBank.d197.s5	0	21	Neuromuscular Blockers	group	DDI-DrugBank.d197.s5.e0
DDI-DrugBank.d197.s5	81	88	PRECEDEX	brand	DDI-DrugBank.d197.s5.e1
DDI-DrugBank.d197.s5	254	263	rocuronium	drug	DDI-DrugBank.d197.s5.e2
DDI-DrugBank.d197.s5	false	DDI-DrugBank.d197.s5.e0	DDI-DrugBank.d197.s5.e1
DDI-DrugBank.d197.s5	false	DDI-DrugBank.d197.s5.e0	DDI-DrugBank.d197.s5.e2
DDI-DrugBank.d197.s5	false	DDI-DrugBank.d197.s5.e1	DDI-DrugBank.d197.s5.e2
DDI-DrugBank.d38.s0|a|ZINECARD does not influence the pharmacokinetics of doxorubicin.
DDI-DrugBank.d38.s0	0	7	ZINECARD	brand	DDI-DrugBank.d38.s0.e0
DDI-DrugBank.d38.s0	52	62	doxorubicin	drug	DDI-DrugBank.d38.s0.e1
DDI-DrugBank.d38.s0	false	DDI-DrugBank.d38.s0.e0	DDI-DrugBank.d38.s0.e1
DDI-DrugBank.d38.s1|a|Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term carcinogenicity studies have been carried out with dexrazoxane in animals.
DDI-DrugBank.d38.s1	117	127	dexrazoxane	drug	DDI-DrugBank.d38.s1.e0
DDI-DrugBank.d38.s2|a|Dexrazoxane was not mutagenic in the Ames test but was found to be clastogenic to human lymphocytes in vitro and to mouse bone marrow erythrocytes in vivo (micronucleus test).
DDI-DrugBank.d38.s2	0	10	Dexrazoxane	drug	DDI-DrugBank.d38.s2.e0
DDI-DrugBank.d38.s3|a|The possible adverse effects of ZINECARD on the fertility of humans and experimental animals, male or female, have not been adequately studied.
DDI-DrugBank.d38.s3	32	39	ZINECARD	brand	DDI-DrugBank.d38.s3.e0
DDI-DrugBank.d38.s4|a|Testicular atrophy was seen with dexrazoxane administration at doses as low as 30 mg/kg weekly for 6 weeks in rats (1/3 the human dose on a mg/m 2 basis) and as low as 20 mg/kg weekly for 13 weeks in dogs (approximately equal to the human dose on a mg/m 2 basis).
DDI-DrugBank.d38.s4	33	43	dexrazoxane	drug	DDI-DrugBank.d38.s4.e0
DDI-DrugBank.d236.s0|a|Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
DDI-DrugBank.d236.s0	0	16	Acidifying agents	group	DDI-DrugBank.d236.s0.e0
DDI-DrugBank.d236.s0	19	52	Gastrointestinal acidifying agents	group	DDI-DrugBank.d236.s0.e1
DDI-DrugBank.d236.s0	55	66	guanethidine	drug	DDI-DrugBank.d236.s0.e2
DDI-DrugBank.d236.s0	69	77	reserpine	drug	DDI-DrugBank.d236.s0.e3
DDI-DrugBank.d236.s0	80	96	glutamic acid HCl	drug	DDI-DrugBank.d236.s0.e4
DDI-DrugBank.d236.s0	99	111	ascorbic acid	drug	DDI-DrugBank.d236.s0.e5
DDI-DrugBank.d236.s0	154	165	amphetamines	group	DDI-DrugBank.d236.s0.e6
DDI-DrugBank.d236.s0	false	DDI-DrugBank.d236.s0.e0	DDI-DrugBank.d236.s0.e1
DDI-DrugBank.d236.s0	false	DDI-DrugBank.d236.s0.e0	DDI-DrugBank.d236.s0.e2
DDI-DrugBank.d236.s0	false	DDI-DrugBank.d236.s0.e0	DDI-DrugBank.d236.s0.e3
DDI-DrugBank.d236.s0	false	DDI-DrugBank.d236.s0.e0	DDI-DrugBank.d236.s0.e4
DDI-DrugBank.d236.s0	false	DDI-DrugBank.d236.s0.e0	DDI-DrugBank.d236.s0.e5
DDI-DrugBank.d236.s0	false	DDI-DrugBank.d236.s0.e0	DDI-DrugBank.d236.s0.e6
DDI-DrugBank.d236.s0	false	DDI-DrugBank.d236.s0.e1	DDI-DrugBank.d236.s0.e2
DDI-DrugBank.d236.s0	false	DDI-DrugBank.d236.s0.e1	DDI-DrugBank.d236.s0.e3
DDI-DrugBank.d236.s0	false	DDI-DrugBank.d236.s0.e1	DDI-DrugBank.d236.s0.e4
DDI-DrugBank.d236.s0	false	DDI-DrugBank.d236.s0.e1	DDI-DrugBank.d236.s0.e5
DDI-DrugBank.d236.s1|a|Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
DDI-DrugBank.d236.s1	0	24	Urinary acidifying agents	group	DDI-DrugBank.d236.s1.e0
DDI-DrugBank.d236.s1	27	43	ammonium chloride	drug	DDI-DrugBank.d236.s1.e1
DDI-DrugBank.d236.s1	46	66	sodium acid phosphate	drug	DDI-DrugBank.d236.s1.e2
DDI-DrugBank.d236.s1	132	142	amphetamine	drug	DDI-DrugBank.d236.s1.e3
DDI-DrugBank.d236.s1	false	DDI-DrugBank.d236.s1.e0	DDI-DrugBank.d236.s1.e1
DDI-DrugBank.d236.s1	false	DDI-DrugBank.d236.s1.e0	DDI-DrugBank.d236.s1.e2
DDI-DrugBank.d236.s1	true	DDI-DrugBank.d236.s1.e0	DDI-DrugBank.d236.s1.e3
DDI-DrugBank.d236.s1	false	DDI-DrugBank.d236.s1.e1	DDI-DrugBank.d236.s1.e2
DDI-DrugBank.d236.s1	true	DDI-DrugBank.d236.s1.e1	DDI-DrugBank.d236.s1.e3
DDI-DrugBank.d236.s1	true	DDI-DrugBank.d236.s1.e2	DDI-DrugBank.d236.s1.e3
DDI-DrugBank.d236.s2|a|Both groups of agents lower blood levels and efficacy of amphetamines.
DDI-DrugBank.d236.s2	57	68	amphetamines	group	DDI-DrugBank.d236.s2.e0
DDI-DrugBank.d236.s3|a|Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.
DDI-DrugBank.d236.s3	0	18	Adrenergic blockers	group	DDI-DrugBank.d236.s3.e0
DDI-DrugBank.d236.s3	21	39	Adrenergic blockers	group	DDI-DrugBank.d236.s3.e1
DDI-DrugBank.d236.s3	58	69	amphetamines	group	DDI-DrugBank.d236.s3.e2
DDI-DrugBank.d236.s3	false	DDI-DrugBank.d236.s3.e0	DDI-DrugBank.d236.s3.e1
DDI-DrugBank.d236.s3	false	DDI-DrugBank.d236.s3.e0	DDI-DrugBank.d236.s3.e2
DDI-DrugBank.d236.s3	true	DDI-DrugBank.d236.s3.e1	DDI-DrugBank.d236.s3.e2
DDI-DrugBank.d236.s4|a|Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.
DDI-DrugBank.d236.s4	59	76	sodium bicarbonate	drug	DDI-DrugBank.d236.s4.e0
DDI-DrugBank.d236.s4	108	119	amphetamines	drug	DDI-DrugBank.d236.s4.e1
DDI-DrugBank.d236.s4	true	DDI-DrugBank.d236.s4.e0	DDI-DrugBank.d236.s4.e1
DDI-DrugBank.d236.s5|a|Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
DDI-DrugBank.d236.s5	29	41	acetazolamide	drug	DDI-DrugBank.d236.s5.e0
DDI-DrugBank.d236.s5	49	57	thiazides	group	DDI-DrugBank.d236.s5.e1
DDI-DrugBank.d236.s5	121	131	amphetamine	drug	DDI-DrugBank.d236.s5.e2
DDI-DrugBank.d236.s5	false	DDI-DrugBank.d236.s5.e0	DDI-DrugBank.d236.s5.e1
DDI-DrugBank.d236.s5	true	DDI-DrugBank.d236.s5.e0	DDI-DrugBank.d236.s5.e2
DDI-DrugBank.d236.s5	true	DDI-DrugBank.d236.s5.e1	DDI-DrugBank.d236.s5.e2
DDI-DrugBank.d236.s6|a|Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.
DDI-DrugBank.d236.s6	84	95	amphetamines	group	DDI-DrugBank.d236.s6.e0
DDI-DrugBank.d236.s7|a|Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
DDI-DrugBank.d236.s7	0	14	Antidepressants	group	DDI-DrugBank.d236.s7.e0
DDI-DrugBank.d236.s7	17	25	tricyclic	group	DDI-DrugBank.d236.s7.e1
DDI-DrugBank.d236.s7	28	39	Amphetamines	group	DDI-DrugBank.d236.s7.e2
DDI-DrugBank.d236.s7	69	77	tricyclic	group	DDI-DrugBank.d236.s7.e3
DDI-DrugBank.d236.s7	82	103	sympathomimetic agents	group	DDI-DrugBank.d236.s7.e4
DDI-DrugBank.d236.s7	false	DDI-DrugBank.d236.s7.e0	DDI-DrugBank.d236.s7.e1
DDI-DrugBank.d236.s7	false	DDI-DrugBank.d236.s7.e0	DDI-DrugBank.d236.s7.e2
DDI-DrugBank.d236.s7	false	DDI-DrugBank.d236.s7.e0	DDI-DrugBank.d236.s7.e3
DDI-DrugBank.d236.s7	false	DDI-DrugBank.d236.s7.e0	DDI-DrugBank.d236.s7.e4
DDI-DrugBank.d236.s7	false	DDI-DrugBank.d236.s7.e1	DDI-DrugBank.d236.s7.e2
DDI-DrugBank.d236.s7	false	DDI-DrugBank.d236.s7.e1	DDI-DrugBank.d236.s7.e3
DDI-DrugBank.d236.s7	false	DDI-DrugBank.d236.s7.e1	DDI-DrugBank.d236.s7.e4
DDI-DrugBank.d236.s7	true	DDI-DrugBank.d236.s7.e2	DDI-DrugBank.d236.s7.e3
DDI-DrugBank.d236.s7	true	DDI-DrugBank.d236.s7.e2	DDI-DrugBank.d236.s7.e4
DDI-DrugBank.d236.s7	false	DDI-DrugBank.d236.s7.e3	DDI-DrugBank.d236.s7.e4
DDI-DrugBank.d236.s8|a|d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DDI-DrugBank.d236.s8	0	12	d-amphetamine	drug	DDI-DrugBank.d236.s8.e0
DDI-DrugBank.d236.s8	19	29	desipramine	drug	DDI-DrugBank.d236.s8.e1
DDI-DrugBank.d236.s8	34	46	protriptyline	drug	DDI-DrugBank.d236.s8.e2
DDI-DrugBank.d236.s8	67	76	tricyclics	group	DDI-DrugBank.d236.s8.e3
DDI-DrugBank.d236.s8	141	153	d-amphetamine	drug	DDI-DrugBank.d236.s8.e4
DDI-DrugBank.d236.s8	true	DDI-DrugBank.d236.s8.e0	DDI-DrugBank.d236.s8.e1
DDI-DrugBank.d236.s8	true	DDI-DrugBank.d236.s8.e0	DDI-DrugBank.d236.s8.e2
DDI-DrugBank.d236.s8	true	DDI-DrugBank.d236.s8.e0	DDI-DrugBank.d236.s8.e3
DDI-DrugBank.d236.s8	false	DDI-DrugBank.d236.s8.e0	DDI-DrugBank.d236.s8.e4
DDI-DrugBank.d236.s8	false	DDI-DrugBank.d236.s8.e1	DDI-DrugBank.d236.s8.e2
DDI-DrugBank.d236.s8	false	DDI-DrugBank.d236.s8.e1	DDI-DrugBank.d236.s8.e3
DDI-DrugBank.d236.s8	false	DDI-DrugBank.d236.s8.e1	DDI-DrugBank.d236.s8.e4
DDI-DrugBank.d236.s8	false	DDI-DrugBank.d236.s8.e2	DDI-DrugBank.d236.s8.e3
DDI-DrugBank.d236.s8	false	DDI-DrugBank.d236.s8.e2	DDI-DrugBank.d236.s8.e4
DDI-DrugBank.d236.s8	false	DDI-DrugBank.d236.s8.e3	DDI-DrugBank.d236.s8.e4
DDI-DrugBank.d236.s9|a|cardiovascular effects can be potentiated.
DDI-DrugBank.d236.s10|a|MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
DDI-DrugBank.d236.s10	0	13	MAO inhibitors	group	DDI-DrugBank.d236.s10.e0
DDI-DrugBank.d236.s10	16	35	MAOI antidepressants	group	DDI-DrugBank.d236.s10.e1
DDI-DrugBank.d236.s10	65	76	furazolidone	drug	DDI-DrugBank.d236.s10.e2
DDI-DrugBank.d236.s10	84	94	amphetamine	group	DDI-DrugBank.d236.s10.e3
DDI-DrugBank.d236.s10	false	DDI-DrugBank.d236.s10.e0	DDI-DrugBank.d236.s10.e1
DDI-DrugBank.d236.s10	false	DDI-DrugBank.d236.s10.e0	DDI-DrugBank.d236.s10.e2
DDI-DrugBank.d236.s10	false	DDI-DrugBank.d236.s10.e0	DDI-DrugBank.d236.s10.e3
DDI-DrugBank.d236.s10	false	DDI-DrugBank.d236.s10.e1	DDI-DrugBank.d236.s10.e2
DDI-DrugBank.d236.s10	true	DDI-DrugBank.d236.s10.e1	DDI-DrugBank.d236.s10.e3
DDI-DrugBank.d236.s10	true	DDI-DrugBank.d236.s10.e2	DDI-DrugBank.d236.s10.e3
DDI-DrugBank.d236.s11|a|This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings;
DDI-DrugBank.d236.s11	25	36	amphetamines	group	DDI-DrugBank.d236.s11.e0
DDI-DrugBank.d236.s12|a|this can cause headaches and other signs of hypertensive crisis.
DDI-DrugBank.d236.s13|a|A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.
DDI-DrugBank.d236.s14|a|Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
DDI-DrugBank.d236.s14	0	13	Antihistamines	group	DDI-DrugBank.d236.s14.e0
DDI-DrugBank.d236.s14	16	27	Amphetamines	group	DDI-DrugBank.d236.s14.e1
DDI-DrugBank.d236.s14	67	80	antihistamines	group	DDI-DrugBank.d236.s14.e2
DDI-DrugBank.d236.s14	false	DDI-DrugBank.d236.s14.e0	DDI-DrugBank.d236.s14.e1
DDI-DrugBank.d236.s14	false	DDI-DrugBank.d236.s14.e0	DDI-DrugBank.d236.s14.e2
DDI-DrugBank.d236.s14	true	DDI-DrugBank.d236.s14.e1	DDI-DrugBank.d236.s14.e2
DDI-DrugBank.d236.s15|a|Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
DDI-DrugBank.d236.s15	0	16	Antihypertensives	group	DDI-DrugBank.d236.s15.e0
DDI-DrugBank.d236.s15	19	30	Amphetamines	group	DDI-DrugBank.d236.s15.e1
DDI-DrugBank.d236.s15	74	90	antihypertensives	group	DDI-DrugBank.d236.s15.e2
DDI-DrugBank.d236.s15	false	DDI-DrugBank.d236.s15.e0	DDI-DrugBank.d236.s15.e1
DDI-DrugBank.d236.s15	false	DDI-DrugBank.d236.s15.e0	DDI-DrugBank.d236.s15.e2
DDI-DrugBank.d236.s15	true	DDI-DrugBank.d236.s15.e1	DDI-DrugBank.d236.s15.e2
DDI-DrugBank.d236.s16|a|Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
DDI-DrugBank.d236.s16	0	13	Chlorpromazine	drug	DDI-DrugBank.d236.s16.e0
DDI-DrugBank.d236.s16	16	29	Chlorpromazine	drug	DDI-DrugBank.d236.s16.e1
DDI-DrugBank.d236.s16	125	136	amphetamines	group	DDI-DrugBank.d236.s16.e2
DDI-DrugBank.d236.s16	164	174	amphetamine	group	DDI-DrugBank.d236.s16.e3
DDI-DrugBank.d236.s16	false	DDI-DrugBank.d236.s16.e0	DDI-DrugBank.d236.s16.e1
DDI-DrugBank.d236.s16	false	DDI-DrugBank.d236.s16.e0	DDI-DrugBank.d236.s16.e2
DDI-DrugBank.d236.s16	false	DDI-DrugBank.d236.s16.e0	DDI-DrugBank.d236.s16.e3
DDI-DrugBank.d236.s16	true	DDI-DrugBank.d236.s16.e1	DDI-DrugBank.d236.s16.e2
DDI-DrugBank.d236.s16	false	DDI-DrugBank.d236.s16.e1	DDI-DrugBank.d236.s16.e3
DDI-DrugBank.d236.s16	false	DDI-DrugBank.d236.s16.e2	DDI-DrugBank.d236.s16.e3
DDI-DrugBank.d236.s17|a|Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
DDI-DrugBank.d236.s17	0	11	Ethosuximide	drug	DDI-DrugBank.d236.s17.e0
DDI-DrugBank.d236.s17	14	25	Amphetamines	group	DDI-DrugBank.d236.s17.e1
DDI-DrugBank.d236.s17	62	73	ethosuximide	drug	DDI-DrugBank.d236.s17.e2
DDI-DrugBank.d236.s17	false	DDI-DrugBank.d236.s17.e0	DDI-DrugBank.d236.s17.e1
DDI-DrugBank.d236.s17	false	DDI-DrugBank.d236.s17.e0	DDI-DrugBank.d236.s17.e2
DDI-DrugBank.d236.s17	true	DDI-DrugBank.d236.s17.e1	DDI-DrugBank.d236.s17.e2
DDI-DrugBank.d236.s18|a|Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
DDI-DrugBank.d236.s18	0	10	Haloperidol	drug	DDI-DrugBank.d236.s18.e0
DDI-DrugBank.d236.s18	13	23	Haloperidol	drug	DDI-DrugBank.d236.s18.e1
DDI-DrugBank.d236.s18	119	130	amphetamines	group	DDI-DrugBank.d236.s18.e2
DDI-DrugBank.d236.s18	false	DDI-DrugBank.d236.s18.e0	DDI-DrugBank.d236.s18.e1
DDI-DrugBank.d236.s18	false	DDI-DrugBank.d236.s18.e0	DDI-DrugBank.d236.s18.e2
DDI-DrugBank.d236.s18	true	DDI-DrugBank.d236.s18.e1	DDI-DrugBank.d236.s18.e2
DDI-DrugBank.d236.s19|a|Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.
DDI-DrugBank.d236.s19	0	16	Lithium carbonate	drug	DDI-DrugBank.d236.s19.e0
DDI-DrugBank.d236.s19	46	57	amphetamines	group	DDI-DrugBank.d236.s19.e1
DDI-DrugBank.d236.s19	79	95	lithium carbonate	drug	DDI-DrugBank.d236.s19.e2
DDI-DrugBank.d236.s19	false	DDI-DrugBank.d236.s19.e0	DDI-DrugBank.d236.s19.e1
DDI-DrugBank.d236.s19	false	DDI-DrugBank.d236.s19.e0	DDI-DrugBank.d236.s19.e2
DDI-DrugBank.d236.s19	true	DDI-DrugBank.d236.s19.e1	DDI-DrugBank.d236.s19.e2
DDI-DrugBank.d236.s20|a|Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
DDI-DrugBank.d236.s20	0	9	Meperidine	drug	DDI-DrugBank.d236.s20.e0
DDI-DrugBank.d236.s20	12	23	Amphetamines	group	DDI-DrugBank.d236.s20.e1
DDI-DrugBank.d236.s20	60	69	meperidine	drug	DDI-DrugBank.d236.s20.e2
DDI-DrugBank.d236.s20	false	DDI-DrugBank.d236.s20.e0	DDI-DrugBank.d236.s20.e1
DDI-DrugBank.d236.s20	false	DDI-DrugBank.d236.s20.e0	DDI-DrugBank.d236.s20.e2
DDI-DrugBank.d236.s20	true	DDI-DrugBank.d236.s20.e1	DDI-DrugBank.d236.s20.e2
DDI-DrugBank.d236.s21|a|Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.
DDI-DrugBank.d236.s21	0	10	Methenamine	drug	DDI-DrugBank.d236.s21.e0
DDI-DrugBank.d236.s21	42	53	amphetamines	group	DDI-DrugBank.d236.s21.e1
DDI-DrugBank.d236.s21	97	113	acidifying agents	group	DDI-DrugBank.d236.s21.e2
DDI-DrugBank.d236.s21	123	133	methenamine	drug	DDI-DrugBank.d236.s21.e3
DDI-DrugBank.d236.s21	false	DDI-DrugBank.d236.s21.e0	DDI-DrugBank.d236.s21.e1
DDI-DrugBank.d236.s21	false	DDI-DrugBank.d236.s21.e0	DDI-DrugBank.d236.s21.e2
DDI-DrugBank.d236.s21	false	DDI-DrugBank.d236.s21.e0	DDI-DrugBank.d236.s21.e3
DDI-DrugBank.d236.s21	true	DDI-DrugBank.d236.s21.e1	DDI-DrugBank.d236.s21.e2
DDI-DrugBank.d236.s21	false	DDI-DrugBank.d236.s21.e1	DDI-DrugBank.d236.s21.e3
DDI-DrugBank.d236.s21	false	DDI-DrugBank.d236.s21.e2	DDI-DrugBank.d236.s21.e3
DDI-DrugBank.d236.s22|a|Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
DDI-DrugBank.d236.s22	0	13	Norepinephrine	drug	DDI-DrugBank.d236.s22.e0
DDI-DrugBank.d236.s22	16	27	Amphetamines	group	DDI-DrugBank.d236.s22.e1
DDI-DrugBank.d236.s22	62	75	norepinephrine	drug	DDI-DrugBank.d236.s22.e2
DDI-DrugBank.d236.s22	false	DDI-DrugBank.d236.s22.e0	DDI-DrugBank.d236.s22.e1
DDI-DrugBank.d236.s22	false	DDI-DrugBank.d236.s22.e0	DDI-DrugBank.d236.s22.e2
DDI-DrugBank.d236.s22	true	DDI-DrugBank.d236.s22.e1	DDI-DrugBank.d236.s22.e2
DDI-DrugBank.d236.s23|a|Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
DDI-DrugBank.d236.s23	0	12	Phenobarbital	drug	DDI-DrugBank.d236.s23.e0
DDI-DrugBank.d236.s23	15	26	Amphetamines	group	DDI-DrugBank.d236.s23.e1
DDI-DrugBank.d236.s23	63	75	phenobarbital	drug	DDI-DrugBank.d236.s23.e2
DDI-DrugBank.d236.s23	false	DDI-DrugBank.d236.s23.e0	DDI-DrugBank.d236.s23.e1
DDI-DrugBank.d236.s23	false	DDI-DrugBank.d236.s23.e0	DDI-DrugBank.d236.s23.e2
DDI-DrugBank.d236.s23	true	DDI-DrugBank.d236.s23.e1	DDI-DrugBank.d236.s23.e2
DDI-DrugBank.d236.s24|a|co-administration of phenobarbital may produce a synergistic anticonvulsant action.
DDI-DrugBank.d236.s24	21	33	phenobarbital	drug	DDI-DrugBank.d236.s24.e0
DDI-DrugBank.d236.s25|a|Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
DDI-DrugBank.d236.s25	0	8	Phenytoin	drug	DDI-DrugBank.d236.s25.e0
DDI-DrugBank.d236.s25	11	22	Amphetamines	group	DDI-DrugBank.d236.s25.e1
DDI-DrugBank.d236.s25	59	67	phenytoin	drug	DDI-DrugBank.d236.s25.e2
DDI-DrugBank.d236.s25	false	DDI-DrugBank.d236.s25.e0	DDI-DrugBank.d236.s25.e1
DDI-DrugBank.d236.s25	false	DDI-DrugBank.d236.s25.e0	DDI-DrugBank.d236.s25.e2
DDI-DrugBank.d236.s25	true	DDI-DrugBank.d236.s25.e1	DDI-DrugBank.d236.s25.e2
DDI-DrugBank.d236.s26|a|co-administration of phenytoin may produce a synergistic anticonvulsant action.
DDI-DrugBank.d236.s26	21	29	phenytoin	drug	DDI-DrugBank.d236.s26.e0
DDI-DrugBank.d236.s27|a|Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
DDI-DrugBank.d236.s27	0	11	Propoxyphene	drug	DDI-DrugBank.d236.s27.e0
DDI-DrugBank.d236.s27	26	37	propoxyphene	drug	DDI-DrugBank.d236.s27.e1
DDI-DrugBank.d236.s27	51	61	amphetamine	group	DDI-DrugBank.d236.s27.e2
DDI-DrugBank.d236.s27	false	DDI-DrugBank.d236.s27.e0	DDI-DrugBank.d236.s27.e1
DDI-DrugBank.d236.s27	false	DDI-DrugBank.d236.s27.e0	DDI-DrugBank.d236.s27.e2
DDI-DrugBank.d236.s27	true	DDI-DrugBank.d236.s27.e1	DDI-DrugBank.d236.s27.e2
DDI-DrugBank.d236.s28|a|Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
DDI-DrugBank.d236.s28	0	17	Veratrum alkaloids	group	DDI-DrugBank.d236.s28.e0
DDI-DrugBank.d236.s28	20	31	Amphetamines	group	DDI-DrugBank.d236.s28.e1
DDI-DrugBank.d236.s28	67	84	veratrum alkaloids	group	DDI-DrugBank.d236.s28.e2
DDI-DrugBank.d236.s28	false	DDI-DrugBank.d236.s28.e0	DDI-DrugBank.d236.s28.e1
DDI-DrugBank.d236.s28	false	DDI-DrugBank.d236.s28.e0	DDI-DrugBank.d236.s28.e2
DDI-DrugBank.d236.s28	true	DDI-DrugBank.d236.s28.e1	DDI-DrugBank.d236.s28.e2
DDI-DrugBank.d236.s29|a|Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.
DDI-DrugBank.d236.s29	35	46	Amphetamines	group	DDI-DrugBank.d236.s29.e0
DDI-DrugBank.d236.s29	92	105	corticosteroid	group	DDI-DrugBank.d236.s29.e1
DDI-DrugBank.d236.s29	true	DDI-DrugBank.d236.s29.e0	DDI-DrugBank.d236.s29.e1
DDI-DrugBank.d236.s30|a|This increase is greatest in the evening.
DDI-DrugBank.d236.s31|a|Amphetamines may interfere with urinary steroid determinations.
DDI-DrugBank.d236.s31	0	11	Amphetamines	group	DDI-DrugBank.d236.s31.e0
DDI-DrugBank.d461.s0|a|Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics, alcohol, and other opiate analgesics.
DDI-DrugBank.d461.s0	50	60	anesthetics	group	DDI-DrugBank.d461.s0.e0
DDI-DrugBank.d461.s0	63	71	sedatives	group	DDI-DrugBank.d461.s0.e1
DDI-DrugBank.d461.s0	74	90	antianxiety drugs	group	DDI-DrugBank.d461.s0.e2
DDI-DrugBank.d461.s0	93	101	hypnotics	group	DDI-DrugBank.d461.s0.e3
DDI-DrugBank.d461.s0	104	110	alcohol	drug	DDI-DrugBank.d461.s0.e4
DDI-DrugBank.d461.s0	123	139	opiate analgesics	group	DDI-DrugBank.d461.s0.e5
DDI-DrugBank.d461.s0	false	DDI-DrugBank.d461.s0.e0	DDI-DrugBank.d461.s0.e1
DDI-DrugBank.d461.s0	false	DDI-DrugBank.d461.s0.e0	DDI-DrugBank.d461.s0.e2
DDI-DrugBank.d461.s0	false	DDI-DrugBank.d461.s0.e0	DDI-DrugBank.d461.s0.e3
DDI-DrugBank.d461.s0	false	DDI-DrugBank.d461.s0.e0	DDI-DrugBank.d461.s0.e4
DDI-DrugBank.d461.s0	false	DDI-DrugBank.d461.s0.e0	DDI-DrugBank.d461.s0.e5
DDI-DrugBank.d461.s0	false	DDI-DrugBank.d461.s0.e1	DDI-DrugBank.d461.s0.e2
DDI-DrugBank.d461.s0	false	DDI-DrugBank.d461.s0.e1	DDI-DrugBank.d461.s0.e3
DDI-DrugBank.d461.s0	false	DDI-DrugBank.d461.s0.e1	DDI-DrugBank.d461.s0.e4
DDI-DrugBank.d461.s0	false	DDI-DrugBank.d461.s0.e1	DDI-DrugBank.d461.s0.e5
DDI-DrugBank.d461.s0	false	DDI-DrugBank.d461.s0.e2	DDI-DrugBank.d461.s0.e3
DDI-DrugBank.d293.s0|a|May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
DDI-DrugBank.d293.s0	44	56	levothyroxine	drug	DDI-DrugBank.d293.s0.e0
DDI-DrugBank.d293.s0	60	65	iodine	drug	DDI-DrugBank.d293.s0.e1
DDI-DrugBank.d293.s0	88	95	antacids	group	DDI-DrugBank.d293.s0.e2
DDI-DrugBank.d293.s0	98	111	H2-antagonists	group	DDI-DrugBank.d293.s0.e3
DDI-DrugBank.d293.s0	120	129	famotidine	drug	DDI-DrugBank.d293.s0.e4
DDI-DrugBank.d293.s0	132	141	ranitidine	drug	DDI-DrugBank.d293.s0.e5
DDI-DrugBank.d293.s0	149	170	proton pump inhibitors	group	DDI-DrugBank.d293.s0.e6
DDI-DrugBank.d293.s0	179	190	lansoprazole	drug	DDI-DrugBank.d293.s0.e7
DDI-DrugBank.d293.s0	193	202	omeprazole	drug	DDI-DrugBank.d293.s0.e8
DDI-DrugBank.d293.s0	false	DDI-DrugBank.d293.s0.e0	DDI-DrugBank.d293.s0.e1
DDI-DrugBank.d293.s0	false	DDI-DrugBank.d293.s0.e0	DDI-DrugBank.d293.s0.e2
DDI-DrugBank.d293.s0	false	DDI-DrugBank.d293.s0.e0	DDI-DrugBank.d293.s0.e3
DDI-DrugBank.d293.s0	false	DDI-DrugBank.d293.s0.e0	DDI-DrugBank.d293.s0.e4
DDI-DrugBank.d293.s0	false	DDI-DrugBank.d293.s0.e0	DDI-DrugBank.d293.s0.e5
DDI-DrugBank.d293.s0	false	DDI-DrugBank.d293.s0.e0	DDI-DrugBank.d293.s0.e6
DDI-DrugBank.d293.s0	false	DDI-DrugBank.d293.s0.e0	DDI-DrugBank.d293.s0.e7
DDI-DrugBank.d293.s0	false	DDI-DrugBank.d293.s0.e0	DDI-DrugBank.d293.s0.e8
DDI-DrugBank.d293.s0	false	DDI-DrugBank.d293.s0.e1	DDI-DrugBank.d293.s0.e2
DDI-DrugBank.d293.s0	false	DDI-DrugBank.d293.s0.e1	DDI-DrugBank.d293.s0.e3
DDI-DrugBank.d293.s1|a|This product can affect the results of certain lab tests.
DDI-DrugBank.d36.s0|a|Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.
DDI-DrugBank.d36.s0	63	69	aspirin	brand	DDI-DrugBank.d36.s0.e0
DDI-DrugBank.d36.s0	75	103	carbonic anhydrase inhibitors	group	DDI-DrugBank.d36.s0.e1
DDI-DrugBank.d36.s0	true	DDI-DrugBank.d36.s0.e0	DDI-DrugBank.d36.s0.e1
DDI-DrugBank.d249.s0|a|Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
DDI-DrugBank.d249.s0	0	6	Aspirin	brand	DDI-DrugBank.d249.s0.e0
DDI-DrugBank.d249.s0	39	48	diclofenac	drug	DDI-DrugBank.d249.s0.e1
DDI-DrugBank.d249.s0	54	60	aspirin	brand	DDI-DrugBank.d249.s0.e2
DDI-DrugBank.d249.s0	89	98	diclofenac	drug	DDI-DrugBank.d249.s0.e3
DDI-DrugBank.d249.s0	177	183	aspirin	brand	DDI-DrugBank.d249.s0.e4
DDI-DrugBank.d249.s0	false	DDI-DrugBank.d249.s0.e0	DDI-DrugBank.d249.s0.e1
DDI-DrugBank.d249.s0	false	DDI-DrugBank.d249.s0.e0	DDI-DrugBank.d249.s0.e2
DDI-DrugBank.d249.s0	false	DDI-DrugBank.d249.s0.e0	DDI-DrugBank.d249.s0.e3
DDI-DrugBank.d249.s0	false	DDI-DrugBank.d249.s0.e0	DDI-DrugBank.d249.s0.e4
DDI-DrugBank.d249.s0	true	DDI-DrugBank.d249.s0.e1	DDI-DrugBank.d249.s0.e2
DDI-DrugBank.d249.s0	false	DDI-DrugBank.d249.s0.e1	DDI-DrugBank.d249.s0.e3
DDI-DrugBank.d249.s0	false	DDI-DrugBank.d249.s0.e1	DDI-DrugBank.d249.s0.e4
DDI-DrugBank.d249.s0	false	DDI-DrugBank.d249.s0.e2	DDI-DrugBank.d249.s0.e3
DDI-DrugBank.d249.s0	false	DDI-DrugBank.d249.s0.e2	DDI-DrugBank.d249.s0.e4
DDI-DrugBank.d249.s0	true	DDI-DrugBank.d249.s0.e3	DDI-DrugBank.d249.s0.e4
DDI-DrugBank.d249.s1|a|Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.
DDI-DrugBank.d249.s1	0	13	Anticoagulants	group	DDI-DrugBank.d249.s1.e0
DDI-DrugBank.d249.s1	45	54	diclofenac	drug	DDI-DrugBank.d249.s1.e1
DDI-DrugBank.d249.s1	73	107	anticoagulants of the warfarin type	group	DDI-DrugBank.d249.s1.e2
DDI-DrugBank.d249.s1	197	202	NSAIDs	group	DDI-DrugBank.d249.s1.e3
DDI-DrugBank.d249.s1	false	DDI-DrugBank.d249.s1.e0	DDI-DrugBank.d249.s1.e1
DDI-DrugBank.d249.s1	false	DDI-DrugBank.d249.s1.e0	DDI-DrugBank.d249.s1.e2
DDI-DrugBank.d249.s1	false	DDI-DrugBank.d249.s1.e0	DDI-DrugBank.d249.s1.e3
DDI-DrugBank.d249.s1	false	DDI-DrugBank.d249.s1.e1	DDI-DrugBank.d249.s1.e2
DDI-DrugBank.d249.s1	true	DDI-DrugBank.d249.s1.e1	DDI-DrugBank.d249.s1.e3
DDI-DrugBank.d249.s1	false	DDI-DrugBank.d249.s1.e2	DDI-DrugBank.d249.s1.e3
DDI-DrugBank.d249.s2|a|Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
DDI-DrugBank.d249.s2	65	70	NSAIDs	group	DDI-DrugBank.d249.s2.e0
DDI-DrugBank.d249.s2	134	139	NSAIDs	group	DDI-DrugBank.d249.s2.e1
DDI-DrugBank.d249.s2	152	161	diclofenac	drug	DDI-DrugBank.d249.s2.e2
DDI-DrugBank.d249.s2	168	175	warfarin	drug	DDI-DrugBank.d249.s2.e3
DDI-DrugBank.d249.s2	253	265	anticoagulant	group	DDI-DrugBank.d249.s2.e4
DDI-DrugBank.d249.s2	false	DDI-DrugBank.d249.s2.e0	DDI-DrugBank.d249.s2.e1
DDI-DrugBank.d249.s2	false	DDI-DrugBank.d249.s2.e0	DDI-DrugBank.d249.s2.e2
DDI-DrugBank.d249.s2	false	DDI-DrugBank.d249.s2.e0	DDI-DrugBank.d249.s2.e3
DDI-DrugBank.d249.s2	false	DDI-DrugBank.d249.s2.e0	DDI-DrugBank.d249.s2.e4
DDI-DrugBank.d249.s2	false	DDI-DrugBank.d249.s2.e1	DDI-DrugBank.d249.s2.e2
DDI-DrugBank.d249.s2	true	DDI-DrugBank.d249.s2.e1	DDI-DrugBank.d249.s2.e3
DDI-DrugBank.d249.s2	false	DDI-DrugBank.d249.s2.e1	DDI-DrugBank.d249.s2.e4
DDI-DrugBank.d249.s2	true	DDI-DrugBank.d249.s2.e2	DDI-DrugBank.d249.s2.e3
DDI-DrugBank.d249.s2	false	DDI-DrugBank.d249.s2.e2	DDI-DrugBank.d249.s2.e4
DDI-DrugBank.d249.s2	false	DDI-DrugBank.d249.s2.e3	DDI-DrugBank.d249.s2.e4
DDI-DrugBank.d249.s3|a|Digoxin, Methotrexate, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.
DDI-DrugBank.d249.s3	0	6	Digoxin	drug	DDI-DrugBank.d249.s3.e0
DDI-DrugBank.d249.s3	9	20	Methotrexate	drug	DDI-DrugBank.d249.s3.e1
DDI-DrugBank.d249.s3	23	34	Cyclosporine	drug	DDI-DrugBank.d249.s3.e2
DDI-DrugBank.d249.s3	37	46	Diclofenac	drug	DDI-DrugBank.d249.s3.e3
DDI-DrugBank.d249.s3	60	65	NSAIDs	group	DDI-DrugBank.d249.s3.e4
DDI-DrugBank.d249.s3	false	DDI-DrugBank.d249.s3.e0	DDI-DrugBank.d249.s3.e1
DDI-DrugBank.d249.s3	false	DDI-DrugBank.d249.s3.e0	DDI-DrugBank.d249.s3.e2
DDI-DrugBank.d249.s3	false	DDI-DrugBank.d249.s3.e0	DDI-DrugBank.d249.s3.e3
DDI-DrugBank.d249.s3	false	DDI-DrugBank.d249.s3.e0	DDI-DrugBank.d249.s3.e4
DDI-DrugBank.d249.s3	false	DDI-DrugBank.d249.s3.e1	DDI-DrugBank.d249.s3.e2
DDI-DrugBank.d249.s3	false	DDI-DrugBank.d249.s3.e1	DDI-DrugBank.d249.s3.e3
DDI-DrugBank.d249.s3	false	DDI-DrugBank.d249.s3.e1	DDI-DrugBank.d249.s3.e4
DDI-DrugBank.d249.s3	false	DDI-DrugBank.d249.s3.e2	DDI-DrugBank.d249.s3.e3
DDI-DrugBank.d249.s3	false	DDI-DrugBank.d249.s3.e2	DDI-DrugBank.d249.s3.e4
DDI-DrugBank.d249.s3	false	DDI-DrugBank.d249.s3.e3	DDI-DrugBank.d249.s3.e4
DDI-DrugBank.d249.s4|a|Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
DDI-DrugBank.d249.s4	13	22	diclofenac	drug	DDI-DrugBank.d249.s4.e0
DDI-DrugBank.d249.s4	61	67	digoxin	drug	DDI-DrugBank.d249.s4.e1
DDI-DrugBank.d249.s4	73	84	methotrexate	drug	DDI-DrugBank.d249.s4.e2
DDI-DrugBank.d249.s4	99	110	cyclosporine	drug	DDI-DrugBank.d249.s4.e3
DDI-DrugBank.d249.s4	true	DDI-DrugBank.d249.s4.e0	DDI-DrugBank.d249.s4.e1
DDI-DrugBank.d249.s4	true	DDI-DrugBank.d249.s4.e0	DDI-DrugBank.d249.s4.e2
DDI-DrugBank.d249.s4	true	DDI-DrugBank.d249.s4.e0	DDI-DrugBank.d249.s4.e3
DDI-DrugBank.d249.s4	false	DDI-DrugBank.d249.s4.e1	DDI-DrugBank.d249.s4.e2
DDI-DrugBank.d249.s4	false	DDI-DrugBank.d249.s4.e1	DDI-DrugBank.d249.s4.e3
DDI-DrugBank.d249.s4	false	DDI-DrugBank.d249.s4.e2	DDI-DrugBank.d249.s4.e3
DDI-DrugBank.d249.s5|a|Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DDI-DrugBank.d249.s5	26	35	diclofenac	drug	DDI-DrugBank.d249.s5.e0
DDI-DrugBank.d249.s5	59	68	diclofenac	drug	DDI-DrugBank.d249.s5.e1
DDI-DrugBank.d249.s5	88	92	NSAID	group	DDI-DrugBank.d249.s5.e2
DDI-DrugBank.d249.s5	107	113	digoxin	drug	DDI-DrugBank.d249.s5.e3
DDI-DrugBank.d249.s5	116	127	methotrexate	drug	DDI-DrugBank.d249.s5.e4
DDI-DrugBank.d249.s5	133	144	cyclosporine	drug	DDI-DrugBank.d249.s5.e5
DDI-DrugBank.d249.s5	false	DDI-DrugBank.d249.s5.e0	DDI-DrugBank.d249.s5.e1
DDI-DrugBank.d249.s5	false	DDI-DrugBank.d249.s5.e0	DDI-DrugBank.d249.s5.e2
DDI-DrugBank.d249.s5	true	DDI-DrugBank.d249.s5.e0	DDI-DrugBank.d249.s5.e3
DDI-DrugBank.d249.s5	true	DDI-DrugBank.d249.s5.e0	DDI-DrugBank.d249.s5.e4
DDI-DrugBank.d249.s5	true	DDI-DrugBank.d249.s5.e0	DDI-DrugBank.d249.s5.e5
DDI-DrugBank.d249.s5	false	DDI-DrugBank.d249.s5.e1	DDI-DrugBank.d249.s5.e2
DDI-DrugBank.d249.s5	false	DDI-DrugBank.d249.s5.e1	DDI-DrugBank.d249.s5.e3
DDI-DrugBank.d249.s5	false	DDI-DrugBank.d249.s5.e1	DDI-DrugBank.d249.s5.e4
DDI-DrugBank.d249.s5	false	DDI-DrugBank.d249.s5.e1	DDI-DrugBank.d249.s5.e5
DDI-DrugBank.d249.s5	true	DDI-DrugBank.d249.s5.e2	DDI-DrugBank.d249.s5.e3
DDI-DrugBank.d249.s6|a|They should be observed closely, particularly if renal function is impaired.
DDI-DrugBank.d249.s7|a|In the case of digoxin, serum levels should be monitored.
DDI-DrugBank.d249.s7	15	21	digoxin	drug	DDI-DrugBank.d249.s7.e0
DDI-DrugBank.d249.s8|a|Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
DDI-DrugBank.d249.s8	0	6	Lithium	drug	DDI-DrugBank.d249.s8.e0
DDI-DrugBank.d249.s8	9	18	Diclofenac	drug	DDI-DrugBank.d249.s8.e1
DDI-DrugBank.d249.s8	30	36	lithium	drug	DDI-DrugBank.d249.s8.e2
DDI-DrugBank.d249.s8	68	74	lithium	drug	DDI-DrugBank.d249.s8.e3
DDI-DrugBank.d249.s8	false	DDI-DrugBank.d249.s8.e0	DDI-DrugBank.d249.s8.e1
DDI-DrugBank.d249.s8	false	DDI-DrugBank.d249.s8.e0	DDI-DrugBank.d249.s8.e2
DDI-DrugBank.d249.s8	false	DDI-DrugBank.d249.s8.e0	DDI-DrugBank.d249.s8.e3
DDI-DrugBank.d249.s8	true	DDI-DrugBank.d249.s8.e1	DDI-DrugBank.d249.s8.e2
DDI-DrugBank.d249.s8	true	DDI-DrugBank.d249.s8.e1	DDI-DrugBank.d249.s8.e3
DDI-DrugBank.d249.s8	false	DDI-DrugBank.d249.s8.e2	DDI-DrugBank.d249.s8.e3
DDI-DrugBank.d249.s9|a|In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.
DDI-DrugBank.d249.s9	19	28	diclofenac	drug	DDI-DrugBank.d249.s9.e0
DDI-DrugBank.d249.s9	34	40	lithium	drug	DDI-DrugBank.d249.s9.e1
DDI-DrugBank.d249.s9	57	63	lithium	drug	DDI-DrugBank.d249.s9.e2
DDI-DrugBank.d249.s9	true	DDI-DrugBank.d249.s9.e0	DDI-DrugBank.d249.s9.e1
DDI-DrugBank.d249.s9	false	DDI-DrugBank.d249.s9.e0	DDI-DrugBank.d249.s9.e2
DDI-DrugBank.d249.s9	false	DDI-DrugBank.d249.s9.e1	DDI-DrugBank.d249.s9.e2
DDI-DrugBank.d249.s10|a|Oral Hypoglycemics: Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents.
DDI-DrugBank.d249.s10	5	17	Hypoglycemics	group	DDI-DrugBank.d249.s10.e0
DDI-DrugBank.d249.s10	20	29	Diclofenac	drug	DDI-DrugBank.d249.s10.e1
DDI-DrugBank.d249.s10	122	140	hypoglycemic agents	group	DDI-DrugBank.d249.s10.e2
DDI-DrugBank.d249.s10	false	DDI-DrugBank.d249.s10.e0	DDI-DrugBank.d249.s10.e1
DDI-DrugBank.d249.s10	false	DDI-DrugBank.d249.s10.e0	DDI-DrugBank.d249.s10.e2
DDI-DrugBank.d249.s10	false	DDI-DrugBank.d249.s10.e1	DDI-DrugBank.d249.s10.e2
DDI-DrugBank.d249.s11|a|There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.
DDI-DrugBank.d249.s11	86	92	insulin	drug	DDI-DrugBank.d249.s11.e0
DDI-DrugBank.d249.s11	102	120	hypoglycemic agents	group	DDI-DrugBank.d249.s11.e1
DDI-DrugBank.d249.s11	141	150	diclofenac	drug	DDI-DrugBank.d249.s11.e2
DDI-DrugBank.d249.s11	false	DDI-DrugBank.d249.s11.e0	DDI-DrugBank.d249.s11.e1
DDI-DrugBank.d249.s11	true	DDI-DrugBank.d249.s11.e0	DDI-DrugBank.d249.s11.e2
DDI-DrugBank.d249.s11	true	DDI-DrugBank.d249.s11.e1	DDI-DrugBank.d249.s11.e2
DDI-DrugBank.d249.s12|a|Both hypo- and hyperglycemic effects have been reported.
DDI-DrugBank.d249.s13|a|A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.
DDI-DrugBank.d249.s13	107	116	diclofenac	drug	DDI-DrugBank.d249.s13.e0
DDI-DrugBank.d249.s13	161	167	insulin	drug	DDI-DrugBank.d249.s13.e1
DDI-DrugBank.d249.s13	177	195	hypoglycemic agents	group	DDI-DrugBank.d249.s13.e2
DDI-DrugBank.d249.s13	true	DDI-DrugBank.d249.s13.e0	DDI-DrugBank.d249.s13.e1
DDI-DrugBank.d249.s13	true	DDI-DrugBank.d249.s13.e0	DDI-DrugBank.d249.s13.e2
DDI-DrugBank.d249.s13	false	DDI-DrugBank.d249.s13.e1	DDI-DrugBank.d249.s13.e2
DDI-DrugBank.d249.s14|a|Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.
DDI-DrugBank.d249.s14	0	8	Diuretics	group	DDI-DrugBank.d249.s14.e0
DDI-DrugBank.d249.s14	11	20	Diclofenac	drug	DDI-DrugBank.d249.s14.e1
DDI-DrugBank.d249.s14	32	37	NSAIDs	group	DDI-DrugBank.d249.s14.e2
DDI-DrugBank.d249.s14	67	75	diuretics	group	DDI-DrugBank.d249.s14.e3
DDI-DrugBank.d249.s14	false	DDI-DrugBank.d249.s14.e0	DDI-DrugBank.d249.s14.e1
DDI-DrugBank.d249.s14	false	DDI-DrugBank.d249.s14.e0	DDI-DrugBank.d249.s14.e2
DDI-DrugBank.d249.s14	false	DDI-DrugBank.d249.s14.e0	DDI-DrugBank.d249.s14.e3
DDI-DrugBank.d249.s14	false	DDI-DrugBank.d249.s14.e1	DDI-DrugBank.d249.s14.e2
DDI-DrugBank.d249.s14	true	DDI-DrugBank.d249.s14.e1	DDI-DrugBank.d249.s14.e3
DDI-DrugBank.d249.s14	true	DDI-DrugBank.d249.s14.e2	DDI-DrugBank.d249.s14.e3
DDI-DrugBank.d249.s15|a|Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium levels.
DDI-DrugBank.d249.s15	27	53	potassium-sparing diuretics	group	DDI-DrugBank.d249.s15.e0
DDI-DrugBank.d249.s16|a|Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
DDI-DrugBank.d249.s16	101	112	azathioprine	drug	DDI-DrugBank.d249.s16.e0
DDI-DrugBank.d249.s16	115	118	gold	group	DDI-DrugBank.d249.s16.e1
DDI-DrugBank.d249.s16	121	131	chloroquine	drug	DDI-DrugBank.d249.s16.e2
DDI-DrugBank.d249.s16	134	148	D-penicillamine	drug	DDI-DrugBank.d249.s16.e3
DDI-DrugBank.d249.s16	151	162	prednisolone	drug	DDI-DrugBank.d249.s16.e4
DDI-DrugBank.d249.s16	165	175	doxycycline	drug	DDI-DrugBank.d249.s16.e5
DDI-DrugBank.d249.s16	181	189	digitoxin	drug	DDI-DrugBank.d249.s16.e6
DDI-DrugBank.d249.s16	254	263	diclofenac	drug	DDI-DrugBank.d249.s16.e7
DDI-DrugBank.d249.s16	false	DDI-DrugBank.d249.s16.e0	DDI-DrugBank.d249.s16.e1
DDI-DrugBank.d249.s16	false	DDI-DrugBank.d249.s16.e0	DDI-DrugBank.d249.s16.e2
DDI-DrugBank.d249.s16	false	DDI-DrugBank.d249.s16.e0	DDI-DrugBank.d249.s16.e3
DDI-DrugBank.d249.s16	false	DDI-DrugBank.d249.s16.e0	DDI-DrugBank.d249.s16.e4
DDI-DrugBank.d249.s16	false	DDI-DrugBank.d249.s16.e0	DDI-DrugBank.d249.s16.e5
DDI-DrugBank.d249.s16	false	DDI-DrugBank.d249.s16.e0	DDI-DrugBank.d249.s16.e6
DDI-DrugBank.d249.s16	false	DDI-DrugBank.d249.s16.e0	DDI-DrugBank.d249.s16.e7
DDI-DrugBank.d249.s16	false	DDI-DrugBank.d249.s16.e1	DDI-DrugBank.d249.s16.e2
DDI-DrugBank.d249.s16	false	DDI-DrugBank.d249.s16.e1	DDI-DrugBank.d249.s16.e3
DDI-DrugBank.d249.s16	false	DDI-DrugBank.d249.s16.e1	DDI-DrugBank.d249.s16.e4
DDI-DrugBank.d249.s17|a|Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.
DDI-DrugBank.d249.s17	0	12	Phenobarbital	drug	DDI-DrugBank.d249.s17.e0
DDI-DrugBank.d249.s17	82	94	phenobarbital	drug	DDI-DrugBank.d249.s17.e1
DDI-DrugBank.d249.s17	134	143	diclofenac	drug	DDI-DrugBank.d249.s17.e2
DDI-DrugBank.d249.s17	false	DDI-DrugBank.d249.s17.e0	DDI-DrugBank.d249.s17.e1
DDI-DrugBank.d249.s17	false	DDI-DrugBank.d249.s17.e0	DDI-DrugBank.d249.s17.e2
DDI-DrugBank.d249.s17	true	DDI-DrugBank.d249.s17.e1	DDI-DrugBank.d249.s17.e2
DDI-DrugBank.d249.s18|a|Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DDI-DrugBank.d249.s18	26	35	diclofenac	drug	DDI-DrugBank.d249.s18.e0
DDI-DrugBank.d249.s18	100	113	salicylic acid	drug	DDI-DrugBank.d249.s18.e1
DDI-DrugBank.d249.s18	142	152	tolbutamide	drug	DDI-DrugBank.d249.s18.e2
DDI-DrugBank.d249.s18	155	166	prednisolone	drug	DDI-DrugBank.d249.s18.e3
DDI-DrugBank.d249.s18	198	205	warfarin	drug	DDI-DrugBank.d249.s18.e4
DDI-DrugBank.d249.s18	true	DDI-DrugBank.d249.s18.e0	DDI-DrugBank.d249.s18.e1
DDI-DrugBank.d249.s18	true	DDI-DrugBank.d249.s18.e0	DDI-DrugBank.d249.s18.e2
DDI-DrugBank.d249.s18	true	DDI-DrugBank.d249.s18.e0	DDI-DrugBank.d249.s18.e3
DDI-DrugBank.d249.s18	true	DDI-DrugBank.d249.s18.e0	DDI-DrugBank.d249.s18.e4
DDI-DrugBank.d249.s18	false	DDI-DrugBank.d249.s18.e1	DDI-DrugBank.d249.s18.e2
DDI-DrugBank.d249.s18	false	DDI-DrugBank.d249.s18.e1	DDI-DrugBank.d249.s18.e3
DDI-DrugBank.d249.s18	false	DDI-DrugBank.d249.s18.e1	DDI-DrugBank.d249.s18.e4
DDI-DrugBank.d249.s18	false	DDI-DrugBank.d249.s18.e2	DDI-DrugBank.d249.s18.e3
DDI-DrugBank.d249.s18	false	DDI-DrugBank.d249.s18.e2	DDI-DrugBank.d249.s18.e4
DDI-DrugBank.d249.s18	false	DDI-DrugBank.d249.s18.e3	DDI-DrugBank.d249.s18.e4
DDI-DrugBank.d249.s19|a|Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
DDI-DrugBank.d249.s19	0	15	Benzylpenicillin	drug	DDI-DrugBank.d249.s19.e0
DDI-DrugBank.d249.s19	18	27	ampicillin	drug	DDI-DrugBank.d249.s19.e1
DDI-DrugBank.d249.s19	30	38	oxacillin	drug	DDI-DrugBank.d249.s19.e2
DDI-DrugBank.d249.s19	41	57	chlortetracycline	drug	DDI-DrugBank.d249.s19.e3
DDI-DrugBank.d249.s19	60	70	doxycycline	drug	DDI-DrugBank.d249.s19.e4
DDI-DrugBank.d249.s19	73	83	cephalothin	drug	DDI-DrugBank.d249.s19.e5
DDI-DrugBank.d249.s19	86	97	erythromycin	drug	DDI-DrugBank.d249.s19.e6
DDI-DrugBank.d249.s19	104	119	sulfamethoxazole	drug	DDI-DrugBank.d249.s19.e7
DDI-DrugBank.d249.s19	174	183	diclofenac	drug	DDI-DrugBank.d249.s19.e8
DDI-DrugBank.d249.s19	false	DDI-DrugBank.d249.s19.e0	DDI-DrugBank.d249.s19.e1
DDI-DrugBank.d249.s19	false	DDI-DrugBank.d249.s19.e0	DDI-DrugBank.d249.s19.e2
DDI-DrugBank.d249.s19	false	DDI-DrugBank.d249.s19.e0	DDI-DrugBank.d249.s19.e3
DDI-DrugBank.d249.s19	false	DDI-DrugBank.d249.s19.e0	DDI-DrugBank.d249.s19.e4
DDI-DrugBank.d249.s19	false	DDI-DrugBank.d249.s19.e0	DDI-DrugBank.d249.s19.e5
DDI-DrugBank.d249.s19	false	DDI-DrugBank.d249.s19.e0	DDI-DrugBank.d249.s19.e6
DDI-DrugBank.d249.s19	false	DDI-DrugBank.d249.s19.e0	DDI-DrugBank.d249.s19.e7
DDI-DrugBank.d249.s19	false	DDI-DrugBank.d249.s19.e0	DDI-DrugBank.d249.s19.e8
DDI-DrugBank.d249.s19	false	DDI-DrugBank.d249.s19.e1	DDI-DrugBank.d249.s19.e2
DDI-DrugBank.d249.s19	false	DDI-DrugBank.d249.s19.e1	DDI-DrugBank.d249.s19.e3
DDI-DrugBank.d249.s20|a|Drug/Laboratory Test Interactions Effect on Blood Coagulation: Diclofenac increases platelet aggregation time but does not affect bleeding time, plasma thrombin clotting time, plasma fibrinogen, or factors V and VII to XII.
DDI-DrugBank.d249.s20	63	72	Diclofenac	drug	DDI-DrugBank.d249.s20.e0
DDI-DrugBank.d249.s21|a|Statistically significant changes in prothrombin and partial thromboplastin times have been reported in normal volunteers.
DDI-DrugBank.d249.s22|a|The mean changes were observed to be less than 1 second in both instances, however, and are unlikely to be clinically important.
DDI-DrugBank.d249.s23|a|Diclofenac is a prostaglandin synthetase inhibitor, however, and all drugs that inhibit prostaglandin synthesis interfere with platelet function to some degree;
DDI-DrugBank.d249.s23	0	9	Diclofenac	drug	DDI-DrugBank.d249.s23.e0
DDI-DrugBank.d249.s24|a|therefore, patients who may be adversely affected by such an action should be carefully observed.
DDI-DrugBank.d517.s0|a|Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.
DDI-DrugBank.d517.s0	0	11	Tetracycline	drug	DDI-DrugBank.d517.s0.e0
DDI-DrugBank.d517.s0	16	40	bacteriostatic antibiotic	group	DDI-DrugBank.d517.s0.e1
DDI-DrugBank.d517.s0	84	93	penicillin	drug	DDI-DrugBank.d517.s0.e2
DDI-DrugBank.d517.s0	false	DDI-DrugBank.d517.s0.e0	DDI-DrugBank.d517.s0.e1
DDI-DrugBank.d517.s0	true	DDI-DrugBank.d517.s0.e0	DDI-DrugBank.d517.s0.e2
DDI-DrugBank.d517.s0	false	DDI-DrugBank.d517.s0.e1	DDI-DrugBank.d517.s0.e2
DDI-DrugBank.d543.s0|a|The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
DDI-DrugBank.d543.s0	69	89	anticholinergic drugs	group	DDI-DrugBank.d543.s0.e0
DDI-DrugBank.d543.s0	92	101	amantadine	drug	DDI-DrugBank.d543.s0.e1
DDI-DrugBank.d543.s0	103	123	antiarrhythmic agents	group	DDI-DrugBank.d543.s0.e2
DDI-DrugBank.d543.s0	140	148	quinidine	drug	DDI-DrugBank.d543.s0.e3
DDI-DrugBank.d543.s0	152	165	antihistamines	group	DDI-DrugBank.d543.s0.e4
DDI-DrugBank.d543.s0	167	186	antipsychotic agents	group	DDI-DrugBank.d543.s0.e5
DDI-DrugBank.d543.s0	194	207	phenothiazines	group	DDI-DrugBank.d543.s0.e6
DDI-DrugBank.d543.s0	211	225	benzodiazepines	group	DDI-DrugBank.d543.s0.e7
DDI-DrugBank.d543.s0	false	DDI-DrugBank.d543.s0.e0	DDI-DrugBank.d543.s0.e1
DDI-DrugBank.d543.s0	false	DDI-DrugBank.d543.s0.e0	DDI-DrugBank.d543.s0.e2
DDI-DrugBank.d543.s0	false	DDI-DrugBank.d543.s0.e0	DDI-DrugBank.d543.s0.e3
DDI-DrugBank.d543.s0	false	DDI-DrugBank.d543.s0.e0	DDI-DrugBank.d543.s0.e4
DDI-DrugBank.d543.s0	false	DDI-DrugBank.d543.s0.e0	DDI-DrugBank.d543.s0.e5
DDI-DrugBank.d543.s0	false	DDI-DrugBank.d543.s0.e0	DDI-DrugBank.d543.s0.e6
DDI-DrugBank.d543.s0	false	DDI-DrugBank.d543.s0.e0	DDI-DrugBank.d543.s0.e7
DDI-DrugBank.d543.s0	false	DDI-DrugBank.d543.s0.e1	DDI-DrugBank.d543.s0.e2
DDI-DrugBank.d543.s0	false	DDI-DrugBank.d543.s0.e1	DDI-DrugBank.d543.s0.e3
DDI-DrugBank.d543.s0	false	DDI-DrugBank.d543.s0.e1	DDI-DrugBank.d543.s0.e4
DDI-DrugBank.d543.s1|a|MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d543.s1	0	13	MAO inhibitors	group	DDI-DrugBank.d543.s1.e0
DDI-DrugBank.d543.s1	16	34	narcotic analgesics	group	DDI-DrugBank.d543.s1.e1
DDI-DrugBank.d543.s1	43	52	meperidine	drug	DDI-DrugBank.d543.s1.e2
DDI-DrugBank.d543.s1	56	63	nitrates	group	DDI-DrugBank.d543.s1.e3
DDI-DrugBank.d543.s1	69	76	nitrites	group	DDI-DrugBank.d543.s1.e4
DDI-DrugBank.d543.s1	79	100	sympathomimetic agents	group	DDI-DrugBank.d543.s1.e5
DDI-DrugBank.d543.s1	103	127	tricyclic antidepressants	group	DDI-DrugBank.d543.s1.e6
DDI-DrugBank.d543.s1	false	DDI-DrugBank.d543.s1.e0	DDI-DrugBank.d543.s1.e1
DDI-DrugBank.d543.s1	false	DDI-DrugBank.d543.s1.e0	DDI-DrugBank.d543.s1.e2
DDI-DrugBank.d543.s1	false	DDI-DrugBank.d543.s1.e0	DDI-DrugBank.d543.s1.e3
DDI-DrugBank.d543.s1	false	DDI-DrugBank.d543.s1.e0	DDI-DrugBank.d543.s1.e4
DDI-DrugBank.d543.s1	false	DDI-DrugBank.d543.s1.e0	DDI-DrugBank.d543.s1.e5
DDI-DrugBank.d543.s1	false	DDI-DrugBank.d543.s1.e0	DDI-DrugBank.d543.s1.e6
DDI-DrugBank.d543.s1	false	DDI-DrugBank.d543.s1.e1	DDI-DrugBank.d543.s1.e2
DDI-DrugBank.d543.s1	false	DDI-DrugBank.d543.s1.e1	DDI-DrugBank.d543.s1.e3
DDI-DrugBank.d543.s1	false	DDI-DrugBank.d543.s1.e1	DDI-DrugBank.d543.s1.e4
DDI-DrugBank.d543.s1	false	DDI-DrugBank.d543.s1.e1	DDI-DrugBank.d543.s1.e5
DDI-DrugBank.d543.s2|a|Anticholinergics antagonize the effects of antiglaucoma agents.
DDI-DrugBank.d543.s2	0	15	Anticholinergics	group	DDI-DrugBank.d543.s2.e0
DDI-DrugBank.d543.s2	43	61	antiglaucoma agents	group	DDI-DrugBank.d543.s2.e1
DDI-DrugBank.d543.s2	false	DDI-DrugBank.d543.s2.e0	DDI-DrugBank.d543.s2.e1
DDI-DrugBank.d543.s3|a|Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corti costeroids..
DDI-DrugBank.d543.s3	0	20	Anticholinergic drugs	group	DDI-DrugBank.d543.s3.e0
DDI-DrugBank.d543.s4|a|Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
DDI-DrugBank.d543.s4	0	21	Anticholinergic agents	group	DDI-DrugBank.d543.s4.e0
DDI-DrugBank.d543.s4	122	128	digoxin	drug	DDI-DrugBank.d543.s4.e1
DDI-DrugBank.d543.s4	true	DDI-DrugBank.d543.s4.e0	DDI-DrugBank.d543.s4.e1
DDI-DrugBank.d543.s5|a|increased serum digoxin concentrations may result.
DDI-DrugBank.d543.s5	16	22	digoxin	drug	DDI-DrugBank.d543.s5.e0
DDI-DrugBank.d543.s6|a|Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.
DDI-DrugBank.d543.s6	0	20	Anticholinergic drugs	group	DDI-DrugBank.d543.s6.e0
DDI-DrugBank.d543.s6	108	121	metoclopramide	drug	DDI-DrugBank.d543.s6.e1
DDI-DrugBank.d543.s6	true	DDI-DrugBank.d543.s6.e0	DDI-DrugBank.d543.s6.e1
DDI-DrugBank.d543.s7|a|Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
DDI-DrugBank.d543.s7	8	15	antacids	group	DDI-DrugBank.d543.s7.e0
DDI-DrugBank.d543.s7	54	75	anticholinergic agents	group	DDI-DrugBank.d543.s7.e1
DDI-DrugBank.d543.s7	true	DDI-DrugBank.d543.s7.e0	DDI-DrugBank.d543.s7.e1
DDI-DrugBank.d543.s8|a|The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonized by agents used to treat achlorhydria and those used to test gastric secretion.
DDI-DrugBank.d543.s8	26	46	anticholinergic drugs	group	DDI-DrugBank.d543.s8.e0
DDI-DrugBank.d43.s0|a|Coadministration of VIDEX with drugs that are known to cause pancreatitis may increase the risk of this toxicity (see WARNINGS) and should be done with extreme caution, only if other alternatives are not available, and only if clearly indicated.
DDI-DrugBank.d43.s0	20	24	VIDEX	brand	DDI-DrugBank.d43.s0.e0
DDI-DrugBank.d43.s1|a|Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including stavudine, and these patients may be at increased risk of neuropathy during VIDEX therapy (see ADVERSE REACTIONS).
DDI-DrugBank.d43.s1	119	127	stavudine	drug	DDI-DrugBank.d43.s1.e0
DDI-DrugBank.d43.s1	195	199	VIDEX	brand	DDI-DrugBank.d43.s1.e1
DDI-DrugBank.d43.s1	false	DDI-DrugBank.d43.s1.e0	DDI-DrugBank.d43.s1.e1
DDI-DrugBank.d43.s2|a|Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
DDI-DrugBank.d43.s2	0	10	Allopurinol	drug	DDI-DrugBank.d43.s2.e0
DDI-DrugBank.d43.s2	24	33	didanosine	drug	DDI-DrugBank.d43.s2.e1
DDI-DrugBank.d43.s2	67	77	allopurinol	drug	DDI-DrugBank.d43.s2.e2
DDI-DrugBank.d43.s2	141	145	VIDEX	brand	DDI-DrugBank.d43.s2.e3
DDI-DrugBank.d43.s2	false	DDI-DrugBank.d43.s2.e0	DDI-DrugBank.d43.s2.e1
DDI-DrugBank.d43.s2	false	DDI-DrugBank.d43.s2.e0	DDI-DrugBank.d43.s2.e2
DDI-DrugBank.d43.s2	false	DDI-DrugBank.d43.s2.e0	DDI-DrugBank.d43.s2.e3
DDI-DrugBank.d43.s2	false	DDI-DrugBank.d43.s2.e1	DDI-DrugBank.d43.s2.e2
DDI-DrugBank.d43.s2	false	DDI-DrugBank.d43.s2.e1	DDI-DrugBank.d43.s2.e3
DDI-DrugBank.d43.s2	true	DDI-DrugBank.d43.s2.e2	DDI-DrugBank.d43.s2.e3
DDI-DrugBank.d43.s3|a|The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known.
DDI-DrugBank.d43.s3	15	25	allopurinol	drug	DDI-DrugBank.d43.s3.e0
DDI-DrugBank.d43.s3	30	39	didanosine	drug	DDI-DrugBank.d43.s3.e1
DDI-DrugBank.d43.s3	false	DDI-DrugBank.d43.s3.e0	DDI-DrugBank.d43.s3.e1
DDI-DrugBank.d43.s4|a|Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
DDI-DrugBank.d43.s4	0	7	Antacids	group	DDI-DrugBank.d43.s4.e0
DDI-DrugBank.d43.s4	40	47	antacids	group	DDI-DrugBank.d43.s4.e1
DDI-DrugBank.d43.s4	60	68	magnesium	drug	DDI-DrugBank.d43.s4.e2
DDI-DrugBank.d43.s4	73	80	aluminum	drug	DDI-DrugBank.d43.s4.e3
DDI-DrugBank.d43.s4	87	91	VIDEX	brand	DDI-DrugBank.d43.s4.e4
DDI-DrugBank.d43.s4	219	225	antacid	group	DDI-DrugBank.d43.s4.e5
DDI-DrugBank.d43.s4	false	DDI-DrugBank.d43.s4.e0	DDI-DrugBank.d43.s4.e1
DDI-DrugBank.d43.s4	false	DDI-DrugBank.d43.s4.e0	DDI-DrugBank.d43.s4.e2
DDI-DrugBank.d43.s4	false	DDI-DrugBank.d43.s4.e0	DDI-DrugBank.d43.s4.e3
DDI-DrugBank.d43.s4	false	DDI-DrugBank.d43.s4.e0	DDI-DrugBank.d43.s4.e4
DDI-DrugBank.d43.s4	false	DDI-DrugBank.d43.s4.e0	DDI-DrugBank.d43.s4.e5
DDI-DrugBank.d43.s4	false	DDI-DrugBank.d43.s4.e1	DDI-DrugBank.d43.s4.e2
DDI-DrugBank.d43.s4	false	DDI-DrugBank.d43.s4.e1	DDI-DrugBank.d43.s4.e3
DDI-DrugBank.d43.s4	true	DDI-DrugBank.d43.s4.e1	DDI-DrugBank.d43.s4.e4
DDI-DrugBank.d43.s4	false	DDI-DrugBank.d43.s4.e1	DDI-DrugBank.d43.s4.e5
DDI-DrugBank.d43.s4	false	DDI-DrugBank.d43.s4.e2	DDI-DrugBank.d43.s4.e3
DDI-DrugBank.d43.s5|a|Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.
DDI-DrugBank.d43.s5	93	104	ketoconazole	drug	DDI-DrugBank.d43.s5.e0
DDI-DrugBank.d43.s5	110	121	itraconazole	drug	DDI-DrugBank.d43.s5.e1
DDI-DrugBank.d43.s5	184	188	VIDEX	brand	DDI-DrugBank.d43.s5.e2
DDI-DrugBank.d43.s5	false	DDI-DrugBank.d43.s5.e0	DDI-DrugBank.d43.s5.e1
DDI-DrugBank.d43.s5	true	DDI-DrugBank.d43.s5.e0	DDI-DrugBank.d43.s5.e2
DDI-DrugBank.d43.s5	true	DDI-DrugBank.d43.s5.e1	DDI-DrugBank.d43.s5.e2
DDI-DrugBank.d43.s6|a|Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).
DDI-DrugBank.d43.s6	0	10	Ganciclovir	drug	DDI-DrugBank.d43.s6.e0
DDI-DrugBank.d43.s6	31	35	VIDEX	brand	DDI-DrugBank.d43.s6.e1
DDI-DrugBank.d43.s6	78	88	ganciclovir	drug	DDI-DrugBank.d43.s6.e2
DDI-DrugBank.d43.s6	159	168	didanosine	drug	DDI-DrugBank.d43.s6.e3
DDI-DrugBank.d43.s6	false	DDI-DrugBank.d43.s6.e0	DDI-DrugBank.d43.s6.e1
DDI-DrugBank.d43.s6	false	DDI-DrugBank.d43.s6.e0	DDI-DrugBank.d43.s6.e2
DDI-DrugBank.d43.s6	false	DDI-DrugBank.d43.s6.e0	DDI-DrugBank.d43.s6.e3
DDI-DrugBank.d43.s6	true	DDI-DrugBank.d43.s6.e1	DDI-DrugBank.d43.s6.e2
DDI-DrugBank.d43.s6	false	DDI-DrugBank.d43.s6.e1	DDI-DrugBank.d43.s6.e3
DDI-DrugBank.d43.s6	false	DDI-DrugBank.d43.s6.e2	DDI-DrugBank.d43.s6.e3
DDI-DrugBank.d43.s7|a|A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
DDI-DrugBank.d43.s7	47	57	ganciclovir	drug	DDI-DrugBank.d43.s7.e0
DDI-DrugBank.d43.s7	77	81	VIDEX	brand	DDI-DrugBank.d43.s7.e1
DDI-DrugBank.d43.s7	117	127	ganciclovir	drug	DDI-DrugBank.d43.s7.e2
DDI-DrugBank.d43.s7	false	DDI-DrugBank.d43.s7.e0	DDI-DrugBank.d43.s7.e1
DDI-DrugBank.d43.s7	false	DDI-DrugBank.d43.s7.e0	DDI-DrugBank.d43.s7.e2
DDI-DrugBank.d43.s7	true	DDI-DrugBank.d43.s7.e1	DDI-DrugBank.d43.s7.e2
DDI-DrugBank.d43.s8|a|Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d43.s8	0	19	Quinolone Antibiotic	group	DDI-DrugBank.d43.s8.e0
DDI-DrugBank.d43.s8	23	27	VIDEX	brand	DDI-DrugBank.d43.s8.e1
DDI-DrugBank.d43.s8	105	117	ciprofloxacin	drug	DDI-DrugBank.d43.s8.e2
DDI-DrugBank.d43.s8	152	164	ciprofloxacin	drug	DDI-DrugBank.d43.s8.e3
DDI-DrugBank.d43.s8	203	210	antacids	group	DDI-DrugBank.d43.s8.e4
DDI-DrugBank.d43.s8	223	231	magnesium	drug	DDI-DrugBank.d43.s8.e5
DDI-DrugBank.d43.s8	234	240	calcium	drug	DDI-DrugBank.d43.s8.e6
DDI-DrugBank.d43.s8	246	253	aluminum	drug	DDI-DrugBank.d43.s8.e7
DDI-DrugBank.d43.s8	false	DDI-DrugBank.d43.s8.e0	DDI-DrugBank.d43.s8.e1
DDI-DrugBank.d43.s8	false	DDI-DrugBank.d43.s8.e0	DDI-DrugBank.d43.s8.e2
DDI-DrugBank.d43.s8	false	DDI-DrugBank.d43.s8.e0	DDI-DrugBank.d43.s8.e3
DDI-DrugBank.d43.s8	false	DDI-DrugBank.d43.s8.e0	DDI-DrugBank.d43.s8.e4
DDI-DrugBank.d43.s8	false	DDI-DrugBank.d43.s8.e0	DDI-DrugBank.d43.s8.e5
DDI-DrugBank.d43.s8	false	DDI-DrugBank.d43.s8.e0	DDI-DrugBank.d43.s8.e6
DDI-DrugBank.d43.s8	false	DDI-DrugBank.d43.s8.e0	DDI-DrugBank.d43.s8.e7
DDI-DrugBank.d43.s8	true	DDI-DrugBank.d43.s8.e1	DDI-DrugBank.d43.s8.e2
DDI-DrugBank.d43.s8	false	DDI-DrugBank.d43.s8.e1	DDI-DrugBank.d43.s8.e3
DDI-DrugBank.d43.s8	false	DDI-DrugBank.d43.s8.e1	DDI-DrugBank.d43.s8.e4
DDI-DrugBank.d43.s9|a|In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.
DDI-DrugBank.d43.s9	56	68	ciprofloxacin	drug	DDI-DrugBank.d43.s9.e0
DDI-DrugBank.d43.s9	127	139	ciprofloxacin	drug	DDI-DrugBank.d43.s9.e1
DDI-DrugBank.d43.s9	229	233	VIDEX	brand	DDI-DrugBank.d43.s9.e2
DDI-DrugBank.d43.s9	false	DDI-DrugBank.d43.s9.e0	DDI-DrugBank.d43.s9.e1
DDI-DrugBank.d43.s9	false	DDI-DrugBank.d43.s9.e0	DDI-DrugBank.d43.s9.e2
DDI-DrugBank.d43.s9	true	DDI-DrugBank.d43.s9.e1	DDI-DrugBank.d43.s9.e2
DDI-DrugBank.d43.s10|a|The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.
DDI-DrugBank.d43.s10	11	23	ciprofloxacin	drug	DDI-DrugBank.d43.s10.e0
DDI-DrugBank.d43.s10	90	102	ciprofloxacin	drug	DDI-DrugBank.d43.s10.e1
DDI-DrugBank.d43.s10	108	117	didanosine	drug	DDI-DrugBank.d43.s10.e2
DDI-DrugBank.d43.s10	false	DDI-DrugBank.d43.s10.e0	DDI-DrugBank.d43.s10.e1
DDI-DrugBank.d43.s10	false	DDI-DrugBank.d43.s10.e0	DDI-DrugBank.d43.s10.e2
DDI-DrugBank.d43.s10	true	DDI-DrugBank.d43.s10.e1	DDI-DrugBank.d43.s10.e2
DDI-DrugBank.d43.s11|a|In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
DDI-DrugBank.d43.s11	38	50	ciprofloxacin	drug	DDI-DrugBank.d43.s11.e0
DDI-DrugBank.d43.s11	76	85	didanosine	drug	DDI-DrugBank.d43.s11.e1
DDI-DrugBank.d43.s11	147	159	ciprofloxacin	drug	DDI-DrugBank.d43.s11.e2
DDI-DrugBank.d43.s11	true	DDI-DrugBank.d43.s11.e0	DDI-DrugBank.d43.s11.e1
DDI-DrugBank.d43.s11	false	DDI-DrugBank.d43.s11.e0	DDI-DrugBank.d43.s11.e2
DDI-DrugBank.d43.s11	false	DDI-DrugBank.d43.s11.e1	DDI-DrugBank.d43.s11.e2
DDI-DrugBank.d43.s12|a|Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d43.s12	25	45	quinolone antibiotics	group	DDI-DrugBank.d43.s12.e0
DDI-DrugBank.d43.s12	84	91	antacids	group	DDI-DrugBank.d43.s12.e1
DDI-DrugBank.d43.s12	104	112	magnesium	drug	DDI-DrugBank.d43.s12.e2
DDI-DrugBank.d43.s12	115	121	calcium	drug	DDI-DrugBank.d43.s12.e3
DDI-DrugBank.d43.s12	127	134	aluminum	drug	DDI-DrugBank.d43.s12.e4
DDI-DrugBank.d43.s12	false	DDI-DrugBank.d43.s12.e0	DDI-DrugBank.d43.s12.e1
DDI-DrugBank.d43.s12	true	DDI-DrugBank.d43.s12.e0	DDI-DrugBank.d43.s12.e2
DDI-DrugBank.d43.s12	true	DDI-DrugBank.d43.s12.e0	DDI-DrugBank.d43.s12.e3
DDI-DrugBank.d43.s12	true	DDI-DrugBank.d43.s12.e0	DDI-DrugBank.d43.s12.e4
DDI-DrugBank.d43.s12	false	DDI-DrugBank.d43.s12.e1	DDI-DrugBank.d43.s12.e2
DDI-DrugBank.d43.s12	false	DDI-DrugBank.d43.s12.e1	DDI-DrugBank.d43.s12.e3
DDI-DrugBank.d43.s12	false	DDI-DrugBank.d43.s12.e1	DDI-DrugBank.d43.s12.e4
DDI-DrugBank.d43.s12	false	DDI-DrugBank.d43.s12.e2	DDI-DrugBank.d43.s12.e3
DDI-DrugBank.d43.s12	false	DDI-DrugBank.d43.s12.e2	DDI-DrugBank.d43.s12.e4
DDI-DrugBank.d43.s12	false	DDI-DrugBank.d43.s12.e3	DDI-DrugBank.d43.s12.e4
DDI-DrugBank.d43.s13|a|The optimal dosing interval for coadministration with VIDEX should be determined by consulting the appropriate quinolone package insert.
DDI-DrugBank.d43.s13	54	58	VIDEX	brand	DDI-DrugBank.d43.s13.e0
DDI-DrugBank.d43.s13	111	119	quinolone	group	DDI-DrugBank.d43.s13.e1
DDI-DrugBank.d43.s13	false	DDI-DrugBank.d43.s13.e0	DDI-DrugBank.d43.s13.e1
DDI-DrugBank.d43.s14|a|Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
DDI-DrugBank.d43.s14	24	43	Antiretroviral Drugs	group	DDI-DrugBank.d43.s14.e0
DDI-DrugBank.d43.s14	82	92	delavirdine	drug	DDI-DrugBank.d43.s14.e1
DDI-DrugBank.d43.s14	104	112	indinavir	drug	DDI-DrugBank.d43.s14.e2
DDI-DrugBank.d43.s14	188	192	VIDEX	brand	DDI-DrugBank.d43.s14.e3
DDI-DrugBank.d43.s14	false	DDI-DrugBank.d43.s14.e0	DDI-DrugBank.d43.s14.e1
DDI-DrugBank.d43.s14	false	DDI-DrugBank.d43.s14.e0	DDI-DrugBank.d43.s14.e2
DDI-DrugBank.d43.s14	false	DDI-DrugBank.d43.s14.e0	DDI-DrugBank.d43.s14.e3
DDI-DrugBank.d43.s14	false	DDI-DrugBank.d43.s14.e1	DDI-DrugBank.d43.s14.e2
DDI-DrugBank.d43.s14	true	DDI-DrugBank.d43.s14.e1	DDI-DrugBank.d43.s14.e3
DDI-DrugBank.d43.s14	true	DDI-DrugBank.d43.s14.e2	DDI-DrugBank.d43.s14.e3
DDI-DrugBank.d43.s15|a|To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
DDI-DrugBank.d43.s15	27	37	delavirdine	drug	DDI-DrugBank.d43.s15.e0
DDI-DrugBank.d43.s15	42	50	indinavir	drug	DDI-DrugBank.d43.s15.e1
DDI-DrugBank.d43.s15	96	100	VIDEX	brand	DDI-DrugBank.d43.s15.e2
DDI-DrugBank.d43.s15	false	DDI-DrugBank.d43.s15.e0	DDI-DrugBank.d43.s15.e1
DDI-DrugBank.d43.s15	true	DDI-DrugBank.d43.s15.e0	DDI-DrugBank.d43.s15.e2
DDI-DrugBank.d43.s15	true	DDI-DrugBank.d43.s15.e1	DDI-DrugBank.d43.s15.e2
DDI-DrugBank.d43.s16|a|The pharmacokinetics of nelfinavir are not altered to a clinically significant degree when it is administered with a light meal 1 hour after VIDEX.
DDI-DrugBank.d43.s16	24	33	nelfinavir	drug	DDI-DrugBank.d43.s16.e0
DDI-DrugBank.d43.s16	141	145	VIDEX	brand	DDI-DrugBank.d43.s16.e1
DDI-DrugBank.d43.s16	false	DDI-DrugBank.d43.s16.e0	DDI-DrugBank.d43.s16.e1
DDI-DrugBank.d570.s0|a|Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
DDI-DrugBank.d570.s0	97	104	estrogen	group	DDI-DrugBank.d570.s0.e0
DDI-DrugBank.d570.s0	122	135	contraceptives	group	DDI-DrugBank.d570.s0.e1
DDI-DrugBank.d570.s0	false	DDI-DrugBank.d570.s0.e0	DDI-DrugBank.d570.s0.e1
DDI-DrugBank.d570.s1|a|The following similar changes may be expected with larger doses of estrogen: - Increased sulfobromophthalein retention
DDI-DrugBank.d570.s1	67	74	estrogen	group	DDI-DrugBank.d570.s1.e0
DDI-DrugBank.d570.s2|a|.
DDI-DrugBank.d570.s3|a|- Increased prothrombin and factors VII, VIII, IX, and X;
DDI-DrugBank.d570.s4|a|decreased antithrombin 3;
DDI-DrugBank.d570.s4	10	23	antithrombin 3	drug	DDI-DrugBank.d570.s4.e0
DDI-DrugBank.d570.s5|a|increased norepinephrine-induced platelet aggregability
DDI-DrugBank.d570.s6|a|.
DDI-DrugBank.d570.s7|a|- Increased thyroid-binding globulin (TBG) leading to in-creased circulating total thyroid hormone;
DDI-DrugBank.d570.s8|a|as measured by PBI, T4 by column, or T4 by radioimmunoassay.
DDI-DrugBank.d570.s9|a|Free T3 resin uptake is decreased, reflecting the elevated TBG;
DDI-DrugBank.d570.s10|a|free T4 concentration is unaltered
DDI-DrugBank.d570.s11|a|.
DDI-DrugBank.d570.s12|a|- Impaired glucose tolerance
DDI-DrugBank.d570.s13|a|.
DDI-DrugBank.d570.s14|a|- Decreased pregnanediol excretion
DDI-DrugBank.d570.s15|a|.
DDI-DrugBank.d570.s16|a|- Reduced response to metyrapone test
DDI-DrugBank.d570.s17|a|.
DDI-DrugBank.d570.s18|a|- Reduced serum folate concentration
DDI-DrugBank.d570.s19|a|.
DDI-DrugBank.d570.s20|a|- Increased serum triglyceride and phospholipid concentration.
DDI-DrugBank.d352.s0|a|Antidiabetic drug requirements (i.e., insulin) may be altered.
DDI-DrugBank.d352.s0	0	16	Antidiabetic drug	group	DDI-DrugBank.d352.s0.e0
DDI-DrugBank.d352.s0	38	44	insulin	drug	DDI-DrugBank.d352.s0.e1
DDI-DrugBank.d352.s0	false	DDI-DrugBank.d352.s0.e0	DDI-DrugBank.d352.s0.e1
DDI-DrugBank.d352.s1|a|Concurrent use with general anesthetics may result in arrhythmias.
DDI-DrugBank.d352.s1	28	38	anesthetics	group	DDI-DrugBank.d352.s1.e0
DDI-DrugBank.d352.s2|a|The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly;
DDI-DrugBank.d352.s2	23	36	diethylpropion	drug	DDI-DrugBank.d352.s2.e0
DDI-DrugBank.d352.s3|a|conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
DDI-DrugBank.d352.s3	12	25	diethylpropion	drug	DDI-DrugBank.d352.s3.e0
DDI-DrugBank.d352.s3	46	67	antihypertensive drugs	group	DDI-DrugBank.d352.s3.e1
DDI-DrugBank.d352.s3	76	87	guanethidine	drug	DDI-DrugBank.d352.s3.e2
DDI-DrugBank.d352.s3	90	101	a-methyldopa	drug	DDI-DrugBank.d352.s3.e3
DDI-DrugBank.d352.s3	true	DDI-DrugBank.d352.s3.e0	DDI-DrugBank.d352.s3.e1
DDI-DrugBank.d352.s3	true	DDI-DrugBank.d352.s3.e0	DDI-DrugBank.d352.s3.e2
DDI-DrugBank.d352.s3	true	DDI-DrugBank.d352.s3.e0	DDI-DrugBank.d352.s3.e3
DDI-DrugBank.d352.s3	false	DDI-DrugBank.d352.s3.e1	DDI-DrugBank.d352.s3.e2
DDI-DrugBank.d352.s3	false	DDI-DrugBank.d352.s3.e1	DDI-DrugBank.d352.s3.e3
DDI-DrugBank.d352.s3	false	DDI-DrugBank.d352.s3.e2	DDI-DrugBank.d352.s3.e3
DDI-DrugBank.d352.s4|a|Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
DDI-DrugBank.d352.s4	18	31	phenothiazines	group	DDI-DrugBank.d352.s4.e0
DDI-DrugBank.d352.s4	72	85	diethylpropion	drug	DDI-DrugBank.d352.s4.e1
DDI-DrugBank.d352.s4	true	DDI-DrugBank.d352.s4.e0	DDI-DrugBank.d352.s4.e1
DDI-DrugBank.d248.s0|a|May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).
DDI-DrugBank.d248.s0	13	26	anticoagulants	group	DDI-DrugBank.d248.s0.e0
DDI-DrugBank.d248.s0	67	78	barbiturates	group	DDI-DrugBank.d248.s0.e1
DDI-DrugBank.d248.s0	81	88	rifampin	drug	DDI-DrugBank.d248.s0.e2
DDI-DrugBank.d248.s0	176	193	diethylstilbestrol	drug	DDI-DrugBank.d248.s0.e3
DDI-DrugBank.d248.s0	197	211	corticosteroids	group	DDI-DrugBank.d248.s0.e4
DDI-DrugBank.d248.s0	234	248	corticosteroids	group	DDI-DrugBank.d248.s0.e5
DDI-DrugBank.d248.s0	false	DDI-DrugBank.d248.s0.e0	DDI-DrugBank.d248.s0.e1
DDI-DrugBank.d248.s0	false	DDI-DrugBank.d248.s0.e0	DDI-DrugBank.d248.s0.e2
DDI-DrugBank.d248.s0	false	DDI-DrugBank.d248.s0.e0	DDI-DrugBank.d248.s0.e3
DDI-DrugBank.d248.s0	false	DDI-DrugBank.d248.s0.e0	DDI-DrugBank.d248.s0.e4
DDI-DrugBank.d248.s0	false	DDI-DrugBank.d248.s0.e0	DDI-DrugBank.d248.s0.e5
DDI-DrugBank.d248.s0	false	DDI-DrugBank.d248.s0.e1	DDI-DrugBank.d248.s0.e2
DDI-DrugBank.d248.s0	false	DDI-DrugBank.d248.s0.e1	DDI-DrugBank.d248.s0.e3
DDI-DrugBank.d248.s0	false	DDI-DrugBank.d248.s0.e1	DDI-DrugBank.d248.s0.e4
DDI-DrugBank.d248.s0	false	DDI-DrugBank.d248.s0.e1	DDI-DrugBank.d248.s0.e5
DDI-DrugBank.d248.s0	false	DDI-DrugBank.d248.s0.e2	DDI-DrugBank.d248.s0.e3
DDI-DrugBank.d132.s0|a|Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
DDI-DrugBank.d132.s0	5	18	Anticoagulants	group	DDI-DrugBank.d132.s0.e0
DDI-DrugBank.d132.s0	82	91	diflunisal	drug	DDI-DrugBank.d132.s0.e1
DDI-DrugBank.d132.s0	97	104	warfarin	drug	DDI-DrugBank.d132.s0.e2
DDI-DrugBank.d132.s0	107	119	acenocoumarol	drug	DDI-DrugBank.d132.s0.e3
DDI-DrugBank.d132.s0	125	137	phenprocoumon	drug	DDI-DrugBank.d132.s0.e4
DDI-DrugBank.d132.s0	false	DDI-DrugBank.d132.s0.e0	DDI-DrugBank.d132.s0.e1
DDI-DrugBank.d132.s0	false	DDI-DrugBank.d132.s0.e0	DDI-DrugBank.d132.s0.e2
DDI-DrugBank.d132.s0	false	DDI-DrugBank.d132.s0.e0	DDI-DrugBank.d132.s0.e3
DDI-DrugBank.d132.s0	false	DDI-DrugBank.d132.s0.e0	DDI-DrugBank.d132.s0.e4
DDI-DrugBank.d132.s0	true	DDI-DrugBank.d132.s0.e1	DDI-DrugBank.d132.s0.e2
DDI-DrugBank.d132.s0	true	DDI-DrugBank.d132.s0.e1	DDI-DrugBank.d132.s0.e3
DDI-DrugBank.d132.s0	true	DDI-DrugBank.d132.s0.e1	DDI-DrugBank.d132.s0.e4
DDI-DrugBank.d132.s0	false	DDI-DrugBank.d132.s0.e2	DDI-DrugBank.d132.s0.e3
DDI-DrugBank.d132.s0	false	DDI-DrugBank.d132.s0.e2	DDI-DrugBank.d132.s0.e4
DDI-DrugBank.d132.s0	false	DDI-DrugBank.d132.s0.e3	DDI-DrugBank.d132.s0.e4
DDI-DrugBank.d132.s1|a|This may occur because diflunisal competitively displaces coumarins from protein binding sites.
DDI-DrugBank.d132.s1	23	32	diflunisal	drug	DDI-DrugBank.d132.s1.e0
DDI-DrugBank.d132.s1	58	66	coumarins	group	DDI-DrugBank.d132.s1.e1
DDI-DrugBank.d132.s1	true	DDI-DrugBank.d132.s1.e0	DDI-DrugBank.d132.s1.e1
DDI-DrugBank.d132.s2|a|Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.
DDI-DrugBank.d132.s2	18	27	diflunisal	drug	DDI-DrugBank.d132.s2.e0
DDI-DrugBank.d132.s2	55	68	anticoagulants	group	DDI-DrugBank.d132.s2.e1
DDI-DrugBank.d132.s2	true	DDI-DrugBank.d132.s2.e0	DDI-DrugBank.d132.s2.e1
DDI-DrugBank.d132.s3|a|Adjustment of dosage of oral anticoagulants may be required.
DDI-DrugBank.d132.s3	29	42	anticoagulants	group	DDI-DrugBank.d132.s3.e0
DDI-DrugBank.d132.s4|a|Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.
DDI-DrugBank.d132.s4	0	10	Tolbutamide	drug	DDI-DrugBank.d132.s4.e0
DDI-DrugBank.d132.s4	44	53	diflunisal	drug	DDI-DrugBank.d132.s4.e1
DDI-DrugBank.d132.s4	59	69	tolbutamide	drug	DDI-DrugBank.d132.s4.e2
DDI-DrugBank.d132.s4	108	118	tolbutamide	drug	DDI-DrugBank.d132.s4.e3
DDI-DrugBank.d132.s4	false	DDI-DrugBank.d132.s4.e0	DDI-DrugBank.d132.s4.e1
DDI-DrugBank.d132.s4	false	DDI-DrugBank.d132.s4.e0	DDI-DrugBank.d132.s4.e2
DDI-DrugBank.d132.s4	false	DDI-DrugBank.d132.s4.e0	DDI-DrugBank.d132.s4.e3
DDI-DrugBank.d132.s4	false	DDI-DrugBank.d132.s4.e1	DDI-DrugBank.d132.s4.e2
DDI-DrugBank.d132.s4	false	DDI-DrugBank.d132.s4.e1	DDI-DrugBank.d132.s4.e3
DDI-DrugBank.d132.s4	false	DDI-DrugBank.d132.s4.e2	DDI-DrugBank.d132.s4.e3
DDI-DrugBank.d132.s5|a|Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.
DDI-DrugBank.d132.s5	0	18	Hydrochlorothiazide	drug	DDI-DrugBank.d132.s5.e0
DDI-DrugBank.d132.s5	73	82	diflunisal	drug	DDI-DrugBank.d132.s5.e1
DDI-DrugBank.d132.s5	88	106	hydrochlorothiazide	drug	DDI-DrugBank.d132.s5.e2
DDI-DrugBank.d132.s5	161	179	hydrochlorothiazide	drug	DDI-DrugBank.d132.s5.e3
DDI-DrugBank.d132.s5	false	DDI-DrugBank.d132.s5.e0	DDI-DrugBank.d132.s5.e1
DDI-DrugBank.d132.s5	false	DDI-DrugBank.d132.s5.e0	DDI-DrugBank.d132.s5.e2
DDI-DrugBank.d132.s5	false	DDI-DrugBank.d132.s5.e0	DDI-DrugBank.d132.s5.e3
DDI-DrugBank.d132.s5	true	DDI-DrugBank.d132.s5.e1	DDI-DrugBank.d132.s5.e2
DDI-DrugBank.d132.s5	false	DDI-DrugBank.d132.s5.e1	DDI-DrugBank.d132.s5.e3
DDI-DrugBank.d132.s5	false	DDI-DrugBank.d132.s5.e2	DDI-DrugBank.d132.s5.e3
DDI-DrugBank.d132.s6|a|Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.
DDI-DrugBank.d132.s6	0	9	Diflunisal	drug	DDI-DrugBank.d132.s6.e0
DDI-DrugBank.d132.s6	49	67	hydrochlorothiazide	drug	DDI-DrugBank.d132.s6.e1
DDI-DrugBank.d132.s6	true	DDI-DrugBank.d132.s6.e0	DDI-DrugBank.d132.s6.e1
DDI-DrugBank.d132.s7|a|Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.
DDI-DrugBank.d132.s7	0	9	Furosemide	drug	DDI-DrugBank.d132.s7.e0
DDI-DrugBank.d132.s7	68	77	diflunisal	drug	DDI-DrugBank.d132.s7.e1
DDI-DrugBank.d132.s7	83	92	furosemide	drug	DDI-DrugBank.d132.s7.e2
DDI-DrugBank.d132.s7	136	145	furosemide	drug	DDI-DrugBank.d132.s7.e3
DDI-DrugBank.d132.s7	false	DDI-DrugBank.d132.s7.e0	DDI-DrugBank.d132.s7.e1
DDI-DrugBank.d132.s7	false	DDI-DrugBank.d132.s7.e0	DDI-DrugBank.d132.s7.e2
DDI-DrugBank.d132.s7	false	DDI-DrugBank.d132.s7.e0	DDI-DrugBank.d132.s7.e3
DDI-DrugBank.d132.s7	false	DDI-DrugBank.d132.s7.e1	DDI-DrugBank.d132.s7.e2
DDI-DrugBank.d132.s7	false	DDI-DrugBank.d132.s7.e1	DDI-DrugBank.d132.s7.e3
DDI-DrugBank.d132.s7	false	DDI-DrugBank.d132.s7.e2	DDI-DrugBank.d132.s7.e3
DDI-DrugBank.d132.s8|a|Diflunisal decreased the hyperuricemic effect of furosemide.
DDI-DrugBank.d132.s8	0	9	Diflunisal	drug	DDI-DrugBank.d132.s8.e0
DDI-DrugBank.d132.s8	49	58	furosemide	drug	DDI-DrugBank.d132.s8.e1
DDI-DrugBank.d132.s8	true	DDI-DrugBank.d132.s8.e0	DDI-DrugBank.d132.s8.e1
DDI-DrugBank.d132.s9|a|Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.
DDI-DrugBank.d132.s9	0	7	Antacids	group	DDI-DrugBank.d132.s9.e0
DDI-DrugBank.d132.s9	40	47	antacids	group	DDI-DrugBank.d132.s9.e1
DDI-DrugBank.d132.s9	77	86	diflunisal	drug	DDI-DrugBank.d132.s9.e2
DDI-DrugBank.d132.s9	false	DDI-DrugBank.d132.s9.e0	DDI-DrugBank.d132.s9.e1
DDI-DrugBank.d132.s9	false	DDI-DrugBank.d132.s9.e0	DDI-DrugBank.d132.s9.e2
DDI-DrugBank.d132.s9	true	DDI-DrugBank.d132.s9.e1	DDI-DrugBank.d132.s9.e2
DDI-DrugBank.d132.s10|a|This effect is small with occasional doses of antacids, but may be clinically significant when antacids are used on a continuous schedule.
DDI-DrugBank.d132.s10	46	53	antacids	group	DDI-DrugBank.d132.s10.e0
DDI-DrugBank.d132.s10	95	102	antacids	group	DDI-DrugBank.d132.s10.e1
DDI-DrugBank.d132.s10	false	DDI-DrugBank.d132.s10.e0	DDI-DrugBank.d132.s10.e1
DDI-DrugBank.d132.s11|a|Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
DDI-DrugBank.d132.s11	0	12	Acetaminophen	drug	DDI-DrugBank.d132.s11.e0
DDI-DrugBank.d132.s11	67	76	diflunisal	drug	DDI-DrugBank.d132.s11.e1
DDI-DrugBank.d132.s11	82	94	acetaminophen	drug	DDI-DrugBank.d132.s11.e2
DDI-DrugBank.d132.s11	156	168	acetaminophen	drug	DDI-DrugBank.d132.s11.e3
DDI-DrugBank.d132.s11	false	DDI-DrugBank.d132.s11.e0	DDI-DrugBank.d132.s11.e1
DDI-DrugBank.d132.s11	false	DDI-DrugBank.d132.s11.e0	DDI-DrugBank.d132.s11.e2
DDI-DrugBank.d132.s11	false	DDI-DrugBank.d132.s11.e0	DDI-DrugBank.d132.s11.e3
DDI-DrugBank.d132.s11	true	DDI-DrugBank.d132.s11.e1	DDI-DrugBank.d132.s11.e2
DDI-DrugBank.d132.s11	false	DDI-DrugBank.d132.s11.e1	DDI-DrugBank.d132.s11.e3
DDI-DrugBank.d132.s11	false	DDI-DrugBank.d132.s11.e2	DDI-DrugBank.d132.s11.e3
DDI-DrugBank.d132.s12|a|Acetaminophen had no effect on plasma levels of diflunisal.
DDI-DrugBank.d132.s12	0	12	Acetaminophen	drug	DDI-DrugBank.d132.s12.e0
DDI-DrugBank.d132.s12	48	57	diflunisal	drug	DDI-DrugBank.d132.s12.e1
DDI-DrugBank.d132.s12	false	DDI-DrugBank.d132.s12.e0	DDI-DrugBank.d132.s12.e1
DDI-DrugBank.d132.s13|a|Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.
DDI-DrugBank.d132.s13	6	18	acetaminophen	drug	DDI-DrugBank.d132.s13.e0
DDI-DrugBank.d132.s13	105	114	diflunisal	drug	DDI-DrugBank.d132.s13.e1
DDI-DrugBank.d132.s13	120	132	acetaminophen	drug	DDI-DrugBank.d132.s13.e2
DDI-DrugBank.d132.s13	false	DDI-DrugBank.d132.s13.e0	DDI-DrugBank.d132.s13.e1
DDI-DrugBank.d132.s13	false	DDI-DrugBank.d132.s13.e0	DDI-DrugBank.d132.s13.e2
DDI-DrugBank.d132.s13	true	DDI-DrugBank.d132.s13.e1	DDI-DrugBank.d132.s13.e2
DDI-DrugBank.d132.s14|a|Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
DDI-DrugBank.d132.s14	30	39	diflunisal	drug	DDI-DrugBank.d132.s14.e0
DDI-DrugBank.d132.s14	45	57	acetaminophen	drug	DDI-DrugBank.d132.s14.e1
DDI-DrugBank.d132.s14	188	197	diflunisal	drug	DDI-DrugBank.d132.s14.e2
DDI-DrugBank.d132.s14	199	211	acetaminophen	drug	DDI-DrugBank.d132.s14.e3
DDI-DrugBank.d132.s14	true	DDI-DrugBank.d132.s14.e0	DDI-DrugBank.d132.s14.e1
DDI-DrugBank.d132.s14	false	DDI-DrugBank.d132.s14.e0	DDI-DrugBank.d132.s14.e2
DDI-DrugBank.d132.s14	false	DDI-DrugBank.d132.s14.e0	DDI-DrugBank.d132.s14.e3
DDI-DrugBank.d132.s14	false	DDI-DrugBank.d132.s14.e1	DDI-DrugBank.d132.s14.e2
DDI-DrugBank.d132.s14	false	DDI-DrugBank.d132.s14.e1	DDI-DrugBank.d132.s14.e3
DDI-DrugBank.d132.s14	false	DDI-DrugBank.d132.s14.e2	DDI-DrugBank.d132.s14.e3
DDI-DrugBank.d132.s15|a|The clinical significance of these findings has not been established.
DDI-DrugBank.d132.s16|a|Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.
DDI-DrugBank.d132.s16	0	11	Methotrexate	drug	DDI-DrugBank.d132.s16.e0
DDI-DrugBank.d132.s16	40	49	diflunisal	drug	DDI-DrugBank.d132.s16.e1
DDI-DrugBank.d132.s16	86	97	methotrexate	drug	DDI-DrugBank.d132.s16.e2
DDI-DrugBank.d132.s16	false	DDI-DrugBank.d132.s16.e0	DDI-DrugBank.d132.s16.e1
DDI-DrugBank.d132.s16	false	DDI-DrugBank.d132.s16.e0	DDI-DrugBank.d132.s16.e2
DDI-DrugBank.d132.s16	true	DDI-DrugBank.d132.s16.e1	DDI-DrugBank.d132.s16.e2
DDI-DrugBank.d132.s17|a|Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
DDI-DrugBank.d132.s17	0	35	Nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d132.s17.e0
DDI-DrugBank.d132.s17	93	104	methotrexate	drug	DDI-DrugBank.d132.s17.e1
DDI-DrugBank.d132.s17	true	DDI-DrugBank.d132.s17.e0	DDI-DrugBank.d132.s17.e1
DDI-DrugBank.d132.s18|a|Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
DDI-DrugBank.d132.s18	0	11	Cyclosporine	drug	DDI-DrugBank.d132.s18.e0
DDI-DrugBank.d132.s18	32	66	nonsteroial anti-inflammatory drugs	group	DDI-DrugBank.d132.s18.e1
DDI-DrugBank.d132.s18	87	98	cyclosporine	drug	DDI-DrugBank.d132.s18.e2
DDI-DrugBank.d132.s18	140	151	cyclosporine	drug	DDI-DrugBank.d132.s18.e3
DDI-DrugBank.d132.s18	false	DDI-DrugBank.d132.s18.e0	DDI-DrugBank.d132.s18.e1
DDI-DrugBank.d132.s18	false	DDI-DrugBank.d132.s18.e0	DDI-DrugBank.d132.s18.e2
DDI-DrugBank.d132.s18	false	DDI-DrugBank.d132.s18.e0	DDI-DrugBank.d132.s18.e3
DDI-DrugBank.d132.s18	true	DDI-DrugBank.d132.s18.e1	DDI-DrugBank.d132.s18.e2
DDI-DrugBank.d132.s18	false	DDI-DrugBank.d132.s18.e1	DDI-DrugBank.d132.s18.e3
DDI-DrugBank.d132.s18	false	DDI-DrugBank.d132.s18.e2	DDI-DrugBank.d132.s18.e3
DDI-DrugBank.d132.s19|a|NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
DDI-DrugBank.d132.s19	0	5	NSAIDs	group	DDI-DrugBank.d132.s19.e0
DDI-DrugBank.d132.s19	54	65	cyclosporine	drug	DDI-DrugBank.d132.s19.e1
DDI-DrugBank.d132.s19	true	DDI-DrugBank.d132.s19.e0	DDI-DrugBank.d132.s19.e1
DDI-DrugBank.d132.s20|a|Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.
DDI-DrugBank.d132.s20	0	35	Nonsteroidal Anti-Inflammatory Drugs	group	DDI-DrugBank.d132.s20.e0
DDI-DrugBank.d132.s20	60	69	diflunisal	drug	DDI-DrugBank.d132.s20.e1
DDI-DrugBank.d132.s20	102	113	indomethacin	drug	DDI-DrugBank.d132.s20.e2
DDI-DrugBank.d132.s20	194	205	indomethacin	drug	DDI-DrugBank.d132.s20.e3
DDI-DrugBank.d132.s20	false	DDI-DrugBank.d132.s20.e0	DDI-DrugBank.d132.s20.e1
DDI-DrugBank.d132.s20	false	DDI-DrugBank.d132.s20.e0	DDI-DrugBank.d132.s20.e2
DDI-DrugBank.d132.s20	false	DDI-DrugBank.d132.s20.e0	DDI-DrugBank.d132.s20.e3
DDI-DrugBank.d132.s20	true	DDI-DrugBank.d132.s20.e1	DDI-DrugBank.d132.s20.e2
DDI-DrugBank.d132.s20	false	DDI-DrugBank.d132.s20.e1	DDI-DrugBank.d132.s20.e3
DDI-DrugBank.d132.s20	false	DDI-DrugBank.d132.s20.e2	DDI-DrugBank.d132.s20.e3
DDI-DrugBank.d132.s21|a|In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
DDI-DrugBank.d132.s21	37	48	indomethacin	drug	DDI-DrugBank.d132.s21.e0
DDI-DrugBank.d132.s21	54	63	diflunisal	drug	DDI-DrugBank.d132.s21.e1
DDI-DrugBank.d132.s21	true	DDI-DrugBank.d132.s21.e0	DDI-DrugBank.d132.s21.e1
DDI-DrugBank.d132.s22|a|Therefore, indomethacin and diflunisal should not be used concomitantly.
DDI-DrugBank.d132.s22	11	22	indomethacin	drug	DDI-DrugBank.d132.s22.e0
DDI-DrugBank.d132.s22	28	37	diflunisal	drug	DDI-DrugBank.d132.s22.e1
DDI-DrugBank.d132.s22	true	DDI-DrugBank.d132.s22.e0	DDI-DrugBank.d132.s22.e1
DDI-DrugBank.d132.s23|a|The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
DDI-DrugBank.d132.s23	23	32	diflunisal	drug	DDI-DrugBank.d132.s23.e0
DDI-DrugBank.d132.s23	52	57	NSAIDs	group	DDI-DrugBank.d132.s23.e1
DDI-DrugBank.d132.s23	true	DDI-DrugBank.d132.s23.e0	DDI-DrugBank.d132.s23.e1
DDI-DrugBank.d132.s24|a|The following information was obtained from studies in normal volunteers.
DDI-DrugBank.d132.s25|a|Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.
DDI-DrugBank.d132.s25	0	6	Aspirin	brand	DDI-DrugBank.d132.s25.e0
DDI-DrugBank.d132.s25	51	60	diflunisal	drug	DDI-DrugBank.d132.s25.e1
DDI-DrugBank.d132.s25	105	114	diflunisal	drug	DDI-DrugBank.d132.s25.e2
DDI-DrugBank.d132.s25	120	126	aspirin	brand	DDI-DrugBank.d132.s25.e3
DDI-DrugBank.d132.s25	false	DDI-DrugBank.d132.s25.e0	DDI-DrugBank.d132.s25.e1
DDI-DrugBank.d132.s25	false	DDI-DrugBank.d132.s25.e0	DDI-DrugBank.d132.s25.e2
DDI-DrugBank.d132.s25	false	DDI-DrugBank.d132.s25.e0	DDI-DrugBank.d132.s25.e3
DDI-DrugBank.d132.s25	false	DDI-DrugBank.d132.s25.e1	DDI-DrugBank.d132.s25.e2
DDI-DrugBank.d132.s25	false	DDI-DrugBank.d132.s25.e1	DDI-DrugBank.d132.s25.e3
DDI-DrugBank.d132.s25	true	DDI-DrugBank.d132.s25.e2	DDI-DrugBank.d132.s25.e3
DDI-DrugBank.d132.s26|a|Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
DDI-DrugBank.d132.s26	0	7	Sulindac	drug	DDI-DrugBank.d132.s26.e0
DDI-DrugBank.d132.s26	44	53	diflunisal	drug	DDI-DrugBank.d132.s26.e1
DDI-DrugBank.d132.s26	59	66	sulindac	drug	DDI-DrugBank.d132.s26.e2
DDI-DrugBank.d132.s26	false	DDI-DrugBank.d132.s26.e0	DDI-DrugBank.d132.s26.e1
DDI-DrugBank.d132.s26	false	DDI-DrugBank.d132.s26.e0	DDI-DrugBank.d132.s26.e2
DDI-DrugBank.d132.s26	true	DDI-DrugBank.d132.s26.e1	DDI-DrugBank.d132.s26.e2
DDI-DrugBank.d132.s27|a|Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
DDI-DrugBank.d132.s27	0	7	Naproxen	drug	DDI-DrugBank.d132.s27.e0
DDI-DrugBank.d132.s27	44	53	diflunisal	drug	DDI-DrugBank.d132.s27.e1
DDI-DrugBank.d132.s27	59	66	naproxen	drug	DDI-DrugBank.d132.s27.e2
DDI-DrugBank.d132.s27	127	134	naproxen	drug	DDI-DrugBank.d132.s27.e3
DDI-DrugBank.d132.s27	190	197	naproxen	drug	DDI-DrugBank.d132.s27.e4
DDI-DrugBank.d132.s27	false	DDI-DrugBank.d132.s27.e0	DDI-DrugBank.d132.s27.e1
DDI-DrugBank.d132.s27	false	DDI-DrugBank.d132.s27.e0	DDI-DrugBank.d132.s27.e2
DDI-DrugBank.d132.s27	false	DDI-DrugBank.d132.s27.e0	DDI-DrugBank.d132.s27.e3
DDI-DrugBank.d132.s27	false	DDI-DrugBank.d132.s27.e0	DDI-DrugBank.d132.s27.e4
DDI-DrugBank.d132.s27	true	DDI-DrugBank.d132.s27.e1	DDI-DrugBank.d132.s27.e2
DDI-DrugBank.d132.s27	false	DDI-DrugBank.d132.s27.e1	DDI-DrugBank.d132.s27.e3
DDI-DrugBank.d132.s27	false	DDI-DrugBank.d132.s27.e1	DDI-DrugBank.d132.s27.e4
DDI-DrugBank.d132.s27	false	DDI-DrugBank.d132.s27.e2	DDI-DrugBank.d132.s27.e3
DDI-DrugBank.d132.s27	false	DDI-DrugBank.d132.s27.e2	DDI-DrugBank.d132.s27.e4
DDI-DrugBank.d132.s27	false	DDI-DrugBank.d132.s27.e3	DDI-DrugBank.d132.s27.e4
DDI-DrugBank.d132.s28|a|Naproxen had no effect on plasma levels of diflunisal.
DDI-DrugBank.d132.s28	0	7	Naproxen	drug	DDI-DrugBank.d132.s28.e0
DDI-DrugBank.d132.s28	43	52	diflunisal	drug	DDI-DrugBank.d132.s28.e1
DDI-DrugBank.d132.s28	false	DDI-DrugBank.d132.s28.e0	DDI-DrugBank.d132.s28.e1
DDI-DrugBank.d132.s29|a|Drug laboratory Test Interactions Serum Salicylate Assays: Caution should be used in interpreting the results of serum salicylate assays when diflunisal is present.
DDI-DrugBank.d132.s29	142	151	diflunisal	drug	DDI-DrugBank.d132.s29.e0
DDI-DrugBank.d132.s30|a|Salicylate levels have been found to be falsely elevated with some assay methods.
DDI-DrugBank.d132.s30	0	9	Salicylate	group	DDI-DrugBank.d132.s30.e0
DDI-DrugBank.d450.s0|a|Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.
DDI-DrugBank.d450.s0	0	28	Potassium-depleting diuretics	group	DDI-DrugBank.d450.s0.e0
DDI-DrugBank.d450.s0	65	73	digitalis	group	DDI-DrugBank.d450.s0.e1
DDI-DrugBank.d450.s0	true	DDI-DrugBank.d450.s0.e0	DDI-DrugBank.d450.s0.e1
DDI-DrugBank.d450.s1|a|Calcium, particularly if administered rapidly by the intravenous route, may produce serious arrhythmias in digitalized patients.
DDI-DrugBank.d450.s1	0	6	Calcium	drug	DDI-DrugBank.d450.s1.e0
DDI-DrugBank.d450.s2|a|Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DDI-DrugBank.d450.s2	0	8	Quinidine	drug	DDI-DrugBank.d450.s2.e0
DDI-DrugBank.d450.s2	11	19	verapamil	drug	DDI-DrugBank.d450.s2.e1
DDI-DrugBank.d450.s2	22	31	amiodarone	drug	DDI-DrugBank.d450.s2.e2
DDI-DrugBank.d450.s2	34	44	propafenone	drug	DDI-DrugBank.d450.s2.e3
DDI-DrugBank.d450.s2	47	58	indomethacin	drug	DDI-DrugBank.d450.s2.e4
DDI-DrugBank.d450.s2	61	72	itraconazole	drug	DDI-DrugBank.d450.s2.e5
DDI-DrugBank.d450.s2	75	84	alprazolam	drug	DDI-DrugBank.d450.s2.e6
DDI-DrugBank.d450.s2	91	104	spironolactone	drug	DDI-DrugBank.d450.s2.e7
DDI-DrugBank.d450.s2	122	128	digoxin	drug	DDI-DrugBank.d450.s2.e8
DDI-DrugBank.d450.s2	248	256	digitalis	group	DDI-DrugBank.d450.s2.e9
DDI-DrugBank.d450.s2	false	DDI-DrugBank.d450.s2.e0	DDI-DrugBank.d450.s2.e1
DDI-DrugBank.d450.s2	false	DDI-DrugBank.d450.s2.e0	DDI-DrugBank.d450.s2.e2
DDI-DrugBank.d450.s2	false	DDI-DrugBank.d450.s2.e0	DDI-DrugBank.d450.s2.e3
DDI-DrugBank.d450.s2	false	DDI-DrugBank.d450.s2.e0	DDI-DrugBank.d450.s2.e4
DDI-DrugBank.d450.s2	false	DDI-DrugBank.d450.s2.e0	DDI-DrugBank.d450.s2.e5
DDI-DrugBank.d450.s2	false	DDI-DrugBank.d450.s2.e0	DDI-DrugBank.d450.s2.e6
DDI-DrugBank.d450.s2	false	DDI-DrugBank.d450.s2.e0	DDI-DrugBank.d450.s2.e7
DDI-DrugBank.d450.s2	true	DDI-DrugBank.d450.s2.e0	DDI-DrugBank.d450.s2.e8
DDI-DrugBank.d450.s2	false	DDI-DrugBank.d450.s2.e0	DDI-DrugBank.d450.s2.e9
DDI-DrugBank.d450.s2	false	DDI-DrugBank.d450.s2.e1	DDI-DrugBank.d450.s2.e2
DDI-DrugBank.d450.s3|a|Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
DDI-DrugBank.d450.s3	0	11	Erythromycin	drug	DDI-DrugBank.d450.s3.e0
DDI-DrugBank.d450.s3	17	30	clarithromycin	drug	DDI-DrugBank.d450.s3.e1
DDI-DrugBank.d450.s3	52	72	macrolide antibiotics	group	DDI-DrugBank.d450.s3.e2
DDI-DrugBank.d450.s3	79	90	tetracycline	drug	DDI-DrugBank.d450.s3.e3
DDI-DrugBank.d450.s3	105	111	digoxin	drug	DDI-DrugBank.d450.s3.e4
DDI-DrugBank.d450.s3	151	157	digoxin	drug	DDI-DrugBank.d450.s3.e5
DDI-DrugBank.d450.s3	215	223	digitalis	group	DDI-DrugBank.d450.s3.e6
DDI-DrugBank.d450.s3	false	DDI-DrugBank.d450.s3.e0	DDI-DrugBank.d450.s3.e1
DDI-DrugBank.d450.s3	false	DDI-DrugBank.d450.s3.e0	DDI-DrugBank.d450.s3.e2
DDI-DrugBank.d450.s3	false	DDI-DrugBank.d450.s3.e0	DDI-DrugBank.d450.s3.e3
DDI-DrugBank.d450.s3	true	DDI-DrugBank.d450.s3.e0	DDI-DrugBank.d450.s3.e4
DDI-DrugBank.d450.s3	false	DDI-DrugBank.d450.s3.e0	DDI-DrugBank.d450.s3.e5
DDI-DrugBank.d450.s3	false	DDI-DrugBank.d450.s3.e0	DDI-DrugBank.d450.s3.e6
DDI-DrugBank.d450.s3	false	DDI-DrugBank.d450.s3.e1	DDI-DrugBank.d450.s3.e2
DDI-DrugBank.d450.s3	false	DDI-DrugBank.d450.s3.e1	DDI-DrugBank.d450.s3.e3
DDI-DrugBank.d450.s3	true	DDI-DrugBank.d450.s3.e1	DDI-DrugBank.d450.s3.e4
DDI-DrugBank.d450.s3	false	DDI-DrugBank.d450.s3.e1	DDI-DrugBank.d450.s3.e5
DDI-DrugBank.d450.s4|a|The risk of this interaction may be reduced if digoxin is given as capsules.
DDI-DrugBank.d450.s4	47	53	digoxin	drug	DDI-DrugBank.d450.s4.e0
DDI-DrugBank.d450.s5|a|Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
DDI-DrugBank.d450.s5	0	12	Propantheline	drug	DDI-DrugBank.d450.s5.e0
DDI-DrugBank.d450.s5	18	30	diphenoxylate	drug	DDI-DrugBank.d450.s5.e1
DDI-DrugBank.d450.s5	74	80	digoxin	drug	DDI-DrugBank.d450.s5.e2
DDI-DrugBank.d450.s5	false	DDI-DrugBank.d450.s5.e0	DDI-DrugBank.d450.s5.e1
DDI-DrugBank.d450.s5	true	DDI-DrugBank.d450.s5.e0	DDI-DrugBank.d450.s5.e2
DDI-DrugBank.d450.s5	true	DDI-DrugBank.d450.s5.e1	DDI-DrugBank.d450.s5.e2
DDI-DrugBank.d450.s6|a|Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DDI-DrugBank.d450.s6	0	7	Antacids	group	DDI-DrugBank.d450.s6.e0
DDI-DrugBank.d450.s6	10	15	kaolin	drug	DDI-DrugBank.d450.s6.e1
DDI-DrugBank.d450.s6	25	37	sulfasalazine	drug	DDI-DrugBank.d450.s6.e2
DDI-DrugBank.d450.s6	40	47	neomycin	drug	DDI-DrugBank.d450.s6.e3
DDI-DrugBank.d450.s6	50	63	cholestyramine	drug	DDI-DrugBank.d450.s6.e4
DDI-DrugBank.d450.s6	96	109	metoclopramide	drug	DDI-DrugBank.d450.s6.e5
DDI-DrugBank.d450.s6	141	147	digoxin	drug	DDI-DrugBank.d450.s6.e6
DDI-DrugBank.d450.s6	false	DDI-DrugBank.d450.s6.e0	DDI-DrugBank.d450.s6.e1
DDI-DrugBank.d450.s6	false	DDI-DrugBank.d450.s6.e0	DDI-DrugBank.d450.s6.e2
DDI-DrugBank.d450.s6	false	DDI-DrugBank.d450.s6.e0	DDI-DrugBank.d450.s6.e3
DDI-DrugBank.d450.s6	false	DDI-DrugBank.d450.s6.e0	DDI-DrugBank.d450.s6.e4
DDI-DrugBank.d450.s6	false	DDI-DrugBank.d450.s6.e0	DDI-DrugBank.d450.s6.e5
DDI-DrugBank.d450.s6	true	DDI-DrugBank.d450.s6.e0	DDI-DrugBank.d450.s6.e6
DDI-DrugBank.d450.s6	false	DDI-DrugBank.d450.s6.e1	DDI-DrugBank.d450.s6.e2
DDI-DrugBank.d450.s6	false	DDI-DrugBank.d450.s6.e1	DDI-DrugBank.d450.s6.e3
DDI-DrugBank.d450.s6	false	DDI-DrugBank.d450.s6.e1	DDI-DrugBank.d450.s6.e4
DDI-DrugBank.d450.s6	false	DDI-DrugBank.d450.s6.e1	DDI-DrugBank.d450.s6.e5
DDI-DrugBank.d450.s7|a|Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.
DDI-DrugBank.d450.s7	0	7	Rifampin	drug	DDI-DrugBank.d450.s7.e0
DDI-DrugBank.d450.s7	28	34	digoxin	drug	DDI-DrugBank.d450.s7.e1
DDI-DrugBank.d450.s7	139	145	digoxin	drug	DDI-DrugBank.d450.s7.e2
DDI-DrugBank.d450.s7	true	DDI-DrugBank.d450.s7.e0	DDI-DrugBank.d450.s7.e1
DDI-DrugBank.d450.s7	false	DDI-DrugBank.d450.s7.e0	DDI-DrugBank.d450.s7.e2
DDI-DrugBank.d450.s7	false	DDI-DrugBank.d450.s7.e1	DDI-DrugBank.d450.s7.e2
DDI-DrugBank.d450.s8|a|There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, penicillamine) on serum digoxin concentration.
DDI-DrugBank.d450.s8	81	87	quinine	drug	DDI-DrugBank.d450.s8.e0
DDI-DrugBank.d450.s8	90	102	penicillamine	drug	DDI-DrugBank.d450.s8.e1
DDI-DrugBank.d450.s8	114	120	digoxin	drug	DDI-DrugBank.d450.s8.e2
DDI-DrugBank.d450.s8	false	DDI-DrugBank.d450.s8.e0	DDI-DrugBank.d450.s8.e1
DDI-DrugBank.d450.s8	false	DDI-DrugBank.d450.s8.e0	DDI-DrugBank.d450.s8.e2
DDI-DrugBank.d450.s8	false	DDI-DrugBank.d450.s8.e1	DDI-DrugBank.d450.s8.e2
DDI-DrugBank.d450.s9|a|Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.
DDI-DrugBank.d450.s9	0	6	Thyroid	group	DDI-DrugBank.d450.s9.e0
DDI-DrugBank.d450.s9	98	104	digoxin	drug	DDI-DrugBank.d450.s9.e1
DDI-DrugBank.d450.s9	true	DDI-DrugBank.d450.s9.e0	DDI-DrugBank.d450.s9.e1
DDI-DrugBank.d450.s10|a|Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.
DDI-DrugBank.d450.s10	19	25	digoxin	drug	DDI-DrugBank.d450.s10.e0
DDI-DrugBank.d450.s10	31	46	sympathomimetics	group	DDI-DrugBank.d450.s10.e1
DDI-DrugBank.d450.s10	true	DDI-DrugBank.d450.s10.e0	DDI-DrugBank.d450.s10.e1
DDI-DrugBank.d450.s11|a|Succinylcholine may cause a sudden extrusion of potassium from muscle cells, and may thereby cause arrhythmias in digitalized patients.
DDI-DrugBank.d450.s11	0	14	Succinylcholine	drug	DDI-DrugBank.d450.s11.e0
DDI-DrugBank.d450.s12|a|Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
DDI-DrugBank.d450.s12	9	32	beta-adrenergic blockers	group	DDI-DrugBank.d450.s12.e0
DDI-DrugBank.d450.s12	37	60	calcium channel blockers	group	DDI-DrugBank.d450.s12.e1
DDI-DrugBank.d450.s12	66	72	digoxin	drug	DDI-DrugBank.d450.s12.e2
DDI-DrugBank.d450.s12	false	DDI-DrugBank.d450.s12.e0	DDI-DrugBank.d450.s12.e1
DDI-DrugBank.d450.s12	true	DDI-DrugBank.d450.s12.e0	DDI-DrugBank.d450.s12.e2
DDI-DrugBank.d450.s12	true	DDI-DrugBank.d450.s12.e1	DDI-DrugBank.d450.s12.e2
DDI-DrugBank.d450.s13|a|Due to the considerable variability of these interactions, the dosage of digoxin should be individualized when patients receive these medications concurrently.
DDI-DrugBank.d450.s13	73	79	digoxin	drug	DDI-DrugBank.d450.s13.e0
DDI-DrugBank.d450.s14|a|Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.
DDI-DrugBank.d450.s14	56	62	digoxin	drug	DDI-DrugBank.d450.s14.e0
DDI-DrugBank.d450.s14	230	236	digoxin	drug	DDI-DrugBank.d450.s14.e1
DDI-DrugBank.d450.s14	false	DDI-DrugBank.d450.s14.e0	DDI-DrugBank.d450.s14.e1
DDI-DrugBank.d410.s0|a|Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.
DDI-DrugBank.d410.s0	0	15	Vasoconstrictors	group	DDI-DrugBank.d410.s0.e0
DDI-DrugBank.d410.s0	18	26	D.H.E. 45	brand	DDI-DrugBank.d410.s0.e1
DDI-DrugBank.d410.s0	30	55	dihydroergotamine mesylate	drug	DDI-DrugBank.d410.s0.e2
DDI-DrugBank.d410.s0	97	123	peripheral vasoconstrictors	group	DDI-DrugBank.d410.s0.e3
DDI-DrugBank.d410.s0	false	DDI-DrugBank.d410.s0.e0	DDI-DrugBank.d410.s0.e1
DDI-DrugBank.d410.s0	false	DDI-DrugBank.d410.s0.e0	DDI-DrugBank.d410.s0.e2
DDI-DrugBank.d410.s0	false	DDI-DrugBank.d410.s0.e0	DDI-DrugBank.d410.s0.e3
DDI-DrugBank.d410.s0	false	DDI-DrugBank.d410.s0.e1	DDI-DrugBank.d410.s0.e2
DDI-DrugBank.d410.s0	true	DDI-DrugBank.d410.s0.e1	DDI-DrugBank.d410.s0.e3
DDI-DrugBank.d410.s0	true	DDI-DrugBank.d410.s0.e2	DDI-DrugBank.d410.s0.e3
DDI-DrugBank.d410.s1|a|Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
DDI-DrugBank.d410.s1	0	10	Sumatriptan	drug	DDI-DrugBank.d410.s1.e0
DDI-DrugBank.d410.s1	13	23	Sumatriptan	drug	DDI-DrugBank.d410.s1.e1
DDI-DrugBank.d410.s1	117	125	D.H.E. 45	brand	DDI-DrugBank.d410.s1.e2
DDI-DrugBank.d410.s1	129	154	dihydroergotamine mesylate	drug	DDI-DrugBank.d410.s1.e3
DDI-DrugBank.d410.s1	false	DDI-DrugBank.d410.s1.e0	DDI-DrugBank.d410.s1.e1
DDI-DrugBank.d410.s1	false	DDI-DrugBank.d410.s1.e0	DDI-DrugBank.d410.s1.e2
DDI-DrugBank.d410.s1	false	DDI-DrugBank.d410.s1.e0	DDI-DrugBank.d410.s1.e3
DDI-DrugBank.d410.s1	true	DDI-DrugBank.d410.s1.e1	DDI-DrugBank.d410.s1.e2
DDI-DrugBank.d410.s1	true	DDI-DrugBank.d410.s1.e1	DDI-DrugBank.d410.s1.e3
DDI-DrugBank.d410.s1	false	DDI-DrugBank.d410.s1.e2	DDI-DrugBank.d410.s1.e3
DDI-DrugBank.d410.s2|a|Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
DDI-DrugBank.d410.s2	0	10	Sumatriptan	drug	DDI-DrugBank.d410.s2.e0
DDI-DrugBank.d410.s2	16	24	D.H.E. 45	brand	DDI-DrugBank.d410.s2.e1
DDI-DrugBank.d410.s2	28	53	dihydroergotamine mesylate	drug	DDI-DrugBank.d410.s2.e2
DDI-DrugBank.d410.s2	true	DDI-DrugBank.d410.s2.e0	DDI-DrugBank.d410.s2.e1
DDI-DrugBank.d410.s2	true	DDI-DrugBank.d410.s2.e0	DDI-DrugBank.d410.s2.e2
DDI-DrugBank.d410.s2	false	DDI-DrugBank.d410.s2.e1	DDI-DrugBank.d410.s2.e2
DDI-DrugBank.d410.s3|a|Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
DDI-DrugBank.d410.s3	0	12	Beta Blockers	group	DDI-DrugBank.d410.s3.e0
DDI-DrugBank.d410.s3	126	134	D.H.E. 45	brand	DDI-DrugBank.d410.s3.e1
DDI-DrugBank.d410.s3	138	163	dihydroergotamine mesylate	drug	DDI-DrugBank.d410.s3.e2
DDI-DrugBank.d410.s3	211	221	propranolol	drug	DDI-DrugBank.d410.s3.e3
DDI-DrugBank.d410.s3	253	263	propranolol	drug	DDI-DrugBank.d410.s3.e4
DDI-DrugBank.d410.s3	311	320	ergotamine	drug	DDI-DrugBank.d410.s3.e5
DDI-DrugBank.d410.s3	false	DDI-DrugBank.d410.s3.e0	DDI-DrugBank.d410.s3.e1
DDI-DrugBank.d410.s3	false	DDI-DrugBank.d410.s3.e0	DDI-DrugBank.d410.s3.e2
DDI-DrugBank.d410.s3	false	DDI-DrugBank.d410.s3.e0	DDI-DrugBank.d410.s3.e3
DDI-DrugBank.d410.s3	false	DDI-DrugBank.d410.s3.e0	DDI-DrugBank.d410.s3.e4
DDI-DrugBank.d410.s3	false	DDI-DrugBank.d410.s3.e0	DDI-DrugBank.d410.s3.e5
DDI-DrugBank.d410.s3	false	DDI-DrugBank.d410.s3.e1	DDI-DrugBank.d410.s3.e2
DDI-DrugBank.d410.s3	false	DDI-DrugBank.d410.s3.e1	DDI-DrugBank.d410.s3.e3
DDI-DrugBank.d410.s3	false	DDI-DrugBank.d410.s3.e1	DDI-DrugBank.d410.s3.e4
DDI-DrugBank.d410.s3	false	DDI-DrugBank.d410.s3.e1	DDI-DrugBank.d410.s3.e5
DDI-DrugBank.d410.s3	false	DDI-DrugBank.d410.s3.e2	DDI-DrugBank.d410.s3.e3
DDI-DrugBank.d410.s4|a|Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
DDI-DrugBank.d410.s4	0	7	Nicotine	drug	DDI-DrugBank.d410.s4.e0
DDI-DrugBank.d410.s4	10	17	Nicotine	drug	DDI-DrugBank.d410.s4.e1
DDI-DrugBank.d410.s4	113	117	ergot	drug	DDI-DrugBank.d410.s4.e2
DDI-DrugBank.d410.s4	false	DDI-DrugBank.d410.s4.e0	DDI-DrugBank.d410.s4.e1
DDI-DrugBank.d410.s4	false	DDI-DrugBank.d410.s4.e0	DDI-DrugBank.d410.s4.e2
DDI-DrugBank.d410.s4	true	DDI-DrugBank.d410.s4.e1	DDI-DrugBank.d410.s4.e2
DDI-DrugBank.d410.s5|a|Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
DDI-DrugBank.d410.s5	0	20	Macrolide Antibiotics	group	DDI-DrugBank.d410.s5.e0
DDI-DrugBank.d410.s5	29	40	erythromycin	drug	DDI-DrugBank.d410.s5.e1
DDI-DrugBank.d410.s5	46	59	troleandomycin	drug	DDI-DrugBank.d410.s5.e2
DDI-DrugBank.d410.s5	77	96	ergot alkaloid class	group	DDI-DrugBank.d410.s5.e3
DDI-DrugBank.d410.s5	108	116	D.H.E. 45	brand	DDI-DrugBank.d410.s5.e4
DDI-DrugBank.d410.s5	120	145	dihydroergotamine mesylate	drug	DDI-DrugBank.d410.s5.e5
DDI-DrugBank.d410.s5	209	219	antibiotics	group	DDI-DrugBank.d410.s5.e6
DDI-DrugBank.d410.s5	228	242	macrolide class	group	DDI-DrugBank.d410.s5.e7
DDI-DrugBank.d410.s5	false	DDI-DrugBank.d410.s5.e0	DDI-DrugBank.d410.s5.e1
DDI-DrugBank.d410.s5	false	DDI-DrugBank.d410.s5.e0	DDI-DrugBank.d410.s5.e2
DDI-DrugBank.d410.s5	false	DDI-DrugBank.d410.s5.e0	DDI-DrugBank.d410.s5.e3
DDI-DrugBank.d410.s5	false	DDI-DrugBank.d410.s5.e0	DDI-DrugBank.d410.s5.e4
DDI-DrugBank.d410.s5	false	DDI-DrugBank.d410.s5.e0	DDI-DrugBank.d410.s5.e5
DDI-DrugBank.d410.s5	false	DDI-DrugBank.d410.s5.e0	DDI-DrugBank.d410.s5.e6
DDI-DrugBank.d410.s5	false	DDI-DrugBank.d410.s5.e0	DDI-DrugBank.d410.s5.e7
DDI-DrugBank.d410.s5	false	DDI-DrugBank.d410.s5.e1	DDI-DrugBank.d410.s5.e2
DDI-DrugBank.d410.s5	false	DDI-DrugBank.d410.s5.e1	DDI-DrugBank.d410.s5.e3
DDI-DrugBank.d410.s5	false	DDI-DrugBank.d410.s5.e1	DDI-DrugBank.d410.s5.e4
DDI-DrugBank.d410.s6|a|Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.
DDI-DrugBank.d410.s6	67	76	ergotamine	drug	DDI-DrugBank.d410.s6.e0
DDI-DrugBank.d410.s6	127	137	antibiotics	group	DDI-DrugBank.d410.s6.e1
DDI-DrugBank.d410.s6	true	DDI-DrugBank.d410.s6.e0	DDI-DrugBank.d410.s6.e1
DDI-DrugBank.d410.s7|a|SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.
DDI-DrugBank.d410.s7	0	4	SSRIs	group	DDI-DrugBank.d410.s7.e0
DDI-DrugBank.d410.s7	81	94	5-HT1 agonists	group	DDI-DrugBank.d410.s7.e1
DDI-DrugBank.d410.s7	127	131	SSRIs	group	DDI-DrugBank.d410.s7.e2
DDI-DrugBank.d410.s7	false	DDI-DrugBank.d410.s7.e0	DDI-DrugBank.d410.s7.e1
DDI-DrugBank.d410.s7	false	DDI-DrugBank.d410.s7.e0	DDI-DrugBank.d410.s7.e2
DDI-DrugBank.d410.s7	true	DDI-DrugBank.d410.s7.e1	DDI-DrugBank.d410.s7.e2
DDI-DrugBank.d410.s8|a|fluoxetine, fluvoxamine, paroxetine, sertraline).
DDI-DrugBank.d410.s8	0	9	fluoxetine	drug	DDI-DrugBank.d410.s8.e0
DDI-DrugBank.d410.s8	12	22	fluvoxamine	drug	DDI-DrugBank.d410.s8.e1
DDI-DrugBank.d410.s8	25	34	paroxetine	drug	DDI-DrugBank.d410.s8.e2
DDI-DrugBank.d410.s8	37	46	sertraline	drug	DDI-DrugBank.d410.s8.e3
DDI-DrugBank.d410.s8	false	DDI-DrugBank.d410.s8.e0	DDI-DrugBank.d410.s8.e1
DDI-DrugBank.d410.s8	false	DDI-DrugBank.d410.s8.e0	DDI-DrugBank.d410.s8.e2
DDI-DrugBank.d410.s8	false	DDI-DrugBank.d410.s8.e0	DDI-DrugBank.d410.s8.e3
DDI-DrugBank.d410.s8	false	DDI-DrugBank.d410.s8.e1	DDI-DrugBank.d410.s8.e2
DDI-DrugBank.d410.s8	false	DDI-DrugBank.d410.s8.e1	DDI-DrugBank.d410.s8.e3
DDI-DrugBank.d410.s8	false	DDI-DrugBank.d410.s8.e2	DDI-DrugBank.d410.s8.e3
DDI-DrugBank.d410.s9|a|There have been no reported cases from spontaneous reports of drug interaction between SSRIs and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
DDI-DrugBank.d410.s9	87	91	SSRIs	group	DDI-DrugBank.d410.s9.e0
DDI-DrugBank.d410.s9	97	105	D.H.E. 45	brand	DDI-DrugBank.d410.s9.e1
DDI-DrugBank.d410.s9	109	134	dihydroergotamine mesylate	drug	DDI-DrugBank.d410.s9.e2
DDI-DrugBank.d410.s9	false	DDI-DrugBank.d410.s9.e0	DDI-DrugBank.d410.s9.e1
DDI-DrugBank.d410.s9	false	DDI-DrugBank.d410.s9.e0	DDI-DrugBank.d410.s9.e2
DDI-DrugBank.d410.s9	false	DDI-DrugBank.d410.s9.e1	DDI-DrugBank.d410.s9.e2
DDI-DrugBank.d410.s10|a|Oral Contraceptives: The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP has not been studied.
DDI-DrugBank.d410.s10	5	18	Contraceptives	group	DDI-DrugBank.d410.s10.e0
DDI-DrugBank.d410.s10	40	53	contraceptives	group	DDI-DrugBank.d410.s10.e1
DDI-DrugBank.d410.s10	82	90	D.H.E. 45	brand	DDI-DrugBank.d410.s10.e2
DDI-DrugBank.d410.s10	94	119	dihydroergotamine mesylate	drug	DDI-DrugBank.d410.s10.e3
DDI-DrugBank.d410.s10	false	DDI-DrugBank.d410.s10.e0	DDI-DrugBank.d410.s10.e1
DDI-DrugBank.d410.s10	false	DDI-DrugBank.d410.s10.e0	DDI-DrugBank.d410.s10.e2
DDI-DrugBank.d410.s10	false	DDI-DrugBank.d410.s10.e0	DDI-DrugBank.d410.s10.e3
DDI-DrugBank.d410.s10	false	DDI-DrugBank.d410.s10.e1	DDI-DrugBank.d410.s10.e2
DDI-DrugBank.d410.s10	false	DDI-DrugBank.d410.s10.e1	DDI-DrugBank.d410.s10.e3
DDI-DrugBank.d410.s10	false	DDI-DrugBank.d410.s10.e2	DDI-DrugBank.d410.s10.e3
DDI-DrugBank.d452.s0|a|Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.
DDI-DrugBank.d452.s0	18	35	thiazide diuretics	group	DDI-DrugBank.d452.s0.e0
DDI-DrugBank.d452.s0	105	122	dihydrotachysterol	drug	DDI-DrugBank.d452.s0.e1
DDI-DrugBank.d452.s0	true	DDI-DrugBank.d452.s0.e0	DDI-DrugBank.d452.s0.e1
DDI-DrugBank.d565.s0|a|Due to the potential for additive effects, caution and careful titration are warranted in patients receiving diltiazem hydrochloride concomitantly with other agents known to affect cardiac contractility and/or conduction.
DDI-DrugBank.d565.s0	109	131	diltiazem hydrochloride	drug	DDI-DrugBank.d565.s0.e0
DDI-DrugBank.d565.s1|a|Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.
DDI-DrugBank.d565.s1	105	117	beta-blockers	group	DDI-DrugBank.d565.s1.e0
DDI-DrugBank.d565.s1	122	130	digitalis	group	DDI-DrugBank.d565.s1.e1
DDI-DrugBank.d565.s1	151	156	Tiazac	brand	DDI-DrugBank.d565.s1.e2
DDI-DrugBank.d565.s1	false	DDI-DrugBank.d565.s1.e0	DDI-DrugBank.d565.s1.e1
DDI-DrugBank.d565.s1	true	DDI-DrugBank.d565.s1.e0	DDI-DrugBank.d565.s1.e2
DDI-DrugBank.d565.s1	true	DDI-DrugBank.d565.s1.e1	DDI-DrugBank.d565.s1.e2
DDI-DrugBank.d565.s2|a|As with all drugs, care should be exercised when treating patients with multiple medications.
DDI-DrugBank.d565.s3|a|Diltiazem is both a substrate and an inhibitor of the cytochrome P-450 3A4 enzyme system.
DDI-DrugBank.d565.s3	0	8	Diltiazem	drug	DDI-DrugBank.d565.s3.e0
DDI-DrugBank.d565.s4|a|Other drugs that are specific substrates, inhibitors, or inducers of the enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem.
DDI-DrugBank.d565.s4	160	168	diltiazem	drug	DDI-DrugBank.d565.s4.e0
DDI-DrugBank.d565.s5|a|Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels.
DDI-DrugBank.d565.s5	204	212	diltiazem	drug	DDI-DrugBank.d565.s5.e0
DDI-DrugBank.d565.s6|a|Beta Blockers
DDI-DrugBank.d565.s6	0	12	Beta Blockers	group	DDI-DrugBank.d565.s6.e0
DDI-DrugBank.d565.s7|a|Controlled and uncontrolled domestic studies suggest that concomitant use of diltiazem hydrochloride and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.
DDI-DrugBank.d565.s7	77	99	diltiazem hydrochloride	drug	DDI-DrugBank.d565.s7.e0
DDI-DrugBank.d565.s7	105	117	beta-blockers	group	DDI-DrugBank.d565.s7.e1
DDI-DrugBank.d565.s7	false	DDI-DrugBank.d565.s7.e0	DDI-DrugBank.d565.s7.e1
DDI-DrugBank.d565.s8|a|Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
DDI-DrugBank.d565.s8	18	40	diltiazem hydrochloride	drug	DDI-DrugBank.d565.s8.e0
DDI-DrugBank.d565.s8	61	71	propranolol	drug	DDI-DrugBank.d565.s8.e1
DDI-DrugBank.d565.s8	121	131	propranolol	drug	DDI-DrugBank.d565.s8.e2
DDI-DrugBank.d565.s8	179	189	propranolol	drug	DDI-DrugBank.d565.s8.e3
DDI-DrugBank.d565.s8	true	DDI-DrugBank.d565.s8.e0	DDI-DrugBank.d565.s8.e1
DDI-DrugBank.d565.s8	false	DDI-DrugBank.d565.s8.e0	DDI-DrugBank.d565.s8.e2
DDI-DrugBank.d565.s8	false	DDI-DrugBank.d565.s8.e0	DDI-DrugBank.d565.s8.e3
DDI-DrugBank.d565.s8	false	DDI-DrugBank.d565.s8.e1	DDI-DrugBank.d565.s8.e2
DDI-DrugBank.d565.s8	false	DDI-DrugBank.d565.s8.e1	DDI-DrugBank.d565.s8.e3
DDI-DrugBank.d565.s8	false	DDI-DrugBank.d565.s8.e2	DDI-DrugBank.d565.s8.e3
DDI-DrugBank.d565.s9|a|In vitro, propranolol appears to be displaced from its binding sites by diltiazem.
DDI-DrugBank.d565.s9	10	20	propranolol	drug	DDI-DrugBank.d565.s9.e0
DDI-DrugBank.d565.s9	72	80	diltiazem	drug	DDI-DrugBank.d565.s9.e1
DDI-DrugBank.d565.s9	true	DDI-DrugBank.d565.s9.e0	DDI-DrugBank.d565.s9.e1
DDI-DrugBank.d565.s10|a|If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted.
DDI-DrugBank.d565.s10	69	79	propranolol	drug	DDI-DrugBank.d565.s10.e0
DDI-DrugBank.d565.s10	103	113	propranolol	drug	DDI-DrugBank.d565.s10.e1
DDI-DrugBank.d565.s10	false	DDI-DrugBank.d565.s10.e0	DDI-DrugBank.d565.s10.e1
DDI-DrugBank.d565.s11|a|Cimetidine
DDI-DrugBank.d565.s11	0	9	Cimetidine	drug	DDI-DrugBank.d565.s11.e0
DDI-DrugBank.d565.s12|a|A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.
DDI-DrugBank.d565.s12	75	83	diltiazem	drug	DDI-DrugBank.d565.s12.e0
DDI-DrugBank.d565.s12	144	153	cimetidine	drug	DDI-DrugBank.d565.s12.e1
DDI-DrugBank.d565.s12	188	196	diltiazem	drug	DDI-DrugBank.d565.s12.e2
DDI-DrugBank.d565.s12	false	DDI-DrugBank.d565.s12.e0	DDI-DrugBank.d565.s12.e1
DDI-DrugBank.d565.s12	false	DDI-DrugBank.d565.s12.e0	DDI-DrugBank.d565.s12.e2
DDI-DrugBank.d565.s12	true	DDI-DrugBank.d565.s12.e1	DDI-DrugBank.d565.s12.e2
DDI-DrugBank.d565.s13|a|Ranitidine produced smaller, nonsignificant increases.
DDI-DrugBank.d565.s13	0	9	Ranitidine	drug	DDI-DrugBank.d565.s13.e0
DDI-DrugBank.d565.s14|a|The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.
DDI-DrugBank.d565.s14	30	39	cimetidine	drug	DDI-DrugBank.d565.s14.e0
DDI-DrugBank.d565.s14	151	159	diltiazem	drug	DDI-DrugBank.d565.s14.e1
DDI-DrugBank.d565.s14	true	DDI-DrugBank.d565.s14.e0	DDI-DrugBank.d565.s14.e1
DDI-DrugBank.d565.s15|a|Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.
DDI-DrugBank.d565.s15	29	37	diltiazem	drug	DDI-DrugBank.d565.s15.e0
DDI-DrugBank.d565.s15	163	172	cimetidine	drug	DDI-DrugBank.d565.s15.e1
DDI-DrugBank.d565.s15	true	DDI-DrugBank.d565.s15.e0	DDI-DrugBank.d565.s15.e1
DDI-DrugBank.d565.s16|a|An adjustment in the diltiazem dose may be warranted.
DDI-DrugBank.d565.s16	21	29	diltiazem	drug	DDI-DrugBank.d565.s16.e0
DDI-DrugBank.d565.s17|a|Digitalis
DDI-DrugBank.d565.s17	0	8	Digitalis	group	DDI-DrugBank.d565.s17.e0
DDI-DrugBank.d565.s18|a|Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.
DDI-DrugBank.d565.s18	18	40	diltiazem hydrochloride	drug	DDI-DrugBank.d565.s18.e0
DDI-DrugBank.d565.s18	47	53	digoxin	drug	DDI-DrugBank.d565.s18.e1
DDI-DrugBank.d565.s18	100	106	digoxin	drug	DDI-DrugBank.d565.s18.e2
DDI-DrugBank.d565.s18	true	DDI-DrugBank.d565.s18.e0	DDI-DrugBank.d565.s18.e1
DDI-DrugBank.d565.s18	false	DDI-DrugBank.d565.s18.e0	DDI-DrugBank.d565.s18.e2
DDI-DrugBank.d565.s18	false	DDI-DrugBank.d565.s18.e1	DDI-DrugBank.d565.s18.e2
DDI-DrugBank.d565.s19|a|Another investigator found no increase in digoxin levels in 12 patients with coronary artery disease.
DDI-DrugBank.d565.s19	42	48	digoxin	drug	DDI-DrugBank.d565.s19.e0
DDI-DrugBank.d565.s20|a|Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.
DDI-DrugBank.d565.s20	66	72	digoxin	drug	DDI-DrugBank.d565.s20.e0
DDI-DrugBank.d565.s20	105	111	digoxin	drug	DDI-DrugBank.d565.s20.e1
DDI-DrugBank.d565.s20	179	201	diltiazem hydrochloride	drug	DDI-DrugBank.d565.s20.e2
DDI-DrugBank.d565.s20	false	DDI-DrugBank.d565.s20.e0	DDI-DrugBank.d565.s20.e1
DDI-DrugBank.d565.s20	false	DDI-DrugBank.d565.s20.e0	DDI-DrugBank.d565.s20.e2
DDI-DrugBank.d565.s20	true	DDI-DrugBank.d565.s20.e1	DDI-DrugBank.d565.s20.e2
DDI-DrugBank.d565.s21|a|Anesthetics
DDI-DrugBank.d565.s21	0	10	Anesthetics	group	DDI-DrugBank.d565.s21.e0
DDI-DrugBank.d565.s22|a|The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.
DDI-DrugBank.d565.s22	121	131	anesthetics	group	DDI-DrugBank.d565.s22.e0
DDI-DrugBank.d565.s22	155	178	calcium channel blockers	group	DDI-DrugBank.d565.s22.e1
DDI-DrugBank.d565.s22	true	DDI-DrugBank.d565.s22.e0	DDI-DrugBank.d565.s22.e1
DDI-DrugBank.d565.s23|a|When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.
DDI-DrugBank.d565.s23	25	35	anesthetics	group	DDI-DrugBank.d565.s23.e0
DDI-DrugBank.d565.s23	41	64	calcium channel blockers	group	DDI-DrugBank.d565.s23.e1
DDI-DrugBank.d565.s23	true	DDI-DrugBank.d565.s23.e0	DDI-DrugBank.d565.s23.e1
DDI-DrugBank.d565.s24|a|Cyclosporine
DDI-DrugBank.d565.s24	0	11	Cyclosporine	drug	DDI-DrugBank.d565.s24.e0
DDI-DrugBank.d565.s25|a|A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.
DDI-DrugBank.d565.s25	38	46	diltiazem	drug	DDI-DrugBank.d565.s25.e0
DDI-DrugBank.d565.s25	52	63	cyclosporine	drug	DDI-DrugBank.d565.s25.e1
DDI-DrugBank.d565.s25	true	DDI-DrugBank.d565.s25.e0	DDI-DrugBank.d565.s25.e1
DDI-DrugBank.d565.s26|a|In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.
DDI-DrugBank.d565.s26	59	70	cyclosporine	drug	DDI-DrugBank.d565.s26.e0
DDI-DrugBank.d565.s26	127	138	cyclosporine	drug	DDI-DrugBank.d565.s26.e1
DDI-DrugBank.d565.s26	209	217	diltiazem	drug	DDI-DrugBank.d565.s26.e2
DDI-DrugBank.d565.s26	false	DDI-DrugBank.d565.s26.e0	DDI-DrugBank.d565.s26.e1
DDI-DrugBank.d565.s26	true	DDI-DrugBank.d565.s26.e0	DDI-DrugBank.d565.s26.e2
DDI-DrugBank.d565.s26	false	DDI-DrugBank.d565.s26.e1	DDI-DrugBank.d565.s26.e2
DDI-DrugBank.d565.s27|a|If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.
DDI-DrugBank.d565.s27	53	64	cyclosporine	drug	DDI-DrugBank.d565.s27.e0
DDI-DrugBank.d565.s27	118	126	diltiazem	drug	DDI-DrugBank.d565.s27.e1
DDI-DrugBank.d565.s27	true	DDI-DrugBank.d565.s27.e0	DDI-DrugBank.d565.s27.e1
DDI-DrugBank.d565.s28|a|The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.
DDI-DrugBank.d565.s28	14	25	cyclosporine	drug	DDI-DrugBank.d565.s28.e0
DDI-DrugBank.d565.s28	30	38	diltiazem	drug	DDI-DrugBank.d565.s28.e1
DDI-DrugBank.d565.s28	false	DDI-DrugBank.d565.s28.e0	DDI-DrugBank.d565.s28.e1
DDI-DrugBank.d565.s29|a|Carbamazepine
DDI-DrugBank.d565.s29	0	12	Carbamazepine	drug	DDI-DrugBank.d565.s29.e0
DDI-DrugBank.d565.s30|a|Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.
DDI-DrugBank.d565.s30	30	38	diltiazem	drug	DDI-DrugBank.d565.s30.e0
DDI-DrugBank.d565.s30	45	57	carbamazepine	drug	DDI-DrugBank.d565.s30.e1
DDI-DrugBank.d565.s30	115	127	carbamazepine	drug	DDI-DrugBank.d565.s30.e2
DDI-DrugBank.d565.s30	true	DDI-DrugBank.d565.s30.e0	DDI-DrugBank.d565.s30.e1
DDI-DrugBank.d565.s30	false	DDI-DrugBank.d565.s30.e0	DDI-DrugBank.d565.s30.e2
DDI-DrugBank.d565.s30	false	DDI-DrugBank.d565.s30.e1	DDI-DrugBank.d565.s30.e2
DDI-DrugBank.d565.s31|a|Patients receiving these drugs concurrently should be monitored for a potential drug interaction.
DDI-DrugBank.d565.s32|a|Benzodiazepines
DDI-DrugBank.d565.s32	0	14	Benzodiazepines	group	DDI-DrugBank.d565.s32.e0
DDI-DrugBank.d565.s33|a|Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
DDI-DrugBank.d565.s33	20	28	diltiazem	drug	DDI-DrugBank.d565.s33.e0
DDI-DrugBank.d565.s33	51	59	midazolam	drug	DDI-DrugBank.d565.s33.e1
DDI-DrugBank.d565.s33	65	73	triazolam	drug	DDI-DrugBank.d565.s33.e2
DDI-DrugBank.d565.s33	true	DDI-DrugBank.d565.s33.e0	DDI-DrugBank.d565.s33.e1
DDI-DrugBank.d565.s33	true	DDI-DrugBank.d565.s33.e0	DDI-DrugBank.d565.s33.e2
DDI-DrugBank.d565.s33	false	DDI-DrugBank.d565.s33.e1	DDI-DrugBank.d565.s33.e2
DDI-DrugBank.d565.s34|a|The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
DDI-DrugBank.d565.s34	29	37	midazolam	drug	DDI-DrugBank.d565.s34.e0
DDI-DrugBank.d565.s34	43	51	triazolam	drug	DDI-DrugBank.d565.s34.e1
DDI-DrugBank.d565.s34	112	120	diltiazem	drug	DDI-DrugBank.d565.s34.e2
DDI-DrugBank.d565.s34	false	DDI-DrugBank.d565.s34.e0	DDI-DrugBank.d565.s34.e1
DDI-DrugBank.d565.s34	true	DDI-DrugBank.d565.s34.e0	DDI-DrugBank.d565.s34.e2
DDI-DrugBank.d565.s34	true	DDI-DrugBank.d565.s34.e1	DDI-DrugBank.d565.s34.e2
DDI-DrugBank.d565.s35|a|These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
DDI-DrugBank.d565.s35	42	50	diltiazem	drug	DDI-DrugBank.d565.s35.e0
DDI-DrugBank.d565.s35	144	152	midazolam	drug	DDI-DrugBank.d565.s35.e1
DDI-DrugBank.d565.s35	158	166	triazolam	drug	DDI-DrugBank.d565.s35.e2
DDI-DrugBank.d565.s35	true	DDI-DrugBank.d565.s35.e0	DDI-DrugBank.d565.s35.e1
DDI-DrugBank.d565.s35	true	DDI-DrugBank.d565.s35.e0	DDI-DrugBank.d565.s35.e2
DDI-DrugBank.d565.s35	false	DDI-DrugBank.d565.s35.e1	DDI-DrugBank.d565.s35.e2
DDI-DrugBank.d565.s36|a|Lovastatin
DDI-DrugBank.d565.s36	0	9	Lovastatin	drug	DDI-DrugBank.d565.s36.e0
DDI-DrugBank.d565.s37|a|In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;
DDI-DrugBank.d565.s37	44	52	diltiazem	drug	DDI-DrugBank.d565.s37.e0
DDI-DrugBank.d565.s37	72	81	lovastatin	drug	DDI-DrugBank.d565.s37.e1
DDI-DrugBank.d565.s37	124	133	lovastatin	drug	DDI-DrugBank.d565.s37.e2
DDI-DrugBank.d565.s37	152	161	lovastatin	drug	DDI-DrugBank.d565.s37.e3
DDI-DrugBank.d565.s37	true	DDI-DrugBank.d565.s37.e0	DDI-DrugBank.d565.s37.e1
DDI-DrugBank.d565.s37	false	DDI-DrugBank.d565.s37.e0	DDI-DrugBank.d565.s37.e2
DDI-DrugBank.d565.s37	false	DDI-DrugBank.d565.s37.e0	DDI-DrugBank.d565.s37.e3
DDI-DrugBank.d565.s37	false	DDI-DrugBank.d565.s37.e1	DDI-DrugBank.d565.s37.e2
DDI-DrugBank.d565.s37	false	DDI-DrugBank.d565.s37.e1	DDI-DrugBank.d565.s37.e3
DDI-DrugBank.d565.s37	false	DDI-DrugBank.d565.s37.e2	DDI-DrugBank.d565.s37.e3
DDI-DrugBank.d565.s38|a|no change in pravastatin AUC and Cmax was observed during diltiazem coadministration.
DDI-DrugBank.d565.s38	13	23	pravastatin	drug	DDI-DrugBank.d565.s38.e0
DDI-DrugBank.d565.s38	58	66	diltiazem	drug	DDI-DrugBank.d565.s38.e1
DDI-DrugBank.d565.s38	false	DDI-DrugBank.d565.s38.e0	DDI-DrugBank.d565.s38.e1
DDI-DrugBank.d565.s39|a|Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.
DDI-DrugBank.d565.s39	0	8	Diltiazem	drug	DDI-DrugBank.d565.s39.e0
DDI-DrugBank.d565.s39	59	68	lovastatin	drug	DDI-DrugBank.d565.s39.e1
DDI-DrugBank.d565.s39	73	83	pravastatin	drug	DDI-DrugBank.d565.s39.e2
DDI-DrugBank.d565.s39	false	DDI-DrugBank.d565.s39.e0	DDI-DrugBank.d565.s39.e1
DDI-DrugBank.d565.s39	false	DDI-DrugBank.d565.s39.e0	DDI-DrugBank.d565.s39.e2
DDI-DrugBank.d565.s39	false	DDI-DrugBank.d565.s39.e1	DDI-DrugBank.d565.s39.e2
DDI-DrugBank.d565.s40|a|Rifampin
DDI-DrugBank.d565.s40	0	7	Rifampin	drug	DDI-DrugBank.d565.s40.e0
DDI-DrugBank.d565.s41|a|Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.
DDI-DrugBank.d565.s41	20	27	rifampin	drug	DDI-DrugBank.d565.s41.e0
DDI-DrugBank.d565.s41	34	42	diltiazem	drug	DDI-DrugBank.d565.s41.e1
DDI-DrugBank.d565.s41	56	64	diltiazem	drug	DDI-DrugBank.d565.s41.e2
DDI-DrugBank.d565.s41	true	DDI-DrugBank.d565.s41.e0	DDI-DrugBank.d565.s41.e1
DDI-DrugBank.d565.s41	false	DDI-DrugBank.d565.s41.e0	DDI-DrugBank.d565.s41.e2
DDI-DrugBank.d565.s41	false	DDI-DrugBank.d565.s41.e1	DDI-DrugBank.d565.s41.e2
DDI-DrugBank.d565.s42|a|Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.
DDI-DrugBank.d565.s42	20	28	diltiazem	drug	DDI-DrugBank.d565.s42.e0
DDI-DrugBank.d565.s42	35	42	rifampin	drug	DDI-DrugBank.d565.s42.e1
DDI-DrugBank.d565.s42	true	DDI-DrugBank.d565.s42.e0	DDI-DrugBank.d565.s42.e1
DDI-DrugBank.d96.s0|a|Dimenhydrinate may decrease emetic response to apomorphine.
DDI-DrugBank.d96.s0	0	13	Dimenhydrinate	drug	DDI-DrugBank.d96.s0.e0
DDI-DrugBank.d96.s0	28	33	emetic	group	DDI-DrugBank.d96.s0.e1
DDI-DrugBank.d96.s0	47	57	apomorphine	drug	DDI-DrugBank.d96.s0.e2
DDI-DrugBank.d96.s0	false	DDI-DrugBank.d96.s0.e0	DDI-DrugBank.d96.s0.e1
DDI-DrugBank.d96.s0	true	DDI-DrugBank.d96.s0.e0	DDI-DrugBank.d96.s0.e2
DDI-DrugBank.d96.s0	false	DDI-DrugBank.d96.s0.e1	DDI-DrugBank.d96.s0.e2
DDI-DrugBank.d181.s0|a|Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
DDI-DrugBank.d181.s0	0	7	Oxytocin	drug	DDI-DrugBank.d181.s0.e0
DDI-DrugBank.d181.s0	18	26	oxytocics	group	DDI-DrugBank.d181.s0.e1
DDI-DrugBank.d181.s0	49	57	dinoprost	drug	DDI-DrugBank.d181.s0.e2
DDI-DrugBank.d181.s0	false	DDI-DrugBank.d181.s0.e0	DDI-DrugBank.d181.s0.e1
DDI-DrugBank.d181.s0	true	DDI-DrugBank.d181.s0.e0	DDI-DrugBank.d181.s0.e2
DDI-DrugBank.d181.s0	true	DDI-DrugBank.d181.s0.e1	DDI-DrugBank.d181.s0.e2
DDI-DrugBank.d181.s1|a|although combinations are sometimes used for therapeutic advantage, when used concurrently, patient should be closely monitored.
DDI-DrugBank.d2.s0|a|PROSTIN E2 may augment the activity of other oxytocic drugs.
DDI-DrugBank.d2.s0	0	9	PROSTIN E2	brand	DDI-DrugBank.d2.s0.e0
DDI-DrugBank.d2.s0	45	58	oxytocic drugs	group	DDI-DrugBank.d2.s0.e1
DDI-DrugBank.d2.s0	true	DDI-DrugBank.d2.s0.e0	DDI-DrugBank.d2.s0.e1
DDI-DrugBank.d2.s1|a|Concomitant use with other oxytocic agents is not recommended.
DDI-DrugBank.d2.s1	27	41	oxytocic agents	group	DDI-DrugBank.d2.s1.e0
DDI-DrugBank.d296.s0|a|Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
DDI-DrugBank.d296.s0	0	28	Diphenhydramine hydrochloride	drug	DDI-DrugBank.d296.s0.e0
DDI-DrugBank.d296.s0	56	62	alcohol	drug	DDI-DrugBank.d296.s0.e1
DDI-DrugBank.d296.s0	74	88	CNS depressants	group	DDI-DrugBank.d296.s0.e2
DDI-DrugBank.d296.s0	91	99	hypnotics	group	DDI-DrugBank.d296.s0.e3
DDI-DrugBank.d296.s0	102	110	sedatives	group	DDI-DrugBank.d296.s0.e4
DDI-DrugBank.d296.s0	113	125	tranquilizers	group	DDI-DrugBank.d296.s0.e5
DDI-DrugBank.d296.s0	true	DDI-DrugBank.d296.s0.e0	DDI-DrugBank.d296.s0.e1
DDI-DrugBank.d296.s0	true	DDI-DrugBank.d296.s0.e0	DDI-DrugBank.d296.s0.e2
DDI-DrugBank.d296.s0	true	DDI-DrugBank.d296.s0.e0	DDI-DrugBank.d296.s0.e3
DDI-DrugBank.d296.s0	true	DDI-DrugBank.d296.s0.e0	DDI-DrugBank.d296.s0.e4
DDI-DrugBank.d296.s0	true	DDI-DrugBank.d296.s0.e0	DDI-DrugBank.d296.s0.e5
DDI-DrugBank.d296.s0	false	DDI-DrugBank.d296.s0.e1	DDI-DrugBank.d296.s0.e2
DDI-DrugBank.d296.s0	false	DDI-DrugBank.d296.s0.e1	DDI-DrugBank.d296.s0.e3
DDI-DrugBank.d296.s0	false	DDI-DrugBank.d296.s0.e1	DDI-DrugBank.d296.s0.e4
DDI-DrugBank.d296.s0	false	DDI-DrugBank.d296.s0.e1	DDI-DrugBank.d296.s0.e5
DDI-DrugBank.d296.s0	false	DDI-DrugBank.d296.s0.e2	DDI-DrugBank.d296.s0.e3
DDI-DrugBank.d296.s1|a|MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
DDI-DrugBank.d296.s1	0	13	MAO inhibitors	group	DDI-DrugBank.d296.s1.e0
DDI-DrugBank.d296.s1	77	90	antihistamines	group	DDI-DrugBank.d296.s1.e1
DDI-DrugBank.d296.s1	true	DDI-DrugBank.d296.s1.e0	DDI-DrugBank.d296.s1.e1
DDI-DrugBank.d120.s0|a|CNS depression producing medications - concurrent use may potentiate the effects of either these medications or diphenidol;
DDI-DrugBank.d120.s0	112	121	diphenidol	drug	DDI-DrugBank.d120.s0.e0
DDI-DrugBank.d120.s1|a|anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol;
DDI-DrugBank.d120.s1	0	15	anticholinergics	group	DDI-DrugBank.d120.s1.e0
DDI-DrugBank.d120.s1	163	172	diphenidol	drug	DDI-DrugBank.d120.s1.e1
DDI-DrugBank.d120.s1	false	DDI-DrugBank.d120.s1.e0	DDI-DrugBank.d120.s1.e1
DDI-DrugBank.d120.s2|a|apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.
DDI-DrugBank.d120.s2	0	10	apomorphine	drug	DDI-DrugBank.d120.s2.e0
DDI-DrugBank.d120.s2	33	42	diphenidol	drug	DDI-DrugBank.d120.s2.e1
DDI-DrugBank.d120.s2	61	66	emetic	group	DDI-DrugBank.d120.s2.e2
DDI-DrugBank.d120.s2	80	90	apomorphine	drug	DDI-DrugBank.d120.s2.e3
DDI-DrugBank.d120.s2	false	DDI-DrugBank.d120.s2.e0	DDI-DrugBank.d120.s2.e1
DDI-DrugBank.d120.s2	false	DDI-DrugBank.d120.s2.e0	DDI-DrugBank.d120.s2.e2
DDI-DrugBank.d120.s2	false	DDI-DrugBank.d120.s2.e0	DDI-DrugBank.d120.s2.e3
DDI-DrugBank.d120.s2	false	DDI-DrugBank.d120.s2.e1	DDI-DrugBank.d120.s2.e2
DDI-DrugBank.d120.s2	true	DDI-DrugBank.d120.s2.e1	DDI-DrugBank.d120.s2.e3
DDI-DrugBank.d120.s2	false	DDI-DrugBank.d120.s2.e2	DDI-DrugBank.d120.s2.e3
DDI-DrugBank.d538.s0|a|Known drug interactions include barbiturates, tranquilizers, and alcohol.
DDI-DrugBank.d538.s0	32	43	barbiturates	group	DDI-DrugBank.d538.s0.e0
DDI-DrugBank.d538.s0	46	58	tranquilizers	group	DDI-DrugBank.d538.s0.e1
DDI-DrugBank.d538.s0	65	71	alcohol	drug	DDI-DrugBank.d538.s0.e2
DDI-DrugBank.d538.s0	false	DDI-DrugBank.d538.s0.e0	DDI-DrugBank.d538.s0.e1
DDI-DrugBank.d538.s0	false	DDI-DrugBank.d538.s0.e0	DDI-DrugBank.d538.s0.e2
DDI-DrugBank.d538.s0	false	DDI-DrugBank.d538.s0.e1	DDI-DrugBank.d538.s0.e2
DDI-DrugBank.d538.s1|a|Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
DDI-DrugBank.d538.s1	0	16	Diphenoxylate HCl	drug	DDI-DrugBank.d538.s1.e0
DDI-DrugBank.d538.s1	22	37	atropine sulfate	drug	DDI-DrugBank.d538.s1.e1
DDI-DrugBank.d538.s1	57	70	MAO inhibitors	group	DDI-DrugBank.d538.s1.e2
DDI-DrugBank.d538.s1	99	125	diphenoxylate hydrochloride	drug	DDI-DrugBank.d538.s1.e3
DDI-DrugBank.d538.s1	false	DDI-DrugBank.d538.s1.e0	DDI-DrugBank.d538.s1.e1
DDI-DrugBank.d538.s1	true	DDI-DrugBank.d538.s1.e0	DDI-DrugBank.d538.s1.e2
DDI-DrugBank.d538.s1	false	DDI-DrugBank.d538.s1.e0	DDI-DrugBank.d538.s1.e3
DDI-DrugBank.d538.s1	true	DDI-DrugBank.d538.s1.e1	DDI-DrugBank.d538.s1.e2
DDI-DrugBank.d538.s1	false	DDI-DrugBank.d538.s1.e1	DDI-DrugBank.d538.s1.e3
DDI-DrugBank.d538.s1	false	DDI-DrugBank.d538.s1.e2	DDI-DrugBank.d538.s1.e3
DDI-DrugBank.d538.s2|a|Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.
DDI-DrugBank.d538.s2	11	23	diphenoxylate	drug	DDI-DrugBank.d538.s2.e0
DDI-DrugBank.d168.s0|a|This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d168.s0	28	34	alcohol	drug	DDI-DrugBank.d168.s0.e0
DDI-DrugBank.d168.s0	45	59	CNS depressants	group	DDI-DrugBank.d168.s0.e1
DDI-DrugBank.d168.s0	135	148	antihistamines	group	DDI-DrugBank.d168.s0.e2
DDI-DrugBank.d168.s0	152	167	anticholinergics	group	DDI-DrugBank.d168.s0.e3
DDI-DrugBank.d168.s0	314	327	antihistamines	group	DDI-DrugBank.d168.s0.e4
DDI-DrugBank.d168.s0	335	368	monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d168.s0.e5
DDI-DrugBank.d168.s0	391	404	antihistamines	drug	DDI-DrugBank.d168.s0.e6
DDI-DrugBank.d168.s0	482	495	antihistamines	drug	DDI-DrugBank.d168.s0.e7
DDI-DrugBank.d168.s0	false	DDI-DrugBank.d168.s0.e0	DDI-DrugBank.d168.s0.e1
DDI-DrugBank.d168.s0	false	DDI-DrugBank.d168.s0.e0	DDI-DrugBank.d168.s0.e2
DDI-DrugBank.d168.s0	false	DDI-DrugBank.d168.s0.e0	DDI-DrugBank.d168.s0.e3
DDI-DrugBank.d168.s0	false	DDI-DrugBank.d168.s0.e0	DDI-DrugBank.d168.s0.e4
DDI-DrugBank.d168.s0	false	DDI-DrugBank.d168.s0.e0	DDI-DrugBank.d168.s0.e5
DDI-DrugBank.d168.s0	false	DDI-DrugBank.d168.s0.e0	DDI-DrugBank.d168.s0.e6
DDI-DrugBank.d168.s0	false	DDI-DrugBank.d168.s0.e0	DDI-DrugBank.d168.s0.e7
DDI-DrugBank.d168.s0	false	DDI-DrugBank.d168.s0.e1	DDI-DrugBank.d168.s0.e2
DDI-DrugBank.d168.s0	false	DDI-DrugBank.d168.s0.e1	DDI-DrugBank.d168.s0.e3
DDI-DrugBank.d168.s0	false	DDI-DrugBank.d168.s0.e1	DDI-DrugBank.d168.s0.e4
DDI-DrugBank.d505.s0|a|No pharmacokinetic drug-drug interaction studies were conducted with PERSANTINE  (dipyridamole USP) Tablets.
DDI-DrugBank.d505.s0	69	78	PERSANTINE	brand	DDI-DrugBank.d505.s0.e0
DDI-DrugBank.d505.s0	82	93	dipyridamole	drug	DDI-DrugBank.d505.s0.e1
DDI-DrugBank.d505.s0	false	DDI-DrugBank.d505.s0.e0	DDI-DrugBank.d505.s0.e1
DDI-DrugBank.d505.s1|a|The following information was obtained from the literature.
DDI-DrugBank.d505.s2|a|Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
DDI-DrugBank.d505.s2	0	8	Adenosine	drug	DDI-DrugBank.d505.s2.e0
DDI-DrugBank.d505.s2	11	22	Dipyridamole	drug	DDI-DrugBank.d505.s2.e1
DDI-DrugBank.d505.s2	102	110	adenosine	drug	DDI-DrugBank.d505.s2.e2
DDI-DrugBank.d505.s2	false	DDI-DrugBank.d505.s2.e0	DDI-DrugBank.d505.s2.e1
DDI-DrugBank.d505.s2	false	DDI-DrugBank.d505.s2.e0	DDI-DrugBank.d505.s2.e2
DDI-DrugBank.d505.s2	true	DDI-DrugBank.d505.s2.e1	DDI-DrugBank.d505.s2.e2
DDI-DrugBank.d505.s3|a|Adjustment of adenosine dosage may be necessary.
DDI-DrugBank.d505.s3	14	22	adenosine	drug	DDI-DrugBank.d505.s3.e0
DDI-DrugBank.d505.s4|a|Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
DDI-DrugBank.d505.s4	0	24	Cholinesterase Inhibitors	group	DDI-DrugBank.d505.s4.e0
DDI-DrugBank.d505.s4	27	38	Dipyridamole	drug	DDI-DrugBank.d505.s4.e1
DDI-DrugBank.d505.s4	88	112	cholinesterase inhibitors	group	DDI-DrugBank.d505.s4.e2
DDI-DrugBank.d505.s4	false	DDI-DrugBank.d505.s4.e0	DDI-DrugBank.d505.s4.e1
DDI-DrugBank.d505.s4	false	DDI-DrugBank.d505.s4.e0	DDI-DrugBank.d505.s4.e2
DDI-DrugBank.d505.s4	true	DDI-DrugBank.d505.s4.e1	DDI-DrugBank.d505.s4.e2
DDI-DrugBank.d522.s0|a|Terfenadine: In a prospective study involving six-healthy-male volunteers, dirithromycin did not affect the metabolism of terfenadine.
DDI-DrugBank.d522.s0	0	10	Terfenadine	drug	DDI-DrugBank.d522.s0.e0
DDI-DrugBank.d522.s0	75	87	dirithromycin	drug	DDI-DrugBank.d522.s0.e1
DDI-DrugBank.d522.s0	122	132	terfenadine	drug	DDI-DrugBank.d522.s0.e2
DDI-DrugBank.d522.s0	false	DDI-DrugBank.d522.s0.e0	DDI-DrugBank.d522.s0.e1
DDI-DrugBank.d522.s0	false	DDI-DrugBank.d522.s0.e0	DDI-DrugBank.d522.s0.e2
DDI-DrugBank.d522.s0	false	DDI-DrugBank.d522.s0.e1	DDI-DrugBank.d522.s0.e2
DDI-DrugBank.d522.s1|a|These six volunteers received terfenadine alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with dirithromycin (500 mg once daily) for 10 days.
DDI-DrugBank.d522.s1	30	40	terfenadine	drug	DDI-DrugBank.d522.s1.e0
DDI-DrugBank.d522.s1	92	102	terfenadine	drug	DDI-DrugBank.d522.s1.e1
DDI-DrugBank.d522.s1	124	136	dirithromycin	drug	DDI-DrugBank.d522.s1.e2
DDI-DrugBank.d522.s1	false	DDI-DrugBank.d522.s1.e0	DDI-DrugBank.d522.s1.e1
DDI-DrugBank.d522.s1	false	DDI-DrugBank.d522.s1.e0	DDI-DrugBank.d522.s1.e2
DDI-DrugBank.d522.s1	false	DDI-DrugBank.d522.s1.e1	DDI-DrugBank.d522.s1.e2
DDI-DrugBank.d522.s2|a|(Both drugs were thus dosed to steady state.)
DDI-DrugBank.d522.s3|a|The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin.
DDI-DrugBank.d522.s3	24	34	terfenadine	drug	DDI-DrugBank.d522.s3.e0
DDI-DrugBank.d522.s3	143	153	terfenadine	drug	DDI-DrugBank.d522.s3.e1
DDI-DrugBank.d522.s3	171	181	terfenadine	drug	DDI-DrugBank.d522.s3.e2
DDI-DrugBank.d522.s3	188	200	dirithromycin	drug	DDI-DrugBank.d522.s3.e3
DDI-DrugBank.d522.s3	false	DDI-DrugBank.d522.s3.e0	DDI-DrugBank.d522.s3.e1
DDI-DrugBank.d522.s3	false	DDI-DrugBank.d522.s3.e0	DDI-DrugBank.d522.s3.e2
DDI-DrugBank.d522.s3	false	DDI-DrugBank.d522.s3.e0	DDI-DrugBank.d522.s3.e3
DDI-DrugBank.d522.s3	false	DDI-DrugBank.d522.s3.e1	DDI-DrugBank.d522.s3.e2
DDI-DrugBank.d522.s3	false	DDI-DrugBank.d522.s3.e1	DDI-DrugBank.d522.s3.e3
DDI-DrugBank.d522.s3	false	DDI-DrugBank.d522.s3.e2	DDI-DrugBank.d522.s3.e3
DDI-DrugBank.d522.s4|a|In five men, terfenadine levels were undetectable ( 5 ng/mL) throughout the study;
DDI-DrugBank.d522.s4	13	23	terfenadine	drug	DDI-DrugBank.d522.s4.e0
DDI-DrugBank.d522.s5|a|in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.
DDI-DrugBank.d522.s5	25	35	terfenadine	drug	DDI-DrugBank.d522.s5.e0
DDI-DrugBank.d522.s5	56	66	terfenadine	drug	DDI-DrugBank.d522.s5.e1
DDI-DrugBank.d522.s5	93	103	terfenadine	drug	DDI-DrugBank.d522.s5.e2
DDI-DrugBank.d522.s5	110	122	dirithromycin	drug	DDI-DrugBank.d522.s5.e3
DDI-DrugBank.d522.s5	false	DDI-DrugBank.d522.s5.e0	DDI-DrugBank.d522.s5.e1
DDI-DrugBank.d522.s5	false	DDI-DrugBank.d522.s5.e0	DDI-DrugBank.d522.s5.e2
DDI-DrugBank.d522.s5	false	DDI-DrugBank.d522.s5.e0	DDI-DrugBank.d522.s5.e3
DDI-DrugBank.d522.s5	false	DDI-DrugBank.d522.s5.e1	DDI-DrugBank.d522.s5.e2
DDI-DrugBank.d522.s5	false	DDI-DrugBank.d522.s5.e1	DDI-DrugBank.d522.s5.e3
DDI-DrugBank.d522.s5	true	DDI-DrugBank.d522.s5.e2	DDI-DrugBank.d522.s5.e3
DDI-DrugBank.d522.s6|a|The mean C max , T max , and AUC of the acid metabolite of terfenadine were not significantly changed.
DDI-DrugBank.d522.s6	59	69	terfenadine	drug	DDI-DrugBank.d522.s6.e0
DDI-DrugBank.d522.s7|a|The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.
DDI-DrugBank.d522.s7	43	53	terfenadine	drug	DDI-DrugBank.d522.s7.e0
DDI-DrugBank.d522.s7	74	84	terfenadine	drug	DDI-DrugBank.d522.s7.e1
DDI-DrugBank.d522.s7	91	103	dirithromycin	drug	DDI-DrugBank.d522.s7.e2
DDI-DrugBank.d522.s7	false	DDI-DrugBank.d522.s7.e0	DDI-DrugBank.d522.s7.e1
DDI-DrugBank.d522.s7	false	DDI-DrugBank.d522.s7.e0	DDI-DrugBank.d522.s7.e2
DDI-DrugBank.d522.s7	true	DDI-DrugBank.d522.s7.e1	DDI-DrugBank.d522.s7.e2
DDI-DrugBank.d522.s8|a|Also, in vitro experiments demonstrated a lack of interaction between dirithromycin and terfenadine.
DDI-DrugBank.d522.s8	70	82	dirithromycin	drug	DDI-DrugBank.d522.s8.e0
DDI-DrugBank.d522.s8	88	98	terfenadine	drug	DDI-DrugBank.d522.s8.e1
DDI-DrugBank.d522.s8	false	DDI-DrugBank.d522.s8.e0	DDI-DrugBank.d522.s8.e1
DDI-DrugBank.d522.s9|a|Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.
DDI-DrugBank.d522.s9	39	50	erythromycin	drug	DDI-DrugBank.d522.s9.e0
DDI-DrugBank.d522.s9	56	66	terfenadine	drug	DDI-DrugBank.d522.s9.e1
DDI-DrugBank.d522.s9	88	100	dirithromycin	drug	DDI-DrugBank.d522.s9.e2
DDI-DrugBank.d522.s9	true	DDI-DrugBank.d522.s9.e0	DDI-DrugBank.d522.s9.e1
DDI-DrugBank.d522.s9	false	DDI-DrugBank.d522.s9.e0	DDI-DrugBank.d522.s9.e2
DDI-DrugBank.d522.s9	false	DDI-DrugBank.d522.s9.e1	DDI-DrugBank.d522.s9.e2
DDI-DrugBank.d522.s10|a|Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.
DDI-DrugBank.d522.s10	91	101	terfenadine	drug	DDI-DrugBank.d522.s10.e0
DDI-DrugBank.d522.s10	128	148	macrolide antibiotics	group	DDI-DrugBank.d522.s10.e1
DDI-DrugBank.d522.s10	true	DDI-DrugBank.d522.s10.e0	DDI-DrugBank.d522.s10.e1
DDI-DrugBank.d522.s11|a|In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.
DDI-DrugBank.d522.s11	18	27	macrolides	group	DDI-DrugBank.d522.s11.e0
DDI-DrugBank.d522.s11	71	81	terfenadine	drug	DDI-DrugBank.d522.s11.e1
DDI-DrugBank.d522.s11	true	DDI-DrugBank.d522.s11.e0	DDI-DrugBank.d522.s11.e1
DDI-DrugBank.d522.s12|a|Theophylline: Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.
DDI-DrugBank.d522.s12	0	11	Theophylline	drug	DDI-DrugBank.d522.s12.e0
DDI-DrugBank.d522.s12	56	68	dirithromycin	drug	DDI-DrugBank.d522.s12.e1
DDI-DrugBank.d522.s12	114	125	theophylline	drug	DDI-DrugBank.d522.s12.e2
DDI-DrugBank.d522.s12	237	248	theophylline	drug	DDI-DrugBank.d522.s12.e3
DDI-DrugBank.d522.s12	false	DDI-DrugBank.d522.s12.e0	DDI-DrugBank.d522.s12.e1
DDI-DrugBank.d522.s12	false	DDI-DrugBank.d522.s12.e0	DDI-DrugBank.d522.s12.e2
DDI-DrugBank.d522.s12	false	DDI-DrugBank.d522.s12.e0	DDI-DrugBank.d522.s12.e3
DDI-DrugBank.d522.s12	false	DDI-DrugBank.d522.s12.e1	DDI-DrugBank.d522.s12.e2
DDI-DrugBank.d522.s12	false	DDI-DrugBank.d522.s12.e1	DDI-DrugBank.d522.s12.e3
DDI-DrugBank.d522.s12	false	DDI-DrugBank.d522.s12.e2	DDI-DrugBank.d522.s12.e3
DDI-DrugBank.d522.s13|a|In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.
DDI-DrugBank.d522.s13	39	51	dirithromycin	drug	DDI-DrugBank.d522.s13.e0
DDI-DrugBank.d522.s13	83	94	theophylline	drug	DDI-DrugBank.d522.s13.e1
DDI-DrugBank.d522.s13	142	153	theophylline	drug	DDI-DrugBank.d522.s13.e2
DDI-DrugBank.d522.s13	179	190	theophylline	drug	DDI-DrugBank.d522.s13.e3
DDI-DrugBank.d522.s13	false	DDI-DrugBank.d522.s13.e0	DDI-DrugBank.d522.s13.e1
DDI-DrugBank.d522.s13	false	DDI-DrugBank.d522.s13.e0	DDI-DrugBank.d522.s13.e2
DDI-DrugBank.d522.s13	false	DDI-DrugBank.d522.s13.e0	DDI-DrugBank.d522.s13.e3
DDI-DrugBank.d522.s13	false	DDI-DrugBank.d522.s13.e1	DDI-DrugBank.d522.s13.e2
DDI-DrugBank.d522.s13	false	DDI-DrugBank.d522.s13.e1	DDI-DrugBank.d522.s13.e3
DDI-DrugBank.d522.s13	false	DDI-DrugBank.d522.s13.e2	DDI-DrugBank.d522.s13.e3
DDI-DrugBank.d522.s14|a|However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given theophylline plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.
DDI-DrugBank.d522.s14	9	20	theophylline	drug	DDI-DrugBank.d522.s14.e0
DDI-DrugBank.d522.s14	169	180	theophylline	drug	DDI-DrugBank.d522.s14.e1
DDI-DrugBank.d522.s14	254	265	theophylline	drug	DDI-DrugBank.d522.s14.e2
DDI-DrugBank.d522.s14	false	DDI-DrugBank.d522.s14.e0	DDI-DrugBank.d522.s14.e1
DDI-DrugBank.d522.s14	false	DDI-DrugBank.d522.s14.e0	DDI-DrugBank.d522.s14.e2
DDI-DrugBank.d522.s14	false	DDI-DrugBank.d522.s14.e1	DDI-DrugBank.d522.s14.e2
DDI-DrugBank.d522.s15|a|Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.
DDI-DrugBank.d522.s15	0	7	Antacids	group	DDI-DrugBank.d522.s15.e0
DDI-DrugBank.d522.s15	12	35	H 2 receptor antagonists	group	DDI-DrugBank.d522.s15.e1
DDI-DrugBank.d522.s15	43	55	dirithromycin	drug	DDI-DrugBank.d522.s15.e2
DDI-DrugBank.d522.s15	95	102	antacids	group	DDI-DrugBank.d522.s15.e3
DDI-DrugBank.d522.s15	107	131	H 2 -receptor antagonists	group	DDI-DrugBank.d522.s15.e4
DDI-DrugBank.d522.s15	152	164	dirithromycin	drug	DDI-DrugBank.d522.s15.e5
DDI-DrugBank.d522.s15	false	DDI-DrugBank.d522.s15.e0	DDI-DrugBank.d522.s15.e1
DDI-DrugBank.d522.s15	false	DDI-DrugBank.d522.s15.e0	DDI-DrugBank.d522.s15.e2
DDI-DrugBank.d522.s15	false	DDI-DrugBank.d522.s15.e0	DDI-DrugBank.d522.s15.e3
DDI-DrugBank.d522.s15	false	DDI-DrugBank.d522.s15.e0	DDI-DrugBank.d522.s15.e4
DDI-DrugBank.d522.s15	false	DDI-DrugBank.d522.s15.e0	DDI-DrugBank.d522.s15.e5
DDI-DrugBank.d522.s15	false	DDI-DrugBank.d522.s15.e1	DDI-DrugBank.d522.s15.e2
DDI-DrugBank.d522.s15	false	DDI-DrugBank.d522.s15.e1	DDI-DrugBank.d522.s15.e3
DDI-DrugBank.d522.s15	false	DDI-DrugBank.d522.s15.e1	DDI-DrugBank.d522.s15.e4
DDI-DrugBank.d522.s15	false	DDI-DrugBank.d522.s15.e1	DDI-DrugBank.d522.s15.e5
DDI-DrugBank.d522.s15	true	DDI-DrugBank.d522.s15.e2	DDI-DrugBank.d522.s15.e3
DDI-DrugBank.d522.s16|a|The following drug interactions have been reported with erythromycin products.
DDI-DrugBank.d522.s16	56	67	erythromycin	drug	DDI-DrugBank.d522.s16.e0
DDI-DrugBank.d522.s17|a|It is presently not known whether these same drug interactions occur with dirithromycin.
DDI-DrugBank.d522.s17	74	86	dirithromycin	drug	DDI-DrugBank.d522.s17.e0
DDI-DrugBank.d522.s18|a|Until further data are available regarding the potential interaction of dirithromycin with these compounds, caution should be used during coadministration.
DDI-DrugBank.d522.s18	72	84	dirithromycin	drug	DDI-DrugBank.d522.s18.e0
DDI-DrugBank.d522.s19|a|Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
DDI-DrugBank.d522.s19	0	8	Triazolam	drug	DDI-DrugBank.d522.s19.e0
DDI-DrugBank.d522.s19	11	22	Erythromycin	drug	DDI-DrugBank.d522.s19.e1
DDI-DrugBank.d522.s19	71	79	triazolam	drug	DDI-DrugBank.d522.s19.e2
DDI-DrugBank.d522.s19	133	141	triazolam	drug	DDI-DrugBank.d522.s19.e3
DDI-DrugBank.d522.s19	false	DDI-DrugBank.d522.s19.e0	DDI-DrugBank.d522.s19.e1
DDI-DrugBank.d522.s19	false	DDI-DrugBank.d522.s19.e0	DDI-DrugBank.d522.s19.e2
DDI-DrugBank.d522.s19	false	DDI-DrugBank.d522.s19.e0	DDI-DrugBank.d522.s19.e3
DDI-DrugBank.d522.s19	true	DDI-DrugBank.d522.s19.e1	DDI-DrugBank.d522.s19.e2
DDI-DrugBank.d522.s19	true	DDI-DrugBank.d522.s19.e1	DDI-DrugBank.d522.s19.e3
DDI-DrugBank.d522.s19	false	DDI-DrugBank.d522.s19.e2	DDI-DrugBank.d522.s19.e3
DDI-DrugBank.d522.s20|a|Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
DDI-DrugBank.d522.s20	0	6	Digoxin	drug	DDI-DrugBank.d522.s20.e0
DDI-DrugBank.d522.s20	39	50	erythromycin	drug	DDI-DrugBank.d522.s20.e1
DDI-DrugBank.d522.s20	56	62	digoxin	drug	DDI-DrugBank.d522.s20.e2
DDI-DrugBank.d522.s20	104	110	digoxin	drug	DDI-DrugBank.d522.s20.e3
DDI-DrugBank.d522.s20	false	DDI-DrugBank.d522.s20.e0	DDI-DrugBank.d522.s20.e1
DDI-DrugBank.d522.s20	false	DDI-DrugBank.d522.s20.e0	DDI-DrugBank.d522.s20.e2
DDI-DrugBank.d522.s20	false	DDI-DrugBank.d522.s20.e0	DDI-DrugBank.d522.s20.e3
DDI-DrugBank.d522.s20	true	DDI-DrugBank.d522.s20.e1	DDI-DrugBank.d522.s20.e2
DDI-DrugBank.d522.s20	false	DDI-DrugBank.d522.s20.e1	DDI-DrugBank.d522.s20.e3
DDI-DrugBank.d522.s20	false	DDI-DrugBank.d522.s20.e2	DDI-DrugBank.d522.s20.e3
DDI-DrugBank.d522.s21|a|Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
DDI-DrugBank.d522.s21	0	13	Anticoagulants	group	DDI-DrugBank.d522.s21.e0
DDI-DrugBank.d522.s21	80	91	erythromycin	drug	DDI-DrugBank.d522.s21.e1
DDI-DrugBank.d522.s21	102	115	anticoagulants	group	DDI-DrugBank.d522.s21.e2
DDI-DrugBank.d522.s21	false	DDI-DrugBank.d522.s21.e0	DDI-DrugBank.d522.s21.e1
DDI-DrugBank.d522.s21	false	DDI-DrugBank.d522.s21.e0	DDI-DrugBank.d522.s21.e2
DDI-DrugBank.d522.s21	true	DDI-DrugBank.d522.s21.e1	DDI-DrugBank.d522.s21.e2
DDI-DrugBank.d522.s22|a|Increased anticoagulation effects due to a drug interaction with erythromycin may be more pronounced in the elderly.
DDI-DrugBank.d522.s22	65	76	erythromycin	drug	DDI-DrugBank.d522.s22.e0
DDI-DrugBank.d522.s23|a|Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DDI-DrugBank.d522.s23	0	9	Ergotamine	drug	DDI-DrugBank.d522.s23.e0
DDI-DrugBank.d522.s23	30	41	erythromycin	drug	DDI-DrugBank.d522.s23.e1
DDI-DrugBank.d522.s23	47	56	ergotamine	drug	DDI-DrugBank.d522.s23.e2
DDI-DrugBank.d522.s23	61	77	dihydroergotamine	drug	DDI-DrugBank.d522.s23.e3
DDI-DrugBank.d522.s23	false	DDI-DrugBank.d522.s23.e0	DDI-DrugBank.d522.s23.e1
DDI-DrugBank.d522.s23	false	DDI-DrugBank.d522.s23.e0	DDI-DrugBank.d522.s23.e2
DDI-DrugBank.d522.s23	false	DDI-DrugBank.d522.s23.e0	DDI-DrugBank.d522.s23.e3
DDI-DrugBank.d522.s23	true	DDI-DrugBank.d522.s23.e1	DDI-DrugBank.d522.s23.e2
DDI-DrugBank.d522.s23	true	DDI-DrugBank.d522.s23.e1	DDI-DrugBank.d522.s23.e3
DDI-DrugBank.d522.s23	false	DDI-DrugBank.d522.s23.e2	DDI-DrugBank.d522.s23.e3
DDI-DrugBank.d522.s24|a|Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d522.s24	84	95	erythromycin	drug	DDI-DrugBank.d522.s24.e0
DDI-DrugBank.d522.s24	130	141	cyclosporine	drug	DDI-DrugBank.d522.s24.e1
DDI-DrugBank.d522.s24	144	155	hexobarbital	drug	DDI-DrugBank.d522.s24.e2
DDI-DrugBank.d522.s24	158	170	carbamazepine	drug	DDI-DrugBank.d522.s24.e3
DDI-DrugBank.d522.s24	173	182	alfentanil	drug	DDI-DrugBank.d522.s24.e4
DDI-DrugBank.d522.s24	185	196	disopyramide	drug	DDI-DrugBank.d522.s24.e5
DDI-DrugBank.d522.s24	199	207	phenytoin	drug	DDI-DrugBank.d522.s24.e6
DDI-DrugBank.d522.s24	210	222	bromocriptine	drug	DDI-DrugBank.d522.s24.e7
DDI-DrugBank.d522.s24	225	233	valproate	drug	DDI-DrugBank.d522.s24.e8
DDI-DrugBank.d522.s24	236	245	astemizole	drug	DDI-DrugBank.d522.s24.e9
DDI-DrugBank.d522.s24	true	DDI-DrugBank.d522.s24.e0	DDI-DrugBank.d522.s24.e1
DDI-DrugBank.d522.s24	true	DDI-DrugBank.d522.s24.e0	DDI-DrugBank.d522.s24.e2
DDI-DrugBank.d522.s24	true	DDI-DrugBank.d522.s24.e0	DDI-DrugBank.d522.s24.e3
DDI-DrugBank.d522.s24	true	DDI-DrugBank.d522.s24.e0	DDI-DrugBank.d522.s24.e4
DDI-DrugBank.d522.s24	true	DDI-DrugBank.d522.s24.e0	DDI-DrugBank.d522.s24.e5
DDI-DrugBank.d522.s24	true	DDI-DrugBank.d522.s24.e0	DDI-DrugBank.d522.s24.e6
DDI-DrugBank.d522.s24	true	DDI-DrugBank.d522.s24.e0	DDI-DrugBank.d522.s24.e7
DDI-DrugBank.d522.s24	true	DDI-DrugBank.d522.s24.e0	DDI-DrugBank.d522.s24.e8
DDI-DrugBank.d522.s24	true	DDI-DrugBank.d522.s24.e0	DDI-DrugBank.d522.s24.e9
DDI-DrugBank.d522.s24	true	DDI-DrugBank.d522.s24.e0	DDI-DrugBank.d522.s24.e10
DDI-DrugBank.d506.s0|a|If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
DDI-DrugBank.d506.s0	3	11	phenytoin	drug	DDI-DrugBank.d506.s0.e0
DDI-DrugBank.d506.s0	74	80	Norpace	brand	DDI-DrugBank.d506.s0.e1
DDI-DrugBank.d506.s0	85	94	Norpace CR	brand	DDI-DrugBank.d506.s0.e2
DDI-DrugBank.d506.s0	120	131	disopyramide	drug	DDI-DrugBank.d506.s0.e3
DDI-DrugBank.d506.s0	true	DDI-DrugBank.d506.s0.e0	DDI-DrugBank.d506.s0.e1
DDI-DrugBank.d506.s0	true	DDI-DrugBank.d506.s0.e0	DDI-DrugBank.d506.s0.e2
DDI-DrugBank.d506.s0	false	DDI-DrugBank.d506.s0.e0	DDI-DrugBank.d506.s0.e3
DDI-DrugBank.d506.s0	false	DDI-DrugBank.d506.s0.e1	DDI-DrugBank.d506.s0.e2
DDI-DrugBank.d506.s0	false	DDI-DrugBank.d506.s0.e1	DDI-DrugBank.d506.s0.e3
DDI-DrugBank.d506.s0	false	DDI-DrugBank.d506.s0.e2	DDI-DrugBank.d506.s0.e3
DDI-DrugBank.d506.s1|a|Monitoring of disopyramide plasma levels is recommended in such concurrent use to avoid ineffective therapy.
DDI-DrugBank.d506.s1	14	25	disopyramide	drug	DDI-DrugBank.d506.s1.e0
DDI-DrugBank.d506.s2|a|Other antiarrhythmic drugs (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.
DDI-DrugBank.d506.s2	6	25	antiarrhythmic drugs	group	DDI-DrugBank.d506.s2.e0
DDI-DrugBank.d506.s2	32	40	quinidine	drug	DDI-DrugBank.d506.s2.e1
DDI-DrugBank.d506.s2	43	54	procainamide	drug	DDI-DrugBank.d506.s2.e2
DDI-DrugBank.d506.s2	57	65	lidocaine	drug	DDI-DrugBank.d506.s2.e3
DDI-DrugBank.d506.s2	68	78	propranolol	drug	DDI-DrugBank.d506.s2.e4
DDI-DrugBank.d506.s2	127	133	Norpace	brand	DDI-DrugBank.d506.s2.e5
DDI-DrugBank.d506.s2	false	DDI-DrugBank.d506.s2.e0	DDI-DrugBank.d506.s2.e1
DDI-DrugBank.d506.s2	false	DDI-DrugBank.d506.s2.e0	DDI-DrugBank.d506.s2.e2
DDI-DrugBank.d506.s2	false	DDI-DrugBank.d506.s2.e0	DDI-DrugBank.d506.s2.e3
DDI-DrugBank.d506.s2	false	DDI-DrugBank.d506.s2.e0	DDI-DrugBank.d506.s2.e4
DDI-DrugBank.d506.s2	false	DDI-DrugBank.d506.s2.e0	DDI-DrugBank.d506.s2.e5
DDI-DrugBank.d506.s2	false	DDI-DrugBank.d506.s2.e1	DDI-DrugBank.d506.s2.e2
DDI-DrugBank.d506.s2	false	DDI-DrugBank.d506.s2.e1	DDI-DrugBank.d506.s2.e3
DDI-DrugBank.d506.s2	false	DDI-DrugBank.d506.s2.e1	DDI-DrugBank.d506.s2.e4
DDI-DrugBank.d506.s2	false	DDI-DrugBank.d506.s2.e1	DDI-DrugBank.d506.s2.e5
DDI-DrugBank.d506.s2	false	DDI-DrugBank.d506.s2.e2	DDI-DrugBank.d506.s2.e3
DDI-DrugBank.d506.s3|a|Excessive widening of the QRS complex and/or prolongation of the Q-T interval may occur in these situations.
DDI-DrugBank.d506.s4|a|In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam.
DDI-DrugBank.d506.s4	76	82	Norpace	brand	DDI-DrugBank.d506.s4.e0
DDI-DrugBank.d506.s4	115	125	propranolol	drug	DDI-DrugBank.d506.s4.e1
DDI-DrugBank.d506.s4	130	137	diazepam	drug	DDI-DrugBank.d506.s4.e2
DDI-DrugBank.d506.s4	false	DDI-DrugBank.d506.s4.e0	DDI-DrugBank.d506.s4.e1
DDI-DrugBank.d506.s4	false	DDI-DrugBank.d506.s4.e0	DDI-DrugBank.d506.s4.e2
DDI-DrugBank.d506.s4	false	DDI-DrugBank.d506.s4.e1	DDI-DrugBank.d506.s4.e2
DDI-DrugBank.d506.s5|a|Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
DDI-DrugBank.d506.s5	30	36	Norpace	brand	DDI-DrugBank.d506.s5.e0
DDI-DrugBank.d506.s5	42	50	quinidine	drug	DDI-DrugBank.d506.s5.e1
DDI-DrugBank.d506.s5	91	102	disopyramide	drug	DDI-DrugBank.d506.s5.e2
DDI-DrugBank.d506.s5	142	150	quinidine	drug	DDI-DrugBank.d506.s5.e3
DDI-DrugBank.d506.s5	true	DDI-DrugBank.d506.s5.e0	DDI-DrugBank.d506.s5.e1
DDI-DrugBank.d506.s5	false	DDI-DrugBank.d506.s5.e0	DDI-DrugBank.d506.s5.e2
DDI-DrugBank.d506.s5	false	DDI-DrugBank.d506.s5.e0	DDI-DrugBank.d506.s5.e3
DDI-DrugBank.d506.s5	false	DDI-DrugBank.d506.s5.e1	DDI-DrugBank.d506.s5.e2
DDI-DrugBank.d506.s5	false	DDI-DrugBank.d506.s5.e1	DDI-DrugBank.d506.s5.e3
DDI-DrugBank.d506.s5	false	DDI-DrugBank.d506.s5.e2	DDI-DrugBank.d506.s5.e3
DDI-DrugBank.d506.s6|a|Norpace does not increase serum digoxin levels.
DDI-DrugBank.d506.s6	0	6	Norpace	brand	DDI-DrugBank.d506.s6.e0
DDI-DrugBank.d506.s6	32	38	digoxin	drug	DDI-DrugBank.d506.s6.e1
DDI-DrugBank.d506.s6	false	DDI-DrugBank.d506.s6.e0	DDI-DrugBank.d506.s6.e1
DDI-DrugBank.d506.s7|a|Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.
DDI-DrugBank.d506.s7	16	37	disopyramide phosphate	drug	DDI-DrugBank.d506.s7.e0
DDI-DrugBank.d506.s7	43	54	erythromycin	drug	DDI-DrugBank.d506.s7.e1
DDI-DrugBank.d506.s7	116	127	disopyramide	drug	DDI-DrugBank.d506.s7.e2
DDI-DrugBank.d506.s7	true	DDI-DrugBank.d506.s7.e0	DDI-DrugBank.d506.s7.e1
DDI-DrugBank.d506.s7	false	DDI-DrugBank.d506.s7.e0	DDI-DrugBank.d506.s7.e2
DDI-DrugBank.d506.s7	false	DDI-DrugBank.d506.s7.e1	DDI-DrugBank.d506.s7.e2
DDI-DrugBank.d506.s8|a|Patients taking disopyramide phosphate and hepatic enzyme inhibitors concomitantly should be closely monitored.
DDI-DrugBank.d506.s8	16	37	disopyramide phosphate	drug	DDI-DrugBank.d506.s8.e0
DDI-DrugBank.d506.s9|a|Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.
DDI-DrugBank.d506.s9	44	52	verapamil	drug	DDI-DrugBank.d506.s9.e0
DDI-DrugBank.d506.s9	58	79	disopyramide phosphate	drug	DDI-DrugBank.d506.s9.e1
DDI-DrugBank.d506.s9	95	106	disopyramide	drug	DDI-DrugBank.d506.s9.e2
DDI-DrugBank.d506.s9	176	184	verapamil	drug	DDI-DrugBank.d506.s9.e3
DDI-DrugBank.d506.s9	false	DDI-DrugBank.d506.s9.e0	DDI-DrugBank.d506.s9.e1
DDI-DrugBank.d506.s9	false	DDI-DrugBank.d506.s9.e0	DDI-DrugBank.d506.s9.e2
DDI-DrugBank.d506.s9	false	DDI-DrugBank.d506.s9.e0	DDI-DrugBank.d506.s9.e3
DDI-DrugBank.d506.s9	false	DDI-DrugBank.d506.s9.e1	DDI-DrugBank.d506.s9.e2
DDI-DrugBank.d506.s9	false	DDI-DrugBank.d506.s9.e1	DDI-DrugBank.d506.s9.e3
DDI-DrugBank.d506.s9	true	DDI-DrugBank.d506.s9.e2	DDI-DrugBank.d506.s9.e3
DDI-DrugBank.d19.s0|a|Disulfiram appears to decrease the rate at which certain drugs are metabolized and therefore may increase the blood levels and the possibility of clinical toxicity of drugs given concomitantly.
DDI-DrugBank.d19.s0	0	9	Disulfiram	drug	DDI-DrugBank.d19.s0.e0
DDI-DrugBank.d19.s1|a|DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.
DDI-DrugBank.d19.s1	0	9	DISULFIRAM	drug	DDI-DrugBank.d19.s1.e0
DDI-DrugBank.d19.s1	67	75	PHENYTOIN	drug	DDI-DrugBank.d19.s1.e1
DDI-DrugBank.d19.s1	true	DDI-DrugBank.d19.s1.e0	DDI-DrugBank.d19.s1.e1
DDI-DrugBank.d19.s2|a|SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
DDI-DrugBank.d19.s2	68	76	PHENYTOIN	drug	DDI-DrugBank.d19.s2.e0
DDI-DrugBank.d19.s2	115	124	DISULFIRAM	drug	DDI-DrugBank.d19.s2.e1
DDI-DrugBank.d19.s2	142	150	PHENYTOIN	drug	DDI-DrugBank.d19.s2.e2
DDI-DrugBank.d19.s2	172	180	PHENYTOIN	drug	DDI-DrugBank.d19.s2.e3
DDI-DrugBank.d19.s2	false	DDI-DrugBank.d19.s2.e0	DDI-DrugBank.d19.s2.e1
DDI-DrugBank.d19.s2	false	DDI-DrugBank.d19.s2.e0	DDI-DrugBank.d19.s2.e2
DDI-DrugBank.d19.s2	false	DDI-DrugBank.d19.s2.e0	DDI-DrugBank.d19.s2.e3
DDI-DrugBank.d19.s2	true	DDI-DrugBank.d19.s2.e1	DDI-DrugBank.d19.s2.e2
DDI-DrugBank.d19.s2	false	DDI-DrugBank.d19.s2.e1	DDI-DrugBank.d19.s2.e3
DDI-DrugBank.d19.s2	false	DDI-DrugBank.d19.s2.e2	DDI-DrugBank.d19.s2.e3
DDI-DrugBank.d19.s3|a|SUBSEQUENT TO INITIATION OF DISULFIRAM THERAPY.
DDI-DrugBank.d19.s3	28	37	DISULFIRAM	drug	DDI-DrugBank.d19.s3.e0
DDI-DrugBank.d19.s4|a|SERUM LEVELS OF PHENYTOIN SHOULD BE DETERMINED ON DIFFERENT DAYS FOR EVIDENCE OF AN INCREASE OR FOR A CONTINUING RISE IN LEVELS.
DDI-DrugBank.d19.s4	16	24	PHENYTOIN	drug	DDI-DrugBank.d19.s4.e0
DDI-DrugBank.d19.s5|a|INCREASED PHENYTOIN LEVELS SHOULD BE TREATED WITH APPROPRIATE DOSAGE ADJUSTMENT.
DDI-DrugBank.d19.s5	10	18	PHENYTOIN	drug	DDI-DrugBank.d19.s5.e0
DDI-DrugBank.d19.s6|a|It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.
DDI-DrugBank.d19.s6	49	62	anticoagulants	group	DDI-DrugBank.d19.s6.e0
DDI-DrugBank.d19.s6	91	100	disulfiram	drug	DDI-DrugBank.d19.s6.e1
DDI-DrugBank.d19.s6	109	118	disulfiram	drug	DDI-DrugBank.d19.s6.e2
DDI-DrugBank.d19.s6	true	DDI-DrugBank.d19.s6.e0	DDI-DrugBank.d19.s6.e1
DDI-DrugBank.d19.s6	false	DDI-DrugBank.d19.s6.e0	DDI-DrugBank.d19.s6.e2
DDI-DrugBank.d19.s6	false	DDI-DrugBank.d19.s6.e1	DDI-DrugBank.d19.s6.e2
DDI-DrugBank.d19.s7|a|Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;
DDI-DrugBank.d19.s7	16	24	isoniazid	drug	DDI-DrugBank.d19.s7.e0
DDI-DrugBank.d19.s7	31	40	disulfiram	drug	DDI-DrugBank.d19.s7.e1
DDI-DrugBank.d19.s7	true	DDI-DrugBank.d19.s7.e0	DDI-DrugBank.d19.s7.e1
DDI-DrugBank.d19.s8|a|the disulfiram should be discontinued if such signs appear.
DDI-DrugBank.d19.s8	4	13	disulfiram	drug	DDI-DrugBank.d19.s8.e0
DDI-DrugBank.d19.s9|a|In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
DDI-DrugBank.d19.s9	35	44	disulfiram	drug	DDI-DrugBank.d19.s9.e0
DDI-DrugBank.d19.s9	50	56	nitrite	drug	DDI-DrugBank.d19.s9.e1
DDI-DrugBank.d19.s9	149	158	disulfiram	drug	DDI-DrugBank.d19.s9.e2
DDI-DrugBank.d19.s9	175	182	nitrites	group	DDI-DrugBank.d19.s9.e3
DDI-DrugBank.d19.s9	true	DDI-DrugBank.d19.s9.e0	DDI-DrugBank.d19.s9.e1
DDI-DrugBank.d19.s9	false	DDI-DrugBank.d19.s9.e0	DDI-DrugBank.d19.s9.e2
DDI-DrugBank.d19.s9	false	DDI-DrugBank.d19.s9.e0	DDI-DrugBank.d19.s9.e3
DDI-DrugBank.d19.s9	false	DDI-DrugBank.d19.s9.e1	DDI-DrugBank.d19.s9.e2
DDI-DrugBank.d19.s9	false	DDI-DrugBank.d19.s9.e1	DDI-DrugBank.d19.s9.e3
DDI-DrugBank.d19.s9	true	DDI-DrugBank.d19.s9.e2	DDI-DrugBank.d19.s9.e3
DDI-DrugBank.d19.s10|a|Disulfiram alone in the rat s diet did not lead to such tumors.
DDI-DrugBank.d19.s10	0	9	Disulfiram	drug	DDI-DrugBank.d19.s10.e0
DDI-DrugBank.d19.s11|a|The relevance of this finding to humans is not known at this time.
DDI-DrugBank.d274.s0|a|Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.
DDI-DrugBank.d274.s0	29	38	dobutamine	drug	DDI-DrugBank.d274.s0.e0
DDI-DrugBank.d274.s0	98	112	b-blocking drug	group	DDI-DrugBank.d274.s0.e1
DDI-DrugBank.d274.s0	true	DDI-DrugBank.d274.s0.e0	DDI-DrugBank.d274.s0.e1
DDI-DrugBank.d274.s1|a|In such a case, the peripheral vascular resistance may increase.
DDI-DrugBank.d274.s2|a|Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
DDI-DrugBank.d274.s2	57	66	dobutamine	drug	DDI-DrugBank.d274.s2.e0
DDI-DrugBank.d274.s2	72	84	nitroprusside	drug	DDI-DrugBank.d274.s2.e1
DDI-DrugBank.d274.s2	true	DDI-DrugBank.d274.s2.e0	DDI-DrugBank.d274.s2.e1
DDI-DrugBank.d274.s3|a|There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
DDI-DrugBank.d274.s3	72	81	dobutamine	drug	DDI-DrugBank.d274.s3.e0
DDI-DrugBank.d274.s3	141	162	digitalis preparations	group	DDI-DrugBank.d274.s3.e1
DDI-DrugBank.d274.s3	165	174	furosemide	drug	DDI-DrugBank.d274.s3.e2
DDI-DrugBank.d274.s3	177	190	spironolactone	drug	DDI-DrugBank.d274.s3.e3
DDI-DrugBank.d274.s3	193	201	lidocaine	drug	DDI-DrugBank.d274.s3.e4
DDI-DrugBank.d274.s3	204	222	glyceryl trinitrate	drug	DDI-DrugBank.d274.s3.e5
DDI-DrugBank.d274.s3	225	244	isosorbide dinitrate	drug	DDI-DrugBank.d274.s3.e6
DDI-DrugBank.d274.s3	247	254	morphine	drug	DDI-DrugBank.d274.s3.e7
DDI-DrugBank.d274.s3	257	264	atropine	drug	DDI-DrugBank.d274.s3.e8
DDI-DrugBank.d274.s3	267	273	heparin	drug	DDI-DrugBank.d274.s3.e9
DDI-DrugBank.d274.s3	false	DDI-DrugBank.d274.s3.e0	DDI-DrugBank.d274.s3.e1
DDI-DrugBank.d274.s3	false	DDI-DrugBank.d274.s3.e0	DDI-DrugBank.d274.s3.e2
DDI-DrugBank.d274.s3	false	DDI-DrugBank.d274.s3.e0	DDI-DrugBank.d274.s3.e3
DDI-DrugBank.d274.s3	false	DDI-DrugBank.d274.s3.e0	DDI-DrugBank.d274.s3.e4
DDI-DrugBank.d274.s3	false	DDI-DrugBank.d274.s3.e0	DDI-DrugBank.d274.s3.e5
DDI-DrugBank.d274.s3	false	DDI-DrugBank.d274.s3.e0	DDI-DrugBank.d274.s3.e6
DDI-DrugBank.d274.s3	false	DDI-DrugBank.d274.s3.e0	DDI-DrugBank.d274.s3.e7
DDI-DrugBank.d274.s3	false	DDI-DrugBank.d274.s3.e0	DDI-DrugBank.d274.s3.e8
DDI-DrugBank.d274.s3	false	DDI-DrugBank.d274.s3.e0	DDI-DrugBank.d274.s3.e9
DDI-DrugBank.d274.s3	false	DDI-DrugBank.d274.s3.e0	DDI-DrugBank.d274.s3.e10
DDI-DrugBank.d371.s0|a|There have been no formal clinical studies to evaluate the drug interactions of TAXOTERE with other medications.
DDI-DrugBank.d371.s0	80	87	TAXOTERE	brand	DDI-DrugBank.d371.s0.e0
DDI-DrugBank.d371.s1|a|In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d371.s1	51	59	docetaxel	drug	DDI-DrugBank.d371.s1.e0
DDI-DrugBank.d371.s1	197	208	cyclosporine	drug	DDI-DrugBank.d371.s1.e1
DDI-DrugBank.d371.s1	211	221	terfenadine	drug	DDI-DrugBank.d371.s1.e2
DDI-DrugBank.d371.s1	224	235	ketoconazole	drug	DDI-DrugBank.d371.s1.e3
DDI-DrugBank.d371.s1	238	249	erythromycin	drug	DDI-DrugBank.d371.s1.e4
DDI-DrugBank.d371.s1	256	269	troleandomycin	drug	DDI-DrugBank.d371.s1.e5
DDI-DrugBank.d371.s1	true	DDI-DrugBank.d371.s1.e0	DDI-DrugBank.d371.s1.e1
DDI-DrugBank.d371.s1	true	DDI-DrugBank.d371.s1.e0	DDI-DrugBank.d371.s1.e2
DDI-DrugBank.d371.s1	true	DDI-DrugBank.d371.s1.e0	DDI-DrugBank.d371.s1.e3
DDI-DrugBank.d371.s1	true	DDI-DrugBank.d371.s1.e0	DDI-DrugBank.d371.s1.e4
DDI-DrugBank.d371.s1	true	DDI-DrugBank.d371.s1.e0	DDI-DrugBank.d371.s1.e5
DDI-DrugBank.d371.s1	false	DDI-DrugBank.d371.s1.e1	DDI-DrugBank.d371.s1.e2
DDI-DrugBank.d371.s1	false	DDI-DrugBank.d371.s1.e1	DDI-DrugBank.d371.s1.e3
DDI-DrugBank.d371.s1	false	DDI-DrugBank.d371.s1.e1	DDI-DrugBank.d371.s1.e4
DDI-DrugBank.d371.s1	false	DDI-DrugBank.d371.s1.e1	DDI-DrugBank.d371.s1.e5
DDI-DrugBank.d371.s1	false	DDI-DrugBank.d371.s1.e2	DDI-DrugBank.d371.s1.e3
DDI-DrugBank.d371.s2|a|Caution should be exercised with these drugs when treating patients receiving TAXOTERE as there is a potential for a significant interaction.
DDI-DrugBank.d371.s2	78	85	TAXOTERE	brand	DDI-DrugBank.d371.s2.e0
DDI-DrugBank.d558.s0|a|Drug/Laboratory Test Interactions None known.
DDI-DrugBank.d558.s1|a|Drug-Drug Interactions Cimetidine: Concomitant use of cimetidine is contraindicated.
DDI-DrugBank.d558.s1	23	32	Cimetidine	drug	DDI-DrugBank.d558.s1.e0
DDI-DrugBank.d558.s1	54	63	cimetidine	drug	DDI-DrugBank.d558.s1.e1
DDI-DrugBank.d558.s1	false	DDI-DrugBank.d558.s1.e0	DDI-DrugBank.d558.s1.e1
DDI-DrugBank.d558.s2|a|Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.
DDI-DrugBank.d558.s2	0	9	Cimetidine	drug	DDI-DrugBank.d558.s2.e0
DDI-DrugBank.d558.s2	76	82	TIKOSYN	brand	DDI-DrugBank.d558.s2.e1
DDI-DrugBank.d558.s2	136	145	dofetilide	drug	DDI-DrugBank.d558.s2.e2
DDI-DrugBank.d558.s2	true	DDI-DrugBank.d558.s2.e0	DDI-DrugBank.d558.s2.e1
DDI-DrugBank.d558.s2	false	DDI-DrugBank.d558.s2.e0	DDI-DrugBank.d558.s2.e2
DDI-DrugBank.d558.s2	false	DDI-DrugBank.d558.s2.e1	DDI-DrugBank.d558.s2.e2
DDI-DrugBank.d558.s3|a|Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).
DDI-DrugBank.d558.s3	0	9	Cimetidine	drug	DDI-DrugBank.d558.s3.e0
DDI-DrugBank.d558.s3	75	84	dofetilide	drug	DDI-DrugBank.d558.s3.e1
DDI-DrugBank.d558.s3	true	DDI-DrugBank.d558.s3.e0	DDI-DrugBank.d558.s3.e1
DDI-DrugBank.d558.s4|a|No studies have been conducted at intermediate doses of cimetidine.
DDI-DrugBank.d558.s4	56	65	cimetidine	drug	DDI-DrugBank.d558.s4.e0
DDI-DrugBank.d558.s5|a|If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
DDI-DrugBank.d558.s5	22	28	TIKOSYN	brand	DDI-DrugBank.d558.s5.e0
DDI-DrugBank.d558.s5	34	43	anti-ulcer	group	DDI-DrugBank.d558.s5.e1
DDI-DrugBank.d558.s5	75	84	omeprazole	drug	DDI-DrugBank.d558.s5.e2
DDI-DrugBank.d558.s5	87	96	ranitidine	drug	DDI-DrugBank.d558.s5.e3
DDI-DrugBank.d558.s5	102	109	antacids	group	DDI-DrugBank.d558.s5.e4
DDI-DrugBank.d558.s5	112	119	aluminum hydroxide	drug	DDI-DrugBank.d558.s5.e5
DDI-DrugBank.d558.s5	135	143	aluminum hydroxide	drug	DDI-DrugBank.d558.s5.e5
DDI-DrugBank.d558.s5	125	143	magnesium hydroxide	drug	DDI-DrugBank.d558.s5.e6
DDI-DrugBank.d558.s5	174	183	cimetidine	drug	DDI-DrugBank.d558.s5.e7
DDI-DrugBank.d558.s5	251	257	TIKOSYN	brand	DDI-DrugBank.d558.s5.e8
DDI-DrugBank.d558.s5	false	DDI-DrugBank.d558.s5.e0	DDI-DrugBank.d558.s5.e1
DDI-DrugBank.d558.s5	false	DDI-DrugBank.d558.s5.e0	DDI-DrugBank.d558.s5.e2
DDI-DrugBank.d558.s5	false	DDI-DrugBank.d558.s5.e0	DDI-DrugBank.d558.s5.e3
DDI-DrugBank.d558.s5	false	DDI-DrugBank.d558.s5.e0	DDI-DrugBank.d558.s5.e4
DDI-DrugBank.d558.s5	false	DDI-DrugBank.d558.s5.e0	DDI-DrugBank.d558.s5.e5
DDI-DrugBank.d558.s5	false	DDI-DrugBank.d558.s5.e0	DDI-DrugBank.d558.s5.e6
DDI-DrugBank.d558.s5	true	DDI-DrugBank.d558.s5.e0	DDI-DrugBank.d558.s5.e7
DDI-DrugBank.d558.s5	false	DDI-DrugBank.d558.s5.e0	DDI-DrugBank.d558.s5.e8
DDI-DrugBank.d558.s5	false	DDI-DrugBank.d558.s5.e1	DDI-DrugBank.d558.s5.e2
DDI-DrugBank.d558.s5	false	DDI-DrugBank.d558.s5.e1	DDI-DrugBank.d558.s5.e3
DDI-DrugBank.d558.s6|a|Verapamil: Concomitant use of verapamil is contraindicated.
DDI-DrugBank.d558.s6	0	8	Verapamil	drug	DDI-DrugBank.d558.s6.e0
DDI-DrugBank.d558.s6	30	38	verapamil	drug	DDI-DrugBank.d558.s6.e1
DDI-DrugBank.d558.s6	false	DDI-DrugBank.d558.s6.e0	DDI-DrugBank.d558.s6.e1
DDI-DrugBank.d558.s7|a|Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
DDI-DrugBank.d558.s7	21	27	TIKOSYN	brand	DDI-DrugBank.d558.s7.e0
DDI-DrugBank.d558.s7	34	42	verapamil	drug	DDI-DrugBank.d558.s7.e1
DDI-DrugBank.d558.s7	69	78	dofetilide	drug	DDI-DrugBank.d558.s7.e2
DDI-DrugBank.d558.s7	136	145	dofetilide	drug	DDI-DrugBank.d558.s7.e3
DDI-DrugBank.d558.s7	true	DDI-DrugBank.d558.s7.e0	DDI-DrugBank.d558.s7.e1
DDI-DrugBank.d558.s7	false	DDI-DrugBank.d558.s7.e0	DDI-DrugBank.d558.s7.e2
DDI-DrugBank.d558.s7	false	DDI-DrugBank.d558.s7.e0	DDI-DrugBank.d558.s7.e3
DDI-DrugBank.d558.s7	false	DDI-DrugBank.d558.s7.e1	DDI-DrugBank.d558.s7.e2
DDI-DrugBank.d558.s7	false	DDI-DrugBank.d558.s7.e1	DDI-DrugBank.d558.s7.e3
DDI-DrugBank.d558.s7	false	DDI-DrugBank.d558.s7.e2	DDI-DrugBank.d558.s7.e3
DDI-DrugBank.d558.s8|a|In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.
DDI-DrugBank.d558.s8	117	125	verapamil	drug	DDI-DrugBank.d558.s8.e0
DDI-DrugBank.d558.s8	132	141	dofetilide	drug	DDI-DrugBank.d558.s8.e1
DDI-DrugBank.d558.s8	true	DDI-DrugBank.d558.s8.e0	DDI-DrugBank.d558.s8.e1
DDI-DrugBank.d558.s9|a|Ketoconazole: Concomitant use of ketoconazole is contraindicated.
DDI-DrugBank.d558.s9	0	11	Ketoconazole	drug	DDI-DrugBank.d558.s9.e0
DDI-DrugBank.d558.s9	33	44	ketoconazole	drug	DDI-DrugBank.d558.s9.e1
DDI-DrugBank.d558.s9	false	DDI-DrugBank.d558.s9.e0	DDI-DrugBank.d558.s9.e1
DDI-DrugBank.d558.s10|a|Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.
DDI-DrugBank.d558.s10	0	11	Ketoconazole	drug	DDI-DrugBank.d558.s10.e0
DDI-DrugBank.d558.s10	91	97	TIKOSYN	brand	DDI-DrugBank.d558.s10.e1
DDI-DrugBank.d558.s10	151	160	dofetilide	drug	DDI-DrugBank.d558.s10.e2
DDI-DrugBank.d558.s10	true	DDI-DrugBank.d558.s10.e0	DDI-DrugBank.d558.s10.e1
DDI-DrugBank.d558.s10	false	DDI-DrugBank.d558.s10.e0	DDI-DrugBank.d558.s10.e2
DDI-DrugBank.d558.s10	false	DDI-DrugBank.d558.s10.e1	DDI-DrugBank.d558.s10.e2
DDI-DrugBank.d558.s11|a|Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.
DDI-DrugBank.d558.s11	0	11	Trimethoprim	drug	DDI-DrugBank.d558.s11.e0
DDI-DrugBank.d558.s11	42	57	Sulfamethoxazole	drug	DDI-DrugBank.d558.s11.e1
DDI-DrugBank.d558.s11	79	90	trimethoprim	drug	DDI-DrugBank.d558.s11.e2
DDI-DrugBank.d558.s11	121	136	sulfamethoxazole	drug	DDI-DrugBank.d558.s11.e3
DDI-DrugBank.d558.s11	false	DDI-DrugBank.d558.s11.e0	DDI-DrugBank.d558.s11.e1
DDI-DrugBank.d558.s11	false	DDI-DrugBank.d558.s11.e0	DDI-DrugBank.d558.s11.e2
DDI-DrugBank.d558.s11	false	DDI-DrugBank.d558.s11.e0	DDI-DrugBank.d558.s11.e3
DDI-DrugBank.d558.s11	false	DDI-DrugBank.d558.s11.e1	DDI-DrugBank.d558.s11.e2
DDI-DrugBank.d558.s11	false	DDI-DrugBank.d558.s11.e1	DDI-DrugBank.d558.s11.e3
DDI-DrugBank.d558.s11	false	DDI-DrugBank.d558.s11.e2	DDI-DrugBank.d558.s11.e3
DDI-DrugBank.d558.s12|a|Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.
DDI-DrugBank.d558.s12	0	18	Hydrochlorothiazide	drug	DDI-DrugBank.d558.s12.e0
DDI-DrugBank.d558.s12	21	24	HCTZ	drug	DDI-DrugBank.d558.s12.e1
DDI-DrugBank.d558.s12	56	66	Triamterene	drug	DDI-DrugBank.d558.s12.e2
DDI-DrugBank.d558.s12	88	91	HCTZ	drug	DDI-DrugBank.d558.s12.e3
DDI-DrugBank.d558.s12	122	132	triamterene	drug	DDI-DrugBank.d558.s12.e4
DDI-DrugBank.d558.s12	false	DDI-DrugBank.d558.s12.e0	DDI-DrugBank.d558.s12.e1
DDI-DrugBank.d558.s12	false	DDI-DrugBank.d558.s12.e0	DDI-DrugBank.d558.s12.e2
DDI-DrugBank.d558.s12	false	DDI-DrugBank.d558.s12.e0	DDI-DrugBank.d558.s12.e3
DDI-DrugBank.d558.s12	false	DDI-DrugBank.d558.s12.e0	DDI-DrugBank.d558.s12.e4
DDI-DrugBank.d558.s12	false	DDI-DrugBank.d558.s12.e1	DDI-DrugBank.d558.s12.e2
DDI-DrugBank.d558.s12	false	DDI-DrugBank.d558.s12.e1	DDI-DrugBank.d558.s12.e3
DDI-DrugBank.d558.s12	false	DDI-DrugBank.d558.s12.e1	DDI-DrugBank.d558.s12.e4
DDI-DrugBank.d558.s12	false	DDI-DrugBank.d558.s12.e2	DDI-DrugBank.d558.s12.e3
DDI-DrugBank.d558.s12	false	DDI-DrugBank.d558.s12.e2	DDI-DrugBank.d558.s12.e4
DDI-DrugBank.d558.s12	false	DDI-DrugBank.d558.s12.e3	DDI-DrugBank.d558.s12.e4
DDI-DrugBank.d558.s13|a|HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).
DDI-DrugBank.d558.s13	0	3	HCTZ	drug	DDI-DrugBank.d558.s13.e0
DDI-DrugBank.d558.s13	17	20	HCTZ	drug	DDI-DrugBank.d558.s13.e1
DDI-DrugBank.d558.s13	22	32	triamterene	drug	DDI-DrugBank.d558.s13.e2
DDI-DrugBank.d558.s13	72	78	TIKOSYN	brand	DDI-DrugBank.d558.s13.e3
DDI-DrugBank.d558.s13	126	133	diuretic	group	DDI-DrugBank.d558.s13.e4
DDI-DrugBank.d558.s13	false	DDI-DrugBank.d558.s13.e0	DDI-DrugBank.d558.s13.e1
DDI-DrugBank.d558.s13	false	DDI-DrugBank.d558.s13.e0	DDI-DrugBank.d558.s13.e2
DDI-DrugBank.d558.s13	false	DDI-DrugBank.d558.s13.e0	DDI-DrugBank.d558.s13.e3
DDI-DrugBank.d558.s13	false	DDI-DrugBank.d558.s13.e0	DDI-DrugBank.d558.s13.e4
DDI-DrugBank.d558.s13	false	DDI-DrugBank.d558.s13.e1	DDI-DrugBank.d558.s13.e2
DDI-DrugBank.d558.s13	false	DDI-DrugBank.d558.s13.e1	DDI-DrugBank.d558.s13.e3
DDI-DrugBank.d558.s13	false	DDI-DrugBank.d558.s13.e1	DDI-DrugBank.d558.s13.e4
DDI-DrugBank.d558.s13	false	DDI-DrugBank.d558.s13.e2	DDI-DrugBank.d558.s13.e3
DDI-DrugBank.d558.s13	false	DDI-DrugBank.d558.s13.e2	DDI-DrugBank.d558.s13.e4
DDI-DrugBank.d558.s13	false	DDI-DrugBank.d558.s13.e3	DDI-DrugBank.d558.s13.e4
DDI-DrugBank.d558.s14|a|In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.
DDI-DrugBank.d558.s14	22	25	HCTZ	drug	DDI-DrugBank.d558.s14.e0
DDI-DrugBank.d558.s14	34	43	dofetilide	drug	DDI-DrugBank.d558.s14.e1
DDI-DrugBank.d558.s14	true	DDI-DrugBank.d558.s14.e0	DDI-DrugBank.d558.s14.e1
DDI-DrugBank.d558.s15|a|However, the pharmacodynamic effect increased by 197% (QTc increase over time) and by 95% (maximum QTc increase).
DDI-DrugBank.d558.s16|a|However, the pharmacodynamic effect increased by 190% (QTc increase over time) and by 84% (Maximum QTc increase).
DDI-DrugBank.d558.s17|a|The pharmacodynamic effects can be explained by a combination of the increase in dofetilide exposure and the reductions in serum potassium.
DDI-DrugBank.d558.s17	81	90	dofetilide	drug	DDI-DrugBank.d558.s17.e0
DDI-DrugBank.d558.s18|a|In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics.
DDI-DrugBank.d558.s18	55	61	TIKOSYN	brand	DDI-DrugBank.d558.s18.e0
DDI-DrugBank.d558.s18	67	75	diuretics	group	DDI-DrugBank.d558.s18.e1
DDI-DrugBank.d558.s18	177	185	diuretics	group	DDI-DrugBank.d558.s18.e2
DDI-DrugBank.d558.s18	false	DDI-DrugBank.d558.s18.e0	DDI-DrugBank.d558.s18.e1
DDI-DrugBank.d558.s18	false	DDI-DrugBank.d558.s18.e0	DDI-DrugBank.d558.s18.e2
DDI-DrugBank.d558.s18	false	DDI-DrugBank.d558.s18.e1	DDI-DrugBank.d558.s18.e2
DDI-DrugBank.d558.s19|a|Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).
DDI-DrugBank.d558.s19	28	56	potassium depleting diuretics	group	DDI-DrugBank.d558.s19.e0
DDI-DrugBank.d558.s19	136	142	TIKOSYN	brand	DDI-DrugBank.d558.s19.e1
DDI-DrugBank.d558.s19	false	DDI-DrugBank.d558.s19.e0	DDI-DrugBank.d558.s19.e1
DDI-DrugBank.d558.s20|a|Potential Drug Interactions Dofetilide is eliminated in the kidney by cationic secretion.
DDI-DrugBank.d558.s20	28	37	Dofetilide	drug	DDI-DrugBank.d558.s20.e0
DDI-DrugBank.d558.s21|a|Inhibitors of renal cationic secretion are contraindicated with TIKOSYN.
DDI-DrugBank.d558.s21	64	70	TIKOSYN	brand	DDI-DrugBank.d558.s21.e0
DDI-DrugBank.d558.s22|a|In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
DDI-DrugBank.d558.s22	68	78	triamterene	drug	DDI-DrugBank.d558.s22.e0
DDI-DrugBank.d558.s22	81	89	metformin	drug	DDI-DrugBank.d558.s22.e1
DDI-DrugBank.d558.s22	95	103	amiloride	drug	DDI-DrugBank.d558.s22.e2
DDI-DrugBank.d558.s22	165	174	dofetilide	drug	DDI-DrugBank.d558.s22.e3
DDI-DrugBank.d558.s22	false	DDI-DrugBank.d558.s22.e0	DDI-DrugBank.d558.s22.e1
DDI-DrugBank.d558.s22	false	DDI-DrugBank.d558.s22.e0	DDI-DrugBank.d558.s22.e2
DDI-DrugBank.d558.s22	true	DDI-DrugBank.d558.s22.e0	DDI-DrugBank.d558.s22.e3
DDI-DrugBank.d558.s22	false	DDI-DrugBank.d558.s22.e1	DDI-DrugBank.d558.s22.e2
DDI-DrugBank.d558.s22	true	DDI-DrugBank.d558.s22.e1	DDI-DrugBank.d558.s22.e3
DDI-DrugBank.d558.s22	true	DDI-DrugBank.d558.s22.e2	DDI-DrugBank.d558.s22.e3
DDI-DrugBank.d558.s23|a|Dofetilide is metabolized to a small extent by the CYP3A4 isoenzyme of the cytochrome P450 system.
DDI-DrugBank.d558.s23	0	9	Dofetilide	drug	DDI-DrugBank.d558.s23.e0
DDI-DrugBank.d558.s24|a|Inhibitors of the CYP3A4 isoenzyme could increase systemic dofetilide exposure.
DDI-DrugBank.d558.s24	59	68	dofetilide	drug	DDI-DrugBank.d558.s24.e0
DDI-DrugBank.d558.s25|a|Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d558.s25	36	56	macrolide antibiotics	group	DDI-DrugBank.d558.s25.e0
DDI-DrugBank.d558.s25	59	81	azole antifungal agents	group	DDI-DrugBank.d558.s25.e1
DDI-DrugBank.d558.s25	84	102	protease inhibitors	group	DDI-DrugBank.d558.s25.e2
DDI-DrugBank.d558.s25	105	133	serotonin reuptake inhibitors	group	DDI-DrugBank.d558.s25.e3
DDI-DrugBank.d558.s25	136	145	amiodarone	drug	DDI-DrugBank.d558.s25.e4
DDI-DrugBank.d558.s25	148	159	cannabinoids	group	DDI-DrugBank.d558.s25.e5
DDI-DrugBank.d558.s25	162	170	diltiazem	drug	DDI-DrugBank.d558.s25.e6
DDI-DrugBank.d558.s25	191	200	nefazadone	drug	DDI-DrugBank.d558.s25.e7
DDI-DrugBank.d558.s25	203	213	norfloxacin	drug	DDI-DrugBank.d558.s25.e8
DDI-DrugBank.d558.s25	216	222	quinine	drug	DDI-DrugBank.d558.s25.e9
DDI-DrugBank.d558.s25	false	DDI-DrugBank.d558.s25.e0	DDI-DrugBank.d558.s25.e1
DDI-DrugBank.d558.s25	false	DDI-DrugBank.d558.s25.e0	DDI-DrugBank.d558.s25.e2
DDI-DrugBank.d558.s25	false	DDI-DrugBank.d558.s25.e0	DDI-DrugBank.d558.s25.e3
DDI-DrugBank.d558.s25	false	DDI-DrugBank.d558.s25.e0	DDI-DrugBank.d558.s25.e4
DDI-DrugBank.d558.s25	false	DDI-DrugBank.d558.s25.e0	DDI-DrugBank.d558.s25.e5
DDI-DrugBank.d558.s25	false	DDI-DrugBank.d558.s25.e0	DDI-DrugBank.d558.s25.e6
DDI-DrugBank.d558.s25	false	DDI-DrugBank.d558.s25.e0	DDI-DrugBank.d558.s25.e7
DDI-DrugBank.d558.s25	false	DDI-DrugBank.d558.s25.e0	DDI-DrugBank.d558.s25.e8
DDI-DrugBank.d558.s25	false	DDI-DrugBank.d558.s25.e0	DDI-DrugBank.d558.s25.e9
DDI-DrugBank.d558.s25	false	DDI-DrugBank.d558.s25.e0	DDI-DrugBank.d558.s25.e10
DDI-DrugBank.d558.s26|a|Dofetilide is not an inhibitor of CYP3A4 nor of other cytochrome P450 isoenzymes (e.g., CYP2C9, CYP2D6) and is not expected to increase levels of drugs metabolized by CYP3A4.
DDI-DrugBank.d558.s26	0	9	Dofetilide	drug	DDI-DrugBank.d558.s26.e0
DDI-DrugBank.d558.s27|a|Other Drug Interaction Information Digoxin: Studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics of digoxin.
DDI-DrugBank.d558.s27	35	41	Digoxin	drug	DDI-DrugBank.d558.s27.e0
DDI-DrugBank.d558.s27	90	96	TIKOSYN	brand	DDI-DrugBank.d558.s27.e1
DDI-DrugBank.d558.s27	138	144	digoxin	drug	DDI-DrugBank.d558.s27.e2
DDI-DrugBank.d558.s27	false	DDI-DrugBank.d558.s27.e0	DDI-DrugBank.d558.s27.e1
DDI-DrugBank.d558.s27	false	DDI-DrugBank.d558.s27.e0	DDI-DrugBank.d558.s27.e2
DDI-DrugBank.d558.s27	false	DDI-DrugBank.d558.s27.e1	DDI-DrugBank.d558.s27.e2
DDI-DrugBank.d558.s28|a|In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.
DDI-DrugBank.d558.s28	47	53	digoxin	drug	DDI-DrugBank.d558.s28.e0
DDI-DrugBank.d558.s28	60	69	dofetilide	drug	DDI-DrugBank.d558.s28.e1
DDI-DrugBank.d558.s28	true	DDI-DrugBank.d558.s28.e0	DDI-DrugBank.d558.s28.e1
DDI-DrugBank.d558.s29|a|It is not clear whether this represents an interaction with TIKOSYN or the presence of more severe structural heart disease in patients on digoxin;
DDI-DrugBank.d558.s29	60	66	TIKOSYN	brand	DDI-DrugBank.d558.s29.e0
DDI-DrugBank.d558.s29	139	145	digoxin	drug	DDI-DrugBank.d558.s29.e1
DDI-DrugBank.d558.s29	false	DDI-DrugBank.d558.s29.e0	DDI-DrugBank.d558.s29.e1
DDI-DrugBank.d558.s30|a|structural heart disease is a known risk factor for arrhythmia.
DDI-DrugBank.d558.s31|a|No increase in mortality was observed in patients taking digoxin as concomitant medication.
DDI-DrugBank.d558.s31	57	63	digoxin	drug	DDI-DrugBank.d558.s31.e0
DDI-DrugBank.d558.s32|a|Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
DDI-DrugBank.d558.s32	36	45	amlodipine	drug	DDI-DrugBank.d558.s32.e0
DDI-DrugBank.d558.s32	48	56	phenytoin	drug	DDI-DrugBank.d558.s32.e1
DDI-DrugBank.d558.s32	59	67	glyburide	drug	DDI-DrugBank.d558.s32.e2
DDI-DrugBank.d558.s32	70	79	ranitidine	drug	DDI-DrugBank.d558.s32.e3
DDI-DrugBank.d558.s32	82	91	omeprazole	drug	DDI-DrugBank.d558.s32.e4
DDI-DrugBank.d558.s32	151	159	estrogens	group	DDI-DrugBank.d558.s32.e5
DDI-DrugBank.d558.s32	165	183	medroxyprogesterone	drug	DDI-DrugBank.d558.s32.e6
DDI-DrugBank.d558.s32	187	193	antacid	group	DDI-DrugBank.d558.s32.e7
DDI-DrugBank.d558.s32	196	203	aluminum hydroxide	drug	DDI-DrugBank.d558.s32.e8
DDI-DrugBank.d558.s32	219	227	aluminum hydroxide	drug	DDI-DrugBank.d558.s32.e8
DDI-DrugBank.d558.s32	209	227	magnesium hydroxide	drug	DDI-DrugBank.d558.s32.e9
DDI-DrugBank.d558.s32	false	DDI-DrugBank.d558.s32.e0	DDI-DrugBank.d558.s32.e1
DDI-DrugBank.d558.s32	false	DDI-DrugBank.d558.s32.e0	DDI-DrugBank.d558.s32.e2
DDI-DrugBank.d558.s32	false	DDI-DrugBank.d558.s32.e0	DDI-DrugBank.d558.s32.e3
DDI-DrugBank.d558.s32	false	DDI-DrugBank.d558.s32.e0	DDI-DrugBank.d558.s32.e4
DDI-DrugBank.d558.s32	false	DDI-DrugBank.d558.s32.e0	DDI-DrugBank.d558.s32.e5
DDI-DrugBank.d558.s32	false	DDI-DrugBank.d558.s32.e0	DDI-DrugBank.d558.s32.e6
DDI-DrugBank.d558.s32	false	DDI-DrugBank.d558.s32.e0	DDI-DrugBank.d558.s32.e7
DDI-DrugBank.d558.s32	false	DDI-DrugBank.d558.s32.e0	DDI-DrugBank.d558.s32.e8
DDI-DrugBank.d558.s32	false	DDI-DrugBank.d558.s32.e0	DDI-DrugBank.d558.s32.e9
DDI-DrugBank.d558.s32	false	DDI-DrugBank.d558.s32.e0	DDI-DrugBank.d558.s32.e10
DDI-DrugBank.d558.s33|a|In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.
DDI-DrugBank.d558.s33	59	65	TIKOSYN	brand	DDI-DrugBank.d558.s33.e0
DDI-DrugBank.d558.s33	127	134	warfarin	drug	DDI-DrugBank.d558.s33.e1
DDI-DrugBank.d558.s33	164	174	propranolol	drug	DDI-DrugBank.d558.s33.e2
DDI-DrugBank.d558.s33	197	205	phenytoin	drug	DDI-DrugBank.d558.s33.e3
DDI-DrugBank.d558.s33	208	219	theophylline	drug	DDI-DrugBank.d558.s33.e4
DDI-DrugBank.d558.s33	230	243	contraceptives	group	DDI-DrugBank.d558.s33.e5
DDI-DrugBank.d558.s33	false	DDI-DrugBank.d558.s33.e0	DDI-DrugBank.d558.s33.e1
DDI-DrugBank.d558.s33	false	DDI-DrugBank.d558.s33.e0	DDI-DrugBank.d558.s33.e2
DDI-DrugBank.d558.s33	false	DDI-DrugBank.d558.s33.e0	DDI-DrugBank.d558.s33.e3
DDI-DrugBank.d558.s33	false	DDI-DrugBank.d558.s33.e0	DDI-DrugBank.d558.s33.e4
DDI-DrugBank.d558.s33	false	DDI-DrugBank.d558.s33.e0	DDI-DrugBank.d558.s33.e5
DDI-DrugBank.d558.s33	false	DDI-DrugBank.d558.s33.e1	DDI-DrugBank.d558.s33.e2
DDI-DrugBank.d558.s33	false	DDI-DrugBank.d558.s33.e1	DDI-DrugBank.d558.s33.e3
DDI-DrugBank.d558.s33	false	DDI-DrugBank.d558.s33.e1	DDI-DrugBank.d558.s33.e4
DDI-DrugBank.d558.s33	false	DDI-DrugBank.d558.s33.e1	DDI-DrugBank.d558.s33.e5
DDI-DrugBank.d558.s33	false	DDI-DrugBank.d558.s33.e2	DDI-DrugBank.d558.s33.e3
DDI-DrugBank.d558.s34|a|Population pharmacokinetic analyses were conducted on plasma concentration data from 1445 patients in clinical trials to examine the effects of concomitant medications on clearance or volume of distribution of dofetilide.
DDI-DrugBank.d558.s34	210	219	dofetilide	drug	DDI-DrugBank.d558.s34.e0
DDI-DrugBank.d558.s35|a|Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
DDI-DrugBank.d558.s35	40	53	ACE inhibitors	group	DDI-DrugBank.d558.s35.e0
DDI-DrugBank.d558.s35	61	74	anticoagulants	group	DDI-DrugBank.d558.s35.e1
DDI-DrugBank.d558.s35	77	100	calcium channel blockers	group	DDI-DrugBank.d558.s35.e2
DDI-DrugBank.d558.s35	103	115	beta blockers	group	DDI-DrugBank.d558.s35.e3
DDI-DrugBank.d558.s35	118	135	cardiac glycosides	group	DDI-DrugBank.d558.s35.e4
DDI-DrugBank.d558.s35	240	247	nitrates	group	DDI-DrugBank.d558.s35.e5
DDI-DrugBank.d558.s35	250	263	sulphonylureas	group	DDI-DrugBank.d558.s35.e6
DDI-DrugBank.d558.s35	266	279	loop diuretics	group	DDI-DrugBank.d558.s35.e7
DDI-DrugBank.d558.s35	282	308	potassium sparing diuretics	group	DDI-DrugBank.d558.s35.e8
DDI-DrugBank.d558.s35	311	328	thiazide diuretics	group	DDI-DrugBank.d558.s35.e9
DDI-DrugBank.d558.s35	false	DDI-DrugBank.d558.s35.e0	DDI-DrugBank.d558.s35.e1
DDI-DrugBank.d558.s35	false	DDI-DrugBank.d558.s35.e0	DDI-DrugBank.d558.s35.e2
DDI-DrugBank.d558.s35	false	DDI-DrugBank.d558.s35.e0	DDI-DrugBank.d558.s35.e3
DDI-DrugBank.d558.s35	false	DDI-DrugBank.d558.s35.e0	DDI-DrugBank.d558.s35.e4
DDI-DrugBank.d558.s35	false	DDI-DrugBank.d558.s35.e0	DDI-DrugBank.d558.s35.e5
DDI-DrugBank.d558.s35	false	DDI-DrugBank.d558.s35.e0	DDI-DrugBank.d558.s35.e6
DDI-DrugBank.d558.s35	false	DDI-DrugBank.d558.s35.e0	DDI-DrugBank.d558.s35.e7
DDI-DrugBank.d558.s35	false	DDI-DrugBank.d558.s35.e0	DDI-DrugBank.d558.s35.e8
DDI-DrugBank.d558.s35	false	DDI-DrugBank.d558.s35.e0	DDI-DrugBank.d558.s35.e9
DDI-DrugBank.d558.s35	false	DDI-DrugBank.d558.s35.e1	DDI-DrugBank.d558.s35.e2
DDI-DrugBank.d558.s36|a|Differences in clearance between patients on these medications (at any occasion in the study) and those off medications varied between -16% and +3%.
DDI-DrugBank.d558.s37|a|The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.
DDI-DrugBank.d558.s37	23	32	dofetilide	drug	DDI-DrugBank.d558.s37.e0
DDI-DrugBank.d558.s37	72	89	thiazide diuretics	group	DDI-DrugBank.d558.s37.e1
DDI-DrugBank.d558.s37	true	DDI-DrugBank.d558.s37.e0	DDI-DrugBank.d558.s37.e1
DDI-DrugBank.d42.s0|a|The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.
DDI-DrugBank.d42.s0	73	82	dolasetron	drug	DDI-DrugBank.d42.s0.e0
DDI-DrugBank.d42.s0	88	102	hydrodolasetron	drug_n	DDI-DrugBank.d42.s0.e1
DDI-DrugBank.d42.s0	182	196	hydrodolasetron	drug_n	DDI-DrugBank.d42.s0.e2
DDI-DrugBank.d42.s0	false	DDI-DrugBank.d42.s0.e0	DDI-DrugBank.d42.s0.e1
DDI-DrugBank.d42.s0	false	DDI-DrugBank.d42.s0.e0	DDI-DrugBank.d42.s0.e2
DDI-DrugBank.d42.s0	false	DDI-DrugBank.d42.s0.e1	DDI-DrugBank.d42.s0.e2
DDI-DrugBank.d42.s1|a|Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
DDI-DrugBank.d42.s1	16	30	hydrodolasetron	drug_n	DDI-DrugBank.d42.s1.e0
DDI-DrugBank.d42.s1	51	60	dolasetron	drug	DDI-DrugBank.d42.s1.e1
DDI-DrugBank.d42.s1	86	95	cimetidine	drug	DDI-DrugBank.d42.s1.e2
DDI-DrugBank.d42.s1	197	204	rifampin	drug	DDI-DrugBank.d42.s1.e3
DDI-DrugBank.d42.s1	false	DDI-DrugBank.d42.s1.e0	DDI-DrugBank.d42.s1.e1
DDI-DrugBank.d42.s1	false	DDI-DrugBank.d42.s1.e0	DDI-DrugBank.d42.s1.e2
DDI-DrugBank.d42.s1	false	DDI-DrugBank.d42.s1.e0	DDI-DrugBank.d42.s1.e3
DDI-DrugBank.d42.s1	true	DDI-DrugBank.d42.s1.e1	DDI-DrugBank.d42.s1.e2
DDI-DrugBank.d42.s1	true	DDI-DrugBank.d42.s1.e1	DDI-DrugBank.d42.s1.e3
DDI-DrugBank.d42.s1	false	DDI-DrugBank.d42.s1.e2	DDI-DrugBank.d42.s1.e3
DDI-DrugBank.d42.s2|a|Dolasetron has been safely coadministered with drugs used in chemotherapy and surgery.
DDI-DrugBank.d42.s2	0	9	Dolasetron	drug	DDI-DrugBank.d42.s2.e0
DDI-DrugBank.d42.s3|a|As with other agents which prolong ECG intervals, caution should be exercised in patients taking drugs which prolong ECG intervals, particularly QTc.
DDI-DrugBank.d42.s4|a|In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
DDI-DrugBank.d42.s4	19	28	furosemide	drug	DDI-DrugBank.d42.s4.e0
DDI-DrugBank.d42.s4	31	40	nifedipine	drug	DDI-DrugBank.d42.s4.e1
DDI-DrugBank.d42.s4	43	51	diltiazem	drug	DDI-DrugBank.d42.s4.e2
DDI-DrugBank.d42.s4	54	67	ACE inhibitors	group	DDI-DrugBank.d42.s4.e3
DDI-DrugBank.d42.s4	70	78	verapamil	drug	DDI-DrugBank.d42.s4.e4
DDI-DrugBank.d42.s4	81	89	glyburide	drug	DDI-DrugBank.d42.s4.e5
DDI-DrugBank.d42.s4	92	102	propranolol	drug	DDI-DrugBank.d42.s4.e6
DDI-DrugBank.d42.s4	178	192	hydrodolasetron	drug_n	DDI-DrugBank.d42.s4.e7
DDI-DrugBank.d42.s4	false	DDI-DrugBank.d42.s4.e0	DDI-DrugBank.d42.s4.e1
DDI-DrugBank.d42.s4	false	DDI-DrugBank.d42.s4.e0	DDI-DrugBank.d42.s4.e2
DDI-DrugBank.d42.s4	false	DDI-DrugBank.d42.s4.e0	DDI-DrugBank.d42.s4.e3
DDI-DrugBank.d42.s4	false	DDI-DrugBank.d42.s4.e0	DDI-DrugBank.d42.s4.e4
DDI-DrugBank.d42.s4	false	DDI-DrugBank.d42.s4.e0	DDI-DrugBank.d42.s4.e5
DDI-DrugBank.d42.s4	false	DDI-DrugBank.d42.s4.e0	DDI-DrugBank.d42.s4.e6
DDI-DrugBank.d42.s4	false	DDI-DrugBank.d42.s4.e0	DDI-DrugBank.d42.s4.e7
DDI-DrugBank.d42.s4	false	DDI-DrugBank.d42.s4.e1	DDI-DrugBank.d42.s4.e2
DDI-DrugBank.d42.s4	false	DDI-DrugBank.d42.s4.e1	DDI-DrugBank.d42.s4.e3
DDI-DrugBank.d42.s4	false	DDI-DrugBank.d42.s4.e1	DDI-DrugBank.d42.s4.e4
DDI-DrugBank.d42.s5|a|Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.
DDI-DrugBank.d42.s5	13	27	hydrodolasetron	drug_n	DDI-DrugBank.d42.s5.e0
DDI-DrugBank.d42.s5	57	75	dolasetron mesylate	drug	DDI-DrugBank.d42.s5.e1
DDI-DrugBank.d42.s5	127	134	atenolol	drug	DDI-DrugBank.d42.s5.e2
DDI-DrugBank.d42.s5	false	DDI-DrugBank.d42.s5.e0	DDI-DrugBank.d42.s5.e1
DDI-DrugBank.d42.s5	false	DDI-DrugBank.d42.s5.e0	DDI-DrugBank.d42.s5.e2
DDI-DrugBank.d42.s5	true	DDI-DrugBank.d42.s5.e1	DDI-DrugBank.d42.s5.e2
DDI-DrugBank.d42.s6|a|Dolasetron does not influence anesthesia recovery time in patients.
DDI-DrugBank.d42.s6	0	9	Dolasetron	drug	DDI-DrugBank.d42.s6.e0
DDI-DrugBank.d42.s7|a|Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.
DDI-DrugBank.d42.s7	0	18	Dolasetron mesylate	drug	DDI-DrugBank.d42.s7.e0
DDI-DrugBank.d42.s7	67	89	chemotherapeutic agents	group	DDI-DrugBank.d42.s7.e1
DDI-DrugBank.d42.s7	92	100	cisplatin	drug	DDI-DrugBank.d42.s7.e2
DDI-DrugBank.d42.s7	103	116	5-fluorouracil	drug	DDI-DrugBank.d42.s7.e3
DDI-DrugBank.d42.s7	119	129	doxorubicin	drug	DDI-DrugBank.d42.s7.e4
DDI-DrugBank.d42.s7	132	147	cyclophosphamide	drug	DDI-DrugBank.d42.s7.e5
DDI-DrugBank.d42.s7	false	DDI-DrugBank.d42.s7.e0	DDI-DrugBank.d42.s7.e1
DDI-DrugBank.d42.s7	false	DDI-DrugBank.d42.s7.e0	DDI-DrugBank.d42.s7.e2
DDI-DrugBank.d42.s7	false	DDI-DrugBank.d42.s7.e0	DDI-DrugBank.d42.s7.e3
DDI-DrugBank.d42.s7	false	DDI-DrugBank.d42.s7.e0	DDI-DrugBank.d42.s7.e4
DDI-DrugBank.d42.s7	false	DDI-DrugBank.d42.s7.e0	DDI-DrugBank.d42.s7.e5
DDI-DrugBank.d42.s7	false	DDI-DrugBank.d42.s7.e1	DDI-DrugBank.d42.s7.e2
DDI-DrugBank.d42.s7	false	DDI-DrugBank.d42.s7.e1	DDI-DrugBank.d42.s7.e3
DDI-DrugBank.d42.s7	false	DDI-DrugBank.d42.s7.e1	DDI-DrugBank.d42.s7.e4
DDI-DrugBank.d42.s7	false	DDI-DrugBank.d42.s7.e1	DDI-DrugBank.d42.s7.e5
DDI-DrugBank.d42.s7	false	DDI-DrugBank.d42.s7.e2	DDI-DrugBank.d42.s7.e3
DDI-DrugBank.d319.s0|a|Drugs that inhibit or Induce CYP 2D6 and CYP 3A4 may affect the concentration on Aricept.
DDI-DrugBank.d319.s0	81	87	Aricept	brand	DDI-DrugBank.d319.s0.e0
DDI-DrugBank.d325.s0|a|Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.
DDI-DrugBank.d325.s0	8	15	dopamine	drug	DDI-DrugBank.d325.s0.e0
DDI-DrugBank.d325.s0	125	132	dopamine	drug	DDI-DrugBank.d325.s0.e1
DDI-DrugBank.d325.s0	false	DDI-DrugBank.d325.s0.e0	DDI-DrugBank.d325.s0.e1
DDI-DrugBank.d325.s1|a|Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.
DDI-DrugBank.d325.s1	36	49	MAO inhibitors	group	DDI-DrugBank.d325.s1.e0
DDI-DrugBank.d325.s1	108	119	dopamine HCl	drug	DDI-DrugBank.d325.s1.e1
DDI-DrugBank.d325.s1	153	164	dopamine HCl	drug	DDI-DrugBank.d325.s1.e2
DDI-DrugBank.d325.s1	true	DDI-DrugBank.d325.s1.e0	DDI-DrugBank.d325.s1.e1
DDI-DrugBank.d325.s1	false	DDI-DrugBank.d325.s1.e0	DDI-DrugBank.d325.s1.e2
DDI-DrugBank.d325.s1	false	DDI-DrugBank.d325.s1.e1	DDI-DrugBank.d325.s1.e2
DDI-DrugBank.d325.s2|a|Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.
DDI-DrugBank.d325.s2	38	49	dopamine HCl	drug	DDI-DrugBank.d325.s2.e0
DDI-DrugBank.d325.s2	55	69	diuretic agents	group	DDI-DrugBank.d325.s2.e1
DDI-DrugBank.d325.s2	true	DDI-DrugBank.d325.s2.e0	DDI-DrugBank.d325.s2.e1
DDI-DrugBank.d325.s3|a|Tricyclic antidepressants may potentiate the cardiovascular effects of adreneric agents.
DDI-DrugBank.d325.s3	0	24	Tricyclic antidepressants	group	DDI-DrugBank.d325.s3.e0
DDI-DrugBank.d325.s4|a|Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
DDI-DrugBank.d325.s4	19	26	dopamine	drug	DDI-DrugBank.d325.s4.e0
DDI-DrugBank.d325.s4	47	77	beta-adrenergic blocking agents	group	DDI-DrugBank.d325.s4.e1
DDI-DrugBank.d325.s4	88	98	propranolol	drug	DDI-DrugBank.d325.s4.e2
DDI-DrugBank.d325.s4	104	113	metoprolol	drug	DDI-DrugBank.d325.s4.e3
DDI-DrugBank.d325.s4	true	DDI-DrugBank.d325.s4.e0	DDI-DrugBank.d325.s4.e1
DDI-DrugBank.d325.s4	true	DDI-DrugBank.d325.s4.e0	DDI-DrugBank.d325.s4.e2
DDI-DrugBank.d325.s4	true	DDI-DrugBank.d325.s4.e0	DDI-DrugBank.d325.s4.e3
DDI-DrugBank.d325.s4	false	DDI-DrugBank.d325.s4.e1	DDI-DrugBank.d325.s4.e2
DDI-DrugBank.d325.s4	false	DDI-DrugBank.d325.s4.e1	DDI-DrugBank.d325.s4.e3
DDI-DrugBank.d325.s4	false	DDI-DrugBank.d325.s4.e2	DDI-DrugBank.d325.s4.e3
DDI-DrugBank.d325.s5|a|The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.
DDI-DrugBank.d325.s5	56	67	dopamine HCl	drug	DDI-DrugBank.d325.s5.e0
DDI-DrugBank.d325.s5	87	118	alpha-adrenergic blocking agents	group	DDI-DrugBank.d325.s5.e1
DDI-DrugBank.d325.s5	true	DDI-DrugBank.d325.s5.e0	DDI-DrugBank.d325.s5.e1
DDI-DrugBank.d325.s6|a|Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or beta-adrenergic blocking agents.
DDI-DrugBank.d325.s6	0	7	Dopamine	drug	DDI-DrugBank.d325.s6.e0
DDI-DrugBank.d325.s6	80	85	alpha-adrenergic blocking agents	group	DDI-DrugBank.d325.s6.e1
DDI-DrugBank.d325.s6	95	120	alpha-adrenergic blocking agents	group	DDI-DrugBank.d325.s6.e1
DDI-DrugBank.d325.s6	90	120	beta-adrenergic blocking agents	drug	DDI-DrugBank.d325.s6.e2
DDI-DrugBank.d325.s6	false	DDI-DrugBank.d325.s6.e0	DDI-DrugBank.d325.s6.e1
DDI-DrugBank.d325.s6	false	DDI-DrugBank.d325.s6.e0	DDI-DrugBank.d325.s6.e2
DDI-DrugBank.d325.s6	false	DDI-DrugBank.d325.s6.e1	DDI-DrugBank.d325.s6.e2
DDI-DrugBank.d325.s7|a|Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
DDI-DrugBank.d325.s7	0	13	Butyrophenones	group	DDI-DrugBank.d325.s7.e0
DDI-DrugBank.d325.s7	24	34	haloperidol	drug	DDI-DrugBank.d325.s7.e1
DDI-DrugBank.d325.s7	41	54	phenothiazines	group	DDI-DrugBank.d325.s7.e2
DDI-DrugBank.d325.s7	73	80	dopamine	drug	DDI-DrugBank.d325.s7.e3
DDI-DrugBank.d325.s7	false	DDI-DrugBank.d325.s7.e0	DDI-DrugBank.d325.s7.e1
DDI-DrugBank.d325.s7	false	DDI-DrugBank.d325.s7.e0	DDI-DrugBank.d325.s7.e2
DDI-DrugBank.d325.s7	true	DDI-DrugBank.d325.s7.e0	DDI-DrugBank.d325.s7.e3
DDI-DrugBank.d325.s7	false	DDI-DrugBank.d325.s7.e1	DDI-DrugBank.d325.s7.e2
DDI-DrugBank.d325.s7	true	DDI-DrugBank.d325.s7.e1	DDI-DrugBank.d325.s7.e3
DDI-DrugBank.d325.s7	true	DDI-DrugBank.d325.s7.e2	DDI-DrugBank.d325.s7.e3
DDI-DrugBank.d325.s8|a|Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
DDI-DrugBank.d325.s8	0	11	Cyclopropane	drug	DDI-DrugBank.d325.s8.e0
DDI-DrugBank.d325.s8	16	50	halogenated hydrocarbon anesthetics	group	DDI-DrugBank.d325.s8.e1
DDI-DrugBank.d325.s8	177	190	catecholamines	group	DDI-DrugBank.d325.s8.e2
DDI-DrugBank.d325.s8	201	208	dopamine	drug	DDI-DrugBank.d325.s8.e3
DDI-DrugBank.d325.s8	false	DDI-DrugBank.d325.s8.e0	DDI-DrugBank.d325.s8.e1
DDI-DrugBank.d325.s8	true	DDI-DrugBank.d325.s8.e0	DDI-DrugBank.d325.s8.e2
DDI-DrugBank.d325.s8	true	DDI-DrugBank.d325.s8.e0	DDI-DrugBank.d325.s8.e3
DDI-DrugBank.d325.s8	true	DDI-DrugBank.d325.s8.e1	DDI-DrugBank.d325.s8.e2
DDI-DrugBank.d325.s8	true	DDI-DrugBank.d325.s8.e1	DDI-DrugBank.d325.s8.e3
DDI-DrugBank.d325.s8	false	DDI-DrugBank.d325.s8.e2	DDI-DrugBank.d325.s8.e3
DDI-DrugBank.d325.s9|a|This interaction appears to be related both to pressor activity and to beta-adrenergic stimulating properties of these catecholamines and may produce ventricular arrhythmias and hypertension.
DDI-DrugBank.d325.s9	119	132	catecholamines	group	DDI-DrugBank.d325.s9.e0
DDI-DrugBank.d325.s10|a|Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.
DDI-DrugBank.d325.s10	66	77	dopamine HCl	drug	DDI-DrugBank.d325.s10.e0
DDI-DrugBank.d325.s10	101	112	cyclopropane	drug	DDI-DrugBank.d325.s10.e1
DDI-DrugBank.d325.s10	117	151	halogenated hydrocarbon anesthetics	group	DDI-DrugBank.d325.s10.e2
DDI-DrugBank.d325.s10	true	DDI-DrugBank.d325.s10.e0	DDI-DrugBank.d325.s10.e1
DDI-DrugBank.d325.s10	true	DDI-DrugBank.d325.s10.e0	DDI-DrugBank.d325.s10.e2
DDI-DrugBank.d325.s10	false	DDI-DrugBank.d325.s10.e1	DDI-DrugBank.d325.s10.e2
DDI-DrugBank.d325.s11|a|It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.
DDI-DrugBank.d325.s11	70	77	dopamine	drug	DDI-DrugBank.d325.s11.e0
DDI-DrugBank.d325.s11	148	158	propranolol	drug	DDI-DrugBank.d325.s11.e1
DDI-DrugBank.d325.s11	true	DDI-DrugBank.d325.s11.e0	DDI-DrugBank.d325.s11.e1
DDI-DrugBank.d325.s12|a|The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.
DDI-DrugBank.d325.s12	23	33	vasopressor	group	DDI-DrugBank.d325.s12.e0
DDI-DrugBank.d325.s12	70	79	ergonovine	drug	DDI-DrugBank.d325.s12.e1
DDI-DrugBank.d325.s12	91	104	oxytocic drugs	group	DDI-DrugBank.d325.s12.e2
DDI-DrugBank.d325.s12	false	DDI-DrugBank.d325.s12.e0	DDI-DrugBank.d325.s12.e1
DDI-DrugBank.d325.s12	true	DDI-DrugBank.d325.s12.e0	DDI-DrugBank.d325.s12.e2
DDI-DrugBank.d325.s12	true	DDI-DrugBank.d325.s12.e1	DDI-DrugBank.d325.s12.e2
DDI-DrugBank.d325.s13|a|Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.
DDI-DrugBank.d325.s13	18	26	phenytoin	drug	DDI-DrugBank.d325.s13.e0
DDI-DrugBank.d325.s13	50	61	dopamine HCl	drug	DDI-DrugBank.d325.s13.e1
DDI-DrugBank.d325.s13	true	DDI-DrugBank.d325.s13.e0	DDI-DrugBank.d325.s13.e1
DDI-DrugBank.d325.s14|a|It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.
DDI-DrugBank.d325.s14	43	54	dopamine HCl	drug	DDI-DrugBank.d325.s14.e0
DDI-DrugBank.d325.s14	73	81	phenytoin	drug	DDI-DrugBank.d325.s14.e1
DDI-DrugBank.d325.s14	101	114	anticonvulsant	group	DDI-DrugBank.d325.s14.e2
DDI-DrugBank.d325.s14	true	DDI-DrugBank.d325.s14.e0	DDI-DrugBank.d325.s14.e1
DDI-DrugBank.d325.s14	false	DDI-DrugBank.d325.s14.e0	DDI-DrugBank.d325.s14.e2
DDI-DrugBank.d325.s14	false	DDI-DrugBank.d325.s14.e1	DDI-DrugBank.d325.s14.e2
DDI-DrugBank.d93.s0|a|Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.
DDI-DrugBank.d93.s0	36	44	Pulmozyme	brand	DDI-DrugBank.d93.s0.e0
DDI-DrugBank.d93.s0	178	188	antibiotics	group	DDI-DrugBank.d93.s0.e1
DDI-DrugBank.d93.s0	191	205	bronchodilators	group	DDI-DrugBank.d93.s0.e2
DDI-DrugBank.d93.s0	228	235	vitamins	group	DDI-DrugBank.d93.s0.e3
DDI-DrugBank.d93.s0	254	268	corticosteroids	group	DDI-DrugBank.d93.s0.e4
DDI-DrugBank.d93.s0	275	284	analgesics	group	DDI-DrugBank.d93.s0.e5
DDI-DrugBank.d93.s0	false	DDI-DrugBank.d93.s0.e0	DDI-DrugBank.d93.s0.e1
DDI-DrugBank.d93.s0	false	DDI-DrugBank.d93.s0.e0	DDI-DrugBank.d93.s0.e2
DDI-DrugBank.d93.s0	false	DDI-DrugBank.d93.s0.e0	DDI-DrugBank.d93.s0.e3
DDI-DrugBank.d93.s0	false	DDI-DrugBank.d93.s0.e0	DDI-DrugBank.d93.s0.e4
DDI-DrugBank.d93.s0	false	DDI-DrugBank.d93.s0.e0	DDI-DrugBank.d93.s0.e5
DDI-DrugBank.d93.s0	false	DDI-DrugBank.d93.s0.e1	DDI-DrugBank.d93.s0.e2
DDI-DrugBank.d93.s0	false	DDI-DrugBank.d93.s0.e1	DDI-DrugBank.d93.s0.e3
DDI-DrugBank.d93.s0	false	DDI-DrugBank.d93.s0.e1	DDI-DrugBank.d93.s0.e4
DDI-DrugBank.d93.s0	false	DDI-DrugBank.d93.s0.e1	DDI-DrugBank.d93.s0.e5
DDI-DrugBank.d93.s0	false	DDI-DrugBank.d93.s0.e2	DDI-DrugBank.d93.s0.e3
DDI-DrugBank.d93.s1|a|No formal drug interaction studies have been performed.
DDI-DrugBank.d34.s0|a|Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).
DDI-DrugBank.d34.s0	94	104	dorzolamide	drug	DDI-DrugBank.d34.s0.e0
DDI-DrugBank.d34.s0	155	183	carbonic anhydrase inhibitors	group	DDI-DrugBank.d34.s0.e1
DDI-DrugBank.d34.s0	286	295	salicylate	group	DDI-DrugBank.d34.s0.e2
DDI-DrugBank.d34.s0	true	DDI-DrugBank.d34.s0.e0	DDI-DrugBank.d34.s0.e1
DDI-DrugBank.d34.s0	false	DDI-DrugBank.d34.s0.e0	DDI-DrugBank.d34.s0.e2
DDI-DrugBank.d34.s0	false	DDI-DrugBank.d34.s0.e1	DDI-DrugBank.d34.s0.e2
DDI-DrugBank.d34.s1|a|Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide.
DDI-DrugBank.d34.s1	95	105	dorzolamide	drug	DDI-DrugBank.d34.s1.e0
DDI-DrugBank.d267.s0|a|Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX.
DDI-DrugBank.d267.s0	24	38	succinylcholine	drug	DDI-DrugBank.d267.s0.e0
DDI-DrugBank.d267.s0	115	121	NUROMAX	brand	DDI-DrugBank.d267.s0.e1
DDI-DrugBank.d267.s0	false	DDI-DrugBank.d267.s0.e0	DDI-DrugBank.d267.s0.e1
DDI-DrugBank.d267.s1|a|The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
DDI-DrugBank.d267.s1	11	17	NUROMAX	brand	DDI-DrugBank.d267.s1.e0
DDI-DrugBank.d267.s1	26	40	succinylcholine	drug	DDI-DrugBank.d267.s1.e1
DDI-DrugBank.d267.s1	83	97	succinylcholine	drug	DDI-DrugBank.d267.s1.e2
DDI-DrugBank.d267.s1	false	DDI-DrugBank.d267.s1.e0	DDI-DrugBank.d267.s1.e1
DDI-DrugBank.d267.s1	false	DDI-DrugBank.d267.s1.e0	DDI-DrugBank.d267.s1.e2
DDI-DrugBank.d267.s1	false	DDI-DrugBank.d267.s1.e1	DDI-DrugBank.d267.s1.e2
DDI-DrugBank.d267.s2|a|There are no clinical data on concomitant use of NUROMAX and other nondepolarizing neuromuscular blocking agents.
DDI-DrugBank.d267.s2	49	55	NUROMAX	brand	DDI-DrugBank.d267.s2.e0
DDI-DrugBank.d267.s2	83	111	neuromuscular blocking agents	group	DDI-DrugBank.d267.s2.e1
DDI-DrugBank.d267.s2	false	DDI-DrugBank.d267.s2.e0	DDI-DrugBank.d267.s2.e1
DDI-DrugBank.d267.s3|a|Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
DDI-DrugBank.d267.s3	0	9	Isoflurane	drug	DDI-DrugBank.d267.s3.e0
DDI-DrugBank.d267.s3	12	20	enflurane	drug	DDI-DrugBank.d267.s3.e1
DDI-DrugBank.d267.s3	27	35	halothane	drug	DDI-DrugBank.d267.s3.e2
DDI-DrugBank.d267.s3	58	64	NUROMAX	brand	DDI-DrugBank.d267.s3.e3
DDI-DrugBank.d267.s3	false	DDI-DrugBank.d267.s3.e0	DDI-DrugBank.d267.s3.e1
DDI-DrugBank.d267.s3	false	DDI-DrugBank.d267.s3.e0	DDI-DrugBank.d267.s3.e2
DDI-DrugBank.d267.s3	true	DDI-DrugBank.d267.s3.e0	DDI-DrugBank.d267.s3.e3
DDI-DrugBank.d267.s3	false	DDI-DrugBank.d267.s3.e1	DDI-DrugBank.d267.s3.e2
DDI-DrugBank.d267.s3	true	DDI-DrugBank.d267.s3.e1	DDI-DrugBank.d267.s3.e3
DDI-DrugBank.d267.s3	true	DDI-DrugBank.d267.s3.e2	DDI-DrugBank.d267.s3.e3
DDI-DrugBank.d267.s4|a|These agents may also prolong the clinically effective duration of action by up to 25%.
DDI-DrugBank.d267.s5|a|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s5	98	104	NUROMAX	brand	DDI-DrugBank.d267.s5.e0
DDI-DrugBank.d267.s5	122	132	antibiotics	group	DDI-DrugBank.d267.s5.e1
DDI-DrugBank.d267.s5	142	156	aminoglycosides	group	DDI-DrugBank.d267.s5.e2
DDI-DrugBank.d267.s5	159	171	tetracyclines	group	DDI-DrugBank.d267.s5.e3
DDI-DrugBank.d267.s5	174	183	bacitracin	group	DDI-DrugBank.d267.s5.e4
DDI-DrugBank.d267.s5	186	195	polymyxins	group	DDI-DrugBank.d267.s5.e5
DDI-DrugBank.d267.s5	198	207	lincomycin	drug	DDI-DrugBank.d267.s5.e6
DDI-DrugBank.d267.s5	210	220	clindamycin	drug	DDI-DrugBank.d267.s5.e7
DDI-DrugBank.d267.s5	223	230	colistin	drug	DDI-DrugBank.d267.s5.e8
DDI-DrugBank.d267.s5	237	257	sodium colistimethate	drug	DDI-DrugBank.d267.s5.e9
DDI-DrugBank.d267.s5	true	DDI-DrugBank.d267.s5.e0	DDI-DrugBank.d267.s5.e1
DDI-DrugBank.d267.s5	true	DDI-DrugBank.d267.s5.e0	DDI-DrugBank.d267.s5.e2
DDI-DrugBank.d267.s5	true	DDI-DrugBank.d267.s5.e0	DDI-DrugBank.d267.s5.e3
DDI-DrugBank.d267.s5	true	DDI-DrugBank.d267.s5.e0	DDI-DrugBank.d267.s5.e4
DDI-DrugBank.d267.s5	true	DDI-DrugBank.d267.s5.e0	DDI-DrugBank.d267.s5.e5
DDI-DrugBank.d267.s5	true	DDI-DrugBank.d267.s5.e0	DDI-DrugBank.d267.s5.e6
DDI-DrugBank.d267.s5	true	DDI-DrugBank.d267.s5.e0	DDI-DrugBank.d267.s5.e7
DDI-DrugBank.d267.s5	true	DDI-DrugBank.d267.s5.e0	DDI-DrugBank.d267.s5.e8
DDI-DrugBank.d267.s5	true	DDI-DrugBank.d267.s5.e0	DDI-DrugBank.d267.s5.e9
DDI-DrugBank.d267.s5	true	DDI-DrugBank.d267.s5.e0	DDI-DrugBank.d267.s5.e10
DDI-DrugBank.d267.s6|a|As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
DDI-DrugBank.d267.s6	19	63	nondepolarizing neuromuscular blocking agents	group	DDI-DrugBank.d267.s6.e0
DDI-DrugBank.d267.s6	118	124	NUROMAX	brand	DDI-DrugBank.d267.s6.e1
DDI-DrugBank.d267.s6	201	209	phenytoin	drug	DDI-DrugBank.d267.s6.e2
DDI-DrugBank.d267.s6	214	226	carbamazepine	drug	DDI-DrugBank.d267.s6.e3
DDI-DrugBank.d267.s6	false	DDI-DrugBank.d267.s6.e0	DDI-DrugBank.d267.s6.e1
DDI-DrugBank.d267.s6	true	DDI-DrugBank.d267.s6.e0	DDI-DrugBank.d267.s6.e2
DDI-DrugBank.d267.s6	true	DDI-DrugBank.d267.s6.e0	DDI-DrugBank.d267.s6.e3
DDI-DrugBank.d267.s6	true	DDI-DrugBank.d267.s6.e1	DDI-DrugBank.d267.s6.e2
DDI-DrugBank.d267.s6	true	DDI-DrugBank.d267.s6.e1	DDI-DrugBank.d267.s6.e3
DDI-DrugBank.d267.s6	false	DDI-DrugBank.d267.s6.e2	DDI-DrugBank.d267.s6.e3
DDI-DrugBank.d332.s0|a|Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
DDI-DrugBank.d332.s0	18	25	doxapram	drug	DDI-DrugBank.d332.s0.e0
DDI-DrugBank.d332.s0	57	71	sympathomimetic	group	DDI-DrugBank.d332.s0.e1
DDI-DrugBank.d332.s0	76	109	monoamine oxidase inhibiting drugs	group	DDI-DrugBank.d332.s0.e2
DDI-DrugBank.d332.s0	true	DDI-DrugBank.d332.s0.e0	DDI-DrugBank.d332.s0.e1
DDI-DrugBank.d332.s0	true	DDI-DrugBank.d332.s0.e0	DDI-DrugBank.d332.s0.e2
DDI-DrugBank.d332.s0	false	DDI-DrugBank.d332.s0.e1	DDI-DrugBank.d332.s0.e2
DDI-DrugBank.d332.s1|a|In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.
DDI-DrugBank.d332.s1	30	45	muscle relaxants	group	DDI-DrugBank.d332.s1.e0
DDI-DrugBank.d332.s1	48	55	doxapram	drug	DDI-DrugBank.d332.s1.e1
DDI-DrugBank.d332.s1	102	122	muscle relaxant drugs	group	DDI-DrugBank.d332.s1.e2
DDI-DrugBank.d332.s1	false	DDI-DrugBank.d332.s1.e0	DDI-DrugBank.d332.s1.e1
DDI-DrugBank.d332.s1	false	DDI-DrugBank.d332.s1.e0	DDI-DrugBank.d332.s1.e2
DDI-DrugBank.d332.s1	true	DDI-DrugBank.d332.s1.e1	DDI-DrugBank.d332.s1.e2
DDI-DrugBank.d332.s2|a|In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for arrhythmias, including ventricular tachycardia and ventricular fibrillation.
DDI-DrugBank.d332.s2	147	154	doxapram	drug	DDI-DrugBank.d332.s2.e0
DDI-DrugBank.d367.s0|a|Most (98%) of plasma doxazosin is protein bound.
DDI-DrugBank.d367.s0	21	29	doxazosin	drug	DDI-DrugBank.d367.s0.e0
DDI-DrugBank.d367.s1|a|In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin.
DDI-DrugBank.d367.s1	44	61	doxazosin mesylate	drug	DDI-DrugBank.d367.s1.e0
DDI-DrugBank.d367.s1	99	105	digoxin	drug	DDI-DrugBank.d367.s1.e1
DDI-DrugBank.d367.s1	108	115	warfarin	drug	DDI-DrugBank.d367.s1.e2
DDI-DrugBank.d367.s1	118	126	phenytoin	drug	DDI-DrugBank.d367.s1.e3
DDI-DrugBank.d367.s1	131	142	indomethacin	drug	DDI-DrugBank.d367.s1.e4
DDI-DrugBank.d367.s1	false	DDI-DrugBank.d367.s1.e0	DDI-DrugBank.d367.s1.e1
DDI-DrugBank.d367.s1	false	DDI-DrugBank.d367.s1.e0	DDI-DrugBank.d367.s1.e2
DDI-DrugBank.d367.s1	false	DDI-DrugBank.d367.s1.e0	DDI-DrugBank.d367.s1.e3
DDI-DrugBank.d367.s1	false	DDI-DrugBank.d367.s1.e0	DDI-DrugBank.d367.s1.e4
DDI-DrugBank.d367.s1	false	DDI-DrugBank.d367.s1.e1	DDI-DrugBank.d367.s1.e2
DDI-DrugBank.d367.s1	false	DDI-DrugBank.d367.s1.e1	DDI-DrugBank.d367.s1.e3
DDI-DrugBank.d367.s1	false	DDI-DrugBank.d367.s1.e1	DDI-DrugBank.d367.s1.e4
DDI-DrugBank.d367.s1	false	DDI-DrugBank.d367.s1.e2	DDI-DrugBank.d367.s1.e3
DDI-DrugBank.d367.s1	false	DDI-DrugBank.d367.s1.e2	DDI-DrugBank.d367.s1.e4
DDI-DrugBank.d367.s1	false	DDI-DrugBank.d367.s1.e3	DDI-DrugBank.d367.s1.e4
DDI-DrugBank.d367.s2|a|There is no information on the effect of other highly plasma protein bound drugs on doxazosin binding.
DDI-DrugBank.d367.s2	84	92	doxazosin	drug	DDI-DrugBank.d367.s2.e0
DDI-DrugBank.d367.s3|a|Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs.
DDI-DrugBank.d367.s3	0	17	Doxazosin mesylate	drug	DDI-DrugBank.d367.s3.e0
DDI-DrugBank.d367.s3	115	132	thiazide diuretics	group	DDI-DrugBank.d367.s3.e1
DDI-DrugBank.d367.s3	135	153	beta-blocking agent	group	DDI-DrugBank.d367.s3.e2
DDI-DrugBank.d367.s3	161	196	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d367.s3.e3
DDI-DrugBank.d367.s3	false	DDI-DrugBank.d367.s3.e0	DDI-DrugBank.d367.s3.e1
DDI-DrugBank.d367.s3	false	DDI-DrugBank.d367.s3.e0	DDI-DrugBank.d367.s3.e2
DDI-DrugBank.d367.s3	false	DDI-DrugBank.d367.s3.e0	DDI-DrugBank.d367.s3.e3
DDI-DrugBank.d367.s3	false	DDI-DrugBank.d367.s3.e1	DDI-DrugBank.d367.s3.e2
DDI-DrugBank.d367.s3	false	DDI-DrugBank.d367.s3.e1	DDI-DrugBank.d367.s3.e3
DDI-DrugBank.d367.s3	false	DDI-DrugBank.d367.s3.e2	DDI-DrugBank.d367.s3.e3
DDI-DrugBank.d367.s4|a|In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.
DDI-DrugBank.d367.s4	96	104	doxazosin	drug	DDI-DrugBank.d367.s4.e0
DDI-DrugBank.d367.s4	145	154	cimetidine	drug	DDI-DrugBank.d367.s4.e1
DDI-DrugBank.d367.s4	219	227	doxazosin	drug	DDI-DrugBank.d367.s4.e2
DDI-DrugBank.d367.s4	331	339	doxazosin	drug	DDI-DrugBank.d367.s4.e3
DDI-DrugBank.d367.s4	true	DDI-DrugBank.d367.s4.e0	DDI-DrugBank.d367.s4.e1
DDI-DrugBank.d367.s4	false	DDI-DrugBank.d367.s4.e0	DDI-DrugBank.d367.s4.e2
DDI-DrugBank.d367.s4	false	DDI-DrugBank.d367.s4.e0	DDI-DrugBank.d367.s4.e3
DDI-DrugBank.d367.s4	false	DDI-DrugBank.d367.s4.e1	DDI-DrugBank.d367.s4.e2
DDI-DrugBank.d367.s4	false	DDI-DrugBank.d367.s4.e1	DDI-DrugBank.d367.s4.e3
DDI-DrugBank.d367.s4	false	DDI-DrugBank.d367.s4.e2	DDI-DrugBank.d367.s4.e3
DDI-DrugBank.d367.s5|a|The clinical significance of this increase in doxazosin AUC is unknown.
DDI-DrugBank.d367.s5	46	54	doxazosin	drug	DDI-DrugBank.d367.s5.e0
DDI-DrugBank.d367.s6|a|In clinical trials, doxazosin mesylate tablets have been administered to patients on a variety of concomitant medications;
DDI-DrugBank.d367.s6	20	37	doxazosin mesylate	drug	DDI-DrugBank.d367.s6.e0
DDI-DrugBank.d367.s7|a|while no formal interaction studies have been conducted, no interactions were observed.
DDI-DrugBank.d367.s8|a|Doxazosin mesylate tablets have been used with the following drugs or drug classes: 1.
DDI-DrugBank.d367.s8	0	17	Doxazosin mesylate	drug	DDI-DrugBank.d367.s8.e0
DDI-DrugBank.d367.s9|a|Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).
DDI-DrugBank.d367.s9	0	8	Analgesic	group	DDI-DrugBank.d367.s9.e0
DDI-DrugBank.d367.s9	10	26	anti-inflammatory	group	DDI-DrugBank.d367.s9.e1
DDI-DrugBank.d367.s9	35	47	acetaminophen	drug	DDI-DrugBank.d367.s9.e2
DDI-DrugBank.d367.s9	50	56	aspirin	brand	DDI-DrugBank.d367.s9.e3
DDI-DrugBank.d367.s9	59	65	codeine	drug	DDI-DrugBank.d367.s9.e4
DDI-DrugBank.d367.s9	71	77	codeine	drug	DDI-DrugBank.d367.s9.e5
DDI-DrugBank.d367.s9	93	101	ibuprofen	drug	DDI-DrugBank.d367.s9.e6
DDI-DrugBank.d367.s9	104	115	indomethacin	drug	DDI-DrugBank.d367.s9.e7
DDI-DrugBank.d367.s9	false	DDI-DrugBank.d367.s9.e0	DDI-DrugBank.d367.s9.e1
DDI-DrugBank.d367.s9	false	DDI-DrugBank.d367.s9.e0	DDI-DrugBank.d367.s9.e2
DDI-DrugBank.d367.s9	false	DDI-DrugBank.d367.s9.e0	DDI-DrugBank.d367.s9.e3
DDI-DrugBank.d367.s9	false	DDI-DrugBank.d367.s9.e0	DDI-DrugBank.d367.s9.e4
DDI-DrugBank.d367.s9	false	DDI-DrugBank.d367.s9.e0	DDI-DrugBank.d367.s9.e5
DDI-DrugBank.d367.s9	false	DDI-DrugBank.d367.s9.e0	DDI-DrugBank.d367.s9.e6
DDI-DrugBank.d367.s9	false	DDI-DrugBank.d367.s9.e0	DDI-DrugBank.d367.s9.e7
DDI-DrugBank.d367.s9	false	DDI-DrugBank.d367.s9.e1	DDI-DrugBank.d367.s9.e2
DDI-DrugBank.d367.s9	false	DDI-DrugBank.d367.s9.e1	DDI-DrugBank.d367.s9.e3
DDI-DrugBank.d367.s9	false	DDI-DrugBank.d367.s9.e1	DDI-DrugBank.d367.s9.e4
DDI-DrugBank.d367.s10|a|2.
DDI-DrugBank.d367.s11|a|Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin).
DDI-DrugBank.d367.s11	0	10	Antibiotics	group	DDI-DrugBank.d367.s11.e0
DDI-DrugBank.d367.s11	19	30	erythromycin	drug	DDI-DrugBank.d367.s11.e1
DDI-DrugBank.d367.s11	33	44	trimethoprim	drug	DDI-DrugBank.d367.s11.e2
DDI-DrugBank.d367.s11	50	65	sulfamethoxazole	drug	DDI-DrugBank.d367.s11.e3
DDI-DrugBank.d367.s11	68	78	amoxicillin	drug	DDI-DrugBank.d367.s11.e4
DDI-DrugBank.d367.s11	false	DDI-DrugBank.d367.s11.e0	DDI-DrugBank.d367.s11.e1
DDI-DrugBank.d367.s11	false	DDI-DrugBank.d367.s11.e0	DDI-DrugBank.d367.s11.e2
DDI-DrugBank.d367.s11	false	DDI-DrugBank.d367.s11.e0	DDI-DrugBank.d367.s11.e3
DDI-DrugBank.d367.s11	false	DDI-DrugBank.d367.s11.e0	DDI-DrugBank.d367.s11.e4
DDI-DrugBank.d367.s11	false	DDI-DrugBank.d367.s11.e1	DDI-DrugBank.d367.s11.e2
DDI-DrugBank.d367.s11	false	DDI-DrugBank.d367.s11.e1	DDI-DrugBank.d367.s11.e3
DDI-DrugBank.d367.s11	false	DDI-DrugBank.d367.s11.e1	DDI-DrugBank.d367.s11.e4
DDI-DrugBank.d367.s11	false	DDI-DrugBank.d367.s11.e2	DDI-DrugBank.d367.s11.e3
DDI-DrugBank.d367.s11	false	DDI-DrugBank.d367.s11.e2	DDI-DrugBank.d367.s11.e4
DDI-DrugBank.d367.s11	false	DDI-DrugBank.d367.s11.e3	DDI-DrugBank.d367.s11.e4
DDI-DrugBank.d367.s12|a|3.
DDI-DrugBank.d367.s13|a|Antihistamines (e.g., chlorpheniramine).
DDI-DrugBank.d367.s13	0	13	Antihistamines	group	DDI-DrugBank.d367.s13.e0
DDI-DrugBank.d367.s13	22	37	chlorpheniramine	group	DDI-DrugBank.d367.s13.e1
DDI-DrugBank.d367.s13	false	DDI-DrugBank.d367.s13.e0	DDI-DrugBank.d367.s13.e1
DDI-DrugBank.d367.s14|a|4.
DDI-DrugBank.d367.s15|a|Cardiovascular agents (e.g., atenolol, hydrochlorothiazide, propranolol).
DDI-DrugBank.d367.s15	29	36	atenolol	drug	DDI-DrugBank.d367.s15.e0
DDI-DrugBank.d367.s15	39	57	hydrochlorothiazide	drug	DDI-DrugBank.d367.s15.e1
DDI-DrugBank.d367.s15	60	70	propranolol	drug	DDI-DrugBank.d367.s15.e2
DDI-DrugBank.d367.s15	false	DDI-DrugBank.d367.s15.e0	DDI-DrugBank.d367.s15.e1
DDI-DrugBank.d367.s15	false	DDI-DrugBank.d367.s15.e0	DDI-DrugBank.d367.s15.e2
DDI-DrugBank.d367.s15	false	DDI-DrugBank.d367.s15.e1	DDI-DrugBank.d367.s15.e2
DDI-DrugBank.d367.s16|a|5.
DDI-DrugBank.d367.s17|a|Corticosteroids.
DDI-DrugBank.d367.s17	0	14	Corticosteroids	group	DDI-DrugBank.d367.s17.e0
DDI-DrugBank.d367.s18|a|6.
DDI-DrugBank.d367.s19|a|Gastrointestinal agents (e.g., antacids).
DDI-DrugBank.d367.s19	31	38	antacids	group	DDI-DrugBank.d367.s19.e0
DDI-DrugBank.d367.s20|a|7.
DDI-DrugBank.d367.s21|a|Hypoglycemics and endocrine drugs.
DDI-DrugBank.d367.s21	0	12	Hypoglycemics	group	DDI-DrugBank.d367.s21.e0
DDI-DrugBank.d367.s22|a|8.
DDI-DrugBank.d367.s23|a|Sedatives and tranquilizers (e.g., diazepam).
DDI-DrugBank.d367.s23	0	8	Sedatives	group	DDI-DrugBank.d367.s23.e0
DDI-DrugBank.d367.s23	14	26	tranquilizers	group	DDI-DrugBank.d367.s23.e1
DDI-DrugBank.d367.s23	35	42	diazepam	drug	DDI-DrugBank.d367.s23.e2
DDI-DrugBank.d367.s23	false	DDI-DrugBank.d367.s23.e0	DDI-DrugBank.d367.s23.e1
DDI-DrugBank.d367.s23	false	DDI-DrugBank.d367.s23.e0	DDI-DrugBank.d367.s23.e2
DDI-DrugBank.d367.s23	false	DDI-DrugBank.d367.s23.e1	DDI-DrugBank.d367.s23.e2
DDI-DrugBank.d367.s24|a|9.
DDI-DrugBank.d367.s25|a|Cold and flu remedies.
DDI-DrugBank.d223.s0|a|Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called poor metabolizers);
DDI-DrugBank.d223.s1|a|reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
DDI-DrugBank.d223.s2|a|Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
DDI-DrugBank.d223.s2	69	93	tricyclic antidepressants	group	DDI-DrugBank.d223.s2.e0
DDI-DrugBank.d223.s2	96	99	TCAs	group	DDI-DrugBank.d223.s2.e1
DDI-DrugBank.d223.s2	false	DDI-DrugBank.d223.s2.e0	DDI-DrugBank.d223.s2.e1
DDI-DrugBank.d223.s3|a|Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).
DDI-DrugBank.d223.s4|a|In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
DDI-DrugBank.d223.s5|a|An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
DDI-DrugBank.d223.s5	47	49	TCA	group	DDI-DrugBank.d223.s5.e0
DDI-DrugBank.d223.s6|a|The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;
DDI-DrugBank.d223.s6	96	104	quinidine	drug	DDI-DrugBank.d223.s6.e0
DDI-DrugBank.d223.s7|a|cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
DDI-DrugBank.d223.s7	0	9	cimetidine	drug	DDI-DrugBank.d223.s7.e0
DDI-DrugBank.d223.s7	66	80	antidepressants	group	DDI-DrugBank.d223.s7.e1
DDI-DrugBank.d223.s7	83	96	phenothiazines	group	DDI-DrugBank.d223.s7.e2
DDI-DrugBank.d223.s7	107	129	Type 1C antiarrhythmics	group	DDI-DrugBank.d223.s7.e3
DDI-DrugBank.d223.s7	131	141	propafenone	drug	DDI-DrugBank.d223.s7.e4
DDI-DrugBank.d223.s7	147	156	flecainide	drug	DDI-DrugBank.d223.s7.e5
DDI-DrugBank.d223.s7	false	DDI-DrugBank.d223.s7.e0	DDI-DrugBank.d223.s7.e1
DDI-DrugBank.d223.s7	false	DDI-DrugBank.d223.s7.e0	DDI-DrugBank.d223.s7.e2
DDI-DrugBank.d223.s7	false	DDI-DrugBank.d223.s7.e0	DDI-DrugBank.d223.s7.e3
DDI-DrugBank.d223.s7	false	DDI-DrugBank.d223.s7.e0	DDI-DrugBank.d223.s7.e4
DDI-DrugBank.d223.s7	false	DDI-DrugBank.d223.s7.e0	DDI-DrugBank.d223.s7.e5
DDI-DrugBank.d223.s7	false	DDI-DrugBank.d223.s7.e1	DDI-DrugBank.d223.s7.e2
DDI-DrugBank.d223.s7	false	DDI-DrugBank.d223.s7.e1	DDI-DrugBank.d223.s7.e3
DDI-DrugBank.d223.s7	false	DDI-DrugBank.d223.s7.e1	DDI-DrugBank.d223.s7.e4
DDI-DrugBank.d223.s7	false	DDI-DrugBank.d223.s7.e1	DDI-DrugBank.d223.s7.e5
DDI-DrugBank.d223.s7	false	DDI-DrugBank.d223.s7.e2	DDI-DrugBank.d223.s7.e3
DDI-DrugBank.d223.s8|a|While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
DDI-DrugBank.d223.s8	14	52	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d223.s8.e0
DDI-DrugBank.d223.s8	55	59	SSRIs	group	DDI-DrugBank.d223.s8.e1
DDI-DrugBank.d223.s8	69	78	citalopram	drug	DDI-DrugBank.d223.s8.e2
DDI-DrugBank.d223.s8	81	92	escitalopram	drug	DDI-DrugBank.d223.s8.e3
DDI-DrugBank.d223.s8	95	104	fluoxetine	drug	DDI-DrugBank.d223.s8.e4
DDI-DrugBank.d223.s8	107	116	sertraline	drug	DDI-DrugBank.d223.s8.e5
DDI-DrugBank.d223.s8	123	132	paroxetine	drug	DDI-DrugBank.d223.s8.e6
DDI-DrugBank.d223.s8	false	DDI-DrugBank.d223.s8.e0	DDI-DrugBank.d223.s8.e1
DDI-DrugBank.d223.s8	false	DDI-DrugBank.d223.s8.e0	DDI-DrugBank.d223.s8.e2
DDI-DrugBank.d223.s8	false	DDI-DrugBank.d223.s8.e0	DDI-DrugBank.d223.s8.e3
DDI-DrugBank.d223.s8	false	DDI-DrugBank.d223.s8.e0	DDI-DrugBank.d223.s8.e4
DDI-DrugBank.d223.s8	false	DDI-DrugBank.d223.s8.e0	DDI-DrugBank.d223.s8.e5
DDI-DrugBank.d223.s8	false	DDI-DrugBank.d223.s8.e0	DDI-DrugBank.d223.s8.e6
DDI-DrugBank.d223.s8	false	DDI-DrugBank.d223.s8.e1	DDI-DrugBank.d223.s8.e2
DDI-DrugBank.d223.s8	false	DDI-DrugBank.d223.s8.e1	DDI-DrugBank.d223.s8.e3
DDI-DrugBank.d223.s8	false	DDI-DrugBank.d223.s8.e1	DDI-DrugBank.d223.s8.e4
DDI-DrugBank.d223.s8	false	DDI-DrugBank.d223.s8.e1	DDI-DrugBank.d223.s8.e5
DDI-DrugBank.d223.s9|a|The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
DDI-DrugBank.d223.s9	20	23	SSRI	group	DDI-DrugBank.d223.s9.e0
DDI-DrugBank.d223.s9	25	27	TCA	group	DDI-DrugBank.d223.s9.e1
DDI-DrugBank.d223.s9	141	144	SSRI	group	DDI-DrugBank.d223.s9.e2
DDI-DrugBank.d223.s9	true	DDI-DrugBank.d223.s9.e0	DDI-DrugBank.d223.s9.e1
DDI-DrugBank.d223.s9	false	DDI-DrugBank.d223.s9.e0	DDI-DrugBank.d223.s9.e2
DDI-DrugBank.d223.s9	false	DDI-DrugBank.d223.s9.e1	DDI-DrugBank.d223.s9.e2
DDI-DrugBank.d223.s10|a|Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
DDI-DrugBank.d223.s10	63	66	TCAs	group	DDI-DrugBank.d223.s10.e0
DDI-DrugBank.d223.s10	84	88	SSRIs	group	DDI-DrugBank.d223.s10.e1
DDI-DrugBank.d223.s10	true	DDI-DrugBank.d223.s10.e0	DDI-DrugBank.d223.s10.e1
DDI-DrugBank.d223.s11|a|Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
DDI-DrugBank.d223.s11	120	129	fluoxetine	drug	DDI-DrugBank.d223.s11.e0
DDI-DrugBank.d223.s12|a|Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
DDI-DrugBank.d223.s12	19	43	tricyclic antidepressants	group	DDI-DrugBank.d223.s12.e0
DDI-DrugBank.d223.s12	156	179	tricyclic antidepressant	group	DDI-DrugBank.d223.s12.e1
DDI-DrugBank.d223.s12	false	DDI-DrugBank.d223.s12.e0	DDI-DrugBank.d223.s12.e1
DDI-DrugBank.d223.s13|a|Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.
DDI-DrugBank.d223.s13	98	121	tricyclic antidepressant	group	DDI-DrugBank.d223.s13.e0
DDI-DrugBank.d223.s14|a|It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
DDI-DrugBank.d223.s14	27	29	TCA	group	DDI-DrugBank.d223.s14.e0
DDI-DrugBank.d223.s14	56	58	TCA	group	DDI-DrugBank.d223.s14.e1
DDI-DrugBank.d223.s14	false	DDI-DrugBank.d223.s14.e0	DDI-DrugBank.d223.s14.e1
DDI-DrugBank.d223.s15|a|Doxepin is primarily metabolized by CYP2D6 (with CYP1A2  and  CYP3A4 as minor pathways).
DDI-DrugBank.d223.s15	0	6	Doxepin	drug	DDI-DrugBank.d223.s15.e0
DDI-DrugBank.d223.s16|a|Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
DDI-DrugBank.d223.s16	42	50	quinidine	drug	DDI-DrugBank.d223.s16.e0
DDI-DrugBank.d223.s16	53	91	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d223.s16.e1
DDI-DrugBank.d223.s16	94	98	SSRIs	group	DDI-DrugBank.d223.s16.e2
DDI-DrugBank.d223.s16	143	149	doxepin	drug	DDI-DrugBank.d223.s16.e3
DDI-DrugBank.d223.s16	false	DDI-DrugBank.d223.s16.e0	DDI-DrugBank.d223.s16.e1
DDI-DrugBank.d223.s16	false	DDI-DrugBank.d223.s16.e0	DDI-DrugBank.d223.s16.e2
DDI-DrugBank.d223.s16	true	DDI-DrugBank.d223.s16.e0	DDI-DrugBank.d223.s16.e3
DDI-DrugBank.d223.s16	false	DDI-DrugBank.d223.s16.e1	DDI-DrugBank.d223.s16.e2
DDI-DrugBank.d223.s16	true	DDI-DrugBank.d223.s16.e1	DDI-DrugBank.d223.s16.e3
DDI-DrugBank.d223.s16	true	DDI-DrugBank.d223.s16.e2	DDI-DrugBank.d223.s16.e3
DDI-DrugBank.d223.s17|a|The extent of interaction depends on the variability of effect on CYP2D6.
DDI-DrugBank.d223.s18|a|The clinical significance of this interaction with doxepin has not been systematically evaluated.
DDI-DrugBank.d223.s18	51	57	doxepin	drug	DDI-DrugBank.d223.s18.e0
DDI-DrugBank.d223.s19|a|MAO Inhibitors: Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors.
DDI-DrugBank.d223.s19	0	13	MAO Inhibitors	group	DDI-DrugBank.d223.s19.e0
DDI-DrugBank.d223.s19	123	136	MAO inhibitors	group	DDI-DrugBank.d223.s19.e1
DDI-DrugBank.d223.s19	false	DDI-DrugBank.d223.s19.e0	DDI-DrugBank.d223.s19.e1
DDI-DrugBank.d223.s20|a|Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN.
DDI-DrugBank.d223.s20	11	24	MAO inhibitors	group	DDI-DrugBank.d223.s20.e0
DDI-DrugBank.d223.s20	117	124	SINEQUAN	brand	DDI-DrugBank.d223.s20.e1
DDI-DrugBank.d223.s20	true	DDI-DrugBank.d223.s20.e0	DDI-DrugBank.d223.s20.e1
DDI-DrugBank.d223.s21|a|The exact length of time may vary and is dependent upon the particular MAO inhibitor being used, the length of time it has been administered, and the dosage involved.
DDI-DrugBank.d223.s21	71	83	MAO inhibitor	group	DDI-DrugBank.d223.s21.e0
DDI-DrugBank.d223.s22|a|Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.
DDI-DrugBank.d223.s22	0	9	Cimetidine	drug	DDI-DrugBank.d223.s22.e0
DDI-DrugBank.d223.s22	12	21	Cimetidine	drug	DDI-DrugBank.d223.s22.e1
DDI-DrugBank.d223.s22	136	160	tricyclic antidepressants	group	DDI-DrugBank.d223.s22.e2
DDI-DrugBank.d223.s22	false	DDI-DrugBank.d223.s22.e0	DDI-DrugBank.d223.s22.e1
DDI-DrugBank.d223.s22	false	DDI-DrugBank.d223.s22.e0	DDI-DrugBank.d223.s22.e2
DDI-DrugBank.d223.s22	true	DDI-DrugBank.d223.s22.e1	DDI-DrugBank.d223.s22.e2
DDI-DrugBank.d223.s23|a|Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.
DDI-DrugBank.d223.s23	156	179	tricyclic antidepressant	group	DDI-DrugBank.d223.s23.e0
DDI-DrugBank.d223.s23	186	195	cimetidine	drug	DDI-DrugBank.d223.s23.e1
DDI-DrugBank.d223.s23	true	DDI-DrugBank.d223.s23.e0	DDI-DrugBank.d223.s23.e1
DDI-DrugBank.d223.s24|a|Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.
DDI-DrugBank.d223.s24	35	58	tricyclic antidepressant	group	DDI-DrugBank.d223.s24.e0
DDI-DrugBank.d223.s24	133	142	cimetidine	drug	DDI-DrugBank.d223.s24.e1
DDI-DrugBank.d223.s24	true	DDI-DrugBank.d223.s24.e0	DDI-DrugBank.d223.s24.e1
DDI-DrugBank.d223.s25|a|In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.
DDI-DrugBank.d223.s25	60	84	tricyclic antidepressants	group	DDI-DrugBank.d223.s25.e0
DDI-DrugBank.d223.s25	107	116	cimetidine	drug	DDI-DrugBank.d223.s25.e1
DDI-DrugBank.d223.s25	146	155	cimetidine	drug	DDI-DrugBank.d223.s25.e2
DDI-DrugBank.d223.s25	218	241	tricyclic antidepressant	group	DDI-DrugBank.d223.s25.e3
DDI-DrugBank.d223.s25	false	DDI-DrugBank.d223.s25.e0	DDI-DrugBank.d223.s25.e1
DDI-DrugBank.d223.s25	false	DDI-DrugBank.d223.s25.e0	DDI-DrugBank.d223.s25.e2
DDI-DrugBank.d223.s25	false	DDI-DrugBank.d223.s25.e0	DDI-DrugBank.d223.s25.e3
DDI-DrugBank.d223.s25	false	DDI-DrugBank.d223.s25.e1	DDI-DrugBank.d223.s25.e2
DDI-DrugBank.d223.s25	false	DDI-DrugBank.d223.s25.e1	DDI-DrugBank.d223.s25.e3
DDI-DrugBank.d223.s25	true	DDI-DrugBank.d223.s25.e2	DDI-DrugBank.d223.s25.e3
DDI-DrugBank.d223.s26|a|Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.
DDI-DrugBank.d223.s26	0	6	Alcohol	drug	DDI-DrugBank.d223.s26.e0
DDI-DrugBank.d223.s26	41	47	alcohol	drug	DDI-DrugBank.d223.s26.e1
DDI-DrugBank.d223.s26	128	135	SINEQUAN	brand	DDI-DrugBank.d223.s26.e2
DDI-DrugBank.d223.s26	false	DDI-DrugBank.d223.s26.e0	DDI-DrugBank.d223.s26.e1
DDI-DrugBank.d223.s26	false	DDI-DrugBank.d223.s26.e0	DDI-DrugBank.d223.s26.e2
DDI-DrugBank.d223.s26	true	DDI-DrugBank.d223.s26.e1	DDI-DrugBank.d223.s26.e2
DDI-DrugBank.d223.s27|a|This is especially important in patients who may use alcohol excessively.
DDI-DrugBank.d223.s27	53	59	alcohol	drug	DDI-DrugBank.d223.s27.e0
DDI-DrugBank.d223.s28|a|Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).
DDI-DrugBank.d223.s28	0	9	Tolazamide	drug	DDI-DrugBank.d223.s28.e0
DDI-DrugBank.d223.s28	104	113	tolazamide	drug	DDI-DrugBank.d223.s28.e1
DDI-DrugBank.d223.s28	156	162	doxepin	drug	DDI-DrugBank.d223.s28.e2
DDI-DrugBank.d223.s28	false	DDI-DrugBank.d223.s28.e0	DDI-DrugBank.d223.s28.e1
DDI-DrugBank.d223.s28	false	DDI-DrugBank.d223.s28.e0	DDI-DrugBank.d223.s28.e2
DDI-DrugBank.d223.s28	true	DDI-DrugBank.d223.s28.e1	DDI-DrugBank.d223.s28.e2
DDI-DrugBank.d127.s0|a|No formal drug interaction studies have been conducted with DOXIL  .
DDI-DrugBank.d127.s0	60	64	DOXIL	brand	DDI-DrugBank.d127.s0.e0
DDI-DrugBank.d127.s1|a|Until specific compatibility data are available, it is not recommended that DOXIL  be mixed with other drugs.
DDI-DrugBank.d127.s1	76	80	DOXIL	brand	DDI-DrugBank.d127.s1.e0
DDI-DrugBank.d127.s2|a|DOXIL  may interact with drugs known to interact with the conventional formulation of doxorubicin HCl.
DDI-DrugBank.d127.s2	0	4	DOXIL	brand	DDI-DrugBank.d127.s2.e0
DDI-DrugBank.d127.s2	86	100	doxorubicin HCl	drug	DDI-DrugBank.d127.s2.e1
DDI-DrugBank.d127.s2	false	DDI-DrugBank.d127.s2.e0	DDI-DrugBank.d127.s2.e1
DDI-DrugBank.d500.s0|a|Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
DDI-DrugBank.d500.s0	8	20	tetracyclines	group	DDI-DrugBank.d500.s0.e0
DDI-DrugBank.d500.s0	98	110	anticoagulant	group	DDI-DrugBank.d500.s0.e1
DDI-DrugBank.d500.s0	161	173	anticoagulant	group	DDI-DrugBank.d500.s0.e2
DDI-DrugBank.d500.s0	true	DDI-DrugBank.d500.s0.e0	DDI-DrugBank.d500.s0.e1
DDI-DrugBank.d500.s0	false	DDI-DrugBank.d500.s0.e0	DDI-DrugBank.d500.s0.e2
DDI-DrugBank.d500.s0	false	DDI-DrugBank.d500.s0.e1	DDI-DrugBank.d500.s0.e2
DDI-DrugBank.d500.s1|a|Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
DDI-DrugBank.d500.s1	73	82	penicillin	drug	DDI-DrugBank.d500.s1.e0
DDI-DrugBank.d500.s1	117	129	tetracyclines	group	DDI-DrugBank.d500.s1.e1
DDI-DrugBank.d500.s1	151	160	penicillin	group	DDI-DrugBank.d500.s1.e2
DDI-DrugBank.d500.s1	false	DDI-DrugBank.d500.s1.e0	DDI-DrugBank.d500.s1.e1
DDI-DrugBank.d500.s1	false	DDI-DrugBank.d500.s1.e0	DDI-DrugBank.d500.s1.e2
DDI-DrugBank.d500.s1	true	DDI-DrugBank.d500.s1.e1	DDI-DrugBank.d500.s1.e2
DDI-DrugBank.d500.s2|a|Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
DDI-DrugBank.d500.s2	14	26	tetracyclines	group	DDI-DrugBank.d500.s2.e0
DDI-DrugBank.d500.s2	43	50	antacids	group	DDI-DrugBank.d500.s2.e1
DDI-DrugBank.d500.s2	63	70	aluminum	drug	DDI-DrugBank.d500.s2.e2
DDI-DrugBank.d500.s2	73	79	calcium	drug	DDI-DrugBank.d500.s2.e3
DDI-DrugBank.d500.s2	85	93	magnesium	drug	DDI-DrugBank.d500.s2.e4
DDI-DrugBank.d500.s2	100	103	iron	drug	DDI-DrugBank.d500.s2.e5
DDI-DrugBank.d500.s2	false	DDI-DrugBank.d500.s2.e0	DDI-DrugBank.d500.s2.e1
DDI-DrugBank.d500.s2	true	DDI-DrugBank.d500.s2.e0	DDI-DrugBank.d500.s2.e2
DDI-DrugBank.d500.s2	true	DDI-DrugBank.d500.s2.e0	DDI-DrugBank.d500.s2.e3
DDI-DrugBank.d500.s2	true	DDI-DrugBank.d500.s2.e0	DDI-DrugBank.d500.s2.e4
DDI-DrugBank.d500.s2	true	DDI-DrugBank.d500.s2.e0	DDI-DrugBank.d500.s2.e5
DDI-DrugBank.d500.s2	false	DDI-DrugBank.d500.s2.e1	DDI-DrugBank.d500.s2.e2
DDI-DrugBank.d500.s2	false	DDI-DrugBank.d500.s2.e1	DDI-DrugBank.d500.s2.e3
DDI-DrugBank.d500.s2	false	DDI-DrugBank.d500.s2.e1	DDI-DrugBank.d500.s2.e4
DDI-DrugBank.d500.s2	false	DDI-DrugBank.d500.s2.e1	DDI-DrugBank.d500.s2.e5
DDI-DrugBank.d500.s2	false	DDI-DrugBank.d500.s2.e2	DDI-DrugBank.d500.s2.e3
DDI-DrugBank.d500.s3|a|Absorption of tetracycline is impaired by bismuth subsalicylate.
DDI-DrugBank.d500.s3	14	25	tetracycline	drug	DDI-DrugBank.d500.s3.e0
DDI-DrugBank.d500.s3	42	62	bismuth subsalicylate	drug	DDI-DrugBank.d500.s3.e1
DDI-DrugBank.d500.s3	true	DDI-DrugBank.d500.s3.e0	DDI-DrugBank.d500.s3.e1
DDI-DrugBank.d500.s4|a|Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
DDI-DrugBank.d500.s4	0	11	Barbiturates	group	DDI-DrugBank.d500.s4.e0
DDI-DrugBank.d500.s4	14	26	carbamazepine	drug	DDI-DrugBank.d500.s4.e1
DDI-DrugBank.d500.s4	33	41	phenytoin	drug	DDI-DrugBank.d500.s4.e2
DDI-DrugBank.d500.s4	69	79	doxycycline	drug	DDI-DrugBank.d500.s4.e3
DDI-DrugBank.d500.s4	false	DDI-DrugBank.d500.s4.e0	DDI-DrugBank.d500.s4.e1
DDI-DrugBank.d500.s4	false	DDI-DrugBank.d500.s4.e0	DDI-DrugBank.d500.s4.e2
DDI-DrugBank.d500.s4	true	DDI-DrugBank.d500.s4.e0	DDI-DrugBank.d500.s4.e3
DDI-DrugBank.d500.s4	false	DDI-DrugBank.d500.s4.e1	DDI-DrugBank.d500.s4.e2
DDI-DrugBank.d500.s4	true	DDI-DrugBank.d500.s4.e1	DDI-DrugBank.d500.s4.e3
DDI-DrugBank.d500.s4	true	DDI-DrugBank.d500.s4.e2	DDI-DrugBank.d500.s4.e3
DDI-DrugBank.d500.s5|a|The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
DDI-DrugBank.d500.s5	22	33	tetracycline	drug	DDI-DrugBank.d500.s5.e0
DDI-DrugBank.d500.s5	39	47	Penthrane	brand	DDI-DrugBank.d500.s5.e1
DDI-DrugBank.d500.s5	50	63	methoxyflurane	drug	DDI-DrugBank.d500.s5.e2
DDI-DrugBank.d500.s5	true	DDI-DrugBank.d500.s5.e0	DDI-DrugBank.d500.s5.e1
DDI-DrugBank.d500.s5	true	DDI-DrugBank.d500.s5.e0	DDI-DrugBank.d500.s5.e2
DDI-DrugBank.d500.s5	false	DDI-DrugBank.d500.s5.e1	DDI-DrugBank.d500.s5.e2
DDI-DrugBank.d500.s6|a|Concurrent use of tetracycline may render oral contraceptives less effective.
DDI-DrugBank.d500.s6	18	29	tetracycline	drug	DDI-DrugBank.d500.s6.e0
DDI-DrugBank.d500.s6	47	60	contraceptives	group	DDI-DrugBank.d500.s6.e1
DDI-DrugBank.d500.s6	true	DDI-DrugBank.d500.s6.e0	DDI-DrugBank.d500.s6.e1
DDI-DrugBank.d500.s7|a|Drug/Laboratory Test Interactions False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.
DDI-DrugBank.d387.s0|a|Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.
DDI-DrugBank.d387.s0	32	41	doxylamine	drug	DDI-DrugBank.d387.s0.e0
DDI-DrugBank.d387.s0	74	83	doxylamine	drug	DDI-DrugBank.d387.s0.e1
DDI-DrugBank.d387.s0	108	127	CNS depressant drugs	group	DDI-DrugBank.d387.s0.e2
DDI-DrugBank.d387.s0	false	DDI-DrugBank.d387.s0.e0	DDI-DrugBank.d387.s0.e1
DDI-DrugBank.d387.s0	false	DDI-DrugBank.d387.s0.e0	DDI-DrugBank.d387.s0.e2
DDI-DrugBank.d387.s0	true	DDI-DrugBank.d387.s0.e1	DDI-DrugBank.d387.s0.e2
DDI-DrugBank.d387.s1|a|Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.
DDI-DrugBank.d387.s1	0	13	Antihistamines	group	DDI-DrugBank.d387.s1.e0
DDI-DrugBank.d387.s1	71	77	heparin	drug	DDI-DrugBank.d387.s1.e1
DDI-DrugBank.d387.s1	82	89	warfarin	drug	DDI-DrugBank.d387.s1.e2
DDI-DrugBank.d387.s1	true	DDI-DrugBank.d387.s1.e0	DDI-DrugBank.d387.s1.e1
DDI-DrugBank.d387.s1	true	DDI-DrugBank.d387.s1.e0	DDI-DrugBank.d387.s1.e2
DDI-DrugBank.d387.s1	false	DDI-DrugBank.d387.s1.e1	DDI-DrugBank.d387.s1.e2
DDI-DrugBank.d387.s2|a|Doxylamine may enhance the effects of epinephrine.
DDI-DrugBank.d387.s2	0	9	Doxylamine	drug	DDI-DrugBank.d387.s2.e0
DDI-DrugBank.d387.s2	38	48	epinephrine	drug	DDI-DrugBank.d387.s2.e1
DDI-DrugBank.d387.s2	true	DDI-DrugBank.d387.s2.e0	DDI-DrugBank.d387.s2.e1
DDI-DrugBank.d129.s0|a|Androgens may increase sensitivity to oral anticoagulahts.
DDI-DrugBank.d129.s0	0	8	Androgens	group	DDI-DrugBank.d129.s0.e0
DDI-DrugBank.d129.s1|a|Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.
DDI-DrugBank.d129.s1	14	26	anticoagulant	group	DDI-DrugBank.d129.s1.e0
DDI-DrugBank.d129.s2|a|Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
DDI-DrugBank.d129.s2	29	43	oxyphenbutazone	drug	DDI-DrugBank.d129.s2.e0
DDI-DrugBank.d129.s2	49	57	androgens	group	DDI-DrugBank.d129.s2.e1
DDI-DrugBank.d129.s2	98	112	oxyphenbutazone	drug	DDI-DrugBank.d129.s2.e2
DDI-DrugBank.d129.s2	true	DDI-DrugBank.d129.s2.e0	DDI-DrugBank.d129.s2.e1
DDI-DrugBank.d129.s2	false	DDI-DrugBank.d129.s2.e0	DDI-DrugBank.d129.s2.e2
DDI-DrugBank.d129.s2	false	DDI-DrugBank.d129.s2.e1	DDI-DrugBank.d129.s2.e2
DDI-DrugBank.d129.s3|a|In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
DDI-DrugBank.d129.s3	47	55	androgens	group	DDI-DrugBank.d129.s3.e0
DDI-DrugBank.d129.s3	99	105	insulin	drug	DDI-DrugBank.d129.s3.e1
DDI-DrugBank.d129.s3	true	DDI-DrugBank.d129.s3.e0	DDI-DrugBank.d129.s3.e1
DDI-DrugBank.d254.s0|a|Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
DDI-DrugBank.d254.s0	6	25	CNS depressant drugs	group	DDI-DrugBank.d254.s0.e0
DDI-DrugBank.d254.s0	33	44	barbiturates	group	DDI-DrugBank.d254.s0.e1
DDI-DrugBank.d254.s0	47	59	tranquilizers	group	DDI-DrugBank.d254.s0.e2
DDI-DrugBank.d254.s0	62	68	opioids	group	DDI-DrugBank.d254.s0.e3
DDI-DrugBank.d254.s0	82	92	anesthetics	group	DDI-DrugBank.d254.s0.e4
DDI-DrugBank.d254.s0	138	145	INAPSINE	brand	DDI-DrugBank.d254.s0.e5
DDI-DrugBank.d254.s0	false	DDI-DrugBank.d254.s0.e0	DDI-DrugBank.d254.s0.e1
DDI-DrugBank.d254.s0	false	DDI-DrugBank.d254.s0.e0	DDI-DrugBank.d254.s0.e2
DDI-DrugBank.d254.s0	false	DDI-DrugBank.d254.s0.e0	DDI-DrugBank.d254.s0.e3
DDI-DrugBank.d254.s0	false	DDI-DrugBank.d254.s0.e0	DDI-DrugBank.d254.s0.e4
DDI-DrugBank.d254.s0	true	DDI-DrugBank.d254.s0.e0	DDI-DrugBank.d254.s0.e5
DDI-DrugBank.d254.s0	false	DDI-DrugBank.d254.s0.e1	DDI-DrugBank.d254.s0.e2
DDI-DrugBank.d254.s0	false	DDI-DrugBank.d254.s0.e1	DDI-DrugBank.d254.s0.e3
DDI-DrugBank.d254.s0	false	DDI-DrugBank.d254.s0.e1	DDI-DrugBank.d254.s0.e4
DDI-DrugBank.d254.s0	true	DDI-DrugBank.d254.s0.e1	DDI-DrugBank.d254.s0.e5
DDI-DrugBank.d254.s0	false	DDI-DrugBank.d254.s0.e2	DDI-DrugBank.d254.s0.e3
DDI-DrugBank.d254.s1|a|When patients have received such drugs, the dose of INAPSINE required will be less than usual.
DDI-DrugBank.d254.s1	52	59	INAPSINE	brand	DDI-DrugBank.d254.s1.e0
DDI-DrugBank.d254.s2|a|Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.
DDI-DrugBank.d254.s2	32	39	INAPSINE	brand	DDI-DrugBank.d254.s2.e0
DDI-DrugBank.d254.s2	60	79	CNS depressant drugs	group	DDI-DrugBank.d254.s2.e1
DDI-DrugBank.d254.s2	true	DDI-DrugBank.d254.s2.e0	DDI-DrugBank.d254.s2.e1
DDI-DrugBank.d190.s0|a|Drug interaction studies with Xigris have not been performed in patients with severe sepsis.
DDI-DrugBank.d190.s0	30	35	Xigris	brand	DDI-DrugBank.d190.s0.e0
DDI-DrugBank.d190.s1|a|However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis.
DDI-DrugBank.d190.s1	59	64	Xigris	brand	DDI-DrugBank.d190.s1.e0
DDI-DrugBank.d190.s1	99	104	Xigris	brand	DDI-DrugBank.d190.s1.e1
DDI-DrugBank.d190.s1	false	DDI-DrugBank.d190.s1.e0	DDI-DrugBank.d190.s1.e1
DDI-DrugBank.d190.s2|a|Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.
DDI-DrugBank.d190.s2	93	99	heparin	drug	DDI-DrugBank.d190.s2.e0
DDI-DrugBank.d190.s2	102	123	unfractionated heparin	drug	DDI-DrugBank.d190.s2.e1
DDI-DrugBank.d190.s2	174	202	low molecular weight heparins	group	DDI-DrugBank.d190.s2.e2
DDI-DrugBank.d190.s2	false	DDI-DrugBank.d190.s2.e0	DDI-DrugBank.d190.s2.e1
DDI-DrugBank.d190.s2	false	DDI-DrugBank.d190.s2.e0	DDI-DrugBank.d190.s2.e2
DDI-DrugBank.d190.s2	false	DDI-DrugBank.d190.s2.e1	DDI-DrugBank.d190.s2.e2
DDI-DrugBank.d190.s3|a|Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial.
DDI-DrugBank.d190.s3	41	47	heparin	drug	DDI-DrugBank.d190.s3.e0
DDI-DrugBank.d190.s3	122	127	Xigris	brand	DDI-DrugBank.d190.s3.e1
DDI-DrugBank.d190.s3	false	DDI-DrugBank.d190.s3.e0	DDI-DrugBank.d190.s3.e1
DDI-DrugBank.d190.s4|a|Drug/Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).
DDI-DrugBank.d190.s4	41	46	Xigris	brand	DDI-DrugBank.d190.s4.e0
DDI-DrugBank.d190.s4	75	80	Xigris	brand	DDI-DrugBank.d190.s4.e1
DDI-DrugBank.d190.s4	false	DDI-DrugBank.d190.s4.e0	DDI-DrugBank.d190.s4.e1
DDI-DrugBank.d190.s5|a|This interference may result in an apparent factor concentration that is lower than the true concentration.
DDI-DrugBank.d190.s6|a|Xigris present in plasma samples does not interfere with one-stage factor assays based on the PT (such as factor II, V, VII, and X assays).
DDI-DrugBank.d190.s6	0	5	Xigris	brand	DDI-DrugBank.d190.s6.e0
DDI-DrugBank.d548.s0|a|Potential for Other Drugs to Affect Duloxetine: Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.
DDI-DrugBank.d548.s0	36	45	Duloxetine	drug	DDI-DrugBank.d548.s0.e0
DDI-DrugBank.d548.s0	91	100	duloxetine	drug	DDI-DrugBank.d548.s0.e1
DDI-DrugBank.d548.s0	false	DDI-DrugBank.d548.s0.e0	DDI-DrugBank.d548.s0.e1
DDI-DrugBank.d548.s1|a|Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.
DDI-DrugBank.d548.s1	41	50	duloxetine	drug	DDI-DrugBank.d548.s1.e0
DDI-DrugBank.d548.s1	57	67	fluvoxamine	drug	DDI-DrugBank.d548.s1.e1
DDI-DrugBank.d548.s1	185	194	duloxetine	drug	DDI-DrugBank.d548.s1.e2
DDI-DrugBank.d548.s1	true	DDI-DrugBank.d548.s1.e0	DDI-DrugBank.d548.s1.e1
DDI-DrugBank.d548.s1	false	DDI-DrugBank.d548.s1.e0	DDI-DrugBank.d548.s1.e2
DDI-DrugBank.d548.s1	false	DDI-DrugBank.d548.s1.e1	DDI-DrugBank.d548.s1.e2
DDI-DrugBank.d548.s2|a|Some quinolone antibiotics would be expected to have similar effects and these combinations should be avoided.
DDI-DrugBank.d548.s2	5	25	quinolone antibiotics	group	DDI-DrugBank.d548.s2.e0
DDI-DrugBank.d548.s3|a|Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.
DDI-DrugBank.d548.s3	52	61	duloxetine	drug	DDI-DrugBank.d548.s3.e0
DDI-DrugBank.d548.s3	94	103	duloxetine	drug	DDI-DrugBank.d548.s3.e1
DDI-DrugBank.d548.s3	177	186	duloxetine	drug	DDI-DrugBank.d548.s3.e2
DDI-DrugBank.d548.s3	false	DDI-DrugBank.d548.s3.e0	DDI-DrugBank.d548.s3.e1
DDI-DrugBank.d548.s3	false	DDI-DrugBank.d548.s3.e0	DDI-DrugBank.d548.s3.e2
DDI-DrugBank.d548.s3	false	DDI-DrugBank.d548.s3.e1	DDI-DrugBank.d548.s3.e2
DDI-DrugBank.d548.s4|a|Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.
DDI-DrugBank.d548.s4	0	9	Paroxetine	drug	DDI-DrugBank.d548.s4.e0
DDI-DrugBank.d548.s4	53	62	duloxetine	drug	DDI-DrugBank.d548.s4.e1
DDI-DrugBank.d548.s4	157	166	paroxetine	drug	DDI-DrugBank.d548.s4.e2
DDI-DrugBank.d548.s4	true	DDI-DrugBank.d548.s4.e0	DDI-DrugBank.d548.s4.e1
DDI-DrugBank.d548.s4	false	DDI-DrugBank.d548.s4.e0	DDI-DrugBank.d548.s4.e2
DDI-DrugBank.d548.s4	false	DDI-DrugBank.d548.s4.e1	DDI-DrugBank.d548.s4.e2
DDI-DrugBank.d548.s5|a|Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine).
DDI-DrugBank.d548.s5	77	86	fluoxetine	drug	DDI-DrugBank.d548.s5.e0
DDI-DrugBank.d548.s5	89	97	quinidine	drug	DDI-DrugBank.d548.s5.e1
DDI-DrugBank.d548.s5	false	DDI-DrugBank.d548.s5.e0	DDI-DrugBank.d548.s5.e1
DDI-DrugBank.d548.s6|a|Potential for Duloxetine to Affect Other Drugs: Drugs Metabolized by CYP1A2: In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity, and it is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.
DDI-DrugBank.d548.s6	14	23	Duloxetine	drug	DDI-DrugBank.d548.s6.e0
DDI-DrugBank.d548.s6	128	137	duloxetine	drug	DDI-DrugBank.d548.s6.e1
DDI-DrugBank.d548.s6	false	DDI-DrugBank.d548.s6.e0	DDI-DrugBank.d548.s6.e1
DDI-DrugBank.d548.s7|a|Drugs Metabolized by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6.
DDI-DrugBank.d548.s7	29	38	Duloxetine	drug	DDI-DrugBank.d548.s7.e0
DDI-DrugBank.d548.s8|a|When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
DDI-DrugBank.d548.s8	5	14	duloxetine	drug	DDI-DrugBank.d548.s8.e0
DDI-DrugBank.d548.s8	101	111	desipramine	drug	DDI-DrugBank.d548.s8.e1
DDI-DrugBank.d548.s8	145	155	desipramine	drug	DDI-DrugBank.d548.s8.e2
DDI-DrugBank.d548.s8	true	DDI-DrugBank.d548.s8.e0	DDI-DrugBank.d548.s8.e1
DDI-DrugBank.d548.s8	false	DDI-DrugBank.d548.s8.e0	DDI-DrugBank.d548.s8.e2
DDI-DrugBank.d548.s8	false	DDI-DrugBank.d548.s8.e1	DDI-DrugBank.d548.s8.e2
DDI-DrugBank.d548.s9|a|Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d548.s9	32	41	Duloxetine	drug	DDI-DrugBank.d548.s9.e0
DDI-DrugBank.d548.s9	170	184	antidepressants	group	DDI-DrugBank.d548.s9.e1
DDI-DrugBank.d548.s9	187	211	tricyclic antidepressants	group	DDI-DrugBank.d548.s9.e2
DDI-DrugBank.d548.s9	214	217	TCAs	group	DDI-DrugBank.d548.s9.e3
DDI-DrugBank.d548.s9	229	241	nortriptyline	drug	DDI-DrugBank.d548.s9.e4
DDI-DrugBank.d548.s9	244	256	amitriptyline	drug	DDI-DrugBank.d548.s9.e5
DDI-DrugBank.d548.s9	263	272	imipramine	drug	DDI-DrugBank.d548.s9.e6
DDI-DrugBank.d548.s9	276	289	phenothiazines	group	DDI-DrugBank.d548.s9.e7
DDI-DrugBank.d548.s9	295	317	Type 1C antiarrhythmics	group	DDI-DrugBank.d548.s9.e8
DDI-DrugBank.d548.s9	326	336	propafenone	drug	DDI-DrugBank.d548.s9.e9
DDI-DrugBank.d548.s9	true	DDI-DrugBank.d548.s9.e0	DDI-DrugBank.d548.s9.e1
DDI-DrugBank.d548.s9	true	DDI-DrugBank.d548.s9.e0	DDI-DrugBank.d548.s9.e2
DDI-DrugBank.d548.s9	true	DDI-DrugBank.d548.s9.e0	DDI-DrugBank.d548.s9.e3
DDI-DrugBank.d548.s9	true	DDI-DrugBank.d548.s9.e0	DDI-DrugBank.d548.s9.e4
DDI-DrugBank.d548.s9	true	DDI-DrugBank.d548.s9.e0	DDI-DrugBank.d548.s9.e5
DDI-DrugBank.d548.s9	true	DDI-DrugBank.d548.s9.e0	DDI-DrugBank.d548.s9.e6
DDI-DrugBank.d548.s9	true	DDI-DrugBank.d548.s9.e0	DDI-DrugBank.d548.s9.e7
DDI-DrugBank.d548.s9	true	DDI-DrugBank.d548.s9.e0	DDI-DrugBank.d548.s9.e8
DDI-DrugBank.d548.s9	true	DDI-DrugBank.d548.s9.e0	DDI-DrugBank.d548.s9.e9
DDI-DrugBank.d548.s9	true	DDI-DrugBank.d548.s9.e0	DDI-DrugBank.d548.s9.e10
DDI-DrugBank.d548.s10|a|Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.
DDI-DrugBank.d548.s10	7	9	TCA	group	DDI-DrugBank.d548.s10.e0
DDI-DrugBank.d548.s10	71	73	TCA	group	DDI-DrugBank.d548.s10.e1
DDI-DrugBank.d548.s10	103	105	TCA	group	DDI-DrugBank.d548.s10.e2
DDI-DrugBank.d548.s10	131	140	Duloxetine	drug	DDI-DrugBank.d548.s10.e3
DDI-DrugBank.d548.s10	false	DDI-DrugBank.d548.s10.e0	DDI-DrugBank.d548.s10.e1
DDI-DrugBank.d548.s10	false	DDI-DrugBank.d548.s10.e0	DDI-DrugBank.d548.s10.e2
DDI-DrugBank.d548.s10	false	DDI-DrugBank.d548.s10.e0	DDI-DrugBank.d548.s10.e3
DDI-DrugBank.d548.s10	false	DDI-DrugBank.d548.s10.e1	DDI-DrugBank.d548.s10.e2
DDI-DrugBank.d548.s10	false	DDI-DrugBank.d548.s10.e1	DDI-DrugBank.d548.s10.e3
DDI-DrugBank.d548.s10	true	DDI-DrugBank.d548.s10.e2	DDI-DrugBank.d548.s10.e3
DDI-DrugBank.d548.s11|a|Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.
DDI-DrugBank.d548.s11	126	137	thioridazine	drug	DDI-DrugBank.d548.s11.e0
DDI-DrugBank.d548.s11	140	149	Duloxetine	drug	DDI-DrugBank.d548.s11.e1
DDI-DrugBank.d548.s11	155	166	thioridazine	drug	DDI-DrugBank.d548.s11.e2
DDI-DrugBank.d548.s11	false	DDI-DrugBank.d548.s11.e0	DDI-DrugBank.d548.s11.e1
DDI-DrugBank.d548.s11	false	DDI-DrugBank.d548.s11.e0	DDI-DrugBank.d548.s11.e2
DDI-DrugBank.d548.s11	true	DDI-DrugBank.d548.s11.e1	DDI-DrugBank.d548.s11.e2
DDI-DrugBank.d548.s12|a|Drugs Metabolized by CYP3A: Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity.
DDI-DrugBank.d548.s12	73	82	duloxetine	drug	DDI-DrugBank.d548.s12.e0
DDI-DrugBank.d548.s13|a|Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
DDI-DrugBank.d548.s13	0	9	Duloxetine	drug	DDI-DrugBank.d548.s13.e0
DDI-DrugBank.d548.s13	87	93	Alcohol	drug	DDI-DrugBank.d548.s13.e1
DDI-DrugBank.d548.s13	101	110	Duloxetine	drug	DDI-DrugBank.d548.s13.e2
DDI-DrugBank.d548.s13	116	122	ethanol	drug	DDI-DrugBank.d548.s13.e3
DDI-DrugBank.d548.s13	214	223	Duloxetine	drug	DDI-DrugBank.d548.s13.e4
DDI-DrugBank.d548.s13	294	300	alcohol	drug	DDI-DrugBank.d548.s13.e5
DDI-DrugBank.d548.s13	false	DDI-DrugBank.d548.s13.e0	DDI-DrugBank.d548.s13.e1
DDI-DrugBank.d548.s13	false	DDI-DrugBank.d548.s13.e0	DDI-DrugBank.d548.s13.e2
DDI-DrugBank.d548.s13	false	DDI-DrugBank.d548.s13.e0	DDI-DrugBank.d548.s13.e3
DDI-DrugBank.d548.s13	false	DDI-DrugBank.d548.s13.e0	DDI-DrugBank.d548.s13.e4
DDI-DrugBank.d548.s13	false	DDI-DrugBank.d548.s13.e0	DDI-DrugBank.d548.s13.e5
DDI-DrugBank.d548.s13	false	DDI-DrugBank.d548.s13.e1	DDI-DrugBank.d548.s13.e2
DDI-DrugBank.d548.s13	false	DDI-DrugBank.d548.s13.e1	DDI-DrugBank.d548.s13.e3
DDI-DrugBank.d548.s13	false	DDI-DrugBank.d548.s13.e1	DDI-DrugBank.d548.s13.e4
DDI-DrugBank.d548.s13	false	DDI-DrugBank.d548.s13.e1	DDI-DrugBank.d548.s13.e5
DDI-DrugBank.d548.s13	false	DDI-DrugBank.d548.s13.e2	DDI-DrugBank.d548.s13.e3
DDI-DrugBank.d548.s14|a|In the Duloxetine clinical trials database, three Duloxetine-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.
DDI-DrugBank.d548.s14	7	16	Duloxetine	drug	DDI-DrugBank.d548.s14.e0
DDI-DrugBank.d548.s14	50	59	Duloxetine	drug	DDI-DrugBank.d548.s14.e1
DDI-DrugBank.d548.s14	false	DDI-DrugBank.d548.s14.e0	DDI-DrugBank.d548.s14.e1
DDI-DrugBank.d548.s15|a|Substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen.
DDI-DrugBank.d548.s15	25	31	ethanol	drug	DDI-DrugBank.d548.s15.e0
DDI-DrugBank.d548.s16|a|CNS Acting Drugs: Given the primary CNS effects of Duloxetine, it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action.
DDI-DrugBank.d548.s16	51	60	Duloxetine	drug	DDI-DrugBank.d548.s16.e0
DDI-DrugBank.d548.s17|a|Potential for Interaction with Drugs that Affect Gastric Acidity: Duloxetine has an enteric coating that resists dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5.
DDI-DrugBank.d548.s17	66	75	Duloxetine	drug	DDI-DrugBank.d548.s17.e0
DDI-DrugBank.d548.s18|a|In extremely acidic conditions, Duloxetine, unprotected by the enteric coating, may undergo hydrolysis to form naphthol.
DDI-DrugBank.d548.s18	32	41	Duloxetine	drug	DDI-DrugBank.d548.s18.e0
DDI-DrugBank.d548.s19|a|Caution is advised in using Duloxetine in patients with conditions that may slow gastric emptying (e.g., some diabetics).
DDI-DrugBank.d548.s19	28	37	Duloxetine	drug	DDI-DrugBank.d548.s19.e0
DDI-DrugBank.d548.s20|a|Drugs that raise the gastrointestinal pH may lead to an earlier release of duloxetine.
DDI-DrugBank.d548.s20	75	84	duloxetine	drug	DDI-DrugBank.d548.s20.e0
DDI-DrugBank.d548.s21|a|However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.
DDI-DrugBank.d548.s21	30	39	Duloxetine	drug	DDI-DrugBank.d548.s21.e0
DDI-DrugBank.d548.s21	46	53	aluminum	drug	DDI-DrugBank.d548.s21.e1
DDI-DrugBank.d548.s21	60	68	magnesium	drug	DDI-DrugBank.d548.s21.e2
DDI-DrugBank.d548.s21	81	88	antacids	group	DDI-DrugBank.d548.s21.e3
DDI-DrugBank.d548.s21	102	111	Duloxetine	drug	DDI-DrugBank.d548.s21.e4
DDI-DrugBank.d548.s21	118	127	famotidine	drug	DDI-DrugBank.d548.s21.e5
DDI-DrugBank.d548.s21	181	190	duloxetine	drug	DDI-DrugBank.d548.s21.e6
DDI-DrugBank.d548.s21	false	DDI-DrugBank.d548.s21.e0	DDI-DrugBank.d548.s21.e1
DDI-DrugBank.d548.s21	false	DDI-DrugBank.d548.s21.e0	DDI-DrugBank.d548.s21.e2
DDI-DrugBank.d548.s21	false	DDI-DrugBank.d548.s21.e0	DDI-DrugBank.d548.s21.e3
DDI-DrugBank.d548.s21	false	DDI-DrugBank.d548.s21.e0	DDI-DrugBank.d548.s21.e4
DDI-DrugBank.d548.s21	false	DDI-DrugBank.d548.s21.e0	DDI-DrugBank.d548.s21.e5
DDI-DrugBank.d548.s21	false	DDI-DrugBank.d548.s21.e0	DDI-DrugBank.d548.s21.e6
DDI-DrugBank.d548.s21	false	DDI-DrugBank.d548.s21.e1	DDI-DrugBank.d548.s21.e2
DDI-DrugBank.d548.s21	false	DDI-DrugBank.d548.s21.e1	DDI-DrugBank.d548.s21.e3
DDI-DrugBank.d548.s21	false	DDI-DrugBank.d548.s21.e1	DDI-DrugBank.d548.s21.e4
DDI-DrugBank.d548.s21	false	DDI-DrugBank.d548.s21.e1	DDI-DrugBank.d548.s21.e5
DDI-DrugBank.d548.s22|a|It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption.
DDI-DrugBank.d548.s22	56	77	proton pump inhibitors	group	DDI-DrugBank.d548.s22.e0
DDI-DrugBank.d548.s22	87	96	duloxetine	drug	DDI-DrugBank.d548.s22.e1
DDI-DrugBank.d548.s22	false	DDI-DrugBank.d548.s22.e0	DDI-DrugBank.d548.s22.e1
DDI-DrugBank.d4.s0|a|Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
DDI-DrugBank.d4.s0	18	41	xanthine bronchodilators	group	DDI-DrugBank.d4.s0.e0
DDI-DrugBank.d4.s0	50	61	theophylline	drug	DDI-DrugBank.d4.s0.e1
DDI-DrugBank.d4.s0	65	73	ephedrine	drug	DDI-DrugBank.d4.s0.e2
DDI-DrugBank.d4.s0	86	116	sympathomimetic bronchodilators	group	DDI-DrugBank.d4.s0.e3
DDI-DrugBank.d4.s0	false	DDI-DrugBank.d4.s0.e0	DDI-DrugBank.d4.s0.e1
DDI-DrugBank.d4.s0	false	DDI-DrugBank.d4.s0.e0	DDI-DrugBank.d4.s0.e2
DDI-DrugBank.d4.s0	true	DDI-DrugBank.d4.s0.e0	DDI-DrugBank.d4.s0.e3
DDI-DrugBank.d4.s0	false	DDI-DrugBank.d4.s0.e1	DDI-DrugBank.d4.s0.e2
DDI-DrugBank.d4.s0	true	DDI-DrugBank.d4.s0.e1	DDI-DrugBank.d4.s0.e3
DDI-DrugBank.d4.s0	true	DDI-DrugBank.d4.s0.e2	DDI-DrugBank.d4.s0.e3
DDI-DrugBank.d4.s1|a|This should be considered whenever these agents are prescribed concomitantly.
DDI-DrugBank.d4.s2|a|Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .
DDI-DrugBank.d4.s2	29	38	dyphylline	drug	DDI-DrugBank.d4.s2.e0
DDI-DrugBank.d4.s2	44	53	probenecid	drug	DDI-DrugBank.d4.s2.e1
DDI-DrugBank.d4.s2	145	154	dyphylline	drug	DDI-DrugBank.d4.s2.e2
DDI-DrugBank.d4.s2	true	DDI-DrugBank.d4.s2.e0	DDI-DrugBank.d4.s2.e1
DDI-DrugBank.d4.s2	false	DDI-DrugBank.d4.s2.e0	DDI-DrugBank.d4.s2.e2
DDI-DrugBank.d4.s2	false	DDI-DrugBank.d4.s2.e1	DDI-DrugBank.d4.s2.e2
DDI-DrugBank.d377.s0|a|Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
DDI-DrugBank.d377.s0	0	17	Phospholine Iodide	drug	DDI-DrugBank.d377.s0.e0
DDI-DrugBank.d377.s0	37	61	cholinesterase inhibitors	group	DDI-DrugBank.d377.s0.e1
DDI-DrugBank.d377.s0	71	85	succinylcholine	drug	DDI-DrugBank.d377.s0.e2
DDI-DrugBank.d377.s0	90	104	organophosphate insecticide	drug_n	DDI-DrugBank.d377.s0.e3
DDI-DrugBank.d377.s0	120	130	organophosphate insecticide	drug_n	DDI-DrugBank.d377.s0.e3
DDI-DrugBank.d377.s0	110	130	carbamate insecticide	drug_n	DDI-DrugBank.d377.s0.e4
DDI-DrugBank.d377.s0	true	DDI-DrugBank.d377.s0.e0	DDI-DrugBank.d377.s0.e1
DDI-DrugBank.d377.s0	true	DDI-DrugBank.d377.s0.e0	DDI-DrugBank.d377.s0.e2
DDI-DrugBank.d377.s0	true	DDI-DrugBank.d377.s0.e0	DDI-DrugBank.d377.s0.e3
DDI-DrugBank.d377.s0	true	DDI-DrugBank.d377.s0.e0	DDI-DrugBank.d377.s0.e4
DDI-DrugBank.d377.s0	false	DDI-DrugBank.d377.s0.e1	DDI-DrugBank.d377.s0.e2
DDI-DrugBank.d377.s0	false	DDI-DrugBank.d377.s0.e1	DDI-DrugBank.d377.s0.e3
DDI-DrugBank.d377.s0	false	DDI-DrugBank.d377.s0.e1	DDI-DrugBank.d377.s0.e4
DDI-DrugBank.d377.s0	false	DDI-DrugBank.d377.s0.e2	DDI-DrugBank.d377.s0.e3
DDI-DrugBank.d377.s0	false	DDI-DrugBank.d377.s0.e2	DDI-DrugBank.d377.s0.e4
DDI-DrugBank.d377.s0	false	DDI-DrugBank.d377.s0.e3	DDI-DrugBank.d377.s0.e4
DDI-DrugBank.d377.s1|a|Patients undergoing systemic anticholinesterase treatment should be warned of the possible additive effects of Phospholine Iodide.
DDI-DrugBank.d377.s1	111	128	Phospholine Iodide	drug	DDI-DrugBank.d377.s1.e0
DDI-DrugBank.d49.s0|a|Drug interaction studies have not been performed with Soliris.
DDI-DrugBank.d49.s0	54	60	Soliris	brand	DDI-DrugBank.d49.s0.e0
DDI-DrugBank.d191.s0|a|There is no known drug interference with standard clinical laboratory tests.
DDI-DrugBank.d191.s1|a|Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7
DDI-DrugBank.d191.s1	0	7	Steroids	group	DDI-DrugBank.d191.s1.e0
DDI-DrugBank.d191.s1	39	62	edetate calcium disodium	drug	DDI-DrugBank.d191.s1.e1
DDI-DrugBank.d191.s1	78	101	Edetate calcium disodium	drug	DDI-DrugBank.d191.s1.e2
DDI-DrugBank.d191.s1	133	144	zinc insulin	drug	DDI-DrugBank.d191.s1.e3
DDI-DrugBank.d191.s1	176	179	zinc	drug	DDI-DrugBank.d191.s1.e4
DDI-DrugBank.d191.s1	true	DDI-DrugBank.d191.s1.e0	DDI-DrugBank.d191.s1.e1
DDI-DrugBank.d191.s1	false	DDI-DrugBank.d191.s1.e0	DDI-DrugBank.d191.s1.e2
DDI-DrugBank.d191.s1	false	DDI-DrugBank.d191.s1.e0	DDI-DrugBank.d191.s1.e3
DDI-DrugBank.d191.s1	false	DDI-DrugBank.d191.s1.e0	DDI-DrugBank.d191.s1.e4
DDI-DrugBank.d191.s1	false	DDI-DrugBank.d191.s1.e1	DDI-DrugBank.d191.s1.e2
DDI-DrugBank.d191.s1	false	DDI-DrugBank.d191.s1.e1	DDI-DrugBank.d191.s1.e3
DDI-DrugBank.d191.s1	false	DDI-DrugBank.d191.s1.e1	DDI-DrugBank.d191.s1.e4
DDI-DrugBank.d191.s1	true	DDI-DrugBank.d191.s1.e2	DDI-DrugBank.d191.s1.e3
DDI-DrugBank.d191.s1	false	DDI-DrugBank.d191.s1.e2	DDI-DrugBank.d191.s1.e4
DDI-DrugBank.d191.s1	false	DDI-DrugBank.d191.s1.e3	DDI-DrugBank.d191.s1.e4
DDI-DrugBank.d292.s0|a|Care should be given when administering this drug to patients with symptoms of myasthenic weakness who are also on anticholinesterase drugs.
DDI-DrugBank.d292.s0	115	138	anticholinesterase drugs	group	DDI-DrugBank.d292.s0.e0
DDI-DrugBank.d292.s1|a|Since symptoms of anticholinesterase overdose (cholinergic crisis) may mimic underdosage (myasthenic weakness), their condition may be worsened by the use of this drug.
DDI-DrugBank.d44.s0|a|No formal drug interaction studies have been performed with RAPTIVA.
DDI-DrugBank.d44.s0	60	66	RAPTIVA	brand	DDI-DrugBank.d44.s0.e0
DDI-DrugBank.d44.s1|a|RAPTIVA should not be used with other immunosuppressive drugs.
DDI-DrugBank.d44.s1	0	6	RAPTIVA	brand	DDI-DrugBank.d44.s1.e0
DDI-DrugBank.d44.s1	38	60	immunosuppressive drugs	group	DDI-DrugBank.d44.s1.e1
DDI-DrugBank.d44.s1	true	DDI-DrugBank.d44.s1.e0	DDI-DrugBank.d44.s1.e1
DDI-DrugBank.d44.s2|a|Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
DDI-DrugBank.d44.s2	0	8	Acellular vaccines	group	DDI-DrugBank.d44.s2.e0
DDI-DrugBank.d44.s2	36	43	Acellular vaccines	group	DDI-DrugBank.d44.s2.e0
DDI-DrugBank.d44.s2	11	14	live vaccines	group	DDI-DrugBank.d44.s2.e1
DDI-DrugBank.d44.s2	36	43	live vaccines	group	DDI-DrugBank.d44.s2.e1
DDI-DrugBank.d44.s2	20	43	live-attenuated vaccines	group	DDI-DrugBank.d44.s2.e2
DDI-DrugBank.d44.s2	79	85	RAPTIVA	brand	DDI-DrugBank.d44.s2.e3
DDI-DrugBank.d44.s2	false	DDI-DrugBank.d44.s2.e0	DDI-DrugBank.d44.s2.e1
DDI-DrugBank.d44.s2	false	DDI-DrugBank.d44.s2.e0	DDI-DrugBank.d44.s2.e2
DDI-DrugBank.d44.s2	true	DDI-DrugBank.d44.s2.e0	DDI-DrugBank.d44.s2.e3
DDI-DrugBank.d44.s2	false	DDI-DrugBank.d44.s2.e1	DDI-DrugBank.d44.s2.e2
DDI-DrugBank.d44.s2	true	DDI-DrugBank.d44.s2.e1	DDI-DrugBank.d44.s2.e3
DDI-DrugBank.d44.s2	true	DDI-DrugBank.d44.s2.e2	DDI-DrugBank.d44.s2.e3
DDI-DrugBank.d44.s3|a|Drug/Laboratory Test Interactions Increases in lymphocyte counts related to the pharmacologic mechanism of action are frequently observed during RAPTIVA treatment.
DDI-DrugBank.d44.s3	145	151	RAPTIVA	brand	DDI-DrugBank.d44.s3.e0
DDI-DrugBank.d531.s0|a|Efavirenz has been shown in vivo to induce CYP3A4.
DDI-DrugBank.d531.s0	0	8	Efavirenz	drug	DDI-DrugBank.d531.s0.e0
DDI-DrugBank.d531.s1|a|Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA (efavirenz).
DDI-DrugBank.d531.s1	112	118	SUSTIVA	brand	DDI-DrugBank.d531.s1.e0
DDI-DrugBank.d531.s1	121	129	efavirenz	drug	DDI-DrugBank.d531.s1.e1
DDI-DrugBank.d531.s1	false	DDI-DrugBank.d531.s1.e0	DDI-DrugBank.d531.s1.e1
DDI-DrugBank.d531.s2|a|In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations.
DDI-DrugBank.d531.s2	40	48	efavirenz	drug	DDI-DrugBank.d531.s2.e0
DDI-DrugBank.d531.s2	112	120	efavirenz	drug	DDI-DrugBank.d531.s2.e1
DDI-DrugBank.d531.s2	false	DDI-DrugBank.d531.s2.e0	DDI-DrugBank.d531.s2.e1
DDI-DrugBank.d531.s3|a|Coadministration of efavirenz with drugs primarily metabolized by these isozymes may result in altered plasma concentrations of the coadministered drug.
DDI-DrugBank.d531.s3	20	28	efavirenz	drug	DDI-DrugBank.d531.s3.e0
DDI-DrugBank.d531.s4|a|Therefore, appropriate dose adjustments may be necessary for these drugs.
DDI-DrugBank.d531.s5|a|Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
DDI-DrugBank.d531.s5	40	52	phenobarbital	drug	DDI-DrugBank.d531.s5.e0
DDI-DrugBank.d531.s5	55	62	rifampin	drug	DDI-DrugBank.d531.s5.e1
DDI-DrugBank.d531.s5	65	73	rifabutin	drug	DDI-DrugBank.d531.s5.e2
DDI-DrugBank.d531.s5	123	131	efavirenz	drug	DDI-DrugBank.d531.s5.e3
DDI-DrugBank.d531.s5	false	DDI-DrugBank.d531.s5.e0	DDI-DrugBank.d531.s5.e1
DDI-DrugBank.d531.s5	false	DDI-DrugBank.d531.s5.e0	DDI-DrugBank.d531.s5.e2
DDI-DrugBank.d531.s5	true	DDI-DrugBank.d531.s5.e0	DDI-DrugBank.d531.s5.e3
DDI-DrugBank.d531.s5	false	DDI-DrugBank.d531.s5.e1	DDI-DrugBank.d531.s5.e2
DDI-DrugBank.d531.s5	true	DDI-DrugBank.d531.s5.e1	DDI-DrugBank.d531.s5.e3
DDI-DrugBank.d531.s5	true	DDI-DrugBank.d531.s5.e2	DDI-DrugBank.d531.s5.e3
DDI-DrugBank.d531.s6|a|Drug interactions with SUSTIVA are summarized in Table 5.
DDI-DrugBank.d531.s6	23	29	SUSTIVA	brand	DDI-DrugBank.d531.s6.e0
DDI-DrugBank.d531.s7|a|Table 5a: Drugs That Should Not Be Coadministered With SUSTIVA
DDI-DrugBank.d531.s7	55	61	SUSTIVA	brand	DDI-DrugBank.d531.s7.e0
DDI-DrugBank.d531.s8|a|Drug Class
DDI-DrugBank.d531.s9|a|Drugs Within Class Not To Be Coadministered With SUSTIVA
DDI-DrugBank.d531.s9	49	55	SUSTIVA	brand	DDI-DrugBank.d531.s9.e0
DDI-DrugBank.d531.s10|a|Antihistamines: Benzodiazepines GI Motility Agents Anti-Migraine Antifungal
DDI-DrugBank.d531.s10	0	13	Antihistamines	group	DDI-DrugBank.d531.s10.e0
DDI-DrugBank.d531.s10	16	30	Benzodiazepines	group	DDI-DrugBank.d531.s10.e1
DDI-DrugBank.d531.s10	51	63	Anti-Migraine	group	DDI-DrugBank.d531.s10.e2
DDI-DrugBank.d531.s10	65	74	Antifungal	group	DDI-DrugBank.d531.s10.e3
DDI-DrugBank.d531.s10	false	DDI-DrugBank.d531.s10.e0	DDI-DrugBank.d531.s10.e1
DDI-DrugBank.d531.s10	false	DDI-DrugBank.d531.s10.e0	DDI-DrugBank.d531.s10.e2
DDI-DrugBank.d531.s10	false	DDI-DrugBank.d531.s10.e0	DDI-DrugBank.d531.s10.e3
DDI-DrugBank.d531.s10	false	DDI-DrugBank.d531.s10.e1	DDI-DrugBank.d531.s10.e2
DDI-DrugBank.d531.s10	false	DDI-DrugBank.d531.s10.e1	DDI-DrugBank.d531.s10.e3
DDI-DrugBank.d531.s10	false	DDI-DrugBank.d531.s10.e2	DDI-DrugBank.d531.s10.e3
DDI-DrugBank.d531.s11|a|astemizole midazolam, triazolam cisapride ergot derivatives voriconazole
DDI-DrugBank.d531.s11	0	9	astemizole	drug	DDI-DrugBank.d531.s11.e0
DDI-DrugBank.d531.s11	11	19	midazolam	drug	DDI-DrugBank.d531.s11.e1
DDI-DrugBank.d531.s11	22	30	triazolam	drug	DDI-DrugBank.d531.s11.e2
DDI-DrugBank.d531.s11	32	40	cisapride	drug	DDI-DrugBank.d531.s11.e3
DDI-DrugBank.d531.s11	60	71	voriconazole	drug	DDI-DrugBank.d531.s11.e4
DDI-DrugBank.d531.s11	false	DDI-DrugBank.d531.s11.e0	DDI-DrugBank.d531.s11.e1
DDI-DrugBank.d531.s11	false	DDI-DrugBank.d531.s11.e0	DDI-DrugBank.d531.s11.e2
DDI-DrugBank.d531.s11	false	DDI-DrugBank.d531.s11.e0	DDI-DrugBank.d531.s11.e3
DDI-DrugBank.d531.s11	false	DDI-DrugBank.d531.s11.e0	DDI-DrugBank.d531.s11.e4
DDI-DrugBank.d531.s11	false	DDI-DrugBank.d531.s11.e1	DDI-DrugBank.d531.s11.e2
DDI-DrugBank.d531.s11	false	DDI-DrugBank.d531.s11.e1	DDI-DrugBank.d531.s11.e3
DDI-DrugBank.d531.s11	false	DDI-DrugBank.d531.s11.e1	DDI-DrugBank.d531.s11.e4
DDI-DrugBank.d531.s11	false	DDI-DrugBank.d531.s11.e2	DDI-DrugBank.d531.s11.e3
DDI-DrugBank.d531.s11	false	DDI-DrugBank.d531.s11.e2	DDI-DrugBank.d531.s11.e4
DDI-DrugBank.d531.s11	false	DDI-DrugBank.d531.s11.e3	DDI-DrugBank.d531.s11.e4
DDI-DrugBank.d531.s12|a|Established Drug Interactions
DDI-DrugBank.d531.s13|a|
DDI-DrugBank.d531.s14|a|Drug Name
DDI-DrugBank.d531.s15|a|Effect
DDI-DrugBank.d531.s16|a|Clinical Comment
DDI-DrugBank.d531.s17|a|Atazanavir
DDI-DrugBank.d531.s17	0	9	Atazanavir	drug	DDI-DrugBank.d531.s17.e0
DDI-DrugBank.d531.s18|a|atazanavir
DDI-DrugBank.d531.s18	0	9	atazanavir	drug	DDI-DrugBank.d531.s18.e0
DDI-DrugBank.d531.s19|a|When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).
DDI-DrugBank.d531.s19	25	31	SUSTIVA	brand	DDI-DrugBank.d531.s19.e0
DDI-DrugBank.d531.s19	86	95	atazanavir	drug	DDI-DrugBank.d531.s19.e1
DDI-DrugBank.d531.s19	112	120	ritonavir	drug	DDI-DrugBank.d531.s19.e2
DDI-DrugBank.d531.s19	133	139	SUSTIVA	brand	DDI-DrugBank.d531.s19.e3
DDI-DrugBank.d531.s19	false	DDI-DrugBank.d531.s19.e0	DDI-DrugBank.d531.s19.e1
DDI-DrugBank.d531.s19	false	DDI-DrugBank.d531.s19.e0	DDI-DrugBank.d531.s19.e2
DDI-DrugBank.d531.s19	false	DDI-DrugBank.d531.s19.e0	DDI-DrugBank.d531.s19.e3
DDI-DrugBank.d531.s19	false	DDI-DrugBank.d531.s19.e1	DDI-DrugBank.d531.s19.e2
DDI-DrugBank.d531.s19	false	DDI-DrugBank.d531.s19.e1	DDI-DrugBank.d531.s19.e3
DDI-DrugBank.d531.s19	false	DDI-DrugBank.d531.s19.e2	DDI-DrugBank.d531.s19.e3
DDI-DrugBank.d531.s20|a|Dosing recommendations for SUSTIVA and atazanavir in treatment-experienced patients have not been established.
DDI-DrugBank.d531.s20	27	33	SUSTIVA	brand	DDI-DrugBank.d531.s20.e0
DDI-DrugBank.d531.s20	39	48	atazanavir	drug	DDI-DrugBank.d531.s20.e1
DDI-DrugBank.d531.s20	false	DDI-DrugBank.d531.s20.e0	DDI-DrugBank.d531.s20.e1
DDI-DrugBank.d531.s21|a|Established Drug Interactions (continued)
DDI-DrugBank.d531.s22|a|Drug Name
DDI-DrugBank.d531.s23|a|Effect
DDI-DrugBank.d531.s24|a|Clinical Comment
DDI-DrugBank.d531.s25|a|Clarithromycin
DDI-DrugBank.d531.s25	0	13	Clarithromycin	drug	DDI-DrugBank.d531.s25.e0
DDI-DrugBank.d531.s26|a|clarithromycin concentration
DDI-DrugBank.d531.s26	0	13	clarithromycin	drug	DDI-DrugBank.d531.s26.e0
DDI-DrugBank.d531.s27|a|Plasma concentrations decreased by SUSTIVA;
DDI-DrugBank.d531.s27	35	41	SUSTIVA	brand	DDI-DrugBank.d531.s27.e0
DDI-DrugBank.d531.s28|a|clinical significance unknown.
DDI-DrugBank.d531.s29|a|In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.
DDI-DrugBank.d531.s29	61	67	SUSTIVA	brand	DDI-DrugBank.d531.s29.e0
DDI-DrugBank.d531.s29	73	86	clarithromycin	drug	DDI-DrugBank.d531.s29.e1
DDI-DrugBank.d531.s29	true	DDI-DrugBank.d531.s29.e0	DDI-DrugBank.d531.s29.e1
DDI-DrugBank.d531.s30|a|No dose adjustment of SUSTIVA is recommended when given with clarithromycin.
DDI-DrugBank.d531.s30	22	28	SUSTIVA	brand	DDI-DrugBank.d531.s30.e0
DDI-DrugBank.d531.s30	61	74	clarithromycin	drug	DDI-DrugBank.d531.s30.e1
DDI-DrugBank.d531.s30	false	DDI-DrugBank.d531.s30.e0	DDI-DrugBank.d531.s30.e1
DDI-DrugBank.d531.s31|a|Alternatives to clarithromycin, such as azithromycin, should be considered.
DDI-DrugBank.d531.s31	16	29	clarithromycin	drug	DDI-DrugBank.d531.s31.e0
DDI-DrugBank.d531.s31	40	51	azithromycin	drug	DDI-DrugBank.d531.s31.e1
DDI-DrugBank.d531.s31	false	DDI-DrugBank.d531.s31.e0	DDI-DrugBank.d531.s31.e1
DDI-DrugBank.d531.s32|a|Other macrolide antibiotics, such as erythromycin, have not been studied in combination with SUSTIVA.
DDI-DrugBank.d531.s32	6	26	macrolide antibiotics	group	DDI-DrugBank.d531.s32.e0
DDI-DrugBank.d531.s32	37	48	erythromycin	drug	DDI-DrugBank.d531.s32.e1
DDI-DrugBank.d531.s32	93	99	SUSTIVA	brand	DDI-DrugBank.d531.s32.e2
DDI-DrugBank.d531.s32	false	DDI-DrugBank.d531.s32.e0	DDI-DrugBank.d531.s32.e1
DDI-DrugBank.d531.s32	false	DDI-DrugBank.d531.s32.e0	DDI-DrugBank.d531.s32.e2
DDI-DrugBank.d531.s32	false	DDI-DrugBank.d531.s32.e1	DDI-DrugBank.d531.s32.e2
DDI-DrugBank.d531.s33|a|
DDI-DrugBank.d531.s34|a|14-OH metabolite concentration
DDI-DrugBank.d531.s35|a|Indinavir
DDI-DrugBank.d531.s35	0	8	Indinavir	drug	DDI-DrugBank.d531.s35.e0
DDI-DrugBank.d531.s36|a|indinavir concentration
DDI-DrugBank.d531.s36	0	8	indinavir	drug	DDI-DrugBank.d531.s36.e0
DDI-DrugBank.d531.s37|a|The optimal dose of indinavir, when given in combination with SUSTIVA, is not known.
DDI-DrugBank.d531.s37	20	28	indinavir	drug	DDI-DrugBank.d531.s37.e0
DDI-DrugBank.d531.s37	62	68	SUSTIVA	brand	DDI-DrugBank.d531.s37.e1
DDI-DrugBank.d531.s37	false	DDI-DrugBank.d531.s37.e0	DDI-DrugBank.d531.s37.e1
DDI-DrugBank.d531.s38|a|Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.
DDI-DrugBank.d531.s38	15	23	indinavir	drug	DDI-DrugBank.d531.s38.e0
DDI-DrugBank.d531.s38	93	101	indinavir	drug	DDI-DrugBank.d531.s38.e1
DDI-DrugBank.d531.s38	121	127	SUSTIVA	brand	DDI-DrugBank.d531.s38.e2
DDI-DrugBank.d531.s38	false	DDI-DrugBank.d531.s38.e0	DDI-DrugBank.d531.s38.e1
DDI-DrugBank.d531.s38	false	DDI-DrugBank.d531.s38.e0	DDI-DrugBank.d531.s38.e2
DDI-DrugBank.d531.s38	true	DDI-DrugBank.d531.s38.e1	DDI-DrugBank.d531.s38.e2
DDI-DrugBank.d531.s39|a|When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.
DDI-DrugBank.d531.s39	5	13	indinavir	drug	DDI-DrugBank.d531.s39.e0
DDI-DrugBank.d531.s39	75	81	SUSTIVA	brand	DDI-DrugBank.d531.s39.e1
DDI-DrugBank.d531.s39	108	116	indinavir	drug	DDI-DrugBank.d531.s39.e2
DDI-DrugBank.d531.s39	210	218	indinavir	drug	DDI-DrugBank.d531.s39.e3
DDI-DrugBank.d531.s39	true	DDI-DrugBank.d531.s39.e0	DDI-DrugBank.d531.s39.e1
DDI-DrugBank.d531.s39	false	DDI-DrugBank.d531.s39.e0	DDI-DrugBank.d531.s39.e2
DDI-DrugBank.d531.s39	false	DDI-DrugBank.d531.s39.e0	DDI-DrugBank.d531.s39.e3
DDI-DrugBank.d531.s39	false	DDI-DrugBank.d531.s39.e1	DDI-DrugBank.d531.s39.e2
DDI-DrugBank.d531.s39	false	DDI-DrugBank.d531.s39.e1	DDI-DrugBank.d531.s39.e3
DDI-DrugBank.d531.s39	false	DDI-DrugBank.d531.s39.e2	DDI-DrugBank.d531.s39.e3
DDI-DrugBank.d531.s40|a|Lopinavir/ritonavir
DDI-DrugBank.d531.s40	0	8	Lopinavir	drug	DDI-DrugBank.d531.s40.e0
DDI-DrugBank.d531.s40	10	18	ritonavir	drug	DDI-DrugBank.d531.s40.e1
DDI-DrugBank.d531.s40	false	DDI-DrugBank.d531.s40.e0	DDI-DrugBank.d531.s40.e1
DDI-DrugBank.d531.s41|a|lopinavir concentration
DDI-DrugBank.d531.s41	0	8	lopinavir	drug	DDI-DrugBank.d531.s41.e0
DDI-DrugBank.d531.s42|a|A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.
DDI-DrugBank.d531.s42	19	27	lopinavir	drug	DDI-DrugBank.d531.s42.e0
DDI-DrugBank.d531.s42	29	37	ritonavir	drug	DDI-DrugBank.d531.s42.e1
DDI-DrugBank.d531.s42	149	155	SUSTIVA	brand	DDI-DrugBank.d531.s42.e2
DDI-DrugBank.d531.s42	false	DDI-DrugBank.d531.s42.e0	DDI-DrugBank.d531.s42.e1
DDI-DrugBank.d531.s42	true	DDI-DrugBank.d531.s42.e0	DDI-DrugBank.d531.s42.e2
DDI-DrugBank.d531.s42	true	DDI-DrugBank.d531.s42.e1	DDI-DrugBank.d531.s42.e2
DDI-DrugBank.d531.s43|a|Methadone
DDI-DrugBank.d531.s43	0	8	Methadone	drug	DDI-DrugBank.d531.s43.e0
DDI-DrugBank.d531.s44|a|methadone concentration
DDI-DrugBank.d531.s44	0	8	methadone	drug	DDI-DrugBank.d531.s44.e0
DDI-DrugBank.d531.s45|a|Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal.
DDI-DrugBank.d531.s45	121	129	methadone	drug	DDI-DrugBank.d531.s45.e0
DDI-DrugBank.d531.s45	144	149	opiate	group	DDI-DrugBank.d531.s45.e1
DDI-DrugBank.d531.s45	false	DDI-DrugBank.d531.s45.e0	DDI-DrugBank.d531.s45.e1
DDI-DrugBank.d531.s46|a|Methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms.
DDI-DrugBank.d531.s46	0	8	Methadone	drug	DDI-DrugBank.d531.s46.e0
DDI-DrugBank.d531.s47|a|Patients should be monitored for signs of withdrawal and their methadone dose increased as required to alleviate withdrawal symptoms.
DDI-DrugBank.d531.s47	63	71	methadone	drug	DDI-DrugBank.d531.s47.e0
DDI-DrugBank.d531.s48|a|Ethinyl estradiol
DDI-DrugBank.d531.s48	0	16	Ethinyl estradiol	drug	DDI-DrugBank.d531.s48.e0
DDI-DrugBank.d531.s49|a|ethinyl estradiol concentration
DDI-DrugBank.d531.s49	0	16	ethinyl estradiol	drug	DDI-DrugBank.d531.s49.e0
DDI-DrugBank.d531.s50|a|Plasma concentrations increased by SUSTIVA (efavirenz);
DDI-DrugBank.d531.s50	35	41	SUSTIVA	brand	DDI-DrugBank.d531.s50.e0
DDI-DrugBank.d531.s50	44	52	efavirenz	drug	DDI-DrugBank.d531.s50.e1
DDI-DrugBank.d531.s50	false	DDI-DrugBank.d531.s50.e0	DDI-DrugBank.d531.s50.e1
DDI-DrugBank.d531.s51|a|clinical significance unknown.
DDI-DrugBank.d531.s52|a|Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.
DDI-DrugBank.d531.s52	37	45	efavirenz	drug	DDI-DrugBank.d531.s52.e0
DDI-DrugBank.d531.s52	57	70	contraceptives	group	DDI-DrugBank.d531.s52.e1
DDI-DrugBank.d531.s52	184	197	contraceptives	group	DDI-DrugBank.d531.s52.e2
DDI-DrugBank.d531.s52	true	DDI-DrugBank.d531.s52.e0	DDI-DrugBank.d531.s52.e1
DDI-DrugBank.d531.s52	false	DDI-DrugBank.d531.s52.e0	DDI-DrugBank.d531.s52.e2
DDI-DrugBank.d531.s52	false	DDI-DrugBank.d531.s52.e1	DDI-DrugBank.d531.s52.e2
DDI-DrugBank.d531.s53|a|Rifabutin
DDI-DrugBank.d531.s53	0	8	Rifabutin	drug	DDI-DrugBank.d531.s53.e0
DDI-DrugBank.d531.s54|a|rifabutin concentration
DDI-DrugBank.d531.s54	0	8	rifabutin	drug	DDI-DrugBank.d531.s54.e0
DDI-DrugBank.d531.s55|a|Increase daily dose of rifabutin by 50%.
DDI-DrugBank.d531.s55	23	31	rifabutin	drug	DDI-DrugBank.d531.s55.e0
DDI-DrugBank.d531.s56|a|Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.
DDI-DrugBank.d531.s56	22	30	rifabutin	drug	DDI-DrugBank.d531.s56.e0
DDI-DrugBank.d531.s56	55	63	rifabutin	drug	DDI-DrugBank.d531.s56.e1
DDI-DrugBank.d531.s56	false	DDI-DrugBank.d531.s56.e0	DDI-DrugBank.d531.s56.e1
DDI-DrugBank.d531.s57|a|Rifampin
DDI-DrugBank.d531.s57	0	7	Rifampin	drug	DDI-DrugBank.d531.s57.e0
DDI-DrugBank.d531.s58|a|efavirenz concentration
DDI-DrugBank.d531.s58	0	8	efavirenz	drug	DDI-DrugBank.d531.s58.e0
DDI-DrugBank.d531.s59|a|Clinical significance of reduced efavirenz concentrations unknown.
DDI-DrugBank.d531.s59	33	41	efavirenz	drug	DDI-DrugBank.d531.s59.e0
DDI-DrugBank.d531.s60|a|Ritonavir
DDI-DrugBank.d531.s60	0	8	Ritonavir	drug	DDI-DrugBank.d531.s60.e0
DDI-DrugBank.d531.s61|a|ritonavir concentration
DDI-DrugBank.d531.s61	0	8	ritonavir	drug	DDI-DrugBank.d531.s61.e0
DDI-DrugBank.d531.s62|a|Combination was associated with a higher frequency of adverse clinical experiences (eg, dizziness, nausea, paresthesia) and laboratory abnormalities (elevated liver enzymes).
DDI-DrugBank.d531.s63|a|Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.
DDI-DrugBank.d531.s63	48	54	SUSTIVA	brand	DDI-DrugBank.d531.s63.e0
DDI-DrugBank.d531.s63	84	92	ritonavir	drug	DDI-DrugBank.d531.s63.e1
DDI-DrugBank.d531.s63	true	DDI-DrugBank.d531.s63.e0	DDI-DrugBank.d531.s63.e1
DDI-DrugBank.d531.s64|a|efavirenz concentration
DDI-DrugBank.d531.s64	0	8	efavirenz	drug	DDI-DrugBank.d531.s64.e0
DDI-DrugBank.d531.s65|a|Saquinavir
DDI-DrugBank.d531.s65	0	9	Saquinavir	drug	DDI-DrugBank.d531.s65.e0
DDI-DrugBank.d531.s66|a|saquinavir concentration
DDI-DrugBank.d531.s66	0	9	saquinavir	drug	DDI-DrugBank.d531.s66.e0
DDI-DrugBank.d531.s67|a|Should not be used as sole protease inhibitor in combination with SUSTIVA.
DDI-DrugBank.d531.s67	27	44	protease inhibitor	group	DDI-DrugBank.d531.s67.e0
DDI-DrugBank.d531.s67	66	72	SUSTIVA	brand	DDI-DrugBank.d531.s67.e1
DDI-DrugBank.d531.s67	false	DDI-DrugBank.d531.s67.e0	DDI-DrugBank.d531.s67.e1
DDI-DrugBank.d531.s68|a|Sertraline
DDI-DrugBank.d531.s68	0	9	Sertraline	drug	DDI-DrugBank.d531.s68.e0
DDI-DrugBank.d531.s69|a|sertraline concentration
DDI-DrugBank.d531.s69	0	9	sertraline	drug	DDI-DrugBank.d531.s69.e0
DDI-DrugBank.d531.s70|a|Increases in sertraline dose should be guided by clinical response.
DDI-DrugBank.d531.s70	13	22	sertraline	drug	DDI-DrugBank.d531.s70.e0
DDI-DrugBank.d531.s71|a|Other Potentially Clinically Significant Drug or Herbal Product Interactions With SUSTIVAb
DDI-DrugBank.d531.s72|a|Anticoagulants: Warfarin
DDI-DrugBank.d531.s72	0	13	Anticoagulants	group	DDI-DrugBank.d531.s72.e0
DDI-DrugBank.d531.s72	16	23	Warfarin	drug	DDI-DrugBank.d531.s72.e1
DDI-DrugBank.d531.s72	false	DDI-DrugBank.d531.s72.e0	DDI-DrugBank.d531.s72.e1
DDI-DrugBank.d531.s73|a|Plasma concentrations and effects potentially increased or decreased by SUSTIVA.
DDI-DrugBank.d531.s73	72	78	SUSTIVA	brand	DDI-DrugBank.d531.s73.e0
DDI-DrugBank.d531.s74|a|Anticonvulsants: Phenytoin Phenobarbital Carbamazepine
DDI-DrugBank.d531.s74	0	14	Anticonvulsants	group	DDI-DrugBank.d531.s74.e0
DDI-DrugBank.d531.s74	17	25	Phenytoin	drug	DDI-DrugBank.d531.s74.e1
DDI-DrugBank.d531.s74	27	39	Phenobarbital	drug	DDI-DrugBank.d531.s74.e2
DDI-DrugBank.d531.s74	41	53	Carbamazepine	drug	DDI-DrugBank.d531.s74.e3
DDI-DrugBank.d531.s74	false	DDI-DrugBank.d531.s74.e0	DDI-DrugBank.d531.s74.e1
DDI-DrugBank.d531.s74	false	DDI-DrugBank.d531.s74.e0	DDI-DrugBank.d531.s74.e2
DDI-DrugBank.d531.s74	false	DDI-DrugBank.d531.s74.e0	DDI-DrugBank.d531.s74.e3
DDI-DrugBank.d531.s74	false	DDI-DrugBank.d531.s74.e1	DDI-DrugBank.d531.s74.e2
DDI-DrugBank.d531.s74	false	DDI-DrugBank.d531.s74.e1	DDI-DrugBank.d531.s74.e3
DDI-DrugBank.d531.s74	false	DDI-DrugBank.d531.s74.e2	DDI-DrugBank.d531.s74.e3
DDI-DrugBank.d531.s75|a|Potential for reduction in anticonvulsant and/or efavirenz plasma levels;
DDI-DrugBank.d531.s75	27	40	anticonvulsant	group	DDI-DrugBank.d531.s75.e0
DDI-DrugBank.d531.s75	49	57	efavirenz	drug	DDI-DrugBank.d531.s75.e1
DDI-DrugBank.d531.s75	true	DDI-DrugBank.d531.s75.e0	DDI-DrugBank.d531.s75.e1
DDI-DrugBank.d531.s76|a|periodic monitoring of anticonvulsant plasma levels should be conducted.
DDI-DrugBank.d531.s76	23	36	anticonvulsant	group	DDI-DrugBank.d531.s76.e0
DDI-DrugBank.d531.s77|a|Antifungals: Itraconazole Ketoconazole
DDI-DrugBank.d531.s77	0	10	Antifungals	group	DDI-DrugBank.d531.s77.e0
DDI-DrugBank.d531.s77	13	24	Itraconazole	drug	DDI-DrugBank.d531.s77.e1
DDI-DrugBank.d531.s77	26	37	Ketoconazole	drug	DDI-DrugBank.d531.s77.e2
DDI-DrugBank.d531.s77	false	DDI-DrugBank.d531.s77.e0	DDI-DrugBank.d531.s77.e1
DDI-DrugBank.d531.s77	false	DDI-DrugBank.d531.s77.e0	DDI-DrugBank.d531.s77.e2
DDI-DrugBank.d531.s77	false	DDI-DrugBank.d531.s77.e1	DDI-DrugBank.d531.s77.e2
DDI-DrugBank.d531.s78|a|Drug interaction studies with SUSTIVA and these imidazole and triazole antifungals have not been conducted.
DDI-DrugBank.d531.s78	30	36	SUSTIVA	brand	DDI-DrugBank.d531.s78.e0
DDI-DrugBank.d531.s78	48	56	imidazole antifungals	group	DDI-DrugBank.d531.s78.e1
DDI-DrugBank.d531.s78	71	81	imidazole antifungals	group	DDI-DrugBank.d531.s78.e1
DDI-DrugBank.d531.s78	62	81	triazole antifungals	group	DDI-DrugBank.d531.s78.e2
DDI-DrugBank.d531.s78	false	DDI-DrugBank.d531.s78.e0	DDI-DrugBank.d531.s78.e1
DDI-DrugBank.d531.s78	false	DDI-DrugBank.d531.s78.e0	DDI-DrugBank.d531.s78.e2
DDI-DrugBank.d531.s78	false	DDI-DrugBank.d531.s78.e1	DDI-DrugBank.d531.s78.e2
DDI-DrugBank.d531.s79|a|SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.
DDI-DrugBank.d531.s79	0	6	SUSTIVA	brand	DDI-DrugBank.d531.s79.e0
DDI-DrugBank.d531.s79	63	74	itraconazole	drug	DDI-DrugBank.d531.s79.e1
DDI-DrugBank.d531.s79	80	91	ketoconazole	drug	DDI-DrugBank.d531.s79.e2
DDI-DrugBank.d531.s79	true	DDI-DrugBank.d531.s79.e0	DDI-DrugBank.d531.s79.e1
DDI-DrugBank.d531.s79	true	DDI-DrugBank.d531.s79.e0	DDI-DrugBank.d531.s79.e2
DDI-DrugBank.d531.s79	false	DDI-DrugBank.d531.s79.e1	DDI-DrugBank.d531.s79.e2
DDI-DrugBank.d531.s80|a|Anti-HIV protease inhibitors: Saquinavir/ritonavir combination
DDI-DrugBank.d531.s80	0	27	Anti-HIV protease inhibitors	group	DDI-DrugBank.d531.s80.e0
DDI-DrugBank.d531.s80	30	39	Saquinavir	drug	DDI-DrugBank.d531.s80.e1
DDI-DrugBank.d531.s80	41	49	ritonavir	drug	DDI-DrugBank.d531.s80.e2
DDI-DrugBank.d531.s80	false	DDI-DrugBank.d531.s80.e0	DDI-DrugBank.d531.s80.e1
DDI-DrugBank.d531.s80	false	DDI-DrugBank.d531.s80.e0	DDI-DrugBank.d531.s80.e2
DDI-DrugBank.d531.s80	false	DDI-DrugBank.d531.s80.e1	DDI-DrugBank.d531.s80.e2
DDI-DrugBank.d531.s81|a|No pharmacokinetic data are available.
DDI-DrugBank.d531.s82|a|Amprenavir
DDI-DrugBank.d531.s82	0	9	Amprenavir	drug	DDI-DrugBank.d531.s82.e0
DDI-DrugBank.d531.s83|a|SUSTIVAhas the potential to decrease serum concentrations of amprenavir.
DDI-DrugBank.d531.s83	61	70	amprenavir	drug	DDI-DrugBank.d531.s83.e0
DDI-DrugBank.d531.s84|a|Non-nucleoside reverse transcriptase inhibitors
DDI-DrugBank.d531.s84	0	46	Non-nucleoside reverse transcriptase inhibitors	group	DDI-DrugBank.d531.s84.e0
DDI-DrugBank.d531.s85|a|No studies have been performed with other NNRTIs.
DDI-DrugBank.d531.s85	42	47	NNRTIs	group	DDI-DrugBank.d531.s85.e0
DDI-DrugBank.d531.s86|a|St. John s wort (Hypericum perforatum)
DDI-DrugBank.d531.s87|a|Expected to substantially decrease plasma levels of efavirenz;has not been studied in combination with SUSTIVA.
DDI-DrugBank.d531.s87	52	60	efavirenz	drug	DDI-DrugBank.d531.s87.e0
DDI-DrugBank.d531.s87	103	109	SUSTIVA	brand	DDI-DrugBank.d531.s87.e1
DDI-DrugBank.d531.s87	false	DDI-DrugBank.d531.s87.e0	DDI-DrugBank.d531.s87.e1
DDI-DrugBank.d531.s88|a|a See Tables 1 and 2.
DDI-DrugBank.d531.s89|a|b This table is not all-inclusive.
DDI-DrugBank.d531.s90|a|Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
DDI-DrugBank.d531.s90	104	110	SUSTIVA	brand	DDI-DrugBank.d531.s90.e0
DDI-DrugBank.d531.s90	113	121	efavirenz	drug	DDI-DrugBank.d531.s90.e1
DDI-DrugBank.d531.s90	153	189	aluminum/magnesium hydroxide antacids	group	DDI-DrugBank.d531.s90.e2
DDI-DrugBank.d531.s90	192	203	azithromycin	drug	DDI-DrugBank.d531.s90.e3
DDI-DrugBank.d531.s90	206	215	cetirizine	drug	DDI-DrugBank.d531.s90.e4
DDI-DrugBank.d531.s90	218	227	famotidine	drug	DDI-DrugBank.d531.s90.e5
DDI-DrugBank.d531.s90	230	240	fluconazole	drug	DDI-DrugBank.d531.s90.e6
DDI-DrugBank.d531.s90	243	252	lamivudine	drug	DDI-DrugBank.d531.s90.e7
DDI-DrugBank.d531.s90	255	263	lorazepam	drug	DDI-DrugBank.d531.s90.e8
DDI-DrugBank.d531.s90	266	275	nelfinavir	drug	DDI-DrugBank.d531.s90.e9
DDI-DrugBank.d531.s90	false	DDI-DrugBank.d531.s90.e0	DDI-DrugBank.d531.s90.e1
DDI-DrugBank.d531.s90	false	DDI-DrugBank.d531.s90.e0	DDI-DrugBank.d531.s90.e2
DDI-DrugBank.d531.s90	false	DDI-DrugBank.d531.s90.e0	DDI-DrugBank.d531.s90.e3
DDI-DrugBank.d531.s90	false	DDI-DrugBank.d531.s90.e0	DDI-DrugBank.d531.s90.e4
DDI-DrugBank.d531.s90	false	DDI-DrugBank.d531.s90.e0	DDI-DrugBank.d531.s90.e5
DDI-DrugBank.d531.s90	false	DDI-DrugBank.d531.s90.e0	DDI-DrugBank.d531.s90.e6
DDI-DrugBank.d531.s90	false	DDI-DrugBank.d531.s90.e0	DDI-DrugBank.d531.s90.e7
DDI-DrugBank.d531.s90	false	DDI-DrugBank.d531.s90.e0	DDI-DrugBank.d531.s90.e8
DDI-DrugBank.d531.s90	false	DDI-DrugBank.d531.s90.e0	DDI-DrugBank.d531.s90.e9
DDI-DrugBank.d531.s90	false	DDI-DrugBank.d531.s90.e0	DDI-DrugBank.d531.s90.e10
DDI-DrugBank.d531.s91|a|Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.
DDI-DrugBank.d531.s91	63	69	SUSTIVA	brand	DDI-DrugBank.d531.s91.e0
DDI-DrugBank.d531.s91	75	79	NRTIs	group	DDI-DrugBank.d531.s91.e1
DDI-DrugBank.d531.s91	92	101	lamivudine	drug	DDI-DrugBank.d531.s91.e2
DDI-DrugBank.d531.s91	107	116	zidovudine	drug	DDI-DrugBank.d531.s91.e3
DDI-DrugBank.d531.s91	false	DDI-DrugBank.d531.s91.e0	DDI-DrugBank.d531.s91.e1
DDI-DrugBank.d531.s91	false	DDI-DrugBank.d531.s91.e0	DDI-DrugBank.d531.s91.e2
DDI-DrugBank.d531.s91	false	DDI-DrugBank.d531.s91.e0	DDI-DrugBank.d531.s91.e3
DDI-DrugBank.d531.s91	false	DDI-DrugBank.d531.s91.e1	DDI-DrugBank.d531.s91.e2
DDI-DrugBank.d531.s91	false	DDI-DrugBank.d531.s91.e1	DDI-DrugBank.d531.s91.e3
DDI-DrugBank.d531.s91	false	DDI-DrugBank.d531.s91.e2	DDI-DrugBank.d531.s91.e3
DDI-DrugBank.d531.s92|a|Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.
DDI-DrugBank.d531.s92	68	72	NRTIs	group	DDI-DrugBank.d531.s92.e0
DDI-DrugBank.d531.s92	117	125	efavirenz	drug	DDI-DrugBank.d531.s92.e1
DDI-DrugBank.d531.s92	false	DDI-DrugBank.d531.s92.e0	DDI-DrugBank.d531.s92.e1
DDI-DrugBank.d375.s0|a|The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.
DDI-DrugBank.d375.s0	41	47	EMTRIVA	brand	DDI-DrugBank.d375.s0.e0
DDI-DrugBank.d375.s0	86	94	indinavir	drug	DDI-DrugBank.d375.s0.e1
DDI-DrugBank.d375.s0	97	105	stavudine	drug	DDI-DrugBank.d375.s0.e2
DDI-DrugBank.d375.s0	108	118	famciclovir	drug	DDI-DrugBank.d375.s0.e3
DDI-DrugBank.d375.s0	125	153	tenofovir disoproxil fumarate	drug	DDI-DrugBank.d375.s0.e4
DDI-DrugBank.d375.s0	false	DDI-DrugBank.d375.s0.e0	DDI-DrugBank.d375.s0.e1
DDI-DrugBank.d375.s0	false	DDI-DrugBank.d375.s0.e0	DDI-DrugBank.d375.s0.e2
DDI-DrugBank.d375.s0	false	DDI-DrugBank.d375.s0.e0	DDI-DrugBank.d375.s0.e3
DDI-DrugBank.d375.s0	false	DDI-DrugBank.d375.s0.e0	DDI-DrugBank.d375.s0.e4
DDI-DrugBank.d375.s0	false	DDI-DrugBank.d375.s0.e1	DDI-DrugBank.d375.s0.e2
DDI-DrugBank.d375.s0	false	DDI-DrugBank.d375.s0.e1	DDI-DrugBank.d375.s0.e3
DDI-DrugBank.d375.s0	false	DDI-DrugBank.d375.s0.e1	DDI-DrugBank.d375.s0.e4
DDI-DrugBank.d375.s0	false	DDI-DrugBank.d375.s0.e2	DDI-DrugBank.d375.s0.e3
DDI-DrugBank.d375.s0	false	DDI-DrugBank.d375.s0.e2	DDI-DrugBank.d375.s0.e4
DDI-DrugBank.d375.s0	false	DDI-DrugBank.d375.s0.e3	DDI-DrugBank.d375.s0.e4
DDI-DrugBank.d375.s1|a|There were no clinically significant drug interactions for any of these drugs
DDI-DrugBank.d375.s2|a|.
DDI-DrugBank.d375.s3|a|
DDI-DrugBank.d107.s0|a|Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.
DDI-DrugBank.d107.s0	55	63	diuretics	drug	DDI-DrugBank.d107.s0.e0
DDI-DrugBank.d107.s0	238	246	enalapril	drug	DDI-DrugBank.d107.s0.e1
DDI-DrugBank.d107.s0	251	261	enalaprilat	drug	DDI-DrugBank.d107.s0.e2
DDI-DrugBank.d107.s0	true	DDI-DrugBank.d107.s0.e0	DDI-DrugBank.d107.s0.e1
DDI-DrugBank.d107.s0	true	DDI-DrugBank.d107.s0.e0	DDI-DrugBank.d107.s0.e2
DDI-DrugBank.d107.s0	false	DDI-DrugBank.d107.s0.e1	DDI-DrugBank.d107.s0.e2
DDI-DrugBank.d107.s1|a|The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
DDI-DrugBank.d107.s1	44	52	enalapril	drug	DDI-DrugBank.d107.s1.e0
DDI-DrugBank.d107.s1	57	67	enalaprilat	drug	DDI-DrugBank.d107.s1.e1
DDI-DrugBank.d107.s1	114	121	diuretic	drug	DDI-DrugBank.d107.s1.e2
DDI-DrugBank.d107.s1	191	199	enalapril	drug	DDI-DrugBank.d107.s1.e3
DDI-DrugBank.d107.s1	204	214	enalaprilat	drug	DDI-DrugBank.d107.s1.e4
DDI-DrugBank.d107.s1	false	DDI-DrugBank.d107.s1.e0	DDI-DrugBank.d107.s1.e1
DDI-DrugBank.d107.s1	true	DDI-DrugBank.d107.s1.e0	DDI-DrugBank.d107.s1.e2
DDI-DrugBank.d107.s1	false	DDI-DrugBank.d107.s1.e0	DDI-DrugBank.d107.s1.e3
DDI-DrugBank.d107.s1	false	DDI-DrugBank.d107.s1.e0	DDI-DrugBank.d107.s1.e4
DDI-DrugBank.d107.s1	true	DDI-DrugBank.d107.s1.e1	DDI-DrugBank.d107.s1.e2
DDI-DrugBank.d107.s1	false	DDI-DrugBank.d107.s1.e1	DDI-DrugBank.d107.s1.e3
DDI-DrugBank.d107.s1	false	DDI-DrugBank.d107.s1.e1	DDI-DrugBank.d107.s1.e4
DDI-DrugBank.d107.s1	false	DDI-DrugBank.d107.s1.e2	DDI-DrugBank.d107.s1.e3
DDI-DrugBank.d107.s1	false	DDI-DrugBank.d107.s1.e2	DDI-DrugBank.d107.s1.e4
DDI-DrugBank.d107.s1	false	DDI-DrugBank.d107.s1.e3	DDI-DrugBank.d107.s1.e4
DDI-DrugBank.d107.s2|a|If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour..
DDI-DrugBank.d107.s2	35	42	diuretic	group	DDI-DrugBank.d107.s2.e0
DDI-DrugBank.d107.s3|a|Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
DDI-DrugBank.d107.s3	61	69	enalapril	drug	DDI-DrugBank.d107.s3.e0
DDI-DrugBank.d107.s3	75	83	enalapril	drug	DDI-DrugBank.d107.s3.e1
DDI-DrugBank.d107.s3	104	126	antihypertensive agents	group	DDI-DrugBank.d107.s3.e2
DDI-DrugBank.d107.s3	160	168	diuretics	group	DDI-DrugBank.d107.s3.e3
DDI-DrugBank.d107.s3	false	DDI-DrugBank.d107.s3.e0	DDI-DrugBank.d107.s3.e1
DDI-DrugBank.d107.s3	true	DDI-DrugBank.d107.s3.e0	DDI-DrugBank.d107.s3.e2
DDI-DrugBank.d107.s3	true	DDI-DrugBank.d107.s3.e0	DDI-DrugBank.d107.s3.e3
DDI-DrugBank.d107.s3	true	DDI-DrugBank.d107.s3.e1	DDI-DrugBank.d107.s3.e2
DDI-DrugBank.d107.s3	true	DDI-DrugBank.d107.s3.e1	DDI-DrugBank.d107.s3.e3
DDI-DrugBank.d107.s3	false	DDI-DrugBank.d107.s3.e2	DDI-DrugBank.d107.s3.e3
DDI-DrugBank.d107.s4|a|Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.
DDI-DrugBank.d107.s4	0	37	Non-steroidal Anti-inflammatory Agents	group	DDI-DrugBank.d107.s4.e0
DDI-DrugBank.d107.s4	116	151	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d107.s4.e1
DDI-DrugBank.d107.s4	179	187	enalapril	drug	DDI-DrugBank.d107.s4.e2
DDI-DrugBank.d107.s4	false	DDI-DrugBank.d107.s4.e0	DDI-DrugBank.d107.s4.e1
DDI-DrugBank.d107.s4	false	DDI-DrugBank.d107.s4.e0	DDI-DrugBank.d107.s4.e2
DDI-DrugBank.d107.s4	true	DDI-DrugBank.d107.s4.e1	DDI-DrugBank.d107.s4.e2
DDI-DrugBank.d107.s5|a|These effects are usually reversible.
DDI-DrugBank.d107.s6|a|In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC.
DDI-DrugBank.d107.s6	34	45	indomethacin	drug	DDI-DrugBank.d107.s6.e0
DDI-DrugBank.d107.s6	50	57	sulindac	drug	DDI-DrugBank.d107.s6.e1
DDI-DrugBank.d107.s6	111	117	VASOTEC	brand	DDI-DrugBank.d107.s6.e2
DDI-DrugBank.d107.s6	false	DDI-DrugBank.d107.s6.e0	DDI-DrugBank.d107.s6.e1
DDI-DrugBank.d107.s6	false	DDI-DrugBank.d107.s6.e0	DDI-DrugBank.d107.s6.e2
DDI-DrugBank.d107.s6	false	DDI-DrugBank.d107.s6.e1	DDI-DrugBank.d107.s6.e2
DDI-DrugBank.d107.s7|a|In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC.
DDI-DrugBank.d107.s7	84	90	VASOTEC	brand	DDI-DrugBank.d107.s7.e0
DDI-DrugBank.d107.s8|a|However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
DDI-DrugBank.d107.s8	30	35	NSAIDs	group	DDI-DrugBank.d107.s8.e0
DDI-DrugBank.d107.s8	81	94	ACE inhibitors	group	DDI-DrugBank.d107.s8.e1
DDI-DrugBank.d107.s8	true	DDI-DrugBank.d107.s8.e0	DDI-DrugBank.d107.s8.e1
DDI-DrugBank.d107.s9|a|This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
DDI-DrugBank.d107.s9	66	71	NSAIDs	group	DDI-DrugBank.d107.s9.e0
DDI-DrugBank.d107.s9	92	105	ACE inhibitors	group	DDI-DrugBank.d107.s9.e1
DDI-DrugBank.d107.s9	true	DDI-DrugBank.d107.s9.e0	DDI-DrugBank.d107.s9.e1
DDI-DrugBank.d107.s10|a|Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
DDI-DrugBank.d107.s10	29	37	Enalapril	drug	DDI-DrugBank.d107.s10.e0
DDI-DrugBank.d107.s10	43	51	enalapril	drug	DDI-DrugBank.d107.s10.e1
DDI-DrugBank.d107.s10	90	120	beta adrenergic-blocking agents	group	DDI-DrugBank.d107.s10.e2
DDI-DrugBank.d107.s10	123	132	methyldopa	drug	DDI-DrugBank.d107.s10.e3
DDI-DrugBank.d107.s10	135	142	nitrates	group	DDI-DrugBank.d107.s10.e4
DDI-DrugBank.d107.s10	145	167	calcium-blocking agents	group	DDI-DrugBank.d107.s10.e5
DDI-DrugBank.d107.s10	170	180	hydralazine	drug	DDI-DrugBank.d107.s10.e6
DDI-DrugBank.d107.s10	183	190	prazosin	drug	DDI-DrugBank.d107.s10.e7
DDI-DrugBank.d107.s10	196	202	digoxin	drug	DDI-DrugBank.d107.s10.e8
DDI-DrugBank.d107.s10	false	DDI-DrugBank.d107.s10.e0	DDI-DrugBank.d107.s10.e1
DDI-DrugBank.d107.s10	false	DDI-DrugBank.d107.s10.e0	DDI-DrugBank.d107.s10.e2
DDI-DrugBank.d107.s10	false	DDI-DrugBank.d107.s10.e0	DDI-DrugBank.d107.s10.e3
DDI-DrugBank.d107.s10	false	DDI-DrugBank.d107.s10.e0	DDI-DrugBank.d107.s10.e4
DDI-DrugBank.d107.s10	false	DDI-DrugBank.d107.s10.e0	DDI-DrugBank.d107.s10.e5
DDI-DrugBank.d107.s10	false	DDI-DrugBank.d107.s10.e0	DDI-DrugBank.d107.s10.e6
DDI-DrugBank.d107.s10	false	DDI-DrugBank.d107.s10.e0	DDI-DrugBank.d107.s10.e7
DDI-DrugBank.d107.s10	false	DDI-DrugBank.d107.s10.e0	DDI-DrugBank.d107.s10.e8
DDI-DrugBank.d107.s10	false	DDI-DrugBank.d107.s10.e1	DDI-DrugBank.d107.s10.e2
DDI-DrugBank.d107.s10	false	DDI-DrugBank.d107.s10.e1	DDI-DrugBank.d107.s10.e3
DDI-DrugBank.d107.s11|a|Enalapril IV has been used concomitantly with digitalis without evidence of clinically significant adverse reactions.
DDI-DrugBank.d107.s11	0	8	Enalapril	drug	DDI-DrugBank.d107.s11.e0
DDI-DrugBank.d107.s11	46	54	digitalis	group	DDI-DrugBank.d107.s11.e1
DDI-DrugBank.d107.s11	false	DDI-DrugBank.d107.s11.e0	DDI-DrugBank.d107.s11.e1
DDI-DrugBank.d107.s12|a|Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.
DDI-DrugBank.d107.s12	35	43	Enalapril	drug	DDI-DrugBank.d107.s12.e0
DDI-DrugBank.d107.s12	49	57	enalapril	drug	DDI-DrugBank.d107.s12.e1
DDI-DrugBank.d107.s12	97	119	thiazide-type diuretics	group	DDI-DrugBank.d107.s12.e2
DDI-DrugBank.d107.s12	false	DDI-DrugBank.d107.s12.e0	DDI-DrugBank.d107.s12.e1
DDI-DrugBank.d107.s12	true	DDI-DrugBank.d107.s12.e0	DDI-DrugBank.d107.s12.e2
DDI-DrugBank.d107.s12	true	DDI-DrugBank.d107.s12.e1	DDI-DrugBank.d107.s12.e2
DDI-DrugBank.d107.s13|a|Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
DDI-DrugBank.d107.s13	0	26	Potassium-sparing diuretics	group	DDI-DrugBank.d107.s13.e0
DDI-DrugBank.d107.s13	35	48	spironolactone	drug	DDI-DrugBank.d107.s13.e1
DDI-DrugBank.d107.s13	51	61	triamterene	drug	DDI-DrugBank.d107.s13.e2
DDI-DrugBank.d107.s13	67	75	amiloride	drug	DDI-DrugBank.d107.s13.e3
DDI-DrugBank.d107.s13	79	87	potassium	drug	DDI-DrugBank.d107.s13.e4
DDI-DrugBank.d107.s13	105	113	potassium	drug	DDI-DrugBank.d107.s13.e5
DDI-DrugBank.d107.s13	false	DDI-DrugBank.d107.s13.e0	DDI-DrugBank.d107.s13.e1
DDI-DrugBank.d107.s13	false	DDI-DrugBank.d107.s13.e0	DDI-DrugBank.d107.s13.e2
DDI-DrugBank.d107.s13	false	DDI-DrugBank.d107.s13.e0	DDI-DrugBank.d107.s13.e3
DDI-DrugBank.d107.s13	false	DDI-DrugBank.d107.s13.e0	DDI-DrugBank.d107.s13.e4
DDI-DrugBank.d107.s13	false	DDI-DrugBank.d107.s13.e0	DDI-DrugBank.d107.s13.e5
DDI-DrugBank.d107.s13	false	DDI-DrugBank.d107.s13.e1	DDI-DrugBank.d107.s13.e2
DDI-DrugBank.d107.s13	false	DDI-DrugBank.d107.s13.e1	DDI-DrugBank.d107.s13.e3
DDI-DrugBank.d107.s13	false	DDI-DrugBank.d107.s13.e1	DDI-DrugBank.d107.s13.e4
DDI-DrugBank.d107.s13	false	DDI-DrugBank.d107.s13.e1	DDI-DrugBank.d107.s13.e5
DDI-DrugBank.d107.s13	false	DDI-DrugBank.d107.s13.e2	DDI-DrugBank.d107.s13.e3
DDI-DrugBank.d107.s14|a|Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.
DDI-DrugBank.d107.s15|a|Potassium sparing agents should generally not be used in patients with heart failure receiving enalapril.
DDI-DrugBank.d107.s15	95	103	enalapril	drug	DDI-DrugBank.d107.s15.e0
DDI-DrugBank.d107.s16|a|Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
DDI-DrugBank.d107.s16	0	6	Lithium	drug	DDI-DrugBank.d107.s16.e0
DDI-DrugBank.d107.s16	9	15	Lithium	drug	DDI-DrugBank.d107.s16.e1
DDI-DrugBank.d107.s16	66	72	lithium	drug	DDI-DrugBank.d107.s16.e2
DDI-DrugBank.d107.s16	144	157	ACE inhibitors	group	DDI-DrugBank.d107.s16.e3
DDI-DrugBank.d107.s16	false	DDI-DrugBank.d107.s16.e0	DDI-DrugBank.d107.s16.e1
DDI-DrugBank.d107.s16	false	DDI-DrugBank.d107.s16.e0	DDI-DrugBank.d107.s16.e2
DDI-DrugBank.d107.s16	false	DDI-DrugBank.d107.s16.e0	DDI-DrugBank.d107.s16.e3
DDI-DrugBank.d107.s16	false	DDI-DrugBank.d107.s16.e1	DDI-DrugBank.d107.s16.e2
DDI-DrugBank.d107.s16	false	DDI-DrugBank.d107.s16.e1	DDI-DrugBank.d107.s16.e3
DDI-DrugBank.d107.s16	true	DDI-DrugBank.d107.s16.e2	DDI-DrugBank.d107.s16.e3
DDI-DrugBank.d107.s17|a|It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.
DDI-DrugBank.d107.s17	29	35	lithium	drug	DDI-DrugBank.d107.s17.e0
DDI-DrugBank.d107.s17	71	79	enalapril	drug	DDI-DrugBank.d107.s17.e1
DDI-DrugBank.d107.s17	116	122	lithium	drug	DDI-DrugBank.d107.s17.e2
DDI-DrugBank.d107.s17	false	DDI-DrugBank.d107.s17.e0	DDI-DrugBank.d107.s17.e1
DDI-DrugBank.d107.s17	false	DDI-DrugBank.d107.s17.e0	DDI-DrugBank.d107.s17.e2
DDI-DrugBank.d107.s17	true	DDI-DrugBank.d107.s17.e1	DDI-DrugBank.d107.s17.e2
DDI-DrugBank.d6.s0|a|The action of nondepolarizing relaxants is augmented by Enflurane.
DDI-DrugBank.d6.s0	56	64	Enflurane	drug	DDI-DrugBank.d6.s0.e0
DDI-DrugBank.d6.s1|a|Less than the usual amounts of these medicines should be used.
DDI-DrugBank.d6.s2|a|If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.
DDI-DrugBank.d6.s2	145	153	Enflurane	drug	DDI-DrugBank.d6.s2.e0
DDI-DrugBank.d6.s2	165	173	halothane	drug	DDI-DrugBank.d6.s2.e1
DDI-DrugBank.d6.s2	178	190	nitrous oxide	drug	DDI-DrugBank.d6.s2.e2
DDI-DrugBank.d6.s2	false	DDI-DrugBank.d6.s2.e0	DDI-DrugBank.d6.s2.e1
DDI-DrugBank.d6.s2	false	DDI-DrugBank.d6.s2.e0	DDI-DrugBank.d6.s2.e2
DDI-DrugBank.d6.s2	false	DDI-DrugBank.d6.s2.e1	DDI-DrugBank.d6.s2.e2
DDI-DrugBank.d535.s0|a|CYP450 Metabolized Drugs Results from in vitro and in vivo studies suggest that enfuvirtide is unlikely to have significant drug interactions with concomitantly administered drugs metabolized by CYP450 enzymes.
DDI-DrugBank.d535.s0	80	90	enfuvirtide	drug	DDI-DrugBank.d535.s0.e0
DDI-DrugBank.d535.s1|a|Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.
DDI-DrugBank.d535.s1	0	20	Antiretroviral Agents	group	DDI-DrugBank.d535.s1.e0
DDI-DrugBank.d535.s1	55	80	antiretroviral medications	group	DDI-DrugBank.d535.s1.e1
DDI-DrugBank.d535.s1	147	157	enfuvirtide	drug	DDI-DrugBank.d535.s1.e2
DDI-DrugBank.d535.s1	189	213	antiretroviral medication	group	DDI-DrugBank.d535.s1.e3
DDI-DrugBank.d535.s1	false	DDI-DrugBank.d535.s1.e0	DDI-DrugBank.d535.s1.e1
DDI-DrugBank.d535.s1	false	DDI-DrugBank.d535.s1.e0	DDI-DrugBank.d535.s1.e2
DDI-DrugBank.d535.s1	false	DDI-DrugBank.d535.s1.e0	DDI-DrugBank.d535.s1.e3
DDI-DrugBank.d535.s1	false	DDI-DrugBank.d535.s1.e1	DDI-DrugBank.d535.s1.e2
DDI-DrugBank.d535.s1	false	DDI-DrugBank.d535.s1.e1	DDI-DrugBank.d535.s1.e3
DDI-DrugBank.d535.s1	false	DDI-DrugBank.d535.s1.e2	DDI-DrugBank.d535.s1.e3
DDI-DrugBank.d395.s0|a|Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.
DDI-DrugBank.d395.s0	0	6	Bismuth	drug	DDI-DrugBank.d395.s0.e0
DDI-DrugBank.d395.s0	9	29	Bismuth subsalicylate	drug	DDI-DrugBank.d395.s0.e1
DDI-DrugBank.d395.s0	57	64	enoxacin	drug	DDI-DrugBank.d395.s0.e2
DDI-DrugBank.d395.s0	90	97	enoxacin	drug	DDI-DrugBank.d395.s0.e3
DDI-DrugBank.d395.s0	125	132	enoxacin	drug	DDI-DrugBank.d395.s0.e4
DDI-DrugBank.d395.s0	false	DDI-DrugBank.d395.s0.e0	DDI-DrugBank.d395.s0.e1
DDI-DrugBank.d395.s0	false	DDI-DrugBank.d395.s0.e0	DDI-DrugBank.d395.s0.e2
DDI-DrugBank.d395.s0	false	DDI-DrugBank.d395.s0.e0	DDI-DrugBank.d395.s0.e3
DDI-DrugBank.d395.s0	false	DDI-DrugBank.d395.s0.e0	DDI-DrugBank.d395.s0.e4
DDI-DrugBank.d395.s0	true	DDI-DrugBank.d395.s0.e1	DDI-DrugBank.d395.s0.e2
DDI-DrugBank.d395.s0	false	DDI-DrugBank.d395.s0.e1	DDI-DrugBank.d395.s0.e3
DDI-DrugBank.d395.s0	false	DDI-DrugBank.d395.s0.e1	DDI-DrugBank.d395.s0.e4
DDI-DrugBank.d395.s0	false	DDI-DrugBank.d395.s0.e2	DDI-DrugBank.d395.s0.e3
DDI-DrugBank.d395.s0	false	DDI-DrugBank.d395.s0.e2	DDI-DrugBank.d395.s0.e4
DDI-DrugBank.d395.s0	false	DDI-DrugBank.d395.s0.e3	DDI-DrugBank.d395.s0.e4
DDI-DrugBank.d395.s1|a|Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.
DDI-DrugBank.d395.s1	36	43	enoxacin	drug	DDI-DrugBank.d395.s1.e0
DDI-DrugBank.d395.s1	49	69	bismuth subsalicylate	drug	DDI-DrugBank.d395.s1.e1
DDI-DrugBank.d395.s1	true	DDI-DrugBank.d395.s1.e0	DDI-DrugBank.d395.s1.e1
DDI-DrugBank.d395.s2|a|Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
DDI-DrugBank.d395.s2	0	7	Caffeine	drug	DDI-DrugBank.d395.s2.e0
DDI-DrugBank.d395.s2	10	17	Enoxacin	drug	DDI-DrugBank.d395.s2.e1
DDI-DrugBank.d395.s2	108	122	methylxanthines	group	DDI-DrugBank.d395.s2.e2
DDI-DrugBank.d395.s2	false	DDI-DrugBank.d395.s2.e0	DDI-DrugBank.d395.s2.e1
DDI-DrugBank.d395.s2	false	DDI-DrugBank.d395.s2.e0	DDI-DrugBank.d395.s2.e2
DDI-DrugBank.d395.s2	true	DDI-DrugBank.d395.s2.e1	DDI-DrugBank.d395.s2.e2
DDI-DrugBank.d395.s3|a|In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
DDI-DrugBank.d395.s3	26	33	enoxacin	drug	DDI-DrugBank.d395.s3.e0
DDI-DrugBank.d395.s3	103	110	caffeine	drug	DDI-DrugBank.d395.s3.e1
DDI-DrugBank.d395.s3	149	156	caffeine	drug	DDI-DrugBank.d395.s3.e2
DDI-DrugBank.d395.s3	239	246	caffeine	drug	DDI-DrugBank.d395.s3.e3
DDI-DrugBank.d395.s3	true	DDI-DrugBank.d395.s3.e0	DDI-DrugBank.d395.s3.e1
DDI-DrugBank.d395.s3	false	DDI-DrugBank.d395.s3.e0	DDI-DrugBank.d395.s3.e2
DDI-DrugBank.d395.s3	false	DDI-DrugBank.d395.s3.e0	DDI-DrugBank.d395.s3.e3
DDI-DrugBank.d395.s3	false	DDI-DrugBank.d395.s3.e1	DDI-DrugBank.d395.s3.e2
DDI-DrugBank.d395.s3	false	DDI-DrugBank.d395.s3.e1	DDI-DrugBank.d395.s3.e3
DDI-DrugBank.d395.s3	false	DDI-DrugBank.d395.s3.e2	DDI-DrugBank.d395.s3.e3
DDI-DrugBank.d395.s4|a|Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.
DDI-DrugBank.d395.s4	14	21	enoxacin	drug	DDI-DrugBank.d395.s4.e0
DDI-DrugBank.d395.s4	56	63	caffeine	drug	DDI-DrugBank.d395.s4.e1
DDI-DrugBank.d395.s4	69	76	enoxacin	drug	DDI-DrugBank.d395.s4.e2
DDI-DrugBank.d395.s4	false	DDI-DrugBank.d395.s4.e0	DDI-DrugBank.d395.s4.e1
DDI-DrugBank.d395.s4	false	DDI-DrugBank.d395.s4.e0	DDI-DrugBank.d395.s4.e2
DDI-DrugBank.d395.s4	true	DDI-DrugBank.d395.s4.e1	DDI-DrugBank.d395.s4.e2
DDI-DrugBank.d395.s5|a|Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
DDI-DrugBank.d395.s5	0	7	Caffeine	drug	DDI-DrugBank.d395.s5.e0
DDI-DrugBank.d395.s5	69	76	caffeine	drug	DDI-DrugBank.d395.s5.e1
DDI-DrugBank.d395.s5	100	107	enoxacin	drug	DDI-DrugBank.d395.s5.e2
DDI-DrugBank.d395.s5	false	DDI-DrugBank.d395.s5.e0	DDI-DrugBank.d395.s5.e1
DDI-DrugBank.d395.s5	false	DDI-DrugBank.d395.s5.e0	DDI-DrugBank.d395.s5.e2
DDI-DrugBank.d395.s5	true	DDI-DrugBank.d395.s5.e1	DDI-DrugBank.d395.s5.e2
DDI-DrugBank.d395.s6|a|Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
DDI-DrugBank.d395.s6	0	11	Cyclosporine	drug	DDI-DrugBank.d395.s6.e0
DDI-DrugBank.d395.s6	39	50	cyclosporine	drug	DDI-DrugBank.d395.s6.e1
DDI-DrugBank.d395.s6	95	106	cyclosporine	drug	DDI-DrugBank.d395.s6.e2
DDI-DrugBank.d395.s6	134	148	quinolone class	group	DDI-DrugBank.d395.s6.e3
DDI-DrugBank.d395.s6	false	DDI-DrugBank.d395.s6.e0	DDI-DrugBank.d395.s6.e1
DDI-DrugBank.d395.s6	false	DDI-DrugBank.d395.s6.e0	DDI-DrugBank.d395.s6.e2
DDI-DrugBank.d395.s6	false	DDI-DrugBank.d395.s6.e0	DDI-DrugBank.d395.s6.e3
DDI-DrugBank.d395.s6	false	DDI-DrugBank.d395.s6.e1	DDI-DrugBank.d395.s6.e2
DDI-DrugBank.d395.s6	false	DDI-DrugBank.d395.s6.e1	DDI-DrugBank.d395.s6.e3
DDI-DrugBank.d395.s6	true	DDI-DrugBank.d395.s6.e2	DDI-DrugBank.d395.s6.e3
DDI-DrugBank.d395.s7|a|Digoxin: Enoxacin may raise serum digoxin levels in some individuals.
DDI-DrugBank.d395.s7	0	6	Digoxin	drug	DDI-DrugBank.d395.s7.e0
DDI-DrugBank.d395.s7	9	16	Enoxacin	drug	DDI-DrugBank.d395.s7.e1
DDI-DrugBank.d395.s7	34	40	digoxin	drug	DDI-DrugBank.d395.s7.e2
DDI-DrugBank.d395.s7	false	DDI-DrugBank.d395.s7.e0	DDI-DrugBank.d395.s7.e1
DDI-DrugBank.d395.s7	false	DDI-DrugBank.d395.s7.e0	DDI-DrugBank.d395.s7.e2
DDI-DrugBank.d395.s7	true	DDI-DrugBank.d395.s7.e1	DDI-DrugBank.d395.s7.e2
DDI-DrugBank.d395.s8|a|If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
DDI-DrugBank.d395.s8	36	42	digoxin	drug	DDI-DrugBank.d395.s8.e0
DDI-DrugBank.d395.s8	64	71	enoxacin	drug	DDI-DrugBank.d395.s8.e1
DDI-DrugBank.d395.s8	77	83	digoxin	drug	DDI-DrugBank.d395.s8.e2
DDI-DrugBank.d395.s8	149	155	digoxin	drug	DDI-DrugBank.d395.s8.e3
DDI-DrugBank.d395.s8	175	181	digoxin	drug	DDI-DrugBank.d395.s8.e4
DDI-DrugBank.d395.s8	false	DDI-DrugBank.d395.s8.e0	DDI-DrugBank.d395.s8.e1
DDI-DrugBank.d395.s8	false	DDI-DrugBank.d395.s8.e0	DDI-DrugBank.d395.s8.e2
DDI-DrugBank.d395.s8	false	DDI-DrugBank.d395.s8.e0	DDI-DrugBank.d395.s8.e3
DDI-DrugBank.d395.s8	false	DDI-DrugBank.d395.s8.e0	DDI-DrugBank.d395.s8.e4
DDI-DrugBank.d395.s8	true	DDI-DrugBank.d395.s8.e1	DDI-DrugBank.d395.s8.e2
DDI-DrugBank.d395.s8	false	DDI-DrugBank.d395.s8.e1	DDI-DrugBank.d395.s8.e3
DDI-DrugBank.d395.s8	false	DDI-DrugBank.d395.s8.e1	DDI-DrugBank.d395.s8.e4
DDI-DrugBank.d395.s8	false	DDI-DrugBank.d395.s8.e2	DDI-DrugBank.d395.s8.e3
DDI-DrugBank.d395.s8	false	DDI-DrugBank.d395.s8.e2	DDI-DrugBank.d395.s8.e4
DDI-DrugBank.d395.s8	false	DDI-DrugBank.d395.s8.e3	DDI-DrugBank.d395.s8.e4
DDI-DrugBank.d395.s9|a|Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.
DDI-DrugBank.d395.s9	0	37	Non-steroidal anti-inflammatory agents	group	DDI-DrugBank.d395.s9.e0
DDI-DrugBank.d395.s9	87	94	enoxacin	drug	DDI-DrugBank.d395.s9.e1
DDI-DrugBank.d395.s9	119	153	nonsteroidal anti-inflammatory drug	group	DDI-DrugBank.d395.s9.e2
DDI-DrugBank.d395.s9	155	162	fenbufen	drug	DDI-DrugBank.d395.s9.e3
DDI-DrugBank.d395.s9	false	DDI-DrugBank.d395.s9.e0	DDI-DrugBank.d395.s9.e1
DDI-DrugBank.d395.s9	false	DDI-DrugBank.d395.s9.e0	DDI-DrugBank.d395.s9.e2
DDI-DrugBank.d395.s9	false	DDI-DrugBank.d395.s9.e0	DDI-DrugBank.d395.s9.e3
DDI-DrugBank.d395.s9	false	DDI-DrugBank.d395.s9.e1	DDI-DrugBank.d395.s9.e2
DDI-DrugBank.d395.s9	true	DDI-DrugBank.d395.s9.e1	DDI-DrugBank.d395.s9.e3
DDI-DrugBank.d395.s9	false	DDI-DrugBank.d395.s9.e2	DDI-DrugBank.d395.s9.e3
DDI-DrugBank.d395.s10|a|Animal studies also suggest an increased potential for seizures when these two drugs are given concomitantly.
DDI-DrugBank.d395.s11|a|Fenbufen is not approved in the United States at this time.
DDI-DrugBank.d395.s11	0	7	Fenbufen	drug	DDI-DrugBank.d395.s11.e0
DDI-DrugBank.d395.s12|a|Sucralfate and antacids: Quinolones form chelates with metal cations.
DDI-DrugBank.d395.s12	0	9	Sucralfate	drug	DDI-DrugBank.d395.s12.e0
DDI-DrugBank.d395.s12	15	22	antacids	group	DDI-DrugBank.d395.s12.e1
DDI-DrugBank.d395.s12	25	34	Quinolones	group	DDI-DrugBank.d395.s12.e2
DDI-DrugBank.d395.s12	false	DDI-DrugBank.d395.s12.e0	DDI-DrugBank.d395.s12.e1
DDI-DrugBank.d395.s12	false	DDI-DrugBank.d395.s12.e0	DDI-DrugBank.d395.s12.e2
DDI-DrugBank.d395.s12	false	DDI-DrugBank.d395.s12.e1	DDI-DrugBank.d395.s12.e2
DDI-DrugBank.d395.s13|a|Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;
DDI-DrugBank.d395.s13	29	38	quinolones	group	DDI-DrugBank.d395.s13.e0
DDI-DrugBank.d395.s13	45	52	antacids	group	DDI-DrugBank.d395.s13.e1
DDI-DrugBank.d395.s13	65	71	calcium	drug	DDI-DrugBank.d395.s13.e2
DDI-DrugBank.d395.s13	74	82	magnesium	drug	DDI-DrugBank.d395.s13.e3
DDI-DrugBank.d395.s13	88	95	aluminum	drug	DDI-DrugBank.d395.s13.e4
DDI-DrugBank.d395.s13	false	DDI-DrugBank.d395.s13.e0	DDI-DrugBank.d395.s13.e1
DDI-DrugBank.d395.s13	false	DDI-DrugBank.d395.s13.e0	DDI-DrugBank.d395.s13.e2
DDI-DrugBank.d395.s13	false	DDI-DrugBank.d395.s13.e0	DDI-DrugBank.d395.s13.e3
DDI-DrugBank.d395.s13	false	DDI-DrugBank.d395.s13.e0	DDI-DrugBank.d395.s13.e4
DDI-DrugBank.d395.s13	false	DDI-DrugBank.d395.s13.e1	DDI-DrugBank.d395.s13.e2
DDI-DrugBank.d395.s13	false	DDI-DrugBank.d395.s13.e1	DDI-DrugBank.d395.s13.e3
DDI-DrugBank.d395.s13	false	DDI-DrugBank.d395.s13.e1	DDI-DrugBank.d395.s13.e4
DDI-DrugBank.d395.s13	false	DDI-DrugBank.d395.s13.e2	DDI-DrugBank.d395.s13.e3
DDI-DrugBank.d395.s13	false	DDI-DrugBank.d395.s13.e2	DDI-DrugBank.d395.s13.e4
DDI-DrugBank.d395.s13	false	DDI-DrugBank.d395.s13.e3	DDI-DrugBank.d395.s13.e4
DDI-DrugBank.d395.s14|a|with sucralfate;
DDI-DrugBank.d395.s14	5	14	sucralfate	drug	DDI-DrugBank.d395.s14.e0
DDI-DrugBank.d395.s15|a|with divalent or trivalent cations such as iron;
DDI-DrugBank.d395.s15	43	46	iron	drug	DDI-DrugBank.d395.s15.e0
DDI-DrugBank.d395.s16|a|or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.
DDI-DrugBank.d395.s16	8	20	multivitamins	group	DDI-DrugBank.d395.s16.e0
DDI-DrugBank.d395.s16	33	36	zinc	drug	DDI-DrugBank.d395.s16.e1
DDI-DrugBank.d395.s16	132	140	quinolone	group	DDI-DrugBank.d395.s16.e2
DDI-DrugBank.d395.s16	false	DDI-DrugBank.d395.s16.e0	DDI-DrugBank.d395.s16.e1
DDI-DrugBank.d395.s16	false	DDI-DrugBank.d395.s16.e0	DDI-DrugBank.d395.s16.e2
DDI-DrugBank.d395.s16	true	DDI-DrugBank.d395.s16.e1	DDI-DrugBank.d395.s16.e2
DDI-DrugBank.d395.s17|a|Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
DDI-DrugBank.d395.s17	0	7	Antacids	group	DDI-DrugBank.d395.s17.e0
DDI-DrugBank.d395.s17	20	37	aluminum hydroxide	drug	DDI-DrugBank.d395.s17.e1
DDI-DrugBank.d395.s17	43	61	magnesium hydroxide	drug	DDI-DrugBank.d395.s17.e2
DDI-DrugBank.d395.s17	93	100	enoxacin	drug	DDI-DrugBank.d395.s17.e3
DDI-DrugBank.d395.s17	false	DDI-DrugBank.d395.s17.e0	DDI-DrugBank.d395.s17.e1
DDI-DrugBank.d395.s17	false	DDI-DrugBank.d395.s17.e0	DDI-DrugBank.d395.s17.e2
DDI-DrugBank.d395.s17	false	DDI-DrugBank.d395.s17.e0	DDI-DrugBank.d395.s17.e3
DDI-DrugBank.d395.s17	false	DDI-DrugBank.d395.s17.e1	DDI-DrugBank.d395.s17.e2
DDI-DrugBank.d395.s17	true	DDI-DrugBank.d395.s17.e1	DDI-DrugBank.d395.s17.e3
DDI-DrugBank.d395.s17	true	DDI-DrugBank.d395.s17.e2	DDI-DrugBank.d395.s17.e3
DDI-DrugBank.d395.s18|a|The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.
DDI-DrugBank.d395.s18	28	35	enoxacin	drug	DDI-DrugBank.d395.s18.e0
DDI-DrugBank.d395.s18	80	89	ranitidine	drug	DDI-DrugBank.d395.s18.e1
DDI-DrugBank.d395.s18	true	DDI-DrugBank.d395.s18.e0	DDI-DrugBank.d395.s18.e1
DDI-DrugBank.d395.s19|a|These agents should not be taken for 8 hours before or for 2 hours after enoxacin administration.
DDI-DrugBank.d395.s19	73	80	enoxacin	drug	DDI-DrugBank.d395.s19.e0
DDI-DrugBank.d395.s20|a|Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
DDI-DrugBank.d395.s20	0	11	Theophylline	drug	DDI-DrugBank.d395.s20.e0
DDI-DrugBank.d395.s20	14	21	Enoxacin	drug	DDI-DrugBank.d395.s20.e1
DDI-DrugBank.d395.s20	112	126	methylxanthines	group	DDI-DrugBank.d395.s20.e2
DDI-DrugBank.d395.s20	false	DDI-DrugBank.d395.s20.e0	DDI-DrugBank.d395.s20.e1
DDI-DrugBank.d395.s20	false	DDI-DrugBank.d395.s20.e0	DDI-DrugBank.d395.s20.e2
DDI-DrugBank.d395.s20	true	DDI-DrugBank.d395.s20.e1	DDI-DrugBank.d395.s20.e2
DDI-DrugBank.d395.s21|a|Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
DDI-DrugBank.d395.s21	0	7	Enoxacin	drug	DDI-DrugBank.d395.s21.e0
DDI-DrugBank.d395.s21	43	54	theophylline	drug	DDI-DrugBank.d395.s21.e1
DDI-DrugBank.d395.s21	107	118	theophylline	drug	DDI-DrugBank.d395.s21.e2
DDI-DrugBank.d395.s21	true	DDI-DrugBank.d395.s21.e0	DDI-DrugBank.d395.s21.e1
DDI-DrugBank.d395.s21	false	DDI-DrugBank.d395.s21.e0	DDI-DrugBank.d395.s21.e2
DDI-DrugBank.d395.s21	false	DDI-DrugBank.d395.s21.e1	DDI-DrugBank.d395.s21.e2
DDI-DrugBank.d395.s22|a|Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.
DDI-DrugBank.d395.s22	0	11	Theophylline	drug	DDI-DrugBank.d395.s22.e0
DDI-DrugBank.d395.s22	68	79	theophylline	drug	DDI-DrugBank.d395.s22.e1
DDI-DrugBank.d395.s22	85	92	enoxacin	drug	DDI-DrugBank.d395.s22.e2
DDI-DrugBank.d395.s22	false	DDI-DrugBank.d395.s22.e0	DDI-DrugBank.d395.s22.e1
DDI-DrugBank.d395.s22	false	DDI-DrugBank.d395.s22.e0	DDI-DrugBank.d395.s22.e2
DDI-DrugBank.d395.s22	true	DDI-DrugBank.d395.s22.e1	DDI-DrugBank.d395.s22.e2
DDI-DrugBank.d395.s23|a|Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
DDI-DrugBank.d395.s23	0	7	Warfarin	drug	DDI-DrugBank.d395.s23.e0
DDI-DrugBank.d395.s23	10	19	Quinolones	group	DDI-DrugBank.d395.s23.e1
DDI-DrugBank.d395.s23	32	39	enoxacin	drug	DDI-DrugBank.d395.s23.e2
DDI-DrugBank.d395.s23	68	77	R-warfarin	drug	DDI-DrugBank.d395.s23.e3
DDI-DrugBank.d395.s23	114	121	warfarin	drug	DDI-DrugBank.d395.s23.e4
DDI-DrugBank.d395.s23	false	DDI-DrugBank.d395.s23.e0	DDI-DrugBank.d395.s23.e1
DDI-DrugBank.d395.s23	false	DDI-DrugBank.d395.s23.e0	DDI-DrugBank.d395.s23.e2
DDI-DrugBank.d395.s23	false	DDI-DrugBank.d395.s23.e0	DDI-DrugBank.d395.s23.e3
DDI-DrugBank.d395.s23	false	DDI-DrugBank.d395.s23.e0	DDI-DrugBank.d395.s23.e4
DDI-DrugBank.d395.s23	false	DDI-DrugBank.d395.s23.e1	DDI-DrugBank.d395.s23.e2
DDI-DrugBank.d395.s23	true	DDI-DrugBank.d395.s23.e1	DDI-DrugBank.d395.s23.e3
DDI-DrugBank.d395.s23	false	DDI-DrugBank.d395.s23.e1	DDI-DrugBank.d395.s23.e4
DDI-DrugBank.d395.s23	true	DDI-DrugBank.d395.s23.e2	DDI-DrugBank.d395.s23.e3
DDI-DrugBank.d395.s23	false	DDI-DrugBank.d395.s23.e2	DDI-DrugBank.d395.s23.e4
DDI-DrugBank.d395.s23	false	DDI-DrugBank.d395.s23.e3	DDI-DrugBank.d395.s23.e4
DDI-DrugBank.d395.s24|a|Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.
DDI-DrugBank.d395.s24	0	7	Enoxacin	drug	DDI-DrugBank.d395.s24.e0
DDI-DrugBank.d395.s24	120	127	enoxacin	drug	DDI-DrugBank.d395.s24.e1
DDI-DrugBank.d395.s24	133	140	warfarin	drug	DDI-DrugBank.d395.s24.e2
DDI-DrugBank.d395.s24	false	DDI-DrugBank.d395.s24.e0	DDI-DrugBank.d395.s24.e1
DDI-DrugBank.d395.s24	false	DDI-DrugBank.d395.s24.e0	DDI-DrugBank.d395.s24.e2
DDI-DrugBank.d395.s24	false	DDI-DrugBank.d395.s24.e1	DDI-DrugBank.d395.s24.e2
DDI-DrugBank.d395.s25|a|Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.
DDI-DrugBank.d395.s25	95	102	warfarin	drug	DDI-DrugBank.d395.s25.e0
DDI-DrugBank.d395.s25	127	134	enoxacin	drug	DDI-DrugBank.d395.s25.e1
DDI-DrugBank.d395.s25	true	DDI-DrugBank.d395.s25.e0	DDI-DrugBank.d395.s25.e1
DDI-DrugBank.d474.s0|a|Unless really needed, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of Lovenox Injection therapy.
DDI-DrugBank.d474.s0	116	122	Lovenox	brand	DDI-DrugBank.d474.s0.e0
DDI-DrugBank.d474.s1|a|These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
DDI-DrugBank.d474.s1	42	55	anticoagulants	group	DDI-DrugBank.d474.s1.e0
DDI-DrugBank.d474.s1	58	76	platelet inhibitors	group	DDI-DrugBank.d474.s1.e1
DDI-DrugBank.d474.s1	88	107	acetylsalicylic acid	drug	DDI-DrugBank.d474.s1.e2
DDI-DrugBank.d474.s1	124	129	NSAIDs	group	DDI-DrugBank.d474.s1.e3
DDI-DrugBank.d474.s1	142	163	ketorolac tromethamine	drug	DDI-DrugBank.d474.s1.e4
DDI-DrugBank.d474.s1	167	178	dipyridamole	drug	DDI-DrugBank.d474.s1.e5
DDI-DrugBank.d474.s1	184	197	sulfinpyrazone	drug	DDI-DrugBank.d474.s1.e6
DDI-DrugBank.d474.s1	false	DDI-DrugBank.d474.s1.e0	DDI-DrugBank.d474.s1.e1
DDI-DrugBank.d474.s1	false	DDI-DrugBank.d474.s1.e0	DDI-DrugBank.d474.s1.e2
DDI-DrugBank.d474.s1	false	DDI-DrugBank.d474.s1.e0	DDI-DrugBank.d474.s1.e3
DDI-DrugBank.d474.s1	false	DDI-DrugBank.d474.s1.e0	DDI-DrugBank.d474.s1.e4
DDI-DrugBank.d474.s1	false	DDI-DrugBank.d474.s1.e0	DDI-DrugBank.d474.s1.e5
DDI-DrugBank.d474.s1	false	DDI-DrugBank.d474.s1.e0	DDI-DrugBank.d474.s1.e6
DDI-DrugBank.d474.s1	false	DDI-DrugBank.d474.s1.e1	DDI-DrugBank.d474.s1.e2
DDI-DrugBank.d474.s1	false	DDI-DrugBank.d474.s1.e1	DDI-DrugBank.d474.s1.e3
DDI-DrugBank.d474.s1	false	DDI-DrugBank.d474.s1.e1	DDI-DrugBank.d474.s1.e4
DDI-DrugBank.d474.s1	false	DDI-DrugBank.d474.s1.e1	DDI-DrugBank.d474.s1.e5
DDI-DrugBank.d474.s2|a|If co-administration is essential, conduct close clinical and laboratory monitoring
DDI-DrugBank.d474.s3|a|.
DDI-DrugBank.d474.s4|a|
DDI-DrugBank.d455.s0|a|In vitro studies of human CYP enzymes showed that entacapone inhibited the CYP enzymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A only at very high concentrations (IC50 from 200 to over 1000 uM;
DDI-DrugBank.d455.s0	50	59	entacapone	drug	DDI-DrugBank.d455.s0.e0
DDI-DrugBank.d455.s1|a|an oral 200 mg dose achieves a highest level of approximately 5 uM in people);
DDI-DrugBank.d455.s2|a|these enzymes would therefore not be expected to be inhibited in clinical use.
DDI-DrugBank.d455.s3|a|Protein Binding: Entacapone is highly protein bound (98%).
DDI-DrugBank.d455.s3	17	26	Entacapone	drug	DDI-DrugBank.d455.s3.e0
DDI-DrugBank.d455.s4|a|In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam.
DDI-DrugBank.d455.s4	60	69	entacapone	drug	DDI-DrugBank.d455.s4.e0
DDI-DrugBank.d455.s4	109	116	warfarin	drug	DDI-DrugBank.d455.s4.e1
DDI-DrugBank.d455.s4	119	132	salicylic acid	drug	DDI-DrugBank.d455.s4.e2
DDI-DrugBank.d455.s4	135	148	phenylbutazone	drug	DDI-DrugBank.d455.s4.e3
DDI-DrugBank.d455.s4	155	162	diazepam	drug	DDI-DrugBank.d455.s4.e4
DDI-DrugBank.d455.s4	false	DDI-DrugBank.d455.s4.e0	DDI-DrugBank.d455.s4.e1
DDI-DrugBank.d455.s4	false	DDI-DrugBank.d455.s4.e0	DDI-DrugBank.d455.s4.e2
DDI-DrugBank.d455.s4	false	DDI-DrugBank.d455.s4.e0	DDI-DrugBank.d455.s4.e3
DDI-DrugBank.d455.s4	false	DDI-DrugBank.d455.s4.e0	DDI-DrugBank.d455.s4.e4
DDI-DrugBank.d455.s4	false	DDI-DrugBank.d455.s4.e1	DDI-DrugBank.d455.s4.e2
DDI-DrugBank.d455.s4	false	DDI-DrugBank.d455.s4.e1	DDI-DrugBank.d455.s4.e3
DDI-DrugBank.d455.s4	false	DDI-DrugBank.d455.s4.e1	DDI-DrugBank.d455.s4.e4
DDI-DrugBank.d455.s4	false	DDI-DrugBank.d455.s4.e2	DDI-DrugBank.d455.s4.e3
DDI-DrugBank.d455.s4	false	DDI-DrugBank.d455.s4.e2	DDI-DrugBank.d455.s4.e4
DDI-DrugBank.d455.s4	false	DDI-DrugBank.d455.s4.e3	DDI-DrugBank.d455.s4.e4
DDI-DrugBank.d455.s5|a|Drugs Metabolized by Catechol-O-methyltransferase (COMT): Hormone levels: Levodopa is known to depress prolactin secretion and increase growth hormone levels.
DDI-DrugBank.d455.s5	74	81	Levodopa	drug	DDI-DrugBank.d455.s5.e0
DDI-DrugBank.d455.s6|a|Treatment with entacapone coadministered with levodopa/dopa decarboxylase inhibitor does not change these effects.
DDI-DrugBank.d455.s6	15	24	entacapone	drug	DDI-DrugBank.d455.s6.e0
DDI-DrugBank.d455.s6	46	53	levodopa	drug	DDI-DrugBank.d455.s6.e1
DDI-DrugBank.d455.s6	55	82	dopa decarboxylase inhibitor	group	DDI-DrugBank.d455.s6.e2
DDI-DrugBank.d455.s6	false	DDI-DrugBank.d455.s6.e0	DDI-DrugBank.d455.s6.e1
DDI-DrugBank.d455.s6	false	DDI-DrugBank.d455.s6.e0	DDI-DrugBank.d455.s6.e2
DDI-DrugBank.d455.s6	false	DDI-DrugBank.d455.s6.e1	DDI-DrugBank.d455.s6.e2
DDI-DrugBank.d455.s7|a|No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29).
DDI-DrugBank.d455.s7	34	48	MAO-B inhibitor	group	DDI-DrugBank.d455.s7.e0
DDI-DrugBank.d455.s7	50	59	selegiline	drug	DDI-DrugBank.d455.s7.e1
DDI-DrugBank.d455.s7	107	116	entacapone	drug	DDI-DrugBank.d455.s7.e2
DDI-DrugBank.d455.s7	144	151	levodopa	drug	DDI-DrugBank.d455.s7.e3
DDI-DrugBank.d455.s7	153	180	dopa decarboxylase inhibitor	group	DDI-DrugBank.d455.s7.e4
DDI-DrugBank.d455.s7	false	DDI-DrugBank.d455.s7.e0	DDI-DrugBank.d455.s7.e1
DDI-DrugBank.d455.s7	false	DDI-DrugBank.d455.s7.e0	DDI-DrugBank.d455.s7.e2
DDI-DrugBank.d455.s7	false	DDI-DrugBank.d455.s7.e0	DDI-DrugBank.d455.s7.e3
DDI-DrugBank.d455.s7	false	DDI-DrugBank.d455.s7.e0	DDI-DrugBank.d455.s7.e4
DDI-DrugBank.d455.s7	false	DDI-DrugBank.d455.s7.e1	DDI-DrugBank.d455.s7.e2
DDI-DrugBank.d455.s7	false	DDI-DrugBank.d455.s7.e1	DDI-DrugBank.d455.s7.e3
DDI-DrugBank.d455.s7	false	DDI-DrugBank.d455.s7.e1	DDI-DrugBank.d455.s7.e4
DDI-DrugBank.d455.s7	false	DDI-DrugBank.d455.s7.e2	DDI-DrugBank.d455.s7.e3
DDI-DrugBank.d455.s7	false	DDI-DrugBank.d455.s7.e2	DDI-DrugBank.d455.s7.e4
DDI-DrugBank.d455.s7	false	DDI-DrugBank.d455.s7.e3	DDI-DrugBank.d455.s7.e4
DDI-DrugBank.d455.s8|a|More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and levodopa/dopa decarboxylase inhibitor.
DDI-DrugBank.d455.s8	71	80	selegiline	drug	DDI-DrugBank.d455.s8.e0
DDI-DrugBank.d455.s8	102	111	entacapone	drug	DDI-DrugBank.d455.s8.e1
DDI-DrugBank.d455.s8	117	124	levodopa	drug	DDI-DrugBank.d455.s8.e2
DDI-DrugBank.d455.s8	126	153	dopa decarboxylase inhibitor	group	DDI-DrugBank.d455.s8.e3
DDI-DrugBank.d455.s8	false	DDI-DrugBank.d455.s8.e0	DDI-DrugBank.d455.s8.e1
DDI-DrugBank.d455.s8	false	DDI-DrugBank.d455.s8.e0	DDI-DrugBank.d455.s8.e2
DDI-DrugBank.d455.s8	false	DDI-DrugBank.d455.s8.e0	DDI-DrugBank.d455.s8.e3
DDI-DrugBank.d455.s8	false	DDI-DrugBank.d455.s8.e1	DDI-DrugBank.d455.s8.e2
DDI-DrugBank.d455.s8	false	DDI-DrugBank.d455.s8.e1	DDI-DrugBank.d455.s8.e3
DDI-DrugBank.d455.s8	false	DDI-DrugBank.d455.s8.e2	DDI-DrugBank.d455.s8.e3
DDI-DrugBank.d455.s9|a|As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with entacapone.
DDI-DrugBank.d455.s9	8	17	entacapone	drug	DDI-DrugBank.d455.s9.e0
DDI-DrugBank.d455.s9	207	216	entacapone	drug	DDI-DrugBank.d455.s9.e1
DDI-DrugBank.d455.s9	false	DDI-DrugBank.d455.s9.e0	DDI-DrugBank.d455.s9.e1
DDI-DrugBank.d455.s10|a|These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).
DDI-DrugBank.d455.s10	14	23	probenecid	drug	DDI-DrugBank.d455.s10.e0
DDI-DrugBank.d455.s10	26	39	cholestyramine	drug	DDI-DrugBank.d455.s10.e1
DDI-DrugBank.d455.s10	51	61	antibiotics	group	DDI-DrugBank.d455.s10.e2
DDI-DrugBank.d455.s10	69	80	erythromycin	drug	DDI-DrugBank.d455.s10.e3
DDI-DrugBank.d455.s10	96	105	ampicillin	drug	DDI-DrugBank.d455.s10.e4
DDI-DrugBank.d455.s10	111	125	chloramphenicol	drug	DDI-DrugBank.d455.s10.e5
DDI-DrugBank.d455.s10	false	DDI-DrugBank.d455.s10.e0	DDI-DrugBank.d455.s10.e1
DDI-DrugBank.d455.s10	false	DDI-DrugBank.d455.s10.e0	DDI-DrugBank.d455.s10.e2
DDI-DrugBank.d455.s10	false	DDI-DrugBank.d455.s10.e0	DDI-DrugBank.d455.s10.e3
DDI-DrugBank.d455.s10	false	DDI-DrugBank.d455.s10.e0	DDI-DrugBank.d455.s10.e4
DDI-DrugBank.d455.s10	false	DDI-DrugBank.d455.s10.e0	DDI-DrugBank.d455.s10.e5
DDI-DrugBank.d455.s10	false	DDI-DrugBank.d455.s10.e1	DDI-DrugBank.d455.s10.e2
DDI-DrugBank.d455.s10	false	DDI-DrugBank.d455.s10.e1	DDI-DrugBank.d455.s10.e3
DDI-DrugBank.d455.s10	false	DDI-DrugBank.d455.s10.e1	DDI-DrugBank.d455.s10.e4
DDI-DrugBank.d455.s10	false	DDI-DrugBank.d455.s10.e1	DDI-DrugBank.d455.s10.e5
DDI-DrugBank.d455.s10	false	DDI-DrugBank.d455.s10.e2	DDI-DrugBank.d455.s10.e3
DDI-DrugBank.d455.s11|a|No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.
DDI-DrugBank.d455.s11	24	47	tricyclic antidepressant	group	DDI-DrugBank.d455.s11.e0
DDI-DrugBank.d455.s11	49	58	imipramine	drug	DDI-DrugBank.d455.s11.e1
DDI-DrugBank.d455.s11	98	107	entacapone	drug	DDI-DrugBank.d455.s11.e2
DDI-DrugBank.d455.s11	132	139	levodopa	drug	DDI-DrugBank.d455.s11.e3
DDI-DrugBank.d455.s11	141	168	dopa-decarboxylase inhibitor	group	DDI-DrugBank.d455.s11.e4
DDI-DrugBank.d455.s11	false	DDI-DrugBank.d455.s11.e0	DDI-DrugBank.d455.s11.e1
DDI-DrugBank.d455.s11	false	DDI-DrugBank.d455.s11.e0	DDI-DrugBank.d455.s11.e2
DDI-DrugBank.d455.s11	false	DDI-DrugBank.d455.s11.e0	DDI-DrugBank.d455.s11.e3
DDI-DrugBank.d455.s11	false	DDI-DrugBank.d455.s11.e0	DDI-DrugBank.d455.s11.e4
DDI-DrugBank.d455.s11	false	DDI-DrugBank.d455.s11.e1	DDI-DrugBank.d455.s11.e2
DDI-DrugBank.d455.s11	false	DDI-DrugBank.d455.s11.e1	DDI-DrugBank.d455.s11.e3
DDI-DrugBank.d455.s11	false	DDI-DrugBank.d455.s11.e1	DDI-DrugBank.d455.s11.e4
DDI-DrugBank.d455.s11	false	DDI-DrugBank.d455.s11.e2	DDI-DrugBank.d455.s11.e3
DDI-DrugBank.d455.s11	false	DDI-DrugBank.d455.s11.e2	DDI-DrugBank.d455.s11.e4
DDI-DrugBank.d455.s11	false	DDI-DrugBank.d455.s11.e3	DDI-DrugBank.d455.s11.e4
DDI-DrugBank.d295.s0|a|Since entecavir is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.
DDI-DrugBank.d295.s0	6	14	entecavir	drug	DDI-DrugBank.d295.s0.e0
DDI-DrugBank.d295.s0	76	84	BARACLUDE	brand	DDI-DrugBank.d295.s0.e1
DDI-DrugBank.d295.s0	208	216	entecavir	drug	DDI-DrugBank.d295.s0.e2
DDI-DrugBank.d295.s0	false	DDI-DrugBank.d295.s0.e0	DDI-DrugBank.d295.s0.e1
DDI-DrugBank.d295.s0	false	DDI-DrugBank.d295.s0.e0	DDI-DrugBank.d295.s0.e2
DDI-DrugBank.d295.s0	false	DDI-DrugBank.d295.s0.e1	DDI-DrugBank.d295.s0.e2
DDI-DrugBank.d295.s1|a|Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.
DDI-DrugBank.d295.s1	20	28	entecavir	drug	DDI-DrugBank.d295.s1.e0
DDI-DrugBank.d295.s1	35	44	lamivudine	drug	DDI-DrugBank.d295.s1.e1
DDI-DrugBank.d295.s1	47	64	adefovir dipivoxil	drug	DDI-DrugBank.d295.s1.e2
DDI-DrugBank.d295.s1	69	97	tenofovir disoproxil fumarate	drug	DDI-DrugBank.d295.s1.e3
DDI-DrugBank.d295.s1	false	DDI-DrugBank.d295.s1.e0	DDI-DrugBank.d295.s1.e1
DDI-DrugBank.d295.s1	false	DDI-DrugBank.d295.s1.e0	DDI-DrugBank.d295.s1.e2
DDI-DrugBank.d295.s1	false	DDI-DrugBank.d295.s1.e0	DDI-DrugBank.d295.s1.e3
DDI-DrugBank.d295.s1	false	DDI-DrugBank.d295.s1.e1	DDI-DrugBank.d295.s1.e2
DDI-DrugBank.d295.s1	false	DDI-DrugBank.d295.s1.e1	DDI-DrugBank.d295.s1.e3
DDI-DrugBank.d295.s1	false	DDI-DrugBank.d295.s1.e2	DDI-DrugBank.d295.s1.e3
DDI-DrugBank.d295.s2|a|The effects of coadministration of BARACLUDE with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when BARACLUDE is coadministered with such drugs.
DDI-DrugBank.d295.s2	35	43	BARACLUDE	brand	DDI-DrugBank.d295.s2.e0
DDI-DrugBank.d295.s2	218	226	BARACLUDE	brand	DDI-DrugBank.d295.s2.e1
DDI-DrugBank.d295.s2	false	DDI-DrugBank.d295.s2.e0	DDI-DrugBank.d295.s2.e1
DDI-DrugBank.d156.s0|a|None Reported
DDI-DrugBank.d247.s0|a|Epinephrine should be used cautiously in patients with hyperthyroidism, hypertension and cardiac arrhythmias.
DDI-DrugBank.d247.s0	0	10	Epinephrine	drug	DDI-DrugBank.d247.s0.e0
DDI-DrugBank.d247.s1|a|All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.
DDI-DrugBank.d247.s1	4	15	vasopressors	group	DDI-DrugBank.d247.s1.e0
DDI-DrugBank.d247.s1	62	95	monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d247.s1.e1
DDI-DrugBank.d247.s1	true	DDI-DrugBank.d247.s1.e0	DDI-DrugBank.d247.s1.e1
DDI-DrugBank.d247.s2|a|Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
DDI-DrugBank.d247.s2	0	10	Epinephrine	drug	DDI-DrugBank.d247.s2.e0
DDI-DrugBank.d247.s2	64	84	sympathomimetic drugs	group	DDI-DrugBank.d247.s2.e1
DDI-DrugBank.d247.s2	95	107	isoproterenol	drug	DDI-DrugBank.d247.s2.e2
DDI-DrugBank.d247.s2	true	DDI-DrugBank.d247.s2.e0	DDI-DrugBank.d247.s2.e1
DDI-DrugBank.d247.s2	true	DDI-DrugBank.d247.s2.e0	DDI-DrugBank.d247.s2.e2
DDI-DrugBank.d247.s2	false	DDI-DrugBank.d247.s2.e1	DDI-DrugBank.d247.s2.e2
DDI-DrugBank.d247.s3|a|Combined effects may induce serious cardiac arrhythmias.
DDI-DrugBank.d247.s4|a|They may be administered alternately when the preceding effect of other such drug has subsided.
DDI-DrugBank.d247.s5|a|Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
DDI-DrugBank.d247.s5	18	28	epinephrine	drug	DDI-DrugBank.d247.s5.e0
DDI-DrugBank.d247.s5	52	63	cyclopropane	drug	DDI-DrugBank.d247.s5.e1
DDI-DrugBank.d247.s5	68	110	halogenated hydrocarbon general anesthetics	group	DDI-DrugBank.d247.s5.e2
DDI-DrugBank.d247.s5	120	128	halothane	drug	DDI-DrugBank.d247.s5.e3
DDI-DrugBank.d247.s5	true	DDI-DrugBank.d247.s5.e0	DDI-DrugBank.d247.s5.e1
DDI-DrugBank.d247.s5	true	DDI-DrugBank.d247.s5.e0	DDI-DrugBank.d247.s5.e2
DDI-DrugBank.d247.s5	true	DDI-DrugBank.d247.s5.e0	DDI-DrugBank.d247.s5.e3
DDI-DrugBank.d247.s5	false	DDI-DrugBank.d247.s5.e1	DDI-DrugBank.d247.s5.e2
DDI-DrugBank.d247.s5	false	DDI-DrugBank.d247.s5.e1	DDI-DrugBank.d247.s5.e3
DDI-DrugBank.d247.s5	false	DDI-DrugBank.d247.s5.e2	DDI-DrugBank.d247.s5.e3
DDI-DrugBank.d247.s6|a|When encountered, such arrhythmias may respond to administration of a beta-adrenergic blocking drug.
DDI-DrugBank.d247.s6	70	98	beta-adrenergic blocking drug	group	DDI-DrugBank.d247.s6.e0
DDI-DrugBank.d247.s7|a|Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
DDI-DrugBank.d247.s7	0	10	Epinephrine	drug	DDI-DrugBank.d247.s7.e0
DDI-DrugBank.d247.s7	67	75	digitalis	group	DDI-DrugBank.d247.s7.e1
DDI-DrugBank.d247.s7	78	87	glycosides	group	DDI-DrugBank.d247.s7.e2
DDI-DrugBank.d247.s7	138	158	sympathomimetic drugs	group	DDI-DrugBank.d247.s7.e3
DDI-DrugBank.d247.s7	true	DDI-DrugBank.d247.s7.e0	DDI-DrugBank.d247.s7.e1
DDI-DrugBank.d247.s7	true	DDI-DrugBank.d247.s7.e0	DDI-DrugBank.d247.s7.e2
DDI-DrugBank.d247.s7	false	DDI-DrugBank.d247.s7.e0	DDI-DrugBank.d247.s7.e3
DDI-DrugBank.d247.s7	false	DDI-DrugBank.d247.s7.e1	DDI-DrugBank.d247.s7.e2
DDI-DrugBank.d247.s7	false	DDI-DrugBank.d247.s7.e1	DDI-DrugBank.d247.s7.e3
DDI-DrugBank.d247.s7	false	DDI-DrugBank.d247.s7.e2	DDI-DrugBank.d247.s7.e3
DDI-DrugBank.d247.s8|a|Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.
DDI-DrugBank.d247.s8	0	14	Diuretic agents	group	DDI-DrugBank.d247.s8.e0
DDI-DrugBank.d247.s8	72	82	epinephrine	drug	DDI-DrugBank.d247.s8.e1
DDI-DrugBank.d247.s8	true	DDI-DrugBank.d247.s8.e0	DDI-DrugBank.d247.s8.e1
DDI-DrugBank.d247.s9|a|Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
DDI-DrugBank.d247.s9	0	10	Epinephrine	drug	DDI-DrugBank.d247.s9.e0
DDI-DrugBank.d247.s9	59	70	guanethidine	drug	DDI-DrugBank.d247.s9.e1
DDI-DrugBank.d247.s9	true	DDI-DrugBank.d247.s9.e0	DDI-DrugBank.d247.s9.e1
DDI-DrugBank.d428.s0|a|ELLENCE when used in combination with other cytotoxic drugs may show on-treatment additive toxicity, especially hematologic and gastrointestinal effects.
DDI-DrugBank.d428.s0	0	6	ELLENCE	brand	DDI-DrugBank.d428.s0.e0
DDI-DrugBank.d428.s1|a|Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.
DDI-DrugBank.d428.s1	19	25	ELLENCE	brand	DDI-DrugBank.d428.s1.e0
DDI-DrugBank.d428.s1	99	122	calcium channel blockers	group	DDI-DrugBank.d428.s1.e1
DDI-DrugBank.d428.s1	true	DDI-DrugBank.d428.s1.e0	DDI-DrugBank.d428.s1.e1
DDI-DrugBank.d428.s2|a|There are few data regarding the coadministration of radiation therapy and epirubicin.
DDI-DrugBank.d428.s2	75	84	epirubicin	drug	DDI-DrugBank.d428.s2.e0
DDI-DrugBank.d428.s3|a|In adjuvant trials of epirubicin-containing CEF-120 or FEC-100 chemotherapies, breast irradiation was delayed until after chemotherapy was completed.
DDI-DrugBank.d428.s3	22	31	epirubicin	drug	DDI-DrugBank.d428.s3.e0
DDI-DrugBank.d428.s4|a|This practice resulted in no apparent increase in local breast cancer recurrence relative to published accounts in the literature.
DDI-DrugBank.d428.s5|a|A small number of patients received epirubicin-based chemotherapy concomitantly with radiation therapy but had chemotherapy interrupted in order to avoid potential overlapping toxicities.
DDI-DrugBank.d428.s5	36	45	epirubicin	drug	DDI-DrugBank.d428.s5.e0
DDI-DrugBank.d428.s6|a|It is likely that use of epirubicin with radiotherapy may sensitize tissues to the cytotoxic actions of irradiation.
DDI-DrugBank.d428.s6	25	34	epirubicin	drug	DDI-DrugBank.d428.s6.e0
DDI-DrugBank.d428.s7|a|Administration of ELLENCE after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation.
DDI-DrugBank.d428.s7	18	24	ELLENCE	brand	DDI-DrugBank.d428.s7.e0
DDI-DrugBank.d428.s8|a|Epirubicin is extensively metabolized by the liver.
DDI-DrugBank.d428.s8	0	9	Epirubicin	drug	DDI-DrugBank.d428.s8.e0
DDI-DrugBank.d428.s9|a|Changes in hepatic function induced by concomitant therapies may affect epirubicin metabolism, pharmacokinetics, therapeutic efficacy, and/or toxicity.
DDI-DrugBank.d428.s9	72	81	epirubicin	drug	DDI-DrugBank.d428.s9.e0
DDI-DrugBank.d428.s10|a|Cimetidine increased the AUC of epirubicin by 50%.
DDI-DrugBank.d428.s10	0	9	Cimetidine	drug	DDI-DrugBank.d428.s10.e0
DDI-DrugBank.d428.s10	32	41	epirubicin	drug	DDI-DrugBank.d428.s10.e1
DDI-DrugBank.d428.s10	true	DDI-DrugBank.d428.s10.e0	DDI-DrugBank.d428.s10.e1
DDI-DrugBank.d428.s11|a|Cimetidine treatment should be stopped during treatment with ELLENCE.
DDI-DrugBank.d428.s11	0	9	Cimetidine	drug	DDI-DrugBank.d428.s11.e0
DDI-DrugBank.d428.s11	61	67	ELLENCE	brand	DDI-DrugBank.d428.s11.e1
DDI-DrugBank.d428.s11	true	DDI-DrugBank.d428.s11.e0	DDI-DrugBank.d428.s11.e1
DDI-DrugBank.d428.s12|a|Drug-Laboratory Test Interactions There are no known interactions between ELLENCE and laboratory tests.
DDI-DrugBank.d428.s12	74	80	ELLENCE	brand	DDI-DrugBank.d428.s12.e0
DDI-DrugBank.d20.s0|a|Inhibitors of CYP3A4-Eplerenone metabolism is predominantly mediated via CYP3A4.
DDI-DrugBank.d20.s0	21	30	Eplerenone	drug	DDI-DrugBank.d20.s0.e0
DDI-DrugBank.d20.s1|a|A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.
DDI-DrugBank.d20.s1	74	79	INSPRA	brand	DDI-DrugBank.d20.s1.e0
DDI-DrugBank.d20.s1	93	104	ketoconazole	drug	DDI-DrugBank.d20.s1.e1
DDI-DrugBank.d20.s1	198	207	eplerenone	drug	DDI-DrugBank.d20.s1.e2
DDI-DrugBank.d20.s1	243	252	eplerenone	drug	DDI-DrugBank.d20.s1.e3
DDI-DrugBank.d20.s1	true	DDI-DrugBank.d20.s1.e0	DDI-DrugBank.d20.s1.e1
DDI-DrugBank.d20.s1	false	DDI-DrugBank.d20.s1.e0	DDI-DrugBank.d20.s1.e2
DDI-DrugBank.d20.s1	false	DDI-DrugBank.d20.s1.e0	DDI-DrugBank.d20.s1.e3
DDI-DrugBank.d20.s1	false	DDI-DrugBank.d20.s1.e1	DDI-DrugBank.d20.s1.e2
DDI-DrugBank.d20.s1	false	DDI-DrugBank.d20.s1.e1	DDI-DrugBank.d20.s1.e3
DDI-DrugBank.d20.s1	false	DDI-DrugBank.d20.s1.e2	DDI-DrugBank.d20.s1.e3
DDI-DrugBank.d20.s2|a|INSPRA should not be used with drugs described as strong inhibitors of CYP3A4 in their labeling.
DDI-DrugBank.d20.s2	0	5	INSPRA	brand	DDI-DrugBank.d20.s2.e0
DDI-DrugBank.d20.s3|a|Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
DDI-DrugBank.d20.s3	18	27	eplerenone	drug	DDI-DrugBank.d20.s3.e0
DDI-DrugBank.d20.s3	65	76	erythromycin	drug	DDI-DrugBank.d20.s3.e1
DDI-DrugBank.d20.s3	90	98	verapamil	drug	DDI-DrugBank.d20.s3.e2
DDI-DrugBank.d20.s3	111	120	saquinavir	drug	DDI-DrugBank.d20.s3.e3
DDI-DrugBank.d20.s3	135	145	fluconazole	drug	DDI-DrugBank.d20.s3.e4
DDI-DrugBank.d20.s3	191	200	eplerenone	drug	DDI-DrugBank.d20.s3.e5
DDI-DrugBank.d20.s3	true	DDI-DrugBank.d20.s3.e0	DDI-DrugBank.d20.s3.e1
DDI-DrugBank.d20.s3	true	DDI-DrugBank.d20.s3.e0	DDI-DrugBank.d20.s3.e2
DDI-DrugBank.d20.s3	true	DDI-DrugBank.d20.s3.e0	DDI-DrugBank.d20.s3.e3
DDI-DrugBank.d20.s3	true	DDI-DrugBank.d20.s3.e0	DDI-DrugBank.d20.s3.e4
DDI-DrugBank.d20.s3	false	DDI-DrugBank.d20.s3.e0	DDI-DrugBank.d20.s3.e5
DDI-DrugBank.d20.s3	false	DDI-DrugBank.d20.s3.e1	DDI-DrugBank.d20.s3.e2
DDI-DrugBank.d20.s3	false	DDI-DrugBank.d20.s3.e1	DDI-DrugBank.d20.s3.e3
DDI-DrugBank.d20.s3	false	DDI-DrugBank.d20.s3.e1	DDI-DrugBank.d20.s3.e4
DDI-DrugBank.d20.s3	false	DDI-DrugBank.d20.s3.e1	DDI-DrugBank.d20.s3.e5
DDI-DrugBank.d20.s3	false	DDI-DrugBank.d20.s3.e2	DDI-DrugBank.d20.s3.e3
DDI-DrugBank.d20.s4|a|ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).
DDI-DrugBank.d20.s4	0	13	ACE Inhibitors	group	DDI-DrugBank.d20.s4.e0
DDI-DrugBank.d20.s4	19	53	Angiotensin II Receptor Antagonists	group	DDI-DrugBank.d20.s4.e1
DDI-DrugBank.d20.s4	152	157	INSPRA	brand	DDI-DrugBank.d20.s4.e2
DDI-DrugBank.d20.s4	185	198	ACE inhibitors	group	DDI-DrugBank.d20.s4.e3
DDI-DrugBank.d20.s4	203	237	angiotensin II receptor antagonists	group	DDI-DrugBank.d20.s4.e4
DDI-DrugBank.d20.s4	240	243	ACEI	group	DDI-DrugBank.d20.s4.e5
DDI-DrugBank.d20.s4	245	247	ARB	group	DDI-DrugBank.d20.s4.e6
DDI-DrugBank.d20.s4	false	DDI-DrugBank.d20.s4.e0	DDI-DrugBank.d20.s4.e1
DDI-DrugBank.d20.s4	false	DDI-DrugBank.d20.s4.e0	DDI-DrugBank.d20.s4.e2
DDI-DrugBank.d20.s4	false	DDI-DrugBank.d20.s4.e0	DDI-DrugBank.d20.s4.e3
DDI-DrugBank.d20.s4	false	DDI-DrugBank.d20.s4.e0	DDI-DrugBank.d20.s4.e4
DDI-DrugBank.d20.s4	false	DDI-DrugBank.d20.s4.e0	DDI-DrugBank.d20.s4.e5
DDI-DrugBank.d20.s4	false	DDI-DrugBank.d20.s4.e0	DDI-DrugBank.d20.s4.e6
DDI-DrugBank.d20.s4	false	DDI-DrugBank.d20.s4.e1	DDI-DrugBank.d20.s4.e2
DDI-DrugBank.d20.s4	false	DDI-DrugBank.d20.s4.e1	DDI-DrugBank.d20.s4.e3
DDI-DrugBank.d20.s4	false	DDI-DrugBank.d20.s4.e1	DDI-DrugBank.d20.s4.e4
DDI-DrugBank.d20.s4	false	DDI-DrugBank.d20.s4.e1	DDI-DrugBank.d20.s4.e5
DDI-DrugBank.d20.s5|a|Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of ACEI/ARB.
DDI-DrugBank.d20.s5	97	100	ACEI	group	DDI-DrugBank.d20.s5.e0
DDI-DrugBank.d20.s5	102	104	ARB	group	DDI-DrugBank.d20.s5.e1
DDI-DrugBank.d20.s5	false	DDI-DrugBank.d20.s5.e0	DDI-DrugBank.d20.s5.e1
DDI-DrugBank.d20.s6|a|ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
DDI-DrugBank.d20.s6	0	13	ACE Inhibitors	group	DDI-DrugBank.d20.s6.e0
DDI-DrugBank.d20.s6	19	53	Angiotensin II Receptor Antagonists	group	DDI-DrugBank.d20.s6.e1
DDI-DrugBank.d20.s6	138	143	INSPRA	brand	DDI-DrugBank.d20.s6.e2
DDI-DrugBank.d20.s6	161	174	ACE inhibitors	group	DDI-DrugBank.d20.s6.e3
DDI-DrugBank.d20.s6	180	214	angiotensin II receptor antagonists	group	DDI-DrugBank.d20.s6.e4
DDI-DrugBank.d20.s6	false	DDI-DrugBank.d20.s6.e0	DDI-DrugBank.d20.s6.e1
DDI-DrugBank.d20.s6	false	DDI-DrugBank.d20.s6.e0	DDI-DrugBank.d20.s6.e2
DDI-DrugBank.d20.s6	false	DDI-DrugBank.d20.s6.e0	DDI-DrugBank.d20.s6.e3
DDI-DrugBank.d20.s6	false	DDI-DrugBank.d20.s6.e0	DDI-DrugBank.d20.s6.e4
DDI-DrugBank.d20.s6	false	DDI-DrugBank.d20.s6.e1	DDI-DrugBank.d20.s6.e2
DDI-DrugBank.d20.s6	false	DDI-DrugBank.d20.s6.e1	DDI-DrugBank.d20.s6.e3
DDI-DrugBank.d20.s6	false	DDI-DrugBank.d20.s6.e1	DDI-DrugBank.d20.s6.e4
DDI-DrugBank.d20.s6	true	DDI-DrugBank.d20.s6.e2	DDI-DrugBank.d20.s6.e3
DDI-DrugBank.d20.s6	true	DDI-DrugBank.d20.s6.e2	DDI-DrugBank.d20.s6.e4
DDI-DrugBank.d20.s6	false	DDI-DrugBank.d20.s6.e3	DDI-DrugBank.d20.s6.e4
DDI-DrugBank.d20.s7|a|In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.
DDI-DrugBank.d20.s7	46	51	INSPRA	brand	DDI-DrugBank.d20.s7.e0
DDI-DrugBank.d20.s7	78	90	ACE inhibitor	group	DDI-DrugBank.d20.s7.e1
DDI-DrugBank.d20.s7	92	100	enalapril	drug	DDI-DrugBank.d20.s7.e2
DDI-DrugBank.d20.s7	189	197	enalapril	drug	DDI-DrugBank.d20.s7.e3
DDI-DrugBank.d20.s7	false	DDI-DrugBank.d20.s7.e0	DDI-DrugBank.d20.s7.e1
DDI-DrugBank.d20.s7	true	DDI-DrugBank.d20.s7.e0	DDI-DrugBank.d20.s7.e2
DDI-DrugBank.d20.s7	false	DDI-DrugBank.d20.s7.e0	DDI-DrugBank.d20.s7.e3
DDI-DrugBank.d20.s7	false	DDI-DrugBank.d20.s7.e1	DDI-DrugBank.d20.s7.e2
DDI-DrugBank.d20.s7	false	DDI-DrugBank.d20.s7.e1	DDI-DrugBank.d20.s7.e3
DDI-DrugBank.d20.s7	false	DDI-DrugBank.d20.s7.e2	DDI-DrugBank.d20.s7.e3
DDI-DrugBank.d20.s8|a|Lithium-A drug interaction study of eplerenone with lithium has not been conducted.
DDI-DrugBank.d20.s8	0	6	Lithium	drug	DDI-DrugBank.d20.s8.e0
DDI-DrugBank.d20.s8	36	45	eplerenone	drug	DDI-DrugBank.d20.s8.e1
DDI-DrugBank.d20.s8	52	58	lithium	drug	DDI-DrugBank.d20.s8.e2
DDI-DrugBank.d20.s8	false	DDI-DrugBank.d20.s8.e0	DDI-DrugBank.d20.s8.e1
DDI-DrugBank.d20.s8	false	DDI-DrugBank.d20.s8.e0	DDI-DrugBank.d20.s8.e2
DDI-DrugBank.d20.s8	false	DDI-DrugBank.d20.s8.e1	DDI-DrugBank.d20.s8.e2
DDI-DrugBank.d20.s9|a|Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.
DDI-DrugBank.d20.s9	6	12	lithium	drug	DDI-DrugBank.d20.s9.e0
DDI-DrugBank.d20.s9	55	60	INSPRA	brand	DDI-DrugBank.d20.s9.e1
DDI-DrugBank.d20.s9	97	103	lithium	drug	DDI-DrugBank.d20.s9.e2
DDI-DrugBank.d20.s9	false	DDI-DrugBank.d20.s9.e0	DDI-DrugBank.d20.s9.e1
DDI-DrugBank.d20.s9	false	DDI-DrugBank.d20.s9.e0	DDI-DrugBank.d20.s9.e2
DDI-DrugBank.d20.s9	true	DDI-DrugBank.d20.s9.e1	DDI-DrugBank.d20.s9.e2
DDI-DrugBank.d20.s10|a|Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of eplerenone with an NSAID has not been conducted.
DDI-DrugBank.d20.s10	0	35	Nonsteroidal Anti-Inflammatory Drugs	group	DDI-DrugBank.d20.s10.e0
DDI-DrugBank.d20.s10	38	43	NSAIDs	group	DDI-DrugBank.d20.s10.e1
DDI-DrugBank.d20.s10	74	83	eplerenone	drug	DDI-DrugBank.d20.s10.e2
DDI-DrugBank.d20.s10	93	97	NSAID	group	DDI-DrugBank.d20.s10.e3
DDI-DrugBank.d20.s10	false	DDI-DrugBank.d20.s10.e0	DDI-DrugBank.d20.s10.e1
DDI-DrugBank.d20.s10	false	DDI-DrugBank.d20.s10.e0	DDI-DrugBank.d20.s10.e2
DDI-DrugBank.d20.s10	false	DDI-DrugBank.d20.s10.e0	DDI-DrugBank.d20.s10.e3
DDI-DrugBank.d20.s10	false	DDI-DrugBank.d20.s10.e1	DDI-DrugBank.d20.s10.e2
DDI-DrugBank.d20.s10	false	DDI-DrugBank.d20.s10.e1	DDI-DrugBank.d20.s10.e3
DDI-DrugBank.d20.s10	false	DDI-DrugBank.d20.s10.e2	DDI-DrugBank.d20.s10.e3
DDI-DrugBank.d20.s11|a|The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.
DDI-DrugBank.d20.s11	28	62	potassium-sparing antihypertensives	group	DDI-DrugBank.d20.s11.e0
DDI-DrugBank.d20.s11	69	74	NSAIDs	group	DDI-DrugBank.d20.s11.e1
DDI-DrugBank.d20.s11	true	DDI-DrugBank.d20.s11.e0	DDI-DrugBank.d20.s11.e1
DDI-DrugBank.d20.s12|a|Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.
DDI-DrugBank.d20.s12	16	21	INSPRA	brand	DDI-DrugBank.d20.s12.e0
DDI-DrugBank.d20.s12	27	32	NSAIDs	group	DDI-DrugBank.d20.s12.e1
DDI-DrugBank.d20.s12	true	DDI-DrugBank.d20.s12.e0	DDI-DrugBank.d20.s12.e1
DDI-DrugBank.d496.s0|a|No evidence of interaction of PROCRIT with other drugs was observed in the course of clinical trials.
DDI-DrugBank.d496.s0	30	36	PROCRIT	brand	DDI-DrugBank.d496.s0.e0
DDI-DrugBank.d241.s0|a|Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
DDI-DrugBank.d241.s0	55	60	FLOLAN	brand	DDI-DrugBank.d241.s0.e0
DDI-DrugBank.d241.s0	83	91	diuretics	group	DDI-DrugBank.d241.s0.e1
DDI-DrugBank.d241.s0	94	116	antihypertensive agents	group	DDI-DrugBank.d241.s0.e2
DDI-DrugBank.d241.s0	128	139	vasodilators	group	DDI-DrugBank.d241.s0.e3
DDI-DrugBank.d241.s0	true	DDI-DrugBank.d241.s0.e0	DDI-DrugBank.d241.s0.e1
DDI-DrugBank.d241.s0	true	DDI-DrugBank.d241.s0.e0	DDI-DrugBank.d241.s0.e2
DDI-DrugBank.d241.s0	true	DDI-DrugBank.d241.s0.e0	DDI-DrugBank.d241.s0.e3
DDI-DrugBank.d241.s0	false	DDI-DrugBank.d241.s0.e1	DDI-DrugBank.d241.s0.e2
DDI-DrugBank.d241.s0	false	DDI-DrugBank.d241.s0.e1	DDI-DrugBank.d241.s0.e3
DDI-DrugBank.d241.s0	false	DDI-DrugBank.d241.s0.e2	DDI-DrugBank.d241.s0.e3
DDI-DrugBank.d241.s1|a|When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
DDI-DrugBank.d241.s1	11	29	antiplatelet agents	group	DDI-DrugBank.d241.s1.e0
DDI-DrugBank.d241.s1	34	47	anticoagulants	group	DDI-DrugBank.d241.s1.e1
DDI-DrugBank.d241.s1	100	105	FLOLAN	brand	DDI-DrugBank.d241.s1.e2
DDI-DrugBank.d241.s1	false	DDI-DrugBank.d241.s1.e0	DDI-DrugBank.d241.s1.e1
DDI-DrugBank.d241.s1	true	DDI-DrugBank.d241.s1.e0	DDI-DrugBank.d241.s1.e2
DDI-DrugBank.d241.s1	true	DDI-DrugBank.d241.s1.e1	DDI-DrugBank.d241.s1.e2
DDI-DrugBank.d241.s2|a|However, patients receiving infusions of FLOLAN in clinical trials were maintained on anticoagulants without evidence of increased bleeding.
DDI-DrugBank.d241.s2	41	46	FLOLAN	brand	DDI-DrugBank.d241.s2.e0
DDI-DrugBank.d241.s2	86	99	anticoagulants	group	DDI-DrugBank.d241.s2.e1
DDI-DrugBank.d241.s2	false	DDI-DrugBank.d241.s2.e0	DDI-DrugBank.d241.s2.e1
DDI-DrugBank.d241.s3|a|In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
DDI-DrugBank.d241.s3	20	25	FLOLAN	brand	DDI-DrugBank.d241.s3.e0
DDI-DrugBank.d241.s3	41	47	digoxin	drug	DDI-DrugBank.d241.s3.e1
DDI-DrugBank.d241.s3	50	58	diuretics	group	DDI-DrugBank.d241.s3.e2
DDI-DrugBank.d241.s3	61	74	anticoagulants	group	DDI-DrugBank.d241.s3.e3
DDI-DrugBank.d241.s3	82	93	vasodilators	group	DDI-DrugBank.d241.s3.e4
DDI-DrugBank.d241.s3	113	118	oxygen	drug	DDI-DrugBank.d241.s3.e5
DDI-DrugBank.d241.s3	202	211	furosemide	drug	DDI-DrugBank.d241.s3.e6
DDI-DrugBank.d241.s3	216	222	digoxin	drug	DDI-DrugBank.d241.s3.e7
DDI-DrugBank.d241.s3	245	250	FLOLAN	brand	DDI-DrugBank.d241.s3.e8
DDI-DrugBank.d241.s3	302	311	furosemide	drug	DDI-DrugBank.d241.s3.e9
DDI-DrugBank.d241.s3	false	DDI-DrugBank.d241.s3.e0	DDI-DrugBank.d241.s3.e1
DDI-DrugBank.d241.s3	false	DDI-DrugBank.d241.s3.e0	DDI-DrugBank.d241.s3.e2
DDI-DrugBank.d241.s3	false	DDI-DrugBank.d241.s3.e0	DDI-DrugBank.d241.s3.e3
DDI-DrugBank.d241.s3	false	DDI-DrugBank.d241.s3.e0	DDI-DrugBank.d241.s3.e4
DDI-DrugBank.d241.s3	false	DDI-DrugBank.d241.s3.e0	DDI-DrugBank.d241.s3.e5
DDI-DrugBank.d241.s3	false	DDI-DrugBank.d241.s3.e0	DDI-DrugBank.d241.s3.e6
DDI-DrugBank.d241.s3	false	DDI-DrugBank.d241.s3.e0	DDI-DrugBank.d241.s3.e7
DDI-DrugBank.d241.s3	false	DDI-DrugBank.d241.s3.e0	DDI-DrugBank.d241.s3.e8
DDI-DrugBank.d241.s3	false	DDI-DrugBank.d241.s3.e0	DDI-DrugBank.d241.s3.e9
DDI-DrugBank.d241.s3	false	DDI-DrugBank.d241.s3.e0	DDI-DrugBank.d241.s3.e10
DDI-DrugBank.d241.s4|a|The change in furosemide clearance value is not likely to be clinically significant.
DDI-DrugBank.d241.s4	14	23	furosemide	drug	DDI-DrugBank.d241.s4.e0
DDI-DrugBank.d241.s5|a|However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.
DDI-DrugBank.d241.s5	21	27	digoxin	drug	DDI-DrugBank.d241.s5.e0
DDI-DrugBank.d241.s5	52	58	digoxin	drug	DDI-DrugBank.d241.s5.e1
DDI-DrugBank.d241.s5	108	113	FLOLAN	brand	DDI-DrugBank.d241.s5.e2
DDI-DrugBank.d241.s5	173	179	digoxin	drug	DDI-DrugBank.d241.s5.e3
DDI-DrugBank.d241.s5	false	DDI-DrugBank.d241.s5.e0	DDI-DrugBank.d241.s5.e1
DDI-DrugBank.d241.s5	true	DDI-DrugBank.d241.s5.e0	DDI-DrugBank.d241.s5.e2
DDI-DrugBank.d241.s5	false	DDI-DrugBank.d241.s5.e0	DDI-DrugBank.d241.s5.e3
DDI-DrugBank.d241.s5	false	DDI-DrugBank.d241.s5.e1	DDI-DrugBank.d241.s5.e2
DDI-DrugBank.d241.s5	false	DDI-DrugBank.d241.s5.e1	DDI-DrugBank.d241.s5.e3
DDI-DrugBank.d241.s5	false	DDI-DrugBank.d241.s5.e2	DDI-DrugBank.d241.s5.e3
DDI-DrugBank.d525.s0|a|Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide.
DDI-DrugBank.d525.s0	0	9	Eprosartan	drug	DDI-DrugBank.d525.s0.e0
DDI-DrugBank.d525.s0	71	77	digoxin	drug	DDI-DrugBank.d525.s0.e1
DDI-DrugBank.d525.s0	107	114	warfarin	drug	DDI-DrugBank.d525.s0.e2
DDI-DrugBank.d525.s0	120	128	glyburide	drug	DDI-DrugBank.d525.s0.e3
DDI-DrugBank.d525.s0	false	DDI-DrugBank.d525.s0.e0	DDI-DrugBank.d525.s0.e1
DDI-DrugBank.d525.s0	false	DDI-DrugBank.d525.s0.e0	DDI-DrugBank.d525.s0.e2
DDI-DrugBank.d525.s0	false	DDI-DrugBank.d525.s0.e0	DDI-DrugBank.d525.s0.e3
DDI-DrugBank.d525.s0	false	DDI-DrugBank.d525.s0.e1	DDI-DrugBank.d525.s0.e2
DDI-DrugBank.d525.s0	false	DDI-DrugBank.d525.s0.e1	DDI-DrugBank.d525.s0.e3
DDI-DrugBank.d525.s0	false	DDI-DrugBank.d525.s0.e2	DDI-DrugBank.d525.s0.e3
DDI-DrugBank.d525.s1|a|Thus no dosing adjustments are necessary during concomitant use with these agents.
DDI-DrugBank.d525.s2|a|Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.
DDI-DrugBank.d525.s2	8	17	eprosartan	drug	DDI-DrugBank.d525.s2.e0
DDI-DrugBank.d525.s2	149	160	ketoconazole	drug	DDI-DrugBank.d525.s2.e1
DDI-DrugBank.d525.s2	166	176	fluconazole	drug	DDI-DrugBank.d525.s2.e2
DDI-DrugBank.d525.s2	266	275	eprosartan	drug	DDI-DrugBank.d525.s2.e3
DDI-DrugBank.d525.s2	false	DDI-DrugBank.d525.s2.e0	DDI-DrugBank.d525.s2.e1
DDI-DrugBank.d525.s2	false	DDI-DrugBank.d525.s2.e0	DDI-DrugBank.d525.s2.e2
DDI-DrugBank.d525.s2	false	DDI-DrugBank.d525.s2.e0	DDI-DrugBank.d525.s2.e3
DDI-DrugBank.d525.s2	false	DDI-DrugBank.d525.s2.e1	DDI-DrugBank.d525.s2.e2
DDI-DrugBank.d525.s2	false	DDI-DrugBank.d525.s2.e1	DDI-DrugBank.d525.s2.e3
DDI-DrugBank.d525.s2	false	DDI-DrugBank.d525.s2.e2	DDI-DrugBank.d525.s2.e3
DDI-DrugBank.d525.s3|a|Ranitidine also has no effect on eprosartan pharmacokinetics.
DDI-DrugBank.d525.s3	0	9	Ranitidine	drug	DDI-DrugBank.d525.s3.e0
DDI-DrugBank.d525.s3	33	42	eprosartan	drug	DDI-DrugBank.d525.s3.e1
DDI-DrugBank.d525.s3	false	DDI-DrugBank.d525.s3.e0	DDI-DrugBank.d525.s3.e1
DDI-DrugBank.d525.s4|a|Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide).
DDI-DrugBank.d525.s4	0	9	Eprosartan	drug	DDI-DrugBank.d525.s4.e0
DDI-DrugBank.d525.s4	97	113	thiazide diuretic	group	DDI-DrugBank.d525.s4.e1
DDI-DrugBank.d525.s4	116	134	hydrochlorothiazide	drug	DDI-DrugBank.d525.s4.e2
DDI-DrugBank.d525.s4	false	DDI-DrugBank.d525.s4.e0	DDI-DrugBank.d525.s4.e1
DDI-DrugBank.d525.s4	false	DDI-DrugBank.d525.s4.e0	DDI-DrugBank.d525.s4.e2
DDI-DrugBank.d525.s4	false	DDI-DrugBank.d525.s4.e1	DDI-DrugBank.d525.s4.e2
DDI-DrugBank.d525.s5|a|Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions.
DDI-DrugBank.d525.s5	0	9	Eprosartan	drug	DDI-DrugBank.d525.s5.e0
DDI-DrugBank.d525.s5	99	122	calcium channel blockers	group	DDI-DrugBank.d525.s5.e1
DDI-DrugBank.d525.s5	143	152	nifedipine	drug	DDI-DrugBank.d525.s5.e2
DDI-DrugBank.d525.s5	false	DDI-DrugBank.d525.s5.e0	DDI-DrugBank.d525.s5.e1
DDI-DrugBank.d525.s5	false	DDI-DrugBank.d525.s5.e0	DDI-DrugBank.d525.s5.e2
DDI-DrugBank.d525.s5	false	DDI-DrugBank.d525.s5.e1	DDI-DrugBank.d525.s5.e2
DDI-DrugBank.d278.s0|a|Enoxaparin dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of eptifibatide or the level of platelet aggregation in healthy adults.
DDI-DrugBank.d278.s0	0	9	Enoxaparin	drug	DDI-DrugBank.d278.s0.e0
DDI-DrugBank.d278.s0	113	124	eptifibatide	drug	DDI-DrugBank.d278.s0.e1
DDI-DrugBank.d278.s0	false	DDI-DrugBank.d278.s0.e0	DDI-DrugBank.d278.s0.e1
DDI-DrugBank.d471.s0|a|Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
DDI-DrugBank.d471.s0	0	10	Mineral oil	drug	DDI-DrugBank.d471.s0.e0
DDI-DrugBank.d471.s0	46	65	fat-soluble vitamins	group	DDI-DrugBank.d471.s0.e1
DDI-DrugBank.d471.s0	78	99	vitamin D preparations	group	DDI-DrugBank.d471.s0.e2
DDI-DrugBank.d471.s0	true	DDI-DrugBank.d471.s0.e0	DDI-DrugBank.d471.s0.e1
DDI-DrugBank.d471.s0	true	DDI-DrugBank.d471.s0.e0	DDI-DrugBank.d471.s0.e2
DDI-DrugBank.d471.s0	false	DDI-DrugBank.d471.s0.e1	DDI-DrugBank.d471.s0.e2
DDI-DrugBank.d471.s1|a|Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.
DDI-DrugBank.d471.s1	18	35	thiazide diuretics	group	DDI-DrugBank.d471.s1.e0
DDI-DrugBank.d471.s1	105	118	ergocalciferol	drug	DDI-DrugBank.d471.s1.e1
DDI-DrugBank.d471.s1	true	DDI-DrugBank.d471.s1.e0	DDI-DrugBank.d471.s1.e1
DDI-DrugBank.d201.s0|a|No reported interactions.
DDI-DrugBank.d59.s0|a|The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
DDI-DrugBank.d59.s0	15	21	ERGOMAR	brand	DDI-DrugBank.d59.s0.e0
DDI-DrugBank.d59.s0	45	65	triacetyloleandomycin	drug	DDI-DrugBank.d59.s0.e1
DDI-DrugBank.d59.s0	100	109	ergotamine	drug	DDI-DrugBank.d59.s0.e2
DDI-DrugBank.d59.s0	true	DDI-DrugBank.d59.s0.e0	DDI-DrugBank.d59.s0.e1
DDI-DrugBank.d59.s0	false	DDI-DrugBank.d59.s0.e0	DDI-DrugBank.d59.s0.e2
DDI-DrugBank.d59.s0	true	DDI-DrugBank.d59.s0.e1	DDI-DrugBank.d59.s0.e2
DDI-DrugBank.d59.s1|a|The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.
DDI-DrugBank.d59.s1	23	29	ERGOMAR	brand	DDI-DrugBank.d59.s1.e0
DDI-DrugBank.d59.s1	41	61	vasoconstrictor drugs	group	DDI-DrugBank.d59.s1.e1
DDI-DrugBank.d59.s1	true	DDI-DrugBank.d59.s1.e0	DDI-DrugBank.d59.s1.e1
DDI-DrugBank.d456.s0|a|Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.
DDI-DrugBank.d456.s0	46	57	ketoconazole	drug	DDI-DrugBank.d456.s0.e0
DDI-DrugBank.d456.s0	69	77	erlotinib	drug	DDI-DrugBank.d456.s0.e1
DDI-DrugBank.d456.s0	true	DDI-DrugBank.d456.s0.e0	DDI-DrugBank.d456.s0.e1
DDI-DrugBank.d456.s1|a|Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d456.s1	52	58	TARCEVA	brand	DDI-DrugBank.d456.s1.e0
DDI-DrugBank.d456.s1	65	76	ketoconazole	drug	DDI-DrugBank.d456.s1.e1
DDI-DrugBank.d456.s1	142	151	atazanavir	drug	DDI-DrugBank.d456.s1.e2
DDI-DrugBank.d456.s1	154	167	clarithromycin	drug	DDI-DrugBank.d456.s1.e3
DDI-DrugBank.d456.s1	170	178	indinavir	drug	DDI-DrugBank.d456.s1.e4
DDI-DrugBank.d456.s1	181	192	itraconazole	drug	DDI-DrugBank.d456.s1.e5
DDI-DrugBank.d456.s1	195	204	nefazodone	drug	DDI-DrugBank.d456.s1.e6
DDI-DrugBank.d456.s1	207	216	nelfinavir	drug	DDI-DrugBank.d456.s1.e7
DDI-DrugBank.d456.s1	219	227	ritonavir	drug	DDI-DrugBank.d456.s1.e8
DDI-DrugBank.d456.s1	230	239	saquinavir	drug	DDI-DrugBank.d456.s1.e9
DDI-DrugBank.d456.s1	true	DDI-DrugBank.d456.s1.e0	DDI-DrugBank.d456.s1.e1
DDI-DrugBank.d456.s1	true	DDI-DrugBank.d456.s1.e0	DDI-DrugBank.d456.s1.e2
DDI-DrugBank.d456.s1	true	DDI-DrugBank.d456.s1.e0	DDI-DrugBank.d456.s1.e3
DDI-DrugBank.d456.s1	true	DDI-DrugBank.d456.s1.e0	DDI-DrugBank.d456.s1.e4
DDI-DrugBank.d456.s1	true	DDI-DrugBank.d456.s1.e0	DDI-DrugBank.d456.s1.e5
DDI-DrugBank.d456.s1	true	DDI-DrugBank.d456.s1.e0	DDI-DrugBank.d456.s1.e6
DDI-DrugBank.d456.s1	true	DDI-DrugBank.d456.s1.e0	DDI-DrugBank.d456.s1.e7
DDI-DrugBank.d456.s1	true	DDI-DrugBank.d456.s1.e0	DDI-DrugBank.d456.s1.e8
DDI-DrugBank.d456.s1	true	DDI-DrugBank.d456.s1.e0	DDI-DrugBank.d456.s1.e9
DDI-DrugBank.d456.s1	true	DDI-DrugBank.d456.s1.e0	DDI-DrugBank.d456.s1.e10
DDI-DrugBank.d456.s2|a|Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.
DDI-DrugBank.d456.s2	38	47	rifampicin	drug	DDI-DrugBank.d456.s2.e0
DDI-DrugBank.d456.s2	59	67	erlotinib	drug	DDI-DrugBank.d456.s2.e1
DDI-DrugBank.d456.s2	true	DDI-DrugBank.d456.s2.e0	DDI-DrugBank.d456.s2.e1
DDI-DrugBank.d456.s3|a|Alternate treatments lacking CYP3A4 inducing activity should be considered.
DDI-DrugBank.d456.s4|a|If an alternative treatment is unavailable, a TARCEVA dose greater than 150 mg should be considered for NSCLC patients, and greater than 100 mg considered for pancreatic cancer patients.
DDI-DrugBank.d456.s4	46	52	TARCEVA	brand	DDI-DrugBank.d456.s4.e0
DDI-DrugBank.d456.s5|a|If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.
DDI-DrugBank.d456.s5	7	13	TARCEVA	brand	DDI-DrugBank.d456.s5.e0
DDI-DrugBank.d456.s5	97	106	rifampicin	drug	DDI-DrugBank.d456.s5.e1
DDI-DrugBank.d456.s5	true	DDI-DrugBank.d456.s5.e0	DDI-DrugBank.d456.s5.e1
DDI-DrugBank.d456.s6|a|Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and St. Johns Wort.
DDI-DrugBank.d456.s6	55	63	rifabutin	drug	DDI-DrugBank.d456.s6.e0
DDI-DrugBank.d456.s6	66	76	rifapentine	drug	DDI-DrugBank.d456.s6.e1
DDI-DrugBank.d456.s6	79	87	phenytoin	drug	DDI-DrugBank.d456.s6.e2
DDI-DrugBank.d456.s6	90	102	carbamazepine	drug	DDI-DrugBank.d456.s6.e3
DDI-DrugBank.d456.s6	105	117	phenobarbital	drug	DDI-DrugBank.d456.s6.e4
DDI-DrugBank.d456.s6	false	DDI-DrugBank.d456.s6.e0	DDI-DrugBank.d456.s6.e1
DDI-DrugBank.d456.s6	false	DDI-DrugBank.d456.s6.e0	DDI-DrugBank.d456.s6.e2
DDI-DrugBank.d456.s6	false	DDI-DrugBank.d456.s6.e0	DDI-DrugBank.d456.s6.e3
DDI-DrugBank.d456.s6	false	DDI-DrugBank.d456.s6.e0	DDI-DrugBank.d456.s6.e4
DDI-DrugBank.d456.s6	false	DDI-DrugBank.d456.s6.e1	DDI-DrugBank.d456.s6.e2
DDI-DrugBank.d456.s6	false	DDI-DrugBank.d456.s6.e1	DDI-DrugBank.d456.s6.e3
DDI-DrugBank.d456.s6	false	DDI-DrugBank.d456.s6.e1	DDI-DrugBank.d456.s6.e4
DDI-DrugBank.d456.s6	false	DDI-DrugBank.d456.s6.e2	DDI-DrugBank.d456.s6.e3
DDI-DrugBank.d456.s6	false	DDI-DrugBank.d456.s6.e2	DDI-DrugBank.d456.s6.e4
DDI-DrugBank.d456.s6	false	DDI-DrugBank.d456.s6.e3	DDI-DrugBank.d456.s6.e4
DDI-DrugBank.d456.s7|a|Hepatotoxicity Asymptomatic increases in liver transaminases have been observed in TARCEVA treated patients;
DDI-DrugBank.d456.s7	83	89	TARCEVA	brand	DDI-DrugBank.d456.s7.e0
DDI-DrugBank.d456.s8|a|therefore, periodic liver function testing (transaminases, bilirubin, and alkaline phosphatase) should be considered.
DDI-DrugBank.d456.s9|a|Dose reduction or interruption of TARCEVA should be considered if changes in liver function are severe.
DDI-DrugBank.d456.s9	34	40	TARCEVA	brand	DDI-DrugBank.d456.s9.e0
DDI-DrugBank.d456.s10|a|Patients with Hepatic Impairment In vitro and in vivo evidence suggest that erlotinib is cleared primarily by the liver.
DDI-DrugBank.d456.s10	76	84	erlotinib	drug	DDI-DrugBank.d456.s10.e0
DDI-DrugBank.d456.s11|a|Therefore, erlotinib exposure may be increased in patients with hepatic dysfunction.
DDI-DrugBank.d456.s11	11	19	erlotinib	drug	DDI-DrugBank.d456.s11.e0
DDI-DrugBank.d456.s12|a|Elevated International Normalized Ratio and Potential Bleeding International Normalized Ratio (INR) elevations and infrequent reports of bleeding events including gastrointestinal and non-gastrointestinal bleedings have been reported in clinical studies, some associated with concomitant warfarin administration.
DDI-DrugBank.d456.s12	288	295	warfarin	drug	DDI-DrugBank.d456.s12.e0
DDI-DrugBank.d456.s13|a|Patients taking warfarin or other coumarin-derivative anticoagulants should be monitored regularly for changes in prothrombin time or INR
DDI-DrugBank.d456.s13	16	23	warfarin	drug	DDI-DrugBank.d456.s13.e0
DDI-DrugBank.d456.s13	34	67	coumarin-derivative anticoagulants	group	DDI-DrugBank.d456.s13.e1
DDI-DrugBank.d456.s13	false	DDI-DrugBank.d456.s13.e0	DDI-DrugBank.d456.s13.e1
DDI-DrugBank.d456.s14|a|.
DDI-DrugBank.d456.s15|a|
DDI-DrugBank.d329.s0|a|When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.
DDI-DrugBank.d329.s0	5	13	ertapenem	drug	DDI-DrugBank.d329.s0.e0
DDI-DrugBank.d329.s0	39	48	probenecid	drug	DDI-DrugBank.d329.s0.e1
DDI-DrugBank.d329.s0	79	88	probenecid	drug	DDI-DrugBank.d329.s0.e2
DDI-DrugBank.d329.s0	163	171	ertapenem	drug	DDI-DrugBank.d329.s0.e3
DDI-DrugBank.d329.s0	false	DDI-DrugBank.d329.s0.e0	DDI-DrugBank.d329.s0.e1
DDI-DrugBank.d329.s0	false	DDI-DrugBank.d329.s0.e0	DDI-DrugBank.d329.s0.e2
DDI-DrugBank.d329.s0	false	DDI-DrugBank.d329.s0.e0	DDI-DrugBank.d329.s0.e3
DDI-DrugBank.d329.s0	false	DDI-DrugBank.d329.s0.e1	DDI-DrugBank.d329.s0.e2
DDI-DrugBank.d329.s0	false	DDI-DrugBank.d329.s0.e1	DDI-DrugBank.d329.s0.e3
DDI-DrugBank.d329.s0	true	DDI-DrugBank.d329.s0.e2	DDI-DrugBank.d329.s0.e3
DDI-DrugBank.d329.s1|a|Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.
DDI-DrugBank.d329.s1	15	23	ertapenem	drug	DDI-DrugBank.d329.s1.e0
DDI-DrugBank.d329.s1	41	50	probenecid	drug	DDI-DrugBank.d329.s1.e1
DDI-DrugBank.d329.s1	true	DDI-DrugBank.d329.s1.e0	DDI-DrugBank.d329.s1.e1
DDI-DrugBank.d329.s2|a|The half-life increased from 4.0 to 4.8 hours.
DDI-DrugBank.d329.s3|a|Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.
DDI-DrugBank.d329.s3	68	77	probenecid	drug	DDI-DrugBank.d329.s3.e0
DDI-DrugBank.d329.s3	106	114	ertapenem	drug	DDI-DrugBank.d329.s3.e1
DDI-DrugBank.d329.s3	true	DDI-DrugBank.d329.s3.e0	DDI-DrugBank.d329.s3.e1
DDI-DrugBank.d329.s4|a|In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
DDI-DrugBank.d329.s4	31	39	ertapenem	drug	DDI-DrugBank.d329.s4.e0
DDI-DrugBank.d329.s4	95	101	digoxin	drug	DDI-DrugBank.d329.s4.e1
DDI-DrugBank.d329.s4	106	116	vinblastine	drug	DDI-DrugBank.d329.s4.e2
DDI-DrugBank.d329.s4	127	135	ertapenem	drug	DDI-DrugBank.d329.s4.e3
DDI-DrugBank.d329.s4	false	DDI-DrugBank.d329.s4.e0	DDI-DrugBank.d329.s4.e1
DDI-DrugBank.d329.s4	false	DDI-DrugBank.d329.s4.e0	DDI-DrugBank.d329.s4.e2
DDI-DrugBank.d329.s4	false	DDI-DrugBank.d329.s4.e0	DDI-DrugBank.d329.s4.e3
DDI-DrugBank.d329.s4	false	DDI-DrugBank.d329.s4.e1	DDI-DrugBank.d329.s4.e2
DDI-DrugBank.d329.s4	false	DDI-DrugBank.d329.s4.e1	DDI-DrugBank.d329.s4.e3
DDI-DrugBank.d329.s4	false	DDI-DrugBank.d329.s4.e2	DDI-DrugBank.d329.s4.e3
DDI-DrugBank.d329.s5|a|In vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the following six cytochrome p450 (CYP) isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.
DDI-DrugBank.d329.s5	57	65	ertapenem	drug	DDI-DrugBank.d329.s5.e0
DDI-DrugBank.d329.s6|a|Drug interactions caused by inhibition of P-glycoprotein-mediated drug clearance or CYP-mediated drug clearance with the listed isoforms are unlikely.
DDI-DrugBank.d329.s7|a|Other than with probenecid, no specific clinical drug interaction studies have been conducted
DDI-DrugBank.d329.s7	16	25	probenecid	drug	DDI-DrugBank.d329.s7.e0
DDI-DrugBank.d329.s8|a|.
DDI-DrugBank.d329.s9|a|
DDI-DrugBank.d397.s0|a|Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
DDI-DrugBank.d397.s0	0	11	Erythromycin	drug	DDI-DrugBank.d397.s0.e0
DDI-DrugBank.d397.s0	61	72	theophylline	drug	DDI-DrugBank.d397.s0.e1
DDI-DrugBank.d397.s0	118	129	theophylline	drug	DDI-DrugBank.d397.s0.e2
DDI-DrugBank.d397.s0	152	163	theophylline	drug	DDI-DrugBank.d397.s0.e3
DDI-DrugBank.d397.s0	true	DDI-DrugBank.d397.s0.e0	DDI-DrugBank.d397.s0.e1
DDI-DrugBank.d397.s0	false	DDI-DrugBank.d397.s0.e0	DDI-DrugBank.d397.s0.e2
DDI-DrugBank.d397.s0	false	DDI-DrugBank.d397.s0.e0	DDI-DrugBank.d397.s0.e3
DDI-DrugBank.d397.s0	false	DDI-DrugBank.d397.s0.e1	DDI-DrugBank.d397.s0.e2
DDI-DrugBank.d397.s0	false	DDI-DrugBank.d397.s0.e1	DDI-DrugBank.d397.s0.e3
DDI-DrugBank.d397.s0	false	DDI-DrugBank.d397.s0.e2	DDI-DrugBank.d397.s0.e3
DDI-DrugBank.d397.s1|a|In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
DDI-DrugBank.d397.s1	11	22	theophylline	drug	DDI-DrugBank.d397.s1.e0
DDI-DrugBank.d397.s1	55	66	theophylline	drug	DDI-DrugBank.d397.s1.e1
DDI-DrugBank.d397.s1	88	99	theophylline	drug	DDI-DrugBank.d397.s1.e2
DDI-DrugBank.d397.s1	162	173	erythromycin	drug	DDI-DrugBank.d397.s1.e3
DDI-DrugBank.d397.s1	false	DDI-DrugBank.d397.s1.e0	DDI-DrugBank.d397.s1.e1
DDI-DrugBank.d397.s1	false	DDI-DrugBank.d397.s1.e0	DDI-DrugBank.d397.s1.e2
DDI-DrugBank.d397.s1	false	DDI-DrugBank.d397.s1.e0	DDI-DrugBank.d397.s1.e3
DDI-DrugBank.d397.s1	false	DDI-DrugBank.d397.s1.e1	DDI-DrugBank.d397.s1.e2
DDI-DrugBank.d397.s1	false	DDI-DrugBank.d397.s1.e1	DDI-DrugBank.d397.s1.e3
DDI-DrugBank.d397.s1	true	DDI-DrugBank.d397.s1.e2	DDI-DrugBank.d397.s1.e3
DDI-DrugBank.d397.s2|a|Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
DDI-DrugBank.d397.s2	30	41	erythromycin	drug	DDI-DrugBank.d397.s2.e0
DDI-DrugBank.d397.s2	47	53	digoxin	drug	DDI-DrugBank.d397.s2.e1
DDI-DrugBank.d397.s2	95	101	digoxin	drug	DDI-DrugBank.d397.s2.e2
DDI-DrugBank.d397.s2	true	DDI-DrugBank.d397.s2.e0	DDI-DrugBank.d397.s2.e1
DDI-DrugBank.d397.s2	false	DDI-DrugBank.d397.s2.e0	DDI-DrugBank.d397.s2.e2
DDI-DrugBank.d397.s2	false	DDI-DrugBank.d397.s2.e1	DDI-DrugBank.d397.s2.e2
DDI-DrugBank.d397.s3|a|There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
DDI-DrugBank.d397.s3	64	75	erythromycin	drug	DDI-DrugBank.d397.s3.e0
DDI-DrugBank.d397.s3	86	99	anticoagulants	group	DDI-DrugBank.d397.s3.e1
DDI-DrugBank.d397.s3	true	DDI-DrugBank.d397.s3.e0	DDI-DrugBank.d397.s3.e1
DDI-DrugBank.d397.s4|a|Increased anticoagulation effects due to interactions of erythromycin with various oral anticoagulents may be more pronounced in the elderly.
DDI-DrugBank.d397.s4	57	68	erythromycin	drug	DDI-DrugBank.d397.s4.e0
DDI-DrugBank.d397.s5|a|Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DDI-DrugBank.d397.s5	18	29	erythromycin	drug	DDI-DrugBank.d397.s5.e0
DDI-DrugBank.d397.s5	35	44	ergotamine	drug	DDI-DrugBank.d397.s5.e1
DDI-DrugBank.d397.s5	49	65	dihydroergotamine	drug	DDI-DrugBank.d397.s5.e2
DDI-DrugBank.d397.s5	true	DDI-DrugBank.d397.s5.e0	DDI-DrugBank.d397.s5.e1
DDI-DrugBank.d397.s5	true	DDI-DrugBank.d397.s5.e0	DDI-DrugBank.d397.s5.e2
DDI-DrugBank.d397.s5	false	DDI-DrugBank.d397.s5.e1	DDI-DrugBank.d397.s5.e2
DDI-DrugBank.d397.s6|a|Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
DDI-DrugBank.d397.s6	0	11	Erythromycin	drug	DDI-DrugBank.d397.s6.e0
DDI-DrugBank.d397.s6	60	68	triazolam	drug	DDI-DrugBank.d397.s6.e1
DDI-DrugBank.d397.s6	74	82	midazolam	drug	DDI-DrugBank.d397.s6.e2
DDI-DrugBank.d397.s6	140	154	benzodiazepines	group	DDI-DrugBank.d397.s6.e3
DDI-DrugBank.d397.s6	true	DDI-DrugBank.d397.s6.e0	DDI-DrugBank.d397.s6.e1
DDI-DrugBank.d397.s6	true	DDI-DrugBank.d397.s6.e0	DDI-DrugBank.d397.s6.e2
DDI-DrugBank.d397.s6	true	DDI-DrugBank.d397.s6.e0	DDI-DrugBank.d397.s6.e3
DDI-DrugBank.d397.s6	false	DDI-DrugBank.d397.s6.e1	DDI-DrugBank.d397.s6.e2
DDI-DrugBank.d397.s6	false	DDI-DrugBank.d397.s6.e1	DDI-DrugBank.d397.s6.e3
DDI-DrugBank.d397.s6	false	DDI-DrugBank.d397.s6.e2	DDI-DrugBank.d397.s6.e3
DDI-DrugBank.d397.s7|a|The use of erythromycin in patients concurrently taking drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these other drugs.
DDI-DrugBank.d397.s7	11	22	erythromycin	drug	DDI-DrugBank.d397.s7.e0
DDI-DrugBank.d397.s8|a|There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8	43	54	erythromycin	drug	DDI-DrugBank.d397.s8.e0
DDI-DrugBank.d397.s8	61	73	carbamazepine	drug	DDI-DrugBank.d397.s8.e1
DDI-DrugBank.d397.s8	76	87	cyclosporine	drug	DDI-DrugBank.d397.s8.e2
DDI-DrugBank.d397.s8	90	99	tacrolimus	drug	DDI-DrugBank.d397.s8.e3
DDI-DrugBank.d397.s8	102	113	hexobarbital	drug	DDI-DrugBank.d397.s8.e4
DDI-DrugBank.d397.s8	116	124	phenytoin	drug	DDI-DrugBank.d397.s8.e5
DDI-DrugBank.d397.s8	127	136	alfentanil	drug	DDI-DrugBank.d397.s8.e6
DDI-DrugBank.d397.s8	139	147	cisapride	drug	DDI-DrugBank.d397.s8.e7
DDI-DrugBank.d397.s8	150	161	disopyramide	drug	DDI-DrugBank.d397.s8.e8
DDI-DrugBank.d397.s8	164	173	lovastatin	drug	DDI-DrugBank.d397.s8.e9
DDI-DrugBank.d397.s8	true	DDI-DrugBank.d397.s8.e0	DDI-DrugBank.d397.s8.e1
DDI-DrugBank.d397.s8	true	DDI-DrugBank.d397.s8.e0	DDI-DrugBank.d397.s8.e2
DDI-DrugBank.d397.s8	true	DDI-DrugBank.d397.s8.e0	DDI-DrugBank.d397.s8.e3
DDI-DrugBank.d397.s8	true	DDI-DrugBank.d397.s8.e0	DDI-DrugBank.d397.s8.e4
DDI-DrugBank.d397.s8	true	DDI-DrugBank.d397.s8.e0	DDI-DrugBank.d397.s8.e5
DDI-DrugBank.d397.s8	true	DDI-DrugBank.d397.s8.e0	DDI-DrugBank.d397.s8.e6
DDI-DrugBank.d397.s8	true	DDI-DrugBank.d397.s8.e0	DDI-DrugBank.d397.s8.e7
DDI-DrugBank.d397.s8	true	DDI-DrugBank.d397.s8.e0	DDI-DrugBank.d397.s8.e8
DDI-DrugBank.d397.s8	true	DDI-DrugBank.d397.s8.e0	DDI-DrugBank.d397.s8.e9
DDI-DrugBank.d397.s8	true	DDI-DrugBank.d397.s8.e0	DDI-DrugBank.d397.s8.e10
DDI-DrugBank.d397.s9|a|Serum concentrations of drugs metabolized by the cytochrome P450 system should be monitored closely in patients concurrently receiving erythromycin.
DDI-DrugBank.d397.s9	135	146	erythromycin	drug	DDI-DrugBank.d397.s9.e0
DDI-DrugBank.d397.s10|a|Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
DDI-DrugBank.d397.s10	0	11	Erythromycin	drug	DDI-DrugBank.d397.s10.e0
DDI-DrugBank.d397.s10	84	97	antihistamines	group	DDI-DrugBank.d397.s10.e1
DDI-DrugBank.d397.s10	99	109	terfenadine	drug	DDI-DrugBank.d397.s10.e2
DDI-DrugBank.d397.s10	115	124	astemizole	drug	DDI-DrugBank.d397.s10.e3
DDI-DrugBank.d397.s10	false	DDI-DrugBank.d397.s10.e0	DDI-DrugBank.d397.s10.e1
DDI-DrugBank.d397.s10	true	DDI-DrugBank.d397.s10.e0	DDI-DrugBank.d397.s10.e2
DDI-DrugBank.d397.s10	true	DDI-DrugBank.d397.s10.e0	DDI-DrugBank.d397.s10.e3
DDI-DrugBank.d397.s10	false	DDI-DrugBank.d397.s10.e1	DDI-DrugBank.d397.s10.e2
DDI-DrugBank.d397.s10	false	DDI-DrugBank.d397.s10.e1	DDI-DrugBank.d397.s10.e3
DDI-DrugBank.d397.s10	false	DDI-DrugBank.d397.s10.e2	DDI-DrugBank.d397.s10.e3
DDI-DrugBank.d397.s11|a|Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QTc interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed.
DDI-DrugBank.d397.s12|a|In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
DDI-DrugBank.d397.s12	81	91	terfenadine	drug	DDI-DrugBank.d397.s12.e0
DDI-DrugBank.d397.s12	97	108	erythromycin	drug	DDI-DrugBank.d397.s12.e1
DDI-DrugBank.d397.s12	true	DDI-DrugBank.d397.s12.e0	DDI-DrugBank.d397.s12.e1
DDI-DrugBank.d397.s13|a|There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
DDI-DrugBank.d397.s13	64	75	erythromycin	drug	DDI-DrugBank.d397.s13.e0
DDI-DrugBank.d397.s13	100	108	cisapride	drug	DDI-DrugBank.d397.s13.e1
DDI-DrugBank.d397.s13	289	297	cisapride	drug	DDI-DrugBank.d397.s13.e2
DDI-DrugBank.d397.s13	302	313	erythromycin	drug	DDI-DrugBank.d397.s13.e3
DDI-DrugBank.d397.s13	true	DDI-DrugBank.d397.s13.e0	DDI-DrugBank.d397.s13.e1
DDI-DrugBank.d397.s13	false	DDI-DrugBank.d397.s13.e0	DDI-DrugBank.d397.s13.e2
DDI-DrugBank.d397.s13	false	DDI-DrugBank.d397.s13.e0	DDI-DrugBank.d397.s13.e3
DDI-DrugBank.d397.s13	false	DDI-DrugBank.d397.s13.e1	DDI-DrugBank.d397.s13.e2
DDI-DrugBank.d397.s13	false	DDI-DrugBank.d397.s13.e1	DDI-DrugBank.d397.s13.e3
DDI-DrugBank.d397.s13	true	DDI-DrugBank.d397.s13.e2	DDI-DrugBank.d397.s13.e3
DDI-DrugBank.d397.s14|a|Fatalities have been reported.
DDI-DrugBank.d397.s15|a|Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;
DDI-DrugBank.d397.s15	31	40	lovastatin	drug	DDI-DrugBank.d397.s15.e0
DDI-DrugBank.d397.s15	46	57	erythromycin	drug	DDI-DrugBank.d397.s15.e1
DDI-DrugBank.d397.s15	true	DDI-DrugBank.d397.s15.e0	DDI-DrugBank.d397.s15.e1
DDI-DrugBank.d397.s16|a|cases of rhabdomyolysis have been reported in seriously ill patients.
DDI-DrugBank.d568.s0|a|CNS Drugs - Given the primary CNS effects of escitalopram, caution should be used when it is taken in combination with other centrally acting drugs.
DDI-DrugBank.d568.s0	45	56	escitalopram	drug	DDI-DrugBank.d568.s0.e0
DDI-DrugBank.d568.s1|a|Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
DDI-DrugBank.d568.s1	0	6	Alcohol	drug	DDI-DrugBank.d568.s1.e0
DDI-DrugBank.d568.s1	19	25	LEXAPRO	brand	DDI-DrugBank.d568.s1.e1
DDI-DrugBank.d568.s1	81	87	alcohol	drug	DDI-DrugBank.d568.s1.e2
DDI-DrugBank.d568.s1	124	147	psychotropic medications	group	DDI-DrugBank.d568.s1.e3
DDI-DrugBank.d568.s1	161	167	alcohol	drug	DDI-DrugBank.d568.s1.e4
DDI-DrugBank.d568.s1	188	194	LEXAPRO	brand	DDI-DrugBank.d568.s1.e5
DDI-DrugBank.d568.s1	false	DDI-DrugBank.d568.s1.e0	DDI-DrugBank.d568.s1.e1
DDI-DrugBank.d568.s1	false	DDI-DrugBank.d568.s1.e0	DDI-DrugBank.d568.s1.e2
DDI-DrugBank.d568.s1	false	DDI-DrugBank.d568.s1.e0	DDI-DrugBank.d568.s1.e3
DDI-DrugBank.d568.s1	false	DDI-DrugBank.d568.s1.e0	DDI-DrugBank.d568.s1.e4
DDI-DrugBank.d568.s1	false	DDI-DrugBank.d568.s1.e0	DDI-DrugBank.d568.s1.e5
DDI-DrugBank.d568.s1	false	DDI-DrugBank.d568.s1.e1	DDI-DrugBank.d568.s1.e2
DDI-DrugBank.d568.s1	false	DDI-DrugBank.d568.s1.e1	DDI-DrugBank.d568.s1.e3
DDI-DrugBank.d568.s1	false	DDI-DrugBank.d568.s1.e1	DDI-DrugBank.d568.s1.e4
DDI-DrugBank.d568.s1	false	DDI-DrugBank.d568.s1.e1	DDI-DrugBank.d568.s1.e5
DDI-DrugBank.d568.s1	false	DDI-DrugBank.d568.s1.e2	DDI-DrugBank.d568.s1.e3
DDI-DrugBank.d568.s2|a|Monoamine Oxidase Inhibitors (MAOIs)
DDI-DrugBank.d568.s2	0	27	Monoamine Oxidase Inhibitors	group	DDI-DrugBank.d568.s2.e0
DDI-DrugBank.d568.s2	30	34	MAOIs	group	DDI-DrugBank.d568.s2.e1
DDI-DrugBank.d568.s2	false	DDI-DrugBank.d568.s2.e0	DDI-DrugBank.d568.s2.e1
DDI-DrugBank.d568.s3|a|Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)
DDI-DrugBank.d568.s3	38	43	NSAIDs	group	DDI-DrugBank.d568.s3.e0
DDI-DrugBank.d568.s3	46	52	Aspirin	brand	DDI-DrugBank.d568.s3.e1
DDI-DrugBank.d568.s3	55	62	Warfarin	drug	DDI-DrugBank.d568.s3.e2
DDI-DrugBank.d568.s3	false	DDI-DrugBank.d568.s3.e0	DDI-DrugBank.d568.s3.e1
DDI-DrugBank.d568.s3	false	DDI-DrugBank.d568.s3.e0	DDI-DrugBank.d568.s3.e2
DDI-DrugBank.d568.s3	false	DDI-DrugBank.d568.s3.e1	DDI-DrugBank.d568.s3.e2
DDI-DrugBank.d568.s4|a|Serotonin release by platelets plays an important role in hemostasis.
DDI-DrugBank.d568.s5|a|Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.
DDI-DrugBank.d568.s5	115	132	psychotropic drugs	group	DDI-DrugBank.d568.s5.e0
DDI-DrugBank.d568.s5	269	273	NSAID	group	DDI-DrugBank.d568.s5.e1
DDI-DrugBank.d568.s5	278	284	aspirin	brand	DDI-DrugBank.d568.s5.e2
DDI-DrugBank.d568.s5	true	DDI-DrugBank.d568.s5.e0	DDI-DrugBank.d568.s5.e1
DDI-DrugBank.d568.s5	true	DDI-DrugBank.d568.s5.e0	DDI-DrugBank.d568.s5.e2
DDI-DrugBank.d568.s5	false	DDI-DrugBank.d568.s5.e1	DDI-DrugBank.d568.s5.e2
DDI-DrugBank.d568.s6|a|Thus, patients should be cautioned about the use of such drugs concurrently with LEXAPRO.
DDI-DrugBank.d568.s6	81	87	LEXAPRO	brand	DDI-DrugBank.d568.s6.e0
DDI-DrugBank.d568.s7|a|Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
DDI-DrugBank.d568.s7	0	9	Cimetidine	drug	DDI-DrugBank.d568.s7.e0
DDI-DrugBank.d568.s7	71	80	citalopram	drug	DDI-DrugBank.d568.s7.e1
DDI-DrugBank.d568.s7	121	130	cimetidine	drug	DDI-DrugBank.d568.s7.e2
DDI-DrugBank.d568.s7	170	179	citalopram	drug	DDI-DrugBank.d568.s7.e3
DDI-DrugBank.d568.s7	false	DDI-DrugBank.d568.s7.e0	DDI-DrugBank.d568.s7.e1
DDI-DrugBank.d568.s7	false	DDI-DrugBank.d568.s7.e0	DDI-DrugBank.d568.s7.e2
DDI-DrugBank.d568.s7	false	DDI-DrugBank.d568.s7.e0	DDI-DrugBank.d568.s7.e3
DDI-DrugBank.d568.s7	true	DDI-DrugBank.d568.s7.e1	DDI-DrugBank.d568.s7.e2
DDI-DrugBank.d568.s7	false	DDI-DrugBank.d568.s7.e1	DDI-DrugBank.d568.s7.e3
DDI-DrugBank.d568.s7	false	DDI-DrugBank.d568.s7.e2	DDI-DrugBank.d568.s7.e3
DDI-DrugBank.d568.s8|a|The clinical significance of these findings is unknown.
DDI-DrugBank.d568.s9|a|Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.
DDI-DrugBank.d568.s9	0	6	Digoxin	drug	DDI-DrugBank.d568.s9.e0
DDI-DrugBank.d568.s9	68	77	citalopram	drug	DDI-DrugBank.d568.s9.e1
DDI-DrugBank.d568.s9	107	116	citalopram	drug	DDI-DrugBank.d568.s9.e2
DDI-DrugBank.d568.s9	122	128	digoxin	drug	DDI-DrugBank.d568.s9.e3
DDI-DrugBank.d568.s9	212	221	citalopram	drug	DDI-DrugBank.d568.s9.e4
DDI-DrugBank.d568.s9	226	232	digoxin	drug	DDI-DrugBank.d568.s9.e5
DDI-DrugBank.d568.s9	false	DDI-DrugBank.d568.s9.e0	DDI-DrugBank.d568.s9.e1
DDI-DrugBank.d568.s9	false	DDI-DrugBank.d568.s9.e0	DDI-DrugBank.d568.s9.e2
DDI-DrugBank.d568.s9	false	DDI-DrugBank.d568.s9.e0	DDI-DrugBank.d568.s9.e3
DDI-DrugBank.d568.s9	false	DDI-DrugBank.d568.s9.e0	DDI-DrugBank.d568.s9.e4
DDI-DrugBank.d568.s9	false	DDI-DrugBank.d568.s9.e0	DDI-DrugBank.d568.s9.e5
DDI-DrugBank.d568.s9	false	DDI-DrugBank.d568.s9.e1	DDI-DrugBank.d568.s9.e2
DDI-DrugBank.d568.s9	false	DDI-DrugBank.d568.s9.e1	DDI-DrugBank.d568.s9.e3
DDI-DrugBank.d568.s9	false	DDI-DrugBank.d568.s9.e1	DDI-DrugBank.d568.s9.e4
DDI-DrugBank.d568.s9	false	DDI-DrugBank.d568.s9.e1	DDI-DrugBank.d568.s9.e5
DDI-DrugBank.d568.s9	false	DDI-DrugBank.d568.s9.e2	DDI-DrugBank.d568.s9.e3
DDI-DrugBank.d568.s10|a|Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.
DDI-DrugBank.d568.s10	0	6	Lithium	drug	DDI-DrugBank.d568.s10.e0
DDI-DrugBank.d568.s10	38	47	citalopram	drug	DDI-DrugBank.d568.s10.e1
DDI-DrugBank.d568.s10	77	83	lithium	drug	DDI-DrugBank.d568.s10.e2
DDI-DrugBank.d568.s10	163	172	citalopram	drug	DDI-DrugBank.d568.s10.e3
DDI-DrugBank.d568.s10	177	183	lithium	drug	DDI-DrugBank.d568.s10.e4
DDI-DrugBank.d568.s10	false	DDI-DrugBank.d568.s10.e0	DDI-DrugBank.d568.s10.e1
DDI-DrugBank.d568.s10	false	DDI-DrugBank.d568.s10.e0	DDI-DrugBank.d568.s10.e2
DDI-DrugBank.d568.s10	false	DDI-DrugBank.d568.s10.e0	DDI-DrugBank.d568.s10.e3
DDI-DrugBank.d568.s10	false	DDI-DrugBank.d568.s10.e0	DDI-DrugBank.d568.s10.e4
DDI-DrugBank.d568.s10	false	DDI-DrugBank.d568.s10.e1	DDI-DrugBank.d568.s10.e2
DDI-DrugBank.d568.s10	false	DDI-DrugBank.d568.s10.e1	DDI-DrugBank.d568.s10.e3
DDI-DrugBank.d568.s10	false	DDI-DrugBank.d568.s10.e1	DDI-DrugBank.d568.s10.e4
DDI-DrugBank.d568.s10	false	DDI-DrugBank.d568.s10.e2	DDI-DrugBank.d568.s10.e3
DDI-DrugBank.d568.s10	false	DDI-DrugBank.d568.s10.e2	DDI-DrugBank.d568.s10.e4
DDI-DrugBank.d568.s10	false	DDI-DrugBank.d568.s10.e3	DDI-DrugBank.d568.s10.e4
DDI-DrugBank.d568.s11|a|Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.
DDI-DrugBank.d568.s11	21	27	lithium	drug	DDI-DrugBank.d568.s11.e0
DDI-DrugBank.d568.s11	91	97	lithium	drug	DDI-DrugBank.d568.s11.e1
DDI-DrugBank.d568.s11	false	DDI-DrugBank.d568.s11.e0	DDI-DrugBank.d568.s11.e1
DDI-DrugBank.d568.s12|a|Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
DDI-DrugBank.d568.s12	8	14	lithium	drug	DDI-DrugBank.d568.s12.e0
DDI-DrugBank.d568.s12	56	67	escitalopram	drug	DDI-DrugBank.d568.s12.e1
DDI-DrugBank.d568.s12	103	109	LEXAPRO	brand	DDI-DrugBank.d568.s12.e2
DDI-DrugBank.d568.s12	115	121	lithium	drug	DDI-DrugBank.d568.s12.e3
DDI-DrugBank.d568.s12	true	DDI-DrugBank.d568.s12.e0	DDI-DrugBank.d568.s12.e1
DDI-DrugBank.d568.s12	false	DDI-DrugBank.d568.s12.e0	DDI-DrugBank.d568.s12.e2
DDI-DrugBank.d568.s12	false	DDI-DrugBank.d568.s12.e0	DDI-DrugBank.d568.s12.e3
DDI-DrugBank.d568.s12	false	DDI-DrugBank.d568.s12.e1	DDI-DrugBank.d568.s12.e2
DDI-DrugBank.d568.s12	false	DDI-DrugBank.d568.s12.e1	DDI-DrugBank.d568.s12.e3
DDI-DrugBank.d568.s12	true	DDI-DrugBank.d568.s12.e2	DDI-DrugBank.d568.s12.e3
DDI-DrugBank.d568.s13|a|Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
DDI-DrugBank.d568.s13	0	7	Pimozide	drug	DDI-DrugBank.d568.s13.e0
DDI-DrugBank.d568.s13	13	18	Celexa	brand	DDI-DrugBank.d568.s13.e1
DDI-DrugBank.d568.s13	62	69	pimozide	drug	DDI-DrugBank.d568.s13.e2
DDI-DrugBank.d568.s13	105	114	citalopram	drug	DDI-DrugBank.d568.s13.e3
DDI-DrugBank.d568.s13	238	245	pimozide	drug	DDI-DrugBank.d568.s13.e4
DDI-DrugBank.d568.s13	false	DDI-DrugBank.d568.s13.e0	DDI-DrugBank.d568.s13.e1
DDI-DrugBank.d568.s13	false	DDI-DrugBank.d568.s13.e0	DDI-DrugBank.d568.s13.e2
DDI-DrugBank.d568.s13	false	DDI-DrugBank.d568.s13.e0	DDI-DrugBank.d568.s13.e3
DDI-DrugBank.d568.s13	false	DDI-DrugBank.d568.s13.e0	DDI-DrugBank.d568.s13.e4
DDI-DrugBank.d568.s13	false	DDI-DrugBank.d568.s13.e1	DDI-DrugBank.d568.s13.e2
DDI-DrugBank.d568.s13	false	DDI-DrugBank.d568.s13.e1	DDI-DrugBank.d568.s13.e3
DDI-DrugBank.d568.s13	false	DDI-DrugBank.d568.s13.e1	DDI-DrugBank.d568.s13.e4
DDI-DrugBank.d568.s13	true	DDI-DrugBank.d568.s13.e2	DDI-DrugBank.d568.s13.e3
DDI-DrugBank.d568.s13	false	DDI-DrugBank.d568.s13.e2	DDI-DrugBank.d568.s13.e4
DDI-DrugBank.d568.s13	false	DDI-DrugBank.d568.s13.e3	DDI-DrugBank.d568.s13.e4
DDI-DrugBank.d568.s14|a|Racemic citalopram did not alter the mean AUC or Cmax of pimozide.
DDI-DrugBank.d568.s14	8	17	citalopram	drug	DDI-DrugBank.d568.s14.e0
DDI-DrugBank.d568.s14	57	64	pimozide	drug	DDI-DrugBank.d568.s14.e1
DDI-DrugBank.d568.s14	false	DDI-DrugBank.d568.s14.e0	DDI-DrugBank.d568.s14.e1
DDI-DrugBank.d568.s15|a|The mechanism of this pharmacodynamic interaction is not known.
DDI-DrugBank.d568.s16|a|Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
DDI-DrugBank.d568.s16	0	10	Sumatriptan	drug	DDI-DrugBank.d568.s16.e0
DDI-DrugBank.d568.s16	149	186	selective serotonin reuptake inhibitor	group	DDI-DrugBank.d568.s16.e1
DDI-DrugBank.d568.s16	189	192	SSRI	group	DDI-DrugBank.d568.s16.e2
DDI-DrugBank.d568.s16	199	209	sumatriptan	drug	DDI-DrugBank.d568.s16.e3
DDI-DrugBank.d568.s16	false	DDI-DrugBank.d568.s16.e0	DDI-DrugBank.d568.s16.e1
DDI-DrugBank.d568.s16	false	DDI-DrugBank.d568.s16.e0	DDI-DrugBank.d568.s16.e2
DDI-DrugBank.d568.s16	false	DDI-DrugBank.d568.s16.e0	DDI-DrugBank.d568.s16.e3
DDI-DrugBank.d568.s16	false	DDI-DrugBank.d568.s16.e1	DDI-DrugBank.d568.s16.e2
DDI-DrugBank.d568.s16	true	DDI-DrugBank.d568.s16.e1	DDI-DrugBank.d568.s16.e3
DDI-DrugBank.d568.s16	true	DDI-DrugBank.d568.s16.e2	DDI-DrugBank.d568.s16.e3
DDI-DrugBank.d568.s17|a|If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d568.s17	30	40	sumatriptan	drug	DDI-DrugBank.d568.s17.e0
DDI-DrugBank.d568.s17	49	52	SSRI	group	DDI-DrugBank.d568.s17.e1
DDI-DrugBank.d568.s17	61	70	fluoxetine	drug	DDI-DrugBank.d568.s17.e2
DDI-DrugBank.d568.s17	73	83	fluvoxamine	drug	DDI-DrugBank.d568.s17.e3
DDI-DrugBank.d568.s17	86	95	paroxetine	drug	DDI-DrugBank.d568.s17.e4
DDI-DrugBank.d568.s17	98	107	sertraline	drug	DDI-DrugBank.d568.s17.e5
DDI-DrugBank.d568.s17	110	119	citalopram	drug	DDI-DrugBank.d568.s17.e6
DDI-DrugBank.d568.s17	122	133	escitalopram	drug	DDI-DrugBank.d568.s17.e7
DDI-DrugBank.d568.s17	true	DDI-DrugBank.d568.s17.e0	DDI-DrugBank.d568.s17.e1
DDI-DrugBank.d568.s17	true	DDI-DrugBank.d568.s17.e0	DDI-DrugBank.d568.s17.e2
DDI-DrugBank.d568.s17	true	DDI-DrugBank.d568.s17.e0	DDI-DrugBank.d568.s17.e3
DDI-DrugBank.d568.s17	true	DDI-DrugBank.d568.s17.e0	DDI-DrugBank.d568.s17.e4
DDI-DrugBank.d568.s17	true	DDI-DrugBank.d568.s17.e0	DDI-DrugBank.d568.s17.e5
DDI-DrugBank.d568.s17	true	DDI-DrugBank.d568.s17.e0	DDI-DrugBank.d568.s17.e6
DDI-DrugBank.d568.s17	true	DDI-DrugBank.d568.s17.e0	DDI-DrugBank.d568.s17.e7
DDI-DrugBank.d568.s17	false	DDI-DrugBank.d568.s17.e1	DDI-DrugBank.d568.s17.e2
DDI-DrugBank.d568.s17	false	DDI-DrugBank.d568.s17.e1	DDI-DrugBank.d568.s17.e3
DDI-DrugBank.d568.s17	false	DDI-DrugBank.d568.s17.e1	DDI-DrugBank.d568.s17.e4
DDI-DrugBank.d568.s18|a|Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
DDI-DrugBank.d568.s18	0	11	Theophylline	drug	DDI-DrugBank.d568.s18.e0
DDI-DrugBank.d568.s18	50	59	citalopram	drug	DDI-DrugBank.d568.s18.e1
DDI-DrugBank.d568.s18	110	121	theophylline	drug	DDI-DrugBank.d568.s18.e2
DDI-DrugBank.d568.s18	186	197	theophylline	drug	DDI-DrugBank.d568.s18.e3
DDI-DrugBank.d568.s18	false	DDI-DrugBank.d568.s18.e0	DDI-DrugBank.d568.s18.e1
DDI-DrugBank.d568.s18	false	DDI-DrugBank.d568.s18.e0	DDI-DrugBank.d568.s18.e2
DDI-DrugBank.d568.s18	false	DDI-DrugBank.d568.s18.e0	DDI-DrugBank.d568.s18.e3
DDI-DrugBank.d568.s18	false	DDI-DrugBank.d568.s18.e1	DDI-DrugBank.d568.s18.e2
DDI-DrugBank.d568.s18	false	DDI-DrugBank.d568.s18.e1	DDI-DrugBank.d568.s18.e3
DDI-DrugBank.d568.s18	false	DDI-DrugBank.d568.s18.e2	DDI-DrugBank.d568.s18.e3
DDI-DrugBank.d568.s19|a|The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.
DDI-DrugBank.d568.s19	14	25	theophylline	drug	DDI-DrugBank.d568.s19.e0
DDI-DrugBank.d568.s19	54	63	citalopram	drug	DDI-DrugBank.d568.s19.e1
DDI-DrugBank.d568.s19	false	DDI-DrugBank.d568.s19.e0	DDI-DrugBank.d568.s19.e1
DDI-DrugBank.d568.s20|a|Warfarin - Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.
DDI-DrugBank.d568.s20	0	7	Warfarin	drug	DDI-DrugBank.d568.s20.e0
DDI-DrugBank.d568.s20	47	56	citalopram	drug	DDI-DrugBank.d568.s20.e1
DDI-DrugBank.d568.s20	109	116	warfarin	drug	DDI-DrugBank.d568.s20.e2
DDI-DrugBank.d568.s20	false	DDI-DrugBank.d568.s20.e0	DDI-DrugBank.d568.s20.e1
DDI-DrugBank.d568.s20	false	DDI-DrugBank.d568.s20.e0	DDI-DrugBank.d568.s20.e2
DDI-DrugBank.d568.s20	false	DDI-DrugBank.d568.s20.e1	DDI-DrugBank.d568.s20.e2
DDI-DrugBank.d568.s21|a|Prothrombin time was increased by 5%, the clinical significance of which is unknown.
DDI-DrugBank.d568.s22|a|Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
DDI-DrugBank.d568.s22	0	12	Carbamazepine	drug	DDI-DrugBank.d568.s22.e0
DDI-DrugBank.d568.s22	51	60	citalopram	drug	DDI-DrugBank.d568.s22.e1
DDI-DrugBank.d568.s22	90	102	carbamazepine	drug	DDI-DrugBank.d568.s22.e2
DDI-DrugBank.d568.s22	194	206	carbamazepine	drug	DDI-DrugBank.d568.s22.e3
DDI-DrugBank.d568.s22	false	DDI-DrugBank.d568.s22.e0	DDI-DrugBank.d568.s22.e1
DDI-DrugBank.d568.s22	false	DDI-DrugBank.d568.s22.e0	DDI-DrugBank.d568.s22.e2
DDI-DrugBank.d568.s22	false	DDI-DrugBank.d568.s22.e0	DDI-DrugBank.d568.s22.e3
DDI-DrugBank.d568.s22	false	DDI-DrugBank.d568.s22.e1	DDI-DrugBank.d568.s22.e2
DDI-DrugBank.d568.s22	false	DDI-DrugBank.d568.s22.e1	DDI-DrugBank.d568.s22.e3
DDI-DrugBank.d568.s22	false	DDI-DrugBank.d568.s22.e2	DDI-DrugBank.d568.s22.e3
DDI-DrugBank.d568.s23|a|Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.
DDI-DrugBank.d568.s23	16	25	citalopram	drug	DDI-DrugBank.d568.s23.e0
DDI-DrugBank.d568.s23	98	110	carbamazepine	drug	DDI-DrugBank.d568.s23.e1
DDI-DrugBank.d568.s23	134	146	carbamazepine	drug	DDI-DrugBank.d568.s23.e2
DDI-DrugBank.d568.s23	180	191	escitalopram	drug	DDI-DrugBank.d568.s23.e3
DDI-DrugBank.d568.s23	false	DDI-DrugBank.d568.s23.e0	DDI-DrugBank.d568.s23.e1
DDI-DrugBank.d568.s23	false	DDI-DrugBank.d568.s23.e0	DDI-DrugBank.d568.s23.e2
DDI-DrugBank.d568.s23	false	DDI-DrugBank.d568.s23.e0	DDI-DrugBank.d568.s23.e3
DDI-DrugBank.d568.s23	false	DDI-DrugBank.d568.s23.e1	DDI-DrugBank.d568.s23.e2
DDI-DrugBank.d568.s23	false	DDI-DrugBank.d568.s23.e1	DDI-DrugBank.d568.s23.e3
DDI-DrugBank.d568.s23	true	DDI-DrugBank.d568.s23.e2	DDI-DrugBank.d568.s23.e3
DDI-DrugBank.d568.s24|a|Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.
DDI-DrugBank.d568.s24	0	8	Triazolam	drug	DDI-DrugBank.d568.s24.e0
DDI-DrugBank.d568.s24	47	56	citalopram	drug	DDI-DrugBank.d568.s24.e1
DDI-DrugBank.d568.s24	119	127	triazolam	drug	DDI-DrugBank.d568.s24.e2
DDI-DrugBank.d568.s24	214	223	citalopram	drug	DDI-DrugBank.d568.s24.e3
DDI-DrugBank.d568.s24	228	236	triazolam	drug	DDI-DrugBank.d568.s24.e4
DDI-DrugBank.d568.s24	false	DDI-DrugBank.d568.s24.e0	DDI-DrugBank.d568.s24.e1
DDI-DrugBank.d568.s24	false	DDI-DrugBank.d568.s24.e0	DDI-DrugBank.d568.s24.e2
DDI-DrugBank.d568.s24	false	DDI-DrugBank.d568.s24.e0	DDI-DrugBank.d568.s24.e3
DDI-DrugBank.d568.s24	false	DDI-DrugBank.d568.s24.e0	DDI-DrugBank.d568.s24.e4
DDI-DrugBank.d568.s24	false	DDI-DrugBank.d568.s24.e1	DDI-DrugBank.d568.s24.e2
DDI-DrugBank.d568.s24	false	DDI-DrugBank.d568.s24.e1	DDI-DrugBank.d568.s24.e3
DDI-DrugBank.d568.s24	false	DDI-DrugBank.d568.s24.e1	DDI-DrugBank.d568.s24.e4
DDI-DrugBank.d568.s24	false	DDI-DrugBank.d568.s24.e2	DDI-DrugBank.d568.s24.e3
DDI-DrugBank.d568.s24	false	DDI-DrugBank.d568.s24.e2	DDI-DrugBank.d568.s24.e4
DDI-DrugBank.d568.s24	false	DDI-DrugBank.d568.s24.e3	DDI-DrugBank.d568.s24.e4
DDI-DrugBank.d568.s25|a|Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
DDI-DrugBank.d568.s25	0	11	Ketoconazole	drug	DDI-DrugBank.d568.s25.e0
DDI-DrugBank.d568.s25	50	59	citalopram	drug	DDI-DrugBank.d568.s25.e1
DDI-DrugBank.d568.s25	73	84	ketoconazole	drug	DDI-DrugBank.d568.s25.e2
DDI-DrugBank.d568.s25	125	136	ketoconazole	drug	DDI-DrugBank.d568.s25.e3
DDI-DrugBank.d568.s25	225	234	citalopram	drug	DDI-DrugBank.d568.s25.e4
DDI-DrugBank.d568.s25	false	DDI-DrugBank.d568.s25.e0	DDI-DrugBank.d568.s25.e1
DDI-DrugBank.d568.s25	false	DDI-DrugBank.d568.s25.e0	DDI-DrugBank.d568.s25.e2
DDI-DrugBank.d568.s25	false	DDI-DrugBank.d568.s25.e0	DDI-DrugBank.d568.s25.e3
DDI-DrugBank.d568.s25	false	DDI-DrugBank.d568.s25.e0	DDI-DrugBank.d568.s25.e4
DDI-DrugBank.d568.s25	true	DDI-DrugBank.d568.s25.e1	DDI-DrugBank.d568.s25.e2
DDI-DrugBank.d568.s25	false	DDI-DrugBank.d568.s25.e1	DDI-DrugBank.d568.s25.e3
DDI-DrugBank.d568.s25	false	DDI-DrugBank.d568.s25.e1	DDI-DrugBank.d568.s25.e4
DDI-DrugBank.d568.s25	false	DDI-DrugBank.d568.s25.e2	DDI-DrugBank.d568.s25.e3
DDI-DrugBank.d568.s25	false	DDI-DrugBank.d568.s25.e2	DDI-DrugBank.d568.s25.e4
DDI-DrugBank.d568.s25	false	DDI-DrugBank.d568.s25.e3	DDI-DrugBank.d568.s25.e4
DDI-DrugBank.d568.s26|a|Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.
DDI-DrugBank.d568.s26	0	8	Ritonavir	drug	DDI-DrugBank.d568.s26.e0
DDI-DrugBank.d568.s26	56	64	ritonavir	drug	DDI-DrugBank.d568.s26.e1
DDI-DrugBank.d568.s26	138	149	escitalopram	drug	DDI-DrugBank.d568.s26.e2
DDI-DrugBank.d568.s26	205	213	ritonavir	drug	DDI-DrugBank.d568.s26.e3
DDI-DrugBank.d568.s26	218	229	escitalopram	drug	DDI-DrugBank.d568.s26.e4
DDI-DrugBank.d568.s26	false	DDI-DrugBank.d568.s26.e0	DDI-DrugBank.d568.s26.e1
DDI-DrugBank.d568.s26	false	DDI-DrugBank.d568.s26.e0	DDI-DrugBank.d568.s26.e2
DDI-DrugBank.d568.s26	false	DDI-DrugBank.d568.s26.e0	DDI-DrugBank.d568.s26.e3
DDI-DrugBank.d568.s26	false	DDI-DrugBank.d568.s26.e0	DDI-DrugBank.d568.s26.e4
DDI-DrugBank.d568.s26	false	DDI-DrugBank.d568.s26.e1	DDI-DrugBank.d568.s26.e2
DDI-DrugBank.d568.s26	false	DDI-DrugBank.d568.s26.e1	DDI-DrugBank.d568.s26.e3
DDI-DrugBank.d568.s26	false	DDI-DrugBank.d568.s26.e1	DDI-DrugBank.d568.s26.e4
DDI-DrugBank.d568.s26	false	DDI-DrugBank.d568.s26.e2	DDI-DrugBank.d568.s26.e3
DDI-DrugBank.d568.s26	false	DDI-DrugBank.d568.s26.e2	DDI-DrugBank.d568.s26.e4
DDI-DrugBank.d568.s26	false	DDI-DrugBank.d568.s26.e3	DDI-DrugBank.d568.s26.e4
DDI-DrugBank.d568.s27|a|CYP3A4 and -2C19 Inhibitors - In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram.
DDI-DrugBank.d568.s27	133	144	escitalopram	drug	DDI-DrugBank.d568.s27.e0
DDI-DrugBank.d568.s28|a|However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.
DDI-DrugBank.d568.s28	29	40	escitalopram	drug	DDI-DrugBank.d568.s28.e0
DDI-DrugBank.d568.s28	54	62	ritonavir	drug	DDI-DrugBank.d568.s28.e1
DDI-DrugBank.d568.s28	157	168	escitalopram	drug	DDI-DrugBank.d568.s28.e2
DDI-DrugBank.d568.s28	false	DDI-DrugBank.d568.s28.e0	DDI-DrugBank.d568.s28.e1
DDI-DrugBank.d568.s28	false	DDI-DrugBank.d568.s28.e0	DDI-DrugBank.d568.s28.e2
DDI-DrugBank.d568.s28	false	DDI-DrugBank.d568.s28.e1	DDI-DrugBank.d568.s28.e2
DDI-DrugBank.d568.s29|a|Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.
DDI-DrugBank.d568.s29	8	19	escitalopram	drug	DDI-DrugBank.d568.s29.e0
DDI-DrugBank.d568.s29	123	134	escitalopram	drug	DDI-DrugBank.d568.s29.e1
DDI-DrugBank.d568.s29	false	DDI-DrugBank.d568.s29.e0	DDI-DrugBank.d568.s29.e1
DDI-DrugBank.d568.s30|a|Drugs Metabolized by Cytochrome P4502D6 - In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6.
DDI-DrugBank.d568.s30	98	109	escitalopram	drug	DDI-DrugBank.d568.s30.e0
DDI-DrugBank.d568.s31|a|In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.
DDI-DrugBank.d568.s31	44	53	citalopram	drug	DDI-DrugBank.d568.s31.e0
DDI-DrugBank.d568.s31	181	190	citalopram	drug	DDI-DrugBank.d568.s31.e1
DDI-DrugBank.d568.s31	232	243	escitalopram	drug	DDI-DrugBank.d568.s31.e2
DDI-DrugBank.d568.s31	332	343	escitalopram	drug	DDI-DrugBank.d568.s31.e3
DDI-DrugBank.d568.s31	false	DDI-DrugBank.d568.s31.e0	DDI-DrugBank.d568.s31.e1
DDI-DrugBank.d568.s31	false	DDI-DrugBank.d568.s31.e0	DDI-DrugBank.d568.s31.e2
DDI-DrugBank.d568.s31	false	DDI-DrugBank.d568.s31.e0	DDI-DrugBank.d568.s31.e3
DDI-DrugBank.d568.s31	false	DDI-DrugBank.d568.s31.e1	DDI-DrugBank.d568.s31.e2
DDI-DrugBank.d568.s31	false	DDI-DrugBank.d568.s31.e1	DDI-DrugBank.d568.s31.e3
DDI-DrugBank.d568.s31	false	DDI-DrugBank.d568.s31.e2	DDI-DrugBank.d568.s31.e3
DDI-DrugBank.d568.s32|a|However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.
DDI-DrugBank.d568.s32	89	100	escitalopram	drug	DDI-DrugBank.d568.s32.e0
DDI-DrugBank.d568.s32	129	140	escitalopram	drug	DDI-DrugBank.d568.s32.e1
DDI-DrugBank.d568.s32	175	198	tricyclic antidepressant	group	DDI-DrugBank.d568.s32.e2
DDI-DrugBank.d568.s32	200	210	desipramine	drug	DDI-DrugBank.d568.s32.e3
DDI-DrugBank.d568.s32	325	335	desipramine	drug	DDI-DrugBank.d568.s32.e4
DDI-DrugBank.d568.s32	false	DDI-DrugBank.d568.s32.e0	DDI-DrugBank.d568.s32.e1
DDI-DrugBank.d568.s32	false	DDI-DrugBank.d568.s32.e0	DDI-DrugBank.d568.s32.e2
DDI-DrugBank.d568.s32	false	DDI-DrugBank.d568.s32.e0	DDI-DrugBank.d568.s32.e3
DDI-DrugBank.d568.s32	false	DDI-DrugBank.d568.s32.e0	DDI-DrugBank.d568.s32.e4
DDI-DrugBank.d568.s32	false	DDI-DrugBank.d568.s32.e1	DDI-DrugBank.d568.s32.e2
DDI-DrugBank.d568.s32	true	DDI-DrugBank.d568.s32.e1	DDI-DrugBank.d568.s32.e3
DDI-DrugBank.d568.s32	false	DDI-DrugBank.d568.s32.e1	DDI-DrugBank.d568.s32.e4
DDI-DrugBank.d568.s32	false	DDI-DrugBank.d568.s32.e2	DDI-DrugBank.d568.s32.e3
DDI-DrugBank.d568.s32	false	DDI-DrugBank.d568.s32.e2	DDI-DrugBank.d568.s32.e4
DDI-DrugBank.d568.s32	false	DDI-DrugBank.d568.s32.e3	DDI-DrugBank.d568.s32.e4
DDI-DrugBank.d568.s33|a|The clinical significance of this finding is unknown.
DDI-DrugBank.d568.s34|a|Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6.
DDI-DrugBank.d568.s34	62	73	escitalopram	drug	DDI-DrugBank.d568.s34.e0
DDI-DrugBank.d568.s35|a|Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).
DDI-DrugBank.d568.s35	0	9	Metoprolol	drug	DDI-DrugBank.d568.s35.e0
DDI-DrugBank.d568.s35	41	47	LEXAPRO	brand	DDI-DrugBank.d568.s35.e1
DDI-DrugBank.d568.s35	149	171	beta-adrenergic blocker	group	DDI-DrugBank.d568.s35.e2
DDI-DrugBank.d568.s35	173	182	metoprolol	drug	DDI-DrugBank.d568.s35.e3
DDI-DrugBank.d568.s35	false	DDI-DrugBank.d568.s35.e0	DDI-DrugBank.d568.s35.e1
DDI-DrugBank.d568.s35	false	DDI-DrugBank.d568.s35.e0	DDI-DrugBank.d568.s35.e2
DDI-DrugBank.d568.s35	false	DDI-DrugBank.d568.s35.e0	DDI-DrugBank.d568.s35.e3
DDI-DrugBank.d568.s35	false	DDI-DrugBank.d568.s35.e1	DDI-DrugBank.d568.s35.e2
DDI-DrugBank.d568.s35	true	DDI-DrugBank.d568.s35.e1	DDI-DrugBank.d568.s35.e3
DDI-DrugBank.d568.s35	false	DDI-DrugBank.d568.s35.e2	DDI-DrugBank.d568.s35.e3
DDI-DrugBank.d568.s36|a|Increased metoprolol plasma levels have been associated with decreased cardioselectivity.
DDI-DrugBank.d568.s36	10	19	metoprolol	drug	DDI-DrugBank.d568.s36.e0
DDI-DrugBank.d568.s37|a|Coadministration of LEXAPRO and metoprolol had no clinically significant effects on blood pressure or heart rate.
DDI-DrugBank.d568.s37	20	26	LEXAPRO	brand	DDI-DrugBank.d568.s37.e0
DDI-DrugBank.d568.s37	32	41	metoprolol	drug	DDI-DrugBank.d568.s37.e1
DDI-DrugBank.d568.s37	false	DDI-DrugBank.d568.s37.e0	DDI-DrugBank.d568.s37.e1
DDI-DrugBank.d568.s38|a|Electroconvulsive Therapy (ECT) - There are no clinical studies of the combined use of ECT and escitalopram.
DDI-DrugBank.d568.s38	95	106	escitalopram	drug	DDI-DrugBank.d568.s38.e0
DDI-DrugBank.d568.s39|a|Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
DDI-DrugBank.d568.s39	40	49	Citalopram	drug	DDI-DrugBank.d568.s39.e0
DDI-DrugBank.d568.s39	51	60	Citalopram	drug	DDI-DrugBank.d568.s39.e1
DDI-DrugBank.d568.s39	70	81	escitalopram	drug	DDI-DrugBank.d568.s39.e2
DDI-DrugBank.d568.s39	115	124	citalopram	drug	DDI-DrugBank.d568.s39.e3
DDI-DrugBank.d568.s39	127	132	Celexa	brand	DDI-DrugBank.d568.s39.e4
DDI-DrugBank.d568.s39	false	DDI-DrugBank.d568.s39.e0	DDI-DrugBank.d568.s39.e1
DDI-DrugBank.d568.s39	false	DDI-DrugBank.d568.s39.e0	DDI-DrugBank.d568.s39.e2
DDI-DrugBank.d568.s39	false	DDI-DrugBank.d568.s39.e0	DDI-DrugBank.d568.s39.e3
DDI-DrugBank.d568.s39	false	DDI-DrugBank.d568.s39.e0	DDI-DrugBank.d568.s39.e4
DDI-DrugBank.d568.s39	false	DDI-DrugBank.d568.s39.e1	DDI-DrugBank.d568.s39.e2
DDI-DrugBank.d568.s39	false	DDI-DrugBank.d568.s39.e1	DDI-DrugBank.d568.s39.e3
DDI-DrugBank.d568.s39	false	DDI-DrugBank.d568.s39.e1	DDI-DrugBank.d568.s39.e4
DDI-DrugBank.d568.s39	true	DDI-DrugBank.d568.s39.e2	DDI-DrugBank.d568.s39.e3
DDI-DrugBank.d568.s39	true	DDI-DrugBank.d568.s39.e2	DDI-DrugBank.d568.s39.e4
DDI-DrugBank.d568.s39	false	DDI-DrugBank.d568.s39.e3	DDI-DrugBank.d568.s39.e4
DDI-DrugBank.d422.s0|a|Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.
DDI-DrugBank.d422.s0	37	45	reserpine	drug	DDI-DrugBank.d422.s0.e0
DDI-DrugBank.d422.s0	92	111	beta blocking agents	group	DDI-DrugBank.d422.s0.e1
DDI-DrugBank.d422.s0	true	DDI-DrugBank.d422.s0.e0	DDI-DrugBank.d422.s0.e1
DDI-DrugBank.d422.s1|a|Patients treated concurrently with BREVIBLOC (esmolol HCl) and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
DDI-DrugBank.d422.s1	35	43	BREVIBLOC	brand	DDI-DrugBank.d422.s1.e0
DDI-DrugBank.d422.s1	46	56	esmolol HCl	drug	DDI-DrugBank.d422.s1.e1
DDI-DrugBank.d422.s1	false	DDI-DrugBank.d422.s1.e0	DDI-DrugBank.d422.s1.e1
DDI-DrugBank.d422.s2|a|A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.
DDI-DrugBank.d422.s2	31	39	BREVIBLOC	brand	DDI-DrugBank.d422.s2.e0
DDI-DrugBank.d422.s2	45	52	warfarin	drug	DDI-DrugBank.d422.s2.e1
DDI-DrugBank.d422.s2	96	104	BREVIBLOC	brand	DDI-DrugBank.d422.s2.e2
DDI-DrugBank.d422.s2	110	117	warfarin	drug	DDI-DrugBank.d422.s2.e3
DDI-DrugBank.d422.s2	134	141	warfarin	drug	DDI-DrugBank.d422.s2.e4
DDI-DrugBank.d422.s2	false	DDI-DrugBank.d422.s2.e0	DDI-DrugBank.d422.s2.e1
DDI-DrugBank.d422.s2	false	DDI-DrugBank.d422.s2.e0	DDI-DrugBank.d422.s2.e2
DDI-DrugBank.d422.s2	false	DDI-DrugBank.d422.s2.e0	DDI-DrugBank.d422.s2.e3
DDI-DrugBank.d422.s2	false	DDI-DrugBank.d422.s2.e0	DDI-DrugBank.d422.s2.e4
DDI-DrugBank.d422.s2	false	DDI-DrugBank.d422.s2.e1	DDI-DrugBank.d422.s2.e2
DDI-DrugBank.d422.s2	false	DDI-DrugBank.d422.s2.e1	DDI-DrugBank.d422.s2.e3
DDI-DrugBank.d422.s2	false	DDI-DrugBank.d422.s2.e1	DDI-DrugBank.d422.s2.e4
DDI-DrugBank.d422.s2	false	DDI-DrugBank.d422.s2.e2	DDI-DrugBank.d422.s2.e3
DDI-DrugBank.d422.s2	false	DDI-DrugBank.d422.s2.e2	DDI-DrugBank.d422.s2.e4
DDI-DrugBank.d422.s2	false	DDI-DrugBank.d422.s2.e3	DDI-DrugBank.d422.s2.e4
DDI-DrugBank.d422.s3|a|BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.
DDI-DrugBank.d422.s3	0	8	BREVIBLOC	brand	DDI-DrugBank.d422.s3.e0
DDI-DrugBank.d422.s3	65	72	warfarin	drug	DDI-DrugBank.d422.s3.e1
DDI-DrugBank.d422.s3	true	DDI-DrugBank.d422.s3.e0	DDI-DrugBank.d422.s3.e1
DDI-DrugBank.d422.s4|a|When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.
DDI-DrugBank.d422.s4	5	11	digoxin	drug	DDI-DrugBank.d422.s4.e0
DDI-DrugBank.d422.s4	17	25	BREVIBLOC	brand	DDI-DrugBank.d422.s4.e1
DDI-DrugBank.d422.s4	126	132	digoxin	drug	DDI-DrugBank.d422.s4.e2
DDI-DrugBank.d422.s4	true	DDI-DrugBank.d422.s4.e0	DDI-DrugBank.d422.s4.e1
DDI-DrugBank.d422.s4	false	DDI-DrugBank.d422.s4.e0	DDI-DrugBank.d422.s4.e2
DDI-DrugBank.d422.s4	false	DDI-DrugBank.d422.s4.e1	DDI-DrugBank.d422.s4.e2
DDI-DrugBank.d422.s5|a|Digoxin did not affect BREVIBLOC pharmacokinetics.
DDI-DrugBank.d422.s5	0	6	Digoxin	drug	DDI-DrugBank.d422.s5.e0
DDI-DrugBank.d422.s5	23	31	BREVIBLOC	brand	DDI-DrugBank.d422.s5.e1
DDI-DrugBank.d422.s5	false	DDI-DrugBank.d422.s5.e0	DDI-DrugBank.d422.s5.e1
DDI-DrugBank.d422.s6|a|When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
DDI-DrugBank.d422.s6	17	24	morphine	drug	DDI-DrugBank.d422.s6.e0
DDI-DrugBank.d422.s6	30	38	BREVIBLOC	brand	DDI-DrugBank.d422.s6.e1
DDI-DrugBank.d422.s6	105	112	morphine	drug	DDI-DrugBank.d422.s6.e2
DDI-DrugBank.d422.s6	141	149	BREVIBLOC	brand	DDI-DrugBank.d422.s6.e3
DDI-DrugBank.d422.s6	218	225	morphine	drug	DDI-DrugBank.d422.s6.e4
DDI-DrugBank.d422.s6	false	DDI-DrugBank.d422.s6.e0	DDI-DrugBank.d422.s6.e1
DDI-DrugBank.d422.s6	false	DDI-DrugBank.d422.s6.e0	DDI-DrugBank.d422.s6.e2
DDI-DrugBank.d422.s6	false	DDI-DrugBank.d422.s6.e0	DDI-DrugBank.d422.s6.e3
DDI-DrugBank.d422.s6	false	DDI-DrugBank.d422.s6.e0	DDI-DrugBank.d422.s6.e4
DDI-DrugBank.d422.s6	false	DDI-DrugBank.d422.s6.e1	DDI-DrugBank.d422.s6.e2
DDI-DrugBank.d422.s6	false	DDI-DrugBank.d422.s6.e1	DDI-DrugBank.d422.s6.e3
DDI-DrugBank.d422.s6	false	DDI-DrugBank.d422.s6.e1	DDI-DrugBank.d422.s6.e4
DDI-DrugBank.d422.s6	false	DDI-DrugBank.d422.s6.e2	DDI-DrugBank.d422.s6.e3
DDI-DrugBank.d422.s6	false	DDI-DrugBank.d422.s6.e2	DDI-DrugBank.d422.s6.e4
DDI-DrugBank.d422.s6	true	DDI-DrugBank.d422.s6.e3	DDI-DrugBank.d422.s6.e4
DDI-DrugBank.d422.s7|a|No other pharmacokinetic parameters were changed.
DDI-DrugBank.d422.s8|a|The effect of BREVIBLOC on the duration of succinylcholine-induced neuromuscular blockade was studied in patients undergoing surgery.
DDI-DrugBank.d422.s8	14	22	BREVIBLOC	drug	DDI-DrugBank.d422.s8.e0
DDI-DrugBank.d422.s8	43	57	succinylcholine	drug	DDI-DrugBank.d422.s8.e1
DDI-DrugBank.d422.s8	false	DDI-DrugBank.d422.s8.e0	DDI-DrugBank.d422.s8.e1
DDI-DrugBank.d422.s9|a|The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.
DDI-DrugBank.d422.s9	39	53	succinylcholine	drug	DDI-DrugBank.d422.s9.e0
DDI-DrugBank.d422.s9	73	81	BREVIBLOC	brand	DDI-DrugBank.d422.s9.e1
DDI-DrugBank.d422.s9	true	DDI-DrugBank.d422.s9.e0	DDI-DrugBank.d422.s9.e1
DDI-DrugBank.d422.s10|a|Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
DDI-DrugBank.d422.s10	102	110	BREVIBLOC	brand	DDI-DrugBank.d422.s10.e0
DDI-DrugBank.d422.s10	188	194	digoxin	drug	DDI-DrugBank.d422.s10.e1
DDI-DrugBank.d422.s10	197	204	morphine	drug	DDI-DrugBank.d422.s10.e2
DDI-DrugBank.d422.s10	207	221	succinylcholine	drug	DDI-DrugBank.d422.s10.e3
DDI-DrugBank.d422.s10	226	233	warfarin	drug	DDI-DrugBank.d422.s10.e4
DDI-DrugBank.d422.s10	true	DDI-DrugBank.d422.s10.e0	DDI-DrugBank.d422.s10.e1
DDI-DrugBank.d422.s10	true	DDI-DrugBank.d422.s10.e0	DDI-DrugBank.d422.s10.e2
DDI-DrugBank.d422.s10	true	DDI-DrugBank.d422.s10.e0	DDI-DrugBank.d422.s10.e3
DDI-DrugBank.d422.s10	true	DDI-DrugBank.d422.s10.e0	DDI-DrugBank.d422.s10.e4
DDI-DrugBank.d422.s10	false	DDI-DrugBank.d422.s10.e1	DDI-DrugBank.d422.s10.e2
DDI-DrugBank.d422.s10	false	DDI-DrugBank.d422.s10.e1	DDI-DrugBank.d422.s10.e3
DDI-DrugBank.d422.s10	false	DDI-DrugBank.d422.s10.e1	DDI-DrugBank.d422.s10.e4
DDI-DrugBank.d422.s10	false	DDI-DrugBank.d422.s10.e2	DDI-DrugBank.d422.s10.e3
DDI-DrugBank.d422.s10	false	DDI-DrugBank.d422.s10.e2	DDI-DrugBank.d422.s10.e4
DDI-DrugBank.d422.s10	false	DDI-DrugBank.d422.s10.e3	DDI-DrugBank.d422.s10.e4
DDI-DrugBank.d422.s11|a|While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.
DDI-DrugBank.d422.s11	13	25	beta blockers	group	DDI-DrugBank.d422.s11.e0
DDI-DrugBank.d422.s12|a|Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
DDI-DrugBank.d422.s12	56	66	epinephrine	drug	DDI-DrugBank.d422.s12.e0
DDI-DrugBank.d422.s13|a|Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.
DDI-DrugBank.d422.s13	56	64	BREVIBLOC	brand	DDI-DrugBank.d422.s13.e0
DDI-DrugBank.d422.s13	70	78	verapamil	drug	DDI-DrugBank.d422.s13.e1
DDI-DrugBank.d422.s13	true	DDI-DrugBank.d422.s13.e0	DDI-DrugBank.d422.s13.e1
DDI-DrugBank.d422.s14|a|Fatal cardiac arrests have occurred in patients receiving both drugs.
DDI-DrugBank.d422.s15|a|Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
DDI-DrugBank.d422.s15	14	22	BREVIBLOC	brand	DDI-DrugBank.d422.s15.e0
DDI-DrugBank.d422.s15	158	165	dopamine	drug	DDI-DrugBank.d422.s15.e1
DDI-DrugBank.d422.s15	168	178	epinephrine	drug	DDI-DrugBank.d422.s15.e2
DDI-DrugBank.d422.s15	185	198	norepinephrine	drug	DDI-DrugBank.d422.s15.e3
DDI-DrugBank.d422.s15	true	DDI-DrugBank.d422.s15.e0	DDI-DrugBank.d422.s15.e1
DDI-DrugBank.d422.s15	true	DDI-DrugBank.d422.s15.e0	DDI-DrugBank.d422.s15.e2
DDI-DrugBank.d422.s15	true	DDI-DrugBank.d422.s15.e0	DDI-DrugBank.d422.s15.e3
DDI-DrugBank.d422.s15	false	DDI-DrugBank.d422.s15.e1	DDI-DrugBank.d422.s15.e2
DDI-DrugBank.d422.s15	false	DDI-DrugBank.d422.s15.e1	DDI-DrugBank.d422.s15.e3
DDI-DrugBank.d422.s15	false	DDI-DrugBank.d422.s15.e2	DDI-DrugBank.d422.s15.e3
DDI-DrugBank.d29.s0|a|Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4.
DDI-DrugBank.d29.s0	0	11	Esomeprazole	drug	DDI-DrugBank.d29.s0.e0
DDI-DrugBank.d29.s1|a|In vitro and in vivo studies have shown that esomeprazole is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1 and 3A4.
DDI-DrugBank.d29.s1	45	56	esomeprazole	drug	DDI-DrugBank.d29.s1.e0
DDI-DrugBank.d29.s2|a|No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected.
DDI-DrugBank.d29.s3|a|Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.
DDI-DrugBank.d29.s3	41	52	esomeprazole	drug	DDI-DrugBank.d29.s3.e0
DDI-DrugBank.d29.s3	113	121	phenytoin	drug	DDI-DrugBank.d29.s3.e1
DDI-DrugBank.d29.s3	124	131	warfarin	drug	DDI-DrugBank.d29.s3.e2
DDI-DrugBank.d29.s3	134	142	quinidine	drug	DDI-DrugBank.d29.s3.e3
DDI-DrugBank.d29.s3	145	158	clarithromycin	drug	DDI-DrugBank.d29.s3.e4
DDI-DrugBank.d29.s3	163	173	amoxicillin	drug	DDI-DrugBank.d29.s3.e5
DDI-DrugBank.d29.s3	false	DDI-DrugBank.d29.s3.e0	DDI-DrugBank.d29.s3.e1
DDI-DrugBank.d29.s3	false	DDI-DrugBank.d29.s3.e0	DDI-DrugBank.d29.s3.e2
DDI-DrugBank.d29.s3	false	DDI-DrugBank.d29.s3.e0	DDI-DrugBank.d29.s3.e3
DDI-DrugBank.d29.s3	false	DDI-DrugBank.d29.s3.e0	DDI-DrugBank.d29.s3.e4
DDI-DrugBank.d29.s3	false	DDI-DrugBank.d29.s3.e0	DDI-DrugBank.d29.s3.e5
DDI-DrugBank.d29.s3	false	DDI-DrugBank.d29.s3.e1	DDI-DrugBank.d29.s3.e2
DDI-DrugBank.d29.s3	false	DDI-DrugBank.d29.s3.e1	DDI-DrugBank.d29.s3.e3
DDI-DrugBank.d29.s3	false	DDI-DrugBank.d29.s3.e1	DDI-DrugBank.d29.s3.e4
DDI-DrugBank.d29.s3	false	DDI-DrugBank.d29.s3.e1	DDI-DrugBank.d29.s3.e5
DDI-DrugBank.d29.s3	false	DDI-DrugBank.d29.s3.e2	DDI-DrugBank.d29.s3.e3
DDI-DrugBank.d29.s4|a|Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy.
DDI-DrugBank.d29.s4	107	114	warfarin	drug	DDI-DrugBank.d29.s4.e0
DDI-DrugBank.d29.s4	120	131	esomeprazole	drug	DDI-DrugBank.d29.s4.e1
DDI-DrugBank.d29.s4	false	DDI-DrugBank.d29.s4.e0	DDI-DrugBank.d29.s4.e1
DDI-DrugBank.d29.s5|a|Increases in INR and prothrombin time may lead to abnormal bleeding and even death.
DDI-DrugBank.d29.s6|a|Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
DDI-DrugBank.d29.s6	22	43	proton pump inhibitors	group	DDI-DrugBank.d29.s6.e0
DDI-DrugBank.d29.s6	49	56	warfarin	drug	DDI-DrugBank.d29.s6.e1
DDI-DrugBank.d29.s6	true	DDI-DrugBank.d29.s6.e0	DDI-DrugBank.d29.s6.e1
DDI-DrugBank.d29.s7|a|Esomeprazole may potentially interfere with CYP2C19, the major esomeprazole metabolizing enzyme.
DDI-DrugBank.d29.s7	0	11	Esomeprazole	drug	DDI-DrugBank.d29.s7.e0
DDI-DrugBank.d29.s7	63	74	esomeprazole	drug	DDI-DrugBank.d29.s7.e1
DDI-DrugBank.d29.s7	false	DDI-DrugBank.d29.s7.e0	DDI-DrugBank.d29.s7.e1
DDI-DrugBank.d29.s8|a|Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.
DDI-DrugBank.d29.s8	20	31	esomeprazole	drug	DDI-DrugBank.d29.s8.e0
DDI-DrugBank.d29.s8	43	50	diazepam	drug	DDI-DrugBank.d29.s8.e1
DDI-DrugBank.d29.s8	117	124	diazepam	drug	DDI-DrugBank.d29.s8.e2
DDI-DrugBank.d29.s8	true	DDI-DrugBank.d29.s8.e0	DDI-DrugBank.d29.s8.e1
DDI-DrugBank.d29.s8	false	DDI-DrugBank.d29.s8.e0	DDI-DrugBank.d29.s8.e2
DDI-DrugBank.d29.s8	false	DDI-DrugBank.d29.s8.e1	DDI-DrugBank.d29.s8.e2
DDI-DrugBank.d29.s9|a|Increased plasma levels of diazepam were observed 12 hours after dosing and onwards.
DDI-DrugBank.d29.s9	27	34	diazepam	drug	DDI-DrugBank.d29.s9.e0
DDI-DrugBank.d29.s10|a|However, at that time, the plasma levels of diazepam were below the therapeutic interval, and thus this interaction is unlikely to be of clinical relevance.
DDI-DrugBank.d29.s10	44	51	diazepam	drug	DDI-DrugBank.d29.s10.e0
DDI-DrugBank.d29.s11|a|Esomeprazole inhibits gastric acid secretion.
DDI-DrugBank.d29.s11	0	11	Esomeprazole	drug	DDI-DrugBank.d29.s11.e0
DDI-DrugBank.d29.s12|a|Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
DDI-DrugBank.d29.s12	11	22	esomeprazole	drug	DDI-DrugBank.d29.s12.e0
DDI-DrugBank.d29.s12	136	147	ketoconazole	drug	DDI-DrugBank.d29.s12.e1
DDI-DrugBank.d29.s12	150	153	iron	drug	DDI-DrugBank.d29.s12.e2
DDI-DrugBank.d29.s12	165	171	digoxin	drug	DDI-DrugBank.d29.s12.e3
DDI-DrugBank.d29.s12	true	DDI-DrugBank.d29.s12.e0	DDI-DrugBank.d29.s12.e1
DDI-DrugBank.d29.s12	true	DDI-DrugBank.d29.s12.e0	DDI-DrugBank.d29.s12.e2
DDI-DrugBank.d29.s12	true	DDI-DrugBank.d29.s12.e0	DDI-DrugBank.d29.s12.e3
DDI-DrugBank.d29.s12	false	DDI-DrugBank.d29.s12.e1	DDI-DrugBank.d29.s12.e2
DDI-DrugBank.d29.s12	false	DDI-DrugBank.d29.s12.e1	DDI-DrugBank.d29.s12.e3
DDI-DrugBank.d29.s12	false	DDI-DrugBank.d29.s12.e2	DDI-DrugBank.d29.s12.e3
DDI-DrugBank.d29.s13|a|Coadministration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
DDI-DrugBank.d29.s13	25	38	contraceptives	group	DDI-DrugBank.d29.s13.e0
DDI-DrugBank.d29.s13	41	48	diazepam	drug	DDI-DrugBank.d29.s13.e1
DDI-DrugBank.d29.s13	51	59	phenytoin	drug	DDI-DrugBank.d29.s13.e2
DDI-DrugBank.d29.s13	65	73	quinidine	drug	DDI-DrugBank.d29.s13.e3
DDI-DrugBank.d29.s13	129	140	esomeprazole	drug	DDI-DrugBank.d29.s13.e4
DDI-DrugBank.d29.s13	false	DDI-DrugBank.d29.s13.e0	DDI-DrugBank.d29.s13.e1
DDI-DrugBank.d29.s13	false	DDI-DrugBank.d29.s13.e0	DDI-DrugBank.d29.s13.e2
DDI-DrugBank.d29.s13	false	DDI-DrugBank.d29.s13.e0	DDI-DrugBank.d29.s13.e3
DDI-DrugBank.d29.s13	false	DDI-DrugBank.d29.s13.e0	DDI-DrugBank.d29.s13.e4
DDI-DrugBank.d29.s13	false	DDI-DrugBank.d29.s13.e1	DDI-DrugBank.d29.s13.e2
DDI-DrugBank.d29.s13	false	DDI-DrugBank.d29.s13.e1	DDI-DrugBank.d29.s13.e3
DDI-DrugBank.d29.s13	false	DDI-DrugBank.d29.s13.e1	DDI-DrugBank.d29.s13.e4
DDI-DrugBank.d29.s13	false	DDI-DrugBank.d29.s13.e2	DDI-DrugBank.d29.s13.e3
DDI-DrugBank.d29.s13	false	DDI-DrugBank.d29.s13.e2	DDI-DrugBank.d29.s13.e4
DDI-DrugBank.d29.s13	false	DDI-DrugBank.d29.s13.e3	DDI-DrugBank.d29.s13.e4
DDI-DrugBank.d29.s14|a|Concomitant administration of clarithromycin with pimozide is contraindicated.
DDI-DrugBank.d29.s14	30	43	clarithromycin	drug	DDI-DrugBank.d29.s14.e0
DDI-DrugBank.d29.s14	50	57	pimozide	drug	DDI-DrugBank.d29.s14.e1
DDI-DrugBank.d29.s14	true	DDI-DrugBank.d29.s14.e0	DDI-DrugBank.d29.s14.e1
DDI-DrugBank.d338.s0|a|If ProSom is given concomitantly with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of all agents.
DDI-DrugBank.d338.s0	3	8	ProSom	brand	DDI-DrugBank.d338.s0.e0
DDI-DrugBank.d338.s1|a|The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
DDI-DrugBank.d338.s1	18	32	benzodiazepines	group	DDI-DrugBank.d338.s1.e0
DDI-DrugBank.d338.s1	56	70	anticonvulsants	group	DDI-DrugBank.d338.s1.e1
DDI-DrugBank.d338.s1	73	86	antihistamines	group	DDI-DrugBank.d338.s1.e2
DDI-DrugBank.d338.s1	89	95	alcohol	drug	DDI-DrugBank.d338.s1.e3
DDI-DrugBank.d338.s1	98	109	barbiturates	group	DDI-DrugBank.d338.s1.e4
DDI-DrugBank.d338.s1	112	139	monoamine oxidase inhibitors	group	DDI-DrugBank.d338.s1.e5
DDI-DrugBank.d338.s1	142	150	narcotics	group	DDI-DrugBank.d338.s1.e6
DDI-DrugBank.d338.s1	153	166	phenothiazines	group	DDI-DrugBank.d338.s1.e7
DDI-DrugBank.d338.s1	169	192	psychotropic medications	group	DDI-DrugBank.d338.s1.e8
DDI-DrugBank.d338.s1	true	DDI-DrugBank.d338.s1.e0	DDI-DrugBank.d338.s1.e1
DDI-DrugBank.d338.s1	true	DDI-DrugBank.d338.s1.e0	DDI-DrugBank.d338.s1.e2
DDI-DrugBank.d338.s1	true	DDI-DrugBank.d338.s1.e0	DDI-DrugBank.d338.s1.e3
DDI-DrugBank.d338.s1	true	DDI-DrugBank.d338.s1.e0	DDI-DrugBank.d338.s1.e4
DDI-DrugBank.d338.s1	true	DDI-DrugBank.d338.s1.e0	DDI-DrugBank.d338.s1.e5
DDI-DrugBank.d338.s1	true	DDI-DrugBank.d338.s1.e0	DDI-DrugBank.d338.s1.e6
DDI-DrugBank.d338.s1	true	DDI-DrugBank.d338.s1.e0	DDI-DrugBank.d338.s1.e7
DDI-DrugBank.d338.s1	true	DDI-DrugBank.d338.s1.e0	DDI-DrugBank.d338.s1.e8
DDI-DrugBank.d338.s1	false	DDI-DrugBank.d338.s1.e1	DDI-DrugBank.d338.s1.e2
DDI-DrugBank.d338.s1	false	DDI-DrugBank.d338.s1.e1	DDI-DrugBank.d338.s1.e3
DDI-DrugBank.d338.s2|a|Smokers have an increased clearance of benzodiazepines as compared to nonsmokers;
DDI-DrugBank.d338.s2	39	53	benzodiazepines	group	DDI-DrugBank.d338.s2.e0
DDI-DrugBank.d338.s3|a|this was seen in studies with estazolam.
DDI-DrugBank.d338.s3	30	38	estazolam	drug	DDI-DrugBank.d338.s3.e0
DDI-DrugBank.d338.s4|a|While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DDI-DrugBank.d338.s4	70	78	estazolam	drug	DDI-DrugBank.d338.s4.e0
DDI-DrugBank.d338.s4	153	165	carbamazepine	drug	DDI-DrugBank.d338.s4.e1
DDI-DrugBank.d338.s4	168	176	phenytoin	drug	DDI-DrugBank.d338.s4.e2
DDI-DrugBank.d338.s4	179	186	rifampin	drug	DDI-DrugBank.d338.s4.e3
DDI-DrugBank.d338.s4	193	204	barbiturates	group	DDI-DrugBank.d338.s4.e4
DDI-DrugBank.d338.s4	237	245	estazolam	drug	DDI-DrugBank.d338.s4.e5
DDI-DrugBank.d338.s4	true	DDI-DrugBank.d338.s4.e0	DDI-DrugBank.d338.s4.e1
DDI-DrugBank.d338.s4	true	DDI-DrugBank.d338.s4.e0	DDI-DrugBank.d338.s4.e2
DDI-DrugBank.d338.s4	true	DDI-DrugBank.d338.s4.e0	DDI-DrugBank.d338.s4.e3
DDI-DrugBank.d338.s4	true	DDI-DrugBank.d338.s4.e0	DDI-DrugBank.d338.s4.e4
DDI-DrugBank.d338.s4	true	DDI-DrugBank.d338.s4.e0	DDI-DrugBank.d338.s4.e5
DDI-DrugBank.d338.s4	false	DDI-DrugBank.d338.s4.e1	DDI-DrugBank.d338.s4.e2
DDI-DrugBank.d338.s4	false	DDI-DrugBank.d338.s4.e1	DDI-DrugBank.d338.s4.e3
DDI-DrugBank.d338.s4	false	DDI-DrugBank.d338.s4.e1	DDI-DrugBank.d338.s4.e4
DDI-DrugBank.d338.s4	false	DDI-DrugBank.d338.s4.e1	DDI-DrugBank.d338.s4.e5
DDI-DrugBank.d338.s4	false	DDI-DrugBank.d338.s4.e2	DDI-DrugBank.d338.s4.e3
DDI-DrugBank.d338.s5|a|Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.
DDI-DrugBank.d338.s5	0	8	Estazolam	drug	DDI-DrugBank.d338.s5.e0
DDI-DrugBank.d338.s5	108	116	estazolam	drug	DDI-DrugBank.d338.s5.e1
DDI-DrugBank.d338.s5	154	172	4-hydroxy-estazolam	drug_n	DDI-DrugBank.d338.s5.e2
DDI-DrugBank.d338.s5	202	224	triazolobenzodiazepines	group	DDI-DrugBank.d338.s5.e3
DDI-DrugBank.d338.s5	false	DDI-DrugBank.d338.s5.e0	DDI-DrugBank.d338.s5.e1
DDI-DrugBank.d338.s5	false	DDI-DrugBank.d338.s5.e0	DDI-DrugBank.d338.s5.e2
DDI-DrugBank.d338.s5	false	DDI-DrugBank.d338.s5.e0	DDI-DrugBank.d338.s5.e3
DDI-DrugBank.d338.s5	false	DDI-DrugBank.d338.s5.e1	DDI-DrugBank.d338.s5.e2
DDI-DrugBank.d338.s5	false	DDI-DrugBank.d338.s5.e1	DDI-DrugBank.d338.s5.e3
DDI-DrugBank.d338.s5	false	DDI-DrugBank.d338.s5.e2	DDI-DrugBank.d338.s5.e3
DDI-DrugBank.d338.s6|a|Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
DDI-DrugBank.d338.s6	14	22	estazolam	drug	DDI-DrugBank.d338.s6.e0
DDI-DrugBank.d338.s6	64	75	ketoconazole	drug	DDI-DrugBank.d338.s6.e1
DDI-DrugBank.d338.s6	81	92	itraconazole	drug	DDI-DrugBank.d338.s6.e2
DDI-DrugBank.d338.s6	true	DDI-DrugBank.d338.s6.e0	DDI-DrugBank.d338.s6.e1
DDI-DrugBank.d338.s6	true	DDI-DrugBank.d338.s6.e0	DDI-DrugBank.d338.s6.e2
DDI-DrugBank.d338.s6	false	DDI-DrugBank.d338.s6.e1	DDI-DrugBank.d338.s6.e2
DDI-DrugBank.d338.s7|a|With drugs inhibiting CYP3A to a lesser, but still significant degree, estazolam should be used only with caution and consideration of appropriate dosage reduction.
DDI-DrugBank.d338.s7	71	79	estazolam	drug	DDI-DrugBank.d338.s7.e0
DDI-DrugBank.d338.s8|a|The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
DDI-DrugBank.d338.s8	85	99	benzodiazepines	group	DDI-DrugBank.d338.s8.e0
DDI-DrugBank.d338.s8	142	151	nefazodone	drug	DDI-DrugBank.d338.s8.e1
DDI-DrugBank.d338.s8	154	164	fluvoxamine	drug	DDI-DrugBank.d338.s8.e2
DDI-DrugBank.d338.s8	167	176	cimetidine	drug	DDI-DrugBank.d338.s8.e3
DDI-DrugBank.d338.s8	179	187	diltiazem	drug	DDI-DrugBank.d338.s8.e4
DDI-DrugBank.d338.s8	190	199	isoniazide	drug	DDI-DrugBank.d338.s8.e5
DDI-DrugBank.d338.s8	211	231	macrolide antibiotics	group	DDI-DrugBank.d338.s8.e6
DDI-DrugBank.d338.s8	true	DDI-DrugBank.d338.s8.e0	DDI-DrugBank.d338.s8.e1
DDI-DrugBank.d338.s8	true	DDI-DrugBank.d338.s8.e0	DDI-DrugBank.d338.s8.e2
DDI-DrugBank.d338.s8	true	DDI-DrugBank.d338.s8.e0	DDI-DrugBank.d338.s8.e3
DDI-DrugBank.d338.s8	true	DDI-DrugBank.d338.s8.e0	DDI-DrugBank.d338.s8.e4
DDI-DrugBank.d338.s8	true	DDI-DrugBank.d338.s8.e0	DDI-DrugBank.d338.s8.e5
DDI-DrugBank.d338.s8	true	DDI-DrugBank.d338.s8.e0	DDI-DrugBank.d338.s8.e6
DDI-DrugBank.d338.s8	false	DDI-DrugBank.d338.s8.e1	DDI-DrugBank.d338.s8.e2
DDI-DrugBank.d338.s8	false	DDI-DrugBank.d338.s8.e1	DDI-DrugBank.d338.s8.e3
DDI-DrugBank.d338.s8	false	DDI-DrugBank.d338.s8.e1	DDI-DrugBank.d338.s8.e4
DDI-DrugBank.d338.s8	false	DDI-DrugBank.d338.s8.e1	DDI-DrugBank.d338.s8.e5
DDI-DrugBank.d338.s9|a|Drug Interaction with Fluoxetine: A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.
DDI-DrugBank.d338.s9	22	31	Fluoxetine	drug	DDI-DrugBank.d338.s9.e0
DDI-DrugBank.d338.s9	94	103	fluoxetine	drug	DDI-DrugBank.d338.s9.e1
DDI-DrugBank.d338.s9	142	150	estazolam	drug	DDI-DrugBank.d338.s9.e2
DDI-DrugBank.d338.s9	false	DDI-DrugBank.d338.s9.e0	DDI-DrugBank.d338.s9.e1
DDI-DrugBank.d338.s9	false	DDI-DrugBank.d338.s9.e0	DDI-DrugBank.d338.s9.e2
DDI-DrugBank.d338.s9	false	DDI-DrugBank.d338.s9.e1	DDI-DrugBank.d338.s9.e2
DDI-DrugBank.d338.s10|a|The pharmacokinetics of estazolam (Cmax and AUC) were not affected during multiple-dose fluoxetine, suggesting no clinically significant pharmacokinetic interaction.
DDI-DrugBank.d338.s10	24	32	estazolam	drug	DDI-DrugBank.d338.s10.e0
DDI-DrugBank.d338.s10	88	97	fluoxetine	drug	DDI-DrugBank.d338.s10.e1
DDI-DrugBank.d338.s10	false	DDI-DrugBank.d338.s10.e0	DDI-DrugBank.d338.s10.e1
DDI-DrugBank.d338.s11|a|Estazolam: Interaction with Other Drugs that are Metabolized by Cytochrome P450 (CYP): At clinically relevant concentrations, in vitro studies indicate that estazolam (0.6 M) was not inhibitory towards the major cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A.
DDI-DrugBank.d338.s11	0	8	Estazolam	drug	DDI-DrugBank.d338.s11.e0
DDI-DrugBank.d338.s11	157	165	estazolam	drug	DDI-DrugBank.d338.s11.e1
DDI-DrugBank.d338.s11	false	DDI-DrugBank.d338.s11.e0	DDI-DrugBank.d338.s11.e1
DDI-DrugBank.d338.s12|a|Therefore, based on these in vitro data, estazolam is very unlikely to inhibit the biotransformation of other drugs metabolized by these CYP isoforms
DDI-DrugBank.d338.s12	41	49	estazolam	drug	DDI-DrugBank.d338.s12.e0
DDI-DrugBank.d338.s13|a|.
DDI-DrugBank.d338.s14|a|
DDI-DrugBank.d301.s0|a|D.
DDI-DrugBank.d301.s1|a|Drug and Laboratory Test Interactions 1.
DDI-DrugBank.d301.s2|a|Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time;
DDI-DrugBank.d301.s3|a|increased platelet count;
DDI-DrugBank.d301.s4|a|increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin;
DDI-DrugBank.d301.s5|a|decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;
DDI-DrugBank.d301.s6|a|increased levels of fibrinogen and fibrinogen activity;
DDI-DrugBank.d301.s7|a|increased plasminogen antigen and activity.
DDI-DrugBank.d301.s8|a|2.
DDI-DrugBank.d301.s9|a|Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.
DDI-DrugBank.d301.s10|a|T3 resin uptake is decreased, reflecting the elevated TBG.
DDI-DrugBank.d301.s11|a|Free T4 and T3 concentrations are unaltered.
DDI-DrugBank.d301.s12|a|Patients on thyroid replacement therapy may require higher doses of thyroid hormone.
DDI-DrugBank.d301.s12	68	82	thyroid hormone	group	DDI-DrugBank.d301.s12.e0
DDI-DrugBank.d301.s13|a|3.
DDI-DrugBank.d301.s14|a|Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.
DDI-DrugBank.d301.s14	170	184	corticosteroids	group	DDI-DrugBank.d301.s14.e0
DDI-DrugBank.d301.s14	190	201	sex steroids	group	DDI-DrugBank.d301.s14.e1
DDI-DrugBank.d301.s14	false	DDI-DrugBank.d301.s14.e0	DDI-DrugBank.d301.s14.e1
DDI-DrugBank.d301.s15|a|Free hormone concentrations may be decreased.
DDI-DrugBank.d301.s16|a|Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
DDI-DrugBank.d301.s17|a|4.
DDI-DrugBank.d301.s18|a|Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.
DDI-DrugBank.d301.s19|a|5.
DDI-DrugBank.d301.s20|a|Impaired glucose tolerance.
DDI-DrugBank.d301.s21|a|6.
DDI-DrugBank.d301.s22|a|Reduced response to metyrapone test.
DDI-DrugBank.d481.s0|a|Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.
DDI-DrugBank.d481.s0	25	31	calcium	drug	DDI-DrugBank.d481.s0.e0
DDI-DrugBank.d481.s0	82	86	EMCYT	brand	DDI-DrugBank.d481.s0.e1
DDI-DrugBank.d481.s0	true	DDI-DrugBank.d481.s0.e0	DDI-DrugBank.d481.s0.e1
DDI-DrugBank.d216.s0|a|CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
DDI-DrugBank.d216.s0	17	23	Ethanol	drug	DDI-DrugBank.d216.s0.e0
DDI-DrugBank.d216.s0	105	115	eszopiclone	drug	DDI-DrugBank.d216.s0.e1
DDI-DrugBank.d216.s0	121	127	ethanol	drug	DDI-DrugBank.d216.s0.e2
DDI-DrugBank.d216.s0	163	169	ethanol	drug	DDI-DrugBank.d216.s0.e3
DDI-DrugBank.d216.s0	false	DDI-DrugBank.d216.s0.e0	DDI-DrugBank.d216.s0.e1
DDI-DrugBank.d216.s0	false	DDI-DrugBank.d216.s0.e0	DDI-DrugBank.d216.s0.e2
DDI-DrugBank.d216.s0	false	DDI-DrugBank.d216.s0.e0	DDI-DrugBank.d216.s0.e3
DDI-DrugBank.d216.s0	true	DDI-DrugBank.d216.s0.e1	DDI-DrugBank.d216.s0.e2
DDI-DrugBank.d216.s0	false	DDI-DrugBank.d216.s0.e1	DDI-DrugBank.d216.s0.e3
DDI-DrugBank.d216.s0	false	DDI-DrugBank.d216.s0.e2	DDI-DrugBank.d216.s0.e3
DDI-DrugBank.d216.s1|a|Paroxetine: Coadministration of single doses of eszopiclone 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.
DDI-DrugBank.d216.s1	0	9	Paroxetine	drug	DDI-DrugBank.d216.s1.e0
DDI-DrugBank.d216.s1	48	58	eszopiclone	drug	DDI-DrugBank.d216.s1.e1
DDI-DrugBank.d216.s1	69	78	paroxetine	drug	DDI-DrugBank.d216.s1.e2
DDI-DrugBank.d216.s1	false	DDI-DrugBank.d216.s1.e0	DDI-DrugBank.d216.s1.e1
DDI-DrugBank.d216.s1	false	DDI-DrugBank.d216.s1.e0	DDI-DrugBank.d216.s1.e2
DDI-DrugBank.d216.s1	false	DDI-DrugBank.d216.s1.e1	DDI-DrugBank.d216.s1.e2
DDI-DrugBank.d216.s2|a|Lorazepam: Coadministration of single doses of eszopiclone 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.
DDI-DrugBank.d216.s2	0	8	Lorazepam	drug	DDI-DrugBank.d216.s2.e0
DDI-DrugBank.d216.s2	47	57	eszopiclone	drug	DDI-DrugBank.d216.s2.e1
DDI-DrugBank.d216.s2	68	76	lorazepam	drug	DDI-DrugBank.d216.s2.e2
DDI-DrugBank.d216.s2	false	DDI-DrugBank.d216.s2.e0	DDI-DrugBank.d216.s2.e1
DDI-DrugBank.d216.s2	false	DDI-DrugBank.d216.s2.e0	DDI-DrugBank.d216.s2.e2
DDI-DrugBank.d216.s2	false	DDI-DrugBank.d216.s2.e1	DDI-DrugBank.d216.s2.e2
DDI-DrugBank.d216.s3|a|Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.
DDI-DrugBank.d216.s3	0	9	Olanzapine	drug	DDI-DrugBank.d216.s3.e0
DDI-DrugBank.d216.s3	32	42	eszopiclone	drug	DDI-DrugBank.d216.s3.e1
DDI-DrugBank.d216.s3	53	62	olanzapine	drug	DDI-DrugBank.d216.s3.e2
DDI-DrugBank.d216.s3	false	DDI-DrugBank.d216.s3.e0	DDI-DrugBank.d216.s3.e1
DDI-DrugBank.d216.s3	false	DDI-DrugBank.d216.s3.e0	DDI-DrugBank.d216.s3.e2
DDI-DrugBank.d216.s3	true	DDI-DrugBank.d216.s3.e1	DDI-DrugBank.d216.s3.e2
DDI-DrugBank.d216.s4|a|The interaction was pharmacodynamic;
DDI-DrugBank.d216.s5|a|there was no alteration in the pharmacokinetics of either drug.
DDI-DrugBank.d216.s6|a|Drugs That Inhibit CYP3A4 (Ketoconazole) CYP3A4 is a major metabolic pathway for elimination of eszopiclone.
DDI-DrugBank.d216.s6	27	38	Ketoconazole	drug	DDI-DrugBank.d216.s6.e0
DDI-DrugBank.d216.s6	96	106	eszopiclone	drug	DDI-DrugBank.d216.s6.e1
DDI-DrugBank.d216.s6	false	DDI-DrugBank.d216.s6.e0	DDI-DrugBank.d216.s6.e1
DDI-DrugBank.d216.s7|a|The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
DDI-DrugBank.d216.s7	11	21	eszopiclone	drug	DDI-DrugBank.d216.s7.e0
DDI-DrugBank.d216.s7	69	80	ketoconazole	drug	DDI-DrugBank.d216.s7.e1
DDI-DrugBank.d216.s7	true	DDI-DrugBank.d216.s7.e0	DDI-DrugBank.d216.s7.e1
DDI-DrugBank.d216.s8|a|Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively.
DDI-DrugBank.d216.s9|a|Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.
DDI-DrugBank.d216.s9	41	52	itraconazole	drug	DDI-DrugBank.d216.s9.e0
DDI-DrugBank.d216.s9	55	68	clarithromycin	drug	DDI-DrugBank.d216.s9.e1
DDI-DrugBank.d216.s9	71	80	nefazodone	drug	DDI-DrugBank.d216.s9.e2
DDI-DrugBank.d216.s9	83	96	troleandomycin	drug	DDI-DrugBank.d216.s9.e3
DDI-DrugBank.d216.s9	99	107	ritonavir	drug	DDI-DrugBank.d216.s9.e4
DDI-DrugBank.d216.s9	110	119	nelfinavir	drug	DDI-DrugBank.d216.s9.e5
DDI-DrugBank.d216.s9	false	DDI-DrugBank.d216.s9.e0	DDI-DrugBank.d216.s9.e1
DDI-DrugBank.d216.s9	false	DDI-DrugBank.d216.s9.e0	DDI-DrugBank.d216.s9.e2
DDI-DrugBank.d216.s9	false	DDI-DrugBank.d216.s9.e0	DDI-DrugBank.d216.s9.e3
DDI-DrugBank.d216.s9	false	DDI-DrugBank.d216.s9.e0	DDI-DrugBank.d216.s9.e4
DDI-DrugBank.d216.s9	false	DDI-DrugBank.d216.s9.e0	DDI-DrugBank.d216.s9.e5
DDI-DrugBank.d216.s9	false	DDI-DrugBank.d216.s9.e1	DDI-DrugBank.d216.s9.e2
DDI-DrugBank.d216.s9	false	DDI-DrugBank.d216.s9.e1	DDI-DrugBank.d216.s9.e3
DDI-DrugBank.d216.s9	false	DDI-DrugBank.d216.s9.e1	DDI-DrugBank.d216.s9.e4
DDI-DrugBank.d216.s9	false	DDI-DrugBank.d216.s9.e1	DDI-DrugBank.d216.s9.e5
DDI-DrugBank.d216.s9	false	DDI-DrugBank.d216.s9.e2	DDI-DrugBank.d216.s9.e3
DDI-DrugBank.d216.s10|a|Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
DDI-DrugBank.d216.s10	26	35	Rifampicin	drug	DDI-DrugBank.d216.s10.e0
DDI-DrugBank.d216.s10	46	54	zopiclone	drug	DDI-DrugBank.d216.s10.e1
DDI-DrugBank.d216.s10	104	113	rifampicin	drug	DDI-DrugBank.d216.s10.e2
DDI-DrugBank.d216.s10	false	DDI-DrugBank.d216.s10.e0	DDI-DrugBank.d216.s10.e1
DDI-DrugBank.d216.s10	false	DDI-DrugBank.d216.s10.e0	DDI-DrugBank.d216.s10.e2
DDI-DrugBank.d216.s10	true	DDI-DrugBank.d216.s10.e1	DDI-DrugBank.d216.s10.e2
DDI-DrugBank.d216.s11|a|A similar effect would be expected with eszopiclone.
DDI-DrugBank.d216.s11	40	50	eszopiclone	drug	DDI-DrugBank.d216.s11.e0
DDI-DrugBank.d216.s12|a|Drugs Highly Bound To Plasma Protein Eszopiclone is not highly bound to plasma proteins (52-59% bound);
DDI-DrugBank.d216.s12	37	47	Eszopiclone	drug	DDI-DrugBank.d216.s12.e0
DDI-DrugBank.d216.s13|a|therefore, the disposition of eszopiclone is not expected to be sensitive to alterations in protein binding.
DDI-DrugBank.d216.s13	30	40	eszopiclone	drug	DDI-DrugBank.d216.s13.e0
DDI-DrugBank.d216.s14|a|Administration of eszopiclone 3 mg to a patient taking another drug that is highly protein-bound would not be expected to cause an alteration in the free concentration of either drug.
DDI-DrugBank.d216.s14	18	28	eszopiclone	drug	DDI-DrugBank.d216.s14.e0
DDI-DrugBank.d216.s15|a|Drugs With A Narrow Therapeutic Index Digoxin A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.
DDI-DrugBank.d216.s15	38	44	Digoxin	drug	DDI-DrugBank.d216.s15.e0
DDI-DrugBank.d216.s15	63	73	eszopiclone	drug	DDI-DrugBank.d216.s15.e1
DDI-DrugBank.d216.s15	119	125	digoxin	drug	DDI-DrugBank.d216.s15.e2
DDI-DrugBank.d216.s15	false	DDI-DrugBank.d216.s15.e0	DDI-DrugBank.d216.s15.e1
DDI-DrugBank.d216.s15	false	DDI-DrugBank.d216.s15.e0	DDI-DrugBank.d216.s15.e2
DDI-DrugBank.d216.s15	false	DDI-DrugBank.d216.s15.e1	DDI-DrugBank.d216.s15.e2
DDI-DrugBank.d216.s16|a|Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin
DDI-DrugBank.d216.s16	0	7	Warfarin	drug	DDI-DrugBank.d216.s16.e0
DDI-DrugBank.d216.s16	10	20	Eszopiclone	drug	DDI-DrugBank.d216.s16.e1
DDI-DrugBank.d216.s16	95	98	(R)-warfarin	drug	DDI-DrugBank.d216.s16.e2
DDI-DrugBank.d216.s16	107	114	(R)-warfarin	drug	DDI-DrugBank.d216.s16.e2
DDI-DrugBank.d216.s16	104	115	(S)-warfarin	drug	DDI-DrugBank.d216.s16.e3
DDI-DrugBank.d216.s16	233	240	warfarin	drug	DDI-DrugBank.d216.s16.e4
DDI-DrugBank.d216.s16	false	DDI-DrugBank.d216.s16.e0	DDI-DrugBank.d216.s16.e1
DDI-DrugBank.d216.s16	false	DDI-DrugBank.d216.s16.e0	DDI-DrugBank.d216.s16.e2
DDI-DrugBank.d216.s16	false	DDI-DrugBank.d216.s16.e0	DDI-DrugBank.d216.s16.e3
DDI-DrugBank.d216.s16	false	DDI-DrugBank.d216.s16.e0	DDI-DrugBank.d216.s16.e4
DDI-DrugBank.d216.s16	false	DDI-DrugBank.d216.s16.e1	DDI-DrugBank.d216.s16.e2
DDI-DrugBank.d216.s16	false	DDI-DrugBank.d216.s16.e1	DDI-DrugBank.d216.s16.e3
DDI-DrugBank.d216.s16	false	DDI-DrugBank.d216.s16.e1	DDI-DrugBank.d216.s16.e4
DDI-DrugBank.d216.s16	false	DDI-DrugBank.d216.s16.e2	DDI-DrugBank.d216.s16.e3
DDI-DrugBank.d216.s16	false	DDI-DrugBank.d216.s16.e2	DDI-DrugBank.d216.s16.e4
DDI-DrugBank.d216.s16	false	DDI-DrugBank.d216.s16.e3	DDI-DrugBank.d216.s16.e4
DDI-DrugBank.d216.s17|a|.
DDI-DrugBank.d216.s18|a|
DDI-DrugBank.d341.s0|a|Specific drug interaction studies have not been conducted with ENBREL .
DDI-DrugBank.d341.s0	63	68	ENBREL	brand	DDI-DrugBank.d341.s0.e0
DDI-DrugBank.d341.s1|a|However, it was observed that the pharmacokinetics of ENBREL  was unaltered by concomitant methotrexate in rheumatoid arthritis patients.
DDI-DrugBank.d341.s1	54	59	ENBREL	brand	DDI-DrugBank.d341.s1.e0
DDI-DrugBank.d341.s1	91	102	methotrexate	drug	DDI-DrugBank.d341.s1.e1
DDI-DrugBank.d341.s1	false	DDI-DrugBank.d341.s1.e0	DDI-DrugBank.d341.s1.e1
DDI-DrugBank.d341.s2|a|In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).
DDI-DrugBank.d341.s2	92	97	ENBREL	brand	DDI-DrugBank.d341.s2.e0
DDI-DrugBank.d341.s2	104	111	anakinra	drug	DDI-DrugBank.d341.s2.e1
DDI-DrugBank.d341.s2	209	214	ENBREL	brand	DDI-DrugBank.d341.s2.e2
DDI-DrugBank.d341.s2	true	DDI-DrugBank.d341.s2.e0	DDI-DrugBank.d341.s2.e1
DDI-DrugBank.d341.s2	false	DDI-DrugBank.d341.s2.e0	DDI-DrugBank.d341.s2.e2
DDI-DrugBank.d341.s2	false	DDI-DrugBank.d341.s2.e1	DDI-DrugBank.d341.s2.e2
DDI-DrugBank.d341.s3|a|Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).
DDI-DrugBank.d341.s3	50	55	ENBREL	brand	DDI-DrugBank.d341.s3.e0
DDI-DrugBank.d341.s3	62	69	anakinra	drug	DDI-DrugBank.d341.s3.e1
DDI-DrugBank.d341.s3	true	DDI-DrugBank.d341.s3.e0	DDI-DrugBank.d341.s3.e1
DDI-DrugBank.d341.s4|a|Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.
DDI-DrugBank.d341.s4	66	78	sulfasalazine	drug	DDI-DrugBank.d341.s4.e0
DDI-DrugBank.d341.s4	90	95	ENBREL	brand	DDI-DrugBank.d341.s4.e1
DDI-DrugBank.d341.s4	216	221	ENBREL	brand	DDI-DrugBank.d341.s4.e2
DDI-DrugBank.d341.s4	229	241	sulfasalazine	drug	DDI-DrugBank.d341.s4.e3
DDI-DrugBank.d341.s4	true	DDI-DrugBank.d341.s4.e0	DDI-DrugBank.d341.s4.e1
DDI-DrugBank.d341.s4	false	DDI-DrugBank.d341.s4.e0	DDI-DrugBank.d341.s4.e2
DDI-DrugBank.d341.s4	false	DDI-DrugBank.d341.s4.e0	DDI-DrugBank.d341.s4.e3
DDI-DrugBank.d341.s4	false	DDI-DrugBank.d341.s4.e1	DDI-DrugBank.d341.s4.e2
DDI-DrugBank.d341.s4	false	DDI-DrugBank.d341.s4.e1	DDI-DrugBank.d341.s4.e3
DDI-DrugBank.d341.s4	false	DDI-DrugBank.d341.s4.e2	DDI-DrugBank.d341.s4.e3
DDI-DrugBank.d341.s5|a|The clinical significance of this observation is unknown.
DDI-DrugBank.d414.s0|a|Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
DDI-DrugBank.d414.s0	0	6	Lithium	drug	DDI-DrugBank.d414.s0.e0
DDI-DrugBank.d414.s0	43	51	diuretics	group	DDI-DrugBank.d414.s0.e1
DDI-DrugBank.d414.s0	116	122	lithium	drug	DDI-DrugBank.d414.s0.e2
DDI-DrugBank.d414.s0	true	DDI-DrugBank.d414.s0.e0	DDI-DrugBank.d414.s0.e1
DDI-DrugBank.d414.s0	false	DDI-DrugBank.d414.s0.e0	DDI-DrugBank.d414.s0.e2
DDI-DrugBank.d414.s0	false	DDI-DrugBank.d414.s0.e1	DDI-DrugBank.d414.s0.e2
DDI-DrugBank.d414.s1|a|Read circulars for lithium preparations before use of such concomitant therapy.
DDI-DrugBank.d414.s1	19	25	lithium	drug	DDI-DrugBank.d414.s1.e0
DDI-DrugBank.d414.s2|a|EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.
DDI-DrugBank.d414.s2	0	6	EDECRIN	brand	DDI-DrugBank.d414.s2.e0
DDI-DrugBank.d414.s2	67	80	aminoglycoside	group	DDI-DrugBank.d414.s2.e1
DDI-DrugBank.d414.s2	91	115	cephalosporin antibiotics	group	DDI-DrugBank.d414.s2.e2
DDI-DrugBank.d414.s2	true	DDI-DrugBank.d414.s2.e0	DDI-DrugBank.d414.s2.e1
DDI-DrugBank.d414.s2	true	DDI-DrugBank.d414.s2.e0	DDI-DrugBank.d414.s2.e2
DDI-DrugBank.d414.s2	false	DDI-DrugBank.d414.s2.e1	DDI-DrugBank.d414.s2.e2
DDI-DrugBank.d414.s3|a|Their concurrent use should be avoided.
DDI-DrugBank.d414.s4|a|A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;
DDI-DrugBank.d414.s4	29	43	ethacrynic acid	drug	DDI-DrugBank.d414.s4.e0
DDI-DrugBank.d414.s4	74	81	warfarin	drug	DDI-DrugBank.d414.s4.e1
DDI-DrugBank.d414.s4	true	DDI-DrugBank.d414.s4.e0	DDI-DrugBank.d414.s4.e1
DDI-DrugBank.d414.s5|a|a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs.
DDI-DrugBank.d414.s5	25	37	anticoagulant	group	DDI-DrugBank.d414.s5.e0
DDI-DrugBank.d414.s6|a|In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
DDI-DrugBank.d414.s6	42	78	non- steroidal antiinflammatory agent	group	DDI-DrugBank.d414.s6.e0
DDI-DrugBank.d414.s6	150	153	loop diuretics	group	DDI-DrugBank.d414.s6.e1
DDI-DrugBank.d414.s6	188	196	loop diuretics	group	DDI-DrugBank.d414.s6.e1
DDI-DrugBank.d414.s6	156	173	potassium- sparing diuretics	group	DDI-DrugBank.d414.s6.e2
DDI-DrugBank.d414.s6	188	196	potassium- sparing diuretics	group	DDI-DrugBank.d414.s6.e2
DDI-DrugBank.d414.s6	179	196	thiazide diuretics	group	DDI-DrugBank.d414.s6.e3
DDI-DrugBank.d414.s6	true	DDI-DrugBank.d414.s6.e0	DDI-DrugBank.d414.s6.e1
DDI-DrugBank.d414.s6	true	DDI-DrugBank.d414.s6.e0	DDI-DrugBank.d414.s6.e2
DDI-DrugBank.d414.s6	true	DDI-DrugBank.d414.s6.e0	DDI-DrugBank.d414.s6.e3
DDI-DrugBank.d414.s6	false	DDI-DrugBank.d414.s6.e1	DDI-DrugBank.d414.s6.e2
DDI-DrugBank.d414.s6	false	DDI-DrugBank.d414.s6.e1	DDI-DrugBank.d414.s6.e3
DDI-DrugBank.d414.s6	false	DDI-DrugBank.d414.s6.e2	DDI-DrugBank.d414.s6.e3
DDI-DrugBank.d414.s7|a|Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
DDI-DrugBank.d414.s7	16	22	EDECRIN	brand	DDI-DrugBank.d414.s7.e0
DDI-DrugBank.d414.s7	28	67	non- steroidal anti- inflammatory agents	group	DDI-DrugBank.d414.s7.e1
DDI-DrugBank.d414.s7	174	181	diuretic	group	DDI-DrugBank.d414.s7.e2
DDI-DrugBank.d414.s7	true	DDI-DrugBank.d414.s7.e0	DDI-DrugBank.d414.s7.e1
DDI-DrugBank.d414.s7	false	DDI-DrugBank.d414.s7.e0	DDI-DrugBank.d414.s7.e2
DDI-DrugBank.d414.s7	false	DDI-DrugBank.d414.s7.e1	DDI-DrugBank.d414.s7.e2
DDI-DrugBank.d160.s0|a|The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
DDI-DrugBank.d160.s0	46	55	ethambutol	drug	DDI-DrugBank.d160.s0.e0
DDI-DrugBank.d160.s0	76	93	aluminum hydroxide	drug	DDI-DrugBank.d160.s0.e1
DDI-DrugBank.d160.s0	106	112	antacid	group	DDI-DrugBank.d160.s0.e2
DDI-DrugBank.d160.s0	220	229	ethambutol	drug	DDI-DrugBank.d160.s0.e3
DDI-DrugBank.d160.s0	314	323	ethambutol	drug	DDI-DrugBank.d160.s0.e4
DDI-DrugBank.d160.s0	349	364	antacid products	group	DDI-DrugBank.d160.s0.e5
DDI-DrugBank.d160.s0	true	DDI-DrugBank.d160.s0.e0	DDI-DrugBank.d160.s0.e1
DDI-DrugBank.d160.s0	false	DDI-DrugBank.d160.s0.e0	DDI-DrugBank.d160.s0.e2
DDI-DrugBank.d160.s0	false	DDI-DrugBank.d160.s0.e0	DDI-DrugBank.d160.s0.e3
DDI-DrugBank.d160.s0	false	DDI-DrugBank.d160.s0.e0	DDI-DrugBank.d160.s0.e4
DDI-DrugBank.d160.s0	false	DDI-DrugBank.d160.s0.e0	DDI-DrugBank.d160.s0.e5
DDI-DrugBank.d160.s0	false	DDI-DrugBank.d160.s0.e1	DDI-DrugBank.d160.s0.e2
DDI-DrugBank.d160.s0	false	DDI-DrugBank.d160.s0.e1	DDI-DrugBank.d160.s0.e3
DDI-DrugBank.d160.s0	false	DDI-DrugBank.d160.s0.e1	DDI-DrugBank.d160.s0.e4
DDI-DrugBank.d160.s0	false	DDI-DrugBank.d160.s0.e1	DDI-DrugBank.d160.s0.e5
DDI-DrugBank.d160.s0	false	DDI-DrugBank.d160.s0.e2	DDI-DrugBank.d160.s0.e3
DDI-DrugBank.d160.s1|a|It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.
DDI-DrugBank.d160.s1	56	65	ethambutol	drug	DDI-DrugBank.d160.s1.e0
DDI-DrugBank.d160.s1	72	89	aluminum hydroxide	drug	DDI-DrugBank.d160.s1.e1
DDI-DrugBank.d160.s1	102	109	antacids	group	DDI-DrugBank.d160.s1.e2
DDI-DrugBank.d160.s1	142	151	ethambutol	drug	DDI-DrugBank.d160.s1.e3
DDI-DrugBank.d160.s1	true	DDI-DrugBank.d160.s1.e0	DDI-DrugBank.d160.s1.e1
DDI-DrugBank.d160.s1	false	DDI-DrugBank.d160.s1.e0	DDI-DrugBank.d160.s1.e2
DDI-DrugBank.d160.s1	false	DDI-DrugBank.d160.s1.e0	DDI-DrugBank.d160.s1.e3
DDI-DrugBank.d160.s1	false	DDI-DrugBank.d160.s1.e1	DDI-DrugBank.d160.s1.e2
DDI-DrugBank.d160.s1	false	DDI-DrugBank.d160.s1.e1	DDI-DrugBank.d160.s1.e3
DDI-DrugBank.d160.s1	false	DDI-DrugBank.d160.s1.e2	DDI-DrugBank.d160.s1.e3
DDI-DrugBank.d405.s0|a|Dicumarol and warfarin may decrease hypoprothrombinemic effect.
DDI-DrugBank.d405.s0	0	8	Dicumarol	drug	DDI-DrugBank.d405.s0.e0
DDI-DrugBank.d405.s0	14	21	warfarin	drug	DDI-DrugBank.d405.s0.e1
DDI-DrugBank.d405.s0	false	DDI-DrugBank.d405.s0.e0	DDI-DrugBank.d405.s0.e1
DDI-DrugBank.d405.s1|a|Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
DDI-DrugBank.d405.s1	27	33	alcohol	drug	DDI-DrugBank.d405.s1.e0
DDI-DrugBank.d405.s1	36	47	barbiturates	group	DDI-DrugBank.d405.s1.e1
DDI-DrugBank.d405.s1	54	58	MAOIs	group	DDI-DrugBank.d405.s1.e2
DDI-DrugBank.d405.s1	110	122	ethchlorvynol	drug	DDI-DrugBank.d405.s1.e3
DDI-DrugBank.d405.s1	false	DDI-DrugBank.d405.s1.e0	DDI-DrugBank.d405.s1.e1
DDI-DrugBank.d405.s1	false	DDI-DrugBank.d405.s1.e0	DDI-DrugBank.d405.s1.e2
DDI-DrugBank.d405.s1	true	DDI-DrugBank.d405.s1.e0	DDI-DrugBank.d405.s1.e3
DDI-DrugBank.d405.s1	false	DDI-DrugBank.d405.s1.e1	DDI-DrugBank.d405.s1.e2
DDI-DrugBank.d405.s1	true	DDI-DrugBank.d405.s1.e1	DDI-DrugBank.d405.s1.e3
DDI-DrugBank.d405.s1	true	DDI-DrugBank.d405.s1.e2	DDI-DrugBank.d405.s1.e3
DDI-DrugBank.d376.s0|a|May interact with addictive medications, especially central nervous system (CNS) depressants with habituating potential (prolonged concurrent use may increase the risk of habituation), alcohol or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate).
DDI-DrugBank.d376.s0	52	91	central nervous system (CNS) depressants	group	DDI-DrugBank.d376.s0.e0
DDI-DrugBank.d376.s0	185	191	alcohol	drug	DDI-DrugBank.d376.s0.e1
DDI-DrugBank.d376.s0	320	329	ethinamate	drug	DDI-DrugBank.d376.s0.e2
DDI-DrugBank.d376.s0	false	DDI-DrugBank.d376.s0.e0	DDI-DrugBank.d376.s0.e1
DDI-DrugBank.d376.s0	false	DDI-DrugBank.d376.s0.e0	DDI-DrugBank.d376.s0.e2
DDI-DrugBank.d376.s0	false	DDI-DrugBank.d376.s0.e1	DDI-DrugBank.d376.s0.e2
DDI-DrugBank.d152.s0|a|Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
DDI-DrugBank.d152.s0	62	69	estrogen	group	DDI-DrugBank.d152.s0.e0
DDI-DrugBank.d152.s0	87	100	contraceptives	group	DDI-DrugBank.d152.s0.e1
DDI-DrugBank.d152.s0	false	DDI-DrugBank.d152.s0.e0	DDI-DrugBank.d152.s0.e1
DDI-DrugBank.d152.s1|a|The following similar changes may be expected with larger doses of estrogen: Increased sulfobromophthalein retention;
DDI-DrugBank.d152.s1	67	74	estrogen	group	DDI-DrugBank.d152.s1.e0
DDI-DrugBank.d152.s2|a|increased prothrombin and factors VII, VIII, IX, and X;
DDI-DrugBank.d152.s3|a|decreased antithrombin 3;
DDI-DrugBank.d152.s4|a|increased norepinephrine-induced platel et aggregation;
DDI-DrugBank.d152.s5|a|increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by PBI, T4 by column, or T4 by radioimmunoassay.
DDI-DrugBank.d152.s6|a|Free T3 resin uptake is decreased, reflecting the elevated TBG;
DDI-DrugBank.d152.s7|a|free T4 concentration is unaltered: impaired glucose tolerance;
DDI-DrugBank.d152.s8|a|decreased pregnanediol excretion;
DDI-DrugBank.d152.s9|a|reduced response to metyrapone test;
DDI-DrugBank.d152.s10|a|reduced serum folate concentration;
DDI-DrugBank.d152.s11|a|increased serum triglyceride and phospholipid concentration.
DDI-DrugBank.d166.s0|a|Trecator has been found to temporarily raise serum concentrations of isoniazid.
DDI-DrugBank.d166.s0	0	7	Trecator	brand	DDI-DrugBank.d166.s0.e0
DDI-DrugBank.d166.s0	69	77	isoniazid	drug	DDI-DrugBank.d166.s0.e1
DDI-DrugBank.d166.s0	true	DDI-DrugBank.d166.s0.e0	DDI-DrugBank.d166.s0.e1
DDI-DrugBank.d166.s1|a|Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.
DDI-DrugBank.d166.s1	0	7	Trecator	brand	DDI-DrugBank.d166.s1.e0
DDI-DrugBank.d166.s1	53	73	antituberculous drugs	group	DDI-DrugBank.d166.s1.e1
DDI-DrugBank.d166.s1	true	DDI-DrugBank.d166.s1.e0	DDI-DrugBank.d166.s1.e1
DDI-DrugBank.d166.s2|a|In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.
DDI-DrugBank.d166.s2	51	61	ethionamide	drug	DDI-DrugBank.d166.s2.e0
DDI-DrugBank.d166.s2	84	94	cycloserine	drug	DDI-DrugBank.d166.s2.e1
DDI-DrugBank.d166.s2	true	DDI-DrugBank.d166.s2.e0	DDI-DrugBank.d166.s2.e1
DDI-DrugBank.d166.s3|a|Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported.
DDI-DrugBank.d166.s3	10	16	ethanol	drug	DDI-DrugBank.d166.s3.e0
DDI-DrugBank.d240.s0|a|Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.
DDI-DrugBank.d240.s0	0	12	Ethopropazine	drug	DDI-DrugBank.d240.s0.e0
DDI-DrugBank.d240.s0	32	38	alcohol	drug	DDI-DrugBank.d240.s0.e1
DDI-DrugBank.d240.s0	49	63	CNS depressants	group	DDI-DrugBank.d240.s0.e2
DDI-DrugBank.d240.s0	true	DDI-DrugBank.d240.s0.e0	DDI-DrugBank.d240.s0.e1
DDI-DrugBank.d240.s0	true	DDI-DrugBank.d240.s0.e0	DDI-DrugBank.d240.s0.e2
DDI-DrugBank.d240.s0	false	DDI-DrugBank.d240.s0.e1	DDI-DrugBank.d240.s0.e2
DDI-DrugBank.d240.s1|a|It may also interact with amantadine or other anticholinergic drugs or MAOIs, which may intensify the anticholinergic action.
DDI-DrugBank.d240.s1	26	35	amantadine	drug	DDI-DrugBank.d240.s1.e0
DDI-DrugBank.d240.s1	46	66	anticholinergic drugs	group	DDI-DrugBank.d240.s1.e1
DDI-DrugBank.d240.s1	71	75	MAOIs	group	DDI-DrugBank.d240.s1.e2
DDI-DrugBank.d240.s1	false	DDI-DrugBank.d240.s1.e0	DDI-DrugBank.d240.s1.e1
DDI-DrugBank.d240.s1	false	DDI-DrugBank.d240.s1.e0	DDI-DrugBank.d240.s1.e2
DDI-DrugBank.d240.s1	false	DDI-DrugBank.d240.s1.e1	DDI-DrugBank.d240.s1.e2
DDI-DrugBank.d240.s2|a|Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
DDI-DrugBank.d240.s2	0	12	Ethopropazine	drug	DDI-DrugBank.d240.s2.e0
DDI-DrugBank.d240.s2	32	45	chlorpromazine	drug	DDI-DrugBank.d240.s2.e1
DDI-DrugBank.d240.s2	77	90	chlorpromazine	drug	DDI-DrugBank.d240.s2.e2
DDI-DrugBank.d240.s2	true	DDI-DrugBank.d240.s2.e0	DDI-DrugBank.d240.s2.e1
DDI-DrugBank.d240.s2	false	DDI-DrugBank.d240.s2.e0	DDI-DrugBank.d240.s2.e2
DDI-DrugBank.d240.s2	false	DDI-DrugBank.d240.s2.e1	DDI-DrugBank.d240.s2.e2
DDI-DrugBank.d205.s0|a|Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
DDI-DrugBank.d205.s0	6	13	Zarontin	brand	DDI-DrugBank.d205.s0.e0
DDI-DrugBank.d205.s0	16	27	ethosuximide	drug	DDI-DrugBank.d205.s0.e1
DDI-DrugBank.d205.s0	74	92	antiepileptic drugs	group	DDI-DrugBank.d205.s0.e2
DDI-DrugBank.d205.s0	168	179	ethosuximide	drug	DDI-DrugBank.d205.s0.e3
DDI-DrugBank.d205.s0	193	201	phenytoin	drug	DDI-DrugBank.d205.s0.e4
DDI-DrugBank.d205.s0	220	232	valproic acid	drug	DDI-DrugBank.d205.s0.e5
DDI-DrugBank.d205.s0	282	293	ethosuximide	drug	DDI-DrugBank.d205.s0.e6
DDI-DrugBank.d205.s0	false	DDI-DrugBank.d205.s0.e0	DDI-DrugBank.d205.s0.e1
DDI-DrugBank.d205.s0	true	DDI-DrugBank.d205.s0.e0	DDI-DrugBank.d205.s0.e2
DDI-DrugBank.d205.s0	false	DDI-DrugBank.d205.s0.e0	DDI-DrugBank.d205.s0.e3
DDI-DrugBank.d205.s0	false	DDI-DrugBank.d205.s0.e0	DDI-DrugBank.d205.s0.e4
DDI-DrugBank.d205.s0	false	DDI-DrugBank.d205.s0.e0	DDI-DrugBank.d205.s0.e5
DDI-DrugBank.d205.s0	false	DDI-DrugBank.d205.s0.e0	DDI-DrugBank.d205.s0.e6
DDI-DrugBank.d205.s0	true	DDI-DrugBank.d205.s0.e1	DDI-DrugBank.d205.s0.e2
DDI-DrugBank.d205.s0	false	DDI-DrugBank.d205.s0.e1	DDI-DrugBank.d205.s0.e3
DDI-DrugBank.d205.s0	false	DDI-DrugBank.d205.s0.e1	DDI-DrugBank.d205.s0.e4
DDI-DrugBank.d205.s0	false	DDI-DrugBank.d205.s0.e1	DDI-DrugBank.d205.s0.e5
DDI-DrugBank.d359.s0|a|PEGANONE used in combination with other drugs known to adversely affect the hematopoietic system should be avoided if possible.
DDI-DrugBank.d359.s0	0	7	PEGANONE	brand	DDI-DrugBank.d359.s0.e0
DDI-DrugBank.d359.s1|a|Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
DDI-DrugBank.d359.s1	44	51	PEGANONE	brand	DDI-DrugBank.d359.s1.e0
DDI-DrugBank.d359.s1	87	95	Phenurone	brand	DDI-DrugBank.d359.s1.e1
DDI-DrugBank.d359.s1	98	108	phenacemide	drug	DDI-DrugBank.d359.s1.e2
DDI-DrugBank.d359.s1	true	DDI-DrugBank.d359.s1.e0	DDI-DrugBank.d359.s1.e1
DDI-DrugBank.d359.s1	true	DDI-DrugBank.d359.s1.e0	DDI-DrugBank.d359.s1.e2
DDI-DrugBank.d359.s1	false	DDI-DrugBank.d359.s1.e1	DDI-DrugBank.d359.s1.e2
DDI-DrugBank.d359.s2|a|A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
DDI-DrugBank.d359.s2	34	56	hydantoin antiepileptic	group	DDI-DrugBank.d359.s2.e0
DDI-DrugBank.d359.s2	59	67	phenytoin	drug	DDI-DrugBank.d359.s2.e1
DDI-DrugBank.d359.s2	78	99	coumarin anticoagulant	group	DDI-DrugBank.d359.s2.e2
DDI-DrugBank.d359.s2	true	DDI-DrugBank.d359.s2.e0	DDI-DrugBank.d359.s2.e1
DDI-DrugBank.d359.s2	true	DDI-DrugBank.d359.s2.e0	DDI-DrugBank.d359.s2.e2
DDI-DrugBank.d359.s2	false	DDI-DrugBank.d359.s2.e1	DDI-DrugBank.d359.s2.e2
DDI-DrugBank.d359.s3|a|Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
DDI-DrugBank.d359.s3	12	20	phenytoin	drug	DDI-DrugBank.d359.s3.e0
DDI-DrugBank.d359.s3	46	53	coumarin	group	DDI-DrugBank.d359.s3.e1
DDI-DrugBank.d359.s3	127	149	coumarin anticoagulants	group	DDI-DrugBank.d359.s3.e2
DDI-DrugBank.d359.s3	true	DDI-DrugBank.d359.s3.e0	DDI-DrugBank.d359.s3.e1
DDI-DrugBank.d359.s3	true	DDI-DrugBank.d359.s3.e0	DDI-DrugBank.d359.s3.e2
DDI-DrugBank.d359.s3	false	DDI-DrugBank.d359.s3.e1	DDI-DrugBank.d359.s3.e2
DDI-DrugBank.d359.s4|a|Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.
DDI-DrugBank.d359.s4	16	38	coumarin anticoagulants	group	DDI-DrugBank.d359.s4.e0
DDI-DrugBank.d359.s4	123	131	phenytoin	drug	DDI-DrugBank.d359.s4.e1
DDI-DrugBank.d359.s4	true	DDI-DrugBank.d359.s4.e0	DDI-DrugBank.d359.s4.e1
DDI-DrugBank.d359.s5|a|Although there is no documentation of such, a similar interaction between ethotoin and the coumarin anticoagulants may occur.
DDI-DrugBank.d359.s5	74	81	ethotoin	drug	DDI-DrugBank.d359.s5.e0
DDI-DrugBank.d359.s5	91	113	coumarin anticoagulants	group	DDI-DrugBank.d359.s5.e1
DDI-DrugBank.d359.s5	false	DDI-DrugBank.d359.s5.e0	DDI-DrugBank.d359.s5.e1
DDI-DrugBank.d359.s6|a|Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.
DDI-DrugBank.d359.s6	48	55	PEGANONE	brand	DDI-DrugBank.d359.s6.e0
DDI-DrugBank.d359.s6	79	101	coumarin anticoagulants	group	DDI-DrugBank.d359.s6.e1
DDI-DrugBank.d359.s6	true	DDI-DrugBank.d359.s6.e0	DDI-DrugBank.d359.s6.e1
DDI-DrugBank.d286.s0|a|Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
DDI-DrugBank.d286.s0	0	12	Ethoxzolamide	drug	DDI-DrugBank.d286.s0.e0
DDI-DrugBank.d286.s0	41	50	tricyclics	group	DDI-DrugBank.d286.s0.e1
DDI-DrugBank.d286.s0	53	64	amphetamines	group	DDI-DrugBank.d286.s0.e2
DDI-DrugBank.d286.s0	67	78	procainamide	drug	DDI-DrugBank.d286.s0.e3
DDI-DrugBank.d286.s0	85	93	quinidine	drug	DDI-DrugBank.d286.s0.e4
DDI-DrugBank.d286.s0	true	DDI-DrugBank.d286.s0.e0	DDI-DrugBank.d286.s0.e1
DDI-DrugBank.d286.s0	true	DDI-DrugBank.d286.s0.e0	DDI-DrugBank.d286.s0.e2
DDI-DrugBank.d286.s0	true	DDI-DrugBank.d286.s0.e0	DDI-DrugBank.d286.s0.e3
DDI-DrugBank.d286.s0	true	DDI-DrugBank.d286.s0.e0	DDI-DrugBank.d286.s0.e4
DDI-DrugBank.d286.s0	false	DDI-DrugBank.d286.s0.e1	DDI-DrugBank.d286.s0.e2
DDI-DrugBank.d286.s0	false	DDI-DrugBank.d286.s0.e1	DDI-DrugBank.d286.s0.e3
DDI-DrugBank.d286.s0	false	DDI-DrugBank.d286.s0.e1	DDI-DrugBank.d286.s0.e4
DDI-DrugBank.d286.s0	false	DDI-DrugBank.d286.s0.e2	DDI-DrugBank.d286.s0.e3
DDI-DrugBank.d286.s0	false	DDI-DrugBank.d286.s0.e2	DDI-DrugBank.d286.s0.e4
DDI-DrugBank.d286.s0	false	DDI-DrugBank.d286.s0.e3	DDI-DrugBank.d286.s0.e4
DDI-DrugBank.d286.s1|a|It may increase excretion of barbiturates, lithium, and ASA and may also increase the toxicity of salicylates.
DDI-DrugBank.d286.s1	29	40	barbiturates	group	DDI-DrugBank.d286.s1.e0
DDI-DrugBank.d286.s1	43	49	lithium	drug	DDI-DrugBank.d286.s1.e1
DDI-DrugBank.d286.s1	56	58	ASA	drug	DDI-DrugBank.d286.s1.e2
DDI-DrugBank.d286.s1	98	108	salicylates	group	DDI-DrugBank.d286.s1.e3
DDI-DrugBank.d286.s1	false	DDI-DrugBank.d286.s1.e0	DDI-DrugBank.d286.s1.e1
DDI-DrugBank.d286.s1	false	DDI-DrugBank.d286.s1.e0	DDI-DrugBank.d286.s1.e2
DDI-DrugBank.d286.s1	false	DDI-DrugBank.d286.s1.e0	DDI-DrugBank.d286.s1.e3
DDI-DrugBank.d286.s1	false	DDI-DrugBank.d286.s1.e1	DDI-DrugBank.d286.s1.e2
DDI-DrugBank.d286.s1	false	DDI-DrugBank.d286.s1.e1	DDI-DrugBank.d286.s1.e3
DDI-DrugBank.d286.s1	false	DDI-DrugBank.d286.s1.e2	DDI-DrugBank.d286.s1.e3
DDI-DrugBank.d286.s2|a|Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
DDI-DrugBank.d286.s2	20	32	ethoxzolamide	drug	DDI-DrugBank.d286.s2.e0
DDI-DrugBank.d286.s2	45	53	diuretics	group	DDI-DrugBank.d286.s2.e1
DDI-DrugBank.d286.s2	56	69	amphotericin B	drug	DDI-DrugBank.d286.s2.e2
DDI-DrugBank.d286.s2	76	90	corticosteroids	group	DDI-DrugBank.d286.s2.e3
DDI-DrugBank.d286.s2	true	DDI-DrugBank.d286.s2.e0	DDI-DrugBank.d286.s2.e1
DDI-DrugBank.d286.s2	true	DDI-DrugBank.d286.s2.e0	DDI-DrugBank.d286.s2.e2
DDI-DrugBank.d286.s2	true	DDI-DrugBank.d286.s2.e0	DDI-DrugBank.d286.s2.e3
DDI-DrugBank.d286.s2	false	DDI-DrugBank.d286.s2.e1	DDI-DrugBank.d286.s2.e2
DDI-DrugBank.d286.s2	false	DDI-DrugBank.d286.s2.e1	DDI-DrugBank.d286.s2.e3
DDI-DrugBank.d286.s2	false	DDI-DrugBank.d286.s2.e2	DDI-DrugBank.d286.s2.e3
DDI-DrugBank.d485.s0|a|Ethinyl estradiol: Substrate of CYP3A4 (major), 3A5-7 (minor);
DDI-DrugBank.d485.s0	0	16	Ethinyl estradiol	drug	DDI-DrugBank.d485.s0.e0
DDI-DrugBank.d485.s1|a|Inhibits CYP1A2 (weak), 2B6 (weak), 2C19 (weak), 3A4 (weak).
DDI-DrugBank.d485.s2|a|Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.
DDI-DrugBank.d485.s2	0	12	Acetaminophen	drug	DDI-DrugBank.d485.s2.e0
DDI-DrugBank.d485.s2	52	70	synthetic estrogens	group	DDI-DrugBank.d485.s2.e1
DDI-DrugBank.d485.s2	true	DDI-DrugBank.d485.s2.e0	DDI-DrugBank.d485.s2.e1
DDI-DrugBank.d485.s3|a|Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.
DDI-DrugBank.d485.s3	12	34	hormonal contraceptives	group	DDI-DrugBank.d485.s3.e0
DDI-DrugBank.d485.s3	82	94	acetaminophen	drug	DDI-DrugBank.d485.s3.e1
DDI-DrugBank.d485.s3	true	DDI-DrugBank.d485.s3.e0	DDI-DrugBank.d485.s3.e1
DDI-DrugBank.d485.s4|a|Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.
DDI-DrugBank.d485.s4	0	8	Acitretin	drug	DDI-DrugBank.d485.s4.e0
DDI-DrugBank.d485.s4	66	74	progestin	group	DDI-DrugBank.d485.s4.e1
DDI-DrugBank.d485.s4	true	DDI-DrugBank.d485.s4.e0	DDI-DrugBank.d485.s4.e1
DDI-DrugBank.d485.s5|a|The effect on other progestational contraceptives (eg, implants, injectables) is unknown.
DDI-DrugBank.d485.s5	20	48	progestational contraceptives	group	DDI-DrugBank.d485.s5.e0
DDI-DrugBank.d485.s6|a|Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s6	0	16	Aminoglutethimide	drug	DDI-DrugBank.d485.s6.e0
DDI-DrugBank.d485.s6	50	59	progestins	group	DDI-DrugBank.d485.s6.e1
DDI-DrugBank.d485.s6	true	DDI-DrugBank.d485.s6.e0	DDI-DrugBank.d485.s6.e1
DDI-DrugBank.d485.s7|a|Use of a nonhormonal contraceptive product is recommended.
DDI-DrugBank.d485.s7	9	41	nonhormonal contraceptive product	group	DDI-DrugBank.d485.s7.e0
DDI-DrugBank.d485.s8|a|Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.
DDI-DrugBank.d485.s8	0	10	Antibiotics	group	DDI-DrugBank.d485.s8.e0
DDI-DrugBank.d485.s8	13	22	ampicillin	drug	DDI-DrugBank.d485.s8.e1
DDI-DrugBank.d485.s8	25	36	tetracycline	drug	DDI-DrugBank.d485.s8.e2
DDI-DrugBank.d485.s8	173	183	antibiotics	group	DDI-DrugBank.d485.s8.e3
DDI-DrugBank.d485.s8	213	230	synthetic steroids	group	DDI-DrugBank.d485.s8.e4
DDI-DrugBank.d485.s8	false	DDI-DrugBank.d485.s8.e0	DDI-DrugBank.d485.s8.e1
DDI-DrugBank.d485.s8	false	DDI-DrugBank.d485.s8.e0	DDI-DrugBank.d485.s8.e2
DDI-DrugBank.d485.s8	false	DDI-DrugBank.d485.s8.e0	DDI-DrugBank.d485.s8.e3
DDI-DrugBank.d485.s8	false	DDI-DrugBank.d485.s8.e0	DDI-DrugBank.d485.s8.e4
DDI-DrugBank.d485.s8	false	DDI-DrugBank.d485.s8.e1	DDI-DrugBank.d485.s8.e2
DDI-DrugBank.d485.s8	false	DDI-DrugBank.d485.s8.e1	DDI-DrugBank.d485.s8.e3
DDI-DrugBank.d485.s8	false	DDI-DrugBank.d485.s8.e1	DDI-DrugBank.d485.s8.e4
DDI-DrugBank.d485.s8	false	DDI-DrugBank.d485.s8.e2	DDI-DrugBank.d485.s8.e3
DDI-DrugBank.d485.s8	false	DDI-DrugBank.d485.s8.e2	DDI-DrugBank.d485.s8.e4
DDI-DrugBank.d485.s8	false	DDI-DrugBank.d485.s8.e3	DDI-DrugBank.d485.s8.e4
DDI-DrugBank.d485.s9|a|Use of a nonhormonal contraceptive product is recommended.
DDI-DrugBank.d485.s9	9	41	nonhormonal contraceptive product	group	DDI-DrugBank.d485.s9.e0
DDI-DrugBank.d485.s10|a|Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.
DDI-DrugBank.d485.s10	0	13	Anticoagulants	group	DDI-DrugBank.d485.s10.e0
DDI-DrugBank.d485.s10	28	50	hormonal contraceptives	group	DDI-DrugBank.d485.s10.e1
DDI-DrugBank.d485.s10	92	111	coumarin derivatives	group	DDI-DrugBank.d485.s10.e2
DDI-DrugBank.d485.s10	false	DDI-DrugBank.d485.s10.e0	DDI-DrugBank.d485.s10.e1
DDI-DrugBank.d485.s10	false	DDI-DrugBank.d485.s10.e0	DDI-DrugBank.d485.s10.e2
DDI-DrugBank.d485.s10	true	DDI-DrugBank.d485.s10.e1	DDI-DrugBank.d485.s10.e2
DDI-DrugBank.d485.s11|a|Combination hormonal contraceptives may also increase risk of thromboembolic disorders.
DDI-DrugBank.d485.s11	12	34	hormonal contraceptives	group	DDI-DrugBank.d485.s11.e0
DDI-DrugBank.d485.s12|a|Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s12	0	14	Anticonvulsants	group	DDI-DrugBank.d485.s12.e0
DDI-DrugBank.d485.s12	17	29	carbamazepine	drug	DDI-DrugBank.d485.s12.e1
DDI-DrugBank.d485.s12	32	40	felbamate	drug	DDI-DrugBank.d485.s12.e2
DDI-DrugBank.d485.s12	43	55	phenobarbital	drug	DDI-DrugBank.d485.s12.e3
DDI-DrugBank.d485.s12	58	66	phenytoin	drug	DDI-DrugBank.d485.s12.e4
DDI-DrugBank.d485.s12	69	78	topiramate	drug	DDI-DrugBank.d485.s12.e5
DDI-DrugBank.d485.s12	109	125	ethinyl estradiol	drug	DDI-DrugBank.d485.s12.e6
DDI-DrugBank.d485.s12	139	148	progestins	group	DDI-DrugBank.d485.s12.e7
DDI-DrugBank.d485.s12	false	DDI-DrugBank.d485.s12.e0	DDI-DrugBank.d485.s12.e1
DDI-DrugBank.d485.s12	false	DDI-DrugBank.d485.s12.e0	DDI-DrugBank.d485.s12.e2
DDI-DrugBank.d485.s12	false	DDI-DrugBank.d485.s12.e0	DDI-DrugBank.d485.s12.e3
DDI-DrugBank.d485.s12	false	DDI-DrugBank.d485.s12.e0	DDI-DrugBank.d485.s12.e4
DDI-DrugBank.d485.s12	false	DDI-DrugBank.d485.s12.e0	DDI-DrugBank.d485.s12.e5
DDI-DrugBank.d485.s12	true	DDI-DrugBank.d485.s12.e0	DDI-DrugBank.d485.s12.e6
DDI-DrugBank.d485.s12	true	DDI-DrugBank.d485.s12.e0	DDI-DrugBank.d485.s12.e7
DDI-DrugBank.d485.s12	false	DDI-DrugBank.d485.s12.e1	DDI-DrugBank.d485.s12.e2
DDI-DrugBank.d485.s12	false	DDI-DrugBank.d485.s12.e1	DDI-DrugBank.d485.s12.e3
DDI-DrugBank.d485.s12	false	DDI-DrugBank.d485.s12.e1	DDI-DrugBank.d485.s12.e4
DDI-DrugBank.d485.s13|a|Use of a nonhormonal contraceptive product is recommended.
DDI-DrugBank.d485.s13	9	41	nonhormonal contraceptive product	group	DDI-DrugBank.d485.s13.e0
DDI-DrugBank.d485.s14|a|Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;
DDI-DrugBank.d485.s14	0	12	Ascorbic acid	drug	DDI-DrugBank.d485.s14.e0
DDI-DrugBank.d485.s14	24	36	ascorbic acid	drug	DDI-DrugBank.d485.s14.e1
DDI-DrugBank.d485.s14	39	47	vitamin C	drug	DDI-DrugBank.d485.s14.e2
DDI-DrugBank.d485.s14	113	131	synthetic estrogens	group	DDI-DrugBank.d485.s14.e3
DDI-DrugBank.d485.s14	false	DDI-DrugBank.d485.s14.e0	DDI-DrugBank.d485.s14.e1
DDI-DrugBank.d485.s14	false	DDI-DrugBank.d485.s14.e0	DDI-DrugBank.d485.s14.e2
DDI-DrugBank.d485.s14	false	DDI-DrugBank.d485.s14.e0	DDI-DrugBank.d485.s14.e3
DDI-DrugBank.d485.s14	false	DDI-DrugBank.d485.s14.e1	DDI-DrugBank.d485.s14.e2
DDI-DrugBank.d485.s14	true	DDI-DrugBank.d485.s14.e1	DDI-DrugBank.d485.s14.e3
DDI-DrugBank.d485.s14	true	DDI-DrugBank.d485.s14.e2	DDI-DrugBank.d485.s14.e3
DDI-DrugBank.d485.s15|a|clinical implications are unclear.
DDI-DrugBank.d485.s16|a|Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.
DDI-DrugBank.d485.s16	0	11	Atorvastatin	drug	DDI-DrugBank.d485.s16.e0
DDI-DrugBank.d485.s16	14	25	Atorvastatin	drug	DDI-DrugBank.d485.s16.e1
DDI-DrugBank.d485.s16	49	61	norethindrone	drug	DDI-DrugBank.d485.s16.e2
DDI-DrugBank.d485.s16	67	83	ethinyl estradiol	drug	DDI-DrugBank.d485.s16.e3
DDI-DrugBank.d485.s16	false	DDI-DrugBank.d485.s16.e0	DDI-DrugBank.d485.s16.e1
DDI-DrugBank.d485.s16	false	DDI-DrugBank.d485.s16.e0	DDI-DrugBank.d485.s16.e2
DDI-DrugBank.d485.s16	false	DDI-DrugBank.d485.s16.e0	DDI-DrugBank.d485.s16.e3
DDI-DrugBank.d485.s16	true	DDI-DrugBank.d485.s16.e1	DDI-DrugBank.d485.s16.e2
DDI-DrugBank.d485.s16	true	DDI-DrugBank.d485.s16.e1	DDI-DrugBank.d485.s16.e3
DDI-DrugBank.d485.s16	false	DDI-DrugBank.d485.s16.e2	DDI-DrugBank.d485.s16.e3
DDI-DrugBank.d485.s17|a|Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
DDI-DrugBank.d485.s17	0	14	Benzodiazepines	group	DDI-DrugBank.d485.s17.e0
DDI-DrugBank.d485.s17	29	51	hormonal contraceptives	group	DDI-DrugBank.d485.s17.e1
DDI-DrugBank.d485.s17	88	102	benzodiazepines	group	DDI-DrugBank.d485.s17.e2
DDI-DrugBank.d485.s17	105	114	alprazolam	drug	DDI-DrugBank.d485.s17.e3
DDI-DrugBank.d485.s17	117	132	chlordiazepoxide	drug	DDI-DrugBank.d485.s17.e4
DDI-DrugBank.d485.s17	135	142	diazepam	drug	DDI-DrugBank.d485.s17.e5
DDI-DrugBank.d485.s17	183	191	lorazepam	drug	DDI-DrugBank.d485.s17.e6
DDI-DrugBank.d485.s17	194	201	oxazepam	drug	DDI-DrugBank.d485.s17.e7
DDI-DrugBank.d485.s17	204	212	temazepam	drug	DDI-DrugBank.d485.s17.e8
DDI-DrugBank.d485.s17	false	DDI-DrugBank.d485.s17.e0	DDI-DrugBank.d485.s17.e1
DDI-DrugBank.d485.s17	false	DDI-DrugBank.d485.s17.e0	DDI-DrugBank.d485.s17.e2
DDI-DrugBank.d485.s17	false	DDI-DrugBank.d485.s17.e0	DDI-DrugBank.d485.s17.e3
DDI-DrugBank.d485.s17	false	DDI-DrugBank.d485.s17.e0	DDI-DrugBank.d485.s17.e4
DDI-DrugBank.d485.s17	false	DDI-DrugBank.d485.s17.e0	DDI-DrugBank.d485.s17.e5
DDI-DrugBank.d485.s17	false	DDI-DrugBank.d485.s17.e0	DDI-DrugBank.d485.s17.e6
DDI-DrugBank.d485.s17	false	DDI-DrugBank.d485.s17.e0	DDI-DrugBank.d485.s17.e7
DDI-DrugBank.d485.s17	false	DDI-DrugBank.d485.s17.e0	DDI-DrugBank.d485.s17.e8
DDI-DrugBank.d485.s17	true	DDI-DrugBank.d485.s17.e1	DDI-DrugBank.d485.s17.e2
DDI-DrugBank.d485.s17	true	DDI-DrugBank.d485.s17.e1	DDI-DrugBank.d485.s17.e3
DDI-DrugBank.d485.s18|a|Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.
DDI-DrugBank.d485.s18	0	13	Clofibric acid	drug_n	DDI-DrugBank.d485.s18.e0
DDI-DrugBank.d485.s18	28	50	hormonal contraceptives	group	DDI-DrugBank.d485.s18.e1
DDI-DrugBank.d485.s18	82	95	clofibric acid	drug_n	DDI-DrugBank.d485.s18.e2
DDI-DrugBank.d485.s18	false	DDI-DrugBank.d485.s18.e0	DDI-DrugBank.d485.s18.e1
DDI-DrugBank.d485.s18	false	DDI-DrugBank.d485.s18.e0	DDI-DrugBank.d485.s18.e2
DDI-DrugBank.d485.s18	true	DDI-DrugBank.d485.s18.e1	DDI-DrugBank.d485.s18.e2
DDI-DrugBank.d485.s19|a|Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;
DDI-DrugBank.d485.s19	0	11	Cyclosporine	drug	DDI-DrugBank.d485.s19.e0
DDI-DrugBank.d485.s19	26	48	hormonal contraceptives	group	DDI-DrugBank.d485.s19.e1
DDI-DrugBank.d485.s19	80	91	cyclosporine	drug	DDI-DrugBank.d485.s19.e2
DDI-DrugBank.d485.s19	false	DDI-DrugBank.d485.s19.e0	DDI-DrugBank.d485.s19.e1
DDI-DrugBank.d485.s19	false	DDI-DrugBank.d485.s19.e0	DDI-DrugBank.d485.s19.e2
DDI-DrugBank.d485.s19	true	DDI-DrugBank.d485.s19.e1	DDI-DrugBank.d485.s19.e2
DDI-DrugBank.d485.s20|a|monitor cyclosporine levels.
DDI-DrugBank.d485.s20	8	19	cyclosporine	drug	DDI-DrugBank.d485.s20.e0
DDI-DrugBank.d485.s21|a|CYP3A4 inducers: CYP3A4 inducers may decrease the levels/effects of ethinyl estradiol.
DDI-DrugBank.d485.s21	68	84	ethinyl estradiol	drug	DDI-DrugBank.d485.s21.e0
DDI-DrugBank.d485.s22|a|Example inducers include aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins.
DDI-DrugBank.d485.s22	25	41	aminoglutethimide	drug	DDI-DrugBank.d485.s22.e0
DDI-DrugBank.d485.s22	44	56	carbamazepine	drug	DDI-DrugBank.d485.s22.e1
DDI-DrugBank.d485.s22	59	67	nafcillin	drug	DDI-DrugBank.d485.s22.e2
DDI-DrugBank.d485.s22	70	79	nevirapine	drug	DDI-DrugBank.d485.s22.e3
DDI-DrugBank.d485.s22	82	94	phenobarbital	drug	DDI-DrugBank.d485.s22.e4
DDI-DrugBank.d485.s22	97	105	phenytoin	drug	DDI-DrugBank.d485.s22.e5
DDI-DrugBank.d485.s22	112	121	rifamycins	group	DDI-DrugBank.d485.s22.e6
DDI-DrugBank.d485.s22	false	DDI-DrugBank.d485.s22.e0	DDI-DrugBank.d485.s22.e1
DDI-DrugBank.d485.s22	false	DDI-DrugBank.d485.s22.e0	DDI-DrugBank.d485.s22.e2
DDI-DrugBank.d485.s22	false	DDI-DrugBank.d485.s22.e0	DDI-DrugBank.d485.s22.e3
DDI-DrugBank.d485.s22	false	DDI-DrugBank.d485.s22.e0	DDI-DrugBank.d485.s22.e4
DDI-DrugBank.d485.s22	false	DDI-DrugBank.d485.s22.e0	DDI-DrugBank.d485.s22.e5
DDI-DrugBank.d485.s22	false	DDI-DrugBank.d485.s22.e0	DDI-DrugBank.d485.s22.e6
DDI-DrugBank.d485.s22	false	DDI-DrugBank.d485.s22.e1	DDI-DrugBank.d485.s22.e2
DDI-DrugBank.d485.s22	false	DDI-DrugBank.d485.s22.e1	DDI-DrugBank.d485.s22.e3
DDI-DrugBank.d485.s22	false	DDI-DrugBank.d485.s22.e1	DDI-DrugBank.d485.s22.e4
DDI-DrugBank.d485.s22	false	DDI-DrugBank.d485.s22.e1	DDI-DrugBank.d485.s22.e5
DDI-DrugBank.d485.s23|a|Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;
DDI-DrugBank.d485.s23	0	11	Griseofulvin	drug	DDI-DrugBank.d485.s23.e0
DDI-DrugBank.d485.s23	14	25	Griseofulvin	drug	DDI-DrugBank.d485.s23.e1
DDI-DrugBank.d485.s23	56	90	combination hormonal contraceptives	group	DDI-DrugBank.d485.s23.e2
DDI-DrugBank.d485.s23	false	DDI-DrugBank.d485.s23.e0	DDI-DrugBank.d485.s23.e1
DDI-DrugBank.d485.s23	false	DDI-DrugBank.d485.s23.e0	DDI-DrugBank.d485.s23.e2
DDI-DrugBank.d485.s23	true	DDI-DrugBank.d485.s23.e1	DDI-DrugBank.d485.s23.e2
DDI-DrugBank.d485.s24|a|pregnancies have been reported.
DDI-DrugBank.d485.s25|a|Use of barrier form of contraception is suggested while on griseofulvin therapy.
DDI-DrugBank.d485.s25	59	70	griseofulvin	drug	DDI-DrugBank.d485.s25.e0
DDI-DrugBank.d485.s26|a|Morphine: Combination hormonal contraceptives may increase the clearance of morphine.
DDI-DrugBank.d485.s26	0	7	Morphine	drug	DDI-DrugBank.d485.s26.e0
DDI-DrugBank.d485.s26	22	44	hormonal contraceptives	group	DDI-DrugBank.d485.s26.e1
DDI-DrugBank.d485.s26	76	83	morphine	drug	DDI-DrugBank.d485.s26.e2
DDI-DrugBank.d485.s26	false	DDI-DrugBank.d485.s26.e0	DDI-DrugBank.d485.s26.e1
DDI-DrugBank.d485.s26	false	DDI-DrugBank.d485.s26.e0	DDI-DrugBank.d485.s26.e2
DDI-DrugBank.d485.s26	true	DDI-DrugBank.d485.s26.e1	DDI-DrugBank.d485.s26.e2
DDI-DrugBank.d485.s27|a|Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;
DDI-DrugBank.d485.s27	0	46	Non-nucleoside reverse transcriptase inhibitors	group	DDI-DrugBank.d485.s27.e0
DDI-DrugBank.d485.s27	49	54	NNRTIs	group	DDI-DrugBank.d485.s27.e1
DDI-DrugBank.d485.s27	58	67	Nevirapine	drug	DDI-DrugBank.d485.s27.e2
DDI-DrugBank.d485.s27	99	133	combination hormonal contraceptives	group	DDI-DrugBank.d485.s27.e3
DDI-DrugBank.d485.s27	false	DDI-DrugBank.d485.s27.e0	DDI-DrugBank.d485.s27.e1
DDI-DrugBank.d485.s27	false	DDI-DrugBank.d485.s27.e0	DDI-DrugBank.d485.s27.e2
DDI-DrugBank.d485.s27	false	DDI-DrugBank.d485.s27.e0	DDI-DrugBank.d485.s27.e3
DDI-DrugBank.d485.s27	false	DDI-DrugBank.d485.s27.e1	DDI-DrugBank.d485.s27.e2
DDI-DrugBank.d485.s27	false	DDI-DrugBank.d485.s27.e1	DDI-DrugBank.d485.s27.e3
DDI-DrugBank.d485.s27	true	DDI-DrugBank.d485.s27.e2	DDI-DrugBank.d485.s27.e3
DDI-DrugBank.d485.s28|a|use of a nonhormonal contraceptive product is recommended.
DDI-DrugBank.d485.s28	9	41	nonhormonal contraceptive product	group	DDI-DrugBank.d485.s28.e0
DDI-DrugBank.d485.s29|a|No data for delavirdine;
DDI-DrugBank.d485.s29	12	22	delavirdine	drug	DDI-DrugBank.d485.s29.e0
DDI-DrugBank.d485.s30|a|incomplete data for efavirenz.
DDI-DrugBank.d485.s30	20	28	efavirenz	drug	DDI-DrugBank.d485.s30.e0
DDI-DrugBank.d485.s31|a|Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.
DDI-DrugBank.d485.s31	0	11	Prednisolone	drug	DDI-DrugBank.d485.s31.e0
DDI-DrugBank.d485.s31	14	30	Ethinyl estradiol	drug	DDI-DrugBank.d485.s31.e1
DDI-DrugBank.d485.s31	62	73	prednisolone	drug	DDI-DrugBank.d485.s31.e2
DDI-DrugBank.d485.s31	false	DDI-DrugBank.d485.s31.e0	DDI-DrugBank.d485.s31.e1
DDI-DrugBank.d485.s31	false	DDI-DrugBank.d485.s31.e0	DDI-DrugBank.d485.s31.e2
DDI-DrugBank.d485.s31	true	DDI-DrugBank.d485.s31.e1	DDI-DrugBank.d485.s31.e2
DDI-DrugBank.d485.s32|a|Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
DDI-DrugBank.d485.s32	0	18	Protease inhibitors	group	DDI-DrugBank.d485.s32.e0
DDI-DrugBank.d485.s32	21	30	Amprenavir	drug	DDI-DrugBank.d485.s32.e1
DDI-DrugBank.d485.s32	33	41	lopinavir	drug	DDI-DrugBank.d485.s32.e2
DDI-DrugBank.d485.s32	44	53	nelfinavir	drug	DDI-DrugBank.d485.s32.e3
DDI-DrugBank.d485.s32	60	68	ritonavir	drug	DDI-DrugBank.d485.s32.e4
DDI-DrugBank.d485.s32	115	149	combination hormonal contraceptives	group	DDI-DrugBank.d485.s32.e5
DDI-DrugBank.d485.s32	false	DDI-DrugBank.d485.s32.e0	DDI-DrugBank.d485.s32.e1
DDI-DrugBank.d485.s32	false	DDI-DrugBank.d485.s32.e0	DDI-DrugBank.d485.s32.e2
DDI-DrugBank.d485.s32	false	DDI-DrugBank.d485.s32.e0	DDI-DrugBank.d485.s32.e3
DDI-DrugBank.d485.s32	false	DDI-DrugBank.d485.s32.e0	DDI-DrugBank.d485.s32.e4
DDI-DrugBank.d485.s32	false	DDI-DrugBank.d485.s32.e0	DDI-DrugBank.d485.s32.e5
DDI-DrugBank.d485.s32	false	DDI-DrugBank.d485.s32.e1	DDI-DrugBank.d485.s32.e2
DDI-DrugBank.d485.s32	false	DDI-DrugBank.d485.s32.e1	DDI-DrugBank.d485.s32.e3
DDI-DrugBank.d485.s32	false	DDI-DrugBank.d485.s32.e1	DDI-DrugBank.d485.s32.e4
DDI-DrugBank.d485.s32	true	DDI-DrugBank.d485.s32.e1	DDI-DrugBank.d485.s32.e5
DDI-DrugBank.d485.s32	false	DDI-DrugBank.d485.s32.e2	DDI-DrugBank.d485.s32.e3
DDI-DrugBank.d485.s33|a|use of a nonhormonal contraceptive product is recommended.
DDI-DrugBank.d485.s33	9	41	nonhormonal contraceptive product	group	DDI-DrugBank.d485.s33.e0
DDI-DrugBank.d485.s34|a|Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.
DDI-DrugBank.d485.s34	0	8	Indinavir	drug	DDI-DrugBank.d485.s34.e0
DDI-DrugBank.d485.s34	54	88	combination hormonal contraceptives	group	DDI-DrugBank.d485.s34.e1
DDI-DrugBank.d485.s34	true	DDI-DrugBank.d485.s34.e0	DDI-DrugBank.d485.s34.e1
DDI-DrugBank.d485.s35|a|No data for saquinavir.
DDI-DrugBank.d485.s35	12	21	saquinavir	drug	DDI-DrugBank.d485.s35.e0
DDI-DrugBank.d485.s36|a|Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
DDI-DrugBank.d485.s36	0	7	Rifampin	drug	DDI-DrugBank.d485.s36.e0
DDI-DrugBank.d485.s36	10	17	Rifampin	drug	DDI-DrugBank.d485.s36.e1
DDI-DrugBank.d485.s36	47	63	ethinyl estradiol	drug	DDI-DrugBank.d485.s36.e2
DDI-DrugBank.d485.s36	74	83	progestins	group	DDI-DrugBank.d485.s36.e3
DDI-DrugBank.d485.s36	86	98	norethindrone	drug	DDI-DrugBank.d485.s36.e4
DDI-DrugBank.d485.s36	false	DDI-DrugBank.d485.s36.e0	DDI-DrugBank.d485.s36.e1
DDI-DrugBank.d485.s36	false	DDI-DrugBank.d485.s36.e0	DDI-DrugBank.d485.s36.e2
DDI-DrugBank.d485.s36	false	DDI-DrugBank.d485.s36.e0	DDI-DrugBank.d485.s36.e3
DDI-DrugBank.d485.s36	false	DDI-DrugBank.d485.s36.e0	DDI-DrugBank.d485.s36.e4
DDI-DrugBank.d485.s36	true	DDI-DrugBank.d485.s36.e1	DDI-DrugBank.d485.s36.e2
DDI-DrugBank.d485.s36	true	DDI-DrugBank.d485.s36.e1	DDI-DrugBank.d485.s36.e3
DDI-DrugBank.d485.s36	true	DDI-DrugBank.d485.s36.e1	DDI-DrugBank.d485.s36.e4
DDI-DrugBank.d485.s36	false	DDI-DrugBank.d485.s36.e2	DDI-DrugBank.d485.s36.e3
DDI-DrugBank.d485.s36	false	DDI-DrugBank.d485.s36.e2	DDI-DrugBank.d485.s36.e4
DDI-DrugBank.d485.s36	false	DDI-DrugBank.d485.s36.e3	DDI-DrugBank.d485.s36.e4
DDI-DrugBank.d485.s37|a|Use of a nonhormonal contraceptive product is recommended.
DDI-DrugBank.d485.s37	9	41	nonhormonal contraceptive product	group	DDI-DrugBank.d485.s37.e0
DDI-DrugBank.d485.s38|a|Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.
DDI-DrugBank.d485.s38	0	13	Salicylic acid	drug	DDI-DrugBank.d485.s38.e0
DDI-DrugBank.d485.s38	28	50	hormonal contraceptives	group	DDI-DrugBank.d485.s38.e1
DDI-DrugBank.d485.s38	82	95	salicylic acid	drug	DDI-DrugBank.d485.s38.e2
DDI-DrugBank.d485.s38	false	DDI-DrugBank.d485.s38.e0	DDI-DrugBank.d485.s38.e1
DDI-DrugBank.d485.s38	false	DDI-DrugBank.d485.s38.e0	DDI-DrugBank.d485.s38.e2
DDI-DrugBank.d485.s38	true	DDI-DrugBank.d485.s38.e1	DDI-DrugBank.d485.s38.e2
DDI-DrugBank.d485.s39|a|Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.
DDI-DrugBank.d485.s39	0	9	Selegiline	drug	DDI-DrugBank.d485.s39.e0
DDI-DrugBank.d485.s39	12	46	Combination hormonal contraceptives	group	DDI-DrugBank.d485.s39.e1
DDI-DrugBank.d485.s39	88	97	selegiline	drug	DDI-DrugBank.d485.s39.e2
DDI-DrugBank.d485.s39	false	DDI-DrugBank.d485.s39.e0	DDI-DrugBank.d485.s39.e1
DDI-DrugBank.d485.s39	false	DDI-DrugBank.d485.s39.e0	DDI-DrugBank.d485.s39.e2
DDI-DrugBank.d485.s39	true	DDI-DrugBank.d485.s39.e1	DDI-DrugBank.d485.s39.e2
DDI-DrugBank.d485.s40|a|Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.
DDI-DrugBank.d485.s40	0	11	Theophylline	drug	DDI-DrugBank.d485.s40.e0
DDI-DrugBank.d485.s40	14	30	Ethinyl estradiol	drug	DDI-DrugBank.d485.s40.e1
DDI-DrugBank.d485.s40	62	73	theophylline	drug	DDI-DrugBank.d485.s40.e2
DDI-DrugBank.d485.s40	false	DDI-DrugBank.d485.s40.e0	DDI-DrugBank.d485.s40.e1
DDI-DrugBank.d485.s40	false	DDI-DrugBank.d485.s40.e0	DDI-DrugBank.d485.s40.e2
DDI-DrugBank.d485.s40	true	DDI-DrugBank.d485.s40.e1	DDI-DrugBank.d485.s40.e2
DDI-DrugBank.d485.s41|a|Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
DDI-DrugBank.d485.s41	0	24	Tricyclic antidepressants	group	DDI-DrugBank.d485.s41.e0
DDI-DrugBank.d485.s41	27	39	amitriptyline	drug	DDI-DrugBank.d485.s41.e1
DDI-DrugBank.d485.s41	42	51	imipramine	drug	DDI-DrugBank.d485.s41.e2
DDI-DrugBank.d485.s41	54	66	nortriptyline	drug	DDI-DrugBank.d485.s41.e3
DDI-DrugBank.d485.s41	101	135	combination hormonal contraceptives	group	DDI-DrugBank.d485.s41.e4
DDI-DrugBank.d485.s41	166	179	antidepressant	group	DDI-DrugBank.d485.s41.e5
DDI-DrugBank.d485.s41	false	DDI-DrugBank.d485.s41.e0	DDI-DrugBank.d485.s41.e1
DDI-DrugBank.d485.s41	false	DDI-DrugBank.d485.s41.e0	DDI-DrugBank.d485.s41.e2
DDI-DrugBank.d485.s41	false	DDI-DrugBank.d485.s41.e0	DDI-DrugBank.d485.s41.e3
DDI-DrugBank.d485.s41	true	DDI-DrugBank.d485.s41.e0	DDI-DrugBank.d485.s41.e4
DDI-DrugBank.d485.s41	false	DDI-DrugBank.d485.s41.e0	DDI-DrugBank.d485.s41.e5
DDI-DrugBank.d485.s41	false	DDI-DrugBank.d485.s41.e1	DDI-DrugBank.d485.s41.e2
DDI-DrugBank.d485.s41	false	DDI-DrugBank.d485.s41.e1	DDI-DrugBank.d485.s41.e3
DDI-DrugBank.d485.s41	true	DDI-DrugBank.d485.s41.e1	DDI-DrugBank.d485.s41.e4
DDI-DrugBank.d485.s41	false	DDI-DrugBank.d485.s41.e1	DDI-DrugBank.d485.s41.e5
DDI-DrugBank.d485.s41	false	DDI-DrugBank.d485.s41.e2	DDI-DrugBank.d485.s41.e3
DDI-DrugBank.d485.s42|a|use caution.
DDI-DrugBank.d485.s43|a|ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.
DDI-DrugBank.d485.s43	0	6	ETHANOL	drug	DDI-DrugBank.d485.s43.e0
DDI-DrugBank.d485.s43	62	69	caffeine	drug	DDI-DrugBank.d485.s43.e1
DDI-DrugBank.d485.s43	90	124	combination hormonal contraceptives	group	DDI-DrugBank.d485.s43.e2
DDI-DrugBank.d485.s43	153	160	caffeine	drug	DDI-DrugBank.d485.s43.e3
DDI-DrugBank.d485.s43	false	DDI-DrugBank.d485.s43.e0	DDI-DrugBank.d485.s43.e1
DDI-DrugBank.d485.s43	false	DDI-DrugBank.d485.s43.e0	DDI-DrugBank.d485.s43.e2
DDI-DrugBank.d485.s43	false	DDI-DrugBank.d485.s43.e0	DDI-DrugBank.d485.s43.e3
DDI-DrugBank.d485.s43	false	DDI-DrugBank.d485.s43.e1	DDI-DrugBank.d485.s43.e2
DDI-DrugBank.d485.s43	false	DDI-DrugBank.d485.s43.e1	DDI-DrugBank.d485.s43.e3
DDI-DrugBank.d485.s43	true	DDI-DrugBank.d485.s43.e2	DDI-DrugBank.d485.s43.e3
DDI-DrugBank.d485.s44|a|Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well;
DDI-DrugBank.d485.s44	27	43	ethinyl estradiol	drug	DDI-DrugBank.d485.s44.e0
DDI-DrugBank.d485.s44	94	105	progesterone	drug	DDI-DrugBank.d485.s44.e1
DDI-DrugBank.d485.s44	false	DDI-DrugBank.d485.s44.e0	DDI-DrugBank.d485.s44.e1
DDI-DrugBank.d485.s45|a|clinical implications are unclear.
DDI-DrugBank.d485.s46|a|Herb/Nutraceutical: St Johns wort may decrease the effectiveness of combination hormonal contraceptives by inducing hepatic enzymes.
DDI-DrugBank.d485.s46	68	102	combination hormonal contraceptives	group	DDI-DrugBank.d485.s46.e0
DDI-DrugBank.d485.s47|a|Avoid dong quai and black cohosh (have estrogen activity).
DDI-DrugBank.d485.s48|a|Avoid saw palmetto, red clover, ginseng.
DDI-DrugBank.d327.s0|a|There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.
DDI-DrugBank.d327.s0	100	109	etidronate	drug	DDI-DrugBank.d327.s0.e0
DDI-DrugBank.d327.s0	124	131	warfarin	drug	DDI-DrugBank.d327.s0.e1
DDI-DrugBank.d327.s0	true	DDI-DrugBank.d327.s0.e0	DDI-DrugBank.d327.s0.e1
DDI-DrugBank.d327.s1|a|The majority of these reports concerned variable elevations in prothrombin times without clinically significant sequelae.
DDI-DrugBank.d327.s2|a|Although the relevance of these reports and any mechanism of coagulation alterations is unclear, patients on warfarin should have their prothrombin time monitored.
DDI-DrugBank.d327.s2	109	116	warfarin	drug	DDI-DrugBank.d327.s2.e0
DDI-DrugBank.d219.s0|a|ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
DDI-DrugBank.d219.s0	0	13	ACE-inhibitors	group	DDI-DrugBank.d219.s0.e0
DDI-DrugBank.d219.s0	36	41	NSAIDs	group	DDI-DrugBank.d219.s0.e1
DDI-DrugBank.d219.s0	87	100	ACE-inhibitors	group	DDI-DrugBank.d219.s0.e2
DDI-DrugBank.d219.s0	false	DDI-DrugBank.d219.s0.e0	DDI-DrugBank.d219.s0.e1
DDI-DrugBank.d219.s0	false	DDI-DrugBank.d219.s0.e0	DDI-DrugBank.d219.s0.e2
DDI-DrugBank.d219.s0	true	DDI-DrugBank.d219.s0.e1	DDI-DrugBank.d219.s0.e2
DDI-DrugBank.d219.s1|a|This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
DDI-DrugBank.d219.s1	66	71	NSAIDs	group	DDI-DrugBank.d219.s1.e0
DDI-DrugBank.d219.s1	92	105	ACE-inhibitors	group	DDI-DrugBank.d219.s1.e1
DDI-DrugBank.d219.s1	true	DDI-DrugBank.d219.s1.e0	DDI-DrugBank.d219.s1.e1
DDI-DrugBank.d219.s2|a|Antacids: The concomitant administration of antacids has no apparent effect on the extent of absorption of Lodine.
DDI-DrugBank.d219.s2	0	7	Antacids	group	DDI-DrugBank.d219.s2.e0
DDI-DrugBank.d219.s2	44	51	antacids	group	DDI-DrugBank.d219.s2.e1
DDI-DrugBank.d219.s2	107	112	Lodine	brand	DDI-DrugBank.d219.s2.e2
DDI-DrugBank.d219.s2	false	DDI-DrugBank.d219.s2.e0	DDI-DrugBank.d219.s2.e1
DDI-DrugBank.d219.s2	false	DDI-DrugBank.d219.s2.e0	DDI-DrugBank.d219.s2.e2
DDI-DrugBank.d219.s2	false	DDI-DrugBank.d219.s2.e1	DDI-DrugBank.d219.s2.e2
DDI-DrugBank.d219.s3|a|However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak.
DDI-DrugBank.d219.s3	9	16	antacids	group	DDI-DrugBank.d219.s3.e0
DDI-DrugBank.d219.s4|a|Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.
DDI-DrugBank.d219.s4	0	6	Aspirin	brand	DDI-DrugBank.d219.s4.e0
DDI-DrugBank.d219.s4	14	19	Lodine	brand	DDI-DrugBank.d219.s4.e1
DDI-DrugBank.d219.s4	42	48	aspirin	brand	DDI-DrugBank.d219.s4.e2
DDI-DrugBank.d219.s4	114	121	etodolac	drug	DDI-DrugBank.d219.s4.e3
DDI-DrugBank.d219.s4	false	DDI-DrugBank.d219.s4.e0	DDI-DrugBank.d219.s4.e1
DDI-DrugBank.d219.s4	false	DDI-DrugBank.d219.s4.e0	DDI-DrugBank.d219.s4.e2
DDI-DrugBank.d219.s4	false	DDI-DrugBank.d219.s4.e0	DDI-DrugBank.d219.s4.e3
DDI-DrugBank.d219.s4	true	DDI-DrugBank.d219.s4.e1	DDI-DrugBank.d219.s4.e2
DDI-DrugBank.d219.s4	false	DDI-DrugBank.d219.s4.e1	DDI-DrugBank.d219.s4.e3
DDI-DrugBank.d219.s4	false	DDI-DrugBank.d219.s4.e2	DDI-DrugBank.d219.s4.e3
DDI-DrugBank.d219.s5|a|The clinical significance of this interaction is not known;
DDI-DrugBank.d219.s6|a|however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.
DDI-DrugBank.d219.s6	23	28	NSAIDs	group	DDI-DrugBank.d219.s6.e0
DDI-DrugBank.d219.s6	61	66	Lodine	brand	DDI-DrugBank.d219.s6.e1
DDI-DrugBank.d219.s6	72	78	aspirin	brand	DDI-DrugBank.d219.s6.e2
DDI-DrugBank.d219.s6	false	DDI-DrugBank.d219.s6.e0	DDI-DrugBank.d219.s6.e1
DDI-DrugBank.d219.s6	false	DDI-DrugBank.d219.s6.e0	DDI-DrugBank.d219.s6.e2
DDI-DrugBank.d219.s6	true	DDI-DrugBank.d219.s6.e1	DDI-DrugBank.d219.s6.e2
DDI-DrugBank.d219.s7|a|Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
DDI-DrugBank.d219.s7	36	41	Lodine	brand	DDI-DrugBank.d219.s7.e0
DDI-DrugBank.d219.s7	55	60	NSAIDs	group	DDI-DrugBank.d219.s7.e1
DDI-DrugBank.d219.s7	192	203	cyclosporine	drug	DDI-DrugBank.d219.s7.e2
DDI-DrugBank.d219.s7	206	212	digoxin	drug	DDI-DrugBank.d219.s7.e3
DDI-DrugBank.d219.s7	215	226	methotrexate	drug	DDI-DrugBank.d219.s7.e4
DDI-DrugBank.d219.s7	false	DDI-DrugBank.d219.s7.e0	DDI-DrugBank.d219.s7.e1
DDI-DrugBank.d219.s7	true	DDI-DrugBank.d219.s7.e0	DDI-DrugBank.d219.s7.e2
DDI-DrugBank.d219.s7	true	DDI-DrugBank.d219.s7.e0	DDI-DrugBank.d219.s7.e3
DDI-DrugBank.d219.s7	true	DDI-DrugBank.d219.s7.e0	DDI-DrugBank.d219.s7.e4
DDI-DrugBank.d219.s7	true	DDI-DrugBank.d219.s7.e1	DDI-DrugBank.d219.s7.e2
DDI-DrugBank.d219.s7	true	DDI-DrugBank.d219.s7.e1	DDI-DrugBank.d219.s7.e3
DDI-DrugBank.d219.s7	true	DDI-DrugBank.d219.s7.e1	DDI-DrugBank.d219.s7.e4
DDI-DrugBank.d219.s7	false	DDI-DrugBank.d219.s7.e2	DDI-DrugBank.d219.s7.e3
DDI-DrugBank.d219.s7	false	DDI-DrugBank.d219.s7.e2	DDI-DrugBank.d219.s7.e4
DDI-DrugBank.d219.s7	false	DDI-DrugBank.d219.s7.e3	DDI-DrugBank.d219.s7.e4
DDI-DrugBank.d219.s8|a|Nephrotoxicity associated with cyclosporine may also be enhanced.
DDI-DrugBank.d219.s8	31	42	cyclosporine	drug	DDI-DrugBank.d219.s8.e0
DDI-DrugBank.d219.s9|a|Patients receiving these drugs who are given Lodine, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs.
DDI-DrugBank.d219.s9	45	50	Lodine	brand	DDI-DrugBank.d219.s9.e0
DDI-DrugBank.d219.s9	66	70	NSAID	group	DDI-DrugBank.d219.s9.e1
DDI-DrugBank.d219.s9	false	DDI-DrugBank.d219.s9.e0	DDI-DrugBank.d219.s9.e1
DDI-DrugBank.d219.s10|a|Diuretics: Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or hydrochlorothiazide.
DDI-DrugBank.d219.s10	0	8	Diuretics	group	DDI-DrugBank.d219.s10.e0
DDI-DrugBank.d219.s10	87	96	furosemide	drug	DDI-DrugBank.d219.s10.e1
DDI-DrugBank.d219.s10	101	119	hydrochlorothiazide	drug	DDI-DrugBank.d219.s10.e2
DDI-DrugBank.d219.s10	false	DDI-DrugBank.d219.s10.e0	DDI-DrugBank.d219.s10.e1
DDI-DrugBank.d219.s10	false	DDI-DrugBank.d219.s10.e0	DDI-DrugBank.d219.s10.e2
DDI-DrugBank.d219.s10	false	DDI-DrugBank.d219.s10.e1	DDI-DrugBank.d219.s10.e2
DDI-DrugBank.d219.s11|a|Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d219.s11	86	91	Lodine	brand	DDI-DrugBank.d219.s11.e0
DDI-DrugBank.d219.s11	130	139	furosemide	drug	DDI-DrugBank.d219.s11.e1
DDI-DrugBank.d219.s11	145	153	thiazides	group	DDI-DrugBank.d219.s11.e2
DDI-DrugBank.d219.s11	true	DDI-DrugBank.d219.s11.e0	DDI-DrugBank.d219.s11.e1
DDI-DrugBank.d219.s11	true	DDI-DrugBank.d219.s11.e0	DDI-DrugBank.d219.s11.e2
DDI-DrugBank.d219.s11	false	DDI-DrugBank.d219.s11.e1	DDI-DrugBank.d219.s11.e2
DDI-DrugBank.d219.s12|a|This response has been attributed to inhibition of renal prostaglandin synthesis.
DDI-DrugBank.d219.s13|a|During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
DDI-DrugBank.d219.s13	32	37	NSAIDs	group	DDI-DrugBank.d219.s13.e0
DDI-DrugBank.d219.s14|a|Glyburide: Etodolac has no apparent pharmacokinetic interaction when administered with glyburide.
DDI-DrugBank.d219.s14	0	8	Glyburide	drug	DDI-DrugBank.d219.s14.e0
DDI-DrugBank.d219.s14	11	18	Etodolac	drug	DDI-DrugBank.d219.s14.e1
DDI-DrugBank.d219.s14	87	95	glyburide	drug	DDI-DrugBank.d219.s14.e2
DDI-DrugBank.d219.s14	false	DDI-DrugBank.d219.s14.e0	DDI-DrugBank.d219.s14.e1
DDI-DrugBank.d219.s14	false	DDI-DrugBank.d219.s14.e0	DDI-DrugBank.d219.s14.e2
DDI-DrugBank.d219.s14	false	DDI-DrugBank.d219.s14.e1	DDI-DrugBank.d219.s14.e2
DDI-DrugBank.d219.s15|a|Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
DDI-DrugBank.d219.s15	0	6	Lithium	drug	DDI-DrugBank.d219.s15.e0
DDI-DrugBank.d219.s15	9	14	NSAIDs	group	DDI-DrugBank.d219.s15.e1
DDI-DrugBank.d219.s15	53	59	lithium	drug	DDI-DrugBank.d219.s15.e2
DDI-DrugBank.d219.s15	93	99	lithium	drug	DDI-DrugBank.d219.s15.e3
DDI-DrugBank.d219.s15	false	DDI-DrugBank.d219.s15.e0	DDI-DrugBank.d219.s15.e1
DDI-DrugBank.d219.s15	false	DDI-DrugBank.d219.s15.e0	DDI-DrugBank.d219.s15.e2
DDI-DrugBank.d219.s15	false	DDI-DrugBank.d219.s15.e0	DDI-DrugBank.d219.s15.e3
DDI-DrugBank.d219.s15	true	DDI-DrugBank.d219.s15.e1	DDI-DrugBank.d219.s15.e2
DDI-DrugBank.d219.s15	false	DDI-DrugBank.d219.s15.e1	DDI-DrugBank.d219.s15.e3
DDI-DrugBank.d219.s15	false	DDI-DrugBank.d219.s15.e2	DDI-DrugBank.d219.s15.e3
DDI-DrugBank.d219.s16|a|The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%.
DDI-DrugBank.d219.s16	17	23	lithium	drug	DDI-DrugBank.d219.s16.e0
DDI-DrugBank.d219.s17|a|These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID.
DDI-DrugBank.d219.s17	89	93	NSAID	group	DDI-DrugBank.d219.s17.e0
DDI-DrugBank.d219.s18|a|Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DDI-DrugBank.d219.s18	11	16	NSAIDs	group	DDI-DrugBank.d219.s18.e0
DDI-DrugBank.d219.s18	22	28	lithium	drug	DDI-DrugBank.d219.s18.e1
DDI-DrugBank.d219.s18	112	118	lithium	drug	DDI-DrugBank.d219.s18.e2
DDI-DrugBank.d219.s18	true	DDI-DrugBank.d219.s18.e0	DDI-DrugBank.d219.s18.e1
DDI-DrugBank.d219.s18	false	DDI-DrugBank.d219.s18.e0	DDI-DrugBank.d219.s18.e2
DDI-DrugBank.d219.s18	false	DDI-DrugBank.d219.s18.e1	DDI-DrugBank.d219.s18.e2
DDI-DrugBank.d219.s19|a|Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.
DDI-DrugBank.d219.s19	0	13	Phenylbutazone	drug	DDI-DrugBank.d219.s19.e0
DDI-DrugBank.d219.s19	16	29	Phenylbutazone	drug	DDI-DrugBank.d219.s19.e1
DDI-DrugBank.d219.s19	86	93	etodolac	drug	DDI-DrugBank.d219.s19.e2
DDI-DrugBank.d219.s19	false	DDI-DrugBank.d219.s19.e0	DDI-DrugBank.d219.s19.e1
DDI-DrugBank.d219.s19	false	DDI-DrugBank.d219.s19.e0	DDI-DrugBank.d219.s19.e2
DDI-DrugBank.d219.s19	true	DDI-DrugBank.d219.s19.e1	DDI-DrugBank.d219.s19.e2
DDI-DrugBank.d219.s20|a|Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.
DDI-DrugBank.d219.s20	54	61	etodolac	drug	DDI-DrugBank.d219.s20.e0
DDI-DrugBank.d219.s20	107	120	phenylbutazone	drug	DDI-DrugBank.d219.s20.e1
DDI-DrugBank.d219.s20	true	DDI-DrugBank.d219.s20.e0	DDI-DrugBank.d219.s20.e1
DDI-DrugBank.d219.s21|a|Phenytoin: Etodolac has no apparent pharmacokinetic interaction when administered with phenytoin.
DDI-DrugBank.d219.s21	0	8	Phenytoin	drug	DDI-DrugBank.d219.s21.e0
DDI-DrugBank.d219.s21	11	18	Etodolac	drug	DDI-DrugBank.d219.s21.e1
DDI-DrugBank.d219.s21	87	95	phenytoin	drug	DDI-DrugBank.d219.s21.e2
DDI-DrugBank.d219.s21	false	DDI-DrugBank.d219.s21.e0	DDI-DrugBank.d219.s21.e1
DDI-DrugBank.d219.s21	false	DDI-DrugBank.d219.s21.e0	DDI-DrugBank.d219.s21.e2
DDI-DrugBank.d219.s21	false	DDI-DrugBank.d219.s21.e1	DDI-DrugBank.d219.s21.e2
DDI-DrugBank.d219.s22|a|Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.
DDI-DrugBank.d219.s22	0	7	Warfarin	drug	DDI-DrugBank.d219.s22.e0
DDI-DrugBank.d219.s22	25	32	warfarin	drug	DDI-DrugBank.d219.s22.e1
DDI-DrugBank.d219.s22	38	43	NSAIDs	group	DDI-DrugBank.d219.s22.e2
DDI-DrugBank.d219.s22	false	DDI-DrugBank.d219.s22.e0	DDI-DrugBank.d219.s22.e1
DDI-DrugBank.d219.s22	false	DDI-DrugBank.d219.s22.e0	DDI-DrugBank.d219.s22.e2
DDI-DrugBank.d219.s22	true	DDI-DrugBank.d219.s22.e1	DDI-DrugBank.d219.s22.e2
DDI-DrugBank.d219.s23|a|Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.
DDI-DrugBank.d219.s23	88	95	warfarin	drug	DDI-DrugBank.d219.s23.e0
DDI-DrugBank.d219.s23	101	106	Lodine	brand	DDI-DrugBank.d219.s23.e1
DDI-DrugBank.d219.s23	110	117	etodolac	drug	DDI-DrugBank.d219.s23.e2
DDI-DrugBank.d219.s23	179	186	warfarin	drug	DDI-DrugBank.d219.s23.e3
DDI-DrugBank.d219.s23	238	245	warfarin	drug	DDI-DrugBank.d219.s23.e4
DDI-DrugBank.d219.s23	true	DDI-DrugBank.d219.s23.e0	DDI-DrugBank.d219.s23.e1
DDI-DrugBank.d219.s23	true	DDI-DrugBank.d219.s23.e0	DDI-DrugBank.d219.s23.e2
DDI-DrugBank.d219.s23	false	DDI-DrugBank.d219.s23.e0	DDI-DrugBank.d219.s23.e3
DDI-DrugBank.d219.s23	false	DDI-DrugBank.d219.s23.e0	DDI-DrugBank.d219.s23.e4
DDI-DrugBank.d219.s23	false	DDI-DrugBank.d219.s23.e1	DDI-DrugBank.d219.s23.e2
DDI-DrugBank.d219.s23	false	DDI-DrugBank.d219.s23.e1	DDI-DrugBank.d219.s23.e3
DDI-DrugBank.d219.s23	false	DDI-DrugBank.d219.s23.e1	DDI-DrugBank.d219.s23.e4
DDI-DrugBank.d219.s23	false	DDI-DrugBank.d219.s23.e2	DDI-DrugBank.d219.s23.e3
DDI-DrugBank.d219.s23	false	DDI-DrugBank.d219.s23.e2	DDI-DrugBank.d219.s23.e4
DDI-DrugBank.d219.s23	false	DDI-DrugBank.d219.s23.e3	DDI-DrugBank.d219.s23.e4
DDI-DrugBank.d219.s24|a|There was no significant difference in the pharmacodynamic effect of warfarin administered alone and warfarin administered with Lodine as measured by prothrombin time.
DDI-DrugBank.d219.s24	69	76	warfarin	drug	DDI-DrugBank.d219.s24.e0
DDI-DrugBank.d219.s24	101	108	warfarin	drug	DDI-DrugBank.d219.s24.e1
DDI-DrugBank.d219.s24	128	133	Lodine	brand	DDI-DrugBank.d219.s24.e2
DDI-DrugBank.d219.s24	false	DDI-DrugBank.d219.s24.e0	DDI-DrugBank.d219.s24.e1
DDI-DrugBank.d219.s24	false	DDI-DrugBank.d219.s24.e0	DDI-DrugBank.d219.s24.e2
DDI-DrugBank.d219.s24	false	DDI-DrugBank.d219.s24.e1	DDI-DrugBank.d219.s24.e2
DDI-DrugBank.d219.s25|a|Thus, concomitant therapy with warfarin and Lodine should not require dosage adjustment of either drug.
DDI-DrugBank.d219.s25	31	38	warfarin	drug	DDI-DrugBank.d219.s25.e0
DDI-DrugBank.d219.s25	44	49	Lodine	brand	DDI-DrugBank.d219.s25.e1
DDI-DrugBank.d219.s25	false	DDI-DrugBank.d219.s25.e0	DDI-DrugBank.d219.s25.e1
DDI-DrugBank.d219.s26|a|However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.
DDI-DrugBank.d219.s26	148	155	etodolac	drug	DDI-DrugBank.d219.s26.e0
DDI-DrugBank.d219.s26	196	203	warfarin	drug	DDI-DrugBank.d219.s26.e1
DDI-DrugBank.d219.s26	true	DDI-DrugBank.d219.s26.e0	DDI-DrugBank.d219.s26.e1
DDI-DrugBank.d219.s27|a|Drug/Laboratory Test Interactions The urine of patients who take Lodine can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of etodolac.
DDI-DrugBank.d219.s27	65	70	Lodine	brand	DDI-DrugBank.d219.s27.e0
DDI-DrugBank.d219.s27	187	194	etodolac	drug	DDI-DrugBank.d219.s27.e1
DDI-DrugBank.d219.s27	false	DDI-DrugBank.d219.s27.e0	DDI-DrugBank.d219.s27.e1
DDI-DrugBank.d219.s28|a|Diagnostic dip-stick methodology, used to detect ketone bodies in urine, has resulted in false-positive findings in some patients treated with Lodine.
DDI-DrugBank.d219.s28	143	148	Lodine	brand	DDI-DrugBank.d219.s28.e0
DDI-DrugBank.d219.s29|a|Generally, this phenomenon has not been associated with other clinically significant events.
DDI-DrugBank.d219.s30|a|No dose relationship has been observed.
DDI-DrugBank.d219.s31|a|Lodine treatment is associated with a small decrease in serum uric acid levels.
DDI-DrugBank.d219.s31	0	5	Lodine	brand	DDI-DrugBank.d219.s31.e0
DDI-DrugBank.d219.s32|a|In clinical trials, mean decreases of 1 to 2 mg/dL were observed in arthritic patients receiving etodolac (600 mg to 1000 mg/day) after 4 weeks of therapy.
DDI-DrugBank.d219.s32	97	104	etodolac	drug	DDI-DrugBank.d219.s32.e0
DDI-DrugBank.d219.s33|a|These levels then remained stable for up to 1 year of therapy.
DDI-DrugBank.d219.s34|a|
DDI-DrugBank.d119.s0|a|The following drug interactions have been reported with etomidate.
DDI-DrugBank.d119.s0	56	64	etomidate	drug	DDI-DrugBank.d119.s0.e0
DDI-DrugBank.d119.s1|a|Drug Effect
DDI-DrugBank.d119.s2|a|Probenecid    Prolonged action of etomidate
DDI-DrugBank.d119.s2	0	9	Probenecid	drug	DDI-DrugBank.d119.s2.e0
DDI-DrugBank.d119.s2	34	42	etomidate	drug	DDI-DrugBank.d119.s2.e1
DDI-DrugBank.d119.s2	false	DDI-DrugBank.d119.s2.e0	DDI-DrugBank.d119.s2.e1
DDI-DrugBank.d119.s3|a|Diazoxide    Hypotension
DDI-DrugBank.d119.s3	0	8	Diazoxide	drug	DDI-DrugBank.d119.s3.e0
DDI-DrugBank.d119.s4|a|Zimelidine    etomidate antagonism
DDI-DrugBank.d119.s4	0	9	Zimelidine	drug_n	DDI-DrugBank.d119.s4.e0
DDI-DrugBank.d119.s4	14	22	etomidate	drug	DDI-DrugBank.d119.s4.e1
DDI-DrugBank.d119.s4	false	DDI-DrugBank.d119.s4.e0	DDI-DrugBank.d119.s4.e1
DDI-DrugBank.d119.s5|a|Opioid analgesics    Decreased antinociceptive action
DDI-DrugBank.d119.s5	0	16	Opioid analgesics	group	DDI-DrugBank.d119.s5.e0
DDI-DrugBank.d119.s6|a|Aminophylline     Etomidate antagonism
DDI-DrugBank.d119.s6	0	12	Aminophylline	drug	DDI-DrugBank.d119.s6.e0
DDI-DrugBank.d119.s6	18	26	Etomidate	drug	DDI-DrugBank.d119.s6.e1
DDI-DrugBank.d119.s6	false	DDI-DrugBank.d119.s6.e0	DDI-DrugBank.d119.s6.e1
DDI-DrugBank.d119.s7|a|Midazolam    Synergism
DDI-DrugBank.d119.s7	0	8	Midazolam	drug	DDI-DrugBank.d119.s7.e0
DDI-DrugBank.d484.s0|a|Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0	0	11	Etonogestrel	drug	DDI-DrugBank.d484.s0.e0
DDI-DrugBank.d484.s0	58	70	acetaminophen	drug	DDI-DrugBank.d484.s0.e1
DDI-DrugBank.d484.s0	73	79	Tylenol	brand	DDI-DrugBank.d484.s0.e2
DDI-DrugBank.d484.s0	83	93	antibiotics	group	DDI-DrugBank.d484.s0.e3
DDI-DrugBank.d484.s0	103	112	ampicillin	drug	DDI-DrugBank.d484.s0.e4
DDI-DrugBank.d484.s0	118	129	tetracycline	drug	DDI-DrugBank.d484.s0.e5
DDI-DrugBank.d484.s0	132	146	anticonvulsants	group	DDI-DrugBank.d484.s0.e6
DDI-DrugBank.d484.s0	149	156	Dilantin	brand	DDI-DrugBank.d484.s0.e7
DDI-DrugBank.d484.s0	159	171	Phenobarbital	drug	DDI-DrugBank.d484.s0.e8
DDI-DrugBank.d484.s0	174	181	Tegretol	brand	DDI-DrugBank.d484.s0.e9
DDI-DrugBank.d484.s0	true	DDI-DrugBank.d484.s0.e0	DDI-DrugBank.d484.s0.e1
DDI-DrugBank.d484.s0	true	DDI-DrugBank.d484.s0.e0	DDI-DrugBank.d484.s0.e2
DDI-DrugBank.d484.s0	true	DDI-DrugBank.d484.s0.e0	DDI-DrugBank.d484.s0.e3
DDI-DrugBank.d484.s0	true	DDI-DrugBank.d484.s0.e0	DDI-DrugBank.d484.s0.e4
DDI-DrugBank.d484.s0	true	DDI-DrugBank.d484.s0.e0	DDI-DrugBank.d484.s0.e5
DDI-DrugBank.d484.s0	true	DDI-DrugBank.d484.s0.e0	DDI-DrugBank.d484.s0.e6
DDI-DrugBank.d484.s0	true	DDI-DrugBank.d484.s0.e0	DDI-DrugBank.d484.s0.e7
DDI-DrugBank.d484.s0	true	DDI-DrugBank.d484.s0.e0	DDI-DrugBank.d484.s0.e8
DDI-DrugBank.d484.s0	true	DDI-DrugBank.d484.s0.e0	DDI-DrugBank.d484.s0.e9
DDI-DrugBank.d484.s0	true	DDI-DrugBank.d484.s0.e0	DDI-DrugBank.d484.s0.e10
DDI-DrugBank.d194.s0|a|Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride).
DDI-DrugBank.d194.s0	47	55	ETOPOPHOS	brand	DDI-DrugBank.d194.s0.e0
DDI-DrugBank.d194.s0	124	147	levamisole hydrochloride	drug	DDI-DrugBank.d194.s0.e1
DDI-DrugBank.d194.s0	true	DDI-DrugBank.d194.s0.e0	DDI-DrugBank.d194.s0.e1
DDI-DrugBank.d194.s1|a|High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.
DDI-DrugBank.d194.s1	10	22	cyclosporin A	drug	DDI-DrugBank.d194.s1.e0
DDI-DrugBank.d194.s1	92	100	etoposide	drug	DDI-DrugBank.d194.s1.e1
DDI-DrugBank.d194.s1	132	140	etoposide	drug	DDI-DrugBank.d194.s1.e2
DDI-DrugBank.d194.s1	198	206	etoposide	drug	DDI-DrugBank.d194.s1.e3
DDI-DrugBank.d194.s1	220	228	etoposide	drug	DDI-DrugBank.d194.s1.e4
DDI-DrugBank.d194.s1	true	DDI-DrugBank.d194.s1.e0	DDI-DrugBank.d194.s1.e1
DDI-DrugBank.d194.s1	false	DDI-DrugBank.d194.s1.e0	DDI-DrugBank.d194.s1.e2
DDI-DrugBank.d194.s1	false	DDI-DrugBank.d194.s1.e0	DDI-DrugBank.d194.s1.e3
DDI-DrugBank.d194.s1	false	DDI-DrugBank.d194.s1.e0	DDI-DrugBank.d194.s1.e4
DDI-DrugBank.d194.s1	false	DDI-DrugBank.d194.s1.e1	DDI-DrugBank.d194.s1.e2
DDI-DrugBank.d194.s1	false	DDI-DrugBank.d194.s1.e1	DDI-DrugBank.d194.s1.e3
DDI-DrugBank.d194.s1	false	DDI-DrugBank.d194.s1.e1	DDI-DrugBank.d194.s1.e4
DDI-DrugBank.d194.s1	false	DDI-DrugBank.d194.s1.e2	DDI-DrugBank.d194.s1.e3
DDI-DrugBank.d194.s1	false	DDI-DrugBank.d194.s1.e2	DDI-DrugBank.d194.s1.e4
DDI-DrugBank.d194.s1	false	DDI-DrugBank.d194.s1.e3	DDI-DrugBank.d194.s1.e4
DDI-DrugBank.d435.s0|a|Exemestane is extensively metabolized by CYP 3A4, but coadministration of ketoconazole, a potent inhibitor of CYP 3A4, has no significant effect on exemestane pharmacokinetics.
DDI-DrugBank.d435.s0	0	9	Exemestane	drug	DDI-DrugBank.d435.s0.e0
DDI-DrugBank.d435.s0	74	85	ketoconazole	drug	DDI-DrugBank.d435.s0.e1
DDI-DrugBank.d435.s0	148	157	exemestane	drug	DDI-DrugBank.d435.s0.e2
DDI-DrugBank.d435.s0	false	DDI-DrugBank.d435.s0.e0	DDI-DrugBank.d435.s0.e1
DDI-DrugBank.d435.s0	false	DDI-DrugBank.d435.s0.e0	DDI-DrugBank.d435.s0.e2
DDI-DrugBank.d435.s0	false	DDI-DrugBank.d435.s0.e1	DDI-DrugBank.d435.s0.e2
DDI-DrugBank.d435.s1|a|Significant pharmacokinetic interactions mediated by inhibition of CYP isoenzymes therefore appear unlikely.
DDI-DrugBank.d435.s2|a|Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
DDI-DrugBank.d435.s2	42	51	rifampicin	drug	DDI-DrugBank.d435.s2.e0
DDI-DrugBank.d435.s2	54	62	phenytoin	drug	DDI-DrugBank.d435.s2.e1
DDI-DrugBank.d435.s2	65	77	carbamazepine	drug	DDI-DrugBank.d435.s2.e2
DDI-DrugBank.d435.s2	80	92	phenobarbital	drug	DDI-DrugBank.d435.s2.e3
DDI-DrugBank.d435.s2	154	163	exemestane	drug	DDI-DrugBank.d435.s2.e4
DDI-DrugBank.d435.s2	false	DDI-DrugBank.d435.s2.e0	DDI-DrugBank.d435.s2.e1
DDI-DrugBank.d435.s2	false	DDI-DrugBank.d435.s2.e0	DDI-DrugBank.d435.s2.e2
DDI-DrugBank.d435.s2	false	DDI-DrugBank.d435.s2.e0	DDI-DrugBank.d435.s2.e3
DDI-DrugBank.d435.s2	true	DDI-DrugBank.d435.s2.e0	DDI-DrugBank.d435.s2.e4
DDI-DrugBank.d435.s2	false	DDI-DrugBank.d435.s2.e1	DDI-DrugBank.d435.s2.e2
DDI-DrugBank.d435.s2	false	DDI-DrugBank.d435.s2.e1	DDI-DrugBank.d435.s2.e3
DDI-DrugBank.d435.s2	true	DDI-DrugBank.d435.s2.e1	DDI-DrugBank.d435.s2.e4
DDI-DrugBank.d435.s2	false	DDI-DrugBank.d435.s2.e2	DDI-DrugBank.d435.s2.e3
DDI-DrugBank.d435.s2	true	DDI-DrugBank.d435.s2.e2	DDI-DrugBank.d435.s2.e4
DDI-DrugBank.d435.s2	true	DDI-DrugBank.d435.s2.e3	DDI-DrugBank.d435.s2.e4
DDI-DrugBank.d435.s3|a|Dose modification is recommended for patients who are also receiving a potent CYP 3A4 inducer.
DDI-DrugBank.d435.s4|a|Drug/Laboratory Tests Interactions No clinically relevant changes in the results of clinical laboratory tests have been observed.
DDI-DrugBank.d112.s0|a|Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.
DDI-DrugBank.d112.s0	20	29	probenecid	drug	DDI-DrugBank.d112.s0.e0
DDI-DrugBank.d112.s0	154	164	penciclovir	drug	DDI-DrugBank.d112.s0.e1
DDI-DrugBank.d112.s0	true	DDI-DrugBank.d112.s0.e0	DDI-DrugBank.d112.s0.e1
DDI-DrugBank.d112.s1|a|The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase.
DDI-DrugBank.d112.s1	18	36	6-deoxy penciclovir	drug_n	DDI-DrugBank.d112.s1.e0
DDI-DrugBank.d112.s1	41	51	penciclovir	drug	DDI-DrugBank.d112.s1.e1
DDI-DrugBank.d112.s1	false	DDI-DrugBank.d112.s1.e0	DDI-DrugBank.d112.s1.e1
DDI-DrugBank.d112.s2|a|Interactions with other drugs metabolized by this enzyme could potentially occur.
DDI-DrugBank.d203.s0|a|No drug interactions have been identified.
DDI-DrugBank.d203.s1|a|Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system.
DDI-DrugBank.d203.s1	13	22	famotidine	drug	DDI-DrugBank.d203.s1.e0
DDI-DrugBank.d203.s2|a|Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.
DDI-DrugBank.d203.s2	32	39	warfarin	drug	DDI-DrugBank.d203.s2.e0
DDI-DrugBank.d203.s2	42	53	theophylline	drug	DDI-DrugBank.d203.s2.e1
DDI-DrugBank.d203.s2	56	64	phenytoin	drug	DDI-DrugBank.d203.s2.e2
DDI-DrugBank.d203.s2	67	74	diazepam	drug	DDI-DrugBank.d203.s2.e3
DDI-DrugBank.d203.s2	77	87	aminopyrine	drug	DDI-DrugBank.d203.s2.e4
DDI-DrugBank.d203.s2	93	102	antipyrine	drug	DDI-DrugBank.d203.s2.e5
DDI-DrugBank.d203.s2	false	DDI-DrugBank.d203.s2.e0	DDI-DrugBank.d203.s2.e1
DDI-DrugBank.d203.s2	false	DDI-DrugBank.d203.s2.e0	DDI-DrugBank.d203.s2.e2
DDI-DrugBank.d203.s2	false	DDI-DrugBank.d203.s2.e0	DDI-DrugBank.d203.s2.e3
DDI-DrugBank.d203.s2	false	DDI-DrugBank.d203.s2.e0	DDI-DrugBank.d203.s2.e4
DDI-DrugBank.d203.s2	false	DDI-DrugBank.d203.s2.e0	DDI-DrugBank.d203.s2.e5
DDI-DrugBank.d203.s2	false	DDI-DrugBank.d203.s2.e1	DDI-DrugBank.d203.s2.e2
DDI-DrugBank.d203.s2	false	DDI-DrugBank.d203.s2.e1	DDI-DrugBank.d203.s2.e3
DDI-DrugBank.d203.s2	false	DDI-DrugBank.d203.s2.e1	DDI-DrugBank.d203.s2.e4
DDI-DrugBank.d203.s2	false	DDI-DrugBank.d203.s2.e1	DDI-DrugBank.d203.s2.e5
DDI-DrugBank.d203.s2	false	DDI-DrugBank.d203.s2.e2	DDI-DrugBank.d203.s2.e3
DDI-DrugBank.d203.s3|a|Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.
DDI-DrugBank.d203.s3	0	16	Indocyanine green	drug_n	DDI-DrugBank.d203.s3.e0
DDI-DrugBank.d434.s0|a|The drug interaction data described in this section were obtained from controlled clinical trials and studies involving otherwise healthy adults with epilepsy.
DDI-DrugBank.d434.s1|a|Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
DDI-DrugBank.d434.s1	30	48	Antiepileptic Drugs	group	DDI-DrugBank.d434.s1.e0
DDI-DrugBank.d434.s1	67	74	Felbatol	brand	DDI-DrugBank.d434.s1.e1
DDI-DrugBank.d434.s1	80	98	antiepileptic drugs	group	DDI-DrugBank.d434.s1.e2
DDI-DrugBank.d434.s1	101	104	AEDs	group	DDI-DrugBank.d434.s1.e3
DDI-DrugBank.d434.s1	157	160	AEDs	group	DDI-DrugBank.d434.s1.e4
DDI-DrugBank.d434.s1	false	DDI-DrugBank.d434.s1.e0	DDI-DrugBank.d434.s1.e1
DDI-DrugBank.d434.s1	false	DDI-DrugBank.d434.s1.e0	DDI-DrugBank.d434.s1.e2
DDI-DrugBank.d434.s1	false	DDI-DrugBank.d434.s1.e0	DDI-DrugBank.d434.s1.e3
DDI-DrugBank.d434.s1	false	DDI-DrugBank.d434.s1.e0	DDI-DrugBank.d434.s1.e4
DDI-DrugBank.d434.s1	true	DDI-DrugBank.d434.s1.e1	DDI-DrugBank.d434.s1.e2
DDI-DrugBank.d434.s1	true	DDI-DrugBank.d434.s1.e1	DDI-DrugBank.d434.s1.e3
DDI-DrugBank.d434.s1	false	DDI-DrugBank.d434.s1.e1	DDI-DrugBank.d434.s1.e4
DDI-DrugBank.d434.s1	false	DDI-DrugBank.d434.s1.e2	DDI-DrugBank.d434.s1.e3
DDI-DrugBank.d434.s1	false	DDI-DrugBank.d434.s1.e2	DDI-DrugBank.d434.s1.e4
DDI-DrugBank.d434.s1	false	DDI-DrugBank.d434.s1.e3	DDI-DrugBank.d434.s1.e4
DDI-DrugBank.d434.s2|a|The net effect of these interactions is summarized in the following table: AED AED Felbatol
DDI-DrugBank.d434.s2	75	77	AED	group	DDI-DrugBank.d434.s2.e0
DDI-DrugBank.d434.s2	79	81	AED	group	DDI-DrugBank.d434.s2.e1
DDI-DrugBank.d434.s2	83	90	Felbatol	brand	DDI-DrugBank.d434.s2.e2
DDI-DrugBank.d434.s2	false	DDI-DrugBank.d434.s2.e0	DDI-DrugBank.d434.s2.e1
DDI-DrugBank.d434.s2	false	DDI-DrugBank.d434.s2.e0	DDI-DrugBank.d434.s2.e2
DDI-DrugBank.d434.s2	false	DDI-DrugBank.d434.s2.e1	DDI-DrugBank.d434.s2.e2
DDI-DrugBank.d434.s3|a|Coadministered Concentration Concentration
DDI-DrugBank.d434.s4|a|Phenytoin
DDI-DrugBank.d434.s4	0	8	Phenytoin	drug	DDI-DrugBank.d434.s4.e0
DDI-DrugBank.d434.s5|a|Valproate    **
DDI-DrugBank.d434.s5	0	8	Valproate	drug	DDI-DrugBank.d434.s5.e0
DDI-DrugBank.d434.s6|a|Carbamazepine (CBZ)
DDI-DrugBank.d434.s6	0	12	Carbamazepine	drug	DDI-DrugBank.d434.s6.e0
DDI-DrugBank.d434.s6	15	17	CBZ	drug	DDI-DrugBank.d434.s6.e1
DDI-DrugBank.d434.s6	false	DDI-DrugBank.d434.s6.e0	DDI-DrugBank.d434.s6.e1
DDI-DrugBank.d434.s7|a|*CBZ epoxide
DDI-DrugBank.d434.s8|a|Phenobarbital
DDI-DrugBank.d434.s8	0	12	Phenobarbital	drug	DDI-DrugBank.d434.s8.e0
DDI-DrugBank.d434.s9|a|*Not administered, but an active metabolite of carbamazepine.
DDI-DrugBank.d434.s9	47	59	carbamazepine	drug	DDI-DrugBank.d434.s9.e0
DDI-DrugBank.d434.s10|a|**No significant effect.
DDI-DrugBank.d434.s11|a|Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.
DDI-DrugBank.d434.s11	20	27	Felbatol	brand	DDI-DrugBank.d434.s11.e0
DDI-DrugBank.d434.s11	39	57	Antiepileptic Drugs	group	DDI-DrugBank.d434.s11.e1
DDI-DrugBank.d434.s11	59	67	Phenytoin	drug	DDI-DrugBank.d434.s11.e2
DDI-DrugBank.d434.s11	70	77	Felbatol	brand	DDI-DrugBank.d434.s11.e3
DDI-DrugBank.d434.s11	115	123	phenytoin	drug	DDI-DrugBank.d434.s11.e4
DDI-DrugBank.d434.s11	false	DDI-DrugBank.d434.s11.e0	DDI-DrugBank.d434.s11.e1
DDI-DrugBank.d434.s11	false	DDI-DrugBank.d434.s11.e0	DDI-DrugBank.d434.s11.e2
DDI-DrugBank.d434.s11	false	DDI-DrugBank.d434.s11.e0	DDI-DrugBank.d434.s11.e3
DDI-DrugBank.d434.s11	false	DDI-DrugBank.d434.s11.e0	DDI-DrugBank.d434.s11.e4
DDI-DrugBank.d434.s11	false	DDI-DrugBank.d434.s11.e1	DDI-DrugBank.d434.s11.e2
DDI-DrugBank.d434.s11	false	DDI-DrugBank.d434.s11.e1	DDI-DrugBank.d434.s11.e3
DDI-DrugBank.d434.s11	false	DDI-DrugBank.d434.s11.e1	DDI-DrugBank.d434.s11.e4
DDI-DrugBank.d434.s11	false	DDI-DrugBank.d434.s11.e2	DDI-DrugBank.d434.s11.e3
DDI-DrugBank.d434.s11	false	DDI-DrugBank.d434.s11.e2	DDI-DrugBank.d434.s11.e4
DDI-DrugBank.d434.s11	true	DDI-DrugBank.d434.s11.e3	DDI-DrugBank.d434.s11.e4
DDI-DrugBank.d434.s12|a|In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steadystate trough (Cmin) phenytoin plasma concentration was 17 5 micrograms/mL.
DDI-DrugBank.d434.s12	57	65	phenytoin	drug	DDI-DrugBank.d434.s12.e0
DDI-DrugBank.d434.s12	98	106	phenytoin	drug	DDI-DrugBank.d434.s12.e1
DDI-DrugBank.d434.s12	false	DDI-DrugBank.d434.s12.e0	DDI-DrugBank.d434.s12.e1
DDI-DrugBank.d434.s13|a|The steady-state Cmin increased to 21 5 micrograms/mL when 1200 mg/day of felbamate was coadministered.
DDI-DrugBank.d434.s13	74	82	felbamate	drug	DDI-DrugBank.d434.s13.e0
DDI-DrugBank.d434.s14|a|Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.
DDI-DrugBank.d434.s14	15	23	felbamate	drug	DDI-DrugBank.d434.s14.e0
DDI-DrugBank.d434.s14	97	105	phenytoin	drug	DDI-DrugBank.d434.s14.e1
DDI-DrugBank.d434.s14	true	DDI-DrugBank.d434.s14.e0	DDI-DrugBank.d434.s14.e1
DDI-DrugBank.d434.s15|a|In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.
DDI-DrugBank.d434.s15	21	29	phenytoin	drug	DDI-DrugBank.d434.s15.e0
DDI-DrugBank.d434.s15	82	90	felbamate	drug	DDI-DrugBank.d434.s15.e1
DDI-DrugBank.d434.s15	115	123	phenytoin	drug	DDI-DrugBank.d434.s15.e2
DDI-DrugBank.d434.s15	false	DDI-DrugBank.d434.s15.e0	DDI-DrugBank.d434.s15.e1
DDI-DrugBank.d434.s15	false	DDI-DrugBank.d434.s15.e0	DDI-DrugBank.d434.s15.e2
DDI-DrugBank.d434.s15	true	DDI-DrugBank.d434.s15.e1	DDI-DrugBank.d434.s15.e2
DDI-DrugBank.d434.s16|a|In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.
DDI-DrugBank.d434.s16	55	63	phenytoin	drug	DDI-DrugBank.d434.s16.e0
DDI-DrugBank.d434.s16	91	98	Felbatol	brand	DDI-DrugBank.d434.s16.e1
DDI-DrugBank.d434.s16	121	129	phenytoin	drug	DDI-DrugBank.d434.s16.e2
DDI-DrugBank.d434.s16	167	174	Felbatol	brand	DDI-DrugBank.d434.s16.e3
DDI-DrugBank.d434.s16	false	DDI-DrugBank.d434.s16.e0	DDI-DrugBank.d434.s16.e1
DDI-DrugBank.d434.s16	false	DDI-DrugBank.d434.s16.e0	DDI-DrugBank.d434.s16.e2
DDI-DrugBank.d434.s16	false	DDI-DrugBank.d434.s16.e0	DDI-DrugBank.d434.s16.e3
DDI-DrugBank.d434.s16	false	DDI-DrugBank.d434.s16.e1	DDI-DrugBank.d434.s16.e2
DDI-DrugBank.d434.s16	false	DDI-DrugBank.d434.s16.e1	DDI-DrugBank.d434.s16.e3
DDI-DrugBank.d434.s16	false	DDI-DrugBank.d434.s16.e2	DDI-DrugBank.d434.s16.e3
DDI-DrugBank.d434.s17|a|Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.
DDI-DrugBank.d434.s17	0	12	Carbamazepine	drug	DDI-DrugBank.d434.s17.e0
DDI-DrugBank.d434.s17	15	22	Felbatol	brand	DDI-DrugBank.d434.s17.e1
DDI-DrugBank.d434.s17	63	75	carbamazepine	drug	DDI-DrugBank.d434.s17.e2
DDI-DrugBank.d434.s17	135	155	carbamazepine epoxide	drug_n	DDI-DrugBank.d434.s17.e3
DDI-DrugBank.d434.s17	false	DDI-DrugBank.d434.s17.e0	DDI-DrugBank.d434.s17.e1
DDI-DrugBank.d434.s17	false	DDI-DrugBank.d434.s17.e0	DDI-DrugBank.d434.s17.e2
DDI-DrugBank.d434.s17	false	DDI-DrugBank.d434.s17.e0	DDI-DrugBank.d434.s17.e3
DDI-DrugBank.d434.s17	true	DDI-DrugBank.d434.s17.e1	DDI-DrugBank.d434.s17.e2
DDI-DrugBank.d434.s17	false	DDI-DrugBank.d434.s17.e1	DDI-DrugBank.d434.s17.e3
DDI-DrugBank.d434.s17	false	DDI-DrugBank.d434.s17.e2	DDI-DrugBank.d434.s17.e3
DDI-DrugBank.d434.s18|a|In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8 2 micrograms/mL.
DDI-DrugBank.d434.s18	59	71	carbamazepine	drug	DDI-DrugBank.d434.s18.e0
DDI-DrugBank.d434.s18	105	117	carbamazepine	drug	DDI-DrugBank.d434.s18.e1
DDI-DrugBank.d434.s18	false	DDI-DrugBank.d434.s18.e0	DDI-DrugBank.d434.s18.e1
DDI-DrugBank.d434.s19|a|The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.
DDI-DrugBank.d434.s19	4	16	carbamazepine	drug	DDI-DrugBank.d434.s19.e0
DDI-DrugBank.d434.s19	76	84	felbamate	drug	DDI-DrugBank.d434.s19.e1
DDI-DrugBank.d434.s19	true	DDI-DrugBank.d434.s19.e0	DDI-DrugBank.d434.s19.e1
DDI-DrugBank.d434.s20|a|Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.0 0.3 to 1.6 0.4 micrograms/mL with the addition of felbamate.
DDI-DrugBank.d434.s20	0	20	Carbamazepine epoxide	drug_n	DDI-DrugBank.d434.s20.e0
DDI-DrugBank.d434.s20	128	136	felbamate	drug	DDI-DrugBank.d434.s20.e1
DDI-DrugBank.d434.s20	false	DDI-DrugBank.d434.s20.e0	DDI-DrugBank.d434.s20.e1
DDI-DrugBank.d434.s21|a|In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen.
DDI-DrugBank.d434.s21	39	51	carbamazepine	drug	DDI-DrugBank.d434.s21.e0
DDI-DrugBank.d434.s21	57	77	carbamazepine epoxide	drug_n	DDI-DrugBank.d434.s21.e1
DDI-DrugBank.d434.s21	false	DDI-DrugBank.d434.s21.e0	DDI-DrugBank.d434.s21.e1
DDI-DrugBank.d434.s22|a|Valproate: Felbatol  causes an increase in steady-state valproate concentrations.
DDI-DrugBank.d434.s22	0	8	Valproate	drug	DDI-DrugBank.d434.s22.e0
DDI-DrugBank.d434.s22	11	18	Felbatol	brand	DDI-DrugBank.d434.s22.e1
DDI-DrugBank.d434.s22	56	64	valproate	drug	DDI-DrugBank.d434.s22.e2
DDI-DrugBank.d434.s22	false	DDI-DrugBank.d434.s22.e0	DDI-DrugBank.d434.s22.e1
DDI-DrugBank.d434.s22	false	DDI-DrugBank.d434.s22.e0	DDI-DrugBank.d434.s22.e2
DDI-DrugBank.d434.s22	true	DDI-DrugBank.d434.s22.e1	DDI-DrugBank.d434.s22.e2
DDI-DrugBank.d434.s23|a|In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63 16 micrograms/mL.
DDI-DrugBank.d434.s23	41	49	valproate	drug	DDI-DrugBank.d434.s23.e0
DDI-DrugBank.d434.s23	83	91	valproate	drug	DDI-DrugBank.d434.s23.e1
DDI-DrugBank.d434.s23	false	DDI-DrugBank.d434.s23.e0	DDI-DrugBank.d434.s23.e1
DDI-DrugBank.d434.s24|a|The steady-state Cmin increased to 78 14 micrograms/mL when 1200 mg/day of felbamate was coadministered.
DDI-DrugBank.d434.s24	75	83	felbamate	drug	DDI-DrugBank.d434.s24.e0
DDI-DrugBank.d434.s25|a|Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.
DDI-DrugBank.d434.s25	15	23	felbamate	drug	DDI-DrugBank.d434.s25.e0
DDI-DrugBank.d434.s25	71	79	valproate	drug	DDI-DrugBank.d434.s25.e1
DDI-DrugBank.d434.s25	true	DDI-DrugBank.d434.s25.e0	DDI-DrugBank.d434.s25.e1
DDI-DrugBank.d434.s26|a|Corresponding values for free valproate Cmin concentrations were 7 3, 9 4, and 11 6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol , respectively.
DDI-DrugBank.d434.s26	30	38	valproate	drug	DDI-DrugBank.d434.s26.e0
DDI-DrugBank.d434.s26	127	134	Felbatol	brand	DDI-DrugBank.d434.s26.e1
DDI-DrugBank.d434.s26	false	DDI-DrugBank.d434.s26.e0	DDI-DrugBank.d434.s26.e1
DDI-DrugBank.d434.s27|a|The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol , respectively.
DDI-DrugBank.d434.s27	34	42	valproate	drug	DDI-DrugBank.d434.s27.e0
DDI-DrugBank.d434.s27	69	77	valproate	drug	DDI-DrugBank.d434.s27.e1
DDI-DrugBank.d434.s27	163	170	Felbatol	brand	DDI-DrugBank.d434.s27.e2
DDI-DrugBank.d434.s27	false	DDI-DrugBank.d434.s27.e0	DDI-DrugBank.d434.s27.e1
DDI-DrugBank.d434.s27	false	DDI-DrugBank.d434.s27.e0	DDI-DrugBank.d434.s27.e2
DDI-DrugBank.d434.s27	false	DDI-DrugBank.d434.s27.e1	DDI-DrugBank.d434.s27.e2
DDI-DrugBank.d434.s28|a|Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
DDI-DrugBank.d434.s28	0	12	Phenobarbital	drug	DDI-DrugBank.d434.s28.e0
DDI-DrugBank.d434.s28	35	43	felbamate	drug	DDI-DrugBank.d434.s28.e1
DDI-DrugBank.d434.s28	50	62	phenobarbital	drug	DDI-DrugBank.d434.s28.e2
DDI-DrugBank.d434.s28	86	98	phenobarbital	drug	DDI-DrugBank.d434.s28.e3
DDI-DrugBank.d434.s28	173	185	phenobarbital	drug	DDI-DrugBank.d434.s28.e4
DDI-DrugBank.d434.s28	219	231	phenobarbital	drug	DDI-DrugBank.d434.s28.e5
DDI-DrugBank.d434.s28	false	DDI-DrugBank.d434.s28.e0	DDI-DrugBank.d434.s28.e1
DDI-DrugBank.d434.s28	false	DDI-DrugBank.d434.s28.e0	DDI-DrugBank.d434.s28.e2
DDI-DrugBank.d434.s28	false	DDI-DrugBank.d434.s28.e0	DDI-DrugBank.d434.s28.e3
DDI-DrugBank.d434.s28	false	DDI-DrugBank.d434.s28.e0	DDI-DrugBank.d434.s28.e4
DDI-DrugBank.d434.s28	false	DDI-DrugBank.d434.s28.e0	DDI-DrugBank.d434.s28.e5
DDI-DrugBank.d434.s28	true	DDI-DrugBank.d434.s28.e1	DDI-DrugBank.d434.s28.e2
DDI-DrugBank.d434.s28	false	DDI-DrugBank.d434.s28.e1	DDI-DrugBank.d434.s28.e3
DDI-DrugBank.d434.s28	false	DDI-DrugBank.d434.s28.e1	DDI-DrugBank.d434.s28.e4
DDI-DrugBank.d434.s28	false	DDI-DrugBank.d434.s28.e1	DDI-DrugBank.d434.s28.e5
DDI-DrugBank.d434.s28	false	DDI-DrugBank.d434.s28.e2	DDI-DrugBank.d434.s28.e3
DDI-DrugBank.d434.s29|a|The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week.
DDI-DrugBank.d434.s29	88	96	felbamate	drug	DDI-DrugBank.d434.s29.e0
DDI-DrugBank.d434.s30|a|Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
DDI-DrugBank.d434.s30	17	35	Antiepileptic Drugs	group	DDI-DrugBank.d434.s30.e0
DDI-DrugBank.d434.s30	40	47	Felbatol	brand	DDI-DrugBank.d434.s30.e1
DDI-DrugBank.d434.s30	50	58	Phenytoin	drug	DDI-DrugBank.d434.s30.e2
DDI-DrugBank.d434.s30	61	69	Phenytoin	drug	DDI-DrugBank.d434.s30.e3
DDI-DrugBank.d434.s30	122	129	Felbatol	brand	DDI-DrugBank.d434.s30.e4
DDI-DrugBank.d434.s30	133	141	felbamate	drug	DDI-DrugBank.d434.s30.e5
DDI-DrugBank.d434.s30	192	200	phenytoin	drug	DDI-DrugBank.d434.s30.e6
DDI-DrugBank.d434.s30	282	289	Felbatol	brand	DDI-DrugBank.d434.s30.e7
DDI-DrugBank.d434.s30	324	331	Felbatol	brand	DDI-DrugBank.d434.s30.e8
DDI-DrugBank.d434.s30	false	DDI-DrugBank.d434.s30.e0	DDI-DrugBank.d434.s30.e1
DDI-DrugBank.d434.s30	false	DDI-DrugBank.d434.s30.e0	DDI-DrugBank.d434.s30.e2
DDI-DrugBank.d434.s30	false	DDI-DrugBank.d434.s30.e0	DDI-DrugBank.d434.s30.e3
DDI-DrugBank.d434.s30	false	DDI-DrugBank.d434.s30.e0	DDI-DrugBank.d434.s30.e4
DDI-DrugBank.d434.s30	false	DDI-DrugBank.d434.s30.e0	DDI-DrugBank.d434.s30.e5
DDI-DrugBank.d434.s30	false	DDI-DrugBank.d434.s30.e0	DDI-DrugBank.d434.s30.e6
DDI-DrugBank.d434.s30	false	DDI-DrugBank.d434.s30.e0	DDI-DrugBank.d434.s30.e7
DDI-DrugBank.d434.s30	false	DDI-DrugBank.d434.s30.e0	DDI-DrugBank.d434.s30.e8
DDI-DrugBank.d434.s30	false	DDI-DrugBank.d434.s30.e1	DDI-DrugBank.d434.s30.e2
DDI-DrugBank.d434.s30	false	DDI-DrugBank.d434.s30.e1	DDI-DrugBank.d434.s30.e3
DDI-DrugBank.d434.s31|a|Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
DDI-DrugBank.d434.s31	0	12	Carbamazepine	drug	DDI-DrugBank.d434.s31.e0
DDI-DrugBank.d434.s31	15	27	Carbamazepine	drug	DDI-DrugBank.d434.s31.e1
DDI-DrugBank.d434.s31	84	91	Felbatol	brand	DDI-DrugBank.d434.s31.e2
DDI-DrugBank.d434.s31	142	154	carbamazepine	drug	DDI-DrugBank.d434.s31.e3
DDI-DrugBank.d434.s31	240	247	Felbatol	brand	DDI-DrugBank.d434.s31.e4
DDI-DrugBank.d434.s31	282	289	Felbatol	brand	DDI-DrugBank.d434.s31.e5
DDI-DrugBank.d434.s31	false	DDI-DrugBank.d434.s31.e0	DDI-DrugBank.d434.s31.e1
DDI-DrugBank.d434.s31	false	DDI-DrugBank.d434.s31.e0	DDI-DrugBank.d434.s31.e2
DDI-DrugBank.d434.s31	false	DDI-DrugBank.d434.s31.e0	DDI-DrugBank.d434.s31.e3
DDI-DrugBank.d434.s31	false	DDI-DrugBank.d434.s31.e0	DDI-DrugBank.d434.s31.e4
DDI-DrugBank.d434.s31	false	DDI-DrugBank.d434.s31.e0	DDI-DrugBank.d434.s31.e5
DDI-DrugBank.d434.s31	true	DDI-DrugBank.d434.s31.e1	DDI-DrugBank.d434.s31.e2
DDI-DrugBank.d434.s31	false	DDI-DrugBank.d434.s31.e1	DDI-DrugBank.d434.s31.e3
DDI-DrugBank.d434.s31	false	DDI-DrugBank.d434.s31.e1	DDI-DrugBank.d434.s31.e4
DDI-DrugBank.d434.s31	false	DDI-DrugBank.d434.s31.e1	DDI-DrugBank.d434.s31.e5
DDI-DrugBank.d434.s31	false	DDI-DrugBank.d434.s31.e2	DDI-DrugBank.d434.s31.e3
DDI-DrugBank.d434.s32|a|Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.
DDI-DrugBank.d434.s32	0	8	Valproate	drug	DDI-DrugBank.d434.s32.e0
DDI-DrugBank.d434.s32	73	81	valproate	drug	DDI-DrugBank.d434.s32.e1
DDI-DrugBank.d434.s32	103	110	Felbatol	brand	DDI-DrugBank.d434.s32.e2
DDI-DrugBank.d434.s32	157	165	valproate	drug	DDI-DrugBank.d434.s32.e3
DDI-DrugBank.d434.s32	225	232	Felbatol	brand	DDI-DrugBank.d434.s32.e4
DDI-DrugBank.d434.s32	236	244	felbamate	drug	DDI-DrugBank.d434.s32.e5
DDI-DrugBank.d434.s32	false	DDI-DrugBank.d434.s32.e0	DDI-DrugBank.d434.s32.e1
DDI-DrugBank.d434.s32	false	DDI-DrugBank.d434.s32.e0	DDI-DrugBank.d434.s32.e2
DDI-DrugBank.d434.s32	false	DDI-DrugBank.d434.s32.e0	DDI-DrugBank.d434.s32.e3
DDI-DrugBank.d434.s32	false	DDI-DrugBank.d434.s32.e0	DDI-DrugBank.d434.s32.e4
DDI-DrugBank.d434.s32	false	DDI-DrugBank.d434.s32.e0	DDI-DrugBank.d434.s32.e5
DDI-DrugBank.d434.s32	false	DDI-DrugBank.d434.s32.e1	DDI-DrugBank.d434.s32.e2
DDI-DrugBank.d434.s32	false	DDI-DrugBank.d434.s32.e1	DDI-DrugBank.d434.s32.e3
DDI-DrugBank.d434.s32	false	DDI-DrugBank.d434.s32.e1	DDI-DrugBank.d434.s32.e4
DDI-DrugBank.d434.s32	false	DDI-DrugBank.d434.s32.e1	DDI-DrugBank.d434.s32.e5
DDI-DrugBank.d434.s32	false	DDI-DrugBank.d434.s32.e2	DDI-DrugBank.d434.s32.e3
DDI-DrugBank.d434.s33|a|Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.
DDI-DrugBank.d434.s33	0	12	Phenobarbital	drug	DDI-DrugBank.d434.s33.e0
DDI-DrugBank.d434.s33	31	43	phenobarbital	drug	DDI-DrugBank.d434.s33.e1
DDI-DrugBank.d434.s33	63	71	felbamate	drug	DDI-DrugBank.d434.s33.e2
DDI-DrugBank.d434.s33	false	DDI-DrugBank.d434.s33.e0	DDI-DrugBank.d434.s33.e1
DDI-DrugBank.d434.s33	false	DDI-DrugBank.d434.s33.e0	DDI-DrugBank.d434.s33.e2
DDI-DrugBank.d434.s33	true	DDI-DrugBank.d434.s33.e1	DDI-DrugBank.d434.s33.e2
DDI-DrugBank.d434.s34|a|Steady-state plasma felbamate concentrations were found to be 29% lower than the mean concentrations of a group of newly diagnosed subjects with epilepsy also receiving 2400 mg of felbamate a day.
DDI-DrugBank.d434.s34	20	28	felbamate	drug	DDI-DrugBank.d434.s34.e0
DDI-DrugBank.d434.s34	180	188	felbamate	drug	DDI-DrugBank.d434.s34.e1
DDI-DrugBank.d434.s34	false	DDI-DrugBank.d434.s34.e0	DDI-DrugBank.d434.s34.e1
DDI-DrugBank.d434.s35|a|Effects of Antacids on Felbatol  The rate and extent of absorption of a 2400 mg dose of Felbatol  as monotherapy given as tablets was not affected when coadministered with antacids.
DDI-DrugBank.d434.s35	11	18	Antacids	group	DDI-DrugBank.d434.s35.e0
DDI-DrugBank.d434.s35	23	30	Felbatol	brand	DDI-DrugBank.d434.s35.e1
DDI-DrugBank.d434.s35	88	95	Felbatol	brand	DDI-DrugBank.d434.s35.e2
DDI-DrugBank.d434.s35	172	179	antacids	group	DDI-DrugBank.d434.s35.e3
DDI-DrugBank.d434.s35	false	DDI-DrugBank.d434.s35.e0	DDI-DrugBank.d434.s35.e1
DDI-DrugBank.d434.s35	false	DDI-DrugBank.d434.s35.e0	DDI-DrugBank.d434.s35.e2
DDI-DrugBank.d434.s35	false	DDI-DrugBank.d434.s35.e0	DDI-DrugBank.d434.s35.e3
DDI-DrugBank.d434.s35	false	DDI-DrugBank.d434.s35.e1	DDI-DrugBank.d434.s35.e2
DDI-DrugBank.d434.s35	false	DDI-DrugBank.d434.s35.e1	DDI-DrugBank.d434.s35.e3
DDI-DrugBank.d434.s35	false	DDI-DrugBank.d434.s35.e2	DDI-DrugBank.d434.s35.e3
DDI-DrugBank.d434.s36|a|Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.
DDI-DrugBank.d434.s36	11	22	Erythromycin	drug	DDI-DrugBank.d434.s36.e0
DDI-DrugBank.d434.s36	27	34	Felbatol	brand	DDI-DrugBank.d434.s36.e1
DDI-DrugBank.d434.s36	61	72	erythromycin	drug	DDI-DrugBank.d434.s36.e2
DDI-DrugBank.d434.s36	182	190	felbamate	drug	DDI-DrugBank.d434.s36.e3
DDI-DrugBank.d434.s36	false	DDI-DrugBank.d434.s36.e0	DDI-DrugBank.d434.s36.e1
DDI-DrugBank.d434.s36	false	DDI-DrugBank.d434.s36.e0	DDI-DrugBank.d434.s36.e2
DDI-DrugBank.d434.s36	false	DDI-DrugBank.d434.s36.e0	DDI-DrugBank.d434.s36.e3
DDI-DrugBank.d434.s36	false	DDI-DrugBank.d434.s36.e1	DDI-DrugBank.d434.s36.e2
DDI-DrugBank.d434.s36	false	DDI-DrugBank.d434.s36.e1	DDI-DrugBank.d434.s36.e3
DDI-DrugBank.d434.s36	false	DDI-DrugBank.d434.s36.e2	DDI-DrugBank.d434.s36.e3
DDI-DrugBank.d434.s37|a|Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
DDI-DrugBank.d434.s37	11	18	Felbatol	brand	DDI-DrugBank.d434.s37.e0
DDI-DrugBank.d434.s37	33	63	Combination Oral Contraceptives	group	DDI-DrugBank.d434.s37.e1
DDI-DrugBank.d434.s37	146	158	contraceptive	group	DDI-DrugBank.d434.s37.e2
DDI-DrugBank.d434.s37	185	201	ethinyl estradiol	drug	DDI-DrugBank.d434.s37.e3
DDI-DrugBank.d434.s37	213	221	gestodene	drug	DDI-DrugBank.d434.s37.e4
DDI-DrugBank.d434.s37	269	277	felbamate	drug	DDI-DrugBank.d434.s37.e5
DDI-DrugBank.d434.s37	347	359	contraceptive	group	DDI-DrugBank.d434.s37.e6
DDI-DrugBank.d434.s37	false	DDI-DrugBank.d434.s37.e0	DDI-DrugBank.d434.s37.e1
DDI-DrugBank.d434.s37	false	DDI-DrugBank.d434.s37.e0	DDI-DrugBank.d434.s37.e2
DDI-DrugBank.d434.s37	false	DDI-DrugBank.d434.s37.e0	DDI-DrugBank.d434.s37.e3
DDI-DrugBank.d434.s37	false	DDI-DrugBank.d434.s37.e0	DDI-DrugBank.d434.s37.e4
DDI-DrugBank.d434.s37	false	DDI-DrugBank.d434.s37.e0	DDI-DrugBank.d434.s37.e5
DDI-DrugBank.d434.s37	false	DDI-DrugBank.d434.s37.e0	DDI-DrugBank.d434.s37.e6
DDI-DrugBank.d434.s37	false	DDI-DrugBank.d434.s37.e1	DDI-DrugBank.d434.s37.e2
DDI-DrugBank.d434.s37	false	DDI-DrugBank.d434.s37.e1	DDI-DrugBank.d434.s37.e3
DDI-DrugBank.d434.s37	false	DDI-DrugBank.d434.s37.e1	DDI-DrugBank.d434.s37.e4
DDI-DrugBank.d434.s37	false	DDI-DrugBank.d434.s37.e1	DDI-DrugBank.d434.s37.e5
DDI-DrugBank.d434.s38|a|Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.
DDI-DrugBank.d434.s38	0	8	Felbamate	drug	DDI-DrugBank.d434.s38.e0
DDI-DrugBank.d434.s38	54	62	gestodene	drug	DDI-DrugBank.d434.s38.e1
DDI-DrugBank.d434.s38	158	174	ethinyl estradiol	drug	DDI-DrugBank.d434.s38.e2
DDI-DrugBank.d434.s38	true	DDI-DrugBank.d434.s38.e0	DDI-DrugBank.d434.s38.e1
DDI-DrugBank.d434.s38	false	DDI-DrugBank.d434.s38.e0	DDI-DrugBank.d434.s38.e2
DDI-DrugBank.d434.s38	false	DDI-DrugBank.d434.s38.e1	DDI-DrugBank.d434.s38.e2
DDI-DrugBank.d434.s39|a|No volunteer showed hormonal evidence of ovulation, but one volunteer reported intermenstrual bleeding during felbamate treatment.
DDI-DrugBank.d434.s39	110	118	felbamate	drug	DDI-DrugBank.d434.s39.e0
DDI-DrugBank.d316.s0|a|CYP3A4 Inhibitors Felodipine is metabolized by CYP3A4.
DDI-DrugBank.d316.s0	0	5	CYP3A4	drug	DDI-DrugBank.d316.s0.e0
DDI-DrugBank.d316.s0	47	52	CYP3A4	drug	DDI-DrugBank.d316.s0.e1
DDI-DrugBank.d316.s0	false	DDI-DrugBank.d316.s0.e0	DDI-DrugBank.d316.s0.e1
DDI-DrugBank.d316.s1|a|Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
DDI-DrugBank.d316.s1	44	55	ketoconazole	drug	DDI-DrugBank.d316.s1.e0
DDI-DrugBank.d316.s1	58	69	itraconazole	drug	DDI-DrugBank.d316.s1.e1
DDI-DrugBank.d316.s1	72	83	erythromycin	drug	DDI-DrugBank.d316.s1.e2
DDI-DrugBank.d316.s1	104	113	cimetidine	drug	DDI-DrugBank.d316.s1.e3
DDI-DrugBank.d316.s1	121	130	felodipine	drug	DDI-DrugBank.d316.s1.e4
DDI-DrugBank.d316.s1	192	201	felodipine	drug	DDI-DrugBank.d316.s1.e5
DDI-DrugBank.d316.s1	false	DDI-DrugBank.d316.s1.e0	DDI-DrugBank.d316.s1.e1
DDI-DrugBank.d316.s1	false	DDI-DrugBank.d316.s1.e0	DDI-DrugBank.d316.s1.e2
DDI-DrugBank.d316.s1	false	DDI-DrugBank.d316.s1.e0	DDI-DrugBank.d316.s1.e3
DDI-DrugBank.d316.s1	false	DDI-DrugBank.d316.s1.e0	DDI-DrugBank.d316.s1.e4
DDI-DrugBank.d316.s1	false	DDI-DrugBank.d316.s1.e0	DDI-DrugBank.d316.s1.e5
DDI-DrugBank.d316.s1	false	DDI-DrugBank.d316.s1.e1	DDI-DrugBank.d316.s1.e2
DDI-DrugBank.d316.s1	false	DDI-DrugBank.d316.s1.e1	DDI-DrugBank.d316.s1.e3
DDI-DrugBank.d316.s1	false	DDI-DrugBank.d316.s1.e1	DDI-DrugBank.d316.s1.e4
DDI-DrugBank.d316.s1	false	DDI-DrugBank.d316.s1.e1	DDI-DrugBank.d316.s1.e5
DDI-DrugBank.d316.s1	false	DDI-DrugBank.d316.s1.e2	DDI-DrugBank.d316.s1.e3
DDI-DrugBank.d316.s2|a|These increases in concentration may lead to increased effects, (lower blood pressure and increased heart rate).
DDI-DrugBank.d316.s3|a|These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor).
DDI-DrugBank.d316.s3	59	70	itraconazole	drug	DDI-DrugBank.d316.s3.e0
DDI-DrugBank.d316.s3	82	87	CYP3A4	drug	DDI-DrugBank.d316.s3.e1
DDI-DrugBank.d316.s3	false	DDI-DrugBank.d316.s3.e0	DDI-DrugBank.d316.s3.e1
DDI-DrugBank.d316.s4|a|Caution should be used when CYP3A4 inhibitors are co-administered with felodipine.
DDI-DrugBank.d316.s4	28	33	CYP3A4	drug	DDI-DrugBank.d316.s4.e0
DDI-DrugBank.d316.s4	71	80	felodipine	drug	DDI-DrugBank.d316.s4.e1
DDI-DrugBank.d316.s4	false	DDI-DrugBank.d316.s4.e0	DDI-DrugBank.d316.s4.e1
DDI-DrugBank.d316.s5|a|A conservative approach to dosing felodipine should be taken.
DDI-DrugBank.d316.s5	34	43	felodipine	drug	DDI-DrugBank.d316.s5.e0
DDI-DrugBank.d316.s6|a|The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.
DDI-DrugBank.d316.s6	130	139	felodipine	drug	DDI-DrugBank.d316.s6.e0
DDI-DrugBank.d316.s6	146	157	itraconazole	drug	DDI-DrugBank.d316.s6.e1
DDI-DrugBank.d316.s6	298	307	felodipine	drug	DDI-DrugBank.d316.s6.e2
DDI-DrugBank.d316.s6	false	DDI-DrugBank.d316.s6.e0	DDI-DrugBank.d316.s6.e1
DDI-DrugBank.d316.s6	false	DDI-DrugBank.d316.s6.e0	DDI-DrugBank.d316.s6.e2
DDI-DrugBank.d316.s6	false	DDI-DrugBank.d316.s6.e1	DDI-DrugBank.d316.s6.e2
DDI-DrugBank.d316.s7|a|Erythromycin Co-administration of felodipine (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.
DDI-DrugBank.d316.s7	34	43	felodipine	drug	DDI-DrugBank.d316.s7.e0
DDI-DrugBank.d316.s7	46	52	PLENDIL	drug	DDI-DrugBank.d316.s7.e1
DDI-DrugBank.d316.s7	60	71	erythromycin	drug	DDI-DrugBank.d316.s7.e2
DDI-DrugBank.d316.s7	191	200	felodipine	drug	DDI-DrugBank.d316.s7.e3
DDI-DrugBank.d316.s7	false	DDI-DrugBank.d316.s7.e0	DDI-DrugBank.d316.s7.e1
DDI-DrugBank.d316.s7	false	DDI-DrugBank.d316.s7.e0	DDI-DrugBank.d316.s7.e2
DDI-DrugBank.d316.s7	false	DDI-DrugBank.d316.s7.e0	DDI-DrugBank.d316.s7.e3
DDI-DrugBank.d316.s7	false	DDI-DrugBank.d316.s7.e1	DDI-DrugBank.d316.s7.e2
DDI-DrugBank.d316.s7	false	DDI-DrugBank.d316.s7.e1	DDI-DrugBank.d316.s7.e3
DDI-DrugBank.d316.s7	false	DDI-DrugBank.d316.s7.e2	DDI-DrugBank.d316.s7.e3
DDI-DrugBank.d316.s8|a|Grapefruit juice Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of felodipine.
DDI-DrugBank.d316.s8	38	47	felodipine	drug	DDI-DrugBank.d316.s8.e0
DDI-DrugBank.d316.s8	171	180	felodipine	drug	DDI-DrugBank.d316.s8.e1
DDI-DrugBank.d316.s8	false	DDI-DrugBank.d316.s8.e0	DDI-DrugBank.d316.s8.e1
DDI-DrugBank.d316.s9|a|Cimetidine Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.
DDI-DrugBank.d316.s9	32	41	felodipine	drug	DDI-DrugBank.d316.s9.e0
DDI-DrugBank.d316.s9	48	57	cimetidine	drug	DDI-DrugBank.d316.s9.e1
DDI-DrugBank.d316.s9	167	176	felodipine	drug	DDI-DrugBank.d316.s9.e2
DDI-DrugBank.d316.s9	false	DDI-DrugBank.d316.s9.e0	DDI-DrugBank.d316.s9.e1
DDI-DrugBank.d316.s9	false	DDI-DrugBank.d316.s9.e0	DDI-DrugBank.d316.s9.e2
DDI-DrugBank.d316.s9	false	DDI-DrugBank.d316.s9.e1	DDI-DrugBank.d316.s9.e2
DDI-DrugBank.d316.s10|a|Beta-Blocking Agents  A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine.
DDI-DrugBank.d316.s10	49	58	felodipine	drug	DDI-DrugBank.d316.s10.e0
DDI-DrugBank.d316.s10	80	89	metoprolol	drug	DDI-DrugBank.d316.s10.e1
DDI-DrugBank.d316.s10	154	163	felodipine	drug	DDI-DrugBank.d316.s10.e2
DDI-DrugBank.d316.s10	false	DDI-DrugBank.d316.s10.e0	DDI-DrugBank.d316.s10.e1
DDI-DrugBank.d316.s10	false	DDI-DrugBank.d316.s10.e0	DDI-DrugBank.d316.s10.e2
DDI-DrugBank.d316.s10	false	DDI-DrugBank.d316.s10.e1	DDI-DrugBank.d316.s10.e2
DDI-DrugBank.d316.s11|a|The AUC and Cmax of metoprolol, however, were increased approximately 31 and 38%, respectively.
DDI-DrugBank.d316.s11	20	29	metoprolol	drug	DDI-DrugBank.d316.s11.e0
DDI-DrugBank.d316.s12|a|In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.
DDI-DrugBank.d316.s12	40	52	beta blockers	drug	DDI-DrugBank.d316.s12.e0
DDI-DrugBank.d316.s12	64	73	metoprolol	drug	DDI-DrugBank.d316.s12.e1
DDI-DrugBank.d316.s12	111	120	felodipine	drug	DDI-DrugBank.d316.s12.e2
DDI-DrugBank.d316.s12	false	DDI-DrugBank.d316.s12.e0	DDI-DrugBank.d316.s12.e1
DDI-DrugBank.d316.s12	false	DDI-DrugBank.d316.s12.e0	DDI-DrugBank.d316.s12.e2
DDI-DrugBank.d316.s12	false	DDI-DrugBank.d316.s12.e1	DDI-DrugBank.d316.s12.e2
DDI-DrugBank.d316.s13|a|Digoxin  When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.
DDI-DrugBank.d316.s13	39	45	PLENDIL	drug	DDI-DrugBank.d316.s13.e0
DDI-DrugBank.d316.s13	71	77	digoxin	drug	DDI-DrugBank.d316.s13.e1
DDI-DrugBank.d316.s13	false	DDI-DrugBank.d316.s13.e0	DDI-DrugBank.d316.s13.e1
DDI-DrugBank.d316.s14|a|Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
DDI-DrugBank.d316.s14	0	14	Anticonvulsants	group	DDI-DrugBank.d316.s14.e0
DDI-DrugBank.d316.s14	78	87	felodipine	drug	DDI-DrugBank.d316.s14.e1
DDI-DrugBank.d316.s14	148	161	anticonvulsant	group	DDI-DrugBank.d316.s14.e2
DDI-DrugBank.d316.s14	176	184	phenytoin	drug	DDI-DrugBank.d316.s14.e3
DDI-DrugBank.d316.s14	187	199	carbamazepine	drug	DDI-DrugBank.d316.s14.e4
DDI-DrugBank.d316.s14	205	217	phenobarbital	drug	DDI-DrugBank.d316.s14.e5
DDI-DrugBank.d316.s14	false	DDI-DrugBank.d316.s14.e0	DDI-DrugBank.d316.s14.e1
DDI-DrugBank.d316.s14	false	DDI-DrugBank.d316.s14.e0	DDI-DrugBank.d316.s14.e2
DDI-DrugBank.d316.s14	false	DDI-DrugBank.d316.s14.e0	DDI-DrugBank.d316.s14.e3
DDI-DrugBank.d316.s14	false	DDI-DrugBank.d316.s14.e0	DDI-DrugBank.d316.s14.e4
DDI-DrugBank.d316.s14	false	DDI-DrugBank.d316.s14.e0	DDI-DrugBank.d316.s14.e5
DDI-DrugBank.d316.s14	true	DDI-DrugBank.d316.s14.e1	DDI-DrugBank.d316.s14.e2
DDI-DrugBank.d316.s14	true	DDI-DrugBank.d316.s14.e1	DDI-DrugBank.d316.s14.e3
DDI-DrugBank.d316.s14	true	DDI-DrugBank.d316.s14.e1	DDI-DrugBank.d316.s14.e4
DDI-DrugBank.d316.s14	true	DDI-DrugBank.d316.s14.e1	DDI-DrugBank.d316.s14.e5
DDI-DrugBank.d316.s14	false	DDI-DrugBank.d316.s14.e2	DDI-DrugBank.d316.s14.e3
DDI-DrugBank.d316.s15|a|In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately 6% of that observed in healthy volunteers.
DDI-DrugBank.d316.s15	42	51	felodipine	drug	DDI-DrugBank.d316.s15.e0
DDI-DrugBank.d316.s16|a|Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.
DDI-DrugBank.d316.s16	75	90	antihypertensive	drug	DDI-DrugBank.d316.s16.e0
DDI-DrugBank.d316.s17|a|Tacrolimus  Felodipine may increase the blood concentration of tacrolimus.
DDI-DrugBank.d316.s17	12	21	Felodipine	drug	DDI-DrugBank.d316.s17.e0
DDI-DrugBank.d316.s17	63	72	tacrolimus	drug	DDI-DrugBank.d316.s17.e1
DDI-DrugBank.d316.s17	false	DDI-DrugBank.d316.s17.e0	DDI-DrugBank.d316.s17.e1
DDI-DrugBank.d316.s18|a|When given concomitantly with felodipine, the tacrolimus blood concentration should be followed and the tacrolimus dose may need to be adjusted.
DDI-DrugBank.d316.s18	30	39	felodipine	drug	DDI-DrugBank.d316.s18.e0
DDI-DrugBank.d316.s18	46	55	tacrolimus	drug	DDI-DrugBank.d316.s18.e1
DDI-DrugBank.d316.s18	false	DDI-DrugBank.d316.s18.e0	DDI-DrugBank.d316.s18.e1
DDI-DrugBank.d316.s19|a|Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.
DDI-DrugBank.d316.s19	102	111	felodipine	drug	DDI-DrugBank.d316.s19.e0
DDI-DrugBank.d316.s19	142	153	indomethacin	drug	DDI-DrugBank.d316.s19.e1
DDI-DrugBank.d316.s19	158	171	spironolactone	drug	DDI-DrugBank.d316.s19.e2
DDI-DrugBank.d316.s19	false	DDI-DrugBank.d316.s19.e0	DDI-DrugBank.d316.s19.e1
DDI-DrugBank.d316.s19	false	DDI-DrugBank.d316.s19.e0	DDI-DrugBank.d316.s19.e2
DDI-DrugBank.d316.s19	false	DDI-DrugBank.d316.s19.e1	DDI-DrugBank.d316.s19.e2
DDI-DrugBank.d316.s20|a|Interaction with Food  See CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism.
DDI-DrugBank.d104.s0|a|Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
DDI-DrugBank.d104.s0	0	11	Fenfluramine	drug	DDI-DrugBank.d104.s0.e0
DDI-DrugBank.d104.s0	49	70	antihypertensive drugs	group	DDI-DrugBank.d104.s0.e1
DDI-DrugBank.d104.s0	79	90	guanethidine	drug	DDI-DrugBank.d104.s0.e2
DDI-DrugBank.d104.s0	93	102	methyldopa	drug	DDI-DrugBank.d104.s0.e3
DDI-DrugBank.d104.s0	105	113	reserpine	drug	DDI-DrugBank.d104.s0.e4
DDI-DrugBank.d104.s0	true	DDI-DrugBank.d104.s0.e0	DDI-DrugBank.d104.s0.e1
DDI-DrugBank.d104.s0	true	DDI-DrugBank.d104.s0.e0	DDI-DrugBank.d104.s0.e2
DDI-DrugBank.d104.s0	true	DDI-DrugBank.d104.s0.e0	DDI-DrugBank.d104.s0.e3
DDI-DrugBank.d104.s0	true	DDI-DrugBank.d104.s0.e0	DDI-DrugBank.d104.s0.e4
DDI-DrugBank.d104.s0	false	DDI-DrugBank.d104.s0.e1	DDI-DrugBank.d104.s0.e2
DDI-DrugBank.d104.s0	false	DDI-DrugBank.d104.s0.e1	DDI-DrugBank.d104.s0.e3
DDI-DrugBank.d104.s0	false	DDI-DrugBank.d104.s0.e1	DDI-DrugBank.d104.s0.e4
DDI-DrugBank.d104.s0	false	DDI-DrugBank.d104.s0.e2	DDI-DrugBank.d104.s0.e3
DDI-DrugBank.d104.s0	false	DDI-DrugBank.d104.s0.e2	DDI-DrugBank.d104.s0.e4
DDI-DrugBank.d104.s0	false	DDI-DrugBank.d104.s0.e3	DDI-DrugBank.d104.s0.e4
DDI-DrugBank.d104.s1|a|Other CNS depressant drugs should be used with caution in patients taking fenfluramine, since the effects may be additive.
DDI-DrugBank.d104.s1	6	25	CNS depressant drugs	group	DDI-DrugBank.d104.s1.e0
DDI-DrugBank.d104.s1	74	85	fenfluramine	drug	DDI-DrugBank.d104.s1.e1
DDI-DrugBank.d104.s1	true	DDI-DrugBank.d104.s1.e0	DDI-DrugBank.d104.s1.e1
DDI-DrugBank.d283.s0|a|Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.
DDI-DrugBank.d283.s0	5	18	Anticoagulants	group	DDI-DrugBank.d283.s0.e0
DDI-DrugBank.d283.s0	53	75	COUMARIN ANTICOAGULANTS	group	DDI-DrugBank.d283.s0.e1
DDI-DrugBank.d283.s0	107	112	TRICOR	brand	DDI-DrugBank.d283.s0.e2
DDI-DrugBank.d283.s0	false	DDI-DrugBank.d283.s0.e0	DDI-DrugBank.d283.s0.e1
DDI-DrugBank.d283.s0	false	DDI-DrugBank.d283.s0.e0	DDI-DrugBank.d283.s0.e2
DDI-DrugBank.d283.s0	true	DDI-DrugBank.d283.s0.e1	DDI-DrugBank.d283.s0.e2
DDI-DrugBank.d283.s1|a|THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS.
DDI-DrugBank.d283.s1	18	31	ANTICOAGULANTS	group	DDI-DrugBank.d283.s1.e0
DDI-DrugBank.d283.s2|a|FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED.
DDI-DrugBank.d283.s3|a|HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
DDI-DrugBank.d283.s3	0	27	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d283.s3.e0
DDI-DrugBank.d283.s3	50	55	TRICOR	brand	DDI-DrugBank.d283.s3.e1
DDI-DrugBank.d283.s3	61	88	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d283.s3.e2
DDI-DrugBank.d283.s3	false	DDI-DrugBank.d283.s3.e0	DDI-DrugBank.d283.s3.e1
DDI-DrugBank.d283.s3	false	DDI-DrugBank.d283.s3.e0	DDI-DrugBank.d283.s3.e2
DDI-DrugBank.d283.s3	true	DDI-DrugBank.d283.s3.e1	DDI-DrugBank.d283.s3.e2
DDI-DrugBank.d283.s4|a|Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.
DDI-DrugBank.d283.s4	0	5	Resins	group	DDI-DrugBank.d283.s4.e0
DDI-DrugBank.d283.s4	14	35	bile acid sequestrants	group	DDI-DrugBank.d283.s4.e1
DDI-DrugBank.d283.s4	99	104	TRICOR	brand	DDI-DrugBank.d283.s4.e2
DDI-DrugBank.d283.s4	150	172	bile acid binding resin	group	DDI-DrugBank.d283.s4.e3
DDI-DrugBank.d283.s4	false	DDI-DrugBank.d283.s4.e0	DDI-DrugBank.d283.s4.e1
DDI-DrugBank.d283.s4	false	DDI-DrugBank.d283.s4.e0	DDI-DrugBank.d283.s4.e2
DDI-DrugBank.d283.s4	false	DDI-DrugBank.d283.s4.e0	DDI-DrugBank.d283.s4.e3
DDI-DrugBank.d283.s4	false	DDI-DrugBank.d283.s4.e1	DDI-DrugBank.d283.s4.e2
DDI-DrugBank.d283.s4	false	DDI-DrugBank.d283.s4.e1	DDI-DrugBank.d283.s4.e3
DDI-DrugBank.d283.s4	true	DDI-DrugBank.d283.s4.e2	DDI-DrugBank.d283.s4.e3
DDI-DrugBank.d283.s5|a|Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
DDI-DrugBank.d283.s5	0	11	Cyclosporine	drug	DDI-DrugBank.d283.s5.e0
DDI-DrugBank.d283.s5	22	33	cyclosporine	drug	DDI-DrugBank.d283.s5.e1
DDI-DrugBank.d283.s5	196	208	fibrate drugs	group	DDI-DrugBank.d283.s5.e2
DDI-DrugBank.d283.s5	220	225	TRICOR	brand	DDI-DrugBank.d283.s5.e3
DDI-DrugBank.d283.s5	false	DDI-DrugBank.d283.s5.e0	DDI-DrugBank.d283.s5.e1
DDI-DrugBank.d283.s5	false	DDI-DrugBank.d283.s5.e0	DDI-DrugBank.d283.s5.e2
DDI-DrugBank.d283.s5	false	DDI-DrugBank.d283.s5.e0	DDI-DrugBank.d283.s5.e3
DDI-DrugBank.d283.s5	true	DDI-DrugBank.d283.s5.e1	DDI-DrugBank.d283.s5.e2
DDI-DrugBank.d283.s5	true	DDI-DrugBank.d283.s5.e1	DDI-DrugBank.d283.s5.e3
DDI-DrugBank.d283.s5	false	DDI-DrugBank.d283.s5.e2	DDI-DrugBank.d283.s5.e3
DDI-DrugBank.d283.s6|a|The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed
DDI-DrugBank.d283.s6	32	37	TRICOR	brand	DDI-DrugBank.d283.s6.e0
DDI-DrugBank.d283.s6	44	61	immunosuppressants	group	DDI-DrugBank.d283.s6.e1
DDI-DrugBank.d283.s6	true	DDI-DrugBank.d283.s6.e0	DDI-DrugBank.d283.s6.e1
DDI-DrugBank.d283.s7|a|.
DDI-DrugBank.d283.s8|a|Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
DDI-DrugBank.d283.s8	83	93	fenofibrate	drug	DDI-DrugBank.d283.s8.e0
DDI-DrugBank.d283.s8	99	113	fenofibric acid	drug_n	DDI-DrugBank.d283.s8.e1
DDI-DrugBank.d283.s8	false	DDI-DrugBank.d283.s8.e0	DDI-DrugBank.d283.s8.e1
DDI-DrugBank.d283.s9|a|They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.
DDI-DrugBank.d283.s10|a|Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR.
DDI-DrugBank.d283.s10	16	43	coumarin-type anticoagulants	group	DDI-DrugBank.d283.s10.e0
DDI-DrugBank.d283.s11|a|Bile acid sequestrants have been shown to bind other drugs given concurrently.
DDI-DrugBank.d283.s11	0	21	Bile acid sequestrants	group	DDI-DrugBank.d283.s11.e0
DDI-DrugBank.d283.s12|a|Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .
DDI-DrugBank.d283.s12	11	21	fenofibrate	drug	DDI-DrugBank.d283.s12.e0
DDI-DrugBank.d283.s12	83	105	bile acid binding resin	group	DDI-DrugBank.d283.s12.e1
DDI-DrugBank.d283.s12	true	DDI-DrugBank.d283.s12.e0	DDI-DrugBank.d283.s12.e1
DDI-DrugBank.d283.s13|a|Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
DDI-DrugBank.d283.s13	30	40	fenofibrate	drug	DDI-DrugBank.d283.s13.e0
DDI-DrugBank.d283.s13	63	68	TRICOR	brand	DDI-DrugBank.d283.s13.e1
DDI-DrugBank.d283.s13	76	86	pravastatin	drug	DDI-DrugBank.d283.s13.e2
DDI-DrugBank.d283.s13	179	189	pravastatin	drug	DDI-DrugBank.d283.s13.e3
DDI-DrugBank.d283.s13	false	DDI-DrugBank.d283.s13.e0	DDI-DrugBank.d283.s13.e1
DDI-DrugBank.d283.s13	true	DDI-DrugBank.d283.s13.e0	DDI-DrugBank.d283.s13.e2
DDI-DrugBank.d283.s13	false	DDI-DrugBank.d283.s13.e0	DDI-DrugBank.d283.s13.e3
DDI-DrugBank.d283.s13	true	DDI-DrugBank.d283.s13.e1	DDI-DrugBank.d283.s13.e2
DDI-DrugBank.d283.s13	false	DDI-DrugBank.d283.s13.e1	DDI-DrugBank.d283.s13.e3
DDI-DrugBank.d283.s13	false	DDI-DrugBank.d283.s13.e2	DDI-DrugBank.d283.s13.e3
DDI-DrugBank.d283.s14|a|A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid.
DDI-DrugBank.d283.s14	17	27	pravastatin	drug	DDI-DrugBank.d283.s14.e0
DDI-DrugBank.d283.s14	91	105	fenofibric acid	drug_n	DDI-DrugBank.d283.s14.e1
DDI-DrugBank.d283.s14	false	DDI-DrugBank.d283.s14.e0	DDI-DrugBank.d283.s14.e1
DDI-DrugBank.d283.s15|a|Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
DDI-DrugBank.d283.s15	30	40	fenofibrate	drug	DDI-DrugBank.d283.s15.e0
DDI-DrugBank.d283.s15	64	69	TRICOR	brand	DDI-DrugBank.d283.s15.e1
DDI-DrugBank.d283.s15	77	88	atorvastatin	drug	DDI-DrugBank.d283.s15.e2
DDI-DrugBank.d283.s15	205	216	atorvastatin	drug	DDI-DrugBank.d283.s15.e3
DDI-DrugBank.d283.s15	false	DDI-DrugBank.d283.s15.e0	DDI-DrugBank.d283.s15.e1
DDI-DrugBank.d283.s15	true	DDI-DrugBank.d283.s15.e0	DDI-DrugBank.d283.s15.e2
DDI-DrugBank.d283.s15	false	DDI-DrugBank.d283.s15.e0	DDI-DrugBank.d283.s15.e3
DDI-DrugBank.d283.s15	true	DDI-DrugBank.d283.s15.e1	DDI-DrugBank.d283.s15.e2
DDI-DrugBank.d283.s15	false	DDI-DrugBank.d283.s15.e1	DDI-DrugBank.d283.s15.e3
DDI-DrugBank.d283.s15	false	DDI-DrugBank.d283.s15.e2	DDI-DrugBank.d283.s15.e3
DDI-DrugBank.d283.s16|a|The atorvastatin Cmax values were not significantly affected by fenofibrate.
DDI-DrugBank.d283.s16	4	15	atorvastatin	drug	DDI-DrugBank.d283.s16.e0
DDI-DrugBank.d283.s16	64	74	fenofibrate	drug	DDI-DrugBank.d283.s16.e1
DDI-DrugBank.d283.s16	false	DDI-DrugBank.d283.s16.e0	DDI-DrugBank.d283.s16.e1
DDI-DrugBank.d283.s17|a|The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin
DDI-DrugBank.d283.s17	24	38	fenofibric acid	drug_n	DDI-DrugBank.d283.s17.e0
DDI-DrugBank.d283.s17	75	86	atorvastatin	drug	DDI-DrugBank.d283.s17.e1
DDI-DrugBank.d283.s17	false	DDI-DrugBank.d283.s17.e0	DDI-DrugBank.d283.s17.e1
DDI-DrugBank.d283.s18|a|.
DDI-DrugBank.d283.s19|a|
DDI-DrugBank.d546.s0|a|Drug Interactions with Beta-Blockers: Concomitant use of fenoldopam with beta-blockers should be avoided.
DDI-DrugBank.d546.s0	23	35	Beta-Blockers	group	DDI-DrugBank.d546.s0.e0
DDI-DrugBank.d546.s0	57	66	fenoldopam	drug	DDI-DrugBank.d546.s0.e1
DDI-DrugBank.d546.s0	73	85	beta-blockers	group	DDI-DrugBank.d546.s0.e2
DDI-DrugBank.d546.s0	false	DDI-DrugBank.d546.s0.e0	DDI-DrugBank.d546.s0.e1
DDI-DrugBank.d546.s0	false	DDI-DrugBank.d546.s0.e0	DDI-DrugBank.d546.s0.e2
DDI-DrugBank.d546.s0	true	DDI-DrugBank.d546.s0.e1	DDI-DrugBank.d546.s0.e2
DDI-DrugBank.d546.s1|a|If the drugs are used together, caution should be exercised because unexpected hypotension could result from beta-blocker inhibition of the sympathetic reflex response to fenoldopam.
DDI-DrugBank.d546.s1	171	180	fenoldopam	drug	DDI-DrugBank.d546.s1.e0
DDI-DrugBank.d546.s2|a|Drug Interactions, General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as digitalis and sublingual nitroglycerin.
DDI-DrugBank.d546.s2	96	105	fenoldopam	drug	DDI-DrugBank.d546.s2.e0
DDI-DrugBank.d546.s2	155	163	digitalis	group	DDI-DrugBank.d546.s2.e1
DDI-DrugBank.d546.s2	180	192	nitroglycerin	drug	DDI-DrugBank.d546.s2.e2
DDI-DrugBank.d546.s2	false	DDI-DrugBank.d546.s2.e0	DDI-DrugBank.d546.s2.e1
DDI-DrugBank.d546.s2	false	DDI-DrugBank.d546.s2.e0	DDI-DrugBank.d546.s2.e2
DDI-DrugBank.d546.s2	false	DDI-DrugBank.d546.s2.e1	DDI-DrugBank.d546.s2.e2
DDI-DrugBank.d546.s3|a|There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and diuretics (both thiazide-like and loop).
DDI-DrugBank.d546.s3	45	67	antihypertensive agents	group	DDI-DrugBank.d546.s3.e0
DDI-DrugBank.d546.s3	77	90	alpha-blockers	group	DDI-DrugBank.d546.s3.e1
DDI-DrugBank.d546.s3	93	116	calcium channel-blockers	group	DDI-DrugBank.d546.s3.e2
DDI-DrugBank.d546.s3	119	132	ACE inhibitors	group	DDI-DrugBank.d546.s3.e3
DDI-DrugBank.d546.s3	139	147	diuretics	group	DDI-DrugBank.d546.s3.e4
DDI-DrugBank.d546.s3	155	162	thiazide	group	DDI-DrugBank.d546.s3.e5
DDI-DrugBank.d546.s3	false	DDI-DrugBank.d546.s3.e0	DDI-DrugBank.d546.s3.e1
DDI-DrugBank.d546.s3	false	DDI-DrugBank.d546.s3.e0	DDI-DrugBank.d546.s3.e2
DDI-DrugBank.d546.s3	false	DDI-DrugBank.d546.s3.e0	DDI-DrugBank.d546.s3.e3
DDI-DrugBank.d546.s3	false	DDI-DrugBank.d546.s3.e0	DDI-DrugBank.d546.s3.e4
DDI-DrugBank.d546.s3	false	DDI-DrugBank.d546.s3.e0	DDI-DrugBank.d546.s3.e5
DDI-DrugBank.d546.s3	false	DDI-DrugBank.d546.s3.e1	DDI-DrugBank.d546.s3.e2
DDI-DrugBank.d546.s3	false	DDI-DrugBank.d546.s3.e1	DDI-DrugBank.d546.s3.e3
DDI-DrugBank.d546.s3	false	DDI-DrugBank.d546.s3.e1	DDI-DrugBank.d546.s3.e4
DDI-DrugBank.d546.s3	false	DDI-DrugBank.d546.s3.e1	DDI-DrugBank.d546.s3.e5
DDI-DrugBank.d546.s3	false	DDI-DrugBank.d546.s3.e2	DDI-DrugBank.d546.s3.e3
DDI-DrugBank.d154.s0|a|The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.
DDI-DrugBank.d154.s0	24	30	aspirin	brand	DDI-DrugBank.d154.s0.e0
DDI-DrugBank.d154.s0	68	77	fenoprofen	drug	DDI-DrugBank.d154.s0.e1
DDI-DrugBank.d154.s0	161	183	hydroxylated fenoprofen	drug_n	DDI-DrugBank.d154.s0.e2
DDI-DrugBank.d154.s0	true	DDI-DrugBank.d154.s0.e0	DDI-DrugBank.d154.s0.e1
DDI-DrugBank.d154.s0	false	DDI-DrugBank.d154.s0.e0	DDI-DrugBank.d154.s0.e2
DDI-DrugBank.d154.s0	false	DDI-DrugBank.d154.s0.e1	DDI-DrugBank.d154.s0.e2
DDI-DrugBank.d154.s1|a|Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.
DDI-DrugBank.d154.s1	46	55	fenoprofen	drug	DDI-DrugBank.d154.s1.e0
DDI-DrugBank.d154.s1	61	67	aspirin	brand	DDI-DrugBank.d154.s1.e1
DDI-DrugBank.d154.s1	128	137	fenoprofen	drug	DDI-DrugBank.d154.s1.e2
DDI-DrugBank.d154.s1	true	DDI-DrugBank.d154.s1.e0	DDI-DrugBank.d154.s1.e1
DDI-DrugBank.d154.s1	false	DDI-DrugBank.d154.s1.e0	DDI-DrugBank.d154.s1.e2
DDI-DrugBank.d154.s1	false	DDI-DrugBank.d154.s1.e1	DDI-DrugBank.d154.s1.e2
DDI-DrugBank.d154.s2|a|Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
DDI-DrugBank.d154.s2	8	13	Nalfon	brand	DDI-DrugBank.d154.s2.e0
DDI-DrugBank.d154.s2	93	99	aspirin	brand	DDI-DrugBank.d154.s2.e1
DDI-DrugBank.d154.s2	119	125	aspirin	brand	DDI-DrugBank.d154.s2.e2
DDI-DrugBank.d154.s2	162	167	Nalfon	brand	DDI-DrugBank.d154.s2.e3
DDI-DrugBank.d154.s2	193	198	Nalfon	brand	DDI-DrugBank.d154.s2.e4
DDI-DrugBank.d154.s2	204	214	salicylates	group	DDI-DrugBank.d154.s2.e5
DDI-DrugBank.d154.s2	false	DDI-DrugBank.d154.s2.e0	DDI-DrugBank.d154.s2.e1
DDI-DrugBank.d154.s2	false	DDI-DrugBank.d154.s2.e0	DDI-DrugBank.d154.s2.e2
DDI-DrugBank.d154.s2	false	DDI-DrugBank.d154.s2.e0	DDI-DrugBank.d154.s2.e3
DDI-DrugBank.d154.s2	false	DDI-DrugBank.d154.s2.e0	DDI-DrugBank.d154.s2.e4
DDI-DrugBank.d154.s2	false	DDI-DrugBank.d154.s2.e0	DDI-DrugBank.d154.s2.e5
DDI-DrugBank.d154.s2	false	DDI-DrugBank.d154.s2.e1	DDI-DrugBank.d154.s2.e2
DDI-DrugBank.d154.s2	false	DDI-DrugBank.d154.s2.e1	DDI-DrugBank.d154.s2.e3
DDI-DrugBank.d154.s2	false	DDI-DrugBank.d154.s2.e1	DDI-DrugBank.d154.s2.e4
DDI-DrugBank.d154.s2	false	DDI-DrugBank.d154.s2.e1	DDI-DrugBank.d154.s2.e5
DDI-DrugBank.d154.s2	true	DDI-DrugBank.d154.s2.e2	DDI-DrugBank.d154.s2.e3
DDI-DrugBank.d154.s3|a|Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.
DDI-DrugBank.d154.s3	26	38	phenobarbital	drug	DDI-DrugBank.d154.s3.e0
DDI-DrugBank.d154.s3	126	135	fenoprofen	drug	DDI-DrugBank.d154.s3.e1
DDI-DrugBank.d154.s3	true	DDI-DrugBank.d154.s3.e0	DDI-DrugBank.d154.s3.e1
DDI-DrugBank.d154.s4|a|When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.
DDI-DrugBank.d154.s4	5	17	phenobarbital	drug	DDI-DrugBank.d154.s4.e0
DDI-DrugBank.d154.s4	81	86	Nalfon	brand	DDI-DrugBank.d154.s4.e1
DDI-DrugBank.d154.s4	true	DDI-DrugBank.d154.s4.e0	DDI-DrugBank.d154.s4.e1
DDI-DrugBank.d154.s5|a|In vitro studies have shown that fenoprofen, because of its affinity for albumin, may displace from their binding sites other drugs that are also albumin bound, and this may lead to drug interaction.
DDI-DrugBank.d154.s5	33	42	fenoprofen	drug	DDI-DrugBank.d154.s5.e0
DDI-DrugBank.d154.s6|a|Theoretically, fenoprofen could likewise be displaced.
DDI-DrugBank.d154.s6	15	24	fenoprofen	drug	DDI-DrugBank.d154.s6.e0
DDI-DrugBank.d154.s7|a|Patients receiving hydantoins, sulfonamides, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.
DDI-DrugBank.d154.s7	19	28	hydantoins	group	DDI-DrugBank.d154.s7.e0
DDI-DrugBank.d154.s7	31	42	sulfonamides	group	DDI-DrugBank.d154.s7.e1
DDI-DrugBank.d154.s7	48	60	sulfonylureas	group	DDI-DrugBank.d154.s7.e2
DDI-DrugBank.d154.s7	false	DDI-DrugBank.d154.s7.e0	DDI-DrugBank.d154.s7.e1
DDI-DrugBank.d154.s7	false	DDI-DrugBank.d154.s7.e0	DDI-DrugBank.d154.s7.e2
DDI-DrugBank.d154.s7	false	DDI-DrugBank.d154.s7.e1	DDI-DrugBank.d154.s7.e2
DDI-DrugBank.d154.s8|a|In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.
DDI-DrugBank.d154.s8	22	49	coumarin-type anticoagulants	group	DDI-DrugBank.d154.s8.e0
DDI-DrugBank.d154.s8	68	73	Nalfon	brand	DDI-DrugBank.d154.s8.e1
DDI-DrugBank.d154.s8	true	DDI-DrugBank.d154.s8.e0	DDI-DrugBank.d154.s8.e1
DDI-DrugBank.d154.s9|a|Patients receiving both drugs should be under careful observation.
DDI-DrugBank.d154.s10|a|Patients treated with Nalfon may be resistant to the effects of loop diuretics.
DDI-DrugBank.d154.s10	22	27	Nalfon	brand	DDI-DrugBank.d154.s10.e0
DDI-DrugBank.d154.s10	64	77	loop diuretics	group	DDI-DrugBank.d154.s10.e1
DDI-DrugBank.d154.s10	true	DDI-DrugBank.d154.s10.e0	DDI-DrugBank.d154.s10.e1
DDI-DrugBank.d154.s11|a|In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.
DDI-DrugBank.d154.s11	22	27	Nalfon	brand	DDI-DrugBank.d154.s11.e0
DDI-DrugBank.d154.s11	35	41	steroid	group	DDI-DrugBank.d154.s11.e1
DDI-DrugBank.d154.s11	75	81	steroid	group	DDI-DrugBank.d154.s11.e2
DDI-DrugBank.d154.s11	163	169	steroid	group	DDI-DrugBank.d154.s11.e3
DDI-DrugBank.d154.s11	true	DDI-DrugBank.d154.s11.e0	DDI-DrugBank.d154.s11.e1
DDI-DrugBank.d154.s11	false	DDI-DrugBank.d154.s11.e0	DDI-DrugBank.d154.s11.e2
DDI-DrugBank.d154.s11	false	DDI-DrugBank.d154.s11.e0	DDI-DrugBank.d154.s11.e3
DDI-DrugBank.d154.s11	false	DDI-DrugBank.d154.s11.e1	DDI-DrugBank.d154.s11.e2
DDI-DrugBank.d154.s11	false	DDI-DrugBank.d154.s11.e1	DDI-DrugBank.d154.s11.e3
DDI-DrugBank.d154.s11	false	DDI-DrugBank.d154.s11.e2	DDI-DrugBank.d154.s11.e3
DDI-DrugBank.d170.s0|a|Agents Affecting Cytochrome P450 3A4 Isoenzyme System Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when DURAGESIC  is given concurrently with agents that affect CYP3A4 activity.
DDI-DrugBank.d170.s0	54	61	Fentanyl	drug	DDI-DrugBank.d170.s0.e0
DDI-DrugBank.d170.s0	194	202	DURAGESIC	brand	DDI-DrugBank.d170.s0.e1
DDI-DrugBank.d170.s0	false	DDI-DrugBank.d170.s0.e0	DDI-DrugBank.d170.s0.e1
DDI-DrugBank.d170.s1|a|Coadminstration with agents that induce 3A4 activity may reduce the efficacy of DURAGESIC .
DDI-DrugBank.d170.s1	80	88	DURAGESIC	brand	DDI-DrugBank.d170.s1.e0
DDI-DrugBank.d170.s2|a|The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s2	35	42	fentanyl	drug	DDI-DrugBank.d170.s2.e0
DDI-DrugBank.d170.s2	49	57	ritonavir	drug	DDI-DrugBank.d170.s2.e1
DDI-DrugBank.d170.s2	98	109	ketoconazole	drug	DDI-DrugBank.d170.s2.e2
DDI-DrugBank.d170.s2	112	123	itraconazole	drug	DDI-DrugBank.d170.s2.e3
DDI-DrugBank.d170.s2	126	139	troleandomycin	drug	DDI-DrugBank.d170.s2.e4
DDI-DrugBank.d170.s2	142	155	clarithromycin	drug	DDI-DrugBank.d170.s2.e5
DDI-DrugBank.d170.s2	158	167	nelfinavir	drug	DDI-DrugBank.d170.s2.e6
DDI-DrugBank.d170.s2	214	221	fentanyl	drug	DDI-DrugBank.d170.s2.e7
DDI-DrugBank.d170.s2	true	DDI-DrugBank.d170.s2.e0	DDI-DrugBank.d170.s2.e1
DDI-DrugBank.d170.s2	true	DDI-DrugBank.d170.s2.e0	DDI-DrugBank.d170.s2.e2
DDI-DrugBank.d170.s2	true	DDI-DrugBank.d170.s2.e0	DDI-DrugBank.d170.s2.e3
DDI-DrugBank.d170.s2	true	DDI-DrugBank.d170.s2.e0	DDI-DrugBank.d170.s2.e4
DDI-DrugBank.d170.s2	true	DDI-DrugBank.d170.s2.e0	DDI-DrugBank.d170.s2.e5
DDI-DrugBank.d170.s2	true	DDI-DrugBank.d170.s2.e0	DDI-DrugBank.d170.s2.e6
DDI-DrugBank.d170.s2	false	DDI-DrugBank.d170.s2.e0	DDI-DrugBank.d170.s2.e7
DDI-DrugBank.d170.s2	false	DDI-DrugBank.d170.s2.e1	DDI-DrugBank.d170.s2.e2
DDI-DrugBank.d170.s2	false	DDI-DrugBank.d170.s2.e1	DDI-DrugBank.d170.s2.e3
DDI-DrugBank.d170.s2	false	DDI-DrugBank.d170.s2.e1	DDI-DrugBank.d170.s2.e4
DDI-DrugBank.d170.s3|a|The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
DDI-DrugBank.d170.s3	55	63	diltiazem	drug	DDI-DrugBank.d170.s3.e0
DDI-DrugBank.d170.s3	69	80	erythromycin	drug	DDI-DrugBank.d170.s3.e1
DDI-DrugBank.d170.s3	99	106	fentanyl	drug	DDI-DrugBank.d170.s3.e2
DDI-DrugBank.d170.s3	142	149	fentanyl	drug	DDI-DrugBank.d170.s3.e3
DDI-DrugBank.d170.s3	false	DDI-DrugBank.d170.s3.e0	DDI-DrugBank.d170.s3.e1
DDI-DrugBank.d170.s3	true	DDI-DrugBank.d170.s3.e0	DDI-DrugBank.d170.s3.e2
DDI-DrugBank.d170.s3	false	DDI-DrugBank.d170.s3.e0	DDI-DrugBank.d170.s3.e3
DDI-DrugBank.d170.s3	true	DDI-DrugBank.d170.s3.e1	DDI-DrugBank.d170.s3.e2
DDI-DrugBank.d170.s3	false	DDI-DrugBank.d170.s3.e1	DDI-DrugBank.d170.s3.e3
DDI-DrugBank.d170.s3	false	DDI-DrugBank.d170.s3.e2	DDI-DrugBank.d170.s3.e3
DDI-DrugBank.d170.s4|a|In this situation, special patient care and observation are appropriate.
DDI-DrugBank.d170.s5|a|Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5	0	33	Central Nervous System Depressants	group	DDI-DrugBank.d170.s5.e0
DDI-DrugBank.d170.s5	59	67	DURAGESIC	brand	DDI-DrugBank.d170.s5.e1
DDI-DrugBank.d170.s5	71	78	fentanyl	drug	DDI-DrugBank.d170.s5.e2
DDI-DrugBank.d170.s5	111	144	central nervous system depressants	group	DDI-DrugBank.d170.s5.e3
DDI-DrugBank.d170.s5	182	188	opioids	group	DDI-DrugBank.d170.s5.e4
DDI-DrugBank.d170.s5	191	199	sedatives	group	DDI-DrugBank.d170.s5.e5
DDI-DrugBank.d170.s5	202	210	hypnotics	group	DDI-DrugBank.d170.s5.e6
DDI-DrugBank.d170.s5	213	225	tranquilizers	group	DDI-DrugBank.d170.s5.e7
DDI-DrugBank.d170.s5	234	248	benzodiazepines	group	DDI-DrugBank.d170.s5.e8
DDI-DrugBank.d170.s5	260	270	anesthetics	group	DDI-DrugBank.d170.s5.e9
DDI-DrugBank.d170.s5	false	DDI-DrugBank.d170.s5.e0	DDI-DrugBank.d170.s5.e1
DDI-DrugBank.d170.s5	false	DDI-DrugBank.d170.s5.e0	DDI-DrugBank.d170.s5.e2
DDI-DrugBank.d170.s5	false	DDI-DrugBank.d170.s5.e0	DDI-DrugBank.d170.s5.e3
DDI-DrugBank.d170.s5	false	DDI-DrugBank.d170.s5.e0	DDI-DrugBank.d170.s5.e4
DDI-DrugBank.d170.s5	false	DDI-DrugBank.d170.s5.e0	DDI-DrugBank.d170.s5.e5
DDI-DrugBank.d170.s5	false	DDI-DrugBank.d170.s5.e0	DDI-DrugBank.d170.s5.e6
DDI-DrugBank.d170.s5	false	DDI-DrugBank.d170.s5.e0	DDI-DrugBank.d170.s5.e7
DDI-DrugBank.d170.s5	false	DDI-DrugBank.d170.s5.e0	DDI-DrugBank.d170.s5.e8
DDI-DrugBank.d170.s5	false	DDI-DrugBank.d170.s5.e0	DDI-DrugBank.d170.s5.e9
DDI-DrugBank.d170.s5	false	DDI-DrugBank.d170.s5.e0	DDI-DrugBank.d170.s5.e10
DDI-DrugBank.d170.s6|a|When such combined therapy is contemplated, the dose of one or both agents should be significantly reduced.
DDI-DrugBank.d170.s7|a|MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
DDI-DrugBank.d170.s7	0	13	MAO Inhibitors	group	DDI-DrugBank.d170.s7.e0
DDI-DrugBank.d170.s7	16	24	DURAGESIC	brand	DDI-DrugBank.d170.s7.e1
DDI-DrugBank.d170.s7	84	87	MAOI	group	DDI-DrugBank.d170.s7.e2
DDI-DrugBank.d170.s7	153	166	MAO inhibitors	group	DDI-DrugBank.d170.s7.e3
DDI-DrugBank.d170.s7	191	207	opioid analgesics	group	DDI-DrugBank.d170.s7.e4
DDI-DrugBank.d170.s7	false	DDI-DrugBank.d170.s7.e0	DDI-DrugBank.d170.s7.e1
DDI-DrugBank.d170.s7	false	DDI-DrugBank.d170.s7.e0	DDI-DrugBank.d170.s7.e2
DDI-DrugBank.d170.s7	false	DDI-DrugBank.d170.s7.e0	DDI-DrugBank.d170.s7.e3
DDI-DrugBank.d170.s7	false	DDI-DrugBank.d170.s7.e0	DDI-DrugBank.d170.s7.e4
DDI-DrugBank.d170.s7	true	DDI-DrugBank.d170.s7.e1	DDI-DrugBank.d170.s7.e2
DDI-DrugBank.d170.s7	false	DDI-DrugBank.d170.s7.e1	DDI-DrugBank.d170.s7.e3
DDI-DrugBank.d170.s7	false	DDI-DrugBank.d170.s7.e1	DDI-DrugBank.d170.s7.e4
DDI-DrugBank.d170.s7	false	DDI-DrugBank.d170.s7.e2	DDI-DrugBank.d170.s7.e3
DDI-DrugBank.d170.s7	false	DDI-DrugBank.d170.s7.e2	DDI-DrugBank.d170.s7.e4
DDI-DrugBank.d170.s7	true	DDI-DrugBank.d170.s7.e3	DDI-DrugBank.d170.s7.e4
DDI-DrugBank.d170.s8|a|.
DDI-DrugBank.d170.s9|a|
DDI-DrugBank.d466.s0|a|Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.
DDI-DrugBank.d466.s0	22	33	Erythromycin	drug	DDI-DrugBank.d466.s0.e0
DDI-DrugBank.d466.s0	39	50	Ketoconazole	drug	DDI-DrugBank.d466.s0.e1
DDI-DrugBank.d466.s0	52	63	Fexofenadine	drug	DDI-DrugBank.d466.s0.e2
DDI-DrugBank.d466.s0	false	DDI-DrugBank.d466.s0.e0	DDI-DrugBank.d466.s0.e1
DDI-DrugBank.d466.s0	false	DDI-DrugBank.d466.s0.e0	DDI-DrugBank.d466.s0.e2
DDI-DrugBank.d466.s0	false	DDI-DrugBank.d466.s0.e1	DDI-DrugBank.d466.s0.e2
DDI-DrugBank.d466.s1|a|However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.
DDI-DrugBank.d466.s1	31	56	fexofenadine hydrochloride	drug	DDI-DrugBank.d466.s1.e0
DDI-DrugBank.d466.s1	70	81	ketoconazole	drug	DDI-DrugBank.d466.s1.e1
DDI-DrugBank.d466.s1	86	97	erythromycin	drug	DDI-DrugBank.d466.s1.e2
DDI-DrugBank.d466.s1	141	152	fexofenadine	drug	DDI-DrugBank.d466.s1.e3
DDI-DrugBank.d466.s1	true	DDI-DrugBank.d466.s1.e0	DDI-DrugBank.d466.s1.e1
DDI-DrugBank.d466.s1	true	DDI-DrugBank.d466.s1.e0	DDI-DrugBank.d466.s1.e2
DDI-DrugBank.d466.s1	false	DDI-DrugBank.d466.s1.e0	DDI-DrugBank.d466.s1.e3
DDI-DrugBank.d466.s1	false	DDI-DrugBank.d466.s1.e1	DDI-DrugBank.d466.s1.e2
DDI-DrugBank.d466.s1	false	DDI-DrugBank.d466.s1.e1	DDI-DrugBank.d466.s1.e3
DDI-DrugBank.d466.s1	false	DDI-DrugBank.d466.s1.e2	DDI-DrugBank.d466.s1.e3
DDI-DrugBank.d466.s2|a|Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.
DDI-DrugBank.d466.s2	0	11	Fexofenadine	drug	DDI-DrugBank.d466.s2.e0
DDI-DrugBank.d466.s2	61	72	erythromycin	drug	DDI-DrugBank.d466.s2.e1
DDI-DrugBank.d466.s2	77	88	ketoconazole	drug	DDI-DrugBank.d466.s2.e2
DDI-DrugBank.d466.s2	false	DDI-DrugBank.d466.s2.e0	DDI-DrugBank.d466.s2.e1
DDI-DrugBank.d466.s2	false	DDI-DrugBank.d466.s2.e0	DDI-DrugBank.d466.s2.e2
DDI-DrugBank.d466.s2	false	DDI-DrugBank.d466.s2.e1	DDI-DrugBank.d466.s2.e2
DDI-DrugBank.d466.s3|a|In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).
DDI-DrugBank.d466.s3	23	48	fexofenadine hydrochloride	drug	DDI-DrugBank.d466.s3.e0
DDI-DrugBank.d466.s3	127	138	erythromycin	drug	DDI-DrugBank.d466.s3.e1
DDI-DrugBank.d466.s3	164	175	ketoconazole	drug	DDI-DrugBank.d466.s3.e2
DDI-DrugBank.d466.s3	false	DDI-DrugBank.d466.s3.e0	DDI-DrugBank.d466.s3.e1
DDI-DrugBank.d466.s3	false	DDI-DrugBank.d466.s3.e0	DDI-DrugBank.d466.s3.e2
DDI-DrugBank.d466.s3	false	DDI-DrugBank.d466.s3.e1	DDI-DrugBank.d466.s3.e2
DDI-DrugBank.d466.s4|a|No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.
DDI-DrugBank.d466.s4	95	120	fexofenadine hydrochloride	drug	DDI-DrugBank.d466.s4.e0
DDI-DrugBank.d466.s4	158	169	erythromycin	drug	DDI-DrugBank.d466.s4.e1
DDI-DrugBank.d466.s4	174	185	ketoconazole	drug	DDI-DrugBank.d466.s4.e2
DDI-DrugBank.d466.s4	false	DDI-DrugBank.d466.s4.e0	DDI-DrugBank.d466.s4.e1
DDI-DrugBank.d466.s4	false	DDI-DrugBank.d466.s4.e0	DDI-DrugBank.d466.s4.e2
DDI-DrugBank.d466.s4	false	DDI-DrugBank.d466.s4.e1	DDI-DrugBank.d466.s4.e2
DDI-DrugBank.d466.s5|a|The findings of these studies are summarized in the following table: Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24)
DDI-DrugBank.d466.s5	93	104	fexofenadine	drug	DDI-DrugBank.d466.s5.e0
DDI-DrugBank.d466.s5	162	187	fexofenadine hydrochloride	drug	DDI-DrugBank.d466.s5.e1
DDI-DrugBank.d466.s5	false	DDI-DrugBank.d466.s5.e0	DDI-DrugBank.d466.s5.e1
DDI-DrugBank.d466.s6|a|Concomitant Drug
DDI-DrugBank.d466.s7|a|cmaxSS (Peak plasma concentration)
DDI-DrugBank.d466.s8|a|AUCss(0-12h) (Extent of systemic exposure)
DDI-DrugBank.d466.s9|a|Erythromycin (500 mg every 8 hrs)
DDI-DrugBank.d466.s9	0	11	Erythromycin	drug	DDI-DrugBank.d466.s9.e0
DDI-DrugBank.d466.s10|a|+82%
DDI-DrugBank.d466.s11|a|+109%
DDI-DrugBank.d466.s12|a|Ketoconazole (400 mg once daily)
DDI-DrugBank.d466.s12	0	11	Ketoconazole	drug	DDI-DrugBank.d466.s12.e0
DDI-DrugBank.d466.s13|a|+135%
DDI-DrugBank.d466.s14|a|+164%
DDI-DrugBank.d466.s15|a|The changes in plasma levels were within the range of plasma levels achieved in adequate and well-controlled clinical trials.
DDI-DrugBank.d466.s16|a|The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models.
DDI-DrugBank.d466.s17|a|These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.
DDI-DrugBank.d466.s17	28	39	ketoconazole	drug	DDI-DrugBank.d466.s17.e0
DDI-DrugBank.d466.s17	44	55	erythromycin	drug	DDI-DrugBank.d466.s17.e1
DDI-DrugBank.d466.s17	84	95	fexofenadine	drug	DDI-DrugBank.d466.s17.e2
DDI-DrugBank.d466.s17	false	DDI-DrugBank.d466.s17.e0	DDI-DrugBank.d466.s17.e1
DDI-DrugBank.d466.s17	true	DDI-DrugBank.d466.s17.e0	DDI-DrugBank.d466.s17.e2
DDI-DrugBank.d466.s17	true	DDI-DrugBank.d466.s17.e1	DDI-DrugBank.d466.s17.e2
DDI-DrugBank.d466.s18|a|This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.
DDI-DrugBank.d466.s18	49	60	fexofenadine	drug	DDI-DrugBank.d466.s18.e0
DDI-DrugBank.d466.s18	205	216	ketoconazole	drug	DDI-DrugBank.d466.s18.e1
DDI-DrugBank.d466.s18	228	239	fexofenadine	drug	DDI-DrugBank.d466.s18.e2
DDI-DrugBank.d466.s18	275	286	erythromycin	drug	DDI-DrugBank.d466.s18.e3
DDI-DrugBank.d466.s18	false	DDI-DrugBank.d466.s18.e0	DDI-DrugBank.d466.s18.e1
DDI-DrugBank.d466.s18	false	DDI-DrugBank.d466.s18.e0	DDI-DrugBank.d466.s18.e2
DDI-DrugBank.d466.s18	false	DDI-DrugBank.d466.s18.e0	DDI-DrugBank.d466.s18.e3
DDI-DrugBank.d466.s18	true	DDI-DrugBank.d466.s18.e1	DDI-DrugBank.d466.s18.e2
DDI-DrugBank.d466.s18	false	DDI-DrugBank.d466.s18.e1	DDI-DrugBank.d466.s18.e3
DDI-DrugBank.d466.s18	false	DDI-DrugBank.d466.s18.e2	DDI-DrugBank.d466.s18.e3
DDI-DrugBank.d466.s19|a|Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
DDI-DrugBank.d466.s19	23	30	Antacids	group	DDI-DrugBank.d466.s19.e0
DDI-DrugBank.d466.s19	60	85	fexofenadine hydrochloride	drug	DDI-DrugBank.d466.s19.e1
DDI-DrugBank.d466.s19	131	138	aluminum	drug	DDI-DrugBank.d466.s19.e2
DDI-DrugBank.d466.s19	144	152	magnesium	drug	DDI-DrugBank.d466.s19.e3
DDI-DrugBank.d466.s19	165	171	antacid	group	DDI-DrugBank.d466.s19.e4
DDI-DrugBank.d466.s19	174	179	Maalox	brand	DDI-DrugBank.d466.s19.e5
DDI-DrugBank.d466.s19	193	204	fexofenadine	drug	DDI-DrugBank.d466.s19.e6
DDI-DrugBank.d466.s19	false	DDI-DrugBank.d466.s19.e0	DDI-DrugBank.d466.s19.e1
DDI-DrugBank.d466.s19	false	DDI-DrugBank.d466.s19.e0	DDI-DrugBank.d466.s19.e2
DDI-DrugBank.d466.s19	false	DDI-DrugBank.d466.s19.e0	DDI-DrugBank.d466.s19.e3
DDI-DrugBank.d466.s19	false	DDI-DrugBank.d466.s19.e0	DDI-DrugBank.d466.s19.e4
DDI-DrugBank.d466.s19	false	DDI-DrugBank.d466.s19.e0	DDI-DrugBank.d466.s19.e5
DDI-DrugBank.d466.s19	false	DDI-DrugBank.d466.s19.e0	DDI-DrugBank.d466.s19.e6
DDI-DrugBank.d466.s19	true	DDI-DrugBank.d466.s19.e1	DDI-DrugBank.d466.s19.e2
DDI-DrugBank.d466.s19	true	DDI-DrugBank.d466.s19.e1	DDI-DrugBank.d466.s19.e3
DDI-DrugBank.d466.s19	true	DDI-DrugBank.d466.s19.e1	DDI-DrugBank.d466.s19.e4
DDI-DrugBank.d466.s19	true	DDI-DrugBank.d466.s19.e1	DDI-DrugBank.d466.s19.e5
DDI-DrugBank.d466.s20|a|ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.
DDI-DrugBank.d466.s20	0	6	ALLEGRA	brand	DDI-DrugBank.d466.s20.e0
DDI-DrugBank.d466.s20	49	56	aluminum	drug	DDI-DrugBank.d466.s20.e1
DDI-DrugBank.d466.s20	62	70	magnesium	drug	DDI-DrugBank.d466.s20.e2
DDI-DrugBank.d466.s20	83	90	antacids	group	DDI-DrugBank.d466.s20.e3
DDI-DrugBank.d466.s20	true	DDI-DrugBank.d466.s20.e0	DDI-DrugBank.d466.s20.e1
DDI-DrugBank.d466.s20	true	DDI-DrugBank.d466.s20.e0	DDI-DrugBank.d466.s20.e2
DDI-DrugBank.d466.s20	false	DDI-DrugBank.d466.s20.e0	DDI-DrugBank.d466.s20.e3
DDI-DrugBank.d466.s20	false	DDI-DrugBank.d466.s20.e1	DDI-DrugBank.d466.s20.e2
DDI-DrugBank.d466.s20	false	DDI-DrugBank.d466.s20.e1	DDI-DrugBank.d466.s20.e3
DDI-DrugBank.d466.s20	false	DDI-DrugBank.d466.s20.e2	DDI-DrugBank.d466.s20.e3
DDI-DrugBank.d466.s21|a|Interactions with Fruit Juices Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.
DDI-DrugBank.d466.s21	128	139	fexofenadine	drug	DDI-DrugBank.d466.s21.e0
DDI-DrugBank.d466.s22|a|This is based on the results from 3 clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.
DDI-DrugBank.d466.s22	59	67	histamine	drug	DDI-DrugBank.d466.s22.e0
DDI-DrugBank.d466.s23|a|The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.
DDI-DrugBank.d466.s23	59	84	fexofenadine hydrochloride	drug	DDI-DrugBank.d466.s23.e0
DDI-DrugBank.d466.s24|a|Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice.
DDI-DrugBank.d466.s25|a|The clinical significance of these observations is unknown.
DDI-DrugBank.d466.s26|a|In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.
DDI-DrugBank.d466.s26	192	203	fexofenadine	drug	DDI-DrugBank.d466.s26.e0
DDI-DrugBank.d466.s27|a|Therefore, to maximize the effects of fexofenadine, it is recommended that ALLEGRA should be taken with water
DDI-DrugBank.d466.s27	38	49	fexofenadine	drug	DDI-DrugBank.d466.s27.e0
DDI-DrugBank.d466.s27	75	81	ALLEGRA	brand	DDI-DrugBank.d466.s27.e1
DDI-DrugBank.d466.s27	false	DDI-DrugBank.d466.s27.e0	DDI-DrugBank.d466.s27.e1
DDI-DrugBank.d466.s28|a|.
DDI-DrugBank.d466.s29|a|
DDI-DrugBank.d1.s0|a|Drug interactions between NEUPOGEN  and other drugs have not been fully evaluated.
DDI-DrugBank.d1.s0	26	33	NEUPOGEN	brand	DDI-DrugBank.d1.s0.e0
DDI-DrugBank.d1.s1|a|Drugs which may potentiate the release of neutrophils, such as lithium, should be used with caution.
DDI-DrugBank.d1.s1	63	69	lithium	drug	DDI-DrugBank.d1.s1.e0
DDI-DrugBank.d209.s0|a|No drug interactions of clinical importance have been identified.
DDI-DrugBank.d209.s1|a|Finasteride does not appear to affect the cytochrome P450-linked drug-metabolizing enzyme system.
DDI-DrugBank.d209.s1	0	10	Finasteride	drug	DDI-DrugBank.d209.s1.e0
DDI-DrugBank.d209.s2|a|Compounds that have been tested in man include antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.
DDI-DrugBank.d209.s2	47	56	antipyrine	drug	DDI-DrugBank.d209.s2.e0
DDI-DrugBank.d209.s2	59	65	digoxin	drug	DDI-DrugBank.d209.s2.e1
DDI-DrugBank.d209.s2	68	78	propranolol	drug	DDI-DrugBank.d209.s2.e2
DDI-DrugBank.d209.s2	81	92	theophylline	drug	DDI-DrugBank.d209.s2.e3
DDI-DrugBank.d209.s2	99	106	warfarin	drug	DDI-DrugBank.d209.s2.e4
DDI-DrugBank.d209.s2	false	DDI-DrugBank.d209.s2.e0	DDI-DrugBank.d209.s2.e1
DDI-DrugBank.d209.s2	false	DDI-DrugBank.d209.s2.e0	DDI-DrugBank.d209.s2.e2
DDI-DrugBank.d209.s2	false	DDI-DrugBank.d209.s2.e0	DDI-DrugBank.d209.s2.e3
DDI-DrugBank.d209.s2	false	DDI-DrugBank.d209.s2.e0	DDI-DrugBank.d209.s2.e4
DDI-DrugBank.d209.s2	false	DDI-DrugBank.d209.s2.e1	DDI-DrugBank.d209.s2.e2
DDI-DrugBank.d209.s2	false	DDI-DrugBank.d209.s2.e1	DDI-DrugBank.d209.s2.e3
DDI-DrugBank.d209.s2	false	DDI-DrugBank.d209.s2.e1	DDI-DrugBank.d209.s2.e4
DDI-DrugBank.d209.s2	false	DDI-DrugBank.d209.s2.e2	DDI-DrugBank.d209.s2.e3
DDI-DrugBank.d209.s2	false	DDI-DrugBank.d209.s2.e2	DDI-DrugBank.d209.s2.e4
DDI-DrugBank.d209.s2	false	DDI-DrugBank.d209.s2.e3	DDI-DrugBank.d209.s2.e4
DDI-DrugBank.d209.s3|a|Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
DDI-DrugBank.d209.s3	84	94	finasteride	drug	DDI-DrugBank.d209.s3.e0
DDI-DrugBank.d209.s3	167	179	acetaminophen	drug	DDI-DrugBank.d209.s3.e1
DDI-DrugBank.d209.s3	182	201	acetylsalicylic acid	drug	DDI-DrugBank.d209.s3.e2
DDI-DrugBank.d209.s3	216	225	analgesics	group	DDI-DrugBank.d209.s3.e3
DDI-DrugBank.d209.s3	228	273	angiotensin-converting enzyme (ACE) inhibitors	group	DDI-DrugBank.d209.s3.e4
DDI-DrugBank.d209.s3	276	290	anticonvulsants	group	DDI-DrugBank.d209.s3.e5
DDI-DrugBank.d209.s3	293	307	benzodiazepines	group	DDI-DrugBank.d209.s3.e6
DDI-DrugBank.d209.s3	310	322	beta blockers	group	DDI-DrugBank.d209.s3.e7
DDI-DrugBank.d209.s3	325	348	calcium-channel blockers	group	DDI-DrugBank.d209.s3.e8
DDI-DrugBank.d209.s3	359	366	nitrates	group	DDI-DrugBank.d209.s3.e9
DDI-DrugBank.d209.s3	false	DDI-DrugBank.d209.s3.e0	DDI-DrugBank.d209.s3.e1
DDI-DrugBank.d209.s3	false	DDI-DrugBank.d209.s3.e0	DDI-DrugBank.d209.s3.e2
DDI-DrugBank.d209.s3	false	DDI-DrugBank.d209.s3.e0	DDI-DrugBank.d209.s3.e3
DDI-DrugBank.d209.s3	false	DDI-DrugBank.d209.s3.e0	DDI-DrugBank.d209.s3.e4
DDI-DrugBank.d209.s3	false	DDI-DrugBank.d209.s3.e0	DDI-DrugBank.d209.s3.e5
DDI-DrugBank.d209.s3	false	DDI-DrugBank.d209.s3.e0	DDI-DrugBank.d209.s3.e6
DDI-DrugBank.d209.s3	false	DDI-DrugBank.d209.s3.e0	DDI-DrugBank.d209.s3.e7
DDI-DrugBank.d209.s3	false	DDI-DrugBank.d209.s3.e0	DDI-DrugBank.d209.s3.e8
DDI-DrugBank.d209.s3	false	DDI-DrugBank.d209.s3.e0	DDI-DrugBank.d209.s3.e9
DDI-DrugBank.d209.s3	false	DDI-DrugBank.d209.s3.e0	DDI-DrugBank.d209.s3.e10
DDI-DrugBank.d209.s4|a|Drug/Laboratory Test Interactions Finasteride had no effect on circulating levels of cortisol, thyroid-stimulating hormone, or thyroxine, nor did it affect the plasma lipid profile (e.g., total cholesterol, low-density lipoproteins, high-density lipoproteins and triglycerides) or bone mineral density.
DDI-DrugBank.d209.s4	34	44	Finasteride	drug	DDI-DrugBank.d209.s4.e0
DDI-DrugBank.d209.s5|a|In studies with finasteride, no clinically meaningful changes in luteinizing hormone (LH), follicle-stimulating hormone (FSH) or prolactin were detected.
DDI-DrugBank.d209.s5	16	26	finasteride	drug	DDI-DrugBank.d209.s5.e0
DDI-DrugBank.d209.s6|a|In healthy volunteers, treatment with finasteride did not alter the response of LH and FSH to gonadotropin-releasing hormone indicating that the hypothalamic-pituitary-testicular axis was not affected.
DDI-DrugBank.d209.s6	38	48	finasteride	drug	DDI-DrugBank.d209.s6.e0
DDI-DrugBank.d209.s7|a|In clinical studies with PROPECIA (finasteride, 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.
DDI-DrugBank.d209.s7	25	32	PROPECIA	brand	DDI-DrugBank.d209.s7.e0
DDI-DrugBank.d209.s7	35	45	finasteride	drug	DDI-DrugBank.d209.s7.e1
DDI-DrugBank.d209.s7	false	DDI-DrugBank.d209.s7.e0	DDI-DrugBank.d209.s7.e1
DDI-DrugBank.d209.s8|a|Further, in clinical studies with PROSCAR (finasteride, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.
DDI-DrugBank.d209.s8	34	40	PROSCAR	brand	DDI-DrugBank.d209.s8.e0
DDI-DrugBank.d209.s8	43	53	finasteride	drug	DDI-DrugBank.d209.s8.e1
DDI-DrugBank.d209.s8	false	DDI-DrugBank.d209.s8.e0	DDI-DrugBank.d209.s8.e1
DDI-DrugBank.d209.s9|a|These findings should be taken into account for proper interpretation of serum PSA when evaluating men treated with finasteride.
DDI-DrugBank.d209.s9	116	126	finasteride	drug	DDI-DrugBank.d209.s9.e0
DDI-DrugBank.d87.s0|a|Drug Interactions.
DDI-DrugBank.d87.s1|a|TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects.
DDI-DrugBank.d87.s1	0	7	TAMBOCOR	brand	DDI-DrugBank.d87.s1.e0
DDI-DrugBank.d87.s1	53	74	digitalis preparations	group	DDI-DrugBank.d87.s1.e1
DDI-DrugBank.d87.s1	79	109	beta-adrenergic blocking agents	group	DDI-DrugBank.d87.s1.e2
DDI-DrugBank.d87.s1	false	DDI-DrugBank.d87.s1.e0	DDI-DrugBank.d87.s1.e1
DDI-DrugBank.d87.s1	false	DDI-DrugBank.d87.s1.e0	DDI-DrugBank.d87.s1.e2
DDI-DrugBank.d87.s1	false	DDI-DrugBank.d87.s1.e1	DDI-DrugBank.d87.s1.e2
DDI-DrugBank.d87.s2|a|During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.
DDI-DrugBank.d87.s2	48	55	TAMBOCOR	brand	DDI-DrugBank.d87.s2.e0
DDI-DrugBank.d87.s2	113	119	digoxin	drug	DDI-DrugBank.d87.s2.e1
DDI-DrugBank.d87.s2	151	157	digoxin	drug	DDI-DrugBank.d87.s2.e2
DDI-DrugBank.d87.s2	true	DDI-DrugBank.d87.s2.e0	DDI-DrugBank.d87.s2.e1
DDI-DrugBank.d87.s2	false	DDI-DrugBank.d87.s2.e0	DDI-DrugBank.d87.s2.e2
DDI-DrugBank.d87.s2	false	DDI-DrugBank.d87.s2.e1	DDI-DrugBank.d87.s2.e2
DDI-DrugBank.d87.s3|a|In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.
DDI-DrugBank.d87.s3	48	55	TAMBOCOR	brand	DDI-DrugBank.d87.s3.e0
DDI-DrugBank.d87.s3	61	71	propranolol	drug	DDI-DrugBank.d87.s3.e1
DDI-DrugBank.d87.s3	94	103	flecainide	drug	DDI-DrugBank.d87.s3.e2
DDI-DrugBank.d87.s3	141	151	propranolol	drug	DDI-DrugBank.d87.s3.e3
DDI-DrugBank.d87.s3	true	DDI-DrugBank.d87.s3.e0	DDI-DrugBank.d87.s3.e1
DDI-DrugBank.d87.s3	false	DDI-DrugBank.d87.s3.e0	DDI-DrugBank.d87.s3.e2
DDI-DrugBank.d87.s3	false	DDI-DrugBank.d87.s3.e0	DDI-DrugBank.d87.s3.e3
DDI-DrugBank.d87.s3	false	DDI-DrugBank.d87.s3.e1	DDI-DrugBank.d87.s3.e2
DDI-DrugBank.d87.s3	false	DDI-DrugBank.d87.s3.e1	DDI-DrugBank.d87.s3.e3
DDI-DrugBank.d87.s3	false	DDI-DrugBank.d87.s3.e2	DDI-DrugBank.d87.s3.e3
DDI-DrugBank.d87.s4|a|In this formal interaction study, TAMBOCOR and propranolol were each found to have negative inotropic effects;
DDI-DrugBank.d87.s4	34	41	TAMBOCOR	brand	DDI-DrugBank.d87.s4.e0
DDI-DrugBank.d87.s4	47	57	propranolol	drug	DDI-DrugBank.d87.s4.e1
DDI-DrugBank.d87.s4	false	DDI-DrugBank.d87.s4.e0	DDI-DrugBank.d87.s4.e1
DDI-DrugBank.d87.s5|a|when the drugs were administered together, the effects were additive.
DDI-DrugBank.d87.s6|a|The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.
DDI-DrugBank.d87.s6	45	52	TAMBOCOR	brand	DDI-DrugBank.d87.s6.e0
DDI-DrugBank.d87.s6	58	68	propranolol	drug	DDI-DrugBank.d87.s6.e1
DDI-DrugBank.d87.s6	true	DDI-DrugBank.d87.s6.e0	DDI-DrugBank.d87.s6.e1
DDI-DrugBank.d87.s7|a|In TAMBOCOR clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects.
DDI-DrugBank.d87.s7	3	10	TAMBOCOR	brand	DDI-DrugBank.d87.s7.e0
DDI-DrugBank.d87.s7	57	69	beta blockers	group	DDI-DrugBank.d87.s7.e1
DDI-DrugBank.d87.s7	false	DDI-DrugBank.d87.s7.e0	DDI-DrugBank.d87.s7.e1
DDI-DrugBank.d87.s8|a|Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.
DDI-DrugBank.d87.s8	72	84	beta blockers	group	DDI-DrugBank.d87.s8.e0
DDI-DrugBank.d87.s8	90	99	flecainide	drug	DDI-DrugBank.d87.s8.e1
DDI-DrugBank.d87.s8	true	DDI-DrugBank.d87.s8.e0	DDI-DrugBank.d87.s8.e1
DDI-DrugBank.d87.s9|a|Flecainide is not extensively bound to plasma proteins.
DDI-DrugBank.d87.s9	0	9	Flecainide	drug	DDI-DrugBank.d87.s9.e0
DDI-DrugBank.d87.s10|a|In vitro studies with several drugs which may be administered concomitantly showed that the extent of flecainide binding to human plasma proteins is either unchanged or only slightly less.
DDI-DrugBank.d87.s10	102	111	flecainide	drug	DDI-DrugBank.d87.s10.e0
DDI-DrugBank.d87.s11|a|Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected.
DDI-DrugBank.d87.s11	82	95	anticoagulants	group	DDI-DrugBank.d87.s11.e0
DDI-DrugBank.d87.s12|a|TAMBOCOR has been used in a large number of patients receiving diuretics without apparent interaction.
DDI-DrugBank.d87.s12	0	7	TAMBOCOR	brand	DDI-DrugBank.d87.s12.e0
DDI-DrugBank.d87.s12	63	71	diuretics	group	DDI-DrugBank.d87.s12.e1
DDI-DrugBank.d87.s12	false	DDI-DrugBank.d87.s12.e0	DDI-DrugBank.d87.s12.e1
DDI-DrugBank.d87.s13|a|Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
DDI-DrugBank.d87.s13	59	67	phenytoin	drug	DDI-DrugBank.d87.s13.e0
DDI-DrugBank.d87.s13	70	82	phenobarbital	drug	DDI-DrugBank.d87.s13.e1
DDI-DrugBank.d87.s13	85	97	carbamazepine	drug	DDI-DrugBank.d87.s13.e2
DDI-DrugBank.d87.s13	145	154	flecainide	drug	DDI-DrugBank.d87.s13.e3
DDI-DrugBank.d87.s13	false	DDI-DrugBank.d87.s13.e0	DDI-DrugBank.d87.s13.e1
DDI-DrugBank.d87.s13	false	DDI-DrugBank.d87.s13.e0	DDI-DrugBank.d87.s13.e2
DDI-DrugBank.d87.s13	true	DDI-DrugBank.d87.s13.e0	DDI-DrugBank.d87.s13.e3
DDI-DrugBank.d87.s13	false	DDI-DrugBank.d87.s13.e1	DDI-DrugBank.d87.s13.e2
DDI-DrugBank.d87.s13	true	DDI-DrugBank.d87.s13.e1	DDI-DrugBank.d87.s13.e3
DDI-DrugBank.d87.s13	true	DDI-DrugBank.d87.s13.e2	DDI-DrugBank.d87.s13.e3
DDI-DrugBank.d87.s14|a|In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.
DDI-DrugBank.d87.s14	30	39	cimetidine	drug	DDI-DrugBank.d87.s14.e0
DDI-DrugBank.d87.s14	75	84	flecainide	drug	DDI-DrugBank.d87.s14.e1
DDI-DrugBank.d87.s14	true	DDI-DrugBank.d87.s14.e0	DDI-DrugBank.d87.s14.e1
DDI-DrugBank.d87.s15|a|When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
DDI-DrugBank.d87.s15	5	14	amiodarone	drug	DDI-DrugBank.d87.s15.e0
DDI-DrugBank.d87.s15	28	37	flecainide	drug	DDI-DrugBank.d87.s15.e1
DDI-DrugBank.d87.s15	55	64	flecainide	drug	DDI-DrugBank.d87.s15.e2
DDI-DrugBank.d87.s15	124	133	flecainide	drug	DDI-DrugBank.d87.s15.e3
DDI-DrugBank.d87.s15	true	DDI-DrugBank.d87.s15.e0	DDI-DrugBank.d87.s15.e1
DDI-DrugBank.d87.s15	false	DDI-DrugBank.d87.s15.e0	DDI-DrugBank.d87.s15.e2
DDI-DrugBank.d87.s15	false	DDI-DrugBank.d87.s15.e0	DDI-DrugBank.d87.s15.e3
DDI-DrugBank.d87.s15	false	DDI-DrugBank.d87.s15.e1	DDI-DrugBank.d87.s15.e2
DDI-DrugBank.d87.s15	false	DDI-DrugBank.d87.s15.e1	DDI-DrugBank.d87.s15.e3
DDI-DrugBank.d87.s15	false	DDI-DrugBank.d87.s15.e2	DDI-DrugBank.d87.s15.e3
DDI-DrugBank.d87.s16|a|Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;
DDI-DrugBank.d87.s16	48	56	quinidine	drug	DDI-DrugBank.d87.s16.e0
DDI-DrugBank.d87.s16	104	113	flecainide	drug	DDI-DrugBank.d87.s16.e1
DDI-DrugBank.d87.s16	147	156	flecainide	drug	DDI-DrugBank.d87.s16.e2
DDI-DrugBank.d87.s16	true	DDI-DrugBank.d87.s16.e0	DDI-DrugBank.d87.s16.e1
DDI-DrugBank.d87.s16	false	DDI-DrugBank.d87.s16.e0	DDI-DrugBank.d87.s16.e2
DDI-DrugBank.d87.s16	false	DDI-DrugBank.d87.s16.e1	DDI-DrugBank.d87.s16.e2
DDI-DrugBank.d87.s17|a|especially if these patients are extensive metabolizers.
DDI-DrugBank.d87.s18|a|There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil.
DDI-DrugBank.d87.s18	62	69	TAMBOCOR	brand	DDI-DrugBank.d87.s18.e0
DDI-DrugBank.d87.s18	82	93	disopyramide	drug	DDI-DrugBank.d87.s18.e1
DDI-DrugBank.d87.s18	98	106	verapamil	drug	DDI-DrugBank.d87.s18.e2
DDI-DrugBank.d87.s18	false	DDI-DrugBank.d87.s18.e0	DDI-DrugBank.d87.s18.e1
DDI-DrugBank.d87.s18	false	DDI-DrugBank.d87.s18.e0	DDI-DrugBank.d87.s18.e2
DDI-DrugBank.d87.s18	false	DDI-DrugBank.d87.s18.e1	DDI-DrugBank.d87.s18.e2
DDI-DrugBank.d87.s19|a|Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
DDI-DrugBank.d87.s19	104	111	TAMBOCOR	brand	DDI-DrugBank.d87.s19.e0
DDI-DrugBank.d87.s19	134	145	disopyramide	drug	DDI-DrugBank.d87.s19.e1
DDI-DrugBank.d87.s19	151	159	verapamil	drug	DDI-DrugBank.d87.s19.e2
DDI-DrugBank.d87.s19	202	209	TAMBOCOR	brand	DDI-DrugBank.d87.s19.e3
DDI-DrugBank.d87.s19	false	DDI-DrugBank.d87.s19.e0	DDI-DrugBank.d87.s19.e1
DDI-DrugBank.d87.s19	false	DDI-DrugBank.d87.s19.e0	DDI-DrugBank.d87.s19.e2
DDI-DrugBank.d87.s19	false	DDI-DrugBank.d87.s19.e0	DDI-DrugBank.d87.s19.e3
DDI-DrugBank.d87.s19	false	DDI-DrugBank.d87.s19.e1	DDI-DrugBank.d87.s19.e2
DDI-DrugBank.d87.s19	true	DDI-DrugBank.d87.s19.e1	DDI-DrugBank.d87.s19.e3
DDI-DrugBank.d87.s19	true	DDI-DrugBank.d87.s19.e2	DDI-DrugBank.d87.s19.e3
DDI-DrugBank.d87.s20|a|There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.
DDI-DrugBank.d87.s20	66	73	TAMBOCOR	brand	DDI-DrugBank.d87.s20.e0
DDI-DrugBank.d87.s20	80	89	nifedipine	drug	DDI-DrugBank.d87.s20.e1
DDI-DrugBank.d87.s20	94	102	diltiazem	drug	DDI-DrugBank.d87.s20.e2
DDI-DrugBank.d87.s20	false	DDI-DrugBank.d87.s20.e0	DDI-DrugBank.d87.s20.e1
DDI-DrugBank.d87.s20	false	DDI-DrugBank.d87.s20.e0	DDI-DrugBank.d87.s20.e2
DDI-DrugBank.d87.s20	false	DDI-DrugBank.d87.s20.e1	DDI-DrugBank.d87.s20.e2
DDI-DrugBank.d361.s0|a|Combination Therapy: Any form of therapy which adds to the stress of the patient, interferes with nutrition or depresses bone marrow function will increase the toxicity of Floxuridine.
DDI-DrugBank.d361.s0	172	182	Floxuridine	drug	DDI-DrugBank.d361.s0.e0
DDI-DrugBank.d453.s0|a|Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.
DDI-DrugBank.d453.s0	0	19	Cytosine arabinoside	drug	DDI-DrugBank.d453.s0.e0
DDI-DrugBank.d453.s0	24	39	cytostatic agent	group	DDI-DrugBank.d453.s0.e1
DDI-DrugBank.d453.s0	101	111	flucytosine	drug	DDI-DrugBank.d453.s0.e2
DDI-DrugBank.d453.s0	false	DDI-DrugBank.d453.s0.e0	DDI-DrugBank.d453.s0.e1
DDI-DrugBank.d453.s0	true	DDI-DrugBank.d453.s0.e0	DDI-DrugBank.d453.s0.e2
DDI-DrugBank.d453.s0	false	DDI-DrugBank.d453.s0.e1	DDI-DrugBank.d453.s0.e2
DDI-DrugBank.d453.s1|a|Drugs which impair glomerular filtration may prolong the biological half-life of flucytosine.
DDI-DrugBank.d453.s1	81	91	flucytosine	drug	DDI-DrugBank.d453.s1.e0
DDI-DrugBank.d453.s2|a|Drug/Laboratory Test Interactions: Measurement of serum creatinine levels should be determined by the Jaffe reaction, since Ancobon does not interfere with the determination of creatinine values by this method.
DDI-DrugBank.d453.s2	124	130	Ancobon	brand	DDI-DrugBank.d453.s2.e0
DDI-DrugBank.d453.s3|a|Most automated equipment for measurement of creatinine makes use of the Jaffe reaction.
DDI-DrugBank.d444.s0|a|The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.
DDI-DrugBank.d444.s0	11	17	FLUDARA	brand	DDI-DrugBank.d444.s0.e0
DDI-DrugBank.d444.s0	53	63	pentostatin	drug	DDI-DrugBank.d444.s0.e1
DDI-DrugBank.d444.s0	true	DDI-DrugBank.d444.s0.e0	DDI-DrugBank.d444.s0.e1
DDI-DrugBank.d526.s0|a|When administered concurrently, the following drugs may interact with adrenal corticosteroids.
DDI-DrugBank.d526.s0	70	92	adrenal corticosteroids	group	DDI-DrugBank.d526.s0.e0
DDI-DrugBank.d526.s1|a|Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.
DDI-DrugBank.d526.s1	0	13	Amphotericin B	drug	DDI-DrugBank.d526.s1.e0
DDI-DrugBank.d526.s1	18	46	potassium-depleting diuretics	group	DDI-DrugBank.d526.s1.e1
DDI-DrugBank.d526.s1	49	65	benzothiadiazines	group	DDI-DrugBank.d526.s1.e2
DDI-DrugBank.d526.s1	86	100	ethacrynic acid	drug	DDI-DrugBank.d526.s1.e3
DDI-DrugBank.d526.s1	106	115	furosemide	drug	DDI-DrugBank.d526.s1.e4
DDI-DrugBank.d526.s1	false	DDI-DrugBank.d526.s1.e0	DDI-DrugBank.d526.s1.e1
DDI-DrugBank.d526.s1	false	DDI-DrugBank.d526.s1.e0	DDI-DrugBank.d526.s1.e2
DDI-DrugBank.d526.s1	false	DDI-DrugBank.d526.s1.e0	DDI-DrugBank.d526.s1.e3
DDI-DrugBank.d526.s1	false	DDI-DrugBank.d526.s1.e0	DDI-DrugBank.d526.s1.e4
DDI-DrugBank.d526.s1	false	DDI-DrugBank.d526.s1.e1	DDI-DrugBank.d526.s1.e2
DDI-DrugBank.d526.s1	false	DDI-DrugBank.d526.s1.e1	DDI-DrugBank.d526.s1.e3
DDI-DrugBank.d526.s1	false	DDI-DrugBank.d526.s1.e1	DDI-DrugBank.d526.s1.e4
DDI-DrugBank.d526.s1	false	DDI-DrugBank.d526.s1.e2	DDI-DrugBank.d526.s1.e3
DDI-DrugBank.d526.s1	false	DDI-DrugBank.d526.s1.e2	DDI-DrugBank.d526.s1.e4
DDI-DrugBank.d526.s1	false	DDI-DrugBank.d526.s1.e3	DDI-DrugBank.d526.s1.e4
DDI-DrugBank.d526.s2|a|Check serum potassium levels at frequent intervals;
DDI-DrugBank.d526.s3|a|use potassium supplements if necessary .
DDI-DrugBank.d526.s3	4	12	potassium	drug	DDI-DrugBank.d526.s3.e0
DDI-DrugBank.d526.s4|a|Digitalis glycosides enhanced possibility of arrhythmias or digitalis toxicity associated with hypokalemia.
DDI-DrugBank.d526.s4	0	19	Digitalis glycosides	group	DDI-DrugBank.d526.s4.e0
DDI-DrugBank.d526.s4	60	68	digitalis	group	DDI-DrugBank.d526.s4.e1
DDI-DrugBank.d526.s4	false	DDI-DrugBank.d526.s4.e0	DDI-DrugBank.d526.s4.e1
DDI-DrugBank.d526.s5|a|Monitor serum potassium levels;
DDI-DrugBank.d526.s6|a|use potassium supplements if necessary.
DDI-DrugBank.d526.s6	4	12	potassium	drug	DDI-DrugBank.d526.s6.e0
DDI-DrugBank.d526.s7|a|Oral anticoagulants decreased prothrombin time response.
DDI-DrugBank.d526.s7	5	18	anticoagulants	group	DDI-DrugBank.d526.s7.e0
DDI-DrugBank.d526.s8|a|Monitor prothrombin levels and adjust anticoagulant dosage accordingly.
DDI-DrugBank.d526.s8	38	50	anticoagulant	group	DDI-DrugBank.d526.s8.e0
DDI-DrugBank.d526.s9|a|Antidiabetic drugs (oral agents and insulin) diminished antidiabetic effect.
DDI-DrugBank.d526.s9	0	17	Antidiabetic drugs	group	DDI-DrugBank.d526.s9.e0
DDI-DrugBank.d526.s9	36	42	insulin	drug	DDI-DrugBank.d526.s9.e1
DDI-DrugBank.d526.s9	false	DDI-DrugBank.d526.s9.e0	DDI-DrugBank.d526.s9.e1
DDI-DrugBank.d526.s10|a|Monitor for symptoms of hyperglycemia;
DDI-DrugBank.d526.s11|a|adjust dosage of antidiabetic drug upward if necessary.
DDI-DrugBank.d526.s11	17	33	antidiabetic drug	group	DDI-DrugBank.d526.s11.e0
DDI-DrugBank.d526.s12|a|Aspirin increased ulcerogenic effect;
DDI-DrugBank.d526.s12	0	6	Aspirin	brand	DDI-DrugBank.d526.s12.e0
DDI-DrugBank.d526.s13|a|decreased pharmacologic effect of aspirin.
DDI-DrugBank.d526.s13	34	40	aspirin	brand	DDI-DrugBank.d526.s13.e0
DDI-DrugBank.d526.s14|a|Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.
DDI-DrugBank.d526.s14	7	16	salicylate	group	DDI-DrugBank.d526.s14.e0
DDI-DrugBank.d526.s14	65	72	steroids	group	DDI-DrugBank.d526.s14.e1
DDI-DrugBank.d526.s14	101	107	aspirin	brand	DDI-DrugBank.d526.s14.e2
DDI-DrugBank.d526.s14	false	DDI-DrugBank.d526.s14.e0	DDI-DrugBank.d526.s14.e1
DDI-DrugBank.d526.s14	false	DDI-DrugBank.d526.s14.e0	DDI-DrugBank.d526.s14.e2
DDI-DrugBank.d526.s14	true	DDI-DrugBank.d526.s14.e1	DDI-DrugBank.d526.s14.e2
DDI-DrugBank.d526.s15|a|Monitor salicylate levels or the therapeutic effect for which aspirin is given;
DDI-DrugBank.d526.s15	8	17	salicylate	group	DDI-DrugBank.d526.s15.e0
DDI-DrugBank.d526.s15	62	68	aspirin	brand	DDI-DrugBank.d526.s15.e1
DDI-DrugBank.d526.s15	false	DDI-DrugBank.d526.s15.e0	DDI-DrugBank.d526.s15.e1
DDI-DrugBank.d526.s16|a|adjust salicylate dosage accordingly if effect is altered.
DDI-DrugBank.d526.s16	7	16	salicylate	group	DDI-DrugBank.d526.s16.e0
DDI-DrugBank.d526.s17|a|Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
DDI-DrugBank.d526.s17	0	11	Barbiturates	group	DDI-DrugBank.d526.s17.e0
DDI-DrugBank.d526.s17	14	22	phenytoin	drug	DDI-DrugBank.d526.s17.e1
DDI-DrugBank.d526.s17	28	35	rifampin	drug	DDI-DrugBank.d526.s17.e2
DDI-DrugBank.d526.s17	70	92	fludrocortisone acetate	drug	DDI-DrugBank.d526.s17.e3
DDI-DrugBank.d526.s17	false	DDI-DrugBank.d526.s17.e0	DDI-DrugBank.d526.s17.e1
DDI-DrugBank.d526.s17	false	DDI-DrugBank.d526.s17.e0	DDI-DrugBank.d526.s17.e2
DDI-DrugBank.d526.s17	true	DDI-DrugBank.d526.s17.e0	DDI-DrugBank.d526.s17.e3
DDI-DrugBank.d526.s17	false	DDI-DrugBank.d526.s17.e1	DDI-DrugBank.d526.s17.e2
DDI-DrugBank.d526.s17	true	DDI-DrugBank.d526.s17.e1	DDI-DrugBank.d526.s17.e3
DDI-DrugBank.d526.s17	true	DDI-DrugBank.d526.s17.e2	DDI-DrugBank.d526.s17.e3
DDI-DrugBank.d526.s18|a|Observe the patient for possible diminished effect of steroid and increase the steroid dosage accordingly.
DDI-DrugBank.d526.s18	54	60	steroid	group	DDI-DrugBank.d526.s18.e0
DDI-DrugBank.d526.s18	79	85	steroid	group	DDI-DrugBank.d526.s18.e1
DDI-DrugBank.d526.s18	false	DDI-DrugBank.d526.s18.e0	DDI-DrugBank.d526.s18.e1
DDI-DrugBank.d526.s19|a|Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.
DDI-DrugBank.d526.s19	0	16	Anabolic steroids	group	DDI-DrugBank.d526.s19.e0
DDI-DrugBank.d526.s19	47	55	androgens	group	DDI-DrugBank.d526.s19.e1
DDI-DrugBank.d526.s19	65	76	oxymetholone	drug	DDI-DrugBank.d526.s19.e2
DDI-DrugBank.d526.s19	79	96	methandrostenolone	drug	DDI-DrugBank.d526.s19.e3
DDI-DrugBank.d526.s19	99	113	norethandrolone	drug	DDI-DrugBank.d526.s19.e4
DDI-DrugBank.d526.s19	false	DDI-DrugBank.d526.s19.e0	DDI-DrugBank.d526.s19.e1
DDI-DrugBank.d526.s19	false	DDI-DrugBank.d526.s19.e0	DDI-DrugBank.d526.s19.e2
DDI-DrugBank.d526.s19	false	DDI-DrugBank.d526.s19.e0	DDI-DrugBank.d526.s19.e3
DDI-DrugBank.d526.s19	false	DDI-DrugBank.d526.s19.e0	DDI-DrugBank.d526.s19.e4
DDI-DrugBank.d526.s19	false	DDI-DrugBank.d526.s19.e1	DDI-DrugBank.d526.s19.e2
DDI-DrugBank.d526.s19	false	DDI-DrugBank.d526.s19.e1	DDI-DrugBank.d526.s19.e3
DDI-DrugBank.d526.s19	false	DDI-DrugBank.d526.s19.e1	DDI-DrugBank.d526.s19.e4
DDI-DrugBank.d526.s19	false	DDI-DrugBank.d526.s19.e2	DDI-DrugBank.d526.s19.e3
DDI-DrugBank.d526.s19	false	DDI-DrugBank.d526.s19.e2	DDI-DrugBank.d526.s19.e4
DDI-DrugBank.d526.s19	false	DDI-DrugBank.d526.s19.e3	DDI-DrugBank.d526.s19.e4
DDI-DrugBank.d526.s20|a|Use caution when giving these drugs together, especially in patients with hepatic or cardiac disease.
DDI-DrugBank.d526.s21|a|Vaccines neurological complications and lack of antibody response .
DDI-DrugBank.d526.s21	0	7	Vaccines	group	DDI-DrugBank.d526.s21.e0
DDI-DrugBank.d526.s22|a|Estrogen increased levels of corticosteroid-binding globulin, thereby increasing the bound (inactive) fraction;
DDI-DrugBank.d526.s22	0	7	Estrogen	group	DDI-DrugBank.d526.s22.e0
DDI-DrugBank.d526.s23|a|this effect is at least balanced by decreased metabolism of corticosteroids.
DDI-DrugBank.d526.s23	60	74	corticosteroids	group	DDI-DrugBank.d526.s23.e0
DDI-DrugBank.d526.s24|a|When estrogen therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when estrogen is terminated.
DDI-DrugBank.d526.s24	5	12	estrogen	group	DDI-DrugBank.d526.s24.e0
DDI-DrugBank.d526.s24	51	64	corticosteroid	group	DDI-DrugBank.d526.s24.e1
DDI-DrugBank.d526.s24	133	140	estrogen	group	DDI-DrugBank.d526.s24.e2
DDI-DrugBank.d526.s24	false	DDI-DrugBank.d526.s24.e0	DDI-DrugBank.d526.s24.e1
DDI-DrugBank.d526.s24	false	DDI-DrugBank.d526.s24.e0	DDI-DrugBank.d526.s24.e2
DDI-DrugBank.d526.s24	false	DDI-DrugBank.d526.s24.e1	DDI-DrugBank.d526.s24.e2
DDI-DrugBank.d526.s25|a|Drug/Laboratory Test Interactions Corticosteroids may affect the nitrobluetetrazolium test for bacterial infection and produce false-negative results
DDI-DrugBank.d526.s25	34	48	Corticosteroids	group	DDI-DrugBank.d526.s25.e0
DDI-DrugBank.d526.s26|a|.
DDI-DrugBank.d526.s27|a|
DDI-DrugBank.d234.s0|a|Interaction with central nervous system depressants other than benzodiazepines has not been specifically studied;
DDI-DrugBank.d234.s0	17	50	central nervous system depressants	group	DDI-DrugBank.d234.s0.e0
DDI-DrugBank.d234.s0	63	77	benzodiazepines	group	DDI-DrugBank.d234.s0.e1
DDI-DrugBank.d234.s0	false	DDI-DrugBank.d234.s0.e0	DDI-DrugBank.d234.s0.e1
DDI-DrugBank.d234.s1|a|however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.
DDI-DrugBank.d234.s1	52	60	ROMAZICON	brand	DDI-DrugBank.d234.s1.e0
DDI-DrugBank.d234.s1	85	93	narcotics	group	DDI-DrugBank.d234.s1.e1
DDI-DrugBank.d234.s1	109	119	anesthetics	group	DDI-DrugBank.d234.s1.e2
DDI-DrugBank.d234.s1	122	137	muscle relaxants	group	DDI-DrugBank.d234.s1.e3
DDI-DrugBank.d234.s1	false	DDI-DrugBank.d234.s1.e0	DDI-DrugBank.d234.s1.e1
DDI-DrugBank.d234.s1	false	DDI-DrugBank.d234.s1.e0	DDI-DrugBank.d234.s1.e2
DDI-DrugBank.d234.s1	false	DDI-DrugBank.d234.s1.e0	DDI-DrugBank.d234.s1.e3
DDI-DrugBank.d234.s1	false	DDI-DrugBank.d234.s1.e1	DDI-DrugBank.d234.s1.e2
DDI-DrugBank.d234.s1	false	DDI-DrugBank.d234.s1.e1	DDI-DrugBank.d234.s1.e3
DDI-DrugBank.d234.s1	false	DDI-DrugBank.d234.s1.e2	DDI-DrugBank.d234.s1.e3
DDI-DrugBank.d234.s2|a|Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.
DDI-DrugBank.d234.s2	43	51	ROMAZICON	brand	DDI-DrugBank.d234.s2.e0
DDI-DrugBank.d234.s2	203	224	cyclic antidepressants	group	DDI-DrugBank.d234.s2.e1
DDI-DrugBank.d234.s2	263	276	benzodiazepine	group	DDI-DrugBank.d234.s2.e2
DDI-DrugBank.d234.s2	288	297	flumazenil	drug	DDI-DrugBank.d234.s2.e3
DDI-DrugBank.d234.s2	true	DDI-DrugBank.d234.s2.e0	DDI-DrugBank.d234.s2.e1
DDI-DrugBank.d234.s2	false	DDI-DrugBank.d234.s2.e0	DDI-DrugBank.d234.s2.e2
DDI-DrugBank.d234.s2	false	DDI-DrugBank.d234.s2.e0	DDI-DrugBank.d234.s2.e3
DDI-DrugBank.d234.s2	false	DDI-DrugBank.d234.s2.e1	DDI-DrugBank.d234.s2.e2
DDI-DrugBank.d234.s2	false	DDI-DrugBank.d234.s2.e1	DDI-DrugBank.d234.s2.e3
DDI-DrugBank.d234.s2	false	DDI-DrugBank.d234.s2.e2	DDI-DrugBank.d234.s2.e3
DDI-DrugBank.d234.s3|a|The use of ROMAZICON is not recommended in epileptic patients who have been receiving benzodiazepine treatment for a prolonged period.
DDI-DrugBank.d234.s3	11	19	ROMAZICON	brand	DDI-DrugBank.d234.s3.e0
DDI-DrugBank.d234.s4|a|Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.
DDI-DrugBank.d234.s4	9	17	ROMAZICON	brand	DDI-DrugBank.d234.s4.e0
DDI-DrugBank.d234.s4	121	134	benzodiazepine	group	DDI-DrugBank.d234.s4.e1
DDI-DrugBank.d234.s4	true	DDI-DrugBank.d234.s4.e0	DDI-DrugBank.d234.s4.e1
DDI-DrugBank.d234.s5|a|ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.
DDI-DrugBank.d234.s5	0	8	ROMAZICON	brand	DDI-DrugBank.d234.s5.e0
DDI-DrugBank.d234.s5	40	54	benzodiazepines	group	DDI-DrugBank.d234.s5.e1
DDI-DrugBank.d234.s5	true	DDI-DrugBank.d234.s5.e0	DDI-DrugBank.d234.s5.e1
DDI-DrugBank.d234.s6|a|The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.
DDI-DrugBank.d234.s6	79	87	zopiclone	drug	DDI-DrugBank.d234.s6.e0
DDI-DrugBank.d234.s6	142	150	ROMAZICON	brand	DDI-DrugBank.d234.s6.e1
DDI-DrugBank.d234.s6	true	DDI-DrugBank.d234.s6.e0	DDI-DrugBank.d234.s6.e1
DDI-DrugBank.d234.s7|a|The pharmacokinetics of benzodiazepines are unaltered in the presence of flumazenil and vice versa.
DDI-DrugBank.d234.s7	24	38	benzodiazepines	group	DDI-DrugBank.d234.s7.e0
DDI-DrugBank.d234.s7	73	82	flumazenil	drug	DDI-DrugBank.d234.s7.e1
DDI-DrugBank.d234.s7	false	DDI-DrugBank.d234.s7.e0	DDI-DrugBank.d234.s7.e1
DDI-DrugBank.d234.s8|a|There is no pharmacokinetic interaction between ethanol and flumazenil.
DDI-DrugBank.d234.s8	48	54	ethanol	drug	DDI-DrugBank.d234.s8.e0
DDI-DrugBank.d234.s8	60	69	flumazenil	drug	DDI-DrugBank.d234.s8.e1
DDI-DrugBank.d234.s8	false	DDI-DrugBank.d234.s8.e0	DDI-DrugBank.d234.s8.e1
DDI-DrugBank.d234.s9|a|Use in Ambulatory Patients The effects of ROMAZICON may wear off before a long-acting benzodiazepine is completely cleared from the body.
DDI-DrugBank.d234.s9	42	50	ROMAZICON	brand	DDI-DrugBank.d234.s9.e0
DDI-DrugBank.d234.s9	74	99	long-acting benzodiazepine	group	DDI-DrugBank.d234.s9.e1
DDI-DrugBank.d234.s9	false	DDI-DrugBank.d234.s9.e0	DDI-DrugBank.d234.s9.e1
DDI-DrugBank.d234.s10|a|In general, if a patient shows no signs of sedation within 2 hours after a 1-mg dose of flumazenil, serious resedation at a later time is unlikely.
DDI-DrugBank.d234.s10	88	97	flumazenil	drug	DDI-DrugBank.d234.s10.e0
DDI-DrugBank.d234.s11|a|An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam) or large doses of short-acting benzodiazepines (such as  10 mg of midazolam) have been used.
DDI-DrugBank.d234.s11	82	108	long-acting benzodiazepines	group	DDI-DrugBank.d234.s11.e0
DDI-DrugBank.d234.s11	119	126	diazepam	drug	DDI-DrugBank.d234.s11.e1
DDI-DrugBank.d234.s11	147	174	short-acting benzodiazepines	group	DDI-DrugBank.d234.s11.e2
DDI-DrugBank.d234.s11	195	203	midazolam	drug	DDI-DrugBank.d234.s11.e3
DDI-DrugBank.d234.s11	false	DDI-DrugBank.d234.s11.e0	DDI-DrugBank.d234.s11.e1
DDI-DrugBank.d234.s11	false	DDI-DrugBank.d234.s11.e0	DDI-DrugBank.d234.s11.e2
DDI-DrugBank.d234.s11	false	DDI-DrugBank.d234.s11.e0	DDI-DrugBank.d234.s11.e3
DDI-DrugBank.d234.s11	false	DDI-DrugBank.d234.s11.e1	DDI-DrugBank.d234.s11.e2
DDI-DrugBank.d234.s11	false	DDI-DrugBank.d234.s11.e1	DDI-DrugBank.d234.s11.e3
DDI-DrugBank.d234.s11	false	DDI-DrugBank.d234.s11.e2	DDI-DrugBank.d234.s11.e3
DDI-DrugBank.d234.s12|a|Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
DDI-DrugBank.d234.s12	84	98	benzodiazepines	group	DDI-DrugBank.d234.s12.e0
DDI-DrugBank.d234.s12	215	228	benzodiazepine	group	DDI-DrugBank.d234.s12.e1
DDI-DrugBank.d234.s12	231	237	alcohol	drug	DDI-DrugBank.d234.s12.e2
DDI-DrugBank.d234.s12	243	250	sedative	group	DDI-DrugBank.d234.s12.e3
DDI-DrugBank.d234.s12	322	330	ROMAZICON	brand	DDI-DrugBank.d234.s12.e4
DDI-DrugBank.d234.s12	false	DDI-DrugBank.d234.s12.e0	DDI-DrugBank.d234.s12.e1
DDI-DrugBank.d234.s12	false	DDI-DrugBank.d234.s12.e0	DDI-DrugBank.d234.s12.e2
DDI-DrugBank.d234.s12	false	DDI-DrugBank.d234.s12.e0	DDI-DrugBank.d234.s12.e3
DDI-DrugBank.d234.s12	false	DDI-DrugBank.d234.s12.e0	DDI-DrugBank.d234.s12.e4
DDI-DrugBank.d234.s12	false	DDI-DrugBank.d234.s12.e1	DDI-DrugBank.d234.s12.e2
DDI-DrugBank.d234.s12	false	DDI-DrugBank.d234.s12.e1	DDI-DrugBank.d234.s12.e3
DDI-DrugBank.d234.s12	false	DDI-DrugBank.d234.s12.e1	DDI-DrugBank.d234.s12.e4
DDI-DrugBank.d234.s12	false	DDI-DrugBank.d234.s12.e2	DDI-DrugBank.d234.s12.e3
DDI-DrugBank.d234.s12	false	DDI-DrugBank.d234.s12.e2	DDI-DrugBank.d234.s12.e4
DDI-DrugBank.d234.s12	false	DDI-DrugBank.d234.s12.e3	DDI-DrugBank.d234.s12.e4
DDI-DrugBank.d214.s0|a|No information available.
DDI-DrugBank.d482.s0|a|Do not take this medicine with thioridizine, or within 5 weeks of taking fluoxetine.
DDI-DrugBank.d482.s0	73	82	fluoxetine	drug	DDI-DrugBank.d482.s0.e0
DDI-DrugBank.d482.s1|a|Talk to your doctor if you are taking certain antibiotics such as erythromycin, clarithromycin or azithromycin.
DDI-DrugBank.d482.s1	46	56	antibiotics	group	DDI-DrugBank.d482.s1.e0
DDI-DrugBank.d482.s1	66	77	erythromycin	drug	DDI-DrugBank.d482.s1.e1
DDI-DrugBank.d482.s1	80	93	clarithromycin	drug	DDI-DrugBank.d482.s1.e2
DDI-DrugBank.d482.s1	98	109	azithromycin	drug	DDI-DrugBank.d482.s1.e3
DDI-DrugBank.d482.s1	false	DDI-DrugBank.d482.s1.e0	DDI-DrugBank.d482.s1.e1
DDI-DrugBank.d482.s1	false	DDI-DrugBank.d482.s1.e0	DDI-DrugBank.d482.s1.e2
DDI-DrugBank.d482.s1	false	DDI-DrugBank.d482.s1.e0	DDI-DrugBank.d482.s1.e3
DDI-DrugBank.d482.s1	false	DDI-DrugBank.d482.s1.e1	DDI-DrugBank.d482.s1.e2
DDI-DrugBank.d482.s1	false	DDI-DrugBank.d482.s1.e1	DDI-DrugBank.d482.s1.e3
DDI-DrugBank.d482.s1	false	DDI-DrugBank.d482.s1.e2	DDI-DrugBank.d482.s1.e3
DDI-DrugBank.d482.s2|a|This medicine should not be taken with MAO inhibitors.
DDI-DrugBank.d482.s2	39	52	MAO inhibitors	group	DDI-DrugBank.d482.s2.e0
DDI-DrugBank.d482.s3|a|Caution should be exercised when taking this medicine certain antibiotics, such as erythromycin, clarithromycin, or azithromycin.
DDI-DrugBank.d482.s3	62	72	antibiotics	group	DDI-DrugBank.d482.s3.e0
DDI-DrugBank.d482.s3	83	94	erythromycin	drug	DDI-DrugBank.d482.s3.e1
DDI-DrugBank.d482.s3	97	110	clarithromycin	drug	DDI-DrugBank.d482.s3.e2
DDI-DrugBank.d482.s3	116	127	azithromycin	drug	DDI-DrugBank.d482.s3.e3
DDI-DrugBank.d482.s3	false	DDI-DrugBank.d482.s3.e0	DDI-DrugBank.d482.s3.e1
DDI-DrugBank.d482.s3	false	DDI-DrugBank.d482.s3.e0	DDI-DrugBank.d482.s3.e2
DDI-DrugBank.d482.s3	false	DDI-DrugBank.d482.s3.e0	DDI-DrugBank.d482.s3.e3
DDI-DrugBank.d482.s3	false	DDI-DrugBank.d482.s3.e1	DDI-DrugBank.d482.s3.e2
DDI-DrugBank.d482.s3	false	DDI-DrugBank.d482.s3.e1	DDI-DrugBank.d482.s3.e3
DDI-DrugBank.d482.s3	false	DDI-DrugBank.d482.s3.e2	DDI-DrugBank.d482.s3.e3
DDI-DrugBank.d482.s4|a|This medicine should not be taken with MAO inhibitors.
DDI-DrugBank.d482.s4	39	52	MAO inhibitors	group	DDI-DrugBank.d482.s4.e0
DDI-DrugBank.d482.s5|a|If you think you are taking an MAO inhibitor talk to your doctor or pharmacist.
DDI-DrugBank.d482.s5	31	43	MAO inhibitor	group	DDI-DrugBank.d482.s5.e0
DDI-DrugBank.d482.s6|a|Do not take this medicine with St. Johns Wort because of the additive effects of sertonin.
DDI-DrugBank.d482.s7|a|This medication should not be taken with MAO inhibitors.
DDI-DrugBank.d482.s7	41	54	MAO inhibitors	group	DDI-DrugBank.d482.s7.e0
DDI-DrugBank.d482.s8|a|Your doctor or pharmacist can give you more information on MAO inhibitors.
DDI-DrugBank.d482.s8	59	72	MAO inhibitors	group	DDI-DrugBank.d482.s8.e0
DDI-DrugBank.d482.s9|a|Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.
DDI-DrugBank.d482.s9	28	39	escitalopram	drug	DDI-DrugBank.d482.s9.e0
DDI-DrugBank.d482.s9	59	85	non-selective MAO inhibitor	group	DDI-DrugBank.d482.s9.e1
DDI-DrugBank.d482.s9	true	DDI-DrugBank.d482.s9.e0	DDI-DrugBank.d482.s9.e1
DDI-DrugBank.d482.s10|a|Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.
DDI-DrugBank.d482.s10	31	43	MAO inhibitor	group	DDI-DrugBank.d482.s10.e0
DDI-DrugBank.d482.s10	61	72	escitalopram	drug	DDI-DrugBank.d482.s10.e1
DDI-DrugBank.d482.s10	true	DDI-DrugBank.d482.s10.e0	DDI-DrugBank.d482.s10.e1
DDI-DrugBank.d482.s11|a|If you are taking medications for migraines such as Imitrex, talk to your doctor before starting this medicine.
DDI-DrugBank.d482.s11	52	58	Imitrex	brand	DDI-DrugBank.d482.s11.e0
DDI-DrugBank.d482.s12|a|If you are taking a tricyclic antidepressant, talk to your doctor before taking this medicine.
DDI-DrugBank.d482.s12	20	43	tricyclic antidepressant	group	DDI-DrugBank.d482.s12.e0
DDI-DrugBank.d482.s13|a|St. John  s Wort should be avoided while taking this medicine due to the additive effects of serotonin.
DDI-DrugBank.d482.s14|a|Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14	63	75	blood thinner	group	DDI-DrugBank.d482.s14.e0
DDI-DrugBank.d482.s14	79	86	Coumadin	brand	DDI-DrugBank.d482.s14.e1
DDI-DrugBank.d482.s14	95	109	antidepressants	group	DDI-DrugBank.d482.s14.e2
DDI-DrugBank.d482.s14	111	120	metoprolol	drug	DDI-DrugBank.d482.s14.e3
DDI-DrugBank.d482.s14	122	135	antihistamines	group	DDI-DrugBank.d482.s14.e4
DDI-DrugBank.d482.s14	137	149	carbamazepine	drug	DDI-DrugBank.d482.s14.e5
DDI-DrugBank.d482.s14	152	159	Tegretol	brand	DDI-DrugBank.d482.s14.e6
DDI-DrugBank.d482.s14	162	171	cimetidine	drug	DDI-DrugBank.d482.s14.e7
DDI-DrugBank.d482.s14	174	180	Tagamet	brand	DDI-DrugBank.d482.s14.e8
DDI-DrugBank.d482.s14	183	191	estrogens	group	DDI-DrugBank.d482.s14.e9
DDI-DrugBank.d482.s14	false	DDI-DrugBank.d482.s14.e0	DDI-DrugBank.d482.s14.e1
DDI-DrugBank.d482.s14	false	DDI-DrugBank.d482.s14.e0	DDI-DrugBank.d482.s14.e2
DDI-DrugBank.d482.s14	false	DDI-DrugBank.d482.s14.e0	DDI-DrugBank.d482.s14.e3
DDI-DrugBank.d482.s14	false	DDI-DrugBank.d482.s14.e0	DDI-DrugBank.d482.s14.e4
DDI-DrugBank.d482.s14	false	DDI-DrugBank.d482.s14.e0	DDI-DrugBank.d482.s14.e5
DDI-DrugBank.d482.s14	false	DDI-DrugBank.d482.s14.e0	DDI-DrugBank.d482.s14.e6
DDI-DrugBank.d482.s14	false	DDI-DrugBank.d482.s14.e0	DDI-DrugBank.d482.s14.e7
DDI-DrugBank.d482.s14	false	DDI-DrugBank.d482.s14.e0	DDI-DrugBank.d482.s14.e8
DDI-DrugBank.d482.s14	false	DDI-DrugBank.d482.s14.e0	DDI-DrugBank.d482.s14.e9
DDI-DrugBank.d482.s14	false	DDI-DrugBank.d482.s14.e0	DDI-DrugBank.d482.s14.e10
DDI-DrugBank.d355.s0|a|Androgens may increase sensitivity to oral anticoagulahts.
DDI-DrugBank.d355.s0	0	8	Androgens	group	DDI-DrugBank.d355.s0.e0
DDI-DrugBank.d355.s1|a|Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.
DDI-DrugBank.d355.s1	14	26	anticoagulant	group	DDI-DrugBank.d355.s1.e0
DDI-DrugBank.d355.s2|a|Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
DDI-DrugBank.d355.s2	29	43	oxyphenbutazone	drug	DDI-DrugBank.d355.s2.e0
DDI-DrugBank.d355.s2	49	57	androgens	group	DDI-DrugBank.d355.s2.e1
DDI-DrugBank.d355.s2	98	112	oxyphenbutazone	drug	DDI-DrugBank.d355.s2.e2
DDI-DrugBank.d355.s2	true	DDI-DrugBank.d355.s2.e0	DDI-DrugBank.d355.s2.e1
DDI-DrugBank.d355.s2	false	DDI-DrugBank.d355.s2.e0	DDI-DrugBank.d355.s2.e2
DDI-DrugBank.d355.s2	false	DDI-DrugBank.d355.s2.e1	DDI-DrugBank.d355.s2.e2
DDI-DrugBank.d355.s3|a|In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
DDI-DrugBank.d355.s3	47	55	androgens	group	DDI-DrugBank.d355.s3.e0
DDI-DrugBank.d355.s3	99	105	insulin	drug	DDI-DrugBank.d355.s3.e1
DDI-DrugBank.d355.s3	true	DDI-DrugBank.d355.s3.e0	DDI-DrugBank.d355.s3.e1
DDI-DrugBank.d13.s0|a|Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
DDI-DrugBank.d13.s0	19	30	Flupenthixol	drug	DDI-DrugBank.d13.s0.e0
DDI-DrugBank.d13.s0	67	94	Monoamine oxidase inhibitors	group	DDI-DrugBank.d13.s0.e1
DDI-DrugBank.d13.s0	97	100	MAOI	group	DDI-DrugBank.d13.s0.e2
DDI-DrugBank.d13.s0	104	107	MAOI	group	DDI-DrugBank.d13.s0.e3
DDI-DrugBank.d13.s0	136	147	flupenthixol	drug	DDI-DrugBank.d13.s0.e4
DDI-DrugBank.d13.s0	168	176	Arecoline	drug_n	DDI-DrugBank.d13.s0.e5
DDI-DrugBank.d13.s0	194	200	Ethanol	drug	DDI-DrugBank.d13.s0.e6
DDI-DrugBank.d13.s0	203	214	Flupenthixol	drug	DDI-DrugBank.d13.s0.e7
DDI-DrugBank.d13.s0	220	226	Ethanol	drug	DDI-DrugBank.d13.s0.e8
DDI-DrugBank.d13.s0	260	284	Tricyclic antidepressants	group	DDI-DrugBank.d13.s0.e9
DDI-DrugBank.d13.s0	true	DDI-DrugBank.d13.s0.e0	DDI-DrugBank.d13.s0.e1
DDI-DrugBank.d13.s0	true	DDI-DrugBank.d13.s0.e0	DDI-DrugBank.d13.s0.e2
DDI-DrugBank.d13.s0	false	DDI-DrugBank.d13.s0.e0	DDI-DrugBank.d13.s0.e3
DDI-DrugBank.d13.s0	false	DDI-DrugBank.d13.s0.e0	DDI-DrugBank.d13.s0.e4
DDI-DrugBank.d13.s0	false	DDI-DrugBank.d13.s0.e0	DDI-DrugBank.d13.s0.e5
DDI-DrugBank.d13.s0	false	DDI-DrugBank.d13.s0.e0	DDI-DrugBank.d13.s0.e6
DDI-DrugBank.d13.s0	false	DDI-DrugBank.d13.s0.e0	DDI-DrugBank.d13.s0.e7
DDI-DrugBank.d13.s0	false	DDI-DrugBank.d13.s0.e0	DDI-DrugBank.d13.s0.e8
DDI-DrugBank.d13.s0	false	DDI-DrugBank.d13.s0.e0	DDI-DrugBank.d13.s0.e9
DDI-DrugBank.d13.s0	false	DDI-DrugBank.d13.s0.e0	DDI-DrugBank.d13.s0.e10
DDI-DrugBank.d529.s0|a|Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).
DDI-DrugBank.d529.s0	0	7	Antacids	group	DDI-DrugBank.d529.s0.e0
DDI-DrugBank.d529.s0	28	39	flurbiprofen	drug	DDI-DrugBank.d529.s0.e1
DDI-DrugBank.d529.s0	89	95	antacid	group	DDI-DrugBank.d529.s0.e2
DDI-DrugBank.d529.s0	130	141	flurbiprofen	drug	DDI-DrugBank.d529.s0.e3
DDI-DrugBank.d529.s0	false	DDI-DrugBank.d529.s0.e0	DDI-DrugBank.d529.s0.e1
DDI-DrugBank.d529.s0	false	DDI-DrugBank.d529.s0.e0	DDI-DrugBank.d529.s0.e2
DDI-DrugBank.d529.s0	false	DDI-DrugBank.d529.s0.e0	DDI-DrugBank.d529.s0.e3
DDI-DrugBank.d529.s0	false	DDI-DrugBank.d529.s0.e1	DDI-DrugBank.d529.s0.e2
DDI-DrugBank.d529.s0	false	DDI-DrugBank.d529.s0.e1	DDI-DrugBank.d529.s0.e3
DDI-DrugBank.d529.s0	false	DDI-DrugBank.d529.s0.e2	DDI-DrugBank.d529.s0.e3
DDI-DrugBank.d529.s1|a|In geriatric subjects (n=7) there was a reduction in the rate but not the extent of flurbiprofen absorption.
DDI-DrugBank.d529.s1	84	95	flurbiprofen	drug	DDI-DrugBank.d529.s1.e0
DDI-DrugBank.d529.s2|a|Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
DDI-DrugBank.d529.s2	0	13	Anticoagulants	group	DDI-DrugBank.d529.s2.e0
DDI-DrugBank.d529.s2	16	27	Flurbiprofen	drug	DDI-DrugBank.d529.s2.e1
DDI-DrugBank.d529.s2	40	75	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d529.s2.e2
DDI-DrugBank.d529.s2	145	159	anti-coagulants	group	DDI-DrugBank.d529.s2.e3
DDI-DrugBank.d529.s2	false	DDI-DrugBank.d529.s2.e0	DDI-DrugBank.d529.s2.e1
DDI-DrugBank.d529.s2	false	DDI-DrugBank.d529.s2.e0	DDI-DrugBank.d529.s2.e2
DDI-DrugBank.d529.s2	false	DDI-DrugBank.d529.s2.e0	DDI-DrugBank.d529.s2.e3
DDI-DrugBank.d529.s2	false	DDI-DrugBank.d529.s2.e1	DDI-DrugBank.d529.s2.e2
DDI-DrugBank.d529.s2	true	DDI-DrugBank.d529.s2.e1	DDI-DrugBank.d529.s2.e3
DDI-DrugBank.d529.s2	true	DDI-DrugBank.d529.s2.e2	DDI-DrugBank.d529.s2.e3
DDI-DrugBank.d529.s3|a|The physician should be cautious when administering flurbiprofen to patients taking anticoagulants.
DDI-DrugBank.d529.s3	52	63	flurbiprofen	drug	DDI-DrugBank.d529.s3.e0
DDI-DrugBank.d529.s3	84	97	anticoagulants	group	DDI-DrugBank.d529.s3.e1
DDI-DrugBank.d529.s3	true	DDI-DrugBank.d529.s3.e0	DDI-DrugBank.d529.s3.e1
DDI-DrugBank.d529.s4|a|Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.
DDI-DrugBank.d529.s4	0	6	Aspirin	brand	DDI-DrugBank.d529.s4.e0
DDI-DrugBank.d529.s4	38	44	aspirin	brand	DDI-DrugBank.d529.s4.e1
DDI-DrugBank.d529.s4	50	61	flurbiprofen	drug	DDI-DrugBank.d529.s4.e2
DDI-DrugBank.d529.s4	91	102	flurbiprofen	drug	DDI-DrugBank.d529.s4.e3
DDI-DrugBank.d529.s4	false	DDI-DrugBank.d529.s4.e0	DDI-DrugBank.d529.s4.e1
DDI-DrugBank.d529.s4	false	DDI-DrugBank.d529.s4.e0	DDI-DrugBank.d529.s4.e2
DDI-DrugBank.d529.s4	false	DDI-DrugBank.d529.s4.e0	DDI-DrugBank.d529.s4.e3
DDI-DrugBank.d529.s4	true	DDI-DrugBank.d529.s4.e1	DDI-DrugBank.d529.s4.e2
DDI-DrugBank.d529.s4	false	DDI-DrugBank.d529.s4.e1	DDI-DrugBank.d529.s4.e3
DDI-DrugBank.d529.s4	false	DDI-DrugBank.d529.s4.e2	DDI-DrugBank.d529.s4.e3
DDI-DrugBank.d529.s5|a|This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).
DDI-DrugBank.d529.s5	15	21	aspirin	brand	DDI-DrugBank.d529.s5.e0
DDI-DrugBank.d529.s5	72	107	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d529.s5.e1
DDI-DrugBank.d529.s5	false	DDI-DrugBank.d529.s5.e0	DDI-DrugBank.d529.s5.e1
DDI-DrugBank.d529.s6|a|Concurrent use of flurbiprofen and aspirin is therefore not recommended.
DDI-DrugBank.d529.s6	18	29	flurbiprofen	drug	DDI-DrugBank.d529.s6.e0
DDI-DrugBank.d529.s6	35	41	aspirin	brand	DDI-DrugBank.d529.s6.e1
DDI-DrugBank.d529.s6	true	DDI-DrugBank.d529.s6.e0	DDI-DrugBank.d529.s6.e1
DDI-DrugBank.d529.s7|a|Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).
DDI-DrugBank.d529.s7	0	30	Beta-adrenergic Blocking Agents	group	DDI-DrugBank.d529.s7.e0
DDI-DrugBank.d529.s7	47	58	flurbiprofen	drug	DDI-DrugBank.d529.s7.e1
DDI-DrugBank.d529.s7	90	100	propranolol	drug	DDI-DrugBank.d529.s7.e2
DDI-DrugBank.d529.s7	106	113	atenolol	drug	DDI-DrugBank.d529.s7.e3
DDI-DrugBank.d529.s7	false	DDI-DrugBank.d529.s7.e0	DDI-DrugBank.d529.s7.e1
DDI-DrugBank.d529.s7	false	DDI-DrugBank.d529.s7.e0	DDI-DrugBank.d529.s7.e2
DDI-DrugBank.d529.s7	false	DDI-DrugBank.d529.s7.e0	DDI-DrugBank.d529.s7.e3
DDI-DrugBank.d529.s7	false	DDI-DrugBank.d529.s7.e1	DDI-DrugBank.d529.s7.e2
DDI-DrugBank.d529.s7	false	DDI-DrugBank.d529.s7.e1	DDI-DrugBank.d529.s7.e3
DDI-DrugBank.d529.s7	false	DDI-DrugBank.d529.s7.e2	DDI-DrugBank.d529.s7.e3
DDI-DrugBank.d529.s8|a|Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol.
DDI-DrugBank.d529.s8	0	11	Flurbiprofen	drug	DDI-DrugBank.d529.s8.e0
DDI-DrugBank.d529.s8	80	90	propranolol	drug	DDI-DrugBank.d529.s8.e1
DDI-DrugBank.d529.s8	100	107	atenolol	drug	DDI-DrugBank.d529.s8.e2
DDI-DrugBank.d529.s8	true	DDI-DrugBank.d529.s8.e0	DDI-DrugBank.d529.s8.e1
DDI-DrugBank.d529.s8	false	DDI-DrugBank.d529.s8.e0	DDI-DrugBank.d529.s8.e2
DDI-DrugBank.d529.s8	false	DDI-DrugBank.d529.s8.e1	DDI-DrugBank.d529.s8.e2
DDI-DrugBank.d529.s9|a|Flurbiprofen did not appear to affect the beta-blocker-mediated reduction in heart rate.
DDI-DrugBank.d529.s9	0	11	Flurbiprofen	drug	DDI-DrugBank.d529.s9.e0
DDI-DrugBank.d529.s10|a|Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolols hypotensive effect is unknown.
DDI-DrugBank.d529.s10	0	11	Flurbiprofen	drug	DDI-DrugBank.d529.s10.e0
DDI-DrugBank.d529.s10	124	134	propranolol	drug	DDI-DrugBank.d529.s10.e1
DDI-DrugBank.d529.s10	true	DDI-DrugBank.d529.s10.e0	DDI-DrugBank.d529.s10.e1
DDI-DrugBank.d529.s11|a|Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.
DDI-DrugBank.d529.s11	21	32	flurbiprofen	drug	DDI-DrugBank.d529.s11.e0
DDI-DrugBank.d529.s11	40	51	beta-blocker	group	DDI-DrugBank.d529.s11.e1
DDI-DrugBank.d529.s11	true	DDI-DrugBank.d529.s11.e0	DDI-DrugBank.d529.s11.e1
DDI-DrugBank.d529.s12|a|Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
DDI-DrugBank.d529.s12	0	9	Cimetidine	drug	DDI-DrugBank.d529.s12.e0
DDI-DrugBank.d529.s12	12	21	Ranitidine	drug	DDI-DrugBank.d529.s12.e1
DDI-DrugBank.d529.s12	70	79	cimetidine	drug	DDI-DrugBank.d529.s12.e2
DDI-DrugBank.d529.s12	84	93	ranitidine	drug	DDI-DrugBank.d529.s12.e3
DDI-DrugBank.d529.s12	110	121	flurbiprofen	drug	DDI-DrugBank.d529.s12.e4
DDI-DrugBank.d529.s12	257	268	flurbiprofen	drug	DDI-DrugBank.d529.s12.e5
DDI-DrugBank.d529.s12	284	293	cimetidine	drug	DDI-DrugBank.d529.s12.e6
DDI-DrugBank.d529.s12	false	DDI-DrugBank.d529.s12.e0	DDI-DrugBank.d529.s12.e1
DDI-DrugBank.d529.s12	false	DDI-DrugBank.d529.s12.e0	DDI-DrugBank.d529.s12.e2
DDI-DrugBank.d529.s12	false	DDI-DrugBank.d529.s12.e0	DDI-DrugBank.d529.s12.e3
DDI-DrugBank.d529.s12	false	DDI-DrugBank.d529.s12.e0	DDI-DrugBank.d529.s12.e4
DDI-DrugBank.d529.s12	false	DDI-DrugBank.d529.s12.e0	DDI-DrugBank.d529.s12.e5
DDI-DrugBank.d529.s12	false	DDI-DrugBank.d529.s12.e0	DDI-DrugBank.d529.s12.e6
DDI-DrugBank.d529.s12	false	DDI-DrugBank.d529.s12.e1	DDI-DrugBank.d529.s12.e2
DDI-DrugBank.d529.s12	false	DDI-DrugBank.d529.s12.e1	DDI-DrugBank.d529.s12.e3
DDI-DrugBank.d529.s12	false	DDI-DrugBank.d529.s12.e1	DDI-DrugBank.d529.s12.e4
DDI-DrugBank.d529.s12	false	DDI-DrugBank.d529.s12.e1	DDI-DrugBank.d529.s12.e5
DDI-DrugBank.d529.s13|a|Digoxin: Studies of concomitant administration of flurbiprofen and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.
DDI-DrugBank.d529.s13	0	6	Digoxin	drug	DDI-DrugBank.d529.s13.e0
DDI-DrugBank.d529.s13	50	61	flurbiprofen	drug	DDI-DrugBank.d529.s13.e1
DDI-DrugBank.d529.s13	67	73	digoxin	drug	DDI-DrugBank.d529.s13.e2
DDI-DrugBank.d529.s13	false	DDI-DrugBank.d529.s13.e0	DDI-DrugBank.d529.s13.e1
DDI-DrugBank.d529.s13	false	DDI-DrugBank.d529.s13.e0	DDI-DrugBank.d529.s13.e2
DDI-DrugBank.d529.s13	false	DDI-DrugBank.d529.s13.e1	DDI-DrugBank.d529.s13.e2
DDI-DrugBank.d529.s14|a|Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.
DDI-DrugBank.d529.s14	0	8	Diuretics	group	DDI-DrugBank.d529.s14.e0
DDI-DrugBank.d529.s14	56	67	flurbiprofen	drug	DDI-DrugBank.d529.s14.e1
DDI-DrugBank.d529.s14	80	115	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d529.s14.e2
DDI-DrugBank.d529.s14	152	161	furosemide	drug	DDI-DrugBank.d529.s14.e3
DDI-DrugBank.d529.s14	false	DDI-DrugBank.d529.s14.e0	DDI-DrugBank.d529.s14.e1
DDI-DrugBank.d529.s14	false	DDI-DrugBank.d529.s14.e0	DDI-DrugBank.d529.s14.e2
DDI-DrugBank.d529.s14	false	DDI-DrugBank.d529.s14.e0	DDI-DrugBank.d529.s14.e3
DDI-DrugBank.d529.s14	false	DDI-DrugBank.d529.s14.e1	DDI-DrugBank.d529.s14.e2
DDI-DrugBank.d529.s14	true	DDI-DrugBank.d529.s14.e1	DDI-DrugBank.d529.s14.e3
DDI-DrugBank.d529.s14	true	DDI-DrugBank.d529.s14.e2	DDI-DrugBank.d529.s14.e3
DDI-DrugBank.d529.s15|a|Although results have varied from study to study, effects have been shown on furosemide-stimulated diuresis, natriuresis, and kaliuresis.
DDI-DrugBank.d529.s15	77	86	furosemide	drug	DDI-DrugBank.d529.s15.e0
DDI-DrugBank.d529.s16|a|Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.
DDI-DrugBank.d529.s16	6	41	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d529.s16.e0
DDI-DrugBank.d529.s16	114	131	thiazide diuretics	group	DDI-DrugBank.d529.s16.e1
DDI-DrugBank.d529.s16	158	184	potassium-sparing diuretics	group	DDI-DrugBank.d529.s16.e2
DDI-DrugBank.d529.s16	true	DDI-DrugBank.d529.s16.e0	DDI-DrugBank.d529.s16.e1
DDI-DrugBank.d529.s16	true	DDI-DrugBank.d529.s16.e0	DDI-DrugBank.d529.s16.e2
DDI-DrugBank.d529.s16	false	DDI-DrugBank.d529.s16.e1	DDI-DrugBank.d529.s16.e2
DDI-DrugBank.d529.s17|a|Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.
DDI-DrugBank.d529.s17	19	30	flurbiprofen	drug	DDI-DrugBank.d529.s17.e0
DDI-DrugBank.d529.s17	36	45	furosemide	drug	DDI-DrugBank.d529.s17.e1
DDI-DrugBank.d529.s17	56	64	diuretics	group	DDI-DrugBank.d529.s17.e2
DDI-DrugBank.d529.s17	true	DDI-DrugBank.d529.s17.e0	DDI-DrugBank.d529.s17.e1
DDI-DrugBank.d529.s17	true	DDI-DrugBank.d529.s17.e0	DDI-DrugBank.d529.s17.e2
DDI-DrugBank.d529.s17	false	DDI-DrugBank.d529.s17.e1	DDI-DrugBank.d529.s17.e2
DDI-DrugBank.d529.s18|a|Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).
DDI-DrugBank.d529.s18	5	23	Hypoglycemic Agents	group	DDI-DrugBank.d529.s18.e0
DDI-DrugBank.d529.s18	40	51	flurbiprofen	drug	DDI-DrugBank.d529.s18.e1
DDI-DrugBank.d529.s18	109	117	glyburide	drug	DDI-DrugBank.d529.s18.e2
DDI-DrugBank.d529.s18	126	134	metformin	drug	DDI-DrugBank.d529.s18.e3
DDI-DrugBank.d529.s18	142	155	chlorpropamide	drug	DDI-DrugBank.d529.s18.e4
DDI-DrugBank.d529.s18	162	171	phenformin	drug	DDI-DrugBank.d529.s18.e5
DDI-DrugBank.d529.s18	183	191	glyburide	drug	DDI-DrugBank.d529.s18.e6
DDI-DrugBank.d529.s18	198	207	phenformin	drug	DDI-DrugBank.d529.s18.e7
DDI-DrugBank.d529.s18	false	DDI-DrugBank.d529.s18.e0	DDI-DrugBank.d529.s18.e1
DDI-DrugBank.d529.s18	false	DDI-DrugBank.d529.s18.e0	DDI-DrugBank.d529.s18.e2
DDI-DrugBank.d529.s18	false	DDI-DrugBank.d529.s18.e0	DDI-DrugBank.d529.s18.e3
DDI-DrugBank.d529.s18	false	DDI-DrugBank.d529.s18.e0	DDI-DrugBank.d529.s18.e4
DDI-DrugBank.d529.s18	false	DDI-DrugBank.d529.s18.e0	DDI-DrugBank.d529.s18.e5
DDI-DrugBank.d529.s18	false	DDI-DrugBank.d529.s18.e0	DDI-DrugBank.d529.s18.e6
DDI-DrugBank.d529.s18	false	DDI-DrugBank.d529.s18.e0	DDI-DrugBank.d529.s18.e7
DDI-DrugBank.d529.s18	false	DDI-DrugBank.d529.s18.e1	DDI-DrugBank.d529.s18.e2
DDI-DrugBank.d529.s18	false	DDI-DrugBank.d529.s18.e1	DDI-DrugBank.d529.s18.e3
DDI-DrugBank.d529.s18	false	DDI-DrugBank.d529.s18.e1	DDI-DrugBank.d529.s18.e4
DDI-DrugBank.d529.s19|a|Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.
DDI-DrugBank.d529.s19	105	116	flurbiprofen	drug	DDI-DrugBank.d529.s19.e0
DDI-DrugBank.d529.s19	122	140	hypoglycemic agents	group	DDI-DrugBank.d529.s19.e1
DDI-DrugBank.d529.s19	true	DDI-DrugBank.d529.s19.e0	DDI-DrugBank.d529.s19.e1
DDI-DrugBank.d442.s0|a|Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.
DDI-DrugBank.d442.s0	79	86	warfarin	drug	DDI-DrugBank.d442.s0.e0
DDI-DrugBank.d442.s0	102	110	flutamide	drug	DDI-DrugBank.d442.s0.e1
DDI-DrugBank.d442.s0	true	DDI-DrugBank.d442.s0.e0	DDI-DrugBank.d442.s0.e1
DDI-DrugBank.d442.s1|a|Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.
DDI-DrugBank.d442.s1	85	97	anticoagulant	group	DDI-DrugBank.d442.s1.e0
DDI-DrugBank.d442.s1	126	132	EULEXIN	brand	DDI-DrugBank.d442.s1.e1
DDI-DrugBank.d442.s1	179	186	warfarin	drug	DDI-DrugBank.d442.s1.e2
DDI-DrugBank.d442.s1	false	DDI-DrugBank.d442.s1.e0	DDI-DrugBank.d442.s1.e1
DDI-DrugBank.d442.s1	false	DDI-DrugBank.d442.s1.e0	DDI-DrugBank.d442.s1.e2
DDI-DrugBank.d442.s1	true	DDI-DrugBank.d442.s1.e1	DDI-DrugBank.d442.s1.e2
DDI-DrugBank.d76.s0|a|Potential for Interaction with Monoamine Oxidase Inhibitors
DDI-DrugBank.d76.s0	31	58	Monoamine Oxidase Inhibitors	group	DDI-DrugBank.d76.s0.e0
DDI-DrugBank.d76.s1|a|In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
DDI-DrugBank.d76.s1	30	62	serotonin reuptake inhibitor drug	group	DDI-DrugBank.d76.s1.e0
DDI-DrugBank.d76.s1	84	111	monoamine oxidase inhibitors	group	DDI-DrugBank.d76.s1.e1
DDI-DrugBank.d76.s1	114	117	MAOI	group	DDI-DrugBank.d76.s1.e2
DDI-DrugBank.d76.s1	true	DDI-DrugBank.d76.s1.e0	DDI-DrugBank.d76.s1.e1
DDI-DrugBank.d76.s1	true	DDI-DrugBank.d76.s1.e0	DDI-DrugBank.d76.s1.e2
DDI-DrugBank.d76.s1	false	DDI-DrugBank.d76.s1.e1	DDI-DrugBank.d76.s1.e2
DDI-DrugBank.d76.s2|a|These reactions have also been reported in patients who have discontinued that drug and have been started on a MAOI.
DDI-DrugBank.d76.s2	111	114	MAOI	group	DDI-DrugBank.d76.s2.e0
DDI-DrugBank.d76.s3|a|Some cases presented with features resembling neuroleptic malignant syndrome.
DDI-DrugBank.d76.s4|a|Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.
DDI-DrugBank.d76.s4	34	44	Fluvoxamine	drug	DDI-DrugBank.d76.s4.e0
DDI-DrugBank.d76.s4	86	90	MAOIs	group	DDI-DrugBank.d76.s4.e1
DDI-DrugBank.d76.s4	145	148	MAOI	group	DDI-DrugBank.d76.s4.e2
DDI-DrugBank.d76.s4	true	DDI-DrugBank.d76.s4.e0	DDI-DrugBank.d76.s4.e1
DDI-DrugBank.d76.s4	true	DDI-DrugBank.d76.s4.e0	DDI-DrugBank.d76.s4.e2
DDI-DrugBank.d76.s4	false	DDI-DrugBank.d76.s4.e1	DDI-DrugBank.d76.s4.e2
DDI-DrugBank.d76.s5|a|After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.
DDI-DrugBank.d76.s5	15	25	Fluvoxamine	drug	DDI-DrugBank.d76.s5.e0
DDI-DrugBank.d76.s5	89	92	MAOI	group	DDI-DrugBank.d76.s5.e1
DDI-DrugBank.d76.s5	true	DDI-DrugBank.d76.s5.e0	DDI-DrugBank.d76.s5.e1
DDI-DrugBank.d76.s6|a|Potential Terfenadine, Astemizole, and Cisapride Interactions
DDI-DrugBank.d76.s6	10	20	Terfenadine	drug	DDI-DrugBank.d76.s6.e0
DDI-DrugBank.d76.s6	23	32	Astemizole	drug	DDI-DrugBank.d76.s6.e1
DDI-DrugBank.d76.s6	39	47	Cisapride	drug	DDI-DrugBank.d76.s6.e2
DDI-DrugBank.d76.s6	false	DDI-DrugBank.d76.s6.e0	DDI-DrugBank.d76.s6.e1
DDI-DrugBank.d76.s6	false	DDI-DrugBank.d76.s6.e0	DDI-DrugBank.d76.s6.e2
DDI-DrugBank.d76.s6	false	DDI-DrugBank.d76.s6.e1	DDI-DrugBank.d76.s6.e2
DDI-DrugBank.d76.s7|a|Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
DDI-DrugBank.d76.s7	0	10	Terfenadine	drug	DDI-DrugBank.d76.s7.e0
DDI-DrugBank.d76.s7	13	22	astemizole	drug	DDI-DrugBank.d76.s7.e1
DDI-DrugBank.d76.s7	28	36	cisapride	drug	DDI-DrugBank.d76.s7.e2
DDI-DrugBank.d76.s7	129	140	ketoconazole	drug	DDI-DrugBank.d76.s7.e3
DDI-DrugBank.d76.s7	false	DDI-DrugBank.d76.s7.e0	DDI-DrugBank.d76.s7.e1
DDI-DrugBank.d76.s7	false	DDI-DrugBank.d76.s7.e0	DDI-DrugBank.d76.s7.e2
DDI-DrugBank.d76.s7	true	DDI-DrugBank.d76.s7.e0	DDI-DrugBank.d76.s7.e3
DDI-DrugBank.d76.s7	false	DDI-DrugBank.d76.s7.e1	DDI-DrugBank.d76.s7.e2
DDI-DrugBank.d76.s7	true	DDI-DrugBank.d76.s7.e1	DDI-DrugBank.d76.s7.e3
DDI-DrugBank.d76.s7	true	DDI-DrugBank.d76.s7.e2	DDI-DrugBank.d76.s7.e3
DDI-DrugBank.d76.s8|a|Increased plasma concentrations of terfenadine, astemizole, and cisapride cause QT prolongation and have been associated with torsades de pointes-type ventricular tachycardia, sometimes fatal.
DDI-DrugBank.d76.s8	35	45	terfenadine	drug	DDI-DrugBank.d76.s8.e0
DDI-DrugBank.d76.s8	48	57	astemizole	drug	DDI-DrugBank.d76.s8.e1
DDI-DrugBank.d76.s8	64	72	cisapride	drug	DDI-DrugBank.d76.s8.e2
DDI-DrugBank.d76.s8	false	DDI-DrugBank.d76.s8.e0	DDI-DrugBank.d76.s8.e1
DDI-DrugBank.d76.s8	false	DDI-DrugBank.d76.s8.e0	DDI-DrugBank.d76.s8.e2
DDI-DrugBank.d76.s8	false	DDI-DrugBank.d76.s8.e1	DDI-DrugBank.d76.s8.e2
DDI-DrugBank.d76.s9|a|As noted below, a sub- for fluvoxamine in combination with alprazolam, a drug that is known to be metabolized by the IIIA4 isozyme.
DDI-DrugBank.d76.s9	27	37	fluvoxamine	drug	DDI-DrugBank.d76.s9.e0
DDI-DrugBank.d76.s9	59	68	alprazolam	drug	DDI-DrugBank.d76.s9.e1
DDI-DrugBank.d76.s9	false	DDI-DrugBank.d76.s9.e0	DDI-DrugBank.d76.s9.e1
DDI-DrugBank.d76.s10|a|Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.
DDI-DrugBank.d76.s10	56	66	fluvoxamine	drug	DDI-DrugBank.d76.s10.e0
DDI-DrugBank.d76.s10	154	164	fluvoxamine	drug	DDI-DrugBank.d76.s10.e1
DDI-DrugBank.d76.s10	171	180	alprazolam	drug	DDI-DrugBank.d76.s10.e2
DDI-DrugBank.d76.s10	false	DDI-DrugBank.d76.s10.e0	DDI-DrugBank.d76.s10.e1
DDI-DrugBank.d76.s10	false	DDI-DrugBank.d76.s10.e0	DDI-DrugBank.d76.s10.e2
DDI-DrugBank.d76.s10	true	DDI-DrugBank.d76.s10.e1	DDI-DrugBank.d76.s10.e2
DDI-DrugBank.d76.s11|a|Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
DDI-DrugBank.d76.s11	37	47	fluvoxamine	drug	DDI-DrugBank.d76.s11.e0
DDI-DrugBank.d76.s11	88	98	terbinafine	drug	DDI-DrugBank.d76.s11.e1
DDI-DrugBank.d76.s11	101	110	astemizole	drug	DDI-DrugBank.d76.s11.e2
DDI-DrugBank.d76.s11	116	124	cisapride	drug	DDI-DrugBank.d76.s11.e3
DDI-DrugBank.d76.s11	true	DDI-DrugBank.d76.s11.e0	DDI-DrugBank.d76.s11.e1
DDI-DrugBank.d76.s11	true	DDI-DrugBank.d76.s11.e0	DDI-DrugBank.d76.s11.e2
DDI-DrugBank.d76.s11	true	DDI-DrugBank.d76.s11.e0	DDI-DrugBank.d76.s11.e3
DDI-DrugBank.d76.s11	false	DDI-DrugBank.d76.s11.e1	DDI-DrugBank.d76.s11.e2
DDI-DrugBank.d76.s11	false	DDI-DrugBank.d76.s11.e1	DDI-DrugBank.d76.s11.e3
DDI-DrugBank.d76.s11	false	DDI-DrugBank.d76.s11.e2	DDI-DrugBank.d76.s11.e3
DDI-DrugBank.d76.s12|a|Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
DDI-DrugBank.d76.s12	47	61	Benzodiazepines	group	DDI-DrugBank.d76.s12.e0
DDI-DrugBank.d76.s12	64	78	Benzodiazepines	group	DDI-DrugBank.d76.s12.e1
DDI-DrugBank.d76.s12	120	129	alprazolam	drug	DDI-DrugBank.d76.s12.e2
DDI-DrugBank.d76.s12	132	140	midazolam	drug	DDI-DrugBank.d76.s12.e3
DDI-DrugBank.d76.s12	143	151	triazolam	drug	DDI-DrugBank.d76.s12.e4
DDI-DrugBank.d76.s12	251	261	fluvoxamine	drug	DDI-DrugBank.d76.s12.e5
DDI-DrugBank.d76.s12	false	DDI-DrugBank.d76.s12.e0	DDI-DrugBank.d76.s12.e1
DDI-DrugBank.d76.s12	false	DDI-DrugBank.d76.s12.e0	DDI-DrugBank.d76.s12.e2
DDI-DrugBank.d76.s12	false	DDI-DrugBank.d76.s12.e0	DDI-DrugBank.d76.s12.e3
DDI-DrugBank.d76.s12	false	DDI-DrugBank.d76.s12.e0	DDI-DrugBank.d76.s12.e4
DDI-DrugBank.d76.s12	false	DDI-DrugBank.d76.s12.e0	DDI-DrugBank.d76.s12.e5
DDI-DrugBank.d76.s12	false	DDI-DrugBank.d76.s12.e1	DDI-DrugBank.d76.s12.e2
DDI-DrugBank.d76.s12	false	DDI-DrugBank.d76.s12.e1	DDI-DrugBank.d76.s12.e3
DDI-DrugBank.d76.s12	false	DDI-DrugBank.d76.s12.e1	DDI-DrugBank.d76.s12.e4
DDI-DrugBank.d76.s12	true	DDI-DrugBank.d76.s12.e1	DDI-DrugBank.d76.s12.e5
DDI-DrugBank.d76.s12	false	DDI-DrugBank.d76.s12.e2	DDI-DrugBank.d76.s12.e3
DDI-DrugBank.d76.s13|a|The clearance of benzodiazepines metabolized by glucuronidation (e. g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine.
DDI-DrugBank.d76.s13	17	31	benzodiazepines	group	DDI-DrugBank.d76.s13.e0
DDI-DrugBank.d76.s13	72	80	lorazepam	drug	DDI-DrugBank.d76.s13.e1
DDI-DrugBank.d76.s13	83	90	oxazepam	drug	DDI-DrugBank.d76.s13.e2
DDI-DrugBank.d76.s13	93	101	temazepam	drug	DDI-DrugBank.d76.s13.e3
DDI-DrugBank.d76.s13	134	144	fluvoxamine	drug	DDI-DrugBank.d76.s13.e4
DDI-DrugBank.d76.s13	false	DDI-DrugBank.d76.s13.e0	DDI-DrugBank.d76.s13.e1
DDI-DrugBank.d76.s13	false	DDI-DrugBank.d76.s13.e0	DDI-DrugBank.d76.s13.e2
DDI-DrugBank.d76.s13	false	DDI-DrugBank.d76.s13.e0	DDI-DrugBank.d76.s13.e3
DDI-DrugBank.d76.s13	false	DDI-DrugBank.d76.s13.e0	DDI-DrugBank.d76.s13.e4
DDI-DrugBank.d76.s13	false	DDI-DrugBank.d76.s13.e1	DDI-DrugBank.d76.s13.e2
DDI-DrugBank.d76.s13	false	DDI-DrugBank.d76.s13.e1	DDI-DrugBank.d76.s13.e3
DDI-DrugBank.d76.s13	false	DDI-DrugBank.d76.s13.e1	DDI-DrugBank.d76.s13.e4
DDI-DrugBank.d76.s13	false	DDI-DrugBank.d76.s13.e2	DDI-DrugBank.d76.s13.e3
DDI-DrugBank.d76.s13	false	DDI-DrugBank.d76.s13.e2	DDI-DrugBank.d76.s13.e4
DDI-DrugBank.d76.s13	false	DDI-DrugBank.d76.s13.e3	DDI-DrugBank.d76.s13.e4
DDI-DrugBank.d76.s14|a|Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
DDI-DrugBank.d76.s14	0	9	Alprazolam	drug	DDI-DrugBank.d76.s14.e0
DDI-DrugBank.d76.s14	17	35	fluvoxamine maleate	drug	DDI-DrugBank.d76.s14.e1
DDI-DrugBank.d76.s14	53	62	alprazolam	drug	DDI-DrugBank.d76.s14.e2
DDI-DrugBank.d76.s14	194	203	alprazolam	drug	DDI-DrugBank.d76.s14.e3
DDI-DrugBank.d76.s14	250	259	alprazolam	drug	DDI-DrugBank.d76.s14.e4
DDI-DrugBank.d76.s14	false	DDI-DrugBank.d76.s14.e0	DDI-DrugBank.d76.s14.e1
DDI-DrugBank.d76.s14	false	DDI-DrugBank.d76.s14.e0	DDI-DrugBank.d76.s14.e2
DDI-DrugBank.d76.s14	false	DDI-DrugBank.d76.s14.e0	DDI-DrugBank.d76.s14.e3
DDI-DrugBank.d76.s14	false	DDI-DrugBank.d76.s14.e0	DDI-DrugBank.d76.s14.e4
DDI-DrugBank.d76.s14	true	DDI-DrugBank.d76.s14.e1	DDI-DrugBank.d76.s14.e2
DDI-DrugBank.d76.s14	false	DDI-DrugBank.d76.s14.e1	DDI-DrugBank.d76.s14.e3
DDI-DrugBank.d76.s14	false	DDI-DrugBank.d76.s14.e1	DDI-DrugBank.d76.s14.e4
DDI-DrugBank.d76.s14	false	DDI-DrugBank.d76.s14.e2	DDI-DrugBank.d76.s14.e3
DDI-DrugBank.d76.s14	false	DDI-DrugBank.d76.s14.e2	DDI-DrugBank.d76.s14.e4
DDI-DrugBank.d76.s14	false	DDI-DrugBank.d76.s14.e3	DDI-DrugBank.d76.s14.e4
DDI-DrugBank.d76.s15|a|oral clearance was reduced by about 50%.
DDI-DrugBank.d76.s16|a|The elevated plasma alprazolam concentrations resulted in decreased psychomotor performance and memory.
DDI-DrugBank.d76.s16	20	29	alprazolam	drug	DDI-DrugBank.d76.s16.e0
DDI-DrugBank.d76.s17|a|This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
DDI-DrugBank.d76.s17	72	82	fluvoxamine	drug	DDI-DrugBank.d76.s17.e0
DDI-DrugBank.d76.s17	170	180	fluvoxamine	drug	DDI-DrugBank.d76.s17.e1
DDI-DrugBank.d76.s17	256	265	alprazolam	drug	DDI-DrugBank.d76.s17.e2
DDI-DrugBank.d76.s17	291	301	Fluvoxamine	drug	DDI-DrugBank.d76.s17.e3
DDI-DrugBank.d76.s17	324	333	alprazolam	drug	DDI-DrugBank.d76.s17.e4
DDI-DrugBank.d76.s17	false	DDI-DrugBank.d76.s17.e0	DDI-DrugBank.d76.s17.e1
DDI-DrugBank.d76.s17	false	DDI-DrugBank.d76.s17.e0	DDI-DrugBank.d76.s17.e2
DDI-DrugBank.d76.s17	false	DDI-DrugBank.d76.s17.e0	DDI-DrugBank.d76.s17.e3
DDI-DrugBank.d76.s17	false	DDI-DrugBank.d76.s17.e0	DDI-DrugBank.d76.s17.e4
DDI-DrugBank.d76.s17	false	DDI-DrugBank.d76.s17.e1	DDI-DrugBank.d76.s17.e2
DDI-DrugBank.d76.s17	false	DDI-DrugBank.d76.s17.e1	DDI-DrugBank.d76.s17.e3
DDI-DrugBank.d76.s17	false	DDI-DrugBank.d76.s17.e1	DDI-DrugBank.d76.s17.e4
DDI-DrugBank.d76.s17	true	DDI-DrugBank.d76.s17.e2	DDI-DrugBank.d76.s17.e3
DDI-DrugBank.d76.s17	false	DDI-DrugBank.d76.s17.e2	DDI-DrugBank.d76.s17.e4
DDI-DrugBank.d76.s17	false	DDI-DrugBank.d76.s17.e3	DDI-DrugBank.d76.s17.e4
DDI-DrugBank.d76.s18|a|No dosage adjustment is required for Fluvoxamine Tablets.
DDI-DrugBank.d76.s18	37	47	Fluvoxamine	drug	DDI-DrugBank.d76.s18.e0
DDI-DrugBank.d76.s19|a|Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.
DDI-DrugBank.d76.s19	0	7	Diazepam	drug	DDI-DrugBank.d76.s19.e0
DDI-DrugBank.d76.s19	35	45	Fluvoxamine	drug	DDI-DrugBank.d76.s19.e1
DDI-DrugBank.d76.s19	59	66	diazepam	drug	DDI-DrugBank.d76.s19.e2
DDI-DrugBank.d76.s19	false	DDI-DrugBank.d76.s19.e0	DDI-DrugBank.d76.s19.e1
DDI-DrugBank.d76.s19	false	DDI-DrugBank.d76.s19.e0	DDI-DrugBank.d76.s19.e2
DDI-DrugBank.d76.s19	true	DDI-DrugBank.d76.s19.e1	DDI-DrugBank.d76.s19.e2
DDI-DrugBank.d76.s20|a|Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
DDI-DrugBank.d76.s20	8	18	fluvoxamine	drug	DDI-DrugBank.d76.s20.e0
DDI-DrugBank.d76.s20	50	57	diazepam	drug	DDI-DrugBank.d76.s20.e1
DDI-DrugBank.d76.s20	86	104	N-desmethyldiazepam	drug_n	DDI-DrugBank.d76.s20.e2
DDI-DrugBank.d76.s20	true	DDI-DrugBank.d76.s20.e0	DDI-DrugBank.d76.s20.e1
DDI-DrugBank.d76.s20	true	DDI-DrugBank.d76.s20.e0	DDI-DrugBank.d76.s20.e2
DDI-DrugBank.d76.s20	false	DDI-DrugBank.d76.s20.e1	DDI-DrugBank.d76.s20.e2
DDI-DrugBank.d76.s21|a|Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.
DDI-DrugBank.d76.s21	75	85	fluvoxamine	drug	DDI-DrugBank.d76.s21.e0
DDI-DrugBank.d76.s21	91	98	diazepam	drug	DDI-DrugBank.d76.s21.e1
DDI-DrugBank.d76.s21	173	183	fluvoxamine	drug	DDI-DrugBank.d76.s21.e2
DDI-DrugBank.d76.s21	234	241	diazepam	drug	DDI-DrugBank.d76.s21.e3
DDI-DrugBank.d76.s21	true	DDI-DrugBank.d76.s21.e0	DDI-DrugBank.d76.s21.e1
DDI-DrugBank.d76.s21	false	DDI-DrugBank.d76.s21.e0	DDI-DrugBank.d76.s21.e2
DDI-DrugBank.d76.s21	false	DDI-DrugBank.d76.s21.e0	DDI-DrugBank.d76.s21.e3
DDI-DrugBank.d76.s21	false	DDI-DrugBank.d76.s21.e1	DDI-DrugBank.d76.s21.e2
DDI-DrugBank.d76.s21	false	DDI-DrugBank.d76.s21.e1	DDI-DrugBank.d76.s21.e3
DDI-DrugBank.d76.s21	false	DDI-DrugBank.d76.s21.e2	DDI-DrugBank.d76.s21.e3
DDI-DrugBank.d76.s22|a|In these subjects (R= B), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study.
DDI-DrugBank.d76.s22	43	50	diazepam	drug	DDI-DrugBank.d76.s22.e0
DDI-DrugBank.d76.s22	83	101	N-desmethyldiazepam	drug_n	DDI-DrugBank.d76.s22.e1
DDI-DrugBank.d76.s22	false	DDI-DrugBank.d76.s22.e0	DDI-DrugBank.d76.s22.e1
DDI-DrugBank.d76.s23|a|It is likely that experience significantly underestimates the degree of accumulation that might occur with repealed diazepam administration.
DDI-DrugBank.d76.s23	116	123	diazepam	drug	DDI-DrugBank.d76.s23.e0
DDI-DrugBank.d76.s24|a|Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.
DDI-DrugBank.d76.s24	24	33	alprazolam	drug	DDI-DrugBank.d76.s24.e0
DDI-DrugBank.d76.s24	50	60	fluvoxamine	drug	DDI-DrugBank.d76.s24.e1
DDI-DrugBank.d76.s24	true	DDI-DrugBank.d76.s24.e0	DDI-DrugBank.d76.s24.e1
DDI-DrugBank.d76.s25|a|Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.
DDI-DrugBank.d76.s25	13	20	diazepam	drug	DDI-DrugBank.d76.s25.e0
DDI-DrugBank.d76.s25	26	36	fluvoxamine	drug	DDI-DrugBank.d76.s25.e1
DDI-DrugBank.d76.s25	true	DDI-DrugBank.d76.s25.e0	DDI-DrugBank.d76.s25.e1
DDI-DrugBank.d76.s26|a|Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.
DDI-DrugBank.d76.s26	0	11	Theophylline	drug	DDI-DrugBank.d76.s26.e0
DDI-DrugBank.d76.s26	41	51	fluvoxamine	drug	DDI-DrugBank.d76.s26.e1
DDI-DrugBank.d76.s26	108	119	Theophylline	drug	DDI-DrugBank.d76.s26.e2
DDI-DrugBank.d76.s26	140	152	aminophylline	drug	DDI-DrugBank.d76.s26.e3
DDI-DrugBank.d76.s26	false	DDI-DrugBank.d76.s26.e0	DDI-DrugBank.d76.s26.e1
DDI-DrugBank.d76.s26	false	DDI-DrugBank.d76.s26.e0	DDI-DrugBank.d76.s26.e2
DDI-DrugBank.d76.s26	false	DDI-DrugBank.d76.s26.e0	DDI-DrugBank.d76.s26.e3
DDI-DrugBank.d76.s26	false	DDI-DrugBank.d76.s26.e1	DDI-DrugBank.d76.s26.e2
DDI-DrugBank.d76.s26	false	DDI-DrugBank.d76.s26.e1	DDI-DrugBank.d76.s26.e3
DDI-DrugBank.d76.s26	false	DDI-DrugBank.d76.s26.e2	DDI-DrugBank.d76.s26.e3
DDI-DrugBank.d76.s27|a|The clearance of theophylline was decreased approximately 3-fold.
DDI-DrugBank.d76.s27	17	28	theophylline	drug	DDI-DrugBank.d76.s27.e0
DDI-DrugBank.d76.s28|a|Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.
DDI-DrugBank.d76.s28	14	25	theophylline	drug	DDI-DrugBank.d76.s28.e0
DDI-DrugBank.d76.s28	51	69	fluvoxamine maleate	drug	DDI-DrugBank.d76.s28.e1
DDI-DrugBank.d76.s28	177	188	theophylline	drug	DDI-DrugBank.d76.s28.e2
DDI-DrugBank.d76.s28	true	DDI-DrugBank.d76.s28.e0	DDI-DrugBank.d76.s28.e1
DDI-DrugBank.d76.s28	false	DDI-DrugBank.d76.s28.e0	DDI-DrugBank.d76.s28.e2
DDI-DrugBank.d76.s28	false	DDI-DrugBank.d76.s28.e1	DDI-DrugBank.d76.s28.e2
DDI-DrugBank.d76.s29|a|No dosage adjustment is required for Fluvoxamine Tablets.
DDI-DrugBank.d76.s29	37	47	Fluvoxamine	drug	DDI-DrugBank.d76.s29.e0
DDI-DrugBank.d76.s30|a|Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
DDI-DrugBank.d76.s30	0	7	Warfarin	drug	DDI-DrugBank.d76.s30.e0
DDI-DrugBank.d76.s30	15	33	fluvoxamine maleate	drug	DDI-DrugBank.d76.s30.e1
DDI-DrugBank.d76.s30	83	90	warfarin	drug	DDI-DrugBank.d76.s30.e2
DDI-DrugBank.d76.s30	107	114	warfarin	drug	DDI-DrugBank.d76.s30.e3
DDI-DrugBank.d76.s30	false	DDI-DrugBank.d76.s30.e0	DDI-DrugBank.d76.s30.e1
DDI-DrugBank.d76.s30	false	DDI-DrugBank.d76.s30.e0	DDI-DrugBank.d76.s30.e2
DDI-DrugBank.d76.s30	false	DDI-DrugBank.d76.s30.e0	DDI-DrugBank.d76.s30.e3
DDI-DrugBank.d76.s30	true	DDI-DrugBank.d76.s30.e1	DDI-DrugBank.d76.s30.e2
DDI-DrugBank.d76.s30	false	DDI-DrugBank.d76.s30.e1	DDI-DrugBank.d76.s30.e3
DDI-DrugBank.d76.s30	false	DDI-DrugBank.d76.s30.e2	DDI-DrugBank.d76.s30.e3
DDI-DrugBank.d76.s31|a|Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.
DDI-DrugBank.d76.s31	29	42	anticoagulants	group	DDI-DrugBank.d76.s31.e0
DDI-DrugBank.d76.s31	48	58	Fluvoxamine	drug	DDI-DrugBank.d76.s31.e1
DDI-DrugBank.d76.s31	123	135	anticoagulant	group	DDI-DrugBank.d76.s31.e2
DDI-DrugBank.d76.s31	true	DDI-DrugBank.d76.s31.e0	DDI-DrugBank.d76.s31.e1
DDI-DrugBank.d76.s31	false	DDI-DrugBank.d76.s31.e0	DDI-DrugBank.d76.s31.e2
DDI-DrugBank.d76.s31	false	DDI-DrugBank.d76.s31.e1	DDI-DrugBank.d76.s31.e2
DDI-DrugBank.d76.s32|a|No dosage adjustment is required for Fluvoxamine Tablets.
DDI-DrugBank.d76.s32	37	47	Fluvoxamine	drug	DDI-DrugBank.d76.s32.e0
DDI-DrugBank.d425.s0|a|Medications that interfere with your bodys ability to use folate may also increase the need for this vitamin.
DDI-DrugBank.d425.s0	101	107	vitamin	group	DDI-DrugBank.d425.s0.e0
DDI-DrugBank.d425.s1|a|Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
DDI-DrugBank.d425.s1	62	87	anticonvulsant medications	group	DDI-DrugBank.d425.s1.e0
DDI-DrugBank.d425.s1	98	106	phenytoin	drug	DDI-DrugBank.d425.s1.e1
DDI-DrugBank.d425.s1	113	121	primidone	drug	DDI-DrugBank.d425.s1.e2
DDI-DrugBank.d425.s1	124	132	metformin	drug	DDI-DrugBank.d425.s1.e3
DDI-DrugBank.d425.s1	199	211	sulfasalazine	drug	DDI-DrugBank.d425.s1.e4
DDI-DrugBank.d425.s1	298	308	triamterene	drug	DDI-DrugBank.d425.s1.e5
DDI-DrugBank.d425.s1	313	320	diuretic	group	DDI-DrugBank.d425.s1.e6
DDI-DrugBank.d425.s1	323	334	Methotrexate	drug	DDI-DrugBank.d425.s1.e7
DDI-DrugBank.d425.s1	389	399	vitamin B12	drug	DDI-DrugBank.d425.s1.e8
DDI-DrugBank.d425.s1	405	414	folic acid	drug	DDI-DrugBank.d425.s1.e9
DDI-DrugBank.d425.s1	false	DDI-DrugBank.d425.s1.e0	DDI-DrugBank.d425.s1.e1
DDI-DrugBank.d425.s1	false	DDI-DrugBank.d425.s1.e0	DDI-DrugBank.d425.s1.e2
DDI-DrugBank.d425.s1	false	DDI-DrugBank.d425.s1.e0	DDI-DrugBank.d425.s1.e3
DDI-DrugBank.d425.s1	false	DDI-DrugBank.d425.s1.e0	DDI-DrugBank.d425.s1.e4
DDI-DrugBank.d425.s1	false	DDI-DrugBank.d425.s1.e0	DDI-DrugBank.d425.s1.e5
DDI-DrugBank.d425.s1	false	DDI-DrugBank.d425.s1.e0	DDI-DrugBank.d425.s1.e6
DDI-DrugBank.d425.s1	false	DDI-DrugBank.d425.s1.e0	DDI-DrugBank.d425.s1.e7
DDI-DrugBank.d425.s1	false	DDI-DrugBank.d425.s1.e0	DDI-DrugBank.d425.s1.e8
DDI-DrugBank.d425.s1	false	DDI-DrugBank.d425.s1.e0	DDI-DrugBank.d425.s1.e9
DDI-DrugBank.d425.s1	false	DDI-DrugBank.d425.s1.e1	DDI-DrugBank.d425.s1.e2
DDI-DrugBank.d425.s2|a|Folic acid supplements can correct the anemia associated with vitamin B12 deficiency.
DDI-DrugBank.d425.s2	0	9	Folic acid	drug	DDI-DrugBank.d425.s2.e0
DDI-DrugBank.d425.s3|a|Unfortunately, folic acid will not correct changes in the nervous system that result from vitamin B12 deficiency.
DDI-DrugBank.d425.s3	15	24	folic acid	drug	DDI-DrugBank.d425.s3.e0
DDI-DrugBank.d425.s4|a|Permanent nerve damage could theoretically occur if vitamin B12 deficiency is not treated.
DDI-DrugBank.d425.s5|a|Therefore, intake of supplemental folic acid should not exceed 1000 micrograms ( g, sometimes mcg) per day to prevent folic acid from masking symptoms of vitamin B12 deficiency.
DDI-DrugBank.d425.s5	34	43	folic acid	drug	DDI-DrugBank.d425.s5.e0
DDI-DrugBank.d425.s5	118	127	folic acid	drug	DDI-DrugBank.d425.s5.e1
DDI-DrugBank.d425.s5	false	DDI-DrugBank.d425.s5.e0	DDI-DrugBank.d425.s5.e1
DDI-DrugBank.d425.s6|a|It is important for older adults to be aware of the relationship between folic acid and vitamin B12 because they are at greater risk of having a vitamin B12 deficiency.
DDI-DrugBank.d425.s6	73	82	folic acid	drug	DDI-DrugBank.d425.s6.e0
DDI-DrugBank.d425.s6	88	98	vitamin B12	drug	DDI-DrugBank.d425.s6.e1
DDI-DrugBank.d425.s6	false	DDI-DrugBank.d425.s6.e0	DDI-DrugBank.d425.s6.e1
DDI-DrugBank.d425.s7|a|If you are 50 years of age or older, ask your physician to check your B12 status before you take a supplement that contains folic acid.
DDI-DrugBank.d425.s7	124	133	folic acid	drug	DDI-DrugBank.d425.s7.e0
DDI-DrugBank.d402.s0|a|No drug/drug interaction studies have been performed.
DDI-DrugBank.d228.s0|a|Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.
DDI-DrugBank.d228.s0	14	20	Antizol	brand	DDI-DrugBank.d228.s0.e0
DDI-DrugBank.d228.s0	124	130	ethanol	drug	DDI-DrugBank.d228.s0.e1
DDI-DrugBank.d228.s0	true	DDI-DrugBank.d228.s0.e0	DDI-DrugBank.d228.s0.e1
DDI-DrugBank.d228.s1|a|Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.
DDI-DrugBank.d228.s1	11	17	ethanol	drug	DDI-DrugBank.d228.s1.e0
DDI-DrugBank.d228.s1	56	62	Antizol	brand	DDI-DrugBank.d228.s1.e1
DDI-DrugBank.d228.s1	true	DDI-DrugBank.d228.s1.e0	DDI-DrugBank.d228.s1.e1
DDI-DrugBank.d228.s2|a|Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
DDI-DrugBank.d228.s2	58	64	Antizol	brand	DDI-DrugBank.d228.s2.e0
DDI-DrugBank.d228.s2	135	143	phenytoin	drug	DDI-DrugBank.d228.s2.e1
DDI-DrugBank.d228.s2	146	158	carbamazepine	drug	DDI-DrugBank.d228.s2.e2
DDI-DrugBank.d228.s2	161	170	cimetidine	drug	DDI-DrugBank.d228.s2.e3
DDI-DrugBank.d228.s2	173	184	ketoconazole	drug	DDI-DrugBank.d228.s2.e4
DDI-DrugBank.d228.s2	true	DDI-DrugBank.d228.s2.e0	DDI-DrugBank.d228.s2.e1
DDI-DrugBank.d228.s2	true	DDI-DrugBank.d228.s2.e0	DDI-DrugBank.d228.s2.e2
DDI-DrugBank.d228.s2	true	DDI-DrugBank.d228.s2.e0	DDI-DrugBank.d228.s2.e3
DDI-DrugBank.d228.s2	true	DDI-DrugBank.d228.s2.e0	DDI-DrugBank.d228.s2.e4
DDI-DrugBank.d228.s2	false	DDI-DrugBank.d228.s2.e1	DDI-DrugBank.d228.s2.e2
DDI-DrugBank.d228.s2	false	DDI-DrugBank.d228.s2.e1	DDI-DrugBank.d228.s2.e3
DDI-DrugBank.d228.s2	false	DDI-DrugBank.d228.s2.e1	DDI-DrugBank.d228.s2.e4
DDI-DrugBank.d228.s2	false	DDI-DrugBank.d228.s2.e2	DDI-DrugBank.d228.s2.e3
DDI-DrugBank.d228.s2	false	DDI-DrugBank.d228.s2.e2	DDI-DrugBank.d228.s2.e4
DDI-DrugBank.d228.s2	false	DDI-DrugBank.d228.s2.e3	DDI-DrugBank.d228.s2.e4
DDI-DrugBank.d228.s3|a|.
DDI-DrugBank.d228.s4|a|
DDI-DrugBank.d15.s0|a|In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
DDI-DrugBank.d15.s0	35	46	Fondaparinux	drug	DDI-DrugBank.d15.s0.e0
DDI-DrugBank.d15.s0	77	90	anticoagulants	group	DDI-DrugBank.d15.s0.e1
DDI-DrugBank.d15.s0	93	100	warfarin	drug	DDI-DrugBank.d15.s0.e2
DDI-DrugBank.d15.s0	104	122	platelet inhibitors	group	DDI-DrugBank.d15.s0.e3
DDI-DrugBank.d15.s0	125	144	acetylsalicylic acid	drug	DDI-DrugBank.d15.s0.e4
DDI-DrugBank.d15.s0	148	153	NSAIDs	group	DDI-DrugBank.d15.s0.e5
DDI-DrugBank.d15.s0	156	164	piroxicam	drug	DDI-DrugBank.d15.s0.e6
DDI-DrugBank.d15.s0	172	178	digoxin	drug	DDI-DrugBank.d15.s0.e7
DDI-DrugBank.d15.s0	250	268	fondaparinux sodium	drug	DDI-DrugBank.d15.s0.e8
DDI-DrugBank.d15.s0	false	DDI-DrugBank.d15.s0.e0	DDI-DrugBank.d15.s0.e1
DDI-DrugBank.d15.s0	false	DDI-DrugBank.d15.s0.e0	DDI-DrugBank.d15.s0.e2
DDI-DrugBank.d15.s0	false	DDI-DrugBank.d15.s0.e0	DDI-DrugBank.d15.s0.e3
DDI-DrugBank.d15.s0	false	DDI-DrugBank.d15.s0.e0	DDI-DrugBank.d15.s0.e4
DDI-DrugBank.d15.s0	false	DDI-DrugBank.d15.s0.e0	DDI-DrugBank.d15.s0.e5
DDI-DrugBank.d15.s0	false	DDI-DrugBank.d15.s0.e0	DDI-DrugBank.d15.s0.e6
DDI-DrugBank.d15.s0	false	DDI-DrugBank.d15.s0.e0	DDI-DrugBank.d15.s0.e7
DDI-DrugBank.d15.s0	false	DDI-DrugBank.d15.s0.e0	DDI-DrugBank.d15.s0.e8
DDI-DrugBank.d15.s0	false	DDI-DrugBank.d15.s0.e1	DDI-DrugBank.d15.s0.e2
DDI-DrugBank.d15.s0	false	DDI-DrugBank.d15.s0.e1	DDI-DrugBank.d15.s0.e3
DDI-DrugBank.d15.s1|a|In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.
DDI-DrugBank.d15.s1	13	24	Fondaparinux	drug	DDI-DrugBank.d15.s1.e0
DDI-DrugBank.d15.s1	69	76	warfarin	drug	DDI-DrugBank.d15.s1.e1
DDI-DrugBank.d15.s1	79	98	acetylsalicylic acid	drug	DDI-DrugBank.d15.s1.e2
DDI-DrugBank.d15.s1	101	109	piroxicam	drug	DDI-DrugBank.d15.s1.e3
DDI-DrugBank.d15.s1	116	122	digoxin	drug	DDI-DrugBank.d15.s1.e4
DDI-DrugBank.d15.s1	153	159	digoxin	drug	DDI-DrugBank.d15.s1.e5
DDI-DrugBank.d15.s1	false	DDI-DrugBank.d15.s1.e0	DDI-DrugBank.d15.s1.e1
DDI-DrugBank.d15.s1	false	DDI-DrugBank.d15.s1.e0	DDI-DrugBank.d15.s1.e2
DDI-DrugBank.d15.s1	false	DDI-DrugBank.d15.s1.e0	DDI-DrugBank.d15.s1.e3
DDI-DrugBank.d15.s1	false	DDI-DrugBank.d15.s1.e0	DDI-DrugBank.d15.s1.e4
DDI-DrugBank.d15.s1	false	DDI-DrugBank.d15.s1.e0	DDI-DrugBank.d15.s1.e5
DDI-DrugBank.d15.s1	false	DDI-DrugBank.d15.s1.e1	DDI-DrugBank.d15.s1.e2
DDI-DrugBank.d15.s1	false	DDI-DrugBank.d15.s1.e1	DDI-DrugBank.d15.s1.e3
DDI-DrugBank.d15.s1	false	DDI-DrugBank.d15.s1.e1	DDI-DrugBank.d15.s1.e4
DDI-DrugBank.d15.s1	false	DDI-DrugBank.d15.s1.e1	DDI-DrugBank.d15.s1.e5
DDI-DrugBank.d15.s1	false	DDI-DrugBank.d15.s1.e2	DDI-DrugBank.d15.s1.e3
DDI-DrugBank.d15.s2|a|Agents that may enhance the risk of hemorrhage should be discontinued prior to initiation of Fondaparinux therapy.
DDI-DrugBank.d15.s2	93	104	Fondaparinux	drug	DDI-DrugBank.d15.s2.e0
DDI-DrugBank.d15.s3|a|If co-administration is essential, close monitoring may be appropriate.
DDI-DrugBank.d15.s4|a|In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i.e., 350 mg/L) was 17-28%.
DDI-DrugBank.d15.s4	86	93	coumarin	group	DDI-DrugBank.d15.s4.e0
DDI-DrugBank.d15.s4	98	109	fondaparinux	drug	DDI-DrugBank.d15.s4.e1
DDI-DrugBank.d15.s4	true	DDI-DrugBank.d15.s4.e0	DDI-DrugBank.d15.s4.e1
DDI-DrugBank.d15.s5|a|Inhibition of the other isozymes evaluated (CYPs 2A1, 2C9, 2C19, 2D6, 3A4, and 3E1) was 0-16%.
DDI-DrugBank.d15.s6|a|Since fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.
DDI-DrugBank.d15.s6	6	17	fondaparinux	drug	DDI-DrugBank.d15.s6.e0
DDI-DrugBank.d15.s6	124	142	fondaparinux sodium	drug	DDI-DrugBank.d15.s6.e1
DDI-DrugBank.d15.s6	false	DDI-DrugBank.d15.s6.e0	DDI-DrugBank.d15.s6.e1
DDI-DrugBank.d15.s7|a|Since fondaparinux sodium does not bind significantly to plasma proteins other than ATIII, no drug interactions by protein-binding displacement are expected.
DDI-DrugBank.d15.s7	6	24	fondaparinux sodium	drug	DDI-DrugBank.d15.s7.e0
DDI-DrugBank.d103.s0|a|Short-Acting beta2-agonists: Aerosol bronchodilators of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using formoterol.
DDI-DrugBank.d103.s0	0	26	Short-Acting beta2-agonists	group	DDI-DrugBank.d103.s0.e0
DDI-DrugBank.d103.s0	37	51	bronchodilators	group	DDI-DrugBank.d103.s0.e1
DDI-DrugBank.d103.s0	159	168	formoterol	drug	DDI-DrugBank.d103.s0.e2
DDI-DrugBank.d103.s0	false	DDI-DrugBank.d103.s0.e0	DDI-DrugBank.d103.s0.e1
DDI-DrugBank.d103.s0	false	DDI-DrugBank.d103.s0.e0	DDI-DrugBank.d103.s0.e2
DDI-DrugBank.d103.s0	false	DDI-DrugBank.d103.s0.e1	DDI-DrugBank.d103.s0.e2
DDI-DrugBank.d103.s1|a|However, increasing use of such preparations to control symptoms indicates deterioration of asthma control and the need to reassess the patient s therapy.
DDI-DrugBank.d103.s2|a|Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.
DDI-DrugBank.d103.s2	36	57	sympathomimetic agents	group	DDI-DrugBank.d103.s2.e0
DDI-DrugBank.d103.s2	101	107	FORADIL	brand	DDI-DrugBank.d103.s2.e1
DDI-DrugBank.d103.s2	true	DDI-DrugBank.d103.s2.e0	DDI-DrugBank.d103.s2.e1
DDI-DrugBank.d103.s3|a|Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
DDI-DrugBank.d103.s3	0	27	Monoamine Oxidase Inhibitors	group	DDI-DrugBank.d103.s3.e0
DDI-DrugBank.d103.s3	33	57	Tricyclic Antidepressants	group	DDI-DrugBank.d103.s3.e1
DDI-DrugBank.d103.s3	60	66	FORADIL	brand	DDI-DrugBank.d103.s3.e2
DDI-DrugBank.d103.s3	143	170	monoamine oxidase inhibitors	group	DDI-DrugBank.d103.s3.e3
DDI-DrugBank.d103.s3	175	199	tricyclic antidepressants	group	DDI-DrugBank.d103.s3.e4
DDI-DrugBank.d103.s3	223	232	formoterol	drug	DDI-DrugBank.d103.s3.e5
DDI-DrugBank.d103.s3	false	DDI-DrugBank.d103.s3.e0	DDI-DrugBank.d103.s3.e1
DDI-DrugBank.d103.s3	false	DDI-DrugBank.d103.s3.e0	DDI-DrugBank.d103.s3.e2
DDI-DrugBank.d103.s3	false	DDI-DrugBank.d103.s3.e0	DDI-DrugBank.d103.s3.e3
DDI-DrugBank.d103.s3	false	DDI-DrugBank.d103.s3.e0	DDI-DrugBank.d103.s3.e4
DDI-DrugBank.d103.s3	false	DDI-DrugBank.d103.s3.e0	DDI-DrugBank.d103.s3.e5
DDI-DrugBank.d103.s3	false	DDI-DrugBank.d103.s3.e1	DDI-DrugBank.d103.s3.e2
DDI-DrugBank.d103.s3	false	DDI-DrugBank.d103.s3.e1	DDI-DrugBank.d103.s3.e3
DDI-DrugBank.d103.s3	false	DDI-DrugBank.d103.s3.e1	DDI-DrugBank.d103.s3.e4
DDI-DrugBank.d103.s3	false	DDI-DrugBank.d103.s3.e1	DDI-DrugBank.d103.s3.e5
DDI-DrugBank.d103.s3	true	DDI-DrugBank.d103.s3.e2	DDI-DrugBank.d103.s3.e3
DDI-DrugBank.d103.s4|a|Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.
DDI-DrugBank.d103.s4	0	14	Corticosteroids	group	DDI-DrugBank.d103.s4.e0
DDI-DrugBank.d103.s4	17	31	Methylxanthines	group	DDI-DrugBank.d103.s4.e1
DDI-DrugBank.d103.s4	37	45	Diuretics	group	DDI-DrugBank.d103.s4.e2
DDI-DrugBank.d103.s4	75	94	xanthine derivatives	group	DDI-DrugBank.d103.s4.e3
DDI-DrugBank.d103.s4	97	104	steroids	group	DDI-DrugBank.d103.s4.e4
DDI-DrugBank.d103.s4	110	118	diuretics	group	DDI-DrugBank.d103.s4.e5
DDI-DrugBank.d103.s4	169	183	beta2-agonists.	group	DDI-DrugBank.d103.s4.e6
DDI-DrugBank.d103.s4	false	DDI-DrugBank.d103.s4.e0	DDI-DrugBank.d103.s4.e1
DDI-DrugBank.d103.s4	false	DDI-DrugBank.d103.s4.e0	DDI-DrugBank.d103.s4.e2
DDI-DrugBank.d103.s4	false	DDI-DrugBank.d103.s4.e0	DDI-DrugBank.d103.s4.e3
DDI-DrugBank.d103.s4	false	DDI-DrugBank.d103.s4.e0	DDI-DrugBank.d103.s4.e4
DDI-DrugBank.d103.s4	false	DDI-DrugBank.d103.s4.e0	DDI-DrugBank.d103.s4.e5
DDI-DrugBank.d103.s4	false	DDI-DrugBank.d103.s4.e0	DDI-DrugBank.d103.s4.e6
DDI-DrugBank.d103.s4	false	DDI-DrugBank.d103.s4.e1	DDI-DrugBank.d103.s4.e2
DDI-DrugBank.d103.s4	false	DDI-DrugBank.d103.s4.e1	DDI-DrugBank.d103.s4.e3
DDI-DrugBank.d103.s4	false	DDI-DrugBank.d103.s4.e1	DDI-DrugBank.d103.s4.e4
DDI-DrugBank.d103.s4	false	DDI-DrugBank.d103.s4.e1	DDI-DrugBank.d103.s4.e5
DDI-DrugBank.d103.s5|a|Hypokalemia may increase susceptibility to cardiac arrhythmias in patients treated with digitalis.
DDI-DrugBank.d103.s5	88	96	digitalis	group	DDI-DrugBank.d103.s5.e0
DDI-DrugBank.d103.s6|a|-adrenergic Blockers:  -adrenergic blockers may weaken or antagonise the effect of FORADIL.
DDI-DrugBank.d103.s6	83	89	FORADIL	brand	DDI-DrugBank.d103.s6.e0
DDI-DrugBank.d103.s7|a|Therefore FORADIL should not be given together with  -adrenergic blockers (including eye drops) unless there are compelling reasons for their use.
DDI-DrugBank.d103.s7	10	16	FORADIL	brand	DDI-DrugBank.d103.s7.e0
DDI-DrugBank.d103.s8|a|Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
DDI-DrugBank.d103.s8	26	34	quinidine	drug	DDI-DrugBank.d103.s8.e0
DDI-DrugBank.d103.s8	37	48	disopyramide	drug	DDI-DrugBank.d103.s8.e1
DDI-DrugBank.d103.s8	51	62	procainamide	drug	DDI-DrugBank.d103.s8.e2
DDI-DrugBank.d103.s8	65	78	phenothiazines	group	DDI-DrugBank.d103.s8.e3
DDI-DrugBank.d103.s8	81	94	antihistamines	group	DDI-DrugBank.d103.s8.e4
DDI-DrugBank.d103.s8	101	125	tricyclic antidepressants	group	DDI-DrugBank.d103.s8.e5
DDI-DrugBank.d103.s8	false	DDI-DrugBank.d103.s8.e0	DDI-DrugBank.d103.s8.e1
DDI-DrugBank.d103.s8	false	DDI-DrugBank.d103.s8.e0	DDI-DrugBank.d103.s8.e2
DDI-DrugBank.d103.s8	false	DDI-DrugBank.d103.s8.e0	DDI-DrugBank.d103.s8.e3
DDI-DrugBank.d103.s8	false	DDI-DrugBank.d103.s8.e0	DDI-DrugBank.d103.s8.e4
DDI-DrugBank.d103.s8	false	DDI-DrugBank.d103.s8.e0	DDI-DrugBank.d103.s8.e5
DDI-DrugBank.d103.s8	false	DDI-DrugBank.d103.s8.e1	DDI-DrugBank.d103.s8.e2
DDI-DrugBank.d103.s8	false	DDI-DrugBank.d103.s8.e1	DDI-DrugBank.d103.s8.e3
DDI-DrugBank.d103.s8	false	DDI-DrugBank.d103.s8.e1	DDI-DrugBank.d103.s8.e4
DDI-DrugBank.d103.s8	false	DDI-DrugBank.d103.s8.e1	DDI-DrugBank.d103.s8.e5
DDI-DrugBank.d103.s8	false	DDI-DrugBank.d103.s8.e2	DDI-DrugBank.d103.s8.e3
DDI-DrugBank.d103.s9|a|INFORMATION TO BE PROVIDED TO THE PATIENT OR GUARDIAN See illustrated Information For The Patient or Guardian section.
DDI-DrugBank.d103.s10|a|It is important that patients understand how to use FORADIL  (formoterol fumarate) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.
DDI-DrugBank.d103.s10	52	58	FORADIL	brand	DDI-DrugBank.d103.s10.e0
DDI-DrugBank.d103.s10	62	80	formoterol fumarate	drug	DDI-DrugBank.d103.s10.e1
DDI-DrugBank.d103.s10	false	DDI-DrugBank.d103.s10.e0	DDI-DrugBank.d103.s10.e1
DDI-DrugBank.d103.s11|a|Patients/Guardians should be given the following information: i.
DDI-DrugBank.d103.s12|a|The recommended dosage (one or two capsules twice daily, morning and evening) should not be exceeded.
DDI-DrugBank.d103.s13|a|ii.
DDI-DrugBank.d103.s14|a|FORADIL is not meant to relieve acute asthma or COPD symptoms and extra doses should not be used for that purpose.
DDI-DrugBank.d103.s14	0	6	FORADIL	brand	DDI-DrugBank.d103.s14.e0
DDI-DrugBank.d103.s15|a|Acute symptoms should be treated with a short-acting, inhaled  beta2-agonist such as salbutamol (the physician should provide the patient with such medication and instruct the patient in how it should be used).
DDI-DrugBank.d103.s15	63	75	beta2-agonist	group	DDI-DrugBank.d103.s15.e0
DDI-DrugBank.d103.s15	85	94	salbutamol	drug	DDI-DrugBank.d103.s15.e1
DDI-DrugBank.d103.s15	false	DDI-DrugBank.d103.s15.e0	DDI-DrugBank.d103.s15.e1
DDI-DrugBank.d103.s16|a|iii.
DDI-DrugBank.d103.s17|a|The physician should be notified immediately if any of the following situations occur, which may be a sign of seriously worsening asthma:   Decreased effectiveness of short-acting, inhaled beta2-agonists;
DDI-DrugBank.d103.s17	167	202	short-acting, inhaled beta2-agonists	group	DDI-DrugBank.d103.s17.e0
DDI-DrugBank.d103.s18|a|Need for more inhalations than usual of short-acting, inhaled beta2-agonists.
DDI-DrugBank.d103.s18	40	75	short-acting, inhaled beta2-agonists	group	DDI-DrugBank.d103.s18.e0
DDI-DrugBank.d103.s19|a|iv.
DDI-DrugBank.d103.s20|a|FORADIL should not be used as a substitute for oral or inhaled corticosteroids.
DDI-DrugBank.d103.s20	0	6	FORADIL	brand	DDI-DrugBank.d103.s20.e0
DDI-DrugBank.d103.s20	63	77	corticosteroids	group	DDI-DrugBank.d103.s20.e1
DDI-DrugBank.d103.s20	false	DDI-DrugBank.d103.s20.e0	DDI-DrugBank.d103.s20.e1
DDI-DrugBank.d103.s21|a|The dosage of these medications should not be changed and they should not be stopped without consulting the physician, even if the patient feels better after initiating treatment with FORADIL.
DDI-DrugBank.d103.s21	184	190	FORADIL	brand	DDI-DrugBank.d103.s21.e0
DDI-DrugBank.d103.s22|a|v. Patients should be cautioned regarding potential adverse cardiovascular effects, such as palpitations or chest pain.
DDI-DrugBank.d103.s23|a|vi.
DDI-DrugBank.d103.s24|a|In patients receiving FORADIL, other inhaled medications should be used only as directed by the physician.
DDI-DrugBank.d103.s24	22	28	FORADIL	brand	DDI-DrugBank.d103.s24.e0
DDI-DrugBank.d103.s25|a|vii.
DDI-DrugBank.d103.s26|a|Guardians of children who have been prescribed FORADIL should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of short-acting  beta2-agonists.
DDI-DrugBank.d103.s26	47	53	FORADIL	brand	DDI-DrugBank.d103.s26.e0
DDI-DrugBank.d103.s26	196	223	short-acting  beta2-agonists	group	DDI-DrugBank.d103.s26.e1
DDI-DrugBank.d103.s26	false	DDI-DrugBank.d103.s26.e0	DDI-DrugBank.d103.s26.e1
DDI-DrugBank.d511.s0|a|A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.
DDI-DrugBank.d511.s0	31	38	FOSCAVIR	brand	DDI-DrugBank.d511.s0.e0
DDI-DrugBank.d511.s0	56	66	pentamidine	drug	DDI-DrugBank.d511.s0.e1
DDI-DrugBank.d511.s0	true	DDI-DrugBank.d511.s0.e0	DDI-DrugBank.d511.s0.e1
DDI-DrugBank.d511.s1|a|Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;
DDI-DrugBank.d511.s1	66	73	FOSCAVIR	brand	DDI-DrugBank.d511.s1.e0
DDI-DrugBank.d511.s1	91	101	pentamidine	drug	DDI-DrugBank.d511.s1.e1
DDI-DrugBank.d511.s1	true	DDI-DrugBank.d511.s1.e0	DDI-DrugBank.d511.s1.e1
DDI-DrugBank.d511.s2|a|one patient died with severe hypocalcemia.
DDI-DrugBank.d511.s3|a|Toxicity associated with concomitant use of aerosolized pentamidine has not been reported.
DDI-DrugBank.d511.s3	56	66	pentamidine	drug	DDI-DrugBank.d511.s3.e0
DDI-DrugBank.d511.s4|a|Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
DDI-DrugBank.d511.s4	11	19	foscarnet	drug	DDI-DrugBank.d511.s4.e0
DDI-DrugBank.d511.s4	69	76	FOSCAVIR	brand	DDI-DrugBank.d511.s4.e1
DDI-DrugBank.d511.s4	154	168	aminoglycosides	group	DDI-DrugBank.d511.s4.e2
DDI-DrugBank.d511.s4	171	184	amphotericin B	drug	DDI-DrugBank.d511.s4.e3
DDI-DrugBank.d511.s4	202	212	pentamidine	drug	DDI-DrugBank.d511.s4.e4
DDI-DrugBank.d511.s4	false	DDI-DrugBank.d511.s4.e0	DDI-DrugBank.d511.s4.e1
DDI-DrugBank.d511.s4	false	DDI-DrugBank.d511.s4.e0	DDI-DrugBank.d511.s4.e2
DDI-DrugBank.d511.s4	false	DDI-DrugBank.d511.s4.e0	DDI-DrugBank.d511.s4.e3
DDI-DrugBank.d511.s4	false	DDI-DrugBank.d511.s4.e0	DDI-DrugBank.d511.s4.e4
DDI-DrugBank.d511.s4	true	DDI-DrugBank.d511.s4.e1	DDI-DrugBank.d511.s4.e2
DDI-DrugBank.d511.s4	true	DDI-DrugBank.d511.s4.e1	DDI-DrugBank.d511.s4.e3
DDI-DrugBank.d511.s4	true	DDI-DrugBank.d511.s4.e1	DDI-DrugBank.d511.s4.e4
DDI-DrugBank.d511.s4	false	DDI-DrugBank.d511.s4.e2	DDI-DrugBank.d511.s4.e3
DDI-DrugBank.d511.s4	false	DDI-DrugBank.d511.s4.e2	DDI-DrugBank.d511.s4.e4
DDI-DrugBank.d511.s4	false	DDI-DrugBank.d511.s4.e3	DDI-DrugBank.d511.s4.e4
DDI-DrugBank.d511.s5|a|Since FOSCAVIR decreases serum concentrations of ionized calcium, concurrent treatment with other drugs known to influence serum calcium concentrations should be used with particular caution.
DDI-DrugBank.d511.s5	6	13	FOSCAVIR	brand	DDI-DrugBank.d511.s5.e0
DDI-DrugBank.d511.s6|a|Ganciclovir: The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.
DDI-DrugBank.d511.s6	0	10	Ganciclovir	drug	DDI-DrugBank.d511.s6.e0
DDI-DrugBank.d511.s6	37	45	foscarnet	drug	DDI-DrugBank.d511.s6.e1
DDI-DrugBank.d511.s6	51	61	ganciclovir	drug	DDI-DrugBank.d511.s6.e2
DDI-DrugBank.d511.s6	false	DDI-DrugBank.d511.s6.e0	DDI-DrugBank.d511.s6.e1
DDI-DrugBank.d511.s6	false	DDI-DrugBank.d511.s6.e0	DDI-DrugBank.d511.s6.e2
DDI-DrugBank.d511.s6	false	DDI-DrugBank.d511.s6.e1	DDI-DrugBank.d511.s6.e2
DDI-DrugBank.d199.s0|a|Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
DDI-DrugBank.d199.s0	0	13	Metoclopramide	drug	DDI-DrugBank.d199.s0.e0
DDI-DrugBank.d199.s0	41	47	MONUROL	brand	DDI-DrugBank.d199.s0.e1
DDI-DrugBank.d199.s0	50	63	metoclopramide	drug	DDI-DrugBank.d199.s0.e2
DDI-DrugBank.d199.s0	172	181	fosfomycin	drug	DDI-DrugBank.d199.s0.e3
DDI-DrugBank.d199.s0	false	DDI-DrugBank.d199.s0.e0	DDI-DrugBank.d199.s0.e1
DDI-DrugBank.d199.s0	false	DDI-DrugBank.d199.s0.e0	DDI-DrugBank.d199.s0.e2
DDI-DrugBank.d199.s0	false	DDI-DrugBank.d199.s0.e0	DDI-DrugBank.d199.s0.e3
DDI-DrugBank.d199.s0	true	DDI-DrugBank.d199.s0.e1	DDI-DrugBank.d199.s0.e2
DDI-DrugBank.d199.s0	false	DDI-DrugBank.d199.s0.e1	DDI-DrugBank.d199.s0.e3
DDI-DrugBank.d199.s0	false	DDI-DrugBank.d199.s0.e2	DDI-DrugBank.d199.s0.e3
DDI-DrugBank.d199.s1|a|Other drugs that increase gastrointestinal motility may produce similar effects.
DDI-DrugBank.d199.s2|a|Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.
DDI-DrugBank.d199.s2	0	9	Cimetidine	drug	DDI-DrugBank.d199.s2.e0
DDI-DrugBank.d199.s2	12	21	Cimetidine	drug	DDI-DrugBank.d199.s2.e1
DDI-DrugBank.d199.s2	63	72	fosfomycin	drug	DDI-DrugBank.d199.s2.e2
DDI-DrugBank.d199.s2	99	105	MONUROL	brand	DDI-DrugBank.d199.s2.e3
DDI-DrugBank.d199.s2	false	DDI-DrugBank.d199.s2.e0	DDI-DrugBank.d199.s2.e1
DDI-DrugBank.d199.s2	false	DDI-DrugBank.d199.s2.e0	DDI-DrugBank.d199.s2.e2
DDI-DrugBank.d199.s2	false	DDI-DrugBank.d199.s2.e0	DDI-DrugBank.d199.s2.e3
DDI-DrugBank.d199.s2	false	DDI-DrugBank.d199.s2.e1	DDI-DrugBank.d199.s2.e2
DDI-DrugBank.d199.s2	false	DDI-DrugBank.d199.s2.e1	DDI-DrugBank.d199.s2.e3
DDI-DrugBank.d199.s2	false	DDI-DrugBank.d199.s2.e2	DDI-DrugBank.d199.s2.e3
DDI-DrugBank.d176.s0|a|Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.
DDI-DrugBank.d176.s0	0	8	Diuretics	group	DDI-DrugBank.d176.s0.e0
DDI-DrugBank.d176.s0	23	31	diuretics	group	DDI-DrugBank.d176.s0.e1
DDI-DrugBank.d176.s0	190	206	fosinopril sodium	drug	DDI-DrugBank.d176.s0.e2
DDI-DrugBank.d176.s0	false	DDI-DrugBank.d176.s0.e0	DDI-DrugBank.d176.s0.e1
DDI-DrugBank.d176.s0	false	DDI-DrugBank.d176.s0.e0	DDI-DrugBank.d176.s0.e2
DDI-DrugBank.d176.s0	true	DDI-DrugBank.d176.s0.e1	DDI-DrugBank.d176.s0.e2
DDI-DrugBank.d176.s1|a|The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium.
DDI-DrugBank.d176.s1	84	91	diuretic	group	DDI-DrugBank.d176.s1.e0
DDI-DrugBank.d176.s1	157	173	fosinopril sodium	drug	DDI-DrugBank.d176.s1.e1
DDI-DrugBank.d176.s1	true	DDI-DrugBank.d176.s1.e0	DDI-DrugBank.d176.s1.e1
DDI-DrugBank.d176.s2|a|If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION.)
DDI-DrugBank.d176.s3|a|Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.
DDI-DrugBank.d176.s3	0	8	Potassium	drug	DDI-DrugBank.d176.s3.e0
DDI-DrugBank.d176.s3	26	52	Potassium-Sparing Diuretics	group	DDI-DrugBank.d176.s3.e1
DDI-DrugBank.d176.s3	55	71	Fosinopril sodium	drug	DDI-DrugBank.d176.s3.e2
DDI-DrugBank.d176.s3	112	129	thiazide diuretics	group	DDI-DrugBank.d176.s3.e3
DDI-DrugBank.d176.s3	false	DDI-DrugBank.d176.s3.e0	DDI-DrugBank.d176.s3.e1
DDI-DrugBank.d176.s3	false	DDI-DrugBank.d176.s3.e0	DDI-DrugBank.d176.s3.e2
DDI-DrugBank.d176.s3	false	DDI-DrugBank.d176.s3.e0	DDI-DrugBank.d176.s3.e3
DDI-DrugBank.d176.s3	false	DDI-DrugBank.d176.s3.e1	DDI-DrugBank.d176.s3.e2
DDI-DrugBank.d176.s3	false	DDI-DrugBank.d176.s3.e1	DDI-DrugBank.d176.s3.e3
DDI-DrugBank.d176.s3	true	DDI-DrugBank.d176.s3.e2	DDI-DrugBank.d176.s3.e3
DDI-DrugBank.d176.s4|a|Potassium-sparing diuretics (spironolactone, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
DDI-DrugBank.d176.s4	0	26	Potassium-sparing diuretics	group	DDI-DrugBank.d176.s4.e0
DDI-DrugBank.d176.s4	29	42	spironolactone	drug	DDI-DrugBank.d176.s4.e1
DDI-DrugBank.d176.s4	45	53	amiloride	drug	DDI-DrugBank.d176.s4.e2
DDI-DrugBank.d176.s4	55	65	triamterene	drug	DDI-DrugBank.d176.s4.e3
DDI-DrugBank.d176.s4	83	91	potassium	drug	DDI-DrugBank.d176.s4.e4
DDI-DrugBank.d176.s4	false	DDI-DrugBank.d176.s4.e0	DDI-DrugBank.d176.s4.e1
DDI-DrugBank.d176.s4	false	DDI-DrugBank.d176.s4.e0	DDI-DrugBank.d176.s4.e2
DDI-DrugBank.d176.s4	false	DDI-DrugBank.d176.s4.e0	DDI-DrugBank.d176.s4.e3
DDI-DrugBank.d176.s4	false	DDI-DrugBank.d176.s4.e0	DDI-DrugBank.d176.s4.e4
DDI-DrugBank.d176.s4	false	DDI-DrugBank.d176.s4.e1	DDI-DrugBank.d176.s4.e2
DDI-DrugBank.d176.s4	false	DDI-DrugBank.d176.s4.e1	DDI-DrugBank.d176.s4.e3
DDI-DrugBank.d176.s4	false	DDI-DrugBank.d176.s4.e1	DDI-DrugBank.d176.s4.e4
DDI-DrugBank.d176.s4	false	DDI-DrugBank.d176.s4.e2	DDI-DrugBank.d176.s4.e3
DDI-DrugBank.d176.s4	false	DDI-DrugBank.d176.s4.e2	DDI-DrugBank.d176.s4.e4
DDI-DrugBank.d176.s4	false	DDI-DrugBank.d176.s4.e3	DDI-DrugBank.d176.s4.e4
DDI-DrugBank.d176.s5|a|Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patients serum potassium should be monitored frequently.
DDI-DrugBank.d176.s6|a|Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
DDI-DrugBank.d176.s6	0	6	Lithium	drug	DDI-DrugBank.d176.s6.e0
DDI-DrugBank.d176.s6	25	31	lithium	drug	DDI-DrugBank.d176.s6.e1
DDI-DrugBank.d176.s6	56	62	lithium	drug	DDI-DrugBank.d176.s6.e2
DDI-DrugBank.d176.s6	114	127	ACE inhibitors	group	DDI-DrugBank.d176.s6.e3
DDI-DrugBank.d176.s6	149	155	lithium	drug	DDI-DrugBank.d176.s6.e4
DDI-DrugBank.d176.s6	false	DDI-DrugBank.d176.s6.e0	DDI-DrugBank.d176.s6.e1
DDI-DrugBank.d176.s6	false	DDI-DrugBank.d176.s6.e0	DDI-DrugBank.d176.s6.e2
DDI-DrugBank.d176.s6	false	DDI-DrugBank.d176.s6.e0	DDI-DrugBank.d176.s6.e3
DDI-DrugBank.d176.s6	false	DDI-DrugBank.d176.s6.e0	DDI-DrugBank.d176.s6.e4
DDI-DrugBank.d176.s6	false	DDI-DrugBank.d176.s6.e1	DDI-DrugBank.d176.s6.e2
DDI-DrugBank.d176.s6	false	DDI-DrugBank.d176.s6.e1	DDI-DrugBank.d176.s6.e3
DDI-DrugBank.d176.s6	false	DDI-DrugBank.d176.s6.e1	DDI-DrugBank.d176.s6.e4
DDI-DrugBank.d176.s6	false	DDI-DrugBank.d176.s6.e2	DDI-DrugBank.d176.s6.e3
DDI-DrugBank.d176.s6	false	DDI-DrugBank.d176.s6.e2	DDI-DrugBank.d176.s6.e4
DDI-DrugBank.d176.s6	true	DDI-DrugBank.d176.s6.e3	DDI-DrugBank.d176.s6.e4
DDI-DrugBank.d176.s7|a|These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.
DDI-DrugBank.d176.s7	84	90	lithium	drug	DDI-DrugBank.d176.s7.e0
DDI-DrugBank.d176.s8|a|If a diuretic is also used, the risk of lithium toxicity may be increased.
DDI-DrugBank.d176.s8	5	12	diuretic	group	DDI-DrugBank.d176.s8.e0
DDI-DrugBank.d176.s9|a|Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
DDI-DrugBank.d176.s9	0	7	Antacids	group	DDI-DrugBank.d176.s9.e0
DDI-DrugBank.d176.s9	67	73	antacid	group	DDI-DrugBank.d176.s9.e1
DDI-DrugBank.d176.s9	76	93	aluminum hydroxide	drug	DDI-DrugBank.d176.s9.e2
DDI-DrugBank.d176.s9	96	114	magnesium hydroxide	drug	DDI-DrugBank.d176.s9.e3
DDI-DrugBank.d176.s9	121	131	simethicone	drug	DDI-DrugBank.d176.s9.e4
DDI-DrugBank.d176.s9	139	148	fosinopril	drug	DDI-DrugBank.d176.s9.e5
DDI-DrugBank.d176.s9	196	207	fosinoprilat	drug_n	DDI-DrugBank.d176.s9.e6
DDI-DrugBank.d176.s9	226	235	fosinopril	drug	DDI-DrugBank.d176.s9.e7
DDI-DrugBank.d176.s9	273	280	antacids	group	DDI-DrugBank.d176.s9.e8
DDI-DrugBank.d176.s9	307	316	fosinopril	drug	DDI-DrugBank.d176.s9.e9
DDI-DrugBank.d176.s9	false	DDI-DrugBank.d176.s9.e0	DDI-DrugBank.d176.s9.e1
DDI-DrugBank.d176.s9	false	DDI-DrugBank.d176.s9.e0	DDI-DrugBank.d176.s9.e2
DDI-DrugBank.d176.s9	false	DDI-DrugBank.d176.s9.e0	DDI-DrugBank.d176.s9.e3
DDI-DrugBank.d176.s9	false	DDI-DrugBank.d176.s9.e0	DDI-DrugBank.d176.s9.e4
DDI-DrugBank.d176.s9	false	DDI-DrugBank.d176.s9.e0	DDI-DrugBank.d176.s9.e5
DDI-DrugBank.d176.s9	false	DDI-DrugBank.d176.s9.e0	DDI-DrugBank.d176.s9.e6
DDI-DrugBank.d176.s9	false	DDI-DrugBank.d176.s9.e0	DDI-DrugBank.d176.s9.e7
DDI-DrugBank.d176.s9	false	DDI-DrugBank.d176.s9.e0	DDI-DrugBank.d176.s9.e8
DDI-DrugBank.d176.s9	false	DDI-DrugBank.d176.s9.e0	DDI-DrugBank.d176.s9.e9
DDI-DrugBank.d176.s9	false	DDI-DrugBank.d176.s9.e1	DDI-DrugBank.d176.s9.e2
DDI-DrugBank.d176.s10|a|Therefore, if concomitant administration of these agents is indicated, dosing should be separated by 2 hours.
DDI-DrugBank.d176.s11|a|Other: Neither fosinopril sodium nor its metabolites have been found to interact with food.
DDI-DrugBank.d176.s11	15	31	fosinopril sodium	drug	DDI-DrugBank.d176.s11.e0
DDI-DrugBank.d176.s12|a|In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
DDI-DrugBank.d176.s12	77	90	chlorthalidone	drug	DDI-DrugBank.d176.s12.e0
DDI-DrugBank.d176.s12	93	102	nifedipine	drug	DDI-DrugBank.d176.s12.e1
DDI-DrugBank.d176.s12	105	114	propanolol	drug	DDI-DrugBank.d176.s12.e2
DDI-DrugBank.d176.s12	117	135	hydrochlorothiazide	drug	DDI-DrugBank.d176.s12.e3
DDI-DrugBank.d176.s12	138	147	cimetidine	drug	DDI-DrugBank.d176.s12.e4
DDI-DrugBank.d176.s12	150	163	metoclopramide	drug	DDI-DrugBank.d176.s12.e5
DDI-DrugBank.d176.s12	166	178	propantheline	drug	DDI-DrugBank.d176.s12.e6
DDI-DrugBank.d176.s12	181	187	digoxin	drug	DDI-DrugBank.d176.s12.e7
DDI-DrugBank.d176.s12	194	201	warfarin	drug	DDI-DrugBank.d176.s12.e8
DDI-DrugBank.d176.s12	227	238	fosinoprilat	drug_n	DDI-DrugBank.d176.s12.e9
DDI-DrugBank.d176.s12	false	DDI-DrugBank.d176.s12.e0	DDI-DrugBank.d176.s12.e1
DDI-DrugBank.d176.s12	false	DDI-DrugBank.d176.s12.e0	DDI-DrugBank.d176.s12.e2
DDI-DrugBank.d176.s12	false	DDI-DrugBank.d176.s12.e0	DDI-DrugBank.d176.s12.e3
DDI-DrugBank.d176.s12	false	DDI-DrugBank.d176.s12.e0	DDI-DrugBank.d176.s12.e4
DDI-DrugBank.d176.s12	false	DDI-DrugBank.d176.s12.e0	DDI-DrugBank.d176.s12.e5
DDI-DrugBank.d176.s12	false	DDI-DrugBank.d176.s12.e0	DDI-DrugBank.d176.s12.e6
DDI-DrugBank.d176.s12	false	DDI-DrugBank.d176.s12.e0	DDI-DrugBank.d176.s12.e7
DDI-DrugBank.d176.s12	false	DDI-DrugBank.d176.s12.e0	DDI-DrugBank.d176.s12.e8
DDI-DrugBank.d176.s12	false	DDI-DrugBank.d176.s12.e0	DDI-DrugBank.d176.s12.e9
DDI-DrugBank.d176.s12	false	DDI-DrugBank.d176.s12.e0	DDI-DrugBank.d176.s12.e10
DDI-DrugBank.d176.s13|a|In a study with concomitant administration of aspirin and fosinopril sodium, the bioavailability of unbound fosinoprilat was not altered.
DDI-DrugBank.d176.s13	46	52	aspirin	brand	DDI-DrugBank.d176.s13.e0
DDI-DrugBank.d176.s13	58	74	fosinopril sodium	drug	DDI-DrugBank.d176.s13.e1
DDI-DrugBank.d176.s13	108	119	fosinoprilat	drug_n	DDI-DrugBank.d176.s13.e2
DDI-DrugBank.d176.s13	false	DDI-DrugBank.d176.s13.e0	DDI-DrugBank.d176.s13.e1
DDI-DrugBank.d176.s13	false	DDI-DrugBank.d176.s13.e0	DDI-DrugBank.d176.s13.e2
DDI-DrugBank.d176.s13	false	DDI-DrugBank.d176.s13.e1	DDI-DrugBank.d176.s13.e2
DDI-DrugBank.d176.s14|a|In a pharmacokinetic interaction study with warfarin, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed.
DDI-DrugBank.d176.s14	44	51	warfarin	drug	DDI-DrugBank.d176.s14.e0
DDI-DrugBank.d176.s14	176	183	warfarin	drug	DDI-DrugBank.d176.s14.e1
DDI-DrugBank.d176.s14	false	DDI-DrugBank.d176.s14.e0	DDI-DrugBank.d176.s14.e1
DDI-DrugBank.d176.s15|a|Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab  RIA Kit for Digoxin.
DDI-DrugBank.d176.s15	33	42	Fosinopril	drug	DDI-DrugBank.d176.s15.e0
DDI-DrugBank.d176.s15	87	93	digoxin	drug	DDI-DrugBank.d176.s15.e1
DDI-DrugBank.d176.s15	134	140	Digoxin	drug	DDI-DrugBank.d176.s15.e2
DDI-DrugBank.d176.s15	false	DDI-DrugBank.d176.s15.e0	DDI-DrugBank.d176.s15.e1
DDI-DrugBank.d176.s15	false	DDI-DrugBank.d176.s15.e0	DDI-DrugBank.d176.s15.e2
DDI-DrugBank.d176.s15	false	DDI-DrugBank.d176.s15.e1	DDI-DrugBank.d176.s15.e2
DDI-DrugBank.d176.s16|a|Other kits, such as the Coat-A-Count  RIA Kit, may be used.
DDI-DrugBank.d40.s0|a|No drugs are known to interfere with the conversion of fosphenytoin to phenytoin.
DDI-DrugBank.d40.s0	55	66	fosphenytoin	drug	DDI-DrugBank.d40.s0.e0
DDI-DrugBank.d40.s0	71	79	phenytoin	drug	DDI-DrugBank.d40.s0.e1
DDI-DrugBank.d40.s0	false	DDI-DrugBank.d40.s0.e0	DDI-DrugBank.d40.s0.e1
DDI-DrugBank.d40.s1|a|Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of fosphenytoin to phenytoin.
DDI-DrugBank.d40.s1	240	251	fosphenytoin	drug	DDI-DrugBank.d40.s1.e0
DDI-DrugBank.d40.s1	256	264	phenytoin	drug	DDI-DrugBank.d40.s1.e1
DDI-DrugBank.d40.s1	false	DDI-DrugBank.d40.s1.e0	DDI-DrugBank.d40.s1.e1
DDI-DrugBank.d40.s2|a|Drugs highly bound to albumin could increase the unbound fraction of fosphenytoin.
DDI-DrugBank.d40.s2	69	80	fosphenytoin	drug	DDI-DrugBank.d40.s2.e0
DDI-DrugBank.d40.s3|a|Although, it is unknown whether this could result in clinically significant effects, caution is advised when administering Cerebyx with other drugs that significantly bind to serum albumin.
DDI-DrugBank.d40.s3	123	129	Cerebyx	brand	DDI-DrugBank.d40.s3.e0
DDI-DrugBank.d40.s4|a|The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.
DDI-DrugBank.d40.s4	44	55	fosphenytoin	drug	DDI-DrugBank.d40.s4.e0
DDI-DrugBank.d40.s4	58	66	phenytoin	drug	DDI-DrugBank.d40.s4.e1
DDI-DrugBank.d40.s4	73	80	diazepam	drug	DDI-DrugBank.d40.s4.e2
DDI-DrugBank.d40.s4	104	111	diazepam	drug	DDI-DrugBank.d40.s4.e3
DDI-DrugBank.d40.s4	117	123	Cerebyx	brand	DDI-DrugBank.d40.s4.e4
DDI-DrugBank.d40.s4	false	DDI-DrugBank.d40.s4.e0	DDI-DrugBank.d40.s4.e1
DDI-DrugBank.d40.s4	false	DDI-DrugBank.d40.s4.e0	DDI-DrugBank.d40.s4.e2
DDI-DrugBank.d40.s4	false	DDI-DrugBank.d40.s4.e0	DDI-DrugBank.d40.s4.e3
DDI-DrugBank.d40.s4	false	DDI-DrugBank.d40.s4.e0	DDI-DrugBank.d40.s4.e4
DDI-DrugBank.d40.s4	false	DDI-DrugBank.d40.s4.e1	DDI-DrugBank.d40.s4.e2
DDI-DrugBank.d40.s4	false	DDI-DrugBank.d40.s4.e1	DDI-DrugBank.d40.s4.e3
DDI-DrugBank.d40.s4	false	DDI-DrugBank.d40.s4.e1	DDI-DrugBank.d40.s4.e4
DDI-DrugBank.d40.s4	false	DDI-DrugBank.d40.s4.e2	DDI-DrugBank.d40.s4.e3
DDI-DrugBank.d40.s4	false	DDI-DrugBank.d40.s4.e2	DDI-DrugBank.d40.s4.e4
DDI-DrugBank.d40.s4	false	DDI-DrugBank.d40.s4.e3	DDI-DrugBank.d40.s4.e4
DDI-DrugBank.d40.s5|a|The most significant drug interactions following administration of Cerebyx are expected to occur with drugs that interact with phenytoin.
DDI-DrugBank.d40.s5	67	73	Cerebyx	brand	DDI-DrugBank.d40.s5.e0
DDI-DrugBank.d40.s5	127	135	phenytoin	drug	DDI-DrugBank.d40.s5.e1
DDI-DrugBank.d40.s5	false	DDI-DrugBank.d40.s5.e0	DDI-DrugBank.d40.s5.e1
DDI-DrugBank.d40.s6|a|Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement.
DDI-DrugBank.d40.s6	0	8	Phenytoin	drug	DDI-DrugBank.d40.s6.e0
DDI-DrugBank.d40.s7|a|Phenytoin is metabolized by hepatic cytochrome P450 enzymes and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism.
DDI-DrugBank.d40.s7	0	8	Phenytoin	drug	DDI-DrugBank.d40.s7.e0
DDI-DrugBank.d40.s8|a|Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity.
DDI-DrugBank.d40.s8	74	82	phenytoin	drug	DDI-DrugBank.d40.s8.e0
DDI-DrugBank.d40.s9|a|Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes.
DDI-DrugBank.d40.s9	0	8	Phenytoin	drug	DDI-DrugBank.d40.s9.e0
DDI-DrugBank.d40.s10|a|The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10	97	105	phenytoin	drug	DDI-DrugBank.d40.s10.e0
DDI-DrugBank.d40.s10	137	143	alcohol	drug	DDI-DrugBank.d40.s10.e1
DDI-DrugBank.d40.s10	153	162	amiodarone	drug	DDI-DrugBank.d40.s10.e2
DDI-DrugBank.d40.s10	182	197	chlordiazepoxide	drug	DDI-DrugBank.d40.s10.e3
DDI-DrugBank.d40.s10	200	209	cimetidine	drug	DDI-DrugBank.d40.s10.e4
DDI-DrugBank.d40.s10	212	219	diazepam	drug	DDI-DrugBank.d40.s10.e5
DDI-DrugBank.d40.s10	222	230	dicumarol	drug	DDI-DrugBank.d40.s10.e6
DDI-DrugBank.d40.s10	233	242	disulfiram	drug	DDI-DrugBank.d40.s10.e7
DDI-DrugBank.d40.s10	245	253	estrogens	group	DDI-DrugBank.d40.s10.e8
DDI-DrugBank.d40.s10	256	267	ethosuximide	drug	DDI-DrugBank.d40.s10.e9
DDI-DrugBank.d40.s10	true	DDI-DrugBank.d40.s10.e0	DDI-DrugBank.d40.s10.e1
DDI-DrugBank.d40.s10	true	DDI-DrugBank.d40.s10.e0	DDI-DrugBank.d40.s10.e2
DDI-DrugBank.d40.s10	true	DDI-DrugBank.d40.s10.e0	DDI-DrugBank.d40.s10.e3
DDI-DrugBank.d40.s10	true	DDI-DrugBank.d40.s10.e0	DDI-DrugBank.d40.s10.e4
DDI-DrugBank.d40.s10	true	DDI-DrugBank.d40.s10.e0	DDI-DrugBank.d40.s10.e5
DDI-DrugBank.d40.s10	true	DDI-DrugBank.d40.s10.e0	DDI-DrugBank.d40.s10.e6
DDI-DrugBank.d40.s10	true	DDI-DrugBank.d40.s10.e0	DDI-DrugBank.d40.s10.e7
DDI-DrugBank.d40.s10	true	DDI-DrugBank.d40.s10.e0	DDI-DrugBank.d40.s10.e8
DDI-DrugBank.d40.s10	true	DDI-DrugBank.d40.s10.e0	DDI-DrugBank.d40.s10.e9
DDI-DrugBank.d40.s10	true	DDI-DrugBank.d40.s10.e0	DDI-DrugBank.d40.s10.e10
DDI-DrugBank.d40.s11|a|.
DDI-DrugBank.d40.s12|a|- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
DDI-DrugBank.d40.s12	33	41	phenytoin	drug	DDI-DrugBank.d40.s12.e0
DDI-DrugBank.d40.s12	67	79	carbamazepine	drug	DDI-DrugBank.d40.s12.e1
DDI-DrugBank.d40.s12	90	96	alcohol	drug	DDI-DrugBank.d40.s12.e2
DDI-DrugBank.d40.s12	105	113	reserpine	drug	DDI-DrugBank.d40.s12.e3
DDI-DrugBank.d40.s12	true	DDI-DrugBank.d40.s12.e0	DDI-DrugBank.d40.s12.e1
DDI-DrugBank.d40.s12	true	DDI-DrugBank.d40.s12.e0	DDI-DrugBank.d40.s12.e2
DDI-DrugBank.d40.s12	true	DDI-DrugBank.d40.s12.e0	DDI-DrugBank.d40.s12.e3
DDI-DrugBank.d40.s12	false	DDI-DrugBank.d40.s12.e1	DDI-DrugBank.d40.s12.e2
DDI-DrugBank.d40.s12	false	DDI-DrugBank.d40.s12.e1	DDI-DrugBank.d40.s12.e3
DDI-DrugBank.d40.s12	false	DDI-DrugBank.d40.s12.e2	DDI-DrugBank.d40.s12.e3
DDI-DrugBank.d40.s13|a|.
DDI-DrugBank.d40.s14|a|- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.
DDI-DrugBank.d40.s14	52	60	phenytoin	drug	DDI-DrugBank.d40.s14.e0
DDI-DrugBank.d40.s14	86	98	phenobarbital	drug	DDI-DrugBank.d40.s14.e1
DDI-DrugBank.d40.s14	120	135	sodium valproate	drug	DDI-DrugBank.d40.s14.e2
DDI-DrugBank.d40.s14	true	DDI-DrugBank.d40.s14.e0	DDI-DrugBank.d40.s14.e1
DDI-DrugBank.d40.s14	true	DDI-DrugBank.d40.s14.e0	DDI-DrugBank.d40.s14.e2
DDI-DrugBank.d40.s14	false	DDI-DrugBank.d40.s14.e1	DDI-DrugBank.d40.s14.e2
DDI-DrugBank.d40.s15|a|Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
DDI-DrugBank.d40.s15	26	34	phenytoin	drug	DDI-DrugBank.d40.s15.e0
DDI-DrugBank.d40.s15	39	51	phenobarbital	drug	DDI-DrugBank.d40.s15.e1
DDI-DrugBank.d40.s15	54	66	valproic acid	drug	DDI-DrugBank.d40.s15.e2
DDI-DrugBank.d40.s15	86	94	valproate	drug	DDI-DrugBank.d40.s15.e3
DDI-DrugBank.d40.s15	true	DDI-DrugBank.d40.s15.e0	DDI-DrugBank.d40.s15.e1
DDI-DrugBank.d40.s15	true	DDI-DrugBank.d40.s15.e0	DDI-DrugBank.d40.s15.e2
DDI-DrugBank.d40.s15	true	DDI-DrugBank.d40.s15.e0	DDI-DrugBank.d40.s15.e3
DDI-DrugBank.d40.s15	false	DDI-DrugBank.d40.s15.e1	DDI-DrugBank.d40.s15.e2
DDI-DrugBank.d40.s15	false	DDI-DrugBank.d40.s15.e1	DDI-DrugBank.d40.s15.e3
DDI-DrugBank.d40.s15	false	DDI-DrugBank.d40.s15.e2	DDI-DrugBank.d40.s15.e3
DDI-DrugBank.d40.s16|a|.
DDI-DrugBank.d40.s17|a|- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted
DDI-DrugBank.d40.s17	40	64	tricyclic antidepressants	group	DDI-DrugBank.d40.s17.e0
DDI-DrugBank.d40.s17	119	125	Cerebyx	brand	DDI-DrugBank.d40.s17.e1
DDI-DrugBank.d40.s17	true	DDI-DrugBank.d40.s17.e0	DDI-DrugBank.d40.s17.e1
DDI-DrugBank.d40.s18|a|.
DDI-DrugBank.d40.s19|a|- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d40.s19	38	46	phenytoin	drug	DDI-DrugBank.d40.s19.e0
DDI-DrugBank.d40.s19	57	70	anticoagulants	group	DDI-DrugBank.d40.s19.e1
DDI-DrugBank.d40.s19	73	87	corticosteroids	group	DDI-DrugBank.d40.s19.e2
DDI-DrugBank.d40.s19	90	97	coumarin	group	DDI-DrugBank.d40.s19.e3
DDI-DrugBank.d40.s19	100	108	digitoxin	drug	DDI-DrugBank.d40.s19.e4
DDI-DrugBank.d40.s19	111	121	doxycycline	drug	DDI-DrugBank.d40.s19.e5
DDI-DrugBank.d40.s19	124	132	estrogens	group	DDI-DrugBank.d40.s19.e6
DDI-DrugBank.d40.s19	135	144	furosemide	drug	DDI-DrugBank.d40.s19.e7
DDI-DrugBank.d40.s19	152	165	contraceptives	group	DDI-DrugBank.d40.s19.e8
DDI-DrugBank.d40.s19	168	175	rifampin	drug	DDI-DrugBank.d40.s19.e9
DDI-DrugBank.d40.s19	true	DDI-DrugBank.d40.s19.e0	DDI-DrugBank.d40.s19.e1
DDI-DrugBank.d40.s19	true	DDI-DrugBank.d40.s19.e0	DDI-DrugBank.d40.s19.e2
DDI-DrugBank.d40.s19	true	DDI-DrugBank.d40.s19.e0	DDI-DrugBank.d40.s19.e3
DDI-DrugBank.d40.s19	true	DDI-DrugBank.d40.s19.e0	DDI-DrugBank.d40.s19.e4
DDI-DrugBank.d40.s19	true	DDI-DrugBank.d40.s19.e0	DDI-DrugBank.d40.s19.e5
DDI-DrugBank.d40.s19	true	DDI-DrugBank.d40.s19.e0	DDI-DrugBank.d40.s19.e6
DDI-DrugBank.d40.s19	true	DDI-DrugBank.d40.s19.e0	DDI-DrugBank.d40.s19.e7
DDI-DrugBank.d40.s19	true	DDI-DrugBank.d40.s19.e0	DDI-DrugBank.d40.s19.e8
DDI-DrugBank.d40.s19	true	DDI-DrugBank.d40.s19.e0	DDI-DrugBank.d40.s19.e9
DDI-DrugBank.d40.s19	true	DDI-DrugBank.d40.s19.e0	DDI-DrugBank.d40.s19.e10
DDI-DrugBank.d40.s20|a|Monitoring of plasma phenytoin concentrations may be helpful when possible drug interactions are suspected.
DDI-DrugBank.d40.s20	21	29	phenytoin	drug	DDI-DrugBank.d40.s20.e0
DDI-DrugBank.d40.s21|a|Drug/Laboratory Test Interactions Phenytoin may decrease serum concentrations of 14.
DDI-DrugBank.d40.s21	34	42	Phenytoin	drug	DDI-DrugBank.d40.s21.e0
DDI-DrugBank.d40.s22|a|It may also produce artifactually low results in dexamethasone or metyrapone tests.
DDI-DrugBank.d40.s23|a|Phenytoin may also cause increased serum concentrations of glucose, alkaline phosphatase, and gamma glutamyl transpeptidase (GGT).
DDI-DrugBank.d40.s23	0	8	Phenytoin	drug	DDI-DrugBank.d40.s23.e0
DDI-DrugBank.d40.s24|a|Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations following Cerebyx administration.
DDI-DrugBank.d40.s24	75	83	phenytoin	drug	DDI-DrugBank.d40.s24.e0
DDI-DrugBank.d40.s24	110	116	Cerebyx	brand	DDI-DrugBank.d40.s24.e1
DDI-DrugBank.d40.s24	false	DDI-DrugBank.d40.s24.e0	DDI-DrugBank.d40.s24.e1
DDI-DrugBank.d426.s0|a|Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.
DDI-DrugBank.d426.s1|a|Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
DDI-DrugBank.d426.s1	67	76	ergotamine	drug	DDI-DrugBank.d426.s1.e0
DDI-DrugBank.d426.s1	92	113	ergot-type medications	group	DDI-DrugBank.d426.s1.e1
DDI-DrugBank.d426.s1	121	137	dihydroergotamine	drug	DDI-DrugBank.d426.s1.e2
DDI-DrugBank.d426.s1	142	153	methysergide	drug	DDI-DrugBank.d426.s1.e3
DDI-DrugBank.d426.s1	160	164	FROVA	brand	DDI-DrugBank.d426.s1.e4
DDI-DrugBank.d426.s1	false	DDI-DrugBank.d426.s1.e0	DDI-DrugBank.d426.s1.e1
DDI-DrugBank.d426.s1	false	DDI-DrugBank.d426.s1.e0	DDI-DrugBank.d426.s1.e2
DDI-DrugBank.d426.s1	false	DDI-DrugBank.d426.s1.e0	DDI-DrugBank.d426.s1.e3
DDI-DrugBank.d426.s1	true	DDI-DrugBank.d426.s1.e0	DDI-DrugBank.d426.s1.e4
DDI-DrugBank.d426.s1	false	DDI-DrugBank.d426.s1.e1	DDI-DrugBank.d426.s1.e2
DDI-DrugBank.d426.s1	false	DDI-DrugBank.d426.s1.e1	DDI-DrugBank.d426.s1.e3
DDI-DrugBank.d426.s1	true	DDI-DrugBank.d426.s1.e1	DDI-DrugBank.d426.s1.e4
DDI-DrugBank.d426.s1	false	DDI-DrugBank.d426.s1.e2	DDI-DrugBank.d426.s1.e3
DDI-DrugBank.d426.s1	true	DDI-DrugBank.d426.s1.e2	DDI-DrugBank.d426.s1.e4
DDI-DrugBank.d426.s1	true	DDI-DrugBank.d426.s1.e3	DDI-DrugBank.d426.s1.e4
DDI-DrugBank.d426.s2|a|Concomitant use of other 5-HT1B/1D agonists within 24 hours of FROVA treatment is not recommended.
DDI-DrugBank.d426.s2	63	67	FROVA	brand	DDI-DrugBank.d426.s2.e0
DDI-DrugBank.d426.s3|a|Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d426.s3	0	38	Selective serotonin reuptake inhibitors	group	DDI-DrugBank.d426.s3.e0
DDI-DrugBank.d426.s3	41	45	SSRIs	group	DDI-DrugBank.d426.s3.e1
DDI-DrugBank.d426.s3	55	64	fluoxetine	drug	DDI-DrugBank.d426.s3.e2
DDI-DrugBank.d426.s3	67	77	fluvoxamine	drug	DDI-DrugBank.d426.s3.e3
DDI-DrugBank.d426.s3	80	89	paroxetine	drug	DDI-DrugBank.d426.s3.e4
DDI-DrugBank.d426.s3	92	101	sertraline	drug	DDI-DrugBank.d426.s3.e5
DDI-DrugBank.d426.s3	210	223	5-HT1 agonists	group	DDI-DrugBank.d426.s3.e6
DDI-DrugBank.d426.s3	false	DDI-DrugBank.d426.s3.e0	DDI-DrugBank.d426.s3.e1
DDI-DrugBank.d426.s3	false	DDI-DrugBank.d426.s3.e0	DDI-DrugBank.d426.s3.e2
DDI-DrugBank.d426.s3	false	DDI-DrugBank.d426.s3.e0	DDI-DrugBank.d426.s3.e3
DDI-DrugBank.d426.s3	false	DDI-DrugBank.d426.s3.e0	DDI-DrugBank.d426.s3.e4
DDI-DrugBank.d426.s3	false	DDI-DrugBank.d426.s3.e0	DDI-DrugBank.d426.s3.e5
DDI-DrugBank.d426.s3	true	DDI-DrugBank.d426.s3.e0	DDI-DrugBank.d426.s3.e6
DDI-DrugBank.d426.s3	false	DDI-DrugBank.d426.s3.e1	DDI-DrugBank.d426.s3.e2
DDI-DrugBank.d426.s3	false	DDI-DrugBank.d426.s3.e1	DDI-DrugBank.d426.s3.e3
DDI-DrugBank.d426.s3	false	DDI-DrugBank.d426.s3.e1	DDI-DrugBank.d426.s3.e4
DDI-DrugBank.d426.s3	false	DDI-DrugBank.d426.s3.e1	DDI-DrugBank.d426.s3.e5
DDI-DrugBank.d426.s4|a|If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d426.s4	30	41	frovatriptan	drug	DDI-DrugBank.d426.s4.e0
DDI-DrugBank.d426.s4	50	53	SSRI	group	DDI-DrugBank.d426.s4.e1
DDI-DrugBank.d426.s4	true	DDI-DrugBank.d426.s4.e0	DDI-DrugBank.d426.s4.e1
DDI-DrugBank.d426.s5|a|Drug/Laboratory Test Interactions FROVA is not known to interfere with commonly employed clinical laboratory tests.
DDI-DrugBank.d426.s5	34	38	FROVA	brand	DDI-DrugBank.d426.s5.e0
DDI-DrugBank.d70.s0|a|Fulvestrant is metabolized by CYP 3A4 in vitro.
DDI-DrugBank.d70.s0	0	10	Fulvestrant	drug	DDI-DrugBank.d70.s0.e0
DDI-DrugBank.d70.s1|a|Clinical studies of the effect of strong CYP 3A4 inhibitors on the pharmacokinetics of fulvestrant have not been performed.
DDI-DrugBank.d70.s1	87	97	fulvestrant	drug	DDI-DrugBank.d70.s1.e0
DDI-DrugBank.d70.s2|a|Carcinogenesis, Mutagenesis and Impairment of Fertility A two-year carcinogenesis study was conducted in female and male rats, at intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days and 10 mg/rat/15 days.
DDI-DrugBank.d70.s3|a|These doses correspond to approximately 1-, 3-, and 5-fold (in females) and 1.3-, 1.3-, and 1.6-fold (in males) the systemic exposure [AUC0-30 days]] achieved in women receiving the recommended dose of 250 mg/month.
DDI-DrugBank.d70.s4|a|An increased incidence of benign ovarian granulosa cell tumors and testicular Leydig cell tumors was evident, in females dosed at 10 mg/rat/15 days and males dosed at 15 mg/rat/30 days, respectively.
DDI-DrugBank.d70.s5|a|Induction of such tumors is consistent with the pharmacology-related endocrine feedback alterations in gonadotropin levels caused by an antiestrogen.
DDI-DrugBank.d70.s5	136	147	antiestrogen	group	DDI-DrugBank.d70.s5.e0
DDI-DrugBank.d70.s6|a|Fulvestrant was not mutagenic or clastogenic in multiple in vitro tests with and without the addition of a mammalian liver metabolic activation factor (bacterial mutation assay in strains of Salmonella typhimurium and Escherichia coli, in vitro cytogenetics study in human lymphocytes, mammalian cell mutation assay in mouse lymphoma cells and in vivo micronucleus test in rat.
DDI-DrugBank.d70.s6	0	10	Fulvestrant	drug	DDI-DrugBank.d70.s6.e0
DDI-DrugBank.d70.s7|a|In female rats, fulvestrant administered at doses   0.01 mg/kg/day (approximately one-hundredth of the human recommended dose based on body surface area [BSA], for 2 weeks prior to and for 1 week following mating, caused a reduction in fertility and embryonic survival.
DDI-DrugBank.d70.s7	16	26	fulvestrant	drug	DDI-DrugBank.d70.s7.e0
DDI-DrugBank.d70.s8|a|No adverse effects on female fertility and embryonic survival were evident in female animals dosed at 0.001 mg/kg/day (approximately one-thousandth of the human dose based on BSA).
DDI-DrugBank.d70.s9|a|Restoration of female fertility to values similar to controls was evident following a 29-day withdrawal period after dosing at 2 mg/kg/day (twice the human dose based on BSA).
DDI-DrugBank.d70.s10|a|The effects of fulvestrant on the fertility of female rats appear to be consistent with its anti-estrogenic activity.
DDI-DrugBank.d70.s10	15	25	fulvestrant	drug	DDI-DrugBank.d70.s10.e0
DDI-DrugBank.d70.s11|a|The potential effects of fulvestrant on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days fulvestrant showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.
DDI-DrugBank.d70.s11	25	35	fulvestrant	drug	DDI-DrugBank.d70.s11.e0
DDI-DrugBank.d70.s11	226	236	fulvestrant	drug	DDI-DrugBank.d70.s11.e1
DDI-DrugBank.d70.s11	false	DDI-DrugBank.d70.s11.e0	DDI-DrugBank.d70.s11.e1
DDI-DrugBank.d70.s12|a|Changes in the testes and epididymides had not recovered 20 weeks after cessation of dosing.
DDI-DrugBank.d70.s13|a|These fulvestrant doses correspond to approximately 2-, 3-, and 3-fold the systemic exposure [AUC0-30 days] achieved in women.
DDI-DrugBank.d70.s13	6	16	fulvestrant	drug	DDI-DrugBank.d70.s13.e0
DDI-DrugBank.d70.s14|a|Pregnancy Pregnancy Category D: .
DDI-DrugBank.d70.s15|a|In studies in female rats at doses   0.01 mg/kg/day (IM;
DDI-DrugBank.d70.s16|a|approximately one-hundredth of the human recommended dose based on body surface area [BSA]), fulvestrant caused a reversible reduction in female fertility, as well as effects on embryo/fetal development consistent with its anti-estrogenic activity.
DDI-DrugBank.d70.s16	93	103	fulvestrant	drug	DDI-DrugBank.d70.s16.e0
DDI-DrugBank.d70.s17|a|Fulvestrant caused an increased incidence of fetal abnormalities in rats (tarsal flexure of the hind paw at 2 mg/kg/day IM;
DDI-DrugBank.d70.s17	0	10	Fulvestrant	drug	DDI-DrugBank.d70.s17.e0
DDI-DrugBank.d70.s18|a|twice the human dose on BSA) and non-ossification of the odontoid and ventral tubercle of the first cervical vertebra at doses   0.1 mg/kg/day IM (approximately one-tenth of the human dose on BSA) when administered during the period of organogenesis.
DDI-DrugBank.d70.s19|a|Rabbits failed to maintain pregnancy when dosed with 1 mg/kg/day fulvestrant IM (twice the human dose on BSA) during the period of organogenesis.
DDI-DrugBank.d70.s19	65	75	fulvestrant	drug	DDI-DrugBank.d70.s19.e0
DDI-DrugBank.d70.s20|a|Further, in rabbits dosed at 0.25 mg/kg/day (about one-half the human dose on BSA), increases in placental weight and post-implantation loss were observed but, there were no observed effects on fetal development.
DDI-DrugBank.d70.s21|a|Fulvestrant was associated with an increased incidence of fetal variations in rabbits (backwards displacement of the pelvic girdle, and 27 pre-sacral vertebrae at 0.25 mg/kg/day IM;
DDI-DrugBank.d70.s21	0	10	Fulvestrant	drug	DDI-DrugBank.d70.s21.e0
DDI-DrugBank.d70.s22|a|one-half the human dose on BSA) when administered during the period of organogenesis.
DDI-DrugBank.d70.s23|a|Because pregnancy could not be maintained in the rabbit following doses of fulvestrant of 1 mg/kg/day and above, this study was inadequate to fully define the possible adverse effects on fetal development at clinically relevant exposures.
DDI-DrugBank.d70.s23	75	85	fulvestrant	drug	DDI-DrugBank.d70.s23.e0
DDI-DrugBank.d70.s24|a|Nursing Mothers Fulvestrant is found in rat milk at levels significantly higher (approximately 12-fold) than plasma after administration of 2 mg/kg.
DDI-DrugBank.d70.s24	16	26	Fulvestrant	drug	DDI-DrugBank.d70.s24.e0
DDI-DrugBank.d70.s25|a|Drug exposure in rodent pups from fulvestrant-treated lactating dams was estimated as 10% of the administered dose.
DDI-DrugBank.d70.s25	34	44	fulvestrant	drug	DDI-DrugBank.d70.s25.e0
DDI-DrugBank.d70.s26|a|It is not known if fulvestrant is excreted in human milk.
DDI-DrugBank.d70.s26	19	29	fulvestrant	drug	DDI-DrugBank.d70.s26.e0
DDI-DrugBank.d70.s27|a|Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions from FASLODEX in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.
DDI-DrugBank.d70.s27	111	118	FASLODEX	brand	DDI-DrugBank.d70.s27.e0
DDI-DrugBank.d70.s28|a|Pediatric Use The safety and efficacy of FASLODEX in pediatric patients have not been established.
DDI-DrugBank.d70.s28	41	48	FASLODEX	brand	DDI-DrugBank.d70.s28.e0
DDI-DrugBank.d70.s29|a|Geriatric Use When tumor response was considered by age, objective responses were seen in 24% and 22% of patients under 65 years of age and in 16% and 11% of patients 65 years of age and older, who were treated with FASLODEX in the European and North American trials, respectively.
DDI-DrugBank.d70.s29	216	223	FASLODEX	brand	DDI-DrugBank.d70.s29.e0
DDI-DrugBank.d231.s0|a|Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.
DDI-DrugBank.d231.s0	0	9	Furosemide	drug	DDI-DrugBank.d231.s0.e0
DDI-DrugBank.d231.s0	50	75	aminoglycoside antibiotics	group	DDI-DrugBank.d231.s0.e1
DDI-DrugBank.d231.s0	true	DDI-DrugBank.d231.s0.e0	DDI-DrugBank.d231.s0.e1
DDI-DrugBank.d231.s1|a|Except in life-threatening situations, avoid this combination.
DDI-DrugBank.d231.s2|a|Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.
DDI-DrugBank.d231.s2	0	9	Furosemide	drug	DDI-DrugBank.d231.s2.e0
DDI-DrugBank.d231.s2	49	63	ethacrynic acid	drug	DDI-DrugBank.d231.s2.e1
DDI-DrugBank.d231.s2	true	DDI-DrugBank.d231.s2.e0	DDI-DrugBank.d231.s2.e1
DDI-DrugBank.d231.s3|a|Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
DDI-DrugBank.d231.s3	33	43	salicylates	group	DDI-DrugBank.d231.s3.e0
DDI-DrugBank.d231.s3	64	73	furosemide	drug	DDI-DrugBank.d231.s3.e1
DDI-DrugBank.d231.s3	116	125	salicylate	group	DDI-DrugBank.d231.s3.e2
DDI-DrugBank.d231.s3	true	DDI-DrugBank.d231.s3.e0	DDI-DrugBank.d231.s3.e1
DDI-DrugBank.d231.s3	false	DDI-DrugBank.d231.s3.e0	DDI-DrugBank.d231.s3.e2
DDI-DrugBank.d231.s3	false	DDI-DrugBank.d231.s3.e1	DDI-DrugBank.d231.s3.e2
DDI-DrugBank.d231.s4|a|Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
DDI-DrugBank.d231.s4	0	9	Furosemide	drug	DDI-DrugBank.d231.s4.e0
DDI-DrugBank.d231.s4	79	90	tubocurarine	drug	DDI-DrugBank.d231.s4.e1
DDI-DrugBank.d231.s4	125	139	succinylcholine	drug	DDI-DrugBank.d231.s4.e2
DDI-DrugBank.d231.s4	true	DDI-DrugBank.d231.s4.e0	DDI-DrugBank.d231.s4.e1
DDI-DrugBank.d231.s4	true	DDI-DrugBank.d231.s4.e0	DDI-DrugBank.d231.s4.e2
DDI-DrugBank.d231.s4	false	DDI-DrugBank.d231.s4.e1	DDI-DrugBank.d231.s4.e2
DDI-DrugBank.d231.s5|a|Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.
DDI-DrugBank.d231.s5	0	6	Lithium	drug	DDI-DrugBank.d231.s5.e0
DDI-DrugBank.d231.s5	43	51	diuretics	group	DDI-DrugBank.d231.s5.e1
DDI-DrugBank.d231.s5	73	79	lithium	drug	DDI-DrugBank.d231.s5.e2
DDI-DrugBank.d231.s5	121	127	lithium	drug	DDI-DrugBank.d231.s5.e3
DDI-DrugBank.d231.s5	true	DDI-DrugBank.d231.s5.e0	DDI-DrugBank.d231.s5.e1
DDI-DrugBank.d231.s5	false	DDI-DrugBank.d231.s5.e0	DDI-DrugBank.d231.s5.e2
DDI-DrugBank.d231.s5	false	DDI-DrugBank.d231.s5.e0	DDI-DrugBank.d231.s5.e3
DDI-DrugBank.d231.s5	false	DDI-DrugBank.d231.s5.e1	DDI-DrugBank.d231.s5.e2
DDI-DrugBank.d231.s5	false	DDI-DrugBank.d231.s5.e1	DDI-DrugBank.d231.s5.e3
DDI-DrugBank.d231.s5	false	DDI-DrugBank.d231.s5.e2	DDI-DrugBank.d231.s5.e3
DDI-DrugBank.d231.s6|a|Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.
DDI-DrugBank.d231.s6	0	9	Furosemide	drug	DDI-DrugBank.d231.s6.e0
DDI-DrugBank.d231.s6	68	89	antihypertensive drugs	group	DDI-DrugBank.d231.s6.e1
DDI-DrugBank.d231.s6	true	DDI-DrugBank.d231.s6.e0	DDI-DrugBank.d231.s6.e1
DDI-DrugBank.d231.s7|a|Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
DDI-DrugBank.d231.s7	25	34	ganglionic adrenergic blocking drugs	group	DDI-DrugBank.d231.s7.e0
DDI-DrugBank.d231.s7	50	74	ganglionic adrenergic blocking drugs	group	DDI-DrugBank.d231.s7.e0
DDI-DrugBank.d231.s7	39	74	peripheral adrenergic blocking drugs	group	DDI-DrugBank.d231.s7.e1
DDI-DrugBank.d231.s7	false	DDI-DrugBank.d231.s7.e0	DDI-DrugBank.d231.s7.e1
DDI-DrugBank.d231.s8|a|Furosemide may decrease arterial responsiveness to norepinephrine.
DDI-DrugBank.d231.s8	0	9	Furosemide	drug	DDI-DrugBank.d231.s8.e0
DDI-DrugBank.d231.s8	51	64	norepinephrine	drug	DDI-DrugBank.d231.s8.e1
DDI-DrugBank.d231.s8	true	DDI-DrugBank.d231.s8.e0	DDI-DrugBank.d231.s8.e1
DDI-DrugBank.d231.s9|a|However, norepinephrine may still be used effectively.
DDI-DrugBank.d231.s9	9	22	norepinephrine	drug	DDI-DrugBank.d231.s9.e0
DDI-DrugBank.d231.s10|a|Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.
DDI-DrugBank.d231.s10	39	48	sucralfate	drug	DDI-DrugBank.d231.s10.e0
DDI-DrugBank.d231.s10	54	63	furosemide	drug	DDI-DrugBank.d231.s10.e1
DDI-DrugBank.d231.s10	132	141	furosemide	drug	DDI-DrugBank.d231.s10.e2
DDI-DrugBank.d231.s10	true	DDI-DrugBank.d231.s10.e0	DDI-DrugBank.d231.s10.e1
DDI-DrugBank.d231.s10	false	DDI-DrugBank.d231.s10.e0	DDI-DrugBank.d231.s10.e2
DDI-DrugBank.d231.s10	false	DDI-DrugBank.d231.s10.e1	DDI-DrugBank.d231.s10.e2
DDI-DrugBank.d231.s11|a|Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
DDI-DrugBank.d231.s11	128	137	furosemide	drug	DDI-DrugBank.d231.s11.e0
DDI-DrugBank.d231.s12|a|The intake of furosemide and sucralfate should be separated by at least two hours.
DDI-DrugBank.d231.s12	14	23	furosemide	drug	DDI-DrugBank.d231.s12.e0
DDI-DrugBank.d231.s12	29	38	sucralfate	drug	DDI-DrugBank.d231.s12.e1
DDI-DrugBank.d231.s12	true	DDI-DrugBank.d231.s12.e0	DDI-DrugBank.d231.s12.e1
DDI-DrugBank.d231.s13|a|Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
DDI-DrugBank.d231.s13	101	110	furosemide	drug	DDI-DrugBank.d231.s13.e0
DDI-DrugBank.d231.s13	116	135	acetylsalicylic acid	drug	DDI-DrugBank.d231.s13.e1
DDI-DrugBank.d231.s13	true	DDI-DrugBank.d231.s13.e0	DDI-DrugBank.d231.s13.e1
DDI-DrugBank.d231.s14|a|There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
DDI-DrugBank.d231.s14	130	139	furosemide	drug	DDI-DrugBank.d231.s14.e0
DDI-DrugBank.d231.s14	170	175	NSAIDs	group	DDI-DrugBank.d231.s14.e1
DDI-DrugBank.d231.s14	true	DDI-DrugBank.d231.s14.e0	DDI-DrugBank.d231.s14.e1
DDI-DrugBank.d231.s15|a|Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.
DDI-DrugBank.d231.s15	53	64	indomethacin	drug	DDI-DrugBank.d231.s15.e0
DDI-DrugBank.d231.s15	125	134	furosemide	drug	DDI-DrugBank.d231.s15.e1
DDI-DrugBank.d231.s15	true	DDI-DrugBank.d231.s15.e0	DDI-DrugBank.d231.s15.e1
DDI-DrugBank.d231.s16|a|Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.
DDI-DrugBank.d231.s16	0	11	Indomethacin	drug	DDI-DrugBank.d231.s16.e0
DDI-DrugBank.d231.s17|a|Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
DDI-DrugBank.d231.s17	24	35	indomethacin	drug	DDI-DrugBank.d231.s17.e0
DDI-DrugBank.d231.s17	41	50	furosemide	drug	DDI-DrugBank.d231.s17.e1
DDI-DrugBank.d231.s17	150	159	furosemide	drug	DDI-DrugBank.d231.s17.e2
DDI-DrugBank.d231.s17	true	DDI-DrugBank.d231.s17.e0	DDI-DrugBank.d231.s17.e1
DDI-DrugBank.d231.s17	false	DDI-DrugBank.d231.s17.e0	DDI-DrugBank.d231.s17.e2
DDI-DrugBank.d231.s17	false	DDI-DrugBank.d231.s17.e1	DDI-DrugBank.d231.s17.e2
DDI-DrugBank.d438.s0|a|In vitro studies were conducted to investigate the potential of gabapentin to inhibit the major cytochrome P450 enzymes (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) that mediate drug and xenobiotic metabolism using isoform selective marker substrates and human liver microsomal preparations.
DDI-DrugBank.d438.s0	64	73	gabapentin	drug	DDI-DrugBank.d438.s0.e0
DDI-DrugBank.d438.s1|a|Only at the highest concentration tested (171
DDI-DrugBank.d438.s2|a|g/mL;
DDI-DrugBank.d438.s3|a|1 mM) was a slight degree of inhibition (14%-30%) of isoform CYP2A6 observed.
DDI-DrugBank.d438.s4|a|No inhibition of any of the other isoforms tested was observed at gabapentin concentrations up to 171 mg/mL (approximately 15 times the Cmax at 3600 mg/day).
DDI-DrugBank.d438.s4	66	75	gabapentin	drug	DDI-DrugBank.d438.s4.e0
DDI-DrugBank.d438.s5|a|Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs.
DDI-DrugBank.d438.s5	0	9	Gabapentin	drug	DDI-DrugBank.d438.s5.e0
DDI-DrugBank.d438.s5	111	129	antiepileptic drugs	group	DDI-DrugBank.d438.s5.e1
DDI-DrugBank.d438.s5	false	DDI-DrugBank.d438.s5.e0	DDI-DrugBank.d438.s5.e1
DDI-DrugBank.d438.s6|a|The drug interaction data described in this section were obtained from studies involving healthy adults and adult patients with epilepsy.
DDI-DrugBank.d438.s7|a|Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.
DDI-DrugBank.d438.s7	0	8	Phenytoin	drug	DDI-DrugBank.d438.s7.e0
DDI-DrugBank.d438.s7	72	80	Neurontin	brand	DDI-DrugBank.d438.s7.e1
DDI-DrugBank.d438.s7	124	132	phenytoin	drug	DDI-DrugBank.d438.s7.e2
DDI-DrugBank.d438.s7	169	178	gabapentin	drug	DDI-DrugBank.d438.s7.e3
DDI-DrugBank.d438.s7	246	254	phenytoin	drug	DDI-DrugBank.d438.s7.e4
DDI-DrugBank.d438.s7	260	268	phenytoin	drug	DDI-DrugBank.d438.s7.e5
DDI-DrugBank.d438.s7	287	296	gabapentin	drug	DDI-DrugBank.d438.s7.e6
DDI-DrugBank.d438.s7	false	DDI-DrugBank.d438.s7.e0	DDI-DrugBank.d438.s7.e1
DDI-DrugBank.d438.s7	false	DDI-DrugBank.d438.s7.e0	DDI-DrugBank.d438.s7.e2
DDI-DrugBank.d438.s7	false	DDI-DrugBank.d438.s7.e0	DDI-DrugBank.d438.s7.e3
DDI-DrugBank.d438.s7	false	DDI-DrugBank.d438.s7.e0	DDI-DrugBank.d438.s7.e4
DDI-DrugBank.d438.s7	false	DDI-DrugBank.d438.s7.e0	DDI-DrugBank.d438.s7.e5
DDI-DrugBank.d438.s7	false	DDI-DrugBank.d438.s7.e0	DDI-DrugBank.d438.s7.e6
DDI-DrugBank.d438.s7	false	DDI-DrugBank.d438.s7.e1	DDI-DrugBank.d438.s7.e2
DDI-DrugBank.d438.s7	false	DDI-DrugBank.d438.s7.e1	DDI-DrugBank.d438.s7.e3
DDI-DrugBank.d438.s7	false	DDI-DrugBank.d438.s7.e1	DDI-DrugBank.d438.s7.e4
DDI-DrugBank.d438.s7	false	DDI-DrugBank.d438.s7.e1	DDI-DrugBank.d438.s7.e5
DDI-DrugBank.d438.s8|a|Carbamazepine: Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;
DDI-DrugBank.d438.s8	0	12	Carbamazepine	drug	DDI-DrugBank.d438.s8.e0
DDI-DrugBank.d438.s8	42	54	carbamazepine	drug	DDI-DrugBank.d438.s8.e1
DDI-DrugBank.d438.s8	60	87	carbamazepine 10, 11 epoxide	drug_n	DDI-DrugBank.d438.s8.e2
DDI-DrugBank.d438.s8	137	146	gabapentin	drug	DDI-DrugBank.d438.s8.e3
DDI-DrugBank.d438.s8	false	DDI-DrugBank.d438.s8.e0	DDI-DrugBank.d438.s8.e1
DDI-DrugBank.d438.s8	false	DDI-DrugBank.d438.s8.e0	DDI-DrugBank.d438.s8.e2
DDI-DrugBank.d438.s8	false	DDI-DrugBank.d438.s8.e0	DDI-DrugBank.d438.s8.e3
DDI-DrugBank.d438.s8	false	DDI-DrugBank.d438.s8.e1	DDI-DrugBank.d438.s8.e2
DDI-DrugBank.d438.s8	false	DDI-DrugBank.d438.s8.e1	DDI-DrugBank.d438.s8.e3
DDI-DrugBank.d438.s8	false	DDI-DrugBank.d438.s8.e2	DDI-DrugBank.d438.s8.e3
DDI-DrugBank.d438.s9|a|N=12) administration.
DDI-DrugBank.d438.s10|a|Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration.
DDI-DrugBank.d438.s10	10	19	gabapentin	drug	DDI-DrugBank.d438.s10.e0
DDI-DrugBank.d438.s10	56	68	carbamazepine	drug	DDI-DrugBank.d438.s10.e1
DDI-DrugBank.d438.s10	false	DDI-DrugBank.d438.s10.e0	DDI-DrugBank.d438.s10.e1
DDI-DrugBank.d438.s11|a|Valproic Acid: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg TID;
DDI-DrugBank.d438.s11	0	12	Valproic Acid	drug	DDI-DrugBank.d438.s11.e0
DDI-DrugBank.d438.s11	50	62	valproic acid	drug	DDI-DrugBank.d438.s11.e1
DDI-DrugBank.d438.s11	111	120	gabapentin	drug	DDI-DrugBank.d438.s11.e2
DDI-DrugBank.d438.s11	false	DDI-DrugBank.d438.s11.e0	DDI-DrugBank.d438.s11.e1
DDI-DrugBank.d438.s11	false	DDI-DrugBank.d438.s11.e0	DDI-DrugBank.d438.s11.e2
DDI-DrugBank.d438.s11	false	DDI-DrugBank.d438.s11.e1	DDI-DrugBank.d438.s11.e2
DDI-DrugBank.d438.s12|a|N=17) were not different and neither were gabapentin pharmacokinetic parameters affected by valproic acid.
DDI-DrugBank.d438.s12	42	51	gabapentin	drug	DDI-DrugBank.d438.s12.e0
DDI-DrugBank.d438.s12	92	104	valproic acid	drug	DDI-DrugBank.d438.s12.e1
DDI-DrugBank.d438.s12	false	DDI-DrugBank.d438.s12.e0	DDI-DrugBank.d438.s12.e1
DDI-DrugBank.d438.s13|a|Phenobarbital: Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg TID;
DDI-DrugBank.d438.s13	0	12	Phenobarbital	drug	DDI-DrugBank.d438.s13.e0
DDI-DrugBank.d438.s13	72	84	phenobarbital	drug	DDI-DrugBank.d438.s13.e1
DDI-DrugBank.d438.s13	89	98	gabapentin	drug	DDI-DrugBank.d438.s13.e2
DDI-DrugBank.d438.s13	false	DDI-DrugBank.d438.s13.e0	DDI-DrugBank.d438.s13.e1
DDI-DrugBank.d438.s13	false	DDI-DrugBank.d438.s13.e0	DDI-DrugBank.d438.s13.e2
DDI-DrugBank.d438.s13	false	DDI-DrugBank.d438.s13.e1	DDI-DrugBank.d438.s13.e2
DDI-DrugBank.d438.s14|a|N=12) are identical whether the drugs are administered alone or together.
DDI-DrugBank.d438.s15|a|Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.
DDI-DrugBank.d438.s15	0	7	Naproxen	drug	DDI-DrugBank.d438.s15.e0
DDI-DrugBank.d438.s15	37	51	naproxen sodium	drug	DDI-DrugBank.d438.s15.e1
DDI-DrugBank.d438.s15	76	84	Neurontin	brand	DDI-DrugBank.d438.s15.e2
DDI-DrugBank.d438.s15	129	138	gabapentin	drug	DDI-DrugBank.d438.s15.e3
DDI-DrugBank.d438.s15	false	DDI-DrugBank.d438.s15.e0	DDI-DrugBank.d438.s15.e1
DDI-DrugBank.d438.s15	false	DDI-DrugBank.d438.s15.e0	DDI-DrugBank.d438.s15.e2
DDI-DrugBank.d438.s15	false	DDI-DrugBank.d438.s15.e0	DDI-DrugBank.d438.s15.e3
DDI-DrugBank.d438.s15	true	DDI-DrugBank.d438.s15.e1	DDI-DrugBank.d438.s15.e2
DDI-DrugBank.d438.s15	false	DDI-DrugBank.d438.s15.e1	DDI-DrugBank.d438.s15.e3
DDI-DrugBank.d438.s15	false	DDI-DrugBank.d438.s15.e2	DDI-DrugBank.d438.s15.e3
DDI-DrugBank.d438.s16|a|Gabapentin had no effect on naproxen pharmacokinetic parameters.
DDI-DrugBank.d438.s16	0	9	Gabapentin	drug	DDI-DrugBank.d438.s16.e0
DDI-DrugBank.d438.s16	28	35	naproxen	drug	DDI-DrugBank.d438.s16.e1
DDI-DrugBank.d438.s16	false	DDI-DrugBank.d438.s16.e0	DDI-DrugBank.d438.s16.e1
DDI-DrugBank.d438.s17|a|These doses are lower than the therapeutic doses for both drugs.
DDI-DrugBank.d438.s18|a|The magnitude of interaction within the recommended dose ranges of either drug is not known.
DDI-DrugBank.d438.s19|a|Hydrocodone: Coadministration of Neurontin  (125 to 500 mg;
DDI-DrugBank.d438.s19	0	10	Hydrocodone	drug	DDI-DrugBank.d438.s19.e0
DDI-DrugBank.d438.s19	33	41	Neurontin	brand	DDI-DrugBank.d438.s19.e1
DDI-DrugBank.d438.s19	false	DDI-DrugBank.d438.s19.e0	DDI-DrugBank.d438.s19.e1
DDI-DrugBank.d438.s20|a|N=48) decreases hydrocodone (10 mg;
DDI-DrugBank.d438.s20	16	26	hydrocodone	drug	DDI-DrugBank.d438.s20.e0
DDI-DrugBank.d438.s21|a|N=50) Cmax and AUC values in a dose-dependent manner relative to administration of hydrocodone alone;
DDI-DrugBank.d438.s21	83	93	hydrocodone	drug	DDI-DrugBank.d438.s21.e0
DDI-DrugBank.d438.s22|a|Cmax and AUC values are 3% to 4% lower, respectively, after administration of 125 mg Neurontin  and 21% to 22% lower, respectively, after administration of 500 mg Neurontin .
DDI-DrugBank.d438.s22	85	93	Neurontin	brand	DDI-DrugBank.d438.s22.e0
DDI-DrugBank.d438.s22	163	171	Neurontin	brand	DDI-DrugBank.d438.s22.e1
DDI-DrugBank.d438.s22	false	DDI-DrugBank.d438.s22.e0	DDI-DrugBank.d438.s22.e1
DDI-DrugBank.d438.s23|a|The mechanism for this interaction is unknown.
DDI-DrugBank.d438.s24|a|Hydrocodone increases gabapentin AUC values by 14%.
DDI-DrugBank.d438.s24	0	10	Hydrocodone	drug	DDI-DrugBank.d438.s24.e0
DDI-DrugBank.d438.s24	22	31	gabapentin	drug	DDI-DrugBank.d438.s24.e1
DDI-DrugBank.d438.s24	true	DDI-DrugBank.d438.s24.e0	DDI-DrugBank.d438.s24.e1
DDI-DrugBank.d438.s25|a|The magnitude of interaction at other doses is not known.
DDI-DrugBank.d438.s26|a|Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.
DDI-DrugBank.d438.s26	0	7	Morphine	drug	DDI-DrugBank.d438.s26.e0
DDI-DrugBank.d438.s26	77	84	morphine	drug	DDI-DrugBank.d438.s26.e1
DDI-DrugBank.d438.s26	137	145	Neurontin	brand	DDI-DrugBank.d438.s26.e2
DDI-DrugBank.d438.s26	169	178	gabapentin	drug	DDI-DrugBank.d438.s26.e3
DDI-DrugBank.d438.s26	213	222	gabapentin	drug	DDI-DrugBank.d438.s26.e4
DDI-DrugBank.d438.s26	245	252	morphine	drug	DDI-DrugBank.d438.s26.e5
DDI-DrugBank.d438.s26	false	DDI-DrugBank.d438.s26.e0	DDI-DrugBank.d438.s26.e1
DDI-DrugBank.d438.s26	false	DDI-DrugBank.d438.s26.e0	DDI-DrugBank.d438.s26.e2
DDI-DrugBank.d438.s26	false	DDI-DrugBank.d438.s26.e0	DDI-DrugBank.d438.s26.e3
DDI-DrugBank.d438.s26	false	DDI-DrugBank.d438.s26.e0	DDI-DrugBank.d438.s26.e4
DDI-DrugBank.d438.s26	false	DDI-DrugBank.d438.s26.e0	DDI-DrugBank.d438.s26.e5
DDI-DrugBank.d438.s26	true	DDI-DrugBank.d438.s26.e1	DDI-DrugBank.d438.s26.e2
DDI-DrugBank.d438.s26	false	DDI-DrugBank.d438.s26.e1	DDI-DrugBank.d438.s26.e3
DDI-DrugBank.d438.s26	false	DDI-DrugBank.d438.s26.e1	DDI-DrugBank.d438.s26.e4
DDI-DrugBank.d438.s26	false	DDI-DrugBank.d438.s26.e1	DDI-DrugBank.d438.s26.e5
DDI-DrugBank.d438.s26	false	DDI-DrugBank.d438.s26.e2	DDI-DrugBank.d438.s26.e3
DDI-DrugBank.d438.s27|a|Morphine pharmacokinetic parameter values were not affected by administration of Neurontin  2 hours after morphine.
DDI-DrugBank.d438.s27	0	7	Morphine	drug	DDI-DrugBank.d438.s27.e0
DDI-DrugBank.d438.s27	81	89	Neurontin	brand	DDI-DrugBank.d438.s27.e1
DDI-DrugBank.d438.s27	106	113	morphine	drug	DDI-DrugBank.d438.s27.e2
DDI-DrugBank.d438.s27	false	DDI-DrugBank.d438.s27.e0	DDI-DrugBank.d438.s27.e1
DDI-DrugBank.d438.s27	false	DDI-DrugBank.d438.s27.e0	DDI-DrugBank.d438.s27.e2
DDI-DrugBank.d438.s27	false	DDI-DrugBank.d438.s27.e1	DDI-DrugBank.d438.s27.e2
DDI-DrugBank.d438.s28|a|The magnitude of interaction at other doses is not known.
DDI-DrugBank.d438.s29|a|Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.
DDI-DrugBank.d438.s29	0	9	Cimetidine	drug	DDI-DrugBank.d438.s29.e0
DDI-DrugBank.d438.s29	31	40	cimetidine	drug	DDI-DrugBank.d438.s29.e1
DDI-DrugBank.d438.s29	99	108	gabapentin	drug	DDI-DrugBank.d438.s29.e2
DDI-DrugBank.d438.s29	false	DDI-DrugBank.d438.s29.e0	DDI-DrugBank.d438.s29.e1
DDI-DrugBank.d438.s29	false	DDI-DrugBank.d438.s29.e0	DDI-DrugBank.d438.s29.e2
DDI-DrugBank.d438.s29	true	DDI-DrugBank.d438.s29.e1	DDI-DrugBank.d438.s29.e2
DDI-DrugBank.d438.s30|a|Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.
DDI-DrugBank.d438.s30	5	14	cimetidine	drug	DDI-DrugBank.d438.s30.e0
DDI-DrugBank.d438.s30	62	71	gabapentin	drug	DDI-DrugBank.d438.s30.e1
DDI-DrugBank.d438.s30	true	DDI-DrugBank.d438.s30.e0	DDI-DrugBank.d438.s30.e1
DDI-DrugBank.d438.s31|a|This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.
DDI-DrugBank.d438.s31	36	45	gabapentin	drug	DDI-DrugBank.d438.s31.e0
DDI-DrugBank.d438.s31	50	59	cimetidine	drug	DDI-DrugBank.d438.s31.e1
DDI-DrugBank.d438.s31	true	DDI-DrugBank.d438.s31.e0	DDI-DrugBank.d438.s31.e1
DDI-DrugBank.d438.s32|a|The effect of gabapentin on cimetidine was not evaluated.
DDI-DrugBank.d438.s32	14	23	gabapentin	drug	DDI-DrugBank.d438.s32.e0
DDI-DrugBank.d438.s32	28	37	cimetidine	drug	DDI-DrugBank.d438.s32.e1
DDI-DrugBank.d438.s32	false	DDI-DrugBank.d438.s32.e0	DDI-DrugBank.d438.s32.e1
DDI-DrugBank.d438.s33|a|Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;
DDI-DrugBank.d438.s33	5	17	Contraceptive	group	DDI-DrugBank.d438.s33.e0
DDI-DrugBank.d438.s33	90	102	norethindrone	drug	DDI-DrugBank.d438.s33.e1
DDI-DrugBank.d438.s33	108	124	ethinyl estradiol	drug	DDI-DrugBank.d438.s33.e2
DDI-DrugBank.d438.s33	183	203	norethindrone acetate	drug	DDI-DrugBank.d438.s33.e3
DDI-DrugBank.d438.s33	219	235	ethinyl estradiol	drug	DDI-DrugBank.d438.s33.e4
DDI-DrugBank.d438.s33	287	296	gabapentin	drug	DDI-DrugBank.d438.s33.e5
DDI-DrugBank.d438.s33	false	DDI-DrugBank.d438.s33.e0	DDI-DrugBank.d438.s33.e1
DDI-DrugBank.d438.s33	false	DDI-DrugBank.d438.s33.e0	DDI-DrugBank.d438.s33.e2
DDI-DrugBank.d438.s33	false	DDI-DrugBank.d438.s33.e0	DDI-DrugBank.d438.s33.e3
DDI-DrugBank.d438.s33	false	DDI-DrugBank.d438.s33.e0	DDI-DrugBank.d438.s33.e4
DDI-DrugBank.d438.s33	false	DDI-DrugBank.d438.s33.e0	DDI-DrugBank.d438.s33.e5
DDI-DrugBank.d438.s33	false	DDI-DrugBank.d438.s33.e1	DDI-DrugBank.d438.s33.e2
DDI-DrugBank.d438.s33	false	DDI-DrugBank.d438.s33.e1	DDI-DrugBank.d438.s33.e3
DDI-DrugBank.d438.s33	false	DDI-DrugBank.d438.s33.e1	DDI-DrugBank.d438.s33.e4
DDI-DrugBank.d438.s33	false	DDI-DrugBank.d438.s33.e1	DDI-DrugBank.d438.s33.e5
DDI-DrugBank.d438.s33	false	DDI-DrugBank.d438.s33.e2	DDI-DrugBank.d438.s33.e3
DDI-DrugBank.d438.s34|a|N=13).
DDI-DrugBank.d438.s35|a|The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;
DDI-DrugBank.d438.s35	12	24	norethindrone	drug	DDI-DrugBank.d438.s35.e0
DDI-DrugBank.d438.s35	73	82	gabapentin	drug	DDI-DrugBank.d438.s35.e1
DDI-DrugBank.d438.s35	true	DDI-DrugBank.d438.s35.e0	DDI-DrugBank.d438.s35.e1
DDI-DrugBank.d438.s36|a|this interaction is not expected to be of clinical importance.
DDI-DrugBank.d438.s37|a|Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.
DDI-DrugBank.d438.s37	0	6	Antacid	group	DDI-DrugBank.d438.s37.e0
DDI-DrugBank.d438.s37	9	14	Maalox	brand	DDI-DrugBank.d438.s37.e1
DDI-DrugBank.d438.s37	19	24	Maalox	brand	DDI-DrugBank.d438.s37.e2
DDI-DrugBank.d438.s37	57	66	gabapentin	drug	DDI-DrugBank.d438.s37.e3
DDI-DrugBank.d438.s37	false	DDI-DrugBank.d438.s37.e0	DDI-DrugBank.d438.s37.e1
DDI-DrugBank.d438.s37	false	DDI-DrugBank.d438.s37.e0	DDI-DrugBank.d438.s37.e2
DDI-DrugBank.d438.s37	false	DDI-DrugBank.d438.s37.e0	DDI-DrugBank.d438.s37.e3
DDI-DrugBank.d438.s37	false	DDI-DrugBank.d438.s37.e1	DDI-DrugBank.d438.s37.e2
DDI-DrugBank.d438.s37	false	DDI-DrugBank.d438.s37.e1	DDI-DrugBank.d438.s37.e3
DDI-DrugBank.d438.s37	true	DDI-DrugBank.d438.s37.e2	DDI-DrugBank.d438.s37.e3
DDI-DrugBank.d438.s38|a|This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.
DDI-DrugBank.d438.s38	51	60	gabapentin	drug	DDI-DrugBank.d438.s38.e0
DDI-DrugBank.d438.s38	93	98	Maalox	brand	DDI-DrugBank.d438.s38.e1
DDI-DrugBank.d438.s38	true	DDI-DrugBank.d438.s38.e0	DDI-DrugBank.d438.s38.e1
DDI-DrugBank.d438.s39|a|It is recommended that gabapentin be taken at least 2 hours following Maalox administration.
DDI-DrugBank.d438.s39	23	32	gabapentin	drug	DDI-DrugBank.d438.s39.e0
DDI-DrugBank.d438.s39	70	75	Maalox	brand	DDI-DrugBank.d438.s39.e1
DDI-DrugBank.d438.s39	true	DDI-DrugBank.d438.s39.e0	DDI-DrugBank.d438.s39.e1
DDI-DrugBank.d438.s40|a|Effect of Probenecid: Probenecid is a blocker of renal tubular secretion.
DDI-DrugBank.d438.s40	10	19	Probenecid	drug	DDI-DrugBank.d438.s40.e0
DDI-DrugBank.d438.s40	22	31	Probenecid	drug	DDI-DrugBank.d438.s40.e1
DDI-DrugBank.d438.s40	false	DDI-DrugBank.d438.s40.e0	DDI-DrugBank.d438.s40.e1
DDI-DrugBank.d438.s41|a|Gabapentin pharmacokinetic parameters without and with probenecid were comparable.
DDI-DrugBank.d438.s41	0	9	Gabapentin	drug	DDI-DrugBank.d438.s41.e0
DDI-DrugBank.d438.s41	55	64	probenecid	drug	DDI-DrugBank.d438.s41.e1
DDI-DrugBank.d438.s41	false	DDI-DrugBank.d438.s41.e0	DDI-DrugBank.d438.s41.e1
DDI-DrugBank.d438.s42|a|This indicates that gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid.
DDI-DrugBank.d438.s42	20	29	gabapentin	drug	DDI-DrugBank.d438.s42.e0
DDI-DrugBank.d438.s42	106	115	probenecid	drug	DDI-DrugBank.d438.s42.e1
DDI-DrugBank.d438.s42	false	DDI-DrugBank.d438.s42.e0	DDI-DrugBank.d438.s42.e1
DDI-DrugBank.d438.s43|a|Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein
DDI-DrugBank.d438.s43	149	158	gabapentin	drug	DDI-DrugBank.d438.s43.e0
DDI-DrugBank.d438.s43	179	197	antiepileptic drugs	group	DDI-DrugBank.d438.s43.e1
DDI-DrugBank.d438.s43	false	DDI-DrugBank.d438.s43.e0	DDI-DrugBank.d438.s43.e1
DDI-DrugBank.d438.s44|a|.
DDI-DrugBank.d438.s45|a|
DDI-DrugBank.d230.s0|a|LABORATORY TEST FINDINGS Asymptomatic, transitory changes in serum iron have been observed.
DDI-DrugBank.d230.s1|a|The clinical significance is unknown.
DDI-DrugBank.d230.s2|a|Omniscan interferes with serum calcium measurements with some colorimetric (complexometric) methods commonly used in hospitals, resulting in serum calcium concentrations lower than the true values.
DDI-DrugBank.d230.s2	0	7	Omniscan	brand	DDI-DrugBank.d230.s2.e0
DDI-DrugBank.d230.s3|a|Thus, it is recommended not to use such methods for 12-24 hours after administration of Omniscan.
DDI-DrugBank.d230.s3	88	95	Omniscan	brand	DDI-DrugBank.d230.s3.e0
DDI-DrugBank.d230.s4|a|If such measurements are necessary, the use of other methods is recommended.
DDI-DrugBank.d230.s5|a|All patients in whom this effect was observed remained asymptomatic.
DDI-DrugBank.d58.s0|a|No formal drug interaction studies have been conducted.
DDI-DrugBank.d159.s0|a|No drug interactions have been observed with the Vitrasert Implant.
DDI-DrugBank.d159.s0	49	57	Vitrasert	brand	DDI-DrugBank.d159.s0.e0
DDI-DrugBank.d159.s1|a|There is limited experience with use of retinal tamponades in conjunction with the Vitrasert Implant.
DDI-DrugBank.d159.s1	83	91	Vitrasert	brand	DDI-DrugBank.d159.s1.e0
DDI-DrugBank.d207.s0|a|Substances that are inducers of CYP3A4 activity increase the metabolism of gefitinib and decrease its plasma concentrations.
DDI-DrugBank.d207.s0	75	83	gefitinib	drug	DDI-DrugBank.d207.s0.e0
DDI-DrugBank.d207.s1|a|In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).
DDI-DrugBank.d207.s1	54	63	rifampicin	drug	DDI-DrugBank.d207.s1.e0
DDI-DrugBank.d207.s1	68	76	phenytoin	drug	DDI-DrugBank.d207.s1.e1
DDI-DrugBank.d207.s1	false	DDI-DrugBank.d207.s1.e0	DDI-DrugBank.d207.s1.e1
DDI-DrugBank.d207.s2|a|International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.
DDI-DrugBank.d207.s2	114	121	warfarin	drug	DDI-DrugBank.d207.s2.e0
DDI-DrugBank.d207.s2	132	137	IRESSA	brand	DDI-DrugBank.d207.s2.e1
DDI-DrugBank.d207.s2	true	DDI-DrugBank.d207.s2.e0	DDI-DrugBank.d207.s2.e1
DDI-DrugBank.d207.s3|a|Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR.
DDI-DrugBank.d207.s3	16	23	warfarin	drug	DDI-DrugBank.d207.s3.e0
DDI-DrugBank.d207.s4|a|Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
DDI-DrugBank.d207.s4	62	73	ketoconazole	drug	DDI-DrugBank.d207.s4.e0
DDI-DrugBank.d207.s4	79	90	itraconazole	drug	DDI-DrugBank.d207.s4.e1
DDI-DrugBank.d207.s4	102	110	gefitinib	drug	DDI-DrugBank.d207.s4.e2
DDI-DrugBank.d207.s4	136	144	gefitinib	drug	DDI-DrugBank.d207.s4.e3
DDI-DrugBank.d207.s4	false	DDI-DrugBank.d207.s4.e0	DDI-DrugBank.d207.s4.e1
DDI-DrugBank.d207.s4	true	DDI-DrugBank.d207.s4.e0	DDI-DrugBank.d207.s4.e2
DDI-DrugBank.d207.s4	true	DDI-DrugBank.d207.s4.e0	DDI-DrugBank.d207.s4.e3
DDI-DrugBank.d207.s4	true	DDI-DrugBank.d207.s4.e1	DDI-DrugBank.d207.s4.e2
DDI-DrugBank.d207.s4	true	DDI-DrugBank.d207.s4.e1	DDI-DrugBank.d207.s4.e3
DDI-DrugBank.d207.s4	false	DDI-DrugBank.d207.s4.e2	DDI-DrugBank.d207.s4.e3
DDI-DrugBank.d207.s5|a|This increase may be clinically relevant as adverse experiences are related to dose and exposure;
DDI-DrugBank.d207.s6|a|therefore, caution should be used when administering CYP3A4 inhibitors with IRESSA.
DDI-DrugBank.d207.s6	76	81	IRESSA	brand	DDI-DrugBank.d207.s6.e0
DDI-DrugBank.d207.s7|a|Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
DDI-DrugBank.d207.s7	64	96	histamine H2-receptor antagonists	group	DDI-DrugBank.d207.s7.e0
DDI-DrugBank.d207.s7	106	115	ranitidine	drug	DDI-DrugBank.d207.s7.e1
DDI-DrugBank.d207.s7	120	129	cimetidine	drug	DDI-DrugBank.d207.s7.e2
DDI-DrugBank.d207.s7	168	173	IRESSA	brand	DDI-DrugBank.d207.s7.e3
DDI-DrugBank.d207.s7	false	DDI-DrugBank.d207.s7.e0	DDI-DrugBank.d207.s7.e1
DDI-DrugBank.d207.s7	false	DDI-DrugBank.d207.s7.e0	DDI-DrugBank.d207.s7.e2
DDI-DrugBank.d207.s7	true	DDI-DrugBank.d207.s7.e0	DDI-DrugBank.d207.s7.e3
DDI-DrugBank.d207.s7	false	DDI-DrugBank.d207.s7.e1	DDI-DrugBank.d207.s7.e2
DDI-DrugBank.d207.s7	true	DDI-DrugBank.d207.s7.e1	DDI-DrugBank.d207.s7.e3
DDI-DrugBank.d207.s7	true	DDI-DrugBank.d207.s7.e2	DDI-DrugBank.d207.s7.e3
DDI-DrugBank.d207.s8|a|Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.
DDI-DrugBank.d207.s8	36	41	IRESSA	brand	DDI-DrugBank.d207.s8.e0
DDI-DrugBank.d207.s8	47	57	vinorelbine	drug	DDI-DrugBank.d207.s8.e1
DDI-DrugBank.d207.s8	103	108	IRESSA	brand	DDI-DrugBank.d207.s8.e2
DDI-DrugBank.d207.s8	151	161	vinorelbine	drug	DDI-DrugBank.d207.s8.e3
DDI-DrugBank.d207.s8	false	DDI-DrugBank.d207.s8.e0	DDI-DrugBank.d207.s8.e1
DDI-DrugBank.d207.s8	false	DDI-DrugBank.d207.s8.e0	DDI-DrugBank.d207.s8.e2
DDI-DrugBank.d207.s8	false	DDI-DrugBank.d207.s8.e0	DDI-DrugBank.d207.s8.e3
DDI-DrugBank.d207.s8	false	DDI-DrugBank.d207.s8.e1	DDI-DrugBank.d207.s8.e2
DDI-DrugBank.d207.s8	false	DDI-DrugBank.d207.s8.e1	DDI-DrugBank.d207.s8.e3
DDI-DrugBank.d207.s8	true	DDI-DrugBank.d207.s8.e2	DDI-DrugBank.d207.s8.e3
DDI-DrugBank.d161.s0|a|No specific drug interaction studies have been conducted.
DDI-DrugBank.d161.s1|a|For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.
DDI-DrugBank.d161.s1	43	48	Gemzar	brand	DDI-DrugBank.d161.s1.e0
DDI-DrugBank.d161.s1	54	62	cisplatin	drug	DDI-DrugBank.d161.s1.e1
DDI-DrugBank.d161.s1	false	DDI-DrugBank.d161.s1.e0	DDI-DrugBank.d161.s1.e1
DDI-DrugBank.d490.s0|a|)
DDI-DrugBank.d490.s1|a|
DDI-DrugBank.d490.s2|a|Clinical Laboratory
DDI-DrugBank.d490.s3|a|
DDI-DrugBank.d490.s4|a|increased creatine
DDI-DrugBank.d490.s5|a|positive antinuclear
DDI-DrugBank.d490.s6|a|
DDI-DrugBank.d490.s7|a|phosphokinase
DDI-DrugBank.d490.s8|a|antibody
DDI-DrugBank.d490.s9|a|
DDI-DrugBank.d490.s10|a|increased bilirubin
DDI-DrugBank.d490.s11|a|
DDI-DrugBank.d490.s12|a|
DDI-DrugBank.d490.s13|a|increased liver
DDI-DrugBank.d490.s14|a|
DDI-DrugBank.d490.s15|a|
DDI-DrugBank.d490.s16|a|transaminases (AST
DDI-DrugBank.d490.s17|a|
DDI-DrugBank.d490.s18|a|
DDI-DrugBank.d490.s19|a|(SGOT), ALT (SGPT)
DDI-DrugBank.d490.s20|a|
DDI-DrugBank.d490.s21|a|
DDI-DrugBank.d490.s22|a|increased alkaline
DDI-DrugBank.d490.s23|a|
DDI-DrugBank.d490.s24|a|
DDI-DrugBank.d490.s25|a|phophatase
DDI-DrugBank.d490.s26|a|
DDI-DrugBank.d490.s27|a|Hematopoietic
DDI-DrugBank.d490.s28|a|anemia
DDI-DrugBank.d490.s29|a|thrombocytopenia
DDI-DrugBank.d490.s30|a|
DDI-DrugBank.d490.s31|a|leukopenia
DDI-DrugBank.d490.s32|a|
DDI-DrugBank.d490.s33|a|
DDI-DrugBank.d490.s34|a|bone marrow hypoplasia
DDI-DrugBank.d490.s35|a|
DDI-DrugBank.d490.s36|a|
DDI-DrugBank.d490.s37|a|eosinophilia
DDI-DrugBank.d490.s38|a|
DDI-DrugBank.d490.s39|a|Immunologic
DDI-DrugBank.d490.s40|a|angioedema
DDI-DrugBank.d490.s41|a|anaphylaxis
DDI-DrugBank.d490.s42|a|
DDI-DrugBank.d490.s43|a|laryngeal edema
DDI-DrugBank.d490.s44|a|Lupus-like syndrome
DDI-DrugBank.d490.s45|a|
DDI-DrugBank.d490.s46|a|urticaria
DDI-DrugBank.d490.s47|a|vasculitis
DDI-DrugBank.d490.s48|a|Integumentary
DDI-DrugBank.d490.s49|a|exfoliative dermatitis
DDI-DrugBank.d490.s50|a|alopecia
DDI-DrugBank.d490.s51|a|
DDI-DrugBank.d490.s52|a|rash
DDI-DrugBank.d490.s53|a|
DDI-DrugBank.d490.s54|a|
DDI-DrugBank.d490.s55|a|dermatitis
DDI-DrugBank.d490.s56|a|
DDI-DrugBank.d490.s57|a|
DDI-DrugBank.d490.s58|a|pruritus
DDI-DrugBank.d490.s59|a|
DDI-DrugBank.d347.s0|a|Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.
DDI-DrugBank.d347.s0	34	40	FACTIVE	brand	DDI-DrugBank.d347.s0.e0
DDI-DrugBank.d347.s0	95	106	theophylline	drug	DDI-DrugBank.d347.s0.e1
DDI-DrugBank.d347.s0	109	115	digoxin	drug	DDI-DrugBank.d347.s0.e2
DDI-DrugBank.d347.s0	123	138	ethinylestradiol	drug	DDI-DrugBank.d347.s0.e3
DDI-DrugBank.d347.s0	160	180	contraceptive product	group	DDI-DrugBank.d347.s0.e4
DDI-DrugBank.d347.s0	false	DDI-DrugBank.d347.s0.e0	DDI-DrugBank.d347.s0.e1
DDI-DrugBank.d347.s0	false	DDI-DrugBank.d347.s0.e0	DDI-DrugBank.d347.s0.e2
DDI-DrugBank.d347.s0	false	DDI-DrugBank.d347.s0.e0	DDI-DrugBank.d347.s0.e3
DDI-DrugBank.d347.s0	false	DDI-DrugBank.d347.s0.e0	DDI-DrugBank.d347.s0.e4
DDI-DrugBank.d347.s0	false	DDI-DrugBank.d347.s0.e1	DDI-DrugBank.d347.s0.e2
DDI-DrugBank.d347.s0	false	DDI-DrugBank.d347.s0.e1	DDI-DrugBank.d347.s0.e3
DDI-DrugBank.d347.s0	false	DDI-DrugBank.d347.s0.e1	DDI-DrugBank.d347.s0.e4
DDI-DrugBank.d347.s0	false	DDI-DrugBank.d347.s0.e2	DDI-DrugBank.d347.s0.e3
DDI-DrugBank.d347.s0	false	DDI-DrugBank.d347.s0.e2	DDI-DrugBank.d347.s0.e4
DDI-DrugBank.d347.s0	false	DDI-DrugBank.d347.s0.e3	DDI-DrugBank.d347.s0.e4
DDI-DrugBank.d347.s1|a|Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
DDI-DrugBank.d347.s1	30	36	FACTIVE	brand	DDI-DrugBank.d347.s1.e0
DDI-DrugBank.d347.s1	42	58	calcium carbonate	drug	DDI-DrugBank.d347.s1.e1
DDI-DrugBank.d347.s1	61	70	cimetidine	drug	DDI-DrugBank.d347.s1.e2
DDI-DrugBank.d347.s1	73	82	omeprazole	drug	DDI-DrugBank.d347.s1.e3
DDI-DrugBank.d347.s1	91	98	estrogen	group	DDI-DrugBank.d347.s1.e4
DDI-DrugBank.d347.s1	100	111	progesterone	drug	DDI-DrugBank.d347.s1.e5
DDI-DrugBank.d347.s1	118	130	contraceptive	group	DDI-DrugBank.d347.s1.e6
DDI-DrugBank.d347.s1	182	193	gemifloxacin	drug	DDI-DrugBank.d347.s1.e7
DDI-DrugBank.d347.s1	true	DDI-DrugBank.d347.s1.e0	DDI-DrugBank.d347.s1.e1
DDI-DrugBank.d347.s1	true	DDI-DrugBank.d347.s1.e0	DDI-DrugBank.d347.s1.e2
DDI-DrugBank.d347.s1	true	DDI-DrugBank.d347.s1.e0	DDI-DrugBank.d347.s1.e3
DDI-DrugBank.d347.s1	true	DDI-DrugBank.d347.s1.e0	DDI-DrugBank.d347.s1.e4
DDI-DrugBank.d347.s1	true	DDI-DrugBank.d347.s1.e0	DDI-DrugBank.d347.s1.e5
DDI-DrugBank.d347.s1	true	DDI-DrugBank.d347.s1.e0	DDI-DrugBank.d347.s1.e6
DDI-DrugBank.d347.s1	false	DDI-DrugBank.d347.s1.e0	DDI-DrugBank.d347.s1.e7
DDI-DrugBank.d347.s1	false	DDI-DrugBank.d347.s1.e1	DDI-DrugBank.d347.s1.e2
DDI-DrugBank.d347.s1	false	DDI-DrugBank.d347.s1.e1	DDI-DrugBank.d347.s1.e3
DDI-DrugBank.d347.s1	false	DDI-DrugBank.d347.s1.e1	DDI-DrugBank.d347.s1.e4
DDI-DrugBank.d347.s2|a|Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.
DDI-DrugBank.d347.s2	30	36	FACTIVE	brand	DDI-DrugBank.d347.s2.e0
DDI-DrugBank.d347.s2	43	52	probenecid	drug	DDI-DrugBank.d347.s2.e1
DDI-DrugBank.d347.s2	105	116	gemifloxacin	drug	DDI-DrugBank.d347.s2.e2
DDI-DrugBank.d347.s2	true	DDI-DrugBank.d347.s2.e0	DDI-DrugBank.d347.s2.e1
DDI-DrugBank.d347.s2	false	DDI-DrugBank.d347.s2.e0	DDI-DrugBank.d347.s2.e2
DDI-DrugBank.d347.s2	false	DDI-DrugBank.d347.s2.e1	DDI-DrugBank.d347.s2.e2
DDI-DrugBank.d347.s3|a|FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy.
DDI-DrugBank.d347.s3	0	6	FACTIVE	brand	DDI-DrugBank.d347.s3.e0
DDI-DrugBank.d347.s3	65	72	warfarin	drug	DDI-DrugBank.d347.s3.e1
DDI-DrugBank.d347.s3	104	111	warfarin	drug	DDI-DrugBank.d347.s3.e2
DDI-DrugBank.d347.s3	false	DDI-DrugBank.d347.s3.e0	DDI-DrugBank.d347.s3.e1
DDI-DrugBank.d347.s3	false	DDI-DrugBank.d347.s3.e0	DDI-DrugBank.d347.s3.e2
DDI-DrugBank.d347.s3	false	DDI-DrugBank.d347.s3.e1	DDI-DrugBank.d347.s3.e2
DDI-DrugBank.d347.s4|a|However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.
DDI-DrugBank.d347.s4	22	31	quinolones	group	DDI-DrugBank.d347.s4.e0
DDI-DrugBank.d347.s4	92	99	warfarin	drug	DDI-DrugBank.d347.s4.e1
DDI-DrugBank.d347.s4	222	244	quinolone antimicrobial	group	DDI-DrugBank.d347.s4.e2
DDI-DrugBank.d347.s4	281	288	warfarin	drug	DDI-DrugBank.d347.s4.e3
DDI-DrugBank.d347.s4	true	DDI-DrugBank.d347.s4.e0	DDI-DrugBank.d347.s4.e1
DDI-DrugBank.d347.s4	false	DDI-DrugBank.d347.s4.e0	DDI-DrugBank.d347.s4.e2
DDI-DrugBank.d347.s4	false	DDI-DrugBank.d347.s4.e0	DDI-DrugBank.d347.s4.e3
DDI-DrugBank.d347.s4	false	DDI-DrugBank.d347.s4.e1	DDI-DrugBank.d347.s4.e2
DDI-DrugBank.d347.s4	false	DDI-DrugBank.d347.s4.e1	DDI-DrugBank.d347.s4.e3
DDI-DrugBank.d347.s4	true	DDI-DrugBank.d347.s4.e2	DDI-DrugBank.d347.s4.e3
DDI-DrugBank.d347.s5|a|Quinolones form chelates with alkaline earth and transition metals.
DDI-DrugBank.d347.s5	0	9	Quinolones	group	DDI-DrugBank.d347.s5.e0
DDI-DrugBank.d347.s6|a|The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.
DDI-DrugBank.d347.s6	23	34	gemifloxacin	drug	DDI-DrugBank.d347.s6.e0
DDI-DrugBank.d347.s6	101	107	antacid	group	DDI-DrugBank.d347.s6.e1
DDI-DrugBank.d347.s6	120	127	aluminum	drug	DDI-DrugBank.d347.s6.e2
DDI-DrugBank.d347.s6	133	141	magnesium	drug	DDI-DrugBank.d347.s6.e3
DDI-DrugBank.d347.s6	false	DDI-DrugBank.d347.s6.e0	DDI-DrugBank.d347.s6.e1
DDI-DrugBank.d347.s6	true	DDI-DrugBank.d347.s6.e0	DDI-DrugBank.d347.s6.e2
DDI-DrugBank.d347.s6	true	DDI-DrugBank.d347.s6.e0	DDI-DrugBank.d347.s6.e3
DDI-DrugBank.d347.s6	false	DDI-DrugBank.d347.s6.e1	DDI-DrugBank.d347.s6.e2
DDI-DrugBank.d347.s6	false	DDI-DrugBank.d347.s6.e1	DDI-DrugBank.d347.s6.e3
DDI-DrugBank.d347.s6	false	DDI-DrugBank.d347.s6.e2	DDI-DrugBank.d347.s6.e3
DDI-DrugBank.d347.s7|a|Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DDI-DrugBank.d347.s7	0	8	Magnesium	drug	DDI-DrugBank.d347.s7.e0
DDI-DrugBank.d347.s7	18	25	aluminum	drug	DDI-DrugBank.d347.s7.e1
DDI-DrugBank.d347.s7	38	45	antacids	group	DDI-DrugBank.d347.s7.e2
DDI-DrugBank.d347.s7	68	82	ferrous sulfate	drug	DDI-DrugBank.d347.s7.e3
DDI-DrugBank.d347.s7	85	88	iron	drug	DDI-DrugBank.d347.s7.e4
DDI-DrugBank.d347.s7	92	116	multivitamin preparations	group	DDI-DrugBank.d347.s7.e5
DDI-DrugBank.d347.s7	129	132	zinc	drug	DDI-DrugBank.d347.s7.e6
DDI-DrugBank.d347.s7	161	165	Videx	brand	DDI-DrugBank.d347.s7.e7
DDI-DrugBank.d347.s7	168	177	didanosine	drug	DDI-DrugBank.d347.s7.e8
DDI-DrugBank.d347.s7	307	313	FACTIVE	brand	DDI-DrugBank.d347.s7.e9
DDI-DrugBank.d347.s7	false	DDI-DrugBank.d347.s7.e0	DDI-DrugBank.d347.s7.e1
DDI-DrugBank.d347.s7	false	DDI-DrugBank.d347.s7.e0	DDI-DrugBank.d347.s7.e2
DDI-DrugBank.d347.s7	false	DDI-DrugBank.d347.s7.e0	DDI-DrugBank.d347.s7.e3
DDI-DrugBank.d347.s7	false	DDI-DrugBank.d347.s7.e0	DDI-DrugBank.d347.s7.e4
DDI-DrugBank.d347.s7	false	DDI-DrugBank.d347.s7.e0	DDI-DrugBank.d347.s7.e5
DDI-DrugBank.d347.s7	false	DDI-DrugBank.d347.s7.e0	DDI-DrugBank.d347.s7.e6
DDI-DrugBank.d347.s7	false	DDI-DrugBank.d347.s7.e0	DDI-DrugBank.d347.s7.e7
DDI-DrugBank.d347.s7	false	DDI-DrugBank.d347.s7.e0	DDI-DrugBank.d347.s7.e8
DDI-DrugBank.d347.s7	true	DDI-DrugBank.d347.s7.e0	DDI-DrugBank.d347.s7.e9
DDI-DrugBank.d347.s7	false	DDI-DrugBank.d347.s7.e1	DDI-DrugBank.d347.s7.e2
DDI-DrugBank.d347.s8|a|Sucralfate should not be taken within 2 hours of FACTIVE.
DDI-DrugBank.d347.s8	0	9	Sucralfate	drug	DDI-DrugBank.d347.s8.e0
DDI-DrugBank.d347.s8	49	55	FACTIVE	brand	DDI-DrugBank.d347.s8.e1
DDI-DrugBank.d347.s8	true	DDI-DrugBank.d347.s8.e0	DDI-DrugBank.d347.s8.e1
DDI-DrugBank.d403.s0|a|There have been no formal drug-interaction studies performed with Mylotarg.
DDI-DrugBank.d403.s0	66	73	Mylotarg	brand	DDI-DrugBank.d403.s0.e0
DDI-DrugBank.d403.s1|a|The potential for drug-drug interaction with drugs affected by cytochrome P450 enzymes may not be ruled out.
DDI-DrugBank.d403.s2|a|Laboratory Test Interactions
DDI-DrugBank.d403.s3|a|Mylotarg is not known to interfere with any routine diagnostic tests.
DDI-DrugBank.d403.s3	0	7	Mylotarg	brand	DDI-DrugBank.d403.s3.e0
DDI-DrugBank.d28.s0|a|Interactions between COPAXONE  and other drugs have not been fully evaluated.
DDI-DrugBank.d28.s0	21	28	COPAXONE	brand	DDI-DrugBank.d28.s0.e0
DDI-DrugBank.d28.s1|a|Results from existing clinical trials suggest no significant interactions between COPAXONE  and other therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days.
DDI-DrugBank.d28.s1	82	89	COPAXONE	brand	DDI-DrugBank.d28.s1.e0
DDI-DrugBank.d28.s1	174	188	corticosteroids	group	DDI-DrugBank.d28.s1.e1
DDI-DrugBank.d28.s1	false	DDI-DrugBank.d28.s1.e0	DDI-DrugBank.d28.s1.e1
DDI-DrugBank.d28.s2|a|COPAXONE  has not been formally evaluated in combination with Interferon beta.
DDI-DrugBank.d28.s2	0	7	COPAXONE	brand	DDI-DrugBank.d28.s2.e0
DDI-DrugBank.d28.s2	62	76	Interferon beta	drug	DDI-DrugBank.d28.s2.e1
DDI-DrugBank.d28.s2	false	DDI-DrugBank.d28.s2.e0	DDI-DrugBank.d28.s2.e1
DDI-DrugBank.d28.s3|a|However, 10 patients who switched from therapy with Interferon beta to COPAXONE  did not report any serious and unexpected adverse reactions thought to be related to treatment.
DDI-DrugBank.d28.s3	52	66	Interferon beta	drug	DDI-DrugBank.d28.s3.e0
DDI-DrugBank.d28.s3	71	78	COPAXONE	brand	DDI-DrugBank.d28.s3.e1
DDI-DrugBank.d28.s3	false	DDI-DrugBank.d28.s3.e0	DDI-DrugBank.d28.s3.e1
DDI-DrugBank.d178.s0|a|The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d178.s0	27	39	sulfonylureas	group	DDI-DrugBank.d178.s0.e0
DDI-DrugBank.d178.s0	87	123	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d178.s0.e1
DDI-DrugBank.d178.s0	172	182	salicylates	group	DDI-DrugBank.d178.s0.e2
DDI-DrugBank.d178.s0	185	196	sulfonamides	group	DDI-DrugBank.d178.s0.e3
DDI-DrugBank.d178.s0	199	213	chloramphenicol	drug	DDI-DrugBank.d178.s0.e4
DDI-DrugBank.d178.s0	216	225	probenecid	drug	DDI-DrugBank.d178.s0.e5
DDI-DrugBank.d178.s0	228	236	coumarins	group	DDI-DrugBank.d178.s0.e6
DDI-DrugBank.d178.s0	239	266	monoamine oxidase inhibitors	group	DDI-DrugBank.d178.s0.e7
DDI-DrugBank.d178.s0	273	303	beta adrenergic blocking agents	group	DDI-DrugBank.d178.s0.e8
DDI-DrugBank.d178.s0	true	DDI-DrugBank.d178.s0.e0	DDI-DrugBank.d178.s0.e1
DDI-DrugBank.d178.s0	true	DDI-DrugBank.d178.s0.e0	DDI-DrugBank.d178.s0.e2
DDI-DrugBank.d178.s0	true	DDI-DrugBank.d178.s0.e0	DDI-DrugBank.d178.s0.e3
DDI-DrugBank.d178.s0	true	DDI-DrugBank.d178.s0.e0	DDI-DrugBank.d178.s0.e4
DDI-DrugBank.d178.s0	true	DDI-DrugBank.d178.s0.e0	DDI-DrugBank.d178.s0.e5
DDI-DrugBank.d178.s0	true	DDI-DrugBank.d178.s0.e0	DDI-DrugBank.d178.s0.e6
DDI-DrugBank.d178.s0	true	DDI-DrugBank.d178.s0.e0	DDI-DrugBank.d178.s0.e7
DDI-DrugBank.d178.s0	true	DDI-DrugBank.d178.s0.e0	DDI-DrugBank.d178.s0.e8
DDI-DrugBank.d178.s0	false	DDI-DrugBank.d178.s0.e1	DDI-DrugBank.d178.s0.e2
DDI-DrugBank.d178.s0	false	DDI-DrugBank.d178.s0.e1	DDI-DrugBank.d178.s0.e3
DDI-DrugBank.d178.s1|a|When such drugs are administered to a patient receiving MICRONASE, the patient should be observed closely for hypoglycemia.
DDI-DrugBank.d178.s1	56	64	MICRONASE	brand	DDI-DrugBank.d178.s1.e0
DDI-DrugBank.d178.s2|a|When such drugs are withdrawn from a patient receiving MICRONASE, the patient should be observed closely for loss of control.
DDI-DrugBank.d178.s2	55	63	MICRONASE	brand	DDI-DrugBank.d178.s2.e0
DDI-DrugBank.d178.s3|a|Certain drugs tend to produce hyperglycemia and may lead to loss of control.
DDI-DrugBank.d178.s4|a|These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
DDI-DrugBank.d178.s4	24	32	thiazides	group	DDI-DrugBank.d178.s4.e0
DDI-DrugBank.d178.s4	44	52	diuretics	group	DDI-DrugBank.d178.s4.e1
DDI-DrugBank.d178.s4	55	69	corticosteroids	group	DDI-DrugBank.d178.s4.e2
DDI-DrugBank.d178.s4	89	104	thyroid products	group	DDI-DrugBank.d178.s4.e3
DDI-DrugBank.d178.s4	107	115	estrogens	group	DDI-DrugBank.d178.s4.e4
DDI-DrugBank.d178.s4	123	136	contraceptives	group	DDI-DrugBank.d178.s4.e5
DDI-DrugBank.d178.s4	139	147	phenytoin	drug	DDI-DrugBank.d178.s4.e6
DDI-DrugBank.d178.s4	150	163	nicotinic acid	drug	DDI-DrugBank.d178.s4.e7
DDI-DrugBank.d178.s4	185	214	calcium channel blocking drugs	group	DDI-DrugBank.d178.s4.e8
DDI-DrugBank.d178.s4	221	229	isoniazid	drug	DDI-DrugBank.d178.s4.e9
DDI-DrugBank.d178.s4	false	DDI-DrugBank.d178.s4.e0	DDI-DrugBank.d178.s4.e1
DDI-DrugBank.d178.s4	false	DDI-DrugBank.d178.s4.e0	DDI-DrugBank.d178.s4.e2
DDI-DrugBank.d178.s4	false	DDI-DrugBank.d178.s4.e0	DDI-DrugBank.d178.s4.e3
DDI-DrugBank.d178.s4	false	DDI-DrugBank.d178.s4.e0	DDI-DrugBank.d178.s4.e4
DDI-DrugBank.d178.s4	false	DDI-DrugBank.d178.s4.e0	DDI-DrugBank.d178.s4.e5
DDI-DrugBank.d178.s4	false	DDI-DrugBank.d178.s4.e0	DDI-DrugBank.d178.s4.e6
DDI-DrugBank.d178.s4	false	DDI-DrugBank.d178.s4.e0	DDI-DrugBank.d178.s4.e7
DDI-DrugBank.d178.s4	false	DDI-DrugBank.d178.s4.e0	DDI-DrugBank.d178.s4.e8
DDI-DrugBank.d178.s4	false	DDI-DrugBank.d178.s4.e0	DDI-DrugBank.d178.s4.e9
DDI-DrugBank.d178.s4	false	DDI-DrugBank.d178.s4.e1	DDI-DrugBank.d178.s4.e2
DDI-DrugBank.d178.s5|a|When such drugs are administered to a patient receiving MICRONASE, the patient should be closely observed for loss of control.
DDI-DrugBank.d178.s5	56	64	MICRONASE	brand	DDI-DrugBank.d178.s5.e0
DDI-DrugBank.d178.s6|a|When such drugs are withdrawn from a patient receiving MICRONASE, the patient should be observed closely for hypoglycemia.
DDI-DrugBank.d178.s6	55	63	MICRONASE	brand	DDI-DrugBank.d178.s6.e0
DDI-DrugBank.d178.s7|a|A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
DDI-DrugBank.d178.s7	31	39	glyburide	drug	DDI-DrugBank.d178.s7.e0
DDI-DrugBank.d178.s7	45	57	ciprofloxacin	drug	DDI-DrugBank.d178.s7.e1
DDI-DrugBank.d178.s7	62	87	fluoroquinolone antibiotic	group	DDI-DrugBank.d178.s7.e2
DDI-DrugBank.d178.s7	167	175	glyburide	drug	DDI-DrugBank.d178.s7.e3
DDI-DrugBank.d178.s7	true	DDI-DrugBank.d178.s7.e0	DDI-DrugBank.d178.s7.e1
DDI-DrugBank.d178.s7	false	DDI-DrugBank.d178.s7.e0	DDI-DrugBank.d178.s7.e2
DDI-DrugBank.d178.s7	false	DDI-DrugBank.d178.s7.e0	DDI-DrugBank.d178.s7.e3
DDI-DrugBank.d178.s7	false	DDI-DrugBank.d178.s7.e1	DDI-DrugBank.d178.s7.e2
DDI-DrugBank.d178.s7	false	DDI-DrugBank.d178.s7.e1	DDI-DrugBank.d178.s7.e3
DDI-DrugBank.d178.s7	false	DDI-DrugBank.d178.s7.e2	DDI-DrugBank.d178.s7.e3
DDI-DrugBank.d178.s8|a|The mechanism for this interaction is not known.
DDI-DrugBank.d178.s9|a|A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
DDI-DrugBank.d178.s9	37	46	miconazole	drug	DDI-DrugBank.d178.s9.e0
DDI-DrugBank.d178.s9	57	75	hypoglycemic agents	group	DDI-DrugBank.d178.s9.e1
DDI-DrugBank.d178.s9	true	DDI-DrugBank.d178.s9.e0	DDI-DrugBank.d178.s9.e1
DDI-DrugBank.d178.s10|a|Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known.
DDI-DrugBank.d178.s10	94	103	miconazole	drug	DDI-DrugBank.d178.s10.e0
DDI-DrugBank.d178.s11|a|Metformin: In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable.
DDI-DrugBank.d178.s11	0	8	Metformin	drug	DDI-DrugBank.d178.s11.e0
DDI-DrugBank.d178.s11	78	86	glyburide	drug	DDI-DrugBank.d178.s11.e1
DDI-DrugBank.d178.s11	false	DDI-DrugBank.d178.s11.e0	DDI-DrugBank.d178.s11.e1
DDI-DrugBank.d178.s12|a|The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmaco-dynamic effects, makes the clinical significance of this interaction uncertain.
DDI-DrugBank.d178.s12	73	81	glyburide	drug	DDI-DrugBank.d178.s12.e0
DDI-DrugBank.d178.s13|a|Coadministration of gly-buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco-dynamics.
DDI-DrugBank.d178.s13	35	43	metformin	drug	DDI-DrugBank.d178.s13.e0
DDI-DrugBank.d178.s13	85	93	metformin	drug	DDI-DrugBank.d178.s13.e1
DDI-DrugBank.d178.s13	false	DDI-DrugBank.d178.s13.e0	DDI-DrugBank.d178.s13.e1
DDI-DrugBank.d521.s0|a|Many other medicines may increase or decrease the effects of glimepiride or affect your condition.
DDI-DrugBank.d521.s0	61	71	glimepiride	drug	DDI-DrugBank.d521.s0.e0
DDI-DrugBank.d521.s1|a|Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d521.s1	14	24	glimepiride	drug	DDI-DrugBank.d521.s1.e0
DDI-DrugBank.d521.s1	96	102	aspirin	brand	DDI-DrugBank.d521.s1.e1
DDI-DrugBank.d521.s1	115	124	salicylate	group	DDI-DrugBank.d521.s1.e2
DDI-DrugBank.d521.s1	134	161	magnesium/choline salicylate	drug	DDI-DrugBank.d521.s1.e3
DDI-DrugBank.d521.s1	164	172	Trilisate	brand	DDI-DrugBank.d521.s1.e4
DDI-DrugBank.d521.s1	176	184	salsalate	drug	DDI-DrugBank.d521.s1.e5
DDI-DrugBank.d521.s1	187	194	Disalcid	brand	DDI-DrugBank.d521.s1.e6
DDI-DrugBank.d521.s1	206	223	choline salicylate	drug	DDI-DrugBank.d521.s1.e7
DDI-DrugBank.d521.s1	226	234	Arthropan	drug	DDI-DrugBank.d521.s1.e8
DDI-DrugBank.d521.s1	238	257	magnesium salicylate	drug	DDI-DrugBank.d521.s1.e9
DDI-DrugBank.d521.s1	true	DDI-DrugBank.d521.s1.e0	DDI-DrugBank.d521.s1.e1
DDI-DrugBank.d521.s1	true	DDI-DrugBank.d521.s1.e0	DDI-DrugBank.d521.s1.e2
DDI-DrugBank.d521.s1	true	DDI-DrugBank.d521.s1.e0	DDI-DrugBank.d521.s1.e3
DDI-DrugBank.d521.s1	true	DDI-DrugBank.d521.s1.e0	DDI-DrugBank.d521.s1.e4
DDI-DrugBank.d521.s1	true	DDI-DrugBank.d521.s1.e0	DDI-DrugBank.d521.s1.e5
DDI-DrugBank.d521.s1	true	DDI-DrugBank.d521.s1.e0	DDI-DrugBank.d521.s1.e6
DDI-DrugBank.d521.s1	true	DDI-DrugBank.d521.s1.e0	DDI-DrugBank.d521.s1.e7
DDI-DrugBank.d521.s1	true	DDI-DrugBank.d521.s1.e0	DDI-DrugBank.d521.s1.e8
DDI-DrugBank.d521.s1	true	DDI-DrugBank.d521.s1.e0	DDI-DrugBank.d521.s1.e9
DDI-DrugBank.d521.s1	true	DDI-DrugBank.d521.s1.e0	DDI-DrugBank.d521.s1.e10
DDI-DrugBank.d521.s2|a|- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
DDI-DrugBank.d521.s2	4	38	nonsteroidal anti-inflammatory drug	group	DDI-DrugBank.d521.s2.e0
DDI-DrugBank.d521.s2	41	45	NSAID	group	DDI-DrugBank.d521.s2.e1
DDI-DrugBank.d521.s2	56	64	ibuprofen	drug	DDI-DrugBank.d521.s2.e2
DDI-DrugBank.d521.s2	67	72	Motrin	brand	DDI-DrugBank.d521.s2.e3
DDI-DrugBank.d521.s2	75	79	Advil	brand	DDI-DrugBank.d521.s2.e4
DDI-DrugBank.d521.s2	82	87	Nuprin	brand	DDI-DrugBank.d521.s2.e5
DDI-DrugBank.d521.s2	99	108	ketoprofen	drug	DDI-DrugBank.d521.s2.e6
DDI-DrugBank.d521.s2	111	116	Orudis	brand	DDI-DrugBank.d521.s2.e7
DDI-DrugBank.d521.s2	119	127	Orudis KT	brand	DDI-DrugBank.d521.s2.e8
DDI-DrugBank.d521.s2	130	136	Oruvail	brand	DDI-DrugBank.d521.s2.e9
DDI-DrugBank.d521.s2	false	DDI-DrugBank.d521.s2.e0	DDI-DrugBank.d521.s2.e1
DDI-DrugBank.d521.s2	false	DDI-DrugBank.d521.s2.e0	DDI-DrugBank.d521.s2.e2
DDI-DrugBank.d521.s2	false	DDI-DrugBank.d521.s2.e0	DDI-DrugBank.d521.s2.e3
DDI-DrugBank.d521.s2	false	DDI-DrugBank.d521.s2.e0	DDI-DrugBank.d521.s2.e4
DDI-DrugBank.d521.s2	false	DDI-DrugBank.d521.s2.e0	DDI-DrugBank.d521.s2.e5
DDI-DrugBank.d521.s2	false	DDI-DrugBank.d521.s2.e0	DDI-DrugBank.d521.s2.e6
DDI-DrugBank.d521.s2	false	DDI-DrugBank.d521.s2.e0	DDI-DrugBank.d521.s2.e7
DDI-DrugBank.d521.s2	false	DDI-DrugBank.d521.s2.e0	DDI-DrugBank.d521.s2.e8
DDI-DrugBank.d521.s2	false	DDI-DrugBank.d521.s2.e0	DDI-DrugBank.d521.s2.e9
DDI-DrugBank.d521.s2	false	DDI-DrugBank.d521.s2.e0	DDI-DrugBank.d521.s2.e10
DDI-DrugBank.d521.s3|a|- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
DDI-DrugBank.d521.s3	29	44	sulfamethoxazole	drug	DDI-DrugBank.d521.s3.e0
DDI-DrugBank.d521.s3	46	57	trimethoprim	drug	DDI-DrugBank.d521.s3.e1
DDI-DrugBank.d521.s3	60	66	Bactrim	brand	DDI-DrugBank.d521.s3.e2
DDI-DrugBank.d521.s3	69	74	Septra	brand	DDI-DrugBank.d521.s3.e3
DDI-DrugBank.d521.s3	78	90	sulfisoxazole	drug	DDI-DrugBank.d521.s3.e4
DDI-DrugBank.d521.s3	93	101	Gantrisin	brand	DDI-DrugBank.d521.s3.e5
DDI-DrugBank.d521.s3	108	120	sulfasalazine	drug	DDI-DrugBank.d521.s3.e6
DDI-DrugBank.d521.s3	123	132	Azulfidine	brand	DDI-DrugBank.d521.s3.e7
DDI-DrugBank.d521.s3	false	DDI-DrugBank.d521.s3.e0	DDI-DrugBank.d521.s3.e1
DDI-DrugBank.d521.s3	false	DDI-DrugBank.d521.s3.e0	DDI-DrugBank.d521.s3.e2
DDI-DrugBank.d521.s3	false	DDI-DrugBank.d521.s3.e0	DDI-DrugBank.d521.s3.e3
DDI-DrugBank.d521.s3	false	DDI-DrugBank.d521.s3.e0	DDI-DrugBank.d521.s3.e4
DDI-DrugBank.d521.s3	false	DDI-DrugBank.d521.s3.e0	DDI-DrugBank.d521.s3.e5
DDI-DrugBank.d521.s3	false	DDI-DrugBank.d521.s3.e0	DDI-DrugBank.d521.s3.e6
DDI-DrugBank.d521.s3	false	DDI-DrugBank.d521.s3.e0	DDI-DrugBank.d521.s3.e7
DDI-DrugBank.d521.s3	false	DDI-DrugBank.d521.s3.e1	DDI-DrugBank.d521.s3.e2
DDI-DrugBank.d521.s3	false	DDI-DrugBank.d521.s3.e1	DDI-DrugBank.d521.s3.e3
DDI-DrugBank.d521.s3	false	DDI-DrugBank.d521.s3.e1	DDI-DrugBank.d521.s3.e4
DDI-DrugBank.d521.s4|a|- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);
DDI-DrugBank.d521.s4	4	30	monoamine oxidase inhibitor	group	DDI-DrugBank.d521.s4.e0
DDI-DrugBank.d521.s4	33	36	MAOI	group	DDI-DrugBank.d521.s4.e1
DDI-DrugBank.d521.s4	47	59	isocarboxazid	drug	DDI-DrugBank.d521.s4.e2
DDI-DrugBank.d521.s4	62	68	Marplan	brand	DDI-DrugBank.d521.s4.e3
DDI-DrugBank.d521.s4	72	86	tranylcypromine	drug	DDI-DrugBank.d521.s4.e4
DDI-DrugBank.d521.s4	89	95	Parnate	brand	DDI-DrugBank.d521.s4.e5
DDI-DrugBank.d521.s4	102	111	phenelzine	drug	DDI-DrugBank.d521.s4.e6
DDI-DrugBank.d521.s4	114	119	Nardil	brand	DDI-DrugBank.d521.s4.e7
DDI-DrugBank.d521.s4	false	DDI-DrugBank.d521.s4.e0	DDI-DrugBank.d521.s4.e1
DDI-DrugBank.d521.s4	false	DDI-DrugBank.d521.s4.e0	DDI-DrugBank.d521.s4.e2
DDI-DrugBank.d521.s4	false	DDI-DrugBank.d521.s4.e0	DDI-DrugBank.d521.s4.e3
DDI-DrugBank.d521.s4	false	DDI-DrugBank.d521.s4.e0	DDI-DrugBank.d521.s4.e4
DDI-DrugBank.d521.s4	false	DDI-DrugBank.d521.s4.e0	DDI-DrugBank.d521.s4.e5
DDI-DrugBank.d521.s4	false	DDI-DrugBank.d521.s4.e0	DDI-DrugBank.d521.s4.e6
DDI-DrugBank.d521.s4	false	DDI-DrugBank.d521.s4.e0	DDI-DrugBank.d521.s4.e7
DDI-DrugBank.d521.s4	false	DDI-DrugBank.d521.s4.e1	DDI-DrugBank.d521.s4.e2
DDI-DrugBank.d521.s4	false	DDI-DrugBank.d521.s4.e1	DDI-DrugBank.d521.s4.e3
DDI-DrugBank.d521.s4	false	DDI-DrugBank.d521.s4.e1	DDI-DrugBank.d521.s4.e4
DDI-DrugBank.d521.s5|a|- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;
DDI-DrugBank.d521.s5	4	15	beta-blocker	group	DDI-DrugBank.d521.s5.e0
DDI-DrugBank.d521.s5	25	35	propranolol	drug	DDI-DrugBank.d521.s5.e1
DDI-DrugBank.d521.s5	38	44	Inderal	brand	DDI-DrugBank.d521.s5.e2
DDI-DrugBank.d521.s5	48	55	atenolol	drug	DDI-DrugBank.d521.s5.e3
DDI-DrugBank.d521.s5	58	65	Tenormin	brand	DDI-DrugBank.d521.s5.e4
DDI-DrugBank.d521.s5	69	78	acebutolol	drug	DDI-DrugBank.d521.s5.e5
DDI-DrugBank.d521.s5	81	87	Sectral	brand	DDI-DrugBank.d521.s5.e6
DDI-DrugBank.d521.s5	91	100	metoprolol	drug	DDI-DrugBank.d521.s5.e7
DDI-DrugBank.d521.s5	103	111	Lopressor	brand	DDI-DrugBank.d521.s5.e8
DDI-DrugBank.d521.s5	false	DDI-DrugBank.d521.s5.e0	DDI-DrugBank.d521.s5.e1
DDI-DrugBank.d521.s5	false	DDI-DrugBank.d521.s5.e0	DDI-DrugBank.d521.s5.e2
DDI-DrugBank.d521.s5	false	DDI-DrugBank.d521.s5.e0	DDI-DrugBank.d521.s5.e3
DDI-DrugBank.d521.s5	false	DDI-DrugBank.d521.s5.e0	DDI-DrugBank.d521.s5.e4
DDI-DrugBank.d521.s5	false	DDI-DrugBank.d521.s5.e0	DDI-DrugBank.d521.s5.e5
DDI-DrugBank.d521.s5	false	DDI-DrugBank.d521.s5.e0	DDI-DrugBank.d521.s5.e6
DDI-DrugBank.d521.s5	false	DDI-DrugBank.d521.s5.e0	DDI-DrugBank.d521.s5.e7
DDI-DrugBank.d521.s5	false	DDI-DrugBank.d521.s5.e0	DDI-DrugBank.d521.s5.e8
DDI-DrugBank.d521.s5	false	DDI-DrugBank.d521.s5.e1	DDI-DrugBank.d521.s5.e2
DDI-DrugBank.d521.s5	false	DDI-DrugBank.d521.s5.e1	DDI-DrugBank.d521.s5.e3
DDI-DrugBank.d521.s6|a|- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;
DDI-DrugBank.d521.s6	4	11	diuretic	group	DDI-DrugBank.d521.s6.e0
DDI-DrugBank.d521.s6	34	52	hydrochlorothiazide	drug	DDI-DrugBank.d521.s6.e1
DDI-DrugBank.d521.s6	55	58	HCTZ	drug	DDI-DrugBank.d521.s6.e2
DDI-DrugBank.d521.s6	61	71	Hydrodiuril	brand	DDI-DrugBank.d521.s6.e3
DDI-DrugBank.d521.s6	75	88	chlorothiazide	drug	DDI-DrugBank.d521.s6.e4
DDI-DrugBank.d521.s6	91	96	Diuril	brand	DDI-DrugBank.d521.s6.e5
DDI-DrugBank.d521.s6	false	DDI-DrugBank.d521.s6.e0	DDI-DrugBank.d521.s6.e1
DDI-DrugBank.d521.s6	false	DDI-DrugBank.d521.s6.e0	DDI-DrugBank.d521.s6.e2
DDI-DrugBank.d521.s6	false	DDI-DrugBank.d521.s6.e0	DDI-DrugBank.d521.s6.e3
DDI-DrugBank.d521.s6	false	DDI-DrugBank.d521.s6.e0	DDI-DrugBank.d521.s6.e4
DDI-DrugBank.d521.s6	false	DDI-DrugBank.d521.s6.e0	DDI-DrugBank.d521.s6.e5
DDI-DrugBank.d521.s6	false	DDI-DrugBank.d521.s6.e1	DDI-DrugBank.d521.s6.e2
DDI-DrugBank.d521.s6	false	DDI-DrugBank.d521.s6.e1	DDI-DrugBank.d521.s6.e3
DDI-DrugBank.d521.s6	false	DDI-DrugBank.d521.s6.e1	DDI-DrugBank.d521.s6.e4
DDI-DrugBank.d521.s6	false	DDI-DrugBank.d521.s6.e1	DDI-DrugBank.d521.s6.e5
DDI-DrugBank.d521.s6	false	DDI-DrugBank.d521.s6.e2	DDI-DrugBank.d521.s6.e3
DDI-DrugBank.d521.s7|a|- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
DDI-DrugBank.d521.s7	4	19	steroid medicine	group	DDI-DrugBank.d521.s7.e0
DDI-DrugBank.d521.s7	29	38	prednisone	drug	DDI-DrugBank.d521.s7.e1
DDI-DrugBank.d521.s7	41	49	Deltasone	brand	DDI-DrugBank.d521.s7.e2
DDI-DrugBank.d521.s7	52	58	Orasone	brand	DDI-DrugBank.d521.s7.e3
DDI-DrugBank.d521.s7	70	87	methylprednisolone	drug	DDI-DrugBank.d521.s7.e4
DDI-DrugBank.d521.s7	90	95	Medrol	brand	DDI-DrugBank.d521.s7.e5
DDI-DrugBank.d521.s7	107	118	prednisolone	drug	DDI-DrugBank.d521.s7.e6
DDI-DrugBank.d521.s7	121	127	Prelone	brand	DDI-DrugBank.d521.s7.e7
DDI-DrugBank.d521.s7	130	138	Pediapred	brand	DDI-DrugBank.d521.s7.e8
DDI-DrugBank.d521.s7	false	DDI-DrugBank.d521.s7.e0	DDI-DrugBank.d521.s7.e1
DDI-DrugBank.d521.s7	false	DDI-DrugBank.d521.s7.e0	DDI-DrugBank.d521.s7.e2
DDI-DrugBank.d521.s7	false	DDI-DrugBank.d521.s7.e0	DDI-DrugBank.d521.s7.e3
DDI-DrugBank.d521.s7	false	DDI-DrugBank.d521.s7.e0	DDI-DrugBank.d521.s7.e4
DDI-DrugBank.d521.s7	false	DDI-DrugBank.d521.s7.e0	DDI-DrugBank.d521.s7.e5
DDI-DrugBank.d521.s7	false	DDI-DrugBank.d521.s7.e0	DDI-DrugBank.d521.s7.e6
DDI-DrugBank.d521.s7	false	DDI-DrugBank.d521.s7.e0	DDI-DrugBank.d521.s7.e7
DDI-DrugBank.d521.s7	false	DDI-DrugBank.d521.s7.e0	DDI-DrugBank.d521.s7.e8
DDI-DrugBank.d521.s7	false	DDI-DrugBank.d521.s7.e1	DDI-DrugBank.d521.s7.e2
DDI-DrugBank.d521.s7	false	DDI-DrugBank.d521.s7.e1	DDI-DrugBank.d521.s7.e3
DDI-DrugBank.d521.s8|a|- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;
DDI-DrugBank.d521.s8	4	16	phenothiazine	group	DDI-DrugBank.d521.s8.e0
DDI-DrugBank.d521.s8	26	39	chlorpromazine	drug	DDI-DrugBank.d521.s8.e1
DDI-DrugBank.d521.s8	42	50	Thorazine	brand	DDI-DrugBank.d521.s8.e2
DDI-DrugBank.d521.s8	54	65	fluphenazine	drug	DDI-DrugBank.d521.s8.e3
DDI-DrugBank.d521.s8	68	75	Prolixin	brand	DDI-DrugBank.d521.s8.e4
DDI-DrugBank.d521.s8	78	85	Permitil	brand	DDI-DrugBank.d521.s8.e5
DDI-DrugBank.d521.s8	89	104	prochlorperazine	drug	DDI-DrugBank.d521.s8.e6
DDI-DrugBank.d521.s8	107	115	Compazine	brand	DDI-DrugBank.d521.s8.e7
DDI-DrugBank.d521.s8	119	130	promethazine	drug	DDI-DrugBank.d521.s8.e8
DDI-DrugBank.d521.s8	133	141	Phenergan	brand	DDI-DrugBank.d521.s8.e9
DDI-DrugBank.d521.s8	false	DDI-DrugBank.d521.s8.e0	DDI-DrugBank.d521.s8.e1
DDI-DrugBank.d521.s8	false	DDI-DrugBank.d521.s8.e0	DDI-DrugBank.d521.s8.e2
DDI-DrugBank.d521.s8	false	DDI-DrugBank.d521.s8.e0	DDI-DrugBank.d521.s8.e3
DDI-DrugBank.d521.s8	false	DDI-DrugBank.d521.s8.e0	DDI-DrugBank.d521.s8.e4
DDI-DrugBank.d521.s8	false	DDI-DrugBank.d521.s8.e0	DDI-DrugBank.d521.s8.e5
DDI-DrugBank.d521.s8	false	DDI-DrugBank.d521.s8.e0	DDI-DrugBank.d521.s8.e6
DDI-DrugBank.d521.s8	false	DDI-DrugBank.d521.s8.e0	DDI-DrugBank.d521.s8.e7
DDI-DrugBank.d521.s8	false	DDI-DrugBank.d521.s8.e0	DDI-DrugBank.d521.s8.e8
DDI-DrugBank.d521.s8	false	DDI-DrugBank.d521.s8.e0	DDI-DrugBank.d521.s8.e9
DDI-DrugBank.d521.s8	false	DDI-DrugBank.d521.s8.e1	DDI-DrugBank.d521.s8.e2
DDI-DrugBank.d521.s9|a|- phenytoin (Dilantin);
DDI-DrugBank.d521.s9	2	10	phenytoin	drug	DDI-DrugBank.d521.s9.e0
DDI-DrugBank.d521.s9	13	20	Dilantin	brand	DDI-DrugBank.d521.s9.e1
DDI-DrugBank.d521.s9	false	DDI-DrugBank.d521.s9.e0	DDI-DrugBank.d521.s9.e1
DDI-DrugBank.d521.s10|a|- isoniazid (Nydrazid);
DDI-DrugBank.d521.s10	2	10	isoniazid	drug	DDI-DrugBank.d521.s10.e0
DDI-DrugBank.d521.s10	13	20	Nydrazid	brand	DDI-DrugBank.d521.s10.e1
DDI-DrugBank.d521.s10	false	DDI-DrugBank.d521.s10.e0	DDI-DrugBank.d521.s10.e1
DDI-DrugBank.d521.s11|a|- rifampin (Rifadin, Rifamate);
DDI-DrugBank.d521.s11	2	9	rifampin	drug	DDI-DrugBank.d521.s11.e0
DDI-DrugBank.d521.s11	12	18	Rifadin	brand	DDI-DrugBank.d521.s11.e1
DDI-DrugBank.d521.s11	21	28	Rifamate	brand	DDI-DrugBank.d521.s11.e2
DDI-DrugBank.d521.s11	false	DDI-DrugBank.d521.s11.e0	DDI-DrugBank.d521.s11.e1
DDI-DrugBank.d521.s11	false	DDI-DrugBank.d521.s11.e0	DDI-DrugBank.d521.s11.e2
DDI-DrugBank.d521.s11	false	DDI-DrugBank.d521.s11.e1	DDI-DrugBank.d521.s11.e2
DDI-DrugBank.d521.s12|a|or - over-the-counter cough, cold, allergy, or weight loss medications.
DDI-DrugBank.d521.s13|a|You may require a dosage adjustment or special monitoring if you are taking any of the medicines listed above.
DDI-DrugBank.d521.s14|a|Drugs other than those listed here may also interact with glimepiride or affect your condition.
DDI-DrugBank.d521.s14	58	68	glimepiride	drug	DDI-DrugBank.d521.s14.e0
DDI-DrugBank.d521.s15|a|Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products.
DDI-DrugBank.d225.s0|a|Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d225.s0	66	78	sulfonylureas	group	DDI-DrugBank.d225.s0.e0
DDI-DrugBank.d225.s0	126	162	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d225.s0.e1
DDI-DrugBank.d225.s0	170	175	azoles	group	DDI-DrugBank.d225.s0.e2
DDI-DrugBank.d225.s0	224	234	salicylates	group	DDI-DrugBank.d225.s0.e3
DDI-DrugBank.d225.s0	237	248	sulfonamides	group	DDI-DrugBank.d225.s0.e4
DDI-DrugBank.d225.s0	251	265	chloramphenicol	drug	DDI-DrugBank.d225.s0.e5
DDI-DrugBank.d225.s0	268	277	probenecid	drug	DDI-DrugBank.d225.s0.e6
DDI-DrugBank.d225.s0	280	288	coumarins	group	DDI-DrugBank.d225.s0.e7
DDI-DrugBank.d225.s0	291	318	monoamine oxidase inhibitors	group	DDI-DrugBank.d225.s0.e8
DDI-DrugBank.d225.s0	325	355	beta adrenergic blocking agents	group	DDI-DrugBank.d225.s0.e9
DDI-DrugBank.d225.s0	true	DDI-DrugBank.d225.s0.e0	DDI-DrugBank.d225.s0.e1
DDI-DrugBank.d225.s0	true	DDI-DrugBank.d225.s0.e0	DDI-DrugBank.d225.s0.e2
DDI-DrugBank.d225.s0	true	DDI-DrugBank.d225.s0.e0	DDI-DrugBank.d225.s0.e3
DDI-DrugBank.d225.s0	true	DDI-DrugBank.d225.s0.e0	DDI-DrugBank.d225.s0.e4
DDI-DrugBank.d225.s0	true	DDI-DrugBank.d225.s0.e0	DDI-DrugBank.d225.s0.e5
DDI-DrugBank.d225.s0	true	DDI-DrugBank.d225.s0.e0	DDI-DrugBank.d225.s0.e6
DDI-DrugBank.d225.s0	true	DDI-DrugBank.d225.s0.e0	DDI-DrugBank.d225.s0.e7
DDI-DrugBank.d225.s0	true	DDI-DrugBank.d225.s0.e0	DDI-DrugBank.d225.s0.e8
DDI-DrugBank.d225.s0	true	DDI-DrugBank.d225.s0.e0	DDI-DrugBank.d225.s0.e9
DDI-DrugBank.d225.s0	false	DDI-DrugBank.d225.s0.e1	DDI-DrugBank.d225.s0.e2
DDI-DrugBank.d225.s1|a|When such drugs are administered to a patient receiving glipizide, the patient should be observed closely for hypoglycemia.
DDI-DrugBank.d225.s1	56	64	glipizide	drug	DDI-DrugBank.d225.s1.e0
DDI-DrugBank.d225.s2|a|When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for loss of control.
DDI-DrugBank.d225.s2	55	63	glipizide	drug	DDI-DrugBank.d225.s2.e0
DDI-DrugBank.d225.s3|a|In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol.
DDI-DrugBank.d225.s3	65	73	glipizide	drug	DDI-DrugBank.d225.s3.e0
DDI-DrugBank.d225.s3	98	108	tolbutamide	drug	DDI-DrugBank.d225.s3.e1
DDI-DrugBank.d225.s3	137	146	salicylate	group	DDI-DrugBank.d225.s3.e2
DDI-DrugBank.d225.s3	151	159	dicumarol	drug	DDI-DrugBank.d225.s3.e3
DDI-DrugBank.d225.s3	false	DDI-DrugBank.d225.s3.e0	DDI-DrugBank.d225.s3.e1
DDI-DrugBank.d225.s3	false	DDI-DrugBank.d225.s3.e0	DDI-DrugBank.d225.s3.e2
DDI-DrugBank.d225.s3	false	DDI-DrugBank.d225.s3.e0	DDI-DrugBank.d225.s3.e3
DDI-DrugBank.d225.s3	false	DDI-DrugBank.d225.s3.e1	DDI-DrugBank.d225.s3.e2
DDI-DrugBank.d225.s3	false	DDI-DrugBank.d225.s3.e1	DDI-DrugBank.d225.s3.e3
DDI-DrugBank.d225.s3	false	DDI-DrugBank.d225.s3.e2	DDI-DrugBank.d225.s3.e3
DDI-DrugBank.d225.s4|a|However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs.
DDI-DrugBank.d225.s4	111	119	glipizide	drug	DDI-DrugBank.d225.s4.e0
DDI-DrugBank.d225.s5|a|Certain drugs tend to produce hyperglycemia and may lead to loss of control.
DDI-DrugBank.d225.s6|a|These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
DDI-DrugBank.d225.s6	24	32	thiazides	group	DDI-DrugBank.d225.s6.e0
DDI-DrugBank.d225.s6	44	52	diuretics	group	DDI-DrugBank.d225.s6.e1
DDI-DrugBank.d225.s6	55	69	corticosteroids	group	DDI-DrugBank.d225.s6.e2
DDI-DrugBank.d225.s6	72	85	phenothiazines	group	DDI-DrugBank.d225.s6.e3
DDI-DrugBank.d225.s6	88	103	thyroid products	group	DDI-DrugBank.d225.s6.e4
DDI-DrugBank.d225.s6	106	114	estrogens	group	DDI-DrugBank.d225.s6.e5
DDI-DrugBank.d225.s6	122	135	contraceptives	group	DDI-DrugBank.d225.s6.e6
DDI-DrugBank.d225.s6	138	146	phenytoin	drug	DDI-DrugBank.d225.s6.e7
DDI-DrugBank.d225.s6	149	162	nicotinic acid	drug	DDI-DrugBank.d225.s6.e8
DDI-DrugBank.d225.s6	165	180	sympathomimetics	group	DDI-DrugBank.d225.s6.e9
DDI-DrugBank.d225.s6	false	DDI-DrugBank.d225.s6.e0	DDI-DrugBank.d225.s6.e1
DDI-DrugBank.d225.s6	false	DDI-DrugBank.d225.s6.e0	DDI-DrugBank.d225.s6.e2
DDI-DrugBank.d225.s6	false	DDI-DrugBank.d225.s6.e0	DDI-DrugBank.d225.s6.e3
DDI-DrugBank.d225.s6	false	DDI-DrugBank.d225.s6.e0	DDI-DrugBank.d225.s6.e4
DDI-DrugBank.d225.s6	false	DDI-DrugBank.d225.s6.e0	DDI-DrugBank.d225.s6.e5
DDI-DrugBank.d225.s6	false	DDI-DrugBank.d225.s6.e0	DDI-DrugBank.d225.s6.e6
DDI-DrugBank.d225.s6	false	DDI-DrugBank.d225.s6.e0	DDI-DrugBank.d225.s6.e7
DDI-DrugBank.d225.s6	false	DDI-DrugBank.d225.s6.e0	DDI-DrugBank.d225.s6.e8
DDI-DrugBank.d225.s6	false	DDI-DrugBank.d225.s6.e0	DDI-DrugBank.d225.s6.e9
DDI-DrugBank.d225.s6	false	DDI-DrugBank.d225.s6.e0	DDI-DrugBank.d225.s6.e10
DDI-DrugBank.d225.s7|a|When such drugs are administered to a patient receiving glipizide, the patient should be closely observed for loss of control.
DDI-DrugBank.d225.s7	56	64	glipizide	drug	DDI-DrugBank.d225.s7.e0
DDI-DrugBank.d225.s8|a|When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for hypoglycemia.
DDI-DrugBank.d225.s8	55	63	glipizide	drug	DDI-DrugBank.d225.s8.e0
DDI-DrugBank.d225.s9|a|A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
DDI-DrugBank.d225.s9	37	46	miconazole	drug	DDI-DrugBank.d225.s9.e0
DDI-DrugBank.d225.s9	57	75	hypoglycemic agents	group	DDI-DrugBank.d225.s9.e1
DDI-DrugBank.d225.s9	true	DDI-DrugBank.d225.s9.e0	DDI-DrugBank.d225.s9.e1
DDI-DrugBank.d225.s10|a|Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.
DDI-DrugBank.d225.s10	95	104	miconazole	drug	DDI-DrugBank.d225.s10.e0
DDI-DrugBank.d225.s11|a|The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.
DDI-DrugBank.d225.s11	44	54	fluconazole	drug	DDI-DrugBank.d225.s11.e0
DDI-DrugBank.d225.s11	60	68	glipizide	drug	DDI-DrugBank.d225.s11.e1
DDI-DrugBank.d225.s11	true	DDI-DrugBank.d225.s11.e0	DDI-DrugBank.d225.s11.e1
DDI-DrugBank.d225.s12|a|All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for seven days.
DDI-DrugBank.d225.s12	22	30	glipizide	drug	DDI-DrugBank.d225.s12.e0
DDI-DrugBank.d225.s12	77	87	fluconazole	drug	DDI-DrugBank.d225.s12.e1
DDI-DrugBank.d225.s12	false	DDI-DrugBank.d225.s12.e0	DDI-DrugBank.d225.s12.e1
DDI-DrugBank.d225.s13|a|The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).
DDI-DrugBank.d225.s13	36	44	glipizide	drug	DDI-DrugBank.d225.s13.e0
DDI-DrugBank.d225.s13	56	66	fluconazole	drug	DDI-DrugBank.d225.s13.e1
DDI-DrugBank.d225.s13	true	DDI-DrugBank.d225.s13.e0	DDI-DrugBank.d225.s13.e1
DDI-DrugBank.d510.s0|a|The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
DDI-DrugBank.d510.s0	22	28	Robinul	brand	DDI-DrugBank.d510.s0.e0
DDI-DrugBank.d510.s0	51	66	anticholinergics	group	DDI-DrugBank.d510.s0.e1
DDI-DrugBank.d510.s0	122	135	phenothiazines	group	DDI-DrugBank.d510.s0.e2
DDI-DrugBank.d510.s0	138	156	antiparkinson drugs	group	DDI-DrugBank.d510.s0.e3
DDI-DrugBank.d510.s0	162	186	tricyclic antidepressants	group	DDI-DrugBank.d510.s0.e4
DDI-DrugBank.d510.s0	true	DDI-DrugBank.d510.s0.e0	DDI-DrugBank.d510.s0.e1
DDI-DrugBank.d510.s0	true	DDI-DrugBank.d510.s0.e0	DDI-DrugBank.d510.s0.e2
DDI-DrugBank.d510.s0	true	DDI-DrugBank.d510.s0.e0	DDI-DrugBank.d510.s0.e3
DDI-DrugBank.d510.s0	true	DDI-DrugBank.d510.s0.e0	DDI-DrugBank.d510.s0.e4
DDI-DrugBank.d510.s0	false	DDI-DrugBank.d510.s0.e1	DDI-DrugBank.d510.s0.e2
DDI-DrugBank.d510.s0	false	DDI-DrugBank.d510.s0.e1	DDI-DrugBank.d510.s0.e3
DDI-DrugBank.d510.s0	false	DDI-DrugBank.d510.s0.e1	DDI-DrugBank.d510.s0.e4
DDI-DrugBank.d510.s0	false	DDI-DrugBank.d510.s0.e2	DDI-DrugBank.d510.s0.e3
DDI-DrugBank.d510.s0	false	DDI-DrugBank.d510.s0.e2	DDI-DrugBank.d510.s0.e4
DDI-DrugBank.d510.s0	false	DDI-DrugBank.d510.s0.e3	DDI-DrugBank.d510.s0.e4
DDI-DrugBank.d510.s1|a|Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.
DDI-DrugBank.d510.s1	30	36	Robinul	brand	DDI-DrugBank.d510.s1.e0
DDI-DrugBank.d510.s1	52	69	potassium chloride	drug	DDI-DrugBank.d510.s1.e1
DDI-DrugBank.d510.s1	true	DDI-DrugBank.d510.s1.e0	DDI-DrugBank.d510.s1.e1
DDI-DrugBank.d369.s0|a|The Factrel test should be conducted in the absence of other drugs which directly affect the pituitary secretion of the gonadotropins.
DDI-DrugBank.d369.s0	4	10	Factrel	brand	DDI-DrugBank.d369.s0.e0
DDI-DrugBank.d369.s1|a|These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.
DDI-DrugBank.d369.s1	60	68	androgens	group	DDI-DrugBank.d369.s1.e0
DDI-DrugBank.d369.s1	71	79	estrogens	group	DDI-DrugBank.d369.s1.e1
DDI-DrugBank.d369.s1	82	91	progestins	group	DDI-DrugBank.d369.s1.e2
DDI-DrugBank.d369.s1	97	111	glucocorticoids	group	DDI-DrugBank.d369.s1.e3
DDI-DrugBank.d369.s1	false	DDI-DrugBank.d369.s1.e0	DDI-DrugBank.d369.s1.e1
DDI-DrugBank.d369.s1	false	DDI-DrugBank.d369.s1.e0	DDI-DrugBank.d369.s1.e2
DDI-DrugBank.d369.s1	false	DDI-DrugBank.d369.s1.e0	DDI-DrugBank.d369.s1.e3
DDI-DrugBank.d369.s1	false	DDI-DrugBank.d369.s1.e1	DDI-DrugBank.d369.s1.e2
DDI-DrugBank.d369.s1	false	DDI-DrugBank.d369.s1.e1	DDI-DrugBank.d369.s1.e3
DDI-DrugBank.d369.s1	false	DDI-DrugBank.d369.s1.e2	DDI-DrugBank.d369.s1.e3
DDI-DrugBank.d369.s2|a|The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.
DDI-DrugBank.d369.s2	55	68	spironolactone	drug	DDI-DrugBank.d369.s2.e0
DDI-DrugBank.d369.s2	93	100	levodopa	drug	DDI-DrugBank.d369.s2.e1
DDI-DrugBank.d369.s2	126	139	contraceptives	group	DDI-DrugBank.d369.s2.e2
DDI-DrugBank.d369.s2	145	151	digoxin	drug	DDI-DrugBank.d369.s2.e3
DDI-DrugBank.d369.s2	false	DDI-DrugBank.d369.s2.e0	DDI-DrugBank.d369.s2.e1
DDI-DrugBank.d369.s2	false	DDI-DrugBank.d369.s2.e0	DDI-DrugBank.d369.s2.e2
DDI-DrugBank.d369.s2	false	DDI-DrugBank.d369.s2.e0	DDI-DrugBank.d369.s2.e3
DDI-DrugBank.d369.s2	false	DDI-DrugBank.d369.s2.e1	DDI-DrugBank.d369.s2.e2
DDI-DrugBank.d369.s2	false	DDI-DrugBank.d369.s2.e1	DDI-DrugBank.d369.s2.e3
DDI-DrugBank.d369.s2	false	DDI-DrugBank.d369.s2.e2	DDI-DrugBank.d369.s2.e3
DDI-DrugBank.d369.s3|a|The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.
DDI-DrugBank.d369.s3	16	22	Factrel	brand	DDI-DrugBank.d369.s3.e0
DDI-DrugBank.d369.s3	42	55	phenothiazines	group	DDI-DrugBank.d369.s3.e1
DDI-DrugBank.d369.s3	61	80	dopamine antagonists	group	DDI-DrugBank.d369.s3.e2
DDI-DrugBank.d369.s3	true	DDI-DrugBank.d369.s3.e0	DDI-DrugBank.d369.s3.e1
DDI-DrugBank.d369.s3	true	DDI-DrugBank.d369.s3.e0	DDI-DrugBank.d369.s3.e2
DDI-DrugBank.d369.s3	false	DDI-DrugBank.d369.s3.e1	DDI-DrugBank.d369.s3.e2
DDI-DrugBank.d50.s0|a|No formal drug-drug interaction studies have been performed.
DDI-DrugBank.d50.s1|a|No confirmed interactions have been reported between ZOLADEX and other drugs
DDI-DrugBank.d50.s1	53	59	ZOLADEX	brand	DDI-DrugBank.d50.s1.e0
DDI-DrugBank.d78.s0|a|Antacids, Sucralfate, Metal Cations, Multivitamins Quinolones form chelates with alkaline earth and transition metal cations.
DDI-DrugBank.d78.s0	0	7	Antacids	group	DDI-DrugBank.d78.s0.e0
DDI-DrugBank.d78.s0	10	19	Sucralfate	drug	DDI-DrugBank.d78.s0.e1
DDI-DrugBank.d78.s0	37	49	Multivitamins	group	DDI-DrugBank.d78.s0.e2
DDI-DrugBank.d78.s0	51	60	Quinolones	group	DDI-DrugBank.d78.s0.e3
DDI-DrugBank.d78.s0	false	DDI-DrugBank.d78.s0.e0	DDI-DrugBank.d78.s0.e1
DDI-DrugBank.d78.s0	false	DDI-DrugBank.d78.s0.e0	DDI-DrugBank.d78.s0.e2
DDI-DrugBank.d78.s0	false	DDI-DrugBank.d78.s0.e0	DDI-DrugBank.d78.s0.e3
DDI-DrugBank.d78.s0	false	DDI-DrugBank.d78.s0.e1	DDI-DrugBank.d78.s0.e2
DDI-DrugBank.d78.s0	false	DDI-DrugBank.d78.s0.e1	DDI-DrugBank.d78.s0.e3
DDI-DrugBank.d78.s0	false	DDI-DrugBank.d78.s0.e2	DDI-DrugBank.d78.s0.e3
DDI-DrugBank.d78.s1|a|Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d78.s1	18	27	quinolones	group	DDI-DrugBank.d78.s1.e0
DDI-DrugBank.d78.s1	34	41	antacids	group	DDI-DrugBank.d78.s1.e1
DDI-DrugBank.d78.s1	54	61	aluminum	drug	DDI-DrugBank.d78.s1.e2
DDI-DrugBank.d78.s1	64	72	magnesium	drug	DDI-DrugBank.d78.s1.e3
DDI-DrugBank.d78.s1	78	84	calcium	drug	DDI-DrugBank.d78.s1.e4
DDI-DrugBank.d78.s1	92	101	sucralfate	drug	DDI-DrugBank.d78.s1.e5
DDI-DrugBank.d78.s1	131	134	iron	drug	DDI-DrugBank.d78.s1.e6
DDI-DrugBank.d78.s1	145	157	multivitamins	group	DDI-DrugBank.d78.s1.e7
DDI-DrugBank.d78.s1	170	173	iron	drug	DDI-DrugBank.d78.s1.e8
DDI-DrugBank.d78.s1	178	181	zinc	drug	DDI-DrugBank.d78.s1.e9
DDI-DrugBank.d78.s1	false	DDI-DrugBank.d78.s1.e0	DDI-DrugBank.d78.s1.e1
DDI-DrugBank.d78.s1	true	DDI-DrugBank.d78.s1.e0	DDI-DrugBank.d78.s1.e2
DDI-DrugBank.d78.s1	true	DDI-DrugBank.d78.s1.e0	DDI-DrugBank.d78.s1.e3
DDI-DrugBank.d78.s1	true	DDI-DrugBank.d78.s1.e0	DDI-DrugBank.d78.s1.e4
DDI-DrugBank.d78.s1	true	DDI-DrugBank.d78.s1.e0	DDI-DrugBank.d78.s1.e5
DDI-DrugBank.d78.s1	true	DDI-DrugBank.d78.s1.e0	DDI-DrugBank.d78.s1.e6
DDI-DrugBank.d78.s1	true	DDI-DrugBank.d78.s1.e0	DDI-DrugBank.d78.s1.e7
DDI-DrugBank.d78.s1	true	DDI-DrugBank.d78.s1.e0	DDI-DrugBank.d78.s1.e8
DDI-DrugBank.d78.s1	true	DDI-DrugBank.d78.s1.e0	DDI-DrugBank.d78.s1.e9
DDI-DrugBank.d78.s1	true	DDI-DrugBank.d78.s1.e0	DDI-DrugBank.d78.s1.e10
DDI-DrugBank.d78.s2|a|These agents should not be taken within 4 hours before or 4 hours after grepafloxacin administration.
DDI-DrugBank.d78.s2	72	84	grepafloxacin	drug	DDI-DrugBank.d78.s2.e0
DDI-DrugBank.d78.s3|a|Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
DDI-DrugBank.d78.s3	0	7	Caffeine	drug	DDI-DrugBank.d78.s3.e0
DDI-DrugBank.d78.s3	9	19	Theobromine	drug	DDI-DrugBank.d78.s3.e1
DDI-DrugBank.d78.s3	21	33	Grepafloxacin	drug	DDI-DrugBank.d78.s3.e2
DDI-DrugBank.d78.s3	47	56	quinolones	group	DDI-DrugBank.d78.s3.e3
DDI-DrugBank.d78.s3	89	96	caffeine	drug	DDI-DrugBank.d78.s3.e4
DDI-DrugBank.d78.s3	102	112	theobromine	drug	DDI-DrugBank.d78.s3.e5
DDI-DrugBank.d78.s3	false	DDI-DrugBank.d78.s3.e0	DDI-DrugBank.d78.s3.e1
DDI-DrugBank.d78.s3	false	DDI-DrugBank.d78.s3.e0	DDI-DrugBank.d78.s3.e2
DDI-DrugBank.d78.s3	false	DDI-DrugBank.d78.s3.e0	DDI-DrugBank.d78.s3.e3
DDI-DrugBank.d78.s3	false	DDI-DrugBank.d78.s3.e0	DDI-DrugBank.d78.s3.e4
DDI-DrugBank.d78.s3	false	DDI-DrugBank.d78.s3.e0	DDI-DrugBank.d78.s3.e5
DDI-DrugBank.d78.s3	false	DDI-DrugBank.d78.s3.e1	DDI-DrugBank.d78.s3.e2
DDI-DrugBank.d78.s3	false	DDI-DrugBank.d78.s3.e1	DDI-DrugBank.d78.s3.e3
DDI-DrugBank.d78.s3	false	DDI-DrugBank.d78.s3.e1	DDI-DrugBank.d78.s3.e4
DDI-DrugBank.d78.s3	false	DDI-DrugBank.d78.s3.e1	DDI-DrugBank.d78.s3.e5
DDI-DrugBank.d78.s3	false	DDI-DrugBank.d78.s3.e2	DDI-DrugBank.d78.s3.e3
DDI-DrugBank.d78.s4|a|These stimulants are commonly found in coffee and tea, respectively.
DDI-DrugBank.d78.s5|a|In some patients, this may lead to reduced clearance, prolongation of plasma half-life, and enhanced effects of caffeine and theobromine.
DDI-DrugBank.d78.s5	112	119	caffeine	drug	DDI-DrugBank.d78.s5.e0
DDI-DrugBank.d78.s5	125	135	theobromine	drug	DDI-DrugBank.d78.s5.e1
DDI-DrugBank.d78.s5	false	DDI-DrugBank.d78.s5.e0	DDI-DrugBank.d78.s5.e1
DDI-DrugBank.d78.s6|a|Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.
DDI-DrugBank.d78.s6	0	11	Theophylline	drug	DDI-DrugBank.d78.s6.e0
DDI-DrugBank.d78.s6	14	26	Grepafloxacin	drug	DDI-DrugBank.d78.s6.e1
DDI-DrugBank.d78.s6	76	87	theophylline	drug	DDI-DrugBank.d78.s6.e2
DDI-DrugBank.d78.s6	false	DDI-DrugBank.d78.s6.e0	DDI-DrugBank.d78.s6.e1
DDI-DrugBank.d78.s6	false	DDI-DrugBank.d78.s6.e0	DDI-DrugBank.d78.s6.e2
DDI-DrugBank.d78.s6	true	DDI-DrugBank.d78.s6.e1	DDI-DrugBank.d78.s6.e2
DDI-DrugBank.d78.s7|a|Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.
DDI-DrugBank.d78.s7	6	17	theophylline	drug	DDI-DrugBank.d78.s7.e0
DDI-DrugBank.d78.s7	48	60	grepafloxacin	drug	DDI-DrugBank.d78.s7.e1
DDI-DrugBank.d78.s7	102	113	theophylline	drug	DDI-DrugBank.d78.s7.e2
DDI-DrugBank.d78.s7	false	DDI-DrugBank.d78.s7.e0	DDI-DrugBank.d78.s7.e1
DDI-DrugBank.d78.s7	false	DDI-DrugBank.d78.s7.e0	DDI-DrugBank.d78.s7.e2
DDI-DrugBank.d78.s7	true	DDI-DrugBank.d78.s7.e1	DDI-DrugBank.d78.s7.e2
DDI-DrugBank.d78.s8|a|When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
DDI-DrugBank.d78.s8	38	50	grepafloxacin	drug	DDI-DrugBank.d78.s8.e0
DDI-DrugBank.d78.s8	79	90	theophylline	drug	DDI-DrugBank.d78.s8.e1
DDI-DrugBank.d78.s8	97	108	theophylline	drug	DDI-DrugBank.d78.s8.e2
DDI-DrugBank.d78.s8	180	192	grepafloxacin	drug	DDI-DrugBank.d78.s8.e3
DDI-DrugBank.d78.s8	218	229	theophylline	drug	DDI-DrugBank.d78.s8.e4
DDI-DrugBank.d78.s8	false	DDI-DrugBank.d78.s8.e0	DDI-DrugBank.d78.s8.e1
DDI-DrugBank.d78.s8	false	DDI-DrugBank.d78.s8.e0	DDI-DrugBank.d78.s8.e2
DDI-DrugBank.d78.s8	false	DDI-DrugBank.d78.s8.e0	DDI-DrugBank.d78.s8.e3
DDI-DrugBank.d78.s8	false	DDI-DrugBank.d78.s8.e0	DDI-DrugBank.d78.s8.e4
DDI-DrugBank.d78.s8	false	DDI-DrugBank.d78.s8.e1	DDI-DrugBank.d78.s8.e2
DDI-DrugBank.d78.s8	false	DDI-DrugBank.d78.s8.e1	DDI-DrugBank.d78.s8.e3
DDI-DrugBank.d78.s8	false	DDI-DrugBank.d78.s8.e1	DDI-DrugBank.d78.s8.e4
DDI-DrugBank.d78.s8	true	DDI-DrugBank.d78.s8.e2	DDI-DrugBank.d78.s8.e3
DDI-DrugBank.d78.s8	false	DDI-DrugBank.d78.s8.e2	DDI-DrugBank.d78.s8.e4
DDI-DrugBank.d78.s8	false	DDI-DrugBank.d78.s8.e3	DDI-DrugBank.d78.s8.e4
DDI-DrugBank.d78.s9|a|Warfarin: In subjects receiving warfarin, no significant change in clotting time was observed when grepafloxacin was coadministered.
DDI-DrugBank.d78.s9	0	7	Warfarin	drug	DDI-DrugBank.d78.s9.e0
DDI-DrugBank.d78.s9	32	39	warfarin	drug	DDI-DrugBank.d78.s9.e1
DDI-DrugBank.d78.s9	99	111	grepafloxacin	drug	DDI-DrugBank.d78.s9.e2
DDI-DrugBank.d78.s9	false	DDI-DrugBank.d78.s9.e0	DDI-DrugBank.d78.s9.e1
DDI-DrugBank.d78.s9	false	DDI-DrugBank.d78.s9.e0	DDI-DrugBank.d78.s9.e2
DDI-DrugBank.d78.s9	false	DDI-DrugBank.d78.s9.e1	DDI-DrugBank.d78.s9.e2
DDI-DrugBank.d78.s10|a|However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.
DDI-DrugBank.d78.s10	22	31	quinolones	group	DDI-DrugBank.d78.s10.e0
DDI-DrugBank.d78.s10	78	85	warfarin	drug	DDI-DrugBank.d78.s10.e1
DDI-DrugBank.d78.s10	196	218	quinolone antimicrobial	group	DDI-DrugBank.d78.s10.e2
DDI-DrugBank.d78.s10	241	248	warfarin	drug	DDI-DrugBank.d78.s10.e3
DDI-DrugBank.d78.s10	true	DDI-DrugBank.d78.s10.e0	DDI-DrugBank.d78.s10.e1
DDI-DrugBank.d78.s10	false	DDI-DrugBank.d78.s10.e0	DDI-DrugBank.d78.s10.e2
DDI-DrugBank.d78.s10	false	DDI-DrugBank.d78.s10.e0	DDI-DrugBank.d78.s10.e3
DDI-DrugBank.d78.s10	false	DDI-DrugBank.d78.s10.e1	DDI-DrugBank.d78.s10.e2
DDI-DrugBank.d78.s10	false	DDI-DrugBank.d78.s10.e1	DDI-DrugBank.d78.s10.e3
DDI-DrugBank.d78.s10	true	DDI-DrugBank.d78.s10.e2	DDI-DrugBank.d78.s10.e3
DDI-DrugBank.d78.s11|a|Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.
DDI-DrugBank.d78.s11	97	109	grepafloxacin	drug	DDI-DrugBank.d78.s11.e0
DDI-DrugBank.d78.s11	114	125	theophylline	drug	DDI-DrugBank.d78.s11.e1
DDI-DrugBank.d78.s11	142	154	grepafloxacin	drug	DDI-DrugBank.d78.s11.e2
DDI-DrugBank.d78.s11	165	176	theophylline	drug	DDI-DrugBank.d78.s11.e3
DDI-DrugBank.d78.s11	false	DDI-DrugBank.d78.s11.e0	DDI-DrugBank.d78.s11.e1
DDI-DrugBank.d78.s11	false	DDI-DrugBank.d78.s11.e0	DDI-DrugBank.d78.s11.e2
DDI-DrugBank.d78.s11	false	DDI-DrugBank.d78.s11.e0	DDI-DrugBank.d78.s11.e3
DDI-DrugBank.d78.s11	false	DDI-DrugBank.d78.s11.e1	DDI-DrugBank.d78.s11.e2
DDI-DrugBank.d78.s11	false	DDI-DrugBank.d78.s11.e1	DDI-DrugBank.d78.s11.e3
DDI-DrugBank.d78.s11	true	DDI-DrugBank.d78.s11.e2	DDI-DrugBank.d78.s11.e3
DDI-DrugBank.d78.s12|a|While no clinical studies have been conducted to evaluate the effect of grepafloxacin on the metabolism of C.P.A.
DDI-DrugBank.d78.s12	72	84	grepafloxacin	drug	DDI-DrugBank.d78.s12.e0
DDI-DrugBank.d78.s13|a|substrates, in vitro data suggest similar effects of grepafloxacin in CYP3A4 mediated metabolism and theophylline metabolism.
DDI-DrugBank.d78.s13	53	65	grepafloxacin	drug	DDI-DrugBank.d78.s13.e0
DDI-DrugBank.d78.s13	101	112	theophylline	drug	DDI-DrugBank.d78.s13.e1
DDI-DrugBank.d78.s13	false	DDI-DrugBank.d78.s13.e0	DDI-DrugBank.d78.s13.e1
DDI-DrugBank.d78.s14|a|In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.
DDI-DrugBank.d78.s14	19	28	quinolones	group	DDI-DrugBank.d78.s14.e0
DDI-DrugBank.d78.s14	95	106	cyclosporine	drug	DDI-DrugBank.d78.s14.e1
DDI-DrugBank.d78.s14	true	DDI-DrugBank.d78.s14.e0	DDI-DrugBank.d78.s14.e1
DDI-DrugBank.d78.s15|a|Other drugs metabolized by C.P.A.
DDI-DrugBank.d78.s16|a|include terfenadine, astemizole, cisapride, midazolam, and triazolam.
DDI-DrugBank.d78.s16	8	18	terfenadine	drug	DDI-DrugBank.d78.s16.e0
DDI-DrugBank.d78.s16	21	30	astemizole	drug	DDI-DrugBank.d78.s16.e1
DDI-DrugBank.d78.s16	33	41	cisapride	drug	DDI-DrugBank.d78.s16.e2
DDI-DrugBank.d78.s16	44	52	midazolam	drug	DDI-DrugBank.d78.s16.e3
DDI-DrugBank.d78.s16	59	67	triazolam	drug	DDI-DrugBank.d78.s16.e4
DDI-DrugBank.d78.s16	false	DDI-DrugBank.d78.s16.e0	DDI-DrugBank.d78.s16.e1
DDI-DrugBank.d78.s16	false	DDI-DrugBank.d78.s16.e0	DDI-DrugBank.d78.s16.e2
DDI-DrugBank.d78.s16	false	DDI-DrugBank.d78.s16.e0	DDI-DrugBank.d78.s16.e3
DDI-DrugBank.d78.s16	false	DDI-DrugBank.d78.s16.e0	DDI-DrugBank.d78.s16.e4
DDI-DrugBank.d78.s16	false	DDI-DrugBank.d78.s16.e1	DDI-DrugBank.d78.s16.e2
DDI-DrugBank.d78.s16	false	DDI-DrugBank.d78.s16.e1	DDI-DrugBank.d78.s16.e3
DDI-DrugBank.d78.s16	false	DDI-DrugBank.d78.s16.e1	DDI-DrugBank.d78.s16.e4
DDI-DrugBank.d78.s16	false	DDI-DrugBank.d78.s16.e2	DDI-DrugBank.d78.s16.e3
DDI-DrugBank.d78.s16	false	DDI-DrugBank.d78.s16.e2	DDI-DrugBank.d78.s16.e4
DDI-DrugBank.d78.s16	false	DDI-DrugBank.d78.s16.e3	DDI-DrugBank.d78.s16.e4
DDI-DrugBank.d78.s17|a|The clinical relevance of the potential effect of grepafloxacin on the metabolism of C.P.A. substrates is not known.
DDI-DrugBank.d78.s17	50	62	grepafloxacin	drug	DDI-DrugBank.d78.s17.e0
DDI-DrugBank.d78.s18|a|Patients receiving concurrent administration of substrates of C.P.A. were not excluded from clinical trials of grepafloxacin.
DDI-DrugBank.d78.s18	111	123	grepafloxacin	drug	DDI-DrugBank.d78.s18.e0
DDI-DrugBank.d78.s19|a|Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.
DDI-DrugBank.d78.s19	0	35	Nonsteroidal Anti-inflammatory Drugs	group	DDI-DrugBank.d78.s19.e0
DDI-DrugBank.d78.s19	38	43	NSAIDs	group	DDI-DrugBank.d78.s19.e1
DDI-DrugBank.d78.s19	83	117	nonsteroidal anti inflammatory drug	group	DDI-DrugBank.d78.s19.e2
DDI-DrugBank.d78.s19	126	134	quinolone	group	DDI-DrugBank.d78.s19.e3
DDI-DrugBank.d78.s19	false	DDI-DrugBank.d78.s19.e0	DDI-DrugBank.d78.s19.e1
DDI-DrugBank.d78.s19	false	DDI-DrugBank.d78.s19.e0	DDI-DrugBank.d78.s19.e2
DDI-DrugBank.d78.s19	false	DDI-DrugBank.d78.s19.e0	DDI-DrugBank.d78.s19.e3
DDI-DrugBank.d78.s19	false	DDI-DrugBank.d78.s19.e1	DDI-DrugBank.d78.s19.e2
DDI-DrugBank.d78.s19	false	DDI-DrugBank.d78.s19.e1	DDI-DrugBank.d78.s19.e3
DDI-DrugBank.d78.s19	true	DDI-DrugBank.d78.s19.e2	DDI-DrugBank.d78.s19.e3
DDI-DrugBank.d78.s20|a|Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.
DDI-DrugBank.d78.s20	0	18	Antidiabetic Agents	group	DDI-DrugBank.d78.s20.e0
DDI-DrugBank.d78.s20	152	161	quinolones	group	DDI-DrugBank.d78.s20.e1
DDI-DrugBank.d78.s20	170	187	antidiabetic agent	group	DDI-DrugBank.d78.s20.e2
DDI-DrugBank.d78.s20	false	DDI-DrugBank.d78.s20.e0	DDI-DrugBank.d78.s20.e1
DDI-DrugBank.d78.s20	false	DDI-DrugBank.d78.s20.e0	DDI-DrugBank.d78.s20.e2
DDI-DrugBank.d78.s20	true	DDI-DrugBank.d78.s20.e1	DDI-DrugBank.d78.s20.e2
DDI-DrugBank.d78.s21|a|Therefore, careful monitoring of blood glucose is recommended when these agents are coadministered.
DDI-DrugBank.d83.s0|a|Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.
DDI-DrugBank.d83.s0	12	38	warfarin-type anticoagulant	group	DDI-DrugBank.d83.s0.e0
DDI-DrugBank.d83.s0	116	127	griseofulvin	drug	DDI-DrugBank.d83.s0.e1
DDI-DrugBank.d83.s0	true	DDI-DrugBank.d83.s0.e0	DDI-DrugBank.d83.s0.e1
DDI-DrugBank.d83.s1|a|Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.
DDI-DrugBank.d83.s1	19	30	barbiturates	group	DDI-DrugBank.d83.s1.e0
DDI-DrugBank.d83.s1	50	61	griseofulvin	drug	DDI-DrugBank.d83.s1.e1
DDI-DrugBank.d83.s1	true	DDI-DrugBank.d83.s1.e0	DDI-DrugBank.d83.s1.e1
DDI-DrugBank.d83.s2|a|The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.
DDI-DrugBank.d83.s2	34	45	griseofulvin	drug	DDI-DrugBank.d83.s2.e0
DDI-DrugBank.d83.s2	96	109	contraceptives	group	DDI-DrugBank.d83.s2.e1
DDI-DrugBank.d83.s2	true	DDI-DrugBank.d83.s2.e0	DDI-DrugBank.d83.s2.e1
DDI-DrugBank.d398.s0|a|The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
DDI-DrugBank.d398.s0	11	17	codeine	drug	DDI-DrugBank.d398.s0.e0
DDI-DrugBank.d398.s0	90	96	alcohol	drug	DDI-DrugBank.d398.s0.e1
DDI-DrugBank.d398.s0	99	112	antihistamines	group	DDI-DrugBank.d398.s0.e2
DDI-DrugBank.d398.s0	115	127	psychotropics	group	DDI-DrugBank.d398.s0.e3
DDI-DrugBank.d398.s0	true	DDI-DrugBank.d398.s0.e0	DDI-DrugBank.d398.s0.e1
DDI-DrugBank.d398.s0	true	DDI-DrugBank.d398.s0.e0	DDI-DrugBank.d398.s0.e2
DDI-DrugBank.d398.s0	true	DDI-DrugBank.d398.s0.e0	DDI-DrugBank.d398.s0.e3
DDI-DrugBank.d398.s0	false	DDI-DrugBank.d398.s0.e1	DDI-DrugBank.d398.s0.e2
DDI-DrugBank.d398.s0	false	DDI-DrugBank.d398.s0.e1	DDI-DrugBank.d398.s0.e3
DDI-DrugBank.d398.s0	false	DDI-DrugBank.d398.s0.e2	DDI-DrugBank.d398.s0.e3
DDI-DrugBank.d398.s1|a|Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).
DDI-DrugBank.d398.s1	31	46	dextromethorphan	drug	DDI-DrugBank.d398.s1.e0
DDI-DrugBank.d398.s1	71	98	monoamine oxidase inhibitors	group	DDI-DrugBank.d398.s1.e1
DDI-DrugBank.d398.s1	101	105	MAOIs	group	DDI-DrugBank.d398.s1.e2
DDI-DrugBank.d398.s1	true	DDI-DrugBank.d398.s1.e0	DDI-DrugBank.d398.s1.e1
DDI-DrugBank.d398.s1	true	DDI-DrugBank.d398.s1.e0	DDI-DrugBank.d398.s1.e2
DDI-DrugBank.d398.s1	false	DDI-DrugBank.d398.s1.e1	DDI-DrugBank.d398.s1.e2
DDI-DrugBank.d398.s2|a|The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
DDI-DrugBank.d398.s2	11	39	dextromethorphan hydrobromide	drug	DDI-DrugBank.d398.s2.e0
DDI-DrugBank.d398.s2	112	118	alcohol	drug	DDI-DrugBank.d398.s2.e1
DDI-DrugBank.d398.s2	121	134	antihistamines	group	DDI-DrugBank.d398.s2.e2
DDI-DrugBank.d398.s2	137	149	psychotropics	group	DDI-DrugBank.d398.s2.e3
DDI-DrugBank.d398.s2	true	DDI-DrugBank.d398.s2.e0	DDI-DrugBank.d398.s2.e1
DDI-DrugBank.d398.s2	true	DDI-DrugBank.d398.s2.e0	DDI-DrugBank.d398.s2.e2
DDI-DrugBank.d398.s2	true	DDI-DrugBank.d398.s2.e0	DDI-DrugBank.d398.s2.e3
DDI-DrugBank.d398.s2	false	DDI-DrugBank.d398.s2.e1	DDI-DrugBank.d398.s2.e2
DDI-DrugBank.d398.s2	false	DDI-DrugBank.d398.s2.e1	DDI-DrugBank.d398.s2.e3
DDI-DrugBank.d398.s2	false	DDI-DrugBank.d398.s2.e2	DDI-DrugBank.d398.s2.e3
DDI-DrugBank.d302.s0|a|http://www.rxlist.com/cgi/generic3/guanethidine_od.htm
DDI-DrugBank.d507.s0|a|The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.
DDI-DrugBank.d507.s0	42	51	guanfacine	drug	DDI-DrugBank.d507.s0.e0
DDI-DrugBank.d507.s0	73	91	CNS-depressant drug	group	DDI-DrugBank.d507.s0.e1
DDI-DrugBank.d507.s0	true	DDI-DrugBank.d507.s0.e0	DDI-DrugBank.d507.s0.e1
DDI-DrugBank.d507.s1|a|The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
DDI-DrugBank.d507.s1	22	31	guanfacine	drug	DDI-DrugBank.d507.s1.e0
DDI-DrugBank.d507.s1	85	97	phenobarbital	drug	DDI-DrugBank.d507.s1.e1
DDI-DrugBank.d507.s1	102	110	phenytoin	drug	DDI-DrugBank.d507.s1.e2
DDI-DrugBank.d507.s1	true	DDI-DrugBank.d507.s1.e0	DDI-DrugBank.d507.s1.e1
DDI-DrugBank.d507.s1	true	DDI-DrugBank.d507.s1.e0	DDI-DrugBank.d507.s1.e2
DDI-DrugBank.d507.s1	false	DDI-DrugBank.d507.s1.e1	DDI-DrugBank.d507.s1.e2
DDI-DrugBank.d507.s2|a|In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response.
DDI-DrugBank.d507.s3|a|Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena.
DDI-DrugBank.d507.s3	12	21	guanfacine	drug	DDI-DrugBank.d507.s3.e0
DDI-DrugBank.d507.s4|a|TCAs decrease the hypotensive effect of guanfacine.
DDI-DrugBank.d507.s4	0	3	TCAs	group	DDI-DrugBank.d507.s4.e0
DDI-DrugBank.d507.s4	40	49	guanfacine	drug	DDI-DrugBank.d507.s4.e1
DDI-DrugBank.d507.s4	true	DDI-DrugBank.d507.s4.e0	DDI-DrugBank.d507.s4.e1
DDI-DrugBank.d507.s5|a|Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
DDI-DrugBank.d507.s5	0	31	Noncardioselective beta-blockers	group	DDI-DrugBank.d507.s5.e0
DDI-DrugBank.d507.s5	34	40	nadolol	drug	DDI-DrugBank.d507.s5.e1
DDI-DrugBank.d507.s5	54	60	timolol	drug	DDI-DrugBank.d507.s5.e2
DDI-DrugBank.d507.s5	104	113	guanfacine	drug	DDI-DrugBank.d507.s5.e3
DDI-DrugBank.d507.s5	false	DDI-DrugBank.d507.s5.e0	DDI-DrugBank.d507.s5.e1
DDI-DrugBank.d507.s5	false	DDI-DrugBank.d507.s5.e0	DDI-DrugBank.d507.s5.e2
DDI-DrugBank.d507.s5	true	DDI-DrugBank.d507.s5.e0	DDI-DrugBank.d507.s5.e3
DDI-DrugBank.d507.s5	false	DDI-DrugBank.d507.s5.e1	DDI-DrugBank.d507.s5.e2
DDI-DrugBank.d507.s5	true	DDI-DrugBank.d507.s5.e1	DDI-DrugBank.d507.s5.e3
DDI-DrugBank.d507.s5	true	DDI-DrugBank.d507.s5.e2	DDI-DrugBank.d507.s5.e3
DDI-DrugBank.d507.s6|a|The beta-blocker should be withdrawn first.
DDI-DrugBank.d507.s6	4	15	beta-blocker	group	DDI-DrugBank.d507.s6.e0
DDI-DrugBank.d507.s7|a|The gradual withdrawal of guafacine or a cardioselective beta-blocker could be substituted.
DDI-DrugBank.d507.s7	26	34	guafacine	drug	DDI-DrugBank.d507.s7.e0
DDI-DrugBank.d507.s7	41	68	cardioselective beta-blocker	group	DDI-DrugBank.d507.s7.e1
DDI-DrugBank.d507.s7	false	DDI-DrugBank.d507.s7.e0	DDI-DrugBank.d507.s7.e1
DDI-DrugBank.d507.s8|a|Anticoagulants: Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks.
DDI-DrugBank.d507.s8	0	13	Anticoagulants	group	DDI-DrugBank.d507.s8.e0
DDI-DrugBank.d507.s8	57	70	anticoagulants	group	DDI-DrugBank.d507.s8.e1
DDI-DrugBank.d507.s8	83	92	guanfacine	drug	DDI-DrugBank.d507.s8.e2
DDI-DrugBank.d507.s8	false	DDI-DrugBank.d507.s8.e0	DDI-DrugBank.d507.s8.e1
DDI-DrugBank.d507.s8	false	DDI-DrugBank.d507.s8.e0	DDI-DrugBank.d507.s8.e2
DDI-DrugBank.d507.s8	false	DDI-DrugBank.d507.s8.e1	DDI-DrugBank.d507.s8.e2
DDI-DrugBank.d507.s9|a|No changes were observed in the degree of anticoagulation.
DDI-DrugBank.d507.s10|a|In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported.
DDI-DrugBank.d507.s10	36	45	guanfacine	drug	DDI-DrugBank.d507.s10.e0
DDI-DrugBank.d507.s10	78	86	diuretics	group	DDI-DrugBank.d507.s10.e1
DDI-DrugBank.d507.s10	false	DDI-DrugBank.d507.s10.e0	DDI-DrugBank.d507.s10.e1
DDI-DrugBank.d507.s11|a|In the long-term safety studies, guanfacine was given concomitantly with many drugs without evidence of any interactions.
DDI-DrugBank.d507.s11	33	42	guanfacine	drug	DDI-DrugBank.d507.s11.e0
DDI-DrugBank.d507.s12|a|The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
DDI-DrugBank.d507.s12	68	85	cardiac glycosides	group	DDI-DrugBank.d507.s12.e0
DDI-DrugBank.d507.s12	94	102	sedatives	group	DDI-DrugBank.d507.s12.e1
DDI-DrugBank.d507.s12	108	116	hypnotics	group	DDI-DrugBank.d507.s12.e2
DDI-DrugBank.d507.s12	125	145	coronary vasodilators	group	DDI-DrugBank.d507.s12.e3
DDI-DrugBank.d507.s12	158	170	hypoglycemics	group	DDI-DrugBank.d507.s12.e4
DDI-DrugBank.d507.s12	212	217	NSAIDs	group	DDI-DrugBank.d507.s12.e5
DDI-DrugBank.d507.s12	225	243	antihyperlipidemics	group	DDI-DrugBank.d507.s12.e6
DDI-DrugBank.d507.s12	251	264	antigout drugs	group	DDI-DrugBank.d507.s12.e7
DDI-DrugBank.d507.s12	277	290	contraceptives	group	DDI-DrugBank.d507.s12.e8
DDI-DrugBank.d507.s12	298	312	bronchodilators	group	DDI-DrugBank.d507.s12.e9
DDI-DrugBank.d507.s12	false	DDI-DrugBank.d507.s12.e0	DDI-DrugBank.d507.s12.e1
DDI-DrugBank.d507.s12	false	DDI-DrugBank.d507.s12.e0	DDI-DrugBank.d507.s12.e2
DDI-DrugBank.d507.s12	false	DDI-DrugBank.d507.s12.e0	DDI-DrugBank.d507.s12.e3
DDI-DrugBank.d507.s12	false	DDI-DrugBank.d507.s12.e0	DDI-DrugBank.d507.s12.e4
DDI-DrugBank.d507.s12	false	DDI-DrugBank.d507.s12.e0	DDI-DrugBank.d507.s12.e5
DDI-DrugBank.d507.s12	false	DDI-DrugBank.d507.s12.e0	DDI-DrugBank.d507.s12.e6
DDI-DrugBank.d507.s12	false	DDI-DrugBank.d507.s12.e0	DDI-DrugBank.d507.s12.e7
DDI-DrugBank.d507.s12	false	DDI-DrugBank.d507.s12.e0	DDI-DrugBank.d507.s12.e8
DDI-DrugBank.d507.s12	false	DDI-DrugBank.d507.s12.e0	DDI-DrugBank.d507.s12.e9
DDI-DrugBank.d507.s12	false	DDI-DrugBank.d507.s12.e0	DDI-DrugBank.d507.s12.e10
DDI-DrugBank.d507.s13|a|Laboratory Test In clinical trials, no clinically relevant laboratory test abnormalities were identified as causally related to drug during short-term treatment with guanfacine.
DDI-DrugBank.d507.s13	166	175	guanfacine	drug	DDI-DrugBank.d507.s13.e0
DDI-DrugBank.d507.s14|a|Drug/Laboratory Test Interactions No laboratory test abnormalities related to the use of guanfacine have been identified.
DDI-DrugBank.d507.s14	89	98	guanfacine	drug	DDI-DrugBank.d507.s14.e0
DDI-DrugBank.d186.s0|a|An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.
DDI-DrugBank.d186.s0	261	267	lithium	drug	DDI-DrugBank.d186.s0.e0
DDI-DrugBank.d186.s0	274	279	HALDOL	brand	DDI-DrugBank.d186.s0.e1
DDI-DrugBank.d186.s0	true	DDI-DrugBank.d186.s0.e0	DDI-DrugBank.d186.s0.e1
DDI-DrugBank.d186.s1|a|A causal relationship between these events and the concomitant administration of lithium and HALDOL has not been established;
DDI-DrugBank.d186.s1	81	87	lithium	drug	DDI-DrugBank.d186.s1.e0
DDI-DrugBank.d186.s1	93	98	HALDOL	brand	DDI-DrugBank.d186.s1.e1
DDI-DrugBank.d186.s1	false	DDI-DrugBank.d186.s1.e0	DDI-DrugBank.d186.s1.e1
DDI-DrugBank.d186.s2|a|however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.
DDI-DrugBank.d186.s3|a|As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
DDI-DrugBank.d186.s3	14	33	antipsychotic agents	group	DDI-DrugBank.d186.s3.e0
DDI-DrugBank.d186.s3	60	65	HALDOL	brand	DDI-DrugBank.d186.s3.e1
DDI-DrugBank.d186.s3	98	112	CNS depressants	group	DDI-DrugBank.d186.s3.e2
DDI-DrugBank.d186.s3	122	132	anesthetics	group	DDI-DrugBank.d186.s3.e3
DDI-DrugBank.d186.s3	135	141	opiates	group	DDI-DrugBank.d186.s3.e4
DDI-DrugBank.d186.s3	148	154	alcohol	drug	DDI-DrugBank.d186.s3.e5
DDI-DrugBank.d186.s3	false	DDI-DrugBank.d186.s3.e0	DDI-DrugBank.d186.s3.e1
DDI-DrugBank.d186.s3	true	DDI-DrugBank.d186.s3.e0	DDI-DrugBank.d186.s3.e2
DDI-DrugBank.d186.s3	true	DDI-DrugBank.d186.s3.e0	DDI-DrugBank.d186.s3.e3
DDI-DrugBank.d186.s3	true	DDI-DrugBank.d186.s3.e0	DDI-DrugBank.d186.s3.e4
DDI-DrugBank.d186.s3	true	DDI-DrugBank.d186.s3.e0	DDI-DrugBank.d186.s3.e5
DDI-DrugBank.d186.s3	true	DDI-DrugBank.d186.s3.e1	DDI-DrugBank.d186.s3.e2
DDI-DrugBank.d186.s3	true	DDI-DrugBank.d186.s3.e1	DDI-DrugBank.d186.s3.e3
DDI-DrugBank.d186.s3	true	DDI-DrugBank.d186.s3.e1	DDI-DrugBank.d186.s3.e4
DDI-DrugBank.d186.s3	true	DDI-DrugBank.d186.s3.e1	DDI-DrugBank.d186.s3.e5
DDI-DrugBank.d186.s3	false	DDI-DrugBank.d186.s3.e2	DDI-DrugBank.d186.s3.e3
DDI-DrugBank.d186.s4|a|In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.
DDI-DrugBank.d186.s4	60	70	haloperidol	drug	DDI-DrugBank.d186.s4.e0
DDI-DrugBank.d186.s4	76	83	rifampin	drug	DDI-DrugBank.d186.s4.e1
DDI-DrugBank.d186.s4	93	103	haloperidol	drug	DDI-DrugBank.d186.s4.e2
DDI-DrugBank.d186.s4	true	DDI-DrugBank.d186.s4.e0	DDI-DrugBank.d186.s4.e1
DDI-DrugBank.d186.s4	false	DDI-DrugBank.d186.s4.e0	DDI-DrugBank.d186.s4.e2
DDI-DrugBank.d186.s4	false	DDI-DrugBank.d186.s4.e1	DDI-DrugBank.d186.s4.e2
DDI-DrugBank.d186.s5|a|In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.
DDI-DrugBank.d186.s5	52	62	haloperidol	drug	DDI-DrugBank.d186.s5.e0
DDI-DrugBank.d186.s5	68	75	rifampin	drug	DDI-DrugBank.d186.s5.e1
DDI-DrugBank.d186.s5	97	104	rifampin	drug	DDI-DrugBank.d186.s5.e2
DDI-DrugBank.d186.s5	143	153	haloperidol	drug	DDI-DrugBank.d186.s5.e3
DDI-DrugBank.d186.s5	false	DDI-DrugBank.d186.s5.e0	DDI-DrugBank.d186.s5.e1
DDI-DrugBank.d186.s5	false	DDI-DrugBank.d186.s5.e0	DDI-DrugBank.d186.s5.e2
DDI-DrugBank.d186.s5	false	DDI-DrugBank.d186.s5.e0	DDI-DrugBank.d186.s5.e3
DDI-DrugBank.d186.s5	false	DDI-DrugBank.d186.s5.e1	DDI-DrugBank.d186.s5.e2
DDI-DrugBank.d186.s5	false	DDI-DrugBank.d186.s5.e1	DDI-DrugBank.d186.s5.e3
DDI-DrugBank.d186.s5	true	DDI-DrugBank.d186.s5.e2	DDI-DrugBank.d186.s5.e3
DDI-DrugBank.d186.s6|a|Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.
DDI-DrugBank.d186.s6	62	69	rifampin	drug	DDI-DrugBank.d186.s6.e0
DDI-DrugBank.d186.s6	106	116	haloperidol	drug	DDI-DrugBank.d186.s6.e1
DDI-DrugBank.d186.s6	true	DDI-DrugBank.d186.s6.e0	DDI-DrugBank.d186.s6.e1
DDI-DrugBank.d74.s0|a|FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.
DDI-DrugBank.d74.s0	0	8	FLUOTHANE	brand	DDI-DrugBank.d74.s0.e0
DDI-DrugBank.d74.s0	33	64	non-depolarising muscle relaxant	group	DDI-DrugBank.d74.s0.e1
DDI-DrugBank.d74.s0	102	116	aminoglycosides	group	DDI-DrugBank.d74.s0.e2
DDI-DrugBank.d74.s0	true	DDI-DrugBank.d74.s0.e0	DDI-DrugBank.d74.s0.e1
DDI-DrugBank.d74.s0	true	DDI-DrugBank.d74.s0.e0	DDI-DrugBank.d74.s0.e2
DDI-DrugBank.d74.s0	false	DDI-DrugBank.d74.s0.e1	DDI-DrugBank.d74.s0.e2
DDI-DrugBank.d74.s1|a|FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.
DDI-DrugBank.d74.s1	0	8	FLUOTHANE	brand	DDI-DrugBank.d74.s1.e0
DDI-DrugBank.d74.s1	82	93	tubocurarine	drug	DDI-DrugBank.d74.s1.e1
DDI-DrugBank.d74.s1	true	DDI-DrugBank.d74.s1.e0	DDI-DrugBank.d74.s1.e1
DDI-DrugBank.d74.s2|a|Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.
DDI-DrugBank.d74.s2	57	66	adrenaline	drug	DDI-DrugBank.d74.s2.e0
DDI-DrugBank.d74.s2	99	107	FLUOTHANE	brand	DDI-DrugBank.d74.s2.e1
DDI-DrugBank.d74.s2	true	DDI-DrugBank.d74.s2.e0	DDI-DrugBank.d74.s2.e1
DDI-DrugBank.d74.s3|a|For this reason the dose of adrenaline should be restricted and an antiarrhythmic agent administered as appropriate.
DDI-DrugBank.d74.s3	28	37	adrenaline	drug	DDI-DrugBank.d74.s3.e0
DDI-DrugBank.d74.s3	67	86	antiarrhythmic agent	group	DDI-DrugBank.d74.s3.e1
DDI-DrugBank.d74.s3	false	DDI-DrugBank.d74.s3.e0	DDI-DrugBank.d74.s3.e1
DDI-DrugBank.d74.s4|a|Caution should also be applied for other sympathomimetics, and for aminophylline and theophylline and tricyclic antidepressants, which may also precipitate arrhythmias.
DDI-DrugBank.d74.s4	41	56	sympathomimetics	group	DDI-DrugBank.d74.s4.e0
DDI-DrugBank.d74.s4	67	79	aminophylline	drug	DDI-DrugBank.d74.s4.e1
DDI-DrugBank.d74.s4	85	96	theophylline	drug	DDI-DrugBank.d74.s4.e2
DDI-DrugBank.d74.s4	102	126	tricyclic antidepressants	group	DDI-DrugBank.d74.s4.e3
DDI-DrugBank.d74.s4	false	DDI-DrugBank.d74.s4.e0	DDI-DrugBank.d74.s4.e1
DDI-DrugBank.d74.s4	false	DDI-DrugBank.d74.s4.e0	DDI-DrugBank.d74.s4.e2
DDI-DrugBank.d74.s4	false	DDI-DrugBank.d74.s4.e0	DDI-DrugBank.d74.s4.e3
DDI-DrugBank.d74.s4	false	DDI-DrugBank.d74.s4.e1	DDI-DrugBank.d74.s4.e2
DDI-DrugBank.d74.s4	false	DDI-DrugBank.d74.s4.e1	DDI-DrugBank.d74.s4.e3
DDI-DrugBank.d74.s4	false	DDI-DrugBank.d74.s4.e2	DDI-DrugBank.d74.s4.e3
DDI-DrugBank.d488.s0|a|Drug Interactions: a. Drugs Enhancing Heparin Effect: Oral anticoagulants: Heparin sodium may prolong the one-stage prothrombin time.
DDI-DrugBank.d488.s0	38	44	Heparin	drug	DDI-DrugBank.d488.s0.e0
DDI-DrugBank.d488.s0	59	72	anticoagulants	group	DDI-DrugBank.d488.s0.e1
DDI-DrugBank.d488.s0	75	88	Heparin sodium	drug	DDI-DrugBank.d488.s0.e2
DDI-DrugBank.d488.s0	false	DDI-DrugBank.d488.s0.e0	DDI-DrugBank.d488.s0.e1
DDI-DrugBank.d488.s0	false	DDI-DrugBank.d488.s0.e0	DDI-DrugBank.d488.s0.e2
DDI-DrugBank.d488.s0	false	DDI-DrugBank.d488.s0.e1	DDI-DrugBank.d488.s0.e2
DDI-DrugBank.d488.s1|a|Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
DDI-DrugBank.d488.s1	16	29	heparin sodium	drug	DDI-DrugBank.d488.s1.e0
DDI-DrugBank.d488.s1	45	53	dicumarol	drug	DDI-DrugBank.d488.s1.e1
DDI-DrugBank.d488.s1	58	72	warfarin sodium	drug	DDI-DrugBank.d488.s1.e2
DDI-DrugBank.d488.s1	true	DDI-DrugBank.d488.s1.e0	DDI-DrugBank.d488.s1.e1
DDI-DrugBank.d488.s1	true	DDI-DrugBank.d488.s1.e0	DDI-DrugBank.d488.s1.e2
DDI-DrugBank.d488.s1	false	DDI-DrugBank.d488.s1.e1	DDI-DrugBank.d488.s1.e2
DDI-DrugBank.d488.s2|a|Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
DDI-DrugBank.d488.s2	0	18	Platelet inhibitors	group	DDI-DrugBank.d488.s2.e0
DDI-DrugBank.d488.s2	35	54	acetylsalicylic acid	drug	DDI-DrugBank.d488.s2.e1
DDI-DrugBank.d488.s2	57	63	dextran	drug	DDI-DrugBank.d488.s2.e2
DDI-DrugBank.d488.s2	66	79	phenylbutazone	drug	DDI-DrugBank.d488.s2.e3
DDI-DrugBank.d488.s2	82	90	ibuprofen	drug	DDI-DrugBank.d488.s2.e4
DDI-DrugBank.d488.s2	93	104	indomethacin	drug	DDI-DrugBank.d488.s2.e5
DDI-DrugBank.d488.s2	107	118	dipyridamole	drug	DDI-DrugBank.d488.s2.e6
DDI-DrugBank.d488.s2	121	138	hydroxychloroquine	drug	DDI-DrugBank.d488.s2.e7
DDI-DrugBank.d488.s2	330	343	heparin sodium	drug	DDI-DrugBank.d488.s2.e8
DDI-DrugBank.d488.s2	false	DDI-DrugBank.d488.s2.e0	DDI-DrugBank.d488.s2.e1
DDI-DrugBank.d488.s2	false	DDI-DrugBank.d488.s2.e0	DDI-DrugBank.d488.s2.e2
DDI-DrugBank.d488.s2	false	DDI-DrugBank.d488.s2.e0	DDI-DrugBank.d488.s2.e3
DDI-DrugBank.d488.s2	false	DDI-DrugBank.d488.s2.e0	DDI-DrugBank.d488.s2.e4
DDI-DrugBank.d488.s2	false	DDI-DrugBank.d488.s2.e0	DDI-DrugBank.d488.s2.e5
DDI-DrugBank.d488.s2	false	DDI-DrugBank.d488.s2.e0	DDI-DrugBank.d488.s2.e6
DDI-DrugBank.d488.s2	false	DDI-DrugBank.d488.s2.e0	DDI-DrugBank.d488.s2.e7
DDI-DrugBank.d488.s2	false	DDI-DrugBank.d488.s2.e0	DDI-DrugBank.d488.s2.e8
DDI-DrugBank.d488.s2	false	DDI-DrugBank.d488.s2.e1	DDI-DrugBank.d488.s2.e2
DDI-DrugBank.d488.s2	false	DDI-DrugBank.d488.s2.e1	DDI-DrugBank.d488.s2.e3
DDI-DrugBank.d488.s3|a|The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.
DDI-DrugBank.d488.s3	28	34	heparin	drug	DDI-DrugBank.d488.s3.e0
DDI-DrugBank.d488.s3	77	92	antithrombin III	drug	DDI-DrugBank.d488.s3.e1
DDI-DrugBank.d488.s3	true	DDI-DrugBank.d488.s3.e0	DDI-DrugBank.d488.s3.e1
DDI-DrugBank.d488.s4|a|Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).
DDI-DrugBank.d488.s4	51	57	heparin	drug	DDI-DrugBank.d488.s4.e0
DDI-DrugBank.d488.s4	96	111	antithrombin III	drug	DDI-DrugBank.d488.s4.e1
DDI-DrugBank.d488.s4	true	DDI-DrugBank.d488.s4.e0	DDI-DrugBank.d488.s4.e1
DDI-DrugBank.d488.s5|a|b.
DDI-DrugBank.d488.s6|a|Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
DDI-DrugBank.d488.s6	17	23	Heparin	drug	DDI-DrugBank.d488.s6.e0
DDI-DrugBank.d488.s6	33	41	Digitalis	group	DDI-DrugBank.d488.s6.e1
DDI-DrugBank.d488.s6	44	56	tetracyclines	group	DDI-DrugBank.d488.s6.e2
DDI-DrugBank.d488.s6	59	66	nicotine	drug	DDI-DrugBank.d488.s6.e3
DDI-DrugBank.d488.s6	72	85	antihistamines	group	DDI-DrugBank.d488.s6.e4
DDI-DrugBank.d488.s6	140	153	heparin sodium	drug	DDI-DrugBank.d488.s6.e5
DDI-DrugBank.d488.s6	false	DDI-DrugBank.d488.s6.e0	DDI-DrugBank.d488.s6.e1
DDI-DrugBank.d488.s6	false	DDI-DrugBank.d488.s6.e0	DDI-DrugBank.d488.s6.e2
DDI-DrugBank.d488.s6	false	DDI-DrugBank.d488.s6.e0	DDI-DrugBank.d488.s6.e3
DDI-DrugBank.d488.s6	false	DDI-DrugBank.d488.s6.e0	DDI-DrugBank.d488.s6.e4
DDI-DrugBank.d488.s6	false	DDI-DrugBank.d488.s6.e0	DDI-DrugBank.d488.s6.e5
DDI-DrugBank.d488.s6	false	DDI-DrugBank.d488.s6.e1	DDI-DrugBank.d488.s6.e2
DDI-DrugBank.d488.s6	false	DDI-DrugBank.d488.s6.e1	DDI-DrugBank.d488.s6.e3
DDI-DrugBank.d488.s6	false	DDI-DrugBank.d488.s6.e1	DDI-DrugBank.d488.s6.e4
DDI-DrugBank.d488.s6	true	DDI-DrugBank.d488.s6.e1	DDI-DrugBank.d488.s6.e5
DDI-DrugBank.d488.s6	false	DDI-DrugBank.d488.s6.e2	DDI-DrugBank.d488.s6.e3
DDI-DrugBank.d488.s7|a|Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.
DDI-DrugBank.d488.s7	0	13	Heparin Sodium	drug	DDI-DrugBank.d488.s7.e0
DDI-DrugBank.d488.s7	50	60	doxorubicin	drug	DDI-DrugBank.d488.s7.e1
DDI-DrugBank.d488.s7	63	72	droperidol	drug	DDI-DrugBank.d488.s7.e2
DDI-DrugBank.d488.s7	75	87	ciprofloxacin	drug	DDI-DrugBank.d488.s7.e3
DDI-DrugBank.d488.s7	93	104	mitoxantrone	drug	DDI-DrugBank.d488.s7.e4
DDI-DrugBank.d488.s7	173	179	heparin	drug	DDI-DrugBank.d488.s7.e5
DDI-DrugBank.d488.s7	false	DDI-DrugBank.d488.s7.e0	DDI-DrugBank.d488.s7.e1
DDI-DrugBank.d488.s7	false	DDI-DrugBank.d488.s7.e0	DDI-DrugBank.d488.s7.e2
DDI-DrugBank.d488.s7	false	DDI-DrugBank.d488.s7.e0	DDI-DrugBank.d488.s7.e3
DDI-DrugBank.d488.s7	false	DDI-DrugBank.d488.s7.e0	DDI-DrugBank.d488.s7.e4
DDI-DrugBank.d488.s7	false	DDI-DrugBank.d488.s7.e0	DDI-DrugBank.d488.s7.e5
DDI-DrugBank.d488.s7	false	DDI-DrugBank.d488.s7.e1	DDI-DrugBank.d488.s7.e2
DDI-DrugBank.d488.s7	false	DDI-DrugBank.d488.s7.e1	DDI-DrugBank.d488.s7.e3
DDI-DrugBank.d488.s7	false	DDI-DrugBank.d488.s7.e1	DDI-DrugBank.d488.s7.e4
DDI-DrugBank.d488.s7	false	DDI-DrugBank.d488.s7.e1	DDI-DrugBank.d488.s7.e5
DDI-DrugBank.d488.s7	false	DDI-DrugBank.d488.s7.e2	DDI-DrugBank.d488.s7.e3
DDI-DrugBank.d488.s8|a|Drug/ Laboratory Tests Interactions Hyperaminotransferasemia: Significant elevations of aminotransferase (SGOT [S-AST] and SGPT [S-ALT]) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin sodium.
DDI-DrugBank.d488.s8	232	245	heparin sodium	drug	DDI-DrugBank.d488.s8.e0
DDI-DrugBank.d488.s9|a|Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease and pulmonary emboli, rises that might be caused by drugs (heparin sodium) should be interpreted with caution.
DDI-DrugBank.d488.s9	181	194	heparin sodium	drug	DDI-DrugBank.d488.s9.e0
DDI-DrugBank.d514.s0|a|Opioids are strong central nervous system depressants, but regular users develop physiological tolerance allowing gradually increased dosages.
DDI-DrugBank.d514.s0	0	6	Opioids	group	DDI-DrugBank.d514.s0.e0
DDI-DrugBank.d514.s0	19	52	central nervous system depressants	group	DDI-DrugBank.d514.s0.e1
DDI-DrugBank.d514.s0	false	DDI-DrugBank.d514.s0.e0	DDI-DrugBank.d514.s0.e1
DDI-DrugBank.d514.s1|a|In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.
DDI-DrugBank.d514.s1	26	59	central nervous system depressants	group	DDI-DrugBank.d514.s1.e0
DDI-DrugBank.d514.s1	62	67	heroin	drug_n	DDI-DrugBank.d514.s1.e1
DDI-DrugBank.d514.s1	true	DDI-DrugBank.d514.s1.e0	DDI-DrugBank.d514.s1.e1
DDI-DrugBank.d514.s2|a|Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
DDI-DrugBank.d514.s2	22	27	heroin	drug_n	DDI-DrugBank.d514.s2.e0
DDI-DrugBank.d514.s2	81	114	central nervous system depressants	group	DDI-DrugBank.d514.s2.e1
DDI-DrugBank.d514.s2	127	133	alcohol	drug	DDI-DrugBank.d514.s2.e2
DDI-DrugBank.d514.s2	136	150	benzodiazepines	group	DDI-DrugBank.d514.s2.e3
DDI-DrugBank.d514.s2	160	167	diazepam	drug	DDI-DrugBank.d514.s2.e4
DDI-DrugBank.d514.s2	170	175	Valium	brand	DDI-DrugBank.d514.s2.e5
DDI-DrugBank.d514.s2	204	212	methadone	drug	DDI-DrugBank.d514.s2.e6
DDI-DrugBank.d514.s2	true	DDI-DrugBank.d514.s2.e0	DDI-DrugBank.d514.s2.e1
DDI-DrugBank.d514.s2	true	DDI-DrugBank.d514.s2.e0	DDI-DrugBank.d514.s2.e2
DDI-DrugBank.d514.s2	true	DDI-DrugBank.d514.s2.e0	DDI-DrugBank.d514.s2.e3
DDI-DrugBank.d514.s2	true	DDI-DrugBank.d514.s2.e0	DDI-DrugBank.d514.s2.e4
DDI-DrugBank.d514.s2	true	DDI-DrugBank.d514.s2.e0	DDI-DrugBank.d514.s2.e5
DDI-DrugBank.d514.s2	true	DDI-DrugBank.d514.s2.e0	DDI-DrugBank.d514.s2.e6
DDI-DrugBank.d514.s2	false	DDI-DrugBank.d514.s2.e1	DDI-DrugBank.d514.s2.e2
DDI-DrugBank.d514.s2	false	DDI-DrugBank.d514.s2.e1	DDI-DrugBank.d514.s2.e3
DDI-DrugBank.d514.s2	false	DDI-DrugBank.d514.s2.e1	DDI-DrugBank.d514.s2.e4
DDI-DrugBank.d514.s2	false	DDI-DrugBank.d514.s2.e1	DDI-DrugBank.d514.s2.e5
DDI-DrugBank.d514.s3|a|Ironically, benzodiazepines are often used in the treatment of heroin addiction while they cause much more severe withdrawal symptoms.
DDI-DrugBank.d514.s3	12	26	benzodiazepines	group	DDI-DrugBank.d514.s3.e0
DDI-DrugBank.d514.s3	63	68	heroin	drug	DDI-DrugBank.d514.s3.e1
DDI-DrugBank.d514.s3	false	DDI-DrugBank.d514.s3.e0	DDI-DrugBank.d514.s3.e1
DDI-DrugBank.d514.s4|a|Cocaine sometimes proves to be fatal when used in combination with heroin.
DDI-DrugBank.d514.s4	0	6	Cocaine	drug	DDI-DrugBank.d514.s4.e0
DDI-DrugBank.d514.s4	67	72	heroin	drug_n	DDI-DrugBank.d514.s4.e1
DDI-DrugBank.d514.s4	true	DDI-DrugBank.d514.s4.e0	DDI-DrugBank.d514.s4.e1
DDI-DrugBank.d421.s0|a|No information available.
DDI-DrugBank.d457.s0|a|Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d457.s0	0	11	Barbiturates	group	DDI-DrugBank.d457.s0.e0
DDI-DrugBank.d457.s0	52	65	contraceptives	group	DDI-DrugBank.d457.s0.e1
DDI-DrugBank.d457.s0	76	86	antibiotics	group	DDI-DrugBank.d457.s0.e2
DDI-DrugBank.d457.s0	89	97	quinidine	drug	DDI-DrugBank.d457.s0.e3
DDI-DrugBank.d457.s0	100	111	theophylline	drug	DDI-DrugBank.d457.s0.e4
DDI-DrugBank.d457.s0	114	128	corticosteroids	group	DDI-DrugBank.d457.s0.e5
DDI-DrugBank.d457.s0	131	144	anticoagulants	group	DDI-DrugBank.d457.s0.e6
DDI-DrugBank.d457.s0	151	163	beta blockers	group	DDI-DrugBank.d457.s0.e7
DDI-DrugBank.d457.s0	true	DDI-DrugBank.d457.s0.e0	DDI-DrugBank.d457.s0.e1
DDI-DrugBank.d457.s0	true	DDI-DrugBank.d457.s0.e0	DDI-DrugBank.d457.s0.e2
DDI-DrugBank.d457.s0	true	DDI-DrugBank.d457.s0.e0	DDI-DrugBank.d457.s0.e3
DDI-DrugBank.d457.s0	true	DDI-DrugBank.d457.s0.e0	DDI-DrugBank.d457.s0.e4
DDI-DrugBank.d457.s0	true	DDI-DrugBank.d457.s0.e0	DDI-DrugBank.d457.s0.e5
DDI-DrugBank.d457.s0	true	DDI-DrugBank.d457.s0.e0	DDI-DrugBank.d457.s0.e6
DDI-DrugBank.d457.s0	true	DDI-DrugBank.d457.s0.e0	DDI-DrugBank.d457.s0.e7
DDI-DrugBank.d457.s0	false	DDI-DrugBank.d457.s0.e1	DDI-DrugBank.d457.s0.e2
DDI-DrugBank.d457.s0	false	DDI-DrugBank.d457.s0.e1	DDI-DrugBank.d457.s0.e3
DDI-DrugBank.d457.s0	false	DDI-DrugBank.d457.s0.e1	DDI-DrugBank.d457.s0.e4
DDI-DrugBank.d31.s0|a|MAO inhibitors should be used with caution in patients receiving hydralazine.
DDI-DrugBank.d31.s0	0	13	MAO inhibitors	group	DDI-DrugBank.d31.s0.e0
DDI-DrugBank.d31.s0	65	75	hydralazine	drug	DDI-DrugBank.d31.s0.e1
DDI-DrugBank.d31.s0	true	DDI-DrugBank.d31.s0.e0	DDI-DrugBank.d31.s0.e1
DDI-DrugBank.d31.s1|a|When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.
DDI-DrugBank.d31.s1	27	48	antihypertensive drugs	group	DDI-DrugBank.d31.s1.e0
DDI-DrugBank.d31.s1	59	67	diazoxide	drug	DDI-DrugBank.d31.s1.e1
DDI-DrugBank.d31.s1	99	109	hydralazine	drug	DDI-DrugBank.d31.s1.e2
DDI-DrugBank.d31.s1	true	DDI-DrugBank.d31.s1.e0	DDI-DrugBank.d31.s1.e1
DDI-DrugBank.d31.s1	true	DDI-DrugBank.d31.s1.e0	DDI-DrugBank.d31.s1.e2
DDI-DrugBank.d31.s1	false	DDI-DrugBank.d31.s1.e1	DDI-DrugBank.d31.s1.e2
DDI-DrugBank.d31.s2|a|Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.
DDI-DrugBank.d31.s2	45	53	diazoxide	drug	DDI-DrugBank.d31.s2.e0
DDI-DrugBank.d31.s2	69	79	hydralazine	drug	DDI-DrugBank.d31.s2.e1
DDI-DrugBank.d31.s2	true	DDI-DrugBank.d31.s2.e0	DDI-DrugBank.d31.s2.e1
DDI-DrugBank.d31.s3|a|Beta-blockers (metoprolol, propranolol) serum concentrations and pharmacologic effects may be increased.
DDI-DrugBank.d31.s3	0	12	Beta-blockers	group	DDI-DrugBank.d31.s3.e0
DDI-DrugBank.d31.s3	15	24	metoprolol	drug	DDI-DrugBank.d31.s3.e1
DDI-DrugBank.d31.s3	27	37	propranolol	drug	DDI-DrugBank.d31.s3.e2
DDI-DrugBank.d31.s3	false	DDI-DrugBank.d31.s3.e0	DDI-DrugBank.d31.s3.e1
DDI-DrugBank.d31.s3	false	DDI-DrugBank.d31.s3.e0	DDI-DrugBank.d31.s3.e2
DDI-DrugBank.d31.s3	false	DDI-DrugBank.d31.s3.e1	DDI-DrugBank.d31.s3.e2
DDI-DrugBank.d31.s4|a|Monitor cardiovascular status.
DDI-DrugBank.d31.s5|a|Propranolol increases hydralazines serum concentrations.
DDI-DrugBank.d31.s5	0	10	Propranolol	drug	DDI-DrugBank.d31.s5.e0
DDI-DrugBank.d31.s5	22	32	hydralazine	drug	DDI-DrugBank.d31.s5.e1
DDI-DrugBank.d31.s5	true	DDI-DrugBank.d31.s5.e0	DDI-DrugBank.d31.s5.e1
DDI-DrugBank.d31.s6|a|Acebutolol, atenolol, and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.
DDI-DrugBank.d31.s6	0	9	Acebutolol	drug	DDI-DrugBank.d31.s6.e0
DDI-DrugBank.d31.s6	12	19	atenolol	drug	DDI-DrugBank.d31.s6.e1
DDI-DrugBank.d31.s6	26	32	nadolol	drug	DDI-DrugBank.d31.s6.e2
DDI-DrugBank.d31.s6	false	DDI-DrugBank.d31.s6.e0	DDI-DrugBank.d31.s6.e1
DDI-DrugBank.d31.s6	false	DDI-DrugBank.d31.s6.e0	DDI-DrugBank.d31.s6.e2
DDI-DrugBank.d31.s6	false	DDI-DrugBank.d31.s6.e1	DDI-DrugBank.d31.s6.e2
DDI-DrugBank.d31.s7|a|NSAIDs may decrease the hemodynamic effects of hydralazine;
DDI-DrugBank.d31.s7	0	5	NSAIDs	group	DDI-DrugBank.d31.s7.e0
DDI-DrugBank.d31.s7	47	57	hydralazine	drug	DDI-DrugBank.d31.s7.e1
DDI-DrugBank.d31.s7	true	DDI-DrugBank.d31.s7.e0	DDI-DrugBank.d31.s7.e1
DDI-DrugBank.d31.s8|a|avoid use if possible or closely monitor cardiovascular status at the end of drug interactions
DDI-DrugBank.d162.s0|a|When given concurrently the following drugs may interact with thiazide diuretics.
DDI-DrugBank.d162.s0	62	79	thiazide diuretics	group	DDI-DrugBank.d162.s0.e0
DDI-DrugBank.d162.s1|a|Alcohol, barbiturates, or narcotics: potentiation of orthostatic hypotension may occur.
DDI-DrugBank.d162.s1	0	6	Alcohol	drug	DDI-DrugBank.d162.s1.e0
DDI-DrugBank.d162.s1	9	20	barbiturates	group	DDI-DrugBank.d162.s1.e1
DDI-DrugBank.d162.s1	26	34	narcotics	group	DDI-DrugBank.d162.s1.e2
DDI-DrugBank.d162.s1	false	DDI-DrugBank.d162.s1.e0	DDI-DrugBank.d162.s1.e1
DDI-DrugBank.d162.s1	false	DDI-DrugBank.d162.s1.e0	DDI-DrugBank.d162.s1.e2
DDI-DrugBank.d162.s1	false	DDI-DrugBank.d162.s1.e1	DDI-DrugBank.d162.s1.e2
DDI-DrugBank.d162.s2|a|Antidiabetic drugs: (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required.
DDI-DrugBank.d162.s2	0	17	Antidiabetic drugs	group	DDI-DrugBank.d162.s2.e0
DDI-DrugBank.d162.s2	37	43	insulin	drug	DDI-DrugBank.d162.s2.e1
DDI-DrugBank.d162.s2	73	89	antidiabetic drug	group	DDI-DrugBank.d162.s2.e2
DDI-DrugBank.d162.s2	false	DDI-DrugBank.d162.s2.e0	DDI-DrugBank.d162.s2.e1
DDI-DrugBank.d162.s2	false	DDI-DrugBank.d162.s2.e0	DDI-DrugBank.d162.s2.e2
DDI-DrugBank.d162.s2	false	DDI-DrugBank.d162.s2.e1	DDI-DrugBank.d162.s2.e2
DDI-DrugBank.d162.s3|a|Other antihypertensive drugs: additive effect or potentiation.
DDI-DrugBank.d162.s3	6	27	antihypertensive drugs	group	DDI-DrugBank.d162.s3.e0
DDI-DrugBank.d162.s4|a|Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
DDI-DrugBank.d162.s4	0	13	Cholestyramine	drug	DDI-DrugBank.d162.s4.e0
DDI-DrugBank.d162.s4	19	28	colestipol	drug	DDI-DrugBank.d162.s4.e1
DDI-DrugBank.d162.s4	30	35	resins	group	DDI-DrugBank.d162.s4.e2
DDI-DrugBank.d162.s4	52	70	hydrochlorothiazide	drug	DDI-DrugBank.d162.s4.e3
DDI-DrugBank.d162.s4	103	125	anionic exchange resins	group	DDI-DrugBank.d162.s4.e4
DDI-DrugBank.d162.s4	false	DDI-DrugBank.d162.s4.e0	DDI-DrugBank.d162.s4.e1
DDI-DrugBank.d162.s4	false	DDI-DrugBank.d162.s4.e0	DDI-DrugBank.d162.s4.e2
DDI-DrugBank.d162.s4	false	DDI-DrugBank.d162.s4.e0	DDI-DrugBank.d162.s4.e3
DDI-DrugBank.d162.s4	false	DDI-DrugBank.d162.s4.e0	DDI-DrugBank.d162.s4.e4
DDI-DrugBank.d162.s4	false	DDI-DrugBank.d162.s4.e1	DDI-DrugBank.d162.s4.e2
DDI-DrugBank.d162.s4	false	DDI-DrugBank.d162.s4.e1	DDI-DrugBank.d162.s4.e3
DDI-DrugBank.d162.s4	false	DDI-DrugBank.d162.s4.e1	DDI-DrugBank.d162.s4.e4
DDI-DrugBank.d162.s4	false	DDI-DrugBank.d162.s4.e2	DDI-DrugBank.d162.s4.e3
DDI-DrugBank.d162.s4	false	DDI-DrugBank.d162.s4.e2	DDI-DrugBank.d162.s4.e4
DDI-DrugBank.d162.s4	true	DDI-DrugBank.d162.s4.e3	DDI-DrugBank.d162.s4.e4
DDI-DrugBank.d162.s5|a|Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
DDI-DrugBank.d162.s5	23	36	cholestyramine	drug	DDI-DrugBank.d162.s5.e0
DDI-DrugBank.d162.s5	41	50	colestipol	drug	DDI-DrugBank.d162.s5.e1
DDI-DrugBank.d162.s5	52	57	resins	group	DDI-DrugBank.d162.s5.e2
DDI-DrugBank.d162.s5	68	86	hydrochlorothiazide	drug	DDI-DrugBank.d162.s5.e3
DDI-DrugBank.d162.s5	false	DDI-DrugBank.d162.s5.e0	DDI-DrugBank.d162.s5.e1
DDI-DrugBank.d162.s5	false	DDI-DrugBank.d162.s5.e0	DDI-DrugBank.d162.s5.e2
DDI-DrugBank.d162.s5	true	DDI-DrugBank.d162.s5.e0	DDI-DrugBank.d162.s5.e3
DDI-DrugBank.d162.s5	false	DDI-DrugBank.d162.s5.e1	DDI-DrugBank.d162.s5.e2
DDI-DrugBank.d162.s5	true	DDI-DrugBank.d162.s5.e1	DDI-DrugBank.d162.s5.e3
DDI-DrugBank.d162.s5	false	DDI-DrugBank.d162.s5.e2	DDI-DrugBank.d162.s5.e3
DDI-DrugBank.d162.s6|a|Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.
DDI-DrugBank.d162.s6	0	14	Corticosteroids	group	DDI-DrugBank.d162.s6.e0
DDI-DrugBank.d162.s6	17	20	ACTH	drug	DDI-DrugBank.d162.s6.e1
DDI-DrugBank.d162.s6	false	DDI-DrugBank.d162.s6.e0	DDI-DrugBank.d162.s6.e1
DDI-DrugBank.d162.s7|a|Pressor amines (e.g., norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.
DDI-DrugBank.d162.s7	22	35	norepinephrine	drug	DDI-DrugBank.d162.s7.e0
DDI-DrugBank.d162.s8|a|Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the muscle relaxant.
DDI-DrugBank.d162.s8	0	24	Skeletal muscle relaxants	group	DDI-DrugBank.d162.s8.e0
DDI-DrugBank.d162.s8	50	61	tubocurarine	drug	DDI-DrugBank.d162.s8.e1
DDI-DrugBank.d162.s8	106	120	muscle relaxant	group	DDI-DrugBank.d162.s8.e2
DDI-DrugBank.d162.s8	false	DDI-DrugBank.d162.s8.e0	DDI-DrugBank.d162.s8.e1
DDI-DrugBank.d162.s8	false	DDI-DrugBank.d162.s8.e0	DDI-DrugBank.d162.s8.e2
DDI-DrugBank.d162.s8	false	DDI-DrugBank.d162.s8.e1	DDI-DrugBank.d162.s8.e2
DDI-DrugBank.d162.s9|a|Lithium: generally should not be given with diuretics.
DDI-DrugBank.d162.s9	0	6	Lithium	drug	DDI-DrugBank.d162.s9.e0
DDI-DrugBank.d162.s9	44	52	diuretics	group	DDI-DrugBank.d162.s9.e1
DDI-DrugBank.d162.s9	true	DDI-DrugBank.d162.s9.e0	DDI-DrugBank.d162.s9.e1
DDI-DrugBank.d162.s10|a|Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
DDI-DrugBank.d162.s10	0	14	Diuretic agents	group	DDI-DrugBank.d162.s10.e0
DDI-DrugBank.d162.s10	46	52	lithium	drug	DDI-DrugBank.d162.s10.e1
DDI-DrugBank.d162.s10	77	83	lithium	drug	DDI-DrugBank.d162.s10.e2
DDI-DrugBank.d162.s10	true	DDI-DrugBank.d162.s10.e0	DDI-DrugBank.d162.s10.e1
DDI-DrugBank.d162.s10	true	DDI-DrugBank.d162.s10.e0	DDI-DrugBank.d162.s10.e2
DDI-DrugBank.d162.s10	false	DDI-DrugBank.d162.s10.e1	DDI-DrugBank.d162.s10.e2
DDI-DrugBank.d162.s11|a|Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.
DDI-DrugBank.d162.s11	32	38	lithium	drug	DDI-DrugBank.d162.s11.e0
DDI-DrugBank.d162.s11	90	108	Hydrochlorothiazide	drug	DDI-DrugBank.d162.s11.e1
DDI-DrugBank.d162.s11	true	DDI-DrugBank.d162.s11.e0	DDI-DrugBank.d162.s11.e1
DDI-DrugBank.d162.s12|a|Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d162.s12	0	36	Non-steroidal Anti-inflammatory Drugs	group	DDI-DrugBank.d162.s12.e0
DDI-DrugBank.d162.s12	81	117	non-steroidal anti-inflammatory agent	group	DDI-DrugBank.d162.s12.e1
DDI-DrugBank.d162.s12	189	192	loop diuretics	group	DDI-DrugBank.d162.s12.e2
DDI-DrugBank.d162.s12	226	234	loop diuretics	group	DDI-DrugBank.d162.s12.e2
DDI-DrugBank.d162.s12	195	211	potassium-sparing diuretics	group	DDI-DrugBank.d162.s12.e3
DDI-DrugBank.d162.s12	226	234	potassium-sparing diuretics	group	DDI-DrugBank.d162.s12.e3
DDI-DrugBank.d162.s12	217	234	thiazide diuretics	group	DDI-DrugBank.d162.s12.e4
DDI-DrugBank.d162.s12	false	DDI-DrugBank.d162.s12.e0	DDI-DrugBank.d162.s12.e1
DDI-DrugBank.d162.s12	false	DDI-DrugBank.d162.s12.e0	DDI-DrugBank.d162.s12.e2
DDI-DrugBank.d162.s12	false	DDI-DrugBank.d162.s12.e0	DDI-DrugBank.d162.s12.e3
DDI-DrugBank.d162.s12	false	DDI-DrugBank.d162.s12.e0	DDI-DrugBank.d162.s12.e4
DDI-DrugBank.d162.s12	true	DDI-DrugBank.d162.s12.e1	DDI-DrugBank.d162.s12.e2
DDI-DrugBank.d162.s12	true	DDI-DrugBank.d162.s12.e1	DDI-DrugBank.d162.s12.e3
DDI-DrugBank.d162.s12	true	DDI-DrugBank.d162.s12.e1	DDI-DrugBank.d162.s12.e4
DDI-DrugBank.d162.s12	false	DDI-DrugBank.d162.s12.e2	DDI-DrugBank.d162.s12.e3
DDI-DrugBank.d162.s12	false	DDI-DrugBank.d162.s12.e2	DDI-DrugBank.d162.s12.e4
DDI-DrugBank.d162.s12	false	DDI-DrugBank.d162.s12.e3	DDI-DrugBank.d162.s12.e4
DDI-DrugBank.d162.s13|a|Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
DDI-DrugBank.d162.s13	16	34	Hydrochlorothiazide	drug	DDI-DrugBank.d162.s13.e0
DDI-DrugBank.d162.s13	40	77	non-steroidal anti-inflammatory agents	group	DDI-DrugBank.d162.s13.e1
DDI-DrugBank.d162.s13	184	191	diuretic	group	DDI-DrugBank.d162.s13.e2
DDI-DrugBank.d162.s13	true	DDI-DrugBank.d162.s13.e0	DDI-DrugBank.d162.s13.e1
DDI-DrugBank.d162.s13	false	DDI-DrugBank.d162.s13.e0	DDI-DrugBank.d162.s13.e2
DDI-DrugBank.d162.s13	false	DDI-DrugBank.d162.s13.e1	DDI-DrugBank.d162.s13.e2
DDI-DrugBank.d396.s0|a|Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
DDI-DrugBank.d396.s0	25	43	narcotic analgesics	group	DDI-DrugBank.d396.s0.e0
DDI-DrugBank.d396.s0	46	59	antipsychotics	group	DDI-DrugBank.d396.s0.e1
DDI-DrugBank.d396.s0	62	79	antianxiety agents	group	DDI-DrugBank.d396.s0.e2
DDI-DrugBank.d396.s0	91	105	CNS depressants	group	DDI-DrugBank.d396.s0.e3
DDI-DrugBank.d396.s0	118	124	alcohol	drug	DDI-DrugBank.d396.s0.e4
DDI-DrugBank.d396.s0	146	156	hydrocodone	drug	DDI-DrugBank.d396.s0.e5
DDI-DrugBank.d396.s0	162	174	acetaminophen	drug	DDI-DrugBank.d396.s0.e6
DDI-DrugBank.d396.s0	false	DDI-DrugBank.d396.s0.e0	DDI-DrugBank.d396.s0.e1
DDI-DrugBank.d396.s0	false	DDI-DrugBank.d396.s0.e0	DDI-DrugBank.d396.s0.e2
DDI-DrugBank.d396.s0	false	DDI-DrugBank.d396.s0.e0	DDI-DrugBank.d396.s0.e3
DDI-DrugBank.d396.s0	false	DDI-DrugBank.d396.s0.e0	DDI-DrugBank.d396.s0.e4
DDI-DrugBank.d396.s0	true	DDI-DrugBank.d396.s0.e0	DDI-DrugBank.d396.s0.e5
DDI-DrugBank.d396.s0	false	DDI-DrugBank.d396.s0.e0	DDI-DrugBank.d396.s0.e6
DDI-DrugBank.d396.s0	false	DDI-DrugBank.d396.s0.e1	DDI-DrugBank.d396.s0.e2
DDI-DrugBank.d396.s0	false	DDI-DrugBank.d396.s0.e1	DDI-DrugBank.d396.s0.e3
DDI-DrugBank.d396.s0	false	DDI-DrugBank.d396.s0.e1	DDI-DrugBank.d396.s0.e4
DDI-DrugBank.d396.s0	true	DDI-DrugBank.d396.s0.e1	DDI-DrugBank.d396.s0.e5
DDI-DrugBank.d396.s1|a|When combined therapy is contemplated, the dose of one or both agents should be reduced.
DDI-DrugBank.d396.s2|a|The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
DDI-DrugBank.d396.s2	11	24	MAO inhibitors	group	DDI-DrugBank.d396.s2.e0
DDI-DrugBank.d396.s2	29	53	tricyclic antidepressants	group	DDI-DrugBank.d396.s2.e1
DDI-DrugBank.d396.s2	60	70	hydrocodone	drug	DDI-DrugBank.d396.s2.e2
DDI-DrugBank.d396.s2	123	136	antidepressant	group	DDI-DrugBank.d396.s2.e3
DDI-DrugBank.d396.s2	141	151	hydrocodone	drug	DDI-DrugBank.d396.s2.e4
DDI-DrugBank.d396.s2	false	DDI-DrugBank.d396.s2.e0	DDI-DrugBank.d396.s2.e1
DDI-DrugBank.d396.s2	true	DDI-DrugBank.d396.s2.e0	DDI-DrugBank.d396.s2.e2
DDI-DrugBank.d396.s2	false	DDI-DrugBank.d396.s2.e0	DDI-DrugBank.d396.s2.e3
DDI-DrugBank.d396.s2	false	DDI-DrugBank.d396.s2.e0	DDI-DrugBank.d396.s2.e4
DDI-DrugBank.d396.s2	true	DDI-DrugBank.d396.s2.e1	DDI-DrugBank.d396.s2.e2
DDI-DrugBank.d396.s2	false	DDI-DrugBank.d396.s2.e1	DDI-DrugBank.d396.s2.e3
DDI-DrugBank.d396.s2	false	DDI-DrugBank.d396.s2.e1	DDI-DrugBank.d396.s2.e4
DDI-DrugBank.d396.s2	false	DDI-DrugBank.d396.s2.e2	DDI-DrugBank.d396.s2.e3
DDI-DrugBank.d396.s2	false	DDI-DrugBank.d396.s2.e2	DDI-DrugBank.d396.s2.e4
DDI-DrugBank.d396.s2	false	DDI-DrugBank.d396.s2.e3	DDI-DrugBank.d396.s2.e4
DDI-DrugBank.d396.s3|a|The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.
DDI-DrugBank.d396.s3	22	37	anticholinergics	group	DDI-DrugBank.d396.s3.e0
DDI-DrugBank.d396.s3	44	54	hydrocodone	drug	DDI-DrugBank.d396.s3.e1
DDI-DrugBank.d396.s3	true	DDI-DrugBank.d396.s3.e0	DDI-DrugBank.d396.s3.e1
DDI-DrugBank.d155.s0|a|No information available.
DDI-DrugBank.d17.s0|a|Anticoagulants, oral
DDI-DrugBank.d17.s0	0	13	Anticoagulants	group	DDI-DrugBank.d17.s0.e0
DDI-DrugBank.d17.s1|a|(Effects may be decreased when used concurrently with thiazide diuretics;
DDI-DrugBank.d17.s1	54	71	thiazide diuretics	group	DDI-DrugBank.d17.s1.e0
DDI-DrugBank.d17.s2|a|dosage adjustments may be necessary.)
DDI-DrugBank.d17.s3|a|Antigout medications
DDI-DrugBank.d17.s3	0	19	Antigout medications	group	DDI-DrugBank.d17.s3.e0
DDI-DrugBank.d17.s4|a|(Thiazide diuretics may raise the level of blood uric acid;
DDI-DrugBank.d17.s4	1	18	Thiazide diuretics	group	DDI-DrugBank.d17.s4.e0
DDI-DrugBank.d17.s5|a|dosage adjustment of antigout medications may be necessary to control hyperuricemia and gout.)
DDI-DrugBank.d17.s5	21	40	antigout medications	group	DDI-DrugBank.d17.s5.e0
DDI-DrugBank.d17.s6|a|Antihypertensive medications, other, especially diazoxide, or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery
DDI-DrugBank.d17.s6	0	27	Antihypertensive medications	group	DDI-DrugBank.d17.s6.e0
DDI-DrugBank.d17.s6	48	56	diazoxide	drug	DDI-DrugBank.d17.s6.e1
DDI-DrugBank.d17.s6	65	74	anesthetic	group	DDI-DrugBank.d17.s6.e2
DDI-DrugBank.d17.s6	117	141	skeletal-muscle relaxants	group	DDI-DrugBank.d17.s6.e3
DDI-DrugBank.d17.s6	false	DDI-DrugBank.d17.s6.e0	DDI-DrugBank.d17.s6.e1
DDI-DrugBank.d17.s6	false	DDI-DrugBank.d17.s6.e0	DDI-DrugBank.d17.s6.e2
DDI-DrugBank.d17.s6	false	DDI-DrugBank.d17.s6.e0	DDI-DrugBank.d17.s6.e3
DDI-DrugBank.d17.s6	false	DDI-DrugBank.d17.s6.e1	DDI-DrugBank.d17.s6.e2
DDI-DrugBank.d17.s6	false	DDI-DrugBank.d17.s6.e1	DDI-DrugBank.d17.s6.e3
DDI-DrugBank.d17.s6	false	DDI-DrugBank.d17.s6.e2	DDI-DrugBank.d17.s6.e3
DDI-DrugBank.d17.s7|a|(Effects may be potentiated when used concurrently with thiazide diuretics;
DDI-DrugBank.d17.s7	56	73	thiazide diuretics	group	DDI-DrugBank.d17.s7.e0
DDI-DrugBank.d17.s8|a|dosage adjustments may be necessary.)
DDI-DrugBank.d17.s9|a|Amphotericin B or Corticosteroids or Corticotropin (ACTH)
DDI-DrugBank.d17.s9	0	13	Amphotericin B	drug	DDI-DrugBank.d17.s9.e0
DDI-DrugBank.d17.s9	18	32	Corticosteroids	group	DDI-DrugBank.d17.s9.e1
DDI-DrugBank.d17.s9	37	49	Corticotropin	drug	DDI-DrugBank.d17.s9.e2
DDI-DrugBank.d17.s9	52	55	ACTH	drug	DDI-DrugBank.d17.s9.e3
DDI-DrugBank.d17.s9	false	DDI-DrugBank.d17.s9.e0	DDI-DrugBank.d17.s9.e1
DDI-DrugBank.d17.s9	false	DDI-DrugBank.d17.s9.e0	DDI-DrugBank.d17.s9.e2
DDI-DrugBank.d17.s9	false	DDI-DrugBank.d17.s9.e0	DDI-DrugBank.d17.s9.e3
DDI-DrugBank.d17.s9	false	DDI-DrugBank.d17.s9.e1	DDI-DrugBank.d17.s9.e2
DDI-DrugBank.d17.s9	false	DDI-DrugBank.d17.s9.e1	DDI-DrugBank.d17.s9.e3
DDI-DrugBank.d17.s9	false	DDI-DrugBank.d17.s9.e2	DDI-DrugBank.d17.s9.e3
DDI-DrugBank.d17.s10|a|(Concurrent use with thiazide diuretics may intensify electrolyte imbalance, particularly hypokalemia.)
DDI-DrugBank.d17.s10	21	38	thiazide diuretics	group	DDI-DrugBank.d17.s10.e0
DDI-DrugBank.d17.s11|a|Cardiac glycosides
DDI-DrugBank.d17.s11	0	17	Cardiac glycosides	group	DDI-DrugBank.d17.s11.e0
DDI-DrugBank.d17.s12|a|(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.)
DDI-DrugBank.d17.s12	21	38	thiazide diuretics	group	DDI-DrugBank.d17.s12.e0
DDI-DrugBank.d17.s12	71	79	digitalis	group	DDI-DrugBank.d17.s12.e1
DDI-DrugBank.d17.s12	true	DDI-DrugBank.d17.s12.e0	DDI-DrugBank.d17.s12.e1
DDI-DrugBank.d17.s13|a|Colestipol
DDI-DrugBank.d17.s13	0	9	Colestipol	drug	DDI-DrugBank.d17.s13.e0
DDI-DrugBank.d17.s14|a|(May inhibit gastrointestinal absorption of the thiazide diuretics;
DDI-DrugBank.d17.s14	48	65	thiazide diuretics	group	DDI-DrugBank.d17.s14.e0
DDI-DrugBank.d17.s15|a|administration 1 hour before or 4 hours after colestipol is recommended.)
DDI-DrugBank.d17.s15	46	55	colestipol	drug	DDI-DrugBank.d17.s15.e0
DDI-DrugBank.d17.s16|a|Hypoglycemics
DDI-DrugBank.d17.s16	0	12	Hypoglycemics	group	DDI-DrugBank.d17.s16.e0
DDI-DrugBank.d17.s17|a|(Thiazide diuretics may raise blood glucose levels;
DDI-DrugBank.d17.s17	1	18	Thiazide diuretics	group	DDI-DrugBank.d17.s17.e0
DDI-DrugBank.d17.s18|a|for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;
DDI-DrugBank.d17.s18	48	71	hypoglycemic medications	group	DDI-DrugBank.d17.s18.e0
DDI-DrugBank.d17.s18	107	123	thiazide diuretic	group	DDI-DrugBank.d17.s18.e1
DDI-DrugBank.d17.s18	true	DDI-DrugBank.d17.s18.e0	DDI-DrugBank.d17.s18.e1
DDI-DrugBank.d17.s19|a|insulin requirements may be increased, decreased, or unchanged.)
DDI-DrugBank.d17.s19	0	6	insulin	drug	DDI-DrugBank.d17.s19.e0
DDI-DrugBank.d17.s20|a|Lithium salts
DDI-DrugBank.d17.s20	0	6	Lithium	drug	DDI-DrugBank.d17.s20.e0
DDI-DrugBank.d17.s21|a|(Concurrent use with thiazide diuretics is not recommended, as they may provoke lithium toxicity because of reduced renal clearance.)
DDI-DrugBank.d17.s21	21	38	thiazide diuretics	group	DDI-DrugBank.d17.s21.e0
DDI-DrugBank.d17.s21	80	86	lithium	drug	DDI-DrugBank.d17.s21.e1
DDI-DrugBank.d17.s21	false	DDI-DrugBank.d17.s21.e0	DDI-DrugBank.d17.s21.e1
DDI-DrugBank.d17.s22|a|Methenamine
DDI-DrugBank.d17.s22	0	10	Methenamine	drug	DDI-DrugBank.d17.s22.e0
DDI-DrugBank.d17.s23|a|(Effectiveness may be decreased when used concurrently with thiazide diuretics because of alkalinization of the urine.)
DDI-DrugBank.d17.s23	60	77	thiazide diuretics	group	DDI-DrugBank.d17.s23.e0
DDI-DrugBank.d17.s24|a|Nonsteroidal anti-inflammatory agents
DDI-DrugBank.d17.s24	0	36	Nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d17.s24.e0
DDI-DrugBank.d17.s25|a|(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
DDI-DrugBank.d17.s25	23	55	steroidal anti-inflammatory agent	group	DDI-DrugBank.d17.s25.e0
DDI-DrugBank.d17.s25	127	130	loop diuretics	group	DDI-DrugBank.d17.s25.e1
DDI-DrugBank.d17.s25	165	173	loop diuretics	group	DDI-DrugBank.d17.s25.e1
DDI-DrugBank.d17.s25	133	149	potassium sparing diuretics	group	DDI-DrugBank.d17.s25.e2
DDI-DrugBank.d17.s25	165	173	potassium sparing diuretics	group	DDI-DrugBank.d17.s25.e2
DDI-DrugBank.d17.s25	156	173	thiazide diuretics	group	DDI-DrugBank.d17.s25.e3
DDI-DrugBank.d17.s25	true	DDI-DrugBank.d17.s25.e0	DDI-DrugBank.d17.s25.e1
DDI-DrugBank.d17.s25	true	DDI-DrugBank.d17.s25.e0	DDI-DrugBank.d17.s25.e2
DDI-DrugBank.d17.s25	true	DDI-DrugBank.d17.s25.e0	DDI-DrugBank.d17.s25.e3
DDI-DrugBank.d17.s25	false	DDI-DrugBank.d17.s25.e1	DDI-DrugBank.d17.s25.e2
DDI-DrugBank.d17.s25	false	DDI-DrugBank.d17.s25.e1	DDI-DrugBank.d17.s25.e3
DDI-DrugBank.d17.s25	false	DDI-DrugBank.d17.s25.e2	DDI-DrugBank.d17.s25.e3
DDI-DrugBank.d17.s26|a|Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)
DDI-DrugBank.d17.s26	16	33	hydroflumethiazide	drug	DDI-DrugBank.d17.s26.e0
DDI-DrugBank.d17.s26	39	75	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d17.s26.e1
DDI-DrugBank.d17.s26	182	189	diuretic	group	DDI-DrugBank.d17.s26.e2
DDI-DrugBank.d17.s26	true	DDI-DrugBank.d17.s26.e0	DDI-DrugBank.d17.s26.e1
DDI-DrugBank.d17.s26	false	DDI-DrugBank.d17.s26.e0	DDI-DrugBank.d17.s26.e2
DDI-DrugBank.d17.s26	false	DDI-DrugBank.d17.s26.e1	DDI-DrugBank.d17.s26.e2
DDI-DrugBank.d17.s27|a|Norepinephrine
DDI-DrugBank.d17.s27	0	13	Norepinephrine	drug	DDI-DrugBank.d17.s27.e0
DDI-DrugBank.d17.s28|a|(Thiazides may decrease arterial responsiveness to norepinephrine.
DDI-DrugBank.d17.s28	1	9	Thiazides	group	DDI-DrugBank.d17.s28.e0
DDI-DrugBank.d17.s28	51	64	norepinephrine	drug	DDI-DrugBank.d17.s28.e1
DDI-DrugBank.d17.s28	true	DDI-DrugBank.d17.s28.e0	DDI-DrugBank.d17.s28.e1
DDI-DrugBank.d17.s29|a|This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.)
DDI-DrugBank.d17.s30|a|Tubocurarine
DDI-DrugBank.d17.s30	0	11	Tubocurarine	drug	DDI-DrugBank.d17.s30.e0
DDI-DrugBank.d17.s31|a|(Thiazide drugs may increase the responsiveness to tubocurarine.)
DDI-DrugBank.d17.s31	1	14	Thiazide drugs	group	DDI-DrugBank.d17.s31.e0
DDI-DrugBank.d17.s31	51	62	tubocurarine	drug	DDI-DrugBank.d17.s31.e1
DDI-DrugBank.d17.s31	true	DDI-DrugBank.d17.s31.e0	DDI-DrugBank.d17.s31.e1
DDI-DrugBank.d17.s32|a|DIAGNOSTIC INTERFERENCE With expected physiologic effects: Blood and urine glucose levels (usually only in patients with a predisposition for glucose intolerance) and Serum bilirubin levels (by displacement from albumin binding) and Serum calcium levels (thiazide diuretics should be discontinued before parathyroid-function tests are carried out) and Serum uric acid levels (may be increased) Serum magnesium, potassium, and sodium levels (may be decreased;
DDI-DrugBank.d17.s32	255	272	thiazide diuretics	group	DDI-DrugBank.d17.s32.e0
DDI-DrugBank.d17.s33|a|serum magnesium levels may increase in uremic patients) Serum protein-bound iodine (PBI) levels (may be decreased) Thiazides should be discontinued before carrying out tests for parathyroid function.
DDI-DrugBank.d17.s33	115	123	Thiazides	group	DDI-DrugBank.d17.s33.e0
DDI-DrugBank.d26.s0|a|Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
DDI-DrugBank.d26.s0	25	42	narcotic analgesic	group	DDI-DrugBank.d26.s0.e0
DDI-DrugBank.d26.s0	54	64	anesthetics	group	DDI-DrugBank.d26.s0.e1
DDI-DrugBank.d26.s0	67	80	phenothiazines	group	DDI-DrugBank.d26.s0.e2
DDI-DrugBank.d26.s0	83	95	tranquilizers	group	DDI-DrugBank.d26.s0.e3
DDI-DrugBank.d26.s0	98	115	sedative-hypnotics	group	DDI-DrugBank.d26.s0.e4
DDI-DrugBank.d26.s0	118	142	tricyclic antidepressants	group	DDI-DrugBank.d26.s0.e5
DDI-DrugBank.d26.s0	153	167	CNS depressants	group	DDI-DrugBank.d26.s0.e6
DDI-DrugBank.d26.s0	180	186	alcohol	drug	DDI-DrugBank.d26.s0.e7
DDI-DrugBank.d26.s0	208	215	DILAUDID	brand	DDI-DrugBank.d26.s0.e8
DDI-DrugBank.d26.s0	false	DDI-DrugBank.d26.s0.e0	DDI-DrugBank.d26.s0.e1
DDI-DrugBank.d26.s0	false	DDI-DrugBank.d26.s0.e0	DDI-DrugBank.d26.s0.e2
DDI-DrugBank.d26.s0	false	DDI-DrugBank.d26.s0.e0	DDI-DrugBank.d26.s0.e3
DDI-DrugBank.d26.s0	false	DDI-DrugBank.d26.s0.e0	DDI-DrugBank.d26.s0.e4
DDI-DrugBank.d26.s0	false	DDI-DrugBank.d26.s0.e0	DDI-DrugBank.d26.s0.e5
DDI-DrugBank.d26.s0	false	DDI-DrugBank.d26.s0.e0	DDI-DrugBank.d26.s0.e6
DDI-DrugBank.d26.s0	false	DDI-DrugBank.d26.s0.e0	DDI-DrugBank.d26.s0.e7
DDI-DrugBank.d26.s0	true	DDI-DrugBank.d26.s0.e0	DDI-DrugBank.d26.s0.e8
DDI-DrugBank.d26.s0	false	DDI-DrugBank.d26.s0.e1	DDI-DrugBank.d26.s0.e2
DDI-DrugBank.d26.s0	false	DDI-DrugBank.d26.s0.e1	DDI-DrugBank.d26.s0.e3
DDI-DrugBank.d26.s1|a|When such combined therapy is contemplated, the dose of one or both agents should be reduced.
DDI-DrugBank.d418.s0|a|No formal drug interaction studies have been conducted with Cyanokit.
DDI-DrugBank.d418.s0	60	67	Cyanokit	brand	DDI-DrugBank.d418.s0.e0
DDI-DrugBank.d16.s0|a|Prospective studies on the potential for hydroxyurea to interact with other drugs have not been performed.
DDI-DrugBank.d16.s0	41	51	hydroxyurea	drug	DDI-DrugBank.d16.s0.e0
DDI-DrugBank.d16.s1|a|Concurrent use of hydroxyurea and other myelosuppressive agents or radiation therapy may increase the likelihood of bone marrow depression or other adverse events.
DDI-DrugBank.d16.s1	18	28	hydroxyurea	drug	DDI-DrugBank.d16.s1.e0
DDI-DrugBank.d16.s2|a|Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary
DDI-DrugBank.d16.s2	6	16	hydroxyurea	drug	DDI-DrugBank.d16.s2.e0
DDI-DrugBank.d16.s2	76	96	uricosuric medication	group	DDI-DrugBank.d16.s2.e1
DDI-DrugBank.d16.s2	true	DDI-DrugBank.d16.s2.e0	DDI-DrugBank.d16.s2.e1
DDI-DrugBank.d16.s3|a|.
DDI-DrugBank.d16.s4|a|
DDI-DrugBank.d308.s0|a|THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
DDI-DrugBank.d308.s0	27	37	HYDROXYZINE	drug	DDI-DrugBank.d308.s0.e0
DDI-DrugBank.d308.s0	100	133	CENTRAL NERVOUS SYSTEM DEPRESSANTS	group	DDI-DrugBank.d308.s0.e1
DDI-DrugBank.d308.s0	143	151	NARCOTICS	group	DDI-DrugBank.d308.s0.e2
DDI-DrugBank.d308.s0	154	176	NON-NARCOTIC ANALGESICS	group	DDI-DrugBank.d308.s0.e3
DDI-DrugBank.d308.s0	182	193	BARBITURATES	group	DDI-DrugBank.d308.s0.e4
DDI-DrugBank.d308.s0	true	DDI-DrugBank.d308.s0.e0	DDI-DrugBank.d308.s0.e1
DDI-DrugBank.d308.s0	true	DDI-DrugBank.d308.s0.e0	DDI-DrugBank.d308.s0.e2
DDI-DrugBank.d308.s0	true	DDI-DrugBank.d308.s0.e0	DDI-DrugBank.d308.s0.e3
DDI-DrugBank.d308.s0	true	DDI-DrugBank.d308.s0.e0	DDI-DrugBank.d308.s0.e4
DDI-DrugBank.d308.s0	false	DDI-DrugBank.d308.s0.e1	DDI-DrugBank.d308.s0.e2
DDI-DrugBank.d308.s0	false	DDI-DrugBank.d308.s0.e1	DDI-DrugBank.d308.s0.e3
DDI-DrugBank.d308.s0	false	DDI-DrugBank.d308.s0.e1	DDI-DrugBank.d308.s0.e4
DDI-DrugBank.d308.s0	false	DDI-DrugBank.d308.s0.e2	DDI-DrugBank.d308.s0.e3
DDI-DrugBank.d308.s0	false	DDI-DrugBank.d308.s0.e2	DDI-DrugBank.d308.s0.e4
DDI-DrugBank.d308.s0	false	DDI-DrugBank.d308.s0.e3	DDI-DrugBank.d308.s0.e4
DDI-DrugBank.d308.s1|a|Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.
DDI-DrugBank.d308.s1	15	48	central nervous system depressants	group	DDI-DrugBank.d308.s1.e0
DDI-DrugBank.d308.s1	86	96	hydroxyzine	drug	DDI-DrugBank.d308.s1.e1
DDI-DrugBank.d308.s1	true	DDI-DrugBank.d308.s1.e0	DDI-DrugBank.d308.s1.e1
DDI-DrugBank.d308.s2|a|Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking Atarax.
DDI-DrugBank.d308.s2	178	183	Atarax	brand	DDI-DrugBank.d308.s2.e0
DDI-DrugBank.d308.s3|a|Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased.
DDI-DrugBank.d308.s3	65	84	CNS depressant drugs	group	DDI-DrugBank.d308.s3.e0
DDI-DrugBank.d308.s3	120	126	alcohol	drug	DDI-DrugBank.d308.s3.e1
DDI-DrugBank.d308.s3	false	DDI-DrugBank.d308.s3.e0	DDI-DrugBank.d308.s3.e1
DDI-DrugBank.d142.s0|a|Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
DDI-DrugBank.d142.s0	76	81	LEVSIN	brand	DDI-DrugBank.d142.s0.e0
DDI-DrugBank.d142.s0	124	138	antimuscarinics	group	DDI-DrugBank.d142.s0.e1
DDI-DrugBank.d142.s0	141	150	amantadine	drug	DDI-DrugBank.d142.s0.e2
DDI-DrugBank.d142.s0	153	163	haloperidol	drug	DDI-DrugBank.d142.s0.e3
DDI-DrugBank.d142.s0	166	179	phenothiazines	group	DDI-DrugBank.d142.s0.e4
DDI-DrugBank.d142.s0	182	215	monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d142.s0.e5
DDI-DrugBank.d142.s0	218	242	tricyclic antidepressants	group	DDI-DrugBank.d142.s0.e6
DDI-DrugBank.d142.s0	252	265	antihistamines	group	DDI-DrugBank.d142.s0.e7
DDI-DrugBank.d142.s0	true	DDI-DrugBank.d142.s0.e0	DDI-DrugBank.d142.s0.e1
DDI-DrugBank.d142.s0	true	DDI-DrugBank.d142.s0.e0	DDI-DrugBank.d142.s0.e2
DDI-DrugBank.d142.s0	true	DDI-DrugBank.d142.s0.e0	DDI-DrugBank.d142.s0.e3
DDI-DrugBank.d142.s0	true	DDI-DrugBank.d142.s0.e0	DDI-DrugBank.d142.s0.e4
DDI-DrugBank.d142.s0	true	DDI-DrugBank.d142.s0.e0	DDI-DrugBank.d142.s0.e5
DDI-DrugBank.d142.s0	true	DDI-DrugBank.d142.s0.e0	DDI-DrugBank.d142.s0.e6
DDI-DrugBank.d142.s0	true	DDI-DrugBank.d142.s0.e0	DDI-DrugBank.d142.s0.e7
DDI-DrugBank.d142.s0	false	DDI-DrugBank.d142.s0.e1	DDI-DrugBank.d142.s0.e2
DDI-DrugBank.d142.s0	false	DDI-DrugBank.d142.s0.e1	DDI-DrugBank.d142.s0.e3
DDI-DrugBank.d142.s0	false	DDI-DrugBank.d142.s0.e1	DDI-DrugBank.d142.s0.e4
DDI-DrugBank.d142.s1|a|Antacids may interfere with the absorption of LEVSIN.
DDI-DrugBank.d142.s1	0	7	Antacids	group	DDI-DrugBank.d142.s1.e0
DDI-DrugBank.d142.s1	46	51	LEVSIN	brand	DDI-DrugBank.d142.s1.e1
DDI-DrugBank.d142.s1	true	DDI-DrugBank.d142.s1.e0	DDI-DrugBank.d142.s1.e1
DDI-DrugBank.d142.s2|a|Administer LEVSIN before meals;
DDI-DrugBank.d142.s2	11	16	LEVSIN	brand	DDI-DrugBank.d142.s2.e0
DDI-DrugBank.d142.s3|a|antacids after meals.
DDI-DrugBank.d142.s3	0	7	antacids	group	DDI-DrugBank.d142.s3.e0
DDI-DrugBank.d440.s0|a|Calcium Supplements/Antacids
DDI-DrugBank.d440.s0	0	6	Calcium	drug	DDI-DrugBank.d440.s0.e0
DDI-DrugBank.d440.s0	20	27	Antacids	group	DDI-DrugBank.d440.s0.e1
DDI-DrugBank.d440.s0	false	DDI-DrugBank.d440.s0.e0	DDI-DrugBank.d440.s0.e1
DDI-DrugBank.d440.s1|a|Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
DDI-DrugBank.d440.s1	20	26	calcium	drug	DDI-DrugBank.d440.s1.e0
DDI-DrugBank.d440.s1	67	74	aluminum	drug	DDI-DrugBank.d440.s1.e1
DDI-DrugBank.d440.s1	77	85	magnesium	drug	DDI-DrugBank.d440.s1.e2
DDI-DrugBank.d440.s1	88	91	iron	drug	DDI-DrugBank.d440.s1.e3
DDI-DrugBank.d440.s1	137	147	Ibandronate	drug	DDI-DrugBank.d440.s1.e4
DDI-DrugBank.d440.s1	false	DDI-DrugBank.d440.s1.e0	DDI-DrugBank.d440.s1.e1
DDI-DrugBank.d440.s1	false	DDI-DrugBank.d440.s1.e0	DDI-DrugBank.d440.s1.e2
DDI-DrugBank.d440.s1	false	DDI-DrugBank.d440.s1.e0	DDI-DrugBank.d440.s1.e3
DDI-DrugBank.d440.s1	true	DDI-DrugBank.d440.s1.e0	DDI-DrugBank.d440.s1.e4
DDI-DrugBank.d440.s1	false	DDI-DrugBank.d440.s1.e1	DDI-DrugBank.d440.s1.e2
DDI-DrugBank.d440.s1	false	DDI-DrugBank.d440.s1.e1	DDI-DrugBank.d440.s1.e3
DDI-DrugBank.d440.s1	true	DDI-DrugBank.d440.s1.e1	DDI-DrugBank.d440.s1.e4
DDI-DrugBank.d440.s1	false	DDI-DrugBank.d440.s1.e2	DDI-DrugBank.d440.s1.e3
DDI-DrugBank.d440.s1	true	DDI-DrugBank.d440.s1.e2	DDI-DrugBank.d440.s1.e4
DDI-DrugBank.d440.s1	true	DDI-DrugBank.d440.s1.e3	DDI-DrugBank.d440.s1.e4
DDI-DrugBank.d440.s2|a|Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).
DDI-DrugBank.d440.s2	0	10	Ibandronate	drug	DDI-DrugBank.d440.s2.e0
DDI-DrugBank.d440.s2	118	125	antacids	group	DDI-DrugBank.d440.s2.e1
DDI-DrugBank.d440.s2	143	150	vitamins	group	DDI-DrugBank.d440.s2.e2
DDI-DrugBank.d440.s2	true	DDI-DrugBank.d440.s2.e0	DDI-DrugBank.d440.s2.e1
DDI-DrugBank.d440.s2	true	DDI-DrugBank.d440.s2.e0	DDI-DrugBank.d440.s2.e2
DDI-DrugBank.d440.s2	false	DDI-DrugBank.d440.s2.e1	DDI-DrugBank.d440.s2.e2
DDI-DrugBank.d440.s3|a|H2 Blockers and Proton Pump Inhibitors (PPIs)
DDI-DrugBank.d440.s3	0	10	H2 Blockers	group	DDI-DrugBank.d440.s3.e0
DDI-DrugBank.d440.s3	16	37	Proton Pump Inhibitors	group	DDI-DrugBank.d440.s3.e1
DDI-DrugBank.d440.s3	40	43	PPIs	group	DDI-DrugBank.d440.s3.e2
DDI-DrugBank.d440.s3	false	DDI-DrugBank.d440.s3.e0	DDI-DrugBank.d440.s3.e1
DDI-DrugBank.d440.s3	false	DDI-DrugBank.d440.s3.e0	DDI-DrugBank.d440.s3.e2
DDI-DrugBank.d440.s3	false	DDI-DrugBank.d440.s3.e1	DDI-DrugBank.d440.s3.e2
DDI-DrugBank.d440.s4|a|Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs).
DDI-DrugBank.d440.s4	38	48	Ibandronate	drug	DDI-DrugBank.d440.s4.e0
DDI-DrugBank.d440.s4	136	146	H2 blockers	group	DDI-DrugBank.d440.s4.e1
DDI-DrugBank.d440.s4	152	155	PPIs	group	DDI-DrugBank.d440.s4.e2
DDI-DrugBank.d440.s4	false	DDI-DrugBank.d440.s4.e0	DDI-DrugBank.d440.s4.e1
DDI-DrugBank.d440.s4	false	DDI-DrugBank.d440.s4.e0	DDI-DrugBank.d440.s4.e2
DDI-DrugBank.d440.s4	false	DDI-DrugBank.d440.s4.e1	DDI-DrugBank.d440.s4.e2
DDI-DrugBank.d440.s5|a|Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate was similar to that in placebo-treated patients.
DDI-DrugBank.d440.s5	111	121	Ibandronate	drug	DDI-DrugBank.d440.s5.e0
DDI-DrugBank.d440.s6|a|Similarly, of over 1600 patients enrolled in a study comparing once-monthly with daily dosing regimens of ibandronate, 14% of patients used anti-peptic agents.
DDI-DrugBank.d440.s6	106	116	ibandronate	drug	DDI-DrugBank.d440.s6.e0
DDI-DrugBank.d440.s7|a|Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily.
DDI-DrugBank.d440.s7	111	121	Ibandronate	drug	DDI-DrugBank.d440.s7.e0
DDI-DrugBank.d440.s7	188	198	Ibandronate	drug	DDI-DrugBank.d440.s7.e1
DDI-DrugBank.d440.s7	false	DDI-DrugBank.d440.s7.e0	DDI-DrugBank.d440.s7.e1
DDI-DrugBank.d440.s8|a|Aspirin/Nonsteroidal Antiinflammatory Drugs (NSAIDs)
DDI-DrugBank.d440.s8	0	6	Aspirin	brand	DDI-DrugBank.d440.s8.e0
DDI-DrugBank.d440.s8	8	41	Nonsteroidal Antiinflammatory Drug	group	DDI-DrugBank.d440.s8.e1
DDI-DrugBank.d440.s8	45	50	NSAIDs	group	DDI-DrugBank.d440.s8.e2
DDI-DrugBank.d440.s8	false	DDI-DrugBank.d440.s8.e0	DDI-DrugBank.d440.s8.e1
DDI-DrugBank.d440.s8	false	DDI-DrugBank.d440.s8.e0	DDI-DrugBank.d440.s8.e2
DDI-DrugBank.d440.s8	false	DDI-DrugBank.d440.s8.e1	DDI-DrugBank.d440.s8.e2
DDI-DrugBank.d440.s9|a|In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients.
DDI-DrugBank.d440.s9	63	69	aspirin	brand	DDI-DrugBank.d440.s9.e0
DDI-DrugBank.d440.s9	75	110	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d440.s9.e1
DDI-DrugBank.d440.s9	false	DDI-DrugBank.d440.s9.e0	DDI-DrugBank.d440.s9.e1
DDI-DrugBank.d440.s10|a|Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).
DDI-DrugBank.d440.s10	6	12	aspirin	brand	DDI-DrugBank.d440.s10.e0
DDI-DrugBank.d440.s10	17	21	NSAID	group	DDI-DrugBank.d440.s10.e1
DDI-DrugBank.d440.s10	110	120	ibandronate	drug	DDI-DrugBank.d440.s10.e2
DDI-DrugBank.d440.s10	false	DDI-DrugBank.d440.s10.e0	DDI-DrugBank.d440.s10.e1
DDI-DrugBank.d440.s10	false	DDI-DrugBank.d440.s10.e0	DDI-DrugBank.d440.s10.e2
DDI-DrugBank.d440.s10	false	DDI-DrugBank.d440.s10.e1	DDI-DrugBank.d440.s10.e2
DDI-DrugBank.d440.s11|a|Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients.
DDI-DrugBank.d440.s11	51	57	aspirin	brand	DDI-DrugBank.d440.s11.e0
DDI-DrugBank.d440.s11	63	98	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d440.s11.e1
DDI-DrugBank.d440.s11	false	DDI-DrugBank.d440.s11.e0	DDI-DrugBank.d440.s11.e1
DDI-DrugBank.d440.s12|a|The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).
DDI-DrugBank.d440.s12	80	86	aspirin	brand	DDI-DrugBank.d440.s12.e0
DDI-DrugBank.d440.s12	91	96	NSAIDs	group	DDI-DrugBank.d440.s12.e1
DDI-DrugBank.d440.s12	129	139	ibandronate	drug	DDI-DrugBank.d440.s12.e2
DDI-DrugBank.d440.s12	false	DDI-DrugBank.d440.s12.e0	DDI-DrugBank.d440.s12.e1
DDI-DrugBank.d440.s12	false	DDI-DrugBank.d440.s12.e0	DDI-DrugBank.d440.s12.e2
DDI-DrugBank.d440.s12	false	DDI-DrugBank.d440.s12.e1	DDI-DrugBank.d440.s12.e2
DDI-DrugBank.d440.s13|a|However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
DDI-DrugBank.d440.s13	15	21	aspirin	brand	DDI-DrugBank.d440.s13.e0
DDI-DrugBank.d440.s13	24	29	NSAIDs	group	DDI-DrugBank.d440.s13.e1
DDI-DrugBank.d440.s13	36	50	bisphosphonates	group	DDI-DrugBank.d440.s13.e2
DDI-DrugBank.d440.s13	159	165	aspirin	brand	DDI-DrugBank.d440.s13.e3
DDI-DrugBank.d440.s13	170	175	NSAIDs	group	DDI-DrugBank.d440.s13.e4
DDI-DrugBank.d440.s13	182	192	Ibandronate	drug	DDI-DrugBank.d440.s13.e5
DDI-DrugBank.d440.s13	false	DDI-DrugBank.d440.s13.e0	DDI-DrugBank.d440.s13.e1
DDI-DrugBank.d440.s13	false	DDI-DrugBank.d440.s13.e0	DDI-DrugBank.d440.s13.e2
DDI-DrugBank.d440.s13	false	DDI-DrugBank.d440.s13.e0	DDI-DrugBank.d440.s13.e3
DDI-DrugBank.d440.s13	false	DDI-DrugBank.d440.s13.e0	DDI-DrugBank.d440.s13.e4
DDI-DrugBank.d440.s13	false	DDI-DrugBank.d440.s13.e0	DDI-DrugBank.d440.s13.e5
DDI-DrugBank.d440.s13	false	DDI-DrugBank.d440.s13.e1	DDI-DrugBank.d440.s13.e2
DDI-DrugBank.d440.s13	false	DDI-DrugBank.d440.s13.e1	DDI-DrugBank.d440.s13.e3
DDI-DrugBank.d440.s13	false	DDI-DrugBank.d440.s13.e1	DDI-DrugBank.d440.s13.e4
DDI-DrugBank.d440.s13	false	DDI-DrugBank.d440.s13.e1	DDI-DrugBank.d440.s13.e5
DDI-DrugBank.d440.s13	false	DDI-DrugBank.d440.s13.e2	DDI-DrugBank.d440.s13.e3
DDI-DrugBank.d440.s14|a|Drug/Laboratory Test Interactions
DDI-DrugBank.d440.s15|a|Bisphosphonates are known to interfere with the use of bone-imaging agents.
DDI-DrugBank.d440.s15	0	14	Bisphosphonates	group	DDI-DrugBank.d440.s15.e0
DDI-DrugBank.d440.s16|a|Specific studies with ibandronate have not been performed.
DDI-DrugBank.d440.s16	22	32	ibandronate	drug	DDI-DrugBank.d440.s16.e0
DDI-DrugBank.d408.s0|a|No formal drug interaction studies have been performed with ZEVALIN.
DDI-DrugBank.d408.s0	60	66	ZEVALIN	brand	DDI-DrugBank.d408.s0.e0
DDI-DrugBank.d408.s1|a|Due to the frequent occurrence of severe and prolonged thrombocytopenia, the potential benefits of medications which interfere with platelet function and/or anticoagulation should be weighed against the potential increased risks of bleeding and hemorrhage.
DDI-DrugBank.d408.s2|a|Patients receiving medications that interfere with platelet function or coagulation should have more frequent laboratory monitoring for thrombocytopenia.
DDI-DrugBank.d408.s3|a|In addition, the transfusion practices for such patients may need to be modified given the increased risk of bleeding.
DDI-DrugBank.d408.s4|a|Patients in clinical studies were prohibited from receiving growth factor treatment for 2 weeks prior to the ZEVALIN therapeutic regimen as well as for 2 weeks following completion of the regimen.
DDI-DrugBank.d408.s4	109	115	ZEVALIN	brand	DDI-DrugBank.d408.s4.e0
DDI-DrugBank.d415.s0|a|Coumarin-Type Anticoagulants: Several short-term controlled studies failed to wshow that ibuprofen significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants.
DDI-DrugBank.d415.s0	0	27	Coumarin-Type Anticoagulants	group	DDI-DrugBank.d415.s0.e0
DDI-DrugBank.d415.s0	89	97	ibuprofen	drug	DDI-DrugBank.d415.s0.e1
DDI-DrugBank.d415.s0	215	242	coumarin-type anticoagulants	group	DDI-DrugBank.d415.s0.e2
DDI-DrugBank.d415.s0	false	DDI-DrugBank.d415.s0.e0	DDI-DrugBank.d415.s0.e1
DDI-DrugBank.d415.s0	false	DDI-DrugBank.d415.s0.e0	DDI-DrugBank.d415.s0.e2
DDI-DrugBank.d415.s0	false	DDI-DrugBank.d415.s0.e1	DDI-DrugBank.d415.s0.e2
DDI-DrugBank.d415.s1|a|However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
DDI-DrugBank.d415.s1	49	57	ibuprofen	drug	DDI-DrugBank.d415.s1.e0
DDI-DrugBank.d415.s1	69	105	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d415.s1.e1
DDI-DrugBank.d415.s1	145	172	coumarin-type anticoagulants	group	DDI-DrugBank.d415.s1.e2
DDI-DrugBank.d415.s1	227	235	ibuprofen	drug	DDI-DrugBank.d415.s1.e3
DDI-DrugBank.d415.s1	252	265	anticoagulants	group	DDI-DrugBank.d415.s1.e4
DDI-DrugBank.d415.s1	false	DDI-DrugBank.d415.s1.e0	DDI-DrugBank.d415.s1.e1
DDI-DrugBank.d415.s1	true	DDI-DrugBank.d415.s1.e0	DDI-DrugBank.d415.s1.e2
DDI-DrugBank.d415.s1	false	DDI-DrugBank.d415.s1.e0	DDI-DrugBank.d415.s1.e3
DDI-DrugBank.d415.s1	false	DDI-DrugBank.d415.s1.e0	DDI-DrugBank.d415.s1.e4
DDI-DrugBank.d415.s1	true	DDI-DrugBank.d415.s1.e1	DDI-DrugBank.d415.s1.e2
DDI-DrugBank.d415.s1	false	DDI-DrugBank.d415.s1.e1	DDI-DrugBank.d415.s1.e3
DDI-DrugBank.d415.s1	false	DDI-DrugBank.d415.s1.e1	DDI-DrugBank.d415.s1.e4
DDI-DrugBank.d415.s1	false	DDI-DrugBank.d415.s1.e2	DDI-DrugBank.d415.s1.e3
DDI-DrugBank.d415.s1	false	DDI-DrugBank.d415.s1.e2	DDI-DrugBank.d415.s1.e4
DDI-DrugBank.d415.s1	true	DDI-DrugBank.d415.s1.e3	DDI-DrugBank.d415.s1.e4
DDI-DrugBank.d415.s2|a|Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
DDI-DrugBank.d415.s2	0	6	Aspirin	brand	DDI-DrugBank.d415.s2.e0
DDI-DrugBank.d415.s2	35	41	aspirin	brand	DDI-DrugBank.d415.s2.e1
DDI-DrugBank.d415.s2	54	90	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d415.s2.e2
DDI-DrugBank.d415.s2	103	111	ibuprofen	drug	DDI-DrugBank.d415.s2.e3
DDI-DrugBank.d415.s2	false	DDI-DrugBank.d415.s2.e0	DDI-DrugBank.d415.s2.e1
DDI-DrugBank.d415.s2	false	DDI-DrugBank.d415.s2.e0	DDI-DrugBank.d415.s2.e2
DDI-DrugBank.d415.s2	false	DDI-DrugBank.d415.s2.e0	DDI-DrugBank.d415.s2.e3
DDI-DrugBank.d415.s2	true	DDI-DrugBank.d415.s2.e1	DDI-DrugBank.d415.s2.e2
DDI-DrugBank.d415.s2	true	DDI-DrugBank.d415.s2.e1	DDI-DrugBank.d415.s2.e3
DDI-DrugBank.d415.s2	false	DDI-DrugBank.d415.s2.e2	DDI-DrugBank.d415.s2.e3
DDI-DrugBank.d415.s3|a|Single dose bioavailability studies in normal volunteers have failed to wshow an effect of aspirin on ibuprofen blood levels.
DDI-DrugBank.d415.s3	91	97	aspirin	brand	DDI-DrugBank.d415.s3.e0
DDI-DrugBank.d415.s3	102	110	ibuprofen	drug	DDI-DrugBank.d415.s3.e1
DDI-DrugBank.d415.s3	false	DDI-DrugBank.d415.s3.e0	DDI-DrugBank.d415.s3.e1
DDI-DrugBank.d415.s4|a|Correlative clinical studies have not been performed.
DDI-DrugBank.d415.s5|a|Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
DDI-DrugBank.d415.s5	0	11	Methotrexate	drug	DDI-DrugBank.d415.s5.e0
DDI-DrugBank.d415.s5	14	22	Ibuprofen	drug	DDI-DrugBank.d415.s5.e1
DDI-DrugBank.d415.s5	42	77	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d415.s5.e2
DDI-DrugBank.d415.s5	122	133	methotrexate	drug	DDI-DrugBank.d415.s5.e3
DDI-DrugBank.d415.s5	false	DDI-DrugBank.d415.s5.e0	DDI-DrugBank.d415.s5.e1
DDI-DrugBank.d415.s5	false	DDI-DrugBank.d415.s5.e0	DDI-DrugBank.d415.s5.e2
DDI-DrugBank.d415.s5	false	DDI-DrugBank.d415.s5.e0	DDI-DrugBank.d415.s5.e3
DDI-DrugBank.d415.s5	false	DDI-DrugBank.d415.s5.e1	DDI-DrugBank.d415.s5.e2
DDI-DrugBank.d415.s5	true	DDI-DrugBank.d415.s5.e1	DDI-DrugBank.d415.s5.e3
DDI-DrugBank.d415.s5	true	DDI-DrugBank.d415.s5.e2	DDI-DrugBank.d415.s5.e3
DDI-DrugBank.d415.s6|a|This may indicate that ibuprofen could enhance the toxicity of methotrexate.
DDI-DrugBank.d415.s6	23	31	ibuprofen	drug	DDI-DrugBank.d415.s6.e0
DDI-DrugBank.d415.s6	63	74	methotrexate	drug	DDI-DrugBank.d415.s6.e1
DDI-DrugBank.d415.s6	true	DDI-DrugBank.d415.s6.e0	DDI-DrugBank.d415.s6.e1
DDI-DrugBank.d415.s7|a|Caution should be used if ibuprofen is administered concomitantly with methotrexate.
DDI-DrugBank.d415.s7	26	34	ibuprofen	drug	DDI-DrugBank.d415.s7.e0
DDI-DrugBank.d415.s7	71	82	methotrexate	drug	DDI-DrugBank.d415.s7.e1
DDI-DrugBank.d415.s7	true	DDI-DrugBank.d415.s7.e0	DDI-DrugBank.d415.s7.e1
DDI-DrugBank.d415.s8|a|H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.
DDI-DrugBank.d415.s8	72	81	cimetidine	drug	DDI-DrugBank.d415.s8.e0
DDI-DrugBank.d415.s8	86	95	ranitidine	drug	DDI-DrugBank.d415.s8.e1
DDI-DrugBank.d415.s8	102	110	ibuprofen	drug	DDI-DrugBank.d415.s8.e2
DDI-DrugBank.d415.s8	141	149	ibuprofen	drug	DDI-DrugBank.d415.s8.e3
DDI-DrugBank.d415.s8	false	DDI-DrugBank.d415.s8.e0	DDI-DrugBank.d415.s8.e1
DDI-DrugBank.d415.s8	false	DDI-DrugBank.d415.s8.e0	DDI-DrugBank.d415.s8.e2
DDI-DrugBank.d415.s8	false	DDI-DrugBank.d415.s8.e0	DDI-DrugBank.d415.s8.e3
DDI-DrugBank.d415.s8	false	DDI-DrugBank.d415.s8.e1	DDI-DrugBank.d415.s8.e2
DDI-DrugBank.d415.s8	false	DDI-DrugBank.d415.s8.e1	DDI-DrugBank.d415.s8.e3
DDI-DrugBank.d415.s8	false	DDI-DrugBank.d415.s8.e2	DDI-DrugBank.d415.s8.e3
DDI-DrugBank.d415.s9|a|Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d415.s9	0	9	Furosemide	drug	DDI-DrugBank.d415.s9.e0
DDI-DrugBank.d415.s9	78	86	ibuprofen	drug	DDI-DrugBank.d415.s9.e1
DDI-DrugBank.d415.s9	125	134	furosemide	drug	DDI-DrugBank.d415.s9.e2
DDI-DrugBank.d415.s9	140	148	thiazides	group	DDI-DrugBank.d415.s9.e3
DDI-DrugBank.d415.s9	false	DDI-DrugBank.d415.s9.e0	DDI-DrugBank.d415.s9.e1
DDI-DrugBank.d415.s9	false	DDI-DrugBank.d415.s9.e0	DDI-DrugBank.d415.s9.e2
DDI-DrugBank.d415.s9	false	DDI-DrugBank.d415.s9.e0	DDI-DrugBank.d415.s9.e3
DDI-DrugBank.d415.s9	true	DDI-DrugBank.d415.s9.e1	DDI-DrugBank.d415.s9.e2
DDI-DrugBank.d415.s9	true	DDI-DrugBank.d415.s9.e1	DDI-DrugBank.d415.s9.e3
DDI-DrugBank.d415.s9	false	DDI-DrugBank.d415.s9.e2	DDI-DrugBank.d415.s9.e3
DDI-DrugBank.d415.s10|a|This response has been attributed to inhibition of renal prostaglandin synthesis.
DDI-DrugBank.d415.s11|a|During concomitant therapy with ibuprofen, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
DDI-DrugBank.d415.s11	32	40	ibuprofen	drug	DDI-DrugBank.d415.s11.e0
DDI-DrugBank.d415.s11	131	138	diuretic	group	DDI-DrugBank.d415.s11.e1
DDI-DrugBank.d415.s11	false	DDI-DrugBank.d415.s11.e0	DDI-DrugBank.d415.s11.e1
DDI-DrugBank.d415.s12|a|Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
DDI-DrugBank.d415.s12	0	6	Lithium	drug	DDI-DrugBank.d415.s12.e0
DDI-DrugBank.d415.s12	9	17	Ibuprofen	drug	DDI-DrugBank.d415.s12.e1
DDI-DrugBank.d415.s12	51	57	lithium	drug	DDI-DrugBank.d415.s12.e2
DDI-DrugBank.d415.s12	91	97	lithium	drug	DDI-DrugBank.d415.s12.e3
DDI-DrugBank.d415.s12	false	DDI-DrugBank.d415.s12.e0	DDI-DrugBank.d415.s12.e1
DDI-DrugBank.d415.s12	false	DDI-DrugBank.d415.s12.e0	DDI-DrugBank.d415.s12.e2
DDI-DrugBank.d415.s12	false	DDI-DrugBank.d415.s12.e0	DDI-DrugBank.d415.s12.e3
DDI-DrugBank.d415.s12	true	DDI-DrugBank.d415.s12.e1	DDI-DrugBank.d415.s12.e2
DDI-DrugBank.d415.s12	false	DDI-DrugBank.d415.s12.e1	DDI-DrugBank.d415.s12.e3
DDI-DrugBank.d415.s12	false	DDI-DrugBank.d415.s12.e2	DDI-DrugBank.d415.s12.e3
DDI-DrugBank.d415.s13|a|The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration.
DDI-DrugBank.d415.s13	17	23	lithium	drug	DDI-DrugBank.d415.s13.e0
DDI-DrugBank.d415.s13	80	86	lithium	drug	DDI-DrugBank.d415.s13.e1
DDI-DrugBank.d415.s13	false	DDI-DrugBank.d415.s13.e0	DDI-DrugBank.d415.s13.e1
DDI-DrugBank.d415.s14|a|This effect has been attributed to inhibition of renal prostaglandin synthesis by ibuprofen.
DDI-DrugBank.d415.s14	82	90	ibuprofen	drug	DDI-DrugBank.d415.s14.e0
DDI-DrugBank.d415.s15|a|Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DDI-DrugBank.d415.s15	11	19	ibuprofen	drug	DDI-DrugBank.d415.s15.e0
DDI-DrugBank.d415.s15	25	31	lithium	drug	DDI-DrugBank.d415.s15.e1
DDI-DrugBank.d415.s15	115	121	lithium	drug	DDI-DrugBank.d415.s15.e2
DDI-DrugBank.d415.s15	true	DDI-DrugBank.d415.s15.e0	DDI-DrugBank.d415.s15.e1
DDI-DrugBank.d415.s15	false	DDI-DrugBank.d415.s15.e0	DDI-DrugBank.d415.s15.e2
DDI-DrugBank.d415.s15	false	DDI-DrugBank.d415.s15.e1	DDI-DrugBank.d415.s15.e2
DDI-DrugBank.d415.s16|a|(Read circulars for lithium preparation before use of such concurrent therapy).
DDI-DrugBank.d415.s16	20	26	lithium	drug	DDI-DrugBank.d415.s16.e0
DDI-DrugBank.d68.s0|a|No specific pharmacokinetic or other formal drug interaction studies were conducted.
DDI-DrugBank.d68.s1|a|Digoxin: Supraventricular arrhythmias may mask the cardiotoxicity associated with excessive digoxin levels.
DDI-DrugBank.d68.s1	0	6	Digoxin	drug	DDI-DrugBank.d68.s1.e0
DDI-DrugBank.d68.s1	92	98	digoxin	drug	DDI-DrugBank.d68.s1.e1
DDI-DrugBank.d68.s1	false	DDI-DrugBank.d68.s1.e0	DDI-DrugBank.d68.s1.e1
DDI-DrugBank.d68.s2|a|Therefore, it is advisable to be particularly cautious in patients whose plasma digoxin levels are above or suspected to be above the usual therapeutic range.
DDI-DrugBank.d68.s2	80	86	digoxin	drug	DDI-DrugBank.d68.s2.e0
DDI-DrugBank.d68.s3|a|Coadministration of digoxin did not have effects on either the safety or efficacy of ibutilide in the clinical trials.
DDI-DrugBank.d68.s3	20	26	digoxin	drug	DDI-DrugBank.d68.s3.e0
DDI-DrugBank.d68.s3	85	93	ibutilide	drug	DDI-DrugBank.d68.s3.e1
DDI-DrugBank.d68.s3	false	DDI-DrugBank.d68.s3.e0	DDI-DrugBank.d68.s3.e1
DDI-DrugBank.d68.s4|a|Calcium channel blocking agents: Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.
DDI-DrugBank.d68.s4	0	30	Calcium channel blocking agents	group	DDI-DrugBank.d68.s4.e0
DDI-DrugBank.d68.s4	53	76	calcium channel blockers	group	DDI-DrugBank.d68.s4.e1
DDI-DrugBank.d68.s4	138	146	ibutilide	drug	DDI-DrugBank.d68.s4.e2
DDI-DrugBank.d68.s4	false	DDI-DrugBank.d68.s4.e0	DDI-DrugBank.d68.s4.e1
DDI-DrugBank.d68.s4	false	DDI-DrugBank.d68.s4.e0	DDI-DrugBank.d68.s4.e2
DDI-DrugBank.d68.s4	false	DDI-DrugBank.d68.s4.e1	DDI-DrugBank.d68.s4.e2
DDI-DrugBank.d68.s5|a|Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.
DDI-DrugBank.d68.s5	0	30	Beta-adrenergic blocking agents	group	DDI-DrugBank.d68.s5.e0
DDI-DrugBank.d68.s5	53	83	beta-adrenergic blocking agents	group	DDI-DrugBank.d68.s5.e1
DDI-DrugBank.d68.s5	145	153	ibutilide	drug	DDI-DrugBank.d68.s5.e2
DDI-DrugBank.d68.s5	false	DDI-DrugBank.d68.s5.e0	DDI-DrugBank.d68.s5.e1
DDI-DrugBank.d68.s5	false	DDI-DrugBank.d68.s5.e0	DDI-DrugBank.d68.s5.e2
DDI-DrugBank.d68.s5	false	DDI-DrugBank.d68.s5.e1	DDI-DrugBank.d68.s5.e2
DDI-DrugBank.d501.s0|a|General No clinical drug interaction studies were performed.
DDI-DrugBank.d501.s1|a|No evaluation of EXTRANEALs effects on the cytochrome P450 system was conducted.
DDI-DrugBank.d501.s1	17	25	EXTRANEAL	brand	DDI-DrugBank.d501.s1.e0
DDI-DrugBank.d501.s2|a|As with other dialysis solutions, blood concentrations of dialyzable drugs may be reduced by dialysis.
DDI-DrugBank.d501.s2	14	31	dialysis solutions	group	DDI-DrugBank.d501.s2.e0
DDI-DrugBank.d501.s3|a|Dosage adjustment of concomitant medications may be necessary.
DDI-DrugBank.d501.s4|a|In patients using cardiac glycosides (digoxin and others), plasma levels of calcium, potassium and magnesium must be carefully monitored.
DDI-DrugBank.d501.s4	18	35	cardiac glycosides	group	DDI-DrugBank.d501.s4.e0
DDI-DrugBank.d501.s4	38	44	digoxin	drug	DDI-DrugBank.d501.s4.e1
DDI-DrugBank.d501.s4	false	DDI-DrugBank.d501.s4.e0	DDI-DrugBank.d501.s4.e1
DDI-DrugBank.d501.s5|a|Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.
DDI-DrugBank.d501.s5	0	6	Insulin	drug	DDI-DrugBank.d501.s5.e0
DDI-DrugBank.d501.s5	93	101	EXTRANEAL	brand	DDI-DrugBank.d501.s5.e1
DDI-DrugBank.d501.s5	106	112	insulin	drug	DDI-DrugBank.d501.s5.e2
DDI-DrugBank.d501.s5	158	164	insulin	drug	DDI-DrugBank.d501.s5.e3
DDI-DrugBank.d501.s5	205	211	insulin	drug	DDI-DrugBank.d501.s5.e4
DDI-DrugBank.d501.s5	253	261	EXTRANEAL	brand	DDI-DrugBank.d501.s5.e5
DDI-DrugBank.d501.s5	false	DDI-DrugBank.d501.s5.e0	DDI-DrugBank.d501.s5.e1
DDI-DrugBank.d501.s5	false	DDI-DrugBank.d501.s5.e0	DDI-DrugBank.d501.s5.e2
DDI-DrugBank.d501.s5	false	DDI-DrugBank.d501.s5.e0	DDI-DrugBank.d501.s5.e3
DDI-DrugBank.d501.s5	false	DDI-DrugBank.d501.s5.e0	DDI-DrugBank.d501.s5.e4
DDI-DrugBank.d501.s5	false	DDI-DrugBank.d501.s5.e0	DDI-DrugBank.d501.s5.e5
DDI-DrugBank.d501.s5	false	DDI-DrugBank.d501.s5.e1	DDI-DrugBank.d501.s5.e2
DDI-DrugBank.d501.s5	false	DDI-DrugBank.d501.s5.e1	DDI-DrugBank.d501.s5.e3
DDI-DrugBank.d501.s5	false	DDI-DrugBank.d501.s5.e1	DDI-DrugBank.d501.s5.e4
DDI-DrugBank.d501.s5	false	DDI-DrugBank.d501.s5.e1	DDI-DrugBank.d501.s5.e5
DDI-DrugBank.d501.s5	false	DDI-DrugBank.d501.s5.e2	DDI-DrugBank.d501.s5.e3
DDI-DrugBank.d501.s6|a|However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.
DDI-DrugBank.d501.s6	85	93	EXTRANEAL	brand	DDI-DrugBank.d501.s6.e0
DDI-DrugBank.d501.s6	120	126	insulin	drug	DDI-DrugBank.d501.s6.e1
DDI-DrugBank.d501.s6	true	DDI-DrugBank.d501.s6.e0	DDI-DrugBank.d501.s6.e1
DDI-DrugBank.d501.s7|a|Heparin: No human drug interaction studies with heparin were conducted.
DDI-DrugBank.d501.s7	0	6	Heparin	drug	DDI-DrugBank.d501.s7.e0
DDI-DrugBank.d501.s7	48	54	heparin	drug	DDI-DrugBank.d501.s7.e1
DDI-DrugBank.d501.s7	false	DDI-DrugBank.d501.s7.e0	DDI-DrugBank.d501.s7.e1
DDI-DrugBank.d501.s8|a|In vitro studies demonstrated no evidence of incompatibility of heparin with EXTRANEAL.
DDI-DrugBank.d501.s8	64	70	heparin	drug	DDI-DrugBank.d501.s8.e0
DDI-DrugBank.d501.s8	77	85	EXTRANEAL	brand	DDI-DrugBank.d501.s8.e1
DDI-DrugBank.d501.s8	false	DDI-DrugBank.d501.s8.e0	DDI-DrugBank.d501.s8.e1
DDI-DrugBank.d501.s9|a|Antibiotics: No human drug interaction studies with antibiotics were conducted.
DDI-DrugBank.d501.s9	0	10	Antibiotics	group	DDI-DrugBank.d501.s9.e0
DDI-DrugBank.d501.s9	52	62	antibiotics	group	DDI-DrugBank.d501.s9.e1
DDI-DrugBank.d501.s9	false	DDI-DrugBank.d501.s9.e0	DDI-DrugBank.d501.s9.e1
DDI-DrugBank.d501.s10|a|In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
DDI-DrugBank.d501.s10	74	83	vancomycin	drug	DDI-DrugBank.d501.s10.e0
DDI-DrugBank.d501.s10	86	94	cefazolin	drug	DDI-DrugBank.d501.s10.e1
DDI-DrugBank.d501.s10	97	106	ampicillin	drug	DDI-DrugBank.d501.s10.e2
DDI-DrugBank.d501.s10	109	118	ampicillin	drug	DDI-DrugBank.d501.s10.e3
DDI-DrugBank.d501.s10	135	145	ceftazidime	drug	DDI-DrugBank.d501.s10.e4
DDI-DrugBank.d501.s10	148	157	gentamicin	drug	DDI-DrugBank.d501.s10.e5
DDI-DrugBank.d501.s10	164	175	amphotericin	drug	DDI-DrugBank.d501.s10.e6
DDI-DrugBank.d501.s10	230	240	antibiotics	group	DDI-DrugBank.d501.s10.e7
DDI-DrugBank.d501.s10	247	255	EXTRANEAL	brand	DDI-DrugBank.d501.s10.e8
DDI-DrugBank.d501.s10	false	DDI-DrugBank.d501.s10.e0	DDI-DrugBank.d501.s10.e1
DDI-DrugBank.d501.s10	false	DDI-DrugBank.d501.s10.e0	DDI-DrugBank.d501.s10.e2
DDI-DrugBank.d501.s10	false	DDI-DrugBank.d501.s10.e0	DDI-DrugBank.d501.s10.e3
DDI-DrugBank.d501.s10	false	DDI-DrugBank.d501.s10.e0	DDI-DrugBank.d501.s10.e4
DDI-DrugBank.d501.s10	false	DDI-DrugBank.d501.s10.e0	DDI-DrugBank.d501.s10.e5
DDI-DrugBank.d501.s10	false	DDI-DrugBank.d501.s10.e0	DDI-DrugBank.d501.s10.e6
DDI-DrugBank.d501.s10	false	DDI-DrugBank.d501.s10.e0	DDI-DrugBank.d501.s10.e7
DDI-DrugBank.d501.s10	false	DDI-DrugBank.d501.s10.e0	DDI-DrugBank.d501.s10.e8
DDI-DrugBank.d501.s10	false	DDI-DrugBank.d501.s10.e1	DDI-DrugBank.d501.s10.e2
DDI-DrugBank.d501.s10	false	DDI-DrugBank.d501.s10.e1	DDI-DrugBank.d501.s10.e3
DDI-DrugBank.d501.s11|a|Drug/Laboratory Test Interactions Blood Glucose Blood glucose measurement must be done with a glucose-specific method to prevent maltose interference with test results.
DDI-DrugBank.d501.s12|a|Since falsely elevated glucose levels have been observed with blood glucose monitoring devices and test strips that use glucose dehydrogenase pyrroloquinolinequinone (GDH PQQ)-based methods, GDH PQQ-based methods should not be used to measure glucose levels in patients administered EXTRANEAL..
DDI-DrugBank.d501.s12	283	291	EXTRANEAL	brand	DDI-DrugBank.d501.s12.e0
DDI-DrugBank.d501.s13|a|Serum Amylase An apparent decrease in serum amylase activity has been observed in patients administered EXTRANEAL.
DDI-DrugBank.d501.s13	104	112	EXTRANEAL	brand	DDI-DrugBank.d501.s13.e0
DDI-DrugBank.d501.s14|a|Preliminary investigations indicate that icodextrin and its metabolites interfere with enzymatic-based amylase assays, resulting in inaccurately low values.
DDI-DrugBank.d501.s14	41	50	icodextrin	drug	DDI-DrugBank.d501.s14.e0
DDI-DrugBank.d501.s15|a|This should be taken into account when evaluating serum amylase levels for diagnosis or monitoring of pancreatitis in patients using EXTRANEAL.
DDI-DrugBank.d501.s15	133	141	EXTRANEAL	brand	DDI-DrugBank.d501.s15.e0
DDI-DrugBank.d35.s0|a|Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
DDI-DrugBank.d35.s0	31	33	EPA	drug	DDI-DrugBank.d35.s0.e0
DDI-DrugBank.d35.s0	51	57	aspirin	brand	DDI-DrugBank.d35.s0.e1
DDI-DrugBank.d35.s0	69	105	non-steroidal anti-inflammatory drugs	group	DDI-DrugBank.d35.s0.e2
DDI-DrugBank.d35.s0	153	158	ginkgo	drug	DDI-DrugBank.d35.s0.e3
DDI-DrugBank.d35.s0	161	173	Ginkgo biloba	drug	DDI-DrugBank.d35.s0.e4
DDI-DrugBank.d35.s0	true	DDI-DrugBank.d35.s0.e0	DDI-DrugBank.d35.s0.e1
DDI-DrugBank.d35.s0	true	DDI-DrugBank.d35.s0.e0	DDI-DrugBank.d35.s0.e2
DDI-DrugBank.d35.s0	true	DDI-DrugBank.d35.s0.e0	DDI-DrugBank.d35.s0.e3
DDI-DrugBank.d35.s0	true	DDI-DrugBank.d35.s0.e0	DDI-DrugBank.d35.s0.e4
DDI-DrugBank.d35.s0	false	DDI-DrugBank.d35.s0.e1	DDI-DrugBank.d35.s0.e2
DDI-DrugBank.d35.s0	false	DDI-DrugBank.d35.s0.e1	DDI-DrugBank.d35.s0.e3
DDI-DrugBank.d35.s0	false	DDI-DrugBank.d35.s0.e1	DDI-DrugBank.d35.s0.e4
DDI-DrugBank.d35.s0	false	DDI-DrugBank.d35.s0.e2	DDI-DrugBank.d35.s0.e3
DDI-DrugBank.d35.s0	false	DDI-DrugBank.d35.s0.e2	DDI-DrugBank.d35.s0.e4
DDI-DrugBank.d35.s0	false	DDI-DrugBank.d35.s0.e3	DDI-DrugBank.d35.s0.e4
DDI-DrugBank.d35.s1|a|Such interactions might be manifested by increased susceptibility to bruising, nosebleeds, hemoptysis, hematemesis, hematuria and blood in the stool.
DDI-DrugBank.d35.s2|a|Most who take EPA supplements and the above drugs or herbs do not suffer from these problems and if they occur, they are rare.
DDI-DrugBank.d35.s2	14	16	EPA	drug	DDI-DrugBank.d35.s2.e0
DDI-DrugBank.d35.s3|a|If they do occur, the EPA dose should be lowered or discontinued.
DDI-DrugBank.d35.s3	22	24	EPA	drug	DDI-DrugBank.d35.s3.e0
DDI-DrugBank.d35.s4|a|Conflicting results have been reported regarding the effects of EPA supplements on glycemic control in non-diabetics with glucose intolerance, and those with type 2 diabetes.
DDI-DrugBank.d35.s4	64	66	EPA	drug	DDI-DrugBank.d35.s4.e0
DDI-DrugBank.d35.s5|a|Some early studies indicated that EPA supplements might have detrimental effects in those groups.
DDI-DrugBank.d35.s5	34	36	EPA	drug	DDI-DrugBank.d35.s5.e0
DDI-DrugBank.d35.s6|a|Recent, better designed studies have not reported these adverse effects.
DDI-DrugBank.d35.s7|a|There is no evidence that EPA supplements have detrimental effects on glucose tolerance, insulin secretion or insulin resistance in non-diabetic subjects.
DDI-DrugBank.d35.s7	26	28	EPA	drug	DDI-DrugBank.d35.s7.e0
DDI-DrugBank.d35.s8|a|Diabetics should discuss the use of these supplements with their physicians and note if the supplements affect their glycemic control.
DDI-DrugBank.d35.s9|a|Diabetics who take EPA supplements should be monitored by their physicians.
DDI-DrugBank.d35.s9	19	21	EPA	drug	DDI-DrugBank.d35.s9.e0
DDI-DrugBank.d91.s0|a|Other medicines - Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur.
DDI-DrugBank.d91.s1|a|In these cases, your doctor may want to change the dose, or other precautions may be necessary.
DDI-DrugBank.d91.s2|a|When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.
DDI-DrugBank.d91.s2	19	29	idoxuridine	drug	DDI-DrugBank.d91.s2.e0
DDI-DrugBank.d91.s2	154	163	boric acid	drug	DDI-DrugBank.d91.s2.e1
DDI-DrugBank.d91.s2	true	DDI-DrugBank.d91.s2.e0	DDI-DrugBank.d91.s2.e1
DDI-DrugBank.d91.s3|a|Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.
DDI-DrugBank.d91.s3	0	9	Boric acid	drug	DDI-DrugBank.d91.s3.e0
DDI-DrugBank.d91.s3	33	43	idoxuridine	drug	DDI-DrugBank.d91.s3.e1
DDI-DrugBank.d91.s3	137	147	idoxuridine	drug	DDI-DrugBank.d91.s3.e2
DDI-DrugBank.d91.s3	true	DDI-DrugBank.d91.s3.e0	DDI-DrugBank.d91.s3.e1
DDI-DrugBank.d91.s3	false	DDI-DrugBank.d91.s3.e0	DDI-DrugBank.d91.s3.e2
DDI-DrugBank.d91.s3	false	DDI-DrugBank.d91.s3.e1	DDI-DrugBank.d91.s3.e2
DDI-DrugBank.d515.s0|a|The physician should be alert for possible combined drug actions, desirable or undesirable, involving ifosfamide even though ifosfamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.
DDI-DrugBank.d515.s0	102	111	ifosfamide	drug	DDI-DrugBank.d515.s0.e0
DDI-DrugBank.d515.s0	125	134	ifosfamide	drug	DDI-DrugBank.d515.s0.e1
DDI-DrugBank.d515.s0	false	DDI-DrugBank.d515.s0.e0	DDI-DrugBank.d515.s0.e1
DDI-DrugBank.d549.s0|a|In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine, diltiazem, or captopril.
DDI-DrugBank.d549.s0	94	101	iloprost	drug	DDI-DrugBank.d549.s0.e0
DDI-DrugBank.d549.s0	114	123	nifedipine	drug	DDI-DrugBank.d549.s0.e1
DDI-DrugBank.d549.s0	126	134	diltiazem	drug	DDI-DrugBank.d549.s0.e2
DDI-DrugBank.d549.s0	140	148	captopril	drug	DDI-DrugBank.d549.s0.e3
DDI-DrugBank.d549.s0	false	DDI-DrugBank.d549.s0.e0	DDI-DrugBank.d549.s0.e1
DDI-DrugBank.d549.s0	false	DDI-DrugBank.d549.s0.e0	DDI-DrugBank.d549.s0.e2
DDI-DrugBank.d549.s0	false	DDI-DrugBank.d549.s0.e0	DDI-DrugBank.d549.s0.e3
DDI-DrugBank.d549.s0	false	DDI-DrugBank.d549.s0.e1	DDI-DrugBank.d549.s0.e2
DDI-DrugBank.d549.s0	false	DDI-DrugBank.d549.s0.e1	DDI-DrugBank.d549.s0.e3
DDI-DrugBank.d549.s0	false	DDI-DrugBank.d549.s0.e2	DDI-DrugBank.d549.s0.e3
DDI-DrugBank.d549.s1|a|However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
DDI-DrugBank.d549.s1	9	16	iloprost	drug	DDI-DrugBank.d549.s1.e0
DDI-DrugBank.d549.s1	74	85	vasodilators	group	DDI-DrugBank.d549.s1.e1
DDI-DrugBank.d549.s1	91	113	antihypertensive agents	group	DDI-DrugBank.d549.s1.e2
DDI-DrugBank.d549.s1	true	DDI-DrugBank.d549.s1.e0	DDI-DrugBank.d549.s1.e1
DDI-DrugBank.d549.s1	true	DDI-DrugBank.d549.s1.e0	DDI-DrugBank.d549.s1.e2
DDI-DrugBank.d549.s1	false	DDI-DrugBank.d549.s1.e1	DDI-DrugBank.d549.s1.e2
DDI-DrugBank.d549.s2|a|Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.
DDI-DrugBank.d549.s2	6	13	iloprost	drug	DDI-DrugBank.d549.s2.e0
DDI-DrugBank.d549.s2	135	148	anticoagulants	group	DDI-DrugBank.d549.s2.e1
DDI-DrugBank.d549.s2	true	DDI-DrugBank.d549.s2.e0	DDI-DrugBank.d549.s2.e1
DDI-DrugBank.d549.s3|a|During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
DDI-DrugBank.d549.s3	24	31	iloprost	drug	DDI-DrugBank.d549.s3.e0
DDI-DrugBank.d549.s3	60	73	anticoagulants	group	DDI-DrugBank.d549.s3.e1
DDI-DrugBank.d549.s3	76	84	diuretics	group	DDI-DrugBank.d549.s3.e2
DDI-DrugBank.d549.s3	87	104	cardiac glycosides	group	DDI-DrugBank.d549.s3.e3
DDI-DrugBank.d549.s3	107	130	calcium channel blockers	group	DDI-DrugBank.d549.s3.e4
DDI-DrugBank.d549.s3	133	142	analgesics	group	DDI-DrugBank.d549.s3.e5
DDI-DrugBank.d549.s3	145	156	antipyretics	group	DDI-DrugBank.d549.s3.e6
DDI-DrugBank.d549.s3	159	189	nonsteroidal antiinflammatories	group	DDI-DrugBank.d549.s3.e7
DDI-DrugBank.d549.s3	192	206	corticosteroids	group	DDI-DrugBank.d549.s3.e8
DDI-DrugBank.d549.s3	false	DDI-DrugBank.d549.s3.e0	DDI-DrugBank.d549.s3.e1
DDI-DrugBank.d549.s3	false	DDI-DrugBank.d549.s3.e0	DDI-DrugBank.d549.s3.e2
DDI-DrugBank.d549.s3	false	DDI-DrugBank.d549.s3.e0	DDI-DrugBank.d549.s3.e3
DDI-DrugBank.d549.s3	false	DDI-DrugBank.d549.s3.e0	DDI-DrugBank.d549.s3.e4
DDI-DrugBank.d549.s3	false	DDI-DrugBank.d549.s3.e0	DDI-DrugBank.d549.s3.e5
DDI-DrugBank.d549.s3	false	DDI-DrugBank.d549.s3.e0	DDI-DrugBank.d549.s3.e6
DDI-DrugBank.d549.s3	false	DDI-DrugBank.d549.s3.e0	DDI-DrugBank.d549.s3.e7
DDI-DrugBank.d549.s3	false	DDI-DrugBank.d549.s3.e0	DDI-DrugBank.d549.s3.e8
DDI-DrugBank.d549.s3	false	DDI-DrugBank.d549.s3.e1	DDI-DrugBank.d549.s3.e2
DDI-DrugBank.d549.s3	false	DDI-DrugBank.d549.s3.e1	DDI-DrugBank.d549.s3.e3
DDI-DrugBank.d549.s4|a|Intravenous infusion of iloprost had no effect on the pharmacokinetics of digoxin.
DDI-DrugBank.d549.s4	24	31	iloprost	drug	DDI-DrugBank.d549.s4.e0
DDI-DrugBank.d549.s4	74	80	digoxin	drug	DDI-DrugBank.d549.s4.e1
DDI-DrugBank.d549.s4	false	DDI-DrugBank.d549.s4.e0	DDI-DrugBank.d549.s4.e1
DDI-DrugBank.d549.s5|a|Acetylsalicylic acid did not alter the clearance (pharmacokinetics) of iloprost.
DDI-DrugBank.d549.s5	0	19	Acetylsalicylic acid	drug	DDI-DrugBank.d549.s5.e0
DDI-DrugBank.d549.s5	71	78	iloprost	drug	DDI-DrugBank.d549.s5.e1
DDI-DrugBank.d549.s5	false	DDI-DrugBank.d549.s5.e0	DDI-DrugBank.d549.s5.e1
DDI-DrugBank.d549.s6|a|Although clinical studies have not been conducted, in vitro studies of iloprost indicate that no relevant inhibition of cytochrome P450 drug metabolism would be expected.
DDI-DrugBank.d549.s6	71	78	iloprost	drug	DDI-DrugBank.d549.s6.e0
DDI-DrugBank.d115.s0|a|Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
DDI-DrugBank.d115.s0	21	28	imatinib	drug	DDI-DrugBank.d115.s0.e0
DDI-DrugBank.d115.s0	76	83	imatinib	drug	DDI-DrugBank.d115.s0.e1
DDI-DrugBank.d115.s0	150	156	Gleevec	brand	DDI-DrugBank.d115.s0.e2
DDI-DrugBank.d115.s0	202	213	ketoconazole	drug	DDI-DrugBank.d115.s0.e3
DDI-DrugBank.d115.s0	216	227	itraconazole	drug	DDI-DrugBank.d115.s0.e4
DDI-DrugBank.d115.s0	230	241	erythromycin	drug	DDI-DrugBank.d115.s0.e5
DDI-DrugBank.d115.s0	244	257	clarithromycin	drug	DDI-DrugBank.d115.s0.e6
DDI-DrugBank.d115.s0	false	DDI-DrugBank.d115.s0.e0	DDI-DrugBank.d115.s0.e1
DDI-DrugBank.d115.s0	false	DDI-DrugBank.d115.s0.e0	DDI-DrugBank.d115.s0.e2
DDI-DrugBank.d115.s0	false	DDI-DrugBank.d115.s0.e0	DDI-DrugBank.d115.s0.e3
DDI-DrugBank.d115.s0	false	DDI-DrugBank.d115.s0.e0	DDI-DrugBank.d115.s0.e4
DDI-DrugBank.d115.s0	false	DDI-DrugBank.d115.s0.e0	DDI-DrugBank.d115.s0.e5
DDI-DrugBank.d115.s0	false	DDI-DrugBank.d115.s0.e0	DDI-DrugBank.d115.s0.e6
DDI-DrugBank.d115.s0	false	DDI-DrugBank.d115.s0.e1	DDI-DrugBank.d115.s0.e2
DDI-DrugBank.d115.s0	false	DDI-DrugBank.d115.s0.e1	DDI-DrugBank.d115.s0.e3
DDI-DrugBank.d115.s0	false	DDI-DrugBank.d115.s0.e1	DDI-DrugBank.d115.s0.e4
DDI-DrugBank.d115.s0	false	DDI-DrugBank.d115.s0.e1	DDI-DrugBank.d115.s0.e5
DDI-DrugBank.d115.s1|a|Substances that inhibit the cytochrome P450 isoenzyme (CYP3A4) activity may decrease metabolism and increase imatinib concentrations.
DDI-DrugBank.d115.s1	109	116	imatinib	drug	DDI-DrugBank.d115.s1.e0
DDI-DrugBank.d115.s2|a|There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).
DDI-DrugBank.d115.s2	47	54	imatinib	drug	DDI-DrugBank.d115.s2.e0
DDI-DrugBank.d115.s2	61	67	Gleevec	brand	DDI-DrugBank.d115.s2.e1
DDI-DrugBank.d115.s2	92	103	ketoconazole	drug	DDI-DrugBank.d115.s2.e2
DDI-DrugBank.d115.s2	false	DDI-DrugBank.d115.s2.e0	DDI-DrugBank.d115.s2.e1
DDI-DrugBank.d115.s2	false	DDI-DrugBank.d115.s2.e0	DDI-DrugBank.d115.s2.e2
DDI-DrugBank.d115.s2	true	DDI-DrugBank.d115.s2.e1	DDI-DrugBank.d115.s2.e2
DDI-DrugBank.d115.s3|a|Drugs that may decrease imatinib plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations.
DDI-DrugBank.d115.s3	24	31	imatinib	drug	DDI-DrugBank.d115.s3.e0
DDI-DrugBank.d115.s3	141	148	imatinib	drug	DDI-DrugBank.d115.s3.e1
DDI-DrugBank.d115.s3	false	DDI-DrugBank.d115.s3.e0	DDI-DrugBank.d115.s3.e1
DDI-DrugBank.d115.s4|a|Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital or St.
DDI-DrugBank.d115.s4	41	53	dexamethasone	drug	DDI-DrugBank.d115.s4.e0
DDI-DrugBank.d115.s4	56	64	phenytoin	drug	DDI-DrugBank.d115.s4.e1
DDI-DrugBank.d115.s4	67	79	carbamazepine	drug	DDI-DrugBank.d115.s4.e2
DDI-DrugBank.d115.s4	82	89	rifampin	drug	DDI-DrugBank.d115.s4.e3
DDI-DrugBank.d115.s4	92	104	phenobarbital	drug	DDI-DrugBank.d115.s4.e4
DDI-DrugBank.d115.s4	false	DDI-DrugBank.d115.s4.e0	DDI-DrugBank.d115.s4.e1
DDI-DrugBank.d115.s4	false	DDI-DrugBank.d115.s4.e0	DDI-DrugBank.d115.s4.e2
DDI-DrugBank.d115.s4	false	DDI-DrugBank.d115.s4.e0	DDI-DrugBank.d115.s4.e3
DDI-DrugBank.d115.s4	false	DDI-DrugBank.d115.s4.e0	DDI-DrugBank.d115.s4.e4
DDI-DrugBank.d115.s4	false	DDI-DrugBank.d115.s4.e1	DDI-DrugBank.d115.s4.e2
DDI-DrugBank.d115.s4	false	DDI-DrugBank.d115.s4.e1	DDI-DrugBank.d115.s4.e3
DDI-DrugBank.d115.s4	false	DDI-DrugBank.d115.s4.e1	DDI-DrugBank.d115.s4.e4
DDI-DrugBank.d115.s4	false	DDI-DrugBank.d115.s4.e2	DDI-DrugBank.d115.s4.e3
DDI-DrugBank.d115.s4	false	DDI-DrugBank.d115.s4.e2	DDI-DrugBank.d115.s4.e4
DDI-DrugBank.d115.s4	false	DDI-DrugBank.d115.s4.e3	DDI-DrugBank.d115.s4.e4
DDI-DrugBank.d115.s5|a|Johns Wort) may significantly reduce exposure to Gleevec.
DDI-DrugBank.d115.s5	49	55	Gleevec	brand	DDI-DrugBank.d115.s5.e0
DDI-DrugBank.d115.s6|a|Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
DDI-DrugBank.d115.s6	58	65	rifampin	drug	DDI-DrugBank.d115.s6.e0
DDI-DrugBank.d115.s6	96	102	Gleevec	brand	DDI-DrugBank.d115.s6.e1
DDI-DrugBank.d115.s6	115	121	Gleevec	brand	DDI-DrugBank.d115.s6.e2
DDI-DrugBank.d115.s6	true	DDI-DrugBank.d115.s6.e0	DDI-DrugBank.d115.s6.e1
DDI-DrugBank.d115.s6	false	DDI-DrugBank.d115.s6.e0	DDI-DrugBank.d115.s6.e2
DDI-DrugBank.d115.s6	false	DDI-DrugBank.d115.s6.e1	DDI-DrugBank.d115.s6.e2
DDI-DrugBank.d115.s7|a|In patients where rifampin or other CYP3A4 inducers are indicated, alternative therapeutic agents with less enzyme induction potential should be considered.
DDI-DrugBank.d115.s7	18	25	rifampin	drug	DDI-DrugBank.d115.s7.e0
DDI-DrugBank.d115.s8|a|Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.
DDI-DrugBank.d115.s8	58	64	Gleevec	brand	DDI-DrugBank.d115.s8.e0
DDI-DrugBank.d115.s8	66	72	Gleevec	brand	DDI-DrugBank.d115.s8.e1
DDI-DrugBank.d115.s8	109	119	simvastatin	drug	DDI-DrugBank.d115.s8.e2
DDI-DrugBank.d115.s8	213	219	Gleevec	brand	DDI-DrugBank.d115.s8.e3
DDI-DrugBank.d115.s8	false	DDI-DrugBank.d115.s8.e0	DDI-DrugBank.d115.s8.e1
DDI-DrugBank.d115.s8	false	DDI-DrugBank.d115.s8.e0	DDI-DrugBank.d115.s8.e2
DDI-DrugBank.d115.s8	false	DDI-DrugBank.d115.s8.e0	DDI-DrugBank.d115.s8.e3
DDI-DrugBank.d115.s8	true	DDI-DrugBank.d115.s8.e1	DDI-DrugBank.d115.s8.e2
DDI-DrugBank.d115.s8	false	DDI-DrugBank.d115.s8.e1	DDI-DrugBank.d115.s8.e3
DDI-DrugBank.d115.s8	false	DDI-DrugBank.d115.s8.e2	DDI-DrugBank.d115.s8.e3
DDI-DrugBank.d115.s9|a|Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).
DDI-DrugBank.d115.s9	53	59	Gleevec	brand	DDI-DrugBank.d115.s9.e0
DDI-DrugBank.d115.s9	129	140	cyclosporine	drug	DDI-DrugBank.d115.s9.e1
DDI-DrugBank.d115.s9	145	152	pimozide	drug	DDI-DrugBank.d115.s9.e2
DDI-DrugBank.d115.s9	true	DDI-DrugBank.d115.s9.e0	DDI-DrugBank.d115.s9.e1
DDI-DrugBank.d115.s9	true	DDI-DrugBank.d115.s9.e0	DDI-DrugBank.d115.s9.e2
DDI-DrugBank.d115.s9	false	DDI-DrugBank.d115.s9.e1	DDI-DrugBank.d115.s9.e2
DDI-DrugBank.d115.s10|a|Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
DDI-DrugBank.d115.s10	0	6	Gleevec	brand	DDI-DrugBank.d115.s10.e0
DDI-DrugBank.d115.s10	92	106	benzodiazepines	group	DDI-DrugBank.d115.s10.e1
DDI-DrugBank.d115.s10	109	148	dihydropyridine calcium channel blockers	group	DDI-DrugBank.d115.s10.e2
DDI-DrugBank.d115.s10	159	186	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d115.s10.e3
DDI-DrugBank.d115.s10	true	DDI-DrugBank.d115.s10.e0	DDI-DrugBank.d115.s10.e1
DDI-DrugBank.d115.s10	true	DDI-DrugBank.d115.s10.e0	DDI-DrugBank.d115.s10.e2
DDI-DrugBank.d115.s10	true	DDI-DrugBank.d115.s10.e0	DDI-DrugBank.d115.s10.e3
DDI-DrugBank.d115.s10	false	DDI-DrugBank.d115.s10.e1	DDI-DrugBank.d115.s10.e2
DDI-DrugBank.d115.s10	false	DDI-DrugBank.d115.s10.e1	DDI-DrugBank.d115.s10.e3
DDI-DrugBank.d115.s10	false	DDI-DrugBank.d115.s10.e2	DDI-DrugBank.d115.s10.e3
DDI-DrugBank.d115.s11|a|Because warfarin is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard heparin.
DDI-DrugBank.d115.s11	8	15	warfarin	drug	DDI-DrugBank.d115.s11.e0
DDI-DrugBank.d115.s11	139	145	heparin	drug	DDI-DrugBank.d115.s11.e1
DDI-DrugBank.d115.s11	false	DDI-DrugBank.d115.s11.e0	DDI-DrugBank.d115.s11.e1
DDI-DrugBank.d115.s12|a|in vitro, Gleevec inhibits the cytochrome P450 isoenzyme CYP2D6 activity at similar concentrations that affect CYP3A4 activity.
DDI-DrugBank.d115.s12	10	16	Gleevec	brand	DDI-DrugBank.d115.s12.e0
DDI-DrugBank.d115.s13|a|Systemic exposure to substrates of CYP2D6 is expected to be increased when coadministered with Gleevec.
DDI-DrugBank.d115.s14|a|No specific studies have been performed and caution is recommended.
DDI-DrugBank.d115.s15|a|in vitro, Gleevec inhibits acetaminophen O-glucuronidation (Ki value of 58.5  M) at therapeutic levels.
DDI-DrugBank.d115.s15	10	16	Gleevec	brand	DDI-DrugBank.d115.s15.e0
DDI-DrugBank.d115.s16|a|Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.
DDI-DrugBank.d115.s16	21	33	acetaminophen	drug	DDI-DrugBank.d115.s16.e0
DDI-DrugBank.d115.s16	88	94	Gleevec	brand	DDI-DrugBank.d115.s16.e1
DDI-DrugBank.d115.s16	true	DDI-DrugBank.d115.s16.e0	DDI-DrugBank.d115.s16.e1
DDI-DrugBank.d115.s17|a|No specific studies in humans have been performed and caution is recommended.
DDI-DrugBank.d115.s18|a|
DDI-DrugBank.d77.s0|a|In occasional susceptible patients or in those receiving anticholinergic drugs (including antiparkinsonism agents) in addition, the atropine-like effects may become more pronounced (e.g., paralytic ileus).
DDI-DrugBank.d77.s0	57	77	anticholinergic drugs	group	DDI-DrugBank.d77.s0.e0
DDI-DrugBank.d77.s1|a|Close supervision and careful adjustment of dosage is required when this drug is administered concomitantly with anticholinergic drugs.
DDI-DrugBank.d77.s1	113	133	anticholinergic drugs	group	DDI-DrugBank.d77.s1.e0
DDI-DrugBank.d77.s2|a|Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
DDI-DrugBank.d77.s2	38	50	decongestants	group	DDI-DrugBank.d77.s2.e0
DDI-DrugBank.d77.s2	62	72	anesthetics	group	DDI-DrugBank.d77.s2.e1
DDI-DrugBank.d77.s2	92	112	sympathomimetic amine	group	DDI-DrugBank.d77.s2.e2
DDI-DrugBank.d77.s2	121	131	epinephrine	drug	DDI-DrugBank.d77.s2.e3
DDI-DrugBank.d77.s2	134	147	norepinephrine	drug	DDI-DrugBank.d77.s2.e4
DDI-DrugBank.d77.s2	183	207	tricyclic antidepressants	group	DDI-DrugBank.d77.s2.e5
DDI-DrugBank.d77.s2	false	DDI-DrugBank.d77.s2.e0	DDI-DrugBank.d77.s2.e1
DDI-DrugBank.d77.s2	false	DDI-DrugBank.d77.s2.e0	DDI-DrugBank.d77.s2.e2
DDI-DrugBank.d77.s2	false	DDI-DrugBank.d77.s2.e0	DDI-DrugBank.d77.s2.e3
DDI-DrugBank.d77.s2	false	DDI-DrugBank.d77.s2.e0	DDI-DrugBank.d77.s2.e4
DDI-DrugBank.d77.s2	true	DDI-DrugBank.d77.s2.e0	DDI-DrugBank.d77.s2.e5
DDI-DrugBank.d77.s2	false	DDI-DrugBank.d77.s2.e1	DDI-DrugBank.d77.s2.e2
DDI-DrugBank.d77.s2	false	DDI-DrugBank.d77.s2.e1	DDI-DrugBank.d77.s2.e3
DDI-DrugBank.d77.s2	false	DDI-DrugBank.d77.s2.e1	DDI-DrugBank.d77.s2.e4
DDI-DrugBank.d77.s2	true	DDI-DrugBank.d77.s2.e1	DDI-DrugBank.d77.s2.e5
DDI-DrugBank.d77.s2	false	DDI-DrugBank.d77.s2.e2	DDI-DrugBank.d77.s2.e3
DDI-DrugBank.d77.s3|a|Caution should be exercised when imipramine hydrochloride is used with agents that lower blood pressure.
DDI-DrugBank.d77.s3	33	56	imipramine hydrochloride	drug	DDI-DrugBank.d77.s3.e0
DDI-DrugBank.d77.s4|a|Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.
DDI-DrugBank.d77.s4	0	23	Imipramine hydrochloride	drug	DDI-DrugBank.d77.s4.e0
DDI-DrugBank.d77.s4	55	74	CNS depressant drugs	group	DDI-DrugBank.d77.s4.e1
DDI-DrugBank.d77.s4	true	DDI-DrugBank.d77.s4.e0	DDI-DrugBank.d77.s4.e1
DDI-DrugBank.d77.s5|a|The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
DDI-DrugBank.d77.s5	28	37	imipramine	drug	DDI-DrugBank.d77.s5.e0
DDI-DrugBank.d77.s5	127	136	cimetidine	drug	DDI-DrugBank.d77.s5.e1
DDI-DrugBank.d77.s5	139	148	fluoxetine	drug	DDI-DrugBank.d77.s5.e2
DDI-DrugBank.d77.s5	228	239	barbiturates	group	DDI-DrugBank.d77.s5.e3
DDI-DrugBank.d77.s5	242	250	phenytoin	drug	DDI-DrugBank.d77.s5.e4
DDI-DrugBank.d77.s5	286	295	imipramine	drug	DDI-DrugBank.d77.s5.e5
DDI-DrugBank.d77.s5	true	DDI-DrugBank.d77.s5.e0	DDI-DrugBank.d77.s5.e1
DDI-DrugBank.d77.s5	true	DDI-DrugBank.d77.s5.e0	DDI-DrugBank.d77.s5.e2
DDI-DrugBank.d77.s5	true	DDI-DrugBank.d77.s5.e0	DDI-DrugBank.d77.s5.e3
DDI-DrugBank.d77.s5	true	DDI-DrugBank.d77.s5.e0	DDI-DrugBank.d77.s5.e4
DDI-DrugBank.d77.s5	false	DDI-DrugBank.d77.s5.e0	DDI-DrugBank.d77.s5.e5
DDI-DrugBank.d77.s5	false	DDI-DrugBank.d77.s5.e1	DDI-DrugBank.d77.s5.e2
DDI-DrugBank.d77.s5	false	DDI-DrugBank.d77.s5.e1	DDI-DrugBank.d77.s5.e3
DDI-DrugBank.d77.s5	false	DDI-DrugBank.d77.s5.e1	DDI-DrugBank.d77.s5.e4
DDI-DrugBank.d77.s5	false	DDI-DrugBank.d77.s5.e1	DDI-DrugBank.d77.s5.e5
DDI-DrugBank.d77.s5	false	DDI-DrugBank.d77.s5.e2	DDI-DrugBank.d77.s5.e3
DDI-DrugBank.d77.s6|a|Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers);
DDI-DrugBank.d77.s7|a|reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
DDI-DrugBank.d77.s8|a|Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
DDI-DrugBank.d77.s8	69	93	tricyclic antidepressants	group	DDI-DrugBank.d77.s8.e0
DDI-DrugBank.d77.s8	96	99	TCAs	group	DDI-DrugBank.d77.s8.e1
DDI-DrugBank.d77.s8	false	DDI-DrugBank.d77.s8.e0	DDI-DrugBank.d77.s8.e1
DDI-DrugBank.d77.s9|a|Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).
DDI-DrugBank.d77.s9	163	165	TCA	group	DDI-DrugBank.d77.s9.e0
DDI-DrugBank.d77.s10|a|In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o.
DDI-DrugBank.d77.s11|a|metabolizers.
DDI-DrugBank.d77.s12|a|An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
DDI-DrugBank.d77.s12	47	49	TCA	group	DDI-DrugBank.d77.s12.e0
DDI-DrugBank.d77.s13|a|The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;
DDI-DrugBank.d77.s13	96	104	quinidine	drug	DDI-DrugBank.d77.s13.e0
DDI-DrugBank.d77.s14|a|cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
DDI-DrugBank.d77.s14	0	9	cimetidine	drug	DDI-DrugBank.d77.s14.e0
DDI-DrugBank.d77.s14	66	80	antidepressants	group	DDI-DrugBank.d77.s14.e1
DDI-DrugBank.d77.s14	83	96	phenothiazines	group	DDI-DrugBank.d77.s14.e2
DDI-DrugBank.d77.s14	107	129	Type 1C antiarrhythmics	group	DDI-DrugBank.d77.s14.e3
DDI-DrugBank.d77.s14	131	141	propafenone	drug	DDI-DrugBank.d77.s14.e4
DDI-DrugBank.d77.s14	147	156	flecainide	drug	DDI-DrugBank.d77.s14.e5
DDI-DrugBank.d77.s14	false	DDI-DrugBank.d77.s14.e0	DDI-DrugBank.d77.s14.e1
DDI-DrugBank.d77.s14	false	DDI-DrugBank.d77.s14.e0	DDI-DrugBank.d77.s14.e2
DDI-DrugBank.d77.s14	false	DDI-DrugBank.d77.s14.e0	DDI-DrugBank.d77.s14.e3
DDI-DrugBank.d77.s14	false	DDI-DrugBank.d77.s14.e0	DDI-DrugBank.d77.s14.e4
DDI-DrugBank.d77.s14	false	DDI-DrugBank.d77.s14.e0	DDI-DrugBank.d77.s14.e5
DDI-DrugBank.d77.s14	false	DDI-DrugBank.d77.s14.e1	DDI-DrugBank.d77.s14.e2
DDI-DrugBank.d77.s14	false	DDI-DrugBank.d77.s14.e1	DDI-DrugBank.d77.s14.e3
DDI-DrugBank.d77.s14	false	DDI-DrugBank.d77.s14.e1	DDI-DrugBank.d77.s14.e4
DDI-DrugBank.d77.s14	false	DDI-DrugBank.d77.s14.e1	DDI-DrugBank.d77.s14.e5
DDI-DrugBank.d77.s14	false	DDI-DrugBank.d77.s14.e2	DDI-DrugBank.d77.s14.e3
DDI-DrugBank.d77.s15|a|While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
DDI-DrugBank.d77.s15	14	52	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d77.s15.e0
DDI-DrugBank.d77.s15	55	59	SSRIs	group	DDI-DrugBank.d77.s15.e1
DDI-DrugBank.d77.s15	70	79	fluoxetine	drug	DDI-DrugBank.d77.s15.e2
DDI-DrugBank.d77.s15	82	91	sertraline	drug	DDI-DrugBank.d77.s15.e3
DDI-DrugBank.d77.s15	98	107	paroxetine	drug	DDI-DrugBank.d77.s15.e4
DDI-DrugBank.d77.s15	false	DDI-DrugBank.d77.s15.e0	DDI-DrugBank.d77.s15.e1
DDI-DrugBank.d77.s15	false	DDI-DrugBank.d77.s15.e0	DDI-DrugBank.d77.s15.e2
DDI-DrugBank.d77.s15	false	DDI-DrugBank.d77.s15.e0	DDI-DrugBank.d77.s15.e3
DDI-DrugBank.d77.s15	false	DDI-DrugBank.d77.s15.e0	DDI-DrugBank.d77.s15.e4
DDI-DrugBank.d77.s15	false	DDI-DrugBank.d77.s15.e1	DDI-DrugBank.d77.s15.e2
DDI-DrugBank.d77.s15	false	DDI-DrugBank.d77.s15.e1	DDI-DrugBank.d77.s15.e3
DDI-DrugBank.d77.s15	false	DDI-DrugBank.d77.s15.e1	DDI-DrugBank.d77.s15.e4
DDI-DrugBank.d77.s15	false	DDI-DrugBank.d77.s15.e2	DDI-DrugBank.d77.s15.e3
DDI-DrugBank.d77.s15	false	DDI-DrugBank.d77.s15.e2	DDI-DrugBank.d77.s15.e4
DDI-DrugBank.d77.s15	false	DDI-DrugBank.d77.s15.e3	DDI-DrugBank.d77.s15.e4
DDI-DrugBank.d77.s16|a|The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.
DDI-DrugBank.d77.s16	20	23	SSRI	group	DDI-DrugBank.d77.s16.e0
DDI-DrugBank.d77.s16	25	27	TCA	group	DDI-DrugBank.d77.s16.e1
DDI-DrugBank.d77.s16	142	145	SSRI	group	DDI-DrugBank.d77.s16.e2
DDI-DrugBank.d77.s16	true	DDI-DrugBank.d77.s16.e0	DDI-DrugBank.d77.s16.e1
DDI-DrugBank.d77.s16	false	DDI-DrugBank.d77.s16.e0	DDI-DrugBank.d77.s16.e2
DDI-DrugBank.d77.s16	false	DDI-DrugBank.d77.s16.e1	DDI-DrugBank.d77.s16.e2
DDI-DrugBank.d77.s17|a|Nevertheless, caution is indicated in the co-administration of TCA5 with any of the SSRIs and also in switching from one class to the other.
DDI-DrugBank.d77.s17	84	88	SSRIs	group	DDI-DrugBank.d77.s17.e0
DDI-DrugBank.d77.s18|a|Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
DDI-DrugBank.d77.s18	120	129	fluoxetine	drug	DDI-DrugBank.d77.s18.e0
DDI-DrugBank.d77.s19|a|Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
DDI-DrugBank.d77.s19	19	43	tricyclic antidepressants	group	DDI-DrugBank.d77.s19.e0
DDI-DrugBank.d77.s19	156	179	tricyclic antidepressant	group	DDI-DrugBank.d77.s19.e1
DDI-DrugBank.d77.s19	false	DDI-DrugBank.d77.s19.e0	DDI-DrugBank.d77.s19.e1
DDI-DrugBank.d77.s20|a|Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of tricyclic antidepressant may be required.
DDI-DrugBank.d77.s20	97	120	tricyclic antidepressant	group	DDI-DrugBank.d77.s20.e0
DDI-DrugBank.d77.s21|a|It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
DDI-DrugBank.d77.s21	27	29	TCA	group	DDI-DrugBank.d77.s21.e0
DDI-DrugBank.d77.s21	56	58	TCA	group	DDI-DrugBank.d77.s21.e1
DDI-DrugBank.d77.s21	false	DDI-DrugBank.d77.s21.e0	DDI-DrugBank.d77.s21.e1
DDI-DrugBank.d555.s0|a|No information available
DDI-DrugBank.d555.s1|a|.
DDI-DrugBank.d555.s2|a|
DDI-DrugBank.d97.s0|a|Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4.
DDI-DrugBank.d97.s0	0	8	Indinavir	drug	DDI-DrugBank.d97.s0.e0
DDI-DrugBank.d97.s1|a|Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects.
DDI-DrugBank.d97.s1	20	27	CRIXIVAN	brand	DDI-DrugBank.d97.s1.e0
DDI-DrugBank.d97.s2|a|Indinavir is metabolized by CYP3A4.
DDI-DrugBank.d97.s2	0	8	Indinavir	drug	DDI-DrugBank.d97.s2.e0
DDI-DrugBank.d97.s3|a|Drugs that induce CYP3A4 activity would be expected to increase the clearance of indinavir, resulting in lowered plasma concentrations of indinavir.
DDI-DrugBank.d97.s3	81	89	indinavir	drug	DDI-DrugBank.d97.s3.e0
DDI-DrugBank.d97.s3	138	146	indinavir	drug	DDI-DrugBank.d97.s3.e1
DDI-DrugBank.d97.s3	false	DDI-DrugBank.d97.s3.e0	DDI-DrugBank.d97.s3.e1
DDI-DrugBank.d97.s4|a|Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.
DDI-DrugBank.d97.s4	20	27	CRIXIVAN	brand	DDI-DrugBank.d97.s4.e0
DDI-DrugBank.d97.s4	95	103	indinavir	drug	DDI-DrugBank.d97.s4.e1
DDI-DrugBank.d97.s4	158	166	indinavir	drug	DDI-DrugBank.d97.s4.e2
DDI-DrugBank.d97.s4	false	DDI-DrugBank.d97.s4.e0	DDI-DrugBank.d97.s4.e1
DDI-DrugBank.d97.s4	false	DDI-DrugBank.d97.s4.e0	DDI-DrugBank.d97.s4.e2
DDI-DrugBank.d97.s4	false	DDI-DrugBank.d97.s4.e1	DDI-DrugBank.d97.s4.e2
DDI-DrugBank.d97.s5|a|Table 8
DDI-DrugBank.d97.s6|a|Drugs That Should Not Be Coadministered with CRIXIVAN
DDI-DrugBank.d97.s6	45	52	CRIXIVAN	brand	DDI-DrugBank.d97.s6.e0
DDI-DrugBank.d97.s7|a|Drug Class: Drug Name Clinical Comment
DDI-DrugBank.d97.s8|a|Antiarrhythmics: amiodarone
DDI-DrugBank.d97.s8	0	14	Antiarrhythmics	group	DDI-DrugBank.d97.s8.e0
DDI-DrugBank.d97.s8	17	26	amiodarone	drug	DDI-DrugBank.d97.s8.e1
DDI-DrugBank.d97.s8	false	DDI-DrugBank.d97.s8.e0	DDI-DrugBank.d97.s8.e1
DDI-DrugBank.d97.s9|a|CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
DDI-DrugBank.d97.s10|a|Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine
DDI-DrugBank.d97.s10	19	35	dihydroergotamine	drug	DDI-DrugBank.d97.s10.e0
DDI-DrugBank.d97.s10	38	47	ergonovine	drug	DDI-DrugBank.d97.s10.e1
DDI-DrugBank.d97.s10	50	59	ergotamine	drug	DDI-DrugBank.d97.s10.e2
DDI-DrugBank.d97.s10	62	77	methylergonovine	drug	DDI-DrugBank.d97.s10.e3
DDI-DrugBank.d97.s10	false	DDI-DrugBank.d97.s10.e0	DDI-DrugBank.d97.s10.e1
DDI-DrugBank.d97.s10	false	DDI-DrugBank.d97.s10.e0	DDI-DrugBank.d97.s10.e2
DDI-DrugBank.d97.s10	false	DDI-DrugBank.d97.s10.e0	DDI-DrugBank.d97.s10.e3
DDI-DrugBank.d97.s10	false	DDI-DrugBank.d97.s10.e1	DDI-DrugBank.d97.s10.e2
DDI-DrugBank.d97.s10	false	DDI-DrugBank.d97.s10.e1	DDI-DrugBank.d97.s10.e3
DDI-DrugBank.d97.s10	false	DDI-DrugBank.d97.s10.e2	DDI-DrugBank.d97.s10.e3
DDI-DrugBank.d97.s11|a|CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
DDI-DrugBank.d97.s12|a|Sedative/hypnotics: midazolam, triazolam
DDI-DrugBank.d97.s12	0	7	Sedative	group	DDI-DrugBank.d97.s12.e0
DDI-DrugBank.d97.s12	9	17	hypnotics	group	DDI-DrugBank.d97.s12.e1
DDI-DrugBank.d97.s12	20	28	midazolam	drug	DDI-DrugBank.d97.s12.e2
DDI-DrugBank.d97.s12	31	39	triazolam	drug	DDI-DrugBank.d97.s12.e3
DDI-DrugBank.d97.s12	false	DDI-DrugBank.d97.s12.e0	DDI-DrugBank.d97.s12.e1
DDI-DrugBank.d97.s12	false	DDI-DrugBank.d97.s12.e0	DDI-DrugBank.d97.s12.e2
DDI-DrugBank.d97.s12	false	DDI-DrugBank.d97.s12.e0	DDI-DrugBank.d97.s12.e3
DDI-DrugBank.d97.s12	false	DDI-DrugBank.d97.s12.e1	DDI-DrugBank.d97.s12.e2
DDI-DrugBank.d97.s12	false	DDI-DrugBank.d97.s12.e1	DDI-DrugBank.d97.s12.e3
DDI-DrugBank.d97.s12	false	DDI-DrugBank.d97.s12.e2	DDI-DrugBank.d97.s12.e3
DDI-DrugBank.d97.s13|a|CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
DDI-DrugBank.d97.s14|a|GI motility agents: cisapride
DDI-DrugBank.d97.s14	20	28	cisapride	drug	DDI-DrugBank.d97.s14.e0
DDI-DrugBank.d97.s15|a|CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
DDI-DrugBank.d97.s16|a|Neuroleptic: pimozide
DDI-DrugBank.d97.s16	0	10	Neuroleptic	group	DDI-DrugBank.d97.s16.e0
DDI-DrugBank.d97.s16	13	20	pimozide	drug	DDI-DrugBank.d97.s16.e1
DDI-DrugBank.d97.s16	false	DDI-DrugBank.d97.s16.e0	DDI-DrugBank.d97.s16.e1
DDI-DrugBank.d97.s17|a|CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
DDI-DrugBank.d97.s18|a|Herbal products: St. John s wort (Hypericum perforatum)
DDI-DrugBank.d97.s19|a|May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors.
DDI-DrugBank.d97.s19	66	73	CRIXIVAN	brand	DDI-DrugBank.d97.s19.e0
DDI-DrugBank.d97.s19	94	112	protease inhibitors	group	DDI-DrugBank.d97.s19.e1
DDI-DrugBank.d97.s19	false	DDI-DrugBank.d97.s19.e0	DDI-DrugBank.d97.s19.e1
DDI-DrugBank.d97.s20|a|Antimycobacterial: rifampin
DDI-DrugBank.d97.s20	0	16	Antimycobacterial	group	DDI-DrugBank.d97.s20.e0
DDI-DrugBank.d97.s20	19	26	rifampin	drug	DDI-DrugBank.d97.s20.e1
DDI-DrugBank.d97.s20	false	DDI-DrugBank.d97.s20.e0	DDI-DrugBank.d97.s20.e1
DDI-DrugBank.d97.s21|a|May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors or other coadministered antiretroviral agents.
DDI-DrugBank.d97.s21	66	73	CRIXIVAN	brand	DDI-DrugBank.d97.s21.e0
DDI-DrugBank.d97.s21	94	112	protease inhibitors	group	DDI-DrugBank.d97.s21.e1
DDI-DrugBank.d97.s21	138	158	antiretroviral agents	group	DDI-DrugBank.d97.s21.e2
DDI-DrugBank.d97.s21	false	DDI-DrugBank.d97.s21.e0	DDI-DrugBank.d97.s21.e1
DDI-DrugBank.d97.s21	false	DDI-DrugBank.d97.s21.e0	DDI-DrugBank.d97.s21.e2
DDI-DrugBank.d97.s21	false	DDI-DrugBank.d97.s21.e1	DDI-DrugBank.d97.s21.e2
DDI-DrugBank.d97.s22|a|HMG-CoA Reductase inhibitors: lovastatin, simvastatin
DDI-DrugBank.d97.s22	0	27	HMG-CoA Reductase inhibitors	group	DDI-DrugBank.d97.s22.e0
DDI-DrugBank.d97.s22	30	39	lovastatin	drug	DDI-DrugBank.d97.s22.e1
DDI-DrugBank.d97.s22	42	52	simvastatin	drug	DDI-DrugBank.d97.s22.e2
DDI-DrugBank.d97.s22	false	DDI-DrugBank.d97.s22.e0	DDI-DrugBank.d97.s22.e1
DDI-DrugBank.d97.s22	false	DDI-DrugBank.d97.s22.e0	DDI-DrugBank.d97.s22.e2
DDI-DrugBank.d97.s22	false	DDI-DrugBank.d97.s22.e1	DDI-DrugBank.d97.s22.e2
DDI-DrugBank.d97.s23|a|Potential for serious reactions such as risk of myopathy including rhabdomyolysis.
DDI-DrugBank.d97.s24|a|Protease inhibitor: atazanavir
DDI-DrugBank.d97.s24	0	17	Protease inhibitor	group	DDI-DrugBank.d97.s24.e0
DDI-DrugBank.d97.s24	20	29	atazanavir	drug	DDI-DrugBank.d97.s24.e1
DDI-DrugBank.d97.s24	false	DDI-DrugBank.d97.s24.e0	DDI-DrugBank.d97.s24.e1
DDI-DrugBank.d97.s25|a|Both CRIXIVAN and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia.
DDI-DrugBank.d97.s25	5	12	CRIXIVAN	brand	DDI-DrugBank.d97.s25.e0
DDI-DrugBank.d97.s25	18	27	atazanavir	drug	DDI-DrugBank.d97.s25.e1
DDI-DrugBank.d97.s25	false	DDI-DrugBank.d97.s25.e0	DDI-DrugBank.d97.s25.e1
DDI-DrugBank.d97.s26|a|Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.
DDI-DrugBank.d97.s26	74	81	CRIXIVAN	brand	DDI-DrugBank.d97.s26.e0
DDI-DrugBank.d97.s26	87	96	atazanavir	drug	DDI-DrugBank.d97.s26.e1
DDI-DrugBank.d97.s26	true	DDI-DrugBank.d97.s26.e0	DDI-DrugBank.d97.s26.e1
DDI-DrugBank.d97.s27|a|Table 9
DDI-DrugBank.d97.s28|a|Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction
DDI-DrugBank.d97.s29|a|Drug Name
DDI-DrugBank.d97.s30|a|Effect
DDI-DrugBank.d97.s31|a|Clinical Comment
DDI-DrugBank.d97.s32|a|HIV Antiviral Agents
DDI-DrugBank.d97.s32	0	19	HIV Antiviral Agents	group	DDI-DrugBank.d97.s32.e0
DDI-DrugBank.d97.s33|a|Delavirdine
DDI-DrugBank.d97.s33	0	10	Delavirdine	drug	DDI-DrugBank.d97.s33.e0
DDI-DrugBank.d97.s34|a|indinavir concentration
DDI-DrugBank.d97.s34	0	8	indinavir	drug	DDI-DrugBank.d97.s34.e0
DDI-DrugBank.d97.s35|a|Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.
DDI-DrugBank.d97.s35	18	25	CRIXIVAN	brand	DDI-DrugBank.d97.s35.e0
DDI-DrugBank.d97.s35	84	94	delavirdine	drug	DDI-DrugBank.d97.s35.e1
DDI-DrugBank.d97.s35	true	DDI-DrugBank.d97.s35.e0	DDI-DrugBank.d97.s35.e1
DDI-DrugBank.d97.s36|a|Didanosine
DDI-DrugBank.d97.s36	0	9	Didanosine	drug	DDI-DrugBank.d97.s36.e0
DDI-DrugBank.d97.s37|a|Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.
DDI-DrugBank.d97.s37	0	8	Indinavir	drug	DDI-DrugBank.d97.s37.e0
DDI-DrugBank.d97.s37	14	23	didanosine	drug	DDI-DrugBank.d97.s37.e1
DDI-DrugBank.d97.s37	true	DDI-DrugBank.d97.s37.e0	DDI-DrugBank.d97.s37.e1
DDI-DrugBank.d97.s38|a|Efavirenz
DDI-DrugBank.d97.s38	0	8	Efavirenz	drug	DDI-DrugBank.d97.s38.e0
DDI-DrugBank.d97.s39|a|indinavir concentration
DDI-DrugBank.d97.s39	0	8	indinavir	drug	DDI-DrugBank.d97.s39.e0
DDI-DrugBank.d97.s40|a|The optimal dose of indinavir, when given in combination with efavirenz, is not known.
DDI-DrugBank.d97.s40	20	28	indinavir	drug	DDI-DrugBank.d97.s40.e0
DDI-DrugBank.d97.s40	62	70	efavirenz	drug	DDI-DrugBank.d97.s40.e1
DDI-DrugBank.d97.s40	false	DDI-DrugBank.d97.s40.e0	DDI-DrugBank.d97.s40.e1
DDI-DrugBank.d97.s41|a|Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.
DDI-DrugBank.d97.s41	15	23	indinavir	drug	DDI-DrugBank.d97.s41.e0
DDI-DrugBank.d97.s41	93	101	indinavir	drug	DDI-DrugBank.d97.s41.e1
DDI-DrugBank.d97.s41	121	129	efavirenz	drug	DDI-DrugBank.d97.s41.e2
DDI-DrugBank.d97.s41	false	DDI-DrugBank.d97.s41.e0	DDI-DrugBank.d97.s41.e1
DDI-DrugBank.d97.s41	false	DDI-DrugBank.d97.s41.e0	DDI-DrugBank.d97.s41.e2
DDI-DrugBank.d97.s41	true	DDI-DrugBank.d97.s41.e1	DDI-DrugBank.d97.s41.e2
DDI-DrugBank.d97.s42|a|Nelfinavir
DDI-DrugBank.d97.s42	0	9	Nelfinavir	drug	DDI-DrugBank.d97.s42.e0
DDI-DrugBank.d97.s43|a|indinavir concentration
DDI-DrugBank.d97.s43	0	8	indinavir	drug	DDI-DrugBank.d97.s43.e0
DDI-DrugBank.d97.s44|a|The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
DDI-DrugBank.d97.s45|a|Nevirapine
DDI-DrugBank.d97.s45	0	9	Nevirapine	drug	DDI-DrugBank.d97.s45.e0
DDI-DrugBank.d97.s46|a|indinavir concentration
DDI-DrugBank.d97.s46	0	8	indinavir	drug	DDI-DrugBank.d97.s46.e0
DDI-DrugBank.d97.s47|a|Indinavir concentrations may be decreased in the presence of nevirapine.
DDI-DrugBank.d97.s47	0	8	Indinavir	drug	DDI-DrugBank.d97.s47.e0
DDI-DrugBank.d97.s47	61	70	nevirapine	drug	DDI-DrugBank.d97.s47.e1
DDI-DrugBank.d97.s47	true	DDI-DrugBank.d97.s47.e0	DDI-DrugBank.d97.s47.e1
DDI-DrugBank.d97.s48|a|The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
DDI-DrugBank.d97.s49|a|Ritonavir
DDI-DrugBank.d97.s49	0	8	Ritonavir	drug	DDI-DrugBank.d97.s49.e0
DDI-DrugBank.d97.s50|a|indinavir concentration   ritonavir concentration
DDI-DrugBank.d97.s50	0	8	indinavir	drug	DDI-DrugBank.d97.s50.e0
DDI-DrugBank.d97.s50	26	34	ritonavir	drug	DDI-DrugBank.d97.s50.e1
DDI-DrugBank.d97.s50	false	DDI-DrugBank.d97.s50.e0	DDI-DrugBank.d97.s50.e1
DDI-DrugBank.d97.s51|a|The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
DDI-DrugBank.d97.s52|a|Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.
DDI-DrugBank.d97.s52	104	112	indinavir	drug	DDI-DrugBank.d97.s52.e0
DDI-DrugBank.d97.s52	134	142	ritonavir	drug	DDI-DrugBank.d97.s52.e1
DDI-DrugBank.d97.s52	165	172	CRIXIVAN	brand	DDI-DrugBank.d97.s52.e2
DDI-DrugBank.d97.s52	true	DDI-DrugBank.d97.s52.e0	DDI-DrugBank.d97.s52.e1
DDI-DrugBank.d97.s52	false	DDI-DrugBank.d97.s52.e0	DDI-DrugBank.d97.s52.e2
DDI-DrugBank.d97.s52	false	DDI-DrugBank.d97.s52.e1	DDI-DrugBank.d97.s52.e2
DDI-DrugBank.d97.s53|a|Saquinavir
DDI-DrugBank.d97.s53	0	9	Saquinavir	drug	DDI-DrugBank.d97.s53.e0
DDI-DrugBank.d97.s54|a|saquinavir concentration
DDI-DrugBank.d97.s54	0	9	saquinavir	drug	DDI-DrugBank.d97.s54.e0
DDI-DrugBank.d97.s55|a|The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
DDI-DrugBank.d97.s56|a|Other Agents
DDI-DrugBank.d97.s57|a|Antiarrhythmics: bepridil, lidocaine (systemic) and quinidine
DDI-DrugBank.d97.s57	0	14	Antiarrhythmics	group	DDI-DrugBank.d97.s57.e0
DDI-DrugBank.d97.s57	17	24	bepridil	drug	DDI-DrugBank.d97.s57.e1
DDI-DrugBank.d97.s57	27	35	lidocaine	drug	DDI-DrugBank.d97.s57.e2
DDI-DrugBank.d97.s57	52	60	quinidine	drug	DDI-DrugBank.d97.s57.e3
DDI-DrugBank.d97.s57	false	DDI-DrugBank.d97.s57.e0	DDI-DrugBank.d97.s57.e1
DDI-DrugBank.d97.s57	false	DDI-DrugBank.d97.s57.e0	DDI-DrugBank.d97.s57.e2
DDI-DrugBank.d97.s57	false	DDI-DrugBank.d97.s57.e0	DDI-DrugBank.d97.s57.e3
DDI-DrugBank.d97.s57	false	DDI-DrugBank.d97.s57.e1	DDI-DrugBank.d97.s57.e2
DDI-DrugBank.d97.s57	false	DDI-DrugBank.d97.s57.e1	DDI-DrugBank.d97.s57.e3
DDI-DrugBank.d97.s57	false	DDI-DrugBank.d97.s57.e2	DDI-DrugBank.d97.s57.e3
DDI-DrugBank.d97.s58|a|antiarrhythmic agents concentration
DDI-DrugBank.d97.s58	0	20	antiarrhythmic agents	group	DDI-DrugBank.d97.s58.e0
DDI-DrugBank.d97.s59|a|Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.
DDI-DrugBank.d97.s59	81	95	antiarrhythmics	group	DDI-DrugBank.d97.s59.e0
DDI-DrugBank.d97.s59	122	129	CRIXIVAN	brand	DDI-DrugBank.d97.s59.e1
DDI-DrugBank.d97.s59	true	DDI-DrugBank.d97.s59.e0	DDI-DrugBank.d97.s59.e1
DDI-DrugBank.d97.s60|a|Anticonvulsants: carbamazepine, phenobarbital, phenytoin
DDI-DrugBank.d97.s60	0	14	Anticonvulsants	group	DDI-DrugBank.d97.s60.e0
DDI-DrugBank.d97.s60	17	29	carbamazepine	drug	DDI-DrugBank.d97.s60.e1
DDI-DrugBank.d97.s60	32	44	phenobarbital	drug	DDI-DrugBank.d97.s60.e2
DDI-DrugBank.d97.s60	47	55	phenytoin	drug	DDI-DrugBank.d97.s60.e3
DDI-DrugBank.d97.s60	false	DDI-DrugBank.d97.s60.e0	DDI-DrugBank.d97.s60.e1
DDI-DrugBank.d97.s60	false	DDI-DrugBank.d97.s60.e0	DDI-DrugBank.d97.s60.e2
DDI-DrugBank.d97.s60	false	DDI-DrugBank.d97.s60.e0	DDI-DrugBank.d97.s60.e3
DDI-DrugBank.d97.s60	false	DDI-DrugBank.d97.s60.e1	DDI-DrugBank.d97.s60.e2
DDI-DrugBank.d97.s60	false	DDI-DrugBank.d97.s60.e1	DDI-DrugBank.d97.s60.e3
DDI-DrugBank.d97.s60	false	DDI-DrugBank.d97.s60.e2	DDI-DrugBank.d97.s60.e3
DDI-DrugBank.d97.s61|a|indinavir concentration
DDI-DrugBank.d97.s61	0	8	indinavir	drug	DDI-DrugBank.d97.s61.e0
DDI-DrugBank.d97.s62|a|Use with caution.
DDI-DrugBank.d97.s63|a|CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.
DDI-DrugBank.d97.s63	0	7	CRIXIVAN	brand	DDI-DrugBank.d97.s63.e0
DDI-DrugBank.d97.s63	47	55	indinavir	drug	DDI-DrugBank.d97.s63.e1
DDI-DrugBank.d97.s63	true	DDI-DrugBank.d97.s63.e0	DDI-DrugBank.d97.s63.e1
DDI-DrugBank.d97.s64|a|Calcium Channel Blockers, Dihydropyridine: e.g., felodipine, nifedipine, nicardipine
DDI-DrugBank.d97.s64	0	23	Calcium Channel Blockers	group	DDI-DrugBank.d97.s64.e0
DDI-DrugBank.d97.s64	26	40	Dihydropyridine	group	DDI-DrugBank.d97.s64.e1
DDI-DrugBank.d97.s64	49	58	felodipine	drug	DDI-DrugBank.d97.s64.e2
DDI-DrugBank.d97.s64	61	70	nifedipine	drug	DDI-DrugBank.d97.s64.e3
DDI-DrugBank.d97.s64	73	83	nicardipine	drug	DDI-DrugBank.d97.s64.e4
DDI-DrugBank.d97.s64	false	DDI-DrugBank.d97.s64.e0	DDI-DrugBank.d97.s64.e1
DDI-DrugBank.d97.s64	false	DDI-DrugBank.d97.s64.e0	DDI-DrugBank.d97.s64.e2
DDI-DrugBank.d97.s64	false	DDI-DrugBank.d97.s64.e0	DDI-DrugBank.d97.s64.e3
DDI-DrugBank.d97.s64	false	DDI-DrugBank.d97.s64.e0	DDI-DrugBank.d97.s64.e4
DDI-DrugBank.d97.s64	false	DDI-DrugBank.d97.s64.e1	DDI-DrugBank.d97.s64.e2
DDI-DrugBank.d97.s64	false	DDI-DrugBank.d97.s64.e1	DDI-DrugBank.d97.s64.e3
DDI-DrugBank.d97.s64	false	DDI-DrugBank.d97.s64.e1	DDI-DrugBank.d97.s64.e4
DDI-DrugBank.d97.s64	false	DDI-DrugBank.d97.s64.e2	DDI-DrugBank.d97.s64.e3
DDI-DrugBank.d97.s64	false	DDI-DrugBank.d97.s64.e2	DDI-DrugBank.d97.s64.e4
DDI-DrugBank.d97.s64	false	DDI-DrugBank.d97.s64.e3	DDI-DrugBank.d97.s64.e4
DDI-DrugBank.d97.s65|a|dihydropyridine calcium channel blockers concentration
DDI-DrugBank.d97.s65	0	39	dihydropyridine calcium channel blockers	group	DDI-DrugBank.d97.s65.e0
DDI-DrugBank.d97.s66|a|Caution is warranted and clinical monitoring of patients is recommended.
DDI-DrugBank.d97.s67|a|Clarithromycin
DDI-DrugBank.d97.s67	0	13	Clarithromycin	drug	DDI-DrugBank.d97.s67.e0
DDI-DrugBank.d97.s68|a|clarithromycin concentration   indinavir concentration
DDI-DrugBank.d97.s68	0	13	clarithromycin	drug	DDI-DrugBank.d97.s68.e0
DDI-DrugBank.d97.s68	31	39	indinavir	drug	DDI-DrugBank.d97.s68.e1
DDI-DrugBank.d97.s68	false	DDI-DrugBank.d97.s68.e0	DDI-DrugBank.d97.s68.e1
DDI-DrugBank.d97.s69|a|The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
DDI-DrugBank.d97.s70|a|HMG-CoA Reductase Inhibitor: atorvastatin
DDI-DrugBank.d97.s70	0	26	HMG-CoA Reductase Inhibitor	group	DDI-DrugBank.d97.s70.e0
DDI-DrugBank.d97.s70	29	40	atorvastatin	drug	DDI-DrugBank.d97.s70.e1
DDI-DrugBank.d97.s70	false	DDI-DrugBank.d97.s70.e0	DDI-DrugBank.d97.s70.e1
DDI-DrugBank.d97.s71|a|atorvastatin concentration
DDI-DrugBank.d97.s71	0	11	atorvastatin	drug	DDI-DrugBank.d97.s71.e0
DDI-DrugBank.d97.s72|a|Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.
DDI-DrugBank.d97.s72	28	39	atorvastatin	drug	DDI-DrugBank.d97.s72.e0
DDI-DrugBank.d97.s72	78	105	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d97.s72.e1
DDI-DrugBank.d97.s72	161	171	pravastatin	drug	DDI-DrugBank.d97.s72.e2
DDI-DrugBank.d97.s72	174	184	fluvastatin	drug	DDI-DrugBank.d97.s72.e3
DDI-DrugBank.d97.s72	190	201	rosuvastatin	drug	DDI-DrugBank.d97.s72.e4
DDI-DrugBank.d97.s72	223	230	CRIXIVAN	brand	DDI-DrugBank.d97.s72.e5
DDI-DrugBank.d97.s72	false	DDI-DrugBank.d97.s72.e0	DDI-DrugBank.d97.s72.e1
DDI-DrugBank.d97.s72	false	DDI-DrugBank.d97.s72.e0	DDI-DrugBank.d97.s72.e2
DDI-DrugBank.d97.s72	false	DDI-DrugBank.d97.s72.e0	DDI-DrugBank.d97.s72.e3
DDI-DrugBank.d97.s72	false	DDI-DrugBank.d97.s72.e0	DDI-DrugBank.d97.s72.e4
DDI-DrugBank.d97.s72	true	DDI-DrugBank.d97.s72.e0	DDI-DrugBank.d97.s72.e5
DDI-DrugBank.d97.s72	false	DDI-DrugBank.d97.s72.e1	DDI-DrugBank.d97.s72.e2
DDI-DrugBank.d97.s72	false	DDI-DrugBank.d97.s72.e1	DDI-DrugBank.d97.s72.e3
DDI-DrugBank.d97.s72	false	DDI-DrugBank.d97.s72.e1	DDI-DrugBank.d97.s72.e4
DDI-DrugBank.d97.s72	true	DDI-DrugBank.d97.s72.e1	DDI-DrugBank.d97.s72.e5
DDI-DrugBank.d97.s72	false	DDI-DrugBank.d97.s72.e2	DDI-DrugBank.d97.s72.e3
DDI-DrugBank.d97.s73|a|Immunosuppressants: cyclosporine, tacrolimus, sirolimus
DDI-DrugBank.d97.s73	0	17	Immunosuppressants	group	DDI-DrugBank.d97.s73.e0
DDI-DrugBank.d97.s73	20	31	cyclosporine	drug	DDI-DrugBank.d97.s73.e1
DDI-DrugBank.d97.s73	34	43	tacrolimus	drug	DDI-DrugBank.d97.s73.e2
DDI-DrugBank.d97.s73	46	54	sirolimus	drug	DDI-DrugBank.d97.s73.e3
DDI-DrugBank.d97.s73	false	DDI-DrugBank.d97.s73.e0	DDI-DrugBank.d97.s73.e1
DDI-DrugBank.d97.s73	false	DDI-DrugBank.d97.s73.e0	DDI-DrugBank.d97.s73.e2
DDI-DrugBank.d97.s73	false	DDI-DrugBank.d97.s73.e0	DDI-DrugBank.d97.s73.e3
DDI-DrugBank.d97.s73	false	DDI-DrugBank.d97.s73.e1	DDI-DrugBank.d97.s73.e2
DDI-DrugBank.d97.s73	false	DDI-DrugBank.d97.s73.e1	DDI-DrugBank.d97.s73.e3
DDI-DrugBank.d97.s73	false	DDI-DrugBank.d97.s73.e2	DDI-DrugBank.d97.s73.e3
DDI-DrugBank.d97.s74|a|immunosuppressant agents concentration
DDI-DrugBank.d97.s74	0	23	immunosuppressant agents	group	DDI-DrugBank.d97.s74.e0
DDI-DrugBank.d97.s75|a|Plasma concentrations may be increased by CRIXIVAN.
DDI-DrugBank.d97.s75	42	49	CRIXIVAN	brand	DDI-DrugBank.d97.s75.e0
DDI-DrugBank.d97.s76|a|Itraconazole
DDI-DrugBank.d97.s76	0	11	Itraconazole	drug	DDI-DrugBank.d97.s76.e0
DDI-DrugBank.d97.s77|a|indinavir concentration
DDI-DrugBank.d97.s77	0	8	indinavir	drug	DDI-DrugBank.d97.s77.e0
DDI-DrugBank.d97.s78|a|Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.
DDI-DrugBank.d97.s78	18	25	CRIXIVAN	brand	DDI-DrugBank.d97.s78.e0
DDI-DrugBank.d97.s78	85	96	itraconazole	drug	DDI-DrugBank.d97.s78.e1
DDI-DrugBank.d97.s78	true	DDI-DrugBank.d97.s78.e0	DDI-DrugBank.d97.s78.e1
DDI-DrugBank.d97.s79|a|Ketoconazole
DDI-DrugBank.d97.s79	0	11	Ketoconazole	drug	DDI-DrugBank.d97.s79.e0
DDI-DrugBank.d97.s80|a|indinavir concentration
DDI-DrugBank.d97.s80	0	8	indinavir	drug	DDI-DrugBank.d97.s80.e0
DDI-DrugBank.d97.s81|a|Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered.
DDI-DrugBank.d97.s81	18	25	CRIXIVAN	brand	DDI-DrugBank.d97.s81.e0
DDI-DrugBank.d97.s82|a|Rifabutin
DDI-DrugBank.d97.s82	0	8	Rifabutin	drug	DDI-DrugBank.d97.s82.e0
DDI-DrugBank.d97.s83|a|indinavir concentration   rifabutin concentration
DDI-DrugBank.d97.s83	0	8	indinavir	drug	DDI-DrugBank.d97.s83.e0
DDI-DrugBank.d97.s83	26	34	rifabutin	drug	DDI-DrugBank.d97.s83.e1
DDI-DrugBank.d97.s83	false	DDI-DrugBank.d97.s83.e0	DDI-DrugBank.d97.s83.e1
DDI-DrugBank.d97.s84|a|Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
DDI-DrugBank.d97.s84	18	26	rifabutin	drug	DDI-DrugBank.d97.s84.e0
DDI-DrugBank.d97.s84	77	84	CRIXIVAN	brand	DDI-DrugBank.d97.s84.e1
DDI-DrugBank.d97.s84	156	164	rifabutin	drug	DDI-DrugBank.d97.s84.e2
DDI-DrugBank.d97.s84	170	177	CRIXIVAN	brand	DDI-DrugBank.d97.s84.e3
DDI-DrugBank.d97.s84	false	DDI-DrugBank.d97.s84.e0	DDI-DrugBank.d97.s84.e1
DDI-DrugBank.d97.s84	false	DDI-DrugBank.d97.s84.e0	DDI-DrugBank.d97.s84.e2
DDI-DrugBank.d97.s84	false	DDI-DrugBank.d97.s84.e0	DDI-DrugBank.d97.s84.e3
DDI-DrugBank.d97.s84	false	DDI-DrugBank.d97.s84.e1	DDI-DrugBank.d97.s84.e2
DDI-DrugBank.d97.s84	false	DDI-DrugBank.d97.s84.e1	DDI-DrugBank.d97.s84.e3
DDI-DrugBank.d97.s84	true	DDI-DrugBank.d97.s84.e2	DDI-DrugBank.d97.s84.e3
DDI-DrugBank.d97.s85|a|Sildenafil
DDI-DrugBank.d97.s85	0	9	Sildenafil	drug	DDI-DrugBank.d97.s85.e0
DDI-DrugBank.d97.s86|a|sildenafil concentration
DDI-DrugBank.d97.s86	0	9	sildenafil	drug	DDI-DrugBank.d97.s86.e0
DDI-DrugBank.d97.s87|a|Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.
DDI-DrugBank.d97.s87	0	9	Sildenafil	drug	DDI-DrugBank.d97.s87.e0
DDI-DrugBank.d97.s87	108	116	indinavir	drug	DDI-DrugBank.d97.s87.e1
DDI-DrugBank.d97.s87	true	DDI-DrugBank.d97.s87.e0	DDI-DrugBank.d97.s87.e1
DDI-DrugBank.d97.s88|a|Tadalafil
DDI-DrugBank.d97.s88	0	8	Tadalafil	drug	DDI-DrugBank.d97.s88.e0
DDI-DrugBank.d97.s89|a|tadalafil concentration
DDI-DrugBank.d97.s89	0	8	tadalafil	drug	DDI-DrugBank.d97.s89.e0
DDI-DrugBank.d97.s90|a|Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.
DDI-DrugBank.d97.s90	0	8	Tadalafil	drug	DDI-DrugBank.d97.s90.e0
DDI-DrugBank.d97.s90	107	115	indinavir	drug	DDI-DrugBank.d97.s90.e1
DDI-DrugBank.d97.s90	true	DDI-DrugBank.d97.s90.e0	DDI-DrugBank.d97.s90.e1
DDI-DrugBank.d97.s91|a|Vardenafil
DDI-DrugBank.d97.s91	0	9	Vardenafil	drug	DDI-DrugBank.d97.s91.e0
DDI-DrugBank.d97.s92|a|vardenafil concentration
DDI-DrugBank.d97.s92	0	9	vardenafil	drug	DDI-DrugBank.d97.s92.e0
DDI-DrugBank.d97.s93|a|Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.
DDI-DrugBank.d97.s93	0	9	Vardenafil	drug	DDI-DrugBank.d97.s93.e0
DDI-DrugBank.d97.s93	108	116	indinavir	drug	DDI-DrugBank.d97.s93.e1
DDI-DrugBank.d97.s93	true	DDI-DrugBank.d97.s93.e0	DDI-DrugBank.d97.s93.e1
DDI-DrugBank.d97.s94|a|Note:
DDI-DrugBank.d97.s95|a|= increase;
DDI-DrugBank.d97.s96|a|= decrease
DDI-DrugBank.d97.s97|a|
DDI-DrugBank.d82.s0|a|In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.
DDI-DrugBank.d82.s0	31	42	indomethacin	drug	DDI-DrugBank.d82.s0.e0
DDI-DrugBank.d82.s0	67	76	diflunisal	drug	DDI-DrugBank.d82.s0.e1
DDI-DrugBank.d82.s0	157	168	indomethacin	drug	DDI-DrugBank.d82.s0.e2
DDI-DrugBank.d82.s0	false	DDI-DrugBank.d82.s0.e0	DDI-DrugBank.d82.s0.e1
DDI-DrugBank.d82.s0	false	DDI-DrugBank.d82.s0.e0	DDI-DrugBank.d82.s0.e2
DDI-DrugBank.d82.s0	true	DDI-DrugBank.d82.s0.e1	DDI-DrugBank.d82.s0.e2
DDI-DrugBank.d82.s1|a|In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.
DDI-DrugBank.d82.s1	34	40	INDOCIN	brand	DDI-DrugBank.d82.s1.e0
DDI-DrugBank.d82.s1	46	55	diflunisal	drug	DDI-DrugBank.d82.s1.e1
DDI-DrugBank.d82.s1	true	DDI-DrugBank.d82.s1.e0	DDI-DrugBank.d82.s1.e1
DDI-DrugBank.d82.s2|a|Therefore, diflunisal and INDOCIN should not be used concomitantly.
DDI-DrugBank.d82.s2	11	20	diflunisal	drug	DDI-DrugBank.d82.s2.e0
DDI-DrugBank.d82.s2	26	32	INDOCIN	brand	DDI-DrugBank.d82.s2.e1
DDI-DrugBank.d82.s2	true	DDI-DrugBank.d82.s2.e0	DDI-DrugBank.d82.s2.e1
DDI-DrugBank.d82.s3|a|In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.
DDI-DrugBank.d82.s3	97	103	aspirin	brand	DDI-DrugBank.d82.s3.e0
DDI-DrugBank.d82.s3	123	134	indomethacin	drug	DDI-DrugBank.d82.s3.e1
DDI-DrugBank.d82.s3	true	DDI-DrugBank.d82.s3.e0	DDI-DrugBank.d82.s3.e1
DDI-DrugBank.d82.s4|a|The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
DDI-DrugBank.d82.s4	23	29	INDOCIN	brand	DDI-DrugBank.d82.s4.e0
DDI-DrugBank.d82.s4	42	47	NSAIDs	group	DDI-DrugBank.d82.s4.e1
DDI-DrugBank.d82.s4	true	DDI-DrugBank.d82.s4.e0	DDI-DrugBank.d82.s4.e1
DDI-DrugBank.d82.s5|a|Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants.
DDI-DrugBank.d82.s5	33	39	INDOCIN	brand	DDI-DrugBank.d82.s5.e0
DDI-DrugBank.d82.s5	96	109	anticoagulants	group	DDI-DrugBank.d82.s5.e1
DDI-DrugBank.d82.s5	false	DDI-DrugBank.d82.s5.e0	DDI-DrugBank.d82.s5.e1
DDI-DrugBank.d82.s6|a|However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.
DDI-DrugBank.d82.s6	45	51	INDOCIN	brand	DDI-DrugBank.d82.s6.e0
DDI-DrugBank.d82.s6	95	107	anticoagulant	group	DDI-DrugBank.d82.s6.e1
DDI-DrugBank.d82.s6	true	DDI-DrugBank.d82.s6.e0	DDI-DrugBank.d82.s6.e1
DDI-DrugBank.d82.s7|a|In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.
DDI-DrugBank.d82.s7	99	112	anticoagulants	group	DDI-DrugBank.d82.s7.e0
DDI-DrugBank.d82.s7	118	124	INDOCIN	brand	DDI-DrugBank.d82.s7.e1
DDI-DrugBank.d82.s7	true	DDI-DrugBank.d82.s7.e0	DDI-DrugBank.d82.s7.e1
DDI-DrugBank.d82.s8|a|Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.
DDI-DrugBank.d82.s8	33	39	INDOCIN	brand	DDI-DrugBank.d82.s8.e0
DDI-DrugBank.d82.s8	45	58	anticoagulants	group	DDI-DrugBank.d82.s8.e1
DDI-DrugBank.d82.s8	true	DDI-DrugBank.d82.s8.e0	DDI-DrugBank.d82.s8.e1
DDI-DrugBank.d82.s9|a|When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.
DDI-DrugBank.d82.s9	5	11	INDOCIN	brand	DDI-DrugBank.d82.s9.e0
DDI-DrugBank.d82.s9	44	53	probenecid	drug	DDI-DrugBank.d82.s9.e1
DDI-DrugBank.d82.s9	77	88	indomethacin	drug	DDI-DrugBank.d82.s9.e2
DDI-DrugBank.d82.s9	true	DDI-DrugBank.d82.s9.e0	DDI-DrugBank.d82.s9.e1
DDI-DrugBank.d82.s9	false	DDI-DrugBank.d82.s9.e0	DDI-DrugBank.d82.s9.e2
DDI-DrugBank.d82.s9	false	DDI-DrugBank.d82.s9.e1	DDI-DrugBank.d82.s9.e2
DDI-DrugBank.d82.s10|a|Therefore, a lower total daily dosage of INDOCIN may produce a satisfactory therapeutic effect.
DDI-DrugBank.d82.s10	41	47	INDOCIN	brand	DDI-DrugBank.d82.s10.e0
DDI-DrugBank.d82.s11|a|When increases in the dose of INDOCIN are made, they should be made carefully and in small increments.
DDI-DrugBank.d82.s11	30	36	INDOCIN	brand	DDI-DrugBank.d82.s11.e0
DDI-DrugBank.d82.s12|a|Caution should be used if INDOCIN is administered simultaneously with methotrexate.
DDI-DrugBank.d82.s12	26	32	INDOCIN	brand	DDI-DrugBank.d82.s12.e0
DDI-DrugBank.d82.s12	70	81	methotrexate	drug	DDI-DrugBank.d82.s12.e1
DDI-DrugBank.d82.s12	true	DDI-DrugBank.d82.s12.e0	DDI-DrugBank.d82.s12.e1
DDI-DrugBank.d82.s13|a|INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
DDI-DrugBank.d82.s13	0	6	INDOCIN	brand	DDI-DrugBank.d82.s13.e0
DDI-DrugBank.d82.s13	63	74	methotrexate	drug	DDI-DrugBank.d82.s13.e1
DDI-DrugBank.d82.s13	true	DDI-DrugBank.d82.s13.e0	DDI-DrugBank.d82.s13.e1
DDI-DrugBank.d82.s14|a|Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
DDI-DrugBank.d82.s14	18	54	non-steroidal anti-inflammatory drugs	group	DDI-DrugBank.d82.s14.e0
DDI-DrugBank.d82.s14	75	86	cyclosporine	drug	DDI-DrugBank.d82.s14.e1
DDI-DrugBank.d82.s14	128	139	cyclosporine	drug	DDI-DrugBank.d82.s14.e2
DDI-DrugBank.d82.s14	true	DDI-DrugBank.d82.s14.e0	DDI-DrugBank.d82.s14.e1
DDI-DrugBank.d82.s14	false	DDI-DrugBank.d82.s14.e0	DDI-DrugBank.d82.s14.e2
DDI-DrugBank.d82.s14	false	DDI-DrugBank.d82.s14.e1	DDI-DrugBank.d82.s14.e2
DDI-DrugBank.d82.s15|a|NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
DDI-DrugBank.d82.s15	0	5	NSAIDs	group	DDI-DrugBank.d82.s15.e0
DDI-DrugBank.d82.s15	54	65	cyclosporine	drug	DDI-DrugBank.d82.s15.e1
DDI-DrugBank.d82.s15	true	DDI-DrugBank.d82.s15.e0	DDI-DrugBank.d82.s15.e1
DDI-DrugBank.d82.s16|a|Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.
DDI-DrugBank.d82.s16	9	15	INDOCIN	brand	DDI-DrugBank.d82.s16.e0
DDI-DrugBank.d82.s16	81	87	lithium	drug	DDI-DrugBank.d82.s16.e1
DDI-DrugBank.d82.s16	112	118	lithium	drug	DDI-DrugBank.d82.s16.e2
DDI-DrugBank.d82.s16	199	205	lithium	drug	DDI-DrugBank.d82.s16.e3
DDI-DrugBank.d82.s16	true	DDI-DrugBank.d82.s16.e0	DDI-DrugBank.d82.s16.e1
DDI-DrugBank.d82.s16	false	DDI-DrugBank.d82.s16.e0	DDI-DrugBank.d82.s16.e2
DDI-DrugBank.d82.s16	false	DDI-DrugBank.d82.s16.e0	DDI-DrugBank.d82.s16.e3
DDI-DrugBank.d82.s16	false	DDI-DrugBank.d82.s16.e1	DDI-DrugBank.d82.s16.e2
DDI-DrugBank.d82.s16	false	DDI-DrugBank.d82.s16.e1	DDI-DrugBank.d82.s16.e3
DDI-DrugBank.d82.s16	false	DDI-DrugBank.d82.s16.e2	DDI-DrugBank.d82.s16.e3
DDI-DrugBank.d82.s17|a|This effect has been attributed to inhibition of prostaglandin synthesis.
DDI-DrugBank.d82.s18|a|As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.
DDI-DrugBank.d82.s18	23	29	INDOCIN	brand	DDI-DrugBank.d82.s18.e0
DDI-DrugBank.d82.s18	35	41	lithium	drug	DDI-DrugBank.d82.s18.e1
DDI-DrugBank.d82.s18	122	128	lithium	drug	DDI-DrugBank.d82.s18.e2
DDI-DrugBank.d82.s18	true	DDI-DrugBank.d82.s18.e0	DDI-DrugBank.d82.s18.e1
DDI-DrugBank.d82.s18	false	DDI-DrugBank.d82.s18.e0	DDI-DrugBank.d82.s18.e2
DDI-DrugBank.d82.s18	false	DDI-DrugBank.d82.s18.e1	DDI-DrugBank.d82.s18.e2
DDI-DrugBank.d82.s19|a|(Read circulars for lithium preparations before use of such concomitant therapy.)
DDI-DrugBank.d82.s19	20	26	lithium	drug	DDI-DrugBank.d82.s19.e0
DDI-DrugBank.d82.s20|a|In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.
DDI-DrugBank.d82.s20	47	53	lithium	drug	DDI-DrugBank.d82.s20.e0
DDI-DrugBank.d82.s21|a|INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
DDI-DrugBank.d82.s21	0	6	INDOCIN	brand	DDI-DrugBank.d82.s21.e0
DDI-DrugBank.d82.s21	33	39	digoxin	drug	DDI-DrugBank.d82.s21.e1
DDI-DrugBank.d82.s21	124	130	digoxin	drug	DDI-DrugBank.d82.s21.e2
DDI-DrugBank.d82.s21	true	DDI-DrugBank.d82.s21.e0	DDI-DrugBank.d82.s21.e1
DDI-DrugBank.d82.s21	false	DDI-DrugBank.d82.s21.e0	DDI-DrugBank.d82.s21.e2
DDI-DrugBank.d82.s21	false	DDI-DrugBank.d82.s21.e1	DDI-DrugBank.d82.s21.e2
DDI-DrugBank.d82.s22|a|Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.
DDI-DrugBank.d82.s22	16	22	INDOCIN	brand	DDI-DrugBank.d82.s22.e0
DDI-DrugBank.d82.s22	28	34	digoxin	drug	DDI-DrugBank.d82.s22.e1
DDI-DrugBank.d82.s22	66	72	digoxin	drug	DDI-DrugBank.d82.s22.e2
DDI-DrugBank.d82.s22	true	DDI-DrugBank.d82.s22.e0	DDI-DrugBank.d82.s22.e1
DDI-DrugBank.d82.s22	false	DDI-DrugBank.d82.s22.e0	DDI-DrugBank.d82.s22.e2
DDI-DrugBank.d82.s22	false	DDI-DrugBank.d82.s22.e1	DDI-DrugBank.d82.s22.e2
DDI-DrugBank.d82.s23|a|In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
DDI-DrugBank.d82.s23	40	46	INDOCIN	brand	DDI-DrugBank.d82.s23.e0
DDI-DrugBank.d82.s23	118	121	loop diuretics	group	DDI-DrugBank.d82.s23.e1
DDI-DrugBank.d82.s23	156	164	loop diuretics	group	DDI-DrugBank.d82.s23.e1
DDI-DrugBank.d82.s23	124	140	potassium-sparing diuretics	group	DDI-DrugBank.d82.s23.e2
DDI-DrugBank.d82.s23	156	164	potassium-sparing diuretics	group	DDI-DrugBank.d82.s23.e2
DDI-DrugBank.d82.s23	147	164	thiazide diuretics	group	DDI-DrugBank.d82.s23.e3
DDI-DrugBank.d82.s23	true	DDI-DrugBank.d82.s23.e0	DDI-DrugBank.d82.s23.e1
DDI-DrugBank.d82.s23	true	DDI-DrugBank.d82.s23.e0	DDI-DrugBank.d82.s23.e2
DDI-DrugBank.d82.s23	true	DDI-DrugBank.d82.s23.e0	DDI-DrugBank.d82.s23.e3
DDI-DrugBank.d82.s23	false	DDI-DrugBank.d82.s23.e1	DDI-DrugBank.d82.s23.e2
DDI-DrugBank.d82.s23	false	DDI-DrugBank.d82.s23.e1	DDI-DrugBank.d82.s23.e3
DDI-DrugBank.d82.s23	false	DDI-DrugBank.d82.s23.e2	DDI-DrugBank.d82.s23.e3
DDI-DrugBank.d82.s24|a|Therefore, when INDOCIN and INDOCIN.
DDI-DrugBank.d82.s24	16	22	INDOCIN	brand	DDI-DrugBank.d82.s24.e0
DDI-DrugBank.d82.s24	28	34	INDOCIN	brand	DDI-DrugBank.d82.s24.e1
DDI-DrugBank.d82.s24	false	DDI-DrugBank.d82.s24.e0	DDI-DrugBank.d82.s24.e1
DDI-DrugBank.d82.s25|a|(Indomethacin) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
DDI-DrugBank.d82.s25	1	12	Indomethacin	drug	DDI-DrugBank.d82.s25.e0
DDI-DrugBank.d82.s25	15	23	diuretics	group	DDI-DrugBank.d82.s25.e1
DDI-DrugBank.d82.s25	130	137	diuretic	group	DDI-DrugBank.d82.s25.e2
DDI-DrugBank.d82.s25	false	DDI-DrugBank.d82.s25.e0	DDI-DrugBank.d82.s25.e1
DDI-DrugBank.d82.s25	false	DDI-DrugBank.d82.s25.e0	DDI-DrugBank.d82.s25.e2
DDI-DrugBank.d82.s25	false	DDI-DrugBank.d82.s25.e1	DDI-DrugBank.d82.s25.e2
DDI-DrugBank.d82.s26|a|INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion.
DDI-DrugBank.d82.s26	0	6	INDOCIN	brand	DDI-DrugBank.d82.s26.e0
DDI-DrugBank.d82.s26	97	106	furosemide	drug	DDI-DrugBank.d82.s26.e1
DDI-DrugBank.d82.s26	false	DDI-DrugBank.d82.s26.e0	DDI-DrugBank.d82.s26.e1
DDI-DrugBank.d82.s27|a|These facts should be considered when evaluating plasma renin activity in hypertensive patients.
DDI-DrugBank.d82.s28|a|It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.
DDI-DrugBank.d82.s28	42	52	triamterene	drug	DDI-DrugBank.d82.s28.e0
DDI-DrugBank.d82.s28	83	89	INDOCIN	brand	DDI-DrugBank.d82.s28.e1
DDI-DrugBank.d82.s28	true	DDI-DrugBank.d82.s28.e0	DDI-DrugBank.d82.s28.e1
DDI-DrugBank.d82.s29|a|INDOCIN and triamterene should not be administered together.
DDI-DrugBank.d82.s29	0	6	INDOCIN	brand	DDI-DrugBank.d82.s29.e0
DDI-DrugBank.d82.s29	12	22	triamterene	drug	DDI-DrugBank.d82.s29.e1
DDI-DrugBank.d82.s29	true	DDI-DrugBank.d82.s29.e0	DDI-DrugBank.d82.s29.e1
DDI-DrugBank.d82.s30|a|INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels.
DDI-DrugBank.d82.s30	0	6	INDOCIN	brand	DDI-DrugBank.d82.s30.e0
DDI-DrugBank.d82.s30	12	38	potassium-sparing diuretics	group	DDI-DrugBank.d82.s30.e1
DDI-DrugBank.d82.s30	false	DDI-DrugBank.d82.s30.e0	DDI-DrugBank.d82.s30.e1
DDI-DrugBank.d82.s31|a|The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.
DDI-DrugBank.d82.s31	25	31	INDOCIN	brand	DDI-DrugBank.d82.s31.e0
DDI-DrugBank.d82.s31	37	63	potassium-sparing diuretics	group	DDI-DrugBank.d82.s31.e1
DDI-DrugBank.d82.s31	true	DDI-DrugBank.d82.s31.e0	DDI-DrugBank.d82.s31.e1
DDI-DrugBank.d82.s32|a|Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.
DDI-DrugBank.d82.s32	37	45	diuretics	group	DDI-DrugBank.d82.s32.e0
DDI-DrugBank.d82.s32	152	158	INDOCIN	brand	DDI-DrugBank.d82.s32.e1
DDI-DrugBank.d82.s32	true	DDI-DrugBank.d82.s32.e0	DDI-DrugBank.d82.s32.e1
DDI-DrugBank.d82.s33|a|Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.
DDI-DrugBank.d82.s33	43	75	beta-adrenoceptor blocking agents	group	DDI-DrugBank.d82.s33.e0
DDI-DrugBank.d82.s33	80	115	non-steroidal antiinflammatory drugs	group	DDI-DrugBank.d82.s33.e1
DDI-DrugBank.d82.s33	127	133	INDOCIN	brand	DDI-DrugBank.d82.s33.e2
DDI-DrugBank.d82.s33	true	DDI-DrugBank.d82.s33.e0	DDI-DrugBank.d82.s33.e1
DDI-DrugBank.d82.s33	true	DDI-DrugBank.d82.s33.e0	DDI-DrugBank.d82.s33.e2
DDI-DrugBank.d82.s33	false	DDI-DrugBank.d82.s33.e1	DDI-DrugBank.d82.s33.e2
DDI-DrugBank.d82.s34|a|Therefore, when using these blocking agents to treat hypertension, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained.
DDI-DrugBank.d82.s35|a|INDOCIN can reduce the antihypertensive effects of captopril and losartan.
DDI-DrugBank.d82.s35	0	6	INDOCIN	brand	DDI-DrugBank.d82.s35.e0
DDI-DrugBank.d82.s35	51	59	captopril	drug	DDI-DrugBank.d82.s35.e1
DDI-DrugBank.d82.s35	65	72	losartan	drug	DDI-DrugBank.d82.s35.e2
DDI-DrugBank.d82.s35	true	DDI-DrugBank.d82.s35.e0	DDI-DrugBank.d82.s35.e1
DDI-DrugBank.d82.s35	true	DDI-DrugBank.d82.s35.e0	DDI-DrugBank.d82.s35.e2
DDI-DrugBank.d82.s35	false	DDI-DrugBank.d82.s35.e1	DDI-DrugBank.d82.s35.e2
DDI-DrugBank.d82.s36|a|False-negative results in the dexamethasone suppression test (DST) in patients being treated with INDOCIN have been reported.
DDI-DrugBank.d82.s36	98	104	INDOCIN	brand	DDI-DrugBank.d82.s36.e0
DDI-DrugBank.d82.s37|a|Thus, results of the DST should be interpreted with caution in these patients.
DDI-DrugBank.d45.s0|a|Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
DDI-DrugBank.d45.s0	29	38	etanercept	drug	DDI-DrugBank.d45.s0.e0
DDI-DrugBank.d45.s0	74	81	anakinra	drug	DDI-DrugBank.d45.s0.e1
DDI-DrugBank.d45.s0	87	110	interleukin-1 antagonist	group	DDI-DrugBank.d45.s0.e2
DDI-DrugBank.d45.s0	true	DDI-DrugBank.d45.s0.e0	DDI-DrugBank.d45.s0.e1
DDI-DrugBank.d45.s0	false	DDI-DrugBank.d45.s0.e0	DDI-DrugBank.d45.s0.e2
DDI-DrugBank.d45.s0	false	DDI-DrugBank.d45.s0.e1	DDI-DrugBank.d45.s0.e2
DDI-DrugBank.d45.s1|a|Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.
DDI-DrugBank.d45.s1	6	25	TNFa-blocking agents	group	DDI-DrugBank.d45.s1.e0
DDI-DrugBank.d45.s1	38	45	REMICADE	brand	DDI-DrugBank.d45.s1.e1
DDI-DrugBank.d45.s1	73	80	anakinra	drug	DDI-DrugBank.d45.s1.e2
DDI-DrugBank.d45.s1	false	DDI-DrugBank.d45.s1.e0	DDI-DrugBank.d45.s1.e1
DDI-DrugBank.d45.s1	true	DDI-DrugBank.d45.s1.e0	DDI-DrugBank.d45.s1.e2
DDI-DrugBank.d45.s1	true	DDI-DrugBank.d45.s1.e1	DDI-DrugBank.d45.s1.e2
DDI-DrugBank.d45.s2|a|Specific drug interaction studies, including interactions with MTX, have not been conducted.
DDI-DrugBank.d45.s2	63	65	MTX	drug	DDI-DrugBank.d45.s2.e0
DDI-DrugBank.d45.s3|a|The majority of patients in rheumatoid arthritis or Crohn s disease clinical studies received one or more concomitant medications.
DDI-DrugBank.d45.s4|a|In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.
DDI-DrugBank.d45.s4	57	59	MTX	drug	DDI-DrugBank.d45.s4.e0
DDI-DrugBank.d45.s4	66	102	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d45.s4.e1
DDI-DrugBank.d45.s4	105	114	folic acid	drug	DDI-DrugBank.d45.s4.e2
DDI-DrugBank.d45.s4	117	131	corticosteroids	group	DDI-DrugBank.d45.s4.e3
DDI-DrugBank.d45.s4	140	148	narcotics	group	DDI-DrugBank.d45.s4.e4
DDI-DrugBank.d45.s4	false	DDI-DrugBank.d45.s4.e0	DDI-DrugBank.d45.s4.e1
DDI-DrugBank.d45.s4	false	DDI-DrugBank.d45.s4.e0	DDI-DrugBank.d45.s4.e2
DDI-DrugBank.d45.s4	false	DDI-DrugBank.d45.s4.e0	DDI-DrugBank.d45.s4.e3
DDI-DrugBank.d45.s4	false	DDI-DrugBank.d45.s4.e0	DDI-DrugBank.d45.s4.e4
DDI-DrugBank.d45.s4	false	DDI-DrugBank.d45.s4.e1	DDI-DrugBank.d45.s4.e2
DDI-DrugBank.d45.s4	false	DDI-DrugBank.d45.s4.e1	DDI-DrugBank.d45.s4.e3
DDI-DrugBank.d45.s4	false	DDI-DrugBank.d45.s4.e1	DDI-DrugBank.d45.s4.e4
DDI-DrugBank.d45.s4	false	DDI-DrugBank.d45.s4.e2	DDI-DrugBank.d45.s4.e3
DDI-DrugBank.d45.s4	false	DDI-DrugBank.d45.s4.e2	DDI-DrugBank.d45.s4.e4
DDI-DrugBank.d45.s4	false	DDI-DrugBank.d45.s4.e3	DDI-DrugBank.d45.s4.e4
DDI-DrugBank.d45.s5|a|Concomitant Crohn s disease medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates.
DDI-DrugBank.d45.s5	45	55	antibiotics	group	DDI-DrugBank.d45.s5.e0
DDI-DrugBank.d45.s5	58	67	antivirals	group	DDI-DrugBank.d45.s5.e1
DDI-DrugBank.d45.s5	70	84	corticosteroids	group	DDI-DrugBank.d45.s5.e2
DDI-DrugBank.d45.s5	87	90	6-MP	drug	DDI-DrugBank.d45.s5.e3
DDI-DrugBank.d45.s5	92	94	AZA	drug	DDI-DrugBank.d45.s5.e4
DDI-DrugBank.d45.s5	false	DDI-DrugBank.d45.s5.e0	DDI-DrugBank.d45.s5.e1
DDI-DrugBank.d45.s5	false	DDI-DrugBank.d45.s5.e0	DDI-DrugBank.d45.s5.e2
DDI-DrugBank.d45.s5	false	DDI-DrugBank.d45.s5.e0	DDI-DrugBank.d45.s5.e3
DDI-DrugBank.d45.s5	false	DDI-DrugBank.d45.s5.e0	DDI-DrugBank.d45.s5.e4
DDI-DrugBank.d45.s5	false	DDI-DrugBank.d45.s5.e1	DDI-DrugBank.d45.s5.e2
DDI-DrugBank.d45.s5	false	DDI-DrugBank.d45.s5.e1	DDI-DrugBank.d45.s5.e3
DDI-DrugBank.d45.s5	false	DDI-DrugBank.d45.s5.e1	DDI-DrugBank.d45.s5.e4
DDI-DrugBank.d45.s5	false	DDI-DrugBank.d45.s5.e2	DDI-DrugBank.d45.s5.e3
DDI-DrugBank.d45.s5	false	DDI-DrugBank.d45.s5.e2	DDI-DrugBank.d45.s5.e4
DDI-DrugBank.d45.s5	false	DDI-DrugBank.d45.s5.e3	DDI-DrugBank.d45.s5.e4
DDI-DrugBank.d45.s6|a|In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents, folic acid and corticosteroids.
DDI-DrugBank.d45.s6	73	75	MTX	drug	DDI-DrugBank.d45.s6.e0
DDI-DrugBank.d45.s6	126	162	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d45.s6.e1
DDI-DrugBank.d45.s6	165	174	folic acid	drug	DDI-DrugBank.d45.s6.e2
DDI-DrugBank.d45.s6	180	194	corticosteroids	group	DDI-DrugBank.d45.s6.e3
DDI-DrugBank.d45.s6	false	DDI-DrugBank.d45.s6.e0	DDI-DrugBank.d45.s6.e1
DDI-DrugBank.d45.s6	false	DDI-DrugBank.d45.s6.e0	DDI-DrugBank.d45.s6.e2
DDI-DrugBank.d45.s6	false	DDI-DrugBank.d45.s6.e0	DDI-DrugBank.d45.s6.e3
DDI-DrugBank.d45.s6	false	DDI-DrugBank.d45.s6.e1	DDI-DrugBank.d45.s6.e2
DDI-DrugBank.d45.s6	false	DDI-DrugBank.d45.s6.e1	DDI-DrugBank.d45.s6.e3
DDI-DrugBank.d45.s6	false	DDI-DrugBank.d45.s6.e2	DDI-DrugBank.d45.s6.e3
DDI-DrugBank.d45.s7|a|Patients with Crohn s disease who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants.
DDI-DrugBank.d45.s7	43	60	immunosuppressants	group	DDI-DrugBank.d45.s7.e0
DDI-DrugBank.d45.s7	135	152	immunosuppressants	group	DDI-DrugBank.d45.s7.e1
DDI-DrugBank.d45.s7	false	DDI-DrugBank.d45.s7.e0	DDI-DrugBank.d45.s7.e1
DDI-DrugBank.d45.s8|a|Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.
DDI-DrugBank.d45.s8	6	15	infliximab	drug	DDI-DrugBank.d45.s8.e0
DDI-DrugBank.d45.s8	136	150	corticosteroids	group	DDI-DrugBank.d45.s8.e1
DDI-DrugBank.d45.s8	153	163	antibiotics	group	DDI-DrugBank.d45.s8.e2
DDI-DrugBank.d45.s8	166	178	metronidazole	drug	DDI-DrugBank.d45.s8.e3
DDI-DrugBank.d45.s8	183	195	ciprofloxacin	drug	DDI-DrugBank.d45.s8.e4
DDI-DrugBank.d45.s8	false	DDI-DrugBank.d45.s8.e0	DDI-DrugBank.d45.s8.e1
DDI-DrugBank.d45.s8	false	DDI-DrugBank.d45.s8.e0	DDI-DrugBank.d45.s8.e2
DDI-DrugBank.d45.s8	false	DDI-DrugBank.d45.s8.e0	DDI-DrugBank.d45.s8.e3
DDI-DrugBank.d45.s8	false	DDI-DrugBank.d45.s8.e0	DDI-DrugBank.d45.s8.e4
DDI-DrugBank.d45.s8	false	DDI-DrugBank.d45.s8.e1	DDI-DrugBank.d45.s8.e2
DDI-DrugBank.d45.s8	false	DDI-DrugBank.d45.s8.e1	DDI-DrugBank.d45.s8.e3
DDI-DrugBank.d45.s8	false	DDI-DrugBank.d45.s8.e1	DDI-DrugBank.d45.s8.e4
DDI-DrugBank.d45.s8	false	DDI-DrugBank.d45.s8.e2	DDI-DrugBank.d45.s8.e3
DDI-DrugBank.d45.s8	false	DDI-DrugBank.d45.s8.e2	DDI-DrugBank.d45.s8.e4
DDI-DrugBank.d45.s8	false	DDI-DrugBank.d45.s8.e3	DDI-DrugBank.d45.s8.e4
DDI-DrugBank.d527.s0|a|A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.
DDI-DrugBank.d527.s0	65	71	insulin	drug	DDI-DrugBank.d527.s0.e0
DDI-DrugBank.d527.s1|a|The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
DDI-DrugBank.d527.s1	157	170	ACE inhibitors	group	DDI-DrugBank.d527.s1.e0
DDI-DrugBank.d527.s1	173	184	disopyramide	drug	DDI-DrugBank.d527.s1.e1
DDI-DrugBank.d527.s1	187	194	fibrates	group	DDI-DrugBank.d527.s1.e2
DDI-DrugBank.d527.s1	197	206	fluoxetine	drug	DDI-DrugBank.d527.s1.e3
DDI-DrugBank.d527.s1	209	222	MAO inhibitors	group	DDI-DrugBank.d527.s1.e4
DDI-DrugBank.d527.s1	225	236	propoxyphene	drug	DDI-DrugBank.d527.s1.e5
DDI-DrugBank.d527.s1	239	249	salicylates	group	DDI-DrugBank.d527.s1.e6
DDI-DrugBank.d527.s1	252	270	somatostatin analog	group	DDI-DrugBank.d527.s1.e7
DDI-DrugBank.d527.s1	279	288	octreotide	drug	DDI-DrugBank.d527.s1.e8
DDI-DrugBank.d527.s1	292	314	sulfonamide antibiotics	group	DDI-DrugBank.d527.s1.e9
DDI-DrugBank.d527.s1	false	DDI-DrugBank.d527.s1.e0	DDI-DrugBank.d527.s1.e1
DDI-DrugBank.d527.s1	false	DDI-DrugBank.d527.s1.e0	DDI-DrugBank.d527.s1.e2
DDI-DrugBank.d527.s1	false	DDI-DrugBank.d527.s1.e0	DDI-DrugBank.d527.s1.e3
DDI-DrugBank.d527.s1	false	DDI-DrugBank.d527.s1.e0	DDI-DrugBank.d527.s1.e4
DDI-DrugBank.d527.s1	false	DDI-DrugBank.d527.s1.e0	DDI-DrugBank.d527.s1.e5
DDI-DrugBank.d527.s1	false	DDI-DrugBank.d527.s1.e0	DDI-DrugBank.d527.s1.e6
DDI-DrugBank.d527.s1	false	DDI-DrugBank.d527.s1.e0	DDI-DrugBank.d527.s1.e7
DDI-DrugBank.d527.s1	false	DDI-DrugBank.d527.s1.e0	DDI-DrugBank.d527.s1.e8
DDI-DrugBank.d527.s1	false	DDI-DrugBank.d527.s1.e0	DDI-DrugBank.d527.s1.e9
DDI-DrugBank.d527.s1	false	DDI-DrugBank.d527.s1.e1	DDI-DrugBank.d527.s1.e2
DDI-DrugBank.d527.s2|a|The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
DDI-DrugBank.d527.s2	94	100	insulin	drug	DDI-DrugBank.d527.s2.e0
DDI-DrugBank.d527.s2	103	117	corticosteroids	group	DDI-DrugBank.d527.s2.e1
DDI-DrugBank.d527.s2	120	126	danazol	drug	DDI-DrugBank.d527.s2.e2
DDI-DrugBank.d527.s2	129	137	diuretics	group	DDI-DrugBank.d527.s2.e3
DDI-DrugBank.d527.s2	140	161	sympathomimetic agents	group	DDI-DrugBank.d527.s2.e4
DDI-DrugBank.d527.s2	170	180	epinephrine	drug	DDI-DrugBank.d527.s2.e5
DDI-DrugBank.d527.s2	183	191	albuterol	drug	DDI-DrugBank.d527.s2.e6
DDI-DrugBank.d527.s2	194	204	terbutaline	drug	DDI-DrugBank.d527.s2.e7
DDI-DrugBank.d527.s2	208	216	isoniazid	drug	DDI-DrugBank.d527.s2.e8
DDI-DrugBank.d527.s2	219	243	phenothiazine derivatives	group	DDI-DrugBank.d527.s2.e9
DDI-DrugBank.d527.s2	false	DDI-DrugBank.d527.s2.e0	DDI-DrugBank.d527.s2.e1
DDI-DrugBank.d527.s2	false	DDI-DrugBank.d527.s2.e0	DDI-DrugBank.d527.s2.e2
DDI-DrugBank.d527.s2	false	DDI-DrugBank.d527.s2.e0	DDI-DrugBank.d527.s2.e3
DDI-DrugBank.d527.s2	false	DDI-DrugBank.d527.s2.e0	DDI-DrugBank.d527.s2.e4
DDI-DrugBank.d527.s2	false	DDI-DrugBank.d527.s2.e0	DDI-DrugBank.d527.s2.e5
DDI-DrugBank.d527.s2	false	DDI-DrugBank.d527.s2.e0	DDI-DrugBank.d527.s2.e6
DDI-DrugBank.d527.s2	false	DDI-DrugBank.d527.s2.e0	DDI-DrugBank.d527.s2.e7
DDI-DrugBank.d527.s2	false	DDI-DrugBank.d527.s2.e0	DDI-DrugBank.d527.s2.e8
DDI-DrugBank.d527.s2	false	DDI-DrugBank.d527.s2.e0	DDI-DrugBank.d527.s2.e9
DDI-DrugBank.d527.s2	false	DDI-DrugBank.d527.s2.e0	DDI-DrugBank.d527.s2.e10
DDI-DrugBank.d527.s3|a|Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
DDI-DrugBank.d527.s3	0	12	Beta-blockers	group	DDI-DrugBank.d527.s3.e0
DDI-DrugBank.d527.s3	15	23	clonidine	drug	DDI-DrugBank.d527.s3.e1
DDI-DrugBank.d527.s3	26	32	lithium	drug	DDI-DrugBank.d527.s3.e2
DDI-DrugBank.d527.s3	45	51	alcohol	drug	DDI-DrugBank.d527.s3.e3
DDI-DrugBank.d527.s3	122	128	insulin	drug	DDI-DrugBank.d527.s3.e4
DDI-DrugBank.d527.s3	false	DDI-DrugBank.d527.s3.e0	DDI-DrugBank.d527.s3.e1
DDI-DrugBank.d527.s3	false	DDI-DrugBank.d527.s3.e0	DDI-DrugBank.d527.s3.e2
DDI-DrugBank.d527.s3	false	DDI-DrugBank.d527.s3.e0	DDI-DrugBank.d527.s3.e3
DDI-DrugBank.d527.s3	true	DDI-DrugBank.d527.s3.e0	DDI-DrugBank.d527.s3.e4
DDI-DrugBank.d527.s3	false	DDI-DrugBank.d527.s3.e1	DDI-DrugBank.d527.s3.e2
DDI-DrugBank.d527.s3	false	DDI-DrugBank.d527.s3.e1	DDI-DrugBank.d527.s3.e3
DDI-DrugBank.d527.s3	true	DDI-DrugBank.d527.s3.e1	DDI-DrugBank.d527.s3.e4
DDI-DrugBank.d527.s3	false	DDI-DrugBank.d527.s3.e2	DDI-DrugBank.d527.s3.e3
DDI-DrugBank.d527.s3	true	DDI-DrugBank.d527.s3.e2	DDI-DrugBank.d527.s3.e4
DDI-DrugBank.d527.s3	true	DDI-DrugBank.d527.s3.e3	DDI-DrugBank.d527.s3.e4
DDI-DrugBank.d527.s4|a|Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.
DDI-DrugBank.d527.s4	0	10	Pentamidine	drug	DDI-DrugBank.d527.s4.e0
DDI-DrugBank.d527.s5|a|In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.
DDI-DrugBank.d527.s5	77	89	beta-blockers	group	DDI-DrugBank.d527.s5.e0
DDI-DrugBank.d527.s5	92	100	clonidine	drug	DDI-DrugBank.d527.s5.e1
DDI-DrugBank.d527.s5	103	114	guanethidine	drug	DDI-DrugBank.d527.s5.e2
DDI-DrugBank.d527.s5	121	129	reserpine	drug	DDI-DrugBank.d527.s5.e3
DDI-DrugBank.d527.s5	false	DDI-DrugBank.d527.s5.e0	DDI-DrugBank.d527.s5.e1
DDI-DrugBank.d527.s5	false	DDI-DrugBank.d527.s5.e0	DDI-DrugBank.d527.s5.e2
DDI-DrugBank.d527.s5	false	DDI-DrugBank.d527.s5.e0	DDI-DrugBank.d527.s5.e3
DDI-DrugBank.d527.s5	false	DDI-DrugBank.d527.s5.e1	DDI-DrugBank.d527.s5.e2
DDI-DrugBank.d527.s5	false	DDI-DrugBank.d527.s5.e1	DDI-DrugBank.d527.s5.e3
DDI-DrugBank.d527.s5	false	DDI-DrugBank.d527.s5.e2	DDI-DrugBank.d527.s5.e3
DDI-DrugBank.d313.s0|a|A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.
DDI-DrugBank.d313.s0	65	71	insulin	drug	DDI-DrugBank.d313.s0.e0
DDI-DrugBank.d313.s1|a|The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
DDI-DrugBank.d313.s1	134	154	antidiabetic products	group	DDI-DrugBank.d313.s1.e0
DDI-DrugBank.d313.s1	157	170	ACE inhibitors	group	DDI-DrugBank.d313.s1.e1
DDI-DrugBank.d313.s1	173	184	disopyramide	drug	DDI-DrugBank.d313.s1.e2
DDI-DrugBank.d313.s1	187	194	fibrates	group	DDI-DrugBank.d313.s1.e3
DDI-DrugBank.d313.s1	197	206	fluoxetine	drug	DDI-DrugBank.d313.s1.e4
DDI-DrugBank.d313.s1	209	242	monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d313.s1.e5
DDI-DrugBank.d313.s1	245	256	propoxyphene	drug	DDI-DrugBank.d313.s1.e6
DDI-DrugBank.d313.s1	259	269	salicylates	group	DDI-DrugBank.d313.s1.e7
DDI-DrugBank.d313.s1	272	290	somatostatin analog	group	DDI-DrugBank.d313.s1.e8
DDI-DrugBank.d313.s1	299	308	octreotide	drug	DDI-DrugBank.d313.s1.e9
DDI-DrugBank.d313.s1	false	DDI-DrugBank.d313.s1.e0	DDI-DrugBank.d313.s1.e1
DDI-DrugBank.d313.s1	false	DDI-DrugBank.d313.s1.e0	DDI-DrugBank.d313.s1.e2
DDI-DrugBank.d313.s1	false	DDI-DrugBank.d313.s1.e0	DDI-DrugBank.d313.s1.e3
DDI-DrugBank.d313.s1	false	DDI-DrugBank.d313.s1.e0	DDI-DrugBank.d313.s1.e4
DDI-DrugBank.d313.s1	false	DDI-DrugBank.d313.s1.e0	DDI-DrugBank.d313.s1.e5
DDI-DrugBank.d313.s1	false	DDI-DrugBank.d313.s1.e0	DDI-DrugBank.d313.s1.e6
DDI-DrugBank.d313.s1	false	DDI-DrugBank.d313.s1.e0	DDI-DrugBank.d313.s1.e7
DDI-DrugBank.d313.s1	false	DDI-DrugBank.d313.s1.e0	DDI-DrugBank.d313.s1.e8
DDI-DrugBank.d313.s1	false	DDI-DrugBank.d313.s1.e0	DDI-DrugBank.d313.s1.e9
DDI-DrugBank.d313.s1	false	DDI-DrugBank.d313.s1.e0	DDI-DrugBank.d313.s1.e10
DDI-DrugBank.d313.s2|a|The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
DDI-DrugBank.d313.s2	92	106	corticosteroids	group	DDI-DrugBank.d313.s2.e0
DDI-DrugBank.d313.s2	109	114	niacin	drug	DDI-DrugBank.d313.s2.e1
DDI-DrugBank.d313.s2	117	123	danazol	drug	DDI-DrugBank.d313.s2.e2
DDI-DrugBank.d313.s2	126	134	diuretics	group	DDI-DrugBank.d313.s2.e3
DDI-DrugBank.d313.s2	137	158	sympathomimetic agents	group	DDI-DrugBank.d313.s2.e4
DDI-DrugBank.d313.s2	167	177	epinephrine	drug	DDI-DrugBank.d313.s2.e5
DDI-DrugBank.d313.s2	180	189	salbutamol	drug	DDI-DrugBank.d313.s2.e6
DDI-DrugBank.d313.s2	192	202	terbutaline	drug	DDI-DrugBank.d313.s2.e7
DDI-DrugBank.d313.s2	206	214	isoniazid	drug	DDI-DrugBank.d313.s2.e8
DDI-DrugBank.d313.s2	217	241	phenothiazine derivatives	group	DDI-DrugBank.d313.s2.e9
DDI-DrugBank.d313.s2	false	DDI-DrugBank.d313.s2.e0	DDI-DrugBank.d313.s2.e1
DDI-DrugBank.d313.s2	false	DDI-DrugBank.d313.s2.e0	DDI-DrugBank.d313.s2.e2
DDI-DrugBank.d313.s2	false	DDI-DrugBank.d313.s2.e0	DDI-DrugBank.d313.s2.e3
DDI-DrugBank.d313.s2	false	DDI-DrugBank.d313.s2.e0	DDI-DrugBank.d313.s2.e4
DDI-DrugBank.d313.s2	false	DDI-DrugBank.d313.s2.e0	DDI-DrugBank.d313.s2.e5
DDI-DrugBank.d313.s2	false	DDI-DrugBank.d313.s2.e0	DDI-DrugBank.d313.s2.e6
DDI-DrugBank.d313.s2	false	DDI-DrugBank.d313.s2.e0	DDI-DrugBank.d313.s2.e7
DDI-DrugBank.d313.s2	false	DDI-DrugBank.d313.s2.e0	DDI-DrugBank.d313.s2.e8
DDI-DrugBank.d313.s2	false	DDI-DrugBank.d313.s2.e0	DDI-DrugBank.d313.s2.e9
DDI-DrugBank.d313.s2	false	DDI-DrugBank.d313.s2.e0	DDI-DrugBank.d313.s2.e10
DDI-DrugBank.d313.s3|a|Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
DDI-DrugBank.d313.s3	0	12	Beta-blockers	group	DDI-DrugBank.d313.s3.e0
DDI-DrugBank.d313.s3	15	23	clonidine	drug	DDI-DrugBank.d313.s3.e1
DDI-DrugBank.d313.s3	26	32	lithium	drug	DDI-DrugBank.d313.s3.e2
DDI-DrugBank.d313.s3	45	51	alcohol	drug	DDI-DrugBank.d313.s3.e3
DDI-DrugBank.d313.s3	122	128	insulin	drug	DDI-DrugBank.d313.s3.e4
DDI-DrugBank.d313.s3	false	DDI-DrugBank.d313.s3.e0	DDI-DrugBank.d313.s3.e1
DDI-DrugBank.d313.s3	false	DDI-DrugBank.d313.s3.e0	DDI-DrugBank.d313.s3.e2
DDI-DrugBank.d313.s3	false	DDI-DrugBank.d313.s3.e0	DDI-DrugBank.d313.s3.e3
DDI-DrugBank.d313.s3	true	DDI-DrugBank.d313.s3.e0	DDI-DrugBank.d313.s3.e4
DDI-DrugBank.d313.s3	false	DDI-DrugBank.d313.s3.e1	DDI-DrugBank.d313.s3.e2
DDI-DrugBank.d313.s3	false	DDI-DrugBank.d313.s3.e1	DDI-DrugBank.d313.s3.e3
DDI-DrugBank.d313.s3	true	DDI-DrugBank.d313.s3.e1	DDI-DrugBank.d313.s3.e4
DDI-DrugBank.d313.s3	false	DDI-DrugBank.d313.s3.e2	DDI-DrugBank.d313.s3.e3
DDI-DrugBank.d313.s3	true	DDI-DrugBank.d313.s3.e2	DDI-DrugBank.d313.s3.e4
DDI-DrugBank.d313.s3	true	DDI-DrugBank.d313.s3.e3	DDI-DrugBank.d313.s3.e4
DDI-DrugBank.d313.s4|a|Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.
DDI-DrugBank.d313.s4	0	10	Pentamidine	drug	DDI-DrugBank.d313.s4.e0
DDI-DrugBank.d313.s5|a|In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.
DDI-DrugBank.d313.s5	77	89	beta-blockers	group	DDI-DrugBank.d313.s5.e0
DDI-DrugBank.d313.s5	92	100	clonidine	drug	DDI-DrugBank.d313.s5.e1
DDI-DrugBank.d313.s5	103	114	guanethidine	drug	DDI-DrugBank.d313.s5.e2
DDI-DrugBank.d313.s5	121	129	reserpine	drug	DDI-DrugBank.d313.s5.e3
DDI-DrugBank.d313.s5	false	DDI-DrugBank.d313.s5.e0	DDI-DrugBank.d313.s5.e1
DDI-DrugBank.d313.s5	false	DDI-DrugBank.d313.s5.e0	DDI-DrugBank.d313.s5.e2
DDI-DrugBank.d313.s5	false	DDI-DrugBank.d313.s5.e0	DDI-DrugBank.d313.s5.e3
DDI-DrugBank.d313.s5	false	DDI-DrugBank.d313.s5.e1	DDI-DrugBank.d313.s5.e2
DDI-DrugBank.d313.s5	false	DDI-DrugBank.d313.s5.e1	DDI-DrugBank.d313.s5.e3
DDI-DrugBank.d313.s5	false	DDI-DrugBank.d313.s5.e2	DDI-DrugBank.d313.s5.e3
DDI-DrugBank.d313.s6|a|Mixing of Insulins
DDI-DrugBank.d313.s6	10	17	Insulins	group	DDI-DrugBank.d313.s6.e0
DDI-DrugBank.d313.s7|a|A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.
DDI-DrugBank.d313.s7	76	82	NovoLog	brand	DDI-DrugBank.d313.s7.e0
DDI-DrugBank.d313.s7	89	105	NPH human insulin	drug	DDI-DrugBank.d313.s7.e1
DDI-DrugBank.d313.s7	191	197	NovoLog	brand	DDI-DrugBank.d313.s7.e2
DDI-DrugBank.d313.s7	259	265	NovoLog	brand	DDI-DrugBank.d313.s7.e3
DDI-DrugBank.d313.s7	false	DDI-DrugBank.d313.s7.e0	DDI-DrugBank.d313.s7.e1
DDI-DrugBank.d313.s7	false	DDI-DrugBank.d313.s7.e0	DDI-DrugBank.d313.s7.e2
DDI-DrugBank.d313.s7	false	DDI-DrugBank.d313.s7.e0	DDI-DrugBank.d313.s7.e3
DDI-DrugBank.d313.s7	false	DDI-DrugBank.d313.s7.e1	DDI-DrugBank.d313.s7.e2
DDI-DrugBank.d313.s7	false	DDI-DrugBank.d313.s7.e1	DDI-DrugBank.d313.s7.e3
DDI-DrugBank.d313.s7	false	DDI-DrugBank.d313.s7.e2	DDI-DrugBank.d313.s7.e3
DDI-DrugBank.d313.s8|a|If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first.
DDI-DrugBank.d313.s8	3	9	NovoLog	brand	DDI-DrugBank.d313.s8.e0
DDI-DrugBank.d313.s8	25	41	NPH human insulin	drug	DDI-DrugBank.d313.s8.e1
DDI-DrugBank.d313.s8	44	50	NovoLog	brand	DDI-DrugBank.d313.s8.e2
DDI-DrugBank.d313.s8	false	DDI-DrugBank.d313.s8.e0	DDI-DrugBank.d313.s8.e1
DDI-DrugBank.d313.s8	false	DDI-DrugBank.d313.s8.e0	DDI-DrugBank.d313.s8.e2
DDI-DrugBank.d313.s8	false	DDI-DrugBank.d313.s8.e1	DDI-DrugBank.d313.s8.e2
DDI-DrugBank.d313.s9|a|The injection should be made immediately after mixing.
DDI-DrugBank.d313.s10|a|Because there are no data on the compatibility of NovoLog and crystalline zinc insulin preparations, NovoLog should not be mixed with these preparations.
DDI-DrugBank.d313.s10	50	56	NovoLog	brand	DDI-DrugBank.d313.s10.e0
DDI-DrugBank.d313.s10	74	85	zinc insulin	drug	DDI-DrugBank.d313.s10.e1
DDI-DrugBank.d313.s10	101	107	NovoLog	brand	DDI-DrugBank.d313.s10.e2
DDI-DrugBank.d313.s10	false	DDI-DrugBank.d313.s10.e0	DDI-DrugBank.d313.s10.e1
DDI-DrugBank.d313.s10	false	DDI-DrugBank.d313.s10.e0	DDI-DrugBank.d313.s10.e2
DDI-DrugBank.d313.s10	false	DDI-DrugBank.d313.s10.e1	DDI-DrugBank.d313.s10.e2
DDI-DrugBank.d313.s11|a|The effects of mixing NovoLog with insulins of animal source or insulin preparations produced by other manufacturers have not been studied .
DDI-DrugBank.d313.s11	22	28	NovoLog	brand	DDI-DrugBank.d313.s11.e0
DDI-DrugBank.d313.s11	35	42	insulins	group	DDI-DrugBank.d313.s11.e1
DDI-DrugBank.d313.s11	64	70	insulin	drug	DDI-DrugBank.d313.s11.e2
DDI-DrugBank.d313.s11	false	DDI-DrugBank.d313.s11.e0	DDI-DrugBank.d313.s11.e1
DDI-DrugBank.d313.s11	false	DDI-DrugBank.d313.s11.e0	DDI-DrugBank.d313.s11.e2
DDI-DrugBank.d313.s11	false	DDI-DrugBank.d313.s11.e1	DDI-DrugBank.d313.s11.e2
DDI-DrugBank.d313.s12|a|Mixtures should not be administered intravenously.
DDI-DrugBank.d313.s13|a|When used in external subcutaneous infusion pumps for insulin, NovoLog should not be mixed with any other insulins or diluent.
DDI-DrugBank.d313.s13	54	60	insulin	drug	DDI-DrugBank.d313.s13.e0
DDI-DrugBank.d313.s13	63	69	NovoLog	brand	DDI-DrugBank.d313.s13.e1
DDI-DrugBank.d313.s13	106	113	insulins	group	DDI-DrugBank.d313.s13.e2
DDI-DrugBank.d313.s13	false	DDI-DrugBank.d313.s13.e0	DDI-DrugBank.d313.s13.e1
DDI-DrugBank.d313.s13	false	DDI-DrugBank.d313.s13.e0	DDI-DrugBank.d313.s13.e2
DDI-DrugBank.d313.s13	false	DDI-DrugBank.d313.s13.e1	DDI-DrugBank.d313.s13.e2
DDI-DrugBank.d433.s0|a|No formal drug interaction studies have been conducted with Rebif .
DDI-DrugBank.d433.s0	60	64	Rebif	brand	DDI-DrugBank.d433.s0.e0
DDI-DrugBank.d433.s1|a|Due to its potential to cause neutropenia and lymphopenia, proper monitoring of patients is required if Rebif  is given in combination with myelosuppressive agents.
DDI-DrugBank.d433.s1	104	108	Rebif	brand	DDI-DrugBank.d433.s1.e0
DDI-DrugBank.d433.s2|a|Also, the potential for hepatic injury should be considered when Rebif  is used in combination with other products associated with hepatic injury, or when new agents are added to the regimen of patients already on Rebif .
DDI-DrugBank.d433.s2	65	69	Rebif	brand	DDI-DrugBank.d433.s2.e0
DDI-DrugBank.d433.s2	214	218	Rebif	brand	DDI-DrugBank.d433.s2.e1
DDI-DrugBank.d433.s2	false	DDI-DrugBank.d433.s2.e0	DDI-DrugBank.d433.s2.e1
DDI-DrugBank.d10.s0|a|Interactions between Betaseron and other drugs have not been fully evaluated.
DDI-DrugBank.d10.s0	21	29	Betaseron	brand	DDI-DrugBank.d10.s0.e0
DDI-DrugBank.d10.s1|a|Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.
DDI-DrugBank.d10.s1	93	106	corticosteroid	group	DDI-DrugBank.d10.s1.e0
DDI-DrugBank.d10.s1	111	114	ACTH	drug	DDI-DrugBank.d10.s1.e1
DDI-DrugBank.d10.s1	219	227	Betaseron	brand	DDI-DrugBank.d10.s1.e2
DDI-DrugBank.d10.s1	false	DDI-DrugBank.d10.s1.e0	DDI-DrugBank.d10.s1.e1
DDI-DrugBank.d10.s1	false	DDI-DrugBank.d10.s1.e0	DDI-DrugBank.d10.s1.e2
DDI-DrugBank.d10.s1	false	DDI-DrugBank.d10.s1.e1	DDI-DrugBank.d10.s1.e2
DDI-DrugBank.d10.s2|a|Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.
DDI-DrugBank.d10.s2	0	8	Betaseron	brand	DDI-DrugBank.d10.s2.e0
DDI-DrugBank.d10.s2	128	137	antipyrine	drug	DDI-DrugBank.d10.s2.e1
DDI-DrugBank.d10.s2	211	219	Betaseron	brand	DDI-DrugBank.d10.s2.e2
DDI-DrugBank.d10.s2	true	DDI-DrugBank.d10.s2.e0	DDI-DrugBank.d10.s2.e1
DDI-DrugBank.d10.s2	false	DDI-DrugBank.d10.s2.e0	DDI-DrugBank.d10.s2.e2
DDI-DrugBank.d10.s2	false	DDI-DrugBank.d10.s2.e1	DDI-DrugBank.d10.s2.e2
DDI-DrugBank.d51.s0|a|ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, and steroids, commonly used in the treatment of chronic obstructive pulmonary disease.
DDI-DrugBank.d51.s0	0	7	ATROVENT	brand	DDI-DrugBank.d51.s0.e0
DDI-DrugBank.d51.s0	84	114	sympathomimetic bronchodilators	group	DDI-DrugBank.d51.s0.e1
DDI-DrugBank.d51.s0	117	131	methylxanthines	group	DDI-DrugBank.d51.s0.e2
DDI-DrugBank.d51.s0	138	145	steroids	group	DDI-DrugBank.d51.s0.e3
DDI-DrugBank.d51.s0	false	DDI-DrugBank.d51.s0.e0	DDI-DrugBank.d51.s0.e1
DDI-DrugBank.d51.s0	false	DDI-DrugBank.d51.s0.e0	DDI-DrugBank.d51.s0.e2
DDI-DrugBank.d51.s0	false	DDI-DrugBank.d51.s0.e0	DDI-DrugBank.d51.s0.e3
DDI-DrugBank.d51.s0	false	DDI-DrugBank.d51.s0.e1	DDI-DrugBank.d51.s0.e2
DDI-DrugBank.d51.s0	false	DDI-DrugBank.d51.s0.e1	DDI-DrugBank.d51.s0.e3
DDI-DrugBank.d51.s0	false	DDI-DrugBank.d51.s0.e2	DDI-DrugBank.d51.s0.e3
DDI-DrugBank.d51.s1|a|With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of ATROVENT Inhalation Aerosol and these drugs with respect to effectiveness.
DDI-DrugBank.d51.s1	22	30	albuterol	drug	DDI-DrugBank.d51.s1.e0
DDI-DrugBank.d51.s1	105	112	ATROVENT	brand	DDI-DrugBank.d51.s1.e1
DDI-DrugBank.d51.s1	false	DDI-DrugBank.d51.s1.e0	DDI-DrugBank.d51.s1.e1
DDI-DrugBank.d51.s2|a|Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
DDI-DrugBank.d51.s2	0	21	Anticholinergic agents	group	DDI-DrugBank.d51.s2.e0
DDI-DrugBank.d51.s2	33	51	ipratropium bromide	drug	DDI-DrugBank.d51.s2.e1
DDI-DrugBank.d51.s2	182	208	anticholinergic medications	group	DDI-DrugBank.d51.s2.e2
DDI-DrugBank.d51.s2	false	DDI-DrugBank.d51.s2.e0	DDI-DrugBank.d51.s2.e1
DDI-DrugBank.d51.s2	false	DDI-DrugBank.d51.s2.e0	DDI-DrugBank.d51.s2.e2
DDI-DrugBank.d51.s2	true	DDI-DrugBank.d51.s2.e1	DDI-DrugBank.d51.s2.e2
DDI-DrugBank.d51.s3|a|Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.
DDI-DrugBank.d51.s3	56	63	ATROVENT	brand	DDI-DrugBank.d51.s3.e0
DDI-DrugBank.d51.s3	95	109	anticholinergic	group	DDI-DrugBank.d51.s3.e1
DDI-DrugBank.d51.s3	true	DDI-DrugBank.d51.s3.e0	DDI-DrugBank.d51.s3.e1
DDI-DrugBank.d27.s0|a|No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.
DDI-DrugBank.d27.s0	119	137	hydrochlorothiazide	drug	DDI-DrugBank.d27.s0.e0
DDI-DrugBank.d27.s0	140	146	digoxin	drug	DDI-DrugBank.d27.s0.e1
DDI-DrugBank.d27.s0	149	156	warfarin	drug	DDI-DrugBank.d27.s0.e2
DDI-DrugBank.d27.s0	163	172	nifedipine	drug	DDI-DrugBank.d27.s0.e3
DDI-DrugBank.d27.s0	false	DDI-DrugBank.d27.s0.e0	DDI-DrugBank.d27.s0.e1
DDI-DrugBank.d27.s0	false	DDI-DrugBank.d27.s0.e0	DDI-DrugBank.d27.s0.e2
DDI-DrugBank.d27.s0	false	DDI-DrugBank.d27.s0.e0	DDI-DrugBank.d27.s0.e3
DDI-DrugBank.d27.s0	false	DDI-DrugBank.d27.s0.e1	DDI-DrugBank.d27.s0.e2
DDI-DrugBank.d27.s0	false	DDI-DrugBank.d27.s0.e1	DDI-DrugBank.d27.s0.e3
DDI-DrugBank.d27.s0	false	DDI-DrugBank.d27.s0.e2	DDI-DrugBank.d27.s0.e3
DDI-DrugBank.d27.s1|a|In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.
DDI-DrugBank.d27.s1	153	164	sulphenazole	drug	DDI-DrugBank.d27.s1.e0
DDI-DrugBank.d27.s1	167	177	tolbutamide	drug	DDI-DrugBank.d27.s1.e1
DDI-DrugBank.d27.s1	183	192	nifedipine	drug	DDI-DrugBank.d27.s1.e2
DDI-DrugBank.d27.s1	false	DDI-DrugBank.d27.s1.e0	DDI-DrugBank.d27.s1.e1
DDI-DrugBank.d27.s1	false	DDI-DrugBank.d27.s1.e0	DDI-DrugBank.d27.s1.e2
DDI-DrugBank.d27.s1	false	DDI-DrugBank.d27.s1.e1	DDI-DrugBank.d27.s1.e2
DDI-DrugBank.d27.s2|a|However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.
DDI-DrugBank.d27.s2	61	70	irbesartan	drug	DDI-DrugBank.d27.s2.e0
DDI-DrugBank.d27.s2	99	106	warfarin	drug	DDI-DrugBank.d27.s2.e1
DDI-DrugBank.d27.s2	false	DDI-DrugBank.d27.s2.e0	DDI-DrugBank.d27.s2.e1
DDI-DrugBank.d27.s3|a|Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isozymes 1A1, 1A2,2A6,2B6,2D6,2E1,or 3A4.
DDI-DrugBank.d27.s4|a|In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.
DDI-DrugBank.d27.s4	63	70	warfarin	drug	DDI-DrugBank.d27.s4.e0
DDI-DrugBank.d27.s4	73	91	hydrochlorothiazide	drug	DDI-DrugBank.d27.s4.e1
DDI-DrugBank.d27.s4	97	103	digoxin	drug	DDI-DrugBank.d27.s4.e2
DDI-DrugBank.d27.s4	106	115	irbesartan	drug	DDI-DrugBank.d27.s4.e3
DDI-DrugBank.d27.s4	184	191	warfarin	drug	DDI-DrugBank.d27.s4.e4
DDI-DrugBank.d27.s4	235	241	digoxin	drug	DDI-DrugBank.d27.s4.e5
DDI-DrugBank.d27.s4	false	DDI-DrugBank.d27.s4.e0	DDI-DrugBank.d27.s4.e1
DDI-DrugBank.d27.s4	false	DDI-DrugBank.d27.s4.e0	DDI-DrugBank.d27.s4.e2
DDI-DrugBank.d27.s4	false	DDI-DrugBank.d27.s4.e0	DDI-DrugBank.d27.s4.e3
DDI-DrugBank.d27.s4	false	DDI-DrugBank.d27.s4.e0	DDI-DrugBank.d27.s4.e4
DDI-DrugBank.d27.s4	false	DDI-DrugBank.d27.s4.e0	DDI-DrugBank.d27.s4.e5
DDI-DrugBank.d27.s4	false	DDI-DrugBank.d27.s4.e1	DDI-DrugBank.d27.s4.e2
DDI-DrugBank.d27.s4	false	DDI-DrugBank.d27.s4.e1	DDI-DrugBank.d27.s4.e3
DDI-DrugBank.d27.s4	false	DDI-DrugBank.d27.s4.e1	DDI-DrugBank.d27.s4.e4
DDI-DrugBank.d27.s4	false	DDI-DrugBank.d27.s4.e1	DDI-DrugBank.d27.s4.e5
DDI-DrugBank.d27.s4	false	DDI-DrugBank.d27.s4.e2	DDI-DrugBank.d27.s4.e3
DDI-DrugBank.d27.s5|a|The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide
DDI-DrugBank.d27.s5	24	33	irbesartan	drug	DDI-DrugBank.d27.s5.e0
DDI-DrugBank.d27.s5	76	85	nifedipine	drug	DDI-DrugBank.d27.s5.e1
DDI-DrugBank.d27.s5	90	108	hydrochlorothiazide	drug	DDI-DrugBank.d27.s5.e2
DDI-DrugBank.d27.s5	false	DDI-DrugBank.d27.s5.e0	DDI-DrugBank.d27.s5.e1
DDI-DrugBank.d27.s5	false	DDI-DrugBank.d27.s5.e0	DDI-DrugBank.d27.s5.e2
DDI-DrugBank.d27.s5	false	DDI-DrugBank.d27.s5.e1	DDI-DrugBank.d27.s5.e2
DDI-DrugBank.d27.s6|a|.
DDI-DrugBank.d27.s7|a|
DDI-DrugBank.d279.s0|a|The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.
DDI-DrugBank.d279.s0	23	31	CAMPTOSAR	brand	DDI-DrugBank.d279.s0.e0
DDI-DrugBank.d279.s0	118	138	antineoplastic agents	group	DDI-DrugBank.d279.s0.e1
DDI-DrugBank.d279.s0	true	DDI-DrugBank.d279.s0.e0	DDI-DrugBank.d279.s0.e1
DDI-DrugBank.d279.s1|a|Patients who have previously received pelvic/ abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR.
DDI-DrugBank.d279.s1	149	157	CAMPTOSAR	brand	DDI-DrugBank.d279.s1.e0
DDI-DrugBank.d279.s2|a|The concurrent administration of CAMPTOSAR with irradiation has not been adequately studied and is not recommended.
DDI-DrugBank.d279.s2	33	41	CAMPTOSAR	brand	DDI-DrugBank.d279.s2.e0
DDI-DrugBank.d279.s3|a|Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.
DDI-DrugBank.d279.s3	56	64	CAMPTOSAR	brand	DDI-DrugBank.d279.s3.e0
DDI-DrugBank.d279.s3	113	125	dexamethasone	drug	DDI-DrugBank.d279.s3.e1
DDI-DrugBank.d279.s3	true	DDI-DrugBank.d279.s3.e0	DDI-DrugBank.d279.s3.e1
DDI-DrugBank.d279.s4|a|However, serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia.
DDI-DrugBank.d279.s5|a|Hyperglycemia has also been reported in patients receiving CAMPTOSAR.
DDI-DrugBank.d279.s5	59	67	CAMPTOSAR	brand	DDI-DrugBank.d279.s5.e0
DDI-DrugBank.d279.s6|a|Usually, this has been observed in patients with a history of diabetes mellitus or evidence of glucose intolerance prior to administration of CAMPTOSAR.
DDI-DrugBank.d279.s6	142	150	CAMPTOSAR	brand	DDI-DrugBank.d279.s6.e0
DDI-DrugBank.d279.s7|a|It is probable that dexamethasone, given as antiemetic prophylaxis, contributed to hyperglycemia in some patients.
DDI-DrugBank.d279.s7	20	32	dexamethasone	drug	DDI-DrugBank.d279.s7.e0
DDI-DrugBank.d279.s8|a|The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).
DDI-DrugBank.d279.s8	115	130	prochlorperazine	drug	DDI-DrugBank.d279.s8.e0
DDI-DrugBank.d279.s8	168	176	CAMPTOSAR	brand	DDI-DrugBank.d279.s8.e1
DDI-DrugBank.d279.s8	true	DDI-DrugBank.d279.s8.e0	DDI-DrugBank.d279.s8.e1
DDI-DrugBank.d279.s9|a|The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.
DDI-DrugBank.d279.s9	82	97	prochlorperazine	drug	DDI-DrugBank.d279.s9.e0
DDI-DrugBank.d279.s10|a|It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.
DDI-DrugBank.d279.s10	26	33	laxative	group	DDI-DrugBank.d279.s10.e0
DDI-DrugBank.d279.s10	59	67	CAMPTOSAR	brand	DDI-DrugBank.d279.s10.e1
DDI-DrugBank.d279.s10	true	DDI-DrugBank.d279.s10.e0	DDI-DrugBank.d279.s10.e1
DDI-DrugBank.d279.s11|a|In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.
DDI-DrugBank.d279.s11	94	102	CAMPTOSAR	brand	DDI-DrugBank.d279.s11.e0
DDI-DrugBank.d279.s11	140	148	diuretics	group	DDI-DrugBank.d279.s11.e1
DDI-DrugBank.d279.s11	169	177	CAMPTOSAR	brand	DDI-DrugBank.d279.s11.e2
DDI-DrugBank.d279.s11	false	DDI-DrugBank.d279.s11.e0	DDI-DrugBank.d279.s11.e1
DDI-DrugBank.d279.s11	false	DDI-DrugBank.d279.s11.e0	DDI-DrugBank.d279.s11.e2
DDI-DrugBank.d279.s11	true	DDI-DrugBank.d279.s11.e1	DDI-DrugBank.d279.s11.e2
DDI-DrugBank.d279.s12|a|Drug-Laboratory Test Interactions There are no known interactions between CAMPTOSAR and laboratory tests.
DDI-DrugBank.d279.s12	74	82	CAMPTOSAR	brand	DDI-DrugBank.d279.s12.e0
DDI-DrugBank.d108.s0|a|Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).
DDI-DrugBank.d108.s0	0	12	Isocarboxazid	drug	DDI-DrugBank.d108.s0.e0
DDI-DrugBank.d108.s0	72	79	Antabuse	brand	DDI-DrugBank.d108.s0.e1
DDI-DrugBank.d108.s0	82	91	disulfiram	drug	DDI-DrugBank.d108.s0.e2
DDI-DrugBank.d108.s0	true	DDI-DrugBank.d108.s0.e0	DDI-DrugBank.d108.s0.e1
DDI-DrugBank.d108.s0	true	DDI-DrugBank.d108.s0.e0	DDI-DrugBank.d108.s0.e2
DDI-DrugBank.d108.s0	false	DDI-DrugBank.d108.s0.e1	DDI-DrugBank.d108.s0.e2
DDI-DrugBank.d108.s1|a|In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.
DDI-DrugBank.d108.s1	63	75	MAO inhibitor	group	DDI-DrugBank.d108.s1.e0
DDI-DrugBank.d108.s1	82	91	disulfiram	drug	DDI-DrugBank.d108.s1.e1
DDI-DrugBank.d108.s1	true	DDI-DrugBank.d108.s1.e0	DDI-DrugBank.d108.s1.e1
DDI-DrugBank.d108.s2|a|Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.
DDI-DrugBank.d108.s2	19	31	Isocarboxazid	drug	DDI-DrugBank.d108.s2.e0
DDI-DrugBank.d108.s2	43	61	psychotropic agents	group	DDI-DrugBank.d108.s2.e1
DDI-DrugBank.d108.s2	true	DDI-DrugBank.d108.s2.e0	DDI-DrugBank.d108.s2.e1
DDI-DrugBank.d108.s3|a|This is especially true in patients who may subject themselves to an overdosage of drugs.
DDI-DrugBank.d108.s4|a|If combination therapy is needed, careful consideration should be given to the pharmacology of all agents to be used.
DDI-DrugBank.d108.s5|a|The monoamine oxidase inhibitory effects of Isocarboxazid may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following Isocarboxazid.
DDI-DrugBank.d108.s5	44	56	Isocarboxazid	drug	DDI-DrugBank.d108.s5.e0
DDI-DrugBank.d108.s5	205	217	Isocarboxazid	drug	DDI-DrugBank.d108.s5.e1
DDI-DrugBank.d108.s5	false	DDI-DrugBank.d108.s5.e0	DDI-DrugBank.d108.s5.e1
DDI-DrugBank.d108.s6|a|To avoid potentiation, the physician wishing to terminate treatment with Isocarboxazid and begin therapy with another agent should allow for an interval of 10 days.
DDI-DrugBank.d108.s6	73	85	Isocarboxazid	drug	DDI-DrugBank.d108.s6.e0
DDI-DrugBank.d541.s0|a|May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).
DDI-DrugBank.d541.s0	33	63	beta-adrenergic blocking agents	group	DDI-DrugBank.d541.s0.e0
DDI-DrugBank.d541.s0	128	153	adrenergic bronchodilators	group	DDI-DrugBank.d541.s0.e1
DDI-DrugBank.d541.s0	182	193	disopyramide	drug	DDI-DrugBank.d541.s0.e2
DDI-DrugBank.d541.s0	196	204	quinidine	drug	DDI-DrugBank.d541.s0.e3
DDI-DrugBank.d541.s0	207	220	phenothiazines	group	DDI-DrugBank.d541.s0.e4
DDI-DrugBank.d541.s0	227	238	procainamide	drug	DDI-DrugBank.d541.s0.e5
DDI-DrugBank.d541.s0	false	DDI-DrugBank.d541.s0.e0	DDI-DrugBank.d541.s0.e1
DDI-DrugBank.d541.s0	false	DDI-DrugBank.d541.s0.e0	DDI-DrugBank.d541.s0.e2
DDI-DrugBank.d541.s0	false	DDI-DrugBank.d541.s0.e0	DDI-DrugBank.d541.s0.e3
DDI-DrugBank.d541.s0	false	DDI-DrugBank.d541.s0.e0	DDI-DrugBank.d541.s0.e4
DDI-DrugBank.d541.s0	false	DDI-DrugBank.d541.s0.e0	DDI-DrugBank.d541.s0.e5
DDI-DrugBank.d541.s0	false	DDI-DrugBank.d541.s0.e1	DDI-DrugBank.d541.s0.e2
DDI-DrugBank.d541.s0	false	DDI-DrugBank.d541.s0.e1	DDI-DrugBank.d541.s0.e3
DDI-DrugBank.d541.s0	false	DDI-DrugBank.d541.s0.e1	DDI-DrugBank.d541.s0.e4
DDI-DrugBank.d541.s0	false	DDI-DrugBank.d541.s0.e1	DDI-DrugBank.d541.s0.e5
DDI-DrugBank.d541.s0	false	DDI-DrugBank.d541.s0.e2	DDI-DrugBank.d541.s0.e3
DDI-DrugBank.d227.s0|a|Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
DDI-DrugBank.d227.s0	0	9	Isoflurane	drug	DDI-DrugBank.d227.s0.e0
DDI-DrugBank.d227.s0	57	72	muscle relaxants	group	DDI-DrugBank.d227.s0.e1
DDI-DrugBank.d227.s0	88	119	nondepolarizing muscle relaxants	group	DDI-DrugBank.d227.s0.e2
DDI-DrugBank.d227.s0	true	DDI-DrugBank.d227.s0.e0	DDI-DrugBank.d227.s0.e1
DDI-DrugBank.d227.s0	true	DDI-DrugBank.d227.s0.e0	DDI-DrugBank.d227.s0.e2
DDI-DrugBank.d227.s0	false	DDI-DrugBank.d227.s0.e1	DDI-DrugBank.d227.s0.e2
DDI-DrugBank.d227.s1|a|See CLINICAL PHARMACOLOGY.
DDI-DrugBank.d187.s0|a|Food: Isoniazid should not be administered with food.
DDI-DrugBank.d187.s0	6	14	Isoniazid	drug	DDI-DrugBank.d187.s0.e0
DDI-DrugBank.d187.s1|a|Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food.
DDI-DrugBank.d187.s1	47	55	isoniazid	drug	DDI-DrugBank.d187.s1.e0
DDI-DrugBank.d187.s2|a|Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.
DDI-DrugBank.d187.s2	0	12	Acetaminophen	drug	DDI-DrugBank.d187.s2.e0
DDI-DrugBank.d187.s2	34	46	acetaminophen	drug	DDI-DrugBank.d187.s2.e1
DDI-DrugBank.d187.s2	93	101	Isoniazid	drug	DDI-DrugBank.d187.s2.e2
DDI-DrugBank.d187.s2	false	DDI-DrugBank.d187.s2.e0	DDI-DrugBank.d187.s2.e1
DDI-DrugBank.d187.s2	false	DDI-DrugBank.d187.s2.e0	DDI-DrugBank.d187.s2.e2
DDI-DrugBank.d187.s2	true	DDI-DrugBank.d187.s2.e1	DDI-DrugBank.d187.s2.e2
DDI-DrugBank.d187.s3|a|It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.
DDI-DrugBank.d187.s3	102	110	isoniazid	drug	DDI-DrugBank.d187.s3.e0
DDI-DrugBank.d187.s3	116	128	acetaminophen	drug	DDI-DrugBank.d187.s3.e1
DDI-DrugBank.d187.s3	true	DDI-DrugBank.d187.s3.e0	DDI-DrugBank.d187.s3.e1
DDI-DrugBank.d187.s4|a|However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver.
DDI-DrugBank.d187.s4	40	48	isoniazid	drug	DDI-DrugBank.d187.s4.e0
DDI-DrugBank.d187.s5|a|Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.
DDI-DrugBank.d187.s5	38	46	isoniazid	drug	DDI-DrugBank.d187.s5.e0
DDI-DrugBank.d187.s5	170	182	acetaminophen	drug	DDI-DrugBank.d187.s5.e1
DDI-DrugBank.d187.s5	true	DDI-DrugBank.d187.s5.e0	DDI-DrugBank.d187.s5.e1
DDI-DrugBank.d187.s6|a|Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats.
DDI-DrugBank.d187.s6	49	57	isoniazid	drug	DDI-DrugBank.d187.s6.e0
DDI-DrugBank.d187.s7|a|Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
DDI-DrugBank.d187.s7	0	12	Carbamazepine	drug	DDI-DrugBank.d187.s7.e0
DDI-DrugBank.d187.s7	15	23	Isoniazid	drug	DDI-DrugBank.d187.s7.e1
DDI-DrugBank.d187.s7	60	72	carbamazepine	drug	DDI-DrugBank.d187.s7.e2
DDI-DrugBank.d187.s7	104	116	Carbamazepine	drug	DDI-DrugBank.d187.s7.e3
DDI-DrugBank.d187.s7	186	194	isoniazid	drug	DDI-DrugBank.d187.s7.e4
DDI-DrugBank.d187.s7	219	231	carbamazepine	drug	DDI-DrugBank.d187.s7.e5
DDI-DrugBank.d187.s7	312	325	anticonvulsant	group	DDI-DrugBank.d187.s7.e6
DDI-DrugBank.d187.s7	false	DDI-DrugBank.d187.s7.e0	DDI-DrugBank.d187.s7.e1
DDI-DrugBank.d187.s7	false	DDI-DrugBank.d187.s7.e0	DDI-DrugBank.d187.s7.e2
DDI-DrugBank.d187.s7	false	DDI-DrugBank.d187.s7.e0	DDI-DrugBank.d187.s7.e3
DDI-DrugBank.d187.s7	false	DDI-DrugBank.d187.s7.e0	DDI-DrugBank.d187.s7.e4
DDI-DrugBank.d187.s7	false	DDI-DrugBank.d187.s7.e0	DDI-DrugBank.d187.s7.e5
DDI-DrugBank.d187.s7	false	DDI-DrugBank.d187.s7.e0	DDI-DrugBank.d187.s7.e6
DDI-DrugBank.d187.s7	true	DDI-DrugBank.d187.s7.e1	DDI-DrugBank.d187.s7.e2
DDI-DrugBank.d187.s7	false	DDI-DrugBank.d187.s7.e1	DDI-DrugBank.d187.s7.e3
DDI-DrugBank.d187.s7	false	DDI-DrugBank.d187.s7.e1	DDI-DrugBank.d187.s7.e4
DDI-DrugBank.d187.s7	false	DDI-DrugBank.d187.s7.e1	DDI-DrugBank.d187.s7.e5
DDI-DrugBank.d187.s8|a|Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.
DDI-DrugBank.d187.s8	0	11	Ketoconazole	drug	DDI-DrugBank.d187.s8.e0
DDI-DrugBank.d187.s8	39	50	Ketoconazole	drug	DDI-DrugBank.d187.s8.e1
DDI-DrugBank.d187.s8	56	64	Isoniazid	drug	DDI-DrugBank.d187.s8.e2
DDI-DrugBank.d187.s8	false	DDI-DrugBank.d187.s8.e0	DDI-DrugBank.d187.s8.e1
DDI-DrugBank.d187.s8	false	DDI-DrugBank.d187.s8.e0	DDI-DrugBank.d187.s8.e2
DDI-DrugBank.d187.s8	true	DDI-DrugBank.d187.s8.e1	DDI-DrugBank.d187.s8.e2
DDI-DrugBank.d187.s9|a|Phenytoin: Isoniazid may increase serum levels of phenytoin.
DDI-DrugBank.d187.s9	0	8	Phenytoin	drug	DDI-DrugBank.d187.s9.e0
DDI-DrugBank.d187.s9	11	19	Isoniazid	drug	DDI-DrugBank.d187.s9.e1
DDI-DrugBank.d187.s9	50	58	phenytoin	drug	DDI-DrugBank.d187.s9.e2
DDI-DrugBank.d187.s9	false	DDI-DrugBank.d187.s9.e0	DDI-DrugBank.d187.s9.e1
DDI-DrugBank.d187.s9	false	DDI-DrugBank.d187.s9.e0	DDI-DrugBank.d187.s9.e2
DDI-DrugBank.d187.s9	true	DDI-DrugBank.d187.s9.e1	DDI-DrugBank.d187.s9.e2
DDI-DrugBank.d187.s10|a|To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made.
DDI-DrugBank.d187.s10	9	17	phenytoin	drug	DDI-DrugBank.d187.s10.e0
DDI-DrugBank.d187.s10	63	76	anticonvulsant	group	DDI-DrugBank.d187.s10.e1
DDI-DrugBank.d187.s10	false	DDI-DrugBank.d187.s10.e0	DDI-DrugBank.d187.s10.e1
DDI-DrugBank.d187.s11|a|Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.
DDI-DrugBank.d187.s11	74	82	isoniazid	drug	DDI-DrugBank.d187.s11.e0
DDI-DrugBank.d187.s11	88	99	theophylline	drug	DDI-DrugBank.d187.s11.e1
DDI-DrugBank.d187.s11	137	148	theophylline	drug	DDI-DrugBank.d187.s11.e2
DDI-DrugBank.d187.s11	213	221	isoniazid	drug	DDI-DrugBank.d187.s11.e3
DDI-DrugBank.d187.s11	true	DDI-DrugBank.d187.s11.e0	DDI-DrugBank.d187.s11.e1
DDI-DrugBank.d187.s11	false	DDI-DrugBank.d187.s11.e0	DDI-DrugBank.d187.s11.e2
DDI-DrugBank.d187.s11	false	DDI-DrugBank.d187.s11.e0	DDI-DrugBank.d187.s11.e3
DDI-DrugBank.d187.s11	false	DDI-DrugBank.d187.s11.e1	DDI-DrugBank.d187.s11.e2
DDI-DrugBank.d187.s11	false	DDI-DrugBank.d187.s11.e1	DDI-DrugBank.d187.s11.e3
DDI-DrugBank.d187.s11	false	DDI-DrugBank.d187.s11.e2	DDI-DrugBank.d187.s11.e3
DDI-DrugBank.d187.s12|a|Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.
DDI-DrugBank.d187.s12	31	42	theophylline	drug	DDI-DrugBank.d187.s12.e0
DDI-DrugBank.d187.s12	54	65	theophylline	drug	DDI-DrugBank.d187.s12.e1
DDI-DrugBank.d187.s12	147	158	theophylline	drug	DDI-DrugBank.d187.s12.e2
DDI-DrugBank.d187.s12	false	DDI-DrugBank.d187.s12.e0	DDI-DrugBank.d187.s12.e1
DDI-DrugBank.d187.s12	false	DDI-DrugBank.d187.s12.e0	DDI-DrugBank.d187.s12.e2
DDI-DrugBank.d187.s12	false	DDI-DrugBank.d187.s12.e1	DDI-DrugBank.d187.s12.e2
DDI-DrugBank.d187.s13|a|Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.
DDI-DrugBank.d187.s13	0	8	Valproate	drug	DDI-DrugBank.d187.s13.e0
DDI-DrugBank.d187.s13	84	92	valproate	drug	DDI-DrugBank.d187.s13.e1
DDI-DrugBank.d187.s13	120	128	isoniazid	drug	DDI-DrugBank.d187.s13.e2
DDI-DrugBank.d187.s13	false	DDI-DrugBank.d187.s13.e0	DDI-DrugBank.d187.s13.e1
DDI-DrugBank.d187.s13	false	DDI-DrugBank.d187.s13.e0	DDI-DrugBank.d187.s13.e2
DDI-DrugBank.d187.s13	true	DDI-DrugBank.d187.s13.e1	DDI-DrugBank.d187.s13.e2
DDI-DrugBank.d187.s14|a|Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.
DDI-DrugBank.d187.s14	7	15	valproate	drug	DDI-DrugBank.d187.s14.e0
DDI-DrugBank.d187.s14	56	64	isoniazid	drug	DDI-DrugBank.d187.s14.e1
DDI-DrugBank.d187.s14	70	78	valproate	drug	DDI-DrugBank.d187.s14.e2
DDI-DrugBank.d187.s14	139	147	valproate	drug	DDI-DrugBank.d187.s14.e3
DDI-DrugBank.d187.s14	false	DDI-DrugBank.d187.s14.e0	DDI-DrugBank.d187.s14.e1
DDI-DrugBank.d187.s14	false	DDI-DrugBank.d187.s14.e0	DDI-DrugBank.d187.s14.e2
DDI-DrugBank.d187.s14	false	DDI-DrugBank.d187.s14.e0	DDI-DrugBank.d187.s14.e3
DDI-DrugBank.d187.s14	true	DDI-DrugBank.d187.s14.e1	DDI-DrugBank.d187.s14.e2
DDI-DrugBank.d187.s14	false	DDI-DrugBank.d187.s14.e1	DDI-DrugBank.d187.s14.e3
DDI-DrugBank.d187.s14	false	DDI-DrugBank.d187.s14.e2	DDI-DrugBank.d187.s14.e3
DDI-DrugBank.d55.s0|a|Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.
DDI-DrugBank.d55.s0	0	26	Isoproterenol hydrochloride	drug	DDI-DrugBank.d55.s0.e0
DDI-DrugBank.d55.s0	42	52	epinephrine	drug	DDI-DrugBank.d55.s0.e1
DDI-DrugBank.d55.s0	true	DDI-DrugBank.d55.s0.e0	DDI-DrugBank.d55.s0.e1
DDI-DrugBank.d55.s1|a|The drugs may, however, be administered alternately provided a proper interval has elapsed between doses.
DDI-DrugBank.d55.s2|a|ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
DDI-DrugBank.d55.s2	0	6	ISUPREL	brand	DDI-DrugBank.d55.s2.e0
DDI-DrugBank.d55.s2	73	83	anesthetics	group	DDI-DrugBank.d55.s2.e1
DDI-DrugBank.d55.s2	93	101	halothane	drug	DDI-DrugBank.d55.s2.e2
DDI-DrugBank.d55.s2	179	200	sympathomimetic amines	group	DDI-DrugBank.d55.s2.e3
DDI-DrugBank.d55.s2	true	DDI-DrugBank.d55.s2.e0	DDI-DrugBank.d55.s2.e1
DDI-DrugBank.d55.s2	true	DDI-DrugBank.d55.s2.e0	DDI-DrugBank.d55.s2.e2
DDI-DrugBank.d55.s2	false	DDI-DrugBank.d55.s2.e0	DDI-DrugBank.d55.s2.e3
DDI-DrugBank.d55.s2	false	DDI-DrugBank.d55.s2.e1	DDI-DrugBank.d55.s2.e2
DDI-DrugBank.d55.s2	false	DDI-DrugBank.d55.s2.e1	DDI-DrugBank.d55.s2.e3
DDI-DrugBank.d55.s2	false	DDI-DrugBank.d55.s2.e2	DDI-DrugBank.d55.s2.e3
DDI-DrugBank.d465.s0|a|The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators.
DDI-DrugBank.d465.s0	28	47	isosorbide dinitrate	drug	DDI-DrugBank.d465.s0.e0
DDI-DrugBank.d465.s0	85	96	vasodilators	group	DDI-DrugBank.d465.s0.e1
DDI-DrugBank.d465.s0	true	DDI-DrugBank.d465.s0.e0	DDI-DrugBank.d465.s0.e1
DDI-DrugBank.d465.s1|a|Alcohol, in particular, has been found to exhibit additive effects of this variety.
DDI-DrugBank.d465.s1	0	6	Alcohol	drug	DDI-DrugBank.d465.s1.e0
DDI-DrugBank.d479.s0|a|The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators.
DDI-DrugBank.d479.s0	28	49	isosorbide mononitrate	drug	DDI-DrugBank.d479.s0.e0
DDI-DrugBank.d479.s0	87	98	vasodilators	group	DDI-DrugBank.d479.s0.e1
DDI-DrugBank.d479.s0	true	DDI-DrugBank.d479.s0.e0	DDI-DrugBank.d479.s0.e1
DDI-DrugBank.d479.s1|a|Alcohol, in particular, has been found to exhibit additive effects of this variety.
DDI-DrugBank.d479.s1	0	6	Alcohol	drug	DDI-DrugBank.d479.s1.e0
DDI-DrugBank.d479.s2|a|Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
DDI-DrugBank.d479.s2	66	89	calcium channel blockers	group	DDI-DrugBank.d479.s2.e0
DDI-DrugBank.d479.s2	95	110	organic nitrates	group	DDI-DrugBank.d479.s2.e1
DDI-DrugBank.d479.s2	true	DDI-DrugBank.d479.s2.e0	DDI-DrugBank.d479.s2.e1
DDI-DrugBank.d479.s3|a|Dose adjustments of either class of agents may be necessary.
DDI-DrugBank.d163.s0|a|Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects
DDI-DrugBank.d163.s0	0	8	Vitamin A	group	DDI-DrugBank.d163.s0.e0
DDI-DrugBank.d163.s0	42	49	Accutane	brand	DDI-DrugBank.d163.s0.e1
DDI-DrugBank.d163.s0	54	62	vitamin A	group	DDI-DrugBank.d163.s0.e2
DDI-DrugBank.d163.s0	107	125	vitamin supplements	group	DDI-DrugBank.d163.s0.e3
DDI-DrugBank.d163.s0	138	146	vitamin A	group	DDI-DrugBank.d163.s0.e4
DDI-DrugBank.d163.s0	false	DDI-DrugBank.d163.s0.e0	DDI-DrugBank.d163.s0.e1
DDI-DrugBank.d163.s0	false	DDI-DrugBank.d163.s0.e0	DDI-DrugBank.d163.s0.e2
DDI-DrugBank.d163.s0	false	DDI-DrugBank.d163.s0.e0	DDI-DrugBank.d163.s0.e3
DDI-DrugBank.d163.s0	false	DDI-DrugBank.d163.s0.e0	DDI-DrugBank.d163.s0.e4
DDI-DrugBank.d163.s0	true	DDI-DrugBank.d163.s0.e1	DDI-DrugBank.d163.s0.e2
DDI-DrugBank.d163.s0	false	DDI-DrugBank.d163.s0.e1	DDI-DrugBank.d163.s0.e3
DDI-DrugBank.d163.s0	false	DDI-DrugBank.d163.s0.e1	DDI-DrugBank.d163.s0.e4
DDI-DrugBank.d163.s0	false	DDI-DrugBank.d163.s0.e2	DDI-DrugBank.d163.s0.e3
DDI-DrugBank.d163.s0	false	DDI-DrugBank.d163.s0.e2	DDI-DrugBank.d163.s0.e4
DDI-DrugBank.d163.s0	false	DDI-DrugBank.d163.s0.e3	DDI-DrugBank.d163.s0.e4
DDI-DrugBank.d163.s1|a|.
DDI-DrugBank.d163.s2|a|Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
DDI-DrugBank.d163.s2	0	12	Tetracyclines	group	DDI-DrugBank.d163.s2.e0
DDI-DrugBank.d163.s2	42	49	Accutane	brand	DDI-DrugBank.d163.s2.e1
DDI-DrugBank.d163.s2	55	67	tetracyclines	group	DDI-DrugBank.d163.s2.e2
DDI-DrugBank.d163.s2	95	102	Accutane	brand	DDI-DrugBank.d163.s2.e3
DDI-DrugBank.d163.s2	252	264	tetracyclines	group	DDI-DrugBank.d163.s2.e4
DDI-DrugBank.d163.s2	false	DDI-DrugBank.d163.s2.e0	DDI-DrugBank.d163.s2.e1
DDI-DrugBank.d163.s2	false	DDI-DrugBank.d163.s2.e0	DDI-DrugBank.d163.s2.e2
DDI-DrugBank.d163.s2	false	DDI-DrugBank.d163.s2.e0	DDI-DrugBank.d163.s2.e3
DDI-DrugBank.d163.s2	false	DDI-DrugBank.d163.s2.e0	DDI-DrugBank.d163.s2.e4
DDI-DrugBank.d163.s2	true	DDI-DrugBank.d163.s2.e1	DDI-DrugBank.d163.s2.e2
DDI-DrugBank.d163.s2	false	DDI-DrugBank.d163.s2.e1	DDI-DrugBank.d163.s2.e3
DDI-DrugBank.d163.s2	false	DDI-DrugBank.d163.s2.e1	DDI-DrugBank.d163.s2.e4
DDI-DrugBank.d163.s2	false	DDI-DrugBank.d163.s2.e2	DDI-DrugBank.d163.s2.e3
DDI-DrugBank.d163.s2	false	DDI-DrugBank.d163.s2.e2	DDI-DrugBank.d163.s2.e4
DDI-DrugBank.d163.s2	true	DDI-DrugBank.d163.s2.e3	DDI-DrugBank.d163.s2.e4
DDI-DrugBank.d163.s3|a|.
DDI-DrugBank.d163.s4|a|Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.
DDI-DrugBank.d163.s4	12	23	Progesterone	drug	DDI-DrugBank.d163.s4.e0
DDI-DrugBank.d163.s4	51	62	progesterone	drug	DDI-DrugBank.d163.s4.e1
DDI-DrugBank.d163.s4	111	118	estrogen	group	DDI-DrugBank.d163.s4.e2
DDI-DrugBank.d163.s4	173	180	Accutane	brand	DDI-DrugBank.d163.s4.e3
DDI-DrugBank.d163.s4	false	DDI-DrugBank.d163.s4.e0	DDI-DrugBank.d163.s4.e1
DDI-DrugBank.d163.s4	false	DDI-DrugBank.d163.s4.e0	DDI-DrugBank.d163.s4.e2
DDI-DrugBank.d163.s4	false	DDI-DrugBank.d163.s4.e0	DDI-DrugBank.d163.s4.e3
DDI-DrugBank.d163.s4	false	DDI-DrugBank.d163.s4.e1	DDI-DrugBank.d163.s4.e2
DDI-DrugBank.d163.s4	true	DDI-DrugBank.d163.s4.e1	DDI-DrugBank.d163.s4.e3
DDI-DrugBank.d163.s4	false	DDI-DrugBank.d163.s4.e2	DDI-DrugBank.d163.s4.e3
DDI-DrugBank.d163.s5|a|Although other hormonal contraceptives are highly effective, there have been reports of pregnancy from women who have used combined oral contraceptives, as well as topical/injectable/implantable/insertable hormonal birth control products.
DDI-DrugBank.d163.s5	15	37	hormonal contraceptives	group	DDI-DrugBank.d163.s5.e0
DDI-DrugBank.d163.s5	123	150	combined oral contraceptives	group	DDI-DrugBank.d163.s5.e1
DDI-DrugBank.d163.s5	false	DDI-DrugBank.d163.s5.e0	DDI-DrugBank.d163.s5.e1
DDI-DrugBank.d163.s6|a|These reports are more frequent for women who use only a single method of contraception.
DDI-DrugBank.d163.s7|a|It is not known if hormonal contraceptives differ in their effectiveness when used with Accutane.
DDI-DrugBank.d163.s7	19	41	hormonal contraceptives	group	DDI-DrugBank.d163.s7.e0
DDI-DrugBank.d163.s7	88	95	Accutane	brand	DDI-DrugBank.d163.s7.e1
DDI-DrugBank.d163.s7	false	DDI-DrugBank.d163.s7.e0	DDI-DrugBank.d163.s7.e1
DDI-DrugBank.d163.s8|a|Therefore, it is critically important for women of childbearing potential to select and commit to use 2 forms of effective contraception simultaneously, at least 1 of which must be a primary form, unless absolute abstinence is the chosen method, or the patient has undergone a hysterectomy
DDI-DrugBank.d163.s9|a|.
DDI-DrugBank.d163.s10|a|Phenytoin: Accutane has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.
DDI-DrugBank.d163.s10	0	8	Phenytoin	drug	DDI-DrugBank.d163.s10.e0
DDI-DrugBank.d163.s10	11	18	Accutane	brand	DDI-DrugBank.d163.s10.e1
DDI-DrugBank.d163.s10	72	80	phenytoin	drug	DDI-DrugBank.d163.s10.e2
DDI-DrugBank.d163.s10	false	DDI-DrugBank.d163.s10.e0	DDI-DrugBank.d163.s10.e1
DDI-DrugBank.d163.s10	false	DDI-DrugBank.d163.s10.e0	DDI-DrugBank.d163.s10.e2
DDI-DrugBank.d163.s10	false	DDI-DrugBank.d163.s10.e1	DDI-DrugBank.d163.s10.e2
DDI-DrugBank.d163.s11|a|These results are consistent with the in vitro finding that neither isotretinoin nor its metabolites induce or inhibit the activity of the CYP 2C9 human hepatic P450 enzyme.
DDI-DrugBank.d163.s11	68	79	isotretinoin	drug	DDI-DrugBank.d163.s11.e0
DDI-DrugBank.d163.s12|a|Phenytoin is known to cause osteomalacia.
DDI-DrugBank.d163.s12	0	8	Phenytoin	drug	DDI-DrugBank.d163.s12.e0
DDI-DrugBank.d163.s13|a|No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between phenytoin and Accutane.
DDI-DrugBank.d163.s13	112	120	phenytoin	drug	DDI-DrugBank.d163.s13.e0
DDI-DrugBank.d163.s13	126	133	Accutane	brand	DDI-DrugBank.d163.s13.e1
DDI-DrugBank.d163.s13	false	DDI-DrugBank.d163.s13.e0	DDI-DrugBank.d163.s13.e1
DDI-DrugBank.d163.s14|a|Therefore, caution should be exercised when using these drugs together
DDI-DrugBank.d163.s15|a|.
DDI-DrugBank.d163.s16|a|Systemic Corticosteroids: Systemic corticosteroids are known to cause osteoporosis.
DDI-DrugBank.d163.s16	0	23	Systemic Corticosteroids	group	DDI-DrugBank.d163.s16.e0
DDI-DrugBank.d163.s16	26	49	Systemic corticosteroids	group	DDI-DrugBank.d163.s16.e1
DDI-DrugBank.d163.s16	false	DDI-DrugBank.d163.s16.e0	DDI-DrugBank.d163.s16.e1
DDI-DrugBank.d163.s17|a|No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between systemic corticosteroids and Accutane.
DDI-DrugBank.d163.s17	112	135	systemic corticosteroids	group	DDI-DrugBank.d163.s17.e0
DDI-DrugBank.d163.s17	141	148	Accutane	brand	DDI-DrugBank.d163.s17.e1
DDI-DrugBank.d163.s17	false	DDI-DrugBank.d163.s17.e0	DDI-DrugBank.d163.s17.e1
DDI-DrugBank.d163.s18|a|Therefore, caution should be exercised when using these drugs together.
DDI-DrugBank.d163.s19|a|Prescribers are advised to consult the package insert of medication administered concomitantly with hormonal contraceptives, since some medications may decrease the effectiveness of these birth control products.
DDI-DrugBank.d163.s19	100	122	hormonal contraceptives	group	DDI-DrugBank.d163.s19.e0
DDI-DrugBank.d163.s20|a|Accutane use is associated with depression in some patients.
DDI-DrugBank.d163.s20	0	7	Accutane	brand	DDI-DrugBank.d163.s20.e0
DDI-DrugBank.d163.s21|a|Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. Johns Wort.
DDI-DrugBank.d163.s21	43	74	combined hormonal contraceptives	group	DDI-DrugBank.d163.s21.e0
DDI-DrugBank.d163.s22|a|Laboratory Tests Pregnancy Test Female patients of childbearing potential must have negative results from 2 urine or serum pregnancy tests with a sensitivity of at least 25 mIU/mL before receiving the initial Accutane prescription.
DDI-DrugBank.d163.s22	209	216	Accutane	brand	DDI-DrugBank.d163.s22.e0
DDI-DrugBank.d163.s23|a|The first test is obtained by the prescriber when the decision is made to pursue qualification of the patient for Accutane (a screening test).
DDI-DrugBank.d163.s23	114	121	Accutane	brand	DDI-DrugBank.d163.s23.e0
DDI-DrugBank.d163.s24|a|The second pregnancy test (a confirmation test) should be done during the first 5 days of the menstrual period immediately preceding the beginning of Accutane therapy.
DDI-DrugBank.d163.s24	150	157	Accutane	brand	DDI-DrugBank.d163.s24.e0
DDI-DrugBank.d163.s25|a|For patients with amenorrhea, the second test should be done at least 11 days after the last act of unprotected sexual intercourse (without using 2 effective forms of contraception).
DDI-DrugBank.d163.s26|a|Each month of therapy, the patient must have a negative result from a urine or serum pregnancy test.
DDI-DrugBank.d163.s27|a|A pregnancy test must be repeated each month prior to the female patient receiving each prescription
DDI-DrugBank.d163.s28|a|.
DDI-DrugBank.d163.s29|a|Lipids: Pretreatment and follow-up blood lipids should be obtained under fasting conditions.
DDI-DrugBank.d163.s30|a|After consumption of alcohol, at least 36 hours should elapse before these determinations are made.
DDI-DrugBank.d163.s30	21	27	alcohol	drug	DDI-DrugBank.d163.s30.e0
DDI-DrugBank.d163.s31|a|It is recommended that these tests be performed at weekly or biweekly intervals until the lipid response to Accutane is established.
DDI-DrugBank.d163.s31	108	115	Accutane	brand	DDI-DrugBank.d163.s31.e0
DDI-DrugBank.d163.s32|a|The incidence of hypertriglyceridemia is 1 patient in 4 on Accutane therapy
DDI-DrugBank.d163.s32	59	66	Accutane	brand	DDI-DrugBank.d163.s32.e0
DDI-DrugBank.d163.s33|a|.
DDI-DrugBank.d163.s34|a|Liver Function Tests: Since elevations of liver enzymes have been observed during clinical trials, and hepatitis has been reported, pretreatment and follow-up liver function tests should be performed at weekly or biweekly intervals until the response to Accutane has been established
DDI-DrugBank.d163.s34	254	261	Accutane	brand	DDI-DrugBank.d163.s34.e0
DDI-DrugBank.d163.s35|a|.
DDI-DrugBank.d163.s36|a|Glucose: Some patients receiving Accutane have experienced problems in the control of their blood sugar.
DDI-DrugBank.d163.s36	33	40	Accutane	brand	DDI-DrugBank.d163.s36.e0
DDI-DrugBank.d163.s37|a|In addition, new cases of diabetes have been diagnosed during Accutane therapy, although no causal relationship has been established
DDI-DrugBank.d163.s37	62	69	Accutane	brand	DDI-DrugBank.d163.s37.e0
DDI-DrugBank.d163.s38|a|.
DDI-DrugBank.d163.s39|a|CPK: Some patients undergoing vigorous physical activity while on Accutane therapy have experienced elevated CPK levels;
DDI-DrugBank.d163.s39	66	73	Accutane	brand	DDI-DrugBank.d163.s39.e0
DDI-DrugBank.d163.s40|a|however, the clinical significance is unknown.
DDI-DrugBank.d163.s41|a|There have been rare postmarketing reports of rhabdomyolysis, some associated with strenuous physical activity.
DDI-DrugBank.d163.s42|a|In a clinical trial of 217 pediatric patients (12 to 17 years) with severe recalcitrant nodular acne, transient elevations in CPK were observed in 12% of patients, including those undergoing strenuous physical activity in association with reported musculoskeletal adverse events such as back pain, arthralgia, limb injury, or muscle sprain.
DDI-DrugBank.d163.s43|a|In these patients, approximately half of the CPK elevations returned to normal within 2 weeks and half returned to normal within 4 weeks.
DDI-DrugBank.d163.s44|a|No cases of rhabdomyolysis were reported in this trial.
DDI-DrugBank.d81.s0|a|Nitroglycerin: DynaCirc  (isradipine) has been safely coadministered with nitroglycerin.
DDI-DrugBank.d81.s0	0	12	Nitroglycerin	drug	DDI-DrugBank.d81.s0.e0
DDI-DrugBank.d81.s0	15	22	DynaCirc	brand	DDI-DrugBank.d81.s0.e1
DDI-DrugBank.d81.s0	26	35	isradipine	drug	DDI-DrugBank.d81.s0.e2
DDI-DrugBank.d81.s0	74	86	nitroglycerin	drug	DDI-DrugBank.d81.s0.e3
DDI-DrugBank.d81.s0	false	DDI-DrugBank.d81.s0.e0	DDI-DrugBank.d81.s0.e1
DDI-DrugBank.d81.s0	false	DDI-DrugBank.d81.s0.e0	DDI-DrugBank.d81.s0.e2
DDI-DrugBank.d81.s0	false	DDI-DrugBank.d81.s0.e0	DDI-DrugBank.d81.s0.e3
DDI-DrugBank.d81.s0	false	DDI-DrugBank.d81.s0.e1	DDI-DrugBank.d81.s0.e2
DDI-DrugBank.d81.s0	false	DDI-DrugBank.d81.s0.e1	DDI-DrugBank.d81.s0.e3
DDI-DrugBank.d81.s0	false	DDI-DrugBank.d81.s0.e2	DDI-DrugBank.d81.s0.e3
DDI-DrugBank.d81.s1|a|Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.
DDI-DrugBank.d81.s1	0	18	Hydrochlorothiazide	drug	DDI-DrugBank.d81.s1.e0
DDI-DrugBank.d81.s1	103	110	DynaCirc	brand	DDI-DrugBank.d81.s1.e1
DDI-DrugBank.d81.s1	114	123	isradipine	drug	DDI-DrugBank.d81.s1.e2
DDI-DrugBank.d81.s1	130	148	hydrochlorothiazide	drug	DDI-DrugBank.d81.s1.e3
DDI-DrugBank.d81.s1	false	DDI-DrugBank.d81.s1.e0	DDI-DrugBank.d81.s1.e1
DDI-DrugBank.d81.s1	false	DDI-DrugBank.d81.s1.e0	DDI-DrugBank.d81.s1.e2
DDI-DrugBank.d81.s1	false	DDI-DrugBank.d81.s1.e0	DDI-DrugBank.d81.s1.e3
DDI-DrugBank.d81.s1	false	DDI-DrugBank.d81.s1.e1	DDI-DrugBank.d81.s1.e2
DDI-DrugBank.d81.s1	false	DDI-DrugBank.d81.s1.e1	DDI-DrugBank.d81.s1.e3
DDI-DrugBank.d81.s1	false	DDI-DrugBank.d81.s1.e2	DDI-DrugBank.d81.s1.e3
DDI-DrugBank.d81.s2|a|In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.
DDI-DrugBank.d81.s2	49	58	isradipine	drug	DDI-DrugBank.d81.s2.e0
DDI-DrugBank.d81.s2	72	90	hydrochlorothiazide	drug	DDI-DrugBank.d81.s2.e1
DDI-DrugBank.d81.s2	154	163	isradipine	drug	DDI-DrugBank.d81.s2.e2
DDI-DrugBank.d81.s2	false	DDI-DrugBank.d81.s2.e0	DDI-DrugBank.d81.s2.e1
DDI-DrugBank.d81.s2	false	DDI-DrugBank.d81.s2.e0	DDI-DrugBank.d81.s2.e2
DDI-DrugBank.d81.s2	false	DDI-DrugBank.d81.s2.e1	DDI-DrugBank.d81.s2.e2
DDI-DrugBank.d81.s3|a|Propranolol: In a single dose study in normal volunteers, coadministration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability.
DDI-DrugBank.d81.s3	0	10	Propranolol	drug	DDI-DrugBank.d81.s3.e0
DDI-DrugBank.d81.s3	78	88	propranolol	drug	DDI-DrugBank.d81.s3.e1
DDI-DrugBank.d81.s3	152	161	isradipine	drug	DDI-DrugBank.d81.s3.e2
DDI-DrugBank.d81.s3	false	DDI-DrugBank.d81.s3.e0	DDI-DrugBank.d81.s3.e1
DDI-DrugBank.d81.s3	false	DDI-DrugBank.d81.s3.e0	DDI-DrugBank.d81.s3.e2
DDI-DrugBank.d81.s3	false	DDI-DrugBank.d81.s3.e1	DDI-DrugBank.d81.s3.e2
DDI-DrugBank.d81.s4|a|Significant increases In AUC (27%) and Cmax (58%) and decreases in tmax (23%) of propranolol were noted in this study.
DDI-DrugBank.d81.s4	81	91	propranolol	drug	DDI-DrugBank.d81.s4.e0
DDI-DrugBank.d81.s5|a|However, concomitant administration of 5 mg b.i.d. isradipine and 40 mg b.i.d.
DDI-DrugBank.d81.s5	51	60	isradipine	drug	DDI-DrugBank.d81.s5.e0
DDI-DrugBank.d81.s6|a|propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.
DDI-DrugBank.d81.s6	0	10	propranolol	drug	DDI-DrugBank.d81.s6.e0
DDI-DrugBank.d81.s6	165	174	isradipine	drug	DDI-DrugBank.d81.s6.e1
DDI-DrugBank.d81.s6	213	223	propranolol	drug	DDI-DrugBank.d81.s6.e2
DDI-DrugBank.d81.s6	238	248	propranolol	drug	DDI-DrugBank.d81.s6.e3
DDI-DrugBank.d81.s6	287	296	isradipine	drug	DDI-DrugBank.d81.s6.e4
DDI-DrugBank.d81.s6	false	DDI-DrugBank.d81.s6.e0	DDI-DrugBank.d81.s6.e1
DDI-DrugBank.d81.s6	false	DDI-DrugBank.d81.s6.e0	DDI-DrugBank.d81.s6.e2
DDI-DrugBank.d81.s6	false	DDI-DrugBank.d81.s6.e0	DDI-DrugBank.d81.s6.e3
DDI-DrugBank.d81.s6	false	DDI-DrugBank.d81.s6.e0	DDI-DrugBank.d81.s6.e4
DDI-DrugBank.d81.s6	false	DDI-DrugBank.d81.s6.e1	DDI-DrugBank.d81.s6.e2
DDI-DrugBank.d81.s6	false	DDI-DrugBank.d81.s6.e1	DDI-DrugBank.d81.s6.e3
DDI-DrugBank.d81.s6	false	DDI-DrugBank.d81.s6.e1	DDI-DrugBank.d81.s6.e4
DDI-DrugBank.d81.s6	false	DDI-DrugBank.d81.s6.e2	DDI-DrugBank.d81.s6.e3
DDI-DrugBank.d81.s6	false	DDI-DrugBank.d81.s6.e2	DDI-DrugBank.d81.s6.e4
DDI-DrugBank.d81.s6	false	DDI-DrugBank.d81.s6.e3	DDI-DrugBank.d81.s6.e4
DDI-DrugBank.d81.s7|a|Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
DDI-DrugBank.d81.s7	0	9	Cimetidine	drug	DDI-DrugBank.d81.s7.e0
DDI-DrugBank.d81.s7	67	76	cimetidine	drug	DDI-DrugBank.d81.s7.e1
DDI-DrugBank.d81.s7	122	131	isradipine	drug	DDI-DrugBank.d81.s7.e2
DDI-DrugBank.d81.s7	172	181	isradipine	drug	DDI-DrugBank.d81.s7.e3
DDI-DrugBank.d81.s7	false	DDI-DrugBank.d81.s7.e0	DDI-DrugBank.d81.s7.e1
DDI-DrugBank.d81.s7	false	DDI-DrugBank.d81.s7.e0	DDI-DrugBank.d81.s7.e2
DDI-DrugBank.d81.s7	false	DDI-DrugBank.d81.s7.e0	DDI-DrugBank.d81.s7.e3
DDI-DrugBank.d81.s7	true	DDI-DrugBank.d81.s7.e1	DDI-DrugBank.d81.s7.e2
DDI-DrugBank.d81.s7	false	DDI-DrugBank.d81.s7.e1	DDI-DrugBank.d81.s7.e3
DDI-DrugBank.d81.s7	false	DDI-DrugBank.d81.s7.e2	DDI-DrugBank.d81.s7.e3
DDI-DrugBank.d81.s8|a|If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.
DDI-DrugBank.d81.s8	3	12	isradipine	drug	DDI-DrugBank.d81.s8.e0
DDI-DrugBank.d81.s8	68	77	cimetidine	drug	DDI-DrugBank.d81.s8.e1
DDI-DrugBank.d81.s8	true	DDI-DrugBank.d81.s8.e0	DDI-DrugBank.d81.s8.e1
DDI-DrugBank.d81.s9|a|Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.
DDI-DrugBank.d81.s9	0	9	Rifampicin	drug	DDI-DrugBank.d81.s9.e0
DDI-DrugBank.d81.s9	66	75	rifampicin	drug	DDI-DrugBank.d81.s9.e1
DDI-DrugBank.d81.s9	125	134	isradipine	drug	DDI-DrugBank.d81.s9.e2
DDI-DrugBank.d81.s9	163	172	isradipine	drug	DDI-DrugBank.d81.s9.e3
DDI-DrugBank.d81.s9	false	DDI-DrugBank.d81.s9.e0	DDI-DrugBank.d81.s9.e1
DDI-DrugBank.d81.s9	false	DDI-DrugBank.d81.s9.e0	DDI-DrugBank.d81.s9.e2
DDI-DrugBank.d81.s9	false	DDI-DrugBank.d81.s9.e0	DDI-DrugBank.d81.s9.e3
DDI-DrugBank.d81.s9	true	DDI-DrugBank.d81.s9.e1	DDI-DrugBank.d81.s9.e2
DDI-DrugBank.d81.s9	false	DDI-DrugBank.d81.s9.e1	DDI-DrugBank.d81.s9.e3
DDI-DrugBank.d81.s9	false	DDI-DrugBank.d81.s9.e2	DDI-DrugBank.d81.s9.e3
DDI-DrugBank.d81.s10|a|If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.
DDI-DrugBank.d81.s10	3	12	rifampicin	drug	DDI-DrugBank.d81.s10.e0
DDI-DrugBank.d81.s10	35	44	isradipine	drug	DDI-DrugBank.d81.s10.e1
DDI-DrugBank.d81.s10	197	206	isradipine	drug	DDI-DrugBank.d81.s10.e2
DDI-DrugBank.d81.s10	true	DDI-DrugBank.d81.s10.e0	DDI-DrugBank.d81.s10.e1
DDI-DrugBank.d81.s10	false	DDI-DrugBank.d81.s10.e0	DDI-DrugBank.d81.s10.e2
DDI-DrugBank.d81.s10	false	DDI-DrugBank.d81.s10.e1	DDI-DrugBank.d81.s10.e2
DDI-DrugBank.d81.s11|a|Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.
DDI-DrugBank.d81.s11	0	7	Warfarin	drug	DDI-DrugBank.d81.s11.e0
DDI-DrugBank.d81.s11	122	131	isradipine	drug	DDI-DrugBank.d81.s11.e1
DDI-DrugBank.d81.s11	145	152	warfarin	drug	DDI-DrugBank.d81.s11.e2
DDI-DrugBank.d81.s11	193	200	warfarin	drug	DDI-DrugBank.d81.s11.e3
DDI-DrugBank.d81.s11	302	311	isradipine	drug	DDI-DrugBank.d81.s11.e4
DDI-DrugBank.d81.s11	false	DDI-DrugBank.d81.s11.e0	DDI-DrugBank.d81.s11.e1
DDI-DrugBank.d81.s11	false	DDI-DrugBank.d81.s11.e0	DDI-DrugBank.d81.s11.e2
DDI-DrugBank.d81.s11	false	DDI-DrugBank.d81.s11.e0	DDI-DrugBank.d81.s11.e3
DDI-DrugBank.d81.s11	false	DDI-DrugBank.d81.s11.e0	DDI-DrugBank.d81.s11.e4
DDI-DrugBank.d81.s11	false	DDI-DrugBank.d81.s11.e1	DDI-DrugBank.d81.s11.e2
DDI-DrugBank.d81.s11	false	DDI-DrugBank.d81.s11.e1	DDI-DrugBank.d81.s11.e3
DDI-DrugBank.d81.s11	false	DDI-DrugBank.d81.s11.e1	DDI-DrugBank.d81.s11.e4
DDI-DrugBank.d81.s11	false	DDI-DrugBank.d81.s11.e2	DDI-DrugBank.d81.s11.e3
DDI-DrugBank.d81.s11	false	DDI-DrugBank.d81.s11.e2	DDI-DrugBank.d81.s11.e4
DDI-DrugBank.d81.s11	false	DDI-DrugBank.d81.s11.e3	DDI-DrugBank.d81.s11.e4
DDI-DrugBank.d81.s12|a|Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.
DDI-DrugBank.d81.s12	16	23	warfarin	drug	DDI-DrugBank.d81.s12.e0
DDI-DrugBank.d81.s12	29	38	isradipine	drug	DDI-DrugBank.d81.s12.e1
DDI-DrugBank.d81.s12	false	DDI-DrugBank.d81.s12.e0	DDI-DrugBank.d81.s12.e1
DDI-DrugBank.d81.s13|a|Digoxin: The concomitant administration of DynaCirc  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.
DDI-DrugBank.d81.s13	0	6	Digoxin	drug	DDI-DrugBank.d81.s13.e0
DDI-DrugBank.d81.s13	43	50	DynaCirc	brand	DDI-DrugBank.d81.s13.e1
DDI-DrugBank.d81.s13	54	63	isradipine	drug	DDI-DrugBank.d81.s13.e2
DDI-DrugBank.d81.s13	70	76	digoxin	drug	DDI-DrugBank.d81.s13.e3
DDI-DrugBank.d81.s13	176	182	digoxin	drug	DDI-DrugBank.d81.s13.e4
DDI-DrugBank.d81.s13	false	DDI-DrugBank.d81.s13.e0	DDI-DrugBank.d81.s13.e1
DDI-DrugBank.d81.s13	false	DDI-DrugBank.d81.s13.e0	DDI-DrugBank.d81.s13.e2
DDI-DrugBank.d81.s13	false	DDI-DrugBank.d81.s13.e0	DDI-DrugBank.d81.s13.e3
DDI-DrugBank.d81.s13	false	DDI-DrugBank.d81.s13.e0	DDI-DrugBank.d81.s13.e4
DDI-DrugBank.d81.s13	false	DDI-DrugBank.d81.s13.e1	DDI-DrugBank.d81.s13.e2
DDI-DrugBank.d81.s13	false	DDI-DrugBank.d81.s13.e1	DDI-DrugBank.d81.s13.e3
DDI-DrugBank.d81.s13	false	DDI-DrugBank.d81.s13.e1	DDI-DrugBank.d81.s13.e4
DDI-DrugBank.d81.s13	false	DDI-DrugBank.d81.s13.e2	DDI-DrugBank.d81.s13.e3
DDI-DrugBank.d81.s13	false	DDI-DrugBank.d81.s13.e2	DDI-DrugBank.d81.s13.e4
DDI-DrugBank.d81.s13	false	DDI-DrugBank.d81.s13.e3	DDI-DrugBank.d81.s13.e4
DDI-DrugBank.d81.s14|a|Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
DDI-DrugBank.d81.s14	0	7	Fentanyl	drug	DDI-DrugBank.d81.s14.e0
DDI-DrugBank.d81.s14	65	72	fentanyl	drug	DDI-DrugBank.d81.s14.e1
DDI-DrugBank.d81.s14	111	122	beta blocker	group	DDI-DrugBank.d81.s14.e2
DDI-DrugBank.d81.s14	130	152	calcium channel blocker	group	DDI-DrugBank.d81.s14.e3
DDI-DrugBank.d81.s14	false	DDI-DrugBank.d81.s14.e0	DDI-DrugBank.d81.s14.e1
DDI-DrugBank.d81.s14	false	DDI-DrugBank.d81.s14.e0	DDI-DrugBank.d81.s14.e2
DDI-DrugBank.d81.s14	false	DDI-DrugBank.d81.s14.e0	DDI-DrugBank.d81.s14.e3
DDI-DrugBank.d81.s14	true	DDI-DrugBank.d81.s14.e1	DDI-DrugBank.d81.s14.e2
DDI-DrugBank.d81.s14	true	DDI-DrugBank.d81.s14.e1	DDI-DrugBank.d81.s14.e3
DDI-DrugBank.d81.s14	false	DDI-DrugBank.d81.s14.e2	DDI-DrugBank.d81.s14.e3
DDI-DrugBank.d81.s15|a|Even though such interactions have not been seen in clinical studies with DynaCirc  (isradipine), an increased volume of circulating fluids might be required if such an interaction were to occur.
DDI-DrugBank.d81.s15	74	81	DynaCirc	brand	DDI-DrugBank.d81.s15.e0
DDI-DrugBank.d81.s15	85	94	isradipine	drug	DDI-DrugBank.d81.s15.e1
DDI-DrugBank.d81.s15	false	DDI-DrugBank.d81.s15.e0	DDI-DrugBank.d81.s15.e1
DDI-DrugBank.d165.s0|a|Both itraconazole and its major metabolite, hydroxyitraconazole, are inhibitors of the cytochrome P450 3A4 enzyme system.
DDI-DrugBank.d165.s0	5	16	itraconazole	drug	DDI-DrugBank.d165.s0.e0
DDI-DrugBank.d165.s0	44	62	hydroxyitraconazole	drug_n	DDI-DrugBank.d165.s0.e1
DDI-DrugBank.d165.s0	false	DDI-DrugBank.d165.s0.e0	DDI-DrugBank.d165.s0.e1
DDI-DrugBank.d165.s1|a|Coadministration of Itraconazole and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects.
DDI-DrugBank.d165.s1	20	31	Itraconazole	drug	DDI-DrugBank.d165.s1.e0
DDI-DrugBank.d165.s2|a|Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary.
DDI-DrugBank.d165.s3|a|Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
DDI-DrugBank.d165.s3	20	30	terfenadine	drug	DDI-DrugBank.d165.s3.e0
DDI-DrugBank.d165.s3	37	48	Itraconazole	drug	DDI-DrugBank.d165.s3.e1
DDI-DrugBank.d165.s3	95	105	terfenadine	drug	DDI-DrugBank.d165.s3.e2
DDI-DrugBank.d165.s3	true	DDI-DrugBank.d165.s3.e0	DDI-DrugBank.d165.s3.e1
DDI-DrugBank.d165.s3	false	DDI-DrugBank.d165.s3.e0	DDI-DrugBank.d165.s3.e2
DDI-DrugBank.d165.s3	false	DDI-DrugBank.d165.s3.e1	DDI-DrugBank.d165.s3.e2
DDI-DrugBank.d165.s4|a|Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.
DDI-DrugBank.d165.s4	13	28	azole antifungal	group	DDI-DrugBank.d165.s4.e0
DDI-DrugBank.d165.s4	31	42	ketoconazole	drug	DDI-DrugBank.d165.s4.e1
DDI-DrugBank.d165.s4	72	81	astemizole	drug	DDI-DrugBank.d165.s4.e2
DDI-DrugBank.d165.s4	131	140	astemizole	drug	DDI-DrugBank.d165.s4.e3
DDI-DrugBank.d165.s4	168	187	desmethylastermizole	drug_n	DDI-DrugBank.d165.s4.e4
DDI-DrugBank.d165.s4	false	DDI-DrugBank.d165.s4.e0	DDI-DrugBank.d165.s4.e1
DDI-DrugBank.d165.s4	false	DDI-DrugBank.d165.s4.e0	DDI-DrugBank.d165.s4.e2
DDI-DrugBank.d165.s4	false	DDI-DrugBank.d165.s4.e0	DDI-DrugBank.d165.s4.e3
DDI-DrugBank.d165.s4	false	DDI-DrugBank.d165.s4.e0	DDI-DrugBank.d165.s4.e4
DDI-DrugBank.d165.s4	true	DDI-DrugBank.d165.s4.e1	DDI-DrugBank.d165.s4.e2
DDI-DrugBank.d165.s4	false	DDI-DrugBank.d165.s4.e1	DDI-DrugBank.d165.s4.e3
DDI-DrugBank.d165.s4	false	DDI-DrugBank.d165.s4.e1	DDI-DrugBank.d165.s4.e4
DDI-DrugBank.d165.s4	false	DDI-DrugBank.d165.s4.e2	DDI-DrugBank.d165.s4.e3
DDI-DrugBank.d165.s4	false	DDI-DrugBank.d165.s4.e2	DDI-DrugBank.d165.s4.e4
DDI-DrugBank.d165.s4	false	DDI-DrugBank.d165.s4.e3	DDI-DrugBank.d165.s4.e4
DDI-DrugBank.d165.s5|a|In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.
DDI-DrugBank.d165.s5	27	38	itraconazole	drug	DDI-DrugBank.d165.s5.e0
DDI-DrugBank.d165.s5	58	69	ketoconazole	drug	DDI-DrugBank.d165.s5.e1
DDI-DrugBank.d165.s5	167	176	astemizole	drug	DDI-DrugBank.d165.s5.e2
DDI-DrugBank.d165.s5	false	DDI-DrugBank.d165.s5.e0	DDI-DrugBank.d165.s5.e1
DDI-DrugBank.d165.s5	true	DDI-DrugBank.d165.s5.e0	DDI-DrugBank.d165.s5.e2
DDI-DrugBank.d165.s5	false	DDI-DrugBank.d165.s5.e1	DDI-DrugBank.d165.s5.e2
DDI-DrugBank.d165.s6|a|Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.
DDI-DrugBank.d165.s6	37	48	itraconazole	drug	DDI-DrugBank.d165.s6.e0
DDI-DrugBank.d165.s6	54	65	ketoconazole	drug	DDI-DrugBank.d165.s6.e1
DDI-DrugBank.d165.s6	88	97	astemizole	drug	DDI-DrugBank.d165.s6.e2
DDI-DrugBank.d165.s6	104	115	itraconazole	drug	DDI-DrugBank.d165.s6.e3
DDI-DrugBank.d165.s6	false	DDI-DrugBank.d165.s6.e0	DDI-DrugBank.d165.s6.e1
DDI-DrugBank.d165.s6	false	DDI-DrugBank.d165.s6.e0	DDI-DrugBank.d165.s6.e2
DDI-DrugBank.d165.s6	false	DDI-DrugBank.d165.s6.e0	DDI-DrugBank.d165.s6.e3
DDI-DrugBank.d165.s6	false	DDI-DrugBank.d165.s6.e1	DDI-DrugBank.d165.s6.e2
DDI-DrugBank.d165.s6	false	DDI-DrugBank.d165.s6.e1	DDI-DrugBank.d165.s6.e3
DDI-DrugBank.d165.s6	true	DDI-DrugBank.d165.s6.e2	DDI-DrugBank.d165.s6.e3
DDI-DrugBank.d165.s7|a|Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.
DDI-DrugBank.d165.s7	47	58	ketoconazole	drug	DDI-DrugBank.d165.s7.e0
DDI-DrugBank.d165.s7	96	104	cisapride	drug	DDI-DrugBank.d165.s7.e1
DDI-DrugBank.d165.s7	161	169	cisapride	drug	DDI-DrugBank.d165.s7.e2
DDI-DrugBank.d165.s7	true	DDI-DrugBank.d165.s7.e0	DDI-DrugBank.d165.s7.e1
DDI-DrugBank.d165.s7	false	DDI-DrugBank.d165.s7.e0	DDI-DrugBank.d165.s7.e2
DDI-DrugBank.d165.s7	false	DDI-DrugBank.d165.s7.e1	DDI-DrugBank.d165.s7.e2
DDI-DrugBank.d165.s8|a|Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
DDI-DrugBank.d165.s8	43	54	ketoconazole	drug	DDI-DrugBank.d165.s8.e0
DDI-DrugBank.d165.s8	60	68	cisapride	drug	DDI-DrugBank.d165.s8.e1
DDI-DrugBank.d165.s8	true	DDI-DrugBank.d165.s8.e0	DDI-DrugBank.d165.s8.e1
DDI-DrugBank.d165.s9|a|In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;
DDI-DrugBank.d165.s9	27	38	itraconazole	drug	DDI-DrugBank.d165.s9.e0
DDI-DrugBank.d165.s9	133	141	cisapride	drug	DDI-DrugBank.d165.s9.e1
DDI-DrugBank.d165.s9	true	DDI-DrugBank.d165.s9.e0	DDI-DrugBank.d165.s9.e1
DDI-DrugBank.d165.s10|a|therefore concomitant administration of Itraconazole with cisapride is contraindicated.
DDI-DrugBank.d165.s10	40	51	Itraconazole	drug	DDI-DrugBank.d165.s10.e0
DDI-DrugBank.d165.s10	58	66	cisapride	drug	DDI-DrugBank.d165.s10.e1
DDI-DrugBank.d165.s10	true	DDI-DrugBank.d165.s10.e0	DDI-DrugBank.d165.s10.e1
DDI-DrugBank.d165.s11|a|Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
DDI-DrugBank.d165.s11	20	31	Itraconazole	drug	DDI-DrugBank.d165.s11.e0
DDI-DrugBank.d165.s11	43	51	midazolam	drug	DDI-DrugBank.d165.s11.e1
DDI-DrugBank.d165.s11	56	64	triazolam	drug	DDI-DrugBank.d165.s11.e2
DDI-DrugBank.d165.s11	true	DDI-DrugBank.d165.s11.e0	DDI-DrugBank.d165.s11.e1
DDI-DrugBank.d165.s11	true	DDI-DrugBank.d165.s11.e0	DDI-DrugBank.d165.s11.e2
DDI-DrugBank.d165.s11	false	DDI-DrugBank.d165.s11.e1	DDI-DrugBank.d165.s11.e2
DDI-DrugBank.d165.s12|a|This may potentiate and prolong hypnotic and sedative effects.
DDI-DrugBank.d165.s13|a|These agents should not be used in patients treated with Itraconazole.
DDI-DrugBank.d165.s13	57	68	Itraconazole	drug	DDI-DrugBank.d165.s13.e0
DDI-DrugBank.d165.s14|a|If midazolam is administered parenterally, special precaution is required since the sedative effect may be prolonged.
DDI-DrugBank.d165.s14	3	11	midazolam	drug	DDI-DrugBank.d165.s14.e0
DDI-DrugBank.d165.s15|a|Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
DDI-DrugBank.d165.s15	20	31	Itraconazole	drug	DDI-DrugBank.d165.s15.e0
DDI-DrugBank.d165.s15	37	48	cyclosporine	drug	DDI-DrugBank.d165.s15.e1
DDI-DrugBank.d165.s15	51	60	tacrolimus	drug	DDI-DrugBank.d165.s15.e2
DDI-DrugBank.d165.s15	65	71	digoxin	drug	DDI-DrugBank.d165.s15.e3
DDI-DrugBank.d165.s15	true	DDI-DrugBank.d165.s15.e0	DDI-DrugBank.d165.s15.e1
DDI-DrugBank.d165.s15	true	DDI-DrugBank.d165.s15.e0	DDI-DrugBank.d165.s15.e2
DDI-DrugBank.d165.s15	true	DDI-DrugBank.d165.s15.e0	DDI-DrugBank.d165.s15.e3
DDI-DrugBank.d165.s15	false	DDI-DrugBank.d165.s15.e1	DDI-DrugBank.d165.s15.e2
DDI-DrugBank.d165.s15	false	DDI-DrugBank.d165.s15.e1	DDI-DrugBank.d165.s15.e3
DDI-DrugBank.d165.s15	false	DDI-DrugBank.d165.s15.e2	DDI-DrugBank.d165.s15.e3
DDI-DrugBank.d165.s16|a|Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
DDI-DrugBank.d165.s16	0	11	Cyclosporine	drug	DDI-DrugBank.d165.s16.e0
DDI-DrugBank.d165.s16	14	23	tacrolimus	drug	DDI-DrugBank.d165.s16.e1
DDI-DrugBank.d165.s16	29	35	digoxin	drug	DDI-DrugBank.d165.s16.e2
DDI-DrugBank.d165.s16	93	104	Itraconazole	drug	DDI-DrugBank.d165.s16.e3
DDI-DrugBank.d165.s16	false	DDI-DrugBank.d165.s16.e0	DDI-DrugBank.d165.s16.e1
DDI-DrugBank.d165.s16	false	DDI-DrugBank.d165.s16.e0	DDI-DrugBank.d165.s16.e2
DDI-DrugBank.d165.s16	true	DDI-DrugBank.d165.s16.e0	DDI-DrugBank.d165.s16.e3
DDI-DrugBank.d165.s16	false	DDI-DrugBank.d165.s16.e1	DDI-DrugBank.d165.s16.e2
DDI-DrugBank.d165.s16	true	DDI-DrugBank.d165.s16.e1	DDI-DrugBank.d165.s16.e3
DDI-DrugBank.d165.s16	true	DDI-DrugBank.d165.s16.e2	DDI-DrugBank.d165.s16.e3
DDI-DrugBank.d165.s17|a|Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.
DDI-DrugBank.d165.s17	55	82	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d165.s17.e0
DDI-DrugBank.d165.s17	150	172	immunosuppressive drugs	group	DDI-DrugBank.d165.s17.e1
DDI-DrugBank.d165.s17	184	195	cyclosporine	drug	DDI-DrugBank.d165.s17.e2
DDI-DrugBank.d165.s17	true	DDI-DrugBank.d165.s17.e0	DDI-DrugBank.d165.s17.e1
DDI-DrugBank.d165.s17	true	DDI-DrugBank.d165.s17.e0	DDI-DrugBank.d165.s17.e2
DDI-DrugBank.d165.s17	false	DDI-DrugBank.d165.s17.e1	DDI-DrugBank.d165.s17.e2
DDI-DrugBank.d165.s18|a|When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.
DDI-DrugBank.d165.s18	5	16	Itraconazole	drug	DDI-DrugBank.d165.s18.e0
DDI-DrugBank.d165.s18	42	50	phenytoin	drug	DDI-DrugBank.d165.s18.e1
DDI-DrugBank.d165.s18	53	60	rifampin	drug	DDI-DrugBank.d165.s18.e2
DDI-DrugBank.d165.s18	114	125	itraconazole	drug	DDI-DrugBank.d165.s18.e3
DDI-DrugBank.d165.s18	true	DDI-DrugBank.d165.s18.e0	DDI-DrugBank.d165.s18.e1
DDI-DrugBank.d165.s18	true	DDI-DrugBank.d165.s18.e0	DDI-DrugBank.d165.s18.e2
DDI-DrugBank.d165.s18	false	DDI-DrugBank.d165.s18.e0	DDI-DrugBank.d165.s18.e3
DDI-DrugBank.d165.s18	false	DDI-DrugBank.d165.s18.e1	DDI-DrugBank.d165.s18.e2
DDI-DrugBank.d165.s18	false	DDI-DrugBank.d165.s18.e1	DDI-DrugBank.d165.s18.e3
DDI-DrugBank.d165.s18	false	DDI-DrugBank.d165.s18.e2	DDI-DrugBank.d165.s18.e3
DDI-DrugBank.d165.s19|a|The physician is advised to monitor the plasma concentrations of itraconazole when any of these drugs is taken concurrently, and to increase the dose of Itraconazole if necessary.
DDI-DrugBank.d165.s19	65	76	itraconazole	drug	DDI-DrugBank.d165.s19.e0
DDI-DrugBank.d165.s19	153	164	Itraconazole	drug	DDI-DrugBank.d165.s19.e1
DDI-DrugBank.d165.s19	false	DDI-DrugBank.d165.s19.e0	DDI-DrugBank.d165.s19.e1
DDI-DrugBank.d165.s20|a|Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;
DDI-DrugBank.d165.s20	71	82	Itraconazole	drug	DDI-DrugBank.d165.s20.e0
DDI-DrugBank.d165.s20	88	96	phenytoin	drug	DDI-DrugBank.d165.s20.e1
DDI-DrugBank.d165.s20	126	134	phenytoin	drug	DDI-DrugBank.d165.s20.e2
DDI-DrugBank.d165.s20	true	DDI-DrugBank.d165.s20.e0	DDI-DrugBank.d165.s20.e1
DDI-DrugBank.d165.s20	false	DDI-DrugBank.d165.s20.e0	DDI-DrugBank.d165.s20.e2
DDI-DrugBank.d165.s20	false	DDI-DrugBank.d165.s20.e1	DDI-DrugBank.d165.s20.e2
DDI-DrugBank.d165.s21|a|therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.
DDI-DrugBank.d165.s21	36	44	phenytoin	drug	DDI-DrugBank.d165.s21.e0
DDI-DrugBank.d165.s21	106	117	Itraconazole	drug	DDI-DrugBank.d165.s21.e1
DDI-DrugBank.d165.s21	true	DDI-DrugBank.d165.s21.e0	DDI-DrugBank.d165.s21.e1
DDI-DrugBank.d165.s22|a|It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.
DDI-DrugBank.d165.s22	26	37	Itraconazole	drug	DDI-DrugBank.d165.s22.e0
DDI-DrugBank.d165.s22	76	83	coumarin	group	DDI-DrugBank.d165.s22.e1
DDI-DrugBank.d165.s22	true	DDI-DrugBank.d165.s22.e0	DDI-DrugBank.d165.s22.e1
DDI-DrugBank.d165.s23|a|Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.
DDI-DrugBank.d165.s23	80	91	Itraconazole	drug	DDI-DrugBank.d165.s23.e0
DDI-DrugBank.d165.s23	97	104	coumarin	group	DDI-DrugBank.d165.s23.e1
DDI-DrugBank.d165.s23	true	DDI-DrugBank.d165.s23.e0	DDI-DrugBank.d165.s23.e1
DDI-DrugBank.d165.s24|a|Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.
DDI-DrugBank.d165.s24	25	47	azole antifungal agents	group	DDI-DrugBank.d165.s24.e0
DDI-DrugBank.d165.s24	90	98	isoniazid	drug	DDI-DrugBank.d165.s24.e1
DDI-DrugBank.d165.s24	true	DDI-DrugBank.d165.s24.e0	DDI-DrugBank.d165.s24.e1
DDI-DrugBank.d165.s25|a|Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.
DDI-DrugBank.d165.s25	0	11	Itraconazole	drug	DDI-DrugBank.d165.s25.e0
DDI-DrugBank.d165.s25	60	71	Itraconazole	drug	DDI-DrugBank.d165.s25.e1
DDI-DrugBank.d165.s25	77	85	isoniazid	drug	DDI-DrugBank.d165.s25.e2
DDI-DrugBank.d165.s25	false	DDI-DrugBank.d165.s25.e0	DDI-DrugBank.d165.s25.e1
DDI-DrugBank.d165.s25	false	DDI-DrugBank.d165.s25.e0	DDI-DrugBank.d165.s25.e2
DDI-DrugBank.d165.s25	true	DDI-DrugBank.d165.s25.e1	DDI-DrugBank.d165.s25.e2
DDI-DrugBank.d165.s26|a|Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.
DDI-DrugBank.d165.s26	74	96	azole antifungal agents	group	DDI-DrugBank.d165.s26.e0
DDI-DrugBank.d165.s26	107	125	hypoglycemic agents	group	DDI-DrugBank.d165.s26.e1
DDI-DrugBank.d165.s26	true	DDI-DrugBank.d165.s26.e0	DDI-DrugBank.d165.s26.e1
DDI-DrugBank.d165.s27|a|Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.
DDI-DrugBank.d165.s27	64	75	Itraconazole	drug	DDI-DrugBank.d165.s27.e0
DDI-DrugBank.d165.s27	86	104	hypoglycemic agents	group	DDI-DrugBank.d165.s27.e1
DDI-DrugBank.d165.s27	true	DDI-DrugBank.d165.s27.e0	DDI-DrugBank.d165.s27.e1
DDI-DrugBank.d165.s28|a|Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.
DDI-DrugBank.d165.s28	86	97	Itraconazole	drug	DDI-DrugBank.d165.s28.e0
DDI-DrugBank.d165.s28	103	111	quinidine	drug	DDI-DrugBank.d165.s28.e1
DDI-DrugBank.d165.s28	true	DDI-DrugBank.d165.s28.e0	DDI-DrugBank.d165.s28.e1
DDI-DrugBank.d165.s29|a|Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.
DDI-DrugBank.d165.s29	60	71	Itraconazole	drug	DDI-DrugBank.d165.s29.e0
DDI-DrugBank.d165.s29	77	116	dihydropyridine calcium channel blockers	group	DDI-DrugBank.d165.s29.e1
DDI-DrugBank.d165.s29	true	DDI-DrugBank.d165.s29.e0	DDI-DrugBank.d165.s29.e1
DDI-DrugBank.d165.s30|a|Appropriate dosage adjustments may be necessary.
DDI-DrugBank.d165.s31|a|The results from a study in which eight HIV-infected individuals were treated with zidovudine, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of Itraconazole, 100 mg b.i.d.
DDI-DrugBank.d165.s31	83	92	zidovudine	drug	DDI-DrugBank.d165.s31.e0
DDI-DrugBank.d165.s31	152	161	zidovudine	drug	DDI-DrugBank.d165.s31.e1
DDI-DrugBank.d165.s31	218	229	Itraconazole	drug	DDI-DrugBank.d165.s31.e2
DDI-DrugBank.d165.s31	false	DDI-DrugBank.d165.s31.e0	DDI-DrugBank.d165.s31.e1
DDI-DrugBank.d165.s31	false	DDI-DrugBank.d165.s31.e0	DDI-DrugBank.d165.s31.e2
DDI-DrugBank.d165.s31	false	DDI-DrugBank.d165.s31.e1	DDI-DrugBank.d165.s31.e2
DDI-DrugBank.d57.s0|a|In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
DDI-DrugBank.d57.s0	22	35	aminoglycoside	group	DDI-DrugBank.d57.s0.e0
DDI-DrugBank.d57.s0	58	68	antibiotics	group	DDI-DrugBank.d57.s0.e1
DDI-DrugBank.d57.s0	71	81	penicillins	group	DDI-DrugBank.d57.s0.e2
DDI-DrugBank.d57.s0	86	99	cephalosporins	group	DDI-DrugBank.d57.s0.e3
DDI-DrugBank.d57.s0	true	DDI-DrugBank.d57.s0.e0	DDI-DrugBank.d57.s0.e1
DDI-DrugBank.d57.s0	true	DDI-DrugBank.d57.s0.e0	DDI-DrugBank.d57.s0.e2
DDI-DrugBank.d57.s0	true	DDI-DrugBank.d57.s0.e0	DDI-DrugBank.d57.s0.e3
DDI-DrugBank.d57.s0	false	DDI-DrugBank.d57.s0.e1	DDI-DrugBank.d57.s0.e2
DDI-DrugBank.d57.s0	false	DDI-DrugBank.d57.s0.e1	DDI-DrugBank.d57.s0.e3
DDI-DrugBank.d57.s0	false	DDI-DrugBank.d57.s0.e2	DDI-DrugBank.d57.s0.e3
DDI-DrugBank.d57.s1|a|Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.
DDI-DrugBank.d57.s1	13	26	aminoglycoside	group	DDI-DrugBank.d57.s1.e0
DDI-DrugBank.d57.s1	34	43	penicillin	group	DDI-DrugBank.d57.s1.e1
DDI-DrugBank.d57.s1	119	132	aminoglycoside	group	DDI-DrugBank.d57.s1.e2
DDI-DrugBank.d57.s1	true	DDI-DrugBank.d57.s1.e0	DDI-DrugBank.d57.s1.e1
DDI-DrugBank.d57.s1	false	DDI-DrugBank.d57.s1.e0	DDI-DrugBank.d57.s1.e2
DDI-DrugBank.d57.s1	false	DDI-DrugBank.d57.s1.e1	DDI-DrugBank.d57.s1.e2
DDI-DrugBank.d57.s2|a|Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function..
DDI-DrugBank.d57.s2	34	47	aminoglycoside	group	DDI-DrugBank.d57.s2.e0
DDI-DrugBank.d57.s3|a|See
DDI-DrugBank.d518.s0|a|Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.
DDI-DrugBank.d518.s0	37	48	barbiturates	group	DDI-DrugBank.d518.s0.e0
DDI-DrugBank.d518.s0	57	65	narcotics	group	DDI-DrugBank.d518.s0.e1
DDI-DrugBank.d518.s0	94	101	ketamine	drug	DDI-DrugBank.d518.s0.e2
DDI-DrugBank.d518.s0	false	DDI-DrugBank.d518.s0.e0	DDI-DrugBank.d518.s0.e1
DDI-DrugBank.d518.s0	true	DDI-DrugBank.d518.s0.e0	DDI-DrugBank.d518.s0.e2
DDI-DrugBank.d518.s0	true	DDI-DrugBank.d518.s0.e1	DDI-DrugBank.d518.s0.e2
DDI-DrugBank.d518.s1|a|Ketamine is clinically compatible with the commonly used general and local anesthetic agents when an adequate respiratory exchange is maintained.
DDI-DrugBank.d518.s1	0	7	Ketamine	drug	DDI-DrugBank.d518.s1.e0
DDI-DrugBank.d518.s1	75	91	anesthetic agents	group	DDI-DrugBank.d518.s1.e1
DDI-DrugBank.d518.s1	false	DDI-DrugBank.d518.s1.e0	DDI-DrugBank.d518.s1.e1
DDI-DrugBank.d458.s0|a|Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system.
DDI-DrugBank.d458.s0	0	11	Ketoconazole	drug	DDI-DrugBank.d458.s0.e0
DDI-DrugBank.d458.s1|a|Coadministration of NIZORAL  Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects.
DDI-DrugBank.d458.s1	20	26	NIZORAL	brand	DDI-DrugBank.d458.s1.e0
DDI-DrugBank.d458.s2|a|Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary.
DDI-DrugBank.d458.s3|a|The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.
DDI-DrugBank.d458.s3	63	69	NIZORAL	brand	DDI-DrugBank.d458.s3.e0
DDI-DrugBank.d458.s3	149	160	Ketoconazole	drug	DDI-DrugBank.d458.s3.e1
DDI-DrugBank.d458.s3	196	206	terfenadine	drug	DDI-DrugBank.d458.s3.e2
DDI-DrugBank.d458.s3	259	269	terfenadine	drug	DDI-DrugBank.d458.s3.e3
DDI-DrugBank.d458.s3	false	DDI-DrugBank.d458.s3.e0	DDI-DrugBank.d458.s3.e1
DDI-DrugBank.d458.s3	false	DDI-DrugBank.d458.s3.e0	DDI-DrugBank.d458.s3.e2
DDI-DrugBank.d458.s3	false	DDI-DrugBank.d458.s3.e0	DDI-DrugBank.d458.s3.e3
DDI-DrugBank.d458.s3	true	DDI-DrugBank.d458.s3.e1	DDI-DrugBank.d458.s3.e2
DDI-DrugBank.d458.s3	false	DDI-DrugBank.d458.s3.e1	DDI-DrugBank.d458.s3.e3
DDI-DrugBank.d458.s3	false	DDI-DrugBank.d458.s3.e2	DDI-DrugBank.d458.s3.e3
DDI-DrugBank.d458.s4|a|The increased plasma concentration of terfenadine or its metabolite may result in prolonged QT intervals.
DDI-DrugBank.d458.s4	38	48	terfenadine	drug	DDI-DrugBank.d458.s4.e0
DDI-DrugBank.d458.s5|a|Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.
DDI-DrugBank.d458.s5	40	51	ketoconazole	drug	DDI-DrugBank.d458.s5.e0
DDI-DrugBank.d458.s5	80	89	astemizole	drug	DDI-DrugBank.d458.s5.e1
DDI-DrugBank.d458.s5	131	140	astemizole	drug	DDI-DrugBank.d458.s5.e2
DDI-DrugBank.d458.s5	168	186	desmethylastemizole	drug_n	DDI-DrugBank.d458.s5.e3
DDI-DrugBank.d458.s5	true	DDI-DrugBank.d458.s5.e0	DDI-DrugBank.d458.s5.e1
DDI-DrugBank.d458.s5	false	DDI-DrugBank.d458.s5.e0	DDI-DrugBank.d458.s5.e2
DDI-DrugBank.d458.s5	false	DDI-DrugBank.d458.s5.e0	DDI-DrugBank.d458.s5.e3
DDI-DrugBank.d458.s5	false	DDI-DrugBank.d458.s5.e1	DDI-DrugBank.d458.s5.e2
DDI-DrugBank.d458.s5	false	DDI-DrugBank.d458.s5.e1	DDI-DrugBank.d458.s5.e3
DDI-DrugBank.d458.s5	false	DDI-DrugBank.d458.s5.e2	DDI-DrugBank.d458.s5.e3
DDI-DrugBank.d458.s6|a|Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.
DDI-DrugBank.d458.s6	20	29	astemizole	drug	DDI-DrugBank.d458.s6.e0
DDI-DrugBank.d458.s6	36	47	ketoconazole	drug	DDI-DrugBank.d458.s6.e1
DDI-DrugBank.d458.s6	true	DDI-DrugBank.d458.s6.e0	DDI-DrugBank.d458.s6.e1
DDI-DrugBank.d458.s7|a|Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.
DDI-DrugBank.d458.s7	47	58	ketoconazole	drug	DDI-DrugBank.d458.s7.e0
DDI-DrugBank.d458.s7	96	104	cisapride	drug	DDI-DrugBank.d458.s7.e1
DDI-DrugBank.d458.s7	156	164	cisapride	drug	DDI-DrugBank.d458.s7.e2
DDI-DrugBank.d458.s7	true	DDI-DrugBank.d458.s7.e0	DDI-DrugBank.d458.s7.e1
DDI-DrugBank.d458.s7	false	DDI-DrugBank.d458.s7.e0	DDI-DrugBank.d458.s7.e2
DDI-DrugBank.d458.s7	false	DDI-DrugBank.d458.s7.e1	DDI-DrugBank.d458.s7.e2
DDI-DrugBank.d458.s8|a|Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
DDI-DrugBank.d458.s8	43	54	ketoconazole	drug	DDI-DrugBank.d458.s8.e0
DDI-DrugBank.d458.s8	60	68	cisapride	drug	DDI-DrugBank.d458.s8.e1
DDI-DrugBank.d458.s8	true	DDI-DrugBank.d458.s8.e0	DDI-DrugBank.d458.s8.e1
DDI-DrugBank.d458.s9|a|Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.
DDI-DrugBank.d458.s9	40	51	ketoconazole	drug	DDI-DrugBank.d458.s9.e0
DDI-DrugBank.d458.s9	66	74	cisapride	drug	DDI-DrugBank.d458.s9.e1
DDI-DrugBank.d458.s9	true	DDI-DrugBank.d458.s9.e0	DDI-DrugBank.d458.s9.e1
DDI-DrugBank.d458.s10|a|Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
DDI-DrugBank.d458.s10	0	11	Ketoconazole	drug	DDI-DrugBank.d458.s10.e0
DDI-DrugBank.d458.s10	49	60	cyclosporine	drug	DDI-DrugBank.d458.s10.e1
DDI-DrugBank.d458.s10	63	72	tacrolimus	drug	DDI-DrugBank.d458.s10.e2
DDI-DrugBank.d458.s10	79	96	methylprednisolone	drug	DDI-DrugBank.d458.s10.e3
DDI-DrugBank.d458.s10	true	DDI-DrugBank.d458.s10.e0	DDI-DrugBank.d458.s10.e1
DDI-DrugBank.d458.s10	true	DDI-DrugBank.d458.s10.e0	DDI-DrugBank.d458.s10.e2
DDI-DrugBank.d458.s10	true	DDI-DrugBank.d458.s10.e0	DDI-DrugBank.d458.s10.e3
DDI-DrugBank.d458.s10	false	DDI-DrugBank.d458.s10.e1	DDI-DrugBank.d458.s10.e2
DDI-DrugBank.d458.s10	false	DDI-DrugBank.d458.s10.e1	DDI-DrugBank.d458.s10.e3
DDI-DrugBank.d458.s10	false	DDI-DrugBank.d458.s10.e2	DDI-DrugBank.d458.s10.e3
DDI-DrugBank.d458.s11|a|Dosage adjustment may be required if cyclosporine, tacrolimus, or methylprednisolone are given concomitantly with NIZORAL  Tablets.
DDI-DrugBank.d458.s11	37	48	cyclosporine	drug	DDI-DrugBank.d458.s11.e0
DDI-DrugBank.d458.s11	51	60	tacrolimus	drug	DDI-DrugBank.d458.s11.e1
DDI-DrugBank.d458.s11	66	83	methylprednisolone	drug	DDI-DrugBank.d458.s11.e2
DDI-DrugBank.d458.s11	114	120	NIZORAL	brand	DDI-DrugBank.d458.s11.e3
DDI-DrugBank.d458.s11	false	DDI-DrugBank.d458.s11.e0	DDI-DrugBank.d458.s11.e1
DDI-DrugBank.d458.s11	false	DDI-DrugBank.d458.s11.e0	DDI-DrugBank.d458.s11.e2
DDI-DrugBank.d458.s11	false	DDI-DrugBank.d458.s11.e0	DDI-DrugBank.d458.s11.e3
DDI-DrugBank.d458.s11	false	DDI-DrugBank.d458.s11.e1	DDI-DrugBank.d458.s11.e2
DDI-DrugBank.d458.s11	false	DDI-DrugBank.d458.s11.e1	DDI-DrugBank.d458.s11.e3
DDI-DrugBank.d458.s11	false	DDI-DrugBank.d458.s11.e2	DDI-DrugBank.d458.s11.e3
DDI-DrugBank.d458.s12|a|Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
DDI-DrugBank.d458.s12	20	26	NIZORAL	brand	DDI-DrugBank.d458.s12.e0
DDI-DrugBank.d458.s12	42	50	midazolam	drug	DDI-DrugBank.d458.s12.e1
DDI-DrugBank.d458.s12	55	63	triazolam	drug	DDI-DrugBank.d458.s12.e2
DDI-DrugBank.d458.s12	true	DDI-DrugBank.d458.s12.e0	DDI-DrugBank.d458.s12.e1
DDI-DrugBank.d458.s12	true	DDI-DrugBank.d458.s12.e0	DDI-DrugBank.d458.s12.e2
DDI-DrugBank.d458.s12	false	DDI-DrugBank.d458.s12.e1	DDI-DrugBank.d458.s12.e2
DDI-DrugBank.d458.s13|a|This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents.
DDI-DrugBank.d458.s14|a|These agents should not be used in patients treated with NIZORAL  Tablets.
DDI-DrugBank.d458.s14	57	63	NIZORAL	brand	DDI-DrugBank.d458.s14.e0
DDI-DrugBank.d458.s15|a|If midazolam is administered parenterally, special precaution is required since the sedative effect may be prolonged.
DDI-DrugBank.d458.s15	3	11	midazolam	drug	DDI-DrugBank.d458.s15.e0
DDI-DrugBank.d458.s16|a|Rare cases of elevated plasma concentrations of digoxin have been reported.
DDI-DrugBank.d458.s16	48	54	digoxin	drug	DDI-DrugBank.d458.s16.e0
DDI-DrugBank.d458.s17|a|It is not clear whether this was due to the combination of therapy.
DDI-DrugBank.d458.s18|a|It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.
DDI-DrugBank.d458.s18	39	45	digoxin	drug	DDI-DrugBank.d458.s18.e0
DDI-DrugBank.d458.s18	84	95	ketoconazole	drug	DDI-DrugBank.d458.s18.e1
DDI-DrugBank.d458.s18	true	DDI-DrugBank.d458.s18.e0	DDI-DrugBank.d458.s18.e1
DDI-DrugBank.d458.s19|a|When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.
DDI-DrugBank.d458.s19	20	38	imidazole compounds	group	DDI-DrugBank.d458.s19.e0
DDI-DrugBank.d458.s19	45	56	ketoconazole	drug	DDI-DrugBank.d458.s19.e1
DDI-DrugBank.d458.s19	98	105	coumarin	group	DDI-DrugBank.d458.s19.e2
DDI-DrugBank.d458.s19	false	DDI-DrugBank.d458.s19.e0	DDI-DrugBank.d458.s19.e1
DDI-DrugBank.d458.s19	true	DDI-DrugBank.d458.s19.e0	DDI-DrugBank.d458.s19.e2
DDI-DrugBank.d458.s19	true	DDI-DrugBank.d458.s19.e1	DDI-DrugBank.d458.s19.e2
DDI-DrugBank.d458.s20|a|In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.
DDI-DrugBank.d458.s20	31	45	imidazole drugs	group	DDI-DrugBank.d458.s20.e0
DDI-DrugBank.d458.s20	51	64	coumarin drugs	group	DDI-DrugBank.d458.s20.e1
DDI-DrugBank.d458.s20	true	DDI-DrugBank.d458.s20.e0	DDI-DrugBank.d458.s20.e1
DDI-DrugBank.d458.s21|a|Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.
DDI-DrugBank.d458.s21	87	96	miconazole	drug	DDI-DrugBank.d458.s21.e0
DDI-DrugBank.d458.s21	102	110	imidazole	group	DDI-DrugBank.d458.s21.e1
DDI-DrugBank.d458.s21	122	140	hypoglycemic agents	group	DDI-DrugBank.d458.s21.e2
DDI-DrugBank.d458.s21	229	240	ketoconazole	drug	DDI-DrugBank.d458.s21.e3
DDI-DrugBank.d458.s21	254	262	imidazole	group	DDI-DrugBank.d458.s21.e4
DDI-DrugBank.d458.s21	false	DDI-DrugBank.d458.s21.e0	DDI-DrugBank.d458.s21.e1
DDI-DrugBank.d458.s21	true	DDI-DrugBank.d458.s21.e0	DDI-DrugBank.d458.s21.e2
DDI-DrugBank.d458.s21	false	DDI-DrugBank.d458.s21.e0	DDI-DrugBank.d458.s21.e3
DDI-DrugBank.d458.s21	false	DDI-DrugBank.d458.s21.e0	DDI-DrugBank.d458.s21.e4
DDI-DrugBank.d458.s21	false	DDI-DrugBank.d458.s21.e1	DDI-DrugBank.d458.s21.e2
DDI-DrugBank.d458.s21	false	DDI-DrugBank.d458.s21.e1	DDI-DrugBank.d458.s21.e3
DDI-DrugBank.d458.s21	false	DDI-DrugBank.d458.s21.e1	DDI-DrugBank.d458.s21.e4
DDI-DrugBank.d458.s21	false	DDI-DrugBank.d458.s21.e2	DDI-DrugBank.d458.s21.e3
DDI-DrugBank.d458.s21	false	DDI-DrugBank.d458.s21.e2	DDI-DrugBank.d458.s21.e4
DDI-DrugBank.d458.s21	false	DDI-DrugBank.d458.s21.e3	DDI-DrugBank.d458.s21.e4
DDI-DrugBank.d458.s22|a|Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.
DDI-DrugBank.d458.s22	30	41	ketoconazole	drug	DDI-DrugBank.d458.s22.e0
DDI-DrugBank.d458.s22	56	64	phenytoin	drug	DDI-DrugBank.d458.s22.e1
DDI-DrugBank.d458.s22	true	DDI-DrugBank.d458.s22.e0	DDI-DrugBank.d458.s22.e1
DDI-DrugBank.d458.s23|a|It is suggested to monitor both ketoconazole and phenytoin.
DDI-DrugBank.d458.s23	32	43	ketoconazole	drug	DDI-DrugBank.d458.s23.e0
DDI-DrugBank.d458.s23	49	57	phenytoin	drug	DDI-DrugBank.d458.s23.e1
DDI-DrugBank.d458.s23	true	DDI-DrugBank.d458.s23.e0	DDI-DrugBank.d458.s23.e1
DDI-DrugBank.d458.s24|a|Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.
DDI-DrugBank.d458.s24	30	37	rifampin	drug	DDI-DrugBank.d458.s24.e0
DDI-DrugBank.d458.s24	44	55	ketoconazole	drug	DDI-DrugBank.d458.s24.e1
DDI-DrugBank.d458.s24	true	DDI-DrugBank.d458.s24.e0	DDI-DrugBank.d458.s24.e1
DDI-DrugBank.d458.s25|a|INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.
DDI-DrugBank.d458.s25	0	2	INH	drug	DDI-DrugBank.d458.s25.e0
DDI-DrugBank.d458.s25	5	13	Isoniazid	drug	DDI-DrugBank.d458.s25.e1
DDI-DrugBank.d458.s25	43	54	ketoconazole	drug	DDI-DrugBank.d458.s25.e2
DDI-DrugBank.d458.s25	false	DDI-DrugBank.d458.s25.e0	DDI-DrugBank.d458.s25.e1
DDI-DrugBank.d458.s25	true	DDI-DrugBank.d458.s25.e0	DDI-DrugBank.d458.s25.e2
DDI-DrugBank.d458.s25	true	DDI-DrugBank.d458.s25.e1	DDI-DrugBank.d458.s25.e2
DDI-DrugBank.d458.s26|a|These drugs should not be given concomitantly.
DDI-DrugBank.d458.s27|a|After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.
DDI-DrugBank.d458.s27	42	53	ketoconazole	drug	DDI-DrugBank.d458.s27.e0
DDI-DrugBank.d458.s27	89	98	loratadine	drug	DDI-DrugBank.d458.s27.e1
DDI-DrugBank.d458.s27	136	145	loratadine	drug	DDI-DrugBank.d458.s27.e2
DDI-DrugBank.d458.s27	true	DDI-DrugBank.d458.s27.e0	DDI-DrugBank.d458.s27.e1
DDI-DrugBank.d458.s27	false	DDI-DrugBank.d458.s27.e0	DDI-DrugBank.d458.s27.e2
DDI-DrugBank.d458.s27	false	DDI-DrugBank.d458.s27.e1	DDI-DrugBank.d458.s27.e2
DDI-DrugBank.d458.s28|a|The AUC and Cmax of descarboethoxyloratadine, an active metabolite, averaged 155% (  27 S.D.) and 141% (  35 S.D.), respectively.
DDI-DrugBank.d458.s28	20	43	descarboethoxyloratadine	drug_n	DDI-DrugBank.d458.s28.e0
DDI-DrugBank.d458.s29|a|However, no related changes were noted in the QT0 on ECG taken at 2, 6, and 24 hours after the coadministration.
DDI-DrugBank.d458.s30|a|Also, there were no clinically significant differences in adverse events when loratadine was administered with or without ketoconazole.
DDI-DrugBank.d458.s30	78	87	loratadine	drug	DDI-DrugBank.d458.s30.e0
DDI-DrugBank.d458.s30	122	133	ketoconazole	drug	DDI-DrugBank.d458.s30.e1
DDI-DrugBank.d458.s30	false	DDI-DrugBank.d458.s30.e0	DDI-DrugBank.d458.s30.e1
DDI-DrugBank.d458.s31|a|Rare cases of a disulfiram-like reaction to alcohol have been reported.
DDI-DrugBank.d458.s31	44	50	alcohol	drug	DDI-DrugBank.d458.s31.e0
DDI-DrugBank.d458.s32|a|These experiences have been characterized by flushing, rash, peripheral edema, nausea, and headache.
DDI-DrugBank.d458.s33|a|Symptoms resolved within a few hours.
DDI-DrugBank.d499.s0|a|The following drug interactions were studied with ketoprofen doses of 200 mg/day.
DDI-DrugBank.d499.s0	50	59	ketoprofen	drug	DDI-DrugBank.d499.s0.e0
DDI-DrugBank.d499.s1|a|The possibility of increased interaction should be kept in mind when Orudis doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs.
DDI-DrugBank.d499.s1	69	74	Orudis	brand	DDI-DrugBank.d499.s1.e0
DDI-DrugBank.d499.s1	131	140	ketoprofen	drug	DDI-DrugBank.d499.s1.e1
DDI-DrugBank.d499.s1	false	DDI-DrugBank.d499.s1.e0	DDI-DrugBank.d499.s1.e1
DDI-DrugBank.d499.s2|a|1.
DDI-DrugBank.d499.s3|a|Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.
DDI-DrugBank.d499.s3	0	7	Antacids	group	DDI-DrugBank.d499.s3.e0
DDI-DrugBank.d499.s3	40	58	magnesium hydroxide	drug	DDI-DrugBank.d499.s3.e1
DDI-DrugBank.d499.s3	64	81	aluminum hydroxide	drug	DDI-DrugBank.d499.s3.e2
DDI-DrugBank.d499.s3	147	156	ketoprofen	drug	DDI-DrugBank.d499.s3.e3
DDI-DrugBank.d499.s3	174	179	Orudis	brand	DDI-DrugBank.d499.s3.e4
DDI-DrugBank.d499.s3	false	DDI-DrugBank.d499.s3.e0	DDI-DrugBank.d499.s3.e1
DDI-DrugBank.d499.s3	false	DDI-DrugBank.d499.s3.e0	DDI-DrugBank.d499.s3.e2
DDI-DrugBank.d499.s3	false	DDI-DrugBank.d499.s3.e0	DDI-DrugBank.d499.s3.e3
DDI-DrugBank.d499.s3	false	DDI-DrugBank.d499.s3.e0	DDI-DrugBank.d499.s3.e4
DDI-DrugBank.d499.s3	false	DDI-DrugBank.d499.s3.e1	DDI-DrugBank.d499.s3.e2
DDI-DrugBank.d499.s3	false	DDI-DrugBank.d499.s3.e1	DDI-DrugBank.d499.s3.e3
DDI-DrugBank.d499.s3	false	DDI-DrugBank.d499.s3.e1	DDI-DrugBank.d499.s3.e4
DDI-DrugBank.d499.s3	false	DDI-DrugBank.d499.s3.e2	DDI-DrugBank.d499.s3.e3
DDI-DrugBank.d499.s3	false	DDI-DrugBank.d499.s3.e2	DDI-DrugBank.d499.s3.e4
DDI-DrugBank.d499.s3	false	DDI-DrugBank.d499.s3.e3	DDI-DrugBank.d499.s3.e4
DDI-DrugBank.d499.s4|a|2.
DDI-DrugBank.d499.s5|a|Aspirin: Ketoprofen does not alter aspirin absorption;
DDI-DrugBank.d499.s5	0	6	Aspirin	brand	DDI-DrugBank.d499.s5.e0
DDI-DrugBank.d499.s5	9	18	Ketoprofen	drug	DDI-DrugBank.d499.s5.e1
DDI-DrugBank.d499.s5	35	41	aspirin	brand	DDI-DrugBank.d499.s5.e2
DDI-DrugBank.d499.s5	false	DDI-DrugBank.d499.s5.e0	DDI-DrugBank.d499.s5.e1
DDI-DrugBank.d499.s5	false	DDI-DrugBank.d499.s5.e0	DDI-DrugBank.d499.s5.e2
DDI-DrugBank.d499.s5	false	DDI-DrugBank.d499.s5.e1	DDI-DrugBank.d499.s5.e2
DDI-DrugBank.d499.s6|a|however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.
DDI-DrugBank.d499.s6	72	78	aspirin	brand	DDI-DrugBank.d499.s6.e0
DDI-DrugBank.d499.s6	90	99	ketoprofen	drug	DDI-DrugBank.d499.s6.e1
DDI-DrugBank.d499.s6	131	140	ketoprofen	drug	DDI-DrugBank.d499.s6.e2
DDI-DrugBank.d499.s6	184	190	aspirin	brand	DDI-DrugBank.d499.s6.e3
DDI-DrugBank.d499.s6	212	218	aspirin	brand	DDI-DrugBank.d499.s6.e4
DDI-DrugBank.d499.s6	true	DDI-DrugBank.d499.s6.e0	DDI-DrugBank.d499.s6.e1
DDI-DrugBank.d499.s6	true	DDI-DrugBank.d499.s6.e0	DDI-DrugBank.d499.s6.e2
DDI-DrugBank.d499.s6	false	DDI-DrugBank.d499.s6.e0	DDI-DrugBank.d499.s6.e3
DDI-DrugBank.d499.s6	false	DDI-DrugBank.d499.s6.e0	DDI-DrugBank.d499.s6.e4
DDI-DrugBank.d499.s6	false	DDI-DrugBank.d499.s6.e1	DDI-DrugBank.d499.s6.e2
DDI-DrugBank.d499.s6	false	DDI-DrugBank.d499.s6.e1	DDI-DrugBank.d499.s6.e3
DDI-DrugBank.d499.s6	false	DDI-DrugBank.d499.s6.e1	DDI-DrugBank.d499.s6.e4
DDI-DrugBank.d499.s6	false	DDI-DrugBank.d499.s6.e2	DDI-DrugBank.d499.s6.e3
DDI-DrugBank.d499.s6	false	DDI-DrugBank.d499.s6.e2	DDI-DrugBank.d499.s6.e4
DDI-DrugBank.d499.s6	false	DDI-DrugBank.d499.s6.e3	DDI-DrugBank.d499.s6.e4
DDI-DrugBank.d499.s7|a|The clinical significance of these changes has not been adequately studied.
DDI-DrugBank.d499.s8|a|Therefore, concurrent use of aspirin and ketoprofen is not recommended.
DDI-DrugBank.d499.s8	29	35	aspirin	brand	DDI-DrugBank.d499.s8.e0
DDI-DrugBank.d499.s8	41	50	ketoprofen	drug	DDI-DrugBank.d499.s8.e1
DDI-DrugBank.d499.s8	true	DDI-DrugBank.d499.s8.e0	DDI-DrugBank.d499.s8.e1
DDI-DrugBank.d499.s9|a|3.
DDI-DrugBank.d499.s10|a|Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
DDI-DrugBank.d499.s10	0	7	Diuretic	group	DDI-DrugBank.d499.s10.e0
DDI-DrugBank.d499.s10	10	28	Hydrochlorothiazide	drug	DDI-DrugBank.d499.s10.e1
DDI-DrugBank.d499.s10	56	65	ketoprofen	drug	DDI-DrugBank.d499.s10.e2
DDI-DrugBank.d499.s10	145	163	hydrochlorothiazide	drug	DDI-DrugBank.d499.s10.e3
DDI-DrugBank.d499.s10	false	DDI-DrugBank.d499.s10.e0	DDI-DrugBank.d499.s10.e1
DDI-DrugBank.d499.s10	false	DDI-DrugBank.d499.s10.e0	DDI-DrugBank.d499.s10.e2
DDI-DrugBank.d499.s10	false	DDI-DrugBank.d499.s10.e0	DDI-DrugBank.d499.s10.e3
DDI-DrugBank.d499.s10	true	DDI-DrugBank.d499.s10.e1	DDI-DrugBank.d499.s10.e2
DDI-DrugBank.d499.s10	false	DDI-DrugBank.d499.s10.e1	DDI-DrugBank.d499.s10.e3
DDI-DrugBank.d499.s10	false	DDI-DrugBank.d499.s10.e2	DDI-DrugBank.d499.s10.e3
DDI-DrugBank.d499.s11|a|Patients taking diuretics are at a greater risk of developing renal failure secondary to a decrease in renal blood flow caused by prostaglandin inhibition.
DDI-DrugBank.d499.s11	16	24	diuretics	group	DDI-DrugBank.d499.s11.e0
DDI-DrugBank.d499.s12|a|4.
DDI-DrugBank.d499.s13|a|Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.
DDI-DrugBank.d499.s13	0	6	Digoxin	drug	DDI-DrugBank.d499.s13.e0
DDI-DrugBank.d499.s13	71	80	ketoprofen	drug	DDI-DrugBank.d499.s13.e1
DDI-DrugBank.d499.s13	86	92	digoxin	drug	DDI-DrugBank.d499.s13.e2
DDI-DrugBank.d499.s13	127	136	ketoprofen	drug	DDI-DrugBank.d499.s13.e3
DDI-DrugBank.d499.s13	172	178	digoxin	drug	DDI-DrugBank.d499.s13.e4
DDI-DrugBank.d499.s13	false	DDI-DrugBank.d499.s13.e0	DDI-DrugBank.d499.s13.e1
DDI-DrugBank.d499.s13	false	DDI-DrugBank.d499.s13.e0	DDI-DrugBank.d499.s13.e2
DDI-DrugBank.d499.s13	false	DDI-DrugBank.d499.s13.e0	DDI-DrugBank.d499.s13.e3
DDI-DrugBank.d499.s13	false	DDI-DrugBank.d499.s13.e0	DDI-DrugBank.d499.s13.e4
DDI-DrugBank.d499.s13	false	DDI-DrugBank.d499.s13.e1	DDI-DrugBank.d499.s13.e2
DDI-DrugBank.d499.s13	false	DDI-DrugBank.d499.s13.e1	DDI-DrugBank.d499.s13.e3
DDI-DrugBank.d499.s13	false	DDI-DrugBank.d499.s13.e1	DDI-DrugBank.d499.s13.e4
DDI-DrugBank.d499.s13	false	DDI-DrugBank.d499.s13.e2	DDI-DrugBank.d499.s13.e3
DDI-DrugBank.d499.s13	false	DDI-DrugBank.d499.s13.e2	DDI-DrugBank.d499.s13.e4
DDI-DrugBank.d499.s13	false	DDI-DrugBank.d499.s13.e3	DDI-DrugBank.d499.s13.e4
DDI-DrugBank.d499.s14|a|5.
DDI-DrugBank.d499.s15|a|Warfarin: In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.
DDI-DrugBank.d499.s15	0	7	Warfarin	drug	DDI-DrugBank.d499.s15.e0
DDI-DrugBank.d499.s15	68	77	ketoprofen	drug	DDI-DrugBank.d499.s15.e1
DDI-DrugBank.d499.s15	130	137	warfarin	drug	DDI-DrugBank.d499.s15.e2
DDI-DrugBank.d499.s15	false	DDI-DrugBank.d499.s15.e0	DDI-DrugBank.d499.s15.e1
DDI-DrugBank.d499.s15	false	DDI-DrugBank.d499.s15.e0	DDI-DrugBank.d499.s15.e2
DDI-DrugBank.d499.s15	false	DDI-DrugBank.d499.s15.e1	DDI-DrugBank.d499.s15.e2
DDI-DrugBank.d499.s16|a|Bleeding from a number of sites may be a complication of warfarin treatment and GI bleeding a complication of ketoprofen treatment.
DDI-DrugBank.d499.s16	57	64	warfarin	drug	DDI-DrugBank.d499.s16.e0
DDI-DrugBank.d499.s16	110	119	ketoprofen	drug	DDI-DrugBank.d499.s16.e1
DDI-DrugBank.d499.s16	false	DDI-DrugBank.d499.s16.e0	DDI-DrugBank.d499.s16.e1
DDI-DrugBank.d499.s17|a|Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.
DDI-DrugBank.d499.s17	64	73	ketoprofen	drug	DDI-DrugBank.d499.s17.e0
DDI-DrugBank.d499.s17	142	151	ketoprofen	drug	DDI-DrugBank.d499.s17.e1
DDI-DrugBank.d499.s17	157	164	warfarin	drug	DDI-DrugBank.d499.s17.e2
DDI-DrugBank.d499.s17	false	DDI-DrugBank.d499.s17.e0	DDI-DrugBank.d499.s17.e1
DDI-DrugBank.d499.s17	false	DDI-DrugBank.d499.s17.e0	DDI-DrugBank.d499.s17.e2
DDI-DrugBank.d499.s17	true	DDI-DrugBank.d499.s17.e1	DDI-DrugBank.d499.s17.e2
DDI-DrugBank.d499.s18|a|6.
DDI-DrugBank.d499.s19|a|Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.
DDI-DrugBank.d499.s19	0	9	Probenecid	drug	DDI-DrugBank.d499.s19.e0
DDI-DrugBank.d499.s19	12	21	Probenecid	drug	DDI-DrugBank.d499.s19.e1
DDI-DrugBank.d499.s19	53	62	ketoprofen	drug	DDI-DrugBank.d499.s19.e2
DDI-DrugBank.d499.s19	100	109	ketoprofen	drug	DDI-DrugBank.d499.s19.e3
DDI-DrugBank.d499.s19	false	DDI-DrugBank.d499.s19.e0	DDI-DrugBank.d499.s19.e1
DDI-DrugBank.d499.s19	false	DDI-DrugBank.d499.s19.e0	DDI-DrugBank.d499.s19.e2
DDI-DrugBank.d499.s19	false	DDI-DrugBank.d499.s19.e0	DDI-DrugBank.d499.s19.e3
DDI-DrugBank.d499.s19	true	DDI-DrugBank.d499.s19.e1	DDI-DrugBank.d499.s19.e2
DDI-DrugBank.d499.s19	false	DDI-DrugBank.d499.s19.e1	DDI-DrugBank.d499.s19.e3
DDI-DrugBank.d499.s19	false	DDI-DrugBank.d499.s19.e2	DDI-DrugBank.d499.s19.e3
DDI-DrugBank.d499.s20|a|Therefore, the combination of ketoprofen and probenecid is not recommended.
DDI-DrugBank.d499.s20	30	39	ketoprofen	drug	DDI-DrugBank.d499.s20.e0
DDI-DrugBank.d499.s20	45	54	probenecid	drug	DDI-DrugBank.d499.s20.e1
DDI-DrugBank.d499.s20	true	DDI-DrugBank.d499.s20.e0	DDI-DrugBank.d499.s20.e1
DDI-DrugBank.d499.s21|a|7.
DDI-DrugBank.d499.s22|a|Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
DDI-DrugBank.d499.s22	0	11	Methotrexate	drug	DDI-DrugBank.d499.s22.e0
DDI-DrugBank.d499.s22	14	23	Ketoprofen	drug	DDI-DrugBank.d499.s22.e1
DDI-DrugBank.d499.s22	37	42	NSAIDs	group	DDI-DrugBank.d499.s22.e2
DDI-DrugBank.d499.s22	85	96	methotrexate	drug	DDI-DrugBank.d499.s22.e3
DDI-DrugBank.d499.s22	false	DDI-DrugBank.d499.s22.e0	DDI-DrugBank.d499.s22.e1
DDI-DrugBank.d499.s22	false	DDI-DrugBank.d499.s22.e0	DDI-DrugBank.d499.s22.e2
DDI-DrugBank.d499.s22	false	DDI-DrugBank.d499.s22.e0	DDI-DrugBank.d499.s22.e3
DDI-DrugBank.d499.s22	false	DDI-DrugBank.d499.s22.e1	DDI-DrugBank.d499.s22.e2
DDI-DrugBank.d499.s22	true	DDI-DrugBank.d499.s22.e1	DDI-DrugBank.d499.s22.e3
DDI-DrugBank.d499.s22	true	DDI-DrugBank.d499.s22.e2	DDI-DrugBank.d499.s22.e3
DDI-DrugBank.d499.s23|a|8.
DDI-DrugBank.d499.s24|a|Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.
DDI-DrugBank.d499.s24	0	6	Lithium	drug	DDI-DrugBank.d499.s24.e0
DDI-DrugBank.d499.s24	9	45	Nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d499.s24.e1
DDI-DrugBank.d499.s24	97	103	lithium	drug	DDI-DrugBank.d499.s24.e2
DDI-DrugBank.d499.s24	false	DDI-DrugBank.d499.s24.e0	DDI-DrugBank.d499.s24.e1
DDI-DrugBank.d499.s24	false	DDI-DrugBank.d499.s24.e0	DDI-DrugBank.d499.s24.e2
DDI-DrugBank.d499.s24	true	DDI-DrugBank.d499.s24.e1	DDI-DrugBank.d499.s24.e2
DDI-DrugBank.d499.s25|a|It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.
DDI-DrugBank.d499.s25	30	36	lithium	drug	DDI-DrugBank.d499.s25.e0
DDI-DrugBank.d499.s25	63	72	ketoprofen	drug	DDI-DrugBank.d499.s25.e1
DDI-DrugBank.d499.s25	97	103	lithium	drug	DDI-DrugBank.d499.s25.e2
DDI-DrugBank.d499.s25	false	DDI-DrugBank.d499.s25.e0	DDI-DrugBank.d499.s25.e1
DDI-DrugBank.d499.s25	false	DDI-DrugBank.d499.s25.e0	DDI-DrugBank.d499.s25.e2
DDI-DrugBank.d499.s25	true	DDI-DrugBank.d499.s25.e1	DDI-DrugBank.d499.s25.e2
DDI-DrugBank.d499.s26|a|DRUG/LABORATORY TEST INTERACTIONS: EFFECT ON BLOOD COAGULATION Ketoprofen decreases platelet adhesion and aggregation.
DDI-DrugBank.d499.s26	63	72	Ketoprofen	drug	DDI-DrugBank.d499.s26.e0
DDI-DrugBank.d499.s27|a|Therefore, it can prolong bleeding time by approximately 3 to 4 minutes from baseline values.
DDI-DrugBank.d499.s28|a|There is no significant change in platelet count, prothrombin time, partial thromboplastin time, or thrombin time.
DDI-DrugBank.d3.s0|a|Ketorolac is highly bound to human plasma protein (mean 99.2%).
DDI-DrugBank.d3.s0	0	8	Ketorolac	drug	DDI-DrugBank.d3.s0.e0
DDI-DrugBank.d3.s1|a|Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
DDI-DrugBank.d3.s1	0	7	Warfarin	drug	DDI-DrugBank.d3.s1.e0
DDI-DrugBank.d3.s1	10	16	Digoxin	drug	DDI-DrugBank.d3.s1.e1
DDI-DrugBank.d3.s1	19	28	Salicylate	group	DDI-DrugBank.d3.s1.e2
DDI-DrugBank.d3.s1	35	41	Heparin	drug	DDI-DrugBank.d3.s1.e3
DDI-DrugBank.d3.s1	67	74	warfarin	drug	DDI-DrugBank.d3.s1.e4
DDI-DrugBank.d3.s1	123	144	ketorolac tromethamine	drug	DDI-DrugBank.d3.s1.e5
DDI-DrugBank.d3.s1	176	184	ketorolac	drug	DDI-DrugBank.d3.s1.e6
DDI-DrugBank.d3.s1	false	DDI-DrugBank.d3.s1.e0	DDI-DrugBank.d3.s1.e1
DDI-DrugBank.d3.s1	false	DDI-DrugBank.d3.s1.e0	DDI-DrugBank.d3.s1.e2
DDI-DrugBank.d3.s1	false	DDI-DrugBank.d3.s1.e0	DDI-DrugBank.d3.s1.e3
DDI-DrugBank.d3.s1	false	DDI-DrugBank.d3.s1.e0	DDI-DrugBank.d3.s1.e4
DDI-DrugBank.d3.s1	false	DDI-DrugBank.d3.s1.e0	DDI-DrugBank.d3.s1.e5
DDI-DrugBank.d3.s1	false	DDI-DrugBank.d3.s1.e0	DDI-DrugBank.d3.s1.e6
DDI-DrugBank.d3.s1	false	DDI-DrugBank.d3.s1.e1	DDI-DrugBank.d3.s1.e2
DDI-DrugBank.d3.s1	false	DDI-DrugBank.d3.s1.e1	DDI-DrugBank.d3.s1.e3
DDI-DrugBank.d3.s1	false	DDI-DrugBank.d3.s1.e1	DDI-DrugBank.d3.s1.e4
DDI-DrugBank.d3.s1	false	DDI-DrugBank.d3.s1.e1	DDI-DrugBank.d3.s1.e5
DDI-DrugBank.d3.s2|a|Ketorolac does not alter digoxin protein binding.
DDI-DrugBank.d3.s2	0	8	Ketorolac	drug	DDI-DrugBank.d3.s2.e0
DDI-DrugBank.d3.s2	25	31	digoxin	drug	DDI-DrugBank.d3.s2.e1
DDI-DrugBank.d3.s2	false	DDI-DrugBank.d3.s2.e0	DDI-DrugBank.d3.s2.e1
DDI-DrugBank.d3.s3|a|In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.
DDI-DrugBank.d3.s3	65	74	salicylate	group	DDI-DrugBank.d3.s3.e0
DDI-DrugBank.d3.s3	105	113	ketorolac	drug	DDI-DrugBank.d3.s3.e1
DDI-DrugBank.d3.s3	215	223	ketorolac	drug	DDI-DrugBank.d3.s3.e2
DDI-DrugBank.d3.s3	true	DDI-DrugBank.d3.s3.e0	DDI-DrugBank.d3.s3.e1
DDI-DrugBank.d3.s3	false	DDI-DrugBank.d3.s3.e0	DDI-DrugBank.d3.s3.e2
DDI-DrugBank.d3.s3	false	DDI-DrugBank.d3.s3.e1	DDI-DrugBank.d3.s3.e2
DDI-DrugBank.d3.s4|a|Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.
DDI-DrugBank.d3.s4	30	36	digoxin	drug	DDI-DrugBank.d3.s4.e0
DDI-DrugBank.d3.s4	39	46	warfarin	drug	DDI-DrugBank.d3.s4.e1
DDI-DrugBank.d3.s4	49	57	ibuprofen	drug	DDI-DrugBank.d3.s4.e2
DDI-DrugBank.d3.s4	60	67	naproxen	drug	DDI-DrugBank.d3.s4.e3
DDI-DrugBank.d3.s4	70	78	piroxicam	drug	DDI-DrugBank.d3.s4.e4
DDI-DrugBank.d3.s4	81	93	acetaminophen	drug	DDI-DrugBank.d3.s4.e5
DDI-DrugBank.d3.s4	96	104	phenytoin	drug	DDI-DrugBank.d3.s4.e6
DDI-DrugBank.d3.s4	135	156	ketorolac tromethamine	drug	DDI-DrugBank.d3.s4.e7
DDI-DrugBank.d3.s4	false	DDI-DrugBank.d3.s4.e0	DDI-DrugBank.d3.s4.e1
DDI-DrugBank.d3.s4	false	DDI-DrugBank.d3.s4.e0	DDI-DrugBank.d3.s4.e2
DDI-DrugBank.d3.s4	false	DDI-DrugBank.d3.s4.e0	DDI-DrugBank.d3.s4.e3
DDI-DrugBank.d3.s4	false	DDI-DrugBank.d3.s4.e0	DDI-DrugBank.d3.s4.e4
DDI-DrugBank.d3.s4	false	DDI-DrugBank.d3.s4.e0	DDI-DrugBank.d3.s4.e5
DDI-DrugBank.d3.s4	false	DDI-DrugBank.d3.s4.e0	DDI-DrugBank.d3.s4.e6
DDI-DrugBank.d3.s4	false	DDI-DrugBank.d3.s4.e0	DDI-DrugBank.d3.s4.e7
DDI-DrugBank.d3.s4	false	DDI-DrugBank.d3.s4.e1	DDI-DrugBank.d3.s4.e2
DDI-DrugBank.d3.s4	false	DDI-DrugBank.d3.s4.e1	DDI-DrugBank.d3.s4.e3
DDI-DrugBank.d3.s4	false	DDI-DrugBank.d3.s4.e1	DDI-DrugBank.d3.s4.e4
DDI-DrugBank.d3.s5|a|In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg warfarin, causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin.
DDI-DrugBank.d3.s5	101	108	warfarin	drug	DDI-DrugBank.d3.s5.e0
DDI-DrugBank.d3.s5	185	192	warfarin	drug	DDI-DrugBank.d3.s5.e1
DDI-DrugBank.d3.s5	false	DDI-DrugBank.d3.s5.e0	DDI-DrugBank.d3.s5.e1
DDI-DrugBank.d3.s6|a|In another study, TORADOLIV/IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo.
DDI-DrugBank.d3.s6	69	75	heparin	drug	DDI-DrugBank.d3.s6.e0
DDI-DrugBank.d3.s6	234	240	heparin	drug	DDI-DrugBank.d3.s6.e1
DDI-DrugBank.d3.s6	false	DDI-DrugBank.d3.s6.e0	DDI-DrugBank.d3.s6.e1
DDI-DrugBank.d3.s7|a|Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
DDI-DrugBank.d3.s7	73	79	TORADOL	brand	DDI-DrugBank.d3.s7.e0
DDI-DrugBank.d3.s7	85	92	warfarin	drug	DDI-DrugBank.d3.s7.e1
DDI-DrugBank.d3.s7	97	103	heparin	drug	DDI-DrugBank.d3.s7.e2
DDI-DrugBank.d3.s7	128	134	TORADOL	brand	DDI-DrugBank.d3.s7.e3
DDI-DrugBank.d3.s7	155	168	anticoagulants	group	DDI-DrugBank.d3.s7.e4
DDI-DrugBank.d3.s7	false	DDI-DrugBank.d3.s7.e0	DDI-DrugBank.d3.s7.e1
DDI-DrugBank.d3.s7	false	DDI-DrugBank.d3.s7.e0	DDI-DrugBank.d3.s7.e2
DDI-DrugBank.d3.s7	false	DDI-DrugBank.d3.s7.e0	DDI-DrugBank.d3.s7.e3
DDI-DrugBank.d3.s7	false	DDI-DrugBank.d3.s7.e0	DDI-DrugBank.d3.s7.e4
DDI-DrugBank.d3.s7	false	DDI-DrugBank.d3.s7.e1	DDI-DrugBank.d3.s7.e2
DDI-DrugBank.d3.s7	false	DDI-DrugBank.d3.s7.e1	DDI-DrugBank.d3.s7.e3
DDI-DrugBank.d3.s7	false	DDI-DrugBank.d3.s7.e1	DDI-DrugBank.d3.s7.e4
DDI-DrugBank.d3.s7	false	DDI-DrugBank.d3.s7.e2	DDI-DrugBank.d3.s7.e3
DDI-DrugBank.d3.s7	false	DDI-DrugBank.d3.s7.e2	DDI-DrugBank.d3.s7.e4
DDI-DrugBank.d3.s7	true	DDI-DrugBank.d3.s7.e3	DDI-DrugBank.d3.s7.e4
DDI-DrugBank.d3.s8|a|Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
DDI-DrugBank.d3.s8	0	9	Furosemide	drug	DDI-DrugBank.d3.s8.e0
DDI-DrugBank.d3.s8	12	18	TORADOL	brand	DDI-DrugBank.d3.s8.e1
DDI-DrugBank.d3.s8	38	45	diuretic	group	DDI-DrugBank.d3.s8.e2
DDI-DrugBank.d3.s8	59	68	furosemide	drug	DDI-DrugBank.d3.s8.e3
DDI-DrugBank.d3.s8	false	DDI-DrugBank.d3.s8.e0	DDI-DrugBank.d3.s8.e1
DDI-DrugBank.d3.s8	false	DDI-DrugBank.d3.s8.e0	DDI-DrugBank.d3.s8.e2
DDI-DrugBank.d3.s8	false	DDI-DrugBank.d3.s8.e0	DDI-DrugBank.d3.s8.e3
DDI-DrugBank.d3.s8	false	DDI-DrugBank.d3.s8.e1	DDI-DrugBank.d3.s8.e2
DDI-DrugBank.d3.s8	true	DDI-DrugBank.d3.s8.e1	DDI-DrugBank.d3.s8.e3
DDI-DrugBank.d3.s8	false	DDI-DrugBank.d3.s8.e2	DDI-DrugBank.d3.s8.e3
DDI-DrugBank.d3.s9|a|Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.
DDI-DrugBank.d3.s9	0	9	Probenecid	drug	DDI-DrugBank.d3.s9.e0
DDI-DrugBank.d3.s9	42	48	TORADOL	brand	DDI-DrugBank.d3.s9.e1
DDI-DrugBank.d3.s9	59	68	probenecid	drug	DDI-DrugBank.d3.s9.e2
DDI-DrugBank.d3.s9	105	113	ketorolac	drug	DDI-DrugBank.d3.s9.e3
DDI-DrugBank.d3.s9	144	152	ketorolac	drug	DDI-DrugBank.d3.s9.e4
DDI-DrugBank.d3.s9	false	DDI-DrugBank.d3.s9.e0	DDI-DrugBank.d3.s9.e1
DDI-DrugBank.d3.s9	false	DDI-DrugBank.d3.s9.e0	DDI-DrugBank.d3.s9.e2
DDI-DrugBank.d3.s9	false	DDI-DrugBank.d3.s9.e0	DDI-DrugBank.d3.s9.e3
DDI-DrugBank.d3.s9	false	DDI-DrugBank.d3.s9.e0	DDI-DrugBank.d3.s9.e4
DDI-DrugBank.d3.s9	true	DDI-DrugBank.d3.s9.e1	DDI-DrugBank.d3.s9.e2
DDI-DrugBank.d3.s9	false	DDI-DrugBank.d3.s9.e1	DDI-DrugBank.d3.s9.e3
DDI-DrugBank.d3.s9	false	DDI-DrugBank.d3.s9.e1	DDI-DrugBank.d3.s9.e4
DDI-DrugBank.d3.s9	false	DDI-DrugBank.d3.s9.e2	DDI-DrugBank.d3.s9.e3
DDI-DrugBank.d3.s9	false	DDI-DrugBank.d3.s9.e2	DDI-DrugBank.d3.s9.e4
DDI-DrugBank.d3.s9	false	DDI-DrugBank.d3.s9.e3	DDI-DrugBank.d3.s9.e4
DDI-DrugBank.d3.s10|a|Therefore, concomitant use of TORADOL and probenecid is contraindicated.
DDI-DrugBank.d3.s10	30	36	TORADOL	brand	DDI-DrugBank.d3.s10.e0
DDI-DrugBank.d3.s10	42	51	probenecid	drug	DDI-DrugBank.d3.s10.e1
DDI-DrugBank.d3.s10	true	DDI-DrugBank.d3.s10.e0	DDI-DrugBank.d3.s10.e1
DDI-DrugBank.d3.s11|a|Lithium: Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.
DDI-DrugBank.d3.s11	0	6	Lithium	drug	DDI-DrugBank.d3.s11.e0
DDI-DrugBank.d3.s11	29	35	lithium	drug	DDI-DrugBank.d3.s11.e1
DDI-DrugBank.d3.s11	81	87	lithium	drug	DDI-DrugBank.d3.s11.e2
DDI-DrugBank.d3.s11	false	DDI-DrugBank.d3.s11.e0	DDI-DrugBank.d3.s11.e1
DDI-DrugBank.d3.s11	false	DDI-DrugBank.d3.s11.e0	DDI-DrugBank.d3.s11.e2
DDI-DrugBank.d3.s11	false	DDI-DrugBank.d3.s11.e1	DDI-DrugBank.d3.s11.e2
DDI-DrugBank.d3.s12|a|The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.
DDI-DrugBank.d3.s12	14	20	TORADOL	brand	DDI-DrugBank.d3.s12.e0
DDI-DrugBank.d3.s12	32	38	lithium	drug	DDI-DrugBank.d3.s12.e1
DDI-DrugBank.d3.s12	85	91	lithium	drug	DDI-DrugBank.d3.s12.e2
DDI-DrugBank.d3.s12	114	120	TORADOL	brand	DDI-DrugBank.d3.s12.e3
DDI-DrugBank.d3.s12	false	DDI-DrugBank.d3.s12.e0	DDI-DrugBank.d3.s12.e1
DDI-DrugBank.d3.s12	false	DDI-DrugBank.d3.s12.e0	DDI-DrugBank.d3.s12.e2
DDI-DrugBank.d3.s12	false	DDI-DrugBank.d3.s12.e0	DDI-DrugBank.d3.s12.e3
DDI-DrugBank.d3.s12	false	DDI-DrugBank.d3.s12.e1	DDI-DrugBank.d3.s12.e2
DDI-DrugBank.d3.s12	false	DDI-DrugBank.d3.s12.e1	DDI-DrugBank.d3.s12.e3
DDI-DrugBank.d3.s12	true	DDI-DrugBank.d3.s12.e2	DDI-DrugBank.d3.s12.e3
DDI-DrugBank.d3.s13|a|Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.
DDI-DrugBank.d3.s13	0	11	Methotrexate	drug	DDI-DrugBank.d3.s13.e0
DDI-DrugBank.d3.s13	44	55	methotrexate	drug	DDI-DrugBank.d3.s13.e1
DDI-DrugBank.d3.s13	66	71	NSAIDs	group	DDI-DrugBank.d3.s13.e2
DDI-DrugBank.d3.s13	118	129	methotrexate	drug	DDI-DrugBank.d3.s13.e3
DDI-DrugBank.d3.s13	158	169	methotrexate	drug	DDI-DrugBank.d3.s13.e4
DDI-DrugBank.d3.s13	false	DDI-DrugBank.d3.s13.e0	DDI-DrugBank.d3.s13.e1
DDI-DrugBank.d3.s13	false	DDI-DrugBank.d3.s13.e0	DDI-DrugBank.d3.s13.e2
DDI-DrugBank.d3.s13	false	DDI-DrugBank.d3.s13.e0	DDI-DrugBank.d3.s13.e3
DDI-DrugBank.d3.s13	false	DDI-DrugBank.d3.s13.e0	DDI-DrugBank.d3.s13.e4
DDI-DrugBank.d3.s13	true	DDI-DrugBank.d3.s13.e1	DDI-DrugBank.d3.s13.e2
DDI-DrugBank.d3.s13	false	DDI-DrugBank.d3.s13.e1	DDI-DrugBank.d3.s13.e3
DDI-DrugBank.d3.s13	false	DDI-DrugBank.d3.s13.e1	DDI-DrugBank.d3.s13.e4
DDI-DrugBank.d3.s13	false	DDI-DrugBank.d3.s13.e2	DDI-DrugBank.d3.s13.e3
DDI-DrugBank.d3.s13	false	DDI-DrugBank.d3.s13.e2	DDI-DrugBank.d3.s13.e4
DDI-DrugBank.d3.s13	false	DDI-DrugBank.d3.s13.e3	DDI-DrugBank.d3.s13.e4
DDI-DrugBank.d3.s14|a|The effect of TORADOL on methotrexate clearance has not been studied.
DDI-DrugBank.d3.s14	14	20	TORADOL	brand	DDI-DrugBank.d3.s14.e0
DDI-DrugBank.d3.s14	25	36	methotrexate	drug	DDI-DrugBank.d3.s14.e1
DDI-DrugBank.d3.s14	false	DDI-DrugBank.d3.s14.e0	DDI-DrugBank.d3.s14.e1
DDI-DrugBank.d3.s15|a|Nondepolarizing Muscle Relaxants: In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and nondepolarizing muscle relaxants that resulted in apnea.
DDI-DrugBank.d3.s15	0	31	Nondepolarizing Muscle Relaxants	group	DDI-DrugBank.d3.s15.e0
DDI-DrugBank.d3.s15	137	168	nondepolarizing muscle relaxants	group	DDI-DrugBank.d3.s15.e1
DDI-DrugBank.d3.s15	false	DDI-DrugBank.d3.s15.e0	DDI-DrugBank.d3.s15.e1
DDI-DrugBank.d3.s16|a|The concurrent use of TORADOL with muscle relaxants has not been formally studied.
DDI-DrugBank.d3.s16	22	28	TORADOL	brand	DDI-DrugBank.d3.s16.e0
DDI-DrugBank.d3.s16	35	50	muscle relaxants	group	DDI-DrugBank.d3.s16.e1
DDI-DrugBank.d3.s16	false	DDI-DrugBank.d3.s16.e0	DDI-DrugBank.d3.s16.e1
DDI-DrugBank.d3.s17|a|ACE Inhibitors: Concomitant use of ACE inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.
DDI-DrugBank.d3.s17	0	13	ACE Inhibitors	group	DDI-DrugBank.d3.s17.e0
DDI-DrugBank.d3.s17	35	48	ACE inhibitors	group	DDI-DrugBank.d3.s17.e1
DDI-DrugBank.d3.s17	false	DDI-DrugBank.d3.s17.e0	DDI-DrugBank.d3.s17.e1
DDI-DrugBank.d3.s18|a|Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
DDI-DrugBank.d3.s18	0	18	Antiepileptic Drugs	group	DDI-DrugBank.d3.s18.e0
DDI-DrugBank.d3.s18	93	99	TORADOL	brand	DDI-DrugBank.d3.s18.e1
DDI-DrugBank.d3.s18	105	123	antiepileptic drugs	group	DDI-DrugBank.d3.s18.e2
DDI-DrugBank.d3.s18	126	134	phenytoin	drug	DDI-DrugBank.d3.s18.e3
DDI-DrugBank.d3.s18	137	149	carbamazepine	drug	DDI-DrugBank.d3.s18.e4
DDI-DrugBank.d3.s18	false	DDI-DrugBank.d3.s18.e0	DDI-DrugBank.d3.s18.e1
DDI-DrugBank.d3.s18	false	DDI-DrugBank.d3.s18.e0	DDI-DrugBank.d3.s18.e2
DDI-DrugBank.d3.s18	false	DDI-DrugBank.d3.s18.e0	DDI-DrugBank.d3.s18.e3
DDI-DrugBank.d3.s18	false	DDI-DrugBank.d3.s18.e0	DDI-DrugBank.d3.s18.e4
DDI-DrugBank.d3.s18	true	DDI-DrugBank.d3.s18.e1	DDI-DrugBank.d3.s18.e2
DDI-DrugBank.d3.s18	true	DDI-DrugBank.d3.s18.e1	DDI-DrugBank.d3.s18.e3
DDI-DrugBank.d3.s18	true	DDI-DrugBank.d3.s18.e1	DDI-DrugBank.d3.s18.e4
DDI-DrugBank.d3.s18	false	DDI-DrugBank.d3.s18.e2	DDI-DrugBank.d3.s18.e3
DDI-DrugBank.d3.s18	false	DDI-DrugBank.d3.s18.e2	DDI-DrugBank.d3.s18.e4
DDI-DrugBank.d3.s18	false	DDI-DrugBank.d3.s18.e3	DDI-DrugBank.d3.s18.e4
DDI-DrugBank.d3.s19|a|Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
DDI-DrugBank.d3.s19	0	17	Psychoactive Drugs	group	DDI-DrugBank.d3.s19.e0
DDI-DrugBank.d3.s19	59	65	TORADOL	brand	DDI-DrugBank.d3.s19.e1
DDI-DrugBank.d3.s19	95	112	psychoactive drugs	group	DDI-DrugBank.d3.s19.e2
DDI-DrugBank.d3.s19	115	124	fluoxetine	drug	DDI-DrugBank.d3.s19.e3
DDI-DrugBank.d3.s19	127	137	thiothixene	drug	DDI-DrugBank.d3.s19.e4
DDI-DrugBank.d3.s19	140	149	alprazolam	drug	DDI-DrugBank.d3.s19.e5
DDI-DrugBank.d3.s19	false	DDI-DrugBank.d3.s19.e0	DDI-DrugBank.d3.s19.e1
DDI-DrugBank.d3.s19	false	DDI-DrugBank.d3.s19.e0	DDI-DrugBank.d3.s19.e2
DDI-DrugBank.d3.s19	false	DDI-DrugBank.d3.s19.e0	DDI-DrugBank.d3.s19.e3
DDI-DrugBank.d3.s19	false	DDI-DrugBank.d3.s19.e0	DDI-DrugBank.d3.s19.e4
DDI-DrugBank.d3.s19	false	DDI-DrugBank.d3.s19.e0	DDI-DrugBank.d3.s19.e5
DDI-DrugBank.d3.s19	true	DDI-DrugBank.d3.s19.e1	DDI-DrugBank.d3.s19.e2
DDI-DrugBank.d3.s19	true	DDI-DrugBank.d3.s19.e1	DDI-DrugBank.d3.s19.e3
DDI-DrugBank.d3.s19	true	DDI-DrugBank.d3.s19.e1	DDI-DrugBank.d3.s19.e4
DDI-DrugBank.d3.s19	true	DDI-DrugBank.d3.s19.e1	DDI-DrugBank.d3.s19.e5
DDI-DrugBank.d3.s19	false	DDI-DrugBank.d3.s19.e2	DDI-DrugBank.d3.s19.e3
DDI-DrugBank.d3.s20|a|Morphine: TORADOLIV/IM has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions.
DDI-DrugBank.d3.s20	0	7	Morphine	drug	DDI-DrugBank.d3.s20.e0
DDI-DrugBank.d3.s20	63	70	morphine	drug	DDI-DrugBank.d3.s20.e1
DDI-DrugBank.d3.s20	false	DDI-DrugBank.d3.s20.e0	DDI-DrugBank.d3.s20.e1
DDI-DrugBank.d3.s21|a|Do not mix TORADOL and morphine in the same syringe.
DDI-DrugBank.d3.s21	11	17	TORADOL	brand	DDI-DrugBank.d3.s21.e0
DDI-DrugBank.d3.s21	23	30	morphine	drug	DDI-DrugBank.d3.s21.e1
DDI-DrugBank.d3.s21	false	DDI-DrugBank.d3.s21.e0	DDI-DrugBank.d3.s21.e1
DDI-DrugBank.d3.s22|a|There is no evidence in animal or human studies that TORADOL induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs
DDI-DrugBank.d3.s22	53	59	TORADOL	brand	DDI-DrugBank.d3.s22.e0
DDI-DrugBank.d3.s23|a|.
DDI-DrugBank.d3.s24|a|
DDI-DrugBank.d95.s0|a|Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.
DDI-DrugBank.d95.s0	0	11	Cyclosporine	drug	DDI-DrugBank.d95.s0.e0
DDI-DrugBank.d95.s0	15	24	L-arginine	drug	DDI-DrugBank.d95.s0.e1
DDI-DrugBank.d95.s0	69	79	cyclosporin	drug	DDI-DrugBank.d95.s0.e2
DDI-DrugBank.d95.s0	false	DDI-DrugBank.d95.s0.e0	DDI-DrugBank.d95.s0.e1
DDI-DrugBank.d95.s0	false	DDI-DrugBank.d95.s0.e0	DDI-DrugBank.d95.s0.e2
DDI-DrugBank.d95.s0	true	DDI-DrugBank.d95.s0.e1	DDI-DrugBank.d95.s0.e2
DDI-DrugBank.d95.s1|a|Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.
DDI-DrugBank.d95.s1	0	8	Ibuprofen	drug	DDI-DrugBank.d95.s1.e0
DDI-DrugBank.d95.s1	12	21	L-arginine	drug	DDI-DrugBank.d95.s1.e1
DDI-DrugBank.d95.s1	54	62	ibuprofen	drug	DDI-DrugBank.d95.s1.e2
DDI-DrugBank.d95.s1	false	DDI-DrugBank.d95.s1.e0	DDI-DrugBank.d95.s1.e1
DDI-DrugBank.d95.s1	false	DDI-DrugBank.d95.s1.e0	DDI-DrugBank.d95.s1.e2
DDI-DrugBank.d95.s1	true	DDI-DrugBank.d95.s1.e1	DDI-DrugBank.d95.s1.e2
DDI-DrugBank.d95.s2|a|Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.
DDI-DrugBank.d95.s2	8	15	nitrates	group	DDI-DrugBank.d95.s2.e0
DDI-DrugBank.d95.s2	19	28	L-arginine	drug	DDI-DrugBank.d95.s2.e1
DDI-DrugBank.d95.s2	94	101	nitrates	drug	DDI-DrugBank.d95.s2.e2
DDI-DrugBank.d95.s2	false	DDI-DrugBank.d95.s2.e0	DDI-DrugBank.d95.s2.e1
DDI-DrugBank.d95.s2	false	DDI-DrugBank.d95.s2.e0	DDI-DrugBank.d95.s2.e2
DDI-DrugBank.d95.s2	true	DDI-DrugBank.d95.s2.e1	DDI-DrugBank.d95.s2.e2
DDI-DrugBank.d95.s3|a|Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.
DDI-DrugBank.d95.s3	0	17	Sildenafil citrate	drug	DDI-DrugBank.d95.s3.e0
DDI-DrugBank.d95.s3	36	45	L-arginine	drug	DDI-DrugBank.d95.s3.e1
DDI-DrugBank.d95.s3	84	101	sildenafil citrate	drug	DDI-DrugBank.d95.s3.e2
DDI-DrugBank.d95.s3	false	DDI-DrugBank.d95.s3.e0	DDI-DrugBank.d95.s3.e1
DDI-DrugBank.d95.s3	false	DDI-DrugBank.d95.s3.e0	DDI-DrugBank.d95.s3.e2
DDI-DrugBank.d95.s3	true	DDI-DrugBank.d95.s3.e1	DDI-DrugBank.d95.s3.e2
DDI-DrugBank.d243.s0|a|No drug, nutritional supplement, food or herb interactions are known.
DDI-DrugBank.d539.s0|a|Interacts with valproic acid
DDI-DrugBank.d539.s0	15	27	valproic acid	drug	DDI-DrugBank.d539.s0.e0
DDI-DrugBank.d92.s0|a|No well-known drug interactions with glutamic acid
DDI-DrugBank.d92.s0	37	49	glutamic acid	drug	DDI-DrugBank.d92.s0.e0
DDI-DrugBank.d66.s0|a|Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.
DDI-DrugBank.d66.s0	0	19	Human growth hormone	drug	DDI-DrugBank.d66.s0.e0
DDI-DrugBank.d66.s0	42	52	L-glutamine	drug	DDI-DrugBank.d66.s0.e1
DDI-DrugBank.d66.s0	58	77	human growth hormone	drug	DDI-DrugBank.d66.s0.e2
DDI-DrugBank.d66.s0	false	DDI-DrugBank.d66.s0.e0	DDI-DrugBank.d66.s0.e1
DDI-DrugBank.d66.s0	false	DDI-DrugBank.d66.s0.e0	DDI-DrugBank.d66.s0.e2
DDI-DrugBank.d66.s0	true	DDI-DrugBank.d66.s0.e1	DDI-DrugBank.d66.s0.e2
DDI-DrugBank.d66.s1|a|L-glutamine has orphan drug status for this indication.
DDI-DrugBank.d66.s1	0	10	L-glutamine	drug	DDI-DrugBank.d66.s1.e0
DDI-DrugBank.d66.s2|a|Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.
DDI-DrugBank.d66.s2	0	11	Indomethacin	drug	DDI-DrugBank.d66.s2.e0
DDI-DrugBank.d66.s2	34	44	L-glutamine	drug	DDI-DrugBank.d66.s2.e1
DDI-DrugBank.d66.s2	50	61	indomethacin	drug	DDI-DrugBank.d66.s2.e2
DDI-DrugBank.d66.s2	122	133	indomethacin	drug	DDI-DrugBank.d66.s2.e3
DDI-DrugBank.d66.s2	false	DDI-DrugBank.d66.s2.e0	DDI-DrugBank.d66.s2.e1
DDI-DrugBank.d66.s2	false	DDI-DrugBank.d66.s2.e0	DDI-DrugBank.d66.s2.e2
DDI-DrugBank.d66.s2	false	DDI-DrugBank.d66.s2.e0	DDI-DrugBank.d66.s2.e3
DDI-DrugBank.d66.s2	true	DDI-DrugBank.d66.s2.e1	DDI-DrugBank.d66.s2.e2
DDI-DrugBank.d66.s2	false	DDI-DrugBank.d66.s2.e1	DDI-DrugBank.d66.s2.e3
DDI-DrugBank.d66.s2	false	DDI-DrugBank.d66.s2.e2	DDI-DrugBank.d66.s2.e3
DDI-DrugBank.d66.s3|a|The reported dose used for L-glutamine was 21 grams daily taken in divided doses three times a day.
DDI-DrugBank.d66.s3	27	37	L-glutamine	drug	DDI-DrugBank.d66.s3.e0
DDI-DrugBank.d66.s4|a|Further, misoprostol is reported to have a synergistic effect with this combination in ameliorating intestinal permeability.
DDI-DrugBank.d66.s4	9	19	misoprostol	drug	DDI-DrugBank.d66.s4.e0
DDI-DrugBank.d66.s5|a|Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.
DDI-DrugBank.d66.s5	0	11	Methotrexate	drug	DDI-DrugBank.d66.s5.e0
DDI-DrugBank.d66.s5	40	51	methotrexate	drug	DDI-DrugBank.d66.s5.e1
DDI-DrugBank.d66.s5	109	119	L-glutamine	drug	DDI-DrugBank.d66.s5.e2
DDI-DrugBank.d66.s5	false	DDI-DrugBank.d66.s5.e0	DDI-DrugBank.d66.s5.e1
DDI-DrugBank.d66.s5	false	DDI-DrugBank.d66.s5.e0	DDI-DrugBank.d66.s5.e2
DDI-DrugBank.d66.s5	true	DDI-DrugBank.d66.s5.e1	DDI-DrugBank.d66.s5.e2
DDI-DrugBank.d66.s6|a|In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.
DDI-DrugBank.d66.s6	96	107	methotrexate	drug	DDI-DrugBank.d66.s6.e0
DDI-DrugBank.d66.s6	150	160	L-glutamine	drug	DDI-DrugBank.d66.s6.e1
DDI-DrugBank.d66.s6	true	DDI-DrugBank.d66.s6.e0	DDI-DrugBank.d66.s6.e1
DDI-DrugBank.d66.s7|a|Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
DDI-DrugBank.d66.s7	0	9	Paclitaxel	drug	DDI-DrugBank.d66.s7.e0
DDI-DrugBank.d66.s7	28	38	L-glutamine	drug	DDI-DrugBank.d66.s7.e1
DDI-DrugBank.d66.s7	112	121	paclitaxel	drug	DDI-DrugBank.d66.s7.e2
DDI-DrugBank.d66.s7	208	217	paclitaxel	drug	DDI-DrugBank.d66.s7.e3
DDI-DrugBank.d66.s7	false	DDI-DrugBank.d66.s7.e0	DDI-DrugBank.d66.s7.e1
DDI-DrugBank.d66.s7	false	DDI-DrugBank.d66.s7.e0	DDI-DrugBank.d66.s7.e2
DDI-DrugBank.d66.s7	false	DDI-DrugBank.d66.s7.e0	DDI-DrugBank.d66.s7.e3
DDI-DrugBank.d66.s7	true	DDI-DrugBank.d66.s7.e1	DDI-DrugBank.d66.s7.e2
DDI-DrugBank.d66.s7	false	DDI-DrugBank.d66.s7.e1	DDI-DrugBank.d66.s7.e3
DDI-DrugBank.d66.s7	false	DDI-DrugBank.d66.s7.e2	DDI-DrugBank.d66.s7.e3
DDI-DrugBank.d365.s0|a|Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.
DDI-DrugBank.d365.s0	0	26	Medroxyprogesterone Acetate	drug	DDI-DrugBank.d365.s0.e0
DDI-DrugBank.d365.s0	30	40	L-histidine	drug	DDI-DrugBank.d365.s0.e1
DDI-DrugBank.d365.s0	100	126	medroxyprogesterone acetate	drug	DDI-DrugBank.d365.s0.e2
DDI-DrugBank.d365.s0	false	DDI-DrugBank.d365.s0.e0	DDI-DrugBank.d365.s0.e1
DDI-DrugBank.d365.s0	false	DDI-DrugBank.d365.s0.e0	DDI-DrugBank.d365.s0.e2
DDI-DrugBank.d365.s0	true	DDI-DrugBank.d365.s0.e1	DDI-DrugBank.d365.s0.e2
DDI-DrugBank.d365.s1|a|H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
DDI-DrugBank.d365.s1	0	1	H1 Blockers	group	DDI-DrugBank.d365.s1.e0
DDI-DrugBank.d365.s1	10	17	H1 Blockers	group	DDI-DrugBank.d365.s1.e0
DDI-DrugBank.d365.s1	7	17	H2 Blockers	group	DDI-DrugBank.d365.s1.e1
DDI-DrugBank.d365.s1	44	54	L-histidine	drug	DDI-DrugBank.d365.s1.e2
DDI-DrugBank.d365.s1	121	122	H1 blockers	group	DDI-DrugBank.d365.s1.e3
DDI-DrugBank.d365.s1	131	138	H1 blockers	group	DDI-DrugBank.d365.s1.e3
DDI-DrugBank.d365.s1	128	138	H2 blockers	group	DDI-DrugBank.d365.s1.e4
DDI-DrugBank.d365.s1	false	DDI-DrugBank.d365.s1.e0	DDI-DrugBank.d365.s1.e1
DDI-DrugBank.d365.s1	false	DDI-DrugBank.d365.s1.e0	DDI-DrugBank.d365.s1.e2
DDI-DrugBank.d365.s1	false	DDI-DrugBank.d365.s1.e0	DDI-DrugBank.d365.s1.e3
DDI-DrugBank.d365.s1	false	DDI-DrugBank.d365.s1.e0	DDI-DrugBank.d365.s1.e4
DDI-DrugBank.d365.s1	false	DDI-DrugBank.d365.s1.e1	DDI-DrugBank.d365.s1.e2
DDI-DrugBank.d365.s1	false	DDI-DrugBank.d365.s1.e1	DDI-DrugBank.d365.s1.e3
DDI-DrugBank.d365.s1	false	DDI-DrugBank.d365.s1.e1	DDI-DrugBank.d365.s1.e4
DDI-DrugBank.d365.s1	true	DDI-DrugBank.d365.s1.e2	DDI-DrugBank.d365.s1.e3
DDI-DrugBank.d365.s1	true	DDI-DrugBank.d365.s1.e2	DDI-DrugBank.d365.s1.e4
DDI-DrugBank.d365.s1	false	DDI-DrugBank.d365.s1.e3	DDI-DrugBank.d365.s1.e4
DDI-DrugBank.d344.s0|a|Concomitant use of calcium supplements and L-lysine may increase calcium absorption
DDI-DrugBank.d344.s0	19	25	calcium	drug	DDI-DrugBank.d344.s0.e0
DDI-DrugBank.d344.s0	43	50	L-lysine	drug	DDI-DrugBank.d344.s0.e1
DDI-DrugBank.d344.s0	65	71	calcium	drug	DDI-DrugBank.d344.s0.e2
DDI-DrugBank.d344.s0	true	DDI-DrugBank.d344.s0.e0	DDI-DrugBank.d344.s0.e1
DDI-DrugBank.d344.s0	false	DDI-DrugBank.d344.s0.e0	DDI-DrugBank.d344.s0.e2
DDI-DrugBank.d344.s0	false	DDI-DrugBank.d344.s0.e1	DDI-DrugBank.d344.s0.e2
DDI-DrugBank.d528.s0|a|Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
DDI-DrugBank.d528.s0	0	12	Acetaminophen	drug	DDI-DrugBank.d528.s0.e0
DDI-DrugBank.d528.s0	18	29	methotrexate	drug	DDI-DrugBank.d528.s0.e1
DDI-DrugBank.d528.s0	33	44	L-methionine	drug	DDI-DrugBank.d528.s0.e2
DDI-DrugBank.d528.s0	90	102	acetaminophen	drug	DDI-DrugBank.d528.s0.e3
DDI-DrugBank.d528.s0	134	145	methotrexate	drug	DDI-DrugBank.d528.s0.e4
DDI-DrugBank.d528.s0	false	DDI-DrugBank.d528.s0.e0	DDI-DrugBank.d528.s0.e1
DDI-DrugBank.d528.s0	false	DDI-DrugBank.d528.s0.e0	DDI-DrugBank.d528.s0.e2
DDI-DrugBank.d528.s0	false	DDI-DrugBank.d528.s0.e0	DDI-DrugBank.d528.s0.e3
DDI-DrugBank.d528.s0	false	DDI-DrugBank.d528.s0.e0	DDI-DrugBank.d528.s0.e4
DDI-DrugBank.d528.s0	false	DDI-DrugBank.d528.s0.e1	DDI-DrugBank.d528.s0.e2
DDI-DrugBank.d528.s0	false	DDI-DrugBank.d528.s0.e1	DDI-DrugBank.d528.s0.e3
DDI-DrugBank.d528.s0	false	DDI-DrugBank.d528.s0.e1	DDI-DrugBank.d528.s0.e4
DDI-DrugBank.d528.s0	true	DDI-DrugBank.d528.s0.e2	DDI-DrugBank.d528.s0.e3
DDI-DrugBank.d528.s0	true	DDI-DrugBank.d528.s0.e2	DDI-DrugBank.d528.s0.e4
DDI-DrugBank.d528.s0	false	DDI-DrugBank.d528.s0.e3	DDI-DrugBank.d528.s0.e4
DDI-DrugBank.d528.s1|a|Theoretically, it may decrease hepatic toxicity in the case of other potential hepatotoxic drugs, as well.
DDI-DrugBank.d528.s2|a|Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.
DDI-DrugBank.d528.s2	0	9	Gentamicin	drug	DDI-DrugBank.d528.s2.e0
DDI-DrugBank.d528.s2	13	22	Methionine	drug	DDI-DrugBank.d528.s2.e1
DDI-DrugBank.d528.s2	68	77	gentamicin	drug	DDI-DrugBank.d528.s2.e2
DDI-DrugBank.d528.s2	false	DDI-DrugBank.d528.s2.e0	DDI-DrugBank.d528.s2.e1
DDI-DrugBank.d528.s2	false	DDI-DrugBank.d528.s2.e0	DDI-DrugBank.d528.s2.e2
DDI-DrugBank.d528.s2	true	DDI-DrugBank.d528.s2.e1	DDI-DrugBank.d528.s2.e2
DDI-DrugBank.d530.s0|a|Non-selective monoamine oxidase (MAO) inhibitors - including phenelzine sulfate, tranylcypromine sulfate and pargyline HC1.
DDI-DrugBank.d530.s0	0	47	Non-selective monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d530.s0.e0
DDI-DrugBank.d530.s0	61	78	phenelzine sulfate	drug	DDI-DrugBank.d530.s0.e1
DDI-DrugBank.d530.s0	81	103	tranylcypromine sulfate	drug	DDI-DrugBank.d530.s0.e2
DDI-DrugBank.d530.s0	109	117	pargyline	drug	DDI-DrugBank.d530.s0.e3
DDI-DrugBank.d530.s0	false	DDI-DrugBank.d530.s0.e0	DDI-DrugBank.d530.s0.e1
DDI-DrugBank.d530.s0	false	DDI-DrugBank.d530.s0.e0	DDI-DrugBank.d530.s0.e2
DDI-DrugBank.d530.s0	false	DDI-DrugBank.d530.s0.e0	DDI-DrugBank.d530.s0.e3
DDI-DrugBank.d530.s0	false	DDI-DrugBank.d530.s0.e1	DDI-DrugBank.d530.s0.e2
DDI-DrugBank.d530.s0	false	DDI-DrugBank.d530.s0.e1	DDI-DrugBank.d530.s0.e3
DDI-DrugBank.d530.s0	false	DDI-DrugBank.d530.s0.e2	DDI-DrugBank.d530.s0.e3
DDI-DrugBank.d530.s1|a|Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.
DDI-DrugBank.d530.s1	19	33	L-phenylalanine	drug	DDI-DrugBank.d530.s1.e0
DDI-DrugBank.d530.s1	39	66	non-selective MAO inhibitors	group	DDI-DrugBank.d530.s1.e1
DDI-DrugBank.d530.s1	true	DDI-DrugBank.d530.s1.e0	DDI-DrugBank.d530.s1.e1
DDI-DrugBank.d530.s2|a|Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.
DDI-DrugBank.d530.s2	0	9	Selegiline	drug	DDI-DrugBank.d530.s2.e0
DDI-DrugBank.d530.s2	13	27	L-phenylalanine	drug	DDI-DrugBank.d530.s2.e1
DDI-DrugBank.d530.s2	37	59	selective MAO inhibitor	group	DDI-DrugBank.d530.s2.e2
DDI-DrugBank.d530.s2	61	70	selegiline	drug	DDI-DrugBank.d530.s2.e3
DDI-DrugBank.d530.s2	false	DDI-DrugBank.d530.s2.e0	DDI-DrugBank.d530.s2.e1
DDI-DrugBank.d530.s2	false	DDI-DrugBank.d530.s2.e0	DDI-DrugBank.d530.s2.e2
DDI-DrugBank.d530.s2	false	DDI-DrugBank.d530.s2.e0	DDI-DrugBank.d530.s2.e3
DDI-DrugBank.d530.s2	false	DDI-DrugBank.d530.s2.e1	DDI-DrugBank.d530.s2.e2
DDI-DrugBank.d530.s2	true	DDI-DrugBank.d530.s2.e1	DDI-DrugBank.d530.s2.e3
DDI-DrugBank.d530.s2	false	DDI-DrugBank.d530.s2.e2	DDI-DrugBank.d530.s2.e3
DDI-DrugBank.d530.s3|a|Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.
DDI-DrugBank.d530.s3	0	16	Neuroleptic Drugs	group	DDI-DrugBank.d530.s3.e0
DDI-DrugBank.d530.s3	20	34	L-phenylalanine	drug	DDI-DrugBank.d530.s3.e1
DDI-DrugBank.d530.s3	92	108	neuroleptic drugs	group	DDI-DrugBank.d530.s3.e2
DDI-DrugBank.d530.s3	true	DDI-DrugBank.d530.s3.e0	DDI-DrugBank.d530.s3.e1
DDI-DrugBank.d530.s3	false	DDI-DrugBank.d530.s3.e0	DDI-DrugBank.d530.s3.e2
DDI-DrugBank.d530.s3	false	DDI-DrugBank.d530.s3.e1	DDI-DrugBank.d530.s3.e2
DDI-DrugBank.d63.s0|a|Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
DDI-DrugBank.d63.s0	0	33	Monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d63.s0.e0
DDI-DrugBank.d63.s0	43	55	isocarboxazid	drug	DDI-DrugBank.d63.s0.e1
DDI-DrugBank.d63.s0	64	70	Marplan	brand	DDI-DrugBank.d63.s0.e2
DDI-DrugBank.d63.s0	74	83	phenelzine	drug	DDI-DrugBank.d63.s0.e3
DDI-DrugBank.d63.s0	92	97	Nardil	brand	DDI-DrugBank.d63.s0.e4
DDI-DrugBank.d63.s0	101	112	procarbazine	drug	DDI-DrugBank.d63.s0.e5
DDI-DrugBank.d63.s0	121	128	Matulane	brand	DDI-DrugBank.d63.s0.e6
DDI-DrugBank.d63.s0	132	141	selegiline	drug	DDI-DrugBank.d63.s0.e7
DDI-DrugBank.d63.s0	150	157	Eldepryl	brand	DDI-DrugBank.d63.s0.e8
DDI-DrugBank.d63.s0	165	179	tranylcypromine	drug	DDI-DrugBank.d63.s0.e9
DDI-DrugBank.d63.s0	false	DDI-DrugBank.d63.s0.e0	DDI-DrugBank.d63.s0.e1
DDI-DrugBank.d63.s0	false	DDI-DrugBank.d63.s0.e0	DDI-DrugBank.d63.s0.e2
DDI-DrugBank.d63.s0	false	DDI-DrugBank.d63.s0.e0	DDI-DrugBank.d63.s0.e3
DDI-DrugBank.d63.s0	false	DDI-DrugBank.d63.s0.e0	DDI-DrugBank.d63.s0.e4
DDI-DrugBank.d63.s0	false	DDI-DrugBank.d63.s0.e0	DDI-DrugBank.d63.s0.e5
DDI-DrugBank.d63.s0	false	DDI-DrugBank.d63.s0.e0	DDI-DrugBank.d63.s0.e6
DDI-DrugBank.d63.s0	false	DDI-DrugBank.d63.s0.e0	DDI-DrugBank.d63.s0.e7
DDI-DrugBank.d63.s0	false	DDI-DrugBank.d63.s0.e0	DDI-DrugBank.d63.s0.e8
DDI-DrugBank.d63.s0	false	DDI-DrugBank.d63.s0.e0	DDI-DrugBank.d63.s0.e9
DDI-DrugBank.d63.s0	false	DDI-DrugBank.d63.s0.e0	DDI-DrugBank.d63.s0.e10
DDI-DrugBank.d111.s0|a|Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.
DDI-DrugBank.d111.s0	0	27	Non-selective MAO inhibitors	group	DDI-DrugBank.d111.s0.e0
DDI-DrugBank.d111.s0	39	61	tranylcypromine sulfate	drug	DDI-DrugBank.d111.s0.e1
DDI-DrugBank.d111.s0	64	81	phenelzine sulfate	drug	DDI-DrugBank.d111.s0.e2
DDI-DrugBank.d111.s0	88	96	pargyline	drug	DDI-DrugBank.d111.s0.e3
DDI-DrugBank.d111.s0	122	131	L-tyrosine	drug	DDI-DrugBank.d111.s0.e4
DDI-DrugBank.d111.s0	151	164	MAO inhibitors	group	DDI-DrugBank.d111.s0.e5
DDI-DrugBank.d111.s0	false	DDI-DrugBank.d111.s0.e0	DDI-DrugBank.d111.s0.e1
DDI-DrugBank.d111.s0	false	DDI-DrugBank.d111.s0.e0	DDI-DrugBank.d111.s0.e2
DDI-DrugBank.d111.s0	false	DDI-DrugBank.d111.s0.e0	DDI-DrugBank.d111.s0.e3
DDI-DrugBank.d111.s0	false	DDI-DrugBank.d111.s0.e0	DDI-DrugBank.d111.s0.e4
DDI-DrugBank.d111.s0	false	DDI-DrugBank.d111.s0.e0	DDI-DrugBank.d111.s0.e5
DDI-DrugBank.d111.s0	false	DDI-DrugBank.d111.s0.e1	DDI-DrugBank.d111.s0.e2
DDI-DrugBank.d111.s0	false	DDI-DrugBank.d111.s0.e1	DDI-DrugBank.d111.s0.e3
DDI-DrugBank.d111.s0	false	DDI-DrugBank.d111.s0.e1	DDI-DrugBank.d111.s0.e4
DDI-DrugBank.d111.s0	false	DDI-DrugBank.d111.s0.e1	DDI-DrugBank.d111.s0.e5
DDI-DrugBank.d111.s0	false	DDI-DrugBank.d111.s0.e2	DDI-DrugBank.d111.s0.e3
DDI-DrugBank.d412.s0|a|In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.
DDI-DrugBank.d412.s0	39	51	labetalol HCl	drug	DDI-DrugBank.d412.s0.e0
DDI-DrugBank.d412.s0	73	97	tricyclic antidepressants	group	DDI-DrugBank.d412.s0.e1
DDI-DrugBank.d412.s0	162	174	labetalol HCl	drug	DDI-DrugBank.d412.s0.e2
DDI-DrugBank.d412.s0	true	DDI-DrugBank.d412.s0.e0	DDI-DrugBank.d412.s0.e1
DDI-DrugBank.d412.s0	false	DDI-DrugBank.d412.s0.e0	DDI-DrugBank.d412.s0.e2
DDI-DrugBank.d412.s0	false	DDI-DrugBank.d412.s0.e1	DDI-DrugBank.d412.s0.e2
DDI-DrugBank.d412.s1|a|The contribution of each of the treatments to this adverse reaction is unknown but the possibility of a drug interaction cannot be excluded.
DDI-DrugBank.d412.s2|a|Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm;
DDI-DrugBank.d412.s2	81	107	beta-receptor agonist drugs	group	DDI-DrugBank.d412.s2.e0
DDI-DrugBank.d412.s3|a|therefore, doses greater than the normal antiasthmatic dose of beta-agonist bronchodilator drugs may be required.
DDI-DrugBank.d412.s3	63	95	beta-agonist bronchodilator drugs	group	DDI-DrugBank.d412.s3.e0
DDI-DrugBank.d412.s4|a|Cimetidine has been shown to increase the bioavailability of labetalol HCl.
DDI-DrugBank.d412.s4	0	9	Cimetidine	drug	DDI-DrugBank.d412.s4.e0
DDI-DrugBank.d412.s4	61	73	labetalol HCl	drug	DDI-DrugBank.d412.s4.e1
DDI-DrugBank.d412.s4	true	DDI-DrugBank.d412.s4.e0	DDI-DrugBank.d412.s4.e1
DDI-DrugBank.d412.s5|a|Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients.
DDI-DrugBank.d412.s5	105	117	labetalol HCl	drug	DDI-DrugBank.d412.s5.e0
DDI-DrugBank.d412.s6|a|Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.
DDI-DrugBank.d412.s6	33	41	halothane	drug	DDI-DrugBank.d412.s6.e0
DDI-DrugBank.d412.s6	85	97	labetalol HCl	drug	DDI-DrugBank.d412.s6.e1
DDI-DrugBank.d412.s6	true	DDI-DrugBank.d412.s6.e0	DDI-DrugBank.d412.s6.e1
DDI-DrugBank.d412.s7|a|During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.
DDI-DrugBank.d412.s7	47	59	labetalol HCl	drug	DDI-DrugBank.d412.s7.e0
DDI-DrugBank.d412.s7	81	89	halothane	drug	DDI-DrugBank.d412.s7.e1
DDI-DrugBank.d412.s7	129	137	halothane	drug	DDI-DrugBank.d412.s7.e2
DDI-DrugBank.d412.s7	true	DDI-DrugBank.d412.s7.e0	DDI-DrugBank.d412.s7.e1
DDI-DrugBank.d412.s7	false	DDI-DrugBank.d412.s7.e0	DDI-DrugBank.d412.s7.e2
DDI-DrugBank.d412.s7	false	DDI-DrugBank.d412.s7.e1	DDI-DrugBank.d412.s7.e2
DDI-DrugBank.d412.s8|a|The anesthesiologist should be informed when a patient is receiving labetalol HCl.
DDI-DrugBank.d412.s8	68	80	labetalol HCl	drug	DDI-DrugBank.d412.s8.e0
DDI-DrugBank.d412.s9|a|Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.
DDI-DrugBank.d412.s9	0	12	Labetalol HCl	drug	DDI-DrugBank.d412.s9.e0
DDI-DrugBank.d412.s9	56	68	nitroglycerin	drug	DDI-DrugBank.d412.s9.e1
DDI-DrugBank.d412.s9	true	DDI-DrugBank.d412.s9.e0	DDI-DrugBank.d412.s9.e1
DDI-DrugBank.d412.s10|a|If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.
DDI-DrugBank.d412.s10	3	15	labetalol HCl	drug	DDI-DrugBank.d412.s10.e0
DDI-DrugBank.d412.s10	30	42	nitroglycerin	drug	DDI-DrugBank.d412.s10.e1
DDI-DrugBank.d412.s10	true	DDI-DrugBank.d412.s10.e0	DDI-DrugBank.d412.s10.e1
DDI-DrugBank.d412.s11|a|Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.
DDI-DrugBank.d412.s11	24	32	labetalol	drug	DDI-DrugBank.d412.s11.e0
DDI-DrugBank.d412.s11	61	78	calcium antagonist	group	DDI-DrugBank.d412.s11.e1
DDI-DrugBank.d412.s11	88	96	verapamil	drug	DDI-DrugBank.d412.s11.e2
DDI-DrugBank.d412.s11	true	DDI-DrugBank.d412.s11.e0	DDI-DrugBank.d412.s11.e1
DDI-DrugBank.d412.s11	false	DDI-DrugBank.d412.s11.e0	DDI-DrugBank.d412.s11.e2
DDI-DrugBank.d412.s11	false	DDI-DrugBank.d412.s11.e1	DDI-DrugBank.d412.s11.e2
DDI-DrugBank.d412.s12|a|Risk of Anaphylactic Reaction While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.
DDI-DrugBank.d412.s12	43	55	beta-blockers	group	DDI-DrugBank.d412.s12.e0
DDI-DrugBank.d412.s13|a|Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
DDI-DrugBank.d412.s13	56	66	epinephrine	drug	DDI-DrugBank.d412.s13.e0
DDI-DrugBank.d412.s14|a|Drug/Laboratory Test Interactions The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine and vanillylmandelic acid when measured by fluorimetric or photometric methods.
DDI-DrugBank.d412.s15|a|In screening patients suspected of having a pheochromocytoma and being treated with labetalol HCl, a specific method, such as a high performance liquid chromatographic assay with solid phase extraction (e.g., J Chromatogr 385:241,1987) should be employed in determining levels of catecholamines.
DDI-DrugBank.d412.s15	84	96	labetalol HCl	drug	DDI-DrugBank.d412.s15.e0
DDI-DrugBank.d412.s16|a|Labetalol HCl has also been reported to produce a false positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A  (thin-layer chromatographic assay) and Emit-d.a.u.  (radioenzymatic assay).
DDI-DrugBank.d412.s16	0	12	Labetalol HCl	drug	DDI-DrugBank.d412.s16.e0
DDI-DrugBank.d412.s16	74	84	amphetamine	drug	DDI-DrugBank.d412.s16.e1
DDI-DrugBank.d412.s16	false	DDI-DrugBank.d412.s16.e0	DDI-DrugBank.d412.s16.e1
DDI-DrugBank.d412.s17|a|When patients being treated with labetalol have a positive urine test for amphetamine using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique.
DDI-DrugBank.d412.s17	33	41	labetalol	drug	DDI-DrugBank.d412.s17.e0
DDI-DrugBank.d412.s17	74	84	amphetamine	drug	DDI-DrugBank.d412.s17.e1
DDI-DrugBank.d412.s17	false	DDI-DrugBank.d412.s17.e0	DDI-DrugBank.d412.s17.e1
DDI-DrugBank.d206.s0|a|Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.
DDI-DrugBank.d206.s0	77	84	antacids	group	DDI-DrugBank.d206.s0.e0
DDI-DrugBank.d206.s0	110	118	lactulose	drug	DDI-DrugBank.d206.s0.e1
DDI-DrugBank.d206.s0	144	152	lactulose	drug	DDI-DrugBank.d206.s0.e2
DDI-DrugBank.d206.s0	true	DDI-DrugBank.d206.s0.e0	DDI-DrugBank.d206.s0.e1
DDI-DrugBank.d206.s0	false	DDI-DrugBank.d206.s0.e0	DDI-DrugBank.d206.s0.e2
DDI-DrugBank.d206.s0	false	DDI-DrugBank.d206.s0.e1	DDI-DrugBank.d206.s0.e2
DDI-DrugBank.d206.s1|a|Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose.
DDI-DrugBank.d206.s1	140	148	lactulose	drug	DDI-DrugBank.d206.s1.e0
DDI-DrugBank.d71.s0|a|Lamivudine is predominantly eliminated in the urine by active organic cationic secretion.
DDI-DrugBank.d71.s0	0	9	Lamivudine	drug	DDI-DrugBank.d71.s0.e0
DDI-DrugBank.d71.s1|a|The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim).
DDI-DrugBank.d71.s1	222	233	trimethoprim	drug	DDI-DrugBank.d71.s1.e0
DDI-DrugBank.d71.s2|a|No change in dose of either drug is recommended.
DDI-DrugBank.d71.s3|a|There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.
DDI-DrugBank.d71.s3	48	57	lamivudine	drug	DDI-DrugBank.d71.s3.e0
DDI-DrugBank.d71.s3	95	97	TMP	drug	DDI-DrugBank.d71.s3.e1
DDI-DrugBank.d71.s3	99	101	SMX	drug	DDI-DrugBank.d71.s3.e2
DDI-DrugBank.d71.s3	false	DDI-DrugBank.d71.s3.e0	DDI-DrugBank.d71.s3.e1
DDI-DrugBank.d71.s3	false	DDI-DrugBank.d71.s3.e0	DDI-DrugBank.d71.s3.e2
DDI-DrugBank.d71.s3	false	DDI-DrugBank.d71.s3.e1	DDI-DrugBank.d71.s3.e2
DDI-DrugBank.d71.s4|a|No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.
DDI-DrugBank.d71.s4	118	127	lamivudine	drug	DDI-DrugBank.d71.s4.e0
DDI-DrugBank.d71.s5|a|Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.
DDI-DrugBank.d71.s5	0	9	Lamivudine	drug	DDI-DrugBank.d71.s5.e0
DDI-DrugBank.d71.s5	15	25	zalcitabine	drug	DDI-DrugBank.d71.s5.e1
DDI-DrugBank.d71.s5	true	DDI-DrugBank.d71.s5.e0	DDI-DrugBank.d71.s5.e1
DDI-DrugBank.d71.s6|a|Therefore, use of lamivudine in combination with zalcitabine is not recommended
DDI-DrugBank.d71.s6	18	27	lamivudine	drug	DDI-DrugBank.d71.s6.e0
DDI-DrugBank.d71.s6	49	59	zalcitabine	drug	DDI-DrugBank.d71.s6.e1
DDI-DrugBank.d71.s6	true	DDI-DrugBank.d71.s6.e0	DDI-DrugBank.d71.s6.e1
DDI-DrugBank.d71.s7|a|.
DDI-DrugBank.d71.s8|a|
DDI-DrugBank.d431.s0|a|Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes.
DDI-DrugBank.d431.s0	0	11	Lansoprazole	drug	DDI-DrugBank.d431.s0.e0
DDI-DrugBank.d431.s1|a|Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
DDI-DrugBank.d431.s1	24	35	lansoprazole	drug	DDI-DrugBank.d431.s1.e0
DDI-DrugBank.d431.s1	155	162	warfarin	drug	DDI-DrugBank.d431.s1.e1
DDI-DrugBank.d431.s1	165	174	antipyrine	drug	DDI-DrugBank.d431.s1.e2
DDI-DrugBank.d431.s1	177	188	indomethacin	drug	DDI-DrugBank.d431.s1.e3
DDI-DrugBank.d431.s1	191	199	ibuprofen	drug	DDI-DrugBank.d431.s1.e4
DDI-DrugBank.d431.s1	202	210	phenytoin	drug	DDI-DrugBank.d431.s1.e5
DDI-DrugBank.d431.s1	213	223	propranolol	drug	DDI-DrugBank.d431.s1.e6
DDI-DrugBank.d431.s1	226	235	prednisone	drug	DDI-DrugBank.d431.s1.e7
DDI-DrugBank.d431.s1	238	245	diazepam	drug	DDI-DrugBank.d431.s1.e8
DDI-DrugBank.d431.s1	248	261	clarithromycin	drug	DDI-DrugBank.d431.s1.e9
DDI-DrugBank.d431.s1	false	DDI-DrugBank.d431.s1.e0	DDI-DrugBank.d431.s1.e1
DDI-DrugBank.d431.s1	false	DDI-DrugBank.d431.s1.e0	DDI-DrugBank.d431.s1.e2
DDI-DrugBank.d431.s1	false	DDI-DrugBank.d431.s1.e0	DDI-DrugBank.d431.s1.e3
DDI-DrugBank.d431.s1	false	DDI-DrugBank.d431.s1.e0	DDI-DrugBank.d431.s1.e4
DDI-DrugBank.d431.s1	false	DDI-DrugBank.d431.s1.e0	DDI-DrugBank.d431.s1.e5
DDI-DrugBank.d431.s1	false	DDI-DrugBank.d431.s1.e0	DDI-DrugBank.d431.s1.e6
DDI-DrugBank.d431.s1	false	DDI-DrugBank.d431.s1.e0	DDI-DrugBank.d431.s1.e7
DDI-DrugBank.d431.s1	false	DDI-DrugBank.d431.s1.e0	DDI-DrugBank.d431.s1.e8
DDI-DrugBank.d431.s1	false	DDI-DrugBank.d431.s1.e0	DDI-DrugBank.d431.s1.e9
DDI-DrugBank.d431.s1	false	DDI-DrugBank.d431.s1.e0	DDI-DrugBank.d431.s1.e10
DDI-DrugBank.d431.s2|a|These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.
DDI-DrugBank.d431.s3|a|When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.
DDI-DrugBank.d431.s3	5	16	lansoprazole	drug	DDI-DrugBank.d431.s3.e0
DDI-DrugBank.d431.s3	54	65	theophylline	drug	DDI-DrugBank.d431.s3.e1
DDI-DrugBank.d431.s3	127	138	theophylline	drug	DDI-DrugBank.d431.s3.e2
DDI-DrugBank.d431.s3	true	DDI-DrugBank.d431.s3.e0	DDI-DrugBank.d431.s3.e1
DDI-DrugBank.d431.s3	false	DDI-DrugBank.d431.s3.e0	DDI-DrugBank.d431.s3.e2
DDI-DrugBank.d431.s3	false	DDI-DrugBank.d431.s3.e1	DDI-DrugBank.d431.s3.e2
DDI-DrugBank.d431.s4|a|Because the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be clinical concern.
DDI-DrugBank.d431.s4	63	74	theophylline	drug	DDI-DrugBank.d431.s4.e0
DDI-DrugBank.d431.s5|a|Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.
DDI-DrugBank.d431.s5	75	86	theophylline	drug	DDI-DrugBank.d431.s5.e0
DDI-DrugBank.d431.s5	100	111	lansoprazole	drug	DDI-DrugBank.d431.s5.e1
DDI-DrugBank.d431.s5	true	DDI-DrugBank.d431.s5.e0	DDI-DrugBank.d431.s5.e1
DDI-DrugBank.d431.s6|a|Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin.
DDI-DrugBank.d431.s6	0	11	Lansoprazole	drug	DDI-DrugBank.d431.s6.e0
DDI-DrugBank.d431.s6	84	94	amoxicillin	drug	DDI-DrugBank.d431.s6.e1
DDI-DrugBank.d431.s6	false	DDI-DrugBank.d431.s6.e0	DDI-DrugBank.d431.s6.e1
DDI-DrugBank.d431.s7|a|In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.
DDI-DrugBank.d431.s7	43	54	lansoprazole	drug	DDI-DrugBank.d431.s7.e0
DDI-DrugBank.d431.s7	66	75	omeprazole	drug	DDI-DrugBank.d431.s7.e1
DDI-DrugBank.d431.s7	130	139	sucralfate	drug	DDI-DrugBank.d431.s7.e2
DDI-DrugBank.d431.s7	167	188	proton pump inhibitors	group	DDI-DrugBank.d431.s7.e3
DDI-DrugBank.d431.s7	307	316	sucralfate	drug	DDI-DrugBank.d431.s7.e4
DDI-DrugBank.d431.s7	false	DDI-DrugBank.d431.s7.e0	DDI-DrugBank.d431.s7.e1
DDI-DrugBank.d431.s7	false	DDI-DrugBank.d431.s7.e0	DDI-DrugBank.d431.s7.e2
DDI-DrugBank.d431.s7	false	DDI-DrugBank.d431.s7.e0	DDI-DrugBank.d431.s7.e3
DDI-DrugBank.d431.s7	false	DDI-DrugBank.d431.s7.e0	DDI-DrugBank.d431.s7.e4
DDI-DrugBank.d431.s7	false	DDI-DrugBank.d431.s7.e1	DDI-DrugBank.d431.s7.e2
DDI-DrugBank.d431.s7	false	DDI-DrugBank.d431.s7.e1	DDI-DrugBank.d431.s7.e3
DDI-DrugBank.d431.s7	false	DDI-DrugBank.d431.s7.e1	DDI-DrugBank.d431.s7.e4
DDI-DrugBank.d431.s7	false	DDI-DrugBank.d431.s7.e2	DDI-DrugBank.d431.s7.e3
DDI-DrugBank.d431.s7	false	DDI-DrugBank.d431.s7.e2	DDI-DrugBank.d431.s7.e4
DDI-DrugBank.d431.s7	true	DDI-DrugBank.d431.s7.e3	DDI-DrugBank.d431.s7.e4
DDI-DrugBank.d431.s8|a|Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.
DDI-DrugBank.d431.s8	11	32	proton pump inhibitors	group	DDI-DrugBank.d431.s8.e0
DDI-DrugBank.d431.s8	79	88	sucralfate	drug	DDI-DrugBank.d431.s8.e1
DDI-DrugBank.d431.s8	true	DDI-DrugBank.d431.s8.e0	DDI-DrugBank.d431.s8.e1
DDI-DrugBank.d431.s9|a|In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules;
DDI-DrugBank.d431.s9	20	27	antacids	group	DDI-DrugBank.d431.s9.e0
DDI-DrugBank.d431.s9	66	77	lansoprazole	drug	DDI-DrugBank.d431.s9.e1
DDI-DrugBank.d431.s9	false	DDI-DrugBank.d431.s9.e0	DDI-DrugBank.d431.s9.e1
DDI-DrugBank.d431.s10|a|this did not interfere with its effect.
DDI-DrugBank.d431.s11|a|Lansoprazole causes a profound and long lasting inhibition of gastric acid secretion;
DDI-DrugBank.d431.s11	0	11	Lansoprazole	drug	DDI-DrugBank.d431.s11.e0
DDI-DrugBank.d431.s12|a|therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
DDI-DrugBank.d431.s12	45	56	lansoprazole	drug	DDI-DrugBank.d431.s12.e0
DDI-DrugBank.d431.s12	171	182	ketoconazole	drug	DDI-DrugBank.d431.s12.e1
DDI-DrugBank.d431.s12	185	194	ampicillin	drug	DDI-DrugBank.d431.s12.e2
DDI-DrugBank.d431.s12	204	207	iron	drug	DDI-DrugBank.d431.s12.e3
DDI-DrugBank.d431.s12	216	222	digoxin	drug	DDI-DrugBank.d431.s12.e4
DDI-DrugBank.d431.s12	true	DDI-DrugBank.d431.s12.e0	DDI-DrugBank.d431.s12.e1
DDI-DrugBank.d431.s12	true	DDI-DrugBank.d431.s12.e0	DDI-DrugBank.d431.s12.e2
DDI-DrugBank.d431.s12	true	DDI-DrugBank.d431.s12.e0	DDI-DrugBank.d431.s12.e3
DDI-DrugBank.d431.s12	true	DDI-DrugBank.d431.s12.e0	DDI-DrugBank.d431.s12.e4
DDI-DrugBank.d431.s12	false	DDI-DrugBank.d431.s12.e1	DDI-DrugBank.d431.s12.e2
DDI-DrugBank.d431.s12	false	DDI-DrugBank.d431.s12.e1	DDI-DrugBank.d431.s12.e3
DDI-DrugBank.d431.s12	false	DDI-DrugBank.d431.s12.e1	DDI-DrugBank.d431.s12.e4
DDI-DrugBank.d431.s12	false	DDI-DrugBank.d431.s12.e2	DDI-DrugBank.d431.s12.e3
DDI-DrugBank.d431.s12	false	DDI-DrugBank.d431.s12.e2	DDI-DrugBank.d431.s12.e4
DDI-DrugBank.d431.s12	false	DDI-DrugBank.d431.s12.e3	DDI-DrugBank.d431.s12.e4
DDI-DrugBank.d135.s0|a|Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.
DDI-DrugBank.d135.s0	11	19	Lapatinib	drug	DDI-DrugBank.d135.s0.e0
DDI-DrugBank.d135.s0	77	85	Lapatinib	drug	DDI-DrugBank.d135.s0.e1
DDI-DrugBank.d135.s0	false	DDI-DrugBank.d135.s0.e0	DDI-DrugBank.d135.s0.e1
DDI-DrugBank.d135.s1|a|Caution should be exercised and dose reduction of the concomitant substrate drug should be considered when dosing lapatinib concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4 or CYP2C8.
DDI-DrugBank.d135.s1	114	122	lapatinib	drug	DDI-DrugBank.d135.s1.e0
DDI-DrugBank.d135.s2|a|Lapatinib did not significantly inhibit the following enzymes in human liver microsomes: CYP1A2, CYP2C9, CYP2C19, and CYP2D6 or UGT enzymes in vitro, however, the clinical significance is unknown.
DDI-DrugBank.d135.s2	0	8	Lapatinib	drug	DDI-DrugBank.d135.s2.e0
DDI-DrugBank.d135.s3|a|Lapatinib inhibits human P-glycoprotein.
DDI-DrugBank.d135.s3	0	8	Lapatinib	drug	DDI-DrugBank.d135.s3.e0
DDI-DrugBank.d135.s4|a|If TYKERB is administered with drugs that are substrates of Pgp, increased concentrations of the substrate drug are likely, and caution should be exercised.
DDI-DrugBank.d135.s4	3	8	TYKERB	brand	DDI-DrugBank.d135.s4.e0
DDI-DrugBank.d135.s5|a|Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.
DDI-DrugBank.d135.s5	57	65	Lapatinib	drug	DDI-DrugBank.d135.s5.e0
DDI-DrugBank.d135.s5	189	197	lapatinib	drug	DDI-DrugBank.d135.s5.e1
DDI-DrugBank.d135.s5	false	DDI-DrugBank.d135.s5.e0	DDI-DrugBank.d135.s5.e1
DDI-DrugBank.d135.s6|a|Dose adjustment of lapatinib should be considered for patients who must receive concomitant strong inhibitors or concomitant strong inducers of CYP3A4 enzymes.
DDI-DrugBank.d135.s6	19	27	lapatinib	drug	DDI-DrugBank.d135.s6.e0
DDI-DrugBank.d135.s7|a|Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
DDI-DrugBank.d135.s7	0	11	Ketoconazole	drug	DDI-DrugBank.d135.s7.e0
DDI-DrugBank.d135.s7	44	55	ketoconazole	drug	DDI-DrugBank.d135.s7.e1
DDI-DrugBank.d135.s7	139	147	lapatinib	drug	DDI-DrugBank.d135.s7.e2
DDI-DrugBank.d135.s7	false	DDI-DrugBank.d135.s7.e0	DDI-DrugBank.d135.s7.e1
DDI-DrugBank.d135.s7	false	DDI-DrugBank.d135.s7.e0	DDI-DrugBank.d135.s7.e2
DDI-DrugBank.d135.s7	true	DDI-DrugBank.d135.s7.e1	DDI-DrugBank.d135.s7.e2
DDI-DrugBank.d135.s8|a|Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.
DDI-DrugBank.d135.s8	0	12	Carbamazepine	drug	DDI-DrugBank.d135.s8.e0
DDI-DrugBank.d135.s8	65	77	carbamazepine	drug	DDI-DrugBank.d135.s8.e1
DDI-DrugBank.d135.s8	176	184	lapatinib	drug	DDI-DrugBank.d135.s8.e2
DDI-DrugBank.d135.s8	false	DDI-DrugBank.d135.s8.e0	DDI-DrugBank.d135.s8.e1
DDI-DrugBank.d135.s8	false	DDI-DrugBank.d135.s8.e0	DDI-DrugBank.d135.s8.e2
DDI-DrugBank.d135.s8	true	DDI-DrugBank.d135.s8.e1	DDI-DrugBank.d135.s8.e2
DDI-DrugBank.d135.s9|a|Drugs that Inhibit Drug Transport Systems Lapatinib is a substrate of the efflux transporter P-glycoprotein (Pgp, ABCB1).
DDI-DrugBank.d135.s9	42	50	Lapatinib	drug	DDI-DrugBank.d135.s9.e0
DDI-DrugBank.d135.s10|a|If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.
DDI-DrugBank.d135.s10	3	8	TYKERB	brand	DDI-DrugBank.d135.s10.e0
DDI-DrugBank.d135.s10	83	91	lapatinib	drug	DDI-DrugBank.d135.s10.e1
DDI-DrugBank.d135.s10	false	DDI-DrugBank.d135.s10.e0	DDI-DrugBank.d135.s10.e1
DDI-DrugBank.d135.s11|a|Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).
DDI-DrugBank.d135.s11	77	85	lapatinib	drug	DDI-DrugBank.d135.s11.e0
DDI-DrugBank.d135.s11	92	103	capecitabine	drug	DDI-DrugBank.d135.s11.e1
DDI-DrugBank.d135.s11	192	203	capecitabine	drug	DDI-DrugBank.d135.s11.e2
DDI-DrugBank.d135.s11	false	DDI-DrugBank.d135.s11.e0	DDI-DrugBank.d135.s11.e1
DDI-DrugBank.d135.s11	false	DDI-DrugBank.d135.s11.e0	DDI-DrugBank.d135.s11.e2
DDI-DrugBank.d135.s11	false	DDI-DrugBank.d135.s11.e1	DDI-DrugBank.d135.s11.e2
DDI-DrugBank.d300.s0|a|No formal drug interaction studies have been conducted.
DDI-DrugBank.d118.s0|a|In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.
DDI-DrugBank.d118.s0	80	89	thimerosal	drug_n	DDI-DrugBank.d118.s0.e0
DDI-DrugBank.d118.s0	106	116	latanoprost	drug	DDI-DrugBank.d118.s0.e1
DDI-DrugBank.d118.s0	false	DDI-DrugBank.d118.s0.e0	DDI-DrugBank.d118.s0.e1
DDI-DrugBank.d118.s1|a|If such drugs are used they should be administered with an interval of at least 5 minutes between applications.
DDI-DrugBank.d41.s0|a|Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
DDI-DrugBank.d41.s0	0	13	Cholestyramine	drug	DDI-DrugBank.d41.s0.e0
DDI-DrugBank.d41.s0	19	26	Charcoal	drug	DDI-DrugBank.d41.s0.e1
DDI-DrugBank.d41.s0	46	59	cholestyramine	drug	DDI-DrugBank.d41.s0.e2
DDI-DrugBank.d41.s0	64	81	activated charcoal	drug	DDI-DrugBank.d41.s0.e3
DDI-DrugBank.d41.s0	208	218	leflunomide	drug	DDI-DrugBank.d41.s0.e4
DDI-DrugBank.d41.s0	false	DDI-DrugBank.d41.s0.e0	DDI-DrugBank.d41.s0.e1
DDI-DrugBank.d41.s0	false	DDI-DrugBank.d41.s0.e0	DDI-DrugBank.d41.s0.e2
DDI-DrugBank.d41.s0	false	DDI-DrugBank.d41.s0.e0	DDI-DrugBank.d41.s0.e3
DDI-DrugBank.d41.s0	false	DDI-DrugBank.d41.s0.e0	DDI-DrugBank.d41.s0.e4
DDI-DrugBank.d41.s0	false	DDI-DrugBank.d41.s0.e1	DDI-DrugBank.d41.s0.e2
DDI-DrugBank.d41.s0	false	DDI-DrugBank.d41.s0.e1	DDI-DrugBank.d41.s0.e3
DDI-DrugBank.d41.s0	false	DDI-DrugBank.d41.s0.e1	DDI-DrugBank.d41.s0.e4
DDI-DrugBank.d41.s0	false	DDI-DrugBank.d41.s0.e2	DDI-DrugBank.d41.s0.e3
DDI-DrugBank.d41.s0	true	DDI-DrugBank.d41.s0.e2	DDI-DrugBank.d41.s0.e4
DDI-DrugBank.d41.s0	true	DDI-DrugBank.d41.s0.e3	DDI-DrugBank.d41.s0.e4
DDI-DrugBank.d41.s1|a|Hepatotoxic Drugs Increased side effects may occur when leflunomide is given concomitantly with hepatotoxic substances.
DDI-DrugBank.d41.s1	56	66	leflunomide	drug	DDI-DrugBank.d41.s1.e0
DDI-DrugBank.d41.s2|a|This is also to be considered when leflunomide treatment is followed by such drugs without a drug elimination procedure.
DDI-DrugBank.d41.s2	35	45	leflunomide	drug	DDI-DrugBank.d41.s2.e0
DDI-DrugBank.d41.s3|a|In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.
DDI-DrugBank.d41.s3	39	43	ARAVA	brand	DDI-DrugBank.d41.s3.e0
DDI-DrugBank.d41.s3	50	61	methotrexate	drug	DDI-DrugBank.d41.s3.e1
DDI-DrugBank.d41.s3	true	DDI-DrugBank.d41.s3.e0	DDI-DrugBank.d41.s3.e1
DDI-DrugBank.d41.s4|a|All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide.
DDI-DrugBank.d41.s4	90	100	leflunomide	drug	DDI-DrugBank.d41.s4.e0
DDI-DrugBank.d41.s5|a|A  3-fold increase was seen in another 5 patients.
DDI-DrugBank.d41.s6|a|All of these also resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide.
DDI-DrugBank.d41.s6	93	103	leflunomide	drug	DDI-DrugBank.d41.s6.e0
DDI-DrugBank.d41.s7|a|Three patients met ACR criteria for liver biopsy (1: Roegnik Grade I, 2: Roegnik Grade IIIa).
DDI-DrugBank.d41.s8|a|No pharmacokinetic interaction was identified.
DDI-DrugBank.d41.s9|a|NSAIDs: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.
DDI-DrugBank.d41.s9	0	5	NSAIDs	group	DDI-DrugBank.d41.s9.e0
DDI-DrugBank.d41.s9	107	116	diclofenac	drug	DDI-DrugBank.d41.s9.e1
DDI-DrugBank.d41.s9	122	130	ibuprofen	drug	DDI-DrugBank.d41.s9.e2
DDI-DrugBank.d41.s9	false	DDI-DrugBank.d41.s9.e0	DDI-DrugBank.d41.s9.e1
DDI-DrugBank.d41.s9	false	DDI-DrugBank.d41.s9.e0	DDI-DrugBank.d41.s9.e2
DDI-DrugBank.d41.s9	false	DDI-DrugBank.d41.s9.e1	DDI-DrugBank.d41.s9.e2
DDI-DrugBank.d41.s10|a|The clinical significance of this finding is unknown;
DDI-DrugBank.d41.s11|a|however, there was extensive concomitant use of NSAIDs in clinical studies and no differential effect was observed.
DDI-DrugBank.d41.s11	48	53	NSAIDs	group	DDI-DrugBank.d41.s11.e0
DDI-DrugBank.d41.s12|a|Tolbutamide: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range.
DDI-DrugBank.d41.s12	0	10	Tolbutamide	drug	DDI-DrugBank.d41.s12.e0
DDI-DrugBank.d41.s12	112	122	tolbutamide	drug	DDI-DrugBank.d41.s12.e1
DDI-DrugBank.d41.s12	false	DDI-DrugBank.d41.s12.e0	DDI-DrugBank.d41.s12.e1
DDI-DrugBank.d41.s13|a|The clinical significance of this finding is unknown.
DDI-DrugBank.d41.s14|a|Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.
DDI-DrugBank.d41.s14	0	7	Rifampin	drug	DDI-DrugBank.d41.s14.e0
DDI-DrugBank.d41.s14	67	71	ARAVA	brand	DDI-DrugBank.d41.s14.e1
DDI-DrugBank.d41.s14	113	120	rifampin	drug	DDI-DrugBank.d41.s14.e2
DDI-DrugBank.d41.s14	181	185	ARAVA	brand	DDI-DrugBank.d41.s14.e3
DDI-DrugBank.d41.s14	false	DDI-DrugBank.d41.s14.e0	DDI-DrugBank.d41.s14.e1
DDI-DrugBank.d41.s14	false	DDI-DrugBank.d41.s14.e0	DDI-DrugBank.d41.s14.e2
DDI-DrugBank.d41.s14	false	DDI-DrugBank.d41.s14.e0	DDI-DrugBank.d41.s14.e3
DDI-DrugBank.d41.s14	true	DDI-DrugBank.d41.s14.e1	DDI-DrugBank.d41.s14.e2
DDI-DrugBank.d41.s14	false	DDI-DrugBank.d41.s14.e1	DDI-DrugBank.d41.s14.e3
DDI-DrugBank.d41.s14	false	DDI-DrugBank.d41.s14.e2	DDI-DrugBank.d41.s14.e3
DDI-DrugBank.d41.s15|a|Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.
DDI-DrugBank.d41.s15	29	33	ARAVA	brand	DDI-DrugBank.d41.s15.e0
DDI-DrugBank.d41.s15	148	152	ARAVA	brand	DDI-DrugBank.d41.s15.e1
DDI-DrugBank.d41.s15	158	165	rifampin	drug	DDI-DrugBank.d41.s15.e2
DDI-DrugBank.d41.s15	false	DDI-DrugBank.d41.s15.e0	DDI-DrugBank.d41.s15.e1
DDI-DrugBank.d41.s15	false	DDI-DrugBank.d41.s15.e0	DDI-DrugBank.d41.s15.e2
DDI-DrugBank.d41.s15	true	DDI-DrugBank.d41.s15.e1	DDI-DrugBank.d41.s15.e2
DDI-DrugBank.d41.s16|a|Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.
DDI-DrugBank.d41.s16	0	7	Warfarin	drug	DDI-DrugBank.d41.s16.e0
DDI-DrugBank.d41.s16	62	66	ARAVA	brand	DDI-DrugBank.d41.s16.e1
DDI-DrugBank.d41.s16	72	79	warfarin	drug	DDI-DrugBank.d41.s16.e2
DDI-DrugBank.d41.s16	false	DDI-DrugBank.d41.s16.e0	DDI-DrugBank.d41.s16.e1
DDI-DrugBank.d41.s16	false	DDI-DrugBank.d41.s16.e0	DDI-DrugBank.d41.s16.e2
DDI-DrugBank.d41.s16	true	DDI-DrugBank.d41.s16.e1	DDI-DrugBank.d41.s16.e2
DDI-DrugBank.d169.s0|a|Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.
DDI-DrugBank.d169.s0	81	88	REVLIMID	brand	DDI-DrugBank.d169.s0.e0
DDI-DrugBank.d169.s0	92	103	lenalidomide	drug	DDI-DrugBank.d169.s0.e1
DDI-DrugBank.d169.s0	200	211	lenalidomide	drug	DDI-DrugBank.d169.s0.e2
DDI-DrugBank.d169.s0	false	DDI-DrugBank.d169.s0.e0	DDI-DrugBank.d169.s0.e1
DDI-DrugBank.d169.s0	false	DDI-DrugBank.d169.s0.e0	DDI-DrugBank.d169.s0.e2
DDI-DrugBank.d169.s0	false	DDI-DrugBank.d169.s0.e1	DDI-DrugBank.d169.s0.e2
DDI-DrugBank.d169.s1|a|Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin.
DDI-DrugBank.d169.s1	48	59	lenalidomide	drug	DDI-DrugBank.d169.s1.e0
DDI-DrugBank.d169.s1	114	115	R- warfarin	drug	DDI-DrugBank.d169.s1.e1
DDI-DrugBank.d169.s1	124	131	R- warfarin	drug	DDI-DrugBank.d169.s1.e1
DDI-DrugBank.d169.s1	121	131	S- warfarin	drug	DDI-DrugBank.d169.s1.e2
DDI-DrugBank.d169.s1	false	DDI-DrugBank.d169.s1.e0	DDI-DrugBank.d169.s1.e1
DDI-DrugBank.d169.s1	false	DDI-DrugBank.d169.s1.e0	DDI-DrugBank.d169.s1.e2
DDI-DrugBank.d169.s1	false	DDI-DrugBank.d169.s1.e1	DDI-DrugBank.d169.s1.e2
DDI-DrugBank.d169.s2|a|Co-administration of single 25-mg dose warfarin had no effect on the pharmacokinetics of total lenalidomide.
DDI-DrugBank.d169.s2	39	46	warfarin	drug	DDI-DrugBank.d169.s2.e0
DDI-DrugBank.d169.s2	95	106	lenalidomide	drug	DDI-DrugBank.d169.s2.e1
DDI-DrugBank.d169.s2	false	DDI-DrugBank.d169.s2.e0	DDI-DrugBank.d169.s2.e1
DDI-DrugBank.d169.s3|a|Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.
DDI-DrugBank.d169.s3	77	84	warfarin	drug	DDI-DrugBank.d169.s3.e0
DDI-DrugBank.d169.s3	153	164	lenalidomide	drug	DDI-DrugBank.d169.s3.e1
DDI-DrugBank.d169.s3	false	DDI-DrugBank.d169.s3.e0	DDI-DrugBank.d169.s3.e1
DDI-DrugBank.d52.s0|a|Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation
DDI-DrugBank.d52.s0	27	39	thrombolytics	group	DDI-DrugBank.d52.s0.e0
DDI-DrugBank.d52.s0	55	67	streptokinase	drug	DDI-DrugBank.d52.s0.e1
DDI-DrugBank.d52.s0	158	165	REFLUDAN	brand	DDI-DrugBank.d52.s0.e2
DDI-DrugBank.d52.s0	false	DDI-DrugBank.d52.s0.e0	DDI-DrugBank.d52.s0.e1
DDI-DrugBank.d52.s0	false	DDI-DrugBank.d52.s0.e0	DDI-DrugBank.d52.s0.e2
DDI-DrugBank.d52.s0	false	DDI-DrugBank.d52.s0.e1	DDI-DrugBank.d52.s0.e2
DDI-DrugBank.d52.s1|a|Concomitant treatment with coumarin derivatives (vitamin K antagonists) and drugs that affect platelet function may also increase the risk of bleeding.
DDI-DrugBank.d52.s1	27	46	coumarin derivatives	group	DDI-DrugBank.d52.s1.e0
DDI-DrugBank.d52.s1	49	69	vitamin K antagonists	group	DDI-DrugBank.d52.s1.e1
DDI-DrugBank.d52.s1	false	DDI-DrugBank.d52.s1.e0	DDI-DrugBank.d52.s1.e1
DDI-DrugBank.d157.s0|a|Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.
DDI-DrugBank.d157.s0	34	43	cimetidine	drug	DDI-DrugBank.d157.s0.e0
DDI-DrugBank.d157.s0	49	56	warfarin	drug	DDI-DrugBank.d157.s0.e1
DDI-DrugBank.d157.s0	97	102	Femara	brand	DDI-DrugBank.d157.s0.e2
DDI-DrugBank.d157.s0	false	DDI-DrugBank.d157.s0.e0	DDI-DrugBank.d157.s0.e1
DDI-DrugBank.d157.s0	false	DDI-DrugBank.d157.s0.e0	DDI-DrugBank.d157.s0.e2
DDI-DrugBank.d157.s0	false	DDI-DrugBank.d157.s0.e1	DDI-DrugBank.d157.s0.e2
DDI-DrugBank.d157.s1|a|(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.
DDI-DrugBank.d157.s1	48	53	Femara	brand	DDI-DrugBank.d157.s1.e0
DDI-DrugBank.d157.s1	59	67	tamoxifen	drug	DDI-DrugBank.d157.s1.e1
DDI-DrugBank.d157.s1	108	116	letrozole	drug	DDI-DrugBank.d157.s1.e2
DDI-DrugBank.d157.s1	true	DDI-DrugBank.d157.s1.e0	DDI-DrugBank.d157.s1.e1
DDI-DrugBank.d157.s1	false	DDI-DrugBank.d157.s1.e0	DDI-DrugBank.d157.s1.e2
DDI-DrugBank.d157.s1	false	DDI-DrugBank.d157.s1.e1	DDI-DrugBank.d157.s1.e2
DDI-DrugBank.d157.s2|a|There is no clinical experience to date on the use of Femara in combination with other anticancer agents.
DDI-DrugBank.d157.s2	54	59	Femara	brand	DDI-DrugBank.d157.s2.e0
DDI-DrugBank.d157.s3|a|Drug/Laboratory Test-Interactions None observed.
DDI-DrugBank.d151.s0|a|Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
DDI-DrugBank.d151.s0	0	9	Folic acid	drug	DDI-DrugBank.d151.s0.e0
DDI-DrugBank.d151.s0	71	83	phenobarbital	drug	DDI-DrugBank.d151.s0.e1
DDI-DrugBank.d151.s0	86	94	phenytoin	drug	DDI-DrugBank.d151.s0.e2
DDI-DrugBank.d151.s0	100	108	primidone	drug	DDI-DrugBank.d151.s0.e3
DDI-DrugBank.d151.s0	true	DDI-DrugBank.d151.s0.e0	DDI-DrugBank.d151.s0.e1
DDI-DrugBank.d151.s0	true	DDI-DrugBank.d151.s0.e0	DDI-DrugBank.d151.s0.e2
DDI-DrugBank.d151.s0	true	DDI-DrugBank.d151.s0.e0	DDI-DrugBank.d151.s0.e3
DDI-DrugBank.d151.s0	false	DDI-DrugBank.d151.s0.e1	DDI-DrugBank.d151.s0.e2
DDI-DrugBank.d151.s0	false	DDI-DrugBank.d151.s0.e1	DDI-DrugBank.d151.s0.e3
DDI-DrugBank.d151.s0	false	DDI-DrugBank.d151.s0.e2	DDI-DrugBank.d151.s0.e3
DDI-DrugBank.d151.s1|a|Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.
DDI-DrugBank.d151.s1	99	108	leucovorin	drug	DDI-DrugBank.d151.s1.e0
DDI-DrugBank.d151.s1	234	245	methotrexate	drug	DDI-DrugBank.d151.s1.e1
DDI-DrugBank.d151.s1	false	DDI-DrugBank.d151.s1.e0	DDI-DrugBank.d151.s1.e1
DDI-DrugBank.d151.s2|a|However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.
DDI-DrugBank.d151.s2	23	32	leucovorin	drug	DDI-DrugBank.d151.s2.e0
DDI-DrugBank.d151.s2	88	99	methotrexate	drug	DDI-DrugBank.d151.s2.e1
DDI-DrugBank.d151.s2	true	DDI-DrugBank.d151.s2.e0	DDI-DrugBank.d151.s2.e1
DDI-DrugBank.d151.s3|a|Leucovorin may enhance the toxicity of 5-fluorouracil.
DDI-DrugBank.d151.s3	0	9	Leucovorin	drug	DDI-DrugBank.d151.s3.e0
DDI-DrugBank.d151.s3	39	52	5-fluorouracil	drug	DDI-DrugBank.d151.s3.e1
DDI-DrugBank.d151.s3	true	DDI-DrugBank.d151.s3.e0	DDI-DrugBank.d151.s3.e1
DDI-DrugBank.d381.s0|a|ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.
DDI-DrugBank.d381.s0	0	8	ERGAMISOL	brand	DDI-DrugBank.d381.s0.e0
DDI-DrugBank.d381.s0	12	35	levamisole hydrochloride	drug	DDI-DrugBank.d381.s0.e1
DDI-DrugBank.d381.s0	124	130	alcohol	drug	DDI-DrugBank.d381.s0.e2
DDI-DrugBank.d381.s0	false	DDI-DrugBank.d381.s0.e0	DDI-DrugBank.d381.s0.e1
DDI-DrugBank.d381.s0	true	DDI-DrugBank.d381.s0.e0	DDI-DrugBank.d381.s0.e2
DDI-DrugBank.d381.s0	true	DDI-DrugBank.d381.s0.e1	DDI-DrugBank.d381.s0.e2
DDI-DrugBank.d381.s1|a|The physician is advised to monitor plasma levels of phenytoin and to decrease the dose if necessary.
DDI-DrugBank.d381.s1	53	61	phenytoin	drug	DDI-DrugBank.d381.s1.e0
DDI-DrugBank.d381.s2|a|Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.
DDI-DrugBank.d381.s2	118	127	levamisole	drug	DDI-DrugBank.d381.s2.e0
DDI-DrugBank.d381.s2	133	147	warfarin sodium	drug	DDI-DrugBank.d381.s2.e1
DDI-DrugBank.d381.s2	232	246	warfarin sodium	drug	DDI-DrugBank.d381.s2.e2
DDI-DrugBank.d381.s2	257	264	coumarin	group	DDI-DrugBank.d381.s2.e3
DDI-DrugBank.d381.s2	true	DDI-DrugBank.d381.s2.e0	DDI-DrugBank.d381.s2.e1
DDI-DrugBank.d381.s2	false	DDI-DrugBank.d381.s2.e0	DDI-DrugBank.d381.s2.e2
DDI-DrugBank.d381.s2	false	DDI-DrugBank.d381.s2.e0	DDI-DrugBank.d381.s2.e3
DDI-DrugBank.d381.s2	false	DDI-DrugBank.d381.s2.e1	DDI-DrugBank.d381.s2.e2
DDI-DrugBank.d381.s2	false	DDI-DrugBank.d381.s2.e1	DDI-DrugBank.d381.s2.e3
DDI-DrugBank.d381.s2	false	DDI-DrugBank.d381.s2.e2	DDI-DrugBank.d381.s2.e3
DDI-DrugBank.d212.s0|a|in vitro data on metabolic interactions indicate that Keppra  is unlikely to produce, or be subject to, pharmacokinetic interactions.
DDI-DrugBank.d212.s0	54	59	Keppra	brand	DDI-DrugBank.d212.s0.e0
DDI-DrugBank.d212.s1|a|Levetiracetam and its major metabolite, at concentrations well above cmax levels achieved within the therapeutic dose range, are neither inhibitors of nor high affinity substrates for human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes.
DDI-DrugBank.d212.s1	0	12	Levetiracetam	drug	DDI-DrugBank.d212.s1.e0
DDI-DrugBank.d212.s2|a|In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.
DDI-DrugBank.d212.s2	13	25	levetiracetam	drug	DDI-DrugBank.d212.s2.e0
DDI-DrugBank.d212.s2	75	87	valproic acid	drug	DDI-DrugBank.d212.s2.e1
DDI-DrugBank.d212.s2	false	DDI-DrugBank.d212.s2.e0	DDI-DrugBank.d212.s2.e1
DDI-DrugBank.d212.s3|a|Levetiracetam circulates largely unbound ( 10% bound) to plasma proteins;
DDI-DrugBank.d212.s3	0	12	Levetiracetam	drug	DDI-DrugBank.d212.s3.e0
DDI-DrugBank.d212.s4|a|clinically significant interactions with other drugs through competition for protein binding sites are therefore unlikely.
DDI-DrugBank.d212.s5|a|Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
DDI-DrugBank.d212.s5	90	98	phenytoin	drug	DDI-DrugBank.d212.s5.e0
DDI-DrugBank.d212.s5	101	109	valproate	drug	DDI-DrugBank.d212.s5.e1
DDI-DrugBank.d212.s5	117	129	contraceptive	group	DDI-DrugBank.d212.s5.e2
DDI-DrugBank.d212.s5	132	138	digoxin	drug	DDI-DrugBank.d212.s5.e3
DDI-DrugBank.d212.s5	141	148	warfarin	drug	DDI-DrugBank.d212.s5.e4
DDI-DrugBank.d212.s5	151	160	probenecid	drug	DDI-DrugBank.d212.s5.e5
DDI-DrugBank.d212.s5	false	DDI-DrugBank.d212.s5.e0	DDI-DrugBank.d212.s5.e1
DDI-DrugBank.d212.s5	false	DDI-DrugBank.d212.s5.e0	DDI-DrugBank.d212.s5.e2
DDI-DrugBank.d212.s5	false	DDI-DrugBank.d212.s5.e0	DDI-DrugBank.d212.s5.e3
DDI-DrugBank.d212.s5	false	DDI-DrugBank.d212.s5.e0	DDI-DrugBank.d212.s5.e4
DDI-DrugBank.d212.s5	false	DDI-DrugBank.d212.s5.e0	DDI-DrugBank.d212.s5.e5
DDI-DrugBank.d212.s5	false	DDI-DrugBank.d212.s5.e1	DDI-DrugBank.d212.s5.e2
DDI-DrugBank.d212.s5	false	DDI-DrugBank.d212.s5.e1	DDI-DrugBank.d212.s5.e3
DDI-DrugBank.d212.s5	false	DDI-DrugBank.d212.s5.e1	DDI-DrugBank.d212.s5.e4
DDI-DrugBank.d212.s5	false	DDI-DrugBank.d212.s5.e1	DDI-DrugBank.d212.s5.e5
DDI-DrugBank.d212.s5	false	DDI-DrugBank.d212.s5.e2	DDI-DrugBank.d212.s5.e3
DDI-DrugBank.d212.s6|a|Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.
DDI-DrugBank.d212.s6	31	36	Keppra	brand	DDI-DrugBank.d212.s6.e0
DDI-DrugBank.d212.s6	49	67	Antiepileptic Drugs	group	DDI-DrugBank.d212.s6.e1
DDI-DrugBank.d212.s6	70	73	AEDs	group	DDI-DrugBank.d212.s6.e2
DDI-DrugBank.d212.s6	76	84	Phenytoin	drug	DDI-DrugBank.d212.s6.e3
DDI-DrugBank.d212.s6	86	91	Keppra	brand	DDI-DrugBank.d212.s6.e4
DDI-DrugBank.d212.s6	162	170	phenytoin	drug	DDI-DrugBank.d212.s6.e5
DDI-DrugBank.d212.s6	false	DDI-DrugBank.d212.s6.e0	DDI-DrugBank.d212.s6.e1
DDI-DrugBank.d212.s6	false	DDI-DrugBank.d212.s6.e0	DDI-DrugBank.d212.s6.e2
DDI-DrugBank.d212.s6	false	DDI-DrugBank.d212.s6.e0	DDI-DrugBank.d212.s6.e3
DDI-DrugBank.d212.s6	false	DDI-DrugBank.d212.s6.e0	DDI-DrugBank.d212.s6.e4
DDI-DrugBank.d212.s6	false	DDI-DrugBank.d212.s6.e0	DDI-DrugBank.d212.s6.e5
DDI-DrugBank.d212.s6	false	DDI-DrugBank.d212.s6.e1	DDI-DrugBank.d212.s6.e2
DDI-DrugBank.d212.s6	false	DDI-DrugBank.d212.s6.e1	DDI-DrugBank.d212.s6.e3
DDI-DrugBank.d212.s6	false	DDI-DrugBank.d212.s6.e1	DDI-DrugBank.d212.s6.e4
DDI-DrugBank.d212.s6	false	DDI-DrugBank.d212.s6.e1	DDI-DrugBank.d212.s6.e5
DDI-DrugBank.d212.s6	false	DDI-DrugBank.d212.s6.e2	DDI-DrugBank.d212.s6.e3
DDI-DrugBank.d212.s7|a|Pharmacokinetics of levetiracetam were also not affected by phenytoin.
DDI-DrugBank.d212.s7	20	32	levetiracetam	drug	DDI-DrugBank.d212.s7.e0
DDI-DrugBank.d212.s7	60	68	phenytoin	drug	DDI-DrugBank.d212.s7.e1
DDI-DrugBank.d212.s7	false	DDI-DrugBank.d212.s7.e0	DDI-DrugBank.d212.s7.e1
DDI-DrugBank.d212.s8|a|Valproate Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.
DDI-DrugBank.d212.s8	0	8	Valproate	drug	DDI-DrugBank.d212.s8.e0
DDI-DrugBank.d212.s8	10	15	Keppra	brand	DDI-DrugBank.d212.s8.e1
DDI-DrugBank.d212.s8	78	86	valproate	drug	DDI-DrugBank.d212.s8.e2
DDI-DrugBank.d212.s8	false	DDI-DrugBank.d212.s8.e0	DDI-DrugBank.d212.s8.e1
DDI-DrugBank.d212.s8	false	DDI-DrugBank.d212.s8.e0	DDI-DrugBank.d212.s8.e2
DDI-DrugBank.d212.s8	false	DDI-DrugBank.d212.s8.e1	DDI-DrugBank.d212.s8.e2
DDI-DrugBank.d212.s9|a|Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion.
DDI-DrugBank.d212.s9	0	8	Valproate	drug	DDI-DrugBank.d212.s9.e0
DDI-DrugBank.d212.s9	66	78	levetiracetam	drug	DDI-DrugBank.d212.s9.e1
DDI-DrugBank.d212.s9	false	DDI-DrugBank.d212.s9.e0	DDI-DrugBank.d212.s9.e1
DDI-DrugBank.d212.s10|a|There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057.
DDI-DrugBank.d212.s11|a|Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
DDI-DrugBank.d212.s11	36	41	Keppra	brand	DDI-DrugBank.d212.s11.e0
DDI-DrugBank.d212.s11	54	57	AEDs	group	DDI-DrugBank.d212.s11.e1
DDI-DrugBank.d212.s11	60	72	carbamazepine	drug	DDI-DrugBank.d212.s11.e2
DDI-DrugBank.d212.s11	75	84	gabapentin	drug	DDI-DrugBank.d212.s11.e3
DDI-DrugBank.d212.s11	87	97	lamotrigine	drug	DDI-DrugBank.d212.s11.e4
DDI-DrugBank.d212.s11	100	112	phenobarbital	drug	DDI-DrugBank.d212.s11.e5
DDI-DrugBank.d212.s11	115	123	phenytoin	drug	DDI-DrugBank.d212.s11.e6
DDI-DrugBank.d212.s11	126	134	primidone	drug	DDI-DrugBank.d212.s11.e7
DDI-DrugBank.d212.s11	140	148	valproate	drug	DDI-DrugBank.d212.s11.e8
DDI-DrugBank.d212.s11	212	224	levetiracetam	drug	DDI-DrugBank.d212.s11.e9
DDI-DrugBank.d212.s11	false	DDI-DrugBank.d212.s11.e0	DDI-DrugBank.d212.s11.e1
DDI-DrugBank.d212.s11	false	DDI-DrugBank.d212.s11.e0	DDI-DrugBank.d212.s11.e2
DDI-DrugBank.d212.s11	false	DDI-DrugBank.d212.s11.e0	DDI-DrugBank.d212.s11.e3
DDI-DrugBank.d212.s11	false	DDI-DrugBank.d212.s11.e0	DDI-DrugBank.d212.s11.e4
DDI-DrugBank.d212.s11	false	DDI-DrugBank.d212.s11.e0	DDI-DrugBank.d212.s11.e5
DDI-DrugBank.d212.s11	false	DDI-DrugBank.d212.s11.e0	DDI-DrugBank.d212.s11.e6
DDI-DrugBank.d212.s11	false	DDI-DrugBank.d212.s11.e0	DDI-DrugBank.d212.s11.e7
DDI-DrugBank.d212.s11	false	DDI-DrugBank.d212.s11.e0	DDI-DrugBank.d212.s11.e8
DDI-DrugBank.d212.s11	false	DDI-DrugBank.d212.s11.e0	DDI-DrugBank.d212.s11.e9
DDI-DrugBank.d212.s11	false	DDI-DrugBank.d212.s11.e0	DDI-DrugBank.d212.s11.e10
DDI-DrugBank.d212.s12|a|These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.
DDI-DrugBank.d212.s12	25	37	levetiracetam	drug	DDI-DrugBank.d212.s12.e0
DDI-DrugBank.d212.s12	92	95	AEDs	group	DDI-DrugBank.d212.s12.e1
DDI-DrugBank.d212.s12	112	115	AEDs	group	DDI-DrugBank.d212.s12.e2
DDI-DrugBank.d212.s12	158	170	levetiracetam	drug	DDI-DrugBank.d212.s12.e3
DDI-DrugBank.d212.s12	false	DDI-DrugBank.d212.s12.e0	DDI-DrugBank.d212.s12.e1
DDI-DrugBank.d212.s12	false	DDI-DrugBank.d212.s12.e0	DDI-DrugBank.d212.s12.e2
DDI-DrugBank.d212.s12	false	DDI-DrugBank.d212.s12.e0	DDI-DrugBank.d212.s12.e3
DDI-DrugBank.d212.s12	false	DDI-DrugBank.d212.s12.e1	DDI-DrugBank.d212.s12.e2
DDI-DrugBank.d212.s12	false	DDI-DrugBank.d212.s12.e1	DDI-DrugBank.d212.s12.e3
DDI-DrugBank.d212.s12	false	DDI-DrugBank.d212.s12.e2	DDI-DrugBank.d212.s12.e3
DDI-DrugBank.d212.s13|a|Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.
DDI-DrugBank.d212.s13	10	13	AEDs	group	DDI-DrugBank.d212.s13.e0
DDI-DrugBank.d212.s13	104	116	levetiracetam	drug	DDI-DrugBank.d212.s13.e1
DDI-DrugBank.d212.s13	167	170	AEDs	group	DDI-DrugBank.d212.s13.e2
DDI-DrugBank.d212.s13	false	DDI-DrugBank.d212.s13.e0	DDI-DrugBank.d212.s13.e1
DDI-DrugBank.d212.s13	false	DDI-DrugBank.d212.s13.e0	DDI-DrugBank.d212.s13.e2
DDI-DrugBank.d212.s13	true	DDI-DrugBank.d212.s13.e1	DDI-DrugBank.d212.s13.e2
DDI-DrugBank.d212.s14|a|Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.
DDI-DrugBank.d212.s14	35	47	Levetiracetam	drug	DDI-DrugBank.d212.s14.e0
DDI-DrugBank.d212.s14	91	103	carbamazepine	drug	DDI-DrugBank.d212.s14.e1
DDI-DrugBank.d212.s14	106	114	valproate	drug	DDI-DrugBank.d212.s14.e2
DDI-DrugBank.d212.s14	117	126	topiramate	drug	DDI-DrugBank.d212.s14.e3
DDI-DrugBank.d212.s14	132	142	lamotrigine	drug	DDI-DrugBank.d212.s14.e4
DDI-DrugBank.d212.s14	false	DDI-DrugBank.d212.s14.e0	DDI-DrugBank.d212.s14.e1
DDI-DrugBank.d212.s14	false	DDI-DrugBank.d212.s14.e0	DDI-DrugBank.d212.s14.e2
DDI-DrugBank.d212.s14	false	DDI-DrugBank.d212.s14.e0	DDI-DrugBank.d212.s14.e3
DDI-DrugBank.d212.s14	false	DDI-DrugBank.d212.s14.e0	DDI-DrugBank.d212.s14.e4
DDI-DrugBank.d212.s14	false	DDI-DrugBank.d212.s14.e1	DDI-DrugBank.d212.s14.e2
DDI-DrugBank.d212.s14	false	DDI-DrugBank.d212.s14.e1	DDI-DrugBank.d212.s14.e3
DDI-DrugBank.d212.s14	false	DDI-DrugBank.d212.s14.e1	DDI-DrugBank.d212.s14.e4
DDI-DrugBank.d212.s14	false	DDI-DrugBank.d212.s14.e2	DDI-DrugBank.d212.s14.e3
DDI-DrugBank.d212.s14	false	DDI-DrugBank.d212.s14.e2	DDI-DrugBank.d212.s14.e4
DDI-DrugBank.d212.s14	false	DDI-DrugBank.d212.s14.e3	DDI-DrugBank.d212.s14.e4
DDI-DrugBank.d212.s15|a|Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.
DDI-DrugBank.d212.s15	29	42	Contraceptives	group	DDI-DrugBank.d212.s15.e0
DDI-DrugBank.d212.s15	44	49	Keppra	brand	DDI-DrugBank.d212.s15.e1
DDI-DrugBank.d212.s15	123	135	contraceptive	group	DDI-DrugBank.d212.s15.e2
DDI-DrugBank.d212.s15	156	172	ethinyl estradiol	drug	DDI-DrugBank.d212.s15.e3
DDI-DrugBank.d212.s15	186	199	levonorgestrel	drug	DDI-DrugBank.d212.s15.e4
DDI-DrugBank.d212.s15	false	DDI-DrugBank.d212.s15.e0	DDI-DrugBank.d212.s15.e1
DDI-DrugBank.d212.s15	false	DDI-DrugBank.d212.s15.e0	DDI-DrugBank.d212.s15.e2
DDI-DrugBank.d212.s15	false	DDI-DrugBank.d212.s15.e0	DDI-DrugBank.d212.s15.e3
DDI-DrugBank.d212.s15	false	DDI-DrugBank.d212.s15.e0	DDI-DrugBank.d212.s15.e4
DDI-DrugBank.d212.s15	false	DDI-DrugBank.d212.s15.e1	DDI-DrugBank.d212.s15.e2
DDI-DrugBank.d212.s15	false	DDI-DrugBank.d212.s15.e1	DDI-DrugBank.d212.s15.e3
DDI-DrugBank.d212.s15	false	DDI-DrugBank.d212.s15.e1	DDI-DrugBank.d212.s15.e4
DDI-DrugBank.d212.s15	false	DDI-DrugBank.d212.s15.e2	DDI-DrugBank.d212.s15.e3
DDI-DrugBank.d212.s15	false	DDI-DrugBank.d212.s15.e2	DDI-DrugBank.d212.s15.e4
DDI-DrugBank.d212.s15	false	DDI-DrugBank.d212.s15.e3	DDI-DrugBank.d212.s15.e4
DDI-DrugBank.d212.s16|a|Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam.
DDI-DrugBank.d212.s16	30	42	contraceptive	group	DDI-DrugBank.d212.s16.e0
DDI-DrugBank.d212.s16	86	98	levetiracetam	drug	DDI-DrugBank.d212.s16.e1
DDI-DrugBank.d212.s16	false	DDI-DrugBank.d212.s16.e0	DDI-DrugBank.d212.s16.e1
DDI-DrugBank.d212.s17|a|Digoxin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day.
DDI-DrugBank.d212.s17	0	6	Digoxin	drug	DDI-DrugBank.d212.s17.e0
DDI-DrugBank.d212.s17	8	13	Keppra	brand	DDI-DrugBank.d212.s17.e1
DDI-DrugBank.d212.s17	107	113	digoxin	drug	DDI-DrugBank.d212.s17.e2
DDI-DrugBank.d212.s17	false	DDI-DrugBank.d212.s17.e0	DDI-DrugBank.d212.s17.e1
DDI-DrugBank.d212.s17	false	DDI-DrugBank.d212.s17.e0	DDI-DrugBank.d212.s17.e2
DDI-DrugBank.d212.s17	false	DDI-DrugBank.d212.s17.e1	DDI-DrugBank.d212.s17.e2
DDI-DrugBank.d212.s18|a|Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.
DDI-DrugBank.d212.s18	20	26	digoxin	drug	DDI-DrugBank.d212.s18.e0
DDI-DrugBank.d212.s18	70	82	levetiracetam	drug	DDI-DrugBank.d212.s18.e1
DDI-DrugBank.d212.s18	false	DDI-DrugBank.d212.s18.e0	DDI-DrugBank.d212.s18.e1
DDI-DrugBank.d212.s19|a|Warfarin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.
DDI-DrugBank.d212.s19	0	7	Warfarin	drug	DDI-DrugBank.d212.s19.e0
DDI-DrugBank.d212.s19	9	14	Keppra	brand	DDI-DrugBank.d212.s19.e1
DDI-DrugBank.d212.s19	81	98	R warfarin	drug	DDI-DrugBank.d212.s19.e2
DDI-DrugBank.d212.s19	89	96	R warfarin	drug	DDI-DrugBank.d212.s19.e2
DDI-DrugBank.d212.s19	87	96	S warfarin	drug	DDI-DrugBank.d212.s19.e3
DDI-DrugBank.d212.s19	false	DDI-DrugBank.d212.s19.e0	DDI-DrugBank.d212.s19.e1
DDI-DrugBank.d212.s19	false	DDI-DrugBank.d212.s19.e0	DDI-DrugBank.d212.s19.e2
DDI-DrugBank.d212.s19	false	DDI-DrugBank.d212.s19.e0	DDI-DrugBank.d212.s19.e3
DDI-DrugBank.d212.s19	false	DDI-DrugBank.d212.s19.e1	DDI-DrugBank.d212.s19.e2
DDI-DrugBank.d212.s19	false	DDI-DrugBank.d212.s19.e1	DDI-DrugBank.d212.s19.e3
DDI-DrugBank.d212.s19	false	DDI-DrugBank.d212.s19.e2	DDI-DrugBank.d212.s19.e3
DDI-DrugBank.d212.s20|a|Prothrombin time was not affected by levetiracetam.
DDI-DrugBank.d212.s20	37	49	levetiracetam	drug	DDI-DrugBank.d212.s20.e0
DDI-DrugBank.d212.s21|a|Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam.
DDI-DrugBank.d212.s21	20	27	warfarin	drug	DDI-DrugBank.d212.s21.e0
DDI-DrugBank.d212.s21	68	80	levetiracetam	drug	DDI-DrugBank.d212.s21.e1
DDI-DrugBank.d212.s21	false	DDI-DrugBank.d212.s21.e0	DDI-DrugBank.d212.s21.e1
DDI-DrugBank.d212.s22|a|Probenecid: Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.
DDI-DrugBank.d212.s22	0	9	Probenecid	drug	DDI-DrugBank.d212.s22.e0
DDI-DrugBank.d212.s22	12	21	Probenecid	drug	DDI-DrugBank.d212.s22.e1
DDI-DrugBank.d212.s22	156	168	levetiracetam	drug	DDI-DrugBank.d212.s22.e2
DDI-DrugBank.d212.s22	false	DDI-DrugBank.d212.s22.e0	DDI-DrugBank.d212.s22.e1
DDI-DrugBank.d212.s22	false	DDI-DrugBank.d212.s22.e0	DDI-DrugBank.d212.s22.e2
DDI-DrugBank.d212.s22	false	DDI-DrugBank.d212.s22.e1	DDI-DrugBank.d212.s22.e2
DDI-DrugBank.d212.s23|a|Cssmax of the metabolite, ucb L057, was approximately doubled in the presence of probenecid while the fraction of drug excreted unchanged in the urine remained the same.
DDI-DrugBank.d212.s23	81	90	probenecid	drug	DDI-DrugBank.d212.s23.e0
DDI-DrugBank.d212.s24|a|Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057.
DDI-DrugBank.d212.s24	47	56	probenecid	drug	DDI-DrugBank.d212.s24.e0
DDI-DrugBank.d212.s25|a|The effect of Keppra  on probenecid was not studied.
DDI-DrugBank.d212.s25	14	19	Keppra	brand	DDI-DrugBank.d212.s25.e0
DDI-DrugBank.d212.s25	25	34	probenecid	drug	DDI-DrugBank.d212.s25.e1
DDI-DrugBank.d212.s25	false	DDI-DrugBank.d212.s25.e0	DDI-DrugBank.d212.s25.e1
DDI-DrugBank.d252.s0|a|Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.
DDI-DrugBank.d252.s0	9	15	BETAGAN	brand	DDI-DrugBank.d252.s0.e0
DDI-DrugBank.d252.s0	117	123	BETAGAN	brand	DDI-DrugBank.d252.s0.e1
DDI-DrugBank.d252.s0	129	139	epinephrine	drug	DDI-DrugBank.d252.s0.e2
DDI-DrugBank.d252.s0	false	DDI-DrugBank.d252.s0.e0	DDI-DrugBank.d252.s0.e1
DDI-DrugBank.d252.s0	false	DDI-DrugBank.d252.s0.e0	DDI-DrugBank.d252.s0.e2
DDI-DrugBank.d252.s0	true	DDI-DrugBank.d252.s0.e1	DDI-DrugBank.d252.s0.e2
DDI-DrugBank.d252.s1|a|Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.
DDI-DrugBank.d252.s1	55	66	beta-blocker	group	DDI-DrugBank.d252.s1.e0
DDI-DrugBank.d252.s1	144	152	reserpine	drug	DDI-DrugBank.d252.s1.e1
DDI-DrugBank.d252.s1	true	DDI-DrugBank.d252.s1.e0	DDI-DrugBank.d252.s1.e1
DDI-DrugBank.d252.s2|a|Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.
DDI-DrugBank.d252.s2	19	49	beta-adrenergic blocking agents	group	DDI-DrugBank.d252.s2.e0
DDI-DrugBank.d252.s2	89	107	calcium antagonists	group	DDI-DrugBank.d252.s2.e1
DDI-DrugBank.d252.s2	true	DDI-DrugBank.d252.s2.e0	DDI-DrugBank.d252.s2.e1
DDI-DrugBank.d252.s3|a|In patients with impaired cardiac function, simultaneous use should be avoided altogether.
DDI-DrugBank.d252.s4|a|The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.
DDI-DrugBank.d252.s4	23	53	beta-adrenergic blocking agents	group	DDI-DrugBank.d252.s4.e0
DDI-DrugBank.d252.s4	60	68	digitalis	group	DDI-DrugBank.d252.s4.e1
DDI-DrugBank.d252.s4	74	91	calcium antagonist	group	DDI-DrugBank.d252.s4.e2
DDI-DrugBank.d252.s4	true	DDI-DrugBank.d252.s4.e0	DDI-DrugBank.d252.s4.e1
DDI-DrugBank.d252.s4	true	DDI-DrugBank.d252.s4.e0	DDI-DrugBank.d252.s4.e2
DDI-DrugBank.d252.s4	false	DDI-DrugBank.d252.s4.e1	DDI-DrugBank.d252.s4.e2
DDI-DrugBank.d252.s5|a|Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.
DDI-DrugBank.d252.s5	0	30	Phenothiazine-related compounds	group	DDI-DrugBank.d252.s5.e0
DDI-DrugBank.d252.s5	36	66	beta-adrenergic blocking agents	group	DDI-DrugBank.d252.s5.e1
DDI-DrugBank.d252.s5	true	DDI-DrugBank.d252.s5.e0	DDI-DrugBank.d252.s5.e1
DDI-DrugBank.d320.s0|a|Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.
DDI-DrugBank.d320.s0	0	9	Chirocaine	brand	DDI-DrugBank.d320.s0.e0
DDI-DrugBank.d320.s0	75	85	anesthetics	group	DDI-DrugBank.d320.s0.e1
DDI-DrugBank.d320.s0	true	DDI-DrugBank.d320.s0.e0	DDI-DrugBank.d320.s0.e1
DDI-DrugBank.d320.s1|a|In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.
DDI-DrugBank.d320.s1	86	100	levobupivacaine	drug	DDI-DrugBank.d320.s1.e0
DDI-DrugBank.d320.s1	105	128	desbutyl levobupivacaine	drug_n	DDI-DrugBank.d320.s1.e1
DDI-DrugBank.d320.s1	134	158	3-hydroxy levobupivacaine	drug_n	DDI-DrugBank.d320.s1.e2
DDI-DrugBank.d320.s1	false	DDI-DrugBank.d320.s1.e0	DDI-DrugBank.d320.s1.e1
DDI-DrugBank.d320.s1	false	DDI-DrugBank.d320.s1.e0	DDI-DrugBank.d320.s1.e2
DDI-DrugBank.d320.s1	false	DDI-DrugBank.d320.s1.e1	DDI-DrugBank.d320.s1.e2
DDI-DrugBank.d320.s2|a|Thus agents likely to be concomitantly administered with Chirocaine that are metabolized by this isoenzyme family may potentially interact with Chirocaine.
DDI-DrugBank.d320.s2	57	66	Chirocaine	brand	DDI-DrugBank.d320.s2.e0
DDI-DrugBank.d320.s2	144	153	Chirocaine	brand	DDI-DrugBank.d320.s2.e1
DDI-DrugBank.d320.s2	false	DDI-DrugBank.d320.s2.e0	DDI-DrugBank.d320.s2.e1
DDI-DrugBank.d320.s3|a|Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
DDI-DrugBank.d320.s3	86	100	levobupivacaine	drug	DDI-DrugBank.d320.s3.e0
DDI-DrugBank.d320.s3	156	164	phenytoin	drug	DDI-DrugBank.d320.s3.e1
DDI-DrugBank.d320.s3	167	179	phenobarbital	drug	DDI-DrugBank.d320.s3.e2
DDI-DrugBank.d320.s3	182	189	rifampin	drug	DDI-DrugBank.d320.s3.e3
DDI-DrugBank.d320.s3	237	248	ketoconazole	drug	DDI-DrugBank.d320.s3.e4
DDI-DrugBank.d320.s3	true	DDI-DrugBank.d320.s3.e0	DDI-DrugBank.d320.s3.e1
DDI-DrugBank.d320.s3	true	DDI-DrugBank.d320.s3.e0	DDI-DrugBank.d320.s3.e2
DDI-DrugBank.d320.s3	true	DDI-DrugBank.d320.s3.e0	DDI-DrugBank.d320.s3.e3
DDI-DrugBank.d320.s3	true	DDI-DrugBank.d320.s3.e0	DDI-DrugBank.d320.s3.e4
DDI-DrugBank.d320.s3	false	DDI-DrugBank.d320.s3.e1	DDI-DrugBank.d320.s3.e2
DDI-DrugBank.d320.s3	false	DDI-DrugBank.d320.s3.e1	DDI-DrugBank.d320.s3.e3
DDI-DrugBank.d320.s3	false	DDI-DrugBank.d320.s3.e1	DDI-DrugBank.d320.s3.e4
DDI-DrugBank.d320.s3	false	DDI-DrugBank.d320.s3.e2	DDI-DrugBank.d320.s3.e3
DDI-DrugBank.d320.s3	false	DDI-DrugBank.d320.s3.e2	DDI-DrugBank.d320.s3.e4
DDI-DrugBank.d320.s3	false	DDI-DrugBank.d320.s3.e3	DDI-DrugBank.d320.s3.e4
DDI-DrugBank.d320.s4|a|certain protease inhibitors e.g., ritanovir;
DDI-DrugBank.d320.s4	8	26	protease inhibitors	group	DDI-DrugBank.d320.s4.e0
DDI-DrugBank.d320.s5|a|macrolide antibiotics e.g., erythromycin;
DDI-DrugBank.d320.s5	0	20	macrolide antibiotics	group	DDI-DrugBank.d320.s5.e0
DDI-DrugBank.d320.s5	28	39	erythromycin	drug	DDI-DrugBank.d320.s5.e1
DDI-DrugBank.d320.s5	false	DDI-DrugBank.d320.s5.e0	DDI-DrugBank.d320.s5.e1
DDI-DrugBank.d320.s6|a|and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).
DDI-DrugBank.d320.s6	4	30	calcium channel antagonists	group	DDI-DrugBank.d320.s6.e0
DDI-DrugBank.d320.s6	38	46	verapamil	drug	DDI-DrugBank.d320.s6.e1
DDI-DrugBank.d320.s6	67	76	omeprazole	drug	DDI-DrugBank.d320.s6.e2
DDI-DrugBank.d320.s6	102	112	furafylline	drug	DDI-DrugBank.d320.s6.e3
DDI-DrugBank.d320.s6	118	131	clarithromycin	drug	DDI-DrugBank.d320.s6.e4
DDI-DrugBank.d320.s6	false	DDI-DrugBank.d320.s6.e0	DDI-DrugBank.d320.s6.e1
DDI-DrugBank.d320.s6	false	DDI-DrugBank.d320.s6.e0	DDI-DrugBank.d320.s6.e2
DDI-DrugBank.d320.s6	false	DDI-DrugBank.d320.s6.e0	DDI-DrugBank.d320.s6.e3
DDI-DrugBank.d320.s6	false	DDI-DrugBank.d320.s6.e0	DDI-DrugBank.d320.s6.e4
DDI-DrugBank.d320.s6	false	DDI-DrugBank.d320.s6.e1	DDI-DrugBank.d320.s6.e2
DDI-DrugBank.d320.s6	false	DDI-DrugBank.d320.s6.e1	DDI-DrugBank.d320.s6.e3
DDI-DrugBank.d320.s6	false	DDI-DrugBank.d320.s6.e1	DDI-DrugBank.d320.s6.e4
DDI-DrugBank.d320.s6	false	DDI-DrugBank.d320.s6.e2	DDI-DrugBank.d320.s6.e3
DDI-DrugBank.d320.s6	false	DDI-DrugBank.d320.s6.e2	DDI-DrugBank.d320.s6.e4
DDI-DrugBank.d320.s6	false	DDI-DrugBank.d320.s6.e3	DDI-DrugBank.d320.s6.e4
DDI-DrugBank.d320.s7|a|Dosage adjustment may be warranted when levobupivacaine is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic levobupivacaine levels may rise resulting in toxicity.
DDI-DrugBank.d320.s7	40	54	levobupivacaine	drug	DDI-DrugBank.d320.s7.e0
DDI-DrugBank.d320.s7	142	156	levobupivacaine	drug	DDI-DrugBank.d320.s7.e1
DDI-DrugBank.d320.s7	false	DDI-DrugBank.d320.s7.e0	DDI-DrugBank.d320.s7.e1
DDI-DrugBank.d242.s0|a|Specific drug interaction studies have not been conducted with Levofloxacin.
DDI-DrugBank.d242.s0	63	74	Levofloxacin	drug	DDI-DrugBank.d242.s0.e0
DDI-DrugBank.d242.s1|a|However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
DDI-DrugBank.d242.s1	45	54	quinolones	group	DDI-DrugBank.d242.s1.e0
DDI-DrugBank.d242.s1	107	118	theophylline	drug	DDI-DrugBank.d242.s1.e1
DDI-DrugBank.d242.s1	154	161	caffeine	drug	DDI-DrugBank.d242.s1.e2
DDI-DrugBank.d242.s1	200	212	anticoagulant	group	DDI-DrugBank.d242.s1.e3
DDI-DrugBank.d242.s1	214	221	warfarin	drug	DDI-DrugBank.d242.s1.e4
DDI-DrugBank.d242.s1	345	356	cyclosporine	drug	DDI-DrugBank.d242.s1.e5
DDI-DrugBank.d242.s1	true	DDI-DrugBank.d242.s1.e0	DDI-DrugBank.d242.s1.e1
DDI-DrugBank.d242.s1	true	DDI-DrugBank.d242.s1.e0	DDI-DrugBank.d242.s1.e2
DDI-DrugBank.d242.s1	false	DDI-DrugBank.d242.s1.e0	DDI-DrugBank.d242.s1.e3
DDI-DrugBank.d242.s1	true	DDI-DrugBank.d242.s1.e0	DDI-DrugBank.d242.s1.e4
DDI-DrugBank.d242.s1	true	DDI-DrugBank.d242.s1.e0	DDI-DrugBank.d242.s1.e5
DDI-DrugBank.d242.s1	false	DDI-DrugBank.d242.s1.e1	DDI-DrugBank.d242.s1.e2
DDI-DrugBank.d242.s1	false	DDI-DrugBank.d242.s1.e1	DDI-DrugBank.d242.s1.e3
DDI-DrugBank.d242.s1	false	DDI-DrugBank.d242.s1.e1	DDI-DrugBank.d242.s1.e4
DDI-DrugBank.d242.s1	false	DDI-DrugBank.d242.s1.e1	DDI-DrugBank.d242.s1.e5
DDI-DrugBank.d242.s1	false	DDI-DrugBank.d242.s1.e2	DDI-DrugBank.d242.s1.e3
DDI-DrugBank.d257.s0|a|Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d257.s0	54	66	Levo-Dromoran	brand	DDI-DrugBank.d257.s0.e0
DDI-DrugBank.d257.s0	77	110	central nervous system depressants	group	DDI-DrugBank.d257.s0.e1
DDI-DrugBank.d257.s0	117	123	alcohol	drug	DDI-DrugBank.d257.s0.e2
DDI-DrugBank.d257.s0	126	134	sedatives	group	DDI-DrugBank.d257.s0.e3
DDI-DrugBank.d257.s0	137	145	hypnotics	group	DDI-DrugBank.d257.s0.e4
DDI-DrugBank.d257.s0	154	160	opioids	group	DDI-DrugBank.d257.s0.e5
DDI-DrugBank.d257.s0	171	181	anesthetics	group	DDI-DrugBank.d257.s0.e6
DDI-DrugBank.d257.s0	184	195	barbiturates	group	DDI-DrugBank.d257.s0.e7
DDI-DrugBank.d257.s0	198	222	tricyclic antidepressants	group	DDI-DrugBank.d257.s0.e8
DDI-DrugBank.d257.s0	225	238	phenothiazines	group	DDI-DrugBank.d257.s0.e9
DDI-DrugBank.d257.s0	true	DDI-DrugBank.d257.s0.e0	DDI-DrugBank.d257.s0.e1
DDI-DrugBank.d257.s0	true	DDI-DrugBank.d257.s0.e0	DDI-DrugBank.d257.s0.e2
DDI-DrugBank.d257.s0	true	DDI-DrugBank.d257.s0.e0	DDI-DrugBank.d257.s0.e3
DDI-DrugBank.d257.s0	true	DDI-DrugBank.d257.s0.e0	DDI-DrugBank.d257.s0.e4
DDI-DrugBank.d257.s0	true	DDI-DrugBank.d257.s0.e0	DDI-DrugBank.d257.s0.e5
DDI-DrugBank.d257.s0	true	DDI-DrugBank.d257.s0.e0	DDI-DrugBank.d257.s0.e6
DDI-DrugBank.d257.s0	true	DDI-DrugBank.d257.s0.e0	DDI-DrugBank.d257.s0.e7
DDI-DrugBank.d257.s0	true	DDI-DrugBank.d257.s0.e0	DDI-DrugBank.d257.s0.e8
DDI-DrugBank.d257.s0	true	DDI-DrugBank.d257.s0.e0	DDI-DrugBank.d257.s0.e9
DDI-DrugBank.d257.s0	true	DDI-DrugBank.d257.s0.e0	DDI-DrugBank.d257.s0.e10
DDI-DrugBank.d257.s1|a|Respiratory depression, hypotension, and profound sedation or coma may occur.
DDI-DrugBank.d257.s2|a|When such combined therapy is contemplated, the dose of one or both agents should be reduced.
DDI-DrugBank.d257.s3|a|Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.
DDI-DrugBank.d257.s3	32	45	MAO inhibitors	group	DDI-DrugBank.d257.s3.e0
DDI-DrugBank.d257.s3	51	63	Levo-Dromoran	brand	DDI-DrugBank.d257.s3.e1
DDI-DrugBank.d257.s3	119	132	MAO inhibitors	group	DDI-DrugBank.d257.s3.e2
DDI-DrugBank.d257.s3	false	DDI-DrugBank.d257.s3.e0	DDI-DrugBank.d257.s3.e1
DDI-DrugBank.d257.s3	false	DDI-DrugBank.d257.s3.e0	DDI-DrugBank.d257.s3.e2
DDI-DrugBank.d257.s3	true	DDI-DrugBank.d257.s3.e1	DDI-DrugBank.d257.s3.e2
DDI-DrugBank.d257.s4|a|Most cases of serious or fatal adverse events involving Levo-Dromoran reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of levorphanol with other drugs affecting respiration.
DDI-DrugBank.d257.s4	56	68	Levo-Dromoran	brand	DDI-DrugBank.d257.s4.e0
DDI-DrugBank.d257.s4	277	287	levorphanol	drug	DDI-DrugBank.d257.s4.e1
DDI-DrugBank.d257.s4	false	DDI-DrugBank.d257.s4.e0	DDI-DrugBank.d257.s4.e1
DDI-DrugBank.d257.s5|a|The initial dose of levorphanol should be reduced by approximately 50% or more when it is given to patients along with another drug affecting respiration.
DDI-DrugBank.d257.s5	20	30	levorphanol	drug	DDI-DrugBank.d257.s5.e0
DDI-DrugBank.d257.s6|a|Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DDI-DrugBank.d257.s6	18	59	Mixed Agonist/Antagonist Opioid Analgesics	group	DDI-DrugBank.d257.s6.e0
DDI-DrugBank.d257.s6	62	90	Agonist/antagonist analgesics	group	DDI-DrugBank.d257.s6.e1
DDI-DrugBank.d257.s6	97	107	pentazocine	drug	DDI-DrugBank.d257.s6.e2
DDI-DrugBank.d257.s6	110	119	nalbuphine	drug	DDI-DrugBank.d257.s6.e3
DDI-DrugBank.d257.s6	122	132	butorphanol	drug	DDI-DrugBank.d257.s6.e4
DDI-DrugBank.d257.s6	135	142	dezocine	drug	DDI-DrugBank.d257.s6.e5
DDI-DrugBank.d257.s6	148	160	buprenorphine	drug	DDI-DrugBank.d257.s6.e6
DDI-DrugBank.d257.s6	263	291	pure agonist opioid analgesic	group	DDI-DrugBank.d257.s6.e7
DDI-DrugBank.d257.s6	301	313	Levo-Dromoran	brand	DDI-DrugBank.d257.s6.e8
DDI-DrugBank.d257.s6	false	DDI-DrugBank.d257.s6.e0	DDI-DrugBank.d257.s6.e1
DDI-DrugBank.d257.s6	false	DDI-DrugBank.d257.s6.e0	DDI-DrugBank.d257.s6.e2
DDI-DrugBank.d257.s6	false	DDI-DrugBank.d257.s6.e0	DDI-DrugBank.d257.s6.e3
DDI-DrugBank.d257.s6	false	DDI-DrugBank.d257.s6.e0	DDI-DrugBank.d257.s6.e4
DDI-DrugBank.d257.s6	false	DDI-DrugBank.d257.s6.e0	DDI-DrugBank.d257.s6.e5
DDI-DrugBank.d257.s6	false	DDI-DrugBank.d257.s6.e0	DDI-DrugBank.d257.s6.e6
DDI-DrugBank.d257.s6	false	DDI-DrugBank.d257.s6.e0	DDI-DrugBank.d257.s6.e7
DDI-DrugBank.d257.s6	false	DDI-DrugBank.d257.s6.e0	DDI-DrugBank.d257.s6.e8
DDI-DrugBank.d257.s6	false	DDI-DrugBank.d257.s6.e1	DDI-DrugBank.d257.s6.e2
DDI-DrugBank.d257.s6	false	DDI-DrugBank.d257.s6.e1	DDI-DrugBank.d257.s6.e3
DDI-DrugBank.d257.s7|a|In opioid-dependent patients, mixed agonist/antagonist analgesics may precipitate withdrawal symptoms.
DDI-DrugBank.d257.s7	3	8	opioid	group	DDI-DrugBank.d257.s7.e0
DDI-DrugBank.d257.s7	30	64	mixed agonist/antagonist analgesics	group	DDI-DrugBank.d257.s7.e1
DDI-DrugBank.d257.s7	false	DDI-DrugBank.d257.s7.e0	DDI-DrugBank.d257.s7.e1
DDI-DrugBank.d189.s0|a|No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.
DDI-DrugBank.d189.s0	34	45	Levosimendan	drug	DDI-DrugBank.d189.s0.e0
DDI-DrugBank.d189.s0	116	124	captopril	drug	DDI-DrugBank.d189.s0.e1
DDI-DrugBank.d189.s0	127	139	beta-blockers	group	DDI-DrugBank.d189.s0.e2
DDI-DrugBank.d189.s0	142	151	felodipine	drug	DDI-DrugBank.d189.s0.e3
DDI-DrugBank.d189.s0	154	160	digoxin	drug	DDI-DrugBank.d189.s0.e4
DDI-DrugBank.d189.s0	163	170	warfarin	drug	DDI-DrugBank.d189.s0.e5
DDI-DrugBank.d189.s0	173	194	isosorbide mononitrate	drug	DDI-DrugBank.d189.s0.e6
DDI-DrugBank.d189.s0	197	206	carvedilol	drug	DDI-DrugBank.d189.s0.e7
DDI-DrugBank.d189.s0	209	215	ethanol	drug	DDI-DrugBank.d189.s0.e8
DDI-DrugBank.d189.s0	220	231	itraconazole	drug	DDI-DrugBank.d189.s0.e9
DDI-DrugBank.d189.s0	false	DDI-DrugBank.d189.s0.e0	DDI-DrugBank.d189.s0.e1
DDI-DrugBank.d189.s0	false	DDI-DrugBank.d189.s0.e0	DDI-DrugBank.d189.s0.e2
DDI-DrugBank.d189.s0	false	DDI-DrugBank.d189.s0.e0	DDI-DrugBank.d189.s0.e3
DDI-DrugBank.d189.s0	false	DDI-DrugBank.d189.s0.e0	DDI-DrugBank.d189.s0.e4
DDI-DrugBank.d189.s0	false	DDI-DrugBank.d189.s0.e0	DDI-DrugBank.d189.s0.e5
DDI-DrugBank.d189.s0	false	DDI-DrugBank.d189.s0.e0	DDI-DrugBank.d189.s0.e6
DDI-DrugBank.d189.s0	false	DDI-DrugBank.d189.s0.e0	DDI-DrugBank.d189.s0.e7
DDI-DrugBank.d189.s0	false	DDI-DrugBank.d189.s0.e0	DDI-DrugBank.d189.s0.e8
DDI-DrugBank.d189.s0	false	DDI-DrugBank.d189.s0.e0	DDI-DrugBank.d189.s0.e9
DDI-DrugBank.d189.s0	false	DDI-DrugBank.d189.s0.e1	DDI-DrugBank.d189.s0.e2
DDI-DrugBank.d411.s0|a|The magnitude and relative importance of the effects noted below are likely to be patient specific and may vary by such factors as age, gender, race, intercurrent illnesses, dose of either agent, additional concomitant medications, and timing of drug administration.
DDI-DrugBank.d411.s1|a|Any agent that alters thyroid hormone synthesis, secretion, distribution, effect on target tissues, metabolism, or elimination may alter the optimal therapeutic dose of levothyroxine sodium.
DDI-DrugBank.d411.s1	169	181	levothyroxine	drug	DDI-DrugBank.d411.s1.e0
DDI-DrugBank.d411.s2|a|Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
DDI-DrugBank.d411.s2	0	19	Levothyroxine Sodium	drug	DDI-DrugBank.d411.s2.e0
DDI-DrugBank.d411.s2	90	109	levothyroxine sodium	drug	DDI-DrugBank.d411.s2.e1
DDI-DrugBank.d411.s2	144	160	aluminum hydoxide	drug	DDI-DrugBank.d411.s2.e2
DDI-DrugBank.d411.s2	163	176	cholestyramine	drug	DDI-DrugBank.d411.s2.e3
DDI-DrugBank.d411.s2	185	208	colestipol hydrochloride	drug	DDI-DrugBank.d411.s2.e4
DDI-DrugBank.d411.s2	211	225	ferrous sulfate	drug	DDI-DrugBank.d411.s2.e5
DDI-DrugBank.d411.s2	228	255	sodium polystyrene sulfonate	drug	DDI-DrugBank.d411.s2.e6
DDI-DrugBank.d411.s2	296	305	sucralfate	drug	DDI-DrugBank.d411.s2.e7
DDI-DrugBank.d411.s2	false	DDI-DrugBank.d411.s2.e0	DDI-DrugBank.d411.s2.e1
DDI-DrugBank.d411.s2	false	DDI-DrugBank.d411.s2.e0	DDI-DrugBank.d411.s2.e2
DDI-DrugBank.d411.s2	false	DDI-DrugBank.d411.s2.e0	DDI-DrugBank.d411.s2.e3
DDI-DrugBank.d411.s2	false	DDI-DrugBank.d411.s2.e0	DDI-DrugBank.d411.s2.e4
DDI-DrugBank.d411.s2	false	DDI-DrugBank.d411.s2.e0	DDI-DrugBank.d411.s2.e5
DDI-DrugBank.d411.s2	false	DDI-DrugBank.d411.s2.e0	DDI-DrugBank.d411.s2.e6
DDI-DrugBank.d411.s2	false	DDI-DrugBank.d411.s2.e0	DDI-DrugBank.d411.s2.e7
DDI-DrugBank.d411.s2	true	DDI-DrugBank.d411.s2.e1	DDI-DrugBank.d411.s2.e2
DDI-DrugBank.d411.s2	true	DDI-DrugBank.d411.s2.e1	DDI-DrugBank.d411.s2.e3
DDI-DrugBank.d411.s2	true	DDI-DrugBank.d411.s2.e1	DDI-DrugBank.d411.s2.e4
DDI-DrugBank.d411.s3|a|Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d411.s3	67	86	levothyroxine sodium	drug	DDI-DrugBank.d411.s3.e0
DDI-DrugBank.d411.s3	169	177	androgens	group	DDI-DrugBank.d411.s3.e1
DDI-DrugBank.d411.s3	191	207	anabolic hormones	group	DDI-DrugBank.d411.s3.e2
DDI-DrugBank.d411.s3	210	221	asparaginase	drug	DDI-DrugBank.d411.s3.e3
DDI-DrugBank.d411.s3	224	233	clofibrate	drug	DDI-DrugBank.d411.s3.e4
DDI-DrugBank.d411.s3	236	244	estrogens	group	DDI-DrugBank.d411.s3.e5
DDI-DrugBank.d411.s3	250	278	estrogen-containing compounds	group	DDI-DrugBank.d411.s3.e6
DDI-DrugBank.d411.s3	281	294	5-fluorouracil	drug	DDI-DrugBank.d411.s3.e7
DDI-DrugBank.d411.s3	297	306	furosemide	drug	DDI-DrugBank.d411.s3.e8
DDI-DrugBank.d411.s3	309	323	glucocorticoids	group	DDI-DrugBank.d411.s3.e9
DDI-DrugBank.d411.s3	true	DDI-DrugBank.d411.s3.e0	DDI-DrugBank.d411.s3.e1
DDI-DrugBank.d411.s3	true	DDI-DrugBank.d411.s3.e0	DDI-DrugBank.d411.s3.e2
DDI-DrugBank.d411.s3	true	DDI-DrugBank.d411.s3.e0	DDI-DrugBank.d411.s3.e3
DDI-DrugBank.d411.s3	true	DDI-DrugBank.d411.s3.e0	DDI-DrugBank.d411.s3.e4
DDI-DrugBank.d411.s3	true	DDI-DrugBank.d411.s3.e0	DDI-DrugBank.d411.s3.e5
DDI-DrugBank.d411.s3	true	DDI-DrugBank.d411.s3.e0	DDI-DrugBank.d411.s3.e6
DDI-DrugBank.d411.s3	true	DDI-DrugBank.d411.s3.e0	DDI-DrugBank.d411.s3.e7
DDI-DrugBank.d411.s3	true	DDI-DrugBank.d411.s3.e0	DDI-DrugBank.d411.s3.e8
DDI-DrugBank.d411.s3	true	DDI-DrugBank.d411.s3.e0	DDI-DrugBank.d411.s3.e9
DDI-DrugBank.d411.s3	true	DDI-DrugBank.d411.s3.e0	DDI-DrugBank.d411.s3.e10
DDI-DrugBank.d411.s4|a|Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
DDI-DrugBank.d411.s4	228	244	aminoglutethimide	drug	DDI-DrugBank.d411.s4.e0
DDI-DrugBank.d411.s4	247	267	p-aminosalicylic acid	drug	DDI-DrugBank.d411.s4.e1
DDI-DrugBank.d411.s4	270	279	amiodarone	drug	DDI-DrugBank.d411.s4.e2
DDI-DrugBank.d411.s4	282	290	androgens	group	DDI-DrugBank.d411.s4.e3
DDI-DrugBank.d411.s4	339	349	thiocyanate	drug	DDI-DrugBank.d411.s4.e4
DDI-DrugBank.d411.s4	352	362	perchlorate	drug	DDI-DrugBank.d411.s4.e5
DDI-DrugBank.d411.s4	365	377	pertechnetate	drug	DDI-DrugBank.d411.s4.e6
DDI-DrugBank.d411.s4	381	397	antithyroid drugs	group	DDI-DrugBank.d411.s4.e7
DDI-DrugBank.d411.s4	400	427	b-adrenergic blocking agents	group	DDI-DrugBank.d411.s4.e8
DDI-DrugBank.d411.s4	430	442	carbamazepine	drug	DDI-DrugBank.d411.s4.e9
DDI-DrugBank.d411.s4	false	DDI-DrugBank.d411.s4.e0	DDI-DrugBank.d411.s4.e1
DDI-DrugBank.d411.s4	false	DDI-DrugBank.d411.s4.e0	DDI-DrugBank.d411.s4.e2
DDI-DrugBank.d411.s4	false	DDI-DrugBank.d411.s4.e0	DDI-DrugBank.d411.s4.e3
DDI-DrugBank.d411.s4	false	DDI-DrugBank.d411.s4.e0	DDI-DrugBank.d411.s4.e4
DDI-DrugBank.d411.s4	false	DDI-DrugBank.d411.s4.e0	DDI-DrugBank.d411.s4.e5
DDI-DrugBank.d411.s4	false	DDI-DrugBank.d411.s4.e0	DDI-DrugBank.d411.s4.e6
DDI-DrugBank.d411.s4	false	DDI-DrugBank.d411.s4.e0	DDI-DrugBank.d411.s4.e7
DDI-DrugBank.d411.s4	false	DDI-DrugBank.d411.s4.e0	DDI-DrugBank.d411.s4.e8
DDI-DrugBank.d411.s4	false	DDI-DrugBank.d411.s4.e0	DDI-DrugBank.d411.s4.e9
DDI-DrugBank.d411.s4	false	DDI-DrugBank.d411.s4.e0	DDI-DrugBank.d411.s4.e10
DDI-DrugBank.d411.s5|a|Adrenocorticoids: Metabolic clearance of adrenocorticoids is decreased in hypothyroid patients and increased in hyperthyroid patients, and may therefore change with changing thyroid status.
DDI-DrugBank.d411.s6|a|Amiodarone: Amiodarone therapy alone can cause hypothyroidism or hyperthyroidism.
DDI-DrugBank.d411.s6	0	9	Amiodarone	drug	DDI-DrugBank.d411.s6.e0
DDI-DrugBank.d411.s6	12	21	Amiodarone	drug	DDI-DrugBank.d411.s6.e1
DDI-DrugBank.d411.s6	false	DDI-DrugBank.d411.s6.e0	DDI-DrugBank.d411.s6.e1
DDI-DrugBank.d411.s7|a|Anticoagulants (Oral): The hypoprothrombinemic effect of anticoagulants may be potentiated, apparently by increased catabloism of vitamin K-dependent clotting factors.
DDI-DrugBank.d411.s7	0	13	Anticoagulants	group	DDI-DrugBank.d411.s7.e0
DDI-DrugBank.d411.s7	57	70	anticoagulants	group	DDI-DrugBank.d411.s7.e1
DDI-DrugBank.d411.s7	false	DDI-DrugBank.d411.s7.e0	DDI-DrugBank.d411.s7.e1
DDI-DrugBank.d411.s8|a|Antidiabetic Agents (Insulin, Sulfonylureas): Requirements for insulin or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
DDI-DrugBank.d411.s8	0	18	Antidiabetic Agents	group	DDI-DrugBank.d411.s8.e0
DDI-DrugBank.d411.s8	21	27	Insulin	drug	DDI-DrugBank.d411.s8.e1
DDI-DrugBank.d411.s8	30	42	Sulfonylureas	group	DDI-DrugBank.d411.s8.e2
DDI-DrugBank.d411.s8	63	69	insulin	drug	DDI-DrugBank.d411.s8.e3
DDI-DrugBank.d411.s8	79	97	antidiabetic agents	group	DDI-DrugBank.d411.s8.e4
DDI-DrugBank.d411.s8	false	DDI-DrugBank.d411.s8.e0	DDI-DrugBank.d411.s8.e1
DDI-DrugBank.d411.s8	false	DDI-DrugBank.d411.s8.e0	DDI-DrugBank.d411.s8.e2
DDI-DrugBank.d411.s8	false	DDI-DrugBank.d411.s8.e0	DDI-DrugBank.d411.s8.e3
DDI-DrugBank.d411.s8	false	DDI-DrugBank.d411.s8.e0	DDI-DrugBank.d411.s8.e4
DDI-DrugBank.d411.s8	false	DDI-DrugBank.d411.s8.e1	DDI-DrugBank.d411.s8.e2
DDI-DrugBank.d411.s8	false	DDI-DrugBank.d411.s8.e1	DDI-DrugBank.d411.s8.e3
DDI-DrugBank.d411.s8	false	DDI-DrugBank.d411.s8.e1	DDI-DrugBank.d411.s8.e4
DDI-DrugBank.d411.s8	false	DDI-DrugBank.d411.s8.e2	DDI-DrugBank.d411.s8.e3
DDI-DrugBank.d411.s8	false	DDI-DrugBank.d411.s8.e2	DDI-DrugBank.d411.s8.e4
DDI-DrugBank.d411.s8	false	DDI-DrugBank.d411.s8.e3	DDI-DrugBank.d411.s8.e4
DDI-DrugBank.d411.s9|a|b-Adrenergic Blocking Agents: Actions of some of beta-blocking agents may be impaired when hypothyroid patients become euthyroid.
DDI-DrugBank.d411.s9	0	27	b-Adrenergic Blocking Agents	group	DDI-DrugBank.d411.s9.e0
DDI-DrugBank.d411.s9	49	68	beta-blocking agents	group	DDI-DrugBank.d411.s9.e1
DDI-DrugBank.d411.s9	false	DDI-DrugBank.d411.s9.e0	DDI-DrugBank.d411.s9.e1
DDI-DrugBank.d411.s10|a|Cytokines (interferon, interleukin): Cytokines have been reported to induce both hyperthyroidism and hypothyroidism.
DDI-DrugBank.d411.s10	0	8	Cytokines	group	DDI-DrugBank.d411.s10.e0
DDI-DrugBank.d411.s10	11	20	interferon	group	DDI-DrugBank.d411.s10.e1
DDI-DrugBank.d411.s10	23	33	interleukin	group	DDI-DrugBank.d411.s10.e2
DDI-DrugBank.d411.s10	37	45	Cytokines	group	DDI-DrugBank.d411.s10.e3
DDI-DrugBank.d411.s10	false	DDI-DrugBank.d411.s10.e0	DDI-DrugBank.d411.s10.e1
DDI-DrugBank.d411.s10	false	DDI-DrugBank.d411.s10.e0	DDI-DrugBank.d411.s10.e2
DDI-DrugBank.d411.s10	false	DDI-DrugBank.d411.s10.e0	DDI-DrugBank.d411.s10.e3
DDI-DrugBank.d411.s10	false	DDI-DrugBank.d411.s10.e1	DDI-DrugBank.d411.s10.e2
DDI-DrugBank.d411.s10	false	DDI-DrugBank.d411.s10.e1	DDI-DrugBank.d411.s10.e3
DDI-DrugBank.d411.s10	false	DDI-DrugBank.d411.s10.e2	DDI-DrugBank.d411.s10.e3
DDI-DrugBank.d411.s11|a|Digitalis Glycosides: Therapeutic effects of digitalis glycosides may be reduced.
DDI-DrugBank.d411.s11	0	19	Digitalis Glycosides	group	DDI-DrugBank.d411.s11.e0
DDI-DrugBank.d411.s11	45	64	digitalis glycosides	group	DDI-DrugBank.d411.s11.e1
DDI-DrugBank.d411.s11	false	DDI-DrugBank.d411.s11.e0	DDI-DrugBank.d411.s11.e1
DDI-DrugBank.d411.s12|a|Serum digitalis levels may be decreased in hyperthyroidism or when a hypothyroid patient becomes euthyroid.
DDI-DrugBank.d411.s12	6	14	digitalis	group	DDI-DrugBank.d411.s12.e0
DDI-DrugBank.d411.s13|a|Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.
DDI-DrugBank.d411.s13	0	7	Ketamine	drug	DDI-DrugBank.d411.s13.e0
DDI-DrugBank.d411.s13	115	134	levothyroxine sodium	drug	DDI-DrugBank.d411.s13.e1
DDI-DrugBank.d411.s13	140	147	ketamine	drug	DDI-DrugBank.d411.s13.e2
DDI-DrugBank.d411.s13	false	DDI-DrugBank.d411.s13.e0	DDI-DrugBank.d411.s13.e1
DDI-DrugBank.d411.s13	false	DDI-DrugBank.d411.s13.e0	DDI-DrugBank.d411.s13.e2
DDI-DrugBank.d411.s13	true	DDI-DrugBank.d411.s13.e1	DDI-DrugBank.d411.s13.e2
DDI-DrugBank.d411.s14|a|Maprotiline: Risk of cardiac arrhythmias may increase.
DDI-DrugBank.d411.s14	0	10	Maprotiline	drug	DDI-DrugBank.d411.s14.e0
DDI-DrugBank.d411.s15|a|Sodium Iodide (123I and 131I), Sodium Pertechnetate Tc99m: Uptake of radiolabeled ions may be decreased.
DDI-DrugBank.d411.s15	0	12	Sodium Iodide	drug	DDI-DrugBank.d411.s15.e0
DDI-DrugBank.d411.s15	31	56	Sodium Pertechnetate Tc99m	drug	DDI-DrugBank.d411.s15.e1
DDI-DrugBank.d411.s15	false	DDI-DrugBank.d411.s15.e0	DDI-DrugBank.d411.s15.e1
DDI-DrugBank.d411.s16|a|Somatrem/Somatropin: Excessive concurrent use of thyroid hormone may accelerate epiphyseal closure.
DDI-DrugBank.d411.s16	0	7	Somatrem	drug	DDI-DrugBank.d411.s16.e0
DDI-DrugBank.d411.s16	9	18	Somatropin	drug	DDI-DrugBank.d411.s16.e1
DDI-DrugBank.d411.s16	49	63	thyroid hormone	group	DDI-DrugBank.d411.s16.e2
DDI-DrugBank.d411.s16	false	DDI-DrugBank.d411.s16.e0	DDI-DrugBank.d411.s16.e1
DDI-DrugBank.d411.s16	false	DDI-DrugBank.d411.s16.e0	DDI-DrugBank.d411.s16.e2
DDI-DrugBank.d411.s16	false	DDI-DrugBank.d411.s16.e1	DDI-DrugBank.d411.s16.e2
DDI-DrugBank.d411.s17|a|Untreated hypothyroidism may interfere with the growth response to somatrem or somatropin.
DDI-DrugBank.d411.s17	67	74	somatrem	drug	DDI-DrugBank.d411.s17.e0
DDI-DrugBank.d411.s17	79	88	somatropin	drug	DDI-DrugBank.d411.s17.e1
DDI-DrugBank.d411.s17	false	DDI-DrugBank.d411.s17.e0	DDI-DrugBank.d411.s17.e1
DDI-DrugBank.d411.s18|a|Theophylline: Theophylline clearance may decrease in hypothyroid patients and return toward normal when a euthyroid state is achieved.
DDI-DrugBank.d411.s18	0	11	Theophylline	drug	DDI-DrugBank.d411.s18.e0
DDI-DrugBank.d411.s18	14	25	Theophylline	drug	DDI-DrugBank.d411.s18.e1
DDI-DrugBank.d411.s18	false	DDI-DrugBank.d411.s18.e0	DDI-DrugBank.d411.s18.e1
DDI-DrugBank.d411.s19|a|Tricyclic Antidepressants: Concurrent use may increase the therapeutic and toxic effects of both drugs, possibly due to increased catecholamine sensitivity.
DDI-DrugBank.d411.s19	0	24	Tricyclic Antidepressants	group	DDI-DrugBank.d411.s19.e0
DDI-DrugBank.d411.s20|a|Onset of action of tricyclics may be accelerated.
DDI-DrugBank.d411.s20	19	28	tricyclics	group	DDI-DrugBank.d411.s20.e0
DDI-DrugBank.d411.s21|a|Sympathomimetic Agents: Possible increased risk of coronary insufficiency in patients with coronary artery disease.
DDI-DrugBank.d411.s21	0	21	Sympathomimetic Agents	group	DDI-DrugBank.d411.s21.e0
DDI-DrugBank.d564.s0|a|The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
DDI-DrugBank.d564.s0	28	47	anesthetic solutions	group	DDI-DrugBank.d564.s0.e0
DDI-DrugBank.d564.s0	60	70	epinephrine	drug	DDI-DrugBank.d564.s0.e1
DDI-DrugBank.d564.s0	75	88	norepinephrine	drug	DDI-DrugBank.d564.s0.e2
DDI-DrugBank.d564.s0	112	139	monoamine oxidase inhibitors	group	DDI-DrugBank.d564.s0.e3
DDI-DrugBank.d564.s0	144	168	tricyclic antidepressants	group	DDI-DrugBank.d564.s0.e4
DDI-DrugBank.d564.s0	false	DDI-DrugBank.d564.s0.e0	DDI-DrugBank.d564.s0.e1
DDI-DrugBank.d564.s0	false	DDI-DrugBank.d564.s0.e0	DDI-DrugBank.d564.s0.e2
DDI-DrugBank.d564.s0	false	DDI-DrugBank.d564.s0.e0	DDI-DrugBank.d564.s0.e3
DDI-DrugBank.d564.s0	false	DDI-DrugBank.d564.s0.e0	DDI-DrugBank.d564.s0.e4
DDI-DrugBank.d564.s0	false	DDI-DrugBank.d564.s0.e1	DDI-DrugBank.d564.s0.e2
DDI-DrugBank.d564.s0	true	DDI-DrugBank.d564.s0.e1	DDI-DrugBank.d564.s0.e3
DDI-DrugBank.d564.s0	true	DDI-DrugBank.d564.s0.e1	DDI-DrugBank.d564.s0.e4
DDI-DrugBank.d564.s0	true	DDI-DrugBank.d564.s0.e2	DDI-DrugBank.d564.s0.e3
DDI-DrugBank.d564.s0	true	DDI-DrugBank.d564.s0.e2	DDI-DrugBank.d564.s0.e4
DDI-DrugBank.d564.s0	false	DDI-DrugBank.d564.s0.e3	DDI-DrugBank.d564.s0.e4
DDI-DrugBank.d564.s1|a|Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
DDI-DrugBank.d564.s1	0	13	Phenothiazines	group	DDI-DrugBank.d564.s1.e0
DDI-DrugBank.d564.s1	19	32	butyrophenones	group	DDI-DrugBank.d564.s1.e1
DDI-DrugBank.d564.s1	78	88	epinephrine	drug	DDI-DrugBank.d564.s1.e2
DDI-DrugBank.d564.s1	false	DDI-DrugBank.d564.s1.e0	DDI-DrugBank.d564.s1.e1
DDI-DrugBank.d564.s1	true	DDI-DrugBank.d564.s1.e0	DDI-DrugBank.d564.s1.e2
DDI-DrugBank.d564.s1	true	DDI-DrugBank.d564.s1.e1	DDI-DrugBank.d564.s1.e2
DDI-DrugBank.d564.s2|a|Concurrent use of these agents should generally be avoided.
DDI-DrugBank.d564.s3|a|In situations when concurrent therapy is necessary, careful patient monitoring is essential.
DDI-DrugBank.d564.s4|a|Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
DDI-DrugBank.d564.s4	29	45	vasopressor drugs	group	DDI-DrugBank.d564.s4.e0
DDI-DrugBank.d564.s4	114	138	ergot-type oxytocic drugs	group	DDI-DrugBank.d564.s4.e1
DDI-DrugBank.d564.s4	false	DDI-DrugBank.d564.s4.e0	DDI-DrugBank.d564.s4.e1
DDI-DrugBank.d130.s0|a|Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
DDI-DrugBank.d130.s0	0	9	Lincomycin	drug	DDI-DrugBank.d130.s0.e0
DDI-DrugBank.d130.s0	105	133	neuromuscular blocking agents	group	DDI-DrugBank.d130.s0.e1
DDI-DrugBank.d130.s0	true	DDI-DrugBank.d130.s0.e0	DDI-DrugBank.d130.s0.e1
DDI-DrugBank.d130.s1|a|Therefore, it should be used in caution in patients receiving such agents.
DDI-DrugBank.d130.s2|a|Antagonism between lincomycin and erythromycin in vitro has been demonstrated.
DDI-DrugBank.d130.s2	19	28	lincomycin	drug	DDI-DrugBank.d130.s2.e0
DDI-DrugBank.d130.s2	34	45	erythromycin	drug	DDI-DrugBank.d130.s2.e1
DDI-DrugBank.d130.s2	true	DDI-DrugBank.d130.s2.e0	DDI-DrugBank.d130.s2.e1
DDI-DrugBank.d130.s3|a|Because of possible clinical significance, the two drugs should not be administered concurrently.
DDI-DrugBank.d268.s0|a|Oils may enhance absorption.
DDI-DrugBank.d268.s1|a|Therefore, simultaneous use of creams, ointments or oils should be avoided.
DDI-DrugBank.d441.s0|a|Monoamine Oxidase Inhibition: Linezolid is a reversible, nonselective inhibitor of monoamine oxidase.
DDI-DrugBank.d441.s0	30	38	Linezolid	drug	DDI-DrugBank.d441.s0.e0
DDI-DrugBank.d441.s1|a|Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.
DDI-DrugBank.d441.s1	11	19	linezolid	drug	DDI-DrugBank.d441.s1.e0
DDI-DrugBank.d441.s1	60	69	adrenergic	group	DDI-DrugBank.d441.s1.e1
DDI-DrugBank.d441.s1	75	93	serotonergic agents	group	DDI-DrugBank.d441.s1.e2
DDI-DrugBank.d441.s1	true	DDI-DrugBank.d441.s1.e0	DDI-DrugBank.d441.s1.e1
DDI-DrugBank.d441.s1	true	DDI-DrugBank.d441.s1.e0	DDI-DrugBank.d441.s1.e2
DDI-DrugBank.d441.s1	false	DDI-DrugBank.d441.s1.e1	DDI-DrugBank.d441.s1.e2
DDI-DrugBank.d441.s2|a|Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
DDI-DrugBank.d441.s2	0	16	Adrenergic Agents	group	DDI-DrugBank.d441.s2.e0
DDI-DrugBank.d441.s2	45	49	ZYVOX	brand	DDI-DrugBank.d441.s2.e1
DDI-DrugBank.d441.s2	134	155	sympathomimetic agents	group	DDI-DrugBank.d441.s2.e2
DDI-DrugBank.d441.s2	158	168	vasopressor	group	DDI-DrugBank.d441.s2.e3
DDI-DrugBank.d441.s2	173	191	dopaminergic agents	group	DDI-DrugBank.d441.s2.e4
DDI-DrugBank.d441.s2	false	DDI-DrugBank.d441.s2.e0	DDI-DrugBank.d441.s2.e1
DDI-DrugBank.d441.s2	false	DDI-DrugBank.d441.s2.e0	DDI-DrugBank.d441.s2.e2
DDI-DrugBank.d441.s2	false	DDI-DrugBank.d441.s2.e0	DDI-DrugBank.d441.s2.e3
DDI-DrugBank.d441.s2	false	DDI-DrugBank.d441.s2.e0	DDI-DrugBank.d441.s2.e4
DDI-DrugBank.d441.s2	true	DDI-DrugBank.d441.s2.e1	DDI-DrugBank.d441.s2.e2
DDI-DrugBank.d441.s2	true	DDI-DrugBank.d441.s2.e1	DDI-DrugBank.d441.s2.e3
DDI-DrugBank.d441.s2	true	DDI-DrugBank.d441.s2.e1	DDI-DrugBank.d441.s2.e4
DDI-DrugBank.d441.s2	false	DDI-DrugBank.d441.s2.e2	DDI-DrugBank.d441.s2.e3
DDI-DrugBank.d441.s2	false	DDI-DrugBank.d441.s2.e2	DDI-DrugBank.d441.s2.e4
DDI-DrugBank.d441.s2	false	DDI-DrugBank.d441.s2.e3	DDI-DrugBank.d441.s2.e4
DDI-DrugBank.d441.s3|a|Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied.
DDI-DrugBank.d441.s3	28	46	phenylpropanolamine	drug	DDI-DrugBank.d441.s3.e0
DDI-DrugBank.d441.s3	52	66	pseudoephedrine	drug	DDI-DrugBank.d441.s3.e1
DDI-DrugBank.d441.s3	false	DDI-DrugBank.d441.s3.e0	DDI-DrugBank.d441.s3.e1
DDI-DrugBank.d441.s4|a|Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response.
DDI-DrugBank.d441.s4	17	33	adrenergic agents	group	DDI-DrugBank.d441.s4.e0
DDI-DrugBank.d441.s4	44	51	dopamine	drug	DDI-DrugBank.d441.s4.e1
DDI-DrugBank.d441.s4	56	66	epinephrine	drug	DDI-DrugBank.d441.s4.e2
DDI-DrugBank.d441.s4	false	DDI-DrugBank.d441.s4.e0	DDI-DrugBank.d441.s4.e1
DDI-DrugBank.d441.s4	false	DDI-DrugBank.d441.s4.e0	DDI-DrugBank.d441.s4.e2
DDI-DrugBank.d441.s4	false	DDI-DrugBank.d441.s4.e1	DDI-DrugBank.d441.s4.e2
DDI-DrugBank.d441.s5|a|Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.
DDI-DrugBank.d441.s5	0	18	Serotonergic Agents	group	DDI-DrugBank.d441.s5.e0
DDI-DrugBank.d441.s5	42	50	linezolid	drug	DDI-DrugBank.d441.s5.e1
DDI-DrugBank.d441.s5	56	74	serotonergic agents	group	DDI-DrugBank.d441.s5.e2
DDI-DrugBank.d441.s5	false	DDI-DrugBank.d441.s5.e0	DDI-DrugBank.d441.s5.e1
DDI-DrugBank.d441.s5	false	DDI-DrugBank.d441.s5.e0	DDI-DrugBank.d441.s5.e2
DDI-DrugBank.d441.s5	false	DDI-DrugBank.d441.s5.e1	DDI-DrugBank.d441.s5.e2
DDI-DrugBank.d441.s6|a|Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
DDI-DrugBank.d441.s6	79	83	ZYVOX	brand	DDI-DrugBank.d441.s6.e0
DDI-DrugBank.d441.s6	89	107	serotonergic agents	group	DDI-DrugBank.d441.s6.e1
DDI-DrugBank.d441.s6	120	134	antidepressants	group	DDI-DrugBank.d441.s6.e2
DDI-DrugBank.d441.s6	144	182	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d441.s6.e3
DDI-DrugBank.d441.s6	185	189	SSRIs	group	DDI-DrugBank.d441.s6.e4
DDI-DrugBank.d441.s6	true	DDI-DrugBank.d441.s6.e0	DDI-DrugBank.d441.s6.e1
DDI-DrugBank.d441.s6	true	DDI-DrugBank.d441.s6.e0	DDI-DrugBank.d441.s6.e2
DDI-DrugBank.d441.s6	true	DDI-DrugBank.d441.s6.e0	DDI-DrugBank.d441.s6.e3
DDI-DrugBank.d441.s6	true	DDI-DrugBank.d441.s6.e0	DDI-DrugBank.d441.s6.e4
DDI-DrugBank.d441.s6	false	DDI-DrugBank.d441.s6.e1	DDI-DrugBank.d441.s6.e2
DDI-DrugBank.d441.s6	false	DDI-DrugBank.d441.s6.e1	DDI-DrugBank.d441.s6.e3
DDI-DrugBank.d441.s6	false	DDI-DrugBank.d441.s6.e1	DDI-DrugBank.d441.s6.e4
DDI-DrugBank.d441.s6	false	DDI-DrugBank.d441.s6.e2	DDI-DrugBank.d441.s6.e3
DDI-DrugBank.d441.s6	false	DDI-DrugBank.d441.s6.e2	DDI-DrugBank.d441.s6.e4
DDI-DrugBank.d441.s6	false	DDI-DrugBank.d441.s6.e3	DDI-DrugBank.d441.s6.e4
DDI-DrugBank.d441.s7|a|Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).
DDI-DrugBank.d441.s7	30	34	ZYVOX	brand	DDI-DrugBank.d441.s7.e0
DDI-DrugBank.d441.s7	52	70	serotonergic agents	group	DDI-DrugBank.d441.s7.e1
DDI-DrugBank.d441.s7	true	DDI-DrugBank.d441.s7.e0	DDI-DrugBank.d441.s7.e1
DDI-DrugBank.d441.s8|a|If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents).
DDI-DrugBank.d441.s8	104	108	ZYVOX	brand	DDI-DrugBank.d441.s8.e0
DDI-DrugBank.d441.s8	125	143	serotonergic agents	group	DDI-DrugBank.d441.s8.e1
DDI-DrugBank.d441.s8	true	DDI-DrugBank.d441.s8.e0	DDI-DrugBank.d441.s8.e1
DDI-DrugBank.d441.s9|a|Drug-Laboratory Test Interactions There are no reported drug-laboratory test interactions.
DDI-DrugBank.d54.s0|a|Oral Anticoagulants: Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors.
DDI-DrugBank.d54.s0	5	18	Anticoagulants	group	DDI-DrugBank.d54.s0.e0
DDI-DrugBank.d54.s0	21	36	Thyroid hormones	group	DDI-DrugBank.d54.s0.e1
DDI-DrugBank.d54.s0	false	DDI-DrugBank.d54.s0.e0	DDI-DrugBank.d54.s0.e1
DDI-DrugBank.d54.s1|a|If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired.
DDI-DrugBank.d54.s1	8	21	anticoagulants	group	DDI-DrugBank.d54.s1.e0
DDI-DrugBank.d54.s2|a|Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.
DDI-DrugBank.d54.s2	28	41	anticoagulants	group	DDI-DrugBank.d54.s2.e0
DDI-DrugBank.d54.s2	68	74	thyroid	group	DDI-DrugBank.d54.s2.e1
DDI-DrugBank.d54.s2	true	DDI-DrugBank.d54.s2.e0	DDI-DrugBank.d54.s2.e1
DDI-DrugBank.d54.s3|a|If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required.
DDI-DrugBank.d54.s3	68	80	anticoagulant	group	DDI-DrugBank.d54.s3.e0
DDI-DrugBank.d54.s4|a|No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy.
DDI-DrugBank.d54.s5|a|Insulin or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.
DDI-DrugBank.d54.s5	0	6	Insulin	drug	DDI-DrugBank.d54.s5.e0
DDI-DrugBank.d54.s5	16	28	Hypoglycemics	group	DDI-DrugBank.d54.s5.e1
DDI-DrugBank.d54.s5	93	99	insulin	drug	DDI-DrugBank.d54.s5.e2
DDI-DrugBank.d54.s5	109	120	hypoglycemic	group	DDI-DrugBank.d54.s5.e3
DDI-DrugBank.d54.s5	false	DDI-DrugBank.d54.s5.e0	DDI-DrugBank.d54.s5.e1
DDI-DrugBank.d54.s5	false	DDI-DrugBank.d54.s5.e0	DDI-DrugBank.d54.s5.e2
DDI-DrugBank.d54.s5	false	DDI-DrugBank.d54.s5.e0	DDI-DrugBank.d54.s5.e3
DDI-DrugBank.d54.s5	false	DDI-DrugBank.d54.s5.e1	DDI-DrugBank.d54.s5.e2
DDI-DrugBank.d54.s5	false	DDI-DrugBank.d54.s5.e1	DDI-DrugBank.d54.s5.e3
DDI-DrugBank.d54.s5	false	DDI-DrugBank.d54.s5.e2	DDI-DrugBank.d54.s5.e3
DDI-DrugBank.d54.s6|a|The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient.
DDI-DrugBank.d54.s6	101	120	thyroid preparations	group	DDI-DrugBank.d54.s6.e0
DDI-DrugBank.d54.s7|a|Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.
DDI-DrugBank.d54.s7	19	25	insulin	drug	DDI-DrugBank.d54.s7.e0
DDI-DrugBank.d54.s7	35	47	hypoglycemics	group	DDI-DrugBank.d54.s7.e1
DDI-DrugBank.d54.s7	false	DDI-DrugBank.d54.s7.e0	DDI-DrugBank.d54.s7.e1
DDI-DrugBank.d54.s8|a|Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
DDI-DrugBank.d54.s8	0	13	Cholestyramine	drug	DDI-DrugBank.d54.s8.e0
DDI-DrugBank.d54.s8	16	29	Cholestyramine	drug	DDI-DrugBank.d54.s8.e1
DDI-DrugBank.d54.s8	42	43	T4	drug	DDI-DrugBank.d54.s8.e2
DDI-DrugBank.d54.s8	49	50	T3	drug	DDI-DrugBank.d54.s8.e3
DDI-DrugBank.d54.s8	105	120	thyroid hormones	group	DDI-DrugBank.d54.s8.e4
DDI-DrugBank.d54.s8	false	DDI-DrugBank.d54.s8.e0	DDI-DrugBank.d54.s8.e1
DDI-DrugBank.d54.s8	false	DDI-DrugBank.d54.s8.e0	DDI-DrugBank.d54.s8.e2
DDI-DrugBank.d54.s8	false	DDI-DrugBank.d54.s8.e0	DDI-DrugBank.d54.s8.e3
DDI-DrugBank.d54.s8	false	DDI-DrugBank.d54.s8.e0	DDI-DrugBank.d54.s8.e4
DDI-DrugBank.d54.s8	true	DDI-DrugBank.d54.s8.e1	DDI-DrugBank.d54.s8.e2
DDI-DrugBank.d54.s8	true	DDI-DrugBank.d54.s8.e1	DDI-DrugBank.d54.s8.e3
DDI-DrugBank.d54.s8	false	DDI-DrugBank.d54.s8.e1	DDI-DrugBank.d54.s8.e4
DDI-DrugBank.d54.s8	false	DDI-DrugBank.d54.s8.e2	DDI-DrugBank.d54.s8.e3
DDI-DrugBank.d54.s8	false	DDI-DrugBank.d54.s8.e2	DDI-DrugBank.d54.s8.e4
DDI-DrugBank.d54.s8	false	DDI-DrugBank.d54.s8.e3	DDI-DrugBank.d54.s8.e4
DDI-DrugBank.d54.s9|a|In vitro studies indicate that the binding is not easily removed.
DDI-DrugBank.d54.s10|a|Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.
DDI-DrugBank.d54.s10	64	77	cholestyramine	drug	DDI-DrugBank.d54.s10.e0
DDI-DrugBank.d54.s10	83	98	thyroid hormones	group	DDI-DrugBank.d54.s10.e1
DDI-DrugBank.d54.s10	true	DDI-DrugBank.d54.s10.e0	DDI-DrugBank.d54.s10.e1
DDI-DrugBank.d54.s11|a|Estrogen, Oral Contraceptives: Estrogens tend to increase serum thyroxine-binding globulin (TBg).
DDI-DrugBank.d54.s11	0	7	Estrogen	group	DDI-DrugBank.d54.s11.e0
DDI-DrugBank.d54.s11	15	28	Contraceptives	group	DDI-DrugBank.d54.s11.e1
DDI-DrugBank.d54.s11	31	39	Estrogens	group	DDI-DrugBank.d54.s11.e2
DDI-DrugBank.d54.s11	false	DDI-DrugBank.d54.s11.e0	DDI-DrugBank.d54.s11.e1
DDI-DrugBank.d54.s11	false	DDI-DrugBank.d54.s11.e0	DDI-DrugBank.d54.s11.e2
DDI-DrugBank.d54.s11	false	DDI-DrugBank.d54.s11.e1	DDI-DrugBank.d54.s11.e2
DDI-DrugBank.d54.s12|a|In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.
DDI-DrugBank.d54.s12	100	112	levothyroxine	drug	DDI-DrugBank.d54.s12.e0
DDI-DrugBank.d54.s12	136	144	estrogens	group	DDI-DrugBank.d54.s12.e1
DDI-DrugBank.d54.s12	174	180	thyroid	group	DDI-DrugBank.d54.s12.e2
DDI-DrugBank.d54.s12	true	DDI-DrugBank.d54.s12.e0	DDI-DrugBank.d54.s12.e1
DDI-DrugBank.d54.s12	false	DDI-DrugBank.d54.s12.e0	DDI-DrugBank.d54.s12.e2
DDI-DrugBank.d54.s12	false	DDI-DrugBank.d54.s12.e1	DDI-DrugBank.d54.s12.e2
DDI-DrugBank.d54.s13|a|However, if the patients thyroid gland has sufficient function, the decreased free thyroxine will result in a compensatory increase in thyroxine output by the thyroid.
DDI-DrugBank.d54.s13	83	90	thyroxin	drug	DDI-DrugBank.d54.s13.e0
DDI-DrugBank.d54.s14|a|Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.
DDI-DrugBank.d54.s14	42	48	thyroid	group	DDI-DrugBank.d54.s14.e0
DDI-DrugBank.d54.s14	138	146	estrogens	group	DDI-DrugBank.d54.s14.e1
DDI-DrugBank.d54.s14	151	158	estrogen	group	DDI-DrugBank.d54.s14.e2
DDI-DrugBank.d54.s14	176	189	contraceptives	group	DDI-DrugBank.d54.s14.e3
DDI-DrugBank.d54.s14	true	DDI-DrugBank.d54.s14.e0	DDI-DrugBank.d54.s14.e1
DDI-DrugBank.d54.s14	false	DDI-DrugBank.d54.s14.e0	DDI-DrugBank.d54.s14.e2
DDI-DrugBank.d54.s14	true	DDI-DrugBank.d54.s14.e0	DDI-DrugBank.d54.s14.e3
DDI-DrugBank.d54.s14	false	DDI-DrugBank.d54.s14.e1	DDI-DrugBank.d54.s14.e2
DDI-DrugBank.d54.s14	false	DDI-DrugBank.d54.s14.e1	DDI-DrugBank.d54.s14.e3
DDI-DrugBank.d54.s14	false	DDI-DrugBank.d54.s14.e2	DDI-DrugBank.d54.s14.e3
DDI-DrugBank.d54.s15|a|Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
DDI-DrugBank.d54.s15	0	24	Tricyclic Antidepressants	group	DDI-DrugBank.d54.s15.e0
DDI-DrugBank.d54.s15	34	49	thyroid products	group	DDI-DrugBank.d54.s15.e1
DDI-DrugBank.d54.s15	56	65	imipramine	drug	DDI-DrugBank.d54.s15.e2
DDI-DrugBank.d54.s15	77	101	tricyclic antidepressants	group	DDI-DrugBank.d54.s15.e3
DDI-DrugBank.d54.s15	false	DDI-DrugBank.d54.s15.e0	DDI-DrugBank.d54.s15.e1
DDI-DrugBank.d54.s15	false	DDI-DrugBank.d54.s15.e0	DDI-DrugBank.d54.s15.e2
DDI-DrugBank.d54.s15	false	DDI-DrugBank.d54.s15.e0	DDI-DrugBank.d54.s15.e3
DDI-DrugBank.d54.s15	true	DDI-DrugBank.d54.s15.e1	DDI-DrugBank.d54.s15.e2
DDI-DrugBank.d54.s15	true	DDI-DrugBank.d54.s15.e1	DDI-DrugBank.d54.s15.e3
DDI-DrugBank.d54.s15	false	DDI-DrugBank.d54.s15.e2	DDI-DrugBank.d54.s15.e3
DDI-DrugBank.d54.s16|a|Thyroid hormone activity may also be enhanced.
DDI-DrugBank.d54.s16	0	14	Thyroid hormone	group	DDI-DrugBank.d54.s16.e0
DDI-DrugBank.d54.s17|a|Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.
DDI-DrugBank.d54.s17	0	8	Digitalis	group	DDI-DrugBank.d54.s17.e0
DDI-DrugBank.d54.s17	11	30	Thyroid preparations	group	DDI-DrugBank.d54.s17.e1
DDI-DrugBank.d54.s17	68	76	digitalis	group	DDI-DrugBank.d54.s17.e2
DDI-DrugBank.d54.s17	false	DDI-DrugBank.d54.s17.e0	DDI-DrugBank.d54.s17.e1
DDI-DrugBank.d54.s17	false	DDI-DrugBank.d54.s17.e0	DDI-DrugBank.d54.s17.e2
DDI-DrugBank.d54.s17	true	DDI-DrugBank.d54.s17.e1	DDI-DrugBank.d54.s17.e2
DDI-DrugBank.d54.s18|a|Thyroid hormonal replacement increases metabolic rate, which requires an increase in digitalis dosage.
DDI-DrugBank.d54.s18	85	93	digitalis	group	DDI-DrugBank.d54.s18.e0
DDI-DrugBank.d54.s19|a|Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.
DDI-DrugBank.d54.s19	0	7	Ketamine	drug	DDI-DrugBank.d54.s19.e0
DDI-DrugBank.d54.s19	45	63	thyroid preparation	group	DDI-DrugBank.d54.s19.e1
DDI-DrugBank.d54.s19	82	91	anesthetic	group	DDI-DrugBank.d54.s19.e2
DDI-DrugBank.d54.s19	false	DDI-DrugBank.d54.s19.e0	DDI-DrugBank.d54.s19.e1
DDI-DrugBank.d54.s19	false	DDI-DrugBank.d54.s19.e0	DDI-DrugBank.d54.s19.e2
DDI-DrugBank.d54.s19	true	DDI-DrugBank.d54.s19.e1	DDI-DrugBank.d54.s19.e2
DDI-DrugBank.d54.s20|a|Use with caution and be prepared to treat hypertension, if necessary.
DDI-DrugBank.d54.s21|a|Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.
DDI-DrugBank.d54.s21	0	10	Vasopressor	group	DDI-DrugBank.d54.s21.e0
DDI-DrugBank.d54.s21	14	22	Thyroxine	drug	DDI-DrugBank.d54.s21.e1
DDI-DrugBank.d54.s21	82	92	epinephrine	drug	DDI-DrugBank.d54.s21.e2
DDI-DrugBank.d54.s21	98	111	norepinephrine	drug	DDI-DrugBank.d54.s21.e3
DDI-DrugBank.d54.s21	false	DDI-DrugBank.d54.s21.e0	DDI-DrugBank.d54.s21.e1
DDI-DrugBank.d54.s21	false	DDI-DrugBank.d54.s21.e0	DDI-DrugBank.d54.s21.e2
DDI-DrugBank.d54.s21	false	DDI-DrugBank.d54.s21.e0	DDI-DrugBank.d54.s21.e3
DDI-DrugBank.d54.s21	true	DDI-DrugBank.d54.s21.e1	DDI-DrugBank.d54.s21.e2
DDI-DrugBank.d54.s21	true	DDI-DrugBank.d54.s21.e1	DDI-DrugBank.d54.s21.e3
DDI-DrugBank.d54.s21	false	DDI-DrugBank.d54.s21.e2	DDI-DrugBank.d54.s21.e3
DDI-DrugBank.d54.s22|a|Therefore, injection of these agents into patients receiving thyroid preparations increases the risk of precipitating coronary insufficiency especially in patients with coronary artery disease.
DDI-DrugBank.d54.s22	61	80	thyroid preparations	group	DDI-DrugBank.d54.s22.e0
DDI-DrugBank.d54.s23|a|Careful observation is required.
DDI-DrugBank.d54.s24|a|Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
DDI-DrugBank.d54.s24	136	150	thyroid hormone	group	DDI-DrugBank.d54.s24.e0
DDI-DrugBank.d54.s24	161	169	androgens	group	DDI-DrugBank.d54.s24.e1
DDI-DrugBank.d54.s24	172	186	corticosteroids	group	DDI-DrugBank.d54.s24.e2
DDI-DrugBank.d54.s24	189	197	estrogens	group	DDI-DrugBank.d54.s24.e3
DDI-DrugBank.d54.s24	205	218	contraceptives	group	DDI-DrugBank.d54.s24.e4
DDI-DrugBank.d54.s24	231	239	estrogens	group	DDI-DrugBank.d54.s24.e5
DDI-DrugBank.d54.s24	242	247	iodine	group	DDI-DrugBank.d54.s24.e6
DDI-DrugBank.d54.s24	314	324	salicylates	group	DDI-DrugBank.d54.s24.e7
DDI-DrugBank.d54.s24	false	DDI-DrugBank.d54.s24.e0	DDI-DrugBank.d54.s24.e1
DDI-DrugBank.d54.s24	false	DDI-DrugBank.d54.s24.e0	DDI-DrugBank.d54.s24.e2
DDI-DrugBank.d54.s24	false	DDI-DrugBank.d54.s24.e0	DDI-DrugBank.d54.s24.e3
DDI-DrugBank.d54.s24	false	DDI-DrugBank.d54.s24.e0	DDI-DrugBank.d54.s24.e4
DDI-DrugBank.d54.s24	false	DDI-DrugBank.d54.s24.e0	DDI-DrugBank.d54.s24.e5
DDI-DrugBank.d54.s24	false	DDI-DrugBank.d54.s24.e0	DDI-DrugBank.d54.s24.e6
DDI-DrugBank.d54.s24	false	DDI-DrugBank.d54.s24.e0	DDI-DrugBank.d54.s24.e7
DDI-DrugBank.d54.s24	false	DDI-DrugBank.d54.s24.e1	DDI-DrugBank.d54.s24.e2
DDI-DrugBank.d54.s24	false	DDI-DrugBank.d54.s24.e1	DDI-DrugBank.d54.s24.e3
DDI-DrugBank.d54.s24	false	DDI-DrugBank.d54.s24.e1	DDI-DrugBank.d54.s24.e4
DDI-DrugBank.d54.s25|a|- Changes in TBg concentration should be taken into consideration in the interpretation of T4 and T3 values.
DDI-DrugBank.d54.s26|a|In such cases, the unbound (free) hormone should be measured.
DDI-DrugBank.d54.s27|a|Pregnancy estrogens and estrogen-containing oral contraceptives increase TBg concentrations.
DDI-DrugBank.d54.s27	10	18	estrogens	group	DDI-DrugBank.d54.s27.e0
DDI-DrugBank.d54.s27	24	31	estrogen	group	DDI-DrugBank.d54.s27.e1
DDI-DrugBank.d54.s27	49	62	contraceptives	group	DDI-DrugBank.d54.s27.e2
DDI-DrugBank.d54.s27	false	DDI-DrugBank.d54.s27.e0	DDI-DrugBank.d54.s27.e1
DDI-DrugBank.d54.s27	false	DDI-DrugBank.d54.s27.e0	DDI-DrugBank.d54.s27.e2
DDI-DrugBank.d54.s27	false	DDI-DrugBank.d54.s27.e1	DDI-DrugBank.d54.s27.e2
DDI-DrugBank.d54.s28|a|TBg may also be increased during infectious hepatitis.
DDI-DrugBank.d54.s29|a|Decreases in TBg concentrations are observed in nephrosis, acromegaly and after androgen or corticosteroid therapy.
DDI-DrugBank.d54.s29	80	87	androgen	group	DDI-DrugBank.d54.s29.e0
DDI-DrugBank.d54.s29	92	105	corticosteroid	group	DDI-DrugBank.d54.s29.e1
DDI-DrugBank.d54.s29	false	DDI-DrugBank.d54.s29.e0	DDI-DrugBank.d54.s29.e1
DDI-DrugBank.d54.s30|a|Familial hyper- or hypo-thyroxine-binding-globulinemias have been described.
DDI-DrugBank.d54.s31|a|The incidence of TBg deficiency approximates 1 in 9000.
DDI-DrugBank.d54.s32|a|The binding of thyroxine by thyroxine-binding prealbumin (TBPA) is inhibited by salicylates
DDI-DrugBank.d54.s32	80	90	salicylates	group	DDI-DrugBank.d54.s32.e0
DDI-DrugBank.d54.s33|a|.
DDI-DrugBank.d54.s34|a|- Medicinal or dietary iodine interferes with all in vivo tests of radio-iodine uptake producing low uptakes which may not be reflective of a true decrease in hormone synthesis
DDI-DrugBank.d54.s34	23	28	iodine	group	DDI-DrugBank.d54.s34.e0
DDI-DrugBank.d54.s35|a|.
DDI-DrugBank.d54.s36|a|- The persistence of clinical and laboratory evidence of hypothyroidism in spite of adequate dosage replacement indicates either poor patient compliance, poor absorption, excessive fecal loss, or inactivity of the preparation.
DDI-DrugBank.d54.s37|a|Intracellular resistance to thyroid hormone is quite rare.
DDI-DrugBank.d54.s37	28	42	thyroid hormone	group	DDI-DrugBank.d54.s37.e0
DDI-DrugBank.d158.s0|a|Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
DDI-DrugBank.d158.s0	40	56	ammonium chloride	drug	DDI-DrugBank.d158.s0.e0
DDI-DrugBank.d158.s0	59	79	sodium acid phosphate	drug	DDI-DrugBank.d158.s0.e1
DDI-DrugBank.d158.s0	145	155	amphetamine	drug	DDI-DrugBank.d158.s0.e2
DDI-DrugBank.d158.s0	false	DDI-DrugBank.d158.s0.e0	DDI-DrugBank.d158.s0.e1
DDI-DrugBank.d158.s0	true	DDI-DrugBank.d158.s0.e0	DDI-DrugBank.d158.s0.e2
DDI-DrugBank.d158.s0	true	DDI-DrugBank.d158.s0.e1	DDI-DrugBank.d158.s0.e2
DDI-DrugBank.d158.s1|a|Both groups of agents lower blood levels and efficacy of amphetamines.
DDI-DrugBank.d158.s1	57	68	amphetamines	group	DDI-DrugBank.d158.s1.e0
DDI-DrugBank.d158.s2|a|Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.
DDI-DrugBank.d158.s2	0	18	Adrenergic blockers	group	DDI-DrugBank.d158.s2.e0
DDI-DrugBank.d158.s2	20	38	Adrenergic blockers	group	DDI-DrugBank.d158.s2.e1
DDI-DrugBank.d158.s2	57	68	amphetamines	group	DDI-DrugBank.d158.s2.e2
DDI-DrugBank.d158.s2	false	DDI-DrugBank.d158.s2.e0	DDI-DrugBank.d158.s2.e1
DDI-DrugBank.d158.s2	false	DDI-DrugBank.d158.s2.e0	DDI-DrugBank.d158.s2.e2
DDI-DrugBank.d158.s2	true	DDI-DrugBank.d158.s2.e1	DDI-DrugBank.d158.s2.e2
DDI-DrugBank.d158.s3|a|Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
DDI-DrugBank.d158.s3	0	14	Antidepressants	group	DDI-DrugBank.d158.s3.e0
DDI-DrugBank.d158.s3	17	25	tricyclic	group	DDI-DrugBank.d158.s3.e1
DDI-DrugBank.d158.s3	27	38	Amphetamines	group	DDI-DrugBank.d158.s3.e2
DDI-DrugBank.d158.s3	68	92	tricyclic antidepressants	drug	DDI-DrugBank.d158.s3.e3
DDI-DrugBank.d158.s3	97	118	sympathomimetic agents	group	DDI-DrugBank.d158.s3.e4
DDI-DrugBank.d158.s3	false	DDI-DrugBank.d158.s3.e0	DDI-DrugBank.d158.s3.e1
DDI-DrugBank.d158.s3	false	DDI-DrugBank.d158.s3.e0	DDI-DrugBank.d158.s3.e2
DDI-DrugBank.d158.s3	false	DDI-DrugBank.d158.s3.e0	DDI-DrugBank.d158.s3.e3
DDI-DrugBank.d158.s3	false	DDI-DrugBank.d158.s3.e0	DDI-DrugBank.d158.s3.e4
DDI-DrugBank.d158.s3	false	DDI-DrugBank.d158.s3.e1	DDI-DrugBank.d158.s3.e2
DDI-DrugBank.d158.s3	false	DDI-DrugBank.d158.s3.e1	DDI-DrugBank.d158.s3.e3
DDI-DrugBank.d158.s3	false	DDI-DrugBank.d158.s3.e1	DDI-DrugBank.d158.s3.e4
DDI-DrugBank.d158.s3	true	DDI-DrugBank.d158.s3.e2	DDI-DrugBank.d158.s3.e3
DDI-DrugBank.d158.s3	true	DDI-DrugBank.d158.s3.e2	DDI-DrugBank.d158.s3.e4
DDI-DrugBank.d158.s3	false	DDI-DrugBank.d158.s3.e3	DDI-DrugBank.d158.s3.e4
DDI-DrugBank.d158.s4|a|d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DDI-DrugBank.d158.s4	0	12	d-amphetamine	drug	DDI-DrugBank.d158.s4.e0
DDI-DrugBank.d158.s4	19	29	desipramine	drug	DDI-DrugBank.d158.s4.e1
DDI-DrugBank.d158.s4	34	46	protriptyline	drug	DDI-DrugBank.d158.s4.e2
DDI-DrugBank.d158.s4	67	76	tricyclics	group	DDI-DrugBank.d158.s4.e3
DDI-DrugBank.d158.s4	141	153	d-amphetamine	drug	DDI-DrugBank.d158.s4.e4
DDI-DrugBank.d158.s4	true	DDI-DrugBank.d158.s4.e0	DDI-DrugBank.d158.s4.e1
DDI-DrugBank.d158.s4	true	DDI-DrugBank.d158.s4.e0	DDI-DrugBank.d158.s4.e2
DDI-DrugBank.d158.s4	true	DDI-DrugBank.d158.s4.e0	DDI-DrugBank.d158.s4.e3
DDI-DrugBank.d158.s4	false	DDI-DrugBank.d158.s4.e0	DDI-DrugBank.d158.s4.e4
DDI-DrugBank.d158.s4	false	DDI-DrugBank.d158.s4.e1	DDI-DrugBank.d158.s4.e2
DDI-DrugBank.d158.s4	false	DDI-DrugBank.d158.s4.e1	DDI-DrugBank.d158.s4.e3
DDI-DrugBank.d158.s4	false	DDI-DrugBank.d158.s4.e1	DDI-DrugBank.d158.s4.e4
DDI-DrugBank.d158.s4	false	DDI-DrugBank.d158.s4.e2	DDI-DrugBank.d158.s4.e3
DDI-DrugBank.d158.s4	false	DDI-DrugBank.d158.s4.e2	DDI-DrugBank.d158.s4.e4
DDI-DrugBank.d158.s4	false	DDI-DrugBank.d158.s4.e3	DDI-DrugBank.d158.s4.e4
DDI-DrugBank.d158.s5|a|cardiovascular effects can be potentiated.
DDI-DrugBank.d158.s6|a|MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
DDI-DrugBank.d158.s6	0	13	MAO inhibitors	group	DDI-DrugBank.d158.s6.e0
DDI-DrugBank.d158.s6	15	34	MAOI antidepressants	group	DDI-DrugBank.d158.s6.e1
DDI-DrugBank.d158.s6	64	75	furazolidone	drug	DDI-DrugBank.d158.s6.e2
DDI-DrugBank.d158.s6	83	93	amphetamine	drug	DDI-DrugBank.d158.s6.e3
DDI-DrugBank.d158.s6	false	DDI-DrugBank.d158.s6.e0	DDI-DrugBank.d158.s6.e1
DDI-DrugBank.d158.s6	false	DDI-DrugBank.d158.s6.e0	DDI-DrugBank.d158.s6.e2
DDI-DrugBank.d158.s6	false	DDI-DrugBank.d158.s6.e0	DDI-DrugBank.d158.s6.e3
DDI-DrugBank.d158.s6	false	DDI-DrugBank.d158.s6.e1	DDI-DrugBank.d158.s6.e2
DDI-DrugBank.d158.s6	true	DDI-DrugBank.d158.s6.e1	DDI-DrugBank.d158.s6.e3
DDI-DrugBank.d158.s6	true	DDI-DrugBank.d158.s6.e2	DDI-DrugBank.d158.s6.e3
DDI-DrugBank.d158.s7|a|This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings;
DDI-DrugBank.d158.s7	25	36	amphetamines	group	DDI-DrugBank.d158.s7.e0
DDI-DrugBank.d158.s8|a|this can cause headaches and other signs of hypertensive crisis.
DDI-DrugBank.d158.s9|a|A variety of toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results.
DDI-DrugBank.d158.s10|a|Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
DDI-DrugBank.d158.s10	0	13	Antihistamines	group	DDI-DrugBank.d158.s10.e0
DDI-DrugBank.d158.s10	16	27	Amphetamines	group	DDI-DrugBank.d158.s10.e1
DDI-DrugBank.d158.s10	67	80	antihistamines	group	DDI-DrugBank.d158.s10.e2
DDI-DrugBank.d158.s10	false	DDI-DrugBank.d158.s10.e0	DDI-DrugBank.d158.s10.e1
DDI-DrugBank.d158.s10	false	DDI-DrugBank.d158.s10.e0	DDI-DrugBank.d158.s10.e2
DDI-DrugBank.d158.s10	true	DDI-DrugBank.d158.s10.e1	DDI-DrugBank.d158.s10.e2
DDI-DrugBank.d158.s11|a|Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
DDI-DrugBank.d158.s11	0	16	Antihypertensives	group	DDI-DrugBank.d158.s11.e0
DDI-DrugBank.d158.s11	19	30	Amphetamines	group	DDI-DrugBank.d158.s11.e1
DDI-DrugBank.d158.s11	74	90	antihypertensives	drug	DDI-DrugBank.d158.s11.e2
DDI-DrugBank.d158.s11	false	DDI-DrugBank.d158.s11.e0	DDI-DrugBank.d158.s11.e1
DDI-DrugBank.d158.s11	false	DDI-DrugBank.d158.s11.e0	DDI-DrugBank.d158.s11.e2
DDI-DrugBank.d158.s11	true	DDI-DrugBank.d158.s11.e1	DDI-DrugBank.d158.s11.e2
DDI-DrugBank.d158.s12|a|Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.
DDI-DrugBank.d158.s12	0	13	Chlorpromazine	drug	DDI-DrugBank.d158.s12.e0
DDI-DrugBank.d158.s12	16	29	Chlorpromazine	drug	DDI-DrugBank.d158.s12.e1
DDI-DrugBank.d158.s12	126	137	amphetamines	group	DDI-DrugBank.d158.s12.e2
DDI-DrugBank.d158.s12	164	174	amphetamine	group	DDI-DrugBank.d158.s12.e3
DDI-DrugBank.d158.s12	false	DDI-DrugBank.d158.s12.e0	DDI-DrugBank.d158.s12.e1
DDI-DrugBank.d158.s12	false	DDI-DrugBank.d158.s12.e0	DDI-DrugBank.d158.s12.e2
DDI-DrugBank.d158.s12	false	DDI-DrugBank.d158.s12.e0	DDI-DrugBank.d158.s12.e3
DDI-DrugBank.d158.s12	true	DDI-DrugBank.d158.s12.e1	DDI-DrugBank.d158.s12.e2
DDI-DrugBank.d158.s12	false	DDI-DrugBank.d158.s12.e1	DDI-DrugBank.d158.s12.e3
DDI-DrugBank.d158.s12	false	DDI-DrugBank.d158.s12.e2	DDI-DrugBank.d158.s12.e3
DDI-DrugBank.d158.s13|a|Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
DDI-DrugBank.d158.s13	0	11	Ethosuximide	drug	DDI-DrugBank.d158.s13.e0
DDI-DrugBank.d158.s13	14	25	Amphetamines	group	DDI-DrugBank.d158.s13.e1
DDI-DrugBank.d158.s13	62	73	ethosuximide	drug	DDI-DrugBank.d158.s13.e2
DDI-DrugBank.d158.s13	false	DDI-DrugBank.d158.s13.e0	DDI-DrugBank.d158.s13.e1
DDI-DrugBank.d158.s13	false	DDI-DrugBank.d158.s13.e0	DDI-DrugBank.d158.s13.e2
DDI-DrugBank.d158.s13	true	DDI-DrugBank.d158.s13.e1	DDI-DrugBank.d158.s13.e2
DDI-DrugBank.d158.s14|a|Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.
DDI-DrugBank.d158.s14	0	10	Haloperidol	drug	DDI-DrugBank.d158.s14.e0
DDI-DrugBank.d158.s14	13	23	Haloperidol	drug	DDI-DrugBank.d158.s14.e1
DDI-DrugBank.d158.s14	101	112	amphetamines	group	DDI-DrugBank.d158.s14.e2
DDI-DrugBank.d158.s14	false	DDI-DrugBank.d158.s14.e0	DDI-DrugBank.d158.s14.e1
DDI-DrugBank.d158.s14	false	DDI-DrugBank.d158.s14.e0	DDI-DrugBank.d158.s14.e2
DDI-DrugBank.d158.s14	true	DDI-DrugBank.d158.s14.e1	DDI-DrugBank.d158.s14.e2
DDI-DrugBank.d158.s15|a|Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.
DDI-DrugBank.d158.s15	0	16	Lithium carbonate	drug	DDI-DrugBank.d158.s15.e0
DDI-DrugBank.d158.s15	60	71	amphetamines	group	DDI-DrugBank.d158.s15.e1
DDI-DrugBank.d158.s15	93	109	lithium carbonate	drug	DDI-DrugBank.d158.s15.e2
DDI-DrugBank.d158.s15	false	DDI-DrugBank.d158.s15.e0	DDI-DrugBank.d158.s15.e1
DDI-DrugBank.d158.s15	false	DDI-DrugBank.d158.s15.e0	DDI-DrugBank.d158.s15.e2
DDI-DrugBank.d158.s15	true	DDI-DrugBank.d158.s15.e1	DDI-DrugBank.d158.s15.e2
DDI-DrugBank.d158.s16|a|Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
DDI-DrugBank.d158.s16	0	9	Meperidine	drug	DDI-DrugBank.d158.s16.e0
DDI-DrugBank.d158.s16	12	23	Amphetamines	group	DDI-DrugBank.d158.s16.e1
DDI-DrugBank.d158.s16	60	69	meperidine	drug	DDI-DrugBank.d158.s16.e2
DDI-DrugBank.d158.s16	false	DDI-DrugBank.d158.s16.e0	DDI-DrugBank.d158.s16.e1
DDI-DrugBank.d158.s16	false	DDI-DrugBank.d158.s16.e0	DDI-DrugBank.d158.s16.e2
DDI-DrugBank.d158.s16	true	DDI-DrugBank.d158.s16.e1	DDI-DrugBank.d158.s16.e2
DDI-DrugBank.d158.s17|a|Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.
DDI-DrugBank.d158.s17	0	10	Methenamine	drug	DDI-DrugBank.d158.s17.e0
DDI-DrugBank.d158.s17	41	52	amphetamines	group	DDI-DrugBank.d158.s17.e1
DDI-DrugBank.d158.s17	121	131	methenamine	drug	DDI-DrugBank.d158.s17.e2
DDI-DrugBank.d158.s17	false	DDI-DrugBank.d158.s17.e0	DDI-DrugBank.d158.s17.e1
DDI-DrugBank.d158.s17	false	DDI-DrugBank.d158.s17.e0	DDI-DrugBank.d158.s17.e2
DDI-DrugBank.d158.s17	true	DDI-DrugBank.d158.s17.e1	DDI-DrugBank.d158.s17.e2
DDI-DrugBank.d158.s18|a|Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
DDI-DrugBank.d158.s18	0	13	Norepinephrine	drug	DDI-DrugBank.d158.s18.e0
DDI-DrugBank.d158.s18	16	27	Amphetamines	group	DDI-DrugBank.d158.s18.e1
DDI-DrugBank.d158.s18	62	75	norepinephrine	drug	DDI-DrugBank.d158.s18.e2
DDI-DrugBank.d158.s18	false	DDI-DrugBank.d158.s18.e0	DDI-DrugBank.d158.s18.e1
DDI-DrugBank.d158.s18	false	DDI-DrugBank.d158.s18.e0	DDI-DrugBank.d158.s18.e2
DDI-DrugBank.d158.s18	true	DDI-DrugBank.d158.s18.e1	DDI-DrugBank.d158.s18.e2
DDI-DrugBank.d158.s19|a|Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
DDI-DrugBank.d158.s19	0	12	Phenobarbital	drug	DDI-DrugBank.d158.s19.e0
DDI-DrugBank.d158.s19	15	26	Amphetamines	group	DDI-DrugBank.d158.s19.e1
DDI-DrugBank.d158.s19	63	75	phenobarbital	drug	DDI-DrugBank.d158.s19.e2
DDI-DrugBank.d158.s19	false	DDI-DrugBank.d158.s19.e0	DDI-DrugBank.d158.s19.e1
DDI-DrugBank.d158.s19	false	DDI-DrugBank.d158.s19.e0	DDI-DrugBank.d158.s19.e2
DDI-DrugBank.d158.s19	true	DDI-DrugBank.d158.s19.e1	DDI-DrugBank.d158.s19.e2
DDI-DrugBank.d158.s20|a|co-administration of phenobarbital may produce a synergistic anticonvulsant action.
DDI-DrugBank.d158.s20	21	33	phenobarbital	drug	DDI-DrugBank.d158.s20.e0
DDI-DrugBank.d158.s21|a|Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
DDI-DrugBank.d158.s21	0	8	Phenytoin	drug	DDI-DrugBank.d158.s21.e0
DDI-DrugBank.d158.s21	11	22	Amphetamines	group	DDI-DrugBank.d158.s21.e1
DDI-DrugBank.d158.s21	59	67	phenytoin	drug	DDI-DrugBank.d158.s21.e2
DDI-DrugBank.d158.s21	false	DDI-DrugBank.d158.s21.e0	DDI-DrugBank.d158.s21.e1
DDI-DrugBank.d158.s21	false	DDI-DrugBank.d158.s21.e0	DDI-DrugBank.d158.s21.e2
DDI-DrugBank.d158.s21	true	DDI-DrugBank.d158.s21.e1	DDI-DrugBank.d158.s21.e2
DDI-DrugBank.d158.s22|a|co-administration of phenytoin may produce a synergistic anticonvulsant action.
DDI-DrugBank.d158.s22	21	29	phenytoin	drug	DDI-DrugBank.d158.s22.e0
DDI-DrugBank.d158.s23|a|Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
DDI-DrugBank.d158.s23	0	11	Propoxyphene	drug	DDI-DrugBank.d158.s23.e0
DDI-DrugBank.d158.s23	26	37	propoxyphene	drug	DDI-DrugBank.d158.s23.e1
DDI-DrugBank.d158.s23	51	61	amphetamine	drug	DDI-DrugBank.d158.s23.e2
DDI-DrugBank.d158.s23	false	DDI-DrugBank.d158.s23.e0	DDI-DrugBank.d158.s23.e1
DDI-DrugBank.d158.s23	false	DDI-DrugBank.d158.s23.e0	DDI-DrugBank.d158.s23.e2
DDI-DrugBank.d158.s23	true	DDI-DrugBank.d158.s23.e1	DDI-DrugBank.d158.s23.e2
DDI-DrugBank.d158.s24|a|Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
DDI-DrugBank.d158.s24	0	17	Veratrum alkaloids	group	DDI-DrugBank.d158.s24.e0
DDI-DrugBank.d158.s24	20	31	Amphetamines	group	DDI-DrugBank.d158.s24.e1
DDI-DrugBank.d158.s24	67	84	veratrum alkaloids	group	DDI-DrugBank.d158.s24.e2
DDI-DrugBank.d158.s24	false	DDI-DrugBank.d158.s24.e0	DDI-DrugBank.d158.s24.e1
DDI-DrugBank.d158.s24	false	DDI-DrugBank.d158.s24.e0	DDI-DrugBank.d158.s24.e2
DDI-DrugBank.d158.s24	true	DDI-DrugBank.d158.s24.e1	DDI-DrugBank.d158.s24.e2
DDI-DrugBank.d158.s25|a|Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.
DDI-DrugBank.d158.s25	35	46	Amphetamines	group	DDI-DrugBank.d158.s25.e0
DDI-DrugBank.d158.s26|a|This increase is greatest in the evening.
DDI-DrugBank.d158.s27|a|Amphetamines may interfere with urinary steroid determinations.
DDI-DrugBank.d158.s27	0	11	Amphetamines	group	DDI-DrugBank.d158.s27.e0
DDI-DrugBank.d334.s0|a|Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.
DDI-DrugBank.d334.s0	56	64	diuretics	group	DDI-DrugBank.d334.s0.e0
DDI-DrugBank.d334.s0	240	247	PRINIVIL	brand	DDI-DrugBank.d334.s0.e1
DDI-DrugBank.d334.s0	true	DDI-DrugBank.d334.s0.e0	DDI-DrugBank.d334.s0.e1
DDI-DrugBank.d334.s1|a|The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.
DDI-DrugBank.d334.s1	44	51	PRINIVIL	brand	DDI-DrugBank.d334.s1.e0
DDI-DrugBank.d334.s1	98	105	diuretic	group	DDI-DrugBank.d334.s1.e1
DDI-DrugBank.d334.s1	175	182	PRINIVIL	brand	DDI-DrugBank.d334.s1.e2
DDI-DrugBank.d334.s1	false	DDI-DrugBank.d334.s1.e0	DDI-DrugBank.d334.s1.e1
DDI-DrugBank.d334.s1	false	DDI-DrugBank.d334.s1.e0	DDI-DrugBank.d334.s1.e2
DDI-DrugBank.d334.s1	true	DDI-DrugBank.d334.s1.e1	DDI-DrugBank.d334.s1.e2
DDI-DrugBank.d334.s2|a|If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.
DDI-DrugBank.d334.s2	35	42	diuretic	group	DDI-DrugBank.d334.s2.e0
DDI-DrugBank.d334.s2	67	74	PRINIVIL	brand	DDI-DrugBank.d334.s2.e1
DDI-DrugBank.d334.s2	true	DDI-DrugBank.d334.s2.e0	DDI-DrugBank.d334.s2.e1
DDI-DrugBank.d334.s3|a|When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.
DDI-DrugBank.d334.s3	7	14	diuretic	group	DDI-DrugBank.d334.s3.e0
DDI-DrugBank.d334.s3	63	70	PRINIVIL	brand	DDI-DrugBank.d334.s3.e1
DDI-DrugBank.d334.s3	true	DDI-DrugBank.d334.s3.e0	DDI-DrugBank.d334.s3.e1
DDI-DrugBank.d334.s4|a|Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.
DDI-DrugBank.d334.s4	13	26	ACE inhibitors	group	DDI-DrugBank.d334.s4.e0
DDI-DrugBank.d334.s4	48	56	diuretics	group	DDI-DrugBank.d334.s4.e1
DDI-DrugBank.d334.s4	88	100	ACE inhibitor	group	DDI-DrugBank.d334.s4.e2
DDI-DrugBank.d334.s4	141	148	diuretic	group	DDI-DrugBank.d334.s4.e3
DDI-DrugBank.d334.s4	false	DDI-DrugBank.d334.s4.e0	DDI-DrugBank.d334.s4.e1
DDI-DrugBank.d334.s4	false	DDI-DrugBank.d334.s4.e0	DDI-DrugBank.d334.s4.e2
DDI-DrugBank.d334.s4	false	DDI-DrugBank.d334.s4.e0	DDI-DrugBank.d334.s4.e3
DDI-DrugBank.d334.s4	false	DDI-DrugBank.d334.s4.e1	DDI-DrugBank.d334.s4.e2
DDI-DrugBank.d334.s4	false	DDI-DrugBank.d334.s4.e1	DDI-DrugBank.d334.s4.e3
DDI-DrugBank.d334.s4	true	DDI-DrugBank.d334.s4.e2	DDI-DrugBank.d334.s4.e3
DDI-DrugBank.d334.s5|a|Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.
DDI-DrugBank.d334.s5	0	37	Non-steroidal Anti-inflammatory Agents	group	DDI-DrugBank.d334.s5.e0
DDI-DrugBank.d334.s5	116	152	non-steroidal anti-inflammatory drugs	group	DDI-DrugBank.d334.s5.e1
DDI-DrugBank.d334.s5	180	189	lisinopril	drug	DDI-DrugBank.d334.s5.e2
DDI-DrugBank.d334.s5	false	DDI-DrugBank.d334.s5.e0	DDI-DrugBank.d334.s5.e1
DDI-DrugBank.d334.s5	false	DDI-DrugBank.d334.s5.e0	DDI-DrugBank.d334.s5.e2
DDI-DrugBank.d334.s5	true	DDI-DrugBank.d334.s5.e1	DDI-DrugBank.d334.s5.e2
DDI-DrugBank.d334.s6|a|These effects are usually reversible.
DDI-DrugBank.d334.s7|a|Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.
DDI-DrugBank.d334.s7	21	26	NSAIDs	group	DDI-DrugBank.d334.s7.e0
DDI-DrugBank.d334.s7	72	85	ACE inhibitors	group	DDI-DrugBank.d334.s7.e1
DDI-DrugBank.d334.s7	98	107	lisinopril	drug	DDI-DrugBank.d334.s7.e2
DDI-DrugBank.d334.s7	true	DDI-DrugBank.d334.s7.e0	DDI-DrugBank.d334.s7.e1
DDI-DrugBank.d334.s7	true	DDI-DrugBank.d334.s7.e0	DDI-DrugBank.d334.s7.e2
DDI-DrugBank.d334.s7	false	DDI-DrugBank.d334.s7.e1	DDI-DrugBank.d334.s7.e2
DDI-DrugBank.d334.s8|a|This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
DDI-DrugBank.d334.s8	66	71	NSAIDs	group	DDI-DrugBank.d334.s8.e0
DDI-DrugBank.d334.s8	92	105	ACE inhibitors	group	DDI-DrugBank.d334.s8.e1
DDI-DrugBank.d334.s8	true	DDI-DrugBank.d334.s8.e0	DDI-DrugBank.d334.s8.e1
DDI-DrugBank.d334.s9|a|In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.
DDI-DrugBank.d334.s9	99	106	PRINIVIL	brand	DDI-DrugBank.d334.s9.e0
DDI-DrugBank.d334.s9	131	138	PRINIVIL	brand	DDI-DrugBank.d334.s9.e1
DDI-DrugBank.d334.s9	165	176	indomethacin	drug	DDI-DrugBank.d334.s9.e2
DDI-DrugBank.d334.s9	190	201	indomethacin	drug	DDI-DrugBank.d334.s9.e3
DDI-DrugBank.d334.s9	false	DDI-DrugBank.d334.s9.e0	DDI-DrugBank.d334.s9.e1
DDI-DrugBank.d334.s9	false	DDI-DrugBank.d334.s9.e0	DDI-DrugBank.d334.s9.e2
DDI-DrugBank.d334.s9	false	DDI-DrugBank.d334.s9.e0	DDI-DrugBank.d334.s9.e3
DDI-DrugBank.d334.s9	false	DDI-DrugBank.d334.s9.e1	DDI-DrugBank.d334.s9.e2
DDI-DrugBank.d334.s9	false	DDI-DrugBank.d334.s9.e1	DDI-DrugBank.d334.s9.e3
DDI-DrugBank.d334.s9	false	DDI-DrugBank.d334.s9.e2	DDI-DrugBank.d334.s9.e3
DDI-DrugBank.d334.s10|a|Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.
DDI-DrugBank.d334.s10	14	21	PRINIVIL	brand	DDI-DrugBank.d334.s10.e0
DDI-DrugBank.d334.s10	56	63	nitrates	group	DDI-DrugBank.d334.s10.e1
DDI-DrugBank.d334.s10	72	78	digoxin	drug	DDI-DrugBank.d334.s10.e2
DDI-DrugBank.d334.s10	false	DDI-DrugBank.d334.s10.e0	DDI-DrugBank.d334.s10.e1
DDI-DrugBank.d334.s10	false	DDI-DrugBank.d334.s10.e0	DDI-DrugBank.d334.s10.e2
DDI-DrugBank.d334.s10	false	DDI-DrugBank.d334.s10.e1	DDI-DrugBank.d334.s10.e2
DDI-DrugBank.d334.s11|a|This included post myocardial infarction patients who were receiving intravenous or transdermal nitroglycerin.
DDI-DrugBank.d334.s11	96	108	nitroglycerin	drug	DDI-DrugBank.d334.s11.e0
DDI-DrugBank.d334.s12|a|No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide.
DDI-DrugBank.d334.s12	67	74	PRINIVIL	brand	DDI-DrugBank.d334.s12.e0
DDI-DrugBank.d334.s12	104	114	propranolol	drug	DDI-DrugBank.d334.s12.e1
DDI-DrugBank.d334.s12	119	137	hydrochlorothiazide	drug	DDI-DrugBank.d334.s12.e2
DDI-DrugBank.d334.s12	false	DDI-DrugBank.d334.s12.e0	DDI-DrugBank.d334.s12.e1
DDI-DrugBank.d334.s12	false	DDI-DrugBank.d334.s12.e0	DDI-DrugBank.d334.s12.e2
DDI-DrugBank.d334.s12	false	DDI-DrugBank.d334.s12.e1	DDI-DrugBank.d334.s12.e2
DDI-DrugBank.d334.s13|a|The presence of food in the stomach does not alter the bioavailability of PRINIVIL.
DDI-DrugBank.d334.s13	74	81	PRINIVIL	brand	DDI-DrugBank.d334.s13.e0
DDI-DrugBank.d334.s14|a|Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.
DDI-DrugBank.d334.s14	35	42	PRINIVIL	brand	DDI-DrugBank.d334.s14.e0
DDI-DrugBank.d334.s14	80	102	thiazide-type diuretics	group	DDI-DrugBank.d334.s14.e1
DDI-DrugBank.d334.s14	true	DDI-DrugBank.d334.s14.e0	DDI-DrugBank.d334.s14.e1
DDI-DrugBank.d334.s15|a|Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
DDI-DrugBank.d334.s15	7	14	PRINIVIL	brand	DDI-DrugBank.d334.s15.e0
DDI-DrugBank.d334.s15	21	47	potassium-sparing diuretics	group	DDI-DrugBank.d334.s15.e1
DDI-DrugBank.d334.s15	56	69	spironolactone	drug	DDI-DrugBank.d334.s15.e2
DDI-DrugBank.d334.s15	72	82	triamterene	drug	DDI-DrugBank.d334.s15.e3
DDI-DrugBank.d334.s15	88	96	amiloride	drug	DDI-DrugBank.d334.s15.e4
DDI-DrugBank.d334.s15	100	108	potassium	drug	DDI-DrugBank.d334.s15.e5
DDI-DrugBank.d334.s15	true	DDI-DrugBank.d334.s15.e0	DDI-DrugBank.d334.s15.e1
DDI-DrugBank.d334.s15	true	DDI-DrugBank.d334.s15.e0	DDI-DrugBank.d334.s15.e2
DDI-DrugBank.d334.s15	true	DDI-DrugBank.d334.s15.e0	DDI-DrugBank.d334.s15.e3
DDI-DrugBank.d334.s15	true	DDI-DrugBank.d334.s15.e0	DDI-DrugBank.d334.s15.e4
DDI-DrugBank.d334.s15	true	DDI-DrugBank.d334.s15.e0	DDI-DrugBank.d334.s15.e5
DDI-DrugBank.d334.s15	false	DDI-DrugBank.d334.s15.e1	DDI-DrugBank.d334.s15.e2
DDI-DrugBank.d334.s15	false	DDI-DrugBank.d334.s15.e1	DDI-DrugBank.d334.s15.e3
DDI-DrugBank.d334.s15	false	DDI-DrugBank.d334.s15.e1	DDI-DrugBank.d334.s15.e4
DDI-DrugBank.d334.s15	false	DDI-DrugBank.d334.s15.e1	DDI-DrugBank.d334.s15.e5
DDI-DrugBank.d334.s15	false	DDI-DrugBank.d334.s15.e2	DDI-DrugBank.d334.s15.e3
DDI-DrugBank.d334.s16|a|Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.
DDI-DrugBank.d334.s17|a|Potassium sparing agents should generally not be used in patients with heart failure who are receiving PRINIVIL.
DDI-DrugBank.d334.s17	103	110	PRINIVIL	brand	DDI-DrugBank.d334.s17.e0
DDI-DrugBank.d334.s18|a|Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
DDI-DrugBank.d334.s18	0	6	Lithium	drug	DDI-DrugBank.d334.s18.e0
DDI-DrugBank.d334.s18	9	15	Lithium	drug	DDI-DrugBank.d334.s18.e1
DDI-DrugBank.d334.s18	66	72	lithium	drug	DDI-DrugBank.d334.s18.e2
DDI-DrugBank.d334.s18	144	157	ACE inhibitors	group	DDI-DrugBank.d334.s18.e3
DDI-DrugBank.d334.s18	false	DDI-DrugBank.d334.s18.e0	DDI-DrugBank.d334.s18.e1
DDI-DrugBank.d334.s18	false	DDI-DrugBank.d334.s18.e0	DDI-DrugBank.d334.s18.e2
DDI-DrugBank.d334.s18	false	DDI-DrugBank.d334.s18.e0	DDI-DrugBank.d334.s18.e3
DDI-DrugBank.d334.s18	false	DDI-DrugBank.d334.s18.e1	DDI-DrugBank.d334.s18.e2
DDI-DrugBank.d334.s18	false	DDI-DrugBank.d334.s18.e1	DDI-DrugBank.d334.s18.e3
DDI-DrugBank.d334.s18	true	DDI-DrugBank.d334.s18.e2	DDI-DrugBank.d334.s18.e3
DDI-DrugBank.d334.s19|a|Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.
DDI-DrugBank.d334.s19	0	6	Lithium	drug	DDI-DrugBank.d334.s19.e0
DDI-DrugBank.d334.s19	64	70	lithium	drug	DDI-DrugBank.d334.s19.e1
DDI-DrugBank.d334.s19	80	92	ACE inhibitor	group	DDI-DrugBank.d334.s19.e2
DDI-DrugBank.d334.s19	false	DDI-DrugBank.d334.s19.e0	DDI-DrugBank.d334.s19.e1
DDI-DrugBank.d334.s19	false	DDI-DrugBank.d334.s19.e0	DDI-DrugBank.d334.s19.e2
DDI-DrugBank.d334.s19	true	DDI-DrugBank.d334.s19.e1	DDI-DrugBank.d334.s19.e2
DDI-DrugBank.d334.s20|a|It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.
DDI-DrugBank.d334.s20	29	35	lithium	drug	DDI-DrugBank.d334.s20.e0
DDI-DrugBank.d334.s20	71	78	PRINIVIL	brand	DDI-DrugBank.d334.s20.e1
DDI-DrugBank.d334.s20	115	121	lithium	drug	DDI-DrugBank.d334.s20.e2
DDI-DrugBank.d334.s20	false	DDI-DrugBank.d334.s20.e0	DDI-DrugBank.d334.s20.e1
DDI-DrugBank.d334.s20	false	DDI-DrugBank.d334.s20.e0	DDI-DrugBank.d334.s20.e2
DDI-DrugBank.d334.s20	true	DDI-DrugBank.d334.s20.e1	DDI-DrugBank.d334.s20.e2
DDI-DrugBank.d454.s0|a|- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives
DDI-DrugBank.d454.s0	2	11	Lofexidine	drug	DDI-DrugBank.d454.s0.e0
DDI-DrugBank.d454.s0	55	61	alcohol	drug	DDI-DrugBank.d454.s0.e1
DDI-DrugBank.d454.s0	64	75	barbiturates	group	DDI-DrugBank.d454.s0.e2
DDI-DrugBank.d454.s0	87	95	sedatives	group	DDI-DrugBank.d454.s0.e3
DDI-DrugBank.d454.s0	true	DDI-DrugBank.d454.s0.e0	DDI-DrugBank.d454.s0.e1
DDI-DrugBank.d454.s0	true	DDI-DrugBank.d454.s0.e0	DDI-DrugBank.d454.s0.e2
DDI-DrugBank.d454.s0	true	DDI-DrugBank.d454.s0.e0	DDI-DrugBank.d454.s0.e3
DDI-DrugBank.d454.s0	false	DDI-DrugBank.d454.s0.e1	DDI-DrugBank.d454.s0.e2
DDI-DrugBank.d454.s0	false	DDI-DrugBank.d454.s0.e1	DDI-DrugBank.d454.s0.e3
DDI-DrugBank.d454.s0	false	DDI-DrugBank.d454.s0.e2	DDI-DrugBank.d454.s0.e3
DDI-DrugBank.d454.s1|a|.
DDI-DrugBank.d454.s2|a|- Lofexidine may enhance the effects of anti-hypertensive drug therapy
DDI-DrugBank.d454.s2	2	11	Lofexidine	drug	DDI-DrugBank.d454.s2.e0
DDI-DrugBank.d454.s2	40	61	anti-hypertensive drug	group	DDI-DrugBank.d454.s2.e1
DDI-DrugBank.d454.s2	true	DDI-DrugBank.d454.s2.e0	DDI-DrugBank.d454.s2.e1
DDI-DrugBank.d454.s3|a|.
DDI-DrugBank.d454.s4|a|- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine.
DDI-DrugBank.d454.s4	21	45	tricyclic antidepressants	group	DDI-DrugBank.d454.s4.e0
DDI-DrugBank.d454.s4	74	83	lofexidine	drug	DDI-DrugBank.d454.s4.e1
DDI-DrugBank.d454.s4	true	DDI-DrugBank.d454.s4.e0	DDI-DrugBank.d454.s4.e1
DDI-DrugBank.d516.s0|a|Theophylline: In three pharmacokinetic studies including 46 normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of lomefloxacin.
DDI-DrugBank.d516.s0	0	11	Theophylline	drug	DDI-DrugBank.d516.s0.e0
DDI-DrugBank.d516.s0	86	97	theophylline	drug	DDI-DrugBank.d516.s0.e1
DDI-DrugBank.d516.s0	177	188	lomefloxacin	drug	DDI-DrugBank.d516.s0.e2
DDI-DrugBank.d516.s0	false	DDI-DrugBank.d516.s0.e0	DDI-DrugBank.d516.s0.e1
DDI-DrugBank.d516.s0	false	DDI-DrugBank.d516.s0.e0	DDI-DrugBank.d516.s0.e2
DDI-DrugBank.d516.s0	false	DDI-DrugBank.d516.s0.e1	DDI-DrugBank.d516.s0.e2
DDI-DrugBank.d516.s1|a|In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.
DDI-DrugBank.d516.s1	51	62	theophylline	drug	DDI-DrugBank.d516.s1.e0
DDI-DrugBank.d516.s1	73	84	lomefloxacin	drug	DDI-DrugBank.d516.s1.e1
DDI-DrugBank.d516.s1	139	150	theophylline	drug	DDI-DrugBank.d516.s1.e2
DDI-DrugBank.d516.s1	192	203	theophylline	drug	DDI-DrugBank.d516.s1.e3
DDI-DrugBank.d516.s1	false	DDI-DrugBank.d516.s1.e0	DDI-DrugBank.d516.s1.e1
DDI-DrugBank.d516.s1	false	DDI-DrugBank.d516.s1.e0	DDI-DrugBank.d516.s1.e2
DDI-DrugBank.d516.s1	false	DDI-DrugBank.d516.s1.e0	DDI-DrugBank.d516.s1.e3
DDI-DrugBank.d516.s1	false	DDI-DrugBank.d516.s1.e1	DDI-DrugBank.d516.s1.e2
DDI-DrugBank.d516.s1	false	DDI-DrugBank.d516.s1.e1	DDI-DrugBank.d516.s1.e3
DDI-DrugBank.d516.s1	false	DDI-DrugBank.d516.s1.e2	DDI-DrugBank.d516.s1.e3
DDI-DrugBank.d516.s2|a|Though individual theophylline levels fluctuated, there were no clinically significant symptoms of drug inter-action.
DDI-DrugBank.d516.s2	18	29	theophylline	drug	DDI-DrugBank.d516.s2.e0
DDI-DrugBank.d516.s3|a|Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
DDI-DrugBank.d516.s3	0	7	Antacids	group	DDI-DrugBank.d516.s3.e0
DDI-DrugBank.d516.s3	13	22	sucralfate	drug	DDI-DrugBank.d516.s3.e1
DDI-DrugBank.d516.s3	25	34	Sucralfate	drug	DDI-DrugBank.d516.s3.e2
DDI-DrugBank.d516.s3	40	47	antacids	group	DDI-DrugBank.d516.s3.e3
DDI-DrugBank.d516.s3	60	68	magnesium	drug	DDI-DrugBank.d516.s3.e4
DDI-DrugBank.d516.s3	73	80	aluminum	drug	DDI-DrugBank.d516.s3.e5
DDI-DrugBank.d516.s3	157	161	Videx	brand	DDI-DrugBank.d516.s3.e6
DDI-DrugBank.d516.s3	165	174	didanosine	drug	DDI-DrugBank.d516.s3.e7
DDI-DrugBank.d516.s3	280	291	lomefloxacin	drug	DDI-DrugBank.d516.s3.e8
DDI-DrugBank.d516.s3	false	DDI-DrugBank.d516.s3.e0	DDI-DrugBank.d516.s3.e1
DDI-DrugBank.d516.s3	false	DDI-DrugBank.d516.s3.e0	DDI-DrugBank.d516.s3.e2
DDI-DrugBank.d516.s3	false	DDI-DrugBank.d516.s3.e0	DDI-DrugBank.d516.s3.e3
DDI-DrugBank.d516.s3	false	DDI-DrugBank.d516.s3.e0	DDI-DrugBank.d516.s3.e4
DDI-DrugBank.d516.s3	false	DDI-DrugBank.d516.s3.e0	DDI-DrugBank.d516.s3.e5
DDI-DrugBank.d516.s3	false	DDI-DrugBank.d516.s3.e0	DDI-DrugBank.d516.s3.e6
DDI-DrugBank.d516.s3	false	DDI-DrugBank.d516.s3.e0	DDI-DrugBank.d516.s3.e7
DDI-DrugBank.d516.s3	false	DDI-DrugBank.d516.s3.e0	DDI-DrugBank.d516.s3.e8
DDI-DrugBank.d516.s3	false	DDI-DrugBank.d516.s3.e1	DDI-DrugBank.d516.s3.e2
DDI-DrugBank.d516.s3	false	DDI-DrugBank.d516.s3.e1	DDI-DrugBank.d516.s3.e3
DDI-DrugBank.d516.s4|a|Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).
DDI-DrugBank.d516.s4	0	9	Sucralfate	drug	DDI-DrugBank.d516.s4.e0
DDI-DrugBank.d516.s4	39	50	lomefloxacin	drug	DDI-DrugBank.d516.s4.e1
DDI-DrugBank.d516.s4	true	DDI-DrugBank.d516.s4.e0	DDI-DrugBank.d516.s4.e1
DDI-DrugBank.d516.s5|a|Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
DDI-DrugBank.d516.s5	0	8	Magnesium	drug	DDI-DrugBank.d516.s5.e0
DDI-DrugBank.d516.s5	15	22	aluminum	drug	DDI-DrugBank.d516.s5.e1
DDI-DrugBank.d516.s5	35	42	antacids	group	DDI-DrugBank.d516.s5.e2
DDI-DrugBank.d516.s5	77	88	lomefloxacin	drug	DDI-DrugBank.d516.s5.e3
DDI-DrugBank.d516.s5	144	155	lomefloxacin	drug	DDI-DrugBank.d516.s5.e4
DDI-DrugBank.d516.s5	false	DDI-DrugBank.d516.s5.e0	DDI-DrugBank.d516.s5.e1
DDI-DrugBank.d516.s5	false	DDI-DrugBank.d516.s5.e0	DDI-DrugBank.d516.s5.e2
DDI-DrugBank.d516.s5	true	DDI-DrugBank.d516.s5.e0	DDI-DrugBank.d516.s5.e3
DDI-DrugBank.d516.s5	false	DDI-DrugBank.d516.s5.e0	DDI-DrugBank.d516.s5.e4
DDI-DrugBank.d516.s5	false	DDI-DrugBank.d516.s5.e1	DDI-DrugBank.d516.s5.e2
DDI-DrugBank.d516.s5	true	DDI-DrugBank.d516.s5.e1	DDI-DrugBank.d516.s5.e3
DDI-DrugBank.d516.s5	false	DDI-DrugBank.d516.s5.e1	DDI-DrugBank.d516.s5.e4
DDI-DrugBank.d516.s5	true	DDI-DrugBank.d516.s5.e2	DDI-DrugBank.d516.s5.e3
DDI-DrugBank.d516.s5	false	DDI-DrugBank.d516.s5.e2	DDI-DrugBank.d516.s5.e4
DDI-DrugBank.d516.s5	false	DDI-DrugBank.d516.s5.e3	DDI-DrugBank.d516.s5.e4
DDI-DrugBank.d516.s6|a|Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;
DDI-DrugBank.d516.s6	24	30	antacid	group	DDI-DrugBank.d516.s6.e0
DDI-DrugBank.d516.s6	36	47	lomefloxacin	drug	DDI-DrugBank.d516.s6.e1
DDI-DrugBank.d516.s6	true	DDI-DrugBank.d516.s6.e0	DDI-DrugBank.d516.s6.e1
DDI-DrugBank.d516.s7|a|therefore, administration of these agents should precede lomefloxacin dosing by 4 hours or follow lomefloxacin dosing by at least 2 hours.
DDI-DrugBank.d516.s7	57	68	lomefloxacin	drug	DDI-DrugBank.d516.s7.e0
DDI-DrugBank.d516.s7	98	109	lomefloxacin	drug	DDI-DrugBank.d516.s7.e1
DDI-DrugBank.d516.s7	false	DDI-DrugBank.d516.s7.e0	DDI-DrugBank.d516.s7.e1
DDI-DrugBank.d516.s8|a|Caffeine: Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at 400 mg qd.
DDI-DrugBank.d516.s8	0	7	Caffeine	drug	DDI-DrugBank.d516.s8.e0
DDI-DrugBank.d516.s8	28	35	caffeine	drug	DDI-DrugBank.d516.s8.e1
DDI-DrugBank.d516.s8	188	199	lomefloxacin	drug	DDI-DrugBank.d516.s8.e2
DDI-DrugBank.d516.s8	false	DDI-DrugBank.d516.s8.e0	DDI-DrugBank.d516.s8.e1
DDI-DrugBank.d516.s8	false	DDI-DrugBank.d516.s8.e0	DDI-DrugBank.d516.s8.e2
DDI-DrugBank.d516.s8	false	DDI-DrugBank.d516.s8.e1	DDI-DrugBank.d516.s8.e2
DDI-DrugBank.d516.s9|a|This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either caffeine or its major metabolite, paraxanthine.
DDI-DrugBank.d516.s9	116	123	caffeine	drug	DDI-DrugBank.d516.s9.e0
DDI-DrugBank.d516.s9	150	161	paraxanthine	drug_n	DDI-DrugBank.d516.s9.e1
DDI-DrugBank.d516.s9	false	DDI-DrugBank.d516.s9.e0	DDI-DrugBank.d516.s9.e1
DDI-DrugBank.d516.s10|a|No data are available on potential interactions in individuals who consume greater than 200 mg of caffeine per day or in those, such as the geriatric population, who are generally believed to be more susceptible to the development of drug-induced CNS-related adverse effects.
DDI-DrugBank.d516.s10	98	105	caffeine	drug	DDI-DrugBank.d516.s10.e0
DDI-DrugBank.d516.s11|a|Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.
DDI-DrugBank.d516.s11	6	15	quinolones	group	DDI-DrugBank.d516.s11.e0
DDI-DrugBank.d516.s11	90	97	caffeine	drug	DDI-DrugBank.d516.s11.e1
DDI-DrugBank.d516.s11	228	235	caffeine	drug	DDI-DrugBank.d516.s11.e2
DDI-DrugBank.d516.s11	true	DDI-DrugBank.d516.s11.e0	DDI-DrugBank.d516.s11.e1
DDI-DrugBank.d516.s11	false	DDI-DrugBank.d516.s11.e0	DDI-DrugBank.d516.s11.e2
DDI-DrugBank.d516.s11	false	DDI-DrugBank.d516.s11.e1	DDI-DrugBank.d516.s11.e2
DDI-DrugBank.d516.s12|a|Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.
DDI-DrugBank.d516.s12	0	9	Cimetidine	drug	DDI-DrugBank.d516.s12.e0
DDI-DrugBank.d516.s12	12	21	Cimetidine	drug	DDI-DrugBank.d516.s12.e1
DDI-DrugBank.d516.s12	88	97	quinolones	group	DDI-DrugBank.d516.s12.e2
DDI-DrugBank.d516.s12	false	DDI-DrugBank.d516.s12.e0	DDI-DrugBank.d516.s12.e1
DDI-DrugBank.d516.s12	false	DDI-DrugBank.d516.s12.e0	DDI-DrugBank.d516.s12.e2
DDI-DrugBank.d516.s12	true	DDI-DrugBank.d516.s12.e1	DDI-DrugBank.d516.s12.e2
DDI-DrugBank.d516.s13|a|This interference has resulted in significant increases in half-life and AUC.
DDI-DrugBank.d516.s14|a|The interaction between lomefloxacin and cimetidine has not been studied.
DDI-DrugBank.d516.s14	24	35	lomefloxacin	drug	DDI-DrugBank.d516.s14.e0
DDI-DrugBank.d516.s14	41	50	cimetidine	drug	DDI-DrugBank.d516.s14.e1
DDI-DrugBank.d516.s14	false	DDI-DrugBank.d516.s14.e0	DDI-DrugBank.d516.s14.e1
DDI-DrugBank.d516.s15|a|Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
DDI-DrugBank.d516.s15	0	11	Cyclosporine	drug	DDI-DrugBank.d516.s15.e0
DDI-DrugBank.d516.s15	39	50	cyclosporine	drug	DDI-DrugBank.d516.s15.e1
DDI-DrugBank.d516.s15	95	106	cyclosporine	drug	DDI-DrugBank.d516.s15.e2
DDI-DrugBank.d516.s15	134	148	quinolone class	group	DDI-DrugBank.d516.s15.e3
DDI-DrugBank.d516.s15	false	DDI-DrugBank.d516.s15.e0	DDI-DrugBank.d516.s15.e1
DDI-DrugBank.d516.s15	false	DDI-DrugBank.d516.s15.e0	DDI-DrugBank.d516.s15.e2
DDI-DrugBank.d516.s15	false	DDI-DrugBank.d516.s15.e0	DDI-DrugBank.d516.s15.e3
DDI-DrugBank.d516.s15	false	DDI-DrugBank.d516.s15.e1	DDI-DrugBank.d516.s15.e2
DDI-DrugBank.d516.s15	false	DDI-DrugBank.d516.s15.e1	DDI-DrugBank.d516.s15.e3
DDI-DrugBank.d516.s15	true	DDI-DrugBank.d516.s15.e2	DDI-DrugBank.d516.s15.e3
DDI-DrugBank.d516.s16|a|Interaction between lomefloxacin and cyclosporine has not been studied.
DDI-DrugBank.d516.s16	20	31	lomefloxacin	drug	DDI-DrugBank.d516.s16.e0
DDI-DrugBank.d516.s16	37	48	cyclosporine	drug	DDI-DrugBank.d516.s16.e1
DDI-DrugBank.d516.s16	false	DDI-DrugBank.d516.s16.e0	DDI-DrugBank.d516.s16.e1
DDI-DrugBank.d516.s17|a|Omeprazole: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.
DDI-DrugBank.d516.s17	0	9	Omeprazole	drug	DDI-DrugBank.d516.s17.e0
DDI-DrugBank.d516.s17	49	60	lomefloxacin	drug	DDI-DrugBank.d516.s17.e1
DDI-DrugBank.d516.s17	140	151	lomefloxacin	drug	DDI-DrugBank.d516.s17.e2
DDI-DrugBank.d516.s17	194	203	omeprazole	drug	DDI-DrugBank.d516.s17.e3
DDI-DrugBank.d516.s17	false	DDI-DrugBank.d516.s17.e0	DDI-DrugBank.d516.s17.e1
DDI-DrugBank.d516.s17	false	DDI-DrugBank.d516.s17.e0	DDI-DrugBank.d516.s17.e2
DDI-DrugBank.d516.s17	false	DDI-DrugBank.d516.s17.e0	DDI-DrugBank.d516.s17.e3
DDI-DrugBank.d516.s17	false	DDI-DrugBank.d516.s17.e1	DDI-DrugBank.d516.s17.e2
DDI-DrugBank.d516.s17	false	DDI-DrugBank.d516.s17.e1	DDI-DrugBank.d516.s17.e3
DDI-DrugBank.d516.s17	false	DDI-DrugBank.d516.s17.e2	DDI-DrugBank.d516.s17.e3
DDI-DrugBank.d516.s18|a|Changes in omeprazole pharmacokinetics were not studied.
DDI-DrugBank.d516.s18	11	20	omeprazole	drug	DDI-DrugBank.d516.s18.e0
DDI-DrugBank.d516.s19|a|Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.
DDI-DrugBank.d516.s19	0	8	Phenytoin	drug	DDI-DrugBank.d516.s19.e0
DDI-DrugBank.d516.s19	60	68	phenytoin	drug	DDI-DrugBank.d516.s19.e1
DDI-DrugBank.d516.s19	146	161	phenytoin sodium	drug	DDI-DrugBank.d516.s19.e2
DDI-DrugBank.d516.s19	210	221	lomefloxacin	drug	DDI-DrugBank.d516.s19.e3
DDI-DrugBank.d516.s19	false	DDI-DrugBank.d516.s19.e0	DDI-DrugBank.d516.s19.e1
DDI-DrugBank.d516.s19	false	DDI-DrugBank.d516.s19.e0	DDI-DrugBank.d516.s19.e2
DDI-DrugBank.d516.s19	false	DDI-DrugBank.d516.s19.e0	DDI-DrugBank.d516.s19.e3
DDI-DrugBank.d516.s19	false	DDI-DrugBank.d516.s19.e1	DDI-DrugBank.d516.s19.e2
DDI-DrugBank.d516.s19	false	DDI-DrugBank.d516.s19.e1	DDI-DrugBank.d516.s19.e3
DDI-DrugBank.d516.s19	false	DDI-DrugBank.d516.s19.e2	DDI-DrugBank.d516.s19.e3
DDI-DrugBank.d516.s20|a|Lomefloxacin is unlikely to have a significant effect on phenytoin metabolism.
DDI-DrugBank.d516.s20	0	11	Lomefloxacin	drug	DDI-DrugBank.d516.s20.e0
DDI-DrugBank.d516.s20	57	65	phenytoin	drug	DDI-DrugBank.d516.s20.e1
DDI-DrugBank.d516.s20	false	DDI-DrugBank.d516.s20.e0	DDI-DrugBank.d516.s20.e1
DDI-DrugBank.d516.s21|a|Probenecid: Probenecid slows the renal elimination of lome-floxacin.
DDI-DrugBank.d516.s21	0	9	Probenecid	drug	DDI-DrugBank.d516.s21.e0
DDI-DrugBank.d516.s21	12	21	Probenecid	drug	DDI-DrugBank.d516.s21.e1
DDI-DrugBank.d516.s21	false	DDI-DrugBank.d516.s21.e0	DDI-DrugBank.d516.s21.e1
DDI-DrugBank.d516.s22|a|An increase of 63% in the mean AUC and increases of 50% and 4%, respectively, in the mean T max and mean C max were noted in 1 study of 6 individuals.
DDI-DrugBank.d516.s23|a|Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.
DDI-DrugBank.d516.s23	0	10	Terfenadine	drug	DDI-DrugBank.d516.s23.e0
DDI-DrugBank.d516.s23	103	113	terfenadine	drug	DDI-DrugBank.d516.s23.e1
DDI-DrugBank.d516.s23	129	140	lomefloxacin	drug	DDI-DrugBank.d516.s23.e2
DDI-DrugBank.d516.s23	196	207	lomefloxacin	drug	DDI-DrugBank.d516.s23.e3
DDI-DrugBank.d516.s23	213	223	terfenadine	drug	DDI-DrugBank.d516.s23.e4
DDI-DrugBank.d516.s23	false	DDI-DrugBank.d516.s23.e0	DDI-DrugBank.d516.s23.e1
DDI-DrugBank.d516.s23	false	DDI-DrugBank.d516.s23.e0	DDI-DrugBank.d516.s23.e2
DDI-DrugBank.d516.s23	false	DDI-DrugBank.d516.s23.e0	DDI-DrugBank.d516.s23.e3
DDI-DrugBank.d516.s23	false	DDI-DrugBank.d516.s23.e0	DDI-DrugBank.d516.s23.e4
DDI-DrugBank.d516.s23	false	DDI-DrugBank.d516.s23.e1	DDI-DrugBank.d516.s23.e2
DDI-DrugBank.d516.s23	false	DDI-DrugBank.d516.s23.e1	DDI-DrugBank.d516.s23.e3
DDI-DrugBank.d516.s23	false	DDI-DrugBank.d516.s23.e1	DDI-DrugBank.d516.s23.e4
DDI-DrugBank.d516.s23	false	DDI-DrugBank.d516.s23.e2	DDI-DrugBank.d516.s23.e3
DDI-DrugBank.d516.s23	false	DDI-DrugBank.d516.s23.e2	DDI-DrugBank.d516.s23.e4
DDI-DrugBank.d516.s23	false	DDI-DrugBank.d516.s23.e3	DDI-DrugBank.d516.s23.e4
DDI-DrugBank.d516.s24|a|Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
DDI-DrugBank.d516.s24	0	7	Warfarin	drug	DDI-DrugBank.d516.s24.e0
DDI-DrugBank.d516.s24	10	19	Quinolones	group	DDI-DrugBank.d516.s24.e1
DDI-DrugBank.d516.s24	57	69	anticoagulant	group	DDI-DrugBank.d516.s24.e2
DDI-DrugBank.d516.s24	72	79	warfarin	drug	DDI-DrugBank.d516.s24.e3
DDI-DrugBank.d516.s24	false	DDI-DrugBank.d516.s24.e0	DDI-DrugBank.d516.s24.e1
DDI-DrugBank.d516.s24	false	DDI-DrugBank.d516.s24.e0	DDI-DrugBank.d516.s24.e2
DDI-DrugBank.d516.s24	false	DDI-DrugBank.d516.s24.e0	DDI-DrugBank.d516.s24.e3
DDI-DrugBank.d516.s24	true	DDI-DrugBank.d516.s24.e1	DDI-DrugBank.d516.s24.e2
DDI-DrugBank.d516.s24	true	DDI-DrugBank.d516.s24.e1	DDI-DrugBank.d516.s24.e3
DDI-DrugBank.d516.s24	false	DDI-DrugBank.d516.s24.e2	DDI-DrugBank.d516.s24.e3
DDI-DrugBank.d516.s25|a|When these products are administered concomitantly, prothrombin or other suitable coagulation tests should be monitored closely.
DDI-DrugBank.d516.s26|a|However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and lomefloxacin under steady-state conditions.
DDI-DrugBank.d516.s26	93	100	warfarin	drug	DDI-DrugBank.d516.s26.e0
DDI-DrugBank.d516.s26	198	205	warfarin	drug	DDI-DrugBank.d516.s26.e1
DDI-DrugBank.d516.s26	211	222	lomefloxacin	drug	DDI-DrugBank.d516.s26.e2
DDI-DrugBank.d516.s26	false	DDI-DrugBank.d516.s26.e0	DDI-DrugBank.d516.s26.e1
DDI-DrugBank.d516.s26	false	DDI-DrugBank.d516.s26.e0	DDI-DrugBank.d516.s26.e2
DDI-DrugBank.d516.s26	false	DDI-DrugBank.d516.s26.e1	DDI-DrugBank.d516.s26.e2
DDI-DrugBank.d125.s0|a|There was no evidence in clinical trials of drug interactions with concurrent medications.
DDI-DrugBank.d351.s0|a|Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.
DDI-DrugBank.d351.s0	0	9	Probenecid	drug	DDI-DrugBank.d351.s0.e0
DDI-DrugBank.d351.s0	26	45	b-lactam antibiotics	group	DDI-DrugBank.d351.s0.e1
DDI-DrugBank.d351.s0	67	76	loracarbef	drug	DDI-DrugBank.d351.s0.e2
DDI-DrugBank.d351.s0	94	103	probenecid	drug	DDI-DrugBank.d351.s0.e3
DDI-DrugBank.d351.s0	164	173	loracarbef	drug	DDI-DrugBank.d351.s0.e4
DDI-DrugBank.d351.s0	false	DDI-DrugBank.d351.s0.e0	DDI-DrugBank.d351.s0.e1
DDI-DrugBank.d351.s0	false	DDI-DrugBank.d351.s0.e0	DDI-DrugBank.d351.s0.e2
DDI-DrugBank.d351.s0	false	DDI-DrugBank.d351.s0.e0	DDI-DrugBank.d351.s0.e3
DDI-DrugBank.d351.s0	false	DDI-DrugBank.d351.s0.e0	DDI-DrugBank.d351.s0.e4
DDI-DrugBank.d351.s0	false	DDI-DrugBank.d351.s0.e1	DDI-DrugBank.d351.s0.e2
DDI-DrugBank.d351.s0	true	DDI-DrugBank.d351.s0.e1	DDI-DrugBank.d351.s0.e3
DDI-DrugBank.d351.s0	false	DDI-DrugBank.d351.s0.e1	DDI-DrugBank.d351.s0.e4
DDI-DrugBank.d351.s0	true	DDI-DrugBank.d351.s0.e2	DDI-DrugBank.d351.s0.e3
DDI-DrugBank.d351.s0	false	DDI-DrugBank.d351.s0.e2	DDI-DrugBank.d351.s0.e4
DDI-DrugBank.d351.s0	false	DDI-DrugBank.d351.s0.e3	DDI-DrugBank.d351.s0.e4
DDI-DrugBank.d258.s0|a|Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.
DDI-DrugBank.d258.s0	0	9	Loratadine	drug	DDI-DrugBank.d258.s0.e0
DDI-DrugBank.d258.s0	80	91	erythromycin	drug	DDI-DrugBank.d258.s0.e1
DDI-DrugBank.d258.s0	94	103	cimetidine	drug	DDI-DrugBank.d258.s0.e2
DDI-DrugBank.d258.s0	110	121	ketoconazole	drug	DDI-DrugBank.d258.s0.e3
DDI-DrugBank.d258.s0	false	DDI-DrugBank.d258.s0.e0	DDI-DrugBank.d258.s0.e1
DDI-DrugBank.d258.s0	false	DDI-DrugBank.d258.s0.e0	DDI-DrugBank.d258.s0.e2
DDI-DrugBank.d258.s0	false	DDI-DrugBank.d258.s0.e0	DDI-DrugBank.d258.s0.e3
DDI-DrugBank.d258.s0	false	DDI-DrugBank.d258.s0.e1	DDI-DrugBank.d258.s0.e2
DDI-DrugBank.d258.s0	false	DDI-DrugBank.d258.s0.e1	DDI-DrugBank.d258.s0.e3
DDI-DrugBank.d258.s0	false	DDI-DrugBank.d258.s0.e2	DDI-DrugBank.d258.s0.e3
DDI-DrugBank.d258.s1|a|Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.
DDI-DrugBank.d258.s1	59	68	loratadine	drug	DDI-DrugBank.d258.s1.e0
DDI-DrugBank.d258.s1	77	100	descarboethoxyloratadine	drug	DDI-DrugBank.d258.s1.e1
DDI-DrugBank.d258.s1	146	155	loratadine	drug	DDI-DrugBank.d258.s1.e2
DDI-DrugBank.d258.s1	294	303	loratadine	drug	DDI-DrugBank.d258.s1.e3
DDI-DrugBank.d258.s1	false	DDI-DrugBank.d258.s1.e0	DDI-DrugBank.d258.s1.e1
DDI-DrugBank.d258.s1	false	DDI-DrugBank.d258.s1.e0	DDI-DrugBank.d258.s1.e2
DDI-DrugBank.d258.s1	false	DDI-DrugBank.d258.s1.e0	DDI-DrugBank.d258.s1.e3
DDI-DrugBank.d258.s1	false	DDI-DrugBank.d258.s1.e1	DDI-DrugBank.d258.s1.e2
DDI-DrugBank.d258.s1	false	DDI-DrugBank.d258.s1.e1	DDI-DrugBank.d258.s1.e3
DDI-DrugBank.d258.s1	false	DDI-DrugBank.d258.s1.e2	DDI-DrugBank.d258.s1.e3
DDI-DrugBank.d258.s2|a|There were no significant effects on QTc intervals, and no reports of sedation or syncope.
DDI-DrugBank.d258.s3|a|No effects on plasma concentrations of cimetidine or ketoconazole were observed.
DDI-DrugBank.d258.s3	39	48	cimetidine	drug	DDI-DrugBank.d258.s3.e0
DDI-DrugBank.d258.s3	53	64	ketoconazole	drug	DDI-DrugBank.d258.s3.e1
DDI-DrugBank.d258.s3	false	DDI-DrugBank.d258.s3.e0	DDI-DrugBank.d258.s3.e1
DDI-DrugBank.d258.s4|a|Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.
DDI-DrugBank.d258.s4	40	51	erythromycin	drug	DDI-DrugBank.d258.s4.e0
DDI-DrugBank.d258.s4	92	101	loratadine	drug	DDI-DrugBank.d258.s4.e1
DDI-DrugBank.d258.s4	134	145	erythromycin	drug	DDI-DrugBank.d258.s4.e2
DDI-DrugBank.d258.s4	true	DDI-DrugBank.d258.s4.e0	DDI-DrugBank.d258.s4.e1
DDI-DrugBank.d258.s4	false	DDI-DrugBank.d258.s4.e0	DDI-DrugBank.d258.s4.e2
DDI-DrugBank.d258.s4	false	DDI-DrugBank.d258.s4.e1	DDI-DrugBank.d258.s4.e2
DDI-DrugBank.d258.s5|a|The clinical relevance of this difference is unknown.
DDI-DrugBank.d258.s6|a|These above findings are summarized in TABLE 1.
DDI-DrugBank.d258.s7|a|TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and Descarboethoxyloratadine After 10 Days of Coadministration (Loratadine 10 mg) in Normal Volunteers
DDI-DrugBank.d258.s7	59	68	Loratadine	drug	DDI-DrugBank.d258.s7.e0
DDI-DrugBank.d258.s7	74	97	Descarboethoxyloratadine	drug	DDI-DrugBank.d258.s7.e1
DDI-DrugBank.d258.s7	134	143	Loratadine	drug	DDI-DrugBank.d258.s7.e2
DDI-DrugBank.d258.s7	false	DDI-DrugBank.d258.s7.e0	DDI-DrugBank.d258.s7.e1
DDI-DrugBank.d258.s7	false	DDI-DrugBank.d258.s7.e0	DDI-DrugBank.d258.s7.e2
DDI-DrugBank.d258.s7	false	DDI-DrugBank.d258.s7.e1	DDI-DrugBank.d258.s7.e2
DDI-DrugBank.d258.s8|a|Loratadine Descarboethoxyloratadine
DDI-DrugBank.d258.s8	0	9	Loratadine	drug	DDI-DrugBank.d258.s8.e0
DDI-DrugBank.d258.s8	11	34	Descarboethoxyloratadine	drug	DDI-DrugBank.d258.s8.e1
DDI-DrugBank.d258.s8	false	DDI-DrugBank.d258.s8.e0	DDI-DrugBank.d258.s8.e1
DDI-DrugBank.d258.s9|a|Erythromycin (500 mg q8h) + 40% +46%
DDI-DrugBank.d258.s9	0	11	Erythromycin	drug	DDI-DrugBank.d258.s9.e0
DDI-DrugBank.d258.s10|a|Cimetidine (300 mg qid) +103% + 6%
DDI-DrugBank.d258.s10	0	9	Cimetidine	drug	DDI-DrugBank.d258.s10.e0
DDI-DrugBank.d258.s11|a|Ketoconazole (200 mg q12h) +307% +73%
DDI-DrugBank.d258.s11	0	11	Ketoconazole	drug	DDI-DrugBank.d258.s11.e0
DDI-DrugBank.d258.s12|a|There does not appear to be an increase in adverse events in subjects who received oral contraceptives and loratadine.
DDI-DrugBank.d258.s12	88	101	contraceptives	group	DDI-DrugBank.d258.s12.e0
DDI-DrugBank.d258.s12	107	116	loratadine	drug	DDI-DrugBank.d258.s12.e1
DDI-DrugBank.d258.s12	false	DDI-DrugBank.d258.s12.e0	DDI-DrugBank.d258.s12.e1
DDI-DrugBank.d18.s0|a|Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
DDI-DrugBank.d18.s0	13	27	benzodiazepines	group	DDI-DrugBank.d18.s0.e0
DDI-DrugBank.d18.s0	40	48	lorazepam	drug	DDI-DrugBank.d18.s0.e1
DDI-DrugBank.d18.s0	125	136	barbiturates	group	DDI-DrugBank.d18.s0.e2
DDI-DrugBank.d18.s0	141	147	alcohol	drug	DDI-DrugBank.d18.s0.e3
DDI-DrugBank.d18.s0	false	DDI-DrugBank.d18.s0.e0	DDI-DrugBank.d18.s0.e1
DDI-DrugBank.d18.s0	true	DDI-DrugBank.d18.s0.e0	DDI-DrugBank.d18.s0.e2
DDI-DrugBank.d18.s0	true	DDI-DrugBank.d18.s0.e0	DDI-DrugBank.d18.s0.e3
DDI-DrugBank.d18.s0	true	DDI-DrugBank.d18.s0.e1	DDI-DrugBank.d18.s0.e2
DDI-DrugBank.d18.s0	true	DDI-DrugBank.d18.s0.e1	DDI-DrugBank.d18.s0.e3
DDI-DrugBank.d18.s0	false	DDI-DrugBank.d18.s0.e2	DDI-DrugBank.d18.s0.e3
DDI-DrugBank.d18.s1|a|Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d18.s1	11	19	Lorazepam	drug	DDI-DrugBank.d18.s1.e0
DDI-DrugBank.d18.s1	54	68	benzodiazepines	group	DDI-DrugBank.d18.s1.e1
DDI-DrugBank.d18.s1	144	156	ethyl alcohol	drug	DDI-DrugBank.d18.s1.e2
DDI-DrugBank.d18.s1	159	172	phenothiazines	group	DDI-DrugBank.d18.s1.e3
DDI-DrugBank.d18.s1	175	186	barbiturates	group	DDI-DrugBank.d18.s1.e4
DDI-DrugBank.d18.s1	189	202	MAO inhibitors	group	DDI-DrugBank.d18.s1.e5
DDI-DrugBank.d18.s1	215	229	antidepressants	group	DDI-DrugBank.d18.s1.e6
DDI-DrugBank.d18.s1	236	246	scopolamine	drug	DDI-DrugBank.d18.s1.e7
DDI-DrugBank.d18.s1	286	294	lorazepam	drug	DDI-DrugBank.d18.s1.e8
DDI-DrugBank.d18.s1	false	DDI-DrugBank.d18.s1.e0	DDI-DrugBank.d18.s1.e1
DDI-DrugBank.d18.s1	true	DDI-DrugBank.d18.s1.e0	DDI-DrugBank.d18.s1.e2
DDI-DrugBank.d18.s1	true	DDI-DrugBank.d18.s1.e0	DDI-DrugBank.d18.s1.e3
DDI-DrugBank.d18.s1	true	DDI-DrugBank.d18.s1.e0	DDI-DrugBank.d18.s1.e4
DDI-DrugBank.d18.s1	true	DDI-DrugBank.d18.s1.e0	DDI-DrugBank.d18.s1.e5
DDI-DrugBank.d18.s1	true	DDI-DrugBank.d18.s1.e0	DDI-DrugBank.d18.s1.e6
DDI-DrugBank.d18.s1	false	DDI-DrugBank.d18.s1.e0	DDI-DrugBank.d18.s1.e7
DDI-DrugBank.d18.s1	false	DDI-DrugBank.d18.s1.e0	DDI-DrugBank.d18.s1.e8
DDI-DrugBank.d18.s1	true	DDI-DrugBank.d18.s1.e1	DDI-DrugBank.d18.s1.e2
DDI-DrugBank.d18.s1	true	DDI-DrugBank.d18.s1.e1	DDI-DrugBank.d18.s1.e3
DDI-DrugBank.d30.s0|a|No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.
DDI-DrugBank.d30.s0	98	116	hydrochlorothiazide	drug	DDI-DrugBank.d30.s0.e0
DDI-DrugBank.d30.s0	119	125	digoxin	drug	DDI-DrugBank.d30.s0.e1
DDI-DrugBank.d30.s0	128	135	warfarin	drug	DDI-DrugBank.d30.s0.e2
DDI-DrugBank.d30.s0	138	147	cimetidine	drug	DDI-DrugBank.d30.s0.e3
DDI-DrugBank.d30.s0	153	165	phenobarbital	drug	DDI-DrugBank.d30.s0.e4
DDI-DrugBank.d30.s0	false	DDI-DrugBank.d30.s0.e0	DDI-DrugBank.d30.s0.e1
DDI-DrugBank.d30.s0	false	DDI-DrugBank.d30.s0.e0	DDI-DrugBank.d30.s0.e2
DDI-DrugBank.d30.s0	false	DDI-DrugBank.d30.s0.e0	DDI-DrugBank.d30.s0.e3
DDI-DrugBank.d30.s0	false	DDI-DrugBank.d30.s0.e0	DDI-DrugBank.d30.s0.e4
DDI-DrugBank.d30.s0	false	DDI-DrugBank.d30.s0.e1	DDI-DrugBank.d30.s0.e2
DDI-DrugBank.d30.s0	false	DDI-DrugBank.d30.s0.e1	DDI-DrugBank.d30.s0.e3
DDI-DrugBank.d30.s0	false	DDI-DrugBank.d30.s0.e1	DDI-DrugBank.d30.s0.e4
DDI-DrugBank.d30.s0	false	DDI-DrugBank.d30.s0.e2	DDI-DrugBank.d30.s0.e3
DDI-DrugBank.d30.s0	false	DDI-DrugBank.d30.s0.e2	DDI-DrugBank.d30.s0.e4
DDI-DrugBank.d30.s0	false	DDI-DrugBank.d30.s0.e3	DDI-DrugBank.d30.s0.e4
DDI-DrugBank.d30.s1|a|Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.
DDI-DrugBank.d30.s1	0	7	Rifampin	drug	DDI-DrugBank.d30.s1.e0
DDI-DrugBank.d30.s1	73	80	losartan	drug	DDI-DrugBank.d30.s1.e1
DDI-DrugBank.d30.s1	true	DDI-DrugBank.d30.s1.e0	DDI-DrugBank.d30.s1.e1
DDI-DrugBank.d30.s2|a|In humans, two inhibitors of P450 3A4 have been studied.
DDI-DrugBank.d30.s3|a|Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.
DDI-DrugBank.d30.s3	0	11	Ketoconazole	drug	DDI-DrugBank.d30.s3.e0
DDI-DrugBank.d30.s3	46	53	losartan	drug	DDI-DrugBank.d30.s3.e1
DDI-DrugBank.d30.s3	116	123	losartan	drug	DDI-DrugBank.d30.s3.e2
DDI-DrugBank.d30.s3	130	141	erythromycin	drug	DDI-DrugBank.d30.s3.e3
DDI-DrugBank.d30.s3	false	DDI-DrugBank.d30.s3.e0	DDI-DrugBank.d30.s3.e1
DDI-DrugBank.d30.s3	false	DDI-DrugBank.d30.s3.e0	DDI-DrugBank.d30.s3.e2
DDI-DrugBank.d30.s3	false	DDI-DrugBank.d30.s3.e0	DDI-DrugBank.d30.s3.e3
DDI-DrugBank.d30.s3	false	DDI-DrugBank.d30.s3.e1	DDI-DrugBank.d30.s3.e2
DDI-DrugBank.d30.s3	false	DDI-DrugBank.d30.s3.e1	DDI-DrugBank.d30.s3.e3
DDI-DrugBank.d30.s3	false	DDI-DrugBank.d30.s3.e2	DDI-DrugBank.d30.s3.e3
DDI-DrugBank.d30.s4|a|Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.
DDI-DrugBank.d30.s4	0	10	Fluconazole	drug	DDI-DrugBank.d30.s4.e0
DDI-DrugBank.d30.s4	95	102	losartan	drug	DDI-DrugBank.d30.s4.e1
DDI-DrugBank.d30.s4	true	DDI-DrugBank.d30.s4.e0	DDI-DrugBank.d30.s4.e1
DDI-DrugBank.d30.s5|a|The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined.
DDI-DrugBank.d30.s5	55	62	losartan	drug	DDI-DrugBank.d30.s5.e0
DDI-DrugBank.d30.s6|a|Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9.
DDI-DrugBank.d30.s6	31	38	losartan	drug	DDI-DrugBank.d30.s6.e0
DDI-DrugBank.d30.s7|a|These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.
DDI-DrugBank.d30.s7	42	49	losartan	drug	DDI-DrugBank.d30.s7.e0
DDI-DrugBank.d30.s8|a|As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
DDI-DrugBank.d30.s8	81	107	potassium-sparing diuretics	group	DDI-DrugBank.d30.s8.e0
DDI-DrugBank.d30.s8	116	129	spironolactone	drug	DDI-DrugBank.d30.s8.e1
DDI-DrugBank.d30.s8	132	142	triamterene	drug	DDI-DrugBank.d30.s8.e2
DDI-DrugBank.d30.s8	145	153	amiloride	drug	DDI-DrugBank.d30.s8.e3
DDI-DrugBank.d30.s8	157	165	potassium	drug	DDI-DrugBank.d30.s8.e4
DDI-DrugBank.d30.s8	false	DDI-DrugBank.d30.s8.e0	DDI-DrugBank.d30.s8.e1
DDI-DrugBank.d30.s8	false	DDI-DrugBank.d30.s8.e0	DDI-DrugBank.d30.s8.e2
DDI-DrugBank.d30.s8	false	DDI-DrugBank.d30.s8.e0	DDI-DrugBank.d30.s8.e3
DDI-DrugBank.d30.s8	false	DDI-DrugBank.d30.s8.e0	DDI-DrugBank.d30.s8.e4
DDI-DrugBank.d30.s8	false	DDI-DrugBank.d30.s8.e1	DDI-DrugBank.d30.s8.e2
DDI-DrugBank.d30.s8	false	DDI-DrugBank.d30.s8.e1	DDI-DrugBank.d30.s8.e3
DDI-DrugBank.d30.s8	false	DDI-DrugBank.d30.s8.e1	DDI-DrugBank.d30.s8.e4
DDI-DrugBank.d30.s8	false	DDI-DrugBank.d30.s8.e2	DDI-DrugBank.d30.s8.e3
DDI-DrugBank.d30.s8	false	DDI-DrugBank.d30.s8.e2	DDI-DrugBank.d30.s8.e4
DDI-DrugBank.d30.s8	false	DDI-DrugBank.d30.s8.e3	DDI-DrugBank.d30.s8.e4
DDI-DrugBank.d30.s9|a|As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin
DDI-DrugBank.d30.s9	14	36	antihypertensive agents	group	DDI-DrugBank.d30.s9.e0
DDI-DrugBank.d30.s9	70	77	losartan	drug	DDI-DrugBank.d30.s9.e1
DDI-DrugBank.d30.s9	101	136	non-steroidal anti-inflammatory drug	group	DDI-DrugBank.d30.s9.e2
DDI-DrugBank.d30.s9	138	149	indomethacin	drug	DDI-DrugBank.d30.s9.e3
DDI-DrugBank.d30.s9	false	DDI-DrugBank.d30.s9.e0	DDI-DrugBank.d30.s9.e1
DDI-DrugBank.d30.s9	false	DDI-DrugBank.d30.s9.e0	DDI-DrugBank.d30.s9.e2
DDI-DrugBank.d30.s9	false	DDI-DrugBank.d30.s9.e0	DDI-DrugBank.d30.s9.e3
DDI-DrugBank.d30.s9	false	DDI-DrugBank.d30.s9.e1	DDI-DrugBank.d30.s9.e2
DDI-DrugBank.d30.s9	true	DDI-DrugBank.d30.s9.e1	DDI-DrugBank.d30.s9.e3
DDI-DrugBank.d30.s9	false	DDI-DrugBank.d30.s9.e2	DDI-DrugBank.d30.s9.e3
DDI-DrugBank.d30.s10|a|.
DDI-DrugBank.d30.s11|a|
DDI-DrugBank.d567.s0|a|CYP3A4 Interactions
DDI-DrugBank.d567.s1|a|Lovastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity;
DDI-DrugBank.d567.s1	0	9	Lovastatin	drug	DDI-DrugBank.d567.s1.e0
DDI-DrugBank.d567.s2|a|therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.
DDI-DrugBank.d567.s3|a|Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of lovastatin.
DDI-DrugBank.d567.s3	97	106	lovastatin	drug	DDI-DrugBank.d567.s3.e0
DDI-DrugBank.d567.s4|a|Pharmacokinetics.
DDI-DrugBank.d567.s5|a|Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
DDI-DrugBank.d567.s5	0	11	Itraconazole	drug	DDI-DrugBank.d567.s5.e0
DDI-DrugBank.d567.s5	13	24	Ketoconazole	drug	DDI-DrugBank.d567.s5.e1
DDI-DrugBank.d567.s5	26	37	Erythromycin	drug	DDI-DrugBank.d567.s5.e2
DDI-DrugBank.d567.s5	39	52	Clarithromycin	drug	DDI-DrugBank.d567.s5.e3
DDI-DrugBank.d567.s5	54	66	Telithromycin	drug	DDI-DrugBank.d567.s5.e4
DDI-DrugBank.d567.s5	68	90	HIV protease inhibitors	group	DDI-DrugBank.d567.s5.e5
DDI-DrugBank.d567.s5	92	101	Nefazodone	drug	DDI-DrugBank.d567.s5.e6
DDI-DrugBank.d567.s5	103	114	Cyclosporine	drug	DDI-DrugBank.d567.s5.e7
DDI-DrugBank.d567.s5	false	DDI-DrugBank.d567.s5.e0	DDI-DrugBank.d567.s5.e1
DDI-DrugBank.d567.s5	false	DDI-DrugBank.d567.s5.e0	DDI-DrugBank.d567.s5.e2
DDI-DrugBank.d567.s5	false	DDI-DrugBank.d567.s5.e0	DDI-DrugBank.d567.s5.e3
DDI-DrugBank.d567.s5	false	DDI-DrugBank.d567.s5.e0	DDI-DrugBank.d567.s5.e4
DDI-DrugBank.d567.s5	false	DDI-DrugBank.d567.s5.e0	DDI-DrugBank.d567.s5.e5
DDI-DrugBank.d567.s5	false	DDI-DrugBank.d567.s5.e0	DDI-DrugBank.d567.s5.e6
DDI-DrugBank.d567.s5	false	DDI-DrugBank.d567.s5.e0	DDI-DrugBank.d567.s5.e7
DDI-DrugBank.d567.s5	false	DDI-DrugBank.d567.s5.e1	DDI-DrugBank.d567.s5.e2
DDI-DrugBank.d567.s5	false	DDI-DrugBank.d567.s5.e1	DDI-DrugBank.d567.s5.e3
DDI-DrugBank.d567.s5	false	DDI-DrugBank.d567.s5.e1	DDI-DrugBank.d567.s5.e4
DDI-DrugBank.d567.s6|a|Interactions with lipid-lowering drugs that can cause myopathy when given alone.
DDI-DrugBank.d567.s7|a|The risk of myopathy is also increased by the following lipid-lowering drugs that are not potent CYP3A4 inhibitors, but which can cause myopathy when given alone.
DDI-DrugBank.d567.s8|a|See WARNINGS, Myopathy/Rhabdomyolysis.
DDI-DrugBank.d567.s9|a|Gemfibrozil Other fibrates Niacin (nicotinic acid) (=1 g/day)
DDI-DrugBank.d567.s9	0	10	Gemfibrozil	drug	DDI-DrugBank.d567.s9.e0
DDI-DrugBank.d567.s9	18	25	fibrates	group	DDI-DrugBank.d567.s9.e1
DDI-DrugBank.d567.s9	27	32	Niacin	drug	DDI-DrugBank.d567.s9.e2
DDI-DrugBank.d567.s9	35	48	nicotinic acid	drug	DDI-DrugBank.d567.s9.e3
DDI-DrugBank.d567.s9	false	DDI-DrugBank.d567.s9.e0	DDI-DrugBank.d567.s9.e1
DDI-DrugBank.d567.s9	false	DDI-DrugBank.d567.s9.e0	DDI-DrugBank.d567.s9.e2
DDI-DrugBank.d567.s9	false	DDI-DrugBank.d567.s9.e0	DDI-DrugBank.d567.s9.e3
DDI-DrugBank.d567.s9	false	DDI-DrugBank.d567.s9.e1	DDI-DrugBank.d567.s9.e2
DDI-DrugBank.d567.s9	false	DDI-DrugBank.d567.s9.e1	DDI-DrugBank.d567.s9.e3
DDI-DrugBank.d567.s9	false	DDI-DrugBank.d567.s9.e2	DDI-DrugBank.d567.s9.e3
DDI-DrugBank.d567.s10|a|Other drug interactions
DDI-DrugBank.d567.s11|a|Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).
DDI-DrugBank.d567.s11	0	6	Danazol	drug	DDI-DrugBank.d567.s11.e0
DDI-DrugBank.d567.s11	91	97	danazol	drug	DDI-DrugBank.d567.s11.e1
DDI-DrugBank.d567.s11	133	142	lovastatin	drug	DDI-DrugBank.d567.s11.e2
DDI-DrugBank.d567.s11	false	DDI-DrugBank.d567.s11.e0	DDI-DrugBank.d567.s11.e1
DDI-DrugBank.d567.s11	false	DDI-DrugBank.d567.s11.e0	DDI-DrugBank.d567.s11.e2
DDI-DrugBank.d567.s11	true	DDI-DrugBank.d567.s11.e1	DDI-DrugBank.d567.s11.e2
DDI-DrugBank.d567.s12|a|Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
DDI-DrugBank.d567.s12	0	9	Amiodarone	drug	DDI-DrugBank.d567.s12.e0
DDI-DrugBank.d567.s12	14	22	Verapamil	drug	DDI-DrugBank.d567.s12.e1
DDI-DrugBank.d567.s12	86	95	amiodarone	drug	DDI-DrugBank.d567.s12.e2
DDI-DrugBank.d567.s12	100	108	verapamil	drug	DDI-DrugBank.d567.s12.e3
DDI-DrugBank.d567.s12	169	201	HMG-CoA reductase inhibitor class	group	DDI-DrugBank.d567.s12.e4
DDI-DrugBank.d567.s12	false	DDI-DrugBank.d567.s12.e0	DDI-DrugBank.d567.s12.e1
DDI-DrugBank.d567.s12	false	DDI-DrugBank.d567.s12.e0	DDI-DrugBank.d567.s12.e2
DDI-DrugBank.d567.s12	false	DDI-DrugBank.d567.s12.e0	DDI-DrugBank.d567.s12.e3
DDI-DrugBank.d567.s12	false	DDI-DrugBank.d567.s12.e0	DDI-DrugBank.d567.s12.e4
DDI-DrugBank.d567.s12	false	DDI-DrugBank.d567.s12.e1	DDI-DrugBank.d567.s12.e2
DDI-DrugBank.d567.s12	false	DDI-DrugBank.d567.s12.e1	DDI-DrugBank.d567.s12.e3
DDI-DrugBank.d567.s12	false	DDI-DrugBank.d567.s12.e1	DDI-DrugBank.d567.s12.e4
DDI-DrugBank.d567.s12	false	DDI-DrugBank.d567.s12.e2	DDI-DrugBank.d567.s12.e3
DDI-DrugBank.d567.s12	true	DDI-DrugBank.d567.s12.e2	DDI-DrugBank.d567.s12.e4
DDI-DrugBank.d567.s12	true	DDI-DrugBank.d567.s12.e3	DDI-DrugBank.d567.s12.e4
DDI-DrugBank.d567.s13|a|Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.
DDI-DrugBank.d567.s13	0	21	Coumarin Anticoagulant	group	DDI-DrugBank.d567.s13.e0
DDI-DrugBank.d567.s13	60	69	lovastatin	drug	DDI-DrugBank.d567.s13.e1
DDI-DrugBank.d567.s13	91	98	warfarin	drug	DDI-DrugBank.d567.s13.e2
DDI-DrugBank.d567.s13	false	DDI-DrugBank.d567.s13.e0	DDI-DrugBank.d567.s13.e1
DDI-DrugBank.d567.s13	false	DDI-DrugBank.d567.s13.e0	DDI-DrugBank.d567.s13.e2
DDI-DrugBank.d567.s13	false	DDI-DrugBank.d567.s13.e1	DDI-DrugBank.d567.s13.e2
DDI-DrugBank.d567.s14|a|However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.
DDI-DrugBank.d567.s14	17	43	HMG-CoA reductase inhibitor	group	DDI-DrugBank.d567.s14.e0
DDI-DrugBank.d567.s14	168	175	warfarin	drug	DDI-DrugBank.d567.s14.e1
DDI-DrugBank.d567.s14	true	DDI-DrugBank.d567.s14.e0	DDI-DrugBank.d567.s14.e1
DDI-DrugBank.d567.s15|a|Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.
DDI-DrugBank.d567.s15	93	114	coumarin anticoagulant	group	DDI-DrugBank.d567.s15.e0
DDI-DrugBank.d567.s15	136	145	lovastatin	drug	DDI-DrugBank.d567.s15.e1
DDI-DrugBank.d567.s15	true	DDI-DrugBank.d567.s15.e0	DDI-DrugBank.d567.s15.e1
DDI-DrugBank.d567.s16|a|It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.
DDI-DrugBank.d567.s16	42	55	anticoagulants	group	DDI-DrugBank.d567.s16.e0
DDI-DrugBank.d567.s16	105	114	lovastatin	drug	DDI-DrugBank.d567.s16.e1
DDI-DrugBank.d567.s16	true	DDI-DrugBank.d567.s16.e0	DDI-DrugBank.d567.s16.e1
DDI-DrugBank.d567.s17|a|Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.
DDI-DrugBank.d567.s17	140	162	coumarin anticoagulants	group	DDI-DrugBank.d567.s17.e0
DDI-DrugBank.d567.s18|a|If the dose of lovastatin is changed, the same procedure should be repeated.
DDI-DrugBank.d567.s18	15	24	lovastatin	drug	DDI-DrugBank.d567.s18.e0
DDI-DrugBank.d567.s19|a|Lovastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.
DDI-DrugBank.d567.s19	0	9	Lovastatin	drug	DDI-DrugBank.d567.s19.e0
DDI-DrugBank.d567.s19	116	129	anticoagulants	group	DDI-DrugBank.d567.s19.e1
DDI-DrugBank.d567.s19	false	DDI-DrugBank.d567.s19.e0	DDI-DrugBank.d567.s19.e1
DDI-DrugBank.d567.s20|a|Propranolol: In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol.
DDI-DrugBank.d567.s20	0	10	Propranolol	drug	DDI-DrugBank.d567.s20.e0
DDI-DrugBank.d567.s20	169	178	lovastatin	drug	DDI-DrugBank.d567.s20.e1
DDI-DrugBank.d567.s20	184	194	propranolol	drug	DDI-DrugBank.d567.s20.e2
DDI-DrugBank.d567.s20	false	DDI-DrugBank.d567.s20.e0	DDI-DrugBank.d567.s20.e1
DDI-DrugBank.d567.s20	false	DDI-DrugBank.d567.s20.e0	DDI-DrugBank.d567.s20.e2
DDI-DrugBank.d567.s20	false	DDI-DrugBank.d567.s20.e1	DDI-DrugBank.d567.s20.e2
DDI-DrugBank.d567.s21|a|Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.
DDI-DrugBank.d567.s21	0	6	Digoxin	drug	DDI-DrugBank.d567.s21.e0
DDI-DrugBank.d567.s21	78	87	lovastatin	drug	DDI-DrugBank.d567.s21.e1
DDI-DrugBank.d567.s21	93	99	digoxin	drug	DDI-DrugBank.d567.s21.e2
DDI-DrugBank.d567.s21	126	132	digoxin	drug	DDI-DrugBank.d567.s21.e3
DDI-DrugBank.d567.s21	false	DDI-DrugBank.d567.s21.e0	DDI-DrugBank.d567.s21.e1
DDI-DrugBank.d567.s21	false	DDI-DrugBank.d567.s21.e0	DDI-DrugBank.d567.s21.e2
DDI-DrugBank.d567.s21	false	DDI-DrugBank.d567.s21.e0	DDI-DrugBank.d567.s21.e3
DDI-DrugBank.d567.s21	false	DDI-DrugBank.d567.s21.e1	DDI-DrugBank.d567.s21.e2
DDI-DrugBank.d567.s21	false	DDI-DrugBank.d567.s21.e1	DDI-DrugBank.d567.s21.e3
DDI-DrugBank.d567.s21	false	DDI-DrugBank.d567.s21.e2	DDI-DrugBank.d567.s21.e3
DDI-DrugBank.d567.s22|a|Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide
DDI-DrugBank.d567.s22	5	23	Hypoglycemic Agents	group	DDI-DrugBank.d567.s22.e0
DDI-DrugBank.d567.s22	56	62	MEVACOR	brand	DDI-DrugBank.d567.s22.e1
DDI-DrugBank.d567.s22	163	171	glipizide	drug	DDI-DrugBank.d567.s22.e2
DDI-DrugBank.d567.s22	181	194	chlorpropamide	drug	DDI-DrugBank.d567.s22.e3
DDI-DrugBank.d567.s22	false	DDI-DrugBank.d567.s22.e0	DDI-DrugBank.d567.s22.e1
DDI-DrugBank.d567.s22	false	DDI-DrugBank.d567.s22.e0	DDI-DrugBank.d567.s22.e2
DDI-DrugBank.d567.s22	false	DDI-DrugBank.d567.s22.e0	DDI-DrugBank.d567.s22.e3
DDI-DrugBank.d567.s22	false	DDI-DrugBank.d567.s22.e1	DDI-DrugBank.d567.s22.e2
DDI-DrugBank.d567.s22	false	DDI-DrugBank.d567.s22.e1	DDI-DrugBank.d567.s22.e3
DDI-DrugBank.d567.s22	false	DDI-DrugBank.d567.s22.e2	DDI-DrugBank.d567.s22.e3
DDI-DrugBank.d504.s0|a|There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.
DDI-DrugBank.d504.s0	122	129	loxapine	drug	DDI-DrugBank.d504.s0.e0
DDI-DrugBank.d504.s0	135	143	lorazepam	drug	DDI-DrugBank.d504.s0.e1
DDI-DrugBank.d504.s0	true	DDI-DrugBank.d504.s0.e0	DDI-DrugBank.d504.s0.e1
DDI-DrugBank.d504.s1|a|The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated.
DDI-DrugBank.d504.s1	18	25	loxapine	drug	DDI-DrugBank.d504.s1.e0
DDI-DrugBank.d504.s2|a|Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.
DDI-DrugBank.d504.s2	67	74	loxapine	drug	DDI-DrugBank.d504.s2.e0
DDI-DrugBank.d79.s0|a|The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
DDI-DrugBank.d79.s0	18	28	lymecycline	drug	DDI-DrugBank.d79.s0.e0
DDI-DrugBank.d79.s0	106	109	iron	drug	DDI-DrugBank.d79.s0.e1
DDI-DrugBank.d79.s0	114	117	zinc	drug	DDI-DrugBank.d79.s0.e2
DDI-DrugBank.d79.s0	true	DDI-DrugBank.d79.s0.e0	DDI-DrugBank.d79.s0.e1
DDI-DrugBank.d79.s0	true	DDI-DrugBank.d79.s0.e0	DDI-DrugBank.d79.s0.e2
DDI-DrugBank.d79.s0	false	DDI-DrugBank.d79.s0.e1	DDI-DrugBank.d79.s0.e2
DDI-DrugBank.d79.s1|a|Oral contraceptives may be less effective while you are taking lymecycline.
DDI-DrugBank.d79.s1	5	18	contraceptives	group	DDI-DrugBank.d79.s1.e0
DDI-DrugBank.d79.s1	63	73	lymecycline	drug	DDI-DrugBank.d79.s1.e1
DDI-DrugBank.d79.s1	true	DDI-DrugBank.d79.s1.e0	DDI-DrugBank.d79.s1.e1
DDI-DrugBank.d113.s0|a|Warfarin: Meclofenamate sodium enhances the effect of warfarin.
DDI-DrugBank.d113.s0	0	7	Warfarin	drug	DDI-DrugBank.d113.s0.e0
DDI-DrugBank.d113.s0	10	29	Meclofenamate sodium	drug	DDI-DrugBank.d113.s0.e1
DDI-DrugBank.d113.s0	54	61	warfarin	drug	DDI-DrugBank.d113.s0.e2
DDI-DrugBank.d113.s0	true	DDI-DrugBank.d113.s0.e0	DDI-DrugBank.d113.s0.e1
DDI-DrugBank.d113.s0	false	DDI-DrugBank.d113.s0.e0	DDI-DrugBank.d113.s0.e2
DDI-DrugBank.d113.s0	false	DDI-DrugBank.d113.s0.e1	DDI-DrugBank.d113.s0.e2
DDI-DrugBank.d113.s1|a|Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.
DDI-DrugBank.d113.s1	16	35	meclofenamate sodium	drug	DDI-DrugBank.d113.s1.e0
DDI-DrugBank.d113.s1	69	76	warfarin	drug	DDI-DrugBank.d113.s1.e1
DDI-DrugBank.d113.s1	93	100	warfarin	drug	DDI-DrugBank.d113.s1.e2
DDI-DrugBank.d113.s1	true	DDI-DrugBank.d113.s1.e0	DDI-DrugBank.d113.s1.e1
DDI-DrugBank.d113.s1	false	DDI-DrugBank.d113.s1.e0	DDI-DrugBank.d113.s1.e2
DDI-DrugBank.d113.s1	false	DDI-DrugBank.d113.s1.e1	DDI-DrugBank.d113.s1.e2
DDI-DrugBank.d113.s2|a|Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.
DDI-DrugBank.d113.s2	0	6	Aspirin	brand	DDI-DrugBank.d113.s2.e0
DDI-DrugBank.d113.s2	38	44	aspirin	brand	DDI-DrugBank.d113.s2.e1
DDI-DrugBank.d113.s2	56	75	meclofenamate sodium	drug	DDI-DrugBank.d113.s2.e2
DDI-DrugBank.d113.s2	false	DDI-DrugBank.d113.s2.e0	DDI-DrugBank.d113.s2.e1
DDI-DrugBank.d113.s2	false	DDI-DrugBank.d113.s2.e0	DDI-DrugBank.d113.s2.e2
DDI-DrugBank.d113.s2	true	DDI-DrugBank.d113.s2.e1	DDI-DrugBank.d113.s2.e2
DDI-DrugBank.d113.s3|a|The urinary excretion of meclofenamate sodium is unaffected by aspirin, indicating no change in meclofenamate sodium absorption.
DDI-DrugBank.d113.s3	25	44	meclofenamate sodium	drug	DDI-DrugBank.d113.s3.e0
DDI-DrugBank.d113.s3	63	69	aspirin	brand	DDI-DrugBank.d113.s3.e1
DDI-DrugBank.d113.s3	96	115	meclofenamate sodium	drug	DDI-DrugBank.d113.s3.e2
DDI-DrugBank.d113.s3	false	DDI-DrugBank.d113.s3.e0	DDI-DrugBank.d113.s3.e1
DDI-DrugBank.d113.s3	false	DDI-DrugBank.d113.s3.e0	DDI-DrugBank.d113.s3.e2
DDI-DrugBank.d113.s3	false	DDI-DrugBank.d113.s3.e1	DDI-DrugBank.d113.s3.e2
DDI-DrugBank.d113.s4|a|Meclofenamate sodium does not affect serum salicylate levels.
DDI-DrugBank.d113.s4	0	19	Meclofenamate sodium	drug	DDI-DrugBank.d113.s4.e0
DDI-DrugBank.d113.s4	43	52	salicylate	group	DDI-DrugBank.d113.s4.e1
DDI-DrugBank.d113.s4	false	DDI-DrugBank.d113.s4.e0	DDI-DrugBank.d113.s4.e1
DDI-DrugBank.d113.s5|a|Greater fecal blood loss results from concomitant administration of both drugs than from either drug alone.
DDI-DrugBank.d113.s6|a|Propoxyphene: The concurrent administration of propoxyphene hydrochloride does not affect the bioavailability of meclofenamate sodium.
DDI-DrugBank.d113.s6	0	11	Propoxyphene	drug	DDI-DrugBank.d113.s6.e0
DDI-DrugBank.d113.s6	47	72	propoxyphene hydrochloride	drug	DDI-DrugBank.d113.s6.e1
DDI-DrugBank.d113.s6	113	132	meclofenamate sodium	drug	DDI-DrugBank.d113.s6.e2
DDI-DrugBank.d113.s6	false	DDI-DrugBank.d113.s6.e0	DDI-DrugBank.d113.s6.e1
DDI-DrugBank.d113.s6	false	DDI-DrugBank.d113.s6.e0	DDI-DrugBank.d113.s6.e2
DDI-DrugBank.d113.s6	false	DDI-DrugBank.d113.s6.e1	DDI-DrugBank.d113.s6.e2
DDI-DrugBank.d113.s7|a|Antacids: Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of meclofenamate sodium.
DDI-DrugBank.d113.s7	0	7	Antacids	group	DDI-DrugBank.d113.s7.e0
DDI-DrugBank.d113.s7	40	47	aluminum hydroxide	drug	DDI-DrugBank.d113.s7.e1
DDI-DrugBank.d113.s7	63	71	aluminum hydroxide	drug	DDI-DrugBank.d113.s7.e1
DDI-DrugBank.d113.s7	53	71	magnesium hydroxide	drug	DDI-DrugBank.d113.s7.e2
DDI-DrugBank.d113.s7	112	131	meclofenamate sodium	drug	DDI-DrugBank.d113.s7.e3
DDI-DrugBank.d113.s7	false	DDI-DrugBank.d113.s7.e0	DDI-DrugBank.d113.s7.e1
DDI-DrugBank.d113.s7	false	DDI-DrugBank.d113.s7.e0	DDI-DrugBank.d113.s7.e2
DDI-DrugBank.d113.s7	false	DDI-DrugBank.d113.s7.e0	DDI-DrugBank.d113.s7.e3
DDI-DrugBank.d113.s7	false	DDI-DrugBank.d113.s7.e1	DDI-DrugBank.d113.s7.e2
DDI-DrugBank.d113.s7	false	DDI-DrugBank.d113.s7.e1	DDI-DrugBank.d113.s7.e3
DDI-DrugBank.d113.s7	false	DDI-DrugBank.d113.s7.e2	DDI-DrugBank.d113.s7.e3
DDI-DrugBank.d400.s0|a|Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
DDI-DrugBank.d400.s0	0	6	Aspirin	brand	DDI-DrugBank.d400.s0.e0
DDI-DrugBank.d400.s0	23	28	NSAIDs	group	DDI-DrugBank.d400.s0.e1
DDI-DrugBank.d400.s0	61	67	Ponstel	brand	DDI-DrugBank.d400.s0.e2
DDI-DrugBank.d400.s0	73	79	aspirin	brand	DDI-DrugBank.d400.s0.e3
DDI-DrugBank.d400.s0	false	DDI-DrugBank.d400.s0.e0	DDI-DrugBank.d400.s0.e1
DDI-DrugBank.d400.s0	false	DDI-DrugBank.d400.s0.e0	DDI-DrugBank.d400.s0.e2
DDI-DrugBank.d400.s0	false	DDI-DrugBank.d400.s0.e0	DDI-DrugBank.d400.s0.e3
DDI-DrugBank.d400.s0	false	DDI-DrugBank.d400.s0.e1	DDI-DrugBank.d400.s0.e2
DDI-DrugBank.d400.s0	true	DDI-DrugBank.d400.s0.e1	DDI-DrugBank.d400.s0.e3
DDI-DrugBank.d400.s0	true	DDI-DrugBank.d400.s0.e2	DDI-DrugBank.d400.s0.e3
DDI-DrugBank.d400.s1|a|Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.
DDI-DrugBank.d400.s1	0	11	Methotrexate	drug	DDI-DrugBank.d400.s1.e0
DDI-DrugBank.d400.s1	14	19	NSAIDs	group	DDI-DrugBank.d400.s1.e1
DDI-DrugBank.d400.s1	65	76	methotrexate	drug	DDI-DrugBank.d400.s1.e2
DDI-DrugBank.d400.s1	false	DDI-DrugBank.d400.s1.e0	DDI-DrugBank.d400.s1.e1
DDI-DrugBank.d400.s1	false	DDI-DrugBank.d400.s1.e0	DDI-DrugBank.d400.s1.e2
DDI-DrugBank.d400.s1	true	DDI-DrugBank.d400.s1.e1	DDI-DrugBank.d400.s1.e2
DDI-DrugBank.d400.s2|a|This may indicate that they could enhance the toxicity of methotrexate.
DDI-DrugBank.d400.s2	58	69	methotrexate	drug	DDI-DrugBank.d400.s2.e0
DDI-DrugBank.d400.s3|a|Caution should be used when NSAIDs are administered concomitantly with methotrexate.
DDI-DrugBank.d400.s3	28	33	NSAIDs	group	DDI-DrugBank.d400.s3.e0
DDI-DrugBank.d400.s3	71	82	methotrexate	drug	DDI-DrugBank.d400.s3.e1
DDI-DrugBank.d400.s3	true	DDI-DrugBank.d400.s3.e0	DDI-DrugBank.d400.s3.e1
DDI-DrugBank.d400.s4|a|ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
DDI-DrugBank.d400.s4	0	13	ACE inhibitors	group	DDI-DrugBank.d400.s4.e0
DDI-DrugBank.d400.s4	37	42	NSAIDs	group	DDI-DrugBank.d400.s4.e1
DDI-DrugBank.d400.s4	88	101	ACE inhibitors	group	DDI-DrugBank.d400.s4.e2
DDI-DrugBank.d400.s4	false	DDI-DrugBank.d400.s4.e0	DDI-DrugBank.d400.s4.e1
DDI-DrugBank.d400.s4	false	DDI-DrugBank.d400.s4.e0	DDI-DrugBank.d400.s4.e2
DDI-DrugBank.d400.s4	true	DDI-DrugBank.d400.s4.e1	DDI-DrugBank.d400.s4.e2
DDI-DrugBank.d400.s5|a|This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
DDI-DrugBank.d400.s5	66	71	NSAIDs	group	DDI-DrugBank.d400.s5.e0
DDI-DrugBank.d400.s5	92	105	ACE inhibitors	group	DDI-DrugBank.d400.s5.e1
DDI-DrugBank.d400.s5	true	DDI-DrugBank.d400.s5.e0	DDI-DrugBank.d400.s5.e1
DDI-DrugBank.d400.s6|a|Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d400.s6	0	9	Furosemide	drug	DDI-DrugBank.d400.s6.e0
DDI-DrugBank.d400.s6	86	91	NSAIDs	group	DDI-DrugBank.d400.s6.e1
DDI-DrugBank.d400.s6	130	139	furosemide	drug	DDI-DrugBank.d400.s6.e2
DDI-DrugBank.d400.s6	145	153	thiazides	group	DDI-DrugBank.d400.s6.e3
DDI-DrugBank.d400.s6	false	DDI-DrugBank.d400.s6.e0	DDI-DrugBank.d400.s6.e1
DDI-DrugBank.d400.s6	false	DDI-DrugBank.d400.s6.e0	DDI-DrugBank.d400.s6.e2
DDI-DrugBank.d400.s6	false	DDI-DrugBank.d400.s6.e0	DDI-DrugBank.d400.s6.e3
DDI-DrugBank.d400.s6	true	DDI-DrugBank.d400.s6.e1	DDI-DrugBank.d400.s6.e2
DDI-DrugBank.d400.s6	true	DDI-DrugBank.d400.s6.e1	DDI-DrugBank.d400.s6.e3
DDI-DrugBank.d400.s6	false	DDI-DrugBank.d400.s6.e2	DDI-DrugBank.d400.s6.e3
DDI-DrugBank.d400.s7|a|This response has been attributed to inhibition of renal prostaglandin synthesis.
DDI-DrugBank.d400.s8|a|During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
DDI-DrugBank.d400.s8	30	36	Ponstel	brand	DDI-DrugBank.d400.s8.e0
DDI-DrugBank.d400.s8	43	52	furosemide	drug	DDI-DrugBank.d400.s8.e1
DDI-DrugBank.d400.s8	true	DDI-DrugBank.d400.s8.e0	DDI-DrugBank.d400.s8.e1
DDI-DrugBank.d400.s9|a|Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
DDI-DrugBank.d400.s9	0	6	Lithium	drug	DDI-DrugBank.d400.s9.e0
DDI-DrugBank.d400.s9	9	14	NSAIDs	group	DDI-DrugBank.d400.s9.e1
DDI-DrugBank.d400.s9	53	59	lithium	drug	DDI-DrugBank.d400.s9.e2
DDI-DrugBank.d400.s9	93	99	lithium	drug	DDI-DrugBank.d400.s9.e3
DDI-DrugBank.d400.s9	false	DDI-DrugBank.d400.s9.e0	DDI-DrugBank.d400.s9.e1
DDI-DrugBank.d400.s9	false	DDI-DrugBank.d400.s9.e0	DDI-DrugBank.d400.s9.e2
DDI-DrugBank.d400.s9	false	DDI-DrugBank.d400.s9.e0	DDI-DrugBank.d400.s9.e3
DDI-DrugBank.d400.s9	true	DDI-DrugBank.d400.s9.e1	DDI-DrugBank.d400.s9.e2
DDI-DrugBank.d400.s9	true	DDI-DrugBank.d400.s9.e1	DDI-DrugBank.d400.s9.e3
DDI-DrugBank.d400.s9	false	DDI-DrugBank.d400.s9.e2	DDI-DrugBank.d400.s9.e3
DDI-DrugBank.d400.s10|a|The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%.
DDI-DrugBank.d400.s10	17	23	lithium	drug	DDI-DrugBank.d400.s10.e0
DDI-DrugBank.d400.s11|a|These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID.
DDI-DrugBank.d400.s11	89	93	NSAID	group	DDI-DrugBank.d400.s11.e0
DDI-DrugBank.d400.s12|a|Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DDI-DrugBank.d400.s12	11	16	NSAIDs	group	DDI-DrugBank.d400.s12.e0
DDI-DrugBank.d400.s12	22	28	lithium	drug	DDI-DrugBank.d400.s12.e1
DDI-DrugBank.d400.s12	112	118	lithium	drug	DDI-DrugBank.d400.s12.e2
DDI-DrugBank.d400.s12	true	DDI-DrugBank.d400.s12.e0	DDI-DrugBank.d400.s12.e1
DDI-DrugBank.d400.s12	false	DDI-DrugBank.d400.s12.e0	DDI-DrugBank.d400.s12.e2
DDI-DrugBank.d400.s12	false	DDI-DrugBank.d400.s12.e1	DDI-DrugBank.d400.s12.e2
DDI-DrugBank.d400.s13|a|Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
DDI-DrugBank.d400.s13	0	7	Warfarin	drug	DDI-DrugBank.d400.s13.e0
DDI-DrugBank.d400.s13	25	32	warfarin	drug	DDI-DrugBank.d400.s13.e1
DDI-DrugBank.d400.s13	38	43	NSAIDs	group	DDI-DrugBank.d400.s13.e2
DDI-DrugBank.d400.s13	false	DDI-DrugBank.d400.s13.e0	DDI-DrugBank.d400.s13.e1
DDI-DrugBank.d400.s13	false	DDI-DrugBank.d400.s13.e0	DDI-DrugBank.d400.s13.e2
DDI-DrugBank.d400.s13	true	DDI-DrugBank.d400.s13.e1	DDI-DrugBank.d400.s13.e2
DDI-DrugBank.d400.s14|a|Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
DDI-DrugBank.d400.s14	0	7	Antacids	group	DDI-DrugBank.d400.s14.e0
DDI-DrugBank.d400.s14	56	62	antacid	group	DDI-DrugBank.d400.s14.e1
DDI-DrugBank.d400.s14	87	105	magnesium hydroxide	drug	DDI-DrugBank.d400.s14.e2
DDI-DrugBank.d400.s14	122	135	mefenamic acid	drug	DDI-DrugBank.d400.s14.e3
DDI-DrugBank.d400.s14	167	180	mefenamic acid	drug	DDI-DrugBank.d400.s14.e4
DDI-DrugBank.d400.s14	271	281	fluconazole	drug	DDI-DrugBank.d400.s14.e5
DDI-DrugBank.d400.s14	284	293	lovastatin	drug	DDI-DrugBank.d400.s14.e6
DDI-DrugBank.d400.s14	299	310	trimethoprim	drug	DDI-DrugBank.d400.s14.e7
DDI-DrugBank.d400.s14	false	DDI-DrugBank.d400.s14.e0	DDI-DrugBank.d400.s14.e1
DDI-DrugBank.d400.s14	false	DDI-DrugBank.d400.s14.e0	DDI-DrugBank.d400.s14.e2
DDI-DrugBank.d400.s14	false	DDI-DrugBank.d400.s14.e0	DDI-DrugBank.d400.s14.e3
DDI-DrugBank.d400.s14	false	DDI-DrugBank.d400.s14.e0	DDI-DrugBank.d400.s14.e4
DDI-DrugBank.d400.s14	false	DDI-DrugBank.d400.s14.e0	DDI-DrugBank.d400.s14.e5
DDI-DrugBank.d400.s14	false	DDI-DrugBank.d400.s14.e0	DDI-DrugBank.d400.s14.e6
DDI-DrugBank.d400.s14	false	DDI-DrugBank.d400.s14.e0	DDI-DrugBank.d400.s14.e7
DDI-DrugBank.d400.s14	false	DDI-DrugBank.d400.s14.e1	DDI-DrugBank.d400.s14.e2
DDI-DrugBank.d400.s14	false	DDI-DrugBank.d400.s14.e1	DDI-DrugBank.d400.s14.e3
DDI-DrugBank.d400.s14	false	DDI-DrugBank.d400.s14.e1	DDI-DrugBank.d400.s14.e4
DDI-DrugBank.d400.s15|a|Drug interaction studies of mefenamic acid and these compounds have not been conducted.
DDI-DrugBank.d400.s15	28	41	mefenamic acid	drug	DDI-DrugBank.d400.s15.e0
DDI-DrugBank.d400.s16|a|The possibility of altered safety and efficacy should be considered when Ponstel is used concomitantly with these drugs.
DDI-DrugBank.d400.s16	73	79	Ponstel	brand	DDI-DrugBank.d400.s16.e0
DDI-DrugBank.d220.s0|a|Drug-drug interactions with Mefloquine have not been explored in detail.
DDI-DrugBank.d220.s0	28	37	Mefloquine	drug	DDI-DrugBank.d220.s0.e0
DDI-DrugBank.d220.s1|a|There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol).
DDI-DrugBank.d220.s1	97	108	beta blocker	group	DDI-DrugBank.d220.s1.e0
DDI-DrugBank.d220.s1	111	121	propranolol	drug	DDI-DrugBank.d220.s1.e1
DDI-DrugBank.d220.s1	false	DDI-DrugBank.d220.s1.e0	DDI-DrugBank.d220.s1.e1
DDI-DrugBank.d220.s2|a|The effects of Mefloquineuine on the compromised cardiovascular system have not been evaluated.
DDI-DrugBank.d220.s3|a|The benefits of Mefloquine therapy should be weighed against the possibility of adverse effects in patients with cardiac disease.
DDI-DrugBank.d220.s3	16	25	Mefloquine	drug	DDI-DrugBank.d220.s3.e0
DDI-DrugBank.d220.s4|a|Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.
DDI-DrugBank.d220.s4	79	90	halofantrine	drug	DDI-DrugBank.d220.s4.e0
DDI-DrugBank.d220.s4	147	156	Mefloquine	drug	DDI-DrugBank.d220.s4.e1
DDI-DrugBank.d220.s4	true	DDI-DrugBank.d220.s4.e0	DDI-DrugBank.d220.s4.e1
DDI-DrugBank.d220.s5|a|Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
DDI-DrugBank.d220.s5	30	39	Mefloquine	drug	DDI-DrugBank.d220.s5.e0
DDI-DrugBank.d220.s5	74	80	quinine	drug	DDI-DrugBank.d220.s5.e1
DDI-DrugBank.d220.s5	83	91	quinidine	drug	DDI-DrugBank.d220.s5.e2
DDI-DrugBank.d220.s5	97	107	chloroquine	drug	DDI-DrugBank.d220.s5.e3
DDI-DrugBank.d220.s5	true	DDI-DrugBank.d220.s5.e0	DDI-DrugBank.d220.s5.e1
DDI-DrugBank.d220.s5	true	DDI-DrugBank.d220.s5.e0	DDI-DrugBank.d220.s5.e2
DDI-DrugBank.d220.s5	true	DDI-DrugBank.d220.s5.e0	DDI-DrugBank.d220.s5.e3
DDI-DrugBank.d220.s5	false	DDI-DrugBank.d220.s5.e1	DDI-DrugBank.d220.s5.e2
DDI-DrugBank.d220.s5	false	DDI-DrugBank.d220.s5.e1	DDI-DrugBank.d220.s5.e3
DDI-DrugBank.d220.s5	false	DDI-DrugBank.d220.s5.e2	DDI-DrugBank.d220.s5.e3
DDI-DrugBank.d220.s6|a|If these drugs are to be used in the initial treatment of severe malaria, Mefloquine administration should be delayed at least 12 hours after the last dose.
DDI-DrugBank.d220.s6	74	83	Mefloquine	drug	DDI-DrugBank.d220.s6.e0
DDI-DrugBank.d220.s7|a|There is evidence that the use of halofantrine after Mefloquineuine causes a significant lengthening of the QTc interval.
DDI-DrugBank.d220.s7	34	45	halofantrine	drug	DDI-DrugBank.d220.s7.e0
DDI-DrugBank.d220.s8|a|Clinically significant QTc prolongation has not been found with Mefloquineuine alone.
DDI-DrugBank.d220.s9|a|This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
DDI-DrugBank.d220.s9	78	87	Mefloquine	drug	DDI-DrugBank.d220.s9.e0
DDI-DrugBank.d220.s9	185	199	anti-arrhythmic	drug	DDI-DrugBank.d220.s9.e1
DDI-DrugBank.d220.s9	204	234	beta-adrenergic blocking agents	group	DDI-DrugBank.d220.s9.e2
DDI-DrugBank.d220.s9	237	260	calcium channel blockers	group	DDI-DrugBank.d220.s9.e3
DDI-DrugBank.d220.s9	263	276	antihistamines	group	DDI-DrugBank.d220.s9.e4
DDI-DrugBank.d220.s9	281	298	H1-blocking agents	group	DDI-DrugBank.d220.s9.e5
DDI-DrugBank.d220.s9	301	325	tricyclic antidepressants	group	DDI-DrugBank.d220.s9.e6
DDI-DrugBank.d220.s9	331	344	phenothiazines	group	DDI-DrugBank.d220.s9.e7
DDI-DrugBank.d220.s9	true	DDI-DrugBank.d220.s9.e0	DDI-DrugBank.d220.s9.e1
DDI-DrugBank.d220.s9	true	DDI-DrugBank.d220.s9.e0	DDI-DrugBank.d220.s9.e2
DDI-DrugBank.d220.s9	true	DDI-DrugBank.d220.s9.e0	DDI-DrugBank.d220.s9.e3
DDI-DrugBank.d220.s9	true	DDI-DrugBank.d220.s9.e0	DDI-DrugBank.d220.s9.e4
DDI-DrugBank.d220.s9	true	DDI-DrugBank.d220.s9.e0	DDI-DrugBank.d220.s9.e5
DDI-DrugBank.d220.s9	true	DDI-DrugBank.d220.s9.e0	DDI-DrugBank.d220.s9.e6
DDI-DrugBank.d220.s9	true	DDI-DrugBank.d220.s9.e0	DDI-DrugBank.d220.s9.e7
DDI-DrugBank.d220.s9	false	DDI-DrugBank.d220.s9.e1	DDI-DrugBank.d220.s9.e2
DDI-DrugBank.d220.s9	false	DDI-DrugBank.d220.s9.e1	DDI-DrugBank.d220.s9.e3
DDI-DrugBank.d220.s9	false	DDI-DrugBank.d220.s9.e1	DDI-DrugBank.d220.s9.e4
DDI-DrugBank.d220.s10|a|There are no data that conclusively establish whether the concomitant administration of Mefloquineuine and the above listed agents has an effect on cardiac function.
DDI-DrugBank.d220.s11|a|In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DDI-DrugBank.d220.s11	22	35	anticonvulsant	group	DDI-DrugBank.d220.s11.e0
DDI-DrugBank.d220.s11	42	54	valproic acid	drug	DDI-DrugBank.d220.s11.e1
DDI-DrugBank.d220.s11	57	69	carbamazepine	drug	DDI-DrugBank.d220.s11.e2
DDI-DrugBank.d220.s11	72	84	phenobarbital	drug	DDI-DrugBank.d220.s11.e3
DDI-DrugBank.d220.s11	89	97	phenytoin	drug	DDI-DrugBank.d220.s11.e4
DDI-DrugBank.d220.s11	124	133	Mefloquine	drug	DDI-DrugBank.d220.s11.e5
DDI-DrugBank.d220.s11	199	212	anticonvulsant	group	DDI-DrugBank.d220.s11.e6
DDI-DrugBank.d220.s11	false	DDI-DrugBank.d220.s11.e0	DDI-DrugBank.d220.s11.e1
DDI-DrugBank.d220.s11	false	DDI-DrugBank.d220.s11.e0	DDI-DrugBank.d220.s11.e2
DDI-DrugBank.d220.s11	false	DDI-DrugBank.d220.s11.e0	DDI-DrugBank.d220.s11.e3
DDI-DrugBank.d220.s11	false	DDI-DrugBank.d220.s11.e0	DDI-DrugBank.d220.s11.e4
DDI-DrugBank.d220.s11	true	DDI-DrugBank.d220.s11.e0	DDI-DrugBank.d220.s11.e5
DDI-DrugBank.d220.s11	false	DDI-DrugBank.d220.s11.e0	DDI-DrugBank.d220.s11.e6
DDI-DrugBank.d220.s11	false	DDI-DrugBank.d220.s11.e1	DDI-DrugBank.d220.s11.e2
DDI-DrugBank.d220.s11	false	DDI-DrugBank.d220.s11.e1	DDI-DrugBank.d220.s11.e3
DDI-DrugBank.d220.s11	false	DDI-DrugBank.d220.s11.e1	DDI-DrugBank.d220.s11.e4
DDI-DrugBank.d220.s11	true	DDI-DrugBank.d220.s11.e1	DDI-DrugBank.d220.s11.e5
DDI-DrugBank.d220.s12|a|Therefore, patients concurrently taking antiseizure medication and Mefloquine should have the blood level of their antiseizure medication monitored and the dosage adjusted appropriately.
DDI-DrugBank.d220.s12	67	76	Mefloquine	drug	DDI-DrugBank.d220.s12.e0
DDI-DrugBank.d220.s13|a|When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.
DDI-DrugBank.d220.s13	5	14	Mefloquine	drug	DDI-DrugBank.d220.s13.e0
DDI-DrugBank.d220.s13	48	68	live typhoid vaccines	group	DDI-DrugBank.d220.s13.e1
DDI-DrugBank.d220.s13	true	DDI-DrugBank.d220.s13.e0	DDI-DrugBank.d220.s13.e1
DDI-DrugBank.d220.s14|a|Vaccinations with attenuated live bacteria should therefore be completed at least 3 days before the first dose of Mefloquine.
DDI-DrugBank.d220.s14	114	123	Mefloquine	drug	DDI-DrugBank.d220.s14.e0
DDI-DrugBank.d220.s15|a|No other drug interactions are known.
DDI-DrugBank.d220.s16|a|Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.
DDI-DrugBank.d220.s16	29	38	Mefloquine	drug	DDI-DrugBank.d220.s16.e0
DDI-DrugBank.d220.s16	118	131	anticoagulants	group	DDI-DrugBank.d220.s16.e1
DDI-DrugBank.d220.s16	true	DDI-DrugBank.d220.s16.e0	DDI-DrugBank.d220.s16.e1
DDI-DrugBank.d220.s17|a|In clinical trials, the concomitant administration of sulfadoxine and pyrimethamine did not alter the adverse reaction profile.
DDI-DrugBank.d220.s17	54	64	sulfadoxine	drug	DDI-DrugBank.d220.s17.e0
DDI-DrugBank.d220.s17	70	82	pyrimethamine	drug	DDI-DrugBank.d220.s17.e1
DDI-DrugBank.d220.s17	false	DDI-DrugBank.d220.s17.e0	DDI-DrugBank.d220.s17.e1
DDI-DrugBank.d139.s0|a|Broad-Spectrum Antibiotics-Broad-spectrum antibiotics may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.
DDI-DrugBank.d139.s0	0	25	Broad-Spectrum Antibiotics	group	DDI-DrugBank.d139.s0.e0
DDI-DrugBank.d139.s0	27	52	Broad-spectrum antibiotics	group	DDI-DrugBank.d139.s0.e1
DDI-DrugBank.d139.s0	95	103	vitamin K	group	DDI-DrugBank.d139.s0.e2
DDI-DrugBank.d139.s0	false	DDI-DrugBank.d139.s0.e0	DDI-DrugBank.d139.s0.e1
DDI-DrugBank.d139.s0	false	DDI-DrugBank.d139.s0.e0	DDI-DrugBank.d139.s0.e2
DDI-DrugBank.d139.s0	false	DDI-DrugBank.d139.s0.e1	DDI-DrugBank.d139.s0.e2
DDI-DrugBank.d139.s1|a|Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
DDI-DrugBank.d139.s1	0	13	Cephalosporins	group	DDI-DrugBank.d139.s1.e0
DDI-DrugBank.d139.s1	15	28	Cephalosporins	group	DDI-DrugBank.d139.s1.e1
DDI-DrugBank.d139.s1	79	89	cefmenoxime	drug	DDI-DrugBank.d139.s1.e2
DDI-DrugBank.d139.s1	92	103	cefoperazone	drug	DDI-DrugBank.d139.s1.e3
DDI-DrugBank.d139.s1	106	114	cefotetan	drug	DDI-DrugBank.d139.s1.e4
DDI-DrugBank.d139.s1	117	127	cefamandole	drug	DDI-DrugBank.d139.s1.e5
DDI-DrugBank.d139.s1	130	138	latamoxef	drug	DDI-DrugBank.d139.s1.e6
DDI-DrugBank.d139.s1	163	171	cefazolin	drug	DDI-DrugBank.d139.s1.e7
DDI-DrugBank.d139.s1	false	DDI-DrugBank.d139.s1.e0	DDI-DrugBank.d139.s1.e1
DDI-DrugBank.d139.s1	false	DDI-DrugBank.d139.s1.e0	DDI-DrugBank.d139.s1.e2
DDI-DrugBank.d139.s1	false	DDI-DrugBank.d139.s1.e0	DDI-DrugBank.d139.s1.e3
DDI-DrugBank.d139.s1	false	DDI-DrugBank.d139.s1.e0	DDI-DrugBank.d139.s1.e4
DDI-DrugBank.d139.s1	false	DDI-DrugBank.d139.s1.e0	DDI-DrugBank.d139.s1.e5
DDI-DrugBank.d139.s1	false	DDI-DrugBank.d139.s1.e0	DDI-DrugBank.d139.s1.e6
DDI-DrugBank.d139.s1	false	DDI-DrugBank.d139.s1.e0	DDI-DrugBank.d139.s1.e7
DDI-DrugBank.d139.s1	false	DDI-DrugBank.d139.s1.e1	DDI-DrugBank.d139.s1.e2
DDI-DrugBank.d139.s1	false	DDI-DrugBank.d139.s1.e1	DDI-DrugBank.d139.s1.e3
DDI-DrugBank.d139.s1	false	DDI-DrugBank.d139.s1.e1	DDI-DrugBank.d139.s1.e4
DDI-DrugBank.d139.s2|a|These cephalosporins are inhibitors of hepatic vitamin K epoxide reductase.
DDI-DrugBank.d139.s2	6	19	cephalosporins	group	DDI-DrugBank.d139.s2.e0
DDI-DrugBank.d139.s3|a|Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.
DDI-DrugBank.d139.s3	0	13	Cholestyramine	drug	DDI-DrugBank.d139.s3.e0
DDI-DrugBank.d139.s3	37	50	cholestyramine	drug	DDI-DrugBank.d139.s3.e1
DDI-DrugBank.d139.s3	56	64	vitamin K	group	DDI-DrugBank.d139.s3.e2
DDI-DrugBank.d139.s3	95	103	vitamin K	group	DDI-DrugBank.d139.s3.e3
DDI-DrugBank.d139.s3	false	DDI-DrugBank.d139.s3.e0	DDI-DrugBank.d139.s3.e1
DDI-DrugBank.d139.s3	false	DDI-DrugBank.d139.s3.e0	DDI-DrugBank.d139.s3.e2
DDI-DrugBank.d139.s3	false	DDI-DrugBank.d139.s3.e0	DDI-DrugBank.d139.s3.e3
DDI-DrugBank.d139.s3	true	DDI-DrugBank.d139.s3.e1	DDI-DrugBank.d139.s3.e2
DDI-DrugBank.d139.s3	false	DDI-DrugBank.d139.s3.e1	DDI-DrugBank.d139.s3.e3
DDI-DrugBank.d139.s3	false	DDI-DrugBank.d139.s3.e2	DDI-DrugBank.d139.s3.e3
DDI-DrugBank.d139.s4|a|Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.
DDI-DrugBank.d139.s4	0	9	Colestipol	drug	DDI-DrugBank.d139.s4.e0
DDI-DrugBank.d139.s4	33	42	colestipol	drug	DDI-DrugBank.d139.s4.e1
DDI-DrugBank.d139.s4	48	56	vitamin K	group	DDI-DrugBank.d139.s4.e2
DDI-DrugBank.d139.s4	87	95	vitamin K	group	DDI-DrugBank.d139.s4.e3
DDI-DrugBank.d139.s4	false	DDI-DrugBank.d139.s4.e0	DDI-DrugBank.d139.s4.e1
DDI-DrugBank.d139.s4	false	DDI-DrugBank.d139.s4.e0	DDI-DrugBank.d139.s4.e2
DDI-DrugBank.d139.s4	false	DDI-DrugBank.d139.s4.e0	DDI-DrugBank.d139.s4.e3
DDI-DrugBank.d139.s4	true	DDI-DrugBank.d139.s4.e1	DDI-DrugBank.d139.s4.e2
DDI-DrugBank.d139.s4	false	DDI-DrugBank.d139.s4.e1	DDI-DrugBank.d139.s4.e3
DDI-DrugBank.d139.s4	false	DDI-DrugBank.d139.s4.e2	DDI-DrugBank.d139.s4.e3
DDI-DrugBank.d139.s5|a|Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.
DDI-DrugBank.d139.s5	0	10	Mineral Oil	drug_n	DDI-DrugBank.d139.s5.e0
DDI-DrugBank.d139.s5	34	44	mineral oil	drug_n	DDI-DrugBank.d139.s5.e1
DDI-DrugBank.d139.s5	50	58	vitamin K	group	DDI-DrugBank.d139.s5.e2
DDI-DrugBank.d139.s5	89	97	vitamin K	group	DDI-DrugBank.d139.s5.e3
DDI-DrugBank.d139.s5	false	DDI-DrugBank.d139.s5.e0	DDI-DrugBank.d139.s5.e1
DDI-DrugBank.d139.s5	false	DDI-DrugBank.d139.s5.e0	DDI-DrugBank.d139.s5.e2
DDI-DrugBank.d139.s5	false	DDI-DrugBank.d139.s5.e0	DDI-DrugBank.d139.s5.e3
DDI-DrugBank.d139.s5	true	DDI-DrugBank.d139.s5.e1	DDI-DrugBank.d139.s5.e2
DDI-DrugBank.d139.s5	false	DDI-DrugBank.d139.s5.e1	DDI-DrugBank.d139.s5.e3
DDI-DrugBank.d139.s5	false	DDI-DrugBank.d139.s5.e2	DDI-DrugBank.d139.s5.e3
DDI-DrugBank.d139.s6|a|Orlistat-Orlistat may decrease the absorption of vitamin K.
DDI-DrugBank.d139.s6	0	7	Orlistat	drug	DDI-DrugBank.d139.s6.e0
DDI-DrugBank.d139.s6	9	16	Orlistat	drug	DDI-DrugBank.d139.s6.e1
DDI-DrugBank.d139.s6	49	57	vitamin K	group	DDI-DrugBank.d139.s6.e2
DDI-DrugBank.d139.s6	false	DDI-DrugBank.d139.s6.e0	DDI-DrugBank.d139.s6.e1
DDI-DrugBank.d139.s6	false	DDI-DrugBank.d139.s6.e0	DDI-DrugBank.d139.s6.e2
DDI-DrugBank.d139.s6	true	DDI-DrugBank.d139.s6.e1	DDI-DrugBank.d139.s6.e2
DDI-DrugBank.d139.s7|a|Salicylates-Salicylates in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.
DDI-DrugBank.d139.s7	0	10	Salicylates	group	DDI-DrugBank.d139.s7.e0
DDI-DrugBank.d139.s7	12	22	Salicylates	group	DDI-DrugBank.d139.s7.e1
DDI-DrugBank.d139.s7	false	DDI-DrugBank.d139.s7.e0	DDI-DrugBank.d139.s7.e1
DDI-DrugBank.d139.s8|a|Warfarin-Vitamin K can antagonize the effect of warfarin
DDI-DrugBank.d139.s8	0	7	Warfarin	drug	DDI-DrugBank.d139.s8.e0
DDI-DrugBank.d139.s8	9	17	Vitamin K	group	DDI-DrugBank.d139.s8.e1
DDI-DrugBank.d139.s8	48	55	warfarin	drug	DDI-DrugBank.d139.s8.e2
DDI-DrugBank.d139.s8	false	DDI-DrugBank.d139.s8.e0	DDI-DrugBank.d139.s8.e1
DDI-DrugBank.d139.s8	false	DDI-DrugBank.d139.s8.e0	DDI-DrugBank.d139.s8.e2
DDI-DrugBank.d139.s8	true	DDI-DrugBank.d139.s8.e1	DDI-DrugBank.d139.s8.e2
DDI-DrugBank.d552.s0|a|Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
DDI-DrugBank.d552.s0	0	7	Nabilone	drug	DDI-DrugBank.d552.s0.e0
DDI-DrugBank.d552.s0	78	95	psychoactive drugs	group	DDI-DrugBank.d552.s0.e1
DDI-DrugBank.d552.s0	100	114	CNS depressants	group	DDI-DrugBank.d552.s0.e2
DDI-DrugBank.d552.s0	127	133	alcohol	drug	DDI-DrugBank.d552.s0.e3
DDI-DrugBank.d552.s0	136	147	barbiturates	group	DDI-DrugBank.d552.s0.e4
DDI-DrugBank.d552.s0	153	171	narcotic analgesics	group	DDI-DrugBank.d552.s0.e5
DDI-DrugBank.d552.s0	true	DDI-DrugBank.d552.s0.e0	DDI-DrugBank.d552.s0.e1
DDI-DrugBank.d552.s0	true	DDI-DrugBank.d552.s0.e0	DDI-DrugBank.d552.s0.e2
DDI-DrugBank.d552.s0	true	DDI-DrugBank.d552.s0.e0	DDI-DrugBank.d552.s0.e3
DDI-DrugBank.d552.s0	true	DDI-DrugBank.d552.s0.e0	DDI-DrugBank.d552.s0.e4
DDI-DrugBank.d552.s0	true	DDI-DrugBank.d552.s0.e0	DDI-DrugBank.d552.s0.e5
DDI-DrugBank.d552.s0	false	DDI-DrugBank.d552.s0.e1	DDI-DrugBank.d552.s0.e2
DDI-DrugBank.d552.s0	false	DDI-DrugBank.d552.s0.e1	DDI-DrugBank.d552.s0.e3
DDI-DrugBank.d552.s0	false	DDI-DrugBank.d552.s0.e1	DDI-DrugBank.d552.s0.e4
DDI-DrugBank.d552.s0	false	DDI-DrugBank.d552.s0.e1	DDI-DrugBank.d552.s0.e5
DDI-DrugBank.d552.s0	false	DDI-DrugBank.d552.s0.e2	DDI-DrugBank.d552.s0.e3
DDI-DrugBank.d552.s1|a|Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
DDI-DrugBank.d552.s1	0	7	Nabilone	drug	DDI-DrugBank.d552.s1.e0
DDI-DrugBank.d552.s1	89	96	diazepam	drug	DDI-DrugBank.d552.s1.e1
DDI-DrugBank.d552.s1	99	118	secobarbitone sodium	brand	DDI-DrugBank.d552.s1.e2
DDI-DrugBank.d552.s1	121	127	alcohol	drug	DDI-DrugBank.d552.s1.e3
DDI-DrugBank.d552.s1	132	138	codeine	drug	DDI-DrugBank.d552.s1.e4
DDI-DrugBank.d552.s1	true	DDI-DrugBank.d552.s1.e0	DDI-DrugBank.d552.s1.e1
DDI-DrugBank.d552.s1	true	DDI-DrugBank.d552.s1.e0	DDI-DrugBank.d552.s1.e2
DDI-DrugBank.d552.s1	true	DDI-DrugBank.d552.s1.e0	DDI-DrugBank.d552.s1.e3
DDI-DrugBank.d552.s1	true	DDI-DrugBank.d552.s1.e0	DDI-DrugBank.d552.s1.e4
DDI-DrugBank.d552.s1	false	DDI-DrugBank.d552.s1.e1	DDI-DrugBank.d552.s1.e2
DDI-DrugBank.d552.s1	false	DDI-DrugBank.d552.s1.e1	DDI-DrugBank.d552.s1.e3
DDI-DrugBank.d552.s1	false	DDI-DrugBank.d552.s1.e1	DDI-DrugBank.d552.s1.e4
DDI-DrugBank.d552.s1	false	DDI-DrugBank.d552.s1.e2	DDI-DrugBank.d552.s1.e3
DDI-DrugBank.d552.s1	false	DDI-DrugBank.d552.s1.e2	DDI-DrugBank.d552.s1.e4
DDI-DrugBank.d552.s1	false	DDI-DrugBank.d552.s1.e3	DDI-DrugBank.d552.s1.e4
DDI-DrugBank.d174.s0|a|In vitro studies have shown that, because of its affinity for protein, 6MNA may displace other protein-bound drugs from their binding site.
DDI-DrugBank.d174.s0	71	74	6MNA	drug_n	DDI-DrugBank.d174.s0.e0
DDI-DrugBank.d174.s1|a|Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
DDI-DrugBank.d174.s1	47	56	nabumetone	drug	DDI-DrugBank.d174.s1.e0
DDI-DrugBank.d174.s1	63	70	warfarin	drug	DDI-DrugBank.d174.s1.e1
DDI-DrugBank.d174.s1	117	122	NSAIDs	group	DDI-DrugBank.d174.s1.e2
DDI-DrugBank.d174.s1	true	DDI-DrugBank.d174.s1.e0	DDI-DrugBank.d174.s1.e1
DDI-DrugBank.d174.s1	false	DDI-DrugBank.d174.s1.e0	DDI-DrugBank.d174.s1.e2
DDI-DrugBank.d174.s1	true	DDI-DrugBank.d174.s1.e1	DDI-DrugBank.d174.s1.e2
DDI-DrugBank.d174.s2|a|Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.
DDI-DrugBank.d174.s2	33	40	aluminum	drug	DDI-DrugBank.d174.s2.e0
DDI-DrugBank.d174.s2	53	59	antacid	group	DDI-DrugBank.d174.s2.e1
DDI-DrugBank.d174.s2	113	116	6MNA	drug_n	DDI-DrugBank.d174.s2.e2
DDI-DrugBank.d174.s2	false	DDI-DrugBank.d174.s2.e0	DDI-DrugBank.d174.s2.e1
DDI-DrugBank.d174.s2	false	DDI-DrugBank.d174.s2.e0	DDI-DrugBank.d174.s2.e2
DDI-DrugBank.d174.s2	false	DDI-DrugBank.d174.s2.e1	DDI-DrugBank.d174.s2.e2
DDI-DrugBank.d174.s3|a|When administered with food or milk, there is more rapid absorption;
DDI-DrugBank.d174.s4|a|however, the total amount of 6MNA in the plasma is unchanged .
DDI-DrugBank.d174.s4	29	32	6MNA	drug_n	DDI-DrugBank.d174.s4.e0
DDI-DrugBank.d204.s0|a|When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.
DDI-DrugBank.d204.s0	70	109	beta-adrenergic receptor blocking agents	group	DDI-DrugBank.d204.s0.e0
DDI-DrugBank.d204.s0	112	122	Anesthetics	group	DDI-DrugBank.d204.s0.e1
DDI-DrugBank.d204.s0	185	195	anesthetics	group	DDI-DrugBank.d204.s0.e2
DDI-DrugBank.d204.s0	true	DDI-DrugBank.d204.s0.e0	DDI-DrugBank.d204.s0.e1
DDI-DrugBank.d204.s0	false	DDI-DrugBank.d204.s0.e0	DDI-DrugBank.d204.s0.e2
DDI-DrugBank.d204.s0	false	DDI-DrugBank.d204.s0.e1	DDI-DrugBank.d204.s0.e2
DDI-DrugBank.d204.s1|a|Antidiabetic drugs (oral agents and insulin): hypoglycemia or hyperglycemia;
DDI-DrugBank.d204.s1	0	17	Antidiabetic drugs	group	DDI-DrugBank.d204.s1.e0
DDI-DrugBank.d204.s1	36	42	insulin	drug	DDI-DrugBank.d204.s1.e1
DDI-DrugBank.d204.s1	false	DDI-DrugBank.d204.s1.e0	DDI-DrugBank.d204.s1.e1
DDI-DrugBank.d204.s2|a|adjust dosage of antidiabetic drug accordingly.
DDI-DrugBank.d204.s2	17	33	antidiabetic drug	group	DDI-DrugBank.d204.s2.e0
DDI-DrugBank.d204.s3|a|Catecholamine-depleting drugs (e.g., reserpine): additive effect;
DDI-DrugBank.d204.s3	37	45	reserpine	drug	DDI-DrugBank.d204.s3.e0
DDI-DrugBank.d204.s4|a|monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension).
DDI-DrugBank.d204.s5|a|Response to Treatment for Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.
DDI-DrugBank.d204.s5	62	74	beta-blockers	group	DDI-DrugBank.d204.s5.e0
DDI-DrugBank.d204.s6|a|Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
DDI-DrugBank.d204.s6	56	66	epinephrine	drug	DDI-DrugBank.d204.s6.e0
DDI-DrugBank.d218.s0|a|No pharmacokinetic-based drug-drug interaction studies have been conducted with SYNAREL.
DDI-DrugBank.d218.s0	80	86	SYNAREL	brand	DDI-DrugBank.d218.s0.e0
DDI-DrugBank.d218.s1|a|However, because nafarelin acetate is a peptide that is primarily degraded by peptidase and not by cytochrome P-450 enzymes, and the drug is only about 80% bound to plasma proteins at 4 C, drug interactions would not be expected to occur.
DDI-DrugBank.d218.s1	17	33	nafarelin acetate	drug	DDI-DrugBank.d218.s1.e0
DDI-DrugBank.d261.s0|a|Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
DDI-DrugBank.d261.s0	0	11	Tetracycline	drug	DDI-DrugBank.d261.s0.e0
DDI-DrugBank.d261.s0	16	40	bacteriostatic antibiotic	group	DDI-DrugBank.d261.s0.e1
DDI-DrugBank.d261.s0	85	94	penicillin	drug	DDI-DrugBank.d261.s0.e2
DDI-DrugBank.d261.s0	false	DDI-DrugBank.d261.s0.e0	DDI-DrugBank.d261.s0.e1
DDI-DrugBank.d261.s0	true	DDI-DrugBank.d261.s0.e0	DDI-DrugBank.d261.s0.e2
DDI-DrugBank.d261.s0	false	DDI-DrugBank.d261.s0.e1	DDI-DrugBank.d261.s0.e2
DDI-DrugBank.d37.s0|a|No specific information available
DDI-DrugBank.d37.s1|a|.
DDI-DrugBank.d37.s2|a|
DDI-DrugBank.d427.s0|a|Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
DDI-DrugBank.d427.s0	26	37	theophylline	drug	DDI-DrugBank.d427.s0.e0
DDI-DrugBank.d427.s0	75	83	quinolone	group	DDI-DrugBank.d427.s0.e1
DDI-DrugBank.d427.s0	true	DDI-DrugBank.d427.s0.e0	DDI-DrugBank.d427.s0.e1
DDI-DrugBank.d427.s1|a|There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.
DDI-DrugBank.d427.s1	27	38	theophylline	drug	DDI-DrugBank.d427.s1.e0
DDI-DrugBank.d427.s1	101	110	quinolones	group	DDI-DrugBank.d427.s1.e1
DDI-DrugBank.d427.s1	116	127	theophylline	drug	DDI-DrugBank.d427.s1.e2
DDI-DrugBank.d427.s1	false	DDI-DrugBank.d427.s1.e0	DDI-DrugBank.d427.s1.e1
DDI-DrugBank.d427.s1	false	DDI-DrugBank.d427.s1.e0	DDI-DrugBank.d427.s1.e2
DDI-DrugBank.d427.s1	true	DDI-DrugBank.d427.s1.e1	DDI-DrugBank.d427.s1.e2
DDI-DrugBank.d427.s2|a|Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.
DDI-DrugBank.d427.s2	25	36	theophylline	drug	DDI-DrugBank.d427.s2.e0
DDI-DrugBank.d427.s2	87	98	theophylline	drug	DDI-DrugBank.d427.s2.e1
DDI-DrugBank.d427.s2	false	DDI-DrugBank.d427.s2.e0	DDI-DrugBank.d427.s2.e1
DDI-DrugBank.d427.s3|a|Quinolones have been shown to interfere with the metabolism of caffeine.
DDI-DrugBank.d427.s3	0	9	Quinolones	group	DDI-DrugBank.d427.s3.e0
DDI-DrugBank.d427.s3	63	70	caffeine	drug	DDI-DrugBank.d427.s3.e1
DDI-DrugBank.d427.s3	true	DDI-DrugBank.d427.s3.e0	DDI-DrugBank.d427.s3.e1
DDI-DrugBank.d427.s4|a|This may lead to reduced clearance of caffeine and the prolongation of its plasma half-life.
DDI-DrugBank.d427.s4	38	45	caffeine	drug	DDI-DrugBank.d427.s4.e0
DDI-DrugBank.d427.s5|a|Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.
DDI-DrugBank.d427.s5	0	9	Quinolones	group	DDI-DrugBank.d427.s5.e0
DDI-DrugBank.d427.s5	22	35	nalidixic acid	drug	DDI-DrugBank.d427.s5.e1
DDI-DrugBank.d427.s5	74	86	anticoagulant	group	DDI-DrugBank.d427.s5.e2
DDI-DrugBank.d427.s5	88	95	warfarin	drug	DDI-DrugBank.d427.s5.e3
DDI-DrugBank.d427.s5	false	DDI-DrugBank.d427.s5.e0	DDI-DrugBank.d427.s5.e1
DDI-DrugBank.d427.s5	false	DDI-DrugBank.d427.s5.e0	DDI-DrugBank.d427.s5.e2
DDI-DrugBank.d427.s5	true	DDI-DrugBank.d427.s5.e0	DDI-DrugBank.d427.s5.e3
DDI-DrugBank.d427.s5	false	DDI-DrugBank.d427.s5.e1	DDI-DrugBank.d427.s5.e2
DDI-DrugBank.d427.s5	true	DDI-DrugBank.d427.s5.e1	DDI-DrugBank.d427.s5.e3
DDI-DrugBank.d427.s5	false	DDI-DrugBank.d427.s5.e2	DDI-DrugBank.d427.s5.e3
DDI-DrugBank.d427.s6|a|When these products are administered concomitantly, prothrombin time or other suitable coagulation test should be closely monitored.
DDI-DrugBank.d427.s7|a|Nitrofurantoin interferes with the therapeutic action of nalidixic acid.
DDI-DrugBank.d427.s7	0	13	Nitrofurantoin	drug	DDI-DrugBank.d427.s7.e0
DDI-DrugBank.d427.s7	57	70	nalidixic acid	drug	DDI-DrugBank.d427.s7.e1
DDI-DrugBank.d427.s7	true	DDI-DrugBank.d427.s7.e0	DDI-DrugBank.d427.s7.e1
DDI-DrugBank.d427.s8|a|Antacids containing magnesium, aluminum, or calcium;
DDI-DrugBank.d427.s8	0	7	Antacids	group	DDI-DrugBank.d427.s8.e0
DDI-DrugBank.d427.s8	20	28	magnesium	drug	DDI-DrugBank.d427.s8.e1
DDI-DrugBank.d427.s8	31	38	aluminum	drug	DDI-DrugBank.d427.s8.e2
DDI-DrugBank.d427.s8	44	50	calcium	drug	DDI-DrugBank.d427.s8.e3
DDI-DrugBank.d427.s8	false	DDI-DrugBank.d427.s8.e0	DDI-DrugBank.d427.s8.e1
DDI-DrugBank.d427.s8	false	DDI-DrugBank.d427.s8.e0	DDI-DrugBank.d427.s8.e2
DDI-DrugBank.d427.s8	false	DDI-DrugBank.d427.s8.e0	DDI-DrugBank.d427.s8.e3
DDI-DrugBank.d427.s8	false	DDI-DrugBank.d427.s8.e1	DDI-DrugBank.d427.s8.e2
DDI-DrugBank.d427.s8	false	DDI-DrugBank.d427.s8.e1	DDI-DrugBank.d427.s8.e3
DDI-DrugBank.d427.s8	false	DDI-DrugBank.d427.s8.e2	DDI-DrugBank.d427.s8.e3
DDI-DrugBank.d427.s9|a|sucralfate or divalent or trivalent cations such as iron;
DDI-DrugBank.d427.s9	0	9	sucralfate	drug	DDI-DrugBank.d427.s9.e0
DDI-DrugBank.d427.s9	52	55	iron	drug	DDI-DrugBank.d427.s9.e1
DDI-DrugBank.d427.s9	false	DDI-DrugBank.d427.s9.e0	DDI-DrugBank.d427.s9.e1
DDI-DrugBank.d427.s10|a|multivitamins containing zinc;
DDI-DrugBank.d427.s10	0	12	multivitamins	group	DDI-DrugBank.d427.s10.e0
DDI-DrugBank.d427.s10	25	28	zinc	drug	DDI-DrugBank.d427.s10.e1
DDI-DrugBank.d427.s10	false	DDI-DrugBank.d427.s10.e0	DDI-DrugBank.d427.s10.e1
DDI-DrugBank.d427.s11|a|and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.
DDI-DrugBank.d427.s11	4	8	Videx	brand	DDI-DrugBank.d427.s11.e0
DDI-DrugBank.d427.s11	13	22	Didanosine	drug	DDI-DrugBank.d427.s11.e1
DDI-DrugBank.d427.s11	145	154	quinolones	group	DDI-DrugBank.d427.s11.e2
DDI-DrugBank.d427.s11	false	DDI-DrugBank.d427.s11.e0	DDI-DrugBank.d427.s11.e1
DDI-DrugBank.d427.s11	true	DDI-DrugBank.d427.s11.e0	DDI-DrugBank.d427.s11.e2
DDI-DrugBank.d427.s11	true	DDI-DrugBank.d427.s11.e1	DDI-DrugBank.d427.s11.e2
DDI-DrugBank.d427.s12|a|These agents should not be taken within the two hour period before or within the two-hour period after nalidixic acid administration.
DDI-DrugBank.d427.s12	103	116	nalidixic acid	drug	DDI-DrugBank.d427.s12.e0
DDI-DrugBank.d427.s13|a|Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.
DDI-DrugBank.d427.s13	25	36	cyclosporine	drug	DDI-DrugBank.d427.s13.e0
DDI-DrugBank.d427.s13	90	99	quinolones	group	DDI-DrugBank.d427.s13.e1
DDI-DrugBank.d427.s13	105	116	cyclosporine	drug	DDI-DrugBank.d427.s13.e2
DDI-DrugBank.d427.s13	false	DDI-DrugBank.d427.s13.e0	DDI-DrugBank.d427.s13.e1
DDI-DrugBank.d427.s13	false	DDI-DrugBank.d427.s13.e0	DDI-DrugBank.d427.s13.e2
DDI-DrugBank.d427.s13	true	DDI-DrugBank.d427.s13.e1	DDI-DrugBank.d427.s13.e2
DDI-DrugBank.d427.s14|a|Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.
DDI-DrugBank.d427.s14	11	22	cyclosporine	drug	DDI-DrugBank.d427.s14.e0
DDI-DrugBank.d427.s14	73	84	cyclosporine	drug	DDI-DrugBank.d427.s14.e1
DDI-DrugBank.d427.s14	false	DDI-DrugBank.d427.s14.e0	DDI-DrugBank.d427.s14.e1
DDI-DrugBank.d346.s0|a|Studies to evaluate possible interactions between REVIA and drugs other than opiates have not been performed.
DDI-DrugBank.d346.s0	50	54	REVIA	brand	DDI-DrugBank.d346.s0.e0
DDI-DrugBank.d346.s0	77	83	opiates	group	DDI-DrugBank.d346.s0.e1
DDI-DrugBank.d346.s0	false	DDI-DrugBank.d346.s0.e0	DDI-DrugBank.d346.s0.e1
DDI-DrugBank.d346.s1|a|Consequently, caution is advised if the concomitant administration of REVIA and other drugs is required.
DDI-DrugBank.d346.s1	70	74	REVIA	brand	DDI-DrugBank.d346.s1.e0
DDI-DrugBank.d346.s2|a|The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.
DDI-DrugBank.d346.s2	46	50	REVIA	brand	DDI-DrugBank.d346.s2.e0
DDI-DrugBank.d346.s2	56	65	disulfiram	drug	DDI-DrugBank.d346.s2.e1
DDI-DrugBank.d346.s2	true	DDI-DrugBank.d346.s2.e0	DDI-DrugBank.d346.s2.e1
DDI-DrugBank.d346.s3|a|Lethargy and somnolence have been reported following doses of REVIA and thioridazine.
DDI-DrugBank.d346.s3	62	66	REVIA	brand	DDI-DrugBank.d346.s3.e0
DDI-DrugBank.d346.s3	72	83	thioridazine	drug	DDI-DrugBank.d346.s3.e1
DDI-DrugBank.d346.s3	true	DDI-DrugBank.d346.s3.e0	DDI-DrugBank.d346.s3.e1
DDI-DrugBank.d346.s4|a|Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
DDI-DrugBank.d346.s4	16	20	REVIA	brand	DDI-DrugBank.d346.s4.e0
DDI-DrugBank.d346.s4	43	48	opioid	group	DDI-DrugBank.d346.s4.e1
DDI-DrugBank.d346.s4	141	157	opioid analgesics	group	DDI-DrugBank.d346.s4.e2
DDI-DrugBank.d346.s4	true	DDI-DrugBank.d346.s4.e0	DDI-DrugBank.d346.s4.e1
DDI-DrugBank.d346.s4	true	DDI-DrugBank.d346.s4.e0	DDI-DrugBank.d346.s4.e2
DDI-DrugBank.d346.s4	false	DDI-DrugBank.d346.s4.e1	DDI-DrugBank.d346.s4.e2
DDI-DrugBank.d346.s5|a|In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.
DDI-DrugBank.d346.s5	92	96	REVIA	brand	DDI-DrugBank.d346.s5.e0
DDI-DrugBank.d346.s5	113	118	opioid	group	DDI-DrugBank.d346.s5.e1
DDI-DrugBank.d346.s5	true	DDI-DrugBank.d346.s5.e0	DDI-DrugBank.d346.s5.e1
DDI-DrugBank.d85.s0|a|The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.
DDI-DrugBank.d85.s0	11	16	NSAIDs	group	DDI-DrugBank.d85.s0.e0
DDI-DrugBank.d85.s0	48	61	ACE inhibitors	group	DDI-DrugBank.d85.s0.e1
DDI-DrugBank.d85.s0	true	DDI-DrugBank.d85.s0.e0	DDI-DrugBank.d85.s0.e1
DDI-DrugBank.d85.s1|a|In vitro studies have shown that naproxen anion, because of its affinity for protein, may displace from their binding sites other drugs which are also albumin-bound .
DDI-DrugBank.d85.s1	33	40	naproxen	drug	DDI-DrugBank.d85.s1.e0
DDI-DrugBank.d85.s2|a|Theoretically, the naproxen anion itself could likewise be displaced.
DDI-DrugBank.d85.s2	19	26	naproxen	drug	DDI-DrugBank.d85.s2.e0
DDI-DrugBank.d85.s3|a|Short-term controlled studies failed to show that taking the drug significantly affects prothrombin times when administered to individuals on coumarin-type anticoagulants.
DDI-DrugBank.d85.s3	142	169	coumarin-type anticoagulants	group	DDI-DrugBank.d85.s3.e0
DDI-DrugBank.d85.s4|a|Caution is advised nonetheless, since interactions have been seen with other nonsteroidal agents of this class.
DDI-DrugBank.d85.s5|a|Similarly, patients receiving the drug and a hydantoin, sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs.
DDI-DrugBank.d85.s5	45	53	hydantoin	group	DDI-DrugBank.d85.s5.e0
DDI-DrugBank.d85.s5	56	66	sulfonamide	group	DDI-DrugBank.d85.s5.e1
DDI-DrugBank.d85.s5	71	82	sulfonylurea	group	DDI-DrugBank.d85.s5.e2
DDI-DrugBank.d85.s5	false	DDI-DrugBank.d85.s5.e0	DDI-DrugBank.d85.s5.e1
DDI-DrugBank.d85.s5	false	DDI-DrugBank.d85.s5.e0	DDI-DrugBank.d85.s5.e2
DDI-DrugBank.d85.s5	false	DDI-DrugBank.d85.s5.e1	DDI-DrugBank.d85.s5.e2
DDI-DrugBank.d85.s6|a|Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
DDI-DrugBank.d85.s6	30	37	naproxen	drug	DDI-DrugBank.d85.s6.e0
DDI-DrugBank.d85.s6	43	49	aspirin	brand	DDI-DrugBank.d85.s6.e1
DDI-DrugBank.d85.s6	78	85	naproxen	drug	DDI-DrugBank.d85.s6.e2
DDI-DrugBank.d85.s6	164	170	aspirin	brand	DDI-DrugBank.d85.s6.e3
DDI-DrugBank.d85.s6	true	DDI-DrugBank.d85.s6.e0	DDI-DrugBank.d85.s6.e1
DDI-DrugBank.d85.s6	false	DDI-DrugBank.d85.s6.e0	DDI-DrugBank.d85.s6.e2
DDI-DrugBank.d85.s6	false	DDI-DrugBank.d85.s6.e0	DDI-DrugBank.d85.s6.e3
DDI-DrugBank.d85.s6	false	DDI-DrugBank.d85.s6.e1	DDI-DrugBank.d85.s6.e2
DDI-DrugBank.d85.s6	false	DDI-DrugBank.d85.s6.e1	DDI-DrugBank.d85.s6.e3
DDI-DrugBank.d85.s6	true	DDI-DrugBank.d85.s6.e2	DDI-DrugBank.d85.s6.e3
DDI-DrugBank.d85.s7|a|The natriuretic effect of furosemide has been reported to be inhibited by some drugs of this class.
DDI-DrugBank.d85.s7	26	35	furosemide	drug	DDI-DrugBank.d85.s7.e0
DDI-DrugBank.d85.s8|a|Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.
DDI-DrugBank.d85.s8	20	26	lithium	drug	DDI-DrugBank.d85.s8.e0
DDI-DrugBank.d85.s8	69	75	lithium	drug	DDI-DrugBank.d85.s8.e1
DDI-DrugBank.d85.s8	false	DDI-DrugBank.d85.s8.e0	DDI-DrugBank.d85.s8.e1
DDI-DrugBank.d85.s9|a|Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
DDI-DrugBank.d85.s9	0	7	Naproxen	drug	DDI-DrugBank.d85.s9.e0
DDI-DrugBank.d85.s9	19	24	NSAIDs	group	DDI-DrugBank.d85.s9.e1
DDI-DrugBank.d85.s9	68	78	propranolol	drug	DDI-DrugBank.d85.s9.e2
DDI-DrugBank.d85.s9	90	102	beta-blockers	group	DDI-DrugBank.d85.s9.e3
DDI-DrugBank.d85.s9	false	DDI-DrugBank.d85.s9.e0	DDI-DrugBank.d85.s9.e1
DDI-DrugBank.d85.s9	true	DDI-DrugBank.d85.s9.e0	DDI-DrugBank.d85.s9.e2
DDI-DrugBank.d85.s9	true	DDI-DrugBank.d85.s9.e0	DDI-DrugBank.d85.s9.e3
DDI-DrugBank.d85.s9	true	DDI-DrugBank.d85.s9.e1	DDI-DrugBank.d85.s9.e2
DDI-DrugBank.d85.s9	true	DDI-DrugBank.d85.s9.e1	DDI-DrugBank.d85.s9.e3
DDI-DrugBank.d85.s9	false	DDI-DrugBank.d85.s9.e2	DDI-DrugBank.d85.s9.e3
DDI-DrugBank.d85.s10|a|Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.
DDI-DrugBank.d85.s10	0	9	Probenecid	drug	DDI-DrugBank.d85.s10.e0
DDI-DrugBank.d85.s10	40	47	naproxen	drug	DDI-DrugBank.d85.s10.e1
DDI-DrugBank.d85.s10	true	DDI-DrugBank.d85.s10.e0	DDI-DrugBank.d85.s10.e1
DDI-DrugBank.d85.s11|a|Caution should be used if naproxen is administered concomitantly with methotrexate.
DDI-DrugBank.d85.s11	26	33	naproxen	drug	DDI-DrugBank.d85.s11.e0
DDI-DrugBank.d85.s11	70	81	methotrexate	drug	DDI-DrugBank.d85.s11.e1
DDI-DrugBank.d85.s11	true	DDI-DrugBank.d85.s11.e0	DDI-DrugBank.d85.s11.e1
DDI-DrugBank.d85.s12|a|Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
DDI-DrugBank.d85.s12	0	7	Naproxen	drug	DDI-DrugBank.d85.s12.e0
DDI-DrugBank.d85.s12	10	24	naproxen sodium	drug	DDI-DrugBank.d85.s12.e1
DDI-DrugBank.d85.s12	36	41	NSAIDs	group	DDI-DrugBank.d85.s12.e2
DDI-DrugBank.d85.s12	97	108	methotrexate	drug	DDI-DrugBank.d85.s12.e3
DDI-DrugBank.d85.s12	166	177	methotrexate	drug	DDI-DrugBank.d85.s12.e4
DDI-DrugBank.d85.s12	false	DDI-DrugBank.d85.s12.e0	DDI-DrugBank.d85.s12.e1
DDI-DrugBank.d85.s12	false	DDI-DrugBank.d85.s12.e0	DDI-DrugBank.d85.s12.e2
DDI-DrugBank.d85.s12	true	DDI-DrugBank.d85.s12.e0	DDI-DrugBank.d85.s12.e3
DDI-DrugBank.d85.s12	false	DDI-DrugBank.d85.s12.e0	DDI-DrugBank.d85.s12.e4
DDI-DrugBank.d85.s12	false	DDI-DrugBank.d85.s12.e1	DDI-DrugBank.d85.s12.e2
DDI-DrugBank.d85.s12	true	DDI-DrugBank.d85.s12.e1	DDI-DrugBank.d85.s12.e3
DDI-DrugBank.d85.s12	false	DDI-DrugBank.d85.s12.e1	DDI-DrugBank.d85.s12.e4
DDI-DrugBank.d85.s12	true	DDI-DrugBank.d85.s12.e2	DDI-DrugBank.d85.s12.e3
DDI-DrugBank.d85.s12	false	DDI-DrugBank.d85.s12.e2	DDI-DrugBank.d85.s12.e4
DDI-DrugBank.d85.s12	false	DDI-DrugBank.d85.s12.e3	DDI-DrugBank.d85.s12.e4
DDI-DrugBank.d85.s13|a|Drug/Laboratory Test Interactions Naproxen may decrease platelet aggregation and prolong bleeding time.
DDI-DrugBank.d85.s13	34	41	Naproxen	drug	DDI-DrugBank.d85.s13.e0
DDI-DrugBank.d85.s14|a|This effect should be kept in mind when bleeding times are determined.
DDI-DrugBank.d85.s15|a|The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-dinitrobenzene used in this assay.
DDI-DrugBank.d85.s15	22	29	naproxen	drug	DDI-DrugBank.d85.s15.e0
DDI-DrugBank.d85.s16|a|Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.
DDI-DrugBank.d85.s16	146	153	naproxen	drug	DDI-DrugBank.d85.s16.e0
DDI-DrugBank.d85.s17|a|Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).
DDI-DrugBank.d85.s17	0	7	Naproxen	drug	DDI-DrugBank.d85.s17.e0
DDI-DrugBank.d478.s0|a|Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.
DDI-DrugBank.d478.s0	0	4	Ergot	group	DDI-DrugBank.d478.s0.e0
DDI-DrugBank.d478.s1|a|Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
DDI-DrugBank.d478.s1	80	89	ergotamine	drug	DDI-DrugBank.d478.s1.e0
DDI-DrugBank.d478.s1	105	126	ergot-type medications	group	DDI-DrugBank.d478.s1.e1
DDI-DrugBank.d478.s1	134	150	dihydroergotamine	drug	DDI-DrugBank.d478.s1.e2
DDI-DrugBank.d478.s1	155	166	methysergide	drug	DDI-DrugBank.d478.s1.e3
DDI-DrugBank.d478.s1	173	183	naratriptan	drug	DDI-DrugBank.d478.s1.e4
DDI-DrugBank.d478.s1	false	DDI-DrugBank.d478.s1.e0	DDI-DrugBank.d478.s1.e1
DDI-DrugBank.d478.s1	false	DDI-DrugBank.d478.s1.e0	DDI-DrugBank.d478.s1.e2
DDI-DrugBank.d478.s1	false	DDI-DrugBank.d478.s1.e0	DDI-DrugBank.d478.s1.e3
DDI-DrugBank.d478.s1	true	DDI-DrugBank.d478.s1.e0	DDI-DrugBank.d478.s1.e4
DDI-DrugBank.d478.s1	false	DDI-DrugBank.d478.s1.e1	DDI-DrugBank.d478.s1.e2
DDI-DrugBank.d478.s1	false	DDI-DrugBank.d478.s1.e1	DDI-DrugBank.d478.s1.e3
DDI-DrugBank.d478.s1	true	DDI-DrugBank.d478.s1.e1	DDI-DrugBank.d478.s1.e4
DDI-DrugBank.d478.s1	false	DDI-DrugBank.d478.s1.e2	DDI-DrugBank.d478.s1.e3
DDI-DrugBank.d478.s1	true	DDI-DrugBank.d478.s1.e2	DDI-DrugBank.d478.s1.e4
DDI-DrugBank.d478.s1	true	DDI-DrugBank.d478.s1.e3	DDI-DrugBank.d478.s1.e4
DDI-DrugBank.d478.s2|a|The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients.
DDI-DrugBank.d478.s2	22	32	naratriptan	drug	DDI-DrugBank.d478.s2.e0
DDI-DrugBank.d478.s2	45	58	5-HT1 agonists	group	DDI-DrugBank.d478.s2.e1
DDI-DrugBank.d478.s2	false	DDI-DrugBank.d478.s2.e0	DDI-DrugBank.d478.s2.e1
DDI-DrugBank.d478.s3|a|Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.
DDI-DrugBank.d478.s3	71	81	naratriptan	drug	DDI-DrugBank.d478.s3.e0
DDI-DrugBank.d478.s3	93	106	5-HT1 agonists	group	DDI-DrugBank.d478.s3.e1
DDI-DrugBank.d478.s3	true	DDI-DrugBank.d478.s3.e0	DDI-DrugBank.d478.s3.e1
DDI-DrugBank.d478.s4|a|Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
DDI-DrugBank.d478.s4	0	38	Selective serotonin reuptake inhibitors	group	DDI-DrugBank.d478.s4.e0
DDI-DrugBank.d478.s4	41	45	SSRIs	group	DDI-DrugBank.d478.s4.e1
DDI-DrugBank.d478.s4	55	64	fluoxetine	drug	DDI-DrugBank.d478.s4.e2
DDI-DrugBank.d478.s4	67	77	fluvoxamine	drug	DDI-DrugBank.d478.s4.e3
DDI-DrugBank.d478.s4	80	89	paroxetine	drug	DDI-DrugBank.d478.s4.e4
DDI-DrugBank.d478.s4	92	101	sertraline	drug	DDI-DrugBank.d478.s4.e5
DDI-DrugBank.d478.s4	false	DDI-DrugBank.d478.s4.e0	DDI-DrugBank.d478.s4.e1
DDI-DrugBank.d478.s4	false	DDI-DrugBank.d478.s4.e0	DDI-DrugBank.d478.s4.e2
DDI-DrugBank.d478.s4	false	DDI-DrugBank.d478.s4.e0	DDI-DrugBank.d478.s4.e3
DDI-DrugBank.d478.s4	false	DDI-DrugBank.d478.s4.e0	DDI-DrugBank.d478.s4.e4
DDI-DrugBank.d478.s4	false	DDI-DrugBank.d478.s4.e0	DDI-DrugBank.d478.s4.e5
DDI-DrugBank.d478.s4	false	DDI-DrugBank.d478.s4.e1	DDI-DrugBank.d478.s4.e2
DDI-DrugBank.d478.s4	false	DDI-DrugBank.d478.s4.e1	DDI-DrugBank.d478.s4.e3
DDI-DrugBank.d478.s4	false	DDI-DrugBank.d478.s4.e1	DDI-DrugBank.d478.s4.e4
DDI-DrugBank.d478.s4	false	DDI-DrugBank.d478.s4.e1	DDI-DrugBank.d478.s4.e5
DDI-DrugBank.d478.s4	false	DDI-DrugBank.d478.s4.e2	DDI-DrugBank.d478.s4.e3
DDI-DrugBank.d478.s5|a|If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d478.s5	30	40	naratriptan	drug	DDI-DrugBank.d478.s5.e0
DDI-DrugBank.d478.s5	49	52	SSRI	group	DDI-DrugBank.d478.s5.e1
DDI-DrugBank.d478.s5	true	DDI-DrugBank.d478.s5.e0	DDI-DrugBank.d478.s5.e1
DDI-DrugBank.d478.s6|a|Drug/ Laboratory Test Interactions AMERGE Tablets are not known to interfere with commonly employed clinical laboratory tests.
DDI-DrugBank.d478.s6	35	40	AMERGE	brand	DDI-DrugBank.d478.s6.e0
DDI-DrugBank.d232.s0|a|After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.
DDI-DrugBank.d232.s0	23	40	interferon beta-1a	drug	DDI-DrugBank.d232.s0.e0
DDI-DrugBank.d232.s0	43	48	AVONEX	brand	DDI-DrugBank.d232.s0.e1
DDI-DrugBank.d232.s0	82	88	TYSABRI	brand	DDI-DrugBank.d232.s0.e2
DDI-DrugBank.d232.s0	false	DDI-DrugBank.d232.s0.e0	DDI-DrugBank.d232.s0.e1
DDI-DrugBank.d232.s0	true	DDI-DrugBank.d232.s0.e0	DDI-DrugBank.d232.s0.e2
DDI-DrugBank.d232.s0	true	DDI-DrugBank.d232.s0.e1	DDI-DrugBank.d232.s0.e2
DDI-DrugBank.d232.s1|a|The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).
DDI-DrugBank.d232.s1	22	28	TYSABRI	brand	DDI-DrugBank.d232.s1.e0
DDI-DrugBank.d232.s1	105	110	AVONEX	brand	DDI-DrugBank.d232.s1.e1
DDI-DrugBank.d232.s1	148	153	AVONEX	brand	DDI-DrugBank.d232.s1.e2
DDI-DrugBank.d232.s1	239	245	TYSABRI	brand	DDI-DrugBank.d232.s1.e3
DDI-DrugBank.d232.s1	false	DDI-DrugBank.d232.s1.e0	DDI-DrugBank.d232.s1.e1
DDI-DrugBank.d232.s1	false	DDI-DrugBank.d232.s1.e0	DDI-DrugBank.d232.s1.e2
DDI-DrugBank.d232.s1	false	DDI-DrugBank.d232.s1.e0	DDI-DrugBank.d232.s1.e3
DDI-DrugBank.d232.s1	false	DDI-DrugBank.d232.s1.e1	DDI-DrugBank.d232.s1.e2
DDI-DrugBank.d232.s1	false	DDI-DrugBank.d232.s1.e1	DDI-DrugBank.d232.s1.e3
DDI-DrugBank.d232.s1	false	DDI-DrugBank.d232.s1.e2	DDI-DrugBank.d232.s1.e3
DDI-DrugBank.d232.s2|a|Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.
DDI-DrugBank.d232.s2	57	63	TYSABRI	brand	DDI-DrugBank.d232.s2.e0
DDI-DrugBank.d232.s2	82	99	interferon beta-1a	drug	DDI-DrugBank.d232.s2.e1
DDI-DrugBank.d232.s2	102	107	AVONEX	brand	DDI-DrugBank.d232.s2.e2
DDI-DrugBank.d232.s2	136	153	glatiramer acetate	drug	DDI-DrugBank.d232.s2.e3
DDI-DrugBank.d232.s2	224	238	beta-interferon	drug	DDI-DrugBank.d232.s2.e4
DDI-DrugBank.d232.s2	243	260	glatiramer acetate	drug	DDI-DrugBank.d232.s2.e5
DDI-DrugBank.d232.s2	false	DDI-DrugBank.d232.s2.e0	DDI-DrugBank.d232.s2.e1
DDI-DrugBank.d232.s2	false	DDI-DrugBank.d232.s2.e0	DDI-DrugBank.d232.s2.e2
DDI-DrugBank.d232.s2	false	DDI-DrugBank.d232.s2.e0	DDI-DrugBank.d232.s2.e3
DDI-DrugBank.d232.s2	false	DDI-DrugBank.d232.s2.e0	DDI-DrugBank.d232.s2.e4
DDI-DrugBank.d232.s2	false	DDI-DrugBank.d232.s2.e0	DDI-DrugBank.d232.s2.e5
DDI-DrugBank.d232.s2	false	DDI-DrugBank.d232.s2.e1	DDI-DrugBank.d232.s2.e2
DDI-DrugBank.d232.s2	false	DDI-DrugBank.d232.s2.e1	DDI-DrugBank.d232.s2.e3
DDI-DrugBank.d232.s2	false	DDI-DrugBank.d232.s2.e1	DDI-DrugBank.d232.s2.e4
DDI-DrugBank.d232.s2	false	DDI-DrugBank.d232.s2.e1	DDI-DrugBank.d232.s2.e5
DDI-DrugBank.d232.s2	false	DDI-DrugBank.d232.s2.e2	DDI-DrugBank.d232.s2.e3
DDI-DrugBank.d460.s0|a|In vitro drug metabolism studies indicate that Starlix is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%).
DDI-DrugBank.d460.s0	47	53	Starlix	brand	DDI-DrugBank.d460.s0.e0
DDI-DrugBank.d460.s1|a|Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.
DDI-DrugBank.d460.s1	0	6	Starlix	brand	DDI-DrugBank.d460.s1.e0
DDI-DrugBank.d460.s1	131	141	tolbutamide	drug	DDI-DrugBank.d460.s1.e1
DDI-DrugBank.d460.s1	true	DDI-DrugBank.d460.s1.e0	DDI-DrugBank.d460.s1.e1
DDI-DrugBank.d460.s2|a|Inhibition of CYP3A4 metabolic reactions was not detected in in vitro experiments.
DDI-DrugBank.d460.s3|a|Glyburide: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.
DDI-DrugBank.d460.s3	0	8	Glyburide	drug	DDI-DrugBank.d460.s3.e0
DDI-DrugBank.d460.s3	114	120	Starlix	brand	DDI-DrugBank.d460.s3.e1
DDI-DrugBank.d460.s3	183	191	glyburide	drug	DDI-DrugBank.d460.s3.e2
DDI-DrugBank.d460.s3	false	DDI-DrugBank.d460.s3.e0	DDI-DrugBank.d460.s3.e1
DDI-DrugBank.d460.s3	false	DDI-DrugBank.d460.s3.e0	DDI-DrugBank.d460.s3.e2
DDI-DrugBank.d460.s3	false	DDI-DrugBank.d460.s3.e1	DDI-DrugBank.d460.s3.e2
DDI-DrugBank.d460.s4|a|There were no clinically relevant alterations in the pharmacokinetics of either agent.
DDI-DrugBank.d460.s5|a|Metformin: When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.
DDI-DrugBank.d460.s5	0	8	Metformin	drug	DDI-DrugBank.d460.s5.e0
DDI-DrugBank.d460.s5	16	22	Starlix	brand	DDI-DrugBank.d460.s5.e1
DDI-DrugBank.d460.s5	99	107	metformin	drug	DDI-DrugBank.d460.s5.e2
DDI-DrugBank.d460.s5	false	DDI-DrugBank.d460.s5.e0	DDI-DrugBank.d460.s5.e1
DDI-DrugBank.d460.s5	false	DDI-DrugBank.d460.s5.e0	DDI-DrugBank.d460.s5.e2
DDI-DrugBank.d460.s5	false	DDI-DrugBank.d460.s5.e1	DDI-DrugBank.d460.s5.e2
DDI-DrugBank.d460.s6|a|Digoxin: When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.
DDI-DrugBank.d460.s6	0	6	Digoxin	drug	DDI-DrugBank.d460.s6.e0
DDI-DrugBank.d460.s6	14	20	Starlix	brand	DDI-DrugBank.d460.s6.e1
DDI-DrugBank.d460.s6	101	107	digoxin	drug	DDI-DrugBank.d460.s6.e2
DDI-DrugBank.d460.s6	false	DDI-DrugBank.d460.s6.e0	DDI-DrugBank.d460.s6.e1
DDI-DrugBank.d460.s6	false	DDI-DrugBank.d460.s6.e0	DDI-DrugBank.d460.s6.e2
DDI-DrugBank.d460.s6	false	DDI-DrugBank.d460.s6.e1	DDI-DrugBank.d460.s6.e2
DDI-DrugBank.d460.s7|a|Warfarin: When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.
DDI-DrugBank.d460.s7	0	7	Warfarin	drug	DDI-DrugBank.d460.s7.e0
DDI-DrugBank.d460.s7	50	56	Starlix	brand	DDI-DrugBank.d460.s7.e1
DDI-DrugBank.d460.s7	147	154	warfarin	drug	DDI-DrugBank.d460.s7.e2
DDI-DrugBank.d460.s7	false	DDI-DrugBank.d460.s7.e0	DDI-DrugBank.d460.s7.e1
DDI-DrugBank.d460.s7	false	DDI-DrugBank.d460.s7.e0	DDI-DrugBank.d460.s7.e2
DDI-DrugBank.d460.s7	false	DDI-DrugBank.d460.s7.e1	DDI-DrugBank.d460.s7.e2
DDI-DrugBank.d460.s8|a|Prothrombin time was not affected.
DDI-DrugBank.d460.s9|a|Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.
DDI-DrugBank.d460.s9	0	9	Diclofenac	drug	DDI-DrugBank.d460.s9.e0
DDI-DrugBank.d460.s9	57	63	Starlix	brand	DDI-DrugBank.d460.s9.e1
DDI-DrugBank.d460.s9	115	124	diclofenac	drug	DDI-DrugBank.d460.s9.e2
DDI-DrugBank.d460.s9	false	DDI-DrugBank.d460.s9.e0	DDI-DrugBank.d460.s9.e1
DDI-DrugBank.d460.s9	false	DDI-DrugBank.d460.s9.e0	DDI-DrugBank.d460.s9.e2
DDI-DrugBank.d460.s9	false	DDI-DrugBank.d460.s9.e1	DDI-DrugBank.d460.s9.e2
DDI-DrugBank.d460.s10|a|Nateglinide is highly bound to plasma proteins (98%), mainly albumin.
DDI-DrugBank.d460.s10	0	10	Nateglinide	drug	DDI-DrugBank.d460.s10.e0
DDI-DrugBank.d460.s11|a|In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
DDI-DrugBank.d460.s11	70	79	furosemide	drug	DDI-DrugBank.d460.s11.e0
DDI-DrugBank.d460.s11	82	92	propranolol	drug	DDI-DrugBank.d460.s11.e1
DDI-DrugBank.d460.s11	95	103	captopril	drug	DDI-DrugBank.d460.s11.e2
DDI-DrugBank.d460.s11	106	116	nicardipine	drug	DDI-DrugBank.d460.s11.e3
DDI-DrugBank.d460.s11	119	129	pravastatin	drug	DDI-DrugBank.d460.s11.e4
DDI-DrugBank.d460.s11	132	140	glyburide	drug	DDI-DrugBank.d460.s11.e5
DDI-DrugBank.d460.s11	143	150	warfarin	drug	DDI-DrugBank.d460.s11.e6
DDI-DrugBank.d460.s11	153	161	phenytoin	drug	DDI-DrugBank.d460.s11.e7
DDI-DrugBank.d460.s11	164	183	acetylsalicylic acid	drug	DDI-DrugBank.d460.s11.e8
DDI-DrugBank.d460.s11	186	196	tolbutamide	drug	DDI-DrugBank.d460.s11.e9
DDI-DrugBank.d460.s11	false	DDI-DrugBank.d460.s11.e0	DDI-DrugBank.d460.s11.e1
DDI-DrugBank.d460.s11	false	DDI-DrugBank.d460.s11.e0	DDI-DrugBank.d460.s11.e2
DDI-DrugBank.d460.s11	false	DDI-DrugBank.d460.s11.e0	DDI-DrugBank.d460.s11.e3
DDI-DrugBank.d460.s11	false	DDI-DrugBank.d460.s11.e0	DDI-DrugBank.d460.s11.e4
DDI-DrugBank.d460.s11	false	DDI-DrugBank.d460.s11.e0	DDI-DrugBank.d460.s11.e5
DDI-DrugBank.d460.s11	false	DDI-DrugBank.d460.s11.e0	DDI-DrugBank.d460.s11.e6
DDI-DrugBank.d460.s11	false	DDI-DrugBank.d460.s11.e0	DDI-DrugBank.d460.s11.e7
DDI-DrugBank.d460.s11	false	DDI-DrugBank.d460.s11.e0	DDI-DrugBank.d460.s11.e8
DDI-DrugBank.d460.s11	false	DDI-DrugBank.d460.s11.e0	DDI-DrugBank.d460.s11.e9
DDI-DrugBank.d460.s11	false	DDI-DrugBank.d460.s11.e0	DDI-DrugBank.d460.s11.e10
DDI-DrugBank.d460.s12|a|Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
DDI-DrugBank.d460.s12	11	21	nateglinide	drug	DDI-DrugBank.d460.s12.e0
DDI-DrugBank.d460.s12	72	82	propranolol	drug	DDI-DrugBank.d460.s12.e1
DDI-DrugBank.d460.s12	85	93	glyburide	drug	DDI-DrugBank.d460.s12.e2
DDI-DrugBank.d460.s12	96	106	nicardipine	drug	DDI-DrugBank.d460.s12.e3
DDI-DrugBank.d460.s12	109	116	warfarin	drug	DDI-DrugBank.d460.s12.e4
DDI-DrugBank.d460.s12	119	127	phenytoin	drug	DDI-DrugBank.d460.s12.e5
DDI-DrugBank.d460.s12	130	149	acetylsalicylic acid	drug	DDI-DrugBank.d460.s12.e6
DDI-DrugBank.d460.s12	156	166	tolbutamide	drug	DDI-DrugBank.d460.s12.e7
DDI-DrugBank.d460.s12	false	DDI-DrugBank.d460.s12.e0	DDI-DrugBank.d460.s12.e1
DDI-DrugBank.d460.s12	false	DDI-DrugBank.d460.s12.e0	DDI-DrugBank.d460.s12.e2
DDI-DrugBank.d460.s12	false	DDI-DrugBank.d460.s12.e0	DDI-DrugBank.d460.s12.e3
DDI-DrugBank.d460.s12	false	DDI-DrugBank.d460.s12.e0	DDI-DrugBank.d460.s12.e4
DDI-DrugBank.d460.s12	false	DDI-DrugBank.d460.s12.e0	DDI-DrugBank.d460.s12.e5
DDI-DrugBank.d460.s12	false	DDI-DrugBank.d460.s12.e0	DDI-DrugBank.d460.s12.e6
DDI-DrugBank.d460.s12	false	DDI-DrugBank.d460.s12.e0	DDI-DrugBank.d460.s12.e7
DDI-DrugBank.d460.s12	false	DDI-DrugBank.d460.s12.e1	DDI-DrugBank.d460.s12.e2
DDI-DrugBank.d460.s12	false	DDI-DrugBank.d460.s12.e1	DDI-DrugBank.d460.s12.e3
DDI-DrugBank.d460.s12	false	DDI-DrugBank.d460.s12.e1	DDI-DrugBank.d460.s12.e4
DDI-DrugBank.d460.s13|a|However, prudent evaluation of individual cases is warranted in the clinical setting.
DDI-DrugBank.d460.s14|a|Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s14	25	61	nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d460.s14.e0
DDI-DrugBank.d460.s14	64	69	NSAIDs	group	DDI-DrugBank.d460.s14.e1
DDI-DrugBank.d460.s14	73	83	salicylates	group	DDI-DrugBank.d460.s14.e2
DDI-DrugBank.d460.s14	86	113	monoamine oxidase inhibitors	group	DDI-DrugBank.d460.s14.e3
DDI-DrugBank.d460.s14	120	164	non-selective beta-adrenergic-blocking agents	group	DDI-DrugBank.d460.s14.e4
DDI-DrugBank.d460.s14	208	214	Starlix	brand	DDI-DrugBank.d460.s14.e5
DDI-DrugBank.d460.s14	231	248	antidiabetic drugs	group	DDI-DrugBank.d460.s14.e6
DDI-DrugBank.d460.s14	false	DDI-DrugBank.d460.s14.e0	DDI-DrugBank.d460.s14.e1
DDI-DrugBank.d460.s14	false	DDI-DrugBank.d460.s14.e0	DDI-DrugBank.d460.s14.e2
DDI-DrugBank.d460.s14	false	DDI-DrugBank.d460.s14.e0	DDI-DrugBank.d460.s14.e3
DDI-DrugBank.d460.s14	false	DDI-DrugBank.d460.s14.e0	DDI-DrugBank.d460.s14.e4
DDI-DrugBank.d460.s14	true	DDI-DrugBank.d460.s14.e0	DDI-DrugBank.d460.s14.e5
DDI-DrugBank.d460.s14	true	DDI-DrugBank.d460.s14.e0	DDI-DrugBank.d460.s14.e6
DDI-DrugBank.d460.s14	false	DDI-DrugBank.d460.s14.e1	DDI-DrugBank.d460.s14.e2
DDI-DrugBank.d460.s14	false	DDI-DrugBank.d460.s14.e1	DDI-DrugBank.d460.s14.e3
DDI-DrugBank.d460.s14	false	DDI-DrugBank.d460.s14.e1	DDI-DrugBank.d460.s14.e4
DDI-DrugBank.d460.s14	true	DDI-DrugBank.d460.s14.e1	DDI-DrugBank.d460.s14.e5
DDI-DrugBank.d460.s15|a|Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s15	24	32	thiazides	group	DDI-DrugBank.d460.s15.e0
DDI-DrugBank.d460.s15	35	49	corticosteroids	group	DDI-DrugBank.d460.s15.e1
DDI-DrugBank.d460.s15	52	67	thyroid products	group	DDI-DrugBank.d460.s15.e2
DDI-DrugBank.d460.s15	74	89	sympathomimetics	group	DDI-DrugBank.d460.s15.e3
DDI-DrugBank.d460.s15	129	135	Starlix	brand	DDI-DrugBank.d460.s15.e4
DDI-DrugBank.d460.s15	152	169	antidiabetic drugs	group	DDI-DrugBank.d460.s15.e5
DDI-DrugBank.d460.s15	false	DDI-DrugBank.d460.s15.e0	DDI-DrugBank.d460.s15.e1
DDI-DrugBank.d460.s15	false	DDI-DrugBank.d460.s15.e0	DDI-DrugBank.d460.s15.e2
DDI-DrugBank.d460.s15	false	DDI-DrugBank.d460.s15.e0	DDI-DrugBank.d460.s15.e3
DDI-DrugBank.d460.s15	true	DDI-DrugBank.d460.s15.e0	DDI-DrugBank.d460.s15.e4
DDI-DrugBank.d460.s15	true	DDI-DrugBank.d460.s15.e0	DDI-DrugBank.d460.s15.e5
DDI-DrugBank.d460.s15	false	DDI-DrugBank.d460.s15.e1	DDI-DrugBank.d460.s15.e2
DDI-DrugBank.d460.s15	false	DDI-DrugBank.d460.s15.e1	DDI-DrugBank.d460.s15.e3
DDI-DrugBank.d460.s15	true	DDI-DrugBank.d460.s15.e1	DDI-DrugBank.d460.s15.e4
DDI-DrugBank.d460.s15	true	DDI-DrugBank.d460.s15.e1	DDI-DrugBank.d460.s15.e5
DDI-DrugBank.d460.s15	false	DDI-DrugBank.d460.s15.e2	DDI-DrugBank.d460.s15.e3
DDI-DrugBank.d460.s16|a|When these drugs are administered to or withdrawn from patients receiving Starlix, the patient should be observed closely for changes in glycemic control.
DDI-DrugBank.d460.s16	74	80	Starlix	brand	DDI-DrugBank.d460.s16.e0
DDI-DrugBank.d61.s0|a|In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators, and inhaled corticosteroids, with no evidence of increased frequency of adverse events or laboratory abnormalities.
DDI-DrugBank.d61.s0	21	26	Tilade	brand	DDI-DrugBank.d61.s0.e0
DDI-DrugBank.d61.s0	116	130	bronchodilators	group	DDI-DrugBank.d61.s0.e1
DDI-DrugBank.d61.s0	145	159	corticosteroids	group	DDI-DrugBank.d61.s0.e2
DDI-DrugBank.d61.s0	false	DDI-DrugBank.d61.s0.e0	DDI-DrugBank.d61.s0.e1
DDI-DrugBank.d61.s0	false	DDI-DrugBank.d61.s0.e0	DDI-DrugBank.d61.s0.e2
DDI-DrugBank.d61.s0	false	DDI-DrugBank.d61.s0.e1	DDI-DrugBank.d61.s0.e2
DDI-DrugBank.d61.s1|a|No formal drug-drug interaction studies, however, have been conducted.
DDI-DrugBank.d340.s0|a|Nelfinavir is an inhibitor of CYP3A (cytochrome P450 3A).
DDI-DrugBank.d340.s0	0	9	Nelfinavir	drug	DDI-DrugBank.d340.s0.e0
DDI-DrugBank.d340.s1|a|Coadministration of VIRACEPT and drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects.
DDI-DrugBank.d340.s1	20	27	VIRACEPT	brand	DDI-DrugBank.d340.s1.e0
DDI-DrugBank.d340.s1	77	116	dihydropyridine calcium channel blockers	group	DDI-DrugBank.d340.s1.e1
DDI-DrugBank.d340.s1	false	DDI-DrugBank.d340.s1.e0	DDI-DrugBank.d340.s1.e1
DDI-DrugBank.d340.s2|a|Nelfinavir is metabolized in proof by C.P.A.
DDI-DrugBank.d340.s2	0	9	Nelfinavir	drug	DDI-DrugBank.d340.s2.e0
DDI-DrugBank.d340.s3|a|Coadministration of VIRACEPT and drugs that induce CYP3A may decrease nelfinavir plasma concentrations and reduce its therapeutic effect.
DDI-DrugBank.d340.s3	20	27	VIRACEPT	brand	DDI-DrugBank.d340.s3.e0
DDI-DrugBank.d340.s3	70	79	nelfinavir	drug	DDI-DrugBank.d340.s3.e1
DDI-DrugBank.d340.s3	false	DDI-DrugBank.d340.s3.e0	DDI-DrugBank.d340.s3.e1
DDI-DrugBank.d340.s4|a|Coadministration of VIRACEPT and drugs that inhibit CYP3A may increase nelfinavir plasma concentrations.
DDI-DrugBank.d340.s4	20	27	VIRACEPT	brand	DDI-DrugBank.d340.s4.e0
DDI-DrugBank.d340.s4	71	80	nelfinavir	drug	DDI-DrugBank.d340.s4.e1
DDI-DrugBank.d340.s4	false	DDI-DrugBank.d340.s4.e0	DDI-DrugBank.d340.s4.e1
DDI-DrugBank.d340.s5|a|Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.
DDI-DrugBank.d340.s5	101	108	VIRACEPT	brand	DDI-DrugBank.d340.s5.e0
DDI-DrugBank.d340.s5	114	120	dapsone	drug	DDI-DrugBank.d340.s5.e1
DDI-DrugBank.d340.s5	123	134	trimethoprim	drug	DDI-DrugBank.d340.s5.e2
DDI-DrugBank.d340.s5	136	151	sulfamethoxazole	drug	DDI-DrugBank.d340.s5.e3
DDI-DrugBank.d340.s5	154	167	clarithromycin	drug	DDI-DrugBank.d340.s5.e4
DDI-DrugBank.d340.s5	170	181	erythromycin	drug	DDI-DrugBank.d340.s5.e5
DDI-DrugBank.d340.s5	184	195	itraconazole	drug	DDI-DrugBank.d340.s5.e6
DDI-DrugBank.d340.s5	200	210	fluconazole	drug	DDI-DrugBank.d340.s5.e7
DDI-DrugBank.d340.s5	false	DDI-DrugBank.d340.s5.e0	DDI-DrugBank.d340.s5.e1
DDI-DrugBank.d340.s5	false	DDI-DrugBank.d340.s5.e0	DDI-DrugBank.d340.s5.e2
DDI-DrugBank.d340.s5	false	DDI-DrugBank.d340.s5.e0	DDI-DrugBank.d340.s5.e3
DDI-DrugBank.d340.s5	false	DDI-DrugBank.d340.s5.e0	DDI-DrugBank.d340.s5.e4
DDI-DrugBank.d340.s5	false	DDI-DrugBank.d340.s5.e0	DDI-DrugBank.d340.s5.e5
DDI-DrugBank.d340.s5	false	DDI-DrugBank.d340.s5.e0	DDI-DrugBank.d340.s5.e6
DDI-DrugBank.d340.s5	false	DDI-DrugBank.d340.s5.e0	DDI-DrugBank.d340.s5.e7
DDI-DrugBank.d340.s5	false	DDI-DrugBank.d340.s5.e1	DDI-DrugBank.d340.s5.e2
DDI-DrugBank.d340.s5	false	DDI-DrugBank.d340.s5.e1	DDI-DrugBank.d340.s5.e3
DDI-DrugBank.d340.s5	false	DDI-DrugBank.d340.s5.e1	DDI-DrugBank.d340.s5.e4
DDI-DrugBank.d340.s6|a|Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d340.s6	45	52	VIRACEPT	brand	DDI-DrugBank.d340.s6.e0
DDI-DrugBank.d340.s6	54	68	Antiarrhythmics	group	DDI-DrugBank.d340.s6.e1
DDI-DrugBank.d340.s6	71	80	amiodarone	drug	DDI-DrugBank.d340.s6.e2
DDI-DrugBank.d340.s6	83	91	quinidine	drug	DDI-DrugBank.d340.s6.e3
DDI-DrugBank.d340.s6	93	106	Antihistamines	group	DDI-DrugBank.d340.s6.e4
DDI-DrugBank.d340.s6	109	118	astemizole	drug	DDI-DrugBank.d340.s6.e5
DDI-DrugBank.d340.s6	121	131	terfenadine	drug	DDI-DrugBank.d340.s6.e6
DDI-DrugBank.d340.s6	147	163	ergot derivatives	group	DDI-DrugBank.d340.s6.e7
DDI-DrugBank.d340.s6	165	188	Antimycobacterial agents	group	DDI-DrugBank.d340.s6.e8
DDI-DrugBank.d340.s6	191	198	rifampin	drug	DDI-DrugBank.d340.s6.e9
DDI-DrugBank.d340.s6	true	DDI-DrugBank.d340.s6.e0	DDI-DrugBank.d340.s6.e1
DDI-DrugBank.d340.s6	true	DDI-DrugBank.d340.s6.e0	DDI-DrugBank.d340.s6.e2
DDI-DrugBank.d340.s6	true	DDI-DrugBank.d340.s6.e0	DDI-DrugBank.d340.s6.e3
DDI-DrugBank.d340.s6	true	DDI-DrugBank.d340.s6.e0	DDI-DrugBank.d340.s6.e4
DDI-DrugBank.d340.s6	true	DDI-DrugBank.d340.s6.e0	DDI-DrugBank.d340.s6.e5
DDI-DrugBank.d340.s6	true	DDI-DrugBank.d340.s6.e0	DDI-DrugBank.d340.s6.e6
DDI-DrugBank.d340.s6	true	DDI-DrugBank.d340.s6.e0	DDI-DrugBank.d340.s6.e7
DDI-DrugBank.d340.s6	true	DDI-DrugBank.d340.s6.e0	DDI-DrugBank.d340.s6.e8
DDI-DrugBank.d340.s6	true	DDI-DrugBank.d340.s6.e0	DDI-DrugBank.d340.s6.e9
DDI-DrugBank.d340.s6	true	DDI-DrugBank.d340.s6.e0	DDI-DrugBank.d340.s6.e10
DDI-DrugBank.d340.s7|a|Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin
DDI-DrugBank.d340.s7	61	68	VIRACEPT	brand	DDI-DrugBank.d340.s7.e0
DDI-DrugBank.d340.s7	70	93	Antimycobacterial agents	group	DDI-DrugBank.d340.s7.e1
DDI-DrugBank.d340.s7	96	104	rifabutin	drug	DDI-DrugBank.d340.s7.e2
DDI-DrugBank.d340.s7	true	DDI-DrugBank.d340.s7.e0	DDI-DrugBank.d340.s7.e1
DDI-DrugBank.d340.s7	true	DDI-DrugBank.d340.s7.e0	DDI-DrugBank.d340.s7.e2
DDI-DrugBank.d340.s7	false	DDI-DrugBank.d340.s7.e1	DDI-DrugBank.d340.s7.e2
DDI-DrugBank.d340.s8|a|* This table is not all inclusive ** VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly
DDI-DrugBank.d340.s8	37	44	VIRACEPT	brand	DDI-DrugBank.d340.s8.e0
DDI-DrugBank.d340.s8	84	93	nelfinavir	drug	DDI-DrugBank.d340.s8.e1
DDI-DrugBank.d340.s8	false	DDI-DrugBank.d340.s8.e0	DDI-DrugBank.d340.s8.e1
DDI-DrugBank.d340.s9|a|Antihistamines
DDI-DrugBank.d340.s9	0	13	Antihistamines	group	DDI-DrugBank.d340.s9.e0
DDI-DrugBank.d340.s10|a|Terfenadine: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;
DDI-DrugBank.d340.s10	0	10	Terfenadine	drug	DDI-DrugBank.d340.s10.e0
DDI-DrugBank.d340.s10	31	41	terfenadine	drug	DDI-DrugBank.d340.s10.e1
DDI-DrugBank.d340.s10	48	55	VIRACEPT	brand	DDI-DrugBank.d340.s10.e2
DDI-DrugBank.d340.s10	97	107	terfenadine	drug	DDI-DrugBank.d340.s10.e3
DDI-DrugBank.d340.s10	false	DDI-DrugBank.d340.s10.e0	DDI-DrugBank.d340.s10.e1
DDI-DrugBank.d340.s10	false	DDI-DrugBank.d340.s10.e0	DDI-DrugBank.d340.s10.e2
DDI-DrugBank.d340.s10	false	DDI-DrugBank.d340.s10.e0	DDI-DrugBank.d340.s10.e3
DDI-DrugBank.d340.s10	false	DDI-DrugBank.d340.s10.e1	DDI-DrugBank.d340.s10.e2
DDI-DrugBank.d340.s10	false	DDI-DrugBank.d340.s10.e1	DDI-DrugBank.d340.s10.e3
DDI-DrugBank.d340.s10	false	DDI-DrugBank.d340.s10.e2	DDI-DrugBank.d340.s10.e3
DDI-DrugBank.d340.s11|a|therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.
DDI-DrugBank.d340.s11	11	18	VIRACEPT	brand	DDI-DrugBank.d340.s11.e0
DDI-DrugBank.d340.s11	65	75	terfenadine	drug	DDI-DrugBank.d340.s11.e1
DDI-DrugBank.d340.s11	true	DDI-DrugBank.d340.s11.e0	DDI-DrugBank.d340.s11.e1
DDI-DrugBank.d340.s12|a|Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.
DDI-DrugBank.d340.s12	41	48	VIRACEPT	brand	DDI-DrugBank.d340.s12.e0
DDI-DrugBank.d340.s12	100	109	astemizole	drug	DDI-DrugBank.d340.s12.e1
DDI-DrugBank.d340.s12	true	DDI-DrugBank.d340.s12.e0	DDI-DrugBank.d340.s12.e1
DDI-DrugBank.d340.s13|a|Anti-HIV Protease Inhibitors
DDI-DrugBank.d340.s13	0	27	Anti-HIV Protease Inhibitors	group	DDI-DrugBank.d340.s13.e0
DDI-DrugBank.d340.s14|a|Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.
DDI-DrugBank.d340.s14	0	8	Indinavir	drug	DDI-DrugBank.d340.s14.e0
DDI-DrugBank.d340.s14	31	39	indinavir	drug	DDI-DrugBank.d340.s14.e1
DDI-DrugBank.d340.s14	46	53	VIRACEPT	brand	DDI-DrugBank.d340.s14.e2
DDI-DrugBank.d340.s14	86	95	nelfinavir	drug	DDI-DrugBank.d340.s14.e3
DDI-DrugBank.d340.s14	130	138	indinavir	drug	DDI-DrugBank.d340.s14.e4
DDI-DrugBank.d340.s14	false	DDI-DrugBank.d340.s14.e0	DDI-DrugBank.d340.s14.e1
DDI-DrugBank.d340.s14	false	DDI-DrugBank.d340.s14.e0	DDI-DrugBank.d340.s14.e2
DDI-DrugBank.d340.s14	false	DDI-DrugBank.d340.s14.e0	DDI-DrugBank.d340.s14.e3
DDI-DrugBank.d340.s14	false	DDI-DrugBank.d340.s14.e0	DDI-DrugBank.d340.s14.e4
DDI-DrugBank.d340.s14	true	DDI-DrugBank.d340.s14.e1	DDI-DrugBank.d340.s14.e2
DDI-DrugBank.d340.s14	false	DDI-DrugBank.d340.s14.e1	DDI-DrugBank.d340.s14.e3
DDI-DrugBank.d340.s14	false	DDI-DrugBank.d340.s14.e1	DDI-DrugBank.d340.s14.e4
DDI-DrugBank.d340.s14	false	DDI-DrugBank.d340.s14.e2	DDI-DrugBank.d340.s14.e3
DDI-DrugBank.d340.s14	false	DDI-DrugBank.d340.s14.e2	DDI-DrugBank.d340.s14.e4
DDI-DrugBank.d340.s14	false	DDI-DrugBank.d340.s14.e3	DDI-DrugBank.d340.s14.e4
DDI-DrugBank.d340.s15|a|Currently, there are no safety and efficacy data available from the use of this combination.
DDI-DrugBank.d340.s16|a|Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.
DDI-DrugBank.d340.s16	0	8	Ritonavir	drug	DDI-DrugBank.d340.s16.e0
DDI-DrugBank.d340.s16	31	39	ritonavir	drug	DDI-DrugBank.d340.s16.e1
DDI-DrugBank.d340.s16	46	53	VIRACEPT	brand	DDI-DrugBank.d340.s16.e2
DDI-DrugBank.d340.s16	86	95	nelfinavir	drug	DDI-DrugBank.d340.s16.e3
DDI-DrugBank.d340.s16	134	142	ritonavir	drug	DDI-DrugBank.d340.s16.e4
DDI-DrugBank.d340.s16	false	DDI-DrugBank.d340.s16.e0	DDI-DrugBank.d340.s16.e1
DDI-DrugBank.d340.s16	false	DDI-DrugBank.d340.s16.e0	DDI-DrugBank.d340.s16.e2
DDI-DrugBank.d340.s16	false	DDI-DrugBank.d340.s16.e0	DDI-DrugBank.d340.s16.e3
DDI-DrugBank.d340.s16	false	DDI-DrugBank.d340.s16.e0	DDI-DrugBank.d340.s16.e4
DDI-DrugBank.d340.s16	true	DDI-DrugBank.d340.s16.e1	DDI-DrugBank.d340.s16.e2
DDI-DrugBank.d340.s16	false	DDI-DrugBank.d340.s16.e1	DDI-DrugBank.d340.s16.e3
DDI-DrugBank.d340.s16	false	DDI-DrugBank.d340.s16.e1	DDI-DrugBank.d340.s16.e4
DDI-DrugBank.d340.s16	false	DDI-DrugBank.d340.s16.e2	DDI-DrugBank.d340.s16.e3
DDI-DrugBank.d340.s16	false	DDI-DrugBank.d340.s16.e2	DDI-DrugBank.d340.s16.e4
DDI-DrugBank.d340.s16	false	DDI-DrugBank.d340.s16.e3	DDI-DrugBank.d340.s16.e4
DDI-DrugBank.d340.s17|a|Currently, there are no safety and efficacy data available from the use of this combination.
DDI-DrugBank.d340.s18|a|Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.
DDI-DrugBank.d340.s18	0	9	Saquinavir	drug	DDI-DrugBank.d340.s18.e0
DDI-DrugBank.d340.s18	32	41	saquinavir	drug	DDI-DrugBank.d340.s18.e1
DDI-DrugBank.d340.s18	102	111	saquinavir	drug	DDI-DrugBank.d340.s18.e2
DDI-DrugBank.d340.s18	126	133	VIRACEPT	brand	DDI-DrugBank.d340.s18.e3
DDI-DrugBank.d340.s18	166	175	nelfinavir	drug	DDI-DrugBank.d340.s18.e4
DDI-DrugBank.d340.s18	213	222	saquinavir	drug	DDI-DrugBank.d340.s18.e5
DDI-DrugBank.d340.s18	false	DDI-DrugBank.d340.s18.e0	DDI-DrugBank.d340.s18.e1
DDI-DrugBank.d340.s18	false	DDI-DrugBank.d340.s18.e0	DDI-DrugBank.d340.s18.e2
DDI-DrugBank.d340.s18	false	DDI-DrugBank.d340.s18.e0	DDI-DrugBank.d340.s18.e3
DDI-DrugBank.d340.s18	false	DDI-DrugBank.d340.s18.e0	DDI-DrugBank.d340.s18.e4
DDI-DrugBank.d340.s18	false	DDI-DrugBank.d340.s18.e0	DDI-DrugBank.d340.s18.e5
DDI-DrugBank.d340.s18	false	DDI-DrugBank.d340.s18.e1	DDI-DrugBank.d340.s18.e2
DDI-DrugBank.d340.s18	true	DDI-DrugBank.d340.s18.e1	DDI-DrugBank.d340.s18.e3
DDI-DrugBank.d340.s18	false	DDI-DrugBank.d340.s18.e1	DDI-DrugBank.d340.s18.e4
DDI-DrugBank.d340.s18	false	DDI-DrugBank.d340.s18.e1	DDI-DrugBank.d340.s18.e5
DDI-DrugBank.d340.s18	false	DDI-DrugBank.d340.s18.e2	DDI-DrugBank.d340.s18.e3
DDI-DrugBank.d340.s19|a|If used in combination with saquinavir hard gelatin capsules at the recommended dose of 600 mg tid, no dose adjustments are needed.
DDI-DrugBank.d340.s19	28	37	saquinavir	drug	DDI-DrugBank.d340.s19.e0
DDI-DrugBank.d340.s20|a|Currently, there are no safety and efficacy data available from the use of this combination.
DDI-DrugBank.d340.s21|a|Antifungal Agents
DDI-DrugBank.d340.s21	0	16	Antifungal Agents	group	DDI-DrugBank.d340.s21.e0
DDI-DrugBank.d340.s22|a|Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.
DDI-DrugBank.d340.s22	0	11	Ketoconazole	drug	DDI-DrugBank.d340.s22.e0
DDI-DrugBank.d340.s22	34	45	ketoconazole	drug	DDI-DrugBank.d340.s22.e1
DDI-DrugBank.d340.s22	52	59	VIRACEPT	brand	DDI-DrugBank.d340.s22.e2
DDI-DrugBank.d340.s22	91	100	nelfinavir	drug	DDI-DrugBank.d340.s22.e3
DDI-DrugBank.d340.s22	false	DDI-DrugBank.d340.s22.e0	DDI-DrugBank.d340.s22.e1
DDI-DrugBank.d340.s22	false	DDI-DrugBank.d340.s22.e0	DDI-DrugBank.d340.s22.e2
DDI-DrugBank.d340.s22	false	DDI-DrugBank.d340.s22.e0	DDI-DrugBank.d340.s22.e3
DDI-DrugBank.d340.s22	true	DDI-DrugBank.d340.s22.e1	DDI-DrugBank.d340.s22.e2
DDI-DrugBank.d340.s22	false	DDI-DrugBank.d340.s22.e1	DDI-DrugBank.d340.s22.e3
DDI-DrugBank.d340.s22	false	DDI-DrugBank.d340.s22.e2	DDI-DrugBank.d340.s22.e3
DDI-DrugBank.d340.s23|a|This change was not considered clinically significant and no dose adjustment is needed when ketoconazole and VIRACEPT are coadministered.
DDI-DrugBank.d340.s23	92	103	ketoconazole	drug	DDI-DrugBank.d340.s23.e0
DDI-DrugBank.d340.s23	109	116	VIRACEPT	brand	DDI-DrugBank.d340.s23.e1
DDI-DrugBank.d340.s23	false	DDI-DrugBank.d340.s23.e0	DDI-DrugBank.d340.s23.e1
DDI-DrugBank.d340.s24|a|Anti-HIV Reverse Transcriptase Inhibitors
DDI-DrugBank.d340.s24	0	40	Anti-HIV Reverse Transcriptase Inhibitors	group	DDI-DrugBank.d340.s24.e0
DDI-DrugBank.d340.s25|a|Didanosine: It is recommended that didanosine be administered on an empty stomach;
DDI-DrugBank.d340.s25	0	9	Didanosine	drug	DDI-DrugBank.d340.s25.e0
DDI-DrugBank.d340.s25	35	44	didanosine	drug	DDI-DrugBank.d340.s25.e1
DDI-DrugBank.d340.s25	false	DDI-DrugBank.d340.s25.e0	DDI-DrugBank.d340.s25.e1
DDI-DrugBank.d340.s26|a|therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.
DDI-DrugBank.d340.s26	11	20	nelfinavir	drug	DDI-DrugBank.d340.s26.e0
DDI-DrugBank.d340.s26	102	111	didanosine	drug	DDI-DrugBank.d340.s26.e1
DDI-DrugBank.d340.s26	true	DDI-DrugBank.d340.s26.e0	DDI-DrugBank.d340.s26.e1
DDI-DrugBank.d340.s27|a|A dose adjustment is not needed when zidovudine is administered with VIRACEPT.
DDI-DrugBank.d340.s27	37	46	zidovudine	drug	DDI-DrugBank.d340.s27.e0
DDI-DrugBank.d340.s27	69	76	VIRACEPT	brand	DDI-DrugBank.d340.s27.e1
DDI-DrugBank.d340.s27	true	DDI-DrugBank.d340.s27.e0	DDI-DrugBank.d340.s27.e1
DDI-DrugBank.d340.s28|a|Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with lamivudine or stavudine.
DDI-DrugBank.d340.s28	77	84	VIRACEPT	brand	DDI-DrugBank.d340.s28.e0
DDI-DrugBank.d340.s28	110	119	lamivudine	drug	DDI-DrugBank.d340.s28.e1
DDI-DrugBank.d340.s28	124	132	stavudine	drug	DDI-DrugBank.d340.s28.e2
DDI-DrugBank.d340.s28	false	DDI-DrugBank.d340.s28.e0	DDI-DrugBank.d340.s28.e1
DDI-DrugBank.d340.s28	false	DDI-DrugBank.d340.s28.e0	DDI-DrugBank.d340.s28.e2
DDI-DrugBank.d340.s28	false	DDI-DrugBank.d340.s28.e1	DDI-DrugBank.d340.s28.e2
DDI-DrugBank.d340.s29|a|Antimycobacterial Agents
DDI-DrugBank.d340.s29	0	23	Antimycobacterial Agents	group	DDI-DrugBank.d340.s29.e0
DDI-DrugBank.d340.s30|a|Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.
DDI-DrugBank.d340.s30	0	8	Rifabutin	drug	DDI-DrugBank.d340.s30.e0
DDI-DrugBank.d340.s30	31	39	rifabutin	drug	DDI-DrugBank.d340.s30.e1
DDI-DrugBank.d340.s30	45	52	VIRACEPT	brand	DDI-DrugBank.d340.s30.e2
DDI-DrugBank.d340.s30	84	93	nelfinavir	drug	DDI-DrugBank.d340.s30.e3
DDI-DrugBank.d340.s30	129	137	rifabutin	drug	DDI-DrugBank.d340.s30.e4
DDI-DrugBank.d340.s30	false	DDI-DrugBank.d340.s30.e0	DDI-DrugBank.d340.s30.e1
DDI-DrugBank.d340.s30	false	DDI-DrugBank.d340.s30.e0	DDI-DrugBank.d340.s30.e2
DDI-DrugBank.d340.s30	false	DDI-DrugBank.d340.s30.e0	DDI-DrugBank.d340.s30.e3
DDI-DrugBank.d340.s30	false	DDI-DrugBank.d340.s30.e0	DDI-DrugBank.d340.s30.e4
DDI-DrugBank.d340.s30	true	DDI-DrugBank.d340.s30.e1	DDI-DrugBank.d340.s30.e2
DDI-DrugBank.d340.s30	false	DDI-DrugBank.d340.s30.e1	DDI-DrugBank.d340.s30.e3
DDI-DrugBank.d340.s30	false	DDI-DrugBank.d340.s30.e1	DDI-DrugBank.d340.s30.e4
DDI-DrugBank.d340.s30	false	DDI-DrugBank.d340.s30.e2	DDI-DrugBank.d340.s30.e3
DDI-DrugBank.d340.s30	false	DDI-DrugBank.d340.s30.e2	DDI-DrugBank.d340.s30.e4
DDI-DrugBank.d340.s30	false	DDI-DrugBank.d340.s30.e3	DDI-DrugBank.d340.s30.e4
DDI-DrugBank.d340.s31|a|It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.
DDI-DrugBank.d340.s31	35	43	rifabutin	drug	DDI-DrugBank.d340.s31.e0
DDI-DrugBank.d340.s31	106	113	VIRACEPT	brand	DDI-DrugBank.d340.s31.e1
DDI-DrugBank.d340.s31	true	DDI-DrugBank.d340.s31.e0	DDI-DrugBank.d340.s31.e1
DDI-DrugBank.d340.s32|a|Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
DDI-DrugBank.d340.s32	0	7	Rifampin	drug	DDI-DrugBank.d340.s32.e0
DDI-DrugBank.d340.s32	30	37	rifampin	drug	DDI-DrugBank.d340.s32.e1
DDI-DrugBank.d340.s32	43	50	VIRACEPT	brand	DDI-DrugBank.d340.s32.e2
DDI-DrugBank.d340.s32	83	92	nelfinavir	drug	DDI-DrugBank.d340.s32.e3
DDI-DrugBank.d340.s32	false	DDI-DrugBank.d340.s32.e0	DDI-DrugBank.d340.s32.e1
DDI-DrugBank.d340.s32	false	DDI-DrugBank.d340.s32.e0	DDI-DrugBank.d340.s32.e2
DDI-DrugBank.d340.s32	false	DDI-DrugBank.d340.s32.e0	DDI-DrugBank.d340.s32.e3
DDI-DrugBank.d340.s32	true	DDI-DrugBank.d340.s32.e1	DDI-DrugBank.d340.s32.e2
DDI-DrugBank.d340.s32	false	DDI-DrugBank.d340.s32.e1	DDI-DrugBank.d340.s32.e3
DDI-DrugBank.d340.s32	false	DDI-DrugBank.d340.s32.e2	DDI-DrugBank.d340.s32.e3
DDI-DrugBank.d340.s33|a|VIRACEPT and rifampin should not be coadministered.
DDI-DrugBank.d340.s33	0	7	VIRACEPT	brand	DDI-DrugBank.d340.s33.e0
DDI-DrugBank.d340.s33	13	20	rifampin	drug	DDI-DrugBank.d340.s33.e1
DDI-DrugBank.d340.s33	true	DDI-DrugBank.d340.s33.e0	DDI-DrugBank.d340.s33.e1
DDI-DrugBank.d340.s34|a|Oral Contraceptives
DDI-DrugBank.d340.s34	5	18	Contraceptives	group	DDI-DrugBank.d340.s34.e0
DDI-DrugBank.d340.s35|a|Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.
DDI-DrugBank.d340.s35	0	16	Ethinyl Estradiol	drug	DDI-DrugBank.d340.s35.e0
DDI-DrugBank.d340.s35	22	34	Norethindrone	drug	DDI-DrugBank.d340.s35.e1
DDI-DrugBank.d340.s35	57	64	VIRACEPT	brand	DDI-DrugBank.d340.s35.e2
DDI-DrugBank.d340.s35	71	78	OVCON-35	brand	DDI-DrugBank.d340.s35.e3
DDI-DrugBank.d340.s35	110	126	ethinyl estradiol	drug	DDI-DrugBank.d340.s35.e4
DDI-DrugBank.d340.s35	151	163	norethindrone	drug	DDI-DrugBank.d340.s35.e5
DDI-DrugBank.d340.s35	false	DDI-DrugBank.d340.s35.e0	DDI-DrugBank.d340.s35.e1
DDI-DrugBank.d340.s35	false	DDI-DrugBank.d340.s35.e0	DDI-DrugBank.d340.s35.e2
DDI-DrugBank.d340.s35	false	DDI-DrugBank.d340.s35.e0	DDI-DrugBank.d340.s35.e3
DDI-DrugBank.d340.s35	false	DDI-DrugBank.d340.s35.e0	DDI-DrugBank.d340.s35.e4
DDI-DrugBank.d340.s35	false	DDI-DrugBank.d340.s35.e0	DDI-DrugBank.d340.s35.e5
DDI-DrugBank.d340.s35	false	DDI-DrugBank.d340.s35.e1	DDI-DrugBank.d340.s35.e2
DDI-DrugBank.d340.s35	false	DDI-DrugBank.d340.s35.e1	DDI-DrugBank.d340.s35.e3
DDI-DrugBank.d340.s35	false	DDI-DrugBank.d340.s35.e1	DDI-DrugBank.d340.s35.e4
DDI-DrugBank.d340.s35	false	DDI-DrugBank.d340.s35.e1	DDI-DrugBank.d340.s35.e5
DDI-DrugBank.d340.s35	true	DDI-DrugBank.d340.s35.e2	DDI-DrugBank.d340.s35.e3
DDI-DrugBank.d340.s36|a|Alternate or additional contraceptive measures should be used during therapy with VIRACEPT
DDI-DrugBank.d340.s36	82	89	VIRACEPT	brand	DDI-DrugBank.d340.s36.e0
DDI-DrugBank.d330.s0|a|Caution should be taken in concurrent or serial use of other neurotoxic and/ or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of neomycin.
DDI-DrugBank.d330.s0	174	181	neomycin	drug	DDI-DrugBank.d330.s0.e0
DDI-DrugBank.d330.s1|a|Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.
DDI-DrugBank.d330.s1	66	80	aminoglycosides	group	DDI-DrugBank.d330.s1.e0
DDI-DrugBank.d330.s1	86	95	polymyxins	group	DDI-DrugBank.d330.s1.e1
DDI-DrugBank.d330.s1	182	197	neomycin sulfate	drug	DDI-DrugBank.d330.s1.e2
DDI-DrugBank.d330.s1	false	DDI-DrugBank.d330.s1.e0	DDI-DrugBank.d330.s1.e1
DDI-DrugBank.d330.s1	false	DDI-DrugBank.d330.s1.e0	DDI-DrugBank.d330.s1.e2
DDI-DrugBank.d330.s1	false	DDI-DrugBank.d330.s1.e1	DDI-DrugBank.d330.s1.e2
DDI-DrugBank.d330.s2|a|Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
DDI-DrugBank.d330.s2	5	12	neomycin	drug	DDI-DrugBank.d330.s2.e0
DDI-DrugBank.d330.s2	58	69	penicillin V	drug	DDI-DrugBank.d330.s2.e1
DDI-DrugBank.d330.s2	77	88	vitamin B-12	drug	DDI-DrugBank.d330.s2.e2
DDI-DrugBank.d330.s2	91	102	methotrexate	drug	DDI-DrugBank.d330.s2.e3
DDI-DrugBank.d330.s2	108	121	5-fluorouracil	drug	DDI-DrugBank.d330.s2.e4
DDI-DrugBank.d330.s2	true	DDI-DrugBank.d330.s2.e0	DDI-DrugBank.d330.s2.e1
DDI-DrugBank.d330.s2	true	DDI-DrugBank.d330.s2.e0	DDI-DrugBank.d330.s2.e2
DDI-DrugBank.d330.s2	true	DDI-DrugBank.d330.s2.e0	DDI-DrugBank.d330.s2.e3
DDI-DrugBank.d330.s2	true	DDI-DrugBank.d330.s2.e0	DDI-DrugBank.d330.s2.e4
DDI-DrugBank.d330.s2	false	DDI-DrugBank.d330.s2.e1	DDI-DrugBank.d330.s2.e2
DDI-DrugBank.d330.s2	false	DDI-DrugBank.d330.s2.e1	DDI-DrugBank.d330.s2.e3
DDI-DrugBank.d330.s2	false	DDI-DrugBank.d330.s2.e1	DDI-DrugBank.d330.s2.e4
DDI-DrugBank.d330.s2	false	DDI-DrugBank.d330.s2.e2	DDI-DrugBank.d330.s2.e3
DDI-DrugBank.d330.s2	false	DDI-DrugBank.d330.s2.e2	DDI-DrugBank.d330.s2.e4
DDI-DrugBank.d330.s2	false	DDI-DrugBank.d330.s2.e3	DDI-DrugBank.d330.s2.e4
DDI-DrugBank.d330.s3|a|The gastrointestinal absorption of digoxin also appears to be inhibited.
DDI-DrugBank.d330.s3	35	41	digoxin	drug	DDI-DrugBank.d330.s3.e0
DDI-DrugBank.d330.s4|a|Therefore, digoxin serum levels should be monitored.
DDI-DrugBank.d330.s4	11	17	digoxin	drug	DDI-DrugBank.d330.s4.e0
DDI-DrugBank.d330.s5|a|Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
DDI-DrugBank.d330.s5	5	20	neomycin sulfate	drug	DDI-DrugBank.d330.s5.e0
DDI-DrugBank.d330.s5	48	55	coumarin	group	DDI-DrugBank.d330.s5.e1
DDI-DrugBank.d330.s5	60	73	anticoagulants	group	DDI-DrugBank.d330.s5.e2
DDI-DrugBank.d330.s5	true	DDI-DrugBank.d330.s5.e0	DDI-DrugBank.d330.s5.e1
DDI-DrugBank.d330.s5	true	DDI-DrugBank.d330.s5.e0	DDI-DrugBank.d330.s5.e2
DDI-DrugBank.d330.s5	false	DDI-DrugBank.d330.s5.e1	DDI-DrugBank.d330.s5.e2
DDI-DrugBank.d498.s0|a|Certain antibiotics, especially neomycin, streptomycin and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.
DDI-DrugBank.d498.s0	8	18	antibiotics	group	DDI-DrugBank.d498.s0.e0
DDI-DrugBank.d498.s0	32	39	neomycin	drug	DDI-DrugBank.d498.s0.e1
DDI-DrugBank.d498.s0	42	53	streptomycin	drug	DDI-DrugBank.d498.s0.e2
DDI-DrugBank.d498.s0	59	67	kanamycin	drug	DDI-DrugBank.d498.s0.e3
DDI-DrugBank.d498.s0	false	DDI-DrugBank.d498.s0.e0	DDI-DrugBank.d498.s0.e1
DDI-DrugBank.d498.s0	false	DDI-DrugBank.d498.s0.e0	DDI-DrugBank.d498.s0.e2
DDI-DrugBank.d498.s0	false	DDI-DrugBank.d498.s0.e0	DDI-DrugBank.d498.s0.e3
DDI-DrugBank.d498.s0	false	DDI-DrugBank.d498.s0.e1	DDI-DrugBank.d498.s0.e2
DDI-DrugBank.d498.s0	false	DDI-DrugBank.d498.s0.e1	DDI-DrugBank.d498.s0.e3
DDI-DrugBank.d498.s0	false	DDI-DrugBank.d498.s0.e2	DDI-DrugBank.d498.s0.e3
DDI-DrugBank.d498.s1|a|These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.
DDI-DrugBank.d498.s1	6	16	antibiotics	group	DDI-DrugBank.d498.s1.e0
DDI-DrugBank.d498.s1	149	166	anticholinesterase	group	DDI-DrugBank.d498.s1.e1
DDI-DrugBank.d498.s1	true	DDI-DrugBank.d498.s1.e0	DDI-DrugBank.d498.s1.e1
DDI-DrugBank.d498.s2|a|Local and some general anesthetics, antiarrhythmic agents and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis;
DDI-DrugBank.d498.s2	23	33	anesthetics	group	DDI-DrugBank.d498.s2.e0
DDI-DrugBank.d498.s2	36	56	antiarrhythmic agents	group	DDI-DrugBank.d498.s2.e1
DDI-DrugBank.d498.s2	false	DDI-DrugBank.d498.s2.e0	DDI-DrugBank.d498.s2.e1
DDI-DrugBank.d498.s3|a|the dose of Prostigmin may have to be increased accordingly.
DDI-DrugBank.d498.s3	12	21	Prostigmin	brand	DDI-DrugBank.d498.s3.e0
DDI-DrugBank.d239.s0|a|No trials specifically examining potential drug interactions with Natrecor were conducted, although many concomitant drugs were used in clinical trials.
DDI-DrugBank.d239.s0	66	73	Natrecor	brand	DDI-DrugBank.d239.s0.e0
DDI-DrugBank.d239.s1|a|No drug interactions were detected except for an increase in symptomatic hypotension in patients receiving oral ACE inhibitors.
DDI-DrugBank.d239.s1	112	125	ACE inhibitors	group	DDI-DrugBank.d239.s1.e0
DDI-DrugBank.d239.s2|a|The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
DDI-DrugBank.d239.s2	25	32	Natrecor	brand	DDI-DrugBank.d239.s2.e0
DDI-DrugBank.d239.s2	42	53	vasodilators	group	DDI-DrugBank.d239.s2.e1
DDI-DrugBank.d239.s2	63	75	nitroglycerin	drug	DDI-DrugBank.d239.s2.e2
DDI-DrugBank.d239.s2	78	90	nitroprusside	drug	DDI-DrugBank.d239.s2.e3
DDI-DrugBank.d239.s2	93	101	milrinone	drug	DDI-DrugBank.d239.s2.e4
DDI-DrugBank.d239.s2	110	123	ACE inhibitors	group	DDI-DrugBank.d239.s2.e5
DDI-DrugBank.d239.s2	191	198	Natrecor	brand	DDI-DrugBank.d239.s2.e6
DDI-DrugBank.d239.s2	false	DDI-DrugBank.d239.s2.e0	DDI-DrugBank.d239.s2.e1
DDI-DrugBank.d239.s2	false	DDI-DrugBank.d239.s2.e0	DDI-DrugBank.d239.s2.e2
DDI-DrugBank.d239.s2	false	DDI-DrugBank.d239.s2.e0	DDI-DrugBank.d239.s2.e3
DDI-DrugBank.d239.s2	false	DDI-DrugBank.d239.s2.e0	DDI-DrugBank.d239.s2.e4
DDI-DrugBank.d239.s2	false	DDI-DrugBank.d239.s2.e0	DDI-DrugBank.d239.s2.e5
DDI-DrugBank.d239.s2	false	DDI-DrugBank.d239.s2.e0	DDI-DrugBank.d239.s2.e6
DDI-DrugBank.d239.s2	false	DDI-DrugBank.d239.s2.e1	DDI-DrugBank.d239.s2.e2
DDI-DrugBank.d239.s2	false	DDI-DrugBank.d239.s2.e1	DDI-DrugBank.d239.s2.e3
DDI-DrugBank.d239.s2	false	DDI-DrugBank.d239.s2.e1	DDI-DrugBank.d239.s2.e4
DDI-DrugBank.d239.s2	false	DDI-DrugBank.d239.s2.e1	DDI-DrugBank.d239.s2.e5
DDI-DrugBank.d417.s0|a|Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
DDI-DrugBank.d417.s0	0	9	Netilmicin	drug	DDI-DrugBank.d417.s0.e0
DDI-DrugBank.d417.s0	64	77	loop diuretics	group	DDI-DrugBank.d417.s0.e1
DDI-DrugBank.d417.s0	87	96	furosemide	drug	DDI-DrugBank.d417.s0.e2
DDI-DrugBank.d417.s0	102	116	ethacrynic acid	drug	DDI-DrugBank.d417.s0.e3
DDI-DrugBank.d417.s0	true	DDI-DrugBank.d417.s0.e0	DDI-DrugBank.d417.s0.e1
DDI-DrugBank.d417.s0	true	DDI-DrugBank.d417.s0.e0	DDI-DrugBank.d417.s0.e2
DDI-DrugBank.d417.s0	true	DDI-DrugBank.d417.s0.e0	DDI-DrugBank.d417.s0.e3
DDI-DrugBank.d417.s0	false	DDI-DrugBank.d417.s0.e1	DDI-DrugBank.d417.s0.e2
DDI-DrugBank.d417.s0	false	DDI-DrugBank.d417.s0.e1	DDI-DrugBank.d417.s0.e3
DDI-DrugBank.d417.s0	false	DDI-DrugBank.d417.s0.e2	DDI-DrugBank.d417.s0.e3
DDI-DrugBank.d270.s0|a|Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A4 and 2B6.
DDI-DrugBank.d270.s0	0	9	Nevirapine	drug	DDI-DrugBank.d270.s0.e0
DDI-DrugBank.d270.s1|a|Nevirapine is known to be an inducer of these enzymes.
DDI-DrugBank.d270.s1	0	9	Nevirapine	drug	DDI-DrugBank.d270.s1.e0
DDI-DrugBank.d270.s2|a|As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when coadministered with nevirapine.
DDI-DrugBank.d270.s2	132	141	nevirapine	drug	DDI-DrugBank.d270.s2.e0
DDI-DrugBank.d270.s3|a|The specific pharmacokinetic changes that occur with co-administration of nevirapine and other drugs are listed in CLINICAL PHARMACOLOGY, Table 1.
DDI-DrugBank.d270.s3	74	83	nevirapine	drug	DDI-DrugBank.d270.s3.e0
DDI-DrugBank.d270.s4|a|Clinical comments about possible dosage modifications based on these pharmacokinetic changes are listed in Table 3.
DDI-DrugBank.d270.s5|a|The data inTables 1 and 3 are based on the results of drug interaction studies conducted in HIV-1 seropositive subjects unless otherwise indicated.
DDI-DrugBank.d270.s6|a|In addition to established drug interactions, there may be potential pharmacokinetic interactions between nevirapine and other drug classes that are metabolized by the cytochrome P450 system.
DDI-DrugBank.d270.s6	106	115	nevirapine	drug	DDI-DrugBank.d270.s6.e0
DDI-DrugBank.d270.s7|a|These potential drug interactions are listed in Table 4.
DDI-DrugBank.d270.s8|a|Although specific drug interaction studies in HIV-1 seropositive subjects have not been conducted for the classes of drugs listed in Table 4, additional clinical monitoring may be warranted when co-administering these drugs.
DDI-DrugBank.d270.s9|a|The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.
DDI-DrugBank.d270.s9	33	42	nevirapine	drug	DDI-DrugBank.d270.s9.e0
DDI-DrugBank.d270.s9	52	71	antithrombotic agent	group	DDI-DrugBank.d270.s9.e1
DDI-DrugBank.d270.s9	73	80	warfarin	drug	DDI-DrugBank.d270.s9.e2
DDI-DrugBank.d270.s9	false	DDI-DrugBank.d270.s9.e0	DDI-DrugBank.d270.s9.e1
DDI-DrugBank.d270.s9	true	DDI-DrugBank.d270.s9.e0	DDI-DrugBank.d270.s9.e2
DDI-DrugBank.d270.s9	false	DDI-DrugBank.d270.s9.e1	DDI-DrugBank.d270.s9.e2
DDI-DrugBank.d270.s10|a|As a result, when giving these drugs concomitantly, plasma warfarin levels may change with the potential for increases in coagulation time.
DDI-DrugBank.d270.s10	59	66	warfarin	drug	DDI-DrugBank.d270.s10.e0
DDI-DrugBank.d270.s11|a|When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
DDI-DrugBank.d270.s11	5	12	warfarin	drug	DDI-DrugBank.d270.s11.e0
DDI-DrugBank.d270.s11	38	47	nevirapine	drug	DDI-DrugBank.d270.s11.e1
DDI-DrugBank.d270.s11	true	DDI-DrugBank.d270.s11.e0	DDI-DrugBank.d270.s11.e1
DDI-DrugBank.d270.s12|a|Table 3 Established Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies
DDI-DrugBank.d270.s13|a|Drug Name
DDI-DrugBank.d270.s14|a|Effect on Concentration of Nevirapine or Concomitant Drug
DDI-DrugBank.d270.s14	27	36	Nevirapine	drug	DDI-DrugBank.d270.s14.e0
DDI-DrugBank.d270.s15|a|Clinical Comment
DDI-DrugBank.d270.s16|a|Clarithromycin
DDI-DrugBank.d270.s16	0	13	Clarithromycin	drug	DDI-DrugBank.d270.s16.e0
DDI-DrugBank.d270.s17|a|Clarithromycin  14OH- clarithromycin
DDI-DrugBank.d270.s17	0	13	Clarithromycin	drug	DDI-DrugBank.d270.s17.e0
DDI-DrugBank.d270.s18|a|Clarithromycin exposure was significantly decreased by nevirapine;
DDI-DrugBank.d270.s18	0	13	Clarithromycin	drug	DDI-DrugBank.d270.s18.e0
DDI-DrugBank.d270.s18	55	64	nevirapine	drug	DDI-DrugBank.d270.s18.e1
DDI-DrugBank.d270.s18	true	DDI-DrugBank.d270.s18.e0	DDI-DrugBank.d270.s18.e1
DDI-DrugBank.d270.s19|a|however, 14-OH metabolite concentrations were increased.Because clarithromycin active metabolite has reduced activity against Mycobacteriumavium-intracellulare complex, overallactivity against this pathogen may bealtered.
DDI-DrugBank.d270.s19	64	77	clarithromycin	drug	DDI-DrugBank.d270.s19.e0
DDI-DrugBank.d270.s20|a|Alternatives to clarithromycin,such as azithromycin, should be considered.
DDI-DrugBank.d270.s20	16	29	clarithromycin	drug	DDI-DrugBank.d270.s20.e0
DDI-DrugBank.d270.s20	39	50	azithromycin	drug	DDI-DrugBank.d270.s20.e1
DDI-DrugBank.d270.s20	false	DDI-DrugBank.d270.s20.e0	DDI-DrugBank.d270.s20.e1
DDI-DrugBank.d270.s21|a|Efavirenz
DDI-DrugBank.d270.s21	0	8	Efavirenz	drug	DDI-DrugBank.d270.s21.e0
DDI-DrugBank.d270.s22|a|Efavirenz
DDI-DrugBank.d270.s22	0	8	Efavirenz	drug	DDI-DrugBank.d270.s22.e0
DDI-DrugBank.d270.s23|a|Appropriate doses for this combination are not established.
DDI-DrugBank.d270.s24|a|Ethinyl estradiol and Norethindrone
DDI-DrugBank.d270.s24	0	16	Ethinyl estradiol	drug	DDI-DrugBank.d270.s24.e0
DDI-DrugBank.d270.s24	22	34	Norethindrone	drug	DDI-DrugBank.d270.s24.e1
DDI-DrugBank.d270.s24	false	DDI-DrugBank.d270.s24.e0	DDI-DrugBank.d270.s24.e1
DDI-DrugBank.d270.s25|a|Ethinyl estradiol Norethindrone
DDI-DrugBank.d270.s25	0	16	Ethinyl estradiol	drug	DDI-DrugBank.d270.s25.e0
DDI-DrugBank.d270.s25	18	30	Norethindrone	drug	DDI-DrugBank.d270.s25.e1
DDI-DrugBank.d270.s25	false	DDI-DrugBank.d270.s25.e0	DDI-DrugBank.d270.s25.e1
DDI-DrugBank.d270.s26|a|Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.
DDI-DrugBank.d270.s26	5	18	contraceptives	group	DDI-DrugBank.d270.s26.e0
DDI-DrugBank.d270.s26	132	141	nevirapine	drug	DDI-DrugBank.d270.s26.e1
DDI-DrugBank.d270.s26	true	DDI-DrugBank.d270.s26.e0	DDI-DrugBank.d270.s26.e1
DDI-DrugBank.d270.s27|a|An alternative or additional method of contraception is recommended.
DDI-DrugBank.d270.s28|a|Fluconazole
DDI-DrugBank.d270.s28	0	10	Fluconazole	drug	DDI-DrugBank.d270.s28.e0
DDI-DrugBank.d270.s29|a|Nevirapine
DDI-DrugBank.d270.s29	0	9	Nevirapine	drug	DDI-DrugBank.d270.s29.e0
DDI-DrugBank.d270.s30|a|Because of the risk of increased exposure tonevirapine, caution should be used inconcomitant administration, and patients should be monitored closely for nevirapine-associated adverse events.
DDI-DrugBank.d270.s30	44	53	nevirapine	drug	DDI-DrugBank.d270.s30.e0
DDI-DrugBank.d270.s31|a|Indinavir
DDI-DrugBank.d270.s31	0	8	Indinavir	drug	DDI-DrugBank.d270.s31.e0
DDI-DrugBank.d270.s32|a|Indinavir
DDI-DrugBank.d270.s32	0	8	Indinavir	drug	DDI-DrugBank.d270.s32.e0
DDI-DrugBank.d270.s33|a|Appropriate doses for this combination arenot established, but an increase in thedosage of indinavir may be required.
DDI-DrugBank.d270.s33	91	99	indinavir	drug	DDI-DrugBank.d270.s33.e0
DDI-DrugBank.d270.s34|a|Ketoconazole
DDI-DrugBank.d270.s34	0	11	Ketoconazole	drug	DDI-DrugBank.d270.s34.e0
DDI-DrugBank.d270.s35|a|Ketoconazole
DDI-DrugBank.d270.s35	0	11	Ketoconazole	drug	DDI-DrugBank.d270.s35.e0
DDI-DrugBank.d270.s36|a|Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.
DDI-DrugBank.d270.s36	0	9	Nevirapine	drug	DDI-DrugBank.d270.s36.e0
DDI-DrugBank.d270.s36	15	26	ketoconazole	drug	DDI-DrugBank.d270.s36.e1
DDI-DrugBank.d270.s36	88	99	ketoconazole	drug	DDI-DrugBank.d270.s36.e2
DDI-DrugBank.d270.s36	true	DDI-DrugBank.d270.s36.e0	DDI-DrugBank.d270.s36.e1
DDI-DrugBank.d270.s36	false	DDI-DrugBank.d270.s36.e0	DDI-DrugBank.d270.s36.e2
DDI-DrugBank.d270.s36	false	DDI-DrugBank.d270.s36.e1	DDI-DrugBank.d270.s36.e2
DDI-DrugBank.d270.s37|a|Lopinavir/Ritonavir
DDI-DrugBank.d270.s37	0	8	Lopinavir	drug	DDI-DrugBank.d270.s37.e0
DDI-DrugBank.d270.s37	10	18	Ritonavir	drug	DDI-DrugBank.d270.s37.e1
DDI-DrugBank.d270.s37	false	DDI-DrugBank.d270.s37.e0	DDI-DrugBank.d270.s37.e1
DDI-DrugBank.d270.s38|a|Lopinavir
DDI-DrugBank.d270.s38	0	8	Lopinavir	drug	DDI-DrugBank.d270.s38.e0
DDI-DrugBank.d270.s39|a|A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
DDI-DrugBank.d270.s39	19	27	lopinavir	drug	DDI-DrugBank.d270.s39.e0
DDI-DrugBank.d270.s39	29	37	ritonavir	drug	DDI-DrugBank.d270.s39.e1
DDI-DrugBank.d270.s39	109	118	nevirapine	drug	DDI-DrugBank.d270.s39.e2
DDI-DrugBank.d270.s39	false	DDI-DrugBank.d270.s39.e0	DDI-DrugBank.d270.s39.e1
DDI-DrugBank.d270.s39	true	DDI-DrugBank.d270.s39.e0	DDI-DrugBank.d270.s39.e2
DDI-DrugBank.d270.s39	true	DDI-DrugBank.d270.s39.e1	DDI-DrugBank.d270.s39.e2
DDI-DrugBank.d270.s40|a|Methadone
DDI-DrugBank.d270.s40	0	8	Methadone	drug	DDI-DrugBank.d270.s40.e0
DDI-DrugBank.d270.s41|a|Methadonea
DDI-DrugBank.d270.s42|a|Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
DDI-DrugBank.d270.s42	0	8	Methadone	drug	DDI-DrugBank.d270.s42.e0
DDI-DrugBank.d270.s42	92	97	opiate	group	DDI-DrugBank.d270.s42.e1
DDI-DrugBank.d270.s42	111	119	Methadone	drug	DDI-DrugBank.d270.s42.e2
DDI-DrugBank.d270.s42	151	160	nevirapine	drug	DDI-DrugBank.d270.s42.e3
DDI-DrugBank.d270.s42	220	228	methadone	drug	DDI-DrugBank.d270.s42.e4
DDI-DrugBank.d270.s42	false	DDI-DrugBank.d270.s42.e0	DDI-DrugBank.d270.s42.e1
DDI-DrugBank.d270.s42	false	DDI-DrugBank.d270.s42.e0	DDI-DrugBank.d270.s42.e2
DDI-DrugBank.d270.s42	false	DDI-DrugBank.d270.s42.e0	DDI-DrugBank.d270.s42.e3
DDI-DrugBank.d270.s42	false	DDI-DrugBank.d270.s42.e0	DDI-DrugBank.d270.s42.e4
DDI-DrugBank.d270.s42	false	DDI-DrugBank.d270.s42.e1	DDI-DrugBank.d270.s42.e2
DDI-DrugBank.d270.s42	false	DDI-DrugBank.d270.s42.e1	DDI-DrugBank.d270.s42.e3
DDI-DrugBank.d270.s42	false	DDI-DrugBank.d270.s42.e1	DDI-DrugBank.d270.s42.e4
DDI-DrugBank.d270.s42	true	DDI-DrugBank.d270.s42.e2	DDI-DrugBank.d270.s42.e3
DDI-DrugBank.d270.s42	false	DDI-DrugBank.d270.s42.e2	DDI-DrugBank.d270.s42.e4
DDI-DrugBank.d270.s42	false	DDI-DrugBank.d270.s42.e3	DDI-DrugBank.d270.s42.e4
DDI-DrugBank.d270.s43|a|Nelfinavir
DDI-DrugBank.d270.s43	0	9	Nelfinavir	drug	DDI-DrugBank.d270.s43.e0
DDI-DrugBank.d270.s44|a|Nelfinavir M8
DDI-DrugBank.d270.s44	0	9	Nelfinavir	drug	DDI-DrugBank.d270.s44.e0
DDI-DrugBank.d270.s45|a|The appropriate dose for nelfinavir incombination with nevirapine, with respectto safety and efficacy, has not been established.
DDI-DrugBank.d270.s45	25	34	nelfinavir	drug	DDI-DrugBank.d270.s45.e0
DDI-DrugBank.d270.s45	55	64	nevirapine	drug	DDI-DrugBank.d270.s45.e1
DDI-DrugBank.d270.s45	false	DDI-DrugBank.d270.s45.e0	DDI-DrugBank.d270.s45.e1
DDI-DrugBank.d270.s46|a|Rifabutin
DDI-DrugBank.d270.s46	0	8	Rifabutin	drug	DDI-DrugBank.d270.s46.e0
DDI-DrugBank.d270.s47|a|Rifabutin
DDI-DrugBank.d270.s47	0	8	Rifabutin	drug	DDI-DrugBank.d270.s47.e0
DDI-DrugBank.d270.s48|a|Rifabutin and its metabolite concentrationswere moderately increased.
DDI-DrugBank.d270.s48	0	8	Rifabutin	drug	DDI-DrugBank.d270.s48.e0
DDI-DrugBank.d270.s49|a|Due to highintersubject variability, however, somepatients may experience large increases inrifabutin exposure and may be at higher riskfor rifabutin toxicity.
DDI-DrugBank.d270.s49	92	100	rifabutin	drug	DDI-DrugBank.d270.s49.e0
DDI-DrugBank.d270.s50|a|Therefore, caution should be used in concomitant administration.
DDI-DrugBank.d270.s51|a|Rifampin
DDI-DrugBank.d270.s51	0	7	Rifampin	drug	DDI-DrugBank.d270.s51.e0
DDI-DrugBank.d270.s52|a|Nevirapine
DDI-DrugBank.d270.s52	0	9	Nevirapine	drug	DDI-DrugBank.d270.s52.e0
DDI-DrugBank.d270.s53|a|Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.
DDI-DrugBank.d270.s53	0	9	Nevirapine	drug	DDI-DrugBank.d270.s53.e0
DDI-DrugBank.d270.s53	15	22	rifampin	drug	DDI-DrugBank.d270.s53.e1
DDI-DrugBank.d270.s53	84	93	nevirapine	drug	DDI-DrugBank.d270.s53.e2
DDI-DrugBank.d270.s53	true	DDI-DrugBank.d270.s53.e0	DDI-DrugBank.d270.s53.e1
DDI-DrugBank.d270.s53	false	DDI-DrugBank.d270.s53.e0	DDI-DrugBank.d270.s53.e2
DDI-DrugBank.d270.s53	false	DDI-DrugBank.d270.s53.e1	DDI-DrugBank.d270.s53.e2
DDI-DrugBank.d270.s54|a|Physicians needing to treatpatients co-infected with tuberculosis andusing a nevirapine containing regimen mayuse rifabutin instead.
DDI-DrugBank.d270.s54	77	86	nevirapine	drug	DDI-DrugBank.d270.s54.e0
DDI-DrugBank.d270.s54	114	122	rifabutin	drug	DDI-DrugBank.d270.s54.e1
DDI-DrugBank.d270.s54	false	DDI-DrugBank.d270.s54.e0	DDI-DrugBank.d270.s54.e1
DDI-DrugBank.d270.s55|a|Saquinavir
DDI-DrugBank.d270.s55	0	9	Saquinavir	drug	DDI-DrugBank.d270.s55.e0
DDI-DrugBank.d270.s56|a|Saquinavir
DDI-DrugBank.d270.s56	0	9	Saquinavir	drug	DDI-DrugBank.d270.s56.e0
DDI-DrugBank.d270.s57|a|Appropriate doses for this combination arenot established, but an increase in thedosage of saquinavir may be required.
DDI-DrugBank.d270.s57	91	100	saquinavir	drug	DDI-DrugBank.d270.s57.e0
DDI-DrugBank.d270.s58|a|aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.
DDI-DrugBank.d270.s58	75	84	nevirapine	drug	DDI-DrugBank.d270.s58.e0
DDI-DrugBank.d270.s58	90	98	methadone	drug	DDI-DrugBank.d270.s58.e1
DDI-DrugBank.d270.s58	165	173	methadone	drug	DDI-DrugBank.d270.s58.e2
DDI-DrugBank.d270.s58	true	DDI-DrugBank.d270.s58.e0	DDI-DrugBank.d270.s58.e1
DDI-DrugBank.d270.s58	false	DDI-DrugBank.d270.s58.e0	DDI-DrugBank.d270.s58.e2
DDI-DrugBank.d270.s58	false	DDI-DrugBank.d270.s58.e1	DDI-DrugBank.d270.s58.e2
DDI-DrugBank.d270.s59|a|Table 4        Potential Drug Interactions:Use With Caution, Dose Adjustment of Co-administered Drug May Be Needed due to Possible Decrease in Clinical Effect
DDI-DrugBank.d270.s60|a|Examples of Drugs in Which Plasma Concentrations May Be Decreased By Co-administration With Nevirapine
DDI-DrugBank.d270.s60	92	101	Nevirapine	drug	DDI-DrugBank.d270.s60.e0
DDI-DrugBank.d270.s61|a|Drug Class Examples of Drugs
DDI-DrugBank.d270.s62|a|Antiarrhythmics
DDI-DrugBank.d270.s62	0	14	Antiarrhythmics	group	DDI-DrugBank.d270.s62.e0
DDI-DrugBank.d270.s63|a|Amiodarone, disopyramide, lidocaine
DDI-DrugBank.d270.s63	0	9	Amiodarone	drug	DDI-DrugBank.d270.s63.e0
DDI-DrugBank.d270.s63	12	23	disopyramide	drug	DDI-DrugBank.d270.s63.e1
DDI-DrugBank.d270.s63	26	34	lidocaine	drug	DDI-DrugBank.d270.s63.e2
DDI-DrugBank.d270.s63	false	DDI-DrugBank.d270.s63.e0	DDI-DrugBank.d270.s63.e1
DDI-DrugBank.d270.s63	false	DDI-DrugBank.d270.s63.e0	DDI-DrugBank.d270.s63.e2
DDI-DrugBank.d270.s63	false	DDI-DrugBank.d270.s63.e1	DDI-DrugBank.d270.s63.e2
DDI-DrugBank.d270.s64|a|Anticonvulsants
DDI-DrugBank.d270.s64	0	14	Anticonvulsants	group	DDI-DrugBank.d270.s64.e0
DDI-DrugBank.d270.s65|a|Carbamazepine, clonazepam, ethosuximide
DDI-DrugBank.d270.s65	0	12	Carbamazepine	drug	DDI-DrugBank.d270.s65.e0
DDI-DrugBank.d270.s65	15	24	clonazepam	drug	DDI-DrugBank.d270.s65.e1
DDI-DrugBank.d270.s65	27	38	ethosuximide	drug	DDI-DrugBank.d270.s65.e2
DDI-DrugBank.d270.s65	false	DDI-DrugBank.d270.s65.e0	DDI-DrugBank.d270.s65.e1
DDI-DrugBank.d270.s65	false	DDI-DrugBank.d270.s65.e0	DDI-DrugBank.d270.s65.e2
DDI-DrugBank.d270.s65	false	DDI-DrugBank.d270.s65.e1	DDI-DrugBank.d270.s65.e2
DDI-DrugBank.d270.s66|a|Antifungals
DDI-DrugBank.d270.s66	0	10	Antifungals	group	DDI-DrugBank.d270.s66.e0
DDI-DrugBank.d270.s67|a|Itraconazole
DDI-DrugBank.d270.s67	0	11	Itraconazole	drug	DDI-DrugBank.d270.s67.e0
DDI-DrugBank.d270.s68|a|Calcium channel blockers
DDI-DrugBank.d270.s68	0	23	Calcium channel blockers	group	DDI-DrugBank.d270.s68.e0
DDI-DrugBank.d270.s69|a|Diltiazem, nifedipine, verapamil
DDI-DrugBank.d270.s69	0	8	Diltiazem	drug	DDI-DrugBank.d270.s69.e0
DDI-DrugBank.d270.s69	11	20	nifedipine	drug	DDI-DrugBank.d270.s69.e1
DDI-DrugBank.d270.s69	23	31	verapamil	drug	DDI-DrugBank.d270.s69.e2
DDI-DrugBank.d270.s69	false	DDI-DrugBank.d270.s69.e0	DDI-DrugBank.d270.s69.e1
DDI-DrugBank.d270.s69	false	DDI-DrugBank.d270.s69.e0	DDI-DrugBank.d270.s69.e2
DDI-DrugBank.d270.s69	false	DDI-DrugBank.d270.s69.e1	DDI-DrugBank.d270.s69.e2
DDI-DrugBank.d270.s70|a|Cancer chemotherapy
DDI-DrugBank.d270.s71|a|Cyclophosphamide
DDI-DrugBank.d270.s71	0	15	Cyclophosphamide	drug	DDI-DrugBank.d270.s71.e0
DDI-DrugBank.d270.s72|a|Ergot alkaloids
DDI-DrugBank.d270.s72	0	14	Ergot alkaloids	group	DDI-DrugBank.d270.s72.e0
DDI-DrugBank.d270.s73|a|Ergotamine
DDI-DrugBank.d270.s73	0	9	Ergotamine	drug	DDI-DrugBank.d270.s73.e0
DDI-DrugBank.d270.s74|a|Immunosuppressants
DDI-DrugBank.d270.s74	0	17	Immunosuppressants	group	DDI-DrugBank.d270.s74.e0
DDI-DrugBank.d270.s75|a|Cyclosporin, tacrolimus, sirolimus
DDI-DrugBank.d270.s75	0	10	Cyclosporin	drug	DDI-DrugBank.d270.s75.e0
DDI-DrugBank.d270.s75	13	22	tacrolimus	drug	DDI-DrugBank.d270.s75.e1
DDI-DrugBank.d270.s75	25	33	sirolimus	drug	DDI-DrugBank.d270.s75.e2
DDI-DrugBank.d270.s75	false	DDI-DrugBank.d270.s75.e0	DDI-DrugBank.d270.s75.e1
DDI-DrugBank.d270.s75	false	DDI-DrugBank.d270.s75.e0	DDI-DrugBank.d270.s75.e2
DDI-DrugBank.d270.s75	false	DDI-DrugBank.d270.s75.e1	DDI-DrugBank.d270.s75.e2
DDI-DrugBank.d270.s76|a|Motility agents
DDI-DrugBank.d270.s77|a|Cisapride
DDI-DrugBank.d270.s77	0	8	Cisapride	drug	DDI-DrugBank.d270.s77.e0
DDI-DrugBank.d270.s78|a|Opiate agonists
DDI-DrugBank.d270.s78	0	14	Opiate agonists	group	DDI-DrugBank.d270.s78.e0
DDI-DrugBank.d270.s79|a|Fentanyl
DDI-DrugBank.d270.s79	0	7	Fentanyl	drug	DDI-DrugBank.d270.s79.e0
DDI-DrugBank.d270.s80|a|Examples of Drugs in Which Plasma Concentrations May Be Increased By Co-administration With Nevirapine
DDI-DrugBank.d270.s80	92	101	Nevirapine	drug	DDI-DrugBank.d270.s80.e0
DDI-DrugBank.d270.s81|a|Antithrombotics
DDI-DrugBank.d270.s81	0	14	Antithrombotics	group	DDI-DrugBank.d270.s81.e0
DDI-DrugBank.d270.s82|a|Warfarin
DDI-DrugBank.d270.s82	0	7	Warfarin	drug	DDI-DrugBank.d270.s82.e0
DDI-DrugBank.d270.s83|a|Potential effect on anticoagulation.
DDI-DrugBank.d270.s84|a|Monitoring of anticoagulation levels is recommended.
DDI-DrugBank.d270.s85|a|Fat redistribution: Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and cushingoid appearance have been observed in patients receiving antiretroviral therapy.
DDI-DrugBank.d270.s85	256	269	antiretroviral	group	DDI-DrugBank.d270.s85.e0
DDI-DrugBank.d270.s86|a|The mechanism and long-term consequences of these events are currently unknown.
DDI-DrugBank.d270.s87|a|A causal relationship has not been established
DDI-DrugBank.d270.s88|a|.
DDI-DrugBank.d270.s89|a|
DDI-DrugBank.d542.s0|a|Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.
DDI-DrugBank.d542.s0	17	26	Vitamin B3	drug	DDI-DrugBank.d542.s0.e0
DDI-DrugBank.d542.s0	29	34	Niacin	drug	DDI-DrugBank.d542.s0.e1
DDI-DrugBank.d542.s0	38	53	Antihypertensive	group	DDI-DrugBank.d542.s0.e2
DDI-DrugBank.d542.s0	64	77	Nicotinic acid	drug	DDI-DrugBank.d542.s0.e3
DDI-DrugBank.d542.s0	109	134	ganglionic blocking agents	group	DDI-DrugBank.d542.s0.e4
DDI-DrugBank.d542.s0	false	DDI-DrugBank.d542.s0.e0	DDI-DrugBank.d542.s0.e1
DDI-DrugBank.d542.s0	false	DDI-DrugBank.d542.s0.e0	DDI-DrugBank.d542.s0.e2
DDI-DrugBank.d542.s0	false	DDI-DrugBank.d542.s0.e0	DDI-DrugBank.d542.s0.e3
DDI-DrugBank.d542.s0	false	DDI-DrugBank.d542.s0.e0	DDI-DrugBank.d542.s0.e4
DDI-DrugBank.d542.s0	false	DDI-DrugBank.d542.s0.e1	DDI-DrugBank.d542.s0.e2
DDI-DrugBank.d542.s0	false	DDI-DrugBank.d542.s0.e1	DDI-DrugBank.d542.s0.e3
DDI-DrugBank.d542.s0	false	DDI-DrugBank.d542.s0.e1	DDI-DrugBank.d542.s0.e4
DDI-DrugBank.d542.s0	false	DDI-DrugBank.d542.s0.e2	DDI-DrugBank.d542.s0.e3
DDI-DrugBank.d542.s0	false	DDI-DrugBank.d542.s0.e2	DDI-DrugBank.d542.s0.e4
DDI-DrugBank.d542.s0	true	DDI-DrugBank.d542.s0.e3	DDI-DrugBank.d542.s0.e4
DDI-DrugBank.d542.s1|a|Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.
DDI-DrugBank.d542.s1	0	6	Aspirin	brand	DDI-DrugBank.d542.s1.e0
DDI-DrugBank.d542.s1	21	27	aspirin	brand	DDI-DrugBank.d542.s1.e1
DDI-DrugBank.d542.s1	69	82	nicotinic acid	drug	DDI-DrugBank.d542.s1.e2
DDI-DrugBank.d542.s1	false	DDI-DrugBank.d542.s1.e0	DDI-DrugBank.d542.s1.e1
DDI-DrugBank.d542.s1	false	DDI-DrugBank.d542.s1.e0	DDI-DrugBank.d542.s1.e2
DDI-DrugBank.d542.s1	true	DDI-DrugBank.d542.s1.e1	DDI-DrugBank.d542.s1.e2
DDI-DrugBank.d542.s2|a|The clinical relevance of this finding is unclear.
DDI-DrugBank.d542.s3|a|Other: Concomitant alcohol or hot drinks may increase the side effects of flushing and pruritus and should be avoided at the time of drug ingestion.
DDI-DrugBank.d542.s3	19	25	alcohol	drug	DDI-DrugBank.d542.s3.e0
DDI-DrugBank.d468.s0|a|Beta-Blockers: In controlled clinical studies, adrenergic beta-receptor blockers have been frequently administered concomitantly with nicardipine HCl.
DDI-DrugBank.d468.s0	0	12	Beta-Blockers	group	DDI-DrugBank.d468.s0.e0
DDI-DrugBank.d468.s0	47	79	adrenergic beta-receptor blockers	group	DDI-DrugBank.d468.s0.e1
DDI-DrugBank.d468.s0	134	148	nicardipine HCl	drug	DDI-DrugBank.d468.s0.e2
DDI-DrugBank.d468.s0	false	DDI-DrugBank.d468.s0.e0	DDI-DrugBank.d468.s0.e1
DDI-DrugBank.d468.s0	false	DDI-DrugBank.d468.s0.e0	DDI-DrugBank.d468.s0.e2
DDI-DrugBank.d468.s0	false	DDI-DrugBank.d468.s0.e1	DDI-DrugBank.d468.s0.e2
DDI-DrugBank.d468.s1|a|The combination is well tolerated.
DDI-DrugBank.d468.s2|a|Cimetidine: Cimetidine increases nicardipine HCl plasma levels.
DDI-DrugBank.d468.s2	0	9	Cimetidine	drug	DDI-DrugBank.d468.s2.e0
DDI-DrugBank.d468.s2	12	21	Cimetidine	drug	DDI-DrugBank.d468.s2.e1
DDI-DrugBank.d468.s2	33	47	nicardipine HCl	drug	DDI-DrugBank.d468.s2.e2
DDI-DrugBank.d468.s2	false	DDI-DrugBank.d468.s2.e0	DDI-DrugBank.d468.s2.e1
DDI-DrugBank.d468.s2	false	DDI-DrugBank.d468.s2.e0	DDI-DrugBank.d468.s2.e2
DDI-DrugBank.d468.s2	true	DDI-DrugBank.d468.s2.e1	DDI-DrugBank.d468.s2.e2
DDI-DrugBank.d468.s3|a|Patients receiving the two drugs concomitantly should be carefully monitored.
DDI-DrugBank.d468.s4|a|Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.
DDI-DrugBank.d468.s4	0	6	Digoxin	drug	DDI-DrugBank.d468.s4.e0
DDI-DrugBank.d468.s4	14	29	calcium blockers	group	DDI-DrugBank.d468.s4.e1
DDI-DrugBank.d468.s4	65	86	digitalis preparations	group	DDI-DrugBank.d468.s4.e2
DDI-DrugBank.d468.s4	false	DDI-DrugBank.d468.s4.e0	DDI-DrugBank.d468.s4.e1
DDI-DrugBank.d468.s4	false	DDI-DrugBank.d468.s4.e0	DDI-DrugBank.d468.s4.e2
DDI-DrugBank.d468.s4	true	DDI-DrugBank.d468.s4.e1	DDI-DrugBank.d468.s4.e2
DDI-DrugBank.d468.s5|a|Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.
DDI-DrugBank.d468.s5	0	14	Nicardipine HCl	drug	DDI-DrugBank.d468.s5.e0
DDI-DrugBank.d468.s5	60	66	digoxin	drug	DDI-DrugBank.d468.s5.e1
DDI-DrugBank.d468.s5	84	90	digoxin	drug	DDI-DrugBank.d468.s5.e2
DDI-DrugBank.d468.s5	150	164	nicardipine HCl	drug	DDI-DrugBank.d468.s5.e3
DDI-DrugBank.d468.s5	false	DDI-DrugBank.d468.s5.e0	DDI-DrugBank.d468.s5.e1
DDI-DrugBank.d468.s5	false	DDI-DrugBank.d468.s5.e0	DDI-DrugBank.d468.s5.e2
DDI-DrugBank.d468.s5	false	DDI-DrugBank.d468.s5.e0	DDI-DrugBank.d468.s5.e3
DDI-DrugBank.d468.s5	false	DDI-DrugBank.d468.s5.e1	DDI-DrugBank.d468.s5.e2
DDI-DrugBank.d468.s5	false	DDI-DrugBank.d468.s5.e1	DDI-DrugBank.d468.s5.e3
DDI-DrugBank.d468.s5	true	DDI-DrugBank.d468.s5.e2	DDI-DrugBank.d468.s5.e3
DDI-DrugBank.d468.s6|a|Maalox * Coadministration of Maalox TC had no effect on nicardipine HCl absorption.
DDI-DrugBank.d468.s6	0	5	Maalox	brand	DDI-DrugBank.d468.s6.e0
DDI-DrugBank.d468.s6	29	37	Maalox TC	brand	DDI-DrugBank.d468.s6.e1
DDI-DrugBank.d468.s6	56	70	nicardipine HCl	drug	DDI-DrugBank.d468.s6.e2
DDI-DrugBank.d468.s6	false	DDI-DrugBank.d468.s6.e0	DDI-DrugBank.d468.s6.e1
DDI-DrugBank.d468.s6	false	DDI-DrugBank.d468.s6.e0	DDI-DrugBank.d468.s6.e2
DDI-DrugBank.d468.s6	false	DDI-DrugBank.d468.s6.e1	DDI-DrugBank.d468.s6.e2
DDI-DrugBank.d468.s7|a|Even though such interactions were not seen during clinical studies with nicardipine HCl, an increased volume of circulating fluids might be required if such an interaction were to occur.
DDI-DrugBank.d468.s7	73	87	nicardipine HCl	drug	DDI-DrugBank.d468.s7.e0
DDI-DrugBank.d468.s8|a|Cyclosporine: Concomitant administration of nicardipine and cyclosporine levels.
DDI-DrugBank.d468.s8	0	11	Cyclosporine	drug	DDI-DrugBank.d468.s8.e0
DDI-DrugBank.d468.s8	44	54	nicardipine	drug	DDI-DrugBank.d468.s8.e1
DDI-DrugBank.d468.s8	60	71	cyclosporine	drug	DDI-DrugBank.d468.s8.e2
DDI-DrugBank.d468.s8	false	DDI-DrugBank.d468.s8.e0	DDI-DrugBank.d468.s8.e1
DDI-DrugBank.d468.s8	false	DDI-DrugBank.d468.s8.e0	DDI-DrugBank.d468.s8.e2
DDI-DrugBank.d468.s8	false	DDI-DrugBank.d468.s8.e1	DDI-DrugBank.d468.s8.e2
DDI-DrugBank.d468.s9|a|Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.
DDI-DrugBank.d468.s9	25	36	cyclosporine	drug	DDI-DrugBank.d468.s9.e0
DDI-DrugBank.d468.s9	138	148	nicardipine	drug	DDI-DrugBank.d468.s9.e1
DDI-DrugBank.d468.s9	true	DDI-DrugBank.d468.s9.e0	DDI-DrugBank.d468.s9.e1
DDI-DrugBank.d468.s10|a|When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
DDI-DrugBank.d468.s10	35	44	furosemide	drug	DDI-DrugBank.d468.s10.e0
DDI-DrugBank.d468.s10	47	57	propranolol	drug	DDI-DrugBank.d468.s10.e1
DDI-DrugBank.d468.s10	60	71	dipyridamole	drug	DDI-DrugBank.d468.s10.e2
DDI-DrugBank.d468.s10	74	81	warfarin	drug	DDI-DrugBank.d468.s10.e3
DDI-DrugBank.d468.s10	84	92	quinidine	drug	DDI-DrugBank.d468.s10.e4
DDI-DrugBank.d468.s10	98	105	naproxen	drug	DDI-DrugBank.d468.s10.e5
DDI-DrugBank.d468.s10	176	190	nicardipine HCl	drug	DDI-DrugBank.d468.s10.e6
DDI-DrugBank.d468.s10	false	DDI-DrugBank.d468.s10.e0	DDI-DrugBank.d468.s10.e1
DDI-DrugBank.d468.s10	false	DDI-DrugBank.d468.s10.e0	DDI-DrugBank.d468.s10.e2
DDI-DrugBank.d468.s10	false	DDI-DrugBank.d468.s10.e0	DDI-DrugBank.d468.s10.e3
DDI-DrugBank.d468.s10	false	DDI-DrugBank.d468.s10.e0	DDI-DrugBank.d468.s10.e4
DDI-DrugBank.d468.s10	false	DDI-DrugBank.d468.s10.e0	DDI-DrugBank.d468.s10.e5
DDI-DrugBank.d468.s10	false	DDI-DrugBank.d468.s10.e0	DDI-DrugBank.d468.s10.e6
DDI-DrugBank.d468.s10	false	DDI-DrugBank.d468.s10.e1	DDI-DrugBank.d468.s10.e2
DDI-DrugBank.d468.s10	false	DDI-DrugBank.d468.s10.e1	DDI-DrugBank.d468.s10.e3
DDI-DrugBank.d468.s10	false	DDI-DrugBank.d468.s10.e1	DDI-DrugBank.d468.s10.e4
DDI-DrugBank.d468.s10	false	DDI-DrugBank.d468.s10.e1	DDI-DrugBank.d468.s10.e5
DDI-DrugBank.d271.s0|a|Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic antidepressants and theophylline.
DDI-DrugBank.d271.s0	72	79	nicotine	drug	DDI-DrugBank.d271.s0.e0
DDI-DrugBank.d271.s0	169	193	tricyclic antidepressants	group	DDI-DrugBank.d271.s0.e1
DDI-DrugBank.d271.s0	199	210	theophylline	drug	DDI-DrugBank.d271.s0.e2
DDI-DrugBank.d271.s0	false	DDI-DrugBank.d271.s0.e0	DDI-DrugBank.d271.s0.e1
DDI-DrugBank.d271.s0	false	DDI-DrugBank.d271.s0.e0	DDI-DrugBank.d271.s0.e2
DDI-DrugBank.d271.s0	false	DDI-DrugBank.d271.s0.e1	DDI-DrugBank.d271.s0.e2
DDI-DrugBank.d271.s1|a|Doses of these and perhaps other medications may need to be adjusted in patients who successfully quit smoking.
DDI-DrugBank.d373.s0|a|Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.
DDI-DrugBank.d373.s0	0	30	Beta-adrenergic Blocking Agents	group	DDI-DrugBank.d373.s0.e0
DDI-DrugBank.d373.s0	147	156	nifedipine	drug	DDI-DrugBank.d373.s0.e1
DDI-DrugBank.d373.s0	162	181	beta-blocking agents	group	DDI-DrugBank.d373.s0.e2
DDI-DrugBank.d373.s0	false	DDI-DrugBank.d373.s0.e0	DDI-DrugBank.d373.s0.e1
DDI-DrugBank.d373.s0	false	DDI-DrugBank.d373.s0.e0	DDI-DrugBank.d373.s0.e2
DDI-DrugBank.d373.s0	true	DDI-DrugBank.d373.s0.e1	DDI-DrugBank.d373.s0.e2
DDI-DrugBank.d373.s1|a|Long Acting Nitrates: Nifedipine may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
DDI-DrugBank.d373.s1	12	19	Nitrates	group	DDI-DrugBank.d373.s1.e0
DDI-DrugBank.d373.s1	22	31	Nifedipine	drug	DDI-DrugBank.d373.s1.e1
DDI-DrugBank.d373.s1	68	75	nitrates	group	DDI-DrugBank.d373.s1.e2
DDI-DrugBank.d373.s1	false	DDI-DrugBank.d373.s1.e0	DDI-DrugBank.d373.s1.e1
DDI-DrugBank.d373.s1	false	DDI-DrugBank.d373.s1.e0	DDI-DrugBank.d373.s1.e2
DDI-DrugBank.d373.s1	false	DDI-DrugBank.d373.s1.e1	DDI-DrugBank.d373.s1.e2
DDI-DrugBank.d373.s2|a|Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
DDI-DrugBank.d373.s2	0	8	Digitalis	group	DDI-DrugBank.d373.s2.e0
DDI-DrugBank.d373.s2	104	110	digoxin	drug	DDI-DrugBank.d373.s2.e1
DDI-DrugBank.d373.s2	164	170	digoxin	drug	DDI-DrugBank.d373.s2.e2
DDI-DrugBank.d373.s2	176	185	nifedipine	drug	DDI-DrugBank.d373.s2.e3
DDI-DrugBank.d373.s2	211	217	digoxin	drug	DDI-DrugBank.d373.s2.e4
DDI-DrugBank.d373.s2	285	294	nifedipine	drug	DDI-DrugBank.d373.s2.e5
DDI-DrugBank.d373.s2	false	DDI-DrugBank.d373.s2.e0	DDI-DrugBank.d373.s2.e1
DDI-DrugBank.d373.s2	false	DDI-DrugBank.d373.s2.e0	DDI-DrugBank.d373.s2.e2
DDI-DrugBank.d373.s2	false	DDI-DrugBank.d373.s2.e0	DDI-DrugBank.d373.s2.e3
DDI-DrugBank.d373.s2	false	DDI-DrugBank.d373.s2.e0	DDI-DrugBank.d373.s2.e4
DDI-DrugBank.d373.s2	false	DDI-DrugBank.d373.s2.e0	DDI-DrugBank.d373.s2.e5
DDI-DrugBank.d373.s2	false	DDI-DrugBank.d373.s2.e1	DDI-DrugBank.d373.s2.e2
DDI-DrugBank.d373.s2	false	DDI-DrugBank.d373.s2.e1	DDI-DrugBank.d373.s2.e3
DDI-DrugBank.d373.s2	false	DDI-DrugBank.d373.s2.e1	DDI-DrugBank.d373.s2.e4
DDI-DrugBank.d373.s2	false	DDI-DrugBank.d373.s2.e1	DDI-DrugBank.d373.s2.e5
DDI-DrugBank.d373.s2	true	DDI-DrugBank.d373.s2.e2	DDI-DrugBank.d373.s2.e3
DDI-DrugBank.d373.s3|a|Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.
DDI-DrugBank.d373.s3	44	53	nifedipine	drug	DDI-DrugBank.d373.s3.e0
DDI-DrugBank.d373.s3	60	66	digoxin	drug	DDI-DrugBank.d373.s3.e1
DDI-DrugBank.d373.s3	78	84	digoxin	drug	DDI-DrugBank.d373.s3.e2
DDI-DrugBank.d373.s3	false	DDI-DrugBank.d373.s3.e0	DDI-DrugBank.d373.s3.e1
DDI-DrugBank.d373.s3	false	DDI-DrugBank.d373.s3.e0	DDI-DrugBank.d373.s3.e2
DDI-DrugBank.d373.s3	true	DDI-DrugBank.d373.s3.e1	DDI-DrugBank.d373.s3.e2
DDI-DrugBank.d373.s4|a|The average increase was 45%.
DDI-DrugBank.d373.s5|a|Another investigator found no increase in digoxin levels in 13 patients with coronary artery disease.
DDI-DrugBank.d373.s5	42	48	digoxin	drug	DDI-DrugBank.d373.s5.e0
DDI-DrugBank.d373.s6|a|In an uncontrolled study of over 200 patients with congestive heart failure during which digoxin blood levels were not measured, digitalis toxicity was not observed.
DDI-DrugBank.d373.s6	89	95	digoxin	drug	DDI-DrugBank.d373.s6.e0
DDI-DrugBank.d373.s7|a|Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
DDI-DrugBank.d373.s7	65	71	digoxin	drug	DDI-DrugBank.d373.s7.e0
DDI-DrugBank.d373.s7	104	110	digoxin	drug	DDI-DrugBank.d373.s7.e1
DDI-DrugBank.d373.s7	178	187	nifedipine	drug	DDI-DrugBank.d373.s7.e2
DDI-DrugBank.d373.s7	false	DDI-DrugBank.d373.s7.e0	DDI-DrugBank.d373.s7.e1
DDI-DrugBank.d373.s7	false	DDI-DrugBank.d373.s7.e0	DDI-DrugBank.d373.s7.e2
DDI-DrugBank.d373.s7	true	DDI-DrugBank.d373.s7.e1	DDI-DrugBank.d373.s7.e2
DDI-DrugBank.d373.s8|a|Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).
DDI-DrugBank.d373.s8	0	8	Quinidine	drug	DDI-DrugBank.d373.s8.e0
DDI-DrugBank.d373.s8	94	102	quinidine	drug	DDI-DrugBank.d373.s8.e1
DDI-DrugBank.d373.s8	108	117	nifedipine	drug	DDI-DrugBank.d373.s8.e2
DDI-DrugBank.d373.s8	153	161	quinidine	drug	DDI-DrugBank.d373.s8.e3
DDI-DrugBank.d373.s8	false	DDI-DrugBank.d373.s8.e0	DDI-DrugBank.d373.s8.e1
DDI-DrugBank.d373.s8	false	DDI-DrugBank.d373.s8.e0	DDI-DrugBank.d373.s8.e2
DDI-DrugBank.d373.s8	false	DDI-DrugBank.d373.s8.e0	DDI-DrugBank.d373.s8.e3
DDI-DrugBank.d373.s8	true	DDI-DrugBank.d373.s8.e1	DDI-DrugBank.d373.s8.e2
DDI-DrugBank.d373.s8	false	DDI-DrugBank.d373.s8.e1	DDI-DrugBank.d373.s8.e3
DDI-DrugBank.d373.s8	false	DDI-DrugBank.d373.s8.e2	DDI-DrugBank.d373.s8.e3
DDI-DrugBank.d373.s9|a|Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.
DDI-DrugBank.d373.s9	0	22	Coumarin Anticoagulants	group	DDI-DrugBank.d373.s9.e0
DDI-DrugBank.d373.s9	103	125	coumarin anticoagulants	group	DDI-DrugBank.d373.s9.e1
DDI-DrugBank.d373.s9	135	144	nifedipine	drug	DDI-DrugBank.d373.s9.e2
DDI-DrugBank.d373.s9	false	DDI-DrugBank.d373.s9.e0	DDI-DrugBank.d373.s9.e1
DDI-DrugBank.d373.s9	false	DDI-DrugBank.d373.s9.e0	DDI-DrugBank.d373.s9.e2
DDI-DrugBank.d373.s9	true	DDI-DrugBank.d373.s9.e1	DDI-DrugBank.d373.s9.e2
DDI-DrugBank.d373.s10|a|However, the relationship to nifedipine therapy is uncertain.
DDI-DrugBank.d373.s10	29	38	nifedipine	drug	DDI-DrugBank.d373.s10.e0
DDI-DrugBank.d373.s11|a|Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.
DDI-DrugBank.d373.s11	0	9	Cimetidine	drug	DDI-DrugBank.d373.s11.e0
DDI-DrugBank.d373.s11	85	94	nifedipine	drug	DDI-DrugBank.d373.s11.e1
DDI-DrugBank.d373.s11	172	181	cimetidine	drug	DDI-DrugBank.d373.s11.e2
DDI-DrugBank.d373.s11	206	215	nifedipine	drug	DDI-DrugBank.d373.s11.e3
DDI-DrugBank.d373.s11	false	DDI-DrugBank.d373.s11.e0	DDI-DrugBank.d373.s11.e1
DDI-DrugBank.d373.s11	false	DDI-DrugBank.d373.s11.e0	DDI-DrugBank.d373.s11.e2
DDI-DrugBank.d373.s11	false	DDI-DrugBank.d373.s11.e0	DDI-DrugBank.d373.s11.e3
DDI-DrugBank.d373.s11	false	DDI-DrugBank.d373.s11.e1	DDI-DrugBank.d373.s11.e2
DDI-DrugBank.d373.s11	false	DDI-DrugBank.d373.s11.e1	DDI-DrugBank.d373.s11.e3
DDI-DrugBank.d373.s11	true	DDI-DrugBank.d373.s11.e2	DDI-DrugBank.d373.s11.e3
DDI-DrugBank.d373.s12|a|Ranitidine produced smaller, non-significant increases.
DDI-DrugBank.d373.s12	0	9	Ranitidine	drug	DDI-DrugBank.d373.s12.e0
DDI-DrugBank.d373.s13|a|The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of nifedipine.
DDI-DrugBank.d373.s13	54	63	cimetidine	drug	DDI-DrugBank.d373.s13.e0
DDI-DrugBank.d373.s13	166	175	nifedipine	drug	DDI-DrugBank.d373.s13.e1
DDI-DrugBank.d373.s13	false	DDI-DrugBank.d373.s13.e0	DDI-DrugBank.d373.s13.e1
DDI-DrugBank.d373.s14|a|If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.
DDI-DrugBank.d373.s14	3	12	nifedipine	drug	DDI-DrugBank.d373.s14.e0
DDI-DrugBank.d373.s14	68	77	cimetidine	drug	DDI-DrugBank.d373.s14.e1
DDI-DrugBank.d373.s14	true	DDI-DrugBank.d373.s14.e0	DDI-DrugBank.d373.s14.e1
DDI-DrugBank.d177.s0|a|In vitro, nilutamide has been shown to inhibit the activity of liver cytochrome P-450 isoenzymes and therefore, may reduce the metabolism of compounds requiring these systems.
DDI-DrugBank.d177.s0	10	19	nilutamide	drug	DDI-DrugBank.d177.s0.e0
DDI-DrugBank.d177.s1|a|Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level.
DDI-DrugBank.d177.s1	59	79	vitamin K antagonists	group	DDI-DrugBank.d177.s1.e0
DDI-DrugBank.d177.s1	82	90	phenytoin	drug	DDI-DrugBank.d177.s1.e1
DDI-DrugBank.d177.s1	97	108	theophylline	drug	DDI-DrugBank.d177.s1.e2
DDI-DrugBank.d177.s1	false	DDI-DrugBank.d177.s1.e0	DDI-DrugBank.d177.s1.e1
DDI-DrugBank.d177.s1	false	DDI-DrugBank.d177.s1.e0	DDI-DrugBank.d177.s1.e2
DDI-DrugBank.d177.s1	false	DDI-DrugBank.d177.s1.e1	DDI-DrugBank.d177.s1.e2
DDI-DrugBank.d177.s2|a|The dosage of these drugs or others with a similar metabolism may need to be modified if they are administered concomitantly with nilutamide.
DDI-DrugBank.d177.s2	130	139	nilutamide	drug	DDI-DrugBank.d177.s2.e0
DDI-DrugBank.d177.s3|a|For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.
DDI-DrugBank.d177.s3	18	38	vitamin K antagonists	group	DDI-DrugBank.d177.s3.e0
DDI-DrugBank.d177.s3	76	85	nilutamide	drug	DDI-DrugBank.d177.s3.e1
DDI-DrugBank.d177.s3	167	187	vitamin K antagonists	group	DDI-DrugBank.d177.s3.e2
DDI-DrugBank.d177.s3	true	DDI-DrugBank.d177.s3.e0	DDI-DrugBank.d177.s3.e1
DDI-DrugBank.d177.s3	false	DDI-DrugBank.d177.s3.e0	DDI-DrugBank.d177.s3.e2
DDI-DrugBank.d177.s3	false	DDI-DrugBank.d177.s3.e1	DDI-DrugBank.d177.s3.e2
DDI-DrugBank.d310.s0|a|It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop .
DDI-DrugBank.d310.s0	55	78	calcium channel blockers	group	DDI-DrugBank.d310.s0.e0
DDI-DrugBank.d310.s0	117	123	Nimotop	brand	DDI-DrugBank.d310.s0.e1
DDI-DrugBank.d310.s0	true	DDI-DrugBank.d310.s0.e0	DDI-DrugBank.d310.s0.e1
DDI-DrugBank.d310.s1|a|In Europe, Nimotop  was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension;
DDI-DrugBank.d310.s1	11	17	Nimotop	brand	DDI-DrugBank.d310.s1.e0
DDI-DrugBank.d310.s1	73	98	antihypertensive compounds	group	DDI-DrugBank.d310.s1.e1
DDI-DrugBank.d310.s1	true	DDI-DrugBank.d310.s1.e0	DDI-DrugBank.d310.s1.e1
DDI-DrugBank.d310.s2|a|this phenomenon was not observed in North American clinical trials.
DDI-DrugBank.d310.s3|a|A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.
DDI-DrugBank.d310.s3	74	83	nimodipine	drug	DDI-DrugBank.d310.s3.e0
DDI-DrugBank.d310.s3	183	192	cimetidine	drug	DDI-DrugBank.d310.s3.e1
DDI-DrugBank.d310.s3	214	223	nimodipine	drug	DDI-DrugBank.d310.s3.e2
DDI-DrugBank.d310.s3	false	DDI-DrugBank.d310.s3.e0	DDI-DrugBank.d310.s3.e1
DDI-DrugBank.d310.s3	false	DDI-DrugBank.d310.s3.e0	DDI-DrugBank.d310.s3.e2
DDI-DrugBank.d310.s3	true	DDI-DrugBank.d310.s3.e1	DDI-DrugBank.d310.s3.e2
DDI-DrugBank.d310.s4|a|This effect may be mediated by the known inhibition of hepatic cytochrome P- 450 by cimetidine, which could decrease first pass metabolism of nimodipine.
DDI-DrugBank.d310.s4	84	93	cimetidine	drug	DDI-DrugBank.d310.s4.e0
DDI-DrugBank.d310.s4	142	151	nimodipine	drug	DDI-DrugBank.d310.s4.e1
DDI-DrugBank.d310.s4	false	DDI-DrugBank.d310.s4.e0	DDI-DrugBank.d310.s4.e1
DDI-DrugBank.d106.s0|a|A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.
DDI-DrugBank.d106.s0	40	50	nisoldipine	drug	DDI-DrugBank.d106.s0.e0
DDI-DrugBank.d106.s0	100	116	cimetidine 400 mg	drug	DDI-DrugBank.d106.s0.e1
DDI-DrugBank.d106.s0	true	DDI-DrugBank.d106.s0.e0	DDI-DrugBank.d106.s0.e1
DDI-DrugBank.d106.s1|a|Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).
DDI-DrugBank.d106.s1	0	9	Ranitidine	drug	DDI-DrugBank.d106.s1.e0
DDI-DrugBank.d106.s1	66	76	nisoldipine	drug	DDI-DrugBank.d106.s1.e1
DDI-DrugBank.d106.s1	false	DDI-DrugBank.d106.s1.e0	DDI-DrugBank.d106.s1.e1
DDI-DrugBank.d106.s2|a|No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.
DDI-DrugBank.d106.s2	37	68	histamine H2 receptor antagonist	group	DDI-DrugBank.d106.s2.e0
DDI-DrugBank.d106.s3|a|Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.
DDI-DrugBank.d106.s3	20	28	phenytoin	drug	DDI-DrugBank.d106.s3.e0
DDI-DrugBank.d106.s3	41	45	SULAR	brand	DDI-DrugBank.d106.s3.e1
DDI-DrugBank.d106.s3	89	99	nisoldipine	drug	DDI-DrugBank.d106.s3.e2
DDI-DrugBank.d106.s3	true	DDI-DrugBank.d106.s3.e0	DDI-DrugBank.d106.s3.e1
DDI-DrugBank.d106.s3	false	DDI-DrugBank.d106.s3.e0	DDI-DrugBank.d106.s3.e2
DDI-DrugBank.d106.s3	false	DDI-DrugBank.d106.s3.e1	DDI-DrugBank.d106.s3.e2
DDI-DrugBank.d106.s4|a|Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.
DDI-DrugBank.d106.s4	20	24	SULAR	brand	DDI-DrugBank.d106.s4.e0
DDI-DrugBank.d106.s4	31	39	phenytoin	drug	DDI-DrugBank.d106.s4.e1
DDI-DrugBank.d106.s4	103	118	antihypertensive	group	DDI-DrugBank.d106.s4.e2
DDI-DrugBank.d106.s4	true	DDI-DrugBank.d106.s4.e0	DDI-DrugBank.d106.s4.e1
DDI-DrugBank.d106.s4	false	DDI-DrugBank.d106.s4.e0	DDI-DrugBank.d106.s4.e2
DDI-DrugBank.d106.s4	false	DDI-DrugBank.d106.s4.e1	DDI-DrugBank.d106.s4.e2
DDI-DrugBank.d106.s5|a|Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.
DDI-DrugBank.d106.s5	37	47	nisoldipine	drug	DDI-DrugBank.d106.s5.e0
DDI-DrugBank.d106.s5	53	65	beta-blockers	group	DDI-DrugBank.d106.s5.e1
DDI-DrugBank.d106.s5	68	75	atenolol	drug	DDI-DrugBank.d106.s5.e2
DDI-DrugBank.d106.s5	78	88	propranolol	drug	DDI-DrugBank.d106.s5.e3
DDI-DrugBank.d106.s5	false	DDI-DrugBank.d106.s5.e0	DDI-DrugBank.d106.s5.e1
DDI-DrugBank.d106.s5	false	DDI-DrugBank.d106.s5.e0	DDI-DrugBank.d106.s5.e2
DDI-DrugBank.d106.s5	false	DDI-DrugBank.d106.s5.e0	DDI-DrugBank.d106.s5.e3
DDI-DrugBank.d106.s5	false	DDI-DrugBank.d106.s5.e1	DDI-DrugBank.d106.s5.e2
DDI-DrugBank.d106.s5	false	DDI-DrugBank.d106.s5.e1	DDI-DrugBank.d106.s5.e3
DDI-DrugBank.d106.s5	false	DDI-DrugBank.d106.s5.e2	DDI-DrugBank.d106.s5.e3
DDI-DrugBank.d106.s6|a|Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.
DDI-DrugBank.d106.s6	0	10	Propranolol	drug	DDI-DrugBank.d106.s6.e0
DDI-DrugBank.d106.s6	93	103	nisoldipine	drug	DDI-DrugBank.d106.s6.e1
DDI-DrugBank.d106.s6	true	DDI-DrugBank.d106.s6.e0	DDI-DrugBank.d106.s6.e1
DDI-DrugBank.d106.s7|a|The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.
DDI-DrugBank.d106.s7	29	33	SULAR	brand	DDI-DrugBank.d106.s7.e0
DDI-DrugBank.d106.s7	71	78	atenolol	drug	DDI-DrugBank.d106.s7.e1
DDI-DrugBank.d106.s7	109	124	antihypertensive	group	DDI-DrugBank.d106.s7.e2
DDI-DrugBank.d106.s7	true	DDI-DrugBank.d106.s7.e0	DDI-DrugBank.d106.s7.e1
DDI-DrugBank.d106.s7	false	DDI-DrugBank.d106.s7.e0	DDI-DrugBank.d106.s7.e2
DDI-DrugBank.d106.s7	false	DDI-DrugBank.d106.s7.e1	DDI-DrugBank.d106.s7.e2
DDI-DrugBank.d106.s8|a|Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
DDI-DrugBank.d106.s8	0	8	Quinidine	drug	DDI-DrugBank.d106.s8.e0
DDI-DrugBank.d106.s8	63	73	nisoldipine	drug	DDI-DrugBank.d106.s8.e1
DDI-DrugBank.d106.s8	true	DDI-DrugBank.d106.s8.e0	DDI-DrugBank.d106.s8.e1
DDI-DrugBank.d106.s9|a|The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.
DDI-DrugBank.d106.s9	60	70	nisoldipine	drug	DDI-DrugBank.d106.s9.e0
DDI-DrugBank.d106.s9	89	97	quinidine	drug	DDI-DrugBank.d106.s9.e1
DDI-DrugBank.d106.s9	true	DDI-DrugBank.d106.s9.e0	DDI-DrugBank.d106.s9.e1
DDI-DrugBank.d106.s10|a|This interaction was not accompanied by ECG changes and its clinical significance is not known.
DDI-DrugBank.d106.s11|a|No significant interactions were found between nisoldipine and warfarin or digoxin.
DDI-DrugBank.d106.s11	47	57	nisoldipine	drug	DDI-DrugBank.d106.s11.e0
DDI-DrugBank.d106.s11	63	70	warfarin	drug	DDI-DrugBank.d106.s11.e1
DDI-DrugBank.d106.s11	75	81	digoxin	drug	DDI-DrugBank.d106.s11.e2
DDI-DrugBank.d106.s11	false	DDI-DrugBank.d106.s11.e0	DDI-DrugBank.d106.s11.e1
DDI-DrugBank.d106.s11	false	DDI-DrugBank.d106.s11.e0	DDI-DrugBank.d106.s11.e2
DDI-DrugBank.d106.s11	false	DDI-DrugBank.d106.s11.e1	DDI-DrugBank.d106.s11.e2
DDI-DrugBank.d354.s0|a|Tizoxanide is highly bound to plasma protein ( 99.9%).
DDI-DrugBank.d354.s0	0	9	Tizoxanide	drug	DDI-DrugBank.d354.s0.e0
DDI-DrugBank.d354.s1|a|Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).
DDI-DrugBank.d354.s1	53	64	nitazoxanide	drug	DDI-DrugBank.d354.s1.e0
DDI-DrugBank.d354.s1	207	214	warfarin	drug	DDI-DrugBank.d354.s1.e1
DDI-DrugBank.d354.s1	true	DDI-DrugBank.d354.s1.e0	DDI-DrugBank.d354.s1.e1
DDI-DrugBank.d354.s2|a|In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.
DDI-DrugBank.d354.s2	51	60	tizoxanide	drug	DDI-DrugBank.d354.s2.e0
DDI-DrugBank.d354.s3|a|Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.
DDI-DrugBank.d354.s3	135	146	nitazoxanide	drug	DDI-DrugBank.d354.s3.e0
DDI-DrugBank.d183.s0|a|No formal drug-interaction studies have been performed, and a clinically significant interaction with other medications used in the treatment of hypoxic respiratory failure cannot be excluded based on the available data.
DDI-DrugBank.d183.s1|a|INOmax has been administered with tolazoline, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.
DDI-DrugBank.d183.s1	0	5	INOmax	brand	DDI-DrugBank.d183.s1.e0
DDI-DrugBank.d183.s1	34	43	tolazoline	drug	DDI-DrugBank.d183.s1.e1
DDI-DrugBank.d183.s1	46	53	dopamine	drug	DDI-DrugBank.d183.s1.e2
DDI-DrugBank.d183.s1	56	65	dobutamine	drug	DDI-DrugBank.d183.s1.e3
DDI-DrugBank.d183.s1	68	75	steroids	group	DDI-DrugBank.d183.s1.e4
DDI-DrugBank.d183.s1	78	87	surfactant	drug	DDI-DrugBank.d183.s1.e5
DDI-DrugBank.d183.s1	false	DDI-DrugBank.d183.s1.e0	DDI-DrugBank.d183.s1.e1
DDI-DrugBank.d183.s1	false	DDI-DrugBank.d183.s1.e0	DDI-DrugBank.d183.s1.e2
DDI-DrugBank.d183.s1	false	DDI-DrugBank.d183.s1.e0	DDI-DrugBank.d183.s1.e3
DDI-DrugBank.d183.s1	false	DDI-DrugBank.d183.s1.e0	DDI-DrugBank.d183.s1.e4
DDI-DrugBank.d183.s1	false	DDI-DrugBank.d183.s1.e0	DDI-DrugBank.d183.s1.e5
DDI-DrugBank.d183.s1	false	DDI-DrugBank.d183.s1.e1	DDI-DrugBank.d183.s1.e2
DDI-DrugBank.d183.s1	false	DDI-DrugBank.d183.s1.e1	DDI-DrugBank.d183.s1.e3
DDI-DrugBank.d183.s1	false	DDI-DrugBank.d183.s1.e1	DDI-DrugBank.d183.s1.e4
DDI-DrugBank.d183.s1	false	DDI-DrugBank.d183.s1.e1	DDI-DrugBank.d183.s1.e5
DDI-DrugBank.d183.s1	false	DDI-DrugBank.d183.s1.e2	DDI-DrugBank.d183.s1.e3
DDI-DrugBank.d183.s2|a|Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
DDI-DrugBank.d183.s2	62	89	nitric oxide donor compounds	group	DDI-DrugBank.d183.s2.e0
DDI-DrugBank.d183.s2	102	121	sodium nitroprusside	drug	DDI-DrugBank.d183.s2.e1
DDI-DrugBank.d183.s2	127	139	nitroglycerin	drug	DDI-DrugBank.d183.s2.e2
DDI-DrugBank.d183.s2	175	180	INOmax	brand	DDI-DrugBank.d183.s2.e3
DDI-DrugBank.d183.s2	false	DDI-DrugBank.d183.s2.e0	DDI-DrugBank.d183.s2.e1
DDI-DrugBank.d183.s2	false	DDI-DrugBank.d183.s2.e0	DDI-DrugBank.d183.s2.e2
DDI-DrugBank.d183.s2	true	DDI-DrugBank.d183.s2.e0	DDI-DrugBank.d183.s2.e3
DDI-DrugBank.d183.s2	false	DDI-DrugBank.d183.s2.e1	DDI-DrugBank.d183.s2.e2
DDI-DrugBank.d183.s2	true	DDI-DrugBank.d183.s2.e1	DDI-DrugBank.d183.s2.e3
DDI-DrugBank.d183.s2	true	DDI-DrugBank.d183.s2.e2	DDI-DrugBank.d183.s2.e3
DDI-DrugBank.d183.s3|a|An association between prilocaine and an increased risk of methaemoglobinaemia, particularly in infants, has specifically been described in a literature case report.
DDI-DrugBank.d183.s3	23	32	prilocaine	drug	DDI-DrugBank.d183.s3.e0
DDI-DrugBank.d183.s4|a|This risk is present whether the drugs are administered as oral, parenteral, or topical formulations.
DDI-DrugBank.d276.s0|a|Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
DDI-DrugBank.d276.s0	0	7	Antacids	group	DDI-DrugBank.d276.s0.e0
DDI-DrugBank.d276.s0	20	40	magnesium trisilicate	drug	DDI-DrugBank.d276.s0.e1
DDI-DrugBank.d276.s0	80	93	nitrofurantoin	drug	DDI-DrugBank.d276.s0.e2
DDI-DrugBank.d276.s0	false	DDI-DrugBank.d276.s0.e0	DDI-DrugBank.d276.s0.e1
DDI-DrugBank.d276.s0	false	DDI-DrugBank.d276.s0.e0	DDI-DrugBank.d276.s0.e2
DDI-DrugBank.d276.s0	true	DDI-DrugBank.d276.s0.e1	DDI-DrugBank.d276.s0.e2
DDI-DrugBank.d276.s1|a|The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.
DDI-DrugBank.d276.s1	61	74	nitrofurantoin	drug	DDI-DrugBank.d276.s1.e0
DDI-DrugBank.d276.s1	96	116	magnesium trisilicate	drug	DDI-DrugBank.d276.s1.e1
DDI-DrugBank.d276.s1	true	DDI-DrugBank.d276.s1.e0	DDI-DrugBank.d276.s1.e1
DDI-DrugBank.d276.s2|a|Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
DDI-DrugBank.d276.s2	0	15	Uricosuric drugs	group	DDI-DrugBank.d276.s2.e0
DDI-DrugBank.d276.s2	26	35	probenecid	drug	DDI-DrugBank.d276.s2.e1
DDI-DrugBank.d276.s2	41	54	sulfinpyrazone	drug	DDI-DrugBank.d276.s2.e2
DDI-DrugBank.d276.s2	96	109	nitrofurantoin	drug	DDI-DrugBank.d276.s2.e3
DDI-DrugBank.d276.s2	false	DDI-DrugBank.d276.s2.e0	DDI-DrugBank.d276.s2.e1
DDI-DrugBank.d276.s2	false	DDI-DrugBank.d276.s2.e0	DDI-DrugBank.d276.s2.e2
DDI-DrugBank.d276.s2	true	DDI-DrugBank.d276.s2.e0	DDI-DrugBank.d276.s2.e3
DDI-DrugBank.d276.s2	false	DDI-DrugBank.d276.s2.e1	DDI-DrugBank.d276.s2.e2
DDI-DrugBank.d276.s2	true	DDI-DrugBank.d276.s2.e1	DDI-DrugBank.d276.s2.e3
DDI-DrugBank.d276.s2	true	DDI-DrugBank.d276.s2.e2	DDI-DrugBank.d276.s2.e3
DDI-DrugBank.d276.s3|a|The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.
DDI-DrugBank.d276.s3	26	39	nitrofurantoin	drug	DDI-DrugBank.d276.s3.e0
DDI-DrugBank.d276.s3	155	167	antibacterial	group	DDI-DrugBank.d276.s3.e1
DDI-DrugBank.d276.s3	false	DDI-DrugBank.d276.s3.e0	DDI-DrugBank.d276.s3.e1
DDI-DrugBank.d276.s4|a|Drug/Laboratory Test Interactions As a result of the presence of nitrofurantoin, a false-positive reaction for glucose in the urine may occur.
DDI-DrugBank.d276.s4	65	78	nitrofurantoin	drug	DDI-DrugBank.d276.s4.e0
DDI-DrugBank.d276.s5|a|This has been observed with Benedict s and Fehling s solutions but not with the glucose enzymatic test.
DDI-DrugBank.d14.s0|a|The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.
DDI-DrugBank.d14.s0	28	40	nitroglycerin	drug	DDI-DrugBank.d14.s0.e0
DDI-DrugBank.d14.s0	78	89	vasodilators	group	DDI-DrugBank.d14.s0.e1
DDI-DrugBank.d14.s0	true	DDI-DrugBank.d14.s0.e0	DDI-DrugBank.d14.s0.e1
DDI-DrugBank.d14.s1|a|Alcohol, in particular, has been found to exhibit additive effects of this variety.
DDI-DrugBank.d14.s1	0	6	Alcohol	drug	DDI-DrugBank.d14.s1.e0
DDI-DrugBank.d14.s2|a|Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
DDI-DrugBank.d14.s2	66	89	calcium channel blockers	group	DDI-DrugBank.d14.s2.e0
DDI-DrugBank.d14.s2	103	110	nitrates	group	DDI-DrugBank.d14.s2.e1
DDI-DrugBank.d14.s2	true	DDI-DrugBank.d14.s2.e0	DDI-DrugBank.d14.s2.e1
DDI-DrugBank.d14.s3|a|Dose adjustments of either class of agents may be necessary.
DDI-DrugBank.d394.s0|a|The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
DDI-DrugBank.d394.s0	26	45	sodium nitroprusside	drug	DDI-DrugBank.d394.s0.e0
DDI-DrugBank.d394.s0	82	98	hypotensive drugs	group	DDI-DrugBank.d394.s0.e1
DDI-DrugBank.d394.s0	111	136	ganglionic blocking agents	group	DDI-DrugBank.d394.s0.e2
DDI-DrugBank.d394.s0	178	188	anesthetics	group	DDI-DrugBank.d394.s0.e3
DDI-DrugBank.d394.s0	true	DDI-DrugBank.d394.s0.e0	DDI-DrugBank.d394.s0.e1
DDI-DrugBank.d394.s0	true	DDI-DrugBank.d394.s0.e0	DDI-DrugBank.d394.s0.e2
DDI-DrugBank.d394.s0	true	DDI-DrugBank.d394.s0.e0	DDI-DrugBank.d394.s0.e3
DDI-DrugBank.d394.s0	false	DDI-DrugBank.d394.s0.e1	DDI-DrugBank.d394.s0.e2
DDI-DrugBank.d394.s0	false	DDI-DrugBank.d394.s0.e1	DDI-DrugBank.d394.s0.e3
DDI-DrugBank.d394.s0	false	DDI-DrugBank.d394.s0.e2	DDI-DrugBank.d394.s0.e3
DDI-DrugBank.d475.s0|a|No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.
DDI-DrugBank.d475.s0	43	52	nizatidine	drug	DDI-DrugBank.d475.s0.e0
DDI-DrugBank.d475.s0	58	69	theophylline	drug	DDI-DrugBank.d475.s0.e1
DDI-DrugBank.d475.s0	72	87	chlordiazepoxide	drug	DDI-DrugBank.d475.s0.e2
DDI-DrugBank.d475.s0	90	98	lorazepam	drug	DDI-DrugBank.d475.s0.e3
DDI-DrugBank.d475.s0	101	109	lidocaine	drug	DDI-DrugBank.d475.s0.e4
DDI-DrugBank.d475.s0	112	120	phenytoin	drug	DDI-DrugBank.d475.s0.e5
DDI-DrugBank.d475.s0	127	134	warfarin	drug	DDI-DrugBank.d475.s0.e6
DDI-DrugBank.d475.s0	false	DDI-DrugBank.d475.s0.e0	DDI-DrugBank.d475.s0.e1
DDI-DrugBank.d475.s0	false	DDI-DrugBank.d475.s0.e0	DDI-DrugBank.d475.s0.e2
DDI-DrugBank.d475.s0	false	DDI-DrugBank.d475.s0.e0	DDI-DrugBank.d475.s0.e3
DDI-DrugBank.d475.s0	false	DDI-DrugBank.d475.s0.e0	DDI-DrugBank.d475.s0.e4
DDI-DrugBank.d475.s0	false	DDI-DrugBank.d475.s0.e0	DDI-DrugBank.d475.s0.e5
DDI-DrugBank.d475.s0	false	DDI-DrugBank.d475.s0.e0	DDI-DrugBank.d475.s0.e6
DDI-DrugBank.d475.s0	false	DDI-DrugBank.d475.s0.e1	DDI-DrugBank.d475.s0.e2
DDI-DrugBank.d475.s0	false	DDI-DrugBank.d475.s0.e1	DDI-DrugBank.d475.s0.e3
DDI-DrugBank.d475.s0	false	DDI-DrugBank.d475.s0.e1	DDI-DrugBank.d475.s0.e4
DDI-DrugBank.d475.s0	false	DDI-DrugBank.d475.s0.e1	DDI-DrugBank.d475.s0.e5
DDI-DrugBank.d475.s1|a|Nizatidine does not inhibit the cytochrome P-450-linked drug-metabolizing enzyme system;
DDI-DrugBank.d475.s1	0	9	Nizatidine	drug	DDI-DrugBank.d475.s1.e0
DDI-DrugBank.d475.s2|a|therefore, drug interactions mediated by inhibition of hepatic metabolism are not expected to occur.
DDI-DrugBank.d475.s3|a|In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
DDI-DrugBank.d475.s3	47	53	aspirin	brand	DDI-DrugBank.d475.s3.e0
DDI-DrugBank.d475.s3	81	90	salicylate	group	DDI-DrugBank.d475.s3.e1
DDI-DrugBank.d475.s3	114	123	nizatidine	drug	DDI-DrugBank.d475.s3.e2
DDI-DrugBank.d475.s3	false	DDI-DrugBank.d475.s3.e0	DDI-DrugBank.d475.s3.e1
DDI-DrugBank.d475.s3	true	DDI-DrugBank.d475.s3.e0	DDI-DrugBank.d475.s3.e2
DDI-DrugBank.d475.s3	false	DDI-DrugBank.d475.s3.e1	DDI-DrugBank.d475.s3.e2
DDI-DrugBank.d306.s0|a|The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
DDI-DrugBank.d306.s0	21	29	progestin	group	DDI-DrugBank.d306.s0.e0
DDI-DrugBank.d306.s0	98	112	anticonvulsants	group	DDI-DrugBank.d306.s0.e1
DDI-DrugBank.d306.s0	114	122	phenytoin	drug	DDI-DrugBank.d306.s0.e2
DDI-DrugBank.d306.s0	125	137	carbamazepine	drug	DDI-DrugBank.d306.s0.e3
DDI-DrugBank.d306.s0	144	155	barbiturates	group	DDI-DrugBank.d306.s0.e4
DDI-DrugBank.d306.s0	166	186	antituberculosis drug	group	DDI-DrugBank.d306.s0.e5
DDI-DrugBank.d306.s0	188	195	rifampin	drug	DDI-DrugBank.d306.s0.e6
DDI-DrugBank.d306.s0	false	DDI-DrugBank.d306.s0.e0	DDI-DrugBank.d306.s0.e1
DDI-DrugBank.d306.s0	true	DDI-DrugBank.d306.s0.e0	DDI-DrugBank.d306.s0.e2
DDI-DrugBank.d306.s0	true	DDI-DrugBank.d306.s0.e0	DDI-DrugBank.d306.s0.e3
DDI-DrugBank.d306.s0	true	DDI-DrugBank.d306.s0.e0	DDI-DrugBank.d306.s0.e4
DDI-DrugBank.d306.s0	false	DDI-DrugBank.d306.s0.e0	DDI-DrugBank.d306.s0.e5
DDI-DrugBank.d306.s0	true	DDI-DrugBank.d306.s0.e0	DDI-DrugBank.d306.s0.e6
DDI-DrugBank.d306.s0	false	DDI-DrugBank.d306.s0.e1	DDI-DrugBank.d306.s0.e2
DDI-DrugBank.d306.s0	false	DDI-DrugBank.d306.s0.e1	DDI-DrugBank.d306.s0.e3
DDI-DrugBank.d306.s0	false	DDI-DrugBank.d306.s0.e1	DDI-DrugBank.d306.s0.e4
DDI-DrugBank.d306.s0	false	DDI-DrugBank.d306.s0.e1	DDI-DrugBank.d306.s0.e5
DDI-DrugBank.d306.s1|a|No significant interaction has been found with broad-spectrum antibiotics.
DDI-DrugBank.d306.s1	62	72	antibiotics	group	DDI-DrugBank.d306.s1.e0
DDI-DrugBank.d217.s0|a|Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
DDI-DrugBank.d217.s0	26	37	theophylline	drug	DDI-DrugBank.d217.s0.e0
DDI-DrugBank.d217.s0	75	83	quinolone	group	DDI-DrugBank.d217.s0.e1
DDI-DrugBank.d217.s0	true	DDI-DrugBank.d217.s0.e0	DDI-DrugBank.d217.s0.e1
DDI-DrugBank.d217.s1|a|There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.
DDI-DrugBank.d217.s1	27	38	theophylline	drug	DDI-DrugBank.d217.s1.e0
DDI-DrugBank.d217.s1	101	111	norfloxacin	drug	DDI-DrugBank.d217.s1.e1
DDI-DrugBank.d217.s1	117	128	theophylline	drug	DDI-DrugBank.d217.s1.e2
DDI-DrugBank.d217.s1	false	DDI-DrugBank.d217.s1.e0	DDI-DrugBank.d217.s1.e1
DDI-DrugBank.d217.s1	false	DDI-DrugBank.d217.s1.e0	DDI-DrugBank.d217.s1.e2
DDI-DrugBank.d217.s1	true	DDI-DrugBank.d217.s1.e1	DDI-DrugBank.d217.s1.e2
DDI-DrugBank.d217.s2|a|Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
DDI-DrugBank.d217.s2	25	36	theophylline	drug	DDI-DrugBank.d217.s2.e0
DDI-DrugBank.d217.s2	87	98	theophylline	drug	DDI-DrugBank.d217.s2.e1
DDI-DrugBank.d217.s2	false	DDI-DrugBank.d217.s2.e0	DDI-DrugBank.d217.s2.e1
DDI-DrugBank.d217.s3|a|Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.
DDI-DrugBank.d217.s3	25	36	cyclosporine	drug	DDI-DrugBank.d217.s3.e0
DDI-DrugBank.d217.s3	81	92	cyclosporine	drug	DDI-DrugBank.d217.s3.e1
DDI-DrugBank.d217.s3	99	109	norfloxacin	drug	DDI-DrugBank.d217.s3.e2
DDI-DrugBank.d217.s3	false	DDI-DrugBank.d217.s3.e0	DDI-DrugBank.d217.s3.e1
DDI-DrugBank.d217.s3	false	DDI-DrugBank.d217.s3.e0	DDI-DrugBank.d217.s3.e2
DDI-DrugBank.d217.s3	true	DDI-DrugBank.d217.s3.e1	DDI-DrugBank.d217.s3.e2
DDI-DrugBank.d217.s4|a|Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.
DDI-DrugBank.d217.s4	11	22	cyclosporine	drug	DDI-DrugBank.d217.s4.e0
DDI-DrugBank.d217.s4	73	84	cyclosporine	drug	DDI-DrugBank.d217.s4.e1
DDI-DrugBank.d217.s4	false	DDI-DrugBank.d217.s4.e0	DDI-DrugBank.d217.s4.e1
DDI-DrugBank.d217.s5|a|Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
DDI-DrugBank.d217.s5	0	9	Quinolones	group	DDI-DrugBank.d217.s5.e0
DDI-DrugBank.d217.s5	22	32	norfloxacin	drug	DDI-DrugBank.d217.s5.e1
DDI-DrugBank.d217.s5	67	80	anticoagulants	group	DDI-DrugBank.d217.s5.e2
DDI-DrugBank.d217.s5	93	100	warfarin	drug	DDI-DrugBank.d217.s5.e3
DDI-DrugBank.d217.s5	false	DDI-DrugBank.d217.s5.e0	DDI-DrugBank.d217.s5.e1
DDI-DrugBank.d217.s5	true	DDI-DrugBank.d217.s5.e0	DDI-DrugBank.d217.s5.e2
DDI-DrugBank.d217.s5	true	DDI-DrugBank.d217.s5.e0	DDI-DrugBank.d217.s5.e3
DDI-DrugBank.d217.s5	true	DDI-DrugBank.d217.s5.e1	DDI-DrugBank.d217.s5.e2
DDI-DrugBank.d217.s5	true	DDI-DrugBank.d217.s5.e1	DDI-DrugBank.d217.s5.e3
DDI-DrugBank.d217.s5	false	DDI-DrugBank.d217.s5.e2	DDI-DrugBank.d217.s5.e3
DDI-DrugBank.d217.s6|a|When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored.
DDI-DrugBank.d217.s7|a|The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
DDI-DrugBank.d217.s7	34	43	quinolones	group	DDI-DrugBank.d217.s7.e0
DDI-DrugBank.d217.s7	55	65	norfloxacin	drug	DDI-DrugBank.d217.s7.e1
DDI-DrugBank.d217.s7	72	80	glyburide	drug	DDI-DrugBank.d217.s7.e2
DDI-DrugBank.d217.s7	85	102	sulfonylurea agent	group	DDI-DrugBank.d217.s7.e3
DDI-DrugBank.d217.s7	false	DDI-DrugBank.d217.s7.e0	DDI-DrugBank.d217.s7.e1
DDI-DrugBank.d217.s7	true	DDI-DrugBank.d217.s7.e0	DDI-DrugBank.d217.s7.e2
DDI-DrugBank.d217.s7	false	DDI-DrugBank.d217.s7.e0	DDI-DrugBank.d217.s7.e3
DDI-DrugBank.d217.s7	true	DDI-DrugBank.d217.s7.e1	DDI-DrugBank.d217.s7.e2
DDI-DrugBank.d217.s7	false	DDI-DrugBank.d217.s7.e1	DDI-DrugBank.d217.s7.e3
DDI-DrugBank.d217.s7	false	DDI-DrugBank.d217.s7.e2	DDI-DrugBank.d217.s7.e3
DDI-DrugBank.d217.s8|a|Therefore, monitoring of blood glucose is recommended when these agents are co-administered.
DDI-DrugBank.d217.s9|a|Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.
DDI-DrugBank.d217.s9	32	42	norfloxacin	drug	DDI-DrugBank.d217.s9.e0
DDI-DrugBank.d217.s9	103	112	probenecid	drug	DDI-DrugBank.d217.s9.e1
DDI-DrugBank.d217.s9	118	128	norfloxacin	drug	DDI-DrugBank.d217.s9.e2
DDI-DrugBank.d217.s9	false	DDI-DrugBank.d217.s9.e0	DDI-DrugBank.d217.s9.e1
DDI-DrugBank.d217.s9	false	DDI-DrugBank.d217.s9.e0	DDI-DrugBank.d217.s9.e2
DDI-DrugBank.d217.s9	true	DDI-DrugBank.d217.s9.e1	DDI-DrugBank.d217.s9.e2
DDI-DrugBank.d217.s10|a|The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.
DDI-DrugBank.d217.s10	23	36	nitrofurantoin	drug	DDI-DrugBank.d217.s10.e0
DDI-DrugBank.d217.s10	63	76	nitrofurantoin	drug	DDI-DrugBank.d217.s10.e1
DDI-DrugBank.d217.s10	121	131	Norfloxacin	drug	DDI-DrugBank.d217.s10.e2
DDI-DrugBank.d217.s10	false	DDI-DrugBank.d217.s10.e0	DDI-DrugBank.d217.s10.e1
DDI-DrugBank.d217.s10	false	DDI-DrugBank.d217.s10.e0	DDI-DrugBank.d217.s10.e2
DDI-DrugBank.d217.s10	true	DDI-DrugBank.d217.s10.e1	DDI-DrugBank.d217.s10.e2
DDI-DrugBank.d217.s11|a|Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s11	0	12	Multivitamins	group	DDI-DrugBank.d217.s11.e0
DDI-DrugBank.d217.s11	44	47	iron	drug	DDI-DrugBank.d217.s11.e1
DDI-DrugBank.d217.s11	52	55	zinc	drug	DDI-DrugBank.d217.s11.e2
DDI-DrugBank.d217.s11	58	65	antacids	group	DDI-DrugBank.d217.s11.e3
DDI-DrugBank.d217.s11	70	79	sucralfate	drug	DDI-DrugBank.d217.s11.e4
DDI-DrugBank.d217.s11	172	182	norfloxacin	drug	DDI-DrugBank.d217.s11.e5
DDI-DrugBank.d217.s11	273	283	norfloxacin	drug	DDI-DrugBank.d217.s11.e6
DDI-DrugBank.d217.s11	false	DDI-DrugBank.d217.s11.e0	DDI-DrugBank.d217.s11.e1
DDI-DrugBank.d217.s11	false	DDI-DrugBank.d217.s11.e0	DDI-DrugBank.d217.s11.e2
DDI-DrugBank.d217.s11	false	DDI-DrugBank.d217.s11.e0	DDI-DrugBank.d217.s11.e3
DDI-DrugBank.d217.s11	false	DDI-DrugBank.d217.s11.e0	DDI-DrugBank.d217.s11.e4
DDI-DrugBank.d217.s11	true	DDI-DrugBank.d217.s11.e0	DDI-DrugBank.d217.s11.e5
DDI-DrugBank.d217.s11	false	DDI-DrugBank.d217.s11.e0	DDI-DrugBank.d217.s11.e6
DDI-DrugBank.d217.s11	false	DDI-DrugBank.d217.s11.e1	DDI-DrugBank.d217.s11.e2
DDI-DrugBank.d217.s11	false	DDI-DrugBank.d217.s11.e1	DDI-DrugBank.d217.s11.e3
DDI-DrugBank.d217.s11	false	DDI-DrugBank.d217.s11.e1	DDI-DrugBank.d217.s11.e4
DDI-DrugBank.d217.s11	true	DDI-DrugBank.d217.s11.e1	DDI-DrugBank.d217.s11.e5
DDI-DrugBank.d217.s12|a|Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s12	0	4	Videx	brand	DDI-DrugBank.d217.s12.e0
DDI-DrugBank.d217.s12	7	16	Didanosine	drug	DDI-DrugBank.d217.s12.e1
DDI-DrugBank.d217.s12	178	188	norfloxacin	drug	DDI-DrugBank.d217.s12.e2
DDI-DrugBank.d217.s12	289	299	norfloxacin	drug	DDI-DrugBank.d217.s12.e3
DDI-DrugBank.d217.s12	false	DDI-DrugBank.d217.s12.e0	DDI-DrugBank.d217.s12.e1
DDI-DrugBank.d217.s12	true	DDI-DrugBank.d217.s12.e0	DDI-DrugBank.d217.s12.e2
DDI-DrugBank.d217.s12	false	DDI-DrugBank.d217.s12.e0	DDI-DrugBank.d217.s12.e3
DDI-DrugBank.d217.s12	true	DDI-DrugBank.d217.s12.e1	DDI-DrugBank.d217.s12.e2
DDI-DrugBank.d217.s12	false	DDI-DrugBank.d217.s12.e1	DDI-DrugBank.d217.s12.e3
DDI-DrugBank.d217.s12	false	DDI-DrugBank.d217.s12.e2	DDI-DrugBank.d217.s12.e3
DDI-DrugBank.d217.s13|a|Some quinolones have also been shown to interfere with the metabolism of caffeine.
DDI-DrugBank.d217.s13	5	14	quinolones	group	DDI-DrugBank.d217.s13.e0
DDI-DrugBank.d217.s13	73	80	caffeine	drug	DDI-DrugBank.d217.s13.e1
DDI-DrugBank.d217.s13	true	DDI-DrugBank.d217.s13.e0	DDI-DrugBank.d217.s13.e1
DDI-DrugBank.d217.s14|a|This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.
DDI-DrugBank.d217.s14	38	45	caffeine	drug	DDI-DrugBank.d217.s14.e0
DDI-DrugBank.d360.s0|a|Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin.
DDI-DrugBank.d360.s0	140	147	rifampin	drug	DDI-DrugBank.d360.s0.e0
DDI-DrugBank.d360.s1|a|A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.
DDI-DrugBank.d360.s1	67	78	barbiturates	group	DDI-DrugBank.d360.s1.e0
DDI-DrugBank.d360.s1	81	94	phenylbutazone	drug	DDI-DrugBank.d360.s1.e1
DDI-DrugBank.d360.s1	97	112	phenytoin sodium	drug	DDI-DrugBank.d360.s1.e2
DDI-DrugBank.d360.s1	115	127	carbamazepine	drug	DDI-DrugBank.d360.s1.e3
DDI-DrugBank.d360.s1	130	141	griseofulvin	drug	DDI-DrugBank.d360.s1.e4
DDI-DrugBank.d360.s1	144	153	topiramate	drug	DDI-DrugBank.d360.s1.e5
DDI-DrugBank.d360.s1	174	183	ampicillin	drug	DDI-DrugBank.d360.s1.e6
DDI-DrugBank.d360.s1	189	201	tetracyclines	group	DDI-DrugBank.d360.s1.e7
DDI-DrugBank.d360.s1	false	DDI-DrugBank.d360.s1.e0	DDI-DrugBank.d360.s1.e1
DDI-DrugBank.d360.s1	false	DDI-DrugBank.d360.s1.e0	DDI-DrugBank.d360.s1.e2
DDI-DrugBank.d360.s1	false	DDI-DrugBank.d360.s1.e0	DDI-DrugBank.d360.s1.e3
DDI-DrugBank.d360.s1	false	DDI-DrugBank.d360.s1.e0	DDI-DrugBank.d360.s1.e4
DDI-DrugBank.d360.s1	false	DDI-DrugBank.d360.s1.e0	DDI-DrugBank.d360.s1.e5
DDI-DrugBank.d360.s1	false	DDI-DrugBank.d360.s1.e0	DDI-DrugBank.d360.s1.e6
DDI-DrugBank.d360.s1	false	DDI-DrugBank.d360.s1.e0	DDI-DrugBank.d360.s1.e7
DDI-DrugBank.d360.s1	false	DDI-DrugBank.d360.s1.e1	DDI-DrugBank.d360.s1.e2
DDI-DrugBank.d360.s1	false	DDI-DrugBank.d360.s1.e1	DDI-DrugBank.d360.s1.e3
DDI-DrugBank.d360.s1	false	DDI-DrugBank.d360.s1.e1	DDI-DrugBank.d360.s1.e4
DDI-DrugBank.d360.s2|a|A possible interaction has been suggested with hormonal contraceptives and the herbal supplement St. Johns Wort based on some reports of oral contraceptive users experiencing breakthrough bleeding shortly after starting St. Johns Wort.
DDI-DrugBank.d360.s2	47	69	hormonal contraceptives	group	DDI-DrugBank.d360.s2.e0
DDI-DrugBank.d360.s2	142	154	contraceptive	group	DDI-DrugBank.d360.s2.e1
DDI-DrugBank.d360.s2	false	DDI-DrugBank.d360.s2.e0	DDI-DrugBank.d360.s2.e1
DDI-DrugBank.d360.s3|a|Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. Johns Wort.
DDI-DrugBank.d360.s3	43	74	combined hormonal contraceptives	group	DDI-DrugBank.d360.s3.e0
DDI-DrugBank.d360.s4|a|Healthcare prescribers are advised to consult the package inserts of medication administered concomitantly with oral contraceptives.
DDI-DrugBank.d360.s4	117	130	contraceptives	group	DDI-DrugBank.d360.s4.e0
DDI-DrugBank.d202.s0|a|Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.
DDI-DrugBank.d202.s0	37	61	tricyclic antidepressants	group	DDI-DrugBank.d202.s0.e0
DDI-DrugBank.d202.s0	108	117	cimetidine	drug	DDI-DrugBank.d202.s0.e1
DDI-DrugBank.d202.s0	true	DDI-DrugBank.d202.s0.e0	DDI-DrugBank.d202.s0.e1
DDI-DrugBank.d202.s1|a|Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.
DDI-DrugBank.d202.s1	147	171	tricyclic antidepressants	group	DDI-DrugBank.d202.s1.e0
DDI-DrugBank.d202.s1	178	187	cimetidine	drug	DDI-DrugBank.d202.s1.e1
DDI-DrugBank.d202.s1	true	DDI-DrugBank.d202.s1.e0	DDI-DrugBank.d202.s1.e1
DDI-DrugBank.d202.s2|a|In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.
DDI-DrugBank.d202.s2	71	95	tricyclic antidepressants	group	DDI-DrugBank.d202.s2.e0
DDI-DrugBank.d202.s2	169	178	cimetidine	drug	DDI-DrugBank.d202.s2.e1
DDI-DrugBank.d202.s2	true	DDI-DrugBank.d202.s2.e0	DDI-DrugBank.d202.s2.e1
DDI-DrugBank.d202.s3|a|In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.
DDI-DrugBank.d202.s3	63	72	cimetidine	drug	DDI-DrugBank.d202.s3.e0
DDI-DrugBank.d202.s3	130	154	tricyclic antidepressants	group	DDI-DrugBank.d202.s3.e1
DDI-DrugBank.d202.s3	true	DDI-DrugBank.d202.s3.e0	DDI-DrugBank.d202.s3.e1
DDI-DrugBank.d202.s4|a|The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.
DDI-DrugBank.d202.s4	28	52	tricyclic antidepressants	group	DDI-DrugBank.d202.s4.e0
DDI-DrugBank.d202.s4	96	105	cimetidine	drug	DDI-DrugBank.d202.s4.e1
DDI-DrugBank.d202.s4	true	DDI-DrugBank.d202.s4.e0	DDI-DrugBank.d202.s4.e1
DDI-DrugBank.d202.s5|a|Several of the tricyclic antidepressants have been cited in these reports.
DDI-DrugBank.d202.s5	15	39	tricyclic antidepressants	group	DDI-DrugBank.d202.s5.e0
DDI-DrugBank.d202.s6|a|There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.
DDI-DrugBank.d202.s6	90	104	antidepressants	group	DDI-DrugBank.d202.s6.e0
DDI-DrugBank.d202.s6	117	129	nortriptyline	drug	DDI-DrugBank.d202.s6.e1
DDI-DrugBank.d202.s6	137	160	fluoxetine hydrochloride	drug	DDI-DrugBank.d202.s6.e2
DDI-DrugBank.d202.s6	false	DDI-DrugBank.d202.s6.e0	DDI-DrugBank.d202.s6.e1
DDI-DrugBank.d202.s6	true	DDI-DrugBank.d202.s6.e0	DDI-DrugBank.d202.s6.e2
DDI-DrugBank.d202.s6	true	DDI-DrugBank.d202.s6.e1	DDI-DrugBank.d202.s6.e2
DDI-DrugBank.d202.s7|a|Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other.
DDI-DrugBank.d202.s7	0	9	Fluoxetine	drug	DDI-DrugBank.d202.s7.e0
DDI-DrugBank.d202.s7	93	105	norfluoxetine	drug_n	DDI-DrugBank.d202.s7.e1
DDI-DrugBank.d202.s7	false	DDI-DrugBank.d202.s7.e0	DDI-DrugBank.d202.s7.e1
DDI-DrugBank.d202.s8|a|Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.
DDI-DrugBank.d202.s8	18	26	reserpine	drug	DDI-DrugBank.d202.s8.e0
DDI-DrugBank.d202.s8	50	73	tricyclic antidepressant	group	DDI-DrugBank.d202.s8.e1
DDI-DrugBank.d202.s8	true	DDI-DrugBank.d202.s8.e0	DDI-DrugBank.d202.s8.e1
DDI-DrugBank.d202.s9|a|Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.
DDI-DrugBank.d202.s9	73	99	nortriptyline hydrochloride	drug	DDI-DrugBank.d202.s9.e0
DDI-DrugBank.d202.s9	120	140	anticholinergic drugs	group	DDI-DrugBank.d202.s9.e1
DDI-DrugBank.d202.s9	145	165	sympathomimetic drugs	group	DDI-DrugBank.d202.s9.e2
DDI-DrugBank.d202.s9	true	DDI-DrugBank.d202.s9.e0	DDI-DrugBank.d202.s9.e1
DDI-DrugBank.d202.s9	true	DDI-DrugBank.d202.s9.e0	DDI-DrugBank.d202.s9.e2
DDI-DrugBank.d202.s9	false	DDI-DrugBank.d202.s9.e1	DDI-DrugBank.d202.s9.e2
DDI-DrugBank.d202.s10|a|The patient should be informed that the response to alcohol may be exaggerated.
DDI-DrugBank.d202.s10	52	58	alcohol	drug	DDI-DrugBank.d202.s10.e0
DDI-DrugBank.d202.s11|a|Drugs Metabolized by P450IID6  A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6.
DDI-DrugBank.d202.s12|a|Such individuals are referred to as  poor metabolizers  of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants.
DDI-DrugBank.d202.s12	73	83	debrisoquin	drug	DDI-DrugBank.d202.s12.e0
DDI-DrugBank.d202.s12	86	101	dextromethorphan	drug	DDI-DrugBank.d202.s12.e1
DDI-DrugBank.d202.s12	112	136	tricyclic antidepressants	group	DDI-DrugBank.d202.s12.e2
DDI-DrugBank.d202.s12	false	DDI-DrugBank.d202.s12.e0	DDI-DrugBank.d202.s12.e1
DDI-DrugBank.d202.s12	false	DDI-DrugBank.d202.s12.e0	DDI-DrugBank.d202.s12.e2
DDI-DrugBank.d202.s12	false	DDI-DrugBank.d202.s12.e1	DDI-DrugBank.d202.s12.e2
DDI-DrugBank.d202.s13|a|These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses.
DDI-DrugBank.d202.s13	73	97	tricyclic antidepressants	group	DDI-DrugBank.d202.s13.e0
DDI-DrugBank.d202.s14|a|In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.
DDI-DrugBank.d202.s14	82	96	antidepressants	group	DDI-DrugBank.d202.s14.e0
DDI-DrugBank.d202.s14	99	123	tricyclic antidepressants	group	DDI-DrugBank.d202.s14.e1
DDI-DrugBank.d202.s14	126	164	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d202.s14.e2
DDI-DrugBank.d202.s14	false	DDI-DrugBank.d202.s14.e0	DDI-DrugBank.d202.s14.e1
DDI-DrugBank.d202.s14	false	DDI-DrugBank.d202.s14.e0	DDI-DrugBank.d202.s14.e2
DDI-DrugBank.d202.s14	false	DDI-DrugBank.d202.s14.e1	DDI-DrugBank.d202.s14.e2
DDI-DrugBank.d202.s15|a|Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
DDI-DrugBank.d202.s15	19	43	tricyclic antidepressants	group	DDI-DrugBank.d202.s15.e0
DDI-DrugBank.d202.s15	160	183	tricyclic antidepressant	group	DDI-DrugBank.d202.s15.e1
DDI-DrugBank.d202.s15	false	DDI-DrugBank.d202.s15.e0	DDI-DrugBank.d202.s15.e1
DDI-DrugBank.d202.s16|a|Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
DDI-DrugBank.d202.s16	32	56	tricyclic antidepressants	group	DDI-DrugBank.d202.s16.e0
DDI-DrugBank.d202.s16	131	145	antidepressants	group	DDI-DrugBank.d202.s16.e1
DDI-DrugBank.d202.s16	148	161	phenothiazines	group	DDI-DrugBank.d202.s16.e2
DDI-DrugBank.d202.s16	164	176	carbamazepine	drug	DDI-DrugBank.d202.s16.e3
DDI-DrugBank.d202.s16	183	205	Type 1C antiarrhythmics	group	DDI-DrugBank.d202.s16.e4
DDI-DrugBank.d202.s16	212	222	propafenone	drug	DDI-DrugBank.d202.s16.e5
DDI-DrugBank.d202.s16	225	234	flecainide	drug	DDI-DrugBank.d202.s16.e6
DDI-DrugBank.d202.s16	241	249	encainide	drug	DDI-DrugBank.d202.s16.e7
DDI-DrugBank.d202.s16	286	294	quinidine	drug	DDI-DrugBank.d202.s16.e8
DDI-DrugBank.d202.s16	true	DDI-DrugBank.d202.s16.e0	DDI-DrugBank.d202.s16.e1
DDI-DrugBank.d202.s16	true	DDI-DrugBank.d202.s16.e0	DDI-DrugBank.d202.s16.e2
DDI-DrugBank.d202.s16	true	DDI-DrugBank.d202.s16.e0	DDI-DrugBank.d202.s16.e3
DDI-DrugBank.d202.s16	true	DDI-DrugBank.d202.s16.e0	DDI-DrugBank.d202.s16.e4
DDI-DrugBank.d202.s16	true	DDI-DrugBank.d202.s16.e0	DDI-DrugBank.d202.s16.e5
DDI-DrugBank.d202.s16	true	DDI-DrugBank.d202.s16.e0	DDI-DrugBank.d202.s16.e6
DDI-DrugBank.d202.s16	true	DDI-DrugBank.d202.s16.e0	DDI-DrugBank.d202.s16.e7
DDI-DrugBank.d202.s16	true	DDI-DrugBank.d202.s16.e0	DDI-DrugBank.d202.s16.e8
DDI-DrugBank.d202.s16	false	DDI-DrugBank.d202.s16.e1	DDI-DrugBank.d202.s16.e2
DDI-DrugBank.d202.s16	false	DDI-DrugBank.d202.s16.e1	DDI-DrugBank.d202.s16.e3
DDI-DrugBank.d307.s0|a|Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4/5 with potentially important effects on plasma concentrations of other drugs.
DDI-DrugBank.d307.s0	0	12	Oxcarbazepine	drug	DDI-DrugBank.d307.s0.e0
DDI-DrugBank.d307.s1|a|In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.
DDI-DrugBank.d307.s1	21	23	AED	group	DDI-DrugBank.d307.s1.e0
DDI-DrugBank.d307.s1	99	111	oxcarbazepine	drug	DDI-DrugBank.d307.s1.e1
DDI-DrugBank.d307.s1	117	119	MHD	drug_n	DDI-DrugBank.d307.s1.e2
DDI-DrugBank.d307.s1	true	DDI-DrugBank.d307.s1.e0	DDI-DrugBank.d307.s1.e1
DDI-DrugBank.d307.s1	false	DDI-DrugBank.d307.s1.e0	DDI-DrugBank.d307.s1.e2
DDI-DrugBank.d307.s1	false	DDI-DrugBank.d307.s1.e1	DDI-DrugBank.d307.s1.e2
DDI-DrugBank.d307.s2|a|Oxcarbazepine was evaluated in human liver microsomes to determine its capacity to inhibit the major cytochrome P450 enzymes responsible for the metabolism of other drugs.
DDI-DrugBank.d307.s2	0	12	Oxcarbazepine	drug	DDI-DrugBank.d307.s2.e0
DDI-DrugBank.d307.s3|a|Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated (CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9 and CYP4A11) with the exception of CYP2C19 and CYP3A4/5.
DDI-DrugBank.d307.s3	25	37	oxcarbazepine	drug	DDI-DrugBank.d307.s3.e0
DDI-DrugBank.d307.s3	99	101	MHD	drug_n	DDI-DrugBank.d307.s3.e1
DDI-DrugBank.d307.s3	false	DDI-DrugBank.d307.s3.e0	DDI-DrugBank.d307.s3.e1
DDI-DrugBank.d307.s4|a|Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.
DDI-DrugBank.d307.s4	36	38	OXC	drug	DDI-DrugBank.d307.s4.e0
DDI-DrugBank.d307.s4	44	46	MHD	drug_n	DDI-DrugBank.d307.s4.e1
DDI-DrugBank.d307.s4	false	DDI-DrugBank.d307.s4.e0	DDI-DrugBank.d307.s4.e1
DDI-DrugBank.d307.s5|a|The inhibition of CYP-2C19 by OXC and MHD, however, is clinically relevant.
DDI-DrugBank.d307.s5	30	32	OXC	drug	DDI-DrugBank.d307.s5.e0
DDI-DrugBank.d307.s5	38	40	MHD	drug_n	DDI-DrugBank.d307.s5.e1
DDI-DrugBank.d307.s5	false	DDI-DrugBank.d307.s5.e0	DDI-DrugBank.d307.s5.e1
DDI-DrugBank.d307.s6|a|In vitro, the UDP-glucuronyl transferase level was increased, indicating induction of this enzyme.
DDI-DrugBank.d307.s7|a|Increases of 22% with MHD and 47% with oxcarbazepine were observed.
DDI-DrugBank.d307.s7	22	24	MHD	drug_n	DDI-DrugBank.d307.s7.e0
DDI-DrugBank.d307.s7	39	51	oxcarbazepine	drug	DDI-DrugBank.d307.s7.e1
DDI-DrugBank.d307.s7	false	DDI-DrugBank.d307.s7.e0	DDI-DrugBank.d307.s7.e1
DDI-DrugBank.d307.s8|a|As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid, lamotrigine).
DDI-DrugBank.d307.s8	3	5	MHD	drug_n	DDI-DrugBank.d307.s8.e0
DDI-DrugBank.d307.s8	222	234	valproic acid	drug	DDI-DrugBank.d307.s8.e1
DDI-DrugBank.d307.s8	237	247	lamotrigine	drug	DDI-DrugBank.d307.s8.e2
DDI-DrugBank.d307.s8	false	DDI-DrugBank.d307.s8.e0	DDI-DrugBank.d307.s8.e1
DDI-DrugBank.d307.s8	false	DDI-DrugBank.d307.s8.e0	DDI-DrugBank.d307.s8.e2
DDI-DrugBank.d307.s8	false	DDI-DrugBank.d307.s8.e1	DDI-DrugBank.d307.s8.e2
DDI-DrugBank.d307.s9|a|In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.
DDI-DrugBank.d307.s9	13	25	oxcarbazepine	drug	DDI-DrugBank.d307.s9.e0
DDI-DrugBank.d307.s9	31	33	MHD	drug_n	DDI-DrugBank.d307.s9.e1
DDI-DrugBank.d307.s9	140	174	dihydropyridine calcium antagonists	group	DDI-DrugBank.d307.s9.e2
DDI-DrugBank.d307.s9	185	198	contraceptives	group	DDI-DrugBank.d307.s9.e3
DDI-DrugBank.d307.s9	false	DDI-DrugBank.d307.s9.e0	DDI-DrugBank.d307.s9.e1
DDI-DrugBank.d307.s9	false	DDI-DrugBank.d307.s9.e0	DDI-DrugBank.d307.s9.e2
DDI-DrugBank.d307.s9	false	DDI-DrugBank.d307.s9.e0	DDI-DrugBank.d307.s9.e3
DDI-DrugBank.d307.s9	false	DDI-DrugBank.d307.s9.e1	DDI-DrugBank.d307.s9.e2
DDI-DrugBank.d307.s9	false	DDI-DrugBank.d307.s9.e1	DDI-DrugBank.d307.s9.e3
DDI-DrugBank.d307.s9	false	DDI-DrugBank.d307.s9.e2	DDI-DrugBank.d307.s9.e3
DDI-DrugBank.d307.s10|a|As binding of MHD to plasma proteins is low (40%), clinically significant interactions with other drugs through competition for protein binding sites are unlikely.
DDI-DrugBank.d307.s10	14	16	MHD	drug_n	DDI-DrugBank.d307.s10.e0
DDI-DrugBank.d307.s11|a|Antiepileptic drugs: Potential interactions between Trileptal and other AEDs were assessed in clinical studies.
DDI-DrugBank.d307.s11	0	18	Antiepileptic drugs	group	DDI-DrugBank.d307.s11.e0
DDI-DrugBank.d307.s11	52	60	Trileptal	brand	DDI-DrugBank.d307.s11.e1
DDI-DrugBank.d307.s11	72	75	AEDs	group	DDI-DrugBank.d307.s11.e2
DDI-DrugBank.d307.s11	false	DDI-DrugBank.d307.s11.e0	DDI-DrugBank.d307.s11.e1
DDI-DrugBank.d307.s11	false	DDI-DrugBank.d307.s11.e0	DDI-DrugBank.d307.s11.e2
DDI-DrugBank.d307.s11	false	DDI-DrugBank.d307.s11.e1	DDI-DrugBank.d307.s11.e2
DDI-DrugBank.d307.s12|a|The effect of these interactions on mean AUCs and Cmin are summarized in Table 2: Table 2: Summary of AED interactions with Trileptal
DDI-DrugBank.d307.s12	124	132	Trileptal	brand	DDI-DrugBank.d307.s12.e0
DDI-DrugBank.d307.s13|a|AED Co-administered
DDI-DrugBank.d307.s13	0	2	AED	group	DDI-DrugBank.d307.s13.e0
DDI-DrugBank.d307.s14|a|Dose of AED (mg/day)
DDI-DrugBank.d307.s14	8	10	AED	group	DDI-DrugBank.d307.s14.e0
DDI-DrugBank.d307.s15|a|Trileptal dose (mg/day)
DDI-DrugBank.d307.s15	0	8	Trileptal	brand	DDI-DrugBank.d307.s15.e0
DDI-DrugBank.d307.s16|a|Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval)
DDI-DrugBank.d307.s16	13	21	Trileptal	brand	DDI-DrugBank.d307.s16.e0
DDI-DrugBank.d307.s16	26	28	AED	group	DDI-DrugBank.d307.s16.e1
DDI-DrugBank.d307.s16	false	DDI-DrugBank.d307.s16.e0	DDI-DrugBank.d307.s16.e1
DDI-DrugBank.d307.s17|a|Influence of AED On MHD Concentration (Mean change, 90% Confidence Interval)
DDI-DrugBank.d307.s17	13	15	AED	group	DDI-DrugBank.d307.s17.e0
DDI-DrugBank.d307.s17	20	22	MHD	drug_n	DDI-DrugBank.d307.s17.e1
DDI-DrugBank.d307.s17	false	DDI-DrugBank.d307.s17.e0	DDI-DrugBank.d307.s17.e1
DDI-DrugBank.d307.s18|a|Carbamazepine
DDI-DrugBank.d307.s18	0	12	Carbamazepine	drug	DDI-DrugBank.d307.s18.e0
DDI-DrugBank.d307.s19|a|400-2000
DDI-DrugBank.d307.s20|a|900
DDI-DrugBank.d307.s21|a|nc1 40% decrease [CI: 17% decrease, 57% decrease]
DDI-DrugBank.d307.s22|a|Phenobarbital
DDI-DrugBank.d307.s22	0	12	Phenobarbital	drug	DDI-DrugBank.d307.s22.e0
DDI-DrugBank.d307.s23|a|100-150
DDI-DrugBank.d307.s24|a|600-1800
DDI-DrugBank.d307.s25|a|14% increase [CI: 2% increase, 24% increase] 25% decrease [CI: 12% decrease, 51% decrease]
DDI-DrugBank.d307.s26|a|Phenytoin
DDI-DrugBank.d307.s26	0	8	Phenytoin	drug	DDI-DrugBank.d307.s26.e0
DDI-DrugBank.d307.s27|a|250-500
DDI-DrugBank.d307.s28|a|600-1800
DDI-DrugBank.d307.s29|a|nc1,2 30% decrease [CI: 3% decrease, 48 % decrease]
DDI-DrugBank.d307.s30|a|1200-2400 up to 40% increase3 [CI: 12% increase, 60 % increase]
DDI-DrugBank.d307.s31|a|Valproic acid
DDI-DrugBank.d307.s31	0	12	Valproic acid	drug	DDI-DrugBank.d307.s31.e0
DDI-DrugBank.d307.s32|a|400-2800
DDI-DrugBank.d307.s33|a|600-1800
DDI-DrugBank.d307.s34|a|nc1 18% decrease [CI: 13% decrease, 40 % decrease]
DDI-DrugBank.d307.s35|a|1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.
DDI-DrugBank.d307.s35	94	102	Trileptal	brand	DDI-DrugBank.d307.s35.e0
DDI-DrugBank.d307.s35	140	148	phenytoin	drug	DDI-DrugBank.d307.s35.e1
DDI-DrugBank.d307.s35	179	187	Trileptal	brand	DDI-DrugBank.d307.s35.e2
DDI-DrugBank.d307.s35	false	DDI-DrugBank.d307.s35.e0	DDI-DrugBank.d307.s35.e1
DDI-DrugBank.d307.s35	false	DDI-DrugBank.d307.s35.e0	DDI-DrugBank.d307.s35.e2
DDI-DrugBank.d307.s35	true	DDI-DrugBank.d307.s35.e1	DDI-DrugBank.d307.s35.e2
DDI-DrugBank.d307.s36|a|Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.
DDI-DrugBank.d307.s36	31	39	Trileptal	brand	DDI-DrugBank.d307.s36.e0
DDI-DrugBank.d307.s36	119	127	phenytoin	drug	DDI-DrugBank.d307.s36.e1
DDI-DrugBank.d307.s36	true	DDI-DrugBank.d307.s36.e0	DDI-DrugBank.d307.s36.e1
DDI-DrugBank.d307.s37|a|The increase of phenobarbital level, however, is small (15%) when given with Trileptal.
DDI-DrugBank.d307.s37	16	28	phenobarbital	drug	DDI-DrugBank.d307.s37.e0
DDI-DrugBank.d307.s37	77	85	Trileptal	brand	DDI-DrugBank.d307.s37.e1
DDI-DrugBank.d307.s37	true	DDI-DrugBank.d307.s37.e0	DDI-DrugBank.d307.s37.e1
DDI-DrugBank.d307.s38|a|Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).
DDI-DrugBank.d307.s38	49	61	carbamazepine	drug	DDI-DrugBank.d307.s38.e0
DDI-DrugBank.d307.s38	64	72	phenytoin	drug	DDI-DrugBank.d307.s38.e1
DDI-DrugBank.d307.s38	78	90	phenobarbital	drug	DDI-DrugBank.d307.s38.e2
DDI-DrugBank.d307.s38	142	144	MHD	drug_n	DDI-DrugBank.d307.s38.e3
DDI-DrugBank.d307.s38	false	DDI-DrugBank.d307.s38.e0	DDI-DrugBank.d307.s38.e1
DDI-DrugBank.d307.s38	false	DDI-DrugBank.d307.s38.e0	DDI-DrugBank.d307.s38.e2
DDI-DrugBank.d307.s38	false	DDI-DrugBank.d307.s38.e0	DDI-DrugBank.d307.s38.e3
DDI-DrugBank.d307.s38	false	DDI-DrugBank.d307.s38.e1	DDI-DrugBank.d307.s38.e2
DDI-DrugBank.d307.s38	false	DDI-DrugBank.d307.s38.e1	DDI-DrugBank.d307.s38.e3
DDI-DrugBank.d307.s38	false	DDI-DrugBank.d307.s38.e2	DDI-DrugBank.d307.s38.e3
DDI-DrugBank.d307.s39|a|No autoinduction has been observed with Trileptal.
DDI-DrugBank.d307.s39	40	48	Trileptal	brand	DDI-DrugBank.d307.s39.e0
DDI-DrugBank.d307.s40|a|Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).
DDI-DrugBank.d307.s40	9	22	contraceptives	group	DDI-DrugBank.d307.s40.e0
DDI-DrugBank.d307.s40	45	53	Trileptal	brand	DDI-DrugBank.d307.s40.e1
DDI-DrugBank.d307.s40	68	80	contraceptive	group	DDI-DrugBank.d307.s40.e2
DDI-DrugBank.d307.s40	168	183	ethinylestradiol	drug	DDI-DrugBank.d307.s40.e3
DDI-DrugBank.d307.s40	194	207	levonorgestrel	drug	DDI-DrugBank.d307.s40.e4
DDI-DrugBank.d307.s40	false	DDI-DrugBank.d307.s40.e0	DDI-DrugBank.d307.s40.e1
DDI-DrugBank.d307.s40	false	DDI-DrugBank.d307.s40.e0	DDI-DrugBank.d307.s40.e2
DDI-DrugBank.d307.s40	false	DDI-DrugBank.d307.s40.e0	DDI-DrugBank.d307.s40.e3
DDI-DrugBank.d307.s40	false	DDI-DrugBank.d307.s40.e0	DDI-DrugBank.d307.s40.e4
DDI-DrugBank.d307.s40	true	DDI-DrugBank.d307.s40.e1	DDI-DrugBank.d307.s40.e2
DDI-DrugBank.d307.s40	false	DDI-DrugBank.d307.s40.e1	DDI-DrugBank.d307.s40.e3
DDI-DrugBank.d307.s40	false	DDI-DrugBank.d307.s40.e1	DDI-DrugBank.d307.s40.e4
DDI-DrugBank.d307.s40	false	DDI-DrugBank.d307.s40.e2	DDI-DrugBank.d307.s40.e3
DDI-DrugBank.d307.s40	false	DDI-DrugBank.d307.s40.e2	DDI-DrugBank.d307.s40.e4
DDI-DrugBank.d307.s40	false	DDI-DrugBank.d307.s40.e3	DDI-DrugBank.d307.s40.e4
DDI-DrugBank.d307.s41|a|The mean AUC values of EE were decreased by 48% [90% CI: 22-65] in one study and 52% [90% CI: 38-52] in another study [1,2].
DDI-DrugBank.d307.s42|a|The mean AUC values of LNG were decreased by 32% [90% CI: 20-45] in one study and 52% [90% CI: 42-52] in another study.
DDI-DrugBank.d307.s43|a|Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.
DDI-DrugBank.d307.s43	29	37	Trileptal	brand	DDI-DrugBank.d307.s43.e0
DDI-DrugBank.d307.s43	44	66	hormonal contraceptives	group	DDI-DrugBank.d307.s43.e1
DDI-DrugBank.d307.s43	85	98	contraceptives	group	DDI-DrugBank.d307.s43.e2
DDI-DrugBank.d307.s43	true	DDI-DrugBank.d307.s43.e0	DDI-DrugBank.d307.s43.e1
DDI-DrugBank.d307.s43	false	DDI-DrugBank.d307.s43.e0	DDI-DrugBank.d307.s43.e2
DDI-DrugBank.d307.s43	false	DDI-DrugBank.d307.s43.e1	DDI-DrugBank.d307.s43.e2
DDI-DrugBank.d307.s44|a|Studies with other oral or implant contraceptives have not been conducted.
DDI-DrugBank.d307.s44	35	48	contraceptives	group	DDI-DrugBank.d307.s44.e0
DDI-DrugBank.d307.s45|a|Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].
DDI-DrugBank.d307.s45	0	17	Calcium Antagonist	group	DDI-DrugBank.d307.s45.e0
DDI-DrugBank.d307.s45	57	65	Trileptal	brand	DDI-DrugBank.d307.s45.e1
DDI-DrugBank.d307.s45	79	88	felodipine	drug	DDI-DrugBank.d307.s45.e2
DDI-DrugBank.d307.s45	false	DDI-DrugBank.d307.s45.e0	DDI-DrugBank.d307.s45.e1
DDI-DrugBank.d307.s45	false	DDI-DrugBank.d307.s45.e0	DDI-DrugBank.d307.s45.e2
DDI-DrugBank.d307.s45	true	DDI-DrugBank.d307.s45.e1	DDI-DrugBank.d307.s45.e2
DDI-DrugBank.d307.s46|a|Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.
DDI-DrugBank.d307.s46	0	8	Verapamil	drug	DDI-DrugBank.d307.s46.e0
DDI-DrugBank.d307.s46	77	79	MHD	drug_n	DDI-DrugBank.d307.s46.e1
DDI-DrugBank.d307.s46	false	DDI-DrugBank.d307.s46.e0	DDI-DrugBank.d307.s46.e1
DDI-DrugBank.d307.s47|a|Other drug interactions Cimetidine, erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.
DDI-DrugBank.d307.s47	24	33	Cimetidine	drug	DDI-DrugBank.d307.s47.e0
DDI-DrugBank.d307.s47	36	47	erythromycin	drug	DDI-DrugBank.d307.s47.e1
DDI-DrugBank.d307.s47	53	70	dextropropoxyphene	drug	DDI-DrugBank.d307.s47.e2
DDI-DrugBank.d307.s47	113	115	MHD	drug_n	DDI-DrugBank.d307.s47.e3
DDI-DrugBank.d307.s47	false	DDI-DrugBank.d307.s47.e0	DDI-DrugBank.d307.s47.e1
DDI-DrugBank.d307.s47	false	DDI-DrugBank.d307.s47.e0	DDI-DrugBank.d307.s47.e2
DDI-DrugBank.d307.s47	false	DDI-DrugBank.d307.s47.e0	DDI-DrugBank.d307.s47.e3
DDI-DrugBank.d307.s47	false	DDI-DrugBank.d307.s47.e1	DDI-DrugBank.d307.s47.e2
DDI-DrugBank.d307.s47	false	DDI-DrugBank.d307.s47.e1	DDI-DrugBank.d307.s47.e3
DDI-DrugBank.d307.s47	false	DDI-DrugBank.d307.s47.e2	DDI-DrugBank.d307.s47.e3
DDI-DrugBank.d307.s48|a|Results with warfarin wshow no evidence of interaction with either single or repeated doses of Trileptal.
DDI-DrugBank.d307.s48	13	20	warfarin	drug	DDI-DrugBank.d307.s48.e0
DDI-DrugBank.d307.s48	95	103	Trileptal	brand	DDI-DrugBank.d307.s48.e1
DDI-DrugBank.d307.s48	false	DDI-DrugBank.d307.s48.e0	DDI-DrugBank.d307.s48.e1
DDI-DrugBank.d288.s0|a|In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).
DDI-DrugBank.d288.s0	45	49	TAXOL	brand	DDI-DrugBank.d288.s0.e0
DDI-DrugBank.d288.s0	71	79	cisplatin	drug	DDI-DrugBank.d288.s0.e1
DDI-DrugBank.d288.s0	169	173	TAXOL	brand	DDI-DrugBank.d288.s0.e2
DDI-DrugBank.d288.s0	191	199	cisplatin	drug	DDI-DrugBank.d288.s0.e3
DDI-DrugBank.d288.s0	239	243	TAXOL	brand	DDI-DrugBank.d288.s0.e4
DDI-DrugBank.d288.s0	252	260	cisplatin	drug	DDI-DrugBank.d288.s0.e5
DDI-DrugBank.d288.s0	false	DDI-DrugBank.d288.s0.e0	DDI-DrugBank.d288.s0.e1
DDI-DrugBank.d288.s0	false	DDI-DrugBank.d288.s0.e0	DDI-DrugBank.d288.s0.e2
DDI-DrugBank.d288.s0	false	DDI-DrugBank.d288.s0.e0	DDI-DrugBank.d288.s0.e3
DDI-DrugBank.d288.s0	false	DDI-DrugBank.d288.s0.e0	DDI-DrugBank.d288.s0.e4
DDI-DrugBank.d288.s0	false	DDI-DrugBank.d288.s0.e0	DDI-DrugBank.d288.s0.e5
DDI-DrugBank.d288.s0	false	DDI-DrugBank.d288.s0.e1	DDI-DrugBank.d288.s0.e2
DDI-DrugBank.d288.s0	false	DDI-DrugBank.d288.s0.e1	DDI-DrugBank.d288.s0.e3
DDI-DrugBank.d288.s0	false	DDI-DrugBank.d288.s0.e1	DDI-DrugBank.d288.s0.e4
DDI-DrugBank.d288.s0	false	DDI-DrugBank.d288.s0.e1	DDI-DrugBank.d288.s0.e5
DDI-DrugBank.d288.s0	true	DDI-DrugBank.d288.s0.e2	DDI-DrugBank.d288.s0.e3
DDI-DrugBank.d288.s1|a|Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.
DDI-DrugBank.d288.s1	68	77	paclitaxel	drug	DDI-DrugBank.d288.s1.e0
DDI-DrugBank.d288.s1	115	119	TAXOL	brand	DDI-DrugBank.d288.s1.e1
DDI-DrugBank.d288.s1	148	156	cisplatin	drug	DDI-DrugBank.d288.s1.e2
DDI-DrugBank.d288.s1	false	DDI-DrugBank.d288.s1.e0	DDI-DrugBank.d288.s1.e1
DDI-DrugBank.d288.s1	false	DDI-DrugBank.d288.s1.e0	DDI-DrugBank.d288.s1.e2
DDI-DrugBank.d288.s1	true	DDI-DrugBank.d288.s1.e1	DDI-DrugBank.d288.s1.e2
DDI-DrugBank.d288.s2|a|The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4.
DDI-DrugBank.d288.s2	18	22	TAXOL	brand	DDI-DrugBank.d288.s2.e0
DDI-DrugBank.d288.s3|a|In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4.
DDI-DrugBank.d288.s3	107	111	TAXOL	brand	DDI-DrugBank.d288.s3.e0
DDI-DrugBank.d288.s4|a|Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
DDI-DrugBank.d288.s4	31	35	TAXOL	brand	DDI-DrugBank.d288.s4.e0
DDI-DrugBank.d288.s4	65	83	protease inhibitors	group	DDI-DrugBank.d288.s4.e1
DDI-DrugBank.d288.s4	86	94	ritonavir	drug	DDI-DrugBank.d288.s4.e2
DDI-DrugBank.d288.s4	97	106	saquinavir	drug	DDI-DrugBank.d288.s4.e3
DDI-DrugBank.d288.s4	109	117	indinavir	drug	DDI-DrugBank.d288.s4.e4
DDI-DrugBank.d288.s4	124	133	nelfinavir	drug	DDI-DrugBank.d288.s4.e5
DDI-DrugBank.d288.s4	false	DDI-DrugBank.d288.s4.e0	DDI-DrugBank.d288.s4.e1
DDI-DrugBank.d288.s4	false	DDI-DrugBank.d288.s4.e0	DDI-DrugBank.d288.s4.e2
DDI-DrugBank.d288.s4	false	DDI-DrugBank.d288.s4.e0	DDI-DrugBank.d288.s4.e3
DDI-DrugBank.d288.s4	false	DDI-DrugBank.d288.s4.e0	DDI-DrugBank.d288.s4.e4
DDI-DrugBank.d288.s4	false	DDI-DrugBank.d288.s4.e0	DDI-DrugBank.d288.s4.e5
DDI-DrugBank.d288.s4	false	DDI-DrugBank.d288.s4.e1	DDI-DrugBank.d288.s4.e2
DDI-DrugBank.d288.s4	false	DDI-DrugBank.d288.s4.e1	DDI-DrugBank.d288.s4.e3
DDI-DrugBank.d288.s4	false	DDI-DrugBank.d288.s4.e1	DDI-DrugBank.d288.s4.e4
DDI-DrugBank.d288.s4	false	DDI-DrugBank.d288.s4.e1	DDI-DrugBank.d288.s4.e5
DDI-DrugBank.d288.s4	false	DDI-DrugBank.d288.s4.e2	DDI-DrugBank.d288.s4.e3
DDI-DrugBank.d288.s5|a|Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.
DDI-DrugBank.d288.s5	56	66	doxorubicin	drug	DDI-DrugBank.d288.s5.e0
DDI-DrugBank.d288.s5	95	107	doxorubicinol	drug_n	DDI-DrugBank.d288.s5.e1
DDI-DrugBank.d288.s5	132	141	paclitaxel	drug	DDI-DrugBank.d288.s5.e2
DDI-DrugBank.d288.s5	147	157	doxorubicin	drug	DDI-DrugBank.d288.s5.e3
DDI-DrugBank.d288.s5	false	DDI-DrugBank.d288.s5.e0	DDI-DrugBank.d288.s5.e1
DDI-DrugBank.d288.s5	false	DDI-DrugBank.d288.s5.e0	DDI-DrugBank.d288.s5.e2
DDI-DrugBank.d288.s5	false	DDI-DrugBank.d288.s5.e0	DDI-DrugBank.d288.s5.e3
DDI-DrugBank.d288.s5	false	DDI-DrugBank.d288.s5.e1	DDI-DrugBank.d288.s5.e2
DDI-DrugBank.d288.s5	false	DDI-DrugBank.d288.s5.e1	DDI-DrugBank.d288.s5.e3
DDI-DrugBank.d288.s5	true	DDI-DrugBank.d288.s5.e2	DDI-DrugBank.d288.s5.e3
DDI-DrugBank.d288.s6|a|Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3.
DDI-DrugBank.d288.s6	12	16	TAXOL	brand	DDI-DrugBank.d288.s6.e0
DDI-DrugBank.d288.s7|a|In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL.
DDI-DrugBank.d288.s7	153	157	TAXOL	brand	DDI-DrugBank.d288.s7.e0
DDI-DrugBank.d288.s8|a|Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level  1500 cells/mm3 and platelets recover to a level  100,000 cells/mm3.
DDI-DrugBank.d288.s8	60	64	TAXOL	brand	DDI-DrugBank.d288.s8.e0
DDI-DrugBank.d288.s9|a|In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended.
DDI-DrugBank.d288.s9	93	97	TAXOL	brand	DDI-DrugBank.d288.s9.e0
DDI-DrugBank.d288.s10|a|For patients with advanced HIV disease and poor-risk AIDS-related Kaposi s sarcoma, TAXOL, at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3.
DDI-DrugBank.d288.s10	84	88	TAXOL	brand	DDI-DrugBank.d288.s10.e0
DDI-DrugBank.d288.s11|a|Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.
DDI-DrugBank.d288.s11	131	141	cyclosporin	drug	DDI-DrugBank.d288.s11.e0
DDI-DrugBank.d288.s11	173	182	teniposide	drug	DDI-DrugBank.d288.s11.e1
DDI-DrugBank.d288.s11	238	242	TAXOL	brand	DDI-DrugBank.d288.s11.e2
DDI-DrugBank.d288.s11	false	DDI-DrugBank.d288.s11.e0	DDI-DrugBank.d288.s11.e1
DDI-DrugBank.d288.s11	true	DDI-DrugBank.d288.s11.e0	DDI-DrugBank.d288.s11.e2
DDI-DrugBank.d288.s11	true	DDI-DrugBank.d288.s11.e1	DDI-DrugBank.d288.s11.e2
DDI-DrugBank.d288.s12|a|In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).
DDI-DrugBank.d288.s12	97	101	TAXOL	brand	DDI-DrugBank.d288.s12.e0
DDI-DrugBank.d288.s12	131	145	corticosteroids	group	DDI-DrugBank.d288.s12.e1
DDI-DrugBank.d288.s12	156	168	dexamethasone	drug	DDI-DrugBank.d288.s12.e2
DDI-DrugBank.d288.s12	193	206	H2 antagonists	group	DDI-DrugBank.d288.s12.e3
DDI-DrugBank.d288.s12	217	226	cimetidine	drug	DDI-DrugBank.d288.s12.e4
DDI-DrugBank.d288.s12	231	240	ranitidine	drug	DDI-DrugBank.d288.s12.e5
DDI-DrugBank.d288.s12	false	DDI-DrugBank.d288.s12.e0	DDI-DrugBank.d288.s12.e1
DDI-DrugBank.d288.s12	false	DDI-DrugBank.d288.s12.e0	DDI-DrugBank.d288.s12.e2
DDI-DrugBank.d288.s12	false	DDI-DrugBank.d288.s12.e0	DDI-DrugBank.d288.s12.e3
DDI-DrugBank.d288.s12	false	DDI-DrugBank.d288.s12.e0	DDI-DrugBank.d288.s12.e4
DDI-DrugBank.d288.s12	false	DDI-DrugBank.d288.s12.e0	DDI-DrugBank.d288.s12.e5
DDI-DrugBank.d288.s12	false	DDI-DrugBank.d288.s12.e1	DDI-DrugBank.d288.s12.e2
DDI-DrugBank.d288.s12	false	DDI-DrugBank.d288.s12.e1	DDI-DrugBank.d288.s12.e3
DDI-DrugBank.d288.s12	false	DDI-DrugBank.d288.s12.e1	DDI-DrugBank.d288.s12.e4
DDI-DrugBank.d288.s12	false	DDI-DrugBank.d288.s12.e1	DDI-DrugBank.d288.s12.e5
DDI-DrugBank.d288.s12	false	DDI-DrugBank.d288.s12.e2	DDI-DrugBank.d288.s12.e3
DDI-DrugBank.d288.s13|a|Minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia do not require interruption of therapy.
DDI-DrugBank.d288.s14|a|However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.
DDI-DrugBank.d288.s14	86	100	bronchodilators	group	DDI-DrugBank.d288.s14.e0
DDI-DrugBank.d288.s14	177	181	TAXOL	brand	DDI-DrugBank.d288.s14.e1
DDI-DrugBank.d288.s14	false	DDI-DrugBank.d288.s14.e0	DDI-DrugBank.d288.s14.e1
DDI-DrugBank.d288.s15|a|Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL.
DDI-DrugBank.d288.s15	94	98	TAXOL	brand	DDI-DrugBank.d288.s15.e0
DDI-DrugBank.d288.s16|a|Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL, but generally do not require treatment.
DDI-DrugBank.d288.s16	103	107	TAXOL	brand	DDI-DrugBank.d288.s16.e0
DDI-DrugBank.d288.s17|a|Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension.
DDI-DrugBank.d288.s17	13	17	TAXOL	brand	DDI-DrugBank.d288.s17.e0
DDI-DrugBank.d288.s18|a|Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended.
DDI-DrugBank.d288.s18	70	74	TAXOL	brand	DDI-DrugBank.d288.s18.e0
DDI-DrugBank.d288.s19|a|Continuous cardiac monitoring is not required except for patients with serious conduction abnormalities.
DDI-DrugBank.d288.s20|a|Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL.
DDI-DrugBank.d288.s20	196	200	TAXOL	brand	DDI-DrugBank.d288.s20.e0
DDI-DrugBank.d288.s21|a|TAXOL contains dehydrated alcohol USP, 396 mg/mL;
DDI-DrugBank.d288.s21	0	4	TAXOL	brand	DDI-DrugBank.d288.s21.e0
DDI-DrugBank.d288.s22|a|consideration should be given to possible CNS and other effects of alcohol.
DDI-DrugBank.d288.s22	67	73	alcohol	drug	DDI-DrugBank.d288.s22.e0
DDI-DrugBank.d288.s23|a|Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin  2 times ULN.
DDI-DrugBank.d288.s23	61	65	TAXOL	brand	DDI-DrugBank.d288.s23.e0
DDI-DrugBank.d288.s24|a|Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17.
DDI-DrugBank.d288.s24	55	59	TAXOL	brand	DDI-DrugBank.d288.s24.e0
DDI-DrugBank.d288.s25|a|InjectionSite Reaction: Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discoloration, or swelling at the injection site.
DDI-DrugBank.d288.s26|a|These reactions have been observed more frequently with the 24-hour infusion than with the 3-hour infusion.
DDI-DrugBank.d288.s27|a|Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely.
DDI-DrugBank.d288.s27	93	97	TAXOL	brand	DDI-DrugBank.d288.s27.e0
DDI-DrugBank.d288.s28|a|Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety.
DDI-DrugBank.d288.s28	180	184	TAXOL	brand	DDI-DrugBank.d288.s28.e0
DDI-DrugBank.d288.s29|a|In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days.
DDI-DrugBank.d288.s30|a|A specific treatment for extravasation reactions is unknown at this time.
DDI-DrugBank.d288.s31|a|Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.
DDI-DrugBank.d196.s0|a|Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.
DDI-DrugBank.d196.s0	15	21	PEGASYS	brand	DDI-DrugBank.d196.s0.e0
DDI-DrugBank.d196.s0	135	146	theophylline	drug	DDI-DrugBank.d196.s0.e1
DDI-DrugBank.d196.s0	true	DDI-DrugBank.d196.s0.e0	DDI-DrugBank.d196.s0.e1
DDI-DrugBank.d196.s1|a|Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.
DDI-DrugBank.d196.s1	0	11	Theophylline	drug	DDI-DrugBank.d196.s1.e0
DDI-DrugBank.d196.s1	114	125	theophylline	drug	DDI-DrugBank.d196.s1.e1
DDI-DrugBank.d196.s1	131	137	PEGASYS	brand	DDI-DrugBank.d196.s1.e2
DDI-DrugBank.d196.s1	false	DDI-DrugBank.d196.s1.e0	DDI-DrugBank.d196.s1.e1
DDI-DrugBank.d196.s1	false	DDI-DrugBank.d196.s1.e0	DDI-DrugBank.d196.s1.e2
DDI-DrugBank.d196.s1	true	DDI-DrugBank.d196.s1.e1	DDI-DrugBank.d196.s1.e2
DDI-DrugBank.d196.s2|a|There was no effect on the pharmacokinetics of representative drugs metabolized by CYP 2C9, CYP 2C19, CYP 2D6 or CYP 3A4.
DDI-DrugBank.d196.s3|a|In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS, PEGASYS treatment did not affect ribavirin distribution or clearance.
DDI-DrugBank.d196.s3	50	56	PEGASYS	brand	DDI-DrugBank.d196.s3.e0
DDI-DrugBank.d196.s3	78	84	COPEGUS	brand	DDI-DrugBank.d196.s3.e1
DDI-DrugBank.d196.s3	87	93	PEGASYS	brand	DDI-DrugBank.d196.s3.e2
DDI-DrugBank.d196.s3	120	128	ribavirin	drug	DDI-DrugBank.d196.s3.e3
DDI-DrugBank.d196.s3	false	DDI-DrugBank.d196.s3.e0	DDI-DrugBank.d196.s3.e1
DDI-DrugBank.d196.s3	false	DDI-DrugBank.d196.s3.e0	DDI-DrugBank.d196.s3.e2
DDI-DrugBank.d196.s3	false	DDI-DrugBank.d196.s3.e0	DDI-DrugBank.d196.s3.e3
DDI-DrugBank.d196.s3	false	DDI-DrugBank.d196.s3.e1	DDI-DrugBank.d196.s3.e2
DDI-DrugBank.d196.s3	false	DDI-DrugBank.d196.s3.e1	DDI-DrugBank.d196.s3.e3
DDI-DrugBank.d196.s3	false	DDI-DrugBank.d196.s3.e2	DDI-DrugBank.d196.s3.e3
DDI-DrugBank.d196.s4|a|Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.
DDI-DrugBank.d196.s4	21	30	Didanosine	drug	DDI-DrugBank.d196.s4.e0
DDI-DrugBank.d196.s4	53	59	COPEGUS	brand	DDI-DrugBank.d196.s4.e1
DDI-DrugBank.d196.s4	65	74	didanosine	drug	DDI-DrugBank.d196.s4.e2
DDI-DrugBank.d196.s4	false	DDI-DrugBank.d196.s4.e0	DDI-DrugBank.d196.s4.e1
DDI-DrugBank.d196.s4	false	DDI-DrugBank.d196.s4.e0	DDI-DrugBank.d196.s4.e2
DDI-DrugBank.d196.s4	true	DDI-DrugBank.d196.s4.e1	DDI-DrugBank.d196.s4.e2
DDI-DrugBank.d196.s5|a|Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials.
DDI-DrugBank.d196.s6|a|Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
DDI-DrugBank.d196.s6	0	8	Stavudine	drug	DDI-DrugBank.d196.s6.e0
DDI-DrugBank.d196.s6	14	23	Zidovudine	drug	DDI-DrugBank.d196.s6.e1
DDI-DrugBank.d196.s6	25	33	Ribavirin	drug	DDI-DrugBank.d196.s6.e2
DDI-DrugBank.d196.s6	85	93	stavudine	drug	DDI-DrugBank.d196.s6.e3
DDI-DrugBank.d196.s6	99	108	zidovudine	drug	DDI-DrugBank.d196.s6.e4
DDI-DrugBank.d196.s6	false	DDI-DrugBank.d196.s6.e0	DDI-DrugBank.d196.s6.e1
DDI-DrugBank.d196.s6	false	DDI-DrugBank.d196.s6.e0	DDI-DrugBank.d196.s6.e2
DDI-DrugBank.d196.s6	false	DDI-DrugBank.d196.s6.e0	DDI-DrugBank.d196.s6.e3
DDI-DrugBank.d196.s6	false	DDI-DrugBank.d196.s6.e0	DDI-DrugBank.d196.s6.e4
DDI-DrugBank.d196.s6	false	DDI-DrugBank.d196.s6.e1	DDI-DrugBank.d196.s6.e2
DDI-DrugBank.d196.s6	false	DDI-DrugBank.d196.s6.e1	DDI-DrugBank.d196.s6.e3
DDI-DrugBank.d196.s6	false	DDI-DrugBank.d196.s6.e1	DDI-DrugBank.d196.s6.e4
DDI-DrugBank.d196.s6	true	DDI-DrugBank.d196.s6.e2	DDI-DrugBank.d196.s6.e3
DDI-DrugBank.d196.s6	true	DDI-DrugBank.d196.s6.e2	DDI-DrugBank.d196.s6.e4
DDI-DrugBank.d196.s6	false	DDI-DrugBank.d196.s6.e3	DDI-DrugBank.d196.s6.e4
DDI-DrugBank.d196.s7|a|Therefore, concomitant use of ribavirin with either of these drugs should be avoided.
DDI-DrugBank.d196.s7	30	38	ribavirin	drug	DDI-DrugBank.d196.s7.e0
DDI-DrugBank.d196.s8|a|Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis PEGASYS has not been tested for its carcinogenic potential.
DDI-DrugBank.d196.s8	68	74	PEGASYS	brand	DDI-DrugBank.d196.s8.e0
DDI-DrugBank.d196.s9|a|Mutagenesis PEGASYS did not cause DNA damage when tested in the Ames bacterial mutagenicity assay and in the in vitro chromosomal aberration assay in human lymphocytes, either in the presence or absence of metabolic activation.
DDI-DrugBank.d196.s9	12	18	PEGASYS	brand	DDI-DrugBank.d196.s9.e0
DDI-DrugBank.d196.s10|a|Use With Ribavirin Ribavirin is genotoxic and mutagenic.
DDI-DrugBank.d196.s10	9	17	Ribavirin	drug	DDI-DrugBank.d196.s10.e0
DDI-DrugBank.d196.s10	19	27	Ribavirin	drug	DDI-DrugBank.d196.s10.e1
DDI-DrugBank.d196.s10	false	DDI-DrugBank.d196.s10.e0	DDI-DrugBank.d196.s10.e1
DDI-DrugBank.d196.s11|a|The carcinogenic potential of ribavirin has not been fully determined.
DDI-DrugBank.d196.s11	30	38	ribavirin	drug	DDI-DrugBank.d196.s11.e0
DDI-DrugBank.d196.s12|a|In a p53 (+/-) mouse carcinogenicity study at doses up to the maximum tolerated dose of 100 mg/kg/day ribavirin was not oncogenic.
DDI-DrugBank.d196.s12	102	110	ribavirin	drug	DDI-DrugBank.d196.s12.e0
DDI-DrugBank.d196.s13|a|However, on a body surface area basis, this dose was 0.5 times maximum recommended human 24-hour dose of ribavirin.
DDI-DrugBank.d196.s13	105	113	ribavirin	drug	DDI-DrugBank.d196.s13.e0
DDI-DrugBank.d196.s14|a|A study in rats to assess the carcinogenic potential of ribavirin is ongoing.
DDI-DrugBank.d196.s14	56	64	ribavirin	drug	DDI-DrugBank.d196.s14.e0
DDI-DrugBank.d196.s15|a|Mutagenesis Impairment of Fertility PEGASYS may impair fertility in women.
DDI-DrugBank.d196.s15	36	42	PEGASYS	brand	DDI-DrugBank.d196.s15.e0
DDI-DrugBank.d196.s16|a|Prolonged menstrual cycles and/or amenorrhea were observed in female cynomolgus monkeys given sc injections of 600 m g/kg/dose (7200 m g/m2/dose) of PEGASYS every other day for one month, at approximately 180 times the recommended weekly human dose for a 60 kg person (based on body surface area).
DDI-DrugBank.d196.s16	149	155	PEGASYS	brand	DDI-DrugBank.d196.s16.e0
DDI-DrugBank.d196.s17|a|Menstrual cycle irregularities were accompanied by both a decrease and delay in the peak 17b -estradiol and progesterone levels following administration of PEGASYS to female monkeys.
DDI-DrugBank.d196.s17	156	162	PEGASYS	brand	DDI-DrugBank.d196.s17.e0
DDI-DrugBank.d196.s18|a|A return to normal menstrual rhythm followed cessation of treatment.
DDI-DrugBank.d196.s19|a|Every other day dosing with 100m g/kg (1200m g/m2) PEGASYS (equivalent to approximately 30 times the recommended human dose) had no effects on cycle duration or reproductive hormone status.
DDI-DrugBank.d196.s19	51	57	PEGASYS	brand	DDI-DrugBank.d196.s19.e0
DDI-DrugBank.d196.s20|a|The effects of PEGASYS on male fertility have not been studied.
DDI-DrugBank.d196.s20	15	21	PEGASYS	brand	DDI-DrugBank.d196.s20.e0
DDI-DrugBank.d196.s21|a|However, no adverse effects on fertility were observed in male Rhesus monkeys treated with non-pegylated interferon alfa-2a for 5 months at doses up to 25 x 106 IU/kg/day.
DDI-DrugBank.d196.s21	95	122	pegylated interferon alfa-2a	drug	DDI-DrugBank.d196.s21.e0
DDI-DrugBank.d196.s22|a|Pregnancy Pregnancy: Category C PEGASYS has not been studied for its teratogenic effect.
DDI-DrugBank.d196.s22	32	38	PEGASYS	brand	DDI-DrugBank.d196.s22.e0
DDI-DrugBank.d196.s23|a|Non-pegylated interferon alfa-2a treatment of pregnant Rhesus monkeys at approximately 20 to 500 times the human weekly dose resulted in a statistically significant increase in abortions.
DDI-DrugBank.d196.s23	0	31	Non-pegylated interferon alfa-2a	drug	DDI-DrugBank.d196.s23.e0
DDI-DrugBank.d196.s24|a|No teratogenic effects were seen in the offspring delivered at term.
DDI-DrugBank.d196.s25|a|PEGASYS should be assumed to have abortifacient potential.
DDI-DrugBank.d196.s25	0	6	PEGASYS	brand	DDI-DrugBank.d196.s25.e0
DDI-DrugBank.d196.s26|a|There are no adequate and well-controlled studies of PEGASYS in pregnant women.
DDI-DrugBank.d196.s26	53	59	PEGASYS	brand	DDI-DrugBank.d196.s26.e0
DDI-DrugBank.d196.s27|a|PEGASYS is to be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
DDI-DrugBank.d196.s27	0	6	PEGASYS	brand	DDI-DrugBank.d196.s27.e0
DDI-DrugBank.d196.s28|a|PEGASYS is recommended for use in women of childbearing potential only when they are using effective contraception during therapy.
DDI-DrugBank.d196.s28	0	6	PEGASYS	brand	DDI-DrugBank.d196.s28.e0
DDI-DrugBank.d196.s29|a|Pregnancy: Category X: Use With Ribavirin (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin.
DDI-DrugBank.d196.s29	32	40	Ribavirin	drug	DDI-DrugBank.d196.s29.e0
DDI-DrugBank.d196.s29	173	181	ribavirin	drug	DDI-DrugBank.d196.s29.e1
DDI-DrugBank.d196.s29	false	DDI-DrugBank.d196.s29.e0	DDI-DrugBank.d196.s29.e1
DDI-DrugBank.d196.s30|a|COPEGUS therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant .
DDI-DrugBank.d196.s30	0	6	COPEGUS	brand	DDI-DrugBank.d196.s30.e0
DDI-DrugBank.d196.s31|a|If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment cessation, such cases should be reported to the COPEGUS Pregnancy Registry at 1-800-526-6367.
DDI-DrugBank.d196.s31	161	167	COPEGUS	brand	DDI-DrugBank.d196.s31.e0
DDI-DrugBank.d196.s32|a|Nursing Mothers It is not known whether peginterferon or ribavirin or its components are excreted in human milk.
DDI-DrugBank.d196.s32	40	52	peginterferon	drug	DDI-DrugBank.d196.s32.e0
DDI-DrugBank.d196.s32	57	65	ribavirin	drug	DDI-DrugBank.d196.s32.e1
DDI-DrugBank.d196.s32	false	DDI-DrugBank.d196.s32.e0	DDI-DrugBank.d196.s32.e1
DDI-DrugBank.d196.s33|a|The effect of orally ingested peginterferon or ribavirin from breast milk on the nursing infant has not been evaluated.
DDI-DrugBank.d196.s33	30	42	peginterferon	drug	DDI-DrugBank.d196.s33.e0
DDI-DrugBank.d196.s33	47	55	ribavirin	drug	DDI-DrugBank.d196.s33.e1
DDI-DrugBank.d196.s33	false	DDI-DrugBank.d196.s33.e0	DDI-DrugBank.d196.s33.e1
DDI-DrugBank.d196.s34|a|Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue PEGASYS and COPEGUS treatment.
DDI-DrugBank.d196.s34	152	158	PEGASYS	brand	DDI-DrugBank.d196.s34.e0
DDI-DrugBank.d196.s34	164	170	COPEGUS	brand	DDI-DrugBank.d196.s34.e1
DDI-DrugBank.d196.s34	false	DDI-DrugBank.d196.s34.e0	DDI-DrugBank.d196.s34.e1
DDI-DrugBank.d196.s35|a|Pediatric Use The safety and effectiveness of PEGASYS, alone or in combination with COPEGUS in patients below the age of 18 years have not been established.
DDI-DrugBank.d196.s35	46	52	PEGASYS	brand	DDI-DrugBank.d196.s35.e0
DDI-DrugBank.d196.s35	84	90	COPEGUS	brand	DDI-DrugBank.d196.s35.e1
DDI-DrugBank.d196.s35	false	DDI-DrugBank.d196.s35.e0	DDI-DrugBank.d196.s35.e1
DDI-DrugBank.d196.s36|a|PEGASYS contains benzyl alcohol.
DDI-DrugBank.d196.s36	0	6	PEGASYS	brand	DDI-DrugBank.d196.s36.e0
DDI-DrugBank.d196.s36	17	30	benzyl alcohol	drug_n	DDI-DrugBank.d196.s36.e1
DDI-DrugBank.d196.s36	false	DDI-DrugBank.d196.s36.e0	DDI-DrugBank.d196.s36.e1
DDI-DrugBank.d196.s37|a|Benzyl alcohol has been reported to be associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal.
DDI-DrugBank.d196.s37	0	13	Benzyl alcohol	drug_n	DDI-DrugBank.d196.s37.e0
DDI-DrugBank.d196.s38|a|Geriatric Use Younger patients have higher virologic response rates than older patients.
DDI-DrugBank.d196.s39|a|Clinical studies of PEGASYS alone or in combination with COPEGUS did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.
DDI-DrugBank.d196.s39	20	26	PEGASYS	brand	DDI-DrugBank.d196.s39.e0
DDI-DrugBank.d196.s39	57	63	COPEGUS	brand	DDI-DrugBank.d196.s39.e1
DDI-DrugBank.d196.s39	false	DDI-DrugBank.d196.s39.e0	DDI-DrugBank.d196.s39.e1
DDI-DrugBank.d196.s40|a|Adverse reactions related to alpha interferons, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of PEGASYS in this population.
DDI-DrugBank.d196.s40	29	44	alpha interferon	drug	DDI-DrugBank.d196.s40.e0
DDI-DrugBank.d196.s40	186	192	PEGASYS	brand	DDI-DrugBank.d196.s40.e1
DDI-DrugBank.d196.s40	false	DDI-DrugBank.d196.s40.e0	DDI-DrugBank.d196.s40.e1
DDI-DrugBank.d196.s41|a|PEGASYS and COPEGUS are excreted by the kidney, and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function.
DDI-DrugBank.d196.s41	0	6	PEGASYS	brand	DDI-DrugBank.d196.s41.e0
DDI-DrugBank.d196.s41	12	18	COPEGUS	brand	DDI-DrugBank.d196.s41.e1
DDI-DrugBank.d196.s41	false	DDI-DrugBank.d196.s41.e0	DDI-DrugBank.d196.s41.e1
DDI-DrugBank.d196.s42|a|Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.
DDI-DrugBank.d196.s43|a|PEGASYS should be used with caution in patients with creatinine clearance  50 mL/min and COPEGUS should not be administered to patients with creatinine clearance  50 mL/min
DDI-DrugBank.d196.s43	0	6	PEGASYS	brand	DDI-DrugBank.d196.s43.e0
DDI-DrugBank.d196.s43	89	95	COPEGUS	brand	DDI-DrugBank.d196.s43.e1
DDI-DrugBank.d196.s43	false	DDI-DrugBank.d196.s43.e0	DDI-DrugBank.d196.s43.e1
DDI-DrugBank.d196.s44|a|.
DDI-DrugBank.d196.s45|a|
DDI-DrugBank.d462.s0|a|Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.
DDI-DrugBank.d462.s0	0	14	Aminoglycosides	group	DDI-DrugBank.d462.s0.e0
DDI-DrugBank.d462.s0	31	42	piperacillin	drug	DDI-DrugBank.d462.s0.e1
DDI-DrugBank.d462.s0	52	65	aminoglycoside	group	DDI-DrugBank.d462.s0.e2
DDI-DrugBank.d462.s0	122	135	aminoglycoside	group	DDI-DrugBank.d462.s0.e3
DDI-DrugBank.d462.s0	false	DDI-DrugBank.d462.s0.e0	DDI-DrugBank.d462.s0.e1
DDI-DrugBank.d462.s0	false	DDI-DrugBank.d462.s0.e0	DDI-DrugBank.d462.s0.e2
DDI-DrugBank.d462.s0	false	DDI-DrugBank.d462.s0.e0	DDI-DrugBank.d462.s0.e3
DDI-DrugBank.d462.s0	true	DDI-DrugBank.d462.s0.e1	DDI-DrugBank.d462.s0.e2
DDI-DrugBank.d462.s0	false	DDI-DrugBank.d462.s0.e1	DDI-DrugBank.d462.s0.e3
DDI-DrugBank.d462.s0	false	DDI-DrugBank.d462.s0.e2	DDI-DrugBank.d462.s0.e3
DDI-DrugBank.d462.s1|a|Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.
DDI-DrugBank.d462.s1	0	9	Vecuronium	drug	DDI-DrugBank.d462.s1.e0
DDI-DrugBank.d462.s1	51	62	piperacillin	drug	DDI-DrugBank.d462.s1.e1
DDI-DrugBank.d462.s1	137	146	vecuronium	drug	DDI-DrugBank.d462.s1.e2
DDI-DrugBank.d462.s1	false	DDI-DrugBank.d462.s1.e0	DDI-DrugBank.d462.s1.e1
DDI-DrugBank.d462.s1	false	DDI-DrugBank.d462.s1.e0	DDI-DrugBank.d462.s1.e2
DDI-DrugBank.d462.s1	true	DDI-DrugBank.d462.s1.e1	DDI-DrugBank.d462.s1.e2
DDI-DrugBank.d462.s2|a|Caution is indicated when piperacillin is used perioperatively.
DDI-DrugBank.d462.s2	26	37	piperacillin	drug	DDI-DrugBank.d462.s2.e0
DDI-DrugBank.d462.s3|a|In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.
DDI-DrugBank.d462.s3	67	78	piperacillin	drug	DDI-DrugBank.d462.s3.e0
DDI-DrugBank.d462.s3	120	129	vecuronium	drug	DDI-DrugBank.d462.s3.e1
DDI-DrugBank.d462.s3	true	DDI-DrugBank.d462.s3.e0	DDI-DrugBank.d462.s3.e1
DDI-DrugBank.d462.s4|a|Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.
DDI-DrugBank.d462.s4	112	144	non-depolarizing muscle relaxants	group	DDI-DrugBank.d462.s4.e0
DDI-DrugBank.d462.s4	184	195	piperacillin	drug	DDI-DrugBank.d462.s4.e1
DDI-DrugBank.d462.s4	true	DDI-DrugBank.d462.s4.e0	DDI-DrugBank.d462.s4.e1
DDI-DrugBank.d462.s5|a|Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.
DDI-DrugBank.d462.s5	0	9	Probenecid	drug	DDI-DrugBank.d462.s5.e0
DDI-DrugBank.d462.s5	36	45	probenecid	drug	DDI-DrugBank.d462.s5.e1
DDI-DrugBank.d462.s5	81	88	PIPRACIL	brand	DDI-DrugBank.d462.s5.e2
DDI-DrugBank.d462.s5	114	125	piperacillin	drug	DDI-DrugBank.d462.s5.e3
DDI-DrugBank.d462.s5	false	DDI-DrugBank.d462.s5.e0	DDI-DrugBank.d462.s5.e1
DDI-DrugBank.d462.s5	false	DDI-DrugBank.d462.s5.e0	DDI-DrugBank.d462.s5.e2
DDI-DrugBank.d462.s5	false	DDI-DrugBank.d462.s5.e0	DDI-DrugBank.d462.s5.e3
DDI-DrugBank.d462.s5	true	DDI-DrugBank.d462.s5.e1	DDI-DrugBank.d462.s5.e2
DDI-DrugBank.d462.s5	false	DDI-DrugBank.d462.s5.e1	DDI-DrugBank.d462.s5.e3
DDI-DrugBank.d462.s5	false	DDI-DrugBank.d462.s5.e2	DDI-DrugBank.d462.s5.e3
DDI-DrugBank.d462.s6|a|Anticoagulants: Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function.
DDI-DrugBank.d462.s6	0	13	Anticoagulants	group	DDI-DrugBank.d462.s6.e0
DDI-DrugBank.d462.s6	148	154	heparin	drug	DDI-DrugBank.d462.s6.e1
DDI-DrugBank.d462.s6	162	175	anticoagulants	group	DDI-DrugBank.d462.s6.e2
DDI-DrugBank.d462.s6	false	DDI-DrugBank.d462.s6.e0	DDI-DrugBank.d462.s6.e1
DDI-DrugBank.d462.s6	false	DDI-DrugBank.d462.s6.e0	DDI-DrugBank.d462.s6.e2
DDI-DrugBank.d462.s6	false	DDI-DrugBank.d462.s6.e1	DDI-DrugBank.d462.s6.e2
DDI-DrugBank.d462.s7|a|Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.
DDI-DrugBank.d462.s7	0	11	Methotrexate	drug	DDI-DrugBank.d462.s7.e0
DDI-DrugBank.d462.s7	14	32	Piperacillin sodium	drug	DDI-DrugBank.d462.s7.e1
DDI-DrugBank.d462.s7	62	73	methotrexate	drug	DDI-DrugBank.d462.s7.e2
DDI-DrugBank.d462.s7	false	DDI-DrugBank.d462.s7.e0	DDI-DrugBank.d462.s7.e1
DDI-DrugBank.d462.s7	false	DDI-DrugBank.d462.s7.e0	DDI-DrugBank.d462.s7.e2
DDI-DrugBank.d462.s7	true	DDI-DrugBank.d462.s7.e1	DDI-DrugBank.d462.s7.e2
DDI-DrugBank.d462.s8|a|Therefore, serum levels of methotrexate should be monitored in patients to avoid drug toxicity.
DDI-DrugBank.d462.s8	27	38	methotrexate	drug	DDI-DrugBank.d462.s8.e0
DDI-DrugBank.d462.s9|a|Drug/Laboratory Test Interactions As with other penicillins, the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper-reduction method.
DDI-DrugBank.d462.s9	48	58	penicillins	drug	DDI-DrugBank.d462.s9.e0
DDI-DrugBank.d462.s9	83	90	PIPRACIL	brand	DDI-DrugBank.d462.s9.e1
DDI-DrugBank.d462.s9	false	DDI-DrugBank.d462.s9.e0	DDI-DrugBank.d462.s9.e1
DDI-DrugBank.d462.s10|a|It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.
DDI-DrugBank.d462.s11|a|There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of Aspergillus infection.
DDI-DrugBank.d462.s11	132	143	piperacillin	drug	DDI-DrugBank.d462.s11.e0
DDI-DrugBank.d462.s11	145	154	tazobactam	drug	DDI-DrugBank.d462.s11.e1
DDI-DrugBank.d462.s11	false	DDI-DrugBank.d462.s11.e0	DDI-DrugBank.d462.s11.e1
DDI-DrugBank.d462.s12|a|Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported.
DDI-DrugBank.d462.s13|a|Therefore, positive test results in patients receiving piperacillin should be interpreted cautiously and confirmed by other diagnostic methods.
DDI-DrugBank.d462.s13	55	66	piperacillin	drug	DDI-DrugBank.d462.s13.e0
DDI-DrugBank.d326.s0|a|Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).
DDI-DrugBank.d326.s0	0	13	Phenothiazines	group	DDI-DrugBank.d326.s0.e0
DDI-DrugBank.d326.s0	24	33	piperazine	drug	DDI-DrugBank.d326.s0.e1
DDI-DrugBank.d326.s0	41	53	phenothiazine	group	DDI-DrugBank.d326.s0.e2
DDI-DrugBank.d326.s0	false	DDI-DrugBank.d326.s0.e0	DDI-DrugBank.d326.s0.e1
DDI-DrugBank.d326.s0	false	DDI-DrugBank.d326.s0.e0	DDI-DrugBank.d326.s0.e2
DDI-DrugBank.d326.s0	true	DDI-DrugBank.d326.s0.e1	DDI-DrugBank.d326.s0.e2
DDI-DrugBank.d326.s1|a|Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.
DDI-DrugBank.d326.s1	0	7	Pyrantel	drug	DDI-DrugBank.d326.s1.e0
DDI-DrugBank.d326.s1	16	24	Antiminth	drug	DDI-DrugBank.d326.s1.e1
DDI-DrugBank.d326.s1	36	45	piperazine	drug	DDI-DrugBank.d326.s1.e2
DDI-DrugBank.d326.s1	51	58	pyrantel	drug	DDI-DrugBank.d326.s1.e3
DDI-DrugBank.d326.s1	97	106	piperazine	drug	DDI-DrugBank.d326.s1.e4
DDI-DrugBank.d326.s1	false	DDI-DrugBank.d326.s1.e0	DDI-DrugBank.d326.s1.e1
DDI-DrugBank.d326.s1	false	DDI-DrugBank.d326.s1.e0	DDI-DrugBank.d326.s1.e2
DDI-DrugBank.d326.s1	false	DDI-DrugBank.d326.s1.e0	DDI-DrugBank.d326.s1.e3
DDI-DrugBank.d326.s1	false	DDI-DrugBank.d326.s1.e0	DDI-DrugBank.d326.s1.e4
DDI-DrugBank.d326.s1	false	DDI-DrugBank.d326.s1.e1	DDI-DrugBank.d326.s1.e2
DDI-DrugBank.d326.s1	false	DDI-DrugBank.d326.s1.e1	DDI-DrugBank.d326.s1.e3
DDI-DrugBank.d326.s1	false	DDI-DrugBank.d326.s1.e1	DDI-DrugBank.d326.s1.e4
DDI-DrugBank.d326.s1	true	DDI-DrugBank.d326.s1.e2	DDI-DrugBank.d326.s1.e3
DDI-DrugBank.d326.s1	false	DDI-DrugBank.d326.s1.e2	DDI-DrugBank.d326.s1.e4
DDI-DrugBank.d326.s1	false	DDI-DrugBank.d326.s1.e3	DDI-DrugBank.d326.s1.e4
DDI-DrugBank.d210.s0|a|ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
DDI-DrugBank.d210.s0	0	13	ACE inhibitors	group	DDI-DrugBank.d210.s0.e0
DDI-DrugBank.d210.s0	37	42	NSAIDs	group	DDI-DrugBank.d210.s0.e1
DDI-DrugBank.d210.s0	88	133	Angiotensin Converting Enzyme (ACE) inhibitors	group	DDI-DrugBank.d210.s0.e2
DDI-DrugBank.d210.s0	false	DDI-DrugBank.d210.s0.e0	DDI-DrugBank.d210.s0.e1
DDI-DrugBank.d210.s0	false	DDI-DrugBank.d210.s0.e0	DDI-DrugBank.d210.s0.e2
DDI-DrugBank.d210.s0	true	DDI-DrugBank.d210.s0.e1	DDI-DrugBank.d210.s0.e2
DDI-DrugBank.d210.s1|a|In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
DDI-DrugBank.d210.s1	81	85	VIOXX	brand	DDI-DrugBank.d210.s1.e0
DDI-DrugBank.d210.s1	96	108	ACE inhibitor	group	DDI-DrugBank.d210.s1.e1
DDI-DrugBank.d210.s1	110	119	benazepril	drug	DDI-DrugBank.d210.s1.e2
DDI-DrugBank.d210.s1	242	254	ACE inhibitor	group	DDI-DrugBank.d210.s1.e3
DDI-DrugBank.d210.s1	false	DDI-DrugBank.d210.s1.e0	DDI-DrugBank.d210.s1.e1
DDI-DrugBank.d210.s1	true	DDI-DrugBank.d210.s1.e0	DDI-DrugBank.d210.s1.e2
DDI-DrugBank.d210.s1	false	DDI-DrugBank.d210.s1.e0	DDI-DrugBank.d210.s1.e3
DDI-DrugBank.d210.s1	false	DDI-DrugBank.d210.s1.e1	DDI-DrugBank.d210.s1.e2
DDI-DrugBank.d210.s1	false	DDI-DrugBank.d210.s1.e1	DDI-DrugBank.d210.s1.e3
DDI-DrugBank.d210.s1	false	DDI-DrugBank.d210.s1.e2	DDI-DrugBank.d210.s1.e3
DDI-DrugBank.d210.s2|a|This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.
DDI-DrugBank.d210.s2	66	70	VIOXX	brand	DDI-DrugBank.d210.s2.e0
DDI-DrugBank.d210.s2	91	104	ACE inhibitors	group	DDI-DrugBank.d210.s2.e1
DDI-DrugBank.d210.s2	true	DDI-DrugBank.d210.s2.e0	DDI-DrugBank.d210.s2.e1
DDI-DrugBank.d210.s3|a|Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
DDI-DrugBank.d210.s3	0	6	Aspirin	brand	DDI-DrugBank.d210.s3.e0
DDI-DrugBank.d210.s3	48	54	aspirin	brand	DDI-DrugBank.d210.s3.e1
DDI-DrugBank.d210.s3	61	65	VIOXX	brand	DDI-DrugBank.d210.s3.e2
DDI-DrugBank.d210.s3	159	163	VIOXX	brand	DDI-DrugBank.d210.s3.e3
DDI-DrugBank.d210.s3	false	DDI-DrugBank.d210.s3.e0	DDI-DrugBank.d210.s3.e1
DDI-DrugBank.d210.s3	false	DDI-DrugBank.d210.s3.e0	DDI-DrugBank.d210.s3.e2
DDI-DrugBank.d210.s3	false	DDI-DrugBank.d210.s3.e0	DDI-DrugBank.d210.s3.e3
DDI-DrugBank.d210.s3	true	DDI-DrugBank.d210.s3.e1	DDI-DrugBank.d210.s3.e2
DDI-DrugBank.d210.s3	false	DDI-DrugBank.d210.s3.e1	DDI-DrugBank.d210.s3.e3
DDI-DrugBank.d210.s3	false	DDI-DrugBank.d210.s3.e2	DDI-DrugBank.d210.s3.e3
DDI-DrugBank.d210.s4|a|In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.
DDI-DrugBank.d210.s4	193	199	aspirin	brand	DDI-DrugBank.d210.s4.e0
DDI-DrugBank.d210.s4	206	210	VIOXX	brand	DDI-DrugBank.d210.s4.e1
DDI-DrugBank.d210.s4	253	261	ibuprofen	drug	DDI-DrugBank.d210.s4.e2
DDI-DrugBank.d210.s4	false	DDI-DrugBank.d210.s4.e0	DDI-DrugBank.d210.s4.e1
DDI-DrugBank.d210.s4	false	DDI-DrugBank.d210.s4.e0	DDI-DrugBank.d210.s4.e2
DDI-DrugBank.d210.s4	false	DDI-DrugBank.d210.s4.e1	DDI-DrugBank.d210.s4.e2
DDI-DrugBank.d210.s5|a|Patients taking low-dose aspirin plus ibuprofen were not studied.
DDI-DrugBank.d210.s5	25	31	aspirin	brand	DDI-DrugBank.d210.s5.e0
DDI-DrugBank.d210.s5	38	46	ibuprofen	drug	DDI-DrugBank.d210.s5.e1
DDI-DrugBank.d210.s5	false	DDI-DrugBank.d210.s5.e0	DDI-DrugBank.d210.s5.e1
DDI-DrugBank.d210.s6|a|At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.
DDI-DrugBank.d210.s6	17	21	VIOXX	brand	DDI-DrugBank.d210.s6.e0
DDI-DrugBank.d210.s6	115	121	aspirin	brand	DDI-DrugBank.d210.s6.e1
DDI-DrugBank.d210.s6	false	DDI-DrugBank.d210.s6.e0	DDI-DrugBank.d210.s6.e1
DDI-DrugBank.d210.s7|a|Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis.
DDI-DrugBank.d210.s7	41	45	VIOXX	brand	DDI-DrugBank.d210.s7.e0
DDI-DrugBank.d210.s7	71	77	aspirin	brand	DDI-DrugBank.d210.s7.e1
DDI-DrugBank.d210.s7	false	DDI-DrugBank.d210.s7.e0	DDI-DrugBank.d210.s7.e1
DDI-DrugBank.d210.s8|a|Therefore, in patients taking VIOXX, antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis.
DDI-DrugBank.d210.s8	30	34	VIOXX	brand	DDI-DrugBank.d210.s8.e0
DDI-DrugBank.d210.s9|a|Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted.
DDI-DrugBank.d210.s9	64	68	VIOXX	brand	DDI-DrugBank.d210.s9.e0
DDI-DrugBank.d210.s9	74	80	aspirin	brand	DDI-DrugBank.d210.s9.e1
DDI-DrugBank.d210.s9	false	DDI-DrugBank.d210.s9.e0	DDI-DrugBank.d210.s9.e1
DDI-DrugBank.d210.s10|a|Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
DDI-DrugBank.d210.s10	0	9	Cimetidine	drug	DDI-DrugBank.d210.s10.e0
DDI-DrugBank.d210.s10	49	58	cimetidine	drug	DDI-DrugBank.d210.s10.e1
DDI-DrugBank.d210.s10	103	111	rofecoxib	drug	DDI-DrugBank.d210.s10.e2
DDI-DrugBank.d210.s10	false	DDI-DrugBank.d210.s10.e0	DDI-DrugBank.d210.s10.e1
DDI-DrugBank.d210.s10	false	DDI-DrugBank.d210.s10.e0	DDI-DrugBank.d210.s10.e2
DDI-DrugBank.d210.s10	true	DDI-DrugBank.d210.s10.e1	DDI-DrugBank.d210.s10.e2
DDI-DrugBank.d210.s11|a|These small changes are not clinically significant and no dose adjustment is necessary.
DDI-DrugBank.d210.s12|a|Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose.
DDI-DrugBank.d210.s12	0	6	Digoxin	drug	DDI-DrugBank.d210.s12.e0
DDI-DrugBank.d210.s12	9	17	Rofecoxib	drug	DDI-DrugBank.d210.s12.e1
DDI-DrugBank.d210.s12	120	126	digoxin	drug	DDI-DrugBank.d210.s12.e2
DDI-DrugBank.d210.s12	false	DDI-DrugBank.d210.s12.e0	DDI-DrugBank.d210.s12.e1
DDI-DrugBank.d210.s12	false	DDI-DrugBank.d210.s12.e0	DDI-DrugBank.d210.s12.e2
DDI-DrugBank.d210.s12	false	DDI-DrugBank.d210.s12.e1	DDI-DrugBank.d210.s12.e2
DDI-DrugBank.d210.s13|a|Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d210.s13	0	9	Furosemide	drug	DDI-DrugBank.d210.s13.e0
DDI-DrugBank.d210.s13	86	91	NSAIDs	group	DDI-DrugBank.d210.s13.e1
DDI-DrugBank.d210.s13	130	139	furosemide	drug	DDI-DrugBank.d210.s13.e2
DDI-DrugBank.d210.s13	145	153	thiazides	group	DDI-DrugBank.d210.s13.e3
DDI-DrugBank.d210.s13	false	DDI-DrugBank.d210.s13.e0	DDI-DrugBank.d210.s13.e1
DDI-DrugBank.d210.s13	false	DDI-DrugBank.d210.s13.e0	DDI-DrugBank.d210.s13.e2
DDI-DrugBank.d210.s13	false	DDI-DrugBank.d210.s13.e0	DDI-DrugBank.d210.s13.e3
DDI-DrugBank.d210.s13	true	DDI-DrugBank.d210.s13.e1	DDI-DrugBank.d210.s13.e2
DDI-DrugBank.d210.s13	true	DDI-DrugBank.d210.s13.e1	DDI-DrugBank.d210.s13.e3
DDI-DrugBank.d210.s13	false	DDI-DrugBank.d210.s13.e2	DDI-DrugBank.d210.s13.e3
DDI-DrugBank.d210.s14|a|This response has been attributed to inhibition of renal prostaglandin synthesis.
DDI-DrugBank.d210.s15|a|Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib.
DDI-DrugBank.d210.s15	0	11	Ketoconazole	drug	DDI-DrugBank.d210.s15.e0
DDI-DrugBank.d210.s15	14	25	Ketoconazole	drug	DDI-DrugBank.d210.s15.e1
DDI-DrugBank.d210.s15	112	120	rofecoxib	drug	DDI-DrugBank.d210.s15.e2
DDI-DrugBank.d210.s15	false	DDI-DrugBank.d210.s15.e0	DDI-DrugBank.d210.s15.e1
DDI-DrugBank.d210.s15	false	DDI-DrugBank.d210.s15.e0	DDI-DrugBank.d210.s15.e2
DDI-DrugBank.d210.s15	false	DDI-DrugBank.d210.s15.e1	DDI-DrugBank.d210.s15.e2
DDI-DrugBank.d210.s16|a|Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
DDI-DrugBank.d210.s16	0	6	Lithium	drug	DDI-DrugBank.d210.s16.e0
DDI-DrugBank.d210.s16	9	14	NSAIDs	group	DDI-DrugBank.d210.s16.e1
DDI-DrugBank.d210.s16	53	59	lithium	drug	DDI-DrugBank.d210.s16.e2
DDI-DrugBank.d210.s16	93	99	lithium	drug	DDI-DrugBank.d210.s16.e3
DDI-DrugBank.d210.s16	false	DDI-DrugBank.d210.s16.e0	DDI-DrugBank.d210.s16.e1
DDI-DrugBank.d210.s16	false	DDI-DrugBank.d210.s16.e0	DDI-DrugBank.d210.s16.e2
DDI-DrugBank.d210.s16	false	DDI-DrugBank.d210.s16.e0	DDI-DrugBank.d210.s16.e3
DDI-DrugBank.d210.s16	true	DDI-DrugBank.d210.s16.e1	DDI-DrugBank.d210.s16.e2
DDI-DrugBank.d210.s16	false	DDI-DrugBank.d210.s16.e1	DDI-DrugBank.d210.s16.e3
DDI-DrugBank.d210.s16	false	DDI-DrugBank.d210.s16.e2	DDI-DrugBank.d210.s16.e3
DDI-DrugBank.d210.s17|a|In post-marketing experience there have been reports of increases in plasma lithium levels.
DDI-DrugBank.d210.s17	76	82	lithium	drug	DDI-DrugBank.d210.s17.e0
DDI-DrugBank.d210.s18|a|Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DDI-DrugBank.d210.s18	11	15	VIOXX	brand	DDI-DrugBank.d210.s18.e0
DDI-DrugBank.d210.s18	21	27	lithium	drug	DDI-DrugBank.d210.s18.e1
DDI-DrugBank.d210.s18	111	117	lithium	drug	DDI-DrugBank.d210.s18.e2
DDI-DrugBank.d210.s18	true	DDI-DrugBank.d210.s18.e0	DDI-DrugBank.d210.s18.e1
DDI-DrugBank.d210.s18	false	DDI-DrugBank.d210.s18.e0	DDI-DrugBank.d210.s18.e2
DDI-DrugBank.d210.s18	false	DDI-DrugBank.d210.s18.e1	DDI-DrugBank.d210.s18.e2
DDI-DrugBank.d210.s19|a|Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.
DDI-DrugBank.d210.s19	0	11	Methotrexate	drug	DDI-DrugBank.d210.s19.e0
DDI-DrugBank.d210.s19	13	17	VIOXX	brand	DDI-DrugBank.d210.s19.e1
DDI-DrugBank.d210.s19	131	142	methotrexate	drug	DDI-DrugBank.d210.s19.e2
DDI-DrugBank.d210.s19	205	216	methotrexate	drug	DDI-DrugBank.d210.s19.e3
DDI-DrugBank.d210.s19	false	DDI-DrugBank.d210.s19.e0	DDI-DrugBank.d210.s19.e1
DDI-DrugBank.d210.s19	false	DDI-DrugBank.d210.s19.e0	DDI-DrugBank.d210.s19.e2
DDI-DrugBank.d210.s19	false	DDI-DrugBank.d210.s19.e0	DDI-DrugBank.d210.s19.e3
DDI-DrugBank.d210.s19	false	DDI-DrugBank.d210.s19.e1	DDI-DrugBank.d210.s19.e2
DDI-DrugBank.d210.s19	false	DDI-DrugBank.d210.s19.e1	DDI-DrugBank.d210.s19.e3
DDI-DrugBank.d210.s19	false	DDI-DrugBank.d210.s19.e2	DDI-DrugBank.d210.s19.e3
DDI-DrugBank.d210.s20|a|At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.
DDI-DrugBank.d210.s20	34	38	VIOXX	brand	DDI-DrugBank.d210.s20.e0
DDI-DrugBank.d210.s20	168	179	methotrexate	drug	DDI-DrugBank.d210.s20.e1
DDI-DrugBank.d210.s20	true	DDI-DrugBank.d210.s20.e0	DDI-DrugBank.d210.s20.e1
DDI-DrugBank.d210.s21|a|At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).
DDI-DrugBank.d210.s21	68	79	methotrexate	drug	DDI-DrugBank.d210.s21.e0
DDI-DrugBank.d210.s21	123	134	methotrexate	drug	DDI-DrugBank.d210.s21.e1
DDI-DrugBank.d210.s21	166	174	rofecoxib	drug	DDI-DrugBank.d210.s21.e2
DDI-DrugBank.d210.s21	186	197	methotrexate	drug	DDI-DrugBank.d210.s21.e3
DDI-DrugBank.d210.s21	false	DDI-DrugBank.d210.s21.e0	DDI-DrugBank.d210.s21.e1
DDI-DrugBank.d210.s21	false	DDI-DrugBank.d210.s21.e0	DDI-DrugBank.d210.s21.e2
DDI-DrugBank.d210.s21	false	DDI-DrugBank.d210.s21.e0	DDI-DrugBank.d210.s21.e3
DDI-DrugBank.d210.s21	true	DDI-DrugBank.d210.s21.e1	DDI-DrugBank.d210.s21.e2
DDI-DrugBank.d210.s21	false	DDI-DrugBank.d210.s21.e1	DDI-DrugBank.d210.s21.e3
DDI-DrugBank.d210.s21	false	DDI-DrugBank.d210.s21.e2	DDI-DrugBank.d210.s21.e3
DDI-DrugBank.d210.s22|a|Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.
DDI-DrugBank.d210.s22	23	34	methotrexate	drug	DDI-DrugBank.d210.s22.e0
DDI-DrugBank.d210.s22	76	80	VIOXX	brand	DDI-DrugBank.d210.s22.e1
DDI-DrugBank.d210.s22	86	97	methotrexate	drug	DDI-DrugBank.d210.s22.e2
DDI-DrugBank.d210.s22	false	DDI-DrugBank.d210.s22.e0	DDI-DrugBank.d210.s22.e1
DDI-DrugBank.d210.s22	false	DDI-DrugBank.d210.s22.e0	DDI-DrugBank.d210.s22.e2
DDI-DrugBank.d210.s22	true	DDI-DrugBank.d210.s22.e1	DDI-DrugBank.d210.s22.e2
DDI-DrugBank.d210.s23|a|Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.
DDI-DrugBank.d210.s23	5	18	Contraceptives	group	DDI-DrugBank.d210.s23.e0
DDI-DrugBank.d210.s23	20	28	Rofecoxib	drug	DDI-DrugBank.d210.s23.e1
DDI-DrugBank.d210.s23	102	118	ethinyl estradiol	drug	DDI-DrugBank.d210.s23.e2
DDI-DrugBank.d210.s23	124	136	norethindrone	drug	DDI-DrugBank.d210.s23.e3
DDI-DrugBank.d210.s23	false	DDI-DrugBank.d210.s23.e0	DDI-DrugBank.d210.s23.e1
DDI-DrugBank.d210.s23	false	DDI-DrugBank.d210.s23.e0	DDI-DrugBank.d210.s23.e2
DDI-DrugBank.d210.s23	false	DDI-DrugBank.d210.s23.e0	DDI-DrugBank.d210.s23.e3
DDI-DrugBank.d210.s23	false	DDI-DrugBank.d210.s23.e1	DDI-DrugBank.d210.s23.e2
DDI-DrugBank.d210.s23	false	DDI-DrugBank.d210.s23.e1	DDI-DrugBank.d210.s23.e3
DDI-DrugBank.d210.s23	false	DDI-DrugBank.d210.s23.e2	DDI-DrugBank.d210.s23.e3
DDI-DrugBank.d210.s24|a|Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.
DDI-DrugBank.d210.s24	0	9	Prednisone	drug	DDI-DrugBank.d210.s24.e0
DDI-DrugBank.d210.s24	11	22	prednisolone	drug	DDI-DrugBank.d210.s24.e1
DDI-DrugBank.d210.s24	25	33	Rofecoxib	drug	DDI-DrugBank.d210.s24.e2
DDI-DrugBank.d210.s24	107	118	prednisolone	drug	DDI-DrugBank.d210.s24.e3
DDI-DrugBank.d210.s24	123	132	prednisone	drug	DDI-DrugBank.d210.s24.e4
DDI-DrugBank.d210.s24	false	DDI-DrugBank.d210.s24.e0	DDI-DrugBank.d210.s24.e1
DDI-DrugBank.d210.s24	false	DDI-DrugBank.d210.s24.e0	DDI-DrugBank.d210.s24.e2
DDI-DrugBank.d210.s24	false	DDI-DrugBank.d210.s24.e0	DDI-DrugBank.d210.s24.e3
DDI-DrugBank.d210.s24	false	DDI-DrugBank.d210.s24.e0	DDI-DrugBank.d210.s24.e4
DDI-DrugBank.d210.s24	false	DDI-DrugBank.d210.s24.e1	DDI-DrugBank.d210.s24.e2
DDI-DrugBank.d210.s24	false	DDI-DrugBank.d210.s24.e1	DDI-DrugBank.d210.s24.e3
DDI-DrugBank.d210.s24	false	DDI-DrugBank.d210.s24.e1	DDI-DrugBank.d210.s24.e4
DDI-DrugBank.d210.s24	false	DDI-DrugBank.d210.s24.e2	DDI-DrugBank.d210.s24.e3
DDI-DrugBank.d210.s24	false	DDI-DrugBank.d210.s24.e2	DDI-DrugBank.d210.s24.e4
DDI-DrugBank.d210.s24	false	DDI-DrugBank.d210.s24.e3	DDI-DrugBank.d210.s24.e4
DDI-DrugBank.d210.s25|a|Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.
DDI-DrugBank.d210.s25	0	7	Rifampin	drug	DDI-DrugBank.d210.s25.e0
DDI-DrugBank.d210.s25	31	35	VIOXX	brand	DDI-DrugBank.d210.s25.e1
DDI-DrugBank.d210.s25	42	49	rifampin	drug	DDI-DrugBank.d210.s25.e2
DDI-DrugBank.d210.s25	145	153	rofecoxib	drug	DDI-DrugBank.d210.s25.e3
DDI-DrugBank.d210.s25	false	DDI-DrugBank.d210.s25.e0	DDI-DrugBank.d210.s25.e1
DDI-DrugBank.d210.s25	false	DDI-DrugBank.d210.s25.e0	DDI-DrugBank.d210.s25.e2
DDI-DrugBank.d210.s25	false	DDI-DrugBank.d210.s25.e0	DDI-DrugBank.d210.s25.e3
DDI-DrugBank.d210.s25	true	DDI-DrugBank.d210.s25.e1	DDI-DrugBank.d210.s25.e2
DDI-DrugBank.d210.s25	false	DDI-DrugBank.d210.s25.e1	DDI-DrugBank.d210.s25.e3
DDI-DrugBank.d210.s25	false	DDI-DrugBank.d210.s25.e2	DDI-DrugBank.d210.s25.e3
DDI-DrugBank.d210.s26|a|Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism.
DDI-DrugBank.d210.s26	45	49	VIOXX	brand	DDI-DrugBank.d210.s26.e0
DDI-DrugBank.d210.s26	113	117	VIOXX	brand	DDI-DrugBank.d210.s26.e1
DDI-DrugBank.d210.s26	false	DDI-DrugBank.d210.s26.e0	DDI-DrugBank.d210.s26.e1
DDI-DrugBank.d210.s27|a|Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.
DDI-DrugBank.d210.s27	0	11	Theophylline	drug	DDI-DrugBank.d210.s27.e0
DDI-DrugBank.d210.s27	13	17	VIOXX	brand	DDI-DrugBank.d210.s27.e1
DDI-DrugBank.d210.s27	91	102	theophylline	drug	DDI-DrugBank.d210.s27.e2
DDI-DrugBank.d210.s27	200	211	theophylline	drug	DDI-DrugBank.d210.s27.e3
DDI-DrugBank.d210.s27	false	DDI-DrugBank.d210.s27.e0	DDI-DrugBank.d210.s27.e1
DDI-DrugBank.d210.s27	false	DDI-DrugBank.d210.s27.e0	DDI-DrugBank.d210.s27.e2
DDI-DrugBank.d210.s27	false	DDI-DrugBank.d210.s27.e0	DDI-DrugBank.d210.s27.e3
DDI-DrugBank.d210.s27	true	DDI-DrugBank.d210.s27.e1	DDI-DrugBank.d210.s27.e2
DDI-DrugBank.d210.s27	false	DDI-DrugBank.d210.s27.e1	DDI-DrugBank.d210.s27.e3
DDI-DrugBank.d210.s27	false	DDI-DrugBank.d210.s27.e2	DDI-DrugBank.d210.s27.e3
DDI-DrugBank.d210.s28|a|Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.
DDI-DrugBank.d210.s28	23	34	theophylline	drug	DDI-DrugBank.d210.s28.e0
DDI-DrugBank.d210.s28	97	101	VIOXX	brand	DDI-DrugBank.d210.s28.e1
DDI-DrugBank.d210.s28	149	160	theophylline	drug	DDI-DrugBank.d210.s28.e2
DDI-DrugBank.d210.s28	false	DDI-DrugBank.d210.s28.e0	DDI-DrugBank.d210.s28.e1
DDI-DrugBank.d210.s28	false	DDI-DrugBank.d210.s28.e0	DDI-DrugBank.d210.s28.e2
DDI-DrugBank.d210.s28	true	DDI-DrugBank.d210.s28.e1	DDI-DrugBank.d210.s28.e2
DDI-DrugBank.d210.s29|a|These data suggest that rofecoxib may produce a modest inhibition of cytochrome P450 (CYP) 1A2.
DDI-DrugBank.d210.s29	24	32	rofecoxib	drug	DDI-DrugBank.d210.s29.e0
DDI-DrugBank.d210.s30|a|Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton).
DDI-DrugBank.d210.s30	107	119	amitriptyline	drug	DDI-DrugBank.d210.s30.e0
DDI-DrugBank.d210.s30	122	128	tacrine	drug	DDI-DrugBank.d210.s30.e1
DDI-DrugBank.d210.s30	135	142	zileuton	drug	DDI-DrugBank.d210.s30.e2
DDI-DrugBank.d210.s30	false	DDI-DrugBank.d210.s30.e0	DDI-DrugBank.d210.s30.e1
DDI-DrugBank.d210.s30	false	DDI-DrugBank.d210.s30.e0	DDI-DrugBank.d210.s30.e2
DDI-DrugBank.d210.s30	false	DDI-DrugBank.d210.s30.e1	DDI-DrugBank.d210.s30.e2
DDI-DrugBank.d210.s31|a|Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.
DDI-DrugBank.d210.s31	0	7	Warfarin	drug	DDI-DrugBank.d210.s31.e0
DDI-DrugBank.d210.s31	118	122	VIOXX	brand	DDI-DrugBank.d210.s31.e1
DDI-DrugBank.d210.s31	154	161	warfarin	drug	DDI-DrugBank.d210.s31.e2
DDI-DrugBank.d210.s31	false	DDI-DrugBank.d210.s31.e0	DDI-DrugBank.d210.s31.e1
DDI-DrugBank.d210.s31	false	DDI-DrugBank.d210.s31.e0	DDI-DrugBank.d210.s31.e2
DDI-DrugBank.d210.s31	true	DDI-DrugBank.d210.s31.e1	DDI-DrugBank.d210.s31.e2
DDI-DrugBank.d210.s32|a|In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.
DDI-DrugBank.d210.s32	71	78	warfarin	drug	DDI-DrugBank.d210.s32.e0
DDI-DrugBank.d210.s32	84	92	rofecoxib	drug	DDI-DrugBank.d210.s32.e1
DDI-DrugBank.d210.s32	true	DDI-DrugBank.d210.s32.e0	DDI-DrugBank.d210.s32.e1
DDI-DrugBank.d210.s33|a|In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
DDI-DrugBank.d210.s33	168	172	VIOXX	brand	DDI-DrugBank.d210.s33.e0
DDI-DrugBank.d210.s33	192	199	warfarin	drug	DDI-DrugBank.d210.s33.e1
DDI-DrugBank.d210.s33	true	DDI-DrugBank.d210.s33.e0	DDI-DrugBank.d210.s33.e1
DDI-DrugBank.d124.s0|a|DRUG INTERACTIONS
DDI-DrugBank.d124.s1|a|Several drug interaction studies have been completed with both INVIRASE and FORTOVASE.
DDI-DrugBank.d124.s1	63	70	INVIRASE	brand	DDI-DrugBank.d124.s1.e0
DDI-DrugBank.d124.s1	76	84	FORTOVASE	brand	DDI-DrugBank.d124.s1.e1
DDI-DrugBank.d124.s1	false	DDI-DrugBank.d124.s1.e0	DDI-DrugBank.d124.s1.e1
DDI-DrugBank.d124.s2|a|Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE.
DDI-DrugBank.d124.s2	48	56	FORTOVASE	brand	DDI-DrugBank.d124.s2.e0
DDI-DrugBank.d124.s2	84	91	INVIRASE	brand	DDI-DrugBank.d124.s2.e1
DDI-DrugBank.d124.s2	false	DDI-DrugBank.d124.s2.e0	DDI-DrugBank.d124.s2.e1
DDI-DrugBank.d124.s3|a|Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent.
DDI-DrugBank.d124.s3	8	16	ritonavir	drug	DDI-DrugBank.d124.s3.e0
DDI-DrugBank.d124.s3	102	110	ritonavir	drug	DDI-DrugBank.d124.s3.e1
DDI-DrugBank.d124.s3	false	DDI-DrugBank.d124.s3.e0	DDI-DrugBank.d124.s3.e1
DDI-DrugBank.d124.s4|a|The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism.
DDI-DrugBank.d124.s4	18	27	saquinavir	drug	DDI-DrugBank.d124.s4.e0
DDI-DrugBank.d124.s5|a|Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp).
DDI-DrugBank.d124.s5	14	23	saquinavir	drug	DDI-DrugBank.d124.s5.e0
DDI-DrugBank.d124.s6|a|Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir.
DDI-DrugBank.d124.s6	83	92	saquinavir	drug	DDI-DrugBank.d124.s6.e0
DDI-DrugBank.d124.s7|a|Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp.
DDI-DrugBank.d124.s7	11	20	saquinavir	drug	DDI-DrugBank.d124.s7.e0
DDI-DrugBank.d124.s8|a|Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS.
DDI-DrugBank.d124.s9|a|Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below.
DDI-DrugBank.d124.s9	68	75	INVIRASE	brand	DDI-DrugBank.d124.s9.e0
DDI-DrugBank.d124.s9	81	89	ritonavir	drug	DDI-DrugBank.d124.s9.e1
DDI-DrugBank.d124.s9	false	DDI-DrugBank.d124.s9.e0	DDI-DrugBank.d124.s9.e1
DDI-DrugBank.d124.s10|a|These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.
DDI-DrugBank.d124.s11|a|With some agents, the metabolism may be induced, resulting in decreased concentrations.
DDI-DrugBank.d124.s12|a|Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir
DDI-DrugBank.d124.s12	45	52	INVIRASE	brand	DDI-DrugBank.d124.s12.e0
DDI-DrugBank.d124.s12	54	62	Ritonavir	drug	DDI-DrugBank.d124.s12.e1
DDI-DrugBank.d124.s12	false	DDI-DrugBank.d124.s12.e0	DDI-DrugBank.d124.s12.e1
DDI-DrugBank.d124.s13|a|Drug Class: Drug Name Clinical Comment
DDI-DrugBank.d124.s14|a|Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
DDI-DrugBank.d124.s14	0	14	Antiarrhythmics	group	DDI-DrugBank.d124.s14.e0
DDI-DrugBank.d124.s14	17	26	Amiodarone	drug	DDI-DrugBank.d124.s14.e1
DDI-DrugBank.d124.s14	29	36	bepridil	drug	DDI-DrugBank.d124.s14.e2
DDI-DrugBank.d124.s14	39	48	flecainide	drug	DDI-DrugBank.d124.s14.e3
DDI-DrugBank.d124.s14	51	61	propafenone	drug	DDI-DrugBank.d124.s14.e4
DDI-DrugBank.d124.s14	64	72	quinidine	drug	DDI-DrugBank.d124.s14.e5
DDI-DrugBank.d124.s14	false	DDI-DrugBank.d124.s14.e0	DDI-DrugBank.d124.s14.e1
DDI-DrugBank.d124.s14	false	DDI-DrugBank.d124.s14.e0	DDI-DrugBank.d124.s14.e2
DDI-DrugBank.d124.s14	false	DDI-DrugBank.d124.s14.e0	DDI-DrugBank.d124.s14.e3
DDI-DrugBank.d124.s14	false	DDI-DrugBank.d124.s14.e0	DDI-DrugBank.d124.s14.e4
DDI-DrugBank.d124.s14	false	DDI-DrugBank.d124.s14.e0	DDI-DrugBank.d124.s14.e5
DDI-DrugBank.d124.s14	false	DDI-DrugBank.d124.s14.e1	DDI-DrugBank.d124.s14.e2
DDI-DrugBank.d124.s14	false	DDI-DrugBank.d124.s14.e1	DDI-DrugBank.d124.s14.e3
DDI-DrugBank.d124.s14	false	DDI-DrugBank.d124.s14.e1	DDI-DrugBank.d124.s14.e4
DDI-DrugBank.d124.s14	false	DDI-DrugBank.d124.s14.e1	DDI-DrugBank.d124.s14.e5
DDI-DrugBank.d124.s14	false	DDI-DrugBank.d124.s14.e2	DDI-DrugBank.d124.s14.e3
DDI-DrugBank.d124.s15|a|Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.
DDI-DrugBank.d124.s15	0	13	Antihistamines	drug	DDI-DrugBank.d124.s15.e0
DDI-DrugBank.d124.s15	16	25	astemizole	drug	DDI-DrugBank.d124.s15.e1
DDI-DrugBank.d124.s15	29	39	terfenadine	drug	DDI-DrugBank.d124.s15.e2
DDI-DrugBank.d124.s15	false	DDI-DrugBank.d124.s15.e0	DDI-DrugBank.d124.s15.e1
DDI-DrugBank.d124.s15	false	DDI-DrugBank.d124.s15.e0	DDI-DrugBank.d124.s15.e2
DDI-DrugBank.d124.s15	false	DDI-DrugBank.d124.s15.e1	DDI-DrugBank.d124.s15.e2
DDI-DrugBank.d124.s16|a|Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
DDI-DrugBank.d124.s16	0	16	Ergot Derivatives	group	DDI-DrugBank.d124.s16.e0
DDI-DrugBank.d124.s16	19	35	Dihydroergotamine	drug	DDI-DrugBank.d124.s16.e1
DDI-DrugBank.d124.s16	38	47	ergonovine	drug	DDI-DrugBank.d124.s16.e2
DDI-DrugBank.d124.s16	50	59	ergotamine	drug	DDI-DrugBank.d124.s16.e3
DDI-DrugBank.d124.s16	62	77	methylergonovine	drug	DDI-DrugBank.d124.s16.e4
DDI-DrugBank.d124.s16	169	173	ergot	group	DDI-DrugBank.d124.s16.e5
DDI-DrugBank.d124.s16	false	DDI-DrugBank.d124.s16.e0	DDI-DrugBank.d124.s16.e1
DDI-DrugBank.d124.s16	false	DDI-DrugBank.d124.s16.e0	DDI-DrugBank.d124.s16.e2
DDI-DrugBank.d124.s16	false	DDI-DrugBank.d124.s16.e0	DDI-DrugBank.d124.s16.e3
DDI-DrugBank.d124.s16	false	DDI-DrugBank.d124.s16.e0	DDI-DrugBank.d124.s16.e4
DDI-DrugBank.d124.s16	false	DDI-DrugBank.d124.s16.e0	DDI-DrugBank.d124.s16.e5
DDI-DrugBank.d124.s16	false	DDI-DrugBank.d124.s16.e1	DDI-DrugBank.d124.s16.e2
DDI-DrugBank.d124.s16	false	DDI-DrugBank.d124.s16.e1	DDI-DrugBank.d124.s16.e3
DDI-DrugBank.d124.s16	false	DDI-DrugBank.d124.s16.e1	DDI-DrugBank.d124.s16.e4
DDI-DrugBank.d124.s16	false	DDI-DrugBank.d124.s16.e1	DDI-DrugBank.d124.s16.e5
DDI-DrugBank.d124.s16	false	DDI-DrugBank.d124.s16.e2	DDI-DrugBank.d124.s16.e3
DDI-DrugBank.d124.s17|a|Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.
DDI-DrugBank.d124.s17	0	23	Antimycobacterial Agents	group	DDI-DrugBank.d124.s17.e0
DDI-DrugBank.d124.s17	26	33	rifampin	drug	DDI-DrugBank.d124.s17.e1
DDI-DrugBank.d124.s17	99	108	saquinavir	drug	DDI-DrugBank.d124.s17.e2
DDI-DrugBank.d124.s17	116	129	antiretroviral	group	DDI-DrugBank.d124.s17.e3
DDI-DrugBank.d124.s17	176	185	saquinavir	drug	DDI-DrugBank.d124.s17.e4
DDI-DrugBank.d124.s17	false	DDI-DrugBank.d124.s17.e0	DDI-DrugBank.d124.s17.e1
DDI-DrugBank.d124.s17	false	DDI-DrugBank.d124.s17.e0	DDI-DrugBank.d124.s17.e2
DDI-DrugBank.d124.s17	false	DDI-DrugBank.d124.s17.e0	DDI-DrugBank.d124.s17.e3
DDI-DrugBank.d124.s17	false	DDI-DrugBank.d124.s17.e0	DDI-DrugBank.d124.s17.e4
DDI-DrugBank.d124.s17	false	DDI-DrugBank.d124.s17.e1	DDI-DrugBank.d124.s17.e2
DDI-DrugBank.d124.s17	false	DDI-DrugBank.d124.s17.e1	DDI-DrugBank.d124.s17.e3
DDI-DrugBank.d124.s17	false	DDI-DrugBank.d124.s17.e1	DDI-DrugBank.d124.s17.e4
DDI-DrugBank.d124.s17	false	DDI-DrugBank.d124.s17.e2	DDI-DrugBank.d124.s17.e3
DDI-DrugBank.d124.s17	false	DDI-DrugBank.d124.s17.e2	DDI-DrugBank.d124.s17.e4
DDI-DrugBank.d124.s17	false	DDI-DrugBank.d124.s17.e3	DDI-DrugBank.d124.s17.e4
DDI-DrugBank.d124.s18|a|Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.
DDI-DrugBank.d124.s18	64	73	saquinavir	drug	DDI-DrugBank.d124.s18.e0
DDI-DrugBank.d124.s18	76	84	FORTOVASE	brand	DDI-DrugBank.d124.s18.e1
DDI-DrugBank.d124.s18	99	116	protease inhibitor	group	DDI-DrugBank.d124.s18.e2
DDI-DrugBank.d124.s18	147	156	saquinavir	drug	DDI-DrugBank.d124.s18.e3
DDI-DrugBank.d124.s18	false	DDI-DrugBank.d124.s18.e0	DDI-DrugBank.d124.s18.e1
DDI-DrugBank.d124.s18	false	DDI-DrugBank.d124.s18.e0	DDI-DrugBank.d124.s18.e2
DDI-DrugBank.d124.s18	false	DDI-DrugBank.d124.s18.e0	DDI-DrugBank.d124.s18.e3
DDI-DrugBank.d124.s18	false	DDI-DrugBank.d124.s18.e1	DDI-DrugBank.d124.s18.e2
DDI-DrugBank.d124.s18	false	DDI-DrugBank.d124.s18.e1	DDI-DrugBank.d124.s18.e3
DDI-DrugBank.d124.s18	false	DDI-DrugBank.d124.s18.e2	DDI-DrugBank.d124.s18.e3
DDI-DrugBank.d124.s19|a|No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules.
DDI-DrugBank.d124.s19	50	57	INVIRASE	brand	DDI-DrugBank.d124.s19.e0
DDI-DrugBank.d124.s19	59	67	ritonavir	drug	DDI-DrugBank.d124.s19.e1
DDI-DrugBank.d124.s19	72	80	FORTOVASE	brand	DDI-DrugBank.d124.s19.e2
DDI-DrugBank.d124.s19	82	90	ritonavir	drug	DDI-DrugBank.d124.s19.e3
DDI-DrugBank.d124.s19	false	DDI-DrugBank.d124.s19.e0	DDI-DrugBank.d124.s19.e1
DDI-DrugBank.d124.s19	false	DDI-DrugBank.d124.s19.e0	DDI-DrugBank.d124.s19.e2
DDI-DrugBank.d124.s19	false	DDI-DrugBank.d124.s19.e0	DDI-DrugBank.d124.s19.e3
DDI-DrugBank.d124.s19	false	DDI-DrugBank.d124.s19.e1	DDI-DrugBank.d124.s19.e2
DDI-DrugBank.d124.s19	false	DDI-DrugBank.d124.s19.e1	DDI-DrugBank.d124.s19.e3
DDI-DrugBank.d124.s19	false	DDI-DrugBank.d124.s19.e2	DDI-DrugBank.d124.s19.e3
DDI-DrugBank.d124.s20|a|GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
DDI-DrugBank.d124.s20	19	27	cisapride	drug	DDI-DrugBank.d124.s20.e0
DDI-DrugBank.d124.s21|a|Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors.
DDI-DrugBank.d124.s21	147	154	INVIRASE	brand	DDI-DrugBank.d124.s21.e0
DDI-DrugBank.d124.s22|a|HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.
DDI-DrugBank.d124.s22	0	27	HMG-CoA Reductase Inhibitors	group	DDI-DrugBank.d124.s22.e0
DDI-DrugBank.d124.s22	30	39	lovastatin	drug	DDI-DrugBank.d124.s22.e1
DDI-DrugBank.d124.s22	42	52	simvastatin	drug	DDI-DrugBank.d124.s22.e2
DDI-DrugBank.d124.s22	false	DDI-DrugBank.d124.s22.e0	DDI-DrugBank.d124.s22.e1
DDI-DrugBank.d124.s22	false	DDI-DrugBank.d124.s22.e0	DDI-DrugBank.d124.s22.e2
DDI-DrugBank.d124.s22	false	DDI-DrugBank.d124.s22.e1	DDI-DrugBank.d124.s22.e2
DDI-DrugBank.d124.s23|a|Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
DDI-DrugBank.d124.s23	0	8	Sedatives	group	DDI-DrugBank.d124.s23.e0
DDI-DrugBank.d124.s23	10	18	Hypnotics	group	DDI-DrugBank.d124.s23.e1
DDI-DrugBank.d124.s23	21	29	triazolam	drug	DDI-DrugBank.d124.s23.e2
DDI-DrugBank.d124.s23	32	40	midazolam	drug	DDI-DrugBank.d124.s23.e3
DDI-DrugBank.d124.s23	false	DDI-DrugBank.d124.s23.e0	DDI-DrugBank.d124.s23.e1
DDI-DrugBank.d124.s23	false	DDI-DrugBank.d124.s23.e0	DDI-DrugBank.d124.s23.e2
DDI-DrugBank.d124.s23	false	DDI-DrugBank.d124.s23.e0	DDI-DrugBank.d124.s23.e3
DDI-DrugBank.d124.s23	false	DDI-DrugBank.d124.s23.e1	DDI-DrugBank.d124.s23.e2
DDI-DrugBank.d124.s23	false	DDI-DrugBank.d124.s23.e1	DDI-DrugBank.d124.s23.e3
DDI-DrugBank.d124.s23	false	DDI-DrugBank.d124.s23.e2	DDI-DrugBank.d124.s23.e3
DDI-DrugBank.d124.s24|a|* No longer marketed in the US.
DDI-DrugBank.d124.s25|a|Drugs That Are Mainly Metabolized by CYP3A4
DDI-DrugBank.d124.s26|a|Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26	122	145	calcium channel blockers	group	DDI-DrugBank.d124.s26.e0
DDI-DrugBank.d124.s26	148	154	dapsone	drug	DDI-DrugBank.d124.s26.e1
DDI-DrugBank.d124.s26	157	168	disopyramide	drug	DDI-DrugBank.d124.s26.e2
DDI-DrugBank.d124.s26	171	177	quinine	drug	DDI-DrugBank.d124.s26.e3
DDI-DrugBank.d124.s26	180	189	amiodarone	drug	DDI-DrugBank.d124.s26.e4
DDI-DrugBank.d124.s26	192	200	quinidine	drug	DDI-DrugBank.d124.s26.e5
DDI-DrugBank.d124.s26	203	210	warfarin	drug	DDI-DrugBank.d124.s26.e6
DDI-DrugBank.d124.s26	213	222	tacrolimus	drug	DDI-DrugBank.d124.s26.e7
DDI-DrugBank.d124.s26	225	236	cyclosporine	drug	DDI-DrugBank.d124.s26.e8
DDI-DrugBank.d124.s26	239	255	ergot derivatives	group	DDI-DrugBank.d124.s26.e9
DDI-DrugBank.d124.s26	false	DDI-DrugBank.d124.s26.e0	DDI-DrugBank.d124.s26.e1
DDI-DrugBank.d124.s26	false	DDI-DrugBank.d124.s26.e0	DDI-DrugBank.d124.s26.e2
DDI-DrugBank.d124.s26	false	DDI-DrugBank.d124.s26.e0	DDI-DrugBank.d124.s26.e3
DDI-DrugBank.d124.s26	false	DDI-DrugBank.d124.s26.e0	DDI-DrugBank.d124.s26.e4
DDI-DrugBank.d124.s26	false	DDI-DrugBank.d124.s26.e0	DDI-DrugBank.d124.s26.e5
DDI-DrugBank.d124.s26	false	DDI-DrugBank.d124.s26.e0	DDI-DrugBank.d124.s26.e6
DDI-DrugBank.d124.s26	false	DDI-DrugBank.d124.s26.e0	DDI-DrugBank.d124.s26.e7
DDI-DrugBank.d124.s26	false	DDI-DrugBank.d124.s26.e0	DDI-DrugBank.d124.s26.e8
DDI-DrugBank.d124.s26	false	DDI-DrugBank.d124.s26.e0	DDI-DrugBank.d124.s26.e9
DDI-DrugBank.d124.s26	false	DDI-DrugBank.d124.s26.e0	DDI-DrugBank.d124.s26.e10
DDI-DrugBank.d124.s27|a|therefore, these combinations should be used with caution.
DDI-DrugBank.d124.s28|a|Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.
DDI-DrugBank.d124.s28	6	13	INVIRASE	brand	DDI-DrugBank.d124.s28.e0
DDI-DrugBank.d124.s28	38	46	ritonavir	drug	DDI-DrugBank.d124.s28.e1
DDI-DrugBank.d124.s28	53	61	ritonavir	drug	DDI-DrugBank.d124.s28.e2
DDI-DrugBank.d124.s28	true	DDI-DrugBank.d124.s28.e0	DDI-DrugBank.d124.s28.e1
DDI-DrugBank.d124.s28	false	DDI-DrugBank.d124.s28.e0	DDI-DrugBank.d124.s28.e2
DDI-DrugBank.d124.s28	false	DDI-DrugBank.d124.s28.e1	DDI-DrugBank.d124.s28.e2
DDI-DrugBank.d124.s29|a|Inducers of CYP3A4
DDI-DrugBank.d124.s30|a|Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DDI-DrugBank.d124.s30	72	84	phenobarbital	drug	DDI-DrugBank.d124.s30.e0
DDI-DrugBank.d124.s30	87	95	phenytoin	drug	DDI-DrugBank.d124.s30.e1
DDI-DrugBank.d124.s30	98	110	dexamethasone	drug	DDI-DrugBank.d124.s30.e2
DDI-DrugBank.d124.s30	113	125	carbamazepine	drug	DDI-DrugBank.d124.s30.e3
DDI-DrugBank.d124.s30	169	178	saquinavir	drug	DDI-DrugBank.d124.s30.e4
DDI-DrugBank.d124.s30	false	DDI-DrugBank.d124.s30.e0	DDI-DrugBank.d124.s30.e1
DDI-DrugBank.d124.s30	false	DDI-DrugBank.d124.s30.e0	DDI-DrugBank.d124.s30.e2
DDI-DrugBank.d124.s30	false	DDI-DrugBank.d124.s30.e0	DDI-DrugBank.d124.s30.e3
DDI-DrugBank.d124.s30	true	DDI-DrugBank.d124.s30.e0	DDI-DrugBank.d124.s30.e4
DDI-DrugBank.d124.s30	false	DDI-DrugBank.d124.s30.e1	DDI-DrugBank.d124.s30.e2
DDI-DrugBank.d124.s30	false	DDI-DrugBank.d124.s30.e1	DDI-DrugBank.d124.s30.e3
DDI-DrugBank.d124.s30	true	DDI-DrugBank.d124.s30.e1	DDI-DrugBank.d124.s30.e4
DDI-DrugBank.d124.s30	false	DDI-DrugBank.d124.s30.e2	DDI-DrugBank.d124.s30.e3
DDI-DrugBank.d124.s30	true	DDI-DrugBank.d124.s30.e2	DDI-DrugBank.d124.s30.e4
DDI-DrugBank.d124.s30	true	DDI-DrugBank.d124.s30.e3	DDI-DrugBank.d124.s30.e4
DDI-DrugBank.d65.s0|a|Sulfacetamide preparations are incompatible with silver preparations.
DDI-DrugBank.d65.s0	0	12	Sulfacetamide	drug	DDI-DrugBank.d65.s0.e0
DDI-DrugBank.d65.s0	49	54	silver	drug	DDI-DrugBank.d65.s0.e1
DDI-DrugBank.d65.s0	true	DDI-DrugBank.d65.s0.e0	DDI-DrugBank.d65.s0.e1
DDI-DrugBank.d179.s0|a|Interations
DDI-DrugBank.d179.s1|a|Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or
DDI-DrugBank.d179.s1	0	12	Sulfapyridine	drug	DDI-DrugBank.d179.s1.e0
DDI-DrugBank.d179.s1	56	68	Acetaminophen	drug	DDI-DrugBank.d179.s1.e1
DDI-DrugBank.d179.s1	77	83	Tylenol	brand	DDI-DrugBank.d179.s1.e2
DDI-DrugBank.d179.s1	true	DDI-DrugBank.d179.s1.e0	DDI-DrugBank.d179.s1.e1
DDI-DrugBank.d179.s1	true	DDI-DrugBank.d179.s1.e0	DDI-DrugBank.d179.s1.e2
DDI-DrugBank.d179.s1	false	DDI-DrugBank.d179.s1.e1	DDI-DrugBank.d179.s1.e2
DDI-DrugBank.d179.s2|a|- Amiodarone (e.g., Cordarone) or
DDI-DrugBank.d179.s2	2	11	Amiodarone	drug	DDI-DrugBank.d179.s2.e0
DDI-DrugBank.d179.s2	20	28	Cordarone	brand	DDI-DrugBank.d179.s2.e1
DDI-DrugBank.d179.s2	false	DDI-DrugBank.d179.s2.e0	DDI-DrugBank.d179.s2.e1
DDI-DrugBank.d179.s3|a|- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
DDI-DrugBank.d179.s3	2	18	Anabolic steroids	group	DDI-DrugBank.d179.s3.e0
DDI-DrugBank.d179.s3	21	30	nandrolone	drug	DDI-DrugBank.d179.s3.e1
DDI-DrugBank.d179.s3	39	46	Anabolin	brand	DDI-DrugBank.d179.s3.e2
DDI-DrugBank.d179.s3	50	60	oxandrolone	drug	DDI-DrugBank.d179.s3.e3
DDI-DrugBank.d179.s3	69	74	Anavar	brand	DDI-DrugBank.d179.s3.e4
DDI-DrugBank.d179.s3	78	89	oxymetholone	drug	DDI-DrugBank.d179.s3.e5
DDI-DrugBank.d179.s3	98	104	Anadrol	brand	DDI-DrugBank.d179.s3.e6
DDI-DrugBank.d179.s3	108	117	stanozolol	drug	DDI-DrugBank.d179.s3.e7
DDI-DrugBank.d179.s3	126	133	Winstrol	brand	DDI-DrugBank.d179.s3.e8
DDI-DrugBank.d179.s3	false	DDI-DrugBank.d179.s3.e0	DDI-DrugBank.d179.s3.e1
DDI-DrugBank.d179.s3	false	DDI-DrugBank.d179.s3.e0	DDI-DrugBank.d179.s3.e2
DDI-DrugBank.d179.s3	false	DDI-DrugBank.d179.s3.e0	DDI-DrugBank.d179.s3.e3
DDI-DrugBank.d179.s3	false	DDI-DrugBank.d179.s3.e0	DDI-DrugBank.d179.s3.e4
DDI-DrugBank.d179.s3	false	DDI-DrugBank.d179.s3.e0	DDI-DrugBank.d179.s3.e5
DDI-DrugBank.d179.s3	false	DDI-DrugBank.d179.s3.e0	DDI-DrugBank.d179.s3.e6
DDI-DrugBank.d179.s3	false	DDI-DrugBank.d179.s3.e0	DDI-DrugBank.d179.s3.e7
DDI-DrugBank.d179.s3	false	DDI-DrugBank.d179.s3.e0	DDI-DrugBank.d179.s3.e8
DDI-DrugBank.d179.s3	false	DDI-DrugBank.d179.s3.e1	DDI-DrugBank.d179.s3.e2
DDI-DrugBank.d179.s3	false	DDI-DrugBank.d179.s3.e1	DDI-DrugBank.d179.s3.e3
DDI-DrugBank.d179.s4|a|- Androgens (male hormones) or
DDI-DrugBank.d179.s4	2	10	Androgens	group	DDI-DrugBank.d179.s4.e0
DDI-DrugBank.d179.s5|a|- Antithyroid agents (medicine for overactive thyroid) or
DDI-DrugBank.d179.s5	2	19	Antithyroid agents	group	DDI-DrugBank.d179.s5.e0
DDI-DrugBank.d179.s6|a|- Carbamazepine (e.g., Tegretol) or
DDI-DrugBank.d179.s6	2	14	Carbamazepine	drug	DDI-DrugBank.d179.s6.e0
DDI-DrugBank.d179.s6	23	30	Tegretol	brand	DDI-DrugBank.d179.s6.e1
DDI-DrugBank.d179.s6	false	DDI-DrugBank.d179.s6.e0	DDI-DrugBank.d179.s6.e1
DDI-DrugBank.d179.s7|a|- Carmustine (e.g., BiCNU) or
DDI-DrugBank.d179.s7	2	11	Carmustine	drug	DDI-DrugBank.d179.s7.e0
DDI-DrugBank.d179.s7	20	24	BiCNU	brand	DDI-DrugBank.d179.s7.e1
DDI-DrugBank.d179.s7	false	DDI-DrugBank.d179.s7.e0	DDI-DrugBank.d179.s7.e1
DDI-DrugBank.d179.s8|a|- Chloroquine (e.g., Aralen) or
DDI-DrugBank.d179.s8	2	12	Chloroquine	drug	DDI-DrugBank.d179.s8.e0
DDI-DrugBank.d179.s8	21	26	Aralen	brand	DDI-DrugBank.d179.s8.e1
DDI-DrugBank.d179.s8	false	DDI-DrugBank.d179.s8.e0	DDI-DrugBank.d179.s8.e1
DDI-DrugBank.d179.s9|a|- Dantrolene (e.g., Dantrium) or
DDI-DrugBank.d179.s9	2	11	Dantrolene	drug	DDI-DrugBank.d179.s9.e0
DDI-DrugBank.d179.s9	20	27	Dantrium	brand	DDI-DrugBank.d179.s9.e1
DDI-DrugBank.d179.s9	false	DDI-DrugBank.d179.s9.e0	DDI-DrugBank.d179.s9.e1
DDI-DrugBank.d179.s10|a|- Daunorubicin (e.g., Cerubidine) or
DDI-DrugBank.d179.s10	2	13	Daunorubicin	drug	DDI-DrugBank.d179.s10.e0
DDI-DrugBank.d179.s10	22	31	Cerubidine	brand	DDI-DrugBank.d179.s10.e1
DDI-DrugBank.d179.s10	false	DDI-DrugBank.d179.s10.e0	DDI-DrugBank.d179.s10.e1
DDI-DrugBank.d179.s11|a|- Disulfiram (e.g., Antabuse) or
DDI-DrugBank.d179.s11	2	11	Disulfiram	drug	DDI-DrugBank.d179.s11.e0
DDI-DrugBank.d179.s11	20	27	Antabuse	brand	DDI-DrugBank.d179.s11.e1
DDI-DrugBank.d179.s11	false	DDI-DrugBank.d179.s11.e0	DDI-DrugBank.d179.s11.e1
DDI-DrugBank.d179.s12|a|- Divalproex (e.g., Depakote) or
DDI-DrugBank.d179.s12	2	11	Divalproex	drug	DDI-DrugBank.d179.s12.e0
DDI-DrugBank.d179.s12	20	27	Depakote	brand	DDI-DrugBank.d179.s12.e1
DDI-DrugBank.d179.s12	false	DDI-DrugBank.d179.s12.e0	DDI-DrugBank.d179.s12.e1
DDI-DrugBank.d179.s13|a|- Estrogens (female hormones) or
DDI-DrugBank.d179.s13	2	10	Estrogens	group	DDI-DrugBank.d179.s13.e0
DDI-DrugBank.d179.s14|a|- Etretinate (e.g., Tegison) or
DDI-DrugBank.d179.s14	2	11	Etretinate	drug	DDI-DrugBank.d179.s14.e0
DDI-DrugBank.d179.s14	20	26	Tegison	brand	DDI-DrugBank.d179.s14.e1
DDI-DrugBank.d179.s14	false	DDI-DrugBank.d179.s14.e0	DDI-DrugBank.d179.s14.e1
DDI-DrugBank.d179.s15|a|- Gold salts (medicine for arthritis) or
DDI-DrugBank.d179.s15	2	5	Gold	drug	DDI-DrugBank.d179.s15.e0
DDI-DrugBank.d179.s16|a|- Hydroxychloroquine (e.g., Plaquenil) or
DDI-DrugBank.d179.s16	2	19	Hydroxychloroquine	drug	DDI-DrugBank.d179.s16.e0
DDI-DrugBank.d179.s16	28	36	Plaquenil	brand	DDI-DrugBank.d179.s16.e1
DDI-DrugBank.d179.s16	false	DDI-DrugBank.d179.s16.e0	DDI-DrugBank.d179.s16.e1
DDI-DrugBank.d179.s17|a|- Mercaptopurine (e.g., Purinethol) or
DDI-DrugBank.d179.s17	2	15	Mercaptopurine	drug	DDI-DrugBank.d179.s17.e0
DDI-DrugBank.d179.s17	24	33	Purinethol	brand	DDI-DrugBank.d179.s17.e1
DDI-DrugBank.d179.s17	false	DDI-DrugBank.d179.s17.e0	DDI-DrugBank.d179.s17.e1
DDI-DrugBank.d179.s18|a|- Naltrexone (e.g., Trexan) (with long-term, high-dose use) or
DDI-DrugBank.d179.s18	2	11	Naltrexone	drug	DDI-DrugBank.d179.s18.e0
DDI-DrugBank.d179.s18	20	25	Trexan	brand	DDI-DrugBank.d179.s18.e1
DDI-DrugBank.d179.s18	false	DDI-DrugBank.d179.s18.e0	DDI-DrugBank.d179.s18.e1
DDI-DrugBank.d179.s19|a|- Oral contraceptives (birth control pills) containing estrogen or
DDI-DrugBank.d179.s19	7	20	contraceptives	group	DDI-DrugBank.d179.s19.e0
DDI-DrugBank.d179.s19	55	62	estrogen	group	DDI-DrugBank.d179.s19.e1
DDI-DrugBank.d179.s19	false	DDI-DrugBank.d179.s19.e0	DDI-DrugBank.d179.s19.e1
DDI-DrugBank.d179.s20|a|- Other anti-infectives by mouth or by injection (medicine for infection) or
DDI-DrugBank.d179.s20	8	22	anti-infectives	group	DDI-DrugBank.d179.s20.e0
DDI-DrugBank.d179.s21|a|- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
DDI-DrugBank.d179.s21	2	15	Phenothiazines	group	DDI-DrugBank.d179.s21.e0
DDI-DrugBank.d179.s21	18	31	acetophenazine	drug	DDI-DrugBank.d179.s21.e1
DDI-DrugBank.d179.s21	40	45	Tindal	brand	DDI-DrugBank.d179.s21.e2
DDI-DrugBank.d179.s21	49	62	chlorpromazine	drug	DDI-DrugBank.d179.s21.e3
DDI-DrugBank.d179.s21	71	79	Thorazine	brand	DDI-DrugBank.d179.s21.e4
DDI-DrugBank.d179.s21	83	94	fluphenazine	drug	DDI-DrugBank.d179.s21.e5
DDI-DrugBank.d179.s21	103	110	Prolixin	brand	DDI-DrugBank.d179.s21.e6
DDI-DrugBank.d179.s21	114	125	mesoridazine	brand	DDI-DrugBank.d179.s21.e7
DDI-DrugBank.d179.s21	134	141	Serentil	brand	DDI-DrugBank.d179.s21.e8
DDI-DrugBank.d179.s21	145	156	perphenazine	drug	DDI-DrugBank.d179.s21.e9
DDI-DrugBank.d179.s21	false	DDI-DrugBank.d179.s21.e0	DDI-DrugBank.d179.s21.e1
DDI-DrugBank.d179.s21	false	DDI-DrugBank.d179.s21.e0	DDI-DrugBank.d179.s21.e2
DDI-DrugBank.d179.s21	false	DDI-DrugBank.d179.s21.e0	DDI-DrugBank.d179.s21.e3
DDI-DrugBank.d179.s21	false	DDI-DrugBank.d179.s21.e0	DDI-DrugBank.d179.s21.e4
DDI-DrugBank.d179.s21	false	DDI-DrugBank.d179.s21.e0	DDI-DrugBank.d179.s21.e5
DDI-DrugBank.d179.s21	false	DDI-DrugBank.d179.s21.e0	DDI-DrugBank.d179.s21.e6
DDI-DrugBank.d179.s21	false	DDI-DrugBank.d179.s21.e0	DDI-DrugBank.d179.s21.e7
DDI-DrugBank.d179.s21	false	DDI-DrugBank.d179.s21.e0	DDI-DrugBank.d179.s21.e8
DDI-DrugBank.d179.s21	false	DDI-DrugBank.d179.s21.e0	DDI-DrugBank.d179.s21.e9
DDI-DrugBank.d179.s21	false	DDI-DrugBank.d179.s21.e0	DDI-DrugBank.d179.s21.e10
DDI-DrugBank.d179.s22|a|- Plicamycin (e.g., Mithracin) or
DDI-DrugBank.d179.s22	2	11	Plicamycin	drug	DDI-DrugBank.d179.s22.e0
DDI-DrugBank.d179.s22	20	28	Mithracin	brand	DDI-DrugBank.d179.s22.e1
DDI-DrugBank.d179.s22	false	DDI-DrugBank.d179.s22.e0	DDI-DrugBank.d179.s22.e1
DDI-DrugBank.d179.s23|a|- Valproic acid (e.g., Depakene) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver
DDI-DrugBank.d179.s23	2	14	Valproic acid	drug	DDI-DrugBank.d179.s23.e0
DDI-DrugBank.d179.s23	23	30	Depakene	brand	DDI-DrugBank.d179.s23.e1
DDI-DrugBank.d179.s23	40	52	sulfapyridine	drug	DDI-DrugBank.d179.s23.e2
DDI-DrugBank.d179.s23	false	DDI-DrugBank.d179.s23.e0	DDI-DrugBank.d179.s23.e1
DDI-DrugBank.d179.s23	false	DDI-DrugBank.d179.s23.e0	DDI-DrugBank.d179.s23.e2
DDI-DrugBank.d179.s23	false	DDI-DrugBank.d179.s23.e1	DDI-DrugBank.d179.s23.e2
DDI-DrugBank.d179.s24|a|- Acetohydroxamic acid (e.g., Lithostat) or
DDI-DrugBank.d179.s24	2	21	Acetohydroxamic acid	drug	DDI-DrugBank.d179.s24.e0
DDI-DrugBank.d179.s24	30	38	Lithostat	brand	DDI-DrugBank.d179.s24.e1
DDI-DrugBank.d179.s24	false	DDI-DrugBank.d179.s24.e0	DDI-DrugBank.d179.s24.e1
DDI-DrugBank.d179.s25|a|- Dapsone or
DDI-DrugBank.d179.s25	2	8	Dapsone	drug	DDI-DrugBank.d179.s25.e0
DDI-DrugBank.d179.s26|a|- Furazolidone (e.g., Furoxone) or
DDI-DrugBank.d179.s26	2	13	Furazolidone	drug	DDI-DrugBank.d179.s26.e0
DDI-DrugBank.d179.s26	22	29	Furoxone	brand	DDI-DrugBank.d179.s26.e1
DDI-DrugBank.d179.s26	false	DDI-DrugBank.d179.s26.e0	DDI-DrugBank.d179.s26.e1
DDI-DrugBank.d179.s27|a|- Nitrofurantoin (e.g., Furadantin) or
DDI-DrugBank.d179.s27	2	15	Nitrofurantoin	drug	DDI-DrugBank.d179.s27.e0
DDI-DrugBank.d179.s27	24	33	Furadantin	brand	DDI-DrugBank.d179.s27.e1
DDI-DrugBank.d179.s27	false	DDI-DrugBank.d179.s27.e0	DDI-DrugBank.d179.s27.e1
DDI-DrugBank.d179.s28|a|- Primaquine or
DDI-DrugBank.d179.s28	2	11	Primaquine	drug	DDI-DrugBank.d179.s28.e0
DDI-DrugBank.d179.s29|a|- Procainamide (e.g., Pronestyl) or
DDI-DrugBank.d179.s29	2	13	Procainamide	drug	DDI-DrugBank.d179.s29.e0
DDI-DrugBank.d179.s29	22	30	Pronestyl	brand	DDI-DrugBank.d179.s29.e1
DDI-DrugBank.d179.s29	false	DDI-DrugBank.d179.s29.e0	DDI-DrugBank.d179.s29.e1
DDI-DrugBank.d179.s30|a|- Quinidine (e.g., Quinidex) or
DDI-DrugBank.d179.s30	2	10	Quinidine	drug	DDI-DrugBank.d179.s30.e0
DDI-DrugBank.d179.s30	19	26	Quinidex	brand	DDI-DrugBank.d179.s30.e1
DDI-DrugBank.d179.s30	false	DDI-DrugBank.d179.s30.e0	DDI-DrugBank.d179.s30.e1
DDI-DrugBank.d179.s31|a|- Quinine (e.g., Quinamm) or
DDI-DrugBank.d179.s31	2	8	Quinine	drug	DDI-DrugBank.d179.s31.e0
DDI-DrugBank.d179.s31	17	23	Quinamm	brand	DDI-DrugBank.d179.s31.e1
DDI-DrugBank.d179.s31	false	DDI-DrugBank.d179.s31.e0	DDI-DrugBank.d179.s31.e1
DDI-DrugBank.d179.s32|a|- Sulfoxone (e.g., Diasone) or
DDI-DrugBank.d179.s32	2	10	Sulfoxone	drug	DDI-DrugBank.d179.s32.e0
DDI-DrugBank.d179.s32	19	25	Diasone	brand	DDI-DrugBank.d179.s32.e1
DDI-DrugBank.d179.s32	false	DDI-DrugBank.d179.s32.e0	DDI-DrugBank.d179.s32.e1
DDI-DrugBank.d179.s33|a|- Vitamin K (e.g., AquaMEPHYTON, Synkayvite) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood
DDI-DrugBank.d179.s33	2	10	Vitamin K	group	DDI-DrugBank.d179.s33.e0
DDI-DrugBank.d179.s33	19	30	AquaMEPHYTON	brand	DDI-DrugBank.d179.s33.e1
DDI-DrugBank.d179.s33	33	42	Synkayvite	brand	DDI-DrugBank.d179.s33.e2
DDI-DrugBank.d179.s33	52	64	sulfapyridine	drug	DDI-DrugBank.d179.s33.e3
DDI-DrugBank.d179.s33	false	DDI-DrugBank.d179.s33.e0	DDI-DrugBank.d179.s33.e1
DDI-DrugBank.d179.s33	false	DDI-DrugBank.d179.s33.e0	DDI-DrugBank.d179.s33.e2
DDI-DrugBank.d179.s33	false	DDI-DrugBank.d179.s33.e0	DDI-DrugBank.d179.s33.e3
DDI-DrugBank.d179.s33	false	DDI-DrugBank.d179.s33.e1	DDI-DrugBank.d179.s33.e2
DDI-DrugBank.d179.s33	false	DDI-DrugBank.d179.s33.e1	DDI-DrugBank.d179.s33.e3
DDI-DrugBank.d179.s33	false	DDI-DrugBank.d179.s33.e2	DDI-DrugBank.d179.s33.e3
DDI-DrugBank.d179.s34|a|- Anticoagulants (blood thinners) or
DDI-DrugBank.d179.s34	2	15	Anticoagulants	group	DDI-DrugBank.d179.s34.e0
DDI-DrugBank.d179.s34	18	30	blood thinner	group	DDI-DrugBank.d179.s34.e1
DDI-DrugBank.d179.s34	false	DDI-DrugBank.d179.s34.e0	DDI-DrugBank.d179.s34.e1
DDI-DrugBank.d179.s35|a|- Ethotoin (e.g., Peganone) or
DDI-DrugBank.d179.s35	2	9	Ethotoin	drug	DDI-DrugBank.d179.s35.e0
DDI-DrugBank.d179.s35	18	25	Peganone	brand	DDI-DrugBank.d179.s35.e1
DDI-DrugBank.d179.s35	false	DDI-DrugBank.d179.s35.e0	DDI-DrugBank.d179.s35.e1
DDI-DrugBank.d179.s36|a|- Mephenytoin (e.g., Mesantoin) Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines
DDI-DrugBank.d179.s36	2	12	Mephenytoin	drug	DDI-DrugBank.d179.s36.e0
DDI-DrugBank.d179.s36	21	29	Mesantoin	brand	DDI-DrugBank.d179.s36.e1
DDI-DrugBank.d179.s36	39	51	sulfapyridine	drug	DDI-DrugBank.d179.s36.e2
DDI-DrugBank.d179.s36	false	DDI-DrugBank.d179.s36.e0	DDI-DrugBank.d179.s36.e1
DDI-DrugBank.d179.s36	false	DDI-DrugBank.d179.s36.e0	DDI-DrugBank.d179.s36.e2
DDI-DrugBank.d179.s36	false	DDI-DrugBank.d179.s36.e1	DDI-DrugBank.d179.s36.e2
DDI-DrugBank.d179.s37|a|- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics
DDI-DrugBank.d179.s37	2	14	Antidiabetics	group	DDI-DrugBank.d179.s37.e0
DDI-DrugBank.d179.s37	72	84	antidiabetics	group	DDI-DrugBank.d179.s37.e1
DDI-DrugBank.d179.s37	91	103	sulfapyridine	drug	DDI-DrugBank.d179.s37.e2
DDI-DrugBank.d179.s37	197	209	antidiabetics	group	DDI-DrugBank.d179.s37.e3
DDI-DrugBank.d179.s37	false	DDI-DrugBank.d179.s37.e0	DDI-DrugBank.d179.s37.e1
DDI-DrugBank.d179.s37	false	DDI-DrugBank.d179.s37.e0	DDI-DrugBank.d179.s37.e2
DDI-DrugBank.d179.s37	false	DDI-DrugBank.d179.s37.e0	DDI-DrugBank.d179.s37.e3
DDI-DrugBank.d179.s37	true	DDI-DrugBank.d179.s37.e1	DDI-DrugBank.d179.s37.e2
DDI-DrugBank.d179.s37	false	DDI-DrugBank.d179.s37.e1	DDI-DrugBank.d179.s37.e3
DDI-DrugBank.d179.s37	false	DDI-DrugBank.d179.s37.e2	DDI-DrugBank.d179.s37.e3
DDI-DrugBank.d179.s38|a|- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate
DDI-DrugBank.d179.s38	2	13	Methotrexate	drug	DDI-DrugBank.d179.s38.e0
DDI-DrugBank.d179.s38	22	27	Mexate	brand	DDI-DrugBank.d179.s38.e1
DDI-DrugBank.d179.s38	37	48	methotrexate	drug	DDI-DrugBank.d179.s38.e2
DDI-DrugBank.d179.s38	55	67	sulfapyridine	drug	DDI-DrugBank.d179.s38.e3
DDI-DrugBank.d179.s38	156	167	methotrexate	drug	DDI-DrugBank.d179.s38.e4
DDI-DrugBank.d179.s38	false	DDI-DrugBank.d179.s38.e0	DDI-DrugBank.d179.s38.e1
DDI-DrugBank.d179.s38	false	DDI-DrugBank.d179.s38.e0	DDI-DrugBank.d179.s38.e2
DDI-DrugBank.d179.s38	false	DDI-DrugBank.d179.s38.e0	DDI-DrugBank.d179.s38.e3
DDI-DrugBank.d179.s38	false	DDI-DrugBank.d179.s38.e0	DDI-DrugBank.d179.s38.e4
DDI-DrugBank.d179.s38	false	DDI-DrugBank.d179.s38.e1	DDI-DrugBank.d179.s38.e2
DDI-DrugBank.d179.s38	false	DDI-DrugBank.d179.s38.e1	DDI-DrugBank.d179.s38.e3
DDI-DrugBank.d179.s38	false	DDI-DrugBank.d179.s38.e1	DDI-DrugBank.d179.s38.e4
DDI-DrugBank.d179.s38	true	DDI-DrugBank.d179.s38.e2	DDI-DrugBank.d179.s38.e3
DDI-DrugBank.d179.s38	false	DDI-DrugBank.d179.s38.e2	DDI-DrugBank.d179.s38.e4
DDI-DrugBank.d179.s38	false	DDI-DrugBank.d179.s38.e3	DDI-DrugBank.d179.s38.e4
DDI-DrugBank.d179.s39|a|- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood
DDI-DrugBank.d179.s39	2	11	Methyldopa	drug	DDI-DrugBank.d179.s39.e0
DDI-DrugBank.d179.s39	20	26	Aldomet	brand	DDI-DrugBank.d179.s39.e1
DDI-DrugBank.d179.s39	36	45	methyldopa	drug	DDI-DrugBank.d179.s39.e2
DDI-DrugBank.d179.s39	52	64	sulfapyridine	drug	DDI-DrugBank.d179.s39.e3
DDI-DrugBank.d179.s39	false	DDI-DrugBank.d179.s39.e0	DDI-DrugBank.d179.s39.e1
DDI-DrugBank.d179.s39	false	DDI-DrugBank.d179.s39.e0	DDI-DrugBank.d179.s39.e2
DDI-DrugBank.d179.s39	false	DDI-DrugBank.d179.s39.e0	DDI-DrugBank.d179.s39.e3
DDI-DrugBank.d179.s39	false	DDI-DrugBank.d179.s39.e1	DDI-DrugBank.d179.s39.e2
DDI-DrugBank.d179.s39	false	DDI-DrugBank.d179.s39.e1	DDI-DrugBank.d179.s39.e3
DDI-DrugBank.d179.s39	true	DDI-DrugBank.d179.s39.e2	DDI-DrugBank.d179.s39.e3
DDI-DrugBank.d179.s40|a|- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin
DDI-DrugBank.d179.s40	2	10	Phenytoin	drug	DDI-DrugBank.d179.s40.e0
DDI-DrugBank.d179.s40	19	26	Dilantin	brand	DDI-DrugBank.d179.s40.e1
DDI-DrugBank.d179.s40	36	44	phenytoin	drug	DDI-DrugBank.d179.s40.e2
DDI-DrugBank.d179.s40	51	63	sulfapyridine	drug	DDI-DrugBank.d179.s40.e3
DDI-DrugBank.d179.s40	152	160	phenytoin	drug	DDI-DrugBank.d179.s40.e4
DDI-DrugBank.d179.s40	false	DDI-DrugBank.d179.s40.e0	DDI-DrugBank.d179.s40.e1
DDI-DrugBank.d179.s40	false	DDI-DrugBank.d179.s40.e0	DDI-DrugBank.d179.s40.e2
DDI-DrugBank.d179.s40	false	DDI-DrugBank.d179.s40.e0	DDI-DrugBank.d179.s40.e3
DDI-DrugBank.d179.s40	false	DDI-DrugBank.d179.s40.e0	DDI-DrugBank.d179.s40.e4
DDI-DrugBank.d179.s40	false	DDI-DrugBank.d179.s40.e1	DDI-DrugBank.d179.s40.e2
DDI-DrugBank.d179.s40	false	DDI-DrugBank.d179.s40.e1	DDI-DrugBank.d179.s40.e3
DDI-DrugBank.d179.s40	false	DDI-DrugBank.d179.s40.e1	DDI-DrugBank.d179.s40.e4
DDI-DrugBank.d179.s40	true	DDI-DrugBank.d179.s40.e2	DDI-DrugBank.d179.s40.e3
DDI-DrugBank.d179.s40	false	DDI-DrugBank.d179.s40.e2	DDI-DrugBank.d179.s40.e4
DDI-DrugBank.d179.s40	false	DDI-DrugBank.d179.s40.e3	DDI-DrugBank.d179.s40.e4
DDI-DrugBank.d277.s0|a|In evaluating the potential for interactions among co-administered antiepilepsy drugs (AEDs), whether or not an AED induces or does not induce metabolic enzymes is an important consideration.
DDI-DrugBank.d277.s0	87	90	AEDs	group	DDI-DrugBank.d277.s0.e0
DDI-DrugBank.d277.s0	112	114	AED	group	DDI-DrugBank.d277.s0.e1
DDI-DrugBank.d277.s0	false	DDI-DrugBank.d277.s0.e0	DDI-DrugBank.d277.s0.e1
DDI-DrugBank.d277.s1|a|Phenytoin, phenobarbital and carbamazepine are ge nerally classified as enzyme inducers;
DDI-DrugBank.d277.s1	0	8	Phenytoin	drug	DDI-DrugBank.d277.s1.e0
DDI-DrugBank.d277.s1	11	23	phenobarbital	drug	DDI-DrugBank.d277.s1.e1
DDI-DrugBank.d277.s1	29	41	carbamazepine	drug	DDI-DrugBank.d277.s1.e2
DDI-DrugBank.d277.s1	false	DDI-DrugBank.d277.s1.e0	DDI-DrugBank.d277.s1.e1
DDI-DrugBank.d277.s1	false	DDI-DrugBank.d277.s1.e0	DDI-DrugBank.d277.s1.e2
DDI-DrugBank.d277.s1	false	DDI-DrugBank.d277.s1.e1	DDI-DrugBank.d277.s1.e2
DDI-DrugBank.d277.s2|a|valproate and gabapentin are not.
DDI-DrugBank.d277.s2	0	8	valproate	drug	DDI-DrugBank.d277.s2.e0
DDI-DrugBank.d277.s2	14	23	gabapentin	drug	DDI-DrugBank.d277.s2.e1
DDI-DrugBank.d277.s2	false	DDI-DrugBank.d277.s2.e0	DDI-DrugBank.d277.s2.e1
DDI-DrugBank.d277.s3|a|GABITRIL is considered to be a non-enzyme inducing AED.
DDI-DrugBank.d277.s3	0	7	GABITRIL	brand	DDI-DrugBank.d277.s3.e0
DDI-DrugBank.d277.s3	51	53	AED	group	DDI-DrugBank.d277.s3.e1
DDI-DrugBank.d277.s3	false	DDI-DrugBank.d277.s3.e0	DDI-DrugBank.d277.s3.e1
DDI-DrugBank.d277.s4|a|The drug interaction data described in this section were obtained from studies involving either healthy subjects or patients with epilepsy.
DDI-DrugBank.d277.s5|a|Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
DDI-DrugBank.d277.s5	11	18	GABITRIL	brand	DDI-DrugBank.d277.s5.e0
DDI-DrugBank.d277.s5	49	52	AEDs	group	DDI-DrugBank.d277.s5.e1
DDI-DrugBank.d277.s5	57	65	Phenytoin	drug	DDI-DrugBank.d277.s5.e2
DDI-DrugBank.d277.s5	68	76	Tiagabine	drug	DDI-DrugBank.d277.s5.e3
DDI-DrugBank.d277.s5	137	145	phenytoin	drug	DDI-DrugBank.d277.s5.e4
DDI-DrugBank.d277.s5	false	DDI-DrugBank.d277.s5.e0	DDI-DrugBank.d277.s5.e1
DDI-DrugBank.d277.s5	false	DDI-DrugBank.d277.s5.e0	DDI-DrugBank.d277.s5.e2
DDI-DrugBank.d277.s5	false	DDI-DrugBank.d277.s5.e0	DDI-DrugBank.d277.s5.e3
DDI-DrugBank.d277.s5	false	DDI-DrugBank.d277.s5.e0	DDI-DrugBank.d277.s5.e4
DDI-DrugBank.d277.s5	false	DDI-DrugBank.d277.s5.e1	DDI-DrugBank.d277.s5.e2
DDI-DrugBank.d277.s5	false	DDI-DrugBank.d277.s5.e1	DDI-DrugBank.d277.s5.e3
DDI-DrugBank.d277.s5	false	DDI-DrugBank.d277.s5.e1	DDI-DrugBank.d277.s5.e4
DDI-DrugBank.d277.s5	false	DDI-DrugBank.d277.s5.e2	DDI-DrugBank.d277.s5.e3
DDI-DrugBank.d277.s5	false	DDI-DrugBank.d277.s5.e2	DDI-DrugBank.d277.s5.e4
DDI-DrugBank.d277.s5	false	DDI-DrugBank.d277.s5.e3	DDI-DrugBank.d277.s5.e4
DDI-DrugBank.d277.s6|a|Carbamazepine: Tiagabine had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.
DDI-DrugBank.d277.s6	0	12	Carbamazepine	drug	DDI-DrugBank.d277.s6.e0
DDI-DrugBank.d277.s6	15	23	Tiagabine	drug	DDI-DrugBank.d277.s6.e1
DDI-DrugBank.d277.s6	84	96	carbamazepine	drug	DDI-DrugBank.d277.s6.e2
DDI-DrugBank.d277.s6	false	DDI-DrugBank.d277.s6.e0	DDI-DrugBank.d277.s6.e1
DDI-DrugBank.d277.s6	false	DDI-DrugBank.d277.s6.e0	DDI-DrugBank.d277.s6.e2
DDI-DrugBank.d277.s6	false	DDI-DrugBank.d277.s6.e1	DDI-DrugBank.d277.s6.e2
DDI-DrugBank.d277.s7|a|Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.
DDI-DrugBank.d277.s7	0	8	Valproate	drug	DDI-DrugBank.d277.s7.e0
DDI-DrugBank.d277.s7	11	19	Tiagabine	drug	DDI-DrugBank.d277.s7.e1
DDI-DrugBank.d277.s7	74	82	valproate	drug	DDI-DrugBank.d277.s7.e2
DDI-DrugBank.d277.s7	false	DDI-DrugBank.d277.s7.e0	DDI-DrugBank.d277.s7.e1
DDI-DrugBank.d277.s7	false	DDI-DrugBank.d277.s7.e0	DDI-DrugBank.d277.s7.e2
DDI-DrugBank.d277.s7	true	DDI-DrugBank.d277.s7.e1	DDI-DrugBank.d277.s7.e2
DDI-DrugBank.d277.s8|a|Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.
DDI-DrugBank.d277.s8	0	12	Phenobarbital	drug	DDI-DrugBank.d277.s8.e0
DDI-DrugBank.d277.s8	17	25	Primidone	drug	DDI-DrugBank.d277.s8.e1
DDI-DrugBank.d277.s8	109	117	tiagabine	drug	DDI-DrugBank.d277.s8.e2
DDI-DrugBank.d277.s8	142	154	phenobarbital	drug	DDI-DrugBank.d277.s8.e3
DDI-DrugBank.d277.s8	159	167	primidone	drug	DDI-DrugBank.d277.s8.e4
DDI-DrugBank.d277.s8	false	DDI-DrugBank.d277.s8.e0	DDI-DrugBank.d277.s8.e1
DDI-DrugBank.d277.s8	false	DDI-DrugBank.d277.s8.e0	DDI-DrugBank.d277.s8.e2
DDI-DrugBank.d277.s8	false	DDI-DrugBank.d277.s8.e0	DDI-DrugBank.d277.s8.e3
DDI-DrugBank.d277.s8	false	DDI-DrugBank.d277.s8.e0	DDI-DrugBank.d277.s8.e4
DDI-DrugBank.d277.s8	false	DDI-DrugBank.d277.s8.e1	DDI-DrugBank.d277.s8.e2
DDI-DrugBank.d277.s8	false	DDI-DrugBank.d277.s8.e1	DDI-DrugBank.d277.s8.e3
DDI-DrugBank.d277.s8	false	DDI-DrugBank.d277.s8.e1	DDI-DrugBank.d277.s8.e4
DDI-DrugBank.d277.s8	false	DDI-DrugBank.d277.s8.e2	DDI-DrugBank.d277.s8.e3
DDI-DrugBank.d277.s8	false	DDI-DrugBank.d277.s8.e2	DDI-DrugBank.d277.s8.e4
DDI-DrugBank.d277.s8	false	DDI-DrugBank.d277.s8.e3	DDI-DrugBank.d277.s8.e4
DDI-DrugBank.d277.s9|a|The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.
DDI-DrugBank.d277.s9	16	24	tiagabine	drug	DDI-DrugBank.d277.s9.e0
DDI-DrugBank.d277.s9	123	135	phenobarbital	drug	DDI-DrugBank.d277.s9.e1
DDI-DrugBank.d277.s9	140	148	primidone	drug	DDI-DrugBank.d277.s9.e2
DDI-DrugBank.d277.s9	false	DDI-DrugBank.d277.s9.e0	DDI-DrugBank.d277.s9.e1
DDI-DrugBank.d277.s9	false	DDI-DrugBank.d277.s9.e0	DDI-DrugBank.d277.s9.e2
DDI-DrugBank.d277.s9	false	DDI-DrugBank.d277.s9.e1	DDI-DrugBank.d277.s9.e2
DDI-DrugBank.d277.s10|a|Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
DDI-DrugBank.d277.s10	37	40	AEDs	group	DDI-DrugBank.d277.s10.e0
DDI-DrugBank.d277.s10	46	53	GABITRIL	brand	DDI-DrugBank.d277.s10.e1
DDI-DrugBank.d277.s10	57	69	Carbamazepine	drug	DDI-DrugBank.d277.s10.e2
DDI-DrugBank.d277.s10	122	130	tiagabine	drug	DDI-DrugBank.d277.s10.e3
DDI-DrugBank.d277.s10	176	188	carbamazepine	drug	DDI-DrugBank.d277.s10.e4
DDI-DrugBank.d277.s10	229	232	AEDs	group	DDI-DrugBank.d277.s10.e5
DDI-DrugBank.d277.s10	false	DDI-DrugBank.d277.s10.e0	DDI-DrugBank.d277.s10.e1
DDI-DrugBank.d277.s10	false	DDI-DrugBank.d277.s10.e0	DDI-DrugBank.d277.s10.e2
DDI-DrugBank.d277.s10	false	DDI-DrugBank.d277.s10.e0	DDI-DrugBank.d277.s10.e3
DDI-DrugBank.d277.s10	false	DDI-DrugBank.d277.s10.e0	DDI-DrugBank.d277.s10.e4
DDI-DrugBank.d277.s10	false	DDI-DrugBank.d277.s10.e0	DDI-DrugBank.d277.s10.e5
DDI-DrugBank.d277.s10	false	DDI-DrugBank.d277.s10.e1	DDI-DrugBank.d277.s10.e2
DDI-DrugBank.d277.s10	false	DDI-DrugBank.d277.s10.e1	DDI-DrugBank.d277.s10.e3
DDI-DrugBank.d277.s10	false	DDI-DrugBank.d277.s10.e1	DDI-DrugBank.d277.s10.e4
DDI-DrugBank.d277.s10	false	DDI-DrugBank.d277.s10.e1	DDI-DrugBank.d277.s10.e5
DDI-DrugBank.d277.s10	false	DDI-DrugBank.d277.s10.e2	DDI-DrugBank.d277.s10.e3
DDI-DrugBank.d277.s11|a|Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.
DDI-DrugBank.d277.s11	0	8	Phenytoin	drug	DDI-DrugBank.d277.s11.e0
DDI-DrugBank.d277.s11	61	69	tiagabine	drug	DDI-DrugBank.d277.s11.e1
DDI-DrugBank.d277.s11	115	123	phenytoin	drug	DDI-DrugBank.d277.s11.e2
DDI-DrugBank.d277.s11	164	167	AEDs	group	DDI-DrugBank.d277.s11.e3
DDI-DrugBank.d277.s11	false	DDI-DrugBank.d277.s11.e0	DDI-DrugBank.d277.s11.e1
DDI-DrugBank.d277.s11	false	DDI-DrugBank.d277.s11.e0	DDI-DrugBank.d277.s11.e2
DDI-DrugBank.d277.s11	false	DDI-DrugBank.d277.s11.e0	DDI-DrugBank.d277.s11.e3
DDI-DrugBank.d277.s11	true	DDI-DrugBank.d277.s11.e1	DDI-DrugBank.d277.s11.e2
DDI-DrugBank.d277.s11	false	DDI-DrugBank.d277.s11.e1	DDI-DrugBank.d277.s11.e3
DDI-DrugBank.d277.s11	false	DDI-DrugBank.d277.s11.e2	DDI-DrugBank.d277.s11.e3
DDI-DrugBank.d277.s12|a|Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
DDI-DrugBank.d277.s12	0	12	Phenobarbital	drug	DDI-DrugBank.d277.s12.e0
DDI-DrugBank.d277.s12	15	23	Primidone	drug	DDI-DrugBank.d277.s12.e1
DDI-DrugBank.d277.s12	77	85	tiagabine	drug	DDI-DrugBank.d277.s12.e2
DDI-DrugBank.d277.s12	131	143	phenobarbital	drug	DDI-DrugBank.d277.s12.e3
DDI-DrugBank.d277.s12	146	154	primidone	drug	DDI-DrugBank.d277.s12.e4
DDI-DrugBank.d277.s12	195	198	AEDs	group	DDI-DrugBank.d277.s12.e5
DDI-DrugBank.d277.s12	false	DDI-DrugBank.d277.s12.e0	DDI-DrugBank.d277.s12.e1
DDI-DrugBank.d277.s12	false	DDI-DrugBank.d277.s12.e0	DDI-DrugBank.d277.s12.e2
DDI-DrugBank.d277.s12	false	DDI-DrugBank.d277.s12.e0	DDI-DrugBank.d277.s12.e3
DDI-DrugBank.d277.s12	false	DDI-DrugBank.d277.s12.e0	DDI-DrugBank.d277.s12.e4
DDI-DrugBank.d277.s12	false	DDI-DrugBank.d277.s12.e0	DDI-DrugBank.d277.s12.e5
DDI-DrugBank.d277.s12	false	DDI-DrugBank.d277.s12.e1	DDI-DrugBank.d277.s12.e2
DDI-DrugBank.d277.s12	false	DDI-DrugBank.d277.s12.e1	DDI-DrugBank.d277.s12.e3
DDI-DrugBank.d277.s12	false	DDI-DrugBank.d277.s12.e1	DDI-DrugBank.d277.s12.e4
DDI-DrugBank.d277.s12	false	DDI-DrugBank.d277.s12.e1	DDI-DrugBank.d277.s12.e5
DDI-DrugBank.d277.s12	true	DDI-DrugBank.d277.s12.e2	DDI-DrugBank.d277.s12.e3
DDI-DrugBank.d277.s13|a|Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
DDI-DrugBank.d277.s13	0	8	Valproate	drug	DDI-DrugBank.d277.s13.e0
DDI-DrugBank.d277.s13	27	35	tiagabine	drug	DDI-DrugBank.d277.s13.e1
DDI-DrugBank.d277.s13	56	64	valproate	drug	DDI-DrugBank.d277.s13.e2
DDI-DrugBank.d277.s13	95	103	tiagabine	drug	DDI-DrugBank.d277.s13.e3
DDI-DrugBank.d277.s13	127	135	valproate	drug	DDI-DrugBank.d277.s13.e4
DDI-DrugBank.d277.s13	161	169	tiagabine	drug	DDI-DrugBank.d277.s13.e5
DDI-DrugBank.d277.s13	false	DDI-DrugBank.d277.s13.e0	DDI-DrugBank.d277.s13.e1
DDI-DrugBank.d277.s13	false	DDI-DrugBank.d277.s13.e0	DDI-DrugBank.d277.s13.e2
DDI-DrugBank.d277.s13	false	DDI-DrugBank.d277.s13.e0	DDI-DrugBank.d277.s13.e3
DDI-DrugBank.d277.s13	false	DDI-DrugBank.d277.s13.e0	DDI-DrugBank.d277.s13.e4
DDI-DrugBank.d277.s13	false	DDI-DrugBank.d277.s13.e0	DDI-DrugBank.d277.s13.e5
DDI-DrugBank.d277.s13	false	DDI-DrugBank.d277.s13.e1	DDI-DrugBank.d277.s13.e2
DDI-DrugBank.d277.s13	false	DDI-DrugBank.d277.s13.e1	DDI-DrugBank.d277.s13.e3
DDI-DrugBank.d277.s13	false	DDI-DrugBank.d277.s13.e1	DDI-DrugBank.d277.s13.e4
DDI-DrugBank.d277.s13	false	DDI-DrugBank.d277.s13.e1	DDI-DrugBank.d277.s13.e5
DDI-DrugBank.d277.s13	false	DDI-DrugBank.d277.s13.e2	DDI-DrugBank.d277.s13.e3
DDI-DrugBank.d277.s14|a|The clinical relevance of this in vitro finding is unknown.
DDI-DrugBank.d277.s15|a|Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.
DDI-DrugBank.d277.s15	15	22	GABITRIL	brand	DDI-DrugBank.d277.s15.e0
DDI-DrugBank.d277.s15	43	52	Cimetidine	drug	DDI-DrugBank.d277.s15.e1
DDI-DrugBank.d277.s15	77	86	cimetidine	drug	DDI-DrugBank.d277.s15.e2
DDI-DrugBank.d277.s15	120	128	tiagabine	drug	DDI-DrugBank.d277.s15.e3
DDI-DrugBank.d277.s15	159	167	tiagabine	drug	DDI-DrugBank.d277.s15.e4
DDI-DrugBank.d277.s15	false	DDI-DrugBank.d277.s15.e0	DDI-DrugBank.d277.s15.e1
DDI-DrugBank.d277.s15	false	DDI-DrugBank.d277.s15.e0	DDI-DrugBank.d277.s15.e2
DDI-DrugBank.d277.s15	false	DDI-DrugBank.d277.s15.e0	DDI-DrugBank.d277.s15.e3
DDI-DrugBank.d277.s15	false	DDI-DrugBank.d277.s15.e0	DDI-DrugBank.d277.s15.e4
DDI-DrugBank.d277.s15	false	DDI-DrugBank.d277.s15.e1	DDI-DrugBank.d277.s15.e2
DDI-DrugBank.d277.s15	false	DDI-DrugBank.d277.s15.e1	DDI-DrugBank.d277.s15.e3
DDI-DrugBank.d277.s15	false	DDI-DrugBank.d277.s15.e1	DDI-DrugBank.d277.s15.e4
DDI-DrugBank.d277.s15	false	DDI-DrugBank.d277.s15.e2	DDI-DrugBank.d277.s15.e3
DDI-DrugBank.d277.s15	false	DDI-DrugBank.d277.s15.e2	DDI-DrugBank.d277.s15.e4
DDI-DrugBank.d277.s15	false	DDI-DrugBank.d277.s15.e3	DDI-DrugBank.d277.s15.e4
DDI-DrugBank.d277.s16|a|Theophylline: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.
DDI-DrugBank.d277.s16	0	11	Theophylline	drug	DDI-DrugBank.d277.s16.e0
DDI-DrugBank.d277.s16	37	45	tiagabine	drug	DDI-DrugBank.d277.s16.e1
DDI-DrugBank.d277.s16	86	97	theophylline	drug	DDI-DrugBank.d277.s16.e2
DDI-DrugBank.d277.s16	false	DDI-DrugBank.d277.s16.e0	DDI-DrugBank.d277.s16.e1
DDI-DrugBank.d277.s16	false	DDI-DrugBank.d277.s16.e0	DDI-DrugBank.d277.s16.e2
DDI-DrugBank.d277.s16	false	DDI-DrugBank.d277.s16.e1	DDI-DrugBank.d277.s16.e2
DDI-DrugBank.d277.s17|a|Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.
DDI-DrugBank.d277.s17	0	7	Warfarin	drug	DDI-DrugBank.d277.s17.e0
DDI-DrugBank.d277.s17	91	100	R-warfarin	drug	DDI-DrugBank.d277.s17.e1
DDI-DrugBank.d277.s17	105	114	S-warfarin	drug	DDI-DrugBank.d277.s17.e2
DDI-DrugBank.d277.s17	137	145	tiagabine	drug	DDI-DrugBank.d277.s17.e3
DDI-DrugBank.d277.s17	false	DDI-DrugBank.d277.s17.e0	DDI-DrugBank.d277.s17.e1
DDI-DrugBank.d277.s17	false	DDI-DrugBank.d277.s17.e0	DDI-DrugBank.d277.s17.e2
DDI-DrugBank.d277.s17	false	DDI-DrugBank.d277.s17.e0	DDI-DrugBank.d277.s17.e3
DDI-DrugBank.d277.s17	false	DDI-DrugBank.d277.s17.e1	DDI-DrugBank.d277.s17.e2
DDI-DrugBank.d277.s17	false	DDI-DrugBank.d277.s17.e1	DDI-DrugBank.d277.s17.e3
DDI-DrugBank.d277.s17	false	DDI-DrugBank.d277.s17.e2	DDI-DrugBank.d277.s17.e3
DDI-DrugBank.d277.s18|a|Prothrombin times were not affected by tiagabine.
DDI-DrugBank.d277.s18	39	47	tiagabine	drug	DDI-DrugBank.d277.s18.e0
DDI-DrugBank.d277.s19|a|Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.
DDI-DrugBank.d277.s19	0	6	Digoxin	drug	DDI-DrugBank.d277.s19.e0
DDI-DrugBank.d277.s19	39	47	tiagabine	drug	DDI-DrugBank.d277.s19.e1
DDI-DrugBank.d277.s19	101	107	digoxin	drug	DDI-DrugBank.d277.s19.e2
DDI-DrugBank.d277.s19	149	155	digoxin	drug	DDI-DrugBank.d277.s19.e3
DDI-DrugBank.d277.s19	false	DDI-DrugBank.d277.s19.e0	DDI-DrugBank.d277.s19.e1
DDI-DrugBank.d277.s19	false	DDI-DrugBank.d277.s19.e0	DDI-DrugBank.d277.s19.e2
DDI-DrugBank.d277.s19	false	DDI-DrugBank.d277.s19.e0	DDI-DrugBank.d277.s19.e3
DDI-DrugBank.d277.s19	false	DDI-DrugBank.d277.s19.e1	DDI-DrugBank.d277.s19.e2
DDI-DrugBank.d277.s19	false	DDI-DrugBank.d277.s19.e1	DDI-DrugBank.d277.s19.e3
DDI-DrugBank.d277.s19	false	DDI-DrugBank.d277.s19.e2	DDI-DrugBank.d277.s19.e3
DDI-DrugBank.d277.s20|a|Ethanol or Triazolam: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.
DDI-DrugBank.d277.s20	0	6	Ethanol	drug	DDI-DrugBank.d277.s20.e0
DDI-DrugBank.d277.s20	11	19	Triazolam	drug	DDI-DrugBank.d277.s20.e1
DDI-DrugBank.d277.s20	90	98	triazolam	drug	DDI-DrugBank.d277.s20.e2
DDI-DrugBank.d277.s20	115	123	tiagabine	drug	DDI-DrugBank.d277.s20.e3
DDI-DrugBank.d277.s20	false	DDI-DrugBank.d277.s20.e0	DDI-DrugBank.d277.s20.e1
DDI-DrugBank.d277.s20	false	DDI-DrugBank.d277.s20.e0	DDI-DrugBank.d277.s20.e2
DDI-DrugBank.d277.s20	false	DDI-DrugBank.d277.s20.e0	DDI-DrugBank.d277.s20.e3
DDI-DrugBank.d277.s20	false	DDI-DrugBank.d277.s20.e1	DDI-DrugBank.d277.s20.e2
DDI-DrugBank.d277.s20	false	DDI-DrugBank.d277.s20.e1	DDI-DrugBank.d277.s20.e3
DDI-DrugBank.d277.s20	false	DDI-DrugBank.d277.s20.e2	DDI-DrugBank.d277.s20.e3
DDI-DrugBank.d277.s21|a|The pharmacokinetics of ethanol were not affected by multiple-dose administration of tiagabine.
DDI-DrugBank.d277.s21	24	30	ethanol	drug	DDI-DrugBank.d277.s21.e0
DDI-DrugBank.d277.s21	85	93	tiagabine	drug	DDI-DrugBank.d277.s21.e1
DDI-DrugBank.d277.s21	false	DDI-DrugBank.d277.s21.e0	DDI-DrugBank.d277.s21.e1
DDI-DrugBank.d277.s22|a|Tiagabine has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or alcohol.
DDI-DrugBank.d277.s22	0	8	Tiagabine	drug	DDI-DrugBank.d277.s22.e0
DDI-DrugBank.d277.s22	105	111	alcohol	drug	DDI-DrugBank.d277.s22.e1
DDI-DrugBank.d277.s22	false	DDI-DrugBank.d277.s22.e0	DDI-DrugBank.d277.s22.e1
DDI-DrugBank.d277.s23|a|Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
DDI-DrugBank.d277.s23	87	93	ethanol	drug	DDI-DrugBank.d277.s23.e0
DDI-DrugBank.d277.s23	98	106	triazolam	drug	DDI-DrugBank.d277.s23.e1
DDI-DrugBank.d277.s23	154	162	tiagabine	drug	DDI-DrugBank.d277.s23.e2
DDI-DrugBank.d277.s23	false	DDI-DrugBank.d277.s23.e0	DDI-DrugBank.d277.s23.e1
DDI-DrugBank.d277.s23	true	DDI-DrugBank.d277.s23.e0	DDI-DrugBank.d277.s23.e2
DDI-DrugBank.d277.s23	true	DDI-DrugBank.d277.s23.e1	DDI-DrugBank.d277.s23.e2
DDI-DrugBank.d277.s24|a|Oral Contraceptives: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.
DDI-DrugBank.d277.s24	5	18	Contraceptives	group	DDI-DrugBank.d277.s24.e0
DDI-DrugBank.d277.s24	53	61	tiagabine	drug	DDI-DrugBank.d277.s24.e1
DDI-DrugBank.d277.s24	129	142	contraceptives	group	DDI-DrugBank.d277.s24.e2
DDI-DrugBank.d277.s24	false	DDI-DrugBank.d277.s24.e0	DDI-DrugBank.d277.s24.e1
DDI-DrugBank.d277.s24	false	DDI-DrugBank.d277.s24.e0	DDI-DrugBank.d277.s24.e2
DDI-DrugBank.d277.s24	false	DDI-DrugBank.d277.s24.e1	DDI-DrugBank.d277.s24.e2
DDI-DrugBank.d277.s25|a|Antipyrine : Antipyrine pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.
DDI-DrugBank.d277.s25	0	9	Antipyrine	drug	DDI-DrugBank.d277.s25.e0
DDI-DrugBank.d277.s25	13	22	Antipyrine	drug	DDI-DrugBank.d277.s25.e1
DDI-DrugBank.d277.s25	91	99	tiagabine	drug	DDI-DrugBank.d277.s25.e2
DDI-DrugBank.d277.s25	false	DDI-DrugBank.d277.s25.e0	DDI-DrugBank.d277.s25.e1
DDI-DrugBank.d277.s25	false	DDI-DrugBank.d277.s25.e0	DDI-DrugBank.d277.s25.e2
DDI-DrugBank.d277.s25	false	DDI-DrugBank.d277.s25.e1	DDI-DrugBank.d277.s25.e2
DDI-DrugBank.d277.s26|a|This indicates that tiagabine does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of antipyrine.
DDI-DrugBank.d277.s26	20	28	tiagabine	drug	DDI-DrugBank.d277.s26.e0
DDI-DrugBank.d277.s26	144	153	antipyrine	drug	DDI-DrugBank.d277.s26.e1
DDI-DrugBank.d277.s26	false	DDI-DrugBank.d277.s26.e0	DDI-DrugBank.d277.s26.e1
DDI-DrugBank.d277.s27|a|Interaction of GABITRIL with Highly Protein Bound Drugs: In vitro data showed that tiagabine is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.
DDI-DrugBank.d277.s27	15	22	GABITRIL	brand	DDI-DrugBank.d277.s27.e0
DDI-DrugBank.d277.s27	83	91	tiagabine	drug	DDI-DrugBank.d277.s27.e1
DDI-DrugBank.d277.s27	false	DDI-DrugBank.d277.s27.e0	DDI-DrugBank.d277.s27.e1
DDI-DrugBank.d277.s28|a|Such an interaction can potentially lead to higher free fractions of either tiagabine or the competing drug.
DDI-DrugBank.d277.s28	76	84	tiagabine	drug	DDI-DrugBank.d277.s28.e0
DDI-DrugBank.d328.s0|a|The drug interaction studies with valdecoxib were performed both with valdecoxib and a rapidly hydrolyzed intravenous prodrug form.
DDI-DrugBank.d328.s0	34	43	valdecoxib	drug	DDI-DrugBank.d328.s0.e0
DDI-DrugBank.d328.s0	70	79	valdecoxib	drug	DDI-DrugBank.d328.s0.e1
DDI-DrugBank.d328.s0	false	DDI-DrugBank.d328.s0.e0	DDI-DrugBank.d328.s0.e1
DDI-DrugBank.d328.s1|a|The results from trials using the intravenous prodrug are reported in this section as they relate to the role of valdecoxib in drug interactions.
DDI-DrugBank.d328.s1	113	122	valdecoxib	drug	DDI-DrugBank.d328.s1.e0
DDI-DrugBank.d328.s2|a|General: In humans, valdecoxib metabolism is predominantly mediated via CYP 3A4 and 2C9 with glucuronidation being a further (20%) route of metabolism.
DDI-DrugBank.d328.s2	20	29	valdecoxib	drug	DDI-DrugBank.d328.s2.e0
DDI-DrugBank.d328.s3|a|In vitro studies indicate that valdecoxib is a moderate inhibitor of CYP 2C19 (IC50 = 6  g/mL or 19  M) and 2C9 (IC50 = 13  g/mL or 41  M), and a weak inhibitor of CYP 2D6 (IC50 = 31  g/mL or 100  M) and 3A4 (IC50 = 44  g/mL or 141  M )..
DDI-DrugBank.d328.s3	31	40	valdecoxib	drug	DDI-DrugBank.d328.s3.e0
DDI-DrugBank.d328.s4|a|Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
DDI-DrugBank.d328.s4	0	6	Aspirin	brand	DDI-DrugBank.d328.s4.e0
DDI-DrugBank.d328.s4	39	45	aspirin	brand	DDI-DrugBank.d328.s4.e1
DDI-DrugBank.d328.s4	52	61	valdecoxib	drug	DDI-DrugBank.d328.s4.e2
DDI-DrugBank.d328.s4	142	151	valdecoxib	drug	DDI-DrugBank.d328.s4.e3
DDI-DrugBank.d328.s4	false	DDI-DrugBank.d328.s4.e0	DDI-DrugBank.d328.s4.e1
DDI-DrugBank.d328.s4	false	DDI-DrugBank.d328.s4.e0	DDI-DrugBank.d328.s4.e2
DDI-DrugBank.d328.s4	false	DDI-DrugBank.d328.s4.e0	DDI-DrugBank.d328.s4.e3
DDI-DrugBank.d328.s4	true	DDI-DrugBank.d328.s4.e1	DDI-DrugBank.d328.s4.e2
DDI-DrugBank.d328.s4	false	DDI-DrugBank.d328.s4.e1	DDI-DrugBank.d328.s4.e3
DDI-DrugBank.d328.s4	false	DDI-DrugBank.d328.s4.e2	DDI-DrugBank.d328.s4.e3
DDI-DrugBank.d328.s5|a|Because of its lack of anti-platelet effect valdecoxib is not a substitute for aspirin for cardiovascular prophylaxis.
DDI-DrugBank.d328.s5	44	53	valdecoxib	drug	DDI-DrugBank.d328.s5.e0
DDI-DrugBank.d328.s5	79	85	aspirin	brand	DDI-DrugBank.d328.s5.e1
DDI-DrugBank.d328.s5	false	DDI-DrugBank.d328.s5.e0	DDI-DrugBank.d328.s5.e1
DDI-DrugBank.d328.s6|a|In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro aspirin-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.
DDI-DrugBank.d328.s6	85	94	valdecoxib	drug	DDI-DrugBank.d328.s6.e0
DDI-DrugBank.d328.s6	134	143	valdecoxib	drug	DDI-DrugBank.d328.s6.e1
DDI-DrugBank.d328.s6	171	177	aspirin	brand	DDI-DrugBank.d328.s6.e2
DDI-DrugBank.d328.s6	false	DDI-DrugBank.d328.s6.e0	DDI-DrugBank.d328.s6.e1
DDI-DrugBank.d328.s6	false	DDI-DrugBank.d328.s6.e0	DDI-DrugBank.d328.s6.e2
DDI-DrugBank.d328.s6	false	DDI-DrugBank.d328.s6.e1	DDI-DrugBank.d328.s6.e2
DDI-DrugBank.d328.s7|a|Methotrexate: Valdecoxib 10 mg BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate.
DDI-DrugBank.d328.s7	0	11	Methotrexate	drug	DDI-DrugBank.d328.s7.e0
DDI-DrugBank.d328.s7	14	29	Valdecoxib 10 mg	drug	DDI-DrugBank.d328.s7.e1
DDI-DrugBank.d328.s7	114	125	methotrexate	drug	DDI-DrugBank.d328.s7.e2
DDI-DrugBank.d328.s7	false	DDI-DrugBank.d328.s7.e0	DDI-DrugBank.d328.s7.e1
DDI-DrugBank.d328.s7	false	DDI-DrugBank.d328.s7.e0	DDI-DrugBank.d328.s7.e2
DDI-DrugBank.d328.s7	false	DDI-DrugBank.d328.s7.e1	DDI-DrugBank.d328.s7.e2
DDI-DrugBank.d328.s8|a|ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
DDI-DrugBank.d328.s8	0	13	ACE-inhibitors	group	DDI-DrugBank.d328.s8.e0
DDI-DrugBank.d328.s8	36	41	NSAIDs	group	DDI-DrugBank.d328.s8.e1
DDI-DrugBank.d328.s8	87	100	ACE-inhibitors	group	DDI-DrugBank.d328.s8.e2
DDI-DrugBank.d328.s8	false	DDI-DrugBank.d328.s8.e0	DDI-DrugBank.d328.s8.e1
DDI-DrugBank.d328.s8	false	DDI-DrugBank.d328.s8.e0	DDI-DrugBank.d328.s8.e2
DDI-DrugBank.d328.s8	true	DDI-DrugBank.d328.s8.e1	DDI-DrugBank.d328.s8.e2
DDI-DrugBank.d328.s9|a|This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.
DDI-DrugBank.d328.s9	66	71	BEXTRA	brand	DDI-DrugBank.d328.s9.e0
DDI-DrugBank.d328.s9	92	105	ACE-inhibitors	group	DDI-DrugBank.d328.s9.e1
DDI-DrugBank.d328.s9	true	DDI-DrugBank.d328.s9.e0	DDI-DrugBank.d328.s9.e1
DDI-DrugBank.d328.s10|a|Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d328.s10	0	9	Furosemide	drug	DDI-DrugBank.d328.s10.e0
DDI-DrugBank.d328.s10	86	91	NSAIDs	group	DDI-DrugBank.d328.s10.e1
DDI-DrugBank.d328.s10	130	139	furosemide	drug	DDI-DrugBank.d328.s10.e2
DDI-DrugBank.d328.s10	145	153	thiazides	group	DDI-DrugBank.d328.s10.e3
DDI-DrugBank.d328.s10	false	DDI-DrugBank.d328.s10.e0	DDI-DrugBank.d328.s10.e1
DDI-DrugBank.d328.s10	false	DDI-DrugBank.d328.s10.e0	DDI-DrugBank.d328.s10.e2
DDI-DrugBank.d328.s10	false	DDI-DrugBank.d328.s10.e0	DDI-DrugBank.d328.s10.e3
DDI-DrugBank.d328.s10	true	DDI-DrugBank.d328.s10.e1	DDI-DrugBank.d328.s10.e2
DDI-DrugBank.d328.s10	true	DDI-DrugBank.d328.s10.e1	DDI-DrugBank.d328.s10.e3
DDI-DrugBank.d328.s10	false	DDI-DrugBank.d328.s10.e2	DDI-DrugBank.d328.s10.e3
DDI-DrugBank.d328.s11|a|This response has been attributed to inhibition of renal prostaglandin synthesis.
DDI-DrugBank.d328.s12|a|Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
DDI-DrugBank.d328.s12	0	14	Anticonvulsants	group	DDI-DrugBank.d328.s12.e0
DDI-DrugBank.d328.s12	17	25	Phenytoin	drug	DDI-DrugBank.d328.s12.e1
DDI-DrugBank.d328.s12	67	76	valdecoxib	drug	DDI-DrugBank.d328.s12.e2
DDI-DrugBank.d328.s12	191	199	phenytoin	drug	DDI-DrugBank.d328.s12.e3
DDI-DrugBank.d328.s12	false	DDI-DrugBank.d328.s12.e0	DDI-DrugBank.d328.s12.e1
DDI-DrugBank.d328.s12	false	DDI-DrugBank.d328.s12.e0	DDI-DrugBank.d328.s12.e2
DDI-DrugBank.d328.s12	false	DDI-DrugBank.d328.s12.e0	DDI-DrugBank.d328.s12.e3
DDI-DrugBank.d328.s12	false	DDI-DrugBank.d328.s12.e1	DDI-DrugBank.d328.s12.e2
DDI-DrugBank.d328.s12	false	DDI-DrugBank.d328.s12.e1	DDI-DrugBank.d328.s12.e3
DDI-DrugBank.d328.s12	true	DDI-DrugBank.d328.s12.e2	DDI-DrugBank.d328.s12.e3
DDI-DrugBank.d328.s13|a|Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.
DDI-DrugBank.d328.s13	31	40	valdecoxib	drug	DDI-DrugBank.d328.s13.e0
DDI-DrugBank.d328.s13	103	111	phenytoin	drug	DDI-DrugBank.d328.s13.e1
DDI-DrugBank.d328.s13	true	DDI-DrugBank.d328.s13.e0	DDI-DrugBank.d328.s13.e1
DDI-DrugBank.d328.s14|a|Valdecoxib did not have a statistically significant effect on the pharmacokinetics of phenytoin (a CYP 2C9 and CYP 2C19 substrate).
DDI-DrugBank.d328.s14	0	9	Valdecoxib	drug	DDI-DrugBank.d328.s14.e0
DDI-DrugBank.d328.s14	86	94	phenytoin	drug	DDI-DrugBank.d328.s14.e1
DDI-DrugBank.d328.s14	false	DDI-DrugBank.d328.s14.e0	DDI-DrugBank.d328.s14.e1
DDI-DrugBank.d328.s15|a|Drug interaction studies with other anticonvulsants have not been conducted.
DDI-DrugBank.d328.s15	36	50	anticonvulsants	group	DDI-DrugBank.d328.s15.e0
DDI-DrugBank.d328.s16|a|Routine monitoring should be performed when therapy with BEXTRA is either initiated or discontinued in patients on anticonvulsant therapy.
DDI-DrugBank.d328.s16	57	62	BEXTRA	brand	DDI-DrugBank.d328.s16.e0
DDI-DrugBank.d328.s17|a|Dextromethorphan: Dextromethorphan is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.
DDI-DrugBank.d328.s17	0	15	Dextromethorphan	drug	DDI-DrugBank.d328.s17.e0
DDI-DrugBank.d328.s17	18	33	Dextromethorphan	drug	DDI-DrugBank.d328.s17.e1
DDI-DrugBank.d328.s17	false	DDI-DrugBank.d328.s17.e0	DDI-DrugBank.d328.s17.e1
DDI-DrugBank.d328.s18|a|Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.
DDI-DrugBank.d328.s18	22	31	valdecoxib	drug	DDI-DrugBank.d328.s18.e0
DDI-DrugBank.d328.s18	94	109	dextromethorphan	drug	DDI-DrugBank.d328.s18.e1
DDI-DrugBank.d328.s18	158	167	valdecoxib	drug	DDI-DrugBank.d328.s18.e2
DDI-DrugBank.d328.s18	true	DDI-DrugBank.d328.s18.e0	DDI-DrugBank.d328.s18.e1
DDI-DrugBank.d328.s18	false	DDI-DrugBank.d328.s18.e0	DDI-DrugBank.d328.s18.e2
DDI-DrugBank.d328.s18	false	DDI-DrugBank.d328.s18.e1	DDI-DrugBank.d328.s18.e2
DDI-DrugBank.d328.s19|a|Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.
DDI-DrugBank.d328.s19	8	23	dextromethorphan	drug	DDI-DrugBank.d328.s19.e0
DDI-DrugBank.d328.s19	80	89	valdecoxib	drug	DDI-DrugBank.d328.s19.e1
DDI-DrugBank.d328.s19	true	DDI-DrugBank.d328.s19.e0	DDI-DrugBank.d328.s19.e1
DDI-DrugBank.d328.s20|a|Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
DDI-DrugBank.d328.s20	0	6	Lithium	drug	DDI-DrugBank.d328.s20.e0
DDI-DrugBank.d328.s20	9	18	Valdecoxib	drug	DDI-DrugBank.d328.s20.e1
DDI-DrugBank.d328.s20	75	81	lithium	drug	DDI-DrugBank.d328.s20.e2
DDI-DrugBank.d328.s20	176	182	lithium	drug	DDI-DrugBank.d328.s20.e3
DDI-DrugBank.d328.s20	false	DDI-DrugBank.d328.s20.e0	DDI-DrugBank.d328.s20.e1
DDI-DrugBank.d328.s20	false	DDI-DrugBank.d328.s20.e0	DDI-DrugBank.d328.s20.e2
DDI-DrugBank.d328.s20	false	DDI-DrugBank.d328.s20.e0	DDI-DrugBank.d328.s20.e3
DDI-DrugBank.d328.s20	true	DDI-DrugBank.d328.s20.e1	DDI-DrugBank.d328.s20.e2
DDI-DrugBank.d328.s20	false	DDI-DrugBank.d328.s20.e1	DDI-DrugBank.d328.s20.e3
DDI-DrugBank.d328.s20	false	DDI-DrugBank.d328.s20.e2	DDI-DrugBank.d328.s20.e3
DDI-DrugBank.d328.s21|a|Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.
DDI-DrugBank.d328.s21	0	6	Lithium	drug	DDI-DrugBank.d328.s21.e0
DDI-DrugBank.d328.s21	98	103	BEXTRA	brand	DDI-DrugBank.d328.s21.e1
DDI-DrugBank.d328.s21	127	133	lithium	drug	DDI-DrugBank.d328.s21.e2
DDI-DrugBank.d328.s21	false	DDI-DrugBank.d328.s21.e0	DDI-DrugBank.d328.s21.e1
DDI-DrugBank.d328.s21	false	DDI-DrugBank.d328.s21.e0	DDI-DrugBank.d328.s21.e2
DDI-DrugBank.d328.s21	true	DDI-DrugBank.d328.s21.e1	DDI-DrugBank.d328.s21.e2
DDI-DrugBank.d328.s22|a|Lithium carbonate (450 mg BID for 7 days) had no effect on valdecoxib pharmacokinetics.
DDI-DrugBank.d328.s22	0	16	Lithium carbonate	drug	DDI-DrugBank.d328.s22.e0
DDI-DrugBank.d328.s22	59	68	valdecoxib	drug	DDI-DrugBank.d328.s22.e1
DDI-DrugBank.d328.s22	false	DDI-DrugBank.d328.s22.e0	DDI-DrugBank.d328.s22.e1
DDI-DrugBank.d328.s23|a|Warfarin: The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.
DDI-DrugBank.d328.s23	0	7	Warfarin	drug	DDI-DrugBank.d328.s23.e0
DDI-DrugBank.d328.s23	24	33	valdecoxib	drug	DDI-DrugBank.d328.s23.e1
DDI-DrugBank.d328.s23	66	73	warfarin	drug	DDI-DrugBank.d328.s23.e2
DDI-DrugBank.d328.s23	145	150	BEXTRA	brand	DDI-DrugBank.d328.s23.e3
DDI-DrugBank.d328.s23	false	DDI-DrugBank.d328.s23.e0	DDI-DrugBank.d328.s23.e1
DDI-DrugBank.d328.s23	false	DDI-DrugBank.d328.s23.e0	DDI-DrugBank.d328.s23.e2
DDI-DrugBank.d328.s23	false	DDI-DrugBank.d328.s23.e0	DDI-DrugBank.d328.s23.e3
DDI-DrugBank.d328.s23	false	DDI-DrugBank.d328.s23.e1	DDI-DrugBank.d328.s23.e2
DDI-DrugBank.d328.s23	false	DDI-DrugBank.d328.s23.e1	DDI-DrugBank.d328.s23.e3
DDI-DrugBank.d328.s23	false	DDI-DrugBank.d328.s23.e2	DDI-DrugBank.d328.s23.e3
DDI-DrugBank.d328.s24|a|Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
DDI-DrugBank.d328.s24	0	9	Valdecoxib	drug	DDI-DrugBank.d328.s24.e0
DDI-DrugBank.d328.s24	78	87	R-warfarin	drug	DDI-DrugBank.d328.s24.e1
DDI-DrugBank.d328.s24	93	102	S-warfarin	drug	DDI-DrugBank.d328.s24.e2
DDI-DrugBank.d328.s24	207	214	warfarin	drug	DDI-DrugBank.d328.s24.e3
DDI-DrugBank.d328.s24	true	DDI-DrugBank.d328.s24.e0	DDI-DrugBank.d328.s24.e1
DDI-DrugBank.d328.s24	true	DDI-DrugBank.d328.s24.e0	DDI-DrugBank.d328.s24.e2
DDI-DrugBank.d328.s24	true	DDI-DrugBank.d328.s24.e0	DDI-DrugBank.d328.s24.e3
DDI-DrugBank.d328.s24	false	DDI-DrugBank.d328.s24.e1	DDI-DrugBank.d328.s24.e2
DDI-DrugBank.d328.s24	false	DDI-DrugBank.d328.s24.e1	DDI-DrugBank.d328.s24.e3
DDI-DrugBank.d328.s24	false	DDI-DrugBank.d328.s24.e2	DDI-DrugBank.d328.s24.e3
DDI-DrugBank.d328.s25|a|While mean INR values were only slightly increased with coadministration of valdecoxib, the day-to-day variability in individual INR values was increased.
DDI-DrugBank.d328.s25	76	85	valdecoxib	drug	DDI-DrugBank.d328.s25.e0
DDI-DrugBank.d328.s26|a|Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.
DDI-DrugBank.d328.s26	0	12	Anticoagulant	brand	DDI-DrugBank.d328.s26.e0
DDI-DrugBank.d328.s26	114	119	BEXTRA	brand	DDI-DrugBank.d328.s26.e1
DDI-DrugBank.d328.s26	143	150	warfarin	drug	DDI-DrugBank.d328.s26.e2
DDI-DrugBank.d328.s26	false	DDI-DrugBank.d328.s26.e0	DDI-DrugBank.d328.s26.e1
DDI-DrugBank.d328.s26	false	DDI-DrugBank.d328.s26.e0	DDI-DrugBank.d328.s26.e2
DDI-DrugBank.d328.s26	true	DDI-DrugBank.d328.s26.e1	DDI-DrugBank.d328.s26.e2
DDI-DrugBank.d328.s27|a|Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.
DDI-DrugBank.d328.s27	0	10	Fluconazole	drug	DDI-DrugBank.d328.s27.e0
DDI-DrugBank.d328.s27	16	27	Ketoconazole	drug	DDI-DrugBank.d328.s27.e1
DDI-DrugBank.d328.s27	30	41	Ketoconazole	drug	DDI-DrugBank.d328.s27.e2
DDI-DrugBank.d328.s27	47	57	fluconazole	drug	DDI-DrugBank.d328.s27.e3
DDI-DrugBank.d328.s27	false	DDI-DrugBank.d328.s27.e0	DDI-DrugBank.d328.s27.e1
DDI-DrugBank.d328.s27	false	DDI-DrugBank.d328.s27.e0	DDI-DrugBank.d328.s27.e2
DDI-DrugBank.d328.s27	false	DDI-DrugBank.d328.s27.e0	DDI-DrugBank.d328.s27.e3
DDI-DrugBank.d328.s27	false	DDI-DrugBank.d328.s27.e1	DDI-DrugBank.d328.s27.e2
DDI-DrugBank.d328.s27	false	DDI-DrugBank.d328.s27.e1	DDI-DrugBank.d328.s27.e3
DDI-DrugBank.d328.s27	false	DDI-DrugBank.d328.s27.e2	DDI-DrugBank.d328.s27.e3
DDI-DrugBank.d328.s28|a|Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
DDI-DrugBank.d328.s28	42	51	valdecoxib	drug	DDI-DrugBank.d328.s28.e0
DDI-DrugBank.d328.s28	82	93	ketoconazole	drug	DDI-DrugBank.d328.s28.e1
DDI-DrugBank.d328.s28	99	109	fluconazole	drug	DDI-DrugBank.d328.s28.e2
DDI-DrugBank.d328.s28	158	167	valdecoxib	drug	DDI-DrugBank.d328.s28.e3
DDI-DrugBank.d328.s28	true	DDI-DrugBank.d328.s28.e0	DDI-DrugBank.d328.s28.e1
DDI-DrugBank.d328.s28	true	DDI-DrugBank.d328.s28.e0	DDI-DrugBank.d328.s28.e2
DDI-DrugBank.d328.s28	false	DDI-DrugBank.d328.s28.e0	DDI-DrugBank.d328.s28.e3
DDI-DrugBank.d328.s28	false	DDI-DrugBank.d328.s28.e1	DDI-DrugBank.d328.s28.e2
DDI-DrugBank.d328.s28	false	DDI-DrugBank.d328.s28.e1	DDI-DrugBank.d328.s28.e3
DDI-DrugBank.d328.s28	false	DDI-DrugBank.d328.s28.e2	DDI-DrugBank.d328.s28.e3
DDI-DrugBank.d328.s29|a|Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
DDI-DrugBank.d328.s29	25	34	valdecoxib	drug	DDI-DrugBank.d328.s29.e0
DDI-DrugBank.d328.s29	79	89	fluconazole	drug	DDI-DrugBank.d328.s29.e1
DDI-DrugBank.d328.s29	124	135	ketoconazole	drug	DDI-DrugBank.d328.s29.e2
DDI-DrugBank.d328.s29	true	DDI-DrugBank.d328.s29.e0	DDI-DrugBank.d328.s29.e1
DDI-DrugBank.d328.s29	true	DDI-DrugBank.d328.s29.e0	DDI-DrugBank.d328.s29.e2
DDI-DrugBank.d328.s29	false	DDI-DrugBank.d328.s29.e1	DDI-DrugBank.d328.s29.e2
DDI-DrugBank.d328.s30|a|Glyburide: Glyburide is a CYP 2C9 substrate.
DDI-DrugBank.d328.s30	0	8	Glyburide	drug	DDI-DrugBank.d328.s30.e0
DDI-DrugBank.d328.s30	11	19	Glyburide	drug	DDI-DrugBank.d328.s30.e1
DDI-DrugBank.d328.s30	false	DDI-DrugBank.d328.s30.e0	DDI-DrugBank.d328.s30.e1
DDI-DrugBank.d328.s31|a|Coadministration of valdecoxib (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.
DDI-DrugBank.d328.s31	20	29	valdecoxib	drug	DDI-DrugBank.d328.s31.e0
DDI-DrugBank.d328.s31	59	67	glyburide	drug	DDI-DrugBank.d328.s31.e1
DDI-DrugBank.d328.s31	142	150	glyburide	drug	DDI-DrugBank.d328.s31.e2
DDI-DrugBank.d328.s31	false	DDI-DrugBank.d328.s31.e0	DDI-DrugBank.d328.s31.e1
DDI-DrugBank.d328.s31	false	DDI-DrugBank.d328.s31.e0	DDI-DrugBank.d328.s31.e2
DDI-DrugBank.d328.s31	false	DDI-DrugBank.d328.s31.e1	DDI-DrugBank.d328.s31.e2
DDI-DrugBank.d328.s32|a|Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.
DDI-DrugBank.d328.s32	20	29	valdecoxib	drug	DDI-DrugBank.d328.s32.e0
DDI-DrugBank.d328.s32	80	88	glyburide	drug	DDI-DrugBank.d328.s32.e1
DDI-DrugBank.d328.s32	216	224	glyburide	drug	DDI-DrugBank.d328.s32.e2
DDI-DrugBank.d328.s32	false	DDI-DrugBank.d328.s32.e0	DDI-DrugBank.d328.s32.e1
DDI-DrugBank.d328.s32	false	DDI-DrugBank.d328.s32.e0	DDI-DrugBank.d328.s32.e2
DDI-DrugBank.d328.s32	false	DDI-DrugBank.d328.s32.e1	DDI-DrugBank.d328.s32.e2
DDI-DrugBank.d328.s33|a|Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
DDI-DrugBank.d328.s33	20	29	valdecoxib	drug	DDI-DrugBank.d328.s33.e0
DDI-DrugBank.d328.s33	80	88	glyburide	drug	DDI-DrugBank.d328.s33.e1
DDI-DrugBank.d328.s33	97	105	glyburide	drug	DDI-DrugBank.d328.s33.e2
DDI-DrugBank.d328.s33	140	148	glyburide	drug	DDI-DrugBank.d328.s33.e3
DDI-DrugBank.d328.s33	180	188	glyburide	drug	DDI-DrugBank.d328.s33.e4
DDI-DrugBank.d328.s33	true	DDI-DrugBank.d328.s33.e0	DDI-DrugBank.d328.s33.e1
DDI-DrugBank.d328.s33	false	DDI-DrugBank.d328.s33.e0	DDI-DrugBank.d328.s33.e2
DDI-DrugBank.d328.s33	false	DDI-DrugBank.d328.s33.e0	DDI-DrugBank.d328.s33.e3
DDI-DrugBank.d328.s33	false	DDI-DrugBank.d328.s33.e0	DDI-DrugBank.d328.s33.e4
DDI-DrugBank.d328.s33	false	DDI-DrugBank.d328.s33.e1	DDI-DrugBank.d328.s33.e2
DDI-DrugBank.d328.s33	false	DDI-DrugBank.d328.s33.e1	DDI-DrugBank.d328.s33.e3
DDI-DrugBank.d328.s33	false	DDI-DrugBank.d328.s33.e1	DDI-DrugBank.d328.s33.e4
DDI-DrugBank.d328.s33	false	DDI-DrugBank.d328.s33.e2	DDI-DrugBank.d328.s33.e3
DDI-DrugBank.d328.s33	false	DDI-DrugBank.d328.s33.e2	DDI-DrugBank.d328.s33.e4
DDI-DrugBank.d328.s33	false	DDI-DrugBank.d328.s33.e3	DDI-DrugBank.d328.s33.e4
DDI-DrugBank.d328.s34|a|Insulin parameters were not affected.
DDI-DrugBank.d328.s35|a|Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.
DDI-DrugBank.d328.s35	47	56	valdecoxib	drug	DDI-DrugBank.d328.s35.e0
DDI-DrugBank.d328.s35	197	205	glyburide	drug	DDI-DrugBank.d328.s35.e1
DDI-DrugBank.d328.s35	236	245	valdecoxib	drug	DDI-DrugBank.d328.s35.e2
DDI-DrugBank.d328.s35	false	DDI-DrugBank.d328.s35.e0	DDI-DrugBank.d328.s35.e1
DDI-DrugBank.d328.s35	false	DDI-DrugBank.d328.s35.e0	DDI-DrugBank.d328.s35.e2
DDI-DrugBank.d328.s35	true	DDI-DrugBank.d328.s35.e1	DDI-DrugBank.d328.s35.e2
DDI-DrugBank.d328.s36|a|Coadministration of glyburide with doses higher than 40 mg valdecoxib (e.g., 40 mg BID) have not been studied.
DDI-DrugBank.d328.s36	20	28	glyburide	drug	DDI-DrugBank.d328.s36.e0
DDI-DrugBank.d328.s36	59	68	valdecoxib	drug	DDI-DrugBank.d328.s36.e1
DDI-DrugBank.d328.s36	false	DDI-DrugBank.d328.s36.e0	DDI-DrugBank.d328.s36.e1
DDI-DrugBank.d328.s37|a|Omeprazole: Omeprazole is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor.
DDI-DrugBank.d328.s37	0	9	Omeprazole	drug	DDI-DrugBank.d328.s37.e0
DDI-DrugBank.d328.s37	12	21	Omeprazole	drug	DDI-DrugBank.d328.s37.e1
DDI-DrugBank.d328.s37	false	DDI-DrugBank.d328.s37.e0	DDI-DrugBank.d328.s37.e1
DDI-DrugBank.d328.s38|a|Valdecoxib steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of omeprazole (40 mg QD).
DDI-DrugBank.d328.s38	0	9	Valdecoxib	drug	DDI-DrugBank.d328.s38.e0
DDI-DrugBank.d328.s38	113	122	omeprazole	drug	DDI-DrugBank.d328.s38.e1
DDI-DrugBank.d328.s38	false	DDI-DrugBank.d328.s38.e0	DDI-DrugBank.d328.s38.e1
DDI-DrugBank.d328.s39|a|Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.
DDI-DrugBank.d328.s39	22	31	valdecoxib	drug	DDI-DrugBank.d328.s39.e0
DDI-DrugBank.d328.s39	55	64	omeprazole	drug	DDI-DrugBank.d328.s39.e1
DDI-DrugBank.d328.s39	true	DDI-DrugBank.d328.s39.e0	DDI-DrugBank.d328.s39.e1
DDI-DrugBank.d328.s40|a|Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of omeprazole and valdecoxib.
DDI-DrugBank.d328.s40	102	111	omeprazole	drug	DDI-DrugBank.d328.s40.e0
DDI-DrugBank.d328.s40	117	126	valdecoxib	drug	DDI-DrugBank.d328.s40.e1
DDI-DrugBank.d328.s40	false	DDI-DrugBank.d328.s40.e0	DDI-DrugBank.d328.s40.e1
DDI-DrugBank.d328.s41|a|However, because higher doses (up to 360 mg QD) of omeprazole are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for omeprazole is recommended at current doses.
DDI-DrugBank.d328.s41	51	60	omeprazole	drug	DDI-DrugBank.d328.s41.e0
DDI-DrugBank.d328.s41	135	144	omeprazole	drug	DDI-DrugBank.d328.s41.e1
DDI-DrugBank.d328.s41	false	DDI-DrugBank.d328.s41.e0	DDI-DrugBank.d328.s41.e1
DDI-DrugBank.d328.s42|a|Coadministration of valdecoxib with doses higher than 40 mg QD omeprazole has not been studied.
DDI-DrugBank.d328.s42	20	29	valdecoxib	drug	DDI-DrugBank.d328.s42.e0
DDI-DrugBank.d328.s42	63	72	omeprazole	drug	DDI-DrugBank.d328.s42.e1
DDI-DrugBank.d328.s42	false	DDI-DrugBank.d328.s42.e0	DDI-DrugBank.d328.s42.e1
DDI-DrugBank.d328.s43|a|Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).
DDI-DrugBank.d328.s43	5	18	Contraceptives	group	DDI-DrugBank.d328.s43.e0
DDI-DrugBank.d328.s43	21	30	Valdecoxib	drug	DDI-DrugBank.d328.s43.e1
DDI-DrugBank.d328.s43	98	110	contraceptive	group	DDI-DrugBank.d328.s43.e2
DDI-DrugBank.d328.s43	112	124	norethindrone	drug	DDI-DrugBank.d328.s43.e3
DDI-DrugBank.d328.s43	126	142	ethinyl estradiol	drug	DDI-DrugBank.d328.s43.e4
DDI-DrugBank.d328.s43	171	181	Ortho-Novum	brand	DDI-DrugBank.d328.s43.e5
DDI-DrugBank.d328.s43	false	DDI-DrugBank.d328.s43.e0	DDI-DrugBank.d328.s43.e1
DDI-DrugBank.d328.s43	false	DDI-DrugBank.d328.s43.e0	DDI-DrugBank.d328.s43.e2
DDI-DrugBank.d328.s43	false	DDI-DrugBank.d328.s43.e0	DDI-DrugBank.d328.s43.e3
DDI-DrugBank.d328.s43	false	DDI-DrugBank.d328.s43.e0	DDI-DrugBank.d328.s43.e4
DDI-DrugBank.d328.s43	false	DDI-DrugBank.d328.s43.e0	DDI-DrugBank.d328.s43.e5
DDI-DrugBank.d328.s43	false	DDI-DrugBank.d328.s43.e1	DDI-DrugBank.d328.s43.e2
DDI-DrugBank.d328.s43	false	DDI-DrugBank.d328.s43.e1	DDI-DrugBank.d328.s43.e3
DDI-DrugBank.d328.s43	false	DDI-DrugBank.d328.s43.e1	DDI-DrugBank.d328.s43.e4
DDI-DrugBank.d328.s43	false	DDI-DrugBank.d328.s43.e1	DDI-DrugBank.d328.s43.e5
DDI-DrugBank.d328.s43	false	DDI-DrugBank.d328.s43.e2	DDI-DrugBank.d328.s43.e3
DDI-DrugBank.d328.s44|a|Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.
DDI-DrugBank.d328.s44	20	29	valdecoxib	drug	DDI-DrugBank.d328.s44.e0
DDI-DrugBank.d328.s44	35	45	Ortho-Novum	brand	DDI-DrugBank.d328.s44.e1
DDI-DrugBank.d328.s44	79	91	norethindrone	drug	DDI-DrugBank.d328.s44.e2
DDI-DrugBank.d328.s44	97	113	ethinyl estradiol	drug	DDI-DrugBank.d328.s44.e3
DDI-DrugBank.d328.s44	true	DDI-DrugBank.d328.s44.e0	DDI-DrugBank.d328.s44.e1
DDI-DrugBank.d328.s44	false	DDI-DrugBank.d328.s44.e0	DDI-DrugBank.d328.s44.e2
DDI-DrugBank.d328.s44	false	DDI-DrugBank.d328.s44.e0	DDI-DrugBank.d328.s44.e3
DDI-DrugBank.d328.s44	false	DDI-DrugBank.d328.s44.e1	DDI-DrugBank.d328.s44.e2
DDI-DrugBank.d328.s44	false	DDI-DrugBank.d328.s44.e1	DDI-DrugBank.d328.s44.e3
DDI-DrugBank.d328.s44	false	DDI-DrugBank.d328.s44.e2	DDI-DrugBank.d328.s44.e3
DDI-DrugBank.d328.s45|a|Although there is little risk for loss of contraceptive efficacy, the clinical significance of these increased exposures in terms of safety is not known.
DDI-DrugBank.d328.s46|a|These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.
DDI-DrugBank.d328.s46	29	41	norethindrone	drug	DDI-DrugBank.d328.s46.e0
DDI-DrugBank.d328.s46	47	63	ethinyl estradiol	drug	DDI-DrugBank.d328.s46.e1
DDI-DrugBank.d328.s46	123	135	contraceptive	group	DDI-DrugBank.d328.s46.e2
DDI-DrugBank.d328.s46	154	163	valdecoxib	drug	DDI-DrugBank.d328.s46.e3
DDI-DrugBank.d328.s46	false	DDI-DrugBank.d328.s46.e0	DDI-DrugBank.d328.s46.e1
DDI-DrugBank.d328.s46	false	DDI-DrugBank.d328.s46.e0	DDI-DrugBank.d328.s46.e2
DDI-DrugBank.d328.s46	false	DDI-DrugBank.d328.s46.e0	DDI-DrugBank.d328.s46.e3
DDI-DrugBank.d328.s46	false	DDI-DrugBank.d328.s46.e1	DDI-DrugBank.d328.s46.e2
DDI-DrugBank.d328.s46	false	DDI-DrugBank.d328.s46.e1	DDI-DrugBank.d328.s46.e3
DDI-DrugBank.d328.s46	true	DDI-DrugBank.d328.s46.e2	DDI-DrugBank.d328.s46.e3
DDI-DrugBank.d328.s47|a|Diazepam: Diazepam (Valium) is a CYP 3A4 and CYP 2C19 substrate.
DDI-DrugBank.d328.s47	0	7	Diazepam	drug	DDI-DrugBank.d328.s47.e0
DDI-DrugBank.d328.s47	10	17	Diazepam	drug	DDI-DrugBank.d328.s47.e1
DDI-DrugBank.d328.s47	20	25	Valium	brand	DDI-DrugBank.d328.s47.e2
DDI-DrugBank.d328.s47	false	DDI-DrugBank.d328.s47.e0	DDI-DrugBank.d328.s47.e1
DDI-DrugBank.d328.s47	false	DDI-DrugBank.d328.s47.e0	DDI-DrugBank.d328.s47.e2
DDI-DrugBank.d328.s47	false	DDI-DrugBank.d328.s47.e1	DDI-DrugBank.d328.s47.e2
DDI-DrugBank.d328.s48|a|Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
DDI-DrugBank.d328.s48	19	26	diazepam	drug	DDI-DrugBank.d328.s48.e0
DDI-DrugBank.d328.s48	89	98	valdecoxib	drug	DDI-DrugBank.d328.s48.e1
DDI-DrugBank.d328.s48	150	159	valdecoxib	drug	DDI-DrugBank.d328.s48.e2
DDI-DrugBank.d328.s48	233	240	diazepam	drug	DDI-DrugBank.d328.s48.e3
DDI-DrugBank.d328.s48	true	DDI-DrugBank.d328.s48.e0	DDI-DrugBank.d328.s48.e1
DDI-DrugBank.d328.s48	false	DDI-DrugBank.d328.s48.e0	DDI-DrugBank.d328.s48.e2
DDI-DrugBank.d328.s48	false	DDI-DrugBank.d328.s48.e0	DDI-DrugBank.d328.s48.e3
DDI-DrugBank.d328.s48	false	DDI-DrugBank.d328.s48.e1	DDI-DrugBank.d328.s48.e2
DDI-DrugBank.d328.s48	false	DDI-DrugBank.d328.s48.e1	DDI-DrugBank.d328.s48.e3
DDI-DrugBank.d328.s48	false	DDI-DrugBank.d328.s48.e2	DDI-DrugBank.d328.s48.e3
DDI-DrugBank.d328.s49|a|Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.
DDI-DrugBank.d328.s49	37	44	diazepam	drug	DDI-DrugBank.d328.s49.e0
DDI-DrugBank.d328.s49	87	96	valdecoxib	drug	DDI-DrugBank.d328.s49.e1
DDI-DrugBank.d328.s49	236	243	diazepam	drug	DDI-DrugBank.d328.s49.e2
DDI-DrugBank.d328.s49	false	DDI-DrugBank.d328.s49.e0	DDI-DrugBank.d328.s49.e1
DDI-DrugBank.d328.s49	false	DDI-DrugBank.d328.s49.e0	DDI-DrugBank.d328.s49.e2
DDI-DrugBank.d328.s49	true	DDI-DrugBank.d328.s49.e1	DDI-DrugBank.d328.s49.e2
DDI-DrugBank.d328.s50|a|Patients should be cautioned against engaging in hazardous activities requiring complete mental alertness such as operating machinery or driving a motor vehicle.
DDI-DrugBank.d198.s0|a|Effect of other drugs on Vardenafil
DDI-DrugBank.d198.s0	25	34	Vardenafil	drug	DDI-DrugBank.d198.s0.e0
DDI-DrugBank.d198.s1|a|In vitro studies: Studies in human liver microsomes showed that vardenafil is metabolized primarily by cytochrome P450 (CYP) isoforms 3A4/5, and to a lesser degree by CYP2C9.
DDI-DrugBank.d198.s1	64	73	vardenafil	drug	DDI-DrugBank.d198.s1.e0
DDI-DrugBank.d198.s2|a|Therefore, inhibitors of these enzymes are expected to reduce vardenafil clearance.
DDI-DrugBank.d198.s2	62	71	vardenafil	drug	DDI-DrugBank.d198.s2.e0
DDI-DrugBank.d198.s3|a|In vivo studies: Cytochrome P450 Inhibitors
DDI-DrugBank.d198.s4|a|Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.
DDI-DrugBank.d198.s4	0	9	Cimetidine	drug	DDI-DrugBank.d198.s4.e0
DDI-DrugBank.d198.s4	44	53	vardenafil	drug	DDI-DrugBank.d198.s4.e1
DDI-DrugBank.d198.s4	113	122	vardenafil	drug	DDI-DrugBank.d198.s4.e2
DDI-DrugBank.d198.s4	156	165	Vardenafil	drug	DDI-DrugBank.d198.s4.e3
DDI-DrugBank.d198.s4	false	DDI-DrugBank.d198.s4.e0	DDI-DrugBank.d198.s4.e1
DDI-DrugBank.d198.s4	false	DDI-DrugBank.d198.s4.e0	DDI-DrugBank.d198.s4.e2
DDI-DrugBank.d198.s4	false	DDI-DrugBank.d198.s4.e0	DDI-DrugBank.d198.s4.e3
DDI-DrugBank.d198.s4	false	DDI-DrugBank.d198.s4.e1	DDI-DrugBank.d198.s4.e2
DDI-DrugBank.d198.s4	false	DDI-DrugBank.d198.s4.e1	DDI-DrugBank.d198.s4.e3
DDI-DrugBank.d198.s4	false	DDI-DrugBank.d198.s4.e2	DDI-DrugBank.d198.s4.e3
DDI-DrugBank.d198.s5|a|Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.
DDI-DrugBank.d198.s5	0	11	Erythromycin	drug	DDI-DrugBank.d198.s5.e0
DDI-DrugBank.d198.s5	58	67	vardenafil	drug	DDI-DrugBank.d198.s5.e1
DDI-DrugBank.d198.s5	129	138	Vardenafil	drug	DDI-DrugBank.d198.s5.e2
DDI-DrugBank.d198.s5	true	DDI-DrugBank.d198.s5.e0	DDI-DrugBank.d198.s5.e1
DDI-DrugBank.d198.s5	false	DDI-DrugBank.d198.s5.e0	DDI-DrugBank.d198.s5.e2
DDI-DrugBank.d198.s5	false	DDI-DrugBank.d198.s5.e1	DDI-DrugBank.d198.s5.e2
DDI-DrugBank.d198.s6|a|It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.
DDI-DrugBank.d198.s6	54	63	Vardenafil	drug	DDI-DrugBank.d198.s6.e0
DDI-DrugBank.d198.s6	115	126	erythromycin	drug	DDI-DrugBank.d198.s6.e1
DDI-DrugBank.d198.s6	true	DDI-DrugBank.d198.s6.e0	DDI-DrugBank.d198.s6.e1
DDI-DrugBank.d198.s7|a|Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.
DDI-DrugBank.d198.s7	0	11	Ketoconazole	drug	DDI-DrugBank.d198.s7.e0
DDI-DrugBank.d198.s7	64	73	vardenafil	drug	DDI-DrugBank.d198.s7.e1
DDI-DrugBank.d198.s7	135	144	Vardenafil	drug	DDI-DrugBank.d198.s7.e2
DDI-DrugBank.d198.s7	true	DDI-DrugBank.d198.s7.e0	DDI-DrugBank.d198.s7.e1
DDI-DrugBank.d198.s7	false	DDI-DrugBank.d198.s7.e0	DDI-DrugBank.d198.s7.e2
DDI-DrugBank.d198.s7	false	DDI-DrugBank.d198.s7.e1	DDI-DrugBank.d198.s7.e2
DDI-DrugBank.d198.s8|a|A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.
DDI-DrugBank.d198.s8	7	16	Vardenafil	drug	DDI-DrugBank.d198.s8.e0
DDI-DrugBank.d198.s8	94	105	ketoconazole	drug	DDI-DrugBank.d198.s8.e1
DDI-DrugBank.d198.s8	true	DDI-DrugBank.d198.s8.e0	DDI-DrugBank.d198.s8.e1
DDI-DrugBank.d198.s9|a|Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.
DDI-DrugBank.d198.s9	22	33	ketoconazole	drug	DDI-DrugBank.d198.s9.e0
DDI-DrugBank.d198.s9	122	131	Vardenafil	drug	DDI-DrugBank.d198.s9.e1
DDI-DrugBank.d198.s9	206	217	ketoconazole	drug	DDI-DrugBank.d198.s9.e2
DDI-DrugBank.d198.s9	false	DDI-DrugBank.d198.s9.e0	DDI-DrugBank.d198.s9.e1
DDI-DrugBank.d198.s9	false	DDI-DrugBank.d198.s9.e0	DDI-DrugBank.d198.s9.e2
DDI-DrugBank.d198.s9	true	DDI-DrugBank.d198.s9.e1	DDI-DrugBank.d198.s9.e2
DDI-DrugBank.d198.s10|a|HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
DDI-DrugBank.d198.s10	0	22	HIV Protease Inhibitors	group	DDI-DrugBank.d198.s10.e0
DDI-DrugBank.d198.s10	25	33	Indinavir	drug	DDI-DrugBank.d198.s10.e1
DDI-DrugBank.d198.s10	72	81	Vardenafil	drug	DDI-DrugBank.d198.s10.e2
DDI-DrugBank.d198.s10	123	132	vardenafil	drug	DDI-DrugBank.d198.s10.e3
DDI-DrugBank.d198.s10	160	169	vardenafil	drug	DDI-DrugBank.d198.s10.e4
DDI-DrugBank.d198.s10	201	210	vardenafil	drug	DDI-DrugBank.d198.s10.e5
DDI-DrugBank.d198.s10	false	DDI-DrugBank.d198.s10.e0	DDI-DrugBank.d198.s10.e1
DDI-DrugBank.d198.s10	false	DDI-DrugBank.d198.s10.e0	DDI-DrugBank.d198.s10.e2
DDI-DrugBank.d198.s10	false	DDI-DrugBank.d198.s10.e0	DDI-DrugBank.d198.s10.e3
DDI-DrugBank.d198.s10	false	DDI-DrugBank.d198.s10.e0	DDI-DrugBank.d198.s10.e4
DDI-DrugBank.d198.s10	false	DDI-DrugBank.d198.s10.e0	DDI-DrugBank.d198.s10.e5
DDI-DrugBank.d198.s10	true	DDI-DrugBank.d198.s10.e1	DDI-DrugBank.d198.s10.e2
DDI-DrugBank.d198.s10	false	DDI-DrugBank.d198.s10.e1	DDI-DrugBank.d198.s10.e3
DDI-DrugBank.d198.s10	false	DDI-DrugBank.d198.s10.e1	DDI-DrugBank.d198.s10.e4
DDI-DrugBank.d198.s10	false	DDI-DrugBank.d198.s10.e1	DDI-DrugBank.d198.s10.e5
DDI-DrugBank.d198.s10	false	DDI-DrugBank.d198.s10.e2	DDI-DrugBank.d198.s10.e3
DDI-DrugBank.d198.s11|a|It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.
DDI-DrugBank.d198.s11	48	57	Vardenafil	drug	DDI-DrugBank.d198.s11.e0
DDI-DrugBank.d198.s11	114	122	indinavir	drug	DDI-DrugBank.d198.s11.e1
DDI-DrugBank.d198.s11	true	DDI-DrugBank.d198.s11.e0	DDI-DrugBank.d198.s11.e1
DDI-DrugBank.d198.s12|a|Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.
DDI-DrugBank.d198.s12	0	8	Ritonavir	drug	DDI-DrugBank.d198.s12.e0
DDI-DrugBank.d198.s12	47	56	Vardenafil	drug	DDI-DrugBank.d198.s12.e1
DDI-DrugBank.d198.s12	97	106	vardenafil	drug	DDI-DrugBank.d198.s12.e2
DDI-DrugBank.d198.s12	138	147	vardenafil	drug	DDI-DrugBank.d198.s12.e3
DDI-DrugBank.d198.s12	true	DDI-DrugBank.d198.s12.e0	DDI-DrugBank.d198.s12.e1
DDI-DrugBank.d198.s12	false	DDI-DrugBank.d198.s12.e0	DDI-DrugBank.d198.s12.e2
DDI-DrugBank.d198.s12	false	DDI-DrugBank.d198.s12.e0	DDI-DrugBank.d198.s12.e3
DDI-DrugBank.d198.s12	false	DDI-DrugBank.d198.s12.e1	DDI-DrugBank.d198.s12.e2
DDI-DrugBank.d198.s12	false	DDI-DrugBank.d198.s12.e1	DDI-DrugBank.d198.s12.e3
DDI-DrugBank.d198.s12	false	DDI-DrugBank.d198.s12.e2	DDI-DrugBank.d198.s12.e3
DDI-DrugBank.d198.s13|a|The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.
DDI-DrugBank.d198.s13	67	76	vardenafil	drug	DDI-DrugBank.d198.s13.e0
DDI-DrugBank.d198.s13	81	89	ritonavir	drug	DDI-DrugBank.d198.s13.e1
DDI-DrugBank.d198.s13	true	DDI-DrugBank.d198.s13.e0	DDI-DrugBank.d198.s13.e1
DDI-DrugBank.d198.s14|a|Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.
DDI-DrugBank.d198.s14	0	8	Ritonavir	drug	DDI-DrugBank.d198.s14.e0
DDI-DrugBank.d198.s14	51	60	vardenafil	drug	DDI-DrugBank.d198.s14.e1
DDI-DrugBank.d198.s14	true	DDI-DrugBank.d198.s14.e0	DDI-DrugBank.d198.s14.e1
DDI-DrugBank.d198.s15|a|Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.
DDI-DrugBank.d198.s15	62	71	Vardenafil	drug	DDI-DrugBank.d198.s15.e0
DDI-DrugBank.d198.s15	128	136	ritonavir	drug	DDI-DrugBank.d198.s15.e1
DDI-DrugBank.d198.s15	true	DDI-DrugBank.d198.s15.e0	DDI-DrugBank.d198.s15.e1
DDI-DrugBank.d198.s16|a|Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, Maalox, and ranitidine.
DDI-DrugBank.d198.s16	79	88	vardenafil	drug	DDI-DrugBank.d198.s16.e0
DDI-DrugBank.d198.s16	115	123	glyburide	drug	DDI-DrugBank.d198.s16.e1
DDI-DrugBank.d198.s16	126	133	warfarin	drug	DDI-DrugBank.d198.s16.e2
DDI-DrugBank.d198.s16	136	142	digoxin	drug	DDI-DrugBank.d198.s16.e3
DDI-DrugBank.d198.s16	145	150	Maalox	brand	DDI-DrugBank.d198.s16.e4
DDI-DrugBank.d198.s16	157	166	ranitidine	drug	DDI-DrugBank.d198.s16.e5
DDI-DrugBank.d198.s16	false	DDI-DrugBank.d198.s16.e0	DDI-DrugBank.d198.s16.e1
DDI-DrugBank.d198.s16	false	DDI-DrugBank.d198.s16.e0	DDI-DrugBank.d198.s16.e2
DDI-DrugBank.d198.s16	false	DDI-DrugBank.d198.s16.e0	DDI-DrugBank.d198.s16.e3
DDI-DrugBank.d198.s16	false	DDI-DrugBank.d198.s16.e0	DDI-DrugBank.d198.s16.e4
DDI-DrugBank.d198.s16	false	DDI-DrugBank.d198.s16.e0	DDI-DrugBank.d198.s16.e5
DDI-DrugBank.d198.s16	false	DDI-DrugBank.d198.s16.e1	DDI-DrugBank.d198.s16.e2
DDI-DrugBank.d198.s16	false	DDI-DrugBank.d198.s16.e1	DDI-DrugBank.d198.s16.e3
DDI-DrugBank.d198.s16	false	DDI-DrugBank.d198.s16.e1	DDI-DrugBank.d198.s16.e4
DDI-DrugBank.d198.s16	false	DDI-DrugBank.d198.s16.e1	DDI-DrugBank.d198.s16.e5
DDI-DrugBank.d198.s16	false	DDI-DrugBank.d198.s16.e2	DDI-DrugBank.d198.s16.e3
DDI-DrugBank.d198.s17|a|In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.
DDI-DrugBank.d198.s17	7	14	warfarin	drug	DDI-DrugBank.d198.s17.e0
DDI-DrugBank.d198.s17	23	32	vardenafil	drug	DDI-DrugBank.d198.s17.e1
DDI-DrugBank.d198.s17	false	DDI-DrugBank.d198.s17.e0	DDI-DrugBank.d198.s17.e1
DDI-DrugBank.d198.s18|a|Effects of Vardenafil on other drugs
DDI-DrugBank.d198.s18	11	20	Vardenafil	drug	DDI-DrugBank.d198.s18.e0
DDI-DrugBank.d198.s19|a|In vitro studies: Vardenafil and its metabolites had no effect on CYP1A2, 2A6, and 2E1 (Ki   100uM).
DDI-DrugBank.d198.s19	18	27	Vardenafil	drug	DDI-DrugBank.d198.s19.e0
DDI-DrugBank.d198.s20|a|Weak inhibitory effects toward other isoforms (CYP2C8, 2C9, 2C19, 2D6, 3A4) were found, but Ki values were in excess of plasma concentrations achieved following dosing.
DDI-DrugBank.d198.s21|a|The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 uM toward CYP3A4, which is about 20 times higher than the M1 Cmax values after an 80 mg Vardenafil dose.
DDI-DrugBank.d198.s21	189	198	Vardenafil	drug	DDI-DrugBank.d198.s21.e0
DDI-DrugBank.d198.s22|a|In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
DDI-DrugBank.d198.s22	17	24	Nitrates	group	DDI-DrugBank.d198.s22.e0
DDI-DrugBank.d198.s22	77	84	nitrates	group	DDI-DrugBank.d198.s22.e1
DDI-DrugBank.d198.s22	121	130	vardenafil	drug	DDI-DrugBank.d198.s22.e2
DDI-DrugBank.d198.s22	227	236	Vardenafil	drug	DDI-DrugBank.d198.s22.e3
DDI-DrugBank.d198.s22	false	DDI-DrugBank.d198.s22.e0	DDI-DrugBank.d198.s22.e1
DDI-DrugBank.d198.s22	false	DDI-DrugBank.d198.s22.e0	DDI-DrugBank.d198.s22.e2
DDI-DrugBank.d198.s22	false	DDI-DrugBank.d198.s22.e0	DDI-DrugBank.d198.s22.e3
DDI-DrugBank.d198.s22	true	DDI-DrugBank.d198.s22.e1	DDI-DrugBank.d198.s22.e2
DDI-DrugBank.d198.s22	false	DDI-DrugBank.d198.s22.e1	DDI-DrugBank.d198.s22.e3
DDI-DrugBank.d198.s22	false	DDI-DrugBank.d198.s22.e2	DDI-DrugBank.d198.s22.e3
DDI-DrugBank.d198.s23|a|These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.
DDI-DrugBank.d198.s23	37	46	Vardenafil	drug	DDI-DrugBank.d198.s23.e0
DDI-DrugBank.d198.s23	84	86	NTG	drug	DDI-DrugBank.d198.s23.e1
DDI-DrugBank.d198.s23	false	DDI-DrugBank.d198.s23.e0	DDI-DrugBank.d198.s23.e1
DDI-DrugBank.d198.s24|a|Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.
DDI-DrugBank.d198.s24	43	50	nitrates	group	DDI-DrugBank.d198.s24.e0
DDI-DrugBank.d198.s24	140	149	Vardenafil	drug	DDI-DrugBank.d198.s24.e1
DDI-DrugBank.d198.s24	155	162	nitrates	group	DDI-DrugBank.d198.s24.e2
DDI-DrugBank.d198.s24	false	DDI-DrugBank.d198.s24.e0	DDI-DrugBank.d198.s24.e1
DDI-DrugBank.d198.s24	false	DDI-DrugBank.d198.s24.e0	DDI-DrugBank.d198.s24.e2
DDI-DrugBank.d198.s24	true	DDI-DrugBank.d198.s24.e1	DDI-DrugBank.d198.s24.e2
DDI-DrugBank.d198.s25|a|Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.
DDI-DrugBank.d198.s25	0	9	Nifedipine	drug	DDI-DrugBank.d198.s25.e0
DDI-DrugBank.d198.s25	12	21	Vardenafil	drug	DDI-DrugBank.d198.s25.e1
DDI-DrugBank.d198.s25	69	78	nifedipine	drug	DDI-DrugBank.d198.s25.e2
DDI-DrugBank.d198.s25	192	201	nifedipine	drug	DDI-DrugBank.d198.s25.e3
DDI-DrugBank.d198.s25	false	DDI-DrugBank.d198.s25.e0	DDI-DrugBank.d198.s25.e1
DDI-DrugBank.d198.s25	false	DDI-DrugBank.d198.s25.e0	DDI-DrugBank.d198.s25.e2
DDI-DrugBank.d198.s25	false	DDI-DrugBank.d198.s25.e0	DDI-DrugBank.d198.s25.e3
DDI-DrugBank.d198.s25	false	DDI-DrugBank.d198.s25.e1	DDI-DrugBank.d198.s25.e2
DDI-DrugBank.d198.s25	false	DDI-DrugBank.d198.s25.e1	DDI-DrugBank.d198.s25.e3
DDI-DrugBank.d198.s25	false	DDI-DrugBank.d198.s25.e2	DDI-DrugBank.d198.s25.e3
DDI-DrugBank.d198.s26|a|Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.
DDI-DrugBank.d198.s26	0	9	Nifedipine	drug	DDI-DrugBank.d198.s26.e0
DDI-DrugBank.d198.s26	46	55	Vardenafil	drug	DDI-DrugBank.d198.s26.e1
DDI-DrugBank.d198.s26	false	DDI-DrugBank.d198.s26.e0	DDI-DrugBank.d198.s26.e1
DDI-DrugBank.d198.s27|a|In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.
DDI-DrugBank.d198.s27	57	66	nifedipine	drug	DDI-DrugBank.d198.s27.e0
DDI-DrugBank.d198.s27	69	78	Vardenafil	drug	DDI-DrugBank.d198.s27.e1
DDI-DrugBank.d198.s27	true	DDI-DrugBank.d198.s27.e0	DDI-DrugBank.d198.s27.e1
DDI-DrugBank.d198.s28|a|Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.
DDI-DrugBank.d198.s28	0	13	Alpha-blockers	group	DDI-DrugBank.d198.s28.e0
DDI-DrugBank.d198.s28	21	30	Vardenafil	drug	DDI-DrugBank.d198.s28.e1
DDI-DrugBank.d198.s28	131	139	terazosin	drug	DDI-DrugBank.d198.s28.e2
DDI-DrugBank.d198.s28	false	DDI-DrugBank.d198.s28.e0	DDI-DrugBank.d198.s28.e1
DDI-DrugBank.d198.s28	false	DDI-DrugBank.d198.s28.e0	DDI-DrugBank.d198.s28.e2
DDI-DrugBank.d198.s28	true	DDI-DrugBank.d198.s28.e1	DDI-DrugBank.d198.s28.e2
DDI-DrugBank.d198.s29|a|With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
DDI-DrugBank.d198.s29	28	37	Vardenafil	drug	DDI-DrugBank.d198.s29.e0
DDI-DrugBank.d198.s29	49	57	terazosin	drug	DDI-DrugBank.d198.s29.e1
DDI-DrugBank.d198.s29	true	DDI-DrugBank.d198.s29.e0	DDI-DrugBank.d198.s29.e1
DDI-DrugBank.d198.s30|a|With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
DDI-DrugBank.d198.s30	28	37	Vardenafil	drug	DDI-DrugBank.d198.s30.e0
DDI-DrugBank.d198.s30	49	57	terazosin	drug	DDI-DrugBank.d198.s30.e1
DDI-DrugBank.d198.s30	true	DDI-DrugBank.d198.s30.e0	DDI-DrugBank.d198.s30.e1
DDI-DrugBank.d198.s31|a|When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.
DDI-DrugBank.d198.s31	5	14	Vardenafil	drug	DDI-DrugBank.d198.s31.e0
DDI-DrugBank.d198.s31	42	50	terazosin	drug	DDI-DrugBank.d198.s31.e1
DDI-DrugBank.d198.s31	109	118	Vardenafil	drug	DDI-DrugBank.d198.s31.e2
DDI-DrugBank.d198.s31	true	DDI-DrugBank.d198.s31.e0	DDI-DrugBank.d198.s31.e1
DDI-DrugBank.d198.s31	false	DDI-DrugBank.d198.s31.e0	DDI-DrugBank.d198.s31.e2
DDI-DrugBank.d198.s31	false	DDI-DrugBank.d198.s31.e1	DDI-DrugBank.d198.s31.e2
DDI-DrugBank.d198.s32|a|In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
DDI-DrugBank.d198.s32	24	33	tamsulosin	drug	DDI-DrugBank.d198.s32.e0
DDI-DrugBank.d198.s32	86	95	Vardenafil	drug	DDI-DrugBank.d198.s32.e1
DDI-DrugBank.d198.s32	107	116	tamsulosin	drug	DDI-DrugBank.d198.s32.e2
DDI-DrugBank.d198.s32	false	DDI-DrugBank.d198.s32.e0	DDI-DrugBank.d198.s32.e1
DDI-DrugBank.d198.s32	false	DDI-DrugBank.d198.s32.e0	DDI-DrugBank.d198.s32.e2
DDI-DrugBank.d198.s32	true	DDI-DrugBank.d198.s32.e1	DDI-DrugBank.d198.s32.e2
DDI-DrugBank.d198.s33|a|Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.
DDI-DrugBank.d198.s33	45	54	Vardenafil	drug	DDI-DrugBank.d198.s33.e0
DDI-DrugBank.d198.s33	66	75	tamsulosin	drug	DDI-DrugBank.d198.s33.e1
DDI-DrugBank.d198.s33	true	DDI-DrugBank.d198.s33.e0	DDI-DrugBank.d198.s33.e1
DDI-DrugBank.d198.s34|a|The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.
DDI-DrugBank.d198.s34	37	46	Vardenafil	drug	DDI-DrugBank.d198.s34.e0
DDI-DrugBank.d198.s34	53	66	alpha-blockers	group	DDI-DrugBank.d198.s34.e1
DDI-DrugBank.d198.s34	false	DDI-DrugBank.d198.s34.e0	DDI-DrugBank.d198.s34.e1
DDI-DrugBank.d198.s35|a|Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.
DDI-DrugBank.d198.s35	21	30	Vardenafil	drug	DDI-DrugBank.d198.s35.e0
DDI-DrugBank.d198.s35	66	78	alpha-blocker	group	DDI-DrugBank.d198.s35.e1
DDI-DrugBank.d198.s35	true	DDI-DrugBank.d198.s35.e0	DDI-DrugBank.d198.s35.e1
DDI-DrugBank.d198.s36|a|Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.
DDI-DrugBank.d198.s36	0	8	Ritonavir	drug	DDI-DrugBank.d198.s36.e0
DDI-DrugBank.d198.s36	14	22	indinavir	drug	DDI-DrugBank.d198.s36.e1
DDI-DrugBank.d198.s36	68	77	Vardenafil	drug	DDI-DrugBank.d198.s36.e2
DDI-DrugBank.d198.s36	95	103	ritonavir	drug	DDI-DrugBank.d198.s36.e3
DDI-DrugBank.d198.s36	126	134	ritonavir	drug	DDI-DrugBank.d198.s36.e4
DDI-DrugBank.d198.s36	false	DDI-DrugBank.d198.s36.e0	DDI-DrugBank.d198.s36.e1
DDI-DrugBank.d198.s36	false	DDI-DrugBank.d198.s36.e0	DDI-DrugBank.d198.s36.e2
DDI-DrugBank.d198.s36	false	DDI-DrugBank.d198.s36.e0	DDI-DrugBank.d198.s36.e3
DDI-DrugBank.d198.s36	false	DDI-DrugBank.d198.s36.e0	DDI-DrugBank.d198.s36.e4
DDI-DrugBank.d198.s36	false	DDI-DrugBank.d198.s36.e1	DDI-DrugBank.d198.s36.e2
DDI-DrugBank.d198.s36	false	DDI-DrugBank.d198.s36.e1	DDI-DrugBank.d198.s36.e3
DDI-DrugBank.d198.s36	false	DDI-DrugBank.d198.s36.e1	DDI-DrugBank.d198.s36.e4
DDI-DrugBank.d198.s36	true	DDI-DrugBank.d198.s36.e2	DDI-DrugBank.d198.s36.e3
DDI-DrugBank.d198.s36	false	DDI-DrugBank.d198.s36.e2	DDI-DrugBank.d198.s36.e4
DDI-DrugBank.d198.s36	false	DDI-DrugBank.d198.s36.e3	DDI-DrugBank.d198.s36.e4
DDI-DrugBank.d198.s37|a|Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.
DDI-DrugBank.d198.s37	32	41	Vardenafil	drug	DDI-DrugBank.d198.s37.e0
DDI-DrugBank.d198.s37	59	67	indinavir	drug	DDI-DrugBank.d198.s37.e1
DDI-DrugBank.d198.s37	90	98	indinavir	drug	DDI-DrugBank.d198.s37.e2
DDI-DrugBank.d198.s37	true	DDI-DrugBank.d198.s37.e0	DDI-DrugBank.d198.s37.e1
DDI-DrugBank.d198.s37	false	DDI-DrugBank.d198.s37.e0	DDI-DrugBank.d198.s37.e2
DDI-DrugBank.d198.s37	false	DDI-DrugBank.d198.s37.e1	DDI-DrugBank.d198.s37.e2
DDI-DrugBank.d198.s38|a|Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.
DDI-DrugBank.d198.s38	0	6	Alcohol	drug	DDI-DrugBank.d198.s38.e0
DDI-DrugBank.d198.s38	9	15	Alcohol	drug	DDI-DrugBank.d198.s38.e1
DDI-DrugBank.d198.s38	103	112	vardenafil	drug	DDI-DrugBank.d198.s38.e2
DDI-DrugBank.d198.s38	false	DDI-DrugBank.d198.s38.e0	DDI-DrugBank.d198.s38.e1
DDI-DrugBank.d198.s38	false	DDI-DrugBank.d198.s38.e0	DDI-DrugBank.d198.s38.e2
DDI-DrugBank.d198.s38	false	DDI-DrugBank.d198.s38.e1	DDI-DrugBank.d198.s38.e2
DDI-DrugBank.d198.s39|a|Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).
DDI-DrugBank.d198.s39	0	9	Vardenafil	drug	DDI-DrugBank.d198.s39.e0
DDI-DrugBank.d198.s39	65	71	alcohol	drug	DDI-DrugBank.d198.s39.e1
DDI-DrugBank.d198.s39	155	161	alcohol	drug	DDI-DrugBank.d198.s39.e2
DDI-DrugBank.d198.s39	false	DDI-DrugBank.d198.s39.e0	DDI-DrugBank.d198.s39.e1
DDI-DrugBank.d198.s39	false	DDI-DrugBank.d198.s39.e0	DDI-DrugBank.d198.s39.e2
DDI-DrugBank.d198.s39	false	DDI-DrugBank.d198.s39.e1	DDI-DrugBank.d198.s39.e2
DDI-DrugBank.d198.s40|a|Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).
DDI-DrugBank.d198.s40	0	6	Aspirin	brand	DDI-DrugBank.d198.s40.e0
DDI-DrugBank.d198.s40	9	18	Vardenafil	drug	DDI-DrugBank.d198.s40.e1
DDI-DrugBank.d198.s40	97	103	aspirin	brand	DDI-DrugBank.d198.s40.e2
DDI-DrugBank.d198.s40	false	DDI-DrugBank.d198.s40.e0	DDI-DrugBank.d198.s40.e1
DDI-DrugBank.d198.s40	false	DDI-DrugBank.d198.s40.e0	DDI-DrugBank.d198.s40.e2
DDI-DrugBank.d198.s40	false	DDI-DrugBank.d198.s40.e1	DDI-DrugBank.d198.s40.e2
DDI-DrugBank.d198.s41|a|Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).
DDI-DrugBank.d198.s41	20	29	Vardenafil	drug	DDI-DrugBank.d198.s41.e0
DDI-DrugBank.d198.s41	72	80	glyburide	drug	DDI-DrugBank.d198.s41.e1
DDI-DrugBank.d198.s41	123	130	warfarin	drug	DDI-DrugBank.d198.s41.e2
DDI-DrugBank.d198.s41	false	DDI-DrugBank.d198.s41.e0	DDI-DrugBank.d198.s41.e1
DDI-DrugBank.d198.s41	false	DDI-DrugBank.d198.s41.e0	DDI-DrugBank.d198.s41.e2
DDI-DrugBank.d198.s41	false	DDI-DrugBank.d198.s41.e1	DDI-DrugBank.d198.s41.e2
DDI-DrugBank.d263.s0|a|Zidovudine: There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.
DDI-DrugBank.d263.s0	0	9	Zidovudine	drug	DDI-DrugBank.d263.s0.e0
DDI-DrugBank.d263.s0	72	74	ZDV	drug	DDI-DrugBank.d263.s0.e1
DDI-DrugBank.d263.s0	80	90	zalcitabine	drug	DDI-DrugBank.d263.s0.e2
DDI-DrugBank.d263.s0	false	DDI-DrugBank.d263.s0.e0	DDI-DrugBank.d263.s0.e1
DDI-DrugBank.d263.s0	false	DDI-DrugBank.d263.s0.e0	DDI-DrugBank.d263.s0.e2
DDI-DrugBank.d263.s0	false	DDI-DrugBank.d263.s0.e1	DDI-DrugBank.d263.s0.e2
DDI-DrugBank.d263.s1|a|Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).
DDI-DrugBank.d263.s1	0	10	Zalcitabine	drug	DDI-DrugBank.d263.s1.e0
DDI-DrugBank.d263.s1	83	85	ZDV	drug	DDI-DrugBank.d263.s1.e1
DDI-DrugBank.d263.s1	true	DDI-DrugBank.d263.s1.e0	DDI-DrugBank.d263.s1.e1
DDI-DrugBank.d263.s2|a|In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.
DDI-DrugBank.d263.s2	36	45	didanosine	drug	DDI-DrugBank.d263.s2.e0
DDI-DrugBank.d263.s2	51	59	stavudine	drug	DDI-DrugBank.d263.s2.e1
DDI-DrugBank.d263.s2	127	137	zalcitabine	drug	DDI-DrugBank.d263.s2.e2
DDI-DrugBank.d263.s2	false	DDI-DrugBank.d263.s2.e0	DDI-DrugBank.d263.s2.e1
DDI-DrugBank.d263.s2	false	DDI-DrugBank.d263.s2.e0	DDI-DrugBank.d263.s2.e2
DDI-DrugBank.d263.s2	false	DDI-DrugBank.d263.s2.e1	DDI-DrugBank.d263.s2.e2
DDI-DrugBank.d263.s3|a|Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.
DDI-DrugBank.d263.s3	0	9	Lamivudine	drug	DDI-DrugBank.d263.s3.e0
DDI-DrugBank.d263.s3	104	113	lamivudine	drug	DDI-DrugBank.d263.s3.e1
DDI-DrugBank.d263.s3	139	149	zalcitabine	drug	DDI-DrugBank.d263.s3.e2
DDI-DrugBank.d263.s3	false	DDI-DrugBank.d263.s3.e0	DDI-DrugBank.d263.s3.e1
DDI-DrugBank.d263.s3	false	DDI-DrugBank.d263.s3.e0	DDI-DrugBank.d263.s3.e2
DDI-DrugBank.d263.s3	true	DDI-DrugBank.d263.s3.e1	DDI-DrugBank.d263.s3.e2
DDI-DrugBank.d263.s4|a|Effects were already seen with doses corresponding to relevant plasma levels in humans, and the intracellular phosphorylation of zalcitabine to its three metabolites (including the active zalcitabine triphosphate metabolite) was significantly inhibited.
DDI-DrugBank.d263.s4	129	139	zalcitabine	drug	DDI-DrugBank.d263.s4.e0
DDI-DrugBank.d263.s5|a|Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);
DDI-DrugBank.d263.s5	0	10	Zalcitabine	drug	DDI-DrugBank.d263.s5.e0
DDI-DrugBank.d263.s5	22	31	lamivudine	drug	DDI-DrugBank.d263.s5.e1
DDI-DrugBank.d263.s5	true	DDI-DrugBank.d263.s5.e0	DDI-DrugBank.d263.s5.e1
DDI-DrugBank.d263.s6|a|however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine.
DDI-DrugBank.d263.s6	78	87	lamivudine	drug	DDI-DrugBank.d263.s6.e0
DDI-DrugBank.d263.s6	135	144	lamivudine	drug	DDI-DrugBank.d263.s6.e1
DDI-DrugBank.d263.s6	206	216	zalcitabine	drug	DDI-DrugBank.d263.s6.e2
DDI-DrugBank.d263.s6	false	DDI-DrugBank.d263.s6.e0	DDI-DrugBank.d263.s6.e1
DDI-DrugBank.d263.s6	false	DDI-DrugBank.d263.s6.e0	DDI-DrugBank.d263.s6.e2
DDI-DrugBank.d263.s6	false	DDI-DrugBank.d263.s6.e1	DDI-DrugBank.d263.s6.e2
DDI-DrugBank.d263.s7|a|These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.
DDI-DrugBank.d263.s7	66	76	zalcitabine	drug	DDI-DrugBank.d263.s7.e0
DDI-DrugBank.d263.s7	82	91	lamivudine	drug	DDI-DrugBank.d263.s7.e1
DDI-DrugBank.d263.s7	173	183	zalcitabine	drug	DDI-DrugBank.d263.s7.e2
DDI-DrugBank.d263.s7	216	229	antiretroviral	group	DDI-DrugBank.d263.s7.e3
DDI-DrugBank.d263.s7	241	251	zalcitabine	drug	DDI-DrugBank.d263.s7.e4
DDI-DrugBank.d263.s7	true	DDI-DrugBank.d263.s7.e0	DDI-DrugBank.d263.s7.e1
DDI-DrugBank.d263.s7	false	DDI-DrugBank.d263.s7.e0	DDI-DrugBank.d263.s7.e2
DDI-DrugBank.d263.s7	false	DDI-DrugBank.d263.s7.e0	DDI-DrugBank.d263.s7.e3
DDI-DrugBank.d263.s7	false	DDI-DrugBank.d263.s7.e0	DDI-DrugBank.d263.s7.e4
DDI-DrugBank.d263.s7	false	DDI-DrugBank.d263.s7.e1	DDI-DrugBank.d263.s7.e2
DDI-DrugBank.d263.s7	false	DDI-DrugBank.d263.s7.e1	DDI-DrugBank.d263.s7.e3
DDI-DrugBank.d263.s7	false	DDI-DrugBank.d263.s7.e1	DDI-DrugBank.d263.s7.e4
DDI-DrugBank.d263.s7	false	DDI-DrugBank.d263.s7.e2	DDI-DrugBank.d263.s7.e3
DDI-DrugBank.d263.s7	false	DDI-DrugBank.d263.s7.e2	DDI-DrugBank.d263.s7.e4
DDI-DrugBank.d263.s7	false	DDI-DrugBank.d263.s7.e3	DDI-DrugBank.d263.s7.e4
DDI-DrugBank.d263.s8|a|It is unknown how the effect seen in these in vitro studies translates into clinical consequences.
DDI-DrugBank.d263.s9|a|Concomitant use of zalcitabine and lamivudine is not recommended.
DDI-DrugBank.d263.s9	19	29	zalcitabine	drug	DDI-DrugBank.d263.s9.e0
DDI-DrugBank.d263.s9	35	44	lamivudine	drug	DDI-DrugBank.d263.s9.e1
DDI-DrugBank.d263.s9	true	DDI-DrugBank.d263.s9.e0	DDI-DrugBank.d263.s9.e1
DDI-DrugBank.d263.s10|a|Saquinavir: The combination of HIVID, saquinavir, and ZDV has been studied (as triple combination) in adults.
DDI-DrugBank.d263.s10	0	9	Saquinavir	drug	DDI-DrugBank.d263.s10.e0
DDI-DrugBank.d263.s10	31	35	HIVID	drug	DDI-DrugBank.d263.s10.e1
DDI-DrugBank.d263.s10	38	47	saquinavir	drug	DDI-DrugBank.d263.s10.e2
DDI-DrugBank.d263.s10	54	56	ZDV	drug	DDI-DrugBank.d263.s10.e3
DDI-DrugBank.d263.s10	false	DDI-DrugBank.d263.s10.e0	DDI-DrugBank.d263.s10.e1
DDI-DrugBank.d263.s10	false	DDI-DrugBank.d263.s10.e0	DDI-DrugBank.d263.s10.e2
DDI-DrugBank.d263.s10	false	DDI-DrugBank.d263.s10.e0	DDI-DrugBank.d263.s10.e3
DDI-DrugBank.d263.s10	false	DDI-DrugBank.d263.s10.e1	DDI-DrugBank.d263.s10.e2
DDI-DrugBank.d263.s10	false	DDI-DrugBank.d263.s10.e1	DDI-DrugBank.d263.s10.e3
DDI-DrugBank.d263.s10	false	DDI-DrugBank.d263.s10.e2	DDI-DrugBank.d263.s10.e3
DDI-DrugBank.d263.s11|a|Pharmacokinetic data suggest that absorption, metabolism, and elimination of each of these drugs are unchanged when they are used together.
DDI-DrugBank.d263.s12|a|Drugs Associated With Peripheral Neuropathy: The concomitant use of HIVID with drugs that have the potential to cause peripheral neuropathy should be avoided where possible.
DDI-DrugBank.d263.s12	68	72	HIVID	drug	DDI-DrugBank.d263.s12.e0
DDI-DrugBank.d263.s13|a|Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
DDI-DrugBank.d263.s13	67	101	antiretroviral nucleoside analogues	drug	DDI-DrugBank.d263.s13.e0
DDI-DrugBank.d263.s13	104	118	chloramphenicol	drug	DDI-DrugBank.d263.s13.e1
DDI-DrugBank.d263.s13	121	129	cisplatin	drug	DDI-DrugBank.d263.s13.e2
DDI-DrugBank.d263.s13	132	138	dapsone	drug	DDI-DrugBank.d263.s13.e3
DDI-DrugBank.d263.s13	141	150	disulfiram	drug	DDI-DrugBank.d263.s13.e4
DDI-DrugBank.d263.s13	153	163	ethionamide	drug	DDI-DrugBank.d263.s13.e5
DDI-DrugBank.d263.s13	166	177	glutethimide	drug	DDI-DrugBank.d263.s13.e6
DDI-DrugBank.d263.s13	180	183	gold	drug	DDI-DrugBank.d263.s13.e7
DDI-DrugBank.d263.s13	186	196	hydralazine	drug	DDI-DrugBank.d263.s13.e8
DDI-DrugBank.d263.s13	199	208	iodoquinol	drug	DDI-DrugBank.d263.s13.e9
DDI-DrugBank.d263.s13	false	DDI-DrugBank.d263.s13.e0	DDI-DrugBank.d263.s13.e1
DDI-DrugBank.d263.s13	false	DDI-DrugBank.d263.s13.e0	DDI-DrugBank.d263.s13.e2
DDI-DrugBank.d263.s13	false	DDI-DrugBank.d263.s13.e0	DDI-DrugBank.d263.s13.e3
DDI-DrugBank.d263.s13	false	DDI-DrugBank.d263.s13.e0	DDI-DrugBank.d263.s13.e4
DDI-DrugBank.d263.s13	false	DDI-DrugBank.d263.s13.e0	DDI-DrugBank.d263.s13.e5
DDI-DrugBank.d263.s13	false	DDI-DrugBank.d263.s13.e0	DDI-DrugBank.d263.s13.e6
DDI-DrugBank.d263.s13	false	DDI-DrugBank.d263.s13.e0	DDI-DrugBank.d263.s13.e7
DDI-DrugBank.d263.s13	false	DDI-DrugBank.d263.s13.e0	DDI-DrugBank.d263.s13.e8
DDI-DrugBank.d263.s13	false	DDI-DrugBank.d263.s13.e0	DDI-DrugBank.d263.s13.e9
DDI-DrugBank.d263.s13	false	DDI-DrugBank.d263.s13.e0	DDI-DrugBank.d263.s13.e10
DDI-DrugBank.d263.s14|a|Concomitant use of HIVID with didanosine is not recommended.
DDI-DrugBank.d263.s14	19	23	HIVID	drug	DDI-DrugBank.d263.s14.e0
DDI-DrugBank.d263.s14	30	39	didanosine	drug	DDI-DrugBank.d263.s14.e1
DDI-DrugBank.d263.s14	true	DDI-DrugBank.d263.s14.e0	DDI-DrugBank.d263.s14.e1
DDI-DrugBank.d263.s15|a|Intravenous Pentamidine: Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.
DDI-DrugBank.d263.s15	12	22	Pentamidine	drug	DDI-DrugBank.d263.s15.e0
DDI-DrugBank.d263.s15	40	44	HIVID	drug	DDI-DrugBank.d263.s15.e1
DDI-DrugBank.d263.s15	false	DDI-DrugBank.d263.s15.e0	DDI-DrugBank.d263.s15.e1
DDI-DrugBank.d263.s16|a|Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.
DDI-DrugBank.d263.s16	68	78	pentamidine	drug	DDI-DrugBank.d263.s16.e0
DDI-DrugBank.d263.s16	84	88	HIVID	drug	DDI-DrugBank.d263.s16.e1
DDI-DrugBank.d263.s16	true	DDI-DrugBank.d263.s16.e0	DDI-DrugBank.d263.s16.e1
DDI-DrugBank.d263.s17|a|If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.
DDI-DrugBank.d263.s17	15	25	pentamidine	drug	DDI-DrugBank.d263.s17.e0
DDI-DrugBank.d263.s17	95	99	HIVID	drug	DDI-DrugBank.d263.s17.e1
DDI-DrugBank.d263.s17	true	DDI-DrugBank.d263.s17.e0	DDI-DrugBank.d263.s17.e1
DDI-DrugBank.d263.s18|a|Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
DDI-DrugBank.d263.s18	0	11	Amphotericin	drug	DDI-DrugBank.d263.s18.e0
DDI-DrugBank.d263.s18	14	22	Foscarnet	drug	DDI-DrugBank.d263.s18.e1
DDI-DrugBank.d263.s18	29	43	Aminoglycosides	group	DDI-DrugBank.d263.s18.e2
DDI-DrugBank.d263.s18	60	71	amphotericin	drug	DDI-DrugBank.d263.s18.e3
DDI-DrugBank.d263.s18	74	82	foscarnet	drug	DDI-DrugBank.d263.s18.e4
DDI-DrugBank.d263.s18	89	103	aminoglycosides	group	DDI-DrugBank.d263.s18.e5
DDI-DrugBank.d263.s18	172	176	HIVID	drug	DDI-DrugBank.d263.s18.e6
DDI-DrugBank.d263.s18	247	257	zalcitabine	drug	DDI-DrugBank.d263.s18.e7
DDI-DrugBank.d263.s18	false	DDI-DrugBank.d263.s18.e0	DDI-DrugBank.d263.s18.e1
DDI-DrugBank.d263.s18	false	DDI-DrugBank.d263.s18.e0	DDI-DrugBank.d263.s18.e2
DDI-DrugBank.d263.s18	false	DDI-DrugBank.d263.s18.e0	DDI-DrugBank.d263.s18.e3
DDI-DrugBank.d263.s18	false	DDI-DrugBank.d263.s18.e0	DDI-DrugBank.d263.s18.e4
DDI-DrugBank.d263.s18	false	DDI-DrugBank.d263.s18.e0	DDI-DrugBank.d263.s18.e5
DDI-DrugBank.d263.s18	false	DDI-DrugBank.d263.s18.e0	DDI-DrugBank.d263.s18.e6
DDI-DrugBank.d263.s18	false	DDI-DrugBank.d263.s18.e0	DDI-DrugBank.d263.s18.e7
DDI-DrugBank.d263.s18	false	DDI-DrugBank.d263.s18.e1	DDI-DrugBank.d263.s18.e2
DDI-DrugBank.d263.s18	false	DDI-DrugBank.d263.s18.e1	DDI-DrugBank.d263.s18.e3
DDI-DrugBank.d263.s18	false	DDI-DrugBank.d263.s18.e1	DDI-DrugBank.d263.s18.e4
DDI-DrugBank.d263.s19|a|Patients who require the use of one of these drugs with HIVID should have frequent clinical and laboratory monitoring with dosage adjustment for any significant change in renal function.
DDI-DrugBank.d263.s19	56	60	HIVID	drug	DDI-DrugBank.d263.s19.e0
DDI-DrugBank.d263.s20|a|Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
DDI-DrugBank.d263.s20	0	9	Probenecid	drug	DDI-DrugBank.d263.s20.e0
DDI-DrugBank.d263.s20	14	23	Cimetidine	drug	DDI-DrugBank.d263.s20.e1
DDI-DrugBank.d263.s20	56	65	probenecid	drug	DDI-DrugBank.d263.s20.e2
DDI-DrugBank.d263.s20	70	79	cimetidine	drug	DDI-DrugBank.d263.s20.e3
DDI-DrugBank.d263.s20	110	120	zalcitabine	drug	DDI-DrugBank.d263.s20.e4
DDI-DrugBank.d263.s20	179	189	zalcitabine	drug	DDI-DrugBank.d263.s20.e5
DDI-DrugBank.d263.s20	false	DDI-DrugBank.d263.s20.e0	DDI-DrugBank.d263.s20.e1
DDI-DrugBank.d263.s20	false	DDI-DrugBank.d263.s20.e0	DDI-DrugBank.d263.s20.e2
DDI-DrugBank.d263.s20	false	DDI-DrugBank.d263.s20.e0	DDI-DrugBank.d263.s20.e3
DDI-DrugBank.d263.s20	false	DDI-DrugBank.d263.s20.e0	DDI-DrugBank.d263.s20.e4
DDI-DrugBank.d263.s20	false	DDI-DrugBank.d263.s20.e0	DDI-DrugBank.d263.s20.e5
DDI-DrugBank.d263.s20	false	DDI-DrugBank.d263.s20.e1	DDI-DrugBank.d263.s20.e2
DDI-DrugBank.d263.s20	false	DDI-DrugBank.d263.s20.e1	DDI-DrugBank.d263.s20.e3
DDI-DrugBank.d263.s20	false	DDI-DrugBank.d263.s20.e1	DDI-DrugBank.d263.s20.e4
DDI-DrugBank.d263.s20	false	DDI-DrugBank.d263.s20.e1	DDI-DrugBank.d263.s20.e5
DDI-DrugBank.d263.s20	false	DDI-DrugBank.d263.s20.e2	DDI-DrugBank.d263.s20.e3
DDI-DrugBank.d263.s21|a|Patients receiving these drugs in combination with zalcitabine should be monitored for signs of toxicity and the dose of zalcitabine reduced if warranted.
DDI-DrugBank.d263.s21	51	61	zalcitabine	drug	DDI-DrugBank.d263.s21.e0
DDI-DrugBank.d263.s21	121	131	zalcitabine	drug	DDI-DrugBank.d263.s21.e1
DDI-DrugBank.d263.s21	false	DDI-DrugBank.d263.s21.e0	DDI-DrugBank.d263.s21.e1
DDI-DrugBank.d263.s22|a|Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.
DDI-DrugBank.d263.s22	0	8	Magnesium	drug	DDI-DrugBank.d263.s22.e0
DDI-DrugBank.d263.s22	10	17	Aluminum	drug	DDI-DrugBank.d263.s22.e1
DDI-DrugBank.d263.s22	30	45	Antacid Products	group	DDI-DrugBank.d263.s22.e2
DDI-DrugBank.d263.s22	62	72	zalcitabine	drug	DDI-DrugBank.d263.s22.e3
DDI-DrugBank.d263.s22	141	149	magnesium	drug	DDI-DrugBank.d263.s22.e4
DDI-DrugBank.d263.s22	151	158	aluminum	drug	DDI-DrugBank.d263.s22.e5
DDI-DrugBank.d263.s22	171	186	antacid products	group	DDI-DrugBank.d263.s22.e6
DDI-DrugBank.d263.s22	false	DDI-DrugBank.d263.s22.e0	DDI-DrugBank.d263.s22.e1
DDI-DrugBank.d263.s22	false	DDI-DrugBank.d263.s22.e0	DDI-DrugBank.d263.s22.e2
DDI-DrugBank.d263.s22	false	DDI-DrugBank.d263.s22.e0	DDI-DrugBank.d263.s22.e3
DDI-DrugBank.d263.s22	false	DDI-DrugBank.d263.s22.e0	DDI-DrugBank.d263.s22.e4
DDI-DrugBank.d263.s22	false	DDI-DrugBank.d263.s22.e0	DDI-DrugBank.d263.s22.e5
DDI-DrugBank.d263.s22	false	DDI-DrugBank.d263.s22.e0	DDI-DrugBank.d263.s22.e6
DDI-DrugBank.d263.s22	false	DDI-DrugBank.d263.s22.e1	DDI-DrugBank.d263.s22.e2
DDI-DrugBank.d263.s22	false	DDI-DrugBank.d263.s22.e1	DDI-DrugBank.d263.s22.e3
DDI-DrugBank.d263.s22	false	DDI-DrugBank.d263.s22.e1	DDI-DrugBank.d263.s22.e4
DDI-DrugBank.d263.s22	false	DDI-DrugBank.d263.s22.e1	DDI-DrugBank.d263.s22.e5
DDI-DrugBank.d263.s23|a|The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
DDI-DrugBank.d263.s23	64	74	zalcitabine	drug	DDI-DrugBank.d263.s23.e0
DDI-DrugBank.d263.s23	130	138	magnesium	drug	DDI-DrugBank.d263.s23.e1
DDI-DrugBank.d263.s23	140	147	aluminum	drug	DDI-DrugBank.d263.s23.e2
DDI-DrugBank.d263.s23	160	167	antacids	group	DDI-DrugBank.d263.s23.e3
DDI-DrugBank.d263.s23	true	DDI-DrugBank.d263.s23.e0	DDI-DrugBank.d263.s23.e1
DDI-DrugBank.d263.s23	true	DDI-DrugBank.d263.s23.e0	DDI-DrugBank.d263.s23.e2
DDI-DrugBank.d263.s23	true	DDI-DrugBank.d263.s23.e0	DDI-DrugBank.d263.s23.e3
DDI-DrugBank.d263.s23	false	DDI-DrugBank.d263.s23.e1	DDI-DrugBank.d263.s23.e2
DDI-DrugBank.d263.s23	false	DDI-DrugBank.d263.s23.e1	DDI-DrugBank.d263.s23.e3
DDI-DrugBank.d263.s23	false	DDI-DrugBank.d263.s23.e2	DDI-DrugBank.d263.s23.e3
DDI-DrugBank.d263.s24|a|Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.
DDI-DrugBank.d263.s24	0	13	Metoclopramide	drug	DDI-DrugBank.d263.s24.e0
DDI-DrugBank.d263.s24	75	85	zalcitabine	drug	DDI-DrugBank.d263.s24.e1
DDI-DrugBank.d263.s24	91	104	metoclopramide	drug	DDI-DrugBank.d263.s24.e2
DDI-DrugBank.d263.s24	false	DDI-DrugBank.d263.s24.e0	DDI-DrugBank.d263.s24.e1
DDI-DrugBank.d263.s24	false	DDI-DrugBank.d263.s24.e0	DDI-DrugBank.d263.s24.e2
DDI-DrugBank.d263.s24	true	DDI-DrugBank.d263.s24.e1	DDI-DrugBank.d263.s24.e2
DDI-DrugBank.d263.s25|a|Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.
DDI-DrugBank.d263.s25	0	10	Doxorubicin	drug	DDI-DrugBank.d263.s25.e0
DDI-DrugBank.d263.s25	13	23	Doxorubicin	drug	DDI-DrugBank.d263.s25.e1
DDI-DrugBank.d263.s25	46	56	zalcitabine	drug	DDI-DrugBank.d263.s25.e2
DDI-DrugBank.d263.s25	false	DDI-DrugBank.d263.s25.e0	DDI-DrugBank.d263.s25.e1
DDI-DrugBank.d263.s25	false	DDI-DrugBank.d263.s25.e0	DDI-DrugBank.d263.s25.e2
DDI-DrugBank.d263.s25	true	DDI-DrugBank.d263.s25.e1	DDI-DrugBank.d263.s25.e2
DDI-DrugBank.d263.s26|a|Although there may be decreased zalcitabine activity because of lessened active metabolite formation, the clinical relevance of these in vitro results are not known.
DDI-DrugBank.d263.s26	32	42	zalcitabine	drug	DDI-DrugBank.d263.s26.e0
DDI-DrugBank.d324.s0|a|As with all drugs, the potential exists for interaction with other drugs by a variety of mechanisms.
DDI-DrugBank.d324.s1|a|CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
DDI-DrugBank.d324.s1	17	23	Ethanol	drug	DDI-DrugBank.d324.s1.e0
DDI-DrugBank.d324.s1	26	31	Sonata	brand	DDI-DrugBank.d324.s1.e1
DDI-DrugBank.d324.s1	80	86	ethanol	drug	DDI-DrugBank.d324.s1.e2
DDI-DrugBank.d324.s1	152	158	ethanol	drug	DDI-DrugBank.d324.s1.e3
DDI-DrugBank.d324.s1	326	332	ethanol	drug	DDI-DrugBank.d324.s1.e4
DDI-DrugBank.d324.s1	false	DDI-DrugBank.d324.s1.e0	DDI-DrugBank.d324.s1.e1
DDI-DrugBank.d324.s1	false	DDI-DrugBank.d324.s1.e0	DDI-DrugBank.d324.s1.e2
DDI-DrugBank.d324.s1	false	DDI-DrugBank.d324.s1.e0	DDI-DrugBank.d324.s1.e3
DDI-DrugBank.d324.s1	false	DDI-DrugBank.d324.s1.e0	DDI-DrugBank.d324.s1.e4
DDI-DrugBank.d324.s1	true	DDI-DrugBank.d324.s1.e1	DDI-DrugBank.d324.s1.e2
DDI-DrugBank.d324.s1	false	DDI-DrugBank.d324.s1.e1	DDI-DrugBank.d324.s1.e3
DDI-DrugBank.d324.s1	false	DDI-DrugBank.d324.s1.e1	DDI-DrugBank.d324.s1.e4
DDI-DrugBank.d324.s1	false	DDI-DrugBank.d324.s1.e2	DDI-DrugBank.d324.s1.e3
DDI-DrugBank.d324.s1	false	DDI-DrugBank.d324.s1.e2	DDI-DrugBank.d324.s1.e4
DDI-DrugBank.d324.s1	false	DDI-DrugBank.d324.s1.e3	DDI-DrugBank.d324.s1.e4
DDI-DrugBank.d324.s2|a|The potentiation resulted from a CNS pharmacodynamic interaction;
DDI-DrugBank.d324.s3|a|zaleplon did not affect the pharmacokinetics of ethanol.
DDI-DrugBank.d324.s3	0	7	zaleplon	drug	DDI-DrugBank.d324.s3.e0
DDI-DrugBank.d324.s3	48	54	ethanol	drug	DDI-DrugBank.d324.s3.e1
DDI-DrugBank.d324.s3	false	DDI-DrugBank.d324.s3.e0	DDI-DrugBank.d324.s3.e1
DDI-DrugBank.d324.s4|a|Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
DDI-DrugBank.d324.s4	0	9	Imipramine	drug	DDI-DrugBank.d324.s4.e0
DDI-DrugBank.d324.s4	48	53	Sonata	brand	DDI-DrugBank.d324.s4.e1
DDI-DrugBank.d324.s4	65	74	imipramine	drug	DDI-DrugBank.d324.s4.e2
DDI-DrugBank.d324.s4	false	DDI-DrugBank.d324.s4.e0	DDI-DrugBank.d324.s4.e1
DDI-DrugBank.d324.s4	false	DDI-DrugBank.d324.s4.e0	DDI-DrugBank.d324.s4.e2
DDI-DrugBank.d324.s4	true	DDI-DrugBank.d324.s4.e1	DDI-DrugBank.d324.s4.e2
DDI-DrugBank.d324.s5|a|The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.
DDI-DrugBank.d324.s6|a|Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.
DDI-DrugBank.d324.s6	0	9	Paroxetine	drug	DDI-DrugBank.d324.s6.e0
DDI-DrugBank.d324.s6	49	54	Sonata	brand	DDI-DrugBank.d324.s6.e1
DDI-DrugBank.d324.s6	66	75	paroxetine	drug	DDI-DrugBank.d324.s6.e2
DDI-DrugBank.d324.s6	false	DDI-DrugBank.d324.s6.e0	DDI-DrugBank.d324.s6.e1
DDI-DrugBank.d324.s6	false	DDI-DrugBank.d324.s6.e0	DDI-DrugBank.d324.s6.e2
DDI-DrugBank.d324.s6	false	DDI-DrugBank.d324.s6.e1	DDI-DrugBank.d324.s6.e2
DDI-DrugBank.d324.s7|a|Additionally, paroxetine did not alter the pharmacokinetics of Sonata, reflecting the absence of a role of CYP2D6 in zaleplon s metabolism.
DDI-DrugBank.d324.s7	14	23	paroxetine	drug	DDI-DrugBank.d324.s7.e0
DDI-DrugBank.d324.s7	63	68	Sonata	brand	DDI-DrugBank.d324.s7.e1
DDI-DrugBank.d324.s7	117	124	zaleplon	drug	DDI-DrugBank.d324.s7.e2
DDI-DrugBank.d324.s7	false	DDI-DrugBank.d324.s7.e0	DDI-DrugBank.d324.s7.e1
DDI-DrugBank.d324.s7	false	DDI-DrugBank.d324.s7.e0	DDI-DrugBank.d324.s7.e2
DDI-DrugBank.d324.s7	false	DDI-DrugBank.d324.s7.e1	DDI-DrugBank.d324.s7.e2
DDI-DrugBank.d324.s8|a|Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
DDI-DrugBank.d324.s8	0	11	Thioridazine	drug	DDI-DrugBank.d324.s8.e0
DDI-DrugBank.d324.s8	50	55	Sonata	brand	DDI-DrugBank.d324.s8.e1
DDI-DrugBank.d324.s8	67	78	thioridazine	drug	DDI-DrugBank.d324.s8.e2
DDI-DrugBank.d324.s8	false	DDI-DrugBank.d324.s8.e0	DDI-DrugBank.d324.s8.e1
DDI-DrugBank.d324.s8	false	DDI-DrugBank.d324.s8.e0	DDI-DrugBank.d324.s8.e2
DDI-DrugBank.d324.s8	true	DDI-DrugBank.d324.s8.e1	DDI-DrugBank.d324.s8.e2
DDI-DrugBank.d324.s9|a|The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.
DDI-DrugBank.d324.s10|a|Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.
DDI-DrugBank.d324.s10	0	10	Venlafaxine	drug	DDI-DrugBank.d324.s10.e0
DDI-DrugBank.d324.s10	50	57	zaleplon	drug	DDI-DrugBank.d324.s10.e1
DDI-DrugBank.d324.s10	87	97	venlafaxine	drug	DDI-DrugBank.d324.s10.e2
DDI-DrugBank.d324.s10	204	211	zaleplon	drug	DDI-DrugBank.d324.s10.e3
DDI-DrugBank.d324.s10	216	226	venlafaxine	drug	DDI-DrugBank.d324.s10.e4
DDI-DrugBank.d324.s10	false	DDI-DrugBank.d324.s10.e0	DDI-DrugBank.d324.s10.e1
DDI-DrugBank.d324.s10	false	DDI-DrugBank.d324.s10.e0	DDI-DrugBank.d324.s10.e2
DDI-DrugBank.d324.s10	false	DDI-DrugBank.d324.s10.e0	DDI-DrugBank.d324.s10.e3
DDI-DrugBank.d324.s10	false	DDI-DrugBank.d324.s10.e0	DDI-DrugBank.d324.s10.e4
DDI-DrugBank.d324.s10	false	DDI-DrugBank.d324.s10.e1	DDI-DrugBank.d324.s10.e2
DDI-DrugBank.d324.s10	false	DDI-DrugBank.d324.s10.e1	DDI-DrugBank.d324.s10.e3
DDI-DrugBank.d324.s10	false	DDI-DrugBank.d324.s10.e1	DDI-DrugBank.d324.s10.e4
DDI-DrugBank.d324.s10	false	DDI-DrugBank.d324.s10.e2	DDI-DrugBank.d324.s10.e3
DDI-DrugBank.d324.s10	false	DDI-DrugBank.d324.s10.e2	DDI-DrugBank.d324.s10.e4
DDI-DrugBank.d324.s10	false	DDI-DrugBank.d324.s10.e3	DDI-DrugBank.d324.s10.e4
DDI-DrugBank.d324.s11|a|In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.
DDI-DrugBank.d324.s11	89	96	zaleplon	drug	DDI-DrugBank.d324.s11.e0
DDI-DrugBank.d324.s11	102	112	venlafaxine	drug	DDI-DrugBank.d324.s11.e1
DDI-DrugBank.d324.s11	false	DDI-DrugBank.d324.s11.e0	DDI-DrugBank.d324.s11.e1
DDI-DrugBank.d324.s12|a|Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
DDI-DrugBank.d324.s12	0	11	Promethazine	drug	DDI-DrugBank.d324.s12.e0
DDI-DrugBank.d324.s12	51	58	zaleplon	drug	DDI-DrugBank.d324.s12.e1
DDI-DrugBank.d324.s12	64	75	promethazine	drug	DDI-DrugBank.d324.s12.e2
DDI-DrugBank.d324.s12	169	176	zaleplon	drug	DDI-DrugBank.d324.s12.e3
DDI-DrugBank.d324.s12	false	DDI-DrugBank.d324.s12.e0	DDI-DrugBank.d324.s12.e1
DDI-DrugBank.d324.s12	false	DDI-DrugBank.d324.s12.e0	DDI-DrugBank.d324.s12.e2
DDI-DrugBank.d324.s12	false	DDI-DrugBank.d324.s12.e0	DDI-DrugBank.d324.s12.e3
DDI-DrugBank.d324.s12	true	DDI-DrugBank.d324.s12.e1	DDI-DrugBank.d324.s12.e2
DDI-DrugBank.d324.s12	false	DDI-DrugBank.d324.s12.e1	DDI-DrugBank.d324.s12.e3
DDI-DrugBank.d324.s12	false	DDI-DrugBank.d324.s12.e2	DDI-DrugBank.d324.s12.e3
DDI-DrugBank.d324.s13|a|However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated.
DDI-DrugBank.d324.s13	53	60	zaleplon	drug	DDI-DrugBank.d324.s13.e0
DDI-DrugBank.d324.s13	66	77	promethazine	drug	DDI-DrugBank.d324.s13.e1
DDI-DrugBank.d324.s13	false	DDI-DrugBank.d324.s13.e0	DDI-DrugBank.d324.s13.e1
DDI-DrugBank.d324.s14|a|Caution should be exercised when these 2 agents are coadministered.
DDI-DrugBank.d324.s15|a|Drugs That Induce CYP3A4 Rifampin: CYP3A4 is ordinarily a minor metabolizing enzyme of zaleplon.
DDI-DrugBank.d324.s15	25	32	Rifampin	drug	DDI-DrugBank.d324.s15.e0
DDI-DrugBank.d324.s15	87	94	zaleplon	drug	DDI-DrugBank.d324.s15.e1
DDI-DrugBank.d324.s15	false	DDI-DrugBank.d324.s15.e0	DDI-DrugBank.d324.s15.e1
DDI-DrugBank.d324.s16|a|Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.
DDI-DrugBank.d324.s16	58	65	rifampin	drug	DDI-DrugBank.d324.s16.e0
DDI-DrugBank.d324.s16	128	135	zaleplon	drug	DDI-DrugBank.d324.s16.e1
DDI-DrugBank.d324.s16	true	DDI-DrugBank.d324.s16.e0	DDI-DrugBank.d324.s16.e1
DDI-DrugBank.d324.s17|a|The coadministration of a potent CYP3A4 enzyme inducer, although not posing a safety concern, thus could lead to ineffectiveness of zaleplon.
DDI-DrugBank.d324.s17	132	139	zaleplon	drug	DDI-DrugBank.d324.s17.e0
DDI-DrugBank.d324.s18|a|An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and phenobarbital.
DDI-DrugBank.d324.s18	36	49	hypnotic agent	group	DDI-DrugBank.d324.s18.e0
DDI-DrugBank.d324.s18	112	119	rifampin	drug	DDI-DrugBank.d324.s18.e1
DDI-DrugBank.d324.s18	122	130	phenytoin	drug	DDI-DrugBank.d324.s18.e2
DDI-DrugBank.d324.s18	133	145	carbamazepine	drug	DDI-DrugBank.d324.s18.e3
DDI-DrugBank.d324.s18	152	164	phenobarbital	drug	DDI-DrugBank.d324.s18.e4
DDI-DrugBank.d324.s18	false	DDI-DrugBank.d324.s18.e0	DDI-DrugBank.d324.s18.e1
DDI-DrugBank.d324.s18	false	DDI-DrugBank.d324.s18.e0	DDI-DrugBank.d324.s18.e2
DDI-DrugBank.d324.s18	false	DDI-DrugBank.d324.s18.e0	DDI-DrugBank.d324.s18.e3
DDI-DrugBank.d324.s18	false	DDI-DrugBank.d324.s18.e0	DDI-DrugBank.d324.s18.e4
DDI-DrugBank.d324.s18	false	DDI-DrugBank.d324.s18.e1	DDI-DrugBank.d324.s18.e2
DDI-DrugBank.d324.s18	false	DDI-DrugBank.d324.s18.e1	DDI-DrugBank.d324.s18.e3
DDI-DrugBank.d324.s18	false	DDI-DrugBank.d324.s18.e1	DDI-DrugBank.d324.s18.e4
DDI-DrugBank.d324.s18	false	DDI-DrugBank.d324.s18.e2	DDI-DrugBank.d324.s18.e3
DDI-DrugBank.d324.s18	false	DDI-DrugBank.d324.s18.e2	DDI-DrugBank.d324.s18.e4
DDI-DrugBank.d324.s18	false	DDI-DrugBank.d324.s18.e3	DDI-DrugBank.d324.s18.e4
DDI-DrugBank.d324.s19|a|Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.
DDI-DrugBank.d324.s19	85	92	zaleplon	drug	DDI-DrugBank.d324.s19.e0
DDI-DrugBank.d324.s19	180	201	5-oxo-desethylzaleplon	drug_n	DDI-DrugBank.d324.s19.e1
DDI-DrugBank.d324.s19	207	240	5-oxo-desethylzaleplon glucuronide	drug_n	DDI-DrugBank.d324.s19.e2
DDI-DrugBank.d324.s19	292	299	zaleplon	drug	DDI-DrugBank.d324.s19.e3
DDI-DrugBank.d324.s19	false	DDI-DrugBank.d324.s19.e0	DDI-DrugBank.d324.s19.e1
DDI-DrugBank.d324.s19	false	DDI-DrugBank.d324.s19.e0	DDI-DrugBank.d324.s19.e2
DDI-DrugBank.d324.s19	false	DDI-DrugBank.d324.s19.e0	DDI-DrugBank.d324.s19.e3
DDI-DrugBank.d324.s19	false	DDI-DrugBank.d324.s19.e1	DDI-DrugBank.d324.s19.e2
DDI-DrugBank.d324.s19	false	DDI-DrugBank.d324.s19.e1	DDI-DrugBank.d324.s19.e3
DDI-DrugBank.d324.s19	false	DDI-DrugBank.d324.s19.e2	DDI-DrugBank.d324.s19.e3
DDI-DrugBank.d324.s20|a|Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
DDI-DrugBank.d324.s20	42	49	zaleplon	drug	DDI-DrugBank.d324.s20.e0
DDI-DrugBank.d324.s20	56	67	erythromycin	drug	DDI-DrugBank.d324.s20.e1
DDI-DrugBank.d324.s20	167	174	zaleplon	drug	DDI-DrugBank.d324.s20.e2
DDI-DrugBank.d324.s20	true	DDI-DrugBank.d324.s20.e0	DDI-DrugBank.d324.s20.e1
DDI-DrugBank.d324.s20	false	DDI-DrugBank.d324.s20.e0	DDI-DrugBank.d324.s20.e2
DDI-DrugBank.d324.s20	false	DDI-DrugBank.d324.s20.e1	DDI-DrugBank.d324.s20.e2
DDI-DrugBank.d324.s21|a|The magnitude of interaction with multiple doses of erythromycin is unknown.
DDI-DrugBank.d324.s21	52	63	erythromycin	drug	DDI-DrugBank.d324.s21.e0
DDI-DrugBank.d324.s22|a|Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.
DDI-DrugBank.d324.s22	49	60	ketoconazole	drug	DDI-DrugBank.d324.s22.e0
DDI-DrugBank.d324.s22	111	118	zaleplon	drug	DDI-DrugBank.d324.s22.e1
DDI-DrugBank.d324.s22	true	DDI-DrugBank.d324.s22.e0	DDI-DrugBank.d324.s22.e1
DDI-DrugBank.d324.s23|a|A routine dosage adjustment of zaleplon is not considered necessary.
DDI-DrugBank.d324.s23	31	38	zaleplon	drug	DDI-DrugBank.d324.s23.e0
DDI-DrugBank.d324.s24|a|Drugs That Inhibit Aldehyde Oxidase The aldehyde oxidase enzyme system is less well studied than the cytochrome P450 enzyme system.
DDI-DrugBank.d324.s25|a|Diphenhydramine: Diphenhydramine is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.
DDI-DrugBank.d324.s25	0	14	Diphenhydramine	drug	DDI-DrugBank.d324.s25.e0
DDI-DrugBank.d324.s25	17	31	Diphenhydramine	drug	DDI-DrugBank.d324.s25.e1
DDI-DrugBank.d324.s25	false	DDI-DrugBank.d324.s25.e0	DDI-DrugBank.d324.s25.e1
DDI-DrugBank.d324.s26|a|There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug.
DDI-DrugBank.d324.s26	48	55	zaleplon	drug	DDI-DrugBank.d324.s26.e0
DDI-DrugBank.d324.s26	61	75	diphenhydramine	drug	DDI-DrugBank.d324.s26.e1
DDI-DrugBank.d324.s26	false	DDI-DrugBank.d324.s26.e0	DDI-DrugBank.d324.s26.e1
DDI-DrugBank.d324.s27|a|However, because both of these compounds have CNS effects, an additive pharmacodynamic effect is possible.
DDI-DrugBank.d324.s28|a|Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.
DDI-DrugBank.d324.s28	52	61	Cimetidine	drug	DDI-DrugBank.d324.s28.e0
DDI-DrugBank.d324.s28	64	73	Cimetidine	drug	DDI-DrugBank.d324.s28.e1
DDI-DrugBank.d324.s28	217	224	zaleplon	drug	DDI-DrugBank.d324.s28.e2
DDI-DrugBank.d324.s28	false	DDI-DrugBank.d324.s28.e0	DDI-DrugBank.d324.s28.e1
DDI-DrugBank.d324.s28	false	DDI-DrugBank.d324.s28.e0	DDI-DrugBank.d324.s28.e2
DDI-DrugBank.d324.s28	true	DDI-DrugBank.d324.s28.e1	DDI-DrugBank.d324.s28.e2
DDI-DrugBank.d324.s29|a|Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
DDI-DrugBank.d324.s29	30	35	Sonata	brand	DDI-DrugBank.d324.s29.e0
DDI-DrugBank.d324.s29	49	58	cimetidine	drug	DDI-DrugBank.d324.s29.e1
DDI-DrugBank.d324.s29	122	129	zaleplon	drug	DDI-DrugBank.d324.s29.e2
DDI-DrugBank.d324.s29	true	DDI-DrugBank.d324.s29.e0	DDI-DrugBank.d324.s29.e1
DDI-DrugBank.d324.s29	false	DDI-DrugBank.d324.s29.e0	DDI-DrugBank.d324.s29.e2
DDI-DrugBank.d324.s29	false	DDI-DrugBank.d324.s29.e1	DDI-DrugBank.d324.s29.e2
DDI-DrugBank.d324.s30|a|An initial dose of 5 mg should be given to patients who are concomitantly being treated with cimetidine.
DDI-DrugBank.d324.s30	93	102	cimetidine	drug	DDI-DrugBank.d324.s30.e0
DDI-DrugBank.d324.s31|a|Drugs Highly Bound to Plasma Protein Zaleplon is not highly bound to plasma proteins (fraction bound 60% 15%);
DDI-DrugBank.d324.s31	37	44	Zaleplon	drug	DDI-DrugBank.d324.s31.e0
DDI-DrugBank.d324.s32|a|therefore, the disposition of zaleplon is not expected to be sensitive to alterations in protein binding.
DDI-DrugBank.d324.s32	30	37	zaleplon	drug	DDI-DrugBank.d324.s32.e0
DDI-DrugBank.d324.s33|a|In addition, administration of Sonata to a patient taking another drug that is highly protein bound should not cause transient increase in free concentrations of the other drug.
DDI-DrugBank.d324.s33	31	36	Sonata	brand	DDI-DrugBank.d324.s33.e0
DDI-DrugBank.d324.s34|a|Drugs with a Narrow Therapeutic Index Digoxin: Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).
DDI-DrugBank.d324.s34	38	44	Digoxin	drug	DDI-DrugBank.d324.s34.e0
DDI-DrugBank.d324.s34	47	52	Sonata	brand	DDI-DrugBank.d324.s34.e1
DDI-DrugBank.d324.s34	127	133	digoxin	drug	DDI-DrugBank.d324.s34.e2
DDI-DrugBank.d324.s34	false	DDI-DrugBank.d324.s34.e0	DDI-DrugBank.d324.s34.e1
DDI-DrugBank.d324.s34	false	DDI-DrugBank.d324.s34.e0	DDI-DrugBank.d324.s34.e2
DDI-DrugBank.d324.s34	false	DDI-DrugBank.d324.s34.e1	DDI-DrugBank.d324.s34.e2
DDI-DrugBank.d324.s35|a|Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.
DDI-DrugBank.d324.s35	0	7	Warfarin	drug	DDI-DrugBank.d324.s35.e0
DDI-DrugBank.d324.s35	33	38	Sonata	brand	DDI-DrugBank.d324.s35.e1
DDI-DrugBank.d324.s35	104	111	warfarin	drug	DDI-DrugBank.d324.s35.e2
DDI-DrugBank.d324.s35	220	227	warfarin	drug	DDI-DrugBank.d324.s35.e3
DDI-DrugBank.d324.s35	false	DDI-DrugBank.d324.s35.e0	DDI-DrugBank.d324.s35.e1
DDI-DrugBank.d324.s35	false	DDI-DrugBank.d324.s35.e0	DDI-DrugBank.d324.s35.e2
DDI-DrugBank.d324.s35	false	DDI-DrugBank.d324.s35.e0	DDI-DrugBank.d324.s35.e3
DDI-DrugBank.d324.s35	false	DDI-DrugBank.d324.s35.e1	DDI-DrugBank.d324.s35.e2
DDI-DrugBank.d324.s35	false	DDI-DrugBank.d324.s35.e1	DDI-DrugBank.d324.s35.e3
DDI-DrugBank.d324.s35	false	DDI-DrugBank.d324.s35.e2	DDI-DrugBank.d324.s35.e3
DDI-DrugBank.d324.s36|a|Drugs That Alter Renal Excretion Ibuprofen: Ibuprofen is known to affect renal function and, consequently, alter the renal excretion of other drugs.
DDI-DrugBank.d324.s36	33	41	Ibuprofen	drug	DDI-DrugBank.d324.s36.e0
DDI-DrugBank.d324.s36	44	52	Ibuprofen	drug	DDI-DrugBank.d324.s36.e1
DDI-DrugBank.d324.s36	false	DDI-DrugBank.d324.s36.e0	DDI-DrugBank.d324.s36.e1
DDI-DrugBank.d324.s37|a|There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug.
DDI-DrugBank.d324.s37	58	65	zaleplon	drug	DDI-DrugBank.d324.s37.e0
DDI-DrugBank.d324.s37	71	79	ibuprofen	drug	DDI-DrugBank.d324.s37.e1
DDI-DrugBank.d324.s37	false	DDI-DrugBank.d324.s37.e0	DDI-DrugBank.d324.s37.e1
DDI-DrugBank.d324.s38|a|This was expected because zaleplon is primarily metabolized and renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.
DDI-DrugBank.d324.s38	26	33	zaleplon	drug	DDI-DrugBank.d324.s38.e0
DDI-DrugBank.d324.s38	93	100	zaleplon	drug	DDI-DrugBank.d324.s38.e1
DDI-DrugBank.d324.s38	false	DDI-DrugBank.d324.s38.e0	DDI-DrugBank.d324.s38.e1
